PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Chandra, J; Hansen, M; Labarriere, N; Marigo, I; Souza-Fonseca-Guimaraes, F; Vujanovic, L; Koguchi, Y; Jacquelot, N				Chandra, Janin; Hansen, Morten; Labarriere, Nathalie; Marigo, Ilaria; Souza-Fonseca-Guimaraes, Fernando; Vujanovic, Lazar; Koguchi, Yoshinobu; Jacquelot, Nicolas			Editorial: Cancer Immunotherapies: From Efficacy to Resistance Mechanisms	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer; immunotherapy; tumor microenvironment; immune checkpoint blockers; adoptive T cell therapy			[Chandra, Janin; Souza-Fonseca-Guimaraes, Fernando] Univ Queensland, Univ Queensland Diamantina Inst, Fac Med, Woolloongabba, Qld, Australia; [Hansen, Morten] Copenhagen Univ Hosp, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark; [Labarriere, Nathalie] Nantes Univ, Univ Angers, INSERM, Immunol & New Concepts ImmunoTherapy, Nantes, France; [Labarriere, Nathalie] Univ Nantes, LabEx IGO, Nantes, France; [Marigo, Ilaria] IRCCS, Veneto Inst Oncol IOV, Padua, Italy; [Marigo, Ilaria] Univ Padua, Dept Surg, Oncol & Gastroenterol, Padua, Italy; [Vujanovic, Lazar] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA 15260 USA; [Vujanovic, Lazar] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Koguchi, Yoshinobu] Providence Canc Inst, Earle Chiles Res Inst, Portland, OR 97213 USA; [Jacquelot, Nicolas] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada	University of Queensland; University of Copenhagen; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Nantes Universite; IRCCS Istituto Oncologico Veneto (IOV); University of Padua; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Chandra, J; Souza-Fonseca-Guimaraes, F (corresponding author), Univ Queensland, Univ Queensland Diamantina Inst, Fac Med, Woolloongabba, Qld, Australia.; Hansen, M (corresponding author), Copenhagen Univ Hosp, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark.; Labarriere, N (corresponding author), Nantes Univ, Univ Angers, INSERM, Immunol & New Concepts ImmunoTherapy, Nantes, France.; Labarriere, N (corresponding author), Univ Nantes, LabEx IGO, Nantes, France.; Marigo, I (corresponding author), IRCCS, Veneto Inst Oncol IOV, Padua, Italy.; Marigo, I (corresponding author), Univ Padua, Dept Surg, Oncol & Gastroenterol, Padua, Italy.; Vujanovic, L (corresponding author), Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA 15260 USA.; Vujanovic, L (corresponding author), Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA.; Koguchi, Y (corresponding author), Providence Canc Inst, Earle Chiles Res Inst, Portland, OR 97213 USA.; Jacquelot, N (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada.		Jacquelot, Nicolas/AAY-6937-2020; Labarriere, Nathalie/H-8876-2015	Labarriere, Nathalie/0000-0002-1407-6546	Cure Cancer Australia; Cancer Australia through the Cancer Australia Priority-driven Cancer Research Scheme [APP1163990, 1158085]; Cancer Council NSW [RG21-05]; US Department of Defense -Breast Cancer Research Program -Breakthrough Award Level 1 [BC200025]; ANZSA Sarcoma Research Grant (Kicking Goals for Xav); ANZSA Sarcoma Research Grant (Stoney's Steps); ANZSA Sarcoma Research Grant (Stop Sarcoma); National Institute of Dental & Craniofacial Research [1R01DE031947-01]; Euronanomed [2019-135, 2021-014]; UQ Diamantina Institute Laboratory Start-Up Package	Cure Cancer Australia; Cancer Australia through the Cancer Australia Priority-driven Cancer Research Scheme; Cancer Council NSW(Cancer Council New South Wales); US Department of Defense -Breast Cancer Research Program -Breakthrough Award Level 1(United States Department of Defense); ANZSA Sarcoma Research Grant (Kicking Goals for Xav); ANZSA Sarcoma Research Grant (Stoney's Steps); ANZSA Sarcoma Research Grant (Stop Sarcoma); National Institute of Dental & Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Euronanomed; UQ Diamantina Institute Laboratory Start-Up Package	This work was supported by grants from Cure Cancer Australia and Cancer Australia through the Cancer Australia Priority-driven Cancer Research Scheme (APP1163990 to NJ, 1158085 to FS-F-G), Cancer Council NSW (RG21-05 to NJ), the US Department of Defense -Breast Cancer Research Program -Breakthrough Award Level 1 (#BC200025 to FSFG), a ANZSA Sarcoma Research Grant (supported by Kicking Goals for Xav, Stoney's Steps and Stop Sarcoma to FS-F-G), National Institute of Dental & Craniofacial Research (LV; 1R01DE031947-01), Euronanomed 2019-135 and 2021-014 (IM) and a UQ Diamantina Institute Laboratory Start-Up Package (to FS-F-G).	Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8; Morad G, 2021, CELL, V184, P5309, DOI 10.1016/j.cell.2021.09.020	2	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								939789	10.3389/fimmu.2022.939789	http://dx.doi.org/10.3389/fimmu.2022.939789			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E2GM	35720421	Green Published, gold			2022-12-18	WOS:000812049800001
J	Chen, LY; Liu, C; Liang, T; Ye, Z; Huang, SS; Chen, JR; Sun, XH; Yi, M; Zhou, CX; Jiang, J; Chen, TY; Li, H; Chen, WH; Guo, H; Chen, WK; Yao, YL; Liao, S; Yu, CJ; Wu, SF; Fan, BG; Gan, ZP; Zhan, XL				Chen, Liyi; Liu, Chong; Liang, Tuo; Ye, Zhen; Huang, Shengsheng; Chen, Jiarui; Sun, Xuhua; Yi, Ming; Zhou, Chenxing; Jiang, Jie; Chen, Tianyou; Li, Hao; Chen, Wuhua; Guo, Hao; Chen, Wenkang; Yao, Yuanlin; Liao, Shian; Yu, Chaojie; Wu, Shaofeng; Fan, Binguang; Gan, Zhaoping; Zhan, Xinli			Mechanism of COVID-19-Related Proteins in Spinal Tuberculosis: Immune Dysregulation	FRONTIERS IN IMMUNOLOGY			English	Article						spinal tuberculosis; COVID-19; nomogram; immune cell; KEGG pathway	MYCOBACTERIUM-TUBERCULOSIS; REVEALS	PurposeThe purpose of this article was to investigate the mechanism of immune dysregulation of COVID-19-related proteins in spinal tuberculosis (STB). MethodsClinical data were collected to construct a nomogram model. C-index, calibration curve, ROC curve, and DCA curve were used to assess the predictive ability and accuracy of the model. Additionally, 10 intervertebral disc samples were collected for protein identification. Bioinformatics was used to analyze differentially expressed proteins (DEPs), including immune cells analysis, Gene Ontology (GO) and KEGG pathway enrichment analysis, and protein-protein interaction networks (PPI). ResultsThe nomogram predicted risk of STB ranging from 0.01 to 0.994. The C-index and AUC in the training set were 0.872 and 0.862, respectively. The results in the external validation set were consistent with the training set. Immune cells scores indicated that B cells naive in STB tissues were significantly lower than non-TB spinal tissues. Hub proteins were calculated by Degree, Closeness, and MCC methods. The main KEGG pathway included Coronavirus disease-COVID-19. There were 9 key proteins in the intersection of COVID-19-related proteins and hub proteins. There was a negative correlation between B cells naive and RPL19. COVID-19-related proteins were associated with immune genes. ConclusionLymphocytes were predictive factors for the diagnosis of STB. Immune cells showed low expression in STB. Nine COVID-19-related proteins were involved in STB mechanisms. These nine key proteins may suppress the immune mechanism of STB by regulating the expression of immune genes.	[Chen, Liyi; Liu, Chong; Liang, Tuo; Ye, Zhen; Huang, Shengsheng; Chen, Jiarui; Sun, Xuhua; Yi, Ming; Zhou, Chenxing; Jiang, Jie; Chen, Tianyou; Li, Hao; Chen, Wuhua; Guo, Hao; Chen, Wenkang; Yao, Yuanlin; Liao, Shian; Yu, Chaojie; Wu, Shaofeng; Fan, Binguang; Zhan, Xinli] Guangxi Med Univ, Affiliated Hosp 1, Spine & Osteopathy Ward, Nanning, Peoples R China; [Gan, Zhaoping] Guangxi Med Univ, Affiliated Hosp 1, Dept Hematol, Nanning, Peoples R China	Guangxi Medical University; Guangxi Medical University	Zhan, XL (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Spine & Osteopathy Ward, Nanning, Peoples R China.; Gan, ZP (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Hematol, Nanning, Peoples R China.	3045275202@qq.com; Zhanxinli@stu.gxmu.edu.cn			National Natural Science Foundation of China [81860393]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was sponsored by the National Natural Science Foundation of China (81560359); National Natural Science Foundation of China (81860393). Funding bodies had no role in the study design, collection, analysis, and interpretation of the data or in writing the manuscript.	Abreu MT, 2014, CLIN EXP MED, V14, P423, DOI 10.1007/s10238-013-0258-1; Ardain A, 2019, NATURE, V570, P528, DOI 10.1038/s41586-019-1276-2; Barreda D, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10123279; Batirel A, 2015, CLIN MICROBIOL INFEC, V21, DOI 10.1016/j.cmi.2015.07.013; Bisht R, 2021, J SOCIAL EC DEV, V23, P342, DOI 10.1007/s40847-020-00117-x; Bosio CM, 2000, J IMMUNOL, V164, P6417, DOI 10.4049/jimmunol.164.12.6417; Chakaya J, 2021, INT J INFECT DIS, V113, pS7, DOI 10.1016/j.ijid.2021.02.107; Corominas M, 2004, INT J TUBERC LUNG D, V8, P98; de Nijs RNJ, 2011, LANCET, V378, pE18, DOI 10.1016/S0140-6736(11)61482-7; Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117; Garg RK, 2011, J SPINAL CORD MED, V34, P440, DOI 10.1179/2045772311Y.0000000023; He GQ, 2020, J MED VIROL, V92, P1802, DOI 10.1002/jmv.25943; He X, 2017, MOL CELL PROTEOMICS, V16, P2243, DOI 10.1074/mcp.RA117.000296; Hoshino A, 2014, PATHOG DIS, V70, P28, DOI 10.1111/2049-632X.12082; Hu SF, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007266; Hussell T, 2014, NAT REV IMMUNOL, V14, P81, DOI 10.1038/nri3600; Izawa Kazutaka, 2015, Kekkaku, V90, P415; Joosten SA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005687; Julian DR, 2021, CURR PATHOBIOL REP, V9, P93, DOI 10.1007/s40139-021-00226-0; Karami H, 2021, J CLIN MED, V10, DOI 10.3390/jcm10163567; Kathamuthu GR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207404; La Manna MP, 2020, AM J RESP CELL MOL, V62, P430, DOI 10.1165/rcmb.2019-0261OC; Lisco G, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132920; Lv DF, 2020, J INT MED RES, V48, DOI 10.1177/0300060520925660; Maglione PJ, 2007, J IMMUNOL, V178, P7222, DOI 10.4049/jimmunol.178.11.7222; Mishra Ajay, 2020, Acta Biomed, V92, pe2021025, DOI 10.23750/abm.v92i1.10738; Miyasaka M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012661; Motta I, 2020, PULMONOLOGY, V26, P233, DOI 10.1016/j.pulmoe.2020.05.002; Nalbandian A, 2021, NAT MED, V27, P601, DOI 10.1038/s41591-021-01283-z; Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232-019-0111-3; Prisic S, 2015, MOL MICROBIOL, V97, P263, DOI 10.1111/mmi.13022; Roca FJ, 2019, CELL, V178, P1344, DOI 10.1016/j.cell.2019.08.004; Rofeal M, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109904; Sadanshiv M, 2018, TROP DOCT, V48, P156, DOI 10.1177/0049475517724689; Sahu KK, 2020, HEART LUNG, V49, P446, DOI 10.1016/j.hrtlng.2020.04.014; Shi RN, 2021, GENOM PROTEOM BIOINF, V19, P707, DOI 10.1016/j.gpb.2021.09.007; Soko RN, 2021, EMERG INFECT DIS, V27, P1831, DOI 10.3201/eid2707.210557; Stochino C, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01708-2020; Tadolini M, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.02328-2020; Torrelles JB, 2017, TRENDS MICROBIOL, V25, P688, DOI 10.1016/j.tim.2017.03.007; Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774-020-01162-6; Uranga-Murillo I, 2022, THERANOSTICS, V12, P290, DOI 10.7150/thno.63463; Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009; Wang H, 2021, J PROTEOMICS, V247, DOI 10.1016/j.jprot.2021.104330; Wu L, 2021, GENET MED, V23, P2076, DOI 10.1038/s41436-021-01243-5; Zhang C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.733171; Zhang Q, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.766922; Zheng MF, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171140	48	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								882651	10.3389/fimmu.2022.882651	http://dx.doi.org/10.3389/fimmu.2022.882651			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E2OK	35720320	Green Published, gold			2022-12-18	WOS:000812070400001
J	Chen, R; Zhang, H; Wu, WT; Li, SY; Wang, ZY; Dai, ZY; Liu, ZQ; Zhang, J; Luo, P; Xia, ZW; Cheng, Q				Chen, Rui; Zhang, Hao; Wu, Wantao; Li, Shuyu; Wang, Zeyu; Dai, Ziyu; Liu, Zaoqu; Zhang, Jian; Luo, Peng; Xia, Zhiwei; Cheng, Quan			Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response (vol 13, 833792, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						antigen presentation machinery; glioma; microenvironment; prognosis; genomic alteration; immunotherapy			[Chen, Rui] Univ South China, Affiliated Nanhua Hosp, Dept Neurosurg, Hengyang, Peoples R China; [Zhang, Hao; Wang, Zeyu; Dai, Ziyu; Cheng, Quan] Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China; [Zhang, Hao; Wu, Wantao; Wang, Zeyu; Dai, Ziyu; Cheng, Quan] Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China; [Wu, Wantao] Cent South Univ, Xiangya Hosp, Dept Oncol, Changsha, Peoples R China; [Li, Shuyu] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Thyroid & Breast Surg, Tongji Med Coll, Wuhan, Peoples R China; [Liu, Zaoqu] Zhengzhou Univ, Dept Intervent Radiol, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Zhang, Jian; Luo, Peng] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China; [Xia, Zhiwei] Hunan Aerosp Hosp, Dept Neurol, Changsha, Peoples R China	University of South China; Central South University; Central South University; Central South University; Huazhong University of Science & Technology; Zhengzhou University; Southern Medical University - China	Cheng, Q (corresponding author), Cent South Univ, Xiangya Hosp, Dept Neurosurg, Changsha, Peoples R China.; Cheng, Q (corresponding author), Cent South Univ, Xiangya Hosp, Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China.; Xia, ZW (corresponding author), Hunan Aerosp Hosp, Dept Neurol, Changsha, Peoples R China.	xiazhiwei2011@gmail.com; chengquan@csu.edu.cn	ziyu, dai/GRR-6048-2022; Chen, Rui/GYU-1896-2022; Zhang, Hao/GWZ-3401-2022	Chen, Rui/0000-0002-3813-1749; Zhang, Hao/0000-0002-4582-2556					0	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								931433	10.3389/fimmu.2022.931433	http://dx.doi.org/10.3389/fimmu.2022.931433			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3WR	35720317	Green Published, gold			2022-12-18	WOS:000812160800001
J	Dowell, AC; Powell, AA; Davis, C; Scott, S; Logan, N; Willett, BJ; Bruton, R; Ayodele, M; Jinks, E; Gunn, J; Spalkova, E; Sylla, P; Nicol, SM; Zuo, JM; Ireland, G; Okike, I; Baawuah, F; Beckmann, J; Ahmad, S; Garstang, J; Brent, AJ; Brent, B; White, M; Collins, A; Davis, F; Lim, M; Cohen, J; Kenny, J; Linley, E; Poh, J; Amirthalingam, G; Brown, K; Ramsay, ME; Azad, R; Wright, J; Waiblinger, D; Moss, P; Ladhani, SN				Dowell, Alexander C.; Powell, Annabel A.; Davis, Chris; Scott, Sam; Logan, Nicola; Willett, Brian J.; Bruton, Rachel; Ayodele, Morenike; Jinks, Elizabeth; Gunn, Juliet; Spalkova, Eliska; Sylla, Panagiota; Nicol, Samantha M.; Zuo, Jianmin; Ireland, Georgina; Okike, Ifeanyichukwu; Baawuah, Frances; Beckmann, Joanne; Ahmad, Shazaad; Garstang, Joanna; Brent, Andrew J.; Brent, Bernadette; White, Marie; Collins, Aedin; Davis, Francesca; Lim, Ming; Cohen, Jonathan; Kenny, Julia; Linley, Ezra; Poh, John; Amirthalingam, Gayatri; Brown, Kevin; Ramsay, Mary E.; Azad, Rafaq; Wright, John; Waiblinger, Dagmar; Moss, Paul; Ladhani, Shamez N.			mRNA or ChAd0x1 COVID-19 Vaccination of Adolescents Induces Robust Antibody and Cellular Responses With Continued Recognition of Omicron Following mRNA-1273	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; vaccine; paediatric; T-cell; antibody; neuro-disabilities; high-risk patients	BNT162B2; SARS-COV-2; IMMUNITY	Children and adolescents generally experience mild COVID-19. However, those with underlying physical health conditions are at a significantly increased risk of severe disease. Here, we present a comprehensive analysis of antibody and cellular responses in adolescents with severe neuro-disabilities who received COVID-19 vaccination with either ChAdOx1 (n=6) or an mRNA vaccine (mRNA-1273, n=8, BNT162b2, n=1). Strong immune responses were observed after vaccination and antibody levels and neutralisation titres were both higher after two doses. Both measures were also higher after mRNA vaccination and were further enhanced by prior natural infection where one vaccine dose was sufficient to generate peak antibody response. Robust T-cell responses were generated after dual vaccination and were also higher following mRNA vaccination. Early T-cells were characterised by a dominant effector-memory CD4+ T-cell population with a type-1 cytokine signature with additional production of IL-10. Antibody levels were well-maintained for at least 3 months after vaccination and 3 of 4 donors showed measurable neutralisation titres against the Omicron variant. T-cell responses also remained robust, with generation of a central/stem cell memory pool and showed strong reactivity against Omicron spike. These data demonstrate that COVID-19 vaccines display strong immunogenicity in adolescents and that dual vaccination, or single vaccination following prior infection, generate higher immune responses than seen after natural infection and develop activity against Omicron. Initial evidence suggests that mRNA vaccination elicits stronger immune responses than adenoviral delivery, although the latter is also higher than seen in adult populations. COVID-19 vaccines are therefore highly immunogenic in high-risk adolescents and dual vaccination might be able to provide relative protection against the Omicron variant that is currently globally dominant.	[Dowell, Alexander C.; Bruton, Rachel; Ayodele, Morenike; Jinks, Elizabeth; Gunn, Juliet; Spalkova, Eliska; Sylla, Panagiota; Nicol, Samantha M.; Zuo, Jianmin; Moss, Paul] Univ Birmingham, Inst Immunol & Immunotherapy, Coll Med & Dent Sci, Birmingham, Warwickshire, England; [Powell, Annabel A.; Ireland, Georgina; Okike, Ifeanyichukwu; Baawuah, Frances; Poh, John; Amirthalingam, Gayatri; Brown, Kevin; Ramsay, Mary E.; Ladhani, Shamez N.] Immunisat & Vaccine Preventable Dis Div, United Kingdom UK Hlth Secur Agcy, London, England; [Davis, Chris; Scott, Sam; Logan, Nicola; Willett, Brian J.] Univ Glasgow Ctr Virus Res, Med Res Council MRC, Glasgow City, England; [Okike, Ifeanyichukwu] Univ Hosp Derby, Burton Natl Hlth Serv NHS Fdn Trust, Derby, Derbyshire, England; [Beckmann, Joanne] East London Natl Hlth Serv NHS Fdn Trust, London, England; [Ahmad, Shazaad] Manchester Univ Natl Hlth Serv NHS Fdn Trust, Manchester, Lancashire, England; [Garstang, Joanna] Birmingham Community Healthcare Natl Hlth Serv NHS, Aston, Birmingham, England; [Brent, Andrew J.; Brent, Bernadette] Oxford Univ Hosp Natl Hlth Serv NHS Fdn Trust, Nuffield Dept Med, Oxford, Oxfordshire, England; [Brent, Andrew J.] Univ Oxford, Oxford, Oxfordshire, England; [White, Marie; Davis, Francesca] Evelina London Childrens Hosp, Dept Gen Paediat, London, England; [Collins, Aedin] Tallaght Univ Hosp, Natl Childrens Hosp, Dublin, Ireland; [Lim, Ming] Evelina London Childrens Hosp Guys, St ThomasNat Hlth Serv NHS Fdn Trust, Kings Hlth Partners Acad Hlth Sci Ctr, Childrens Neurosci, London, England; [Lim, Ming; Kenny, Julia] Kings Coll London, Sch Life Course Sci SoLCS, Dept Women & Childrens Hlth, London, England; [Cohen, Jonathan; Kenny, Julia] Immunol Evelina London Childrens Hosp, Dept Paediat Infect Dis, London, England; [Linley, Ezra] Manchester Royal Infirm, United Kingdom UK Hlth Secur Agcy, Manchester, Lancashire, England; [Azad, Rafaq; Wright, John; Waiblinger, Dagmar] Bradford Teaching Hosp Natl Hlth Serv NHS Fdn Trus, Bradford Inst Hlth Res, Bradford, England; [Ladhani, Shamez N.] St Georges Univ London, Paediat Infect Dis Res Grp, London, England	University of Birmingham; Oxford University Hospitals NHS Foundation Trust; University of Oxford; University of Oxford; Trinity College Dublin; King's Health Partners; University of London; King's College London; University of Manchester; St Georges University London	Ladhani, SN (corresponding author), Immunisat & Vaccine Preventable Dis Div, United Kingdom UK Hlth Secur Agcy, London, England.; Ladhani, SN (corresponding author), St Georges Univ London, Paediat Infect Dis Res Grp, London, England.	Shamez.Ladhani@phe.gov.uk	; Moss, Paul/D-1728-2009	Ireland, Georgina/0000-0001-8932-2783; Zuo, Jianmin/0000-0002-8341-465X; Moss, Paul/0000-0002-6895-1967; davis, chris/0000-0002-7317-3266				Aiano F, 2022, ARCH DIS CHILD, V107, DOI 10.1136/archdischild-2021-323162; Ali K, 2021, NEW ENGL J MED, V385, P2241, DOI 10.1056/NEJMoa2109522; Bird PK, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7222-2; Dieudonne Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00840; Dowell AC, 2022, NAT IMMUNOL, V23, P40, DOI 10.1038/s41590-021-01089-8; Fenwick C, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abi8452; Folegatti PM, 2020, LANCET, V396, P467, DOI 10.1016/S0140-6736(20)31604-4; Frenck RW, 2021, NEW ENGL J MED, V385, P239, DOI 10.1056/NEJMoa2107456; Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]; Le Bert N, 2021, J EXP MED, V218, DOI 10.1084/jem.20202617; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Mazzoni A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149150; Mikhak Z, 2013, J EXP MED, V210, P1855, DOI 10.1084/jem.20130091; Moss B, 2021, EXTENDED INTERVAL BN, DOI [10.1101/2021.05.15.21257017, DOI 10.1101/2021.05.15.21257017]; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Olson SM, 2022, NEW ENGL J MED, V386, P713, DOI 10.1056/NEJMoa2117995; Parry H, 2021, IMMUN AGEING, V18, DOI 10.1186/s12979-021-00246-9; Payne RP, 2021, CELL, V184, P5699, DOI 10.1016/j.cell.2021.10.011; Pegu A, 2021, SCIENCE, V373, P1372, DOI 10.1126/science.abj4176; Rihn SJ, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001091; Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Skelly DT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25167-5; Smith C, 2022, NAT MED, V28, P185, DOI 10.1038/s41591-021-01578-1; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Tartof SY, 2021, LANCET, V398, P1407, DOI 10.1016/S0140-6736(21)02183-8; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Ward JL, 2022, NAT MED, V28, P193, DOI 10.1038/s41591-021-01627-9; Willett B.J., 2022, PREPRINT, DOI [10.1101/2022.01.03.21268111, DOI 10.1101/2022.01.03.21268111V1, DOI 10.1101/2022.01.03.21268111]; Wong BLH, 2021, ARCH DIS CHILD, V106, P1147, DOI 10.1136/archdischild-2020-321225; Zuo JM, 2021, NAT IMMUNOL, V22, P620, DOI 10.1038/s41590-021-00902-8	31	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								882515	10.3389/fimmu.2022.882515	http://dx.doi.org/10.3389/fimmu.2022.882515			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D9UM	35720281	Green Accepted, Green Published, gold			2022-12-18	WOS:000811882700001
J	Gonzales, SJ; Clarke, KN; Batugedara, G; Garza, R; Braddom, AE; Reyes, RA; Ssewanyana, I; Garrison, KC; Ippolito, GC; Greenhouse, B; Bol, S; Bunnik, EM				Gonzales, S. Jake; Clarke, Kathleen N.; Batugedara, Gayani; Garza, Rolando; Braddom, Ashley E.; Reyes, Raphael A.; Ssewanyana, Isaac; Garrison, Kendra C.; Ippolito, Gregory C.; Greenhouse, Bryan; Bol, Sebastiaan; Bunnik, Evelien M.			A Molecular Analysis of Memory B Cell and Antibody Responses Against Plasmodium falciparum Merozoite Surface Protein 1 in Children and Adults From Uganda	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; adaptive immune response; humoral immunity; antibodies; memory B cells; IgM; IgG; somatic hypermutation	INFECTED ERYTHROCYTES; ACQUIRED ANTIBODIES; ALLELIC DIMORPHISM; MALARIA IMMUNITY; ANTIGENS; PROTECTION; BLOOD; VACCINE; MAGNITUDE; EFFICACY	Memory B cells (MBCs) and plasma antibodies against Plasmodium falciparum (Pf) merozoite antigens are important components of the protective immune response against malaria. To gain understanding of how responses against Pf develop in these two arms of the humoral immune system, we evaluated MBC and antibody responses against the most abundant merozoite antigen, full-length Pf merozoite surface protein 1 (PfMSP1(FL)), in individuals from a region in Uganda with high Pf transmission. Our results showed that PfMSP1(FL)-specific B cells in adults with immunological protection against malaria were predominantly IgG(+) classical MBCs, while children with incomplete protection mainly harbored IgM(+) PfMSP1(FL)-specific classical MBCs. In contrast, anti-PfMSP1(FL) plasma IgM reactivity was minimal in both children and adults. Instead, both groups showed high plasma IgG reactivity against PfMSP1(FL), with broadening of the response against non-3D7 strains in adults. The B cell receptors encoded by PfMSP1(FL)-specific IgG(+) MBCs carried high levels of amino acid substitutions and recognized relatively conserved epitopes on the highly variable PfMSP1 protein. Proteomics analysis of PfMSP1(19)-specific IgG in plasma of an adult revealed a limited repertoire of anti-MSP1 antibodies, most of which were IgG(1) or IgG(3). Similar to B cell receptors of PfMSP1(FL)-specific MBCs, anti-PfMSP1(19) IgGs had high levels of amino acid substitutions and their sequences were predominantly found in classical MBCs, not atypical MBCs. Collectively, these results showed evolution of the PfMSP1-specific humoral immune response with cumulative Pf exposure, with a shift from IgM(+) to IgG(+) B cell memory, diversification of B cells from germline, and stronger recognition of PfMSP1 variants by the plasma IgG repertoire.	[Gonzales, S. Jake; Clarke, Kathleen N.; Batugedara, Gayani; Garza, Rolando; Braddom, Ashley E.; Reyes, Raphael A.; Bol, Sebastiaan; Bunnik, Evelien M.] Univ Texas Hlth Sci Ctr San Antonio, Long Sch Med, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA; [Ssewanyana, Isaac] Infect Dis Res Collaborat, Kampala, Uganda; [Ssewanyana, Isaac] London Sch Hyg & Trop Med, Dept Infect Biol, London, England; [Garrison, Kendra C.] Univ Texas Austin, Dept Chem Engn, Austin, TX USA; [Ippolito, Gregory C.] Univ Texas Austin, Dell Med Sch, Dept Mol Biosci, Austin, TX USA; [Greenhouse, Bryan] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Ippolito, Gregory C.] Univ Texas Austin, Dell Med Sch, Dept Oncol, Austin, TX USA	University of Texas System; University of Texas Health San Antonio; University of London; London School of Hygiene & Tropical Medicine; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of California System; University of California San Francisco; University of Texas System; University of Texas Austin	Bunnik, EM (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Long Sch Med, Dept Microbiol Immunol & Mol Genet, San Antonio, TX 78229 USA.	bunnik@uthscsa.edu		Bol, Sebastiaan/0000-0002-3843-6657	NIAID, NIH [R01 AI153425, T32 AI138944, NIH-NCI P30 CA054174-20, UL1 TR001120]; National Institutes of Health/National Institute of Allergy and Infectious Diseases [P30 CA054174]; Graduate Research in Immunology Program training grant [1S10OD021805-01]; Translational Science Training award; UT Health [RP160732]; CTSA grant; UT Health San Antonio, NIH-NCI; NIH Shared Instrument grant; CPRIT Core Facility Award	NIAID, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); National Institutes of Health/National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Graduate Research in Immunology Program training grant; Translational Science Training award; UT Health; CTSA grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); UT Health San Antonio, NIH-NCI; NIH Shared Instrument grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CPRIT Core Facility Award	This work was supported by National Institutes of Health/National Institute of Allergy and Infectious Diseases (R01 AI153425 to EB). SG and AB were supported by Graduate Research in Immunology Program training grant NIH T32 AI138944. RR was supported by Translational Science Training award TL1 TR002647. Data were generated in the Flow Cytometry Shared Resource Facility, which is supported by UT Health, NIH-NCI P30 CA054174-20 (CTRC at UT Health) and UL1 TR001120 (CTSA grant) and in the Genome Sequencing Facility, which is supported by UT Health San Antonio, NIH-NCI P30 CA054174 (Cancer Center at UT Health San Antonio), NIH Shared Instrument grant 1S10OD021805-01 (S10 grant), and CPRIT Core Facility Award (RP160732).	Acquah FK, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-3146-7; Adu B, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1146-4; Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Alamyar Eltaf, 2012, Methods Mol Biol, V882, P569, DOI 10.1007/978-1-61779-842-9_32; Andrews SF, 2019, IMMUNITY, V51, P398, DOI 10.1016/j.immuni.2019.06.024; Ayieko C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067230; Boyle MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax4489; Boyle MJ, 2015, IMMUNITY, V42, P580, DOI 10.1016/j.immuni.2015.02.012; Boyle MJ, 2010, P NATL ACAD SCI USA, V107, P14378, DOI 10.1073/pnas.1009198107; Braddom AE, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00726-21; Braddom AE, 2020, INT J PARASITOL, V50, P1033, DOI 10.1016/j.ijpara.2020.08.003; Bushell KM, 2008, GENOME RES, V18, P622, DOI 10.1101/gr.7187808; Cavanagh DR, 1997, MOL BIOCHEM PARASIT, V85, P197, DOI 10.1016/S0166-6851(96)02826-5; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; Conway DJ, 2000, NAT MED, V6, P689, DOI 10.1038/76272; Crompton PD, 2014, ANNU REV IMMUNOL, V32, P157, DOI 10.1146/annurev-immunol-032713-120220; Crompton PD, 2010, P NATL ACAD SCI USA, V107, P6958, DOI 10.1073/pnas.1001323107; Crosnier C, 2013, MOL CELL PROTEOMICS, V12, P3976, DOI 10.1074/mcp.O113.028357; Dent AE, 2015, J INFECT DIS, V212, P1429, DOI 10.1093/infdis/jiv224; Dodoo D, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-142; Dorfman JR, 2005, J INFECT DIS, V191, P1623, DOI 10.1086/429671; Duah NO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007381; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Fowkes FJI, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000218; Ghoshal S, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2592-y; Gonzales SJ, 2021, MALARIA J, V20, DOI 10.1186/s12936-021-03970-1; Gonzales SJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.594653; Gonzalez-Quintela A, 2008, CLIN EXP IMMUNOL, V151, P42, DOI 10.1111/j.1365-2249.2007.03545.x; Gotz A, 2017, P NATL ACAD SCI USA, V114, pE10568, DOI 10.1073/pnas.1708383114; Hill DL, 2016, INFECT IMMUN, V84, P2175, DOI 10.1128/IAI.00145-16; Holder AA, 2009, PARASITOLOGY, V136, P1445, DOI 10.1017/S0031182009990515; Hopp CS, 2021, J EXP MED, V218, DOI 10.1084/jem.20200901; Huang JH, 2013, NAT PROTOC, V8, P1907, DOI 10.1038/nprot.2013.117; Ismail HA, 2013, CLIN VACCINE IMMUNOL, V20, P1170, DOI 10.1128/CVI.00156-13; Kamya MR, 2015, AM J TROP MED HYG, V92, P903, DOI 10.4269/ajtmh.14-0312; Kana IH, 2019, J INFECT DIS, V220, P275, DOI 10.1093/infdis/jiz088; Kapteyn J, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-413; Kenderes KJ, 2018, CELL REP, V24, P824, DOI 10.1016/j.celrep.2018.06.074; Khan SR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664526; Kidgell C, 2006, PLOS PATHOG, V2, P562, DOI 10.1371/journal.ppat.0020057; Kilama M, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-111; Krishnamurty AT, 2016, IMMUNITY, V45, P402, DOI 10.1016/j.immuni.2016.06.014; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Lavinder JJ, 2014, P NATL ACAD SCI USA, V111, P2259, DOI 10.1073/pnas.1317793111; Liao HX, 2009, J VIROL METHODS, V158, P171, DOI 10.1016/j.jviromet.2009.02.014; Lindner JM, 2019, IMMUNITY, V50, P668, DOI 10.1016/j.immuni.2019.02.003; Malkin EM, 2005, INFECT IMMUN, V73, P3677, DOI 10.1128/IAI.73.6.3677-3685.2005; MILLER LH, 1993, MOL BIOCHEM PARASIT, V59, P1, DOI 10.1016/0166-6851(93)90002-F; Naung Myo T, 2022, PLoS Comput Biol, V18, pe1009801, DOI 10.1371/journal.pcbi.1009801; Ndungu FM, 2013, EUR J IMMUNOL, V43, P2919, DOI 10.1002/eji.201343630; Ndungu FM, 2012, P NATL ACAD SCI USA, V109, P8247, DOI 10.1073/pnas.1200472109; Ndungu FM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000690; Neafsey DE, 2015, NEW ENGL J MED, V373, P2025, DOI 10.1056/NEJMoa1505819; Nogaro SI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025582; Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708; Osier FHA, 2008, INFECT IMMUN, V76, P2240, DOI 10.1128/IAI.01585-07; Osier FHA, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-108; Pack AD, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109586; PAUL F, 1981, LANCET, V2, P70; Perez-Mazliah D, 2018, ELIFE, V7, DOI 10.7554/eLife.39800; Portugal S, 2017, CELL IMMUNOL, V321, P18, DOI 10.1016/j.cellimm.2017.07.003; Rasmussen SM, 2015, CYTOM PART B-CLIN CY, V88, P40, DOI 10.1002/cyto.b.21192; Reiling L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08528-z; Richards JS, 2013, J IMMUNOL, V191, P795, DOI 10.4049/jimmunol.1300778; Richards JS, 2010, CLIN INFECT DIS, V51, pE50, DOI 10.1086/656413; Roskin KM, 2020, NAT IMMUNOL, V21, P199, DOI 10.1038/s41590-019-0581-0; Sheehy SH, 2012, MOL THER, V20, P2355, DOI 10.1038/mt.2012.223; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; Stanisic DI, 2015, INFECT IMMUN, V83, P646, DOI 10.1128/IAI.02398-14; Sutton HJ, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108684; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; Tanabe K, 2007, GENE, V397, P153, DOI 10.1016/j.gene.2007.04.033; Taylor JJ, 2012, J EXP MED, V209, P2065, DOI 10.1084/jem.20112272; Thouvenel CD, 2021, J EXP MED, V218, DOI 10.1084/jem.20200942; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Turchaninova MA, 2016, NAT PROTOC, V11, P1599, DOI 10.1038/nprot.2016.093; Viant C, 2020, CELL, V183, P1298, DOI 10.1016/j.cell.2020.09.063; Vijay R, 2020, NAT IMMUNOL, V21, P790, DOI 10.1038/s41590-020-0678-5; Voss WN, 2021, SCIENCE, V372, P1108, DOI 10.1126/science.abg5268; Walker MR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0243943; Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912; WHO, 2016, WORLD MAL REP 2016; Wipasa J, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000770; Yman V, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1255-3; Zajac P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0085270	86	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								809264	10.3389/fimmu.2022.809264	http://dx.doi.org/10.3389/fimmu.2022.809264			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E2OT	35720313	gold, Green Published			2022-12-18	WOS:000812071300001
J	Hames, RG; Jasiunaite, Z; Ercoli, G; Wanford, JJ; Carreno, D; Straatman, K; Martinez-Pomares, L; Yesilkaya, H; Glenn, S; Moxon, ER; Andrew, PW; Kyriacou, CP; Oggioni, MR				Hames, Ryan G.; Jasiunaite, Zydrune; Ercoli, Giuseppe; Wanford, Joseph J.; Carreno, David; Straatman, Kornelis; Martinez-Pomares, Luisa; Yesilkaya, Hasan; Glenn, Sarah; Moxon, E. Richard; Andrew, Peter W.; Kyriacou, Charalambos P.; Oggioni, Marco R.			Diurnal Differences in Intracellular Replication Within Splenic Macrophages Correlates With the Outcome of Pneumococcal Infection	FRONTIERS IN IMMUNOLOGY			English	Article						circadian rhythm; Streptococcus pneumoniae; macrophage; spleen; immunohistochemistry; image analysis; microscopy; mouse	TUMOR-NECROSIS-FACTOR; STREPTOCOCCUS-PNEUMONIAE; CIRCADIAN-RHYTHM; SUSCEPTIBILITY; DISEASE; CLOCK; PERIODICITY; RECEPTOR; BURDEN; MICE	Circadian rhythms affect the progression and severity of bacterial infections including those caused by Streptococcus pneumoniae, but the mechanisms responsible for this phenomenon remain largely elusive. Following advances in our understanding of the role of replication of S. pneumoniae within splenic macrophages, we sought to investigate whether events within the spleen correlate with differential outcomes of invasive pneumococcal infection. Utilising murine invasive pneumococcal disease (IPD) models, here we report that infection during the murine active phase (zeitgeber time 15; 15h after start of light cycle, 3h after start of dark cycle) resulted in significantly faster onset of septicaemia compared to rest phase (zeitgeber time 3; 3h after start of light cycle) infection. This correlated with significantly higher pneumococcal burden within the spleen of active phase-infected mice at early time points compared to rest phase-infected mice. Whole-section confocal microscopy analysis of these spleens revealed that the number of pneumococci is significantly higher exclusively within marginal zone metallophilic macrophages (MMMs) known to allow intracellular pneumococcal replication as a prerequisite step to the onset of septicaemia. Pneumococcal clusters within MMMs were more abundant and increased in size over time in active phase-infected mice compared to those in rest phase-infected mice which decreased in size and were present in a lower percentage of MMMs. This phenomenon preceded significantly higher levels of bacteraemia alongside serum IL-6 and TNF-alpha concentrations in active phase-infected mice following re-seeding of pneumococci into the blood. These data greatly advance our fundamental knowledge of pneumococcal infection by linking susceptibility to invasive pneumococcal infection to variation in the propensity of MMMs to allow persistence and replication of phagocytosed bacteria. These findings also outline a somewhat rare scenario whereby the active phase of an organism's circadian cycle plays a seemingly counterproductive role in the control of invasive infection.	[Hames, Ryan G.; Jasiunaite, Zydrune; Wanford, Joseph J.; Carreno, David; Kyriacou, Charalambos P.; Oggioni, Marco R.] Univ Leicester, Dept Genet & Genome Biol, Leicester, England; [Ercoli, Giuseppe] Univ Coll Med Sch, Ctr Inflammat & Tissue Repair, Div Med, UCL Resp, London, England; [Straatman, Kornelis] Univ Leicester, Adv Imaging Facil, Leicester, England; [Martinez-Pomares, Luisa] Univ Nottingham, Sch Life Sci, Nottingham, England; [Yesilkaya, Hasan; Andrew, Peter W.] Univ Leicester, Dept Resp Sci, Leicester, England; [Glenn, Sarah] Univ Leicester, Preclin Res Facil, Leicester, England; [Moxon, E. Richard] Univ Oxford, Dept Paediat, Oxford, England; [Oggioni, Marco R.] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy	University of Leicester; University of London; University College London; University of Leicester; University of Nottingham; University of Leicester; University of Leicester; University of Oxford; University of Bologna	Oggioni, MR (corresponding author), Univ Leicester, Dept Genet & Genome Biol, Leicester, England.; Oggioni, MR (corresponding author), Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.	mro5@leicester.ac.uk	Carreno, David/ABA-6416-2021; Oggioni, Marco Rinaldo/K-3839-2016	Carreno, David/0000-0002-4649-7230; Oggioni, Marco Rinaldo/0000-0003-4117-793X	University of Oxford [MRC MR/M003078/1]; BBSRC [BB/S507052/1]	University of Oxford; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	Authors thank the staff of the Leicester Preclinical Research Facility for support with the mouse experiments and the University of Leicester Advanced Imaging Facility (RRID : SCR_020967) for use of microscope equipment. The work was in part supported by a collaboration agreement with the University of Oxford and grants from the MRC MR/M003078/1 and BBSRC BB/S507052/1 to MRO. ZJ is funded by BBSRC BB/S507052/1.	Barriga C, 2001, J PINEAL RES, V30, P180, DOI 10.1034/j.1600-079X.2001.300307.x; Baxter M, 2020, IMMUNOLOGY, V161, P261, DOI 10.1111/imm.13166; Bellet MM, 2013, P NATL ACAD SCI USA, V110, P9897, DOI 10.1073/pnas.1120636110; Borsa N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174220; Broadley SP, 2016, CELL HOST MICROBE, V20, P36, DOI 10.1016/j.chom.2016.05.023; Carreno D, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103601; Chung WY, 2019, ALTEX-ALTERN ANIM EX, V36, P29, DOI 10.14573/altex.1805131; de Bree LCJ, 2020, J CLIN INVEST, V130, P5603, DOI 10.1172/JCI133934; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; Deniset JF, 2017, J EXP MED, V214, P1333, DOI 10.1084/jem.20161621; Ercoli G, 2018, NAT MICROBIOL, V3, P600, DOI 10.1038/s41564-018-0147-1; FEIGIN RD, 1969, NATURE, V224, P379, DOI 10.1038/224379a0; Gerlini A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004026; Gibbs J, 2014, NAT MED, V20, P919, DOI 10.1038/nm.3599; Gonzalez-Juarbe N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005337; Honke N, 2012, NAT IMMUNOL, V13, P51, DOI 10.1038/ni.2169; Kadioglu A, 2011, J INFECT DIS, V204, P1971, DOI 10.1093/infdis/jir657; KALISS N, 1950, P SOC EXP BIOL MED, V75, P16, DOI 10.3181/00379727-75-18083; Kang YS, 2004, P NATL ACAD SCI USA, V101, P215, DOI 10.1073/pnas.0307124101; Keller M, 2009, P NATL ACAD SCI USA, V106, P21407, DOI 10.1073/pnas.0906361106; Kim JY, 2015, ONCOTARGET, V6, P44161, DOI 10.18632/oncotarget.6592; Kitchen GB, 2020, P NATL ACAD SCI USA, V117, P1543, DOI 10.1073/pnas.1915932117; Kurt ANC, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/31397; Lanie JA, 2007, J BACTERIOL, V189, P38, DOI 10.1128/JB.01148-06; Lanoue A, 2004, J EXP MED, V200, P1383, DOI 10.1084/jem.20040795; Magna M, 2014, MOL MED, V20, P138, DOI 10.2119/molmed.2013.00164; Miggin SM, 2007, P NATL ACAD SCI USA, V104, P3372, DOI 10.1073/pnas.0608100104; Nguyen KD, 2013, SCIENCE, V341, P1483, DOI 10.1126/science.1240636; Nobis CC, 2019, P NATL ACAD SCI USA, V116, P20077, DOI 10.1073/pnas.1905080116; Oliva-Ramirez J, 2014, IMMUNOLOGY, V143, P490, DOI 10.1111/imm.12329; Patke A, 2020, NAT REV MOL CELL BIO, V21, P67, DOI 10.1038/s41580-019-0179-2; Pearson JA, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.721004; Pereira PM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00675; Petrovsky N, 1998, Int Rev Immunol, V16, P635, DOI 10.3109/08830189809043012; Pierrakos C, 2010, CRIT CARE, V14, DOI 10.1186/cc8872; Scheiermann C, 2013, NAT REV IMMUNOL, V13, P190, DOI 10.1038/nri3386; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schulte W, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/165974; SHACKELFORD PG, 1973, SCIENCE, V182, P285, DOI 10.1126/science.182.4109.285; Silke J, 2015, NAT IMMUNOL, V16, P689, DOI [10.1038/ni.3206, 10.1038/ni0815-889b]; Song J, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4618-7; SPOONER CE, 1992, CLIN IMMUNOL IMMUNOP, V62, pS11, DOI 10.1016/0090-1229(92)90036-N; Trappetti C, 2017, MBIO, V8, DOI 10.1128/mBio.02269-16; Wahl B, 2018, LANCET GLOB HEALTH, V6, pE744, DOI 10.1016/S2214-109X(18)30247-X; Wang HD, 2016, LANCET, V388, P1459, DOI 10.1016/S0140-6736(16)31012-1; Wang W, 2022, J BIOL RHYTHM, V37, P124, DOI 10.1177/07487304211059315; WARA DW, 1981, REV INFECT DIS, V3, P299; WONGWIWAT M, 1972, INFECT IMMUN, V5, P442, DOI 10.1128/IAI.5.4.442-448.1972; Zeng ZT, 2016, CELL HOST MICROBE, V20, P99, DOI 10.1016/j.chom.2016.06.002	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								907461	10.3389/fimmu.2022.907461	http://dx.doi.org/10.3389/fimmu.2022.907461			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3GA	35720383	Green Published, Green Submitted, gold			2022-12-18	WOS:000812116200001
J	He, WW; Wang, CH; Wu, L; Wan, G; Li, BS; Han, YT; Li, HJ; Leng, XF; Du, KY; Chen, HJ; Wang, QF; Peng, L				He, Wenwu; Wang, Chenghao; Wu, Lei; Wan, Gang; Li, Baisen; Han, Yongtao; Li, Haojun; Leng, Xuefeng; Du, Kunyi; Chen, Haijun; Wang, Qifeng; Peng, Lin			Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study	FRONTIERS IN IMMUNOLOGY			English	Article						neoadjuvant chemoradiotherapy; neoadjuvant chemoimmunotherapy; total neoadjuvant therapy; esophageal squamous cell carcinoma; tislelizumab; protocol	CANCER; SURGERY; CHINA	BackgroundEsophageal squamous cell carcinoma (ESCC) remains a challenging malignant tumor with poor prognosis and limited treatment methods worldwide, and most patients are at a locally advanced stage at diagnosis. High recurrence and metastasis rates remain the main factors leading to the failure of the current standard treatment of neoadjuvant chemoradiotherapy plus surgery for resectable locally advanced ESCC. Improving the pathological complete response (pCR) rate may significantly benefit the survival of patients with resectable locally advanced ESCC after neoadjuvant therapy. MethodsTislelizumab plus sequential neoadjuvant chemotherapy was administered to non-clinical complete response (cCR) patients after neoadjuvant chemoradiotherapy for locally advanced ESCC. The patients then received surgery and adjuvant therapy according to the postoperative pathological results. Eighty patients with locally advanced ESCC were recruited for the study. The primary outcomes of the pCR rate and the incidence of adverse events will be analyzed completely within 24 months, and the secondary endpoints will include cCR rate, major pathological response rate, objective response rate, R0 resection rate, event-free survival, and overall survival. DiscussionThis study explored the safety and efficacy of tislelizumab plus chemotherapy sequential neoadjuvant therapy for non-cCR patients and provided a total neoadjuvant therapy model that can benefit patients with locally advanced ESCC.	[He, Wenwu; Wang, Chenghao; Han, Yongtao; Li, Haojun; Leng, Xuefeng; Du, Kunyi; Peng, Lin] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China; [Wu, Lei; Wan, Gang; Li, Baisen; Wang, Qifeng] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China; [Chen, Haijun] BeiGene Beijing Co Ltd, Dept Med Affairs, Beijing, Peoples R China	University of Electronic Science & Technology of China; University of Electronic Science & Technology of China	Peng, L (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China.; Wang, QF (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Sch Med, Chengdu, Peoples R China.	littlecancer@163.com; penglinms@126.com						Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Arnold M, 2020, GASTROENTEROLOGY, V159, P335, DOI 10.1053/j.gastro.2020.02.068; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cercek A, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0071; Chan AW, 2013, ANN INTERN MED, V158, P200, DOI 10.7326/0003-4819-158-3-201302050-00583; Chen Ru, 2019, Zhonghua Yufang Yixue Zazhi, V53, P1094, DOI 10.3760/cma.j.issn.0253-9624.2019.11.004; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Eyck B, 2021, J CLIN ONCOL, V39, P1995, DOI 10.1200/JCO.20.03614; Kasi A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.30097; Kato K, 2019, LANCET ONCOL, V20, P1506, DOI 10.1016/S1470-2045(19)30626-6; Kelly RJ, 2021, NEW ENGL J MED, V384, P1191, DOI 10.1056/NEJMoa2032125; Kelly RJ, 2018, ANN SURG, V268, P992, DOI 10.1097/SLA.0000000000002410; Kesler KA, 2005, ANN THORAC SURG, V79, P1116, DOI 10.1016/j.athoracsur.2004.08.042; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Ludmir EB, 2017, CANCER-AM CANCER SOC, V123, P1497, DOI 10.1002/cncr.30600; Petrelli F, 2020, ANN SURG, V271, P440, DOI 10.1097/SLA.0000000000003471; Satoh T, 2021, ESOPHAGUS-TOKYO, V18, P835, DOI 10.1007/s10388-021-00850-0; Shah MA, 2019, JAMA ONCOL, V5, P546, DOI 10.1001/jamaoncol.2018.5441; Shen JF, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3331; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yang H, 2021, JAMA SURG, V156, P721, DOI 10.1001/jamasurg.2021.2373; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Zheng Y, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5404	24	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								853922	10.3389/fimmu.2022.853922	http://dx.doi.org/10.3389/fimmu.2022.853922			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E1JM	35720312	Green Published, gold			2022-12-18	WOS:000811989800001
J	Im, Y; Park, SE; Lee, SY; Kim, JC; Kim, JS				Im, Yeram; Park, So-Eun; Lee, Sue Yeon; Kim, Jong-Cheol; Kim, Jae Su			Early-Stage Defense Mechanism of the Cotton Aphid Aphis gossypii Against Infection With the Insect-Killing Fungus Beauveria bassiana JEF-544	FRONTIERS IN IMMUNOLOGY			English	Article						Aphis gossypii; cotton aphid; Beauveria bassiana; transcriptome; ecdysone	GLOVER HEMIPTERA; RESISTANCE; HOMOPTERA; HORMONE; MELANIZATION; HEMOCYTES; RECEPTOR; CASCADE; GENE	Aphis gossypii, commonly known as the cotton aphid, is a widely distributed pest of agricultural crops and acts as a vector for many serious plant viruses. Cotton aphid shows high resistance to chemical insecticides due to rapid rates of genetic diversity as a result of its short life cycle, seasonal migration, and host alteration. As an alternative, entomopathogenic fungi can be used to control cotton aphids in an environmentally sound manner. However, little is known about how cotton aphids respond to fungal infection. In this work, a new Beauveria bassiana strain JEF-544 (Bb JEF-544) was selected and isolated through bioassays with high virulence against cotton aphid. Early response of cotton aphid to Bb JEF-544 infection was analyzed at the transcriptome level. Infected aphids were collected two days after treatment at 25% lethal time (LT25), and total RNA of non-infected and Bb JEF-544-infected aphids was independently subjected to sequencing. Infected aphids showed significant up-regulation of the insect hormone biosynthesis pathway. Bursicon (Burs) and crustacean cardioactive peptide (CCAP) receptors involved in molting along with ecdysone synthesis were also strongly up-regulated in the aphid response to the fungal infection. In the immune response, melanization in the hemocoel was significantly up-regulated, while phagocytosis was less actively transcribed. In conclusion, cotton aphids protect themselves from Bb JEF-544 infection by activating the immune response including melanization and insect molting hormones to shed infected cuticles. In addition to describing the initial stages of Bb JEF-544 infection at the transcriptome level, this work provides potential treatment targets and insight into how fungal isolates can effectively be used to control this serious aphid species.	[Im, Yeram; Park, So-Eun; Lee, Sue Yeon; Kim, Jong-Cheol; Kim, Jae Su] Jeonbuk Natl Univ, Coll Agr & Life Sci, Dept Agr Biol, Jeonju, South Korea; [Kim, Jae Su] Jeonbuk Natl Univ, Dept Agr Convergence Technol, Jeonju, South Korea	Jeonbuk National University; Jeonbuk National University	Kim, JS (corresponding author), Jeonbuk Natl Univ, Coll Agr & Life Sci, Dept Agr Biol, Jeonju, South Korea.; Kim, JS (corresponding author), Jeonbuk Natl Univ, Dept Agr Convergence Technol, Jeonju, South Korea.	jskim10@jbnu.ac.kr						Abdel-Raheem M., 2020, PLANT ARCH, V20, P479; Abdel-Raheem M, 2019, PLANT ARCH, V19, P1061; Abdel-Raheem M. A., 2021, Romanian Biotechnological Letters, V26, P2862, DOI 10.25083/rbl/26.4/2862-2868; Abdel-Raheem MA, 2019, EGYPT J BIOL PEST CO, V29, DOI 10.1186/s41938-019-0200-2; Abdullah-Zawawi MR, 2021, REV AQUACULT, V13, P1938, DOI 10.1111/raq.12552; AKEY DH, 1989, SOUTHWEST ENTOMOL, V14, P295; Akmal M, 2013, PAK J ZOOL, V45, P71; Amnuaykanjanasin A, 2013, BIOCONTROL, V58, P379, DOI 10.1007/s10526-012-9499-2; An SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034510; Andrews S., 2010, FASTQC QUALITY CONTR; Basu M., 2007, Journal of Plant Protection and Environment, V4, P74; Bidochka MJ, 2010, MICROBIOL-SGM, V156, P2164, DOI 10.1099/mic.0.038216-0; Blackman R. L., 2000, Aphids on the world's crops: an identification and information guide.; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560; Choo YM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010393; Davis MM, 2007, DEVELOPMENT, V134, P4395, DOI 10.1242/dev.009902; Dong YM, 2006, PLOS BIOL, V4, P1137, DOI 10.1371/journal.pbio.0040229; Ebert TA, 1997, SOUTHWEST ENTOMOL, V22, P116; Gerardo NM, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r21; Graham J, 1968, PRINCIPLES CROWDING; GULDEMOND JA, 1994, ENVIRON ENTOMOL, V23, P1235, DOI 10.1093/ee/23.5.1235; Herron G, 2000, AUST J ENTOMOL, V39, P33, DOI 10.1046/j.1440-6055.2000.00134.x; Herron GA, 2001, AUST J ENTOMOL, V40, P85, DOI 10.1046/j.1440-6055.2001.00200.x; Hillyer JF, 2003, J PARASITOL, V89, P62, DOI 10.1645/0022-3395(2003)089[0062:RPAMOB]2.0.CO;2; Hillyer JF, 2010, ADV EXP MED BIOL, V708, P218; Honegger HW, 2008, J COMP PHYSIOL A, V194, P989, DOI 10.1007/s00359-008-0386-3; Kennedy J. S., 1962, A conspectus of aphids as vectors of plant viruses; Kim JC, 2018, J ASIA-PAC ENTOMOL, V21, P196, DOI 10.1016/j.aspen.2017.11.018; Kim JC, 2021, J FUNGI, V7, DOI 10.3390/jof7050373; KRING JAMES B., 1959, ANN ENT SOC AMER, V52, P284, DOI 10.1093/aesa/52.3.284; Laughton AM, 2011, J INSECT PHYSIOL, V57, P830, DOI 10.1016/j.jinsphys.2011.03.015; Lee MR, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.643389; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Ma KS, 2016, J INSECT SCI, V16, DOI 10.1093/jisesa/iew003; Ma L, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008627; Mahmood Z, 2019, BIOL CONTROL, V137, DOI 10.1016/j.biocontrol.2019.104017; Moores G., 1988, BRIGHTON CROP PROTEC; Nassel DR, 2020, CELL TISSUE RES, V382, P233, DOI 10.1007/s00441-020-03264-z; Ogawa K, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00001; Puthumana J, 2017, COMP BIOCHEM PHYS C, V192, P7, DOI 10.1016/j.cbpc.2016.11.002; Qu S, 2018, DEV COMP IMMUNOL, V83, P96, DOI 10.1016/j.dci.2018.01.010; Quan QM, 2019, INSECT BIOCHEM MOLEC, V105, P25, DOI 10.1016/j.ibmb.2018.12.007; Rosales C ., 2017, INSECT PHYSL ECOLOGY, DOI [10.5772/67107, DOI 10.5772/67107]; Saito T, 2000, APPL ENTOMOL ZOOL, V35, P171, DOI 10.1303/aez.2000.171; Shang QL, 2012, CROP PROT, V31, P15, DOI 10.1016/j.cropro.2011.09.014; Shi Y, 2022, J INSECT PHYSIOL, V137, DOI 10.1016/j.jinsphys.2022.104364; SHIM J Y, 1979, Korean Journal of Plant Protection, V18, P85; Shin TY, 2020, ARCH INSECT BIOCHEM, V105, DOI 10.1002/arch.21747; Sigle LT, 2016, DEV COMP IMMUNOL, V55, P90, DOI 10.1016/j.dci.2015.10.018; TAKADA H, 1988, J APPL ENTOMOL, V106, P188, DOI 10.1111/j.1439-0418.1988.tb00582.x; Tanada Y., 2012, INSECT PATHOLOGY; Tang HP, 2006, J BIOL CHEM, V281, P28097, DOI 10.1074/jbc.M601642200; Truman JW, 2005, VITAM HORM, V73, P1, DOI 10.1016/S0083-6729(05)73001-6; Ullah S, 2022, EGYPT J BIOL PEST CO, V32, DOI 10.1186/s41938-021-00500-8; Wang HY, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.705343; Wang JH, 2018, PEST MANAG SCI, V74, P1677, DOI 10.1002/ps.4861; Wang KY, 2002, J ECON ENTOMOL, V95, P407, DOI 10.1603/0022-0493-95.2.407; Xu L, 2019, INSECT MOL BIOL, V28, P176, DOI 10.1111/imb.12536; Yu SJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162659; Zhu YP, 2008, BRAZ J MICROBIOL, V39, P314, DOI [10.1590/S1517-83822008000200022, 10.1590/S1517-838220080002000022]; Zitnan D, 1999, NEURON, V23, P523, DOI 10.1016/S0896-6273(00)80805-3	62	0	0	16	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								907088	10.3389/fimmu.2022.907088	http://dx.doi.org/10.3389/fimmu.2022.907088			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D9GU	35720408	Green Published, gold			2022-12-18	WOS:000811847100001
J	Khan, SR; Vanoverschelde, A; Lahousse, L; Peeters, RP; van Hagen, PM; Brusselle, G; Chaker, L; Dalm, VASH				Khan, Samer R.; Vanoverschelde, Anna; Lahousse, Lies; Peeters, Robin P.; van Hagen, P. Martin; Brusselle, Guy; Chaker, Layal; Dalm, Virgil A. S. H.			Serum Immunoglobulins, Pneumonia Risk, and Lung Function in Middle-Aged and Older Individuals: A Population-Based Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						pneumonia; immunoglobulin A; immunoglobulin G; immunoglobulin M; pulmonary ventilation	INTRAVENOUS IMMUNOGLOBULIN; INFLAMMATION; HOSPITALIZATION; PREVENTION; SPIROMETRY; MORTALITY; EFFICACY; COPD	IntroductionImmunoglobulins (Igs) play a pivotal role in host defense and prevention of pneumonia. Aging influences serum Ig levels, but the association between Igs and pneumonia in community-dwelling older individuals remains unknown. We evaluated the association of serum IgA, IgG, and IgM with pneumonia and lung function in middle-aged and older individuals. MethodsWe performed Cox and negative binomial regression analyses for the association of Igs with incident pneumonia and pneumonia-related mortality, and recurrent pneumonia respectively. We performed logistic regression analyses for the association between Igs and lung function values. Associations were adjusted for age, sex, smoking, comorbidities, and serum C-reactive protein. ResultsWe included 8,766 participants (median age 62.2 years, 57% women, median follow-up 9.8 years). Higher IgA (hazard ratio [HR]: 1.15; 95% confidence interval [95% CI]: 1.00-1.32) and IgG (HR: 1.13; 95% CI: 1.06-1.19) were associated with an increased pneumonia risk. Higher IgG was associated with an increased risk of pneumonia-related mortality (HR: 1.08; 95% CI: 1.01-1.16) and recurrent pneumonia (incidence rate ratio: 1.04; 95% CI: 1.00-1.09). Higher IgA and IgG were also associated with lower forced expiratory volume in one second (FEV1), lower forced vital capacity (FVC), and an increased odds of preserved ratio impaired spirometry (PRISm, i.e. FEV1 <80% and FEV1/FVC ratio >= 70%). No association was seen with an obstructive spirometry pattern. DiscussionHigher serum IgA and IgG levels were associated with pneumonia, pneumonia-related mortality, and PRISm in middle-aged and older individuals from the general population. Future studies should validate our findings and elucidate underlying pathophysiology.	[Khan, Samer R.; van Hagen, P. Martin; Dalm, Virgil A. S. H.] Erasmus MC, Dept Internal Med, Div Allergy & Clin Immunol, Rotterdam, Netherlands; [Khan, Samer R.; Vanoverschelde, Anna; Lahousse, Lies; Peeters, Robin P.; Brusselle, Guy; Chaker, Layal] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands; [Vanoverschelde, Anna; Lahousse, Lies] Univ Ghent, Dept Bioanal, Pharmaceut Care Unit, Ghent, Belgium; [Peeters, Robin P.; Chaker, Layal] Erasmus MC, Dept Internal Med, Div Endocrinol, Rotterdam, Netherlands; [van Hagen, P. Martin; Dalm, Virgil A. S. H.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands; [Brusselle, Guy] Ghent Univ Hosp, Dept Resp Med, Ghent, Belgium; [Brusselle, Guy] Erasmus MC, Dept Resp Med, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Ghent University; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Ghent University; Ghent University Hospital; Erasmus University Rotterdam; Erasmus MC	Dalm, VASH (corresponding author), Erasmus MC, Dept Internal Med, Div Allergy & Clin Immunol, Rotterdam, Netherlands.; Dalm, VASH (corresponding author), Erasmus MC, Dept Immunol, Rotterdam, Netherlands.	v.dalm@erasmusmc.nl			Takeda Pharmaceutical Company Limited [IIR-NLD-002671]; Erasmus Medical Center, Erasmus University Rotterdam; Netherlands Organization for Scientific Research (NWO); Netherlands Organisation for Health Research and Development (ZonMw); Netherlands Heart Foundation; Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative (NGI); Ministry of Education, Culture and Science; Ministry of Health Welfare and Sports; European Commission (DG XII); Municipality of Rotterdam; Fund for Scientific Research Flanders [3G037618]	Takeda Pharmaceutical Company Limited(Takeda Pharmaceutical Company Ltd); Erasmus Medical Center, Erasmus University Rotterdam; Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); Netherlands Organisation for Health Research and Development (ZonMw)(Netherlands Organization for Health Research and Development); Netherlands Heart Foundation(Netherlands Heart Foundation); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative (NGI); Ministry of Education, Culture and Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health Welfare and Sports; European Commission (DG XII)(European CommissionEuropean Commission Joint Research Centre); Municipality of Rotterdam; Fund for Scientific Research Flanders(FWO)	This work was supported by Takeda Pharmaceutical Company Limited [grant number IIR-NLD-002671 to V.A.S.H. Dalm]. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. The Rotterdam Study was supported by the Erasmus Medical Center, Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organisation for Health Research and Development (ZonMw), the Netherlands Heart Foundation, the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Genomics Initiative (NGI), the Ministry of Education, Culture and Science; the Ministry of Health Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. Lung research was financially supported by the Fund for Scientific Research Flanders [grant number 3G037618].	Aghamohammadi A, 2004, FEMS IMMUNOL MED MIC, V40, P113, DOI 10.1016/S0928-8244(03)00304-3; Boyd AR, 2011, AGING DIS, V2, P487; Brandenberger C, 2017, CELL TISSUE RES, V367, P469, DOI 10.1007/s00441-016-2511-x; BURNETT D, 1986, THORAX, V41, P337, DOI 10.1136/thx.41.5.337; Busse PJ, 2002, J ALLERGY CLIN IMMUN, V109, P1001, DOI 10.1067/mai.2002.124999; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Chen Y, 2011, J ALLERGY CLIN IMMUN, V127, P1414, DOI 10.1016/j.jaci.2011.03.041; de la Torre MC, 2016, BMJ OPEN RESPIR RES, V3, DOI 10.1136/bmjresp-2016-000152; de la Torre MC, 2013, RESP MED, V107, P2038, DOI 10.1016/j.rmed.2013.09.005; Demirdag YY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.634181; Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4; Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057; Herriot R, 2008, J CLIN PATHOL, V61, P994, DOI 10.1136/jcp.2007.051177; Hinojosa E, 2009, J INFECT DIS, V200, P546, DOI 10.1086/600870; Ikram MA, 2020, EUR J EPIDEMIOL, V35, P483, DOI 10.1007/s10654-020-00640-5; Khan SR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664526; Khan SR, 2021, J CLIN IMMUNOL, V41, P1902, DOI 10.1007/s10875-021-01120-5; Kristic J, 2014, J GERONTOL A-BIOL, V69, P779, DOI 10.1093/gerona/glt190; Kristinsson SY, 2012, HAEMATOL-HEMATOL J, V97, P854, DOI 10.3324/haematol.2011.054015; Langan RC, 2020, AM FAM PHYSICIAN, V101, P362; Lee H, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-60; Leitao FS, 2020, CHEST, V158, P1420, DOI 10.1016/j.chest.2020.04.058; Liapikou A, 2018, EXPERT OPIN DRUG SAF, V17, P991, DOI 10.1080/14740338.2018.1519545; Lipinski JH, 2020, AM J PHYSIOL-LUNG C, V319, pL675, DOI 10.1152/ajplung.00258.2020; Luchsinger V, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000022390; Meyer KC, 1996, AM J RESP CRIT CARE, V153, P1072, DOI 10.1164/ajrccm.153.3.8630547; Mizgerd JP, 2018, CLIN CHEST MED, V39, P669, DOI 10.1016/j.ccm.2018.07.002; Nunez B, 2011, AM J RESP CRIT CARE, V183, P1025, DOI 10.1164/rccm.201001-0029OC; Orange JS, 2010, CLIN IMMUNOL, V137, P21, DOI 10.1016/j.clim.2010.06.012; Patel SY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00033; Phillips AC, 2015, J EPIDEMIOL COMMUN H, V69, P129, DOI 10.1136/jech-2014-204345; Puchta A, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005368; Putcha N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194924; Quinton LJ, 2018, PHYSIOL REV, V98, P1417, DOI 10.1152/physrev.00032.2017; Rich AL, 2008, CLIN EXP IMMUNOL, V151, P110, DOI 10.1111/j.1365-2249.2007.03550.x; Romero-Steiner S, 1999, CLIN INFECT DIS, V29, P281, DOI 10.1086/520200; Saito A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082460; SCHONELL ME, 1971, CLIN EXP IMMUNOL, V8, P63; Seth S, 2020, CURR HEMATOL MALIG R, V15, P45, DOI 10.1007/s11899-020-00569-2; Siljan WW, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy002; Skloot GS, 2017, CLIN GERIATR MED, V33, P447, DOI 10.1016/j.cger.2017.06.001; SNAPPER CM, 1993, IMMUNOL TODAY, V14, P15, DOI 10.1016/0167-5699(93)90318-F; Torres A, 2013, THORAX, V68, P1057, DOI 10.1136/thoraxjnl-2013-204282; Wijnant SRA, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01217-2019; Yende S, 2005, AM J RESP CRIT CARE, V172, P1440, DOI 10.1164/rccm.200506-888OC; Zhao EJ, 2021, LANCET HAEMATOL, V8, pE365, DOI 10.1016/S2352-3026(21)00056-9	46	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								868973	10.3389/fimmu.2022.868973	http://dx.doi.org/10.3389/fimmu.2022.868973			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2I1MC	35757724	Green Published, gold			2022-12-18	WOS:000814746600001
J	Leonel, TB; Gabrili, JJM; Squaiella-Baptistao, CC; Woodruff, TM; Lambris, JD; Tambourgi, DV				Leonel, Thyago Bispo; Gabrili, Joel Jose Megale; Squaiella-Baptistao, Carla Cristina; Woodruff, Trent M.; Lambris, John D.; Tambourgi, Denise V.			Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System	FRONTIERS IN IMMUNOLOGY			English	Article						human whole blood; inflammation; complement system and inhibitors; Bothrops jararaca; snake venom	C5A RECEPTOR ANTAGONIST; RAT MODEL; COMBINED INHIBITION; OXIDATIVE BURST; IMMUNE-RESPONSE; INNATE IMMUNITY; TNF-ALPHA; IN-VITRO; CELLS; CD14	The clinical manifestations of envenomation by Bothrops species are complex and characterized by prominent local effects that can progress to tissue loss, physical disability, or amputation. Systemic signs can also occur, such as hemorrhage, coagulopathy, shock, and acute kidney failure. The rapid development of local clinical manifestations is accompanied by the presence of mediators of the inflammatory process originating from tissues damaged by the bothropic venom. Considering the important role that the complement system plays in the inflammatory response, in this study, we analyzed the action of Bothrops jararaca snake venom on the complement system and cell surface receptors involved in innate immunity using an ex vivo human whole blood model. B. jararaca venom was able to induce activation of the complement system in the human whole blood model and promoted a significant increase in the production of anaphylatoxins C3a/C3a-desArg, C4a/C4a-desArg, C5a/C5a-desArg and sTCC. In leukocytes, the venom of B. jararaca reduced the expression of CD11b, CD14 and C5aR1. Inhibition of the C3 component by Cp40, an inhibitor of C3, resulted in a reduction of C3a/C3a-desArg, C5a/C5a-desArg and sTCC to basal levels in samples stimulated with the venom. Exposure to B. jararaca venom induced the production of inflammatory cytokines and chemokines such as TNF-alpha, IL-8/CXCL8, MCP-1/CCL2 and MIG/CXCL9 in the human whole blood model. Treatment with Cp40 promoted a significant reduction in the production of TNF-alpha, IL-8/CXCL8 and MCP-1/CCL2. C5aR1 inhibition with PMX205 also promoted a reduction of TNF-alpha and IL-8/CXCL8 to basal levels in the samples stimulated with venom. In conclusion, the data presented here suggest that the activation of the complement system promoted by the venom of the snake B. jararaca in the human whole blood model significantly contributes to the inflammatory process. The control of several inflammatory parameters using Cp40, an inhibitor of the C3 component, and PMX205, a C5aR1 antagonist, indicates that complement inhibition may represent a potential therapeutic tool in B. jararaca envenoming.	[Leonel, Thyago Bispo; Gabrili, Joel Jose Megale; Squaiella-Baptistao, Carla Cristina; Tambourgi, Denise V.] Inst Butantan, Immunochemistry Lab, Sao Paulo, Brazil; [Woodruff, Trent M.] Univ Queensland, Fac Med, Sch Biomed Sci, St Lucia, Qld, Australia; [Lambris, John D.] Univ Penn, Perelman Sch Med, Dept Pathol, Lab Med, Philadelphia, PA USA	Instituto Butantan; University of Queensland; University of Pennsylvania; Pennsylvania Medicine	Tambourgi, DV (corresponding author), Inst Butantan, Immunochemistry Lab, Sao Paulo, Brazil.	denise.tambourgi@butantan.gov.br	Instituto Butantan, Center of Toxins Immune Response and Cell Signaling CeTICS/J-5731-2015		Sao Paulo Research Foundation (FAPESP) [2013/07467-1]; CNPq	Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by Sao Paulo Research Foundation (FAPESP) funding to the Center of Toxins, Immune Response and Cell Signaling (CeTICS) [grant 2013/07467-1]. DVT is a recipient of the CNPq Research Productivity Fellowship. The funding agencies had no influence on study design, data interpretation or formation of the manuscript.	Arborea G, 2017, MOL IMMUNOL, V89, P2, DOI 10.1016/j.molimm.2017.05.012; Avila-Aguero ML, 2001, PEDIATR EMERG CARE, V17, P425, DOI 10.1097/00006565-200112000-00006; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Beck KD, 2010, BRAIN, V133, P433, DOI 10.1093/brain/awp322; Bexborn F, 2009, J BIOMED MATER RES A, V89A, P951, DOI 10.1002/jbm.a.32034; Bradley JR, 2008, J PATHOL, V214, P149, DOI 10.1002/path.2287; Brekke OL, 2008, MOL IMMUNOL, V45, P3804, DOI 10.1016/j.molimm.2008.05.017; Brekke OL, 2007, J LEUKOCYTE BIOL, V81, P1404, DOI 10.1189/jlb.0806538; Butantan-British IBothrops/I Systematics Project, 2002, P111; Carballido DM, 2006, CHEM IMMUNOL ALLERGY, V91, P147; CARDOSO J.L.C., 2003, Rev. Inst. Med. trop. S. Paulo, V45, P338; Chippaux JP, 2017, J VENOM ANIM TOXINS, V23, DOI 10.1186/s40409-017-0127-6; Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515; Costa EP, 2002, INFLAMMATION, V26, P13, DOI 10.1023/A:1014465611487; da Silva Wilmar Dias, 2011, Inflammation & Allergy Drug Targets, V10, P343; Delafontaine M, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3462136; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Dobrina A, 2002, BLOOD, V99, P185, DOI 10.1182/blood.V99.1.185; Farsky SHP, 1997, TOXICON, V35, P185, DOI 10.1016/S0041-0101(96)00135-3; Farsky SHP, 2000, MEDIAT INFLAMM, V9, P213, DOI 10.1080/09629350020025728; Fernandes CM, 2006, TOXICON, V47, P549, DOI 10.1016/j.toxicon.2006.01.009; Fonseca MI, 2009, J IMMUNOL, V183, P1375, DOI 10.4049/jimmunol.0901005; Freitas AP, 2021, IMMUNOL LETT, V240, P56, DOI 10.1016/j.imlet.2021.09.012; FURLAN M, 1983, BIOCHIM BIOPHYS ACTA, V742, P25, DOI 10.1016/0167-4838(83)90354-0; Luchini LSG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01137; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Guo RF, 2003, FASEB J, V17, P1889, DOI 10.1096/fj.03-0009fje; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Gustavsen A, 2016, J INFECT DIS, V214, P140, DOI 10.1093/infdis/jiw100; GUTIERREZ JM, 1986, REV BIOL TROP, V34, P209; Gutierrez JM, 2000, BIOCHIMIE, V82, P841, DOI 10.1016/S0300-9084(00)01163-9; Gutierrez JM, 2017, NAT REV DIS PRIMERS, V3, DOI [10.1038/nrdp.2017.79, 10.1038/nrdp.2017.63]; Hajishengallis G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00406; Hajishengallis G, 2016, IMMUNOL REV, V274, P233, DOI 10.1111/imr.12467; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Hardison JL, 2006, INFECT IMMUN, V74, P125, DOI 10.1128/IAI.74.1.125-134.2006; Hasturk H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI152973; Hawksworth OA, 2017, MOL IMMUNOL, V89, P36, DOI 10.1016/j.molimm.2017.05.015; Huber-Lang MS, 2002, FASEB J, V16, P1567, DOI 10.1096/fj.02-0209com; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Johnson C, 2018, MOL IMMUNOL, V102, P167, DOI 10.1016/j.molimm.2018.06.106; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Lappegard KT, 2009, P NATL ACAD SCI USA, V106, P15861, DOI 10.1073/pnas.0903613106; Lau C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117261; Manthey HD, 2009, INT J BIOCHEM CELL B, V41, P2114, DOI 10.1016/j.biocel.2009.04.005; Manzoni-de-Almeida D, 2018, MOL IMMUNOL, V94, P45, DOI 10.1016/j.molimm.2017.12.009; Markland FS, 1998, TOXICON, V36, P1749, DOI 10.1016/S0041-0101(98)00126-3; Mastellos DC, 2020, CLIN IMMUNOL, V220, DOI 10.1016/j.clim.2020.108598; Mastellos DC, 2015, EUR J CLIN INVEST, V45, P423, DOI 10.1111/eci.12419; Mastellos DC, 2014, EXPERT REV HEMATOL, V7, P583, DOI 10.1586/17474086.2014.953926; Matsukawa A, 2000, Rev Immunogenet, V2, P339; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Miyata R, 1999, J LEUKOCYTE BIOL, V66, P437, DOI 10.1002/jlb.66.3.437; Mollnes TE, 2002, BLOOD, V100, P1869; Monsinjon T, 2003, FASEB J, V17, P1003, DOI 10.1096/fj.02-0737com; Moreira V, 2012, TOXICON, V60, P12, DOI 10.1016/j.toxicon.2012.03.004; Otero R, 2002, TOXICON, V40, P1107, DOI 10.1016/S0041-0101(02)00104-6; Park MK, 2002, J IMMUNOL, V169, P1433, DOI 10.4049/jimmunol.169.3.1433; Patterson S, 2005, J IMMUNOL, V174, P8200, DOI 10.4049/jimmunol.174.12.8200; Pidde-Queiroz G, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002519; Pidde-Queiroz G, 2010, MOL IMMUNOL, V47, P2537, DOI 10.1016/j.molimm.2010.07.003; Pratt KP, 1997, P NATL ACAD SCI USA, V94, P7176, DOI 10.1073/pnas.94.14.7176; Qu HC, 2013, IMMUNOBIOLOGY, V218, P496, DOI 10.1016/j.imbio.2012.06.003; Reis ES, 2019, NAT REV IMMUNOL, V19, P503, DOI 10.1038/s41577-019-0168-x; Reis ES, 2015, IMMUNOBIOLOGY, V220, P476, DOI 10.1016/j.imbio.2014.10.026; Ribeiro L A, 1997, Rev Soc Bras Med Trop, V30, P475, DOI 10.1590/S0037-86821997000600006; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rosenfeld G., 1971, VENOMOUS ANIMALS THE, P687, DOI DOI 10.1016/B978-0-12-138902-4.50021-0; Russo RC, 2014, EXPERT REV CLIN IMMU, V10, P593, DOI 10.1586/1744666X.2014.894886; Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0; Serrano SMT, 2005, TOXICON, V45, P1115, DOI 10.1016/j.toxicon.2005.02.020; de Franca FS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652242; Tambourgi DV, 2014, MOL IMMUNOL, V61, P153, DOI 10.1016/j.molimm.2014.06.020; Tedesco F, 1997, J EXP MED, V185, P1619, DOI 10.1084/jem.185.9.1619; Teixeira C, 2009, TOXICON, V54, P67, DOI 10.1016/j.toxicon.2009.03.019; Ullah A, 2018, INT J BIOL MACROMOL, V114, P788, DOI 10.1016/j.ijbiomac.2018.03.164; van den Berg CW, 2014, J IMMUNOL, V192, P1787, DOI 10.4049/jimmunol.1301920; van Griensven M, 2019, SHOCK, V51, P78, DOI 10.1097/SHK.0000000000001127; Waters JP, 2013, J PATHOL, V230, P132, DOI 10.1002/path.4187; Woodruff TM, 2005, J PHARMACOL EXP THER, V314, P811, DOI 10.1124/jpet.105.086835; Woodruff TM, 2004, J SURG RES, V116, P81, DOI 10.1016/j.jss.2003.04.001; Woodruff TM, 2003, J IMMUNOL, V171, P5514, DOI 10.4049/jimmunol.171.10.5514; Woodruff TM, 2002, ARTHRITIS RHEUM-US, V46, P2476, DOI 10.1002/art.10449; Woodruff TM, 2006, FASEB J, V20, P1407, DOI 10.1096/fj.05-5814com; Woodruff TM, 2010, NEUROMOL MED, V12, P179, DOI 10.1007/s12017-009-8085-y; World Health Organization, 2019, SNAK ENV STRAT PREV; Zhang XH, 2007, BLOOD, V110, P228, DOI 10.1182/blood-2006-12-063636	90	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								885223	10.3389/fimmu.2022.885223	http://dx.doi.org/10.3389/fimmu.2022.885223			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E2KO	35720304	Green Published, gold			2022-12-18	WOS:000812060400001
J	Liang, GB; He, ZH				Liang, Guibin; He, Zhihui			High Mobility Group Proteins in Sepsis	FRONTIERS IN IMMUNOLOGY			English	Review						high mobility group; protein; sepsis; non-coding RNAs; programmed cell death; drugs	GROUP BOX 1; INHIBITS HMGB1 RELEASE; SINGLE NUCLEOTIDE POLYMORPHISMS; NUCLEOSOMAL BINDING-PROTEIN; ACUTE LUNG INJURY; RAW 264.7 CELLS; NONCODING RNA; KAPPA-B; AMELIORATES SEPSIS; ENDOTHELIAL-CELLS	Sepsis, a systemic inflammatory response disease, is the most severe complication of infection and a deadly disease. High mobility group proteins (HMGs) are non-histone nuclear proteins binding nucleosomes and regulate chromosome architecture and gene transcription, which act as a potent pro-inflammatory cytokine involved in the delayed endotoxin lethality and systemic inflammatory response. HMGs increase in serum and tissues during infection, especially in sepsis. A growing number of studies have demonstrated HMGs are not only cytokines which can mediate inflammation, but also potential therapeutic targets in sepsis. To reduce sepsis-related mortality, a better understanding of HMGs is essential. In this review, we described the structure and function of HMGs, summarized the definition, epidemiology and pathophysiology of sepsis, and discussed the HMGs-related mechanisms in sepsis from the perspectives of non-coding RNAs (microRNA, long non-coding RNA, circular RNA), programmed cell death (apoptosis, necroptosis and pyroptosis), drugs and other pathophysiological aspects to provide new targets and ideas for the diagnosis and treatment of sepsis.	[Liang, Guibin; He, Zhihui] Cent South Univ, Xiangya Hosp 3, Dept Crit Care Med, Changsha, Peoples R China	Central South University	He, ZH (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Crit Care Med, Changsha, Peoples R China.	hzh703@csu.edu.cn			Natural Science Foundation of Hunan Province [2021JJ31005]	Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province)	Funding The work was supported by the Natural Science Foundation of Hunan Province (2021JJ31005).	Abraham AB, 2013, PROTEOME SCI, V11, DOI 10.1186/1477-5956-11-18; Agaimy A, 2022, AM J SURG PATHOL, V46, P190, DOI 10.1097/PAS.0000000000001783; Amanzadeh E, 2014, APPL BIOCHEM BIOTECH, V174, P437, DOI 10.1007/s12010-014-0926-y; Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Andersson U, 2018, SEMIN IMMUNOL, V38, P40, DOI 10.1016/j.smim.2018.02.011; Angus DC, 2000, JAMA-J AM MED ASSOC, V283, P1723, DOI 10.1001/jama.283.13.1723; Barile L, 2017, PHARMACOL THERAPEUT, V174, P63, DOI 10.1016/j.pharmthera.2017.02.020; Baron RM, 2018, J LEUKOCYTE BIOL, V104, P677, DOI 10.1002/JLB.4HI0817-333RR; Bi XW, 2021, TOXICOL APPL PHARM, V433, DOI 10.1016/j.taap.2021.115778; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007; Birger Y, 2001, DNA CELL BIOL, V20, P257; Cai ZL, 2020, INT J BIOL SCI, V16, P1798, DOI 10.7150/ijbs.39947; Calis J, 2013, NEW ENGL J MED, V369, P2062, DOI [10.1056/NEJMc1312359, 10.1056/NEJMra1208623]; Cao C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2015-1; Catena R, 2009, BIOL REPROD, V80, P358, DOI 10.1095/biolreprod.108.070243; Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2; Chan JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051310; Chang KC, 2015, THROMB RES, V136, P456, DOI 10.1016/j.thromres.2015.06.017; Chen HM, 2014, AM J CHINESE MED, V42, P785, DOI 10.1142/S0192415X14500505; Chen J, 2018, J IMMUNOTHER, V41, P118, DOI 10.1097/CJI.0000000000000211; Chen LF, 2020, INFLAMMATION, V43, P2075, DOI 10.1007/s10753-020-01275-0; Chen RC, 2022, EXP MOL MED, V54, P91, DOI 10.1038/s12276-022-00736-w; Chen SG, 2016, AM J THER, V23, pE1819, DOI 10.1097/MJT.0000000000000296; Chen S, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00433; Chen WW, 2017, EXP CELL RES, V350, P318, DOI 10.1016/j.yexcr.2016.12.008; Cheng ZX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01918; Condrat CE, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020276; Cui W, 2021, FUTURE ONCOL, V17, P541, DOI 10.2217/fon-2020-0555; Cui WJ, 2019, MED SCI MONITOR, V25, P5795, DOI 10.12659/MSM.916044; Cui YZ, 2021, NATURE, V593, P602, DOI 10.1038/s41586-021-03524-0; Deng MH, 2018, IMMUNITY, V49, P740, DOI 10.1016/j.immuni.2018.08.016; Denning NL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02536; Fan B, 2019, ONCOL LETT, V17, P1160, DOI 10.3892/ol.2018.9668; Fan YH, 2022, BMC INFECT DIS, V22, DOI 10.1186/s12879-022-07056-4; Fernandez-Diaz D, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.842509; Fleischmann C, 2016, AM J RESP CRIT CARE, V193, P259, DOI 10.1164/rccm.201504-0781OC; Foretz M, 2019, NAT REV ENDOCRINOL, V15, P569, DOI 10.1038/s41574-019-0242-2; Foti D, 2005, NAT MED, V11, P765, DOI 10.1038/nm1254; Gao HF, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20201738; Gauley J, 2009, AUTOIMMUNITY, V42, P299, DOI 10.1080/08916930902831522; GOODWIN GH, 1977, FEBS LETT, V80, P413, DOI 10.1016/0014-5793(77)80488-2; Gougeon ML, 2012, CELL DEATH DIFFER, V19, P96, DOI 10.1038/cdd.2011.134; Ha TZ, 2011, AM J PHYSIOL-HEART C, V301, pH848, DOI 10.1152/ajpheart.01007.2010; Hagiwara S, 2008, INTENS CARE MED, V34, P1812, DOI 10.1007/s00134-008-1161-1; Hamatani T, 2004, P NATL ACAD SCI USA, V101, P10326, DOI 10.1073/pnas.0402597101; Huang LF, 2012, WORLD J EMERG MED, V3, P165, DOI [10.5847/wjem.j.1920-8642.2012.03.001, 10.5847/wjem.j.issn.1920-8642.2012.03.001]; Huang WY, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974-022-02406-0; Huang X, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107016; Huang Y, 2020, INT J BURNS TRAUMA, V10, P60; Jia C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2021-3; Jiang JH, 2020, NEUROREPORT, V31, P902, DOI 10.1097/WNR.0000000000001478; Jiang WY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.789610; Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287; Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001; Kim J, 2021, PHARMACOL REP, V73, P786, DOI 10.1007/s43440-020-00212-0; King LM, 2001, GENOMICS, V71, P163, DOI 10.1006/geno.2000.6443; Kong H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.774370; Kornblit B, 2007, TISSUE ANTIGENS, V70, P151, DOI 10.1111/j.1399-0039.2007.00854.x; Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005; Kuchler R, 2013, ANTIMICROB AGENTS CH, V57, P4782, DOI 10.1128/AAC.00805-13; Kugler JE, 2012, BBA-GENE REGUL MECH, V1819, P652, DOI 10.1016/j.bbagrm.2012.01.013; Kwon MY, 2021, J LEUKOCYTE BIOL, V110, P711, DOI 10.1002/JLB.4A0720-424R; Lai PF, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/716481; Laszlo I, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/510436; Lau KM, 2012, ACTA NEUROPATHOL, V123, P553, DOI 10.1007/s00401-011-0934-8; Lee K, 2016, YONSEI MED J, V57, P111, DOI 10.3349/ymj.2016.57.1.111; Lee W, 2020, PHYTOMEDICINE, V69, DOI 10.1016/j.phymed.2020.153200; Lee W, 2017, TOXICOL APPL PHARM, V329, P202, DOI 10.1016/j.taap.2017.06.006; Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222; Li DD, 2016, CELL CYCLE, V15, P2792, DOI 10.1080/15384101.2016.1220459; Li KH, 2016, INT IMMUNOPHARMACOL, V34, P114, DOI 10.1016/j.intimp.2016.01.021; Li M, 2021, MOL MED, V27, DOI 10.1186/s10020-021-00305-3; Li W, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.780790; Li YX, 2021, INFECT GENET EVOL, V89, DOI 10.1016/j.meegid.2020.104681; Li ZL, 2020, PHARM BIOL, V58, P898, DOI 10.1080/13880209.2020.1787469; Liang GB, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/9369035; Liang IC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222112049; Ling L, 2021, INFLAMMATION, V44, P1263, DOI 10.1007/s10753-020-01411-w; Liu Feng-Lin, 2012, Acta Anaesthesiol Taiwan, V50, P172, DOI 10.1016/j.aat.2012.12.001; Liu J, 2021, BIOENGINEERED, V12, P11936, DOI 10.1080/21655979.2021.2006967; Liu XP, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21996; Liu Y, 2015, J HEPATOL, V63, P114, DOI 10.1016/j.jhep.2015.02.009; Luo YY, 2021, CYTOKINE, V143, DOI 10.1016/j.cyto.2021.155509; Ma XF, 2020, EUR REV MED PHARMACO, V24, P9712, DOI 10.26355/eurrev_202009_23063; Maass PG, 2014, J MOL MED, V92, P337, DOI 10.1007/s00109-014-1131-8; Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534; Martinotti S, 2015, IMMUNOTARGETS THER, V4, P101, DOI 10.2147/ITT.S58064; Meng C, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023361; Nanduri R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020449; Nemeth MJ, 2005, BLOOD, V105, P627, DOI 10.1182/blood-2004-07-2551; Nemeth MJ, 2003, BLOOD, V102, P1298, DOI 10.1182/blood-2002-11-3541; Ni JY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00109; Obeng E., 2021, Braz. J. Biol., V81, P1133, DOI 10.1590/1519-6984.228437; Pan JY, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-03022-x; Papantonis A, 2021, TRENDS GENET, V37, P986, DOI 10.1016/j.tig.2021.07.004; Park S, 2012, BIOCHEMISTRY-US, V51, P6728, DOI 10.1021/bi300649v; Peluso S, 2010, BREAST CARE, V5, P81, DOI 10.1159/000297717; Postnikov Y, 2010, BBA-GENE REGUL MECH, V1799, P62, DOI 10.1016/j.bbagrm.2009.11.016; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Qin SX, 2006, J EXP MED, V203, P1637, DOI 10.1084/jem.20052203; Qing DY, 2014, AM J RESP CRIT CARE, V190, P1243, DOI 10.1164/rccm.201406-1095OC; Qiu P, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.671164; Qiu P, 2013, CRIT CARE MED, V41, P2419, DOI 10.1097/CCM.0b013e3182982add; Qiu Y, 2021, J CELL MOL MED, V25, P8244, DOI 10.1111/jcmm.16738; Ramos GC, 2007, BRIT J PHARMACOL, V151, P844, DOI 10.1038/sj.bjp.0707302; Reeves R, 2001, BBA-GENE STRUCT EXPR, V1519, P13, DOI 10.1016/S0167-4781(01)00215-9; Reeves R, 2005, DNA REPAIR, V4, P926, DOI 10.1016/j.dnarep.2005.04.010; Reeves R, 2010, BBA-GENE REGUL MECH, V1799, P3, DOI 10.1016/j.bbagrm.2009.09.001; Ren C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.665579; Ren C, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/6197084; Rhodes A, 2017, CRIT CARE MED, V45, P486, DOI 10.1097/CCM.0000000000002255; Rodrigues PRS, 2021, EXPERT OPIN DRUG DIS, V16, P537, DOI 10.1080/17460441.2021.1851186; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Seo KH, 2017, J KOREAN MED SCI, V32, P542, DOI 10.3346/jkms.2017.32.3.542; Shen J, 2018, LIFE SCI, V210, P185, DOI 10.1016/j.lfs.2018.08.041; Shi H, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.848747; Shirakawa H, 2000, J BIOL CHEM, V275, P6368, DOI 10.1074/jbc.275.9.6368; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Sohun M, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.05.36; Steinhagen F, 2020, PHARMACOL THERAPEUT, V208, DOI 10.1016/j.pharmthera.2020.107476; Stevens NE, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06205-z; Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008; Su LJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103710; Sun JL, 2021, BMC PULM MED, V21, DOI 10.1186/s12890-021-01552-0; Taeb AM, 2017, NUTR CLIN PRACT, V32, P296, DOI 10.1177/0884533617695243; Takaishi H, 2012, J GASTROENTEROL, V47, P969, DOI 10.1007/s00535-012-0566-3; Tan YH, 2015, J TRAUMA ACUTE CARE, V78, P784, DOI 10.1097/TA.0000000000000588; Tang DL, 2021, TRENDS IMMUNOL, V42, P508, DOI 10.1016/j.it.2021.04.001; Taniguchi N, 2018, HUM CELL, V31, P1, DOI 10.1007/s13577-017-0182-x; Tian Y, 2020, CLIN SCI, V134, P2075, DOI 10.1042/CS20200553; Tripathi A, 2019, TOXICOL REP, V6, P253, DOI 10.1016/j.toxrep.2019.03.002; Tsoyi K, 2011, BRIT J PHARMACOL, V162, P1498, DOI 10.1111/j.1476-5381.2010.01126.x; Ueno H, 2004, AM J RESP CRIT CARE, V170, P1310, DOI 10.1164/rccm.200402-188OC; Vaccari T, 1998, GENOMICS, V49, P247, DOI 10.1006/geno.1998.5214; Venereau E, 2016, PHARMACOL RES, V111, P534, DOI 10.1016/j.phrs.2016.06.031; WALKER JM, 1980, BIOCHEM J, V185, P383, DOI 10.1042/bj1850383; Wang HZ, 2017, CLIN INVEST MED, V40, pE66, DOI 10.25011/cim.v40i2.28197; Wang HC, 2006, J NUTR, V136, P360, DOI 10.1093/jn/136.2.360; Wang LL, 2012, CANCER BIOTHER RADIO, V27, P329, DOI 10.1089/cbr.2012.1199; Wang M, 2017, INT J BIOL SCI, V13, P1497, DOI 10.7150/ijbs.22531; Wang Q, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/860259; Wang XW, 2014, J CARDIOTHORAC SURG, V9, DOI 10.1186/s13019-014-0133-5; Wang XD, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200527; Wang Z, 2021, J ETHNOPHARMACOL, V270, DOI 10.1016/j.jep.2021.113783; Wen B, 2021, MOL CELL BIOCHEM, V476, P1729, DOI 10.1007/s11010-020-04015-y; Williams DL, 1999, SURGERY, V126, P54, DOI 10.1067/msy.1999.99058; Wu J, 2014, J BIOL CHEM, V289, P20000, DOI 10.1074/jbc.M114.555425; Xie JF, 2020, CRIT CARE MED, V48, pE209, DOI 10.1097/CCM.0000000000004155; Xie KL, 2010, SHOCK, V34, P90, DOI 10.1097/SHK.0b013e3181cdc4ae; Xiu GH, 2018, CELL TISSUE RES, V373, P395, DOI 10.1007/s00441-018-2823-0; Xu EJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5630124; Xu HP, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.660269; Xu LN, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118505; Xu W, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.851169; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yang K, 2022, CELL DEATH DIFFER, V29, P133, DOI 10.1038/s41418-021-00841-9; Yang MH, 2013, BIOCHEM PHARMACOL, V86, P410, DOI 10.1016/j.bcp.2013.05.013; Yang P, 2020, J SURG RES, V256, P23, DOI 10.1016/j.jss.2020.05.101; Yang R, 2017, INT J INFLAMM, V2017, DOI 10.1155/2017/1817564; Yang SM, 2019, AM J CHINESE MED, V47, P613, DOI 10.1142/S0192415X19500320; Yang XY, 2020, BLOOD, V135, P1087, DOI 10.1182/blood.2019002282; Yang ZY, 2008, WORLD J GASTROENTERO, V14, P4546, DOI 10.3748/wjg.14.4546; Ye CT, 2012, P NATL ACAD SCI USA, V109, P21052, DOI 10.1073/pnas.1216195109; Yin J, 2021, WORLD J EMERG MED, V12, P185, DOI 10.5847/wjem.j.1920-8642.2021.03.004; Yoo H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88970-6; Yu CY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0523-z; Yu Y, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00093; Yu Y, 2017, SHOCK, V48, P364, DOI 10.1097/SHK.0000000000000856; Zeng L, 2012, SURGERY, V151, P427, DOI 10.1016/j.surg.2011.07.075; Zhang LM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091425; Zhang Y, 2019, EUR REV MED PHARMACO, V23, P10950, DOI 10.26355/eurrev_201912_19798; Zhao F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9719647; Zhou HC, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8019467; Zhou MA, 2021, ANTIOXID REDOX SIGN, V35, P1308, DOI 10.1089/ars.2021.0008; Zhou WH, 2016, INT J MOL MED, V38, P312, DOI 10.3892/ijmm.2016.2613; Zhu CY, 2018, ONCOL LETT, V16, P5027, DOI 10.3892/ol.2018.9308; Zhu JF, 2019, CELL CYCLE, V18, P1948, DOI 10.1080/15384101.2019.1635869	179	0	0	10	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								911152	10.3389/fimmu.2022.911152	http://dx.doi.org/10.3389/fimmu.2022.911152			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3TM	35720285	gold, Green Published			2022-12-18	WOS:000812152300001
J	Man, Y; Lu, ZX; Yao, XM; Gong, YM; Yang, TH; Wang, YJ				Man, Yan; Lu, Zhixiang; Yao, Xiangmei; Gong, Yuemin; Yang, Tonghua; Wang, Yajie			Recent Advancements in Poor Graft Function Following Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						hematopoietic stem cell transplantation; poor graft function; prognosis; bone marrow microenvironment (BMME); hematopoietic stem cell (HSC)	BONE-MARROW MICROENVIRONMENT; ACUTE MYELOID-LEUKEMIA; PERIPHERAL-BLOOD STEM; ANTI-HLA ANTIBODIES; CYTOMEGALOVIRUS REACTIVATION; PROGENITOR CELLS; LETERMOVIR PROPHYLAXIS; IRON OVERLOAD; RISK-FACTORS; RECONSTITUTION	Poor graft function (PGF) is a life-threatening complication that occurs after transplantation and has a poor prognosis. With the rapid development of haploidentical hematopoietic stem cell transplantation, the pathogenesis of PGF has become an important issue. Studies of the pathogenesis of PGF have resulted in some success in CD34(+)-selected stem cell boosting. Mesenchymal stem cells, N-acetyl-l-cysteine, and eltrombopag have also been investigated as therapeutic strategies for PGF. However, predicting and preventing PGF remains challenging. Here, we propose that the seed, soil, and insect theories of aplastic anemia also apply to PGF; CD34(+) cells are compared to seeds; the bone marrow microenvironment to soil; and virus infection, iron overload, and donor-specific anti-human leukocyte antigen antibodies to insects. From this perspective, we summarize the available information on the common risk factors of PGF, focusing on its potential mechanism. In addition, the safety and efficacy of new strategies for treating PGF are discussed to provide a foundation for preventing and treating this complex clinical problem.	[Man, Yan; Lu, Zhixiang; Yao, Xiangmei; Yang, Tonghua; Wang, Yajie] First Peoples Hosp Yunnan Prov, Yunnan Blood Dis Hosp, Yunnan Blood Dis Clin Med Ctr, Dept Hematol, Kunming, Peoples R China; [Gong, Yuemin] Nanjing Med Univ, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Dept Hematol,Affiliated Hosp 1, Nanjing, Peoples R China	Nanjing Medical University	Yang, TH; Wang, YJ (corresponding author), First Peoples Hosp Yunnan Prov, Yunnan Blood Dis Hosp, Yunnan Blood Dis Clin Med Ctr, Dept Hematol, Kunming, Peoples R China.	ynanblood@aliyun.com; kbb165wyj@sina.com			National Natural Science Foundation of China [82070173, 82060810, 81900109]; Basic Applied Research Projects of Yunnan Province [202101AW070017]; Doctoral Research Fund of the First Peoples Hospital of Yunnan Province [KHBS-2020-007]; Open Project of Yunnan Blood Disease Clinical Medical Center [2020LCZXKF-XY14]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Basic Applied Research Projects of Yunnan Province; Doctoral Research Fund of the First Peoples Hospital of Yunnan Province; Open Project of Yunnan Blood Disease Clinical Medical Center	This work was supported by the National Natural Science Foundation of China (82070173, 82060810,81900109), the Basic Applied Research Projects of Yunnan Province (202101AW070017), the Doctoral Research Fund of the First Peoples Hospital of Yunnan Province (KHBS-2020-007), the Open Project of Yunnan Blood Disease Clinical Medical Center (2020LCZXKF-XY14).	Adler SP, 2019, J INFECT DIS, V220, P411, DOI 10.1093/infdis/jiz141; Akahoshi Y, 2021, CLIN INFECT DIS, V73, pE620, DOI 10.1093/cid/ciaa1871; Al Malki MM, 2020, BIOL BLOOD MARROW TR, V26, P1697, DOI 10.1016/j.bbmt.2020.06.002; Al-Samkari H, 2022, BRIT J HAEMATOL, V197, P359, DOI 10.1111/bjh.18081; Alchalby H, 2016, BONE MARROW TRANSPL, V51, P1223, DOI 10.1038/bmt.2016.98; Allhorn M, 2010, BLOOD, V115, P5080, DOI 10.1182/blood-2009-08-239020; Arcuri LJ, 2020, BIOL BLOOD MARROW TR, V26, P2311, DOI 10.1016/j.bbmt.2020.09.007; Ball LM, 2007, BLOOD, V110, P2764, DOI 10.1182/blood-2007-04-087056; Carrancio S, 2013, CELL TRANSPLANT, V22, P1171, DOI 10.3727/096368912X657431; Carreras E., 2019, EBMT HDB HEMATOPOIET, V7th; Chang YJ, 2020, BONE MARROW TRANSPL, V55, P1326, DOI 10.1038/s41409-020-0928-z; Chang YJ, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0182-9; Chang YJ, 2012, SEMIN ONCOL, V39, P653, DOI 10.1053/j.seminoncol.2012.09.003; Chen H, 2015, BIOL BLOOD MARROW TR, V21, P1110, DOI 10.1016/j.bbmt.2015.02.009; Chen Q, 2019, CELL STEM CELL, V25, P768, DOI 10.1016/j.stem.2019.10.006; Choe Hannah, 2019, Biol Blood Marrow Transplant, V25, pe60, DOI 10.1016/j.bbmt.2018.10.018; Ciurea SO, 2019, BONE MARROW TRANSPL, V54, P784, DOI 10.1038/s41409-018-0332-0; Ciurea SO, 2015, BIOL BLOOD MARROW TR, V21, P1392, DOI 10.1016/j.bbmt.2015.05.001; Ciurea SO, 2012, BIOL BLOOD MARROW TR, V18, P1835, DOI 10.1016/j.bbmt.2012.07.003; Ciurea SO, 2011, BLOOD, V118, P5957, DOI 10.1182/blood-2011-06-362111; Crane GM, 2017, NAT REV IMMUNOL, V17, P573, DOI 10.1038/nri.2017.53; Crippa S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.663316; Cuadrado MM, 2020, HAEMATOLOGICA, V105, P2639, DOI 10.3324/haematol.2019.226340; Dallalio G, 2006, BLOOD, V107, P2702, DOI 10.1182/blood-2005-07-2854; De Groof TWM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24608-5; de Latour RP, 2022, NEW ENGL J MED, V386, P11, DOI 10.1056/NEJMoa2109965; Degli-Esposti MA, 2022, BLOOD, V139, P1277, DOI 10.1182/blood.2020010028; Einsele H, 2020, BLOOD, V135, P1619, DOI 10.1182/blood.2019000956; Elfeky R, 2019, J ALLERGY CLIN IMMUN, V144, P280, DOI 10.1016/j.jaci.2019.01.030; Fuji S, 2020, BONE MARROW TRANSPL, V55, P722, DOI 10.1038/s41409-019-0712-0; Gardenghi S, 2010, J CLIN INVEST, V120, P4466, DOI 10.1172/JCI41717; Ghobadi A, 2017, BIOL BLOOD MARROW TR, V23, P1072, DOI 10.1016/j.bbmt.2017.03.019; Giammarco S, 2021, BONE MARROW TRANSPL, V56, P1291, DOI 10.1038/s41409-020-01183-9; Guo HD, 2021, CELL MOL IMMUNOL, V18, P1172, DOI 10.1038/s41423-020-00597-1; Hafsi H, 2011, ANTIOXID REDOX SIGN, V15, P1655, DOI 10.1089/ars.2010.3771; Hassan S, 2021, TRANSFUSION, V61, P1980, DOI 10.1111/trf.16411; Hooper AT, 2009, CELL STEM CELL, V4, P263, DOI 10.1016/j.stem.2009.01.006; Hosokawa K, 2021, LEUKEMIA, V35, P906, DOI 10.1038/s41375-020-0950-6; Hu LP, 2021, BLOOD, V137, P3339, DOI 10.1182/blood.2020007362; Hu LP, 2014, BLOOD, V124, pE45, DOI 10.1182/blood-2014-03-559369; Imlay HN, 2021, CLIN INFECT DIS, V73, P156, DOI 10.1093/cid/ciaa1713; Iolascon A, 2020, BLOOD, V136, P1274, DOI 10.1182/blood.2019000948; Jin X, 2018, HAEMATOLOGICA, V103, P1627, DOI 10.3324/haematol.2018.193128; Kao YR, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aas9563; Kautz L, 2014, BLOOD, V124, P479, DOI 10.1182/blood-2014-05-516252; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kong Y, 2016, BONE MARROW TRANSPL, V51, P249, DOI 10.1038/bmt.2015.229; Kong Y, 2019, BLOOD ADV, V3, P1303, DOI 10.1182/bloodadvances.2018029454; Kong Y, 2017, J TRANSL MED, V15, DOI [10.1186/s12967-017-1159-y, 10.14801/jkiit.2017.15.9.57]; Kong Y, 2016, ONCOTARGET, V7, P30892, DOI 10.18632/oncotarget.8810; Kong Y, 2013, BIOL BLOOD MARROW TR, V19, P1465, DOI 10.1016/j.bbmt.2013.07.014; Kumar D, 2017, AM J TRANSPLANT, V17, P2468, DOI 10.1111/ajt.14347; Leserer S, 2021, AM J HEMATOL, V96, P436, DOI 10.1002/ajh.26094; Lewandowski D, 2010, BLOOD, V115, P443, DOI 10.1182/blood-2009-05-222711; Li HH, 2010, NAT MED, V16, P177, DOI 10.1038/nm.2073; Li RN, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02170-7; Li T, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02304-x; Lin JX, 2020, AM J TRANSPLANT, V20, P2356, DOI 10.1111/ajt.15851; Liu XD, 2014, CELL TRANSPLANT, V23, P1087, DOI 10.3727/096368912X661319; Ljungman P, 2002, BLOOD, V99, P3050, DOI 10.1182/blood.V99.8.3050; Ljungman P, 2020, CLIN INFECT DIS, V70, P1525, DOI 10.1093/cid/ciz490; Lorant T, 2018, AM J TRANSPLANT, V18, P2752, DOI 10.1111/ajt.14733; Lu DP, 2006, BLOOD, V107, P3065, DOI 10.1182/blood-2005-05-2146; Luo Y, 2018, BLOOD ADV, V2, P859, DOI 10.1182/bloodadvances.2018015685; Lyu ZS, 2022, BONE MARROW TRANSPL, V57, P38; Lyu ZS, 2020, EBIOMEDICINE, V53, DOI 10.1016/j.ebiom.2020.102677; Ma YR, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.631625; Maertens J, 2019, NEW ENGL J MED, V381, P1136, DOI 10.1056/NEJMoa1714656; Mainardi C, 2018, BRIT J HAEMATOL, V180, P90, DOI 10.1111/bjh.15012; Marty FM, 2017, NEW ENGL J MED, V377, P2433, DOI 10.1056/NEJMoa1706640; Marty FM, 2013, NEW ENGL J MED, V369, P1227, DOI 10.1056/NEJMoa1303688; McLornan DP, 2021, LEUKEMIA, V35, P2445, DOI 10.1038/s41375-021-01294-2; Menger L, 2015, BLOOD, V126, P2781, DOI 10.1182/blood-2015-08-664755; Mesnieres M, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109618; Metafuni E, 2018, BONE MARROW TRANSPL, V53, P1560, DOI 10.1038/s41409-018-0200-y; Moirangthem RD, 2015, STEM CELLS DEV, V24, P2423, DOI 10.1089/scd.2015.0112; Mori Y, 2021, BONE MARROW TRANSPL, V56, P853, DOI 10.1038/s41409-020-01082-z; Okabe H, 2014, EUR J HAEMATOL, V93, P118, DOI 10.1111/ejh.12309; Penack O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00586; Plein A, 2018, NATURE, V562, P223, DOI 10.1038/s41586-018-0552-x; Prabahran A, 2021, LEUKEMIA LYMPHOMA, V62, P1482, DOI 10.1080/10428194.2021.1872072; Purtill D, 2020, BLOOD ADV, V4, P4147, DOI 10.1182/bloodadvances.2020002431; Reddehase MJ, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081530; Ruggeri A, 2018, CANCER-AM CANCER SOC, V124, P1428, DOI 10.1002/cncr.31228; Ruggeri A, 2013, HAEMATOLOGICA, V98, P1154, DOI 10.3324/haematol.2012.077685; Sakamoto S, 2017, CANCER MED-US, V6, P120, DOI 10.1002/cam4.974; Salter AB, 2009, BLOOD, V113, P2104, DOI 10.1182/blood-2008-06-162941; Sassine J, 2021, CLIN INFECT DIS, V73, P1346, DOI 10.1093/cid/ciab298; Schleiss MR, 2018, P NATL ACAD SCI USA, V115, P6110, DOI 10.1073/pnas.1806420115; Selby PR, 2021, CLIN PHARMACOKINET, V60, P727, DOI 10.1007/s40262-020-00982-z; Sharma N, 2021, J CLIN MED, V10, DOI 10.3390/jcm10132843; Shen HM, 2012, BLOOD, V119, P3629, DOI 10.1182/blood-2011-08-373621; Shi MM, 2016, BLOOD, V128, P2988, DOI 10.1182/blood-2016-03-702803; Shoulars K, 2016, BLOOD, V127, P2346, DOI 10.1182/blood-2015-08-666990; Sidney LE, 2014, STEM CELLS, V32, P1380, DOI 10.1002/stem.1661; Song Y, 2018, BIOL BLOOD MARROW TR, V24, P1981, DOI 10.1016/j.bbmt.2018.06.021; Srour SA, 2020, AM J HEMATOL, V95, P1187, DOI 10.1002/ajh.25924; Storz P, 2011, ANTIOXID REDOX SIGN, V14, P593, DOI 10.1089/ars.2010.3405; Suessmuth Y, 2015, BLOOD, V125, P3835, DOI 10.1182/blood-2015-03-631853; Sun YQ, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.604085; Sun YQ, 2019, ANN HEMATOL, V98, P1877, DOI 10.1007/s00277-019-03715-w; Sun YQ, 2015, ANN HEMATOL, V94, P1699, DOI 10.1007/s00277-015-2440-x; Takenaka K, 2015, BIOL BLOOD MARROW TR, V21, P2008, DOI 10.1016/j.bbmt.2015.07.019; Tang C, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0649-6; Teira P, 2016, BLOOD, V127, P2427, DOI 10.1182/blood-2015-11-679639; Tenneti P, 2021, BONE MARROW TRANSPL, V56, P1794, DOI 10.1038/s41409-021-01244-7; Trottier BJ, 2013, BLOOD, V122, P1678, DOI 10.1182/blood-2013-04-499772; Turki AT, 2022, BLOOD ADV, V6, P28, DOI 10.1182/bloodadvances.2021005509; Vlachodimitropoulou E, 2017, BLOOD, V130, P1923, DOI 10.1182/blood-2016-10-740241; Wang Y, 2018, LEUKEMIA, V32, P492, DOI 10.1038/leu.2017.199; Wang Y, 2020, BRIT J HAEMATOL, V189, P153, DOI 10.1111/bjh.16303; Wang YT, 2016, BIOL BLOOD MARROW TR, V22, P1376, DOI 10.1016/j.bbmt.2016.04.016; Watts MJ, 2016, BRIT J HAEMATOL, V175, P771, DOI 10.1111/bjh.14378; Watts MJ, 2016, BRIT J HAEMATOL, V175, P673, DOI 10.1111/bjh.14276; Xiao Y, 2014, INT J MED SCI, V11, P652, DOI 10.7150/ijms.6337; Xu LP, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0564-x; Yeh AC, 2021, BLOOD, V138, P2874, DOI 10.1182/blood.2020009492; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yoshihara S, 2012, BONE MARROW TRANSPL, V47, P508, DOI 10.1038/bmt.2011.131; Yu SJ, 2020, LEUKEMIA, V34, P1433, DOI 10.1038/s41375-019-0686-3; Yu XT, 2019, CRIT REV ONCOL HEMAT, V133, P120, DOI 10.1016/j.critrevonc.2018.05.017; Zamora D, 2021, BLOOD, V138, P34, DOI 10.1182/blood.2020009396; Zeng LY, 2012, CELL BIOCHEM BIOPHYS, V64, P213, DOI 10.1007/s12013-012-9387-5; Zhang XH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01159-2; Zhao HY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00627-y; Zhao HY, 2018, BRIT J HAEMATOL, V182, P679, DOI 10.1111/bjh.15452; Zhao XS, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/1043836; Zhao YM, 2019, BIOL BLOOD MARROW TR, V25, P1898, DOI 10.1016/j.bbmt.2019.05.036; Zheng QQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0552-7; Zhou JR, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.620891	130	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								911174	10.3389/fimmu.2022.911174	http://dx.doi.org/10.3389/fimmu.2022.911174			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3TH	35720412	Green Published, gold			2022-12-18	WOS:000812151800001
J	Ouyang, XF; Gong, YP				Ouyang, Xianfeng; Gong, Yuping			One Stone, Two Birds: N6-Methyladenosine RNA Modification in Leukemia Stem Cells and the Tumor Immune Microenvironment in Acute Myeloid Leukemia	FRONTIERS IN IMMUNOLOGY			English	Review						N6-methyladenosine; RNA methylation; acute myeloid leukemia; leukemia stem cells; tumor immune microenvironment	M(6)A READER YTHDC1; MESSENGER-RNA; SELF-RENEWAL; NUCLEAR-RNA; METHYLATION; DEMETHYLASE; TRANSLATION; MAINTAINS; TARGET; ALKBH5	Acute myeloid leukemia is the most common acute leukemia in adults, with accumulation of abundant blasts and impairment of hematogenic function. Despite great advances in diagnosis and therapy, the overall survival of patients with acute myeloid leukemia remains poor. Leukemia stem cells are the root cause of relapse and chemoresistance in acute myeloid leukemia. The tumor immune microenvironment is another trigger to induce recurrence and drug resistance. Understanding the underlying factors influencing leukemia stem cells and the tumor immune microenvironment is an urgent and unmet need. Intriguingly, N6-methyladenosine, the most widespread internal mRNA modification in eukaryotes, is found to regulate both leukemia stem cells and the tumor immune microenvironment. Methyltransferases and demethylases cooperatively make N6-methyladenosine modification reversible and dynamic. Increasing evidence demonstrates that N6-methyladenosine modification extensively participates in tumorigenesis and progression in various cancers, including acute myeloid leukemia. In this review, we summarize the current progress in studies on the functions of N6-methyladenosine modification in acute myeloid leukemia, especially in leukemia stem cells and the tumor immune microenvironment. We generalize the landscape of N6-methyladenosine modification in self-renewal of leukemia stem cells and immune microenvironment regulation, as well as in the initiation, growth, proliferation, differentiation, and apoptosis of leukemia cells. In addition, we further explore the clinical application of N6-methyladenosine modification in diagnosis, prognostic stratification, and effect evaluation. Considering the roles of N6-methyladenosine modification in leukemia stem cells and the tumor immune microenvironment, we propose targeting N6-methyladenosine regulators as one stone to kill two birds for acute myeloid leukemia treatment.	[Ouyang, Xianfeng; Gong, Yuping] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China; [Ouyang, Xianfeng] Jiujiang First Peoples Hosp, Dept Hematol, Jiujiang, Peoples R China	Sichuan University	Gong, YP (corresponding author), Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China.	gongyuping2010@aliyun.com			Foundation of the Science and Technology Department of Sichuan Province [2019YFS0026]	Foundation of the Science and Technology Department of Sichuan Province	Funding The work was supported by the Foundation of the Science and Technology Department of Sichuan Province (NO.2019YFS0026).	Alarcon CR, 2015, CELL, V162, P1299, DOI 10.1016/j.cell.2015.08.011; Bahr C, 2017, EMBO J, V36, P2667, DOI 10.15252/embj.201797773; Bansal H, 2014, LEUKEMIA, V28, P1171, DOI 10.1038/leu.2014.16; Barbieri I, 2017, NATURE, V552, P126, DOI 10.1038/nature24678; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Bawankar P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23892-5; Buss EC, 2011, INT J CANCER, V129, P2328, DOI 10.1002/ijc.26318; Camacho V, 2017, INT J HEMATOL, V105, P566, DOI 10.1007/s12185-017-2184-6; Chen Z, 2021, ONCOGENE, V40, P3786, DOI 10.1038/s41388-021-01818-1; Chen ZH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02795-1; Cheng YM, 2021, CANCER CELL, V39, P958, DOI 10.1016/j.ccell.2021.04.017; Chong W, 2021, THERANOSTICS, V11, P2201, DOI 10.7150/thno.52717; Craddock C, 2013, LEUKEMIA, V27, P1028, DOI 10.1038/leu.2012.312; Cui Q, 2017, CELL REP, V18, P2622, DOI 10.1016/j.celrep.2017.02.059; Deng M, 2018, NATURE, V562, P605, DOI 10.1038/s41586-018-0615-z; Depreter B, 2021, PEDIATR RES, V89, P1695, DOI 10.1038/s41390-020-01199-3; DESROSIERS R, 1974, P NATL ACAD SCI USA, V71, P3971, DOI 10.1073/pnas.71.10.3971; Dohner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184; Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Dohner H, 2021, NAT REV CLIN ONCOL, V18, P577, DOI 10.1038/s41571-021-00509-w; Dombret H, 2016, BLOOD, V127, P53, DOI 10.1182/blood-2015-08-604520; Dong F, 2021, CANCER RES, V81, P5876, DOI 10.1158/0008-5472.CAN-21-1456; Du AS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.789914; Du YY, 2021, ACS NANO, V15, P17689, DOI 10.1021/acsnano.1c05547; Elcheva IA, 2020, LEUKEMIA, V34, P1354, DOI 10.1038/s41375-019-0656-9; Feng MD, 2021, BLOOD, V138, P71, DOI 10.1182/blood.2020009676; Ferrara F, 2013, LANCET, V381, P484, DOI 10.1016/S0140-6736(12)61727-9; Herbrich S, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002968; Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang Y, 2019, CANCER CELL, V35, P677, DOI 10.1016/j.ccell.2019.03.006; Iwasaki M, 2015, CELL STEM CELL, V17, P412, DOI 10.1016/j.stem.2015.08.008; Jain D, 2018, ELIFE, V7, DOI 10.7554/eLife.30919; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Jordan CT, 2000, LEUKEMIA, V14, P1777, DOI 10.1038/sj.leu.2401903; Kikushige Y, 2015, CELL STEM CELL, V17, P341, DOI 10.1016/j.stem.2015.07.011; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kretschmer J, 2018, RNA, V24, P1339, DOI 10.1261/rna.064238.117; Kumar S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9060690; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Li D, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.770451; Li JZ, 2021, NAT STRUCT MOL BIOL, V28, P460, DOI 10.1038/s41594-021-00606-5; Li N, 2020, P NATL ACAD SCI USA, V117, P20159, DOI 10.1073/pnas.1918986117; Li ZJ, 2017, CANCER CELL, V31, P127, DOI 10.1016/j.ccell.2016.11.017; Liao SH, 2018, GENOM PROTEOM BIOINF, V16, P99, DOI 10.1016/j.gpb.2018.04.002; Lin YT, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/2769689; Liu NA, 2017, NUCLEIC ACIDS RES, V45, P6051, DOI 10.1093/nar/gkx141; Liu N, 2015, NATURE, V518, P560, DOI 10.1038/nature14234; Liu Y, 2021, CELL METAB, V33, P1221, DOI 10.1016/j.cmet.2021.04.001; Lytle NK, 2018, NAT REV CANCER, V18, P669, DOI 10.1038/s41568-018-0056-x; Ma J, 2010, ANTI-CANCER AGENT ME, V10, P131, DOI 10.2174/187152010790909254; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mao YH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13317-9; Mendez LM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01162; Meyer KD, 2017, ANNU REV CELL DEV BI, V33, P319, DOI 10.1146/annurev-cellbio-100616-060758; Moshaver B, 2019, LEUKEMIA RES, V81, P27, DOI 10.1016/j.leukres.2019.04.004; Naren D, 2021, J CANCER RES CLIN, V147, P33, DOI 10.1007/s00432-020-03373-w; Newell LF, 2021, BMJ-BRIT MED J, V375, DOI 10.1136/bmj.n2026; Tran NV, 2019, NUCLEIC ACIDS RES, V47, P7719, DOI 10.1093/nar/gkz619; Noviello M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08871-1; Paczulla AM, 2019, NATURE, V572, P254, DOI 10.1038/s41586-019-1410-1; Pan YT, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0590-8; Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021; Patil DP, 2016, NATURE, V537, P369, DOI 10.1038/nature19342; Pendleton KE, 2017, CELL, V169, P824, DOI 10.1016/j.cell.2017.05.003; Perry JM, 2020, NAT CELL BIOL, V22, P689, DOI 10.1038/s41556-020-0507-y; Ping XL, 2014, CELL RES, V24, P177, DOI 10.1038/cr.2014.3; Prokhorov A, 2015, INT J BIOCHEM CELL B, V59, P11, DOI 10.1016/j.biocel.2014.11.017; Qin Q, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3404; Qing Y, 2021, MOL CELL, V81, P922, DOI 10.1016/j.molcel.2020.12.026; Riether C, 2017, J EXP MED, V214, P359, DOI 10.1084/jem.20152008; Roundtree IA, 2017, ELIFE, V6, DOI 10.7554/eLife.31311; Schatton T, 2009, ANN NY ACAD SCI, V1176, P154, DOI 10.1111/j.1749-6632.2009.04568.x; Scholler E, 2018, RNA, V24, P499, DOI 10.1261/rna.064063.117; Selberg S, 2021, ACS OMEGA, V6, P13310, DOI 10.1021/acsomega.1c01289; Sendinc E, 2019, MOL CELL, V75, P620, DOI 10.1016/j.molcel.2019.05.030; Shen C, 2020, CELL STEM CELL, V27, P64, DOI 10.1016/j.stem.2020.04.009; Sheng Y, 2021, BLOOD, V138, P2838, DOI 10.1182/blood.2021011707; Shi HL, 2017, CELL RES, V27, P315, DOI 10.1038/cr.2017.15; Shlush LI, 2017, NATURE, V547, P104, DOI 10.1038/nature22993; Silva IG, 2017, EBIOMEDICINE, V22, P44, DOI 10.1016/j.ebiom.2017.07.018; Sorci M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0843-z; Su R, 2020, CANCER CELL, V38, P79, DOI 10.1016/j.ccell.2020.04.017; Su R, 2018, CELL, V172, P90, DOI 10.1016/j.cell.2017.11.031; Sun H, 2015, INT J HEMATOL, V102, P579, DOI 10.1007/s12185-015-1865-2; Sun KJ, 2021, THERANOSTICS, V11, P5831, DOI 10.7150/thno.55574; Taghiloo S, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103164; Teague RM, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-13; Thomas D, 2017, BLOOD, V129, P1577, DOI 10.1182/blood-2016-10-696054; Tsuchiya H, 2021, REGEN THER, V17, P20, DOI 10.1016/j.reth.2021.02.006; Tsuruta N, 2020, BIOCHEM BIOPH RES CO, V530, P235, DOI 10.1016/j.bbrc.2020.06.153; Ueda Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep42271; van Rhenen A, 2007, BLOOD, V110, P2659, DOI 10.1182/blood-2007-03-083048; Vu LP, 2017, NAT MED, V23, P1369, DOI 10.1038/nm.4416; Wang JZ, 2020, CELL STEM CELL, V27, P81, DOI 10.1016/j.stem.2020.04.001; Wang LL, 2020, EMBO J, V39, DOI 10.15252/embj.2020104514; Wang RY, 2018, MOL PHARMACEUT, V15, P4092, DOI 10.1021/acs.molpharmaceut.8b00522; Wang X, 2016, NATURE, V534, P575, DOI 10.1038/nature18298; Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wei JB, 2018, MOL CELL, V71, P973, DOI 10.1016/j.molcel.2018.08.011; Wen J, 2018, MOL CELL, V69, P1028, DOI 10.1016/j.molcel.2018.02.015; Weng HY, 2018, CELL STEM CELL, V22, P191, DOI 10.1016/j.stem.2017.11.016; Xiang Y, 2017, NATURE, V543, P573, DOI 10.1038/nature21671; Xiao W, 2016, MOL CELL, V61, P507, DOI 10.1016/j.molcel.2016.01.012; Xu C, 2014, NAT CHEM BIOL, V10, P927, DOI [10.1038/nchembio.1654, 10.1038/NCHEMBIO.1654]; Xu L, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.686156; Yan F, 2018, CELL RES, V28, P1062, DOI 10.1038/s41422-018-0097-4; Yang L, 2015, J BIOL CHEM, V290, P26627, DOI 10.1074/jbc.M115.667717; Yankova E, 2021, NATURE, V593, P597, DOI 10.1038/s41586-021-03536-w; Yue YA, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0019-0; Zhang CZ, 2016, P NATL ACAD SCI USA, V113, pE2047, DOI 10.1073/pnas.1602883113; Zhang FF, 2017, HAEMATOLOGICA, V102, P707, DOI 10.3324/haematol.2016.151555; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang ZH, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.525; Zhao X, 2014, CELL RES, V24, P1403, DOI 10.1038/cr.2014.151; Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015; Zheng X, 2021, BIOMARK RES, V9, DOI 10.1186/s40364-021-00293-w	121	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								912526	10.3389/fimmu.2022.912526	http://dx.doi.org/10.3389/fimmu.2022.912526			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D8YX	35720276	gold, Green Published			2022-12-18	WOS:000811826600001
J	Rossi, F; Fredericks, N; Snowden, A; Allegrezza, MJ; Moreno-Nieves, UY				Rossi, Fiorella; Fredericks, Nathaniel; Snowden, Andrew; Allegrezza, Michael J.; Moreno-Nieves, Uriel Y.			Next Generation Natural Killer Cells for Cancer Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						NK cell; iPSC (induced pluripotent stem cell); CAR (chimeric antigen receptor); engineering; stealth	CHIMERIC ANTIGEN RECEPTOR; MHC CLASS-I; FC-GAMMA-RIIIA; IMMUNOGLOBULIN-LIKE RECEPTOR; PERIPHERAL-BLOOD LYMPHOCYTES; ACUTE MYELOID-LEUKEMIA; MODIFIED T-CELLS; NK CELLS; ANTITUMOR-ACTIVITY; STEM-CELLS	In recent years, immunotherapy for cancer has become mainstream with several products now authorized for therapeutic use in the clinic and are becoming the standard of care for some malignancies. Chimeric antigen receptor (CAR)-T cell therapies have demonstrated substantial efficacy for the treatment of hematological malignancies; however, they are complex and currently expensive to manufacture, and they can generate life-threatening adverse events such as cytokine release syndrome (CRS). The limitations of current CAR-T cells therapies have spurred an interest in alternative immunotherapy approaches with safer risk profiles and with less restrictive manufacturing constraints. Natural killer (NK) cells are a population of immune effector cells with potent anti-viral and anti-tumor activity; they have the capacity to swiftly recognize and kill cancer cells without the need of prior stimulation. Although NK cells are naturally equipped with cytotoxic potential, a growing body of evidence shows the added benefit of engineering them to better target tumor cells, persist longer in the host, and be fitter to resist the hostile tumor microenvironment (TME). NK-cell-based immunotherapies allow for the development of allogeneic off-the-shelf products, which have the potential to be less expensive and readily available for patients in need. In this review, we will focus on the advances in the development of engineering of NK cells for cancer immunotherapy. We will discuss the sourcing of NK cells, the technologies available to engineer NK cells, current clinical trials utilizing engineered NK cells, advances on the engineering of receptors adapted for NK cells, and stealth approaches to avoid recipient immune responses. We will conclude with comments regarding the next generation of NK cell products, i.e., armored NK cells with enhanced functionality, fitness, tumor-infiltration potential, and with the ability to overcome tumor heterogeneity and immune evasion.	[Rossi, Fiorella; Fredericks, Nathaniel; Snowden, Andrew; Allegrezza, Michael J.; Moreno-Nieves, Uriel Y.] Pharmaceut Co Johnson & Johnson, Janssen Res & Dev LLC, Spring House, PA 19002 USA	Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Moreno-Nieves, UY (corresponding author), Pharmaceut Co Johnson & Johnson, Janssen Res & Dev LLC, Spring House, PA 19002 USA.	umorenon@its.jnj.com						Abel AM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01869; Abramson JS, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127508; Al-Moussawy M, 2022, IMMUNOGENETICS, V74, P179, DOI 10.1007/s00251-021-01240-7; Alvaro-Naranjo T, 2005, LEUKEMIA LYMPHOMA, V46, P1581, DOI 10.1080/10428190500220654; Amrolia PJ, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-118616; Anders C, 2008, ONCOLOGY-NY, V22, P1233; Atsavapranee ES, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103354; Bachanova V, 2014, BLOOD, V123, P3855, DOI 10.1182/blood-2013-10-532531; Bachanova V, 2010, CANCER IMMUNOL IMMUN, V59, P1739, DOI 10.1007/s00262-010-0896-z; Barkal AA, 2018, NAT IMMUNOL, V19, P76, DOI 10.1038/s41590-017-0004-z; Dezfouli AB, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10123390; Batchu RB, 2019, SURGERY, V166, P503, DOI 10.1016/j.surg.2019.05.047; Benjamin R, 2020, LANCET, V396, P1885, DOI 10.1016/S0140-6736(20)32334-5; Berdeja JG, 2021, LANCET, V398, P314, DOI 10.1016/S0140-6736(21)00933-8; Berrien-Elliott MM, 2022, BLOOD, V139, P1177, DOI 10.1182/blood.2021011532; Bexte T, 2021, BLOOD, V138, DOI 10.1182/blood-2021-153999; Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463; Boissel L, 2012, LEUKEMIA LYMPHOMA, V53, P958, DOI 10.3109/10428194.2011.634048; Boissel L, 2009, LEUKEMIA RES, V33, P1255, DOI 10.1016/j.leukres.2008.11.024; Bollard CM, 2018, J CLIN ONCOL, V36, P1128, DOI 10.1200/JCO.2017.74.3179; Boudreau JE, 2018, TRENDS IMMUNOL, V39, P222, DOI 10.1016/j.it.2017.12.001; Bray F, 2021, CANCER-AM CANCER SOC, V127, P3029, DOI 10.1002/cncr.33587; BROCKER T, 1995, J EXP MED, V181, P1653, DOI 10.1084/jem.181.5.1653; Brown CE, 2016, NEW ENGL J MED, V375, P2561, DOI 10.1056/NEJMoa1610497; Bryceson YT, 2006, BLOOD, V107, P159, DOI 10.1182/blood-2005-04-1351; Burns LJ, 2003, BONE MARROW TRANSPL, V32, P177, DOI 10.1038/sj.bmt.1704086; Caligiuri MA, 2008, BLOOD, V112, P461, DOI 10.1182/blood-2007-09-077438; Cannella S, 2007, CANCER-AM CANCER SOC, V109, P2566, DOI 10.1002/cncr.22718; Carayol G, 1998, EUR J IMMUNOL, V28, P1991, DOI 10.1002/(SICI)1521-4141(199806)28:06<1991::AID-IMMU1991>3.0.CO;2-7; Carlsten M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00105; Carlsten M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00266; Cartron G, 2002, BLOOD, V99, P754, DOI 10.1182/blood.V99.3.754; Castagna L, 2016, TRANSFUS APHER SCI, V54, P345, DOI 10.1016/j.transci.2016.05.011; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Chandrasekaran S, 2016, BIOMATERIALS, V77, P66, DOI 10.1016/j.biomaterials.2015.11.001; Chang ZNL, 2018, NAT CHEM BIOL, V14, P317, DOI [10.1038/nchembio.2565, 10.1038/NCHEMBIO.2565]; Chen ZH, 2022, BIOMATERIALS, V280, DOI 10.1016/j.biomaterials.2021.121259; Cheng ZF, 2021, BIOCHEM BIOPHYS REP, V26, DOI 10.1016/j.bbrep.2021.100935; Chmielewski M, 2014, IMMUNOL REV, V257, P83, DOI 10.1111/imr.12125; Chmielewski M, 2012, CANCER IMMUNOL IMMUN, V61, P1269, DOI 10.1007/s00262-012-1202-z; Clementi R, 2005, BLOOD, V105, P4424, DOI 10.1182/blood-2004-04-1477; Coca S, 1997, CANCER-AM CANCER SOC, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P; Colamartino ABL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02873; Conlon KC, 2015, J CLIN ONCOL, V33, P74, DOI 10.1200/JCO.2014.57.3329; Cooley S, 2010, BLOOD, V116, P2411, DOI 10.1182/blood-2010-05-283051; Cooper MA, 2009, P NATL ACAD SCI USA, V106, P1915, DOI 10.1073/pnas.0813192106; Crowther MD, 2020, NAT IMMUNOL, V21, P178, DOI 10.1038/s41590-019-0578-8; Cursons J, 2019, CANCER IMMUNOL RES, V7, P1162, DOI 10.1158/2326-6066.CIR-18-0500; Curti A, 2011, BLOOD, V118, P3273, DOI 10.1182/blood-2011-01-329508; Daher M, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1274; Dai HH, 2020, SCIENCE, V368, P1122, DOI 10.1126/science.aax4040; Delconte RB, 2016, NAT IMMUNOL, V17, P816, DOI 10.1038/ni.3470; Denning W, 2013, MOL BIOTECHNOL, V53, P308, DOI 10.1007/s12033-012-9528-5; Deuse T, 2021, J EXP MED, V218, DOI 10.1084/jem.20200839; Deuse T, 2019, NAT BIOTECHNOL, V37, P252, DOI 10.1038/s41587-019-0016-3; DeWolf S, 2017, J CLIN INVEST, V127, P2473, DOI 10.1172/JCI90595; DiTommaso T, 2018, P NATL ACAD SCI USA, V115, pE10907, DOI 10.1073/pnas.1809671115; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Eisenberg V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01212; El-Mayta R, 2021, CANCER GENE THER, V28, P947, DOI 10.1038/s41417-021-00336-2; Epling-Burnette PK, 2007, BLOOD, V109, P4816, DOI 10.1182/blood-2006-07-035519; Esfahani K, 2020, CURR ONCOL, V27, pS87, DOI 10.3747/co.27.5223; ESHHAR Z, 1993, P NATL ACAD SCI USA, V90, P720, DOI 10.1073/pnas.90.2.720; Ettinghausen SE., 1986, CANCER RES, V46, P51, DOI [10.1007/BF00201905, DOI 10.1007/BF00201905]; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Fedorov VD, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006597; Freud AG, 2017, IMMUNITY, V47, P820, DOI 10.1016/j.immuni.2017.10.008; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Giebel S, 2003, BLOOD, V102, P814, DOI 10.1182/blood-2003-01-0091; Giebel S, 2009, EUR J HAEMATOL, V83, P343, DOI 10.1111/j.1600-0609.2009.01280.x; GLAS R, 1992, J EXP MED, V175, P843, DOI 10.1084/jem.175.3.843; Gonzalez-Rodriguez AP, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101557; Goodridge JP, 2020, BLOOD, V136, DOI 10.1182/blood-2020-142750; GRIMM EA, 1983, J EXP MED, V158, P1356, DOI 10.1084/jem.158.4.1356; GRIMM EA, 1982, J EXP MED, V155, P1823, DOI 10.1084/jem.155.6.1823; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Guo CJ, 2019, MOL IMMUNOL, V114, P108, DOI 10.1016/j.molimm.2019.07.009; Guven H, 2005, EXP HEMATOL, V33, P1320, DOI 10.1016/j.exphem.2005.07.006; Gwalani LA, 2018, J IMMUNOL, V200, P3231, DOI 10.4049/jimmunol.1701500; Han X, 2019, P NATL ACAD SCI USA, V116, P10441, DOI 10.1073/pnas.1902566116; HARRISON D, 1991, J IMMUNOL, V147, P3459; Hashemi E, 2020, CANCERS, V12, DOI 10.3390/cancers12061553; Hermanson DL, 2016, STEM CELLS, V34, P93, DOI 10.1002/stem.2230; Hirayasu K, 2015, J HUM GENET, V60, P703, DOI 10.1038/jhg.2015.64; Hoerster K, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586168; Hong SL, 2021, ANGEW CHEM INT EDIT, V60, P3603, DOI 10.1002/anie.202005934; Hossain N, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-110142; Hudecek M, 2018, CURR OPIN GENET DEV, V52, P100, DOI 10.1016/j.gde.2018.06.003; Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140-6736(00)03231-1; Imamura M, 2014, BLOOD, V124, P1081, DOI 10.1182/blood-2014-02-556837; Inoue M, 2012, ONCOIMMUNOLOGY, V1, P1104, DOI 10.4161/onci.21056; Ishigami S, 2000, CANCER, V88, P577, DOI 10.1002/(SICI)1097-0142(20000201)88:3<577::AID-CNCR13>3.0.CO;2-V; Ito S, 2014, MOL THER, V22, P1388, DOI 10.1038/mt.2014.50; Jing YW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121788; Jurisic V, 2007, MED ONCOL, V24, P312, DOI 10.1007/s12032-007-0007-y; Kim KS, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13040525; Kim KS, 2019, BIOMATERIALS, V221, DOI 10.1016/j.biomaterials.2019.119418; Kim MS, 2017, MOL CELLS, V40, P533, DOI 10.14348/molcells.2017.0139; Klingemann H G, 1996, Biol Blood Marrow Transplant, V2, P68; Kloss CC, 2018, MOL THER, V26, P1855, DOI 10.1016/j.ymthe.2018.05.003; Kloss CC, 2013, NAT BIOTECHNOL, V31, P71, DOI 10.1038/nbt.2459; Knorr DA, 2013, STEM CELL TRANSL MED, V2, P274, DOI 10.5966/sctm.2012-0084; Kobayashi H, 2000, CANCER RES, V60, P3577; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; Kuroki K, 2005, HUM MOL GENET, V14, P2469, DOI 10.1093/hmg/ddi247; KUWANA Y, 1987, BIOCHEM BIOPH RES CO, V149, P960, DOI 10.1016/0006-291X(87)90502-X; LAFRENIERE R, 1985, CANCER RES, V45, P3735; Lanitis E, 2013, CANCER IMMUNOL RES, V1, P43, DOI 10.1158/2326-6066.CIR-13-0008; Lanza R, 2019, NAT REV IMMUNOL, V19, P723, DOI 10.1038/s41577-019-0200-1; Lee H, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1537581; Leivas A, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00537-w; Leko V, 2020, CANCER CELL, V38, P454, DOI 10.1016/j.ccell.2020.07.013; Li BL, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136570; Li HK, 2021, CANCERS, V13, DOI 10.3390/cancers13112724; Li MF, 2020, BIOCHEM BIOPH RES CO, V523, P745, DOI 10.1016/j.bbrc.2020.01.005; Li Y, 2018, CELL STEM CELL, V23, P181, DOI 10.1016/j.stem.2018.06.002; Li Y, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001328; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Liu H, 2015, ONCOL REP, V33, P95, DOI 10.3892/or.2014.3548; Liu XJ, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0381-z; Loo J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00893-4; Louis CU, 2011, BLOOD, V118, P6050, DOI 10.1182/blood-2011-05-354449; Lowe E, 2016, METHODS MOL BIOL, V1441, P241, DOI 10.1007/978-1-4939-3684-7_20; Lu CG, 2020, MOL IMMUNOL, V122, P200, DOI 10.1016/j.molimm.2020.04.016; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Majzner RG, 2019, CLIN CANCER RES, V25, P2560, DOI 10.1158/1078-0432.CCR-18-0432; Malmberg KJ, 2017, IMMUNOGENETICS, V69, P547, DOI 10.1007/s00251-017-1011-9; Marino J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00582; Marks-Konczalik J, 2000, P NATL ACAD SCI USA, V97, P11445, DOI 10.1073/pnas.200363097; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.2801.2801; Michel T, 2016, J IMMUNOL, V196, P2923, DOI 10.4049/jimmunol.1502570; Miller JS, 2005, BLOOD, V105, P3051, DOI 10.1182/blood-2004-07-2974; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Mizia-Malarz A, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/3596983; Mo FY, 2021, NAT BIOTECHNOL, V39, P56, DOI 10.1038/s41587-020-0601-5; MOLLICONE R, 1988, BLOOD, V71, P1113; Montaldo E, 2016, IMMUNOL LETT, V179, P2, DOI 10.1016/j.imlet.2016.01.007; Montgomery RA, 2011, SEMIN IMMUNOL, V23, P224, DOI 10.1016/j.smim.2011.08.021; Moreno-Nieves UY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101169118; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Muller N, 2015, J IMMUNOTHER, V38, P197, DOI 10.1097/CJI.0000000000000082; MULE JJ, 1984, SCIENCE, V225, P1487, DOI 10.1126/science.6332379; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Nersesian S, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100930; Ng YY, 2020, MOL THER-ONCOLYTICS, V16, P75, DOI 10.1016/j.omto.2019.12.006; Oberg L, 2004, EUR J IMMUNOL, V34, P1646, DOI 10.1002/eji.200424913; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Pahl JHW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02796; Parkhurst MR, 2011, CLIN CANCER RES, V17, P6287, DOI 10.1158/1078-0432.CCR-11-1347; Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272; Passweg JR, 2004, LEUKEMIA, V18, P1835, DOI 10.1038/sj.leu.2403524; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Peng H, 2017, SEMIN IMMUNOL, V31, P3, DOI 10.1016/j.smim.2017.07.006; PHILLIPS JH, 1986, J EXP MED, V164, P814, DOI 10.1084/jem.164.3.814; Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603; Pomeroy EJ, 2020, MOL THER, V28, P52, DOI 10.1016/j.ymthe.2019.10.009; Pont MJ, 2019, BLOOD, V134, P1585, DOI 10.1182/blood.2019000050; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Rambaldi A, 2015, LEUKEMIA, V29, P1, DOI 10.1038/leu.2014.189; Riggan L, 2019, TRENDS IMMUNOL, V40, P909, DOI 10.1016/j.it.2019.08.005; Roemer MGM, 2016, CANCER IMMUNOL RES, V4, P910, DOI 10.1158/2326-6066.CIR-16-0201; Romano E, 2021, STEM CELL RES, V57, DOI 10.1016/j.scr.2021.102580; Romee R, 2013, BLOOD, V121, P3599, DOI 10.1182/blood-2012-04-425397; ROSENBERG SA, 1993, JNCI-J NATL CANCER I, V85, P622, DOI 10.1093/jnci/85.8.622; Rosenberg SA, 2000, CANCER J, V6, pS2; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Roybal KT, 2016, CELL, V164, P770, DOI 10.1016/j.cell.2016.01.011; Rubnitz JE, 2010, J CLIN ONCOL, V28, P955, DOI 10.1200/JCO.2009.24.4590; Ruggeri L, 2002, SCIENCE, V295, P2097, DOI 10.1126/science.1068440; Saetersmoen ML, 2019, SEMIN IMMUNOPATHOL, V41, P59, DOI 10.1007/s00281-018-0721-x; Sander JD, 2014, NAT BIOTECHNOL, V32, P347, DOI 10.1038/nbt.2842; Sarvaria A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00329; Sato Y, 2019, CYTOTHERAPY, V21, P1095, DOI 10.1016/j.jcyt.2019.10.001; Savoldo B, 2011, J CLIN INVEST, V121, P1822, DOI 10.1172/JCI46110; Schneider D, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0246-1; Schultz LM, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117445; Sharei A, 2013, P NATL ACAD SCI USA, V110, P2082, DOI 10.1073/pnas.1218705110; Shi J, 2008, BRIT J HAEMATOL, V143, P641, DOI 10.1111/j.1365-2141.2008.07340.x; Shifrin N, 2014, SEMIN IMMUNOL, V26, P138, DOI 10.1016/j.smim.2014.02.007; Shimasaki N, 2020, NAT REV DRUG DISCOV, V19, P200, DOI 10.1038/s41573-019-0052-1; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Siegler EL, 2017, MOL THER, V25, P2607, DOI 10.1016/j.ymthe.2017.08.010; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Somanchi SS, 2012, BLOOD, V119, P5164, DOI 10.1182/blood-2011-11-389924; Spanholtz J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020740; STANCOVSKI I, 1993, J IMMUNOL, V151, P6577; Sterner RC, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00459-7; Streltsova MA, 2017, J IMMUNOL METHODS, V450, P90, DOI 10.1016/j.jim.2017.08.003; Sullivan EM, 2014, CLIN CANCER RES, V20, P5986, DOI 10.1158/1078-0432.CCR-14-0479; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Sungur Can M., 2014, Critical Reviews in Oncogenesis, V19, P57; Symons HJ, 2010, BIOL BLOOD MARROW TR, V16, P533, DOI 10.1016/j.bbmt.2009.11.022; Takanami I, 2001, J THORAC CARDIOV SUR, V121, P1058, DOI 10.1067/mtc.2001.113026; Takizawa H, 2007, NAT IMMUNOL, V8, P1287, DOI 10.1038/ni1207-1287; Tal Y, 2014, ONCOTARGET, V5, P10949, DOI 10.18632/oncotarget.1919; Tang XW, 2018, AM J CANCER RES, V8, P1083; TOSI MF, 1992, J CLIN INVEST, V90, P462, DOI 10.1172/JCI115882; Tran HC, 2017, CLIN CANCER RES, V23, P804, DOI 10.1158/1078-0432.CCR-16-1743; Valamehr B, 2014, STEM CELL REP, V2, P366, DOI 10.1016/j.stemcr.2014.01.014; van Houdt IS, 2008, INT J CANCER, V123, P609, DOI 10.1002/ijc.23543; Villegas FR, 2002, LUNG CANCER-J IASLC, V35, P23, DOI 10.1016/S0169-5002(01)00292-6; Vitale M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00258; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Waiseng E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11126-y; Wang B, 2021, NAT BIOMED ENG, V5, P429, DOI 10.1038/s41551-021-00730-z; Wang N, 2020, BLOOD, V135, P17, DOI 10.1182/blood.2019000017; Wang XW, 2020, ACS CENTRAL SCI, V6, P382, DOI 10.1021/acscentsci.9b00956; Wang ZJ, 2017, CANCER IMMUNOL IMMUN, V66, P537, DOI 10.1007/s00262-017-1959-1; Wei SC, 2018, CANCER DISCOV, V8, P1069, DOI 10.1158/2159-8290.CD-18-0367; Wendel P, 2021, CANCERS, V13, DOI 10.3390/cancers13061481; Wilk AJ, 2020, BLOOD ADV, V4, P4244, DOI 10.1182/bloodadvances.2020002355; Woan KV, 2021, CELL STEM CELL, V28, P2062, DOI 10.1016/j.stem.2021.08.013; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616; Wu MR, 2015, GENE THER, V22, P675, DOI 10.1038/gt.2015.29; Xiao L, 2019, MOL THER, V27, P1114, DOI 10.1016/j.ymthe.2019.03.011; Xu HG, 2019, CELL STEM CELL, V24, P566, DOI 10.1016/j.stem.2019.02.005; Yang LY, 2011, LEUKEMIA RES, V35, P196, DOI 10.1016/j.leukres.2010.06.016; Yang SH, 2019, SMALL, V15, DOI 10.1002/smll.201900903; Yvon ES, 2017, CYTOTHERAPY, V19, P408, DOI 10.1016/j.jcyt.2016.12.005; Zhang S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01242; Zhang T, 2012, J IMMUNOL, V189, P2290, DOI 10.4049/jimmunol.1103495; Zhao LM, 2014, STEM CELL RES, V13, P342, DOI 10.1016/j.scr.2014.08.004; Zhu H, 2020, CELL STEM CELL, V27, P224, DOI 10.1016/j.stem.2020.05.008; Zhu H, 2020, BLOOD, V135, P399, DOI 10.1182/blood.2019000621	232	0	0	9	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								886429	10.3389/fimmu.2022.886429	http://dx.doi.org/10.3389/fimmu.2022.886429			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3GB	35720306	gold, Green Published			2022-12-18	WOS:000812116300001
J	Schwartz, DM; Parel, P; Li, HO; Sorokin, AV; Berg, AR; Chen, MR; Dey, A; Hong, CSG.; Playford, M; Sylvester, M; Teague, H; Siegel, E; Mehta, NN				Schwartz, Daniella M.; Parel, Philip; Li, Haiou; Sorokin, Alexander V.; Berg, Alexander R.; Chen, Marcus; Dey, Amit; Hong, Christin G.; Playford, Martin; Sylvester, McKella; Teague, Heather; Siegel, Evan; Mehta, Nehal N.			PET/CT-Based Characterization of 18F-FDG Uptake in Various Tissues Reveals Novel Potential Contributions to Coronary Artery Disease in Psoriatic Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; psoriatic arthritis; cardiovascular disease; atherogenesis; PSA; imaging	CARDIOVASCULAR EVENTS; BURDEN; RISK	Background and ObjectivesPsoriasis is a heterogeneous inflammatory disease that involves the skin, joints, liver, heart, and other organs. Psoriatic arthritis (PsA) is associated with cardiovascular disease (CVD), but the relative contributions of inflammatory and metabolic dysregulation to CVD are incompletely understood. We set out to discover novel potential contributors to CVD in PsA patients by comprehensively phenotyping a cohort of PsA patients using these advanced technologies. MethodsIn this cross-sectional analysis of a cohort study, we investigated associations of systemic inflammation and metabolic dysregulation with Coronary CT angiography (CCTA)-proven coronary artery disease (CAD) in 39 subjects with PsA. We measured traditional CVD risk factors [blood pressure, Body Mass Index (BMI), diabetes, age, sex, smoking], serum markers of systemic inflammation (hsCRP, GlycA) and metabolic dysfunction (cholesterol efflux capacity), and inflammatory cytokines (IL-1 beta, IL-6, IL-12/IL-23, IL-17A, TNF-alpha, IFN-gamma). We also incorporated radiographic measures of metabolic dysfunction (visceral and subcutaneous adipose volume) and tissue-specific inflammation (positron emission tomography-computed tomography, PET-CT). To quantify relative contributions of FDG (fluorodeoxyglucose) uptake and adiposity to coronary plaque, we performed multiple linear regression, controlling for Framingham risk score (FRS) and FRS + visceral adiposity. ResultsCompared with non-psoriatic volunteers, subjects with PsA had elevated markers of metabolic and inflammatory disease, which was more pronounced in subjects with moderate-to-severe skin disease. This included visceral (p = 0.005) and subcutaneous (p = 0.004) adiposity, BMI (p = 0.001), hemoglobin A1C (p = 0.037), high sensitivity C-reactive protein (p = 0.005), IL-6 (p = 0.003), IFN-gamma (p = 0.006), and liver FDG uptake (p = 0.03). In subjects with PsA, visceral adiposity correlated significantly with subclinical CAD (standardized beta = 0.681, p = 0.002), as did FDG uptake in bone marrow (standardized beta = 0.488, p = 0.008), liver (standardized beta = 0.619, p < 0.001), spleen (standardized beta = 0.523, p = 0.004), and subcutaneous adipose (standardized beta = 0.524, p = 0.003). InterpretationTogether, these findings reveal inflammatory and metabolic potential contributors to subclinical CAD in PsA, including adipose inflammation, and suggesting novel targets for CVD prevention and treatment in PsA.	[Schwartz, Daniella M.; Sylvester, McKella] NIH, Natl Inst Allergy & Infect Dis, Bethesda, MD 20892 USA; [Schwartz, Daniella M.] Univ Pittsburgh, Sch Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15213 USA; [Parel, Philip; Li, Haiou; Sorokin, Alexander V.; Berg, Alexander R.; Chen, Marcus; Hong, Christin G.; Playford, Martin; Teague, Heather; Mehta, Nehal N.] NHLBI, NIH, Bethesda, MD 20892 USA; [Dey, Amit] Georgetown Univ Med Ctr, Dept Internal Med, Washington, DC USA; [Siegel, Evan] Arthrit & Rheumatism Associates, Wheaton, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Georgetown University	Schwartz, DM (corresponding author), NIH, Natl Inst Allergy & Infect Dis, Bethesda, MD 20892 USA.; Schwartz, DM (corresponding author), Univ Pittsburgh, Sch Med, Div Rheumatol & Clin Immunol, Pittsburgh, PA 15213 USA.	Daniella.Schwartz@nih.gov		Parel, Philip/0000-0002-1272-3316; Berg, Alexander/0000-0002-8480-0181				Bastard JP, 1999, CIRCULATION, V99, P2221; Cheng Isaac T, 2020, RMD Open, V6, DOI 10.1136/rmdopen-2020-001364; Choi H, 2020, CIRC-CARDIOVASC IMAG, V13, DOI 10.1161/CIRCIMAGING.120.011199; Colunga-Pedraza IJ, 2021, ANN RHEUM DIS, V80, P1629, DOI 10.1136/annrheumdis-2021-220782; Connelly MA, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1321-6; Dey AK, 2017, JAMA CARDIOL, V2, P1013, DOI 10.1001/jamacardio.2017.1213; Eder L, 2016, ANN RHEUM DIS, V75, P1680, DOI 10.1136/annrheumdis-2015-207980; Eder L, 2013, ANN RHEUM DIS, V72, P1956, DOI 10.1136/annrheumdis-2012-202325; Fischer C, 2013, J CARDIOVASC COMPUT, V7, P256, DOI 10.1016/j.jcct.2013.08.006; Gladman DD, 2009, ANN RHEUM DIS, V68, P1131, DOI 10.1136/ard.2008.094839; Goncalves RSG, 2020, ANN RHEUM DIS, V79, DOI 10.1136/annrheumdis-2019-215960; Harrington CL, 2017, AM J PHYSIOL-HEART C, V312, pH867, DOI 10.1152/ajpheart.00774.2016; Husted JA, 2011, ARTHRIT CARE RES, V63, P1729, DOI 10.1002/acr.20627; Lam SHM, 2020, ANN RHEUM DIS, V79, P1320, DOI 10.1136/annrheumdis-2020-217595; Lerman JB, 2017, CIRCULATION, V136, P263, DOI 10.1161/CIRCULATIONAHA.116.026859; Manyak GA, 2022, J INVEST DERMATOL, V142, P2030, DOI 10.1016/j.jid.2021.10.031; Mease PJ, 2016, ARTHRITIS RHEUMATOL, V68, P2163, DOI 10.1002/art.39700; Neter J, 2005, APPL LINEAR STAT MOD, V5th; Ogdie A, 2015, ANN RHEUM DIS, V74, P326, DOI 10.1136/annrheumdis-2014-205675; Powell-Wiley TM, 2021, CIRCULATION, V143, pE984, DOI 10.1161/CIR.0000000000000973; Ridker PM, 2021, CIRC RES, V128, P1728, DOI 10.1161/CIRCRESAHA.121.319077; Rose S, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0258-2; Rose S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4676; Sajja A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142534; Salahuddin T, 2015, EUR HEART J, V36, P2662, DOI 10.1093/eurheartj/ehv339; Teklu M, 2021, J AM ACAD DERMATOL, V84, P1329, DOI 10.1016/j.jaad.2020.12.044; Yiu KH, 2013, J INTERN MED, V273, P273, DOI 10.1111/joim.12002	27	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								909760	10.3389/fimmu.2022.909760	http://dx.doi.org/10.3389/fimmu.2022.909760			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E1YM	35720288	gold, Green Published			2022-12-18	WOS:000812029000001
J	Shi, ZZ; Takeuchi, T; Nakanishi, Y; Kato, T; Beck, K; Nagata, R; Kageyama, T; Ito, A; Ohno, H; Satoh-Takayama, N				Shi, Zhengzheng; Takeuchi, Tadashi; Nakanishi, Yumiko; Kato, Tamotsu; Beck, Katharina; Nagata, Ritsu; Kageyama, Tomoko; Ito, Ayumi; Ohno, Hiroshi; Satoh-Takayama, Naoko			A Japanese Herbal Formula, Daikenchuto, Alleviates Experimental Colitis by Reshaping Microbial Profiles and Enhancing Group 3 Innate Lymphoid Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Japanese herbal medicine (Kampo medicine); Daikenchuto (DKT); biomolecular functions of herbal medicine; experimental colitis; Lactobacillaceae; gut microbiota; colonic homeostasis; group 3 innate lymphoid cells (ILC3s)	GUT MICROBIOTA; MUC2 MUCIN; MEDICINE; COLON; EXPRESSION; RESPONSES; DISEASE	Daikenchuto (DKT) is one of the most widely used Japanese herbal formulae for various gastrointestinal disorders. It consists of Zanthoxylum Fructus (Japanese pepper), Zingiberis Siccatum Rhizoma (processed ginger), Ginseng radix, and maltose powder. However, the use of DKT in clinical settings is still controversial due to the limited molecular evidence and largely unknown therapeutic effects. Here, we investigated the anti-inflammatory actions of DKT in the dextran sodium sulfate (DSS)-induced colitis model in mice. We observed that DKT remarkably attenuated the severity of experimental colitis while maintaining the members of the symbiotic microbiota such as family Lactobacillaceae and increasing levels of propionate, an immunomodulatory microbial metabolite, in the colon. DKT also protected colonic epithelial integrity by upregulating the fucosyltransferase gene Fut2 and the antimicrobial peptide gene Reg3g. More remarkably, DKT restored the reduced colonic group 3 innate lymphoid cells (ILC3s), mainly ROR gamma t(high)-ILC3s, in DSS-induced colitis. We further demonstrated that ILC3-deficient mice showed increased mortality during experimental colitis, suggesting that ILC3s play a protective function on colonic inflammation. These findings demonstrate that DKT possesses anti-inflammatory activity, partly via ILC3 function, to maintain the colonic microenvironment. Our study also provides insights into the molecular basis of herbal medicine effects, promotes more profound mechanistic studies towards herbal formulae and contributes to future drug development.	[Shi, Zhengzheng; Takeuchi, Tadashi; Nakanishi, Yumiko; Kato, Tamotsu; Beck, Katharina; Nagata, Ritsu; Kageyama, Tomoko; Ito, Ayumi; Ohno, Hiroshi; Satoh-Takayama, Naoko] RIKEN Ctr Integrat Med Sci, Lab Intestinal Ecosyst, Yokohama, Japan; [Shi, Zhengzheng; Ohno, Hiroshi] Chiba Univ, Grad Sch Med & Pharmaceut Sci, Lab Immune Regulat, Chiba, Japan; [Nakanishi, Yumiko; Kato, Tamotsu; Nagata, Ritsu; Kageyama, Tomoko; Ito, Ayumi; Ohno, Hiroshi; Satoh-Takayama, Naoko] Yokohama City Univ, Grad Sch Med Life Sci, Immunobiol Lab, Yokohama, Japan	RIKEN; Chiba University; Yokohama City University	Satoh-Takayama, N (corresponding author), RIKEN Ctr Integrat Med Sci, Lab Intestinal Ecosyst, Yokohama, Japan.; Satoh-Takayama, N (corresponding author), Yokohama City Univ, Grad Sch Med Life Sci, Immunobiol Lab, Yokohama, Japan.	naoko.satoh@riken.jp			RIKEN Junior Research Associate (JRA) Program; Deutsche Forschungsgemeinschaft (DFG) [BE 6909/1-1]; Japan Society for the Promotion of Science KAKENHI [20KK0360, 19H01030, 19F19785]; Japan Agency for Medical Research and Development AMED-PRIME; Yakult Bio-Science foundation	RIKEN Junior Research Associate (JRA) Program; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Agency for Medical Research and Development AMED-PRIME(Japan Agency for Medical Research and Development (AMED)); Yakult Bio-Science foundation	ZS, TT and RN are recipients of RIKEN Junior Research Associate (JRA) Program. KB was supported by Deutsche Forschungsgemeinschaft (DFG; BE 6909/1-1). NS-T was supported by the Japan Society for the Promotion of Science KAKENHI (20KK0360), the Japan Agency for Medical Research and Development AMED-PRIME and Yakult Bio-Science foundation. HO was supported by the Japan Society for the Promotion of Science KAKENHI (19H01030, 19F19785).	Acosta A, 2016, J NEUROGASTROENTEROL, V22, P69, DOI 10.5056/jnm15120; Alatab S, 2020, LANCET GASTROENTEROL, V5, P17, DOI 10.1016/S2468-1253(19)30333-4; Bachmanov AA, 2002, BEHAV GENET, V32, P435, DOI 10.1023/A:1020884312053; Bent S, 2008, J GEN INTERN MED, V23, P854, DOI 10.1007/s11606-008-0632-y; Brinkman BM, 2013, INFLAMM BOWEL DIS, V19, P2560, DOI 10.1097/MIB.0b013e3182a8759a; Chen CC, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00789; Derrien M, 2015, TRENDS MICROBIOL, V23, P354, DOI 10.1016/j.tim.2015.03.002; Eardley S, 2012, FORSCH KOMPLEMENTMED, V19, P18, DOI 10.1159/000342708; Eberl G, 2004, NAT IMMUNOL, V5, P64, DOI 10.1038/ni1022; Ekor M, 2014, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00177; El Hage R, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01206; Endo M, 2014, J GASTROENTEROL, V49, P1026, DOI 10.1007/s00535-013-0854-6; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Goldberg R, 2015, NAT REV GASTRO HEPAT, V12, P271, DOI 10.1038/nrgastro.2015.52; Goto Y, 2014, SCIENCE, V345, P1310, DOI 10.1126/science.1254009; Hager C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143824; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Ho S, 2013, CURR PHARM DESIGN, V19, P40; Hueber W, 2012, GUT, V61, P1693, DOI 10.1136/gutjnl-2011-301668; Iturrino J, 2013, ALIMENT PHARM THER, V37, P776, DOI 10.1111/apt.12264; Jakobsson HE, 2015, EMBO REP, V16, P164, DOI 10.15252/embr.201439263; Jang YJ, 2019, GUT MICROBES, V10, P696, DOI 10.1080/19490976.2019.1589281; Johansson MEV, 2011, P NATL ACAD SCI USA, V108, P4659, DOI 10.1073/pnas.1006451107; Kanazawa A, 2014, SURG TODAY, V44, P1506, DOI 10.1007/s00595-013-0747-6; Katayama K, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/576973; Kim DH, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2020.151391; Kogure Y, 2020, JGH OPEN, V4, P1146, DOI 10.1002/jgh3.12410; Kono T, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00159; Kono T, 2010, J CROHNS COLITIS, V4, P161, DOI 10.1016/j.crohns.2009.09.006; Kostic AD, 2015, CELL HOST MICROBE, V17, P260, DOI 10.1016/j.chom.2015.01.001; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matsunaga T, 2017, GASTROENT RES PRACT, V2017, DOI 10.1155/2017/1298263; Mattar AF, 2002, PEDIATR SURG INT, V18, P586, DOI 10.1007/s00383-002-0855-7; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Melo-Gonzalez F, 2017, IMMUNOLOGY, V150, P265, DOI 10.1111/imm.12697; Misselwitz B, 2020, DIGESTION, V101, P69, DOI 10.1159/000507782; Miyoshi J, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/7415975; Mukhopadhya I, 2012, NAT REV GASTRO HEPAT, V9, P219, DOI 10.1038/nrgastro.2012.14; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0; Ohbe H, 2021, JPEN-PARENTER ENTER, V45, P1703, DOI 10.1002/jpen.2076; Oyama F, 2020, ASIA-PAC J CLIN ONCO, V16, P254, DOI 10.1111/ajco.13329; Venegas DP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00277; Qiu J, 2012, IMMUNITY, V36, P92, DOI 10.1016/j.immuni.2011.11.011; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Satoh-Takayama N, 2010, J EXP MED, V207, P273, DOI 10.1084/jem.20092029; Schlenner SM, 2010, IMMUNITY, V32, P426, DOI 10.1016/j.immuni.2010.03.005; Shinyama S, 2017, PEDIATR SURG INT, V33, P1109, DOI 10.1007/s00383-017-4145-9; Skalnikova HK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122697; Subramani DB, 2010, BENEF MICROBES, V1, P343, DOI 10.3920/BM2010.0039; Takeuchi T, 2021, NATURE, V595, P560, DOI 10.1038/s41586-021-03727-5; Ueno N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097456; Vacca M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8040573; Vieco-Saiz N, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00057; Wang YW, 2017, GASTROENTEROLOGY, V152, P193, DOI 10.1053/j.gastro.2016.09.004; Watanabe K, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/neq067; Withers DR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01298; Yoshikawa K, 2015, J AM COLL SURGEONS, V221, P571, DOI 10.1016/j.jamcollsurg.2015.03.004; Zeng BN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1540-2	61	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								903459	10.3389/fimmu.2022.903459	http://dx.doi.org/10.3389/fimmu.2022.903459			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3DV	35720414	Green Published, gold			2022-12-18	WOS:000812110500001
J	Stosik, M; Tokarz-Deptula, B; Deptula, W				Stosik, Michal; Tokarz-Deptula, Beata; Deptula, Wieslaw			Haematopoiesis in Zebrafish (Danio Rerio)	FRONTIERS IN IMMUNOLOGY			English	Review						haematopoietic stem cells; embryonic period haematopoiesis; post-embryonic haematopoiesis; haematopoietic niches; Danio rerio (zebrafish)	STEM-CELLS; DEFINITIVE HEMATOPOIESIS; ADULT ZEBRAFISH; AORTIC ENDOTHELIUM; VASCULAR NICHE; PROGENITOR; BLOOD; REVEALS; DIFFERENTIATION; ROLES	Haematopoiesis in fish and mammals is a complex process, and many aspects regarding its model and the differentiation of haematopoietic stem cells (HSCs) still remain enigmatic despite advanced studies. The effects of microenvironmental factors or HSCs niche and signalling pathways on haematopoiesis are also unclear. This review presents Danio rerio as a model organism for studies on haematopoiesis in vertebrates and discusses the development of this process during the embryonic period and in adult fish. It describes the role of the microenvironment of the haematopoietic process in regulating the formation and function of HSCs/HSPCs (hematopoietic stem/progenitor cells) and highlights facts and research areas important for haematopoiesis in fish and mammals.	[Stosik, Michal] Univ Zielona Gora, Inst Biol Sci, Fac Biol Sci, Zielona Gora, Poland; [Tokarz-Deptula, Beata] Univ Szczecin, Inst Biol, Szczecin, Poland; [Deptula, Wieslaw] Nicolaus Copernicus Univ Torun, Inst Vet Med, Fac Biol & Vet Sci, Torun, Poland	University of Zielona Gora; University of Szczecin; Nicolaus Copernicus University	Tokarz-Deptula, B (corresponding author), Univ Szczecin, Inst Biol, Szczecin, Poland.	beata.tokarz-deptula@usz.edu.pl		Stosik, Michal/0000-0003-3866-5035; Deptula, Wieslaw/0000-0001-5367-7670				Avagyan S, 2016, HUM GENE THER, V27, P287, DOI 10.1089/hum.2016.024; Bertrand JY, 2007, DEVELOPMENT, V134, P4147, DOI 10.1242/dev.012385; Bertrand JY, 2010, BLOOD, V115, P2777, DOI 10.1182/blood-2009-09-244590; Bertrand JY, 2010, NATURE, V464, P108, DOI 10.1038/nature08738; Bertrand JY, 2009, CURR OPIN HEMATOL, V16, P243, DOI 10.1097/MOH.0b013e32832c05e4; Boisset JC, 2010, NATURE, V464, P116, DOI 10.1038/nature08764; Bresciani E, 2014, BLOOD, V124, P70, DOI 10.1182/blood-2013-10-531988; Brown G, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00104; Buenrostro JD, 2018, CELL, V173, P1535, DOI 10.1016/j.cell.2018.03.074; Burns CE, 2005, GENE DEV, V19, P2331, DOI 10.1101/gad.1337005; Campbell C, 2015, EXP HEMATOL, V43, P1047, DOI 10.1016/j.exphem.2015.09.001; Cao JY, 2018, SCIENCE, V361, P1380, DOI 10.1126/science.aau0730; Capron C, 2006, BLOOD, V107, P4678, DOI 10.1182/blood-2005-08-3145; Carradice D, 2008, BLOOD, V111, P3331, DOI 10.1182/blood-2007-10-052761; Carrelha J, 2018, NATURE, V554, P106, DOI 10.1038/nature25455; Chen AT, 2009, J CELL BIOCHEM, V108, P35, DOI 10.1002/jcb.22251; Cheng H, 2020, PROTEIN CELL, V11, P34, DOI 10.1007/s13238-019-0633-0; Ciau-Uitz A, 2014, EXP HEMATOL, V42, P669, DOI 10.1016/j.exphem.2014.06.001; Clements WK, 2013, NAT REV IMMUNOL, V13, P336, DOI 10.1038/nri3443; Cusanovich DA, 2018, CELL, V174, P1309, DOI 10.1016/j.cell.2018.06.052; D'Agati G, 2017, DEV BIOL, V430, P11, DOI 10.1016/j.ydbio.2017.07.017; Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943; Ellett F, 2011, BLOOD, V117, pE49, DOI 10.1182/blood-2010-10-314120; Espin-Palazon R, 2014, CELL, V159, P1070, DOI 10.1016/j.cell.2014.10.031; Gioacchino E, 2021, BLOOD ADV, V5, P2687, DOI 10.1182/bloodadvances.2020002993; Glass TJ, 2011, BLOOD, V118, P766, DOI 10.1182/blood-2011-01-328476; Gore AV, 2018, WIRES DEV BIOL, V7, DOI 10.1002/wdev.312; Gore AV, 2016, EXP HEMATOL, V44, P783, DOI 10.1016/j.exphem.2016.04.013; Gore AV, 2016, ELIFE, V5, DOI 10.7554/eLife.11813; Greig KT, 2008, SEMIN IMMUNOL, V20, P247, DOI 10.1016/j.smim.2008.05.003; Henninger J, 2017, NAT CELL BIOL, V19, P17, DOI 10.1038/ncb3444; Hsia N, 2005, EXP HEMATOL, V33, P1007, DOI 10.1016/j.exphem.2005.06.013; Jagannathan-Bogdan M, 2013, DEVELOPMENT, V140, P2463, DOI 10.1242/dev.083147; Jin H, 2007, BLOOD, V109, P5208, DOI 10.1182/blood-2007-01-069005; Karamitros D, 2018, NAT IMMUNOL, V19, P85, DOI 10.1038/s41590-017-0001-2; Kawakami K, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-S1-S7; Kissa K, 2010, NATURE, V464, P112, DOI 10.1038/nature08761; Kobayashi I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50672-5; Konantz M, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.040360; Kwan KM, 2007, DEV DYNAM, V236, P3088, DOI 10.1002/dvdy.21343; Laurenti E, 2018, NATURE, V553, P418, DOI 10.1038/nature25022; Lefrancais E, 2017, NATURE, V544, P105, DOI 10.1038/nature21706; Li DT, 2018, NATURE, V564, P119, DOI 10.1038/s41586-018-0709-7; Li PL, 2015, NATURE, V523, P468, DOI 10.1038/nature14569; Loughran SJ, 2008, NAT IMMUNOL, V9, P810, DOI 10.1038/ni.1617; Ma DD, 2011, BLOOD, V118, P289, DOI 10.1182/blood-2010-12-327403; Macaulay IC, 2016, CELL REP, V14, P966, DOI 10.1016/j.celrep.2015.12.082; Mahony CB, 2018, STEM CELL REP, V10, P1920, DOI 10.1016/j.stemcr.2018.04.016; Mahony CB, 2016, BLOOD, V128, P1336, DOI 10.1182/blood-2016-04-710137; Massberg S, 2007, CELL, V131, P994, DOI 10.1016/j.cell.2007.09.047; Monteiro R, 2016, DEV CELL, V38, P358, DOI 10.1016/j.devcel.2016.06.024; Murayama E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9375; Nagano T, 2013, NATURE, V502, P59, DOI 10.1038/nature12593; Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025; Page DM, 2013, BLOOD, V122, pE1, DOI 10.1182/blood-2012-12-471029; Paik EJ, 2010, INT J DEV BIOL, V54, P1127, DOI 10.1387/ijdb.093042ep; Nguyen PD, 2014, NATURE, V512, P314, DOI 10.1038/nature13678; Pineault N, 2002, EXP HEMATOL, V30, P49, DOI 10.1016/S0301-472X(01)00757-3; Quesenberry PJ, 2015, STEM CELLS, V33, P15, DOI 10.1002/stem.1829; Quillien A, 2014, DEVELOPMENT, V141, P1544, DOI 10.1242/dev.099986; Rajpurohit SK, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081963; Rossi A, 2015, NATURE, V524, P230, DOI 10.1038/nature14580; Rouf M.A., 2022, GENES DIS, DOI [10.1016/j.gendis.2021.12.003, DOI 10.1016/J.GENDIS.2021.12.003]; Satpathy AT, 2018, NAT MED, V24, P580, DOI 10.1038/s41591-018-0008-8; Stachura DL, 2009, BLOOD, V114, P279, DOI 10.1182/blood-2009-02-203638; Stosik M, 2019, J VET RES, V63, P123, DOI 10.2478/jvetres-2019-0017; Svoboda O, 2014, BLOOD, V124, P220, DOI 10.1182/blood-2014-03-564682; Tamplin OJ, 2015, CELL, V160, P241, DOI 10.1016/j.cell.2014.12.032; Tang Q, 2017, J EXP MED, V214, P2875, DOI 10.1084/jem.20170976; Theodore LN, 2017, STEM CELL REP, V8, P1226, DOI 10.1016/j.stemcr.2017.03.016; Travnickova J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7227; Velten L, 2017, NAT CELL BIOL, V19, P271, DOI 10.1038/ncb3493; Wattrus SJ, 2018, BLOOD ADV, V2, P3063, DOI 10.1182/bloodadvances.2018021725; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; Wolf A, 2017, SCI REP-UK, V7, DOI 10.1038/srep44644; Xia J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2015748118; Xu J, 2018, BLOOD ADV, V2, P2637, DOI 10.1182/bloodadvances.2018023705; Xue YY, 2017, DEV CELL, V42, P349, DOI 10.1016/j.devcel.2017.07.012; Yamamoto R, 2013, CELL, V154, P1112, DOI 10.1016/j.cell.2013.08.007; Yokota T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101138; Zhen FH, 2013, DEVELOPMENT, V140, P3977, DOI 10.1242/dev.097071	81	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								902941	10.3389/fimmu.2022.902941	http://dx.doi.org/10.3389/fimmu.2022.902941			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E1OB	35720291	Green Published, gold			2022-12-18	WOS:000812001800001
J	Torres-Atencio, I; Campble, A; Goodridge, A; Martin, M				Torres-Atencio, Ivonne; Campble, Ariadne; Goodridge, Amador; Martin, Margarita			Uncovering the Mast Cell Response to Mycobacterium tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Review						tuberculosis; mast cells; disease control; histamine; co-infection; biomarker; anti-TB therapy; disease progression	TOLL-LIKE RECEPTOR-2; INNATE IMMUNITY; ANTIMICROBIAL ACTIVITY; LATENT TUBERCULOSIS; LIPOTEICHOIC ACID; HOST-DEFENSE; ACTIVATION; INFECTION; LUNG; INFLAMMATION	The immunologic mechanisms that contribute to the response to Mycobacterium tuberculosis infection still represent a challenge in the clinical management and scientific understanding of tuberculosis disease. In this scenario, the role of the different cells involved in the host response, either in terms of innate or adaptive immunity, remains key for defeating this disease. Among this coordinated cell response, mast cells remain key for defeating tuberculosis infection and disease. Together with its effector's molecules, membrane receptors as well as its anatomical locations, mast cells play a crucial role in the establishment and perpetuation of the inflammatory response that leads to the generation of the granuloma during tuberculosis. This review highlights the current evidences that support the notion of mast cells as key link to reinforce the advancements in tuberculosis diagnosis, disease progression, and novel therapeutic strategies. Special focus on mast cells capacity for the modulation of the inflammatory response among patients suffering multidrug resistant tuberculosis or in co-infections such as current COVID-19 pandemic.	[Torres-Atencio, Ivonne] Univ Panama, Fac Med, Dept Farmacol, Panama City, Panama; [Torres-Atencio, Ivonne; Campble, Ariadne; Goodridge, Amador] AIP, Serv Alta Tecnol INDICASAT AIP, TB Biomarker Res Unit,Ctr Biol Mol & Celular Enfer, Inst Invest Cientif & Serv Alta Tecnol INDICASAT, Ciudad Del Saber, Panama; [Martin, Margarita] Univ Barcelona, Fac Med, Biomed Dept, Biochem Unit, Barcelona, Spain; [Martin, Margarita] IDIBAPS, Lab Clin & Expt Resp Immunoallergy, August Pi I Sunyer Biomed Res Inst, Barcelona, Spain	Universidad de Panama; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Goodridge, A (corresponding author), AIP, Serv Alta Tecnol INDICASAT AIP, TB Biomarker Res Unit,Ctr Biol Mol & Celular Enfer, Inst Invest Cientif & Serv Alta Tecnol INDICASAT, Ciudad Del Saber, Panama.	agoodridge@indicasat.org.pa	Goodridge, Amador/F-9026-2011	Goodridge, Amador/0000-0003-3910-0482				Abraham SN, 2010, NAT REV IMMUNOL, V10, P440, DOI 10.1038/nri2782; Afrin LB, 2020, INT J INFECT DIS, V100, P327, DOI 10.1016/j.ijid.2020.09.016; Al-Afif A, 2015, J ALLERGY CLIN IMMUN, V136, P1346, DOI 10.1016/j.jaci.2015.01.042; Aoki R, 2016, J INVEST DERMATOL, V136, P1290, DOI 10.1016/j.jid.2016.01.030; Ballarin A, 2012, AM J RESP CRIT CARE, V186, P233, DOI 10.1164/rccm.201112-2142OC; Bozzano F, 2014, MEDITERR J HEMATOL I, V6, DOI 10.4084/MJHID.2014.027; Bradding P, 2016, CLIN EXP ALLERGY, V46, P194, DOI 10.1111/cea.12675; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Bussi C, 2019, FEMS MICROBIOL REV, V43, P341, DOI 10.1093/femsre/fuz006; Campillo-Navarro M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01161; Caramori G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022637; Cardinal-Fernandez P, 2016, CHEST, V149, P1155, DOI 10.1016/j.chest.2016.02.635; Carlos D, 2007, J INFECT DIS, V196, P1361, DOI 10.1086/521830; Carlos D, 2009, MICROBES INFECT, V11, P770, DOI 10.1016/j.micinf.2009.04.025; CHAMPSI J, 1995, IMMUNOLOGY, V84, P549; Crisan-Dabija R, 2020, CAN RESPIR J, V2020, DOI 10.1155/2020/1401053; Dawicki W, 2007, CURR OPIN IMMUNOL, V19, P31, DOI 10.1016/j.coi.2006.11.006; Dheda K, 2010, RESPIROLOGY, V15, P433, DOI 10.1111/j.1440-1843.2010.01739.x; Feger F, 2002, TRENDS IMMUNOL, V23, P151, DOI 10.1016/S1471-4906(01)02156-1; Ganbat D, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0185-5; Garcia-Rodriguez KM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01290; Garcia-Rodriguez KM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89659-6; Gengenbacher M, 2012, FEMS MICROBIOL REV, V36, P514, DOI 10.1111/j.1574-6976.2012.00331.x; Gurish MF, 2012, IMMUNITY, V37, P25, DOI 10.1016/j.immuni.2012.07.003; Heemskerk D, 2015, SPRBRIEF PUB HEALT, P1, DOI 10.1007/978-3-319-19132-4; Hoffmann J, 2011, EUR RESPIR J, V37, P1400, DOI 10.1183/09031936.00043310; Jimenez M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685865; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Keshavjee S, 2019, AM J RESP CRIT CARE, V199, P564, DOI 10.1164/rccm.201806-1053PP; Komi DEA, 2022, CLIN REV ALLERG IMMU, V62, P160, DOI 10.1007/s12016-021-08861-6; Komi DEA, 2020, CLIN REV ALLERG IMMU, V58, P298, DOI 10.1007/s12016-019-08729-w; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Liebler JM, 1998, THORAX, V53, P823, DOI 10.1136/thx.53.10.823; Liu QY, 2018, EXP THER MED, V15, P2719, DOI 10.3892/etm.2018.5775; Lyon SM, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.TNMI7-0032-2016; Magalhaes GDO, 2008, ACTA TROP, V105, P62, DOI 10.1016/j.actatropica.2007.10.001; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Marshall JS, 2004, J ALLERGY CLIN IMMUN, V114, P21, DOI 10.1016/j.jaci.2004.04.045; McCurdy JD, 2003, J IMMUNOL, V170, P1625, DOI 10.4049/jimmunol.170.4.1625; Mendez-Enriquez E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00821; Mollerherm H, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00265; Monarrez-Espino J, 2014, MEM I OSWALDO CRUZ, V109, P863, DOI 10.1590/0074-0276140085; Montagna NAD, 2005, CLIN NEUROPATHOL, V24, P284; Munoz S, 2003, J IMMUNOL, V170, P5590, DOI 10.4049/jimmunol.170.11.5590; Munoz S, 2009, SCAND J IMMUNOL, V70, P256, DOI 10.1111/j.1365-3083.2009.02295.x; Murdaca G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102754; Naqvi N, 2021, CELL IMMUNOL, V365, DOI 10.1016/j.cellimm.2021.104380; Pahari S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00193; Paivandy A, 2021, J INNATE IMMUN, V13, P131, DOI 10.1159/000513582; Pejler G, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.00685-2019; PESCI A, 1993, CHEST, V103, P989, DOI 10.1378/chest.103.4.989; Piliponsky AM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122851; Queiroz A, 2017, REV SOC BRAS MED TRO, V50, P9, DOI 10.1590/0037-8682-0230-2016; RATNAM S, 1977, CAN J MICROBIOL, V23, P1245, DOI 10.1139/m77-186; Rios Fernando, 2017, Rev. bras. ter. intensiva, V29, P354, DOI [10.5935/0103-507x.20170044, 10.5935/0103-507X.20170044]; Rivas N, 2020, AM J TROP MED HYG, V103, P1597, DOI 10.4269/ajtmh.20-0756; Saluja R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043547; Schaller T, 2022, ALLERGY, V77, P2237, DOI 10.1111/all.15293; Scriba TJ, 2017, AM J RESP CRIT CARE, V196, P772, DOI 10.1164/rccm.201706-1208OC; Shin JS, 2001, FEMS MICROBIOL LETT, V197, P131, DOI 10.1016/S0378-1097(01)00108-2; Shin K, 2008, J IMMUNOL, V180, P4885, DOI 10.4049/jimmunol.180.7.4885; Simons FER, 2011, J ALLERGY CLIN IMMUN, V128, P1139, DOI 10.1016/j.jaci.2011.09.005; St John AL, 2013, J IMMUNOL, V190, P4458, DOI 10.4049/jimmunol.1203420; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Tan CY, 2022, CLIN EXP ALLERGY, V52, P324, DOI 10.1111/cea.14023; Tancowny BP, 2010, IMMUNOLOGY, V131, P220, DOI 10.1111/j.1365-2567.2010.03296.x; Tang Xiaolei, 2021, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V37, P481; Taweevisit Mana, 2007, Southeast Asian Journal of Tropical Medicine and Public Health, V38, P115; Thangam EB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01873; Theoharides TC, 2004, TRENDS PHARMACOL SCI, V25, P563, DOI 10.1016/j.tips.2004.09.007; Torres-Atencio I, 2018, AM J RESP CRIT CARE, V198, P813, DOI 10.1164/rccm.201803-0436LE; Trivedi NH, 2013, EXPERT REV CLIN IMMU, V9, P129, DOI [10.1586/ECI.12.95, 10.1586/eci.12.95]; van Leth F, 2015, FUTURE MICROBIOL, V10, P905, DOI [10.2217/FMB.15.30, 10.2217/fmb.15.30]; von Kockritz-Blickwede M, 2008, BLOOD, V111, P3070, DOI 10.1182/blood-2007-07-104018; Wang ZP, 2012, J IMMUNOL, V189, P1551, DOI 10.4049/jimmunol.1200471; Wechsler JB, 2022, ALLERGY, V77, P1288, DOI 10.1111/all.15188; Wernersson S, 2014, NAT REV IMMUNOL, V14, P478, DOI 10.1038/nri3690; WHO, 2021, TUBERCULOSIS; Yan SY, 2019, PEERJ, V7, DOI 10.7717/peerj.7404; Yang D, 2001, J LEUKOCYTE BIOL, V69, P691	81	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								886044	10.3389/fimmu.2022.886044	http://dx.doi.org/10.3389/fimmu.2022.886044			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E0FB	35720353	Green Published, gold			2022-12-18	WOS:000811910200001
J	Wang, BJ; Wang, CJ; Feng, JL; Hao, ML; Guo, SG				Wang, Baojie; Wang, Chunjuan; Feng, Jianli; Hao, Maolin; Guo, Shougang			Clinical Features, Treatment, and Prognostic Factors in Neuronal Surface Antibody-Mediated Severe Autoimmune Encephalitis	FRONTIERS IN IMMUNOLOGY			English	Article						severe; autoimmune encephalitis; rituximab; bortezomib; treatment and prognosis	RECEPTOR ENCEPHALITIS	ObjectiveThis study aimed to determine the clinical characteristics and evaluate the efficacy of immunotherapy and the long-term prognosis of severe autoimmune encephalitis (AE) in China. MethodsClinical features, laboratory or radiological findings, and treatment outcomes of 60 severe patients with AE from January 1, 2014, to December 31, 2020, were collected. Continuous variables were compared using the t-test and the nonparametric Mann-Whitney U test, as appropriate. Univariate and multivariable logistic regression analyses were performed to assess the correlations between factors, treatment responses, and prognosis of severe AE. ResultsThe median age of symptom onset was 35 years. Tumors were identified in 23.3% of patients, and 36/60 (60%) patients responded to first-line immunotherapy. Second-line immunotherapy was implemented in 26/60 (43.3%) patients. A significant clinical benefit was observed in 19/26 (73.1%) patients treated with lower dosage rituximab; seven patients were still refractory and received bortezomib as an add-on therapy. During the last follow-up, 48/60 (80%) patients achieved good outcomes (mRS, 0-2), and 10 died. Seventeen patients experienced relapses. A high CD19(+) B-cell count (OR, 1.197; 95% CI [1.043-1.496]; p = 0.041) and a lower neutrophil-to-lymphocyte ratio (NLR; OR, 0.686; 95% CI [0.472-0.884]; p = 0.015) predict the response to first-line treatment and good prognosis, respectively. ConclusionsPatients with severe AE were in critical condition at baseline but could be salvaged after effective rescue immunotherapy. A lower dosage of rituximab could be an optimal option for severe AE. CD19(+) B-cell count and NLR may provide prognostic information for predicting treatment response and outcome of severe AE.	[Wang, Baojie] Shandong Univ, Shandong Prov Hosp, Cheeloo Coll Med, Dept Neurol, Jinan, Peoples R China; [Wang, Baojie; Feng, Jianli; Hao, Maolin] Shandong Second Prov Gen Hosp, Dept Neurol, Jinan, Peoples R China; [Wang, Chunjuan] Shandong First Med Univ, Shandong Prov Hosp, Dept Neurol, Jinan, Peoples R China; [Guo, Shougang] Shandong Univ, Shandong Prov Hosp, Dept Neurol, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong University	Guo, SG (corresponding author), Shandong Univ, Shandong Prov Hosp, Dept Neurol, Jinan, Peoples R China.		wang, jie/GRS-0942-2022; WANG, JINGYI/GSJ-1241-2022		National Natural Science Foundation of China [NSFC82072079]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (Grant No. NSFC82072079).	Abboud H, 2021, J NEUROL NEUROSUR PS, V92, P897, DOI 10.1136/jnnp-2020-325302; Broadley J, 2021, J NEUROIMMUNOL, V353, DOI 10.1016/j.jneuroim.2021.577508; Broadley J, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.597858; Chen B, 2022, J NEUROIMMUNOL, V362, DOI 10.1016/j.jneuroim.2021.577779; da Costa BK, 2020, NEUROLOGY, V95, P733, DOI 10.1212/WNL.0000000000010789; Dalmau J, 2018, NEW ENGL J MED, V378, P840, DOI 10.1056/NEJMra1708712; Dinoto A, 2021, J NEUROIMMUNOL, V356, DOI 10.1016/j.jneuroim.2021.577586; Dubey D, 2018, ANN NEUROL, V83, P166, DOI 10.1002/ana.25131; Durr M, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001086; Gable MS, 2012, CLIN INFECT DIS, V54, P899, DOI 10.1093/cid/cir1038; Gu YX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02611; Hayden Z, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.611597; Lee WJ, 2021, NEUROTHERAPEUTICS, V18, P474, DOI 10.1007/s13311-020-00921-7; Lim JA, 2019, ANN NEUROL, V85, P352, DOI 10.1002/ana.25421; Messina G, 2021, J INTEGR NEUROSCI, V20, P509, DOI 10.31083/j.jin2002054; Nepal G, 2020, ACTA NEUROL SCAND, V142, P449, DOI 10.1111/ane.13291; Shan W, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621599; Sonar SA, 2018, J LEUKOCYTE BIOL, V103, P839, DOI 10.1002/JLB.1RU1117-428R; Thaler FS, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001088; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tuzun E, 2009, ACTA NEUROPATHOL, V118, P737, DOI 10.1007/s00401-009-0582-4; van Sonderen A, 2016, NEUROLOGY, V87, P1449; Vitaliani R, 2005, ANN NEUROL, V58, P594, DOI 10.1002/ana.20614; Vogrig A, 2020, THER ADV NEUROL DISO, V13, DOI 10.1177/1756286420932797; Wagnon I, 2020, BRAIN, V143, P2957, DOI 10.1093/brain/awaa250; Wang TT, 2021, J NEUROIMMUNOL, V354, DOI 10.1016/j.jneuroim.2021.577527; Wesselingh R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02066; Xu XL, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000633; Yu YC, 2021, MULT SCLER RELAT DIS, V47, DOI 10.1016/j.msard.2020.102604; Zeng ZL, 2019, NEUROSCI LETT, V694, P129, DOI 10.1016/j.neulet.2018.12.003; Zhang Y, 2021, ANN CLIN TRANSL NEUR, V8, P763, DOI 10.1002/acn3.51313	31	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								890656	10.3389/fimmu.2022.890656	http://dx.doi.org/10.3389/fimmu.2022.890656			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2WL	35720290	gold, Green Published			2022-12-18	WOS:000812773600001
J	Weng, SC; Wen, MC; Hsieh, SL; Chen, NJ; Tarng, DC				Weng, Shuo-Chun; Wen, Mei-Chin; Hsieh, Shie-Liang; Chen, Nien-Jung; Tarng, Der-Cherng			Decoy Receptor 3 Suppresses T-Cell Priming and Promotes Apoptosis of Effector T-Cells in Acute Cell-Mediated Rejection: The Role of Reverse Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						adaptor protein; decoy receptor; minor antigenic determinant; knockout; phenotype; transgenic mice	NECROSIS-FACTOR RECEPTOR; FAS LIGAND; DEATH; TRADD; PROGRESSION; MODULATION; ACTIVATION; EXPRESSION	BackgroundDecoy receptor 3 (DcR3) belongs to the tumor necrosis factor (TNF) receptor superfamily and neutralizes TNF ligands, including FasL and TRAIL, to prevent T activation during T-cell priming. However, the cellular mechanisms underlying acute cell-mediated rejection (ACMR) remain unknown. MethodsWe generated DcR3 transgenic (Tg) mice and mice with high DcR3 expression (HDE) to study both in vivo and in vitro. FasR RNA knockdown in immortalized CD4(+)CD8(+) T-cells was used to survey the role of DcR3 on FasR/Fas-associated protein with death domain (FADD)/caspase 8 pathway and its cross-link to TNF receptor-associated factor 1 (TNFR1)-associated death domain protein (TRADD) in suppressing TNFR1. TNF/TRADD knockout mice were used to show the importance of TNF adaptor protein. ResultsDcR3.Fc suppressed C57BL/6 female T-cell activation and transformation into CD4(+)CD69(+), CD4(+)CD44(+), and CD4(+)CD25(+)Foxp3(+) when compared with isotype IgG1 and its co-treatment with FasL/TRAIL after exposing to bone marrow-derived dendritic cells (BMDCs) that carried alloantigen with male H-Y and minor antigenic determinant. Interleukin-17 and interferon-gamma productions by BMDC-activated T-cells were lowered after co-treating with DcR3.Fc. DcR3.Fc induced effector T-cells (Teffs) and was susceptible to FasR-mediated apoptosis through the FADD/TRADD/caspase 8 pathway. After exposing to DcR3.Fc, TRADD was silenced, likely turning down the inflammatory response. The systemic effects of DcR3 Tg mice and HDE phenotype induced by the promoter of cytomegalovirus not only attenuated ACMR severity but also ameliorated the high serum creatinine and blood urea nitrogen levels even with high T-cell exposure frequencies. Besides this, DcR3 has minor biological effects on both MHC-matched and MHC-mismatched models. ConclusionsHigh DcR3 doses protect renal tubular epithelial cells from acute T-cell attack during the T-cell priming stage via interfering with TNF ligand-mediated reverse signaling and possibly promoting Teff apoptosis through FasR upregulation. Our findings supported that the decoy receptor is involved in T-cell modulation in kidney transplant rejection.	[Weng, Shuo-Chun] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan; [Weng, Shuo-Chun; Hsieh, Shie-Liang; Tarng, Der-Cherng] Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Coll Med, Sch Med, Taipei, Taiwan; [Weng, Shuo-Chun] Taichung Vet Gen Hosp, Ctr Geriatr & Gerontol, Dept Internal Med, Div Nephrol, Taichung, Taiwan; [Wen, Mei-Chin] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Wen, Mei-Chin] Taichung Vet Gen Hosp, Dept Pathol, Lab Med, Taichung, Taiwan; [Hsieh, Shie-Liang] Acad Sinica, Genom Res Ctr, Taipei, Taiwan; [Hsieh, Shie-Liang] Taipei Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan; [Hsieh, Shie-Liang] Taipei Med Univ, Dept Clin Pharm, Taipei, Taiwan; [Chen, Nien-Jung] Natl Yang Ming Chiao Tung Univ, Inst Microbiol & Immunol, Coll Life Sci, Taipei, Taiwan; [Chen, Nien-Jung] Natl Yang Ming Chiao Tung Univ, Inflammat & Immun Res Ctr, Taipei, Taiwan; [Tarng, Der-Cherng] Natl Yang Ming Chiao Tung Univ, Dept & Inst Physiol, Taipei, Taiwan; [Tarng, Der-Cherng] Taipei Vet Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan; [Tarng, Der-Cherng] Natl Yang Ming Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices, Hsinchu, Taiwan	National Chung Hsing University; National Yang Ming Chiao Tung University; Taichung Veterans General Hospital; Chung Shan Medical University; Taichung Veterans General Hospital; Academia Sinica - Taiwan; Taipei Veterans General Hospital; Taipei Medical University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University	Tarng, DC (corresponding author), Natl Yang Ming Chiao Tung Univ, Inst Clin Med, Coll Med, Sch Med, Taipei, Taiwan.; Chen, NJ (corresponding author), Natl Yang Ming Chiao Tung Univ, Inst Microbiol & Immunol, Coll Life Sci, Taipei, Taiwan.; Chen, NJ (corresponding author), Natl Yang Ming Chiao Tung Univ, Inflammat & Immun Res Ctr, Taipei, Taiwan.; Tarng, DC (corresponding author), Natl Yang Ming Chiao Tung Univ, Dept & Inst Physiol, Taipei, Taiwan.; Tarng, DC (corresponding author), Taipei Vet Gen Hosp, Dept Med, Div Nephrol, Taipei, Taiwan.; Tarng, DC (corresponding author), Natl Yang Ming Chiao Tung Univ, Ctr Intelligent Drug Syst & Smart Biodevices, Hsinchu, Taiwan.	njchen@nycu.edu.tw; dctarng@vghtpe.gov.tw			Taichung Veterans General Hospital, Taichung [TCVGH-YM1040103, TCVGH-YM1050101, TCVGH-YM1060103, TCVGH-1078201B, TCVGH-YM1070101, TCVGH-1088201B, TCVGH-YM1080103, TCVGH-1098201B, TCVGH-YM1090105, TCVGH-1108201B, TCVGH-1118202C]; Taiwan Ministry of Science and Technology [MOST 106-2314-B-075A-003, MOST 109-2314-B-075-097-MY3]; Foundation for Poison Control [2022-04]	Taichung Veterans General Hospital, Taichung; Taiwan Ministry of Science and Technology; Foundation for Poison Control	We are deeply indebted to Taichung Veterans General Hospital, Taichung, for providing the grants for this study (TCVGH-YM1040103, TCVGH-YM1050101, TCVGH-YM1060103, TCVGH-1078201B, TCVGH-YM1070101, TCVGH-1088201B, TCVGH-YM1080103, TCVGH-1098201B, TCVGH-YM1090105, TCVGH-1108201B, and TCVGH-1118202C). This study was also supported by the Taiwan Ministry of Science and Technology (MOST 106-2314-B-075A-003 and MOST 109-2314-B-075-097-MY3) and Foundation for Poison Control (2022-04).	Al-Lamki RS, 2001, LAB INVEST, V81, P1503, DOI 10.1038/labinvest.3780364; Chen NJ, 2008, P NATL ACAD SCI USA, V105, P12429, DOI 10.1073/pnas.0806585105; Chen NJ, 2001, J IMMUNOL, V166, P270, DOI 10.4049/jimmunol.166.1.270; Granger SW, 2003, CYTOKINE GROWTH F R, V14, P289, DOI 10.1016/S1359-6101(03)00031-5; Haas M, 2014, AM J TRANSPLANT, V14, P272, DOI 10.1111/ajt.12590; Hsieh SL, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0347-7; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hsu TL, 2005, J IMMUNOL, V175, P5135, DOI 10.4049/jimmunol.175.8.5135; Hsu TL, 2002, J IMMUNOL, V168, P4846, DOI 10.4049/jimmunol.168.10.4846; Ka SM, 2007, J AM SOC NEPHROL, V18, P2473, DOI 10.1681/ASN.2006111242; Ka SM, 2011, AM J PHYSIOL-RENAL, V301, pF1218, DOI 10.1152/ajprenal.00050.2011; Kaushal GP, 2014, J AM SOC NEPHROL, V25, P877, DOI 10.1681/ASN.2013070780; Kawamoto K, 2006, TRANSPLANTATION, V81, P789, DOI 10.1097/01.tp.0000199266.07237.25; Lin WW, 2011, BIOCHEM PHARMACOL, V81, P838, DOI 10.1016/j.bcp.2011.01.011; Lunemann JD, 2002, J IMMUNOL, V168, P4881, DOI 10.4049/jimmunol.168.10.4881; Nielsen HS, 2011, HUM REPROD UPDATE, V17, P558, DOI 10.1093/humupd/dmr005; Paulsen M, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-7; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Ren X, 2007, CELL DEATH DIFFER, V14, P2076, DOI 10.1038/sj.cdd.4402220; Robertson NJ, 2007, J IMMUNOL, V178, P3558, DOI 10.4049/jimmunol.178.6.3558; Shultz Leonard D, 2014, Cold Spring Harb Protoc, V2014, P737, DOI 10.1101/pdb.prot078089; Strasser A, 2009, IMMUNITY, V30, P180, DOI 10.1016/j.immuni.2009.01.001; Sun M, 2007, J IMMUNOL, V179, P4307, DOI 10.4049/jimmunol.179.7.4307; Sung HH, 2004, J EXP MED, V199, P1143, DOI 10.1084/jem.20031939; Suzuki I, 2000, P NATL ACAD SCI USA, V97, P1707, DOI 10.1073/pnas.97.4.1707; Tai SK, 2012, J IMMUNOL, V188, P2464, DOI 10.4049/jimmunol.1101101; Terryn S, 2007, AM J PHYSIOL-RENAL, V293, pF476, DOI 10.1152/ajprenal.00363.2006; Wan XC, 2003, J CELL BIOCHEM, V89, P603, DOI 10.1002/jcb.10523; Wang W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074272; Weng SC, 2015, SCI REP-UK, V5, DOI 10.1038/srep12769; Wu YL, 2003, DIABETES, V52, P2279, DOI 10.2337/diabetes.52.9.2279; Wu YY, 2004, J BIOL CHEM, V279, P44211, DOI 10.1074/jbc.408842200; Xing YF, 2017, KIDNEY INT, V91, P1236, DOI 10.1016/j.kint.2016.12.015; Yang B, 2018, J AM SOC NEPHROL, V29, P1900, DOI 10.1681/ASN.2017050581; You RI, 2008, BLOOD, V111, P1480, DOI 10.1182/blood-2007-09-114850; Zhang J, 2001, J CLIN INVEST, V107, P1459, DOI 10.1172/JCI12159; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006; Zmuda EJ, 2011, JOVE-J VIS EXP, DOI 10.3791/2096	39	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								879648	10.3389/fimmu.2022.879648	http://dx.doi.org/10.3389/fimmu.2022.879648			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3AJ	35720343	Green Published, gold			2022-12-18	WOS:000812101500001
J	Wu, D; Fan, Z; Li, JN; Zhang, YY; Xu, QY; Wang, L; Wang, LS				Wu, Di; Fan, Ze; Li, Jinnan; Zhang, Yuanyuan; Xu, Qiyou; Wang, Liang; Wang, Liansheng			Low Protein Diets Supplemented With Alpha-Ketoglutarate Enhance the Growth Performance, Immune Response, and Intestinal Health in Common Carp (Cyprinus carpio)	FRONTIERS IN IMMUNOLOGY			English	Article						alpha-ketoglutarate; common carp; growth performance; immune response; intestinal health	GUT MICROBIOTA; OXIDATIVE STRESS; GENE-EXPRESSION; ENERGY STATUS; METABOLISM; ACID; CAPACITY; BARRIER; KINASE; PHOSPHORUS	To investigate the effects of alpha-ketoglutarate (AKG) supplementation in a low protein (LP) diet on the growth performance, immune response, and intestinal health of common carp (Cyprinus carpio), 600 carp were randomly divided into five dietary groups: a normal protein (NP) diet containing 32% crude protein, an LP diet formulated with 28% crude protein, and LP with AKG at 0.4%, 0.8%, and 1.2% (dry matter). After an 8-week trial period, the results demonstrated that an LP diet led to a decrease in performance, immune response, and intestinal barrier function. Compared with the LP group, the final body weight and weight gain rate in the LP+0.4% AKG group were significantly higher, the feed conversion ratio was significantly decreased with the addition of 0.4% and 0.8% AKG. The supplementation with 0.4% and 0.8% AKG markedly increased the activities of T-SOD and GSH-Px, as well as the expression levels of GPX1a and GPX1b relative to the LP group, whereas the MDA content was significantly decreased in the LP+0.4% AKG group. In addition, the expression levels of tight junctions including claudin-3, claudin-7, ZO-1, and MLCK were significantly up-regulated in the LP+0.4% AKG group, and the relative expression levels of the pro-inflammatory factors IL-1 beta and IL-6 alpha were significantly lower with the addition of 0.4%, 0.8%, and 1.2% AKG. Moreover, the abundance of Proteobacteria in the LP+0.4% AKG group was lower than that in the LP group, and the abundance of Firmicutes and Fusobacteria was higher at the phylum level. The abundance of Citrobacter in the LP+0.4% AKG group was decreased compared to the LP group, while the abundance of Aeromonas was increased at the genus level. In short, the effects of AKG on the intestinal health of the common carp were systematically and comprehensively evaluated from the perspectives of intestinal physical barrier, chemical barrier, biological barrier, and immune barrier. We found that an LP diet supplemented with 0.4% AKG was beneficial to the growth performance and intestinal health of common carp.	[Wu, Di; Fan, Ze; Li, Jinnan; Zhang, Yuanyuan; Wang, Liansheng] Chinese Acad Fishery Sci, Heilongjiang River Fisheries Res Inst, Key Lab Aquat Anim Dis & Immune Technol Heilongjia, Harbin, Peoples R China; [Xu, Qiyou] Huzhou Univ, Sch Life Sci, Huzhou, Peoples R China; [Wang, Liang] Weifang Addeasy Biotechnol Co Ltd, AHP Applicat Res Inst, Weifang, Peoples R China	Chinese Academy of Fishery Sciences; Heilongjiang River Fisheries Research Institute, CAFS; Huzhou University	Wang, LS (corresponding author), Chinese Acad Fishery Sci, Heilongjiang River Fisheries Res Inst, Key Lab Aquat Anim Dis & Immune Technol Heilongjia, Harbin, Peoples R China.	wangliansheng@hrfri.ac.cn	Wang, Liansheng/GPF-4024-2022		Central Public-interest Scientific Institution Basal Research Fund, CAFS [2022XT0402]; Central Public-interest Scientific Institution Basal Research Fund, HRFRI [HSY202206Q, HSY202002M]; National Natural Science Foundation of China [31972800, 31802305]; China Agriculture Research System of MOF and MARA	Central Public-interest Scientific Institution Basal Research Fund, CAFS; Central Public-interest Scientific Institution Basal Research Fund, HRFRI; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea)	This work was supported by the Central Public-interest Scientific Institution Basal Research Fund, CAFS (2022XT0402), the Central Public-interest Scientific Institution Basal Research Fund, HRFRI (HSY202206Q, HSY202002M), the National Natural Science Foundation of China (31972800, 31802305), the China Agriculture Research System of MOF and MARA.	Ai F, 2019, AQUACULTURE, V507, P393, DOI 10.1016/j.aquaculture.2019.03.047; Akinola FF, 2010, SCI RES ESSAYS, V5, P1145; Al-Sadi R, 2013, AM J PATHOL, V183, P1871, DOI 10.1016/j.ajpath.2013.09.001; Amasheh S, 2011, ACTA PHYSIOL, V201, P133, DOI 10.1111/j.1748-1716.2010.02148.x; Baird L, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00099-20; Blank R, 1999, J ANIM SCI, V77, P2974; Brenes-Soto A, 2019, ILAR J, V60, P197, DOI 10.1093/ilar/ilaa006; Chen JS, 2017, ANIM FEED SCI TECH, V226, P21, DOI 10.1016/j.anifeedsci.2016.12.013; Chen JS, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01057; Chen S, 2021, ANIM NUTR, V7, P356, DOI 10.1016/j.aninu.2020.12.005; Cynober L A, 1999, Curr Opin Clin Nutr Metab Care, V2, P33, DOI 10.1097/00075197-199901000-00007; de Miranda MB, 2019, BIOMED PHARMACOTHER, V109, P610, DOI 10.1016/j.biopha.2018.10.116; de Sousa SM, 2018, NUTR NEUROSCI, V21, P580, DOI 10.1080/1028415X.2017.1325974; Dyck JRB, 1999, EUR J BIOCHEM, V262, P184, DOI 10.1046/j.1432-1327.1999.00371.x; Fazal F, 2005, MOL CELL BIOL, V25, P6259, DOI 10.1128/MCB.25.14.6259-6266.2005; Giuliani ME, 2014, AQUAT TOXICOL, V150, P117, DOI 10.1016/j.aquatox.2014.03.003; Gu M, 2021, FISH SHELLFISH IMMUN, V114, P49, DOI 10.1016/j.fsi.2021.04.013; Guo SS, 2017, ANIM SCI J, V88, P1753, DOI 10.1111/asj.12824; Hao YT, 2017, AQUAC RES, V48, P5595, DOI 10.1111/are.13381; He L, 2017, ONCOTARGET, V8, P102974, DOI 10.18632/oncotarget.16875; He LQ, 2016, J AGR FOOD CHEM, V64, P2668, DOI 10.1021/acs.jafc.6b00433; He LQ, 2015, CURR PROTEIN PEPT SC, V16, P576, DOI 10.2174/1389203716666150630140157; Hou YQ, 2011, BRIT J NUTR, V106, P357, DOI 10.1017/S0007114511000249; Hou YQ, 2011, FRONT BIOSCI-LANDMRK, V16, P1186, DOI 10.2741/3783; Hou YQ, 2010, AMINO ACIDS, V39, P555, DOI 10.1007/s00726-010-0473-y; Kamada N, 2013, NAT REV IMMUNOL, V13, P321, DOI 10.1038/nri3430; Kong XF, 2014, LIVEST SCI, V160, P97, DOI 10.1016/j.livsci.2013.11.023; Li JinNan, 2014, Chinese Journal of Animal Nutrition, V26, P1347; Li SF, 2010, ASIAN J ANDROL, V12, P247, DOI 10.1038/aja.2009.78; Li XY, 2020, AMINO ACIDS, V52, P671, DOI 10.1007/s00726-020-02851-2; Lin X, 2020, AQUACULT INT, V28, P511, DOI 10.1007/s10499-019-00475-2; Liu XC, 2020, FISH SHELLFISH IMMUN, V97, P182, DOI 10.1016/j.fsi.2019.11.055; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luthada-Raswiswi R, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11093854; MacDonald TT, 2003, INT J MED MICROBIOL, V293, P87, DOI 10.1078/1438-4221-00247; Magnadottir B, 2006, FISH SHELLFISH IMMUN, V20, P137, DOI 10.1016/j.fsi.2004.09.006; McCarty MF, 2021, MED HYPOTHESES, V149, DOI 10.1016/j.mehy.2021.110518; Motta JP, 2021, NAT REV GASTRO HEPAT, V18, P314, DOI 10.1038/s41575-020-00397-y; Rombout JHWM, 2011, FISH SHELLFISH IMMUN, V31, P616, DOI 10.1016/j.fsi.2010.09.001; Rzeski W, 2012, SCAND J GASTROENTERO, V47, P565, DOI 10.3109/00365521.2012.660539; Sardar P, 2011, INDIAN J ANIM SCI, V81, P537; Shin NR, 2015, TRENDS BIOTECHNOL, V33, P496, DOI 10.1016/j.tibtech.2015.06.011; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Tao XF, 2019, RSC ADV, V9, P5025, DOI 10.1039/c8ra09547g; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Vargas-Albores F, 2021, AQUACULTURE, V544, DOI 10.1016/j.aquaculture.2021.737050; Wang HS, 2021, ANIM NUTR, V7, P770, DOI 10.1016/j.aninu.2021.03.003; Wang L, 2017, AQUACULT NUTR, V23, P926, DOI 10.1111/anu.12460; Wang LS, 2017, AQUAC RES, V48, P2266, DOI 10.1111/are.13063; Wang Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19360-1; Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.690234; Wu G, 2011, J ANIM SCI, V89, P2017, DOI 10.2527/jas.2010-3614; Wu N, 2016, BIOMOL THER, V24, P1, DOI 10.4062/biomolther.2015.078; Xia H, 2019, ISR J AQUACULT-BAMID, V71; Yamamoto M, 2018, PHYSIOL REV, V98, P1169, DOI 10.1152/physrev.00023.2017; Yao YR, 2020, EXPERT REV CLIN IMMU, V16, P1127, DOI 10.1080/1744666X.2021.1850269; Zhang HL, 2020, REV FISH BIOL FISHER, V30, P569, DOI 10.1007/s11160-020-09614-y; Zhao L, 2020, J ANIM PHYSIOL AN N, V104, P300, DOI 10.1111/jpn.13230; Zhou JY, 2020, FOOD FUNCT, V11, P493, DOI [10.1039/C9FO02724F, 10.1039/c9fo02724f]; Zhu HJ, 2020, MICROBIOLOGYOPEN, V9, DOI 10.1002/mbo3.1000; Zuo L, 2020, CELL MOL GASTROENTER, V10, P327, DOI 10.1016/j.jcmgh.2020.04.001	61	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								915657	10.3389/fimmu.2022.915657	http://dx.doi.org/10.3389/fimmu.2022.915657			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3AK	35720284	gold, Green Published			2022-12-18	WOS:000812101600001
J	Xia, XY; Cheng, AC; Wang, MS; Ou, XM; Sun, D; Mao, S; Huang, J; Yang, Q; Wu, Y; Chen, S; Zhang, SQ; Zhu, DK; Jia, RY; Liu, MF; Zhao, XX; Gao, Q; Tian, B				Xia, Xiaoyan; Cheng, Anchun; Wang, Mingshu; Ou, Xumin; Sun, Di; Mao, Sai; Huang, Juan; Yang, Qiao; Wu, Ying; Chen, Shun; Zhang, Shaqiu; Zhu, Dekang; Jia, Renyong; Liu, Mafeng; Zhao, Xin-Xin; Gao, Qun; Tian, Bin			Functions of Viroporins in the Viral Life Cycle and Their Regulation of Host Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Review						viroporins; function; viral life cycle; host cell response; interactions; inhibitors	RESPIRATORY SYNDROME CORONAVIRUS; VIRUS M2 PROTEIN; HUMAN-PAPILLOMAVIRUS TYPE-16; INFLUENZA-B VIRUS; INFECTIOUS-BRONCHITIS VIRUS; SMALL HYDROPHOBIC PROTEIN; NF-KAPPA-B; ION-CHANNEL; ENDOPLASMIC-RETICULUM; SUBCELLULAR-LOCALIZATION	Viroporins are virally encoded transmembrane proteins that are essential for viral pathogenicity and can participate in various stages of the viral life cycle, thereby promoting viral proliferation. Viroporins have multifaceted effects on host cell biological functions, including altering cell membrane permeability, triggering inflammasome formation, inducing apoptosis and autophagy, and evading immune responses, thereby ensuring that the virus completes its life cycle. Viroporins are also virulence factors, and their complete or partial deletion often reduces virion release and reduces viral pathogenicity, highlighting the important role of these proteins in the viral life cycle. Thus, viroporins represent a common drug-protein target for inhibiting drugs and the development of antiviral therapies. This article reviews current studies on the functions of viroporins in the viral life cycle and their regulation of host cell responses, with the aim of improving the understanding of this growing family of viral proteins.	[Xia, Xiaoyan; Cheng, Anchun; Wang, Mingshu; Ou, Xumin; Sun, Di; Mao, Sai; Huang, Juan; Yang, Qiao; Wu, Ying; Chen, Shun; Zhang, Shaqiu; Jia, Renyong; Liu, Mafeng; Zhao, Xin-Xin; Gao, Qun; Tian, Bin] Sichuan Agr Univ, Inst Prevent Vet Med, Chengdu, Peoples R China; [Xia, Xiaoyan; Cheng, Anchun; Wang, Mingshu; Ou, Xumin; Sun, Di; Mao, Sai; Huang, Juan; Yang, Qiao; Wu, Ying; Chen, Shun; Zhang, Shaqiu; Zhu, Dekang; Jia, Renyong; Liu, Mafeng; Zhao, Xin-Xin; Gao, Qun] Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Chengdu, Peoples R China; [Xia, Xiaoyan; Cheng, Anchun; Wang, Mingshu; Ou, Xumin; Sun, Di; Mao, Sai; Huang, Juan; Yang, Qiao; Wu, Ying; Chen, Shun; Zhang, Shaqiu; Zhu, Dekang; Jia, Renyong; Liu, Mafeng; Zhao, Xin-Xin; Gao, Qun; Tian, Bin] Sichuan Agr Univ, Coll Vet Med, Avian Dis Res Ctr, Chengdu, Peoples R China	Sichuan Agricultural University; Key Laboratory of Animal Disease & Human Health of Sichuan Province; Sichuan Agricultural University; Sichuan Agricultural University	Wang, MS (corresponding author), Sichuan Agr Univ, Inst Prevent Vet Med, Chengdu, Peoples R China.; Wang, MS (corresponding author), Sichuan Agr Univ, Key Lab Anim Dis & Human Hlth Sichuan Prov, Chengdu, Peoples R China.; Wang, MS (corresponding author), Sichuan Agr Univ, Coll Vet Med, Avian Dis Res Ctr, Chengdu, Peoples R China.	mshwang@163.com			China Agriculture Research System of MOF and MARA; Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System [SCCXTD-2020-18]	China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea); Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System	This work was supported by the China Agriculture Research System of MOF and MARA, and the Sichuan Veterinary Medicine and Drug Innovation Group of China Agricultural Research System (SCCXTD-2020-18).	Agirre A, 2002, J BIOL CHEM, V277, P40434, DOI 10.1074/jbc.M205393200; Aguirre S, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.37; Aguirre S, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002934; Akari H, 2001, J EXP MED, V194, P1299, DOI 10.1084/jem.194.9.1299; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Alvarez E, 2010, VIROLOGY, V402, P281, DOI 10.1016/j.virol.2010.03.015; An SW, 1999, J VIROL, V73, P7853, DOI 10.1128/JVI.73.9.7853-7859.1999; Ao D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125828; Avia M, 2019, EMBO REP, V20, DOI 10.15252/embr.201948766; Bao DQ, 2022, J VIROL, V96, DOI 10.1128/jvi.00373-22; Bao XY, 2008, J VIROL, V82, P8224, DOI 10.1128/JVI.02584-07; Beale R, 2014, CELL HOST MICROBE, V15, P239, DOI 10.1016/j.chom.2014.01.006; BIENZ K, 1994, ARCH VIROL, P147; Boal-Carvalho I, 2020, EMBO REP, V21, DOI 10.15252/embr.202050421; Bodelon G, 2002, J BIOL CHEM, V277, P17789, DOI 10.1074/jbc.M202018200; Bonzano C, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00200; Boscarino JA, 2008, J VIROL, V82, P2989, DOI 10.1128/JVI.01906-07; Boson B, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016175; Brohm C, 2009, J VIROL, V83, P11682, DOI 10.1128/JVI.00691-09; Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58; Cabrera-Garcia D, 2021, J PHYSIOL-LONDON, V599, P2851, DOI [10.1113/JP281601, 10.1113/JP281037]; Campanella M, 2004, J BIOL CHEM, V279, P18440, DOI 10.1074/jbc.M309494200; Cao YP, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.565797; Carrere-Kremer S, 2002, J VIROL, V76, P3720, DOI 10.1128/JVI.76.8.3720-3730.2002; Castano-Rodriguez C, 2018, MBIO, V9, DOI 10.1128/mBio.02325-17; Celma CCP, 2011, J VIROL, V85, P4783, DOI 10.1128/JVI.02352-10; Celma CCP, 2009, J VIROL, V83, P6806, DOI 10.1128/JVI.00263-09; Chan CM, 2009, INT J BIOCHEM CELL B, V41, P2232, DOI 10.1016/j.biocel.2009.04.019; Chen BJ, 2008, J VIROL, V82, P10059, DOI 10.1128/JVI.01184-08; Chen CY, 2007, J INFECT DIS, V196, P405, DOI 10.1086/519166; Chen IY, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00050; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Cheung PHH, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008611; Cheung PHH, 2020, J LEUKOCYTE BIOL, V108, P1655, DOI 10.1002/JLB.4AB0420-694R; Choe SS, 2005, VIROLOGY, V337, P18, DOI 10.1016/j.virol.2005.03.036; Cong HL, 2016, J VIROL, V90, P9862, DOI 10.1128/JVI.01499-16; Cong LJ, 2021, MBIO, V12, DOI 10.1128/mBio.01920-21; CONRAD M, 1993, J VIROL, V67, P6170, DOI 10.1128/JVI.67.10.6170-6178.1993; Convery O, 2019, FASEB J, V33, P8732, DOI 10.1096/fj.201800629RR; Cornell CT, 2007, J VIROL, V81, P6785, DOI 10.1128/JVI.00198-07; Corse E, 2000, J VIROL, V74, P4319, DOI 10.1128/JVI.74.9.4319-4326.2000; Cortese MS, 2010, INT J CANCER, V126, P1675, DOI 10.1002/ijc.25004; Crawford SE, 2020, J VIROL, V94, DOI 10.1128/JVI.01341-19; Crawford SE, 2013, AUTOPHAGY, V9, P797, DOI 10.4161/auto.23959; Crawford SE, 2012, P NATL ACAD SCI USA, V109, pE3405, DOI 10.1073/pnas.1216539109; Dalrymple NA, 2015, MBIO, V6, DOI 10.1128/mBio.00553-15; Daniels R, 2007, PLOS PATHOG, V3, P928, DOI 10.1371/journal.ppat.0030098; Daniels R, 2006, MOL CELL, V24, P955, DOI 10.1016/j.molcel.2006.11.001; de Jong AS, 2008, J VIROL, V82, P3782, DOI 10.1128/JVI.02076-07; De Jong AS, 2006, J BIOL CHEM, V281, P14144, DOI 10.1074/jbc.M511766200; DeDiego ML, 2007, J VIROL, V81, P1701, DOI 10.1128/JVI.01467-06; DeDiego ML, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002315; Deitz SB, 2000, P NATL ACAD SCI USA, V97, P13790, DOI 10.1073/pnas.250483097; Demers A, 2014, J GEN VIROL, V95, P1211, DOI 10.1099/vir.0.063511-0; Dey D, 2020, COMPUT BIOL MED, V127, DOI 10.1016/j.compbiomed.2020.104063; Disbrow GL, 2005, J VIROL, V79, P5839, DOI 10.1128/JVI.79.9.5839-5846.2005; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; Dudek SE, 2011, BIOL CHEM, V392, P1135, DOI [10.1515/BC-2011-174, 10.1515/BC.2011.174]; Ettayebi K, 2003, J VIROL, V77, P11790, DOI 10.1128/JVI.77.21.11790-11797.2003; Fan Y, 2017, J BIOL CHEM, V292, P5070, DOI 10.1074/jbc.M117.776112; Farag NS, 2017, BBA-MOL BASIS DIS, V1863, P712, DOI 10.1016/j.bbadis.2016.12.006; Fett C, 2013, J VIROL, V87, P6551, DOI 10.1128/JVI.00087-13; Fielding BC, 2006, BIOCHEM BIOPH RES CO, V343, P1201, DOI 10.1016/j.bbrc.2006.03.091; Fuentes S, 2007, J VIROL, V81, P8361, DOI 10.1128/JVI.02717-06; Furukawa T, 2011, J VIROL, V85, P1322, DOI 10.1128/JVI.01367-10; Gannage M, 2010, AUTOPHAGY, V6, P166, DOI 10.4161/auto.6.1.10624; Gannage M, 2009, CELL HOST MICROBE, V6, P367, DOI 10.1016/j.chom.2009.09.005; Geiger R, 2011, NAT CELL BIOL, V13, P1305, DOI 10.1038/ncb2339; Giorda KM, 2013, DNA CELL BIOL, V32, P557, DOI 10.1089/dna.2013.2159; Giorda KM, 2013, J BIOL CHEM, V288, P2510, DOI 10.1074/jbc.M112.428425; Gladue DP, 2018, J VIROL, V92, DOI [10.1128/JVI.01360-18, 10.1128/jvi.01360-18]; Gladue DP, 2012, J VIROL, V86, P6778, DOI 10.1128/JVI.00560-12; Gonzalez ME, 2003, FEBS LETT, V552, P28, DOI 10.1016/S0014-5793(03)00780-4; Gordon NA, 2017, ANTIVIR RES, V147, P100, DOI 10.1016/j.antiviral.2017.10.009; Gordon-Shaag A, 2003, J VIROL, V77, P4273, DOI 10.1128/JVI.77.7.4273-4282.2003; Goto T, 2017, J VIROL, V91, DOI 10.1128/JVI.00773-17; Green AM, 2014, J MOL BIOL, V426, P1148, DOI 10.1016/j.jmb.2013.11.023; Greninger AL, 2012, J VIROL, V86, P3605, DOI 10.1128/JVI.06778-11; Griffin SDC, 2003, FEBS LETT, V535, P34, DOI 10.1016/S0014-5793(02)03851-6; Guan ZH, 2010, PROTEIN CELL, V1, P944, DOI 10.1007/s13238-010-0115-x; GUINEA R, 1990, EMBO J, V9, P2011, DOI 10.1002/j.1460-2075.1990.tb08329.x; Guo HC, 2013, INT J BIOCHEM CELL B, V45, P1186, DOI 10.1016/j.biocel.2013.03.021; Han XD, 2017, J GEN VIROL, V98, P422, DOI 10.1099/jgv.0.000705; Han ZY, 2004, J BIOL CHEM, V279, P43092, DOI 10.1074/jbc.M403663200; Hastings AK, 2016, VIROLOGY, V494, P248, DOI 10.1016/j.virol.2016.04.022; He J, 2017, J VIROL, V91, DOI 10.1128/JVI.00438-17; HEINZ BA, 1995, J VIROL, V69, P4189, DOI 10.1128/JVI.69.7.4189-4197.1995; Henkel M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011112; Horova V, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007962; Hsu K, 2010, BIOPHYS J, V99, P1718, DOI 10.1016/j.bpj.2010.07.027; Hu B, 2020, J VIROL, V94, DOI 10.1128/JVI.01605-19; Hu SQ, 2017, BIOCHEM J, V474, P715, DOI 10.1042/BCJ20160861; Hyde JL, 2010, VIROLOGY, V406, P138, DOI 10.1016/j.virol.2010.06.047; Hyser JM, 2015, ANNU REV VIROL, V2, P473, DOI 10.1146/annurev-virology-100114-054846; Hyser JM, 2013, J VIROL, V87, P13579, DOI 10.1128/JVI.02629-13; Hyser JM, 2010, MBIO, V1, DOI 10.1128/mBio.00265-10; Ichinohe T, 2010, NAT IMMUNOL, V11, P404, DOI 10.1038/ni.1861; Imai M, 2004, J VIROL, V78, P11007, DOI 10.1128/JVI.78.20.11007-11015.2004; Imai M, 2008, J VIROL, V82, P728, DOI 10.1128/JVI.01752-07; Ito M, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002857; Jackson WT, 2005, PLOS BIOL, V3, P861, DOI 10.1371/journal.pbio.0030156; Javier RT, 2011, J VIROL, V85, P11544, DOI 10.1128/JVI.05410-11; Jimenez-Guardeno JM, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004320; Jin J, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010022; Jing HY, 2014, VIROLOGY, V458, P162, DOI 10.1016/j.virol.2014.04.031; Joubert DA, 2014, J VIROL, V88, P1591, DOI 10.1128/JVI.01812-13; Kang M, 2004, P NATL ACAD SCI USA, V101, P5318, DOI 10.1073/pnas.0307824100; Kanzawa N, 2006, FEBS LETT, V580, P6807, DOI 10.1016/j.febslet.2006.11.046; Kesinger E, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199227; Khoury G, 2010, ANTIMICROB AGENTS CH, V54, P835, DOI 10.1128/AAC.01308-09; Kondratova AA, 2005, CELL CYCLE, V4, P1403, DOI 10.4161/cc.4.10.2041; Kowalinski E, 2011, CELL, V147, P423, DOI 10.1016/j.cell.2011.09.039; Krawczyk E, 2010, J VIROL, V84, P1696, DOI 10.1128/JVI.01968-09; Kundlacz C, 2019, J VIROL, V93, DOI 10.1128/JVI.00336-19; Kuwahara T, 2019, MBIO, V10, DOI 10.1128/mBio.02867-19; La Gruta NL, 2008, P NATL ACAD SCI USA, V105, P2034, DOI 10.1073/pnas.0711682102; Lakadamyali M, 2003, P NATL ACAD SCI USA, V100, P9280, DOI 10.1073/pnas.0832269100; LAMA J, 1992, J BIOL CHEM, V267, P15932; Langer S, 2019, ELIFE, V8, DOI 10.7554/eLife.41930; Lateef Z, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3417-4; Lazrak A, 2009, FASEB J, V23, P3829, DOI 10.1096/fj.09-135590; Le Goffic R, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002202; Le Goffic R, 2010, J IMMUNOL, V185, P4812, DOI 10.4049/jimmunol.0903952; Lee HR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030897; Leon-Juarez M, 2016, VIROL J, V13, DOI 10.1186/s12985-015-0456-4; Leonov H, 2011, J AM CHEM SOC, V133, P9903, DOI 10.1021/ja202288m; Li M, 2018, BIOCHEM BIOPH RES CO, V504, P238, DOI 10.1016/j.bbrc.2018.08.161; Li N, 2019, SCI BULL, V64, P180, DOI 10.1016/j.scib.2018.08.013; Li SM, 2020, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.03022; Li Y, 2015, VIROLOGY, V482, P105, DOI 10.1016/j.virol.2015.03.034; Li Y, 2014, J VIROL, V88, P11899, DOI 10.1128/JVI.00839-14; Li ZR, 2021, VET MICROBIOL, V254, DOI 10.1016/j.vetmic.2021.108986; Liao J, 2019, J MOL CELL BIOL, V11, P107, DOI 10.1093/jmcb/mjy030; Lim KP, 2001, J BIOL CHEM, V276, P17515, DOI 10.1074/jbc.M009731200; Liu HS, 2021, VIROL SIN, V36, P608, DOI 10.1007/s12250-020-00322-2; Liu HS, 2019, J VIROL, V93, DOI [10.1128/JVI.00124-19, 10.1128/jvi.00124-19]; Liu HS, 2018, FASEB J, V32, P6706, DOI 10.1096/fj.201701351; Liu W, 2017, ELIFE, V6, DOI 10.7554/eLife.24425; Liu XM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24724-2; Liu ZZ, 2021, POULTRY SCI, V100, DOI 10.1016/j.psj.2021.101331; Londino JD, 2013, AM J PHYSIOL-LUNG C, V304, pL582, DOI 10.1152/ajplung.00314.2012; Lopez T, 2005, J VIROL, V79, P184, DOI 10.1128/JVI.79.1.184-192.2005; Lu S, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108666; Lu W, 2006, P NATL ACAD SCI USA, V103, P12540, DOI 10.1073/pnas.0605402103; Luganini A, 2018, P NATL ACAD SCI USA, V115, pE12370, DOI 10.1073/pnas.1813183115; Nieva JL, 2012, NAT REV MICROBIOL, V10, P563, DOI 10.1038/nrmicro2820; Lulla V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17906-x; Luscombe CA, 2010, ANTIVIR RES, V86, P144, DOI 10.1016/j.antiviral.2010.02.312; Ma HL, 2012, J VIROL, V86, P1789, DOI 10.1128/JVI.06003-11; Madan V, 2010, CELL MICROBIOL, V12, P1144, DOI 10.1111/j.1462-5822.2010.01460.x; Madan V, 2010, BBA-BIOMEMBRANES, V1798, P52, DOI 10.1016/j.bbamem.2009.10.013; Madan V, 2008, CELL MICROBIOL, V10, P437, DOI 10.1111/j.1462-5822.2007.01057.x; Madsen JJ, 2018, P NATL ACAD SCI USA, V115, pE8595, DOI 10.1073/pnas.1805443115; Mandala VS, 2020, NAT STRUCT MOL BIOL, V27, P160, DOI 10.1038/s41594-019-0371-2; Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]; Martinez-Gil L, 2011, J VIROL, V85, P11315, DOI 10.1128/JVI.05421-11; Masante C, 2014, J VIROL, V88, P6423, DOI 10.1128/JVI.02848-13; Mazel-Sanchez B, 2018, J VIROL, V92, DOI [10.1128/JVI.00425-18, 10.1128/jvi.00425-18]; Mazur I, 2008, CELL MICROBIOL, V10, P1140, DOI 10.1111/j.1462-5822.2008.01116.x; McAuley JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003392; McCune BT, 2017, MBIO, V8, DOI 10.1128/mBio.00668-17; McNatt MW, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003299; Mehnert T, 2008, PROTEINS, V70, P1488, DOI 10.1002/prot.21642; Melton JV, 2002, J BIOL CHEM, V277, P46923, DOI 10.1074/jbc.M207847200; Merabova N, 2008, J VIROL, V82, P1558, DOI 10.1128/JVI.01680-07; Mi SF, 2010, SCI CHINA LIFE SCI, V53, P1098, DOI 10.1007/s11427-010-4048-7; Miao GY, 2021, DEV CELL, V56, P427, DOI 10.1016/j.devcel.2020.12.010; Minakshi R, 2014, VIROL J, V11, DOI 10.1186/1743-422X-11-75; Minakshi R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008342; Moffat K, 2007, J VIROL, V81, P1129, DOI 10.1128/JVI.00393-06; Moriyama M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12632-5; Narayanan K, 2008, VIRUS RES, V133, P113, DOI 10.1016/j.virusres.2007.10.009; Neil SJD, 2008, NATURE, V451, P425, DOI 10.1038/nature06553; Nguyen NV, 2018, INNATE IMMUN-LONDON, V24, P490, DOI 10.1177/1753425918803674; Nieto-Torres JL, 2015, VIROLOGY, V485, P330, DOI 10.1016/j.virol.2015.08.010; Nieto-Torres JL, 2015, VIRUSES-BASEL, V7, P3552, DOI 10.3390/v7072786; Nieto-Torres JL, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004077; Nieto-Torres JL, 2011, VIROLOGY, V415, P69, DOI 10.1016/j.virol.2011.03.029; Oh JM, 2010, CARCINOGENESIS, V31, P402, DOI 10.1093/carcin/bgp318; Okada Y, 2005, EMBO REP, V6, P452, DOI 10.1038/sj.embor.7400406; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Padhan K, 2008, J GEN VIROL, V89, P1960, DOI 10.1099/vir.0.83665-0; Padhan K, 2007, J GEN VIROL, V88, P3067, DOI 10.1099/vir.0.82856-0; Parr RD, 2006, J VIROL, V80, P2842, DOI 10.1128/JVI.80.6.2842-2854.2006; Patel H, 2019, VIROLOGY, V537, P97, DOI 10.1016/j.virol.2019.08.013; Paulmann D, 2008, J GEN VIROL, V89, P1593, DOI 10.1099/vir.0.83521-0; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pham T, 2017, SCI REP-UK, V7, DOI 10.1038/srep43487; Pham TNQ, 2014, RETROVIROLOGY, V11, DOI 10.1186/1742-4690-11-15; Pinar A, 2017, J BIOL CHEM, V292, P826, DOI 10.1074/jbc.M116.756379; Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Plugge B, 2000, SCIENCE, V287, P1641, DOI 10.1126/science.287.5458.1641; Pokhrel R, 2019, PHYS CHEM CHEM PHYS, V21, P5578, DOI 10.1039/c8cp07323f; Pollock N, 2017, J GEN VIROL, V98, P1587, DOI 10.1099/jgv.0.000855; Raamsman MJB, 2000, J VIROL, V74, P2333, DOI 10.1128/JVI.74.5.2333-2342.2000; Raghava S, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002116; Regan JA, 2008, J VIROL, V82, P10042, DOI 10.1128/JVI.01240-08; Regla-Nava JA, 2015, J VIROL, V89, P3870, DOI 10.1128/JVI.03566-14; Ren YZ, 2016, J VIROL, V90, P591, DOI 10.1128/JVI.00576-15; Ren YJ, 2020, CELL MOL IMMUNOL, V17, P881, DOI 10.1038/s41423-020-0485-9; Rossman JS, 2010, CELL, V142, P902, DOI 10.1016/j.cell.2010.08.029; Rossman JS, 2010, J VIROL, V84, P5078, DOI 10.1128/JVI.00119-10; Rossman JS, 2009, CELL HOST MICROBE, V6, P299, DOI 10.1016/j.chom.2009.09.009; Ruch TR, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002674; Ruch TR, 2012, VIRUSES-BASEL, V4, P363, DOI 10.3390/v4030363; Ruch TR, 2011, J VIROL, V85, P675, DOI 10.1128/JVI.01570-10; Safak M, 2001, J VIROL, V75, P1476, DOI 10.1128/JVI.75.3.1476-1486.2001; Sanchez DJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137951; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Sanz MA, 2003, J BIOL CHEM, V278, P2051, DOI 10.1074/jbc.M206611200; Sapin C, 2002, J VIROL, V76, P4591, DOI 10.1128/JVI.76.9.4591-4602.2002; Sarkar R, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071324; Schmidt NW, 2013, J AM CHEM SOC, V135, P13710, DOI 10.1021/ja400146z; Schwarz S, 2011, ANTIVIR RES, V90, P64, DOI 10.1016/j.antiviral.2011.02.008; Scott ML, 2020, J VIROL, V94, DOI 10.1128/JVI.01582-19; Shmulevitz M, 2000, EMBO J, V19, P902, DOI 10.1093/emboj/19.5.902; Shrivastava G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00352; Shukla A, 2015, SCI REP-UK, V5, DOI 10.1038/srep15884; Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R; Siu YL, 2008, J VIROL, V82, P11318, DOI 10.1128/JVI.01052-08; Song J, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020133; Steinmann E, 2007, PLOS PATHOG, V3, P962, DOI 10.1371/journal.ppat.0030103; STRAIGHT SW, 1995, J VIROL, V69, P3185, DOI 10.1128/JVI.69.5.3185-3192.1995; Strtak AC, 2019, MSPHERE, V4, DOI 10.1128/mSphere.00506-19; Su WC, 2018, J VIROL, V92, DOI 10.1128/JVI.01972-17; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Sun LJ, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-108; Sun MH, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.762869; Sunstrom NA, 1996, J MEMBRANE BIOL, V150, P127, DOI 10.1007/s002329900037; Suzuki T, 2005, J BIOL CHEM, V280, P24948, DOI 10.1074/jbc.M411499200; Suzuki T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000801; Taylor A, 2016, J VIROL, V90, P4150, DOI 10.1128/JVI.03192-15; Techaarpornkul S, 2001, J VIROL, V75, P6825, DOI 10.1128/JVI.75.15.6825-6834.2001; Teoh KT, 2010, MOL BIOL CELL, V21, P3838, DOI 10.1091/mbc.E10-04-0338; Teoule F, 2013, J VIROL, V87, P11031, DOI 10.1128/JVI.00304-13; Teterina NL, 2006, J VIROL, V80, P5327, DOI 10.1128/JVI.02684-05; Teterina NL, 2003, J VIROL, V77, P12679, DOI 10.1128/JVI.77.23.12679-12691.2003; Tomar PPS, 2020, BIOCHEM BIOPH RES CO, V530, P10, DOI 10.1016/j.bbrc.2020.05.206; Torabifard H, 2020, P NATL ACAD SCI USA, V117, P3583, DOI 10.1073/pnas.1913385117; Torres J, 2007, PROTEIN SCI, V16, P2065, DOI 10.1110/ps.062730007; Triantafilou K, 2013, AM J RESP CELL MOL, V49, P923, DOI 10.1165/rcmb.2013-0032OC; Triantafilou K, 2013, THORAX, V68, P66, DOI 10.1136/thoraxjnl-2012-202182; Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002; Van Damme N, 2008, CELL HOST MICROBE, V3, P245, DOI 10.1016/j.chom.2008.03.001; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; Varga ZT, 2012, J VIROL, V86, P8359, DOI 10.1128/JVI.01122-12; Varga ZT, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002067; Verma S, 2011, BLOOD, V117, P6600, DOI 10.1182/blood-2011-01-333427; Vijayvergiya V, 2004, BIOPHYS J, V87, P1697, DOI 10.1529/biophysj.104.043018; Vives-Adrian L, 2015, J VIROL, V89, P3648, DOI 10.1128/JVI.02881-14; Wang K, 2011, BBA-BIOMEMBRANES, V1808, P510, DOI 10.1016/j.bbamem.2010.05.006; Wang RF, 2021, AUTOPHAGY, V17, P496, DOI 10.1080/15548627.2020.1725375; Wang RF, 2019, AUTOPHAGY, V15, P1163, DOI 10.1080/15548627.2019.1580089; Wang RF, 2019, J VIROL, V93, DOI 10.1128/JVI.01984-18; Watkins LC, 2022, J AM CHEM SOC, V144, P769, DOI 10.1021/jacs.1c09281; Westerbeck JW, 2019, J VIROL, V93, DOI [10.1128/JVI.00015-19, 10.1128/jvi.00015-19]; Westerbeck JW, 2015, J VIROL, V89, P9313, DOI 10.1128/JVI.01237-15; Wetherill LF, 2012, J VIROL, V86, P5341, DOI 10.1128/JVI.06243-11; Wilson L, 2004, VIROLOGY, V330, P322, DOI 10.1016/j.virol.2004.09.033; Wilson L, 2006, VIROLOGY, V353, P294, DOI 10.1016/j.virol.2006.05.028; Wirblich C, 2006, J VIROL, V80, P460, DOI 10.1128/JVI.80.1.460-473.2006; Wohlgemuth N, 2018, J VIROL, V92, DOI 10.1128/JVI.01425-18; Wozniak AL, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001087; Wu H, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8050131; Wu RH, 2015, J VIROL, V89, P4281, DOI 10.1128/JVI.03011-14; Xie SQ, 2011, CELL RES, V21, P1271, DOI 10.1038/cr.2011.112; Xie XP, 2013, J VIROL, V87, P4609, DOI 10.1128/JVI.02424-12; Xu AM, 2000, EMBO J, V19, P6465, DOI 10.1093/emboj/19.23.6465; Yang Y, 2005, BIOCHEM J, V392, P135, DOI 10.1042/BJ20050698; Ye Y, 2007, J VIROL, V81, P3597, DOI 10.1128/JVI.01472-06; Yoshizumi T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5713; Yu CY, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002780; Yuan XL, 2005, VIRUS RES, V109, P191, DOI 10.1016/j.virusres.2005.01.001; Yue Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0917-y; Zamarin Dmitriy, 2005, PLoS Pathogens, V1, P40; Zhang H, 2015, MOL CELL BIOCHEM, V403, P187, DOI 10.1007/s11010-015-2349-7; Zhang RH, 2015, J VIROL, V89, P11383, DOI 10.1128/JVI.01986-15; Zhang RH, 2014, BBA-BIOMEMBRANES, V1838, P1088, DOI 10.1016/j.bbamem.2013.07.025; Zhang XL, 2020, EUR J IMMUNOL, V50, P1268, DOI 10.1002/eji.202048785; Zhang ZW, 2017, MICROB PATHOGENESIS, V112, P111, DOI 10.1016/j.micpath.2017.09.039; Zhi XY, 2020, RNA BIOL, V17, P335, DOI 10.1080/15476286.2019.1700058; Zhirnov OP, 2013, J VIROL, V87, P13107, DOI 10.1128/JVI.02148-13; Zhou Y, 2018, BBA-MOL BASIS DIS, V1864, P60, DOI 10.1016/j.bbadis.2017.09.028; Zhu PY, 2017, J VIROL, V91, DOI [10.1128/JVI.01757-16, 10.1128/jvi.01757-16]; Zhu ZX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.170; Zhu ZX, 2016, J VIROL, V90, P11106, DOI 10.1128/JVI.01310-16; Zou JH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084128	291	0	0	10	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								890549	10.3389/fimmu.2022.890549	http://dx.doi.org/10.3389/fimmu.2022.890549			25	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3EZ	35720341	gold, Green Published			2022-12-18	WOS:000812113500001
J	Xu, LW; Tian, D; Zhou, MS; Ma, JY; Sun, GY; Jin, H; Li, MY; Zhang, D; Wu, J				Xu, Longwei; Tian, Dan; Zhou, Minsi; Ma, Jiuyue; Sun, Guangyong; Jin, Hua; Li, Mingyang; Zhang, Dong; Wu, Jing			OX40 Expression in Eosinophils Aggravates OVA-Induced Eosinophilic Gastroenteritis	FRONTIERS IN IMMUNOLOGY			English	Article						eosinophils; OX40; type 2 immunity; NF-kappa B signaling pathway; eosinophilic gastrointestinal diseases	MURINE MODEL; EX-VIVO; LIGAND; CELLS; ACTIVATION; IMMUNITY; INNATE; HEALTH	Background & Aims: Eosinophils are the main inflammatory effector cells that damage gastrointestinal tissue in eosinophilic gastrointestinal diseases (EGIDs). Activation of the OX40 pathway aggravates allergic diseases, such as asthma, but it is not clear whether OX40 is expressed in eosinophils to regulate inflammation in EGIDs. In this study, we assessed the expression and effect of OX40 on eosinophils in WT and Ox40(-/-) eosinophilic gastroenteritis (EGE) mice. Methods: Eosinophil infiltration, ovalbumin (OVA)-specific Ig production, OX40 expression and inflammatory factor levels in the intestine and bone marrow (BM) were investigated to evaluate inflammation. Results: We confirmed that OVA-challenged mice produced high levels of Ox40, Mbp, Ccl11, Il5, Il4, Il13, and Il6 mRNA and a low level of Ifng mRNA in the intestine. Increased eosinophils were observed in intestinal and lymph tissues, accompanied by significantly upregulated OX40 and Type 2 cytokine production in eosinophils of EGE mice. Ox40 deficiency ameliorated OVA-induced inflammation, eosinophil infiltration, and cytokine production in the intestine. Consistently, Ox40(-/) (-) eosinophils exhibited decreased proliferation and proinflammatory function. The stimulation of the agonistic anti-OX40 antibody, OX86, promoted the effect of OX40 on eosinophils. The present study also showed that Ox40 deficiency dampened the Traf2/6-related NF-kappa B signaling pathway in eosinophils. Conclusions; OX40 may play a critical role in the progress of OVA-induced EGE by promoting the maturation and function of eosinophils via the Traf2/6-related NF-kappa B signaling pathway.	[Xu, Longwei; Wu, Jing] Peking Univ, Ninth Sch Clin Med, Dept Gastroenterol, Beijing, Peoples R China; [Tian, Dan; Sun, Guangyong; Jin, Hua; Li, Mingyang; Zhang, Dong] Beijing Key Lab Tolerance Induct & Organ Protect T, Beijing, Peoples R China; [Tian, Dan; Sun, Guangyong; Jin, Hua; Li, Mingyang; Zhang, Dong] Capital Med Univ, Beijing Friendship Hosp, Immunol Res Ctr Oral & Syst Hlth, Beijing, Peoples R China; [Tian, Dan; Sun, Guangyong; Jin, Hua; Li, Mingyang; Zhang, Dong] Beijing Clin Res Inst, Beijing, Peoples R China; [Zhou, Minsi; Ma, Jiuyue; Wu, Jing] Capital Med Univ, Beijing Friendship Hosp, Dept Gastroenterol, Beijing, Peoples R China; [Zhou, Minsi; Ma, Jiuyue; Zhang, Dong; Wu, Jing] Natl Clin Res Ctr Digest Dis, Beijing, Peoples R China	Peking University; Capital Medical University; Capital Medical University	Wu, J (corresponding author), Peking Univ, Ninth Sch Clin Med, Dept Gastroenterol, Beijing, Peoples R China.; Zhang, D (corresponding author), Beijing Key Lab Tolerance Induct & Organ Protect T, Beijing, Peoples R China.; Zhang, D (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Immunol Res Ctr Oral & Syst Hlth, Beijing, Peoples R China.; Zhang, D (corresponding author), Beijing Clin Res Inst, Beijing, Peoples R China.; Wu, J (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Gastroenterol, Beijing, Peoples R China.; Zhang, D; Wu, J (corresponding author), Natl Clin Res Ctr Digest Dis, Beijing, Peoples R China.	zhangd@ccmu.edu.cn; wujing36youyi@ccmu.edu.cn	Li, Mingyang/HGF-2294-2022; Zhang, Dong/AAU-5380-2020	Li, Mingyang/0000-0003-1446-6381; Zhang, Dong/0000-0002-3404-5173; Tian, Dan/0000-0002-6894-2673	Youth Beijing Scholar [035]; Beijing Municipal Administration of Hospitals' Youth Program [QMS20200103]; Scientific Research Common Program of Beijing Municipal Commission of Education [KM202110025015]; Digestive Medical Coordinated Development Center of Beijing Hospitals Authority [XXZ015]; Science and Technology Development Project of China State Railway Group [N2019Z004]; Special Scientific Research Fund for Tutor of Beijing Friendship Hospital [YYDSZX201901]; Beijing Science and Technology Program [Z211100002921028]	Youth Beijing Scholar; Beijing Municipal Administration of Hospitals' Youth Program; Scientific Research Common Program of Beijing Municipal Commission of Education(Beijing Municipal Commission of Education); Digestive Medical Coordinated Development Center of Beijing Hospitals Authority; Science and Technology Development Project of China State Railway Group; Special Scientific Research Fund for Tutor of Beijing Friendship Hospital; Beijing Science and Technology Program	This work was supported by grants from the Youth Beijing Scholar (No. 035), the Beijing Municipal Administration of Hospitals' Youth Program (No. QMS20200103), the Scientific Research Common Program of Beijing Municipal Commission of Education (No. KM202110025015), the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (No. XXZ015), the Science and Technology Development Project of China State Railway Group (No. N2019Z004), the Special Scientific Research Fund for Tutor of Beijing Friendship Hospital (No. YYDSZX201901), and the Beijing Science and Technology Program (No. Z211100002921028).	AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; Baumann R, 2004, EUR J IMMUNOL, V34, P2268, DOI 10.1002/eji.200424863; Berek C, 2016, METHODS MOL BIOL, V1422, P213, DOI 10.1007/978-1-4939-3603-8_20; Blanchard C, 2011, J ALLERGY CLIN IMMUN, V127, P208, DOI 10.1016/j.jaci.2010.10.039; Burgess JK, 2004, J ALLERGY CLIN IMMUN, V113, P683, DOI 10.1016/j.jaci.2003.12.311; Chu VT, 2012, EUR J IMMUNOL, V42, P130, DOI 10.1002/eji.201141953; Dewson G, 1999, AM J RESP CELL MOL, V20, P720, DOI 10.1165/ajrcmb.20.4.3453; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Elsner JSH, 2020, ACTA DERM-VENEREOL, V100, DOI 10.2340/00015555-3452; Farhan RK, 2016, IMMUNOLOGY, V149, P413, DOI 10.1111/imm.12658; Furuta GT, 2005, AM J PHYSIOL-GASTR L, V289, pG890, DOI 10.1152/ajpgi.00015.2005; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Hogan SP, 2013, CURR OPIN GASTROEN, V29, P7, DOI 10.1097/MOG.0b013e32835ab29a; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Ierna MX, 2006, IMMUNOLOGY, V117, P108, DOI 10.1111/j.1365-2567.2005.02271.x; Ishii N, 2010, ADV IMMUNOL, V105, P63, DOI 10.1016/S0065-2776(10)05003-0; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; Jin H, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129736; Kaur D, 2012, CHEST, V141, P494, DOI 10.1378/chest.11-1730; Kawamata S, 1998, J BIOL CHEM, V273, P5808, DOI 10.1074/jbc.273.10.5808; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909, DOI 10.4049/jimmunol.173.10.5909; Peterson K, 2021, J ALLER CL IMM-PRACT, V9, P3276, DOI 10.1016/j.jaip.2021.07.031; Ravin KA, 2016, CLIN REV ALLERG IMMU, V50, P214, DOI 10.1007/s12016-015-8525-4; Rosenberg HF, 2013, NAT REV IMMUNOL, V13, P9, DOI 10.1038/nri3341; Schwartz C, 2015, BLOOD, V125, P3896, DOI 10.1182/blood-2014-10-607788; Song Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36102-y; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Sun GY, 2018, CELL REP, V25, P3786, DOI 10.1016/j.celrep.2018.12.006; Tian D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12243-0; Travers J, 2015, MUCOSAL IMMUNOL, V8, P464, DOI 10.1038/mi.2015.2; Visekruna A, 2019, J CLIN INVEST, V129, P1972, DOI 10.1172/JCI98929; Ward-Kavanagh LK, 2016, IMMUNITY, V44, P1005, DOI 10.1016/j.immuni.2016.04.019; Webb GJ, 2016, CLIN REV ALLERG IMMU, V50, P312, DOI 10.1007/s12016-015-8498-3; Wechsler JB, 2014, GASTROENTEROL CLIN N, V43, P281, DOI 10.1016/j.gtc.2014.02.006; Willoughby J, 2017, MOL IMMUNOL, V83, P13, DOI 10.1016/j.molimm.2017.01.006; Yan BM, 2009, GUT, V58, P721, DOI 10.1136/gut.2008.165894; Youngblood BA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126219	40	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								841141	10.3389/fimmu.2022.841141	http://dx.doi.org/10.3389/fimmu.2022.841141			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E3FH	35720294	Green Published, gold			2022-12-18	WOS:000812114300001
J	Yang, YL; Fan, YB; Gao, L; Zhang, C; Gu, JL; Pan, WH; Fang, W				Yang, Ya-li; Fan, Yi-bin; Gao, Lei; Zhang, Chao; Gu, Ju-lin; Pan, Wei-hua; Fang, Wei			Cryptococcus neoformans Csn1201 Is Associated With Pulmonary Immune Responses and Disseminated Infection	FRONTIERS IN IMMUNOLOGY			English	Article						Cryptococcus neoformans; Csn1201; immune evasion; cell wall remodelling; virulence	VIRULENCE FACTORS; DENDRITIC CELLS; ACTIVATION	Cryptococcus neoformans is a major etiological agent of fungal meningoencephalitis. The outcome of cryptococcosis depends on the complex interactions between the pathogenic fungus and host immunity. The understanding of how C. neoformans manipulates the host immune response through its pathogenic factors remains incomplete. In this study, we defined the roles of a previously uncharacterized protein, Csn1201, in cryptococcal fitness and host immunity. Use of both inhalational and intravenous mouse models demonstrated that the CSN1201 deletion significantly blocked the pulmonary infection and extrapulmonary dissemination of C. neoformans. The in vivo hypovirulent phenotype of the csn1201 Delta mutant was attributed to a combination of multiple factors, including preferential dendritic cell accumulation, enhanced Th1 and Th17 immune responses, decreased intracellular survival inside macrophages, and attenuated blood-brain barrier transcytosis rather than exclusively to pathogenic fitness. The csn1201 Delta mutant exhibited decreased tolerance to various stressors in vitro, along with reduced capsule production and enhanced cell wall thickness under host-relevant conditions, indicating that the CSN1201 deletion might promote the exposure of cell wall components and thus induce a protective immune response. Taken together, our results strongly support the importance of cryptococcal Csn1201 in pulmonary immune responses and disseminated infection.	[Yang, Ya-li] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Dermatol, Sch Med, Shanghai, Peoples R China; [Yang, Ya-li; Fang, Wei] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Laser & Aesthet Med, Sch Med, Shanghai, Peoples R China; [Yang, Ya-li; Zhang, Chao; Pan, Wei-hua; Fang, Wei] Naval Mil Med Univ, Changzheng Hosp, Dept Dermatol & Venereol, Shanghai Key Lab Mol Med Mycol, Shanghai, Peoples R China; [Fan, Yi-bin] Zhejiang Prov Peoples Hosp, Peoples Hosp, Dept Dermatol, Hangzhou Med Coll, Hangzhou, Peoples R China; [Gao, Lei] Westlake Univ, Microscopy Core Facil, Biomed Res Core Facil, Hangzhou, Peoples R China; [Gu, Ju-lin] Naval Mil Med Univ, Dept Dermatol, Affiliated Hosp 3, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Naval Medical University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Westlake University; Naval Medical University	Fang, W (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Laser & Aesthet Med, Sch Med, Shanghai, Peoples R China.; Pan, WH; Fang, W (corresponding author), Naval Mil Med Univ, Changzheng Hosp, Dept Dermatol & Venereol, Shanghai Key Lab Mol Med Mycol, Shanghai, Peoples R China.; Gu, JL (corresponding author), Naval Mil Med Univ, Dept Dermatol, Affiliated Hosp 3, Shanghai, Peoples R China.	wujgjl@126.com; panweihua9@sina.com; weifang081782@163.com	Yang, Ya-Li/GYU-4320-2022; yang, yang/HGT-7999-2022		National Science Foundation of China [81501728, 82072259, 81772159, 82073453, 81902041]	National Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by the National Science Foundation of China (81501728, 82072259, 81772159, 82073453 and 81902041).	Ballou ER, 2017, CURR OPIN MICROBIOL, V40, P88, DOI 10.1016/j.mib.2017.10.012; Blankenship JR, 2003, EUKARYOT CELL, V2, P422, DOI 10.1128/EC.2.3.422-430.2003; Botts MR, 2010, CURR OPIN MICROBIOL, V13, P437, DOI 10.1016/j.mib.2010.05.003; Casadevall A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00855; Chen GH, 2016, J IMMUNOL, V196, P1810, DOI 10.4049/jimmunol.1501512; Desalermos A, 2015, J INFECT DIS, V211, P298, DOI 10.1093/infdis/jiu441; Esher SK, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007126; Fa ZZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01725; Fa ZZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01055; Fang W, 2017, CNS NEUROSCI THER, V23, P291, DOI 10.1111/cns.12673; Fang W, 2015, FUNGAL GENET BIOL, V78, P7, DOI 10.1016/j.fgb.2014.10.017; Fang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038326; Gilbert AS, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a019661; Gushiken AC, 2021, INFECT DIS CLIN N AM, V35, P493, DOI 10.1016/j.idc.2021.03.012; Hardison SE, 2010, AM J PATHOL, V176, P774, DOI 10.2353/ajpath.2010.090634; He XM, 2012, AM J PATHOL, V181, P1356, DOI 10.1016/j.ajpath.2012.06.012; Hole CR, 2020, MBIO, V11, DOI 10.1128/mBio.03373-19; Kavanagh K, 2004, FEMS MICROBIOL REV, V28, P101, DOI 10.1016/j.femsre.2003.09.002; Liu OW, 2008, CELL, V135, P174, DOI 10.1016/j.cell.2008.07.046; Masso-Silva J, 2018, MBIO, V9, DOI [10.1128/mBio.01828-17, 10.1128/mbio.01828-17]; Maziarz EK, 2016, INFECT DIS CLIN N AM, V30, P179, DOI 10.1016/j.idc.2015.10.006; Mednick AJ, 2003, EUR J IMMUNOL, V33, P1744, DOI 10.1002/eji.200323626; Movahed E, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0269-5; O'Meara TR, 2013, MBIO, V4, DOI 10.1128/mBio.00522-12; Ost KS, 2017, MBIO, V8, DOI [10.1128/mBio.02290-16, 10.1128/mbio.02290-16]; Osterholzer JJ, 2009, AM J PATHOL, V174, P932, DOI 10.2353/ajpath.2009.080673; Perfect JR, 2014, J CLIN INVEST, V124, P1893, DOI 10.1172/JCI75241; Piehler D, 2011, AM J PATHOL, V179, P733, DOI 10.1016/j.ajpath.2011.04.025; Pietrella D, 2005, INFECT IMMUN, V73, P820, DOI 10.1128/IAI.73.2.820-827.2005; Qiu YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047853; Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/s1473-3099(17)30243-8, 10.1016/S1473-3099(17)30243-8]; Reese AJ, 2007, MOL MICROBIOL, V63, P1385, DOI 10.1111/j.1365-2958.2006.05551.x; Rohatgi S, 2015, FUTURE MICROBIOL, V10, P565, DOI [10.2217/FMB.14.132, 10.2217/fmb.14.132]; Sang JJ, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006206; Scheel H, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-71; Wager CML, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007358; Wormley FL, 2007, INFECT IMMUN, V75, P1453, DOI 10.1128/IAI.00274-06; Wozniak KL, 2018, J FUNGI, V4, DOI 10.3390/jof4010036; Wozniak KL, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-65; Wozniak KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006854; Zaragoza O, 2019, VIRULENCE, V10, P490, DOI 10.1080/21505594.2019.1614383; Zhao JY, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.570269	42	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								890258	10.3389/fimmu.2022.890258	http://dx.doi.org/10.3389/fimmu.2022.890258			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E0DQ	35720283	Green Published, gold			2022-12-18	WOS:000811906500001
J	Ye, LF; Zuo, Y; Chen, F; Xu, YT; Zhang, PL; Yang, HX; Peng, QL; Wang, GC; Shu, XM				Ye, Lifang; Zuo, Yu; Chen, Fang; Xu, Yuetong; Zhang, Puli; Yang, Hongxia; Peng, Qinglin; Wang, Guochun; Shu, Xiaoming			Adrenomedullin Expression Is Associated With the Severity and Poor Prognosis of Interstitial Lung Disease in Dermatomyositis Patients	FRONTIERS IN IMMUNOLOGY			English	Article						adrenomedullin; interstitial lung disease; dermatomyositis; prognosis; disease severity	IDIOPATHIC INFLAMMATORY MYOPATHIES; PLASMA ADRENOMEDULLIN; CLASSIFICATION; ADULT; CYTOKINES	ObjectiveTo evaluate adrenomedullin mRNA levels in the peripheral blood mononuclear cells (PBMCs) of patients with dermatomyositis (DM) as well as their correlation with the severity of interstitial lung disease (ILD). MethodsA total of 41 DM patients and seven immune-mediated necrotizing myopathy (IMNM) patients were recruited, in addition to 21 healthy controls (HCs). The adrenomedullin mRNA levels in PBMCs were measured via quantitative reverse-transcription real-time polymerase chain reaction (qRT-PCR). The associations between adrenomedullin expression levels and major clinical, laboratory, pulmonary function parameters and the prognosis of patients with DM-related ILD (DM-ILD) were analyzed. Immunohistochemical analysis was performed on lung tissues of DM-ILD patients to determine adrenomedullin expression. ResultsAdrenomedullin mRNA levels in PBMCs were significantly higher in DM patients than in IMNM patients and HCs (p = 0.022 and p<0.001, respectively). Among DM patients, the levels were significantly higher in those with rapidly progressive ILD (RP-ILD) than in those with chronic ILD (p = 0.002) or without ILD (p < 0.001). The adrenomedullin mRNA levels in DM-ILD were positively correlated with serum ferritin (r =0.507, p =0.002), lactate dehydrogenase (LDH) (r =0.350, p =0.045), and lung visual analog scale (VAS) (r=0.392, p=0.021) and were negatively correlated with pulmonary function test parameters, including predicted forced vital capacity (FVC)% (r = -0.523, p = 0.025), forced expiratory volume in 1 s (FEV1)% (r = -0.539, p = 0.020), and diffusing capacity of carbon monoxide (DLco)% (r = -0.495, p = 0.036). Immunohistochemical analysis of adrenomedullin confirmed higher expression in the alveolar epithelial cells and macrophages of DM patients with RP-ILD. Among the DM patients with ILD, the six decedents exhibited higher adrenomedullin levels than the 28 survivors (p = 0.042). The cumulative survival rate was significantly lower (62.5% vs. 100%, P = 0.005) in patients with an adrenomedullin level > 0.053 than in those with a level ConclusionsAdrenomedullin levels are upregulated in DM patients with RP-ILD and are associated with ILD severity and poor prognosis. Adrenomedullin may be a potential prognostic biomarker in DM patients with ILD, although need further investigation.	[Ye, Lifang; Zuo, Yu; Chen, Fang; Xu, Yuetong; Zhang, Puli; Yang, Hongxia; Peng, Qinglin; Wang, Guochun; Shu, Xiaoming] China Japan Friendship Hosp, Dept Rheumatol, Key Lab Myositis, Beijing, Peoples R China; [Ye, Lifang; Xu, Yuetong; Wang, Guochun] Chinese Acad Med Sci, Peking Union Med Coll, Beijing, Peoples R China; [Zhang, Puli; Yang, Hongxia] Peking Univ, China Japan Friendship Sch Clin Med, Beijing, Peoples R China	China-Japan Friendship Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking University	Wang, GC; Shu, XM (corresponding author), China Japan Friendship Hosp, Dept Rheumatol, Key Lab Myositis, Beijing, Peoples R China.; Wang, GC (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll, Beijing, Peoples R China.	guochunwang@hotmail.com; sxm992283@hotmail.com						Allenbach Y, 2018, NEUROMUSCULAR DISORD, V28, P87, DOI 10.1016/j.nmd.2017.09.016; Amer Thoracic Soc, 2000, AM J RESP CRIT CARE, V161, P646; American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias, 2002, AM J RESP CRIT CARE, V165, P277, DOI [10.1164/ajrccm.165.2.ats01, DOI 10.1164/AJRCCM.165.2.ATS01]; Ashizuka S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9081068; Cerezo LA, 2020, CURR OPIN RHEUMATOL, V32, P534, DOI 10.1097/BOR.0000000000000744; Cheung B, 1997, CLIN SCI, V92, P59, DOI 10.1042/cs0920059; Chosa E, 2003, J RHEUMATOL, V30, P2553; Georgantas RW, 2014, ARTHRITIS RHEUMATOL, V66, P1022, DOI 10.1002/art.38292; Gono T, 2012, RHEUMATOLOGY, V51, P1563, DOI 10.1093/rheumatology/kes102; Gono T, 2010, RHEUMATOLOGY, V49, P1878, DOI 10.1093/rheumatology/keq196; Green L, 2013, CLIN EXP RHEUMATOL, V31, P672; Hunninghake GM, 2022, CHEST, V161, P470, DOI 10.1016/j.chest.2021.06.035; Isenberg DA, 2004, RHEUMATOLOGY, V43, P49, DOI 10.1093/rheumatology/keg427; Kameda Hideto, 2006, Endocrine Metabolic & Immune Disorders-Drug Targets, V6, P409; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kobayashi N, 2015, RHEUMATOLOGY, V54, P784, DOI 10.1093/rheumatology/keu385; Kubo A, 1998, J BIOL CHEM, V273, P16730, DOI 10.1074/jbc.273.27.16730; Lee JS, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1835-9; Li YH, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00363; Lundberg IE, 2018, NAT REV RHEUMATOL, V14, P269, DOI 10.1038/nrrheum.2018.41; Lundberg IE, 2017, ARTHRITIS RHEUMATOL, V69, P2271, DOI 10.1002/art.40320; Mak A, 2006, RHEUMATOLOGY, V45, P1266, DOI 10.1093/rheumatology/kel105; Mandal J, 2019, PULM PHARMACOL THER, V56, P8, DOI 10.1016/j.pupt.2019.01.006; Mok MY, 2007, J RHEUMATOL, V34, P2224; Nanke Y, 2000, ANN RHEUM DIS, V59, P493; Schnabel A, 2003, SEMIN ARTHRITIS RHEU, V32, P273, DOI 10.1053/sarh.2002.50012; Selva-O'Callaghan A, 2018, LANCET NEUROL, V17, P816, DOI 10.1016/S1474-4422(18)30254-0; SUGO S, 1995, BIOCHEM BIOPH RES CO, V207, P25, DOI 10.1006/bbrc.1995.1148; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; Takano S, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/9832430; Waldman R, 2020, J AM ACAD DERMATOL, V82, P283, DOI 10.1016/j.jaad.2019.05.105; Wang YK, 2020, RHEUMATOLOGY, V59, P2024, DOI 10.1093/rheumatology/kez571; Yadav A, 2022, COMPUT INTEL NEUROSC, V2022, DOI 10.1155/2022/2832400; Zuo Y, 2020, RHEUMATOLOGY, V59, P2829, DOI 10.1093/rheumatology/keaa034	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								885142	10.3389/fimmu.2022.885142	http://dx.doi.org/10.3389/fimmu.2022.885142			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E2RV	35720354	Green Published, gold			2022-12-18	WOS:000812079300001
J	Zheng, Z; Wei, QF; Wan, XH; Zhong, XM; Liu, LJ; Zeng, JQ; Mao, LH; Han, XJ; Tou, FF; Rao, J				Zheng, Zhi; Wei, Qingfeng; Wan, Xianghui; Zhong, Xiaoming; Liu, Lijuan; Zeng, Jiquan; Mao, Lihua; Han, Xiaojian; Tou, Fangfang; Rao, Jun			Correlation Analysis Between Trace Elements and Colorectal Cancer Metabolism by Integrated Serum Proteome and Metabolome	FRONTIERS IN IMMUNOLOGY			English	Article						colorectal cancer; Mg; cholesterol metabolism; DIA-MS; UPLC; Q-TOF-MS; MS	MAGNESIUM; ASSOCIATION; GROWTH; IGF-2; IRON; ZINC	Colorectal cancer (CRC) is currently the third most common cancer with a high mortality rate. The underlying molecular mechanism of CRC, especially advanced CRC, remains poorly understood, resulting in few available therapeutic plans. To expand our knowledge of the molecular characteristics of advanced CRC and explore possible new therapeutic strategies, we herein conducted integrated proteomics and metabolomics analyses of 40 serum samples collected from 20 advanced CRC patients before and after treatment. The mass spectrometry-based proteomics analysis was performed under data-independent acquisition (DIA), and the metabolomics analysis was performed by ultra-performance liquid chromatography coupled with time-of-flight tandem mass spectrometry (UPLC-TOF-MS/MS). Trace elements including Mg, Zn, and Fe were measured by inductively coupled plasma spectrometry (ICP-MS) analysis. Four of the 20 patients had progressive disease (PD) after treatment, and clinical test results indicated that they all had impaired liver functions. In the proteomics analysis, 64 proteins were discovered to be significantly altered after treatment. These proteins were enriched in cancer-related pathways and pathways participating immune responses, such as MAPK signaling pathway and complement/coagulation cascades. In the metabolomics analysis, 128 metabolites were found to be significantly changed after treatment, and most of them are enriched in pathways associated with lipid metabolism. The cholesterol metabolism pathway was significantly enriched in both the proteomics and metabolomics pathway enrichment analyses. The concentrations of Mg in the serums of CRC patients were significantly lower than those in healthy individuals, which returned to the normal range after treatment. Correlation analysis linked key lipids, proteins, and Mg as immune modulators in the development of advanced CRC. The results of this study not only extended our knowledge on the molecular basis of advanced CRC but also provided potential novel therapeutic targets for CRC treatment.	[Zheng, Zhi; Mao, Lihua; Han, Xiaojian; Tou, Fangfang] Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Affiliated Hosp 1, Nanchang, Peoples R China; [Wei, Qingfeng; Wan, Xianghui; Zhong, Xiaoming; Liu, Lijuan; Zeng, Jiquan; Rao, Jun] Jiangxi Canc Hosp, Nanchang Med Coll, Jiangxi Clin Res Ctr Canc, Affiliated Hosp 2, Nanchang, Peoples R China		Tou, FF (corresponding author), Jiangxi Prov Peoples Hosp, Nanchang Med Coll, Affiliated Hosp 1, Nanchang, Peoples R China.; Rao, J (corresponding author), Jiangxi Canc Hosp, Nanchang Med Coll, Jiangxi Clin Res Ctr Canc, Affiliated Hosp 2, Nanchang, Peoples R China.	toufangfang@163.com; raojun1986@126.com			National Natural Science Foundation of China [81960865]; Jiangxi Provincial Department of Science [20212BCJL23056, 20212BAG70040]; Excellent Young Scientists Fund of Jiangxi Cancer Hospital [2021EYS01]; National Cancer Center Climbing Fund [NCC201814B045]; Science and Technology Plan Project of Jiangxi Provincial Administration of Traditional Chinese Medicine [2019A057]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangxi Provincial Department of Science; Excellent Young Scientists Fund of Jiangxi Cancer Hospital; National Cancer Center Climbing Fund; Science and Technology Plan Project of Jiangxi Provincial Administration of Traditional Chinese Medicine	Funding This work was supported by grants from the National Natural Science Foundation of China (No. 81960865), Jiangxi Provincial Department of Science (No. 20212BCJL23056 and No. 20212BAG70040), the Excellent Young Scientists Fund of Jiangxi Cancer Hospital (2021EYS01), and National Cancer Center Climbing Fund (No. NCC201814B045). The work was also funded in part by grants from the Science and Technology Plan Project of Jiangxi Provincial Administration of Traditional Chinese Medicine (No. 2019A057).	Attar T., 2020, CHEM REV LETT, V3, P117, DOI 10.22034/crl.2020.229025.1058; Chen XL, 2019, J PROTEOME RES, V18, P2321, DOI 10.1021/acs.jproteome.9b00149; Corey KE, 2022, J HEPATOL, V76, P25, DOI 10.1016/j.jhep.2021.09.026; Deng W, 2020, J CHROMATOGR B, V1136, DOI 10.1016/j.jchromb.2019.121882; Ding R, 2022, J PHYSIOL BIOCHEM, V78, P99, DOI 10.1007/s13105-021-00843-8; Han QF, 2019, CANCER MED-US, V8, P6487, DOI 10.1002/cam4.2524; Huang BL, 2020, NAT METAB, V2, P132, DOI 10.1038/s42255-020-0174-0; Huang H, 2021, J EXPO SCI ENV EPID, V31, P571, DOI 10.1038/s41370-021-00319-3; Jouybari L, 2019, J TRACE ELEM MED BIO, V56, P90, DOI 10.1016/j.jtemb.2019.06.017; Juloski JT, 2020, J TRACE ELEM MED BIO, V59, DOI 10.1016/j.jtemb.2020.126451; Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8; Lima ND, 2022, J HEPATOL, V76, P11, DOI 10.1016/j.jhep.2021.09.008; Lin XQ, 2018, ENVIRON SCI POLLUT R, V25, P17611, DOI 10.1007/s11356-018-1914-5; Mikolasevic I, 2017, POSTGRAD MED J, V93, P153, DOI 10.1136/postgradmedj-2016-134383; Nakagomi T, 2019, CANCERS, V11, DOI 10.3390/cancers11040552; Parizadeh SM, 2019, EXPERT REV GASTROENT, V13, P633, DOI 10.1080/17474124.2019.1617696; Pehkonen H, 2021, ONCOGENE, V40, P6406, DOI 10.1038/s41388-021-02048-1; Peters G, 2003, VIRCHOWS ARCH, V443, P139, DOI 10.1007/s00428-003-0856-5; Polter EJ, 2019, CANCER EPIDEM BIOMAR, V28, P1292, DOI 10.1158/1055-9965.EPI-18-1300; Probst-Hensch NM, 2001, BRIT J CANCER, V85, P1695, DOI 10.1054/bjoc.2001.2172; Rao J, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.687229; RAYSSIGUIER Y, 1981, J NUTR, V111, P1876, DOI 10.1093/jn/111.11.1876; Schmidt DR, 2021, CA-CANCER J CLIN, V71, P333, DOI 10.3322/caac.21670; Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601; Sun Y, 2019, FOOD FUNCT, V10, P7444, DOI [10.1039/C9FO01966A, 10.1039/c9fo01966a]; Tejpar S, 2007, LANCET ONCOL, V8, P387, DOI 10.1016/S1470-2045(07)70108-0; Teng LC, 2015, J TRADIT CHIN MED, V35, P546; Torti SV, 2018, ANNU REV NUTR, V38, P97, DOI 10.1146/annurev-nutr-082117-051732; Vincenzi B, 2008, CLIN CANCER RES, V14, P4219, DOI 10.1158/1078-0432.CCR-08-0077; Visal TH, 2022, BRIT J CANCER, V127, P173, DOI 10.1038/s41416-022-01768-9; Wu X, 2018, FOOD FUNCT, V9, P87, DOI 10.1039/c7fo01155e; Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174; Yu L, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.636917; Zhang J, 2021, CANCER GENE THER, V28, P1269, DOI 10.1038/s41417-020-00276-3	34	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								921317	10.3389/fimmu.2022.921317	http://dx.doi.org/10.3389/fimmu.2022.921317			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2K0AE	35720415	Green Published, gold			2022-12-18	WOS:000816007200001
J	Zhou, JY; Werner, JM; Glehr, G; Geissler, EK; Hutchinson, JA; Kronenberg, K				Zhou, Jordi Yang; Werner, Jens M.; Glehr, Gunther; Geissler, Edward K.; Hutchinson, James A.; Kronenberg, Katharina			Identification and Isolation of Type II NKT Cell Subsets in Human Blood and Liver	FRONTIERS IN IMMUNOLOGY			English	Article						NKT; isolation; expansion; FoxP3; liver; steatotic	T-CELLS; PLZF; HEALTH	Background: Steatotic livers are more prone to rejection, but are often transplanted owing to the shortage of available organs. Type II NKT (T2NKT) cells are liver-resident lymphocytes that react to lipids presented by CD1d. The role of T2NKT cells in rejection of fatty liver transplants is unclear, partly because of a lack of T2NKT cell markers and their very low frequency in blood. Here, we quantify human T2NKT cells in blood and liver tissue by flow cytometry and provide a strategy for their enrichment and expansion. Methods: Human T2NKT cells were identified as CD3(+) CD56(+) CD161(+) TCR-gamma delta(-), TCRV alpha 7.2(-) and TCRV alpha 24(-) cells. T2NKT cells were enriched from blood by sequential positive selection using CD56 and CD3 microbeads. These were subsequently FACS-sorted to purity then expanded in vitro for 3 weeks using anti-CD3/CD28 beads and TGF-beta 1. Results: The frequency of human T2NKT cells in blood was very low (0.8 +/- 0.4% of CD3(+) T cells) but they were a more abundant population in liver (6.3 +/- 0.9%). Enriched T2NKT cells expressed the transcription factor PLZF. A novel subset of FoxP3(+) T2NKT cells was discovered in blood and liver tissue. T2NKT cells were expanded in culture by 15- to 28-fold over 3 weeks, during which time they maintained expression of all identifying markers, including PLZF and FoxP3. Conclusions: Our work defines new strategies for identifying and isolating T2NKT cells from human blood and liver tissue. We showed that this rare population can be expanded in vitro in order to obtain experimentally amenable cell numbers. Further, we identified a novel T2NKT cell subset that stably expresses FoxP3, which might play a role in regulating innate-like lymphocyte responses in steatotic liver transplants.	[Zhou, Jordi Yang; Werner, Jens M.; Glehr, Gunther; Geissler, Edward K.; Hutchinson, James A.; Kronenberg, Katharina] Univ Hosp Regensburg, Dept Surg, Regensburg, Germany; [Zhou, Jordi Yang; Geissler, Edward K.] Leibniz Inst Immunotherapy, Regensburg, Germany; [Geissler, Edward K.] Fraunhofer Inst Toxicol & Expt Med, Inst Toxicol & Expt Med Regensburg ITEM R, Regensburg, Germany; [Geissler, Edward K.] Univ Regensburg, Regensburg Int Grad Sch Life Sci, Regensburg, Germany	University of Regensburg; Fraunhofer Gesellschaft; University of Regensburg	Kronenberg, K (corresponding author), Univ Hosp Regensburg, Dept Surg, Regensburg, Germany.	katharina.kronenberg@ukr.de		Glehr, Gunther/0000-0002-1495-9162				Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531; Chaudhry MS, 2014, J IMMUNOL, V193, P4761, DOI 10.4049/jimmunol.1401805; Cossarizza A, 2019, EUR J IMMUNOL, V49, P1457, DOI 10.1002/eji.201970107; Dhodapkar MV, 2017, J IMMUNOL, V198, P1015, DOI 10.4049/jimmunol.1601399; Gleimer M, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00374; Hutchinson JA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21572-y; Jackson Kyle R, 2019, Clin Liver Dis (Hoboken), V14, P191, DOI 10.1002/cld.847; Klibi J, 2021, J IMMUNOL, V207, P809, DOI 10.4049/jimmunol.2001444; Kuylenstierna C, 2011, EUR J IMMUNOL, V41, P1913, DOI 10.1002/eji.200940278; Linares I, 2019, TRANSPLANTATION, V103, P78, DOI 10.1097/TP.0000000000002466; Marcellin P, 2018, LIVER INT, V38, P2, DOI 10.1111/liv.13682; McCormack L, 2007, ANN SURG, V246, P940, DOI 10.1097/SLA.0b013e31815c2a3f; Nair S, 2015, BLOOD, V125, P1256, DOI 10.1182/blood-2014-09-600270; Nishioka Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00548; Raulet DH, 2003, NAT REV IMMUNOL, V3, P781, DOI 10.1038/nri1199; Riquelme P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05167-8; Savage AK, 2008, IMMUNITY, V29, P391, DOI 10.1016/j.immuni.2008.07.011; Seino K, 2005, J EXP MED, V202, P1623, DOI 10.1084/jem.20051600; Singh AK, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12794; Singh AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01969; Zhao J, 2014, P NATL ACAD SCI USA, V111, P2674, DOI 10.1073/pnas.1323845111	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 2	2022	13								898473	10.3389/fimmu.2022.898473	http://dx.doi.org/10.3389/fimmu.2022.898473			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2K0IC	35720369	Green Published, gold			2022-12-18	WOS:000816028000001
J	Bai, ZR; Lu, ZM; Liu, R; Tang, YW; Ye, XK; Jin, ML; Wang, G; Li, X				Bai, Ziran; Lu, Zhimin; Liu, Rui; Tang, Yawei; Ye, Xiaokang; Jin, Minli; Wang, Guan; Li, Xia			Iguratimod Restrains Circulating Follicular Helper T Cell Function by Inhibiting Glucose Metabolism via Hif1 alpha-HK2 Axis in Rheumatoid Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						rheumatoid arthritis; circulating follicular helper T cells; iguratimod; glucose metabolism; Hif1 alpha-HK2 axis	B-CELLS; ACTIVATION; T-614; DIFFERENTIATION	Iguratimod (IGU) is a novel disease modified anti-rheumatic drug, which has been found to act directly on B cells for inhibiting the production of antibodies in rheumatoid arthritis (RA) patients. Follicular helper T (Tfh) cells, a key T cell subsets in supporting B cell differentiation and antibody production, have been shown to play critical roles in RA. However, whether IGU can inhibit RA Tfh cells which further restrains B cell function remains unclear. Here, we aimed to explore the roles of IGU in regulating RA circulating Tfh (cTfh) cell function and investigate the potential mechanism associated with cell glucose metabolism. In our study, we found that IGU could act on RA-CD4(+) T cells to reduce T cell-dependent antibody production. IGU decreased the percentage of RA cTfh cells and the expression of Tfh cell-related molecules and cytokines which were involved in B cell functions. Importantly, our data showed that IGU significantly restrained the cTfh cell function by inhibiting glucose metabolism, which relied on Hif1 alpha-HK2 axis. In summary, we clarified a new target and mechanism of IGU by restraining RA cTfh cell function via inhibiting Hif1 alpha-HK2-glucose metabolism axis. Our study demonstrates the potential application of IGU in the treatment of diseases related to abnormal metabolism and function of Tfh cells.	[Bai, Ziran; Lu, Zhimin; Tang, Yawei; Ye, Xiaokang; Jin, Minli; Wang, Guan; Li, Xia] Dalian Med Univ, Coll Basic Med Sci, Dept Immunol, Dalian, Peoples R China; [Lu, Zhimin] Affiliated Hosp Nantong Univ, Dept Rheumatol, Nantong, Peoples R China; [Liu, Rui] Nanjing Med Univ, Dept Rheumatol, Affiliated Hosp 1, Nanjing, Peoples R China	Dalian Medical University; Nantong University; Nanjing Medical University	Wang, G; Li, X (corresponding author), Dalian Med Univ, Coll Basic Med Sci, Dept Immunol, Dalian, Peoples R China.	moonstonewg@sina.com; lixia416@163.com			National Natural Science Foundation of China [82071834, 81801609, 82101896]; Liaoning Distinguished Professor program; "Seedling" project of young scientific and technological talents of Liaoning Provincial Department of Education [LZ2019061]; China International Medical Foundation; Rheumatoid Special Fund [Z-2018-40]; Science and Technology Innovation Foundation of Dalian [2021JJ13SN48]; Dalian key laboratory of human microorganism homeostasis and immunological mechanism research of diseases	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Liaoning Distinguished Professor program; "Seedling" project of young scientific and technological talents of Liaoning Provincial Department of Education; China International Medical Foundation; Rheumatoid Special Fund; Science and Technology Innovation Foundation of Dalian; Dalian key laboratory of human microorganism homeostasis and immunological mechanism research of diseases	This work was supported by the National Natural Science Foundation of China [grant numbers 82071834, 81801609, 82101896]; the Liaoning Distinguished Professor program [Liao taught 2018 to 2020]; the "Seedling" project of young scientific and technological talents of Liaoning Provincial Department of Education [grant number LZ2019061]; China International Medical Foundation and Rheumatoid Special Fund [grant number Z-2018-40]; Science and Technology Innovation Foundation of Dalian (2021JJ13SN48); Dalian key laboratory of human microorganism homeostasis and immunological mechanism research of diseases.	Abboud G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01973; Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425; Cho SH, 2019, P NATL ACAD SCI USA, V116, P8975, DOI 10.1073/pnas.1811702116; Choi SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06686-0; Crotty S, 2011, ANNU REV IMMUNOL, V29, P621, DOI 10.1146/annurev-immunol-031210-101400; Dimeloe S, 2017, IMMUNOLOGY, V150, P35, DOI 10.1111/imm.12655; Dong L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111450; Dukhande VV, 2011, MOL CELL BIOCHEM, V357, P189, DOI 10.1007/s11010-011-0889-z; Hale JS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00016; Hara Masako, 2007, Mod Rheumatol, V17, P1, DOI 10.1007/s10165-006-0542-y; Iwata Shigeru, 2015, Nihon Rinsho Meneki Gakkai Kaishi, V38, P398, DOI 10.2177/jsci.38.398; Iwata S, 2015, ARTHRITIS RHEUMATOL, V67, P63, DOI 10.1002/art.38895; Jacobs SR, 2008, J IMMUNOL, V180, P4476, DOI 10.4049/jimmunol.180.7.4476; Ji LS, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/1826587; Jiang HH, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109704; Kolan SS, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12956; Kuriyama K, 2002, BIOCHEM BIOPH RES CO, V299, P903, DOI 10.1016/S0006-291X(02)02754-7; Lu LJ, 2009, ARTHRIT RHEUM-ARTHR, V61, P979, DOI 10.1002/art.24643; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; McGarry T, 2018, ARTHRITIS RHEUMATOL, V70, P1959, DOI 10.1002/art.40569; Pallet N, 2018, INT REV CEL MOL BIO, V341, P169, DOI 10.1016/bs.ircmb.2018.05.009; Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014; Qiu JT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652771; Ramiscal RR, 2013, IMMUNOL REV, V252, P146, DOI 10.1111/imr.12031; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140-6736(10)60826-4; Tan SY, 2020, J IMMUNOL, V205, P957, DOI 10.4049/jimmunol.2000137; Tanaka K, 2003, RHEUMATOLOGY, V42, P1365, DOI 10.1093/rheumatology/keg381; van Delft MAM, 2020, J AUTOIMMUN, V110, DOI 10.1016/j.jaut.2019.102392; Wahl DR, 2010, LUPUS, V19, P1492, DOI 10.1177/0961203310373109; Weyand CM, 2017, CURR OPIN IMMUNOL, V46, P112, DOI 10.1016/j.coi.2017.04.010; Wu YX, 2017, MOL MED REP, V16, P8200, DOI 10.3892/mmr.2017.7648; Xia LY, 2019, CELL METAB, V29, P103, DOI 10.1016/j.cmet.2018.09.020; Xie SS, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00073; Xu YZ, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/356040; Yang Z, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0542-4; Ye Y, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1874-2; Yoshitomi H, 2021, CELL MOL IMMUNOL, V18, P523, DOI 10.1038/s41423-020-00529-z; Zeng H, 2016, IMMUNITY, V45, P540, DOI 10.1016/j.immuni.2016.08.017; Zhan JF, 2017, CLIN EXP PHARMACOL P, V44, P556, DOI 10.1111/1440-1681.12740; Zhu YY, 2016, INT IMMUNOL, V28, P173, DOI 10.1093/intimm/dxv079	41	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								757616	10.3389/fimmu.2022.757616	http://dx.doi.org/10.3389/fimmu.2022.757616			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D8VG	35720293	gold, Green Published			2022-12-18	WOS:000811816800001
J	Docando, F; Nunez-Ortiz, N; Goncalves, G; Serra, CR; Gomez-Casado, E; Martin, D; Abos, B; Oliva-Teles, A; Tafalla, C; Diaz-Rosales, P				Docando, Felix; Nunez-Ortiz, Noelia; Goncalves, Gabriela; Serra, Claudia R.; Gomez-Casado, Eduardo; Martin, Diana; Abos, Beatriz; Oliva-Teles, Aires; Tafalla, Carolina; Diaz-Rosales, Patricia			Bacillus subtilis Expressing the Infectious Pancreatic Necrosis Virus VP2 Protein Retains Its Immunostimulatory Properties and Induces a Specific Antibody Response	FRONTIERS IN IMMUNOLOGY			English	Article						probiotics; Bacillus subtilis; infectious pancreatic necrosis virus (IPNV); VP2; vaccines; rainbow trout	TROUT ONCORHYNCHUS-MYKISS; RAINBOW-TROUT; CLONORCHIS-SINENSIS; ORAL DELIVERY; GRASS-CARP; IMMUNE-RESPONSES; DNA VACCINATION; HIGH PROTECTION; VACCINES; IPNV	Bacillus subtilis has been documented in the past years as an effective probiotic for different aquacultured species, with recognized beneficial effects on water quality, fish growth and immune status. Furthermore, its potential as a vaccine adjuvant has also been explored in different species. In the current work, we have used B. subtilis spores as delivery vehicles for the presentation of the VP2 protein from infectious pancreatic necrosis virus (IPNV). For this, the VP2 gene was amplified and translationally fused to the crust protein CotY. The successful expression of VP2 on the spores was confirmed by Western blot. We then compared the immunostimulatory potential of this VP2-expressing strain (CRS208) to that of the original B. subtilis strain (168) on rainbow trout (Oncorhynchus mykiss) leukocytes obtained from spleen, head kidney and the peritoneal cavity. Our results demonstrated that both strains significantly increased the percentage of IgM(+) B cells and the number of IgM-secreting cells in all leukocyte cultures. Both strains also induced the transcription of a wide range of immune genes in these cultures, with small differences between them. Importantly, specific anti-IPNV antibodies were detected in fish intraperitoneally or orally vaccinated with the CRS208 strain. Altogether, our results demonstrate B. subtilis spores expressing foreign viral proteins retain their immunomodulatory potential while inducing a significant antibody response, thus constituting a promising vaccination strategy.	[Docando, Felix; Nunez-Ortiz, Noelia; Martin, Diana; Abos, Beatriz; Tafalla, Carolina; Diaz-Rosales, Patricia] Natl Agr & Food Res & Technol Inst INIA, Anim Hlth Res Ctr CISA, Spanish Natl Res Council CSIC, Fish Immunol & Pathol Grp, Madrid, Spain; [Docando, Felix] Univ Autonoma Madrid, Madrid, Spain; [Goncalves, Gabriela; Serra, Claudia R.; Oliva-Teles, Aires] Univ Porto, Ctr Interdisciplinar Invest Marinha & Ambiental CI, Terminal Cruzeiros Porto Leixoes, Matosinhos, Portugal; [Goncalves, Gabriela; Serra, Claudia R.; Oliva-Teles, Aires] Univ Porto, Fac Ciencias, Dept Biol, Rua Campo Alegre, Porto, Portugal; [Gomez-Casado, Eduardo] Natl Agr & Food Res & Technol Inst INIA, Spanish Natl Res Council CSIC, Dept Biotechnol, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid; Universidade do Porto; Universidade do Porto; Consejo Superior de Investigaciones Cientificas (CSIC)	Tafalla, C; Diaz-Rosales, P (corresponding author), Natl Agr & Food Res & Technol Inst INIA, Anim Hlth Res Ctr CISA, Spanish Natl Res Council CSIC, Fish Immunol & Pathol Grp, Madrid, Spain.	tafalla@inia.csic.es; pdiazrosales@inia.csic.es	Nuñez-Ortiz, Noelia/HDM-1787-2022; Nuñez-Ortiz, Noelia/N-6062-2018; Díaz-Rosales, Patricia/GPG-6820-2022; Oliva-Teles, Aires/B-3555-2008; Serra, Claudia/D-6771-2011	Nuñez-Ortiz, Noelia/0000-0003-2524-0759; Nuñez-Ortiz, Noelia/0000-0003-2524-0759; Oliva-Teles, Aires/0000-0002-5730-836X; Serra, Claudia/0000-0002-9852-2426; Goncalves, Gabriela/0000-0002-0823-4624; Docando, Felix/0000-0001-8835-9349				Adams A, 2019, FISH SHELLFISH IMMUN, V90, P210, DOI 10.1016/j.fsi.2019.04.066; Adel M, 2021, MICROORGANISMS SUSTA, V2, P191, DOI [10.1007/978-981-16-0223-8_8, DOI 10.1007/978-981-16-0223-8_8]; Ahmadivand S, 2017, DEV COMP IMMUNOL, V74, P178, DOI 10.1016/j.dci.2017.05.004; Ballesteros NA, 2014, FISH SHELLFISH IMMUN, V37, P220, DOI 10.1016/j.fsi.2014.02.003; Ballesteros NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066118; Ballesteros NA, 2012, FISH SHELLFISH IMMUN, V33, P1249, DOI 10.1016/j.fsi.2012.09.004; Barbosa TM, 2005, APPL ENVIRON MICROB, V71, P968, DOI 10.1128/AEM.71.2.968-978.2005; Bartels J, 2018, ACS SYNTH BIOL, V7, P452, DOI 10.1021/acssynbio.7b00285; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Chen K, 2010, IMMUNITY, V33, P479, DOI 10.1016/j.immuni.2010.09.013; Chen LH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109337; Chen YP, 2020, FISH SHELLFISH IMMUN, V100, P18, DOI 10.1016/j.fsi.2020.03.001; de las Heras AI, 2010, FISH SHELLFISH IMMUN, V28, P562, DOI 10.1016/j.fsi.2009.12.006; DELUCA D, 1983, EUR J IMMUNOL, V13, P546, DOI 10.1002/eji.1830130706; Di J, 2019, FISH SHELLFISH IMMUN, V93, P711, DOI 10.1016/j.fsi.2019.08.020; DOBOS P, 1977, J VIROL, V24, P805, DOI 10.1128/JVI.24.3.805-820.1977; DOBOS P, 1977, J VIROL, V22, P150, DOI 10.1128/JVI.22.1.150-159.1977; Dodoo CC, 2017, INT J PHARMACEUT, V530, P224, DOI 10.1016/j.ijpharm.2017.07.068; Dopazo CP, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9020094; Duan KX, 2018, FISH SHELLFISH IMMUN, V83, P223, DOI 10.1016/j.fsi.2018.09.034; Embregts CWE, 2016, DEV COMP IMMUNOL, V64, P118, DOI 10.1016/j.dci.2016.03.024; Guo X, 2016, FISH SHELLFISH IMMUN, V52, P74, DOI 10.1016/j.fsi.2016.03.017; HEPPELL J, 1995, VIROLOGY, V214, P40, DOI 10.1006/viro.1995.9956; Hua XJ, 2021, AQUACULTURE, V535, DOI 10.1016/j.aquaculture.2021.736425; Jiang BY, 2019, APPL MICROBIOL BIOT, V103, P3941, DOI 10.1007/s00253-019-09770-7; Jiang HY, 2017, FISH SHELLFISH IMMUN, V60, P318, DOI 10.1016/j.fsi.2016.10.011; Kumar R, 2008, FISH SHELLFISH IMMUN, V24, P168, DOI 10.1016/j.fsi.2007.10.008; Lauksund S, 2015, VIRUS RES, V196, P113, DOI 10.1016/j.virusres.2014.11.018; Liu HT, 2017, FISH SHELLFISH IMMUN, V60, P326, DOI 10.1016/j.fsi.2016.12.003; Liu M, 2012, FISH SHELLFISH IMMUN, V32, P196, DOI 10.1016/j.fsi.2011.11.015; Martinez-Lopez A, 2013, J BIOTECHNOL, V164, P171, DOI 10.1016/j.jbiotec.2012.08.005; Munang'andu HM, 2012, VACCINE, V30, P4007, DOI 10.1016/j.vaccine.2012.04.039; Munang'andu HM, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00542; Munang'andu HM, 2014, DEV COMP IMMUNOL, V43, P184, DOI 10.1016/j.dci.2013.08.008; Munang'andu HM, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-7; Munoz-Atienza E, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622377; Nayak SK, 2021, REV AQUACULT, V13, P862, DOI 10.1111/raq.12503; Neutra MR, 2006, NAT REV IMMUNOL, V6, P148, DOI 10.1038/nri1777; Newaj-Fyzul A, 2007, J APPL MICROBIOL, V103, P1699, DOI 10.1111/j.1365-2672.2007.03402.x; Plant KP, 2011, DEV COMP IMMUNOL, V35, P1256, DOI 10.1016/j.dci.2011.03.007; Raida MK, 2003, J FISH DIS, V26, P495, DOI 10.1046/j.1365-2761.2003.00480.x; Rajput IR, 2012, PAK VET J, V32, P303; Ren YW, 2017, CURR MICROBIOL, V74, P718, DOI 10.1007/s00284-017-1236-8; Reyes M, 2017, VACCINE, V35, P626, DOI 10.1016/j.vaccine.2016.12.013; Servin AL, 2003, BEST PRACT RES CL GA, V17, P741, DOI 10.1016/S1521-6918(03)00052-0; Setlow P, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.TBS-0003-2012; Simon R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653025; Soltani M, 2019, REV AQUACULT, V11, P1325, DOI 10.1111/raq.12295; Spinosa MR, 2000, RES MICROBIOL, V151, P361, DOI 10.1016/S0923-2508(00)00159-5; Sun HC, 2020, APPL MICROBIOL BIOT, V104, P1633, DOI 10.1007/s00253-019-10316-0; Sun HC, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2757-0; Tam NKM, 2006, J BACTERIOL, V188, P2692, DOI 10.1128/JB.188.7.2692-2700.2006; Tang ZL, 2017, FISH SHELLFISH IMMUN, V64, P287, DOI 10.1016/j.fsi.2017.03.030; Tapia D, 2022, REV AQUACULT, V14, P751, DOI 10.1111/raq.12623; WOLF K, 1960, P SOC EXP BIOL MED, V104, P105; Zahl IH, 2012, FISH PHYSIOL BIOCHEM, V38, P201, DOI 10.1007/s10695-011-9565-1; Zhou S, 2019, FISH SHELLFISH IMMUN, V84, P1115, DOI 10.1016/j.fsi.2018.10.058	57	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								888311	10.3389/fimmu.2022.888311	http://dx.doi.org/10.3389/fimmu.2022.888311			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D6IN	35720351	Green Published, gold			2022-12-18	WOS:000811648300001
J	Furukawa, M; Chan, ERG.; Ryan, JP; Hyzny, EJ; Sacha, LM; Coster, JN; Pilewski, JM; Lendermon, EA; Kilaru, SD; McDyer, JF; Sanchez, PG				Furukawa, Masashi; Chan, Ernest G.; Ryan, John P.; Hyzny, Eric J.; Sacha, Lauren M.; Coster, Jenalee N.; Pilewski, Joseph M.; Lendermon, Elizabeth A.; Kilaru, Silpa D.; McDyer, John F.; Sanchez, Pablo G.			Induction Strategies in Lung Transplantation: Alemtuzumab vs. Basiliximab a Single-Center Experience	FRONTIERS IN IMMUNOLOGY			English	Article						lung transplant; induction immunosuppression therapy; basiliximab; alemtuzumab; acute cellular rejection		BackgroundInduction therapy is used in about 80% of lung transplant centers and is increasing globally. Currently, there are no standards or guidelines for the use of induction therapy. At our institution, we have two induction strategies, basiliximab, and alemtuzumab. The goal of this manuscript is to share our experience and practice since this is an area of controversy. MethodsWe retrospectively reviewed 807 lung transplants performed at our institution between 2011 and 2020. Indications for the use of the basiliximab protocol were as follows: patients over the age of 70 years, history of cancer, hepatitis C virus or human immunodeficiency virus infection history, and cytomegalovirus or Epstein-Barr virus (donor positive/ recipient negative). In the absence of these clinical factors, the alemtuzumab protocol was used. Results453 patients underwent alemtuzumab induction and 354 patients underwent basiliximab. There were significant differences in delayed chest closure (24.7% alemtuzumab vs 31.4% basiliximab, p = 0.037), grade 3 primary graft dysfunction observed within 72 hours (19.9% alemtuzumab vs 29.9% basiliximab, p = 0.002), postoperative hepatic dysfunction (8.8% alemtuzumab vs 14.7% basiliximab, p = 0.009), acute cellular rejection in first year (39.1% alemtuzumab vs 53.4% basiliximab, p < 0.001). The overall survival rate of the patients with alemtuzumab induction was significantly higher than those of the patients with basiliximab induction (5 years survival rate: 64.1% alemtuzumab vs 52.3%, basiliximab, p < 0.001). Multivariate Cox regression analysis confirmed lower 5-year survival for basiliximab induction (HR = 1.41, p = 0.02), recipient cytomegalovirus positive (HR = 1.49, p = 0.01), postoperative hepatic dysfunction (HR = 2.20, p < 0.001), and acute kidney injury requiring renal replacement therapy (HR = 2.27, p < 0.001). ConclusionsIn this single center retrospective review, there was a significant difference in survival rates between induction strategies. This outcome may be attributable to differences in recipient characteristics between the groups. However, the Alemtuzumab group experienced less episodes of acute cellular rejection within the first year.	[Furukawa, Masashi; Chan, Ernest G.; Ryan, John P.; Hyzny, Eric J.; Coster, Jenalee N.; Sanchez, Pablo G.] Univ Pittsburgh, Dept Cardiothorac Surg, Div Thorac Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Sacha, Lauren M.] Univ Pittsburgh, Dept Pharm, Med Ctr, Pittsburgh, PA USA; [Pilewski, Joseph M.; Lendermon, Elizabeth A.; Kilaru, Silpa D.; McDyer, John F.] Univ Pittsburgh, Dept Pulmonol, Med Ctr, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Furukawa, M (corresponding author), Univ Pittsburgh, Dept Cardiothorac Surg, Div Thorac Surg, Med Ctr, Pittsburgh, PA 15260 USA.	furukawam@upmc.edu		Ryan, John/0000-0003-4466-4418				Benazzo A, 2021, TRANSPL INT, V34, P2633, DOI 10.1111/tri.14153; Benazzo A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210443; Chambers DC, 2019, J HEART LUNG TRANSPL, V38, P1042, DOI 10.1016/j.healun.2019.08.001; Furukawa M, 2022, J CARDIAC SURG, V37, P950, DOI 10.1111/jocs.16291; Furuya Y, 2016, AM J TRANSPLANT, V16, P2334, DOI 10.1111/ajt.13739; Iasella CJ, 2020, AM J TRANSPLANT, V20, P1439, DOI 10.1111/ajt.15756; Jaksch P, 2014, AM J TRANSPLANT, V14, P1839, DOI 10.1111/ajt.12824; Shyu S, 2011, J HEART LUNG TRANSPL, V30, P743, DOI 10.1016/j.healun.2011.01.714; Whited LK, 2015, TRANSPLANTATION, V99, P2190, DOI 10.1097/TP.0000000000000687; Whitson BA, 2014, CLIN TRANSPLANT, V28, P450, DOI 10.1111/ctr.12339	10	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								864545	10.3389/fimmu.2022.864545	http://dx.doi.org/10.3389/fimmu.2022.864545			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D4PP	35720296	Green Published, gold			2022-12-18	WOS:000811531400001
J	Liu, S; Liu, YL; Lu, JL; Mao, JX; Lin, ZH; Xue, QG				Liu, Sheng; Liu, Youli; Lu, Jiali; Mao, Jinxia; Lin, Zhihua; Xue, Qinggang			Genome Wide Identification and Expression Profiling Indicate Expansion of Family I84 Protease Inhibitor via Gene Tandem Duplication and Divergence in Razor Clam Sinonovacula constricta	FRONTIERS IN IMMUNOLOGY			English	Article						family I84 protease inhibitor; genome-wide identification; duplication; differentiation; host defense; mollusk	MULTIPLE SEQUENCE ALIGNMENT; CRASSOSTREA-VIRGINICA; MOLECULAR-CLONING; SERINE; EVOLUTION; RESISTANCE; SELECTION	Family I84 protease inhibitors represent a novel family in the MEROPS peptidase database and are likely unique for molluscan host defense. Two Family I84 members, scSI-1 and scSI-2, were reported from the razor clam Sinonovacula constricta in a previous research. In the present study, 12 additional genes, named scSI-3 to scSI-14, were identified via genome wide sequence analyses. Among them, 10 genes were predicted to have a signal sequence, but one (scSI-7) was not. Besides, one sequence (scSI-14) was likely to encode a prematurely terminated peptide. The predicted mature peptides shared characteristics including 12 conserved cysteine residues, isoelectric points of 4.98 to 6.11, and molecular weights of 7.1 to 9.3 kDa with previously reported family members. Four motifs were characterized in 13 predicted mature peptides (with exception of scSI-14), which shared two to four conserved cysteine residues, are possibly to form two functional domain comprised 6 cysteine residues, respectively. At genomic level, all the 14 razor clam Family I84 genes were organized into 3 exons and 2 introns; 13 of them clustered in 3 regions of 100 kb on 3 separate chromosomes, suggesting tandem duplications of related genes. The promoter region of all the 14 genes was predicted to share some transcription factor binding sites, in particular those responsive to pathological and physiological stimuli, but no shared motifs were identified. Analyses also revealed differences in expression patterns among the genes. One gene in a tandem duplicated gene pairs usually showed a higher expression level than the other whereas non-tandem duplicated genes exhibited a higher degree of correlation in expression level. In addition, 8 of the 14 genes demonstrated higher level of expression in Vibrio tolerant clams than in non-tolerant clams following challenges with Vibrio parahaemolyticus. These results generated important information about the evolution of Family I84 protease inhibitors in S. constricta.	[Liu, Sheng; Liu, Youli; Lin, Zhihua; Xue, Qinggang] Zhejiang Wanli Univ, Ninghai Inst Mariculture Breeding & Seed Ind, Ningbo, Peoples R China; [Liu, Sheng; Liu, Youli; Lu, Jiali; Mao, Jinxia; Lin, Zhihua] Zhejiang Wanli Univ, Zhejiang Key Lab Aquat Germplasm Resource, Ningbo, Peoples R China; [Xue, Qinggang] Pilot Natl Lab Marine Sci & Technol Qingdao, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China	Zhejiang Wanli University; Zhejiang Wanli University; Qingdao National Laboratory for Marine Science & Technology	Xue, QG (corresponding author), Zhejiang Wanli Univ, Ninghai Inst Mariculture Breeding & Seed Ind, Ningbo, Peoples R China.; Xue, QG (corresponding author), Pilot Natl Lab Marine Sci & Technol Qingdao, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China.	qxue@zwu.edu.cn			National Natural Science Foundation of China [32002428, 32073010]; Fundamental Research Funds for Zhejiang Province Universities; Agriculture Research System of MOF and MARA; 3315" Innovative Team of Ningbo City	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for Zhejiang Province Universities; Agriculture Research System of MOF and MARA; 3315" Innovative Team of Ningbo City	This work was financially supported by National Natural Science Foundation of China (32002428, 32073010), "3315" Innovative Team of Ningbo City, the Fundamental Research Funds for Zhejiang Province Universities and China Agriculture Research System of MOF and MARA.	Armstrong PB, 2001, TRENDS IMMUNOL, V22, P47, DOI 10.1016/S1471-4906(00)01803-2; Chen CJ, 2020, MOL PLANT, V13, P1194, DOI 10.1016/j.molp.2020.06.009; Christeller JT, 2005, FEBS J, V272, P5710, DOI 10.1111/j.1742-4658.2005.04975.x; Dong YH, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00664; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Gao FL, 2019, ECOL EVOL, V9, P3891, DOI 10.1002/ece3.5015; Gerdol M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00758; Gerdol M, 2019, MAR DRUGS, V17, DOI 10.3390/md17100583; Gu ZL, 2002, MOL BIOL EVOL, V19, P256, DOI 10.1093/oxfordjournals.molbev.a004079; Gutierrez-Rivera JN, 2015, DIS AQUAT ORGAN, V112, P185, DOI 10.3354/dao02808; He Y, 2012, FISH SHELLFISH IMMUN, V33, P411, DOI 10.1016/j.fsi.2012.05.028; Jongsma MA, 2011, CURR PROTEIN PEPT SC, V12, P437; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; La Peyre JF, 2010, DEV COMP IMMUNOL, V34, P84, DOI 10.1016/j.dci.2009.08.007; LASKOWSKI M, 1987, COLD SPRING HARB SYM, V52, P545, DOI 10.1101/SQB.1987.052.01.062; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lu JL, 2021, DIS AQUAT ORGAN, V145, P89, DOI 10.3354/dao03602; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; McDowell IC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105097; Montagnani C, 2001, FEBS LETT, V500, P64, DOI 10.1016/S0014-5793(01)02559-5; Nikapitiya C, 2014, FISH SHELLFISH IMMUN, V41, P27, DOI 10.1016/j.fsi.2014.06.015; Papp B, 2003, NATURE, V424, P194, DOI 10.1038/nature01771; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Rawlings ND, 2018, NUCLEIC ACIDS RES, V46, pD624, DOI 10.1093/nar/gkx1134; Rey-Campos M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10060943; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; Rubio T, 2019, P NATL ACAD SCI USA, V116, P14238, DOI 10.1073/pnas.1905747116; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI [10.1093/molbev/mst197, 10.1093/molbev/msr121]; Wagner GP, 2012, THEOR BIOSCI, V131, P281, DOI 10.1007/s12064-012-0162-3; Wang B, 2008, FISH SHELLFISH IMMUN, V24, P629, DOI 10.1016/j.fsi.2008.01.017; Wang XR, 2018, FISH SHELLFISH IMMUN, V75, P149, DOI 10.1016/j.fsi.2018.02.016; Waterhouse AM, 2009, BIOINFORMATICS, V25, P1189, DOI 10.1093/bioinformatics/btp033; Xue QG, 2006, COMP BIOCHEM PHYS B, V145, P16, DOI 10.1016/j.cbpb.2006.05.010; Xue QG, 2019, J INVERTEBR PATHOL, V166, DOI 10.1016/j.jip.2019.107214; Xue QG, 2017, FISH SHELLFISH IMMUN, V62, P332, DOI 10.1016/j.fsi.2017.01.040; Xue QG, 2009, FISH SHELLFISH IMMUN, V27, P250, DOI 10.1016/j.fsi.2009.05.006; Yu HY, 2011, FISH SHELLFISH IMMUN, V30, P757, DOI 10.1016/j.fsi.2010.12.015; Yu Q, 2017, FISH SHELLFISH IMMUN, V70, P156, DOI 10.1016/j.fsi.2017.09.018; Zhang LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep08693; Zhao P, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4443-1; Zhao XL, 2021, AQUACULTURE, V544, DOI 10.1016/j.aquaculture.2021.737109; Zhu L, 2006, FISH SHELLFISH IMMUN, V20, P320, DOI 10.1016/j.fsi.2005.05.009	42	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								907274	10.3389/fimmu.2022.907274	http://dx.doi.org/10.3389/fimmu.2022.907274			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E0CH	35720365	Green Published, gold			2022-12-18	WOS:000811903000001
J	Moalem, Y; Malis, Y; Voloshin, K; Dukhovny, A; Hirschberg, K; Sklan, EH				Moalem, Yarden; Malis, Yehonathan; Voloshin, Konstantin; Dukhovny, Anna; Hirschberg, Koret; Sklan, Ella H.			Sandfly Fever Viruses Attenuate the Type I Interferon Response by Targeting the Phosphorylation of JAK-STAT Components	FRONTIERS IN IMMUNOLOGY			English	Article						sandfly viruses; interferon; phleboviruses; STAT1; Jak1	NONSTRUCTURAL PROTEIN NSS; OUTBREAK; PHLEBOVIRUS; INHIBITION; PATHWAY; REGION	Sandfly fever viruses are emerging Phleboviruses typically causing mild febrile illness. Some strains, however, can cause severe and occasionally fatal neuro-invasive disease. Like most viruses, Phleboviruses have devised various strategies to inhibit the type I interferon (IFN) response to support a productive infection. Still, most of the strategies identified so far focus on inhibiting the sensing arm of the IFN response. In contrast, the effect of sandfly virus infection on signaling from the IFN receptor is less characterized. Therefore, we tested the effect of sandfly fever virus Naples (SFNV) and Sicily (SFSV) infection on IFN signaling. We found that infection with either of these viruses inhibits signaling from the IFN receptor by inhibiting STAT1 phosphorylation and nuclear localization. We show that the viral nonstructural protein NSs mediates these effects, but only NSs from SFNV was found to interact with STAT1 directly. Thus, we tested the upstream IFN signaling components and found that Janus kinase 1 (Jak1) phosphorylation is also impaired by infection.Furthermore, the NSs proteins from both viruses directly interacted with Jak1. Last, we show that IFN inhibition by SFNV and SFSV is most likely downstream of the IFN receptor at the Jak1 level. Overall, our results reveal the multiple strategies used by these related viruses to overcome host defenses.	[Moalem, Yarden; Voloshin, Konstantin; Dukhovny, Anna; Sklan, Ella H.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel; [Malis, Yehonathan; Hirschberg, Koret] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine	Sklan, EH (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, Tel Aviv, Israel.	sklan@tauex.tau.ac.il		Malis, Yehonathan/0000-0001-5170-7215				Alkan C, 2013, ANTIVIR RES, V100, P54, DOI 10.1016/j.antiviral.2013.07.005; Arnaud N, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002289; Ayhan N, 2017, CURR OPIN INSECT SCI, V22, P117, DOI 10.1016/j.cois.2017.05.019; Ayhan N, 2016, VECTOR-BORNE ZOONOT, V16, P802, DOI 10.1089/vbz.2016.2002; Babon JJ, 2012, IMMUNITY, V36, P239, DOI 10.1016/j.immuni.2011.12.015; Best SM, 2005, J VIROL, V79, P12828, DOI 10.1128/JVI.79.20.12828-12839.2005; Billecocq A, 2004, J VIROL, V78, P9798, DOI 10.1128/JVI.78.18.9798-9806.2004; Bino S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11050469; Blakqori G, 2007, J VIROL, V81, P4991, DOI 10.1128/JVI.01933-06; Caignard G, 2007, VIROLOGY, V368, P351, DOI 10.1016/j.virol.2007.06.037; Chen X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172744; Dalrymple NA, 2015, MBIO, V6, DOI 10.1128/mBio.00553-15; Danziger O, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00094; Depaquit J, 2010, EUROSURVEILLANCE, V15, P40; Dersch R, 2021, BMC NEUROL, V21, DOI 10.1186/s12883-021-02528-7; Ellis SB, 2008, MIL MED, V173, P949, DOI 10.7205/MILMED.173.10.949; Feng K, 2019, J BIOL CHEM, V294, P9503, DOI 10.1074/jbc.RA118.006563; Guler S, 2012, INT J INFECT DIS, V16, pE244, DOI 10.1016/j.ijid.2011.12.001; Guo JT, 2005, J VIROL, V79, P1343, DOI 10.1128/JVI.79.3.1343-1350.2005; Hasan M, 2013, NAT IMMUNOL, V14, P61, DOI 10.1038/ni.2475; Ivashkiv LB, 2014, NAT REV IMMUNOL, V14, P36, DOI 10.1038/nri3581; Kitagawa Y, 2018, MICROBES INFECT, V20, P360, DOI 10.1016/j.micinf.2018.05.007; Lvov D.K., 2015, ZOONOTIC VIRUSES NO, V1st edn; Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149; Moriyama M, 2018, J VIROL, V92, DOI 10.1128/JVI.00706-18; Ning YJ, 2015, J VIROL, V89, P4227, DOI 10.1128/JVI.00154-15; Papa A, 2006, CLIN MICROBIOL INFEC, V12, P192, DOI 10.1111/j.1469-0691.2005.01330.x; Rezelj VV, 2015, J VIROL, V89, P4849, DOI 10.1128/JVI.03511-14; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Savellini GG, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008186; Savellini GG, 2015, VIROLOGY, V486, P255, DOI 10.1016/j.virol.2015.09.021; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; ter Horst S, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2039; Tufan ZK, 2011, J INFECTION, V63, P375, DOI 10.1016/j.jinf.2011.07.011; Valmas C, 2011, J VIROL, V85, P4309, DOI 10.1128/JVI.02575-10; van Knippenberg I, 2010, J GEN VIROL, V91, P2002, DOI 10.1099/vir.0.021774-0; Vera-Otaroola J, 2020, J VIROL, V94, DOI 10.1128/JVI.00454-20; Wang J, 2020, EMERG INFECT DIS, V26, P2435, DOI 10.3201/eid2610.191374; Woelfl F, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040400; Woyessa AB, 2014, AM J TROP MED HYG, V91, P1250, DOI 10.4269/ajtmh.14-0299; Wuerth JD, 2021, J GEN VIROL, V102, DOI 10.1099/jgv.0.001676; Wuerth JD, 2018, J VIROL, V92, DOI [10.1128/JVI.01202-18, 10.1128/jvi.01202-18]; Wuerth JD, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060174; Yokota S, 2001, VIROLOGY, V286, P119, DOI 10.1006/viro.2001.0941; Yoshikawa R, 2019, J VIROL, V93, DOI 10.1128/JVI.02226-18	45	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								865797	10.3389/fimmu.2022.865797	http://dx.doi.org/10.3389/fimmu.2022.865797			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D6WM	35720342	gold, Green Published			2022-12-18	WOS:000811684600001
J	Pareek, S; Flegle, AS; Boagni, D; Kim, JY; Yoo, D; Trujillo-Ocampo, A; Lee, SE; Zhang, M; Jon, S; Im, JS				Pareek, Sumedha; Flegle, Alexandra S.; Boagni, Drew; Kim, Jin Yong; Yoo, Dohyun; Trujillo-Ocampo, Abel; Lee, Sung-Eun; Zhang, Mao; Jon, Sangyong; Im, Jin S.			Post Transplantation Bilirubin Nanoparticles Ameliorate Murine Graft Versus Host Disease via a Reduction of Systemic and Local Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						bilirubin; nanomedicine; graft-versus-host-disease (GVHD); anti-inflammatory therapy; nanoparticles; leukemia	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NANOMEDICINE; ANTIOXIDANT; BIOLOGY; MODEL	Allogeneic stem cell transplantation is a curative immunotherapy where patients receive myeloablative chemotherapy and/or radiotherapy, followed by donor stem cell transplantation. Graft versus host disease (GVHD) is a major complication caused by dysregulated donor immune system, thus a novel strategy to modulate donor immunity is needed to mitigate GVHD. Tissue damage by conditioning regimen is thought to initiate the inflammatory milieu that recruits various donor immune cells for cross-priming of donor T cells against alloantigen and eventually promote strong Th1 cytokine storm escalating further tissue damage. Bilirubin nanoparticles (BRNP) are water-soluble conjugated of bilirubin and polyethylene glycol (PEG) with potent anti-inflammatory properties through its ability to scavenge reactive oxygen species generated at the site of inflammation. Here, we evaluated whether BRNP treatment post-transplantation can reduce initial inflammation and subsequently prevent GVHD in a major histocompatibility (MHC) mismatched murine GVHD model. After myeloablative irradiation, BALB/c mice received bone marrow and splenocytes isolated from C57BL/6 mice, with or without BRNP (10 mg/kg) daily on days 0 through 4 post-transplantation, and clinical GVHD and survival was monitored for 90 days. First, BRNP treatment significantly improved clinical GVHD score compared to untreated mice (3.4 vs 0.3, p=0.0003), and this translated into better overall survival (HR 0.0638, p=0.0003). Further, BRNPs showed a preferential accumulation in GVHD target organs leading to a reduced systemic and local inflammation evidenced by lower pathologic GVHD severity as well as circulating inflammatory cytokines such as IFN-gamma. Lastly, BRNP treatment post-transplantation facilitated the reconstitution of CD4(+) iNK T cells and reduced expansion of proinflammatory CD8 alpha(+) iNK T cells and neutrophils especially in GVHD organs. Lastly, BRNP treatment decreased ICOS+ or CTLA-4(+) T cells but not PD-1(+) T cells suggesting a decreased level of T cell activation but maintaining T cell tolerance. In conclusion, we demonstrated that BRNP treatment post-transplantation ameliorates murine GVHD via diminishing the initial tissue damage and subsequent inflammatory responses from immune subsets.	[Pareek, Sumedha; Flegle, Alexandra S.; Boagni, Drew; Im, Jin S.] Univ Texas MD Anderson Canc Ctr, UTHealth Grad Sch Biomed Sci, Houston, TX 77030 USA; [Flegle, Alexandra S.; Boagni, Drew; Trujillo-Ocampo, Abel; Zhang, Mao; Im, Jin S.] MD Anderson Canc Ctr, Dept Hematopoiet Biol & Malignancy, Div Canc Med, Houston, TX 77030 USA; [Kim, Jin Yong; Yoo, Dohyun; Jon, Sangyong] Korea Adv Inst Sci & Technol KAIST, Grad Sch Med Sci & Engn, Daejeo, South Korea; [Kim, Jin Yong; Yoo, Dohyun; Jon, Sangyong] Inst BioCentury, Korea Adv Inst Sci & Technol KAIST, Dept Biol Sci, Daejeon, South Korea; [Lee, Sung-Eun] Seoul St Marys Hosp, Coll Med, Dept Hematol, Seoul St, Seoul, South Korea; [Im, Jin S.] MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Div Canc Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST); Seoul St. Mary's Hospital; University of Texas System; UTMD Anderson Cancer Center	Im, JS (corresponding author), Univ Texas MD Anderson Canc Ctr, UTHealth Grad Sch Biomed Sci, Houston, TX 77030 USA.; Im, JS (corresponding author), MD Anderson Canc Ctr, Dept Hematopoiet Biol & Malignancy, Div Canc Med, Houston, TX 77030 USA.; Im, JS (corresponding author), MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Div Canc Med, Houston, TX 77030 USA.			Flegle, Alexandra/0000-0002-4639-7889	MDACC Institutional Research Grant; Start-Up Fund [P30CA016672]; Basic Science Research Program of the National Research Foundation of Korea [NRF2018R1A3B1052661]	MDACC Institutional Research Grant; Start-Up Fund; Basic Science Research Program of the National Research Foundation of Korea(National Research Foundation of Korea)	The research was supported by MDACC Institutional Research Grant and Start-Up Fund (JI), the South Campus Flow Cytometry and Cell Sorting Core (NCI # P30CA016672) and by the Basic Science Research Program of the National Research Foundation of Korea (NRF2018R1A3B1052661) funded by the Ministry of Science and ICT (SJ).	Ai W, 2021, J AM HEART ASSOC, V10, DOI 10.1161/JAHA.121.021212; Alconcel SNS, 2011, POLYM CHEM-UK, V2, P1442, DOI 10.1039/c1py00034a; Blazar BR, 2012, NAT REV IMMUNOL, V12, P443, DOI 10.1038/nri3212; Cooke KR, 1996, BLOOD, V88, P3230, DOI 10.1182/blood.V88.8.3230.bloodjournal8883230; Dignan FL, 2012, BRIT J HAEMATOL, V158, P30, DOI 10.1111/j.1365-2141.2012.09129.x; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Fujiwara R, 2018, HEPATOLOGY, V67, P1609, DOI 10.1002/hep.29599; Henden AS, 2015, J IMMUNOL, V194, P4604, DOI 10.4049/jimmunol.1500117; Jaglowski SM, 2014, CURR OPIN HEMATOL, V21, P141, DOI 10.1097/MOH.0000000000000026; Keum H, 2021, BIOMATERIALS, V275, DOI 10.1016/j.biomaterials.2021.120986; Kim DE, 2017, BIOMATERIALS, V140, P37, DOI 10.1016/j.biomaterials.2017.06.014; Kim JY, 2017, BIOMATERIALS, V133, P1, DOI 10.1016/j.biomaterials.2017.04.011; Kim MJ, 2017, BIOMATERIALS, V133, P242, DOI 10.1016/j.biomaterials.2017.04.029; Kim TW, 2021, J CONTROL RELEASE, V331, P74, DOI 10.1016/j.jconrel.2021.01.019; Koreth J, 2016, BLOOD, V128, P130, DOI 10.1182/blood-2016-02-702852; Lee S, 2018, BIOMACROMOLECULES, V19, P2270, DOI 10.1021/acs.biomac.8b00189; Lee Y, 2016, ANGEW CHEM INT EDIT, V55, P10676, DOI 10.1002/anie.201604858; Lee Y, 2016, ANGEW CHEM INT EDIT, V55, P7460, DOI 10.1002/anie.201602525; Liu YR, 2008, J IMMUNOL, V181, P1887, DOI 10.4049/jimmunol.181.3.1887; Liu YR, 2003, J NEUROIMMUNOL, V139, P27, DOI 10.1016/S0165-5728(03)00132-2; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Mohamed FA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757836; Nocentini A, 2022, J ENZYM INHIB MED CH, V37, P487, DOI 10.1080/14756366.2021.2020773; Paczesny S, 2010, BONE MARROW TRANSPL, V45, P1, DOI 10.1038/bmt.2009.328; Rezende BM, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/9015292; Schneidawind D, 2014, BLOOD, V124, P3320, DOI 10.1182/blood-2014-05-576017; Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065-2776(07)96002-2; Tegla Cosmin, 2020, Clin Hematol Int, V2, P5, DOI 10.2991/chi.d.200115.001; Westphal S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169630; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zeiser R, 2018, NEW ENGL J MED, V378, P586	31	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								893659	10.3389/fimmu.2022.893659	http://dx.doi.org/10.3389/fimmu.2022.893659			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D4RZ	35720391	Green Published, gold			2022-12-18	WOS:000811537600001
J	Peng, Q; Guo, XJ; Luo, Y; Wang, GC; Zhong, LY; Zhu, JM; Li, YZ; Zeng, X; Feng, ZY				Peng, Qiao; Guo, Xuejiao; Luo, Yang; Wang, Guocan; Zhong, Lingyu; Zhu, Jiamin; Li, Yunze; Zeng, Xun; Feng, Zhiying			Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients With Herpes Zoster and Postherpetic Neuralgia	FRONTIERS IN IMMUNOLOGY			English	Article						varicella-zoster virus; herpes zoster; postherpetic neuralgia; CyTOF; VZV-specific T cells	TNF-ALPHA; VIRUS; MECHANISMS; CD4(+); REACTIVATION; INFECTION; INNATE	ObjectivesVaricella-zoster virus (VZV) can induce herpes zoster (HZ) and postherpetic neuralgia (PHN). Immune cells play an important role in regulating HZ and PHN pathogenesis, but the dynamic immune profiles and molecular mechanisms remain unclear. This study aimed to screen dynamic immune signatures during HZ progression and elucidate the mechanism of VZV-specific T cells in PHN. MethodsWe used cytometry by time-of-flight (CyTOF) to analyze peripheral blood mononuclear cells (PBMC) samples from 45 patients with HZ and eight age-sex-matched healthy controls, eight PHN samples and seven non-PHN samples. Correlations between the immune subsets and clinical pain-related scores were performed. Further, the characteristics of VZV-specific T cells between PHN and non-PHN patients were evaluated by VZV peptide pools stimulation. The expression level of cytokines, including granzyme B, interleukin (IL)-2, interferon (IFN)-gamma, and tumor necrosis factor (TNF)-alpha was performed via cytometric bead array. Finally, we analyzed the alteration of Ca2+ signals in dorsal root ganglion (DRG)-derived cells after TNF-alpha stimulation. ResultsWe investigated the dynamic characteristics of the immune landscape of peripheral blood samples of patients with HZ and PHN, and depicted two major dynamic signatures in NK, CD4(+) and CD8(+) T subsets in patients with HZ, which closely correlated with clinical pain-related scores. The frequency of PD-1(+)CD4(+) T cells, VZV-specific PD-1(+)CD4(+) T cells, and the amount of TNF-alpha produced by VZV-specific T cells were higher in patients with PHN than without PHN. Furthermore, we showed that TNF-alpha could induce calcium influx in DRG-derived cells in a dose-dependent manner. ConclusionsOur results profiled the dynamic signatures of immune cells in patients with HZ and highlighted the important role of VZV-specific T cells in the pathogenesis of PHN.	[Peng, Qiao; Wang, Guocan; Zhong, Lingyu; Zeng, Xun] Zhejiang Univ Sch Med, Affiliated Hosp 1, Natl Clin Res Ctr Infect Dis, Natl Med Ctr Infect Dis, Hangzhou, Peoples R China; [Guo, Xuejiao; Zhu, Jiamin; Li, Yunze; Feng, Zhiying] Zhejiang Univ Sch Med, Affiliated Hosp 1, Dept Pain Med, Hangzhou, Peoples R China; [Luo, Yang] Zhejiang Univ Sch Med, Ctr Stem Cell & Regenerat Med, Hangzhou, Peoples R China		Zeng, X (corresponding author), Zhejiang Univ Sch Med, Affiliated Hosp 1, Natl Clin Res Ctr Infect Dis, Natl Med Ctr Infect Dis, Hangzhou, Peoples R China.; Feng, ZY (corresponding author), Zhejiang Univ Sch Med, Affiliated Hosp 1, Dept Pain Med, Hangzhou, Peoples R China.	xunzeng@zju.edu.cn; Fengfzy1972@zju.edu.cn	Zeng, Xun/HHM-7791-2022		Zhejiang Provincial Department of Science and Technology [2022C03081]; National Natural Science Foundation of China [31870899, 32070899, 82103304]; Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases [2022zz07]	Zhejiang Provincial Department of Science and Technology; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases	Funding This work was supported by Zhejiang Provincial Department of Science and Technology (2022C03081 to ZF), the National Natural Science Foundation of China (31870899, 32070899 to XZ, and 82103304 to QP) and the Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases (2022zz07 to QP).	Anderson M, 2018, NEUROSCI BULL, V34, P194, DOI 10.1007/s12264-017-0139-9; Arvin AM, 2010, CURR TOP MICROBIOL, V342, P189, DOI 10.1007/82_2010_29; Cabrera R, 2004, HEPATOLOGY, V40, P1062, DOI 10.1002/hep.20454; Calzascia T, 2007, J CLIN INVEST, V117, P3833, DOI 10.1172/JCI32567; Campbell JN, 2006, NEURON, V52, P77, DOI 10.1016/j.neuron.2006.09.021; Che JW, 2015, J VIROL, V89, P2112, DOI 10.1128/JVI.02245-14; Cheung TC, 2009, J IMMUNOL, V183, P7286, DOI 10.4049/jimmunol.0902490; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Crawford A, 2014, IMMUNITY, V40, P289, DOI 10.1016/j.immuni.2014.01.005; Feng C, 2015, VIRAL IMMUNOL, V28, P418, DOI 10.1089/vim.2015.0062; Fergusson JR, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00036; Gowrishankar K, 2010, J VIROL, V84, P8861, DOI 10.1128/JVI.01020-10; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Johnson RW, 2014, NEW ENGL J MED, V371, P1526, DOI 10.1056/NEJMcp1403062; Jones D, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007650; Kalia V, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.aba6006; Kennedy PGE, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10110609; Kleemann P, 2012, HAEMATOL-HEMATOL J, V97, P874, DOI 10.3324/haematol.2011.052597; Laemmle L, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01634; Laing KJ, 2018, J INFECT DIS, V218, pS68, DOI 10.1093/infdis/jiy403; Leung L, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-27; Ma JX, 2020, NEUROSPINE, V17, P42, DOI 10.14245/ns.2040052.026; Macatangay BJC, 2020, AIDS, V34, P15, DOI 10.1097/QAD.0000000000002406; Maggi L, 2010, EUR J IMMUNOL, V40, P2174, DOI 10.1002/eji.200940257; Marchand F, 2005, NAT REV NEUROSCI, V6, P521, DOI 10.1038/nrn1700; Moretta A, 2008, CELL DEATH DIFFER, V15, P226, DOI 10.1038/sj.cdd.4402170; Nagel MA, 2018, J INFECT DIS, V218, pS107, DOI 10.1093/infdis/jiy425; Ngo AL, 2020, ADV THER, V37, P2003, DOI 10.1007/s12325-020-01335-9; Ning ZC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654960; Oliver SL, 2020, BIOCHEM SOC T, V48, P2415, DOI 10.1042/BST20190511; Ouwendijk WJD, 2013, CURR OPIN VIROL, V3, P452, DOI 10.1016/j.coviro.2013.04.004; Ruterbusch M, 2020, ANNU REV IMMUNOL, V38, P705, DOI 10.1146/annurev-immunol-103019-085803; Schmader K, 2018, ANN INTERN MED, V169, pITC17, DOI 10.7326/AITC201808070; Sedy JR, 2005, NAT IMMUNOL, V6, P90, DOI 10.1038/ni1144; Sen N, 2014, CELL REP, V8, P633, DOI 10.1016/j.celrep.2014.06.024; Shrestha M, 2018, KOREAN J PAIN, V31, P235, DOI 10.3344/kjp.2018.31.4.235; Smith SM, 2016, PAIN, V157, P1056, DOI 10.1097/j.pain.0000000000000502; Steain M, 2014, J VIROL, V88, P2704, DOI 10.1128/JVI.03445-13; Torigoe S, 2000, MICROBIOL IMMUNOL, V44, P1027, DOI 10.1111/j.1348-0421.2000.tb02599.x; Tracey I, 2019, NEURON, V101, P783, DOI 10.1016/j.neuron.2019.02.019; Utzschneider DT, 2020, NAT IMMUNOL, V21, P1256, DOI 10.1038/s41590-020-0760-z; Wagner R, 1996, NEUROREPORT, V7, P2897, DOI 10.1097/00001756-199611250-00018; Wan ZK, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12873; Wang JP, 2005, J VIROL, V79, P12658, DOI 10.1128/JVI.79.20.12658-12666.2005; Watts TH, 2005, ANNU REV IMMUNOL, V23, P23, DOI 10.1146/annurev.immunol.23.021704.115839; Wei L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15390-w; Weinberg A, 2009, J INFECT DIS, V200, P1068, DOI 10.1086/605611; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Xing Q, 2013, ARCH DERMATOL RES, V305, P715, DOI 10.1007/s00403-013-1367-0; Yu WC, 2018, CELL REP, V25, P2379, DOI 10.1016/j.celrep.2018.10.105; Zeng JC, 2014, AM J TRANSL RES, V6, P494; Zerboni L, 2014, NAT REV MICROBIOL, V12, P197, DOI 10.1038/nrmicro3215	53	0	0	10	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								887892	10.3389/fimmu.2022.887892	http://dx.doi.org/10.3389/fimmu.2022.887892			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D2JD	35720399	gold, Green Published			2022-12-18	WOS:000811379100001
J	Pollenus, E; Pham, TT; Vandermosten, L; Robalo, Q; Possemiers, H; Knoops, S; Opdenakker, G; van den Steen, PE				Pollenus, Emilie; Pham, Thao-Thy; Vandermosten, Leen; Robalo, Queeny; Possemiers, Hendrik; Knoops, Sofie; Opdenakker, Ghislain; van den Steen, Philippe E.			CCR2 Is Dispensable for Disease Resolution but Required for the Restoration of Leukocyte Homeostasis Upon Experimental Malaria-Associated Acute Respiratory Distress Syndrome (vol 11, 628643, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						malaria; inflammation; resolution; monocytes; immunology; parasitology; eosinophils			[Pollenus, Emilie; Pham, Thao-Thy; Vandermosten, Leen; Robalo, Queeny; Possemiers, Hendrik; Knoops, Sofie; van den Steen, Philippe E.] Univ Leuven, Lab Immunoparasitol, Dept Microbiol Immunol & Transplantat, Rega Inst Med Res,KU Leuven, Leuven, Belgium; [Opdenakker, Ghislain] Univ Leuven, Immunobiol Lab, Dept Microbiol Immunol & Transplantat, Rega Inst Med Res,KU Leuven, Leuven, Belgium	KU Leuven; KU Leuven	van den Steen, PE (corresponding author), Univ Leuven, Lab Immunoparasitol, Dept Microbiol Immunol & Transplantat, Rega Inst Med Res,KU Leuven, Leuven, Belgium.	Philippe.vandensteen@kuleuven.be	Opdenakker, Ghislain/Q-3130-2017	Opdenakker, Ghislain/0000-0003-1714-2294; Pollenus, Emilie/0000-0002-2706-6259; Possemiers, Hendrik/0000-0001-7565-9668					0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								926032	10.3389/fimmu.2022.926032	http://dx.doi.org/10.3389/fimmu.2022.926032			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D8UY	35720305	Green Published, gold			2022-12-18	WOS:000811816000001
J	Shi, XY; Li, T; Liu, YT; Yin, LJ; Xiao, L; Fu, LY; Zhu, YX; Chen, H; Wang, KK; Xiao, XZ; Zhang, HL; Tan, SC; Tan, SP				Shi, Xueyan; Li, Tao; Liu, Yanting; Yin, Leijin; Xiao, Lan; Fu, Liyao; Zhu, Yaxi; Chen, Huan; Wang, Kangkai; Xiao, Xianzhong; Zhang, Huali; Tan, Sichuang; Tan, Sipin			HSF1 Protects Sepsis-Induced Acute Lung Injury by Inhibiting NLRP3 Inflammasome Activation	FRONTIERS IN IMMUNOLOGY			English	Article						HSF1; sepsis; NLRP3 inflammasome; TRAF3; SGT1	TRAF3; LIPOPOLYSACCHARIDE; UBIQUITINATION; INFILTRATION; DEGRADATION; MECHANISM; ROLES	As an important transcription factor, heat shock factor 1 (HSF1) plays an endogenous anti-inflammation role in the body and can alleviate multiple organ dysfunction caused by sepsis, which contributes to an uncontrolled inflammatory response. The NLRP3 inflammasome is a supramolecular complex that plays key roles in immune surveillance. Inflammation is accomplished by NLRP3 inflammasome activation, which leads to the proteolytic maturation of IL-1 beta and pyroptosis. However, whether HSF1 is involved in the activation of the NLRP3 inflammasome in septic acute lung injury (ALI) has not been reported. Here, we show that HSF1 suppresses NLRP3 inflammasome activation in transcriptional and post-translational modification levels. HSF1 can repress NLRP3 expression via inhibiting NF-kappa B phosphorylation. HSF1 can inhibit caspase-1 activation and IL-1 beta maturation via promoting NLRP3 ubiquitination. Our finding not only elucidates a novel mechanism for HSF1-mediated protection of septic ALI but also identifies new therapeutic targets for septic ALI and related diseases.	[Shi, Xueyan; Li, Tao; Liu, Yanting; Yin, Leijin; Fu, Liyao; Zhu, Yaxi; Chen, Huan; Wang, Kangkai; Xiao, Xianzhong; Zhang, Huali; Tan, Sipin] Cent South Univ, Sepsis Translat Med Key Lab Hunan Prov, Changsha, Peoples R China; [Shi, Xueyan] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, State Key Lab Mol Oncol, Natl Canc Ctr Natl Clin Res, Beijing, Peoples R China; [Li, Tao] Med Coll Jiaying Univ, Dept Pathophysiol, Meizhou, Peoples R China; [Liu, Yanting; Yin, Leijin; Zhu, Yaxi; Chen, Huan; Wang, Kangkai; Xiao, Xianzhong; Zhang, Huali; Tan, Sipin] Cent South Univ, Xiangya Sch Med, Dept Pathophysiol, Changsha, Peoples R China; [Xiao, Lan] Cent South Univ, Xiangya Hosp 3, Dept Tradit Chinese Med, Changsha, Peoples R China; [Fu, Liyao; Tan, Sichuang] Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China	Central South University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Central South University; Central South University; Central South University	Tan, SP (corresponding author), Cent South Univ, Sepsis Translat Med Key Lab Hunan Prov, Changsha, Peoples R China.; Tan, SP (corresponding author), Cent South Univ, Xiangya Sch Med, Dept Pathophysiol, Changsha, Peoples R China.; Tan, SC (corresponding author), Cent South Univ, Xiangya Hosp 2, Changsha, Peoples R China.	strongtan@csu.edu.cn; springtan@csu.edu.cn	liu, yan/HGV-1365-2022; Xiao, Xiao/GQP-7793-2022; xiao, xiang/GWU-6035-2022		National Natural Science Fund of China [82170095]; Hunan Natural Science Fund of China [2019JJ40393]; Changsha Municipal Natural Science Foundation [kq2014228]	National Natural Science Fund of China(National Natural Science Foundation of China (NSFC)); Hunan Natural Science Fund of China; Changsha Municipal Natural Science Foundation	Funding This study is supported by the National Natural Science Fund of China (Grant No. 81870071), National Natural Science Fund of China (Grant No. 82170095), Hunan Natural Science Fund of China (Grant No. 2019JJ40393), and Changsha Municipal Natural Science Foundation (Grant No. kq2014228).	Bhavsar AP, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003518; Chen SH, 2012, J LEUKOCYTE BIOL, V92, P851, DOI 10.1189/jlb.0212060; Choudhury A, 2020, ALCOHOL CLIN EXP RES, V44, P1300, DOI 10.1111/acer.14338; Chousterman BG, 2017, SEMIN IMMUNOPATHOL, V39, P517, DOI 10.1007/s00281-017-0639-8; Dang XB, 2019, J CELL BIOCHEM, V120, P544, DOI 10.1002/jcb.27409; Ding RY, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5086516; Dong XW, 2020, CELL MOL IMMUNOL, V17, P261, DOI 10.1038/s41423-019-0201-9; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Gomez-Pastor R, 2018, NAT REV MOL CELL BIO, V19, P4, DOI 10.1038/nrm.2017.73; Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585; Hacker H, 2011, NAT REV IMMUNOL, V11, P457, DOI 10.1038/nri2998; Han S, 2015, J BIOL CHEM, V290, P18124, DOI 10.1074/jbc.M115.645549; Jin YT, 2020, CELL MOL IMMUNOL, V17, P1245, DOI 10.1038/s41423-019-0318-x; Karki R, 2019, NAT REV CANCER, V19, P197, DOI 10.1038/s41568-019-0123-y; Khodir AE, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117907; Kim SR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15983-6; Levi-Galibov O, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20054-x; Liu T, 2016, SCI REP-UK, V6, DOI 10.1038/srep39473; Liu XT, 2021, J HAZARD MATER, V404, DOI 10.1016/j.jhazmat.2020.124050; Lopez-Castejon G, 2020, FEBS J, V287, P11, DOI 10.1111/febs.15118; Niikura Y, 2017, CELL CYCLE, V16, P1683, DOI 10.1080/15384101.2017.1325039; Palazon-Riquelme P, 2018, EMBO REP, V19, DOI 10.15252/embr.201744766; Rayego-Mateos S, 2020, J AM SOC NEPHROL, V31, P2026, DOI 10.1681/ASN.2019111206; Renaudin F, 2020, ANN RHEUM DIS, V79, P1506, DOI 10.1136/annrheumdis-2020-217342; Shi XY, 2021, ONCOTARGETS THER, V14, P1305, DOI 10.2147/OTT.S291812; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Siu KL, 2019, FASEB J, V33, P8865, DOI 10.1096/fj.201802418R; Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727; Stancu IC, 2019, ACTA NEUROPATHOL, V137, P599, DOI 10.1007/s00401-018-01957-y; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Timmons A, 2020, P NATL ACAD SCI USA, V117, P15763, DOI 10.1073/pnas.1916290117; Tong ZY, 2014, SHOCK, V41, P449, DOI 10.1097/SHK.0000000000000118; Tumurkhuu G, 2016, CIRC RES, V119, pE76, DOI 10.1161/CIRCRESAHA.116.308362; Wang Y, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101699; Weng L, 2018, INTENS CARE MED, V44, P1071, DOI 10.1007/s00134-018-5203-z; Willhoft O, 2017, SCI REP-UK, V7, DOI 10.1038/srep41626; Xian HX, 2021, IMMUNITY, V54, P1463, DOI 10.1016/j.immuni.2021.05.004; Yang XD, 2015, IMMUNOL REV, V266, P56, DOI 10.1111/imr.12311; Yi ZA, 2014, CYTOKINE GROWTH F R, V25, P147, DOI 10.1016/j.cytogfr.2013.12.002; Zhang HQ, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/6687555; Zhang XY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.676297; Zou PF, 2020, FISH SHELLFISH IMMUN, V97, P114, DOI 10.1016/j.fsi.2019.12.024	42	0	0	9	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								781003	10.3389/fimmu.2022.781003	http://dx.doi.org/10.3389/fimmu.2022.781003			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D2LU	35720321	Green Published, gold			2022-12-18	WOS:000811386000001
J	Tomaz, D; Pereira, PM; Guerra, N; Dyson, J; Gould, K; Henriques, R				Tomaz, David; Pereira, Pedro Matos; Guerra, Nadia; Dyson, Julian; Gould, Keith; Henriques, Ricardo			Nanoscale Colocalization of NK Cell Activating and Inhibitory Receptors Controls Signal Integration	FRONTIERS IN IMMUNOLOGY			English	Article						NK cell signaling; nanoscale colocalization; NKG2D; Ly49A; NK cell receptors and ligands; FRET; signal integration	NATURAL-KILLER-CELLS; SEGREGATION MODEL; T-CELLS; NKG2D; GENERATION; COMPLEX; MICE; NANOCLUSTERS; RECOGNITION; DIMENSIONS	Natural killer (NK) cell responses depend on the balance of signals from inhibitory and activating receptors. However, how the integration of antagonistic signals occurs upon NK cell-target cell interaction is not fully understood. Here we provide evidence that NK cell inhibition via the inhibitory receptor Ly49A is dependent on its relative colocalization at the nanometer scale with the activating receptor NKG2D upon immune synapse (IS) formation. NKG2D and Ly49A signal integration and colocalization were studied using NKG2D-GFP and Ly49A-RFP-expressing primary NK cells, forming ISs with NIH3T3 target cells, with or without the expression of single-chain trimer (SCT) H2-Dd and an extended form of SCT H2-Dd-CD4 MHC-I molecules. Nanoscale colocalization was assessed by Forster resonance energy transfer between NKG2D-GFP and Ly49A-RFP and measured for each synapse. In the presence of their respective cognate ligands, NKG2D and Ly49A colocalize at the nanometer scale, leading to NK cell inhibition. However, increasing the size of the Ly49A ligand reduced the nanoscale colocalization with NKG2D, consequently impairing Ly49A-mediated inhibition. Thus, our data shows that NK cell signal integration is critically dependent on the dimensions of NK cell ligand-receptor pairs by affecting their relative nanometer-scale colocalization at the IS. Our results together suggest that the balance of NK cell signals and NK cell responses is determined by the relative nanoscale colocalization of activating and inhibitory receptors in the immune synapse.	[Tomaz, David; Gould, Keith] Imperial Coll London, Wright Fleming Inst, Dept Immunol, London, England; [Tomaz, David; Dyson, Julian] Imperial Coll London, Hammersmith Hosp, Dept Immunol, London, England; [Pereira, Pedro Matos; Henriques, Ricardo] UCL, Med Res Council Lab Mol Cell Biol, London, England; [Pereira, Pedro Matos] Univ Nova Lisboa, Bacterial Cell Biol, Inst Tecnol Quim & Biol Antonio Xavier, Oeiras, Portugal; [Guerra, Nadia] Imperial Coll London, Fac Nat Sci, Div Cell & Mol Biol, London, England; [Henriques, Ricardo] UCL, Div Infect & Immun, London, England; [Henriques, Ricardo] Inst Gulbenkian Ciencias, Opt Cell Biol Lab, Oeiras, Portugal	Imperial College London; Imperial College London; University of London; University College London; Universidade Nova de Lisboa; Imperial College London; University of London; University College London; Instituto Gulbenkian de Ciencia	Henriques, R (corresponding author), UCL, Med Res Council Lab Mol Cell Biol, London, England.; Henriques, R (corresponding author), UCL, Div Infect & Immun, London, England.; Henriques, R (corresponding author), Inst Gulbenkian Ciencias, Opt Cell Biol Lab, Oeiras, Portugal.	rjhenriques@igc.gulbenkian.pt	Pereira, Pedro/I-9375-2014	Pereira, Pedro/0000-0002-1426-9540	Fundacao para a Ciencia e a Tecnologia (Portugal) [SFRH/BD/68935/2010]; Welcome Trust RCDF [088381/Z/09/Z]; UK Biotechnology and Biological Sciences Research Council [BB/M022374/1, BB/P027431/1, BB/R000697/1]; UK Medical Research Council [MR/K015826/1]; Wellcome Trust [203276/Z/16/Z]; Gulbenkian Foundation from the European Research Council under the European Unions Horizon 2020 research and innovation program [101001332]; European Molecular Biology Organization Installation Grant [EMBO-2020-IG-4734]; St. Marys Development Trust	Fundacao para a Ciencia e a Tecnologia (Portugal)(Portuguese Foundation for Science and Technology); Welcome Trust RCDF; UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Gulbenkian Foundation from the European Research Council under the European Unions Horizon 2020 research and innovation program; European Molecular Biology Organization Installation Grant; St. Marys Development Trust	This work was supported by a Ph.D. scholarship grant (SFRH/BD/68935/2010) from Fundacao para a Ciencia e a Tecnologia (Portugal) to DT and by a Welcome Trust RCDF 088381/Z/09/Z to NG. PMP and RH are funded by grants from the UK Biotechnology and Biological Sciences Research Council (BB/M022374/1, BB/P027431/1, and BB/R000697/1), the UK Medical Research Council (MR/K015826/1), and Wellcome Trust (203276/Z/16/Z). RH is further supported by Gulbenkian Foundation, funding from the European Research Council under the European Unions Horizon 2020 research and innovation program (grant agreement number 101001332), and the European Molecular Biology Organization Installation Grant (EMBO-2020-IG-4734). We also acknowledge financial support from the St. Marys Development Trust. We thank Dr. Istvan Bartok for help with the retrogenic mice technique, Dr. Fiona Culley, Prof. Charles Bangham, and his laboratory members for useful discussions and lab support, Dr. Hugh Brady and Dr. Vicky Male for help with the in vitro differentiation of NK cells, Dr. Malte Paulsen for help with flow cytometry and cell sorting, Dr. Marco A. Purbhoo for helping with the confocal microscopy, and Cetus Corp. for the generous gift of rIL-2.	Abeyweera TP, 2011, J CELL BIOL, V192, P675, DOI 10.1083/jcb.201009135; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bettini ML, 2013, NAT PROTOC, V8, P1837, DOI 10.1038/nprot.2013.111; Biron CA, 2001, CURR OPIN IMMUNOL, V13, P458, DOI 10.1016/S0952-7915(00)00241-7; Bottier C, 2011, LAB CHIP, V11, P3855, DOI 10.1039/c1lc20807a; Brown ACN, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001152; Brzostek J, 2010, EUR J IMMUNOL, V40, P2050, DOI 10.1002/eji.201040335; Burroughs NJ, 2006, BIOPHYS J, V91, P1619, DOI 10.1529/biophysj.105.080044; Chan CJ, 2014, NAT IMMUNOL, V15, P431, DOI 10.1038/ni.2850; Chang VT, 2016, NAT IMMUNOL, V17, P574, DOI 10.1038/ni.3392; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Choudhuri K, 2009, J BIOL CHEM, V284, P26096, DOI 10.1074/jbc.M109.039966; Cordoba SP, 2013, BLOOD, V121, P4295, DOI 10.1182/blood-2012-07-442251; Culley S, 2018, NAT METHODS, V15, P263, DOI [10.1038/NMETH.4605, 10.1038/nmeth.4605]; Davis DM, 1999, P NATL ACAD SCI USA, V96, P15062, DOI 10.1073/pnas.96.26.15062; Davis SJ, 2006, NAT IMMUNOL, V7, P803, DOI 10.1038/ni1369; Daws MR, 1999, IMMUNOLOGY, V97, P656; Delcassian D, 2013, NANO LETT, V13, P5608, DOI 10.1021/nl403252x; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Dushek O, 2012, IMMUNOL REV, V250, P258, DOI 10.1111/imr.12008; Fernandes RA., 2017, CONSTRAINING CD45 EX, V116, P14002, DOI [10.1101/109785, DOI 10.1101/109785]; Freitag J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109199; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Guerra N, 2008, IMMUNITY, V28, P571, DOI 10.1016/j.immuni.2008.02.016; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Holland SJ, 2012, P NATL ACAD SCI USA, V109, pE3111, DOI 10.1073/pnas.1210882109; Holst J, 2006, NAT PROTOC, V1, P406, DOI 10.1038/nprot.2006.61; Ito D, 2009, P NATL ACAD SCI USA, V106, P11264, DOI 10.1073/pnas.0900664106; Jost S, 2013, ANNU REV IMMUNOL, V31, P163, DOI 10.1146/annurev-immunol-032712-100001; KAUFMAN DS, 1995, P NATL ACAD SCI USA, V92, P6484, DOI 10.1073/pnas.92.14.6484; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kohler K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015374; Li Y, 2015, BIOPHYS J, V109, P670, DOI 10.1016/j.bpj.2015.07.006; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Lovett DB, 2013, CELL MOL BIOENG, V6, P230, DOI 10.1007/s12195-013-0270-2; Mandelboim O, 2001, NATURE, V409, P1055, DOI 10.1038/35059110; Masilamani M, 2006, J IMMUNOL, V177, P3590, DOI 10.4049/jimmunol.177.6.3590; Neelam S, 2016, SCI REP-UK, V6, DOI 10.1038/srep19689; Oszmiana A, 2016, CELL REP, V15, P1957, DOI 10.1016/j.celrep.2016.04.075; Pageon SV, 2016, P NATL ACAD SCI USA, V113, pE5454, DOI 10.1073/pnas.1607436113; Pageon SV, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003947; Pageon SV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00308; Regunathan J, 2005, BLOOD, V105, P233, DOI 10.1182/blood-2004-03-1075; Roszik J, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-346; Sahl SJ, 2017, NAT REV MOL CELL BIO, V18, P685, DOI 10.1038/nrm.2017.71; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schleinitz N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003278; Sheppard S, 2013, BLOOD, V121, P5025, DOI 10.1182/blood-2012-12-471607; Stanietsky N, 2010, FEBS LETT, V584, P4895, DOI 10.1016/j.febslet.2010.08.047; Tomasello E, 2000, SEMIN IMMUNOL, V12, P139, DOI 10.1006/smim.2000.0216; Treanor B, 2006, J CELL BIOL, V174, P153, DOI 10.1083/jcb.200601108; Valiante NM, 1996, J EXP MED, V184, P2243, DOI 10.1084/jem.184.6.2243; Vivier E, 2004, SCIENCE, V306, P1517, DOI 10.1126/science.1103478; Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687; Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025; Williams NS, 1999, J IMMUNOL, V163, P2648; Zamai L, 2007, J IMMUNOL, V178, P4011, DOI 10.4049/jimmunol.178.7.4011; Zompi S, 2003, NAT IMMUNOL, V4, P565, DOI 10.1038/ni930	58	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								868496	10.3389/fimmu.2022.868496	http://dx.doi.org/10.3389/fimmu.2022.868496			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E0BM	35720315	Green Submitted, gold, Green Published			2022-12-18	WOS:000811900900001
J	Xiang, YY; Dong, XX; Zeng, C; Liu, JH; Liu, HJ; Hu, XF; Feng, JZ; Du, SL; Wang, JJ; Han, YL; Luo, Q; Chen, SX; Li, YM				Xiang, Yayun; Dong, Xiaoxuan; Zeng, Chun; Liu, Junhang; Liu, Hanjing; Hu, Xiaofei; Feng, Jinzhou; Du, Silin; Wang, Jingjie; Han, Yongliang; Luo, Qi; Chen, Shanxiong; Li, Yongmei			Clinical Variables, Deep Learning and Radiomics Features Help Predict the Prognosis of Adult Anti-N-methyl-D-aspartate Receptor Encephalitis Early: A Two-Center Study in Southwest China	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune encephalitis; anti-N-methyl-D-aspartate receptor; deep learning; radiomics; clinical features; prognosis; predictor; multiparametric MRI (mpMRI)	AUTOIMMUNE ENCEPHALITIS; DIAGNOSIS	ObjectiveTo develop a fusion model combining clinical variables, deep learning (DL), and radiomics features to predict the functional outcomes early in patients with adult anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in Southwest China. MethodsFrom January 2012, a two-center study of anti-NMDAR encephalitis was initiated to collect clinical and MRI data from acute patients in Southwest China. Two experienced neurologists independently assessed the patients' prognosis at 24 moths based on the modified Rankin Scale (mRS) (good outcome defined as mRS 0-2; bad outcome defined as mRS 3-6). Risk factors influencing the prognosis of patients with acute anti-NMDAR encephalitis were investigated using clinical data. Five DL and radiomics models trained with four single or combined four MRI sequences (T1-weighted imaging, T2-weighted imaging, fluid-attenuated inversion recovery imaging and diffusion weighted imaging) and a clinical model were developed to predict the prognosis of anti-NMDAR encephalitis. A fusion model combing a clinical model and two machine learning-based models was built. The performances of the fusion model, clinical model, DL-based models and radiomics-based models were compared using the area under the receiver operating characteristic curve (AUC) and accuracy and then assessed by paired t-tests (P < 0.05 was considered significant). ResultsThe fusion model achieved the significantly greatest predictive performance in the internal test dataset with an AUC of 0.963 [95% CI: (0.874-0.999)], and also significantly exhibited an equally good performance in the external validation dataset, with an AUC of 0.927 [95% CI: (0.688-0.975)]. The radiomics_combined model (AUC: 0.889; accuracy: 0.857) provided significantly superior predictive performance than the DL_combined (AUC: 0.845; accuracy: 0.857) and clinical models (AUC: 0.840; accuracy: 0.905), whereas the clinical model showed significantly higher accuracy. Compared with all single-sequence models, the DL_combined model and the radiomics_combined model had significantly greater AUCs and accuracies. ConclusionsThe fusion model combining clinical variables and machine learning-based models may have early predictive value for poor outcomes associated with anti-NMDAR encephalitis.	[Xiang, Yayun; Zeng, Chun; Liu, Junhang; Liu, Hanjing; Du, Silin; Wang, Jingjie; Han, Yongliang; Luo, Qi; Li, Yongmei] Chongqing Med Univ, Affiliated Hosp 1, Dept Radiol, Chongqing, Peoples R China; [Dong, Xiaoxuan; Chen, Shanxiong] Coll Comp & Informat Sci, Chongqing, Peoples R China; [Hu, Xiaofei] Third Mil Med Univ, Southwest Hosp, Dept Neurol, Chongqing, Peoples R China; [Feng, Jinzhou] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurol, Chongqing, Peoples R China	Chongqing Medical University; Army Medical University; Chongqing Medical University	Li, YM (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Radiol, Chongqing, Peoples R China.; Chen, SX (corresponding author), Coll Comp & Informat Sci, Chongqing, Peoples R China.	csxpml@163.com; lymzhang70@aliyun.com		Dong, Xiaoxuan/0000-0002-1031-157X	Medicine Scientific Key Research Project of Chongqing Municipal Health and Family Planning Commission of China [2016ZDXM002]; Chongqing Basic Research and Frontier Exploration Project of Chongqing Science and Technology Commission; Medical Scientific Youth Project of Chongqing Municipal Health and Family Planning Commission of China [2018QNXM004]; Chongqing Natural Science Foundation [cstc2019jcyj-msxmX0130]	Medicine Scientific Key Research Project of Chongqing Municipal Health and Family Planning Commission of China; Chongqing Basic Research and Frontier Exploration Project of Chongqing Science and Technology Commission; Medical Scientific Youth Project of Chongqing Municipal Health and Family Planning Commission of China; Chongqing Natural Science Foundation(Natural Science Foundation of Chongqing)	Funding This study was supported by the Medicine Scientific Key Research Project of Chongqing Municipal Health and Family Planning Commission of China (NO.2016ZDXM002), the Chongqing Basic Research and Frontier Exploration Project of Chongqing Science and Technology Commission (NO.cstc2018jcyjAX0584), the Medical Scientific Youth Project of Chongqing Municipal Health and Family Planning Commission of China (NO.2018QNXM004) and the Chongqing Natural Science Foundation (cstc2019jcyj-msxmX0130).	Aerts HJWL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5006; Armangue T, 2014, CURR OPIN NEUROL, V27, P361, DOI 10.1097/WCO.0000000000000087; Balu R, 2019, NEUROLOGY, V92, pE244, DOI 10.1212/WNL.0000000000006783; Bien CG, 2012, BRAIN, V135, P1622, DOI 10.1093/brain/aws082; Broadley J, 2019, J AUTOIMMUN, V96, P24, DOI 10.1016/j.jaut.2018.10.014; Bron EE, 2021, NEUROIMAGE-CLIN, V31, DOI 10.1016/j.nicl.2021.102712; Chi X, 2017, ACTA NEUROL SCAND, V136, P298, DOI 10.1111/ane.12723; Davies G, 2010, CRIT CARE MED, V38, P679, DOI 10.1097/CCM.0b013e3181cb0968; Dubey D, 2015, SEIZURE-EUR J EPILEP, V29, P143, DOI 10.1016/j.seizure.2015.04.007; Finke C, 2016, BIOL PSYCHIAT, V79, P727, DOI 10.1016/j.biopsych.2015.02.024; Finke C, 2013, ANN NEUROL, V74, P284, DOI 10.1002/ana.23932; Gong X, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000958; Graus F, 2016, LANCET NEUROL, V15, P391, DOI 10.1016/S1474-4422(15)00401-9; Gu YX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02611; Heine J, 2015, NEUROSCIENCE, V309, P68, DOI 10.1016/j.neuroscience.2015.05.037; Hu QY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67441-4; Kelley BP, 2017, AM J NEURORADIOL, V38, P1070, DOI 10.3174/ajnr.A5086; Lambin P, 2017, NAT REV CLIN ONCOL, V14, P749, DOI 10.1038/nrclinonc.2017.141; Li J, 2020, EUR RADIOL, V30, P2324, DOI 10.1007/s00330-019-06621-x; Liu YX, 2019, IEEE T SYST MAN CY-S, V49, P1946, DOI 10.1109/TSMC.2019.2898982; Lo Gullo R, 2020, BREAST, V49, P115, DOI 10.1016/j.breast.2019.11.009; Qiu XW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01286; Sacca V, 2019, BRAIN IMAGING BEHAV, V13, P1103, DOI 10.1007/s11682-018-9926-9; Sun QC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00053; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; Tran D, 2018, PROC CVPR IEEE, P6450, DOI 10.1109/CVPR.2018.00675; Truhn D, 2019, RADIOLOGY, V290, P290, DOI 10.1148/radiol.2018181352; Wang JL, 2022, IEEE T PATTERN ANAL, V44, P3791, DOI 10.1109/TPAMI.2021.3057833; Wang W, 2016, EUR J NEUROL, V23, P621, DOI 10.1111/ene.12911; Warren N, 2020, J PSYCHIATR RES, V125, P28, DOI 10.1016/j.jpsychires.2020.03.007; Wu WL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.639062; Xia XW, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00418; Xiang YY, 2022, J MAGN RESON IMAGING, V55, P1082, DOI 10.1002/jmri.27909; Xu YY, 2021, J MAGN RESON IMAGING, V54, P571, DOI 10.1002/jmri.27536; Yin P, 2020, J MAGN RESON IMAGING, V51, P435, DOI 10.1002/jmri.26834; Yin P, 2019, J MAGN RESON IMAGING, V49, P752, DOI 10.1002/jmri.26238; Yuan YX, 2019, MED PHYS, V46, P756, DOI 10.1002/mp.13367; Zhang WJ, 2020, RADIOTHER ONCOL, V145, P13, DOI 10.1016/j.radonc.2019.11.023	38	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								913703	10.3389/fimmu.2022.913703	http://dx.doi.org/10.3389/fimmu.2022.913703			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D2LG	35720336	gold, Green Published			2022-12-18	WOS:000811384600001
J	Zhang, YF; Chen, X; Li, L; Li, Y; Lin, L; Cao, Y; Wang, N; Yang, DL; Pang, AM; Zhang, RL; Ma, QL; Zhai, WH; He, Y; Wei, JL; Jiang, ER; Han, MZ; Zhang, YC; Feng, SZ				Zhang, Yuanfeng; Chen, Xin; Li, Lin; Li, Yun; Lin, Li; Cao, Yang; Wang, Na; Yang, Donglin; Pang, Aiming; Zhang, Rongli; Ma, Qiaoling; Zhai, Weihua; He, Yi; Wei, Jialin; Jiang, Erlie; Han, MingZhe; Zhang, Yicheng; Feng, Sizhou			Retrospective Comparison of Efficacy and Safety of Rabbit Anti-Thymocyte Globulin and Porcine Anti-Lymphocyte Globulin in Patients With Acquired Aplastic Anemia Undergoing Hematopoietic Stem Cell Transplantation From Matched Sibling Donors	FRONTIERS IN IMMUNOLOGY			English	Article						rabbit; porcine; aplastic anemia; stem cell transplantation; matched sibling donors	BONE-MARROW-TRANSPLANTATION; TERM-FOLLOW-UP; ANTITHYMOCYTE GLOBULIN; EUROPEAN GROUP; 1ST-LINE TREATMENT; PERIPHERAL-BLOOD; CYCLOSPORINE-A; ADULT PATIENTS; OUTCOMES; CYCLOPHOSPHAMIDE	We compared the efficacy and safety of porcine anti-lymphocyte globulin (pALG) (n=140) and rabbit anti-thymocyte globulin (rATG) (n=86) in patients with acquired aplastic anemia (AA) receiving hematopoietic stem cell transplantation (HSCT) from matched sibling donors (MSD) in two transplantation centers in China ranging from 2005 to 2020. The groups had similar baseline characteristics except for a higher number of infused mononuclear cells (P<0.001) and a higher proportion of peripheral blood stem cells as graft sources (P=0.003) in the pALG group. The rates of neutrophil engraftment at day 28 (P=1), platelet engraftment at day 28 (P=0.228), bloodstream infection before engraftment (P=0.867), invasive fungal diseases (P=0.362), cytomegalovirus viremia (P=0.667), and graft rejection (P=0.147) were similar in the two groups. A higher cumulative incidence of grades II-IV acute graft versus host disease (aGvHD) at 100 days occurred in the pALG group (19% vs. 8%, P=0.035) while no significant differences in grades III-IV aGvHD (P=0.572), mild to severe chronic GvHD (cGvHD) (P=0.181), and moderate to severe cGvHD (P=0.586) were observed. The actuarial 5-year overall survival (OS), failure-free survival (FFS), and GvHD-free, FFS rates of the pALG group were 87% (95% confidence interval [CI], 82-93), 85% (95% CI, 80-92), and 78% (95% CI, 72-92) versus 91% (95% CI, 86-99) (P=0.33), 88% (95% CI, 82-97) (P=0.428), and 79% (95% CI, 72-90) (P=0.824) in the rATG group, respectively. A busulfan-containing conditioning regimen was the only adverse risk factor for OS and FFS in multivariate analysis. In conclusion, pALG is an alternative to rATG in patients with severe AA receiving MSD-HSCT. A prospective, large-sample study is needed to explore this therapy further.	[Zhang, Yuanfeng; Chen, Xin; Yang, Donglin; Pang, Aiming; Zhang, Rongli; Ma, Qiaoling; Zhai, Weihua; He, Yi; Wei, Jialin; Jiang, Erlie; Han, MingZhe; Feng, Sizhou] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China; [Zhang, Yuanfeng] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hematol, Wuhan, Peoples R China; [Li, Lin; Li, Yun; Lin, Li; Cao, Yang; Wang, Na; Zhang, Yicheng] Qingdao Univ, Dept Hematol, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China; [Li, Lin] Zhejiang Univ, Affiliated Hosp 1, Bone Marrow Transplantat Ctr, Sch Med, Hangzhou, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College; Huazhong University of Science & Technology; Qingdao University; Zhejiang University	Feng, SZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis,Haihe Lab Cell Ecosyst, Tianjin, Peoples R China.; Zhang, YC (corresponding author), Qingdao Univ, Dept Hematol, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China.	yczhang@tjh.tjmu.edu.cn; doctor_szhfeng@163.com	zhai, weihua/GQH-8692-2022					Atta EH, 2012, BIOL BLOOD MARROW TR, V18, P1876, DOI 10.1016/j.bbmt.2012.07.004; Bacigalupo A, 2000, SEMIN HEMATOL, V37, P69, DOI 10.1016/S0037-1963(00)90031-3; Bacigalupo A, 2015, HAEMATOLOGICA, V100, P696, DOI 10.3324/haematol.2014.115345; Bacigalupo A, 2012, HAEMATOL-HEMATOL J, V97, P1142, DOI 10.3324/haematol.2011.054841; Bacigalupo A, 2009, BIOL BLOOD MARROW TR, V15, P1628, DOI 10.1016/j.bbmt.2009.07.004; Baron F, 2006, LEUKEMIA, V20, P1690, DOI 10.1038/sj.leu.2404335; Bejanyan N, 2019, BLOOD ADV, V3, P3123, DOI 10.1182/bloodadvances.2019000722; Chen J, 2022, HEMATOLOGY, V27, P293, DOI 10.1080/16078454.2022.2042064; Chen M, 2018, LEUKEMIA RES, V65, P55, DOI 10.1016/j.leukres.2018.01.001; Chen M, 2016, EUR J HAEMATOL, V96, P291, DOI 10.1111/ejh.12590; Chen X, 2018, BIOL BLOOD MARROW TR, V24, P86, DOI 10.1016/j.bbmt.2017.10.007; DEEG HJ, 1994, BLOOD, V83, P3417; Doney K, 1997, ANN INTERN MED, V126, P107, DOI 10.7326/0003-4819-126-2-199701150-00003; Dufour C, 2015, BRIT J HAEMATOL, V169, P565, DOI 10.1111/bjh.13297; ElGohary G, 2020, BONE MARROW TRANSPL, V55, P1906, DOI 10.1038/s41409-020-0897-2; Feng XM, 2014, HAEMATOLOGICA, V99, P1433, DOI 10.3324/haematol.2014.106542; Han B, 2010, ACTA HAEMATOL-BASEL, V124, P245, DOI 10.1159/000321790; Holtan SG, 2015, BLOOD, V125, P1333, DOI 10.1182/blood-2014-10-609032; Kahl C, 2005, BRIT J HAEMATOL, V130, P747, DOI 10.1111/j.1365-2141.2005.05667.x; Kekre N, 2017, HAEMATOLOGICA, V102, P1291, DOI 10.3324/haematol.2017.164459; Killick SB, 2016, BRIT J HAEMATOL, V172, P187, DOI 10.1111/bjh.13853; Lee SE, 2016, BONE MARROW TRANSPL, V51, P1323, DOI 10.1038/bmt.2016.140; Li L, 2020, ANN HEMATOL, V99, P1863, DOI 10.1007/s00277-020-04111-5; Liu LM, 2020, LEUKEMIA, V34, P3359, DOI 10.1038/s41375-020-0933-7; Locasciulli A, 2007, HAEMATOL-HEMATOL J, V92, P11, DOI 10.3324/haematol.10075; Ma XR, 2016, EUR J HAEMATOL, V96, P260, DOI 10.1111/ejh.12584; Maury S, 2009, HAEMATOL-HEMATOL J, V94, P1312, DOI 10.3324/haematol.2009.006916; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Samarasinghe S, 2019, AM J HEMATOL, V94, P80, DOI 10.1002/ajh.25314; Scheinberg P, 2011, NEW ENGL J MED, V365, P430, DOI 10.1056/NEJMoa1103975; Schrezenmeier H, 2007, BLOOD, V110, P1397, DOI 10.1182/blood-2007-03-081596; Shin SH, 2016, BONE MARROW TRANSPL, V51, P1456, DOI 10.1038/bmt.2016.171; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; STORB R, 1994, BLOOD, V84, P941, DOI 10.1182/blood.V84.3.941.941; Storb R, 1997, BLOOD, V89, P3890, DOI 10.1182/blood.V89.10.3890.3890_3890_3890; Wei J, 2015, ANN HEMATOL, V94, P955, DOI 10.1007/s00277-015-2308-0; Yoshida N, 2014, HAEMATOLOGICA, V99, P1784, DOI 10.3324/haematol.2014.109355	37	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	JUN 1	2022	13								889784	10.3389/fimmu.2022.889784	http://dx.doi.org/10.3389/fimmu.2022.889784			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1XL	35784311	Green Published, gold			2022-12-18	WOS:000811348500001
J	Amo, L; Diez-Garcia, J; Tamayo-Orbegozo, E; Maruri, N; Larrucea, S				Amo, Laura; Diez-Garcia, Javier; Tamayo-Orbegozo, Estibaliz; Maruri, Natalia; Larrucea, Susana			Podocalyxin Expressed in Antigen Presenting Cells Promotes Interaction With T Cells and Alters Centrosome Translocation to the Contact Site	FRONTIERS IN IMMUNOLOGY			English	Article						podocalyxin; dendritic cells; T cells; cell interaction; centrosome polarization; antigen presenting cells; immune synapse; immune system	HUMAN DENDRITIC CELLS; MAJOR SIALOPROTEIN; POLARIZATION; ACTIVATION; ADHESION; BREAST; ROLES; DIFFERENTIATION; IDENTIFICATION; NONINTEGRIN	Podocalyxin (PODXL), a cell surface sialomucin expressed in diverse types of normal and malignant cells, mediates cellular adhesion to extracellular matrix and cell-to-cell interaction. A previous study reported the expression of PODXL protein on monocytes undergoing macrophage differentiation, yet the expression of this molecule in other antigen presenting cells (APCs) and its function in the immune system still remain undetermined. In this study, we report that PODXL is expressed in human monocyte-derived immature dendritic cells at both the mRNA and protein levels. Following dendritric cells maturation using pro-inflammatory stimuli, PODXL expression level decreased substantially. Furthermore, we found that PODXL expression is positively regulated by IL-4 through MEK/ERK and JAK3/STAT6 signaling pathways. Our results revealed a polarized distribution of PODXL during the interaction of APCs with CD4(+) T cells, partially colocalizing with F-actin. Notably, PODXL overexpression in APCs promoted their interaction with CD4(+) T cells and CD8(+) T cells and decreased the expression of MHC-I, MHC-II, and the costimulatory molecule CD86. In addition, PODXL reduced the translocation of CD4(+) T-cell centrosome toward the APC-contact site. These findings suggest a regulatory role for PODXL expressed by APCs in immune responses, thus representing a potential target for therapeutic blockade in infection and cancer.	[Amo, Laura; Tamayo-Orbegozo, Estibaliz; Larrucea, Susana] Biocruces Bizkaia Hlth Res Inst, Regulat Immune Syst Grp, Baracaldo, Spain; [Diez-Garcia, Javier] Biocruces Bizkaia Hlth Res Inst, Microscopy Facil, Baracaldo, Spain; [Maruri, Natalia] Cruces Univ Hosp, Biocruces Bizkaia Hlth Res Inst, Regulat Immune Syst Grp, Baracaldo, Spain	Hospital Universitario Cruces	Larrucea, S (corresponding author), Biocruces Bizkaia Hlth Res Inst, Regulat Immune Syst Grp, Baracaldo, Spain.	slarrucea@osakidetza.eus		, Laura/0000-0003-0322-0167				Abdallah F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.717998; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Amo L, 2015, CANCER LETT, V368, P26, DOI 10.1016/j.canlet.2015.06.029; Bachmann MF, 1997, IMMUNITY, V7, P549, DOI 10.1016/S1074-7613(00)80376-3; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Martin-Cofreces NB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01174; Blumenthal D, 2020, ELIFE, V9, DOI 10.7554/eLife.55995; Bryant DM, 2014, DEV CELL, V31, P171, DOI 10.1016/j.devcel.2014.08.027; Cait J, 2019, P NATL ACAD SCI USA, V116, P4518, DOI 10.1073/pnas.1814766116; Calvo V, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.629097; Choudhuri K, 2014, NATURE, V507, P118, DOI 10.1038/nature12951; de Winde CM, 2020, MED MICROBIOL IMMUN, V209, P515, DOI 10.1007/s00430-020-00680-4; Domogalla MP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01764; Doyonnas R, 2005, BLOOD, V105, P4170, DOI 10.1182/blood-2004-10-4077; Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; Faure S, 2004, NAT IMMUNOL, V5, P272, DOI 10.1038/ni1039; Fernandez D, 2013, BIOCHEM BIOPH RES CO, V432, P302, DOI 10.1016/j.bbrc.2013.01.112; Frose J, 2018, CELL REP, V24, P962, DOI 10.1016/j.celrep.2018.06.092; Garrett WS, 2000, CELL, V102, P325, DOI 10.1016/S0092-8674(00)00038-6; Geijtenbeek TBH, 2016, NAT REV IMMUNOL, V16, P433, DOI 10.1038/nri.2016.55; Gerard A, 2021, TRENDS IMMUNOL, V42, P706, DOI 10.1016/j.it.2021.06.004; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Guo Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040179; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; HORVAT R, 1986, J CELL BIOL, V102, P484, DOI 10.1083/jcb.102.2.484; Hosseini BH, 2009, P NATL ACAD SCI USA, V106, P17852, DOI 10.1073/pnas.0905384106; Huang ZH, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2023216118; INABA K, 1989, J EXP MED, V170, P527, DOI 10.1084/jem.170.2.527; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Jenner J, 2006, EXP HEMATOL, V34, P1212, DOI 10.1016/j.exphem.2006.04.016; Jin CZ, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/357060; Kelley TW, 2005, AM J CLIN PATHOL, V124, P134, DOI 10.1309/7BHLAHHU0N4MHT7Q; KERJASCHKI D, 1984, J CELL BIOL, V98, P1591, DOI 10.1083/jcb.98.4.1591; Kerosuo L, 2004, BRIT J HAEMATOL, V124, P809, DOI 10.1111/j.1365-2141.2004.04840.x; Kershaw DB, 1997, J BIOL CHEM, V272, P15708, DOI 10.1074/jbc.272.25.15708; Lammermann T, 2009, BLOOD, V113, P5703, DOI 10.1182/blood-2008-11-191882; Larrucea S, 2008, EXP CELL RES, V314, P2004, DOI 10.1016/j.yexcr.2008.03.009; Lee AW, 2002, VACCINE, V20, pA8, DOI 10.1016/S0264-410X(02)00382-1; Leithner A, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202006081; Li P, 2017, EXP HEMATOL, V50, P77, DOI 10.1016/j.exphem.2017.04.001; Lin CW, 2014, CARCINOGENESIS, V35, P2425, DOI 10.1093/carcin/bgu139; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Martin-Cofreces NB, 2008, J CELL BIOL, V182, P951, DOI 10.1083/jcb.200801014; Massa C, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0528-7; McAleer JP, 2008, CRIT REV IMMUNOL, V28, P281; Meder D, 2005, J CELL BIOL, V168, P303, DOI 10.1083/jcb.200407072; Mezger M, 2008, CLIN MICROBIOL INFEC, V14, P228, DOI 10.1111/j.1469-0691.2007.01902.x; Miettinen A, 1999, AM J PATHOL, V154, P813, DOI 10.1016/S0002-9440(10)65328-X; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Montoya MC, 2002, NAT IMMUNOL, V3, P159, DOI 10.1038/ni753; Tran NL, 2021, CANCERS, V13, DOI 10.3390/cancers13122863; Nielsen JS, 2009, J AM SOC NEPHROL, V20, P1669, DOI 10.1681/ASN.2008070782; Palucka K, 1999, J CLIN IMMUNOL, V19, P12, DOI 10.1023/A:1020558317162; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Puig-Kroger A, 2004, J BIOL CHEM, V279, P25680, DOI 10.1074/jbc.M311516200; Pulecio J, 2010, J EXP MED, V207, P2719, DOI 10.1084/jem.20100007; Riccioni R, 2006, BLOOD CELL MOL DIS, V37, P218, DOI 10.1016/j.bcmd.2006.09.001; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Schulz AM, 2015, J CELL BIOL, V211, P553, DOI 10.1083/jcb.201503128; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sizemore S, 2007, CANCER RES, V67, P6183, DOI 10.1158/0008-5472.CAN-06-3575; Stamatos NM, 2010, J LEUKOCYTE BIOL, V88, P1227, DOI 10.1189/jlb.1209776; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Takeda Tetsuro, 2003, Clin Exp Nephrol, V7, P260, DOI 10.1007/s10157-003-0257-8; Tamayo-Orbegozo E, 2017, ONCOTARGET, V8, P99722, DOI 10.18632/oncotarget.21283; Tiberio L, 2018, CELL MOL IMMUNOL, V15, P346, DOI 10.1038/s41423-018-0005-3; Tsun A, 2011, J CELL BIOL, V192, P663, DOI 10.1083/jcb.201008140; Vento-Tormo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-015-0863-2; Vitureira N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012003; Weinhold B, 2012, J AM SOC NEPHROL, V23, P1319, DOI 10.1681/ASN.2011090947; Xie J, 2005, EXP HEMATOL, V33, P564, DOI 10.1016/j.exphem.2005.03.001; Zhao P, 2015, CELL MOL IMMUNOL, V12, P692, DOI 10.1038/cmi.2014.108	76	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								835527	10.3389/fimmu.2022.835527	http://dx.doi.org/10.3389/fimmu.2022.835527			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1OV	35711462	gold, Green Published			2022-12-18	WOS:000811326100001
J	Ariyakumar, G; Gee, S; Das, A; Kamdar, S; Tribe, RM; Gibbons, DL				Ariyakumar, Gaayathri; Gee, Sarah; Das, Abhishek; Kamdar, Shraddha; Tribe, Rachel M.; Gibbons, Deena L.			Activation of Lymphocytes in Healthy Neonates Within Hours of Birth	FRONTIERS IN IMMUNOLOGY			English	Article						Immunology; T cell; activation; neonate; infection; cord blood; heel prick	BLOOD	It is now established that immune maturation occurs along a defined trajectory in the weeks and months after birth, but the immediate changes that occur within immune cells following birth is less clear. In this study, we monitored the immune profile of neonates via analysis of paired samples (n= 28) of cord blood and heel prick blood taken at varying times post term delivery by planned elective caesarean section. This paired approach accounted for the between-subject variability often observed over the first week of life. We identified rapid changes in immune cell populations within hours of birth. Specifically, we observed increased proliferation in effector T cells (but not regulatory T cells) that exhibited an increase in cytokine producing ability and also an increase in the percentage of CD3 T cells over this short time frame. This indicates that the mobilisation of the immune system is immediate post birth, presumably as a response to sudden exposure to the external environment, antigen or stress. Hence, immune development may start to occur more rapidly than previously proposed and as such, to study this trajectory, blood sampling should begin as soon after birth as possible.	[Ariyakumar, Gaayathri; Gee, Sarah; Das, Abhishek; Kamdar, Shraddha; Gibbons, Deena L.] Guys Hosp, Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England; [Tribe, Rachel M.] St ThomasHospital, Kings Coll London, Fac Life Sci & Med, Sch Life Course & Populat Sci, London, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London	Gibbons, DL (corresponding author), Guys Hosp, Kings Coll London, Sch Immunol & Microbial Sci, Peter Gorer Dept Immunobiol, London, England.	deena.gibbons@kcl.ac.uk		Gibbons, Deena/0000-0002-7953-3576; Tribe, Rachel/0000-0003-3675-9978				Bennike TB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.578505; Carroll JA, 2012, DOMEST ANIM ENDOCRIN, V43, P146, DOI 10.1016/j.domaniend.2011.12.008; Chis A, 2017, PSYCHONEUROENDOCRINO, V86, P203, DOI 10.1016/j.psyneuen.2017.09.024; Di Rosa F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653974; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Garcia-Serna AM, 2021, INT J ENV RES PUB HE, V18, DOI 10.3390/ijerph18083962; Gee S, 2021, NAT IMMUNOL, V22, P1490, DOI 10.1038/s41590-021-01049-2; Heikkila MP, 2003, J APPL MICROBIOL, V95, P471, DOI 10.1046/j.1365-2672.2003.02002.x; Kamdar S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14923-8; Lee AH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08794-x; Nepsha OS, 2016, B EXP BIOL MED+, V160, P791, DOI 10.1007/s10517-016-3311-8; Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045; Werlang ICR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205962; Shao Y, 2019, NATURE, V574, P117, DOI 10.1038/s41586-019-1560-1; Simon AK, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.3085; Stewart CJ, 2018, NATURE, V562, P583, DOI 10.1038/s41586-018-0617-x; Stoll BJ, 2020, JAMA PEDIATR, V174, DOI 10.1001/jamapediatrics.2020.0593; Tornblom SA, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-33; Tribe RM, 2018, J PHYSIOL-LONDON, V596, P5709, DOI 10.1113/JP275429; van Egmond A, 2016, HUM IMMUNOL, V77, P898, DOI 10.1016/j.humimm.2016.07.233	20	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								883933	10.3389/fimmu.2022.883933	http://dx.doi.org/10.3389/fimmu.2022.883933			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5UE	35711432	Green Published, gold			2022-12-18	WOS:000810932500001
J	Chen, Y; Zhang, Y; Lu, JY; Liu, ZC; Zhao, SS; Zhang, MM; Lu, MZ; Xu, W; Sun, FY; Wu, Q; Zhong, Q; Cui, ZQ				Chen, Yan; Zhang, Yue; Lu, Jiayi; Liu, Zhongchen; Zhao, Shasha; Zhang, Mengmei; Lu, Mingzhi; Xu, Wen; Sun, Fenyong; Wu, Qi; Zhong, Qi; Cui, Zhongqi			Characteristics of Prognostic Programmed Cell Death-Related Long Noncoding RNAs Associated With Immune Infiltration and Therapeutic Responses to Colon Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						programmed cell death; colon cancer; lncRNA; immune infiltration; TMB; therapeutic response	APOPTOSIS; STATISTICS; GROWTH	Programmed cell death (PCD) plays an important role in the onset and progression of various cancers. The molecular events surrounding the occurrence of abnormally expressed long noncoding RNAs (lncRNAs) leading to colon cancer (CC) have become a focus. We comprehensively evaluated the roles of PCD-related lncRNAs in the clinical management of CC and their immune responses. Therefore, we screened 41 prognostic PCD-related lncRNAs in The Cancer Genome Atlas database using co-expression analysis and assigned patients to groups according to the results of cluster analysis. The immune response and functions of cluster 2 were substantially suppressed, which might explain the poor prognosis in this group. A prognostic model comprising eight PCD-related lncRNAs was developed, and its effectiveness was verified using an external database. High-and low-risk groups had different epigenetic modifications and changes in immune cell infiltration. Patients in the high-risk group were resistant to immunotherapy and various chemotherapeutic drugs. Studies in vitro and in vivo further confirmed a carcinogenic role of the lncRNA U62317.4. Our findings of the prognostic value of PCD-related lncRNAs revealed their important roles in immune response disorders, thus providing valuable insights into the clinical management and molecular mechanisms of CC.	[Chen, Yan; Zhang, Yue; Lu, Jiayi; Zhao, Shasha; Zhang, Mengmei; Lu, Mingzhi; Xu, Wen; Sun, Fenyong; Wu, Qi; Zhong, Qi; Cui, Zhongqi] Tongji Univ, Shanghai Peoples Hosp 10, Dept Clin Lab, Shanghai, Peoples R China; [Zhang, Yue] Shanghai Tenth Peoples Hosp, Dept Cent Lab, Clin Med Sci & Tech Innovat Pk, Shanghai, Peoples R China; [Liu, Zhongchen] TongJi Univ, Dept Gastrointestinal Surg, Shanghai Peoples Hosp 10, Shanghai, Peoples R China; [Lu, Mingzhi; Xu, Wen] Anhui Med Univ, Shanghai Clin Coll, Hefei, Peoples R China	Tongji University; Tongji University; Anhui Medical University	Wu, Q; Zhong, Q; Cui, ZQ (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Clin Lab, Shanghai, Peoples R China.	wuqi496@163.com; zhongqi0607@163.com; 1632084@tongji.edu.cn			Research Fund of Shanghai Municipal Health Bureau [2019cxjq03]; National Natural Science Foundation of China [81930066, 81772941, 82102449]; Shanghai Tenth People's Hospital Climbing Training Program [2021SYPDRC060]; Shanghai Municipal Health Commission [20204Y0088]	Research Fund of Shanghai Municipal Health Bureau; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Tenth People's Hospital Climbing Training Program; Shanghai Municipal Health Commission	This work was supported by the Research Fund of Shanghai Municipal Health Bureau (No. 2019cxjq03), National Natural Science Foundation of China (Nos. 81930066, 81772941, and 82102449), Shanghai Tenth People's Hospital Climbing Training Program (2021SYPDRC060), and Shanghai Municipal Health Commission (No. 20204Y0088).	Ahluwalia P, 2021, CANCERS, V13, DOI 10.3390/cancers13010155; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Chan JJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051310; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cui ZQ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.684322; Dolloff NG, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001384; Emambux S, 2018, EXPERT OPIN BIOL TH, V18, P561, DOI 10.1080/14712598.2018.1445222; Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6; Green DR, 2019, CELL, V177, P1094, DOI 10.1016/j.cell.2019.04.024; Guo F, 2020, CELL DEATH DIFFER, V27, P1938, DOI 10.1038/s41418-019-0473-8; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Hess-Stumpp H, 2007, INT J BIOCHEM CELL B, V39, P1388, DOI 10.1016/j.biocel.2007.02.009; Hosseinkhani N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218305; Hui LL, 2015, CANCER LETT, V368, P7, DOI 10.1016/j.canlet.2015.07.039; Jacobs J, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/158038; Jan R, 2019, ADV PHARM BULL, V9, P205, DOI 10.15171/apb.2019.024; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Legrand AJ, 2019, MOL CELL, V76, P232, DOI 10.1016/j.molcel.2019.09.006; Li J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2298-2; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li YQ, 2021, AGING-US, V13, P477, DOI 10.18632/aging.202157; Lichtenstern CR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030618; Lv WC, 2021, J CELL MOL MED, V25, P10403, DOI 10.1111/jcmm.16969; Mallmann-Gottschalk N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194693; Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2; Merghoub T, 2001, BLOOD CELL MOL DIS, V27, P231, DOI 10.1006/bcmd.2001.0385; Moujalled D, 2021, CELL DEATH DIFFER, V28, P2029, DOI 10.1038/s41418-021-00814-y; Nagorsen D, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-62; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nie H, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12815; Nie JH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.654076; Noh KH, 2012, J CLIN INVEST, V122, P4077, DOI 10.1172/JCI64057; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pietrantonio F, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003370; Racle J, 2020, METHODS MOL BIOL, V2120, P233, DOI 10.1007/978-1-0716-0327-7_17; Rye IH, 2022, MOL ONCOL, V16, P88, DOI 10.1002/1878-0261.13047; Saibil SD, 2020, CURR ONCOL, V27, pS98, DOI 10.3747/co.27.5285; Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Tan C, 2021, CELL BIOL INT, V45, P1487, DOI 10.1002/cbin.11588; Tang R, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00946-7; Wang M, 2019, CELL DEATH DIFFER, V26, P2329, DOI 10.1038/s41418-019-0304-y; Xiang HD, 2020, CANCER IMMUNOL RES, V8, P436, DOI 10.1158/2326-6066.CIR-19-0507; Ye Y, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00451-x; Zhan Y, 2012, FREE RADICAL BIO MED, V53, P532, DOI 10.1016/j.freeradbiomed.2012.05.018; Zhao WY, 2018, CANCER MED-US, V7, P842, DOI 10.1002/cam4.1353	48	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								828243	10.3389/fimmu.2022.828243	http://dx.doi.org/10.3389/fimmu.2022.828243			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5QX	35711417	gold, Green Published			2022-12-18	WOS:000810924000001
J	Coutinho-da-Silva, MS; Sucupira, PHF; Bicalho, KA; Campi-Azevedo, AC; Brito-de-Sousa, JP; Peruhype-Magalhaes, V; Rios, M; Teixeira-Carvalho, A; Coelho-dos-Reis, JGA; Antonelli, LRD; de Rezende, VB; de Melo, FLR; Garcia, CC; Silva-Andrade, JC; Costa-Rocha, IAD; Bastos, MD; Rocha, LAD; Silva, VA; Ferreira, ED; Marinho, EPM; Costa, AG; Gomes, MD; Amaral, LR; Furtado, ECD; da Silva, EVP; Ramos, BA; Santos, EBD; Freitas, MNO; Vasconcelos, PFD; Martins, OA; Araujo, MSS; Ferreira, MS; Martins, LC				Coutinho-da-Silva, Mikelly Santos; Sucupira, Pedro Henrique Ferreira; Bicalho, Kelly Alves; Campi-Azevedo, Ana Carolina; Brito-de-Sousa, Joaquim Pedro; Peruhype-Magalhaes, Vanessa; Rios, Maria; Teixeira-Carvalho, Andrea; Coelho-dos-Reis, Jordana Grazziela Alves; Antonelli, Lis Ribeiro do Valle; de Rezende, Vitor Bortolo; de Melo, Fernanda Ludolf Ribeiro; Garcia, Cristiana Couto; Silva-Andrade, Jesuanne Carla; Costa-Rocha, Ismael Artur da; Bastos, Michele de Souza; Rocha, Lucia Alves da; Silva, Valderjane Aprigio; Ferreira, Ewerton da Silva; Marinho, Eveny Perlize Melo; Costa, Allyson Guimaraes; Gomes, Matheus de Souza; Amaral, Laurence Rodrigues; Furtado, Erilene Cristina da Silva; da Silva, Eliana Vieira Pinto; Ramos, Bruna Alves; Santos, eder Barros dos; Freitas, Maria Nazare Oliveira; Vasconcelos, Pedro Fernando da Costa; Martins-Filho, Olindo Assis; Araujo, Marcio Sobreira Silva; Ferreira, Milene Silveira; Martins, Livia Caricio			Serum Soluble Mediator Profiles and Networks During Acute Infection With Distinct DENV Serotypes	FRONTIERS IN IMMUNOLOGY			English	Article						dengue infection; dengue virus; immune response; DENV serotypes; chemokines; cytokines	DENGUE-VIRUS; EXPRESSION; CELLS; PATHOGENESIS; REPLICATION; RESPONSES; CULTURES; LEAKAGE; TYPE-2; FEVER	A panoramic analysis of chemokines, pro-inflammatory/regulatory cytokines, and growth factors was performed in serum samples from patients with acute DENV infection (n=317) by a high-throughput microbeads array. Most soluble mediators analyzed were increased in DENV patients regardless of the DENV serotype. The substantial increase (>= 10-fold) of CXCL10, IL-6, and IFN-gamma, and decreased levels of PDGF (<0.4-fold) was universally identified in all DENV serotypes. Of note, increased levels of CXCL8, CCL4, and IL-12 (>= 3-9-fold) were selectively observed in DENV2 as compared to DENV1 and DENV4. Heatmap and biomarker signatures further illustrated the massive release of soluble mediators observed in DENV patients, confirming the marked increase of several soluble mediators in DENV2. Integrative correlation matrices and networks showed that DENV infection exhibited higher connectivity among soluble mediators. Of note, DENV2 displayed a more complex network, with higher connectivity involving a higher number of soluble mediators. The timeline kinetics (Day 0-1, D2, D3, D4-6) analysis additionally demonstrated differences among DENV serotypes. While DENV1 triggers a progressive increase of soluble mediators towards D3 and with a decline at D4-6, DENV2 and DENV4 develop with a progressive increase towards D4-6 with an early plateau observed in DENV4. Overall, our results provided a comprehensive overview of the immune response elicited by DENV infection, revealing that infection with distinct DENV serotypes causes distinct profiles, rhythms, and dynamic network connectivity of soluble mediators. Altogether, these findings may provide novel insights to understand the pathogenesis of acute infection with distinct DENV serotypes.	[Coutinho-da-Silva, Mikelly Santos; Furtado, Erilene Cristina da Silva; da Silva, Eliana Vieira Pinto; Ramos, Bruna Alves; Santos, eder Barros dos; Freitas, Maria Nazare Oliveira; Vasconcelos, Pedro Fernando da Costa; Ferreira, Milene Silveira; Martins, Livia Caricio] Inst Evandro Chagas, Dept Arboviroses & Febres Hemorrag, Ananindeua, Brazil; [Sucupira, Pedro Henrique Ferreira; Bicalho, Kelly Alves; Campi-Azevedo, Ana Carolina; Brito-de-Sousa, Joaquim Pedro; Peruhype-Magalhaes, Vanessa; Teixeira-Carvalho, Andrea; Antonelli, Lis Ribeiro do Valle; de Rezende, Vitor Bortolo; de Melo, Fernanda Ludolf Ribeiro; Garcia, Cristiana Couto; Silva-Andrade, Jesuanne Carla; Costa-Rocha, Ismael Artur da; Martins-Filho, Olindo Assis; Araujo, Marcio Sobreira Silva] Fundacao Oswaldo Cruz FIOCRUZ Minas, Inst Rene Rachou, Belo Horizonte, Brazil; [Rios, Maria] US Food & Drug Adm FDA, Ctr Biol Evaluat & Res CBER, Off Blood Res & Review OBRR, Silver Spring, MD USA; [Coelho-dos-Reis, Jordana Grazziela Alves] Univ Fed Minas Gerais UFMG, Dept Microbiol, Inst Ciencias Biol, Belo Horizonte, Brazil; [de Melo, Fernanda Ludolf Ribeiro] Univ Fed Minas Gerais, Fac Med, Belo Horizonte, Brazil; [Garcia, Cristiana Couto] Inst Oswaldo Cruz, Lab Virus Resp & Sarampo, Fiocruz, RJ, Brazil; [Bastos, Michele de Souza; Rocha, Lucia Alves da; Silva, Valderjane Aprigio; Ferreira, Ewerton da Silva; Costa, Allyson Guimaraes] Fundacao Med Trop Dr Heitor Vieira Dourado, Inst Pesquisa Clin Carlos Borborema, Manaus, Brazil; [Bastos, Michele de Souza; Rocha, Lucia Alves da; Marinho, Eveny Perlize Melo; Costa, Allyson Guimaraes] Univ Fed Amazonas UFAM, Escola Enfermagem Manaus, Manaus, Brazil; [Costa, Allyson Guimaraes] Fundacao Hosp Hematol & Hemoterapia Amazonas HEMOA, Diretoria Ensino & Pesquisa, Manaus, Brazil; [Gomes, Matheus de Souza; Amaral, Laurence Rodrigues] Univ Fed Uberlandia UFU, Lab Bioinformat & Anal Mol, Rede Multidisciplinar Pesquisa Ciencia & Tecnol, Patos De Minas, Brazil	Instituto Evandro Chagas; Fundacao Oswaldo Cruz; US Food & Drug Administration (FDA); Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Fundacao Oswaldo Cruz; Universidade Federal de Amazonas	Martins, OA; Araujo, MSS (corresponding author), Fundacao Oswaldo Cruz FIOCRUZ Minas, Inst Rene Rachou, Belo Horizonte, Brazil.	olindo.filho@fiocruz.br; marcio.sobreira@fiocruz.br	Costa, Allyson Guimarães/AAD-3923-2021; Bastos, Michele/AAS-7386-2020; Garcia, Cristiana Couto/AAE-4290-2022; ludolf, Fernanda/AAL-9440-2021	Costa, Allyson Guimarães/0000-0002-7312-6822; Bastos, Michele/0000-0003-3450-666X; Garcia, Cristiana Couto/0000-0002-4400-9141; ludolf, Fernanda/0000-0003-3357-9816; Nazare Oliveira Freitas, Maria/0000-0002-5834-9649; Sucupira, Pedro/0000-0002-1997-1590	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq; Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM/PPP-CNPq) [016/2014]; Ministerio da Saude do Brasil [01/2012, 776823/2012]; INCT para Febres Hemorragicas Virais (INCT-FHV) [573739/2008-0]	Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM/PPP-CNPq); Ministerio da Saude do Brasil; INCT para Febres Hemorragicas Virais (INCT-FHV)	The study was supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq. Funding was also obtained from Fundacao de Amparo a Pesquisa do Estado do Amazonas (FAPEAM/PPP-CNPq, EDITAL N. 016/2014), Ministerio da Saude do Brasil (Chamada Publica no 01/2012, Convenio # 776823/2012) and INCT para Febres Hemorragicas Virais (INCT-FHV - 573739/2008-0).	AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Azeredo EL, 2006, MEM I OSWALDO CRUZ, V101, P437, DOI 10.1590/S0074-02762006000400016; Badolato-Correa J, 2018, IMMUN INFLAMM DIS, V6, P194, DOI 10.1002/iid3.203; Bozza FA, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-86; Campos K. R., 2015, Revista do Instituto Adolfo Lutz, V74, P57; Chao DY, 2007, J CLIN MICROBIOL, V45, P584, DOI 10.1128/JCM.00842-06; Charnsilpa W, 2005, J MED VIROL, V77, P89, DOI 10.1002/jmv.20418; Chaturvedi UC, 2001, FEMS IMMUNOL MED MIC, V30, P181, DOI 10.1111/j.1574-695X.2001.tb01568.x; Chen JP, 2006, J IMMUNOL, V177, P3185, DOI 10.4049/jimmunol.177.5.3185; Clyde K, 2006, J VIROL, V80, P11418, DOI 10.1128/JVI.01257-06; Costa VV, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001663; Costa VV, 2013, AM J PATHOL, V182, P1950, DOI 10.1016/j.ajpath.2013.02.027; de-Oliveira-Pinto LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038527; de-Oliveira-Pinto LM, 2012, MEM I OSWALDO CRUZ, V107, P48, DOI 10.1590/S0074-02762012000100007; Fagundes CT, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001449; Fares RCG, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/321873; Friberg H, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006975; Groger M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005391; GUBLER DJ, 1984, AM J TROP MED HYG, V33, P158, DOI 10.4269/ajtmh.1984.33.158; Gunther VJ, 2011, VACCINE, V29, P3895, DOI 10.1016/j.vaccine.2011.03.038; Guzman MG, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.55; Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460; Harapan H, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12080829; Holmes EC, 2003, INFECT GENET EVOL, V3, P19, DOI [10.1016/S1567-1348(03)00004-2, 10.1016/S1567-1348(02)00153-3]; IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531; Jacob-Nascimento LC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.744183; KUNO G, 1987, AM J TROP MED HYG, V36, P153, DOI 10.4269/ajtmh.1987.36.153; LANCIOTTI RS, 1992, J CLIN MICROBIOL, V30, P545, DOI 10.1128/JCM.30.3.545-551.1992; Lee YR, 2007, VIRUS RES, V126, P216, DOI 10.1016/j.virusres.2007.03.003; Luplerdlop N, 2006, EMBO REP, V7, P1176, DOI 10.1038/sj.embor.7400814; Malavige GN, 2017, IMMUNOLOGY, V151, P261, DOI 10.1111/imm.12748; Marianneau P, 1999, J VIROL, V73, P5201, DOI 10.1128/JVI.73.6.5201-5206.1999; Martina BEE, 2009, CLIN MICROBIOL REV, V22, P564, DOI 10.1128/CMR.00035-09; Naveca FG, 2018, MEM I OSWALDO CRUZ, V113, DOI 10.1590/0074-02760170542; Pacsa AS, 2000, FEMS IMMUNOL MED MIC, V28, P151, DOI 10.1111/j.1574-695X.2000.tb01470.x; RICOHESSE R, 1990, VIROLOGY, V174, P479, DOI 10.1016/0042-6822(90)90102-W; RicoHesse R, 1997, VIROLOGY, V230, P244, DOI 10.1006/viro.1997.8504; Rothman AL, 2011, NAT REV IMMUNOL, V11, P532, DOI 10.1038/nri3014; Shen BQ, 2001, J BIOL CHEM, V276, P5281, DOI 10.1074/jbc.M007969200; Simmons CP, 2012, NEW ENGL J MED, V366, P1423, DOI 10.1056/NEJMra1110265; Srikiatkhachorn A, 2017, SEMIN IMMUNOPATHOL, V39, P563, DOI 10.1007/s00281-017-0625-1; Srikiatkhachorn A, 2009, THROMB HAEMOSTASIS, V102, P1042, DOI 10.1160/TH09-03-0208; World Health Organization, 2021, DENG SEV DENG	43	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								892990	10.3389/fimmu.2022.892990	http://dx.doi.org/10.3389/fimmu.2022.892990			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C6GG	35711447	Green Published, gold			2022-12-18	WOS:000810963900001
J	Da, M; Chen, LX; Enk, A; Ring, SBE; Mahnke, K				Da, Meihong; Chen, Luxia; Enk, Alexander; Ring, Sabine; Mahnke, Karsten			The Multifaceted Actions of CD73 During Development and Suppressive Actions of Regulatory T Cells	FRONTIERS IN IMMUNOLOGY			English	Review						adenosine; regulatory T cells; immune suppression; CD73; immune checkpoint	ADENOSINE A(2A) RECEPTOR; SALT-INDUCIBLE KINASES; HUMAN BREAST-CANCER; ATP RELEASE; EXTRACELLULAR VESICLES; PURINERGIC RECEPTORS; LYMPHOCYTE BINDING; ENDOTHELIAL-CELLS; POOR-PROGNOSIS; P2X7 RECEPTOR	Adenosine (Ado) has been shown to have immunosuppressive effects in a variety of diseases. It can either be released directly into the extracellular environment by cells, or it can be produced by degradation of ATP within the extracellular spaces. This extracellular pathway is facilitated by the concerted actions of the ectoenzymes CD39 and CD73. In a first step CD39 dephosphorylates ATP to ADP and AMP, respectively, and in a second step CD73 converts AMP to Ado. Thus, activity of CD73 on the cell surface of cells is the rate limiting step in the generation of extracellular Ado. Among T cells, CD73 is most abundantly expressed by regulatory T cells (Tregs) and is even upregulated after their activation. Functionally, the generation of Ado by CD73(+) Tregs has been shown to play a role in immune suppression of dendritic cells, monocytes and T cells, and the defined expression of CD73 by Tregs in immunosuppressive environments, such as tumors, made CD73 a novel checkpoint inhibitor. Therefore, therapeutical intervention by anti-CD73 antibodies or by chemical inhibitors of the enzymatic function is currently under investigation in some preclinical animal models. In the following we summarize the expression pattern and the possible functions of CD73 in T cells and Tregs, and exemplify novel ways to manipulate CD73 functions in Tregs to stimulate anti-tumor immunity.	[Da, Meihong; Chen, Luxia; Enk, Alexander; Ring, Sabine; Mahnke, Karsten] Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany	Ruprecht Karls University Heidelberg	Mahnke, K (corresponding author), Univ Hosp Heidelberg, Dept Dermatol, Heidelberg, Germany.	karsten.mahnke@med.uni-heidelberg.de			Deutsche Forschungsgemeinschaft [TR156]; Heidelberg University; CSC [201806090291, 202006320072]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Heidelberg University; CSC	This work was supported by the Deutsche Forschungsgemeinschaft TR156 B03 and C04. MD and LC are supported by a scholarship CSC 201806090291 and 202006320072, respectively. Publication was supported by the Deutsche Forschungsgemeinschaft within the funding programme "Open Access Publikationskosten" as well as by Heidelberg University.	Adinolfi E, 2019, CURR OPIN PHARMACOL, V47, P59, DOI 10.1016/j.coph.2019.02.012; Agarwal A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00555; Airas L, 1998, LEUKEMIA LYMPHOMA, V29, P37, DOI 10.3109/10428199809058380; Airas L, 2000, J IMMUNOL, V165, P5411, DOI 10.4049/jimmunol.165.10.5411; AIRAS L, 1995, J EXP MED, V182, P1603, DOI 10.1084/jem.182.5.1603; Allard B, 2013, CLIN CANCER RES, V19, P5626, DOI 10.1158/1078-0432.CCR-13-0545; Allard B, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/485156; Bao R, 2016, INT J MOL MED, V38, P969, DOI 10.3892/ijmm.2016.2679; Beldi G, 2008, HEPATOLOGY, V48, P841, DOI 10.1002/hep.22401; Berzofsky JA, 2009, CURR MOL MED, V9, P667, DOI 10.2174/156652409788970706; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; Bopp T, 2007, J EXP MED, V204, P1303, DOI 10.1084/jem.20062129; Borea PA, 2018, PHYSIOL REV, V98, P1591, DOI 10.1152/physrev.00049.2017; Borea PA, 2016, TRENDS PHARMACOL SCI, V37, P419, DOI 10.1016/j.tips.2016.02.006; Brandao-Burch Andrea, 2012, Front Endocrinol (Lausanne), V3, P41, DOI 10.3389/fendo.2012.00041; Briceno P, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.638037; Cappellari AR, 2012, MOL CELL BIOCHEM, V359, P315, DOI 10.1007/s11010-011-1025-9; Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4; Chalmin F, 2012, IMMUNITY, V36, P362, DOI 10.1016/j.immuni.2011.12.019; Chen SQ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08123-8; Clark K, 2012, P NATL ACAD SCI USA, V109, P16986, DOI 10.1073/pnas.1215450109; Clayton A, 2011, J IMMUNOL, V187, P676, DOI 10.4049/jimmunol.1003884; Colombo MP, 2017, CLIN CANCER RES, V23, P5999, DOI 10.1158/1078-0432.CCR-17-2332; De Marchi E, 2019, ONCOGENE, V38, P3636, DOI 10.1038/s41388-019-0684-y; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Deng WW, 2018, INT J CANCER, V143, P1494, DOI 10.1002/ijc.31534; Di Virgilio F, 2017, ONCOGENE, V36, P293, DOI 10.1038/onc.2016.206; Di Virgilio F, 2017, IMMUNITY, V47, P15, DOI 10.1016/j.immuni.2017.06.020; DIANZANI U, 1993, J IMMUNOL, V151, P3961; Dosch M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041222; Dwyer KM, 2020, NAT REV NEPHROL, V16, P509, DOI 10.1038/s41581-020-0304-7; Ehrentraut H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032416; Ernst PB, 2010, J IMMUNOL, V185, P1993, DOI 10.4049/jimmunol.1000108; Faigle M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002801; Fang FQ, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109981; Flores-Santibanez F, 2015, IMMUNOLOGY, V146, P582, DOI 10.1111/imm.12529; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Greig AVH, 2003, J INVEST DERMATOL, V121, P1145, DOI 10.1046/j.1523-1747.2003.12567.x; Han KL, 2013, J IMMUNOL, V190, P458, DOI 10.4049/jimmunol.1201325; Hay CM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1208875; Henttinen T, 2003, J BIOL CHEM, V278, P24888, DOI 10.1074/jbc.M300779200; Huang SK, 2021, CELL, V184, P1884, DOI 10.1016/j.cell.2021.02.041; Iyer SS, 2013, EUR J IMMUNOL, V43, P3219, DOI 10.1002/eji.201343469; Jarvis LB, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02721-x; Johnsen B, 2019, PURINERG SIGNAL, V15, P155, DOI 10.1007/s11302-019-09654-5; Kalekar LA, 2017, J IMMUNOL, V198, P2527, DOI 10.4049/jimmunol.1602031; Kepp O, 2017, IMMUNOL REV, V280, P83, DOI 10.1111/imr.12571; Kinsey GR, 2012, J AM SOC NEPHROL, V23, P1528, DOI 10.1681/ASN.2012010070; Klein M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00315; KLEMENS MR, 1990, BIOCHEM BIOPH RES CO, V172, P1371, DOI 10.1016/0006-291X(90)91601-N; Knapp K, 2012, STRUCTURE, V20, P2161, DOI 10.1016/j.str.2012.10.001; Lee DJ, 2013, J IMMUNOL, V191, P4103, DOI 10.4049/jimmunol.1300182; Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev-immunol-051116-052406; Loi S, 2013, P NATL ACAD SCI USA, V110, P11091, DOI 10.1073/pnas.1222251110; Lovaszi M, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2021.114419; Lucca LE, 2020, NAT REV IMMUNOL, V20, P680, DOI 10.1038/s41577-020-0296-3; Ma XL, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0724-7; MacKenzie KF, 2013, J IMMUNOL, V190, P565, DOI 10.4049/jimmunol.1202462; Mattarollo SR, 2012, CANCER DRUG DISCOV D, P111, DOI 10.1007/978-1-4614-0613-6_7; Minciacchi VR, 2015, SEMIN CELL DEV BIOL, V40, P41, DOI 10.1016/j.semcdb.2015.02.010; MOSER GH, 1989, AM J PHYSIOL, V256, pC799, DOI 10.1152/ajpcell.1989.256.4.C799; Nejime N, 2009, CLIN EXP PHARMACOL P, V36, P278, DOI 10.1111/j.1440-1681.2008.05060.x; Novak J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14501-x; OGATA S, 1990, BIOCHEMISTRY-US, V29, P7923, DOI 10.1021/bi00486a021; Ohta A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00190; Okada SF, 2004, J GEN PHYSIOL, V124, P513, DOI 10.1085/jgp.200409154; Onami K, 2014, J INVEST DERMATOL, V134, P1951, DOI 10.1038/jid.2014.93; Pegoraro A, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04378-0; Perrot I, 2019, CELL REP, V27, P2411, DOI 10.1016/j.celrep.2019.04.091; Record M, 2014, PLACENTA, V35, P297, DOI 10.1016/j.placenta.2014.02.009; Resta R, 1997, CELL SIGNAL, V9, P131, DOI 10.1016/S0898-6568(96)00132-5; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; RESTA R, 1994, J IMMUNOL, V153, P1046; Ring S, 2010, J IMMUNOL, V184, P3408, DOI 10.4049/jimmunol.0901751; Ring S, 2009, J ALLERGY CLIN IMMUN, V123, P1287, DOI 10.1016/j.jaci.2009.03.022; Romio M, 2011, AM J PHYSIOL-CELL PH, V301, pC530, DOI 10.1152/ajpcell.00385.2010; Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003; Scaletti E, 2021, PURINERG SIGNAL, V17, P693, DOI 10.1007/s11302-021-09802-w; Schmitz F, 2008, EUR J IMMUNOL, V38, P2981, DOI 10.1002/eji.200838761; Schneider E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26134-w; Schneider E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01729; Schwiebert EM, 1999, AM J PHYSIOL-CELL PH, V276, pC1, DOI 10.1152/ajpcell.1999.276.1.C1; Seminario-Vidal L, 2011, J BIOL CHEM, V286, P26277, DOI 10.1074/jbc.M111.260562; Smyth LA, 2013, EUR J IMMUNOL, V43, P2430, DOI 10.1002/eji.201242909; Sundberg TB, 2014, P NATL ACAD SCI USA, V111, P12468, DOI 10.1073/pnas.1412308111; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Tahkola K, 2021, VIRCHOWS ARCH, V478, P209, DOI 10.1007/s00428-020-02888-4; Taruno A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030808; Terp MG, 2013, J IMMUNOL, V191, P4165, DOI 10.4049/jimmunol.1301274; Turcotte M, 2015, CANCER RES, V75, P4494, DOI 10.1158/0008-5472.CAN-14-3569; Vultaggio-Poma V, 2022, THERANOSTICS, V12, P859, DOI 10.7150/thno.66274; Vultaggio-Poma V, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112496; Wang L, 2011, J CLIN INVEST, V121, P2371, DOI 10.1172/JCI45559; Weichhart T, 2015, NAT REV IMMUNOL, V15, P599, DOI 10.1038/nri3901; Whiteside TL, 2011, CURR MED CHEM, V18, P5217; Woehrle T, 2010, BLOOD, V116, P3475, DOI 10.1182/blood-2010-04-277707; Wu Q, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.843412; Xu ZJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2403-6; Yang L, 2005, J IMMUNOL, V175, P6458, DOI 10.4049/jimmunol.175.10.6458; Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646; Zhou P, 2007, CANCER BIOL THER, V6, P426, DOI 10.4161/cbt.6.3.3762	101	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								914799	10.3389/fimmu.2022.914799	http://dx.doi.org/10.3389/fimmu.2022.914799			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D2UP	35711418	gold, Green Published			2022-12-18	WOS:000811409000001
J	Liu, MY; Sun, CX; Zheng, XC; Zhou, QL; Liu, B; Zhou, YF; Xu, P				Liu, Mingyang; Sun, Cunxin; Zheng, Xiaochuan; Zhou, Qunlan; Liu, Bo; Zhou, Yifan; Xu, Pao			Comparative Proteomic Analysis Revealed the Mechanism of Tea Tree Oil Targeting Lipid Metabolism and Antioxidant System to Protect Hepatopancreatic Health in Macrobrachium rosenbergii	FRONTIERS IN IMMUNOLOGY			English	Article						Macrobrachium rosenbergii; tea tree oil; lipid metabolism; antioxidant capacity; hepatopancreatic health	OXIDATIVE STRESS; PHYSIOLOGICAL-RESPONSES; GROWTH-PERFORMANCE; DISEASE RESISTANCE; GUT MICROBIOTA; LABEL-FREE; LIVER; COENZYME; CYTOCHROME-P450; INVOLVEMENT	Tea tree oil (TTO) is a pure natural plant essential oil. The studies evaluated the hepatopancreas lipid metabolism and antioxidant efficacy of Macrobrachium rosenbergii fed with 0 (CT group) and 100 mg/kg TTO (TT group) by label-free quantification proteomic analysis. Compared to the CT group, the TT group improved growth performance and increased the survival rate after stress. Dietary TTO also decreased hemolymph AST and ALT activities and decreased hepatopancreatic vacuolation. At the same time, hepatopancreas lipids droplets and hemolymph lipids (TG, TC, LDL-C) were decreased, and the peroxidation products content (MDA, LPO, 4-HNE) was also decreased. In addition, the levels of hepatopancreas antioxidant enzymes (T-AOC, CAT, and SOD) were increased in the TT group. With proteomic analysis, a total of 151 differentially expressed proteins (DEPs) (99 up-regulated and 52 down-regulated) were identified in the hepatopancreas. Kyoto Encyclopedia of Genes and Genomes (KEGG) and protein-protein interaction analysis showed that the 16 DEPs have interactions, which are mainly involved in the pathways related to lipid metabolism (fatty acid biosynthesis, fatty acid metabolism, glycerophospholipid metabolism) and redox reaction (cytochrome P450 enzyme systems). Furthermore, the mRNA expression of 15 proteins followed the proteomic analysis with qRT-PCR validation. Pearson correlation analysis showed that fatty acids and glycerophospholipid metabolism-related proteins were highly correlated to peroxide content, glycerophospholipid metabolism, and cytochrome P450 system-related proteins (CYP1A1, GSTT1, GPX4) were highly correlated to AST and ALT. Additionally, GPX4 is closely related to peroxide content and antioxidant enzyme activity. Our results revealed that TTO plays a protective role in the hepatopancreas targeting the critical enzymes and antioxidant reactions in lipid metabolism. Provides a new perspective to elucidate the action path of TTO in protecting invertebrate hepatopancreas, highlights the influence of lipid metabolism on hepatopancreas health and the interaction between lipid metabolism and antioxidant system in the regulation of TTO.						sun, cunxin/0000-0001-7733-5608	Project of National Key R&D Program of China [2019YFD0900200]; China Agriculture Research System of MOF and MARA [CARS-48]; National Natural Science Foundation of China [32002404]; Central Public-interest Scientific Institution Basal Research Fund, CAFS [2020TD59]	Project of National Key R&D Program of China; China Agriculture Research System of MOF and MARA(Ministry of Oceans & Fisheries (MOF), Republic of Korea); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Central Public-interest Scientific Institution Basal Research Fund, CAFS	This work was supported by the Project of National Key R & D Program of China (2019YFD0900200), China Agriculture Research System of MOF and MARA (CARS-48), the National Natural Science Foundation of China (32002404), Central Public-interest Scientific Institution Basal Research Fund, CAFS (2020TD59). The authors would like to express their sincere thanks to the personnel of these teams for their kind assistance.	Tadese DA, 2021, AQUAC RES, V52, P2424, DOI 10.1111/are.15092; Alagawany M, 2020, REV AQUACULT, V12, P2481, DOI 10.1111/raq.12453; Anand A, 2008, J INSECT PHYSIOL, V54, P1323, DOI 10.1016/j.jinsphys.2008.06.006; Asadi MS, 2018, AQUACULT NUTR, V24, P1466, DOI 10.1111/anu.12683; Atencio L, 2009, TOXICON, V53, P269, DOI 10.1016/j.toxicon.2008.11.011; Aydin I, 2021, AQUACULTURE, V543, DOI 10.1016/j.aquaculture.2021.736981; Bain PA, 2012, COMP BIOCHEM PHYS B, V161, P392, DOI 10.1016/j.cbpb.2012.01.004; Baldissera MD, 2017, AQUACULTURE, V480, P11, DOI 10.1016/j.aquaculture.2017.07.042; Bento MHL, 2013, VET MED-CZECH, V58, P449, DOI 10.17221/7029-VETMED; BIDLACK WR, 1973, LIPIDS, V8, P177, DOI 10.1007/BF02544631; Cagol L, 2020, AQUAC RES, V51, P2243, DOI 10.1111/are.14569; Carneiro CLD, 2021, AQUACULT NUTR, V27, P1221, DOI 10.1111/anu.13263; Chung KH, 2007, J MICROBIOL BIOTECHN, V17, P1848; Cox SD, 2000, J APPL MICROBIOL, V88, P170, DOI 10.1046/j.1365-2672.2000.00943.x; Craddock CP, 2015, PLANT CELL, V27, P1251, DOI 10.1105/tpc.15.00037; Cui YZ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01190; Cun W, 2019, FISH SHELLFISH IMMUN, V94, P497, DOI 10.1016/j.fsi.2019.09.043; Dong XJ, 2021, AQUACULT NUTR, V27, P1789, DOI 10.1111/anu.13316; Duan YF, 2019, AQUACULT NUTR, V25, P897, DOI 10.1111/anu.12908; Farooqui AA, 2000, CHEM PHYS LIPIDS, V106, P1, DOI 10.1016/S0009-3084(00)00128-6; Franz C, 2010, FLAVOUR FRAG J, V25, P327, DOI 10.1002/ffj.1967; Freccia A, 2014, REV BRAS ZOOTECN, V43, P1, DOI 10.1590/S1516-35982014000100001; Gallagher EP, 2007, TOXICOL IN VITRO, V21, P1365, DOI 10.1016/j.tiv.2007.04.004; Gallardo D, 2009, ANIM GENET, V40, P410, DOI 10.1111/j.1365-2052.2009.01854.x; Ghanima MMA, 2021, POULTRY SCI, V100, DOI 10.1016/j.psj.2021.101443; Ghobadloo SM, 2004, J GASTROINTEST SURG, V8, P423, DOI 10.1016/j.gassur.2004.02.005; Guengerich FP, 2006, AAPS J, V8, pE101, DOI 10.1208/aapsj080112; Hauffe R, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136283; He WQ, 2017, FISH SHELLFISH IMMUN, V70, P164, DOI 10.1016/j.fsi.2017.09.007; Helvig C, 2004, P NATL ACAD SCI USA, V101, P4024, DOI 10.1073/pnas.0306980101; Higgins LG, 2011, DRUG METAB REV, V43, P92, DOI 10.3109/03602532.2011.567391; Ishii Y, 2010, DRUG METAB PHARMACOK, V25, P134, DOI 10.2133/dmpk.25.134; Jayasundara N, 2015, J EXP BIOL, V218, P1359, DOI 10.1242/jeb.118760; Kaleo IV, 2019, FISH SHELLFISH IMMUN, V89, P603, DOI 10.1016/j.fsi.2019.03.039; Kiegerl B, 2019, BBA-MOL CELL BIOL L, V1864, DOI 10.1016/j.bbalip.2019.08.005; Lee B, 2015, PROG NEURO-PSYCHOPH, V56, P1, DOI 10.1016/j.pnpbp.2014.07.004; Li LQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072537; Li XY, 2005, COMP BIOCHEM PHYS C, V141, P292, DOI 10.1016/j.cca.2005.07.004; Li Z, 2012, J PROTEOME RES, V11, P1582, DOI 10.1021/pr200748h; Liang X., 2022, FRONT NUTR, V9, DOI [10.3389/fnut.2022.830934, DOI 10.3389/FNUT.2022.830934]; Liu B, 2013, FISH SHELLFISH IMMUN, V34, P1395, DOI 10.1016/j.fsi.2013.02.028; Liu B, 2010, FISH SHELLFISH IMMUN, V29, P49, DOI 10.1016/j.fsi.2010.02.018; Liu MY, 2022, FISH SHELLFISH IMMUN, V120, P458, DOI 10.1016/j.fsi.2021.12.025; Liu MY, 2022, J WORLD AQUACULT SOC, V53, P542, DOI 10.1111/jwas.12831; Loomba RS, 2010, AM J THER, V17, pE182, DOI 10.1097/MJT.0b013e3181dcf72b; Lv B, 2021, AQUACULTURE, V536, DOI 10.1016/j.aquaculture.2021.736435; Madureira TV, 2016, FISH PHYSIOL BIOCHEM, V42, P389, DOI 10.1007/s10695-015-0146-6; Maheshwari G, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091259; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Merl J, 2012, PROTEOMICS, V12, P1902, DOI 10.1002/pmic.201100549; Miyamoto S, 2001, FREE RADICAL BIO MED, V31, pS87; Nadella RK, 2018, AQUAC RES, V49, P81, DOI 10.1111/are.13436; New MB, 2000, FRESHWATER PRAWN CULTURE, P1, DOI 10.1002/9780470999554.ch1; Niederberger C, 2012, J UROLOGY, V187, P1376, DOI 10.1016/j.juro.2011.12.089; Niu J, 2013, AQUACULTURE, V372, P1, DOI 10.1016/j.aquaculture.2012.10.021; Perticone M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040456; Prasad SS, 2011, J LIPID RES, V52, P451, DOI 10.1194/jlr.M007575; Roszer T, 2014, CELL TISSUE RES, V358, P685, DOI 10.1007/s00441-014-1985-7; Sanchez-Paz A, 2007, J EXP MAR BIOL ECOL, V340, P184, DOI 10.1016/j.jembe.2006.09.006; Santamaria E, 2003, P NATL ACAD SCI USA, V100, P3065, DOI 10.1073/pnas.0536625100; Saray P, 2018, FISH SHELLFISH IMMUN, V75, P164, DOI 10.1016/j.fsi.2018.02.008; SATOH K, 1978, CLIN CHIM ACTA, V90, P37; Sheweita SA, 2001, TOXICOLOGY, V169, P83, DOI 10.1016/S0300-483X(01)00473-5; Smith A, 2018, PESTIC BIOCHEM PHYS, V150, P48, DOI 10.1016/j.pestbp.2018.07.003; Song CY, 2017, SCI REP-UK, V7, DOI 10.1038/srep40356; Tadese DA, 2020, AQUACULTURE, V525, DOI 10.1016/j.aquaculture.2020.735281; Tiong IKR, 2020, AQUACULT REP, V18, DOI 10.1016/j.aqrep.2020.100433; Traurig MT, 2013, OBESITY, V21, P193, DOI 10.1002/oby.20243; Turck CW, 2007, MOL CELL PROTEOMICS, V6, P1291, DOI 10.1074/mcp.M700165-MCP200; VANVELDHOVEN PP, 1992, J BIOL CHEM, V267, P20065; Vehmas AP, 2016, J PROTEOMICS, V133, P66, DOI 10.1016/j.jprot.2015.12.009; Wang GW, 2019, PHYTOMEDICINE, V53, P263, DOI 10.1016/j.phymed.2018.09.023; Wei BH, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01430; Xu CJ, 2005, ARCH PHARM RES, V28, P249, DOI 10.1007/BF02977789; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yang ZF, 2019, COMP BIOCHEM PHYS A, V231, P19, DOI 10.1016/j.cbpa.2019.01.006; Yu DS, 2018, J CELL PHYSIOL, V233, P4770, DOI 10.1002/jcp.26270; Yu K, 2021, AQUACULTURE, V531, DOI 10.1016/j.aquaculture.2020.735977; Zanger UM, 2013, PHARMACOL THERAPEUT, V138, P103, DOI 10.1016/j.pharmthera.2012.12.007; Zeng XY, 2021, COMP BIOCHEM PHYS D, V38, DOI 10.1016/j.cbd.2021.100801; Zhang RR, 2009, J ETHNOPHARMACOL, V126, P207, DOI 10.1016/j.jep.2009.08.044; Zhang XQ, 2010, HEPATOLOGY, V51, P1190, DOI 10.1002/hep.23486	82	0	0	18	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								906435	10.3389/fimmu.2022.906435	http://dx.doi.org/10.3389/fimmu.2022.906435			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E6OC	35711420	Green Published, gold			2022-12-18	WOS:000812345200001
J	McLeish, KR; Shrestha, R; Vashishta, A; Rane, MJ; Barati, MT; Brier, ME; Lau, MG; Hu, XL; Chen, OS; Wessel, CR; Spalding, T; Bush, SE; Ijemere, K; Hopkins, CD; Cooke, EA; Tandon, S; Manning, T; Uriarte, SM; Huang, JP; Yan, J				McLeish, Kenneth R.; Shrestha, Rejeena; Vashishta, Aruna; Rane, Madhavi J.; Barati, Michelle T.; Brier, Michael E.; Lau, Mario Gutierrez; Hu, Xiaoling; Chen, Oscar; Wessel, Caitlin R.; Spalding, Travis; Bush, Sarah E.; Ijemere, Kenechi; Hopkins, C. Danielle; Cooke, Elizabeth A.; Tandon, Shweta; Manning, Terri; Uriarte, Silvia M.; Huang, Jiapeng; Yan, Jun			Differential Functional Responses of Neutrophil Subsets in Severe COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil; COVID-19; low density neutrophil; respiratory burst; exocytosis; NET formation; T cell proliferation	SECRETORY VESICLES; GRANULE SUBSETS; ACTIVATION; EXOCYTOSIS; DISTINCT	Neutrophils play a significant role in determining disease severity following SARS-CoV-2 infection. Gene and protein expression defines several neutrophil clusters in COVID-19, including the emergence of low density neutrophils (LDN) that are associated with severe disease. The functional capabilities of these neutrophil clusters and correlation with gene and protein expression are unknown. To define host defense and immunosuppressive functions of normal density neutrophils (NDN) and LDN from COVID-19 patients, we recruited 64 patients with severe COVID-19 and 26 healthy donors (HD). Phagocytosis, respiratory burst activity, degranulation, neutrophil extracellular trap (NET) formation, and T-cell suppression in those neutrophil subsets were measured. NDN from severe/critical COVID-19 patients showed evidence of priming with enhanced phagocytosis, respiratory burst activity, and degranulation of secretory vesicles and gelatinase and specific granules, while NET formation was similar to HD NDN. COVID LDN response was impaired except for enhanced NET formation. A subset of COVID LDN with intermediate CD16 expression (CD16(Int) LDN) promoted T cell proliferation to a level similar to HD NDN, while COVID NDN and the CD16(Hi) LDN failed to stimulate T-cell activation. All 3 COVID-19 neutrophil populations suppressed stimulation of IFN-gamma production, compared to HD NDN. We conclude that NDN and LDN from COVID-19 patients possess complementary functional capabilities that may act cooperatively to determine disease severity. We predict that global neutrophil responses that induce COVID-19 ARDS will vary depending on the proportion of neutrophil subsets.	[McLeish, Kenneth R.; Rane, Madhavi J.; Barati, Michelle T.; Brier, Michael E.; Tandon, Shweta; Manning, Terri] Univ Louisville, Dept Med, Div Nephrol & Hypertens, Louisville, KY 40292 USA; [Shrestha, Rejeena; Yan, Jun] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA; [Vashishta, Aruna; Lau, Mario Gutierrez; Uriarte, Silvia M.] Univ Louisville, Sch Dent, Dept Oral Immunol & Infect Dis, Louisville, KY USA; [Hu, Xiaoling; Yan, Jun] Univ Louisville, Brown Canc Ctr, Div Immunotherapy, Immuno Oncol Program,Dept Surg, Louisville, KY 40292 USA; [Chen, Oscar; Wessel, Caitlin R.; Spalding, Travis; Bush, Sarah E.; Ijemere, Kenechi; Hopkins, C. Danielle; Cooke, Elizabeth A.; Huang, Jiapeng] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville	McLeish, KR (corresponding author), Univ Louisville, Dept Med, Div Nephrol & Hypertens, Louisville, KY 40292 USA.; Yan, J (corresponding author), Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40292 USA.; Yan, J (corresponding author), Univ Louisville, Brown Canc Ctr, Div Immunotherapy, Immuno Oncol Program,Dept Surg, Louisville, KY 40292 USA.		Hu, Xiao/GQI-0007-2022; Yan, Jun/A-8988-2008	Hu, Xiao/0000-0003-1128-4099; 	Jewish Heritage Fund for Excellence Research Enhancement Grant Program; Endowment in Translational Research at the University of Louisville School of Medicine; National Center For Advancing Translational Sciences [U18TR003787]; National Institute of Environmental Health Sciences [P30 (P30ES030283)]; Gilead Sciences COMMIT COVID-19 RFP Program [IN-US-983-6063]	Jewish Heritage Fund for Excellence Research Enhancement Grant Program; Endowment in Translational Research at the University of Louisville School of Medicine; National Center For Advancing Translational Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); National Institute of Environmental Health Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Gilead Sciences COMMIT COVID-19 RFP Program	This work was supported in part by a grant from the Jewish Heritage Fund for Excellence Research Enhancement Grant Program and the Endowment in Translational Research at the University of Louisville School of Medicine (JY). JH is supported by National Center For Advancing Translational Sciences [U18TR003787]; the National Institute of Environmental Health Sciences [P30 (P30ES030283)]; and Gilead Sciences COMMIT COVID-19 RFP Program [IN-US-983-6063].	Agrati C, 2020, CELL DEATH DIFFER, V27, P3196, DOI 10.1038/s41418-020-0572-6; Aschenbrenner AC, 2021, GENOME MED, V13, DOI 10.1186/s13073-020-00823-5; Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652; Blanco-Camarillo C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672520; Bost P, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21702-6; Cabrera LE, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009721; Cambier S, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.155055; Carmona-Rivera C, 2013, SEMIN IMMUNOPATHOL, V35, P455, DOI 10.1007/s00281-013-0375-7; Cowland JB, 2016, IMMUNOL REV, V273, P11, DOI 10.1111/imr.12440; Denny MR, 2010, J IMMUNOL, V184, P3284, DOI 10.4049/jimmunol.0902199; Flores EJ, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.01043-16; Ginestra JC, 2022, ANNU REV MED, V73, P95, DOI 10.1146/annurev-med-042420-110629; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Gueant JL, 2021, ALLERGY, V76, P1846, DOI 10.1111/all.14746; HASLETT C, 1985, AM J PATHOL, V119, P101; Hazeldine J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.680134; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jog NR, 2007, AM J PHYSIOL-CELL PH, V292, pC1690, DOI 10.1152/ajpcell.00384.2006; Karawajczyk M, 2021, THER ADV INFECT DIS, V8, DOI 10.1177/20499361211034065; Koushki K, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112346; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; Laforge M, 2020, NAT REV IMMUNOL, V20, P515, DOI 10.1038/s41577-020-0407-1; Lei RW, 2020, CRIT REV IMMUNOL, V40, P497, DOI 10.1615/CritRevImmunol.2020035652; Leppkes M, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102925; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Liu JY, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02374-0; Liu YW, 2020, J INFECTION, V81, pE6, DOI 10.1016/j.jinf.2020.04.002; Lourda M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2109123118; Masso-Silva JA, 2022, CLIN INFECT DIS, V74, P479, DOI 10.1093/cid/ciab437; Matthay MA, 2020, LANCET RESP MED, V8, P433, DOI 10.1016/S2213-2600(20)30127-2; Matthay MA, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0069-0; Mazzitelli I, 2021, J INFECT DIS, V224, P575, DOI 10.1093/infdis/jiab174; McLeish KR, 2013, J INNATE IMMUN, V5, P277, DOI 10.1159/000345992; McLeish KR, 1998, J LEUKOCYTE BIOL, V64, P537, DOI 10.1002/jlb.64.4.537; Meizlish ML, 2021, BLOOD ADV, V5, P1164, DOI 10.1182/bloodadvances.2020003568; Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008; Minns D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.633486; Minns D, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21533-5; Minns D, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/8968943; Mistry P, 2019, P NATL ACAD SCI USA, V116, P25222, DOI 10.1073/pnas.1908576116; Mo PZ, 2021, CLIN INFECT DIS, V73, pE4208, DOI 10.1093/cid/ciaa270; Morrissey SM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.148435; Mukund K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.738073; Nauseef WM, 2007, IMMUNOL REV, V219, P88, DOI 10.1111/j.1600-065X.2007.00550.x; Nicolai L, 2020, CIRCULATION, V142, P1176, DOI 10.1161/CIRCULATIONAHA.120.048488; Ouwendijk WJD, 2021, J INFECT DIS, V223, P1512, DOI 10.1093/infdis/jiab050; Parackova Z, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102206; Peruzzi B, 2020, IMMUNOLOGY, V161, P345, DOI 10.1111/imm.13254; Radermecker C, 2020, J EXP MED, V217, DOI 10.1084/jem.20201012; Rahman S, 2019, ANN RHEUM DIS, V78, P957, DOI 10.1136/annrheumdis-2018-214620; Reyes Leila, 2021, Wellcome Open Res, V6, P38, DOI 10.12688/wellcomeopenres.16584.1; Ronit A, 2021, J ALLERGY CLIN IMMUN, V147, P81, DOI 10.1016/j.jaci.2020.09.009; Rorvig S, 2013, J LEUKOCYTE BIOL, V94, P711, DOI 10.1189/jlb.1212619; Sacchi A, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03125-1; Sanchez-Pino MD, 2021, CELL IMMUNOL, V362, DOI 10.1016/j.cellimm.2021.104302; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Seery V, 2021, EBIOMEDICINE, V67, DOI 10.1016/j.ebiom.2021.103357; Seman BG, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10091091; SENGELOV H, 1995, J IMMUNOL, V154, P4157; SENGELOV H, 1993, J IMMUNOL, V150, P1535; Seren S, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03755-2020; Shaath H, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112374; Silvestre-Roig C, 2019, TRENDS IMMUNOL, V40, P565, DOI 10.1016/j.it.2019.04.012; Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002; Singel KL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122311; Sinha S, 2022, NAT MED, V28, P201, DOI 10.1038/s41591-021-01576-3; Spijkerman R, 2021, J LEUKOCYTE BIOL, V109, P99, DOI 10.1002/JLB.5COVA0820-520RRR; Tay S, 2020, ARTHRITIS RHEUMATOL, V72, P1587, DOI 10.1002/art.41395; Ueland T, 2020, J INFECTION, V81, pE41, DOI 10.1016/j.jinf.2020.06.061; Ueland T, 2021, J ALLERGY CLIN IMMUN, V147, P92, DOI 10.1016/j.jaci.2020.09.007; Uriarte Silvia M, 2011, J Immunol, V187, P391, DOI 10.4049/jimmunol.1003112; Vardhana SA, 2020, J EXP MED, V217, DOI 10.1084/jem.20200678; Veras FP, 2020, J EXP MED, V217, DOI 10.1084/jem.20201129; Vitte J, 2020, J INFECT DIS, V222, P1985, DOI 10.1093/infdis/jiaa591; Wang J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02063; Wilk AJ, 2021, J EXP MED, V218, DOI [10.1084/jem.20210582, 10.1126/sciimmunol.aay6017]; World Health Organization, 2021, LIV GUID CLIN MAN CO; Zhou Z, 2020, CELL HOST MICROBE, V27, P883, DOI 10.1016/j.chom.2020.04.017	78	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								879686	10.3389/fimmu.2022.879686	http://dx.doi.org/10.3389/fimmu.2022.879686			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C6GQ	35711435	Green Published, gold			2022-12-18	WOS:000810964900001
J	Motta-Raymundo, A; Rosmaninho, P; Santos, DF; Ferreira, RD; Silva, SP; Ferreira, C; Sousa, AE; Silva, SL				Motta-Raymundo, Adriana; Rosmaninho, Pedro; Santos, Diana F.; Ferreira, Ruben D.; Silva, Sara P.; Ferreira, Cristina; Sousa, Ana E.; Silva, Susana L.			Contribution of Helicobacter pylori to the Inflammatory Complications of Common Variable Immunodeficiency	FRONTIERS IN IMMUNOLOGY			English	Article						Helicobacter pylori; common variable immunodeficiency (CVID); gastric cancer; inflammatory CVID complications; inborn error of immunity (IEI); primary immunodeficiency	REGULATORY T-CELLS; INFECTION; DISEASE; RECOMMENDATION; AUTOIMMUNITY; EXPRESSION	Common Variable Immunodeficiency (CVID), the most prevalent symptomatic primary immunodeficiency, is frequently associated with severe inflammatory complications that determine its morbidity and mortality. We hypothesize that Helicobacter pylori (HP), a very common worldwide infection, may contribute to the clinical and immune phenotype of CVID. We stratified 41 CVID patients into HP+ (n=26) and HPneg (n=15) groups, according to previous urease breath test and/or gastric biopsies, and compared their clinical manifestations and immune profile evaluated by flow cytometry. No genetic variants with known potential impact in HP infection were found upon WES/WGS. Gastric complications were significantly more frequent in HP+ patients. Importantly, the six CVID patients with gastric cancer were infected with HP. In contrast, a significantly higher frequency of cytopenias was observed in the HPneg. Moreover, HP+ did not feature higher prevalence of organ auto-immunity, as well as of lung, liver or intestinal inflammatory manifestations. We observed the same B-cell profiles in HP+ and HPneg groups, accompanied by marked CD4 and CD8 T-cell activation, increased IFN gamma production, and contraction of naive compartments. Notably, HP+ patients featured low CD25 despite preserved Foxp3 levels in CD4 T cells. Overall, HP impact in CVID inflammatory complications was mainly restricted to the gastric mucosa, contributing to increased incidence of early onset gastric cancer. Thus, early HP screening and eradication should be performed in all CVID patients irrespective of symptoms.	[Motta-Raymundo, Adriana; Rosmaninho, Pedro; Santos, Diana F.; Ferreira, Ruben D.; Silva, Sara P.; Ferreira, Cristina; Sousa, Ana E.; Silva, Susana L.] Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal; [Motta-Raymundo, Adriana; Rosmaninho, Pedro; Santos, Diana F.; Ferreira, Ruben D.; Silva, Sara P.; Ferreira, Cristina; Sousa, Ana E.; Silva, Susana L.] Ctr Acad Med Lisboa, Ctr Imunodeficiencias Primarias, Lisbon, Portugal; [Silva, Sara P.; Ferreira, Cristina; Silva, Susana L.] Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon, Portugal	Universidade de Lisboa; Universidade de Lisboa; Hospital Santa Maria	Silva, SL (corresponding author), Univ Lisbon, Fac Med, Inst Med Mol Joao Lobo Antunes, Lisbon, Portugal.; Silva, SL (corresponding author), Ctr Acad Med Lisboa, Ctr Imunodeficiencias Primarias, Lisbon, Portugal.; Silva, SL (corresponding author), Ctr Hosp Univ Lisboa Norte, Hosp Santa Maria, Lisbon, Portugal.	susanasilva@medicina.ulisboa.pt						Abou Tayoun AN, 2018, HUM MUTAT, V39, P1517, DOI 10.1002/humu.23626; Alfarouk KO, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00075; Algood HMS, 2020, J IMMUNOL, V204, P1421, DOI 10.4049/jimmunol.1901307; Arandi N, 2013, SCAND J IMMUNOL, V77, P405, DOI 10.1111/sji.12040; Azizi G, 2017, CELL IMMUNOL, V315, P11, DOI 10.1016/j.cellimm.2016.12.007; Azizi G, 2017, EXPERT REV CLIN IMMU, V13, P101, DOI 10.1080/1744666X.2016.1224664; Barbosa RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022848; Berbers RM, 2021, J CLIN IMMUNOL, V41, P362, DOI 10.1007/s10875-020-00908-1; Biesecker LG, 2018, GENET MED, V20, P1687, DOI 10.1038/gim.2018.42; Blanco E, 2018, J ALLERGY CLIN IMMUN, V141, P2208, DOI 10.1016/j.jaci.2018.02.017; Bogstedt AK, 1996, CLIN EXP IMMUNOL, V105, P202, DOI 10.1046/j.1365-2249.1996.d01-745.x; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Camilo V, 2017, HELICOBACTER, V22, DOI 10.1111/hel.12405; Carter CRD, 2013, J CLIN PATHOL, V66, P146, DOI 10.1136/jclinpath-2012-201046; Chey WD, 2017, AM J GASTROENTEROL, V112, P212, DOI 10.1038/ajg.2016.563; Chmiela M, 2017, WORLD J GASTROENTERO, V23, P1521, DOI 10.3748/wjg.v23.i9.1521; Clyne M, 1997, GUT, V40, P731, DOI 10.1136/gut.40.6.731; Crowe SE, 2019, NEW ENGL J MED, V380, P1158, DOI 10.1056/NEJMcp1710945; De DD, 2015, WORLD J GASTROENTERO, V21, P2883, DOI 10.3748/wjg.v21.i10.2883; Dhalla F, 2011, CLIN EXP IMMUNOL, V165, P1, DOI 10.1111/j.1365-2249.2011.04384.x; Dolan B, 2018, INT J MED MICROBIOL, V308, P247, DOI 10.1016/j.ijmm.2017.11.005; Flores-Montero J, 2017, LEUKEMIA, V31, P2094, DOI 10.1038/leu.2017.29; Franchini M, 2017, EXPERT REV HEMATOL, V10, P99, DOI 10.1080/17474086.2017.1271319; Freudenhammer M, 2020, J IMMUNOL, V205, P2016, DOI 10.4049/jimmunol.2000343; Ghosh R, 2018, HUM MUTAT, V39, P1525, DOI 10.1002/humu.23642; Gullo I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061498; Hou Y, 2017, ONCOTARGET, V8, P115691, DOI 10.18632/oncotarget.22929; Kopanos C, 2019, BIOINFORMATICS, V35, P1978, DOI 10.1093/bioinformatics/bty897; Korotkaya Y, 2020, PEDIATR REV, V41, P585, DOI 10.1542/pir.2019-0048; Kumar P, 2016, IMMUNITY, V44, P659, DOI 10.1016/j.immuni.2016.02.007; Leone P, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020451; Li WL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00159; Lopez-Herrera G, 2019, ALLERGOL IMMUNOPATH, V47, P457, DOI 10.1016/j.aller.2019.01.003; Lopo I, 2018, HELICOBACTER, V23, DOI 10.1111/hel.12493; Malfertheiner P, 2017, GUT, V66, P6, DOI 10.1136/gutjnl-2016-312288; Marashi SM, 2012, J ALLERGY CLIN IMMUN, V129, P1349, DOI 10.1016/j.jaci.2012.02.011; McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4; Mooney D, 2017, CRIT REV MICROBIOL, V43, P508, DOI [10.1080/1040841X.2016.1268568, 10.1080/1040841x.2016.1268568]; Morais S, 2016, EUR J CANCER PREV, V25, P275, DOI 10.1097/CEJ.0000000000000183; Pulvirenti F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02546; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rowland M, 2018, CLIN MICROBIOL INFEC, V24, P980, DOI 10.1016/j.cmi.2017.10.020; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Smyk DS, 2014, WORLD J GASTROENTERO, V20, P613, DOI 10.3748/wjg.v20.i3.613; Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Unger S, 2018, J ALLERGY CLIN IMMUN, V141, P730, DOI 10.1016/j.jaci.2017.04.041; Woodward J, 2017, CLIN EXP IMMUNOL, V188, P363, DOI 10.1111/cei.12884; Yasuda K, 2019, SEMIN IMMUNOPATHOL, V41, P283, DOI 10.1007/s00281-019-00733-8; Yesillik S, 2019, INT ARCH ALLERGY IMM, V180, P150, DOI 10.1159/000501457; Zullo A, 1999, GUT, V45, P77, DOI 10.1136/gut.45.1.77	51	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								834137	10.3389/fimmu.2022.834137	http://dx.doi.org/10.3389/fimmu.2022.834137			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5HF	35711410	Green Published, gold			2022-12-18	WOS:000810898800001
J	Razonable, RR; Chen, PT				Razonable, Raymund R.; Chen, Peter			Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						SARS; CoV; 2; neutralizing antibodies; COVID-19 vaccines; COVID-19 Therapeutics; Convalescent plasma (CP) therapy			[Razonable, Raymund R.] Mayo Clin, Dept Med, Div Publ Hlth, Infect Dis & Occupat Med, Rochester, MN USA; [Chen, Peter] Cedars Sinai Med Ctr, Womens Guild Lung Inst, Dept Med, Los Angeles, CA 90048 USA	Mayo Clinic; Cedars Sinai Medical Center	Chen, PT (corresponding author), Cedars Sinai Med Ctr, Womens Guild Lung Inst, Dept Med, Los Angeles, CA 90048 USA.			Chen, Peter/0000-0002-5330-1718	Mayo Clinic [R01HL155759, R01HL137076]	Mayo Clinic	This work was supported by R01HL155759 (PC), R01HL137076 (PC), and an intramural grant at Mayo Clinic (RR).		0	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								938069	10.3389/fimmu.2022.938069	http://dx.doi.org/10.3389/fimmu.2022.938069			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D3EN	35720338	Green Published, gold			2022-12-18	WOS:000811434900001
J	Wang, ZG; Song, YL; Jiang, JZ; Piao, YH; Li, L; Bai, QY; Xu, C; Liu, HY; Li, LC; Piao, HM; Yan, GH				Wang, Zhiguang; Song, Yilan; Jiang, Jingzhi; Piao, Yihua; Li, Li; Bai, Qiaoyun; Xu, Chang; Liu, Hanye; Li, Liangchang; Piao, Hongmei; Yan, Guanghai			MicroRNA-182-5p Attenuates Asthmatic Airway Inflammation by Targeting NOX4	FRONTIERS IN IMMUNOLOGY			English	Article						miR-182-5p; NOX4; airway inflammation; asthma; Ovalbumin (OVA)	NLRP3 INFLAMMASOME; MURINE ASTHMA; MITOCHONDRIAL; EXPRESSION; APOPTOSIS; PATHWAYS; STRESS; CELLS; MODEL; MICE	Bronchial asthma is characterized by chronic airway inflammation, airway hyperresponsiveness, and airway remodeling. MicroRNA (miRNA) has recently been implicated in the pathogenesis of asthma. However, the mechanisms of different miRNAs in asthma are complicated, and the mechanism of miRNA-182-5p in asthma is still unclear. Here, we aim to explore the mechanism of miRNA182-5p in asthma-related airway inflammation. Ovalbumin (OVA)-induced asthma model was established. MiRNA Microarray Analysis was performed to analyze the differentially expressed miRNAs in the asthma model. We found that the expression of miRNA-182-5p was significantly decreased in OVA-induced asthma. In vitro, IL-13 stimulation of BEAS-2B cells resulted in a significant up-regulation of NOX4 (nicotinamide adenine dinucleotide phosphate oxidase 4), accompanied by mitochondrial damage-induced apoptosis, NLRP3 (NOD-like receptor family pyrin domain-containing 3)/IL-1 beta activation, and reduced miRNA-182-5p. In contrast, overexpression of miRNA-182-5p significantly inhibited epithelial cell apoptosis and NLRP3/IL-1 beta activation. In addition, we found that miRNA-182-5p could bind to the 3' untranscripted region of NOX4 mRNA and inhibit epithelial cell inflammation by reducing oxidative stress and mitochondrial damage. In vivo, miRNA-182-5p agomir treatment significantly reduced the percentage of eosinophils in bronchoalveolar lavage fluid, and down-regulated Th2 inflammatory factors, including IL-4, IL-5, and OVA induced IL-13. Meanwhile, miRNA-182-5p agomir reduced the peribronchial inflammatory cell infiltration, goblet cell proliferation and collagen deposition. In summary, targeting miRNA-182-5p may provide a new strategy for the treatment of asthma.	[Wang, Zhiguang; Song, Yilan; Jiang, Jingzhi; Piao, Yihua; Li, Li; Bai, Qiaoyun; Xu, Chang; Liu, Hanye; Li, Liangchang; Piao, Hongmei; Yan, Guanghai] Yanbian Univ, Jilin Key Lab Immune & Targeting Res Common Allerg, Yanji, Peoples R China; [Wang, Zhiguang; Piao, Hongmei] Yanbian Univ, Affiliated Hosp, Dept Resp Med, Yanji, Peoples R China; [Song, Yilan; Jiang, Jingzhi; Li, Li; Bai, Qiaoyun; Xu, Chang; Liu, Hanye; Li, Liangchang; Yan, Guanghai] Yanbian Univ Med Coll, Dept Anat Histol & Embryol, Yanji, Peoples R China; [Piao, Yihua] Yanbian Univ, Affiliated Hosp, Dept Intens Care Unit, Yanji, Peoples R China	Yanbian University; Yanbian University; Yanbian University; Yanbian University	Piao, HM; Yan, GH (corresponding author), Yanbian Univ, Jilin Key Lab Immune & Targeting Res Common Allerg, Yanji, Peoples R China.; Piao, HM (corresponding author), Yanbian Univ, Affiliated Hosp, Dept Resp Med, Yanji, Peoples R China.; Yan, GH (corresponding author), Yanbian Univ Med Coll, Dept Anat Histol & Embryol, Yanji, Peoples R China.	piaohm1969@126.com; ghyan2015@sina.com			National Natural Science Foundation of China [82060004, 81970018, 81860729, 81660003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by National Natural Science Foundation of China (Nos.: 82060004, 81970018, 81860729 and 81660003).	Besnard AG, 2011, ALLERGY, V66, P1047, DOI 10.1111/j.1398-9995.2011.02586.x; Borowski A, 2008, CLIN EXP ALLERGY, V38, P619, DOI 10.1111/j.1365-2222.2008.02944.x; Chan YL, 2019, AM J PHYSIOL-LUNG C, V317, pL424, DOI 10.1152/ajplung.00232.2019; Chen Y, 2020, HUM EXP TOXICOL, V39, P683, DOI 10.1177/0960327119895549; Cid-Castro C, 2018, CELL MOL NEUROBIOL, V38, P995, DOI 10.1007/s10571-018-0584-7; Du XJ, 2020, J CELL PHYSIOL, V235, P563, DOI 10.1002/jcp.28995; Estaquier J, 2012, ADV EXP MED BIOL, V942, P157, DOI 10.1007/978-94-007-2869-1_7; Fan CC, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101571; Grohm J, 2010, BRAIN BEHAV IMMUN, V24, P831, DOI 10.1016/j.bbi.2009.11.015; Guo CX, 2018, CHEMOSPHERE, V210, P183, DOI 10.1016/j.chemosphere.2018.06.170; Guo CX, 2015, INT J NANOMED, V10, P1463, DOI 10.2147/IJN.S76114; Guo XT, 2018, BMC PULM MED, V18, DOI 10.1186/s12890-018-0680-y; Hara H, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7080086; Huang KW, 2019, LANCET, V394, P407, DOI 10.1016/S0140-6736(19)31147-X; Jaffer OA, 2015, AM J RESP CELL MOL, V52, P106, DOI 10.1165/rcmb.2013-0519OC; Jiang JY, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101638; Kalogeris T, 2014, REDOX BIOL, V2, P702, DOI 10.1016/j.redox.2014.05.006; Kim RY, 2017, AM J RESP CRIT CARE, V196, P283, DOI 10.1164/rccm.201609-1830OC; Kleniewska P, 2017, BIOMED PHARMACOTHER, V94, P100, DOI 10.1016/j.biopha.2017.07.066; Kuruvilla ME, 2019, CLIN REV ALLERG IMMU, V56, P219, DOI 10.1007/s12016-018-8712-1; Li ZM, 2021, J CELL PHYSIOL, V236, P1628, DOI 10.1002/jcp.30005; Liu YS, 2020, CNS NEUROSCI THER, V26, P902, DOI 10.1111/cns.13383; Lou LL, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109692; Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034; Minutoli L, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2183026; Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1; Parulekar AD, 2018, CURR OPIN PULM MED, V24, P50, DOI 10.1097/MCP.0000000000000436; Qin SB, 2018, J CELL PHYSIOL, V233, P6630, DOI 10.1002/jcp.26389; Qu JJ, 2017, J THORAC DIS, V9, pE32, DOI 10.21037/jtd.2017.01.05; Rodrigo-Munoz JM, 2019, ALLERGY, V74, P507, DOI 10.1111/all.13570; Sahiner UM, 2018, PEDIAT ALLERG IMM-UK, V29, P789, DOI 10.1111/pai.12965; Specjalski K, 2019, ARCH IMMUNOL THER EX, V67, P213, DOI 10.1007/s00005-019-00547-4; Sutcliffe A, 2012, AM J RESP CRIT CARE, V185, P267, DOI 10.1164/rccm.201107-1281OC; Tao WY, 2021, MOL THER, V29, P396, DOI 10.1016/j.ymthe.2020.09.006; Theofani E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101615; Wan WYH, 2016, CHEST, V149, P1445, DOI 10.1016/j.chest.2016.01.024; Wang QL, 2018, METHODS MOL BIOL, V1732, P507, DOI 10.1007/978-1-4939-7598-3_32; Wen W, 2019, J CELL BIOCHEM, V120, P17602, DOI 10.1002/jcb.29028; Wu M, 2018, MOL CELL ENDOCRINOL, V478, P115, DOI 10.1016/j.mce.2018.08.002; Xiao K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03034-3; Xing S, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01295-2; Xu SC, 2016, J PINEAL RES, V60, P291, DOI 10.1111/jpi.12310; Xu YF, 2013, INT J MOL MED, V31, P628, DOI 10.3892/ijmm.2013.1232; Yan SS, 2020, CANCER LETT, V488, P18, DOI 10.1016/j.canlet.2020.04.021; Yang CG, 2021, MOL THER, V29, P2088, DOI 10.1016/j.ymthe.2021.02.006; Zeng C, 2020, REDOX BIOL, V34, DOI 10.1016/j.redox.2020.101523; Zhang K, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.148103; Zhang LS, 2020, BIOCHEM BIOPH RES CO, V529, P784, DOI 10.1016/j.bbrc.2020.06.073	48	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								853848	10.3389/fimmu.2022.853848	http://dx.doi.org/10.3389/fimmu.2022.853848			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2K0BV	35711428	Green Published, gold			2022-12-18	WOS:000816011600001
J	Wieczorek, L; Zemil, M; Merbah, M; Dussupt, V; Kavusak, E; Molnar, S; Heller, J; Beckman, B; Wollen-Roberts, S; Peachman, KK; Darden, JM; Krebs, S; Rolland, M; Peel, SA; Polonis, VR				Wieczorek, Lindsay; Zemil, Michelle; Merbah, Melanie; Dussupt, Vincent; Kavusak, Erin; Molnar, Sebastian; Heller, Jonah; Beckman, Bradley; Wollen-Roberts, Suzanne; Peachman, Kristina K.; Darden, Janice M.; Krebs, Shelly; Rolland, Morgane; Peel, Sheila A.; Polonis, Victoria R.			Evaluation of Antibody-Dependent Fc-Mediated Viral Entry, as Compared With Neutralization, in SARS-CoV-2 Infection	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; coronavirus; COVID-19; variant of concern; antibody dependent enhancement; neutralization; pseudovirus; Fc-mediated virus entry; spike (S) protein	FUNCTIONAL RECEPTOR; SARS CORONAVIRUS; DISEASE SEVERITY; ENHANCEMENT; VIRUS; PATHOGENESIS; PROTEIN	Fc-mediated virus entry has been observed for many viruses, but the characterization of this activity in convalescent plasma against SARS-CoV-2 Variants of Concern (VOC) is undefined. In this study, we evaluated Fc-mediated viral entry (FVE) on Fc gamma RIIa-expressing HEK293 cells in the presence of SARS-CoV-2 convalescent plasma and compared it with SARS-CoV-2 pseudovirus neutralization using ACE2-expressing HEK293 cells. The plasma were collected early in the pandemic from 39 individuals. We observed both neutralization and FVE against the infecting Washington SARS-CoV-2 strain for 31% of plasmas, neutralization, but not FVE for 61% of plasmas, and no neutralization or FVE for 8% of plasmas. Neutralization titer correlated significantly with the plasma dilution at which maximum FVE was observed, indicating Fc-mediated uptake peaked as neutralization potency waned. While total Spike-specific plasma IgG levels were similar between plasma that mediated FVE and those that did not, Spike-specific plasma IgM levels were significantly higher in plasma that did not mediate FVE. Plasma neutralization titers against the Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) VOC were significantly lower than titers against the Washington strain, while plasma FVE activity against the VOC was either higher or similar. This is the first report to demonstrate a functional shift in convalescent plasma antibodies from neutralizing and FVE-mediating against the earlier Washington strain, to an activity mediating only FVE and no neutralization activity against the emerging VOC, specifically the Beta (B.1.351) and Gamma (P.1) VOC. It will be important to determine the in vivo relevance of these findings.	[Wieczorek, Lindsay; Zemil, Michelle; Merbah, Melanie; Dussupt, Vincent; Kavusak, Erin; Molnar, Sebastian; Heller, Jonah; Beckman, Bradley; Wollen-Roberts, Suzanne; Krebs, Shelly; Rolland, Morgane; Polonis, Victoria R.] Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA; [Wieczorek, Lindsay; Zemil, Michelle; Merbah, Melanie; Dussupt, Vincent; Kavusak, Erin; Molnar, Sebastian; Heller, Jonah; Beckman, Bradley; Wollen-Roberts, Suzanne; Darden, Janice M.; Krebs, Shelly; Rolland, Morgane] Henry M Jackson Fdn Advancement Mil Med, Bethesda, MD USA; [Peachman, Kristina K.; Darden, Janice M.; Peel, Sheila A.] Walter Reed Army Inst Res, Diagnost & Countermeasures Branch, Silver Spring, MD USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR)	Polonis, VR (corresponding author), Walter Reed Army Inst Res, US Mil HIV Res Program, Silver Spring, MD 20910 USA.	VPolonis@hivresearch.org		Merbah, Melanie/0000-0002-5641-8612; Beckman, Bradley/0000-0001-9077-2925; Wollen-Roberts, Suzanne/0000-0002-9409-2756				Amjadi Maya F, 2021, Immunohorizons, V5, P466, DOI 10.4049/immunohorizons.2100022; Andreano E, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103154118; Benton DJ, 2020, NATURE, V588, DOI 10.1038/s41586-020-2772-0; Bhatt P, 2021, CURR MICROBIOL, V78, P17, DOI 10.1007/s00284-020-02284-w; Bohan D, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009743; Bonheur AN, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06482-0; Cervia C, 2021, J ALLERGY CLIN IMMUN, V147, P545, DOI 10.1016/j.jaci.2020.10.040; Chakraborty S, 2021, NAT IMMUNOL, V22, P67, DOI [10.1038/s41590-020-00828-7, 10.1101/2020.05.15.20103341]; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Davies NG, 2021, SCIENCE, V372, P149, DOI 10.1126/science.abg3055; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Dussupt V, 2021, NAT IMMUNOL, V22, P1503, DOI 10.1038/s41590-021-01068-z; Dussupt V, 2020, NAT MED, V26, P228, DOI 10.1038/s41591-019-0746-2; Gadanec LK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22030992; Gasser R, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108790; Gorman MJ, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100405; Gu YQ, 2022, CELL RES, V32, P600, DOI 10.1038/s41422-022-00654-6; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; HALSTEAD SB, 1970, YALE J BIOL MED, V42, P311; HALSTEAD SB, 1973, J INFECT DIS, V128, P15, DOI 10.1093/infdis/128.1.15; HALSTEAD SB, 1973, NATURE-NEW BIOL, V243, P24; Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Hastie KM, 2021, SCIENCE, V374, P472, DOI 10.1126/science.abh2315; Higgins V, 2021, CRIT REV CL LAB SCI, V58, P297, DOI 10.1080/10408363.2020.1860895; Hoffmann M, 2022, CELL, V185, P447, DOI 10.1016/j.cell.2021.12.032; Houser KV, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006565; Izmirly AM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01055; Jackson CB, 2022, NAT REV MOL CELL BIO, V23, P3, DOI 10.1038/s41580-021-00418-x; Katzelnick LC, 2017, SCIENCE, V358, P929, DOI 10.1126/science.aan6836; Khandia R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00597; Ku ZQ, 2021, NATURE, V595, P718, DOI 10.1038/s41586-021-03673-2; Larsen MD, 2021, SCIENCE, V371, P907, DOI 10.1126/science.abc8378; Lee WS, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100296; Li Dapeng, 2021, bioRxiv, DOI 10.1101/2020.12.31.424729; Li WH, 2003, NATURE, V426, P450, DOI 10.1038/nature02145; Liu XM, 2020, EMERG MICROBES INFEC, V9, P1269, DOI 10.1080/22221751.2020.1773324; Liu YF, 2021, CELL, V184, P3452, DOI 10.1016/j.cell.2021.05.032; M. T. Sofonea, 2022, medRxiv, DOI 10.1101/2021.12.31.21268583; Maemura T, 2021, MBIO, V12, DOI 10.1128/mBio.01987-21; Hurtado-Monzon AM, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2100; Marconato M, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI158190; Marklund E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241104; McLean G, 2022, MBIO, V13, DOI [10.1128/mbio.02979-21, 10.7326/M15-0288]; Merbah M, 2020, J IMMUNOL METHODS, V487, DOI 10.1016/j.jim.2020.112874; O'Donnell MR, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150646; OCHIAI H, 1992, J MED VIROL, V36, P217, DOI 10.1002/jmv.1890360312; Ortigoza MB, 2022, JAMA INTERN MED, V182, P115, DOI 10.1001/jamainternmed.2021.6850; Pollara J, 2014, J VIROL, V88, P7715, DOI 10.1128/JVI.00156-14; PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7; Pulliam JRC, 2022, SCIENCE, V376, P596, DOI 10.1126/science.abn4947; Rappazzo CG, 2021, SCIENCE, V371, P823, DOI 10.1126/science.abf4830; Ricke DO, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640093; Ricke DO, 2020, MED COUNTERMEASURES, DOI [10.20944/preprints202003.200138.v202001, 10.20944/preprints202003.0138.v1]; ROBINSON WE, 1988, LANCET, V1, P790; Rogers TF, 2020, SCIENCE, V369, P956, DOI 10.1126/science.abc7520; Rong Y, 2021, AM J TRANSL RES, V13, P1197; Roozendaal R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26117-x; Salje H, 2018, NATURE, V557, P719, DOI 10.1038/s41586-018-0157-4; Schafer A, 2021, J EXP MED, V218, DOI 10.1084/jem.20201993; Sheikh A, 2022, LANCET INFECT DIS, V22, P959, DOI 10.1016/S1473-3099(22)00141-4; Smatti MK, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02991; Strohl WR, 2022, BIODRUGS, V36, P231, DOI 10.1007/s40259-022-00529-7; Sullivan David J, 2021, medRxiv, DOI 10.1101/2021.12.10.21267485; Suryadevara N, 2021, CELL, V184, P2316, DOI 10.1016/j.cell.2021.03.029; Takada A, 2003, J VIROL, V77, P7539, DOI 10.1128/JVI.77.13.7539-7544.2003; Ullah Irfan, 2021, bioRxiv, DOI 10.1101/2021.03.22.436337; Vigon L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.742631; Walls AC, 2019, CELL, V176, P1026, DOI 10.1016/j.cell.2018.12.028; Wan YS, 2020, J VIROL, V94, DOI 10.1128/JVI.02015-19; Wang K, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00426-x; Wang SF, 2014, BIOCHEM BIOPH RES CO, V451, P208, DOI 10.1016/j.bbrc.2014.07.090; Weisblum Y., 2020, ELIFE, DOI [10.1101/2020.07.21.214759, DOI 10.7554/ELIFE.61312, 10.7554/eLife.61312.sa2]; Wolter N, 2022, LANCET, V399, P437, DOI 10.1016/S0140-6736(22)00017-4; Wu F., 2020, MEDRXIV, V3, P9114, DOI [10.1101/2020.10.08.20209114, DOI 10.1101/2020.10.08.20209114]; Yates JL, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100329; Yuan Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15092	78	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								901217	10.3389/fimmu.2022.901217	http://dx.doi.org/10.3389/fimmu.2022.901217			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5EG	35711449	Green Published, gold			2022-12-18	WOS:000810891100001
J	Yu, XL; Wang, L; Yang, XR; Zhang, SS; Li, GW; Zhang, LL; Li, JX; Wang, XA; Zhou, H; Jiang, YP; Cui, W; Li, YJ; Tang, LJ; Qiao, XY				Yu, Xiaoli; Wang, Li; Yang, Xinru; Zhang, Songsong; Li, Guiwei; Zhang, Lanlan; Li, Jiaxuan; Wang, Xiaona; Zhou, Han; Jiang, Yanping; Cui, Wen; Li, Yijing; Tang, Lijie; Qiao, Xinyuan			Lactobacillus casei Ghosts as a Vehicle for the Delivery of DNA Vaccines Mediate Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						delivery system; bacterial ghost; dendritic cell; macrophages; deoxyribonucleic acid (DNA) vaccines	BACTERIAL GHOSTS; DENDRITIC CELLS; MACROPHAGES; EXPRESSION; PROTECTION; ALLERGENS; ANTIGEN; CARRIER	We developed Lactobacillus casei bacterial ghosts (BGs) as vehicles for delivering DNA vaccines and analyzed their effects on immune responses. Uptake of the plasmids encoding the enhanced green fluorescent protein (pCI-EGFP) and BGs loaded with pCI-EGFP by macrophages was investigated using fluorescence microscopy and flow cytometry. The results showed that pCI-EGFP-loaded L. casei BGs were efficiently taken up by macrophages. Lactobacillus casei BGs loaded with plasmids encoding VP6 protein of PoRV (pCI-PoRV-VP6) significantly upregulated the mRNA expression of interleukin (IL)-1 beta, IL-10, tumor necrosis factor (TNF)-alpha, inducible nitric oxide synthase (iNOS), arginase-1 (Arg-1), Mannose receptor (CD206) toll-like receptor (TLR)-2, TLR4, and TLR9 in macrophages. The levels of markers of M1 polarization (IL-10 and TNF-alpha) and M2 polarization (Arg-1 and CD206) were increased in macrophages incubated with pCI-PoRV-VP6-loaded BGs compared with the control group. The results of the enzyme-linked immunosorbent assay showed that the secretion of IL-1 beta, IL-10, and TNF-alpha in macrophages was significantly upregulated compared with the control group. Flow cytometry demonstrated that L. casei BGs loaded with pCI-PoRV-VP6 promoted the maturation of dendritic cells (DCs). Following incubation with pCI-PoRV-VP6-loaded BGs, the mRNA expression levels of IL-1 beta, IL-6 and interferon (IFN)-gamma in DCs were significantly increased. ELISA assay showed the secretion of the IL-1 beta, IL-6, IFN-gamma IL-10 and TNF-alpha in DCs were upregulated significantly. Thus, L. casei BGs promoted the maturation and activation of DCs. We analyzed the stimulatory capacity of DCs in a mixed lymphocyte reaction with allogeneic T cells. T cell proliferation increased upon incubation with DCs stimulated by BGs. After immunizing mice with BGs loaded with pCI-PoRV-VP6, the specific IgG levels in the serum were higher than those elicited by BGs loaded with pCI-PoRV-VP6. BGs loaded with pCI-PoRV-VP6 on Th1 and Th2 cytokines polarized T cells into the Th1 type and increased the proportion of CD4(+)/CD8(+) T cells. These results indicate L. casei BGs effectively mediate immune responses and can be used as delivery system for DNA vaccination.	[Yu, Xiaoli; Wang, Li; Yang, Xinru; Zhang, Songsong; Li, Jiaxuan; Wang, Xiaona; Zhou, Han; Jiang, Yanping; Cui, Wen; Li, Yijing; Tang, Lijie; Qiao, Xinyuan] Northeast Agr Univ, Coll Vet Med, Dept Prevent Vet Med, Heilongjiang Key Lab Anim Dis Control & Pharmaceut, Harbin, Peoples R China; [Li, Guiwei] Heilongjiang Acad Agr Sci, Branch Anim Husb & Vet, Qiqihar, Peoples R China; [Zhang, Lanlan] Heilongjiang Fishery Technol Extens Stn, Harbin, Peoples R China	Northeast Agricultural University - China; Heilongjiang Academy of Agricultural Sciences	Qiao, XY (corresponding author), Northeast Agr Univ, Coll Vet Med, Dept Prevent Vet Med, Heilongjiang Key Lab Anim Dis Control & Pharmaceut, Harbin, Peoples R China.	qiaoxinyuan@126.com						Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Batah AM, 2020, EXPERT REV VACCINES, V19, P549, DOI 10.1080/14760584.2020.1777862; Brisse M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583077; Cai K, 2015, SCI REP-UK, V5, DOI 10.1038/srep17479; Cao J, 2018, MICROBIOLOGYOPEN, V7, DOI 10.1002/mbo3.576; Choi JP, 2016, ALLERGY ASTHMA IMMUN, V8, P362, DOI 10.4168/aair.2016.8.4.362; Dar P, 2013, VACCINE, V31, P3327, DOI 10.1016/j.vaccine.2013.05.078; Dieterlen MT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676175; Fanuel S, 2017, HUM VACC IMMUNOTHER, V13, P2428, DOI 10.1080/21645515.2017.1365208; Gaiser AK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691155; Gholijani N, 2016, J IMMUNOTOXICOL, V13, P157, DOI 10.3109/1547691X.2015.1029145; Hafkamp FMJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.732992; Hajam IA, 2017, VET RES, V48, DOI 10.1186/s13567-017-0442-5; Hajam IA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144397; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Hong S, 2018, J MICROBIOL BIOTECHN, V28, P115, DOI 10.4014/jmb.1709.09017; Hong SJ, 2017, MOL IMMUNOL, V81, P135, DOI 10.1016/j.molimm.2016.12.008; Hou R, 2018, BMC MICROBIOL, V18, DOI 10.1186/s12866-018-1216-6; Huter V, 1999, J CONTROL RELEASE, V61, P51, DOI 10.1016/S0168-3659(99)00099-1; Jawale CV, 2014, VACCINE, V32, P5925, DOI 10.1016/j.vaccine.2014.08.072; Ji GF, 2021, ADV MATER, V33, DOI 10.1002/adma.202004559; Kudela P, 2010, VACCINE, V28, P5760, DOI 10.1016/j.vaccine.2010.06.087; Lee JH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15569-1; Li SY, 2021, MICROB PATHOGENESIS, V154, DOI 10.1016/j.micpath.2021.104865; Mader HJ, 1997, VACCINE, V15, P195, DOI 10.1016/S0264-410X(96)00141-7; Montanaro J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S84370; Pasare C, 2004, SEMIN IMMUNOL, V16, P23, DOI 10.1016/j.smim.2003.10.006; Paukner S, 2005, MOL THER, V11, P215, DOI 10.1016/j.ymthe.2004.09.024; Peng W, 2011, IMMUNOBIOLOGY, V216, P558, DOI 10.1016/j.imbio.2010.10.001; Pires-Lapa MA, 2019, PROSTAG OTH LIPID M, V141, P34, DOI 10.1016/j.prostaglandins.2019.02.001; Rabea S, 2020, SAUDI PHARM J, V28, P1253, DOI 10.1016/j.jsps.2020.08.016; Rojas JM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6104054; Ru ZY, 2021, FOOD SCI NUTR, V9, P6162, DOI 10.1002/fsn3.2569; Sanlier N, 2019, CRIT REV FOOD SCI, V59, P506, DOI 10.1080/10408398.2017.1383355; Scott K, 2005, IMMUNOLOGY, V116, P245, DOI 10.1111/j.1365-2567.2005.02218.x; Sei JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109273; Senevirathne A, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104252; Stuve O, 2006, ARCH NEUROL-CHICAGO, V63, P1383, DOI 10.1001/archneur.63.10.1383; Subramanian N, 2017, J GEN VIROL, V98, P3068, DOI 10.1099/jgv.0.000976; Sun HX, 2015, CARBOHYD POLYM, V121, P388, DOI 10.1016/j.carbpol.2014.12.023; Nguyen TL, 2020, ACS NANO, V14, P11623, DOI 10.1021/acsnano.0c04188; Wen J, 2012, VACCINE, V30, P5733, DOI 10.1016/j.vaccine.2012.07.008; WITTE A, 1990, J BACTERIOL, V172, P4109, DOI 10.1128/jb.172.7.4109-4114.1990; Yrlid U, 2000, FEMS IMMUNOL MED MIC, V27, P313, DOI 10.1111/j.1574-695X.2000.tb01445.x; Zhou P, 2019, IMMUNOBIOLOGY, V224, P739, DOI 10.1016/j.imbio.2019.09.002	45	0	0	17	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								849409	10.3389/fimmu.2022.849409	http://dx.doi.org/10.3389/fimmu.2022.849409			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5ID	35711427	gold, Green Published			2022-12-18	WOS:000810901200001
J	Zhuang, XY; Chen, LR; Yang, SH; Xia, SN; Xu, ZQ; Zhang, T; Zeng, BY; Yu, T; Yu, N; Wang, W; Lu, HJ; Tian, MY; Jin, NY				Zhuang, Xinyu; Chen, Luer; Yang, Songhui; Xia, Shengnan; Xu, Zhiqiang; Zhang, Tong; Zeng, Boyu; Yu, Tong; Yu, Ning; Wang, Wei; Lu, Huijun; Tian, Mingyao; Jin, Ningyi			R848 Adjuvant Laden With Self-Assembled Nanoparticle-Based mRNA Vaccine Elicits Protective Immunity Against H5N1 in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						mRNA vaccine; ferritin; CD5 signal peptide; R848	INFLUENZA; FERRITIN; VECTOR	In order to perfect the design strategy of messenger RNA (mRNA) vaccines against the H5N1 influenza virus, we investigated whether different antigen designs and the use of adjuvants could improve the immune effect of mRNA vaccines. We designed three different forms of antigen genes, including Flu [H1/H3/H5/B-HA2(aa90~105)-M2e(24aa)], Flu-Fe (Fe, ferritin), and CD5-Flu-Fe (CD5, a secretion signal peptide). Meanwhile, R848 (Requimod) was selected as the adjuvant of the mRNA vaccine. We prepared cationic lipid nanoparticles for mRNA delivery, named LNP-Man (mannose-modified lipid nanoparticles). Cell transfection results showed that Flu-Fe/CD5-Flu-Fe containing ferritin could express the target antigens HA2 and M2e more efficiently than Flu. In the mice immune experiment, five immune groups (LNP-Man/Flu, LNP-Man/Flu-Fe, LNP-Man/CD5-Flu-Fe, LNP-Man/Flu-Fe+R848, and LNP-Man/CD5-Flu-Fe+R848) and two control groups (LNP-Man, PBS) were set up. After being infected with the 1xLD(50) H5N1 avian influenza virus, the survival rate of the mice in the LNP-Man/CD5-Flu-Fe, LNP-Man/Flu-Fe+R848, and LNP-Man/CD5-Flu-Fe+R848 were 100%. More importantly, in LNP-Man/Flu-Fe+R848 and LNP-Man/CD5-Flu-Fe+R848 groups, there was no residual virus detected in the mice lung tissue on the 5th day postchallenge. Overall, this study provides a new idea for the design of H5N1 avian influenza virus mRNA vaccines in terms of antigen designs and adjuvant selection.	[Zhuang, Xinyu; Lu, Huijun; Tian, Mingyao; Jin, Ningyi] Chinese Acad Agr Sci, Changchun Vet Res Inst, Changchun, Peoples R China; [Chen, Luer; Zhang, Tong; Yu, Ning; Jin, Ningyi] Jilin Univ, Coll Vet Med, Changchun, Peoples R China; [Yang, Songhui; Xu, Zhiqiang] Yanbian Univ, Agr Coll Yanbian Univ, Coll Agr, Yanji, Peoples R China; [Xia, Shengnan; Zeng, Boyu] Yangzhou Univ, Coll Vet Med, Yangzhou, Peoples R China; [Yu, Tong] Jilin Agr Univ, Coll Vet Med, Changchun, Peoples R China; [Wang, Wei] Guangxi Univ, Coll Anim Sci & Technol, Nanning, Peoples R China; [Wang, Wei; Lu, Huijun] Wenzhou Univ, Inst Virol, Wenzhou, Peoples R China	Chinese Academy of Agricultural Sciences; Jilin University; Yanbian University; Yangzhou University; Jilin Agricultural University; Guangxi University; Wenzhou University	Lu, HJ; Tian, MY; Jin, NY (corresponding author), Chinese Acad Agr Sci, Changchun Vet Res Inst, Changchun, Peoples R China.; Jin, NY (corresponding author), Jilin Univ, Coll Vet Med, Changchun, Peoples R China.; Lu, HJ (corresponding author), Wenzhou Univ, Inst Virol, Wenzhou, Peoples R China.				National Major Scientific and Technological Special Project [2018ZX10102-001]	National Major Scientific and Technological Special Project	This work was supported by National Major Scientific and Technological Special Project (2018ZX10102-001). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam MM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02982; Ananthaswamy N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08825-7; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Chakraborti S, 2019, ADV EXP MED BIOL, V1174, P313, DOI 10.1007/978-981-13-9791-2_10; Ciminski K, 2021, TRENDS MOL MED, V27, P104, DOI 10.1016/j.molmed.2020.09.014; Clemens EA, 2021, J INFECT DIS, V224, P351, DOI 10.1093/infdis/jiaa728; Fiers W, 2004, VIRUS RES, V103, P173, DOI 10.1016/j.virusres.2004.02.030; Fiers W, 2009, VACCINE, V27, P6280, DOI 10.1016/j.vaccine.2009.07.007; Gong X, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.51; Goswami R, 2019, ACS INFECT DIS, V5, P1546, DOI 10.1021/acsinfecdis.9b00084; Guan S, 2017, GENE THER, V24, P133, DOI 10.1038/gt.2017.5; Holbrook BC, 2017, VACCINE, V35, P6137, DOI 10.1016/j.vaccine.2017.09.054; Johnson KEE, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006450; Kalaiyarasu S, 2021, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.571999; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Kariko K, 2008, MOL THER, V16, P1833, DOI 10.1038/mt.2008.200; Kitaoka M, 2017, BIOENG TRANSL MED, V2, P102, DOI 10.1002/btm2.10048; Klomp M, 2021, J LEUKOCYTE BIOL, V110, P115, DOI 10.1002/JLB.4RU0820-232R; Kuhn JH, 2004, CELL MOL LIFE SCI, V61, P2738, DOI 10.1007/s00018-004-4242-5; Lee S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.710647; Liu S, 2020, TRANSBOUND EMERG DIS, V67, P1463, DOI 10.1111/tbed.13515; Nazeri S, 2020, EXP PARASITOL, V216, DOI 10.1016/j.exppara.2020.107944; Neumann G, 2010, CELL RES, V20, P51, DOI 10.1038/cr.2009.124; Nguyen QD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041934; Qi YP, 2020, TRANSBOUND EMERG DIS, V67, P1861, DOI 10.1111/tbed.13564; Qiu M, 2021, ACCOUNTS CHEM RES, V54, P4001, DOI 10.1021/acs.accounts.1c00500; Rauch S, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00311-w; Richards KA, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00227-x; Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6; Thess A, 2015, MOL THER, V23, P1456, DOI 10.1038/mt.2015.103; Tortorici MA, 2019, NAT STRUCT MOL BIOL, V26, P481, DOI 10.1038/s41594-019-0233-y; Watanabe Y, 2012, TRENDS MICROBIOL, V20, P11, DOI 10.1016/j.tim.2011.10.003; Yamashita I, 2010, BBA-GEN SUBJECTS, V1800, P846, DOI 10.1016/j.bbagen.2010.03.005; Yuan S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.659419; Zakhartchouk AN, 2007, DNA CELL BIOL, V26, P721, DOI 10.1089/dna.2007.0616; Zhang C, 2019, MSYSTEMS, V4, DOI 10.1128/mSystems.00431-19; Zhou YC, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.617522; Zhuang XY, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010123	38	0	0	41	41	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 31	2022	13								836274	10.3389/fimmu.2022.836274	http://dx.doi.org/10.3389/fimmu.2022.836274			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1SX	35711431	gold, Green Published			2022-12-18	WOS:000811336700001
J	Bai, SH; Chen, L; Yan, YL; Li, R; Zhou, Y; Wang, X; Kang, HJ; Feng, ZD; Li, GZ; Zhou, SL; Drokow, EK; Ren, J				Bai, Shuheng; Chen, Ling; Yan, Yanli; Li, Rong; Zhou, Yun; Wang, Xuan; Kang, Haojing; Feng, Zhaode; Li, Guangzu; Zhou, Shuling; Drokow, Emmanuel Kwateng; Ren, Juan			Exploration of Different Hypoxia Patterns and Construction of a Hypoxia-Related Gene Prognostic Index in Colorectal Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						colorectal cancer; hypoxia; immune checkpoint inhibitors; tumor microenvironment (TME); hypoxia signaling pathway	TUMOR MICROENVIRONMENT; EXTRACELLULAR-MATRIX; INDUCIBLE FACTORS; IMMUNE CELLS; BLOCKADE; EXPRESSION; OXYGEN; PD-L1	IntroductionImmune checkpoint inhibitor (ICI) therapy has been proven to be a highly efficacious treatment for colorectal adenocarcinoma (COAD). However, it is still unclear how to identify those who might benefit the most from ICI therapy. Hypoxia facilitates the progression of the tumor from different aspects, including proliferation, metabolism, angiogenesis, and migration, and improves resistance to ICI. Therefore, it is essential to conduct a comprehensive understanding of the influences of hypoxia in COAD and identify a biomarker for predicting the benefit of ICI. MethodsAn unsupervised consensus clustering algorithm was used to identify distinct hypoxia-related patterns for COAD patients from TCGA and the GEO cohorts. The ssGSEA algorithm was then used to explore the different biological processes, KEGG pathways, and immune characteristics among distinct hypoxia-related clusters. Some hypoxia-related hub genes were then selected by weighted gene coexpression network analysis (WGCNA). Subsequently, univariate Cox regression analysis, multivariate Cox regression analysis, and least absolute shrinkage and selection operator (LASSO) regression were utilized to construct a hypoxia-related gene prognostic index (HRGPI). Finally, validation was also conducted for HRGPI in prognostic value, distinguishing hypoxia-related characteristics and benefits of ICI. ResultsWe identified four hypoxia-related clusters and found that different hypoxia response patterns induced different prognoses significantly. Again, we found different hypoxia response patterns presented distinct characteristics of biological processes, signaling pathways, and immune features. Severe hypoxia conditions promoted activation of some cancer-related signaling pathways, including Wnt, Notch, ECM-related pathways, and remodeled the tumor microenvironment of COAD, tending to present as an immune-excluded phenotype. Subsequently, we selected nine genes (ANO1, HOXC6, SLC2A4, VIP, CD1A, STC2, OLFM2, ATP6V1B1, HMCN2) to construct our HRGPI, which has shown an excellent prognostic value. Finally, we found that HRGPI has an advantage in distinguishing immune and molecular characteristics of hypoxia response patterns, and it could also be an excellent predictive indicator for clinical response to ICI therapy. ConclusionDifferent hypoxia response patterns activate different signaling pathways, presenting distinct biological processes and immune features. HRGPI is an independent prognostic factor for COAD patients, and it could also be used as an excellent predictive indicator for clinical response to ICI therapy.	[Bai, Shuheng; Yan, Yanli; Li, Rong; Wang, Xuan; Kang, Haojing; Feng, Zhaode; Li, Guangzu; Ren, Juan] Xi An Jiao Tong Univ, Dept Radiotherapy, Affiliated Hosp 1, Xi'an, Peoples R China; [Bai, Shuheng; Zhou, Yun; Zhou, Shuling] Xi An Jiao Tong Univ, Sch Med, Xi'an, Peoples R China; [Chen, Ling] Xi An Jiao Tong Univ, Dept Chemotherapy, Affiliated Hosp 1, Xi'an, Peoples R China; [Drokow, Emmanuel Kwateng] Zhengzhou Univ Peoples Hosp, Dept Radiat Oncol, Xi'an, Peoples R China; [Drokow, Emmanuel Kwateng] Henan Prov Peoples Hosp, Xi'an, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong University; Zhengzhou University	Ren, J (corresponding author), Xi An Jiao Tong Univ, Dept Radiotherapy, Affiliated Hosp 1, Xi'an, Peoples R China.	869491533@qq.com	ZHOU, SHULING/HGU-0907-2022		Scientific and Technological Research Foundation of Shaan'xi Province [2020JM-368]	Scientific and Technological Research Foundation of Shaan'xi Province	This manuscript is supported by the Scientific and Technological Research Foundation of Shaan'xi Province (Juan Ren, 2020JM-368).	Aruleba RT, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020386; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Casey SC, 2015, SEMIN CANCER BIOL, V35, pS199, DOI 10.1016/j.semcancer.2015.02.007; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chauhan VP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3516; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Collado B, 2006, MOL CELL ENDOCRINOL, V249, P116, DOI 10.1016/j.mce.2006.02.004; Cui CB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1233-9; Diop-Frimpong B, 2011, P NATL ACAD SCI USA, V108, P2909, DOI 10.1073/pnas.1018892108; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Garufi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048342; Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726; Gordon-Weeks A, 2020, CANCERS, V12, DOI 10.3390/cancers12113331; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hatfield SM, 2016, CURR OPIN PHARMACOL, V29, P90, DOI 10.1016/j.coph.2016.06.009; Hatfield SM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1260; He Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1002-1; Hsu TS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18731-y; Jacome AA, 2019, EXPERT OPIN BIOL TH, V19, P1247, DOI 10.1080/14712598.2019.1680636; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; Jung G, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113520; Kuppen PJK, 2001, HISTOCHEM CELL BIOL, V115, P67, DOI 10.1007/s004180000224; La Rocca G, 2004, IMMUNOL LETT, V95, P1, DOI 10.1016/j.imlet.2004.05.006; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mylonis I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030214; Noman MZ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091083; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; O'Neil BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189848; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pear WS, 2005, CANCER CELL, V8, P435, DOI 10.1016/j.ccr.2005.11.016; Picard E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00369; Qi LN, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03630-x; Qie S, 2012, CELL CYCLE, V11, P3679, DOI 10.4161/cc.21944; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shao CC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0869-y; Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395; Tang B, 2014, INT J ONCOL, V44, P1023, DOI 10.3892/ijo.2014.2276; Tolba MF, 2020, INT J CANCER, V147, P2996, DOI 10.1002/ijc.33056; Vaupel P, 2018, ADV EXP MED BIOL, V1072, P171, DOI 10.1007/978-3-319-91287-5_27; Wang YS, 2019, FASEB J, V33, P3901, DOI 10.1096/fj.201801099RR; Yan YY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0925-x; Yang G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218162; Yang YM, 2020, AGING-US, V12, P35, DOI 10.18632/aging.102228; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; You L, 2021, MED RES REV, V41, P1622, DOI 10.1002/med.21771; Zhang CX, 2019, ONCOTARGETS THER, V12, P1249, DOI 10.2147/OTT.S191609; Zhang YY, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.665364; Zhou JY, 2019, ARTIF CELL NANOMED B, V47, P2715, DOI 10.1080/21691401.2019.1635136	59	0	0	23	23	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								853352	10.3389/fimmu.2022.853352	http://dx.doi.org/10.3389/fimmu.2022.853352			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1FV	35711425	Green Published, gold			2022-12-18	WOS:000811302700001
J	Barbati, C; Celia, AI; Colasanti, T; Vomero, M; Speziali, M; Putro, E; Buoncuore, G; Savino, F; Colafrancesco, S; Ucci, FM; Ciancarella, C; Balbinot, E; Scarpa, S; Natalucci, F; Pellegrino, G; Ceccarelli, F; Spinelli, FR; Mastroianni, CM; Conti, F; Alessandri, C				Barbati, Cristiana; Celia, Alessandra Ida; Colasanti, Tania; Vomero, Marta; Speziali, Mariangela; Putro, Erisa; Buoncuore, Giorgia; Savino, Flavia; Colafrancesco, Serena; Ucci, Federica Maria; Ciancarella, Claudia; Balbinot, Eugenia; Scarpa, Susanna; Natalucci, Francesco; Pellegrino, Greta; Ceccarelli, Fulvia; Spinelli, Francesca Romana; Mastroianni, Claudio Maria; Conti, Fabrizio; Alessandri, Cristiano			Autophagy Hijacking in PBMC From COVID-19 Patients Results in Lymphopenia	FRONTIERS IN IMMUNOLOGY			English	Article						autophagy; apoptosis; inflammation; lymphocytes; SARS-CoV-2; COVID-19	CELL; APOPTOSIS	Autophagy is a homeostatic process responsible for the self-digestion of intracellular components and antimicrobial defense by inducing the degradation of pathogens into autophagolysosomes. Recent findings suggest an involvement of this process in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, the role of autophagy in the immunological mechanisms of coronavirus disease 2019 (COVID-19) pathogenesis remains largely unexplored. This study reveals the presence of autophagy defects in peripheral immune cells from COVID-19 patients. The impairment of the autophagy process resulted in a higher percentage of lymphocytes undergoing apoptosis in COVID-19 patients. Moreover, the inverse correlation between autophagy markers levels and peripheral lymphocyte counts in COVID-19 patients confirms how a defect in autophagy might contribute to lymphopenia, causing a reduction in the activation of viral defense. These results provided intriguing data that could help in understanding the cellular underlying mechanisms in COVID-19 infection, especially in severe forms.	[Barbati, Cristiana; Celia, Alessandra Ida; Colasanti, Tania; Speziali, Mariangela; Putro, Erisa; Buoncuore, Giorgia; Savino, Flavia; Colafrancesco, Serena; Ucci, Federica Maria; Ciancarella, Claudia; Balbinot, Eugenia; Natalucci, Francesco; Pellegrino, Greta; Ceccarelli, Fulvia; Spinelli, Francesca Romana; Conti, Fabrizio; Alessandri, Cristiano] Sapienza Univ Rome, Arthrit Ctr, Dipartimento Sci Clin Internist Anestesiol & Cardi, Rome, Italy; [Vomero, Marta] Univ Campus Biomed Roma, Dept Med, Immunol & Clin Med Unit, Rheumatol, Rome, Italy; [Scarpa, Susanna] Sapienza Univ, Dept Expt Med, Rome, Italy; [Mastroianni, Claudio Maria] Sapienza Univ, Dept Publ Hlth & Infect Dis, Rome, Italy	Sapienza University Rome; University Campus Bio-Medico - Rome Italy; Sapienza University Rome; Sapienza University Rome	Barbati, C (corresponding author), Sapienza Univ Rome, Arthrit Ctr, Dipartimento Sci Clin Internist Anestesiol & Cardi, Rome, Italy.	cristiana.barbati1@gmail.com	Putro, ERISA/GLS-1277-2022; Celia, Alessandra Ida/GQH-0075-2022	Putro, ERISA/0000-0002-3552-9743; 				Alessandri C, 2012, FASEB J, V26, P4722, DOI 10.1096/fj.12-206060; Barbati C, 2021, CLIN EXP RHEUMATOL, V39, P606, DOI 10.55563/clinexprheumatol/uiqdtq; Chakraborty I, 2020, SCI TOTAL ENVIRON, V728, DOI 10.1016/j.scitotenv.2020.138882; Cui B, 2019, ADV EXP MED BIOL, V1206, P595, DOI 10.1007/978-981-15-0602-4_27; Fathi N, 2020, CELL BIOL INT, V44, P1792, DOI 10.1002/cbin.11403; Hasichaolu, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7570981; Kliosnky D, 2016, AUTOPHAGY, V12, P443, DOI 10.1080/15548627.2016.1147886; Liao YC, 2002, J IMMUNOL, V169, P4288, DOI 10.4049/jimmunol.169.8.4288; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421; Puleston DJ, 2014, IMMUNOLOGY, V141, P1, DOI 10.1111/imm.12165; Shojaei S, 2020, VIRULENCE, V11, P805, DOI 10.1080/21505594.2020.1780088; Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735; Tan L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0148-4; Vomero M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.569849; Wang FJ, 2017, CELLS-BASEL, V6, DOI 10.3390/cells6030016; Yang L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00679-0; Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]; Zaboli E, 2021, J MED VIROL, V93, P5425, DOI 10.1002/jmv.27060	20	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								903498	10.3389/fimmu.2022.903498	http://dx.doi.org/10.3389/fimmu.2022.903498			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1EX	35711451	gold, Green Published			2022-12-18	WOS:000811300200001
J	Canto-Gomes, J; Silva, CS; Rb-Silva, R; Boleixa, D; da Silva, AM; Cheynier, R; Costa, P; Gonzalez-Suarez, I; Correia-Neves, M; Cerqueira, JJ; Nobrega, C				Canto-Gomes, Joao; Silva, Carolina S.; Rb-Silva, Rita; Boleixa, Daniela; da Silva, Ana Martins; Cheynier, Remi; Costa, Patricio; Gonzalez-Suarez, Ines; Correia-Neves, Margarida; Cerqueira, Joao J.; Nobrega, Claudia			Low Memory T Cells Blood Counts and High Naive Regulatory T Cells Percentage at Relapsing Remitting Multiple Sclerosis Diagnosis	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; T cells; regulatory T cell (Treg); newly diagnosed; NK cell; treatment-naive patients	MYELIN PROTEOLIPID PROTEIN; CYTOKINE RESPONSES; EFFECTOR MEMORY; HOMEOSTASIS; SUBSETS; PROGRESSION; FREQUENCY; PEPTIDES; LESIONS; DRIVEN	ObjectiveThe aim of this study is to assess the peripheral immune system of newly diagnosed patients with relapsing remitting multiple sclerosis (RRMS) and compare it to healthy controls (HC). MethodsThis cross-sectional study involves 30 treatment-naive newly diagnosed patients with RRMS and 33 sex- and age-matched HC. Peripheral blood mononuclear cells were analyzed regarding: i) thymic function surrogates [T cell receptor excision circles (TRECs) and recent thymic emigrants (RTEs)]; ii) naive and memory CD4(+) and CD8(+) T cells subsets; iii) T helper (Th) phenotype and chemokine receptors expression on CD8(+) T cells subsets; iv) regulatory T cell (Tregs) phenotype; and exclude expression of activating/inhibitory receptors by natural killer (NK) and NKT cells. Analyses were controlled for age, sex, and human cytomegalovirus (HCMV) IgG seroprevalence. ResultsNewly diagnosed patients with RRMS and HC have equivalent thymic function as determined by similar numbers of RTEs and levels of sjTRECs, DJ beta TRECs, and sj/DJ beta TREC ratio. In the CD8(+) T cells compartment, patients with RRMS have a higher naive to memory ratio and lower memory cell counts in blood, specifically of effector memory and TemRA CD8(+) T cells. Interestingly, higher numbers and percentages of central memory CD8(+) T cells are associated with increasing time from the relapse. Among CD4(+) T cells, lower blood counts of effector memory cells are found in patients upon controlling for sex, age, and anti-HCMV IgG seroprevalence. Higher numbers of CD4(+) T cells (both naive and memory) and of Th2 cells are associated with increasing time from the relapse; lower numbers of Th17 cells are associated with higher MS severity scores (MSSS). Patients with RRMS have a higher percentage of naive Tregs compared with HC, and lower percentages of these cells are associated with higher MSSS. Percentages of immature CD56(bright) NK cells expressing the inhibitory receptor KLRG1 and of mature CD56(dim)CD57(+) NK cells expressing NKp30 are higher in patients. No major alterations are observed on NKT cells. ConclusionCharacterization of the peripheral immune system of treatment-naive newly diagnosed patients with RRMS unveiled immune features present at clinical onset including lower memory T cells blood counts, particularly among CD8(+) T cells, higher percentage of naive Tregs and altered percentages of NK cells subsets expressing inhibitory or activating receptors. These findings might set the basis to better understand disease pathogenesis.	[Canto-Gomes, Joao; Silva, Carolina S.; Costa, Patricio; Correia-Neves, Margarida; Cerqueira, Joao J.; Nobrega, Claudia] Univ Minho, Life & Hlth Sci Res Inst, Sch Med, Braga, Portugal; [Canto-Gomes, Joao; Silva, Carolina S.; Costa, Patricio; Correia-Neves, Margarida; Cerqueira, Joao J.; Nobrega, Claudia] PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal; [Silva, Carolina S.; Correia-Neves, Margarida] Karolinska Inst, Dept Med Solna, Div Infect Dis, Stockholm, Sweden; [Silva, Carolina S.] Karolinska Univ Hosp, Dept Infect Dis, Stockholm, Sweden; [Rb-Silva, Rita] Portuguese Inst Oncol Porto, Dept Onco Hematol, Porto, Portugal; [Rb-Silva, Rita] Univ Porto, Dept Microscopy, Lab Histol & Embryol, ICBAS, Porto, Portugal; [Boleixa, Daniela; da Silva, Ana Martins] Univ Porto, Hosp Ctr, Porto, Portugal; [da Silva, Ana Martins] Univ Porto, Multidisciplinary Unit Biomed Res UMIB, Inst Ciencias Biomed Abel Salazar ICBAS, Porto, Portugal; [Cheynier, Remi] Univ Paris Cite, Inst Cochin, CNRS, INSERM, Paris, France; [Gonzalez-Suarez, Ines] Univ Hosp Complex Vigo, Ctr Mol Med, Dept Med Solna, Vigo, Spain; [Gonzalez-Suarez, Ines] Alvaro Cunqueiro Hosp, Vigo, Spain; [Cerqueira, Joao J.] Hosp Braga, Braga, Portugal; [Cerqueira, Joao J.] Hosp Braga, Clin Acad Ctr, Braga, Portugal	Universidade do Minho; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Universidade de Coimbra; Universidade do Porto; Universidade do Porto; Universidade do Porto; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Hospital de Braga; Hospital de Braga	Nobrega, C (corresponding author), Univ Minho, Life & Hlth Sci Res Inst, Sch Med, Braga, Portugal.; Nobrega, C (corresponding author), PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal.	claudianobrega@med.uminho.pt	Cerqueira, Joao J/B-4579-2008; Costa, Patricio/A-3072-2013	Cerqueira, Joao J/0000-0003-3155-2775; Costa, Patricio/0000-0002-1201-9177; Nobrega, Claudia/0000-0002-0282-9619	Health Sciences Research Institute (ICVS), University of Minho - Academic Clinical Centre of Hospital of Braga; Academic Clinical Centre of Hospital of Braga; National funds, through the Foundation for Science and Technology (FCT) [UIDB/50026/2020, UIDP/50026/2020, NORTE-01-0145-FEDER-000039]; Norte Portugal Regional Operational Programme (NORTE 2020) through European Regional Development Fund (ERDF); FCT [PD/BD/137433/2018]	Health Sciences Research Institute (ICVS), University of Minho - Academic Clinical Centre of Hospital of Braga; Academic Clinical Centre of Hospital of Braga; National funds, through the Foundation for Science and Technology (FCT)(Portuguese Foundation for Science and Technology); Norte Portugal Regional Operational Programme (NORTE 2020) through European Regional Development Fund (ERDF); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	The work presented was performed at Life and Health Sciences Research Institute (ICVS), University of Minho. This work has been funded by a research grant from the Academic Clinical Centre of Hospital of Braga and by National funds, through the Foundation for Science and Technology (FCT) - project UIDB/50026/2020 and UIDP/50026/2020 and by the project NORTE-01-0145-FEDER-000039, supported by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). JC-G is supported by an FCT PhD grant, in the context of the Doctoral Program in Aging and Chronic Diseases (PD/BD/137433/2018). CS is supported by an FCT PhD grant, in the context of the Doctoral Program in Applied Health Sciences (PD/BDE/142976/2018). CN is a junior researcher under the scope of the FCT Transitional Rule DL57/2016. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Babbe H, 2000, J EXP MED, V192, P393, DOI 10.1084/jem.192.3.393; Baecher-Allan C, 2006, J IMMUNOL, V176, P4622, DOI 10.4049/jimmunol.176.8.4622; Balint B, 2013, NEUROLOGY, V81, P784, DOI 10.1212/WNL.0b013e3182a2ce0e; Bjerg L, 2012, J NEUROIMMUNOL, V249, P76, DOI 10.1016/j.jneuroim.2012.04.012; Brodin P, 2015, CELL, V160, P37, DOI 10.1016/j.cell.2014.12.020; Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889; Chiarini M, 2015, MULT SCLER J, V21, P726, DOI 10.1177/1352458514551456; Ciccocioppo F, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45433-3; Cohen J., 1988, STAT POWER ANAL BEHA; Constantinescu CS, 2011, BRIT J PHARMACOL, V164, P1079, DOI 10.1111/j.1476-5381.2011.01302.x; Cooper MA, 2001, TRENDS IMMUNOL, V22, P633, DOI 10.1016/S1471-4906(01)02060-9; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Dion Marie-Lise, 2007, Methods Mol Biol, V380, P197; Duszczyszyn DA, 2006, CLIN EXP IMMUNOL, V143, P305, DOI 10.1111/j.1365-2249.2005.02990.x; Duszczyszyn DA, 2010, J NEUROIMMUNOL, V221, P73, DOI 10.1016/j.jneuroim.2010.02.005; Gately CM, 2013, J NEUROIMMUNOL, V259, P1, DOI 10.1016/j.jneuroim.2013.02.020; Gerdes LA, 2020, P NATL ACAD SCI USA, V117, P21546, DOI 10.1073/pnas.2003339117; Giefing-Kroll C, 2015, AGING CELL, V14, P309, DOI 10.1111/acel.12326; Gilli F, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00616; Goverman J, 2009, NAT REV IMMUNOL, V9, P393, DOI 10.1038/nri2550; Greer JM, 2004, J AUTOIMMUN, V22, P345, DOI 10.1016/j.jaut.2004.03.004; Greer JM, 1997, BRAIN, V120, P1447, DOI 10.1093/brain/120.8.1447; Haas J, 2007, J IMMUNOL, V179, P1322, DOI 10.4049/jimmunol.179.2.1322; Haegert DG, 2011, J NEUROIMMUNOL, V233, P233, DOI 10.1016/j.jneuroim.2010.12.007; Hochmeister S, 2012, EXP NEUROL, V237, P70, DOI 10.1016/j.expneurol.2012.06.010; Hug A, 2003, J IMMUNOL, V171, P432, DOI 10.4049/jimmunol.171.1.432; Kaufmann M, 2021, MED-CAMBRIDGE, V2, P296, DOI 10.1016/j.medj.2021.01.006; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Knochelmann HM, 2018, CELL MOL IMMUNOL, V15, P458, DOI 10.1038/s41423-018-0004-4; Laroni A, 2016, J AUTOIMMUN, V72, P8, DOI 10.1016/j.jaut.2016.04.003; Marques P, 2016, HUM BRAIN MAPP, V37, P3310, DOI 10.1002/hbm.23242; Marquez EJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14396-9; Moldovan IR, 2008, J NEUROIMMUNOL, V193, P161, DOI 10.1016/j.jneuroim.2007.10.010; Morandi B, 2008, PHARMACOL RES, V57, P1, DOI 10.1016/j.phrs.2007.11.003; Ngono AE, 2012, CLIN IMMUNOL, V144, P117, DOI 10.1016/j.clim.2012.05.009; Nikolich-Zugich J, 2008, NAT REV IMMUNOL, V8, P512, DOI 10.1038/nri2318; Pallmer K, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00251; Patin E, 2018, NAT IMMUNOL, V19, P302, DOI 10.1038/s41590-018-0049-7; Pelfrey CM, 2002, J NEUROIMMUNOL, V130, P211, DOI 10.1016/S0165-5728(02)00224-2; Pender MP, 2014, MULT SCLER J, V20, P1825, DOI 10.1177/1352458514536252; Pender MP, 2012, AUTOIMMUN DIS, V2012, DOI 10.1155/2012/189096; Puissant-Lubrano B, 2008, J NEUROIMMUNOL, V193, P188, DOI 10.1016/j.jneuroim.2007.10.027; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Saule P, 2006, MECH AGEING DEV, V127, P274, DOI 10.1016/j.mad.2005.11.001; Schneider-Hohendorf T, 2010, EUR J IMMUNOL, V40, P3581, DOI 10.1002/eji.201040558; Schweitzer F, 2021, J NEUROL, V268, P2379, DOI 10.1007/s00415-019-09690-6; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Tabachnick B. G., 2006, USING MULTIVARIATE S; Tapia-Maltos MA, 2021, MULT SCLER J, V27, P1695, DOI 10.1177/1352458520977045; Teniente-Serra A, 2016, AUTOIMMUNITY, V49, P219, DOI 10.3109/08916934.2016.1138271; Thewissen M, 2005, ANN NY ACAD SCI, V1051, P255, DOI 10.1196/annals.1361.066; Venken K, 2008, J IMMUNOL, V180, P6411, DOI 10.4049/jimmunol.180.9.6411; Verma ND, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88448-5; Wingender G, 2015, CYTOM PART A, V87A, P1067, DOI 10.1002/cyto.a.22788	54	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								901165	10.3389/fimmu.2022.901165	http://dx.doi.org/10.3389/fimmu.2022.901165			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1EN	35711452	Green Submitted, Green Published, gold			2022-12-18	WOS:000811299100001
J	Garcia-Leon, MJ; Mosquera, M; Cela, C; Alcain, J; Zuklys, S; Hollander, G; Toribio, ML				Garcia-Leon, Maria Jesus; Mosquera, Marta; Cela, Carmela; Alcain, Juan; Zuklys, Saulius; Hollander, Georg; Toribio, Maria L.			Abrogation of Notch Signaling in Embryonic TECs Impacts Postnatal mTEC Homeostasis and Thymic Involution	FRONTIERS IN IMMUNOLOGY			English	Article						thymus; notch; thymic epithelial cells; premature degeneration; thymic involution	DELTA-LIKE 4; STEM-CELLS; MEDULLARY; PROGENITOR; EXPRESSION; ACTIVATION; SELECTION; BIPOTENT; REVEALS; LIGAND	Notch signaling is crucial for fate specification and maturation of thymus-seeding progenitors along the T-cell lineage. Recent studies have extended the role of Notch signaling to thymic epithelial cells (TECs), showing that Notch regulates TEC progenitor maintenance and emergence of medullary TECs (mTECs) in fetal thymopoiesis. Based on immunohistochemistry studies of spatiotemporal regulation of Notch activation in the postnatal thymus, we show that in vivo Notch activation is not confined to fetal TECs. Rather, Notch signaling, likely mediated through the Notch1 receptor, is induced in postnatal cortical and medullary TECs, and increases significantly with age in the latter, in both humans and mice, suggesting a conserved role for Notch signaling in TEC homeostasis during thymus aging. To investigate the functional impact of Notch activation in postnatal TEC biology, we used a mouse model in which RPBJ kappa, the transcriptional effector of canonical Notch signaling, is deleted in epithelial cells, including TECs, under the control of the transcription factor Foxn1. Immunohistochemistry and flow cytometry analyses revealed no significant differences in TEC composition in mutant (RPBJ kappa-KOTEC) and wild-type (WT) littermate mice at early postnatal ages. However, a significant reduction of the medullary region was observed in mutant compared to WT older thymi, which was accompanied by an accelerated decrease of postnatal mTEC numbers. Also, we found that organization and integrity of the postnatal thymic medulla critically depends on activation of the canonical Notch signaling pathway, as abrogation of Notch signaling in TECs led to the disruption of the medullary thymic microenvironment and to an accelerated thymus atrophy. These features paralleled a significant increase in the proportion of intrathymic non-T lineage cells, mostly B cells, and a slight decrease of DP thymocyte numbers compatible with a compromised thymic function in mutant mice. Therefore, impaired Notch signaling induced in embryonic development impacts postnatal TECs and leads to an accelerated mTEC degeneration and a premature thymus involution. Collectively, our data have uncovered a new role for Notch1 signaling in the control of adult mTEC homeostasis, and point toward Notch signaling manipulation as a novel strategy for thymus regeneration and functional recovery from immunosenescence.	[Garcia-Leon, Maria Jesus; Mosquera, Marta; Cela, Carmela; Alcain, Juan; Toribio, Maria L.] Univ Autonoma Madrid UAM, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient CSIC, Immune Syst Dev & Funct Unit, Madrid, Spain; [Zuklys, Saulius; Hollander, Georg] Univ Basel, Univ Childrens Hosp Basel, Basel, Switzerland; [Hollander, Georg] Univ Oxford, Weatherall Inst Mol Med, Oxford, Oxfordshire, England; [Hollander, Georg] Univ Oxford, Dept Paediat, Oxford, Oxfordshire, England; [Zuklys, Saulius; Hollander, Georg] Univ Basel, Dept Biomed, Basel, Switzerland	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); University of Basel; University of Oxford; University of Oxford; University of Basel	Toribio, ML (corresponding author), Univ Autonoma Madrid UAM, Ctr Biol Mol Severo Ochoa, Consejo Super Invest Cient CSIC, Immune Syst Dev & Funct Unit, Madrid, Spain.	mtoribio@cbm.csic.es		Hollander, Georg/0000-0002-8790-0874	European Union Seventh Framework Programme (FP7/2007-2013) collaborative project ThymiStem [602587]; Spanish Ministry of Science and Innovation. (Agencia Estatal de Investigacion/European Regional Development Fund, European Union) [SAF2014-62233-EXP, SAF2016-75442-R, PID2019-105623RB-I00]; Fundacion Ramon Areces and Banco de Santander	European Union Seventh Framework Programme (FP7/2007-2013) collaborative project ThymiStem; Spanish Ministry of Science and Innovation. (Agencia Estatal de Investigacion/European Regional Development Fund, European Union); Fundacion Ramon Areces and Banco de Santander	This work has been supported by the European Union Seventh Framework Programme (FP7/2007-2013) collaborative project ThymiStem (602587 to MLT) and by Spanish Ministry of Science and Innovation. (Agencia Estatal de Investigacion/European Regional Development Fund, European Union, SAF2014-62233-EXP, SAF2016-75442-R and PID2019-105623RB-I00 to MLT). Institutional grants from the Fundacion Ramon Areces and Banco de Santander to the Centro de Biologia Molecular Severo Ochoa are also acknowledged.	Abramson J, 2017, ANNU REV IMMUNOL, V35, P85, DOI 10.1146/annurev-immunol-051116-052320; Alves NL, 2014, EUR J IMMUNOL, V44, P16, DOI 10.1002/eji.201344110; Anderson G, 2012, TRENDS IMMUNOL, V33, P256, DOI 10.1016/j.it.2012.03.005; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baik S, 2013, EUR J IMMUNOL, V43, P589, DOI 10.1002/eji.201243209; Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850; Bennett AR, 2002, IMMUNITY, V16, P803, DOI 10.1016/S1074-7613(02)00321-7; Bleul CC, 2005, J IMMUNOL, V175, P5213, DOI 10.4049/jimmunol.175.8.5213; Bleul CC, 2006, NATURE, V441, P992, DOI 10.1038/nature04850; Boehm T, 2013, NAT REV IMMUNOL, V13, P831, DOI 10.1038/nri3534; Chen LZ, 2009, BLOOD, V113, P567, DOI 10.1182/blood-2008-05-156265; Cheng LL, 2010, J BIOL CHEM, V285, P5836, DOI 10.1074/jbc.M109.072124; Ciofani M, 2007, ANNU REV CELL DEV BI, V23, P463, DOI 10.1146/annurev.cellbio.23.090506.123547; Cowan JE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00897; Cowan JE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13465-y; Demehri S, 2009, DEVELOPMENT, V136, P891, DOI 10.1242/dev.030700; Desanti GE, 2012, J IMMUNOL, V189, P5519, DOI 10.4049/jimmunol.1201815; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Garcia-Leon MJ, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.165597; Gill J, 2002, NAT IMMUNOL, V3, P635, DOI 10.1038/ni812; Goldfarb Y, 2016, CELL REP, V15, P651, DOI 10.1016/j.celrep.2016.03.048; Gordon J, 2004, NAT IMMUNOL, V5, P546, DOI 10.1038/ni1064; Gray DHD, 2006, BLOOD, V108, P3777, DOI 10.1182/blood-2006-02-004531; Hamazaki Y, 2007, NAT IMMUNOL, V8, P304, DOI 10.1038/ni1438; Han H, 2002, INT IMMUNOL, V14, P637, DOI 10.1093/intimm/dxf030; Hozumi K, 2008, J EXP MED, V205, P2507, DOI 10.1084/jem.20080134; Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046; Johnson SJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10607; Kadouri N, 2020, NAT REV IMMUNOL, V20, P239, DOI 10.1038/s41577-019-0238-0; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Li CH, 1998, PATTERN RECOGN LETT, V19, P771, DOI 10.1016/S0167-8655(98)00057-9; Li J, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.178988; Liu D, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.178582; Mackall CL, 1998, EUR J IMMUNOL, V28, P1886, DOI 10.1002/(SICI)1521-4141(199806)28:06<1886::AID-IMMU1886>3.0.CO;2-M; Manley NR, 2011, FRONT BIOSCI-LANDMRK, V16, P2461, DOI 10.2741/3866; Martin-Gayo E, 2017, J EXP MED, V214, P3361, DOI 10.1084/jem.20161564; Masuda K, 2009, MOL IMMUNOL, V46, P1756, DOI 10.1016/j.molimm.2009.01.015; MILLER JF, 1961, LANCET, V2, P748; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Ohigashi I, 2015, CELL REP, V13, P1432, DOI 10.1016/j.celrep.2015.10.012; Ohigashi I, 2013, P NATL ACAD SCI USA, V110, P9885, DOI 10.1073/pnas.1301799110; OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076; Petrie HT, 2007, ANNU REV IMMUNOL, V25, P649, DOI 10.1146/annurev.immunol.23.021704.115715; Provinciali M, 1998, CYTOMETRY, V32, P1; Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074-7613(00)80105-3; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; RITTER MA, 1993, IMMUNOL TODAY, V14, P462, DOI 10.1016/0167-5699(93)90250-O; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Rode I, 2015, J IMMUNOL, V195, P5678, DOI 10.4049/jimmunol.1502010; Rossi SW, 2006, NATURE, V441, P988, DOI 10.1038/nature04813; Schmitt TM, 2004, J EXP MED, V200, P469, DOI 10.1084/jem.20040394; Shanley DP, 2009, TRENDS IMMUNOL, V30, P374, DOI 10.1016/j.it.2009.05.001; Su DM, 2003, NAT IMMUNOL, V4, P1128, DOI 10.1038/ni983; Ucar A, 2014, IMMUNITY, V41, P257, DOI 10.1016/j.immuni.2014.07.005; Ulyanchenko S, 2016, CELL REP, V14, P2819, DOI 10.1016/j.celrep.2016.02.080; Van de Walle I, 2009, BLOOD, V113, P2988, DOI 10.1182/blood-2008-06-164871; VANEWIJK W, 1994, IMMUNOL TODAY, V15, P214, DOI 10.1016/0167-5699(94)90246-1; Venables T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11879-2; Wong K, 2014, CELL REP, V8, P1198, DOI 10.1016/j.celrep.2014.07.029; Zuklys S, 2009, J IMMUNOL, V182, P2997, DOI 10.4049/jimmunol.0713723	62	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								867302	10.3389/fimmu.2022.867302	http://dx.doi.org/10.3389/fimmu.2022.867302			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B5AF	35707539	Green Published, gold			2022-12-18	WOS:000810200000001
J	He, XQ; Liu, YF; Wang, HY; Sun, W; Lu, YH; Shan, ZY; Teng, WP; Li, J				He, Xiaoqing; Liu, Yifu; Wang, Haoyu; Sun, Wei; Lu, Yihan; Shan, Zhongyan; Teng, Weiping; Li, Jing			A Predictive Role of Autoantibodies Against the Epitope aa168-183 of ENO1 in the Occurrence of Miscarriage Related to Thyroid Autoimmunity	FRONTIERS IN IMMUNOLOGY			English	Article						alpha-enolase; autoantibodies; epitope; miscarriage; thyroid autoimmunity	RECURRENT PREGNANCY LOSS; ALPHA-ENOLASE; 1ST TRIMESTER; POSTPARTUM PERIOD; WOMEN; ANTIBODIES; RISK; OUTCOMES; DISEASE; LEVOTHYROXINE	Objective: The aim of the research is to study the association between the serum levels of autoantibodies against one important epitope ((168)FMILPVGAANFREAMR(183), designated as P6) of alpha-enolase (ENO1-P6Abs) and miscarriage among euthyroid females with thyroid autoimmunity (TAI). Methods: Anti-ENO1-P6 total IgG was investigated in 432 euthyroid women, and its four subclasses were analyzed in 184 euthyroid women. The serum FT4, TSH, TgAb, and TPOAb levels were determined using an electrochemiluminescence immunoassay. The serum ENO1-P6Ab and anti-protein disulfide isomerase A3 autoantibody (PDIA3Ab) levels were determined using an enzyme-linked immunosorbent assay. Results: The serum levels of anti-ENO1-P6 total IgG, IgG2, IgG3, and IgG4 were significantly higher in euthyroid TAI females than in non-TAI controls. Additionally, anti-ENO1-P6 total IgG and its 4 subtypes were all markedly higher in euthyroid TAI females with pregnancy loss than those without miscarriage. Moreover, logistic regression analysis showed that highly expressed anti-ENO1-P6 total IgG, IgG1, IgG2, and IgG3 subtypes in the serum were all independent risk factors for euthyroid TAI-related miscarriage, and its IgG1 was also for non-TAI-related abortion. According to the trend test, the prevalence of miscarriage was increased in a titer-dependent manner with the raised levels of serum anti-ENO1-P6 total IgG and IgG1, IgG2, and IgG3 subtypes among euthyroid TAI females. The receiver operating characteristic curve analysis of anti-ENO1-P6 total IgG and IgG1, IgG2, and IgG3 subclass expressions in the serum for miscarriage prediction in euthyroid TAI females exhibited that the total areas under the curves were 0.773 +/- 0.041, 0.761 +/- 0.053, 0.827 +/- 0.043, and 0.760 & PLUSMN; 0.050, respectively (all P < 0.0001). Their corresponding optimal cut-off OD450 values were 0.68 (total IgG), 0.26 (IgG1), 0.97 (IgG2), and 0.48 (IgG3), with sensitivities of 70.8, 87.5, 83.3, and 85.4%, and specificities of 70.8, 59.1, 77.3, and 56.8%, respectively. There was an additive interaction between serum anti-ENO1-P6 and anti-PDIA3 total IgGs on the development of miscarriage (RERI = 23.6, AP = 0.79, SI = 5.37). Conclusion: The highly expressed ENO1-P6Abs may be important risk factors for euthyroid TAI-related miscarriage. The serum levels of ENO1-P6Abs may become good predictive markers for pregnancy loss in euthyroid TAI females, especially its IgG2 subclass expression.	[He, Xiaoqing; Liu, Yifu; Wang, Haoyu; Sun, Wei; Lu, Yihan; Shan, Zhongyan; Teng, Weiping; Li, Jing] China Med Univ, First Affiliated Hosp, Inst Endocrinol, NHC Key Lab Diag & Treatment Thyroid Dis,Dept Endo, Shenyang, Peoples R China	China Medical University	Li, J (corresponding author), China Med Univ, First Affiliated Hosp, Inst Endocrinol, NHC Key Lab Diag & Treatment Thyroid Dis,Dept Endo, Shenyang, Peoples R China.	jli23@cmu.edu.cn			National Nature Science Foundation of China [81771741, 81570709]; Distinguished Professor at Educational Department of Liaoning Province [[2014]187]; National Science and Technology Support Program [2014BA106B02]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Distinguished Professor at Educational Department of Liaoning Province; National Science and Technology Support Program	Funding This work was supported by the National Nature Science Foundation of China (grant numbers 81771741 and 81570709), the Distinguished Professor at Educational Department of Liaoning Province (grant number No. [2014]187), and the National Science and Technology Support Program (grant number 2014BA106B02).	Adamus G, 1998, J AUTOIMMUN, V11, P671, DOI 10.1006/jaut.1998.0239; Ander SE, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aat6114; Ashoor G, 2010, THYROID, V20, P989, DOI 10.1089/thy.2010.0058; Bagis T, 2001, THYROID, V11, P1049, DOI 10.1089/105072501753271743; Breymann C, 2011, J PERINAT MED, V39, P113, DOI [10.1515/JPM.2010.132, 10.1515/jpm.2010.132]; Bruschi M, 2014, J AM SOC NEPHROL, V25, P2483, DOI 10.1681/ASN.2013090987; Burton GJ, 2017, PLACENTA, V56, P14, DOI 10.1016/j.placenta.2017.01.130; Cappello P, 2017, FRONT BIOSCI-LANDMRK, V22, P944, DOI 10.2741/4526; Cappello P, 2013, GASTROENTEROLOGY, V144, P1098, DOI 10.1053/j.gastro.2013.01.020; Caucheteux SM, 2003, IMMUNITY, V18, P169, DOI 10.1016/S1074-7613(03)00028-1; Cavalcante MB, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13215; Cellini M, 2020, THYROID, V30, P457, DOI 10.1089/thy.2019.0456; De Carolis C, 2004, AM J REPROD IMMUNOL, V52, P263, DOI 10.1111/j.1600-0897.2004.00215.x; Dhillon-Smith RK, 2019, NEW ENGL J MED, V380, P1316, DOI 10.1056/NEJMoa1812537; Diaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795; Effraimidis G, 2014, EUR J ENDOCRINOL, V170, pR241, DOI 10.1530/EJE-14-0047; Frohlich E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00521; Fujii A, 2005, J NEUROIMMUNOL, V162, P130, DOI 10.1016/j.jneuroim.2005.02.004; Gerstner C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00494; Gharesi-Fard B, 2014, J REPROD DEVELOP, V60, P261, DOI 10.1262/jrd.2013-096; Girardi G, 2006, MOL IMMUNOL, V43, P68, DOI 10.1016/j.molimm.2005.06.017; Gong X, 2019, J ENDOCRINOL INVEST, V42, P599, DOI 10.1007/s40618-018-0960-7; Grossmann M, 2013, REPROD BIOL ENDOCRIN, V11, DOI 10.1186/1477-7827-11-40; Guo Ya-Ping, 2014, Curr Ther Res Clin Exp, V76, P116, DOI 10.1016/j.curtheres.2014.06.004; Hou YY, 2019, THYROID, V29, P577, DOI 10.1089/thy.2018.0097; Hu ZG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163682; Iijima T, 1997, OBSTET GYNECOL, V90, P364, DOI 10.1016/S0029-7844(97)00283-4; Kim NY, 2011, AM J REPROD IMMUNOL, V65, P78, DOI 10.1111/j.1600-0897.2010.00911.x; KOTANI T, 1995, AUTOIMMUNITY, V20, P231, DOI 10.3109/08916939508995700; Lefranc D, 2004, J IMMUNOL, V172, P669, DOI 10.4049/jimmunol.172.1.669; Li CY, 2016, J CLIN ENDOCR METAB, V101, P1290, DOI 10.1210/jc.2015-3519; Li CY, 2014, J CLIN ENDOCR METAB, V99, P73, DOI 10.1210/jc.2013-1674; Li JS, 2019, ENDOCR CONNECT, V8, P1288, DOI 10.1530/EC-19-0316; Li YH, 2018, AUST J GEN PRACT, V47, P432, DOI 10.31128/AJGP-01-18-4459; Li YZ, 2020, THYROID, V30, P568, DOI 10.1089/thy.2019.0067; Lin CM, 2016, MINERVA MED, V107, P173; Liu HX, 2014, THYROID, V24, P1642, DOI 10.1089/thy.2014.0029; Liu S, 2020, J REPROD IMMUNOL, V139, DOI 10.1016/j.jri.2020.103118; Liu Y, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.670019; Lu YH, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106563; McLachlan SM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01845; Negro R, 2005, HUM REPROD, V20, P1529, DOI 10.1093/humrep/deh843; Pancholi V, 2001, CELL MOL LIFE SCI, V58, P902, DOI 10.1007/PL00000910; Poppe K, 2008, NAT CLIN PRACT ENDOC, V4, P394, DOI 10.1038/ncpendmet0846; Prado Leandro L, 2018, Clin Exp Rheumatol, V36, P28; Pratesi F, 2000, J RHEUMATOL, V27, P109; Pringle KG, 2010, HUM REPROD UPDATE, V16, P415, DOI 10.1093/humupd/dmp046; REISS NA, 1988, NEUROSCI LETT, V84, P197, DOI 10.1016/0304-3940(88)90407-7; Roberts J, 1996, EUR J ENDOCRINOL, V134, P84, DOI 10.1530/eje.0.1340084; Rodrigues VD, 2019, REV BRAS GINECOL OBS, V41, P621, DOI 10.1055/s-0039-1697982; Sarapik A, 2010, AM J REPROD IMMUNOL, V63, P349, DOI 10.1111/j.1600-0897.2010.00808.x; Seki SM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01549; Shoenfeld Y, 2004, LUPUS, V13, P643, DOI 10.1191/0961203304lu2009oa; Stagnaro-Green A, 2011, THYROID, V21, P1081, DOI 10.1089/thy.2011.0087; STAGNAROGREEN A, 1990, JAMA-J AM MED ASSOC, V264, P1422, DOI 10.1001/jama.264.11.1422; Stevenson M, 2022, EPIR TOOLS ANAL EPID; Sundblad V, 2006, CLIN ENDOCRINOL, V65, P745, DOI 10.1111/j.1365-2265.2006.02661.x; Terrier B, 2007, AUTOIMMUN REV, V6, P176, DOI 10.1016/j.autrev.2006.10.004; Thangaratinam S, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2616; Toulis KA, 2010, EUR J ENDOCRINOL, V162, P643, DOI 10.1530/EJE-09-0850; Twig G, 2012, J AUTOIMMUN, V38, pJ275, DOI 10.1016/j.jaut.2011.11.014; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Walter M, 1995, J AUTOIMMUN, V8, P931, DOI 10.1016/S0896-8411(95)80027-1; Wang JW, 2021, J TRANSL INTERN MED, V9, P76, DOI 10.2478/jtim-2021-0001; Wang X, 2020, FERTIL STERIL, V114, P1306, DOI 10.1016/j.fertnstert.2020.06.034; WHO/UNICEF/ICCIDD, 2007, ASS IOD DEF DIS MON; Yang WQ, 2020, CLIN IMMUNOL, V212, P67, DOI 10.1016/j.clim.2020.108350; Yang Z, 2022, INT IMMUNOPHARMACOL, V104, DOI 10.1016/j.intimp.2021.108507; Ye Y, 2019, EBIOMEDICINE, V41, P610, DOI 10.1016/j.ebiom.2019.02.027; Yuan N, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03176-4; Zeng LT, 2020, J ETHNOPHARMACOL, V263, DOI 10.1016/j.jep.2020.113156; Zhang XM, 2016, THYROID, V26, P1786, DOI 10.1089/thy.2016.0002; Zhang Y, 2020, J CLIN ENDOCR METAB, V105, pE368, DOI 10.1210/clinem/dgz167	73	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								890502	10.3389/fimmu.2022.890502	http://dx.doi.org/10.3389/fimmu.2022.890502			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B5DN	35707546	gold, Green Published			2022-12-18	WOS:000810208800001
J	Hua, H; Meydan, C; Afshin, EE; Lili, LN; D'Adamo, CR; Rickard, N; Dudley, JT; Price, ND; Zhang, BD; Mason, CE				Hua, Hui; Meydan, Cem; Afshin, Evan E.; Lili, Loukia N.; D'Adamo, Christopher R.; Rickard, Nate; Dudley, Joel T.; Price, Nathan D.; Zhang, Bodi; Mason, Christopher E.			A Wipe-Based Stool Collection and Preservation Kit for Microbiome Community Profiling	FRONTIERS IN IMMUNOLOGY			English	Article						microbiome; wipe; metagenomics; DESS; stool collection	FECAL MICROBIOTA; GUT MICROBIOTA; DISEASE; SAMPLES	While a range of methods for stool collection exist, many require complicated, self-directed protocols and stool transfer. In this study, we introduce and validate a novel, wipe-based approach to fecal sample collection and stabilization for metagenomics analysis. A total of 72 samples were collected across four different preservation types: freezing at -20 degrees C, room temperature storage, a commercial DNA preservation kit, and a dissolvable wipe used with DESS (dimethyl sulfoxide, ethylenediaminetetraacetic acid, sodium chloride) solution. These samples were sequenced and analyzed for taxonomic abundance metrics, bacterial metabolic pathway classification, and diversity analysis. Overall, the DESS wipe results validated the use of a wipe-based capture method to collect stool samples for microbiome analysis, showing an R-2 of 0.96 for species across all kingdoms, as well as exhibiting a maintenance of Shannon diversity (3.1-3.3) and species richness (151-159) compared to frozen samples. Moreover, DESS showed comparable performance to the commercially available preservation kit (R-2 of 0.98), and samples consistently clustered by subject across each method. These data support that the DESS wipe method can be used for stable, room temperature collection and transport of human stool specimens.	[Hua, Hui; Meydan, Cem; Afshin, Evan E.; Lili, Loukia N.; Rickard, Nate; Dudley, Joel T.; Price, Nathan D.; Zhang, Bodi; Mason, Christopher E.] Thorne HlthTech, New York, NY 10019 USA; [D'Adamo, Christopher R.] Univ Maryland, Sch Med, Dept Family & Community Med, Baltimore, MD USA; [Price, Nathan D.] Inst Syst Biol, Seattle, WA USA; [Mason, Christopher E.] WorldQuant Initiat Quantitat Predict, New York, NY 10065 USA	University System of Maryland; University of Maryland Baltimore; Institute for Systems Biology (ISB)	Hua, H; Mason, CE (corresponding author), Thorne HlthTech, New York, NY 10019 USA.; Mason, CE (corresponding author), WorldQuant Initiat Quantitat Predict, New York, NY 10065 USA.		Mason, Christopher/HCH-3977-2022	Hua, Hui/0000-0002-2015-8388				Bahl MI, 2012, FEMS MICROBIOL LETT, V329, P193, DOI 10.1111/j.1574-6968.2012.02523.x; Bana B, 2019, ANNU REV GENET, V53, P239, DOI 10.1146/annurev-genet-112618-043650; Beghini F, 2021, ELIFE, V10, DOI 10.7554/eLife.65088; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Breitwieser FP, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1568-0; Carroll IM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046953; Chen H, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00508; Chen J, 2012, BIOINFORMATICS, V28, P2106, DOI 10.1093/bioinformatics/bts342; Desbonnet L, 2010, NEUROSCIENCE, V170, P1179, DOI 10.1016/j.neuroscience.2010.08.005; Diener C, 2021, MSYSTEMS, V6, DOI 10.1128/mSystems.00964-21; Dyrda G, 2019, MOL BIOL REP, V46, P3225, DOI 10.1007/s11033-019-04782-y; Fouhy F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119355; Gray MA, 2013, FEMS MICROBIOL ECOL, V83, P468, DOI 10.1111/1574-6941.12008; Gruber J, 2017, CELL, V169, P1168, DOI 10.1016/j.cell.2017.05.048; Guo Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26648; He Q, 2016, APPL MICROBIOL BIOT, V100, P4485, DOI 10.1007/s00253-015-7205-x; Kisiel JB, 2013, THER ADV GASTROENTER, V6, P371, DOI 10.1177/1756283X13487941; Lauber CL, 2010, FEMS MICROBIOL LETT, V307, P80, DOI 10.1111/j.1574-6968.2010.01965.x; Lecky DM, 2014, BRIT J GEN PRACT, V64, pE684, DOI 10.3399/bjgp14X682261; Lee KM, 2019, PEERJ, V7, DOI 10.7717/peerj.6414; Leeming ER, 2021, GENOME MED, V13, DOI 10.1186/s13073-020-00813-7; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liang PS, 2016, AM J GASTROENTEROL, V111, P105, DOI 10.1038/ajg.2015.367; Lu J, 2017, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.104; Manor O, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18871-1; Mayer EA, 2011, NAT REV NEUROSCI, V12, P453, DOI 10.1038/nrn3071; Pribyl AL, 2021, ISME COMMUN, V1, P14, DOI [10.1038/s43705-021-00014-2, DOI 10.1038/S43705-021-00014-2]; Price ND, 2017, NAT BIOTECHNOL, V35, P747, DOI 10.1038/nbt.3870; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Reck M, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1694-y; Roesch Luiz F W, 2009, Open Microbiol J, V3, P40, DOI 10.2174/1874285800903010040; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; Song SJ, 2016, MSYSTEMS, V1, DOI 10.1128/mSystems.00021-16; Stewart CJ, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0295-1; Tang ZZ, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00454; Thomas V, 2015, FUTURE MICROBIOL, V10, P1485, DOI 10.2217/fmb.15.87; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vernocchi P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103688; Vogtmann E, 2017, AM J EPIDEMIOL, V185, P115, DOI 10.1093/aje/kww177; Wang Z, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00301; Wilmanski T, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1907270; Wilmanski T, 2021, NAT METAB, V3, P274, DOI 10.1038/s42255-021-00348-0; Wu GD, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-206	44	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								889702	10.3389/fimmu.2022.889702	http://dx.doi.org/10.3389/fimmu.2022.889702			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D0YF	35711426	gold, Green Submitted, Green Published			2022-12-18	WOS:000811282100001
J	Jerome, AD; Atkinson, JR; Moffatt, AL; Sepeda, JA; Segal, BM; Sas, AR				Jerome, Andrew D.; Atkinson, Jeffrey R.; Moffatt, Arnetta L.; Sepeda, Jesse A.; Segal, Benjamin M.; Sas, Andrew R.			Characterization of Zymosan-Modulated Neutrophils With Neuroregenerative Properties	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; regeneration; heterogeneity; transcriptomics; proteomics	SYSTEM; CELLS; INFLAMMATION; MACROPHAGES; SUBSETS; CNS	Recent studies using advanced techniques such as single cell RNA sequencing (scRNAseq), high parameter flow cytometry, and proteomics reveal that neutrophils are more heterogeneous than previously appreciated. Unique subsets have been identified in the context of bacterial and parasitic infections, cancer, and tissue injury and repair. The characteristics of infiltrating neutrophils differ depending on the nature of the inflammation-inciting stimulus, the stage of the inflammatory response, as well as the tissue microenvironment in which they accumulate. We previously described a new subpopulation of immature Ly6G(low) neutrophils that accumulate in the peritoneal cavity 3 days following intraperitoneal (i.p.) administration of the fungal cell wall extract, zymosan. These neutrophils express markers of alternative activation and possess neuroprotective/regenerative properties. In addition to inducing neurite outgrowth of explanted neurons, they enhance neuronal survival and axon regeneration in vivo following traumatic injury to the optic nerve or spinal cord. In contrast, the majority of neutrophils that accumulate in the peritoneal fluid 4 hours following i.p. zymosan injection (4h N phi) have features of conventional, mature Ly6G(hi) neutrophils and lack neuroprotective or neuroregenerative properties. In the current study, we expand upon on our previously published observations by performing a granular, in-depth analysis of these i.p. zymosan-modulated neutrophil populations using scRNAseq and high parameter flow cytometry. We also analyze cell lysates of each neutrophil population by liquid chromatography/mass spectrometry. Circulating blood neutrophils, harvested from naive mice, are analyzed in parallel as a control. When samples were pooled from all three groups, scRNAseq revealed 11 distinct neutrophil clusters. Pathway analyses demonstrated that 3d N phi upregulate genes involved in tissue development and wound healing, while 4h N phi upregulate genes involved in cytokine production and perpetuation of the immune response. Proteomics analysis revealed that 3d N phi and 4h N phi also express distinct protein signatures. Adding to our earlier findings, 3d N phi expressed a number of neuroprotective/neuroregenerative candidate proteins that may contribute to their biological functions. Collectively, the data generated by the current study add to the growing literature on neutrophil heterogeneity and functional sub-specialization and might provide new insights in elucidating the mechanisms of action of pro-regenerative, neuroprotective neutrophil subsets.	[Jerome, Andrew D.; Atkinson, Jeffrey R.; Moffatt, Arnetta L.; Sepeda, Jesse A.; Segal, Benjamin M.; Sas, Andrew R.] Ohio State Med Ctr, Dept Neurol, Columbus, OH 43210 USA; [Jerome, Andrew D.; Atkinson, Jeffrey R.; Moffatt, Arnetta L.; Sepeda, Jesse A.; Segal, Benjamin M.; Sas, Andrew R.] Ohio State Univ, Neurosci Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Sas, AR (corresponding author), Ohio State Med Ctr, Dept Neurol, Columbus, OH 43210 USA.; Sas, AR (corresponding author), Ohio State Univ, Neurosci Res Inst, Columbus, OH 43210 USA.			Jerome, Andrew/0000-0002-6748-8114; Atkinson, Jeffrey/0000-0002-0250-2210				Aalinkeel R, 2016, NEURAL REGEN RES, V11, P896, DOI 10.4103/1673-5374.184455; Nicolas-Avila JA, 2017, IMMUNITY, V46, P15, DOI 10.1016/j.immuni.2016.12.012; Arora S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-11-r166; Baldwin KT, 2015, P NATL ACAD SCI USA, V112, P2581, DOI 10.1073/pnas.1423221112; Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x; Deerhake ME, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.670574; Duan X, 2015, NEURON, V85, P1244, DOI 10.1016/j.neuron.2015.02.017; Eguchi J, 2013, DIABETES, V62, P3394, DOI 10.2337/db12-1327; Evrard M, 2018, IMMUNITY, V48, P364, DOI 10.1016/j.immuni.2018.02.002; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gadani SP, 2015, NEURON, V87, P47, DOI 10.1016/j.neuron.2015.05.019; Gambarotta G, 2014, NEURAL REGEN RES, V9, P1183, DOI 10.4103/1673-5374.135324; Giladi A, 2018, NAT CELL BIOL, V20, P836, DOI 10.1038/s41556-018-0121-4; Giles DA, 2018, ANN NEUROL, V83, P131, DOI 10.1002/ana.25128; Ginhoux F, 2014, NAT REV IMMUNOL, V14, P392, DOI 10.1038/nri3671; Gordon S, 2016, IMMUNITY, V44, P463, DOI 10.1016/j.immuni.2016.02.026; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Han XP, 2018, CELL, V173, P1307, DOI 10.1016/j.cell.2018.05.012; Hebert AS, 2018, ANAL CHEM, V90, P9529, DOI 10.1021/acs.analchem.8b02233; Hirahara K, 2016, INT IMMUNOL, V28, P163, DOI 10.1093/intimm/dxw006; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Cuartero MI, 2013, STROKE, V44, P3498, DOI 10.1161/STROKEAHA.113.002470; Johansen LM, 2001, MOL CELL BIOL, V21, P3789, DOI 10.1128/MCB.21.11.3789-3806.2001; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kurimoto T, 2013, J NEUROSCI, V33, P14816, DOI 10.1523/JNEUROSCI.5511-12.2013; Lee PY, 2013, J LEUKOCYTE BIOL, V94, P585, DOI 10.1189/jlb.0113014; Mehrpouya-Bahrami P, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.141326; Nakabo S, 2022, J INVEST DERMATOL, V142, P823, DOI 10.1016/j.jid.2021.04.014; Park J, 2018, SCIENCE, V360, P758, DOI 10.1126/science.aar2131; Paul F, 2016, CELL, V164, P325, DOI 10.1016/j.cell.2015.12.046; Rumble JM, 2015, J EXP MED, V212, P23, DOI 10.1084/jem.20141015; Sas AR, 2020, NAT IMMUNOL, V21, P1496, DOI 10.1038/s41590-020-00813-0; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tao J, 2012, BRAIN RES, V1436, P130, DOI 10.1016/j.brainres.2011.11.063; Todd L, 2015, MOL CELL NEUROSCI, V69, P54, DOI 10.1016/j.mcn.2015.10.004; Tourki B, 2017, FASEB J, V31, P4226, DOI 10.1096/fj.201700109R; Tsuda Y, 2004, IMMUNITY, V21, P215, DOI 10.1016/j.immuni.2004.07.006; Tyanova S, 2016, NAT PROTOC, V11, P2301, DOI 10.1038/nprot.2016.136; Veglia F, 2021, J EXP MED, V218, DOI 10.1084/jem.20201803; Xie XM, 2020, NAT IMMUNOL, V21, P1119, DOI 10.1038/s41590-020-0736-z; Yang Q, 2017, ONCOGENE, V36, P2969, DOI 10.1038/onc.2016.448; Yang WT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09046-8	43	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								912193	10.3389/fimmu.2022.912193	http://dx.doi.org/10.3389/fimmu.2022.912193			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C6YO	35711408	gold, Green Published			2022-12-18	WOS:000811011500001
J	Kimingi, HW; Kinyua, AW; Achieng, NA; Wambui, KM; Mwangi, S; Nguti, R; Kivisi, CA; Jensen, ATR; Bejon, P; Kapulu, MC; Abdi, AI; Kinyanjui, SM; Team				Kimingi, Hannah W.; Kinyua, Ann W.; Achieng, Nicole A.; Wambui, Kennedy M.; Mwangi, Shaban; Nguti, Roselyne; Kivisi, Cheryl A.; Jensen, Anja T. R.; Bejon, Philip; Kapulu, Melisa C.; Abdi, Abdirahman I.; Kinyanjui, Samson M.; CHMI-SIKA Study Team			Breadth of Antibodies to Plasmodium falciparum Variant Surface Antigens Is Associated With Immunity in a Controlled Human Malaria Infection Study	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; Plasmodium falciparum; CHMI; variant surface antigens; anti-VSA antibodies; antibody breadth; PfEMP1; ICAM1	NATURALLY ACQUIRED-IMMUNITY; PHASE-3 TRIAL; VACCINE; ERYTHROCYTES; PROTECTION; TARGETS; PFEMP1; BINDING; FAMILY; SUSCEPTIBILITY	BackgroundPlasmodium falciparum variant surface antigens (VSAs) contribute to malaria pathogenesis by mediating cytoadhesion of infected red blood cells to the microvasculature endothelium. In this study, we investigated the association between anti-VSA antibodies and clinical outcome in a controlled human malaria infection (CHMI) study. MethodWe used flow cytometry and ELISA to measure levels of IgG antibodies to VSAs of five heterologous and one homologous P. falciparum parasite isolates, and to two PfEMP1 DBL beta domains in blood samples collected a day before the challenge and 14 days after infection. We also measured the ability of an individual's plasma to inhibit the interaction between PfEMP1 and ICAM1 using competition ELISA. We then assessed the association between the antibody levels, function, and CHMI defined clinical outcome during a 21-day follow-up period post infection using Cox proportional hazards regression. ResultsAntibody levels to the individual isolate VSAs, or to two ICAM1-binding DBL beta domains of PfEMP1, were not associated with a significantly reduced risk of developing parasitemia or of meeting treatment criteria after the challenge after adjusting for exposure. However, anti-VSA antibody breadth (i.e., cumulative response to all the isolates) was a significant predictor of reduced risk of requiring treatment [HR 0.23 (0.10-0.50) p= 0.0002]. ConclusionThe breadth of IgG antibodies to VSAs, but not to individual isolate VSAs, is associated with protection in CHMI.	[Kimingi, Hannah W.; Kinyua, Ann W.; Achieng, Nicole A.; Wambui, Kennedy M.; Mwangi, Shaban; Nguti, Roselyne; Bejon, Philip; Kapulu, Melisa C.; Abdi, Abdirahman I.; Kinyanjui, Samson M.] Kenya Med Res Inst KEMRI, Wellcome Trust Res Programme, Kilifi, Kenya; [Kimingi, Hannah W.; Nguti, Roselyne; Kivisi, Cheryl A.] Pwani Univ, Dept Biol Sci, Kilifi, Kenya; [Wambui, Kennedy M.] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa; [Kivisi, Cheryl A.; Abdi, Abdirahman I.; Kinyanjui, Samson M.] Pwani Univ, Pwani Univ, Biosci Res Ctr, Kilifi, Kenya; [Jensen, Anja T. R.] Univ Copenhagen, Fac Hlth & Med Sci, Ctr Med Parasitol, Dept Immunol & Microbiol, Copenhagen, Denmark; [Bejon, Philip; Kapulu, Melisa C.; Kinyanjui, Samson M.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England; [Kinyanjui, Samson M.] Strathmore Univ, Sch Business Studies, Nairobi, Kenya	Kenya Medical Research Institute; Pwani University; University of Witwatersrand; Pwani University; University of Copenhagen; University of Oxford; Strathmore University	Kinyanjui, SM (corresponding author), Kenya Med Res Inst KEMRI, Wellcome Trust Res Programme, Kilifi, Kenya.; Kinyanjui, SM (corresponding author), Pwani Univ, Pwani Univ, Biosci Res Ctr, Kilifi, Kenya.; Kinyanjui, SM (corresponding author), Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England.; Kinyanjui, SM (corresponding author), Strathmore Univ, Sch Business Studies, Nairobi, Kenya.	skmuchina@kemri-wellcome.org		Mwangi, Shaban/0000-0003-1961-3205; Kimingi, Hannah/0000-0002-6327-0302; OLOO, JAMES AGGREY/0000-0001-7495-1827; Ong'echa, John/0000-0003-3928-6774				Agnandji ST, 2011, NEW ENGL J MED, V365, P1863, DOI 10.1056/NEJMoa1102287; Bachmann A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049540; Bengtsson A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069999; Bengtsson A, 2013, J IMMUNOL, V190, P240, DOI 10.4049/jimmunol.1202578; Boyle MJ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax4489; Bull PC, 1999, INFECT IMMUN, V67, P733, DOI 10.1128/IAI.67.2.733-739.1999; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Bull PC, 2016, PARASITOLOGY, V143, P171, DOI 10.1017/S0031182015001274; Cator LJ, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-164; Chan JA, 2019, J INFECT DIS, V219, P819, DOI 10.1093/infdis/jiy580; Chan JA, 2014, CELL MOL LIFE SCI, V71, P3633, DOI 10.1007/s00018-014-1614-3; Chan JA, 2012, J CLIN INVEST, V122, P3227, DOI 10.1172/JCI62182; COHEN S, 1961, NATURE, V192, P733, DOI 10.1038/192733a0; Dent AE, 2015, J INFECT DIS, V212, P1429, DOI 10.1093/infdis/jiv224; Feng GQ, 2009, J INFECT DIS, V200, P299, DOI 10.1086/599841; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gupta S, 1999, P ROY SOC B-BIOL SCI, V266, P33, DOI 10.1098/rspb.1999.0600; Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560; Hviid L, 2015, ADV PARASIT, V88, P51, DOI 10.1016/bs.apar.2015.02.004; Jensen AR, 2020, IMMUNOL REV, V293, P230, DOI 10.1111/imr.12807; Kapulu MC, 2022, BMC INFECT DIS, V22, DOI 10.1186/s12879-022-07044-8; Kapulu MC, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146443; Kapulu Melissa C, 2018, Wellcome Open Res, V3, P155, DOI [10.12688/wellcomeopenres.14909.1, 10.12688/wellcomeopenres.14909.2]; Kinyanjui SM, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-242; Kinyanjui SM, 2004, J IMMUNOL METHODS, V288, P9, DOI 10.1016/j.jim.2004.01.022; Lennartz F, 2017, CELL HOST MICROBE, V21, P403, DOI 10.1016/j.chom.2017.02.009; Liu NN, 2015, ANNU REV ENTOMOL, V60, P537, DOI 10.1146/annurev-ento-010814-020828; Mackintosh CL, 2008, INT J PARASITOL, V38, P1445, DOI 10.1016/j.ijpara.2008.03.009; Mahmoudi S, 2017, HUM VACC IMMUNOTHER, V13, P2098, DOI 10.1080/21645515.2017.1295906; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; Nkumama IN, 2017, TRENDS PARASITOL, V33, P128, DOI 10.1016/j.pt.2016.11.006; Ofori MF, 2002, INFECT IMMUN, V70, P2982, DOI 10.1128/IAI.70.6.2982-2988.2002; Ogutu BR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004708; Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257; Olsen RW, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00622-17, 10.1128/iai.00622-17]; Osier FH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008705; Peters JM, 2007, J INFECT DIS, V195, P748, DOI 10.1086/511436; Recker M, 2004, NATURE, V429, P555, DOI 10.1038/nature02486; Rosenthal PJ, 2018, AM J TROP MED HYG, V99, P1357, DOI 10.4269/ajtmh.18-0845; SABCHAREON A, 1991, AM J TROP MED HYG, V45, P297, DOI 10.4269/ajtmh.1991.45.297; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; SU XZ, 1995, CELL, V82, P89, DOI 10.1016/0092-8674(95)90055-1; Tan J, 2019, ANNU REV IMMUNOL, V37, P225, DOI 10.1146/annurev-immunol-042617-053301; Tebo AE, 2002, AM J TROP MED HYG, V67, P597, DOI 10.4269/ajtmh.2002.67.597; Tilly AK, 2015, SCI REP-UK, V5, DOI 10.1038/srep16766; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Tuju J, 2017, IMMUNOLOGY, V152, P195, DOI 10.1111/imm.12780; UDEINYA IJ, 1983, EXP PARASITOL, V56, P207, DOI 10.1016/0014-4894(83)90064-4; Wamae K, 2019, J INFECT DIS, V219, P936, DOI 10.1093/infdis/jiy591; Weiss GE, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000912; WHO, 2011, WORLD MALARIA REPORT 2011, P1	53	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								894770	10.3389/fimmu.2022.894770	http://dx.doi.org/10.3389/fimmu.2022.894770			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C5QQ	35711446				2022-12-18	WOS:000810923300001
J	Liu, J; Zha, Y; Zhang, P; He, P; He, LJ				Liu, Jing; Zha, Yang; Zhang, Peng; He, Peng; He, Lijie			The Association Between Serum Complement 4 and Kidney Disease Progression in Idiopathic Membranous Nephropathy: A Multicenter Retrospective Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						serum complement 4; idiopathic membranous nephropathy; renal function progression; risk factor; progression	C4; PROTEIN; INJURY; SYSTEM; DAMAGE; RISK	IntroductionComplement system plays an important role in the pathogenesis of idiopathic membranous nephropathy (IMN), however, the relationship between serum complement 4 (C4) and kidney disease progression in IMN is unclear. This study aims to investigate the association of serum C4 level with the risk of kidney disease progression among patients with IMN. MethodsThe retrospective cohort assessed 1,254 participants with biopsy-proven IMN from three centers in Xi 'an, Shaanxi Province, China. Baseline serum C4 levels were measured at renal biopsy. The association between baseline serum C4 and the risk of renal function progression, defined as a 30% decline in renal function or end stage renal disease, was evaluated in Cox proportional hazards models. ResultsA total of 328 patients with IMN and nephrotic proteinuria were eligible, and 11.3% (37/328) of them attained the renal function progression events after a median follow-up of 51 months (37-59 months). After adjustment for other confounders, a higher value of serum C4 was independently associated with a higher risk of renal function progression event with a hazard ratio (HR) of 4.76 (95% confidence interval [95% CI], 1.77-12.79) per natural log-transformed C4. In reference to the low level of C4, the adjusted HRs were 2.72 (95% CI, 1.02-7.24) and 3.65 (95% CI, 1.39-9.60), respectively, for the median and high levels of C4 (P for trend=0.008). Additionally, the results were robust and reliable in the sensitivity and subgroup analyses. ConclusionAmong patients with IMN and nephrotic proteinuria, serum C4 at renal biopsy is an independent predictor for kidney disease progression regardless of other confounders.	[Liu, Jing; Zha, Yang; Zhang, Peng; He, Peng; He, Lijie] Fourth Mil Med Univ, Xijing Hosp, Dept Nephrol, Xi'an, Peoples R China; [Liu, Jing; Zha, Yang] Xian Med Univ, Dept Postgrad Student, Xi'an, Peoples R China	Air Force Military Medical University; Xi'an Medical University	He, P; He, LJ (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Nephrol, Xi'an, Peoples R China.	hepenglov@163.com; helijie@fmmu.edu.cn			National Natural Science Foundation of China [NSFC: 81770764, 81770669]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding The study was supported by grants from the National Natural Science Foundation of China (NSFC: 81770764 and 81770669).	Beck LH, 2010, KIDNEY INT, V77, P765, DOI 10.1038/ki.2010.34; Bell EK, 2012, AM J HYPERTENS, V25, P789, DOI 10.1038/ajh.2012.48; Bi TD, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1420-0; Carroll MV, 2011, ADV DRUG DELIVER REV, V63, P965, DOI 10.1016/j.addr.2011.06.005; Couser WG, 2017, CLIN J AM SOC NEPHRO, V12, P983, DOI 10.2215/CJN.11761116; da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664; Dean MM, 2005, J CLIN IMMUNOL, V25, P346, DOI 10.1007/s10875-005-4702-1; Drawz PE, 2020, AM J KIDNEY DIS, V75, P426, DOI 10.1053/j.ajkd.2019.08.030; Kaartinen K, 2019, SEMIN IMMUNOL, V45, DOI 10.1016/j.smim.2019.101331; Keri KC, 2019, POSTGRAD MED J, V95, P23, DOI 10.1136/postgradmedj-2018-135729; Kong XL, 2013, NEPHROL DIAL TRANSPL, V28, P641, DOI 10.1093/ndt/gfs491; Lai WL, 2015, J FORMOS MED ASSOC, V114, P102, DOI 10.1016/j.jfma.2014.11.002; Ma R, 2013, J CLIN IMMUNOL, V33, P172, DOI 10.1007/s10875-012-9772-2; McCullough JW, 2013, SEMIN NEPHROL, V33, P543, DOI 10.1016/j.semnephrol.2013.08.005; Mizuno M, 2018, CLIN EXP NEPHROL, V22, P3, DOI 10.1007/s10157-017-1405-x; Pan M, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0658-7; Petermann AT, 2003, KIDNEY INT, V64, P1222, DOI 10.1046/j.1523-1755.2003.00217.x; Pippin JW, 2003, J CLIN INVEST, V111, P877, DOI 10.1172/JCI200315645; Reinhard L, 2020, MOL IMMUNOL, V128, P195, DOI 10.1016/j.molimm.2020.10.017; Ronco P, 2020, ANNU REV PATHOL-MECH, V15, P287, DOI 10.1146/annurev-pathol-020117-043811; Sheerin NS, 2002, CLIN EXP IMMUNOL, V130, P1, DOI 10.1046/j.1365-2249.2002.01979.x; Thurman JM, 2020, ADV CHRONIC KIDNEY D, V27, P86, DOI 10.1053/j.ackd.2019.10.003; Trujillo H, 2020, NEPHRON, V144, P261, DOI 10.1159/000506948; Tsai SF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42689-7; van den Brand JAJG, 2012, CLIN J AM SOC NEPHRO, V7, P1242, DOI 10.2215/CJN.00670112; Vignesh P, 2017, CLIN CHIM ACTA, V465, P123, DOI 10.1016/j.cca.2016.12.017; WELCH TR, 1993, J CLIN INVEST, V92, P1451, DOI 10.1172/JCI116722; Yang Y, 2003, J IMMUNOL, V171, P2734, DOI 10.4049/jimmunol.171.5.2734; Yu CY, 2003, PROG NUCLEIC ACID RE, V75, P217; Zhang MF, 2018, CLIN CHIM ACTA, V485, P152, DOI 10.1016/j.cca.2018.06.050; Zhou WD, 2001, KIDNEY INT, V59, P1227, DOI 10.1046/j.1523-1755.2001.0590041227.x; Zhou WD, 1997, J AM SOC NEPHROL, V8, P214; Zuo K, 2013, CLIN NEPHROL, V79, P445, DOI 10.5414/CN107681	33	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								896654	10.3389/fimmu.2022.896654	http://dx.doi.org/10.3389/fimmu.2022.896654			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4PP	35707542	Green Published, gold			2022-12-18	WOS:000810172200001
J	Lu, SX; Sun, Z; Liu, LL; Li, P; Li, B; Li, WJ; Wu, ZJ; Zhao, MM; Liu, WN; Wang, YJ; Wang, B				Lu, Shixiang; Sun, Zhen; Liu, Lili; Li, Peng; Li, Bin; Li, Wenjing; Wu, Zhaojun; Zhao, Mingming; Liu, Wenna; Wang, Yongjie; Wang, Bin			Tumor-Derived Exosomes Regulate Apoptosis of CD45(+)EpCAM(+) Cells in Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						CD45(+)EpCAM(+) cells; HCC827 cells; tumor-derived exosomes; PBMC; apoptosis	EPITHELIAL-MESENCHYMAL TRANSITION; T-CELLS; STEM-CELLS; EOSINOPHILS; BIOGENESIS; EXPRESSION; MICRORNAS; VESICLES; FAMILY	Lung cancer has the highest mortality rate among human cancers, and the majority of deaths result from metastatic spread. The tumor microenvironment plays an important role in suppressing the immune surveillance and elimination of tumor cells. A few studies have reported the presence of CD45(+)EpCAM(+) double-positive cells in cancer, but the underlying mechanism remains unclear with respect to how these cells originate and their function in cancer biology. In this study, we analyzed 25 lung tumor samples. We confirmed the presence of CD45(+)EpCAM(+) cells in lung cancer, and these cells exhibited higher apoptosis than CD45(+)EpCAM(-) cells. Using co-culture of lung cancer cell-derived exosomes with healthy donor peripheral blood mononuclear cells, we recapitulated CD45(+)EpCAM(+) cell formation and increased apoptosis that occurs in patients with primary lung cancer. Further analysis suggested that microRNAs in lung cancer cell-derived exosomes may alter the gene expression profile of CD45(+)EpCAM(+) cells, resulting in elevated TP53 expression and increased apoptosis. To our knowledge, this is the first report of cancer cell-derived exosomes that can inhibit the immune system by promoting immune cell apoptosis.	[Lu, Shixiang; Wang, Bin] Qingdao Univ, Sch Basic Med, Dept Special Med, Qingdao, Peoples R China; [Sun, Zhen; Li, Bin; Li, Wenjing; Wu, Zhaojun; Zhao, Mingming; Liu, Wenna] Sino Cell Biomed Co Ltd, Dept Res & Dev, Qingdao, Peoples R China; [Liu, Lili] Qingdao Univ, Sch Basic Med, Qingdao, Peoples R China; [Li, Peng; Wang, Yongjie] Qingdao Univ, Dept Thorac Surg, Affiliated Hosp, Qingdao, Peoples R China	Qingdao University; Qingdao University; Qingdao University	Wang, B (corresponding author), Qingdao Univ, Sch Basic Med, Dept Special Med, Qingdao, Peoples R China.; Wang, YJ (corresponding author), Qingdao Univ, Dept Thorac Surg, Affiliated Hosp, Qingdao, Peoples R China.	wangyongjie@qduhospital.cn; wangbin532@126.com			Wu Jieping Medical Foundation [320.6750.2021-01-4]; Project for "Clinical Medicine + X"; Affiliated Hospital of Qingdao University [QYFY-X2021032/3731]	Wu Jieping Medical Foundation; Project for "Clinical Medicine + X"; Affiliated Hospital of Qingdao University	This work was supported in part by grants from the Wu Jieping Medical Foundation to YW (320.6750.2021-01-4) and the Project for "Clinical Medicine + X" supported by the Affiliated Hospital of Qingdao University to YW (QYFY-X2021032/3731).	AFELTRA A, 1993, ANN RHEUM DIS, V52, P457, DOI 10.1136/ard.52.6.457; Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175; Akhter MZ, 2018, ONCOGENE, V37, P2089, DOI 10.1038/s41388-017-0106-y; Andre F, 2002, LANCET, V360, P295, DOI 10.1016/S0140-6736(02)09552-1; Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349; Clayton A, 2011, J IMMUNOL, V187, P676, DOI 10.4049/jimmunol.1003884; Deng Z, 2017, ONCOGENE, V36, P639, DOI 10.1038/onc.2016.229; Du CC, 2020, J CELL MOL MED, V24, P7802, DOI 10.1111/jcmm.15411; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fan H, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009419; Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0; Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hasim MS, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abj3286; Ishizawa K, 2019, CLIN CANCER RES, V25, P6756, DOI 10.1158/1078-0432.CCR-19-0545; Jemal A., 2017, CA-CANCER J CLIN, V67, p7{30, DOI 10.3322/caac.21387; Julius P, 1999, EUR RESPIR J, V13, P1253, DOI 10.1034/j.1399-3003.1999.13f07.x; Liu YC, 2019, THERANOSTICS, V9, P5261, DOI 10.7150/thno.33183; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Oser MG, 2015, LANCET ONCOL, V16, pE165, DOI 10.1016/S1470-2045(14)71180-5; Plebanek MP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01433-3; Radstake TRDJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005903; Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138; Ricklefs FL, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2766; Robbins PD, 2014, NAT REV IMMUNOL, V14, P195, DOI 10.1038/nri3622; Ruivo CF, 2017, CANCER RES, V77, P6480, DOI 10.1158/0008-5472.CAN-17-0994; Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555-013-9420-1; Shao YR, 2019, BIOMED PHARMACOTHER, V109, P1233, DOI 10.1016/j.biopha.2018.10.108; Sharpe AH, 2007, NAT IMMUNOL, V8, P239, DOI 10.1038/ni1443; Skotland T, 2017, PROG LIPID RES, V66, P30, DOI 10.1016/j.plipres.2017.03.001; Song YX, 2017, STEM CELLS, V35, P1208, DOI 10.1002/stem.2564; Sun ZQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0897-7; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Toma T, 2005, PEDIATR INT, V47, P32, DOI 10.1111/j.1442-200x.2004.02004.x; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang PP, 2019, THERANOSTICS, V9, P1714, DOI 10.7150/thno.30716; Wang QL, 2018, THERANOSTICS, V8, P4912, DOI 10.7150/thno.27608; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Wolfers J, 2001, NAT MED, V7, P297, DOI 10.1038/85438; Yin Y, 2014, CELL RES, V24, P1164, DOI 10.1038/cr.2014.121; Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w; Zhang HY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15016; Zomer Anoek, 2010, Commun Integr Biol, V3, P447, DOI 10.4161/cib.3.5.12339	47	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								903882	10.3389/fimmu.2022.903882	http://dx.doi.org/10.3389/fimmu.2022.903882			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4UX	35711455	Green Published, gold			2022-12-18	WOS:000810186100001
J	Morton, SU; Schnur, M; Kerper, R; Young, V; O'Connell, AE				Morton, Sarah U.; Schnur, Maureen; Kerper, Rylee; Young, Vanessa; O'Connell, Amy E.			Premature Infants Have Normal Maturation of the T Cell Receptor Repertoire at Term	FRONTIERS IN IMMUNOLOGY			English	Article						prematurity; immunity; T cell; T cell repertoire; immune repertoire; neonate; bronchopulmonary dysplasia; T cell receptor excision circle	EXTREMELY PRETERM INFANTS; IMMUNODEFICIENCY; OUTCOMES	Premature infants are known to have immature immune systems compared to term infants; however, the impacts of ex utero immune development are not well characterized. Our previous retrospective clinical review showed prolonged T cell lymphopenia in a subset of extremely premature infants, suggesting that they may have lasting abnormalities in their T cell compartments. We used T cell receptor (TCR) repertoire sequencing to analyze the composition of the T cell compartment in premature and term infants in our NICU. We collected twenty-eight samples from individual subjects and analyzed the number of clonotypes, repertoire diversity, CDR3 length, and V gene usage between groups based on gestational age at birth and postmenstrual age at the time of sample collection. Further, we examined the TCR repertoire in infants with severe bronchopulmonary dysplasia (BPD) and those with abnormal T cell receptor excision circle (TREC) assays. Former extremely premature infants who were corrected to term postmenstrual age had TCR repertoire diversity that was more similar to term born infants than extremely premature infants, supporting normal maturation of the repertoire. Infants with severe BPD did not appear to have increased abnormalities in repertoire diversity. Decreased TCR repertoire diversity was associated with repeatedly abnormal TREC screening, although the diversity was within the normal range for subjects without low TRECs. This study suggests that extremely premature infants demonstrate normal maturation of the T cell repertoire ex utero. Further work is needed to better characterize postnatal T cell development and function in this population.	[Morton, Sarah U.; Schnur, Maureen; Kerper, Rylee; Young, Vanessa; O'Connell, Amy E.] Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA; [Morton, Sarah U.; O'Connell, Amy E.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA; [O'Connell, Amy E.] Boston Childrens Hosp BCH, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital	O'Connell, AE (corresponding author), Boston Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA.; O'Connell, AE (corresponding author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.; O'Connell, AE (corresponding author), Boston Childrens Hosp BCH, Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.	amy.oconnell@childrens.harvard.edu			Boston Children's Hospital Office of Faculty Development Career Development Award; Manton Center Innovation Fund	Boston Children's Hospital Office of Faculty Development Career Development Award; Manton Center Innovation Fund	This work was supported by Boston Children's Hospital Office of Faculty Development Career Development Award (SM), and the Manton Center Innovation Fund (AO).	Amatuni GS, 2019, J ALLERGY CLIN IMMUN, V144, P1674, DOI 10.1016/j.jaci.2019.05.038; Barbaro M, 2017, J CLIN IMMUNOL, V37, P51, DOI 10.1007/s10875-016-0347-5; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Bolotin DA, 2017, NAT BIOTECHNOL, V35, P908, DOI 10.1038/nbt.3979; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Britanova OV, 2014, J IMMUNOL, V192, P2689, DOI 10.4049/jimmunol.1302064; Carey AJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01859; de Greef PC, 2020, ELIFE, V9, DOI 10.7554/eLife.49900; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Fang MY, 2022, J CLIN IMMUNOL, V42, P375, DOI 10.1007/s10875-021-01178-1; Frazer LC, 2021, PEDIATR RES, V89, P549, DOI 10.1038/s41390-020-0886-6; Gaimann MU, 2020, ELIFE, V9, DOI 10.7554/eLife.61639; Gaspar HB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002715; Goedicke-Fritz S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01266; Gordon SM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.758373; Greenberg RG, 2018, CONT CLIN TRIAL COMM, V9, P33, DOI 10.1016/j.conctc.2017.11.005; ImmunoMind, 2021, IMMUNARCH R PACKAGE, DOI 10.5281/zenodo.3367200; Knight V, 2020, INT J NEONAT SCREEN, V6, DOI 10.3390/ijns6030052; Kwan A, 2014, JAMA-J AM MED ASSOC, V312, P729, DOI 10.1001/jama.2014.9132; Le BL, 2021, J IMMUNOL, V207, P2445, DOI 10.4049/jimmunol.2100566; Lee YN, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aah6109; Garcia-Garcia ML, 2015, PEDIATR INFECT DIS J, V34, P693, DOI 10.1097/INF.0000000000000718; Mora Thierry, 2019, Current Opinion in Systems Biology, V18, P104, DOI 10.1016/j.coisb.2019.10.001; O'Connell Amy E, 2019, Neoreviews, V20, pe67, DOI 10.1542/neo.20-2-e67; O'Connell AE, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00340; Olin A, 2018, CELL, V174, P1277, DOI 10.1016/j.cell.2018.06.045; Poindexter BB, 2015, ANN AM THORAC SOC, V12, P1822, DOI 10.1513/AnnalsATS.201504-218OC; Qazi KR, 2020, J IMMUNOL, V204, P68, DOI 10.4049/jimmunol.1900941; R Development Core Team, 2018, R LANG ENV STAT COMP; Rechavi E, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0072; Reis M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640595; Scheible KM, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96724; Sitaru AG, 2005, PLATELETS, V16, P203, DOI 10.1080/09537100400016862; Soto C, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107882; Stoll BJ, 2010, PEDIATRICS, V126, P443, DOI 10.1542/peds.2009-2959; Weiss EM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.32106; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	37	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								854414	10.3389/fimmu.2022.854414	http://dx.doi.org/10.3389/fimmu.2022.854414			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4ZH	35707545	gold, Green Published			2022-12-18	WOS:000810197600001
J	Olguin-Martinez, E; Munoz-Paleta, O; Ruiz-Medina, BE; Ramos-Balderas, JL; Licona-Limon, I; Licona-Limon, P				Olguin-Martinez, Enrique; Munoz-Paleta, Ofelia; Ruiz-Medina, Blanca E.; Ramos-Balderas, Jose Luis; Licona-Limon, Ileana; Licona-Limon, Paula			IL-33 and the PKA Pathway Regulate ILC2 Populations Expressing IL-9 and ST2	FRONTIERS IN IMMUNOLOGY			English	Article						IL-9; ILC2; ST2; IL-33; PKA; pathway; regulation	INNATE LYMPHOID-CELLS; KINASE; DIFFERENTIATION; T(H)2; INDUCTION; PROMOTES; PROLIFERATION; INHIBITION; IMMUNITY	Type 2 Innate lymphoid cells (ILC2s) are tissue-resident immune cells activated by epithelial-derived alarmins upon tissue damage. They regulate immunity against helminth parasites and allergies by expressing type 2 immune response cytokines including IL-9, known to be critical for inducing and potentiating the immune response in such context. Although ILC2s are reported to be the main source of IL-9 in mice during N. brasiliensis infection, the mechanisms that regulate the expression of IL-9 in these cells are yet to be described. Recent studies have shown that in addition to cytokines, multiple molecules can differentially modulate the functions of ILC2s in various contexts both in vitro and in vivo. Among these stimuli are lipid mediators and neuropeptides, which activate the PKA pathway and have been associated with the regulation of type 2 immune cytokines. In this work we found that ILC2s in mice infected with N. brasiliensis can be classified into different groups based on the expression of IL-9 and ST2. These distinct populations were distributed in the lung and the small intestine. Through the development of an in vitro culture system, we sought to determine the stimuli that regulate the expression of these markers in ILC2s. We identified the alarmin IL-33 as being a key player for increased IL-9 expression. Additionally, we found the PKA pathway to be a dual regulator of ILC2 cells, working synergistically with IL-33 to enhance IL-9 production and capable of modulating proliferation and the expression of ILC2 markers. These data provide further evidence of a high heterogeneity between ILC2 subsets in a context dependent manner and calls for careful consideration when choosing the markers to identify these cells in vivo. Distinguishing ILC2 subsets and dissecting their mechanisms of activation is critical for a deeper understanding of the biology of these cells, allowing their manipulation for therapeutic purposes.	[Olguin-Martinez, Enrique; Munoz-Paleta, Ofelia; Ruiz-Medina, Blanca E.; Ramos-Balderas, Jose Luis; Licona-Limon, Paula] Univ Nacl Autonoma Mex, Dept Biol Celular & Desarrollo, Inst Fisiol Celular, Mexico City, Mexico; [Licona-Limon, Ileana] Yale Univ, Immunobiol Dept, New Haven, CT USA	Universidad Nacional Autonoma de Mexico; Yale University	Licona-Limon, P (corresponding author), Univ Nacl Autonoma Mex, Dept Biol Celular & Desarrollo, Inst Fisiol Celular, Mexico City, Mexico.	plicona@ifc.unam.mx		Ruiz-Medina, Blanca E./0000-0003-1947-4014				BAUMAN GP, 1994, CELL IMMUNOL, V158, P182, DOI 10.1006/cimm.1994.1266; Beavo JA, 2002, NAT REV MOL CELL BIO, V3, P710, DOI 10.1038/nrm911; Cautivo KM, 2022, IMMUNITY, V55, P254, DOI 10.1016/j.immuni.2021.12.014; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Ferrer-Font L, 2020, ELIFE, V9, DOI 10.7554/eLife.51678; Flamar AL, 2020, IMMUNITY, V52, P606, DOI 10.1016/j.immuni.2020.02.009; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Huang YF, 2018, SCIENCE, V359, P114, DOI 10.1126/science.aam5809; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hung LY, 2013, P NATL ACAD SCI USA, V110, P282, DOI 10.1073/pnas.1206587110; Johansson K, 2018, IMMUNOLOGY, V153, P268, DOI 10.1111/imm.12842; Kabata H, 2018, IMMUNOL REV, V286, P37, DOI 10.1111/imr.12706; Kim BS, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016337; Licona-Limon P, 2013, IMMUNITY, V39, P744, DOI 10.1016/j.immuni.2013.07.020; Licona-Limon P, 2013, NAT IMMUNOL, V14, P536, DOI 10.1038/ni.2617; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Maric J, 2018, J ALLERGY CLIN IMMUN, V141, P1761, DOI 10.1016/j.jaci.2017.09.050; Mikami N, 2013, J IMMUNOL, V190, P4046, DOI 10.4049/jimmunol.1203102; Mohapatra A, 2016, MUCOSAL IMMUNOL, V9, P275, DOI 10.1038/mi.2015.59; Mohrs K, 2005, IMMUNITY, V23, P419, DOI 10.1016/j.immuni.2005.09.006; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Moriyama S, 2018, SCIENCE, V359, P1056, DOI 10.1126/science.aan4829; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Osbourn M, 2017, IMMUNITY, V47, P739, DOI 10.1016/j.immuni.2017.09.015; Pelly VS, 2016, MUCOSAL IMMUNOL, V9, P1407, DOI 10.1038/mi.2016.4; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Raker VK, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00123; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Rodriguez G, 2013, J BIOL CHEM, V288, P7137, DOI 10.1074/jbc.M112.408765; Ryan N, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00153; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Satoh-Takayama N, 2020, IMMUNITY, V52, P635, DOI 10.1016/j.immuni.2020.03.002; Stier MT, 2018, J EXP MED, V215, P263, DOI 10.1084/jem.20170449; Tokoyoda K, 2004, INT IMMUNOL, V16, P643, DOI 10.1093/intimm/dxh072; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; van Oirschot BA, 2001, J BIOL CHEM, V276, P33854, DOI 10.1074/jbc.M104395200; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Zambon AC, 2011, J BIOL CHEM, V286, P33260, DOI 10.1074/jbc.M111.268979; Zhou WS, 2016, AM J RESP CRIT CARE, V193, P31, DOI 10.1164/rccm.201410-1793OC; Zhou Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00501; Zhu JF, 2015, CYTOKINE, V75, P14, DOI 10.1016/j.cyto.2015.05.010	46	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								787713	10.3389/fimmu.2022.787713	http://dx.doi.org/10.3389/fimmu.2022.787713			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1QP	35711429	Green Published, gold			2022-12-18	WOS:000811330700001
J	Olude, MA; Mouihate, A; Mustapha, OA; Farina, C; Quintana, FJ; Olopade, JO				Olude, Matthew Ayokunle; Mouihate, Abdeslam; Mustapha, Oluwaseun Ahmed; Farina, Cinthia; Quintana, Francisco Javier; Olopade, James Olukayode			Astrocytes and Microglia in Stress-Induced Neuroinflammation: The African Perspective	FRONTIERS IN IMMUNOLOGY			English	Review						astrocytes; microglia; reactive oxygen species; malnutrition; environmental pollution	CENTRAL-NERVOUS-SYSTEM; MATERNAL IMMUNE ACTIVATION; ROTENONE-INDUCED NEUROTOXICITY; BRAIN ENERGY-METABOLISM; NF-KAPPA-B; MULTIPLE-SCLEROSIS; PROINFLAMMATORY CYTOKINES; NEUROLOGICAL DISORDERS; POSSIBLE INVOLVEMENT; PRENATAL INFECTION	Background: Africa is laden with a youthful population, vast mineral resources and rich fauna. However, decades of unfortunate historical, sociocultural and leadership challenges make the continent a hotspot for poverty, indoor and outdoor pollutants with attendant stress factors such as violence, malnutrition, infectious outbreaks and psychological perturbations. The burden of these stressors initiate neuroinflammatory responses but the pattern and mechanisms of glial activation in these scenarios are yet to be properly elucidated. Africa is therefore most vulnerable to neurological stressors when placed against a backdrop of demographics that favor explosive childbearing, a vast population of unemployed youths making up a projected 42% of global youth population by 2030, repressive sociocultural policies towards women, poor access to healthcare, malnutrition, rapid urbanization, climate change and pollution. Early life stress, whether physical or psychological, induces neuroinflammatory response in developing nervous system and consequently leads to the emergence of mental health problems during adulthood. Brain inflammatory response is driven largely by inflammatory mediators released by glial cells; namely astrocytes and microglia. These inflammatory mediators alter the developmental trajectory of fetal and neonatal brain and results in long-lasting maladaptive behaviors and cognitive deficits. This review seeks to highlight the patterns and mechanisms of stressors such as poverty, developmental stress, environmental pollutions as well as malnutrition stress on astrocytes and microglia in neuroinflammation within the African context.	[Olude, Matthew Ayokunle; Mustapha, Oluwaseun Ahmed] Fed Univ Agr, Coll Vet Med, Vertebrate Morphol Environm Toxicol & Neurosci Uni, Abeokuta, Nigeria; [Mouihate, Abdeslam] Kuwait Univ, Fac Med, Hlth Sci Ctr, Dept Physiol, Kuwait, Kuwait; [Farina, Cinthia] Ist Ricovero Cura Carattere Sci IRCSS San Raffaele, Inst Expt Neurol INSPE, Milan, Italy; [Quintana, Francisco Javier] Harvard Med Sch, Ann Romney Ctr Neurol Dis, Brigham & Womens Hosp, Boston, MA USA; [Olopade, James Olukayode] Univ Ibadan, Fac Vet Med, Dept Vet Anat, Neurosci Unit, Ibadan, Nigeria; [Farina, Cinthia] Div Neurosci, Milan, Italy	University of Agriculture, Abeokuta; Kuwait University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Ibadan	Olude, MA (corresponding author), Fed Univ Agr, Coll Vet Med, Vertebrate Morphol Environm Toxicol & Neurosci Uni, Abeokuta, Nigeria.	oludema@funaab.edu.ng		MUSTAPHA, OLUWASEUN AHMED/0000-0001-6049-7379	Italian Ministry for Health (Ricerca Corrente) [RF-2018-12367731]; FISM (Fondazione Italiana Sclerosi Multipla) [2016/R/14]; 5 per mille public funding; Kuwait University [YM04/21, YM11/17]	Italian Ministry for Health (Ricerca Corrente); FISM (Fondazione Italiana Sclerosi Multipla)(Fondazione Italiana Sclerosi Multipla (FISM)); 5 per mille public funding; Kuwait University	CF's research is supported by Italian Ministry for Health (Ricerca Corrente and RF-2018-12367731), FISM (Fondazione Italiana Sclerosi Multipla, grant number 2016/R/14) and cofinanced with the 5 per mille public funding. AM was supported by research grants from Kuwait University, Research Sector (YM04/21 and YM11/17).	Aaseth J, 2020, CURR OPIN TOXICOL, V19, P80, DOI 10.1016/j.cotox.2020.01.005; Abbink MR, 2019, GLIA, V67, P1637, DOI 10.1002/glia.23625; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Afkham A, 2019, J CELL PHYSIOL, V234, P2229, DOI 10.1002/jcp.27189; Ahmed T, 2012, ANN NUTR METAB, V61, P8, DOI 10.1159/000345165; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Akombi BJ, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-016-0770-z; Allaman I, 2011, PSYCHOPHARMACOLOGY, V216, P75, DOI 10.1007/s00213-011-2190-y; Allen JW, 2002, NEUROTOXICOLOGY, V23, P755, DOI 10.1016/S0161-813X(01)00076-6; ASCHNER M, 1993, BRAIN RES, V602, P181, DOI 10.1016/0006-8993(93)90680-L; ASCHNER M, 1991, NEUROSCI BIOBEHAV R, V15, P333, DOI 10.1016/S0149-7634(05)80026-0; Ashdown H, 2006, MOL PSYCHIATR, V11, P47, DOI 10.1038/sj.mp.4001748; Atreya R, 2000, NAT MED, V6, P583, DOI 10.1038/75068; Bachiller S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00488; Baird L, 2011, ARCH TOXICOL, V85, P241, DOI 10.1007/s00204-011-0674-5; Bale TL, 2010, BIOL PSYCHIAT, V68, P314, DOI 10.1016/j.biopsych.2010.05.028; Barroso A, 2021, CURR OPIN IMMUNOL, V70, P33, DOI 10.1016/j.coi.2021.02.003; Barroso A, 2021, CELL MOL IMMUNOL, V18, P259, DOI 10.1038/s41423-020-00585-5; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Belyaeva EA, 2012, SCI WORLD J, DOI 10.1100/2012/136063; Berntssen MHG, 2017, WOODHEAD PUBL FOOD S, P517, DOI 10.1016/B978-0-08-100674-0.00020-5; Bertotto LB, 2020, NEUROTOXICOLOGY, V76, P235, DOI 10.1016/j.neuro.2019.11.008; Bhargava V, 2020, DEV CELL, V52, P38, DOI 10.1016/j.devcel.2019.11.007; Blanchard OL, 2015, FASEB J, V29, P1629, DOI 10.1096/fj.14-269043; Block ML, 2009, TRENDS NEUROSCI, V32, P506, DOI 10.1016/j.tins.2009.05.009; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Boksa P, 2010, BRAIN BEHAV IMMUN, V24, P881, DOI 10.1016/j.bbi.2010.03.005; Bolton Jessica L, 2017, Front Synaptic Neurosci, V9, P10, DOI 10.3389/fnsyn.2017.00010; Boulanger-Bertolus J, 2018, FRONT BEHAV NEUROSCI, V12, DOI 10.3389/fnbeh.2018.00230; Bourke CD, 2016, TRENDS IMMUNOL, V37, P386, DOI 10.1016/j.it.2016.04.003; Bradl M, 2009, ANN NEUROL, V66, P630, DOI 10.1002/ana.21837; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brambilla R, 2009, J NEUROCHEM, V110, P765, DOI 10.1111/j.1471-4159.2009.06190.x; Brown AS, 2014, MOL PSYCHIATR, V19, P259, DOI 10.1038/mp.2012.197; Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774; Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049; Burton KJ, 2003, ANN TROP PAEDIATR, V23, P139, DOI 10.1179/027249303235002215; Calaforra JM, 2002, CARBONATE EVAPORITE, V17, P134, DOI 10.1017/S1368980019002969; Canetta S, 2014, AM J PSYCHIAT, V171, P960, DOI 10.1176/appi.ajp.2014.13121579; Ceccariglia S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010175; Cedile O, 2017, APMIS, V125, P945, DOI 10.1111/apm.12740; Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675; Chan MPL, 2006, ENVIRON TOXICOL, V21, P223, DOI 10.1002/tox.20175; Chao CC, 2019, CELL, V179, P1483, DOI 10.1016/j.cell.2019.11.016; Charli A, 2016, NEUROTOXICOLOGY, V53, P302, DOI 10.1016/j.neuro.2015.06.007; Chen C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202183; Cheray M, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00243; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Chertoff M., 2015, BRAIN DISORDERS THER, V04, P171, DOI [10.4172/2168-975x.1000171, DOI 10.4172/2168-975X.1000171, 10.4172/2168-975X.1000171]; Chibowska K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122140; Christian P, 2018, ANN NUTR METAB, V72, P316, DOI 10.1159/000488865; Cirac A, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001043; Clark IC, 2021, SCIENCE, V372, P360, DOI 10.1126/science.abf1230; Colombo E, 2016, TRENDS IMMUNOL, V37, P608, DOI 10.1016/j.it.2016.06.006; Colombo E, 2012, J EXP MED, V209, P521, DOI 10.1084/jem.20110698; CORDERO ME, 1982, PEDIATR RES, V16, P187, DOI 10.1203/00006450-198203000-00005; Cordiglieri Chiara, 2010, Current Immunology Reviews, V6, P150; Costa LG, 2006, CLIN CHIM ACTA, V366, P1, DOI 10.1016/j.cca.2005.10.008; Costa LG, 2017, NEUROTOXICOLOGY, V59, P133, DOI 10.1016/j.neuro.2015.11.008; Coulthard LG, 2018, TRENDS NEUROSCI, V41, P373, DOI 10.1016/j.tins.2018.03.009; Cui YH, 2018, NATURE, V554, P323, DOI 10.1038/nature25752; Cunningham CL, 2013, J NEUROSCI, V33, P4216, DOI 10.1523/JNEUROSCI.3441-12.2013; D'Ambrosi N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01394; da Silva IF, 2018, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00366; De Miranda BR, 2015, MOL PHARMACOL, V87, P1021, DOI 10.1124/mol.114.095398; Del Rio Hortega P., 1924, B SOC ESP BIOL, V11, P33; Del Rio-Hortega P., 1928, MEM REAL SOC ESP HIS, V14, P5; DIAZCINTRA S, 1990, J COMP NEUROL, V292, P117, DOI 10.1002/cne.902920108; Diz-Chaves Y, 2013, BRAIN BEHAV IMMUN, V28, P196, DOI 10.1016/j.bbi.2012.11.013; Diz-Chaves Y, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-71; Djukic B, 2007, J NEUROSCI, V27, P11354, DOI 10.1523/JNEUROSCI.0723-07.2007; Dong YS, 1999, J IMMUNOL, V162, P4731; Dukhi N., 2020, MALNUTRITION; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Ellis S, 2006, J PHYSIOL-LONDON, V571, P695, DOI 10.1113/jphysiol.2005.102939; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Escartin C, 2021, NAT NEUROSCI, V24, P312, DOI 10.1038/s41593-020-00783-4; Eskes C, 2002, GLIA, V37, P43, DOI 10.1002/glia.10019; Estes ML, 2016, SCIENCE, V353, P772, DOI 10.1126/science.aag3194; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fatola OI, 2019, BRAIN RES BULL, V145, P75, DOI 10.1016/j.brainresbull.2018.03.010; Filipello F, 2016, ONCOTARGET, V7, P5143, DOI 10.18632/oncotarget.6914; Filipov NM, 2012, J APPL TOXICOL, V32, P310, DOI 10.1002/jat.1762; Filipov NM, 2005, TOXICOL SCI, V84, P139, DOI 10.1093/toxsci/kfi055; Franz L, 2017, AUTISM RES, V10, P723, DOI 10.1002/aur.1766; Freeman MR, 2010, SCIENCE, V330, P774, DOI 10.1126/science.1190928; Fuchtbauer L, 2011, BRAIN BEHAV IMMUN, V25, P897, DOI 10.1016/j.bbi.2010.09.015; Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0; Galgamuwa LS, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4311-y; Galler JR, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-2828I; Garabadu D, 2020, NEUROMOL MED, V22, P314, DOI 10.1007/s12017-019-08590-2; Gavillet M, 2008, GLIA, V56, P975, DOI 10.1002/glia.20671; Genovese G, 2016, NAT NEUROSCI, V19, P1433, DOI 10.1038/nn.4402; Gensel JC, 2012, CELL TISSUE RES, V349, P201, DOI 10.1007/s00441-012-1425-5; George CM, 2018, TROP MED INT HEALTH, V23, P26, DOI 10.1111/tmi.13002; Gilmartin AA, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0143; Gimsa U, 2004, J MOL MED-JMM, V82, P364, DOI 10.1007/s00109-004-0531-6; Girard S, 2010, J IMMUNOL, V184, P3997, DOI 10.4049/jimmunol.0903349; Glass CK, 2010, NAT REV IMMUNOL, V10, P365, DOI 10.1038/nri2748; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Godfrey KM, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1875-x; Goettel JA, 2016, CELL REP, V17, P1318, DOI 10.1016/j.celrep.2016.09.082; Goldmann T, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/208093; Gomez-Gonzalez B, 2010, ACTA NEUROPATHOL, V119, P303, DOI 10.1007/s00401-009-0590-4; Graciarena M, 2013, BRAIN BEHAV IMMUN, V34, P17, DOI 10.1016/j.bbi.2013.05.007; Gressens P, 1997, DEV BRAIN RES, V103, P21, DOI 10.1016/S0165-3806(97)00109-0; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Gulsuner S, 2020, SCIENCE, V367, P569, DOI 10.1126/science.aay8833; Gunter TE, 2010, TOXICOL APPL PHARM, V249, P65, DOI 10.1016/j.taap.2010.08.018; Gutierrez-Vazquez C, 2018, IMMUNITY, V48, P19, DOI 10.1016/j.immuni.2017.12.012; Guttenplan KA, 2021, NATURE, V599, P102, DOI 10.1038/s41586-021-03960-y; Hagemeyer N, 2017, ACTA NEUROPATHOL, V134, P441, DOI 10.1007/s00401-017-1747-1; Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356; Han VX, 2021, NAT REV NEUROL, V17, P564, DOI 10.1038/s41582-021-00530-8; Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632; Herwerth M, 2016, ANN NEUROL, V79, P794, DOI 10.1002/ana.24630; Hindinger C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042088; Hirsch EC, 2009, LANCET NEUROL, V8, P382, DOI 10.1016/S1474-4422(09)70062-6; Hoeffel G, 2015, IMMUNITY, V42, P665, DOI 10.1016/j.immuni.2015.03.011; Hoshiko M, 2012, J NEUROSCI, V32, P15106, DOI 10.1523/JNEUROSCI.1167-12.2012; Hossain MM, 2015, TOXICOL SCI, V143, P220, DOI 10.1093/toxsci/kfu226; Howerton CL, 2012, HORM BEHAV, V62, P237, DOI 10.1016/j.yhbeh.2012.03.007; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Imamura M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249632; Instanes JT, 2017, BIOL PSYCHIAT, V81, P452, DOI 10.1016/j.biopsych.2015.11.024; Ip WKE, 2017, SCIENCE, V356, P513, DOI 10.1126/science.aal3535; Iqubal A, 2020, ENVIRON SCI POLLUT R, V27, P41175, DOI 10.1007/s11356-020-10539-z; Iqubal A, 2019, LIFE SCI, V218, P112, DOI 10.1016/j.lfs.2018.12.018; IZUORA GI, 1989, ANN TROP PAEDIATR, V9, P185, DOI 10.1080/02724936.1989.11748629; Jiang HY, 2016, BRAIN BEHAV IMMUN, V58, P165, DOI 10.1016/j.bbi.2016.06.005; Kelley KW, 2018, NEURON, V98, P306, DOI 10.1016/j.neuron.2018.03.010; Kenison JE, 2020, P NATL ACAD SCI USA, V117, P32017, DOI 10.1073/pnas.2016451117; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Keusch GT, 2014, CLIN INFECT DIS, V59, pS207, DOI 10.1093/cid/ciu485; Kieffer TEC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00625; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kitazawa M, 2001, FREE RADICAL BIO MED, V31, P1473, DOI 10.1016/S0891-5849(01)00726-2; Knuesel I, 2014, NAT REV NEUROL, V10, P643, DOI 10.1038/nrneurol.2014.187; Ko EM, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-105; Kogel V, 2021, J MOL NEUROSCI, V71, P2368, DOI 10.1007/s12031-021-01800-2; Komuczki J, 2019, IMMUNITY, V50, P1289, DOI 10.1016/j.immuni.2019.04.006; Koopmans F, 2019, NEURON, V103, P217, DOI 10.1016/j.neuron.2019.05.002; Korpe PS, 2012, TRENDS MOL MED, V18, P328, DOI 10.1016/j.molmed.2012.04.007; Koyama Y, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00261; Krumbholz M, 2006, BRAIN, V129, P200, DOI 10.1093/brain/awh680; Krumbholz M, 2005, J EXP MED, V201, P195, DOI 10.1084/jem.20041674; Kumawat KL, 2014, NEUROTOXICOLOGY, V41, P143, DOI 10.1016/j.neuro.2014.02.002; Lenz KM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00698; Lenz KM, 2013, J NEUROSCI, V33, P2761, DOI 10.1523/JNEUROSCI.1268-12.2013; Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006; Lim SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081218; Linnerbauer M, 2020, NEURON, V108, P608, DOI 10.1016/j.neuron.2020.08.012; Liu L, 2015, CELL, V160, P177, DOI 10.1016/j.cell.2014.12.019; Lloyd AF, 2019, NAT REV NEUROL, V15, P447, DOI 10.1038/s41582-019-0184-2; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Magistretti PJ, 2015, NEURON, V86, P883, DOI 10.1016/j.neuron.2015.03.035; Mall S, 2020, PSYCHOL MED, V50, P1570, DOI 10.1017/S0033291719001703; Martino D, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.567407; Mascanfroni ID, 2015, NAT MED, V21, P638, DOI 10.1038/nm.3868; Matejuk A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01416; Mayo L, 2014, NAT MED, V20, P1147, DOI 10.1038/nm.3681; McDonald CR, 2013, TRENDS PARASITOL, V29, P213, DOI 10.1016/j.pt.2013.03.005; McKenna CG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226041; McQualter JL, 2001, J EXP MED, V194, P873, DOI 10.1084/jem.194.7.873; Mendiola AS, 2020, NAT IMMUNOL, V21, P513, DOI 10.1038/s41590-020-0654-0; Meyer U, 2008, MOL PSYCHIATR, V13, P208, DOI 10.1038/sj.mp.4002042; Meyer U, 2014, BIOL PSYCHIAT, V75, P307, DOI 10.1016/j.biopsych.2013.07.011; Minakova E, 2018, BIRTH DEFECTS RES, V110, P1539, DOI 10.1002/bdr2.1416; Mishra S., 2019, ENV BIOTECHNOLOGY SU, V1st, P103, DOI 10.1007/978-981-10-7284-0_5; Misu T, 2007, BRAIN, V130, P1224, DOI 10.1093/brain/awm047; Miyamoto A, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12540; Mondal D, 2012, CLIN INFECT DIS, V54, P185, DOI 10.1093/cid/cir807; Monier A, 2006, J COMP NEUROL, V499, P565, DOI 10.1002/cne.21123; Morken TS, 2005, TOXICOL SCI, V87, P169, DOI 10.1093/toxsci/kfi227; Mortuza TB, 2019, DRUG METAB DISPOS, V47, P234, DOI 10.1124/dmd.118.084822; Mouihate A, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00173; Mouihate A, 2016, PEDIATR RES, V79, P781, DOI 10.1038/pr.2015.86; Mouihate A, 2010, J NEUROSCI, V30, P7975, DOI 10.1523/JNEUROSCI.6078-09.2010; Muller O, 2005, CAN MED ASSOC J, V173, P279, DOI 10.1503/cmaj.050342; Mursaleen L, 2020, J PARKINSON DIS, V10, P99, DOI 10.3233/JPD-191754; Nachega JB, 2021, AM J TROP MED HYG, V104, P461, DOI 10.4269/ajtmh.20-1553; Nelson LH, 2017, BEHAV BRAIN RES, V316, P279, DOI 10.1016/j.bbr.2016.09.006; NOTTIDGE VA, 1991, DEV MED CHILD NEUROL, V33, P241; Obasohan PE, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17238782; Ohgoh M, 2002, J NEUROIMMUNOL, V125, P170, DOI 10.1016/S0165-5728(02)00029-2; Olloquequi J, 2018, J PSYCHOPHARMACOL, V32, P265, DOI 10.1177/0269881118754680; Olude MA, 2015, FRONT NEUROANAT, V9, DOI 10.3389/fnana.2015.00067; Ozaki K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78294-2; Paolicelli RC, 2011, SCIENCE, V333, P1456, DOI 10.1126/science.1202529; Park E, 2016, NEUROREPORT, V27, P1140, DOI 10.1097/WNR.0000000000000667; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Pasteur I, 2020, COVID 19 PANDEMIC IN; Patten KT, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0845-3; Patterson PH, 2002, CURR OPIN NEUROBIOL, V12, P115, DOI 10.1016/S0959-4388(02)00299-4; Paul D, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-10; Peng Q, 2018, ONCOL LETT, V15, P1379, DOI 10.3892/ol.2017.7491; Perez EJ, 2017, J CLIN INVEST, V127, P3114, DOI 10.1172/JCI92300; Petronilho F., 2019, BLOOD BRAIN BARRIER, V142, P197, DOI [10.1007/978-1-4939-8946-1_12, DOI 10.1007/978-1-4939-8946-1_12]; Phares TW, 2013, J VIROL, V87, P3382, DOI 10.1128/JVI.03307-12; Plagemann A, 2000, J NUTR, V130, P2582, DOI 10.1093/jn/130.10.2582; Prendergast A, 2012, AM J TROP MED HYG, V86, P756, DOI 10.4269/ajtmh.2012.11-0743; Prinz M, 2021, ANNU REV IMMUNOL, V39, P251, DOI 10.1146/annurev-immunol-093019-110159; Prinz M, 2019, CELL, V179, P292, DOI 10.1016/j.cell.2019.08.053; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Purgato M, 2012, INT J MENT HEALTH SY, V6, DOI 10.1186/1752-4458-6-9; Putra M, 2020, ANN NY ACAD SCI, V1479, P75, DOI 10.1111/nyas.14314; Quintana FJ, 2013, PHARMACOL REV, V65, P1148, DOI 10.1124/pr.113.007823; Raasch J, 2011, BRAIN, V134, P1184, DOI 10.1093/brain/awq359; Ranade SC, 2012, BRIT J NUTR, V107, P1167, DOI 10.1017/S0007114511004119; Rio-Hortega P. del., 1920, Trav Lab Invest Biol Univ Madrid, V18, P37; Roh JS, 2018, IMMUNE NETW, V18, DOI 10.4110/in.2018.18.e27; Rothhammer V, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000946; Rothhammer V, 2019, NAT REV IMMUNOL, V19, P184, DOI 10.1038/s41577-019-0125-8; Rothhammer V, 2018, NATURE, V557, P724, DOI 10.1038/s41586-018-0119-x; Sachs JD, 2005, LANCET, V365, P347, DOI 10.1016/S0140-6736(05)70201-4; Saijo K, 2009, CELL, V137, P47, DOI 10.1016/j.cell.2009.01.038; Sakamoto M, 2008, NEUROSCI LETT, V442, P292, DOI 10.1016/j.neulet.2008.07.019; Samoilova EB, 1998, J IMMUNOL, V161, P6480; Sancho L, 2021, NEUROSCI RES, V167, P17, DOI 10.1016/j.neures.2020.11.005; Sanmarco LM, 2021, J EXP MED, V218, DOI 10.1084/jem.20202715; Savarin C, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0293-9; Say L, 2014, LANCET GLOB HEALTH, V2, pE323, DOI 10.1016/S2214-109X(14)70227-X; Shigemoto-Mogami Y, 2014, J NEUROSCI, V34, P2231, DOI 10.1523/JNEUROSCI.1619-13.2014; Shokeir AA, 2014, ACTA PHYSIOL, V210, P342, DOI 10.1111/apha.12164; Silberberg D, 2006, DISEASE AND MORTALITY IN SUB-SAHARAN AFRICA, 2ND EDITION, P351; Singer M, 2013, INFECT DIS POVERTY, V2, DOI 10.1186/2049-9957-2-26; Slavich GM, 2015, BRAIN BEHAV IMMUN, V45, P13, DOI 10.1016/j.bbi.2014.10.012; Smith BC, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01861-x; Smith SEP, 2007, J NEUROSCI, V27, P10695, DOI 10.1523/JNEUROSCI.2178-07.2007; Soderlund DM, 2012, ARCH TOXICOL, V86, P165, DOI 10.1007/s00204-011-0726-x; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Soos JM, 1998, J IMMUNOL, V161, P5959; Suchdev PS, 2017, PEDIATRICS, V139, DOI [10.1542/peds.2016-2828E, 10.1542/peds.2016-2828e]; SULLIVAN PB, 1992, J PEDIATR GASTR NUTR, V14, P208, DOI 10.1097/00005176-199202000-00016; Supplie LM, 2017, J NEUROSCI, V37, P4231, DOI 10.1523/JNEUROSCI.0756-16.2017; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Suzumura A, 2013, ADV NEUROBIOL, V7, P1, DOI 10.1007/978-1-4614-8313-7; Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x; Tette EMA, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0496-3; Thomas D, 2002, B WORLD HEALTH ORGAN, V80, P106; Tong CK, 2016, EXP BIOL MED, V241, P1669, DOI 10.1177/1535370216664430; Touil H, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1136-2; Tsaktanis T, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000000933; Tsuda S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00573; Tay TL, 2017, J PHYSIOL-LONDON, V595, P1929, DOI 10.1113/JP272134; UNICEF, 2019, CHILDR FOOD NUTR GRO; Vainchtein ID, 2018, SCIENCE, V359, P1269, DOI 10.1126/science.aal3589; VanRyzin JW, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0297-16.2016; Vargas R, 2017, TOXICOL REP, V4, P467, DOI 10.1016/j.toxrep.2017.08.002; Vercellino M, 2007, J NEUROPATH EXP NEUR, V66, P732, DOI 10.1097/nen.0b013e31812571b0; Verney C, 2010, J ANAT, V217, P436, DOI 10.1111/j.1469-7580.2010.01245.x; Vickers NJ, 2017, CURR BIOL, V27, pR713, DOI 10.1016/j.cub.2017.05.064; Vonaesch P, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1189-5; Vorster HH, 2010, HEALTH SA GESONDHEID, V15, DOI 10.4102/hsag.v15i1.435; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009; Walker SP, 2007, LANCET, V369, P145, DOI 10.1016/S0140-6736(07)60076-2; Wang X, 2013, EUR J IMMUNOL, V43, P115, DOI 10.1002/eji.201242679; Wheeler MA, 2020, NATURE, V578, P593, DOI 10.1038/s41586-020-1999-0; Wheeler MA, 2019, CELL, V176, P581, DOI 10.1016/j.cell.2018.12.012; WHO, 2020, FACT SHEETS MALN; WHO, 2021, MALNUTRITION 0609; WHO, 2014, WHO GUID IND AIR QUA; WHO Global Maternal Sepsis Study (GLOSS) Research Group, 2020, LANCET GLOB HEALTH, V8, P661; Wlodarczyk A, 2017, EMBO J, V36, P3292, DOI 10.15252/embj.201696056; Wohleb ES, 2017, PROG NEURO-PSYCHOPH, V79, P40, DOI 10.1016/j.pnpbp.2016.04.013; Yabe J, 2010, J VET MED SCI, V72, P1257, DOI 10.1292/jvms.10-0058; Yeste A, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad0612; Yeste A, 2012, P NATL ACAD SCI USA, V109, P11270, DOI 10.1073/pnas.1120611109; YUSUF HKM, 1981, J NEUROCHEM, V36, P924, DOI 10.1111/j.1471-4159.1981.tb01683.x; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zeng R, 2019, TOXICOL REP, V6, P637, DOI 10.1016/j.toxrep.2019.06.014; Zhang P, 2010, J NEUROCHEM, V112, P434, DOI 10.1111/j.1471-4159.2009.06477.x; Zhao F, 2009, TOXICOL SCI, V107, P156, DOI 10.1093/toxsci/kfn213; Zhuang ZY, 2010, J NEUROSCI, V30, P16015, DOI 10.1523/JNEUROSCI.0481-10.2010; Zurolo E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-280	276	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								795089	10.3389/fimmu.2022.795089	http://dx.doi.org/10.3389/fimmu.2022.795089			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B5VI	35707531	gold, Green Published			2022-12-18	WOS:000810255300001
J	Perlas, A; Argilaguet, J; Bertran, K; Sanchez-Gonzalez, R; Nofrarias, M; Valle, R; Ramis, A; Cortey, M; Majo, N				Perlas, Albert; Argilaguet, Jordi; Bertran, Kateri; Sanchez-Gonzalez, Raul; Nofrarias, Miquel; Valle, Rosa; Ramis, Antonio; Cortey, Marti; Majo, Natalia			Dual Host and Pathogen RNA-Seq Analysis Unravels Chicken Genes Potentially Involved in Resistance to Highly Pathogenic Avian Influenza Virus Infection (vol 12, 800188, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						chicken; avian influenza; innate immune response; genetic resistance; RNA-Seq; PLAU			[Perlas, Albert; Argilaguet, Jordi; Bertran, Kateri; Sanchez-Gonzalez, Raul; Nofrarias, Miquel; Valle, Rosa; Ramis, Antonio; Majo, Natalia] IRTA UAB, Inst Recerca & Tecnol Agroalimentaries IRTA, Ctr Recerca Sanitat Anim CReSA, Campus Univ Autonoma Barcelona UAB, Bellaterra, Spain; [Perlas, Albert; Sanchez-Gonzalez, Raul; Ramis, Antonio; Cortey, Marti; Majo, Natalia] Univ Autonoma Barcelona, Dept Sanitat & Anat Anim, Campus Univ Autonoma Barcelona UAB, Bellaterra, Spain	Autonomous University of Barcelona; IRTA; Autonomous University of Barcelona	Perlas, A (corresponding author), IRTA UAB, Inst Recerca & Tecnol Agroalimentaries IRTA, Ctr Recerca Sanitat Anim CReSA, Campus Univ Autonoma Barcelona UAB, Bellaterra, Spain.; Perlas, A (corresponding author), Univ Autonoma Barcelona, Dept Sanitat & Anat Anim, Campus Univ Autonoma Barcelona UAB, Bellaterra, Spain.	albert.perlas@irta.cat							0	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								939849	10.3389/fimmu.2022.939849	http://dx.doi.org/10.3389/fimmu.2022.939849			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E0DH	35707537	Green Published, gold			2022-12-18	WOS:000811905600001
J	Plantinga, M; Affandi, AJ				Plantinga, Maud; Affandi, Alsya J.			Editorial: Novel Platform for Antigen Delivery to Dendritic Cells for Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						dendritic cells; vaccine; antigen; immunotherapy; cancer; infection; allergy; autoimmunity			[Plantinga, Maud] Univ Med Ctr Utrecht, Ctr Translat Immunol, Div Lab, Apotheek Biomed Genet dLAB, Utrecht, Netherlands; [Affandi, Alsya J.] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Mol Cell Biol & Immunol, Amsterdam, Netherlands; [Affandi, Alsya J.] Canc Ctr Amsterdam, Canc Biol & Immunol, Amsterdam, Netherlands; [Affandi, Alsya J.] Amsterdam Inst Infect & Immun, Canc Immunol, Amsterdam, Netherlands	Utrecht University; Utrecht University Medical Center; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam	Affandi, AJ (corresponding author), Vrije Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Mol Cell Biol & Immunol, Amsterdam, Netherlands.; Affandi, AJ (corresponding author), Canc Ctr Amsterdam, Canc Biol & Immunol, Amsterdam, Netherlands.; Affandi, AJ (corresponding author), Amsterdam Inst Infect & Immun, Canc Immunol, Amsterdam, Netherlands.	a.affandi@amsterdamumc.nl						Cabeza-Cabrerizo M, 2021, ANNU REV IMMUNOL, V39, P131, DOI 10.1146/annurev-immunol-061020-053707; Kreutz M, 2013, BLOOD, V121, P2836, DOI 10.1182/blood-2012-09-452078; Lubbers J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02807; Phillips BE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01279; Richardson Naomi, 2021, Immunother Adv, V1, pltab009, DOI 10.1093/immadv/ltab009; See P, 2017, SCIENCE, V356, DOI 10.1126/science.aag3009; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z	8	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								915604	10.3389/fimmu.2022.915604	http://dx.doi.org/10.3389/fimmu.2022.915604			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1VO	35711423	gold, Green Published			2022-12-18	WOS:000811343600001
J	Poppelaars, F; de Jorge, EG; Jongerius, I; Baeumner, AJ; Steiner, MS; Jozsi, M; Toonen, EJM; Pauly, D				Poppelaars, Felix; Goicoechea de Jorge, Elena; Jongerius, Ilse; Baeumner, Antje J.; Steiner, Mark-Steven; Jozsi, Mihaly; Toonen, Erik J. M.; Pauly, Diana			A Family Affair: Addressing the Challenges of Factor H and the Related Proteins (vol 12, 660194, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						complement system; factor H (FH); factor H-related protein; factor H-like protein 1; challenges; development directions			[Poppelaars, Felix] Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, Div Nephrol, Groningen, Netherlands; [Goicoechea de Jorge, Elena] Univ Complutense Madrid, Res Inst Hosp Octubre 12 imas12, Fac Med, Dept Immunol, Madrid, Spain; [Jongerius, Ilse] Univ Amsterdam, Sanquin Res & Landsteiner Lab Acad Med Ctr, Dept Immunopathol, Amsterdam, Netherlands; [Jongerius, Ilse] Amsterdam Univ Med Ctr, Emma Childrens Hosp, Dept Pediat Immunol Rheumatol & Infectious Dis, Amsterdam, Netherlands; [Baeumner, Antje J.] Univ Regensburg, Inst Analyt Chem, Fac Chem & Pharm, Regensburg, Germany; [Steiner, Mark-Steven] Microcoat Biotechnol GmbH, Bernried am Starnberger S, Germany; [Jozsi, Mihaly] ELTE Eotv Lorand Univ, Dept Immunol, Budapest, Hungary; [Jozsi, Mihaly] Eotv Lorand Res Network ELKH, Dept Immunol, MTA ELTE Complement Res Grp, Budapest, Hungary; [Toonen, Erik J. M.] R&D Dept, Hycult Biotech, Uden, Netherlands; [Pauly, Diana] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany; [Pauly, Diana] Univ Marburg, Expt Ophthalmol, Marburg, Germany	University of Groningen; Complutense University of Madrid; University of Amsterdam; Emma Children's Hospital; University of Amsterdam; University of Regensburg; Eotvos Lorand Research Network; University of Regensburg; Philipps University Marburg	Pauly, D (corresponding author), Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.; Pauly, D (corresponding author), Univ Marburg, Expt Ophthalmol, Marburg, Germany.		Toonen, Erik/G-7337-2015	Toonen, Erik/0000-0001-9039-635X; Poppelaars, Felix/0000-0002-5173-8078	European Unions Horizon 2020 research and innovation programme [899163]	European Unions Horizon 2020 research and innovation programme	This project has received funding from the European Unions Horizon 2020 research and innovation programme under grant agreement No 899163.		0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								937609	10.3389/fimmu.2022.937609	http://dx.doi.org/10.3389/fimmu.2022.937609			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B7MG	35707529	gold, Green Published			2022-12-18	WOS:000810368000001
J	Clemente, NS; Penner, J; Breuer, J; Ip, W; Booth, C				Sanchez Clemente, Nuria; Penner, Justin; Breuer, Judith; Ip, Winnie; Booth, Claire			Case Report: A Severe Paediatric Presentation of COVID-19 in APDS2 Immunodeficiency	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency; APDS2; SARS-CoV-2; COVID-19; case report		Critical respiratory manifestations of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are rare in children, and little is known about how immunocompromised children respond to the infection. We report a case of a 4-year-old boy with activated PI3K delta syndrome type 2 (APDS2) with a protracted and severe COVID-19 course with both inflammatory and acute respiratory features. He was treated with remdesivir, nitazoxanide, high-dose corticosteroids, and tocilizumab and made a full recovery. We propose that remdesivir may be used in combination with nitazoxanide to improve viral clearance and reduce the chance of resistance in treating acute SARS-CoV-2 infection.	[Sanchez Clemente, Nuria; Penner, Justin] Great Ormond St Hosp Sick Children, Immunol & Infect Dis Dept, London, England; [Sanchez Clemente, Nuria] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England; [Breuer, Judith; Ip, Winnie; Booth, Claire] UCL, Infect Immun & Inflammat Dept, Great Ormond St Inst Child Hlth, London, England; [Ip, Winnie; Booth, Claire] Great Ormond St Hosp Sick Children, Dept Paediat Immunol, London, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Clemente, NS (corresponding author), Great Ormond St Hosp Sick Children, Immunol & Infect Dis Dept, London, England.; Clemente, NS (corresponding author), London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London, England.	nuriasanchezclemente@gmail.com		Breuer, Judith/0000-0001-8246-0534				Angulo I, 2013, SCIENCE, V342, P866, DOI 10.1126/science.1243292; Boshier F., 2020, PREPRINTS, DOI [10.1101/2020.11.18.20230599, DOI 10.1101/2020.11.18.20230599]; Brown LAK, 2021, TRIALS, V22, DOI 10.1186/s13063-021-05139-2; Buckland MS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19761-2; Cenciarelli S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603428; Chappell H, 2022, J INFECTION, V84, P31, DOI 10.1016/j.jinf.2021.11.005; Delavari S, 2021, J CLIN IMMUNOL, V41, P345, DOI 10.1007/s10875-020-00928-x; Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2; Harwood R, 2022, ECLINICALMEDICINE, V44, DOI 10.1016/j.eclinm.2022.101287; Horby PW, 2022, LANCET, V399, P665, DOI 10.1016/S0140-6736(22)00163-5; Issitt R., 2020, MEDRXIV, DOI [10.1101/2020.05.20.20107904, DOI 10.1101/2020.05.20.20107904]; Lokhande AS, 2021, EUR J PHARMACOL, V891, DOI 10.1016/j.ejphar.2020.173748; Marcus N, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.614086; Meyts I, 2021, J ALLERGY CLIN IMMUN, V147, P520, DOI 10.1016/j.jaci.2020.09.010; Mifsud EJ, 2019, ANTIVIR RES, V169, DOI 10.1016/j.antiviral.2019.104545; Shields AM, 2021, J ALLERGY CLIN IMMUN, V147, P870, DOI 10.1016/j.jaci.2020.12.620	16	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								881259	10.3389/fimmu.2022.881259	http://dx.doi.org/10.3389/fimmu.2022.881259			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4US	35707532	Green Published, gold			2022-12-18	WOS:000810185600001
J	Stapleton, JT				Stapleton, Jack T.			Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?	FRONTIERS IN IMMUNOLOGY			English	Review						Pegivirus; GB virus; immune modulation; viral co-infection; Flavivirus	HEPATITIS-G VIRUS; C/HEPATITIS G VIRUS; T-CELL-ACTIVATION; BLOOD MONONUCLEAR-CELLS; ENVELOPE GLYCOPROTEIN E2; HIV-INFECTED INDIVIDUALS; NATURAL-KILLER-CELL; GBV-C INFECTION; LIVER-DISEASE; NON-A	Two groups identified a novel human flavivirus in the mid-1990s. One group named the virus hepatitis G virus (HGV) and the other named it GB Virus type C (GBV-C). Sequence analyses found these two isolates to be the same virus, and subsequent studies found that the virus does not cause hepatitis despite sharing genome organization with hepatitis C virus. Although HGV/GBV-C infection is common and may cause persistent infection in humans, the virus does not appear to directly cause any other known disease state. Thus, the virus was renamed "human pegivirus 1" (HPgV-1) for "persistent G" virus. HPgV-1 is found primarily in lymphocytes and not hepatocytes, and several studies found HPgV-1 infection associated with prolonged survival in people living with HIV. Co-infection of human lymphocytes with HPgV-1 and HIV inhibits HIV replication. Although three viral proteins directly inhibit HIV replication in vitro, the major effects of HPgV-1 leading to reduced HIV-related mortality appear to result from a global reduction in immune activation. HPgV-1 specifically interferes with T cell receptor signaling (TCR) by reducing proximal activation of the lymphocyte specific Src kinase LCK. Although TCR signaling is reduced, T cell activation is not abolished and with sufficient stimulus, T cell functions are enabled. Consequently, HPgV-1 is not associated with immune suppression. The HPgV-1 immunomodulatory effects are associated with beneficial outcomes in other diseases including Ebola virus infection and possibly graft-versus-host-disease following stem cell transplantation. Better understanding of HPgV-1 immune escape and mechanisms of inflammation may identify novel therapies for immune-based diseases.	[Stapleton, Jack T.] Iowa City Vet Adm Healthcare, Med Serv, Iowa City, IA 52246 USA; [Stapleton, Jack T.] Univ Iowa, Dept Internal Med, Microbiol & Immunol, Iowa City, IA 52242 USA	University of Iowa	Stapleton, JT (corresponding author), Iowa City Vet Adm Healthcare, Med Serv, Iowa City, IA 52246 USA.; Stapleton, JT (corresponding author), Univ Iowa, Dept Internal Med, Microbiol & Immunol, Iowa City, IA 52242 USA.	jack-stapleton@uiowa.edu						Adams MJ, 2013, ARCH VIROL, V158, P2023, DOI 10.1007/s00705-013-1688-5; Adams NJ, 1998, J GEN VIROL, V79, P1871, DOI 10.1099/0022-1317-79-8-1871; Alter HJ, 1997, HEPATOLOGY, V26, pS29, DOI 10.1002/hep.510260705; Alter HJ, 1997, TRANSFUSION, V37, P569, DOI 10.1046/j.1537-2995.1997.37697335149.x; ALTER HJ, 1990, J HEPATOL, V11, pS19, DOI 10.1016/0168-8278(90)90158-N; Alter HJ, 1997, NEW ENGL J MED, V336, P747, DOI 10.1056/NEJM199703133361102; Alter MJ, 1997, NEW ENGL J MED, V336, P741, DOI 10.1056/NEJM199703133361101; Bailey AL, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006692; Bailey AL, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3467; Balcom EF, 2018, ANN NEUROL, V84, P781, DOI 10.1002/ana.25343; Belyaev AS, 1998, J VIROL, V72, P868, DOI 10.1128/JVI.72.1.868-872.1998; Berg MG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005325; Berg T, 1999, HEPATOLOGY, V29, P245, DOI 10.1002/hep.510290121; Berzsenyi MD, 2007, GASTROENTEROLOGY, V133, P1821, DOI 10.1053/j.gastro.2007.08.076; Berzsenyi MD, 2011, J HEPATOL, V55, P536, DOI 10.1016/j.jhep.2010.12.021; Bhardwaj B, 1997, J MED VIROL, V52, P92, DOI 10.1002/(SICI)1096-9071(199705)52:1&lt;92::AID-JMV15&gt;3.0.CO;2-2; Bhattarai N, 2013, J IMMUNOL, V190, P6351, DOI 10.4049/jimmunol.1300589; Bhattarai N, 2012, J INFECT DIS, V206, P1469, DOI 10.1093/infdis/jis515; Bhattarai N, 2012, J IMMUNOL, V189, P2211, DOI 10.4049/jimmunol.1201324; Bhattarai N, 2012, TRENDS MICROBIOL, V20, P124, DOI 10.1016/j.tim.2012.01.004; Birkenmeyer LG, 1998, J MED VIROL, V56, P44, DOI 10.1002/(SICI)1096-9071(199809)56:1<44::AID-JMV8>3.0.CO;2-N; Bjorkman P, 2004, AIDS, V18, P877, DOI [10.1097/01.aids.0000125908.52357.4c, 10.1097/00002030-200404090-00005]; Bjorkman P, 1998, TRANSFUSION, V38, P378, DOI 10.1046/j.1537-2995.1998.38498257377.x; Bjorkman P, 2007, AIDS, V21, P1641, DOI 10.1097/QAD.0b013e32823bc9b7; Blackard JT, 2017, J MED VIROL, V89, P1904, DOI 10.1002/jmv.24836; Blackard JT, 2016, J GEN VIROL, V97, P1537, DOI 10.1099/jgv.0.000477; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brown KE, 1997, NEW ENGL J MED, V336, P1059, DOI 10.1056/NEJM199704103361504; Bukh J, 1998, J INFECT DIS, V177, P855, DOI 10.1086/515255; Bukh J, 1997, VIROLOGY, V229, P429, DOI 10.1006/viro.1997.8461; Canuti M, 2019, ARCH VIROL, V164, P509, DOI 10.1007/s00705-018-4099-9; Cartier C, 1999, J BIOL CHEM, V274, P19434, DOI 10.1074/jbc.274.27.19434; Chandriani S, 2013, P NATL ACAD SCI USA, V110, pE1407, DOI 10.1073/pnas.1219217110; Chang CM, 2014, CANCER RES, V74, P5553, DOI 10.1158/0008-5472.CAN-14-0209; Chang Q, 2007, J GEN VIROL, V88, P3341, DOI 10.1099/vir.0.83198-0; Chivero ET, 2015, VIROLOGY, V485, P116, DOI 10.1016/j.virol.2015.07.008; Chivero ET, 2015, J GEN VIROL, V96, P1521, DOI 10.1099/vir.0.000086; Chivero ET, 2014, J GEN VIROL, V95, P1307, DOI 10.1099/vir.0.063016-0; Chowdhury AY, 2014, VIROLOGY, V456, P300, DOI 10.1016/j.virol.2014.03.018; Da Mota LD, 2019, J MED VIROL, V91, P31, DOI 10.1002/jmv.25291; Dawson GJ, 1996, J MED VIROL, V50, P97, DOI 10.1002/(SICI)1096-9071(199609)50:1&lt;97::AID-JMV16&gt;3.0.CO;2-V; DEINHARDT F, 1967, J EXP MED, V125, P673, DOI 10.1084/jem.125.4.673; Deinhardt F., 1984, HEPATITIS, P185; Devereux H, 1998, J MED VIROL, V56, P316, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;316::AID-JMV5&gt;3.0.CO;2-K; Dille BJ, 1997, J INFECT DIS, V175, P458, DOI 10.1093/infdis/175.2.458; Doan MAL, 2021, J VIROL, V95, DOI 10.1128/JVI.01074-21; Epstein JH, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000972; Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131; Fama A, 2020, CLIN INFECT DIS, V71, P1221, DOI 10.1093/cid/ciz940; Fama A, 2018, BRIT J HAEMATOL, V182, P644, DOI 10.1111/bjh.15416; Fargion S., 1997, Journal of Hepatology, V26, P207; Feng Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021151; Fernandez-Vidal M, 2007, PROTEIN PEPTIDE LETT, V14, P865, DOI 10.2174/092986607782110239; Firth C, 2014, MBIO, V5, DOI 10.1128/mBio.01933-14; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Fogeda M, 2000, J VIROL, V74, P7936, DOI 10.1128/JVI.74.17.7936-7942.2000; Fogeda M, 1999, J VIROL, V73, P4052, DOI 10.1128/JVI.73.5.4052-4061.1999; Frey SE, 2002, CLIN INFECT DIS, V34, P1033, DOI 10.1086/339206; Fried MW, 1997, HEPATOLOGY, V25, P1271, DOI 10.1002/hep.510250536; Fujisawa T, 2000, J GASTROEN HEPATOL, V15, P632, DOI 10.1046/j.1440-1746.2000.02196.x; George SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030653; George SL, 2006, J INFECT DIS, V193, P451, DOI 10.1086/499435; George SL, 2005, J INFECT DIS, V191, P2156, DOI 10.1086/430504; George SL, 2003, VIROLOGY, V316, P191, DOI 10.1016/S0042-6822(03)00585-3; Geskus RB, 2000, STAT MED, V19, P1753, DOI 10.1002/1097-0258(20000715)19:13&lt;1753::AID-SIM487&gt;3.0.CO;2-F; Gomara MJ, 2016, BBA-GEN SUBJECTS, V1860, P1139, DOI 10.1016/j.bbagen.2016.02.008; GonzalezPerez MA, 1997, J MED VIROL, V52, P149, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;149::AID-JMV5&gt;3.0.CO;2-3; Greenhalgh S, 2019, AM J EPIDEMIOL, V188, P1586, DOI 10.1093/aje/kwz139; Gretch D, 2012, CLIN INFECT DIS, V55, P1020, DOI 10.1093/cid/cis591; Gutierrez RA, 1997, J MED VIROL, V53, P167, DOI 10.1002/(SICI)1096-9071(199710)53:2&lt;167::AID-JMV10&gt;3.0.CO;2-G; Gutierrez RA, 1997, J VIROL METHODS, V69, P1, DOI 10.1016/S0166-0934(97)00140-7; Handelsman E, 2007, HIV MED, V8, P561, DOI 10.1111/j.1468-1293.2007.00510.x; Haro I, 2011, BBA-BIOMEMBRANES, V1808, P1567, DOI 10.1016/j.bbamem.2011.02.019; Hartlage AS, 2016, ANNU REV VIROL, V3, P53, DOI 10.1146/annurev-virology-100114-055104; Hassoba HM, 1998, J MED VIROL, V56, P253, DOI 10.1002/(SICI)1096-9071(199811)56:3&lt;253::AID-JMV13&gt;3.0.CO;2-F; Heffron AS, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8101509; Heringlake S, 1998, J INFECT DIS, V177, P1723, DOI 10.1086/517431; Heringlake S, 1996, LANCET, V348, P1626, DOI 10.1016/S0140-6736(96)04413-3; Herrera E, 2010, J MED CHEM, V53, P6054, DOI 10.1021/jm100452c; Herrera E, 2009, J PHYS CHEM B, V113, P7383, DOI 10.1021/jp900707t; Heuft HG, 1998, VOX SANG, V74, P161, DOI 10.1159/000030925; Hoffmann R, 2021, CHEMMEDCHEM, V16, P1290, DOI 10.1002/cmdc.202000892; Hollingsworth RC, 1998, J VIRAL HEPATITIS, V5, P165, DOI 10.1046/j.1365-2893.1998.00102.x; Horemheb-Rubio G, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184494; Hoseini MHM, 2007, ARCH MED RES, V38, P868, DOI 10.1016/j.arcmed.2007.05.009; Hunt PW, 2008, J INFECT DIS, V197, P126, DOI 10.1086/524143; Hunt PW, 2006, J INFECT DIS, V194, P1632, DOI 10.1086/509627; Hunt PW, 2003, J INFECT DIS, V187, P1534, DOI 10.1086/374786; Jarvis LM, 1998, SCAND J GASTROENTERO, V33, P195, DOI 10.1080/00365529850166941; Sanchez-Martin MJ, 2011, CHEMPHYSCHEM, V12, P2816, DOI 10.1002/cphc.201100407; Sanchez-Martin MJ, 2011, BBA-BIOMEMBRANES, V1808, P2178, DOI 10.1016/j.bbamem.2011.05.020; Sanchez-Martin MJ, 2011, J COLLOID INTERF SCI, V360, P124, DOI 10.1016/j.jcis.2011.04.053; Jones JM, 2020, TRANSFUSION, V60, pS1, DOI 10.1111/trf.15604; Jung S, 2005, AIDS, V19, P1267, DOI 10.1097/01.aids.0000180097.50393.df; Jung S, 2007, AIDS, V21, P645, DOI 10.1097/QAD.0b013e32803277c7; Kanda T, 1997, HEPATOLOGY, V25, P1261, DOI 10.1002/hep.510250534; Kanda T, 1997, J HEPATOL, V27, P464, DOI 10.1016/S0168-8278(97)80349-2; Kapoor A, 2015, MBIO, V6, DOI 10.1128/mBio.01466-15; Kapoor A, 2013, MBIO, V4, DOI 10.1128/mBio.00216-13; Kapoor A, 2013, J VIROL, V87, P7185, DOI 10.1128/JVI.00324-13; Kato T, 1999, J MED VIROL, V57, P376, DOI 10.1002/(SICI)1096-9071(199904)57:4&lt;376::AID-JMV9&gt;3.0.CO;2-#; Kaufman TM, 2007, AIDS, V21, P1045, DOI 10.1097/QAD.0b013e3280f77412; Kim JP, 1997, J VIRAL HEPATITIS, V4, P77, DOI 10.1111/j.1365-2893.1997.tb00208.x; Kim Y, 2018, CELL HOST MICROBE, V23, P14, DOI 10.1016/j.chom.2017.12.004; Koedel Y, 2011, J VIROL, V85, P7037, DOI 10.1128/JVI.02366-10; Krajden M, 2010, INT J CANCER, V126, P2885, DOI 10.1002/ijc.25035; Kriesel JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031886; Kubo S, 1997, J HEPATOL, V27, P91, DOI 10.1016/S0168-8278(97)80285-1; Kupfer B, 2005, J CLIN VIROL, V34, P42, DOI 10.1016/j.jcv.2005.01.008; Lalle E, 2008, INT J IMMUNOPATH PH, V21, P161, DOI 10.1177/039463200802100118; Lanteri MC, 2015, J INFECT DIS, V211, P1585, DOI 10.1093/infdis/jiu660; Laskus T, 1997, J VIROL, V71, P7804, DOI 10.1128/JVI.71.10.7804-7806.1997; Lau DTY, 1999, J INFECT DIS, V180, P1334, DOI 10.1086/315031; Lauck M, 2015, J VIROL, V89, P2425, DOI 10.1128/JVI.02752-14; Leary TP, 1996, J VIROL, V70, P9028, DOI 10.1128/JVI.70.12.9028-9030.1996; Leary TP, 1996, J MED VIROL, V48, P60, DOI 10.1002/(SICI)1096-9071(199601)48:1&lt;60::AID-JMV10&gt;3.0.CO;2-A; Lefrere JJ, 1999, J MED VIROL, V59, P32, DOI 10.1002/(SICI)1096-9071(199909)59:1&lt;32::AID-JMV6&gt;3.0.CO;2-O; Lin HH, 1998, J INFECT DIS, V177, P1202, DOI 10.1086/515264; Lin R, 1998, J GASTROEN HEPATOL, V13, P773, DOI 10.1111/j.1440-1746.1998.tb00732.x; Linnen J, 1996, SCIENCE, V271, P505, DOI 10.1126/science.271.5248.505; Madejon A, 1997, GASTROENTEROLOGY, V113, P573, DOI 10.1053/gast.1997.v113.pm9247478; MAHALINGAM M, 1993, CLIN EXP IMMUNOL, V93, P337, DOI 10.1111/j.1365-2249.1993.tb08182.x; Maidana-Giret MT, 2009, AIDS, V23, P2277, DOI 10.1097/QAD.0b013e32832d7a11; Malherbe DC, 2018, J VIROL, V92, DOI 10.1128/JVI.01092-17; Mandl JN, 2015, CELL, V160, P20, DOI 10.1016/j.cell.2014.12.003; Marano G, 2017, ACTA VIROL, V61, P401, DOI 10.4149/av_2017_402; Martinot M, 1997, ANN INTERN MED, V126, P874, DOI 10.7326/0003-4819-126-11-199706010-00004; McLinden JH, 2006, J VIROL, V80, P12131, DOI 10.1128/JVI.01206-06; Moenkemeyer M, 2008, J MED VIROL, V80, P1933, DOI 10.1002/jmv.21305; Mohr EL, 2010, J IMMUNOL, V185, P4496, DOI 10.4049/jimmunol.1001980; Mohr EL, 2009, J VIRAL HEPATITIS, V16, P757, DOI 10.1111/j.1365-2893.2009.01194.x; Mrzljak Anna, 2022, World J Transplant, V12, P1, DOI 10.5500/wjt.v12.i1.1; Muerhoff AS, 2006, J MED VIROL, V78, P105, DOI 10.1002/jmv.20510; MUERHOFF AS, 1995, J VIROL, V69, P5621, DOI 10.1128/JVI.69.9.5621-5630.1995; Muerhoff AS, 1997, J VIROL, V71, P6501, DOI 10.1128/JVI.71.9.6501-6508.1997; N'Guessan KF, 2017, OPEN FORUM INFECT DI, V4, DOI 10.1093/ofid/ofx222; Nagao Y, 1997, J ORAL PATHOL MED, V26, P138, DOI 10.1111/j.1600-0714.1997.tb00037.x; Nagayama R, 1997, J MED VIROL, V52, P156, DOI 10.1002/(SICI)1096-9071(199706)52:2&lt;156::AID-JMV6&gt;3.0.CO;2-2; Nattermann J, 2004, J VIRAL HEPATITIS, V11, P519, DOI 10.1111/j.1365-2893.2004.00545.x; Nattermann J, 2003, AIDS, V17, P1457, DOI 10.1097/00002030-200307040-00006; Nishizawa T, 2021, VIRUS RES, V301, DOI 10.1016/j.virusres.2021.198452; Nunnari G, 2003, ANN INTERN MED, V139, P26, DOI 10.7326/0003-4819-139-1-200307010-00009; Okamoto H, 1997, J GEN VIROL, V78, P737, DOI 10.1099/0022-1317-78-4-737; Pessoa MG, 1997, HEPATOLOGY, V25, P1266, DOI 10.1002/hep.510250535; PilotMatias TJ, 1996, J MED VIROL, V48, P329, DOI 10.1002/(SICI)1096-9071(199604)48:4&lt;329::AID-JMV6&gt;3.0.CO;2-9; PilotMatias TJ, 1996, VIROLOGY, V225, P282, DOI 10.1006/viro.1996.0602; Polgreen PM, 2003, MICROBES INFECT, V5, P1255, DOI 10.1016/j.micinf.2003.08.006; Porter AF, 2020, VIRUS EVOL, V6, DOI 10.1093/ve/veaa064; Pujol FH, 1998, J CLIN MICROBIOL, V36, P470, DOI 10.1128/JCM.36.2.470-474.1998; Quan PL, 2013, P NATL ACAD SCI USA, V110, P8194, DOI 10.1073/pnas.1303037110; Radkowski M, 2000, BLOOD, V95, P3986; Radkowski M, 1999, BIOCHEM BIOPH RES CO, V258, P296, DOI 10.1006/bbrc.1999.0632; Rambusch EG, 1998, Z GASTROENTEROL, V36, P41; Richardson MW, 2012, J IMMUNOL, V189, P3815, DOI 10.4049/jimmunol.1201431; Rodrigues TCS, 2019, VIRUS RES, V263, P98, DOI 10.1016/j.virusres.2019.01.002; Rydze RT, 2012, ANTIVIR THER, V17, P1271, DOI 10.3851/IMP2309; Rydze RT, 2012, J INFECT DIS, V206, P69, DOI 10.1093/infdis/jis312; Sallie R, 1996, LANCET, V347, P1552, DOI 10.1016/S0140-6736(96)90704-7; Santos LM, 2017, INT J GYNECOL OBSTET, V138, P113, DOI 10.1002/ijgo.12175; Sarrazin C, 2000, J MED VIROL, V62, P191, DOI 10.1002/1096-9071(200010)62:2&lt;191::AID-JMV10&gt;3.0.CO;2-7; Scallan MF, 1998, J MED VIROL, V55, P203, DOI 10.1002/(SICI)1096-9071(199807)55:3&lt;203::AID-JMV4&gt;3.0.CO;2-5; Schmolke S, 1998, J VIROL, V72, P4541, DOI 10.1128/JVI.72.5.4541-4545.1998; Schwarze-Zander C, 2010, ANTIVIR THER, V15, P745, DOI 10.3851/IMP1602; Shi M, 2016, J VIROL, V90, P659, DOI 10.1128/JVI.02036-15; Sibley SD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098569; Simmonds P, 2017, J GEN VIROL, V98, P2, DOI 10.1099/jgv.0.000672; Simons JN, 2000, CURR TOP MICROBIOL, V242, P341; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; Simons JN, 1996, J VIROL, V70, P6126, DOI 10.1128/JVI.70.9.6126-6135.1996; SIMONS JN, 1995, NAT MED, V1, P564, DOI 10.1038/nm0695-564; Smith A, 2015, CANCER EPIDEMIOL, V39, P1103, DOI 10.1016/j.canep.2015.08.015; Smith DB, 2000, J GEN VIROL, V81, P769, DOI 10.1099/0022-1317-81-3-769; Smith DB, 2016, J GEN VIROL, V97, P2894, DOI 10.1099/jgv.0.000612; Smith DB, 2014, HEPATOLOGY, V59, P318, DOI 10.1002/hep.26744; de Souza AJS, 2015, ACTA TROP, V152, P56, DOI 10.1016/j.actatropica.2015.08.014; Stapleton J, 2007, GASTROENTEROLOGY, V133, P2042, DOI 10.1053/j.gastro.2007.10.032; Stapleton JT, 2013, AIDS, V27, P1829, DOI 10.1097/QAD.0b013e328363089f; Stapleton JT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050563; Stapleton JT, 2011, J GEN VIROL, V92, P233, DOI 10.1099/vir.0.027490-0; Stapleton JT, 2009, AIDS, V23, P605, DOI 10.1097/QAD.0b013e32831f1b00; Stapleton JT, 2005, J INFECT DIS, V191, P2157, DOI 10.1086/430505; Stapleton JT, 2003, SEMIN LIVER DIS, V23, P137; Supapol WB, 2008, J INFECT DIS, V197, P1369, DOI 10.1086/587488; Tacke M, 1997, HEPATOLOGY, V26, P1626, DOI 10.1002/hep.510260635; Tagger A, 1997, HEPATOLOGY, V26, P1653; Tanaka E, 1998, J VIRAL HEPATITIS, V5, P153, DOI 10.1046/j.1365-2893.1998.00095.x; Tanaka E, 1998, J CLIN MICROBIOL, V36, P110, DOI 10.1128/JCM.36.1.110-114.1998; Theodore D, 1997, HEPATOLOGY, V25, P1285, DOI 10.1002/hep.510250541; Thomas DL, 1997, J INFECT DIS, V176, P586, DOI 10.1086/514078; Tillmann HL, 2001, ANTIVIR RES, V52, P83, DOI 10.1016/S0166-3542(01)00172-3; Tillmann HL, 1998, HEPATOLOGY, V28, P379, DOI 10.1002/hep.510280213; Tillmann HL, 2001, NEW ENGL J MED, V345, P715, DOI 10.1056/NEJMoa010398; Timmons CL, 2013, J INFECT DIS, V207, P1171, DOI 10.1093/infdis/jit001; Tomlinson JE, 2019, J VET INTERN MED, V33, P258, DOI 10.1111/jvim.15362; Tomlinson JE, 2019, J VET INTERN MED, V33, P251, DOI 10.1111/jvim.15368; Toyoda H, 1998, J ACQ IMMUN DEF SYND, V17, P209, DOI 10.1097/00042560-199803010-00004; Tucker TJ, 2000, J MED VIROL, V61, P52, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;52::AID-JMV8&gt;3.0.CO;2-L; Vahidnia F, 2012, CLIN INFECT DIS, V55, P1012, DOI 10.1093/cid/cis589; Valdez H, 2003, J INFECT DIS, V187, P320, DOI 10.1086/346056; Van der Bij AK, 2005, J INFECT DIS, V191, P678, DOI 10.1086/427559; Vu DL, 2019, CLIN MICROBIOL INFEC, V25, P225, DOI 10.1016/j.cmi.2018.05.004; Wan ZW, 2020, EMERG MICROBES INFEC, V9, P485, DOI 10.1080/22221751.2020.1730247; Williams CF, 2004, NEW ENGL J MED, V350, P981, DOI 10.1056/NEJMoa030107; Wu Z, 2020, J VIROL, V94, DOI 10.1128/JVI.01150-20; Wunschmann S, 2000, J VIROL, V74, P10055, DOI 10.1128/JVI.74.21.10055-10062.2000; Xiang JH, 2005, J INFECT DIS, V192, P2147, DOI 10.1086/498170; Xiang JH, 2005, J INTERF CYTOK RES, V25, P261, DOI 10.1089/jir.2005.25.261; Xiang JH, 2004, LANCET, V363, P2040, DOI 10.1016/S0140-6736(04)16453-2; Xiang JH, 2001, NEW ENGL J MED, V345, P707, DOI 10.1056/NEJMoa003364; Xiang JH, 2000, J VIROL, V74, P9125, DOI 10.1128/JVI.74.19.9125-9133.2000; Xiang JH, 2006, P NATL ACAD SCI USA, V103, P15570, DOI 10.1073/pnas.0604728103; Xiang JH, 2012, VIROLOGY, V430, P53, DOI 10.1016/j.virol.2012.04.019; Xiang JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002580; Yang N, 2020, VOX SANG, V115, P107, DOI 10.1111/vox.12876; Yeo AET, 2000, ANN INTERN MED, V132, P959, DOI 10.7326/0003-4819-132-12-200006200-00006; YOSHIBA M, 1995, LANCET, V346, P1131, DOI 10.1016/S0140-6736(95)91802-7; Yu YQ, 2022, VIRULENCE, V13, P324, DOI 10.1080/21505594.2022.2029328; Zanetti AR, 1998, J MED VIROL, V54, P107, DOI 10.1002/(SICI)1096-9071(199802)54:2&lt;107::AID-JMV7&gt;3.0.CO;2-A; Zhang W, 2006, HIV MED, V7, P173, DOI 10.1111/j.1468-1293.2006.00366.x; Zhen W, 2021, POULTRY SCI, V100, DOI 10.1016/j.psj.2021.101251; Zignego AL, 1997, BRIT J HAEMATOL, V98, P778, DOI 10.1046/j.1365-2141.1997.d01-3531.x; Zimmerman J, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2257; Zuckerman AJ, 1983, VIRAL HEPATITIS LAB, P3	223	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								887760	10.3389/fimmu.2022.887760	http://dx.doi.org/10.3389/fimmu.2022.887760			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4SV	35707535	Green Published, gold			2022-12-18	WOS:000810180700001
J	Sunaga, S; Tsunoda, J; Teratani, T; Mikami, Y; Kanai, T				Sunaga, Shogo; Tsunoda, Junya; Teratani, Toshiaki; Mikami, Yohei; Kanai, Takanori			Heterogeneity of ILC2s in the Intestine; Homeostasis and Pathology	FRONTIERS IN IMMUNOLOGY			English	Review						ILC2; group 2 innate lymphoid cell; IBD; inflammatory bowel disease; Crohn's disease; ulcerative colitis; mucosal immunology	INNATE LYMPHOID-CELLS; TRANSCRIPTION FACTOR GATA3; T-CELL; MAINTENANCE THERAPY; SIGNALING PROTECTS; IL-33 PROMOTES; INFLAMMATION; CYTOKINE; COLITIS; TL1A	Group 2 innate lymphoid cells (ILC2s) were identified in 2010 as a novel lymphocyte subset lacking antigen receptors, such as T-cell or B-cell receptors. ILC2s induce local immune responses characterized by producing type 2 cytokines and play essential roles for maintaining tissue homeostasis. ILC2s are distributed across various organs, including the intestine where immune cells are continuously exposed to external antigens. Followed by luminal antigen stimulation, intestinal epithelial cells produce alarmins, such as IL-25, IL-33, and thymic stromal lymphopoietin, and activate ILC2s to expand and produce cytokines. In the context of parasite infection, the tuft cell lining in the epithelium has been revealed as a dominant source of intestinal IL-25 and possesses the capability to regulate ILC2 homeostasis. Neuronal systems also regulate ILC2s through neuropeptides and neurotransmitters, and interact with ILC2s bidirectionally, a process termed "neuro-immune crosstalk". Activated ILC2s produce type 2 cytokines, which contribute to epithelial barrier function, clearance of luminal antigens and tissue repair, while ILC2s are also involved in chronic inflammation and tissue fibrosis. Recent studies have shed light on the contribution of ILC2s to inflammatory bowel diseases, mainly comprising ulcerative colitis and Crohn's disease, as defined by chronic immune activation and inflammation. Modern single-cell analysis techniques provide a tissue-specific picture of ILC2s and their roles in regulating homeostasis in each organ. Particularly, single-cell analysis helps our understanding of the uniqueness and commonness of ILC2s across tissues and opens the novel research area of ILC2 heterogeneity. ILC2s are classified into different phenotypes depending on tissue and phase of inflammation, mainly inflammatory and natural ILC2 cells. ILC2s can also switch phenotype to ILC1- or ILC3-like subsets. Hence, recent studies have revealed the heterogeneity and plasticity of ILC2, which indicate dynamicity of inflammation and the immune system. In this review, we describe the regulatory mechanisms, function, and pathological roles of ILC2s in the intestine.	[Sunaga, Shogo; Teratani, Toshiaki; Mikami, Yohei; Kanai, Takanori] Keio Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sch Med, Shinju Ku, Tokyo, Japan; [Tsunoda, Junya] Keio Univ, Dept Surg, Sch Med, Tokyo, Japan; [Kanai, Takanori] Japan Agcy Med Res & Dev, AMED CREST, Tokyo, Japan	Keio University; Keio University	Mikami, Y; Kanai, T (corresponding author), Keio Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Sch Med, Shinju Ku, Tokyo, Japan.; Kanai, T (corresponding author), Japan Agcy Med Res & Dev, AMED CREST, Tokyo, Japan.	yoheimikami@keio.jp; takagast@keio.jp	MIKAMI, YOHEI/GRJ-8133-2022	MIKAMI, YOHEI/0000-0001-5104-4415				Abraham C, 2009, NEW ENGL J MED, V361, P2066, DOI 10.1056/NEJMra0804647; Angkasekwinai P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184684; Bailey JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052332; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Camelo A, 2012, J GASTROENTEROL, V47, P1198, DOI 10.1007/s00535-012-0591-2; Cardoso V, 2017, NATURE, V549, P277, DOI 10.1038/nature23469; Cayrol C, 2018, NAT IMMUNOL, V19, P375, DOI 10.1038/s41590-018-0067-5; Cephus JY, 2017, CELL REP, V21, P2487, DOI 10.1016/j.celrep.2017.10.110; Chinen H, 2007, GASTROENTEROLOGY, V133, P559, DOI 10.1053/j.gastro.2007.05.017; Chu C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe3218; Chu C, 2020, IMMUNITY, V52, P464, DOI 10.1016/j.immuni.2020.02.017; Corren J, 2019, NAT IMMUNOL, V20, P1603, DOI 10.1038/s41590-019-0524-9; Danese S, 2015, GUT, V64, P243, DOI 10.1136/gutjnl-2014-308004; De Salvo C, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140624; De Salvo C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585319; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Duffield JS, 2013, ANNU REV PATHOL-MECH, V8, P241, DOI 10.1146/annurev-pathol-020712-163930; Feagan BG, 2016, NEW ENGL J MED, V375, P1946, DOI 10.1056/NEJMoa1602773; Fichtner-Feigl S, 2007, J IMMUNOL, V178, P5859, DOI 10.4049/jimmunol.178.9.5859; Flamar AL, 2020, IMMUNITY, V52, P606, DOI 10.1016/j.immuni.2020.02.009; Fonseca-Pereira D, 2014, NATURE, V514, P98, DOI 10.1038/nature13498; Forkel M, 2019, J CROHNS COLITIS, V13, P67, DOI 10.1093/ecco-jcc/jjy119; Frisbee AL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10733-9; Furness JB, 2013, NAT REV GASTRO HEPAT, V10, P729, DOI 10.1038/nrgastro.2013.180; Furusawa J, 2013, J IMMUNOL, V191, P1818, DOI 10.4049/jimmunol.1300379; Galle-Treger L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13202; Gasteiger G, 2015, SCIENCE, V350, P981, DOI 10.1126/science.aac9593; Gauvreau GM, 2020, EXPERT OPIN THER TAR, V24, P777, DOI 10.1080/14728222.2020.1783242; Geremia A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01296; Geremia A, 2014, AUTOIMMUN REV, V13, P3, DOI 10.1016/j.autrev.2013.06.004; Godinho-Silva C, 2019, ANNU REV IMMUNOL, V37, P19, DOI 10.1146/annurev-immunol-042718-041812; Graham DB, 2020, NATURE, V578, P527, DOI 10.1038/s41586-020-2025-2; Gury-BenAri M, 2016, CELL, V166, P1231, DOI 10.1016/j.cell.2016.07.043; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Hams E, 2014, P NATL ACAD SCI USA, V111, P367, DOI 10.1073/pnas.1315854111; Heller F, 2005, GASTROENTEROLOGY, V129, P550, DOI 10.1053/j.gastro.2005.05.002; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Herro R, 2015, J ALLERGY CLIN IMMUN, V136, P757, DOI 10.1016/j.jaci.2014.12.1936; Hikichi Y, 2021, J EXP MED, V218, DOI 10.1084/jem.20210181; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang YF, 2018, SCIENCE, V359, P114, DOI 10.1126/science.aam5809; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Huh JR, 2020, NAT REV IMMUNOL, V20, P217, DOI 10.1038/s41577-019-0247-z; Johnson EN, 2004, J IMMUNOL, V173, P7230, DOI 10.4049/jimmunol.173.12.7230; Kabata H, 2020, MUCOSAL IMMUNOL, V13, P626, DOI 10.1038/s41385-020-0266-x; Kabata H, 2019, J CLIN INVEST, V129, P1475, DOI 10.1172/JCI124609; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kang L, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.609400; Khor B, 2011, NATURE, V474, P307, DOI 10.1038/nature10209; Kiniwa T, 2021, INT IMMUNOL, V33, P251, DOI 10.1093/intimm/dxab001; Klose CSN, 2021, EUR J IMMUNOL, V51, P1602, DOI 10.1002/eji.202048812; Klose CSN, 2017, NATURE, V549, P282, DOI 10.1038/nature23676; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Knipfer L, 2019, J EXP MED, V216, P2763, DOI 10.1084/jem.20182111; Kobayashi T., 2021, INT IMMUNOL, V33, P705, DOI [10.1093/intimm/dxab063, DOI 10.1093/INTIMM/DXAB063]; Kobori A, 2010, J GASTROENTEROL, V45, P999, DOI 10.1007/s00535-010-0245-1; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Kotas ME, 2021, MUCOSAL IMMUNOL, V14, P1295, DOI 10.1038/s41385-021-00430-6; Kramer B, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006373; Krause P, 2014, GASTROENTEROLOGY, V146, P1752, DOI 10.1053/j.gastro.2014.02.010; Kuwada T, 2021, GASTROENTEROLOGY, V160, P2383, DOI 10.1053/j.gastro.2021.02.019; Laurent P, 2021, ANN RHEUM DIS, V80, P1594, DOI 10.1136/annrheumdis-2020-219748; Lawrance IC, 2003, GASTROENTEROLOGY, V125, P1750, DOI 10.1053/j.gastro.2003.08.027; Lee JU, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-017-0380-z; Lees CW, 2011, GUT, V60, P1739, DOI 10.1136/gut.2009.199679; Li SY, 2018, IMMUNITY, V49, P915, DOI 10.1016/j.immuni.2018.09.015; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Liu SC, 2018, J ALLERGY CLIN IMMUN, V141, P257, DOI 10.1016/j.jaci.2017.03.032; Longman RS, 2014, J EXP MED, V211, P1571, DOI 10.1084/jem.20140678; Lu JX, 2021, J CELL MOL MED, V25, P3041, DOI 10.1111/jcmm.16348; Macho-Fernandez E, 2015, MUCOSAL IMMUNOL, V8, P403, DOI 10.1038/mi.2014.78; Madden KB, 2004, J IMMUNOL, V172, P5616, DOI 10.4049/jimmunol.172.9.5616; Maggi L, 2021, MOL ASPECTS MED, V80, DOI 10.1016/j.mam.2021.100981; Markovic I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01557; Matera MG, 2020, DRUGS, V80, P449, DOI 10.1007/s40265-020-01273-4; Matta BM, 2014, J IMMUNOL, V193, P4010, DOI 10.4049/jimmunol.1400481; Matteoli G, 2014, GUT, V63, P938, DOI 10.1136/gutjnl-2013-304676; McGinty JW, 2020, IMMUNITY, V52, P528, DOI 10.1016/j.immuni.2020.02.005; Mchedlidze T, 2013, IMMUNITY, V39, P357, DOI 10.1016/j.immuni.2013.07.018; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Meylan F, 2014, MUCOSAL IMMUNOL, V7, P958, DOI 10.1038/mi.2013.114; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Mikami Y, 2018, CYTOKINE GROWTH F R, V42, P27, DOI 10.1016/j.cytogfr.2018.07.002; Mizuno S, 2014, INFLAMM BOWEL DIS, V20, P1426, DOI 10.1097/MIB.0000000000000105; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; Monticelli LA, 2015, P NATL ACAD SCI USA, V112, P10762, DOI 10.1073/pnas.1509070112; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Moriyama M, 2005, J EXP MED, V202, P217, DOI 10.1084/jem.20050248; Moriyama S, 2018, SCIENCE, V359, P1056, DOI 10.1126/science.aan4829; Moro K, 2016, NAT IMMUNOL, V17, P76, DOI 10.1038/ni.3309; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Nagashima H, 2019, IMMUNITY, V51, P682, DOI 10.1016/j.immuni.2019.06.009; Nakayama T, 2017, ANNU REV IMMUNOL, V35, P53, DOI 10.1146/annurev-immunol-051116-052350; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Olguin-Martinez E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757967; Pelly VS, 2016, MUCOSAL IMMUNOL, V9, P1407, DOI 10.1038/mi.2016.4; Phuong NNT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669787; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Pizarro TT, 2011, INFLAMM BOWEL DIS, V17, P2566, DOI 10.1002/ibd.21638; Powell N, 2015, GASTROENTEROLOGY, V149, P456, DOI 10.1053/j.gastro.2015.04.017; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rauber S, 2017, NAT MED, V23, P938, DOI 10.1038/nm.4373; Reinisch W, 2015, GUT, V64, P894, DOI 10.1136/gutjnl-2014-308337; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Rivas MN, 2016, J ALLERGY CLIN IMMUN, V138, P801, DOI 10.1016/j.jaci.2016.02.030; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Roussel L, 2013, J ALLERGY CLIN IMMUN, V131, P913, DOI 10.1016/j.jaci.2012.10.019; Saez A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147618; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Sands BE, 2019, NEW ENGL J MED, V381, P1201, DOI 10.1056/NEJMoa1900750; Satoh-Takayama N, 2020, IMMUNITY, V52, P635, DOI 10.1016/j.immuni.2020.03.002; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Schneider C, 2019, NAT REV IMMUNOL, V19, P584, DOI 10.1038/s41577-019-0176-x; Schneider C, 2018, CELL, V174, P271, DOI 10.1016/j.cell.2018.05.014; Schuppan D, 2008, LANCET, V371, P838, DOI 10.1016/S0140-6736(08)60383-9; Sedhom MAK, 2013, GUT, V62, P1714, DOI 10.1136/gutjnl-2011-301785; Seehus CR, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02023-z; Shao JY, 2010, ENDOCRINOLOGY, V151, P3728, DOI 10.1210/en.2010-0319; Shih DQ, 2014, MUCOSAL IMMUNOL, V7, P1492, DOI 10.1038/mi.2014.37; Shih DQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016090; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Takayama T, 2010, GASTROENTEROLOGY, V139, P882, DOI 10.1053/j.gastro.2010.05.040; Talbot S, 2015, NEURON, V87, P341, DOI 10.1016/j.neuron.2015.06.007; Teratani T, 2020, NATURE, V585, P591, DOI 10.1038/s41586-020-2425-3; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Uddin MJ, 2022, MUCOSAL IMMUNOL, V15, P165, DOI 10.1038/s41385-021-00442-2; Varricchi G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01595; Vila-Caballer M, 2019, J MOL CELL CARDIOL, V132, P154, DOI 10.1016/j.yjmcc.2019.05.009; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; von Moltke J, 2016, NATURE, V529, P221, DOI 10.1038/nature16161; Waddell A, 2015, INFLAMM BOWEL DIS, V21, P2737, DOI 10.1097/MIB.0000000000000532; Wallrapp A, 2019, IMMUNITY, V51, P709, DOI 10.1016/j.immuni.2019.09.005; Wallrapp A, 2017, NATURE, V549, P351, DOI 10.1038/nature24029; Wick G, 2013, ANNU REV IMMUNOL, V31, P107, DOI 10.1146/annurev-immunol-032712-095937; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Xu HP, 2019, IMMUNITY, V51, P696, DOI 10.1016/j.immuni.2019.09.004; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yan YQ, 2021, IMMUNITY, V54, P499, DOI 10.1016/j.immuni.2021.02.002; Ye Y, 2021, IMMUNOLOGY, V162, P17, DOI 10.1111/imm.13257; YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x; You Y, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/5018975; Yu X, 2014, MUCOSAL IMMUNOL, V7, P730, DOI 10.1038/mi.2013.92; Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715; Zhao AP, 2003, J IMMUNOL, V171, P948, DOI 10.4049/jimmunol.171.2.948; Zheng DP, 2020, CELL RES, V30, P492, DOI 10.1038/s41422-020-0332-7; Zheng L, 2013, EUR J MICROBIOL IMMU, V3, P11, DOI 10.1556/EuJMI.3.2013.1.2	154	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								867351	10.3389/fimmu.2022.867351	http://dx.doi.org/10.3389/fimmu.2022.867351			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4UU	35707544	gold, Green Published			2022-12-18	WOS:000810185800001
J	Wang, Y; Liu, F; Chen, L; Fang, C; Li, SY; Yuan, SK; Qian, XY; Yin, Y; Yu, B; Fu, BQ; Zhang, XW; Li, Y				Wang, Yong; Liu, Fen; Chen, Lin; Fang, Chen; Li, Shuangyan; Yuan, Shangkun; Qian, Xiaoying; Yin, Yan; Yu, Biao; Fu, Biqi; Zhang, Xinwei; Li, Yong			Neutrophil Extracellular Traps (NETs) Promote Non-Small Cell Lung Cancer Metastasis by Suppressing lncRNA MIR503HG to Activate the NF-kappa B/NLRP3 Inflammasome Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophil extracellular traps (NETs); NOD-like receptor protein 3 (NLRP3); MIR503HG; epithelial to mesenchymal transition (EMT); non-small cell lung cancer (NSCLC)	NLRP3 INFLAMMASOME; PROGRESSION; MICROENVIRONMENT; PROLIFERATION; ANGIOGENESIS; APOPTOSIS; IMMUNITY; STAGE	Neutrophil extracellular traps (NETs) that are produced in the tumour microenvironment (TME) have been suggested to play an essential role in the dissemination of metastatic cancer under multiple infectious and inflammatory conditions. However, the functions of NETs in promoting non-small cell lung cancer (NSCLC) metastasis and the underlying mechanisms remain incompletely understood. Here, we found that NETs promoted NSCLC cell invasion and migration by inducing epithelial to mesenchymal transition (EMT). To explore how NETs contribute to NSCLC metastasis, microarrays were performed to identify substantial numbers of long noncoding RNAs (lncRNAs) and mRNAs that were differentially expressed in NSCLC cells after stimulation with NETs. Interestingly, we observed that the expression of lncRNA MIR503HG was downregulated after NETs stimulation, and ectopic MIR503HG expression reversed the metastasis-promoting effect of NETs in vitro and in vivo. Notably, bioinformatics analysis revealed that differentially expressed genes were involved in the NOD-like receptor and NF-kappa B signalling pathways that are associated with inflammation. NETs facilitated EMT and thereby contributed to NSCLC metastasis by activating the NF-kappa B/NOD-like receptor protein 3 (NLRP3) signalling pathway. Further studies revealed that MIR503HG inhibited NETs-triggered NSCLC cell metastasis in an NF-kappa B/NLRP3-dependent manner, as overexpression of NF-kappa B or NLRP3 impaired the suppressive effect of MIR503HG on NETs-induced cancer cell metastasis. Together, these results show that NETs activate the NF-kappa B/NLRP3 pathway by downregulating MIR503HG expression to promote EMT and NSCLC metastasis. Targeting the formation of NETs may be a novel therapeutic strategy for treating NSCLC metastasis.	[Wang, Yong; Fang, Chen; Yuan, Shangkun; Qian, Xiaoying; Yu, Biao; Zhang, Xinwei; Li, Yong] Nanchang Univ, Affiliated Hosp 1, Dept Med Oncol, Nanchang, Peoples R China; [Wang, Yong; Fang, Chen; Li, Shuangyan; Yuan, Shangkun; Qian, Xiaoying; Zhang, Xinwei] Nanchang Univ, Affiliated Hosp 1, Med Innovat Ctr, Nanchang, Peoples R China; [Liu, Fen; Li, Shuangyan] Nanchang Univ, Affiliated Hosp 1, Crit Care Med, Nanchang, Peoples R China; [Chen, Lin] Nanchang Univ, Affiliated Hosp 2, Dept Internal Neurol, Nanchang, Peoples R China; [Yin, Yan] Nanchang Univ, Affiliated Hosp 1, Dept Pathol, Nanchang, Peoples R China; [Fu, Biqi] Nanchang Univ, Affiliated Hosp 1, Dept Rheumatol, Nanchang, Peoples R China	Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University; Nanchang University	Li, Y (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Med Oncol, Nanchang, Peoples R China.	liyongcsco@email.ncu.edu.cn						Acha-Sagredo A, 2020, BRIT J CANCER, V122, P1050, DOI 10.1038/s41416-020-0742-9; Ahmad I, 2013, TOXICOL APPL PHARM, V270, P70, DOI 10.1016/j.taap.2013.03.027; Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227; Aldabbous L, 2016, ARTERIOSCL THROM VAS, V36, P2078, DOI 10.1161/ATVBAHA.116.307634; Nicolas-Avila JA, 2017, IMMUNITY, V46, P15, DOI 10.1016/j.immuni.2016.12.012; Baker KJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01197; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Cao X, 2020, DIABET METAB SYND OB, V13, P4507, DOI 10.2147/DMSO.S277869; Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003; Chen VW, 2014, CANCER-AM CANCER SOC, V120, P3781, DOI 10.1002/cncr.29045; Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484; Demers M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22946; Ekeke CN, 2021, CLIN LUNG CANCER, V22, pE132, DOI 10.1016/j.cllc.2020.09.002; Fan SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089961; Fang C, 2021, AGING-US, V13, P17864, DOI 10.18632/aging.203289; Fiedler J, 2015, J AM COLL CARDIOL, V66, P2005, DOI 10.1016/j.jacc.2015.07.081; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002; Hu H, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0761-9; Hu QY, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-018-1800-z; Huang W, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00318-7; Kahlenberg JM, 2013, J IMMUNOL, V190, P1217, DOI 10.4049/jimmunol.1202388; Kajioka H, 2021, CANCER LETT, V497, P1, DOI 10.1016/j.canlet.2020.10.015; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karki R, 2017, CANCER IMMUNOL RES, V5, P94, DOI 10.1158/2326-6066.CIR-16-0269; Khan S, 2021, LIFE SCI, V271, DOI 10.1016/j.lfs.2021.119152; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee J, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1008257; Lin H, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.708501; Lin YK, 2021, THERANOSTICS, V11, P426, DOI 10.7150/thno.50281; Liu D, 2019, CLIN SCI, V133, P565, DOI 10.1042/CS20180600; Luo DB, 2020, EUR REV MED PHARMACO, V24, P1233, DOI 10.26355/eurrev_202002_20176; Ma MR, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12525; Masucci MT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01749; Missiroli S, 2021, CANCERS, V13, DOI 10.3390/cancers13102297; Moossavi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0900-3; Muys BR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151560; Najmeh S, 2015, JOVE-J VIS EXP, DOI 10.3791/52687; Oklu R, 2017, CARDIOVASC DIAGN THE, V7, pS140, DOI 10.21037/cdt.2017.08.01; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rayes RF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128008; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI [10.3322/caac.21590, 10.3322/caac.21601]; Song SP, 2021, DIGEST LIVER DIS, V53, P107, DOI 10.1016/j.dld.2020.09.008; Stankovic B, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03101; Tall AR, 2019, J LIPID RES, V60, P721, DOI 10.1194/jlr.S091280; Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001; Tohme S, 2016, CANCER RES, V76, P1367, DOI 10.1158/0008-5472.CAN-15-1591; Tuting T, 2016, SCIENCE, V352, P145, DOI 10.1126/science.aaf7300; Wang SM, 2021, MOL THER-ONCOLYTICS, V21, P62, DOI 10.1016/j.omto.2021.03.009; Wang YL, 2016, ONCOL REP, V35, P2053, DOI 10.3892/or.2016.4569; Wang Z, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4063562; Warnatsch A, 2015, SCIENCE, V349, P316, DOI 10.1126/science.aaa8064; Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6; Yang LY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0836-0; Yang LY, 2020, J CANCER, V11, P4384, DOI 10.7150/jca.44215; Yi H, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.451; Zha CJ, 2020, CANCER BIOL MED, V17, P154, DOI 10.20892/j.issn.2095-3941.2019.0353; Zhou JW, 2019, ONCOL LETT, V18, P181, DOI 10.3892/ol.2019.10290; Zhu BL, 2021, EXP CELL RES, V405, DOI 10.1016/j.yexcr.2021.112707; Zhu T, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4960; Zhuang XQ, 2019, TRENDS PHARMACOL SCI, V40, P419, DOI 10.1016/j.tips.2019.04.005; Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224; Zou J, 2018, BIOMED PHARMACOTHER, V108, P130, DOI 10.1016/j.biopha.2018.09.051	70	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								867516	10.3389/fimmu.2022.867516	http://dx.doi.org/10.3389/fimmu.2022.867516			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4VA	35707534	Green Published, gold			2022-12-18	WOS:000810186400001
J	Wiedemann, GM				Wiedemann, Gabriela M.			Localization Matters: Epigenetic Regulation of Natural Killer Cells in Different Tissue Microenvironments	FRONTIERS IN IMMUNOLOGY			English	Review						NK cell; epigenetic regulation; histone modification; tumor microenvironment; tissue microenvironment; cancer immunology	INNATE LYMPHOID-CELLS; NK CELLS; HISTONE MODIFICATIONS; TRANSCRIPTION FACTOR; DNA METHYLATION; T-CELL; CHROMATIN STATE; BINDING; CONVERSION; LANDSCAPE	Natural Killer cells (NK cells) are cytotoxic innate lymphoid cells (ILCs), which play a key role in the early protection against viral infection and cancer. In addition to mounting rapid effector responses, NK cells possess the capacity to generate long-lived memory cells in response to certain stimuli, thus blurring the lines between innate and adaptive immunity and making NK cells an ideal candidate for tumor immunotherapy. NK cell development, activation and memory formation are regulated by epigenetic alterations driven by a complex interplay of external and internal signals. These epigenetic modifications can convey long-lasting functional and phenotypic changes and critically modify their response to stimulation. Here, we review how NK cell functionality and plasticity are regulated at the epigenetic level in different tissue microenvironments and within tumor microenvironments. An in-depth understanding of the epigenetic modifications underlying NK cell functional diversity in different environments is an essential step in the development of NK cell-based cancer therapies.	[Wiedemann, Gabriela M.] Tech Univ Munich, Sch Med, Dept Internal Med 2, Klinikum Rechts Isar, Munich, Germany	Technical University of Munich	Wiedemann, GM (corresponding author), Tech Univ Munich, Sch Med, Dept Internal Med 2, Klinikum Rechts Isar, Munich, Germany.	gabriela.wiedemann@tum.de			Deutsche Forschungsgemeinschaft (DFG) Emmy Noether program [WI4927/2-1]; TUM Junior Fellows Fund (Technical University of Munich)	Deutsche Forschungsgemeinschaft (DFG) Emmy Noether program(German Research Foundation (DFG)); TUM Junior Fellows Fund (Technical University of Munich)	GMW is funded by the Deutsche Forschungsgemeinschaft (DFG) Emmy Noether program (WI4927/2-1) and by the TUM Junior Fellows Fund (Technical University of Munich).	Adams NM, 2018, IMMUNITY, V48, P1172, DOI 10.1016/j.immuni.2018.04.018; Aliahmad P, 2010, NAT IMMUNOL, V11, P945, DOI 10.1038/ni.1930; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Angelo LS, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.810080; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; BENHATTAR J, 1988, GENE, V65, P219, DOI 10.1016/0378-1119(88)90458-1; Berndsen CE, 2008, CURR OPIN STRUC BIOL, V18, P682, DOI 10.1016/j.sbi.2008.11.004; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Bogliotti YS, 2012, EPIGENETICS-US, V7, P976, DOI 10.4161/epi.21615; Boos MD, 2007, J EXP MED, V204, P1119, DOI 10.1084/jem.20061959; Bronchud Miguel H, 2018, Oncotarget, V9, P6028, DOI 10.18632/oncotarget.23488; Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038; Cerdeira AS, 2013, J IMMUNOL, V190, P3939, DOI 10.4049/jimmunol.1202582; Chan IS, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202001134; Clements A, 2003, MOL CELL, V12, P461, DOI 10.1016/S1097-2765(03)00288-0; Collins PL, 2019, CELL, V176, P348, DOI 10.1016/j.cell.2018.11.045; Cortez VS, 2016, IMMUNITY, V44, P1127, DOI 10.1016/j.immuni.2016.03.007; Cribbs A, 2018, J BIOL CHEM, V293, P2422, DOI 10.1074/jbc.RA117.000698; Cuff AO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02180; Dadi S, 2016, CELL, V164, P365, DOI 10.1016/j.cell.2016.01.002; Dahariya S, 2019, MOL IMMUNOL, V112, P82, DOI 10.1016/j.molimm.2019.04.011; Di Censo C, 2021, EUR J IMMUNOL, V51, P2568, DOI 10.1002/eji.202149209; Donatelli SS, 2014, P NATL ACAD SCI USA, V111, P4203, DOI 10.1073/pnas.1319269111; Espinoza JL, 2012, HAEMATOL-HEMATOL J, V97, P1295, DOI 10.3324/haematol.2011.058529; Friedrich C, 2021, NAT IMMUNOL, V22, P1256, DOI 10.1038/s41590-021-01013-0; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Gamliel M, 2018, IMMUNITY, V48, P951, DOI 10.1016/j.immuni.2018.03.030; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Geary C, 2019, J IMMUNOL, V202; Gopalakrishnan S, 2008, MUTAT RES-FUND MOL M, V647, P30, DOI 10.1016/j.mrfmmm.2008.08.006; Gordon SM, 2012, IMMUNITY, V36, P55, DOI 10.1016/j.immuni.2011.11.016; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Gu TP, 2011, NATURE, V477, P606, DOI 10.1038/nature10443; Gury-BenAri M, 2016, CELL, V166, P1231, DOI 10.1016/j.cell.2016.07.043; Hammer Q, 2018, NAT IMMUNOL, V19, P453, DOI 10.1038/s41590-018-0082-6; He B, 2016, IMMUNITY, V45, P1341, DOI 10.1016/j.immuni.2016.11.009; Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829; Henikoff S, 2020, ELIFE, V9, DOI 10.7554/eLife.63274; HERBERMAN RB, 1975, INT J CANCER, V16, P216, DOI 10.1002/ijc.2910160204; Hildreth AD, 2021, NAT IMMUNOL, V22, P639, DOI 10.1038/s41590-021-00922-4; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; Holt D, 2011, CANCER IMMUNOL IMMUN, V60, P1577, DOI 10.1007/s00262-011-1064-9; Horowitz A, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006702; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Jambhekar A, 2019, NAT REV MOL CELL BIO, V20, P625, DOI 10.1038/s41580-019-0151-1; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957; Jorda M, 2017, GENOME RES, V27, P118, DOI 10.1101/gr.207522.116; Judge SJ, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00049; Kamizono S, 2009, J EXP MED, V206, P2977, DOI 10.1084/jem.20092176; Karmodiya K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-424; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Kebede AF, 2015, FEBS J, V282, P1658, DOI 10.1111/febs.13047; Klemm SL, 2019, NAT REV GENET, V20, P207, DOI 10.1038/s41576-018-0089-8; Koues OI, 2016, CELL, V165, P1134, DOI 10.1016/j.cell.2016.04.014; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Lanier LL, 1998, ANNU REV IMMUNOL, V16, P359, DOI 10.1146/annurev.immunol.16.1.359; Lara-Astiaso D, 2014, SCIENCE, V345, P943, DOI 10.1126/science.1256271; Lau CM, 2022, IMMUNOL REV, V305, P90, DOI 10.1111/imr.13031; Lau CM, 2018, NAT IMMUNOL, V19, P963, DOI 10.1038/s41590-018-0176-1; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133; Li K, 2020, GENOM PROTEOM BIOINF, V18, P501, DOI 10.1016/j.gpb.2020.12.003; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Luetke-Eversloh M, 2014, EUR J IMMUNOL, V44, P2074, DOI 10.1002/eji.201344072; Mattick JS, 2001, EMBO REP, V2, P986, DOI 10.1093/embo-reports/kve230; McFarland AP, 2021, IMMUNITY, V54, P1320, DOI 10.1016/j.immuni.2021.03.024; Merino A, 2019, J CLIN INVEST, V129, P3770, DOI 10.1172/JCI125916; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Miller JS, 2019, ANNU REV CANC BIOL, V3, P77, DOI 10.1146/annurev-cancerbio-030518-055653; Morales-Nebreda L, 2019, TRANSL RES, V204, P1, DOI 10.1016/j.trsl.2018.08.001; Mowel WK, 2017, IMMUNITY, V47, P435, DOI 10.1016/j.immuni.2017.08.012; Nixon BG, 2022, SCI IMMUNOL, V7, DOI 10.1126/sciimmunol.abi8642; Nussbaum K, 2017, J EXP MED, V214, P2331, DOI 10.1084/jem.20162031; O'Sullivan TE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02235; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Peng V, 2022, NAT IMMUNOL, V23, P619, DOI 10.1038/s41590-022-01164-8; Petermann F, 2019, MOL CELL, V75, P1229, DOI 10.1016/j.molcel.2019.06.025; Philip M, 2017, NATURE, V545, P452, DOI 10.1038/nature22367; Rapp M, 2018, SEMIN IMMUNOPATHOL, V40, P343, DOI 10.1007/s00281-018-0686-9; Rapp M, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan3796; Regadas I, 2021, MOL CELL, V81, P1766, DOI 10.1016/j.molcel.2021.01.041; Riggan L, 2019, TRENDS IMMUNOL, V40, P909, DOI 10.1016/j.it.2019.08.005; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Ross S, 2006, EMBO J, V25, P4490, DOI 10.1038/sj.emboj.7601332; Santos F, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-39; Sciume G, 2020, IMMUNITY, V53, P745, DOI 10.1016/j.immuni.2020.09.008; Shih HY, 2016, CELL, V165, P1120, DOI 10.1016/j.cell.2016.04.029; Stary V, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba6232; Stegmann KA, 2016, SCI REP-UK, V6, DOI 10.1038/srep26157; Sun JC, 2009, NATURE, V457, P557, DOI 10.1038/nature07665; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Trinh TL, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1557372; Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232; Townsend MJ, 2004, IMMUNITY, V20, P477, DOI 10.1016/S1074-7613(04)00076-7; VetteseDadey M, 1996, EMBO J, V15, P2508, DOI 10.1002/j.1460-2075.1996.tb00608.x; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Wang FY, 2021, CELL MOL IMMUNOL, V18, P2101, DOI 10.1038/s41423-021-00739-z; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; Weizman OE, 2017, CELL, V171, P795, DOI 10.1016/j.cell.2017.09.052; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; Wiedemann GM, 2021, NAT IMMUNOL, V22, P627, DOI 10.1038/s41590-021-00909-1; Wiedemann GM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108498; Wiedemann GM, 2020, J IMMUNOL, V205, P21, DOI 10.4049/jimmunol.2000086; Winter DR, 2014, IMMUNOL REV, V261, P9, DOI 10.1111/imr.12200; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815; Yates KB, 2021, NAT IMMUNOL, V22, P1020, DOI 10.1038/s41590-021-00979-1; Yin J, 2015, P NATL ACAD SCI USA, V112, P15988, DOI 10.1073/pnas.1521740112; Yomogida K, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2117965118; Yoshida N, 2008, CLIN CANCER RES, V14, P7251, DOI 10.1158/1078-0432.CCR-08-0991; Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366; Zhang J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25758-2; Zhang PJ, 2019, J INTEGR BIOINFORMAT, V16, DOI 10.1515/jib-2019-0027; Zhang XP, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225573; Zhao DZ, 2016, CELL REP, V15, P288, DOI 10.1016/j.celrep.2016.03.035; Zhu P, 2018, NAT GENET, V50, P12, DOI 10.1038/s41588-017-0007-6	128	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 30	2022	13								913054	10.3389/fimmu.2022.913054	http://dx.doi.org/10.3389/fimmu.2022.913054			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D9PU	35707540	Green Published, gold			2022-12-18	WOS:000811870500001
J	Jr, CBE; Powell-Pierce, AD; Skare, JT; Garcia, BL				Booth Jr, Charles E.; Powell-Pierce, Alexandra D.; Skare, Jon T.; Garcia, Brandon L.			Borrelia miyamotoi FbpA and FbpB Are Immunomodulatory Outer Surface Lipoproteins With Distinct Structures and Functions	FRONTIERS IN IMMUNOLOGY			English	Article						complement C1r; classical pathway of complement; Borrelia miyamotoi; complement evasion; spirochete; BBK32	FIBRONECTIN-BINDING PROTEIN; HUMAN-COMPLEMENT C1; LYME-DISEASE; 1ST COMPONENT; BURGDORFERI; ACTIVATION; BBK32; REGION; IDENTIFICATION; PATHOGEN	Pathogens that traffic in the blood of their hosts must employ mechanisms to evade the host innate immune system, including the complement cascade. The Lyme disease spirochete, Borreliella burgdorferi, has evolved numerous outer membrane lipoproteins that interact directly with host proteins. Compared to Lyme disease-associated spirochetes, relatively little is known about how an emerging tick-borne spirochetal pathogen, Borrelia miyamotoi, utilizes surface lipoproteins to interact with a human host. B. burgdorferi expresses the multifunctional lipoprotein, BBK32, that inhibits the classical pathway of complement through interaction with the initiating protease C1r, and also interacts with fibronectin using a separate intrinsically disordered domain. B. miyamotoi encodes two separate bbk32 orthologs denoted fbpA and fbpB; however, the activities of these proteins are unknown. Here, we show that B. miyamotoi FbpA binds human fibronectin in a manner similar to B. burgdorferi BBK32, whereas FbpB does not. FbpA and FbpB both bind human complement C1r and protect a serum-sensitive B. burgdorferi strain from complement-mediated killing, but surprisingly, differ in their ability to recognize activated C1r versus zymogen states of C1r. To better understand the observed differences in C1r recognition and inhibition properties, high-resolution X-ray crystallography structures were solved of the C1r-binding regions of B. miyamotoi FbpA and FbpB at 1.9 angstrom and 2.1 angstrom, respectively. Collectively, these data suggest that FbpA and FbpB have partially overlapping functions but are functionally and structurally distinct. The data presented herein enhances our overall understanding of how bloodborne pathogens interact with fibronectin and modulate the complement system.	[Booth Jr, Charles E.; Garcia, Brandon L.] East Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville 27858 SP, NC USA; [Powell-Pierce, Alexandra D.; Skare, Jon T.] Texas A&M Univ, Coll Med, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77843 USA	University of North Carolina; East Carolina University; Texas A&M University System; Texas A&M University College Station	Garcia, BL (corresponding author), East Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville 27858 SP, NC USA.; Skare, JT (corresponding author), Texas A&M Univ, Coll Med, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77843 USA.	jskare@tamu.edu; garciabr18@ecu.edu		Booth, Charles/0000-0001-8737-4627	National Institute of Allergy and Infectious Diseases [R01-AI146930]	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Support was provided by Public Health Service Grant R01-AI146930 from the National Institute of Allergy and Infectious Diseases (to JS and BG). X-ray diffraction data were collected at Southeast Regional Collaborative Access Team 22-ID beamline at the Advanced Photon Source, Argonne National Laboratory. Supporting institutions may be found at www.ser-cat.org/members.html.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BARBOUR AG, 1988, REV INFECT DIS, V10, pS399; Barbour AG, 2006, P NATL ACAD SCI USA, V103, P18290, DOI 10.1073/pnas.0605302103; Barbour AG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146283; Barbour AG, 2009, AM J TROP MED HYG, V81, P1120, DOI 10.4269/ajtmh.2009.09-0208; Bjanes E, 2021, MICROBIOL MOL BIOL R, V85, DOI 10.1128/MMBR.00177-20; Brenner C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063437; Budayova-Spano M, 2002, STRUCTURE, V10, P1509, DOI 10.1016/S0969-2126(02)00881-X; Coburn J, 2021, CURR ISSUES MOL BIOL, V42, P473, DOI 10.21775/cimb.042.473; Cutler S, 2019, EUROSURVEILLANCE, V24, P12, DOI 10.2807/1560-7917.ES.2019.24.18.1800170; Dworkin MS, 2008, INFECT DIS CLIN N AM, V22, P449, DOI 10.1016/j.idc.2008.03.006; Ebady R, 2016, CELL REP, V16, P2593, DOI 10.1016/j.celrep.2016.08.013; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Frank MM, 2001, NAT MED, V7, P1285, DOI 10.1038/nm1201-1285; FUKUNAGA M, 1995, INT J SYST BACTERIOL, V45, P804, DOI 10.1099/00207713-45-4-804; Garcia BL, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005404; Garrigues RJ, 2021, J IMMUNOL, V207, P2856, DOI 10.4049/jimmunol.2100815; Geisbrecht BV, 2006, PROTEIN EXPRES PURIF, V46, P23, DOI 10.1016/j.pep.2005.09.003; Grosskinsky S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004858; Hamase A, 1996, FEMS MICROBIOL LETT, V140, P131, DOI 10.1111/j.1574-6968.1996.tb08326.x; HARLOW E, 1998, USING ANTIBODIES LAB; Harris G, 2014, J BIOL CHEM, V289, P22490, DOI 10.1074/jbc.M114.578419; Hyde JA, 2011, MOL MICROBIOL, V82, P99, DOI 10.1111/j.1365-2958.2011.07801.x; Johnston D, 2022, CLIN INFECT DIS, DOI 10.1093/cid/ciac107; Kardos J, 2001, J IMMUNOL, V167, P5202, DOI 10.4049/jimmunol.167.9.5202; Karplus PA, 2012, SCIENCE, V336, P1030, DOI [10.1126/science.1218231, 10.1126/science.121823]; Kim JH, 2004, J BIOL CHEM, V279, P41706, DOI 10.1074/jbc.M401691200; Koetsveld J, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00535-17, 10.1128/aac.00535-17]; Krause PJ, 2013, NEW ENGL J MED, V368, P291, DOI 10.1056/NEJMc1215469; Kullberg BJ, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1041; Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824; LEPOW IH, 1958, J EXP MED, V107, P451, DOI 10.1084/jem.107.3.451; Lewis ERG, 2014, INFECT IMMUN, V82, P2520, DOI 10.1128/IAI.01582-14; Liang XW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159118; Lin YP, 2015, CELL MICROBIOL, V17, P860, DOI 10.1111/cmi.12407; Lopez J, 2021, CURR ISSUES MOL BIOL, V42, P519, DOI 10.21775/cimb.042.519; Lopez Job E, 2016, Vet Sci, V3, DOI 10.3390/vetsci3030016; Lynn GE, 2019, TICKS TICK-BORNE DIS, V10, P352, DOI 10.1016/j.ttbdis.2018.11.017; Mastellos DC, 2019, NAT REV DRUG DISCOV, V18, P707, DOI 10.1038/s41573-019-0031-6; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262; Moriarty TJ, 2012, MOL MICROBIOL, V86, P1116, DOI 10.1111/mmi.12045; Moriarty TJ, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000090; Nguyen NTT, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00023; Niddam AF, 2017, P NATL ACAD SCI USA, V114, pE3490, DOI 10.1073/pnas.1615007114; NILSSON UR, 1984, J IMMUNOL METHODS, V72, P49, DOI 10.1016/0022-1759(84)90432-0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pereira Michael J, 2022, Proc Natl Acad Sci U S A, V119, pe2117770119, DOI 10.1073/pnas.2117770119; Prabhakaran S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005412; PROBERT WS, 1995, INFECT IMMUN, V63, P1933, DOI 10.1128/IAI.63.5.1933-1939.1995; Probert WS, 1998, MOL MICROBIOL, V30, P1003, DOI 10.1046/j.1365-2958.1998.01127.x; Probert WS, 2001, INFECT IMMUN, V69, P4129, DOI 10.1128/IAI.69.6.4129-4133.2001; Radolf JD, 2021, CURR ISSUES MOL BIOL, V42, P333, DOI 10.21775/cimb.042.333; Raibaud S, 2005, J BIOL CHEM, V280, P18803, DOI 10.1074/jbc.M501731200; Ricklin D, 2018, NAT REV NEPHROL, V14, P26, DOI 10.1038/nrneph.2017.156; Ricklin D, 2013, J IMMUNOL, V190, P3831, DOI 10.4049/jimmunol.1203487; Rottgerding F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00412-4; Roos A, 2003, MOL IMMUNOL, V39, P655, DOI 10.1016/S0161-5890(02)00254-7; Rushing BR, 2020, MOLECULES, V25, DOI 10.3390/molecules25174016; SADZIENE A, 1993, INFECT IMMUN, V61, P2192, DOI 10.1128/IAI.61.5.2192-2195.1993; Samuels DS, 2018, METHODS MOL BIOL, V1690, P183, DOI 10.1007/978-1-4939-7383-5_15; Sato K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85069-w; Schmidt FL, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84533-x; Seshu J, 2006, MOL MICROBIOL, V59, P1591, DOI 10.1111/j.1365-2958.2005.05042.x; Skare JT, 2020, TRENDS MICROBIOL, V28, P889, DOI 10.1016/j.tim.2020.05.004; Steere AC, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.90; Summers BJ, 2015, MOL IMMUNOL, V67, P193, DOI 10.1016/j.molimm.2015.05.012; Talagrand-Reboul E, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00098; Teegler A, 2014, TICKS TICK-BORNE DIS, V5, P898, DOI 10.1016/j.ttbdis.2014.07.011; Telford SR, 2015, CLIN LAB MED, V35, P867, DOI 10.1016/j.cll.2015.08.002; Varela JC, 2015, HEMATOL ONCOL CLIN N, V29, P409, DOI 10.1016/j.hoc.2015.02.001; Wagemakers A, 2016, J IMMUNOL, V196, P4185, DOI 10.4049/jimmunol.1600014; Wagemakers A, 2015, TRENDS PARASITOL, V31, P260, DOI 10.1016/j.pt.2015.03.008; Wagemakers A, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-418; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Xie JL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007659; ZICCARDI RJ, 1983, SPRINGER SEMIN IMMUN, V6, P213; ZICCARDI RJ, 1976, J IMMUNOL, V116, P504; ZICCARDI RJ, 1982, J IMMUNOL, V128, P2500; Zwart Peter H., 2008, V426, P419, DOI 10.1007/978-1-60327-058-8_28	80	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								886733	10.3389/fimmu.2022.886733	http://dx.doi.org/10.3389/fimmu.2022.886733			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B4WJ	35693799	Green Published, gold			2022-12-18	WOS:000810189900001
J	Even-Or, E; Schejter, YD; NaserEddin, A; Zaidman, I; Shadur, B; Stepensky, P				Even-Or, Ehud; Schejter, Yael Dinur; NaserEddin, Adeeb; Zaidman, Irina; Shadur, Bella; Stepensky, Polina			Autoimmune Cytopenias Post Hematopoietic Stem Cell Transplantation in Pediatric Patients With Osteopetrosis and Other Nonmalignant Diseases	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune cytopenia; hematopoietic stem cell transplantation; osteopetrosis; nonmalignant; immune thrombocytopenia; autoimmune hemolytic anemia; autoimmune neutropenia; pediatrics	T-CELLS; ENGRAFTMENT	Autoimmune cytopenia (AIC) is a rare complication post hematopoietic stem cell transplantation (HSCT), with a higher incidence in nonmalignant diseases. The etiology of post-HSCT AIC is poorly understood, and in many cases, the cytopenia is prolonged and refractory to treatment. Diagnosis of post-HSCT AIC may be challenging, and there is no consensus for a standard of care. In this retrospective study, we summarize our experience over the past five years with post-HSCT AIC in pediatric patients with osteopetrosis and other nonmalignant diseases. All pediatric patients who underwent HSCT for nonmalignant diseases at Hadassah Medical Center over the past five years were screened for post-HSCT AIC, and data were collected from the patient's medical records. From January 2017 through December 2021, 140 pediatric patients underwent HSCT for osteopetrosis (n=40), and a variety of other nonmalignant diseases. Thirteen patients (9.3%) presented with post-HSCT AIC. Of these, 7 had osteopetrosis (17.5%), and 6 had other underlying nonmalignant diseases. Factors associated with developing AIC included unrelated or non-sibling family donors (n=10), mixed chimerism (n=6), and chronic GvHD (n=5). Treatment modalities included steroids, IVIG, rituximab, bortezomib, daratumumab, eltrombopag, plasmapheresis, and repeated HSCT. Response to treatment was variable; Seven patients (54%) recovered completely, and three patients (23%) recovered partially, still suffering from mild-moderate thrombocytopenia. Three patients died (23%), two following progressive lung disease and one from sepsis and multi-organ failure after a 3(rd) HSCT. In our experience, post-HSCT AICs in pediatric patients with nonmalignant diseases may pose a challenging post-transplant complication with a variable presentation and a wide spectrum of severity. A relatively high prevalence is seen in patients with osteopetrosis, possibly due to difficult engraftment and high rates of mixed chimerism. There is a dire need for novel treatment modalities for better management of the more severe and refractory cases.	[Even-Or, Ehud; Schejter, Yael Dinur; NaserEddin, Adeeb; Zaidman, Irina; Stepensky, Polina] Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Bone Marrow Transplantat & Canc Immunotherapy, Jerusalem, Israel; [Shadur, Bella] Univ New South Wales, Garvan Inst Med Res, Immunol Div, Grad Res Sch, Sydney, NSW, Australia	Hebrew University of Jerusalem; Hadassah University Medical Center; Garvan Institute of Medical Research; University of New South Wales Sydney	Even-Or, E (corresponding author), Hebrew Univ Jerusalem, Fac Med, Hadassah Med Ctr, Dept Bone Marrow Transplantat & Canc Immunotherapy, Jerusalem, Israel.	evenor@hadassah.org.il						Bride KL, 2016, BLOOD, V127, P17, DOI 10.1182/blood-2015-07-657981; Buxbaum NP, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02017; Cao L, 2018, LEUKEMIA LYMPHOMA, V59, P2500, DOI 10.1080/10428194.2017.1421759; Driouk Lina, 2021, Mol Cell Pediatr, V8, P5, DOI 10.1186/s40348-021-00114-y; Dvorak CC, 2012, BIOL BLOOD MARROW TR, V18, pS101, DOI 10.1016/j.bbmt.2011.10.024; Even-Or E, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28841; Even-Or E, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28010; Galvin RT, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.01.015; Gambineri E, 2015, J ALLERGY CLIN IMMUN, V135, P260, DOI 10.1016/j.jaci.2014.09.009; Guilcher GMT, 2016, PEDIATR REV, V37, P135, DOI 10.1542/pir.2015-0044; Hanash AM, 2005, BLOOD, V105, P1828, DOI 10.1182/blood-2004-08-3213; Hess J, 2018, TRANSFUSION, V58, P2122, DOI 10.1111/trf.14907; Kruizinga MD, 2018, BIOL BLOOD MARROW TR, V24, P772, DOI 10.1016/j.bbmt.2017.12.782; Lum SH, 2020, J ALLERGY CLIN IMMUN, V146, P406, DOI 10.1016/j.jaci.2020.04.053; Mehta B, 2014, PEDIATR BLOOD CANCER, V61, P2324, DOI 10.1002/pbc.25172; Neely JA, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00171; Neunert CE, 2019, PEDIATR BLOOD CANCER, V66, DOI 10.1002/pbc.27569; Orchard PJ, 2015, BLOOD, V126, P270, DOI 10.1182/blood-2015-01-625541; Seidel MG, 2009, BLOOD, V113, P5689, DOI 10.1182/blood-2009-02-206359; Szanto CL, 2020, BIOL BLOOD MARROW TR, V26, P114, DOI 10.1016/j.bbmt.2019.07.022; Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952; Tolar J, 2012, BIOL BLOOD MARROW TR, V18, pS166, DOI 10.1016/j.bbmt.2011.10.023; Yao YF, 2021, EXPERT REV HEMATOL, V14, P1041, DOI 10.1080/17474086.2021.2009337	23	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								879994	10.3389/fimmu.2022.879994	http://dx.doi.org/10.3389/fimmu.2022.879994			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Z2MN	35693771	gold, Green Published			2022-12-18	WOS:000808664800001
J	Guo, XM; Mao, XR; Tian, D; Liao, YX; Su, BT; Ye, CL; Shi, DL; Liu, TF; Ling, Y; Hao, Y				Guo, Xiaoman; Mao, Xinru; Tian, Di; Liao, Yixin; Su, Bintao; Ye, Chaoliang; Shi, Dongling; Liu, Tie Fu; Ling, Yun; Hao, Yi			Cryptococcus neoformans Infection Induces IL-17 Production by Promoting STAT3 Phosphorylation in CD4(+) T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						IL-17; STAT3; CD4(+) T cells; Cryptococcus neoformans meningitis; phosphorylation	ACTIVATED MACROPHAGES; PENICILLIUM-MARNEFFEI; RHEUMATOID-ARTHRITIS; CROSS-TALK; IFN-GAMMA; DIFFERENTIATION; LYMPHOCYTES; MENINGITIS; IMMUNITY; DISEASE	Cryptococcus neoformans infection in the central nervous system is a severe infectious disease with poor outcomes and high mortality. It has been estimated that there are 220,000 new cases each year. Over 90% of C. neoformans meningitis cases were diagnosed in AIDS patients with CD4(+) T cell count <100 cells/mu l; however, the mechanism of cryptococcal meningitis in patients with normal immune functions remains unclear. IL-17 is a pro-inflammatory cytokine and plays an important role in anti-fungal immunity. Here we report that significantly high levels of IL-17 were predominantly detected in the cerebrospinal fluid of patients with either AIDS- or non-AIDS-associated C. neoformans meningitis but not in patients with tuberculous meningitis or non-neurosyphilis. Antifungal therapy minimized the IL-17 level in the cerebrospinal fluid. An in vitro mechanistic study showed that C. neoformans stimulation of healthy peripheral blood mononuclear cells prompted IL-17 production, and CD4(+) T cells were the predominant IL-17-producing cells. IL-17 production by C. neoformans stimulation was STAT3 signaling dependent. Inhibition of STAT3 phosphorylation attenuated the C. neoformans-mediated IL-17 expression. Our data highlighted the significance of CD4(+) T cells in antifungal immunity and suggested IL-17 as a diagnostic biomarker of C. neoformans infection and STAT3 as a checkpoint for antifungal targeted therapies.	[Guo, Xiaoman; Mao, Xinru; Su, Bintao; Ye, Chaoliang; Hao, Yi] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China; [Tian, Di; Liao, Yixin; Liu, Tie Fu] Fudan Univ, Sci Res Ctr, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China; [Su, Bintao] Huazhong Univ Sci & Technol, Wuhan No Hosp 1, Tongji Med Coll, Dept Lab Med, Wuhan, Peoples R China; [Shi, Dongling; Ling, Yun] Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, Shanghai, Peoples R China; [Hao, Yi] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Geriatr, Wuhan, Peoples R China	Huazhong University of Science & Technology; Fudan University; Huazhong University of Science & Technology; Fudan University; Huazhong University of Science & Technology	Hao, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China.; Liu, TF (corresponding author), Fudan Univ, Sci Res Ctr, Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China.; Ling, Y (corresponding author), Fudan Univ, Shanghai Publ Hlth Clin Ctr, Dept Infect Dis, Shanghai, Peoples R China.; Hao, Y (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Geriatr, Wuhan, Peoples R China.	liutiefu@shphc.org.cn; yun.ling@shphc.org.cn; haoyi@hust.edu.cn		Yun, Ling/0000-0002-4289-3594				AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Albanesi C, 1999, J IMMUNOL, V162, P494; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Berthet FX, 1998, MICROBIOL-UK, V144, P3195, DOI 10.1099/00221287-144-11-3195; Boengler K, 2013, CURR PHARM DESIGN, V19, P6890, DOI 10.2174/138161281939131127115940; Brodin P, 2004, TRENDS MICROBIOL, V12, P500, DOI 10.1016/j.tim.2004.09.007; Buchanan KL, 2000, INFECT IMMUN, V68, P456, DOI 10.1128/IAI.68.2.456-462.2000; Chen M, 2018, FRONT MED-PRC, V12, P58, DOI 10.1007/s11684-017-0601-0; Chen YC, 2012, MYCOPATHOLOGIA, V173, P329, DOI 10.1007/s11046-011-9471-1; Cho ML, 2004, ARTHRITIS RHEUM-US, V50, P776, DOI 10.1002/art.20106; COLLINS HL, 1992, EUR J IMMUNOL, V22, P1447, DOI 10.1002/eji.1830220617; Conti HR, 2015, J IMMUNOL, V195, P780, DOI 10.4049/jimmunol.1500909; Cooper CR, 1997, ARCH PATHOL LAB MED, V121, P798; Drummond RA, 2019, SEMIN CELL DEV BIOL, V89, P78, DOI 10.1016/j.semcdb.2018.01.008; FLESCH IEA, 1989, J IMMUNOL, V142, P3219; Ganguly N, 2008, TUBERCULOSIS, V88, P510, DOI 10.1016/j.tube.2008.05.002; Glimaker M, 2015, CLIN INFECT DIS, V60, P1162, DOI 10.1093/cid/civ011; Haan S, 2005, CELL SIGNAL, V17, P1542, DOI 10.1016/j.cellsig.2005.03.010; Harris TJ, 2007, J IMMUNOL, V179, P4313, DOI 10.4049/jimmunol.179.7.4313; HILL JO, 1994, J IMMUNOL, V152, P2344; Hole CR, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00291; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107, DOI 10.4049/jimmunol.165.11.6107; Jarvis JN, 2007, AIDS, V21, P2119, DOI 10.1097/QAD.0b013e3282a4a64d; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Li X, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003203; Liu QQ, 2020, J MICROBIOL IMMUNOL, V53, P216, DOI 10.1016/j.jmii.2018.08.019; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Marais S, 2016, AIDS, V30, P395, DOI 10.1097/QAD.0000000000000904; Mathur AN, 2007, J IMMUNOL, V178, P4901, DOI 10.4049/jimmunol.178.8.4901; Mills KHG, 2008, EUR J IMMUNOL, V38, P2636, DOI 10.1002/eji.200838535; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Miranda-Carus ME, 2004, J IMMUNOL, V173, P1463, DOI 10.4049/jimmunol.173.2.1463; MODY CH, 1990, J IMMUNOL, V144, P1472; Muller U, 2007, J IMMUNOL, V179, P5367, DOI 10.4049/jimmunol.179.8.5367; Narimatsu M, 2001, MOL CELL BIOL, V21, P6615, DOI 10.1128/MCB.21.19.6615-6625.2001; Okongo M, 1998, INT J EPIDEMIOL, V27, P698, DOI 10.1093/ije/27.4.698; Parsons LM, 2002, J CLIN MICROBIOL, V40, P2339, DOI 10.1128/JCM.40.7.2339-2345.2002; Peck A, 2010, INFECT IMMUN, V78, P32, DOI 10.1128/IAI.00929-09; Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858; POWDERLY WG, 1993, CLIN INFECT DIS, V17, P837, DOI 10.1093/clinids/17.5.837; Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/s1473-3099(17)30243-8, 10.1016/S1473-3099(17)30243-8]; Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525; Rivera J, 2002, J IMMUNOL, V168, P3419, DOI 10.4049/jimmunol.168.7.3419; Ru HW, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00239; Taylor PR, 2016, J LEUKOCYTE BIOL, V100, P213, DOI 10.1189/jlb.4A1015-483R; Tran CN, 2007, AM J PATHOL, V171, P1588, DOI 10.2353/ajpath.2007.070004; Tugume L, 2019, J INFECT DIS, V219, P877, DOI 10.1093/infdis/jiy602; Valdez PA, 2012, IMMUNITY, V36, P668, DOI 10.1016/j.immuni.2012.02.013; Wang CM, 2016, J DIABETES COMPLICAT, V30, P1426, DOI 10.1016/j.jdiacomp.2016.07.005; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wormley FL, 2007, INFECT IMMUN, V75, P1453, DOI 10.1128/IAI.00274-06; Wozniak KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006854; Wu T. C., 2008, Hong Kong Medical Journal, V14, P103; Wu X, 2017, ONCOTARGET, V8, P44242, DOI 10.18632/oncotarget.17797; Yang J, 2005, CANCER RES, V65, P939; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Zhang Z, 2021, J MOL ENDOCRINOL, V66, P259, DOI 10.1530/JME-20-0321; Zhu JF, 2010, IMMUNOL REV, V238, P247, DOI 10.1111/j.1600-065X.2010.00951.x	59	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								872286	10.3389/fimmu.2022.872286	http://dx.doi.org/10.3389/fimmu.2022.872286			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1BY	35720334	Green Published, gold			2022-12-18	WOS:000811292100001
J	Hu, KJ; Lv, LB; Huang, H; Yin, GN; Gao, J; Liu, JP; Yang, YY; Zeng, WX; Chen, Y; Zhang, N; Zhang, FY; Ma, YH; Chen, FL				Hu, Kaijiao; Lv, Longbao; Huang, Hui; Yin, Guangnian; Gao, Jie; Liu, Jianping; Yang, Yaying; Zeng, Wenxin; Chen, Yan; Zhang, Ni; Zhang, Feiyan; Ma, Yuhua; Chen, Feilan			A Novel Tree Shrew Model of Chronic Experimental Autoimmune Uveitis and Its Disruptive Application	FRONTIERS IN IMMUNOLOGY			English	Article						experimental autoimmune uveitis (EAU); chronic; tree shrew; differentially expressed gene (DEG); metabolic pathways; microglia; T-cell response; regulators of G-protein signaling 4 (RGS4)	INFLAMMATION; ACTIVATION; ACUITY; CONES	BackgroundPrevious studies have established several animal models for experimental autoimmune uveitis (EAU) in rodents without the fovea centralis in the human retina. This study aimed to develop and explore the application of a novel EAU model in tree shrews with a cone-dominated retina resembling the human fovea. MethodsTree shrews were clinically and pathologically evaluated for the development and characteristics of EAU immunized with six inter-photoreceptor retinoid-binding proteins (IRBPs). IRBP-specific T-cell proliferation and serum cytokine of tree shrews were evaluated to determine the immune responses. Differentially expressed genes (DEGs) were identified in the eyes of tree shrews with EAU by RNA-sequencing. The disruptive effects of the DEG RGS4 inhibitor CCG 203769 and dihydroartemisinin on the EAU were investigated to evaluate the potential application of tree shrew EAU. ResultsIRBP(1197-1211) and R14 successfully induced chronic EAU with subretinal deposits and retinal damage in the tree shrews. The immunological characteristics presented the predominant infiltration of microglia/macrophages, dendritic cells, and CD4-T-cells into the uvea and retina and pathogenic T helper (Th) 1 and Th17 responses. The subretinal deposits positively expressed amyloid beta-protein (A beta), CD8, and P2Y purinoceptor 12 (P2RY12). The crucial DEGs in R14-induced EAU, such as P2RY2 and adenylate cyclase 4 (ADCY4), were enriched for several pathways, including inflammatory mediator regulation of transient receptor potential (TRP) channels. The upregulated RGS4 in IRBP-induced EAU was associated with mitogen-activated protein kinase (MAPK) activity. RGS4 inhibition and dihydroartemisinin could significantly alleviate the retinal pathological injuries of IRBP1197-1211-induced EAU by decreasing the expression of CD4 T-cells. ConclusionOur study provides a novel chronic EAU in tree shrews elicited by bovine R14 and tree shrew IRBP1197-1211 characterized by retinal degeneration, retinal damage with subretinal A beta deposits and microglia/macrophage infiltration, and T-cell response, probably by altering important pathways and genes related to bacterial invasion, inflammatory pain, microglial phagocytosis, and lipid and glucose metabolism. The findings advance the knowledge of the pathogenesis and therapeutics of the fovea-involved visual disturbance in human uveitis.	[Hu, Kaijiao; Huang, Hui; Yin, Guangnian; Gao, Jie; Zeng, Wenxin; Chen, Feilan] Chongqing Med Univ, Lab Anim Ctr, Chongqing, Peoples R China; [Hu, Kaijiao; Huang, Hui; Yin, Guangnian; Gao, Jie; Zeng, Wenxin; Chen, Feilan] Chongqing Engn Res Ctr Rodent Lab Anim, Chongqing, Peoples R China; [Lv, Longbao; Zhang, Feiyan; Ma, Yuhua] Kunming Inst Zool, Chinese Acad Sci, Lab Anim Ctr, Kunming, Peoples R China; [Yin, Guangnian] Army Med Univ, Dept Clin Lab, Affiliated Hosp 2, Chongqing, Peoples R China; [Liu, Jianping; Yang, Yaying; Chen, Yan] Chongqing Med Univ, Dept Pathol, Chongqing, Peoples R China; [Zhang, Ni] Chongqing Med Univ, Chongqing Eye Inst, Affiliated Hosp 1, Chongqing, Peoples R China	Chongqing Medical University; Chinese Academy of Sciences; Kunming Institute of Zoology; Army Medical University; Chongqing Medical University; Chongqing Medical University	Chen, FL (corresponding author), Chongqing Med Univ, Lab Anim Ctr, Chongqing, Peoples R China.; Chen, FL (corresponding author), Chongqing Engn Res Ctr Rodent Lab Anim, Chongqing, Peoples R China.	chenfl@cqmu.edu.cn						Barone I, 2014, MOL VIS, V20, P1545; Blazer LL, 2015, ACS CHEM NEUROSCI, V6, P911, DOI 10.1021/acschemneuro.5b00063; Burkholder BM, 2021, BMJ-BRIT MED J, V372, DOI 10.1136/bmj.m4979; Caspi RR, 2010, J CLIN INVEST, V120, P3073, DOI 10.1172/JCI42440; Caspi Rachel R, 2003, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1506s53; CHAN CC, 1990, J AUTOIMMUN, V3, P247, DOI 10.1016/0896-8411(90)90144-H; Chen Y, 2018, CURR MOL MED, V18, P602, DOI 10.2174/1566524019666190112132610; Delirezh N, 2009, CELL IMMUNOL, V257, P23, DOI 10.1016/j.cellimm.2009.02.002; du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI 10.1111/bph.15193; El Hamdaoui M, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.5.1; Fishman ES, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.654385; Fuentes N, 2021, PHARMACOL THERAPEUT, V223, DOI 10.1016/j.pharmthera.2021.107818; Gaffney M, 2021, EXP BIOL MED, V246, P2192, DOI 10.1177/15353702211029582; Horai R, 2011, J INTERF CYTOK RES, V31, P733, DOI 10.1089/jir.2011.0042; Ingram NT, 2020, P NATL ACAD SCI USA, V117, P19599, DOI 10.1073/pnas.2001776117; Karlen SJ, 2020, ANNU REV VIS SCI, V6, P149, DOI 10.1146/annurev-vision-121219-081730; Ke Y, 2011, J IMMUNOL, V187, P2130, DOI 10.4049/jimmunol.1100482; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Lin B, 2009, EXP EYE RES, V88, P589, DOI 10.1016/j.exer.2008.11.022; MULLER B, 1989, J COMP NEUROL, V282, P581, DOI 10.1002/cne.902820409; Narayan DS, 2017, CLIN EXP OPHTHALMOL, V45, P730, DOI 10.1111/ceo.12952; Novak T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724900; Okunuki Y, 2019, P NATL ACAD SCI USA, V116, P9989, DOI 10.1073/pnas.1820387116; Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115; Provis JM, 2013, PROG RETIN EYE RES, V35, P63, DOI 10.1016/j.preteyeres.2013.01.005; Rivera A, 2016, CURR DRUG TARGETS, V17, P1829, DOI 10.2174/1389450117666160711154529; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Samuels BC, 2018, INVEST OPHTH VIS SCI, V59, P3136, DOI 10.1167/iovs.18-24261; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saraswathy S, 2009, INVEST OPHTH VIS SCI, V50, P5559, DOI 10.1167/iovs.08-2842; Sipe GO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10905; TRIZIO D, 1974, J IMMUNOL, V113, P1093; Wohler JE, 2009, MOL IMMUNOL, V46, P1007, DOI 10.1016/j.molimm.2008.09.017; Xu L, 2020, VET OPHTHALMOL, V23, P797, DOI 10.1111/vop.12799; Yao YG, 2017, ZOOL RES, V38, P118, DOI 10.24272/j.issn.2095-8137.2017.032; Zhong ZY, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100866; Zhou H, 2012, P NATL ACAD SCI USA, V109, P19977, DOI 10.1073/pnas.1214337109	37	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								889596	10.3389/fimmu.2022.889596	http://dx.doi.org/10.3389/fimmu.2022.889596			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1AT	35711454	Green Published, gold			2022-12-18	WOS:000811288800001
J	Jiang, SM; Di, DX; Jiao, YY; Zou, GM; Gao, HM; Li, WE				Jiang, Shimin; Di, Dingxin; Jiao, Yuanyuan; Zou, Guming; Gao, Hongmei; Li, Wenge			Complement Deposition Predicts Worsening Kidney Function and Underlines the Clinical Significance of the 2010 Renal Pathology Society Classification of Diabetic Nephropathy	FRONTIERS IN IMMUNOLOGY			English	Article						complement system; C3; RPS classification; diabetic nephropathy; prognosis	SYSTEM	ObjectivesConverging evidence points towards a role of the complement system in the pathogenesis of diabetic nephropathy (DN). The classification system of diabetic kidney lesions devised by the Renal Pathology Society (RPS) in 2010 are based on the pathogenic process of DN. Therefore, we investigated the correlation between glomerular C3 deposits and RPS DN classification and the combined deleterious effects thereof on kidney function. MethodsThe study analyzed data from 217 diabetic patients who underwent renal biopsy between 2010 and 2021 and were found to have DN as the only glomerular disease. C3 deposition was considered positive if the glomerular C3 immunofluorescence intensity was at the trace or >= 1+ level. We divided DN into five glomerular lesion classes and separately evaluated the degree of interstitial and vascular involvement. The primary outcome was the composite of a >= 50% decline from the initial estimated glomerular filtration rate, end-stage renal disease, and death. ResultsNone of the patients were classified into class I, and few were classified into classes IIa (7.8%) and IV (9.2%). Most patients were classified as IIb (30.9%) and III (52.1%). C3 deposition was detected in 53.9% of patients. Multivariate logistic regression analysis showed that DN class was significantly correlated with C3 deposits [odds ratio, 1.59; 95% confidence interval (CI), 1.08-2.36; p = 0.02). During a median follow-up of 22 months, 123 (56.7%) patients reached the composite outcome. The endpoints occurred more frequently in patients with C3 deposition (69.2 vs. 42%) compared with those without C3 deposition. Patients with C3 deposition in either class IIb [hazards ratio (HR), 3.9 (95% CI, 1.14-13.17) vs. 2.46 (95% CI, 0.68-8.89)] or III [HR, 4.98 (95% CI, 1.53-16.23) vs. 2.63 (95% CI, 0.77-9.0)] had a higher risk of adverse kidney outcomes than those without C3 deposition. The prognostic accuracy of the combination of DN class and C3 deposits at 1 and 3 years was higher than that for DN class only. ConclusionsComplement deposition together with DN class predicts more rapid deterioration of kidney function in DN, which underlines the clinical significance of the DN phenotype according to the RPS classification.	[Jiang, Shimin; Zou, Guming; Gao, Hongmei; Li, Wenge] China Japan Friendship Hosp, Dept Nephrol, Beijing, Peoples R China; [Di, Dingxin; Jiao, Yuanyuan] Peking Union Med Coll & Chinese Acad Med Sci, Grad Sch Peking Union Med Coll, Beijing, Peoples R China	China-Japan Friendship Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Li, WE (corresponding author), China Japan Friendship Hosp, Dept Nephrol, Beijing, Peoples R China.	wenge_lee2002@126.com			Beijing Municipal Natural Science Foundation [7202179]; Science and Technology Project of Beijing [D171100002817003]; National Key Clinical Specialty Capacity Building Project [2019-542]	Beijing Municipal Natural Science Foundation(Beijing Natural Science Foundation); Science and Technology Project of Beijing; National Key Clinical Specialty Capacity Building Project	Funding This work was supported by grants from the Beijing Municipal Natural Science Foundation (7202179), the Science and Technology Project of Beijing (D171100002817003), and National Key Clinical Specialty Capacity Building Project (2019-542).	Amer Diabet Assoc, 2014, DIABETES CARE, V37, pS14, DOI 10.2337/dc14-S014; An Y, 2015, NEPHROL DIAL TRANSPL, V30, P257, DOI 10.1093/ndt/gfu250; Angeletti A, 2020, J EXP MED, V217, DOI 10.1084/jem.20191699; Atlas D., 2015, IDF DIABETES ATLAS, V7th; Budge K, 2021, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.599236; Duan SY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02073; Flyvbjerg A, 2017, NAT REV NEPHROL, V13, P311, DOI 10.1038/nrneph.2017.31; Hovind P, 2005, DIABETES, V54, P1523, DOI 10.2337/diabetes.54.5.1523; Huang YQ, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00459; Inker LA, 2012, NEW ENGL J MED, V367, P20, DOI 10.1056/NEJMoa1114248; Jiao YY, 2022, J DIABETES INVEST, V13, P839, DOI 10.1111/jdi.13739; Koopman JJE, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.599974; Li XQ, 2019, DIABETES METAB, V45, P248, DOI 10.1016/j.diabet.2018.04.001; Liu LF, 2021, FASEB J, V35, DOI 10.1096/fj.202002814RR; Lu QM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.147716; Mise K, 2014, NEPHROL DIAL TRANSPL, V29, P109, DOI 10.1093/ndt/gft349; Mottl AK, 2018, J AM SOC NEPHROL, V29, P694, DOI 10.1681/ASN.2017020192; Najafian B, 2015, AM J KIDNEY DIS, V66, pE37, DOI 10.1053/j.ajkd.2015.08.010; Oh SW, 2012, DIABETES RES CLIN PR, V97, P418, DOI 10.1016/j.diabres.2012.03.016; Pippin JW, 2003, J CLIN INVEST, V111, P877, DOI 10.1172/JCI200315645; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Schrijvers BF, 2004, ENDOCR REV, V25, P971, DOI 10.1210/er.2003-0018; Sun ZJ, 2019, DIABETES METAB, V45, P363, DOI 10.1016/j.diabet.2018.08.011; Tervaert TWC, 2010, J AM SOC NEPHROL, V21, P556, DOI 10.1681/ASN.2010010010; Truong LD, 2019, HUM PATHOL, V85, P136, DOI 10.1016/j.humpath.2018.10.032; WHO, 2014, GLOBAL STATUS REPORT ON VIOLENCE PREVENTION 2014, P1; Yiu WH, 2018, NEPHROL DIAL TRANSPL, V33, P1323, DOI 10.1093/ndt/gfx336; Zou WZ, 2014, PATHOLOGY RENAL BIOP, V3rd, P27	28	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								868127	10.3389/fimmu.2022.868127	http://dx.doi.org/10.3389/fimmu.2022.868127			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1DN	35711407	Green Published, gold			2022-12-18	WOS:000811296400001
J	Li, HD; Li, R; Kong, Y; Zhang, WY; Qi, CY; Wang, D; Hao, HY; Liu, Q				Li, Han-Dong; Li, Ran; Kong, Ying; Zhang, Wenyan; Qi, Caiyun; Wang, Dan; Hao, Hongying; Liu, Qiang			Selective Sphingosine 1-Phosphate Receptor 1 Modulation Augments Thrombolysis of Low-Dose Tissue Plasminogen Activator Following Cerebrovascular Thrombosis	FRONTIERS IN IMMUNOLOGY			English	Article						two-photon microscopy; tPA; thrombolysis; microcirculation; ischemic stroke	STROKE; ALTEPLASE; AGONIST	BackgroundResults from our recent study demonstrate that sphingosine-1-phosphate receptor 1 (S1PR1) modulation improves microvascular hemodynamics after cerebrovascular thrombosis. This study was to determine the microvascular hemodynamic effects of a sub-thrombolytic dose of tPA combined with a selective S1PR1 modulator ozanimod in a mouse model of cerebrovascular thrombosis. MethodsMicrovascular circulation in mice was monitored in vivo by two-photon microscopy. Thrombosis was induced in cortical arterioles by laser irradiation. Arteriolar flow velocity was measured by line-scanning following plasma-labeling with fluorescein-dextran. ResultsLaser-induced thrombosis led to a persistent reduction of flow velocity in cortical arterioles. Sub-thrombolytic dose of tPA along with vehicle control did not improve the flow velocity in cortical arterioles following thrombosis. In contrast, a sub-thrombolytic dose of tPA along with ozanimod dramatically restored flow velocity in cortical arterioles following thrombosis. Ozanimod did not affect coagulation and bleeding time. Notably, ozanimod reduced thrombus volume without altering microvascular lumen diameter. In addition, ozanimod reduced leukocyte components within the thrombus. ConclusionsThese findings demonstrate that the thrombolytic effect of a sub-thrombolytic dose of tPA is markedly enhanced by S1PR1 modulation, implying that S1PR1 modulation may improve the therapeutic benefit of low-dose tPA in patients with acute ischemic stroke.	[Li, Han-Dong; Li, Ran; Kong, Ying; Zhang, Wenyan; Qi, Caiyun; Wang, Dan; Hao, Hongying; Liu, Qiang] Tianjin Med Univ Gen Hosp, Inst Neuroimmunol, Dept Neurol, Tianjin, Peoples R China	Tianjin Medical University	Liu, Q (corresponding author), Tianjin Med Univ Gen Hosp, Inst Neuroimmunol, Dept Neurol, Tianjin, Peoples R China.	qliu@tmu.edu.cn						Alexandrov AV, 2002, NEUROLOGY, V59, P862, DOI 10.1212/WNL.59.6.862; Anderson CS, 2016, NEW ENGL J MED, V374, P2313, DOI 10.1056/NEJMoa1515510; Brait VH, 2016, STROKE, V47, P3053, DOI 10.1161/STROKEAHA.116.015371; Chamorro A, 2016, LANCET NEUROL, V15, P869, DOI 10.1016/S1474-4422(16)00114-9; De Meyer SF, 2016, STROKE, V47, P1165, DOI 10.1161/STROKEAHA.115.011238; Fu Y, 2015, NAT REV NEUROL, V11, P524, DOI 10.1038/nrneurol.2015.144; Iwasawa E, 2018, J STROKE CEREBROVASC, V27, P1237, DOI 10.1016/j.jstrokecerebrovasdis.2017.11.040; Li HD, 2019, FASEB J, V33, P10935, DOI 10.1096/fj.201900282R; Li YJ, 2020, NEUROSCI LETT, V735, DOI 10.1016/j.neulet.2020.135160; Lou NH, 2016, P NATL ACAD SCI USA, V113, P1074, DOI 10.1073/pnas.1520398113; Nishimura N, 2006, NAT METHODS, V3, P99, DOI 10.1038/NMETH844; Scott FL, 2016, BRIT J PHARMACOL, V173, P1778, DOI 10.1111/bph.13476; Shi KB, 2021, CIRC RES, V128, P62, DOI 10.1161/CIRCRESAHA.120.317596; Stoll G, 2019, NAT REV NEUROL, V15, P473, DOI 10.1038/s41582-019-0221-1; Sun N, 2016, STROKE, V47, P1899, DOI 10.1161/STROKEAHA.115.012236; Thiebaut AM, 2018, LANCET NEUROL, V17, P1121, DOI 10.1016/S1474-4422(18)30323-5; Tian DC, 2018, ANN NEUROL, V84, P717, DOI 10.1002/ana.25352; Wang X, 2020, INT J STROKE, V15, P39, DOI 10.1177/1747493019858775; Wang X, 2017, JAMA NEUROL, V74, P1328, DOI 10.1001/jamaneurol.2017.2286; Xue MZ, 2020, LANCET NEUROL, V19, P1023, DOI 10.1016/S1474-4422(20)30364-1	20	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								801727	10.3389/fimmu.2022.801727	http://dx.doi.org/10.3389/fimmu.2022.801727			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1JO	35720286	Green Submitted, Green Published, gold			2022-12-18	WOS:000811312400001
J	Miyake, K; Ito, J; Karasuyama, H				Miyake, Kensuke; Ito, Junya; Karasuyama, Hajime			Role of Basophils in a Broad Spectrum of Disorders	FRONTIERS IN IMMUNOLOGY			English	Review						basophils; allergy; IL-4; tissue repair; fibrosis; autoimmune diseases; tumor; COVID-19	CHRONIC SPONTANEOUS URTICARIA; CLASS-II COMPLEXES; ALLERGIC INFLAMMATION; ATOPIC-DERMATITIS; MAST-CELLS; CLINICAL-EFFICACY; TISSUE-REPAIR; NASAL POLYPS; OMALIZUMAB; RESPONSES	Basophils are the rarest granulocytes and have long been overlooked in immunological research due to their rarity and similarities with tissue-resident mast cells. In the last two decades, non-redundant functions of basophils have been clarified or implicated in a broad spectrum of immune responses, particularly by virtue of the development of novel analytical tools for basophils. Basophils infiltrate inflamed tissues of patients with various disorders, even though they circulate in the bloodstream under homeostatic conditions. Depletion of basophils results in the amelioration or exaggeration of inflammation, depending on models of disease, indicating basophils can play either beneficial or deleterious roles in a context-dependent manner. In this review, we summarize the recent findings of basophil pathophysiology under various conditions in mice and humans, including allergy, autoimmunity, tumors, tissue repair, fibrosis, and COVID-19. Further mechanistic studies on basophil biology could lead to the identification of novel biomarkers or therapeutic targets in a broad range of diseases.	[Miyake, Kensuke; Ito, Junya; Karasuyama, Hajime] Tokyo Med & Dent Univ TMDU, Adv Res Inst, Inflammat Infect & Immun Lab, Tokyo, Japan	Tokyo Medical & Dental University (TMDU)	Miyake, K (corresponding author), Tokyo Med & Dent Univ TMDU, Adv Res Inst, Inflammat Infect & Immun Lab, Tokyo, Japan.	miyake.mbch@tmd.ac.jp		Miyake, Kensuke/0000-0003-1149-3755	Japanese Ministry of Education, Culture, Sports, Science and Technology [20K16277, 19H01025, 22K07115, 21K18255, 22H02845]; SENSHIN Medical Research Foundation; Takeda Science Foundation; KANAE Foundation for the Promotion of Medical Science; Uehara Memorial Foundation; Naito Foundation; Ohyama Health Foundation	Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); SENSHIN Medical Research Foundation(SENSHIN Medical Research Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); KANAE Foundation for the Promotion of Medical Science; Uehara Memorial Foundation(Uehara Memorial Foundation); Naito Foundation(Naito Memorial Foundation); Ohyama Health Foundation	This work was supported by research grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology [20K16277(KM), 19H01025 (HK), 22K07115 (KM), 21K18255 (HK), 22H02845 (HK)], SENSHIN Medical Research Foundation (KM), Takeda Science Foundation (KM), KANAE Foundation for the Promotion of Medical Science (KM), The Uehara Memorial Foundation (KM), The Naito Foundation (KM), and Ohyama Health Foundation (KM).	Akdogan N, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12966; Alnor A, 2021, SCAND J CLIN LAB INV, V81, P213, DOI 10.1080/00365513.2021.1894601; Altrichter S, 2020, ALLERGY, V75, P3208, DOI 10.1111/all.14412; Asero R, 2020, CLIN EXP IMMUNOL, V200, P242, DOI 10.1111/cei.13428; Askenase PW, 2021, NEW ENGL J MED, V385, P1720, DOI 10.1056/NEJMc2111452; Atta AM, 2010, INT ARCH ALLERGY IMM, V152, P401, DOI 10.1159/000288293; Baba T, 2016, BLOOD, V127, P2607, DOI 10.1182/blood-2015-10-673087; Balam S, 2019, J IMMUNOL, V202, P3514, DOI 10.4049/jimmunol.1801269; Bax HJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071631; Beck LA, 2014, NEW ENGL J MED, V371, P130, DOI 10.1056/NEJMoa1314768; Bleriot C, 2015, IMMUNITY, V42, P145, DOI 10.1016/j.immuni.2014.12.020; Bonam SR, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.838448; Bracken SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00627; Brauweiler AM, 2020, J INVEST DERMATOL, V140, P915, DOI 10.1016/j.jid.2019.09.004; Brooks CR, 2017, ALLERGY, V72, P1583, DOI 10.1111/all.13185; Burton OT, 2013, MUCOSAL IMMUNOL, V6, P740, DOI 10.1038/mi.2012.112; Callewaert C, 2020, J INVEST DERMATOL, V140, P191, DOI 10.1016/j.jid.2019.05.024; Cardenas EI, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.830859; Castro M, 2018, NEW ENGL J MED, V378, P2486, DOI 10.1056/NEJMoa1804092; Cevikbas F, 2014, J ALLERGY CLIN IMMUN, V133, P448, DOI 10.1016/j.jaci.2013.10.048; Charles N, 2021, CURR OPIN IMMUNOL, V72, P75, DOI 10.1016/j.coi.2021.03.003; Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159; Chauhan J, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11030438; Cheng LE, 2015, J EXP MED, V212, P513, DOI 10.1084/jem.20141671; Conde E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22834-5; Crawford G, 2018, NAT IMMUNOL, V19, P859, DOI 10.1038/s41590-018-0161-8; Dema B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08516-7; Dema B, 2014, J EXP MED, V211, P2159, DOI 10.1084/jem.20140066; Dema B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090424; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; DVORAK HF, 1976, J ALLERGY CLIN IMMUN, V58, P229, DOI 10.1016/0091-6749(76)90159-7; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Eberle JU, 2019, J INVEST DERMATOL, V139, P1957, DOI 10.1016/j.jid.2019.03.1129; Eberle JU, 2016, SEMIN IMMUNOPATHOL, V38, P605, DOI 10.1007/s00281-016-0563-3; Egawa M, 2013, IMMUNITY, V38, P570, DOI 10.1016/j.immuni.2012.11.014; Furue M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155382; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Guttman-Yassky E, 2019, J ALLERGY CLIN IMMUN, V143, P155, DOI 10.1016/j.jaci.2018.08.022; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Han HW, 2014, J CLIN INVEST, V124, P5442, DOI 10.1172/JCI77798; Hasni S, 2019, ARTHRITIS RHEUMATOL, V71, P1135, DOI 10.1002/art.40828; Hayes MD, 2020, ELIFE, V9, DOI 10.7554/eLife.51862; He XD, 2021, ANN SURG ONCOL, V28, P6439, DOI 10.1245/s10434-021-09815-0; Hemmings O, 2018, CURR ALLERGY ASTHM R, V18, DOI 10.1007/s11882-018-0831-5; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Huang AH, 2020, J ALLER CL IMM-PRACT, V8, P793, DOI 10.1016/j.jaip.2019.08.004; Hussain M, 2018, J ALLERGY CLIN IMMUN, V141, P223, DOI 10.1016/j.jaci.2017.02.035; Iki M, 2016, BLOOD, V128, P2909, DOI 10.1182/blood-2016-07-729392; Imai Y, 2019, J INVEST DERMATOL, V139, P2185, DOI 10.1016/j.jid.2019.04.016; Imamura S, 2021, ALLERGOL INT, V70, P327, DOI 10.1016/j.alit.2021.01.005; Inclan-Rico JM, 2020, NAT IMMUNOL, V21, P1181, DOI 10.1038/s41590-020-0753-y; Ito Y, 2011, ALLERGY, V66, P1107, DOI 10.1111/j.1398-9995.2011.02570.x; Jogdand P, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00110-2019; Johal KJ, 2021, J ALLERGY CLIN IMMUN, V147, P2271, DOI 10.1016/j.jaci.2021.02.038; Kabashima K, 2013, J DERMATOL SCI, V70, P3, DOI 10.1016/j.jdermsci.2013.02.001; Kabata H, 2020, MUCOSAL IMMUNOL, V13, P626, DOI 10.1038/s41385-020-0266-x; Kagoya R, 2015, ANN ALLERG ASTHMA IM, V114, P30, DOI 10.1016/j.anai.2014.09.017; Kaplan AP, 2017, ALLERGY, V72, P519, DOI 10.1111/all.13083; Kaplan A, 2016, J ALLERGY CLIN IMMUN, V137, P474, DOI 10.1016/j.jaci.2015.08.023; Karasuyama H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601504; Kashiwakura JI, 2019, ALLERGY, V74, P1992, DOI 10.1111/all.13834; KATZ SI, 1978, J INVEST DERMATOL, V71, P70, DOI 10.1111/1523-1747.ep12544415; Kazancioglu S, 2020, EPIDEMIOL INFECT, V148, DOI 10.1017/S095026882000271X; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053, DOI 10.1164/ajrccm.164.6.2102025; Kim BS, 2014, J IMMUNOL, V193, P3717, DOI 10.4049/jimmunol.1401307; Kim BE, 2008, CLIN IMMUNOL, V126, P332, DOI 10.1016/j.clim.2007.11.006; Kishimoto I, 2019, ALLERGOL INT, V68, P388, DOI 10.1016/j.alit.2019.02.002; Kobayashi T, 2015, IMMUNITY, V42, P756, DOI 10.1016/j.immuni.2015.03.014; Korosec P, 2017, J ALLERGY CLIN IMMUN, V140, P750, DOI 10.1016/j.jaci.2016.12.989; Koshino T, 1996, J ASTHMA, V33, P89, DOI 10.3109/02770909609054536; Kulkarni T, 2016, AM J RESP CELL MOL, V54, P751, DOI 10.1165/rcmb.2015-0166PS; Labella M, 2022, ALLERGY, V77, P2067, DOI 10.1111/all.15148; Laing AG, 2020, NAT MED, V26, P1623, DOI 10.1038/s41591-020-1038-6; Lamri Y, 2021, J ALLERGY CLIN IMMUN, V147, P1478, DOI 10.1016/j.jaci.2020.12.622; Le Floc'h A, 2020, ALLERGY, V75, P1188, DOI 10.1111/all.14151; Leyva-Castillo JM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3847; Leyva-Castillo JM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.149953; Lin YH, 2020, INT IMMUNOL, V32, P213, DOI 10.1093/intimm/dxz075; Liu Y, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101582; Lommatzsch M, 2020, CLIN EXP ALLERGY, V50, P1267, DOI 10.1111/cea.13720; Lourda M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2109123118; MacGlashan D, 2019, J ALLERGY CLIN IMMUN, V143, P1100, DOI 10.1016/j.jaci.2018.05.019; MacGlashan D, 2021, J ALLERGY CLIN IMMUN, V147, P2295, DOI 10.1016/j.jaci.2021.02.039; MacGlashan DW, 2017, J ALLERGY CLIN IMMUN, V139, P1680, DOI 10.1016/j.jaci.2016.12.965; Mahdavinia M, 2014, J ALLERGY CLIN IMMUN, V133, P1759, DOI 10.1016/j.jaci.2013.12.1092; Marone G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02103; Matsuoka K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060958; Maurer M, 2013, NEW ENGL J MED, V368, P924, DOI 10.1056/NEJMoa1215372; McKenzie CI, 2021, ALLERGY, V76, P3028, DOI 10.1111/all.14832; Metz M, 2017, THERANOSTICS, V7, P1266, DOI 10.7150/thno.18304; Meulenbroeks C, 2015, J INVEST DERMATOL, V135, P222, DOI 10.1038/jid.2014.329; Miyake K, 2021, ALLERGY, V76, P1693, DOI 10.1111/all.14662; Miyake K, 2017, P NATL ACAD SCI USA, V114, P1111, DOI 10.1073/pnas.1615973114; Morita H, 2015, IMMUNITY, V43, P175, DOI 10.1016/j.immuni.2015.06.021; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Mukai K, 2012, BLOOD, V120, P76, DOI 10.1182/blood-2011-12-399113; Mukaida Naofumi, 2021, Mol Biomed, V2, P7, DOI 10.1186/s43556-021-00030-7; Murdaca G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102754; Muto T, 2014, INT IMMUNOL, V26, P539, DOI 10.1093/intimm/dxu058; Nakashima C, 2018, J DERMATOL SCI, V91, P3, DOI 10.1016/j.jdermsci.2018.03.007; Nakatsuji T, 2016, J INVEST DERMATOL, V136, P2192, DOI 10.1016/j.jid.2016.05.127; Noti M, 2014, J ALLERGY CLIN IMMUN, V133, P1390, DOI 10.1016/j.jaci.2014.01.021; Noti M, 2013, NAT MED, V19, P1005, DOI 10.1038/nm.3281; Numata T, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-01248-x; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Oetjen LK, 2017, CELL, V171, P217, DOI 10.1016/j.cell.2017.08.006; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Otsuka A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2740; Pan QJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00348; Pelaia C, 2021, J ASTHMA ALLERGY, V14, P163, DOI 10.2147/JAA.S297273; Pellefigues C, 2021, J ALLERGY CLIN IMMUN, V148, P799, DOI 10.1016/j.jaci.2021.02.018; Pellefigues C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02143; Pellefigues C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03129-8; Peng JY, 2021, SEMIN IMMUNOL, V53, DOI 10.1016/j.smim.2021.101529; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Poddighe D, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102790; Poddighe D, 2020, CELL IMMUNOL, V358, DOI 10.1016/j.cellimm.2020.104215; Prabhu SD, 2016, CIRC RES, V119, P91, DOI 10.1161/CIRCRESAHA.116.303577; Puan KJ, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02295-8; Puan KJ, 2017, ALLERGY, V72, P373, DOI 10.1111/all.12952; Qi Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.732209; Raap U, 2017, CLIN EXP ALLERGY, V47, P499, DOI 10.1111/cea.12875; Rauber MM, 2017, ALLERGY, V72, P1904, DOI 10.1111/all.13215; Rijavec M, 2021, ALLERGY, V76, P1254, DOI 10.1111/all.14577; Rodriguez L, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100078; Russkamp D, 2019, ALLERGY, V74, P1549, DOI 10.1111/all.13759; Saini SS, 2017, J INVEST DERMATOL, V137, P958, DOI 10.1016/j.jid.2016.11.025; Saini SS, 2009, CURR ALLERGY ASTHM R, V9, P286, DOI 10.1007/s11882-009-0040-3; Santos AF, 2021, ALLERGY, V76, P2420, DOI 10.1111/all.14747; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P1123, DOI 10.1016/j.jaci.2012.05.039; Sawaguchi M, 2012, J IMMUNOL, V188, P1809, DOI 10.4049/jimmunol.1101746; Schett G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05800-6; Schiechl G, 2016, AM J TRANSPLANT, V16, P2574, DOI 10.1111/ajt.13764; Schmid JM, 2021, ALLERGY, V76, P1528, DOI 10.1111/all.14264; Sektioglu IM, 2017, CANCER RES, V77, P291, DOI 10.1158/0008-5472.CAN-16-0993; Sharma M, 2015, NAT REV RHEUMATOL, V11, P129, DOI 10.1038/nrrheum.2014.199; Shibata S, 2018, P NATL ACAD SCI USA, V115, P13057, DOI 10.1073/pnas.1813927115; Sicklinger F, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136778; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stevens WW, 2021, J ALLERGY CLIN IMMUN, V148, P439, DOI 10.1016/j.jaci.2021.02.045; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Sun YT, 2021, J PERS MED, V11, DOI 10.3390/jpm11030195; Suzuki Y, 2017, ALLERGY, V72, P1532, DOI 10.1111/all.13197; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Ten-Caten F, 2021, INT J INFECT DIS, V105, P579, DOI 10.1016/j.ijid.2021.03.016; Troelnikov A, 2021, J ALLERGY CLIN IMMUN, V148, P91, DOI 10.1016/j.jaci.2021.04.032; Tsai M, 2020, J ALLERGY CLIN IMMUN, V145, P885, DOI 10.1016/j.jaci.2019.10.038; Tsujimura Y, 2008, IMMUNITY, V28, P581, DOI 10.1016/j.immuni.2008.02.008; Vantur R, 2020, CLIN TRANSL ALLERGY, V10, DOI 10.1186/s13601-020-00367-2; Varricchi G, 2018, IMMUNOL REV, V282, P8, DOI 10.1111/imr.12627; Venturelli N, 2016, J ALLERGY CLIN IMMUN, V138, P1367, DOI 10.1016/j.jaci.2016.02.034; Vitte J, 2020, J INFECT DIS, V222, P1985, DOI 10.1093/infdis/jiaa591; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wang F, 2021, CELL, V184, P422, DOI 10.1016/j.cell.2020.12.033; Warren CM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.25524; Watanabe T, 2018, TRENDS IMMUNOL, V39, P874, DOI 10.1016/j.it.2018.09.005; Watanabe T, 2013, J GASTROENTEROL, V48, P247, DOI 10.1007/s00535-012-0626-8; Winter NA, 2021, J ALLERGY CLIN IMMUN, V148, P428, DOI 10.1016/j.jaci.2021.01.033; Yamaga S, 2020, ALLERGOL INT, V69, P78, DOI 10.1016/j.alit.2019.05.009; Yamanishi Y, 2020, ALLERGY, V75, P2613, DOI 10.1111/all.14362; Yamanishi Y, 2016, SEMIN IMMUNOPATHOL, V38, P615, DOI 10.1007/s00281-016-0568-y; Yanagawa M, 2018, J GASTROENTEROL, V53, P449, DOI 10.1007/s00535-017-1390-6; Yang G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082867; Yang TLB, 2019, J ALLERGY CLIN IMMUN, V144, P353, DOI 10.1016/j.jaci.2019.06.016; Yoshikawa S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav2060; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Yuk CM, 2017, SCI REP-UK, V7, DOI 10.1038/srep41744	169	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								902494	10.3389/fimmu.2022.902494	http://dx.doi.org/10.3389/fimmu.2022.902494			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A6TD	35693800	Green Published, gold			2022-12-18	WOS:000809631200001
J	Ogric, M; Zigon, P; Podovsovnik, E; Lakota, K; Sodin-Semrl, S; Rotar, Z; Cucnik, S				Ogric, Manca; Zigon, Polona; Podovsovnik, Eva; Lakota, Katja; Sodin-Semrl, Snezna; Rotar, Ziga; Cucnik, Sasa			Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naive and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; BNT162b2 vaccine; anti-S antibody dynamics; healthcare professionals; humoral immune response		BackgroundSafe and effective vaccines against COVID-19 are critical for preventing the spread of SARS-CoV-2, but little is known about the humoral immune response more than 9 months after vaccination. We aimed to assess the humoral immune response after the first, second, and third (booster) doses of BNT162b2 vaccine in SARS-CoV-2 naive and previously infected healthcare professionals (HCP) and the humoral immune response after infection in vaccinated HCP. MethodsWe measured anti-spike (anti-S) and anti-nucleocapsid antibodies at different time points up to 12 months in the sera of 300 HCP who had received two or three doses of BNT162b2 vaccine. Mixed-model analyses were used to assess anti-S antibody dynamics and to determine their predictors (age, sex, BMI, and previous infection). ResultsNaive individuals had statistically lower anti-S antibody concentrations after the first dose (median 253 BAU/ml) than previously infected individuals (median 3648 BAU/ml). After the second dose, anti-S antibody concentrations increased in naive individuals (median 3216 BAU/ml), whereas the second dose did not significantly increase concentrations in previously infected individuals (median 4503 BAU/ml). The third dose resulted in an additional increase in concentrations (median 4844 BAU/ml in naive and median 5845 BAU/ml in previously infected individuals). Anti-S antibody concentrations steadily decreased after the second dose and after the third dose in naive and previously infected individuals. In addition, we found that age had an effect on the humoral immune response. Younger individuals had higher anti-S antibody concentrations after the first and second doses. After infection with the new variant Omicron, a further increase in anti-S antibody concentrations to a median value of 4794 BAU/ml was observed in three times vaccinated HCP whose anti-S antibody concentrations were relatively high before infection (median 2141 BAU/ml). Our study also showed that individuals with systemic adverse events achieved higher anti-S antibody concentrations. ConclusionIn this study, significant differences in humoral immune responses to BNT162b2 vaccine were observed between naive and previously infected individuals, with age playing an important role, suggesting that a modified vaccination schedule should be practiced in previously infected individuals. In addition, we showed that the high anti-S antibodies were not protective against new variants of SARS-CoV-2.	[Ogric, Manca; Zigon, Polona; Lakota, Katja; Sodin-Semrl, Snezna; Rotar, Ziga; Cucnik, Sasa] Univ Med Ctr Ljubljana, Dept Rheumatol, Ljubljana, Slovenia; [Zigon, Polona; Lakota, Katja; Sodin-Semrl, Snezna] Univ Primorska, Fac Math Nat Sci & Informat Technol, Koper, Slovenia; [Podovsovnik, Eva] Valdoltra Orthopaed Hosp, Ankaran, Slovenia; [Rotar, Ziga] Univ Ljubljana, Fac Med, Ljubljana, Slovenia; [Cucnik, Sasa] Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia	University Medical Centre Ljubljana; University of Primorska; University of Ljubljana; University of Ljubljana	Cucnik, S (corresponding author), Univ Med Ctr Ljubljana, Dept Rheumatol, Ljubljana, Slovenia.; Cucnik, S (corresponding author), Univ Ljubljana, Fac Pharm, Ljubljana, Slovenia.	sasa.cucnik@kclj.si	Podovšovnik, Eva/W-6505-2018; Žigon, Polona/H-2865-2019	Podovšovnik, Eva/0000-0001-7449-7038; Žigon, Polona/0000-0001-6637-9744				Abu Jabal K, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.6.2100096; Abu-Raddad LJ, 2022, NEW ENGL J MED, V386, P1804, DOI 10.1056/NEJMoa2200797; Anichini G, 2021, NEW ENGL J MED, V385, P90, DOI 10.1056/NEJMc2103825; [Anonymous], 2021, MMWR MORB MORTAL WKL, V70, P1731, DOI [DOI 10.15585/MMWR.MM7011A1EXTERNALICON, 10.1101/2021.12.07.21267432, 10.15585/mmwr.mm7050-1]; Appelman B, 2021, EBIOMEDICINE, V72, DOI 10.1016/j.ebiom.2021.103589; Barda N, 2021, LANCET, V398, P2093, DOI 10.1016/S0140-6736(21)02249-2; Bensouna I, 2022, AM J KIDNEY DIS, V79, P185, DOI 10.1053/j.ajkd.2021.08.005; Cheng MP, 2020, ANN INTERN MED, V173, P450, DOI 10.7326/M20-2854; Chodick G, 2022, CLIN INFECT DIS, V74, P472, DOI 10.1093/cid/ciab438; Cocomazzi G, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080913; Collier AY, 2021, NEW ENGL J MED, V385, P2010, DOI 10.1056/NEJMc2115596; Dagan N, 2021, NEW ENGL J MED, V384, P1412, DOI 10.1056/NEJMoa2101765; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dekervel M, 2021, CLIN KIDNEY J, V14, P2349, DOI 10.1093/ckj/sfab152; Ebinger JE, 2021, NAT MED, V27, P981, DOI 10.1038/s41591-021-01325-6; El-Masry EA, 2021, AFR HEALTH SCI, V21, P1574, DOI 10.4314/ahs.v21i4.11; Falsey AR, 2021, NEW ENGL J MED, V385, P1627, DOI 10.1056/NEJMc2113468; Favresse J, 2021, EMERG MICROBES INFEC, V10, P1495, DOI 10.1080/22221751.2021.1953403; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Ibarrondo FJ, 2021, ACS NANO, V15, P11180, DOI 10.1021/acsnano.1c03972; Israel A., 2021, MEDRXIV, DOI [10.1101/2021.08.19.21262111, DOI 10.1101/2021.08.19.21262111, DOI 10.1101/2021.08.19.21262111V1]; Kim JH, 2021, NAT MED, V27, P205, DOI 10.1038/s41591-021-01230-y; Krammer F., 2021, MEDRXIV, p29.21250653, DOI [DOI 10.1101/2021.01.29.21250653, 10.1101/2021.01.29.21250653]; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Manisty C, 2021, LANCET, V397, P1057, DOI 10.1016/S0140-6736(21)00501-8; Muller L, 2021, CLIN INFECT DIS, V73, P2065, DOI 10.1093/cid/ciab381; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Nomura Y, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091042; Pavia CS, 2021, INT J ANTIMICROB AG, V57, DOI 10.1016/j.ijantimicag.2020.106275; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Richards NE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.24331; Saadat S, 2021, JAMA-J AM MED ASSOC, V325, P1467, DOI 10.1001/jama.2021.3341; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Samanovic Marie I, 2021, medRxiv, DOI 10.1101/2021.02.07.21251311; Shrotri M., 2021, SPIKE ANTIBODY RESPO, V05; Shrotri M, 2021, LANCET, V398, P385, DOI 10.1016/S0140-6736(21)01642-1; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								876533	10.3389/fimmu.2022.876533	http://dx.doi.org/10.3389/fimmu.2022.876533			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2K0BI	35711413	gold, Green Published			2022-12-18	WOS:000816010200001
J	Peng, J; Yao, XY; Yuan, CY; Liu, XL; Xia, RX; He, J; Li, R; Yao, YQ				Peng, Jing; Yao, Xueying; Yuan, Chunyan; Liu, Xiaoli; Xia, Renxiang; He, Jian; Li, Rui; Yao, Yunqing			The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients	FRONTIERS IN IMMUNOLOGY			English	Article						OBI; T lymphocyte; B lymphocyte; hepatitis B vaccine; anti-HBs; immunotherapy; therapeutic potential	ANTIBODY	ObjectivesThere is no effective treatment for occult hepatitis B virus infection (OBI) patients, and immunotherapy may be one of the most promising options. We aim to investigate the underlying mechanism and therapeutic potential of hepatitis B vaccine immunotherapy for OBI patients. MethodsOutpatient OBI patients were screened and randomly divided into treatment (Group A) and control (Group B) groups. At weeks 0, 4, and 24, patients in Group A received a subcutaneous/intramuscular injection of hepatitis B vaccine (Engerix-B, 20 mu g/time) according to the standard vaccination schedule; patients in Group B served as blank control. The patients were followed for 36 weeks, with clinical, biochemical, virological, immunological, and imaging data collected and analyzed at weeks 0, 12, 24, and 36, respectively, and the relation between the virology and immunology results was analyzed. ResultsOf the 228 OBI patients, 28 were excluded, and 200 were enrolled for observation. In the end, 44 patients were included in Group A and 39 in Group B after excluding lost cases. At week 0 (baseline), some patients in two groups had liver disease symptoms, HBV-related liver function damage, and liver fibrosis. 86.36% (38/44) and 82.05% (32/39) patients were positive for serum hepatitis B surface antibodies (anti-HBs) in Group A and Group B, respectively, with the median (quartile) of 42.47 (16.85, 109.1) and 39.27 (16.06, 117.4) mIU/ml, respectively. Reduced peripheral blood CD4(+)T, CD8(+)T, and B lymphocytes were found in some patients in two groups. These results were not statistically different between Group A and Group B (P>0.05). At week 36, all patients were serum anti-HBs (+) in Group A, with a median (quartile) of 1000 (483.9, 1000) mIU/ml, which was significantly higher than that at week 0 (P<0.05) and that in Group B (P<0.05). Compared to week 0, the number of CD8(+) T and B lymphocytes increased significantly and were significantly higher than Group B at the same point. Two patients in Group B were found to have hepatitis B virus reactivation from week 12 to week 36. Correlation AnalysisAnti-HBs in Group A patients were positively correlated with B lymphocytes (r=0.3431, 0.3087, and 0.3041, respectively) and positively correlated with CD8(+) T lymphocytes (r=0.4954, 0.3054, and 0.3455, respectively) at weeks 12, 24, and 36. ConclusionVirological reactivation is a risk for OBI patients. Serum hepatitis B surface antibodies were significantly increased after hepatitis B vaccine treatment, the same as the numbers of peripheral blood B and CD8(+) T lymphocytes; changes in hepatitis B surface antibody levels were positively correlated with the changes in peripheral blood B and CD8(+) T lymphocytes.	[Peng, Jing; Yuan, Chunyan; Liu, Xiaoli; Xia, Renxiang; He, Jian; Li, Rui; Yao, Yunqing] Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 1, Chongqing, Peoples R China; [Yao, Xueying] Chongqing Med Univ, Dept Radiol, Affiliated Hosp 2, Chongqing, Peoples R China	Chongqing Medical University; Chongqing Medical University	Yao, YQ (corresponding author), Chongqing Med Univ, Dept Infect Dis, Affiliated Hosp 1, Chongqing, Peoples R China.	yaoyunqing@hospital.cqmu.edu.cn	Liu, Xiaoli/HGE-7614-2022					Cao ZH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0242559; Chen MH, 2021, ANN RHEUM DIS, V80, P1393, DOI 10.1136/annrheumdis-2021-220774; Eltom K, 2020, JGH OPEN, V4, P800, DOI 10.1002/jgh3.12411; European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021; Hehle V, 2020, J EXP MED, V217, DOI 10.1084/jem.20200840; Jang JW, 2021, CLIN MOL HEPATOL, V27, P207, DOI 10.3350/cmh.2020.0115; Kato M, 2017, J GASTROENTEROL, V52, P1051, DOI 10.1007/s00535-017-1316-3; Le Bert N, 2020, J HEPATOL, V72, P34, DOI 10.1016/j.jhep.2019.07.015; Paul S, 2017, HEPATOLOGY, V66, P379, DOI 10.1002/hep.29082; Pisaturo M, 2020, J MED VIROL, V92, P2917, DOI 10.1002/jmv.25867; Pisaturo M, 2020, J VIRAL HEPATITIS, V27, P415, DOI 10.1111/jvh.13248; Raimondo G, 2019, J HEPATOL, V71, P397, DOI 10.1016/j.jhep.2019.03.034; Sarin SK, 2016, HEPATOL INT, V10, P1, DOI 10.1007/s12072-015-9675-4; Song AX, 2021, J VIRAL HEPATITIS, V28, P601, DOI 10.1111/jvh.13471; Sosa-Jurado F, 2021, EUR CYTOKINE NETW, V32, P23, DOI 10.1684/ecn.2021.0466; Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800; Testoni B, 2019, J HEPATOL, V70, P615, DOI 10.1016/j.jhep.2018.11.030; Tian C, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0034-0; Wang RJ, 2021, HEPATOL INT, V15, P328, DOI 10.1007/s12072-021-10156-z; World Health Organization, 2021, GLOB PROGR REP HIV V; Xia RX, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.840825; Xu H, 2022, J HEPATOL, V76, P34, DOI 10.1016/j.jhep.2021.07.031; Yao X, 2007, VACCINE, V25, P1771, DOI 10.1016/j.vaccine.2006.11.019; Yuan CY, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.865124; Zhu DM, 2016, J IMMUNOL, V196, P3079, DOI 10.4049/jimmunol.1502061	25	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								903685	10.3389/fimmu.2022.903685	http://dx.doi.org/10.3389/fimmu.2022.903685			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2H0FL	35747142	gold, Green Published			2022-12-18	WOS:000813975000001
J	Roberts, LB; Berkachy, R; Wane, M; Patel, DF; Schnoeller, C; Lord, GM; Gounaris, K; Ryffel, B; Quesniaux, V; Darby, M; Horsnell, WGC; Selkirk, ME				Roberts, Luke B.; Berkachy, Rita; Wane, Madina; Patel, Dhiren F.; Schnoeller, Corinna; Lord, Graham M.; Gounaris, Kleoniki; Ryffel, Bernhard; Quesniaux, Valerie; Darby, Matthew; Horsnell, William G. C.; Selkirk, Murray E.			Differential Regulation of Allergic Airway Inflammation by Acetylcholine	FRONTIERS IN IMMUNOLOGY			English	Article						lung; alternaria; ILC2; neutrophil; eosinophil; inflammation; chemokine; acetylcholine	NONNEURONAL SECRETED ACETYLCHOLINESTERASE; NEURAL SIGNALS; ATP RELEASE; SIGLEC-F; T-CELLS; LUNG; RECRUITMENT; ACTIVATION; INNATE; ASTHMA	Acetylcholine (ACh) from neuronal and non-neuronal sources plays an important role in the regulation of immune responses and is associated with the development of several disease pathologies. We have previously demonstrated that group 2 innate lymphoid cell (ILC2)-derived ACh is required for optimal type 2 responses to parasitic infection and therefore sought to determine whether this also plays a role in allergic inflammation. Rora(Cre+)Chat(LoxP) mice (in which ILC2s cannot synthesize ACh) were exposed to an allergenic extract of the fungus Alternaria alternata, and immune responses in the airways and lung tissues were analyzed. Airway neutrophilia and expression of the neutrophil chemoattractants CXCL1 and CXCL2 were enhanced 24 h after exposure, suggesting that ILC2-derived ACh plays a role in limiting excessive pulmonary neutrophilic inflammation. The effect of non-selective depletion of ACh was examined by intranasal administration of a stable parasite-secreted acetylcholinesterase. Depletion of airway ACh in this manner resulted in a more profound enhancement of neutrophilia and chemokine expression, suggesting multiple cellular sources for the release of ACh. In contrast, depletion of ACh inhibited Alternaria-induced activation of ILC2s, suppressing the expression of IL-5, IL-13, and subsequent eosinophilia. Depletion of ACh reduced macrophages with an alternatively activated M2 phenotype and an increase in M1 macrophage marker expression. These data suggest that ACh regulates allergic airway inflammation in several ways, enhancing ILC2-driven eosinophilia but suppressing neutrophilia through reduced chemokine expression.	[Roberts, Luke B.; Berkachy, Rita; Wane, Madina; Schnoeller, Corinna; Gounaris, Kleoniki; Selkirk, Murray E.] Imperial Coll London, Dept Life Sci, London, England; [Roberts, Luke B.; Lord, Graham M.] Kings Coll London, Sch Immunol & Microbial Sci, London, England; [Patel, Dhiren F.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Lord, Graham M.] Univ Manchester, Fac Biol Med & Hlth, Manchester, England; [Ryffel, Bernhard; Quesniaux, Valerie; Horsnell, William G. C.] Univ Orleans, Lab Mol & Expt Immunol & Neurogenet, UMR 7355, CNRS, Rue Dupanloup, Orleans, France; [Ryffel, Bernhard; Quesniaux, Valerie; Horsnell, William G. C.] Le Studium Inst Adv Studies, Rue Dupanloup, Orleans, France; [Darby, Matthew; Horsnell, William G. C.] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa; [Horsnell, William G. C.] Univ Birmingham, Coll Med & Dent Sci, Birmingham, England	Imperial College London; University of London; King's College London; Imperial College London; University of Manchester; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Orleans; University of Cape Town; University of Birmingham	Roberts, LB; Selkirk, ME (corresponding author), Imperial Coll London, Dept Life Sci, London, England.; Roberts, LB (corresponding author), Kings Coll London, Sch Immunol & Microbial Sci, London, England.	luke.roberts@kcl.ac.uk; m.selkirk@imperial.ac.uk		Selkirk, Murray/0000-0002-6274-6014; Horsnell, William Gordon Charles/0000-0001-7172-408X	BBSRC [BB/R015856/1]; Wellcome Trust [097011]	BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Wellcome Trust(Wellcome Trust)	This work was funded by a project grant to MS from the BBSRC (BB/R015856/1) and a PhD studentship to LR from the Wellcome Trust (097011).	Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Birder LA, 2003, AM J PHYSIOL-RENAL, V285, pF423, DOI 10.1152/ajprenal.00056.2003; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bosnjak B, 2014, PULM PHARMACOL THER, V27, P44, DOI 10.1016/j.pupt.2013.09.004; Cass SP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740330; Castilow EM, 2008, J IMMUNOL, V180, P2376, DOI 10.4049/jimmunol.180.4.2376; Chen F, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2021.110215; Chu C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe3218; Cox MA, 2019, SCIENCE, V363, P639, DOI 10.1126/science.aau9072; Daines M, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.683194; Darby M, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004636; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Galle-Treger L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13202; Gibbings SL, 2015, BLOOD, V126, P1357, DOI 10.1182/blood-2015-01-624809; Girbl T, 2018, IMMUNITY, V49, P1062, DOI 10.1016/j.immuni.2018.09.018; Gosens R, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01247-2017; Hol J, 2010, J LEUKOCYTE BIOL, V87, P501, DOI 10.1189/jlb.0809532; Horkowitz AP, 2020, IMMUNOTARGETS THER, V9, P333, DOI 10.2147/ITT.S279228; Hussein AS, 1999, J BIOL CHEM, V274, P9312, DOI 10.1074/jbc.274.14.9312; Hussein AS, 2000, EUR J BIOCHEM, V267, P2276, DOI 10.1046/j.1432-1327.2000.01232.x; Huston JM, 2009, J IMMUNOL, V183, P552, DOI 10.4049/jimmunol.0802684; Kambara K, 2015, AM J PATHOL, V185, P162, DOI 10.1016/j.ajpath.2014.09.005; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; Kistemaker LEM, 2015, TRENDS PHARMACOL SCI, V36, P164, DOI 10.1016/j.tips.2014.11.005; Kistemaker LEM, 2013, EUR RESPIR J, V42, P1677, DOI 10.1183/09031936.00112412; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kummer W, 2014, CURR OPIN PHARMACOL, V16, P43, DOI 10.1016/j.coph.2014.03.001; Martinez-Gonzalez I, 2015, TRENDS IMMUNOL, V36, P189, DOI 10.1016/j.it.2015.01.005; Matsuyama T, 2021, ALLERGY, V76, P2785, DOI 10.1111/all.14836; McMillan SJ, 2014, IMMUNOL LETT, V160, P11, DOI 10.1016/j.imlet.2014.03.008; McSorley HJ, 2014, MUCOSAL IMMUNOL, V7, P1068, DOI 10.1038/mi.2013.123; Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084; Pan J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00606; Pera T, 2011, EUR RESPIR J, V38, P789, DOI 10.1183/09031936.00146610; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594, DOI 10.1067/mai.2001.118600; Qian ZJ, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091150; Reardon C, 2013, P NATL ACAD SCI USA, V110, P1410, DOI 10.1073/pnas.1221655110; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Roberts LB, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abd0359; Rosas-Ballina M, 2011, SCIENCE, V334, P98, DOI 10.1126/science.1209985; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Saeed RW, 2005, J EXP MED, V201, P1113, DOI 10.1084/jem.20040463; Saluzzo S, 2017, CELL REP, V18, P1893, DOI 10.1016/j.celrep.2017.01.071; Schloss MJ, 2022, NAT IMMUNOL, V23, P605, DOI 10.1038/s41590-022-01165-7; Segal M, 2007, IMMUNOL CELL BIOL, V85, P518, DOI 10.1038/sj.icb.7100075; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Sui GP, 2014, AM J PHYSIOL-RENAL, V306, pF286, DOI 10.1152/ajprenal.00291.2013; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Van Nevel S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.677848; Vaux R, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005998; Viola A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01462; Yuan F, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.598165; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255	54	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								893844	10.3389/fimmu.2022.893844	http://dx.doi.org/10.3389/fimmu.2022.893844			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2K0QY	35711456	Green Published, Green Submitted, gold			2022-12-18	WOS:000816051300001
J	Sasaki, I; Kato, T; Hemmi, H; Fukuda-Ohta, Y; Wakaki-Nishiyama, N; Yamamoto, A; Kaisho, T				Sasaki, Izumi; Kato, Takashi; Hemmi, Hiroaki; Fukuda-Ohta, Yuri; Wakaki-Nishiyama, Naoko; Yamamoto, Asumi; Kaisho, Tsuneyasu			Conventional Type 1 Dendritic Cells in Intestinal Immune Homeostasis	FRONTIERS IN IMMUNOLOGY			English	Review						XCR1; intestine; gene targeting; T cell; dendritic cell; subset	T-REG-CELLS; INTRAEPITHELIAL LYMPHOCYTES; CHEMOKINE RECEPTOR; MEDIATED INDUCTION; CROSS-PRESENTATION; CRITICAL ROLES; MYELOID CELLS; GERM-FREE; GENERATION; SUBSET	Dendritic cells (DC) play critical roles in linking innate and adaptive immunity. DC are heterogenous and there are subsets with various distinct functions. One DC subset, conventional type 1 DC (cDC1), can be defined by expression of CD8 alpha/CD103 in mice and CD141 in humans, or by expression of a chemokine receptor, XCR1, which is a conserved marker in both mice and human. cDC1 are characterized by high ability to ingest dying cells and to cross-present antigens for generating cytotoxic CD8 T cell responses. Through these activities, cDC1 play crucial roles in immune responses against infectious pathogens or tumors. Meanwhile, cDC1 involvement in homeostatic situations is not fully understood. Analyses by using mutant mice, in which cDC1 are ablated in vivo, revealed that cDC1 are critical for maintaining intestinal immune homeostasis. Here, we review the homeostatic roles of cDC1, focusing upon intestinal immunity.	[Sasaki, Izumi; Kato, Takashi; Hemmi, Hiroaki; Fukuda-Ohta, Yuri; Wakaki-Nishiyama, Naoko; Yamamoto, Asumi; Kaisho, Tsuneyasu] Wakayama Med Univ, Inst Adv Med, Dept Immunol, Wakayama, Japan; [Hemmi, Hiroaki] Okayama Univ Sci, Fac Vet Med, Lab Immunol, Ehime, Japan	Wakayama Medical University; Okayama University of Science	Sasaki, I; Kaisho, T (corresponding author), Wakayama Med Univ, Inst Adv Med, Dept Immunol, Wakayama, Japan.	izumisas@wakayama-med.ac.jp; tkaisho@wakayama-med.ac.jp			Practical Research Project for Rare/Intractable Diseases [JP19ek0109199, JP21K06956, JP17H05799, JP19H04813, JP17K19568, JP21K19384, JP16K19585, JP18K16096, JP21J22615]; Uehara Memorial Foundation; Takeda Science Foundation; Ichiro Kanehara Foundation for the promotion of Medical Sciences and Medical care; Inamori Foundation; GSK Japan Research Grant 2021; Kowa Life Science Foundation; Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University; Cooperative Research Grant from the Institute for Enzyme Research, Joint Usage/Research Center, Tokushima University; Joint Research Program of the Institute for Genetic Medicine Hokkaido University; Joint Research Project of the Institute of Medical Science, the University of Tokyo; Wakayama Medical University;  [JP26293106];  [JP17H04088];  [JP20H03505];  [JP19K07628];  [JP18K07071]	Practical Research Project for Rare/Intractable Diseases; Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); Ichiro Kanehara Foundation for the promotion of Medical Sciences and Medical care; Inamori Foundation; GSK Japan Research Grant 2021; Kowa Life Science Foundation; Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University; Cooperative Research Grant from the Institute for Enzyme Research, Joint Usage/Research Center, Tokushima University; Joint Research Program of the Institute for Genetic Medicine Hokkaido University; Joint Research Project of the Institute of Medical Science, the University of Tokyo; Wakayama Medical University; ; ; ; ; 	This work was supported by the Practical Research Project for Rare/Intractable Diseases under Grant Numbers JP19ek0109199 (to HH and TsK), and Grant-in-Aids for Scientific Research (B) (JP26293106, JP17H04088 and JP20H03505 to TsK), for Scientific Research (C) (JP19K07628 to IS, JP18K07071 and JP21K06956 to HH), for Scientific Research on Innovative Areas (JP17H05799 and JP19H04813 to TsK), for Exploratory Research (JP17K19568, JP21K19384 to TsK), for Young Scientists (B) (JP16K19585 and JP18K16096 to YF-O), and for JSPS Research Fellow (JP21J22615 to TaK). This work was also supported by the Uehara Memorial Foundation (to IS and TsK); by Takeda Science Foundation (to IS, HH, and TsK); by the Ichiro Kanehara Foundation for the promotion of Medical Sciences and Medical care (to HH); by the Inamori Foundation (to IS); by GSK Japan Research Grant 2021 (to IS); by Kowa Life Science Foundation (to IS); by the Extramural Collaborative Research Grant of Cancer Research Institute, Kanazawa University; by a Cooperative Research Grant from the Institute for Enzyme Research, Joint Usage/Research Center, Tokushima University; by the Grant for Joint Research Program of the Institute for Genetic Medicine Hokkaido University; by the Grant for Joint Research Project of the Institute of Medical Science, the University of Tokyo; by Wakayama Medical University Special Grant-in-Aid for Research Projects.	Alexandre YO, 2016, J EXP MED, V213, P75, DOI 10.1084/jem.20142350; Aliberti J, 2003, BLOOD, V101, P305, DOI 10.1182/blood-2002-04-1088; Arnold IC, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007866; Ashour D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135143; Atarashi K, 2017, SCIENCE, V358, P359, DOI 10.1126/science.aan4526; Audsley KM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.735133; Audsley KM, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030565; Bachem A, 2010, J EXP MED, V207, P1273, DOI 10.1084/jem.20100348; Bajana S, 2012, J IMMUNOL, V189, P3368, DOI 10.4049/jimmunol.1102613; Bertolini TB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672449; Brewitz A, 2017, IMMUNITY, V46, P205, DOI 10.1016/j.immuni.2017.01.003; Briseno CG, 2018, P NATL ACAD SCI USA, V115, P10726, DOI 10.1073/pnas.1809925115; Brockschniedier D, 2006, GENESIS, V44, P322, DOI 10.1002/dvg.20218; Cancel JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00009; Cervantes-Barragan L, 2017, SCIENCE, V357, P806, DOI 10.1126/science.aah5825; Choi JH, 2011, IMMUNITY, V35, P819, DOI 10.1016/j.immuni.2011.09.014; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Crozat K, 2010, J EXP MED, V207, P1283, DOI 10.1084/jem.20100223; Daniels NJ, 2016, MUCOSAL IMMUNOL, V9, P229, DOI 10.1038/mi.2015.55; Das G, 2003, P NATL ACAD SCI USA, V100, P5324, DOI 10.1073/pnas.0831037100; Deczkowska A, 2021, NAT MED, V27, P1043, DOI 10.1038/s41591-021-01344-3; Demiri M, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12458; Denning TL, 2011, J IMMUNOL, V187, P733, DOI 10.4049/jimmunol.1002701; Dorner BG, 2009, IMMUNITY, V31, P823, DOI 10.1016/j.immuni.2009.08.027; Durai V, 2016, IMMUNITY, V45, P719, DOI 10.1016/j.immuni.2016.10.010; Edelson BT, 2011, IMMUNITY, V35, P236, DOI 10.1016/j.immuni.2011.06.012; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Eickhoff S, 2015, CELL, V162, P1322, DOI 10.1016/j.cell.2015.08.004; Esterhazy D, 2019, NATURE, V569, P126, DOI 10.1038/s41586-019-1125-3; Esterhazy D, 2016, NAT IMMUNOL, V17, P545, DOI 10.1038/ni.3408; Ferris ST, 2020, NATURE, V584, P624, DOI 10.1038/s41586-020-2611-3; Ferris ST, 2014, IMMUNITY, V41, P657, DOI 10.1016/j.immuni.2014.09.012; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Heath WR, 2001, ANNU REV IMMUNOL, V19, P47, DOI 10.1146/annurev.immunol.19.1.47; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Jiang W, 2013, J EXP MED, V210, P2465, DOI 10.1084/jem.20122490; Kayama H, 2012, P NATL ACAD SCI USA, V109, P5010, DOI 10.1073/pnas.1114931109; Kitano M, 2016, P NATL ACAD SCI USA, V113, P1044, DOI 10.1073/pnas.1513607113; Kumamoto Y, 2013, IMMUNITY, V39, P733, DOI 10.1016/j.immuni.2013.08.029; Lei Y, 2011, J EXP MED, V208, P383, DOI 10.1084/jem.20102327; Linehan JL, 2015, P NATL ACAD SCI USA, V112, P12782, DOI 10.1073/pnas.1513532112; Liu K, 2010, IMMUNOL REV, V234, P45, DOI 10.1111/j.0105-2896.2009.00879.x; Luda KM, 2016, IMMUNITY, V44, P860, DOI 10.1016/j.immuni.2016.02.008; Mattiuz R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02805; Mayer JU, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.592325; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Moreira TG, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25115-3; Moriya T, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102424; Mowat AM, 2014, NAT REV IMMUNOL, V14, P667, DOI 10.1038/nri3738; Muzaki ARBM, 2016, MUCOSAL IMMUNOL, V9, P336, DOI 10.1038/mi.2015.64; Ohta T, 2016, SCI REP-UK, V6, DOI 10.1038/srep23505; Olivares-Villagomez D, 2008, P NATL ACAD SCI USA, V105, P17931, DOI 10.1073/pnas.0808242105; Persson EK, 2013, IMMUNITY, V38, P958, DOI 10.1016/j.immuni.2013.03.009; Piva L, 2012, J IMMUNOL, V189, P1128, DOI 10.4049/jimmunol.1201171; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Poussier P, 2002, J EXP MED, V195, P1491, DOI 10.1084/jem.20011793; Pulido AD, 2021, IMMUNITY, V54, P1154, DOI 10.1016/j.immuni.2021.04.019; Roberts EW, 2016, CANCER CELL, V30, P324, DOI 10.1016/j.ccell.2016.06.003; Sanchez-Paulete AR, 2016, CANCER DISCOV, V6, P71, DOI 10.1158/2159-8290.CD-15-0510; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Satpathy AT, 2013, NAT IMMUNOL, V14, P937, DOI 10.1038/ni.2679; Schiavoni G, 2002, J EXP MED, V196, P1415, DOI 10.1084/jem.20021263; Schlitzer A, 2015, SEMIN CELL DEV BIOL, V41, P9, DOI 10.1016/j.semcdb.2015.03.011; Schlitzer A, 2013, IMMUNITY, V38, P970, DOI 10.1016/j.immuni.2013.04.011; Schraml BU, 2013, CELL, V154, P843, DOI 10.1016/j.cell.2013.07.014; Shimizu K, 2013, J IMMUNOL, V190, P5609, DOI 10.4049/jimmunol.1300033; Spranger S, 2017, CANCER CELL, V31, P711, DOI 10.1016/j.ccell.2017.04.003; Steinman RM, 2012, ANNU REV IMMUNOL, V30, P1, DOI 10.1146/annurev-immunol-100311-102839; Stutte S, 2021, BRAIN BEHAV IMMUN, V95, P429, DOI 10.1016/j.bbi.2021.04.018; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Suzuki H, 2002, EXP MOL PATHOL, V72, P230, DOI 10.1006/exmp.2002.2433; Suzuki S, 2004, P NATL ACAD SCI USA, V101, P8981, DOI 10.1073/pnas.0402139101; Tsuchiya N, 2019, CELL REP, V29, P162, DOI 10.1016/j.celrep.2019.08.086; Tussiwand R, 2015, IMMUNITY, V42, P916, DOI 10.1016/j.immuni.2015.04.017; Tussiwand R, 2012, NATURE, V490, P502, DOI 10.1038/nature11531; UMESAKI Y, 1993, IMMUNOLOGY, V79, P32; Van der Borght K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02714; Welty NE, 2013, J EXP MED, V210, P2011, DOI 10.1084/jem.20130728; Wohn C, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba1896; Yamazaki C, 2013, J IMMUNOL, V190, P6071, DOI 10.4049/jimmunol.1202798; Yamazaki C, 2010, BIOCHEM BIOPH RES CO, V397, P756, DOI 10.1016/j.bbrc.2010.06.029; Yu SH, 2008, P NATL ACAD SCI USA, V105, P20834, DOI 10.1073/pnas.0808700106; Zeng R, 2016, MUCOSAL IMMUNOL, V9, P183, DOI 10.1038/mi.2015.50	86	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								857954	10.3389/fimmu.2022.857954	http://dx.doi.org/10.3389/fimmu.2022.857954			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y9NO	35693801	gold, Green Published			2022-12-18	WOS:000808463500001
J	Schmidt, T; Afonso, S; Perie, L; Heidenreich, K; Wulf, S; Krebs, CF; Zipfel, PF; Wiech, T				Schmidt, Tilman; Afonso, Sara; Perie, Luce; Heidenreich, Karin; Wulf, Sonia; Krebs, Christian F.; Zipfel, Peter F.; Wiech, Thorsten			An Interdisciplinary Diagnostic Approach to Guide Therapy in C3 Glomerulopathy	FRONTIERS IN IMMUNOLOGY			English	Article						C3 glomerulopathy; membranoproliferative glomerulonephritis; complement; factor H; eculizumab; FHL1	HEMOLYTIC-UREMIC SYNDROME; DENSE DEPOSIT DISEASE; COMPLEMENT; ECULIZUMAB	Since the re-classification of membranoproliferative glomerulonephritis the new disease entity C3 glomerulopathy is diagnosed if C3 deposition is clearly dominant over immunoglobulins in immunohistochemistry or immunofluorescence. Although this new definition is more orientated at the pathophysiology as mediated by activity of the alternative complement pathway C3 glomerulopathy remains a heterogenous group of disorders. Genetic or autoimmune causes are associated in several but not in all patients with this disease. However, prognosis is poorly predictable, and clinicians cannot directly identify patients that might benefit from therapy. Moreover, therapy may range from supportive care alone, unspecific immune suppression, plasma treatment, or plasma exchange to complement inhibition. The current biopsy based diagnostic approaches sometimes combined with complement profiling are not sufficient to guide clinicians neither (i) whether to treat an individual patient, nor (ii) to choose the best therapy. With this perspective, we propose an interdisciplinary diagnostic approach, including detailed analysis of the kidney biopsy for morphological alterations and immunohistochemical staining, for genetic analyses of complement genes, complement activation patterning in plasma, and furthermore for applying novel approaches for convertase typing and complement profiling directly in renal tissue. Such a combined diagnostic approach was used here for a 42-year-old female patient with a novel mutation in the Factor H gene, C3 glomerulopathy and signs of chronic endothelial damage. We present here an approach that might in future help to guide therapy of renal diseases with relevant complement activation, especially since diverse new anti-complement agents are under clinical investigation.	[Schmidt, Tilman] Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Hamburg, Germany; [Afonso, Sara; Perie, Luce; Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Hans Knoll Inst, Dept Infect Biol, Jena, Germany; [Heidenreich, Karin] Eleva GmbH, Med Alliance, Freiburg, Germany; [Wulf, Sonia; Wiech, Thorsten] Univ Hosp Hamburg Eppendorf, Inst Pathol, Nephropathol Sect, Hamburg, Germany; [Krebs, Christian F.] Univ Med Ctr Hamburg Eppendorf, Dept Med 3, Div Translat Immunol, Hamburg, Germany; [Krebs, Christian F.] Univ Med Ctr Hamburg Eppendorf, Hamburg Ctr Translat Immunol HCTI, Hamburg, Germany; [Zipfel, Peter F.] Friedrich Schiller Univ, Inst Microbiol, Jena, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Hans Knoll Institute (HKI); University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Friedrich Schiller University of Jena	Wiech, T (corresponding author), Univ Hosp Hamburg Eppendorf, Inst Pathol, Nephropathol Sect, Hamburg, Germany.	t.wiech@uke.de			Deutsche Forschungsgemeinschaft as part of the collaborative research program 'Immune-Mediated Glomerular Diseases' [SFB1192]; Kidneeds foundation	Deutsche Forschungsgemeinschaft as part of the collaborative research program 'Immune-Mediated Glomerular Diseases'(German Research Foundation (DFG)); Kidneeds foundation	This work was supported by a grant from the Deutsche Forschungsgemeinschaft as part of the collaborative research program 'Immune-Mediated Glomerular Diseases' SFB1192, Project B6 to TW and PFZ, Project C1 to TW, as well as the Kidneeds foundation to PFZ.	Avasare RS, 2018, CLIN J AM SOC NEPHRO, V13, P406, DOI 10.2215/CJN.09080817; Bomback AS, 2012, CLIN J AM SOC NEPHRO, V7, P748, DOI 10.2215/CJN.12901211; Busutti M, 2021, KIDNEY INT REP, V6, P534, DOI 10.1016/j.ekir.2020.10.037; Caliskan Y, 2017, AM J NEPHROL, V46, P96, DOI 10.1159/000479012; Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252; Caravaca-Fontan F, 2020, CLIN J AM SOC NEPHRO, V15, P1287, DOI 10.2215/CJN.15241219; Chen Q, 2014, J CLIN INVEST, V124, P145, DOI 10.1172/JCI71866; Fakhouri F, 2010, KIDNEY INT, V78, P279, DOI 10.1038/ki.2010.132; Goodship THJ, 2017, KIDNEY INT, V91, P539, DOI 10.1016/j.kint.2016.10.005; Iatropoulos P, 2018, J AM SOC NEPHROL, V29, P283, DOI 10.1681/ASN.2017030258; Iatropoulos P, 2016, MOL IMMUNOL, V71, P131, DOI 10.1016/j.molimm.2016.01.010; Kasahara Katsuaki, 2020, Clin Nephrol Case Stud, V8, P96, DOI 10.5414/CNCS110309; Larsen CP, 2013, KIDNEY INT, V83, P331, DOI 10.1038/ki.2012.385; Le Quintrec M, 2015, AM J KIDNEY DIS, V65, P484, DOI 10.1053/j.ajkd.2014.09.025; Licht C, 2005, AM J KIDNEY DIS, V45, P415, DOI 10.1053/j.ajkd.2004.10.018; Medjeral-Thomas NR, 2014, CLIN J AM SOC NEPHRO, V9, P46, DOI 10.2215/CJN.04700513; Oosterveld MJS, 2015, CLIN J AM SOC NEPHRO, V10, P1773, DOI 10.2215/CJN.01360215; Person F, 2020, KIDNEY INT REP, V5, P927, DOI 10.1016/j.ekir.2020.03.009; Pickering MC, 2013, KIDNEY INT, V84, P1079, DOI 10.1038/ki.2013.377; Rabasco C, 2015, KIDNEY INT, V88, P1153, DOI 10.1038/ki.2015.227; Ravindran A, 2018, MAYO CLIN PROC, V93, P991, DOI 10.1016/j.mayocp.2018.05.019; Ruggenenti P, 2019, AM J KIDNEY DIS, V74, P224, DOI 10.1053/j.ajkd.2018.12.046; Schmidt CQ, 2011, PROTEIN EXPRES PURIF, V76, P254, DOI 10.1016/j.pep.2010.12.002; Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63; Smith RJH, 2019, NAT REV NEPHROL, V15, P129, DOI 10.1038/s41581-018-0107-2; Zhang YZ, 2012, CLIN J AM SOC NEPHRO, V7, P265, DOI 10.2215/CJN.07900811; Zipfel PF, 2020, J AM SOC NEPHROL, V31, P241, DOI 10.1681/ASN.2019050515; Zipfel PF, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02166; Zipfel PF, 2015, MOL IMMUNOL, V67, P21, DOI 10.1016/j.molimm.2015.03.012; Zipfel PF., 2021, CELL TISSUE RES, V385, P355, DOI [10.1007/S00441-021-03485-W, DOI 10.1007/s00441-021-03485-w]	30	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								826513	10.3389/fimmu.2022.826513	http://dx.doi.org/10.3389/fimmu.2022.826513			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A6RN	35693785	gold, Green Published			2022-12-18	WOS:000809627000001
J	Silvera-Ruiz, SM; Gemperle, C; Peano, N; Olivero, V; Becerra, A; Haberle, J; Gruppi, A; Larovere, LE; Motrich, RD				Silvera-Ruiz, Silene M.; Gemperle, Corinne; Peano, Natalia; Olivero, Valentina; Becerra, Adriana; Haberle, Johannes; Gruppi, Adriana; Larovere, Laura E.; Motrich, Ruben D.			Immune Alterations in a Patient With Hyperornithinemia-Hyperammonemia-Homocitrullinuria Syndrome: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						urea cycle defects; HHH syndrome; infection; hyperammonemia; immunodeficiency; T cells; B cells; case report	UREA CYCLE DISORDERS; T-CELLS; HHH SYNDROME; ORNITHINE; MULTICENTER; MUTATIONS; PEOPLE; GENE	The hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome is a rare autosomal recessive inborn error of the urea cycle caused by mutations in the SLC25A15 gene. Besides the well-known metabolic complications, patients often present intercurrent infections associated with acute hyperammonemia and metabolic decompensation. However, it is currently unknown whether intercurrent infections are associated with immunological alterations besides the known metabolic imbalances. Herein, we describe the case of a 3-years-old girl affected by the HHH syndrome caused by two novel SLC25A15 gene mutations associated with immune phenotypic and functional alterations. She was admitted to the hospital with an episode of recurrent otitis, somnolence, confusion, and lethargy. Laboratory tests revealed severe hyperammonemia, elevated serum levels of liver transaminases, hemostasis alterations, hyperglutaminemia and strikingly increased orotic aciduria. Noteworthy, serum protein electrophoresis showed a reduction in the gamma globulin fraction. Direct sequencing of the SLC25A15 gene revealed two heterozygous non-conservative substitutions in the exon 5: c.649G>A (p.Gly217Arg) and c.706A>G (p.Arg236Gly). In silico analysis indicated that both mutations significantly impair protein structure and function and are consistent with the patient clinical status confirming the diagnosis of HHH syndrome. In addition, the immune analysis revealed reduced levels of serum IgG and striking phenotypic and functional alterations in the T and B cell immune compartments. Our study has identified two non-previously described mutations in the SLC25A15 gene underlying the HHH syndrome. Moreover, we are reporting for the first time functional and phenotypic immunologic alterations in this rare inborn error of metabolism that would render the patient immunocompromised and might be related to the high frequency of intercurrent infections observed in patients bearing urea cycle disorders. Our results point out the importance of a comprehensive analysis to gain further insights into the underlying pathophysiology of the disease that would allow better patient care and quality of life.	[Silvera-Ruiz, Silene M.; Gruppi, Adriana; Motrich, Ruben D.] Univ Nacl Cordoba, Fac Ciencias Quim, Ctr Invest Bioquim Clin Inmunol CIB CONICET, Cordoba, Argentina; [Silvera-Ruiz, Silene M.; Larovere, Laura E.] Univ Nacl Cordoba, Hosp Ninos Santisima Trinidad, Fac Ciencias Med, Ctr Estudio Metabolopatias Congenitas CEMECO, Cordoba, Argentina; [Gemperle, Corinne; Haberle, Johannes] Univ Childrens Hosp Zurich, Childrens Res Ctr, Div Metab, Zurich, Switzerland; [Peano, Natalia; Olivero, Valentina] Fdn Progreso Med, Cordoba, Argentina; [Becerra, Adriana] Hosp Ninos St isima Trin, Div Enfermedades Metab, Cordoba, Argentina; [Larovere, Laura E.] Univ Nacl Cordoba, Fac Ciencias Med, Catedra Clin Pediat, Cordoba, Argentina	National University of Cordoba; National University of Cordoba; University Children's Hospital Zurich; National University of Cordoba	Motrich, RD (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Ctr Invest Bioquim Clin Inmunol CIB CONICET, Cordoba, Argentina.	rmotrich@unc.edu.ar	Silvera-Ruiz, Silene M/AAG-1266-2020	Silvera-Ruiz, Silene M/0000-0001-5214-1233	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT-FONCyT) [PICT 2014-2195, 2019-2451]; CONICET [PIP0100652]; Secretaria de Ciencia y Tecnologia de la Universidad Nacional de Cordoba (Secyt-UNC)	Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT-FONCyT)(ANPCyTFONCyT); CONICET(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Secretaria de Ciencia y Tecnologia de la Universidad Nacional de Cordoba (Secyt-UNC)(Secretaria de Ciencia y Tecnologia (SECYT))	This work was supported by the Agencia Nacional de Promocion Cientifica y Tecnologica (ANPCyT-FONCyT, grant PICT 2014-2195 and 2019-2451), CONICET (grant PIP0100652) and Secretaria de Ciencia y Tecnologia de la Universidad Nacional de Cordoba (Secyt-UNC).	[Anonymous], 2022, SLC25A15; Bao L, 2005, BIOINFORMATICS, V21, P2185, DOI 10.1093/bioinformatics/bti365; Batshaw ML, 2014, MOL GENET METAB, V113, P127, DOI 10.1016/j.ymgme.2014.08.001; Bonnel AR, 2011, CLIN GASTROENTEROL H, V9, P727, DOI 10.1016/j.cgh.2011.02.031; Brusilow SW HA., 1995, METABOLIC MOL BASES, P1187; Camacho JA, 1999, NAT GENET, V22, P151, DOI 10.1038/9658; Debray FG, 2008, J MED GENET, V45, P759, DOI 10.1136/jmg.2008.059097; Fecarotta S, 2006, J INHERIT METAB DIS, V29, P186, DOI 10.1007/s10545-006-0120-7; Fenwick C, 2019, IMMUNOL REV, V292, P149, DOI 10.1111/imr.12823; FERGUSON FG, 1995, J GERONTOL A-BIOL, V50, pB378, DOI 10.1093/gerona/50A.6.B378; GATFIELD PD, 1975, PEDIATR RES, V9, P488, DOI 10.1203/00006450-197505000-00006; Haberle J, 2019, J INHERIT METAB DIS, V42, P1192, DOI 10.1002/jimd.12100; Hady-Cohen R, 2021, EUR J PAEDIATR NEURO, V35, P93, DOI 10.1016/j.ejpn.2021.10.002; Hainaut M, 2011, CLIN EXP IMMUNOL, V165, P77, DOI 10.1111/j.1365-2249.2011.04403.x; Henson SM, 2012, CURR OPIN IMMUNOL, V24, P476, DOI 10.1016/j.coi.2012.04.001; Ho CH, 2015, J INFECT DIS, V211, P115, DOI 10.1093/infdis/jiu388; HOMMES FA, 1982, J INHERIT METAB DIS, V5, P41, DOI 10.1007/BF01799753; Ioannidis NM, 2016, AM J HUM GENET, V99, P877, DOI 10.1016/j.ajhg.2016.08.016; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86; Lamontagne A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064992; Lebosse F, 2019, EBIOMEDICINE, V49, P258, DOI 10.1016/j.ebiom.2019.10.011; Lukkarinen M, 1999, CLIN EXP IMMUNOL, V116, P430; Luo C, 2014, J IMMUNOL, V193, P1080, DOI 10.4049/jimmunol.1303218; Mahmoud NA., 2019, BIORXIV, DOI [10.1101/786301, DOI 10.1101/786301]; Martinelli D, 2015, ORPHANET J RARE DIS, V10, DOI 10.1186/s13023-015-0242-9; Matsumoto S, 2019, J HUM GENET, V64, P833, DOI 10.1038/s10038-019-0614-4; McGuire PJ, 2013, J PEDIATR-US, V163, P1705, DOI 10.1016/j.jpeds.2013.08.029; Mittelbrunn M, 2021, NAT IMMUNOL, V22, P687, DOI 10.1038/s41590-021-00927-z; Monaco G, 2019, CELL REP, V26, P1627, DOI 10.1016/j.celrep.2019.01.041; Monne M, 2015, AMINO ACIDS, V47, P1763, DOI 10.1007/s00726-015-1990-5; Monne M, 2012, J BIOL CHEM, V287, P7925, DOI 10.1074/jbc.M111.324855; Motrich RD, 2020, BJU INT, V126, P379, DOI 10.1111/bju.15117; NAKAJIMA M, 1988, BRAIN DEV-JPN, V10, P181, DOI 10.1016/S0387-7604(88)80025-1; Ndumbi P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117039; Palmieri F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040655; Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056; Pierri CL, 2014, CELL MOL LIFE SCI, V71, P349, DOI 10.1007/s00018-013-1389-y; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Rentzsch P, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00835-9; Saule P, 2006, MECH AGEING DEV, V127, P274, DOI 10.1016/j.mad.2005.11.001; Shawcross DI, 2008, HEPATOLOGY, V48, P1202, DOI 10.1002/hep.22474; Shirakawa K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092435; Silvera-Ruiz SM, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1177-3; Singh RH, 2005, CRIT CARE CLIN, V21, pS27, DOI 10.1016/j.ccc.2005.08.003; Spyridopoulos I, 2009, CIRCULATION, V120, P1364, DOI 10.1161/CIRCULATIONAHA.109.854299; Summar ML, 2008, ACTA PAEDIATR, V97, P1420, DOI 10.1111/j.1651-2227.2008.00952.x; Tarasenko TN, 2015, J LEUKOCYTE BIOL, V97, P273, DOI 10.1189/jlb.1AB0714-365R; Tessa A, 2009, HUM MUTAT, V30, P741, DOI 10.1002/humu.20930; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5; Tuchman M, 2008, MOL GENET METAB, V94, P397, DOI 10.1016/j.ymgme.2008.05.004; Valle D SO., 2001, METABOLIC MOL BASIS, P1909; van der Meer W, 2007, J CLIN PATHOL, V60, P838, DOI 10.1136/jcp.2005.033787; Verma K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177405; Weltevrede M, 2016, EXP GERONTOL, V77, P87, DOI 10.1016/j.exger.2016.02.005; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Wong GK, 2016, J CLIN PATHOL, V69, P672, DOI 10.1136/jclinpath-2015-203351	57	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								861516	10.3389/fimmu.2022.861516	http://dx.doi.org/10.3389/fimmu.2022.861516			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1AX	35711415	gold, Green Published			2022-12-18	WOS:000811289300001
J	Ud-Din, S; Bayat, A				Ud-Din, Sara; Bayat, Ardeshir			Controlling Inflammation Pre-Emptively or at the Time of Cutaneous Injury Optimises Outcome of Skin Scarring	FRONTIERS IN IMMUNOLOGY			English	Article						skin scarring; wound healing; hypertrophic scars; keloid scars; inflammation; skin priming; pre-emptive skin priming	TOXIN TYPE-A; EARLY POSTOPERATIVE TREATMENT; PROANGIOGENIC GROWTH-FACTORS; BOTULINUM-TOXIN; HYPERTROPHIC SCARS; MAST-CELLS; SPLIT-SCAR; FRACTIONAL CO2-LASER; KELOID DISEASE; LASER	Inflammation plays an active role during the wound healing process. There is a direct association between the extent of injury as well as inflammation and the amount of subsequent cutaneous scarring. Evidence to date demonstrates that high levels of inflammation are associated with excessive dermal scarring and formation of abnormal pathological scars such as keloids and hypertrophic scars. In view of the multiple important cell types being involved in the inflammatory process and their influence on the extent of scar formation, many scar therapies should aim to target these cells in order to control inflammation and by association help improve scar outcome. However, most current treatment strategies for the management of a newly formed skin scar often adopt a watch-and-wait approach prior to commencing targeted anti-inflammatory therapy. Moreover, most of these therapies have been evaluated in the remodelling phase of wound healing and the evaluation of anti-inflammatory treatments at earlier stages of healing have not been fully explored and remain limited. Taken together, in order to minimise the risk of developing a poor scar outcome, it is clear that adopting an early intervention prior to skin injury would be optimal, however, the concept of pre-emptively priming the skin prior to injury has not yet been thoroughly evaluated. Therefore, the aim of this review was to evaluate the available literature regarding scar therapies that aim to target inflammation which are commenced prior to when a scar is formed or immediately after injury, with a particular focus on the role of pre-emptive priming of skin prior to injury in order to control inflammation for the prevention of poor scarring outcome.	[Ud-Din, Sara; Bayat, Ardeshir] Univ Manchester, Manchester Biomed Res Ctr, Natl Inst Hlth Res NIHR, Plast & Reconstruct Surg Res, Manchester, Lancs, England; [Bayat, Ardeshir] Univ Cape Town, MRC South Afr MRC SA, Div Dermatol, Wound Healing Unit, Cape Town, South Africa	University of Manchester; University of Cape Town	Bayat, A (corresponding author), Univ Manchester, Manchester Biomed Res Ctr, Natl Inst Hlth Res NIHR, Plast & Reconstruct Surg Res, Manchester, Lancs, England.; Bayat, A (corresponding author), Univ Cape Town, MRC South Afr MRC SA, Div Dermatol, Wound Healing Unit, Cape Town, South Africa.	ardeshir.bayat@uct.ac.za		BAYAT, ARDESHIR/0000-0002-4116-6491	National Institute for Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC; Medical Research Council of South Africa	National Institute for Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC; Medical Research Council of South Africa(South African Medical Research Council)	We would like to acknowledge the National Institute for Health Research Manchester Biomedical Research Centre (NIHR Manchester BRC) and Medical Research Council of South Africa for their support.	Ackermann M, 2014, INT J MOL MED, V33, P833, DOI 10.3892/ijmm.2014.1630; Ackermann M, 2011, EUR SURG RES, V47, P81, DOI 10.1159/000328143; Al-Nimer MSM, 2015, SAUDI PHARM J, V23, P483, DOI 10.1016/j.jsps.2015.01.002; An MK, 2019, PLAST RECONSTR SURG, V144, p659E, DOI 10.1097/PRS.0000000000006064; Anitha B, 2010, J Cutan Aesthet Surg, V3, P186, DOI 10.4103/0974-2077.74500; Antoniou GA, 2019, J VASC SURG, V70, P1700, DOI 10.1016/j.jvs.2019.01.083; Arsiwala Shehnaz Z, 2019, J Cutan Aesthet Surg, V12, P85, DOI 10.4103/JCAS.JCAS_171_18; Artuc M, 1999, EXP DERMATOL, V8, P1, DOI 10.1111/j.1600-0625.1999.tb00342.x; Bagabir R, 2012, BRIT J DERMATOL, V167, P1053, DOI 10.1111/j.1365-2133.2012.11190.x; Bayat A, 2003, BRIT MED J, V326, P88, DOI 10.1136/bmj.326.7380.88; Bi ML, 2019, MED SCI MONITOR, V25, P2950, DOI 10.12659/MSM.916305; Bjorn M, 2014, LASER SURG MED, V46, P89, DOI 10.1002/lsm.22165; Chen XE, 2017, EXP THER MED, V13, P3607, DOI 10.3892/etm.2017.4438; Chen Y, 2019, EXP CELL RES, V383, DOI 10.1016/j.yexcr.2019.111549; Choi JE, 2014, J DERMATOL TREAT, V25, P299, DOI 10.3109/09546634.2013.782090; Chrysanthopoulou A, 2014, J PATHOL, V233, P294, DOI 10.1002/path.4359; Conti V, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.569514; DeBruler DM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197558; Delavary BM, 2011, IMMUNOBIOLOGY, V216, P753, DOI 10.1016/j.imbio.2011.01.001; Du FY, 2018, J COSMET LASER THER, V20, P102, DOI 10.1080/14764172.2017.1358452; Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337; Fujita M, 2019, J INVEST DERMATOL, V139, P333, DOI 10.1016/j.jid.2018.07.044; Gauglitz GG, 2011, MOL MED, V17, P113, DOI 10.2119/molmed.2009.00153; Gonzales KAU, 2021, SCIENCE, V374, P1097, DOI 10.1126/science.abh2444; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Herndon D, 2018, ANN SURG, V268, P431, DOI 10.1097/SLA.0000000000002926; Hsu TSJ, 2004, ARCH DERMATOL, V140, P1351, DOI 10.1001/archderm.140.11.1351; Huang HP, 2021, J MATERN-FETAL NEO M, V34, P2498, DOI 10.1080/14767058.2019.1668924; Huang LP, 2015, THER CLIN RISK MANAG, V11, P1089, DOI 10.2147/TCRM.S82961; Jin Q, 2018, EXP CELL RES, V362, P472, DOI 10.1016/j.yexcr.2017.12.011; Jung JY, 2011, DERMATOL SURG, V37, P217, DOI 10.1111/j.1524-4725.2010.01853.x; Kannan S, 2020, DERMATOL SURG, V46, P1300, DOI 10.1097/DSS.0000000000002324; Kent RA, 2020, DERMATOL SURG, V46, P402, DOI 10.1097/DSS.0000000000001887; Kim YS, 2014, WOUND REPAIR REGEN, V22, P605, DOI 10.1111/wrr.12204; Kolli H, 2020, J DRUGS DERMATOL, V19, P1040, DOI 10.36849/JDD.2020.5244; Lee BJ, 2009, CLIN EXP OTORHINOLAR, V2, P20, DOI 10.3342/ceo.2009.2.1.20; Lee SH, 2013, DERMATOL SURG, V39, P1190, DOI 10.1111/dsu.12228; Lee S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218050; Li K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78738-9; Liu XJ, 2013, J INVEST DERMATOL, V133, P1351, DOI 10.1038/jid.2012.486; Lucas T, 2010, J IMMUNOL, V184, P3964, DOI 10.4049/jimmunol.0903356; Majid Imran, 2014, J Cutan Aesthet Surg, V7, P87, DOI 10.4103/0974-2077.138326; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Murao N, 2014, EXP DERMATOL, V23, P266, DOI 10.1111/exd.12368; Nguyen JK, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3546-6; Ogawa R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030606; Ogawa R, 2016, J NIPPON MED SCH, V83, P46, DOI 10.1272/jnms.83.46; Ozog DM, 2011, ARCH DERMATOL, V147, P1108, DOI 10.1001/archdermatol.2011.248; Pangkanon W, 2021, J COSMET DERMATOL-US, V20, P1146, DOI 10.1111/jocd.13933; Prodromidou A, 2015, PLAST SURG-CHIR PLAS, V23, P260, DOI 10.1177/229255031502300402; Rutkowski D, 2015, BRIT J DERMATOL, V173, P690, DOI 10.1111/bjd.13752; Saulis AS, 2002, PLAST RECONSTR SURG, V110, P177, DOI 10.1097/00006534-200207000-00029; Shaker SA, 2011, APPL IMMUNOHISTO M M, V19, P153, DOI 10.1097/PAI.0b013e3181efa2ef; Shi Y, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-1715; Sidgwick GP, 2016, ARCH DERMATOL RES, V308, P297, DOI 10.1007/s00403-016-1645-8; Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093; Stahl S, 2010, PLAST RECONSTR SURG, V125, P135, DOI 10.1097/PRS.0b013e3181c2a46e; Syed F, 2013, LAB INVEST, V93, P946, DOI 10.1038/labinvest.2013.82; Taudorf EH, 2016, J EUR ACAD DERMATOL, V30, P550, DOI 10.1111/jdv.12955; Tawfic SO, 2020, LASER SURG MED, V52, P959, DOI 10.1002/lsm.23249; Trace AP, 2016, AM J CLIN DERMATOL, V17, P201, DOI 10.1007/s40257-016-0175-7; Ud-Din S, 2013, BRIT J DERMATOL, V169, P71, DOI 10.1111/bjd.12588; Ud-Din S, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13040510; Ud-Din S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.552205; Ud-Din S, 2019, J INVEST DERMATOL, V139, P1680, DOI 10.1016/j.jid.2019.01.030; Ud-Din S, 2013, ARCH DERMATOL RES, V305, P423, DOI 10.1007/s00403-013-1328-7; Vas K, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/204532; Voss M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094589; Wang F, 2020, INT WOUND J, V17, P765, DOI 10.1111/iwj.13337; Wang MJ, 2019, INT J NANOMED, V14, P1385, DOI 10.2147/IJN.S195375; Wang YJ, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12650; Wang ZC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.603187; Wang ZW, 2015, SEMIN CANCER BIOL, V35, pS224, DOI 10.1016/j.semcancer.2015.01.001; Weitzmann A, 2020, J INVEST DERMATOL, V140, P2433, DOI 10.1016/j.jid.2020.03.963; Wilgus TA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249673; Wilgus Traci A, 2020, Plast Aesthet Res, V7, DOI 10.20517/2347-9264.2020.150; Wilgus TA, 2019, ADV WOUND CARE, V8, P671, DOI 10.1089/wound.2018.0796; Wilgus TA, 2014, ADV WOUND CARE, V3, P356, DOI 10.1089/wound.2013.0457; Wulff BC, 2019, WOUND REPAIR REGEN, V27, P19, DOI 10.1111/wrr.12687; Wulff BC, 2012, J INVEST DERMATOL, V132, P458, DOI 10.1038/jid.2011.324; Yang XJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4693528; Zhang DS, 2013, J PHARMACOL EXP THER, V345, P69, DOI 10.1124/jpet.112.202481; Zhang L, 2015, DRUG DES DEV THER, V9, P2139, DOI 10.2147/DDDT.S81390; Zhang QZ, 2006, J INVEST DERMATOL, V126, P2607, DOI 10.1038/sj.jid.5700472; Zhibo X, 2008, MED HYPOTHESES, V71, P623, DOI 10.1016/j.mehy.2008.04.018	85	0	0	10	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								883239	10.3389/fimmu.2022.883239	http://dx.doi.org/10.3389/fimmu.2022.883239			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1RA	35711461	gold, Green Published			2022-12-18	WOS:000811331800001
J	Zhu, LD; Liu, J; Kong, PY; Gao, SC; Wang, L; Liu, HF; Zhang, C; Gao, L; Feng, YM; Chen, T; Gao, L; Zhang, X				Zhu, Lidan; Liu, Jia; Kong, Peiyan; Gao, Shichun; Wang, Lu; Liu, Huanfeng; Zhang, Cheng; Gao, Li; Feng, Yimei; Chen, Ting; Gao, Lei; Zhang, Xi			Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						avatrombopag; allogeneic hematopoietic stem cell transplantation (AlloHCT); safety; thrombocytopenia; umbilical cord MSCs	PROLONGED ISOLATED THROMBOCYTOPENIA; VERSUS-HOST-DISEASE; PHARMACOKINETICS; MICROENVIRONMENT; RECOVERY	Platelet graft failure (PGF) is a frequent and serious complication after Allogeneic hematopoietic stem cell transplantation (allo-HSCT) and lacks effective treatment strategies, which could affect the prognosis of patients and even cause death. The exact underlying mechanism of PGF remains unclear, and lacks standard treatment. Here, we conduct a retrospective study to evaluate the efficacy and safety of avatrombopag combined with mesenchymal stem cells (MSCs) in 16 patients with thrombocytopenia after allo-HSCT. Patients were administered the following treatment regimen: 20 mg/d avatrombopag; if the PLT count was less than 50x10(<^>)9/L for at least 2 weeks, the dose was increased to 40 mg/d; if the PLT count was 200-400x10(<^>)9/L, the dose was reduced; and if the PLT count was greater than 400x10<^>9/L, avatrombopag was terminated. Umbilical cord MSCs (1x10(<^>)6 cells/kg) infusion was performed every week for 4-6 weeks. Among the 16 patients, 13 patients (81.3%) achieved a complete response (CR), 2 patients (12.5%) got a partial response (PR), and 1 patient (6.3%) had no response (NR). The median time to obtain CR was 32 (7-426) days after treatment with avatrombopag combined with umbilical cord MSCs. The time to reach 20x10(<^>)9/L <= PLT <50x10(<^>)9/L in the 2 patients with PR was 52 and 230 days after treatment, respectively. One patient had a severe pulmonary infection and died of cytomegalovirus pneumonia. Overall, our results indicated that combination of avatrombopag with MSCs can promote platelet recovery after transplantation, thereby improving the survival rate of patients and improving the quality of life of patients after transplantation, and providing a new method and strategy for the treatment of thrombocytopenia after allo-HSCT.	[Zhu, Lidan; Liu, Jia; Kong, Peiyan; Gao, Shichun; Wang, Lu; Liu, Huanfeng; Zhang, Cheng; Gao, Li; Feng, Yimei; Chen, Ting; Gao, Lei; Zhang, Xi] Army Med Univ, Affiliated Hosp 2, Med Ctr Hematol, Chongqing, Peoples R China	Army Medical University	Gao, L (corresponding author), Army Med Univ, Affiliated Hosp 2, Med Ctr Hematol, Chongqing, Peoples R China.	gaolei7765@163.com						Abe M, 2011, EUR J PHARMACOL, V650, P58, DOI 10.1016/j.ejphar.2010.09.072; Akahoshi Y, 2016, BIOL BLOOD MARROW TR, V22, P1678, DOI 10.1016/j.bbmt.2016.06.003; Dominietto A, 2001, BRIT J HAEMATOL, V112, P219, DOI 10.1046/j.1365-2141.2001.02468.x; FIRST LR, 1985, BLOOD, V65, P368; Fu HX, 2019, BONE MARROW TRANSPL, V54, P1310, DOI 10.1038/s41409-019-0435-2; Gao L, 2016, J CLIN ONCOL, V34, P2843, DOI 10.1200/JCO.2015.65.3642; Guo L, 2017, LEUKEMIA RES, V57, P27, DOI 10.1016/j.leukres.2017.02.006; Jurczak W, 2018, BRIT J HAEMATOL, V183, P479, DOI 10.1111/bjh.15573; Kang JM, 2018, TISSUE ENG PT A, V24, P616, DOI [10.1089/ten.tea.2017.0260, 10.1089/ten.TEA.2017.0260]; Khayyata S, 2007, ANN TRANSPL, V12, P11; Kong Y, 2018, BRIT J HAEMATOL, V180, P863, DOI 10.1111/bjh.15119; Kong Y, 2014, BIOL BLOOD MARROW TR, V20, P1190, DOI 10.1016/j.bbmt.2014.04.015; Liu XD, 2014, CELL TRANSPLANT, V23, P1087, DOI 10.3727/096368912X661319; Mahat Upendra, 2020, Biol Blood Marrow Transplant, V26, pe65, DOI 10.1016/j.bbmt.2019.12.003; Masetti R, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28208; Michalicka M, 2017, STEM CELLS DEV, V26, P1735, DOI 10.1089/scd.2017.0133; Michelson AD, 2018, J THROMB HAEMOST, V16, P2515, DOI 10.1111/jth.14295; Nomoto M, 2018, CLIN PHARM DRUG DEV, V7, P188, DOI 10.1002/cpdd.349; Prebet T, 2010, EXP HEMATOL, V38, P55, DOI 10.1016/j.exphem.2009.10.004; Song Y, 2018, BIOL BLOOD MARROW TR, V24, P1981, DOI 10.1016/j.bbmt.2018.06.021; Song Y, 2017, BIOL BLOOD MARROW TR, V23, P906, DOI 10.1016/j.bbmt.2017.02.021; Terrault N, 2018, GASTROENTEROLOGY, V155, P705, DOI 10.1053/j.gastro.2018.05.025; Wang M, 2019, BLOOD ADV, V3, P1416, DOI 10.1182/bloodadvances.2018026690; Williams DD, 2009, CLIN THER, V31, P764, DOI 10.1016/j.clinthera.2009.04.010; Xu LP, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0564-x; Yao YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104607; Yuan C, 2019, BIOL BLOOD MARROW TR, V25, P1320, DOI 10.1016/j.bbmt.2019.01.027; Zaja F, 2011, AM J HEMATOL, V86, P790, DOI 10.1002/ajh.22086; Zhang XH, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0216-3; Zhang XH, 2011, BIOL BLOOD MARROW TR, V17, P274, DOI 10.1016/j.bbmt.2010.09.007; Zhao XS, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/1043836	31	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 27	2022	13								910893	10.3389/fimmu.2022.910893	http://dx.doi.org/10.3389/fimmu.2022.910893			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y7CG	35693772	Green Published, gold			2022-12-18	WOS:000808297500001
J	Baleeiro, RB; Dunmall, LSC; Liu, P; Lu, SS; Lone, Y; Lemoine, NR; Wang, YH				Baleeiro, Renato B.; Dunmall, Louisa S. Chard; Liu, Peng; Lu, Shuangshuang; Lone, Yuchun; Lemoine, Nicholas R.; Wang, Yaohe			Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						RAS; neo-antigens; cancer immunotherapy; cancer vaccine; cancer peptides; T-cells	T-CELLS; CANCER; IDENTIFICATION; SEQUENCE; KRAS; IMMUNOGENICITY; AFFINITY; THERAPY; NETWORK; BINDING	RAS mutations occur in approximately 20% of all cancers and given their clonality, key role as driver mutation, association with poor prognosis and undruggability, they represent attractive targets for immunotherapy. We have identified immunogenic peptides derived from codon 12 mutant RAS (G12A, G12C, G12D, G12R, G12S and G12V), which bind to HLA-A*02:01 and HLA-A*03:01 and elicit strong peptide-specific CD8+ T cell responses, indicating that there is an effective CD8+ T-cell repertoire against these mutant RAS-derived peptides that can be mobilized. Alterations in anchor residues of these peptides enhanced their binding affinity to HLA-A*02:01 molecules and allowed generation of CD8+ T cells that responded to target cells pulsed with the anchor-modified and also with the original peptide. Cytotoxic T cells generated against these peptides specifically lysed tumor cells expressing mutant RAS. Vaccination of transgenic humanized HLA-A2/DR1 mice with a long peptide encompassing an anchor-modified 9-mer G12V epitope generated CD8+ T cells reactive to the original 9-mer and to a HLA-A*02:01-positive human cancer cell line harboring the G12V mutation. Our data provide strong evidence that mutant RAS can be targeted by immunotherapy.	[Baleeiro, Renato B.; Dunmall, Louisa S. Chard; Liu, Peng; Lemoine, Nicholas R.; Wang, Yaohe] Queen Mary Univ London, Barts Canc Inst, Ctr Canc Biomarkers & Biotherapeut, London, England; [Lu, Shuangshuang; Lemoine, Nicholas R.; Wang, Yaohe] Zhengzhou Univ, Acad Med Sci, Sino British Res Ctr Mol Oncol, Natl Ctr Int Res Cell & Gene Therapy,Sch Basic Med, Zhengzhou, Peoples R China; [Lone, Yuchun] Ctr Natl Rech Sci CNRS, Transgenese & Archivage Animaux Modeles TAAM, Orleans, France	University of London; Queen Mary University London; Zhengzhou University; Centre National de la Recherche Scientifique (CNRS)	Wang, YH (corresponding author), Queen Mary Univ London, Barts Canc Inst, Ctr Canc Biomarkers & Biotherapeut, London, England.; Wang, YH (corresponding author), Zhengzhou Univ, Acad Med Sci, Sino British Res Ctr Mol Oncol, Natl Ctr Int Res Cell & Gene Therapy,Sch Basic Med, Zhengzhou, Peoples R China.							Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Baleeiro RB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063039; Bergmann-Leitner ES, 1998, CELL IMMUNOL, V187, P103, DOI 10.1006/cimm.1998.1325; Eriksen JA, 2017, ANN ONCOL, V28; Escobar P, 1999, CLIN EXP IMMUNOL, V116, P214; Gallou C, 2016, ONCOTARGET, V7, P59417, DOI 10.18632/oncotarget.11086; Gjertsen MK, 2001, INT J CANCER, V92, P441, DOI 10.1002/ijc.1205; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hamdy S, 2011, ADV DRUG DELIVER REV, V63, P943, DOI 10.1016/j.addr.2011.05.021; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Jonckheere N, 2017, CRIT REV ONCOL HEMAT, V111, P7, DOI 10.1016/j.critrevonc.2017.01.002; Kessler JH, 2003, HUM IMMUNOL, V64, P245, DOI 10.1016/S0198-8859(02)00787-5; Kotsakis A, 2014, LUNG CANCER, V86, P59, DOI 10.1016/j.lungcan.2014.07.018; Kubuschok B, 2006, CLIN CANCER RES, V12, P1365, DOI 10.1158/1078-0432.CCR-05-1672; Li L, 2017, ANN ONCOL, V28, P11, DOI 10.1093/annonc/mdx681; Lollini PL, 2015, VACCINES-BASEL, V3, P467, DOI 10.3390/vaccines3020467; Matsuo Y, 2012, CURR PHARM DESIGN, V18, P2416, DOI 10.2174/13816128112092416; Melero I, 2014, NAT REV CLIN ONCOL, V11, P509, DOI 10.1038/nrclinonc.2014.111; Pardoll DM, 1999, P NATL ACAD SCI USA, V96, P5340, DOI 10.1073/pnas.96.10.5340; PARKER KC, 1992, J IMMUNOL, V149, P3580; Prior IA, 2020, CANCER RES, V80, P2969, DOI 10.1158/0008-5472.CAN-19-3682; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Quinlan MP, 2009, FUTURE ONCOL, V5, P105, DOI 10.2217/14796694.5.1.105; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; Rogers MF, 2020, BIOINFORMATICS, V36, P3637, DOI 10.1093/bioinformatics/btaa242; Schultze JL, 1997, J CLIN INVEST, V100, P2757, DOI 10.1172/JCI119822; Sette A, 1999, IMMUNOGENETICS, V50, P201, DOI 10.1007/s002510050594; Sheng WY, 2011, PHARM RES-DORDR, V28, P200, DOI 10.1007/s11095-010-0258-8; Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1; Tourdot S, 2000, EUR J IMMUNOL, V30, P3411, DOI 10.1002/1521-4141(2000012)30:12<3411::AID-IMMU3411>3.0.CO;2-R; Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wang QJ, 2016, CANCER IMMUNOL RES, V4, P204, DOI 10.1158/2326-6066.CIR-15-0188; Weden S, 2011, INT J CANCER, V128, P1120, DOI 10.1002/ijc.25449; Witkiewicz AK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7744	37	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								902709	10.3389/fimmu.2022.902709	http://dx.doi.org/10.3389/fimmu.2022.902709			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2SQ	35720289	gold, Green Published			2022-12-18	WOS:000812763700001
J	Brown, ME; Peters, LD; Hanbali, SR; Arnoletti, JM; Sachs, LK; Nguyen, KQ; Carpenter, EB; Seay, HR; Fuhrman, CA; Posgai, AL; Shapiro, MR; Brusko, TM				Brown, Matthew E.; Peters, Leeana D.; Hanbali, Seif R.; Arnoletti, Juan M.; Sachs, Lindsey K.; Nguyen, Kayla Q.; Carpenter, Emma B.; Seay, Howard R.; Fuhrman, Christopher A.; Posgai, Amanda L.; Shapiro, Melanie R.; Brusko, Todd M.			Human CD4(+)CD25(+)CD226(-) Tregs Demonstrate Increased Purity, Lineage Stability, and Suppressive Capacity Versus CD4(+)CD25(+)CD127(lo/-) Tregs for Adoptive Cell Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						CD226; Treg; lineage stability; suppressive function; autoimmune disease; adoptive cell therapy	REGULATORY T-CELLS; FOXP3 EXPRESSION; TYPE-1 CELLS; EXPANSION; ANTIGEN; LYMPHOPENIA; PHENOTYPE; RESPONSES; TH1	Regulatory T cell (Treg) adoptive cell therapy (ACT) represents an emerging strategy for restoring immune tolerance in autoimmune diseases. Tregs are commonly purified using a CD4(+)CD25(+)CD127(lo/-) gating strategy, which yields a mixed population: 1) cells expressing the transcription factors, FOXP3 and Helios, that canonically define lineage stable thymic Tregs and 2) unstable FOXP3(+)Helios(-) Tregs. Our prior work identified the autoimmune disease risk-associated locus and costimulatory molecule, CD226, as being highly expressed not only on effector T cells but also, interferon-gamma (IFN-gamma) producing peripheral Tregs (pTreg). Thus, we sought to determine whether isolating Tregs with a CD4(+)CD25(+)CD226(-) strategy yields a population with increased purity and suppressive capacity relative to CD4(+)CD25(+)CD127(lo/-) cells. After 14d of culture, expanded CD4(+)CD25(+)CD226(-) cells displayed a decreased proportion of pTregs relative to CD4(+)CD25(+)CD127(lo/-) cells, as measured by FOXP3(+)Helios(-) expression and the epigenetic signature at the FOXP3 Treg-specific demethylated region (TSDR). Furthermore, CD226(-) Tregs exhibited decreased production of the effector cytokines, IFN-gamma, TNF, and IL-17A, along with increased expression of the immunoregulatory cytokine, TGF-beta 1. Lastly, CD226(-) Tregs demonstrated increased in vitro suppressive capacity as compared to their CD127(lo/-) counterparts. These data suggest that the exclusion of CD226-expressing cells during Treg sorting yields a population with increased purity, lineage stability, and suppressive capabilities, which may benefit Treg ACT for the treatment of autoimmune diseases.	[Brown, Matthew E.; Peters, Leeana D.; Hanbali, Seif R.; Arnoletti, Juan M.; Sachs, Lindsey K.; Nguyen, Kayla Q.; Carpenter, Emma B.; Seay, Howard R.; Fuhrman, Christopher A.; Posgai, Amanda L.; Shapiro, Melanie R.; Brusko, Todd M.] Univ Florida, Diabet Inst, Coll Med, Dept Pathol, Gainesville, FL 32611 USA; [Seay, Howard R.] ROSALIND Inc, San Diego, CA USA; [Fuhrman, Christopher A.] NanoString Technol Inc, Seattle, WA USA; [Brusko, Todd M.] Univ Florida, Diabet Inst, Coll Med, Dept Pediat, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Brusko, TM (corresponding author), Univ Florida, Diabet Inst, Coll Med, Dept Pathol, Gainesville, FL 32611 USA.; Brusko, TM (corresponding author), Univ Florida, Diabet Inst, Coll Med, Dept Pediat, Gainesville, FL 32611 USA.	tbrusko@ufl.edu		Shapiro, Melanie/0000-0003-2090-0877; Arnoletti, Juan Martin/0000-0002-1313-8725				Akimova T, 2016, METHODS MOL BIOL, V1371, P43, DOI 10.1007/978-1-4939-3139-2_4; Akimova T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024226; Akkaya B, 2019, NAT IMMUNOL, V20, P218, DOI 10.1038/s41590-018-0280-2; Almawi WY, 1999, J CLIN ENDOCR METAB, V84, P1497, DOI 10.1210/jc.84.5.1497; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Ash S, 2014, IMMUNOL RES, V58, P101, DOI 10.1007/s12026-013-8476-x; Baeten P, 2022, CLIN REV ALLERG IMMU, V62, P363, DOI 10.1007/s12016-021-08866-1; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Bommireddy R, 2007, TRENDS MOL MED, V13, P492, DOI 10.1016/j.molmed.2007.08.005; Booth DR, 2009, GENES IMMUN, V10, P11, DOI 10.1038/gene.2008.83; Borsellino G, 2007, BLOOD, V110, P1225, DOI 10.1182/blood-2006-12-064527; Brusko TM, 2005, DIABETES, V54, P1407, DOI 10.2337/diabetes.54.5.1407; Brusko TM, 2008, IMMUNOL REV, V223, P371, DOI 10.1111/j.1600-065X.2008.00637.x; Brusko TM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011726; Brusko TM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007980; Buckner JH, 2010, NAT REV IMMUNOL, V10, P849, DOI 10.1038/nri2889; Cabello-Kindelan C, 2020, DIABETES, V69, P215, DOI 10.2337/db19-0061; Chauvin JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000957; Mattana TCC, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/694948; Dall'Era M, 2019, ARTHRITIS RHEUMATOL, V71, P431, DOI 10.1002/art.40737; Elkord E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00276; Fletcher JM, 2009, J IMMUNOL, V183, P7602, DOI 10.4049/jimmunol.0901881; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Fuhrman CA, 2015, J IMMUNOL, V195, P145, DOI 10.4049/jimmunol.1402381; Gearty SV, 2022, NATURE, V602, P156, DOI 10.1038/s41586-021-04248-x; Giganti G, 2021, EUR J IMMUNOL, V51, P39, DOI 10.1002/eji.201948131; Granados HM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183887; Gregori S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00233; Gu J, 2017, CELL MOL IMMUNOL, V14, P521, DOI 10.1038/cmi.2016.30; Hoffmann P, 2006, BLOOD, V108, P4260, DOI 10.1182/blood-2006-06-027409; Hornero RA, 2017, TRANSPLANTATION, V101, P302, DOI 10.1097/TP.0000000000001278; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Hull CM, 2017, DIABETOLOGIA, V60, P1839, DOI 10.1007/s00125-017-4377-1; Ishigame H, 2013, P NATL ACAD SCI USA, V110, P6961, DOI 10.1073/pnas.1304498110; Jung MK, 2017, IMMUNE NETW, V17, P276, DOI 10.4110/in.2017.17.5.276; Kannan AK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53240-z; Lam AJ, 2022, EUR J IMMUNOL, V52, P75, DOI 10.1002/eji.202149318; Lei H, 2015, AM J TRANSPLANT, V15, P2625, DOI 10.1111/ajt.13315; Li YY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/638470; Liu T, 2018, CELL PHYSIOL BIOCHEM, V45, P2338, DOI 10.1159/000488182; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Lozano E, 2013, J IMMUNOL, V191, P3673, DOI 10.4049/jimmunol.1300945; Marek-Trzonkowska N, 2013, PEDIATR DIABETES, V14, P322, DOI 10.1111/pedi.12029; Marshall Gregory P 2nd, 2018, Cell Gene Ther Insights, V4, P405, DOI 10.18609/cgti.2018.042; McClymont SA, 2011, J IMMUNOL, V186, P3918, DOI 10.4049/jimmunol.1003099; Motwani K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00611; Passerini L, 2008, INT IMMUNOL, V20, P421, DOI 10.1093/intimm/dxn002; Puronen CE, 2012, J INFECT DIS, V205, P1382, DOI 10.1093/infdis/jis219; Putnam AL, 2009, DIABETES, V58, P652, DOI 10.2337/db08-1168; Qiu ZX, 2013, HUM IMMUNOL, V74, P249, DOI 10.1016/j.humimm.2012.10.009; Roederer M, 2011, CYTOM PART A, V79A, P95, DOI 10.1002/cyto.a.21010; Romano M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00043; Roncarolo MG, 2018, IMMUNITY, V49, P1004, DOI 10.1016/j.immuni.2018.12.001; Rosenblum MD, 2016, NAT REV IMMUNOL, V16, P90, DOI 10.1038/nri.2015.1; Rouxel O, 2017, NAT IMMUNOL, V18, P1321, DOI 10.1038/ni.3854; SAD S, 1994, J IMMUNOL, V153, P3514; Sawant DV, 2014, IMMUNOL REV, V259, P173, DOI 10.1111/imr.12173; Schulze-Koops H, 2004, ARTHRITIS RES THER, V6, P178, DOI 10.1186/ar1208; Seay HR, 2017, MOL THER-METH CLIN D, V4, P178, DOI 10.1016/j.omtm.2016.12.003; Shapiro MR, 2021, IMMUNOL CELL BIOL, V99, P496, DOI 10.1111/imcb.12438; Shapiro MR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02180; Shevach EM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01048; Shevyrev D, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03100; Sobel ES, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3387; Tahara-Hanaoka S, 2004, INT IMMUNOL, V16, P533, DOI 10.1093/intimm/dxh059; Tang QZ, 2008, NAT IMMUNOL, V9, P239, DOI 10.1038/ni1572; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tarbell KV, 2004, J EXP MED, V199, P1467, DOI 10.1084/jem.20040180; Tonkin DR, 2008, J IMMUNOL, V181, P4516, DOI 10.4049/jimmunol.181.7.4516; Toomer KH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08960-1; Ukena SN, 2011, EXP HEMATOL, V39, P1152, DOI 10.1016/j.exphem.2011.08.010; Wang N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01883; Weber EW, 2021, SCIENCE, V372, P49, DOI 10.1126/science.aba1786; Yates K, 2018, P NATL ACAD SCI USA, V115, P2162, DOI 10.1073/pnas.1720447115; Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747	78	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								873560	10.3389/fimmu.2022.873560	http://dx.doi.org/10.3389/fimmu.2022.873560			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6KT	35693814	gold, Green Published			2022-12-18	WOS:000808252000001
J	Chen, BD; Mu, CL; Zhang, ZW; He, XL; Liu, X				Chen, Baode; Mu, Chenglin; Zhang, Zhiwei; He, Xuelin; Liu, Xia			The Love-Hate Relationship Between TGF-beta Signaling and the Immune System During Development and Tumorigenesis	FRONTIERS IN IMMUNOLOGY			English	Review						TGF-beta; immune system; tumor progression; tumor microenvironment; cancer therapy	GROWTH-FACTOR-BETA; HEMATOPOIETIC STEM-CELLS; T-CELL; TRANSFORMING GROWTH-FACTOR-BETA-1; MYELOID CELLS; TUMOR-GROWTH; NK CELLS; CANCER; EXPRESSION; RECEPTOR	Since TGF-beta was recognized as an essential secreted cytokine in embryogenesis and adult tissue homeostasis a decade ago, our knowledge of the role of TGF-beta in mammalian development and disease, particularly cancer, has constantly been updated. Mounting evidence has confirmed that TGF-beta is the principal regulator of the immune system, as deprivation of TGF-beta signaling completely abrogates adaptive immunity. However, enhancing TGF-beta signaling constrains the immune response through multiple mechanisms, including boosting Treg cell differentiation and inducing CD8(+) T-cell apoptosis in the disease context. The love-hate relationship between TGF-beta signaling and the immune system makes it challenging to develop effective monotherapies targeting TGF-beta, especially for cancer treatment. Nonetheless, recent work on combination therapies of TGF-beta inhibition and immunotherapy have provide insights into the development of TGF-beta-targeted therapies, with favorable outcomes in patients with advanced cancer. Hence, we summarize the entanglement between TGF-beta and the immune system in the developmental and tumor contexts and recent progress on hijacking crucial TGF-beta signaling pathways as an emerging area of cancer therapy.	[Chen, Baode] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Lab Med, Hangzhou, Peoples R China; [Mu, Chenglin; Zhang, Zhiwei; Liu, Xia] Zhejiang Univ ZJU Hangzhou Global Sci, Inst Intelligent Bio Chem Mfg iBCM, Technol Innovat Ctr, Hangzhou, Peoples R China; [He, Xuelin] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Liu, X (corresponding author), Zhejiang Univ ZJU Hangzhou Global Sci, Inst Intelligent Bio Chem Mfg iBCM, Technol Innovat Ctr, Hangzhou, Peoples R China.; He, XL (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Kidney Dis Ctr, Hangzhou, Peoples R China.		mu, chenglin/HDL-8203-2022	chen, baode/0000-0003-1362-4296				Aarts J, 2020, ANN RHEUM DIS, V79, P1337, DOI 10.1136/annrheumdis-2020-eular.1301; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; [Anonymous], 2021, LANCET ONCOL, V22, P893, DOI 10.1016/S1470-2045(21)00353-3; Arumugam V, 2015, J LEUKOCYTE BIOL, V98, P703, DOI 10.1189/jlb.2HIMA1214-578R; Arwert EN, 2018, CELL REP, V23, P1239, DOI 10.1016/j.celrep.2018.04.007; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Batard P, 2000, J CELL SCI, V113, P383; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Brenet F, 2013, J EXP MED, V210, P623, DOI 10.1084/jem.20121610; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Capron C, 2010, BLOOD, V116, P1244, DOI 10.1182/blood-2009-05-221093; Carthy JM, 2015, J CELL PHYSIOL, V230, P3084, DOI 10.1002/jcp.25049; Castriconi R, 2003, P NATL ACAD SCI USA, V100, P4120, DOI 10.1073/pnas.0730640100; Cazac BB, 2000, IMMUNITY, V13, P443, DOI 10.1016/S1074-7613(00)00044-3; Chang HC, 2010, NAT IMMUNOL, V11, P527, DOI 10.1038/ni.1867; Choi J, 2018, HISTOL HISTOPATHOL, V33, P133, DOI 10.14670/HH-11-916; Chung JYF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147575; Ciardiello D, 2020, ANN ONCOL, V31, P1336, DOI 10.1016/j.annonc.2020.07.009; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; David CJ, 2018, NAT REV MOL CELL BIO, V19, P419, DOI 10.1038/s41580-018-0007-0; Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1; Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183; Dimeloe S, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav3334; Dodagatta-Marri E, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-018-0493-9; Doisne JM, 2009, J EXP MED, V206, P1365, DOI 10.1084/jem.20090127; Dominguez CX, 2020, CANCER DISCOV, V10, P232, DOI 10.1158/2159-8290.CD-19-0644; Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4; Drabsch Y, 2012, CANCER METAST REV, V31, P553, DOI 10.1007/s10555-012-9375-7; Duda DG, 2003, ONCOGENE, V22, P6857, DOI 10.1038/sj.onc.1206751; Fedeli M, 2016, P NATL ACAD SCI USA, V113, pE8286, DOI 10.1073/pnas.1612024114; Felker P, 2010, J IMMUNOL, V185, P5326, DOI 10.4049/jimmunol.0903950; Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808; Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076; Gorelik L, 2001, NAT MED, V7, P1118, DOI 10.1038/nm1001-1118; Grauel AL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19920-5; Guasch G, 2007, CANCER CELL, V12, P313, DOI 10.1016/j.ccr.2007.08.020; Gunderson AJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15404-8; Hahn JN, 2011, J CLIN INVEST, V121, P4030, DOI 10.1172/JCI45114; Hanks BA, 2013, J CLIN INVEST, V123, P3925, DOI 10.1172/JCI65745; Havenar-Daughton C, 2012, BLOOD, V119, P3486, DOI 10.1182/blood-2012-01-401604; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; Hessmann E, 2018, GUT, V67, P497, DOI 10.1136/gutjnl-2016-311954; Higgins SP, 2018, CELL SIGNAL, V43, P1, DOI 10.1016/j.cellsig.2017.11.005; Holmgaard RB, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0356-4; Huang CY, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111046; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Ito Y, 2001, DEV BIOL, V236, P181, DOI 10.1006/dbio.2001.0332; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Jung SY, 2020, CANCER CHEMOTH PHARM, V85, P173, DOI 10.1007/s00280-019-03979-z; Junker U, 1996, CYTOKINE, V8, P794, DOI 10.1006/cyto.1996.0105; Jurberg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00442; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; KEHRL JH, 1991, ANN NY ACAD SCI, V628, P345, DOI 10.1111/j.1749-6632.1991.tb17267.x; Kersten C, 2006, EXP HEMATOL, V34, P72, DOI 10.1016/j.exphem.2005.09.010; Khasraw Mustafa, 2021, Neurooncol Adv, V3, pvdab058, DOI 10.1093/noajnl/vdab058; Kim BN, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67325-7; Kim BG, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01053-x; Kim SV, 2013, SCIENCE, V340, P1456, DOI 10.1126/science.1237013; Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997; Knudson KM, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1426519; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Laouar Y, 2005, NAT IMMUNOL, V6, P600, DOI 10.1038/ni1197; Larsson J, 2005, EXP HEMATOL, V33, P592, DOI 10.1016/j.exphem.2005.02.003; Larsson J, 2003, BLOOD, V102, P3129, DOI 10.1182/blood-2003-04-1300; Lee CR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030869; LEE G, 1987, J EXP MED, V166, P1290, DOI 10.1084/jem.166.5.1290; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Lee YS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1469; Letterio JJ, 1996, J CLIN INVEST, V98, P2109, DOI 10.1172/JCI119017; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Li MO, 2006, IMMUNITY, V25, P455, DOI 10.1016/j.immuni.2006.07.011; Li S, 2020, NATURE, V587, P121, DOI 10.1038/s41586-020-2850-3; Lin JT, 2005, J IMMUNOL, V174, P5950, DOI 10.4049/jimmunol.174.10.5950; Liu M, 2020, NATURE, V587, P115, DOI 10.1038/s41586-020-2836-1; Liu M, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800063; Liu Y, 2012, J IMMUNOL, V188, P5500, DOI 10.4049/jimmunol.1103505; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; LOMO J, 1995, J IMMUNOL, V154, P1634; Lukas D, 2017, P NATL ACAD SCI USA, V114, pE1480, DOI 10.1073/pnas.1615065114; Malek E, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.8039; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; Marie JC, 2006, IMMUNITY, V25, P441, DOI 10.1016/j.immuni.2006.07.012; Marshall HD, 2015, ELIFE, V4, DOI 10.7554/eLife.04851; Martin CJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay8456; Mayer CT, 2011, EUR J IMMUNOL, V41, P716, DOI 10.1002/eji.201040913; McCarron MJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13456-z; Melisi D, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002068; Miao YX, 2019, CELL, V177, P1172, DOI 10.1016/j.cell.2019.03.025; Mlecnik B, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6352; Nakatsukasa H, 2015, NAT IMMUNOL, V16, P1077, DOI 10.1038/ni.3252; Noh KE, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168706; O'Garra A, 2011, NAT IMMUNOL, V12, P288, DOI 10.1038/ni.2003; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Ouyang WM, 2010, IMMUNITY, V32, P642, DOI 10.1016/j.immuni.2010.04.012; Pang YL, 2013, CANCER DISCOV, V3, P936, DOI 10.1158/2159-8290.CD-12-0527; Papaspyridonos M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7840; Park BV, 2016, CANCER DISCOV, V6, P1366, DOI 10.1158/2159-8290.CD-15-1347; Park JH, 2004, IMMUNITY, V21, P289, DOI 10.1016/j.immuni.2004.07.016; Pei SY, 2021, J EXP MED, V218, DOI 10.1084/jem.20202144; Penke LR, 2019, CELL MOL LIFE SCI, V76, P4179, DOI 10.1007/s00018-019-03212-3; PETITKOSKAS E, 1988, EUR J IMMUNOL, V18, P111, DOI 10.1002/eji.1830180117; Pillai MR, 2014, CURR OPIN IMMUNOL, V31, P38, DOI 10.1016/j.coi.2014.09.005; Putheti P, 2017, METHODS MOL BIOL, V1585, P73, DOI 10.1007/978-1-4939-6877-0_6; Ravi R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02696-6; Regis S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00311; Robb RJ, 2012, BLOOD, V119, P5898, DOI 10.1182/blood-2011-12-396119; Rouce RH, 2016, LEUKEMIA, V30, P800, DOI 10.1038/leu.2015.327; SAD S, 1994, J IMMUNOL, V153, P3514; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sere K, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23083; Sere KM, 2012, EUR J CELL BIOL, V91, P515, DOI 10.1016/j.ejcb.2011.09.007; Shaim H, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI142116; Shen J, 2013, ARTHRITIS RHEUM-US, V65, P3107, DOI 10.1002/art.38122; Shingai Y, 2021, STEM CELLS, V39, P723, DOI 10.1002/stem.3348; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sitnicka E, 1996, BLOOD, V88, P82; Slattery K, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002044; Strobl H, 1999, MICROBES INFECT, V1, P1283, DOI 10.1016/S1286-4579(99)00256-7; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Szeto SG, 2016, J AM SOC NEPHROL, V27, P3117, DOI 10.1681/ASN.2015050499; Takimoto T, 2010, J IMMUNOL, V185, P842, DOI 10.4049/jimmunol.0904100; Tauriello DVF, 2022, NAT REV CANCER, V22, P25, DOI 10.1038/s41568-021-00413-6; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Thepmalee C, 2018, HUM VACC IMMUNOTHER, V14, P1423, DOI 10.1080/21645515.2018.1431598; Thomas DA, 2005, CANCER CELL, V8, P369, DOI 10.1016/j.ccr.2005.10.012; Tolcher AW, 2017, CANCER CHEMOTH PHARM, V79, P673, DOI 10.1007/s00280-017-3245-5; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Tsuda M, 2019, MUCOSAL IMMUNOL, V12, P644, DOI 10.1038/s41385-018-0122-4; Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; van der Heide LP, 2011, J BIOL CHEM, V286, P5003, DOI 10.1074/jbc.M110.167379; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Wang BY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02120-9; Wang HC, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03488-z; Wang Q, 2017, CELL STEM CELL, V20, P70, DOI 10.1016/j.stem.2016.10.002; Wang Z, 2020, CHINESE J CANCER RES, V32, P72, DOI 10.21147/j.issn.1000-9604.2020.01.09; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Xue G, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09401-9; Yamazaki S, 2006, EMBO J, V25, P3515, DOI 10.1038/sj.emboj.7601236; Yamazaki S, 2011, CELL, V147, P1146, DOI 10.1016/j.cell.2011.09.053; Yamazaki S, 2009, BLOOD, V113, P1250, DOI 10.1182/blood-2008-04-146480; Yan HYH, 2015, CANCER RES, V75, P5283, DOI 10.1158/0008-5472.CAN-15-2282-T; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Yap TA, 2021, CLIN CANCER RES, V27, P6666, DOI 10.1158/1078-0432.CCR-21-1504; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yoo C, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000564; Yoshida GJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092256; Yu Q, 2000, GENE DEV, V14, P163; Zhang Y, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022145; Zhao M, 2014, NAT MED, V20, P1321, DOI 10.1038/nm.3706; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zhong ZJ, 2010, CLIN CANCER RES, V16, P1191, DOI 10.1158/1078-0432.CCR-09-1634; Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878	171	0	0	10	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								891268	10.3389/fimmu.2022.891268	http://dx.doi.org/10.3389/fimmu.2022.891268			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F5TM	35720407	gold, Green Published			2022-12-18	WOS:000812971700001
J	Chen, J; Meng, JL; Li, XL; Li, X; Liu, Y; Jin, C; Zhang, L; Hao, ZY; Chen, XG; Zhang, M; Liang, CZ				Chen, Jing; Meng, Jialin; Li, Xiaoling; Li, Xiao; Liu, Yi; Jin, Chen; Zhang, Li; Hao, Zongyao; Chen, Xianguo; Zhang, Meng; Liang, Chaozhao			HA/CD44 Regulates the T Helper 1 Cells Differentiation by Activating Annexin A1/Akt/mTOR Signaling to Drive the Pathogenesis of EAP	FRONTIERS IN IMMUNOLOGY			English	Article						chronic prostatitis; chronic pelvic pain syndrome; CD44; hyaluronan; ANX A1; Th1 cells	NONOBESE DIABETIC MICE; AUTOIMMUNE PROSTATITIS; CD44; INFLAMMATION; RESISTANCE; TH1	CD44 partcipates in multiple inflammatory reactions. Here, we aimed to investigate the role of CD44 and the ligand, hyaluronan (HA), on chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) pathogenesis. We found that CD44 was universally expressed in CD4(+) lymphocytes in the peripheral blood of CP/CPPS patients. After silencing CD44 expression or delivering 4-methylumbelliferone (4-MU), the pain severity and prostatic inflammation were significantly relieved. In vitro assay found that HA/CD44 was able to regulate T helper 1 (Th1) cells differentiation, the deficiency of which diminished experimental autoimmune prostatitis (EAP) susceptibility. Bioinformatic analysis suggested that after HA or 4-MU treatment, mTOR signaling was significantly altered, and these results were confirmed by subsequent Western blotting assay. Besides, mass spectrometry and co-immunoprecipitation assays found that CD44 was able to interact with Annexin A1 (ANX A1), and this kind of interaction stabilized ANX A1 protein and maintained the activation of Akt/mTOR pathway. Meanwhile, HA-treatment-enhanced prostatic inflammation, Th1 cell differentiation, and Akt/mTOR pathway activation were reversed after silencing the expression of ANX A1 using shANX A1-lentivirus. The present study systematically investigates the functional role of HA/CD44 in CP/CPPS and identifies novel mechanisms for HA/CD44 promoting Th1 cell differentiation. Targeting the HA/CD44/ANX A1/Akt/mTOR signaling represents novel potential therapeutic strategies for patients with CP/CPPS.	[Chen, Jing; Meng, Jialin; Li, Xiaoling; Li, Xiao; Liu, Yi; Jin, Chen; Zhang, Li; Hao, Zongyao; Chen, Xianguo; Zhang, Meng; Liang, Chaozhao] Anhui Med Univ, Dept Urol, Affiliated Hosp 1, Hefei, Peoples R China; [Chen, Jing; Meng, Jialin; Li, Xiaoling; Li, Xiao; Liu, Yi; Jin, Chen; Zhang, Li; Hao, Zongyao; Chen, Xianguo; Zhang, Meng; Liang, Chaozhao] Anhui Med Univ, Inst Urol, Hefei, Peoples R China; [Chen, Jing; Meng, Jialin; Li, Xiaoling; Li, Xiao; Liu, Yi; Jin, Chen; Zhang, Li; Hao, Zongyao; Chen, Xianguo; Zhang, Meng; Liang, Chaozhao] Anhui Med Univ, Anhui Prov Key Lab Genitourinary Dis, Hefei, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University	Chen, XG; Zhang, M; Liang, CZ (corresponding author), Anhui Med Univ, Dept Urol, Affiliated Hosp 1, Hefei, Peoples R China.; Chen, XG; Zhang, M; Liang, CZ (corresponding author), Anhui Med Univ, Inst Urol, Hefei, Peoples R China.; Chen, XG; Zhang, M; Liang, CZ (corresponding author), Anhui Med Univ, Anhui Prov Key Lab Genitourinary Dis, Hefei, Peoples R China.	cxg7866186@126.com; zhangmeng1930@126.com; liang_chaozhao@ahmu.edu.cn		Jin, Chen/0000-0001-6803-5785; Meng, Jialin/0000-0002-4622-833X	National Natural Science Foundation of China [81630019, 81870519, 81802827]; Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province [2017ZHYX02]; Medical and Health Law Research Center Project of Sichuan Province [YF18-19]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province; Medical and Health Law Research Center Project of Sichuan Province	This study was supported by the National Natural Science Foundation of China (81630019, 81870519, and 81802827), Scientific Research Foundation of the Institute for Translational Medicine of Anhui Province (2017ZHYX02), and the Medical and Health Law Research Center Project of Sichuan Province (YF18-19).	Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Chen J, 2021, PROSTATE, V81, P1078, DOI 10.1002/pros.24205; Collins MM, 1998, J UROLOGY, V159, P1224, DOI 10.1016/S0022-5347(01)63564-X; D'Acquisto F, 2007, BLOOD, V109, P1095, DOI 10.1182/blood-2006-05-022798; DeWitt-Foy ME, 2019, EUR UROL FOCUS, V5, P2, DOI 10.1016/j.euf.2018.08.027; Gao JJ, 2014, J SEX MED, V11, P3093, DOI 10.1111/jsm.12696; Guan HB, 2011, J IMMUNOL, V186, P6955, DOI 10.4049/jimmunol.1004043; Guan HB, 2009, J IMMUNOL, V183, P172, DOI 10.4049/jimmunol.0802325; Hosokawa H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11289; Kuipers HF, 2016, P NATL ACAD SCI USA, V113, P1339, DOI 10.1073/pnas.1525086113; Liang CZ, 2009, J UROLOGY, V182, P558, DOI 10.1016/j.juro.2009.04.011; MIKECZ K, 1995, NAT MED, V1, P558, DOI 10.1038/nm0695-558; Motrich RD, 2005, HUM REPROD, V20, P2567, DOI 10.1093/humrep/dei073; Motrich RD, 2016, PAIN, V157, P585, DOI 10.1097/j.pain.0000000000000405; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Murphy SF, 2014, NAT REV UROL, V11, P259, DOI 10.1038/nrurol.2014.63; Naor D, 2007, ANN NY ACAD SCI, V1110, P233, DOI 10.1196/annals.1423.025; Okamoto K, 2018, PROSTATE, V78, P707, DOI 10.1002/pros.23514; Patel HB, 2012, ANN RHEUM DIS, V71, P1872, DOI 10.1136/annrheumdis-2011-201180; Penna G, 2007, J IMMUNOL, V179, P1559, DOI 10.4049/jimmunol.179.3.1559; Penna G, 2006, J IMMUNOL, V177, P8504, DOI 10.4049/jimmunol.177.12.8504; Pontari MA, 2008, J UROLOGY, V179, pS61, DOI 10.1016/j.juro.2008.03.139; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Suarez-Fueyo A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02172; Weiss L, 2000, P NATL ACAD SCI USA, V97, P285, DOI 10.1073/pnas.97.1.285; Zhang M, 2020, J CELL MOL MED, V24, P14099, DOI 10.1111/jcmm.16021	26	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								875412	10.3389/fimmu.2022.875412	http://dx.doi.org/10.3389/fimmu.2022.875412			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6YF	35693826	gold, Green Published			2022-12-18	WOS:000808287000001
J	dos Santos, CDP; Vacani-Martins, N; Cascabulho, CM; Pereira, MCD; Crispe, IN; Henriques-Pons, A				De Lima Pereira dos Santos, Carina; Vacani-Martins, Natalia; Cascabulho, Cynthia Machado; Pereira, Mirian Claudia de Souza; Crispe, Ian Nicholas; Henriques-Pons, Andrea			In the Acute Phase of Trypanosoma cruzi Infection, Liver Lymphoid and Myeloid Cells Display an Ambiguous Phenotype Combining Pro- and Anti-Inflammatory Markers	FRONTIERS IN IMMUNOLOGY			English	Article						hepatic immune response; Trypanosoma cruzi infection; immunological tolerance; liver; inflammation	CD8-ALPHA(+) DENDRITIC CELLS; ANTIGEN-PRESENTING CELLS; KILLER T-CELLS; CHAGAS-DISEASE; REGULATORY ACTIVITY; AUTOCRINE IL-10; IFN-GAMMA; TOLERANCE; INFLAMMATION; RECOGNITION	Multiple cell populations, cellular biochemical pathways, and the autonomic nervous system contribute to maintaining the immunological tolerance in the liver. This tolerance is coherent because the organ is exposed to high levels of bacterial pathogen-associated molecular pattern (PAMP) molecules from the intestinal microbiota, such as lipopolysaccharide endotoxin (LPS). In the case of Trypanosoma cruzi infection, although there is a dramatic acute immune response in the liver, we observed intrahepatic cell populations combining pro- and anti-inflammatory markers. There was loss of fully mature Kupffer cells and an increase in other myeloid cells, which are likely to include monocytes. Among dendritic cells (DCs), the cDC1 population expanded relative to the others, and these cells lost both some macrophage markers (F4/80) and immunosuppressive cytokines (IL-10, TGF-beta 1). In parallel, a massive T cell response occured with loss of naive cells and increase in several post-activation subsets. However, these activated T cells expressed both markers programmed cell death protein (PD-1) and cytokines consistent with immunosuppressive function (IL-10, TGF-beta 1). NK and NK-T cells broadly followed the pattern of T cell activation, while TCR-gamma delta cells appeared to be bystanders. While no data were obtained concerning IL-2, several cell populations also synthesized IFN-gamma and TNF-alpha, which has been linked to host defense but also to tissue injury. It therefore appears that T. cruzi exerts control over liver immunity, causing T cell activation via cDC1 but subverting multiple populations of T cells into immunosuppressive pathways. In this way, T. cruzi engages a mechanism of hepatic T cell tolerance that is familiar from liver allograft tolerance, in which activation and proliferation are followed by T cell inactivation.	[De Lima Pereira dos Santos, Carina; Vacani-Martins, Natalia; Cascabulho, Cynthia Machado; Henriques-Pons, Andrea] Fundacao Oswaldo Cruz, Lab Inovacoeses Terapias Ensino & Bioprod, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Pereira, Mirian Claudia de Souza] Fundacao Oswaldo Cruz, Lab Ultraestrutura Celular, Inst Oswaldo Cruz, Rio De Janeiro, Brazil; [Crispe, Ian Nicholas] Univ Washington Med Ctr, Lab Med & Pathol, Seattle, WA USA	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; University of Washington; University of Washington Seattle	dos Santos, CDP (corresponding author), Fundacao Oswaldo Cruz, Lab Inovacoeses Terapias Ensino & Bioprod, Inst Oswaldo Cruz, Rio De Janeiro, Brazil.	carinalp@ioc.fiocruz.br	Henriques-Pons, Andrea/J-4030-2014	Henriques-Pons, Andrea/0000-0001-9136-240X				Affolter T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217276; Aufderheide AC, 2004, P NATL ACAD SCI USA, V101, P2034, DOI 10.1073/pnas.0307312101; Balan S, 2019, INT REV CEL MOL BIO, V348, P1, DOI 10.1016/bs.ircmb.2019.07.004; Benson JM, 1999, J IMMUNOL, V162, P6247; Bertolino P, 2002, IMMUNOL CELL BIOL, V80, P84, DOI 10.1046/j.0818-9641.2001.01048.x; Cao O, 2007, BLOOD, V110, P1132, DOI 10.1182/blood-2007-02-073304; Cardillo F, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv082; dos Santos VRC, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760190364; Chang WS, 2008, J IMMUNOL, V181, P6707, DOI 10.4049/jimmunol.181.10.6707; Chaussabel D, 2003, LAB INVEST, V83, P1373, DOI 10.1097/01.LAB.0000087587.93781.6F; Corinti S, 2001, J IMMUNOL, V166, P4312, DOI 10.4049/jimmunol.166.7.4312; Crispe IN, 2011, J HEPATOL, V54, P357, DOI 10.1016/j.jhep.2010.10.005; Demangel C, 2002, EUR J IMMUNOL, V32, P994, DOI 10.1002/1521-4141(200204)32:4<994::AID-IMMU994>3.3.CO;2-Y; Duthie MS, 2005, INFECT IMMUN, V73, P181, DOI 10.1128/IAI.73.1.181-192.2005; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; GALE RP, 1978, SCIENCE, V201, P937, DOI 10.1126/science.356266; Gil-Jaramillo N, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01076; Henriques-Pons A, 2002, INT J EXP PATHOL, V83, P67, DOI 10.1046/j.1365-2613.2002.00215.x; Heymann F, 2015, HEPATOLOGY, V62, P279, DOI 10.1002/hep.27793; HIGUCHI MD, 1993, CARDIOVASC PATHOL, V2, P101, DOI 10.1016/1054-8807(93)90021-S; Higuchi MD, 2003, CARDIOVASC RES, V60, P96, DOI 10.1016/S0008-6363(03)00361-4; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hoeres T, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1550618; Huang HT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02401; Kara K, 2004, INDIAN J MED RES, V119, P110; Koblansky AA, 2013, IMMUNITY, V38, P119, DOI 10.1016/j.immuni.2012.09.016; Lattes R, 2014, CLIN MICROBIOL INFEC, V20, P300, DOI 10.1111/1469-0691.12585; Lau AH, 2003, GUT, V52, P1075, DOI 10.1136/gut.52.8.1075; Lopes MF, 1999, EUR J IMMUNOL, V29, P81, DOI 10.1002/(SICI)1521-4141(199901)29:01&lt;81::AID-IMMU81&gt;3.0.CO;2-Y; Manno CS, 2006, NAT MED, V12, P342, DOI 10.1038/nm1358; Mashayekhi M, 2011, IMMUNITY, V35, P249, DOI 10.1016/j.immuni.2011.08.008; Mendez-Sanchez N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641240; Meuser-Batista M, 2020, J LEUKOCYTE BIOL, V107, P695, DOI 10.1002/JLB.3A0220-399RR; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Morita H, 1998, P NATL ACAD SCI USA, V95, P6947, DOI 10.1073/pnas.95.12.6947; Onofrio LI, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003464; Pilones KA, 2009, CLIN CANCER RES, V15, P597, DOI 10.1158/1078-0432.CCR-08-1277; Pistulli R, 2020, ESC HEART FAIL, V7, P2305, DOI 10.1002/ehf2.12767; Planelles L, 2003, CLIN EXP IMMUNOL, V131, P41, DOI 10.1046/j.1365-2249.2003.02022.x; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; Racanelli V, 2006, HEPATOLOGY, V43, pS54, DOI 10.1002/hep.21060; Rassi A, 2010, LANCET, V375, P1388, DOI 10.1016/S0140-6736(10)60061-X; Reina-San-Martin B, 2000, NAT MED, V6, P890, DOI 10.1038/78651; Ribeiro S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00015; Rossjohn J, 2012, NAT REV IMMUNOL, V12, P845, DOI 10.1038/nri3328; Santos ED, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00488; Sardinha LR, 2006, INFECT IMMUN, V74, P2031, DOI 10.1128/IAI.74.4.2031-2042.2006; Sardinha LR, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000578; Schlitzer Andreas, 2018, F1000Res, V7, DOI 10.12688/f1000research.14793.1; Schmunis GA, 2007, MEM I OSWALDO CRUZ, V102, P75, DOI 10.1590/S0074-02762007005000093; Soto CDA, 2003, INFECT IMMUN, V71, P1194, DOI 10.1128/IAI.71.3.1194-1199.2003; Stojanovic A, 2014, J IMMUNOL, V192, P4184, DOI 10.4049/jimmunol.1302091; Thomson AW, 2010, NAT REV IMMUNOL, V10, P753, DOI 10.1038/nri2858; TORRICO F, 1991, J IMMUNOL, V146, P3626; Vacani-Martins N, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10091074; Vacani-Martins N, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9090717; Van Overtvelt L, 1999, INFECT IMMUN, V67, P4033, DOI 10.1128/IAI.67.8.4033-4040.1999; Wang CM, 1998, TRANSPLANTATION, V65, P188; Wang Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581301; Wrenshall LE, 2001, TRANSPLANTATION, V71, P841, DOI 10.1097/00007890-200104150-00004; Wu WH, 2006, MICROSURG, V26, P17, DOI 10.1002/micr.20204; YANG R, 1994, J PEDIATR SURG, V29, P1145, DOI 10.1016/0022-3468(94)90297-6	62	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								868574	10.3389/fimmu.2022.868574	http://dx.doi.org/10.3389/fimmu.2022.868574			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2PB	35720410	gold, Green Published			2022-12-18	WOS:000812754400001
J	Fineschi, S; Klar, J; Gustafsson, KA; Jonsson, K; Karlsson, B; Dahl, N				Fineschi, Serena; Klar, Joakim; Gustafsson, Kristin Ayoola; Jonsson, Kent; Karlsson, Bo; Dahl, Niklas			Inflammation and Interferon Signatures in Peripheral B-Lymphocytes and Sera of Individuals With Fibromyalgia	FRONTIERS IN IMMUNOLOGY			English	Article						fibromyalgia; B-lymphocytes; RNA sequencing; interferon signature; inflammation; inflammatory proteins; fibromyalgia score; fatigue	CYTOKINES; CRITERIA; LIGHT; IL-8; PAIN	Fibromyalgia (FM) is an idiopathic chronic disease characterized by widespread musculoskeletal pain, hyperalgesia and allodynia, often accompanied by fatigue, cognitive dysfunction and other symptoms. Autoimmunity and neuroinflammatory mechanisms have been suggested to play important roles in the pathophysiology of FM supported by recently identified interferon signatures in affected individuals. However, the contribution of different components in the immune system, such as the B-lymphocytes, in the progression to FM are yet unknown. Furthermore, there is a great need for biomarkers that may improve diagnostics of FM. Herein, we investigated the gene expression profile in peripheral B-cells, as well as a panel of inflammatory serum proteins, in 30 FM patients and 23 healthy matched control individuals. RNA sequence analysis revealed 60 differentially expressed genes when comparing the two groups. The group of FM patients showed increased expression of twenty-five interferon-regulated genes, such as S100A8 and S100A9, VCAM, CD163, SERPINA1, ANXA1, and an increased interferon score. Furthermore, FM was associated with elevated levels of 19 inflammatory serum proteins, such as IL8, AXIN1, SIRT2 and STAMBP, that correlated with the FM severity score. Together, the results shows that FM is associated with an interferon signature in B-cells and increased levels of a set of inflammatory serum proteins. Our findings bring further support for immune activation in the pathogenesis of FM and highlight candidate biomarkers for diagnosis and intervention in the management of FM.	[Fineschi, Serena] Osthammar Hlth Care Ctr, Osthammar, Sweden; [Fineschi, Serena; Jonsson, Kent; Karlsson, Bo] Uppsala Univ, Dept Publ Hlth & Caring Sci, Unit Gen Practice, Uppsala, Sweden; [Klar, Joakim; Gustafsson, Kristin Ayoola; Dahl, Niklas] Uppsala Univ, Dept Immunol Genet & Pathol, Sci Life Lab, Uppsala, Sweden; [Jonsson, Kent] Nykoping Hosp, Dept Geriatr & Rehabil Med, Nykoping, Sweden	Uppsala University; Uppsala University	Fineschi, S (corresponding author), Osthammar Hlth Care Ctr, Osthammar, Sweden.; Fineschi, S (corresponding author), Uppsala Univ, Dept Publ Hlth & Caring Sci, Unit Gen Practice, Uppsala, Sweden.	serena.fineschi@pubcare.uu.se	Klar, Joakim/H-2900-2019	Klar, Joakim/0000-0003-4185-7409	Healthcare Board, Region of Uppsala, Sweden (FoU); Swedish Fibromyalgia Association; Swedish Research Council [2020-01947]; Uppsala University and Science for Life Laboratory	Healthcare Board, Region of Uppsala, Sweden (FoU); Swedish Fibromyalgia Association; Swedish Research Council(Swedish Research CouncilEuropean Commission); Uppsala University and Science for Life Laboratory	The study was funded by grants from the Healthcare Board, Region of Uppsala, Sweden (FoU grant to SF) with contributions from the Swedish Fibromyalgia Association (to SF), the Swedish Research Council 2020-01947 (to ND), Uppsala University and Science for Life Laboratory.	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Atzeni Fabiola, 2019, Clin Exp Rheumatol, V37 Suppl 116, P3; Aw E, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02003-z; Backryd E, 2017, J PAIN RES, V10, DOI 10.2147/JPR.S128508; Bair MJ, 2020, ANN INTERN MED, V172, pITC33, DOI 10.7326/AITC202003030; Barragan-Iglesias P, 2020, J NEUROSCI, V40, P3517, DOI 10.1523/JNEUROSCI.3055-19.2020; Bazzichi L, 2009, PROTEOM CLIN APPL, V3, P1296, DOI 10.1002/prca.200900076; Bist P, 2013, J IMMUNOL, V191, P4375, DOI 10.4049/jimmunol.1301504; Bodewes ILA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00312; Bote ME, 2014, BRAIN BEHAV IMMUN, V39, P107, DOI 10.1016/j.bbi.2013.11.009; Bruschi M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051348; Cetin A., 2019, ANN MED RES, V26, P389, DOI [10.5455/annalsmedres.2019.01.034, DOI 10.5455/ANNALSMEDRES.2019.01.034]; Chang MY, 2017, AM J PHYSIOL-LUNG C, V313, pL1069, DOI 10.1152/ajplung.00353.2017; Cordero MD, 2014, ANTIOXID REDOX SIGN, V20, P1169, DOI 10.1089/ars.2013.5198; D'Agnelli S, 2019, MOL PAIN, V15, DOI 10.1177/1744806918819944; Dolcino M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061814; dos Santos GG, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03061; Ebrahimi B, 2021, CLIN RHEUMATOL, V40, P1709, DOI 10.1007/s10067-020-05446-0; Ernberg M, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/3985154; Gavins FNE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00354; Hackshaw KV, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11020156; Hamarsheh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15497-1; Hauser Winfried, 2019, Clin Exp Rheumatol, V37 Suppl 116, P90; Hauser W, 2017, PAIN REP, V2, DOI 10.1097/PR9.0000000000000598; Herro R, 2015, J INVEST DERMATOL, V135, P2109, DOI 10.1038/jid.2015.110; Imgenberg-Kreuz J, 2018, SCAND J IMMUNOL, V87, DOI 10.1111/sji.12662; Jarlborg M, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02190-3; Jones KD, 2016, CLIN EXP RHEUMATOL, V34, pS89; Kasperska-Zajac A, 2018, INT J IMMUNOPATH PH, V32, DOI 10.1177/2058738418784431; Kim WJ, 2005, IMMUNOLOGY, V114, P272, DOI 10.1111/j.1365-2567.2004.02004.x; Kirou KA, 2004, ARTHRITIS RHEUM, V50, P3958, DOI 10.1002/art.20798; Malik UR, 2001, CANCER, V92, P1664, DOI 10.1002/1097-0142(20010915)92:6+<1664::AID-CNCR1494>3.0.CO;2-9; Marques AP, 2017, REV BRAS REUMATOL, V57, P356, DOI [10.1016/j.rbre.2017.01.005, 10.1016/j.rbr.2016.10.004]; Matsushita T, 2019, EXPERT REV MOL DIAGN, V19, P197, DOI 10.1080/14737159.2019.1571911; Mejia-Vilet JM, 2020, J AM SOC NEPHROL, V31, P1335, DOI 10.1681/ASN.2019121285; Mendieta D, 2016, J NEUROIMMUNOL, V290, P22, DOI 10.1016/j.jneuroim.2015.11.011; Mihaylova N, 2020, CLIN EXP IMMUNOL, V199, P278, DOI 10.1111/cei.13399; Moller HJ, 2012, SCAND J CLIN LAB INV, V72, P1, DOI 10.3109/00365513.2011.626868; O'Mahony LF, 2021, RHEUMATOLOGY, V60, P2602, DOI 10.1093/rheumatology/keab146; Ohgidani M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11506-4; Ometto F, 2017, EXP BIOL MED, V242, P859, DOI 10.1177/1535370216681551; Peck MM, 2020, CUREUS, V12, DOI 10.7759/cureus.10276; Pernambuco AP, 2013, CLIN EXP RHEUMATOL, V31, pS60; Perretti M, 2009, NAT REV IMMUNOL, V9, P62, DOI 10.1038/nri2470; Pin A, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9030113; Raffaeli W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041499; Ramanujam M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102668; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Ronnblom L, 2013, CURR OPIN RHEUMATOL, V25, P248, DOI 10.1097/BOR.0b013e32835c7e32; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Russell A, 2019, PSYCHONEUROENDOCRINO, V100, P276, DOI 10.1016/j.psyneuen.2018.11.032; Sarzi-Puttini P, 2020, NAT REV RHEUMATOL, V16, P645, DOI 10.1038/s41584-020-00506-w; Seo S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246152; Silva Rita, 2021, Front Pain Res (Lausanne), V2, P684684, DOI 10.3389/fpain.2021.684684; Siracusa R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083891; Sommer C, 2018, PAIN, V159, P595, DOI 10.1097/j.pain.0000000000001122; Sonar S, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00364; Sturgill J, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/938576; Theoharides TC, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00353; Tripp NH, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2016-000282; Tsilioni I, 2016, J PHARMACOL EXP THER, V356, P664, DOI 10.1124/jpet.115.230060; Wang HL, 2008, J RHEUMATOL, V35, P1366; Wang SW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01298; Wang Z, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4063562; Wigerblad G, 2016, ANN RHEUM DIS, V75, P730, DOI 10.1136/annrheumdis-2015-208094; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 2016, SEMIN ARTHRITIS RHEU, V46, P319, DOI 10.1016/j.semarthrit.2016.08.012; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140; Zhao SL, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2191-5	69	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								874490	10.3389/fimmu.2022.874490	http://dx.doi.org/10.3389/fimmu.2022.874490			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6PZ	35693781	Green Published, gold			2022-12-18	WOS:000808265600001
J	Fratzke, AP; van Schaik, EJ; Samuel, JE				Fratzke, Alycia P.; van Schaik, Erin J.; Samuel, James E.			Immunogenicity and Reactogenicity in Q Fever Vaccine Development	FRONTIERS IN IMMUNOLOGY			English	Review						Q fever; Coxiella burnetii; vaccine; reactogenicity; hypersensitivity; immunogenicity	COXIELLA-BURNETII INFECTION; PHASE-I; T-CELLS; INACTIVATED VACCINE; INFLUENZA VACCINE; ADJUVANT ACTIVITY; IMMUNE-RESPONSES; B-CELLS; Q-VAX; PROPHYLAXIS	Coxiella burnetii is an obligate intracellular bacterium which, in humans, causes the disease Q fever. Although Q fever is most often a mild, self-limiting respiratory disease, it can cause a range of severe syndromes including hepatitis, myocarditis, spontaneous abortion, chronic valvular endocarditis, and Q fever fatigue syndrome. This agent is endemic worldwide, except for New Zealand and Antarctica, transmitted via aerosols, persists in the environment for long periods, and is maintained through persistent infections in domestic livestock. Because of this, elimination of this bacterium is extremely challenging and vaccination is considered the best strategy for prevention of infection in humans. Many vaccines against C. burnetii have been developed, however, only a formalin-inactivated, whole cell vaccine derived from virulent C. burnetii is currently licensed for use in humans. Unfortunately, widespread use of this whole cell vaccine is impaired due to the severity of reactogenic responses associated with it. This reactogenicity continues to be a major barrier to access to preventative vaccines against C. burnetii and the pathogenesis of this remains only partially understood. This review provides an overview of past and current research on C. burnetii vaccines, our knowledge of immunogenicity and reactogenicity in C. burnetii vaccines, and future strategies to improve the safety of vaccines against C. burnetii.	[Fratzke, Alycia P.; Samuel, James E.] Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA; [Fratzke, Alycia P.; van Schaik, Erin J.; Samuel, James E.] Texas A&M Univ, Coll Med, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Samuel, JE (corresponding author), Texas A&M Univ, Coll Vet Med & Biomed Sci, Dept Vet Pathobiol, College Stn, TX 77843 USA.; Samuel, JE (corresponding author), Texas A&M Univ, Coll Med, Dept Microbial Pathogenesis & Immunol, Bryan, TX 77843 USA.				National Institutes of Health Institutional Training Grant T32 fellowship [5 OD 11083-11]	National Institutes of Health Institutional Training Grant T32 fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding Support for this review was provided by the National Institutes of Health Institutional Training Grant T32 fellowship 5 OD 11083-11.	ABINANTI FR, 1957, AM J HYG, V66, P173, DOI 10.1093/oxfordjournals.aje.a119894; ACKLAND JR, 1994, MED J AUSTRALIA, V160, P704, DOI 10.5694/j.1326-5377.1994.tb125909.x; ANACKER RL, 1963, J BACTERIOL, V85, P1165, DOI 10.1128/JB.85.5.1165-1170.1963; ANACKER RL, 1962, J IMMUNOL, V89, P145; Andoh M, 2007, INFECT IMMUN, V75, P3245, DOI 10.1128/IAI.01767-06; Angelakis E, 2013, EUR J CLIN MICROBIOL, V32, P361, DOI 10.1007/s10096-012-1750-3; Arricau-Bouvery N, 2005, VACCINE, V23, P4392, DOI 10.1016/j.vaccine.2005.04.010; Bacchetta R, 2005, AUTOIMMUN REV, V4, P491, DOI 10.1016/j.autrev.2005.04.005; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; BELL JF, 1964, MIL MED, V129, P591, DOI 10.1093/milmed/129.7.591; Bernstein DI, 2019, VACCINE, V37, P602, DOI 10.1016/j.vaccine.2018.12.011; BIBERSTEIN EL, 1974, CORNELL VET, V64, P387; Boyaka PN, 2017, J IMMUNOL, V199, P9, DOI 10.4049/jimmunol.1601775; BURNET FM, 1983, REV INFECT DIS, V5, P800; Burny W, 2019, VACCINE, V37, P2004, DOI 10.1016/j.vaccine.2019.02.015; Buttrum L, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00602-17; Chen C, 2019, J INFECT DIS, V220, P624, DOI 10.1093/infdis/jiz146; Davis G. E., 1938, Public Health Reports Washington, V53, P2259, DOI 10.2307/4582746; de Cremoux R, 2012, FEMS IMMUNOL MED MIC, V64, P104, DOI 10.1111/j.1574-695X.2011.00892.x; Del Giudice G, 2018, SEMIN IMMUNOL, V39, P14, DOI 10.1016/j.smim.2018.05.001; DERRICK E. H., 1939, Medical Journal of Australia, V1, P14; Derrick EH, 1944, J HYG-CAMBRIDGE, V43, P357, DOI 10.1017/S0022172400013085; Dowling JK, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.22; Dyer RE, 1939, PUBLIC HEALTH REP, V54, P1229, DOI 10.2307/4582947; DYER R. E., 1938, Public Health Reports, V53, P2277; Echeverria G, 2019, INFECT DRUG RESIST, V12, P701, DOI 10.2147/IDR.S195940; Eldin C, 2017, CLIN MICROBIOL REV, V30, P115, DOI 10.1128/CMR.00045-16; Fan YC, 2017, WIRES NANOMED NANOBI, V9, DOI 10.1002/wnan.1403; Feng JX, 2019, VACCINE, V37, P6076, DOI 10.1016/j.vaccine.2019.08.041; Fournier PE, 2001, CLIN INFECT DIS, V32, P1440, DOI 10.1086/320159; Fratzke AP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.754712; Fratzke AP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653092; Freytag LC, 2005, VACCINE, V23, P1804, DOI 10.1016/j.vaccine.2004.11.010; GENIG V. A., 1965, VOP VIRUSOL, V10, P319; Gilkes AP, 2020, J IMMUNOL, V204, P611, DOI 10.4049/jimmunol.1900991; Giuliani MM, 1998, J EXP MED, V187, P1123, DOI 10.1084/jem.187.7.1123; Gregory AE, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100461; Guatteo R, 2008, VACCINE, V26, P4320, DOI 10.1016/j.vaccine.2008.06.023; Hawken J, 2012, VACCINE, V30, P6971, DOI 10.1016/j.vaccine.2012.09.059; Herve C, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0132-6; Hirschmann JV, 2019, AM J MED SCI, V358, P3, DOI 10.1016/j.amjms.2019.04.006; Hogerwerf L, 2011, EMERG INFECT DIS, V17, P379, DOI 10.3201/eid1703.101157; HUMPHRES RC, 1981, INFECT IMMUN, V31, P641, DOI 10.1128/IAI.31.2.641-645.1981; IZZO AA, 1988, J INFECT DIS, V157, P781, DOI 10.1093/infdis/157.4.781; JOHNSON JW, 1977, J INFECT DIS, V135, P995, DOI 10.1093/infdis/135.6.995; KAZAR J, 1982, B WORLD HEALTH ORGAN, V60, P389; KISHIMOTO RA, 1977, INFECT IMMUN, V15, P601, DOI 10.1128/IAI.15.2.601-607.1977; Kumaresan V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.754690; Lavelle EC, 2022, NAT REV IMMUNOL, V22, P236, DOI 10.1038/s41577-021-00583-2; Ledbetter L, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00824-19; Lee S, 2015, IMMUNE NETW, V15, P51, DOI 10.4110/in.2015.15.2.51; Lemoine C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020304; Lepidi H, 2003, J INFECT DIS, V187, P1097, DOI 10.1086/368219; Lewis DJM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/909406; Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999; Long CM, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00296-6; Madariaga MG, 2003, LANCET INFECT DIS, V3, P709, DOI 10.1016/S1473-3099(03)00804-1; Male D. K., 2012, IMMUNOLOGY; Marmion B P, 1967, Med J Aust, V2, P1074; MARMION BP, 1990, EPIDEMIOL INFECT, V104, P275, DOI 10.1017/S0950268800059458; MARMION BP, 1984, LANCET, V2, P1411; Marrie TJ, 2010, INFECT DIS CLIN N AM, V24, P27, DOI 10.1016/j.idc.2009.10.004; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; Mastelic B, 2013, BIOLOGICALS, V41, P458, DOI 10.1016/j.biologicals.2013.08.006; Maurin M, 1999, CLIN MICROBIOL REV, V12, P518, DOI 10.1128/CMR.12.4.518; MCCAUL TF, 1981, J BACTERIOL, V147, P1063, DOI 10.1128/JB.147.3.1063-1076.1981; McGonagle D, 2021, J AUTOIMMUN, V121, DOI 10.1016/j.jaut.2021.102662; McNeil MM, 2018, J ALLERGY CLIN IMMUN, V141, P463, DOI 10.1016/j.jaci.2017.12.971; Meyer BK, 2019, VACCINE-X, V2, DOI 10.1016/j.jvacx.2019.100030; Million M, 2010, LANCET INFECT DIS, V10, P527, DOI 10.1016/S1473-3099(10)70135-3; Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08; Morris CB, 2000, VACCINE, V18, P1944, DOI 10.1016/S0264-410X(99)00447-8; Mostafavi E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211781; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Nanishi E, 2020, CURR OPIN PEDIATR, V32, P125, DOI 10.1097/MOP.0000000000000868; ORMSBEE RA, 1964, J IMMUNOL, V92, P404; Pan SC, 2020, VACCINE, V38, P1048, DOI 10.1016/j.vaccine.2019.11.047; Peng Y, 2012, J IMMUNOL, V189, P4909, DOI 10.4049/jimmunol.1201622; Pool V, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030385; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Qadri F, 2020, LANCET INFECT DIS, V20, P208, DOI 10.1016/S1473-3099(19)30571-7; Read AJ, 2010, INFECT IMMUN, V78, P3019, DOI 10.1128/IAI.00101-10; ROBBINS FC, 1946, AM J HYG, V44, P51, DOI 10.1093/oxfordjournals.aje.a119083; ROBBINS FC, 1946, AM J HYG, V44, P23, DOI 10.1093/oxfordjournals.aje.a119082; ROBINSON DM, 1974, APPL MICROBIOL, V27, P777, DOI 10.1128/AEM.27.4.777-783.1974; Rock MT, 2004, J INFECT DIS, V189, P1401, DOI 10.1086/382510; RONNBERG B, 1995, VACCINE, V13, P1375, DOI 10.1016/0264-410X(95)00105-A; Rouphael NG, 2017, LANCET, V390, P649, DOI 10.1016/S0140-6736(17)30575-5; Royal J, 2013, AM J TROP MED HYG, V89, P991, DOI 10.4269/ajtmh.12-0174; Saper CB, 2012, NAT NEUROSCI, V15, P1088, DOI 10.1038/nn.3159; Schoffelen T, 2014, VACCINE, V32, P6622, DOI 10.1016/j.vaccine.2014.09.061; Schoffelen T, 2014, J INFECTION, V69, P161, DOI 10.1016/j.jinf.2014.03.008; Schulze LSC, 2016, J DAIRY SCI, V99, P541, DOI 10.3168/jds.2015-9628; Sellens E, 2020, ZOONOSES PUBLIC HLTH, V67, P79, DOI 10.1111/zph.12658; Sellens E, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6040083; Shannon JG, 2009, IMMUNOL RES, V43, P138, DOI 10.1007/s12026-008-8059-4; Siegrist CA, 2007, J COMP PATHOL, V137, pS46, DOI 10.1016/j.jcpa.2007.04.012; Siegrist C-A., 2013, VACCINES-BASEL, V6th, DOI [DOI 10.1016/B978-1-4557-0090-5.00004-5, 10.1016/B978-1-4557-0090-5.00004-5]; Smirnov D, 2011, VACCINE, V29, P5434, DOI 10.1016/j.vaccine.2011.05.061; SNYDER MJ, 1947, J BACTERIOL, V54, P77; Steinhagen F, 2011, VACCINE, V29, P3341, DOI 10.1016/j.vaccine.2010.08.002; STOKER MGP, 1956, CAN J MICROBIOL, V2, P310, DOI 10.1139/m56-036; Stone CA, 2019, BRIT J CLIN PHARMACO, V85, P2694, DOI 10.1111/bcp.14112; Straily A, 2017, CLIN INFECT DIS, V65, P1872, DOI 10.1093/cid/cix702; Sukocheva OA, 2010, QJM-INT J MED, V103, P847, DOI 10.1093/qjmed/hcq113; Thavarajah Rooban, 2012, J Oral Maxillofac Pathol, V16, P400, DOI 10.4103/0973-029X.102496; Tom JK, 2019, TRENDS BIOTECHNOL, V37, P373, DOI 10.1016/j.tibtech.2018.10.004; van Schaik EJ, 2013, NAT REV MICROBIOL, V11, P561, DOI 10.1038/nrmicro3049; Vigil A, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.006304; Vigil A, 2010, PROTEOMICS, V10, P2259, DOI 10.1002/pmic.201000064; Waag DM, 2008, CLIN VACCINE IMMUNOL, V15, P1505, DOI 10.1128/CVI.00119-08; Waag DM, 1997, VACCINE, V15, P1779, DOI 10.1016/S0264-410X(97)00107-2; Wilhelmsen CL, 2000, COMPARATIVE MED, V50, P374; WILLIAMS JC, 1990, ANN NY ACAD SCI, V590, P370, DOI 10.1111/j.1749-6632.1990.tb42243.x; WILLIAMS JC, 1992, ANN NY ACAD SCI, V653, P88, DOI 10.1111/j.1749-6632.1992.tb19633.x; Xiong XL, 2017, J INFECT DIS, V215, P1580, DOI 10.1093/infdis/jiw470; Xiong XL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087206; Zhang GQ, 2004, INFECT IMMUN, V72, P844, DOI 10.1128/IAI.72.2.844-852.2004; Zhang GQ, 2007, J IMMUNOL, V179, P8372, DOI 10.4049/jimmunol.179.12.8372; Zhang GQ, 2013, INFECT IMMUN, V81, P2112, DOI 10.1128/IAI.00297-13	120	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								886810	10.3389/fimmu.2022.886810	http://dx.doi.org/10.3389/fimmu.2022.886810			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6DS	35693783	gold, Green Published			2022-12-18	WOS:000808233700001
J	Gohring, J; Schrangl, L; Schutz, GJ; Huppa, JB				Gohring, Janett; Schrangl, Lukas; Schutz, Gerhard J.; Huppa, Johannes B.			Mechanosurveillance: Tiptoeing T Cells	FRONTIERS IN IMMUNOLOGY			English	Review						immune surveillance; mechanical force; T-cell antigen recognition; glycocalyx; physical barriers; microvilli; membrane ultrastructure	IMMUNOLOGICAL SYNAPSE FORMATION; DENDRITIC CELLS; ENDOTHELIAL GLYCOCALYX; RECEPTOR MICROCLUSTERS; MECHANICAL-PROPERTIES; ACTIVATION; PEPTIDE; FORCES; TCR; ACTIN	Efficient scanning of tissue that T cells encounter during their migratory life is pivotal to protective adaptive immunity. In fact, T cells can detect even a single antigenic peptide/MHC complex (pMHC) among thousands of structurally similar yet non-stimulatory endogenous pMHCs on the surface of antigen-presenting cells (APCs) or target cells. Of note, the glycocalyx of target cells, being composed of proteoglycans and bulky proteins, is bound to affect and even modulate antigen recognition by posing as a physical barrier. T cell-resident microvilli are actin-rich membrane protrusions that puncture through such barriers and thereby actively place the considerably smaller T-cell antigen receptors (TCRs) in close enough proximity to APC-presented pMHCs so that productive interactions may occur efficiently yet under force. We here review our current understanding of how the plasticity of T-cell microvilli and physicochemical properties of the glycocalyx may affect early events in T-cell activation. We assess insights gained from studies on T-cell plasma membrane ultrastructure and provide an update on current efforts to integrate biophysical aspects such as the amplitude and directionality of TCR-imposed mechanical forces and the distribution and lateral mobility of plasma membrane-resident signaling molecules into a more comprehensive view on sensitized T-cell antigen recognition.	[Gohring, Janett; Huppa, Johannes B.] Med Univ Vienna, Inst Hyg & Appl Immunol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria; [Gohring, Janett; Schrangl, Lukas; Schutz, Gerhard J.] TU Wien, Inst Appl Phys, Vienna, Austria	Medical University of Vienna; Technische Universitat Wien	Gohring, J (corresponding author), Med Univ Vienna, Inst Hyg & Appl Immunol, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria.; Gohring, J (corresponding author), TU Wien, Inst Appl Phys, Vienna, Austria.	janett.goehring@meduniwien.ac.at			Austrian Science Fund (FWF) [P32307-B, I5056-B]; Vienna Science and Technology Fund (WWTF) [LS13-030]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); Vienna Science and Technology Fund (WWTF)	This work was supported by the Austrian Science Fund (FWF) project P32307-B (JG, LS, and GS), and I5056-B (LS and GS), and by the Vienna Science and Technology Fund (WWTF) project LS13-030 (JG, LS, JH, and GS).	Abadier M, 2017, CELL REP, V21, P3885, DOI 10.1016/j.celrep.2017.11.099; Agrawal B, 1998, CANCER RES, V58, P4079; Al-Aghbar MA, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003-021-02995-1; Alatoom A, 2020, ADV BIOSYST, V4, DOI 10.1002/adbi.202000039; Aleksic M, 2010, IMMUNITY, V32, P163, DOI 10.1016/j.immuni.2009.11.013; Allard JF, 2012, BIOPHYS J, V102, P1265, DOI 10.1016/j.bpj.2012.02.006; Aramesh M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2107535118; Aramesh M, 2021, NANO LETT, V21, P507, DOI 10.1021/acs.nanolett.0c03964; Arasa J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051269; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; Bai K, 2012, J R SOC INTERFACE, V9, P2290, DOI 10.1098/rsif.2011.0901; Bao G, 2003, NAT MATER, V2, P715, DOI 10.1038/nmat1001; Bashour KT, 2014, P NATL ACAD SCI USA, V111, P2241, DOI 10.1073/pnas.1315606111; Basu R, 2017, TRENDS CELL BIOL, V27, P241, DOI 10.1016/j.tcb.2016.10.005; Basu R, 2016, CELL, V165, P100, DOI 10.1016/j.cell.2016.01.021; Becker N, 2003, NAT MATER, V2, P278, DOI 10.1038/nmat858; BELL GI, 1984, BIOPHYS J, V45, P1051, DOI 10.1016/S0006-3495(84)84252-6; Bernardeau K, 2005, EUR J IMMUNOL, V35, P2864, DOI 10.1002/eji.200526307; Bi SG, 2009, BBA-GEN SUBJECTS, V1790, P1599, DOI 10.1016/j.bbagen.2009.07.027; Blanchard A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24602-x; Blumenthal D, 2020, ELIFE, V9, DOI 10.7554/eLife.55995; Brenner MD, 2016, NANO LETT, V16, P2096, DOI 10.1021/acs.nanolett.6b00305; Brodovitch A, 2015, CELL MOL BIOENG, V8, P178, DOI 10.1007/s12195-014-0361-8; Brodovitch A, 2013, J IMMUNOL, V191, P2064, DOI 10.4049/jimmunol.1300523; Brossard C, 2005, EUR J IMMUNOL, V35, P1741, DOI 10.1002/eji.200425857; Bufi N, 2015, BIOPHYS J, V108, P2181, DOI 10.1016/j.bpj.2015.03.047; Bunnell SC, 2002, J CELL BIOL, V158, P1263, DOI 10.1083/jcb.200203043; Cai E, 2017, SCIENCE, V356, DOI 10.1126/science.aal3118; Campi G, 2005, J EXP MED, V202, P1031, DOI 10.1084/jem.20051182; Carman CV, 2007, IMMUNITY, V26, P784, DOI 10.1016/j.immuni.2007.04.015; Chabaud M, 2020, BIOL CELL, V112, P196, DOI 10.1111/boc.201900093; Chang AC, 2016, ACS NANO, V10, P10745, DOI 10.1021/acsnano.6b03314; Chang VT, 2016, NAT IMMUNOL, V17, P574, DOI 10.1038/ni.3392; Choudhuri K, 2005, NATURE, V436, P578, DOI 10.1038/nature03843; Cloosen S, 2004, INT IMMUNOL, V16, P1561, DOI 10.1093/intimm/dxh157; Colin-York H, 2019, CELL REP, V26, P3369, DOI 10.1016/j.celrep.2019.02.074; Comrie WA, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00068; Comrie WA, 2015, J CELL BIOL, V208, P457, DOI 10.1083/jcb.201406120; DAI JW, 1995, BIOPHYS J, V68, P988, DOI 10.1016/S0006-3495(95)80274-2; Das DK, 2015, P NATL ACAD SCI USA, V112, P1517, DOI 10.1073/pnas.1424829112; Davis SJ, 2006, NAT IMMUNOL, V7, P803, DOI 10.1038/ni1369; DeMond AL, 2008, BIOPHYS J, V94, P3286, DOI 10.1529/biophysj.107.119099; Dillard P, 2014, BIOPHYS J, V107, P2629, DOI 10.1016/j.bpj.2014.10.044; Dustin ML, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002311; Dustin ML, 2001, ANNU REV CELL DEV BI, V17, P133, DOI 10.1146/annurev.cellbio.17.1.133; Farrell MV, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00609; Feng YN, 2017, P NATL ACAD SCI USA, V114, pE8204, DOI 10.1073/pnas.1703559114; Fernandes RA, 2019, P NATL ACAD SCI USA, V116, P14002, DOI 10.1073/pnas.1817255116; Folser M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020235; Ghasempour S, 2021, FEBS J, DOI 10.1111/febs.16236; Ghosh S, 2020, CELL REP, V30, P3434, DOI 10.1016/j.celrep.2020.02.069; Giannone G, 2004, CELL, V116, P431, DOI 10.1016/S0092-8674(04)00058-3; Glazier R, 2017, BBA-BIOMEMBRANES, V1859, P1465, DOI 10.1016/j.bbamem.2017.05.005; Gohring J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22775-z; Guimaraes CF, 2020, NAT REV MATER, V5, P351, DOI 10.1038/s41578-019-0169-1; Hellmeier JP, 2020, BIOPHYS J, V118, p245A; Hivroz C, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00046; Hong JS, 2015, J IMMUNOL, V195, P3557, DOI 10.4049/jimmunol.1501407; Hor JL, 2015, IMMUNITY, V43, P554, DOI 10.1016/j.immuni.2015.07.020; Hosseini BH, 2009, P NATL ACAD SCI USA, V106, P17852, DOI 10.1073/pnas.0905384106; Hsu CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032398; Hu KH, 2016, J CELL BIOL, V213, P535, DOI 10.1083/jcb.201511053; Hui KL, 2015, MOL BIOL CELL, V26, P685, DOI 10.1091/mbc.E14-03-0830; Hunter MC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00520; Huppa JB, 2003, NAT IMMUNOL, V4, P749, DOI 10.1038/ni951; Huppa JB, 2010, NATURE, V463, P963, DOI 10.1038/nature08746; Husson J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019680; Imbert PRC, 2021, CURR BIOL, V31, P77, DOI 10.1016/j.cub.2020.09.082; Ji L, 2008, NAT CELL BIOL, V10, P1393, DOI 10.1038/ncb1797; Johnson LA, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000908; Judokusumo E, 2012, BIOPHYS J, V102, pL5, DOI 10.1016/j.bpj.2011.12.011; Jung YM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23792-8; Jung YM, 2016, P NATL ACAD SCI USA, V113, pE5916, DOI 10.1073/pnas.1605399113; Kaizuka Y, 2007, P NATL ACAD SCI USA, V104, P20296, DOI 10.1073/pnas.0710258105; Kim ST, 2009, J BIOL CHEM, V284, P31028, DOI 10.1074/jbc.M109.052712; Kuhns MS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00159; Kumari S, 2020, EMBO J, V39, DOI 10.15252/embj.2019102783; Labernadie A, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6343; Lee KH, 2002, SCIENCE, V295, P1539, DOI 10.1126/science.1067710; Li YC, 2010, J IMMUNOL, V184, P5959, DOI 10.4049/jimmunol.0900775; Lim TS, 2011, J IMMUNOL, V187, P258, DOI 10.4049/jimmunol.1100267; Limozin L, 2019, P NATL ACAD SCI USA, V116, P16943, DOI 10.1073/pnas.1902141116; Liu BY, 2015, EUR J IMMUNOL, V45, P2099, DOI 10.1002/eji.201445358; Liu BY, 2014, CELL, V157, P357, DOI 10.1016/j.cell.2014.02.053; Liu Y, 2016, P NATL ACAD SCI USA, V113, P5610, DOI 10.1073/pnas.1600163113; Luxembourg AT, 1998, J IMMUNOL, V161, P5226; Ma R, 2019, P NATL ACAD SCI USA, V116, P16949, DOI 10.1073/pnas.1904034116; Ma VPY, 2016, NANO LETT, V16, P4552, DOI 10.1021/acs.nanolett.6b01817; Ma ZY, 2008, FASEB J, V22, P1002, DOI 10.1096/fj.07-9331hyp; Majstoravich S, 2004, BLOOD, V104, P1396, DOI 10.1182/blood-2004-02-0437; Malissen B, 2015, ANNU REV IMMUNOL, V33, P539, DOI 10.1146/annurev-immunol-032414-112158; Mallis RJ, 2015, P NATL ACAD SCI USA, V112, P8373, DOI 10.1073/pnas.1504971112; Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406; MECHERI S, 1990, J IMMUNOL, V144, P1361; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Miller MJ, 2004, J EXP MED, V200, P847, DOI 10.1084/jem.20041236; Miller MJ, 2004, P NATL ACAD SCI USA, V101, P998, DOI 10.1073/pnas.0306407101; Mockl L, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00253; Mockl L, 2019, DEV CELL, V50, P57, DOI 10.1016/j.devcel.2019.04.035; Moreau Joshua M, 2021, JID Innov, V1, P100014, DOI 10.1016/j.xjidi.2021.100014; Morimatsu M, 2013, NANO LETT, V13, P3985, DOI 10.1021/nl4005145; Mummert ME, 2002, J IMMUNOL, V169, P4322, DOI 10.4049/jimmunol.169.8.4322; Murugesan S, 2016, J CELL BIOL, V215, P383, DOI 10.1083/jcb.201603080; Nataraj NM, 2018, J BIOMED MATER RES A, V106, P3001, DOI 10.1002/jbm.a.36489; O'Connor RS, 2012, J IMMUNOL, V189, P1330, DOI 10.4049/jimmunol.1102757; Orbach R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02187; Paszek MJ, 2014, NATURE, V511, P319, DOI 10.1038/nature13535; Pettmann J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02152; Pielak RM, 2017, P NATL ACAD SCI USA, V114, P12190, DOI 10.1073/pnas.1613140114; POLLIACK A, 1981, J MICROSC-OXFORD, V123, P177, DOI 10.1111/j.1365-2818.1981.tb01293.x; POLLIACK A, 1973, J EXP MED, V138, P607, DOI 10.1084/jem.138.3.607; Pryshchep S, 2014, J IMMUNOL, V193, P68, DOI 10.4049/jimmunol.1303436; Puech PH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022344; Pullen RH, 2019, MOL BIOL CELL, V30, P2087, DOI 10.1091/mbc.E19-01-0048; Purbhoo MA, 2004, NAT IMMUNOL, V5, P524, DOI 10.1038/ni1058; Razvag Y, 2019, CELL REP, V29, P3506, DOI 10.1016/j.celrep.2019.11.022; Razvag Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03127-w; Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8; Robert P, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00108; Rossboth B, 2018, NAT IMMUNOL, V19, P821, DOI 10.1038/s41590-018-0162-7; Sage PT, 2012, J IMMUNOL, V188, P3686, DOI 10.4049/jimmunol.1102594; Saitakis M, 2017, ELIFE, V6, DOI 10.7554/eLife.23190; SANDERSON CJ, 1979, IMMUNOLOGY, V36, P119; Sawicka A, 2017, MOL BIOL CELL, V28, P3229, DOI 10.1091/mbc.E17-06-0385; Schwarz US, 2012, J CELL SCI, V125, P3051, DOI 10.1242/jcs.093716; Segura JM, 2008, J BIOL CHEM, V283, P24254, DOI 10.1074/jbc.M803549200; Sibener LV, 2018, CELL, V174, P672, DOI 10.1016/j.cell.2018.06.017; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Tamzalit F, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav5445; Tarbell JM, 2006, J INTERN MED, V259, P339, DOI 10.1111/j.1365-2796.2006.01620.x; Teijeira A, 2017, CELL REP, V18, P857, DOI 10.1016/j.celrep.2016.12.078; Tello-Lafoz M, 2021, IMMUNITY, V54, P1037, DOI 10.1016/j.immuni.2021.02.020; Treanor B, 2009, BIOCHEM SOC T, V37, P1014, DOI 10.1042/BST0371014; Ueda H, 2015, J IMMUNOL, V195, P4117, DOI 10.4049/jimmunol.1402175; Ueda H, 2011, P NATL ACAD SCI USA, V108, P17099, DOI 10.1073/pnas.1113703108; van Ewijk W, 1980, Ciba Found Symp, V71, P21, DOI 10.1002/9780470720547.ch3; Varma R, 2006, IMMUNITY, V25, P117, DOI 10.1016/j.immuni.2006.04.010; Weinbaum S, 2007, ANNU REV BIOMED ENG, V9, P121, DOI 10.1146/annurev.bioeng.9.060906.151959; Yi J, 2012, MOL BIOL CELL, V23, P834, DOI 10.1091/mbc.E11-08-0731; Yokosuka T, 2005, NAT IMMUNOL, V6, P1253, DOI 10.1038/ni1272; Zak A, 2021, BIOPHYS J, V120, P1692, DOI 10.1016/j.bpj.2021.02.042; Zhao YH, 2001, BIOPHYS J, V80, P1124, DOI 10.1016/S0006-3495(01)76090-0; Zhu C, 2019, CURR OPIN CHEM BIOL, V53, P88, DOI 10.1016/j.cbpa.2019.08.005; Zucchetti AE, 2021, BIOL CELL, V113, P250, DOI 10.1111/boc.202000133	145	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								886328	10.3389/fimmu.2022.886328	http://dx.doi.org/10.3389/fimmu.2022.886328			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6WA	35693808	Green Published, gold			2022-12-18	WOS:000808281300001
J	Guillem, P; Mintoff, D; Kabbani, M; Cogan, E; Vlaeminck-Guillem, V; Duquesne, A; Benhadou, F				Guillem, Philippe; Mintoff, Dillon; Kabbani, Mariam; Cogan, Elie; Vlaeminck-Guillem, Virginie; Duquesne, Agnes; Benhadou, Farida			Case Report: Comorbid Hyper-IgD Syndrome and Hidradenitis Suppurativa - A New Syndromic Form of HS? A Report of Two Cases	FRONTIERS IN IMMUNOLOGY			English	Article						hidradenitis suppurativa; mevalonate kinase deficiency; hyper-IgD syndrome; autoinflammatory keratinization disease; autoinflammation		Hidradenitis Suppurativa (HS) is a chronic suppurative disease of the pilosebaceous unit. The current model of HS pathophysiology describes the condition as the product of hyperkeratinisation and inflammation at the hair follicular unit. Environmental factors (such as smoking and obesity), gender, genetic predisposition, and skin dysbiosis are considered the main pathogenic drivers of the disease. Autoinflammatory syndromes associated with HS are rare but may help to highlight the potential roles of autoinflammation and dysregulated innate immune system in HS. Therefore, it is of major relevance to increase the awareness about these diseases in order to improve the understanding of the disease and to optimize the management of the patients. Herein, we report for the first time, to our knowledge, two clinical cases of Hyper-IgD syndrome-associated HS. Hyper-IgD is an autoinflammatory syndrome caused by a mevalonate kinase deficiency (MKD), a key kinase in the sterol and isoprenoid production pathway. We describe the potentially shared pathophysiological mechanisms underpinning comorbid MKD-HS and propose therapeutic options for the management of these patients.	[Guillem, Philippe] Clin Val Ouest, Dept Surg, Lyon, France; [Guillem, Philippe; Benhadou, Farida] ResoVerneuil, Paris, France; [Guillem, Philippe; Mintoff, Dillon; Benhadou, Farida] European Hidradenitis Suppurativa Fdn e V, Dessau, Germany; [Mintoff, Dillon] Mater Dei Hosp, Dept Dermatol, Msida, Malta; [Mintoff, Dillon] Univ Malta, Fac Med & Surg, Dept Pathol, Msida, Malta; [Kabbani, Mariam; Benhadou, Farida] Univ Libre Bruxelles, Hop Univ Erasme, Dept Dermatol, Brussels, Belgium; [Cogan, Elie] Univ Libre Bruxelles, Hop Univ Erasme, Dept Internal Med, Brussels, Belgium; [Cogan, Elie] Hop Delta, Dept Internal Med, CHIREC, Brussels, Belgium; [Vlaeminck-Guillem, Virginie] Univ Claude Bernard Lyon 1, Ctr Leon Berard, Ctr Rech Cancerol Lyon 9, INSERM 1052,CNRS 5286, Lyon, France; [Vlaeminck-Guillem, Virginie] Hosp Civils Lyon, Hop Lyon Sud, Ctr Biol Sud, Pierre Benite, France; [Duquesne, Agnes] Hosp Civils Lyon, Hop Femme Mere Enfant, Dept Paediat Nephrol Rheumatol & Dermatol, Bron, France	University of Malta; Universite Libre de Bruxelles; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; CHU Lyon; CHU Lyon	Benhadou, F (corresponding author), ResoVerneuil, Paris, France.; Benhadou, F (corresponding author), European Hidradenitis Suppurativa Fdn e V, Dessau, Germany.; Benhadou, F (corresponding author), Univ Libre Bruxelles, Hop Univ Erasme, Dept Dermatol, Brussels, Belgium.	Dr.farida.Benhadou@gmail.com	Mintoff, Dillon/ABG-2301-2020	Mintoff, Dillon/0000-0003-3705-0119				Frew John W, 2020, JAAD Int, V1, P62, DOI 10.1016/j.jdin.2020.05.005; Frew John W, 2018, F1000Res, V7, P1930, DOI 10.12688/f1000research.17267.1; Garcovich S, 2021, CLIN DERMATOL, V39, P240, DOI 10.1016/j.clindermatol.2020.10.016; Govindaraj GM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237999; Jafari SMS, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00068; Jfri A, 2021, JAMA DERMATOL, V157, P924, DOI 10.1001/jamadermatol.2021.1677; Marzano AV, 2022, DERMATOLOGY, V238, P860, DOI 10.1159/000521263; Nikolakis Georgios, 2021, Dermatology, V237, P673, DOI 10.1159/000509873; Nomura T, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00847; Sarkissian SD, 2022, JAMA DERMATOL, V158, P300, DOI 10.1001/jamadermatol.2021.4926; Thorlacius L, 2019, BRIT J DERMATOL, V181, P483, DOI 10.1111/bjd.17716; Wang BX, 2010, SCIENCE, V330, P1065, DOI 10.1126/science.1196284; Zouboulis CC, 2019, BRIT J DERMATOL, V181, P852, DOI 10.1111/bjd.17982; Zouboulis CC, 2017, BRIT J DERMATOL, V177, P1401, DOI 10.1111/bjd.15748; Zouboulis CC, 2020, EXP DERMATOL, V29, P1154, DOI 10.1111/exd.14214	15	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								883811	10.3389/fimmu.2022.883811	http://dx.doi.org/10.3389/fimmu.2022.883811			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F1WE	35720358	Green Published, gold			2022-12-18	WOS:000812705100001
J	Harakal, J; Qiao, H; Wheeler, K; Rival, C; Paul, AGA; Hardy, DM; Cheng, CY; Goldberg, E; Tung, KSK				Harakal, Jessica; Qiao, Hui; Wheeler, Karen; Rival, Claudia; Paul, Alberta G. A.; Hardy, Daniel M.; Cheng, C. Yan; Goldberg, Erwin; Tung, Kenneth S. K.			Exposed and Sequestered Antigens in Testes and Their Protection by Regulatory T Cell-Dependent Systemic Tolerance	FRONTIERS IN IMMUNOLOGY			English	Review						testis autoantigens and autoantibodies; exposed and sequestered testis autoantigens; the residual bodies and cytoplasmic droplets; experimental and human autoimmune orchitis; post-vasectomy tolerance versus orchitis; Foxp3+regulatory T cells and systemic tolerance	PHYSIOLOGICAL SELF-ANTIGEN; AUTOIMMUNE-DISEASE; GERM-CELLS; THYMECTOMY; SPERM; MOUSE; SPERMATOGENESIS; IDENTIFICATION; EXPRESSION; INDUCTION	Continuous exposure of tissue antigen (Ag) to the autoantigen-specific regulatory T cells (Treg) is required to maintain Treg-dependent systemic tolerance. Thus, testis autoantigens, previously considered as sequestered, may not be protected by systemic tolerance. We now document that the complete testis antigen sequestration is not valid. The haploid sperm Ag lactate dehydrogenase 3 (LDH3) is continuously exposed and not sequestered. It enters the residual body (RB) to egress from the seminiferous tubules and interact with circulating antibody (Ab). Some LDH3 also remains inside the sperm cytoplasmic droplets (CD). Treg-depletion in the DEREG mice that express diphtheria toxin receptor on the Foxp3 promoter results in spontaneous experimental autoimmune orchitis (EAO) and Ab to LDH3. Unlike the wild-type male mice, mice deficient in LDH3 (wild-type female or LDH3 NULL males) respond vigorously to LDH3 immunization. However, partial Treg depletion elevated the wild-type male LDH3 responses to the level of normal females. In contrast to LDH3, zonadhesin (ZAN) in the sperm acrosome displays properties of a sequestered Ag. However, when ZAN and other sperm Ag are exposed by vasectomy, they rapidly induce testis Ag-specific tolerance, which is terminated by partial Treg-depletion, leading to bilateral EAO and ZAN Ab response. We conclude that some testis/sperm Ag are normally exposed because of the unique testicular anatomy and physiology. The exposed Ag: 1) maintain normal Treg-dependent systemic tolerance, and 2) are pathogenic and serve as target Ag to initiate EAO. Unexpectedly, the sequestered Ags, normally non-tolerogenic, can orchestrate de novo Treg-dependent, systemic tolerance when exposed in vasectomy.	[Harakal, Jessica; Qiao, Hui; Rival, Claudia; Paul, Alberta G. A.; Tung, Kenneth S. K.] Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA; [Harakal, Jessica; Wheeler, Karen; Tung, Kenneth S. K.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22904 USA; [Harakal, Jessica; Qiao, Hui; Wheeler, Karen; Rival, Claudia; Paul, Alberta G. A.; Tung, Kenneth S. K.] Univ Virginia, Bierne B Carter Ctr Immunol Res, Charlottesville, VA 22904 USA; [Hardy, Daniel M.] Texas Tech Univ Hlth Sci Ctr HSC, Cell Biol & Biochem Dept, Lubbock, TX USA; [Cheng, C. Yan] Populat Council, Ctr Biomed Res, New York, NY USA; [Goldberg, Erwin] Northwestern Univ, Mol Biochem Dept, Evanstan, IL USA	University of Virginia; University of Virginia; University of Virginia; Population Council; Northwestern University	Tung, KSK (corresponding author), Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA.; Tung, KSK (corresponding author), Univ Virginia, Dept Microbiol, Charlottesville, VA 22904 USA.; Tung, KSK (corresponding author), Univ Virginia, Bierne B Carter Ctr Immunol Res, Charlottesville, VA 22904 USA.							Abramson J, 2016, IMMUNOL REV, V271, P127, DOI 10.1111/imr.12419; Alard P, 2001, J IMMUNOL, V166, P4363, DOI 10.4049/jimmunol.166.7.4363; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Atanassova N, 2009, FOLIA HISTOCHEM CYTO, V47, P117, DOI 10.2478/v10042-009-0002-6; Au CE, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150080; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; del Rio R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003140; Dym M, 1970, Biology Reprod., V3, P308; Figueiredo AFA, 2021, DIFFERENTIATION, V120, P36, DOI 10.1016/j.diff.2021.06.002; Fijak M, 2006, IMMUNOL REV, V213, P66, DOI 10.1111/j.1600-065X.2006.00438.x; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Garza KM, 2000, J IMMUNOL, V164, P3982, DOI 10.4049/jimmunol.164.8.3982; Hedger MP, 2002, J REPROD IMMUNOL, V57, P19, DOI 10.1016/S0165-0378(02)00016-5; Hickox JR, 2001, J BIOL CHEM, V276, P41502, DOI 10.1074/jbc.M106795200; HINTZ M, 1977, DEV BIOL, V57, P375, DOI 10.1016/0012-1606(77)90222-6; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Klawon DEJ, 2021, J EXP MED, V218, DOI 10.1084/jem.20200701; KOJIMA A, 1981, IMMUNOGENETICS, V14, P15, DOI 10.1007/BF00344296; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Lee R, 2009, J UROLOGY, V181, P264, DOI 10.1016/j.juro.2008.09.004; Leichtmann-Bardoogo Y, 2012, AM J PHYSIOL-ENDOC M, V302, pE1519, DOI 10.1152/ajpendo.00007.2012; Leonard JD, 2017, IMMUNITY, V47, P107, DOI 10.1016/j.immuni.2017.06.015; Li N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00152; LUO AM, 1993, J CLIN INVEST, V92, P2117, DOI 10.1172/JCI116812; Lustig L., 2019, AUTOIMMUN DIS, V6th; Ma RLZ, 2002, SCIENCE, V297, P620, DOI 10.1126/science.1072810; Meng J, 2005, P NATL ACAD SCI USA, V102, P16696, DOI 10.1073/pnas.0506084102; Mital P, 2011, BIOL REPROD, V84, P851, DOI 10.1095/biolreprod.110.087452; NISHIZUK.Y, 1969, SCIENCE, V166, P753, DOI 10.1126/science.166.3906.753; O'Donnell L, 2021, FASEB J, V35, DOI 10.1096/fj.202002484R; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; Plotz PH, 2003, NAT REV IMMUNOL, V3, P73, DOI 10.1038/nri976; Riella LV, 2012, AM J TRANSPLANT, V12, P2575, DOI 10.1111/j.1600-6143.2012.04224.x; Rival C, 2013, J REPROD IMMUNOL, V100, P66, DOI 10.1016/j.jri.2013.08.004; Russell L. D., 1990, HISTOLOGICAL HISTOPA; SAKAGUCHI S, 1982, J EXP MED, V156, P1577, DOI 10.1084/jem.156.6.1577; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Samy ET, 2006, IMMUNOL REV, V212, P170, DOI 10.1111/j.0105-2896.2006.00404.x; Savage PA, 2020, ANNU REV IMMUNOL, V38, P421, DOI 10.1146/annurev-immunol-100219-020937; Schmidt SV, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00274; Schuppe HC, 2008, ANDROLOGIA, V40, P84, DOI 10.1111/j.1439-0272.2008.00837.x; Setiady YY, 2006, BLOOD, V107, P1056, DOI 10.1182/blood-2005-08-3088; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Smith BE, 2012, SCIENCE, V338, P798, DOI 10.1126/science.1219969; Steinman RM, 2007, EUR J IMMUNOL, V37, pS53, DOI 10.1002/eji.200737400; TAGUCHI O, 1994, IMMUNOLOGY, V82, P365; TAGUCHI O, 1981, CLIN EXP IMMUNOL, V46, P425; TAGUCHI O, 1987, J EXP MED, V165, P146, DOI 10.1084/jem.165.1.146; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Tomofuji Y, 2020, NAT IMMUNOL, V21, P892, DOI 10.1038/s41590-020-0717-2; Tung KSK, 2017, J CLIN INVEST, V127, P1046, DOI 10.1172/JCI89927; TUNG KSK, 1987, J IMMUNOL, V138, P752; Vogl AW, 2013, INT REV CEL MOL BIO, V303, P319, DOI 10.1016/B978-0-12-407697-6.00008-8; Wheeler K, 2011, P NATL ACAD SCI USA, V108, P7511, DOI 10.1073/pnas.1017615108; Xiao CY, 2017, ANDROLOGIA, V49, DOI 10.1111/and.12786; Yan HHN, 2008, FASEB J, V22, P1945, DOI 10.1096/fj.06-070342; Yuan SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077466; YULE TD, 1988, J IMMUNOL, V141, P1161; Zhao ZH, 2021, CLIN IMMUNOL, V224, DOI 10.1016/j.clim.2021.108675; Zhu K, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03109	60	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								809247	10.3389/fimmu.2022.809247	http://dx.doi.org/10.3389/fimmu.2022.809247			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6RE	35693780	Green Published, gold			2022-12-18	WOS:000808268700001
J	Kar, U; Khaleeq, S; Garg, P; Bhat, M; Reddy, P; Vignesh, VS; Upadhyaya, A; Das, M; Chakshusmathi, G; Pandey, S; Dutta, S; Varadarajan, R				Kar, Uddipan; Khaleeq, Sara; Garg, Priyanka; Bhat, Madhuraj; Reddy, Poorvi; Vignesh, Venkada Subramanian; Upadhyaya, Aditya; Das, Mili; Chakshusmathi, Ghadiyaram; Pandey, Suman; Dutta, Somnath; Varadarajan, Raghavan			Comparative Immunogenicity of Bacterially Expressed Soluble Trimers and Nanoparticle Displayed Influenza Hemagglutinin Stem Immunogens	FRONTIERS IN IMMUNOLOGY			English	Article						protein design; stabilization; thermal tolerance; competition assay; oligomer; antibody response; pandemic; B-cell	RESEARCH-AND-DEVELOPMENT; RECEPTOR-BINDING; NEUTRALIZING EPITOPE; ANTIBODY RECOGNITION; VACCINE; DESIGN; DOMAIN; VIRUSES; FLEXIBILITY; LINKERS	Current influenza vaccines need to be updated annually due to mutations in the globular head of the viral surface protein, hemagglutinin (HA). To address this, vaccine candidates have been designed based on the relatively conserved HA stem domain and have shown protective efficacy in animal models. Oligomerization of the antigens either by fusion to oligomerization motifs or display on self-assembling nanoparticle scaffolds, can induce more potent immune responses compared to the corresponding monomeric antigen due to multivalent engagement of B-cells. Since nanoparticle display can increase manufacturing complexity, and often involves one or more mammalian cell expressed components, it is important to characterize and compare various display and oligomerization scaffolds. Using a structure guided approach, we successfully displayed multiple copies of a previously designed soluble, trimeric influenza stem domain immunogen, pH1HA10, on the ferritin like protein, MsDps2 (12 copies), Ferritin (24 copies) and Encapsulin (180 copies). All proteins were expressed in Escherichia coli. The nanoparticle fusion immunogens were found to be well folded and bound to the influenza stem directed broadly neutralizing antibodies with high affinity. An 8.5 angstrom Cryo-EM map of Msdps2-pH1HA10 confirmed the successful design of the nanoparticle fusion immunogen. Mice immunization studies with the soluble trimeric stem and nanoparticle fusion constructs revealed that all of them were immunogenic, and protected mice against homologous (A/Belgium/145-MA/2009) and heterologous (A/Puerto Rico/8/1934) challenge with 10MLD(50) mouse adapted virus. Although nanoparticle display conferred a small but statistically significant improvement in protection relative to the soluble trimer in a homologous challenge, heterologous protection was similar in both nanoparticle-stem immunized and trimeric stem immunized groups. Such rapidly producible, bacterially expressed antigens and nanoparticle scaffolds are useful modalities to tackle future influenza pandemics.	[Kar, Uddipan; Khaleeq, Sara; Garg, Priyanka; Vignesh, Venkada Subramanian; Dutta, Somnath; Varadarajan, Raghavan] Indian Inst Sci, Mol Biophys Unit MBU, Bengaluru, India; [Bhat, Madhuraj; Reddy, Poorvi; Upadhyaya, Aditya; Das, Mili; Chakshusmathi, Ghadiyaram; Pandey, Suman] Mynvax Pvt Ltd, Soc Innovat & Dev SID, Indian Inst Sci, Entrepreneurship Ctr,ES12, Bengaluru, India	Indian Institute of Science (IISC) - Bangalore; Indian Institute of Science (IISC) - Bangalore	Varadarajan, R (corresponding author), Indian Inst Sci, Mol Biophys Unit MBU, Bengaluru, India.	varadar@iisc.ac.in		Venkadasubramanian, Vignesh/0000-0003-1700-7439	Uchchatar Avishkar Yojana (UAY), Ministry of Human Resource Development [IISc_005]; DBT-ENDFLU - European Union's Horizon 2020 research and innovation programme [BT/IN/EU-INF/15/RV/19-20, 874650]; Department of Biotechnology, Ministry of Science and Technology, Government of India [BT/IN/EU-INF/15/RV/19-20]; Bill and Melinda Gates Foundation [INV-005948]; DST-FIST; UGC Centre of Advanced Study; MHRD-FAST; DBT-IISc Partnership Program; JC Bose Fellowship from DST; DBT Cryo-EM facility [BT/INF/22/SP22844/2017SM]; DBT-JRF [DBT/JRF/BET-18/I/2018/AL/168]; UGC-CSIR	Uchchatar Avishkar Yojana (UAY), Ministry of Human Resource Development; DBT-ENDFLU - European Union's Horizon 2020 research and innovation programme; Department of Biotechnology, Ministry of Science and Technology, Government of India(Department of Biotechnology (DBT) IndiaMinistry of Science and Technology, Government of India); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); DST-FIST(Department of Science & Technology (India)); UGC Centre of Advanced Study; MHRD-FAST; DBT-IISc Partnership Program; JC Bose Fellowship from DST; DBT Cryo-EM facility; DBT-JRF; UGC-CSIR	We sincerely acknowledge funding from Uchchatar Avishkar Yojana (UAY), Ministry of Human Resource Development (IISc_005) grant to RV, DBT-ENDFLU (BT/IN/EU-INF/15/RV/19-20) funded by European Union's Horizon 2020 research and innovation programme under grant agreement No. 874650 and the Department of Biotechnology, Ministry of Science and Technology, Government of India (BT/IN/EU-INF/15/RV/19-20), and a grant from the Bill and Melinda Gates Foundation (INV-005948). We acknowledge funding for infrastructural support from DST-FIST, UGC Centre of Advanced Study, MHRD-FAST, the DBT-IISc Partnership Program, and of a JC Bose Fellowship from DST to RV. SD acknowledges the support of the DBT Cryo-EM facility (BT/INF/22/SP22844/2017SM). SK acknowledges fellowship from DBT-JRF (DBT/JRF/BET-18/I/2018/AL/168). UK acknowledges fellowship from UGC-CSIR.	Antanasijevic A, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008665; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bell JM, 2016, METHODS, V100, P25, DOI 10.1016/j.ymeth.2016.02.018; Belser JA, 2007, J VIROL, V81, P11139, DOI 10.1128/JVI.01235-07; Bommakanti G, 2012, J VIROL, V86, P13434, DOI 10.1128/JVI.01429-12; BOTH GW, 1983, J VIROL, V48, P52, DOI 10.1128/JVI.48.1.52-60.1983; Boyoglu-Barnum S, 2021, NATURE, V592, P623, DOI 10.1038/s41586-021-03365-x; Nguyen B, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00330-7; Brouwer PJM, 2021, CELL, V184, P1188, DOI 10.1016/j.cell.2021.01.035; Chattopadhyay G, 2019, PROTEIN SCI, V28, P1127, DOI 10.1002/pro.3622; Chen XY, 2013, ADV DRUG DELIVER REV, V65, P1357, DOI 10.1016/j.addr.2012.09.039; Corbett KS, 2019, MBIO, V10, DOI 10.1128/mBio.02810-18; Corti D, 2011, SCIENCE, V333, P850, DOI 10.1126/science.1205669; Deng L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02725-4; Du LY, 2010, MICROBES INFECT, V12, P280, DOI 10.1016/j.micinf.2010.01.001; Ekiert DC, 2011, SCIENCE, V333, P843, DOI 10.1126/science.1204839; Ekiert DC, 2009, SCIENCE, V324, P246, DOI 10.1126/science.1171491; Georgiev IS, 2018, ACS INFECT DIS, V4, P788, DOI 10.1021/acsinfecdis.7b00192; Ghosh E, 2019, CELL REP, V28, P3287, DOI 10.1016/j.celrep.2019.08.053; Girard MP, 2005, VACCINE, V23, P5708, DOI 10.1016/j.vaccine.2005.07.046; Gu MG, 2021, EMERG MICROBES INFEC, V10, P2016, DOI 10.1080/22221751.2021.1994354; He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041; Impagliazzo A, 2015, SCIENCE, V349, P1301, DOI 10.1126/science.aac7263; Jardine J, 2013, SCIENCE, V340, P711, DOI 10.1126/science.1234150; Jerabek-Willemsen M, 2014, J MOL STRUCT, V1077, P101, DOI 10.1016/j.molstruc.2014.03.009; Jerabek-Willemsen M, 2011, ASSAY DRUG DEV TECHN, V9, P342, DOI 10.1089/adt.2011.0380; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Keech C, 2020, NEW ENGL J MED, V383, P2320, DOI 10.1056/NEJMoa2026920; Kimanius D, 2016, ELIFE, V5, DOI 10.7554/eLife.18722; Krammer F, 2013, CURR OPIN VIROL, V3, P521, DOI 10.1016/j.coviro.2013.07.007; Kumar S, 2019, J VIROL, V93, DOI 10.1128/JVI.01495-18; Lee LA, 2006, NANOMED-NANOTECHNOL, V2, P137, DOI 10.1016/j.nano.2006.07.009; Lopez-Sagaseta J, 2016, COMPUT STRUCT BIOTEC, V14, P58, DOI 10.1016/j.csbj.2015.11.001; Lu Y, 2014, P NATL ACAD SCI USA, V111, P125, DOI 10.1073/pnas.1308701110; Malladi SK, 2021, ACS INFECT DIS, V7, P2546, DOI 10.1021/acsinfecdis.1c00276; Mallajosyula VVA, 2014, P NATL ACAD SCI USA, V111, pE2514, DOI 10.1073/pnas.1402766111; Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046; McHugh CA, 2014, EMBO J, V33, P1896, DOI 10.15252/embj.201488566; Mittal N, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091710; NOBUSAWA E, 1991, VIROLOGY, V182, P475, DOI 10.1016/0042-6822(91)90588-3; O'Hagan DT, 2013, EXPERT REV VACCINES, V12, P13, DOI [10.1586/ERV.12.140, 10.1586/erv.12.140]; OKUNO Y, 1993, J VIROL, V67, P2552, DOI 10.1128/JVI.67.5.2552-2558.1993; Pang IK, 2013, P NATL ACAD SCI USA, V110, P13910, DOI 10.1073/pnas.1303275110; Pati R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02224; Paules CI, 2017, IMMUNITY, V47, P599, DOI 10.1016/j.immuni.2017.09.007; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pica N, 2013, ANNU REV MED, V64, P189, DOI [10.1146/annurev-med-120611-145115, 10.1146/annure]; Rawson S, 2016, METHODS, V100, P35, DOI 10.1016/j.ymeth.2016.03.011; Reed C, 2009, EMERG INFECT DIS, V15, P2004, DOI 10.3201/eid1512.091413; Rohou A, 2015, J STRUCT BIOL, V192, P216, DOI 10.1016/j.jsb.2015.08.008; Roy S, 2008, J MOL BIOL, V375, P948, DOI 10.1016/j.jmb.2007.10.023; Safdar A, 2007, EXPERT OPIN INV DRUG, V16, P927, DOI 10.1517/13543784.16.7.927; SANCHEZFAUQUIER A, 1991, ARCH VIROL, V116, P285, DOI 10.1007/BF01319250; Scheres SHW, 2012, J STRUCT BIOL, V180, P519, DOI 10.1016/j.jsb.2012.09.006; Scorza FB, 2016, VACCINE, V34, P2926, DOI 10.1016/j.vaccine.2016.03.085; Sharma A, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.02037; Shi Y, 2014, NAT REV MICROBIOL, V12, P822, DOI 10.1038/nrmicro3362; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Steel J, 2010, MBIO, V1, DOI 10.1128/mBio.00018-10; Sui JH, 2009, NAT STRUCT MOL BIOL, V16, P265, DOI 10.1038/nsmb.1566; Sutton TC, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0036-2; Throsby M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003942; Tong SX, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003657; Ueda G, 2020, ELIFE, V9, DOI 10.7554/eLife.57659; van Heel M, 2005, J STRUCT BIOL, V151, P250, DOI 10.1016/j.jsb.2005.05.009; van Rosmalen M, 2017, BIOCHEMISTRY-US, V56, P6565, DOI 10.1021/acs.biochem.7b00902; Vu MN, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103699; Wienken CJ, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1093; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; Xu R, 2013, NAT STRUCT MOL BIOL, V20, P363, DOI 10.1038/nsmb.2500; Xu R, 2010, SCIENCE, V328, P357, DOI 10.1126/science.1186430; Yassine HM, 2015, NAT MED, V21, P1065, DOI 10.1038/nm.3927; Zhang Y, 2011, INT J MOL SCI, V12, P5406, DOI 10.3390/ijms12085406; Zhao L, 2014, VACCINE, V32, P327, DOI 10.1016/j.vaccine.2013.11.069; Zheng SQ, 2017, NAT METHODS, V14, P331, DOI 10.1038/nmeth.4193	75	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								890622	10.3389/fimmu.2022.890622	http://dx.doi.org/10.3389/fimmu.2022.890622			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F4OC	35720346	Green Published, Green Accepted, gold			2022-12-18	WOS:000812889800001
J	Koetzier, SC; van Langelaar, J; Wierenga-Wolf, AF; Melief, MJ; Pol, K; Musters, S; Lubberts, E; Dik, WA; Smolders, J; van Luijn, MM				Koetzier, Steven C.; van Langelaar, Jamie; Wierenga-Wolf, Annet F.; Melief, Marie-Jose; Pol, Kim; Musters, Suzanne; Lubberts, Erik; Dik, Willem A.; Smolders, Joost; van Luijn, Marvin M.			Improving Glucocorticoid Sensitivity of Brain-Homing CD4(+) T Helper Cells by Steroid Hormone Crosstalk	FRONTIERS IN IMMUNOLOGY			English	Article						calcitriol; progesterone; steroid resistance; T helper 17; 1; multiple sclerosis	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; VITAMIN-D; MULTIPLE-SCLEROSIS; METHYLPREDNISOLONE THERAPY; GENE-EXPRESSION; METABOLISM; PROTECTION; MECHANISM; CNS	In early multiple sclerosis (MS), an IFN-gamma(high)GM-(CSFIL)-I-high-17(low) CD4(+) T-cell subset termed T helper 17.1 (Th17.1) reveals enhanced capacity to infiltrate the central nervous system. Th17.1 cells express high levels of multidrug resistance protein 1 (MDR1), which contributes to their poor glucocorticoid responsiveness. In this study, we explored whether glucocorticoid sensitivity of Th17.1 cells can generically be improved through synergy between steroid hormones, including calcitriol (1,25(OH)(2)D-3), estradiol (E2) and progesterone (P4). We showed that human blood Th17.1 cells were less sensitive to 1,25(OH)(2)D-3 than Th17 cells, as reflected by lower vitamin D receptor (VDR) levels and reduced modulation of MDR1, IFN-gamma and GM-CSF expression after 1,25(OH)(2)D-3 exposure. Upon T-cell activation, VDR levels were increased, but still lower in Th17.1 versus Th17 cells, which was accompanied by a 1,25(OH)(2)D-3-mediated decline in MDR1 surface expression as well as secretion of IFN-gamma and GM-CSF. In activated Th17.1 cells, 1,25(OH)(2)D-3 amplified the suppressive effects of methylprednisolone (MP) on proliferation, MDR1 surface levels, secretion of IFN-gamma and granzyme B, as well as expression of brain-homing markers CCR6 and VLA-4. The addition of P4 to 1,25(OH)(2)D-3 further enhanced MP-mediated reduction in proliferation, CD25, CCR6 and CXCR3. Overall, this study indicates that glucocorticoid sensitivity of Th17.1 cells can be enhanced by treatment with 1,25(OH)(2)D-3 and further improved with P4. Our observations implicate steroid hormone crosstalk as a therapeutic avenue in Th17.1-associated inflammatory diseases including MS.	[Koetzier, Steven C.; van Langelaar, Jamie; Wierenga-Wolf, Annet F.; Melief, Marie-Jose; Pol, Kim; Musters, Suzanne; Dik, Willem A.; Smolders, Joost; van Luijn, Marvin M.] Univ Med Ctr Rotterdam, Erasmus Med Ctr MC, Dept Immunol, Rotterdam, Netherlands; [Koetzier, Steven C.; van Langelaar, Jamie; Wierenga-Wolf, Annet F.; Melief, Marie-Jose; Pol, Kim; Musters, Suzanne; Smolders, Joost; van Luijn, Marvin M.] Univ Med Ctr Rotterdam, Multiple Sclerosis MS Ctr ErasMS, Erasmus Med Ctr MC, Rotterdam, Netherlands; [Lubberts, Erik] Univ Med Ctr Rotterdam, Erasmus Med Ctr MC, Dept Rheumatol, Rotterdam, Netherlands; [Dik, Willem A.] Univ Med Ctr Rotterdam, Erasmus Med Ctr MC, Lab Med Immunol, Rotterdam, Netherlands; [Smolders, Joost] Univ Med Ctr Rotterdam, Erasmus Med Ctr MC, Dept Neurol, Rotterdam, Netherlands; [Smolders, Joost] Netherlands Inst Neurosci, Neuroimmunol Res Grp, Amsterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	van Luijn, MM (corresponding author), Univ Med Ctr Rotterdam, Erasmus Med Ctr MC, Dept Immunol, Rotterdam, Netherlands.; van Luijn, MM (corresponding author), Univ Med Ctr Rotterdam, Multiple Sclerosis MS Ctr ErasMS, Erasmus Med Ctr MC, Rotterdam, Netherlands.	m.vanluijn@erasmusmc.nl	Smolders, Joost/B-7658-2009	Smolders, Joost/0000-0001-9766-8661				Agliardi C, 2011, BRAIN BEHAV IMMUN, V25, P1460, DOI 10.1016/j.bbi.2011.05.015; Agnello L, 2018, J MOL NEUROSCI, V66, P77, DOI 10.1007/s12031-018-1152-9; Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016; Brusaferri F, 2000, J NEUROL, V247, P435, DOI 10.1007/s004150070172; Busse D, 2010, P NATL ACAD SCI USA, V107, P3058, DOI 10.1073/pnas.0812851107; Cantorna MT, 2015, NUTRIENTS, V7, P3011, DOI 10.3390/nu7043011; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Correale J, 2009, BRAIN, V132, P1146, DOI 10.1093/brain/awp033; Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005; Damoiseaux J, 2018, EBIOMEDICINE, V31, P9, DOI 10.1016/j.ebiom.2018.04.013; Dankers W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01504; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Hartmann FJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6056; Hayes CE, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00100; Hoepner R, 2019, ACTA NEUROPATHOL, V138, P443, DOI 10.1007/s00401-019-02018-8; Killick J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.598727; Koetzier SC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.642038; Koetzier SC, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000894; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; Leussink VI, 2001, ARCH NEUROL-CHICAGO, V58, P91, DOI 10.1001/archneur.58.1.91; LYONS PR, 1988, J NEUROL NEUROSUR PS, V51, P285, DOI 10.1136/jnnp.51.2.285; Martinez-Caceres EM, 2002, CLIN EXP IMMUNOL, V127, P165, DOI 10.1046/j.1365-2249.2002.01725.x; McGinley MP, 2021, JAMA-J AM MED ASSOC, V325, P765, DOI 10.1001/jama.2020.26858; Mimpen M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0261097; Nashold FE, 2009, J IMMUNOL, V183, P3672, DOI 10.4049/jimmunol.0901351; Papapavlou G, 2021, EUR J IMMUNOL, V51, P2430, DOI 10.1002/eji.202049144; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Reboldi A, 2009, NAT IMMUNOL, V10, P514, DOI 10.1038/ni.1716; Runia TF, 2012, NEUROLOGY, V79, P261, DOI 10.1212/WNL.0b013e31825fdec7; Saeki M, 2008, BIOCHEM PHARMACOL, V76, P531, DOI 10.1016/j.bcp.2008.05.030; Schweingruber N, 2014, ACTA NEUROPATHOL, V127, P713, DOI 10.1007/s00401-014-1248-4; Smolders J, 2019, CNS DRUGS, V33, P1187, DOI 10.1007/s40263-019-00674-8; Smolders J, 2011, J NEUROIMMUNOL, V235, P91, DOI 10.1016/j.jneuroim.2011.03.012; Sorensen TL, 2002, J NEUROIMMUNOL, V127, P59, DOI 10.1016/S0165-5728(02)00097-8; Spach KM, 2005, J IMMUNOL, V175, P4119, DOI 10.4049/jimmunol.175.6.4119; Spanier JA, 2015, J NEUROIMMUNOL, V286, P48, DOI 10.1016/j.jneuroim.2015.06.015; Thangamani S, 2015, J IMMUNOL, V194, P883, DOI 10.4049/jimmunol.1401923; van Langelaar J, 2018, BRAIN, V141, P1334, DOI 10.1093/brain/awy069; van Winsen LML, 2005, J CLIN ENDOCR METAB, V90, P734, DOI 10.1210/jc.2004-0306; von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851; Wust S, 2008, J IMMUNOL, V180, P8434, DOI 10.4049/jimmunol.180.12.8434; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0	43	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								893702	10.3389/fimmu.2022.893702	http://dx.doi.org/10.3389/fimmu.2022.893702			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6LI	35693770	Green Published, gold			2022-12-18	WOS:000808253500001
J	Krawczyk, KT; Locht, C; Kowalewicz-Kulbat, M				Krawczyk, Krzysztof T.; Locht, Camille; Kowalewicz-Kulbat, Magdalena			Halophilic Archaea Halorhabdus Rudnickae and Natrinema Salaciae Activate Human Dendritic Cells and Orient T Helper Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						halophilic archaea; Halorhabdus rudnickae; Natrinema salaciae; dendritic cells; T cells	SP NOV.; BACTERIA; HALOTHERAPY; DIVERSITY; ASTHMA	Halophilic archaea are procaryotic organisms distinct from bacteria, known to thrive in hypersaline environments, including salt lakes, salterns, brines and salty food. They have also been identified in the human microbiome. The biological significance of halophiles for human health has rarely been examined. The interactions between halophilic archaea and human dendritic cells (DCs) and T cells have not been identified so far. Here, we show for the first time that the halophilic archaea Halorhabdus rudnickae and Natrinema salaciae activate human monocyte-derived DCs, induce DC maturation, cytokine production and autologous T cell activation. In vitro both strains induced DC up-regulation of the cell-surface receptors CD86, CD80 and CD83, and cytokine production, including IL-12p40, IL-10 and TNF-alpha, but not IL-23 and IL-12p70. Furthermore, autologous CD4(+) T cells produced significantly higher amounts of IFN-gamma and IL-13, but not IL-17A when co-cultured with halophile-stimulated DCs in comparison to T cells co-cultured with unstimulated DCs. IFN-gamma was almost exclusively produced by naive T cells, while IL-13 was produced by both naive and memory CD4(+) T cells. Our findings thus show that halophilic archaea are recognized by human DCs and are able to induce a balanced cytokine response. The immunomodulatory functions of halophilic archaea and their potential ability to re-establish the immune balance may perhaps participate in the beneficial effects of halotherapies.	[Krawczyk, Krzysztof T.; Locht, Camille; Kowalewicz-Kulbat, Magdalena] Univ Lodz, Inst Microbiol, Fac Biol & Environm Protect, Dept Immunol & Infect Biol, Lodz, Poland; [Locht, Camille] Univ Lille, Inst Pasteur Lille, CNRS, Inserm,CHU Lille,U1019,UMR9017,CIIL,Ctr Infect & I, Lille, France	University of Lodz; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; CHU Lille; Universite de Lille	Kowalewicz-Kulbat, M (corresponding author), Univ Lodz, Inst Microbiol, Fac Biol & Environm Protect, Dept Immunol & Infect Biol, Lodz, Poland.	magdalena.kowalewicz@biol.uni.lodz.pl		Krawczyk, Krzysztof/0000-0003-0415-6363	National Science Centre [2017/27/N/NZ6/02850]; Visiting Research Fellow "Initiative of Excellence -Research University (IDUB) project, University of Lodz	National Science Centre(National Science Centre, Poland); Visiting Research Fellow "Initiative of Excellence -Research University (IDUB) project, University of Lodz	This work was supported by the National Science Centre grant no 2017/27/N/NZ6/02850 awarded to KK and Visiting Research Fellow "Initiative of Excellence -Research University (IDUB) project, University of Lodz 2021 awarded to CL.	Achkar MA., 2015, INT J RESPIR PULM ME, V2, P1, DOI [10.23937/2378-3516/1410009, DOI 10.23937/2378-3516/1410009]; Adamiak N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.746235; Albuquerque L, 2016, SYST APPL MICROBIOL, V39, P100, DOI 10.1016/j.syapm.2015.12.004; Albuquerque L, 2012, SYST APPL MICROBIOL, V35, P368, DOI 10.1016/j.syapm.2012.06.005; Aminov RI, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00042; Aponte M, 2010, LETT APPL MICROBIOL, V51, P697, DOI 10.1111/j.1472-765X.2010.02956.x; Bang C, 2015, FEMS MICROBIOL REV, V39, P631, DOI 10.1093/femsre/fuv010; Bang C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099411; Borrel G, 2020, NAT REV MICROBIOL, V18, P622, DOI 10.1038/s41579-020-0407-y; Caporaso JG, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-5-r50; Cavicchioli R, 2011, NAT REV MICROBIOL, V9, P51, DOI 10.1038/nrmicro2482; Chaudhary PP, 2018, APPL MICROBIOL BIOT, V102, P3095, DOI 10.1007/s00253-018-8871-2; Coker OO, 2020, GASTROENTEROLOGY, V159, P1459, DOI 10.1053/j.gastro.2020.06.042; Crisan-Dabija R, 2021, HEALTHCARE-BASEL, V9, DOI 10.3390/healthcare9111604; Edbeib MF, 2016, WORLD J MICROB BIOT, V32, P135, DOI 10.1007/s11274-016-2081-9; Gardner A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00924; Gebarowska E, 2018, AEROBIOLOGIA, V34, P127, DOI 10.1007/s10453-017-9502-6; Gelardi M, 2013, INT J PEDIATR OTORHI, V77, P1818, DOI 10.1016/j.ijporl.2013.08.013; Gorny RL, 2020, J ENVIRON HEALTH SCI, V18, P1437, DOI 10.1007/s40201-020-00559-9; Haghi F, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6115-1; Hulcr J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047712; Khelaifia S, 2018, EXTREMOPHILES, V22, P485, DOI 10.1007/s00792-018-1011-1; Kim JY, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-00894-x; Klechevsky E, 2015, ADV EXP MED BIOL, V850, P43, DOI 10.1007/978-3-319-15774-0_4; Kowalewicz-Kulbat M, 2018, VACCINE, V36, P4566, DOI 10.1016/j.vaccine.2018.05.068; Lecours PB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087734; Lecours PB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023326; Lee HS, 2013, J MICROBIOL BIOTECHN, V23, P1645, DOI 10.4014/jmb.1308.08015; Messmer D, 2000, J VIROL, V74, P2406, DOI 10.1128/JVI.74.5.2406-2413.2000; Mohammadi A, 2015, BIOTECH HISTOCHEM, V90, P445, DOI 10.3109/10520295.2015.1017536; Oxley APA, 2010, ENVIRON MICROBIOL, V12, P2398, DOI 10.1111/j.1462-2920.2010.02212.x; Pochard P, 2005, J ALLERGY CLIN IMMUN, V116, P198, DOI 10.1016/j.jaci.2005.02.037; Rashleigh R, 2014, INT J CHRONIC OBSTR, V9, P239, DOI 10.2147/COPD.S57511; Ratajczak C, 2007, J BIOMED BIOTECHNOL, DOI 10.1155/2007/71921; Vierbuchen T, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01535; Waisman A, 2017, SEMIN IMMUNOPATHOL, V39, P153, DOI 10.1007/s00281-016-0583-z; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576; Yamabe K, 2008, FEMS MICROBIOL LETT, V287, P69, DOI 10.1111/j.1574-6968.2008.01304.x; Yang SH, 2016, J ASTHMA, V53, P446, DOI 10.3109/02770903.2015.1104692; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zajac J, 2014, ANN AGR ENV MED, V21, P124	41	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								833635	10.3389/fimmu.2022.833635	http://dx.doi.org/10.3389/fimmu.2022.833635			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F3TP	35720372	gold, Green Published			2022-12-18	WOS:000812835200001
J	Li, RX; Zhou, JT; Liu, ZY; Chen, X; Long, QQ; Yang, Y; Lin, SY; Jia, JS; He, GS; Li, JY				Li, Ruixin; Zhou, Jiongtao; Liu, Zhengyuan; Chen, Xi; Long, Qiqiang; Yang, Yan; Lin, Shengyun; Jia, Jinsong; He, Guangsheng; Li, JianYong			Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag	FRONTIERS IN IMMUNOLOGY			English	Article						eltrombopag; intensive immunosuppressive therapy; rabbit antithymocyte immunoglobulin; efficacy; severe aplastic anemia	GLOBULIN; HEMATOPOIESIS; CYCLOSPORINE	Addition of eltrombopag (E-PAG) to intensive immunosuppressive therapy (IST) contributes to restoring hematopoiesis in patients with severe aplastic anemia (SAA). Used at relatively low doses in the East Asian population, the efficacies of E-PAG and the predictors for efficacy are not clear. We conducted a retrospective, multicenter study to analyze the efficacy and the possible predicting factors at 6 months in 58 adult SAA patients with rabbit ATG-based IST and E-PAG. The response rate and complete response rate at 6 months were 76% and 21%, respectively. The baseline reticulocyte percentage [area under a curve (AUC)=0.798, 95% confidence interval (CI) 0.640-0.956, P=0.006], absolute reticulocyte count (ARC) (AUC =0.808, 95%CI 0.647-0.970, P=0.004), red cell distribution width - coefficient of variation (RDW-CV) (AUC=0.722, 95%CI 0.494-0.950, P=0.040), and absolute lymphocyte count (ALC) (AUC=0.706, 95%CI 0.522-0.890, P=0.057) were highly predictive of response at 6 months. The tipping values of reticulocyte percentage, ARC, RDW-CV, and ALC were 0.45%, 7.36x10(9)/L, 11.75%, and 1.06x10(9)/L, respectively. The sensitivity and specificity of reticulocyte percentages were 81.6% and 66.7%; ARC were 86.8% and 66.7%, RDW-CV were 94.7% and 55.6%; ALC were 55.3% and 88.9%. At a median follow-up of 15.5 months, the 2-year cumulative overall survival was 92%. The baseline reticulocyte percentage, ARC, RDW-CV, and ALC were potential factors in predicting a favorable effect of rabbit-ATG based IST plus E-PAG in SAA patients of East Asia (ChiCTR2100045895).	[Li, Ruixin; Zhou, Jiongtao; Liu, Zhengyuan; He, Guangsheng; Li, JianYong] First Affiliated Hosp Nanjing Med Univ, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Dept Hematol, Nanjing, Peoples R China; [Chen, Xi; Long, Qiqiang] Second Hosp Nanjing, Dept Hematol, Nanjing, Peoples R China; [Yang, Yan] First Bethune Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China; [Lin, Shengyun] First Affiliated Hosp Zhejiang Chinese Med Univ, Zhejiang Prov Hosp Tradit Chinese Med, Dept Hematol, Hangzhou, Peoples R China; [Jia, Jinsong] Peking Univ Peoples Hosp, Peking Univ Inst Hematol, Dept Hematol, Beijing, Peoples R China	Nanjing Medical University; Zhejiang Chinese Medical University	He, GS (corresponding author), First Affiliated Hosp Nanjing Med Univ, Jiangsu Prov Hosp, Collaborat Innovat Ctr Canc Personalized Med, Dept Hematol, Nanjing, Peoples R China.	heguangsheng1972@sina.com						Alvarado LJ, 2019, BLOOD, V133, P2043, DOI 10.1182/blood-2018-11-884486; Assi R, 2018, CANCER-AM CANCER SOC, V124, P4192, DOI 10.1002/cncr.31658; Bacigalupo A, 2018, AM J HEMATOL, V93, P643, DOI 10.1002/ajh.25081; Bacigalupo A, 2017, BLOOD, V129, P1428, DOI 10.1182/blood-2016-08-693481; Calado RT, 2008, BLOOD, V111, P4446, DOI 10.1182/blood-2007-08-019729; de Latour RP, 2022, NEW ENGL J MED, V386, P11, DOI 10.1056/NEJMoa2109965; Desmond R, 2014, BLOOD, V123, P1818, DOI 10.1182/blood-2013-10-534743; Fattizzo B, 2019, HAEMATOLOGICA, V104, pE494, DOI 10.3324/haematol.2019.216374; Killick SB, 2016, BRIT J HAEMATOL, V172, P187, DOI 10.1111/bjh.13853; Kojima S, 2000, BLOOD, V96, P2049; Kuter DJ, 2009, ANNU REV MED, V60, P193, DOI 10.1146/annurev.med.60.042307.181154; National Institutes of Health(NIH), 2017, COMMON TERMINOLOGY C; Olnes MJ, 2012, NEW ENGL J MED, V367, P11, DOI 10.1056/NEJMoa1200931; de Oliveira BQ, 2021, BRIT J HAEMATOL, V193, P410, DOI 10.1111/bjh.17140; Rosenfeld S, 2003, JAMA-J AM MED ASSOC, V289, P1130, DOI 10.1001/jama.289.9.1130; Scheinberg P, 2011, NEW ENGL J MED, V365, P430, DOI 10.1056/NEJMoa1103975; Scheinberg P, 2009, BRIT J HAEMATOL, V144, P206, DOI 10.1111/j.1365-2141.2008.07450.x; Schoettler ML, 2018, HEMATOL ONCOL CLIN N, V32, P581, DOI 10.1016/j.hoc.2018.03.001; Sloand E, 2002, BLOOD, V100, P1185, DOI 10.1182/blood-2002-01-0035; Sloand E, 2007, BLOOD, V110, p506A; Sousa R, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0485-0; Sugimori C, 2006, BLOOD, V107, P1308, DOI 10.1182/blood-2005-06-2485; Townsley DM, 2017, NEW ENGL J MED, V376, P1540, DOI 10.1056/NEJMoa1613878; Yagasaki H, 2006, BLOOD, V108, p294A, DOI 10.1182/blood.V108.11.984.984; Yamazaki H, 2019, INT J HEMATOL, V110, P187, DOI 10.1007/s12185-019-02683-1; Young NS, 2018, NEW ENGL J MED, V379, P1643, DOI 10.1056/NEJMra1413485; Zaimoku Y, 2022, HAEMATOLOGICA, V107, P126, DOI 10.3324/haematol.2021.278413	27	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								884312	10.3389/fimmu.2022.884312	http://dx.doi.org/10.3389/fimmu.2022.884312			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F3UW	35720405	Green Published, gold			2022-12-18	WOS:000812838500001
J	Li, Y; Wang, XL; Yang, HX; Li, YL; Gui, JA; Cui, YH				Li, Ying; Wang, Xiaolin; Yang, Hanxue; Li, Yanlin; Gui, Jingang; Cui, Yonghua			Profiles of Proinflammatory Cytokines and T Cells in Patients With Tourette Syndrome: A Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						Tourette syndrome; proinflammatory cytokines; T cell; immunological dysfunction; meta-analysis	NECROSIS-FACTOR-ALPHA; TIC DISORDERS; INTERLEUKIN-12; MACROPHAGES; CHILDREN	BackgroundTic disorder is a neurodevelopmental disorder characterized by motor and phonic tic symptoms. Tourette syndrome (TS) is a subtype of tic disorder that shows more persistent tic symptoms. The etiological mechanism of TS concerning immune dysfunction remains unclear due to limited evidence, especially for pediatric TS patients. MethodIn the present study, a meta-analysis was performed to confirm the identified changes in proinflammatory cytokines and T cells of pediatric TS patients. A total of five databases, including PubMed, Web of Science, PsycINFO, Google Scholar and the China National Knowledge Infrastructure (CNKI), were used for the literature search. The standardized mean difference (SMD) and mean difference (MD) with a 95% confidence interval (CI) were used to present the effect size of each type of proinflammatory cytokine and T cell. Sensitivity analysis, subgroup analysis and meta-regression analysis were used to explore the heterogeneity of the meta-analysis. This meta-analysis was registered in the International Platform of Registered Systematic Review and Meta-analysis Protocols (number: INPLASY2021110079). ResultsIn the 25 studies included in this meta-analysis, thirteen studies focused on the levels of T cells, and twelve studies focused on the levels of proinflammatory cytokines. Based on the random-effects model, the pooled MDs are -1.45 (95% CI: -3.44, 0.54) for CD3 cells, -4.44 (95% CI: -6.80, -2.08) for CD4 cells, and 1.94 (95% CI: -0.08, 3.97) for CD8 cells. The pooled SMDs are1.36 for IL-6 (95% CI: 0.00, 2.72) and 2.39 for tumor necrosis factor alpha (TNF-alpha) (95% CI: 0.93, 3.84). ConclusionWe provided evidence of immune dysfunction in pediatric TS patients, with elevated levels of particular proinflammatory cytokines and disproportionate changes in T-cell subpopulations. Small to large effect sizes were identified for increased IL-6 levels as well as a reduced number of T helper cells, while a large effect size was identified for increased TNF-alpha levels. These results indicate a close association between peripheral immune activation and TS. However, the most direct and meaningful interaction between peripheral immune status and microglial activation in the central nervous system in TS patients requires further exploration.	[Li, Ying; Li, Yanlin; Cui, Yonghua] Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Psychiat, Beijing, Peoples R China; [Wang, Xiaolin; Gui, Jingang] Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Natl Ctr Childrens Hlth,Lab Tumor Immunol, Beijing, Peoples R China; [Yang, Hanxue] Chinese Acad Sci, Inst Psychol, Neuropsychol & Appl Cognit Neurosci Lab, Beijing, Peoples R China; [Yang, Hanxue] Chinese Acad Sci, Inst Psychol, Key Lab Mental Hlth, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Chinese Academy of Sciences; Institute of Psychology, CAS; Chinese Academy of Sciences; Institute of Psychology, CAS	Cui, YH (corresponding author), Capital Med Univ, Beijing Childrens Hosp, Natl Ctr Childrens Hlth, Dept Psychiat, Beijing, Peoples R China.; Gui, JA (corresponding author), Capital Med Univ, Beijing Childrens Hosp, Beijing Pediat Res Inst, Natl Ctr Childrens Hlth,Lab Tumor Immunol, Beijing, Peoples R China.	guijingang@bch.com.cn; cuiyonghua@bch.com.cn	Gui, Jingang/GPW-6809-2022; Yang, Hanxue/GQA-6412-2022	Gui, Jingang/0000-0003-3431-8749; 				American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU, V5th, DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]; [Anonymous], 2015, CHINA HLTH STAND MAN, V6, P124; Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117; Banks WA, 2010, NEUROBIOL DIS, V37, P26, DOI 10.1016/j.nbd.2009.07.031; Billnitzer A, 2020, NEUROTHERAPEUTICS, V17, P1681, DOI 10.1007/s13311-020-00914-6; Black KJ, 2021, CURR DEV DISORD REP, V8, P121, DOI 10.1007/s40474-021-00231-3; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Chen AQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1716-9; Chen Y-Z., 2016, J CLIN RES, V33, P2171; [程德君 Cheng Dejun], 2016, [中华医院感染学杂志, Chinese Journal of Nosocomiology], V26, P4070; Cheng YH, 2012, J MOL NEUROSCI, V48, P219, DOI 10.1007/s12031-012-9811-8; Cohen J., 1988, STAT POWER ANAL BEHA; Copas J, 2000, Biostatistics, V1, P247, DOI 10.1093/biostatistics/1.3.247; Dale RC, 2017, CURR OPIN PEDIATR, V29, P665, DOI 10.1097/MOP.0000000000000546; Dehning S, 2009, J CLIN PSYCHIAT, V70, P1606, DOI 10.4088/JCP.08l04321whi; Domenech L, 2021, PSYCHOL MED, V51, P2201, DOI 10.1017/S0033291721000234; Dop D, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9526; Fan F., 2017, JINAGSU MED J, V43, P1005; Frick L, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8606057; Fujihara K, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000841; Gabbay V, 2009, PROG NEURO-PSYCHOPH, V33, P967, DOI 10.1016/j.pnpbp.2009.05.001; Gao C., 2016, CHIN J DIFFICULT COM, V15, P1259; Groth C, 2019, J CHILD NEUROL, V34, P913, DOI 10.1177/0883073819867245; Hao L-Y., 2018, CLIN EFFICACY AFFECT; Hoekstra PJ, 2013, NEUROSCI BIOBEHAV R, V37, P1040, DOI 10.1016/j.neubiorev.2012.10.010; Hou Xiao-Jun, 2018, Zhongguo Dang Dai Er Ke Za Zhi, V20, P519; Hsu CJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020853; Huang CY, 2020, CHINESE J PHYSIOL, V63, P7, DOI 10.4103/CJP.CJP_75_19; Ji J-P, 2011, STUDY RELATIONSHIP T; Jones HF, 2021, BRAIN BEHAV IMMUN, V94, P308, DOI 10.1016/j.bbi.2020.12.035; Kaji R, 2018, J DAIRY SCI, V101, P2838, DOI 10.3168/jds.2017-13868; Kawikova I, 2007, BIOL PSYCHIAT, V61, P273, DOI 10.1016/j.biopsych.2006.06.012; Kleimaker M, 2020, BRAIN, V143, P1934, DOI 10.1093/brain/awaa111; Lamothe H, 2021, EUR J NEUROL, V28, P3187, DOI 10.1111/ene.14983; Leckman JF, 2005, BIOL PSYCHIAT, V57, P667, DOI 10.1016/j.biopsych.2004.12.004; Lennington JB, 2016, BIOL PSYCHIAT, V79, P372, DOI 10.1016/j.biopsych.2014.07.018; Li EZ, 2015, CHILD NERV SYST, V31, P1157, DOI 10.1007/s00381-015-2692-8; Li N., 2013, CHIN J CHILD HLTH CA, V21, P688; Liu H., 2020, CHIN J REPROD HLTH, V31, P440; Liu XM, 2021, INT J DEV NEUROSCI, V81, P159, DOI 10.1002/jdn.10085; [刘张 Liu Zhang], 2013, [中国现代医学杂志, China Journal of Modern Medicine], V23, P101; Lu Y., 2007, CLIN FOCUS, V14, P1022; Luo J-X., 2014, ACAD J SHANGHAI U TR, V28, P44; Ma S-W., 2021, MED INNOVATION CHINA, V18, P5; Ma Xiaojing, 2015, F1000Res, V4, DOI 10.12688/f1000research.7010.1; Mao Y-Y, 2007, THESIS JILIN U JILIN; Martino D, 2011, DEV MED CHILD NEUROL, V53, P951, DOI 10.1111/j.1469-8749.2011.04018.x; Matz J, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-29; Moller JC, 2008, EUR J NEUROL, V15, P749, DOI 10.1111/j.1468-1331.2008.02159.x; Naro A, 2020, PROG NEUROBIOL, V194, DOI 10.1016/j.pneurobio.2020.101884; Pranzatelli MR, 2017, CYTOKINE, V96, P49, DOI 10.1016/j.cyto.2017.03.003; Quigley JM, 2019, J EVAL CLIN PRACT, V25, P44, DOI 10.1111/jep.12889; Riazi K, 2008, P NATL ACAD SCI USA, V105, P17151, DOI 10.1073/pnas.0806682105; Rizzo R, 2018, FRONT PSYCHIATRY, V9, DOI 10.3389/fpsyt.2018.00100; Scahill L, 2014, J OBSESS-COMPULS REL, V3, P394, DOI 10.1016/j.jocrd.2014.06.002; Schnell J, 2022, BRAIN BEHAV IMMUN, V99, P281, DOI 10.1016/j.bbi.2021.10.012; Schrag AE, 2022, NEUROLOGY, V98, pE1175, DOI 10.1212/WNL.0000000000013298; Sonar SA, 2017, IMMUNOL CELL BIOL, V95, P843, DOI 10.1038/icb.2017.56; Swedo SE, 2010, NEUROLOGY, V74, P1397, DOI 10.1212/WNL.0b013e3181d8a638; Tang Hai-Xia, 2014, Zhongguo Zhong Xi Yi Jie He Za Zhi, V34, P435; Tsai CS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003347; Ueda K, 2021, CURR DEV DISORD REP, V8, P112, DOI 10.1007/s40474-021-00230-4; Williams V, 2020, BMJ EVID-BASED MED, V25, P9, DOI 10.1136/bmjebm-2018-111132; Yildirim Z, 2021, NORD J PSYCHIAT, V75, P18, DOI 10.1080/08039488.2020.1779808; [张建昭 Zhang Jianzhao], 2014, [中华精神科杂志, Chinese Journal of Psychiatry], V47, P95; Zhang S, 2008, THESIS JILIN U JILIN	66	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								843247	10.3389/fimmu.2022.843247	http://dx.doi.org/10.3389/fimmu.2022.843247			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6EW	35693824	Green Published, gold			2022-12-18	WOS:000808236700001
J	Liu, GQ; He, GS; Zhang, J; Zhang, ZM; Wang, L				Liu, Guoqiang; He, Guisong; Zhang, Jie; Zhang, Zhongmin; Wang, Liang			Identification of SCRG1 as a Potential Therapeutic Target for Human Synovial Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						osteoarthritis; synovium; SCRG1; LASSO; pharmaceutical therapy	OSTEOARTHRITIS YEAR; EPIDEMIOLOGY; CHONDROCYTE; EXPRESSION; SCRAPIE; PROTEIN; IL-17; GENE	Synovial inflammation of joint tissue is the most important cause of tissue damage, joint destruction, and disability and is associated with higher morbidity or mortality. Therefore, this study aims to identify key genes in osteoarthritis synovitis tissue to increase our understanding of the underlying mechanisms of osteoarthritis and identify new therapeutic targets. Five GEO datasets with a total of 41 normal synovial membrane tissues and 45 osteoarthritis synovial membrane samples were used for analysis, and seven common differential genes were identified. The classification model constructed by LASSO analysis showed that six genes including CDKN1A, FOSB, STMN2, SLC2A3, TAC, and SCRG1 can be used as biomarkers of osteoarthritis, and the SCRG1 gene shows importance in osteoarthritis. Furthermore, drug database enrichment found that these six DEGs may be the drug targets of synovitis in osteoarthritis, and Valproic Acid CTD 00006977 may be a potential targeted therapeutic drug of SCRG1. Spearman correlation analysis was performed on the SCRG1 gene, and 27 genes with consistent expression were obtained. Functional analysis showed that 27 genes were mainly involved in metabolism, complement, antigen presentation, apoptosis, and regulation of immune pathways. The co-regulatory network of TFs-miRNA suggested that the SCRG1 gene may be regulated by hsa-miR-363-3p miRNA. In conclusion, SCRG1, as a diagnostic marker of osteoarthritis, co-regulates immune-related pathways through the interaction of related proteins, playing an important role in the occurrence and development of osteoarthritis, which may be a novel drug target.	[Liu, Guoqiang; Zhang, Jie; Zhang, Zhongmin; Wang, Liang] Southern Med Univ, Affiliated Hosp 3, Acad Orthoped, Dept Orthoped, Guangzhou, Peoples R China; [He, Guisong] Guangzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Guangzhou, Peoples R China; [Zhang, Zhongmin] Southern Med Univ, Nanfang Hosp, Dept Orthoped, Div Spine Surg, Guangzhou, Peoples R China	Southern Medical University - China; Guangzhou Medical University; Southern Medical University - China	Zhang, ZM; Wang, L (corresponding author), Southern Med Univ, Affiliated Hosp 3, Acad Orthoped, Dept Orthoped, Guangzhou, Peoples R China.; Zhang, ZM (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Orthoped, Div Spine Surg, Guangzhou, Peoples R China.	nfzzm@163.com; liang091@aliyun.com						Aomatsu E, 2014, SCI REP-UK, V4, DOI 10.1038/srep03652; Bannuru RR, 2019, OSTEOARTHR CARTILAGE, V27, P1578, DOI 10.1016/j.joca.2019.06.011; Benderdour M, 2002, J RHEUMATOL, V29, P1262; Berenbaum F, 2013, OSTEOARTHR CARTILAGE, V21, P16, DOI 10.1016/j.joca.2012.11.012; Chang HZ, 2020, PEERJ, V8, DOI 10.7717/peerj.10120; Choi WS, 2019, NATURE, V566, P254, DOI 10.1038/s41586-019-0920-1; Chow YY, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8293921; Coryell PR, 2021, NAT REV RHEUMATOL, V17, P47, DOI 10.1038/s41584-020-00533-7; Dandoy-Dron F, 2003, EUR J NEUROSCI, V18, P2449, DOI 10.1046/j.1460-9568.2003.03009.x; Dandoy-Dron F, 1998, J BIOL CHEM, V273, P7691, DOI 10.1074/jbc.273.13.7691; de la Rica L, 2013, J AUTOIMMUN, V41, P6, DOI 10.1016/j.jaut.2012.12.005; Ding L, 2010, OSTEOARTHR CARTILAGE, V18, P1509, DOI 10.1016/j.joca.2010.08.014; Dron M, 2005, EUR J NEUROSCI, V22, P133, DOI 10.1111/j.1460-9568.2005.04172.x; Dron M, 2000, GENOMICS, V70, P140, DOI 10.1006/geno.2000.6358; Dron M, 2006, AUTOPHAGY, V2, P58, DOI 10.4161/auto.2228; Faust HJ, 2020, J CLIN INVEST, V130, P5493, DOI 10.1172/JCI134091; Goldring MB, 2011, CURR OPIN RHEUMATOL, V23, P471, DOI 10.1097/BOR.0b013e328349c2b1; Goodwin W, 2010, J ORTHOP RES, V28, P1057, DOI 10.1002/jor.21091; Inoue M, 2017, MOL MED REP, V15, P4069, DOI 10.3892/mmr.2017.6492; Jiang L, 2020, HEREDITAS, V157, DOI 10.1186/s41065-020-00128-y; Kim G, 2020, OSTEOARTHR CARTILAGE, V28, pS123; Kloppenburg M, 2020, OSTEOARTHR CARTILAGE, V28, P242, DOI 10.1016/j.joca.2020.01.002; Kroon FPB, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen-2018-000734; Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584-020-00518-6; Lee BC, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-01920-3; Li CS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157876; Loeser RF, 2012, ARTHRITIS RHEUM-US, V64, P1697, DOI 10.1002/art.34453; Mathiessen A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1229-9; Monteagudo S, 2018, NAT REV RHEUMATOL, V14, P563, DOI 10.1038/s41584-018-0076-7; Murphy CA, 2019, ANNU REV BIOMED ENG, V21, P495, DOI 10.1146/annurev-bioeng-060418-052547; Naot D, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100287; Nishimura H, 2020, J NEUROENDOCRINOL, V32, DOI 10.1111/jne.12892; Ochi K, 2006, OSTEOARTHR CARTILAGE, V14, P30, DOI 10.1016/j.joca.2005.07.015; Pelletier JP, 2016, SEMIN ARTHRITIS RHEU, V45, pS22, DOI 10.1016/j.semarthrit.2015.11.009; Reynard LN, 2020, OSTEOARTHR CARTILAGE, V28, P275, DOI 10.1016/j.joca.2019.11.010; Savvidou O, 2019, MOL CELL ENDOCRINOL, V480, P153, DOI 10.1016/j.mce.2018.11.001; Scanzello CR, 2012, BONE, V51, P249, DOI 10.1016/j.bone.2012.02.012; Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159; Stampella A, 2017, BEST PRACT RES CL RH, V31, P721, DOI 10.1016/j.berh.2018.03.004; Stanaway JD, 2018, LANCET, V392, P1923, DOI 10.1016/s0140-6736(18)32225-6; Tanideh N, 2021, ARTIF ORGANS, V45, P1405, DOI 10.1111/aor.14026; Tavallaee G, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00376; Tecchio C, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00508; Tuerlings M, 2021, ARTHRITIS RHEUMATOL, V73, P789, DOI 10.1002/art.41600; van den Berg WB, 2011, OSTEOARTHR CARTILAGE, V19, P338, DOI 10.1016/j.joca.2011.01.022; Vina ER, 2018, CURR OPIN RHEUMATOL, V30, P160, DOI 10.1097/BOR.0000000000000479; Wang QY, 2017, J CELL BIOCHEM, V118, P3775, DOI 10.1002/jcb.26025; Xie JW, 2021, AGEING RES REV, V70, DOI 10.1016/j.arr.2021.101413; Xie JX, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9761; Yang H, 2020, AGING-US, V12, P12750, DOI 10.18632/aging.103177; Zhang RQ, 2019, MOL MED REP, V19, P30, DOI 10.3892/mmr.2018.9677; Zhang W, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00431; Zhao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.665442; Zhou F, 2019, ACTA PHARM SIN B, V9, P973, DOI 10.1016/j.apsb.2019.01.015; Zuo B, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193823	55	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								893301	10.3389/fimmu.2022.893301	http://dx.doi.org/10.3389/fimmu.2022.893301			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2SA	35720295	gold, Green Published			2022-12-18	WOS:000812762100001
J	Lu, G; Zheng, FY; Ou, JJ; Yin, X; Li, SJ				Lu, Gang; Zheng, Feiyan; Ou, Jiajun; Yin, Xin; Li, Shoujun			Investigating Influenza Virus Polymerase Activity in Feline Cells Based on the Influenza Virus Minigenome Replication System Driven by the Feline RNA Polymerase I Promoter	FRONTIERS IN IMMUNOLOGY			English	Article						RNA polymerase I promoter; feline; influenza virus; polymerase activity; minigenome replication system	REVERSE-GENETICS SYSTEM; A-VIRUS; SPECIES-SPECIFICITY; TRANSCRIPTION; ESTABLISHMENT; CLONING	Emerging influenza virus poses a health threat to humans and animals. Domestic cats have recently been identified as a potential source of zoonotic influenza virus. The influenza virus minigenome replication system based on the ribonucleic acid (RNA) polymerase I (PolI) promoter is the most widely used tool for investigating polymerase activity. It could help determine host factors or viral proteins influencing influenza virus polymerase activity in vitro. However, influenza virus polymerase activity has never been studied in feline cells thus far. In the present study, the feline RNA PolI promoter was identified in the intergenic spacer regions between adjacent upstream 28S and downstream 18S rRNA genes in the cat (Felis catus) genome using bioinformatics strategies. The transcription initiation site of the feline RNA PolI promoter was predicted. The feline RNA PolI promoter was cloned from CRFK cells, and a promoter size of 250 bp contained a sequence with sufficient PolI promoter activity by a dual-luciferase reporter assay. The influenza virus minigenome replication system based on the feline RNA PolI promoter was then established. Using this system, the feline RNA PolI promoter was determined to have significantly higher transcriptional activity than the human and chicken RNA PolI promoters in feline cells, and equine (H3N8) influenza virus presented higher polymerase activity than human (H1N1) and canine (H3N2) influenza viruses. In addition, feline myxovirus resistance protein 1 (Mx1) and baloxavir were observed to inhibit influenza virus polymerase activity in vitro in a dose-dependent manner. Our study will help further investigations on the molecular mechanism of host adaptation and cross-species transmission of influenza virus in cats.	[Lu, Gang; Zheng, Feiyan; Ou, Jiajun; Li, Shoujun] South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China; [Yin, Xin] Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China; [Li, Shoujun] Guangdong Prov Key Lab Prevent & Control Severe Cl, Guangzhou, Peoples R China; [Li, Shoujun] Guangdong Technol Engn Res Ctr Pet, Guangzhou, Peoples R China	South China Agricultural University; Chinese Academy of Agricultural Sciences; Harbin Veterinary Research Institute, CAAS	Li, SJ (corresponding author), South China Agr Univ, Coll Vet Med, Guangzhou, Peoples R China.; Yin, X (corresponding author), Chinese Acad Agr Sci, Harbin Vet Res Inst, State Key Lab Vet Biotechnol, Harbin, Peoples R China.; Li, SJ (corresponding author), Guangdong Prov Key Lab Prevent & Control Severe Cl, Guangzhou, Peoples R China.; Li, SJ (corresponding author), Guangdong Technol Engn Res Ctr Pet, Guangzhou, Peoples R China.	yinxin@caas.cn; shoujunli@scau.edu.cn	Ou, Jiajun/GYQ-8851-2022		Natural Science Foundation of Guangdong Province [2018B030311037]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	Funding This work was supported by Natural Science Foundation of Guangdong Province (2018B030311037).	Campagnolo ER, 2011, ZOONOSES PUBLIC HLTH, V58, P500, DOI 10.1111/j.1863-2378.2011.01390.x; de Wit E, 2007, J GEN VIROL, V88, P1281, DOI 10.1099/vir.0.82452-0; Eberhard D, 1996, DNA CELL BIOL, V15, P167, DOI 10.1089/dna.1996.15.167; Hatta M, 2018, EMERG INFECT DIS, V24, P75, DOI 10.3201/eid2401.171240; Heix J, 1997, P NATL ACAD SCI USA, V94, P1733, DOI 10.1073/pnas.94.5.1733; HEIX J, 1995, CURR OPIN GENET DEV, V5, P652, DOI 10.1016/0959-437X(95)80035-2; Hempel WM, 1996, MOL CELL BIOL, V16, P557; Hoffmann E, 2000, P NATL ACAD SCI USA, V97, P6108, DOI 10.1073/pnas.100133697; Kirui J, 2014, J VIROL, V88, P5977, DOI 10.1128/JVI.00508-14; Leschnik M, 2007, EMERG INFECT DIS, V13, P243, DOI 10.3201/eid1302.060608; Lu G, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060119; Marinova-Petkova A, 2017, EMERG INFECT DIS, V23, P2046, DOI 10.3201/eid2312.170798; Massin P, 2005, J VIROL, V79, P13811, DOI 10.1128/JVI.79.21.13811-13816.2005; Mondal A, 2017, ELIFE, V6, DOI 10.7554/eLife.26910; Murakami S, 2008, J VIROL, V82, P1605, DOI 10.1128/JVI.01876-07; Song DS, 2011, J GEN VIROL, V92, P2350, DOI 10.1099/vir.0.033522-0; Song MS, 2013, J GEN VIROL, V94, P1230, DOI 10.1099/vir.0.051284-0; Sponseller BA, 2010, EMERG INFECT DIS, V16, P534, DOI 10.3201/eid1603.091737; Su S, 2014, EMERG INFECT DIS, V20, P2096, DOI 10.3201/eid2012.140867; Taft AS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8491; Wang K, 2017, VIRUS GENES, V53, P661, DOI 10.1007/s11262-017-1457-8; Wang ZT, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-102; Yamayoshi S, 2014, J VIROL, V88, P3127, DOI 10.1128/JVI.03155-13; Yu ZJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep10704; Zhong GX, 2018, J VIROL, V92, DOI 10.1128/JVI.01557-17	25	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								827681	10.3389/fimmu.2022.827681	http://dx.doi.org/10.3389/fimmu.2022.827681			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Z1UX	35693765	gold, Green Published			2022-12-18	WOS:000808619000001
J	Lu, JJ; Wang, Y; Li, Y; Zhong, XY; Gong, Y; Ding, YF; Yu, N; Shi, YL				Lu, Jiajing; Wang, Yu; Li, Ying; Zhong, Xiaoyuan; Gong, Yu; Ding, Yangfeng; Yu, Ning; Shi, Yuling			Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated With Guselkumab for Psoriasis	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; guselkumab; RNA-seq; biomarkers; neutrophils	MODERATE; CXCL17; CELLS	Psoriasis is a worldwide chronic inflammatory skin disease. The treatment of disease is usually designed according to its severity. In this research, RNA-seq was performed on 37 patients with psoriasis treated with guselkumab before and after treatment, and the patients were divided into fast responder and slow responder according to PASI score to analyze the differentially expressed genes (DEGs) between them. Moreover, The biological mechanism of psoriasis was explored by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, Gene Ontology (GO) analysis, and Gene Set Enrichment Analysis (GSEA) analysis. And then, this protein-protein interaction network was constructed and 17 DEGs including IL-1 beta, CXCL8, S100A12 and MMP9 were analyzed by GSVA. DEGs were detected by GO and KEGG analysis of target genes, which were primarily associated with immune response, neutrophil activation, neutrophil degranulation. GSEA reminded that fast responders were mainly involved in low-density neutrophils and abundant NK cells. And the GSVA showed that the DEGs were down-regulated after the early stage of the fast responder and the reverse in the slow responder by GSVA analysis. On the whole, these results indicated that these DEGs may serve as a psoriasis potential diagnostic and predictive biomarkers after been treated by guselkumab.	[Lu, Jiajing; Wang, Yu; Li, Ying; Zhong, Xiaoyuan; Gong, Yu; Ding, Yangfeng; Yu, Ning; Shi, Yuling] Tongji Univ, Shanghai Skin Dis Hosp, Sch Med, Dept Dermatol, Shanghai, Peoples R China; [Lu, Jiajing; Wang, Yu; Li, Ying; Zhong, Xiaoyuan; Gong, Yu; Ding, Yangfeng; Yu, Ning; Shi, Yuling] Tongji Univ, Inst Psoriasis, Sch Med, Shanghai, Peoples R China	Tongji University; Tongji University	Yu, N; Shi, YL (corresponding author), Tongji Univ, Shanghai Skin Dis Hosp, Sch Med, Dept Dermatol, Shanghai, Peoples R China.; Yu, N; Shi, YL (corresponding author), Tongji Univ, Inst Psoriasis, Sch Med, Shanghai, Peoples R China.	bonyuyu@163.com; shiyuling1973@tongji.edu.cn			National Natural Science Foundation of China [81872522, 82073429]; Youth Program of National Natural Science Foundation of China [82003335, 81803120]; Innovation Program of Shanghai Municipal Education Commission; Program of Science and Excellent Subject Leader Program of Shanghai Municipal Commission of Health and Family Planning [2018BR30]; Technology Commission of Shanghai Municipality [18140901800]; Clinical Research Program of Shanghai Hospital Development Center [SHDC2020CR1014B, SHDC12018X06]; Program of Shanghai Academic Research Leader [20XD1403300]; National Key Research and Development Program of China [2018YFC1705301, 2018YFC1705305, lcfy2020-02]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Program of National Natural Science Foundation of China; Innovation Program of Shanghai Municipal Education Commission(Innovation Program of Shanghai Municipal Education Commission); Program of Science and Excellent Subject Leader Program of Shanghai Municipal Commission of Health and Family Planning; Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Clinical Research Program of Shanghai Hospital Development Center; Program of Shanghai Academic Research Leader; National Key Research and Development Program of China	This work was sponsored by grants from National Natural Science Foundation of China (No.81872522, 82073429), Youth Program of National Natural Science Foundation of China (No.82003335, 81803120). Innovation Program of Shanghai Municipal Education Commission (No.2019-01-07-00-07-E00046), the Program of Science and Excellent Subject Leader Program of Shanghai Municipal Commission of Health and Family Planning (No. 2018BR30), Technology Commission of Shanghai Municipality (No. 18140901800), Clinical Research Program of Shanghai Hospital Development Center (No. SHDC2020CR1014B, SHDC12018X06), Program of Shanghai Academic Research Leader (No. 20XD1403300) and The National Key Research and Development Program of China (no. 2018YFC1705301, 2018YFC1705305), Clinical training program (lcfy2020-02).	Choreno-Parra JA, 2020, CYTOKINE GROWTH F R, V53, P53, DOI 10.1016/j.cytogfr.2020.04.004; Bai F, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2546161; Blauvelt A, 2017, J AM ACAD DERMATOL, V76, P405, DOI 10.1016/j.jaad.2016.11.041; Choudhary S, 2021, INT J MOL MED, V47, P219, DOI 10.3892/ijmm.2020.4771; Choudhary S, 2020, CURR PHARM DESIGN, V26, P3619, DOI 10.2174/1381612826666200311130133; Fan FX, 2021, PEERJ, V9, DOI 10.7717/peerj.11018; Gao LJ, 2020, DERMATOL THER, V33, DOI 10.1111/dth.13993; Greb JE, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.82; Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013; Lebwohl M, 2015, NEW ENGL J MED, V373, P1318, DOI 10.1056/NEJMoa1503824; Lepore F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02750; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Ma Bing-Zhi, 2021, Zhongguo Zhong Yao Za Zhi, V46, P5330, DOI 10.19540/j.cnki.cjcmm.20210703.401; Oka T, 2017, J IMMUNOL, V198, P3897, DOI 10.4049/jimmunol.1601607; Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475; Sigurdardottir G, 2018, DERMATOLOGY, V234, P173, DOI 10.1159/000491819; Sofen H, 2014, J ALLERGY CLIN IMMUN, V133, P1032, DOI 10.1016/j.jaci.2014.01.025; Swindell WR, 2016, J INVEST DERMATOL, V136, P1820, DOI 10.1016/j.jid.2016.04.035; Tang L, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.579625; van Lieshout AWT, 2009, ANN RHEUM DIS, V68, P1036, DOI 10.1136/ard.2007.086611; Verma D, 2021, J INVEST DERMATOL, V141, P586, DOI 10.1016/j.jid.2020.07.012	21	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								865875	10.3389/fimmu.2022.865875	http://dx.doi.org/10.3389/fimmu.2022.865875			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6OX	35693833	gold, Green Published			2022-12-18	WOS:000808262800001
J	Maliekal, TT; Dharmapal, D; Sengupta, S				Maliekal, Tessy Thomas; Dharmapal, Dhrishya; Sengupta, Suparna			Tubulin Isotypes: Emerging Roles in Defining Cancer Stem Cell Niche	FRONTIERS IN IMMUNOLOGY			English	Review						tubulin; tubulin-interacting proteins; cancer stem cell niche; metabolic reprogramming; immune evasion; GLUT1; GRP78; EphrinB1	GLUCOSE-TRANSPORTER GLUT1; ALPHA-TUBULIN; IMMUNE EVASION; UP-REGULATION; SELF-RENEWAL; EXPRESSION; ACETYLATION; PROMOTES; BINDING; PROTEINS	Although the role of microtubule dynamics in cancer progression is well-established, the roles of tubulin isotypes, their cargos and their specific function in the induction and sustenance of cancer stem cells (CSCs) were poorly explored. But emerging reports urge to focus on the transport function of tubulin isotypes in defining orchestrated expression of functionally critical molecules in establishing a stem cell niche, which is the key for CSC regulation. In this review, we summarize the role of specific tubulin isotypes in the transport of functional molecules that regulate metabolic reprogramming, which leads to the induction of CSCs and immune evasion. Recently, the surface expression of GLUT1 and GRP78 as well as voltage-dependent anion channel (VDAC) permeability, regulated by specific isotypes of beta-tubulins have been shown to impart CSC properties to cancer cells, by implementing a metabolic reprogramming. Moreover, beta IVb tubulin is shown to be critical in modulating EphrinB1signaling to sustain CSCs in oral carcinoma. These tubulin-interacting molecules, Ephrins, GLUT1 and GRP78, are also important regulators of immune evasion, by evoking PD-L1 mediated T-cell suppression. Thus, the recent advances in the field implicate that tubulins play a role in the controlled transport of molecules involved in CSC niche. The indication of tubulin isotypes in the regulation of CSCs offers a strategy to specifically target those tubulin isotypes to eliminate CSCs, rather than the general inhibition of microtubules, which usually leads to therapy resistance.	[Maliekal, Tessy Thomas; Dharmapal, Dhrishya; Sengupta, Suparna] Rajiv Gandhi Ctr Biotechnol, Canc Res, Thiruvananthapuram, India; [Maliekal, Tessy Thomas; Sengupta, Suparna] Reg Ctr Biotechnol, Faridabad, India; [Dharmapal, Dhrishya; Sengupta, Suparna] Univ Kerala, Dept Biotechnol, Thiruvananthapuram, India	Department of Biotechnology (DBT) India; Rajiv Gandhi Centre for Biotechnology (RGCB); Department of Biotechnology (DBT) India; Regional Centre for Biotechnology; University of Kerala	Maliekal, TT; Sengupta, S (corresponding author), Rajiv Gandhi Ctr Biotechnol, Canc Res, Thiruvananthapuram, India.; Maliekal, TT; Sengupta, S (corresponding author), Reg Ctr Biotechnol, Faridabad, India.; Sengupta, S (corresponding author), Univ Kerala, Dept Biotechnol, Thiruvananthapuram, India.				Department of Biotechnology; Department of Science and Technology [SR/S0/HS/0133/2010]; Department of Biotechnology [BT/PR14379/Med/30/536/2010]; University Grants Commission [22/06/2014]; Indian Council of Medical Research, Government of India [3/2/2/39/2020-NCD-III]	Department of Biotechnology; Department of Science and Technology(Department of Science & Technology (India)); Department of Biotechnology; University Grants Commission(University Grants Commission, India); Indian Council of Medical Research, Government of India(Indian Council of Medical Research (ICMR))	The work was supported by the institutional core funding from the Department of Biotechnology to SS and TM; and extramural grant to TM from Department of Science and Technology (SR/S0/HS/0133/2010) and Department of Biotechnology (BT/PR14379/Med/30/536/2010). DD is thankful to the University Grants Commission (22/06/2014(i)EU-V) and Indian Council of Medical Research (3/2/2/39/2020-NCD-III), Government of India, for fellowship supports.	Abbassi RH, 2019, ACS PHARMACOL TRANSL, V2, P402, DOI 10.1021/acsptsci.9b00045; Aguilar E, 2016, STEM CELLS, V34, P1163, DOI 10.1002/stem.2286; Ai XL, 2017, MOL CELL BIOCHEM, V428, P109, DOI 10.1007/s11010-016-2921-9; Akhmanova A, 2010, CURR OPIN CELL BIOL, V22, P479, DOI 10.1016/j.ceb.2010.04.008; Alvarez-Trotta A, 2021, CANCER RES, V81, P3347, DOI 10.1158/0008-5472.CAN-20-3611; Bao LS, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.773028; Barlan K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a025817; Barr FA, 2005, J CELL BIOL, V168, P993, DOI 10.1083/jcb.200501088; Martin-Cofreces NB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01174; Bodakuntla S, 2019, TRENDS CELL BIOL, V29, P804, DOI 10.1016/j.tcb.2019.07.004; Boggs AE, 2015, CANCER RES, V75, P203, DOI 10.1158/0008-5472.CAN-13-3563; Bracey K, 2008, J MEMBRANE BIOL, V222, P115, DOI 10.1007/s00232-008-9104-x; Cai HB, 2019, J CANCER RES THER, V15, P1547, DOI 10.4103/jcrt.JCRT_482_17; Carre M, 2002, J BIOL CHEM, V277, P33664, DOI 10.1074/jbc.M203834200; Chakraborty S, 2010, INDIA J SURG ONCOL, V1, P284, DOI 10.1007/s13193-011-0054-x; Chen L, 2020, HEREDITAS, V157, DOI 10.1186/s41065-020-00152-y; Chen XH, 2021, ONCOTARGETS THER, V14, P3069, DOI 10.2147/OTT.S300423; Chou CW, 2020, AM J CANCER RES, V10, P2621; Christoph DC, 2012, BRIT J CANCER, V107, P823, DOI 10.1038/bjc.2012.324; Cicchillitti L, 2008, MOL CANCER THER, V7, P2070, DOI 10.1158/1535-7163.MCT-07-2370; Deng SS, 2020, MOL CANCER THER, V19, P348, DOI 10.1158/1535-7163.MCT-19-0536; Dharmapal D, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.788024; Downing KH, 2000, ANNU REV CELL DEV BI, V16, P89, DOI 10.1146/annurev.cellbio.16.1.89; Du Y, 2019, STEM CELLS, V37, P865, DOI 10.1002/stem.3013; Fan CM, 2021, SCI CHINA LIFE SCI, V64, P534, DOI 10.1007/s11427-019-1735-4; Fang WY, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-32; Fong A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030586; Gadadhar Sudarshan, 2023, Semin Cell Dev Biol, V137, P26, DOI 10.1016/j.semcdb.2021.12.003; Gadau S, 2008, ARCH ITAL BIOL, V146, P107; Gopal U, 2021, J CELL PHYSIOL, V236, P2352, DOI 10.1002/jcp.30030; Gopal U, 2017, ONCOTARGET, V8, P107947, DOI 10.18632/oncotarget.22431; Guda MR, 2019, CANCERS, V11, DOI 10.3390/cancers11091308; Hamann I, 2018, FASEB J, V32, P5104, DOI 10.1096/fj.201800360R; Han YS, 2011, GASTROENT RES PRACT, V2011, DOI 10.1155/2011/561719; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; Hasegawa S, 2003, CLIN CANCER RES, V9, P2992; Huang X, 2012, GENE DEV, V26, P1780, DOI 10.1101/gad.193789.112; Im S, 2013, KOREAN J PATHOL, V47, P534, DOI 10.4132/KoreanJPathol.2013.47.6.534; Janke C, 2020, NAT REV MOL CELL BIO, V21, P307, DOI 10.1038/s41580-020-0214-3; Jurewicz E, 2018, CELL SIGNAL, V42, P21, DOI 10.1016/j.cellsig.2017.10.004; Kanakkanthara A, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188607; Kang EY, 2008, CELL COMMUN ADHES, V15, P397, DOI 10.1080/15419060902783833; Kareva I, 2013, CANCER RES, V73, P2737, DOI 10.1158/0008-5472.CAN-12-3696; Kazan JM, 2019, CANCERS, V11, DOI 10.3390/cancers11040460; Kim H, 2020, FEBS LETT, V594, P1021, DOI 10.1002/1873-3468.13686; Kim J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071691; Konishi Y, 2009, NAT NEUROSCI, V12, P559, DOI 10.1038/nn.2314; Koo BK, 2009, GASTROENTEROLOGY, V137, P145, DOI 10.1053/j.gastro.2009.03.046; Kumar B, 2017, CURR CANCER DRUG TAR, V17, P357, DOI 10.2174/1568009616666160928110818; Kunz TH, 2007, BBA-GEN SUBJECTS, V1770, P1145, DOI 10.1016/j.bbagen.2007.04.002; Lamiche C, 2012, CLIN EXP METASTAS, V29, P111, DOI 10.1007/s10585-011-9434-4; Lane JD, 1999, MOL BIOL CELL, V10, P1909, DOI 10.1091/mbc.10.6.1909; Lei MML, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.692940; Li ZW, 2014, ONCOTARGET, V5, P5369, DOI 10.18632/oncotarget.2105; Liu HY, 2020, EUR J MED CHEM, V200, DOI 10.1016/j.ejmech.2020.112332; Lopes D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112356; Luan JC, 2021, J CANCER, V12, P3715, DOI 10.7150/jca.51059; Maahs L, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222510; Maldonado EN, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00004; Melkov A, 2018, CELL MOL LIFE SCI, V75, P163, DOI 10.1007/s00018-017-2590-1; Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479; Naghavi MH, 2017, J VIROL, V91, DOI 10.1128/JVI.00538-17; Nami B, 2018, CANCERS, V10, DOI 10.3390/cancers10080274; Nienstedt JC, 2017, J ORAL PATHOL MED, V46, P986, DOI 10.1111/jop.12607; Nirschl JJ, 2016, CELL REP, V14, P2637, DOI 10.1016/j.celrep.2016.02.046; Ouiddir A, 1999, AM J RESP CELL MOL, V21, P710, DOI 10.1165/ajrcmb.21.6.3751; Oztop S, 2019, ANTICANCER RES, V39, P655, DOI 10.21873/anticanres.13160; Parker AL, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071434; Parker AL, 2016, CARCINOGENESIS, V37, P787, DOI 10.1093/carcin/bgw058; Parker AL, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00153; Prassanawar SS, 2019, BIOCHEM J, V476, P1359, DOI 10.1042/BCJ20190123; Pu J, 2016, J CELL SCI, V129, P4329, DOI 10.1242/jcs.196287; Puurand M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030239; Reed NA, 2006, CURR BIOL, V16, P2166, DOI 10.1016/j.cub.2006.09.014; Ruksha K, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010025; Sekino Y, 2020, ONCOLOGY-BASEL, V98, P689, DOI 10.1159/000506775; Shen LF, 2020, ONCOTARGETS THER, V13, P11221, DOI 10.2147/OTT.S269767; Shen YA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071772; Shibuya K, 2015, ONCOTARGET, V6, P651, DOI 10.18632/oncotarget.2892; Shin D, 2020, CLIN PROTEOM, V17, DOI 10.1186/s12014-020-09280-z; Sirajuddin M, 2014, NAT CELL BIOL, V16, P335, DOI 10.1038/ncb2920; Sobierajska K, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080810; Spiliotis ET, 2021, TRENDS CELL BIOL, V31, P979, DOI 10.1016/j.tcb.2021.06.004; Tsuchiya H, 2021, REGEN THER, V17, P20, DOI 10.1016/j.reth.2021.02.006; Uchida Y, 2021, FEBS LETT, V595, P563, DOI 10.1002/1873-3468.14032; Vasudevan S, 2015, CARCINOGENESIS, V36, P883, DOI 10.1093/carcin/bgv072; Vemu A, 2017, MOL BIOL CELL, V28, P3564, DOI 10.1091/mbc.E17-02-0124; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Walter WJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042218; Wang QL, 2020, ONCOL REP, V44, P2725, DOI 10.3892/or.2020.7789; Wang Z, 2012, PHARM RES-DORDR, V29, P3040, DOI 10.1007/s11095-012-0726-4; Wattanathamsan O, 2021, CANCER GENE THER, DOI 10.1038/s41417-021-00396-4; Wattanathamsan O, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00453-9; Wawro ME, 2017, CELL SIGNAL, V38, P26, DOI 10.1016/j.cellsig.2017.06.014; Yang WH, 2018, CANCER RES, V78, P3761, DOI 10.1158/0008-5472.CAN-18-0040; Yeh IT, 2004, CELL MOTIL CYTOSKEL, V57, P96, DOI 10.1002/cm.10157; Yeh TS, 2004, CANCER RES, V64, P8334, DOI 10.1158/0008-5472.CAN-04-2197; Yildiz A, 2021, NAT REV MOL CELL BIO, V22, P73, DOI 10.1038/s41580-020-00320-y; Yu L, 2019, MOL CANCER RES, V17, P2383, DOI 10.1158/1541-7786.MCR-19-0493; Zhang Y, 2017, CANCER RES, V77, P3082, DOI 10.1158/0008-5472.CAN-16-1633; Zheng WB, 2020, CANCER BIOL THER, V21, P688, DOI 10.1080/15384047.2020.1762419	101	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								876278	10.3389/fimmu.2022.876278	http://dx.doi.org/10.3389/fimmu.2022.876278			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y7NK	35693789	Green Published, gold			2022-12-18	WOS:000808326600001
J	Meisinger, C; Gosslau, Y; Warm, TD; Leone, V; Hyhlik-Duerr, A; Linseisen, J; Kirchberger, I				Meisinger, Christa; Gosslau, Yvonne; Warm, Tobias D.; Leone, Vincenza; Hyhlik-Duerr, Alexander; Linseisen, Jakob; Kirchberger, Inge			Post-COVID-19 Fatigue and SARS-CoV-2 Specific Humoral and T-Cell Responses in Male and Female Outpatients	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; fatigue; outpatients; T-cells; ELISpot; inflammation		BackgroundInformation on the clinical characteristics and pathophysiological mechanisms underlying post-COVID-19 fatigue are scarce. The main objective of this study was to evaluate sex-specific humoral and T-cell responses associated with post-COVID-19 fatigue in a sample of individuals treated as outpatients. MethodsAt a median time of 279 (179;325) days after the acute infection, a total of 281 individuals (45.9% men) aged 18-87 years old were included in the analysis. The participants were examined at the University Hospital of Augsburg, Southern Germany. Fatigue was assessed using the Fatigue Assessment Scale (FAS). Levels of anti-SARS-CoV2-spike IgG antibodies were measured by an enzyme-linked immunosorbent assay (ELISA), and for exploration of the SARS-CoV2-specific T-cell response, ex vivo ELISpot/FLUOROspot assays were conducted using an interferon-gamma (IFN-gamma) and interleukin-2 (IL-2) SARS-CoV-iSpot kit. ResultsWomen more significantly suffered from post-COVID-19 fatigue in comparison to men (47.4% versus 25.6%, p=0.0002). Females but not males with fatigue showed a significantly lower number of T-cells producing IFN-gamma, IL-2 or both IL-2 and IFN gamma in comparison with females without fatigue. In both sexes, serum levels of anti-SARS-CoV2-spike IgG antibodies did not differ significantly between participants with or without fatigue. ConclusionsDevelopment of fatigue after acute COVID-19 disease might be associated with SARS-CoV-2-specific T-cell responses in women, but not men after a mild infection course treated outpatient.	[Meisinger, Christa; Leone, Vincenza; Linseisen, Jakob; Kirchberger, Inge] Univ Augsburg, Fac Med, Epidemiol, Augsburg, Germany; [Gosslau, Yvonne; Warm, Tobias D.; Hyhlik-Duerr, Alexander] Univ Augsburg, Fac Med, Vasc Surg, Augsburg, Germany; [Linseisen, Jakob; Kirchberger, Inge] Ludwig Maximilians Univ Munchen LMU Munich, Inst Med Informat Proc Biometry & Epidemiol IBE, Munich, Germany	University of Augsburg; University of Augsburg; University of Munich	Meisinger, C (corresponding author), Univ Augsburg, Fac Med, Epidemiol, Augsburg, Germany.	christine.meisinger@med.uni-augsburg.de						[Anonymous], ILDCARE; Bateman L, 2021, MAYO CLIN PROC, V96, P2861, DOI 10.1016/j.mayocp.2021.07.004; Breton G, 2021, J EXP MED, V218, DOI 10.1084/jem.20202515; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Dennehy KM, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9121439; Ganesh R, 2022, MAYO CLIN PROC, V97, P454, DOI 10.1016/j.mayocp.2021.11.033; Gluck V, 2021, INFECTION, V49, P739, DOI 10.1007/s15010-021-01598-6; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Hickie I, 2006, BRIT MED J, V333, P575, DOI 10.1136/bmj.38933.585764.AE; Jilma B, 1997, J LAB CLIN MED, V130, P69, DOI 10.1016/S0022-2143(97)90060-3; Karlsson AC, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe8063; Klimas NG, 2012, BRAIN BEHAV IMMUN, V26, P1202, DOI 10.1016/j.bbi.2012.06.006; Komaroff AL, 2017, P NATL ACAD SCI USA, V114, P8914, DOI 10.1073/pnas.1712475114; Komaroff AL, 2011, SEMIN NEUROL, V31, P325, DOI 10.1055/s-0031-1287654; Kutlubaev MA, 2012, ACTA NEUROL SCAND, V125, P219, DOI 10.1111/j.1600-0404.2011.01618.x; Michielsen HJ, 2003, J PSYCHOSOM RES, V54, P345, DOI 10.1016/S0022-3999(02)00392-6; Milivojevic M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236148; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; PAWLIKOWSKA T, 1994, BRIT MED J, V308, P763, DOI 10.1136/bmj.308.6931.763; Rank A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10153305; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Roerink ME, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0796-7; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI 10.1038/s41564-020-00813-8; Sulheim D, 2014, JAMA PEDIATR, V168, P351, DOI 10.1001/jamapediatrics.2013.4647; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5; Wu SM, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007030.pub3	27	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								902140	10.3389/fimmu.2022.902140	http://dx.doi.org/10.3389/fimmu.2022.902140			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6LU	35693828	gold, Green Published			2022-12-18	WOS:000808254700001
J	Ozieblo, D; Leja, ML; Jeznach, A; Orzechowska, M; Skirecki, T; Wiesik-Szewczyk, E; Furmanek, M; Baldyga, N; Skarzynski, H; Oldak, M				Ozieblo, Dominika; Leja, Marcin L.; Jeznach, Aldona; Orzechowska, Magdalena; Skirecki, Tomasz; Wiesik-Szewczyk, Ewa; Furmanek, Mariusz; Baldyga, Natalia; Skarzynski, Henryk; Oldak, Monika			Hearing Loss as the Main Clinical Presentation in NLRP3-Associated Autoinflammatory Disease	FRONTIERS IN IMMUNOLOGY			English	Article						NLRP3 inflammasome; hearing loss; anakinra; autoinflammation; fluid attenuated inversion recovery (FLAIR); cochlear enhancement; DNA sequencing; interleukin-1	NLRP3 INFLAMMASOME; MUTATION; PROGRESSION; PREVENTION; GUIDELINES; MONOCYTES; ANAKINRA	The NLRP3 gene mutations are the cause of autosomal dominant autoinflammatory disorders (NLRP3-AID). Recently, hearing loss (HL) has been found to be the sole or major manifestation of NLRP3-AID. Here, we tested 110 autosomal dominant HL families with a custom panel of 237 HL genes and found one family carrying the NLRP3 c.1872C>G, p.Ser624Arg mutation. Functional studies revealed that this novel variant is a gain of function mutation, leading to increased activity of caspase-1 and subsequent oversecretion of proinflammatory interleukin-1 beta. Clinical reanalysis of the affected individuals, together with serological evidence of inflammation and pathological cochlear enhancement on FLAIR-MRI images, guided our diagnosis to atypical NLRP3-AID. The study highlights the role of genetic analysis in patients with progressive postlingual HL. This can help to identify individuals with hereditary HL as a consequence of NLRP3-AID and allow timely and effective treatment with interleukin-1-receptor antagonist.	[Ozieblo, Dominika; Leja, Marcin L.; Orzechowska, Magdalena; Baldyga, Natalia; Oldak, Monika] Inst Physiol & Pathol Hearing, Dept Genet, Warsaw, Poland; [Leja, Marcin L.] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland; [Jeznach, Aldona; Skirecki, Tomasz] Ctr Postgrad Med Educ, Lab Flow Cytometry, Warsaw, Poland; [Wiesik-Szewczyk, Ewa] Cent Clin Hosp Minist Natl Def, Mil Inst Med, Dept Internal Med, Pneumonol & Clin Immunol, Warsaw, Poland; [Furmanek, Mariusz] Inst Physiol & Pathol Hearing, Bioimaging Res Ctr, Warsaw, Poland; [Skarzynski, Henryk] Inst Physiol & Pathol Hearing, Oto Rhino Laryngol Surg Clin, Warsaw, Poland	Institute of Physiology & Hearing Pathology; Medical University of Warsaw; Centre of Postgraduate Medical Education - Poland; Military Institute of Aviation Medicine; Institute of Physiology & Hearing Pathology; Institute of Physiology & Hearing Pathology	Oldak, M (corresponding author), Inst Physiol & Pathol Hearing, Dept Genet, Warsaw, Poland.	m.oldak@ifps.org.pl		Leja, Marcin Ludwik/0000-0002-3856-8377; Ozieblo, Dominika/0000-0002-3454-8002				Ahmadi N, 2011, OTOLARYNG HEAD NECK, V145, P295, DOI 10.1177/0194599811402296; Chen PH, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/3018132; Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012; Gattorno M, 2007, ARTHRITIS RHEUM, V56, P3138, DOI 10.1002/art.22842; Gattorno M, 2019, ANN RHEUM DIS, V78, P1025, DOI 10.1136/annrheumdis-2019-215048; Goldbach-Mansky R, 2006, NEW ENGL J MED, V355, P581, DOI 10.1056/NEJMoa055137; Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x; Hoffman HM, 2004, LANCET, V364, P1779, DOI 10.1016/S0140-6736(04)17401-1; Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756; Katsnelson MA, 2016, AM J PHYSIOL-CELL PH, V311, pC83, DOI 10.1152/ajpcell.00298.2015; Kim BJ, 2021, RHEUMATOLOGY, V60, P1523, DOI 10.1093/rheumatology/keaa511; Kone-Paut I, 2014, EXPERT REV CLIN IMMU, V10, P7, DOI 10.1586/1744666X.2014.861325; Kuemmerle-Deschner JB, 2011, ARTHRITIS RHEUM-US, V63, P840, DOI 10.1002/art.30149; Magupalli VG, 2020, SCIENCE, V369, P1448, DOI 10.1126/science.aas8995; Martinez GJ, 2018, ATHEROSCLEROSIS, V269, P262, DOI 10.1016/j.atherosclerosis.2017.12.027; Nakanishi H, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00141; Nakanishi H, 2018, OTOL NEUROTOL, V39, pE181, DOI 10.1097/MAO.0000000000001715; Nakanishi H, 2017, P NATL ACAD SCI USA, V114, pE7766, DOI 10.1073/pnas.1702946114; Oonk AMM, 2013, HEARING RES, V299, P88, DOI 10.1016/j.heares.2012.12.015; Oza AM, 2018, HUM MUTAT, V39, P1593, DOI 10.1002/humu.23630; Ozieblo D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89645-y; Ozieblo D, 2020, GENES-BASEL, V11, DOI 10.3390/genes11091060; Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30; Rieber N, 2015, CLIN IMMUNOL, V157, P56, DOI 10.1016/j.clim.2015.01.003; Shearer AE, 1999, GENEREVIEWS; Sibley CH, 2012, ARTHRITIS RHEUM-US, V64, P2375, DOI 10.1002/art.34409; Tassi S, 2010, P NATL ACAD SCI USA, V107, P9789, DOI 10.1073/pnas.1000779107; Welzel T, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010128	28	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								904632	10.3389/fimmu.2022.904632	http://dx.doi.org/10.3389/fimmu.2022.904632			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2TC	35720340	gold, Green Published			2022-12-18	WOS:000812764900001
J	Pani, A; Romandini, A; Schianchi, A; Senatore, M; Gagliardi, OM; Gazzaniga, G; Agliardi, S; Conti, T; Schenardi, PA; Maggi, M; D'Onghia, S; Panetta, V; Renica, S; Molteni, SN; Vismara, C; Campisi, D; Bertuzzi, M; Giroldi, S; Zoppini, L; Moreno, M; Merli, M; Bosio, M; Puoti, M; Scaglione, F				Pani, Arianna; Romandini, Alessandra; Schianchi, Alice; Senatore, Michele; Gagliardi, Oscar M.; Gazzaniga, Gianluca; Agliardi, Stefano; Conti, Tommaso; Schenardi, Paolo A.; Maggi, Matteo; D'Onghia, Stefano; Panetta, Valentina; Renica, Silvia; Molteni, Silvia Nerini; Vismara, Chiara; Campisi, Daniela; Bertuzzi, Michaela; Giroldi, Simona; Zoppini, Laura; Moreno, Mauro; Merli, Marco; Bosio, Marco; Puoti, Massimo; Scaglione, Francesco			Antibody Response to COVID-19 Booster Vaccination in Healthcare Workers	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; vaccine booster; healthcare workers (HCWs); antibody response		ObjectiveTo evaluate the mean increase of anti-S IgG antibody titer between the basal, pre-booster level to the titer assessed 14 days after the booster dose of BNT162b2. Patients and MethodsThe RENAISSANCE study is an observational, longitudinal, prospective, population-based study, conducted on healthcare workers of Niguarda Hospital in Milan, Italy who received a BNT162b2 booster dose at least 180 days after their second dose or after positivity for SARS-CoV-2 and accepted to take part in the study. The RENAISSANCE study was conducted from January 1, 2021 through December 28, 2021. Findings1,738 subjects were enrolled among healthcare workers registered for the booster administration at our hospital. Overall, 0.4% of subjects were seronegative at the pre-booster evaluation, and 1 subject had a titer equal to 50 AU/ml: none of the evaluated subjects was seronegative after the booster dose. Thus, the efficacy of the booster in our population was universal. Mean increase of pre- to post-booster titer was more significant in subjects who never had SARS-CoV-2 (44 times CI 95% 42-46) compared to those who had it, before (33 times, CI 95% 13-70) or after the first vaccination cycle (12 times, CI 95% 11-14). Differently from sex, age and pre-booster titers affected the post-booster antibody response. Nevertheless, the post-booster titer was very similar in all subgroups, and independent of a prior exposure to SARS-CoV-2, pre-booster titer, sex or age. ConclusionOur study shows a potent universal antibody response of the booster dose of BNT162b2, regardless of pre-booster vaccine seronegativity.	[Pani, Arianna; Romandini, Alessandra; Schianchi, Alice; Senatore, Michele; Gagliardi, Oscar M.; Gazzaniga, Gianluca; Agliardi, Stefano; Conti, Tommaso; Schenardi, Paolo A.; Maggi, Matteo; D'Onghia, Stefano; Scaglione, Francesco] Univ Milan, Oncol & Hemato Oncol Dept, Milan, Italy; [Senatore, Michele; Scaglione, Francesco] Osped Niguarda Ca Granda, Lab Med Dept, Chem Clin Anal Unit, Milan, Italy; [Panetta, Valentina] Biostat Off, Laltrastatist srl Consultancy & Training, Rome, Italy; [Renica, Silvia; Molteni, Silvia Nerini; Vismara, Chiara; Campisi, Daniela] Osped Niguarda Ca Granda, Lab Med Dept, Microbiol Unit, Milan, Italy; [Bertuzzi, Michaela] Azienda Socio Sanit Territoriale ASST Grande Osped, Qual & Risk Control Data Management, Milan, Italy; [Giroldi, Simona; Zoppini, Laura] Azienda Socio Sanit Territoriale ASST Grande Osped, Socio Sanit Direct, Milan, Italy; [Moreno, Mauro; Bosio, Marco] Azienda Socio Sanit Territoriale ASST Grande Osped, Healthcare Management Dept, Milan, Italy; [Merli, Marco; Puoti, Massimo] Azienda Socio Sanit Territoriale ASST Grande Osped, Infect Dis Unit, Milan, Italy; [Puoti, Massimo] Univ Milano Bicocca, Sch Med & Surg, Milan, Italy	University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; University of Milano-Bicocca	Pani, A (corresponding author), Univ Milan, Oncol & Hemato Oncol Dept, Milan, Italy.	arianna.pani@unimi.it	DOnghia, Stefano/GQB-0059-2022					Bar-On YM, 2021, NEW ENGL J MED, V385, P1393, DOI 10.1056/NEJMoa2114255; Ben David SS, 2021, CLIN IMMUNOL, V232, DOI 10.1016/j.clim.2021.108860; Bensouna I, 2022, AM J KIDNEY DIS, V79, P185, DOI 10.1053/j.ajkd.2021.08.005; Bruce MG, 2016, J INFECT DIS, V214, P16, DOI 10.1093/infdis/jiv748; cov lineages, COV LINEAGES OMICRON; covariants, COV PROV OV SARS COV; Eliakim-Raz N, 2021, JAMA-J AM MED ASSOC, V326, P2203, DOI 10.1001/jama.2021.19885; fda, 2021, COMIRNATY SUMMARY PR; Feng S, 2021, NAT MED, V27, P2032, DOI [DOI 10.1038/s41591-021-01540-1, 10.1038/s41591-021-01540-1]; Galli C., 2021, CORE LAB ABBOTT ANTI; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Greenberger LM, 2021, CANCER CELL, V39, P1297, DOI 10.1016/j.ccell.2021.09.001; investors, MODERNA ANNOUNCES PR; investors, PFIZER BIONTECH PROV; Painter MM, 2021, IMMUNITY, V54, P2133, DOI 10.1016/j.immuni.2021.08.001; Pani A, 2021, MAYO CLIN PROC, V96, P2966, DOI 10.1016/j.mayocp.2021.08.013; Patalon T, 2022, JAMA INTERN MED, V182, P179, DOI 10.1001/jamainternmed.2021.7382; Peled Y, 2022, J HEART LUNG TRANSPL, V41, P148, DOI 10.1016/j.healun.2021.08.010; Petras M, 2018, EPIDEMIOL INFECT, V146, P2079, DOI 10.1017/S095026881800242X; Puranik A., 2021, MEDRXIV, DOI [10.1101/2021.08.06.21261707, DOI 10.1101/2021.08.06.21261707]; Ramos A, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12010205; Shroff RT, 2021, NAT MED, V27, P2002, DOI 10.1038/s41591-021-01542-z; Tang P, 2021, NAT MED, V27, P2136, DOI 10.1038/s41591-021-01583-4; Yahav D, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2021-055611	24	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								872667	10.3389/fimmu.2022.872667	http://dx.doi.org/10.3389/fimmu.2022.872667			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2IK	35720366	Green Published, gold			2022-12-18	WOS:000812736900001
J	Park, JH; Kang, I; Lee, HK				Park, Jang Hyun; Kang, In; Lee, Heung Kyu			gamma delta T Cells in Brain Homeostasis and Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						gamma delta T cell; central nervous system; brain; neuroimmunology; brain diseases	CEREBROSPINAL-FLUID; LINEAGE COMMITMENT; PERIPHERAL-BLOOD; IMMUNE-RESPONSE; ALPHA-BETA; RECEPTOR; TCR; SYSTEM; EXPRESSION; FETAL	gamma delta T cells are a distinct subset of T cells expressing gamma delta T cell receptor (TCR) rather than alpha beta TCR. Since their discovery, the critical roles of gamma delta T cells in multiple physiological systems and diseases have been investigated. gamma delta T cells are preferentially located at mucosal surfaces, such as the gut, although a small subset of gamma delta T cells can circulate the blood. Additionally, a subset of gamma delta T cells reside in the meninges in the central nervous system. Recent findings suggest gamma delta T cells in the meninges have critical roles in brain function and homeostasis. In addition, several lines of evidence have shown gamma delta T cells can infiltrate the brain parenchyma and regulate inflammatory responses in multiple diseases, including neurodegenerative diseases. Although the importance of gamma delta T cells in the brain is well established, their roles are still incompletely understood due to the complexity of their biology. Because gamma delta T cells rapidly respond to changes in brain status and regulate disease progression, understanding the role of gamma delta T cells in the brain will provide critical information that is essential for interpreting neuroimmune modulation. In this review, we summarize the complex role of gamma delta T cells in the brain and discuss future directions for research.	[Park, Jang Hyun; Kang, In; Lee, Heung Kyu] Korea Adv Inst Sci & Technol KAIST, Grad Sch Med Sci & Engn, Daejeon, South Korea	Korea Advanced Institute of Science & Technology (KAIST)	Lee, HK (corresponding author), Korea Adv Inst Sci & Technol KAIST, Grad Sch Med Sci & Engn, Daejeon, South Korea.	heungkyu.lee@kaist.ac.kr			National Research Foundation of Korea - Ministry of Science and ICT of Korea [NRF-2021M3A9D3026428, NRF-2021M3A9H3015688]	National Research Foundation of Korea - Ministry of Science and ICT of Korea	This study was supported by the National Research Foundation of Korea (NRF-2021M3A9D3026428 and NRF-2021M3A9H3015688) funded by the Ministry of Science and ICT of Korea.	Afroz KF, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87678-x; Afroz KF, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1666-2; Albertsson AM, 2018, AM J PATHOL, V188, P757, DOI 10.1016/j.ajpath.2017.11.012; Aliseychik M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00012; de Lima KA, 2020, NAT IMMUNOL, V21, P1421, DOI 10.1038/s41590-020-0776-4; Amor S, 2010, IMMUNOLOGY, V129, P154, DOI 10.1111/j.1365-2567.2009.03225.x; Arlehamn CSL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15626-w; Arunachalam P, 2017, STROKE, V48, P1957, DOI 10.1161/STROKEAHA.117.016753; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531; Barbee SD, 2011, P NATL ACAD SCI USA, V108, P3330, DOI 10.1073/pnas.1010890108; Barros-Martins J, 2016, J IMMUNOL, V196, P3642, DOI 10.4049/jimmunol.1501921; Beck BH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122387; Benakis C, 2016, NAT MED, V22, P516, DOI 10.1038/nm.4068; Benveniste PM, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aav4036; Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222; Boyden LM, 2008, NAT GENET, V40, P656, DOI 10.1038/ng.108; Brigas HC, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109574; Brioschi S, 2021, SCIENCE, V373, P408, DOI 10.1126/science.abf9277; Brown MC, 2022, TRENDS CANCER, V8, P345, DOI 10.1016/j.trecan.2022.01.006; Bruder J, 2012, J BIOL CHEM, V287, P20986, DOI 10.1074/jbc.M112.356709; Bryant NL, 2009, NEURO-ONCOLOGY, V11, P357, DOI 10.1215/15228517-2008-111; Buus TB, 2016, ONCOTARGET, V7, P19341, DOI 10.18632/oncotarget.8464; Cardona AE, 2002, J IMMUNOL, V169, P3163, DOI 10.4049/jimmunol.169.6.3163; CHIEN Y, 1984, NATURE, V312, P31, DOI 10.1038/312031a0; Choi GB, 2016, SCIENCE, V351, P933, DOI 10.1126/science.aad0314; Coffey F, 2014, J EXP MED, V211, P329, DOI 10.1084/jem.20131540; Correia DV, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22892; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; Cugurra A, 2021, SCIENCE, V373, P409, DOI 10.1126/science.abf7844; de Lima KA, 2020, ANNU REV IMMUNOL, V38, P597, DOI 10.1146/annurev-immunol-102319-103410; Derkow K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135898; Edwards SC, 2020, J EXP MED, V217, DOI 10.1084/jem.20190834; Egan CE, 2005, J IMMUNOL, V175, P8191, DOI 10.4049/jimmunol.175.12.8191; Eimer WA, 2018, NEURON, V100, P1527, DOI 10.1016/j.neuron.2018.11.043; Essand M, 1999, P NATL ACAD SCI USA, V96, P9287, DOI 10.1073/pnas.96.16.9287; Facoetti A, 2005, CLIN CANCER RES, V11, P8304, DOI 10.1158/1078-0432.CCR-04-2588; Faraco G, 2018, NAT NEUROSCI, V21, P240, DOI 10.1038/s41593-017-0059-z; Ferber IA, 1996, J IMMUNOL, V156, P5; Fichtner AS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040800; FISZER U, 1994, J NEUROL SCI, V121, P39, DOI 10.1016/0022-510X(94)90154-6; FREEDMAN MS, 1991, ANN NEUROL, V30, P794, DOI 10.1002/ana.410300608; Garg AD, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1295903; Gate D, 2021, SCIENCE, V374, P868, DOI 10.1126/science.abf7266; Gate D, 2020, NATURE, V577, P399, DOI 10.1038/s41586-019-1895-7; Gelderblom M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00368; Gelderblom M, 2012, BLOOD, V120, P3793, DOI 10.1182/blood-2012-02-412726; Gentek R, 2018, J EXP MED, V215, P2994, DOI 10.1084/jem.20181206; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Germain RN, 2002, NAT REV IMMUNOL, V2, P309, DOI 10.1038/nri798; Haas JD, 2012, IMMUNITY, V37, P48, DOI 10.1016/j.immuni.2012.06.003; Haks MC, 2005, IMMUNITY, V22, P595, DOI 10.1016/j.immuni.2005.04.003; Haque A, 2001, AM J PATHOL, V158, P163, DOI 10.1016/S0002-9440(10)63954-5; HAVRAN WL, 1988, NATURE, V335, P443, DOI 10.1038/335443a0; Hayday A, 2008, MUCOSAL IMMUNOL, V1, P172, DOI 10.1038/mi.2008.8; HAYDAY AC, 1985, CELL, V40, P259, DOI 10.1016/0092-8674(85)90140-0; Hayday AC, 2019, J IMMUNOL, V203, P311, DOI 10.4049/jimmunol.1800934; HEILIG JS, 1986, NATURE, V322, P836, DOI 10.1038/322836a0; Hu Y, 2021, CELL MOL IMMUNOL, V18, P954, DOI 10.1038/s41423-021-00656-1; ITOHARA S, 1990, NATURE, V343, P754, DOI 10.1038/343754a0; Jandke A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17557-y; Jarry U, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1168554; Karachi A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.705580; Kastrukoff LF, 2010, VIROLOGY, V400, P248, DOI 10.1016/j.virol.2010.02.013; Khairallah C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00105; Kim S, 2017, NATURE, V549, P528, DOI 10.1038/nature23910; Kobayashi Y, 1997, J NEUROIMMUNOL, V73, P169, DOI 10.1016/S0165-5728(96)00187-7; Koenecke C, 2009, EUR J IMMUNOL, V39, P372, DOI 10.1002/eji.200838741; Kreslavsky T, 2008, J EXP MED, V205, P1173, DOI 10.1084/jem.20072425; Lakomy R, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00840; Lamb LS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051805; Lanz TV, 2022, NATURE, DOI 10.1038/s41586-022-04432-7; Lawand M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00761; Lee M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00555; Lewis EL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.741518; Lim M, 2018, NAT REV CLIN ONCOL, V15, P422, DOI 10.1038/s41571-018-0003-5; Lino CNR, 2017, EUR J IMMUNOL, V47, P970, DOI 10.1002/eji.201646753; Liu JY, 2018, BRIT J HAEMATOL, V180, P276, DOI 10.1111/bjh.15037; Lopes N, 2021, NAT IMMUNOL, V22, P179, DOI 10.1038/s41590-020-00848-3; Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432; Lu L, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107678; Lu Y, 2015, J IMMUNOL, V195, P4273, DOI 10.4049/jimmunol.1500939; Maimaitijiang G, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1574-5; Marlin R, 2017, P NATL ACAD SCI USA, V114, P3163, DOI 10.1073/pnas.1621052114; McCarthy NE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00985; McKenzie DR, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15632; McVay LD, 1996, J IMMUNOL, V157, P2873; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; Melandri D, 2018, NAT IMMUNOL, V19, P1352, DOI 10.1038/s41590-018-0253-5; Mohebiany AN, 2020, CELL REP, V30, P1585, DOI 10.1016/j.celrep.2019.12.097; MULLER N, 1994, ANN NY ACAD SCI, V741, P305; Muschaweckh A, 2017, J IMMUNOL, V199, P2668, DOI 10.4049/jimmunol.1700287; Ono T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10928; Ostrom QT, 2015, NEURO-ONCOLOGY, V17, P1, DOI [10.1093/neuonc/noab200, 10.1093/neuonc/noaa200, 10.1093/neuonc/nov189]; Owens GC, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0352-2; Pang DJ, 2012, IMMUNOLOGY, V136, P283, DOI 10.1111/j.1365-2567.2012.03582.x; Papadopoulos Z, 2020, J IMMUNOL, V204, P286, DOI 10.4049/jimmunol.1900838; Papotto PH, 2017, EMBO REP, V18, P1957, DOI 10.15252/embr.201744200; Park JH, 2021, EXP MOL MED, V53, P318, DOI 10.1038/s12276-021-00576-0; Park JH, 2021, NAT IMMUNOL, V22, P336, DOI 10.1038/s41590-020-00860-7; Pellicci DG, 2020, NAT REV IMMUNOL, V20, P756, DOI 10.1038/s41577-020-0345-y; Pinget GV, 2016, IMMUNOL CELL BIOL, V94, P623, DOI 10.1038/icb.2016.48; Polese B, 2018, CLIN TRANSL IMMUNOL, V7, DOI 10.1002/cti2.1008; Ponomarev ED, 2004, J IMMUNOL, V173, P1587, DOI 10.4049/jimmunol.173.3.1587; Ramsburg E, 2003, J EXP MED, V198, P1403, DOI 10.1084/jem.20030050; Ravens S, 2020, P NATL ACAD SCI USA, V117, P18649, DOI 10.1073/pnas.1922588117; Readhead B, 2018, NEURON, V99, P64, DOI 10.1016/j.neuron.2018.05.023; Ren SS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.623451; Ribeiro M, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay5199; Ribot JC, 2021, NAT REV IMMUNOL, V21, P221, DOI 10.1038/s41577-020-00452-4; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516; Rincon-Orozco B, 2005, J IMMUNOL, V175, P2144, DOI 10.4049/jimmunol.175.4.2144; Roy S, 2016, J IMMUNOL, V196, P1933, DOI 10.4049/jimmunol.1502202; Rustenhoven J, 2021, CELL, V184, P1000, DOI 10.1016/j.cell.2020.12.040; Salim M, 2016, J BIOL CHEM, V291, P9310, DOI 10.1074/jbc.M116.722066; Salvador AF, 2021, NAT REV IMMUNOL, V21, P526, DOI 10.1038/s41577-021-00508-z; Sampson JH, 2020, NAT REV CANCER, V20, P12, DOI 10.1038/s41568-019-0224-7; Seaks CE, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008596; Seki D, 2021, CELL HOST MICROBE, V29, P1558, DOI 10.1016/j.chom.2021.08.004; Shibata K, 2014, J IMMUNOL, V192, P2210, DOI 10.4049/jimmunol.1302145; SHIMONKEVITZ R, 1993, P NATL ACAD SCI USA, V90, P923, DOI 10.1073/pnas.90.3.923; Silva-Santos B, 2012, EUR J IMMUNOL, V42, P3101, DOI 10.1002/eji.201270101; Smeets MFMA, 2014, EUR J IMMUNOL, V44, P2617, DOI 10.1002/eji.201444442; STINISSEN P, 1995, J IMMUNOL, V154, P4883; Sumaria N, 2017, CELL REP, V19, P2469, DOI 10.1016/j.celrep.2017.05.071; Sutoh Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01059; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Suzuki Y, 1997, INFECT IMMUN, V65, P2339, DOI 10.1128/IAI.65.6.2339-2345.1997; Szymanska B, 1999, J NEUROIMMUNOL, V100, P260, DOI 10.1016/S0165-5728(99)00204-0; Tan LK, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf0125; Tieppo P, 2020, J EXP MED, V217, DOI 10.1084/jem.20190580; Weenink B, 2020, CANCERS, V12, DOI 10.3390/cancers12030751; Weinreich MA, 2008, J IMMUNOL, V181, P2265, DOI 10.4049/jimmunol.181.4.2265; Welte T, 2008, FEMS IMMUNOL MED MIC, V53, P275, DOI 10.1111/j.1574-695X.2008.00430.x; Welte T, 2011, FEMS IMMUNOL MED MIC, V63, P183, DOI 10.1111/j.1574-695X.2011.00840.x; Wencker M, 2014, NAT IMMUNOL, V15, P80, DOI 10.1038/ni.2773; Wilck N, 2017, NATURE, V551, P585, DOI 10.1038/nature24628; Willcox BE, 2019, NAT IMMUNOL, V20, P121, DOI 10.1038/s41590-018-0304-y; Willcox CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01501; Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394; Willenborg DO, 1996, J IMMUNOL, V157, P3223; Wo J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.580304; Wohler JE, 2009, EUR J IMMUNOL, V39, P1516, DOI 10.1002/eji.200839176; Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984; Yang K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aas9818; Yang XB, 2015, P NATL ACAD SCI USA, V112, P8166, DOI 10.1073/pnas.1510127112; Yazdanifar M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051305; Zeine R, 1998, J NEUROIMMUNOL, V87, P49, DOI 10.1016/S0165-5728(98)00047-2; Zeng X, 2012, IMMUNITY, V37, P524, DOI 10.1016/j.immuni.2012.06.011; Zepp J, 2011, TRENDS IMMUNOL, V32, P232, DOI 10.1016/j.it.2011.02.007; Zhao ZY, 2017, FASEB J, V31, P4903, DOI 10.1096/fj.201700533R	152	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								886397	10.3389/fimmu.2022.886397	http://dx.doi.org/10.3389/fimmu.2022.886397			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y8IL	35693762	Green Published, gold			2022-12-18	WOS:000808382100001
J	Pratesi, F; Errante, F; Pacini, L; Pena-Moreno, IC; Quiceno, S; Carotenuto, A; Balam, S; Konate, D; Diakite, MM; Arevalo-Herrera, M; Kajava, AV; Rovero, P; Corradin, G; Migliorini, P; Papini, AM; Herrera, S				Pratesi, Federico; Errante, Fosca; Pacini, Lorenzo; Pena-Moreno, Irina Charlot; Quiceno, Sebastian; Carotenuto, Alfonso; Balam, Saidou; Konate, Drissa; Diakite, Mahamadou M.; Arevalo-Herrera, Myriam; Kajava, Andrey V.; Rovero, Paolo; Corradin, Giampietro; Migliorini, Paola; Papini, Anna M.; Herrera, Socrates			A SARS-CoV-2 Spike Receptor Binding Motif Peptide Induces Anti-Spike Antibodies in Mice andIs Recognized by COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; receptor binding motif; COVID-19; immunized animals; neutralizing Abs; spike (S) protein	PROTEIN SECONDARY STRUCTURE; VACCINE	The currently devastating pandemic of severe acute respiratory syndrome known as coronavirus disease 2019 or COVID-19 is caused by the coronavirus SARS-CoV-2. Both the virus and the disease have been extensively studied worldwide. A trimeric spike (S) protein expressed on the virus outer bilayer leaflet has been identified as a ligand that allows the virus to penetrate human host cells and cause infection. Its receptor-binding domain (RBD) interacts with the angiotensin-converting enzyme 2 (ACE2), the host-cell viral receptor, and is, therefore, the subject of intense research for the development of virus control means, particularly vaccines. In this work, we search for smaller fragments of the S protein able to elicit virus-neutralizing antibodies, suitable for production by peptide synthesis technology. Based on the analysis of available data, we selected a 72 aa long receptor binding motif (RBM436-507) of RBD. We used ELISA to study the antibody response to each of the three antigens (S protein, its RBD domain and the RBM436-507 synthetic peptide) in humans exposed to the infection and in immunized mice. The seroreactivity analysis showed that anti-RBM antibodies are produced in COVID-19 patients and immunized mice and may exert neutralizing function, although with a frequency lower than anti-S and -RBD. These results provide a basis for further studies towards the development of vaccines or treatments focused on specific regions of the S virus protein, which can benefit from the absence of folding problems, conformational constraints and other advantages of the peptide synthesis production.	[Pratesi, Federico; Migliorini, Paola] Univ Hosp Pisa, Dept Clin & Expt Med, Pisa, Italy; [Errante, Fosca; Rovero, Paolo] Univ Florence, Dept NeuroFarBa, Interdept Lab Peptide & Prot Chem & Biol, Sesto Fiorentino, Italy; [Pacini, Lorenzo; Papini, Anna M.] Univ Florence, Dept Chem Ugo Schiff, Interdept Lab Peptide & Prot Chem & Biol, Sesto Fiorentino, Italy; [Pena-Moreno, Irina Charlot; Quiceno, Sebastian; Herrera, Socrates] Caucaseco Sci Res Ctr, Dept Immunol, Cali, Colombia; [Carotenuto, Alfonso] Univ Naples Federico II, Dept Pharm, Naples, Italy; [Balam, Saidou; Konate, Drissa; Diakite, Mahamadou M.] Univ Sci Tech & Technol Bamako USTTB, Immunogenet Lab & Parasitol, Bamako, Mali; [Balam, Saidou] Univ Hosp Regensburg, Dept Nephrol, Regensburg, Germany; [Arevalo-Herrera, Myriam] Malaria Vaccine & Drug Dev Ctr, Dept Immunol, Cali, Colombia; [Kajava, Andrey V.] Univ Montpellier, CRBM, CNRS, Montpellier, France; [Corradin, Giampietro] Univ Lausanne, Biochem Dept, Lausanne, Switzerland	University of Pisa; Azienda Ospedaliero Universitaria Pisana; University of Florence; University of Florence; University of Naples Federico II; University of Science & Technology of Bamako; University of Regensburg; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Lausanne	Herrera, S (corresponding author), Caucaseco Sci Res Ctr, Dept Immunol, Cali, Colombia.	sherrera@inmuno.org	Errante, Fosca/HDM-7430-2022	Errante, Fosca/0000-0001-7790-9886; Papini, Anna Maria/0000-0002-2947-7107; BALAM, Dr Saidou/0000-0002-7178-7758	MVDC/CIV Foundation [150820]; Italian Ministry of Health [COVID-2020-12371849]	MVDC/CIV Foundation; Italian Ministry of Health(Ministry of Health, Italy)	This work was funded by MVDC/CIV Foundation (grant 150820) and by the Italian Ministry of Health grant COVID-2020-12371849	Amanat F, 2020, IMMUNITY, V52, P583, DOI 10.1016/j.immuni.2020.03.007; [Anonymous], 2022, SARS COV 2 VARIANTS; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Bellan M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77698-4; Cai YF, 2020, SCIENCE, V369, P1586, DOI [10.1126/science.abd4251, 10.1101/2020.05.16.099317]; Du LY, 2009, NAT REV MICROBIOL, V7, P226, DOI 10.1038/nrmicro2090; Fan XY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17371-6; FDA, 2021, EM US AUTH 108; Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Krause PR, 2021, LANCET, V398, P1377, DOI 10.1016/S0140-6736(21)02046-8; Li CX, 2022, BIOMED PHARMACOTHER, V146, DOI 10.1016/j.biopha.2021.112550; Marien J, 2021, J VIROL METHODS, V297, DOI 10.1016/j.jviromet.2021.114228; O'Driscoll M, 2020, NATURE, DOI 10.1038/s41586-020-2918-0; Olugbile S, 2011, VACCINE, V29, P7090, DOI 10.1016/j.vaccine.2011.06.122; Olugbile S, 2010, CURR OPIN MOL THER, V12, P64; Parums DV, 2022, MED SCI MONITOR, V28, DOI 10.12659/MSM.935952; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Pino P, 2020, PROCESSES, V8, DOI 10.3390/pr8121539; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pratesi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060672; Rizzolo F, 2011, J PEPT SCI, V17, P708, DOI 10.1002/psc.1395; Roberts A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.732756; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Sharma O, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585354; Shrock E, 2020, SCIENCE, V370, P1058, DOI 10.1126/science.abd4250; Silveira MM, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118919; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Tortorici MA, 2020, SCIENCE, V370, P950, DOI 10.1126/science.abe3354; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Whitmore L, 2004, NUCLEIC ACIDS RES, V32, pW668, DOI 10.1093/nar/gkh371; WHO, 2022, COVID 19 WEEKLY EPID; Wierbowski SD, 2021, NAT METHODS, V18, P1477, DOI 10.1038/s41592-021-01318-w; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Zhou TQ, 2020, CELL HOST MICROBE, V28, P867, DOI 10.1016/j.chom.2020.11.004	39	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								879946	10.3389/fimmu.2022.879946	http://dx.doi.org/10.3389/fimmu.2022.879946			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6QA	35693806	Green Published, gold, Green Submitted			2022-12-18	WOS:000808265700001
J	Rodriguez, C; Vega, IA; Castro-Vazquez, A				Rodriguez, Cristian; Vega, Israel A.; Castro-Vazquez, Alfredo			A Dissenters' View on AppleSnail Immunobiology	FRONTIERS IN IMMUNOLOGY			English	Review						Biomphalaria; hematopoiesis; hemocyte; nodulation; Pomacea; rhogocyte; hemocyanin; reno-pericardial complex	AMEBOCYTE-PRODUCING ORGAN; FRESH-WATER SNAIL; POMACEA-CANALICULATA CAENOGASTROPODA; KEYHOLE LIMPET HEMOCYANIN; BIOMPHALARIA-GLABRATA; MITOTIC RESPONSES; SCHISTOSOMA-MANSONI; ANTIMICROBIAL PEPTIDES; MYCOBACTERIUM-MARINUM; MARISA-CORNUARIETIS	We stand as dissenters against the acceptance of scientific knowledge that has not been built on empirical data. With this in mind, this review synthesizes selected aspects of the immunobiology of gastropods and of apple snails (Ampullariidae) in particular, from morphological to molecular and "omics" studies. Our trip went through more than two centuries of history and was guided by an evo-devo hypothesis: that the gastropod immune system originally developed in the mesenchymal connective tissue of the reno-pericardial complex, and that in that tissue some cells differentiated into hematopoietically committed progenitor cells that integrate constitutive hemocyte aggregations in the reno-pericardial territory, whether concentrated in the pericardium or the kidney in a species-specific manner. However, some of them may be freed from those aggregations, circulate in the blood, and form distant contingent aggregations anywhere in the body, but always in response to intruders (i.e., pathogens or any other immune challenge). After that, we reviewed the incipient immunology of the Ampullariidae by critically revising the findings in Pomacea canaliculata and Marisa cornuarietis, the only ampullariid species that have been studied in this respect, and we attempted to identify the effectors and the processes in which they are involved. Particularly for P. canaliculata, which is by far the most studied species, we ask which hemocytes are involved, in which tissues or organs are integrated, and what cellular reactions to intruders this species has in common with other animals. Furthermore, we wondered what humoral factors could also integrate its internal defense system. Among the cellular defenses, we give an outstanding position to the generation of hemocyte nodules, which seems to be an important process for these snails, serving the isolation and elimination of intruders. Finally, we discuss hematopoiesis in apple snails. There have been contrasting views about some of these aspects, but we envision a hematopoietic system centered in the constitutive hemocyte islets in the ampullariid kidney.	[Rodriguez, Cristian; Vega, Israel A.; Castro-Vazquez, Alfredo] Univ Nacl Cuyo, IHEM, CONICET, Mendoza, Argentina; [Rodriguez, Cristian; Vega, Israel A.; Castro-Vazquez, Alfredo] Univ Nacl Cuyo, Fac Ciencias Exactas & Nat, Dept Biol, Mendoza, Argentina; [Rodriguez, Cristian; Vega, Israel A.; Castro-Vazquez, Alfredo] Univ Nacl Cuyo, Fac Ciencias Med, Inst Fisiol, Mendoza, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza	Castro-Vazquez, A (corresponding author), Univ Nacl Cuyo, IHEM, CONICET, Mendoza, Argentina.; Castro-Vazquez, A (corresponding author), Univ Nacl Cuyo, Fac Ciencias Exactas & Nat, Dept Biol, Mendoza, Argentina.; Castro-Vazquez, A (corresponding author), Univ Nacl Cuyo, Fac Ciencias Med, Inst Fisiol, Mendoza, Argentina.	a.castrovazquez@gmail.com			Universidad Nacional de Cuyo; Consejo Nacional de Investigaciones Cientificas y Tecnicas; Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion [PICT 2019-03211]	Universidad Nacional de Cuyo; Consejo Nacional de Investigaciones Cientificas y Tecnicas(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion	The work in the authors' laboratory during the last years has been supported by grants from Universidad Nacional de Cuyo, Consejo Nacional de Investigaciones Cientificas y Tecnicas, and Agencia Nacional de Promocion de la Investigacion, el Desarrollo Tecnologico y la Innovacion (PICT 2019-03211).	Accorsi A, 2021, ELIFE, V10, DOI 10.7554/eLife.65372; Accorsi A, 2017, DEV COMP IMMUNOL, V72, P37, DOI 10.1016/j.dci.2017.02.001; Accorsi A, 2014, FISH SHELLFISH IMMUN, V38, P56, DOI 10.1016/j.fsi.2014.03.003; Accorsi A, 2013, FISH SHELLFISH IMMUN, V34, P1260, DOI 10.1016/j.fsi.2013.02.008; Adema CM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15451; Adema CM, 2015, RESULTS PROBL CELL D, V57, P111, DOI 10.1007/978-3-319-20819-0_5; Andrews E. B., 1965, Journal of Zoology London, V146, P70; Andrews E. B., 1965, Proceedings of the Zoological Society of London, V145, P19; ANDREWS EB, 1976, J ZOOL, V179, P85; ANDREWS EB, 1981, J MOLLUS STUD, V47, P248; Arason GJ, 1989, INTERNAL DEFENCE REA; BALDO BA, 1974, VOX SANG, V27, P67, DOI 10.1111/j.1423-0410.1974.tb02390.x; BARROS RMF, 1993, COMP BIOCHEM PHYS B, V105, P725, DOI 10.1016/0305-0491(93)90112-I; Barsanti G., 1994, ROMANTICISM SCI SCIE, P47; Bartolomaeus T, 1997, ZOOL ANZ, V235, P165; Becker M.I., 2014, IMMUNE RESPONSE ACTI, P45, DOI [10.5772/57552, DOI 10.5772/57552]; Bergamini G., 21 SCI M ITALIAN ASS; Biswas C, 2000, MOL IMMUNOL, V37, P745, DOI 10.1016/S0161-5890(00)00096-1; Boraldi F, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10101049; Boraldi F, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800314; Bouchet P, 2017, MALACOLOGIA, V61, P1; Bouvier E. L., 1888, Mem Soc Philom Cent, P63; BOYD WC, 1966, J IMMUNOL, V96, P301; BOYD WC, 1954, SCIENCE, V119, P419, DOI 10.1126/science.119.3091.419; CANICATTI C, 1989, B ZOOL, V56, P275; CHENG TC, 1975, ANN NY ACAD SCI, V266, P343, DOI 10.1111/j.1749-6632.1975.tb35116.x; Cuenot L., 1891, Arch Z exper 1891 (2nd ser), Vix, P13; Cuenot L., 1914, Archives de Zoologie Paris, V54; Cuenot L, 1896, CR HEBD ACAD SCI, V123, P1078; Cueto JA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123964; Cueto JA, 2013, FISH SHELLFISH IMMUN, V34, P443, DOI 10.1016/j.fsi.2012.11.035; Cueto JA, 2011, MOLLUSCAN RES, V31, P57; Davis JM, 2009, CELL, V136, P37, DOI 10.1016/j.cell.2008.11.014; Davis JM, 2002, IMMUNITY, V17, P693, DOI 10.1016/S1074-7613(02)00475-2; Dreon MS, 2004, ARCH BIOCHEM BIOPHYS, V422, P1, DOI 10.1016/j.abb.2003.11.018; FRETTER V, 1982, J MOLLUS STUD, V48, P105; GEORGE WC, 1950, J MORPHOL, V86, P315, DOI 10.1002/jmor.1050860205; Gerdol M, 2017, ISJ-INVERT SURVIV J, V14, P103; Gerdol M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00758; Giraud-Billoud M, 2008, J MOLLUS STUD, V74, P259, DOI 10.1093/mollus/eyn017; Giraud-Billoud M, 2013, J EXP BIOL, V216, P614, DOI 10.1242/jeb.075655; Giraud-Billoud M, 2011, COMP BIOCHEM PHYS A, V158, P506, DOI 10.1016/j.cbpa.2010.12.012; Garcia MG, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111473; Gorbushin AM, 2019, DEV COMP IMMUNOL, V94, P35, DOI 10.1016/j.dci.2019.01.010; Gorbushin AM, 2018, DEV COMP IMMUNOL, V84, P250, DOI 10.1016/j.dci.2018.02.018; Guimaraes-Costa Anderson B, 2012, J Parasitol Res, V2012, P929743, DOI 10.1155/2012/929743; Harris JR, 1999, MICRON, V30, P597, DOI 10.1016/S0968-4328(99)00036-0; Hartenstein V, 2006, ANNU REV CELL DEV BI, V22, P677, DOI 10.1146/annurev.cellbio.22.010605.093317; HASZPRUNAR G, 1992, B ZOOL, V59, P1, DOI 10.1080/11250009209386641; Haszprunar G, 1996, J MOLLUS STUD, V62, P185, DOI 10.1093/mollus/62.2.185; HAUGHTON ISABEL, 1934, JOUR ROY MICROSC SOC, V54, P246; Heras H, 2008, TOXICON, V52, P481, DOI 10.1016/j.toxicon.2008.06.022; Hsiao CY, 2010, FISH SHELLFISH IMMUN, V28, P77, DOI 10.1016/j.fsi.2009.10.016; Hyman L., 1967, INVERTEBRATES; Ip JCH, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4553-9; Ituarte S, 2008, MOL REPROD DEV, V75, P1441, DOI 10.1002/mrd.20880; Ituarte S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050115; JEONG KH, 1983, DEV COMP IMMUNOL, V7, P217, DOI 10.1016/0145-305X(83)90003-4; Kato Sanae, 2018, Biophys Rev, V10, P191, DOI 10.1007/s12551-017-0349-4; Koch E, 2009, BIOCELL, V33, P49; Kokkinopoulou M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141195; Kokkinopoulou M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101078; Lamarck J-BPAdMd, 1822, HIST NATURELLE ANIMA, Vsixieme; Lange MK, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-016-1961-z; LEVER J, 1965, EXPERIENTIA, V21, P395, DOI 10.1007/BF02139763; Li H, 2011, ISJ-INVERT SURVIV J, V8, P85; Li YQ, 2016, DEV COMP IMMUNOL, V55, P179, DOI 10.1016/j.dci.2015.10.025; LIE KJ, 1976, J PARASITOL, V62, P286, DOI 10.2307/3279288; LIE KJ, 1975, J PARASITOL, V61, P574, DOI 10.2307/3279358; LIE KJ, 1975, INT J PARASITOL, V5, P621, DOI 10.1016/0020-7519(75)90061-2; Loker ES, 2010, ADV EXP MED BIOL, V708, P17; Loker ES., 2018, ADV COMP IMMUNOLOGY, P343, DOI 10.1007/978-3-319-76768-0_12; Markl J, 2013, BBA-PROTEINS PROTEOM, V1834, P1840, DOI 10.1016/j.bbapap.2013.02.020; Marsollier L, 2004, APPL ENVIRON MICROB, V70, P6296, DOI 10.1128/AEM.70.10.6296-6298.2004; Martin AM, 2011, INVERTEBR BIOL, V130, P302, DOI 10.1111/j.1744-7410.2011.00249.x; Martin GG, 2021, INVERTEBR BIOL, V140, DOI 10.1111/ivb.12355; Martin GG, 1996, J MORPHOL, V227, P227, DOI 10.1002/(SICI)1097-4687(199602)227:2<227::AID-JMOR8>3.0.CO;2-5; MARTOJA M, 1980, J EXP MAR BIOL ECOL, V43, P251, DOI 10.1016/0022-0981(80)90051-9; Matricon-Gondran M, 1999, J INVERTEBR PATHOL, V74, P235, DOI 10.1006/jipa.1999.4877; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; Metchnikoff E, 1892, LECONS PATHOLOGIE CO; Mueck K., 2020, Journal of Shellfish Research, V39, P133, DOI 10.2983/035.039.0113; MULLER G, 1956, Z ZELLFORSCH MIK ANA, V44, P519; Nelson D.L, 2013, LEHNINGER PRINCIPLES, V6th; Nguyen GT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00373; OTTAVIANI E, 1983, DEV COMP IMMUNOL, V7, P209, DOI 10.1016/0145-305X(83)90002-2; OTTAVIANI E, 1991, TISSUE CELL, V23, P317, DOI 10.1016/0040-8166(91)90049-Y; Ottaviani E, 2013, BRAIN RES, V1537, P18, DOI 10.1016/j.brainres.2013.09.009; Ottaviani E, 2011, GEN COMP ENDOCR, V174, P1, DOI 10.1016/j.ygcen.2011.06.018; Paludan SR, 2021, NAT REV IMMUNOL, V21, P137, DOI 10.1038/s41577-020-0391-5; PAN C. T., 1958, Bulletin of the Museum of Comparative Zoology at Harvard College, V119, P237; PAN CT, 1956, J PARASITOL, V42, P33; PAN CT, 1965, AM J TROP MED HYG, V14, P931, DOI 10.4269/ajtmh.1965.14.931; Penagos-Tabares F, 2018, PARASITOL RES, V117, P1211, DOI 10.1007/s00436-018-5803-0; Perrier R., 1889, ANN SCI NAT        Z, V7, P61; Pickett JA, 2006, TRAFFIC, V7, P109, DOI 10.1111/j.1600-0854.2005.00372.x; Pila EA, 2016, DEV COMP IMMUNOL, V58, P119, DOI 10.1016/j.dci.2015.11.010; Ponder WF, 2020, BIOLOGY AND EVOLUTION OF THE MOLLUSCA, VOL 1, P1, DOI 10.1201/9781351115667; Ponder WF, 1997, ZOOL J LINN SOC-LOND, V119, P83, DOI 10.1111/j.1096-3642.1997.tb00137.x; Pozos TC, 2004, CURR OPIN IMMUNOL, V16, P499, DOI 10.1016/j.coi.2004.05.011; Chiumiento IR, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228325; Ramakrishnan L, 2012, NAT REV IMMUNOL, V12, P352, DOI 10.1038/nri3211; Robb CT, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5627; Robinson JM, 2009, HISTOCHEM CELL BIOL, V131, P465, DOI 10.1007/s00418-009-0565-5; Rodriguez C, 2021, PEERJ, V9, DOI 10.7717/peerj.10763; Rodriguez C, 2020, FISH SHELLFISH IMMUN, V107, P95, DOI 10.1016/j.fsi.2020.09.026; Rodriguez C, 2019, PEERJ, V7, DOI 10.7717/peerj.7342; Rodriguez C, 2018, PEERJ, V6, DOI 10.7717/peerj.5789; Sairi F, 2015, MAR BIOTECHNOL, V17, P168, DOI 10.1007/s10126-014-9605-9; Salamat Z, 2008, J PARASITOL, V94, P1170, DOI 10.1645/GE-1554.1; Scott M. I. H., 1958, Revista del Museo Argentino de las Ciencias Naturales Zool, V3, P233; Dreon MS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063782; Dreon MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015059; Selander B, 2006, J CLIN INVEST, V116, P1425, DOI 10.1172/JCI25982; Sharon N, 2004, GLYCOBIOLOGY, V14, p53R, DOI 10.1093/glycob/cwh122; SHOZAWA A, 1990, DEV COMP IMMUNOL, V14, P175, DOI 10.1016/0145-305X(90)90089-W; Simkiss K., 1983, P101; Skala V, 2018, DEV COMP IMMUNOL, V79, P137, DOI 10.1016/j.dci.2017.10.011; SMINIA T, 1972, Z ZELLFORSCH MIK ANA, V130, P497, DOI 10.1007/BF00307004; SMINIA T, 1974, CELL TISSUE RES, V150, P443; Smith VJ, 2016, EVOLUTION OF THE IMMUNE SYSTEM: CONSERVATION AND DIVERSIFICATION, P1, DOI 10.1016/B978-0-12-801975-7.00001-3; Soderhall I, 2005, J IMMUNOL, V174, P6153, DOI 10.4049/jimmunol.174.10.6153; Soderhall I, 2016, DEV COMP IMMUNOL, V58, P129, DOI 10.1016/j.dci.2015.12.009; Stewart H, 2014, INVERTEBR BIOL, V133, P47, DOI 10.1111/ivb.12041; Strong EE, 2003, ZOOL J LINN SOC-LOND, V137, P447, DOI 10.1046/j.1096-3642.2003.00058.x; Sullivan JT, 2007, J PARASITOL, V93, P213, DOI 10.1645/GE-956R.1; SULLIVAN JT, 1988, T AM MICROSC SOC, V107, P355, DOI 10.2307/3226330; Sullivan JT, 2004, J PARASITOL, V90, P92, DOI 10.1645/GE-3266; SULLIVAN JT, 1984, J INVERTEBR PATHOL, V44, P114, DOI 10.1016/0022-2011(84)90054-5; Sun J, 2019, MOL BIOL EVOL, V36, P1507, DOI 10.1093/molbev/msz084; Sun J, 2013, J PROTEOME RES, V12, P5271, DOI 10.1021/pr400570a; Swaim LE, 2006, INFECT IMMUN, V74, P6108, DOI 10.1128/IAI.00887-06; Tobin DM, 2008, CELL MICROBIOL, V10, P1027, DOI 10.1111/j.1462-5822.2008.01133.x; Ueki S, 2016, CURR ALLERGY ASTHM R, V16, DOI 10.1007/s11882-016-0634-5; UHLENBRUCK G, 1972, BLUT, V25, P335, DOI 10.1007/BF01631815; VANDERKNAAP WPW, 1981, DEV COMP IMMUNOL, V5, P21, DOI 10.1016/S0145-305X(81)80004-3; Vega IA, 2007, VELIGER, V48, P276; Wanninger A., 2015, EVOLUTIONARY DEV BIO; Wartha F, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.121pe25; Yang QQ, 2019, ZOOL STUD, V58, DOI 10.6620/ZS.2019.58-13; YOUSIF F, 1980, Z PARASITENKD, V62, P179, DOI 10.1007/BF00927863; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	142	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								879122	10.3389/fimmu.2022.879122	http://dx.doi.org/10.3389/fimmu.2022.879122			24	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6YI	35693764	Green Published, gold			2022-12-18	WOS:000808287300001
J	Saleem, M; Shaikh, S; Hu, Z; Pozzi, N; Java, A				Saleem, Maryam; Shaikh, Sana; Hu, Zheng; Pozzi, Nicola; Java, Anuja			Post-Transplant Thrombotic Microangiopathy due to a Pathogenic Mutation in Complement Factor I in a Patient With Membranous Nephropathy: Case Report and Review of Literature	FRONTIERS IN IMMUNOLOGY			English	Review						thrombotic microangiopathy; kidney transplantation; complement factor I; membranous nephropathy; atypical hemolytic uremic syndrome; complement functional analysis	MECHANISMS	Thrombotic microangiopathy (TMA) is characterized by microangiopathic hemolytic anemia, thrombocytopenia and organ injury occurring due to endothelial cell damage and microthrombi formation in small vessels. TMA is primary when a genetic or acquired defect is identified, as in atypical hemolytic uremic syndrome (aHUS) or secondary when occurring in the context of another disease process such as infection, autoimmune disease, malignancy or drugs. Differentiating between a primary complement-mediated process and one triggered by secondary factors is critical to initiate timely treatment but can be challenging for clinicians, especially after a kidney transplant due to presence of multiple confounding factors. Similarly, primary membranous nephropathy is an immune-mediated glomerular disease associated with circulating autoantibodies (directed against the M-type phospholipase A2 receptor (PLA2R) in 70% cases) while secondary membranous nephropathy is associated with infections, drugs, cancer, or other autoimmune diseases. Complement activation has also been proposed as a possible mechanism in the etiopathogenesis of primary membranous nephropathy; however, despite complement being a potentially common link, aHUS and primary membranous nephropathy have not been reported together. Herein we describe a case of aHUS due to a pathogenic mutation in complement factor I that developed after a kidney transplant in a patient with an underlying diagnosis of PLA2R antibody associated-membranous nephropathy. We highlight how a systematic and comprehensive analysis helped to define the etiology of aHUS, establish mechanism of disease, and facilitated timely treatment with eculizumab that led to recovery of his kidney function. Nonetheless, ongoing anti-complement therapy did not prevent recurrence of membranous nephropathy in the allograft. To our knowledge, this is the first report of a patient with primary membranous nephropathy and aHUS after a kidney transplant.	[Saleem, Maryam; Java, Anuja] Washington Univ, Dept Med, Div Nephrol, Sch Med, St. Louis, MO 63130 USA; [Shaikh, Sana] Univ Calif San Francisco, Dept Med, Div Nephrol, San Francisco, CA USA; [Hu, Zheng] Washington Univ, Dept Med, Div Rheumatol, Sch Med, St. Louis, MO USA; [Pozzi, Nicola] St Louis Univ, Edward A Doisy Res Ctr, Dept Biochem & Mol Biol, Sch Med, St. Louis, MO USA	Washington University (WUSTL); University of California System; University of California San Francisco; Washington University (WUSTL); Saint Louis University	Java, A (corresponding author), Washington Univ, Dept Med, Div Nephrol, Sch Med, St. Louis, MO 63130 USA.	ajava@wustl.edu	Pozzi, Nicola/AAC-1771-2021	Pozzi, Nicola/0000-0003-2309-7100				Ayoub I, 2021, KIDNEY INT REP, V6, P484, DOI 10.1016/j.ekir.2020.11.032; Brglez V, 2020, KIDNEY INT REP, V5, P572, DOI 10.1016/j.ekir.2020.02.1033; Cunningham PN, 2005, J AM SOC NEPHROL, V16, P1214, DOI 10.1681/ASN.2005010096; Forneris F, 2016, EMBO J, V35, P1133, DOI 10.15252/embj.201593673; Garg N, 2018, TRANSPLANT REV-ORLAN, V32, P58, DOI 10.1016/j.trre.2017.10.001; George JN, 2014, NEW ENGL J MED, V371, P654, DOI 10.1056/NEJMra1312353; Java A, 2019, KIDNEY INT REP, V4, P1007, DOI 10.1016/j.ekir.2019.04.003; Java A, 2013, ANNU REV MED, V64, P307, DOI 10.1146/annurev-med-072211-110606; Luo WT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01433; Ma H, 2013, SEMIN NEPHROL, V33, P531, DOI 10.1016/j.semnephrol.2013.08.004; Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528; Nilsson SC, 2009, EUR J IMMUNOL, V39, P310, DOI 10.1002/eji.200838702; Passerini P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01326; Palma LMP, 2021, KIDNEY INT REP, V6, P11, DOI 10.1016/j.ekir.2020.10.009; Reynolds JC, 2003, AM J KIDNEY DIS, V42, P1058, DOI 10.1016/j.ajkd.2003.07.008; SALANT DJ, 1989, KIDNEY INT, V35, P976, DOI 10.1038/ki.1989.81; Scully M, 2017, J THROMB HAEMOST, V15, P312, DOI 10.1111/jth.13571; Seikrit C, 2018, NEW ENGL J MED, V379, P2479, DOI 10.1056/NEJMc1805857; Sethi S, 2022, J AM SOC NEPHROL, V33, P1033, DOI 10.1681/ASN.2021111488; Zhang MF, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1509-5	20	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								909503	10.3389/fimmu.2022.909503	http://dx.doi.org/10.3389/fimmu.2022.909503			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2UY	35720299	Green Published, gold			2022-12-18	WOS:000812769700001
J	Tang, S; Li, J; Chang, YF; Lin, WC				Tang, Shuang; Li, Jie; Chang, Yung-Fu; Lin, Wencheng			Avian Leucosis Virus-Host Interaction: The Involvement of Host Factors in Viral Replication	FRONTIERS IN IMMUNOLOGY			English	Review						avian leukemia virus; interaction; immunosuppression; host factors; replication	PREMATURE STOP CODON; SUBGROUP-J; DECREASED SUSCEPTIBILITY; TVB RECEPTOR; INFECTION; SARCOMA; RESISTANCE; CHICKENS; DIFFERENTIATION; IDENTIFICATION	Avian leukosis virus (ALV) causes various diseases associated with tumor formation and decreased fertility. Moreover, ALV induces severe immunosuppression, increasing susceptibility to other microbial infections and the risk of failure in subsequent vaccination against other diseases. There is growing evidence showing the interaction between ALV and the host. In this review, we will survey the present knowledge of the involvement of host factors in the important molecular events during ALV infection and discuss the futuristic perspectives from this angle.	[Tang, Shuang; Lin, Wencheng] South China Agr Univ, Coll Anim Sci, Guangdong Prov Key Lab Agroanim Genom & Mol Breedi, Guangzhou, Peoples R China; [Li, Jie; Chang, Yung-Fu] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY USA; [Tang, Shuang; Lin, Wencheng] South China Agr Univ, Coll Anim Sci, Key Lab Chicken Genet Breeding & Reprod Minist Agr, Guangzhou, Peoples R China	South China Agricultural University; Cornell University; South China Agricultural University	Lin, WC (corresponding author), South China Agr Univ, Coll Anim Sci, Guangdong Prov Key Lab Agroanim Genom & Mol Breedi, Guangzhou, Peoples R China.; Lin, WC (corresponding author), South China Agr Univ, Coll Anim Sci, Key Lab Chicken Genet Breeding & Reprod Minist Agr, Guangzhou, Peoples R China.	wenchenglin@scau.edu.cn			National Natural Science Foundation of China [32072842, 31802206]; Natural Science Foundation of Guangdong Province [2021A1515011147]; Natural Science Foundation of Guangzhou [202102020942]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Natural Science Foundation of Guangzhou	Funding This work was supported by the National Natural Science Foundation of China (32072842, 31802206), the Natural Science Foundation of Guangdong Province (2021A1515011147), and the Natural Science Foundation of Guangzhou (202102020942).	Adkins HB, 1997, P NATL ACAD SCI USA, V94, P11617, DOI 10.1073/pnas.94.21.11617; Adkins HB, 2000, J VIROL, V74, P3572, DOI 10.1128/JVI.74.8.3572-3578.2000; Adkins HB, 2001, J VIROL, V75, P3520, DOI 10.1128/JVI.75.8.3520-3526.2001; Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Avila-Moreno F, 2006, CANCER IMMUNOL IMMUN, V55, P598, DOI 10.1007/s00262-005-0060-3; Barnard RJO, 2006, VIROLOGY, V344, P25, DOI 10.1016/j.virol.2005.09.021; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Braukmann M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122540; Chai N, 2006, P NATL ACAD SCI USA, V103, P5531, DOI 10.1073/pnas.0509785103; Chen J, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.596586; Chen SH, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.788317; Chen SH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.603131; Chen WG, 2017, ONCOTARGET, V8, P105942, DOI 10.18632/oncotarget.22512; Chen WG, 2015, SCI REP-UK, V5, DOI 10.1038/srep09900; Chesters PM, 2006, J GEN VIROL, V87, P2685, DOI 10.1099/vir.0.81884-0; Dai MM, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.747094; Dai MM, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010114; Dai MM, 2017, ONCOTARGET, V8, P99889, DOI 10.18632/oncotarget.21906; Dai MM, 2016, SCI REP-UK, V6, DOI 10.1038/srep19226; Dai M, 2017, MICROB PATHOGENESIS, V102, P29, DOI 10.1016/j.micpath.2016.11.014; Dai ZK, 2015, VIRUSES-BASEL, V7, P6538, DOI 10.3390/v7122956; Duan YY, 2022, MBIO, V13, DOI 10.1128/mbio.03287-21; Elleder D, 2005, J VIROL, V79, P10408, DOI 10.1128/JVI.79.16.10408-10419.2005; Elleder D, 2004, J VIROL, V78, P13489, DOI 10.1128/JVI.78.24.13489-13500.2004; Feng M, 2017, POULTRY SCI, V96, P42, DOI 10.3382/ps/pew229; Feng SZ, 2011, J GEN VIROL, V92, P1688, DOI 10.1099/vir.0.030866-0; Feng WG, 2017, MICROB PATHOGENESIS, V104, P48, DOI 10.1016/j.micpath.2017.01.013; Gao YN, 2016, ONCOTARGET, V7, P80275, DOI 10.18632/oncotarget.13282; Guan XL, 2018, J VIROL, V92, DOI [10.1128/JVI.01627-17, 10.1128/jvi.01627-17]; He SH, 2021, VET RES, V52, DOI 10.1186/s13567-021-00989-9; He SH, 2020, VET MICROBIOL, V247, DOI 10.1016/j.vetmic.2020.108781; He SH, 2019, RETROVIROLOGY, V16, DOI 10.1186/s12977-018-0463-9; Hellmich Romina, 2020, Front Genome Ed, V2, P3, DOI 10.3389/fgeed.2020.00003; Hendus-Altenburger R, 2014, CURR TOP MEMBR, V73, P69, DOI 10.1016/B978-0-12-800223-0.00002-5; Izquierdo-Useros N, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004146; Kawai K, 2018, HUM IMMUNOL, V79, P294, DOI 10.1016/j.humimm.2017.12.013; Kemp G, 2008, CHANNELS, V2, P329, DOI 10.4161/chan.2.5.6898; Klucking S, 2004, VIROLOGY, V318, P371, DOI 10.1016/j.virol.2003.09.024; Klucking S, 2002, J VIROL, V76, P7918, DOI 10.1128/JVI.76.15.7918-7921.2002; Knauss DJ, 2002, J VIROL, V76, P5404, DOI 10.1128/JVI.76.11.5404-5410.2002; Li LO, 2009, J BIOL CHEM, V284, P27816, DOI 10.1074/jbc.M109.022467; Li L, 2019, POULTRY SCI, V98, P6019, DOI 10.3382/ps/pez408; Li XJ, 2018, J VIROL, V92, DOI 10.1128/JVI.01770-17; Li ZH, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00017; Li ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep10294; Liao ZH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02841-y; Lin WC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01089; Liu D, 2016, INFECT GENET EVOL, V44, P130, DOI 10.1016/j.meegid.2016.06.045; Liu D, 2016, SCI REP-UK, V6, DOI 10.1038/srep20188; Mo GD, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.748795; Pang P, 2010, ACTA VIROL, V54, P119, DOI 10.4149/av_2010_02_119; Pang YL, 2022, VET MICROBIOL, V264, DOI 10.1016/j.vetmic.2021.109278; Pang Y, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.565773; Pang Y, 2019, VIRUS RES, V264, P32, DOI 10.1016/j.virusres.2019.02.014; Payne LN, 2012, AVIAN PATHOL, V41, P11, DOI 10.1080/03079457.2011.646237; Prikryl D, 2019, J VIROL, V93, DOI 10.1128/JVI.00580-19; Qiao DD, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13101968; Reinisova M, 2008, J VIROL, V82, P2097, DOI 10.1128/JVI.02206-07; Reinisova M, 2012, J VIROL, V86, P2021, DOI 10.1128/JVI.05771-11; Ren CQ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11080728; Ren CQ, 2018, VIROLOGY, V519, P121, DOI 10.1016/j.virol.2018.04.008; Ruan ZH, 2021, VIRUS RES, V296, DOI 10.1016/j.virusres.2021.198344; Salter D, 1999, POULTRY SCI, V78, P230, DOI 10.1093/ps/78.2.230; Smith JG, 2007, PLOS PATHOG, V3, P1971, DOI 10.1371/journal.ppat.0030198; Smith JG, 2004, J VIROL, V78, P1403, DOI 10.1128/JVI.78.3.1403-1410.2004; Tacke F, 2006, IMMUNOBIOLOGY, V211, P609, DOI 10.1016/j.imbio.2006.05.025; TSUKAMOTO K, 1992, J VET MED SCI, V54, P99, DOI 10.1292/jvms.54.99; Venugopal K, 1999, RES VET SCI, V67, P113, DOI 10.1053/rvsc.1998.0283; Wang F, 2011, J VET SCI, V12, P235, DOI 10.4142/jvs.2011.12.3.235; Wang Q, 2013, J GEN VIROL, V94, P2287, DOI 10.1099/vir.0.054007-0; Wang QJ, 2019, VET MICROBIOL, V236, DOI 10.1016/j.vetmic.2019.07.028; Wang Y, 2019, NAT CELL BIOL, V21, P1346, DOI 10.1038/s41556-019-0416-0; Witter RL, 2001, AVIAN PATHOL, V30, P641, DOI 10.1080/03079450120092134; Xiang Y, 2021, VET RES, V52, DOI 10.1186/s13567-021-00979-x; Xie TT, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060498; Xu MR, 2022, J VIROL, V96, DOI 10.1128/JVI.01549-21; Yao Y, 2014, J VIROL, V88, P2, DOI 10.1128/JVI.02921-13; Yu HL, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.587889; Zhang HM, 2005, AVIAN PATHOL, V34, P324, DOI 10.1080/03079450500179491; Zhang QH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.774323; Zhang XH, 2020, EXP THER MED, V20, P530, DOI 10.3892/etm.2020.8711; Zhang XH, 2019, RNA BIOL, V16, P118, DOI 10.1080/15476286.2018.1564462; Zhang Y, 2020, J VIROL, V94, DOI 10.1128/JVI.01232-20; Zhou JR, 2020, VET RES, V51, DOI 10.1186/s13567-020-00870-1; Zhou J, 2022, J VIROL, V96, DOI [10.1128/jvi.01657-21, 10.1128/JVI.01657-21]; Zhou LY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215454	86	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								907287	10.3389/fimmu.2022.907287	http://dx.doi.org/10.3389/fimmu.2022.907287			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6JY	35693802	Green Published, gold			2022-12-18	WOS:000808249900001
J	Tran, MH; Schoeder, CT; Schey, KL; Meiler, J				Tran, Minh H.; Schoeder, Clara T.; Schey, Kevin L.; Meiler, Jens			Computational Structure Prediction for Antibody-Antigen Complexes From Hydrogen-Deuterium Exchange Mass Spectrometry: Challenges and Outlook	FRONTIERS IN IMMUNOLOGY			English	Review						hydrogen-deuterium exchange mass spectrometry (HDX-MS); antibody-antigen interaction; epitope-paratope identification; protein-protein docking; structure modeling; integrative structural biology	PROTEIN-PROTEIN DOCKING; HIGHER-ORDER STRUCTURE; HYDROGEN/DEUTERIUM EXCHANGE; PROTEOLYTIC FRAGMENTATION; RESIDUE RESOLUTION; PROTECTION FACTORS; DYNAMICS; EPITOPE; THERAPEUTICS; DOMAIN	Although computational structure prediction has had great successes in recent years, it regularly fails to predict the interactions of large protein complexes with residue-level accuracy, or even the correct orientation of the protein partners. The performance of computational docking can be notably enhanced by incorporating experimental data from structural biology techniques. A rapid method to probe protein-protein interactions is hydrogen-deuterium exchange mass spectrometry (HDX-MS). HDX-MS has been increasingly used for epitope-mapping of antibodies (Abs) to their respective antigens (Ags) in the past few years. In this paper, we review the current state of HDX-MS in studying protein interactions, specifically Ab-Ag interactions, and how it has been used to inform computational structure prediction calculations. Particularly, we address the limitations of HDX-MS in epitope mapping and techniques and protocols applied to overcome these barriers. Furthermore, we explore computational methods that leverage HDX-MS to aid structure prediction, including the computational simulation of HDX-MS data and the combination of HDX-MS and protein docking. We point out challenges in interpreting and incorporating HDX-MS data into Ab-Ag complex docking and highlight the opportunities they provide to build towards a more optimized hybrid method, allowing for more reliable, high throughput epitope identification.	[Tran, Minh H.] Vanderbilt Univ, Chem & Phys Biol Program, Nashville, TN USA; [Tran, Minh H.; Schoeder, Clara T.; Meiler, Jens] Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA; [Tran, Minh H.; Schey, Kevin L.] Vanderbilt Univ, Mass Spectrometry Res Ctr, Dept Biochem, Nashville, TN 37235 USA; [Schoeder, Clara T.; Meiler, Jens] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; [Schoeder, Clara T.; Meiler, Jens] Univ Leipzig, Inst Drug Discovery, Med Sch, Leipzig, Germany	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Leipzig University	Meiler, J (corresponding author), Vanderbilt Univ, Ctr Struct Biol, Nashville, TN 37235 USA.; Schey, KL (corresponding author), Vanderbilt Univ, Mass Spectrometry Res Ctr, Dept Biochem, Nashville, TN 37235 USA.; Meiler, J (corresponding author), Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA.; Meiler, J (corresponding author), Univ Leipzig, Inst Drug Discovery, Med Sch, Leipzig, Germany.	k.schey@vanderbilt.edu; jens@meilerlab.org		Tran, Minh/0000-0002-3093-3659	National Institute of Health (NIH) [R01 GM073151]; RosettaCommons; NIH [U01 AI150739, U19 AI117905]	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RosettaCommons; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by a grant from the National Institute of Health (NIH) (R01 GM073151) and the RosettaCommons. Work in the Meiler laboratory is supported by the NIH (U01 AI150739 and U19 AI117905).	Abzalimov RR, 2010, ANAL CHEM, V82, P942, DOI 10.1021/ac9021874; Ahn J, 2013, BBA-PROTEINS PROTEOM, V1834, P1222, DOI 10.1016/j.bbapap.2012.10.003; Althaus Ernst, 2010, BMC Bioinformatics, V11, P424, DOI 10.1186/1471-2105-11-424; Babic D, 2019, RAPID COMMUN MASS SP, V33, P1248, DOI 10.1002/rcm.8460; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BAI YW, 1995, SCIENCE, V269, P192, DOI 10.1126/science.7618079; Balasubramaniam D, 2013, BBA-PROTEINS PROTEOM, V1834, P1202, DOI 10.1016/j.bbapap.2012.10.009; Bangaru S, 2019, CELL, V177, P1136, DOI 10.1016/j.cell.2019.04.011; Bender BJ, 2016, BIOCHEMISTRY-US, V55, P4748, DOI 10.1021/acs.biochem.6b00444; Bennett MR, 2019, MBIO, V10, DOI 10.1128/mBio.02473-19; Bennett MR, 2019, J INFECT DIS, V219, P1264, DOI 10.1093/infdis/jiy635; Best RB, 2006, STRUCTURE, V14, P97, DOI 10.1016/j.str.2005.09.012; Borysik AJ, 2017, ANGEW CHEM INT EDIT, V56, P9396, DOI 10.1002/anie.201704604; Bradshaw RT, 2020, BIOPHYS J, V118, P1649, DOI 10.1016/j.bpj.2020.02.005; Buss NAPS, 2012, CURR OPIN PHARMACOL, V12, P615, DOI 10.1016/j.coph.2012.08.001; Chalmers MJ, 2011, EXPERT REV PROTEOMIC, V8, P43, DOI [10.1586/epr.10.109, 10.1586/EPR.10.109]; Chaudhury S, 2008, J MOL BIOL, V381, P1068, DOI 10.1016/j.jmb.2008.05.042; Chaudhury S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022477; Cieplak-Rotowska MK, 2018, J AM SOC MASS SPECTR, V29, P158, DOI 10.1007/s13361-017-1830-9; Claesen J, 2019, J AM SOC MASS SPECTR, V30, P67, DOI 10.1007/s13361-018-2068-x; Comamala G, 2020, J AM SOC MASS SPECTR, V31, P2305, DOI 10.1021/jasms.0c00258; Comeau SR, 2004, BIOINFORMATICS, V20, P45, DOI 10.1093/bioinformatics/btg371; Craig PO, 2011, J AM CHEM SOC, V133, P17463, DOI 10.1021/ja207506z; Crowe JE, 2017, CELL HOST MICROBE, V22, P193, DOI 10.1016/j.chom.2017.07.013; Deng B, 2017, MABS-AUSTIN, V9, P1327, DOI 10.1080/19420862.2017.1379641; Deng B, 2016, ANAL CHIM ACTA, V940, P8, DOI 10.1016/j.aca.2016.08.006; Devaurs D, 2022, J AM SOC MASS SPECTR, V33, P215, DOI 10.1021/jasms.1c00328; Dovidchenko NV, 2009, BIOCHEMISTRY-MOSCOW+, V74, P888, DOI 10.1134/S0006297909080100; Engen JR, 2021, ANAL CHEM, V93, P567, DOI 10.1021/acs.analchem.0c04281; Engen JR, 2020, TRENDS BIOCHEM SCI, V45, P906, DOI 10.1016/j.tibs.2020.05.005; Fields JK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.779100; Fruton JS, 1938, SCIENCE, V87, P557, DOI 10.1126/science.87.2268.557; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Gallagher ES, 2016, METHOD ENZYMOL, V566, P357, DOI 10.1016/bs.mie.2015.08.010; Garcia NK, 2015, STRUCTURE, V23, P665, DOI 10.1016/j.str.2015.02.006; Gershoni JM, 2007, BIODRUGS, V21, P145, DOI 10.2165/00063030-200721030-00002; Gessner C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03922-3; Gramlich M, 2021, ANTIBODIES, V10, DOI 10.3390/antib10010011; Grauslund LR, 2021, J AM SOC MASS SPECTR, V32, P1575, DOI 10.1021/jasms.0c00431; Gray JJ, 2003, J MOL BIOL, V331, P281, DOI 10.1016/S0022-2836(03)00670-3; Guest JD, 2021, STRUCTURE, V29, P606, DOI 10.1016/j.str.2021.01.005; Hamuro Y, 2018, J AM SOC MASS SPECTR, V29, P989, DOI 10.1007/s13361-018-1892-3; Hamuro Y, 2018, J AM SOC MASS SPECTR, V29, P623, DOI 10.1007/s13361-017-1860-3; Hamuro Y, 2017, J AM SOC MASS SPECTR, V28, P486, DOI 10.1007/s13361-016-1571-1; Hansen J, 2020, SCIENCE, V369, P1010, DOI 10.1126/science.abd0827; Harris MJ, 2019, J AM SOC MASS SPECTR, V30, P58, DOI 10.1007/s13361-018-2070-3; Hauri S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07986-1; Houde Damian, 2013, Methods Mol Biol, V988, P269, DOI 10.1007/978-1-62703-327-5_17; Houde D, 2011, J PHARM SCI-US, V100, P2071, DOI 10.1002/jps.22432; Huang J, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-7; Huang LW, 2019, RAPID COMMUN MASS SP, V33, P83, DOI 10.1002/rcm.8307; Huang RYC, 2018, MABS-AUSTIN, V10, P95, DOI 10.1080/19420862.2017.1393595; Huang RYC, 2017, J AM SOC MASS SPECTR, V28, P795, DOI 10.1007/s13361-016-1452-7; Huang RYC, 2014, ANAL BIOANAL CHEM, V406, P6541, DOI 10.1007/s00216-014-7924-3; Hudgens JW, 2019, ANAL CHEM, V91, P7336, DOI 10.1021/acs.analchem.9b01100; Iacob RE, 2012, J AM SOC MASS SPECTR, V23, P1003, DOI 10.1007/s13361-012-0377-z; Illiano A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091986; James EI, 2022, CHEM REV, V122, P7562, DOI 10.1021/acs.chemrev.1c00279; Jensen PF, 2016, ANAL CHEM, V88, P12479, DOI 10.1021/acs.analchem.6b03951; Kan ZY, 2013, P NATL ACAD SCI USA, V110, P16438, DOI 10.1073/pnas.1315532110; Kastritis PL, 2014, J CHEM INF MODEL, V54, P826, DOI 10.1021/ci4005332; Keppel TR, 2015, J AM SOC MASS SPECTR, V26, P547, DOI 10.1007/s13361-014-1033-6; Kim SS, 2018, J PHYS CHEM B, V122, P3920, DOI 10.1021/acs.jpcb.8b01763; Komolov KE, 2017, CELL, V169, P407, DOI 10.1016/j.cell.2017.03.047; Konermann L, 2011, CHEM SOC REV, V40, P1224, DOI 10.1039/c0cs00113a; Kuenze G, 2019, STRUCTURE, V27, P1721, DOI 10.1016/j.str.2019.08.012; Kwong PD, 2020, SEMIN IMMUNOL, V50, DOI 10.1016/j.smim.2020.101428; Lin SJ, 2019, TOXINS, V11, DOI 10.3390/toxins11040233; Liu JKH, 2014, ANN MED SURG, V3, P113, DOI 10.1016/j.amsu.2014.09.001; Liu T, 2012, J AM SOC MASS SPECTR, V23, P43, DOI 10.1007/s13361-011-0267-9; Lu RM, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-019-0592-z; Mandell JG, 2001, PROTEIN ENG, V14, P105, DOI 10.1093/protein/14.2.105; Marcsisin SR, 2010, ANAL BIOANAL CHEM, V397, P967, DOI 10.1007/s00216-010-3556-4; Marze NA, 2017, PROTEINS, V85, P479, DOI 10.1002/prot.25168; Marzolf DR, 2021, J CHEM THEORY COMPUT, V17, P2619, DOI 10.1021/acs.jctc.1c00077; Masson GR, 2019, NAT METHODS, V16, P595, DOI 10.1038/s41592-019-0459-y; McAllister RG, 2015, BIOCHEMISTRY-US, V54, P2683, DOI 10.1021/acs.biochem.5b00215; Mohammadiarani H, 2018, J PHYS CHEM B, V122, P9314, DOI 10.1021/acs.jpcb.8b07494; Moller IR, 2019, ANAL CHEM, V91, P10970, DOI 10.1021/acs.analchem.9b00973; Morris Glenn E, 2005, Methods Mol Biol, V295, P255; Narang D, 2021, J AM SOC MASS SPECTR, V32, P1593, DOI 10.1021/jasms.0c00465; Narang D, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8070224; Nguyen D, 2018, J AM SOC MASS SPECTR, V29, P1936, DOI 10.1007/s13361-018-2021-z; Nikita V Dovidchenko, 2008, Open Biochem J, V2, P77, DOI 10.2174/1874091X00802010077; Nirudodhi SN, 2017, J PHARM SCI-US, V106, P530, DOI 10.1016/j.xphs.2016.10.023; Oganesyan I, 2018, METHODS, V144, P27, DOI 10.1016/j.ymeth.2018.04.023; Pancsa R, 2016, NUCLEIC ACIDS RES, V44, pD429, DOI 10.1093/nar/gkv1185; Pandit D, 2012, J MOL RECOGNIT, V25, P114, DOI 10.1002/jmr.1169; Park IH, 2015, J CHEM INF MODEL, V55, P1914, DOI 10.1021/acs.jcim.5b00185; Persson F, 2015, P NATL ACAD SCI USA, V112, P10383, DOI 10.1073/pnas.1506079112; Petruk AA, 2013, J CHEM THEORY COMPUT, V9, P658, DOI 10.1021/ct300519v; Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097; Pu CL, 2017, MEDCHEMCOMM, V8, P1452, DOI 10.1039/c7md00184c; Puchades C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41179-0; Rand KD, 2014, ACCOUNTS CHEM RES, V47, P3018, DOI 10.1021/ar500194w; Rob T, 2013, LAB CHIP, V13, P2528, DOI 10.1039/c3lc00007a; Roberts VA, 2017, BIOCHEMISTRY-US, V56, P6329, DOI 10.1021/acs.biochem.7b00643; Rodgers KR, 2016, BIOTECHNOL ADV, V34, P1149, DOI 10.1016/j.biotechadv.2016.07.004; Saltzberg DJ, 2017, J PHYS CHEM B, V121, P3493, DOI 10.1021/acs.jpcb.6b09358; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Schoeder CT, 2021, BIOCHEMISTRY-US, V60, P825, DOI 10.1021/acs.biochem.0c00912; Seffernick JT, 2020, J CHEM PHYS, V153, DOI 10.1063/5.0026025; Seffernick JT, 2019, J PHYS CHEM B, V123, P7103, DOI 10.1021/acs.jpcb.9b04333; Sela-Culang I, 2012, J IMMUNOL, V189, P4890, DOI 10.4049/jimmunol.1201493; Sevy AM, 2013, J THROMB HAEMOST, V11, P2128, DOI 10.1111/jth.12433; Sevy AM, 2019, P NATL ACAD SCI USA, V116, P1597, DOI 10.1073/pnas.1806004116; Sivasubramanian A, 2006, STRUCTURE, V14, P401, DOI 10.1016/j.str.2005.11.022; Sivasubramanian A, 2009, PROTEINS, V74, P497, DOI 10.1002/prot.22309; Skinner JJ, 2012, PROTEIN SCI, V21, P987, DOI 10.1002/pro.2082; Skinner SP, 2019, BIOPHYS J, V116, P1194, DOI 10.1016/j.bpj.2019.02.024; Sljoka A, 2013, PHYS BIOL, V10, DOI 10.1088/1478-3975/10/5/056013; Thornburg NJ, 2013, J CLIN INVEST, V123, P4405, DOI 10.1172/JCI69377; Trabjerg E, 2018, TRAC-TREND ANAL CHEM, V106, P125, DOI 10.1016/j.trac.2018.06.008; Tremblay C. Y., 2021, J AM SOC MASS SPECTR, V32, P1237, DOI [10.1021/jasms.1c00072, DOI 10.1021/JASMS.1C00072]; Turner HL, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000139; Vendruscolo M, 2003, J AM CHEM SOC, V125, P15686, DOI 10.1021/ja036523z; Vertrees J, 2005, BIOINFORMATICS, V21, P3318, DOI 10.1093/bioinformatics/bti520; Wales TE, 2006, MASS SPECTROM REV, V25, P158, DOI 10.1002/mas.20064; Walsh G, 2014, NAT BIOTECHNOL, V32, P992, DOI 10.1038/nbt.3040; Wang C, 2007, J MOL BIOL, V373, P503, DOI 10.1016/j.jmb.2007.07.050; Wang W, 2007, J PHARM SCI-US, V96, P1, DOI 10.1002/jps.20727; Wei H, 2014, DRUG DISCOV TODAY, V19, P95, DOI 10.1016/j.drudis.2013.07.019; Weitzner BD, 2017, NAT PROTOC, V12, P401, DOI 10.1038/nprot.2016.180; Wilson DJ, 2003, ANAL CHEM, V75, P6408, DOI 10.1021/ac0346757; Xiao KH, 2018, NAT PROTOC, V13, P1403, DOI 10.1038/nprot.2018.037; Xu JC, 2019, ELIFE, V8, DOI 10.7554/eLife.50928; Zehl M, 2008, J AM CHEM SOC, V130, P17453, DOI 10.1021/ja805573h; Zhang MM, 2020, ANAL CHEM, V92, P9086, DOI 10.1021/acs.analchem.0c01291; Zhang MM, 2019, ANAL CHEM, V91, P15709, DOI 10.1021/acs.analchem.9b03879; Zhang ZQ, 2020, ANAL CHEM, V92, P6486, DOI 10.1021/acs.analchem.9b05724; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522; Zhu R, 2017, METHOD ENZYMOL, V585, P397, DOI 10.1016/bs.mie.2016.11.009; Zhu SL, 2019, BIOCHEMISTRY-US, V58, P646, DOI 10.1021/acs.biochem.8b01123; Zhu SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120416	136	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								859964	10.3389/fimmu.2022.859964	http://dx.doi.org/10.3389/fimmu.2022.859964			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F4FM	35720345	gold, Green Published			2022-12-18	WOS:000812867400001
J	Wang, H; Yin, J; Gu, XY; Shao, WH; Jia, ZJ; Chen, HB; Xia, WW				Wang, Hao; Yin, Jie; Gu, Xinyan; Shao, Wenhui; Jia, Zhanjun; Chen, Hongbing; Xia, Weiwei			Immune Regulator Retinoic Acid-Inducible Gene I (RIG-I) in the Pathogenesis of Cardiovascular Disease	FRONTIERS IN IMMUNOLOGY			English	Review						RIG-I; activators; signal pathway; inflammation; cardiovascular diseases	PATTERN-RECOGNITION RECEPTORS; DOUBLE-STRANDED-RNA; ENDOTHELIAL-CELLS; POSSIBLE INVOLVEMENT; KAPPA-B; INFLAMMATION; ACTIVATION; EXPRESSION; VIRUS; INDUCTION	Retinoic acid-inducible gene I (RIG-I) is a cytosolic pattern recognition receptor that contains two CARD domains, an RNA helicase domain, and a C-terminal domain. RIG-I initiates antiviral innate immunity by recognizing exogenous viral RNAs/DNAs. However, some studies have reported that RIG-I activation leads to damage in various organs and tissues in diverse circumstances. Recent studies have shown that RIG-I is involved in cancer, lupus nephritis, immunoglobulin A nephropathy, Crohn's disease, and atherosclerosis. These reports indicate that RIG-I not only participates in antiviral signaling pathways but also exerts an influence on non-viral infectious diseases. RIG-I is widely expressed in immune and non-immune cells including smooth muscle cells, endothelial cells, and cardiomyocytes. A succinct overview of RIG-I and its signaling pathways, with respect to the cardiovascular system, will aid in the development of novel therapeutics for cardiovascular diseases. In this review, we summarize the structure, activation, signaling pathways, and role of RIG-I in cardiovascular diseases.	[Wang, Hao; Chen, Hongbing; Xia, Weiwei] Nanjing Med Univ, Childrens Hosp, Dept Clin Lab, Nanjing, Peoples R China; [Yin, Jie] Nanjing Med Univ, Childrens Hosp, Dept Cardiol, Nanjing, Peoples R China; [Gu, Xinyan; Shao, Wenhui] Nanjing Med Univ, Sch Pediat, Nanjing, Peoples R China; [Jia, Zhanjun; Xia, Weiwei] Nanjing Med Univ, Childrens Hosp, Dept Nephrol, Nanjing, Peoples R China; [Jia, Zhanjun; Xia, Weiwei] Nanjing Med Univ, Jiangsu Key Lab Pediat, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Chen, HB; Xia, WW (corresponding author), Nanjing Med Univ, Childrens Hosp, Dept Clin Lab, Nanjing, Peoples R China.; Jia, ZJ; Xia, WW (corresponding author), Nanjing Med Univ, Childrens Hosp, Dept Nephrol, Nanjing, Peoples R China.; Jia, ZJ; Xia, WW (corresponding author), Nanjing Med Univ, Jiangsu Key Lab Pediat, Nanjing, Peoples R China.	jiazj72@hotmail.com; chenghb1999@126.com; xiawwpku@163.com			National Natural Science Foundation of China [82070760, 82070701, 81600352,82100779]; Jiangsu Provincial Maternal and Child Health Research Institute [JSFY202105]; Nanjing National Commission on Health and Family Planning [ZKX19042, YKK18146]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial Maternal and Child Health Research Institute; Nanjing National Commission on Health and Family Planning	Funding This study was supported by a grant from the National Natural Science Foundation of China (no. 82070760, 82070701, 81600352,82100779), Jiangsu Provincial Maternal and Child Health Research Institute (no. JSFY202105); grants from the Nanjing National Commission on Health and Family Planning (no. ZKX19042 and YKK18146).	Ablasser A, 2009, NAT IMMUNOL, V10, P1065, DOI 10.1038/ni.1779; Anchisi S, 2015, MBIO, V6, DOI 10.1128/mBio.02349-14; Ando M, 2017, FREE RADICAL BIO MED, V112, P553, DOI 10.1016/j.freeradbiomed.2017.08.027; Araujo A, 2021, ELIFE, V10, DOI [10.7554/eLife.60478, 10.7554/eLife.60478.sa1, 10.7554/eLife.60478.sa2]; Asada Y, 2018, J ATHEROSCLER THROMB, V25, P653, DOI 10.5551/jat.RV17022; Asdonk T, 2012, BIOCHEM BIOPH RES CO, V420, P66, DOI 10.1016/j.bbrc.2012.02.116; Batool M, 2022, MED RES REV, V42, P399, DOI 10.1002/med.21845; Brisse M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01586; Carrion M, 2011, ARTHRITIS RHEUM-US, V63, P1626, DOI 10.1002/art.30294; Catalina MD, 1999, BLOOD, V93, P580, DOI 10.1182/blood.V93.2.580.402k16_580_589; Choi MK, 2009, P NATL ACAD SCI USA, V106, P17870, DOI 10.1073/pnas.0909545106; Chung HC, 2018, CELL, V172, P811, DOI 10.1016/j.cell.2017.12.038; da Conceicao TM, 2013, VIROLOGY, V435, P281, DOI 10.1016/j.virol.2012.09.038; Dayang EZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01169; Del Re DP, 2019, PHYSIOL REV, V99, P1763, DOI 10.1152/physrev.00022.2018; Devarkar SC, 2016, P NATL ACAD SCI USA, V113, P596, DOI 10.1073/pnas.1515152113; Errett JS, 2015, VIROL SIN, V30, P163, DOI 10.1007/s12250-015-3604-5; Fenyo IM, 2013, IMMUNOBIOLOGY, V218, P1376, DOI 10.1016/j.imbio.2013.06.005; Ferrage F, 2012, STRUCTURE, V20, P2048, DOI 10.1016/j.str.2012.09.003; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Funke B, 2011, INFLAMM BOWEL DIS, V17, P1943, DOI 10.1002/ibd.21572; Gaitzsch E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01148-x; Gao HY, 2022, GENE, V827, DOI 10.1016/j.gene.2022.146472; Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Hou J, 2014, CANCER CELL, V25, P49, DOI 10.1016/j.ccr.2013.11.011; Hu JB, 2021, MOL THER-NUCL ACIDS, V23, P55, DOI 10.1016/j.omtn.2020.10.034; Imaizumi T, 2005, PROSTAG OTH LIPID M, V78, P46, DOI 10.1016/j.prostaglandins.2005.02.006; Imaizumi T, 2004, ENDOTHELIUM-J ENDOTH, V11, P169, DOI 10.1080/10623320490512156; Imaizumi T, 2004, LIFE SCI, V75, P1171, DOI 10.1016/j.lfs.2004.01.030; Imaizumi T, 2010, LUPUS, V19, P830, DOI 10.1177/0961203309360540; Imaizumi T, 2002, BIOCHEM BIOPH RES CO, V292, P274, DOI 10.1006/bbrc.2002.6650; Imaizumi T, 2007, J ATHEROSCLER THROMB, V14, P51, DOI 10.5551/jat.14.51; Imaizumi T, 2009, IMMUNOL LETT, V122, P89, DOI 10.1016/j.imlet.2008.12.005; Jablonska A, 2018, J VASC SURG, V68, p39S, DOI 10.1016/j.jvs.2017.10.087; Jang MA, 2015, AM J HUM GENET, V96, P266, DOI 10.1016/j.ajhg.2014.11.019; Jiang LJ, 2011, P NATL ACAD SCI USA, V108, P1897, DOI 10.1073/pnas.1019059108; Jordan AM, 2022, TRANSPLANT REV-ORLAN, V36, DOI 10.1016/j.trre.2021.100672; Kamaladasa A, 2016, ANTIVIR RES, V133, P183, DOI 10.1016/j.antiviral.2016.07.016; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kell AM, 2015, VIROLOGY, V479, P110, DOI 10.1016/j.virol.2015.02.017; Kumar H, 2006, J EXP MED, V203, P1795, DOI 10.1084/jem.20060792; Lassig C, 2018, ELIFE, V7, DOI 10.7554/eLife.38958; Le TM, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-03023-w; Li Z, 2021, MOL CELL BIOCHEM, V476, P3241, DOI 10.1007/s11010-021-04157-7; Lin QY, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.560170; Liu F, 2011, NAT CELL BIOL, V13, P254, DOI 10.1038/ncb2167; Lobo-Silva D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0763-8; Luedde M, 2014, CARDIOVASC RES, V103, P206, DOI 10.1093/cvr/cvu146; Matsukawa A, 2000, Rev Immunogenet, V2, P339; McMaster WG, 2015, CIRC RES, V116, P1022, DOI 10.1161/CIRCRESAHA.116.303697; McNamara S, 2010, LEUKEMIA, V24, P729, DOI 10.1038/leu.2010.27; Merino I, 2022, CRIT CARE, V26, DOI 10.1186/s13054-022-03948-8; Myong S, 2009, SCIENCE, V323, P1070, DOI 10.1126/science.1168352; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Ramachandran B, 2018, J BIOL CHEM, V293, P7942, DOI 10.1074/jbc.RA118.002046; Rehwinkel J, 2010, SCIENCE, V327, P284, DOI 10.1126/science.1185068; Ringseis R, 2015, EXERC IMMUNOL REV, V21, P58; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Saito T, 2008, NATURE, V454, P523, DOI 10.1038/nature07106; Sakaki H, 2005, ORAL MICROBIOL IMMUN, V20, P47, DOI 10.1111/j.1399-302X.2005.00181.x; Schlee M, 2009, IMMUNITY, V31, P25, DOI 10.1016/j.immuni.2009.05.008; Schuberth-Wagner C, 2015, IMMUNITY, V43, P41, DOI 10.1016/j.immuni.2015.06.015; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Shan QL, 2014, TOXICOL APPL PHARM, V276, P136, DOI 10.1016/j.taap.2014.02.007; Shi FY, 2020, BMC VET RES, V16, DOI 10.1186/s12917-020-02486-1; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Tan YQ, 2022, BIOMED PHARMACOTHER, V148, DOI 10.1016/j.biopha.2022.112726; Thoresen D, 2021, IMMUNOL REV, V304, P154, DOI 10.1111/imr.13022; Tigano M, 2021, NATURE, V591, P477, DOI 10.1038/s41586-021-03269-w; Tsuruga K, 2015, NEPHROLOGY, V20, P916, DOI 10.1111/nep.12533; Verbsky J, 2022, CRIT CARE CLIN, V38, P443, DOI 10.1016/j.ccc.2021.11.012; Walsh D, 2013, CYTOKINE GROWTH F R, V24, P91, DOI 10.1016/j.cytogfr.2012.09.003; Wang F, 2012, CARDIOVASC RES, V93, P190, DOI 10.1093/cvr/cvr260; Wang L, 2020, COMPUT MATH METHOD M, V2020, DOI 10.1155/2020/8183420; Wang XW, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008024; Weber M, 2014, CYTOKINE GROWTH F R, V25, P621, DOI 10.1016/j.cytogfr.2014.05.004; Wei XM, 2021, BIOMED PHARMACOTHER, V143, DOI 10.1016/j.biopha.2021.112194; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Zendehdel A, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1157; Zeng Y, 2016, AGING CLIN EXP RES, V28, P69, DOI 10.1007/s40520-015-0371-y; Zhao JM, 2019, CELL CYCLE, V18, P3378, DOI 10.1080/15384101.2019.1677074; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967	88	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								893204	10.3389/fimmu.2022.893204	http://dx.doi.org/10.3389/fimmu.2022.893204			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6LL	35693778	gold, Green Published			2022-12-18	WOS:000808253800001
J	Wu, HW; Dong, JJ; Yu, HY; Wang, K; Dai, WE; Zhang, XZ; Hu, N; Yin, LH; Tang, DE; Liu, FN; Dai, Y				Wu, Hongwei; Dong, Jingjing; Yu, Haiyan; Wang, Kang; Dai, Weier; Zhang, Xinzhou; Hu, Nan; Yin, Lianghong; Tang, Donge; Liu, Fanna; Dai, Yong			Single-Cell RNA and ATAC Sequencing Reveal Hemodialysis-Related Immune Dysregulation of Circulating Immune Cell Subpopulations	FRONTIERS IN IMMUNOLOGY			English	Article						maintenance hemodialysis; single-cell RNA sequencing; single-cell assaying transposase accessible chromatin sequencing; T cell receptor; antigen presentation; immune pathways	DISEASE PATIENTS; PATHWAY; ATHEROSCLEROSIS; ACTIVATION; MONOCYTES; APOPTOSIS; RISK	BackgroundAn increased risk of infection, malignancy, and cardiovascular diseases in maintenance hemodialysis patients is associated with hemodialysis-related immunity disturbances. Although defects in T-lymphocyte-dependent immune responses and preactivation of antigen-presenting cells have been documented in hemodialysis patients, the effects of long-term hemodialysis on the transcriptional program and chromosomal accessibility of circulating immune cell subpopulations remain poorly defined. MethodsWe integrated single-cell RNA sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin sequencing (scATAC-seq) to characterize the transcriptome profiles of peripheral mononuclear cells (PBMCs) from healthy controls and maintenance hemodialysis patients. Validation of differentially expressed genes in CD4+ T cells and monocytes were performed by magnetic bead separation and quantitative real-time PCR. ResultsWe identified 16 and 15 PBMC subgroups in scRNA-seq and scATAC-seq datasets, respectively. Hemodialysis significantly suppressed the expression levels of T cell receptor (TCR) genes in CD4+ T cell subsets (e.g., TRAV4, CD45, CD3G, CD3D, CD3E) and major histocompatibility complex II (MHC-II) pathway-related genes in monocytes (HLA-DRB1, HLA-DQA2, HLA-DQA1, HLA-DPB1). Downstream pathways of TCR signaling, including PI3K-Akt-mTOR, MAPK, TNF, and NF-kappa B pathways, were also inhibited in CD4+ T cell subpopulations during the hemodialysis procedure. Hemodialysis altered cellular communication patterns between PBMC subgroups, particularly TGF-TGFBR, HVEM-BTLA, and IL16-CD4 signalings between CD4+ T cells and monocytes. Additionally, we found that hemodialysis inhibited the expression of AP-1 family transcription factors (JUN, JUND, FOS, FOSB) by interfering with the chromatin accessibility profile. ConclusionsOur study provides a valuable framework for future investigations of hemodialysis-related immune dysregulation and identifies potential therapeutic targets for reconstituting the circulating immune system in maintenance hemodialysis patients.	[Wu, Hongwei; Dong, Jingjing; Yu, Haiyan; Wang, Kang; Zhang, Xinzhou; Hu, Nan; Tang, Donge; Dai, Yong] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Peoples R China; [Wu, Hongwei; Dong, Jingjing; Yin, Lianghong; Liu, Fanna] Jinan Univ, Affiliated Hosp 1, Inst Nephrol & Blood Purificat, Guangzhou, Peoples R China; [Dai, Weier] Univ Texas Austin, Coll Nat Sci, Austin, TX USA	Jinan University; Jinan University; University of Texas System; University of Texas Austin	Tang, DE; Dai, Y (corresponding author), Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Shenzhen, Peoples R China.; Liu, FN (corresponding author), Jinan Univ, Affiliated Hosp 1, Inst Nephrol & Blood Purificat, Guangzhou, Peoples R China.	donge66@126.com; lfn-au@126.com; daiyong22@aliyun.com		, donge66/0000-0001-7011-196X; Dai, Yong/0000-0002-6840-9158	Science and Technology Plan of Shenzhen [JCYJ20190807153405508]; Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties [SZGSP001]; Key Renal Laboratory of Shenzhen, Department of Nephrology [ZDSYS201504301616234]; key-area Research in General Colleges and Universities of Guangdong Province [2021ZDZX2042]	Science and Technology Plan of Shenzhen; Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties; Key Renal Laboratory of Shenzhen, Department of Nephrology; key-area Research in General Colleges and Universities of Guangdong Province	This work was supported by The Science and Technology Plan of Shenzhen (NO.JCYJ20190807153405508), Shenzhen Fund for Guangdong Provincial High-level Clinical Key Specialties (NO.SZGSP001), Key Renal Laboratory of Shenzhen, Department of Nephrology (ZDSYS201504301616234), The key-area Research in General Colleges and Universities of Guangdong Province (2021ZDZX2042).	Angeletti A, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56020071; Borges A, 2011, RENAL FAILURE, V33, P138, DOI 10.3109/0886022X.2011.553300; Cai GF, 2009, IMMUNOL REV, V229, P244, DOI 10.1111/j.1600-065X.2009.00783.x; Herrero-Sanchez MC, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0343-5; Carracedo J, 2005, CONTRIB NEPHROL, V149, P208, DOI 10.1159/000085542; Cheung CY, 2016, AM J NEPHROL, V43, P153, DOI 10.1159/000445362; Collier S, 2014, NEPHROL DIAL TRANSPL, V29, P2158, DOI 10.1093/ndt/gfu321; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ducloux D, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-018-0121-z; Eleftheriadis T, 2007, SEMIN DIALYSIS, V20, P440, DOI 10.1111/J.1525-139X.2007.00283.x; Feng LP, 2021, RES VET SCI, V136, P622, DOI 10.1016/j.rvsc.2021.01.020; GIRNDT M, 1993, KIDNEY INT, V44, P359, DOI 10.1038/ki.1993.252; Glassman CR, 2018, CELL REP, V22, P1263, DOI 10.1016/j.celrep.2017.12.104; Gohda T, 2017, SCI REP-UK, V7, DOI 10.1038/srep43520; Granja JM, 2021, NAT GENET, V53, P403, DOI 10.1038/s41588-021-00790-6; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Hauser AB, 2008, PERITON DIALYSIS INT, V28, pS183; Horl WH, 2004, KIDNEY INT, V66, P1719, DOI 10.1111/j.1523-1755.2004.00944.x; Huang L, 2015, IMMUN AGEING, V12, DOI 10.1186/s12979-015-0055-7; Jiao XY, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1475-y; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; KAY N E, 1986, Blood Purification, V4, P120, DOI 10.1159/000169435; Kim KW, 2012, EXP MOL MED, V44, P465, DOI 10.3858/emm.2012.44.8.053; Kokubo K, 2015, BLOOD PURIFICAT, V40, P293, DOI 10.1159/000441576; Lau CI, 2021, DEVELOPMENT, V148, DOI 10.1242/dev.199754; Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730; Liakopoulos V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31889-2; Lisowska KA, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41619-x; Losappio V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103422; MALEFYT RD, 1991, J EXP MED, V174, P1209; Mehta AK, 2018, CYTOKINE, V101, P14, DOI 10.1016/j.cyto.2016.08.003; MEUER SC, 1987, J CLIN INVEST, V80, P743, DOI 10.1172/JCI113129; Mintz MA, 2019, IMMUNITY, V51, P310, DOI 10.1016/j.immuni.2019.05.022; Moura RA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182927; Nongnuch A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227719; Ouyang WM, 2013, IMMUNITY, V39, P335, DOI 10.1016/j.immuni.2013.07.016; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Riera-Sans L, 2007, J IMMUNOL, V178, P5690, DOI 10.4049/jimmunol.178.9.5690; Sarnak MJ, 2001, CHEST, V120, P1883, DOI 10.1378/chest.120.6.1883; Satpathy AT, 2019, NAT BIOTECHNOL, V37, P925, DOI 10.1038/s41587-019-0206-z; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; STACHOWSKI J, 1994, NEPHROL DIAL TRANSPL, V9, P144; Stagsted LVW, 2021, ELIFE, V10, DOI 10.7554/eLife.63088; Stefoni S, 2002, KIDNEY INT, V61, P324, DOI 10.1046/j.1523-1755.2002.00119.x; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Wang XL, 2021, GENOM PROTEOM BIOINF, V19, P253, DOI 10.1016/j.gpb.2020.02.005; Zaza G, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-17	50	0	0	9	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								878226	10.3389/fimmu.2022.878226	http://dx.doi.org/10.3389/fimmu.2022.878226			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F3QG	35720370	gold, Green Published			2022-12-18	WOS:000812826500001
J	Xu, LX; Yu, ZQ; He, K; Wen, ZH; Aleem, MT; Yan, RF; Song, XK; Lu, MM; Li, XR				Xu, Lixin; Yu, Zhengqing; He, Ke; Wen, Zhaohai; Aleem, Muhammad Tahir; Yan, Ruofeng; Song, Xiaokai; Lu, Mingmin; Li, XiangRui			PLGA Nanospheres as Delivery Platforms for Eimeria mitis 1a Protein: A Novel Strategy to Improve Specific Immunity	FRONTIERS IN IMMUNOLOGY			English	Article						Eimeria mitis; 1a protein; PLGA; chitosan; emulsion; protective efficacy	PROTECTIVE IMMUNITY; T-CELLS; VACCINE; CHITOSAN; DIFFERENTIATION; INFECTIONS; IDENTIFICATION; COCCIDIOSIS; ACERVULINA; ACTIVATION	The infections of chicken coccidiosis impact the welfare of chickens and the economical production of poultry. Eimeria mitis is ubiquitous in chicken coccidiosis, and E. mitis infection can significantly affect the productivity of birds. Up to now, few efficient vaccines against E. mitis have been reported, whereas the recombinant subunit vaccines delivered by nanomaterials may elicit an encouraging outcome. Thus, in this study, we chose E. mitis 1a (Em1a) protein as the candidate antigen to generate Em1a preparations. The recombinant Em1a (rEm1a) protein was encapsulated with poly lactic-co-glycolic acid (PLGA) and chitosan (CS) nanospheres. The physical characterization of the rEm1a-PLGA and rEm1a-CS nanospheres was investigated, and the resulting nanospheres were proven to be nontoxic. The protective efficacy of rEm1a-PLGA and rEm1a-CS preparations was evaluated in E. mitis-challenged birds in comparison with two preparations containing rEm1a antigen emulsified in commercially available adjuvants. ELISA assay, flow cytometry analysis, and quantitative real-time PCR (qPCR) analysis indicated that vaccination with rEm1a-loaded nanospheres significantly upregulated the secretions of antibodies and cytokines and proportions of CD4(+) and CD8(+) T lymphocytes. Compared with the other three preparations, rEm1a-PLGA nanosphere was more effective in improving growth performance and inhibiting oocyst output in feces, indicating that the PLGA nanosphere was associated with optimal protection against E. mitis. Collectively, our results highlighted the advantages of nanovaccine in eliciting protective immunity and may provide a new perspective for developing effective vaccines against chicken coccidiosis.	[Xu, Lixin; Yu, Zhengqing; He, Ke; Wen, Zhaohai; Aleem, Muhammad Tahir; Yan, Ruofeng; Song, Xiaokai; Lu, Mingmin; Li, XiangRui] Nanjing Agr Univ, Coll Vet Med, Minist Educ MOE, Joint Int Res Lab Anim Hlth & Food Safety, Nanjing, Peoples R China	Nanjing Agricultural University	Li, XR (corresponding author), Nanjing Agr Univ, Coll Vet Med, Minist Educ MOE, Joint Int Res Lab Anim Hlth & Food Safety, Nanjing, Peoples R China.	lixiangrui@njau.edu.cn	Lu, Mingmin/AHC-9178-2022	Lu, Mingmin/0000-0002-7343-7815	National Natural Science Foundation of China; Pakistan Science Foundation (NSFCPSF) [31661143017]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Pakistan Science Foundation (NSFCPSF)	This research was funded by a Joint Research Project between the National Natural Science Foundation of China and the Pakistan Science Foundation (NSFCPSF) (31661143017).	Ababneh H, 2021, INT J BIOL MACROMOL, V186, P314, DOI 10.1016/j.ijbiomac.2021.06.161; Allahyari M, 2016, HUM VACC IMMUNOTHER, V12, P806, DOI 10.1080/21645515.2015.1102804; Bedke T, 2019, SEMIN IMMUNOL, V44, DOI 10.1016/j.smim.2019.101335; Blake DP, 2020, VET RES, V51, DOI 10.1186/s13567-020-00837-2; Blake DP, 2014, TRENDS PARASITOL, V30, P12, DOI 10.1016/j.pt.2013.10.003; Blake DP, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001279; Bretscher PA, 2019, SCAND J IMMUNOL, V89, DOI 10.1111/sji.12762; Chapman HD, 2014, POULTRY SCI, V93, P501, DOI 10.3382/ps.2013-03634; Chereddy KK, 2016, WOUND REPAIR REGEN, V24, P223, DOI 10.1111/wrr.12404; Clark EL, 2017, TRENDS PARASITOL, V33, P231, DOI 10.1016/j.pt.2016.08.007; Dalloul RA, 2006, EXPERT REV VACCINES, V5, P143, DOI 10.1586/14760584.5.1.143; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Dimeloe S, 2017, IMMUNOLOGY, V150, P35, DOI 10.1111/imm.12655; Du XR, 2021, INT J NANOMED, V16, P1819, DOI 10.2147/IJN.S296527; Fan W, 2012, COLLOID SURFACE B, V90, P21, DOI 10.1016/j.colsurfb.2011.09.042; Fatoba AJ, 2020, ACTA TROP, V205, DOI 10.1016/j.actatropica.2020.105417; FITZCOY SH, 1992, AVIAN DIS, V36, P44, DOI 10.2307/1591713; FITZCOY SH, 1992, AVIAN DIS, V36, P718, DOI 10.2307/1591771; Francis MJ, 2018, VET CLIN N AM-SMALL, V48, P231, DOI 10.1016/j.cvsm.2017.10.002; Gaud G, 2018, NAT REV IMMUNOL, V18, P485, DOI 10.1038/s41577-018-0020-8; Gratton SEA, 2008, P NATL ACAD SCI USA, V105, P11613, DOI 10.1073/pnas.0801763105; Haseeb M, 2022, PARASITOL RES, V121, P675, DOI 10.1007/s00436-021-07420-4; Haug A, 2007, VET PARASITOL, V146, P35, DOI 10.1016/j.vetpar.2006.12.015; Herdiana Y, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2021.e08674; Hong YH, 2006, VET IMMUNOL IMMUNOP, V114, P209, DOI 10.1016/j.vetimm.2006.07.007; Hong YH, 2006, VET IMMUNOL IMMUNOP, V110, P339, DOI 10.1016/j.vetimm.2005.11.002; Huang JM, 2021, POULTRY SCI, V100, DOI 10.1016/j.psj.2021.101083; Illum L, 1998, PHARM RES-DORDR, V15, P1326; Iwaszko M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10113000; JOYNER LP, 1958, PARASITOLOGY, V48, P101, DOI 10.1017/S0031182000021090; JOYNER LP, 1983, PARASITOLOGY, V86, P381, DOI 10.1017/S0031182000050575; Kheirollahpour Mehdi, 2020, Pharmaceutical Nanotechnology, V8, P6, DOI 10.2174/2211738507666191024162042; Kim WH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02732; Koppolu BP, 2014, BIOMATERIALS, V35, P4382, DOI 10.1016/j.biomaterials.2014.01.078; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kwon YJ, 2005, P NATL ACAD SCI USA, V102, P18264, DOI 10.1073/pnas.0509541102; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Lee SH, 2010, VACCINE, V28, P6498, DOI 10.1016/j.vaccine.2010.06.116; Li J, 2018, EXP PARASITOL, V191, P1, DOI 10.1016/j.exppara.2018.05.003; Licona-Limon P, 2017, SEMIN IMMUNOPATHOL, V39, P29, DOI 10.1007/s00281-016-0606-9; Liu M, 2018, BIOESSAYS, V40, DOI 10.1002/bies.201800063; Liu TQ, 2018, VET PARASITOL, V253, P79, DOI 10.1016/j.vetpar.2018.02.027; Lopez-Osorio S, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00384; Mcallister MM, 2014, PARASITOLOGY, V141, P624, DOI 10.1017/S0031182013002060; Mesa-Pineda C, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.787653; MICHALSKI WP, 1992, INT J PARASITOL, V22, P1157, DOI 10.1016/0020-7519(92)90035-J; Min W, 2013, DEV COMP IMMUNOL, V41, P418, DOI 10.1016/j.dci.2013.04.003; Mittrucker HW, 2014, ARCH IMMUNOL THER EX, V62, P449, DOI 10.1007/s00005-014-0293-y; Moreno SNJ, 2011, ESSAYS BIOCHEM, V51, P97, DOI [10.1042/BSE0510097, 10.1042/bse0510097]; Ogedengbe JD, 2011, VET PARASITOL, V178, P350, DOI 10.1016/j.vetpar.2011.01.009; Parvizpour S, 2020, DRUG DISCOV TODAY, V25, P1034, DOI 10.1016/j.drudis.2020.03.006; Peek LJ, 2008, ADV DRUG DELIVER REV, V60, P915, DOI 10.1016/j.addr.2007.05.017; QUENTMEIER H, 1992, J IMMUNOL, V149, P3316; Rafiqi SI, 2018, VET PARASITOL, V258, P108, DOI 10.1016/j.vetpar.2018.06.013; Reddy ST, 2007, NAT BIOTECHNOL, V25, P1159, DOI [10.1038/nbt1332, 10.1038/nbtl332]; ROSE ME, 1991, PARASITE IMMUNOL, V13, P63, DOI 10.1111/j.1365-3024.1991.tb00263.x; RUFF MD, 1982, AM J VET RES, V43, P507; Salari F, 2015, INT IMMUNOPHARMACOL, V29, P672, DOI 10.1016/j.intimp.2015.09.011; Sasai K, 2000, VET MICROBIOL, V74, P345, DOI 10.1016/S0378-1135(00)00193-0; Schlosser PM, 2015, ENVIRON HEALTH PERSP, V123, P114, DOI 10.1289/ehp.1308030; SCHMATZ DM, 1989, MOL BIOCHEM PARASIT, V32, P263, DOI 10.1016/0166-6851(89)90075-3; Schnitzler BE, 1998, AVIAN PATHOL, V27, P490, DOI 10.1080/03079459808419373; Schnitzler BE, 1999, AVIAN PATHOL, V28, P89, DOI 10.1080/03079459995091; Skop NB, 2013, ACTA BIOMATER, V9, P6834, DOI 10.1016/j.actbio.2013.02.043; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Soutter F, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00101; Subramanian BM, 2008, VACCINE, V26, P3489, DOI 10.1016/j.vaccine.2008.04.024; Tan L, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2067-y; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Tang XM, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00888-17, 10.1128/iai.00888-17]; Tomley F, 1997, METHODS, V13, P171, DOI 10.1006/meth.1997.0509; van Riet E, 2014, ADV DRUG DELIVER REV, V74, P28, DOI 10.1016/j.addr.2014.05.011; Vasir JK, 2008, BIOMATERIALS, V29, P4244, DOI 10.1016/j.biomaterials.2008.07.020; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Venkatas J, 2019, PARASITOL RES, V118, P1701, DOI 10.1007/s00436-019-06338-2; Verdon DJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197357; VERMEULEN AN, 1993, FEMS MICROBIOL LETT, V110, P223, DOI 10.1111/j.1574-6968.1993.tb06324.x; Vrba V, 2010, VET PARASITOL, V174, P183, DOI 10.1016/j.vetpar.2010.09.006; Wallach M, 2010, TRENDS PARASITOL, V26, P382, DOI 10.1016/j.pt.2010.04.004; Wang WQ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020487; Wang YK, 2021, VET PARASITOL, V292, DOI 10.1016/j.vetpar.2021.109415; Williams RB, 2002, AVIAN PATHOL, V31, P317, DOI 10.1080/03079450220148988; Witcombe DM, 2014, PARASITOLOGY, V141, P1379, DOI 10.1017/S0031182014000195; Xing L, 2018, MOLECULES, V23, DOI 10.3390/molecules23020229; Xu QM, 2008, VET PARASITOL, V156, P319, DOI 10.1016/j.vetpar.2008.05.025; Zhang L, 2013, EXP PARASITOL, V133, P121, DOI 10.1016/j.exppara.2012.11.009; Zhang Y, 2014, ADV EXP MED BIOL, V841, P15, DOI 10.1007/978-94-017-9487-9_2; Zhang ZC, 2016, J EUKARYOT MICROBIOL, V63, P709, DOI 10.1111/jeu.12318; Zhang ZC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115411; Zhao PF, 2020, VET PARASITOL, V278, DOI 10.1016/j.vetpar.2020.109032; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	91	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								901758	10.3389/fimmu.2022.901758	http://dx.doi.org/10.3389/fimmu.2022.901758			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6YP	35693811	Green Published, gold			2022-12-18	WOS:000808288000001
J	Zang, SQ; Lv, LX; Liu, CF; Zhang, P; Li, C; Wang, JX				Zang, Shaoqing; Lv, Li-Xia; Liu, Chen-Fei; Zhang, Peng; Li, Cang; Wang, Jin-Xing			Metabolomic Investigation of Ultraviolet Ray-Inactivated White Spot Syndrome Virus-Induced Trained Immunity in Marsupenaeus japonicus	FRONTIERS IN IMMUNOLOGY			English	Article						trained immunity; shrimp; WSSV; GC-MS; MS; metabolites	DIETARY ARACHIDONIC-ACID; C-TYPE LECTIN; HEMOLYMPH MICROBIOTA; LITOPENAEUS-VANNAMEI; PROTEIN-SYNTHESIS; QUINIC ACID; SHRIMP; INNATE; INFECTION; MEMORY	Trained immunity is driven by metabolism and epigenetics in innate immune cells in mammals. The phenomenon of trained immunity has been identified in invertebrates, including shrimp, but the underlying mechanisms remain unclear. To elucidate mechanisms of trained immunity in shrimp, the metabolomic changes in hemolymph of Marsupenaeus japonicus trained by the UV-inactivated white spot syndrome virus (UV-WSSV) were analyzed using tandem gas chromatography-mass/mass spectrometry. The metabolomic profiles of shrimp trained with UV-WSSV followed WSSV infection showed significant differences comparison with the control groups, PBS injection followed WSSV infection. 16 differential metabolites in total of 154 metabolites were identified, including D-fructose-6-phosphate, D-glucose-6-phosphate, and D-fructose-6-phosphate, and metabolic pathways, glycolysis, pentose phosphate pathway, and AMPK signaling pathway were enriched in the UV-WSSV trained groups. Further study found that histone monomethylation and trimethylation at H3K4 (H3K4me1 and H3K4me3) were involved in the trained immunity. Our data suggest that the UV-WSSV induced trained immunity leads to metabolism reprogramming in the shrimp and provide insights for WSSV control in shrimp aquaculture.	[Zang, Shaoqing; Lv, Li-Xia; Liu, Chen-Fei; Zhang, Peng; Li, Cang; Wang, Jin-Xing] Shandong Univ, Sch Life Sci, Shandong Prov Key Lab Anim Cells & Dev Biol, Qingdao, Peoples R China; [Wang, Jin-Xing] Shandong Univ, State Key Lab Microbial Technol, Qingdao, Peoples R China	Shandong University; Shandong University	Wang, JX (corresponding author), Shandong Univ, Sch Life Sci, Shandong Prov Key Lab Anim Cells & Dev Biol, Qingdao, Peoples R China.; Wang, JX (corresponding author), Shandong Univ, State Key Lab Microbial Technol, Qingdao, Peoples R China.	jxwang@sdu.edu.cn						Aguilar V, 2012, AQUACULT NUTR, V18, P258, DOI 10.1111/j.1365-2095.2011.00892.x; Appuhamy JADRN, 2012, J NUTR, V142, P484, DOI 10.3945/jn.111.152595; Arts RJW, 2016, CELL METAB, V24, P807, DOI 10.1016/j.cmet.2016.10.008; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Bekkering S, 2019, CELL METAB, V30, P1, DOI 10.1016/j.cmet.2019.05.014; Chang YH, 2018, DEV COMP IMMUNOL, V80, P53, DOI 10.1016/j.dci.2017.03.003; Chen IT, 2011, J VIROL, V85, P12919, DOI 10.1128/JVI.05385-11; Chen YR, 2015, J CANCER RES CLIN, V141, P705, DOI 10.1007/s00432-014-1846-5; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Chidambaram A, 2017, INVEST NEW DRUG, V35, P691, DOI 10.1007/s10637-017-0489-1; Chong IG, 2005, CHEMOMETR INTELL LAB, V78, P103, DOI 10.1016/j.chemolab.2004.12.011; D'Aniello C, 2017, STEM CELL REP, V8, P1, DOI 10.1016/j.stemcr.2016.11.011; Damink SWMO, 2007, HEPATOLOGY, V45, P560, DOI 10.1002/hep.21463; Das Q, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00150; Dhondge SS, 2015, J CHEM THERMODYN, V81, P34, DOI 10.1016/j.jct.2014.09.011; Ding ZL, 2018, AQUACULTURE, V484, P112, DOI 10.1016/j.aquaculture.2017.11.010; Divangahi M, 2021, NAT IMMUNOL, V22, P2, DOI 10.1038/s41590-020-00845-6; Donohoe DR, 2012, J CELL PHYSIOL, V227, P3169, DOI 10.1002/jcp.24054; Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335; Gao J, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109761; Gu CS, 2019, CURR PROTEIN PEPT SC, V20, P644, DOI 10.2174/1389203720666190305163135; Hernandez-Palomares MLE, 2018, FISH SHELLFISH IMMUN, V74, P401, DOI 10.1016/j.fsi.2018.01.011; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Kalafati L, 2020, CELL, V183, P771, DOI 10.1016/j.cell.2020.09.058; Kamng'ona A, 2011, J ENZYM INHIB MED CH, V26, P843, DOI 10.3109/14756366.2011.566220; Kelly B, 2020, CELL METAB, V32, P154, DOI 10.1016/j.cmet.2020.06.010; Kongnum K, 2012, FISH SHELLFISH IMMUN, V32, P170, DOI 10.1016/j.fsi.2011.11.008; Li C, 2021, J IMMUNOL, V206, P2075, DOI 10.4049/jimmunol.2001318; Li C, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009479; Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027; Low CF, 2017, J FISH DIS, V40, P1267, DOI 10.1111/jfd.12610; Naiel MAE, 2021, AQUACULT INT, V29, P219, DOI 10.1007/s10499-020-00620-2; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; Netea MG, 2019, CELL HOST MICROBE, V25, P13, DOI 10.1016/j.chom.2018.12.006; Netea MG, 2016, SCIENCE, V352, DOI 10.1126/science.aaf1098; Netea MG, 2011, CELL HOST MICROBE, V9, P355, DOI 10.1016/j.chom.2011.04.006; Norouzitallab P, 2016, SCI REP-UK, V6, DOI 10.1038/srep21166; Norouzitallab P, 2015, FISH SHELLFISH IMMUN, V42, P426, DOI 10.1016/j.fsi.2014.11.029; Pereira AD, 2003, Z NATURFORSCH C, V58, P590; Pinta MN, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201800396; Ramirez-Prado JS, 2018, TRENDS PLANT SCI, V23, P833, DOI 10.1016/j.tplants.2018.06.004; Rodriguez RM, 2019, TRENDS IMMUNOL, V40, P66, DOI 10.1016/j.it.2018.11.006; Roy S, 2020, REV AQUACULT, V12, P2351, DOI 10.1111/raq.12438; Sangster T, 2006, ANALYST, V131, P1075, DOI 10.1039/b604498k; Schroeder EA, 2012, CELL METAB, V15, P417, DOI 10.1016/j.cmet.2012.03.011; Tao SY, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01764; Thevenot EA, 2015, J PROTEOME RES, V14, P3322, DOI 10.1021/acs.jproteome.5b00354; Tretter L, 2016, BBA-BIOENERGETICS, V1857, P1086, DOI 10.1016/j.bbabio.2016.03.012; Trygg J, 2002, J CHEMOMETR, V16, P119, DOI 10.1002/cem.695; Wang SA, 2009, MOL BIOL REP, V36, P1683, DOI 10.1007/s11033-008-9369-2; Wang XW, 2015, MOL IMMUNOL, V68, P404, DOI 10.1016/j.molimm.2015.06.018; Wang XW, 2014, J IMMUNOL, V193, P2106, DOI 10.4049/jimmunol.1400552; Wang XW, 2014, J BIOL CHEM, V289, P11779, DOI 10.1074/jbc.M114.552307; Want EJ, 2013, NAT PROTOC, V8, P17, DOI 10.1038/nprot.2012.135; Want EJ, 2010, NAT PROTOC, V5, P1005, DOI 10.1038/nprot.2010.50; Zanello PR, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0443-9; Zarse K, 2012, CELL METAB, V15, P451, DOI 10.1016/j.cmet.2012.02.013	58	0	0	20	21	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								885782	10.3389/fimmu.2022.885782	http://dx.doi.org/10.3389/fimmu.2022.885782			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6LC	35693782	Green Published, gold			2022-12-18	WOS:000808252900001
J	Zawistowska-Deniziak, A; Lambooij, JM; Kalinowska, A; Patente, TA; Lapinski, M; van der Zande, HJP; Basalaj, K; de Korne, CM; Chaye, MAM; Gasan, TA; Norbury, LJ; Giera, M; Zaldumbide, A; Smits, HH; Guigas, B				Zawistowska-Deniziak, Anna; Lambooij, Joost M.; Kalinowska, Alicja; Patente, Thiago A.; Lapinski, Maciej; van der Zande, Hendrik J. P.; Basalaj, Katarzyna; de Korne, Clarize M.; Chaye, Mathilde A. M.; Gasan, Thomas A.; Norbury, Luke J.; Giera, Martin; Zaldumbide, Arnaud; Smits, Hermelijn H.; Guigas, Bruno			Fasciola hepatica Fatty Acid Binding Protein 1 Modulates T cell Polarization by Promoting Dendritic Cell Thrombospondin-1 Secretion Without Affecting Metabolic Homeostasis in Obese Mice	FRONTIERS IN IMMUNOLOGY			English	Article						helminths; liver fluke; dendritic cells; Th2; Th1; TSP-1; metaflammation; immunometabolism	TGF-BETA; INFECTION; HELMINTHS; INDUCE; MACROPHAGES; EXPRESSION; RESPONSES; ANTIGENS; DIFFERENTIATION; INFLAMMATION	BackgroundThe parasitic trematode Fasciola hepatica evades host immune defenses through secretion of various immunomodulatory molecules. Fatty Acid Binding Proteins (fhFABPs) are among the main excreted/secreted proteins and have been shown to display anti-inflammatory properties. However, little is currently known regarding their impact on dendritic cells (DCs) and their subsequent capacity to prime specific CD4(+) T cell subsets. Methodology/Principal FindingsThe immunomodulatory effects of both native F. hepatica extracts and recombinant fhFABPs were assessed on monocyte-derived human DCs (moDCs) and the underlying mechanism was next investigated using various approaches, including DC-allogenic T cell co-culture and DC phenotyping through transcriptomic, proteomic and FACS analyses. We mainly showed that fhFABP1 induced a tolerogenic-like phenotype in LPS-stimulated moDCs characterized by a dose-dependent increase in the cell-surface tolerogenic marker CD103 and IL-10 secretion, while DC co-stimulatory markers were not affected. A significant decrease in secretion of the pro-inflammatory cytokines IL-12p70 and IL-6 was also observed. In addition, these effects were associated with an increase in both Th2-on-Th1 ratio and IL-10 secretion by CD4(+) T cells following DC-T cell co-culture. RNA sequencing and targeted proteomic analyses identified thrombospondin-1 (TSP-1) as a non-canonical factor highly expressed and secreted by fhFABP1-primed moDCs. The effect of fhFABP1 on T cell skewing was abolished when using a TSP-1 blocking antibody during DC-T cell co-culture. Immunomodulation by helminth molecules has been linked to improved metabolic homeostasis during obesity. Although fhFABP1 injection in high-fat diet-fed obese mice induced a potent Th2 immune response in adipose tissue, it did not improved insulin sensitivity or glucose homeostasis. Conclusions/SignificanceWe show that fhFABP1 modulates T cell polarization, notably by promoting DC TSP-1 secretion in vitro, without affecting metabolic homeostasis in a mouse model of type 2 diabetes.	[Zawistowska-Deniziak, Anna; Lambooij, Joost M.; Patente, Thiago A.; van der Zande, Hendrik J. P.; de Korne, Clarize M.; Chaye, Mathilde A. M.; Gasan, Thomas A.; Smits, Hermelijn H.; Guigas, Bruno] Leiden Univ Med Ctr, Dept Parasitol, Leiden, Netherlands; [Zawistowska-Deniziak, Anna; Kalinowska, Alicja; Basalaj, Katarzyna; Norbury, Luke J.] Polish Acad Sci, Witold Stefanski Inst Parasitol, Warsaw, Poland; [Zawistowska-Deniziak, Anna; Lambooij, Joost M.; Patente, Thiago A.; van der Zande, Hendrik J. P.; de Korne, Clarize M.; Chaye, Mathilde A. M.; Gasan, Thomas A.; Smits, Hermelijn H.; Guigas, Bruno] Leiden Univ, Ctr Infect Dis, Leiden, Netherlands; [Lapinski, Maciej] Int Inst Mol & Cell Biol, Warsaw, Poland; [de Korne, Clarize M.] Leiden Univ Med Ctr, Dept Radiol, Intervent Mol Imaging Lab, Leiden, Netherlands; [Norbury, Luke J.] Royal Melbourne Inst Technol RMIT Univ, STEM Coll, Sch Sci, Bundoora, VIC, Australia; [Giera, Martin] Leiden Univ Med Ctr, Ctr Prote & Metabol, Leiden, Netherlands; [Zaldumbide, Arnaud] Leiden Univ Med Ctr, Dept Cell & Chem Biol, Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Polish Academy of Sciences; Witold Stefanski Institute of Parasitology of the Polish Academy of Sciences; Leiden University; Leiden University - Excl LUMC; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Leiden University; Leiden University Medical Center (LUMC); Royal Melbourne Institute of Technology (RMIT); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC)	Zawistowska-Deniziak, A; Guigas, B (corresponding author), Leiden Univ Med Ctr, Dept Parasitol, Leiden, Netherlands.; Zawistowska-Deniziak, A (corresponding author), Polish Acad Sci, Witold Stefanski Inst Parasitol, Warsaw, Poland.; Zawistowska-Deniziak, A; Guigas, B (corresponding author), Leiden Univ, Ctr Infect Dis, Leiden, Netherlands.	anna.zawistowska@twarda.pan.pl; b.g.a.guigas@lumc.nl						Adorini L, 2003, ANN NY ACAD SCI, V987, P258, DOI 10.1111/j.1749-6632.2003.tb06057.x; Aldridge A, 2016, EUR J IMMUNOL, V46, P1180, DOI 10.1002/eji.201545905; Bakdash G, 2014, VACCINE, V32, P6294, DOI 10.1016/j.vaccine.2014.08.075; Baska P, 2013, ACTA PARASITOL, V58, P215, DOI 10.2478/s11686-013-0126-x; Becerro-Recio D, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10060725; Carvalho L, 2009, IMMUNOLOGY, V126, P28, DOI 10.1111/j.1365-2567.2008.03008.x; Clery DG, 1998, RES VET SCI, V65, P169, DOI 10.1016/S0034-5288(98)90171-0; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Cwiklinski K, 2016, PARASITE IMMUNOL, V38, P558, DOI 10.1111/pim.12343; Doyen V, 2003, J EXP MED, V198, P1277, DOI 10.1084/jem.20030705; Embgenbroich M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103304118; Everts B, 2010, EUR J IMMUNOL, V40, P1525, DOI 10.1002/eji.200940109; Falcon C, 2010, VET IMMUNOL IMMUNOP, V137, P36, DOI 10.1016/j.vetimm.2010.04.007; Falcon CR, 2012, J INFECT DIS, V205, P506, DOI 10.1093/infdis/jir606; Ferreira GB, 2015, CELL REP, V10, P711, DOI 10.1016/j.celrep.2015.01.013; Figueroa-Santiago O, 2014, INFECT IMMUN, V82, P5005, DOI 10.1128/IAI.02541-14; Flynn RJ, 2008, INT J PARASITOL, V38, P1673, DOI 10.1016/j.ijpara.2008.05.008; Grimbert P, 2006, J IMMUNOL, V177, P3534, DOI 10.4049/jimmunol.177.6.3534; Guasconi L, 2015, IMMUNOBIOLOGY, V220, P934, DOI 10.1016/j.imbio.2015.02.001; Hamilton CM, 2009, INFECT IMMUN, V77, P2488, DOI 10.1128/IAI.00919-08; Hansen IS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03318-5; Hill DA, 2018, P NATL ACAD SCI USA, V115, pE5096, DOI 10.1073/pnas.1802611115; Hotamisligil GS, 2017, NATURE, V542, P177, DOI 10.1038/nature21363; Huby T, 2022, NAT REV IMMUNOL, V22, P429, DOI 10.1038/s41577-021-00639-3; Hussaarts L, 2015, FASEB J, V29, P3027, DOI 10.1096/fj.14-266239; Hussaarts L, 2013, IMMUNOL CELL BIOL, V91, P486, DOI 10.1038/icb.2013.31; Jaitin DA, 2019, CELL, V178, P686, DOI 10.1016/j.cell.2019.05.054; Jefferies JR, 2001, PROTEOMICS, V1, P1128, DOI 10.1002/1615-9861(200109)1:9<1128::AID-PROT1128>3.0.CO;2-0; Kuipers ME, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1753420; Li C, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126453; Loetscher P, 2001, J BIOL CHEM, V276, P2986, DOI 10.1074/jbc.M005652200; Loukas A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.88; Maizels RM, 2018, IMMUNITY, V49, P801, DOI 10.1016/j.immuni.2018.10.016; Maizels RM, 2016, J ALLERGY CLIN IMMUN, V138, P666, DOI 10.1016/j.jaci.2016.07.007; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Manicassamy S, 2011, IMMUNOL REV, V241, P206, DOI 10.1111/j.1600-065X.2011.01015.x; Marsland BJ, 2005, IMMUNITY, V22, P493, DOI 10.1016/j.immuni.2005.02.010; McSorley HJ, 2012, CLIN MICROBIOL REV, V25, P585, DOI 10.1128/CMR.05040-11; Mlocicki D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02487; Molofsky AB, 2013, J EXP MED, V210, P535, DOI 10.1084/jem.20121964; Morelli AE, 2007, NAT REV IMMUNOL, V7, P610, DOI 10.1038/nri2132; Morphew RM, 2007, MOL CELL PROTEOMICS, V6, P963, DOI 10.1074/mcp.M600375-MCP200; Norbury LJ, 2018, VET PARASITOL, V258, P14, DOI 10.1016/j.vetpar.2018.05.008; O'Neill SM, 2000, PARASITE IMMUNOL, V22, P147, DOI 10.1046/j.1365-3024.2000.00290.x; Patente TA, 2019, CURR OPIN IMMUNOL, V58, P16, DOI 10.1016/j.coi.2019.02.003; Pearce EJ, 2015, NAT REV IMMUNOL, V15, P18, DOI 10.1038/nri3771; Perrigoue JG, 2008, CELL MICROBIOL, V10, P1757, DOI 10.1111/j.1462-5822.2008.01174.x; Ricardo-Gonzalez RR, 2010, P NATL ACAD SCI USA, V107, P22617, DOI 10.1073/pnas.1009152108; Robinson MW, 2009, MOL CELL PROTEOMICS, V8, P1891, DOI 10.1074/mcp.M900045-MCP200; Rodriguez E, 2017, SCI REP-UK, V7, DOI 10.1038/srep46748; Rodriguez-Jimenez P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01268; Roe MM, 2017, J LEUKOCYTE BIOL, V101, P1169, DOI 10.1189/jlb.1MA0316-131R; Rohm TV, 2022, IMMUNITY, V55, P31, DOI 10.1016/j.immuni.2021.12.013; Roncarolo MG, 2018, IMMUNITY, V49, P1004, DOI 10.1016/j.immuni.2018.12.001; Ruiz-Jimenez C, 2021, EXP PARASITOL, V231, DOI 10.1016/j.exppara.2021.108174; Ryan S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02182; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Schulke S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00455; Soto-Pantoja DR, 2015, CRIT REV BIOCHEM MOL, V50, P212, DOI 10.3109/10409238.2015.1014024; Timanova-Atanasova A, 2004, BBA-GEN SUBJECTS, V1674, P200, DOI 10.1016/j.bbagen.2004.06.018; Trim WV, 2022, NAT REV IMMUNOL, V22, P371, DOI 10.1038/s41577-021-00635-7; van der Zande HJP, 2021, FASEB J, V35, DOI 10.1096/fj.202001973R; van der Zande HJP, 2019, TRENDS PARASITOL, V35, P795, DOI 10.1016/j.pt.2019.07.014; Vukman KV, 2013, PARASITE IMMUNOL, V35, P234, DOI 10.1111/pim.12033; Walsh KP, 2009, J IMMUNOL, V183, P1577, DOI 10.4049/jimmunol.0803803; Wculek SK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00775; White MPJ, 2020, IMMUNOLOGY, V160, P248, DOI 10.1111/imm.13190; Wu D, 2011, SCIENCE, V332, P243, DOI 10.1126/science.1201475; Zawistowska-Deniziak A, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020174	69	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								884663	10.3389/fimmu.2022.884663	http://dx.doi.org/10.3389/fimmu.2022.884663			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F1QH	35720355	Green Submitted, gold, Green Published			2022-12-18	WOS:000812689800001
J	Zhai, SY; Kong, MCG.; Xia, YM				Zhai, Si-yue; Kong, Michael G.; Xia, Yu-min			Cold Atmospheric Plasma Ameliorates Skin Diseases Involving Reactive Oxygen/Nitrogen Species-Mediated Functions	FRONTIERS IN IMMUNOLOGY			English	Review						cold atmospheric plasma; reactive oxygen species; reactive nitrogen species; skin disease; therapy	BARRIER DISCHARGE TREATMENT; STEM-CELLS; IN-VITRO; JET; INACTIVATION; BIOFILM; ROS; PATHOGENESIS; INHIBITION; EXPRESSION	Skin diseases are mainly divided into infectious diseases, non-infectious inflammatory diseases, cancers, and wounds. The pathogenesis might include microbial infections, autoimmune responses, aberrant cellular proliferation or differentiation, and the overproduction of inflammatory factors. The traditional therapies for skin diseases, such as oral or topical drugs, have still been unsatisfactory, partly due to systematic side effects and reappearance. Cold atmospheric plasma (CAP), as an innovative and non-invasive therapeutic approach, has demonstrated its safe and effective functions in dermatology. With its generation of reactive oxygen species and reactive nitrogen species, CAP exhibits significant efficacies in inhibiting bacterial, viral, and fungal infections, facilitating wound healing, restraining the proliferation of cancers, and ameliorating psoriatic or vitiligous lesions. This review summarizes recent advances in CAP therapies for various skin diseases and implicates future strategies for increasing effectiveness or broadening clinical indications.	[Zhai, Si-yue; Xia, Yu-min] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Dermatol, Xi'an, Peoples R China; [Zhai, Si-yue; Kong, Michael G.] Xi An Jiao Tong Univ, Ctr Plasma Biomed, State Key Lab Elect Insulat & Power Equipment, Xi'an, Peoples R China; [Kong, Michael G.] Xi An Jiao Tong Univ, Sch Elect Engn, Xi'an, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong University	Xia, YM (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Dermatol, Xi'an, Peoples R China.; Kong, MCG. (corresponding author), Xi An Jiao Tong Univ, Ctr Plasma Biomed, State Key Lab Elect Insulat & Power Equipment, Xi'an, Peoples R China.; Kong, MCG. (corresponding author), Xi An Jiao Tong Univ, Sch Elect Engn, Xi'an, Peoples R China.	mglin5g@gmail.com; xiayumin1202@163.com			National Natural Science Foundation of China [82173445]; Innovation Capability Support Plan of Shaanxi Province [2019TD-034]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Capability Support Plan of Shaanxi Province	We thank helpful discussions with Dr. Ding-xin Liu (State Key Laboratory of Electrical Insulation and Power Equipment, Xi'an Jiaotong University). And we also thank the financial support by the National Natural Science Foundation of China (No. 82173445) and the Innovation Capability Support Plan of Shaanxi Province (No.2019TD-034).	Aboubakr HA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194618; Akimoto Y, 2016, ARCH BIOCHEM BIOPHYS, V605, P86, DOI 10.1016/j.abb.2016.01.012; Ali A, 2014, CURR APPL PHYS, V14, pS142, DOI 10.1016/j.cap.2013.12.034; Almeida ND, 2019, WORLD NEUROSURG, V130, P369, DOI 10.1016/j.wneu.2019.06.209; Arndt S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120041; Arndt S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079325; Arndt S, 2013, EXP DERMATOL, V22, P284, DOI 10.1111/exd.12127; Balzer J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144968; Bauer G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50291-0; Bekeschus S., 2013, PLASMA MED, V3, P267, DOI DOI 10.1615/PLASMAMED.2014011972; Bekeschus S, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5910695; Bernhardt T, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3873928; Brun P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104397; Brun P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033245; Cahill OJ, 2014, APPL ENVIRON MICROB, V80, P2004, DOI 10.1128/AEM.03480-13; Chernets N, 2015, PLASMA PROCESS POLYM, V12, P1400, DOI 10.1002/ppap.201500140; Colagar AH, 2013, APPL BIOCHEM BIOTECH, V171, P1617, DOI 10.1007/s12010-013-0430-9; Daeschlein G, 2015, SURG INNOV, V22, P394, DOI 10.1177/1553350615573584; Daeschlein G, 2011, IEEE T PLASMA SCI, V39, P815, DOI 10.1109/TPS.2010.2063441; Daeschlein G, 2010, PLASMA PROCESS POLYM, V7, P224, DOI 10.1002/ppap.200900059; Dai XF, 2020, CANCERS, V12, DOI 10.3390/cancers12113360; Dai XF, 2020, PLASMA PROCESS POLYM, V17, DOI 10.1002/ppap.201900178; Dai XF, 2018, TRENDS BIOTECHNOL, V36, P1183, DOI 10.1016/j.tibtech.2018.06.010; Dezest M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173618; Eyerich K, 2018, J EUR ACAD DERMATOL, V32, P692, DOI 10.1111/jdv.14673; Ezzedine K, 2015, LANCET, V386, P74, DOI 10.1016/S0140-6736(14)60763-7; Fahmide F, 2021, IRAN J BASIC MED SCI, V24, P744, DOI 10.22038/ijbms.2021.52541.11866; Fricke K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042539; Friedman PC, 2020, INT J DERMATOL, V59, P1171, DOI 10.1111/ijd.15110; Galdiero S, 2014, J PEPT SCI, V20, P468, DOI 10.1002/psc.2649; Gan L, 2019, FREE RADICAL RES, V53, P269, DOI 10.1080/10715762.2018.1564920; Govaert M, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02524; Guo L, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9051072; Guo L, 2021, CHEM ENG J, V421, DOI 10.1016/j.cej.2020.127742; Guo L, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.00726-18; Guo L, 2018, FREE RADICAL RES, V52, P783, DOI 10.1080/10715762.2018.1471476; Hahnel M, 2010, PLASMA PROCESS POLYM, V7, P244, DOI 10.1002/ppap.200900076; Han X, 2014, EUR PHYS J D, V68, DOI 10.1140/epjd/e2014-40753-y; Heinlin J, 2013, FUTURE MICROBIOL, V8, P1097, DOI 10.2217/fmb.13.86; Helmke A, 2011, PLASMA PROCESS POLYM, V8, P278, DOI 10.1002/ppap.201000168; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Ishaq M, 2015, PHYS PLASMAS, V22, DOI 10.1063/1.4933366; Joshi SG, 2011, ANTIMICROB AGENTS CH, V55, P1053, DOI 10.1128/AAC.01002-10; Kalghatgi S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016270; Keidar M, 2011, BRIT J CANCER, V105, P1295, DOI 10.1038/bjc.2011.386; Lee YS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15725-7; Li WT, 2019, FREE RADICAL BIO MED, V130, P71, DOI 10.1016/j.freeradbiomed.2018.10.429; Lin A, 2015, PLASMA PROCESS POLYM, V12, P1117, DOI 10.1002/ppap.201400232; Lin YT, 2015, J INVEST DERMATOL, V135, P258, DOI 10.1038/jid.2014.288; Losquadro WD, 2017, FACIAL PLAST SURG CL, V25, P283, DOI 10.1016/j.fsc.2017.03.001; Lugovic-Mihic L, 2019, ACTA DERMATOVENER CR, V27, P163; Del Pozo JL, 2018, EXPERT REV ANTI-INFE, V16, P51, DOI 10.1080/14787210.2018.1417036; Lukes P, 2014, PLASMA SOURCES SCI T, V23, DOI 10.1088/0963-0252/23/1/015019; Miao YJ, 2021, VIRULENCE, V12, P679, DOI 10.1080/21505594.2021.1883933; Michalek IM, 2017, J EUR ACAD DERMATOL, V31, P205, DOI 10.1111/jdv.13854; Mitra S, 2019, CANCERS, V11, DOI 10.3390/cancers11071030; Modic M, 2017, INT J ANTIMICROB AG, V49, P375, DOI 10.1016/j.ijantimicag.2016.11.022; Mruwat R, 2013, IMMUNOTHERAPY-UK, V5, P315, DOI [10.2217/IMT.13.18, 10.2217/imt.13.18]; Nguyen DB, 2016, RSC ADV, V6, P26505, DOI 10.1039/c6ra01485b; Niemira BA, 2014, J FOOD SCI, V79, pM917, DOI 10.1111/1750-3841.12379; Nussbaum L, 2021, BRIT J DERMATOL, V184, P14, DOI 10.1111/bjd.19380; Ogawa E, 2018, J DERMATOL, V45, P264, DOI 10.1111/1346-8138.14139; Ouf SA, 2015, J MED MICROBIOL, V64, P1151, DOI 10.1099/jmm.0.000133; Patange A, 2019, INT J FOOD MICROBIOL, V293, P137, DOI 10.1016/j.ijfoodmicro.2019.01.005; Rendon A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061475; Schmidt A, 2017, EXP DERMATOL, V26, P156, DOI 10.1111/exd.13156; Schmidt A, 2015, CLIN PLASMA MED, V3, P24, DOI 10.1016/j.cpme.2015.05.003; Schmidt A, 2013, FREE RADICAL RES, V47, P577, DOI 10.3109/10715762.2013.804623; Schneider C, 2019, CANCERS, V11, DOI 10.3390/cancers11050671; Shome D, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/4910280; Speeckaert R, 2017, AM J CLIN DERMATOL, V18, P733, DOI 10.1007/s40257-017-0298-5; Theinkom F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223925; Tian Y, 2022, INT J MED SCI, V19, P640, DOI 10.7150/ijms.66940; Van Loenhout J, 2019, CANCERS, V11, DOI 10.3390/cancers11101597; Vlaski-Lafarge M, 2015, J CELL SCI, V128, P3849, DOI 10.1242/jcs.171496; von Woedtke T, 2014, CONTRIB PLASM PHYS, V54, P104, DOI 10.1002/ctpp.201310068; Wang B., 2016, IEEE T PLASMA SCI, V44, P1, DOI [10.1109/TPS.2016.0620565, DOI 10.1109/TPS.2016.0620565]; Wang LY, 2019, FUTURE ONCOL, V15, P495, DOI 10.2217/fon-2018-0419; Wang PY, 2022, THERANOSTICS, V12, P2811, DOI 10.7150/thno.70098; Wang PY, 2021, CANCERS, V13, DOI 10.3390/cancers13122889; Wang PH, 2018, J CHIN MED ASSOC, V81, P94, DOI 10.1016/j.jcma.2017.11.002; Weiss M, 2017, J MED VIROL, V89, P952, DOI 10.1002/jmv.24701; Wende K, 2014, CELL BIOL INT, V38, P412, DOI 10.1002/cbin.10200; Xia J, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800046; Xiang LJ, 2018, FREE RADICAL BIO MED, V124, P205, DOI 10.1016/j.freeradbiomed.2018.06.001; Xiang YT, 2020, LANCET, V395, P684, DOI 10.1016/S0140-6736(20)30375-5; Xu XY, 2018, PLASMA PROCESS POLYM, V15, DOI 10.1002/ppap.201800052; Yang XY, 2020, INT J ONCOL, V56, P1262, DOI 10.3892/ijo.2020.5009; Yasuda H, 2010, PLASMA PROCESS POLYM, V7, P301, DOI 10.1002/ppap.200900088; Zhai SY, 2020, J INVEST DERMATOL, V141, P2710, DOI 10.1016/j.jid.2021.04.019; Zhang H, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121057; Zhong SY, 2016, BRIT J DERMATOL, V174, P542, DOI 10.1111/bjd.14236; Zhou X, 2020, J CANCER, V11, P2273, DOI 10.7150/jca.38613; Zimmermann JL, 2011, J PHYS D APPL PHYS, V44, DOI 10.1088/0022-3727/44/50/505201	94	0	0	13	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								868386	10.3389/fimmu.2022.868386	http://dx.doi.org/10.3389/fimmu.2022.868386			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F4EA	35720416	Green Published, gold			2022-12-18	WOS:000812863600001
J	Zhang, JY; Peng, JW; Li, DM; Mei, H; Yu, Y; Li, XF; She, XD; Liu, WD				Zhang, Jingyun; Peng, Jingwen; Li, Dongmei; Mei, Huan; Yu, Yu; Li, Xiaofang; She, Xiaodong; Liu, Weida			Divergent EGFR/MAPK-Mediated Immune Responses to Clinical Candida Pathogens in Vulvovaginal Candidiasis	FRONTIERS IN IMMUNOLOGY			English	Article						Candida albicans; non-albicans Candida species; vaginal epithelial cells; EGFR; MAPK; vulvovaginal candidiasis (VVC)	EPITHELIAL-CELLS; ALBICANS; INFECTIONS; ESTABLISH; EGFR	Vulvovaginal candidiasis (VVC) is characterized by symptomatic inflammatory responses in the vagina caused by Candida albicans and non-albicans Candida (NAC) species. The epidermal growth factor receptor (EGFR) -mitogen-activated protein kinase (MAPK) signaling pathway has been linked to immune responses of oral mucosa after C. albicans exposure, but whether this pathway plays a similar response in vaginal epithelial cells is not known. Here, we observed that phosphorylation of EGFR and p38 was continuously activated in vaginal epithelial cells by C. albicans strain SC5314. This differs markedly from oral epithelial cells, which respond in a biphasic manner in order to properly discriminate the morphology of C. albicans. When compared with SC5314, a highly azole-resistant C. albicans isolate 1052 can induce a stronger phosphorylated signal of EGFR and p38, while clinically-isolated NAC strains including C. tropicalis, C. glabrata, C. parapsilosis and C. auris trigger higher levels of phosphorylated ERK1/2 and c-Fos than C. albicans. Inhibition of EGFR significantly reduces inflammatory response and epithelial damage induced by C. albicans both in vitro and in vivo, while inhibition of p38 leads to significant repair of epithelial damage triggered by both C. albicans and NAC species. These results confirm the importance of the EGFR-MAPK signaling in VVC pathogenesis and highlight the remarkable immunogenic differences between C. albicans and NAC species in host-microbe interactions.	[Zhang, Jingyun; Peng, Jingwen; Mei, Huan; Yu, Yu; Li, Xiaofang; She, Xiaodong; Liu, Weida] Chinese Acad Med Sci CAMS & Peking Union Med Coll, Inst Dermatol, Dept Med Mycol, Nanjing, Peoples R China; [Zhang, Jingyun; Peng, Jingwen; Mei, Huan; Yu, Yu; Li, Xiaofang; She, Xiaodong; Liu, Weida] Jiangsu Key Lab Mol Biol Skin Dis & STIs, Nanjing, Peoples R China; [Li, Dongmei] Georgetown Univ, Med Ctr, Dept Microbiol & Immunol, Washington, DC 20007 USA; [Liu, Weida] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Dermatology - CAMS; Georgetown University; Nanjing Medical University	She, XD; Liu, WD (corresponding author), Chinese Acad Med Sci CAMS & Peking Union Med Coll, Inst Dermatol, Dept Med Mycol, Nanjing, Peoples R China.; She, XD; Liu, WD (corresponding author), Jiangsu Key Lab Mol Biol Skin Dis & STIs, Nanjing, Peoples R China.; Liu, WD (corresponding author), Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Nanjing, Peoples R China.	shexd1979@163.com; liuwd@pumcderm.cams.cn			National Natural Science Foundation of China [81972949]; National Natural Science Foundation of Jiangsu Province, China [BK20191137]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Jiangsu Province, China(Natural Science Foundation of Jiangsu Province)	Funding This study was financially supported by the National Natural Science Foundation of China (No. 81972949) to WL, the National Natural Science Foundation of Jiangsu Province, China (BK20191137) to XS.	Alsina-Beauchamp D, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708485; Ardizzoni A, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.692491; Bitew A, 2018, BMC WOMENS HEALTH, V18, DOI 10.1186/s12905-018-0607-z; Brandolt TM, 2017, BRAZ J MICROBIOL, V48, P145, DOI 10.1016/j.bjm.2016.09.006; Break TJ, 2021, SCIENCE, V371, P252, DOI 10.1126/science.aay5731; Casadevall A, 2003, NAT REV MICROBIOL, V1, P17, DOI 10.1038/nrmicro732; Cassone A, 2015, BJOG-INT J OBSTET GY, V122, P785, DOI 10.1111/1471-0528.12994; Chen JZ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.721439; D'Enfert C., 2021, FEMS Microbiology Reviews, V45, DOI 10.1093/femsre/fuaa060; Dong JC, 2021, MYCOSES, V64, P651, DOI 10.1111/myc.13260; Farah CS, 2002, INFECT IMMUN, V70, P724, DOI 10.1128/IAI.70.2.724-731.2002; Fidel PL, 2020, J FUNGI, V6, DOI 10.3390/jof6010035; Fidel PL, 2004, INFECT IMMUN, V72, P2939, DOI 10.1128/IAI.72.5.2939-2946.2004; Gerwien F, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00393-20; Hamad M, 2014, MYCOSES, V57, P184, DOI 10.1111/myc.12141; Hanaoka M, 2021, INT IMMUNOL, V33, P161, DOI 10.1093/intimm/dxaa070; Hardbower DM, 2016, J CLIN INVEST, V126, P3296, DOI 10.1172/JCI83585; Ho J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09915-2; Jabra-Rizk MA, 2016, INFECT IMMUN, V84, P2724, DOI 10.1128/IAI.00469-16; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kumar D, 2015, J INFECT DEV COUNTR, V9, P435, DOI 10.3855/jidc.4582; Liu JY, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009884; Luna-Tapia A, 2018, MBIO, V9, DOI [10.1128/mBio.00225-18, 10.1128/mbio.00225-18]; Makanjuola O, 2018, J FUNGI, V4, DOI 10.3390/jof4040121; Moyes DL, 2016, NATURE, V532, P64, DOI 10.1038/nature17625; Moyes DL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026580; Moyes DL, 2012, MED MICROBIOL IMMUN, V201, P93, DOI 10.1007/s00430-011-0209-y; Moyes DL, 2010, CELL HOST MICROBE, V8, P225, DOI 10.1016/j.chom.2010.08.002; Netea MG, 2010, CELL HOST MICROBE, V8, P219, DOI 10.1016/j.chom.2010.08.008; Parazzini F, 2000, EUR J OBSTET GYN R B, V93, P141, DOI 10.1016/S0301-2115(00)00289-X; Pekmezovic M, 2021, NAT MICROBIOL, V6, P643, DOI 10.1038/s41564-021-00875-2; Pfaller MA, 2010, J CLIN MICROBIOL, V48, P1366, DOI 10.1128/JCM.02117-09; Richardson JP, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00645-17; Rosati D, 2020, J INFECT DIS, V225, P1796, DOI 10.1093/infdis/jiaa444; Roselletti E, 2019, J INFECT DIS, V220, P1645, DOI 10.1093/infdis/jiz365; Shostak K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6232; Sobel JD, 1998, AM J OBSTET GYNECOL, V178, P203, DOI 10.1016/S0002-9378(98)80001-X; Song N, 2022, J EUR ACAD DERMATOL, V36, P566, DOI 10.1111/jdv.17874; Swidergall M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009221; Swidergall M, 2018, NAT MICROBIOL, V3, DOI 10.1038/s41564-017-0059-5; Verma AH, 2018, J IMMUNOL, V201, P627, DOI 10.4049/jimmunol.1800515; Verma AH, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aam8834; Wang L, 2016, MYCOPATHOLOGIA, V181, P29, DOI 10.1007/s11046-015-9947-5; Weindl G, 2007, J CLIN INVEST, V117, P3664, DOI 10.1172/JCI28115; Willems HME, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00527-18; Wormley FL, 2003, MED MYCOL, V41, P401, DOI 10.1080/3693780310001597683; Wozniak KL, 2002, INFECT IMMUN, V70, P5790, DOI 10.1128/IAI.70.10.5790-5799.2002; Yano J, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00684-17; Yano J, 2017, MBIO, V8, DOI [10.1128/mBio.00211-17, 10.1128/mbio.00211-17]; Zhu WD, 2012, P NATL ACAD SCI USA, V109, P14194, DOI 10.1073/pnas.1117676109	50	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								894069	10.3389/fimmu.2022.894069	http://dx.doi.org/10.3389/fimmu.2022.894069			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2G3BC	35720274	Green Published, gold			2022-12-18	WOS:000813471200001
J	Zhao, ZY; Yin, W; Peng, X; Cai, QD; He, BX; Shi, S; Peng, WL; Tu, GX; Li, YP; Li, DT; Tao, YG; Peng, MY; Wang, X; Yu, FL				Zhao, Zhenyu; Yin, Wei; Peng, Xiong; Cai, Qidong; He, Boxue; Shi, Shuai; Peng, Weilin; Tu, Guangxu; Li, Yunping; Li, Dateng; Tao, Yongguang; Peng, Muyun; Wang, Xiang; Yu, Fenglei			A Machine-Learning Approach to Developing a Predictive Signature Based on Transcriptome Profiling of Ground-Glass Opacities for Accurate Classification and Exploring the Immune Microenvironment of Early-Stage LUAD	FRONTIERS IN IMMUNOLOGY			English	Article						GGO (ground-glass opacity); LUAD; TCGA; GEO; prognosis	SUPPORT VECTOR MACHINE; LUNG-CANCER; PROGNOSTIC-SIGNIFICANCE; MANAGEMENT; FEATURES; LESIONS; SIZE	Screening for early-stage lung cancer with low-dose computed tomography is recommended for high-risk populations; consequently, the incidence of pure ground-glass opacity (pGGO) is increasing. Ground-glass opacity (GGO) is considered the appearance of early lung cancer, and there remains an unmet clinical need to understand the pathology of small GGO (<1 cm in diameter). The objective of this study was to use the transcriptome profiling of pGGO specimens <1 cm in diameter to construct a pGGO-related gene risk signature to predict the prognosis of early-stage lung adenocarcinoma (LUAD) and explore the immune microenvironment of GGO. pGGO-related differentially expressed genes (DEGs) were screened to identify prognostic marker genes with two machine learning algorithms. A 15-gene risk signature was constructed from the DEGs that were shared between the algorithms. Risk scores were calculated using the regression coefficients for the pGGO-related DEGs. Patients with Stage I/II LUAD or Stage IA LUAD and high-risk scores had a worse prognosis than patients with low-risk scores. The prognosis of high-risk patients with Stage IA LUAD was almost identical to that of patients with Stage II LUAD, suggesting that treatment strategies for patients with Stage II LUAD may be beneficial in high-risk patients with Stage IA LUAD. pGGO-related DEGs were mainly enriched in immune-related pathways. Patients with high-risk scores and high tumor mutation burden had a worse prognosis and may benefit from immunotherapy. A nomogram was constructed to facilitate the clinical application of the 15-gene risk signature. Receiver operating characteristic curves and decision curve analysis validated the predictive ability of the nomogram in patients with Stage I LUAD in the TCGA-LUAD cohort and GEO datasets.	[Zhao, Zhenyu; Yin, Wei; Peng, Xiong; Cai, Qidong; He, Boxue; Shi, Shuai; Peng, Weilin; Tu, Guangxu; Tao, Yongguang; Peng, Muyun; Wang, Xiang; Yu, Fenglei] Cent South Univ, Dept Thorac Surg, Xiangya Hosp 2, Changsha, Peoples R China; [Zhao, Zhenyu; Yin, Wei; Peng, Xiong; Cai, Qidong; He, Boxue; Shi, Shuai; Peng, Weilin; Tu, Guangxu; Tao, Yongguang; Peng, Muyun; Wang, Xiang; Yu, Fenglei] Cent South Univ, Hunan Key Lab Early Diag & Precise Treatment Lung, Xiangya Hosp 2, Changsha, Peoples R China; [Li, Yunping] Cent South Univ, Dept Ophthalmol, Xiangya Hosp 2, Changsha, Peoples R China; [Tao, Yongguang] Cent South Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha, Peoples R China; [Tao, Yongguang] Cent South Univ, Key Lab Carcinogenesis, Canc Res Inst, Sch Basic Med,Natl Hlth Council NHC, Changsha, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University	Peng, MY; Wang, X; Yu, FL (corresponding author), Cent South Univ, Dept Thorac Surg, Xiangya Hosp 2, Changsha, Peoples R China.; Peng, MY; Wang, X; Yu, FL (corresponding author), Cent South Univ, Hunan Key Lab Early Diag & Precise Treatment Lung, Xiangya Hosp 2, Changsha, Peoples R China.	pengmuyu@csu.edu.cn; wangxiang@csu.edu.cn; yufenglei@csu.edu.cn		Yu, Fenglei/0000-0003-3409-065X	National Natural Science Foundation of China [81972195, 82072594]; Fundamental Research Funds for the Central Universities of Central South University [2021zzts0385]; Hunan Provincial Key Area RD Programmes [2019SK2253, 2020K53424, 2021SK2013]; Scientific Research Program of Hunan Provincial Health Commission [20201047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities of Central South University; Hunan Provincial Key Area RD Programmes; Scientific Research Program of Hunan Provincial Health Commission	This work was supported by the National Natural Science Foundation of China (81972195, FY; 82072594, YT), Fundamental Research Funds for the Central Universities of Central South University (2021zzts0385), the Hunan Provincial Key Area R&D Programmes (2019SK2253, FY, XW; 2020K53424, 2021SK2013), and the Scientific Research Program of Hunan Provincial Health Commission (Grant number: 20201047).	Aokage K, 2017, GEN THORAC CARDIOVAS, V65, P267, DOI 10.1007/s11748-016-0741-1; Baldwin DR, 2015, THORAX, V70, P794, DOI 10.1136/thoraxjnl-2015-207221; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Chen KZ, 2021, AM J RESP CRIT CARE, V204, P1180, DOI 10.1164/rccm.202101-0119OC; Chen QG, 2018, NEURAL NETWORKS, V101, P94, DOI 10.1016/j.neunet.2018.02.006; Craig SEL, 2015, SEMIN CELL DEV BIOL, V37, P108, DOI 10.1016/j.semcdb.2014.09.004; Dienstmann R, 2019, ANN ONCOL, V30, P1622, DOI 10.1093/annonc/mdz287; Ettinger DS, 2021, J NATL COMPR CANC NE, V19, P254, DOI 10.6004/jnccn.2021.0013; Fu FQ, 2019, J THORAC ONCOL, V14, P2133, DOI 10.1016/j.jtho.2019.08.002; Gao JW, 2017, TRANSL LUNG CANCER R, V6, P68, DOI 10.21037/tlcr.2017.01.02; Gardini E, 2020, BIOINFORMATICS, V36, P4664, DOI 10.1093/bioinformatics/btaa273; Golpour P, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17186449; Han SJ, 2020, EUR J CARDIO-THORAC, V57, P1189, DOI 10.1093/ejcts/ezaa016; Hattori A, 2019, J THORAC ONCOL, V14, P265, DOI 10.1016/j.jtho.2018.09.026; Hiramatsu M, 2008, J THORAC ONCOL, V3, P1245, DOI 10.1097/JTO.0b013e318189f526; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Huang CC, 2019, J CANCER, V10, P6888, DOI 10.7150/jca.33132; Itoh N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00030; Jarmolinska AI, 2019, J CHEM INF MODEL, V59, P625, DOI 10.1021/acs.jcim.8b00690; Kamarudin AN, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0332-6; Kobayashi Y, 2018, TRANSL LUNG CANCER R, V7, P487, DOI 10.21037/tlcr.2018.07.04; Kobayashi Y, 2013, TRANSL LUNG CANCER R, V2, P354, DOI 10.3978/j.issn.2218-6751.2013.09.03; MacMahon H, 2017, RADIOLOGY, V284, P228, DOI 10.1148/radiol.2017161659; Mangiola S, 2021, BIOINFORMATICS, V37, P4100, DOI 10.1093/bioinformatics/btab404; Martinez-Jimenez F, 2020, NAT REV CANCER, V20, P555, DOI 10.1038/s41568-020-0290-x; Migliore M, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2017.07.28; Mimae T, 2020, ANN THORAC SURG, V109, P1530, DOI 10.1016/j.athoracsur.2019.12.008; Nedaie A, 2018, NEURAL NETWORKS, V98, P87, DOI 10.1016/j.neunet.2017.11.006; Niu J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0883-1; Oh JY, 2007, LUNG CANCER, V55, P67, DOI 10.1016/j.lungcan.2006.09.009; Planells-Ferrer L, 2016, J NEUROCHEM, V139, P11, DOI 10.1111/jnc.13729; Powers RK, 2018, BIOINFORMATICS, V34, P555, DOI 10.1093/bioinformatics/bty271; Qian J, 2018, TRANSL LUNG CANCER R, V7, pS31, DOI 10.21037/tlcr.2018.01.03; Qin YZ, 2020, THORAC CANCER, V11, P2767, DOI 10.1111/1759-7714.13575; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robbins HA, 2019, J THORAC ONCOL, V14, P1662, DOI 10.1016/j.jtho.2019.05.012; Rosales RA, 2017, BIOINFORMATICS, V33, P8, DOI 10.1093/bioinformatics/btw572; Sakurai H, 2014, TRANSL LUNG CANCER R, V3, P164, DOI 10.3978/j.issn.2218-6751.2014.06.11; Sharma G, 2020, BIOINFORMATICS, V36, P3592, DOI 10.1093/bioinformatics/btaa183; She KL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.690142; Stewart DJ, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt356; Tang JJ, 2018, NEURAL NETWORKS, V106, P96, DOI 10.1016/j.neunet.2018.06.017; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tu ZW, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00642; Wang CY, 2019, NEURAL NETWORKS, V114, P47, DOI 10.1016/j.neunet.2019.01.016; Xu M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00064; Yu J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56367-1; Zhang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1058-6; Zhang Y, 2020, ANN THORAC SURG, V110, P1796, DOI 10.1016/j.athoracsur.2020.04.094; Zhao Y, 2021, PEERJ, V9, DOI 10.7717/peerj.11946; Zhou YJ, 2019, J CELL BIOCHEM, V120, P8238, DOI 10.1002/jcb.28107	51	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								872387	10.3389/fimmu.2022.872387	http://dx.doi.org/10.3389/fimmu.2022.872387			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y6ZW	35693786	gold, Green Published			2022-12-18	WOS:000808291300001
J	Zheng, DW; Wang, XD; Cheng, L; Qin, L; Jiang, ZW; Zhao, RC; Li, Y; Shi, JX; Wu, QT; Long, YG; Wang, SA; Tang, ZY; Wei, W; Yang, J; Li, YQ; Zhou, HS; Liu, QF; Liu, PT; Chen, XW; Yao, Y; Yang, LH; Li, P				Zheng, Diwei; Wang, Xindong; Cheng, Lin; Qin, Le; Jiang, Zhiwu; Zhao, Ruocong; Li, Yao; Shi, Jingxuan; Wu, Qiting; Long, Youguo; Wang, Suna; Tang, Zhaoyang; Wei, Wei; Yang, Jie; Li, Yangqiu; Zhou, Hongsheng; Liu, Qifa; Liu, Pentao; Chen, Xinwen; Yao, Yao; Yang, LiHua; Li, Peng			The Chemokine Receptor CCR8 Is a Target of Chimeric Antigen T Cells for Treating T Cell Malignancies	FRONTIERS IN IMMUNOLOGY			English	Article						CCR8; TAX; ATLL; T cell malignancy; CAR T cells	LEUKEMIA-CELLS; IDENTIFICATION; FEATURES; CAR	Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell leukemia and lymphoma, but still have many challenges in their use for treating T cell malignancies, such as the lack of unique tumor antigens, their limitation of T cell expansion, and the need for third party donors or genome editing. Therefore, we need to find novel targets for CAR T cell therapy to overcome these challenges. Here, we found that both adult T-cell leukemia/lymphoma (ATLL) patients and ATLL cells had increased CCR8 expression but did not express CD7. Moreover, targeting CCR8 in T cells did not impair T cell expansion in vitro. Importantly, anti-CCR8 CAR T cells exhibited antitumor effects on ATLL- and other CCR8-expressing T-ALL cells in vitro and in vivo, and prolonged the survival of ATLL and Jurkat tumor-bearing mouse models. In conclusion, these collective results show that anti-CCR8 CAR T cells possess strong antitumor activity and represent a promising therapeutic approach for ATLL and CCR8(+) tumors.	[Zheng, Diwei; Qin, Le; Jiang, Zhiwu; Li, Yao; Shi, Jingxuan; Wu, Qiting; Long, Youguo; Wang, Suna; Chen, Xinwen; Yao, Yao; Li, Peng] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Chinese Acad Sci Key Lab Stem Cell & Regenerat Med, China New Zealand Joint Lab Biomedine & Hlth,State, Guangzhou, Peoples R China; [Zheng, Diwei; Li, Yao; Shi, Jingxuan; Li, Peng] Univ Chinese Acad Sci, Beijing, Peoples R China; [Wang, Xindong; Cheng, Lin; Li, Peng] Bioland Lab Guangzhou Regenerat Med & Hlth Guangdo, Guangzhou, Peoples R China; [Zhao, Ruocong; Li, Peng] Chinese Acad Sci, Hong Kong Inst Sci & Innovat, Ctr Regenerat Med & Hlth, Hong Kong, Peoples R China; [Tang, Zhaoyang] Guangdong Zhaotai Vivo Biomed Ltd, Guangzhou, Peoples R China; [Tang, Zhaoyang] Guangdong Zhaotai Cell Biol Technol Ltd, Foshan, Peoples R China; [Wei, Wei] Guangdong Cord Blood Bank, Guangzhou, Peoples R China; [Yang, Jie] Guangdong Women & Children Hosp, Guangzhou, Peoples R China; [Li, Yangqiu] Jinan Univ, Affiliated Hosp 1, Dept Hematol, Guangzhou, Peoples R China; [Zhou, Hongsheng; Liu, Qifa] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China; [Liu, Pentao] Univ Hong Kong, Li Ka Shing Fac Med, Sch Biomed Sci, Stem Cell & Regenerat Med Consortium, Hong Kong, Peoples R China; [Yang, LiHua] Southern Med Univ, Zhujiang Hosp, Dept Pediat Hematol, Guangzhou, Peoples R China	Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Jinan University; Southern Medical University - China; University of Hong Kong; Southern Medical University - China	Li, P (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Chinese Acad Sci Key Lab Stem Cell & Regenerat Med, China New Zealand Joint Lab Biomedine & Hlth,State, Guangzhou, Peoples R China.; Li, P (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.; Li, P (corresponding author), Bioland Lab Guangzhou Regenerat Med & Hlth Guangdo, Guangzhou, Peoples R China.; Li, P (corresponding author), Chinese Acad Sci, Hong Kong Inst Sci & Innovat, Ctr Regenerat Med & Hlth, Hong Kong, Peoples R China.	li_peng@gibh.ac.in			National Key Research and Development Plan [2021YFE0202800]; National Natural Science Foundation of China [81961128003, 81972672, 81773301, 81870121, 81873847, 32170946]; Youth Innovation Promotion Association of the Chinese Academy of Sciences [2020351]; Guangdong Provincial Significant New Drugs Development [2019B020202003, 2019A1515010062, 2020A1515011516]; Guangzhou Science and Technology Plan Project [201907010042, 2020B1212060052]; Frontier Research Program of the Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR110105003]; Science and Technology Planning Project of Guangdong Province, China [2020B1212060052]; Science and Technology Program of Guangzhou, China [202002020083]; Open Project of the State Key Laboratory of Respiratory Disease [SKLRD-OP-202002]; University Grants Committee/Research Grants Council of Hong Kong [AoE/M-401/20]; Innovation and Technology Fund (ITF) from the Hong Kong SAR government; Youth Talent Promotion project of Guangzhou Association for Science and Technology [X20210201015]	National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of the Chinese Academy of Sciences; Guangdong Provincial Significant New Drugs Development; Guangzhou Science and Technology Plan Project; Frontier Research Program of the Guangzhou Regenerative Medicine and Health Guangdong Laboratory; Science and Technology Planning Project of Guangdong Province, China; Science and Technology Program of Guangzhou, China; Open Project of the State Key Laboratory of Respiratory Disease; University Grants Committee/Research Grants Council of Hong Kong; Innovation and Technology Fund (ITF) from the Hong Kong SAR government; Youth Talent Promotion project of Guangzhou Association for Science and Technology	This study was supported by the National Key Research and Development Plan (No. 2021YFE0202800 to PTL), the National Natural Science Foundation of China (Nos. 81961128003 to PTL, 81972672 to PTL, 81773301 to ZJ, 81870121 to PTL, 81873847 to JY, and 32170946 to ZJ), The Youth Innovation Promotion Association of the Chinese Academy of Sciences (No. 2020351 to ZJ), the Guangdong Provincial Significant New Drugs Development (Nos. 2019B020202003 to PTL, 2019A1515010062 to YY, and 2020A1515011516 to XW), the Guangzhou Science and Technology Plan Project (No. 201907010042 to PTL), 2020B1212060052, the Frontier Research Program of the Guangzhou Regenerative Medicine and Health Guangdong Laboratory (No. 2018GZR110105003 to PTL), the Science and Technology Planning Project of Guangdong Province, China (2020B1212060052), the Science and Technology Program of Guangzhou, China (No. 202002020083 to XL), the Open Project of the State Key Laboratory of Respiratory Disease (No. SKLRD-OP-202002 to ZZ), the University Grants Committee/Research Grants Council of Hong Kong (Project No. AoE/M-401/20), and the Innovation and Technology Fund (ITF) from the Hong Kong SAR government, the Youth Talent Promotion project of Guangzhou Association for Science and Technology(No. X20210201015 to LY).	Aktas E, 2009, CELL IMMUNOL, V254, P149, DOI 10.1016/j.cellimm.2008.08.007; Barsheshet Y, 2017, P NATL ACAD SCI USA, V114, P6086, DOI 10.1073/pnas.1621280114; Campbell JR, 2021, CANCER RES, V81, P2983, DOI 10.1158/0008-5472.CAN-20-3585; Dahmoush L, 2002, CANCER CYTOPATHOL, V96, P110, DOI 10.1002/cncr.10480; Dai HR, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00856-8; Fujikawa D, 2016, BLOOD, V127, P1790, DOI 10.1182/blood-2015-08-662593; Gomes-Silva D, 2017, BLOOD, V130, P285, DOI 10.1182/blood-2017-01-761320; HATTORI T, 1981, BLOOD, V58, P645; Hotta T, 2005, HEMATOLOGY, V10, P193, DOI 10.1080/10245330512331390393; Ishitsuka K, 2014, LANCET ONCOL, V15, pE517, DOI 10.1016/S1470-2045(14)70202-5; Lai Y, 2018, LEUKEMIA, V32, P801, DOI 10.1038/leu.2017.249; Li SQ, 2021, CLIN CANCER RES, V27, P1242, DOI 10.1158/1078-0432.CCR-20-1271; Li W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0285-x; Locke FL, 2019, LANCET ONCOL, V20, P31, DOI 10.1016/S1470-2045(18)30864-7; Mamonkin M, 2015, BLOOD, V126, P983, DOI 10.1182/blood-2015-02-629527; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Pan J, 2021, J CLIN ONCOL, V39, P3340, DOI 10.1200/JCO.21.00389; Plitas G, 2016, IMMUNITY, V45, P1122, DOI 10.1016/j.immuni.2016.10.032; Roos RS, 1997, J BIOL CHEM, V272, P17251, DOI 10.1074/jbc.272.28.17251; Ruckes T, 2001, BLOOD, V98, P1150, DOI 10.1182/blood.V98.4.1150; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Tang N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133977; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; Utsunomiya A, 2015, CANCER SCI, V106, P344, DOI 10.1111/cas.12617; Weng JY, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0572-x; Ye W, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0156-y; Zhou TC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00629	28	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								808347	10.3389/fimmu.2022.808347	http://dx.doi.org/10.3389/fimmu.2022.808347			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y7AH	35693763	Green Published, gold			2022-12-18	WOS:000808292400001
J	Zheng, HT; Xu, J; Chu, YL; Jiang, WZ; Yao, WJ; Mo, SW; Song, XC; Zhou, J				Zheng, Haitao; Xu, Jie; Chu, Yongli; Jiang, Wenzhou; Yao, Wenjie; Mo, Shaowen; Song, Xicheng; Zhou, Jin			A Global Regulatory Network for Dysregulated Gene Expression and Abnormal Metabolic Signaling in Immune Cells in the Microenvironment of Graves' Disease and Hashimoto's Thyroiditis	FRONTIERS IN IMMUNOLOGY			English	Article						Hashimoto's thyroiditis; Graves' disease; immune dysregulation; cell communication; thyroid tissue	AUTOIMMUNE-DISEASES; PERIPHERAL-BLOOD; PATHOGENESIS; POLARIZATION; MACROPHAGES; CYTOKINES	BackgroundAlthough the pathogenetic mechanisms of Hashimoto's thyroiditis (HT) and Graves' disease (GD) have been elucidated, the molecular mechanisms by which the abnormal immune function of cellular subpopulations trigger an autoimmune attack on thyroid tissue largely remains unexplained. MethodsThe study included 2 HT patients, 2 GD patients, and 1 control donor. The thyroid samples were extracted for single-cell RNA sequencing, whole transcriptome, full-length transcriptome (Oxford Nanopore Technologies), and metabolome sequencing. Identification of immune cells with dysregulated gene expression and abnormal metabolic signaling was performed in the microenvironment, both at the bulk and single-cell levels. Based on functional enrichment analysis, the biological processes and pathways involved in abnormal immune cells were further explored. Finally, according to cell communication analysis, the global regulatory network of immune cells was constructed. ResultsCD4(+) T cells, CD8(+) T cells, and macrophages were abnormally increased in patients with HT and GD. The differentially expressed genes of these cells were significantly involved in signaling pathways, including Th1 and Th2 cell differentiation, Th17 cell differentiation, cytokine-cytokine receptor interaction, and NF-kappa B signaling pathway. Moreover, in HT, CD4(+) T cells interact with macrophages via the IL16-CCR5/FGF10-FGFR1/CXCL13-CXCR3 axis, and macrophages interact with CD8(+) T cells via the CD70-CD27 axis, thereby activating the T-cell receptor signaling pathway and NF-kappa B signaling pathway. In GD, CD4(+) T cells interact with macrophages via the CXCR3-CXCL10/PKM-CD44/MHCII-NFKBIE axis, and macrophages interact with CD8(+) T cells via the IFNG-IFNGR1/CCR7-CCL21 axis, thereby activating T-cell receptor signaling pathway, Th1 and Th2 cell differentiation, and chemokine signaling pathway. ConclusionIn HT and GD, immune dysregulated cells interact and activate relevant immune pathways and further aggravate the immune response. This may trigger the immune cells to target the thyroid tissue and influence the development of the disease.	[Zheng, Haitao] Qingdao Univ Med Coll, Dept Thyroid Surg, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China; [Xu, Jie] Qingdao Univ Med Coll, Dept Clin Nutr, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China; [Chu, Yongli] Qingdao Univ Med Coll, Dept Sci Res, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China; [Jiang, Wenzhou] Longkou Peoples Hosp, Dept Neurol, Longkou, Peoples R China; [Yao, Wenjie] BinZhou Med Univ, Dept Endocrinol, Yantai, Peoples R China; [Mo, Shaowen] YuanDong Int Acad Life Sci, Dept Basic Sci, Nanning, Peoples R China; [Song, Xicheng] Affiliated Yantai Yuhuangding Hosp Qingdao Univ Me, Dept Otorhinolaryngol Head & Neck Surg, Yantai, Peoples R China; [Zhou, Jin] Qingdao Univ Med Coll, Dept Endocrinol, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China	Qingdao University; Qingdao University; Qingdao University; Binzhou Medical University; Qingdao University	Mo, SW (corresponding author), YuanDong Int Acad Life Sci, Dept Basic Sci, Nanning, Peoples R China.; Song, XC (corresponding author), Affiliated Yantai Yuhuangding Hosp Qingdao Univ Me, Dept Otorhinolaryngol Head & Neck Surg, Yantai, Peoples R China.; Zhou, J (corresponding author), Qingdao Univ Med Coll, Dept Endocrinol, Affiliated Yantai Yuhuangding Hosp, Yantai, Peoples R China.	swmo@ydlife.org; drxchsong@163.com; ZhouJ1811222@outlook.com			National Natural Science Foundation of China [81700695]; Taishan Scholars Project; China Scholarship Council [201909370036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Project; China Scholarship Council(China Scholarship Council)	Funding This project was supported by the National Natural Science Foundation of China (No. 81700695), Taishan Scholars Project (No. ts20190991), and China Scholarship Council (No. 201909370036).	Ajjan RA, 1996, CLIN EXP IMMUNOL, V105, P523, DOI 10.1046/j.1365-2249.1996.d01-784.x; Antonelli A, 2015, AUTOIMMUN REV, V14, P174, DOI 10.1016/j.autrev.2014.10.016; Ben-Skowronek I, 2013, WORLD J PEDIATR, V9, P245, DOI 10.1007/s12519-013-0398-0; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Eshaghkhani Y, 2016, MINERVA ENDOCRINOL, V41, P28; Fallahi P, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz289; Fallahi P, 2016, EXPERT REV CLIN PHAR, V9, P853, DOI 10.1586/17512433.2016.1157468; Figueroa-Vega N, 2010, J CLIN ENDOCR METAB, V95, P953, DOI 10.1210/jc.2009-1719; Grant CR, 2015, AUTOIMMUN REV, V14, P105, DOI 10.1016/j.autrev.2014.10.012; Guan LJ, 2015, CYTOKINE, V72, P160, DOI 10.1016/j.cyto.2014.11.005; Guijas C, 2018, ANAL CHEM, V90, P3156, DOI 10.1021/acs.analchem.7b04424; Iddah M A, 2013, ISRN Endocrinol, V2013, P509764, DOI 10.1155/2013/509764; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; Kyritsi EM, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00543; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Li DP, 2013, CLIN IMMUNOL, V149, P411, DOI 10.1016/j.clim.2013.10.001; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Li H, 2013, FRONT BIOSCI-LANDMRK, V18, P782, DOI 10.2741/4141; Li Q, 2019, J CELL PHYSIOL, V234, P2204, DOI 10.1002/jcp.27180; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Martin AP, 2004, J IMMUNOL, V173, P4791, DOI 10.4049/jimmunol.173.8.4791; McLachlan SM, 2014, ENDOCR REV, V35, P59, DOI 10.1210/er.2013-1055; McLachlan SM, 2005, ENDOCR REV, V26, P800, DOI 10.1210/er.2004-0023; Mikos H, 2014, ENDOKRYNOL POL, V65, P150, DOI 10.5603/EP.2014.0021; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; O'Sullivan B, 2007, EXPERT OPIN THER TAR, V11, P111, DOI 10.1517/14728222.11.2.111; Pertea Geo, 2020, F1000Res, V9, P304, DOI 10.12688/f1000research.23297.1; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Qi YC, 2015, ENDOCRINE, V50, P123, DOI 10.1007/s12020-015-0552-7; Ralli M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102649; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Ruytinx P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01930; Safdari Vahid, 2017, Sultan Qaboos Univ Med J, V17, pe174, DOI 10.18295/squmj.2016.17.02.007; Shi Y, 2010, SCAND J IMMUNOL, V72, P250, DOI 10.1111/j.1365-3083.2010.02425.x; Shoenfeld Y., 2010, DIAGNOSTIC CRITERIA; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tsatsoulis A, 2006, ANN NY ACAD SCI, V1088, P382, DOI 10.1196/annals.1366.015; VANDERPUMP MPJ, 1995, CLIN ENDOCRINOL, V43, P55, DOI 10.1111/j.1365-2265.1995.tb01894.x; Wang Y., 2019, BIORXIV, DOI [10.1101/507871, DOI 10.1101/507871]; Weetman A., 2000, WERNER INGBARS THYRO; Weetman AP, 2003, EUR J ENDOCRINOL, V148, P1, DOI 10.1530/eje.0.1480001; Xuan WJ, 2015, J LEUKOCYTE BIOL, V97, P61, DOI 10.1189/jlb.1A0314-170R; Yin QL, 2020, J ENDOCRINOL, V246, P161, DOI 10.1530/JOE-19-0501; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yuan Q, 2017, J ENDOCRINOL INVEST, V40, P397, DOI 10.1007/s40618-016-0575-9; Zaletel K, 2011, CURR GENOMICS, V12, P576, DOI 10.2174/138920211798120763; Zuniga LA, 2013, IMMUNOL REV, V252, P78, DOI 10.1111/imr.12036	50	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 26	2022	13								879824	10.3389/fimmu.2022.879824	http://dx.doi.org/10.3389/fimmu.2022.879824			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2F2MV	35720300	Green Published, gold			2022-12-18	WOS:000812748600001
J	Bai, XY; Yang, WX; Li, HQ; Zhao, YA; Fan, WH; Zhang, H; Liu, WJ; Sun, L				Bai, Xiaoyuan; Yang, Wenxian; Li, Heqiao; Zhao, Yuna; Fan, Wenhui; Zhang, He; Liu, Wenjun; Sun, Lei			Cyclosporine A Regulates Influenza A Virus-induced Macrophages Polarization and Inflammatory Responses by Targeting Cyclophilin A	FRONTIERS IN IMMUNOLOGY			English	Article						influenza A virus; macrophages polarization; cyclosporine A; cyclophilin A; inflammation	NF-KAPPA-B; NUCLEAR-FACTOR; LUNG INJURY; PATHOGENESIS; ACTIVATION; INFECTION; CALCINEURIN; DYSFUNCTION; MECHANISMS; COMMON	Cyclosporine A (CsA) is an immunosuppressive drug that suppresses T cell responses and is broadly used in transplantation. Its immunosuppressive action is closely linked to its binding of cyclophilin A (CypA), which widely distributed in different cell types. CsA also regulates the functions of innate immune cells, but the mechanism remains elusive. Here, we investigate the role of CsA in regulating macrophages polarization in influenza A virus-infected mice and mouse bone marrow-derived macrophages. CsA downregulates pro-inflammatory cytokines expression and upregulates anti-inflammatory cytokines expression. Mechanically, CsA decreases the polarization of macrophages into pro-inflammatory M1 phenotype and increases the polarization of macrophages into anti-inflammatory M2 phenotype. Further studies show that CsA regulates macrophages polarization-associated IFN-gamma/STAT1 and IL-4/STAT6 signaling pathways. Meanwhile, all these roles of CsA are eliminated when CypA is absent, suggesting that CsA regulates macrophages polarization and inflammatory responses depend on its binding to CypA. Collectively, these results reveal a crucial mechanism of CsA in attenuating IAV-induced inflammatory responses by a switch in macrophages polarization.	[Bai, Xiaoyuan; Yang, Wenxian; Li, Heqiao; Zhao, Yuna; Fan, Wenhui; Liu, Wenjun; Sun, Lei] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China; [Bai, Xiaoyuan; Yang, Wenxian; Zhang, He; Liu, Wenjun] Inst Infect Dis, Shenzhen Bay Lab, Shenzhen, Peoples R China; [Li, Heqiao; Liu, Wenjun; Sun, Lei] Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China; [Zhao, Yuna; Liu, Wenjun] Guangxi Univ, Coll Anim Sci & Vet Med, State Key Lab Conservat & Utilizat Subtrop Agrobio, Nanning, Peoples R China; [Liu, Wenjun] Guangxi Univ, Coll Anim Sci & Vet Med, Lab Anim Infect Dis, Nanning, Peoples R China	Chinese Academy of Sciences; Institute of Microbiology, CAS; Shenzhen Bay Laboratory; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Guangxi University; Guangxi University	Sun, L (corresponding author), Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing, Peoples R China.; Sun, L (corresponding author), Univ Chinese Acad Sci, Savaid Med Sch, Beijing, Peoples R China.	sunlei362@im.ac.cn	SUN, LEI/B-3288-2018	SUN, LEI/0000-0003-0141-2093	National Natural Science Foundation of China [31972657]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB29010000]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences)	Funding This work was supported by grants from the National Natural Science Foundation of China (31972657) and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB29010000).	Bai XY, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109159; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Chighizola CB, 2017, CLIN REV ALLERG IMMU, V52, P401, DOI 10.1007/s12016-016-8582-3; Cole SL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91868; Cui GF, 2017, PESTIC BIOCHEM PHYS, V142, P91, DOI 10.1016/j.pestbp.2017.01.010; Davis TL, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000439; Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491; FUJISAWA H, 1987, J GEN VIROL, V68, P425, DOI 10.1099/0022-1317-68-2-425; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Greenblatt MB, 2010, J EXP MED, V207, P923, DOI 10.1084/jem.20092531; Gui QY, 2021, INT IMMUNOPHARMACOL, V93, DOI 10.1016/j.intimp.2021.107420; Gupta AK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097088; Hajkova M, 2017, J TISSUE ENG REGEN M, V11, P1456, DOI 10.1002/term.2044; Halstead ES, 2018, RESP RES, V19, DOI 10.1186/s12931-017-0708-5; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Hasegawa H, 2013, LUPUS, V22, P316, DOI 10.1177/0961203313476355; Herold S, 2015, EUR RESPIR J, V45, P1463, DOI 10.1183/09031936.00186214; Hofmann P, 1997, J LEUKOCYTE BIOL, V61, P408, DOI 10.1002/jlb.61.4.408; Huai Q, 2002, P NATL ACAD SCI USA, V99, P12037, DOI 10.1073/pnas.192206699; Julkunen I, 2000, VACCINE, V19, pS32, DOI 10.1016/S0264-410X(00)00275-9; Julkunen I, 2001, CYTOKINE GROWTH F R, V12, P171, DOI 10.1016/S1359-6101(00)00026-5; Kido H, 2012, BBA-PROTEINS PROTEOM, V1824, P186, DOI 10.1016/j.bbapap.2011.07.001; Kuithanan K, 2019, ALLERGY ASTHMA IMMUN, V11, P736, DOI 10.4168/aair.2019.11.5.736; Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374; Li M, 2019, BIOCHEM BIOPH RES CO, V513, P1005, DOI 10.1016/j.bbrc.2019.04.020; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Liu JM, 2017, MOL MED REP, V15, P3739, DOI 10.3892/mmr.2017.6421; Liu JX, 2020, AM J INFECT CONTROL, V48, P1231, DOI 10.1016/j.ajic.2020.01.013; Liu W, 2017, ELIFE, V6, DOI 10.7554/eLife.24425; Matsuda S, 2000, IMMUNOPHARMACOLOGY, V47, P119, DOI 10.1016/S0162-3109(00)00192-2; Neumann G, 1999, P NATL ACAD SCI USA, V96, P9345, DOI 10.1073/pnas.96.16.9345; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; Porta C, 2009, P NATL ACAD SCI USA, V106, P14978, DOI 10.1073/pnas.0809784106; Ranjan R, 2014, J INNATE IMMUN, V6, P754, DOI 10.1159/000362647; Sallam MY, 2017, EUR J PHARMACOL, V797, P143, DOI 10.1016/j.ejphar.2017.01.023; SCHILTKNECHT E, 1985, CELL IMMUNOL, V91, P227, DOI 10.1016/0008-8749(85)90046-2; SHAW MW, 1992, CLIN MICROBIOL REV, V5, P74, DOI 10.1128/CMR.5.1.74-92.1992; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Snelgrove RJ, 2011, TRENDS IMMUNOL, V32, P328, DOI 10.1016/j.it.2011.04.006; Teijaro JR, 2011, CELL, V146, P980, DOI 10.1016/j.cell.2011.08.015; Wang SY, 2010, J INFECT DIS, V202, P991, DOI 10.1086/656044; Whyte CS, 2011, J LEUKOCYTE BIOL, V90, P845, DOI 10.1189/jlb.1110644; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354; Zhao XF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104506; Zheng HC, 2019, AM J PHYSIOL-LUNG C, V317, pL381, DOI 10.1152/ajplung.00253.2018	46	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								861292	10.3389/fimmu.2022.861292	http://dx.doi.org/10.3389/fimmu.2022.861292			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y9HY	35693825	gold, Green Published			2022-12-18	WOS:000808448900001
J	Bergamaschi, C; Pagoni, M; Rosati, M; Angel, M; Tzannou, I; Vlachou, M; Darmani, I; Ullah, A; Bear, J; Devasundaram, S; Burns, R; Baltadakis, I; Gigantes, S; Dimopoulos, MA; Pavlakis, GN; Terpos, E; Felber, BK				Bergamaschi, Cristina; Pagoni, Maria; Rosati, Margherita; Angel, Matthew; Tzannou, Ifigeneia; Vlachou, Margarita; Darmani, Ismini; Ullah, Amirah; Bear, Jenifer; Devasundaram, Santhi; Burns, Robert; Baltadakis, Ioannis; Gigantes, Stavros; Dimopoulos, Meletios-Athanasios; Pavlakis, George N.; Terpos, Evangelos; Felber, Barbara K.			Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies	FRONTIERS IN IMMUNOLOGY			English	Article						humoral response; cytokine; SARS-CoV-2 BNT162b2 mRNA vaccine; IFN-gamma; CXCL10; IL-15; transplantation; hematological cancer	YELLOW-FEVER VACCINE; COVID-19 VACCINE; IMMUNOGENICITY; RESPONSES	Immunocompromised individuals including patients with hematological malignancies constitute a population at high risk of developing severe disease upon SARS-CoV-2 infection. Protection afforded by vaccination is frequently low and the biology leading to altered vaccine efficacy is not fully understood. A patient cohort who had received bone marrow transplantation or CAR-T cells was studied following a 2-dose BNT162b2 mRNA vaccination and compared to healthy vaccine recipients. Anti-Spike antibody and systemic innate responses were compared in the two vaccine cohorts. The patients had significantly lower SARS-CoV-2 Spike antibodies to the Wuhan strain, with proportional lower cross-recognition of Beta, Delta, and Omicron Spike-RBD proteins. Both cohorts neutralized the wildtype WA1 and Delta but not Omicron. Vaccination elicited an innate cytokine signature featuring IFN-gamma, IL-15 and IP-10/CXCL10, but most patients showed a diminished systemic cytokine response. In patients who failed to develop antibodies, the innate systemic response was dominated by IL-8 and MIP-1 alpha with significant attenuation in the IFN-gamma, IL-15 and IP-10/CXCL10 signature response. Changes in IFN-gamma and IP-10/CXCL10 at priming vaccination and IFN-gamma, IL-15, IL-7 and IL-10 upon booster vaccination correlated with the Spike antibody magnitude and were predictive of successful antibody development. Overall, the patients showed heterogeneous adaptive and innate responses with lower humoral and reduced innate cytokine responses to vaccination compared to naive vaccine recipients. The pattern of responses described offer novel prognostic approaches for potentiating the effectiveness of COVID-19 vaccination in transplant patients with hematological malignancies.	[Bergamaschi, Cristina; Ullah, Amirah; Bear, Jenifer; Devasundaram, Santhi; Burns, Robert; Felber, Barbara K.] Natl Canc Inst Frederick, Ctr Canc Res, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Frederick, MD 21702 USA; [Pagoni, Maria; Tzannou, Ifigeneia; Darmani, Ismini; Baltadakis, Ioannis; Gigantes, Stavros] Evangelismos Gen Hosp, Dept Hematol & Lymphomas, Athens, Greece; [Rosati, Margherita; Pavlakis, George N.] Natl Canc Inst Frederick, Ctr Canc Res, Human Retrovirus Sect, Vaccine Branch, Frederick, MD USA; [Angel, Matthew] NCI, Ctr Canc Res, Vaccine Branch, Bethesda, MD USA; [Angel, Matthew] Leidos Biomed Res Inc, Frederick Natl Lab Canc Res, Ctr Canc Res Collaborat Bioinformat Resource, Frederick, MD USA; [Vlachou, Margarita] Evangelismos Gen Hosp, Pharm Dept, Athens, Greece; [Dimopoulos, Meletios-Athanasios; Terpos, Evangelos] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece; [Pagoni, Maria; Tzannou, Ifigeneia; Darmani, Ismini; Baltadakis, Ioannis; Gigantes, Stavros] Evangelismos Gen Hosp, Bone Marrow Transplantat Unit, Athens, Greece	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Evangelismos Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Evangelismos Hospital; Athens Medical School; National & Kapodistrian University of Athens; Evangelismos Hospital	Felber, BK (corresponding author), Natl Canc Inst Frederick, Ctr Canc Res, Human Retrovirus Pathogenesis Sect, Vaccine Branch, Frederick, MD 21702 USA.	Barbara.felber@nih.gov	Devasundaram, Santhi/AAA-1846-2020	Devasundaram, Santhi/0000-0002-2803-7118	Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research	Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research	This work was supported by funds from the Intramural Research Program, National Institutes of Health, National Cancer Institute, Center for Cancer Research to GP. and BF. The funders had no role in the experimental design, collection of data or writing the paper.	Agha Mounzer E, 2021, Open Forum Infect Dis, V8, pofab353, DOI 10.1093/ofid/ofab353; Andersen-Nissen E, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009363; Arunachalam PS, 2021, NATURE, V596, P410, DOI 10.1038/s41586-021-03791-x; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Bergamaschi C, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109504; Bergman P, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103705; Canti L, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01190-3; Cheng SMS, 2022, NAT MED, V28, P486, DOI 10.1038/s41591-022-01704-7; Chiarucci M, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.737300; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Gaucher D, 2008, J EXP MED, V205, P3119, DOI 10.1084/jem.20082292; Gavriatopoulou M, 2021, BLOOD ADV, V5, P4398, DOI 10.1182/bloodadvances.2021005444; Gavriatopoulou M, 2022, BRIT J HAEMATOL, V196, P356, DOI 10.1111/bjh.17841; Greenberger LM, 2021, CANCER CELL, V39, P1031, DOI 10.1016/j.ccell.2021.07.012; Herishanu Y, 2022, BLOOD, V139, P678, DOI 10.1182/blood.2021014085; Knabl L., 2021, RES SQ, DOI [10.21203/rs.3.rs-509143/v1, DOI 10.21203/RS.3.RS-509143/V1]; Liebers N, 2022, BLOOD, V139, P142, DOI 10.1182/blood.2021013445; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Malard F, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00534-z; Muik A, 2022, SCIENCE, V375, P678, DOI 10.1126/science.abn7591; Parvathaneni K, 2022, JAMA ONCOL, V8, P164, DOI 10.1001/jamaoncol.2021.6030; Peiris Malik, 2022, Res Sq, DOI 10.21203/rs.3.rs-1207071/v1; Perez-Then E, 2022, NAT MED, V28, P481, DOI 10.1038/s41591-022-01705-6; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Ram R, 2021, TRANSPL CELL THER, V27, P788, DOI 10.1016/j.jtct.2021.06.024; Ribas A, 2021, BLOOD CANCER DISCOV, V2, P562, DOI 10.1158/2643-3230.BCD-21-0166; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Rosati M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.793953; Rosati M, 2022, AM J HEMATOL, V97, pE3, DOI 10.1002/ajh.26380; Rosati M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009701; Schmidt F, 2022, NEW ENGL J MED, V386, P599, DOI 10.1056/NEJMc2119641; Schmidt F, 2020, J EXP MED, V217, DOI 10.1084/jem.20201181; Shem-Tov N, 2022, BRIT J HAEMATOL, V196, P884, DOI 10.1111/bjh.17918; Tamari R, 2021, BLOOD CANCER DISCOV, V2, P577, DOI 10.1158/2643-3230.BCD-21-0142; Tamariz-Amador LE, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00594-1; Terpos E, 2021, CANCERS, V13, DOI 10.3390/cancers13174480; Terpos E, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00530-3; Terpos E, 2021, EUR J INTERN MED, V89, P87, DOI 10.1016/j.ejim.2021.05.010; Terpos E, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01099-x; Terpos E, 2021, AM J HEMATOL, V96, pE321, DOI 10.1002/ajh.26248; Terpos E, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121885; Thwaites RS, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg9873; Yeshurun M, 2022, CLIN MICROBIOL INFEC, V28, DOI 10.1016/j.cmi.2021.10.007; Zak DE, 2012, P NATL ACAD SCI USA, V109, pE3503, DOI 10.1073/pnas.1208972109; Zeng C, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00713-2	45	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								899972	10.3389/fimmu.2022.899972	http://dx.doi.org/10.3389/fimmu.2022.899972			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Z0XM	35693807	Green Published, gold			2022-12-18	WOS:000808557100001
J	Chen, YH; Yi, XL; Sun, NY; Guo, WA; Li, CY				Chen, Yuhan; Yi, Xiuli; Sun, Ningyue; Guo, Weinan; Li, Chunying			Epigenetics Regulates Antitumor Immunity in Melanoma	FRONTIERS IN IMMUNOLOGY			English	Review						epigenetics; antitumor immunity; melanoma; immunotherapy; DNA methylation	CLASS-I ANTIGENS; DNA METHYLATION; HISTONE DEMETHYLASES; ADAPTIVE RESISTANCE; CANCER STATISTICS; CELL-DEVELOPMENT; T-CELLS; EXPRESSION; ACTIVATION; INHIBITION	Melanoma is the most malignant skin cancer, which originates from epidermal melanocytes, with increasing worldwide incidence. The escape of immune surveillance is a hallmark of the tumor, which is manifested by the imbalance between the enhanced immune evasion of tumor cells and the impaired antitumor capacity of infiltrating immune cells. According to this notion, the invigoration of the exhausted immune cells by immune checkpoint blockades has gained encouraging outcomes in eliminating tumor cells and significantly prolonged the survival of patients, particularly in melanoma. Epigenetics is a pivotal non-genomic modulatory paradigm referring to heritable changes in gene expression without altering genome sequence, including DNA methylation, histone modification, non-coding RNAs, and m(6)A RNA methylation. Accumulating evidence has demonstrated how the dysregulation of epigenetics regulates multiple biological behaviors of tumor cells and contributes to carcinogenesis and tumor progression in melanoma. Nevertheless, the linkage between epigenetics and antitumor immunity, as well as its implication in melanoma immunotherapy, remains elusive. In this review, we first introduce the epidemiology, clinical characteristics, and therapeutic innovations of melanoma. Then, the tumor microenvironment and the functions of different types of infiltrating immune cells are discussed, with an emphasis on their involvement in antitumor immunity in melanoma. Subsequently, we systemically summarize the linkage between epigenetics and antitumor immunity in melanoma, from the perspective of distinct paradigms of epigenetics. Ultimately, the progression of the clinical trials regarding epigenetics-based melanoma immunotherapy is introduced.	[Chen, Yuhan; Yi, Xiuli; Sun, Ningyue; Guo, Weinan; Li, Chunying] Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China; [Chen, Yuhan; Sun, Ningyue] Fourth Mil Med Univ, Sch Basic Med Sci, Xian, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Guo, WA; Li, CY (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Dermatol, Xian, Peoples R China.	guown@fmmu.edu.cn; lichying@fmmu.edu.cn		Guo, Weinan/0000-0002-3517-3898	National Natural Science Foundation of China [81902791]; Support Program of Young Talents in Shaanxi Province [20200303]; Young Eagle Project of Fourth Military Medical University [2019cyjhgwn]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Support Program of Young Talents in Shaanxi Province; Young Eagle Project of Fourth Military Medical University	This work has received funding from the National Natural Science Foundation of China (No. 81902791), Support Program of Young Talents in Shaanxi Province (No. 20200303), and Young Eagle Project of Fourth Military Medical University (No. 2019cyjhgwn).	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Al Emran A, 2019, TRENDS IMMUNOL, V40, P328, DOI 10.1016/j.it.2019.02.004; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Amon L, 2019, INT REV CEL MOL BIO, V349, P55, DOI 10.1016/bs.ircmb.2019.10.001; Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22; Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860; Berger MF, 2012, NATURE, V485, P502, DOI 10.1038/nature11071; Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200; Blankenstein T, 2012, NAT REV CANCER, V12, P307, DOI 10.1038/nrc3246; Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168; Bretz AC, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0745-3; Broseghini E, 2021, NON-CODING RNA, V7, DOI 10.3390/ncrna7040063; Bugide S, 2018, TRENDS CANCER, V4, P553, DOI 10.1016/j.trecan.2018.06.004; Burgstaller-Muehlbacher S, 2015, MELANOMA RES, V25, P412, DOI 10.1097/CMR.0000000000000179; Campos DS, 2017, CIENC SAUDE COLETIVA, V22, P3955, DOI 10.1590/1413-812320172212.25062017; Cavalli G, 2019, NATURE, V571, P489, DOI 10.1038/s41586-019-1411-0; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chatterjee A, 2018, ISCIENCE, V4, P312, DOI 10.1016/j.isci.2018.05.021; Chen DH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.778582; Chen SY, 2017, NATURE, V549, P399, DOI 10.1038/nature23887; Cheng PF, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0594-4; Chiappinelli KB, 2016, CANCER RES, V76, P1683, DOI 10.1158/0008-5472.CAN-15-2125; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Dai EY, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01464-x; de Groot Amber E, 2018, Oncotarget, V9, P20908, DOI 10.18632/oncotarget.24556; Dewaele S, 2022, ONCOGENE, V41, P15, DOI 10.1038/s41388-021-02006-x; Di Giacomo AM, 2019, CLIN CANCER RES, V25, P7351, DOI 10.1158/1078-0432.CCR-19-1335; Diener J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25326-8; Dong Y, 2021, BIOACT MATER, V6, P2870, DOI 10.1016/j.bioactmat.2021.02.008; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; Falahat R, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2013598118; Fietz S, 2021, CANCER IMMUNOL IMMUN, V70, P1781, DOI 10.1007/s00262-020-02777-4; Filipski K, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002226; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Fonsatti E, 2003, INT J CANCER, V105, P430, DOI 10.1002/ijc.11077; Frohlich A, 2020, EBIOMEDICINE, V59, DOI 10.1016/j.ebiom.2020.102962; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gandini S, 2011, PROG BIOPHYS MOL BIO, V107, P362, DOI 10.1016/j.pbiomolbio.2011.09.011; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027; Gerritsen B, 2016, IMMUNOL CELL BIOL, V94, P236, DOI 10.1038/icb.2015.118; Giblin W, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI138926; Gilot D, 2017, NAT CELL BIOL, V19, P1348, DOI 10.1038/ncb3623; Giunta EF, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082048; Goltz D, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96793; Gordon-Alonso M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00925-6; Guo S, 2016, J INVEST DERMATOL, V136, P985, DOI 10.1016/j.jid.2015.12.041; Guo WN, 2020, CLIN CANCER RES, V26, P2725, DOI 10.1158/1078-0432.CCR-19-1359; Han SJ, 2021, CANCER RES, V81, P2918, DOI 10.1158/0008-5472.CAN-20-3145; He FL, 2021, MOL THER, V29, P2121, DOI 10.1016/j.ymthe.2021.02.014; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoffmann F, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148-020-00883-9; Holderried TAW, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0752-8; Huber V, 2018, J CLIN INVEST, V128, P5505, DOI 10.1172/JCI98060; Jespersen H, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5623-3; Ji Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09882-8; Jia RB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1088-x; Jin B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01173-x; John RM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00130; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jun HJ, 2009, CANCER RES, V69, P2180, DOI 10.1158/0008-5472.CAN-08-3351; Jung H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12159-9; Khan ANH, 2008, CANCER IMMUNOL IMMUN, V57, P647, DOI 10.1007/s00262-007-0402-4; Kinner-Bibeau LB, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15648; Knox T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42237-3; Kumar BV, 2018, IMMUNITY, V48, P202, DOI 10.1016/j.immuni.2018.01.007; Kusumoto F, 2008, CARDIOL CLIN, V26, P481, DOI 10.1016/j.ccl.2008.03.002; Lahav TG, 2019, INT J CANCER, V145, P2521, DOI 10.1002/ijc.32521; Laino AS, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0517-0; Lauss M, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0147-4; Leucci E, 2016, PIGM CELL MELANOMA R, V29, P619, DOI 10.1111/pcmr.12537; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Levidou G, 2021, CANCERS, V13, DOI 10.3390/cancers13194763; Li F, 2020, MOL THER-NUCL ACIDS, V22, P456, DOI 10.1016/j.omtn.2020.09.008; Li N, 2020, P NATL ACAD SCI USA, V117, P20159, DOI 10.1073/pnas.1918986117; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Licht JD, 2015, CELL, V162, P938, DOI 10.1016/j.cell.2015.08.005; Limagne E, 2017, CELL REP, V19, P746, DOI 10.1016/j.celrep.2017.04.004; Liu C, 2016, FEBS J, V283, P2731, DOI 10.1111/febs.13656; Liu JQ, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-015-0753-0; Liu KY, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2021.13172; Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796; Luo GY, 2020, J CELL PHYSIOL, V235, P7107, DOI 10.1002/jcp.29608; Marcus A, 2014, ADV IMMUNOL, V122, P91, DOI 10.1016/B978-0-12-800267-4.00003-1; Martinez-Usatorre A, 2019, CANCER IMMUNOL RES, V7, P1013, DOI 10.1158/2326-6066.CIR-18-0504; Marzese DM, 2014, NEURO-ONCOLOGY, V16, P1499, DOI 10.1093/neuonc/nou107; Mashima E, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010422; Masopust D, 2013, NAT REV IMMUNOL, V13, P309, DOI 10.1038/nri3442; Mastroianni J, 2019, CANCER RES, V79, P183, DOI 10.1158/0008-5472.CAN-18-1397; Mempel TR, 2004, NATURE, V427, P154, DOI 10.1038/nature02238; Micevic G, 2019, PIGM CELL MELANOMA R, V32, P435, DOI 10.1111/pcmr.12745; Micevic G, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0332-8; Mitra S, 2020, MOL ONCOL, V14, P933, DOI 10.1002/1878-0261.12663; Nguyen QP, 2019, IMMUNOLOGY, V157, P3, DOI 10.1111/imm.13059; Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x; Ny L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25332-w; Olino K, 2020, SEMIN CANCER BIOL, V65, P114, DOI 10.1016/j.semcancer.2020.01.001; Orouji E, 2019, INT J CANCER, V145, P3462, DOI 10.1002/ijc.32432; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Polyak K, 2009, TRENDS GENET, V25, P30, DOI 10.1016/j.tig.2008.10.012; Radosevich M, 2007, EXP MOL PATHOL, V82, P68, DOI 10.1016/j.yexmp.2006.03.005; Ramakrishnan S, 2019, CELL DEATH DIFFER, V26, P2100, DOI 10.1038/s41418-019-0278-9; Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746; Serrano A, 2001, INT J CANCER, V94, P243, DOI 10.1002/ijc.1452; Setiadi AF, 2008, CANCER RES, V68, P9601, DOI 10.1158/0008-5472.CAN-07-5270; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shakhova O, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004877; Sheng WQ, 2018, CELL, V174, P549, DOI 10.1016/j.cell.2018.05.052; Shitara K, 2018, ANN NY ACAD SCI, V1417, P104, DOI 10.1111/nyas.13625; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sigalotti L, 2007, J CELL PHYSIOL, V212, P330, DOI 10.1002/jcp.21066; Soengas MS, 2017, NAT CELL BIOL, V19, P1311, DOI 10.1038/ncb3637; Tiffen J, 2020, J INVEST DERMATOL, V140, P2442, DOI 10.1016/j.jid.2020.02.042; Tu WJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01228; Tung Kaity H, 2019, J Immunol Sci, V3, P4, DOI 10.29245/2578-3009/2019/1.1165; van den Hurk K, 2012, BBA-REV CANCER, V1826, P89, DOI 10.1016/j.bbcan.2012.03.011; Vardabasso C, 2015, MOL CELL, V59, P75, DOI 10.1016/j.molcel.2015.05.009; Vento-Tormo R, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-015-0863-2; Venza M, 2015, BBA-GENE REGUL MECH, V1849, P247, DOI 10.1016/j.bbagrm.2014.12.004; Verfaillie A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7683; Vignard V, 2020, CANCER IMMUNOL RES, V8, P255, DOI 10.1158/2326-6066.CIR-19-0522; Wang LL, 2020, EMBO J, V39, DOI 10.15252/embj.2020104514; Wang LW, 2018, AUTOPHAGY, V14, P518, DOI 10.1080/15548627.2017.1384886; Woan KV, 2015, MOL ONCOL, V9, P1447, DOI 10.1016/j.molonc.2015.04.002; Wong DJL, 2014, CANCER IMMUNOL RES, V2, P459, DOI 10.1158/2326-6066.CIR-13-0188; Woods DM, 2015, CANCER IMMUNOL RES, V3, P1375, DOI 10.1158/2326-6066.CIR-15-0077-T; Xing YL, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57591-w; Xu YP, 2019, J CLIN INVEST, V129, P4316, DOI 10.1172/JCI129317; Xu YZ, 2021, AGING-US, V13, P15538, DOI 10.18632/aging.203114; Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0; Yau HL, 2021, MOL CELL, V81, P1469, DOI 10.1016/j.molcel.2021.01.038; Yin HL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21514-8; Yoon SR, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.114; Yu Y, 2018, CANCER CELL, V33, P322, DOI 10.1016/j.ccell.2018.01.002; Zhang MC, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92445-z	137	0	0	10	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								868786	10.3389/fimmu.2022.868786	http://dx.doi.org/10.3389/fimmu.2022.868786			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Z0XJ	35693795	gold, Green Published			2022-12-18	WOS:000808556800001
J	Dunphy, RW; Wahid, AA; Back, CR; Martin, RL; Watts, AG; Dodson, CA; Crennell, SJ; van den Elsen, JMH				Dunphy, Rhys W.; Wahid, Ayla A.; Back, Catherine R.; Martin, Rebecca L.; Watts, Andrew G.; Dodson, Charlotte A.; Crennell, Susan J.; van den Elsen, Jean M. H.			Staphylococcal Complement Evasion Protein Sbi Stabilises C3d Dimers by Inducing an N-Terminal Helix Swap	FRONTIERS IN IMMUNOLOGY			English	Article						complement; structural biology; Staphylococcus aureus; C3d; 3D domain swapping	BINDING PROTEIN; FACTOR-H; STRUCTURAL BASIS; C5 CONVERTASE; RECEPTOR; PATHWAY; DOMAIN; FRAGMENTS; LIGAND	Staphylococcus aureus is an opportunistic pathogen that is able to thwart an effective host immune response by producing a range of immune evasion molecules, including S. aureus binder of IgG (Sbi) which interacts directly with the central complement component C3, its fragments and associated regulators. Recently we reported the first structure of a disulfide-linked human C3d(17C) dimer and highlighted its potential role in modulating B-cell activation. Here we present an X-ray crystal structure of a disulfide-linked human C3d(17C) dimer, which undergoes a structurally stabilising N-terminal 3D domain swap when in complex with Sbi. These structural studies, in combination with circular dichroism and fluorescence spectroscopic analyses, reveal the mechanism underpinning this unique helix swap event and could explain the origins of a previously discovered N-terminally truncated C3dg dimer isolated from rat serum. Overall, our study unveils a novel staphylococcal complement evasion mechanism which enables the pathogen to harness the ability of dimeric C3d to modulate B-cell activation.	[Dunphy, Rhys W.; Wahid, Ayla A.; Back, Catherine R.; Crennell, Susan J.; van den Elsen, Jean M. H.] Univ Bath, Dept Biol & Biochem, Bath, England; [Martin, Rebecca L.; Watts, Andrew G.; Dodson, Charlotte A.] Univ Bath, Dept Pharm & Pharmacol, Bath, England; [van den Elsen, Jean M. H.] Univ Bath, Ctr Therapeut Innovat, Bath, England	University of Bath; University of Bath; University of Bath	van den Elsen, JMH (corresponding author), Univ Bath, Dept Biol & Biochem, Bath, England.; van den Elsen, JMH (corresponding author), Univ Bath, Ctr Therapeut Innovat, Bath, England.	J.M.H.V.Elsen@bath.ac.uk		van den Elsen, Jean/0000-0002-0367-1956; Dodson, Charlotte/0000-0002-8403-726X				Amdahl H, 2013, J IMMUNOL, V191, P1775, DOI 10.4049/jimmunol.1300638; ARNAOUT MA, 1981, J IMMUNOL, V127, P1348; Burman JD, 2008, J BIOL CHEM, V283, P17579, DOI 10.1074/jbc.M800265200; Clark EA, 2011, MOL IMMUNOL, V48, P452, DOI 10.1016/j.molimm.2010.09.017; Hammel M, 2007, J BIOL CHEM, V282, P30051, DOI 10.1074/jbc.M704247200; Hammel M, 2007, NAT IMMUNOL, V8, P430, DOI 10.1038/ni1450; Haupt K, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000250; HONG KS, 1991, J IMMUNOL, V146, P1868; Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172; Janssen BJC, 2005, NATURE, V437, P505, DOI 10.1038/nature04005; Jelezarova E, 2003, J BIOL CHEM, V278, P51806, DOI 10.1074/jbc.M304613200; Kajander T, 2011, P NATL ACAD SCI USA, V108, P2897, DOI 10.1073/pnas.1017087108; Kelly SM, 2000, CURR PROTEIN PEPT SC, V1, P349, DOI 10.2174/1389203003381315; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; Laarman A, 2010, J MOL MED, V88, P115, DOI 10.1007/s00109-009-0572-y; Law SKA, 1997, PROTEIN SCI, V6, P263; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; MELAMED J, 1982, J IMMUNOL, V128, P2313; Morgan HP, 2011, NAT STRUCT MOL BIOL, V18, P463, DOI 10.1038/nsmb.2018; Nagar B, 1998, SCIENCE, V280, P1277, DOI 10.1126/science.280.5367.1277; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Ricklin D, 2008, J IMMUNOL, V181, P7463, DOI 10.4049/jimmunol.181.11.7463; Rooijakkers SHM, 2009, NAT IMMUNOL, V10, P721, DOI 10.1038/ni.1756; Rousseau F, 2012, ADV EXP MED BIOL, V747, P137, DOI 10.1007/978-1-4614-3229-6_9; Sahu A, 2001, IMMUNOL REV, V180, P35, DOI 10.1034/j.1600-065X.2001.1800103.x; Sato S, 2006, J MOL BIOL, V360, P850, DOI 10.1016/j.jmb.2006.05.051; SHIGEOKA AO, 1988, AM J PATHOL, V133, P623; Smith EJ, 2012, MOL MICROBIOL, V83, P789, DOI 10.1111/j.1365-2958.2011.07966.x; Wahid AA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.714055; Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427; Yang Y, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03139; Zanotti G, 2000, BBA-PROTEIN STRUCT M, V1478, P232, DOI 10.1016/S0167-4838(00)00040-6; Zhang LH, 1998, MICROBIOL-UK, V144, P985, DOI 10.1099/00221287-144-4-985	33	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								892234	10.3389/fimmu.2022.892234	http://dx.doi.org/10.3389/fimmu.2022.892234			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X9PY	35693766	Green Published, gold			2022-12-18	WOS:000807781800001
J	Gill, PS; Ozment, TR; Lewis, NH; Sherwood, ER; Williams, DL				Gill, P. Spencer; Ozment, Tammy R.; Lewis, Nicole H.; Sherwood, Edward R.; Williams, David L.			Trained Immunity Enhances Human Monocyte Function in Aging and Sepsis	FRONTIERS IN IMMUNOLOGY			English	Article						trained immunity; aging; immunosenescence; innate immunity; monocytes	RECOGNITION; INNATE; INFECTION; AGE	Aging plays a critical role in the incidence and severity of infection, with age emerging as an independent predictor of mortality in sepsis. Trained immunity reprograms immunocytes to respond more rapidly and effectively to pathogens and serves as a potential approach to improve immune function in aging and/or sepsis. However, there is very little data on trained immunity in the aging immune system or in the presence of sepsis. We examined the impact of beta-glucan induced innate immune training on monocytes from aging healthy humans (>60 years old) as well as sepsis patients. We observed increased metabolic capacity, upregulated cytokine secretion, increased H3K27 acetylation, and upregulation of crucial intracellular signaling pathways in trained monocytes from healthy aging subjects. The response to trained immunity in healthy aging monocytes was equivalent to the response of monocytes from younger, i.e., 18 - 59 years, individuals. Additionally, we found that trained immunity induced a unique expression pattern of cell surface markers in monocytes that was consistent across age groups. Trained monocytes from sepsis patients also displayed enhanced metabolic capacity and increased cytokine production. These results indicate that immune training can be induced in aging monocytes as well as monocytes from critically ill sepsis patients.	[Gill, P. Spencer; Ozment, Tammy R.; Williams, David L.] East Tennessee State Univ, James H Quillen Coll Med, Dept Surg, Johnson City, TN 37614 USA; [Gill, P. Spencer; Ozment, Tammy R.; Williams, David L.] East Tennessee State Univ, Quillen Coll Med, Ctr Inflammat Infect Dis & Immun, Johnson City, TN 37614 USA; [Lewis, Nicole H.] East Tennessee State Univ, Quillen Coll Med, Dept Med Educ, Johnson City, TN USA; [Sherwood, Edward R.] Vanderbilt Univ Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Sherwood, Edward R.] Vanderbilt Univ Sch Med, Dept Anesthesiol, Nashville, TN USA	East Tennessee State University; East Tennessee State University; East Tennessee State University; Vanderbilt University; Vanderbilt University	Williams, DL (corresponding author), East Tennessee State Univ, James H Quillen Coll Med, Dept Surg, Johnson City, TN 37614 USA.; Williams, DL (corresponding author), East Tennessee State Univ, Quillen Coll Med, Ctr Inflammat Infect Dis & Immun, Johnson City, TN 37614 USA.	williamd@etsu.edu			National Institutes of Health (NIH) [R01GM122934, RO1 AI151210, R01GM119197, RO1GM083016, C0RR036551]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported, in part, by the National Institutes of Health (NIH) Grants R01GM122934 to TO, RO1 AI151210 to consistency, R01GM119197 to ES and DW, RO1GM083016 to DW and C0RR036551 to ETSU. The funding agency had no role in the study design, data collection, data interpretation or preparation of this manuscript. Content of this manuscript has previously appeared online in P. Spencer Gill's doctoral dissertation "Trained Immunity Enhances the Immune Response and Maintains Microbiome Diversity in Aging and Sepsis."	Akha AAS, 2018, J IMMUNOL METHODS, V463, P21, DOI 10.1016/j.jim.2018.08.005; [Anonymous], 2014, J INTENSIVE CARE MED, V29, P87, DOI 10.1177/0885066612467162; Arts RJW, 2018, CELL HOST MICROBE, V23, P89, DOI 10.1016/j.chom.2017.12.010; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684; Cirovic B, 2020, CELL HOST MICROBE, V28, P322, DOI 10.1016/j.chom.2020.05.014; Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9; Cunha LL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01748; Delano MJ, 2016, IMMUNOL REV, V274, P330, DOI 10.1111/imr.12499; Delano MJ, 2016, J CLIN INVEST, V126, P23, DOI 10.1172/JCI82224; Deleidi M, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00172; Divangahi M, 2021, NAT IMMUNOL, V22, P2, DOI 10.1038/s41590-020-00845-6; Fernandes CJ, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/896430; Garcia-Valtanen P, 2017, IMMUNOL CELL BIOL, V95, P601, DOI 10.1038/icb.2017.13; Giamarellos-Bourboulis EJ, 2020, CELL, V183, P315, DOI 10.1016/j.cell.2020.08.051; Goodridge HS, 2009, IMMUNOL REV, V230, P38, DOI 10.1111/j.1600-065X.2009.00793.x; Ifrim DC, 2014, CLIN VACCINE IMMUNOL, V21, P534, DOI 10.1128/CVI.00688-13; Jackaman C, 2017, AGEING RES REV, V36, P105, DOI 10.1016/j.arr.2017.03.008; Kleinnijenhuis J, 2012, P NATL ACAD SCI USA, V109, P17537, DOI 10.1073/pnas.1202870109; Kline KA, 2016, CURR OPIN MICROBIOL, V29, P63, DOI 10.1016/j.mib.2015.11.003; Koeken VACM, 2020, J CLIN INVEST, V130, P5591, DOI 10.1172/JCI133935; Leonhardt J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02818; Lowman DW, 2014, J BIOL CHEM, V289, P3432, DOI 10.1074/jbc.M113.529131; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA; Mayr FB, 2014, VIRULENCE, V5, P4, DOI 10.4161/viru.27372; Metcalf TU, 2017, J IMMUNOL, V199, P1405, DOI 10.4049/jimmunol.1700148; Metcalf TU, 2015, AGING CELL, V14, P421, DOI 10.1111/acel.12320; Mocsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765; Moorlag SJCFM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108387; Netea MG, 2020, NAT REV IMMUNOL, V20, P375, DOI 10.1038/s41577-020-0285-6; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; Patel AA, 2017, J EXP MED, V214, P1913, DOI 10.1084/jem.20170355; Pence Brandt D, 2020, Immunometabolism, V2, pe200025, DOI 10.20900/immunometab20200025; Pence BD, 2018, EXP GERONTOL, V108, P112, DOI 10.1016/j.exger.2018.04.008; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Safi W, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.11; Seidler S, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-30; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Stothers CL, 2021, J IMMUNOL, V207, P2785, DOI 10.4049/jimmunol.2100107; van Vught LA, 2016, JAMA-J AM MED ASSOC, V315, P1469, DOI 10.1001/jama.2016.2691; Ventura Maria Teresa, 2017, Clin Mol Allergy, V15, P21, DOI 10.1186/s12948-017-0077-0; Weyand CM, 2016, ANN AM THORAC SOC, V13, pS422, DOI 10.1513/AnnalsATS.201602-095AW	43	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								872652	10.3389/fimmu.2022.872652	http://dx.doi.org/10.3389/fimmu.2022.872652			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Z0WG	35693816	Green Published, gold			2022-12-18	WOS:000808553900001
J	Moran, JA; Turner, SR; Marsden, MD				Moran, Jose A.; Turner, Shireen R.; Marsden, Matthew D.			Contribution of Sex Differences to HIV Immunology, Pathogenesis, and Cure Approaches	FRONTIERS IN IMMUNOLOGY			English	Review						HIV; sex differences; pathogenesis; persistence; latency; cure; sexual dimorphism	VIRAL LOAD; ANTIRETROVIRAL THERAPY; GENDER-DIFFERENCES; LANGERHANS CELLS; VAGINAL TRANSMISSION; ESTROGEN PROTECTS; MALE CIRCUMCISION; LATENT RESERVOIR; GENITAL-TRACT; INFECTION	Approximately 38 million people were living with human immunodeficiency virus (HIV) in 2020 and 53% of those infected were female. A variety of virological and immunological sex-associated differences (sexual dimorphism) in HIV infection have been recognized in males versus females. Social, behavioral, and societal influences play an important role in how the HIV pandemic has affected men and women differently. However, biological factors including anatomical, physiologic, hormonal, and genetic differences in sex chromosomes can each contribute to the distinct characteristics of HIV infection observed in males versus females. One striking example of this is the tendency for women to have lower HIV plasma viral loads than their male counterparts early in infection, though both progress to AIDS at similar rates. Sex differences in acquisition of HIV, innate and adaptive anti-HIV immune responses, efficacy/suitability of specific antiretroviral drugs, and viral pathogenesis have all been identified. Sex differences also have the potential to affect viral persistence, latency, and cure approaches. In this brief review, we summarize the major biological male/female sex differences in HIV infection and their importance to viral acquisition, pathogenesis, treatment, and cure efforts.	[Moran, Jose A.; Turner, Shireen R.; Marsden, Matthew D.] Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA; [Marsden, Matthew D.] Univ Calif Irvine, Sch Med, Dept Med, Div Infect Dis, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Marsden, MD (corresponding author), Univ Calif Irvine, Sch Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA.; Marsden, MD (corresponding author), Univ Calif Irvine, Sch Med, Dept Med, Div Infect Dis, Irvine, CA 92697 USA.			Moran, Jose/0000-0002-7537-6307				Asin SN, 2008, AIDS RES HUM RETROV, V24, P701, DOI 10.1089/aid.2007.0108; Atashili J, 2008, AIDS, V22, P1493, DOI 10.1097/QAD.0b013e3283021a37; Baggaley RF, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.13039; Ballweber L, 2011, J VIROL, V85, P13443, DOI 10.1128/JVI.05615-11; Barnabas RV, 2011, JAIDS-J ACQ IMM DEF, V57, P238, DOI 10.1097/QAI.0b013e31821acb5; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bernin H, 2014, J INFECT DIS, V209, pS107, DOI 10.1093/infdis/jit610; Blankson JN, 2008, IMMUNITY, V29, P845, DOI 10.1016/j.immuni.2008.12.002; Boily MC, 2009, LANCET INFECT DIS, V9, P118, DOI 10.1016/S1473-3099(09)70021-0; Breskin A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172367; Browne EP, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8111787; Burton DR, 2016, ANNU REV IMMUNOL, V34, P635, DOI 10.1146/annurev-immunol-041015-055515; Byrne EH, 2016, LANCET INFECT DIS, V16, P441, DOI 10.1016/S1473-3099(15)00429-6; Carrington M, 2012, ANNU REV MED, V63, P131, DOI 10.1146/annurev-med-062909-130018; CDC, PREP EFF; CDC, HIV WOM HIV DIAGN; Cesarman E, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0060-9; Chouchana L, 2020, LANCET INFECT DIS, V20, P405, DOI 10.1016/S1473-3099(20)30117-1; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Clark R, 2005, DRUG SAFETY, V28, P1075, DOI 10.2165/00002018-200528120-00003; Cook IF, 2008, VACCINE, V26, P3551, DOI 10.1016/j.vaccine.2008.04.054; Cooley TP, 1996, AIDS, V10, P1221, DOI 10.1097/00002030-199609000-00007; Crowell TA, 2015, J INFECT DIS, V211, P1692, DOI 10.1093/infdis/jiu809; Curno MJ, 2016, JAIDS-J ACQ IMM DEF, V71, P181, DOI 10.1097/QAI.0000000000000842; Cuzin L, 2015, AIDS, V29, P1665, DOI 10.1097/QAD.0000000000000723; Das B, 2018, P NATL ACAD SCI USA, V115, pE7795, DOI 10.1073/pnas.1803468115; de Jong MAWP, 2008, J CLIN INVEST, V118, P3440, DOI 10.1172/JCI34721; Dickson N, 2014, SEX TRANSM INFECT, V90, P243, DOI 10.1136/sextrans-2013-051235; Douek DC, 2003, ANNU REV IMMUNOL, V21, P265, DOI 10.1146/annurev.immunol.21.120601.141053; Esra RT, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00245; Falcinelli SD, 2020, J INFECT DIS, V222, P1843, DOI 10.1093/infdis/jiaa298; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Fathi A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601170; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fourati S, 2014, J ANTIMICROB CHEMOTH, V69, P753, DOI 10.1093/jac/dkt428; Frank TD, 2019, LANCET HIV, V6, pE831, DOI 10.1016/S2352-3018(19)30196-1; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Gandhi M, 2004, ANNU REV PHARMACOL, V44, P499, DOI 10.2165/00003088-200948030-00001; Gandhi M, 2002, CLIN INFECT DIS, V35, P313, DOI 10.1086/341249; Gardner MB, 2008, ILAR J, V49, P220, DOI 10.1093/ilar.49.2.220; Gay L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.698121; Geldmacher C, 2012, TRENDS IMMUNOL, V33, P207, DOI 10.1016/j.it.2012.01.011; Gilad J, 2003, EUR J OBSTET GYN R B, V109, P199, DOI 10.1016/S0301-2115(03)00048-4; Goldstein RH, 2019, NEW ENGL J MED, V381, P2491, DOI 10.1056/NEJMp1913547; Gomes AR, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1892-5; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Goujard C, 2012, ANTIVIR THER, V17, P1001, DOI 10.3851/IMP2273; Govender RD, 2021, J EPIDEMIOL GLOB HEA, V11, P296, DOI 10.2991/jegh.k.210621.001; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Gray RH, 2007, LANCET, V369, P657, DOI 10.1016/S0140-6736(07)60313-4; Griesbeck M, 2016, CLIN SCI, V130, P1435, DOI 10.1042/CS20160112; Guery JC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.729233; Gupta P, 1997, J VIROL, V71, P6271, DOI 10.1128/JVI.71.8.6271-6275.1997; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Gupta RK, 2020, LANCET HIV, V7, pE340, DOI 10.1016/S2352-3018(20)30069-2; Hatziioannou T, 2012, NAT REV MICROBIOL, V10, P852, DOI 10.1038/nrmicro2911; Haynes BF, 2017, IMMUNOL REV, V275, P5, DOI 10.1111/imr.12517; Heumann C, 2018, CURR INFECT DIS REP, V20, DOI 10.1007/s11908-018-0618-9; HIV.gov, HIV BASICS OVERVIEW; Ho YC, 2013, CELL, V155, P540, DOI 10.1016/j.cell.2013.09.020; Houlihan CF, 2012, AIDS, V26, P2211, DOI 10.1097/QAD.0b013e328358d908; Hsu J., 2022, CROI C RETROVIRUSES; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; Jacobsen H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.720952; Jaillon S, 2019, CLIN REV ALLERG IMMU, V56, P308, DOI 10.1007/s12016-017-8648-x; Kaplan JE, 2000, CLIN INFECT DIS, V30, pS5, DOI 10.1086/313843; Kaushic C, 2011, J REPROD IMMUNOL, V88, P204, DOI 10.1016/j.jri.2010.12.004; Klatt NR, 2017, SCIENCE, V356, P938, DOI 10.1126/science.aai9383; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Krebs SJ, 2016, AIDS, V30, P1533, DOI 10.1097/QAD.0000000000001096; Krieger JN, 2012, WORLD J UROL, V30, P3, DOI 10.1007/s00345-011-0696-x; Li JZ, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI149414; Looker KJ, 2017, LANCET INFECT DIS, V17, P1303, DOI 10.1016/S1473-3099(17)30405-X; Macedo AB, 2018, AIDS RES HUM RETROV, V34, P769, DOI [10.1089/aid.2018.0098, 10.1089/AID.2018.0098]; Madec Y, 2005, AIDS, V19, P2001, DOI 10.1097/01.aids.0000194134.28135.cd; Malekinejad M, 2021, SEX TRANSM DIS, V48, pE138, DOI 10.1097/OLQ.0000000000001403; Marsden MD, 2017, ANNU REV VIROL, V4, P393, DOI 10.1146/annurev-virology-101416-041703; Marsden MD, 2013, BIOORG MED CHEM LETT, V23, P4003, DOI 10.1016/j.bmcl.2013.05.032; Masese L, 2015, AIDS, V29, P1077, DOI 10.1097/QAD.0000000000000646; Masha SC, 2019, SEX TRANSM INFECT, V95, P36, DOI 10.1136/sextrans-2018-053713; Mathad JS, 2016, JAIDS-J ACQ IMM DEF, V73, P123, DOI 10.1097/QAI.0000000000001095; McClelland RS, 2007, J INFECT DIS, V195, P698, DOI 10.1086/511278; Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004; Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA486, DOI 10.1016/j.autrev.2011.11.023; Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission, RECOMMENDATIONS USE; Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174; PHILLIPS AN, 1994, AIDS, V8, P831, DOI 10.1097/00002030-199406000-00017; Portales P, 2001, ANN INTERN MED, V134, P81, DOI 10.7326/0003-4819-134-1-200101020-00023; Prins M, 1999, AIDS, V13, P2361, DOI 10.1097/00002030-199912030-00007; Prodger JL, 2017, AIDS RES THER, V14, DOI 10.1186/s12981-017-0167-6; Riddell J, 2018, JAMA-J AM MED ASSOC, V319, P1261, DOI 10.1001/jama.2018.1917; Rohner E, 2017, CLIN INFECT DIS, V65, P1316, DOI 10.1093/cid/cix480; Rositch AF, 2014, AIDS, V28, P745, DOI 10.1097/QAD.0000000000000092; Ruel TD, 2011, CLIN INFECT DIS, V53, P592, DOI 10.1093/cid/cir484; Saag MS, 2020, JAMA-J AM MED ASSOC, V324, P1651, DOI 10.1001/jama.2020.17025; Scully EP, 2021, CURR OPIN HIV AIDS, V16, P48, DOI 10.1097/COH.0000000000000661; Scully EP, 2019, J INFECT DIS, V219, P1084, DOI 10.1093/infdis/jiy617; Sengupta S, 2018, IMMUNITY, V48, P872, DOI 10.1016/j.immuni.2018.04.030; Shafran S D, 1992, Can J Infect Dis, V3, P82; Sharp PM, 2011, CSH PERSPECT MED, V1, DOI 10.1101/cshperspect.a006841; Shiau S, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-39; Smith SA, 2004, AIDS, V18, P1637, DOI 10.1097/01.aids.0000131393.76221.cc; Smith SM, 2000, J INFECT DIS, V182, P708, DOI 10.1086/315776; Sohler NL, 2009, AIDS PATIENT CARE ST, V23, P775, DOI 10.1089/apc.2009.0041; Soldin OP, 2009, CLIN PHARMACOKINET, V48, P143, DOI 10.2165/00003088-200948030-00001; Souyris M, 2019, SEMIN IMMUNOPATHOL, V41, P153, DOI 10.1007/s00281-018-0712-y; Souyris M, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8855; Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001; Szaniawski MA, 2019, J INFECT DIS, V219, P777, DOI 10.1093/infdis/jiy583; Szotek EL, 2013, VIROLOGY, V443, P375, DOI 10.1016/j.virol.2013.05.027; Tukiainen T, 2017, NATURE, V550, P244, DOI 10.1038/nature24265; UNAIDS, GLOB HIV AIDS STAT F; Utay Netanya S, 2016, Pathog Immun, V1, P107; Vergis EN, 2000, INFECT DIS CLIN N AM, V14, P809, DOI 10.1016/S0891-5520(05)70135-5; vom Steeg LG, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005374; Williams JP, 2014, ELIFE, V3, DOI 10.7554/eLife.03821; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Wong ME, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01435; Youness A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031114; Zash R, 2018, NEW ENGL J MED, V379, P979, DOI 10.1056/NEJMc1807653; Zhou ZC, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002100	123	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								905773	10.3389/fimmu.2022.905773	http://dx.doi.org/10.3389/fimmu.2022.905773			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y7EC	35693831	Green Published, gold			2022-12-18	WOS:000808302300001
J	Niinistoe, S; Miettinen, ME; Cuthbertson, D; Honkanen, J; Hakola, L; Autio, R; Erlund, I; Arohonka, P; Vuorela, A; Haerkoenen, T; Hyoety, H; Krischer, JP; Vaarala, O; Knip, M; Virtanen, SM				Niinistoe, Sari; Miettinen, Maija E.; Cuthbertson, David; Honkanen, Jarno; Hakola, Leena; Autio, Reija; Erlund, Iris; Arohonka, Petra; Vuorela, Arja; Haerkoenen, Taina; Hyoety, Heikki; Krischer, Jeffrey P.; Vaarala, Outi; Knip, Mikael; Virtanen, Suvi M.			Associations Between Serum Fatty Acids and Immunological Markers in Children Developing Islet Autoimmunity-The TRIGR Nested Case-Control Study	FRONTIERS IN IMMUNOLOGY			English	Article						fatty acids; immunological markers; cytokines; chemokines; growth factors; islet autoimmunity; children; type 1 diabetes	BETA-CELL AUTOIMMUNITY; PLASMALOGEN STATUS; TYPE-1; RISK; INFLAMMATION; IMMUNITY; INFANCY; CXCL10; LINE	AimsAltered immune functions as well as fatty acid intake and status have been associated with the development of type 1 diabetes. We aimed to study the relationship between fatty acids and immunological markers in young children with increased genetic risk for type 1 diabetes in order to define putative mechanisms related to development of islet autoimmunity. MethodsSerum samples for fatty acid and immunological marker measurements were obtained in the Trial to Reduce IDDM in the Genetically at Risk (TRIGR) ancillary study (Divia) from children born between 2002 and 2007 in 15 countries. Case children (n = 95) were defined as having repeated positivity for at least two out of four diabetes-associated autoantibodies. For each case child, control children were selected matched for country and date of birth (n = 173). Serum fatty acids and immunological markers were measured from cord serum and at the age of 6 and 12 months. Spearman correlation coefficients were calculated between fatty acids and immunological markers. ResultsCorrelations between circulating fatty acids and immunological markers were different in case children who developed islet autoimmunity than in control children already at birth continuing across the first year of life. In case children, saturated fatty acids (SFAs) showed stronger correlations with immunological markers, while in controls, polyunsaturated fatty acids (PUFAs) showed stronger correlations. ConclusionsIn cases, SFAs were associated with several immunological markers (CXCL10, IL-6, IL-9, IL-17, and CM-CSF) previously linked to the type 1 diabetes disease process. Findings indicate that fatty acids could have immunomodulatory potential in the early phase of the disease development, although causality between fatty acids and the immunological pathways remains to be explored. Trial registry numberNCT00179777	[Niinistoe, Sari; Miettinen, Maija E.; Virtanen, Suvi M.] Finnish Inst Hlth & Welf, Dept Publ Hlth & Welf, Helsinki, Finland; [Cuthbertson, David; Krischer, Jeffrey P.] Univ S Florida, Hlth Informat Inst, Morsani Coll Med, Tampa, FL USA; [Honkanen, Jarno; Vuorela, Arja; Haerkoenen, Taina; Vaarala, Outi] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland; [Hakola, Leena; Autio, Reija; Virtanen, Suvi M.] Tampere Univ, Fac Social Sci, Unit Hlth Sci, Tampere, Finland; [Hakola, Leena; Virtanen, Suvi M.] Tampere Univ Hosp, Res Dev & Innovat Ctr, Tampere, Finland; [Erlund, Iris; Arohonka, Petra] Finnish Inst Hlth & Welf, Dept Govt Serv, Helsinki, Finland; [Hyoety, Heikki] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland; [Hyoety, Heikki] Fimlab Labs, Pirkanmaa Hosp Dist, Tampere, Finland; [Knip, Mikael] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland; [Knip, Mikael] Univ Helsinki, Res Program Clin & Mol Metab, Helsinki, Finland; [Knip, Mikael; Virtanen, Suvi M.] Tampere Univ, Ctr Child Hlth Res, Tampere, Finland	State University System of Florida; University of South Florida; University of Helsinki; Tampere University; Tampere University; Tampere University Hospital; Tampere University; Pirkanmaa Hospital District; University of Helsinki; University of Helsinki; Tampere University	Niinistoe, S (corresponding author), Finnish Inst Hlth & Welf, Dept Publ Hlth & Welf, Helsinki, Finland.	sari.niinisto@thl.fi		Vuorela, Arja/0000-0001-9987-1903				Abdel-Moneim A, 2018, BIOMED PHARMACOTHER, V101, P287, DOI 10.1016/j.biopha.2018.02.103; Alnek K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142976; Antonelli A, 2014, CYTOKINE GROWTH F R, V25, P57, DOI 10.1016/j.cytogfr.2014.01.006; Arif S, 2011, DIABETES, V60, P2112, DOI 10.2337/db10-1643; Balzano-Nogueira L, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02262-w; Beriou G, 2010, J IMMUNOL, V185, P46, DOI 10.4049/jimmunol.1000356; Chase HP, 2015, PEDIATR DIABETES, V16, P271, DOI 10.1111/pedi.12170; Fu YW, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/8879227; Gaposchkin DP, 2008, BBA-MOL CELL BIOL L, V1781, P213, DOI 10.1016/j.bbalip.2008.01.007; Gaposchkin DP, 1999, J LIPID RES, V40, P495; Grieco FA, 2014, DIABETOLOGIA, V57, P502, DOI 10.1007/s00125-013-3135-2; Hakola L, 2021, PEDIATR DIABETES, V22, P577, DOI 10.1111/pedi.13189; Honkanen J, 2010, J IMMUNOL, V185, P1959, DOI 10.4049/jimmunol.1000788; Ilonen J, 2019, NAT REV ENDOCRINOL, V15, P635, DOI 10.1038/s41574-019-0254-y; Johnson RK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51251-4; Kallionpaa H, 2019, DIABETES, V68, P2024, DOI 10.2337/db19-0287; Kallionpaa H, 2014, DIABETES, V63, P2402, DOI 10.2337/db13-1775; Kawasaki E, 2004, DIABETES RES CLIN PR, V66, pS27, DOI 10.1016/j.diabres.2003.09.015; Knip M, 2018, JAMA-J AM MED ASSOC, V319, P38, DOI 10.1001/jama.2017.19826; Knip M, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0933-9; Knip M, 2010, NEW ENGL J MED, V363, P1900, DOI 10.1056/NEJMoa1004809; La Torre D, 2013, DIABETES, V62, P3951, DOI 10.2337/db13-0215; Lamichhane S, 2019, DIABETOLOGIA, V62, P2287, DOI 10.1007/s00125-019-04980-0; Lankinen M, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111785; Li KL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088103; Lindehammer SR, 2011, AM J REPROD IMMUNOL, V66, P495, DOI 10.1111/j.1600-0897.2011.01057.x; Lu JL, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1122; Miller MR, 2011, PEDIATR DIABETES, V12, P669, DOI 10.1111/j.1399-5448.2011.00760.x; Nicoletti F, 2002, DIABETOLOGIA, V45, P1107, DOI 10.1007/s00125-002-0879-5; Niinisto S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82200-9; Niinisto S, 2017, DIABETOLOGIA, V60, P1223, DOI 10.1007/s00125-017-4280-9; Norris JM, 2014, DIABETOLOGIA, V57, P295, DOI 10.1007/s00125-013-3106-7; Oki E, 2017, BRIT J NUTR, V117, P1663, DOI 10.1017/S0007114517001416; Oresic M, 2008, J EXP MED, V205, P2975, DOI 10.1084/jem.20081800; Ormrod J. E., 1999, BIOSTAT ANAL, V3, DOI DOI 10.2307/2265725; Radzikowska U, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122990; Reinert-Hartwall L, 2014, DIABETES-METAB RES, V30, P749, DOI 10.1002/dmrr.2550; Reinert-Hartwall L, 2015, J IMMUNOL, V194, P68, DOI 10.4049/jimmunol.1401653; Roep BO, 2010, CLIN EXP IMMUNOL, V159, P338, DOI 10.1111/j.1365-2249.2009.04087.x; Rutti S, 2016, MOL METAB, V5, P122, DOI 10.1016/j.molmet.2015.11.003; Sheshkin D.J., 2004, HDB PARAMETRIC NONPA, V3; Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303; Viladomiu M, 2016, EUR J PHARMACOL, V785, P87, DOI 10.1016/j.ejphar.2015.03.095; Virtanen SM, 2010, EUR J CLIN NUTR, V64, P792, DOI 10.1038/ejcn.2010.75; Vistnes M, 2018, AM J REPROD IMMUNOL, V79, DOI 10.1111/aji.12802; Waugh K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174840; Wu Y, 2019, J AGR FOOD CHEM, V67, P7716, DOI 10.1021/acs.jafc.9b02485; Yu JC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01759	48	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								858875	10.3389/fimmu.2022.858875	http://dx.doi.org/10.3389/fimmu.2022.858875			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y7IS	35693790	Green Published, gold			2022-12-18	WOS:000808314400001
J	Pan, SD; Yu, YY; Wang, SY; Tu, B; Shen, YJ; Qiu, Q; Liu, XM; Su, N; Zuo, YM; Luan, JQ; Zhang, JY; Shi, M; Meng, FP; Wang, FS				Pan, Shida; Yu, Yingying; Wang, Siyu; Tu, Bo; Shen, Yingjuan; Qiu, Qin; Liu, Xiaomeng; Su, Nan; Zuo, Yanmei; Luan, Junqing; Zhang, Ji-Yuan; Shi, Ming; Meng, Fanping; Wang, Fu-Sheng			Correlation of HBV DNA and Hepatitis B Surface Antigen Levels With Tumor Response, Liver Function and Immunological Indicators in Liver Cancer Patients With HBV Infection Undergoing PD-1 Inhibition Combinational Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						hepatitis B virus; hepatitis B surface antigen; HBV reactivation; median survival time; C-reactive protein; interleukin-6	UNRESECTABLE HEPATOCELLULAR-CARCINOMA; VIRUS REACTIVATION; VIRAL LOAD; OPEN-LABEL; SURVIVAL; ATEZOLIZUMAB; MULTICENTER; BEVACIZUMAB; SEVERITY; SUBSETS	BackgroundThus far, few studies have investigated the safety and efficacy of programmed death-1 (PD-1) immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) antibodies in patients with hepatitis B virus (HBV)-related liver cancer. ObjectiveTo investigate the effect of combination therapy with programmed death-1 (PD-1) immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) on HBV-related liver cancer. MethodsUntil January 31, 2022, liver cancer patients with hepatitis B surface antigen (HBsAg) or HBV DNA positivity, treated with PD-1 ICIs and TKIs combined with nucleoside analogs (NAs), were retrospectively reviewed. The correlation between the change in HBV DNA and HBsAg levels and tumor response was analyzed using the chi(2) test. Cox univariate and multivariate survival analyses and Kaplan-Meier curves were used to identify and compare risk factors and overall survival (OS). ResultsA total of 48 patients were enrolled in the study, with an objective response rate (ORR) of 31.3%, a disease control rate (DCR) of 66.7%; the incidence of adverse events was mostly mild. A significant decrease in HBV DNA and HBsAg levels was observed at 12 and 24 weeks compared with the baseline (p < 0.05). Compared to patients with progressive disease (PD), patients with disease control showed a more significant decrease in HBV DNA and HBsAg levels at 12 and 24 weeks (p < 0.001). Eleven patients showed elevations in HBV DNA level and one of them showed HBV reactivation; however, the reactivation was not associated hepatitis. Moreover, eight patients showed elevation in HBsAg. Elevation in HBV DNA level was associated with poor tumor response (P=0.001, OR=18.643 [95% CI: 3.271-106.253]). Cox survival analysis suggested that HBV DNA increase (P=0.011, HR=4.816, 95% CI: 1.439-16.117) and HBsAg increase (P=0.022, HR=4.161, 95% CI: 1.224-16.144) were independent risk factors associated with survival time. Kaplan-Meier curves suggested that patients who exhibited an increase in HBV DNA (6.87 months vs undefined, log-rank test: p= 0.004) and HBsAg (8.07 months vs undefined, log-rank test: p= 0.004) levels had a shorter median survival time (MST). Patients without increased HBsAg showed better baseline liver function and routine blood tests (p<0.05) than patients with increased HBsAg. An increase in C-reactive protein (CRP) and interleukin-6 (IL-6), and a decrease in T lymphocytes, CD4+ T lymphocytes, and B lymphocytes at 1-week post-treatment associated with HBsAg well-controlled. ConclusionHBV-related liver cancer patients treated with combination therapy showed improved efficacy and safety profiles. Combination therapy has some effect on HBV infection, and a correlation between tumor response and antiviral efficacy was found. Elevation of HBV DNA and HBsAg levels may indicate poorer tumor response and survival time. Better baseline liver function and early immune activation may be associated with decline in HBsAg levels.	[Pan, Shida; Wang, Siyu; Zuo, Yanmei; Meng, Fanping; Wang, Fu-Sheng] Chinese Peoples Liberat Army PLA Med Sch, Beijing, Peoples R China; [Pan, Shida; Yu, Yingying; Wang, Siyu; Tu, Bo; Shen, Yingjuan; Qiu, Qin; Liu, Xiaomeng; Su, Nan; Zuo, Yanmei; Luan, Junqing; Zhang, Ji-Yuan; Shi, Ming; Meng, Fanping; Wang, Fu-Sheng] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 5, Dept Infect Dis, Beijing, Peoples R China; [Yu, Yingying; Shi, Ming] Peking Univ, Clin Med Sch 302, Beijing, Peoples R China; [Su, Nan] Southern Med Univ, Sch Clin Med 2, Guangzhou, Peoples R China	Peking University; Southern Medical University - China	Meng, FP; Wang, FS (corresponding author), Chinese Peoples Liberat Army PLA Med Sch, Beijing, Peoples R China.; Shi, M; Meng, FP; Wang, FS (corresponding author), Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 5, Dept Infect Dis, Beijing, Peoples R China.; Shi, M (corresponding author), Peking Univ, Clin Med Sch 302, Beijing, Peoples R China.	himing302@sina.com; drmengfanping@126.com; fswang302@163.com	yu, yingying/GRR-7851-2022		National Natural Science Foundation of China [82070617]; Innovative Research Group Project of the National Natural Science Foundation of China [81721002]; Beijing Municipal Science and Technology Commission [Z201100005520047]; National Key Research and Development Program of China [2019YFC0840704]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovative Research Group Project of the National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Municipal Science and Technology Commission(Beijing Municipal Science & Technology Commission); National Key Research and Development Program of China	Funding This work was supported by grants from the National Natural Science Foundation of China (82070617); the Innovative Research Group Project of the National Natural Science Foundation of China(81721002); Beijing Municipal Science and Technology Commission (Z201100005520047) and National Key Research and Development Program of China (2019YFC0840704).	Benechet AP, 2017, J HEPATOL, V66, P228, DOI 10.1016/j.jhep.2016.07.011; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen JZ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-6063; Chen LT, 2020, ANN ONCOL, V31, P334, DOI 10.1016/j.annonc.2019.12.001; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Cheng Y, 2021, IMMUNITY, V54, P1825, DOI 10.1016/j.immuni.2021.06.013; Cui TM, 2020, ONCOTARGETS THER, V13, P11725, DOI 10.2147/OTT.S279858; Dan JQ, 2013, EJSO-EUR J SURG ONC, V39, P865, DOI 10.1016/j.ejso.2013.03.020; El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2; Feng RM, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0368-6; Finn RS, 2020, J CLIN ONCOL, V38, P2960, DOI 10.1200/JCO.20.00808; Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745; Fioravanti J, 2017, J HEPATOL, V67, P543, DOI 10.1016/j.jhep.2017.04.020; Fisicaro P, 2010, GASTROENTEROLOGY, V138, P682, DOI 10.1053/j.gastro.2009.09.052; Freites-Martinez A, 2021, ACTAS DERMO-SIFILOGR, V112, P90, DOI 10.1016/j.ad.2019.05.009; Gane E, 2019, J HEPATOL, V71, P900, DOI 10.1016/j.jhep.2019.06.028; Huang G, 2013, ANN SURG, V257, P490, DOI 10.1097/SLA.0b013e318262b218; Huang W, 2014, CANCER SCI, V105, P697, DOI 10.1111/cas.12400; Ikeda M, 2016, CLIN CANCER RES, V22, P1385, DOI 10.1158/1078-0432.CCR-15-1354; Jiang M, 2020, J INFECT DIS, V222, P198, DOI 10.1093/infdis/jiaa252; Kudo M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4072; Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1; Lee MS, 2020, LANCET ONCOL, V21, P808, DOI 10.1016/S1470-2045(20)30156-X; Lee PC, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001072; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; Li MR, 2011, DIGESTION, V84, P134, DOI 10.1159/000324197; Liu SS, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.582504; Liu ZQ, 2019, CANCER MED-US, V8, P5787, DOI 10.1002/cam4.2477; Llovet JM, 2020, J HEPATOL, V72, P288, DOI 10.1016/j.jhep.2019.09.026; Loomba R, 2017, GASTROENTEROLOGY, V152, P1297, DOI 10.1053/j.gastro.2017.02.009; Maier H, 2007, J IMMUNOL, V178, P2714, DOI 10.4049/jimmunol.178.5.2714; Paik JM, 2020, HEPATOLOGY, V72, P1605, DOI 10.1002/hep.31173; Qin SK, 2020, LANCET ONCOL, V21, P571, DOI 10.1016/S1470-2045(20)30011-5; Rao Q, 2020, HEPATOL INT, V14, P765, DOI 10.1007/s12072-020-10064-8; Shao YY, 2011, ANTICANCER RES, V31, P4007; Sun FR, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08483-3; Sun XQ, 2020, J HEPATOCELL CARCINO, V7, P337, DOI 10.2147/JHC.S278527; Tang TJ, 2005, J HEPATOL, V43, P45, DOI 10.1016/j.jhep.2005.01.038; Tang YJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01708; Terrault NA, 2018, HEPATOLOGY, V67, P1560, DOI 10.1002/hep.29800; Tzeng HT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039179; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wang KY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003195; Wang MJ, 2017, INT J INFECT DIS, V65, P15, DOI 10.1016/j.ijid.2017.09.003; Wu SP, 2018, J THORAC ONCOL, V13, P521, DOI 10.1016/j.jtho.2017.11.132; Xu JM, 2019, CLIN CANCER RES, V25, P515, DOI 10.1158/1078-0432.CCR-18-2484; Yang PH, 2020, INFECT DIS POVERTY, V9, DOI 10.1186/s40249-020-00780-6; Yang Y, 2015, LIVER INT, V35, P2147, DOI 10.1111/liv.12805; Yau T, 2020, JAMA ONCOL, V6, DOI 10.1001/jamaoncol.2020.4564; Yau T, 2019, J HEPATOL, V71, P543, DOI 10.1016/j.jhep.2019.05.014; Yeo W, 2007, HEPATOLOGY, V45, P1382, DOI 10.1002/hep.21572; Yu SJ, 2013, RADIOLOGY, V267, P638, DOI 10.1148/radiol.13121498; Yuan GS, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3020; Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X; Zhang SS, 2019, JPN J CLIN ONCOL, V49, P646, DOI 10.1093/jjco/hyz046; Zhang W, 2020, INT J INFECT DIS, V99, P92, DOI 10.1016/j.ijid.2020.06.079; Zhang XY, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0808-5; Zheng MJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02525; Zhu AX, 2018, LANCET ONCOL, V19, P940, DOI 10.1016/S1470-2045(18)30351-6	59	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								892618	10.3389/fimmu.2022.892618	http://dx.doi.org/10.3389/fimmu.2022.892618			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C6PZ	35711409	gold, Green Published			2022-12-18	WOS:000810989200001
J	Patarroyo, ME; Pabon, L; Alba, MP; Bermudez, A; Rugeles, MT; Diaz-Arevalo, D; Zapata-Builes, W; Zapata, MI; Reyes, C; Suarez, CF; Agudelo, W; Lopez, C; Aza-Conde, J; Melo, M; Escamilla, L; Oviedo, J; Guzman, F; Silva, Y; Forero, M; Florez-alvarez, L; Aguilar-Jimenez, W; Moreno-Vranich, A; Garry, J; Avendano, C				Patarroyo, Manuel E.; Pabon, Laura; Alba, Martha P.; Bermudez, Adriana; Rugeles, Maria Teresa; Diaz-Arevalo, Diana; Zapata-Builes, Wildeman; Zapata, Maria Isabel; Reyes, Cesar; Suarez, Carlos F.; Agudelo, William; Lopez, Carolina; Aza-Conde, Jorge; Melo, Miguel; Escamilla, Luis; Oviedo, Jairo; Guzman, Fanny; Silva, Yolanda; Forero, Martha; Florez-alvarez, Lizdany; Aguilar-Jimenez, Wbeimar; Moreno-Vranich, Armando; Garry, Jason; Avendano, Catalina			SM-COLSARSPROT: Highly Immunogenic Supramutational Synthetic Peptides Covering the World's Population	FRONTIERS IN IMMUNOLOGY			English	Article						modified synthetic peptides; SARS-CoV-2; mutational variants; multiepitope; supramutational; worldwide coverage	HYDROGEN-BONDS; PROTECTIVE IMMUNITY; CRYSTAL-STRUCTURE; SARS-COV-2 SPIKE; MALARIAL PEPTIDE; PHI PHI; SPECIFICITY; HELIX; PPII; VISUALIZATION	Fifty ~20-amino acid (aa)-long peptides were selected from functionally relevant SARS-CoV-2 S, M, and E proteins for trial B-21 and another 53 common ones, plus some new ones derived from the virus' main genetic variants for complementary trial C-21. Peptide selection was based on tremendous SARS-CoV-2 genetic variability for analysing them concerning vast human immunogenetic polymorphism for developing the first supramutational, Colombian SARS-protection (SM-COLSARSPROT), peptide mixture. Specific physicochemical rules were followed, i.e., aa predilection for polyproline type II left-handed (PPIIL) formation, replacing beta-branched, aromatic aa, short-chain backbone H-bond-forming residues, pi-pi interactions (n ->pi* and pi-CH), aa interaction with pi systems, and molecular fragments able to interact with them, disrupting PPIIL propensity formation. All these modified structures had PPIIL formation propensity to enable target peptide interaction with human leukocyte antigen-DR beta 1* (HLA-DR beta 1*) molecules to mediate antigen presentation and induce an appropriate immune response. Such modified peptides were designed for human use; however, they induced high antibody titres against S, M, and E parental mutant peptides and neutralising antibodies when suitably modified and chemically synthesised for immunising 61 major histocompatibility complex class II (MHCII) DNA genotyped Aotus monkeys (matched with their corresponding HLA-DR beta 1* molecules), predicted to cover 77.5% to 83.1% of the world's population. Such chemically synthesised peptide mixture represents an extremely pure, stable, reliable, and cheap vaccine for COVID-19 pandemic control, providing a new approach for a logical, rational, and soundly established methodology for other vaccine development.					Avendano, Catalina/GVT-6444-2022; Zapata, Wildeman/C-1622-2018	Avendano, Catalina/0000-0001-6466-5181; Zapata Cardona, Maria Isabel/0000-0003-2714-9190; Zapata, Wildeman/0000-0002-7351-8738				Alba MP, 2016, BIOCHEM BIOPH RES CO, V477, P654, DOI 10.1016/j.bbrc.2016.06.115; [Anonymous], SWISS MODEL EXPASY; [Anonymous], MODIFIED NCOV 2019 S; [Anonymous], 2022, WHO CORONAVIRUS COVI; Babb PL, 2011, AM J PHYS ANTHROPOL, V146, P209, DOI 10.1002/ajpa.21567; Bartlett GJ, 2013, J AM CHEM SOC, V135, P18682, DOI 10.1021/ja4106122; Bartlett GJ, 2010, NAT CHEM BIOL, V6, P615, DOI [10.1038/NCHEMBIO.406, 10.1038/nchembio.406]; Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049; Bermudez A, 2008, VACCINE, V26, P6908, DOI 10.1016/j.vaccine.2008.09.071; Birnbaum ME, 2014, CELL, V157, P1073, DOI 10.1016/j.cell.2014.03.047; Brown AM, 2012, BIOCHEMISTRY-US, V51, P5041, DOI 10.1021/bi3002924; Cai YF, 2020, SCIENCE, V369, P1586, DOI [10.1126/science.abd4251, 10.1101/2020.05.16.099317]; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; Carvajal-Rondanelli P, 2018, AMINO ACIDS, V50, P557, DOI 10.1007/s00726-018-2542-6; Chourasia M, 2011, INT J BIOL MACROMOL, V48, P540, DOI 10.1016/j.ijbiomac.2011.01.008; Donermeyer DL, 2006, J IMMUNOL, V177, P6911, DOI 10.4049/jimmunol.177.10.6911; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; Patarroyo ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123249; Patarroyo ME, 2011, CHEM REV, V111, P3459, DOI 10.1021/cr100223m; Espejo F, 2001, ANGEW CHEM INT EDIT, V40, P4654, DOI 10.1002/1521-3773(20011217)40:24<4654::AID-ANIE4654>3.0.CO;2-F; Eswar N, 2000, PROTEIN ENG, V13, P227, DOI 10.1093/protein/13.4.227; Gillingham MAF, 2021, MOL ECOL RESOUR, V21, P982, DOI 10.1111/1755-0998.13290; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Henderson R., 2020, NAT STRUCT MOL BIOL, V27, P925, DOI [DOI 10.1038/s41594-020-0479-4, 10.1038/s41594-020-0479-4]; Herrera Natalia G, 2020, bioRxiv, DOI [10.1021/acsomega.0c03512, 10.1101/2020.06.14.150607]; Horng JC, 2006, PROTEIN SCI, V15, P74, DOI 10.1110/ps.051779806; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; Hu J, 2021, CELL MOL IMMUNOL, V18, P1061, DOI 10.1038/s41423-021-00648-1; Jardetzky TS, 1996, P NATL ACAD SCI USA, V93, P734, DOI 10.1073/pnas.93.2.734; Jensen KK, 2018, IMMUNOLOGY, V154, P394, DOI 10.1111/imm.12889; Juraszek J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20321-x; Kashala O, 2002, VACCINE, V20, P2263, DOI 10.1016/S0264-410X(02)00115-9; Klasse PJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe8065; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Krause PR, 2021, NEW ENGL J MED, V385, P179, DOI 10.1056/NEJMsr2105280; Kuemin M, 2009, J AM CHEM SOC, V131, P15474, DOI 10.1021/ja906466q; Lee WS, 2020, NAT MICROBIOL, V5, P1185, DOI 10.1038/s41564-020-00789-5; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Liao W, 2011, CURR OPIN IMMUNOL, V23, P598, DOI 10.1016/j.coi.2011.08.003; Lopez C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096973; Lovitch SB, 2006, J IMMUNOL, V176, P2958, DOI 10.4049/jimmunol.176.5.2958; Mahtarin R, 2022, J BIOMOL STRUCT DYN, V40, P4725, DOI 10.1080/07391102.2020.1861983; Mehrizi AA, 2018, PARASITE IMMUNOL, V40, DOI 10.1111/pim.12538; Newberry RW, 2017, ACCOUNTS CHEM RES, V50, P1838, DOI 10.1021/acs.accounts.7b00121; Newberry RW, 2016, NAT CHEM BIOL, V12, P1084, DOI [10.1038/NCHEMBIO.2206, 10.1038/nchembio.2206]; Newberry RW, 2014, PROTEIN SCI, V23, P284, DOI 10.1002/pro.2413; Nino-Vasquez JJ, 2000, IMMUNOGENETICS, V51, P219, DOI 10.1007/s002510050035; Nishio M, 2014, PHYS CHEM CHEM PHYS, V16, P12648, DOI 10.1039/c4cp00099d; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Pandey AK, 2014, BIOCHEMISTRY-US, V53, P5307, DOI 10.1021/bi500696k; Patarroyo MA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009771; Patarroyo ME, 2008, ACCOUNTS CHEM RES, V41, P377, DOI 10.1021/ar700120t; Patarroyo ME, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724060; Patarroyo ME, 2012, BIOCHEM BIOPH RES CO, V429, P75, DOI 10.1016/j.bbrc.2012.10.089; Patarroyo ME, 2012, BIOCHEM BIOPH RES CO, V429, P81, DOI 10.1016/j.bbrc.2012.10.088; PATARROYO ME, 1987, NATURE, V328, P629, DOI 10.1038/328629a0; PATARROYO ME, 1988, NATURE, V332, P158, DOI 10.1038/332158a0; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Plante JA, 2021, CELL HOST MICROBE, V29, P508, DOI 10.1016/j.chom.2021.02.020; Rambaut A, 2020, NAT MICROBIOL, V5, P1403, DOI 10.1038/s41564-020-0770-5; Reyes C, 2017, BIOCHEM BIOPH RES CO, V484, P501, DOI 10.1016/j.bbrc.2017.01.077; Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874; Rodriguez LE, 2008, CHEM REV, V108, P3656, DOI 10.1021/cr068407v; Sebastian A, 2016, MOL ECOL RESOUR, V16, P498, DOI 10.1111/1755-0998.12453; Shepley-McTaggart A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251955; Somervuo P, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2262-7; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Suarez CF, 2017, BIOCHEM BIOPH RES CO, V491, P1062, DOI 10.1016/j.bbrc.2017.08.012; Surya W, 2018, BBA-BIOMEMBRANES, V1860, P1309, DOI 10.1016/j.bbamem.2018.02.017; Tang T, 2020, ANTIVIR RES, V178, DOI 10.1016/j.antiviral.2020.104792; Thomsen MCF, 2012, NUCLEIC ACIDS RES, V40, pW281, DOI 10.1093/nar/gks469; Toelzer C, 2020, SCIENCE, V370, P725, DOI 10.1126/science.abd3255; Vasudev PG, 2012, PROTEINS, V80, P991, DOI 10.1002/prot.24001; Vijayakumar M, 1999, PROTEINS, V34, P497, DOI 10.1002/(SICI)1097-0134(19990301)34:4<497::AID-PROT9>3.0.CO;2-G; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wilhelm P, 2014, J AM CHEM SOC, V136, P15829, DOI 10.1021/ja507405j; Wu F, 2020, SSRN ELECT, DOI [10.1101/2020.03.30.20047365, DOI 10.2139/SSRN.3566211, https://doi.org/10.1101/2020.03.30.20047365]; Xia S, 2020, CELL RES, V30, P343, DOI 10.1038/s41422-020-0305-x; Xu C, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe5575; Yan RH, 2020, SCIENCE, V367, P1444, DOI 10.1126/science.abb2762; Yarmarkovich M, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100036; Zhang ZY, 2018, ADV PHYS-X, V3, DOI 10.1080/23746149.2018.1428915; Zhou TQ, 2020, CELL HOST MICROBE, V28, P867, DOI 10.1016/j.chom.2020.11.004	83	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								859905	10.3389/fimmu.2022.859905	http://dx.doi.org/10.3389/fimmu.2022.859905			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2E5FD	35693819	gold, Green Published			2022-12-18	WOS:000812252100001
J	Qu, H; Zong, QF; Wang, HF; Wu, SL; Cai, DM; Bao, WB				Qu, Huan; Zong, Qiufang; Wang, Haifei; Wu, Shenglong; Cai, Demin; Bao, Wenbin			C/EBPa Epigenetically Modulates TFF1 Expression via mC-6 Methylation in the Jejunum Inflammation Induced by a Porcine Coronavirus	FRONTIERS IN IMMUNOLOGY			English	Article						TFF1; DNA methylation; C/EBP alpha; porcine epidemic diarrhea virus; intestinal epithelial barrier; coronavirus	EPIDEMIC DIARRHEA VIRUS; TREFOIL FACTOR; GENE; ACTIVATION; INFECTION; PEPTIDES; MUCOSA; TUMORIGENESIS; PATHOGENESIS; EPITHELIUM	Porcine epidemic diarrhea virus (PEDV) is an emerging coronavirus which causes acute diarrhea and destroys gastrointestinal barrier function in neonatal pigs. Trefoil factor 1 (TFF1) is a protective peptide for maintaining the integrity of gastrointestinal mucosa and reducing intestinal inflammation. However, its role in protecting intestinal epithelium against PEDV infection is still unclear. In this study, we discovered that TFF1 expression was activated in the jejunum of pigs with PEDV infection and TFF1 is required for the growth of porcine intestinal epithelial cells. For instance, inhibited cell proliferation and cell arrest were observed when TFF1 is genetically knocked-out using CRISPR-Cas9. Additionally, TFF1 depletion increased viral copy number and PEDV titer, along with the elevated genes involved in antiviral and inflammatory cytokines. The decreased TFF1 mRNA expression is in line with hypermethylation on the gene promoter. Notably, the strong interactions of protein-DNA complexes containing CCAAT motif significantly increased C/EBP alpha accessibility, whereas hypermethylation of mC-6 loci decreased C/EBP alpha binding occupancies in TFF1 promoter. Overall, our findings show that PEDV triggers the C/EBP alpha-mediated epigenetic regulation of TFF1 in intestine epithelium and facilitates host resistance to PEDV and other Coronavirus infections.	[Qu, Huan; Zong, Qiufang; Wang, Haifei; Wu, Shenglong; Cai, Demin; Bao, Wenbin] Yangzhou Univ, Coll Anim Sci & Technol, Yangzhou, Peoples R China; [Wang, Haifei; Wu, Shenglong; Cai, Demin; Bao, Wenbin] Yangzhou Univ, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou, Peoples R China	Yangzhou University; Yangzhou University	Cai, DM; Bao, WB (corresponding author), Yangzhou Univ, Coll Anim Sci & Technol, Yangzhou, Peoples R China.; Cai, DM; Bao, WB (corresponding author), Yangzhou Univ, Joint Int Res Lab Agr & Agriprod Safety, Yangzhou, Peoples R China.	demincai@yzu.edu.cn; wbbao@yzu.edu.cn			National Natural Science Foundation of China [31972535]; Jiangsu Agricultural Science And Technology Innovation Fund [CX(21)2014]; Science and Technology Support Program of Jiangsu Province [BE2019344]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Agricultural Science And Technology Innovation Fund; Science and Technology Support Program of Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions	Funding This study was supported by the National Natural Science Foundation of China (No. 31972535), the Jiangsu Agricultural Science And Technology Innovation Fund [CX(21)2014], the Science and Technology Support Program of Jiangsu Province (BE2019344) and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596; Bhargavan B, 2016, CELL SIGNAL, V28, P7, DOI 10.1016/j.cellsig.2015.11.005; Bossenmeyer-Pourie C, 2002, J CELL BIOL, V157, P761, DOI 10.1083/jcb200108056; Caluwaerts S, 2010, ORAL ONCOL, V46, P564, DOI 10.1016/j.oraloncology.2010.04.008; Carvalho R, 2002, LAB INVEST, V82, P1319, DOI 10.1097/01.LAB.0000029205.76632.A8; Chatagnon A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009665; Feng GX, 2014, MOL MED REP, V9, P109, DOI 10.3892/mmr.2013.1772; Friedman AD, 2015, INT J HEMATOL, V101, P330, DOI 10.1007/s12185-015-1764-6; Gonzaga IM, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0429-0; Greenberg MVC, 2019, NAT REV MOL CELL BIO, V20, P590, DOI 10.1038/s41580-019-0159-6; Hirata Y, 2007, J IMMUNOL, V179, P5425, DOI 10.4049/jimmunol.179.8.5425; HOFFMANN W, 1993, TRENDS BIOCHEM SCI, V18, P239, DOI 10.1016/0968-0004(93)90170-R; Huynh E, 2015, APPL MICROBIOL BIOT, V99, P4667, DOI 10.1007/s00253-015-6542-0; Jung K, 2015, VET J, V204, P134, DOI 10.1016/j.tvjl.2015.02.017; Jung K, 2015, VET MICROBIOL, V178, P31, DOI 10.1016/j.vetmic.2015.04.022; Lalani EN, 1999, LAB INVEST, V79, P537; Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259; Li HY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-019-0089-y; Li Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06056-w; Liu C, 2016, J BIOL CHEM, V291, P24779, DOI 10.1074/jbc.M116.740746; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Longman RJ, 2000, GUT, V47, P792, DOI 10.1136/gut.47.6.792; Lugrin J, 2014, BIOL CHEM, V395, P203, DOI 10.1515/hsz-2013-0241; Miyabe FM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78797-y; MOON HW, 1972, VET PATHOL, V9, P3, DOI 10.1177/030098587200900102; MOON HW, 1971, P SOC EXP BIOL MED, V137, P151, DOI 10.3181/00379727-137-35533; Movassagh M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008564; Pabst T, 2009, CLIN CANCER RES, V15, P5303, DOI 10.1158/1078-0432.CCR-08-2941; Park WS, 2000, GASTROENTEROLOGY, V119, P691, DOI 10.1053/gast.2000.16483; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Qi XY, 2020, REV BRAS ZOOTECN, V49, DOI 10.37496/rbz4920200064; Regalo G, 2010, LAB INVEST, V90, P1132, DOI 10.1038/labinvest.2010.79; Ren JL, 2005, WORLD J GASTROENTERO, V11, P2674, DOI 10.3748/wjg.v11.i17.2674; Ribieras S, 1998, BBA-REV CANCER, V1378, pF61, DOI 10.1016/S0304-419X(98)00016-X; RIO MC, 1988, CR ACAD SCI III-VIE, V307, P825; Romano E, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072018; Ruchaud-Sparagano MH, 2004, CELL MOL LIFE SCI, V61, P1946, DOI 10.1007/s00018-004-4124-x; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Sheikh IA, 2013, J BIOL CHEM, V288, P20404, DOI 10.1074/jbc.M113.467860; Shibata I, 2000, VET MICROBIOL, V72, P173, DOI 10.1016/S0378-1135(99)00199-6; Song D, 2015, CLIN EXP VACCINE RES, V4, P166, DOI 10.7774/cevr.2015.4.2.166; Song D, 2012, VIRUS GENES, V44, P167, DOI 10.1007/s11262-012-0713-1; Soutto M, 2015, GUT, V64, P1028, DOI 10.1136/gutjnl-2014-307191; Soutto M, 2014, ONCOTARGET, V5, P5663, DOI 10.18632/oncotarget.2156; Suzuki T, 2016, J GEN VIROL, V97, P1823, DOI 10.1099/jgv.0.000513; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Thim L, 1997, CELL MOL LIFE SCI, V53, P888, DOI 10.1007/s000180050108; Thomas JT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139266; Tizard IR, 2020, VACCINE, V38, P5123, DOI 10.1016/j.vaccine.2020.06.026; Vandenbroucke K, 2004, GASTROENTEROLOGY, V127, P502, DOI 10.1053/j.gastro.2004.05.020; Wang HF, 2019, ANIMALS-BASEL, V9, DOI 10.3390/ani9080523; Wang SQ, 2021, GENE, V775, DOI 10.1016/j.gene.2021.145448; Wang SQ, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00075; Zhang HW, 2018, MICROB PATHOGENESIS, V117, P247, DOI 10.1016/j.micpath.2018.02.004	54	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								881289	10.3389/fimmu.2022.881289	http://dx.doi.org/10.3389/fimmu.2022.881289			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X9YR	35693767	Green Published, gold			2022-12-18	WOS:000807804500001
J	Ricano-Ponce, I; Peeters, T; Matzaraki, V; Houben, B; Achten, R; Cools, P; Netea, MG; Gyssens, IC; Kumar, V				Ricano-Ponce, Isis; Peeters, Toon; Matzaraki, Vasiliki; Houben, Bert; Achten, Ruth; Cools, Peter; Netea, Mihai G.; Gyssens, Inge C.; Kumar, Vinod			Impact of Human Genetic Variation on C-Reactive Protein Concentrations and Acute Appendicitis	FRONTIERS IN IMMUNOLOGY			English	Article						C-reactive protein (CRP); appendicitis; functional genetics; biomarker; quantitative trait	GENOME-WIDE ASSOCIATION; GENOTYPE; DISEASE; BURDEN; LIVER	BackgroundAcute appendicitis is one of the most common abdominal emergencies worldwide. Both environmental and genetic factors contribute to the disease. C-reactive protein (CRP) is an important biomarker in the diagnosis of acute appendicitis. CRP concentrations are significantly affected by genetic variation. However, whether such genetic variation is causally related to appendicitis risk remains unclear. In this study, the causal relationship between single-nucleotide polymorphisms (SNPs) associated with circulating CRP concentrations and the risk and severity of acute appendicitis was investigated. MethodsCRP concentrations in serum of appendicitis patients (n = 325) were measured. Appendicitis was categorized as complicated/uncomplicated and gangrenous/non-gangrenous. Imputed SNP data (n = 287) were generated. A genome-wide association study (GWAS) on CRP concentrations and appendicitis severity was performed. Intersection and colocalization of the GWAS results were performed with appendicitis and CRP-associated loci from the Pan-UKBB cohort. A functional-genomics approach to prioritize genes was employed. ResultsThirteen percent of significant CRP quantitative trait loci (QTLs) that were previously identified in a large cohort of healthy individuals were replicated in our small patient cohort. Significant enrichment of CRP-QTLs in association with appendicitis was observed. Among these shared loci, the two top loci at chromosomes 1q41 and 8p23.1 were characterized. The top SNP at chromosome 1q41 is located within the promoter of H2.0 Like Homeobox (HLX) gene, which is involved in blood cell differentiation, and liver and gut organogeneses. The expression of HLX is increased in the appendix of appendicitis patients compared to controls. The locus at 8p23.1 contains multiple genes, including cathepsin B (CTSB), which is overexpressed in appendix tissue from appendicitis patients. The risk allele of the top SNP in this locus also increases CTSB expression in the sigmoid colon of healthy individuals. CTSB is involved in collagen degradation, MHC class II antigen presentation, and neutrophil degranulation. ConclusionsThe results of this study prioritize HLX and CTSB as potential causal genes for appendicitis and suggest a shared genetic mechanism between appendicitis and CRP concentrations.	[Ricano-Ponce, Isis; Peeters, Toon; Matzaraki, Vasiliki; Netea, Mihai G.; Gyssens, Inge C.; Kumar, Vinod] Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands; [Peeters, Toon; Gyssens, Inge C.] Jessa Hosp, Dept Infect Dis & Immun, Hasselt, Belgium; [Peeters, Toon; Gyssens, Inge C.] Hasselt Univ, Fac Med & Life Sci, Hasselt, Belgium; [Houben, Bert; Achten, Ruth] Jessa Hosp, Dept Gen & Abdominal Surg, Hasselt, Belgium; [Cools, Peter] GZA Hosp, Dept Abdominal Surg, Antwerp, Belgium; [Netea, Mihai G.] Craiova Univ Med & Pharm, Human Genom Lab, Craiova, Romania; [Kumar, Vinod] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Kumar, Vinod] Nitte, Nitte Univ Ctr Sci Educ & Res, Mangalore, India; [Ricano-Ponce, Isis; Peeters, Toon; Matzaraki, Vasiliki; Netea, Mihai G.; Gyssens, Inge C.; Kumar, Vinod] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Med Ctr, Nijmegen, Netherlands	Radboud University Nijmegen; Hasselt University; University of Medicine & Pharmacy of Craiova; University of Groningen; NITTE (Deemed to be University); Nitte University Center for Science Education & Research (NUCSER); Radboud University Nijmegen	Kumar, V (corresponding author), Radboud Univ Nijmegen, Dept Internal Med, Med Ctr, Nijmegen, Netherlands.; Kumar, V (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands.; Kumar, V (corresponding author), Nitte, Nitte Univ Ctr Sci Educ & Res, Mangalore, India.; Kumar, V (corresponding author), Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Med Ctr, Nijmegen, Netherlands.	V.Kumar@radboudumc.nl	Matzaraki, Vasiliki/GZB-0509-2022; Gyssens, Inge/ABB-9031-2021; Kumar, Vinod/ABC-4866-2020	Matzaraki, Vasiliki/0000-0002-5852-6801; Gyssens, Inge/0000-0002-9226-0752; Kumar, Vinod/0000-0002-2775-6049; Ricano-Ponce, Isis/0000-0002-7530-9526				Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Ali F, 2007, GUT, V56, P1, DOI 10.1136/gut.2006.117598; Azodi OS, 2009, BRIT J SURG, V96, P1336, DOI 10.1002/bjs.6736; BASTA M, 1990, AM J HUM GENET, V46, P377; Chang CC, 2015, GIGASCIENCE, V4, DOI 10.1186/s13742-015-0047-8; Deelen Patrick, 2014, BMC Res Notes, V7, P901, DOI 10.1186/1756-0500-7-901; FinnGen, 2021, FINNGEN DOC R5 REL; Han XK, 2020, EUR J EPIDEMIOL, V35, P139, DOI 10.1007/s10654-019-00598-z; Hentsch B, 1996, GENE DEV, V10, P70, DOI 10.1101/gad.10.1.70; Hrdlickova B, 2018, EUR J GASTROEN HEPAT, V30, P828, DOI 10.1097/MEG.0000000000001168; Kotlyar M, 2019, NUCLEIC ACIDS RES, V47, pD581, DOI 10.1093/nar/gky1037; Kristjansson RP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03353-0; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Lee JC, 2017, NAT GENET, V49, P262, DOI 10.1038/ng.3755; Lee JH, 2010, J EPIDEMIOL, V20, P97, DOI 10.2188/jea.JE20090011; Li DF, 2019, NUCLEIC ACIDS RES, V47, pW158, DOI 10.1093/nar/gkz348; Li HM, 2018, J PEDIATR-US, V203, P330, DOI 10.1016/j.jpeds.2018.07.071; Ligthart S, 2018, AM J HUM GENET, V103, P691, DOI 10.1016/j.ajhg.2018.09.009; Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088; McCarthy S, 2016, NAT GENET, V48, P1279, DOI 10.1038/ng.3643; MIKAELSSON C, 1984, ANN CHIR GYNAECOL FE, V73, P281; Murphy CG, 2008, MUCOSAL IMMUNOL, V1, P297, DOI 10.1038/mi.2008.13; Oldmeadow C, 2009, TWIN RES HUM GENET, V12, P150, DOI 10.1375/twin.12.2.150; Orlova E, 2019, HUM GENET, V138, P37, DOI 10.1007/s00439-018-1956-2; Peeters T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73798-3; Peeters T, 2019, FUTURE MICROBIOL, V14, P111, DOI 10.2217/fmb-2018-0203; Rivera-Chavez FA, 2004, ANN SURG, V240, P269, DOI 10.1097/01.sla.0000133184.10676.26; Sarsu SB, 2015, ITAL J PEDIATR, V41, DOI 10.1186/s13052-015-0206-7; Shah TS, 2012, BIOINFORMATICS, V28, P1598, DOI 10.1093/bioinformatics/bts180; Shommu NS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193563; Stewart B, 2014, BRIT J SURG, V101, pE9, DOI 10.1002/bjs.9329; Sun BB, 2018, NATURE, V558, P73, DOI 10.1038/s41586-018-0175-2; Team P-U, 2020, PAN UK BIOBANK; Yang J, 2019, EMERG MED INT, V2019, DOI 10.1155/2019/4608053; Yazdanyar S, 2010, J INTERN MED, V267, P228, DOI 10.1111/j.1365-2796.2009.02137.x; Zheng XJ, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00307	36	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								862742	10.3389/fimmu.2022.862742	http://dx.doi.org/10.3389/fimmu.2022.862742			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y9IX	35693796	Green Published, gold			2022-12-18	WOS:000808451400001
J	Schmitt, T; Pircher, J; Steinert, L; Meier, K; Ghoreschi, K; Vielmuth, F; Kugelmann, D; Waschke, J				Schmitt, Thomas; Pircher, Julia; Steinert, Letyfee; Meier, Katharina; Ghoreschi, Kamran; Vielmuth, Franziska; Kugelmann, Daniela; Waschke, Jens			Dsg1 and Dsg3 Composition of Desmosomes Across Human Epidermis and Alterations in Pemphigus Vulgaris Patient Skin	FRONTIERS IN IMMUNOLOGY			English	Article						pemphigus; dermatology; desmoglein; desmosome; adhesion; epidermis; skin; autoimmune disease (AD)	KERATINOCYTE COHESION; DYNAMIC DESMOSOME; ADHESION; IMPAIRMENTS; INHIBITION	Desmosomes are important epidermal adhesion units and signalling hubs, which play an important role in pemphigus pathogenesis. Different expression patterns of the pemphigus autoantigens desmoglein (Dsg)1 and Dsg3 across different epidermal layers have been demonstrated. However, little is known about changes in desmosome composition in different epidermal layers or in patient skin. The aim of this study was thus to characterize desmosome composition in healthy and pemphigus skin using super-resolution microscopy. An increasing Dsg1/Dsg3 ratio from lower basal (BL) to uppermost granular layer (GL) was observed. Within BL desmosomes, Dsg1 and Dsg3 were more homogeneously distributed whereas superficial desmosomes mostly comprised one of the two molecules or domains containing either one but not both. Extradesmosomal, desmoplakin (Dp)-independent, co-localization of Dsg3 with plakoglobin (Pg) was found mostly in BL and extradesmosomal Dsg1 co-localization with Pg in all layers. In contrast, in the spinous layer (SL) most Dsg1 and Dsg3 staining was confined to desmosomes, as revealed by the co-localization with Dp. In pemphigus patient skin, Dsg1 and Dsg3 immunostaining was altered especially along blister edges. The number of desmosomes in patient skin was reduced significantly in basal and spinous layer keratinocytes with only few split desmosomes found. In addition, Dsg1-Pg co-localization at the apical BL and Dsg3-Pg co-localization in SL were significantly reduced in patients, suggesting that that extradesmosomal Dsg molecules were affected. These results support the hypothesis that pemphigus is a desmosome assembly disease and may help to explain histopathologic differences between pemphigus phenotypes.	[Schmitt, Thomas; Pircher, Julia; Steinert, Letyfee; Vielmuth, Franziska; Kugelmann, Daniela; Waschke, Jens] Ludwig Maximilian Univ Munchen LMU Munich, Fac Med, Chair Vegetat Anat, Inst Anat, Munich, Germany; [Meier, Katharina; Ghoreschi, Kamran] Charite Univ Med Berlin, Dept Dermatol Venereol & Allergol, Berlin, Germany; [Meier, Katharina; Ghoreschi, Kamran] Free Univ Berlin, Berlin, Germany; [Meier, Katharina; Ghoreschi, Kamran] Humboldt Univ, Berlin, Germany; [Meier, Katharina; Ghoreschi, Kamran] Berlin Inst Hlth, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health	Waschke, J (corresponding author), Ludwig Maximilian Univ Munchen LMU Munich, Fac Med, Chair Vegetat Anat, Inst Anat, Munich, Germany.	jens.waschke@med.uni-muenchen.de		Ghoreschi, Kamran/0000-0002-5526-7517	DG [FOR 2497]	DG	The study was supported by DG (FOR 2497) to JW, FV and KG.	Al-Amoudi A, 2011, P NATL ACAD SCI USA, V108, P6480, DOI 10.1073/pnas.1019469108; Amagai M, 1996, J INVEST DERMATOL, V106, P351, DOI 10.1111/1523-1747.ep12343081; Berika M, 2014, CELL COMMUN ADHES, V21, P65, DOI 10.3109/15419061.2013.876018; Broussard JA, 2021, CURR BIOL, V31, P3275, DOI 10.1016/j.cub.2021.05.021; Egu DT, 2020, BRIT J DERMATOL, V182, P987, DOI 10.1111/bjd.18237; Egu DT, 2017, BRIT J DERMATOL, V177, P1612, DOI 10.1111/bjd.15721; Egu DT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02883; Getsios S, 2004, NAT REV MOL CELL BIO, V5, P271, DOI 10.1038/nrm1356; Getsios S, 2009, J CELL BIOL, V185, P1243, DOI 10.1083/jcb.200809044; Godsel LM, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI144363; Green Kathleen J, 2019, F1000Res, V8, DOI 10.12688/f1000research.20942.1; Harmon RM, 2013, J CLIN INVEST, V123, P1556, DOI 10.1172/JCI65220; Hartlieb E, 2014, J BIOL CHEM, V289, P17043, DOI 10.1074/jbc.M113.489336; Ishida-Yamamoto A, 2015, CELL TISSUE RES, V360, P477, DOI 10.1007/s00441-014-2037-z; Johnson JL, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015297; Kasperkiewicz M, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.26; Kitajima Y, 2014, CELL COMMUN ADHES, V21, P269, DOI 10.3109/15419061.2014.943397; Kitajima Y, 2013, EUR J DERMATOL, V23, P43, DOI 10.1684/ejd.2013.1976; Kneisel A, 2011, J DTSCH DERMATOL GES, V9, P927, DOI [10.1111/j.1610-0387.2011.07749.x, 10.1111/j.1610-0387.2011.07809.x]; Kroger C, 2013, J CELL BIOL, V201, P681, DOI 10.1083/jcb.201208162; Kugelmann D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00626; Kugelmann D, 2019, J INVEST DERMATOL, V139, P1596, DOI 10.1016/j.jid.2019.01.002; LEVER WF, 1953, MEDICINE, V32, P1; North AJ, 1999, J CELL SCI, V112, P4325; Price AJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07523-0; Rotzer V, 2015, CELL MOL LIFE SCI, V72, P4885, DOI 10.1007/s00018-015-1977-0; Safia S., 2016, INT ARCH BIOMED CLIN, V2, P13, DOI [10.21276/iabcr.2016.2.3.3, DOI 10.21276/IABCR.2016.2.3.3]; Schlogl E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00858; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Schmitt T, 2021, BRIT J DERMATOL, V185, P595, DOI 10.1111/bjd.20091; Schmitt T, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.701809; Sikora M, 2020, P NATL ACAD SCI USA, V117, P27132, DOI 10.1073/pnas.2004563117; Sokol E, 2015, J INVEST DERMATOL, V135, P1763, DOI 10.1038/jid.2015.109; Spindler V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00136; Spindler V, 2018, J INVEST DERMATOL, V138, P32, DOI 10.1016/j.jid.2017.06.022; Spindler V, 2014, J INVEST DERMATOL, V134, P1655, DOI 10.1038/jid.2014.21; Stahley SN, 2016, J INVEST DERMATOL, V136, P59, DOI 10.1038/JID.2015.353; Udey MC, 1999, JAMA-J AM MED ASSOC, V282, P572, DOI 10.1001/jama.282.6.572; Vielmuth F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00485; Vielmuth F, 2018, J INVEST DERMATOL, V138, P121, DOI 10.1016/j.jid.2017.08.033; Walter E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01128; Walter E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03697-7; Waschke J, 2008, HISTOCHEM CELL BIOL, V130, P21, DOI 10.1007/s00418-008-0420-0; Waschke J, 2006, J CELL BIOL, V175, P721, DOI 10.1083/jcb.200605125; Waschke J, 2014, MED RES REV, V34, P1127, DOI 10.1002/med.21310	45	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								884241	10.3389/fimmu.2022.884241	http://dx.doi.org/10.3389/fimmu.2022.884241			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D0XY	35711465	Green Published, gold			2022-12-18	WOS:000811281400001
J	Son, M; Park, IS; Kim, S; Ma, HW; Kim, JH; Kim, TI; Kim, WH; Han, J; Kim, SW; Cheon, JH				Son, Mijeong; Park, I. Seul; Kim, Soochan; Ma, Hyun Woo; Kim, Ji Hyung; Kim, Tae Il; Kim, Won Ho; Han, Jaeyong; Kim, Seung Won; Cheon, Jae Hee			Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function	FRONTIERS IN IMMUNOLOGY			English	Article						Bacteroides vulgatus; inflammatory bowel disease; potassium-competitive acid blocker; proton pump inhibitor; gut barrier function	PROTON PUMP INHIBITOR; INFLAMMATORY BOWEL DISEASES; BACTEROIDES-VULGATUS; THERAPY; RISK; PATHOGENESIS; MICROBIOTA; BACTERIA; TAK-438; ECOLOGY	Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors in genetically susceptible individuals. Proton pump inhibitors (PPIs) such as rabeprazole are frequently employed for gastric acid inhibition. However, long-term PPI administration can alter the intestinal microbiome composition, possibly worsening IBD severity. The present study revealed that tegoprazan, a potassium-competitive acid blocker, significantly improved colitis in mice and enhanced the intestinal epithelial barrier function. Tegoprazan alleviated gut microbiota dysbiosis and enhanced the growth of Bacteroides vulgatus. In turn, B. vulgatus alleviated intestinal inflammation by inhibiting epithelial adhesion of pathogenic bacteria. Unlike rabeprazole, tegoprazan did not induce gut dysbiosis. Our findings provide novel insights into the potential role of tegoprazan as an intestinal protectant for IBD and as a therapeutic agent for gastric acid-related diseases.	[Son, Mijeong; Park, I. Seul; Kim, Soochan; Ma, Hyun Woo; Kim, Ji Hyung; Kim, Tae Il; Kim, Won Ho; Kim, Seung Won; Cheon, Jae Hee] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; [Han, Jaeyong] CHA Univ, Cha Ilsan Med Ctr, Dept Internal Med, Goyang, South Korea; [Kim, Seung Won; Cheon, Jae Hee] Yonsei Univ, Severance Biomed Sci Inst, Coll Med, Seoul, South Korea; [Son, Mijeong; Park, I. Seul; Kim, Soochan; Ma, Hyun Woo; Kim, Ji Hyung; Kim, Tae Il; Kim, Won Ho; Kim, Seung Won; Cheon, Jae Hee] Yonsei Univ, Inst Gastroenterol, Grad Sch Med Sci, Brain Korea Project 21,Coll Med, Seoul, South Korea	Yonsei University; Yonsei University Health System; Pochon Cha University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Kim, SW; Cheon, JH (corresponding author), Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea.; Han, J (corresponding author), CHA Univ, Cha Ilsan Med Ctr, Dept Internal Med, Goyang, South Korea.; Kim, SW; Cheon, JH (corresponding author), Yonsei Univ, Severance Biomed Sci Inst, Coll Med, Seoul, South Korea.; Kim, SW; Cheon, JH (corresponding author), Yonsei Univ, Inst Gastroenterol, Grad Sch Med Sci, Brain Korea Project 21,Coll Med, Seoul, South Korea.		; Cheon, Jae Hee/B-4523-2015	Kim, Tae Il/0000-0003-4807-890X; Kim, Ji Hyung/0000-0001-5381-3628; Han, Jaeyong/0000-0002-6359-9407; KIM, Jee Hung/0000-0002-9044-8540; Cheon, Jae Hee/0000-0002-2282-8904; Kim, Seung Won/0000-0002-1692-1192; Kim, Won Ho/0000-0002-5682-9972; Kim, Soochan/0000-0002-2577-2969				Andersson K, 2005, PHARMACOL THERAPEUT, V108, P294, DOI 10.1016/j.pharmthera.2005.05.005; Arikawa Y, 2012, J MED CHEM, V55, P4446, DOI 10.1021/jm300318t; Azad MA, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9478630; Bloom SM, 2011, CELL HOST MICROBE, V9, P390, DOI 10.1016/j.chom.2011.04.009; Carvalho FA, 2012, CELL HOST MICROBE, V12, P139, DOI 10.1016/j.chom.2012.07.004; Cong YZ, 2002, J IMMUNOL, V169, P6112, DOI 10.4049/jimmunol.169.11.6112; Crespo-Piazuelo D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30932-6; de Jager CPC, 2012, ALIMENT PHARM THER, V36, P941, DOI 10.1111/apt.12069; Deshpande A, 2012, CLIN GASTROENTEROL H, V10, P225, DOI 10.1016/j.cgh.2011.09.030; Dick LK, 2005, APPL ENVIRON MICROB, V71, P3184, DOI 10.1128/AEM.71.6.3184-3191.2005; Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Gordon JI, 2012, SCIENCE, V336, P1251, DOI 10.1126/science.1224686; Hillman ET, 2017, MICROBES ENVIRON, V32, P300, DOI 10.1264/jsme2.ME17017; Hoentjen F, 2007, INFLAMM BOWEL DIS, V13, P317, DOI 10.1002/ibd.20040; Horvath A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59550-x; Human Microbiome Project Consortium, 2012, Nature, V486, P207, DOI 10.1038/nature11234; Imhann F, 2016, GUT, V65, P740, DOI 10.1136/gutjnl-2015-310376; Inatomi N, 2016, PHARMACOL THERAPEUT, V168, P12, DOI 10.1016/j.pharmthera.2016.08.001; Jandhyala SM, 2015, WORLD J GASTROENTERO, V21, P8787, DOI 10.3748/wjg.v21.i29.8787; JEPSON MA, 1995, INFECT IMMUN, V63, P356, DOI 10.1128/IAI.63.1.356-359.1995; Kim DK, 2019, J PHARMACOL EXP THER, V369, P318, DOI 10.1124/jpet.118.254904; King SJ, 2019, INTEST RES, V17, P177, DOI 10.5217/ir.2018.00170; Lee M, 2021, GASTROENTEROLOGY, V160, P524, DOI 10.1053/j.gastro.2020.09.056; Maharshak N, 2013, GUT MICROBES, V4, P316, DOI 10.4161/gmic.25486; Malfertheiner P, 2017, NAT REV GASTRO HEPAT, V14, P697, DOI 10.1038/nrgastro.2017.117; Martinsen TC, 2005, BASIC CLIN PHARMACOL, V96, P94, DOI 10.1111/j.1742-7843.2005.pto960202.x; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mizoguchi E, 2020, INTEST RES, V18, P151, DOI 10.5217/ir.2019.09154; Morampudi V, 2014, JOVE-J VIS EXP, DOI 10.3791/51297; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Ofek I, 2003, FEMS IMMUNOL MED MIC, V38, P181, DOI 10.1016/S0928-8244(03)00228-1; ONDERDONK AB, 1983, INFECT IMMUN, V42, P783, DOI 10.1128/IAI.42.2.783-788.1983; Pastorelli L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00280; Randhawa PK, 2014, KOREAN J PHYSIOL PHA, V18, P279, DOI 10.4196/kjpp.2014.18.4.279; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rhee KJ, 2004, J IMMUNOL, V172, P1118, DOI 10.4049/jimmunol.172.2.1118; Ribet D, 2015, MICROBES INFECT, V17, P173, DOI 10.1016/j.micinf.2015.01.004; Rigottier-Gois L, 2013, ISME J, V7, P1256, DOI 10.1038/ismej.2013.80; Saier MH, 2007, WATER AIR SOIL POLL, V181, P1, DOI 10.1007/s11270-007-9372-6; Sambuy Y, 2005, CELL BIOL TOXICOL, V21, P1, DOI 10.1007/s10565-005-0085-6; Scott DR, 2015, ALIMENT PHARM THER, V42, P1315, DOI 10.1111/apt.13414; Shah R, 2017, DIGESTION, V95, P188, DOI 10.1159/000455008; Takashima S, 2020, NEUROGASTROENT MOTIL, V32, DOI 10.1111/nmo.13841; Troy EB, 2010, FRONT BIOSCI-LANDMRK, V15, P25, DOI 10.2741/3603; Waidmann M, 2003, GASTROENTEROLOGY, V125, P162, DOI 10.1016/S0016-5085(03)00672-3; Walujkar SA, 2014, GUT PATHOG, V6, DOI 10.1186/1757-4749-6-22; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Xia B, 2021, GASTROENTEROLOGY, V161, P1842, DOI 10.1053/j.gastro.2021.08.005; Yang I, 2013, FEMS MICROBIOL REV, V37, P736, DOI 10.1111/1574-6976.12027; Yang YX, 2006, JAMA-J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947; Yoshida N, 2018, CIRCULATION, V138, P2486, DOI 10.1161/CIRCULATIONAHA.118.033714; You JS, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0746-y; Zhang Z, 2006, INFLAMM BOWEL DIS, V12, P382, DOI 10.1097/01.MIB.0000218764.06959.91	54	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								870817	10.3389/fimmu.2022.870817	http://dx.doi.org/10.3389/fimmu.2022.870817			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y0TJ	35693794	gold, Green Published			2022-12-18	WOS:000807858500001
J	Wang, CL; Daley, SR				Wang, Chenglong; Daley, Stephen R.			How Thymocyte Deletion in the Cortex May Curtail Antigen-Specific T-Regulatory Cell Development in the Medulla	FRONTIERS IN IMMUNOLOGY			English	Article						thymus; T-cell selection; T-cell tolerance; T-cell deletion; T-regulatory cells; self-antigen recognition; autoimmune disease	THYMIC EPITHELIAL-CELLS; PROMISCUOUS GENE-EXPRESSION; SELF-ANTIGEN; NEGATIVE SELECTION; CD4(+) THYMOCYTES; CLONAL DELETION; DENDRITIC CELLS; TOLERANCE; AIRE; PEPTIDE	CD4(+) T cell responses to self-antigens are pivotal for immunological self-tolerance. Activation of Foxp3(-) T-conventional (T-conv) cells can precipitate autoimmune disease, whereas activation of Foxp3(+) T-regulatory (T-reg) cells is essential to prevent autoimmune disease. This distinction indicates the importance of the thymus in controlling the differentiation of self-reactive CD4(+) T cells. Thymocytes and thymic antigen-presenting cells (APC) depend on each other for normal maturation and differentiation. In this Hypothesis and Theory article, we propose this mutual dependence dictates which self-antigens induce T-reg cell development in the thymic medulla. We postulate self-reactive CD4(+) CD8(-) thymocytes deliver signals that stabilize and amplify the presentation of their cognate self-antigen by APC in the thymic medulla, thereby seeding a niche for the development of T-reg cells specific for the same self-antigen. By limiting the number of antigen-specific CD4(+) thymocytes in the medulla, thymocyte deletion in the cortex may impede the formation of medullary T-reg niches containing certain self-antigens. Susceptibility to autoimmune disease may arise from cortical deletion creating a "hole" in the self-antigen repertoire recognized by T-reg cells.	[Wang, Chenglong; Daley, Stephen R.] Queensland Univ Technol, Fac Hlth, Ctr Immunol & Infect Control, Sch Biomed Sci, Brisbane, Qld, Australia	Queensland University of Technology (QUT)	Daley, SR (corresponding author), Queensland Univ Technol, Fac Hlth, Ctr Immunol & Infect Control, Sch Biomed Sci, Brisbane, Qld, Australia.				Queensland University of Technology; National Health and Medical Research Council [1188589]	Queensland University of Technology; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	Funding CW and SD received support from the Queensland University of Technology. SD received support from the National Health and Medical Research Council (grant 1188589).	Akiyama T, 2008, IMMUNITY, V29, P423, DOI 10.1016/j.immuni.2008.06.015; Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; Baran-Gale J, 2020, ELIFE, V9, DOI 10.7554/eLife.56221; Bautista JL, 2009, NAT IMMUNOL, V10, P610, DOI 10.1038/ni.1739; Boehm T, 2003, J EXP MED, V198, P757, DOI 10.1084/jem.20030794; Brennecke P, 2015, NAT IMMUNOL, V16, P933, DOI 10.1038/ni.3246; Burchill MA, 2008, IMMUNITY, V28, P112, DOI 10.1016/j.immuni.2007.11.022; Chu HH, 2010, J IMMUNOL, V185, P4705, DOI 10.4049/jimmunol.1002276; Cowan JE, 2016, CELL REP, V14, P1041, DOI 10.1016/j.celrep.2016.01.003; Cowan JE, 2014, J IMMUNOL, V193, P1204, DOI 10.4049/jimmunol.1400993; Daley SR, 2017, IMMUNOL REV, V277, P9, DOI 10.1111/imr.12532; Daley SR, 2013, J EXP MED, V210, P269, DOI 10.1084/jem.20121458; Dendrou CA, 2018, NAT REV IMMUNOL, V18, P325, DOI 10.1038/nri.2017.143; Derbinski J, 2005, J EXP MED, V202, P33, DOI 10.1084/jem.20050471; Derbinski J, 2001, NAT IMMUNOL, V2, P1032, DOI 10.1038/ni723; Dhalla F, 2020, EMBO J, V39, DOI 10.15252/embj.2019101828; Douek DC, 1996, INT IMMUNOL, V8, P1413, DOI 10.1093/intimm/8.9.1413; Ebert PJR, 2008, IMMUNITY, V29, P734, DOI 10.1016/j.immuni.2008.09.014; Ehrlich LIR, 2009, IMMUNITY, V31, P986, DOI 10.1016/j.immuni.2009.09.020; Fazilleau N, 2006, EUR J IMMUNOL, V36, P533, DOI 10.1002/eji.200535021; Ferrante A, 2013, IMMUNOL RES, V56, P85, DOI 10.1007/s12026-012-8342-2; Fontenot JD, 2005, J EXP MED, V202, P901, DOI 10.1084/jem.20050784; Fulford TS, 2021, EUR J IMMUNOL, V51, P2006, DOI 10.1002/eji.202048900; Guerau-De-Arellano M, 2009, J EXP MED, V206, P1245, DOI 10.1084/jem.20090300; Halkias J, 2013, J CLIN INVEST, V123, P2131, DOI 10.1172/JCI67175; Hassler T, 2019, P NATL ACAD SCI USA, V116, P18537, DOI 10.1073/pnas.1907615116; Hemmers S, 2019, J EXP MED, V216, P2466, DOI 10.1084/jem.20190993; Hu DY, 2017, CELL DEATH DIFFER, V24, P1007, DOI 10.1038/cdd.2017.38; Hu DY, 2016, IMMUNOL CELL BIOL, V94, P357, DOI 10.1038/icb.2015.95; Hu ZC, 2015, J EXP MED, V212, P1947, DOI 10.1084/jem.20150178; Invernizzi P, 2009, J AUTOIMMUN, V33, P290, DOI 10.1016/j.jaut.2009.07.008; Irla M, 2008, IMMUNITY, V29, P451, DOI 10.1016/j.immuni.2008.08.007; Irla M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052591; Kalekar LA, 2016, NAT IMMUNOL, V17, P304, DOI 10.1038/ni.3331; Kieback E, 2016, IMMUNITY, V44, P1114, DOI 10.1016/j.immuni.2016.04.018; Klein L, 2019, NAT REV IMMUNOL, V19, P7, DOI 10.1038/s41577-018-0083-6; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Koble C, 2009, J EXP MED, V206, P1505, DOI 10.1084/jem.20082449; Kurd NS, 2021, MUCOSAL IMMUNOL, V14, P68, DOI 10.1038/s41385-020-0295-5; Ladi E, 2008, J IMMUNOL, V181, P7014, DOI 10.4049/jimmunol.181.10.7014; Lee HM, 2009, J IMMUNOL, V183, P2261, DOI 10.4049/jimmunol.0901304; Lee HM, 2012, IMMUNITY, V37, P475, DOI 10.1016/j.immuni.2012.07.009; Legoux FP, 2015, IMMUNITY, V43, P896, DOI 10.1016/j.immuni.2015.10.011; Lenz TL, 2015, NAT GENET, V47, P1085, DOI 10.1038/ng.3379; Leonard JD, 2017, IMMUNITY, V47, P107, DOI 10.1016/j.immuni.2017.06.015; Leung MWL, 2009, J EXP MED, V206, P2121, DOI 10.1084/jem.20091033; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Liblau RS, 1996, P NATL ACAD SCI USA, V93, P3031, DOI 10.1073/pnas.93.7.3031; Lio CWJQ, 2008, IMMUNITY, V28, P100, DOI 10.1016/j.immuni.2007.11.021; Liston A, 2008, P NATL ACAD SCI USA, V105, P11903, DOI 10.1073/pnas.0801506105; Lkhagvasuren E, 2013, J IMMUNOL, V190, P5110, DOI 10.4049/jimmunol.1203203; Lopes N, 2022, ELIFE, V11, DOI [10.7554/eLife.69982, 10.7554/eLife.69982.sa0, 10.7554/eLife.69982.sa1, 10.7554/eLife.69982.sa2]; Lucca LE, 2016, EUR J IMMUNOL, V46, P2247, DOI 10.1002/eji.201646416; Malhotra D, 2016, NAT IMMUNOL, V17, P187, DOI 10.1038/ni.3327; McCarthy NI, 2015, J IMMUNOL, V195, P2675, DOI 10.4049/jimmunol.1501226; McCaughtry TM, 2008, J EXP MED, V205, P2575, DOI 10.1084/jem.20080866; McCaughtry TM, 2007, J EXP MED, V204, P2513, DOI 10.1084/jem.20070601; McDonald BD, 2015, IMMUNITY, V43, P859, DOI 10.1016/j.immuni.2015.09.009; Melichar HJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004400; Meredith M, 2015, NAT IMMUNOL, V16, P942, DOI 10.1038/ni.3247; Metzger TC, 2013, CELL REP, V5, P166, DOI 10.1016/j.celrep.2013.08.038; Millet V, 2008, EUR J IMMUNOL, V38, P1257, DOI 10.1002/eji.200737982; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Nelson RW, 2015, IMMUNITY, V42, P95, DOI 10.1016/j.immuni.2014.12.022; Oh J, 2018, J IMMUNOL, V200, P1399, DOI 10.4049/jimmunol.1700768; Ooi JD, 2017, NATURE, V545, P243, DOI 10.1038/nature22329; Ooi JD, 2013, J AM SOC NEPHROL, V24, P419, DOI 10.1681/ASN.2012070705; Owen DL, 2019, NAT IMMUNOL, V20, P195, DOI 10.1038/s41590-018-0289-6; Owen DL, 2018, J IMMUNOL, V200, P3926, DOI 10.4049/jimmunol.1800097; PENIT C, 1986, J IMMUNOL, V137, P2115; Perry JSA, 2014, IMMUNITY, V41, P414, DOI 10.1016/j.immuni.2014.08.007; Peterson DA, 1999, J IMMUNOL, V162, P3117; Phelps RG, 1999, KIDNEY INT, V56, P1638, DOI 10.1046/j.1523-1755.1999.00720.x; Picca CC, 2011, P NATL ACAD SCI USA, V108, P14890, DOI 10.1073/pnas.1103810108; Pinto S, 2013, P NATL ACAD SCI USA, V110, pE3497, DOI 10.1073/pnas.1308311110; Randall KL, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1236; RAVIOLA E, 1972, J EXP MED, V136, P466, DOI 10.1084/jem.136.3.466; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Sansom SN, 2014, GENOME RES, V24, P1918, DOI 10.1101/gr.171645.113; Savage PA, 2020, ANNU REV IMMUNOL, V38, P421, DOI 10.1146/annurev-immunol-100219-020937; Sinclair C, 2013, P NATL ACAD SCI USA, V110, pE2905, DOI 10.1073/pnas.1304859110; Stadinski BD, 2019, NAT IMMUNOL, V20, P1046, DOI 10.1038/s41590-019-0414-1; Stadinski BD, 2011, IMMUNITY, V35, P694, DOI 10.1016/j.immuni.2011.10.012; Stritesky GL, 2013, P NATL ACAD SCI USA, V110, P4679, DOI 10.1073/pnas.1217532110; Tai X, 2013, IMMUNITY, V38, P1116, DOI 10.1016/j.immuni.2013.02.022; Takaba H, 2015, CELL, V163, P975, DOI 10.1016/j.cell.2015.10.013; Thiault N, 2015, NAT IMMUNOL, V16, P628, DOI 10.1038/ni.3150; Tykocinski LO, 2010, P NATL ACAD SCI USA, V107, P19426, DOI 10.1073/pnas.1009265107; Ueno T, 2004, J EXP MED, V200, P493, DOI 10.1084/jem.20040643; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; Watanabe M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20070-x; Weist BM, 2015, NAT IMMUNOL, V16, P635, DOI 10.1038/ni.3171; Wells KL, 2020, ELIFE, V9, DOI 10.7554/eLife.60188; White AJ, 2014, J IMMUNOL, V192, P2659, DOI 10.4049/jimmunol.1303057; Wirasinha RC, 2021, J EXP MED, V218, DOI 10.1084/jem.20200476; Wirasinha RC, 2019, CELL DEATH DIFFER, V26, P2727, DOI 10.1038/s41418-019-0331-8; Wong DC, 2001, KIDNEY INT, V60, P1777, DOI 10.1046/j.1523-1755.2001.00014.x; Yang SY, 2015, SCIENCE, V348, P589, DOI 10.1126/science.aaa7017; Yap JY, 2018, IMMUNOLOGY, V154, P522, DOI 10.1111/imm.12904; Zammit NW, 2019, NAT IMMUNOL, V20, P1299, DOI 10.1038/s41590-019-0492-0	100	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								892498	10.3389/fimmu.2022.892498	http://dx.doi.org/10.3389/fimmu.2022.892498			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y0CG	35693793	gold, Green Published			2022-12-18	WOS:000807813900001
J	Weiss, E; Ramos, GC; Delgobo, M				Weiss, Emil; Ramos, Gustavo Campos; Delgobo, Murilo			Myocardial-Treg Crosstalk: How to Tame a Wolf	FRONTIERS IN IMMUNOLOGY			English	Review						Tregs (regulatory T cells); Foxp3; myocardial infarction; heart; fibrosis; T-cells	REGULATORY T-CELLS; HEART-FAILURE; INFARCTION; TOLERANCE; MICE; ACCUMULATION; REGENERATION; COOPERATION; ACTIVATION; PHENOTYPE	The immune system plays a vital role in maintaining tissue integrity and organismal homeostasis. The sudden stress caused by myocardial infarction (MI) poses a significant challenge for the immune system: it must quickly substitute dead myocardial with fibrotic tissue while controlling overt inflammatory responses. In this review, we will discuss the central role of myocardial regulatory T-cells (Tregs) in orchestrating tissue repair processes and controlling local inflammation in the context of MI. We herein compile recent advances enabled by the use of transgenic mouse models with defined cardiac antigen specificity, explore whole-heart imaging techniques, outline clinical studies and summarize deep-phenotyping conducted by independent labs using single-cell transcriptomics and T-cell repertoire analysis. Furthermore, we point to multiple mechanisms and cell types targeted by Tregs in the infarcted heart, ranging from pro-fibrotic responses in mesenchymal cells to local immune modulation in myeloid and lymphoid lineages. We also discuss how both cardiac-specific and polyclonal Tregs participate in MI repair. In addition, we consider intriguing novel evidence on how the myocardial milieu takes control of potentially auto-aggressive local immune reactions by shaping myosin-specific T-cell development towards a regulatory phenotype. Finally, we examine the potential use of Treg manipulating drugs in the clinic after MI.	[Weiss, Emil; Ramos, Gustavo Campos; Delgobo, Murilo] Univ Hosp Wurzburg, Dept Internal Medicine1, Wurzburg, Germany; [Weiss, Emil; Ramos, Gustavo Campos; Delgobo, Murilo] Univ Hosp Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Delgobo, M (corresponding author), Univ Hosp Wurzburg, Dept Internal Medicine1, Wurzburg, Germany.; Delgobo, M (corresponding author), Univ Hosp Wurzburg, Comprehens Heart Failure Ctr, Wurzburg, Germany.	Delgobo_M@ukw.de						Albany CJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02795; Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Ashour D, 2021, CARDIOVASC RES, V117, pE84, DOI 10.1093/cvr/cvab157; Bansal SS, 2019, CIRCULATION, V139, P206, DOI 10.1161/CIRCULATIONAHA.118.036065; Barth SD, 2016, EBIOMEDICINE, V11, P151, DOI 10.1016/j.ebiom.2016.07.035; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Borg N, 2017, CIRCULATION, V136, P297, DOI 10.1161/CIRCULATIONAHA.116.023365; Borges TJ, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142909; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Chen X, 2005, J LEUKOCYTE BIOL, V78, P114, DOI 10.1189/jlb.0604341; Cho J, 2019, P NATL ACAD SCI USA, V116, P26727, DOI 10.1073/pnas.1914848116; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Dolejsi T, 2022, EUR HEART J, V43, P2698, DOI 10.1093/eurheartj/ehac153; Eriksson U, 2003, NAT MED, V9, P1484, DOI 10.1038/nm960; Feng GS, 2022, CIRCULATION, V145, P765, DOI 10.1161/CIRCULATIONAHA.121.055888; Filippi C, 2003, J EXP MED, V198, P201, DOI 10.1084/jem.20021893; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gil-Cruz C, 2019, SCIENCE, V366, P881, DOI 10.1126/science.aav3487; Ginhoux F, 2022, IMMUNITY, V55, P393, DOI 10.1016/j.immuni.2022.02.006; Godoy GJ, 2020, IMMUNOL LETT, V223, P17, DOI 10.1016/j.imlet.2020.04.006; Hammer A, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/6079713; Haubner BJ, 2012, AGING-US, V4, P966, DOI 10.18632/aging.100526; Hofer T, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00268; Hofmann U, 2016, EUR HEART J, V37, P873, DOI 10.1093/eurheartj/ehv639; Hofmann U, 2012, CIRCULATION, V125, P1652, DOI 10.1161/CIRCULATIONAHA.111.044164; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hui SP, 2017, DEV CELL, V43, P659, DOI 10.1016/j.devcel.2017.11.010; Hulsmans M, 2017, CELL, V169, P510, DOI 10.1016/j.cell.2017.03.050; Ikeuchi M, 2004, CARDIOVASC RES, V64, P526, DOI 10.1016/j.cardiores.2004.07.017; Jung MR, 2017, BASIC RES CARDIOL, V112, DOI 10.1007/s00395-017-0622-5; Kallikourdis M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14680; Kuswanto W, 2016, IMMUNITY, V44, P355, DOI 10.1016/j.immuni.2016.01.009; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; Li JT, 2019, THERANOSTICS, V9, P4324, DOI 10.7150/thno.32734; Lv HJ, 2011, J CLIN INVEST, V121, P1561, DOI 10.1172/JCI44583; M. Delgobo, 2022, bioRxiv, DOI 10.1101/2022.03.25.485791; Martini E, 2019, CIRCULATION, V140, P2089, DOI 10.1161/CIRCULATIONAHA.119.041694; Meng X, 2016, NAT REV CARDIOL, V13, P167, DOI 10.1038/nrcardio.2015.169; Miragaia RJ, 2019, IMMUNITY, V50, P493, DOI 10.1016/j.immuni.2019.01.001; Mor A, 2006, EUR HEART J, V27, P2530, DOI 10.1093/eurheartj/ehl222; NEU N, 1987, J IMMUNOL, V139, P3630; Nevers T, 2015, CIRC-HEART FAIL, V8, P776, DOI 10.1161/CIRCHEARTFAILURE.115.002225; Nickel AG, 2015, CELL METAB, V22, P472, DOI 10.1016/j.cmet.2015.07.008; Nindl V, 2012, EUR J IMMUNOL, V42, P2311, DOI 10.1002/eji.201142209; Nosbaum A, 2016, J IMMUNOL, V196, P2010, DOI 10.4049/jimmunol.1502139; OHKI H, 1988, DEVELOPMENT, V104, P619; Okamoto N, 2014, INT HEART J, V55, P271, DOI 10.1536/ihj.13-343; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Porrello ER, 2011, SCIENCE, V331, P1078, DOI 10.1126/science.1200708; Ramjee V, 2017, J CLIN INVEST, V127, P899, DOI 10.1172/JCI88759; Ramos G, 2016, J MOL CELL CARDIOL, V92, P41, DOI 10.1016/j.yjmcc.2016.01.018; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Rieckmann M, 2019, J CLIN INVEST, V129, P4922, DOI 10.1172/JCI123859; Rumpret M, 2020, NAT REV IMMUNOL, V20, P771, DOI 10.1038/s41577-020-0352-z; Rurik JG, 2022, SCIENCE, V375, P91, DOI 10.1126/science.abm0594; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2020, ANNU REV IMMUNOL, V38, P541, DOI 10.1146/annurev-immunol-042718-041717; Saxena A, 2014, AM J PHYSIOL-HEART C, V307, pH1233, DOI 10.1152/ajpheart.00328.2014; Scatena M, 2007, ARTERIOSCL THROM VAS, V27, P2302, DOI 10.1161/ATVBAHA.107.144824; Sintou A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00695; SMITH SC, 1992, P NATL ACAD SCI USA, V89, P9131, DOI 10.1073/pnas.89.19.9131; Swirski FK, 2018, NAT REV IMMUNOL, V18, P733, DOI 10.1038/s41577-018-0065-8; Tang TT, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-011-0232-6; Thygesen K, 2018, KARDIOL POL, V76, P1383, DOI [10.1161/CIR.0000000000000617, 10.1016/j.gheart.2018.08.004, 10.5603/KP.2018.0203]; Van der Borght K, 2017, CELL REP, V18, P3005, DOI 10.1016/j.celrep.2017.02.079; Wang K, 2020, P NATL ACAD SCI USA, V117, P5402, DOI 10.1073/pnas.1922559117; Wang Y, 2019, CIRCULATION, V139, P1798, DOI 10.1161/CIRCULATIONAHA.118.036053; Weirather J, 2014, CIRC RES, V115, P55, DOI 10.1161/CIRCRESAHA.115.303895; Wigren M, 2012, ARTERIOSCL THROM VAS, V32, P2000, DOI 10.1161/ATVBAHA.112.251579; Xia N, 2020, CIRCULATION, V142, P1956, DOI 10.1161/CIRCULATIONAHA.120.046789; Xia N, 2015, CLIN SCI, V128, P679, DOI 10.1042/CS20140672; Ye CX, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0002-5; Zacchigna S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04908-z; Zhao T., 2021, NEJM EVIDENCE, V1, DOI [10.1056/EVIDoa2100009, DOI 10.1056/EVIDOA2100009]; Zhao TX, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022452	77	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								914033	10.3389/fimmu.2022.914033	http://dx.doi.org/10.3389/fimmu.2022.914033			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y0SE	35693830	Green Published, gold			2022-12-18	WOS:000807855400001
J	Zhao, T; Xie, ZH; Xi, YJ; Liu, L; Li, ZF; Qin, DD				Zhao, Ting; Xie, Zhaohu; Xi, Yujiang; Liu, Li; Li, Zhaofu; Qin, Dongdong			How to Model Rheumatoid Arthritis in Animals: From Rodents to Non-Human Primates	FRONTIERS IN IMMUNOLOGY			English	Review						rheumatoid arthritis; animal models; rodents; NHPs; autoimmune diseases	AUTOIMMUNE ARTHRITIS; PRECLINICAL MODELS; II COLLAGEN; INDUCTION; DISEASE; AUTOANTIBODIES; INFLAMMATION; ACTIVATION; ANTIBODIES; MONKEYS	Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease influenced by both genetic and environmental factors. At present, rodent models are primarily used to study the pathogenesis and treatment of RA. However, the genetic divergences between rodents and humans determine differences in the development of RA, which makes it necessary to explore the establishment of new models. Compared to rodents, non-human primates (NHPs) are much more closely related to humans in terms of the immune system, metabolic conditions, and genetic make-up. NHPs model provides a powerful tool to study the development of RA and potential complications, as well as preclinical studies in drug development. This review provides a brief overview of the RA animal models, emphasizes the replication methods, pros and cons, as well as evaluates the validity of the rodent and NHPs models.	[Zhao, Ting; Xie, Zhaohu; Xi, Yujiang; Li, Zhaofu; Qin, Dongdong] Yunnan Univ Chinese Med, Sch Basic Med Sci, Kunming, Peoples R China; [Liu, Li] Ge Jiu Peoples Hosp, Yunnan Honghe Prefecture Cent Hosp, Gejiu, Peoples R China	Yunnan University of Chinese Medicine	Li, ZF; Qin, DD (corresponding author), Yunnan Univ Chinese Med, Sch Basic Med Sci, Kunming, Peoples R China.; Liu, L (corresponding author), Ge Jiu Peoples Hosp, Yunnan Honghe Prefecture Cent Hosp, Gejiu, Peoples R China.		秦, 冬/GQA-7638-2022		National Natural Science Foundation of China [31960178, 81960863, 81960870, 82160901]; Construction Project of National Traditional Chinese Medicine Clinical Research Base [131, 202102AA310006]; Yunnan Provincial Fund for Medical Research Center: Clinical Evaluation and Basic Research on the Treatment of rheumatoid arthritis and gout by Traditional Chinese medicine [31960178, 201507001-07]; Yunnan Provincial Key Laboratory Construction Project; National Natural Science Foundation of China; Clinical Trial for the Treatment of Rheumatoid Arthritis with Warming yang and Smoothening Meridians [202102AA310006]; Clinical Cooperative Project of Chinese and Western Medicine for Major and Knotty Diseases [201507001-07]; Yunnan Provincial Key Laboratory Construction Project Funding; Yunnan Provincial Key Laboratory of Chinese Medicine Rheumatology and Immunology; Yunnan Provincial Ten Thousands Program Famous Doctor Special; Yunnan Province Qingguo Wang Expert Workstation Construction Project; Yunnan Applied Basic Research Projects-Union Foundation [31960178]; Applied Basic Research Programs of Science and Technology Commission Foundation of Yunnan Province [81960863]; Scientific Research Fund Project of Yunnan Provincial Department of Education [81960870];  [202005AF150017];  [2019FF002(-031)];  [2019FA007];  [2021Y461]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Construction Project of National Traditional Chinese Medicine Clinical Research Base; Yunnan Provincial Fund for Medical Research Center: Clinical Evaluation and Basic Research on the Treatment of rheumatoid arthritis and gout by Traditional Chinese medicine; Yunnan Provincial Key Laboratory Construction Project; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Clinical Trial for the Treatment of Rheumatoid Arthritis with Warming yang and Smoothening Meridians; Clinical Cooperative Project of Chinese and Western Medicine for Major and Knotty Diseases; Yunnan Provincial Key Laboratory Construction Project Funding; Yunnan Provincial Key Laboratory of Chinese Medicine Rheumatology and Immunology; Yunnan Provincial Ten Thousands Program Famous Doctor Special; Yunnan Province Qingguo Wang Expert Workstation Construction Project; Yunnan Applied Basic Research Projects-Union Foundation; Applied Basic Research Programs of Science and Technology Commission Foundation of Yunnan Province; Scientific Research Fund Project of Yunnan Provincial Department of Education; ; ; ; 	National Natural Science Foundation of China (31960178, 81960863, 81960870, 82160901); Construction Project of National Traditional Chinese Medicine Clinical Research Base (2018 No. 131); Yunnan Provincial Fund for Medical Research Center: Clinical Evaluation and Basic Research on the Treatment of rheumatoid arthritis and gout by Traditional Chinese medicine (202102AA310006); Clinical Trial for the Treatment of Rheumatoid Arthritis with Warming yang and Smoothening Meridians (201507001-07, registration number: ChiCTR-INR-16010290); Clinical Cooperative Project of Chinese and Western Medicine for Major and Knotty Diseases; Yunnan Provincial Key Laboratory Construction Project Funding; Yunnan Provincial Key Laboratory of Chinese Medicine Rheumatology and Immunology; Yunnan Provincial "Ten Thousands Program" Famous Doctor Special; Yunnan Province Qingguo Wang Expert Workstation Construction Project (202005AF150017); Yunnan Applied Basic Research Projects-Union Foundation (2019FF002(-031)); Applied Basic Research Programs of Science and Technology Commission Foundation of Yunnan Province (2019FA007); Scientific Research Fund Project of Yunnan Provincial Department of Education (2021Y461).	Alamanos Y, 2005, AUTOIMMUN REV, V4, P130, DOI 10.1016/j.autrev.2004.09.002; Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Atkinson SM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3867; Bitoun S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01816; Bockermann R, 2005, ARTHRITIS RES THER, V7, pR1316, DOI 10.1186/ar1829; Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173; [蔡理 Cai Li], 2019, [中国免疫学杂志, Chinese Journal of Immunology], V35, P1937; Carlsen S, 2008, ARTHRITIS RHEUM-US, V58, P2000, DOI 10.1002/art.23554; Chandrupatla DMSH, 2018, TRANSL RES, V199, P24, DOI 10.1016/j.trsl.2018.04.001; Chen MH, 2021, BIOCHEM PHARMACOL, V185, DOI 10.1016/j.bcp.2021.114413; Choi EW, 2019, COMPARATIVE MED, V69, P228, DOI 10.30802/AALAS-CM-18-000058; Choudhary N, 2018, IMMUNOPHARM IMMUNOT, V40, P193, DOI 10.1080/08923973.2018.1434793; Chung E, 2005, CLIN DIAGN LAB IMMUN, V12, P426, DOI 10.1128/CDLI.12.3.426-435.2005; Cordova KN, 2013, J IMMUNOL, V190, P1457, DOI 10.4049/jimmunol.1201517; COURTENAY JS, 1980, NATURE, V283, P666, DOI 10.1038/283666a0; Croll L, 2019, EPILEPSIA, V60, P1526, DOI 10.1111/epi.16089; Dusad A, 2014, IMMUNOL RES, V58, P51, DOI 10.1007/s12026-013-8479-7; Fang ZY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00958; Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426; Goldbach-Mansky R, 2000, ARTHRITIS RES, V2, P236, DOI 10.1186/ar93; Hama AT, 2013, CNS NEUROL DISORD-DR, V12, P1257; Hanyecz A, 2004, ARTHRITIS RHEUM-US, V50, P1665, DOI 10.1002/art.20180; Holmdahl R, 2001, IMMUNOL REV, V184, P184, DOI 10.1034/j.1600-065x.2001.1840117.x; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; [黄诗畅 Huang Shichang], 2017, [华西药学杂志, West China Journal of Pharmaceutical Sciences], V32, P43; Jagessar SA, 2013, EXP ANIM TOKYO, V62, P159, DOI 10.1538/expanim.62.159; Kato M, 2020, IMMUNOL MED, V43, P72, DOI 10.1080/25785826.2020.1751908; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Kimpel D, 2002, CLIN IMMUNOL, V105, P351, DOI 10.1006/clim.2002.5305; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; Kuhn KA, 2006, J CLIN INVEST, V116, P961, DOI 10.1172/JCI25422; Lane MA, 2000, EXP GERONTOL, V35, P533, DOI 10.1016/S0531-5565(00)00102-9; Lerner A, 2018, BEST PRACT RES CL RH, V32, P550, DOI 10.1016/j.berh.2019.01.006; Li XW, 2021, EXP CELL RES, V398, DOI 10.1016/j.yexcr.2020.112404; Liu Z, 2016, NATURE, V530, P98, DOI 10.1038/nature16533; Maufort JP, 2019, J AM HEART ASSOC, V8, DOI 10.1161/JAHA.119.012135; Na HS, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02402-z; Nandakumar Kutty Selva, 2007, V136, P215; Narazaki M, 2017, EXPERT REV CLIN IMMU, V13, P535, DOI 10.1080/1744666X.2017.1295850; Oton T, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.101477; PEARSON CM, 1956, P SOC EXP BIOL MED, V91, P95, DOI 10.3181/00379727-91-22179; Pei B, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20182431; Phillips KA, 2014, AM J PRIMATOL, V76, P801, DOI 10.1002/ajp.22281; Prins NW, 2017, J NEUROSCI METH, V284, P35, DOI 10.1016/j.jneumeth.2017.04.004; Qin DD, 2019, BRAIN RES BULL, V146, P87, DOI 10.1016/j.brainresbull.2018.12.018; Roodgar M, 2020, GIGASCIENCE, V9, DOI 10.1093/gigascience/giaa069; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Seeuws S, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3119; Shen CH, 2018, J CHROMATOGR B, V1090, P73, DOI 10.1016/j.jchromb.2018.05.021; Szekanecz Z, 2008, CLIN REV ALLERG IMMU, V34, P26, DOI 10.1007/s12016-007-8022-5; t'Hart BA, 1998, BRIT J RHEUMATOL, V37, P314; Takei S, 2013, J VET MED SCI, V75, P531, DOI 10.1292/jvms.12-0405; van den Berg Wim B., 2007, V136, P243; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; Vierboom M, 2008, EXPERT OPIN DRUG DIS, V3, P299, DOI 10.1517/17460441.3.3.299; Vierboom M, 2012, EXPERT OPIN DRUG DIS, V7, P315, DOI 10.1517/17460441.2012.666523; Vierboom MPM, 2007, DRUG DISCOV TODAY, V12, P327, DOI 10.1016/j.drudis.2007.02.012; Vierboom MPM, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3172; Vierboom MPM, 2005, ARTHRITIS RES THER, V7, P145, DOI 10.1186/ar1773; Ishikawa LLW, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/148594; Wigerblad G, 2016, ANN RHEUM DIS, V75, P730, DOI 10.1136/annrheumdis-2015-208094; Zeng FX, 2018, J MOL CELL CARDIOL, V125, P50, DOI 10.1016/j.yjmcc.2018.10.015; Zhao YJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.631249; Zhou LL, 2018, MOL MED REP, V18, P3219, DOI 10.3892/mmr.2018.9322	65	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								887460	10.3389/fimmu.2022.887460	http://dx.doi.org/10.3389/fimmu.2022.887460			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y0AB	35693791	Green Published, gold			2022-12-18	WOS:000807808100001
J	Zhong, ZX; Wang, YH; Wang, GQ; Zhou, FF				Zhong, Zixing; Wang, Yuhan; Wang, Guiqin; Zhou, Feifei			Case Report: TNF-Alpha Inhibitors to Rescue Pregnancy in Women With Potential Pregnancy Loss: A Report of Ten Cases	FRONTIERS IN IMMUNOLOGY			English	Article						miscarriage; case series; hCG (human chorionic gonadotrophin); TNF; pregnancy-rescue management; TNFi	RECURRENT SPONTANEOUS-ABORTION; NECROSIS-FACTOR-ALPHA; ANTIRHEUMATIC DRUGS; MISCARRIAGE; ASSOCIATION; DISEASE; TRIAL	Miscarriage poses a significant threat to pregnant women globally. Recurrent miscarriages or potential poor embryonic development indicated by early drops in serum human chorionic gonadotrophin (hCG) are even more catastrophic for pregnant women. However, these patients receive either individualized medical intervention supported by limited evidence or no treatment at all. In this study, we report ten patients who shared at least one episode of an early decline of hCG in the first trimester and were treated with compassionate use of tumor necrosis factor-alpha inhibitor (TNFi). They were then followed up regularly with caution. Their hCG trajectory all resumed a normal pattern within one week and the obstetric outcomes were promising. No adverse fetal, neonatal, or maternal health issues have been observed. This case series supports current safety evidence of TNFi and provides new insight into its use in pregnancy when the embryo is in danger. Further well-designed clinical trials should be carried out to consolidate the evidence.	[Zhong, Zixing] Zhejiang Prov Peoples Hosp, Hangzhou Med Coll, Affiliated Peoples Hosp, Ctr Reprod Med, Hangzhou, Peoples R China; [Wang, Yuhan] Zhejiang Chinese Med Univ, Clin Coll 1, Hangzhou, Peoples R China; [Wang, Guiqin] Fertil Ctr Melinda Women, Dalian, Peoples R China; [Zhou, Feifei] Zhejiang Prov Peoples Hosp, Hangzhou Med Coll, Affiliated Peoples Hosp, Ctr Reprod Med, Hangzhou, Peoples R China; [Zhou, Feifei] Zhejiang Univ, Zhejiang Womens Hosp, Sch Med, Hangzhou, Peoples R China; [Wang, Guiqin] Childrens Hosp, Dalian, Peoples R China	Hangzhou Medical College; Zhejiang Provincial People's Hospital; Zhejiang Chinese Medical University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Zhejiang University	Zhou, FF (corresponding author), Zhejiang Prov Peoples Hosp, Hangzhou Med Coll, Affiliated Peoples Hosp, Ctr Reprod Med, Hangzhou, Peoples R China.; Zhou, FF (corresponding author), Zhejiang Univ, Zhejiang Womens Hosp, Sch Med, Hangzhou, Peoples R China.	5510025@zju.edu.cn		Wang, Yuhan/0000-0001-9422-3835; Zhong, Zixing/0000-0002-2150-2419	Zhejiang Provincial Project for Medical and Health Science and Technology [2022503241]; Zhejiang Provincial Project for Medical Education [Y202146113]	Zhejiang Provincial Project for Medical and Health Science and Technology; Zhejiang Provincial Project for Medical Education	Funding This study is co-supported by Zhejiang Provincial Project for Medical and Health Science and Technology (Grant no. 2022503241) and Zhejiang Provincial Project for Medical Education (Grant no. Y202146113).	Alijotas-Reig J, 2019, SEMIN ARTHRITIS RHEU, V49, P314, DOI 10.1016/j.semarthrit.2019.02.006; Anim-Nyame N, 2003, CARDIOVASC RES, V58, P162, DOI 10.1016/S0008-6363(02)00844-1; Arck PC, 2013, NAT MED, V19, P548, DOI 10.1038/nm.3160; Atik RB, 2018, HUM REPROD OPEN, V2018, DOI 10.1093/hropen/hoy004; Barnhart KT, 2004, OBSTET GYNECOL, V104, P50, DOI 10.1097/01.AOG.0000128174.48843.12; Barnhart KT, 2016, OBSTET GYNECOL, V128, P504, DOI 10.1097/AOG.0000000000001568; Bauer S, 2004, J CLIN ENDOCR METAB, V89, P812, DOI 10.1210/jc.2003-031351; Boerma T, 2018, LANCET, V392, P1341, DOI 10.1016/S0140-6736(18)31928-7; Brogin Moreli Jusciele, 2012, ISRN Obstet Gynecol, V2012, P230742, DOI 10.5402/2012/230742; Clowse MEB, 2018, ARTHRITIS RHEUMATOL, V70, P1399, DOI 10.1002/art.40508; Coomarasamy A, 2019, NEW ENGL J MED, V380, P1815, DOI 10.1056/NEJMoa1813730; Cunningham F, 2014, WILLIAMS OBSTET, V24e; Flint J, 2016, RHEUMATOLOGY, V55, P1693, DOI 10.1093/rheumatology/kev404; Fu JH, 2019, TAIWAN J OBSTET GYNE, V58, P621, DOI 10.1016/j.tjog.2019.07.007; Furer V, 2020, ANN RHEUM DIS, V79, P39, DOI 10.1136/annrheumdis-2019-215882; Grimbizis GF, 2013, HUM REPROD, V28, P2032, DOI 10.1093/humrep/det098; Hunt JS, 1996, BIOL REPROD, V54, P554, DOI 10.1095/biolreprod54.3.554; Kavanaugh A, 2015, ARTHRIT CARE RES, V67, P313, DOI 10.1002/acr.22516; Mahadevan U, 2019, GASTROENTEROLOGY, V156, P1508, DOI 10.1053/j.gastro.2018.12.022; Mahadevan U, 2021, GASTROENTEROLOGY, V160, P1131, DOI 10.1053/j.gastro.2020.11.038; Mariette X, 2018, ANN RHEUM DIS, V77, P228, DOI 10.1136/annrheumdis-2017-212196; Mills BS, 2020, J RHEUMATOL, V47, P149, DOI 10.3899/jrheum.181067; Nelson-Piercy C., 2015, HDB OBSTET MED; Ng SC, 2002, AM J REPROD IMMUNOL, V48, P77, DOI 10.1034/j.1600-0897.2002.01105.x; O'Byrne LJ, 2022, BJOG-INT J OBSTET GY, V129, P1236, DOI 10.1111/1471-0528.17093; Pillai RN, 2016, HUM REPROD UPDATE, V22, P228, DOI 10.1093/humupd/dmv054; Qi H., 2018, CHIN J OBSTET GYNECO, V53, P7, DOI [10.3760/cma.j.issn.1007-9408.2018.03.001, DOI 10.3760/CMA.J.ISSN.1007-9408.2018.03.001]; Quenby S, 2021, LANCET, V397, P1658, DOI 10.1016/S0140-6736(21)00682-6; Seow CH, 2017, ALIMENT PHARM THER, V45, P1329, DOI 10.1111/apt.14040; Shahine L, 2015, OBSTET GYN CLIN N AM, V42, P117, DOI 10.1016/j.ogc.2014.10.002; Skorpen CG, 2016, ANN RHEUM DIS, V75, P795, DOI 10.1136/annrheumdis-2015-208840; Whittaker PG, 2018, REPROD BIOL ENDOCRIN, V16, DOI 10.1186/s12958-018-0415-1; Winger EE, 2008, AM J REPROD IMMUNOL, V60, P8, DOI 10.1111/j.1600-0897.2008.00585.x; Zhang CD, 2016, AM J REPROD IMMUNOL, V75, P86, DOI 10.1111/aji.12447	34	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 25	2022	13								900537	10.3389/fimmu.2022.900537	http://dx.doi.org/10.3389/fimmu.2022.900537			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X9YU	35693803	gold, Green Published			2022-12-18	WOS:000807804800001
J	Cuburu, N; Finn, OJ; van der Burg, SH				Cuburu, Nicolas; Finn, Olivera J.; van der Burg, Sjoerd H.			Editorial: Cancer Prevention: Targeting Premalignant Epithelial Neoplasms in the Era of Cancer Immunotherapy and Vaccines	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccine; immunotherapy; antigen discovery; animal model; premalignant lesion; tumor microenvironment			[Cuburu, Nicolas] Natl Canc Inst NIH, Ctr Canc Res, Lab Cellular Oncol, Bethesda, MD 20814 USA; [Finn, Olivera J.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA; [van der Burg, Sjoerd H.] Leiden Univ, Dept Med Oncol, Med Ctr, Leiden, Netherlands	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Cuburu, N (corresponding author), Natl Canc Inst NIH, Ctr Canc Res, Lab Cellular Oncol, Bethesda, MD 20814 USA.; Finn, OJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15260 USA.; van der Burg, SH (corresponding author), Leiden Univ, Dept Med Oncol, Med Ctr, Leiden, Netherlands.	cuburun@mail.nih.gov; ojfinn@pitt.edu; S.H.van_der_Burg@lumc.nl						Brossart P, 2020, CLIN CANCER RES, V26, P4442, DOI 10.1158/1078-0432.CCR-20-0305; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Ehx G, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0642-x; Enokida T, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146956; Gebert J, 2021, GASTROENTEROLOGY, V161, P1288, DOI 10.1053/j.gastro.2021.06.073; Kenter GG, 2009, NEW ENGL J MED, V361, P1838, DOI 10.1056/NEJMoa0810097; Mascaux C, 2019, NATURE, V571, P570, DOI 10.1038/s41586-019-1330-0; Spira A, 2016, P NATL ACAD SCI USA, V113, P10750, DOI 10.1073/pnas.1608077113; Srivastava S, 2018, TRENDS CANCER, V4, P523, DOI 10.1016/j.trecan.2018.06.007; Trimble CL, 2015, LANCET, V386, P2078, DOI 10.1016/S0140-6736(15)00239-1	10	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								924099	10.3389/fimmu.2022.924099	http://dx.doi.org/10.3389/fimmu.2022.924099			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X9IC	35686125	gold, Green Published			2022-12-18	WOS:000807761400001
J	dos Santos, JDB; do Amaral, JB; Franca, CN; Monteiro, FR; Alvares-Saraiva, AM; Kalil, S; Durigon, EL; Oliveira, DBL; Rodrigues, SS; Heller, D; Welter, EAR; Pinho, JRR; Vieira, RP; Bachi, ALL				dos Santos, Juliana de Melo Batista; do Amaral, Jonatas Bussador; Franca, Carolina Nunes; Monteiro, Fernanda Rodrigues; Alvares-Saraiva, Anuska Marcelino; Kalil, Sandra; Durigon, Edison Luiz; Oliveira, Danielle Bruna Leal; Rodrigues, Silvia Sanches; Heller, Debora; Welter, Eliane Aparecida Rosseto; Pinho, Joao Renato Rebello; Vieira, Rodolfo P.; Bachi, Andre Luis Lacerda			Distinct Immunological Profiles Help in the Maintenance of Salivary Secretory IgA Production in Mild Symptoms COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						mucosal immunity; saliva; cytokines; interferon; interleukin; SARS-CoV-2	INNATE LYMPHOID-CELLS; VIRUS-INFECTION; CYTOKINE RESPONSES; IMMUNOGLOBULIN-A; OXIDATIVE STRESS; IFN-GAMMA; INTERLEUKIN-12; INTERFERON; PROGRESSION; IMMUNITY	BackgroundRelevant aspects regarding the SARS-CoV-2 pathogenesis and the systemic immune response to this infection have been reported. However, the mucosal immune response of the upper airways two months after SARS-CoV-2 infection in patients with mild/moderate symptoms is still not completely described. Therefore, we investigated the immune/inflammatory responses of the mucosa of the upper airways of mild/moderate symptom COVID-19 patients two months after the SARS-CoV-2 infection in comparison to a control group composed of non-COVID-19 healthy individuals. MethodsA cohort of 80 volunteers (age 37.2 +/- 8.2), including non-COVID-19 healthy individuals (n=24) and COVID-19 patients (n=56) who presented mild/moderate symptoms during a COVID-19 outbreak in Brazil in November and December of 2020. Saliva samples were obtained two months after the COVID-19 diagnosis to assess the levels of SIgA by ELISA and the cytokines by multiplex analysis. ResultsSalivary levels of SIgA were detected in 39 volunteers into the COVID-19 group and, unexpectedly, in 14 volunteers in the control group. Based on this observation, we distributed the volunteers of the control group into without SIgA or with SIgA sub-groups, and COVID-19 group into without SIgA or with SIgA sub-groups. Individuals with SIgA showed higher levels of IL-10, IL-17A, IFN-gamma, IL-12p70, IL-13, and IFN-alpha than those without SIgA. In intergroup analysis, the COVID-19 groups showed higher salivary levels of IL-10, IL-13, IL-17A, and IFN-alpha than the control group. No statistical differences were verified in the salivary levels of IL-6 and IFN-beta. Lower IL-12p70/IL-10 and IFN-gamma/IL-10 ratios were found in the control group without SIgA than the control group with SIgA and the COVID-19 group with SIgA. ConclusionWe were able to present, for the first time, that associations between distinct immunological profiles can help the mucosal immunity to maintain the salivary levels of SIgA in COVID-19 patients two months after the SARS-CoV-2 infection.	[dos Santos, Juliana de Melo Batista; Vieira, Rodolfo P.] Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human & Rehabil, Santos, Brazil; [do Amaral, Jonatas Bussador; Bachi, Andre Luis Lacerda] Fed Univ Sao Paulo UNIFESP, Dept Otorhinolaryngol Head & Neck Surg, ENT Res Lab, Sao Paulo, Brazil; [Franca, Carolina Nunes; Monteiro, Fernanda Rodrigues; Bachi, Andre Luis Lacerda] Santo Amaro Univ UNISA, Postgrad Program Hlth Sci, Sao Paulo, Brazil; [Alvares-Saraiva, Anuska Marcelino; Kalil, Sandra] Univ Paulista Unip, Programa Pos Grad Patol Ambiental & Expt, Sao Paulo, Brazil; [Durigon, Edison Luiz; Oliveira, Danielle Bruna Leal] Univ Sao Paulo, Dept Microbiol, Lab Clin & Mol Virol, Inst Biomed Sci, Sao Paulo, Brazil; [Durigon, Edison Luiz] Univ Sao Paulo, Sci Platform Pasteur, Sao Paulo, Brazil; [Oliveira, Danielle Bruna Leal; Rodrigues, Silvia Sanches; Heller, Debora; Welter, Eliane Aparecida Rosseto; Pinho, Joao Renato Rebello] Hosp Israelita Albert Einstein, Albert Einstein Inst Teaching & Res IIEP, Sao Paulo, Brazil; [Heller, Debora] Univ Cruzeiro, Post Grad Program Dent, Sao Paulo, Brazil; [Heller, Debora] Univ Texas Hlth Sci Ctr San Antonio, Sch Dent, Dept Periodontol, San Antonio, TX USA; [Pinho, Joao Renato Rebello] Univ Sao Paulo, Fac Med, Dept Gastroenterol LIM07, Sao Paulo, Brazil; [Pinho, Joao Renato Rebello] Univ Sao Paulo, Hosp Clin, Fac Med, Div Clin Labs LIM 03, Sao Paulo, Brazil; [Vieira, Rodolfo P.] Unievangelica, Postgrad Program Human Movement & Rehabil, Anapolis, Brazil; [Vieira, Rodolfo P.] Univ Brasil, Postgrad Program Bioengn, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao Paulo (UNIFESP); Universidade de Santo Amaro (UNISA); Universidade Paulista; Universidade de Sao Paulo; Universidade de Sao Paulo; Hospital Israelita Albert Einstein; University of Texas System; University of Texas Health San Antonio; Universidade de Sao Paulo; Universidade de Sao Paulo; Centro Universitario de Anapolis; Universidade Brasil	dos Santos, JDB (corresponding author), Fed Univ Sao Paulo UNIFESP, Postgrad Program Sci Human & Rehabil, Santos, Brazil.	juliana.melo@unifesp.br	Monteiro, Fernanda Rodrigues/AFN-1365-2022; Bachi, Andre/T-6931-2018; dos Santos, Juliana de Melo Batista/U-2855-2019; Alvares-Saraiva, Anuska/J-1128-2016	Monteiro, Fernanda Rodrigues/0000-0001-9413-447X; Bachi, Andre/0000-0001-8266-1416; dos Santos, Juliana de Melo Batista/0000-0003-0527-0723; Alvares-Saraiva, Anuska/0000-0001-8899-4182	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	Funding Funding was granted by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Grants No. 2016/20045-7 and 2020/06409-1 (ED), No. 2012/15165-2 (RV) and 2019/14115-0 (AB).	Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Allen JE, 2011, NAT REV IMMUNOL, V11, P375, DOI 10.1038/nri2992; Almeida EB, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2852181; Anka AU, 2021, SCAND J IMMUNOL, V93, DOI 10.1111/sji.12998; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Assiri A, 2013, NEW ENGL J MED, V369, P407, DOI 10.1056/NEJMoa1306742; dos Santos JDB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.595343; Bene MC, 2020, CLIN INFECT DIS, V71, P897, DOI 10.1093/cid/ciaa426; Boyaka PN, 1999, IMMUNOL RES, V20, P207, DOI 10.1007/BF02790404; Buczko P, 2015, J PHYSIOL PHARMACOL, V66, P3; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; COATES RA, 1992, J CLIN EPIDEMIOL, V45, P245, DOI 10.1016/0895-4356(92)90084-Z; Contoli M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.648004; Corman VM, 2020, EUROSURVEILLANCE, V25, P23, DOI 10.2807/1560-7917.ES.2020.25.3.2000045; Dare RK, 2007, J INFECT DIS, V196, P1321, DOI 10.1086/521308; De Diego ML, 2014, VIRUS RES, V194, P124, DOI 10.1016/j.virusres.2014.07.024; Dezfuli Neda K, 2020, Tanaffos, V19, P274; Eduardo FD, 2022, CLIN ORAL INVEST, V26, P1561, DOI 10.1007/s00784-021-04129-7; Emery SL, 2004, EMERG INFECT DIS, V10, P311, DOI 10.3201/eid1002.030759; Faure E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088716; Fernandes LL, 2020, J DENT RES, V99, P1435, DOI 10.1177/0022034520960070; Ford JG, 2001, J IMMUNOL, V167, P1769, DOI 10.4049/jimmunol.167.3.1769; Foster R, 2019, NEUROIMMUNOMODULAT, V26, P1, DOI 10.1159/000494559; Fry AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015098; Fukushi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021207; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Ghebreyesus TA, 2020, COMMUNICATION 0311; Guo LY, 2012, TRENDS IMMUNOL, V33, P598, DOI 10.1016/j.it.2012.07.006; Gustine JN, 2021, AM J PATHOL, V191, P4, DOI 10.1016/j.ajpath.2020.08.009; Hamada H, 2009, J IMMUNOL, V182, P3469, DOI 10.4049/jimmunol.0801814; Hayden FG, 1998, J CLIN INVEST, V101, P643, DOI 10.1172/JCI1355; Heim A, 2003, J MED VIROL, V70, P228, DOI 10.1002/jmv.10382; HIRANO T, 1988, EUR J IMMUNOL, V18, P1797, DOI 10.1002/eji.1830181122; Hoffmann JP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672523; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Hupin C, 2013, ALLERGY, V68, P1589, DOI 10.1111/all.12274; Jafarzadeh A, 2021, VIRAL IMMUNOL, V34, P307, DOI 10.1089/vim.2020.0076; Jartti T, 2014, ALLERGY, V69, P658, DOI 10.1111/all.12396; Jin YF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040372; KATZ MH, 1992, AIDS, V6, P95, DOI 10.1097/00002030-199201000-00013; Khalid I, 2016, RESP CARE, V61, P340, DOI 10.4187/respcare.04325; Ko JH, 2016, J INFECTION, V73, P468, DOI 10.1016/j.jinf.2016.08.005; Kodani M, 2011, J CLIN MICROBIOL, V49, P2175, DOI 10.1128/JCM.02270-10; Kudva A, 2011, J IMMUNOL, V186, P1666, DOI 10.4049/jimmunol.1002194; Kumar N, 2020, SCIENCE, V367, P1008, DOI 10.1126/science.aaz5807; Li L, 1996, CELL IMMUNOL, V168, P133, DOI 10.1006/cimm.1996.0059; Liang B, 2001, J VIROL, V75, P5416, DOI 10.1128/JVI.75.11.5416-5420.2001; Liu J, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102763; Lowery SA, 2021, CELL HOST MICROBE, V29, P1052, DOI 10.1016/j.chom.2021.05.004; Lu X, 2006, ARCH VIROL, V151, P1587, DOI 10.1007/s00705-005-0722-7; Lu XY, 2008, J CLIN MICROBIOL, V46, P533, DOI 10.1128/JCM.01739-07; Mahallawi WH, 2018, CYTOKINE, V104, P8, DOI 10.1016/j.cyto.2018.01.025; Malmgaard L, 2004, J INTERF CYTOK RES, V24, P439, DOI 10.1089/1079990041689665; Malmgaard L, 2003, J GEN VIROL, V84, P2497, DOI 10.1099/vir.0.19251-0; Marashian SM, 2015, IRAN J ALLERGY ASTHM, V14, P346; MATSUKI Y, 1992, IMMUNOLOGY, V76, P42; Metzger DW, 1997, EUR J IMMUNOL, V27, P1958, DOI 10.1002/eji.1830270820; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Morgan OW, 2013, INFLUENZA OTHER RESP, V7, P280, DOI 10.1111/j.1750-2659.2012.00393.x; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Naruishi K, 2018, J CELL PHYSIOL, V233, P6393, DOI 10.1002/jcp.26521; Noda K, 2011, MICROBIOL IMMUNOL, V55, P574, DOI 10.1111/j.1348-0421.2011.00352.x; Prasso JE, 2017, CLIN CHEST MED, V38, P127, DOI 10.1016/j.ccm.2016.11.006; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Samuel PJ, 2020, J INTERF CYTOK RES, V40, P511, DOI 10.1089/jir.2020.0089; Santini SM, 2000, J EXP MED, V191, P1777, DOI 10.1084/jem.191.10.1777; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Sawa S, 2010, SCIENCE, V330, P665, DOI 10.1126/science.1194597; Smith PD, 2013, PRINCIPLES OF MUCOSAL IMMUNOLOGY, P1; Spadaro F, 2012, BLOOD, V119, P1407, DOI 10.1182/blood-2011-06-363564; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Tang L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570993; Tekkanat KK, 2001, AM J PATHOL, V159, P631, DOI 10.1016/S0002-9440(10)61734-8; Tekkanat KK, 2001, J IMMUNOL, V166, P3542, DOI 10.4049/jimmunol.166.5.3542; Tompkins WA, 1999, J INTERF CYTOK RES, V19, P817, DOI 10.1089/107999099313325; Totura AL, 2012, CURR OPIN VIROL, V2, P264, DOI 10.1016/j.coviro.2012.04.004; Trinchieri G, 1996, J LEUKOCYTE BIOL, V59, P505, DOI 10.1002/jlb.59.4.505; Trondsen M, 2015, SCAND J IMMUNOL, V81, P305, DOI 10.1111/sji.12288; Vaisberg M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071678; Vogel LA, 1996, INT IMMUNOL, V8, P1955, DOI 10.1093/intimm/8.12.1955; Wang J, 2015, FREE RADICAL BIO MED, V85, P95, DOI 10.1016/j.freeradbiomed.2015.04.005; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Woof JM, 2006, J PATHOL, V208, P270, DOI 10.1002/path.1877; Wu MM, 2016, MOL NUTR FOOD RES, V60, P1637, DOI 10.1002/mnfr.201600026; Yao ZX, 2020, AGING-US, V12, P7639, DOI 10.18632/aging.103101; Zhang Y, 2016, PERIODONTOL 2000, V70, P38, DOI 10.1111/prd.12099; Zhao SZ, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/9316763	87	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								890887	10.3389/fimmu.2022.890887	http://dx.doi.org/10.3389/fimmu.2022.890887			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X4QT	35686128	Green Published, gold			2022-12-18	WOS:000807441100001
J	Kang, CK; Kim, M; Hong, J; Kim, G; Lee, S; Chang, E; Choe, PG; Kim, NJ; Kim, IS; Seo, JY; Song, D; Lee, DS; Shin, HM; Kim, YW; Lee, CH; Park, WB; Kim, HR; Oh, MD				Kang, Chang Kyung; Kim, Minji; Hong, Jisu; Kim, Gwanghun; Lee, Soojin; Chang, Euijin; Choe, Pyoeng Gyun; Kim, Nam Joong; Kim, Ik Soo; Seo, Jun-Young; Song, Daesub; Lee, Dong-Sup; Shin, Hyun Mu; Kim, Yong-Woo; Lee, Chang-Han; Park, Wan Beom; Kim, Hang-Rae; Oh, Myoung-don			Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity (vol 13, 830433, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						SARS-CoV-2; antibody; phagocytosis; memory B cells; memory T cells			[Kang, Chang Kyung; Chang, Euijin; Choe, Pyoeng Gyun; Kim, Nam Joong; Park, Wan Beom; Oh, Myoung-don] Seoul Natl Univ Coll Med, Dept Internal Med, Seoul, South Korea; [Kim, Minji; Hong, Jisu; Kim, Gwanghun; Lee, Soojin; Lee, Dong-Sup; Shin, Hyun Mu; Lee, Chang-Han; Kim, Hang-Rae] Seoul Natl Univ Coll Med, Dept Biomed Sci, Seoul, South Korea; [Kim, Minji; Kim, Gwanghun; Lee, Soojin; Lee, Dong-Sup; Kim, Hang-Rae] Seoul Natl Univ Coll Med, Dept Anat & Cell Biol, Seoul, South Korea; [Kim, Minji; Hong, Jisu; Kim, Gwanghun; Lee, Soojin; Lee, Dong-Sup; Shin, Hyun Mu; Lee, Chang-Han; Kim, Hang-Rae] Seoul Natl Univ Coll Med, FOUR Biomed Sci Project BrainKorea21 BK21, Seoul, South Korea; [Hong, Jisu; Lee, Chang-Han] Seoul Natl Univ Coll Med, Dept Pharmacol, Seoul, South Korea; [Kim, Ik Soo] Gachon Univ, Sch Med, Dept Microbiol, Incheon, South Korea; [Seo, Jun-Young] Yonsei Univ Coll Med, Severance Biomed Sci Inst, Seoul, South Korea; [Seo, Jun-Young] Yonsei Univ Coll Med, Project Med Sci BrainKorea21 BK21, Seoul, South Korea; [Song, Daesub] Korea Univ, Coll Pharm, Sejong, South Korea; [Lee, Dong-Sup; Kim, Hang-Rae] Seoul Natl Univ Coll Med, Med Res Inst, Seoul, South Korea; [Lee, Dong-Sup; Shin, Hyun Mu; Kim, Yong-Woo; Lee, Chang-Han; Kim, Hang-Rae] Seoul Natl Univ, Wide River Inst Immunol, Hongcheon, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Seoul National University (SNU); Gachon University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Korea University; Seoul National University (SNU); Seoul National University (SNU)	Park, WB (corresponding author), Seoul Natl Univ Coll Med, Dept Internal Med, Seoul, South Korea.; Lee, CH; Kim, HR (corresponding author), Seoul Natl Univ Coll Med, Dept Biomed Sci, Seoul, South Korea.; Kim, HR (corresponding author), Seoul Natl Univ Coll Med, Dept Anat & Cell Biol, Seoul, South Korea.; Lee, CH; Kim, HR (corresponding author), Seoul Natl Univ Coll Med, FOUR Biomed Sci Project BrainKorea21 BK21, Seoul, South Korea.; Lee, CH (corresponding author), Seoul Natl Univ Coll Med, Dept Pharmacol, Seoul, South Korea.; Kim, HR (corresponding author), Seoul Natl Univ Coll Med, Med Res Inst, Seoul, South Korea.; Lee, CH; Kim, HR (corresponding author), Seoul Natl Univ, Wide River Inst Immunol, Hongcheon, South Korea.		Park, Wan Beom/GLU-9886-2022; kim, minji/GRX-9996-2022					Kang CK, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.830433	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								929770	10.3389/fimmu.2022.929770	http://dx.doi.org/10.3389/fimmu.2022.929770			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X9QN	35686133	gold, Green Published			2022-12-18	WOS:000807783300001
J	Kobayashi, S; Nagafuchi, Y; Shoda, H; Fujio, K				Kobayashi, Satomi; Nagafuchi, Yasuo; Shoda, Hirofumi; Fujio, Keishi			The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Review						systemic sclerosis; the early disease phase; immune cells; regulatory T cells; transcriptome analysis	EXPRESSION; SKIN; ASSOCIATION; DISEASE; DIFFERENTIATION; IDENTIFICATION; POLYMORPHISMS; POLARIZATION; FIBROBLASTS; ACTIVATION	Systemic sclerosis (SSc) is an autoimmune disease that is characterized by vascular damage and fibrosis. Both clinical manifestations and immunological disturbances are diverse according to the disease duration. Particularly, changes in immunological processes are prominent in the early phase of SSc. The orchestration of several subsets of immune cells promotes autoimmune responses and inflammation, and eventually stimulates pro-fibrotic processes. Many reports have indicated that CD4(+) T cells play pivotal roles in pathogenesis in the early phase of SSc. In particular, the pathogenic roles of regulatory T (Treg) cells have been investigated. Although the results were controversial, recent reports suggested an increase of Treg cells in the early phase of SSc patients. Treg cells secrete transforming growth factor-beta (TGF-beta), which promotes myofibroblast activation and fibrosis. In addition, the dysfunction of Treg cells in the early phase of SSc was reported, which results in the development of autoimmunity and inflammation. Notably, Treg cells have the plasticity to convert to T-helper17 (Th17) cells under pro-inflammatory conditions. Th17 cells secrete IL-17A, which could also promote myofibroblast transformation and fibrosis and contributes to vasculopathy, although the issue is still controversial. Our recent transcriptomic comparison between the early and late phases of SSc revealed a clear difference of gene expression patterns only in Treg cells. The gene signature of an activated Treg cell subpopulation was expanded in the early phase of SSc and the oxidative phosphorylation pathway was enhanced, which can promote Th17 differentiation. And this result was accompanied by the increase in Th17 cells frequency. Therefore, an imbalance between Treg and Th17 cells could also have an important role in the pathogenesis of the early phase of SSc. In this review, we outlined the roles of Treg cells in the early phase of SSc, summarizing the data of both human and mouse models. The contributions of Treg cells to autoimmunity, vasculopathy, and fibrosis were revealed, based on the dysfunction and imbalance of Treg cells. We also referred to the potential development in treatment strategies in SSc.	[Kobayashi, Satomi; Nagafuchi, Yasuo; Shoda, Hirofumi; Fujio, Keishi] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, Tokyo, Japan; [Kobayashi, Satomi] Tokyo Metropolitan Geriatr Hosp, Dept Med & Rheumatol, Itabashi Ku, Tokyo, Japan; [Nagafuchi, Yasuo] Univ Tokyo, Grad Sch Med, Dept Funct Genom & Immunol Dis, Bunkyo Ku, Tokyo, Japan	University of Tokyo; University of Tokyo	Shoda, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, Tokyo, Japan.	shodah-int@h.u-tokyo.ac.jp		Kobayashi, Satomi/0000-0002-5454-1051				Abbasifard M, 2020, J GENE MED, V22, DOI 10.1002/jgm.3204; Almanzar G, 2016, INT ARCH ALLERGY IMM, V171, P141, DOI 10.1159/000450949; Antiga E, 2010, BRIT J DERMATOL, V162, P1056, DOI 10.1111/j.1365-2133.2010.09633.x; Bellando-Randone S, 2021, LANCET RHEUMATOL, V3, pE834; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; Birjandi SZ, 2016, AM J PATHOL, V186, P2008, DOI 10.1016/j.ajpath.2016.03.020; Bosello S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1569-0; Boveda-Ruiz D, 2013, IMMUNOBIOLOGY, V218, P245, DOI 10.1016/j.imbio.2012.05.020; Brembilla NC, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4334; Chiba M, 2017, J DERMATOL, V44, P194, DOI 10.1111/1346-8138.13610; Cossu M, 2017, ARTHRITIS RHEUMATOL, V69, P2359, DOI 10.1002/art.40243; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; D'Amico F, 2017, IMMUNOBIOLOGY, V223, P112, DOI 10.1016/j.imbio.2017.10.004; de Vries S, 2013, J BIOL CHEM, V288, P5815, DOI 10.1074/jbc.M112.420711; Deng CW, 2017, SCI REP-UK, V7, DOI 10.1038/srep43532; Denton CP, 2017, LANCET, V390, P1685, DOI 10.1016/S0140-6736(17)30933-9; Diaz-Gallo L, 2011, ANN RHEUM DIS, V70, P454, DOI 10.1136/ard.2010.130138; Distler O, 2019, NEW ENGL J MED, V380, P2518, DOI 10.1056/NEJMoa1903076; Dufour AM, 2020, J INVEST DERMATOL, V140, P103, DOI 10.1016/j.jid.2019.05.026; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Fox DA, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-020-02383-w; Frantz C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02356; Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103; Gieseck RL, 2018, NAT REV IMMUNOL, V18, P62, DOI 10.1038/nri.2017.90; Gilbane AJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4230; Gunther J, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4503; Hachulla E, 2009, CHEST, V136, P1211, DOI 10.1378/chest.08-3042; Hasegawa M, 2013, RHEUMATOLOGY, V52, P242, DOI 10.1093/rheumatology/kes258; Herrick AL, 2010, ARTHRITIS RHEUM-US, V62, P2595, DOI 10.1002/art.27543; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hori S, 2010, CURR OPIN IMMUNOL, V22, P575, DOI 10.1016/j.coi.2010.08.004; Janssen E, 2016, J CLIN INVEST, V126, P3837, DOI 10.1172/JCI85774; Kamio K, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0783-2; Karatas A, 2021, INT J RHEUM DIS, V24, P795, DOI 10.1111/1756-185X.14114; Kataoka H, 2015, MOD RHEUMATOL, V25, P90, DOI 10.3109/14397595.2014.899736; Kato H, 2018, ARTHRITIS RHEUMATOL, V70, P427, DOI 10.1002/art.40380; Khanna D, 2020, LANCET RESP MED, V8, P963, DOI 10.1016/S2213-2600(20)30318-0; Kobayashi S, 2022, RHEUMATOLOGY, V61, P4163, DOI 10.1093/rheumatology/keac031; Kobayashi S, 2021, J AUTOIMMUN, V116, DOI 10.1016/j.jaut.2020.102547; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432; Kowal-Bielecka O, 2017, ANN RHEUM DIS, V76, P1327, DOI 10.1136/annrheumdis-2016-209909; Krasimirova Ekaterina, 2017, World J Exp Med, V7, P84, DOI 10.5493/wjem.v7.i3.84; Kubo S, 2019, RHEUMATOLOGY, V58, P2273, DOI 10.1093/rheumatology/kez244; Kurasawa K, 2000, ARTHRITIS RHEUM-US, V43, P2455, DOI 10.1002/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K; Lafyatis R, 2007, ARTHRITIS RHEUM, V56, P3167, DOI 10.1002/art.22847; Lafyatis R, 2014, NAT REV RHEUMATOL, V10, P706, DOI 10.1038/nrrheum.2014.137; Lei Ling, 2012, Beijing Da Xue Xue Bao Yi Xue Ban, V44, P259; LeRoy EC, 2001, J RHEUMATOL, V28, P1573; Levine AG, 2014, NAT IMMUNOL, V15, P1070, DOI 10.1038/ni.3004; Li D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.124020; Li MO, 2016, NAT REV IMMUNOL, V16, P220, DOI 10.1038/nri.2016.26; Liu MG, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0512-2; Liu XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064531; Lopez-Isac E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12760-y; MacDonald KG, 2015, J ALLERGY CLIN IMMUN, V135, P946, DOI 10.1016/j.jaci.2014.12.1932; Maehara T, 2020, J CLIN INVEST, V130, P2451, DOI 10.1172/JCI131700; Mahoney JM, 2015, PLOS COMPUT BIOL, V11, DOI 10.1371/journal.pcbi.1004005; Marie I, 2014, ALIMENT PHARM THER, V40, P189, DOI 10.1111/apt.12818; Marie I, 2014, AUTOIMMUN REV, V13, P151, DOI 10.1016/j.autrev.2013.10.002; Masui Y, 2013, RHEUMATOLOGY, V52, P1239, DOI 10.1093/rheumatology/ket010; Mathian A, 2012, ANN RHEUM DIS, V71, P1227, DOI 10.1136/annrheumdis-2011-200709; Matucci-Cerinic M, 2009, ANN RHEUM DIS, V68, P1377, DOI 10.1136/ard.2008.106302; Medsger TA, 2003, RHEUM DIS CLIN N AM, V29, P255, DOI 10.1016/S0889-857X(03)00023-1; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Miura S, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02520-z; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Mo CL, 2018, BIOMED PHARMACOTHER, V108, P177, DOI 10.1016/j.biopha.2018.09.037; Murata M, 2008, J DERMATOL SCI, V50, P240, DOI 10.1016/j.jdermsci.2008.01.001; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nakashima T, 2012, J IMMUNOL, V188, P3573, DOI 10.4049/jimmunol.1100591; Nicola S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092106; Nihtyanova SI, 2014, ARTHRITIS RHEUMATOL, V66, P1625, DOI 10.1002/art.38390; Okamoto Y, 2012, ARTHRITIS RHEUM-US, V64, P3726, DOI 10.1002/art.34643; Ota M, 2021, CELL, V184, P3006, DOI 10.1016/j.cell.2021.03.056; Ota Y, 2021, INFLAMM REGEN, V41, DOI 10.1186/s41232-021-00167-6; Papp G, 2012, CLIN RHEUMATOL, V31, P1293, DOI 10.1007/s10067-012-2000-x; Park MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01611; Radstake TRDJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005903; Radstake TRDJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005981; Randone SB, 2008, AUTOIMMUN REV, V8, P36, DOI 10.1016/j.autrev.2008.07.022; ROUMM AD, 1984, ARTHRITIS RHEUM, V27, P645, DOI 10.1002/art.1780270607; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakkas LI, 2002, J IMMUNOL, V168, P3649, DOI 10.4049/jimmunol.168.7.3649; Sasada T, 2003, CANCER-AM CANCER SOC, V98, P1089, DOI 10.1002/cncr.11618; Sato S, 2000, J IMMUNOL, V165, P6635, DOI 10.4049/jimmunol.165.11.6635; Shah A, 2022, RHEUMATOLOGY, V61, P4155, DOI 10.1093/rheumatology/keac015; Shin BY, 2020, CELL REP, V30, P1898, DOI 10.1016/j.celrep.2020.01.022; Shin JY, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw0790; Siqueira VS, 2022, RHEUMATOLOGY, V61, P3686, DOI 10.1093/rheumatology/keac006; SJOGREN RW, 1994, ARTHRITIS RHEUM-US, V37, P1265, DOI 10.1002/art.1780370902; Skaug B, 2022, ANN RHEUM DIS, V81, P516, DOI 10.1136/annrheumdis-2021-221352; Skaug B, 2020, ANN RHEUM DIS, V79, P379, DOI 10.1136/annrheumdis-2019-215894; Truchetet ME, 2013, ARTHRITIS RHEUM-US, V65, P1347, DOI 10.1002/art.37860; Truchetet ME, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3486; Tsopoulidis N, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aav1987; Ugor E, 2017, CLIN IMMUNOL, V184, P54, DOI 10.1016/j.clim.2017.05.013; van Bon L, 2014, NEW ENGL J MED, V370, P433, DOI 10.1056/NEJMoa1114576; Vettori S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00220; Vettori S, 2014, J CLIN IMMUNOL, V34, P663, DOI 10.1007/s10875-014-0037-0; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wei P, 2016, ARTHRITIS RHEUMATOL, V68, P749, DOI 10.1002/art.39476; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Wu MH, 2017, ARTHRITIS RHEUMATOL, V69, P1871, DOI 10.1002/art.40171; Xu Y, 2016, INT J DERMATOL, V55, P408, DOI 10.1111/ijd.12839; Yamamoto T, 2001, J DERMATOL SCI, V26, P133, DOI 10.1016/S0923-1811(00)00169-9; Yanaba K, 2013, ARCH DERMATOL RES, V305, P17, DOI 10.1007/s00403-012-1292-7; Yang XQ, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4430; YOO ZB, 1995, J IMMUNOL, V155, P5483; York MR, 2007, ARTHRITIS RHEUM-US, V56, P1010, DOI 10.1002/art.22382; Yoshizaki A, 2011, ARTHRITIS RHEUM-US, V63, P3575, DOI 10.1002/art.30539; Zemmour D, 2018, NAT IMMUNOL, V19, P291, DOI 10.1038/s41590-018-0051-0; Zhou Y, 2015, HUM IMMUNOL, V76, P22, DOI 10.1016/j.humimm.2014.12.008; Zuber JP, 2006, RHEUMATOLOGY, V45, P23, DOI 10.1093/rheumatology/kel285	114	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								900638	10.3389/fimmu.2022.900638	http://dx.doi.org/10.3389/fimmu.2022.900638			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X7IU	35686127	gold, Green Published			2022-12-18	WOS:000807625100001
J	Kong, H; Zhu, HJ; Zheng, XY; Jiang, MC; Chen, LS; Lan, LQ; Ren, JH; Luo, XF; Zheng, J; Zheng, ZH; Chen, ZZ; Hu, JD; Yang, T				Kong, Hui; Zhu, Haojie; Zheng, Xiaoyun; Jiang, Meichen; Chen, Lushan; Lan, Lingqiong; Ren, Jinhua; Luo, Xiaofeng; Zheng, Jing; Zheng, Zhihong; Chen, Zhizhe; Hu, Jianda; Yang, Ting			Machine Learning Models for the Diagnosis and Prognosis Prediction of High-Grade B-Cell Lymphoma	FRONTIERS IN IMMUNOLOGY			English	Article						high-grade B-cell lymphoma; clinical characteristics; diagnostic predictor; machine learning; classification models	RITUXIMAB PLUS CYCLOPHOSPHAMIDE; DOUBLE-HIT LYMPHOMA; PROTEIN EXPRESSION; HODGKINS-DISEASE; BURKITT-LYMPHOMA; MYC; BCL2; SURVIVAL; OUTCOMES; IMPACT	High-grade B-cell lymphoma (HGBL) is a newly introduced category of rare and heterogeneous invasive B-cell lymphoma (BCL), which is diagnosed depending on fluorescence in situ hybridization (FISH), an expensive and laborious analysis. In order to identify HGBL with minimal workup and costs, a total of 187 newly diagnosed BCL patients were enrolled in a cohort study. As a result, the overall survival (OS) and progression-free survival (PFS) of the HGBL group were inferior to those of the non-HGBL group. HGBL (n = 35) was more likely to have a high-grade histomorphology appearance, extranodal involvement, bone marrow involvement, and whole-body maximum standardized uptake (SUVmax). The machine learning classification models indicated that histomorphology appearance, Ann Arbor stage, lactate dehydrogenase (LDH), and International Prognostic Index (IPI) risk group were independent risk factors for diagnosing HGBL. Patients in the high IPI risk group, who are CD10 positive, and who have extranodal involvement, high LDH, high white blood cell (WBC), bone marrow involvement, old age, advanced Ann Arbor stage, and high SUVmax had a higher risk of death within 1 year. In addition, these models prompt the clinical features with which the patients should be recommended to undergo a FISH test. Furthermore, this study supports that first-line treatment with R-CHOP has dismal efficacy in HGBL. A novel induction therapeutic regimen is still urgently needed to ameliorate the poor outcome of HGBL patients.	[Kong, Hui; Zhu, Haojie; Zheng, Xiaoyun; Ren, Jinhua; Luo, Xiaofeng; Zheng, Jing; Zheng, Zhihong; Chen, Zhizhe; Hu, Jianda; Yang, Ting] Fujian Med Univ Union Hosp, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China; [Jiang, Meichen; Chen, Lushan] Fujian Med Univ Union Hosp, Dept Pathol, Fuzhou, Peoples R China; [Lan, Lingqiong] Second Hosp Longyan, Dept Hematol, Longyan, Peoples R China		Hu, JD; Yang, T (corresponding author), Fujian Med Univ Union Hosp, Fujian Inst Hematol, Dept Hematol, Fujian Prov Key Lab Hematol, Fuzhou, Peoples R China.				National Natural Science Foundation of China [81870138, U2005204]; Startup Fund for Scientific Research Project of Fujian Medical University [2020QH2021]; National Key Clinical Specialty Discipline Construction Program [2021-76]; Clinical Research Center for Hematological Malignancies of Fujian Province [2020Y2006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Startup Fund for Scientific Research Project of Fujian Medical University; National Key Clinical Specialty Discipline Construction Program; Clinical Research Center for Hematological Malignancies of Fujian Province	This work was funded by the National Natural Science Foundation of China (81870138, U2005204), Startup Fund for Scientific Research Project of Fujian Medical University (2020QH2021), National Key Clinical Specialty Discipline Construction Program (2021-76), and Clinical Research Center for Hematological Malignancies of Fujian Province (2020Y2006).	Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; CARBONE PP, 1971, CANCER RES, V31, P1860; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Dunleavy K, 2014, HEMATOL-AM SOC HEMAT, P107, DOI 10.1182/asheducation-2014.1.107; Foot NJ, 2011, J CLIN PATHOL, V64, P802, DOI 10.1136/jclinpath-2011-200015; Green TM, 2012, J CLIN ONCOL, V30, P3460, DOI 10.1200/JCO.2011.41.4342; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hilton LK, 2019, BLOOD, V134, P1528, DOI 10.1182/blood.2019002600; Horn H, 2013, BLOOD, V121, P2253, DOI 10.1182/blood-2012-06-435842; Hu SM, 2013, BLOOD, V121, P4021, DOI 10.1182/blood-2012-10-460063; Johnson NA, 2012, J CLIN ONCOL, V30, P3452, DOI 10.1200/JCO.2011.41.0985; Kidd AC, 2018, BMJ OPEN RESPIR RES, V5, DOI 10.1136/bmjresp-2017-000240; Landsburg DJ, 2017, J CLIN ONCOL, V35, P2260, DOI 10.1200/JCO.2017.72.2157; Landsburg DJ, 2016, CANCER-AM CANCER SOC, V122, P559, DOI 10.1002/cncr.29781; Laude MC, 2021, AM J HEMATOL, V96, P302, DOI 10.1002/ajh.26068; Li SY, 2018, EXPERT REV HEMATOL, V11, P637, DOI 10.1080/17474086.2018.1494567; Li SY, 2013, ADV ANAT PATHOL, V20, P315, DOI 10.1097/PAP.0b013e3182a289f2; LISTER TA, 1989, J CLIN ONCOL, V7, P1630, DOI 10.1200/JCO.1989.7.11.1630; Mationg-Kalaw E, 2012, HISTOPATHOLOGY, V61, P1214, DOI 10.1111/j.1365-2559.2012.04351.x; Novo M, 2019, EXPERT REV HEMATOL, V12, P497, DOI 10.1080/17474086.2019.1624157; Perry AM, 2014, BRIT J HAEMATOL, V165, P382, DOI 10.1111/bjh.12763; Petrich AM, 2014, BLOOD, V124, P2354, DOI 10.1182/blood-2014-05-578963; Pillai RK, 2013, AM J SURG PATHOL, V37, P323, DOI 10.1097/PAS.0b013e31826cebad; Sauerbrei W, 2007, STAT MED, V26, P5512, DOI 10.1002/sim.3148; Scott DW, 2018, BLOOD, V131, P2060, DOI 10.1182/blood-2017-12-820605; Seegmiller AC, 2010, MODERN PATHOL, V23, P909, DOI 10.1038/modpathol.2010.76; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; Swerdlow SH, 2016, BLOOD, V127, P2375, DOI 10.1182/blood-2016-01-643569; Swerdlow SH, 2014, HEMATOL-AM SOC HEMAT, P90, DOI 10.1182/asheducation-2014.1.90; Tsai CC, 2021, CANCERS, V13, DOI 10.3390/cancers13071620; Valera A, 2013, HAEMATOLOGICA, V98, P1554, DOI 10.3324/haematol.2013.086173; Wang W, 2015, AM J SURG PATHOL, V39, P1132, DOI 10.1097/PAS.0000000000000434; [谢微 Xie Wei], 2018, [上海交通大学学报. 医学版, Journal of Shanghai Jiaotong University .Medical Science], V38, P955; Zhang JJ, 2020, AM J SURG PATHOL, V44, P1602, DOI 10.1097/PAS.0000000000001577; Zhang XY, 2019, J CANCER RES CLIN, V145, P117, DOI 10.1007/s00432-018-2771-9	36	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								919012	10.3389/fimmu.2022.919012	http://dx.doi.org/10.3389/fimmu.2022.919012			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X6PF	35686130	Green Published, gold			2022-12-18	WOS:000807573600001
J	Peng, HY; Xing, J; Wang, XH; Ding, XM; Tang, XY; Zou, JL; Wang, SJ; Liu, YZ				Peng, Huiyong; Xing, Jie; Wang, Xuehua; Ding, Xiangmei; Tang, Xinyi; Zou, Junli; Wang, Shengjun; Liu, Yingzhao			Circular RNA circNUP214 Modulates the T Helper 17 Cell Response in Patients With Rheumatoid Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						circular RNA; circNUP214; Th17 cells; IL-23R; rheumatoid arthritis	DISEASE-ACTIVITY; RECEPTOR; DIFFERENTIATION; INTERLEUKIN-23; EXPRESSION	Circular RNAs (circRNAs) are important transcriptional regulators of genome expression that participate in the pathogenesis of human diseases. Mechanistically, circRNAs, as competitive endogenous RNAs (ceRNAs), can sponge microRNAs (miRNAs) with miRNA response elements. A previous study identified that hsa_circ_0089172 (circNUP214) is abnormally expressed in Hashimoto's thyroiditis. However, the role of circNUP214 in rheumatoid arthritis (RA) remains unclear. In total, 28 RA patients and 28 healthy controls were enrolled in this study. We found that circNUP214 is an abundant and stable circRNA in RA patients that can potentially differentiate RA patients from healthy subjects. Additionally, the elevated levels of IL-23R positively correlated with circNUP214 expression. The knockdown of circNUP214 resulted in the reduction of IL-23R at both transcriptional and translational levels in human CD4(+) T cells. The proportion of circulating Th17 cells and the transcript levels of IL-17A were increased in RA patients and were both positively correlated with IL-23R expression. Moreover, positive correlations between the transcript levels of circNUP214 and the percentage of Th17 cells and the transcript levels of IL-17A were observed in RA patients. The downregulation of circNUP214 decreased the proportion of Th17 cells and the transcript levels of IL-17A in vitro. Furthermore, circNUP214 functioned as a ceRNA for miR-125a-3p in RA patients. Taken together, our results indicate that elevated levels of circNUP214 contribute to the Th17 cell response in RA patients.	[Peng, Huiyong; Xing, Jie; Wang, Shengjun] Jiangsu Univ, Zhenjiang Med Sch Nanjing Med Univ, Affiliated Peoples Hosp, Dept Lab Med, Zhenjiang, Peoples R China; [Peng, Huiyong] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Genet Toxicol, Nanjing, Peoples R China; [Wang, Xuehua] Jiangsu Univ, Affiliated Hosp 4, Dept Endocrinol, Zhenjiang, Peoples R China; [Ding, Xiangmei; Zou, Junli; Liu, Yingzhao] Jiangsu Univ, Zhenjiang Med Sch Nanjing Med Univ, Affiliated Peoples Hosp, Dept Endocrinol, Zhenjiang, Peoples R China; [Tang, Xinyi] Mayo Clin, Div Hematol & Internal Med, Rochester, MN USA	Jiangsu University; Nanjing Medical University; Jiangsu University; Jiangsu University; Mayo Clinic	Wang, SJ (corresponding author), Jiangsu Univ, Zhenjiang Med Sch Nanjing Med Univ, Affiliated Peoples Hosp, Dept Lab Med, Zhenjiang, Peoples R China.; Liu, YZ (corresponding author), Jiangsu Univ, Zhenjiang Med Sch Nanjing Med Univ, Affiliated Peoples Hosp, Dept Endocrinol, Zhenjiang, Peoples R China.							Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Aletaha D, 2011, ANN RHEUM DIS, V70, P733, DOI 10.1136/ard.2010.138693; Alvandpur N, 2020, HUM IMMUNOL, V81, P228, DOI 10.1016/j.humimm.2020.02.008; Anderson J, 2012, ARTHRIT CARE RES, V64, P640, DOI 10.1002/acr.21649; ARNBERG AC, 1980, CELL, V19, P313, DOI 10.1016/0092-8674(80)90505-X; Bergstrom B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01384; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Capone A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00348; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Chen X, 2019, THERANOSTICS, V9, P588, DOI 10.7150/thno.29678; Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014; Conn VM, 2017, NAT PLANTS, V3, DOI 10.1038/nplants.2017.53; Derksen VFAM, 2017, SEMIN IMMUNOPATHOL, V39, P437, DOI 10.1007/s00281-017-0627-z; Fang Y, 2018, FUTUR SCI OA, V4, DOI 10.4155/fsoa-2018-0036; Farid SS, 2013, INT J RHEUM DIS, V16, P379, DOI 10.1111/1756-185X.12129; Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006; Fonseca S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030729; Fujita Y, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-02158-3; Gilliam Brooke E, 2012, Expert Opin Med Diagn, V6, P359, DOI 10.1517/17530059.2012.694423; Greenmyer JR, 2020, ACR OPEN RHEUMATOL, V2, P507, DOI 10.1002/acr2.11171; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; HSU MT, 1979, NATURE, V280, P339, DOI 10.1038/280339a0; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Kay J, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4469; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kosik KS, 2013, NATURE, V495, P322, DOI 10.1038/nature11956; Li XY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00131; Liu YZ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01195; Liu YP, 2020, THYROID, V30, P1327, DOI 10.1089/thy.2019.0552; Luo Q, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/2073139; Ma C, 2022, CURR DRUG TARGETS, V23, P330, DOI 10.2174/1389450122666210806124425; McGeachy MJ, 2009, NAT IMMUNOL, V10, P314, DOI 10.1038/ni.1698; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Patel DD, 2015, IMMUNITY, V43, P1040, DOI 10.1016/j.immuni.2015.12.003; Patop IL, 2019, EMBO J, V38, DOI 10.15252/embj.2018100836; Peng HY, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/6401978; Peng HY, 2015, IMMUNOL RES, V62, P129, DOI 10.1007/s12026-015-8643-3; PETERSEN CM, 1992, EXP CELL RES, V201, P160, DOI 10.1016/0014-4827(92)90360-K; Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526; Qian L, 2018, BBA-REV CANCER, V1870, P247, DOI 10.1016/j.bbcan.2018.06.002; Rubbert-Roth A, 2020, NEW ENGL J MED, V383, P1511, DOI 10.1056/NEJMoa2008250; Sallusto F, 2012, EUR J IMMUNOL, V42, P2215, DOI 10.1002/eji.201242741; SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852; Soysal E, 2022, RHEUMATOL INT, V42, P555, DOI 10.1007/s00296-021-04881-9; Takeuchi Y, 2020, IMMUNOL REV, V294, P164, DOI 10.1111/imr.12841; Tang XY, 2016, INFLAMMATION, V39, P759, DOI 10.1007/s10753-016-0304-8; van Hamburg JP, 2018, J AUTOIMMUN, V87, P69, DOI 10.1016/j.jaut.2017.12.006; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Vyas SP, 2019, INT REV IMMUNOL, V38, P212, DOI 10.1080/08830185.2019.1621865; Wen JT, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20193160; Whittingham SF, 2017, ANTIBODIES, V6, DOI 10.3390/antib6020006; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Xiong S, 2019, MOL THER-NUCL ACIDS, V17, P38, DOI 10.1016/j.omtn.2019.05.004; Xu S, 2018, PEERJ, V6, DOI 10.7717/peerj.5503; Yang L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02977; Zhou Z, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1744-5; Zurawska A, 2019, J NEUROIMMUNOL, V334, DOI 10.1016/j.jneuroim.2019.576971	58	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								885896	10.3389/fimmu.2022.885896	http://dx.doi.org/10.3389/fimmu.2022.885896			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X4DT	35686126	Green Published, gold			2022-12-18	WOS:000807407200001
J	Sodhi, EU; Philpott, HT; Carter, MM; Birmingham, TB; Appleton, CT				Sodhi, Emily U.; Philpott, Holly T.; Carter, McKenzie M.; Birmingham, Trevor B.; Appleton, C. Thomas			Sex-Differences and Associations Between Complement Activation and Synovial Vascularization in Patients with Late-Stage Knee Osteoarthritis	FRONTIERS IN IMMUNOLOGY			English	Article						complement; synovium; osteoarthritis; sex-differences; inflammation; histopathology; vascularization	ANGIOGENESIS; SYSTEM; INFLAMMATION; VALIDATION; GENDER	PurposeSynovial inflammation in knee osteoarthritis (OA) causes disorganized synovial angiogenesis and complement activation in synovial fluid, but links between complement and synovial microvascular pathology have not been established. Since complement causes vascular pathology in other diseases and since sex-differences exist in complement activation and in OA, we investigated sex differences in synovial fluid complement factors, synovial tissue vascular pathology, and associations between complement and synovial vascular pathology in patients with late-stage knee OA. MethodsPatients with symptomatic, late-stage radiographic knee OA undergoing total knee arthroplasty or high tibial osteotomy provided matched synovial fluid and tissue biopsies during surgery. Complement factors (C2, C5, adipsin, MBL, and CFI) and terminal complement complex (sC5b-C9) were measured in synovial fluid by multiplex or enzyme-linked immunosorbent assay, respectively. Features of synovial vascular pathology (vascularization, perivascular edema, and vasculopathy) were assessed by histopathology. Multivariate linear regression models were used to assess associations between synovial fluid complement factors and histopathological features of vascular pathology, with adjustment for age, sex, body mass index, and sex interaction. Sex-disaggregated comparisons were completed. ResultsSynovial fluid biomarker and histopathology data were included from 97 patients. Most synovial fluid complement factors and synovial tissue histopathological features were similar between sexes. Synovial fluid C5 trended to lower levels in males (-20.93 ng/mL [95%CI -42.08, 0.23] p=0.05). Median vasculopathy scores (0.42 [95%CI 0.07, 0.77] p=0.02) were higher in males. In the full cohort, C5 concentration was associated with lower vascularization scores (-0.005 [95%CI -0.010, -0.0001] p=0.04) while accounting for sex*C5 interaction. In sex-disaggregated analyses, increased C5 concentration was associated with lower vascularization scores (-0.005 [95%CI -0.009, -0.0001] p=0.04) in male patients, but not in female patients. Males had higher sC5b-C9 compared to females. Additionally, males with high C5 had a higher synovial fluid concentration of sC5b-C9 compared to males with low C5. No differences were found in females. ConclusionHigher synovial fluid C5 levels were associated with increased complement activation and decreased synovial vascularization in males but not in females with OA. Future studies should test whether synovial fluid complement activation suppresses synovial angiogenesis and identify mechanisms accounting for C5-related sex-differences in synovial fluid complement activation in patients with knee OA.	[Sodhi, Emily U.; Carter, McKenzie M.; Appleton, C. Thomas] Western Univ, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada; [Philpott, Holly T.; Birmingham, Trevor B.; Appleton, C. Thomas] Western Univ, Fac Hlth Sci, Hlth & Rehabil Sci, London, ON, Canada; [Philpott, Holly T.; Carter, McKenzie M.; Birmingham, Trevor B.; Appleton, C. Thomas] Western Univ, Bone & Joint Inst, London, ON, Canada; [Appleton, C. Thomas] Western Univ, Schulich Sch Med, Dept Med, London, ON, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Appleton, CT (corresponding author), Western Univ, Schulich Sch Med & Dent, Dept Physiol & Pharmacol, London, ON, Canada.; Appleton, CT (corresponding author), Western Univ, Fac Hlth Sci, Hlth & Rehabil Sci, London, ON, Canada.; Appleton, CT (corresponding author), Western Univ, Bone & Joint Inst, London, ON, Canada.; Appleton, CT (corresponding author), Western Univ, Schulich Sch Med, Dept Med, London, ON, Canada.	tom.appleton@sjhc.london.on.ca	Birmingham, Trevor/G-3409-2013	Birmingham, Trevor/0000-0002-3300-7677	Academic Medical Organization of Southwestern Ontario (AMOSO) [INN17-004]; Canada Research Chairs program; Western University's Bone and Joint Institute; CIHR	Academic Medical Organization of Southwestern Ontario (AMOSO); Canada Research Chairs program(Canada Research Chairs); Western University's Bone and Joint Institute; CIHR(Canadian Institutes of Health Research (CIHR))	This work was funded in part by grants from the Academic Medical Organization of Southwestern Ontario (AMOSO; INN17-004), the Canada Research Chairs program, and Western University's Bone and Joint Institute. HP is supported by Frederick Banting and Charles Best Doctoral Award from CIHR.	Assirelli E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.535010; Ayral X, 2005, OSTEOARTHR CARTILAGE, V13, P361, DOI 10.1016/j.joca.2005.01.005; Baker K, 2010, ANN RHEUM DIS, V69, P1779, DOI 10.1136/ard.2009.121426; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bhattaram P, 2017, SEMIN CELL DEV BIOL, V62, P86, DOI 10.1016/j.semcdb.2016.05.009; Bonnet CS, 2005, RHEUMATOLOGY, V44, P7, DOI 10.1093/rheumatology/keh344; Bossi F, 2014, P NATL ACAD SCI USA, V111, P4209, DOI 10.1073/pnas.1311968111; Cho HJ, 2011, J ARTHROPLASTY, V26, P994, DOI 10.1016/j.arth.2011.01.007; Cho HJ, 2010, CLIN ORTHOP RELAT R, V468, P1749, DOI 10.1007/s11999-010-1282-z; Cohen J., 1988, STAT POWER ANAL BEHA; da Costa MG, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02664; De Bari C, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075-015-0634-1; DiScipio R., 2013, J BIOMED SCI ENG, V6, P1, DOI [10.4236/jbise.2013.68a1001, DOI 10.4236/JBISE.2013.68A1001]; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Farkas I, 2002, J PHYSIOL-LONDON, V539, P537, DOI 10.1113/jphysiol.2001.013381; Gaudenzio N, 2016, J CLIN INVEST, V126, P3981, DOI 10.1172/JCI85538; Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016; Haywood L, 2003, ARTHRITIS RHEUM, V48, P2173, DOI 10.1002/art.11094; Haywood L, 2001, HISTOL HISTOPATHOL, V16, P277, DOI 10.14670/HH-16.277; John T, 2007, HISTOL HISTOPATHOL, V22, P781, DOI 10.14670/HH-22.781; KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kotimaa J, 2016, MOL IMMUNOL, V76, P13, DOI 10.1016/j.molimm.2016.06.004; Langer HF, 2010, BLOOD, V116, P4395, DOI 10.1182/blood-2010-01-261503; Leopold SS, 2003, J BONE JOINT SURG AM, V85A, P1197, DOI 10.2106/00004623-200307000-00003; Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80; Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655; Markiewski MM, 2020, ANTIBODIES, V9, DOI 10.3390/antib9040067; Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257; Minten MJM, 2019, OSTEOARTHR CARTILAGE, V27, P71, DOI 10.1016/j.joca.2018.10.014; Philosophe B, 2014, CLIN TRANSPLANT, V28, P897, DOI 10.1111/ctr.12400; Public Health Agency of Canada, 2020, AG CHRON DIS PROF CA; Rafail S, 2015, J IMMUNOL, V194, P1285, DOI 10.4049/jimmunol.1402354; Rodrigues M, 2019, PHYSIOL REV, V99, P665, DOI 10.1152/physrev.00067.2017; Roemer FW, 2011, ANN RHEUM DIS, V70, P1804, DOI 10.1136/ard.2011.150243; Sarma JV, 2011, CELL TISSUE RES, V343, P227, DOI 10.1007/s00441-010-1034-0; Scanzello CR, 2008, CURR OPIN RHEUMATOL, V20, P565, DOI 10.1097/BOR.0b013e32830aba34; Seelen MA, 2005, J IMMUNOL METHODS, V296, P187, DOI 10.1016/j.jim.2004.11.016; Silawal S, 2018, CLIN MED INSIGHTS-AR, V11, DOI 10.1177/1179544117751430; Sweigard JH, 2014, FASEB J, V28, P3171, DOI 10.1096/fj.14-251041; Wang Q, 2011, NAT MED, V17, P1674, DOI 10.1038/nm.2543; Zhang YQ, 2010, CLIN GERIATR MED, V26, P355, DOI [10.1016/j.cger.2010.03.001, 10.1016/j.rdc.2012.10.004]	42	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								890094	10.3389/fimmu.2022.890094	http://dx.doi.org/10.3389/fimmu.2022.890094			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X5BU	35686134	Green Published, gold			2022-12-18	WOS:000807469900001
J	Su, H; Imai, K; Jia, W; Li, ZG; DiCioccio, RA; Serody, JS; Poe, JC; Chen, BJ; Doan, PL; Sarantopoulos, S				Su, Hsuan; Imai, Kazuhiro; Jia, Wei; Li, Zhiguo; DiCioccio, Rachel A.; Serody, Jonathan S.; Poe, Jonathan C.; Chen, Benny J.; Doan, Phuong L.; Sarantopoulos, Stefanie			Alphavirus Replicon Particle Vaccine Breaks B Cell Tolerance and Rapidly Induces IgG to Murine Hematolymphoid Tumor Associated Antigens	FRONTIERS IN IMMUNOLOGY			English	Article						alphavirus replicon particle; hematolymphoid tumor; B cell tolerance; autoantigen; antitumor antibody; VRP; cancer vaccine	EQUINE ENCEPHALITIS-VIRUS; VERSUS-HOST-DISEASE; AUTOANTIBODY PRODUCTION; MONOCLONAL-ANTIBODIES; ADJUVANT ACTIVITY; DENDRITIC CELLS; CHRONIC GVHD; CANCER; NEU; IMMUNOTHERAPY	De novo immune responses to myeloid and other blood-borne tumors are notably limited and ineffective, making our ability to promote immune responses with vaccines a major challenge. While focus has been largely on cytotoxic cell-mediated tumor eradication, B-cells and the antibodies they produce also have roles in anti-tumor responses. Indeed, therapeutic antibody-mediated tumor cell killing is routinely employed in patients with hematolymphoid cancers, but whether endogenous antibody responses can be incited to blood-born tumors remains poorly studied. A major limitation of immunoglobulin therapies is that cell surface expression of tumor-associated antigen (TAA) targets is dynamic and varied, making promotion of polyclonal, endogenous B cell responses appealing. Since many TAAs are self-antigens, developing tumor vaccines that enable production of antibodies to non-polymorphic antigen targets remains a challenge. As B cell responses to RNA vaccines are known to occur, we employed the Viral Replicon Particles (VRP) which was constructed to encode mouse FLT3. The VRP-FLT3 vaccine provoked a rapid IgG B-cell response to this self-antigen in leukemia and lymphoma mouse models. In addition, IgGs to other TAAs were also produced. Our data suggest that vaccination with RNA viral particle vectors incites a loss of B-cell tolerance that enables production of anti-tumor antibodies. This proof of principle work provides impetus to employ such strategies that lead to a break in B-cell tolerance and enable production of broadly reactive anti-TAA antibodies as potential future therapeutic agents for patients with hematolymphoid cancers.	[Su, Hsuan; Imai, Kazuhiro; Jia, Wei; DiCioccio, Rachel A.; Poe, Jonathan C.; Chen, Benny J.; Doan, Phuong L.; Sarantopoulos, Stefanie] Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27708 USA; [Imai, Kazuhiro] Akita Univ, Grad Sch Med, Dept Thorac Surg, Akita, Japan; [Li, Zhiguo] Duke Univ, Med Ctr, Biostat & Bioinformat, Basic Sci Dept, Durham, NC USA; [Li, Zhiguo; Chen, Benny J.; Doan, Phuong L.; Sarantopoulos, Stefanie] Duke Univ, Duke Canc Inst, Durham, NC 27708 USA; [Serody, Jonathan S.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA; [Serody, Jonathan S.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA; [Serody, Jonathan S.] Univ North Carolina Chapel Hill, Dept Microbiol & Immunol, Chapel Hill, NC USA; [Sarantopoulos, Stefanie] Duke Univ, Sch Med, Dept Immunol, Durham, NC 27708 USA	Duke University; Akita University; Duke University; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Duke University	Sarantopoulos, S (corresponding author), Duke Univ, Med Ctr, Dept Med, Div Hematol Malignancies & Cellular Therapy, Durham, NC 27708 USA.; Sarantopoulos, S (corresponding author), Duke Univ, Duke Canc Inst, Durham, NC 27708 USA.; Sarantopoulos, S (corresponding author), Duke Univ, Sch Med, Dept Immunol, Durham, NC 27708 USA.	stefanie.sarantopoulos@duke.edu	Imai, Kazuhiro/GSE-4264-2022	Imai, Kazuhiro/0000-0003-4490-7862; Poe, Jonathan/0000-0002-7789-1564	Department of Defense, Congressionally Mediated Research Program [W81XWH1-8-1-0239, CA171068]	Department of Defense, Congressionally Mediated Research Program(United States Department of Defense)	This work was funded by the Department of Defense, Congressionally Mediated Research Program W81XWH1-8-1-0239 (CA171068).	Amos SM, 2011, BLOOD, V118, P499, DOI 10.1182/blood-2011-01-325266; Avogadri F, 2014, CANCER IMMUNOL RES, V2, P448, DOI 10.1158/2326-6066.CIR-13-0220; Avogadri F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012670; Barrett AJ, 2010, CLIN EXP IMMUNOL, V161, P223, DOI 10.1111/j.1365-2249.2010.04197.x; Bernstein DI, 2009, VACCINE, V28, P484, DOI 10.1016/j.vaccine.2009.09.135; Burgents JE, 2010, J IMMUNOTHER, V33, P482, DOI 10.1097/CJI.0b013e3181d756bb; Carpentier KS, 2018, CURR OPIN VIROL, V28, P53, DOI 10.1016/j.coviro.2017.11.006; Cervenak L, 2001, IMMUNOL LETT, V78, P89, DOI 10.1016/S0165-2478(01)00239-5; Corbiere V, 2011, CANCER RES, V71, P1253, DOI 10.1158/0008-5472.CAN-10-2693; Crosby EJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001662; Crosby EJ, 2019, CLIN CANCER RES, V25, P2725, DOI 10.1158/1078-0432.CCR-18-3102; Daver N, 2019, LEUKEMIA, V33, P299, DOI 10.1038/s41375-018-0357-9; Davis NL, 2000, J VIROL, V74, P371, DOI 10.1128/JVI.74.1.371-378.2000; Degn SE, 2017, CELL, V170, P913, DOI 10.1016/j.cell.2017.07.026; Durso RJ, 2007, CLIN CANCER RES, V13, P3999, DOI 10.1158/1078-0432.CCR-06-2202; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Garcia-Hernandez MDL, 2007, CANCER RES, V67, P1344, DOI 10.1158/0008-5472.CAN-06-2996; Giltiay NV, 2013, J EXP MED, V210, P2773, DOI 10.1084/jem.20122798; Goldberg SM, 2005, CLIN CANCER RES, V11, P8114, DOI 10.1158/1078-0432.CCR-05-1410; Gulley JL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw261; Jia W, 2021, BLOOD, V137, P2544, DOI 10.1182/blood.2020008040; Jin H, 2016, BLOOD, V127, P2249, DOI 10.1182/blood-2015-09-668145; Johnson LA, 2017, CELL RES, V27, P38, DOI 10.1038/cr.2016.154; Khalil SM, 2014, J VIROL, V88, P9182, DOI 10.1128/JVI.00327-14; Lau CM, 2005, J EXP MED, V202, P1171, DOI 10.1084/jem.20050630; Laust AK, 2007, BREAST CANCER RES TR, V106, P371, DOI 10.1007/s10549-007-9517-8; Lundstrom K, 2014, VIRUSES-BASEL, V6, P2392, DOI 10.3390/v6062392; MacDonald GH, 2000, J VIROL, V74, P914, DOI 10.1128/JVI.74.2.914-922.2000; Mehta RS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00283; Miklos DB, 2005, BLOOD, V105, P2973, DOI 10.1182/blood-2004-09-3660; Moran TP, 2007, VACCINE, V25, P6604, DOI 10.1016/j.vaccine.2007.06.058; Morse MA, 2010, J CLIN INVEST, V120, P3234, DOI 10.1172/JCI42672; Nelson EL, 2003, BREAST CANCER RES TR, V82, P169, DOI 10.1023/B:BREA.0000004373.09678.bb; Nundel K, 2015, J IMMUNOL, V194, P2504, DOI 10.4049/jimmunol.1402425; Osada T, 2012, CANCER IMMUNOL IMMUN, V61, P1941, DOI 10.1007/s00262-012-1248-y; Poe JC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122430; Pushko P, 1997, VIROLOGY, V239, P389, DOI 10.1006/viro.1997.8878; Rayner JO, 2002, REV MED VIROL, V12, P279, DOI 10.1002/rmv.360; Reuschenbach M, 2009, CANCER IMMUNOL IMMUN, V58, P1535, DOI 10.1007/s00262-009-0733-4; Sarantopoulos S, 2015, BLOOD, V125, P1703, DOI 10.1182/blood-2014-12-567834; Sarantopoulos S, 2015, BIOL BLOOD MARROW TR, V21, P16, DOI 10.1016/j.bbmt.2014.10.029; Sharonov GV, 2020, NAT REV IMMUNOL, V20, P294, DOI 10.1038/s41577-019-0257-x; Slovin SF, 2013, VACCINE, V31, P943, DOI 10.1016/j.vaccine.2012.11.096; Small D, 2008, SEMIN HEMATOL, V45, pS17, DOI 10.1053/j.seminhematol.2008.07.007; Srinivasan M, 2012, BLOOD, V119, P1570, DOI 10.1182/blood-2011-07-364414; Suthers AN, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00775; Teo ECY, 2016, CRIT REV ONCOL HEMAT, V97, P72, DOI 10.1016/j.critrevonc.2015.08.014; Thien M, 2004, IMMUNITY, V20, P785, DOI 10.1016/j.immuni.2004.05.010; Thompson JM, 2006, P NATL ACAD SCI USA, V103, P3722, DOI 10.1073/pnas.0600287103; Thompson JM, 2008, VACCINE, V26, P4267, DOI 10.1016/j.vaccine.2008.05.046; Tobon GJ, 2013, AUTOIMMUN DIS, V2013, DOI 10.1155/2013/827254; Tonkin DR, 2012, VACCINE, V30, P4532, DOI 10.1016/j.vaccine.2012.04.030; Tonkin DR, 2010, VACCINE, V28, P3238, DOI 10.1016/j.vaccine.2010.02.010; Wadia PP, 2010, BLOOD, V115, P2077, DOI 10.1182/blood-2009-03-211375; Wang XY, 2005, BREAST CANCER RES, V7, pR145, DOI 10.1186/bcr962; Wang Y, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01311-z; Wardemann H, 2003, SCIENCE, V301, P1374, DOI 10.1126/science.1086907; Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744; Weiner LM, 2009, LANCET, V373, P1033, DOI 10.1016/S0140-6736(09)60251-8; Wu CJ, 2000, J CLIN INVEST, V106, P705, DOI 10.1172/JCI10196; Yang XF, 2002, CANCER RES, V62, P5517; Yang XF, 2001, P NATL ACAD SCI USA, V98, P7492, DOI 10.1073/pnas.131590998	62	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								865486	10.3389/fimmu.2022.865486	http://dx.doi.org/10.3389/fimmu.2022.865486			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X6QD	35686131	Green Published, gold			2022-12-18	WOS:000807576100001
J	Tang, HQ; Yang, D; Zhu, L; Shi, F; Ye, G; Guo, HR; Deng, HD; Zhao, L; Xu, ZW; Li, YL				Tang, Huaqiao; Yang, Dan; Zhu, Ling; Shi, Fei; Ye, Gang; Guo, Hongrui; Deng, Huidan; Zhao, Ling; Xu, Zhiwen; Li, Yinglun			Paeonol Interferes With Quorum-Sensing in Pseudomonas aeruginosa and Modulates Inflammatory Responses In Vitro and In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						paeonol; P; aeruginosa; RAW264; 7; quorum sensing; inflammation	STAPHYLOCOCCUS-AUREUS; MACROPHAGE PLASTICITY; CYSTIC-FIBROSIS; PHAGOCYTOSIS; INFECTION; IMMUNITY; SIGNALS; POLARIZATION; ACTIVATION; RESISTANCE	Developing quorum-sensing (QS) based anti-infection drugs is one of the most powerful strategies to combat multidrug-resistant bacteria. Paeonol has been proven to attenuate the QS-controlled virulence factors of P. aeruginosa by down-regulating the transcription of QS signal molecules. This research aimed to assess the anti-virulence activity and mechanism of paeonol against P. aeruginosa infection in vitro and in vivo. In this study, paeonol was found to reduce the adhesion and invasion of P.aeruginosa to macrophages and resist the cytotoxicity induced by P.aeruginosa. Paeonol reduced the expression of virulence factors of P.aeruginosa by inhibiting QS, thereby reducing the LDH release and damage of P.aeruginosa-infected macrophages. Paeonol can inhibit bacterial virulence and enhance the ability of macrophages to clear P.aeruginosa. In addition, paeonol exerts anti-inflammatory activity by reducing the expression of inflammatory cytokines and increasing the production of anti-inflammatory cytokines. Paeonol treatment significantly inhibited the activation of TLR4/MyD88/NF-kappa B signaling pathway and decreased the inflammation response of P. aeruginosa-infected macrophages. Paeonol also significantly reduced the ability of P.aeruginosa to infect mice and reduced the inflammatory response. These data suggest that paeonol can inhibit the virulence of P.aeruginosa and decrease the inflammation response in P.aeruginosa-infected macrophages and mice, which can decrease the damage induced by P.aeruginosa infection and enhance the ability of macrophages to clear bacteria. This study supports the further development of new potential anti-infective drugs based on inhibition of QS and virulence factors.	[Tang, Huaqiao; Yang, Dan; Zhu, Ling; Shi, Fei; Ye, Gang; Guo, Hongrui; Deng, Huidan; Zhao, Ling; Xu, Zhiwen; Li, Yinglun] Sichuan Agr Univ, Coll Vet Med, Chengdu, Peoples R China	Sichuan Agricultural University	Xu, ZW; Li, YL (corresponding author), Sichuan Agr Univ, Coll Vet Med, Chengdu, Peoples R China.	abtcxzw@126.com; liyinglun02@163.com			International Science and Technology Cooperation Program of Sichuan [2020YFH0143]	International Science and Technology Cooperation Program of Sichuan	Funding This study was supported by the International Science and Technology Cooperation Program of Sichuan: 2020YFH0143.	Aachoui Y, 2013, CURR OPIN MICROBIOL, V16, P319, DOI 10.1016/j.mib.2013.04.004; Adonizio A, 2008, ANTIMICROB AGENTS CH, V52, P198, DOI 10.1128/AAC.00612-07; Antunes JC, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020195; Anwar MA, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.28; Banerjee D, 2004, EUR RESPIR J, V23, P685, DOI 10.1183/09031936.04.00056804; Bassler BL, 2006, CELL, V125, P237, DOI 10.1016/j.cell.2006.04.001; Cohen TS, 2013, J CLIN INVEST, V123, P1630, DOI 10.1172/JCI66142; Davies DG, 1998, SCIENCE, V280, P295, DOI 10.1126/science.280.5361.295; Davies J, 2010, MICROBIOL MOL BIOL R, V74, P417, DOI 10.1128/MMBR.00016-10; Cendra MD, 2020, VIRULENCE, V11, P862, DOI 10.1080/21505594.2020.1787034; Deligianni E, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-38; Epelman S, 2004, J IMMUNOL, V173, P2031, DOI 10.4049/jimmunol.173.3.2031; FLEISZIG SMJ, 1994, INFECT IMMUN, V62, P3485, DOI 10.1128/IAI.62.8.3485-3493.1994; Geisenberger O, 2000, FEMS MICROBIOL LETT, V184, P273, DOI 10.1111/j.1574-6968.2000.tb09026.x; Goodman AL, 2004, CURR OPIN MICROBIOL, V7, P39, DOI 10.1016/j.mib.2003.12.009; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Hao SQ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094946; Harshey RM, 2003, ANNU REV MICROBIOL, V57, P249, DOI 10.1146/annurev.micro.57.030502.091014; Hauser AR, 2011, CLIN MICROBIOL REV, V24, P29, DOI 10.1128/CMR.00036-10; Hilliam Y, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.02108-2016; Huang H, 2008, INFLAMM RES, V57, P189, DOI 10.1007/s00011-007-7190-3; Iwasaki A, 2015, NAT IMMUNOL, V16, P343, DOI 10.1038/ni.3123; Kang CI, 2003, CLIN INFECT DIS, V37, P745, DOI 10.1086/377200; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kharazmi A, 1989, Antibiot Chemother (1971), V42, P42; Levin AS, 1999, CLIN INFECT DIS, V28, P1008, DOI 10.1086/514732; Lin HC, 1999, PLANTA MED, V65, P595, DOI 10.1055/s-1999-14030; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Mesaros N, 2007, CLIN MICROBIOL INFEC, V13, P560, DOI 10.1111/j.1469-0691.2007.01681.x; Miao JF, 2021, J CELL MOL MED, V25, P2885, DOI 10.1111/jcmm.16319; Miller LG, 2005, NEW ENGL J MED, V352, P1445, DOI 10.1056/NEJMoa042683; Moradali MF, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00039; Moussouni M, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79678-0; Murphy TF, 2009, CURR OPIN PULM MED, V15, P138, DOI 10.1097/MCP.0b013e328321861a; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; O'May C, 2011, APPL ENVIRON MICROB, V77, P3061, DOI 10.1128/AEM.02677-10; Pollard AJ, 2004, CELL MICROBIOL, V6, P638, DOI 10.1111/j.1462-5822.2004.00388.x; Rada B, 2013, TRENDS MICROBIOL, V21, P73, DOI 10.1016/j.tim.2012.10.004; Romagne F, 2007, DRUG DISCOV TODAY, V12, P80, DOI 10.1016/j.drudis.2006.11.007; Rudrappa T, 2008, J AGR FOOD CHEM, V56, P1955, DOI 10.1021/jf072591j; Sadikot RT, 2005, AM J RESP CRIT CARE, V171, P1209, DOI 10.1164/rccm.200408-1044SO; Santajit S, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01172; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Singh PK, 2000, NATURE, V407, P762, DOI 10.1038/35037627; Stehling EG, 2008, BRAZ J INFECT DIS, V12, P86, DOI 10.1590/S1413-86702008000100018; Sun MX, 2013, INVEST OPHTH VIS SCI, V54, P3451, DOI 10.1167/iovs.12-10938; Swift S, 1996, TRENDS BIOCHEM SCI, V21, P214; Thurlow LR, 2011, J IMMUNOL, V186, P6585, DOI 10.4049/jimmunol.1002794; Traber KE, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221029; Trinchieri G, 2007, NAT REV IMMUNOL, V7, P179, DOI 10.1038/nri2038; Wang JL, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003697; Yang D, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.692474; Zhang JL, 2013, CELL IMMUNOL, V286, P11, DOI 10.1016/j.cellimm.2013.10.006; Zhang L, 2019, INT IMMUNOPHARMACOL, V72, P413, DOI 10.1016/j.intimp.2019.04.033; Zhang L, 2014, HEPATOB PANCREAT DIS, V13, P138, DOI 10.1016/S1499-3872(14)60024-2; Zhao G, 2017, J CELL MOL MED, V21, P2796, DOI 10.1111/jcmm.13194; Zoumot Z, 2010, CURR OPIN INFECT DIS, V23, P165, DOI 10.1097/QCO.0b013e328335af91	57	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								896874	10.3389/fimmu.2022.896874	http://dx.doi.org/10.3389/fimmu.2022.896874			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X3ZY	35686124	Green Published, gold			2022-12-18	WOS:000807397200001
J	Wang, Q; Tang, HM; Luo, XH; Chen, J; Zhang, XY; Li, XY; Li, YS; Chen, YT; Xu, YA; Han, SX				Wang, Qi; Tang, Hanmin; Luo, Xuehui; Chen, Jie; Zhang, Xinyue; Li, Xinyue; Li, Yuesen; Chen, Yuetong; Xu, Yungang; Han, Suxia			Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						renal clear cell carcinoma (ccRCC); immune checkpoint inhibition; IRPDGs; tumor microenvironment; prognostic biomarker	INTERFERON ALPHA-2A; TUMOR-SUPPRESSOR; PLUS AXITINIB; BREAST-CANCER; OPEN-LABEL; BAP1; SUNITINIB; SURVIVAL; STAGE; MICROENVIRONMENT	As the most common type of renal cell carcinoma (RCC), the renal clear cell carcinoma (ccRCC) is highly malignant and insensitive to chemotherapy or radiotherapy. Although systemic immunotherapies have been successfully applied to ccRCC in recent years, screening for patients who can benefit most from these therapies is still essential and challenging due to immunological heterogeneity of ccRCC patients. To this end, we implemented a series of deep investigation on the expression and clinic data of ccRCC from The Cancer Genome Atlas (TCGA) International Consortium for Cancer Genomics (ICGC). We identified a total of 946 immune-related genes that were differentially expressed. Among them, five independent genes, including SHC1, WNT5A, NRP1, TGFA, and IL4R, were significantly associated with survival and used to construct the immune-related prognostic differential gene signature (IRPDGs). Then the ccRCC patients were categorized into high-risk and low-risk subgroups based on the median risk score of the IRPDGs. IRPDGs subgroups displays distinct genomic and immunological characteristics. Known immunotherapy-related genes show different mutation burden, wherein the mutation rate of VHL was higher than 40% in the two IRPDGs subgroups, and SETD2 and BAP1 mutations differed most between two groups with higher frequency in the high-risk subgroup. Moreover, IRPDGs subgroups had different abundance in tumor-infiltrating immune cells (TIICs) with distinct immunotherapy efficacy. Plasma cells, regulatory cells (Tregs), follicular helper T cells (Tfh), and M0 macrophages were enriched in the high-risk group with a higher tumor immune dysfunction and rejection (TIDE) score. In contrast, the low-risk group had abundant M1 macrophages, mast cell resting and dendritic cell resting infiltrates with lower TIDE score and benefited more from immune checkpoint inhibitors (ICI) treatment. Compared with other biomarkers, such as TIDE and tumor inflammatory signatures (TIS), IRPDGs demonstrated to be a better biomarker for assessing the prognosis of ccRCC and the efficacy of ICI treatment with the promise in screening precise patients for specific immunotherapies.	[Wang, Qi; Tang, Hanmin; Luo, Xuehui; Chen, Jie; Zhang, Xinyue; Li, Xinyue; Li, Yuesen; Chen, Yuetong; Han, Suxia] Xi An Jiao Tong Univ, Dept Radiat Oncol, Affiliated Hosp 1, Xian, Peoples R China; [Xu, Yungang] Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Hlth Sci Ctr, Xian, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University	Han, SX (corresponding author), Xi An Jiao Tong Univ, Dept Radiat Oncol, Affiliated Hosp 1, Xian, Peoples R China.; Xu, YA (corresponding author), Xi An Jiao Tong Univ, Sch Basic Med Sci, Dept Cell Biol & Genet, Hlth Sci Ctr, Xian, Peoples R China.	yungang.xu@xjtu.edu.cn; shan87@mail.xjtu.edu.cn	Xu, Yungang/GWV-2305-2022					Abdel-Rahman MH, 2011, J MED GENET, V48, P856, DOI 10.1136/jmedgenet-2011-100156; Ahn R, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14638; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Badawy AAG, 2015, APMIS, V123, P823, DOI 10.1111/apm.12431; Borcherding N, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-020-01625-6; Braun DA, 2021, CANCER CELL, V39, P632, DOI 10.1016/j.ccell.2021.02.013; Brugarolas J, 2013, CANCER J, V19, P324, DOI 10.1097/PPO.0b013e3182a102d1; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-S4-S11; Choueiri TK, 2021, NEW ENGL J MED, V384, P829, DOI 10.1056/NEJMoa2026982; Choueiri TK, 2020, ANN ONCOL, V31, P1030, DOI [10.1016/j.annonc.2020.04.010, 10.1016/j.annoc.2020.04.010]; Cristescu R, 2022, CLIN CANCER RES, V28, P1680, DOI 10.1158/1078-0432.CCR-21-3329; Dannenmann SR, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23562; DeHaan AM, 2009, PROSTATE, V69, P528, DOI 10.1002/pros.20903; Diaz-Montero CM, 2020, NAT REV NEPHROL, V16, P721, DOI 10.1038/s41581-020-0316-3; Fahey CC, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026468; Frank I, 2002, J UROLOGY, V168, P2395, DOI 10.1016/S0022-5347(05)64153-5; Garcia CGJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.769385; Giraldo NA, 2015, CLIN CANCER RES, V21, P3031, DOI 10.1158/1078-0432.CCR-14-2926; Giricz O, 2013, INT J CANCER, V133, P2587, DOI 10.1002/ijc.28295; Gong J, 2016, ASIAN J UROL, V3, P286, DOI 10.1016/j.ajur.2016.08.006; Grossman SR, 2007, CLIN CANCER RES, V13, P5798, DOI 10.1158/1078-0432.CCR-07-0073; Gulati S, 2014, EUR UROL, V66, P936, DOI 10.1016/j.eururo.2014.06.053; Hanze J, 2020, TARGET ONCOL, V15, P377, DOI 10.1007/s11523-020-00728-8; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x; Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809; Hong CS, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.762095; Horsophonphong S, 2021, J APPL ORAL SCI, V29, DOI 10.1590/1678-7757-2020-1074; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Hutson TE, 2013, LANCET ONCOL, V14, P1287, DOI 10.1016/S1470-2045(13)70465-0; Jamieson NB, 2017, CANCER GENE THER, V24, P134, DOI 10.1038/cgt.2016.63; Jansen CS, 2019, NATURE, V576, P465, DOI 10.1038/s41586-019-1836-5; Janzen NK, 2003, UROL CLIN N AM, V30, P843, DOI 10.1016/S0094-0143(03)00056-9; Ji ZW, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007344; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jin Y, 2013, DNA CELL BIOL, V32, P302, DOI 10.1089/dna.2013.1977; Junttila IS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00888; Kim MC, 2021, CANCERS, V13, DOI 10.3390/cancers13225856; Krishna C, 2021, CANCER CELL, V39, P662, DOI 10.1016/j.ccell.2021.03.007; Landry AP, 2021, J CLIN PATHOL, DOI 10.1136/jclinpath-2021-207952; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Lei X, 2020, CANCER LETT, V470, P126, DOI 10.1016/j.canlet.2019.11.009; Li YS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071151; Liu Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0260103; Masclef L, 2021, CELL DEATH DIFFER, V28, P606, DOI 10.1038/s41418-020-00709-4; Matek TR, 2008, ANNU REV IMMUNOL, V26, P453, DOI 10.1146/annurev.immunol.26.021607.090357; Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755; MINASIAN LM, 1993, J CLIN ONCOL, V11, P1368, DOI 10.1200/JCO.1993.11.7.1368; Mollica V, 2019, CANCERS, V11, DOI 10.3390/cancers11060830; Moore LE, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002312; Morin E, 2020, J PATHOL, V250, P387, DOI 10.1002/path.5380; Motzer RJ, 2018, NEW ENGL J MED, V378, P1277, DOI 10.1056/NEJMoa1712126; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530; Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.20.1.289; Motzer R, 2021, NEW ENGL J MED, V384, P1289, DOI 10.1056/NEJMoa2035716; Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047; Motzer RJ, 2015, J CLIN ONCOL, V33, P1430, DOI 10.1200/JCO.2014.59.0703; Murakami T, 2021, CANCER IMMUNOL IMMUN, V70, P3001, DOI 10.1007/s00262-021-03006-2; Murali R, 2013, PATHOLOGY, V45, P116, DOI 10.1097/PAT.0b013e32835d0efb; Negrier S, 1998, NEW ENGL J MED, V338, P1272, DOI 10.1056/NEJM199804303381805; Newbold RF, 2010, ANTICANCER RES, V30, P3309; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Pan QF, 2020, J CANCER, V11, P3207, DOI 10.7150/jca.37285; Powles T, 2020, LANCET ONCOL, V21, P1563, DOI 10.1016/S1470-2045(20)30436-8; Qin ZL, 2016, J CELL PHYSIOL, V231, P120, DOI 10.1002/jcp.25060; Remark R, 2013, CLIN CANCER RES, V19, P4079, DOI 10.1158/1078-0432.CCR-12-3847; Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Senbabaoglu Y, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1092-z; Shen CQ, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2020.106274; Tomita Y, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.6_suppl.301; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9; van den Heuvel CNAM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00117; Ventii KH, 2008, CANCER RES, V68, P6953, DOI 10.1158/0008-5472.CAN-08-0365; Vuong L, 2019, CANCER DISCOV, V9, P1349, DOI 10.1158/2159-8290.CD-19-0499; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Zhang XT, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.643362; Zhao YB, 2020, CARCINOGENESIS, V41, P274, DOI 10.1093/carcin/bgz147; Zheng B, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.760031	83	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								890150	10.3389/fimmu.2022.890150	http://dx.doi.org/10.3389/fimmu.2022.890150			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X4QS	35686121	gold, Green Published			2022-12-18	WOS:000807441000001
J	Wang, YJ; Wei, H; Shen, LP; Su, XH; Liu, J; Xu, XF; Li, M; Yang, L; Liu, JY; Wang, AN; Jiang, Y; Peng, FH				Wang, Yijie; Wei, Hang; Shen, Liping; Su, Xiaohong; Liu, Jia; Xu, Xiaofeng; Li, Min; Yang, Lu; Liu, Junyu; Wang, Anni; Jiang, Ying; Peng, Fuhua			Immunological Predictors of Post Infectious Inflammatory Response Syndrome in HIV-Negative Immunocompetent Cryptococcal Meningitis	FRONTIERS IN IMMUNOLOGY			English	Article						cryptococcal meningitis; HIV-negative; immunocompetent; postinfectious inflammatory response syndrome; predictor	COLONY-STIMULATING FACTOR; ANTIRETROVIRAL THERAPY	ObjectiveThis research aims to study the correlation between serum immune factors and post-infectious inflammatory response syndrome (PIIRS) in immunocompetent cryptococcal meningitis (CM), and explore whether serum immune factors could be used to predict the development of PIIRS. MethodsA cohort of 30 patients with PIIRS and 87 patients without PIIRS was selected from 347 CM patients. We analyzed the general clinical information and immunological indexes (cytokines, complement, immunoglobulin, inflammation, related cytological and biochemical indexes). Spearman correlation analysis and principal component analysis were used to explore the effects of the variables on PIIRS. Additionally, the variables were identified by a random forest-based classifier for predicting the development of PIIRS. The clinical value of predictors was verified by survival analysis. ResultsCompared with patients without PIIRS, patients with PIIRS had lower baseline serum interleukin-6 (IL-6, P = 0.006), immunoglobulin M (IgM, P = 0.004), and a higher baseline neutrophil ratio (P <0.001). The baseline neutrophil ratio (r = 0.359, P = 0.001), IgM (r = -0.272, P = 0.025), and IL-6 (r = -0.259, P = 0.027) were significantly correlated with PIIRS. Combining principal component analysis and random forest results, neutrophil ratio, neutrophil count, IgM, IL-6, and D-dimer were useful predictors. The accuracy of random forest prediction was 75.00%, AUC, and sensitivity were 0.76 and 70%, respectively. Further survival analysis of the time from treatment to PIIRS revealed that the development of PIIRS was associated with IgM (more than 98 days of treatment) and neutrophil ratio/count. ConclusionBaseline neutrophils ratio, neutrophil count, IgM, IL-6, and D-dimer may be clinically useful predictors of PIIRS in HIV-negative immunocompetent CM patients.	[Wang, Yijie; Shen, Liping; Su, Xiaohong; Liu, Jia; Xu, Xiaofeng; Li, Min; Yang, Lu; Liu, Junyu; Wang, Anni; Jiang, Ying; Peng, Fuhua] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurol, Guangzhou, Peoples R China; [Wei, Hang] Guangzhou Univ Chinese Med, Sch Med Informat Engn, Guangzhou, Peoples R China	Sun Yat Sen University; Guangzhou University of Chinese Medicine	Jiang, Y; Peng, FH (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Neurol, Guangzhou, Peoples R China.	jiangy9@mail.sysu.edu.cn; pengfh@mail.sysu.edu.cn	Jiang, Ying/GPK-7637-2022	Liu, Junyu/0000-0001-8291-9720	China Postdoctoral Science Foundation [2019M660230]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study is supported by the general program of the China Postdoctoral Science Foundation (No. 2019M660230).	Anjum S, 2019, CURR FUNGAL INFECT R, V13, P99, DOI 10.1007/s12281-019-00345-7; Bahr NC, 2014, BIOMARK MED, V8, P1085, DOI [10.2217/BMM.14.67, 10.2217/bmm.14.67]; Boulware DR, 2011, J INFECT DIS, V203, P1637, DOI 10.1093/infdis/jir134; Boulware DR, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000384; Chai HC, 2009, MYCOSES, V52, P166, DOI 10.1111/j.1439-0507.2008.01549.x; Chang CC, 2013, J INFECT DIS, V208, P898, DOI 10.1093/infdis/jit271; Chen GH, 2007, AM J PATHOL, V170, P1028, DOI 10.2353/ajpath.2007.060595; Elsegeiny W, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00651; Gaiottino J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075091; Gressler AE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.709695; Jarvis JN, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004754; Kaufman-Francis K, 2018, AM J PATHOL, V188, P1653, DOI 10.1016/j.ajpath.2018.03.015; Liu J, 2021, J NEUROL NEUROSUR PS, V92, P680, DOI 10.1136/jnnp-2020-324921; Liu J, 2020, FUTURE MICROBIOL, V15, P613, DOI 10.2217/fmb-2019-0252; Ma J, 2020, CLIN IMMUNOL, V214, DOI 10.1016/j.clim.2020.108408; Musubire AK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209337; Neal LM, 2017, MBIO, V8, DOI 10.1128/mBio.01415-17; Lien NTK, 2021, CLIN EXP MED, DOI 10.1007/s10238-021-00774-0; Nidhi A., 2017, BMJ CASE REP, V2017, DOI [10.1093/cid/ciw739, DOI 10.1093/CID/CIW739]; Panackal AA, 2017, CLIN INFECT DIS, V64, P275, DOI 10.1093/cid/ciw739; Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858; Pyrgos V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056269; ROILIDES E, 1991, J INFECT DIS, V163, P579, DOI 10.1093/infdis/163.3.579; Sereti I, 2020, CLIN INFECT DIS, V71, P652, DOI 10.1093/cid/ciz877; Soni M, 2020, DIABETES METAB SYND, V14, P2245, DOI 10.1016/j.dsx.2020.11.007; Subramaniam KS, 2010, J IMMUNOL, V184, P5755, DOI 10.4049/jimmunol.0901638; Williamson Peter R, 2015, Macrophage (Houst), V2; Williamson PR, 2017, NAT REV NEUROL, V13, P13, DOI 10.1038/nrneurol.2016.167; Zhang KM, 2021, MYCOPATHOLOGIA, V186, P857, DOI 10.1007/s11046-021-00553-1	29	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 24	2022	13								895456	10.3389/fimmu.2022.895456	http://dx.doi.org/10.3389/fimmu.2022.895456			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X6LW	35686135	gold, Green Published			2022-12-18	WOS:000807564900001
J	Deng, MY; Li, Y; Li, YL; Mao, XL; Ke, H; Liang, WL; Lei, XG; Lau, YL; Mao, HW				Deng, Mengyue; Li, Yue; Li, Yulu; Mao, Xiaolan; Ke, Han; Liang, Weiling; Lei, Xiaoguang; Lau, Yu-Lung; Mao, Huawei			A Novel STAT3 Gain-of-Function Mutation in Fatal Infancy-Onset Interstitial Lung Disease	FRONTIERS IN IMMUNOLOGY			English	Article						STAT3; gain-of-function mutation; interstitial lung disease; autoimmune disease; STAT3 inhibitor; JAK inhibitor		Signal transducer and activator of transcription 3 (STAT3) gain-of-function (GOF) mutations cause early-onset immune dysregulation syndrome, characterized by multi-organ autoimmunity and lymphoproliferation. Of them, interstitial lung disease (ILD) usually develops after the involvement of other organs, and the onset time is childhood and beyond rather than infancy. Here, we reported a patient who presented with fatal infancy-onset ILD, finally succumbing to death. Next-generation sequencing identified a novel heterozygous mutation in STAT3 (c.989C>G, p.P330R). Functional experiments revealed it was a gain-of-function mutation. Upon interleukin 6 stimulation, this mutation caused a much higher activation of STAT3 than the wild-type control. In addition, the mutation also activated STAT3 under the steady state. The T helper 17 cell level in the patient was significantly higher than that in normal controls, which may contribute to the autoimmune pathology caused by the STAT3(P330R) mutation. Apart from Janus kinase (JAK) inhibitors, we also provided experimental evidence of a STAT3 selective inhibitor (Stattic) effectively suppressing the activation of mutant STAT3 in vitro. Collectively, our study expanded the clinical spectrum of STAT3 GOF syndrome. STAT3 GOF mutation appears as a new etiology of ILD and should be considered in patients with early-onset ILDs. In addition to JAK inhibitors, the specific STAT3 inhibitor would be an appealing option for the targeted treatment.	[Deng, Mengyue; Li, Yue; Li, Yulu; Mao, Xiaolan; Mao, Huawei] Chongqing Med Univ, Dept Pediat Res Inst, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ Key Lab Child Dev & Disorders,Children, Chongqing, Peoples R China; [Ke, Han; Lei, Xiaoguang] Peking Univ, Coll Chem & Mol Engn, Synthet & Funct Biomol Ctr, Dept Chem Biol,Beijing Natl Lab Mol Sci,Key Lab Bi, Beijing, Peoples R China; [Liang, Weiling; Lau, Yu-Lung] Univ Hong Kong, Shenzhen Hosp, Dept Pediat, Shenzhen, Peoples R China; [Lau, Yu-Lung] Univ Hong Kong, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China; [Ke, Han; Lei, Xiaoguang] Peking Univ, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China	Chongqing Medical University; Peking University; University of Hong Kong; University of Hong Kong; Peking University	Mao, HW (corresponding author), Chongqing Med Univ, Dept Pediat Res Inst, Natl Clin Res Ctr Child Hlth & Disorders, Minist Educ Key Lab Child Dev & Disorders,Children, Chongqing, Peoples R China.	maohwei@qq.com						Cortes-Santiago N, 2021, PEDIATR DEVEL PATHOL, V24, P227, DOI 10.1177/1093526620980615; Deenick EK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00168; Dong C, 2008, NAT REV IMMUNOL, V8, P337, DOI 10.1038/nri2295; Erdos M, 2021, CLIN EXP IMMUNOL, V205, P354, DOI 10.1111/cei.13625; Fabre A, 2019, J ALLER CL IMM-PRACT, V7, P1958, DOI 10.1016/j.jaip.2019.02.018; Fabre A, 2018, AM J RESP CRIT CARE, V197, pE22, DOI 10.1164/rccm.201707-1500IM; Flanagan SE, 2014, NAT GENET, V46, P812, DOI 10.1038/ng.3040; Forbes LR, 2018, J ALLERGY CLIN IMMUN, V142, P1665, DOI 10.1016/j.jaci.2018.07.020; Gadina M, 2019, RHEUMATOLOGY, V58, P4, DOI 10.1093/rheumatology/key432; Giovannini-Chami L, 2019, RHEUMATOLOGY, V58, P365, DOI 10.1093/rheumatology/key308; Gothe F, 2021, PEDIATR PULM, V56, P3934, DOI 10.1002/ppul.25684; Gutierrez M, 2018, MOL CELL ENDOCRINOL, V473, P166, DOI 10.1016/j.mce.2018.01.016; Haapaniemi EM, 2015, BLOOD, V125, P639, DOI 10.1182/blood-2014-04-570101; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Lin L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-217; Mauracher AA, 2020, J ALLERGY CLIN IMMUN, V145, P1297, DOI 10.1016/j.jaci.2019.11.042; Mertens C, 2015, P NATL ACAD SCI USA, V112, P14811, DOI 10.1073/pnas.1515876112; Milner JD, 2015, BLOOD, V125, P591, DOI 10.1182/blood-2014-09-602763; O'Shea JJ, 2011, NAT REV IMMUNOL, V11, P239, DOI 10.1038/nri2958; Sarfati E, 2021, J CLIN IMMUNOL, V41, P807, DOI 10.1007/s10875-020-00914-3; Silva-Carmona M, 2020, AM J RESP CRIT CARE, V202, P893, DOI 10.1164/rccm.201906-1204LE; Tanita K, 2021, J CLIN IMMUNOL, V41, P780, DOI 10.1007/s10875-021-00975-y; Weinreich MA, 2017, FRONT PEDIATR, V5, DOI 10.3389/fped.2017.00049; Wienke J, 2015, ONCOTARGET, V6, P20037, DOI 10.18632/oncotarget.5042	24	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								866638	10.3389/fimmu.2022.866638	http://dx.doi.org/10.3389/fimmu.2022.866638			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W2QZ	35677041	gold, Green Published			2022-12-18	WOS:000806623400001
J	Fan, XX; Wu, Q				Fan, Xing-Xing; Wu, Qiang			Decoding Lung Cancer at Single-Cell Level	FRONTIERS IN IMMUNOLOGY			English	Review						lung cancer; single-cell analysis; scRNA-seq; tumor microenvironment; drug resistance	CIRCULATING TUMOR-CELLS; LANDSCAPE	Lung cancer is the leading cause of cancer death due to its high degree of malignancy, rapid growth, and early metastasis. Recent studies have found that lung cancer has a high degree of heterogeneity which is characterized by the mixture of different tumor cell types. However, the driving genetic/epigenetic mechanism of lung cancer heterogeneity, how different types of cells interact, and the relationship between heterogeneity and drug resistance have been poorly understood. Single-cell technology can decompose high throughput sequencing information into each cell and provide single-cell information in high resolution. By using single-cell analysis, researchers can not only fully understand the molecular characteristics of different cell types in the same tissue, but also define completely new cell types. Thus, single-cell analysis has been widely utilized in systems biology, drug discovery, disease diagnosis and precision medicine. We review recent exploration of the mechanism of heterogeneity, tumor microenvironment and drug resistance in lung cancer by using single-cell analysis. We propose that the recent findings may pave new ways for the treatment strategies of lung cancer.	[Fan, Xing-Xing] Macau Univ Sci & Technol, Dr Nehers Biophys Lab Innovat Drug Discovery, State Key Lab Qual Res Chinese Med, Macau, Peoples R China; [Wu, Qiang] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China	Macau University of Science & Technology; Macau University of Science & Technology	Fan, XX (corresponding author), Macau Univ Sci & Technol, Dr Nehers Biophys Lab Innovat Drug Discovery, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.; Wu, Q (corresponding author), Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.	xxfan@must.edu.mo; qwu@must.edu.mo		Wu, Qiang/0000-0003-2049-1639	Macau Science and Technology Development Fund project [0003/2018/A1, 0058/2020/A2]; Macau University of Science and Technology foundation [0072/2019/A2, FRG-20-003-SKL]; Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery [001/2020/ALC]	Macau Science and Technology Development Fund project; Macau University of Science and Technology foundation; Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery	This work was funded by Macau Science and Technology Development Fund project (Grant no. 0003/2018/A1 and 0058/2020/A2) and Macau University of Science and Technology foundation (Grant no. FRG-20-003-SKL) granted to Dr. Xing-Xing Fan. Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery (Grant no. 001/2020/ALC). Qiang Wu is supported by Macau University of Science and Technology foundation (0072/2019/A2).	Chan JM, 2021, CANCER CELL, V39, P1479, DOI 10.1016/j.ccell.2021.09.008; Chen J, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02064-6; Chong ZX, 2021, J CHIN MED ASSOC, V84, P563, DOI 10.1097/JCMA.0000000000000535; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Darragh LB, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03154; Desa DE, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07713-4; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; Garrido-Martin EM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000778; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Haque A, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0467-4; Hunter MV, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26614-z; Kim KT, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0692-3; Kim N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16164-1; Lambrechts D, 2018, NAT MED, V24, P1277, DOI 10.1038/s41591-018-0096-5; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Leader AM, 2021, CANCER CELL, V39, P1594, DOI 10.1016/j.ccell.2021.10.009; Li JS, 2020, J GENET GENOMICS, V47, P373, DOI 10.1016/j.jgg.2020.06.006; Lu T, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-00200-x; Mantri M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21892-z; Maynard A, 2020, CELL, V182, P1232, DOI 10.1016/j.cell.2020.07.017; Murciano-Goroff YR, 2020, CELL RES, V30, P507, DOI 10.1038/s41422-020-0337-2; Neophytou CM, 2021, CANCERS, V13, DOI 10.3390/cancers13092053; Ni XH, 2013, P NATL ACAD SCI USA, V110, P21083, DOI 10.1073/pnas.1320659110; Petitprez F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00784; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Stewart CA, 2020, NAT CANCER, V1, P423, DOI 10.1038/s43018-019-0020-z; Stuart T, 2019, NAT REV GENET, V20, P257, DOI 10.1038/s41576-019-0093-7; Su Z, 2019, CLIN CANCER RES, V25, P5049, DOI 10.1158/1078-0432.CCR-18-3571; Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/NMETH.1315, 10.1038/nmeth.1315]; Vistain LF, 2021, TRENDS BIOCHEM SCI, V46, P661, DOI 10.1016/j.tibs.2021.01.013; Wang Y, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21409-8; Wu FY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22801-0; Wu QZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg1850; Yousefi M, 2020, CELL ONCOL, V43, P31, DOI 10.1007/s13402-019-00470-y; Zhu CX, 2020, NAT METHODS, V17, P11, DOI 10.1038/s41592-019-0691-5; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009	37	0	0	9	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								883758	10.3389/fimmu.2022.883758	http://dx.doi.org/10.3389/fimmu.2022.883758			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W4RQ	35677034	gold, Green Published			2022-12-18	WOS:000806762700001
J	Shabgah, AG; Jadidi-Niaragh, F; Mohammadi, H; Ebrahimzadeh, F; Oveisee, M; Jahanara, A; Navashenaq, JG				Gowhari Shabgah, Arezoo; Jadidi-Niaragh, Farhad; Mohammadi, Hamed; Ebrahimzadeh, Farnoosh; Oveisee, Maziar; Jahanara, Abbas; Gholizadeh Navashenaq, Jamshid			The Role of Atypical Chemokine Receptor D6 (ACKR2) in Physiological and Pathological Conditions; Friend, Foe, or Both?	FRONTIERS IN IMMUNOLOGY			English	Review						ACKR2; cancer; inflammation; atypical chemokine receptor D6; infection	MONOCYTE CHEMOATTRACTANT PROTEIN-1; TRAUMATIC BRAIN-INJURY; VIRUS TYPE-1 HIV-1; SYSTEMIC-SCLEROSIS; IMMUNE SURVEILLANCE; SCAVENGER RECEPTOR; CUTTING EDGE; LYMPH-NODES; INFLAMMATION; EXPRESSION	Chemokines exert crucial roles in inducing immune responses through ligation to their canonical receptors. Besides these receptors, there are other atypical chemokine receptors (ACKR1-4) that can bind to a wide range of chemokines and carry out various functions in the body. ACKR2, due to its ability to bind various CC chemokines, has attracted much attention during the past few years. ACKR2 has been shown to be expressed in different cells, including trophoblasts, myeloid cells, and especially lymphoid endothelial cells. In terms of molecular functions, ACKR2 scavenges various inflammatory chemokines and affects inflammatory microenvironments. In the period of pregnancy and fetal development, ACKR2 plays a pivotal role in maintaining the fetus from inflammatory reactions and inhibiting subsequent abortion. In adults, ACKR2 is thought to be a resolving agent in the body because it scavenges chemokines. This leads to the alleviation of inflammation in different situations, including cardiovascular diseases, autoimmune diseases, neurological disorders, and infections. In cancer, ACKR2 exerts conflicting roles, either tumor-promoting or tumor-suppressing. On the one hand, ACKR2 inhibits the recruitment of tumor-promoting cells and suppresses tumor-promoting inflammation to blockade inflammatory responses that are favorable for tumor growth. In contrast, scavenging chemokines in the tumor microenvironment might lead to disruption in NK cell recruitment to the tumor microenvironment. Other than its involvement in diseases, analyzing the expression of ACKR2 in body fluids and tissues can be used as a biomarker for diseases. In conclusion, this review study has tried to shed more light on the various effects of ACKR2 on different inflammatory conditions.	[Gowhari Shabgah, Arezoo] Bam Univ Med Sci, Sch Med, Bam, Iran; [Jadidi-Niaragh, Farhad] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz, Iran; [Jadidi-Niaragh, Farhad] Tabriz Univ Med Sci, Fac Med, Dept Immunol, Tabriz, Iran; [Mohammadi, Hamed] Alborz Univ Med Sci, Sch Med, Dept Immunol, Karaj, Iran; [Mohammadi, Hamed] Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran; [Ebrahimzadeh, Farnoosh] Mashhad Univ Med Sci, Fac Med, Dept Internal Med, Mashhad, Iran; [Oveisee, Maziar; Jahanara, Abbas] Bam Univ Med Sci, Pastor Educ Hosp, Clin Res Ctr, Bam, Iran; [Gholizadeh Navashenaq, Jamshid] Bam Univ Med Sci, Noncommunicable Dis Res Ctr, Bam, Iran	Tabriz University of Medical Science; Tabriz University of Medical Science; Mashhad University Medical Science	Navashenaq, JG (corresponding author), Bam Univ Med Sci, Noncommunicable Dis Res Ctr, Bam, Iran.		Oveisee, Maziar/HGA-4929-2022	Gholizadeh Navashenaq, Jamshid/0000-0002-3073-5302				Ahola-Olli AV, 2017, AM J HUM GENET, V100, P40, DOI 10.1016/j.ajhg.2016.11.007; Algood HMS, 2003, CYTOKINE GROWTH F R, V14, P467, DOI 10.1016/S1359-6101(03)00054-6; Alves JC, 2008, SHOCK, V30, P3, DOI 10.1097/SHK.0b013e3181818466; Amiresmaili S, 2021, ECOTOX ENVIRON SAFE, V213, DOI 10.1016/j.ecoenv.2021.111987; Azuma A, 2005, AM J RESP CELL MOL, V32, P93, DOI 10.1165/rcmb.2003-0374OC; Bachelerie F, 2014, NAT IMMUNOL, V15, P207, DOI 10.1038/ni.2812; Bacon K, 2002, J INTERF CYTOK RES, V22, P1067; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bandinelli F, 2012, CLIN EXP RHEUMATOL, V30, pS44; Bazzan E, 2013, CHEST, V143, P98, DOI 10.1378/chest.11-3220; Bideak A, 2018, KIDNEY INT, V93, P826, DOI 10.1016/j.kint.2017.11.013; Birbrair A, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt512; Blackburn PE, 2004, BIOCHEM J, V379, P263, DOI 10.1042/BJ20031266; Bodduluri SR, 2018, CANCER IMMUNOL RES, V6, P332, DOI 10.1158/2326-6066.CIR-17-0424; Bonecchi R, 2004, J IMMUNOL, V172, P4972, DOI 10.4049/jimmunol.172.8.4972; Bonecchi R, 2008, BLOOD, V112, P493, DOI 10.1182/blood-2007-08-108316; Bonecchi R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00224; Bordon Y, 2009, J IMMUNOL, V182, P5032, DOI 10.4049/jimmunol.0802802; Borroni EM, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003627; Bulmer JN, 2010, INT J DEV BIOL, V54, P281, DOI 10.1387/ijdb.082763jb; Butenko S, 2021, FASEB J, V35, DOI 10.1096/fj.202002395RR; Cardani A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006140; Carvalheiro T, 2018, INFLAMM RES, V67, P169, DOI 10.1007/s00011-017-1106-7; Chevigne A, 2021, CANCERS, V13, DOI 10.3390/cancers13051054; Cho Geum Joon, 2015, Obstet Gynecol Sci, V58, P333, DOI 10.5468/ogs.2015.58.5.333; Chow MT, 2012, SEMIN CANCER BIOL, V22, P23, DOI 10.1016/j.semcancer.2011.12.004; Cochain C, 2012, ARTERIOSCL THROM VAS, V32, P2206, DOI 10.1161/ATVBAHA.112.254409; Codullo V, 2011, ANN RHEUM DIS, V70, P1115, DOI 10.1136/ard.2010.137349; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Crosslin DR, 2013, HUM MOL GENET, V22, P2119, DOI 10.1093/hmg/ddt010; Culley FJ, 2006, J VIROL, V80, P8151, DOI 10.1128/JVI.00496-06; da Silva JM, 2019, CYTOKINE, V118, P160, DOI 10.1016/j.cyto.2018.03.001; Dalli J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01400; Darby IA, 2014, CLIN COSMET INV DERM, V7, P301, DOI 10.2147/CCID.S50046; de la Torre YM, 2007, P NATL ACAD SCI USA, V104, P2319, DOI 10.1073/pnas.0607514104; de Martino M, 2019, FRONT PEDIATR, V7, DOI 10.3389/fped.2019.00350; De Souza CT, 2005, ENDOCRINOLOGY, V146, P4192, DOI 10.1210/en.2004-1520; Di Liberto D, 2008, J EXP MED, V205, P2075, DOI 10.1084/jem.20070608; Dietrich T, 2010, J IMMUNOL, V184, P535, DOI 10.4049/jimmunol.0903180; Distler JHW, 2006, ARTHRITIS RHEUM-US, V54, P214, DOI 10.1002/art.21497; Distler O, 2008, RHEUMATOLOGY, V47, pV1, DOI 10.1093/rheumatology/ken351; Drake PM, 2004, DEV DYNAM, V229, P877, DOI 10.1002/dvdy.10477; Duan ZJ, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00506-6; Fantini MC, 2008, CURR DRUG TARGETS, V9, P375, DOI 10.2174/138945008784221206; Fioravante M, 2019, BBA-MOL BASIS DIS, V1865, P1126, DOI 10.1016/j.bbadis.2019.01.001; Freire MO, 2013, PERIODONTOL 2000, V63, P149, DOI 10.1111/prd.12034; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; Gabuzda D, 1998, SEMIN IMMUNOL, V10, P203, DOI 10.1006/smim.1998.0133; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gouon-Evans V, 2000, DEVELOPMENT, V127, P2269; Gouraud SS, 2011, J HYPERTENS, V29, P732, DOI 10.1097/HJH.0b013e328344224d; Granot Z, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01710; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Gulubova M, 2009, J GASTROEN HEPATOL, V24, P1265, DOI 10.1111/j.1440-1746.2007.05009.x; Hajrasouliha AR, 2013, MOL VIS, V19, P2517; Han ZP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179677; Hansell CAH, 2015, IMMUNOL CELL BIOL, V93, P167, DOI 10.1038/icb.2014.90; Hansell CAH, 2011, BLOOD, V117, P5413, DOI 10.1182/blood-2010-11-317115; Hansell CAH, 2020, EUR J IMMUNOL, V50, P666, DOI 10.1002/eji.201948374; Hansell CAH, 2018, J IMMUNOL, V201, P2510, DOI 10.4049/jimmunol.1800131; Hewit KD, 2014, J BIOL CHEM, V289, P12330, DOI 10.1074/jbc.M113.534545; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Hou T, 2013, GYNECOL ONCOL, V130, P181, DOI 10.1016/j.ygyno.2013.04.015; Ishii M, 2000, AM J REPROD IMMUNOL, V44, P365, DOI 10.1111/j.8755-8920.2000.440608.x; Joo P, 2014, J IMMUNOL, V193, P5218, DOI 10.4049/jimmunol.1401096; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kania G, 2019, NAT REV RHEUMATOL, V15, P288, DOI 10.1038/s41584-019-0212-z; Kaufmann SHE, 2013, CURR OPIN IMMUNOL, V25, P441, DOI 10.1016/j.coi.2013.05.005; Kwak JY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/615130; Landen NX, 2016, CELL MOL LIFE SCI, V73, P3861, DOI 10.1007/s00018-016-2268-0; Langenes V, 2013, CANCER IMMUNOL IMMUN, V62, P1687, DOI 10.1007/s00262-013-1472-0; Le YY, 2004, CELL MOL IMMUNOL, V1, P95; Lee KM, 2014, EMBO J, V33, P2564, DOI 10.15252/embj.201488887; Lee KM, 2011, BLOOD, V118, P6220, DOI 10.1182/blood-2011-03-344044; Lewandowska P, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010008; Liu LP, 2006, J IMMUNOL, V177, P17, DOI 10.4049/jimmunol.177.1.17; Locati M, 2005, CYTOKINE GROWTH F R, V16, P679, DOI 10.1016/j.cytogfr.2005.05.003; Lux M, 2019, AM J PATHOL, V189, P231, DOI 10.1016/j.ajpath.2018.09.016; Mabuchi T, 2017, J INVEST DERMATOL, V137, P7, DOI 10.1016/j.jid.2016.09.035; Madigan J, 2010, J IMMUNOL, V184, P3202, DOI 10.4049/jimmunol.0902118; Mantovani A, 2006, NAT REV IMMUNOL, V6, P907, DOI 10.1038/nri1964; Mapara MY, 2006, BIOL BLOOD MARROW TR, V12, P623, DOI 10.1016/j.bbmt.2006.02.005; Marques RE, 2013, EXPERT OPIN THER TAR, V17, P1439, DOI 10.1517/14728222.2013.837886; Massara M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03080-8; Mays AC, 2016, ANTICANCER RES, V36, P4013; McCulloch CV, 2008, J BIOL CHEM, V283, P7972, DOI 10.1074/jbc.M710128200; McKimmie CS, 2008, J IMMUNOL, V181, P3353, DOI 10.4049/jimmunol.181.5.3353; McKimmie CS, 2013, BLOOD, V121, P3768, DOI 10.1182/blood-2012-04-425314; Mikolajczyk T, 2021, J HYPERTENS, V39, pE49; Morari J, 2014, DIABETES, V63, P3770, DOI 10.2337/db13-1495; Motta F, 2021, RHEUMATOLOGY, V60, P3307, DOI 10.1093/rheumatology/keaa782; Murcia JDG, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64755-1; Naert G, 2011, J NEUROSCI, V31, P6208, DOI 10.1523/JNEUROSCI.0299-11.2011; Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49; Nakasone Y, 2012, AM J PATHOL, V180, P365, DOI 10.1016/j.ajpath.2011.09.005; Neil SJD, 2005, J VIROL, V79, P9618, DOI 10.1128/JVI.79.15.9618-9624.2005; Nibbs RJB, 1997, J BIOL CHEM, V272, P32078, DOI 10.1074/jbc.272.51.32078; Nibbs RJB, 2001, AM J PATHOL, V158, P867, DOI 10.1016/S0002-9440(10)64035-7; Nibbs RJB, 2007, J CLIN INVEST, V117, P1884, DOI 10.1172/JCI30068; Nibbs RJB, 2013, NAT REV IMMUNOL, V13, P815, DOI 10.1038/nri3544; Nielsen HJ, 1999, J PATHOL, V189, P487, DOI 10.1002/(SICI)1096-9896(199912)189:4<487::AID-PATH484>3.0.CO;2-I; Pacifico Francesco, 2017, Genes Cancer, V8, P577, DOI 10.18632/genesandcancer.141; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Polterauer S, 2010, BRIT J CANCER, V103, P613, DOI 10.1038/sj.bjc.6605801; Qasim Waseem, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007884; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Red-Horse K, 2001, AM J PATHOL, V159, P2199, DOI 10.1016/S0002-9440(10)63071-4; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Ribatti D, 2012, BBA-MOL BASIS DIS, V1822, P2, DOI 10.1016/j.bbadis.2010.11.010; Rouillard AD, 2016, DATABASE-OXFORD, DOI 10.1093/database/baw100; Russo RC, 2018, AM J PHYSIOL-LUNG C, V314, pL1010, DOI 10.1152/ajplung.00233.2017; Sacmaci H, 2020, MULT SCLER RELAT DIS, V38, DOI 10.1016/j.msard.2019.101524; Safari-Alighiarloo Nahid, 2014, Gastroenterol Hepatol Bed Bench, V7, P17; Sasindran SJ, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00002; Satyanarayanan SK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10903-9; Savino B, 2014, CANCER IMMUNOL RES, V2, P679, DOI 10.1158/2326-6066.CIR-13-0202; Savino B, 2012, BLOOD, V119, P5250, DOI 10.1182/blood-2011-10-388082; Schloss MJ, 2017, ARTERIOSCL THROM VAS, V37, P1640, DOI 10.1161/ATVBAHA.117.309259; Schwartz TW, 2006, ANNU REV PHARMACOL, V46, P481, DOI 10.1146/annurev.pharmtox.46.120604.141218; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Shabgah AG, 2021, CURR DRUG TARGETS, V22, P1524, DOI 10.2174/1389450122666210216091953; Shams K, 2018, J BIOL CHEM, V293, P3003, DOI 10.1074/jbc.M117.809780; Shams K, 2017, J INVEST DERMATOL, V137, P85, DOI 10.1016/j.jid.2016.07.039; Shen XF, 2017, J CELL MOL MED, V21, P1687, DOI 10.1111/jcmm.13112; Castanheira FVES, 2018, SHOCK, V49, P682, DOI 10.1097/SHK.0000000000000969; Singh MD, 2012, AM J PATHOL, V181, P1158, DOI 10.1016/j.ajpath.2012.06.042; Sjoberg E, 2019, CLIN CANCER RES, V25, P3702, DOI 10.1158/1078-0432.CCR-18-1294; Smith GCS, 2004, JAMA-J AM MED ASSOC, V292, P2249, DOI 10.1001/jama.292.18.2249; Sonego F, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00155; Stewart TA, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00250; Tavares LP, 2020, AM J PHYSIOL-LUNG C, V318, pL655, DOI 10.1152/ajplung.00134.2019; Tersigni C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164747; Traglia M, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0576-8; Vacchini A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030542; Valdearcos M, 2017, CELL METAB, V26, P185, DOI 10.1016/j.cmet.2017.05.015; van Mourik MSM, 2009, J LEUKOCYTE BIOL, V85, P4, DOI 10.1189/jlb.0708395; Velloso LA, 2011, INT J OBESITY, V35, P1455, DOI 10.1038/ijo.2011.56; Vermeulen CJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.01280-2019; Vetrano S, 2010, GUT, V59, P197, DOI 10.1136/gut.2009.183772; Weber M, 2004, MOL BIOL CELL, V15, P2492, DOI 10.1091/mbc.E03-09-0634; Weber-Gerlach M, 2016, CURR OPIN IMMUNOL, V42, P71, DOI 10.1016/j.coi.2016.05.016; Westin K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030525; Whitehead GS, 2007, AM J RESP CRIT CARE, V175, P243, DOI 10.1164/rccm.200606-839OC; Wiederholt T, 2008, HUM IMMUNOL, V69, P861, DOI 10.1016/j.humimm.2008.08.275; Willey SJ, 2003, J VIROL, V77, P6138, DOI 10.1128/JVI.77.11.6138-6152.2003; Wilson GJ, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.187815; Wilson GJ, 2017, DEVELOPMENT, V144, P74, DOI 10.1242/dev.139733; Woodcock TM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188305; Wu FY, 2008, MOL CANCER RES, V6, P1276, DOI 10.1158/1541-7786.MCR-07-2108; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yan SJ, 2020, PLACENTA, V90, P121, DOI 10.1016/j.placenta.2019.12.015; Yanaba K, 2006, ANN RHEUM DIS, V65, P124, DOI 10.1136/ard.2005.040782; Yang C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078901; Yu T, 2018, GRAEF ARCH CLIN EXP, V256, P1875, DOI 10.1007/s00417-018-4070-1; Yu Tian, 2016, World J Transplant, V6, P10, DOI 10.5500/wjt.v6.i1.10; Zeng XH, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0145-y; Zeng XH, 2011, BREAST CANCER RES TR, V125, P715, DOI 10.1007/s10549-010-0875-2; Zhou Z, 2020, AM J PATHOL, V190, P614, DOI 10.1016/j.ajpath.2019.11.012; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	160	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								861931	10.3389/fimmu.2022.861931	http://dx.doi.org/10.3389/fimmu.2022.861931			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W4SB	35677043	gold, Green Published			2022-12-18	WOS:000806763900001
J	Lesueur, J; Walachowski, S; Barbey, S; Cebron, N; Lefebvre, R; Launay, F; Boichard, D; Germon, P; Corbiere, F; Foucras, G				Lesueur, Jeremy; Walachowski, Sarah; Barbey, Sarah; Cebron, Nathan; Lefebvre, Rachel; Launay, Frederic; Boichard, Didier; Germon, Pierre; Corbiere, Fabien; Foucras, Gilles			Standardized Whole Blood Assay and Bead-Based Cytokine Profiling Reveal Commonalities and Diversity of the Response to Bacteria and TLR Ligands in Cattle	FRONTIERS IN IMMUNOLOGY			English	Article						cytokine; bead-based assay; cattle; inflammation; bacteria; MAMPs; whole blood stimulation	BOVINE ALVEOLAR MACROPHAGES; MESSENGER-RNA; IMMUNE-RESPONSES; TNF-ALPHA; LIPOPOLYSACCHARIDE; TUBERCULOSIS; STIMULATION; EXPRESSION; GAMMA; COWS	Recent developments in multiplex technologies enable the determination of a large nu\mber of soluble proteins such as cytokines in various biological samples. More than a one-by-one determination of the concentration of immune mediators, they permit the establishment of secretion profiles for a more accurate description of conditions related to infectious diseases or vaccination. Cytokine profiling has recently been made available for bovine species with the development of a Luminex (R) technology-based 15-plex assay. Independently from the manufacturer, we evaluated the bovine cytokine/chemokine multiplex assay for limits of detection, recovery rate, and reproducibility. Furthermore, we assessed cytokine secretion in blood samples from 107 cows upon stimulation with heat-killed bacteria and TLR2/4 ligands compared to a null condition. Secretion patterns were analyzed either using the absolute concentration of cytokines or using their relative concentration with respect to the overall secretion level induced by each stimulus. Using Partial Least Square-Discriminant Analysis, we show that the 15-cytokine profile is different under Escherichia coli, Staphylococcus aureus, and Streptococcus uberis conditions, and that IFN-gamma, IL-1 beta, and TNF-alpha contribute the most to differentiate these conditions. LPS and E. coli induced largely overlapping biological responses, but S. aureus and S. uberis were associated with distinct cytokine profiles than their respective TLR ligands. Finally, results based on adjusted or absolute cytokine levels yielded similar discriminative power, but led to different stimuli-related signatures.	[Lesueur, Jeremy; Walachowski, Sarah; Cebron, Nathan; Corbiere, Fabien; Foucras, Gilles] Univ Toulouse, IHAP, INRAE, ENVT, Toulouse, France; [Barbey, Sarah; Launay, Frederic] INRAE, Unite Experimentale Pin, Le Pin Au Haras, France; [Lefebvre, Rachel; Boichard, Didier] Univ Paris Saclay, GABI, INRAE, AgroParisTech, Jouy En Josas, France; [Germon, Pierre] Univ Tours, ISP, INRAE, Nouzilly, France	INRAE; Universite de Toulouse; Ecole Nationale Veterinaire de Toulouse; INRAE; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; INRAE; Universite de Tours	Foucras, G (corresponding author), Univ Toulouse, IHAP, INRAE, ENVT, Toulouse, France.	gilles.foucras@envt.fr	FOUCRAS, Gilles/A-3061-2014	FOUCRAS, Gilles/0000-0002-0363-0337; Walachowski, Sarah/0000-0001-5702-3404	APIS-GENE; MERCK-Millipore; INRAE	APIS-GENE; MERCK-Millipore; INRAE	The BOVIMMUNE research program was supported by APIS-GENE, who contributed financially to the development of the multiplex assay by MERCK-Millipore under the contract agreement with INRAE.	Adel-Patient K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.700521; Breen EJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep26996; Canchola J.A., 2017, MOJ PROTEOM BIOINFOR, V6, P316, DOI [DOI 10.15406/MOJPB.2017.06.00200, 10.15406/mojpb.2017.06.00200]; Cao KAL, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-253; Chen JW, 2010, J IMMUNOL METHODS, V357, P33, DOI 10.1016/j.jim.2010.03.006; Clifford V, 2015, TUBERCULOSIS, V95, P639, DOI 10.1016/j.tube.2015.07.002; Cohen L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01338; Damsgaard CT, 2009, J IMMUNOL METHODS, V340, P95, DOI 10.1016/j.jim.2008.10.005; Davies PL, 2016, J CLIN MICROBIOL, V54, P68, DOI 10.1128/JCM.01583-15; Davis MM, 2020, CURR OPIN IMMUNOL, V65, P79, DOI 10.1016/j.coi.2020.06.006; DEGROOTE D, 1992, CYTOKINE, V4, P239, DOI 10.1016/1043-4666(92)90062-V; Duffy D, 2014, IMMUNITY, V40, P436, DOI 10.1016/j.immuni.2014.03.002; Ellsworth SG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183239; Findlay JWA, 2000, J PHARMACEUT BIOMED, V21, P1249, DOI 10.1016/S0731-7085(99)00244-7; Galan JE, 2009, CELL HOST MICROBE, V5, P571, DOI 10.1016/j.chom.2009.04.008; Ghazavi A, 2021, CYTOKINE, V137, DOI 10.1016/j.cyto.2020.155323; Gilbert FB, 2013, VET RES, V44, DOI 10.1186/1297-9716-44-40; Gunther A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.572634; He JQ, 2020, CYTOKINE, V135, DOI 10.1016/j.cyto.2020.155218; Ingvartsen KL, 2013, ANIMAL, V7, P112, DOI 10.1017/S175173111200170X; Ito T, 1996, RES VET SCI, V60, P94, DOI 10.1016/S0034-5288(96)90140-X; Jalkanen J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162353; Jaumdally SZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30663-8; Kagan JC, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016253; Kappeli N, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00234; Krysko O, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.715072; Lee AH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08794-x; Lee N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026050; Lin JX, 2019, ANNU REV IMMUNOL, V37, P295, DOI 10.1146/annurev-immunol-042718-041447; Liquet B, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-325; Luminex corporation, 2014, 890000200417 LUM COR; Magee DA, 2014, TUBERCULOSIS, V94, P441, DOI 10.1016/j.tube.2014.04.004; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; McLean MR, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1355; Mehrzad J, 2002, J DAIRY SCI, V85, P3268, DOI 10.3168/jds.S0022-0302(02)74415-9; Mudd PA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abe3024; O'Brien MB, 2020, VET IMMUNOL IMMUNOP, V221, DOI 10.1016/j.vetimm.2020.110025; Pulendran B, 2010, IMMUNITY, V33, P516, DOI 10.1016/j.immuni.2010.10.006; R Development Core Team, 2018, R LANG ENV STAT COMP; Reid C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96493-3; Rivas AL, 2002, CAN J VET RES, V66, P125; Robison HM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-99754-3; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Sanz H, 2015, DRLUMI MULTIPLEX IMM; Sanz H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187901; SCHINDLER R, 1990, J BIOL CHEM, V265, P10232; Shebl FM, 2010, CANCER EPIDEM BIOMAR, V19, P978, DOI 10.1158/1055-9965.EPI-10-0064; Smith K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639605; Stokkeland LMT, 2019, CYTOKINE, V119, P188, DOI 10.1016/j.cyto.2019.03.013; Strandberg Y, 2005, CYTOKINE, V31, P72, DOI 10.1016/j.cyto.2005.02.010; Sullivan KE, 2000, CLIN DIAGN LAB IMMUN, V7, P920, DOI 10.1128/CDLI.7.6.920-924.2000; Taraktsoglou M, 2011, VET IMMUNOL IMMUNOP, V140, P130, DOI 10.1016/j.vetimm.2010.12.002; Urrutia A, 2016, CELL REP, V16, P2777, DOI 10.1016/j.celrep.2016.08.011; Vasilev G, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94841-x; Vlasova AN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.643206; Wanichthanarak K, 2019, COMPUT STRUCT BIOTEC, V17, P611, DOI 10.1016/j.csbj.2019.04.009; Westerhuis JA, 2010, METABOLOMICS, V6, P119, DOI 10.1007/s11306-009-0185-z; Wilson JG, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140289; Wurfel MM, 2005, J IMMUNOL, V175, P2570, DOI 10.4049/jimmunol.175.4.2570; Zandstra J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.631308	60	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								871780	10.3389/fimmu.2022.871780	http://dx.doi.org/10.3389/fimmu.2022.871780			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W4SM	35677047	Green Published, gold			2022-12-18	WOS:000806765000001
J	Liu, P; Wu, JQ; Sun, DD; Li, HL; Qi, ZH; Tang, XY; Su, W; Li, YZ; Qin, XZ				Liu, Peng; Wu, Jianqiang; Sun, Dandan; Li, Haolong; Qi, Zhihong; Tang, Xiaoyue; Su, Wei; Li, Yongzhe; Qin, Xuzhen			Proteomic Profiling of Cryoglobulinemia	FRONTIERS IN IMMUNOLOGY			English	Article						proteomics; serum; biomarker; cyroglobulinemia; metabolic pathway	HEPATITIS-C VIRUS; CHOLESTEROL; CELLS	ObjectiveWe aimed to explore and identify candidate protein biomarkers of cryoglobulinemia (CGE) in disease control patients with negative cryoglobulin (DC) or healthy controls (HCs). MethodsThe tandem mass tag (TMT)-labeled serum quantitative proteomics approach was used to identify differentially expressed proteins between the CGE and DC groups. Ingenuity pathway analysis was used for functional annotation of differentially expressed proteins. Biomarker candidates were validated in another cohort using the parallel reaction monitoring (PRM) method. Apolipoprotein A1 (APOA1), apolipoprotein CIII (APOC3), adiponectin, and proprotein convertase subtilisin/kexin type-9 (PCSK9), which represent key proteins involved in the cholesterol metabolism pathway, were further verified in an increased number of samples by enzyme-linked immunosorbent assay (ELISA). ResultsA total of 1004 proteins were identified, of which 109 proteins were differentially expressed between the CGE and DC groups. These differentially expressed proteins were primarily involved in hepatic fibrosis/hepatic stellate cell activation and immune/inflammation-related pathways. In the disease and biofunction analysis, these proteins were mainly associated with the adhesion of blood cells, leukocyte migration, cholesterol transport, and transport of lipids. Twelve candidate biomarkers were validated by PRM-based proteomics, and proteins involved in the cholesterol metabolism pathway were further verified. APOA1, APOC3, adiponectin and PCSK9 concentrations were increased in CGE patients compared with healthy controls (P=0.0123, 0.1136, 0.5760, and 0.0019, respectively). ConclusionThis report describes the first application of a TMT-PRM-ELISA workflow to identify and validate CGE-specific biomarkers in serum. APOA1 and PCSK9 have been confirmed to be increased in CGE patients, demonstrating that proteins involved in cholesterol metabolism are also implicated in the development of CGE. These findings contribute to pathogenesis research and biomarker discovery in CGE.	[Liu, Peng; Wu, Jianqiang; Tang, Xiaoyue] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Med Res Ctr, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China; [Sun, Dandan; Li, Haolong; Qi, Zhihong; Su, Wei; Li, Yongzhe; Qin, Xuzhen] Chinese Acad Med Sci & Peking Union Med Coll, Dept Lab Med, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Su, W; Li, YZ; Qin, XZ (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Dept Lab Med, Beijing, Peoples R China.	suwei_64@163.com; yongzhelipumch@126.com; qxz_01@163.com	Wu, Jianqiang/GQH-5519-2022; Wu, Jianqiang/AAX-7995-2021; sun, dandan/GZG-6540-2022; Liu, Peng/AGH-0228-2022	Wu, Jianqiang/0000-0001-6773-9289; 	CAMS Innovation Fund for Medical Sciences [CIFMS 2021-I2M-1-003]; Basic Research Funds of Central Public Research Institutes, Chinese Academy of Medical Sciences [2020-RW330-004]	CAMS Innovation Fund for Medical Sciences; Basic Research Funds of Central Public Research Institutes, Chinese Academy of Medical Sciences	Funding This work was supported by grants from CAMS Innovation Fund for Medical Sciences (CIFMS 2021-I2M-1-003) and Basic Research Funds of Central Public Research Institutes, Chinese Academy of Medical Sciences (2020-RW330-004).	Bonacci M, 2018, GASTROENTEROLOGY, V155, P311, DOI 10.1053/j.gastro.2018.04.024; Chan JCY, 2009, P NATL ACAD SCI USA, V106, P9820, DOI 10.1073/pnas.0903849106; Chinese Bureau of Disease Control and Prevention, 2019, EP SIT STAT REP INF; Coliche V, 2019, CLIN KIDNEY J, V12, P365, DOI 10.1093/ckj/sfy096; Damoc E, 2003, PROTEOMICS, V3, P1425, DOI 10.1002/pmic.200300482; Guo YN, 2021, J CELL PHYSIOL, V236, P2333, DOI 10.1002/jcp.30025; Huang MY, 2010, PEDIATR CARDIOL, V31, P1209, DOI 10.1007/s00246-010-9801-y; Huynh K, 2018, NAT REV CARDIOL, V15, DOI 10.1038/nrcardio.2017.204; Ito A, 2016, IMMUNITY, V45, P1311, DOI 10.1016/j.immuni.2016.11.008; Lee AYS, 2020, ANN RHEUM DIS, V79, P163, DOI 10.1136/annrheumdis-2019-216091; Liu AQ, 2020, LUPUS, V29, P825, DOI 10.1177/0961203320926253; Lu ZG, 2017, NAT MED, V23, P79, DOI 10.1038/nm.4252; Makinen P, 2020, CURR ATHEROSCLER REP, V22, DOI 10.1007/s11883-020-0826-2; Monti G, 2014, AUTOIMMUN REV, V13, P609, DOI 10.1016/j.autrev.2013.11.005; Muschen M, 2019, NAT REV IMMUNOL, V19, P337, DOI 10.1038/s41577-019-0154-3; Ochoa E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146990; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Quemeneur T, 2007, SEMIN ARTHRITIS RHEU, V37, P149, DOI 10.1016/j.semarthrit.2007.03.002; Roccatello D, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0009-4; Shen YJ, 2022, BLOOD, V139, P73, DOI 10.1182/blood.2021012327; Sun HY, 2018, GUT, V67, P1342, DOI 10.1136/gutjnl-2017-313832; Visentini M, 2019, LIVER INT, V39, P628, DOI 10.1111/liv.14053; Wallace ZS, 2019, ARTHRITIS RHEUMATOL, V71, P1879, DOI 10.1002/art.41006; Wang JJ, 2018, ARTHRITIS RHEUMATOL, V70, P1617, DOI 10.1002/art.40539; Weisel FJ, 2020, NAT IMMUNOL, V21, P331, DOI 10.1038/s41590-020-0598-4; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Xuzhen Qin PL., 2018, CHIN J LAB MED, V41, P5, DOI [10.3760/cma.j.issn.1009-9158.2018.11.009, DOI 10.3760/CMA.J.ISSN.1009-9158.2018.11.009]; Xuzhen Qin WS., 2015, CHINESE MED J-PEKING, V95, P4, DOI [10.3760/cma.j.issn.0376-2491.2015.06.015, DOI 10.3760/CMA.J.ISSN.0376-2491.2015.06.015]; Zhan Y., 2016, J CLIN NEPHROL, V16, P4, DOI [10.3969/j.issn.1671-2390.2016.01.001, DOI 10.3969/J.ISSN.1671-2390.2016.01.001]; Zignego AL, 2014, GENES IMMUN, V15, P500, DOI 10.1038/gene.2014.41	30	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								855513	10.3389/fimmu.2022.855513	http://dx.doi.org/10.3389/fimmu.2022.855513			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W2QE	35677050	Green Published, gold			2022-12-18	WOS:000806621300001
J	Lv, H; Gu, X; Shan, XY; Zhu, TL; Ma, BK; Zhang, HT; Bambini-Junior, V; Zhang, TT; Li, WG; Gao, XL; Li, F				Lv, Hui; Gu, Xiao; Shan, Xingyue; Zhu, Tailin; Ma, Bingke; Zhang, Hao-Tian; Bambini-Junior, Victorio; Zhang, Tiantian; Li, Wei-Guang; Gao, Xiaoling; Li, Fei			Nanoformulated Bumetanide Ameliorates Social Deficiency in BTBR Mice Model of Autism Spectrum Disorder	FRONTIERS IN IMMUNOLOGY			English	Article						autism spectrum disorder; bumetanide; nanoparticle; social behavior; microglia	MICROGLIAL ACTIVATION; MOUSE MODEL; BRAIN; EXCITATION/INHIBITION; NANOPARTICLES; INHIBITION; DELIVERY; CORTEX; NKCC1	Autism spectrum disorder (ASD) is a prevalent neurodevelopmental disorder with few medication options. Bumetanide, an FDA-approved diuretic, has been proposed as a viable candidate to treat core symptoms of ASD, however, neither the brain region related to its effect nor the cell-specific mechanism(s) is clear. The availability of nanoparticles provides a viable way to identify pharmacological mechanisms for use in ASD. Here, we found that treatment with bumetanide, in a systemic and medial prefrontal cortex (mPFC) region-specific way, attenuated social deficits in BTBR mice. Furthermore, using poly (ethylene glycol)-poly(l-lactide) (PEG-PLA) nanoparticles [NP(bumetanide)], we showed that the administration of NP(bumetanide) in a mPFC region-specific way also alleviated the social deficits of BTBR mice. Mechanistically, the behavioral effect of NP(bumetanide) was dependent on selective microglia-specific targeting in the mPFC. Pharmacological depletion of microglia significantly reduced the effect of nanoencapsulation and depletion of microglia alone did not improve the social deficits in BTBR mice. These findings suggest the potential therapeutic capabilities of nanotechnology for ASD, as well as the relevant link between bumetanide and immune cells.	[Lv, Hui; Zhu, Tailin; Li, Fei] Shanghai Jiao Tong Univ, Dept Dev & Behav Pediat & Child Primary Care, Xinhua Hosp,Sch Med, Brain & Behav Res Unit,Shanghai Inst Pediat Res, Shanghai, Peoples R China; [Lv, Hui; Zhu, Tailin; Li, Fei] Shanghai Jiao Tong Univ, Xinhua Hosp, Shanghai Key Lab Childrens Environm Hlth, Minist Educ,Sch Med, Shanghai, Peoples R China; [Gu, Xiao; Gao, Xiaoling] Shanghai Jiao Tong Univ, Shanghai Univ Collaborat Innovat Ctr Translat Med, Sch Med, Dept Pharmacol & Chem Biol, Shanghai, Peoples R China; [Shan, Xingyue; Ma, Bingke] East China Normal Univ, Minist Educ, Sch Life Sci, Shanghai Key Lab Brain Funct Genom, Shanghai, Peoples R China; [Zhang, Hao-Tian] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Brain & Behav Res Unit,Shanghai Inst Pediat Res, Shanghai, Peoples R China; [Zhang, Hao-Tian] Shanghai Jiao Tong Univ, Xinhua Hosp, Shanghai Key Lab Childrens Environm Hlth, Minist Educ MOE,Sch Med, Shanghai, Peoples R China; [Bambini-Junior, Victorio] Univ Lancaster, Fac Hlth & Med, Div Biomed & Life Sci, Lancaster, England; [Li, Wei-Guang] Fudan Univ, State Key Lab Med Neurobiol, Inst Translat Brain Res, Huashan Hosp,Dept Rehabil Med, Shanghai, Peoples R China; [Li, Wei-Guang] Fudan Univ, Ctr Brain Sci, Minist Educ, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; East China Normal University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Lancaster University; Fudan University; Fudan University	Li, F (corresponding author), Shanghai Jiao Tong Univ, Dept Dev & Behav Pediat & Child Primary Care, Xinhua Hosp,Sch Med, Brain & Behav Res Unit,Shanghai Inst Pediat Res, Shanghai, Peoples R China.; Li, F (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Shanghai Key Lab Childrens Environm Hlth, Minist Educ,Sch Med, Shanghai, Peoples R China.; Gao, XL (corresponding author), Shanghai Jiao Tong Univ, Shanghai Univ Collaborat Innovat Ctr Translat Med, Sch Med, Dept Pharmacol & Chem Biol, Shanghai, Peoples R China.	shellygao1@sjtu.edu.cn; feili@shsmu.edu.cn	Gao, xiao ling/GQI-2790-2022		National Natural Science Foundation of China [82125032, 81930095, 81761128035]; Science and Technology Commission of Shanghai Municipality [19410713500, 2018SHZDZX01]; Shanghai Municipal Commission of Health and Family Planning [2020CXJQ01, 2018YJRC03, shslczdzk02902]; Shanghai Clinical Key Subject Construction Project [2018B030335001]; Guangdong Key Project; innovative research team of high-level local universities in Shanghai;  [GWV-10.1-XK07]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM)); Shanghai Municipal Commission of Health and Family Planning; Shanghai Clinical Key Subject Construction Project; Guangdong Key Project; innovative research team of high-level local universities in Shanghai; 	This study was supported by grants from the National Natural Science Foundation of China (82125032, 81930095 and 81761128035), the Science and Technology Commission of Shanghai Municipality (19410713500 and 2018SHZDZX01), the Shanghai Municipal Commission of Health and Family Planning (GWV-10.1-XK07, 2020CXJQ01, 2018YJRC03), the Shanghai Clinical Key Subject Construction Project (shslczdzk02902), the Guangdong Key Project (2018B030335001), and innovative research team of high-level local universities in Shanghai.	Accordino RE, 2016, EXPERT OPIN PHARMACO, V17, P937, DOI 10.1517/14656566.2016.1154536; Amodeo DA, 2012, BEHAV BRAIN RES, V227, P64, DOI 10.1016/j.bbr.2011.10.032; Bambini V, 2014, SCIENCE, V346, DOI 10.1126/science.1255679; Bolivar VJ, 2007, BEHAV BRAIN RES, V176, P21, DOI 10.1016/j.bbr.2006.09.007; Brumback AC, 2018, MOL PSYCHIATR, V23, P2078, DOI 10.1038/mp.2017.213; Castanon N, 2003, PSYCHONEUROENDOCRINO, V28, P19, DOI 10.1016/S0306-4530(02)00005-7; Crutel V, 2021, J AUTISM DEV DISORD, V51, P2959, DOI 10.1007/s10803-020-04709-8; Dai Y, 2021, SCI BULL, V66, P1591, DOI 10.1016/j.scib.2021.01.008; de Ferron BS, 2017, ADDICT BIOL, V22, P1870, DOI 10.1111/adb.12465; Eftekhari S, 2014, SCIENCE, V346, DOI 10.1126/science.1256009; Eissa N, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091251; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Filipello F, 2018, IMMUNITY, V48, P979, DOI 10.1016/j.immuni.2018.04.016; Gandal MJ, 2018, SCIENCE, V359, P693, DOI 10.1126/science.aad6469; Gao XL, 2006, BIOMATERIALS, V27, P3482, DOI 10.1016/j.biomaterials.2006.01.038; Han S, 2014, NEURON, V81, P1282, DOI 10.1016/j.neuron.2014.01.016; Heo Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020912; Hung CM, 2018, BIOCHEM PHARMACOL, V156, P60, DOI 10.1016/j.bcp.2018.08.013; James BJ, 2019, ANN PHARMACOTHER, V53, P537, DOI 10.1177/1060028018817304; Jawaid S, 2018, GLIA, V66, P789, DOI 10.1002/glia.23284; Kana RK, 2015, MOL AUTISM, V6, DOI 10.1186/s13229-015-0052-x; Kim HR, 2021, SCI ADV, V7, DOI 10.1126/sciadv.aba5032; Kim KC, 2016, BIOMOL THER, V24, P207, DOI 10.4062/biomolther.2016.061; Lemonnier E, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.124; Liang B, 2018, NEURON, V100, P700, DOI 10.1016/j.neuron.2018.08.043; Loo L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08079-9; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; Lozovaya N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45635-9; Mattei D, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.80; McFarlane HG, 2008, GENES BRAIN BEHAV, V7, P152, DOI 10.1111/j.1601-183X.2007.00330.x; Morgan JT, 2010, BIOL PSYCHIAT, V68, P368, DOI 10.1016/j.biopsych.2010.05.024; Murray AJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16778; Pierce K, 2004, BRAIN, V127, P2703, DOI 10.1093/brain/awh289; Rubenstein JLR, 2003, GENES BRAIN BEHAV, V2, P255, DOI 10.1034/j.1601-183X.2003.00037.x; Savardi A, 2021, TRENDS PHARMACOL SCI, V42, P1009, DOI 10.1016/j.tips.2021.09.005; Savardi A, 2020, CHEM-US, V6, P2073, DOI 10.1016/j.chempr.2020.06.017; Song QX, 2014, ACS NANO, V8, P2345, DOI 10.1021/nn4058215; Sprengers JJ, 2021, J AM ACAD CHILD PSY, V60, P865, DOI 10.1016/j.jaac.2020.07.888; Suzuki K, 2013, JAMA PSYCHIAT, V70, P49, DOI 10.1001/jamapsychiatry.2013.272; Tetreault NA, 2012, J AUTISM DEV DISORD, V42, P2569, DOI 10.1007/s10803-012-1513-0; Toth K, 2022, PLOS BIOL, V20, DOI 10.1371/journal.pbio.3001526; Tyzio R, 2014, SCIENCE, V343, P675, DOI 10.1126/science.1247190; Urakawa S, 2015, BRAIN TOPOGR, V28, P691, DOI 10.1007/s10548-014-0414-2; Voineagu I, 2011, NATURE, V474, P380, DOI 10.1038/nature10110; Xu ZX, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15530-3; Yao L, 2016, J CONTROL RELEASE, V226, P1, DOI 10.1016/j.jconrel.2016.01.055; Yizhar O, 2011, NATURE, V477, P171, DOI 10.1038/nature10360; Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641; Zhang LL, 2020, TRANSL PSYCHIAT, V10, DOI 10.1038/s41398-020-0692-2	49	0	0	5	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								870577	10.3389/fimmu.2022.870577	http://dx.doi.org/10.3389/fimmu.2022.870577			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y7UG	35693812	gold, Green Published			2022-12-18	WOS:000808344400001
J	Neitzke-Montinelli, V; Caloba, C; Melo, G; Frade, BB; Caramez, E; Mazzoccoli, L; Goncalves, ANA; Nakaya, HI; Pereira, RM; Werneck, MBF; Viola, JPB				Neitzke-Montinelli, Vanessa; Caloba, Carolina; Melo, Guilherme; Frade, Bianca B.; Caramez, Enzo; Mazzoccoli, Luciano; Goncalves, Andre N. A.; Nakaya, Helder I.; Pereira, Renata M.; Werneck, Miriam B. F.; Viola, Joao P. B.			Differentiation of Memory CD8 T Cells Unravel Gene Expression Pattern Common to Effector and Memory Precursors	FRONTIERS IN IMMUNOLOGY			English	Article						CD8 T cell differentiation; immunological memory; cytotoxicity; adoptive cell transfer; immunotherapy	TERMINAL DIFFERENTIATION; CUTTING EDGE; TRANSCRIPTION FACTORS; BET; REPRESSION; GENERATION; INSIGHTS; IL-7; ZEB2	Long-term immunological protection relies on the differentiation and maintenance of memory lymphocytes. Since the knowledge of memory generation has been centered on in vivo models of infection, there are obstacles to deep molecular analysis of differentiating subsets. Here we defined a novel in vitro CD8 T cell activation and culture regimen using low TCR engagement and cytokines to generate differentiated cells consistent with central memory-like cells, as shown by surface phenotype, gene expression profile and lack of cytotoxic function after challenge. Our results showed an effector signature expressed by in vitro memory precursors and their plasticity under specific conditions. Moreover, memory CD8 T cells conferred long-term protection against bacterial infection and slowed in vivo tumor growth more efficiently than effector cells. This model may allow further understanding of CD8 T cell memory molecular differentiation subsets and be suited for generating cells to be used for immunotherapy.	[Neitzke-Montinelli, Vanessa; Mazzoccoli, Luciano; Viola, Joao P. B.] Brazilian Natl Canc Inst, Program Immunol & Tumor Biol, Inst Nacl Canc INCA, Rio De Janeiro, Brazil; [Caloba, Carolina; Frade, Bianca B.; Caramez, Enzo; Werneck, Miriam B. F.] Univ Fed Rio De Janeiro UFRJ, Fed Univ Rio De Janeiro, Inst Biophys Carlos Chagas Filho, Rio De Janeiro, Brazil; [Melo, Guilherme; Pereira, Renata M.] Fed Univ Rio De Janeiro UFRJ, Inst Microbiol & Immunol, Rio De Janeiro, Brazil; [Goncalves, Andre N. A.; Nakaya, Helder I.] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin & Toxicol Anal, Sao Paulo, Brazil; [Nakaya, Helder I.] Hosp Israelita Albert Einstein, Sao Paulo, Brazil	National Cancer Institute (Inca); Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade de Sao Paulo; Hospital Israelita Albert Einstein	Viola, JPB (corresponding author), Brazilian Natl Canc Inst, Program Immunol & Tumor Biol, Inst Nacl Canc INCA, Rio De Janeiro, Brazil.; Werneck, MBF (corresponding author), Univ Fed Rio De Janeiro UFRJ, Fed Univ Rio De Janeiro, Inst Biophys Carlos Chagas Filho, Rio De Janeiro, Brazil.	mwerneck@biof.ufrj.br; jpviola@inca.gov.br	Pereira, Renata/V-6194-2019; Werneck, Miriam B.F./H-5802-2012; Aquime Goncalves, Andre Nicolau/Q-8326-2018	Aquime Goncalves, Andre Nicolau/0000-0001-5264-8368; Afonso Melo, Guilherme/0000-0001-5144-5139	CNPq [408127/2016-3, 307042/2017-0, 203.007/2016]; FAPERJ [479022/2013-5, 111.274/2014, 203.277/2016, 010.002250/2016]; INCA	CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPERJ(Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio De Janeiro (FAPERJ)); INCA(Institut National du Cancer (INCA) France)	This work was supported by grants to JV from CNPq (408127/2016-3 and 307042/2017-0) and FAPERJ (203.007/2016), and grants to MW from CNPq (479022/2013-5) and FAPERJ (111.274/2014, 203.277/2016 and 010.002250/2016). VN-M was supported by fellowships from INCA and CC and BF were supported by fellowships from CNPq.	Akondy RS, 2017, NATURE, V552, P362, DOI 10.1038/nature24633; Araki K, 2017, NAT IMMUNOL, V18, P1046, DOI 10.1038/ni.3795; Best JA, 2013, NAT IMMUNOL, V14, P404, DOI 10.1038/ni.2536; Chandele A, 2005, J IMMUNOL, V175, P5619, DOI 10.4049/jimmunol.175.9.5619; Chen Y, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02826; Cruz-Guilloty F, 2009, J EXP MED, V206, P51, DOI 10.1084/jem.20081242; Delpoux A, 2017, P NATL ACAD SCI USA, V114, pE8865, DOI 10.1073/pnas.1618916114; Dogra P, 2016, EUR J IMMUNOL, V46, P1548, DOI 10.1002/eji.201545550; Dominguez CX, 2015, J EXP MED, V212, P2041, DOI 10.1084/jem.20150186; Enamorado M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16073; Gerlach C, 2013, SCIENCE, V340, P635, DOI 10.1126/science.1235487; Graef P, 2014, IMMUNITY, V41, P116, DOI 10.1016/j.immuni.2014.05.018; Gray SM, 2017, IMMUNITY, V46, P596, DOI 10.1016/j.immuni.2017.03.012; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Haining WN, 2008, J IMMUNOL, V181, P1859, DOI 10.4049/jimmunol.181.3.1859; Harrington LE, 2000, J EXP MED, V191, P1241, DOI 10.1084/jem.191.7.1241; Herndler-Brandstetter D, 2018, IMMUNITY, V48, P716, DOI 10.1016/j.immuni.2018.03.015; Intlekofer AM, 2005, NAT IMMUNOL, V6, P1236, DOI 10.1038/ni1268; Intlekofer AM, 2007, J EXP MED, V204, P2015, DOI 10.1084/jem.20070841; Ji Y, 2011, NAT IMMUNOL, V12, P1230, DOI 10.1038/ni.2153; Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307; Kakaradov B, 2017, NAT IMMUNOL, V18, P422, DOI 10.1038/ni.3688; Kallies A, 2009, IMMUNITY, V31, P283, DOI 10.1016/j.immuni.2009.06.021; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; Knudson KM, 2013, CELL REP, V4, P554, DOI 10.1016/j.celrep.2013.07.008; Lazarevic V, 2013, NAT REV IMMUNOL, V13, P777, DOI 10.1038/nri3536; Lee JY, 2013, P NATL ACAD SCI USA, V110, P13498, DOI 10.1073/pnas.1307572110; Litterman AJ, 2014, CANCER IMMUNOL RES, V2, P839, DOI 10.1158/2326-6066.CIR-14-0038; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Manjunath N, 2001, J CLIN INVEST, V108, P871, DOI 10.1172/JCI200113296; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Menares E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12319-x; Nizard M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15221; Omilusik KD, 2015, J EXP MED, V212, P2027, DOI 10.1084/jem.20150194; Pachulec E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00411; Park JH, 2004, IMMUNITY, V21, P289, DOI 10.1016/j.immuni.2004.07.016; Perret R, 2008, TISSUE ANTIGENS, V72, P187, DOI 10.1111/j.1399-0039.2008.01088.x; Phan AT, 2017, IMMUNITY, V46, P714, DOI 10.1016/j.immuni.2017.04.016; Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012; Richard AC, 2018, NAT IMMUNOL, V19, P849, DOI 10.1038/s41590-018-0160-9; Rutishauser RL, 2009, IMMUNITY, V31, P296, DOI 10.1016/j.immuni.2009.05.014; Scharer CD, 2017, J IMMUNOL, V198, P2238, DOI 10.4049/jimmunol.1602086; Scott-Browne JP, 2016, IMMUNITY, V45, P1327, DOI 10.1016/j.immuni.2016.10.028; Smith NL, 2018, CELL, V174, P117, DOI 10.1016/j.cell.2018.05.029; Smith-Garvin JE, 2010, BLOOD, V116, P5548, DOI 10.1182/blood-2010-06-292748; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sukumar M, 2013, J CLIN INVEST, V123, P4479, DOI 10.1172/JCI69589; Takemoto N, 2006, J IMMUNOL, V177, P7515, DOI 10.4049/jimmunol.177.11.7515; Tan JT, 2001, P NATL ACAD SCI USA, V98, P8732, DOI 10.1073/pnas.161126098; Teixeiro E, 2009, SCIENCE, V323, P502, DOI 10.1126/science.1163612; Topham DJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00515; Verbist KC, 2016, NATURE, V532, P389, DOI 10.1038/nature17442; Wherry EJ, 2003, NAT IMMUNOL, V4, P225, DOI 10.1038/ni889; White JT, 2017, NAT REV IMMUNOL, V17, P391, DOI 10.1038/nri.2017.34; Williams MA, 2007, ANNU REV IMMUNOL, V25, P171, DOI 10.1146/annurev.immunol.25.022106.141548; Willinger T, 2005, J IMMUNOL, V175, P5895, DOI 10.4049/jimmunol.175.9.5895; Wilson DC, 2008, J IMMUNOL, V180, P5935, DOI 10.4049/jimmunol.180.9.5935; Youngblood B, 2017, NATURE, V552, P404, DOI 10.1038/nature25144; Yu BF, 2017, NAT IMMUNOL, V18, P573, DOI 10.1038/ni.3706; Zhou XY, 2010, IMMUNITY, V33, P229, DOI 10.1016/j.immuni.2010.08.002	61	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								840203	10.3389/fimmu.2022.840203	http://dx.doi.org/10.3389/fimmu.2022.840203			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X0LR	35677061	gold, Green Published			2022-12-18	WOS:000807156400001
J	Rapoport, BL; Steel, HC; Hlatshwayo, N; Theron, AJ; Meyer, PWA; Nayler, S; Benn, CA; Smit, T; Kwofie, LLI; Heyman, L; Anderson, R				Rapoport, Bernardo L.; Steel, Helen C.; Hlatshwayo, Nomsa; Theron, Annette J.; Meyer, Pieter W. A.; Nayler, Simon; Benn, Carol-Ann; Smit, Teresa; Kwofie, Luyanda L. I.; Heyman, Liezl; Anderson, Ronald			Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules	FRONTIERS IN IMMUNOLOGY			English	Article						breast cancer; CTLA-4; co-inhibitory and co-stimulatory immune checkpoints; immune dysregulation; CD28; GITR; PD-1; PD-L1; TIM-3	COLONY-STIMULATING FACTOR; TUMOR-ASSOCIATED MACROPHAGES; DENDRITIC CELL SUBSETS; FACTOR-I; PERIPHERAL-BLOOD; MAMMARY-GLAND; TISSUE; PROGRESSION; BIOMARKERS; CD1C(+)	Breast cancer cells exploit the up-regulation or down-regulation of immune checkpoint proteins to evade anti-tumor immune responses. To explore the possible involvement of this mechanism in promoting systemic immunosuppression, the pre-treatment levels of soluble co-inhibitory and co-stimulatory immune checkpoint molecules, as well as those of cytokines, chemokines, and growth factors were measured in 98 newly diagnosed breast cancer patients and compared with those of 45 healthy controls using multiplex bead array and ELISA technologies. Plasma concentrations of the co-stimulatory immune checkpoints, GITR, GITRL, CD27, CD28, CD40, CD80, CD86 and ICOS, as well as the co-inhibitory molecules, PD-L1, CTLA-4 and TIM-3, were all significantly lower in early breast cancer patients compared to healthy controls, as were those of HVEM and sTLR-2, whereas the plasma concentrations of CX3CL1 (fractalkine), CCL5 (RANTES) and those of the growth factors, M-CSF, FGF-21 and GDF-15 were significantly increased. However, when analyzed according to the patients' breast cancer characteristics, these being triple negative breast cancer (TNBC) vs. non-TNBC, tumor size, stage, nodal status and age, no significant differences were detected between the plasma levels of the various immune checkpoint molecules, cytokines, chemokines and growth factors. Additionally, none of these biomarkers correlated with pathological complete response. This study has identified low plasma levels of soluble co-stimulatory and co-inhibitory immune checkpoint molecules in newly diagnosed, non-metastatic breast cancer patients compared to healthy controls, which is a novel finding seemingly consistent with a state of systemic immune dysregulation. Plausible mechanisms include an association with elevated levels of M-CSF and CCL5, implicating the involvement of immune suppressor cells of the M2-macrophage/monocyte phenotype as possible drivers of this state of systemic immune quiescence/dysregulation.	[Rapoport, Bernardo L.; Steel, Helen C.; Hlatshwayo, Nomsa; Theron, Annette J.; Meyer, Pieter W. A.; Kwofie, Luyanda L. I.; Anderson, Ronald] Univ Pretoria, Fac Hlth Sci, Dept Immunol, Pretoria, South Africa; [Rapoport, Bernardo L.; Smit, Teresa; Heyman, Liezl] Med Oncol Ctr Rosebank, Johannesburg, South Africa; [Hlatshwayo, Nomsa; Meyer, Pieter W. A.; Kwofie, Luyanda L. I.] Dept Immunol, Natl Hlth Lab Serv, Tshwane Acad Div, Pretoria, South Africa; [Nayler, Simon] Drs Gritzman & Thatcher Inc Labs, Johannesburg, South Africa; [Nayler, Simon] Univ Witwatersrand Donald Gordon Med Ctr, Johannesburg, South Africa; [Benn, Carol-Ann] Netcare Breast Care Ctr, Johannesburg, South Africa	University of Pretoria; Tshwane University of Technology	Rapoport, BL (corresponding author), Univ Pretoria, Fac Hlth Sci, Dept Immunol, Pretoria, South Africa.; Rapoport, BL (corresponding author), Med Oncol Ctr Rosebank, Johannesburg, South Africa.	bernardo.rapoport@up.ac.za	; Meyer, Pieter/S-6184-2017	Steel, Helen/0000-0001-5899-4472; Meyer, Pieter/0000-0002-7318-1055; Heyman, Liezl/0000-0002-2518-215X				Ahmed Ibrahim, 2020, J Cell Immunol, V2, P108, DOI 10.33696/immunology.2.029; Allen BM, 2020, NAT MED, V26, P1125, DOI 10.1038/s41591-020-0892-6; Almand B, 2000, CLIN CANCER RES, V6, P1755; Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; An GL, 2019, ONCOL REP, V42, P2499, DOI 10.3892/or.2019.7344; [Anonymous], EXPR GFRAL CANC SUMM; Arfsten H, 2019, EUR J CLIN INVEST, V49, DOI 10.1111/eci.13168; Aukes K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185736; Danai PA, 2006, CHEST, V129, P1432, DOI 10.1378/chest.129.6.1432; Della Bella S, 2003, BRIT J CANCER, V89, P1463, DOI 10.1038/sj.bjc.6601243; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Dumeaux V, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005680; Knott ME, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-1577; Failli A, 2013, CANCER LETT, V337, P184, DOI 10.1016/j.canlet.2013.05.013; Giordano C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073797; Guo LW, 2015, SCI REP-UK, V5, DOI 10.1038/srep10508; Hao ZX, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.754138; Hiam-Galvez KJ, 2021, NAT REV CANCER, V21, P345, DOI 10.1038/s41568-021-00347-z; Im JH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17914-x; Jung SB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03998-z; Kluger HM, 2004, CLIN CANCER RES, V10, P173, DOI 10.1158/1078-0432.CCR-0699-3; Lawicki S, 2016, ANN LAB MED, V36, P223, DOI 10.3343/alm.2016.36.3.223; Li HT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02677-9; Lin JH, 2020, J EXP MED, V217, DOI 10.1084/jem.20190673; Lu CS, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00887-1; Lu XQ, 2019, INT J BIOL SCI, V15, P2859, DOI 10.7150/ijbs.39063; Mastelic-Gavillet B, 2020, EUR J CANCER, V135, P173, DOI 10.1016/j.ejca.2020.04.036; Morandi A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027450; Mu XM, 2018, CELL CYCLE, V17, P428, DOI 10.1080/15384101.2018.1444305; Obeid E, 2013, INT J ONCOL, V43, P5, DOI 10.3892/ijo.2013.1938; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Peranzoni E, 2018, P NATL ACAD SCI USA, V115, pE4041, DOI 10.1073/pnas.1720948115; POLLARD JW, 1994, P NATL ACAD SCI USA, V91, P9312, DOI 10.1073/pnas.91.20.9312; Ramos RN, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1108; Rawat A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.587946; Reed JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045877; Richardsen E, 2015, ANTICANCER RES, V35, P865; Sapi E, 2004, EXP BIOL MED, V229, P1; Sasahara A, 2017, ONCOTARGET, V8, P24869, DOI 10.18632/oncotarget.15276; Schlick K, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0039-4; Schmid P, 2022, NEW ENGL J MED, V386, P556, DOI 10.1056/NEJMoa2112651; Scholl SM, 1996, BREAST CANCER RES TR, V39, P275, DOI 10.1007/BF01806155; Sousa S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0621-0; Tabarkiewicz J, 2008, ONCOL REP, V19, P237; Takenouchi Y, 2020, EXP CELL RES, V391, DOI 10.1016/j.yexcr.2020.112010; Tamimi RM, 2008, CANCER RES, V68, P18, DOI 10.1158/0008-5472.CAN-07-3234; te Marvelde L, 2020, AUST NZ J PUBL HEAL, V44, P53, DOI 10.1111/1753-6405.12935; Thomas JK, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40514-9; Urakawa N, 2015, LAB INVEST, V95, P491, DOI 10.1038/labinvest.2015.36; van Cruijsen H, 2008, CLIN CANCER RES, V14, P5884, DOI 10.1158/1078-0432.CCR-08-0656; Vidyarthi A, 2019, CANCER IMMUNOL IMMUN, V68, P1995, DOI 10.1007/s00262-019-02423-8; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Wolfsberger J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017089118; Yang YJ, 2014, CANCER BIOL THER, V15, P99, DOI 10.4161/cbt.26718; Zhang BK, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711571; Zhang F, 2016, ONCOTARGET, V7, P52294, DOI 10.18632/oncotarget.10561; Zou YT, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920940928	57	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								823842	10.3389/fimmu.2022.823842	http://dx.doi.org/10.3389/fimmu.2022.823842			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W9TC	35677046	Green Published, gold			2022-12-18	WOS:000807108100001
J	Song, QX; Nasri, U; Nakamura, R; Martin, PJ; Zeng, DF				Song, Qingxiao; Nasri, Ubaydah; Nakamura, Ryotaro; Martin, Paul J.; Zeng, Defu			Retention of Donor T Cells in Lymphohematopoietic Tissue and Augmentation of Tissue PD-L1 Protection for Prevention of GVHD While Preserving GVL Activity	FRONTIERS IN IMMUNOLOGY			English	Review						graft versus leukaemia (GVL); graft versus host disease (GVHD); naive T cell depletion; PD-L1; chemokine and chemokine receptors; anti-IL-2	GRAFT-VERSUS-HOST; MESENCHYMAL STEM-CELLS; BONE-MARROW-TRANSPLANTATION; MURINE ACUTE GVHD; DENDRITIC CELL; LYMPHOCYTE INFUSIONS; IN-VITRO; MYELOID-LEUKEMIA; JAK-INHIBITOR; LEUKOCYTE INFUSIONS	Allogeneic hematopoietic cell transplantation (Allo-HCT) is a curative therapy for hematological malignancies (i.e., leukemia and lymphoma) due to the graft-versus-leukemia (GVL) activity mediated by alloreactive T cells that can eliminate residual malignant cells and prevent relapse. However, the same alloreactive T cells can cause a serious side effect, known as graft-versus-host disease (GVHD). GVHD and GVL occur in distinct organ and tissues, with GVHD occurring in target organs (e.g., the gut, liver, lung, skin, etc.) and GVL in lympho-hematopoietic tissues where hematological cancer cells primarily reside. Currently used immunosuppressive drugs for the treatment of GVHD inhibit donor T cell activation and expansion, resulting in a decrease in both GVHD and GVL activity that is associated with cancer relapse. To prevent GVHD, it is important to allow full activation and expansion of alloreactive T cells in the lympho-hematopoietic tissues, as well as prevent donor T cells from migrating into the GVHD target tissues, and tolerize infiltrating T cells via protective mechanisms, such as PD-L1 interacting with PD-1, in the target tissues. In this review, we will summarize major approaches that prevent donor T cell migration into GVHD target tissues and approaches that augment tolerization of the infiltrating T cells in the GVHD target tissues while preserving strong GVL activity in the lympho-hematopoietic tissues.	[Song, Qingxiao; Nasri, Ubaydah; Zeng, Defu] City Hope Natl Med Ctr, Arthur D Riggs Diabet & Metab Res Inst, Beckman Res Inst, Duarte, CA 91010 USA; [Song, Qingxiao; Nasri, Ubaydah; Nakamura, Ryotaro; Zeng, Defu] City Hope Natl Med Ctr, Hematol Malignancies & Stem Cell Transplantat Inst, Duarte, CA 91010 USA; [Song, Qingxiao] Fujian Med Univ, Ctr Translat Hematol, Fujian Inst Hematol, Fuzhou, Peoples R China; [Song, Qingxiao] Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China; [Martin, Paul J.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Fujian Medical University; Fujian Medical University; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Song, QX; Zeng, DF (corresponding author), City Hope Natl Med Ctr, Arthur D Riggs Diabet & Metab Res Inst, Beckman Res Inst, Duarte, CA 91010 USA.; Song, QX; Zeng, DF (corresponding author), City Hope Natl Med Ctr, Hematol Malignancies & Stem Cell Transplantat Inst, Duarte, CA 91010 USA.; Song, QX (corresponding author), Fujian Med Univ, Ctr Translat Hematol, Fujian Inst Hematol, Fuzhou, Peoples R China.; Song, QX (corresponding author), Fujian Med Univ, Union Hosp, Fuzhou, Peoples R China.		Song, Qingxiao/HGC-1595-2022	Song, Qingxiao/0000-0001-9243-5666	National Institutes of Health [R01 CA228465]; National Natural Science Foundation of China [82100226]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by National Institutes of Health Grant R01 CA228465 (to DZ) and National Natural Science Foundation of China (grant no. 82100226) to QS.	Abouelnasr A, 2013, BIOL BLOOD MARROW TR, V19, P12, DOI 10.1016/j.bbmt.2012.06.020; Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Alexander KA, 2014, J CLIN INVEST, V124, P4266, DOI 10.1172/JCI75935; Anderson BE, 2003, J CLIN INVEST, V112, P101, DOI 10.1172/JCI200317601; Anderson BE, 2008, BIOL BLOOD MARROW TR, V14, P19; Anderson BE, 2008, BLOOD, V111, P5242, DOI 10.1182/blood-2007-09-107953; Andolfi G, 2012, MOL THER, V20, P1778, DOI 10.1038/mt.2012.71; Anker PSI, 2003, HAEMATOLOGICA, V88, P845; Appelbaum FR, 2001, NATURE, V411, P385, DOI 10.1038/35077251; Auffermann-Gretzinger S, 2002, BLOOD, V99, P1442, DOI 10.1182/blood.V99.4.1442; Bacchetta R, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00016; Baron F, 2010, BIOL BLOOD MARROW TR, V16, P838, DOI 10.1016/j.bbmt.2010.01.011; Bent EH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26407-4; Betts BC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01797; Betts BC, 2018, P NATL ACAD SCI USA, V115, P1582, DOI 10.1073/pnas.1712452115; Beyth S, 2005, BLOOD, V105, P2214, DOI 10.1182/blood-2004-07-2921; Billiau AD, 2002, BLOOD, V100, P1894, DOI 10.1182/blood-2002-02-0419; Bleakley M, 2019, MULTICENTER PHASE 2; Bleakley M., 2019, PHASE 2 RANDOMIZED C; Bleakley M, 2022, J CLIN ONCOL, V40, P1174, DOI 10.1200/JCO.21.01755; Bleakley M, 2015, J CLIN INVEST, V125, P2677, DOI 10.1172/JCI81229; Bleakley M, 2010, BLOOD, V115, P4923, DOI 10.1182/blood-2009-12-260539; Boekstegers AM, 2017, BONE MARROW TRANSPL, V52, P1221, DOI 10.1038/bmt.2017.107; Bogunia-Kubik K, 2006, HAEMATOLOGICA, V91, P1628; Butte MJ, 2008, MOL IMMUNOL, V45, P3567, DOI 10.1016/j.molimm.2008.05.014; Butte MJ, 2007, IMMUNITY, V27, P111, DOI 10.1016/j.immuni.2007.05.016; Carniti C, 2015, CLIN CANCER RES, V21, P3740, DOI 10.1158/1078-0432.CCR-14-2758; Cassady K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03061; Cetkovic-Cvrlje M, 2001, BLOOD, V98, P1607, DOI 10.1182/blood.V98.5.1607; Chakraverty R, 2006, J EXP MED, V203, P2021, DOI 10.1084/jem.20060376; Chen BJ, 2004, BLOOD, V103, P1534, DOI 10.1182/blood-2003-08-2987; Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405; Chen PP, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf5264; Chen X, 2009, BLOOD, V114, P891, DOI 10.1182/blood-2009-01-197178; Chen YB, 2013, BONE MARROW TRANSPL, V48, P598, DOI 10.1038/bmt.2012.191; Chen YB, 2009, BIOL BLOOD MARROW TR, V15, P1066, DOI 10.1016/j.bbmt.2009.05.003; Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002; Choe H, 2020, BLOOD, V136, DOI 10.1182/blood-2020-140747; Choi J, 2018, LEUKEMIA, V32, P2483, DOI 10.1038/s41375-018-0123-z; Choi J, 2012, BLOOD, V120, P4093, DOI 10.1182/blood-2012-01-403196; Choi SW, 2012, BIOL BLOOD MARROW TR, V18, P1525, DOI 10.1016/j.bbmt.2012.03.013; Cieniewicz B, 2021, HAEMATOLOGICA, V106, P2588, DOI 10.3324/haematol.2020.263129; Coltoff A, 2018, BONE MARROW TRANSPL, V53, P900, DOI 10.1038/s41409-018-0094-8; Corcione A, 2006, BLOOD, V107, P367, DOI 10.1182/blood-2005-07-2657; Courtois J, 2021, BONE MARROW TRANSPL, V56, P2672, DOI 10.1038/s41409-021-01363-1; Meirelles LDS, 2006, J CELL SCI, V119, P2204, DOI 10.1242/jcs.02932; Danylesko I, 2019, BONE MARROW TRANSPL, V54, P987, DOI 10.1038/s41409-018-0364-5; Dazzi F, 2000, BLOOD, V96, P2712; Deng RS, 2015, J IMMUNOL, V194, P560, DOI 10.4049/jimmunol.1402157; Dey BR, 2003, BIOL BLOOD MARROW TR, V9, P320, DOI 10.1016/S1083-8791(03)00077-6; Divito SJ, 2020, J CLIN INVEST, V130, P4624, DOI 10.1172/JCI129965; Huu DL, 2013, ARTHRITIS RHEUM-US, V65, P1624, DOI 10.1002/art.37933; DROBYSKI WR, 1992, BONE MARROW TRANSPL, V10, P301; Duffner U, 2003, EXP HEMATOL, V31, P897, DOI 10.1016/S0301-472X(03)00198-X; Dutt S, 2005, BLOOD, V106, P4009, DOI 10.1182/blood-2005-06-2339; Dutt S, 2007, J IMMUNOL, V179, P6547, DOI 10.4049/jimmunol.179.10.6547; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Falkenburg JHF, 2019, EBMT HANDBOOK: HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPIES, P443, DOI 10.1007/978-3-030-02278-5_59; Farber DL, 2014, NAT REV IMMUNOL, V14, P24, DOI 10.1038/nri3567; Fefer A, 2003, THOMAS HEMATOPOIETIC, P369, DOI [10.1002/9780470987070.ch28, DOI 10.1002/9780470987070.CH28]; Ferrara JLM, 2009, LANCET, V373, P1550, DOI 10.1016/S0140-6736(09)60237-3; Fife BT, 2009, NAT IMMUNOL, V10, P1185, DOI 10.1038/ni.1790; Floisand Y, 2021, BONE MARROW TRANSPL, V56, P2477, DOI 10.1038/s41409-021-01356-0; Floisand Y, 2019, BIOL BLOOD MARROW TR, V25, P720, DOI 10.1016/j.bbmt.2018.11.013; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Fu YY, 2019, IMMUNITY, V51, P90, DOI 10.1016/j.immuni.2019.06.003; Fujii S, 2018, STEM CELLS, V36, P434, DOI 10.1002/stem.2759; Gado K, 2000, CELL BIOL INT, V24, P195, DOI 10.1006/cbir.2000.0497; Gartlan KH, 2019, BLOOD ADV, V3, P2859, DOI 10.1182/bloodadvances.2019000053; Gauthier J, 2018, BLOOD ADV, V2, P10, DOI 10.1182/bloodadvances.2017011478; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; Hasegawa H, 2008, GENE THER, V15, P171, DOI 10.1038/sj.gt.3303051; Hashimoto D, 2007, EUR J IMMUNOL, V37, P271, DOI 10.1002/eji.200636123; Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12; Haverkos BM, 2017, BLOOD, V130, P221, DOI 10.1182/blood-2017-01-761346; He S, 2008, J IMMUNOL, V181, P7581, DOI 10.4049/jimmunol.181.11.7581; He W, 2014, BIOL BLOOD MARROW TR, V20, P920, DOI 10.1016/j.bbmt.2014.03.029; Heine A, 2013, BLOOD, V122, P1192, DOI 10.1182/blood-2013-03-484642; Heinrichs J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1146842; Hill GR, 2020, BLOOD, V136, P418, DOI 10.1182/blood.2019000952; Hill GR, 1999, J CLIN INVEST, V104, P459, DOI 10.1172/JCI6896; Holtzman NG, 2020, BLOOD, V136, DOI 10.1182/blood-2020-140392; Hsiao M, 2020, WORLD J ONCOL, V11, P112, DOI 10.14740/wjon1263; Hsieh MH, 2000, BLOOD, V96, P1047, DOI 10.1182/blood.V96.3.1047.015k36_1047_1055; Huang W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00624; Iamsawat S, 2019, BLOOD ADV, V3, P4187, DOI 10.1182/bloodadvances.2019000531; Igura K, 2004, CYTOTHERAPY, V6, P543, DOI 10.1080/14653240410005366-1; Ito M, 1999, Biol Blood Marrow Transplant, V5, P357, DOI 10.1016/S1083-8791(99)70012-1; Jagasia M, 2020, BLOOD, V135, P1739, DOI 10.1182/blood.2020004823; Jiang XX, 2005, BLOOD, V105, P4120, DOI 10.1182/blood-2004-02-0586; Ju XP, 2005, BONE MARROW TRANSPL, V35, P1179, DOI 10.1038/sj.bmt.1704972; Kallekleiv M, 2016, CYTOTHERAPY, V18, P172, DOI 10.1016/j.jcyt.2015.11.010; Keir ME, 2006, J EXP MED, V203, P883, DOI 10.1084/jem.20051776; Kennedy GA, 2021, BLOOD, V137, P1970, DOI 10.1182/blood.2020009050; Kern S, 2006, STEM CELLS, V24, P1294, DOI 10.1634/stemcells.2005-0342; Keshav S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060094; Khuat LT, 2021, BLOOD, V138, P2583, DOI 10.1182/blood.2021011216; Kim TD, 2008, BLOOD, V111, P2929, DOI 10.1182/blood-2007-06-096602; Kim YM, 2003, J CLIN INVEST, V111, P659, DOI 10.1172/JCI200316950; Kitko CL, 2016, BIOL BLOOD MARROW TR, V22, P862, DOI 10.1016/j.bbmt.2015.11.002; Kittan NA, 2010, CURR TOP MICROBIOL, V341, P97, DOI 10.1007/82_2010_23; Kong XH, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135468; Korngold R, 2003, BIOL BLOOD MARROW TR, V9, P292, DOI 10.1016/S1083-8791(03)00087-9; Lai PL, 2019, BIOMARK RES, V7, DOI 10.1186/s40364-019-0156-0; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Li NN, 2009, BLOOD, V113, P953, DOI 10.1182/blood-2008-06-165522; Li N, 2011, BLOOD, V118, P5965, DOI 10.1182/blood-2011-07-367011; Li XF, 2012, J IMMUNOL, V188, P724, DOI 10.4049/jimmunol.1102630; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Locafaro G, 2017, MOL THER, V25, P2254, DOI 10.1016/j.ymthe.2017.06.029; Ludwig AK, 2012, INT J BIOCHEM CELL B, V44, P11, DOI 10.1016/j.biocel.2011.10.005; Mamcarz E, 2020, BONE MARROW TRANSPL, V55, P929, DOI 10.1038/s41409-019-0750-7; Mapara MY, 2003, TRANSPLANTATION, V76, P297, DOI 10.1097/01.TP.0000072014.83469.2D; Mapara MY, 2002, BLOOD, V100, P1903, DOI 10.1182/blood-2002-01-0023; Mapara MY, 2005, METH MOLEC MED, V109, P469; Marigo I, 2011, SEMIN IMMUNOPATHOL, V33, P593, DOI 10.1007/s00281-011-0267-7; Markey KA, 2010, BLOOD, V115, P122, DOI 10.1182/blood-2009-01-199927; Mehta RS, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2020.12.011; Moy RH, 2017, BLOOD, V129, P906, DOI 10.1182/blood-2016-08-735076; Murai M, 1999, J CLIN INVEST, V104, P49, DOI 10.1172/JCI6642; Na IK, 2010, J CLIN INVEST, V120, P343, DOI 10.1172/JCI39395; NAPARSTEK E, 1995, BRIT J HAEMATOL, V89, P506, DOI 10.1111/j.1365-2141.1995.tb08356.x; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Nguyen DG, 2003, J BIOL CHEM, V278, P52347, DOI 10.1074/jbc.M309009200; Ni X, 2017, J CLIN INVEST, V127, P1960, DOI 10.1172/JCI91138; Ni XH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1273-7; Ning H, 2008, LEUKEMIA, V22, P593, DOI 10.1038/sj.leu.2405090; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Okiyama N, 2014, J INVEST DERMATOL, V134, P992, DOI 10.1038/jid.2013.476; Palmer LA, 2010, BIOL BLOOD MARROW TR, V16, P311, DOI 10.1016/j.bbmt.2009.12.002; Park JJ, 2010, BLOOD, V116, P1291, DOI 10.1182/blood-2010-01-265975; Pease JE, 2009, EXPERT OPIN THER PAT, V19, P199, DOI 10.1517/13543770802641353; Perkey E, 2018, ANNU REV PATHOL-MECH, V13, P219, DOI 10.1146/annurev-pathol-020117-043720; Piper KP, 2007, BLOOD, V110, P3827, DOI 10.1182/blood-2006-12-061408; Poggi A, 2008, HUM IMMUNOL, V69, P755, DOI 10.1016/j.humimm.2008.08.278; Polchert D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129; Radujkovic A, 2015, BIOL BLOOD MARROW TR, V21, P1230, DOI 10.1016/j.bbmt.2015.03.012; Randolph GJ, 2008, ANNU REV IMMUNOL, V26, P293, DOI 10.1146/annurev.immunol.26.021607.090254; Rasmusson I, 2003, TRANSPLANTATION, V76, P1208, DOI 10.1097/01.TP.0000082540.43730.80; Reddy P, 2005, NAT MED, V11, P1244, DOI 10.1038/nm1309; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Reshef R, 2012, NEW ENGL J MED, V367, P135, DOI 10.1056/NEJMoa1201248; Riddell SR, 2008, BIOL BLOOD MARROW TR, V14, P2, DOI 10.1016/j.bbmt.2007.10.004; Sackstein R, 2006, BIOL BLOOD MARROW TR, V12, P2, DOI 10.1016/j.bbmt.2005.09.015; Saha A, 2016, J CLIN INVEST, V126, P2642, DOI 10.1172/JCI85796; Saruta M, 2007, J IMMUNOL, V178, P3293, DOI 10.4049/jimmunol.178.5.3293; Schmaltz C, 2001, BLOOD, V97, P2886, DOI 10.1182/blood.V97.9.2886; Schreder A, 2015, BIOL BLOOD MARROW TR, V21, P2069, DOI 10.1016/j.bbmt.2015.08.038; Schroeder MA, 2020, BLOOD ADV, V4, P1656, DOI 10.1182/bloodadvances.2019001043; Schwartz DM, 2016, NAT REV RHEUMATOL, V12, P25, DOI 10.1038/nrrheum.2015.167; Sharma N, 2021, CANCERS, V13, DOI 10.3390/cancers13040613; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shlomchik WD, 2007, NAT REV IMMUNOL, V7, P340, DOI 10.1038/nri2000; Shook DR, 2015, PEDIATR BLOOD CANCER, V62, P666, DOI 10.1002/pbc.25352; Song QX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.700857; Song QX, 2021, BLOOD, V137, P2243, DOI 10.1182/blood.2020006345; Spitzer TR, 2000, BIOL BLOOD MARROW TR, V6, P309, DOI 10.1016/S1083-8791(00)70056-5; Spoerl S, 2014, BLOOD, V123, P3832, DOI 10.1182/blood-2013-12-543736; Studeny M, 2002, CANCER RES, V62, P3603; Sugimoto N, 2003, EUR J IMMUNOL, V33, P243, DOI 10.1002/immu.200390027; Sugiura D, 2019, SCIENCE, V364, P558, DOI 10.1126/science.aav7062; Sun Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639217; Taylor PA, 2007, BLOOD, V110, P3480, DOI 10.1182/blood-2007-05-087940; He TP, 2007, CELL MOL IMMUNOL, V4, P105; Triplett BM, 2015, BONE MARROW TRANSPL, V50, P968, DOI 10.1038/bmt.2014.324; Triplett BM, 2018, TRANSPL INFECT DIS, V20, DOI 10.1111/tid.12823; Trotta E, 2018, NAT MED, V24, P1005, DOI 10.1038/s41591-018-0070-2; Ueha S, 2007, J LEUKOCYTE BIOL, V81, P176, DOI 10.1189/jlb.0306231; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Waldman E, 2006, BLOOD, V107, P1703, DOI 10.1182/blood-2005-08-3445; Waller EK, 2020, BLOOD, V135, P520, DOI 10.1182/blood.2019004681; Wang R, 2021, CYTOTHERAPY, V23, P996, DOI 10.1016/j.jcyt.2021.07.009; Wang SP, 2014, ANN RHEUM DIS, V73, P2213, DOI 10.1136/annrheumdis-2014-205615; Wang WH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.764786; Wang Z, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.650; Whiteley AE, 2021, NAT REV CANCER, V21, P461, DOI 10.1038/s41568-021-00355-z; Wilkinson AN, 2019, BLOOD, V134, P2092, DOI 10.1182/blood.2019000396; Wu T, 2013, J IMMUNOL, V191, P488, DOI 10.4049/jimmunol.1300657; Wysocki CA, 2005, BLOOD, V105, P4191, DOI 10.1182/blood-2004-12-4726; Wysocki CA, 2004, J IMMUNOL, V173, P845, DOI 10.4049/jimmunol.173.2.845; Yi TS, 2008, BLOOD, V112, P2101, DOI 10.1182/blood-2007-12-126987; Yi TS, 2009, BLOOD, V114, P3101, DOI 10.1182/blood-2009-05-219402; Zannettino ACW, 2008, J CELL PHYSIOL, V214, P413, DOI 10.1002/jcp.21210; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Zeiser R, 2004, BONE MARROW TRANSPL, V34, P923, DOI 10.1038/sj.bmt.1704670; Zeiser R, 2015, LEUKEMIA, V29, P2062, DOI 10.1038/leu.2015.212; Zeiser R, 2021, NEW ENGL J MED, V385, P228, DOI 10.1056/NEJMoa2033122; Zeiser R, 2020, NEW ENGL J MED, V382, P1800, DOI 10.1056/NEJMoa1917635; Zeiser R, 2019, BRIT J HAEMATOL, V187, P563, DOI 10.1111/bjh.16190; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zeng DF, 1998, J EXP MED, V187, P525, DOI 10.1084/jem.187.4.525; Zeng DF, 2002, BLOOD, V99, P1449, DOI 10.1182/blood.V99.4.1449; Zhang Y, 2004, BLOOD, V103, P3970, DOI 10.1182/blood-2003-09-3135; Zhang Y, 2007, J IMMUNOL, V179, P3305, DOI 10.4049/jimmunol.179.5.3305; Zhao YM, 2020, BIOL BLOOD MARROW TR, V26, pE128, DOI 10.1016/j.bbmt.2020.01.012; Zhao YL, 2019, IMMUNITY, V51, P1059, DOI 10.1016/j.immuni.2019.11.003; Zheng H, 2008, BLOOD, V111, P2476, DOI 10.1182/blood-2007-08-109678; Zheng H, 2009, J IMMUNOL, V182, P5938, DOI 10.4049/jimmunol.0802212	198	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								907673	10.3389/fimmu.2022.907673	http://dx.doi.org/10.3389/fimmu.2022.907673			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W5YH	35677056	gold, Green Published			2022-12-18	WOS:000806849000001
J	Tang, R; Zhong, T; Fan, L; Xie, YT; Li, J; Li, X				Tang, Rong; Zhong, Ting; Fan, Li; Xie, Yuting; Li, Juan; Li, Xia			Enhanced T Cell Glucose Uptake Is Associated With Progression of Beta-Cell Function in Type 1 Diabetes	FRONTIERS IN IMMUNOLOGY			English	Article						type 1 diabetes; T cell; cellular glucose uptake; beta-cell function; immunometabolism	METABOLISM; ACTIVATION; DIFFERENTIATION	BackgroundAbnormal intracellular glucose/fatty acid metabolism of T cells has tremendous effects on their immuno-modulatory function, which is related to the pathogenesis of autoimmune diseases. However, the association between the status of intracellular metabolism of T cells and type 1 diabetes is unclear. This study aimed to investigate the uptake of glucose and fatty acids in T cells and its relationship with disease progression in type 1 diabetes. MethodsA total of 86 individuals with type 1 diabetes were recruited to detect the uptake of glucose and fatty acids in T cells. 2-NBDG uptake and expression of glucose transporter 1 (GLUT1); or BODIPY uptake and expression of carnitine palmitoyltransferase 1A(CPT1A) were used to assess the status of glucose or fatty acid uptake in T cells. Patients with type 1 diabetes were followed up every 3-6 months for 36 months, the progression of beta-cell function was assessed using generalized estimating equations, and survival analysis was performed to determine the status of beta-cell function preservation (defined as 2-hour postprandial C-peptide >200 pmol/L). ResultsPatients with type 1 diabetes demonstrated enhanced intracellular glucose uptake of T cells as indicated by higher 2NBDG uptake and GLUT1 expression, while no significant differences in fatty acid uptake were observed. The increased T cells glucose uptake is associated with lower C-peptide and higher hemoglobin A1c levels. Notably, patients with low T cell glucose uptake at onset maintained high levels of C-peptide within 36 months of the disease course [fasting C-petite and 2-hour postprandial C-peptide are 60.6 (95%CI: 21.1-99.8) pmol/L and 146.3 (95%CI: 14.1-278.5) pmol/L higher respectively], And they also have a higher proportion of beta-cell function preservation during this follow-up period (P<0.001). ConclusionsIntracellular glucose uptake of T cells is abnormally enhanced in type 1 diabetes and is associated with beta-cell function and its progression.	[Li, Xia] Cent South Univ, Xiangya Hosp 2, Natl Clin Res Ctr Metab Dis, Key Lab Diabet Immunol, Changsha, Peoples R China; Cent South Univ, Dept Metab & Endocrinol, Xiangya Hosp 2, Changsha, Peoples R China	Central South University; Central South University	Li, X (corresponding author), Cent South Univ, Xiangya Hosp 2, Natl Clin Res Ctr Metab Dis, Key Lab Diabet Immunol, Changsha, Peoples R China.	lixia@csu.edu.cn			National Natural Science Foundation of China [82070812]; science and technology innovation Program of Hunan Province [2020RC4044, DMRFP_I_04]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); science and technology innovation Program of Hunan Province	Funding This work was supported by National Natural Science Foundation of China (Grant No 82070812), the science and technology innovation Program of Hunan Province (2020RC4044), and DMRFP_I_04 from SHMHDF.	Ahmed S, 2019, DIABETES, V68, P1366, DOI 10.2337/db19-0119; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Atkinson MA, 2019, LANCET DIABETES ENDO, V7, P52, DOI 10.1016/S2213-8587(18)30112-8; Bantug GR, 2018, NAT REV IMMUNOL, V18, P19, DOI 10.1038/nri.2017.99; Bettini M, 2021, DIABETES, V70, P1211, DOI 10.2337/dbi18-0058; Bordignon C, 2017, CURR DIABETES REP, V17, DOI 10.1007/s11892-017-0848-5; Buck MD, 2016, CELL, V166, P63, DOI 10.1016/j.cell.2016.05.035; Chang CH, 2016, NAT IMMUNOL, V17, P364, DOI 10.1038/ni.3415; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chavez MD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.703972; Cohen S, 2017, EUR J IMMUNOL, V47, P225, DOI 10.1002/eji.201646423; Delmastro-Greenwood MM, 2013, ANTIOXID REDOX SIGN, V19, P1902, DOI 10.1089/ars.2012.5167; Di Dedda C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194962; Dimeloe S, 2017, IMMUNOLOGY, V150, P35, DOI 10.1111/imm.12655; Diskin C, 2021, IMMUNITY, V54, P19, DOI 10.1016/j.immuni.2020.09.014; Galgani M, 2020, CURR OPIN IMMUNOL, V67, P10, DOI 10.1016/j.coi.2020.07.002; Galgani M, 2015, MOL IMMUNOL, V68, P558, DOI 10.1016/j.molimm.2015.07.035; Garyu JW, 2016, J BIOL CHEM, V291, P11230, DOI 10.1074/jbc.M115.713362; Geltink RIK, 2018, ANNU REV IMMUNOL, V36, P461, DOI 10.1146/annurev-immunol-042617-053019; Grohova A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00079; Hu ZL, 2018, FRONT MED-PRC, V12, P463, DOI 10.1007/s11684-018-0668-2; Huang G, 2016, DIABETES-METAB RES, V32, P615, DOI 10.1002/dmrr.2779; Katsarou A, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.16; Koga T, 2019, ARTHRITIS RHEUMATOL, V71, P766, DOI 10.1002/art.40785; Kolan SS, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12956; Kong BS, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109447; Kouidhi S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00270; Kunkl M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060575; Lau EYM, 2019, CLIN EXP IMMUNOL, V197, P205, DOI 10.1111/cei.13344; Lee YS, 2015, TOXICOL APPL PHARM, V284, P254, DOI 10.1016/j.taap.2014.12.016; Li X, 2020, J CLIN ENDOCR METAB, V105, P1947, DOI 10.1210/clinem/dgaa130; Li X, 2017, DIABETES CARE, V40, P577, DOI 10.2337/dc16-1774; Li XY, 2019, NAT REV CLIN ONCOL, V16, P425, DOI 10.1038/s41571-019-0203-7; Madden MZ, 2021, CANCER DISCOV, V11, P1636, DOI 10.1158/2159-8290.CD-20-0569; Martins CP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669456; Nakayama M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.777788; Nojima I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71946-3; Patel CH, 2017, CURR OPIN IMMUNOL, V46, P82, DOI 10.1016/j.coi.2017.04.006; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Pearce Erika L, 2013, Science, V342, P1242454, DOI 10.1126/science.1242454; Previte DM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175549; Qiu JT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.652771; Seay HR, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88242; Shan J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01027; Sharabi A, 2020, NAT REV RHEUMATOL, V16, P100, DOI 10.1038/s41584-019-0356-x; Shi M, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3461; Shi XJ, 2019, DIABETOLOGIA, V62, P399, DOI 10.1007/s00125-018-4799-4; Tan CL, 2021, J EXP MED, V218, DOI 10.1084/jem.20182232; Teniente-Serra A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.784110; Tucker CG, 2021, CURR DIABETES REP, V21, DOI 10.1007/s11892-021-01384-6; Vignali D, 2018, DIABETES, V67, P936, DOI 10.2337/db17-1390; Watson MJ, 2021, NATURE, V591, P645, DOI 10.1038/s41586-020-03045-2; Xiang YF, 2019, DIABETES OBES METAB, V21, P893, DOI 10.1111/dom.13595; Yeo L, 2018, J CLIN INVEST, V128, P3460, DOI 10.1172/JCI120555; Yin YM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0835; Zhang DF, 2019, IMMUNITY, V51, P671, DOI 10.1016/j.immuni.2019.08.001	56	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								897047	10.3389/fimmu.2022.897047	http://dx.doi.org/10.3389/fimmu.2022.897047			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W9TA	35677051	Green Published, gold			2022-12-18	WOS:000807107900001
J	Wang, WJ; Fan, YS; Wang, XC				Wang, Weijie; Fan, Yongsheng; Wang, Xinchang			Lactobacillus: Friend or Foe for Systemic Lupus Erythematosus?	FRONTIERS IN IMMUNOLOGY			English	Review						Lactobacillus; systemic lupus erythematosus (SLE); immunoregulators; pathogenesis; microbiota	INTESTINAL EPITHELIAL BARRIER; GUT MICROBIOTA; CELL; RESPONSES; RECEPTOR; PROBIOTICS; PLANTARUM; NEPHRITIS; BACTERIA; ADHESION	The cause of Systemic Lupus Erythematosus (SLE) remains largely unknown, despite the fact that it is well understood that a complex interaction between genes and environment is required for disease development. Microbiota serve as activators and are essential to immune homeostasis. Lactobacillus is thought to be an environmental agent affecting the development of SLE. However, beneficial therapeutic and anti-inflammatory effects of Lactobacillus on SLE were also explored. The discovery of Lactobacillus involvement in SLE will shed light on how SLE develops, as well as finding microbiota-targeted biomarkers and novel therapies. In this review, we attempt to describe the two sides of Lactobacillus in the occurrence, development, treatment and prognosis of SLE. We also discuss the effect of different strains Lactobacillus on immune cells, murine lupus, and patients. Finally, we try to illustrate the potential immunological mechanisms of Lactobacillus on SLE and provide evidence for further microbiota-targeted therapies.	[Wang, Weijie; Wang, Xinchang] Zhejiang Chinese Med Univ, Affiliated Hosp 2, Dept Rheumatol, Hangzhou, Peoples R China; [Fan, Yongsheng] Zhejiang Chinese Med Univ, Sch Basic Med Sci, Hangzhou, Peoples R China	Zhejiang Chinese Medical University; Zhejiang Chinese Medical University	Wang, WJ; Wang, XC (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 2, Dept Rheumatol, Hangzhou, Peoples R China.	jack1987168@163.com; ossani@126.com						Almaani S, 2017, CLIN J AM SOC NEPHRO, V12, P825, DOI 10.2215/CJN.05780616; Arai S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199018; Ashraf R, 2014, CRIT REV FOOD SCI, V54, P938, DOI 10.1080/10408398.2011.619671; Bagavant H, 2019, CLIN EXP RHEUMATOL, V37, P106; Berer K, 2011, NATURE, V479, P538, DOI 10.1038/nature10554; Berthier CC, 2012, J IMMUNOL, V189, P988, DOI 10.4049/jimmunol.1103031; Blair HA, 2018, DRUGS, V78, P355, DOI 10.1007/s40265-018-0872-z; Bornholdt J, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1854639; Brownlie RJ, 2008, J EXP MED, V205, P883, DOI 10.1084/jem.20072565; Brun PJ, 2015, FASEB J, V29, P671, DOI 10.1096/fj.14-256743; Cervantes-Barragan L, 2017, SCIENCE, V357, P806, DOI 10.1126/science.aah5825; Chaves LD, 2018, AM J PHYSIOL-RENAL, V315, pF487, DOI 10.1152/ajprenal.00092.2018; Chen BD, 2021, ARTHRITIS RHEUMATOL, V73, P232, DOI 10.1002/art.41511; Chen XX, 2020, FOOD FUNCT, V11, P10554, DOI [10.1039/d0fo02124e, 10.1039/D0FO02124E]; Chen YY, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-018-1756-4; Cuervo A, 2015, NUTRIENTS, V7, P1301, DOI 10.3390/nu7021301; de la Visitacion N, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10091426; de la Visitacion N, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082669; de Lema GP, 2004, KIDNEY INT, V66, P1018, DOI 10.1111/j.1523-1755.2004.00850.x; Dias CB, 2017, J NEPHROL, V30, P87, DOI 10.1007/s40620-015-0252-7; Domeier PP, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910464; Dorgham K, 2015, EUR J IMMUNOL, V45, P3174, DOI 10.1002/eji.201445144; Durcan L, 2019, LANCET, V393, P2332, DOI 10.1016/S0140-6736(19)30237-5; Ehlers M, 2006, J EXP MED, V203, P553, DOI 10.1084/jem.20052438; Esmaeili SA, 2021, IRAN J BASIC MED SCI, V24, P1509, DOI [10.22038/IJBMS.2021.58438.12982, 10.22038/ijbms.2021.58438.12982]; Esmaeili SA, 2018, J CELL BIOCHEM, V119, P7865, DOI 10.1002/jcb.27203; Fine RL, 2020, ADV IMMUNOL, V146, P29, DOI 10.1016/bs.ai.2020.02.002; Gerges MA, 2021, INT J MICROBIOL, V2021, DOI 10.1155/2021/9934533; Guo MC, 2020, GUT MICROBES, V11, P1758, DOI 10.1080/19490976.2020.1768644; Halkom A, 2020, INT REV IMMUNOL, V39, P174, DOI 10.1080/08830185.2020.1742712; He ZX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00978; He ZX, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0146-9; Hevia A, 2014, MBIO, V5, DOI 10.1128/mBio.01548-14; Hill GS, 2001, KIDNEY INT, V59, P304, DOI 10.1046/j.1523-1755.2001.00492.x; Hsu TC, 2017, BRIT J NUTR, V117, P1066, DOI [10.1017/S0007114517001039, 10.1017/s0007114517001039]; Hu WS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185098; Ingvarsson RF, 2016, LUPUS, V25, P772, DOI 10.1177/0961203316635288; Jhun J, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02477-8; Jia L, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1213; Jing CZ, 2020, P NATL ACAD SCI USA, V117, P15160, DOI 10.1073/pnas.2000943117; Juang JH, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/435481; Kaneko Y, 2006, J EXP MED, V203, P789, DOI 10.1084/jem.20051900; Khorasani S, 2019, J CELL PHYSIOL, V234, P9778, DOI 10.1002/jcp.27663; Kim D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.696074; Kim JW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194871; Kwon MS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01905; Li BZ, 2020, ARCH ORAL BIOL, V113, DOI 10.1016/j.archoralbio.2020.104708; Li R, 2012, RHEUMATOLOGY, V51, P721, DOI 10.1093/rheumatology/ker370; Li Y, 2019, CLIN SCI, V133, P821, DOI 10.1042/CS20180841; Liu FP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626217; Luo XM, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.02288-17; Ma YYZ, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0102-5; Maeda Y, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0283-6; Mardani F, 2019, J CELL PHYSIOL, V234, P642, DOI 10.1002/jcp.26819; Maria NI, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926-017-0708-y; Mike A, 1999, CLIN EXP IMMUNOL, V117, P368; Mockel T, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2020.102736; Morrison DJ, 2016, GUT MICROBES, V7, P189, DOI 10.1080/19490976.2015.1134082; Mu QH, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0300-8; Mu QH, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00608; Ohland CL, 2010, AM J PHYSIOL-GASTR L, V298, pG807, DOI 10.1152/ajpgi.00243.2009; Perry D, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/271694; Polak-Berecka M, 2014, ANTON LEEUW INT J G, V106, P751, DOI 10.1007/s10482-014-0245-x; Reid G, 2016, BEST PRACT RES CL GA, V30, P17, DOI 10.1016/j.bpg.2015.12.001; Ren SS, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.623451; Rescigno M, 2011, TRENDS IMMUNOL, V32, P256, DOI 10.1016/j.it.2011.04.003; Rios-Covian D, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00185; Rocha-Ramirez LM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4607491; Sabatino A, 2015, NEPHROL DIAL TRANSPL, V30, P924, DOI 10.1093/ndt/gfu287; Sanchez P, 2022, NUTRIENTS, V14, DOI 10.3390/nu14020354; Shi CW, 2020, J CELL MOL MED, V24, P8883, DOI 10.1111/jcmm.15574; Singh JA, 2021, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010668.pub2; Singh NP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023522; Thanou A, 2021, J AUTOIMMUN, V119, DOI 10.1016/j.jaut.2021.102615; Theus MH, 2017, J HISTOCHEM CYTOCHEM, V65, P69, DOI 10.1369/0022155416679638; Toral M, 2019, FASEB J, V33, P10005, DOI 10.1096/fj.201900545RR; Tsioni V, 2015, CLIN EXP RHEUMATOL, V33, P681; Tzang BS, 2017, BRIT J NUTR, V118, P333, DOI [10.1017/S0007114517002112, 10.1017/s0007114517002112]; Udayan S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85347-7; Ugarte-Gil MF, 2019, LUPUS, V28, P1031, DOI 10.1177/0961203319860907; Pacheco GV, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00022; van der Meulen TA, 2019, J AUTOIMMUN, V97, P77, DOI 10.1016/j.jaut.2018.10.009; Wang MZ, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02620-w; Wang Y, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15017522; Wei S, 2016, ARTHRITIS RHEUMATOL, V68, P2503, DOI 10.1002/art.39741; Wen M, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/5579608; Wilck N, 2017, NATURE, V551, P585, DOI 10.1038/nature24628; Xie JH, 2016, J AGR FOOD CHEM, V64, P1291, DOI 10.1021/acs.jafc.5b06177; Yadav AK, 2015, ARCH MICROBIOL, V197, P155, DOI 10.1007/s00203-014-1034-7; Yeh YL, 2021, PROBIOTICS ANTIMICRO, V13, P51, DOI 10.1007/s12602-020-09668-1; Yilmaz I, 2019, TURK J GASTROENTEROL, V30, P242, DOI 10.5152/tjg.2018.18227; Zegarra-Ruiz DF, 2019, CELL HOST MICROBE, V25, P113, DOI 10.1016/j.chom.2018.11.009; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zhang HS, 2014, APPL ENVIRON MICROB, V80, P7551, DOI 10.1128/AEM.02676-14; Zhang Y, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00628; Zhao Y, 2020, SAUDI J BIOL SCI, V27, P2111, DOI 10.1016/j.sjbs.2020.05.035	96	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								883747	10.3389/fimmu.2022.883747	http://dx.doi.org/10.3389/fimmu.2022.883747			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W5TP	35677055	Green Published, gold			2022-12-18	WOS:000806836300001
J	Weaver, GC; Arya, R; Schneider, CL; Hudson, AW; Stern, LJ				Weaver, Grant C.; Arya, Richa; Schneider, Christine L.; Hudson, Amy W.; Stern, Lawrence J.			Structural Models for Roseolovirus U20 And U21: Non-Classical MHC-I Like Proteins From HHV-6A, HHV-6B, and HHV-7 (vol 13, 864898, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						human herpesvirus; major histocompatibility protein; immunoevasion; machine learning; structure prediction; MHC1b; natural killer cell ligand; immune recognition			[Weaver, Grant C.; Stern, Lawrence J.] UMass Chan Med Sch, Morningside Grad Sch Biomed Sci, Immunol & Microbiol Grad Program, Worcester, MA 01655 USA; [Weaver, Grant C.; Arya, Richa; Stern, Lawrence J.] UMass Chan Med Sch, Dept Pathol, Worcester, MA 01655 USA; [Schneider, Christine L.] Carroll Univ, Dept Life Sci, Waukesha, WI USA; [Hudson, Amy W.] Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI USA; [Stern, Lawrence J.] UMass Chan Med Sch, Dept Biochem & Mol Biotechnol, Worcester, MA 01655 USA	Medical College of Wisconsin	Stern, LJ (corresponding author), UMass Chan Med Sch, Morningside Grad Sch Biomed Sci, Immunol & Microbiol Grad Program, Worcester, MA 01655 USA.; Stern, LJ (corresponding author), UMass Chan Med Sch, Dept Pathol, Worcester, MA 01655 USA.; Stern, LJ (corresponding author), UMass Chan Med Sch, Dept Biochem & Mol Biotechnol, Worcester, MA 01655 USA.	lawrence.stern@umassmed.edu						Weaver GC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.864898	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								936968	10.3389/fimmu.2022.936968	http://dx.doi.org/10.3389/fimmu.2022.936968			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X3FN	35677042	gold, Green Published			2022-12-18	WOS:000807343900001
J	Wittenbecher, F; Lesch, S; Kolling, S; Blau, IW; Vuong, L; Borchert, F; Movasshagi, K; Tietze-Buerger, C; Penack, O; Ahn, J; Bullinger, L; Frentsch, M; Na, IK				Wittenbecher, Friedrich; Lesch, Stella; Kolling, Stefan; Blau, Igor-Wolfgang; Vuong, Lam; Borchert, Franziska; Movasshagi, Kamran; Tietze-Buerger, Carola; Penack, Olaf; Ahn, Johann; Bullinger, Lars; Frentsch, Marco; Na, Il-Kang			Paired Donor and Recipient Immunophenotyping in Allogeneic Hematopoietic Stem Cell Transplantation: A Cellular Network Approach	FRONTIERS IN IMMUNOLOGY			English	Article						allogeneic hematopoietic stem cell transplantation (HSCT); immune subsets; reconstitution; granulocyte-colony stimulating factor (G-CSF); mobilization; immune cell network	VERSUS-HOST-DISEASE; IMMUNE RECONSTITUTION; DENDRITIC CELLS; BONE-MARROW; IMPROVED SURVIVAL; POST TRANSPLANT; ACUTE GVHD; T-CELLS; PREDICTS; GRAFTS	Success and complications of allogeneic hematopoietic stem cell transplantation (alloHSCT) are closely connected to the transferred graft and immune reconstitution post alloHSCT. Due to the variety of immune cells and their distinct roles, a broad evaluation of the immune cellular network is warranted in mobilization and reconstitution studies in alloHSCT. Here, we propose a comprehensive phenotypic analysis of 26 immune cell subsets with multicolor flow cytometry from only 100 mu l whole blood per time point. Using this approach, we provide an extensive longitudinal analysis of almost 200 time points from 21 donor-recipient pairs. We observe a broad mobilization of innate and adaptive immune cell subsets after granulocyte-colony stimulating factor (G-CSF) treatment of healthy donors. Our data suggest that the relative quantitative immune cell subset composition in recipients approaches that of healthy donors from day +180 post alloHSCT onwards. Correlation of donor and recipient cell counts reveals distinct association patterns for different immune cell subsets and hierarchical clustering of recipient cell counts identifies distinct reconstitution groups in the first month after transplantation. We suggest our comprehensive immune subset analysis as a feasible and time efficient approach for a broad immune assessment for future clinical studies in the context of alloHSCT. This comprehensive cell composition assessment can be a critical step towards personalized graft composition strategies and individualized therapy management in areas such as GvHD prophylaxis in the highly complex immunological setting of alloHSCT.	[Wittenbecher, Friedrich; Lesch, Stella; Kolling, Stefan; Blau, Igor-Wolfgang; Vuong, Lam; Borchert, Franziska; Movasshagi, Kamran; Tietze-Buerger, Carola; Penack, Olaf; Ahn, Johann; Bullinger, Lars; Frentsch, Marco; Na, Il-Kang] Corp Member ofFreie Univ Berlin, Humboldt Univ Berlin, Dept Hematol, Oncol & Tumour Immunol, Berlin, Germany; [Wittenbecher, Friedrich; Penack, Olaf; Frentsch, Marco; Na, Il-Kang] Berlin Inst Hlth, BIH Ctr Regenerat Therapies BCRT, Charite Universitatsmedizin Berlin, Berlin, Germany; [Bullinger, Lars; Na, Il-Kang] Corp Member Freie Univ Berlin, Humboldt Univ Berlin, Charite Universitatsmedizin Berlin, German Canc Consortium DKTK, Berlin, Germany; [Bullinger, Lars; Na, Il-Kang] Corp Member Freie Univ Berlin, Humboldt Univ Berlin, ECRC Expt & Clin Res Ctr, Charite Universitatsmedizin Berlin, Berlin, Germany	Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; German Cancer Research Center (DKFZ); Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Na, IK (corresponding author), Corp Member ofFreie Univ Berlin, Humboldt Univ Berlin, Dept Hematol, Oncol & Tumour Immunol, Berlin, Germany.; Na, IK (corresponding author), Berlin Inst Hlth, BIH Ctr Regenerat Therapies BCRT, Charite Universitatsmedizin Berlin, Berlin, Germany.; Na, IK (corresponding author), Corp Member Freie Univ Berlin, Humboldt Univ Berlin, Charite Universitatsmedizin Berlin, German Canc Consortium DKTK, Berlin, Germany.; Na, IK (corresponding author), Corp Member Freie Univ Berlin, Humboldt Univ Berlin, ECRC Expt & Clin Res Ctr, Charite Universitatsmedizin Berlin, Berlin, Germany.			Na, Il-Kang/0000-0001-9902-5424; Bullinger, Lars/0000-0002-5890-5510				Alexander MP, 2018, AM J KIDNEY DIS, V72, P325, DOI 10.1053/j.ajkd.2018.03.017; Ando T, 2020, BLOOD ADV, V4, P408, DOI 10.1182/bloodadvances.2019001021; Aphalo P., 2022, GGPMISC MISCELLANEOU; Auletta JJ, 2016, BONE MARROW TRANSPL, V51, P333, DOI 10.1038/bmt.2015.301; Baron F, 2020, HAEMATOLOGICA, V105, P1138, DOI 10.3324/haematol.2019.227603; Chen J, 2019, TRANSFUSION, V59, P1765, DOI 10.1111/trf.15186; De Vries A, 2016, GGDENDRO CREATE DEND; Dekker L, 2020, CANCERS, V12, DOI 10.3390/cancers12071974; Gul Z, 2015, BONE MARROW TRANSPL, V50, P432, DOI 10.1038/bmt.2014.284; Horvath R, 2009, CLIN IMMUNOL, V131, P60, DOI 10.1016/j.clim.2008.10.009; Kassambara A., 2020, R PACKAGE VERSION 06; Kassambara Alboukadel, 2020, CRAN; Kharfan-Dabaja MA, 2011, INT J HEMATOL, V93, P578, DOI 10.1007/s12185-011-0855-2; Khoder A, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01937; Loke J, 2020, BRIT J HAEMATOL, V188, P129, DOI 10.1111/bjh.16355; Melve GK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00845; Melve GK, 2011, EXPERT REV HEMATOL, V4, P563, DOI [10.1586/ehm.11.54, 10.1586/EHM.11.54]; Mensen A, 2014, BLOOD, V124, P963, DOI 10.1182/blood-2013-11-539031; Michonneau D, 2009, BRIT J HAEMATOL, V145, P107, DOI 10.1111/j.1365-2141.2008.07574.x; Miklos D, 2017, BLOOD, V130, P2243, DOI 10.1182/blood-2017-07-793786; Ogonek J, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00507; Ottinger HD, 1996, BLOOD, V88, P2775, DOI 10.1182/blood.V88.7.2775.bloodjournal8872775; Pabst C, 2007, CLIN CANCER RES, V13, P2916, DOI 10.1158/1078-0432.CCR-06-2602; Perez-Andres M, 2010, CYTOM PART B-CLIN CY, V78B, pS47, DOI 10.1002/cyto.b.20547; Pham HP, 2021, TRANSFUSION, V61, P1518, DOI 10.1111/trf.16370; R Core Team, 2020, R LANG ENV STAT COMP; R Studio Team, 2020, INTEGRATED DEV R; Rajasekar R, 2008, BIOL BLOOD MARROW TR, V14, P344, DOI 10.1016/j.bbmt.2007.12.494; Rajasekar R, 2010, BIOL BLOOD MARROW TR, V16, P854, DOI 10.1016/j.bbmt.2010.01.013; Reshef R, 2015, J CLIN ONCOL, V33, P2392, DOI 10.1200/JCO.2014.60.1203; Roll P, 2015, EUR J HAEMATOL, V95, P514, DOI 10.1111/ejh.12524; Saraceni F, 2015, BONE MARROW TRANSPL, V50, P886, DOI 10.1038/bmt.2014.330; Sarantopoulos S, 2009, BLOOD, V113, P3865, DOI 10.1182/blood-2008-09-177840; Seggewiss R, 2010, BLOOD, V115, P3861, DOI 10.1182/blood-2009-12-234096; Singh AK, 2016, CANCER RES, V76, P6445, DOI 10.1158/0008-5472.CAN-16-1311; Small TN, 2009, BIOL BLOOD MARROW TR, V15, P104, DOI 10.1016/j.bbmt.2008.10.016; Srinivasan M, 2012, BLOOD, V119, P1570, DOI 10.1182/blood-2011-07-364414; Storek J, 2001, BLOOD, V97, P3380, DOI 10.1182/blood.V97.11.3380; Talarn C, 2006, BONE MARROW TRANSPL, V37, P873, DOI 10.1038/sj.bmt.1705345; Vakkila J, 2005, BONE MARROW TRANSPL, V35, P501, DOI 10.1038/sj.bmt.1704827; van der Maas NG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00782; Waller EK, 2019, BLOOD ADV, V3, P2250, DOI 10.1182/bloodadvances.2018029892; Waller EK, 2019, BIOL BLOOD MARROW TR, V25, P2002, DOI 10.1016/j.bbmt.2019.06.023; Waller EK, 2014, J CLIN ONCOL, V32, P2365, DOI 10.1200/JCO.2013.54.4577; Waller EK, 2001, BLOOD, V97, P2948, DOI 10.1182/blood.V97.10.2948; Warnes GR., 2021, GTOOLS VARIOUS R PRO; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wickham H, 2011, J STAT SOFTW, V40, P1, DOI 10.18637/jss.v040.i01; Wickham H, 2007, J STAT SOFTW, V21, P1; Xu Zhijing, 2019, Epidemics, V27, P19, DOI 10.1016/j.epidem.2018.12.003; Zeiser R, 2017, NEW ENGL J MED, V377, P2565, DOI 10.1056/NEJMra1703472; Zeiser R, 2017, NEW ENGL J MED, V377, P2167, DOI 10.1056/NEJMra1609337; Zhao XY, 2009, BONE MARROW TRANSPL, V44, P721, DOI 10.1038/bmt.2009.73	53	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								874499	10.3389/fimmu.2022.874499	http://dx.doi.org/10.3389/fimmu.2022.874499			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Y0EZ	35677053	Green Published, Green Accepted, gold			2022-12-18	WOS:000807821000001
J	Wu, XL; Schmidt-Wolf, IGH				Wu, Xiaolong; Schmidt-Wolf, Ingo G. H.			An Alternative Source for Allogeneic CAR T Cells With a High Safety Profile	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						CIK (cytokine-induced killer) cells; CAR (chimeric antigen receptor) T cells; allogeneic; safety; efficacy	INDUCED KILLER-CELLS; ACUTE LYMPHOBLASTIC-LEUKEMIA; INDUCTION		[Wu, Xiaolong] Sichuan Univ, West China Hosp, Clin Trial Ctr, Natl Med Prod Adm Key Lab Clin Res & Evaluat Innov, Chengdu, Peoples R China; [Wu, Xiaolong; Schmidt-Wolf, Ingo G. H.] Univ Hosp Bonn, Ctr Integrated Oncol CIO Bonn, Dept Integrated Oncol, Bonn, Germany	Sichuan University; University of Bonn	Schmidt-Wolf, IGH (corresponding author), Univ Hosp Bonn, Ctr Integrated Oncol CIO Bonn, Dept Integrated Oncol, Bonn, Germany.	Ingo.Schmidt-Wolf@ukbonn.de			Deutsche Krebshilfe	Deutsche Krebshilfe(Deutsche Krebshilfe)	The CIO Aachen Bonn Koeln Duesseldorf is kindly supported by the Deutsche Krebshilfe.	[Anonymous], 2022, GEN CELL RNA THER LA; Baker J, 2001, BLOOD, V97, P2923, DOI 10.1182/blood.V97.10.2923; Bartolo-Ibars A, 2021, CANCERS, V13, DOI 10.3390/cancers13184664; Benjamin R, 2020, LANCET, V396, P1885, DOI 10.1016/S0140-6736(20)32334-5; Cappuzzello E, 2017, CYTOKINE GROWTH F R, V36, P99, DOI 10.1016/j.cytogfr.2017.06.003; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446; Heczey A, 2020, NAT MED, V26, P1686, DOI 10.1038/s41591-020-1074-2; Hombach AA, 2013, MOL THER, V21, P2268, DOI 10.1038/mt.2013.192; Kamiya T, 2018, BLOOD ADV, V2, P517, DOI 10.1182/bloodadvances.2017012823; Leuci V, 2020, CLIN CANCER RES, V26, P6321, DOI 10.1158/1078-0432.CCR-20-0357; LU PH, 1994, J IMMUNOL, V153, P1687; Magnani CF, 2020, J CLIN INVEST, V130, P6021, DOI 10.1172/JCI138473; Magnani CF, 2016, ONCOTARGET, V7, P51581, DOI 10.18632/oncotarget.9955; Makkouk A, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003441; Merker M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581468; Merker M, 2019, BIOL BLOOD MARROW TR, V25, P1281, DOI 10.1016/j.bbmt.2019.03.004; Oelsner S, 2016, INT J CANCER, V139, P1799, DOI 10.1002/ijc.30217; Ramos CA, 2021, BLOOD, V138, DOI 10.1182/blood-2021-149712; Rettinger E, 2012, CYTOTHERAPY, V14, P91, DOI 10.3109/14653249.2011.613931; Rozenbaum M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01347; Ruella M, 2018, NAT MED, V24, P1499, DOI 10.1038/s41591-018-0201-9; SCHMIDTWOLF IGH, 1993, EXP HEMATOL, V21, P1673; SCHMIDTWOLF IGH, 1991, J EXP MED, V174, P139, DOI 10.1084/jem.174.1.139; Sheridan C, 2022, NAT BIOTECHNOL, V40, P5, DOI 10.1038/d41587-021-00027-1; Stenger D, 2020, BLOOD, V136, P1407, DOI 10.1182/blood.2020005185; van Bruggen JAC, 2019, BLOOD, V134, P44, DOI 10.1182/blood.2018885863; Wu XL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.731767	28	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								913123	10.3389/fimmu.2022.913123	http://dx.doi.org/10.3389/fimmu.2022.913123			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1X1UM	35677035	Green Published, gold			2022-12-18	WOS:000807247000001
J	Yan, SP; Zhang, CH; Ji, XX; Wu, G; Huang, XH; Zhang, YF; Zhang, YS				Yan, Shuping; Zhang, Chonghao; Ji, Xiaoxia; Wu, Gang; Huang, Xinhe; Zhang, Yafeng; Zhang, Yuanshu			MSC-ACE2 Ameliorates Streptococcus uberis-Induced Inflammatory Injury in Mammary Epithelial Cells by Upregulating the IL-10/STAT3/SOCS3 Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						S; uberis; MSC-ACE2; inflammatory injury; pyroptosis; blood-milk barrier; mammary epithelial cells	MESENCHYMAL STEM-CELLS; BLOOD-MILK BARRIER; MASTITIS; TRANSPLANTATION; APOPTOSIS; CASPASES; PROTECTS; IL-10	In the dairy industry, Streptococcus uberis (S. uberis) is one of the most important pathogenic bacteria associated with mastitis in milk-producing cows, causing vast economic loss. To date, the only real effective method of treating and preventing streptococcal mastitis is antimicrobial therapy. In many inflammatory diseases, mesenchymal stem cells (MSCs) and angiotensin-converting enzyme 2 (ACE2) play an anti-inflammatory and anti-injurious role. Accordingly, we hypothesized that MSCs overexpressing ACE2 (MSC-ACE2) would ameliorate the inflammatory injury caused by S. uberis in mammary epithelial cells more efficiently than MSC alone. By activating the transcription 3/suppressor of cytokine signaling 3 (IL-10/STAT3/SOCS3) signaling pathway, MSC-ACE2 inhibited the NF-kappa B, MAPKs, apoptosis, and pyroptosis passways. Moreover, MSC-ACE2 overturned the downregulation of Occludin, Zonula occludens 1 (ZO-1), and Claudin-3 expression levels caused by S. uberis, suggesting that MSC-ACE2 promotes the repair of the blood-milk barrier. MSC-ACE2 demonstrated greater effectiveness than MSC alone, as expected. Based on these results, MSC-ACE2 effectively inhibits EpH4-Ev cell's inflammatory responses induced by S. uberis, and would be an effective therapeutic tool for treating streptococcal mastitis.	[Yan, Shuping; Zhang, Chonghao; Ji, Xiaoxia; Wu, Gang; Huang, Xinhe; Zhang, Yafeng; Zhang, Yuanshu] Nanjing Agr Univ, Coll Vet Med, Key Lab Anim Physiol & Biochem, Minist Agr, Nanjing, Peoples R China	Ministry of Agriculture & Rural Affairs; Nanjing Agricultural University	Zhang, YS (corresponding author), Nanjing Agr Univ, Coll Vet Med, Key Lab Anim Physiol & Biochem, Minist Agr, Nanjing, Peoples R China.	zhangyuanshu3014@126.com			National Natural Science Foundation of China [31972640]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions	This research was funded by the National Natural Science Foundation of China, grant number 31972640, and Priority Academic Program Development of Jiangsu Higher Education Institutions.	Assis BS, 2015, BENEF MICROBES, V6, P879, DOI 10.3920/BM2015.0019; Banas A, 2008, STEM CELLS, V26, P2705, DOI 10.1634/stemcells.2008-0034; Bonfield TL, 2021, STEM CELL TRANSL MED, V10, P1202, DOI 10.1002/sctm.20-0521; Bruckmaier RM, 2017, J ANIM SCI, V95, P5720, DOI 10.2527/jas2017.1845; Dalanezi FM, 2020, J DAIRY SCI, V103, P3648, DOI 10.3168/jds.2019-16841; Dang RL, 2021, AGING CELL, V20, DOI 10.1111/acel.13480; Duan XH, 2017, INT J NANOMED, V12, P6705, DOI 10.2147/IJN.S146742; Duan YQ, 2019, CIRC RES, V125, P969, DOI 10.1161/CIRCRESAHA.119.315743; Fang L, 2014, CELL SIGNAL, V26, P806, DOI 10.1016/j.cellsig.2013.12.016; Ferrarini I, 2022, HAEMATOLOGICA, V107, P790, DOI 10.3324/haematol.2021.280201; Fessia AS, 2022, MICROBES INFECT, V24, DOI 10.1016/j.micinf.2021.104914; Gao Y, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006809; Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228; Heikkila AM, 2018, J DAIRY SCI, V101, P9493, DOI 10.3168/jds.2018-14824; Hofmann M, 2005, CIRCULATION, V111, P2198, DOI 10.1161/01.CIR.0000163546.27639.AA; Hovinen M, 2016, J DAIRY RES, V83, P219, DOI 10.1017/S0022029916000224; Hu XY, 2020, ISME J, V14, P1897, DOI 10.1038/s41396-020-0651-1; Islam D, 2019, AM J RESP CRIT CARE, V199, P1214, DOI 10.1164/rccm.201802-0356OC; Jahan S, 2017, CURR MED CHEM, V24, P1645, DOI 10.2174/0929867324666170227121619; Keane OM, 2019, J DAIRY SCI, V102, P4713, DOI 10.3168/jds.2018-15326; Kobayashi K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062187; Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544; Kumar DN, 2020, ACS SENSORS, V5, P1969, DOI 10.1021/acssensors.0c00348; Lan RG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.696101; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Lee DH, 2008, BIOCHEM PHARMACOL, V75, P2020, DOI 10.1016/j.bcp.2008.02.023; Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430; Lee KC, 2016, J HEPATOL, V64, P989, DOI 10.1016/j.jhep.2015.12.011; Li XL, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287-021-02690-2; Li ZQ, 2022, PEPTIDES, V149, DOI 10.1016/j.peptides.2021.170717; Marx C, 2021, STEM CELL TRANSL MED, V10, P1666, DOI 10.1002/sctm.21-0058; Naserian S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-02057-z; Ravenscroft H, 2022, AM J PATHOL, V192, P956, DOI 10.1016/j.ajpath.2022.02.005; Rottenberg ME, 2014, SEMIN IMMUNOL, V26, P518, DOI 10.1016/j.smim.2014.10.004; Saffari S, 2021, NEURAL REGEN RES, V16, P1510, DOI 10.4103/1673-5374.303009; Saleem R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222413458; Saraiva M, 2010, NAT REV IMMUNOL, V10, P170, DOI 10.1038/nri2711; Schmetterer KG, 2017, EUR J IMMUNOL, V47, P1256, DOI 10.1002/eji.201646710; Sherwin VE, 2021, J DAIRY SCI, V104, P12042, DOI 10.3168/jds.2021-20310; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Siddiqui WA, 2015, ARCH TOXICOL, V89, P289, DOI 10.1007/s00204-014-1448-7; Tsugami Y, 2017, J AGR FOOD CHEM, V65, P11118, DOI 10.1021/acs.jafc.7b04786; Van Opdenbosch N, 2019, IMMUNITY, V50, P1352, DOI 10.1016/j.immuni.2019.05.020; Wald R, 2020, J DAIRY SCI, V103, P1820, DOI 10.3168/jds.2019-16930; Wan ZX, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106142; Wang J, 2015, PANCREAS, V44, P266, DOI 10.1097/MPA.0000000000000247; Wang JJ, 2017, BRIT J PHARMACOL, V174, P3811, DOI 10.1111/bph.13976; Wang K, 2017, INT IMMUNOPHARMACOL, V46, P23, DOI 10.1016/j.intimp.2017.02.016; Wen ZH, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.787091; Wen ZH, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-021-05115-4; Whidbey C, 2015, EMBO MOL MED, V7, P488, DOI 10.15252/emmm.201404883; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Xu JF, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.793829; Xu ZC, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.572425; Yan SP, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.796744; Yin BH, 2022, THERANOSTICS, V12, P207, DOI 10.7150/thno.62708; You LT, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/1045345; Zheng M, 2020, IMMUNOL REV, V297, P26, DOI 10.1111/imr.12909; Zhou H, 2022, INT J BIOL MACROMOL, V198, P1, DOI 10.1016/j.ijbiomac.2021.12.112; Zhou Y, 2022, NEURAL REGEN RES, V17, P194, DOI 10.4103/1673-5374.314323; Ziesch M, 2018, J VET PHARMACOL THER, V41, P11, DOI 10.1111/jvp.12415	62	0	0	10	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								870780	10.3389/fimmu.2022.870780	http://dx.doi.org/10.3389/fimmu.2022.870780			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W4TQ	35677060	Green Published, gold			2022-12-18	WOS:000806768000001
J	Zhang, CL; Zhang, YX; Tan, GY; Mi, WQ; Zhong, XL; Zhang, Y; Zhao, ZY; Li, F; Xu, YJ; Zhang, YP				Zhang, Chunlong; Zhang, Yuxi; Tan, Guiyuan; Mi, Wanqi; Zhong, Xiaoling; Zhang, Yu; Zhao, Ziyan; Li, Feng; Xu, Yanjun; Zhang, Yunpeng			Prognostic Features of the Tumor Immune Microenvironment in Glioma and Their Clinical Applications: Analysis of Multiple Cohorts	FRONTIERS IN IMMUNOLOGY			English	Article						glioma; immune microenvironment; prognosis; subpathway; multiple cohorts	MICROGLIA; CELLS	Glioma is the most common malignant tumor of the central nervous system. Tumor purity is a source of important prognostic factor for glioma patients, showing the key roles of the microenvironment in glioma prognosis. In this study, we systematically screened functional characterization related to the tumor immune microenvironment and constructed a risk model named Glioma MicroEnvironment Functional Signature (GMEFS) based on eight cohorts. The prognostic value of the GMEFS model was also verified in another two glioma cohorts, glioblastoma (GBM) and low-grade glioma (LGG) cohorts, from The Cancer Genome Atlas (TCGA). Nomograms were established in the training and testing cohorts to validate the clinical use of this model. Furthermore, the relationships between the risk score, intrinsic molecular subtypes, tumor purity, and tumor-infiltrating immune cell abundance were also evaluated. Meanwhile, the performance of the GMEFS model in glioma formation and glioma recurrence was systematically analyzed based on 16 glioma cohorts from the Gene Expression Omnibus (GEO) database. Based on multiple-cohort integrated analysis, risk subpathway signatures were identified, and a drug-subpathway association network was further constructed to explore candidate therapy target regions. Three subpathways derived from Focal adhesion (path: 04510) were identified and contained known targets including platelet derived growth factor receptor alpha (PDGFRA), epidermal growth factor receptor (EGFR), and erb-b2 receptor tyrosine kinase 2 (ERBB2). In conclusion, the novel functional signatures identified in this study could serve as a robust prognostic biomarker, and this study provided a framework to identify candidate therapeutic target regions, which further guide glioma patients' clinical decision.	[Zhang, Chunlong; Zhang, Yuxi; Tan, Guiyuan; Mi, Wanqi; Zhong, Xiaoling; Zhang, Yu; Zhao, Ziyan; Li, Feng; Xu, Yanjun; Zhang, Yunpeng] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China	Harbin Medical University	Li, F; Xu, YJ; Zhang, YP (corresponding author), Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.	lifeng@hrbmu.edu.cn; xuyanjun@hrbmu.edu.cn; zhangyp@hrbmu.edu.cn		Xu, Yanjun/0000-0002-6552-4476	National Natural Science Foundation of China [62172131, 62101164]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (Grant Nos. 62172131 and 62101164).	Aran D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9971; Bagaev A, 2021, CANCER CELL, V39, P845, DOI 10.1016/j.ccell.2021.04.014; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Cheng FX, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10744-6; Cheng Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.686909; Franzen O, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz046; Frigerio CS, 2019, CELL REP, V27, P1293, DOI 10.1016/j.celrep.2019.03.099; Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109; Goeman JJ, 2010, BIOMETRICAL J, V52, P70, DOI 10.1002/bimj.200900028; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791; Jiang J, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101769; Johansson P, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107897; Li CQ, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt161; Li CQ, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp667; Li HN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.698278; Lin SJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.541401; Lin WZ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00796; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Lu JJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08456-6; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Mischel PS, 2003, BRAIN PATHOL, V13, P52; Muller S, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1362-4; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Olah M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19737-2; Prinz M, 2014, NAT REV NEUROSCI, V15, P300, DOI 10.1038/nrn3722; Prinz M, 2011, NAT NEUROSCI, V14, P1227, DOI 10.1038/nn.2923; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Simmons GW, 2011, J NEUROPATH EXP NEUR, V70, P51, DOI 10.1097/NEN.0b013e3182032d37; Tan YQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.606164; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Wolf DM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088309; Wu F, 2020, J PATHOL, V251, P272, DOI 10.1002/path.5468; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu WL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.706936; Zhang CB, 2017, CLIN CANCER RES, V23, P6279, DOI 10.1158/1078-0432.CCR-16-2598; Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900; Zhao BH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.557994; Zhao WJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.682415; Zheng Y, 2021, J CELL MOL MED, V25, P3080, DOI 10.1111/jcmm.16368; Zhou Y, 2022, NUCLEIC ACIDS RES, V50, pD1398, DOI 10.1093/nar/gkab953; Zolotovskaia M, 2021, CANCERS, V13, DOI 10.3390/cancers13164117	43	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								853074	10.3389/fimmu.2022.853074	http://dx.doi.org/10.3389/fimmu.2022.853074			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W6AF	35677045	gold, Green Published			2022-12-18	WOS:000806854000001
J	Zhang, MM; Fei, SG; Xia, JM; Wang, YY; Wu, HY; Li, X; Guo, YY; Swevers, L; Sun, JC; Feng, M				Zhang, Mengmeng; Fei, Shigang; Xia, Junming; Wang, Yeyuan; Wu, Hongyun; Li, Xian; Guo, Yiyao; Swevers, Luc; Sun, Jingchen; Feng, Min			Sirt5 Inhibits BmNPV Replication by Promoting a Relish-Mediated Antiviral Pathway in Bombyx mori	FRONTIERS IN IMMUNOLOGY			English	Article						sirtuins; Sirt5; Bombyx mori; BmNPV; Relish	GENOME; SIRTUINS; METABOLISM; SILKWORM; SEQUENCE	Silent information regulators (Sirtuins) belong to the family of nicotinamide adenine dinucleotide (NAD(+))-dependent histone deacetylases (HDACs) that have diverse functions in cells. Mammalian Sirtuins have seven isoforms (Sirt1-7) which have been found to play a role in viral replication. However, Sirtuin members of insects are very different from mammals, and the function of insect Sirtuins in regulating virus replication is unclear. The silkworm, Bombyx mori, as a model species of Lepidoptera, is also an important economical insect. B. mori nucleopolyhedrovirus (BmNPV) is a major pathogen that specifically infects silkworms and causes serious losses in the sericulture industry. Here, we used the infection of the silkworm by BmNPV as a model to explore the effect of Sirtuins on virus replication. We initially knocked down all silkworm Sirtuins, and then infected with BmNPV to analyze its replication. Sirt2 and Sirt5 were found to have potential antiviral functions in the silkworm. We further confirmed the antiviral function of silkworm Sirt5 through its effects on viral titers during both knockdown and overexpression experiments. Additionally, Suramin, a Sirt5 inhibitor, was found to promote BmNPV replication. In terms of molecular mechanism, it was found that silkworm Sirt5 might promote the immune pathway mediated by Relish, thereby enhancing the host antiviral response. This study is the first to explore the role of Sirtuins in insect-virus interactions, providing new insights into the functional role of members of the insect Sirtuin family.	[Zhang, Mengmeng; Fei, Shigang; Xia, Junming; Wang, Yeyuan; Wu, Hongyun; Li, Xian; Guo, Yiyao; Sun, Jingchen; Feng, Min] South China Agr Univ, Coll Anim Sci, Guangdong Prov Key Lab Agroanim Genom & Mol Breedi, Guangzhou, Peoples R China; [Swevers, Luc] Natl Ctr Sci Res Demokritos, Inst Biosci & Applicat, Insect Mol Genet & Biotechnol, Athens, Greece	South China Agricultural University; National Centre of Scientific Research "Demokritos"	Sun, JC; Feng, M (corresponding author), South China Agr Univ, Coll Anim Sci, Guangdong Prov Key Lab Agroanim Genom & Mol Breedi, Guangzhou, Peoples R China.	cyfz@scau.edu.cn; hunanfengmin@scau.edu.cn			Basic and Applied Basic Research Project of Guangzhou Basic Research Program; Natural Science Foundation of Guangdong Basic and Applied Basic Research Fund [2022A1515012657]; South China Agricultural University high-level talent launch project; Guangdong Provincial Promotion Project on Preservation and Utilization of Local Breed of Livestock and Poultry (No.2018-143) [2018-143]	Basic and Applied Basic Research Project of Guangzhou Basic Research Program; Natural Science Foundation of Guangdong Basic and Applied Basic Research Fund; South China Agricultural University high-level talent launch project; Guangdong Provincial Promotion Project on Preservation and Utilization of Local Breed of Livestock and Poultry (No.2018-143)	This work was supported by the Basic and Applied Basic Research Project of Guangzhou Basic Research Program (2022, Project Title: Functional study on the regulation of BmNPV replication by the silkworm Sirtuin gene family), The Natural Science Foundation of Guangdong Basic and Applied Basic Research Fund (2022A1515012657); South China Agricultural University high-level talent launch project; and Guangdong Provincial Promotion Project on Preservation and Utilization of Local Breed of Livestock and Poultry (No.2018-143).	Alqarni MH, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020460; Budayeva HG, 2016, J VIROL, V90, P5, DOI 10.1128/JVI.03220-14; Choi JE, 2014, CURR OPIN GENET DEV, V26, P24, DOI 10.1016/j.gde.2014.05.005; Fukuda Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082623; Ghedin E, 2007, SCIENCE, V317, P1756, DOI 10.1126/science.1145406; Goldberg T, 2014, NUCLEIC ACIDS RES, V42, pW350, DOI 10.1093/nar/gku396; Gomi S, 1999, J GEN VIROL, V80, P1323, DOI 10.1099/0022-1317-80-5-1323; Greiss S, 2009, MOL CELLS, V28, P407, DOI 10.1007/s10059-009-0169-x; He XY, 2021, THERANOSTICS, V11, P7235, DOI 10.7150/thno.52934; Hong YA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186686; Hua XT, 2018, J BIOL CHEM, V293, P11878, DOI 10.1074/jbc.RA117.000194; Huarachi Olivera Ronald Eleazar, 2020, Rev Fac Cien Med Univ Nac Cordoba, V77, P117, DOI 10.31053/1853.0605.v77.n2.28196; Jiang L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639092; Jin QH, 2007, J CELL PHYSIOL, V213, P88, DOI 10.1002/jcp.21091; Kingsolver MB, 2013, J MOL BIOL, V425, P4921, DOI 10.1016/j.jmb.2013.10.006; Koyuncu E, 2014, MBIO, V5, DOI 10.1128/mBio.02249-14; Li QH, 2014, J VIROL, V88, P6355, DOI 10.1128/JVI.00219-14; Lu F, 2020, NUCLEIC ACIDS RES, V48, pD749, DOI 10.1093/nar/gkz919; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; Mesquita I, 2016, CELL MOL LIFE SCI, V73, P1225, DOI 10.1007/s00018-015-2119-4; Michishita E, 2005, MOL BIOL CELL, V16, P4623, DOI 10.1091/mbc.E05-01-0033; Piracha ZZ, 2020, J VIROL, V94, DOI 10.1128/JVI.00926-20; Qin KW, 2017, J AUTOIMMUN, V81, P120, DOI 10.1016/j.jaut.2017.04.006; Rajabi N, 2018, PROG MOL BIOL TRANSL, V154, P25, DOI 10.1016/bs.pmbts.2017.11.003; Ramakrishnan Muthannan Andavar, 2016, World J Virol, V5, P85, DOI 10.5501/wjv.v5.i2.85; Richards S, 2008, NATURE, V452, P949, DOI 10.1038/nature06784; SAKURAI H, 1990, BIOCHIM BIOPHYS ACTA, V1087, P18, DOI 10.1016/0167-4781(90)90115-I; Schuetz A, 2007, STRUCTURE, V15, P377, DOI 10.1016/j.str.2007.02.002; Sheng XL, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009506; Solignac M, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-403; Song JB, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.01.18; Stein LD, 2003, PLOS BIOL, V1, P166, DOI 10.1371/journal.pbio.0000045; Symantec, 2019, US; Tanno M, 2007, J BIOL CHEM, V282, P6823, DOI 10.1074/jbc.M609554200; Yang T, 2015, REV MED VIROL, V25, P431, DOI 10.1002/rmv.1858; Yao LG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032510	36	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 23	2022	13								906738	10.3389/fimmu.2022.906738	http://dx.doi.org/10.3389/fimmu.2022.906738			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A6TL	35693834	Green Published, gold			2022-12-18	WOS:000809632000001
J	Bernard, NF; Kant, S; Kiani, Z; Tremblay, C; Dupuy, FP				Bernard, Nicole F.; Kant, Sanket; Kiani, Zahra; Tremblay, Cecile; Dupuy, Franck P.			Natural Killer Cells in Antibody Independent and Antibody Dependent HIV Control	FRONTIERS IN IMMUNOLOGY			English	Review						HIV; elite controllers; NK cells; killer immunoglobulin-like receptors; HLA; ADCC; antibody dependent NK cell activation	IMMUNODEFICIENCY-VIRUS TYPE-1; MHC CLASS-I; HUMAN CYTOMEGALOVIRUS-INFECTION; COPY-NUMBER VARIATION; HLA-C EXPRESSION; MEMORY B-CELL; NK CELLS; INHIBITORY RECEPTORS; VACCINE EFFICACY; CYTOTOXICITY RESPONSES	Infection with the human immunodeficiency virus (HIV), when left untreated, typically leads to disease progression towards acquired immunodeficiency syndrome. Some people living with HIV (PLWH) control their virus to levels below the limit of detection of standard viral load assays, without treatment. As such, they represent examples of a functional HIV cure. These individuals, called Elite Controllers (ECs), are rare, making up <1% of PLWH. Genome wide association studies mapped genes in the major histocompatibility complex (MHC) class I region as important in HIV control. ECs have potent virus specific CD8(+) T cell responses often restricted by protective MHC class I antigens. Natural Killer (NK) cells are innate immune cells whose activation state depends on the integration of activating and inhibitory signals arising from cell surface receptors interacting with their ligands on neighboring cells. Inhibitory NK cell receptors also use a subset of MHC class I antigens as ligands. This interaction educates NK cells, priming them to respond to HIV infected cell with reduced MHC class I antigen expression levels. NK cells can also be activated through the crosslinking of the activating NK cell receptor, CD16, which binds the fragment crystallizable portion of immunoglobulin G. This mode of activation confers NK cells with specificity to HIV infected cells when the antigen binding portion of CD16 bound immunoglobulin G recognizes HIV Envelope on infected cells. Here, we review the role of NK cells in antibody independent and antibody dependent HIV control.	[Bernard, Nicole F.; Kant, Sanket; Kiani, Zahra; Dupuy, Franck P.] Res Inst McGill Univ Hlth Ctr, Montreal, PQ, Canada; [Bernard, Nicole F.; Kant, Sanket; Kiani, Zahra] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Bernard, Nicole F.; Kant, Sanket; Kiani, Zahra; Dupuy, Franck P.] Res Inst McGill Univ Hlth Ctr, Infect Dis Immunol & Global Hlth Program, Montreal, PQ, Canada; [Bernard, Nicole F.] McGill Univ Hlth Ctr, Div Clin Immunol, Montreal, PQ, Canada; [Tremblay, Cecile] Ctr Rech Ctr Hospitalier Univ Montreal CRCHUM, Montreal, PQ, Canada; [Tremblay, Cecile] Univ Montreal, Dept Microbiol Infectiol & Immunol, Montreal, PQ, Canada	McGill University; McGill University; Universite de Montreal	Bernard, NF (corresponding author), Res Inst McGill Univ Hlth Ctr, Montreal, PQ, Canada.; Bernard, NF (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ, Canada.; Bernard, NF (corresponding author), Res Inst McGill Univ Hlth Ctr, Infect Dis Immunol & Global Hlth Program, Montreal, PQ, Canada.; Bernard, NF (corresponding author), McGill Univ Hlth Ctr, Div Clin Immunol, Montreal, PQ, Canada.	nicole.bernard@mcgill.ca			Canadian Institute for Health Research (CIHR) [MOP-142494, PJT-148491]; Fonds de Recherche du Quebec-Sante (FRQ-S) AIDS and Infectious Diseases Network grant	Canadian Institute for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Fonds de Recherche du Quebec-Sante (FRQ-S) AIDS and Infectious Diseases Network grant	Funding This work was supported by Canadian Institute for Health Research (CIHR) operating grant MOP-142494 and project grant # PJT-148491 and by the Fonds de Recherche du Quebec-Sante (FRQ-S) AIDS and Infectious Diseases Network grant.	Ackerman ME, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005315; Ahlenstiel G, 2008, J CLIN INVEST, V118, P1017, DOI 10.1172/JCI32400; Ahmad R, 2001, J CLIN IMMUNOL, V21, P227, DOI 10.1023/A:1011087132180; Alberti MO, 2015, AIDS RES HUM RETROV, V31, P1278, DOI 10.1089/aid.2015.0074; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Alsulami K, 2021, J VIROL, V95, DOI 10.1128/JVI.00417-21; Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100; Alter G, 2007, J EXP MED, V204, P3027, DOI 10.1084/jem.20070695; Alter G, 2007, J INFECT DIS, V195, P1452, DOI 10.1086/513878; Alter G, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20177881; Alter G, 2011, NATURE, V476, P96, DOI 10.1038/nature10237; Anand SP, 2021, J VIROL, V95, DOI 10.1128/JVI.00796-21; Anfossi N, 2006, IMMUNITY, V25, P331, DOI 10.1016/j.immuni.2006.06.013; Apps R, 2016, CELL HOST MICROBE, V19, P686, DOI 10.1016/j.chom.2016.04.005; Apps R, 2013, SCIENCE, V340, P87, DOI 10.1126/science.1232685; Berger CT, 2011, J VIROL, V85, P9334, DOI 10.1128/JVI.00460-11; Bernard NF., 2011, HIV INFECT ERA HIGHL; Bernard Nicole F, 2017, Front Immunol, V8, P1033, DOI 10.3389/fimmu.2017.01033; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; BIASSONI R, 1995, J EXP MED, V182, P605, DOI 10.1084/jem.182.2.605; Blais ME, 2011, IMMUNOLOGY, V133, P1, DOI 10.1111/j.1365-2567.2011.03422.x; Blankson JN, 2007, J VIROL, V81, P2508, DOI 10.1128/JVI.02165-06; Blankson JN, 2010, DISCOV MED, V9, P261; Bonaparte MI, 2004, BLOOD, V104, P2087, DOI 10.1182/blood-2004-02-0696; Boudreau JE, 2018, TRENDS IMMUNOL, V39, P222, DOI 10.1016/j.it.2017.12.001; Boudreau JE, 2016, J IMMUNOL, V196, P3398, DOI 10.4049/jimmunol.1502469; Boulet S, 2010, J IMMUNOL, V184, P2057, DOI 10.4049/jimmunol.0902621; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brodin P, 2009, TRENDS IMMUNOL, V30, P143, DOI 10.1016/j.it.2009.01.006; Bruel T, 2017, J VIROL, V91, DOI 10.1128/JVI.02440-16; Bruel T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10844; Buckner CM, 2016, J INFECT DIS, V214, P390, DOI 10.1093/infdis/jiw163; Bussmann BM, 2010, VIROLOGY, V397, P7, DOI 10.1016/j.virol.2009.11.003; Carlson JM, 2012, J VIROL, V86, P5230, DOI 10.1128/JVI.06728-11; Ochoa MC, 2017, IMMUNOL CELL BIOL, V95, P347, DOI 10.1038/icb.2017.6; Carr WH, 2005, J IMMUNOL, V175, P5222, DOI 10.4049/jimmunol.175.8.5222; Carrington M., THE KIR GENE CLUSTER, P1; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; Cerwenka A, 2016, NAT REV IMMUNOL, V16, P112, DOI 10.1038/nri.2015.9; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; Checkley MA, 2011, J MOL BIOL, V410, P582, DOI 10.1016/j.jmb.2011.04.042; Chen X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02322; Chereau F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173893; Chung AW, 2011, JAIDS-J ACQ IMM DEF, V58, P127, DOI 10.1097/QAI.0b013e31822c62b9; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COLONNA M, 1993, P NATL ACAD SCI USA, V90, P12000, DOI 10.1073/pnas.90.24.12000; Corrah TW, 2011, J VIROL, V85, P3367, DOI 10.1128/JVI.02276-10; Cox A, 2021, TRENDS PHARMACOL SCI, V42, P789, DOI 10.1016/j.tips.2021.06.004; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Ding SL, 2016, J VIROL, V90, P2127, DOI 10.1128/JVI.02779-15; Dupuy FP, 2019, MBIO, V10, DOI 10.1128/mBio.02690-19; Edmonds TG, 2010, VIROLOGY, V408, P1, DOI 10.1016/j.virol.2010.08.028; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; El-Far M, 2016, SCI REP-UK, V6, DOI 10.1038/srep22902; Elliott JM, 2011, TRENDS IMMUNOL, V32, P364, DOI 10.1016/j.it.2011.06.001; Emu B, 2005, J VIROL, V79, P14169, DOI 10.1128/JVI.79.22.14169-14178.2005; Emu B, 2008, J VIROL, V82, P5398, DOI 10.1128/JVI.02176-07; Farsakoglu Y, 2019, CELL REP, V26, P2307, DOI 10.1016/j.celrep.2019.01.104; Fauriat C, 2010, BLOOD, V115, P1166, DOI 10.1182/blood-2009-09-245746; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Fellay J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000791; Fernandez NC, 1999, NAT MED, V5, P405, DOI 10.1038/7403; Gao XJ, 2005, NAT MED, V11, P1290, DOI 10.1038/nm1333; Garcia-Beltran WF, 2016, NAT IMMUNOL, V17, P1067, DOI 10.1038/ni.3513; Gianella S, 2015, J INFECT DIS, V212, P845, DOI 10.1093/infdis/jiv148; Gillespie GMA, 2007, AIDS RES HUM RETROV, V23, P451, DOI 10.1089/aid.2006.0165; Gomez-Roman VP, 2006, JAIDS-J ACQ IMM DEF, V43, P270; Gomez-Roman VR, 2006, J IMMUNOL METHODS, V308, P53, DOI 10.1016/j.jim.2005.09.018; Goncalves A, 2016, HUM GENET, V135, P939, DOI 10.1007/s00439-016-1694-2; Gondois-Rey F, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.22; Gonzalo-Gil E, 2017, YALE J BIOL MED, V90, P245; Goodier MR, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1244; Goujard C, 2009, CLIN INFECT DIS, V49, P982, DOI 10.1086/605504; Gray GE, 2021, NEW ENGL J MED, V384, P1089, DOI 10.1056/NEJMoa2031499; Guan YJ, 2009, P NATL ACAD SCI USA, V106, P3952, DOI 10.1073/pnas.0813392106; Guma M, 2004, BLOOD, V104, P3664, DOI 10.1182/blood-2004-05-2058; Guma M, 2006, J INFECT DIS, V194, P38, DOI 10.1086/504719; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; Gurdasani D, 2014, AIDS, V28, P149, DOI 10.1097/QAD.0000000000000049; Hammer Q, 2018, NAT IMMUNOL, V19, P453, DOI 10.1038/s41590-018-0082-6; Haynes BF, 2012, NEW ENGL J MED, V366, P1275, DOI 10.1056/NEJMoa1113425; Hikami K, 2003, GENES IMMUN, V4, P160, DOI 10.1038/sj.gene.6363940; Horowitz A, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1672; Howard LM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0167488; HOWELL DN, 1985, J IMMUNOL, V134, P971; Hsu KC, 2002, IMMUNOL REV, V190, P40, DOI 10.1034/j.1600-065X.2002.19004.x; Huang YD, 2016, J IMMUNOL, V197, P4603, DOI 10.4049/jimmunol.1601197; Isitman G, 2015, AIDS, V29, P1433, DOI 10.1097/QAD.0000000000000729; Jiang CY, 2020, NATURE, V585, P261, DOI 10.1038/s41586-020-2651-8; Jiang W, 2012, GENOME RES, V22, P1845, DOI 10.1101/gr.137976.112; Joncker NT, 2009, J IMMUNOL, V182, P4572, DOI 10.4049/jimmunol.0803900; Kamya P, 2011, J VIROL, V85, P5949, DOI 10.1128/JVI.02652-10; Kant S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583820; Kant S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11060487; Kaslow RA, 1996, NAT MED, V2, P405, DOI 10.1038/nm0496-405; Khakoo SI, 2004, SCIENCE, V305, P872, DOI 10.1126/science.1097670; Kiani Z, 2019, J VIROL, V93, DOI 10.1128/JVI.01185-19; Kiani Z, 2018, J IMMUNOL, V201, P113, DOI 10.4049/jimmunol.1701370; Kim S, 2005, NATURE, V436, P709, DOI 10.1038/nature03847; Kim S, 2008, P NATL ACAD SCI USA, V105, P3053, DOI 10.1073/pnas.0712229105; Korner C, 2017, CELL HOST MICROBE, V22, P111, DOI 10.1016/j.chom.2017.06.008; Kramski M, 2012, J IMMUNOL METHODS, V384, P51, DOI 10.1016/j.jim.2012.07.006; Kulkarni S, 2011, NATURE, V472, P495, DOI 10.1038/nature09914; Kulpa DA, 2011, IMMUNOLOGY, V134, P116, DOI 10.1111/j.1365-2567.2011.03474.x; Lambotte O, 2005, CLIN INFECT DIS, V41, P1053, DOI 10.1086/433188; Lambotte O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074855; Lambotte O, 2009, AIDS, V23, P897, DOI 10.1097/QAD.0b013e328329f97d; Lanier LL, 1998, IMMUNITY, V8, P693, DOI 10.1016/S1074-7613(00)80574-9; Lee J, 2015, IMMUNITY, V42, P431, DOI 10.1016/j.immuni.2015.02.013; Lee N, 1998, J IMMUNOL, V160, P4951; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Leslie A, 2010, J VIROL, V84, P9879, DOI 10.1128/JVI.00320-10; Li APY, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00289-5; Lisovsky I, 2019, J LEUKOCYTE BIOL, V105, P551, DOI 10.1002/JLB.4A0617-242RRR; Liu LL, 2016, CELL REP, V15, P1088, DOI 10.1016/j.celrep.2016.04.005; Llano M, 1998, EUR J IMMUNOL, V28, P2854, DOI 10.1002/(SICI)1521-4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W; Long EO, 1999, ANNU REV IMMUNOL, V17, P875, DOI 10.1146/annurev.immunol.17.1.875; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108; Luetke-Eversloh M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004441; Ma MC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01176; Madec Y, 2013, AIDS, V27, P2451, DOI 10.1097/01.aids.0000431945.72365.01; Madhavi V, 2017, J VIROL, V91, DOI 10.1128/JVI.00700-17; Magadan JG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000869; Maldarelli F, 2016, J CLIN INVEST, V126, P438, DOI 10.1172/JCI80564; Malnati MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep42470; Marras F, 2017, J VIROL, V91, DOI 10.1128/JVI.00647-17; Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035; Martin MP, 2018, J CLIN INVEST, V128, P1903, DOI 10.1172/JCI98463; Martin MP, 2002, NAT GENET, V31, P429, DOI 10.1038/ng934; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Maxwell LD, 2002, TISSUE ANTIGENS, V60, P254, DOI 10.1034/j.1399-0039.2002.600307.x; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Middleton D, 2007, HUM IMMUNOL, V68, P128, DOI 10.1016/j.humimm.2006.12.007; Middleton D, 2010, IMMUNOLOGY, V129, P8, DOI 10.1111/j.1365-2567.2009.03208.x; Migueles SA, 2000, P NATL ACAD SCI USA, V97, P2709, DOI 10.1073/pnas.050567397; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Milligan C, 2015, CELL HOST MICROBE, V17, P500, DOI 10.1016/j.chom.2015.03.002; Miyashita R, 2004, INT IMMUNOL, V16, P163, DOI 10.1093/intimm/dxh013; Moesta AK, 2008, J IMMUNOL, V180, P3969, DOI 10.4049/jimmunol.180.6.3969; Moir S, 2009, NAT REV IMMUNOL, V9, P235, DOI 10.1038/nri2524; Moraru M, 2012, TISSUE ANTIGENS, V80, P184, DOI 10.1111/j.1399-0039.2012.01911.x; Munz C, 2005, J EXP MED, V202, P203, DOI 10.1084/jem.20050810; Nagel L, 2021, J VIROL, V95, DOI 10.1128/JVI.01625-21; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; O'Connor GM, 2007, CLIN IMMUNOL, V124, P277, DOI 10.1016/j.clim.2007.05.016; O'Connor GM, 2015, J VIROL, V89, P5213, DOI 10.1128/JVI.03586-14; Okulicz JF, 2011, CURR OPIN HIV AIDS, V6, P163, DOI 10.1097/COH.0b013e328344f35e; Okulicz JF, 2009, J INFECT DIS, V200, P1714, DOI 10.1086/646609; Oliva A, 1998, J CLIN INVEST, V102, P223, DOI 10.1172/JCI2323; Oliviero B, 2009, GASTROENTEROLOGY, V137, P1151, DOI 10.1053/j.gastro.2009.05.047; Olson AD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086719; Pando MJ, 2003, J IMMUNOL, V171, P6640, DOI 10.4049/jimmunol.171.12.6640; Parsons MS, 2012, J VIROL, V86, P4488, DOI 10.1128/JVI.06112-11; Parsons MS, 2010, J INFECT DIS, V202, pS356, DOI 10.1086/655966; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Pernas M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031928; Pohlmeyer CW, 2019, J VIROL, V93, DOI 10.1128/JVI.01790-18; Pollara J, 2011, CYTOM PART A, V79A, P603, DOI 10.1002/cyto.a.21084; Pyo CW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015115; Qi Y, 2006, PLOS PATHOG, V2, P741, DOI 10.1371/journal.ppat.0020079; Ramsuran V, 2018, SCIENCE, V359, P86, DOI 10.1126/science.aam8825; RAVETCH JV, 1989, J EXP MED, V170, P481, DOI 10.1084/jem.170.2.481; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Richard J, 2018, TRENDS MICROBIOL, V26, P253, DOI 10.1016/j.tim.2017.10.007; Richard J, 2018, MBIO, V9, DOI 10.1128/mBio.00358-18; Richard J, 2017, J VIROL, V91, DOI [10.1128/jvi.00219-17, 10.1128/JVI.00219-17]; Richard J, 2014, J VIROL METHODS, V208, P107, DOI 10.1016/j.jviromet.2014.08.003; Rydyznski C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7375; Rydyznski CE, 2018, CELL REP, V24, P3367, DOI 10.1016/j.celrep.2018.08.075; Rydyznski CE, 2015, TRENDS IMMUNOL, V36, P536, DOI 10.1016/j.it.2015.07.004; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Savoy SKA, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11100959; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Shields RL, 2002, J BIOL CHEM, V277, P26733, DOI 10.1074/jbc.M202069200; Singh KK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151364; Song RJ, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003867; Tallon BJM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110480; Taner SB, 2011, J IMMUNOL, V186, P62, DOI 10.4049/jimmunol.0903657; Thomas R, 2012, AIDS RES HUM RETROV, V28, P844, DOI [10.1089/aid.2011.0253, 10.1089/AID.2011.0253]; Thomas R, 2009, NAT GENET, V41, P1290, DOI 10.1038/ng.486; Tiemessen CT, 2010, J INFECT DIS, V202, P1444, DOI 10.1086/656535; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1; Trkola A, 1999, J VIROL, V73, P8966, DOI 10.1128/JVI.73.11.8966-8974.1999; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Trowsdale J, 2001, IMMUNOL REV, V181, P20, DOI 10.1034/j.1600-065X.2001.1810102.x; Trundley A, 2007, EUR J IMMUNOL, V37, P780, DOI 10.1002/eji.200636773; Veillette M, 2014, J VIROL, V88, P2633, DOI 10.1128/JVI.03230-13; Vieillard V, 2010, JAIDS-J ACQ IMM DEF, V53, P564, DOI 10.1097/QAI.0b013e3181d0c5b4; Vieira VA, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1010090; von Bredow B, 2016, J VIROL, V90, P6127, DOI 10.1128/JVI.00347-16; Wang B, 2002, VIROLOGY, V304, P246, DOI 10.1006/viro.2002.1706; Watzl C, 2000, J IMMUNOL, V165, P3545, DOI 10.4049/jimmunol.165.7.3545; Wende H, 1999, MAMM GENOME, V10, P154, DOI 10.1007/s003359900961; Weng WK, 2003, J CLIN ONCOL, V21, P3940, DOI 10.1200/JCO.2003.05.013; Williams KL, 2015, EBIOMEDICINE, V2, P1464, DOI 10.1016/j.ebiom.2015.09.001; Winter CC, 1998, J IMMUNOL, V161, P571; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616; Wu N, 2016, CURR OPIN IMMUNOL, V38, P45, DOI 10.1016/j.coi.2015.11.003; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Yawata M, 2008, BLOOD, V112, P2369, DOI 10.1182/blood-2008-03-143727; Yu J, 2007, J IMMUNOL, V179, P5977, DOI 10.4049/jimmunol.179.9.5977; Zhang TX, 2013, J IMMUNOL, V190, P1402, DOI 10.4049/jimmunol.1203034; Zipeto D, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-39; Zwirner NW, 2021, J LEUKOCYTE BIOL, V109, P185, DOI 10.1002/JLB.3MR0820-685R	214	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								879124	10.3389/fimmu.2022.879124	http://dx.doi.org/10.3389/fimmu.2022.879124			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5AP	35720328	Green Published, gold			2022-12-18	WOS:000806102600001
J	Bhat, J; Placek, K; Faissner, S				Bhat, Jaydeep; Placek, Katarzyna; Faissner, Simon			Contemplating Dichotomous Nature of Gamma Delta T Cells for Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						gamma delta T cells; immunotherapy; cancers; infection; neuroimmunology; metabolism; multi-omics	ADOPTIVE IMMUNOTHERAPY; SYSTEMS IMMUNOLOGY; CANCER; TUMOR; RECOGNITION; ANTIGEN; CYTOTOXICITY; EXPRESSION; RECEPTORS; STRESS	gamma delta T cells are unconventional T cells, distinguished from alpha beta T cells in a number of functional properties. Being small in number compared to alpha beta T cells, gamma delta T cells have surprised us with their pleiotropic roles in various diseases. gamma delta T cells are ambiguous in nature as they can produce a number of cytokines depending on the (micro) environmental cues and engage different immune response mechanisms, mainly due to their epigenetic plasticity. Depending on the disease condition, gamma delta T cells contribute to beneficial or detrimental response. In this review, we thus discuss the dichotomous nature of gamma delta T cells in cancer, neuroimmunology and infectious diseases. We shed light on the importance of equal consideration for systems immunology and personalized approaches, as exemplified by changes in metabolic requirements. While providing the status of immunotherapy, we will assess the metabolic (and other) considerations for better outcome of gamma delta T cell-based treatments.	[Bhat, Jaydeep] Ruhr Univ Bochum, Dept Mol Immunol, Bochum, Germany; [Placek, Katarzyna] Univ Bonn, Life & Med Sci Inst, Dept Mol Immunol & Cell Biol, Bonn, Germany; [Faissner, Simon] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany	Ruhr University Bochum; University of Bonn; Ruhr University Bochum	Bhat, J (corresponding author), Ruhr Univ Bochum, Dept Mol Immunol, Bochum, Germany.							Aaby P, 2011, J INFECT DIS, V204, P245, DOI 10.1093/infdis/jir240; Almeida AR, 2016, CLIN CANCER RES, V22, P5795, DOI 10.1158/1078-0432.CCR-16-0597; de Lima KA, 2020, NAT IMMUNOL, V21, P1421, DOI 10.1038/s41590-020-0776-4; Arguello RJ, 2020, CELL METAB, V32, DOI 10.1016/j.cmet.2020.11.007; Bai L, 2012, EUR J IMMUNOL, V42, P2505, DOI 10.1002/eji.201242531; BANK I, 1986, NATURE, V322, P179, DOI 10.1038/322179a0; Baum TP, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-224; Benn CS, 2013, TRENDS IMMUNOL, V34, P431, DOI 10.1016/j.it.2013.04.004; Bhat J, 2021, CELL MOL IMMUNOL, V18, P1332, DOI 10.1038/s41423-020-0518-4; Bhat J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00512; Bhat J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1006088; Bhat SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01615; Blais ME, 2008, J IMMUNOL, V180, P2299, DOI 10.4049/jimmunol.180.4.2299; Boissiere-Michot F, 2021, CANCERS, V13, DOI 10.3390/cancers13040765; Boufea K, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000680; Braza MS, 2011, HAEMATOL-HEMATOL J, V96, P400, DOI 10.3324/haematol.2010.029520; BRENNER MB, 1986, NATURE, V322, P145, DOI 10.1038/322145a0; Cairo C, 2010, HUM IMMUNOL, V71, P968, DOI 10.1016/j.humimm.2010.06.014; Castella B, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15663; Catalan-Serra I, 2017, J CROHNS COLITIS, V11, P1135, DOI 10.1093/ecco-jcc/jjx039; Cerapio JP, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1939518; Chauvin C, 2019, CLIN CANCER RES, V25, P7218, DOI 10.1158/1078-0432.CCR-19-0375; Chen HC, 2017, IMMUNOL CELL BIOL, V95, P620, DOI 10.1038/icb.2017.21; Clark BL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238903; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Cui JW, 2014, INT J CANCER, V134, P342, DOI 10.1002/ijc.28372; Davis MM, 2017, NAT IMMUNOL, V18, P725, DOI 10.1038/ni.3768; Deseke M, 2020, CELL MOL IMMUNOL, V17, P914, DOI 10.1038/s41423-020-0503-y; Di Lorenzo B, 2019, CANCER IMMUNOL RES, V7, P552, DOI 10.1158/2326-6066.CIR-18-0647; Edwards SC, 2020, J EXP MED, V217, DOI 10.1084/jem.20190834; Ganesan R, 2021, LEUKEMIA, V35, P2274, DOI 10.1038/s41375-021-01122-7; Gao YF, 2003, J EXP MED, V198, P433, DOI 10.1084/jem.20030584; Garly ML, 2003, VACCINE, V21, P2782, DOI 10.1016/S0264-410X(03)00181-6; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gherardin NA, 2021, CANCER IMMUNOL RES, V9, P612, DOI 10.1158/2326-6066.CIR-20-0817; Glusman G, 2001, IMMUNITY, V15, P337, DOI 10.1016/S1074-7613(01)00200-X; Goldberg EL, 2020, NAT METAB, V2, P50, DOI 10.1038/s42255-019-0160-6; Gonnermann D, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.988460; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; Han XP, 2020, NATURE, V581, P303, DOI 10.1038/s41586-020-2157-4; Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harly C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.aba9010; Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood-2012-05-430470; Herrmann T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.876493; Higgins JPT, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5170; Hirano M, 2013, NATURE, V501, P435, DOI 10.1038/nature12467; Hoft DF, 1998, J IMMUNOL, V161, P1045; Howard J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02760; Hu B, 2020, NATURE, V578, P610, DOI 10.1038/s41586-020-2028-z; Hu Y, 2021, CELL MOL IMMUNOL, V18, P954, DOI 10.1038/s41423-021-00656-1; Jaeger N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22164-6; Junqueira C, 2021, NAT IMMUNOL, V22, P347, DOI 10.1038/s41590-020-00847-4; Kabelitz D, 2020, CELL MOL IMMUNOL, V17, P925, DOI 10.1038/s41423-020-0504-x; Kapsenberg ML, 2009, IMMUNITY, V31, P181, DOI 10.1016/j.immuni.2009.08.004; Karlsson M, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh2169; Kaufmann M, 2021, MED-CAMBRIDGE, V2, P296, DOI 10.1016/j.medj.2021.01.006; Kobayashi H, 2007, CANCER IMMUNOL IMMUN, V56, P469, DOI 10.1007/s00262-006-0199-6; Kohlgruber AC, 2018, NAT IMMUNOL, V19, P464, DOI 10.1038/s41590-018-0094-2; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kouakanou L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63572-w; LADEL CH, 1995, EUR J IMMUNOL, V25, P2877, DOI 10.1002/eji.1830251025; Le Nours J, 2019, SCIENCE, V366, P1522, DOI 10.1126/science.aav3900; Lee M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18155-8; Li L, 2019, ONCOGENE, V38, P2830, DOI 10.1038/s41388-018-0627-z; Li Y, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.619954; Li ZH, 2022, SCI BULL, V67, P408, DOI 10.1016/j.scib.2021.11.013; Lopes N, 2021, NAT IMMUNOL, V22, P179, DOI 10.1038/s41590-020-00848-3; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Maimaitijiang G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00748; Makkouk A, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003441; Mangino M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13850; Marchitto MC, 2019, P NATL ACAD SCI USA, V116, P10917, DOI 10.1073/pnas.1818256116; Marlin R, 2017, P NATL ACAD SCI USA, V114, P3163, DOI 10.1073/pnas.1621052114; Martin B, 2009, IMMUNITY, V31, P321, DOI 10.1016/j.immuni.2009.06.020; McGinley AM, 2020, IMMUNITY, V52, P342, DOI 10.1016/j.immuni.2020.01.002; Melandri D, 2018, NAT IMMUNOL, V19, P1352, DOI 10.1038/s41590-018-0253-5; Melenhorst JJ, 2022, NATURE, V602, P503, DOI 10.1038/s41586-021-04390-6; Meraviglia S, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1347742; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Mirji G, 2016, LEUKEMIA RES, V45, P33, DOI 10.1016/j.leukres.2016.03.002; Monteiro A, 2018, J NEUROIMMUNOL, V318, P65, DOI 10.1016/j.jneuroim.2018.02.009; MUNK ME, 1990, J IMMUNOL, V145, P2434; Nishimoto KP, 2022, CLIN TRANSL IMMUNOL, V11, DOI 10.1002/cti2.1373; Oberg HH, 2020, J LEUKOCYTE BIOL, V107, P1081, DOI 10.1002/JLB.5MA1119-265R; Papotto PH, 2017, EMBO REP, V18, P1957, DOI 10.15252/embr.201744200; Park JE, 2020, SCIENCE, V367, P868, DOI 10.1126/science.aay3224; Patil RS, 2016, INT J CANCER, V139, P869, DOI 10.1002/ijc.30134; Petermann F, 2010, IMMUNITY, V33, P351, DOI 10.1016/j.immuni.2010.08.013; Peters C, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1522471; Pizzolato G, 2019, P NATL ACAD SCI USA, V116, P11906, DOI 10.1073/pnas.1818488116; Puan KJ, 2007, INT IMMUNOL, V19, P657, DOI 10.1093/intimm/dxm031; Pulendran B, 2020, SCIENCE, V369, P1582, DOI 10.1126/science.aay4014; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Rajoriya N, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00400; Reitermaier R, 2021, J EXP MED, V218, DOI 10.1084/jem.20201189; Ribot JC, 2021, NAT REV IMMUNOL, V21, P221, DOI 10.1038/s41577-020-00452-4; Ribot JC, 2014, J IMMUNOL, V192, P2237, DOI 10.4049/jimmunol.1303119; Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516; Rosenbaum L, 2017, NEW ENGL J MED, V377, P1313, DOI 10.1056/NEJMp1711886; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; Rozenbaum M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01347; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sagar, 2020, EMBO J, V39, DOI 10.15252/embj.2019104159; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; Sanchez-Martinez D., 2022, GENERATION PROOF CON, V2022, DOI [10.1101/2022.03.15.484289, DOI 10.1101/2022.03.15.484289]; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; Schafflick D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14118-w; Schaum N, 2018, NATURE, V562, P367, DOI 10.1038/s41586-018-0590-4; Schmolka N, 2013, NAT IMMUNOL, V14, P1093, DOI 10.1038/ni.2702; Sebestyen Z, 2020, NAT REV DRUG DISCOV, V19, P169, DOI 10.1038/s41573-019-0038-z; Sebestyen Z, 2016, CELL REP, V15, P1973, DOI 10.1016/j.celrep.2016.04.081; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Singh AK, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00260; Straetemans T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01062; Sureshbabu SK, 2020, CLIN EXP IMMUNOL, V201, P40, DOI 10.1111/cei.13436; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Suzuki T, 2020, IMMUNOL REV, V298, P198, DOI 10.1111/imr.12916; Tan LK, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf0125; Tan LK, 2019, CELL REP, V27, P3657, DOI 10.1016/j.celrep.2019.05.064; Todaro M, 2009, J IMMUNOL, V182, P7287, DOI 10.4049/jimmunol.0804288; Tokuyama H, 2008, INT J CANCER, V122, P2526, DOI 10.1002/ijc.23365; Tosolini M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284723; Uldrich AP, 2013, NAT IMMUNOL, V14, P1137, DOI 10.1038/ni.2713; Villani AC, 2018, ANNU REV IMMUNOL, V36, P813, DOI 10.1146/annurev-immunol-042617-053035; Vyborova A, 2020, J CLIN INVEST, V130, P4637, DOI 10.1172/JCI132489; Wang HS, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003339; Wang JT, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1353858; Wang XF, 2021, ADV SCI, V8, DOI 10.1002/advs.202101447; Wang XF, 2018, FRONT MED-PRC, V12, P262, DOI 10.1007/s11684-017-0584-x; Watkin L, 2020, J ALLERGY CLIN IMMUN, V145, pAB244, DOI 10.1016/j.jaci.2019.12.151; Wawrzyniecka PA, 2022, LEUKEMIA, V36, P577, DOI 10.1038/s41375-021-01385-0; Wilhelm M, 2003, BLOOD, V102, P200, DOI 10.1182/blood-2002-12-3665; Willcox BE, 2019, NAT IMMUNOL, V20, P121, DOI 10.1038/s41590-018-0304-y; Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394; Wu P, 2014, IMMUNITY, V40, P785, DOI 10.1016/j.immuni.2014.03.013; Xu WL, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051181; Xu Y, 2021, CELL MOL IMMUNOL, V18, P427, DOI 10.1038/s41423-020-0515-7; Yang K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aas9818; Yang Y, 2020, CANCERS, V12, DOI 10.3390/cancers12123586; Zeine R, 1998, J NEUROIMMUNOL, V87, P49, DOI 10.1016/S0165-5728(98)00047-2; Zeng X, 2012, IMMUNITY, V37, P524, DOI 10.1016/j.immuni.2012.06.011; ZOCCHI MR, 1990, EUR J IMMUNOL, V20, P2685	144	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								894580	10.3389/fimmu.2022.894580	http://dx.doi.org/10.3389/fimmu.2022.894580			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V4FD	35669772	gold, Green Published			2022-12-18	WOS:000806046800001
J	Biradar, S; Agarwal, Y; Lotze, MT; Bility, MT; Mailliard, RB				Biradar, Shivkumar; Agarwal, Yash; Lotze, Michael T.; Bility, Moses T.; Mailliard, Robbie B.			The BLT Humanized Mouse Model as a Tool for Studying Human Gamma Delta T Cell-HIV Interactions In Vivo	FRONTIERS IN IMMUNOLOGY			English	Article						BLT mice; humanized mice; gamma delta T cells; HIV infection; HIV immunopathogenesis	MUCOSAL; TRANSMISSION; VITRO	Gamma-delta (gamma delta) T cells recognize antigens in a major histocompatibility complex (MHC) independent and have cytotoxic capability. Human immunodeficiency virus (HIV) infection reduces the proportion of the V delta 2 cell subset compared to the V delta 1 cell subset of gamma delta T cells in the blood in most infected individuals, except for elite controllers. The capacity of V delta 2 T cells to kill HIV-infected targets has been demonstrated in vitro, albeit in vivo confirmatory studies are lacking. Here, we provide the first characterization of gamma delta T cell-HIV interactions in bone marrow-liver-thymus (BLT) humanized mice and examined the immunotherapeutic potential of V delta 2 T cells in controlling HIV replication in vivo. We demonstrate a reduced proportion of V delta 2 T cells and an increased proportion of V delta 1 T cells in HIV-infected BLT humanized mice, like in HIV-positive individuals. HIV infection in BLT humanized mice also impaired the ex vivo expansion of V delta 2 T cells, like in HIV-positive individuals. Adoptive transfer of activated V delta 2 T cells did not control HIV replication during cell-associated HIV transmission in BLT humanized mice but instead exacerbated viremia, suggesting that V delta 2 T cells may serve as early targets for HIV replication. Our findings demonstrate that BLT humanized mice can model gamma delta T cell-HIV interactions in vivo.	[Biradar, Shivkumar; Agarwal, Yash; Bility, Moses T.; Mailliard, Robbie B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA; [Lotze, Michael T.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; [Lotze, Michael T.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA; [Lotze, Michael T.] Univ Pittsburgh, Sch Med, Dept Bioengn, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Bility, MT; Mailliard, RB (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Infect Dis & Microbiol, Pittsburgh, PA 15260 USA.	mtbility@pitt.edu; rbm19@pitt.edu		Bility, Moses/0000-0001-5153-2718				Alexander AAZ, 2008, CLIN CANCER RES, V14, P4232, DOI 10.1158/1078-0432.CCR-07-4912; Anderson DJ, 2014, J INFECT DIS, V210, pS648, DOI 10.1093/infdis/jiu537; [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373; Berges BK, 2008, VIROLOGY, V373, P342, DOI 10.1016/j.virol.2007.11.020; Bhatnagar N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01189; Biswas N, 2012, VIROLOGY, V422, P265, DOI 10.1016/j.virol.2011.10.024; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; BUKOWSKI JF, 1995, J IMMUNOL, V154, P998; Clutton GT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01452; Deng K, 2015, NATURE, V517, P381, DOI 10.1038/nature14053; Denton PW, 2008, PLOS MED, V5, P79, DOI 10.1371/journal.pmed.0050016; du Sert NP, 2020, BRIT J PHARMACOL, V177, P3617, DOI 10.1111/bph.15193; Emert-Sedlak L, 2009, ACS CHEM BIOL, V4, P939, DOI 10.1021/cb900195c; GAN YH, 1995, CLIN EXP IMMUNOL, V102, P251; Garrido C, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120121; Gu Siyi, 2014, Front Immunol, V5, P688, DOI 10.3389/fimmu.2014.00688; He X, 2013, AIDS RES HUM RETROV, V29, P1562, DOI [10.1089/aid.2013.0111, 10.1089/AID.2013.0111]; Juno JA, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1069; KABAT D, 1994, J VIROL, V68, P2570, DOI 10.1128/JVI.68.4.2570-2577.1994; KOZBOR D, 1989, J EXP MED, V169, P1847, DOI 10.1084/jem.169.5.1847; Lei L, 2020, J CELL MOL MED, V24, P11603, DOI 10.1111/jcmm.15620; Lemmer ER, 1998, J HEPATOL, V29, P450, DOI 10.1016/S0168-8278(98)80064-0; Li HS, 2013, CELL MOL IMMUNOL, V10, P42, DOI 10.1038/cmi.2012.50; Li WF, 2020, J BIOL CHEM, V295, P5163, DOI 10.1074/jbc.RA120.012536; Lo Presti E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01401; Mamedov MR, 2018, IMMUNITY, V48, P350, DOI 10.1016/j.immuni.2018.01.009; Nada MH, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0209-6; Nolan DJ, 2018, AIDS RES HUM RETROV, V34, P123, DOI [10.1089/AID.2017.0254, 10.1089/aid.2017.0254]; Pauza CD, 2015, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00687; Poccia F, 1999, J INFECT DIS, V180, P858, DOI 10.1086/314925; Poccia F, 2009, AIDS, V23, P555, DOI 10.1097/QAD.0b013e3283244619; Poe JA, 2009, J MOL BIOL, V394, P329, DOI 10.1016/j.jmb.2009.09.047; Poles MA, 2003, J VIROL, V77, P10456, DOI 10.1128/JVI.77.19.10456-10467.2003; Poonia B, 2012, CYTOTHERAPY, V14, P173, DOI 10.3109/14653249.2011.623693; Qaqish A, 2017, J IMMUNOL, V198, P4753, DOI 10.4049/jimmunol.1602019; Radestad E, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/578741; Riedel DJ, 2009, AIDS, V23, P1955, DOI 10.1097/QAD.0b013e32832ff1ff; Samal J, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120430; SCIAMMAS R, 1994, IMMUNOL RES, V13, P268, DOI 10.1007/BF02935618; Shan L, 2012, IMMUNITY, V36, P491, DOI 10.1016/j.immuni.2012.01.014; Showa SP, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222574; Soriano-Sarabia N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005201; Tuero I, 2016, J IMMUNOL, V197, P4686, DOI 10.4049/jimmunol.1600579; VROOM TM, 1991, J CLIN PATHOL, V44, P1012, DOI 10.1136/jcp.44.12.1012; Wallace M, 1996, CLIN EXP IMMUNOL, V103, P177, DOI 10.1046/j.1365-2249.1996.d01-625.x; Wilhelm M, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-45	46	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								881607	10.3389/fimmu.2022.881607	http://dx.doi.org/10.3389/fimmu.2022.881607			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5VC	35669780	gold, Green Published			2022-12-18	WOS:000806156000001
J	Chen, C; Zhang, Y; Liu, JH; Wang, MY; Lu, MM; Xu, LX; Yan, RF; Li, XR; Song, XK				Chen, Chen; Zhang, Yue; Liu, Jianhua; Wang, Mingyue; Lu, Mingmin; Xu, Lixin; Yan, Ruofeng; Li, Xiangrui; Song, Xiaokai			An Eimeria maxima Antigen: Its Functions on Stimulating Th1 Cytokines and Protective Efficacy Against Coccidiosis	FRONTIERS IN IMMUNOLOGY			English	Article						Eimeria maxima; Th1 cytokines stimulating antigen; EmARM-beta; protective efficacy; DNA vaccine	INTESTINAL IMMUNE-RESPONSES; DNA VACCINES; TRANSCRIPTION FACTOR; T-BET; INTERFERON-GAMMA; GENE-EXPRESSION; IFN-GAMMA; TENELLA; ACERVULINA; IMMUNIZATION	A consensus is that the Th1 immune response plays a predominant role against avian coccidiosis. Therefore, an antigen with the ability to induce Th1 cytokine responses is an ideal candidate for the development of coccidiosis vaccines. In our previous study, EmARM-beta, a Th1 cytokines-stimulating antigen, was screened from the cDNA expression library of Eimeria maxima (E. maxima). Herein, we verified its stimulative effects on Th1 cytokine productions and evaluated its protective efficacy against E. maxima infection. Recombinant EmARM-beta protein was expressed, and eukaryotic expression plasmid pVAX1-EmARM-beta was also constructed for the immunization of birds. An immunofluorescence assay was performed to detect the native form of EmARM-beta protein in the stage of sporozoites. Expressions of specific transcription factors and cytokines in immunized chickens were measured using qPCR and ELISA to verify its stimulating function on Th1 cytokines. Specific IgG antibody levels and T lymphocyte subpopulation in the immunized chickens were detected using ELISA and indirect flow cytometry to determine induced immune responses. The results showed that EmARM-beta native protein is massively expressed in the sporozoites stage of E. maxima. Effective stimulation from the EmARM-beta antigen to T-bet and Th1 cytokines (IL-2 and IFN-gamma) was observed in vivo. After being immunized with rEmARM-beta or pVAX1-EmARM-beta, significant promotion to the proportion of CD4(+) and CD8(+) T cells and the level of antigen-specific IgG antibodies in immunized chickens was also observed. Furthermore, vaccination with rEmARM-beta antigen or pVAX1-EmARM-beta resulted in alleviated weight loss and enteric lesion, reduced oocyst output, and higher anticoccidial index (ACI) in challenged birds. These results indicate that EmARM-beta antigen can effectively stimulate the expression of Th1 cytokines and initiate host immune responses, providing moderate protective efficacy against E. maxima. Notably, EmARM-beta protein is a promising candidate for developing a novel anticoccidial vaccine.	[Chen, Chen; Zhang, Yue; Liu, Jianhua; Wang, Mingyue; Lu, Mingmin; Xu, Lixin; Yan, Ruofeng; Li, Xiangrui; Song, Xiaokai] Nanjing Agr Univ, Coll Vet Med, Joint Int Res Lab Anim Hlth & Food Safety, Minist Educ MOE, Nanjing, Peoples R China	Nanjing Agricultural University	Song, XK (corresponding author), Nanjing Agr Univ, Coll Vet Med, Joint Int Res Lab Anim Hlth & Food Safety, Minist Educ MOE, Nanjing, Peoples R China.		Lu, Mingmin/AHC-9178-2022	Lu, Mingmin/0000-0002-7343-7815	National Natural Science Foundation of China [31972705, 31672545]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (Grant No. 31972705 and 31672545).	Allen PC, 2002, CLIN MICROBIOL REV, V15, P58, DOI 10.1128/CMR.15.1.58-65.2002; Barry MA, 2004, IMMUNOL REV, V199, P68, DOI 10.1111/j.0105-2896.2004.00143.x; Belli SI, 2004, VACCINE, V22, P4316, DOI 10.1016/j.vaccine.2004.04.019; Bessay M, 1996, VET RES, V27, P503; Blake DP, 2021, AVIAN PATHOL, V50, P209, DOI 10.1080/03079457.2021.1912288; Blake DP, 2020, VET RES, V51, DOI 10.1186/s13567-020-00837-2; Blake DP, 2014, TRENDS PARASITOL, V30, P12, DOI 10.1016/j.pt.2013.10.003; Chapman HD, 2013, ADV PARASIT, V83, P93, DOI 10.1016/B978-0-12-407705-8.00002-1; Chen C, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.614229; Constantinoiu CC, 2008, VET PARASITOL, V154, P193, DOI 10.1016/j.vetpar.2008.03.029; Cornelissen JBWJ, 2009, VET PARASITOL, V162, P58, DOI 10.1016/j.vetpar.2009.02.001; Dalloul RA, 2006, EXPERT REV VACCINES, V5, P143, DOI 10.1586/14760584.5.1.143; Dhama K, 2008, VET RES COMMUN, V32, P341, DOI 10.1007/s11259-008-9040-3; Ding XC, 2004, INFECT IMMUN, V72, P6939, DOI 10.1128/IAI.72.12.6939-6944.2004; Engwerda CR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00498; Erf GF, 2004, POULTRY SCI, V83, P580, DOI 10.1093/ps/83.4.580; Gacerez AT, 2018, CANCER GENE THER, V25, P117, DOI 10.1038/s41417-018-0012-7; HODGSON JN, 1970, EXP PARASITOL, V28, P99, DOI 10.1016/0014-4894(70)90073-1; JENKINS MC, 1988, EXP PARASITOL, V66, P96, DOI 10.1016/0014-4894(88)90054-9; JOHNSON J, 1970, EXP PARASITOL, V28, P30, DOI 10.1016/0014-4894(70)90063-9; Kim WH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02732; Kim WH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00560; Lakho SA, 2020, MICROB PATHOGENESIS, V143, DOI 10.1016/j.micpath.2020.104162; Li ZR, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00533; Lighvani AA, 2001, P NATL ACAD SCI USA, V98, P15137, DOI 10.1073/pnas.261570598; Lillehoj HS, 2007, POULTRY SCI, V86, P1491, DOI 10.1093/ps/86.7.1491; Lillehoj HS, 1998, AVIAN DIS, V42, P307, DOI 10.2307/1592481; Lillehoj HS, 2005, AVIAN DIS, V49, P112, DOI 10.1637/7249-073004R; Lillehoj HS, 1996, CLIN MICROBIOL REV, V9, P349, DOI 10.1128/CMR.9.3.349; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Ma CL, 2017, EXP PARASITOL, V178, P14, DOI 10.1016/j.exppara.2017.05.001; MCDONALD V, 1988, PARASITE IMMUNOL, V10, P649, DOI 10.1111/j.1365-3024.1988.tb00251.x; MCMANUS EC, 1968, J PARASITOL, V54, P1190, DOI 10.2307/3276989; Min WG, 2001, VACCINE, V20, P267, DOI 10.1016/S0264-410X(01)00270-5; Moraes PO, 2019, ANIMAL, V13, P2190, DOI 10.1017/S1751731119000600; Passero LFD, 2015, PARASITOL INT, V64, P32, DOI 10.1016/j.parint.2015.01.006; Pereira VB, 2014, WORLD J VACCIN, V4, P50, DOI [10.4236/wjv.2014.42008, DOI 10.4236/WJV.2014.42008]; Peterson RA, 2012, TOXICOL PATHOL, V40, P186, DOI 10.1177/0192623311430693; Refega S, 2003, VET PARASITOL, V113, P19, DOI 10.1016/S0304-4017(03)00033-5; ROSE ME, 1992, PARASITOLOGY, V105, P349, DOI 10.1017/S0031182000074515; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Sasai K, 2000, VET MICROBIOL, V74, P345, DOI 10.1016/S0378-1135(00)00193-0; Sehrawat Sharvan, 2017, Front Immunol, V8, P341, DOI 10.3389/fimmu.2017.00341; Sharman PA, 2010, PARASITE IMMUNOL, V32, P590, DOI 10.1111/j.1365-3024.2010.01209.x; Soares-Silva M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00183; Song HY, 2010, EXP PARASITOL, V126, P224, DOI 10.1016/j.exppara.2010.05.015; Song XK, 2015, EXP PARASITOL, V156, P19, DOI 10.1016/j.exppara.2015.05.003; Song XK, 2015, VET IMMUNOL IMMUNOP, V166, P79, DOI 10.1016/j.vetimm.2015.05.005; Song XK, 2015, ACTA PARASITOL, V60, P500, DOI 10.1515/ap-2015-0071; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tian L, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01245; TOMLEY FM, 1994, INFECT IMMUN, V62, P4656, DOI 10.1128/IAI.62.10.4656-4658.1994; Trout JM, 1996, VET IMMUNOL IMMUNOP, V53, P163, DOI 10.1016/0165-2427(95)05544-4; Vermeulen AN, 1998, INT J PARASITOL, V28, P1121, DOI 10.1016/S0020-7519(98)00080-0; Yang XC, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2029-4; Yun CH, 2000, DEV COMP IMMUNOL, V24, P303, DOI 10.1016/S0145-305X(99)00080-4; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu HL, 2012, MOL BIOCHEM PARASIT, V186, P21, DOI 10.1016/j.molbiopara.2012.09.002; Zhu HL, 2012, PARASITOLOGY, V139, P1711, DOI 10.1017/S0031182012001163; Zhu JF, 2012, IMMUNITY, V37, P660, DOI 10.1016/j.immuni.2012.09.007	60	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								872015	10.3389/fimmu.2022.872015	http://dx.doi.org/10.3389/fimmu.2022.872015			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W2TA	35669766	gold, Green Published			2022-12-18	WOS:000806628700001
J	Chen, L; Huang, SL; Liu, Q; Kong, XY; Su, ZH; Zhu, ML; Fang, Y; Zhang, L; Li, XR; Wang, J				Chen, Li; Huang, Shaolong; Liu, Qiang; Kong, Xiangyi; Su, Zhaohui; Zhu, Mengliu; Fang, Yi; Zhang, Lin; Li, Xingrui; Wang, Jing			PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						breast cancer; immune checkpoint inhibitors; programmed cell death 1 (PD-1); programmed cell death ligand-1 (PD-L1); neoadjuvant chemotherapy	DEATH LIGAND 1; SOLID TUMORS; IMMUNOTHERAPY; PATHWAY; MARKER; RISK	Objective: This study aims to investigate the potential prognostic significance of programmed death ligand-1 (PD-L1) protein expression in tumor cells of breast cancer patients received neoadjuvant chemotherapy (NACT). Methods: Using semiquantitative immunohistochemistry, the PD-L1 protein expression in breast cancer tissues was analyzed. The correlations between PD-L1 protein expression and clinicopathologic characteristics were analyzed using Chi-square test or Fisher's exact test. The survival curve was stemmed from Kaplan-Meier assay, and the log-rank test was used to compare survival distributions against individual index levels. Univariate and multivariate Cox proportional hazards regression models were accessed to analyze the associations between PD-L1 protein expression and survival outcomes. A predictive nomogram model was constructed in accordance with the results of multivariate Cox model. Calibration analyses and decision curve analyses (DCA) were performed for the calibration of the nomogram model, and subsequently adopted to assess the accuracy and benefits of the nomogram model. Results: A total of 104 breast cancer patients received NACT were enrolled into this study. According to semiquantitative scoring for IHC, patients were divided into: low PD-L1 group (61 cases) and high PD-L1 group (43 cases). Patients with high PD-L1 protein expression were associated with longer disease free survival (DFS) (mean: 48.21 months vs. 31.16 months; P=0.011) and overall survival (OS) (mean: 83.18 months vs. 63.31 months; P=0.019) than those with low PD-L1 protein expression. Univariate and multivariate analyses indicated that PD-L1, duration of neoadjuvant therapy, E-Cadherin, targeted therapy were the independent prognostic factors for patients' DFS and OS. Nomogram based on these independent prognostic factors was used to evaluate the DFS and OS time. The calibration plots shown PD-L1 based nomogram predictions were basically consistent with actual observations for assessments of 1-, 3-, and 5-year DFS and OS time. The DCA curves indicated the PD-L1 based nomogram had better predictive clinical applications regarding prognostic assessments of 3- and 5-year DFS and OS, respectively. Conclusion: High PD-L1 protein expression was associated with significantly better prognoses and longer DFS and OS in breast cancer patients. Furthermore, PD-L1 protein expression was found to be a significant prognostic factor for patients who received NACT.	[Chen, Li; Li, Xingrui] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thyroid & Breast Surg, Wuhan, Peoples R China; [Chen, Li; Liu, Qiang; Kong, Xiangyi; Zhu, Mengliu; Fang, Yi; Wang, Jing] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Breast Surg Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China; [Huang, Shaolong] Tongren City Peoples Hosp, Dept Thyroid & Breast Burn & Plast Surg, Tongren, Peoples R China; [Su, Zhaohui] Southeast Univ, Sch Publ Hlth, Nanjing, Peoples R China; [Zhang, Lin] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia; [Zhang, Lin] Ctr Canc Res, Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia; [Zhang, Lin] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Beijing, Peoples R China	Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Southeast University - China; University of Melbourne; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Li, XR (corresponding author), Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Thyroid & Breast Surg, Wuhan, Peoples R China.; Wang, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Breast Surg Oncol, Natl Clin Res Ctr Canc,Canc Hosp, Beijing, Peoples R China.; Zhang, L (corresponding author), Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.; Zhang, L (corresponding author), Ctr Canc Res, Victorian Comprehens Canc Ctr, Melbourne, Vic, Australia.; Zhang, L (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Beijing, Peoples R China.	tony1982110@gmail.com; lixingrui@tjh.tjmu.edu.cn; wangjing@cicams.ac.cn		Zhang, Lin/0000-0002-2064-8440	National Nature Science Foundation of China [81872160, 82072940, 82103047, 82102887, 81802676]; Beijing Nature Science Foundation of China [7191009, 7204293]; National Key R&D Program of China [2018YFC1312100]; China National Key R&D (or Research and Development) Program [2020AAA0105000, 2020AAA0105004]; Special Research Fund for Central Universities, Peking Union Medical College [3332019053]; Cancer Foundation of China [LC2020L01, LC2019B03, LC2019L07]; Wuhan Youth Cadre Project [2017zqnlxr01, 2017zqnlxr02]; Clinical Research Physician Program of Tongji Medical College, HUST [5001540018]; Golden Bridge Project Seed Fund of Beijing Association for Science and Technology [ZZ20004]; Chinese Young Breast Experts Research project [CYBER-2021-005]; Chaoyang District Social Development Science and Technology Plan Project (Medical and Health Field) [CYSF2115]; Beijing Xisike Clinical Oncology Research Foundation [Y-Young2021-0017]; XianSheng Clinical Research Special Fund of China International Medical Foundation [Z-2014-06-2103]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Nature Science Foundation of China(Beijing Natural Science Foundation); National Key R&D Program of China; China National Key R&D (or Research and Development) Program; Special Research Fund for Central Universities, Peking Union Medical College; Cancer Foundation of China; Wuhan Youth Cadre Project; Clinical Research Physician Program of Tongji Medical College, HUST; Golden Bridge Project Seed Fund of Beijing Association for Science and Technology; Chinese Young Breast Experts Research project; Chaoyang District Social Development Science and Technology Plan Project (Medical and Health Field); Beijing Xisike Clinical Oncology Research Foundation; XianSheng Clinical Research Special Fund of China International Medical Foundation	The work is partly supported by research grants from The National Nature Science Foundation of China (No. 81872160, No. 82072940, No. 82103047, No. 82102887 and No.81802676), Beijing Nature Science Foundation of China (No. 7191009, No. 7204293), and National Key R&D Program of China (No. 2018YFC1312100), the China National Key R&D (or Research and Development) Program (No. 2020AAA0105000 and 2020AAA0105004), the Special Research Fund for Central Universities, Peking Union Medical College (No. 3332019053), the Beijing Hope Run Special Fund of Cancer Foundation of China (No. LC2020L01, No. LC2019B03, No. LC2019L07), Wuhan Youth Cadre Pr o j e c t (2017zqnlxr01 and 2017zqnlxr02), Clinical Research Physician Program of Tongji Medical College, HUST (5001540018), the Golden Bridge Project Seed Fund of Beijing Association for Science and Technology (No. ZZ20004), the Chinese Young Breast Experts Research project (No. CYBER-2021-005), the 2021 Chaoyang District Social Development Science and Technology Plan Project (Medical and Health Field) (No. CYSF2115), the Beijing Xisike Clinical Oncology Research Foundation (No. Y-Young2021-0017), the XianSheng Clinical Research Special Fund of China International Medical Foundation (No. Z-2014-06-2103).	Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Ahmed FS, 2020, CLIN CANCER RES, V26, P5456, DOI 10.1158/1078-0432.CCR-20-1303; Ali HR, 2015, ANN ONCOL, V26, P1488, DOI 10.1093/annonc/mdv192; Asano Y, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1458-y; Baraibar I, 2019, DRUG SAFETY, V42, P281, DOI 10.1007/s40264-018-0774-8; Basu A, 2019, ADV CANCER RES, V143, P295, DOI 10.1016/bs.acr.2019.03.006; Botti G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020459; Brody R, 2017, LUNG CANCER, V112, P200, DOI 10.1016/j.lungcan.2017.08.005; Cha JH, 2019, MOL CELL, V76, P359, DOI 10.1016/j.molcel.2019.09.030; Chen L, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.656693; Chen S, 2017, INT J CANCER, V140, P1384, DOI 10.1002/ijc.30552; Constantinidou A, 2019, PHARMACOL THERAPEUT, V194, P84, DOI 10.1016/j.pharmthera.2018.09.008; Del Alcazar CRG, 2020, CANCER IMMUNOL RES, V8, P422, DOI 10.1158/2326-6066.CIR-19-0786; Domschke C, 2016, BREAST CARE, V11, P102, DOI 10.1159/000446061; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Emens LA, 2018, CLIN CANCER RES, V24, P511, DOI 10.1158/1078-0432.CCR-16-3001; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Hou YJ, 2018, BREAST J, V24, P911, DOI 10.1111/tbj.13112; Iwasaki K, 2020, CLIN EXP IMMUNOL, V202, P249, DOI 10.1111/cei.13482; Jiang C, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0955-2; Jin HT, 2011, CURR TOP MICROBIOL, V350, P17, DOI 10.1007/82_2010_116; Kawaji H, 2021, CANCER MED-US, V10, P529, DOI 10.1002/cam4.3619; Keenan TE, 2020, J NATL COMPR CANC NE, V18, P479, DOI 10.6004/jnccn.2020.7554; Li X, 2018, CANCER LETT, V418, P1, DOI 10.1016/j.canlet.2018.01.005; Loibl S, 2019, ANN ONCOL, V30, P1279, DOI 10.1093/annonc/mdz158; Matikas A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-001032; Matikas A, 2019, CLIN CANCER RES, V25, P5717, DOI 10.1158/1078-0432.CCR-19-1131; Mocan T, 2019, CLIN TRANSL ONCOL, V21, P702, DOI 10.1007/s12094-018-1975-4; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Noske A, 2019, EUR J CANCER, V114, P76, DOI 10.1016/j.ejca.2019.04.010; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Park SY, 2018, J THORAC CARDIOV SUR, V155, DOI 10.1016/j.jtcvs.2017.12.107; Parvathareddy SK, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020229; Paver EC, 2021, PATHOLOGY, V53, P141, DOI 10.1016/j.pathol.2020.10.007; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Ponde NF, 2019, NAT REV CLIN ONCOL, V16, P27, DOI 10.1038/s41571-018-0089-9; Ralser DJ, 2021, J IMMUNOTHER, V44, P319, DOI 10.1097/CJI.0000000000000384; Shen X, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3529; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sugie T, 2018, CHIN CLIN ONCOL, V7, DOI 10.21037/cco.2018.05.05; Sun LJ, 2021, CANCER CELL, V39, P1361, DOI 10.1016/j.ccell.2021.08.005; Wang XP, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01200-x; Wesolowski R, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06949-4; Yang MW, 2019, WORLD J GASTROENTERO, V25, P1684, DOI 10.3748/wjg.v25.i14.1684; Yokoyama S, 2016, CLIN CANCER RES, V22, P4727, DOI 10.1158/1078-0432.CCR-16-0434; Zhou TT, 2018, ANTI-CANCER DRUG, V29, P904, DOI 10.1097/CAD.0000000000000683	46	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								849468	10.3389/fimmu.2022.849468	http://dx.doi.org/10.3389/fimmu.2022.849468			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5H3MP	35669769	Green Published			2022-12-18	WOS:000867586400001
J	Garlant, HN; Ellappan, K; Hewitt, M; Perumal, P; Pekeleke, S; Wand, N; Southern, J; Kumar, SV; Belgode, H; Abubakar, I; Sinha, S; Vasan, S; Joseph, NM; Kempsell, KE				Garlant, Harriet N.; Ellappan, Kalaiarasan; Hewitt, Matthew; Perumal, Prem; Pekeleke, Simon; Wand, Nadina; Southern, Jo; Kumar, Saka Vinod; Belgode, Harish; Abubakar, Ibrahim; Sinha, Sanjeev; Vasan, Seshadri; Joseph, Noyal Mariya; Kempsell, Karen E.			Evaluation of Host Protein Biomarkers by ELISA From Whole Lysed Peripheral Blood for Development of Diagnostic Tests for Active Tuberculosis	FRONTIERS IN IMMUNOLOGY			English	Article						biomarker; protein; ELISA; tuberculosis; diagnostic; assay; diagnosis	TB; DISEASE; AUTOPHAGY; FAMILY; ASSAYS; TLR3	Tuberculosis (TB) remains a significant global health crisis and the number one cause of death for an infectious disease. The health consequences in high-burden countries are significant. Barriers to TB control and eradication are in part caused by difficulties in diagnosis. Improvements in diagnosis are required for organisations like the World Health Organisation (WHO) to meet their ambitious target of reducing the incidence of TB by 50% by the year 2025, which has become hard to reach due to the COVID-19 pandemic. Development of new tests for TB are key priorities of the WHO, as defined in their 2014 report for target product profiles (TPPs). Rapid triage and biomarker-based confirmatory tests would greatly enhance the diagnostic capability for identifying and diagnosing TB-infected individuals. Protein-based test methods e.g. lateral flow devices (LFDs) have a significant advantage over other technologies with regard to assay turnaround time (minutes as opposed to hours) field-ability, ease of use by relatively untrained staff and without the need for supporting laboratory infrastructure. Here we evaluate the diagnostic performance of nine biomarkers from our previously published biomarker qPCR validation study; CALCOCO2, CD274, CD52, GBP1, IFIT3, IFITM3, SAMD9L, SNX10 and TMEM49, as protein targets assayed by ELISA. This preliminary evaluation study was conducted to quantify the level of biomarker protein expression across latent, extra-pulmonary or pulmonary TB groups and negative controls, collected across the UK and India, in whole lysed blood samples (WLB). We also investigated associative correlations between the biomarkers and assessed their suitability for ongoing diagnostic test development, using receiver operating characteristic/area under the curve (ROC) analyses, singly and in panel combinations. The top performing single biomarkers for pulmonary TB versus controls were CALCOCO2, SAMD9L, GBP1, IFITM3, IFIT3 and SNX10. TMEM49 was also significantly differentially expressed but downregulated in TB groups. CD52 expression was not highly differentially expressed across most of the groups but may provide additional patient stratification information and some limited use for incipient latent TB infection. These show therefore great potential for diagnostic test development either in minimal configuration panels for rapid triage or more complex formulations to capture the diversity of disease presentations.	[Garlant, Harriet N.; Hewitt, Matthew; Perumal, Prem; Pekeleke, Simon; Wand, Nadina; Kempsell, Karen E.] UK Hlth Secur Agcy, Sci Grp Res & Evaluat, Salisbury, England; [Ellappan, Kalaiarasan; Kumar, Saka Vinod; Belgode, Harish; Joseph, Noyal Mariya] Jawaharlal Inst Postgrad Med Educ & Res, Dept Microbiol, Pondicherry, India; [Southern, Jo; Abubakar, Ibrahim] UCL, Mortimer Market Ctr, Sch Life & Med Sci, London, England; [Sinha, Sanjeev] All India Inst Med Sci, Dept Med, New Delhi, India; [Vasan, Seshadri] Univ York, Dept Hlth Sci, York, England	Jawaharlal Institute of Postgraduate Medical Education & Research; University of London; University College London; All India Institute of Medical Sciences (AIIMS) New Delhi; University of York - UK	Kempsell, KE (corresponding author), UK Hlth Secur Agcy, Sci Grp Res & Evaluat, Salisbury, England.	Karen.Kempsell@phe.gov.uk		Hewitt, Matthew/0000-0001-8915-1996; Kempsell, Karen/0000-0002-3059-9718; Abubakar, Ibrahim/0000-0002-0370-1430; Ellappan, Kalaiarasan/0000-0002-8271-3754; Joseph, Noyal/0000-0001-6586-2742				Abubakar I, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22560; Abubakar I, 2018, LANCET INFECT DIS, V18, P1077, DOI 10.1016/S1473-3099(18)30355-4; Adikesavalu H, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57060522; Armstrong Edward, 2014, Confl Health, V8, P25, DOI 10.1186/1752-1505-8-25; Athman JJ, 2017, J IMMUNOL, V198, P2028, DOI 10.4049/jimmunol.1601199; Chegou NN, 2016, THORAX, V71, P785, DOI 10.1136/thoraxjnl-2015-207999; Conte DD, 2021, BRAZ J MICROBIOL, V52, P1161, DOI 10.1007/s42770-021-00498-z; Dass B, 2002, SPINAL CORD, V40, P604, DOI 10.1038/sj.sc.3101365; De Groote MA, 2017, J CLIN MICROBIOL, V55, P3057, DOI [10.1128/JCM.00467-17, 10.1128/jcm.00467-17]; de Matos AL, 2013, BMC EVOL BIOL, V13, DOI 10.1186/1471-2148-13-121; Dickinson S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0258299; Fisch D, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108008; Gambhir S, 2017, INT J INFECT DIS, V56, P237, DOI 10.1016/j.ijid.2016.11.003; Garay-Baquero DJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137427; Gong WP, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.745592; Gupta RK, 2020, LANCET RESP MED, V8, P395, DOI 10.1016/S2213-2600(19)30282-6; Gupta RK, 2020, AM J RESP CRIT CARE, V201, P984, DOI 10.1164/rccm.201905-0969OC; Haushalter KJ, 2016, ACS OMEGA, V1, P586, DOI 10.1021/acsomega.6b00188; He PJW, 2018, BIOSENSORS-BASEL, V8, DOI 10.3390/bios8040097; Humbert MV, 2019, EMERG MICROBES INFEC, V8, P1178, DOI 10.1080/22221751.2019.1635430; Iles AH, 2022, TALANTA, V237, DOI 10.1016/j.talanta.2021.122944; Imaizumi T, 2018, J NEUROIMMUNOL, V324, P16, DOI 10.1016/j.jneuroim.2018.08.016; Ishrat R., 2018, BIORXIV414110, P14110, DOI [10.1101/414110, DOI 10.1101/414110]; Islam MT, 2014, INT J MYCOBACT, V3, P88, DOI 10.1016/j.ijmyco.2014.03.003; Jacobs R, 2016, ONCOTARGET, V7, P57581, DOI 10.18632/oncotarget.11420; Jiang TT, 2018, BIOCHEM BIOPH RES CO, V503, P2263, DOI 10.1016/j.bbrc.2018.06.147; Jiang TT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173304; Jin SH, 2018, AUTOPHAGY, V14, P171, DOI 10.1080/15548627.2017.1393590; Kant S, 2017, RURAL REMOTE HEALTH, V17, DOI [10.22605/rrh4158, 10.22605/RRH4158]; Kim BH, 2011, SCIENCE, V332, P717, DOI 10.1126/science.1201711; Kritsaneepaiboon S, 2017, PEDIATR RADIOL, V47, P1249, DOI 10.1007/s00247-017-3867-0; Kuo CJ, 2018, AUTOPHAGY, V14, P233, DOI 10.1080/15548627.2017.1389824; Kwan PKW, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05116-1; Lin X, 2008, INT J TUBERC LUNG D, V12, P288; Macdonald SHF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038488; MacLean E, 2019, NAT MICROBIOL, V4, P748, DOI 10.1038/s41564-019-0380-2; Martin DR, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11081352; Mathiasen VD, 2019, RESPIRATION, V97, P576, DOI 10.1159/000499052; Matsumoto M, 2008, ADV DRUG DELIVER REV, V60, P805, DOI 10.1016/j.addr.2007.11.005; Morris TC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.639174; Mutavhatsindi H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.607827; Nagamachi A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI140147; Nguipdop-Djomo P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240879; Pappas DJ, 2009, PHYSIOL GENOMICS, V38, P362, DOI 10.1152/physiolgenomics.00058.2009; Perumal P, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.612564; Rasmi Y, 2021, ANAL BIOANAL CHEM, V413, P4137, DOI 10.1007/s00216-021-03377-6; Riebisch AK, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020110; Santos JC, 2018, J LEUKOCYTE BIOL, V104, P729, DOI 10.1002/JLB.4MR0118-038R; Sharma Nandini, 2019, Indian J Tuberc, V66, P30, DOI 10.1016/j.ijtb.2018.10.006; Shizukuishi S, 2020, AUTOPHAGY, V16, P1152, DOI 10.1080/15548627.2020.1743937; Shuber AP, 1997, HUM MOL GENET, V6, P337, DOI 10.1093/hmg/6.3.337; Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/srep44121; Tan JMJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24982-0; Tattoli I, 2012, AUTOPHAGY, V8, P1848, DOI 10.4161/auto.21863; Teasdale RD, 2001, BIOCHEM J, V358, P7, DOI 10.1042/0264-6021:3580007; Telisinghe L, 2021, ECLINICALMEDICINE, V40, DOI 10.1016/j.eclinm.2021.101127; Toonkomdang S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236496; Tripathi-Giesgen I, 2021, EMBO REP, V22, DOI 10.15252/embr.202152864; UK Health Security Agency, 2021, TUB ENGL 2021 REP; UN, 2015, SUSTAINABLE DEV GOAL; van Hooij A, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.102006; VANBELKUM A, 1995, CELL MOL BIOL, V41, P615; Westwood M, 2021, HEALTH TECHNOL ASSES, V25, P1, DOI 10.3310/hta25330; WHO, 2014, WHONMHNHDMNM146; WHO, 2021, TUB DEATHS RIS 1 TIM; WHO, 2021, TRUE DEATH TOLL COVI; Worby CA, 2002, NAT REV MOL CELL BIO, V3, P919, DOI 10.1038/nrm974; World Health Organisation, 2020, GLOB VECT CONTR RESP, P1; World Health Organization, 2022, PREAMBL CONST WHO AD; Xie XQ, 2015, AUTOPHAGY, V11, P1775, DOI 10.1080/15548627.2015.1082025; Zambuzi FA, 2016, CYTOKINE, V88, P99, DOI 10.1016/j.cyto.2016.08.030; Zellweger JP, 2020, MED LAV, V111, P170, DOI 10.23749/mdl.v111i3.9983	72	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								854327	10.3389/fimmu.2022.854327	http://dx.doi.org/10.3389/fimmu.2022.854327			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V4XI	35720382	Green Published, gold			2022-12-18	WOS:000806094100001
J	He, XS; Zhou, TY; Cai, YC; Liu, Y; Zhao, SQ; Zhang, JH; Wang, XL; Zhang, R				He, Xueshan; Zhou, Tianyang; Cai, Yuchen; Liu, Yang; Zhao, Siqi; Zhang, Jinghai; Wang, Xialu; Zhang, Rong			A Versatile Hemolin With Pattern Recognitional Contributions to the Humoral Immune Responses of the Chinese Oak Silkworm Antheraea pernyi	FRONTIERS IN IMMUNOLOGY			English	Article						pattern recognition receptor; hemolin; humoral immunity; prophenoloxidase activating system; antimicrobial peptide synthesis	IMMUNOGLOBULIN SUPERFAMILY; MANDUCA-SEXTA; PROTEIN HEMOLIN; INSECT; EXPRESSION; BACTERIAL; MEMBER; GENE; LIPOPOLYSACCHARIDE; RECEPTORS	Hemolin is a distinctive immunoglobulin superfamily member involved in invertebrate immune events. Although it is believed that hemolin regulates hemocyte phagocytosis and microbial agglutination in insects, little is known about its contribution to the humoral immune system. In the present study, we focused on hemolin in Antheraea pernyi (Ap-hemolin) by studying its pattern recognition property and humoral immune functions. Tissue distribution analysis demonstrated the mRNA level of Ap-hemolin was extremely immune-inducible in different tissues. The results of western blotting and biolayer interferometry showed recombinant Ap-hemolin bound to various microbes and pathogen-associated molecular patterns. In further immune functional studies, it was detected that knockdown of hemolin regulated the expression level of antimicrobial peptide genes and decreased prophenoloxidase activation in the A. pernyi hemolymph stimulated by microbial invaders. Together, these data suggest that hemolin is a multifunctional pattern recognition receptor that plays critical roles in the humoral immune responses of A. pernyi.	[He, Xueshan; Cai, Yuchen; Zhang, Jinghai; Wang, Xialu] Shenyang Pharmaceut Univ, Sch Med Devices, Shenyang, Peoples R China; [Zhou, Tianyang; Zhao, Siqi; Zhang, Rong] Shenyang Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Shenyang, Peoples R China; [Liu, Yang] Liaoning Applos Biotechnol Co Ltd, Res & Dev Dept, Shenyang, Peoples R China	Shenyang Pharmaceutical University; Shenyang Pharmaceutical University	Wang, XL (corresponding author), Shenyang Pharmaceut Univ, Sch Med Devices, Shenyang, Peoples R China.; Zhang, R (corresponding author), Shenyang Pharmaceut Univ, Sch Life Sci & Biopharmaceut, Shenyang, Peoples R China.	wangxialu1985@163.com; zhangrong_spu@163.com			National Natural Science Foundation of China [31772518, 31970485]; Innovation Team Project and Talent Support Program of Liaoning Province Colleges and Universities [LT2019013, LR2019071]; Starting Foundation of Liaoning [2019-BS-230]; Innovation and Entrepreneurship Training Program for Students of Shenyang Pharmaceutical University [YQ202115]; Rolling Support Plan of Shenyang Pharmaceutical University for Youth Development [ZQN2014A05]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Team Project and Talent Support Program of Liaoning Province Colleges and Universities; Starting Foundation of Liaoning; Innovation and Entrepreneurship Training Program for Students of Shenyang Pharmaceutical University; Rolling Support Plan of Shenyang Pharmaceutical University for Youth Development	This work was financially supported by the National Natural Science Foundation of China (Grant numbers: 31772518 and 31970485); the Innovation Team Project and Talent Support Program of Liaoning Province Colleges and Universities (Grant number: LT2019013 and LR2019071); the Ph.D. Starting Foundation of Liaoning (Grant number: 2019-BS-230); the Innovation and Entrepreneurship Training Program for Students of Shenyang Pharmaceutical University (Grant number: YQ202115) and the Rolling Support Plan of Shenyang Pharmaceutical University for Youth Development (Grant numbers: ZQN2014A05).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Aye TT, 2008, J INSECT PHYSIOL, V54, P1301, DOI 10.1016/j.jinsphys.2008.07.003; Bao YY, 2007, COMP BIOCHEM PHYS B, V146, P147, DOI 10.1016/j.cbpb.2006.10.092; Basbous N, 2011, EMBO REP, V12, P327, DOI 10.1038/embor.2011.19; Beck G, 1996, SCI AM, V275, P60, DOI 10.1038/scientificamerican1196-60; Bettencourt R, 2000, MECH DEVELOP, V95, P301, DOI 10.1016/S0925-4773(00)00359-2; Bettencourt R, 1997, EUR J BIOCHEM, V250, P630, DOI 10.1111/j.1432-1033.1997.00630.x; Bettencourt R, 1999, EUR J BIOCHEM, V266, P964, DOI 10.1046/j.1432-1327.1999.00934.x; Costa A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007436; Daffre S, 1997, FEBS LETT, V408, P127, DOI 10.1016/S0014-5793(97)00397-9; Eleftherianos I, 2007, CELL MICROBIOL, V9, P1137, DOI 10.1111/j.1462-5822.2006.00855.x; Eleftherianos I, 2006, DEV COMP IMMUNOL, V30, P1099, DOI 10.1016/j.dci.2006.02.008; Eleftherianos I, 2006, INSECT BIOCHEM MOLEC, V36, P517, DOI 10.1016/j.ibmb.2006.04.001; Ghosh J, 2011, DEV COMP IMMUNOL, V35, P959, DOI 10.1016/j.dci.2010.12.009; Hirai M, 2004, INSECT MOL BIOL, V13, P399, DOI 10.1111/j.0962-1075.2004.00497.x; Ishii KJ, 2008, CELL HOST MICROBE, V3, P352, DOI 10.1016/j.chom.2008.05.003; Jung J, 2019, J ASIA-PAC ENTOMOL, V22, P947, DOI 10.1016/j.aspen.2019.08.002; Kurata S, 2014, DEV COMP IMMUNOL, V42, P36, DOI 10.1016/j.dci.2013.06.006; LADENDORFF NE, 1991, ARCH INSECT BIOCHEM, V18, P285, DOI 10.1002/arch.940180410; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LanzMendoza H, 1996, CELL IMMUNOL, V169, P47, DOI 10.1006/cimm.1996.0089; Lee KY, 2002, INSECT BIOCHEM MOLEC, V32, P1457, DOI 10.1016/S0965-1748(02)00066-8; Liu B, 2016, CELL, V164, P406, DOI 10.1016/j.cell.2015.12.029; Liu CY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17931-w; Manniello MD, 2021, CELL MOL LIFE SCI, V78, P4259, DOI 10.1007/s00018-021-03784-z; Mendoza HL, 1999, DEV COMP IMMUNOL, V23, P359, DOI 10.1016/S0145-305X(99)00017-8; Neuert H, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.181479; Qian C, 2017, INT IMMUNOPHARMACOL, V42, P74, DOI 10.1016/j.intimp.2016.11.020; Resnik-Docampo M, 2021, STEM CELL REP, V16, P1584, DOI 10.1016/j.stemcr.2021.04.006; Rosales C ., 2017, INSECT PHYSL ECOLOGY, DOI [10.5772/67107, DOI 10.5772/67107]; SCHMIDT O, 1993, DEV COMP IMMUNOL, V17, P195, DOI 10.1016/0145-305X(93)90038-R; Shaik HA, 2009, J INSECT PHYSIOL, V55, P781, DOI 10.1016/j.jinsphys.2009.04.010; Shin SW, 1998, INSECT BIOCHEM MOLEC, V28, P827, DOI 10.1016/S0965-1748(98)00077-0; Su XD, 1998, SCIENCE, V281, P991, DOI 10.1126/science.281.5379.991; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; Sun Y, 2015, INT IMMUNOPHARMACOL, V26, P65, DOI 10.1016/j.intimp.2015.03.010; Terenius O, 2007, DEV COMP IMMUNOL, V31, P571, DOI 10.1016/j.dci.2006.09.006; Terenius O, 2009, DEV COMP IMMUNOL, V33, P1176, DOI 10.1016/j.dci.2009.06.009; Trenczek T, 1998, ZOOL-ANAL COMPLEX SY, V101, P298; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Verschueren E, 2020, CELL, V182, P329, DOI 10.1016/j.cell.2020.06.007; Wan XS, 2021, J INSECT SCI, V21, DOI 10.1093/jisesa/ieab073; Wang F, 2018, DEV COMP IMMUNOL, V87, P216, DOI 10.1016/j.dci.2018.06.007; Wang XL, 2017, DEV COMP IMMUNOL, V69, P1, DOI 10.1016/j.dci.2016.11.022; WANG Y, 1995, INSECT MOL BIOL, V4, P113, DOI 10.1111/j.1365-2583.1995.tb00015.x; Wen DH, 2017, DEV COMP IMMUNOL, V77, P221, DOI 10.1016/j.dci.2017.08.010; Wen DH, 2016, DEV COMP IMMUNOL, V65, P124, DOI 10.1016/j.dci.2016.07.001; WHITE JM, 1989, CELL, V56, P725, DOI 10.1016/0092-8674(89)90674-0; Yu XQ, 2002, EUR J BIOCHEM, V269, P1827, DOI 10.1046/j.1432-1033.2002.02830.x; Yu XQ, 1999, ARCH INSECT BIOCHEM, V42, P198, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;198::AID-ARCH4&gt;3.0.CO;2-G; Zhao L, 1996, J INSECT PHYSIOL, V42, P73, DOI 10.1016/0022-1910(95)00084-4	51	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								904862	10.3389/fimmu.2022.904862	http://dx.doi.org/10.3389/fimmu.2022.904862			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W1PE	35669768	Green Published, gold			2022-12-18	WOS:000806550800001
J	Heng, JY; Liu, HW; Xu, JH; Huang, X; Sun, XT; Yang, RZ; Xia, QY; Zhao, P				Heng, Jingya; Liu, Huawei; Xu, Jiahui; Huang, Xuan; Sun, Xiaotong; Yang, Runze; Xia, Qingyou; Zhao, Ping			KPI5 Is Involved in the Regulation of the Expression of Antibacterial Peptide Genes and Hemolymph Melanization in the Silkworm, Bombyx mori	FRONTIERS IN IMMUNOLOGY			English	Article						Bombyx mori; Kunitz-type protease inhibitor; innate immunity; antimicrobial peptide; hemolymph melanization	AMINO-ACID-SEQUENCE; PROPHENOLOXIDASE ACTIVATION; CHYMOTRYPSIN INHIBITOR; PROTEASE INHIBITORS; TOBACCO HORNWORM; IMMUNE-RESPONSE; RECOGNITION; PURIFICATION; CASCADE; CLONING	Kunitz-type protease inhibitors (KPIs) are ubiquitously found in many organisms, and participate in various physiological processes. However, their function in insects remains to be elucidated. In the present study, we characterized and functionally analyzed silkworm KPI5. Sequence analysis showed that KPI5 contains 85 amino acids with six conserved cysteine residues, and the P1 site is a phenylalanine residue. Inhibitory activity and stability analyses indicated that recombinant KPI5 protein significantly inhibited the activity of chymotrypsin and was highly tolerant to temperature and pH. The spatio-temporal expression profile analysis showed that KPI5 was synthesized in the fat body and secreted into the hemolymph. In vivo induction analysis showed that the expression of KPI5 in the fat body was significantly upregulated by pathogen-associated molecular patterns (PAMPs). Binding assays suggested that KPI5 can bind to pathogens and PAMPs. In vitro pathogen growth inhibition assay and encapsulation analysis indicated that KPI5 can neither kill pathogenic bacteria directly nor promote the encapsulation of agarose beads by silkworm hemocytes. Recombinant protein injection test and CRISPR/Cas9-mediated knockdown showed that KPI5 promotes the expression of antimicrobial peptides (AMPs) in the fat body. Moreover, the survival rate of individuals in the KPI5 knockdown group was significantly lower than that of the control group after pathogen infection. Phenoloxidase (PO) activity assays showed that KPI5 significantly inhibited the hemolymph PO activity and melanization induced by PAMPs. These findings suggested that KPI5 plays a dual regulatory role in innate immunity by promoting the expression of antimicrobial peptides in the fat body and inhibiting hemolymph melanization. Our study furthers the understanding of the function of insect KPIs and provides new insights into the regulatory mechanism of insect immune homeostasis.	[Heng, Jingya; Liu, Huawei; Xu, Jiahui; Huang, Xuan; Sun, Xiaotong; Yang, Runze; Xia, Qingyou; Zhao, Ping] Southwest Univ, Biol Sci Res Ctr, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China; [Heng, Jingya; Liu, Huawei; Xu, Jiahui; Huang, Xuan; Xia, Qingyou; Zhao, Ping] Southwest Univ, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing Key Lab Sericultural Sci, Chongqing, Peoples R China	Southwest University - China; Southwest University - China	Zhao, P (corresponding author), Southwest Univ, Biol Sci Res Ctr, State Key Lab Silkworm Genome Biol, Chongqing, Peoples R China.; Zhao, P (corresponding author), Southwest Univ, Chongqing Engn & Technol Res Ctr Novel Silk Mat, Chongqing Key Lab Sericultural Sci, Chongqing, Peoples R China.	zhaop@swu.edu.cn	xu, jia/GSD-6347-2022		National Natural Science Foundation of China [32030103, 32172798]; Fundamental Research Funds for the Central Universities [SWU-KQ22008]; Chongqing Science and Technology Commission [cstc2020jcyj-cxttX0001]; National Training Program of Innovation and Entrepreneurship for Undergraduates [202010635030]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Chongqing Science and Technology Commission(Natural Science Foundation Project of CQ CSTC); National Training Program of Innovation and Entrepreneurship for Undergraduates	Funding The authors would like to thank grants from the National Natural Science Foundation of China (32030103; 32172798), the Fundamental Research Funds for the Central Universities (SWU-KQ22008), the Chongqing Science and Technology Commission (cstc2020jcyj-cxttX0001) and National Training Program of Innovation and Entrepreneurship for Undergraduates (202010635030).	An CJ, 2011, DEV COMP IMMUNOL, V35, P135, DOI 10.1016/j.dci.2010.09.004; An CJ, 2010, INSECT BIOCHEM MOLEC, V40, P683, DOI 10.1016/j.ibmb.2010.07.001; ASO Y, 1994, BIOCHEM MOL BIOL INT, V33, P751; Chu Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep45256; Chu Y, 2015, INSECT BIOCHEM MOLEC, V61, P53, DOI 10.1016/j.ibmb.2015.03.007; de Magalhaes MTQ, 2018, MICROBES INFECT, V20, P606, DOI 10.1016/j.micinf.2018.01.003; Decrem Y, 2009, J EXP MED, V206, P2381, DOI 10.1084/jem.20091007; Dolezal T, 2019, INSECT BIOCHEM MOLEC, V109, P31, DOI 10.1016/j.ibmb.2019.04.005; Dong ZM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.735497; Fernando MDA, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004117; Ferrandon D, 2007, NAT REV IMMUNOL, V7, P862, DOI 10.1038/nri2194; He NJ, 2004, BIOSCI BIOTECH BIOCH, V68, P835, DOI 10.1271/bbb.68.835; Hughes AL, 2012, IMMUNOGENETICS, V64, P549, DOI 10.1007/s00251-012-0610-8; Ji CY, 2004, J BIOL CHEM, V279, P34101, DOI 10.1074/jbc.M404584200; Jiang HB, 2005, INSECT BIOCHEM MOLEC, V35, P931, DOI 10.1016/j.ibmb.2005.03.009; Jiang R, 2009, J BIOL CHEM, V284, P35652, DOI 10.1074/jbc.M109.071001; Kanost MR, 2015, CURR OPIN INSECT SCI, V11, P47, DOI 10.1016/j.cois.2015.09.003; Kounatidis I, 2017, CELL REP, V19, P836, DOI 10.1016/j.celrep.2017.04.007; LanzMendoza H, 1996, CELL IMMUNOL, V169, P47, DOI 10.1006/cimm.1996.0089; Lavine MD, 2002, INSECT BIOCHEM MOLEC, V32, P1295, DOI 10.1016/S0965-1748(02)00092-9; Lee JH, 2010, INSECT BIOCHEM MOLEC, V40, P873, DOI 10.1016/j.ibmb.2010.08.007; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Li JL, 2016, INSECT BIOCHEM MOLEC, V73, P27, DOI 10.1016/j.ibmb.2016.04.003; Li YS, 2015, INSECT BIOCHEM MOLEC, V57, P11, DOI 10.1016/j.ibmb.2014.11.006; Ling EJ, 2006, DEV COMP IMMUNOL, V30, P289, DOI 10.1016/j.dci.2005.05.005; Liu DR, 2015, DEV COMP IMMUNOL, V51, P22, DOI 10.1016/j.dci.2015.02.013; Lu AR, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00252; Lu YZ, 2020, DEV COMP IMMUNOL, V102, DOI 10.1016/j.dci.2019.103468; Ma SY, 2014, SCI REP-UK, V4, DOI 10.1038/srep04489; Meekins DA, 2017, SEMIN CELL DEV BIOL, V62, P105, DOI 10.1016/j.semcdb.2016.09.001; Mishra M, 2020, J MOL EVOL, V88, P537, DOI 10.1007/s00239-020-09959-9; Nakhleh J, 2017, ADV INSECT PHYSIOL, V52, P83, DOI 10.1016/bs.aiip.2016.11.002; PAPAYANNOPOULOS IA, 1992, PROTEIN SCI, V1, P278; RAMESH N, 1988, J BIOL CHEM, V263, P11523; Ranasinghe S, 2013, DEV COMP IMMUNOL, V39, P219, DOI 10.1016/j.dci.2012.10.005; Rao XJ, 2018, DEV COMP IMMUNOL, V83, P80, DOI 10.1016/j.dci.2017.12.007; SASAKI T, 1988, BIOL CHEM H-S, V369, P1235, DOI 10.1515/bchm3.1988.369.2.1235; SASAKI T, 1984, FEBS LETT, V168, P227, DOI 10.1016/0014-5793(84)80251-3; Scheidig AJ, 1997, PROTEIN SCI, V6, P1806, DOI 10.1002/pro.5560060902; Shakeel M, 2019, ARCH INSECT BIOCHEM, V102, DOI 10.1002/arch.21556; SUGUMARAN M, 1985, BIOCHEM BIOPH RES CO, V132, P1124, DOI 10.1016/0006-291X(85)91923-0; Suwanchaichinda C, 2013, INSECT BIOCHEM MOLEC, V43, P555, DOI 10.1016/j.ibmb.2013.03.015; Tamura T, 2000, NAT BIOTECHNOL, V18, P81, DOI 10.1038/71978; Tsujimoto H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029964; Wang F, 2018, DEV COMP IMMUNOL, V87, P216, DOI 10.1016/j.dci.2018.06.007; Wang LL, 2019, DEV COMP IMMUNOL, V91, P123, DOI 10.1016/j.dci.2018.10.006; Wang Q, 2021, DEV COMP IMMUNOL, V115, DOI 10.1016/j.dci.2020.103903; Wang Y, 2020, P NATL ACAD SCI USA, V117, P23581, DOI 10.1073/pnas.2004761117; Yan YL, 2010, BMC GENOMICS, V11, DOI [10.1186/1471-2164-11-405, 10.1186/1471-2164-11-11]; Yang JL, 2010, DEV COMP IMMUNOL, V34, P1274, DOI 10.1016/j.dci.2010.07.004; Yi HY, 2014, APPL MICROBIOL BIOT, V98, P5807, DOI 10.1007/s00253-014-5792-6; Yuan CF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006645; Zhang W, 2021, CELL SIGNAL, V83, DOI 10.1016/j.cellsig.2021.110003; Zhang XL, 2020, INSECT BIOCHEM MOLEC, V116, DOI 10.1016/j.ibmb.2019.103258; Zhang Y, 2014, AMINO ACIDS, V46, P1021, DOI 10.1007/s00726-014-1665-7; Zhao P, 2007, PROTEIN J, V26, P349, DOI 10.1007/s10930-007-9077-0; Zhao P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031168; Zhu YF, 2003, J BIOL CHEM, V278, P46556, DOI 10.1074/jbc.M309682200; Zou Z, 2005, J BIOL CHEM, V280, P14341, DOI 10.1074/jbc.M500570200	59	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								907427	10.3389/fimmu.2022.907427	http://dx.doi.org/10.3389/fimmu.2022.907427			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5YX	35669774	gold, Green Published			2022-12-18	WOS:000806165900001
J	Jing, LA; Zhang, X; Liu, D; Yang, YH; Xiong, HB; Dong, GJ				Jing, Lina; Zhang, Xin; Liu, Dong; Yang, Yonghong; Xiong, Huabao; Dong, Guanjun			ACK1 Contributes to the Pathogenesis of Inflammation and Autoimmunity by Promoting the Activation of TLR Signaling Pathways	FRONTIERS IN IMMUNOLOGY			English	Article						ACK1; TLR; macrophages; dendritic cells; inflammation; autoimmunity	TYROSINE KINASE ACK1; TOLL-LIKE RECEPTORS; IDENTIFICATION; CANCER	Toll-like receptors (TLRs) are the first line of defense in the immune system, whose activation plays a key role in the pathogenesis of inflammation and autoimmunity. TLRs can activate a variety of immune cells such as macrophages and dendritic cells, which produce proinflammatory cytokines, chemokines, and co-stimulatory molecules that lead to the development of inflammation and autoimmune diseases. As a nonreceptor tyrosine kinase, ACK1 is involved in multiple signaling pathways and physiological processes. However, the roles of ACK1 in the activation of TLR pathways and in the pathogenesis of inflammation and autoimmune diseases have not yet been reported. We found that the expression of ACK1 could be upregulated by TLR pathways in vivo and in vitro. Intriguingly, overexpression of ACK1 significantly promoted the activation of TLR4, TLR7, and TLR9 pathways, while knockdown of ACK1 or the use of the ACK1 inhibitor AIM-100 significantly inhibited the activation of TLR4, TLR7, and TLR9 pathways. In vivo studies showed that the inhibition of ACK1 activity by AIM-100 could significantly protect mice from the TLR4 agonist lipopolysaccharide (LPS)-mediated endotoxin shock and alleviate the condition of imiquimod-mediated lupus-prone mice and MRL/lpr mice. In summary, ACK1 participates in TLR-mediated inflammation and autoimmunity and has great potential in controlling inflammation and alleviating autoimmune diseases.	[Jing, Lina] Shandong Univ, Cheeloo Coll Med, Jinan, Peoples R China; [Jing, Lina; Zhang, Xin; Xiong, Huabao; Dong, Guanjun] Jining Med Univ, Inst Immunol & Mol Med, Jining, Peoples R China; [Zhang, Xin] Weifang Med Univ, Sch Med Lab, Weifang, Peoples R China; [Liu, Dong] Jining Med Univ, Dept Clin Lab, Affiliated Hosp, Jining, Peoples R China; [Yang, Yonghong] Jining Med Univ, Med Res Ctr, Affiliated Hosp, Jining, Peoples R China; [Xiong, Huabao; Dong, Guanjun] Jining Med Univ, Jining Key Lab Immunol, Jining, Peoples R China	Shandong University; Jining Medical University; Weifang Medical University; Jining Medical University; Jining Medical University; Jining Medical University	Xiong, HB; Dong, GJ (corresponding author), Jining Med Univ, Inst Immunol & Mol Med, Jining, Peoples R China.; Xiong, HB; Dong, GJ (corresponding author), Jining Med Univ, Jining Key Lab Immunol, Jining, Peoples R China.	xionghbl@yahoo.com; guanjun0323@mail.jnmc.edu.cn			National Natural Science Foundation of China [82071824, 81901655]; Project of Shandong Province Higher Educational Youth Innovation Science and Technology Program [2021KJ074]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Project of Shandong Province Higher Educational Youth Innovation Science and Technology Program	Funding This work was supported by the National Natural Science Foundation of China (NO. 82071824 and 81901655), Project of Shandong Province Higher Educational Youth Innovation Science and Technology Program (2021KJ074).	Abdul-Sater AA, 2017, NAT IMMUNOL, V18, P26, DOI 10.1038/ni.3618; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Anwar MA, 2019, MED RES REV, V39, P1053, DOI 10.1002/med.21553; Ahmadabad RA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22116153; Ayala-Cuellar AP, 2019, J CELL PHYSIOL, V234, P21707, DOI 10.1002/jcp.28879; Behzadi P, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/9914854; Brown M, 2019, CLIN EXP IMMUNOL, V195, P310, DOI 10.1111/cei.13238; Cao LL, 2021, EUR J IMMUNOL, V51, P380, DOI 10.1002/eji.202048617; Masdeu MD, 2017, ONCOTARGET, V8, P101146, DOI 10.18632/oncotarget.20929; Fillatreau S, 2021, NAT REV RHEUMATOL, V17, P98, DOI 10.1038/s41584-020-00544-4; Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041; Francian A, 2021, J DRUG TARGET, V29, P754, DOI 10.1080/1061186X.2021.1878364; Furlow B, 2006, LANCET ONCOL, V7, P17, DOI 10.1016/S1470-2045(05)70525-8; Germic N, 2019, CELL DEATH DIFFER, V26, P715, DOI 10.1038/s41418-019-0297-6; Ghildiyal R, 2022, CANCER RES, V82, P155, DOI 10.1158/0008-5472.CAN-20-3845; Hamidzadeh K, 2017, ANNU REV PHYSIOL, V79, P567, DOI 10.1146/annurev-physiol-022516-034348; Hirsch I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00394; Ishida H, 2021, NAT STRUCT MOL BIOL, V28, P173, DOI 10.1038/s41594-020-00542-w; Kong DF, 2022, BMC CANCER, V22, DOI 10.1186/s12885-021-09165-w; Li ZN, 2020, BIOORG MED CHEM LETT, V30, DOI 10.1016/j.bmcl.2020.127456; Mahajan K, 2017, CANCER CELL, V31, P790, DOI 10.1016/j.ccell.2017.05.003; Mahajan K, 2013, CANCER LETT, V338, P185, DOI 10.1016/j.canlet.2013.04.004; Molagoda IMN, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87257-0; Patra MC, 2020, SEMIN CANCER BIOL, V64, P61, DOI 10.1016/j.semcancer.2019.05.002; Sahoo BR, 2020, INT J BIOL MACROMOL, V161, P1602, DOI 10.1016/j.ijbiomac.2020.07.293; Skorka K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040867; Song Y, 2021, CELL MOL IMMUNOL, V18, P339, DOI 10.1038/s41423-019-0323-0; Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793; Thaker YR, 2017, J BIOL CHEM, V292, P6281, DOI 10.1074/jbc.M116.759555; Walshaw RC, 2020, INT J RADIAT ONCOL, V108, P27, DOI 10.1016/j.ijrobp.2020.04.020; Wang AX, 2021, J MED CHEM, V64, P16328, DOI 10.1021/acs.jmedchem.1c01030; Wang LJ, 2021, J CROHNS COLITIS, V15, P2103, DOI 10.1093/ecco-jcc/jjab086; Wang YB, 2020, ACCOUNTS CHEM RES, V53, P1046, DOI 10.1021/acs.accounts.9b00631; Wu XY, 2017, ONCOTARGET, V8, P2971, DOI 10.18632/oncotarget.13579; Xu SH, 2017, ONCOTARGET, V8, P12705, DOI 10.18632/oncotarget.6194; Xun Y, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01191-2; Zhang T, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01202-9; Zhao XM, 2018, CELL BIOL INT, V42, P1097, DOI 10.1002/cbin.10875; Zhu JH, 2021, AGING-US, V13, P4482, DOI 10.18632/aging.202408; Zhu JH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01132	40	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								864995	10.3389/fimmu.2022.864995	http://dx.doi.org/10.3389/fimmu.2022.864995			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5TO	35669783	gold, Green Published			2022-12-18	WOS:000806152000001
J	Kong, ER; Li, YC; Deng, MQ; Hua, T; Yang, M; Li, J; Feng, XD; Yuan, HB				Kong, Erliang; Li, Yongchang; Deng, Mengqiu; Hua, Tong; Yang, Mei; Li, Jian; Feng, Xudong; Yuan, Hongbin			Glycometabolism Reprogramming of Glial Cells in Central Nervous System: Novel Target for Neuropathic Pain	FRONTIERS IN IMMUNOLOGY			English	Review						inflammation; glycolysis; microglia; astrocyte; synapse; neuropathic pain; glycometabolism reprogramming	SPINAL DORSAL-HORN; TOLL-LIKE RECEPTOR; SYNAPTIC PLASTICITY; GLUTAMATE TRANSPORTERS; GENE-EXPRESSION; PROTEIN-KINASE; LACTATE; METABOLISM; MACROPHAGES; GLYCOLYSIS	Neuropathic pain is characterized by hyperalgesia and allodynia. Inflammatory response is conducive to tissue recovery upon nerve injury, but persistent and exaggerated inflammation is detrimental and participates in neuropathic pain. Synaptic transmission in the nociceptive pathway, and particularly the balance between facilitation and inhibition, could be affected by inflammation, which in turn is regulated by glial cells. Importantly, glycometabolism exerts a vital role in the inflammatory process. Glycometabolism reprogramming of inflammatory cells in neuropathic pain is characterized by impaired oxidative phosphorylation in mitochondria and enhanced glycolysis. These changes induce phenotypic transition of inflammatory cells to promote neural inflammation and oxidative stress in peripheral and central nervous system. Accumulation of lactate in synaptic microenvironment also contributes to synaptic remodeling and central sensitization. Previous studies mainly focused on the glycometabolism reprogramming in peripheral inflammatory cells such as macrophage or lymphocyte, little attention was paid to the regulation effects of glycometabolism reprogramming on the inflammatory responses in glial cells. This review summarizes the evidences for glycometabolism reprogramming in peripheral inflammatory cells, and presents a small quantity of present studies on glycometabolism in glial cells, expecting to promote the exploration in glycometabolism in glial cells of neuropathic pain.	[Kong, Erliang; Li, Yongchang; Deng, Mengqiu; Hua, Tong; Yang, Mei; Li, Jian; Yuan, Hongbin] Naval Med Univ, Affiliated Hosp 2, Changzheng Hosp, Dept Anesthesiol, Shanghai, Peoples R China; [Kong, Erliang; Feng, Xudong] No 988 Hosp Joint Logist Support Force Chinese Peo, Dept Anesthesiol, Zhengzhou, Peoples R China	Naval Medical University	Yuan, HB (corresponding author), Naval Med Univ, Affiliated Hosp 2, Changzheng Hosp, Dept Anesthesiol, Shanghai, Peoples R China.				National Natural Science Foundation of China [81971046, 82171220]; Medical Science and Technology Research Program of Henan Province [SBGJ202003056, SBGJ202102204, LHGJ20200781]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Science and Technology Research Program of Henan Province	Funding This work was supported by National Natural Science Foundation of China (81971046 and 82171220) and Medical Science and Technology Research Program of Henan Province (SBGJ202003056, SBGJ202102204 and LHGJ20200781).	Abbott NJ, 2002, J ANAT, V200, P629, DOI 10.1046/j.1469-7580.2002.00064.x; Alvarez Z, 2016, CEREB CORTEX, V26, P1046, DOI 10.1093/cercor/bhu281; Ameruoso A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01411; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Arts RJW, 2016, CELL METAB, V24, P807, DOI 10.1016/j.cmet.2016.10.008; Baik SH, 2019, CELL METAB, V30, P493, DOI 10.1016/j.cmet.2019.06.005; Bambouskova M, 2018, NATURE, V556, P501, DOI 10.1038/s41586-018-0052-z; Bannister K, 2020, ANNU REV PHARMACOL, V60, P257, DOI 10.1146/annurev-pharmtox-010818-021524; Bliss TVP, 2016, NAT REV NEUROSCI, V17, P485, DOI 10.1038/nrn.2016.68; Bohlen CJ, 2019, ANNU REV GENET, V53, P263, DOI 10.1146/annurev-genet-112618-043515; Calcutt NA, 2020, PAIN, V161, pS65, DOI 10.1097/j.pain.0000000000001922; Campbell JN, 2006, NEURON, V52, P77, DOI 10.1016/j.neuron.2006.09.021; Chang CC, 2016, ONCOTARGET, V7, P35270, DOI 10.18632/oncotarget.9136; Chisolm DA, 2018, ANNU REV IMMUNOL, V36, P221, DOI 10.1146/annurev-immunol-042617-053127; Chisolm DA, 2017, IMMUNITY, V47, P251, DOI 10.1016/j.immuni.2017.07.015; Colloca L, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.2; Cordes T, 2016, J BIOL CHEM, V291, P14274, DOI 10.1074/jbc.M115.685792; Descalzi G, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0495-2; Devanney NA, 2020, EXP NEUROL, V329, DOI 10.1016/j.expneurol.2020.113310; Diaz-Zuniga J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588036; Diering GH, 2018, NEURON, V100, P314, DOI 10.1016/j.neuron.2018.10.018; Errea A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163694; Falnikar A, 2016, GLIA, V64, P396, DOI 10.1002/glia.22936; Barros LF, 2013, TRENDS NEUROSCI, V36, P396, DOI 10.1016/j.tins.2013.04.002; Finnerup NB, 2021, PHYSIOL REV, V101, P259, DOI 10.1152/physrev.00045.2019; Gao YJ, 2010, PHARMACOL THERAPEUT, V126, P56, DOI 10.1016/j.pharmthera.2010.01.002; Gimeno-Bayon J, 2014, J NEUROSCI RES, V92, P723, DOI 10.1002/jnr.23356; Hashimoto T, 2007, FASEB J, V21, P2602, DOI 10.1096/fj.07-8174com; Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015; Hollander AP, 2001, ARTHRITIS RHEUM-US, V44, P1540, DOI 10.1002/1529-0131(200107)44:7<1540::AID-ART277>3.0.CO;2-7; Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014; Huang YX, 2021, NEUROIMMUNOMODULAT, V27, P104, DOI 10.1159/000510399; Infantino V, 2011, BIOCHEM J, V438, P433, DOI 10.1042/BJ20111275; Jiang S, 2017, CANCER LETT, V390, P45, DOI 10.1016/j.canlet.2017.01.019; Joshi L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041968; Keiran N, 2019, NAT IMMUNOL, V20, P581, DOI 10.1038/s41590-019-0372-7; Ko CW, 2018, J BIOL CHEM, V293, P3399, DOI 10.1074/jbc.M117.819136; Kong EL., 2018, NEUROPSYCHIATRY LOND, V08, P761, DOI [10.4172/Neuropsychiatry.1000401, DOI 10.4172/NEUROPSYCHIATRY.1000401]; Kuner R, 2010, NAT MED, V16, P1258, DOI 10.1038/nm.2231; Lauro C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00493; Lenz M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.614509; Li MM, 2021, MOL IMMUNOL, V140, P250, DOI 10.1016/j.molimm.2021.10.017; Li QY, 2018, NAT REV IMMUNOL, V18, P225, DOI 10.1038/nri.2017.125; Li XJ, 2016, MOL CELL, V61, P705, DOI 10.1016/j.molcel.2016.02.009; Lindberg D, 2019, ALCOHOL CLIN EXP RES, V43, P1838, DOI 10.1111/acer.14137; Littlewood-Evans A, 2016, J EXP MED, V213, P1655, DOI 10.1084/jem.20160061; Liu JJ, 2019, IMMUNOLOGY, V156, P56, DOI 10.1111/imm.12998; Liu PS, 2017, NAT IMMUNOL, V18, P985, DOI 10.1038/ni.3796; Liu S, 2013, PAIN, V154, P2823, DOI 10.1016/j.pain.2013.08.017; Liu YN, 2014, EUR J PAIN, V18, P1120, DOI 10.1002/j.1532-2149.2014.00455.x; Lopez-Gambero AJ, 2019, MOL NEUROBIOL, V56, P769, DOI 10.1007/s12035-018-1099-4; MacDonald John F., 2006, Critical Reviews in Neurobiology, V18, P71; Machelska H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00300; Machler P, 2016, CELL METAB, V23, P94, DOI 10.1016/j.cmet.2015.10.010; Magistretti PJ, 2018, NAT REV NEUROSCI, V19, P235, DOI 10.1038/nrn.2018.19; Estrada-Sanchez AM, 2010, NEUROCHEM RES, V35, P1156, DOI 10.1007/s11064-010-0168-5; Mateos-Aparicio P, 2020, ADV EXP MED BIOL, V1131, P965, DOI 10.1007/978-3-030-12457-1_38; McBride MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01043; Miyamoto KS, 2019, GLIA, V67, P27, DOI 10.1002/glia.23474; Morland C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15557; Muraleedharan R, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108092; Murphy-Royal C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15778-9; Nasi A, 2013, J IMMUNOL, V191, P3090, DOI 10.4049/jimmunol.1300772; Pan B, 2011, J NEUROSCI, V31, P11244, DOI 10.1523/JNEUROSCI.1040-11.2011; Park BY, 2018, DIABETES, V67, P2054, DOI 10.2337/db17-1529; Patgiri A, 2020, NAT BIOTECHNOL, V38, P309, DOI 10.1038/s41587-019-0377-7; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Peruzzotti-Jametti L, 2018, TRENDS MOL MED, V24, P838, DOI 10.1016/j.molmed.2018.07.007; Peruzzotti-Jametti L, 2018, CELL STEM CELL, V22, P355, DOI 10.1016/j.stem.2018.01.020; Qiu J, 2019, CELL REP, V27, P2063, DOI 10.1016/j.celrep.2019.04.022; Rahman MH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19576-1; Requardt RP, 2012, J NEUROCHEM, V120, P1014, DOI 10.1111/j.1471-4159.2012.07645.x; Samuvel DJ, 2009, J IMMUNOL, V182, P2476, DOI 10.4049/jimmunol.0802059; Saraiva AL, 2018, FASEB J, V32, P6550, DOI 10.1096/fj.201800285; Schain M, 2017, CURR NEUROL NEUROSCI, V17, DOI 10.1007/s11910-017-0733-2; Shan J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01027; Singh V, 2020, INFLAMMATION, V43, P1589, DOI 10.1007/s10753-020-01242-9; Soto-Heredero G, 2020, FEBS J, V287, P3350, DOI 10.1111/febs.15327; Sun WP, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00248; Sun Y, 2020, THERANOSTICS, V10, P8430, DOI 10.7150/thno.44370; Suzuki A, 2011, CELL, V144, P810, DOI 10.1016/j.cell.2011.02.018; Tsubaki H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249357; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tyrakis PA, 2016, NATURE, V540, P236, DOI 10.1038/nature20165; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Van Deijk ALF, 2017, GLIA, V65, P670, DOI 10.1002/glia.23120; van der Poel M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08976-7; Vannucci SJ, 2003, AM J PHYSIOL-ENDOC M, V285, pE1127, DOI 10.1152/ajpendo.00187.2003; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Verdin E, 2015, SCIENCE, V350, P1208, DOI 10.1126/science.aac4854; Veys K, 2020, CIRC RES, V127, P466, DOI 10.1161/CIRCRESAHA.119.316463; Volkenhoff A, 2015, CELL METAB, V22, P437, DOI 10.1016/j.cmet.2015.07.006; Wang Y, 2021, NEUROSCI LETT, V764, DOI 10.1016/j.neulet.2021.136205; Wang ZX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00202; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wetzels S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00855; Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141; Winkler U, 2015, NEUROCHEM RES, V40, P2394, DOI 10.1007/s11064-015-1526-0; Wong CB, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8030398; Wu TS, 2020, J APPL TOXICOL, V40, P388, DOI 10.1002/jat.3912; Yan XS, 2014, GLIA, V62, P1093, DOI 10.1002/glia.22665; Yang JY, 2014, P NATL ACAD SCI USA, V111, P12228, DOI 10.1073/pnas.1322912111; Ye JS, 2018, J HEADACHE PAIN, V19, DOI 10.1186/s10194-018-0941-4; Yellen G, 2018, J CELL BIOL, V217, P2235, DOI 10.1083/jcb.201803152; Yu WW, 2019, MOL CELL, V75, P1147, DOI 10.1016/j.molcel.2019.06.039; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zeilhofer HU, 2012, ANNU REV PHARMACOL, V52, P111, DOI 10.1146/annurev-pharmtox-010611-134636; Zhang D, 2019, NATURE, V574, P575, DOI 10.1038/s41586-019-1678-1; Zhou J, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0113-2; Zhuo M, 2008, TRENDS NEUROSCI, V31, P199, DOI 10.1016/j.tins.2008.01.003	111	0	0	14	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								861290	10.3389/fimmu.2022.861290	http://dx.doi.org/10.3389/fimmu.2022.861290			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5HX	35669777	gold, Green Published			2022-12-18	WOS:000806121600001
J	Lin, WY; Li, LH; Hsiao, YY; Wong, WT; Chiu, HW; Hsu, HT; Peng, YJ; Ho, CL; Chernikov, OV; Cheng, SM; Yang, SP; Hua, KF				Lin, Wen-Yu; Li, Lan-Hui; Hsiao, Ya-Yun; Wong, Wei-Ting; Chiu, Hsiao-Wen; Hsu, Hsien-Ta; Peng, Yi-Jen; Ho, Chen-Lung; Chernikov, Oleg V.; Cheng, Shu-Meng; Yang, Shih-Ping; Hua, Kuo-Feng			Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity	FRONTIERS IN IMMUNOLOGY			English	Article						NLRP3 inflammasome; candesartan; angiotensin II receptor antagonist; drug repositioning; peritonitis	ACTIVATION; DISEASE; IDENTIFICATION	Aberrant activation of the NLRP3 inflammasome promotes the pathogenesis of many inflammatory diseases. The development of the NLRP3 inflammasome inhibitors from existing drugs for new therapeutic purposes is becoming more important. Candesartan is an angiotensin II receptor antagonist widely used as a blood pressure-lowering drug; however, the inhibitory potential of candesartan on the NLRP3 inflammasome has not yet been investigated. We demonstrated that candesartan significantly inhibited the NLRP3 inflammasome and pyroptosis in macrophages. Mechanistic analysis revealed that candesartan inhibited the expression of NLRP3 and proIL-1 beta by suppressing NF-kappa B activation and reducing the phosphorylation of ERK1/2 and JNK1/2. Candesartan reduced mitochondrial damage and inhibited the NLRP3 inflammasome assembly by suppressing NLRP3 binding to PKR, NEK7 and ASC. In addition, candesartan inhibited IL-1 beta secretion partially through autophagy induction. Furthermore, oral administration of candesartan reduced peritoneal neutrophil influx, NLRP3 and ASC expression in peritoneal cells, and lavage fluid concentrations of active caspase-1, IL-1 beta, IL-6 and MCP-1 in uric acid crystal-injected mice. These results indicated that candesartan has board anti-inflammatory effects and has the potential to be repositioned to ameliorate inflammatory diseases or NLRP3-associated complications.	[Lin, Wen-Yu; Cheng, Shu-Meng; Yang, Shih-Ping] Triserv Gen Hosp, Natl Def Med Ctr, Dept Internal Med, Div Cardiol, Taipei, Taiwan; [Li, Lan-Hui] Taipei City Hosp, Dept Lab Med, Chinese Med & Kunming Branch, Linsen, Taipei, Taiwan; [Li, Lan-Hui; Hsiao, Ya-Yun; Peng, Yi-Jen; Hua, Kuo-Feng] Triserv Gen Hosp, Natl Def Med Ctr, Dept Pathol, Taipei, Taiwan; [Wong, Wei-Ting; Chiu, Hsiao-Wen; Hua, Kuo-Feng] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan; [Hsu, Hsien-Ta] Taipei Tzu Chi Hosp, Buddhist Tzu Chi Med Fdn, Div Neurosurg, New Taipei City, Taiwan; [Hsu, Hsien-Ta] Bu ddhist Tzu Chi Univ, Sch Med, Hualien, Taiwan; [Ho, Chen-Lung] Taiwan Forestry Res Inst, Div Wood Cellulose, Taipei, Taiwan; [Chernikov, Oleg V.] GB Elyakov Pacific Inst, Bioorgan Chem Far Eastern Branch Russian Acad Sci, Vladivostok, Russia; [Hua, Kuo-Feng] China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan	National Defense Medical Center; Tri-Service General Hospital; Taipei City Hospital; National Defense Medical Center; Tri-Service General Hospital; National Ilan University; Buddhist Tzu Chi General Hospital; Taipei Tzu Chi Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Hua, KF (corresponding author), Triserv Gen Hosp, Natl Def Med Ctr, Dept Pathol, Taipei, Taiwan.; Hua, KF (corresponding author), Natl Ilan Univ, Dept Biotechnol & Anim Sci, Ilan, Taiwan.; Hua, KF (corresponding author), China Med Univ, China Med Univ Hosp, Dept Med Res, Taichung, Taiwan.	kuofenghua@gmail.com			Ministry of Science and Technology of Taiwan [MOST 110-2628-B-197-001, MOST 110-2923-B-197-001-MY3, MOST 110-2811-B-197-002]; Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan [TSGH-E-109208, 20170211]	Ministry of Science and Technology of Taiwan(Ministry of Science and Technology, Taiwan); Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan	This research work is supported by the funding from the Ministry of Science and Technology of Taiwan (MOST 110-2628-B-197-001; MOST 110-2923-B-197-001-MY3; MOST 110-2811-B-197-002) and Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan (TSGH-E-109208; 20170211).	Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Biasizzo M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591803; Chen KP, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974-022-02419-9; Chernikov OV, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06647-5; Chiu HW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42130-z; Coll RC, 2019, NAT CHEM BIOL, V15, P556, DOI 10.1038/s41589-019-0277-7; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Daniels MJD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12504; Darakhshan S, 2015, PHARMACOL RES, V91, P15, DOI 10.1016/j.phrs.2014.10.009; Elkahloun AG, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110653; Erttmann SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11169-x; Garcia-Lainez G, 2017, APOPTOSIS, V22, P1310, DOI 10.1007/s10495-017-1405-z; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; He Y, 2016, NATURE, V530, P354, DOI 10.1038/nature16959; Heneka MT, 2013, NATURE, V493, P674, DOI 10.1038/nature11729; Huang Y, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708689; Ihara M, 2020, J ALZHEIMERS DIS, V74, P1013, DOI 10.3233/JAD-200049; Jiang H, 2017, J EXP MED, V214, P3219, DOI 10.1084/jem.20171419; Joost A, 2011, EXPERT OPIN PHARMACO, V12, P1769, DOI 10.1517/14656566.2011.587000; Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541; Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328; Kepp O, 2011, NAT IMMUNOL, V12, P199, DOI 10.1038/ni0311-199; Kim MJ, 2019, EUR J PHARMACOL, V852, P25, DOI 10.1016/j.ejphar.2019.02.035; Lamkanfi M, 2017, J EXP MED, V214, P3147, DOI 10.1084/jem.20171848; Lamkanfi M, 2009, J CELL BIOL, V187, P61, DOI 10.1083/jcb.200903124; Larrayoz IM, 2009, J HYPERTENS, V27, P2365, DOI 10.1097/HJH.0b013e3283314bc7; Li YY, 2021, J CELL MOL MED, V25, P8087, DOI 10.1111/jcmm.16798; Liao PC, 2013, INFLAMM RES, V62, P89, DOI 10.1007/s00011-012-0555-2; Lien CH, 2021, LIFE-BASEL, V11, DOI 10.3390/life11080864; Lu B, 2012, NATURE, V488, P670, DOI 10.1038/nature11290; Man SM, 2015, IMMUNOL REV, V265, P6, DOI 10.1111/imr.12296; Marques-Da-Silva C, 2011, BRIT J PHARMACOL, V163, P912, DOI 10.1111/j.1476-5381.2011.01254.x; Misawa T, 2013, NAT IMMUNOL, V14, P454, DOI 10.1038/ni.2550; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Otani K, 2016, SCI REP-UK, V6, DOI 10.1038/srep32587; Patel MN, 2017, TRENDS MOL MED, V23, P165, DOI 10.1016/j.molmed.2016.12.007; Pellegrini C, 2021, MED RES REV, V41, P1883, DOI 10.1002/med.21781; Qie SY, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420974900; Schwaid AG, 2021, J MED CHEM, V64, P101, DOI 10.1021/acs.jmedchem.0c01307; Sharif H, 2019, NATURE, V570, P338, DOI 10.1038/s41586-019-1295-z; Sharma BR, 2021, NAT IMMUNOL, V22, P550, DOI 10.1038/s41590-021-00886-5; Tapia-Abelian A, 2019, NAT CHEM BIOL, V15, P560, DOI 10.1038/s41589-019-0278-6; Torika N, 2018, CNS NEUROSCI THER, V24, P231, DOI 10.1111/cns.12802; Wong WT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01920; Xue HQ, 2018, INT J BIOL SCI, V14, P1232, DOI 10.7150/ijbs.24612; Yazdi AS, 2010, P NATL ACAD SCI USA, V107, P19449, DOI 10.1073/pnas.1008155107; Yu C, 2007, J AM SOC NEPHROL, V18, P750, DOI 10.1681/ASN.2006070770; Yu Y, 2019, AN ACAD BRAS CIENC, V91, DOI 10.1590/0001-3765201920180699; Zhao N, 2021, CYTOKINE GROWTH F R, V61, P2, DOI 10.1016/j.cytogfr.2021.06.002; Zhen Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00276; Zheng RX, 2018, ECOTOX ENVIRON SAFE, V163, P612, DOI 10.1016/j.ecoenv.2018.07.076	52	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								870627	10.3389/fimmu.2022.870627	http://dx.doi.org/10.3389/fimmu.2022.870627			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W0VK	35669789	gold, Green Published			2022-12-18	WOS:000806499300001
J	Liu, SG; Yuan, XQ; Su, H; Liu, FH; Zhuang, Z; Chen, YF				Liu, Shougang; Yuan, Xiuqing; Su, Hang; Liu, Fanghua; Zhuang, Zhe; Chen, Yongfeng			ZNF384: A Potential Therapeutic Target for Psoriasis and Alzheimer's Disease Through Inflammation and Metabolism	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; Alzheimer's disease; inflammation; metabolic disorders; transcription factors	ACUTE LYMPHOBLASTIC-LEUKEMIA; NF-KAPPA-B; TRANSCRIPTION FACTOR; PPAR-GAMMA; UP-REGULATION; HLX; PIOGLITAZONE; EPIGENETICS; EXPRESSION; PROTEINS	BackgroundPsoriasis is an immune-related skin disease notable for its chronic inflammation of the entire system. Alzheimer's disease (AD) is more prevalent in psoriasis than in the general population. Immune-mediated pathophysiologic processes may link these two diseases, but the mechanism is still unclear. This article aimed to explore potential molecular mechanisms in psoriasis and AD. MethodsGene expression profiling data of psoriasis and AD were acquired in the Gene Expression Omnibus (GEO) database. Gene Set Enrichment Analysis (GSEA) and single-sample GSEA (ssGSEA) were first applied in two datasets. Differentially expressed genes (DEGs) of two diseases were identified, and common DEGs were selected. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed to explore common biological pathways. Signature transcription factors (STFs) were identified and their diagnostic values was calculated by receiver operating characteristic (ROC) curve analysis in the exploration cohort and verified in the validation cohort. The expression levels of STFs were further investigated in the validation cohort and the GTEx Portal Database. Additionally, four kinds of interaction analysis were performed: correlation analysis among STFs, gene-gene, chemical-protein, and protein-ligand interaction analyses. In the end, we predicted the transcription factor that potentially regulates STFs. ResultsBiosynthesis and metabolic pathways were enriched in GSEA analysis. In ssGSEA analysis, most immunoreaction gene lists exhibited differential enrichment in psoriasis cases, whereas three receptor-related gene lists did in AD. The KEGG analysis of common DEGs redetermined inflammatory and metabolic pathways essential in both diseases. 5 STFs (PPARG, ZFPM2, ZNF415, HLX, and ANHX) were screened from common DEGs. The ROC analysis indicated that all STFs have diagnostic values in two diseases, especially ZFPM2. The correlation analysis, gene-gene, chemical-protein, and protein-ligand interaction analyses suggested that STFs interplay and involve inflammation and aberrant metabolism. Eventually, ZNF384 was the predicted transcription factor regulating PPARG, ZNF415, HLX, and ANHX. ConclusionsThe STFs (PPARG, ZFPM2, ZNF415, HLX, and ANHX) may increase the morbidity rate of AD in psoriasis by initiating a positive feedback loop of excessive inflammation and metabolic disorders. ZNF384 is a potential therapeutic target for psoriasis and AD by regulating PPARG, ZNF415, HLX, and ANHX.	[Liu, Shougang; Yuan, Xiuqing; Su, Hang; Liu, Fanghua; Zhuang, Zhe; Chen, Yongfeng] Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China	Southern Medical University - China	Chen, YF (corresponding author), Southern Med Univ, Dermatol Hosp, Guangzhou, Peoples R China.	gdcyf@163.com						Alexander TB, 2018, NATURE, V562, P373, DOI 10.1038/s41586-018-0436-0; Ariga T, 2010, ASN NEURO, V2, DOI 10.1042/AN20100021; Bagu ET, 2013, BIOMETALS, V26, P1051, DOI 10.1007/s10534-013-9683-6; Becknell B, 2007, BLOOD, V109, P2481, DOI 10.1182/blood-2006-10-050096; Bhattacharya S, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.15; Bissonnette R, 2021, J AM ACAD DERMATOL, V84, P1059, DOI 10.1016/j.jaad.2020.10.085; Boehncke WH, 2015, LANCET, V386, P983, DOI 10.1016/S0140-6736(14)61909-7; Chang GZ, 2020, J DERMATOL TREAT, V31, P680, DOI 10.1080/09546634.2019.1610552; Chen JJ, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.566922; Cheng YD, 2006, BIOCHEM BIOPH RES CO, V351, P33, DOI 10.1016/j.bbrc.2006.09.161; Chiricozzi A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010179; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Cristiano C, 2019, BRIT J PHARMACOL, V176, P3544, DOI 10.1111/bph.14586; Dauden E, 2018, J EUR ACAD DERMATOL, V32, P2058, DOI 10.1111/jdv.15177; Dave N, 2021, ACTA NEUROPATHOL, V142, P279, DOI 10.1007/s00401-021-02323-1; de la Monte SM, 2017, DRUGS, V77, P47, DOI 10.1007/s40265-016-0674-0; Dodington DW, 2018, TRENDS ENDOCRIN MET, V29, P55, DOI 10.1016/j.tem.2017.11.001; Emery JG, 2001, TRENDS PHARMACOL SCI, V22, P233, DOI 10.1016/S0165-6147(00)01661-8; Espinoza LC, 2019, NANOMED-NANOTECHNOL, V19, P115, DOI 10.1016/j.nano.2019.03.017; Forli S, 2016, NAT PROTOC, V11, P905, DOI 10.1038/nprot.2016.051; Furue M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215424; Gazon H, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02686; Glancy E, 2021, CURR OPIN STRUC BIOL, V67, P135, DOI 10.1016/j.sbi.2020.10.017; Gocho Y, 2015, LEUKEMIA, V29, P2445, DOI 10.1038/leu.2015.111; Goldminz AM, 2013, J DERMATOL SCI, V69, P89, DOI 10.1016/j.jdermsci.2012.11.002; Gonzalez JN, 2021, NUCLEIC ACIDS RES, V49, pD1046, DOI 10.1093/nar/gkaa1070; Greb JE, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.82; Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3; Griffiths CEM, 2021, LANCET, V397, P1301, DOI 10.1016/S0140-6736(20)32549-6; Guo YJ, 2016, DIABETES, V65, P2151, DOI 10.2337/db15-1565; Gutierrez-Repiso C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910417; Hachwell E, 2007, TRENDS GENET, V23, P588, DOI 10.1016/j.tig.2007.08.010; Hamilton JS, 2021, PROSTAG LEUKOTR ESS, V175, DOI 10.1016/j.plefa.2021.102366; Heppner FL, 2015, NAT REV NEUROSCI, V16, P358, DOI 10.1038/nrn3880; Hodson R, 2018, NATURE, V559, pS1, DOI 10.1038/d41586-018-05717-6; Huang YWA, 2017, CELL, V168, P427, DOI 10.1016/j.cell.2016.12.044; Hwang JY, 2017, NAT REV NEUROSCI, V18, P347, DOI 10.1038/nrn.2017.46; Karlawish Jason, 2017, Alzheimers Dement, V13, P374, DOI 10.1016/j.jalz.2017.02.006; Kim M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63550-2; Kloet SL, 2015, FEBS J, V282, P1774, DOI 10.1111/febs.12972; Klotz L, 2009, J EXP MED, V206, P2079, DOI 10.1084/jem.20082771; Kurmi K, 2020, TRENDS CELL BIOL, V30, P408, DOI 10.1016/j.tcb.2020.02.005; Lambert SA, 2018, CELL, V172, P650, DOI 10.1016/j.cell.2018.01.029; Liu YF, 2016, EBIOMEDICINE, V8, P173, DOI 10.1016/j.ebiom.2016.04.038; Loos AM, 2018, J AM ACAD DERMATOL, V79, P135, DOI 10.1016/j.jaad.2018.02.027; Lowes MA, 2014, ANNU REV IMMUNOL, V32, P227, DOI 10.1146/annurev-immunol-032713-120225; Loy CT, 2014, LANCET, V383, P828, DOI 10.1016/S0140-6736(13)60630-3; Lu T, 2014, NATURE, V507, P448, DOI 10.1038/nature13163; Mastrofrancesco A, 2014, J INVEST DERMATOL, V134, P1001, DOI 10.1038/jid.2013.448; McClure BJ, 2018, BRIT J CANCER, V118, P1000, DOI 10.1038/s41416-018-0022-0; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Meng H, 2015, ACCOUNTS CHEM RES, V48, P2242, DOI 10.1021/acs.accounts.5b00226; Mullen AC, 2002, NAT IMMUNOL, V3, P652, DOI 10.1038/ni807; Mustafa HA, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-0258-1; Novak K, 2000, NAT MED, V6, P864, DOI 10.1038/78615; Novoszel P, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202012409; Oberstein TJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01213; Osama A, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101206; Pollock RA, 2017, J AUTOIMMUN, V78, P29, DOI 10.1016/j.jaut.2016.12.002; Qu Z, 2020, FREE RADICAL BIO MED, V159, P87, DOI 10.1016/j.freeradbiomed.2020.06.028; Reichenbach N, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809665; Robertshaw H, 2005, BRIT J DERMATOL, V152, P189, DOI 10.1111/j.1365-2133.2005.06369.x; Rochin L, 2013, P NATL ACAD SCI USA, V110, P10658, DOI 10.1073/pnas.1220748110; Roura AJ, 2021, J MOL MED, V99, P241, DOI 10.1007/s00109-020-02005-7; Semple RK, 2006, J CLIN INVEST, V116, P581, DOI 10.1172/JCI28003; Shafiq N, 2005, INT J DERMATOL, V44, P328, DOI 10.1111/j.1365-4632.2005.02504.x; Shi D, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.762651; Snow AD, 1996, EXP NEUROL, V138, P305, DOI 10.1006/exnr.1996.0069; Spitz F, 2012, NAT REV GENET, V13, P613, DOI 10.1038/nrg3207; Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277; Teleman AA, 2010, CELL METAB, V11, P8, DOI 10.1016/j.cmet.2009.12.004; Tevosian SG, 1999, P NATL ACAD SCI USA, V96, P950, DOI 10.1073/pnas.96.3.950; Tobinick EL, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-27; Uluckan O, 2016, CLIN EXP RHEUMATOL, V34, pS17; Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538; Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396; Xiao YS, 2022, INT J BIOL SCI, V18, P82, DOI 10.7150/ijbs.57919; Yaguchi A, 2017, INT J HEMATOL, V106, P269, DOI 10.1007/s12185-017-2220-6; Yasuda T, 2016, NAT GENET, V48, P569, DOI 10.1038/ng.3535; Ye JP, 2008, BIOCHEM BIOPH RES CO, V374, P405, DOI 10.1016/j.bbrc.2008.07.068; Yim YY, 2020, NAT REV NEUROSCI, V21, P471, DOI 10.1038/s41583-020-0334-y; Yokoyama JS, 2016, JAMA NEUROL, V73, P691, DOI 10.1001/jamaneurol.2016.0150; Zenz R, 2005, NATURE, V437, P369, DOI 10.1038/nature03963; Zhang HY, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108433; Zheng WP, 2004, J IMMUNOL, V172, P114, DOI 10.4049/jimmunol.172.1.114; Zhou MS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229819; Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008	89	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								892368	10.3389/fimmu.2022.892368	http://dx.doi.org/10.3389/fimmu.2022.892368			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W0VO	35669784	Green Published, gold			2022-12-18	WOS:000806499700001
J	Podrazil, M; Taborska, P; Stakheev, D; Rataj, M; Lastovicka, J; Vlachova, A; Pohunek, P; Bartunkova, J; Smrz, D				Podrazil, Michal; Taborska, Pavla; Stakheev, Dmitry; Rataj, Michal; Lastovicka, Jan; Vlachova, Alena; Pohunek, Petr; Bartunkova, Jirina; Smrz, Daniel			Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						severe asthma patients on biological therapy; SARS-CoV-2; COVID-19 vaccination; cellular immunity; humoral immunity	COVID-19; OMALIZUMAB; BNT162B2; SAFETY	Coronavirus disease 2019 (COVID-19) vaccines effectively elicit humoral and cellular immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in healthy populations. This immunity decreases several months after vaccination. However, the efficacy of vaccine-induced immunity and its durability in patients with severe asthma on biological therapy are unknown. In this study, we evaluated the effectiveness and durability of mRNA vaccine-induced SARS-CoV-2-specific humoral and cellular immunity in severe asthma patients on biological therapy. The study included 34 patients with severe asthma treated with anti-IgE (omalizumab, n=17), anti-IL5 (mepolizumab, n=13; reslizumab, n=3), or anti-IL5R (benralizumab, n=1) biological therapy. All patients were vaccinated with two doses of the BNT162b2 mRNA vaccine with a 6-week interval between the doses. We found that this COVID-19 vaccination regimen elicited SARS-CoV-2-specific humoral and cellular immunity, which had significantly declined 6 months after receipt of the second dose of the vaccine. The type of biological treatment did not affect vaccine-elicited immunity. However, patient age negatively impacted the vaccine-induced humoral response. On the other hand, no such age-related impact on vaccine-elicited cellular immunity was observed. Our findings show that treatment of patients with severe asthma with biological therapy does not compromise the effectiveness or durability of COVID-19 vaccine-induced immunity.	[Podrazil, Michal; Taborska, Pavla; Stakheev, Dmitry; Rataj, Michal; Lastovicka, Jan; Bartunkova, Jirina; Smrz, Daniel] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Immunol, Prague, Czech Republic; [Vlachova, Alena] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Pneumol, Prague, Czech Republic; [Pohunek, Petr] Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Pediat, Prague, Czech Republic	Charles University Prague; Motol University Hospital; Charles University Prague; Motol University Hospital; Charles University Prague; Motol University Hospital	Smrz, D (corresponding author), Charles Univ Prague, Motol Univ Hosp, Fac Med 2, Dept Immunol, Prague, Czech Republic.	daniel.smrz@lfmotol.cuni.cz		Stakheev, Dmitry/0000-0001-8839-8030				Altmann DM, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd6160; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Becerril-Gaitan A, 2022, EUR J CANCER, V160, P243, DOI 10.1016/j.ejca.2021.10.014; Boyarsky BJ, 2021, JAMA-J AM MED ASSOC, V325, P2204, DOI 10.1001/jama.2021.7489; Bradley AJ, 1999, BBA-BIOMEMBRANES, V1418, P19, DOI 10.1016/S0005-2736(99)00013-9; Brusselle GG, 2022, NEW ENGL J MED, V386, P157, DOI 10.1056/NEJMra2032506; Caminati M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080853; Castro M, 2015, LANCET RESP MED, V3, P355, DOI [10.1016/S2213-2600(15)00042-9, 10.1016/S2213-2600(15)00119-8]; Chen JJ, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.31749; Chhiba KD, 2020, J ALLERGY CLIN IMMUN, V146, P307, DOI 10.1016/j.jaci.2020.06.010; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Combadiere B, 2004, J EXP MED, V199, P1585, DOI 10.1084/jem.20032083; Deeks SG, 2004, J INFECT DIS, V189, P312, DOI 10.1086/380098; Dolgin E, 2021, NATURE, V597, P606, DOI 10.1038/d41586-021-02532-4; Dunkle LM, 2022, NEW ENGL J MED, V386, P531, DOI 10.1056/NEJMoa2116185; Edris A, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1138-3; Esquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OC; Farmani AR, 2021, IMMUNOPHARM IMMUNOT, V43, P259, DOI 10.1080/08923973.2021.1925906; Galipeau Y, 2021, EBIOMEDICINE, V74, DOI 10.1016/j.ebiom.2021.103700; Goldberg Y, 2021, NEW ENGL J MED, V385, pE85, DOI 10.1056/NEJMoa2114228; Guerrera G, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl5344; Haberman RH, 2021, ANN RHEUM DIS, V80, P1339, DOI 10.1136/annrheumdis-2021-220597; Havlin J, 2022, TRANSPLANTATION, V106, pE183, DOI 10.1097/TP.0000000000004021; Havlin J, 2021, J HEART LUNG TRANSPL, V40, P754, DOI 10.1016/j.healun.2021.05.004; Israelow B, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abl4509; Jackson DJ, 2020, DRUG SAFETY, V43, P409, DOI 10.1007/s40264-020-00926-3; Kemp SA, 2021, NATURE, V592, P277, DOI 10.1038/s41586-021-03291-y; Khan WH, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.690621; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Lombardi Carlo, 2021, Asthma Res Pract, V7, P9, DOI 10.1186/s40733-021-00075-z; Lovinsky-Desir S, 2020, J ALLERGY CLIN IMMUN, V146, P1027, DOI 10.1016/j.jaci.2020.07.026; Marion O, 2021, ANN INTERN MED, V174, P1336, DOI 10.7326/M21-1341; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mudd PA, 2012, NATURE, V491, P129, DOI 10.1038/nature11443; Muller L, 2021, CLIN INFECT DIS, V73, P2065, DOI 10.1093/cid/ciab381; Munro APS, 2021, LANCET, V398, P2258, DOI 10.1016/S0140-6736(21)02717-3; Naaber P, 2021, LANCET REG HEALTH-EU, V10, DOI 10.1016/j.lanepe.2021.100208; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Pineros YSS, 2019, AM J RESP CRIT CARE, V199, P508, DOI 10.1164/rccm.201803-0461OC; Poddighe D, 2021, J INFLAMM RES, V14, P6845, DOI 10.2147/JIR.S345665; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Reddel HK, 2022, J ALLER CL IMM-PRACT, V10, pS1, DOI 10.1016/j.jaip.2021.10.001; Reddel HK, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01046-2019; Robinson LB, 2021, J ALLER CL IMM-PRACT, V9, P497, DOI 10.1016/j.jaip.2020.10.021; Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194; Romero-Olmedo AJ, 2022, NAT MICROBIOL, V7, P195, DOI 10.1038/s41564-021-01046-z; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; Rowe RK, 2017, J ALLERGY CLIN IMMUN, V140, P294, DOI 10.1016/j.jaci.2016.11.035; Sadoff J, 2021, NEW ENGL J MED, V384, P2187, DOI 10.1056/NEJMoa2101544; Smits VAJ, 2021, BIOCHEM BIOPH RES CO, V543, P45, DOI 10.1016/j.bbrc.2021.01.073; Taborska P, 2018, J IMMUNOL METHODS, V458, P63, DOI 10.1016/j.jim.2018.04.005; Taborska P, 2021, IMMUN INFLAMM DIS, V9, P1452, DOI 10.1002/iid3.496; Taborska P, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.629102; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Yang JM, 2020, J ALLERGY CLIN IMMUN, V146, P790, DOI 10.1016/j.jaci.2020.08.008; Zhu ZZ, 2020, J ALLERGY CLIN IMMUN, V146, P327, DOI 10.1016/j.jaci.2020.06.001	58	0	0	8	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								892277	10.3389/fimmu.2022.892277	http://dx.doi.org/10.3389/fimmu.2022.892277			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V4FV	35669765	Green Published, gold, Green Submitted			2022-12-18	WOS:000806048600001
J	Saika, S; Veldhuis, N; Krizaj, D; Rahaman, SO				Saika, Shizuya; Veldhuis, Nicholas; Krizaj, David; Rahaman, Shaik O.			Editorial: New Insights into Mechanotransduction by Immune Cells in Physiological and Pathological Conditions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mechanotransduction; inflammation; immunity; TRP channels; Piezo channels			[Saika, Shizuya] Wakayama Med Univ, Dept Ophthalmol, Wakayama, Wakayama, Japan; [Veldhuis, Nicholas] Monash Univ, Monash Inst Pharmaceut Sci, Drug Discovery Biol Theme, Parkville, Vic, Australia; [Krizaj, David] Univ Utah, Sch Med, Dept Ophthalmol, Salt Lake City, UT USA; [Rahaman, Shaik O.] Univ Maryland, Dept Nutr & Food Sci, College Pk, MD 20742 USA	Wakayama Medical University; Monash University; Utah System of Higher Education; University of Utah; University System of Maryland; University of Maryland College Park	Rahaman, SO (corresponding author), Univ Maryland, Dept Nutr & Food Sci, College Pk, MD 20742 USA.	srahaman@umd.edu		Krizaj, David/0000-0003-4468-3029	ARC Centre of Excellence in Convergent Bio-Nano Science and Technology [R01EB024556]; Prevent Blindness [R01EY027920, R01EY031817, P30EY014800]	ARC Centre of Excellence in Convergent Bio-Nano Science and Technology(Australian Research Council); Prevent Blindness(Research to Prevent Blindness (RPB))	This work was supported by an R01EB024556 grant to SR, the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology to NV, R01EY027920, R01EY031817, P30EY014800 to DK, and unrestricted support from Research to Prevent Blindness to the Moran Eye Institute at the University of Utah.	Dutta B, 2020, LAB INVEST, V100, P178, DOI 10.1038/s41374-019-0334-6; Farge E, 2011, CURR TOP DEV BIOL, V95, P243, DOI 10.1016/B978-0-12-385065-2.00008-6; Kumar S, 2014, NAT MATER, V13, P918, DOI 10.1038/nmat4094; Meli VS, 2019, J LEUKOCYTE BIOL, V106, P283, DOI 10.1002/JLB.MR0318-126R; Plotnikov SV, 2013, CURR OPIN CELL BIOL, V25, P619, DOI 10.1016/j.ceb.2013.06.003; Trepat X, 2012, COMPR PHYSIOL, V2, P2369, DOI 10.1002/cphy.c110012; Tschumperlin DJ, 2013, PHYSIOLOGY, V28, P380, DOI 10.1152/physiol.00024.2013; Webster KD, 2014, BIOPHYS J, V107, P146, DOI 10.1016/j.bpj.2014.04.051; Wells RG, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.110pe13; Wong SW, 2021, ACTA BIOMATER, V133, P126, DOI 10.1016/j.actbio.2021.07.075; Wong VW, 2012, NAT MED, V18, P148, DOI 10.1038/nm.2574; Zhang HM, 2012, J CELL SCI, V125, P3039, DOI 10.1242/jcs.093666; Zhang XX, 2020, CURR OPIN BIOTECH, V66, P236, DOI 10.1016/j.copbio.2020.09.004; Zhu C, 2019, NAT IMMUNOL, V20, P1269, DOI 10.1038/s41590-019-0491-1	14	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								930362	10.3389/fimmu.2022.930362	http://dx.doi.org/10.3389/fimmu.2022.930362			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W3GT	35669790	gold, Green Published			2022-12-18	WOS:000806664700001
J	Teixeira, AR; Perez-Cabezas, B; Costa, DM; Sa, M; Golba, S; Sefiane-Djemaoune, H; Ribeiro, J; Kaneko, I; Iwanaga, S; Yuda, M; Tsuji, M; Boscardin, SB; Amino, R; Cordeiro-da-Silva, A; Tavares, J				Teixeira, Ana Rafaela; Perez-Cabezas, Begona; Costa, David M.; Sa, Monica; Golba, Sylvain; Sefiane-Djemaoune, Helena; Ribeiro, Joana; Kaneko, Izumi; Iwanaga, Shiroh; Yuda, Masao; Tsuji, Moriya; Boscardin, Silvia Beatriz; Amino, Rogerio; Cordeiro-da-Silva, Anabela; Tavares, Joana			Immunization with CSP and a RIG-I Agonist is Effective in Inducing a Functional and Protective Humoral Response Against Plasmodium	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; Plasmodium; sporozoites; subunit vaccines; CSP; adjuvants; RLR agonists; TLR3 agonist	POLYRIBOINOSINIC-POLYRIBOCYTIDYLIC ACID; MALARIA VACCINE; DENDRITIC CELLS; EFFECTIVE ADJUVANT; ANTIBODY; RNA; EFFICACY; IMMUNITY; INFECTION; RECEPTOR	Malaria is a major public health concern, as a highly effective human vaccine remains elusive. The efficacy of a subunit vaccine targeting the most abundant protein of the sporozoite surface, the circumsporozoite protein (CSP) has been hindered by difficulties in generating an effective humoral response in both quantity and quality. Using the rodent Plasmodium yoelii model we report here that immunization with CSP adjuvanted with 5'ppp-dsRNA, a RIG-I agonist, confers early and long-lasting sterile protection in mice against stringent sporozoite and mosquito bite challenges. The immunization induced high levels of antibodies, which were functional in targeting and killing the sporozoites and were sustained over time through the accumulation of long-lived plasma cells in the bone marrow. Moreover, 5'ppp-dsRNA-adjuvanted immunization with the CSP of P. falciparum was also significantly protective against challenges using a transgenic PfCSP-expressing P. yoelii parasite. Conversely, using the TLR3 agonist poly(A:U) as adjuvant resulted in a formulation that despite inducing high antibody levels was unable to generate equally functional antibodies and was, consequently, less protective. In conclusion, we demonstrate that using 5'ppp-dsRNA as an adjuvant to vaccines targeting CSP induces effective anti-Plasmodium humoral immunity.	[Teixeira, Ana Rafaela; Perez-Cabezas, Begona; Costa, David M.; Sa, Monica; Ribeiro, Joana; Tavares, Joana] Univ Porto, Inst Invest & Inovacao Saude, Host Parasite Interact Grp, Porto, Portugal; [Teixeira, Ana Rafaela; Perez-Cabezas, Begona; Costa, David M.; Sa, Monica; Ribeiro, Joana; Cordeiro-da-Silva, Anabela; Tavares, Joana] Univ Porto, Inst Biol Mol & Celular, Porto, Portugal; [Teixeira, Ana Rafaela; Sa, Monica; Cordeiro-da-Silva, Anabela; Tavares, Joana] Univ Porto, Fac Farm, Dept Ciencias Biol, Porto, Portugal; [Golba, Sylvain; Sefiane-Djemaoune, Helena] Inst Pasteur, Ctr Prod & Infect Anopheles, Paris, France; [Kaneko, Izumi; Yuda, Masao] Mie Univ, Dept Med Zool, Grad Sch Med, Mie, Japan; [Iwanaga, Shiroh] Osaka Univ, Res Inst Microbial Dis, Osaka, Japan; [Tsuji, Moriya] Columbia Univ, Aaron Diamond AIDS Res Ctr, Dept Med, Irving Med Ctr, New York, NY USA; [Boscardin, Silvia Beatriz] Inst Invest Immunol iii INCT, Sao Paulo, Brazil; [Boscardin, Silvia Beatriz] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo, Brazil; [Amino, Rogerio] Inst Pasteur, Unit Malaria Infect & Immun, Paris, France; [Cordeiro-da-Silva, Anabela] Univ Porto, Inst Invest & Inovacao Saude, Parasite Dis Grp, Porto, Portugal	Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto; Universidade do Porto; Universidade do Porto; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Mie University; Osaka University; Columbia University; NewYork-Presbyterian Hospital; Universidade de Sao Paulo; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto	Tavares, J (corresponding author), Univ Porto, Inst Invest & Inovacao Saude, Host Parasite Interact Grp, Porto, Portugal.; Tavares, J (corresponding author), Univ Porto, Inst Biol Mol & Celular, Porto, Portugal.; Tavares, J (corresponding author), Univ Porto, Fac Farm, Dept Ciencias Biol, Porto, Portugal.	jtavares@ibmc.up.pt	Tavares, Joana/J-7395-2013; Boscardin, Silvia Beatriz/C-3397-2012	Tavares, Joana/0000-0003-0391-2622; Costa, David/0000-0003-0213-5673; Boscardin, Silvia Beatriz/0000-0002-7845-7110	Fundacao para a Ciencia e Tecnologia (FCT)/Ministerio da Educacao e Ciencia (MEC); FEDER [PTDC/SAU-PAR/31340/2017, 4293]; French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" [ANR-10-LABX-62-IBEID]; FCT [CEECIND/02362/2017, SFRH/BD/123734/2016, SFRH/BD/133485/2017, SFRH/BD/133276/2017]	Fundacao para a Ciencia e Tecnologia (FCT)/Ministerio da Educacao e Ciencia (MEC)(Portuguese Foundation for Science and Technology); FEDER(European Commission); French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases"(French National Research Agency (ANR)); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	The work was funded by Fundacao para a Ciencia e Tecnologia (FCT)/Ministerio da Educacao e Ciencia (MEC) and FEDER through the project PTDC/SAU-PAR/31340/2017 (to JT) and the research Unit No. 4293. The authors acknowledge funding from French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant no. ANR-10-LABX-62-IBEID to RA). JT, DC, MS, and AR received individual funding from FCT (CEECIND/02362/2017, SFRH/BD/123734/2016, SFRH/BD/133485/2017 and SFRH/BD/133276/2017, respectively).	Akkaya M, 2020, NAT REV IMMUNOL, V20, P229, DOI 10.1038/s41577-019-0244-2; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprandini E, 2018, NAT MICROBIOL, V3, P1224, DOI 10.1038/s41564-018-0254-z; Amino R, 2007, NAT PROTOC, V2, P1705, DOI 10.1038/nprot.2007.120; Belmonte M, 2003, J PARASITOL, V89, P602, DOI 10.1645/0022-3395(2003)089[0602:TIOPYI]2.0.CO;2; Borden EC, 2007, NAT REV DRUG DISCOV, V6, P975, DOI 10.1038/nrd2422; Boscardin SB, 2006, J EXP MED, V203, P599, DOI 10.1084/jem.20051639; Cawlfield A, 2019, VACCINE, V37, P3793, DOI 10.1016/j.vaccine.2019.05.059; Coccia M, 2017, NPJ VACCINES, V2, DOI 10.1038/s41541-017-0027-3; Cockburn IA, 2018, NAT IMMUNOL, V19, P1199, DOI 10.1038/s41590-018-0228-6; Collins KA, 2017, SCI REP-UK, V7, DOI 10.1038/srep46621; Conforti R, 2010, CANCER RES, V70, P490, DOI 10.1158/0008-5472.CAN-09-1890; Datoo MS, 2021, LANCET, V397, P1809, DOI 10.1016/S0140-6736(21)00943-0; Doener F, 2019, VACCINE, V37, P1819, DOI 10.1016/j.vaccine.2019.02.024; Draper SJ, 2018, CELL HOST MICROBE, V24, P43, DOI 10.1016/j.chom.2018.06.008; Draper SJ, 2010, NAT REV MICROBIOL, V8, P62, DOI 10.1038/nrmicro2240; Flores-Garcia Y, 2018, MBIO, V9, DOI [10.1128/mBio.02194-18, 10.1128/mbio.02194-18]; Gantt SM, 1998, ANTIMICROB AGENTS CH, V42, P2731, DOI 10.1128/AAC.42.10.2731; Genito CJ, 2017, VACCINE, V35, P3865, DOI 10.1016/j.vaccine.2017.05.070; Greenwood B, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0433; Heidenreich R, 2015, INT J CANCER, V137, P372, DOI 10.1002/ijc.29402; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Iurescia S, 2020, CANCERS, V12, DOI 10.3390/cancers12113158; Jangra S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.729189; Kastenmuller K, 2013, INFECT IMMUN, V81, P789, DOI 10.1128/IAI.01108-12; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Keitany GJ, 2016, CELL REP, V17, P3193, DOI 10.1016/j.celrep.2016.11.060; Khan A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.592333; Kisalu NK, 2018, NAT MED, V24, P408, DOI 10.1038/nm.4512; Kulkarni RR, 2014, J VIROL, V88, P13990, DOI 10.1128/JVI.02273-14; Kumar H, 2008, J IMMUNOL, V180, P683, DOI 10.4049/jimmunol.180.2.683; Le Naour J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1771143; LEVINE AS, 1979, CANCER RES, V39, P1645; Liu SG, 1997, CLIN BIOCHEM, V30, P455, DOI 10.1016/S0009-9120(97)00049-0; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085; Menard R, 2013, NAT REV MICROBIOL, V11, P701, DOI 10.1038/nrmicro3111; Murray CJL, 2014, LANCET, V384, P1005, DOI 10.1016/S0140-6736(14)60844-8; Murugan R, 2020, NAT MED, V26, P1135, DOI 10.1038/s41591-020-0881-9; Murugan R, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aap8029; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446; Odendahl M, 2005, BLOOD, V105, P1614, DOI 10.1182/blood-2004-07-2507; Olotu A, 2016, NEW ENGL J MED, V374, P2519, DOI 10.1056/NEJMoa1515257; Ono T, 2007, EXP PARASITOL, V115, P310, DOI 10.1016/j.exppara.2006.09.008; Perrot I, 2010, J IMMUNOL, V185, P2080, DOI 10.4049/jimmunol.1000532; Piot P, 2019, NATURE, V575, P119, DOI 10.1038/s41586-019-1656-7; Probst P, 2017, VACCINE, V35, P1964, DOI 10.1016/j.vaccine.2017.01.053; Radbruch A, 2006, NAT REV IMMUNOL, V6, P741, DOI 10.1038/nri1886; Regules JA, 2011, EXPERT REV VACCINES, V10, P589, DOI [10.1586/erv.11.57, 10.1586/ERV.11.57]; ROBINSON RA, 1976, JNCI-J NATL CANCER I, V57, P599, DOI 10.1093/jnci/57.3.599; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sinden Robert E, 2002, Methods Mol Med, V72, P25, DOI 10.1385/1-59259-271-6:25; Slocombe T, 2013, J IMMUNOL, V191, P3128, DOI 10.4049/jimmunol.1301163; Sprokholt JK, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006738; Sugiyama T, 2008, INT IMMUNOL, V20, P1, DOI 10.1093/intimm/dxm112; Suscovich TJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb4757; Tan J, 2018, NAT MED, V24, P401, DOI 10.1038/nm.4513; Tewari K, 2010, VACCINE, V28, P7256, DOI 10.1016/j.vaccine.2010.08.098; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Vanderberg JP, 2004, INT J PARASITOL, V34, P991, DOI 10.1016/j.ijpara.2004.05.005; Wang LL, 2002, J CLIN INVEST, V110, P1175, DOI 10.1172/JCI200215536; White MT, 2015, LANCET INFECT DIS, V15, P1450, DOI 10.1016/S1473-3099(15)00239-X; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2021, WHO REC GROUNDBR MAL; World Health Organization, 2017, MAL VACC RAIN TABL; World Health Organization, 2016, WEEKLY EPIDEMIOLOGIC, V91, P33; Wykes MN, 2009, EUR J IMMUNOL, V39, P2004, DOI 10.1002/eji.200939552; Wykes MN, 2005, J IMMUNOL, V175, P2510, DOI 10.4049/jimmunol.175.4.2510; Yong HY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01379; Zhang M, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1248-z; Ziegler A, 2017, J IMMUNOL, V198, P1595, DOI 10.4049/jimmunol.1601129	72	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								868305	10.3389/fimmu.2022.868305	http://dx.doi.org/10.3389/fimmu.2022.868305			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W0WD	35669785	gold, Green Published			2022-12-18	WOS:000806501200001
J	Wei, W; Mu, SC; Han, Y; Chen, Y; Kuang, ZS; Wu, XY; Luo, Y; Tong, CY; Zhang, YQ; Yang, YL; Song, ZJ				Wei, Wei; Mu, Sucheng; Han, Yi; Chen, Yao; Kuang, Zhongshu; Wu, Xingyue; Luo, Yue; Tong, Chaoyang; Zhang, Yiqun; Yang, Yilin; Song, Zhenju			Gpr174 Knockout Alleviates DSS-Induced Colitis via Regulating the Immune Function of Dendritic Cells	FRONTIERS IN IMMUNOLOGY			English	Article						GPR174; inflammatory bowel disease; dendritic cells; intestinal barrier function; T cell activation	EPITHELIAL BARRIER DYSFUNCTION; INFLAMMATORY-BOWEL-DISEASE; SODIUM-INDUCED COLITIS; STEADY-STATE; T-CELLS; MODEL; SUSCEPTIBILITY; SUPPRESSION; MATURATION; CYTOKINES	BackgroundDysfunction of the immune system would disturb the intestinal homeostasis and lead to inflammatory bowel disease (IBD). Dendritic cells (DCs) help maintain intestinal homeostasis and immediately respond to pathogens or injuries once the mucosa barriers are destroyed during IBD. G protein-coupled receptors(GPR)174 is an essential regulator of immunity that is widely expressed in most immune cells, including DCs. However, the role of GPR174 in regulating the immune function of DC in colitis has not been investigated. MethodsDextran sodium sulfate (DSS) was administered to establish the mice colitis model. Data of weight, length of colon, disease activity index (DAI), and macroscopic scores were collected. The flow cytometry was used to detect the infiltrations of T cells and DCs, the mean fluorescence intensity (MFI) of CD80, CD86, CD40, and major histocompatibility complex-II (MHC-II). And T cells proliferataion was measured by carboxyfluorescein diacetate succinimidyl ester (CFSE). The expression of cytokines (tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-10 (IL-10), interferon-gamma (IFN-gamma), interleukin -4 (IL-4)) and GPR174 mRNA were measured by Elisa, quantitative polymerase chain reaction (qPCR), and immunofluorescence. RNA of bone-marrow-derived dendritic cells (BMDCs) was extracted for sequencing. Adoptive transfer of BMDCs was administrated intravenously. ResultsGpr174(-/-) mice exposed to 3% DSS showed significant alleviation characterized by reduced loss of weight, more minor colon damage, and better DAI and macroscopic scores. The expression of pro-inflammatory cytokines (TNF-alpha, IL-6) decreased, while anti-inflammatory cytokine (IL-10) increased compared with WT mice. In vitro, Gpr174(-/-) BMDCs showed less maturity, with a declined expression of MHC-II, CD80, CD86 and reduced TNF-alpha, higher IL-10 after LPS stimulation. Gpr174(-/-) BMDCs were less capable of activating OT-II naive CD4(+) T cells than WT BMDCs and induced more Th0 cells to differentiate into Treg while less into Th1. Furthermore, the transcriptome sequencing analysis exhibited that Gpr174 participated in TNF-alpha (NF-kappa B) signaling, leukocyte transendothelial migration, and Th1/Th2 cell differentiation pathways. Adoptive transfer of Gpr174(-/-) BMDCs to WT mice ameliorated DSS-induced colitis. ConclusionOur study indicated that GPR174 was involved in the pathogenesis of IBD by regulating the maturation of the dendritic cells to maintain immune homeostasis. TNF-alpha (NF-kappa B) signaling pathway, leukocyte transendothelial migration, and Th1/Th2 cell differentiation pathways may be the target pathway.	[Wei, Wei; Mu, Sucheng; Han, Yi; Chen, Yao; Kuang, Zhongshu; Wu, Xingyue; Luo, Yue; Tong, Chaoyang; Yang, Yilin; Song, Zhenju] Fudan Univ, Zhongshan Hosp, Dept Emergency Med, Shanghai, Peoples R China; [Zhang, Yiqun] Fudan Univ, Zhongshan Hosp, Endoscopy Res Inst, Endoscopy Ctr, Shanghai, Peoples R China; [Song, Zhenju] Shanghai Key Lab Lung Inflammat & Injury, Shanghai, Peoples R China; [Song, Zhenju] Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Sch Publ Hlth, Shanghai, Peoples R China; [Zhang, Yiqun] Fudan Univ, Zhongshan Hosp, Endoscopy Res Inst, Shanghai, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Yang, YL; Song, ZJ (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Emergency Med, Shanghai, Peoples R China.; Zhang, YQ (corresponding author), Fudan Univ, Zhongshan Hosp, Endoscopy Res Inst, Endoscopy Ctr, Shanghai, Peoples R China.; Song, ZJ (corresponding author), Shanghai Key Lab Lung Inflammat & Injury, Shanghai, Peoples R China.; Song, ZJ (corresponding author), Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Sch Publ Hlth, Shanghai, Peoples R China.; Zhang, YQ (corresponding author), Fudan Univ, Zhongshan Hosp, Endoscopy Res Inst, Shanghai, Peoples R China.		Zhang, YiQun/HCI-2427-2022					An GY, 2007, J EXP MED, V204, P1417, DOI 10.1084/jem.20061929; Bai AP, 2010, J INTERF CYTOK RES, V30, P399, DOI 10.1089/jir.2009.0028; Baumgart DC, 2011, CLIN EXP IMMUNOL, V166, P46, DOI 10.1111/j.1365-2249.2011.04439.x; Baumgart DC, 2005, GUT, V54, P228, DOI 10.1136/gut.2004.040360; Berges C, 2005, BIOCHEM BIOPH RES CO, V333, P896, DOI 10.1016/j.bbrc.2005.05.171; Breynaert C, 2016, J CROHNS COLITIS, V10, P1336, DOI 10.1093/ecco-jcc/jjw101; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Chu X, 2013, J MED GENET, V50, P479, DOI 10.1136/jmedgenet-2013-101595; Connor LM, 2014, J IMMUNOL, V193, P2709, DOI 10.4049/jimmunol.1400374; DIELEMAN LA, 1994, GASTROENTEROLOGY, V107, P1643, DOI 10.1016/0016-5085(94)90803-6; Ferrer-Picon E, 2020, INFLAMM BOWEL DIS, V26, P43, DOI 10.1093/ibd/izz119; Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986; Gad M, 2004, IMMUNOLOGY, V113, P499, DOI 10.1111/j.1365-2567.2004.01977.x; Geremia A, 2014, AUTOIMMUN REV, V13, P3, DOI 10.1016/j.autrev.2013.06.004; Ghia JE, 2008, J CLIN INVEST, V118, P2209, DOI 10.1172/JCI32849; Hammer GE, 2013, ANNU REV IMMUNOL, V31, P743, DOI 10.1146/annurev-immunol-020711-074929; Head Kathleen A, 2003, Altern Med Rev, V8, P247; Janelsins BM, 2009, BLOOD, V113, P3017, DOI 10.1182/blood-2008-06-163121; Jiang LY, 2010, WORLD J EMERG MED, V1, P138; Kimball ES, 2004, NEUROGASTROENT MOTIL, V16, P811, DOI 10.1111/j.1365-2982.2004.00549.x; Lammermann T, 2019, IMMUNOL REV, V289, P205, DOI 10.1111/imr.12752; Larmonier CB, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/504638; Li JJ, 2022, ADV SCI, V9, DOI 10.1002/advs.202104006; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; MADARA JL, 1989, J CLIN INVEST, V83, P724, DOI 10.1172/JCI113938; Marafini I, 2019, EXPERT OPIN BIOL TH, V19, P1207, DOI 10.1080/14712598.2019.1652267; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; Middel P, 2006, GUT, V55, P220, DOI 10.1136/gut.2004.063008; Napier C, 2015, J CLIN ENDOCR METAB, V100, pE187, DOI 10.1210/jc.2014-2694; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Olson TS, 2004, J CLIN INVEST, V114, P389, DOI 10.1172/jci200420855; Qiu DZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1462-z; Qualls JE, 2009, INFLAMM BOWEL DIS, V15, P236, DOI 10.1002/ibd.20733; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Schmitz H, 1999, J CELL SCI, V112, P137; Shahbaz SK, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106603; Stagg AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02883; Szekanecz Z, 2016, NAT REV RHEUMATOL, V12, P5, DOI 10.1038/nrrheum.2015.157; Ungaro R, 2017, LANCET, V389, P1756, DOI 10.1016/S0140-6736(16)32126-2; Watari A, 2017, CELL PHYSIOL BIOCHEM, V41, P1924, DOI 10.1159/000472367; Williams IR, 2006, ANN NY ACAD SCI, V1072, P52, DOI 10.1196/annals.1326.036; Woodruff MC, 2014, J EXP MED, V211, P1611, DOI 10.1084/jem.20132327; Worbs T, 2017, NAT REV IMMUNOL, V17, P30, DOI 10.1038/nri.2016.116; Ye XL, 2017, INT J MOL MED, V39, P1206, DOI 10.3892/ijmm.2017.2928; Zhao RZ, 2020, NATURE, V577, P416, DOI 10.1038/s41586-019-1873-0; Zhu M, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2019.106034	46	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								841254	10.3389/fimmu.2022.841254	http://dx.doi.org/10.3389/fimmu.2022.841254			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V4VY	35669778	Green Published, gold			2022-12-18	WOS:000806090500001
J	Zhou, XY; Ren, T; Zan, HY; Hua, CY; Guo, XF				Zhou, Xueyin; Ren, Ting; Zan, Hongyuan; Hua, Chunyan; Guo, Xufeng			Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets	FRONTIERS IN IMMUNOLOGY			English	Review						LAG-3; TIM-3; TIGIT; esophageal cancer; immunotherapy; biomarker	NEGATIVE REGULATORY FUNCTION; PROMOTES TUMOR PROGRESSION; ACTIVATION GENE-3 LAG-3; T-CELL; TIM-3; EXPRESSION; TIGIT; IMMUNOTHERAPY; RESPONSES; CD223	Esophageal cancer ranks as the sixth most common cause of cancer death worldwide. Due to the limited efficacy of conventional therapeutic strategies, including surgery, chemotherapy, and radiotherapy, treatments are still far from satisfactory in terms of survival, prompting the search for novel treatment methods. Immune checkpoints play crucial roles in immune evasion mediated by tumor cells, and successful clinical outcomes have been achieved via blocking these pathways. However, only a small fraction of patients can benefit from current immune checkpoint inhibitors targeting programmed cell death ligand-1 (PD-L1) and cytotoxic T-lymphocyte-associated protein-4. Unfortunately, some patients show primary and/or acquired resistance to immune checkpoint inhibitors. Until now, novel immune checkpoint pathways have rarely been studied in esophageal cancer, and there is a great need for biomarkers to predict who will benefit from existing strategies. Herein, we primarily discuss the roles of new immune checkpoints as predictive biomarkers and therapeutic targets for esophageal cancer. In addition, we summarize the ongoing clinical trials and provide future research directions targeting these pathways.	[Zhou, Xueyin; Zan, Hongyuan] Wenzhou Med Univ, Sch Med, Wenzhou, Peoples R China; [Ren, Ting; Guo, Xufeng] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China; [Hua, Chunyan] Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou, Peoples R China	Wenzhou Medical University; Shanghai Jiao Tong University; Wenzhou Medical University	Guo, XF (corresponding author), Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Thorac Surg, Shanghai, Peoples R China.; Hua, CY (corresponding author), Wenzhou Med Univ, Sch Basic Med Sci, Wenzhou, Peoples R China.	huachunyan@wmu.edu.cn; shandagxf@126.com		zhou, xue yin/0000-0002-0209-5248	National Natural Science Foundation of China [81901660]; China Scholarship Council [201808330646]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Scholarship Council(China Scholarship Council)	Funding This work was supported by grants from the National Natural Science Foundation of China [81901660], and China Scholarship Council [201808330646].	Abnet CC, 2018, GASTROENTEROLOGY, V154, P360, DOI 10.1053/j.gastro.2017.08.023; Ahmed H, 2015, CLIN MED INSIGHTS-ON, V9, P113, DOI 10.4137/CMO.S29462; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Andrews LP, 2019, NAT IMMUNOL, V20, P1425, DOI 10.1038/s41590-019-0512-0; Andrews LP, 2017, IMMUNOL REV, V276, P80, DOI 10.1111/imr.12519; Angelopoulou E, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9040086; Annunziato F, 1996, FASEB J, V10, P769, DOI 10.1096/fasebj.10.7.8635694; Baba Y, 2020, CANCER SCI, V111, P3132, DOI 10.1111/cas.14541; Babar Laila, 2019, Oncotarget, V10, P4546, DOI 10.18632/oncotarget.27052; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buisson S, 2005, IMMUNOLOGY, V114, P369, DOI 10.1111/j.1365-2567.2004.02087.x; Ceeraz S, 2013, TRENDS IMMUNOL, V34, P556, DOI 10.1016/j.it.2013.07.003; Chauvin JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000957; Chauvin JM, 2020, CLIN CANCER RES, V26, P5520, DOI 10.1158/1078-0432.CCR-20-0575; Chen LJ, 2015, AM J TRANSL RES, V7, P2646; Chen YL, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0744-4; Chen ZJ, 2021, CURR CANCER DRUG TAR, V21, P244, DOI 10.2174/1568009620666201120152333; Chiu DKC, 2020, GASTROENTEROLOGY, V159, P609, DOI 10.1053/j.gastro.2020.03.074; Chou FC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020430; Das M, 2017, IMMUNOL REV, V276, P97, DOI 10.1111/imr.12520; Davidson D, 2007, MOL CELL BIOL, V27, P1960, DOI 10.1128/MCB.01983-06; de Weyer PSV, 2006, BIOCHEM BIOPH RES CO, V351, P571, DOI 10.1016/j.bbrc.2006.10.079; Demeure CE, 2001, EUR J CANCER, V37, P1709, DOI 10.1016/S0959-8049(01)00184-8; Dienz O, 2007, P NATL ACAD SCI USA, V104, P7175, DOI 10.1073/pnas.0610442104; Doki Y, 2022, NEW ENGL J MED, V386, P449, DOI 10.1056/NEJMoa2111380; Doroshow DB, 2021, NAT REV CLIN ONCOL, V18, P345, DOI 10.1038/s41571-021-00473-5; Durham NM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109080; Flem-Karlsen K, 2018, TRENDS CANCER, V4, P401, DOI 10.1016/j.trecan.2018.03.010; Freed-Pastor WA, 2021, CANCER CELL, V39, P1342, DOI 10.1016/j.ccell.2021.07.007; Hakemi MG, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.601661; Gavrieli M, 2006, ADV IMMUNOL, V92, P157, DOI 10.1016/S0065-2776(06)92004-5; Gebauer F, 2020, J CANCER RES CLIN, V146, P2319, DOI 10.1007/s00432-020-03295-7; Graydon CG, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615317; Guo MZ, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02469-8; Harjunpaa H, 2020, CLIN EXP IMMUNOL, V200, P108, DOI 10.1111/cei.13407; He WL, 2017, CANCER RES, V77, P6375, DOI 10.1158/0008-5472.CAN-17-0381; He YY, 2018, ONCOTARGETS THER, V11, P4781, DOI 10.2147/OTT.S164178; Hu SY, 2020, J AUTOIMMUN, V112, DOI 10.1016/j.jaut.2020.102504; Huang X, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00917-y; Huang YH, 2015, NATURE, V517, P386, DOI 10.1038/nature13848; Hung AL, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1466769; Iouzalen N, 2001, EUR J IMMUNOL, V31, P2885, DOI 10.1002/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2; Joller N, 2017, CURR TOP MICROBIOL, V410, P127, DOI 10.1007/82_2017_62; Josefsson SE, 2018, CLIN CANCER RES, V24, P870, DOI 10.1158/1078-0432.CCR-17-2337; Judge SJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001355; Kamal AM, 2021, CLIN BIOCHEM, V96, P13, DOI 10.1016/j.clinbiochem.2021.06.007; Kanzaki M, 2012, ENDOCRINOLOGY, V153, P612, DOI 10.1210/en.2011-1579; Kawashima S, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003134; Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888; Kouo T, 2015, CANCER IMMUNOL RES, V3, P412, DOI 10.1158/2326-6066.CIR-14-0150; Lecocq Q, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010075; Lee J, 2011, MOL CELL BIOL, V31, P3963, DOI 10.1128/MCB.05297-11; Li CQ, 2021, EUR J CANCER, V144, P232, DOI 10.1016/j.ejca.2020.11.039; Li N, 2018, CANCER BIOMARK, V23, P341, DOI 10.3233/CBM-181278; Li NY, 2007, EMBO J, V26, P494, DOI 10.1038/sj.emboj.7601520; Liu D, 2019, CELL RES, V29, P365, DOI 10.1038/s41422-019-0155-6; Liu FF, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0667-4; Liu ZP, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000978; Loeser H, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1581546; Maeda TK, 2019, J BIOL CHEM, V294, P6017, DOI 10.1074/jbc.RA119.007455; Mao XB, 2016, SCIENCE, V353, DOI 10.1126/science.aah3374; Maruhashi T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001014; Mei Z, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-0084-8; Melaiu O, 2022, SEMIN CANCER BIOL, V79, P18, DOI 10.1016/j.semcancer.2020.07.001; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Mulati K, 2019, BRIT J CANCER, V120, P115, DOI 10.1038/s41416-018-0313-5; Nair VS, 2018, IMMUNOL CELL BIOL, V96, P21, DOI 10.1111/imcb.1003; Nguyen LT, 2015, NAT REV IMMUNOL, V15, P45, DOI 10.1038/nri3790; Niu J, 2022, ANN ONCOL, V33, P169, DOI 10.1016/j.annonc.2021.11.002; Nowak EC, 2017, IMMUNOL REV, V276, P66, DOI 10.1111/imr.12525; Onaitis M, 2021, J THORAC CARDIOV SUR, V161, P844, DOI 10.1016/j.jtcvs.2020.12.027; Pietra G, 2020, CLIN CANCER RES, V26, P5274, DOI 10.1158/1078-0432.CCR-20-2538; Poh A, 2020, CANCER DISCOV, V10, P7, DOI 10.1158/2159-8290.CD-NB2019-136; Puhr HC, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000482; Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2; Rangachari M, 2012, NAT MED, V18, P1394, DOI 10.1038/nm.2871; Raphael I, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.637146; Reches A, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000266; Ren XB, 2019, CANCER BIOL MED, V16, P205, DOI 10.20892/j.issn.2095-3941.2018.0141; Roudi R, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108322; Ruffo E, 2019, SEMIN IMMUNOL, V42, DOI 10.1016/j.smim.2019.101305; Sabatos CA, 2003, NAT IMMUNOL, V4, P1102, DOI 10.1038/ni988; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Savitsky D, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3819; Schnell A, 2020, CELL RES, V30, P285, DOI 10.1038/s41422-020-0277-x; Shan CC, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12070; Shang SJ, 2021, CANCER COMMUN, V41, P1086, DOI 10.1002/cac2.12226; Shen RL, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abf5107; Shi AP, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.785091; Shin DS, 2015, CURR OPIN IMMUNOL, V33, P23, DOI 10.1016/j.coi.2015.01.006; Sidaway Peter, 2017, Nat Rev Clin Oncol, V14, P712, DOI [10.1038/nrclinonc.2017.162, 10.1038/nrclinonc.2017.164]; Smida M, 2007, BLOOD, V110, P596, DOI 10.1182/blood-2006-07-038752; Sobottka B, 2021, BREAST CANCER RES, V23, DOI 10.1186/s13058-020-01380-w; Solinas C, 2019, CANCERS, V11, DOI 10.3390/cancers11081213; Sun JW, 2021, CLIN CANCER RES, V27, P680, DOI 10.1158/1078-0432.CCR-19-2925; Sun JM, 2021, LANCET, V398, P759, DOI 10.1016/S0140-6736(21)01234-4; Tang RH, 2019, SEMIN IMMUNOL, V42, DOI 10.1016/j.smim.2019.101302; Tawbi HA, 2022, NEW ENGL J MED, V386, P24, DOI 10.1056/NEJMoa2109970; Thijssen VL, 2015, BBA-REV CANCER, V1855, P235, DOI 10.1016/j.bbcan.2015.03.003; Triebel F, 2006, CANCER LETT, V235, P147, DOI 10.1016/j.canlet.2005.04.015; Triebel F, 2003, TRENDS IMMUNOL, V24, P619, DOI 10.1016/j.it.2003.10.001; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; Wang H, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0746-1; Wang JH, 2019, IMMUNOLOGY, V156, P74, DOI 10.1111/imm.13001; Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591-019-0374-x; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Wang L, 2016, TUMOR BIOL, V37, P2961, DOI 10.1007/s13277-015-4132-5; Wang PP, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002836; Wang QC, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0810-y; Wang S, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023599; Wang WJ, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.38; Weulersse M, 2020, IMMUNITY, V53, P824, DOI 10.1016/j.immuni.2020.09.006; Whelan S, 2019, CANCER IMMUNOL RES, V7, P257, DOI 10.1158/2326-6066.CIR-18-0442; Wolf Y, 2020, NAT REV IMMUNOL, V20, P173, DOI 10.1038/s41577-019-0224-6; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Workman CJ, 2004, J IMMUNOL, V172, P5450, DOI 10.4049/jimmunol.172.9.5450; Workman CJ, 2003, EUR J IMMUNOL, V33, P970, DOI 10.1002/eji.200323382; Workman CJ, 2002, J IMMUNOL, V169, P5392, DOI 10.4049/jimmunol.169.10.5392; Xie JH, 2016, ONCOTARGET, V7, P63669, DOI 10.18632/oncotarget.11611; Xu F, 2014, CANCER RES, V74, P3418, DOI 10.1158/0008-5472.CAN-13-2690; Yan WJ, 2015, GUT, V64, P1593, DOI 10.1136/gutjnl-2014-307671; Yang D, 2017, IMMUNOL REV, V280, P41, DOI 10.1111/imr.12577; Yang L, 2008, J IMMUNOL, V180, P4409, DOI 10.4049/jimmunol.180.7.4409; Yang YM, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00323-3; Yi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0864-3; Yoshida J, 2019, MED ONCOL, V36, DOI 10.1007/s12032-019-1285-x; Yu WD, 2019, CANCER LETT, V452, P66, DOI 10.1016/j.canlet.2019.02.048; Yu XJ, 2019, MABS-AUSTIN, V11, P1139, DOI 10.1080/19420862.2019.1629239; Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674; Yuan Y, 2021, CANCERS, V13, DOI 10.3390/cancers13040663; Zhang HL, 2018, ONCOGENE, V37, P2456, DOI 10.1038/s41388-018-0140-4; Zhang L, 2016, EXPERT REV GASTROENT, V10, P595, DOI 10.1586/17474124.2016.1140036; Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0; Zhang WT, 2021, ACTA PHARMACOL SIN, V42, P1921, DOI 10.1038/s41401-020-00574-4; Zhang W, 2019, EXP CELL RES, V376, P124, DOI 10.1016/j.yexcr.2019.02.007; Zhang Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019664; Zhang Y, 2018, J CANCER, V9, P4287, DOI 10.7150/jca.26949; Zhao JJ, 2018, CANCER MANAG RES, V10, P6457, DOI 10.2147/CMAR.S181949; Zhao KK, 2021, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.608404; Zhao Q, 2019, CANCER MED-US, V8, P4519, DOI 10.1002/cam4.2336; Zheng YJ, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1917-0; Zhong WJ, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107662; Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017; Zhou XM, 2020, ANGEW CHEM INT EDIT, V59, P15114, DOI 10.1002/anie.202002783; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	148	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								864202	10.3389/fimmu.2022.864202	http://dx.doi.org/10.3389/fimmu.2022.864202			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V3KI	35669786	Green Published, gold			2022-12-18	WOS:000805992700001
J	Zhou, Y; Li, X; Shen, R; Wang, XZ; Zhang, F; Liu, SX; Li, D; Liu, J; Li, PH; Yan, YF; Dong, P; Zhang, ZG; Wu, HP; Zhuang, LH; Chowdhury, R; Miller, M; Issa, M; Mao, YC; Chen, HL; Feng, J; Li, J; Bai, C; He, F; Tao, WK				Zhou, Yu; Li, Xin; Shen, Ru; Wang, Xiangzhu; Zhang, Fan; Liu, Suxing; Li, Di; Liu, Jian; Li, Puhui; Yan, Yinfa; Dong, Ping; Zhang, Zhigao; Wu, Heping; Zhuang, Linghang; Chowdhury, Rasheduzzaman; Miller, Matthew; Issa, Mena; Mao, Yuchang; Chen, Hongli; Feng, Jun; Li, Jing; Bai, Chang; He, Feng; Tao, Weikang			Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways	FRONTIERS IN IMMUNOLOGY			English	Article						Tyrosine Kinase 2 (TYK2); Janus Kinases (JAK); JAK homology 2 (JH2) pseudokinase regulatory domain; cytokine pathways; small molecule inhibitors; selectivity	TYK2; JAK; SUSCEPTIBILITY; INHIBITOR; IDENTIFICATION; TOFACITINIB; DISCOVERY; RESPONSES; REVEALS; VARIANT	A member of the Janus kinase (JAK) family, Tyrosine Kinase 2 (TYK2), is crucial in mediating various cytokine-signaling pathways such as interleukin-23 (IL23), interleukin-12 (IL12) and type I Interferons (IFN) which contribute to autoimmune disorders (e.g., psoriasis, lupus, and inflammatory bowel disease). Thus, TYK2 represents an attractive target to develop small-molecule therapeutics for the treatment of cytokine-driven inflammatory diseases. Selective inhibition of TYK2 over other JAK isoforms is critical to achieve a favorable therapeutic index in the development of TYK2 inhibitors. However, designing small molecule inhibitors to target the adenosine triphosphate (ATP) binding site of TYK2 kinase has been challenging due to the substantial structural homology of the JAK family catalytic domains. Here, we employed an approach to target the JAK homology 2 (JH2) pseudokinase regulatory domain of the TYK2 protein. We developed a series of small-molecule TYK2 pseudokinase ligands, which suppress the TYK2 catalytic activity through allosteric regulation. The TYK2 pseudokinase-binding small molecules in this study simultaneously achieve high affinity-binding for the TYK2 JH2 domain while also affording significantly reduced affinity for the TYK2 JAK homology 1 (JH1) kinase domain. These TYK2 JH2 selective molecules, although possessing little effect on suppressing the catalytic activity of the isolated TYK2 JH1 catalytic domain in the kinase assays, can still significantly block the TYK2-mediated receptor-stimulated pathways by binding to the TYK2 JH2 domain and allosterically regulating the TYK2 JH1 kinase. These compounds are potent towards human T-cell lines and primary immune cells as well as in human whole-blood specimens. Moreover, TYK2 JH2-binding ligands exhibit remarkable selectivity of TYK2 over JAK isoforms not only biochemically but also in a panel of receptor-stimulated JAK1/JAK2/JAK3-driven cellular functional assays. In addition, the TYK2 JH2-targeting ligands also demonstrate high selectivity in a multi-kinase screening panel. The data in the current study underscores that the TYK2 JH2 pseudokinase is a promising therapeutic target for achieving a high degree of biological selectivity. Meanwhile, targeting the JH2 domain represents an appealing strategy for the development of clinically well-tolerated TYK2 inhibitors that would have superior efficacy and a favorable safety profile compared to the existing Janus kinase inhibitors against autoimmune diseases.	[Zhou, Yu; Shen, Ru; Wang, Xiangzhu; Zhang, Fan; Liu, Suxing; Li, Di; Liu, Jian; Li, Puhui; Yan, Yinfa; Wu, Heping; Zhuang, Linghang; Chowdhury, Rasheduzzaman; Miller, Matthew; Issa, Mena; Li, Jing] Etern Biosci Inc, R&D Ctr, Cranbury, NJ 08512 USA; [Li, Xin; Dong, Ping; Zhang, Zhigao; Mao, Yuchang; Chen, Hongli; Feng, Jun; Bai, Chang; He, Feng; Tao, Weikang] Shanghai Hengrui Pharmaceut Co Ltd, R&D Ctr, Shanghai, Peoples R China		Zhou, Y (corresponding author), Etern Biosci Inc, R&D Ctr, Cranbury, NJ 08512 USA.; Li, X (corresponding author), Shanghai Hengrui Pharmaceut Co Ltd, R&D Ctr, Shanghai, Peoples R China.	yuzhou8200@gmail.com; xin.li.xl6@hengrui.com	tao, wei/GXN-4445-2022					[Anonymous], 2019, SAFETY TRIAL FINDS R; [Anonymous], 2021, FDA REQUIRES WARNING; [Anonymous], 2021, INITIAL SAFETY TRIAL; [Anonymous], 2019, FDA APPROVES BOXED W; Ban M, 2009, EUR J HUM GENET, V17, P1309, DOI 10.1038/ejhg.2009.41; Banerjee S, 2017, DRUGS, V77, P521, DOI 10.1007/s40265-017-0701-9; Banfield C, 2018, J CLIN PHARMACOL, V58, P434, DOI 10.1002/jcph.1046; Boisson-Dupuis S, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aau8714; Burke JR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw1736; Choy EH, 2019, RHEUMATOLOGY, V58, P1122, DOI 10.1093/rheumatology/kez002; Clark JD, 2014, J MED CHEM, V57, P5023, DOI 10.1021/jm401490p; Contreras-Cubas C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48451-3; Couturier N, 2011, BRAIN, V134, P693, DOI 10.1093/brain/awr010; Cutolo M, 2013, J INFLAMM RES, V6, P129, DOI 10.2147/JIR.S35901; Danese S., 2021, INFLAMM BOWEL DIS, V27, P2023, DOI [10.1093/ibd/izab135, DOI 10.1093/IBD/IZAB135]; Dendrou CA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1974; Di Cesare A, 2009, J INVEST DERMATOL, V129, P1339, DOI 10.1038/jid.2009.59; Diogo D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122271; Dowty ME, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.537; Dyment DA, 2012, NEUROLOGY, V79, P406, DOI 10.1212/WNL.0b013e3182616fc4; Forman SB, 2020, J INVEST DERMATOL, V140, P2359, DOI 10.1016/j.jid.2020.03.962; Forster M, 2016, CELL CHEM BIOL, V23, P1335, DOI 10.1016/j.chembiol.2016.10.008; Fuchs S, 2016, EUR J IMMUNOL, V46, P2639, DOI 10.1002/eji.201646519; Gadina M, 2020, J IMMUNOL, V204, P2011, DOI 10.4049/jimmunol.1901477; Gerstenberger BS, 2020, J MED CHEM, V63, P13561, DOI 10.1021/acs.jmedchem.0c00948; Ghoreschi K, 2021, LANCET, V397, P754, DOI 10.1016/S0140-6736(21)00184-7; Gorman JA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00044; Harrison DA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011205; Hawkes JE, 2018, J IMMUNOL, V201, P1605, DOI 10.4049/jimmunol.1800013; He XR, 2019, EXPERT OPIN THER PAT, V29, P137, DOI 10.1080/13543776.2019.1567713; HORI T, 1987, BLOOD, V70, P1069; Ishizaki M, 2011, INT IMMUNOL, V23, P575, DOI 10.1093/intimm/dxr057; Kerner G, 2019, P NATL ACAD SCI USA, V116, P10430, DOI 10.1073/pnas.1903561116; Krainer J, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102421; Kreins AY, 2015, J EXP MED, V212, P1641, DOI 10.1084/jem.20140280; Kvist-Hansen A, 2020, DERMATOLOGY THER, V10, P29, DOI 10.1007/s13555-019-00347-w; Laurence Arian, 2012, Open Rheumatol J, V6, P232, DOI 10.2174/1874312901206010232; Liu CJ, 2019, ACS MED CHEM LETT, V10, P383, DOI 10.1021/acsmedchemlett.9b00035; Lupardus PJ, 2014, P NATL ACAD SCI USA, V111, P8025, DOI 10.1073/pnas.1401180111; Lv G, 2022, PEDIAT ALLERG IMM-UK, V33, DOI 10.1111/pai.13671; Mero IL, 2010, EUR J HUM GENET, V18, P502, DOI 10.1038/ejhg.2009.195; Minegishi Y, 2006, IMMUNITY, V25, P745, DOI 10.1016/j.immuni.2006.09.009; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Morris R, 2018, PROTEIN SCI, V27, P1984, DOI 10.1002/pro.3519; Muromoto Ryuta, 2022, World J Biol Chem, V13, P1, DOI 10.4331/wjbc.v13.i1.1; Nogueira M, 2020, DRUGS, V80, P341, DOI 10.1007/s40265-020-01261-8; O'Brien A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672461; O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev-med-051113-024537; O'Shea JJ, 2012, IMMUNITY, V36, P542, DOI 10.1016/j.immuni.2012.03.014; Oyamada A, 2009, J IMMUNOL, V183, P7539, DOI 10.4049/jimmunol.0902740; Page KM, 2020, J INVEST DERMATOL, V140, P1546, DOI 10.1016/j.jid.2019.11.027; Palmroth M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.738481; Papp K, 2018, NEW ENGL J MED, V379, P1313, DOI 10.1056/NEJMoa1806382; Papp KA, 2016, J AM ACAD DERMATOL, V74, P841, DOI 10.1016/j.jaad.2016.01.013; Puleo DE, 2017, ACS MED CHEM LETT, V8, P618, DOI 10.1021/acsmedchemlett.7b00153; Renauld JC, 2003, NAT REV IMMUNOL, V3, P667, DOI 10.1038/nri1153; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 2002, J BIOL CHEM, V277, P47954, DOI 10.1074/jbc.M205156200; Sasaki-Iwaoka H, 2018, EUR J PHARMACOL, V828, P89, DOI 10.1016/j.ejphar.2018.03.036; Schon MP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01323; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Schwartz DM, 2018, NAT REV DRUG DISCOV, V17, DOI 10.1038/nrd.2017.267; Schwartz DM, 2016, NAT REV RHEUMATOL, V12, P25, DOI 10.1038/nrrheum.2015.167; Singer JW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222944; Sohn SJ, 2013, J IMMUNOL, V191, P2205, DOI 10.4049/jimmunol.1202859; Spach KM, 2009, J IMMUNOL, V182, P7776, DOI 10.4049/jimmunol.0900142; Tokarski JS, 2015, J BIOL CHEM, V290, P11061, DOI 10.1074/jbc.M114.619502; Traves PG, 2021, ANN RHEUM DIS, V80, P865, DOI 10.1136/annrheumdis-2020-219012; Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366; Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Winthrop KL, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.51; Wrobleski ST, 2019, J MED CHEM, V62, P8973, DOI 10.1021/acs.jmedchem.9b00444	72	0	0	9	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 20	2022	13								884399	10.3389/fimmu.2022.884399	http://dx.doi.org/10.3389/fimmu.2022.884399			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A6VI	35693820	Green Published, gold			2022-12-18	WOS:000809636900001
J	Alvarez, C; Abdalla, H; Suliman, S; Rojas, P; Wu, YC; Almarhoumi, R; Huang, RY; Galindo, M; Vernal, R; Kantarci, A				Alvarez, Carla; Abdalla, Henrique; Suliman, Salwa; Rojas, Paola; Wu, Yu-Chiao; Almarhoumi, Rawan; Huang, Ren-Yeong; Galindo, Mario; Vernal, Rolando; Kantarci, Alpdogan			RvE1 Impacts the Gingival Inflammatory Infiltrate by Inhibiting the T Cell Response in Experimental Periodontitis (vol 12, 664756, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						T cells; Periodontal disease; inflammation; RvE1; SPMs (specialized pro-resolving mediators)			[Alvarez, Carla; Abdalla, Henrique; Suliman, Salwa; Rojas, Paola; Wu, Yu-Chiao; Almarhoumi, Rawan; Huang, Ren-Yeong; Kantarci, Alpdogan] Forsyth Inst, Cambridge, MA 02142 USA; [Abdalla, Henrique] Inst Pesquisas Sao Leopoldo Mand, Fac Sao Leopoldo Mand, Lab Neuroimmune Interface Pain Res, Campinas, Brazil; [Suliman, Salwa] Univ Bergen, Ctr Clin Dent Res, Dept Clin Dent, Bergen, Norway; [Wu, Yu-Chiao; Almarhoumi, Rawan; Kantarci, Alpdogan] Harvard Sch Dent Med, Boston, MA 02115 USA; [Huang, Ren-Yeong] Natl Def Med Ctr, Sch Dent, Taipei, Taiwan; [Galindo, Mario] Univ Chile, Inst Biomed Sci ICBM, Fac Med, Program Cellular & Mol Biol, Santiago, Chile; [Galindo, Mario] Univ Chile, Millennium Inst Immunol & Immunotherapy, Fac Med, Santiago, Chile; [Vernal, Rolando] Univ Chile, Dent Fac, Periodontal Biol Lab, Santiago, Chile	Harvard University; Forsyth Institute; Faculdade Sao Leopoldo Mandic; University of Bergen; Harvard University; Harvard School of Dental Medicine; National Defense Medical Center; Universidad de Chile; Universidad de Chile; Universidad de Chile	Kantarci, A (corresponding author), Forsyth Inst, Cambridge, MA 02142 USA.; Kantarci, A (corresponding author), Harvard Sch Dent Med, Boston, MA 02115 USA.	akantarci@forsyth.org		Ballassini Abdalla, Henrique/0000-0002-7517-2830				ALVAREZ C, 2022, FRONTIERS IMMUNOLOGY	1	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								936102	10.3389/fimmu.2022.936102	http://dx.doi.org/10.3389/fimmu.2022.936102			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W2KD	35664005	Green Published, gold			2022-12-18	WOS:000806605500001
J	Chang, ML; Chen, WT; Chan, TM; Lin, CY; Chang, MY; Chen, SC; Chien, RN				Chang, Ming-Ling; Chen, Wei-Ting; Chan, Tien-Ming; Lin, Cheng-Yu; Chang, Ming-Yu; Chen, Shiang-Chi; Chien, Rong-Nan			Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years	FRONTIERS IN IMMUNOLOGY			English	Article						antimitochondrial antibodies (AMA); primary biliary cholangitis (PBC); UDCA; alkaline phospatase; cirrhosis	CLINICAL-SIGNIFICANCE; ANTINUCLEAR ANTIBODIES; PYRUVATE-DEHYDROGENASE; OBETICHOLIC ACID; CIRRHOSIS; MULTICENTER; COMPLEX	BackgroundHow anti-mitochondrial antibody (AMA) and liver biochemistry levels change in primary biliary cholangitis (PBC) patients treated with ursodeoxycholic acid (UDCA) remains unclear. MethodsA 28-year cohort of 157 PBC patients was conducted. Patients with alkaline phosphatase (Alk-p) levels >1.67 x upper limit of normal after 1 year of UDCA treatment were considered nonresponders. ResultsAt baseline, of 157 (mean age: 54.41 years), 136 (86.6%) were female, 51 (32.5%) had cirrhosis, and 128 (81.5%) had detectable AMAs (immunoglobulin G). UDCA nonresponders (n=61) were younger and had higher Alk-p and total bilirubin levels and cirrhosis rates than UDCA responders (n=84). Alk-p levels and cirrhosis were negatively associated with UDCA response. Regardless of cirrhosis and UDCA response, most PBC patients had decreased Alk-p and gamma-glutamyltransferase levels at last follow-up (up to 28.73 years) compared with baseline levels. Patients with baseline cirrhosis (2.78 +/- 2.56 vs. 6.84 +/- 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 +/- 2.19 vs. 4.51 +/- 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 +/- 84.5 vs. 58.9 +/- 43.7 U/L, p<0.001; ALT: 107.3 +/- 122.5 vs. 50.7 +/- 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 +/- 101.3 vs. 45.58 +/- 38.42 U/L, p=0.014; ALT: 95.10 +/- 144.6 vs. 39.12 +/- 30.65 U/L, p=0.009) had decreased aminotransferase levels. Only UDCA responders had decreased AMA titers from 1 year after UDCA treatment (p=0.028) until the last follow-up (p<0.001). ConclusionsUDCA responders exhibited decreased AMA titers 1 year after treatment. Regardless of UDCA response, PBC patients showed improved cholestatic features, but only UDCA responders and patients without baseline cirrhosis exhibited attenuated hepatobiliary damage following UDCA treatment.	[Chang, Ming-Ling; Chen, Wei-Ting; Lin, Cheng-Yu; Chien, Rong-Nan] Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Div Hepatol, Taoyuan, Taiwan; [Chang, Ming-Ling; Chan, Tien-Ming; Chien, Rong-Nan] Chang Gung Univ, Coll Med, Dept Med, Taoyuan, Taiwan; [Chan, Tien-Ming] Chang Gung Mem Hosp, Dept Internal Med, Div Rheumatol Allergy & Immunology, Taoyuan, Taiwan; [Chang, Ming-Yu] Chang Gung Mem Hosp, Div Pediat, Keelung, Taiwan; [Chen, Shiang-Chi] Taipei Med Univ, Dept Nursing, Taipei, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Taipei Medical University	Chang, ML; Chien, RN (corresponding author), Chang Gung Mem Hosp, Dept Gastroenterol & Hepatol, Div Hepatol, Taoyuan, Taiwan.; Chang, ML; Chien, RN (corresponding author), Chang Gung Univ, Coll Med, Dept Med, Taoyuan, Taiwan.	mlchang8210@gmail.com; ronald@cgmh.org.tw			Chang Gung Medical Research Program [CMRPG3I0413, CMRPG3L1191, CMRPG3M0211, CMRPG1K0111-3]; National Science Council, Taiwan [MOST 110-2629-B-182-001, 110-2314-B-182-044-]	Chang Gung Medical Research Program; National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	This study was supported by grants from the Chang Gung Medical Research Program (CMRPG3I0413, CMRPG3L1191, CMRPG3M0211 and CMRPG1K0111-3), and the National Science Council, Taiwan (MOST 110-2629-B-182-001- and 110-2314-B-182-044-). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The opinions expressed in this paper are those of the authors and do not necessarily represent those of Chang Gung Medical Hospital and National Science Council, Taiwan.	BATTEZZATI PM, 1993, J HEPATOL, V17, P332, DOI 10.1016/S0168-8278(05)80214-4; Benson Gordon D, 2004, Clin Dev Immunol, V11, P129, DOI 10.1080/10446670410001722113; Berdichevski T, 2017, HEPATOL RES, V47, P742, DOI 10.1111/hepr.12809; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Carbone M, 2018, LANCET GASTROENTEROL, V3, P626, DOI 10.1016/S2468-1253(18)30163-8; Chang ML, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031552; Chang ML, 2020, CLIN GASTROENTEROL H, V18, P2064, DOI 10.1016/j.cgh.2020.01.018; Dahlqvist G, 2017, HEPATOLOGY, V65, P152, DOI 10.1002/hep.28859; Dellavance A, 2013, HEPATOL INT, V7, P775, DOI 10.1007/s12072-012-9413-0; Dohmen K, 2004, WORLD J GASTROENTERO, V10, P894; Gabeta S, 2007, J CLIN IMMUNOL, V27, P378, DOI 10.1007/s10875-007-9092-0; Gatselis NK, 2013, AUTOIMMUNITY, V46, P471, DOI 10.3109/08916934.2013.801461; Granito A, 2006, ALIMENT PHARM THER, V24, P1575, DOI 10.1111/j.1365-2036.2006.03172.x; Granito A, 2021, WORLD J GASTROENTERO, V27, DOI 10.3748/wjg.v27.i22.2994; Granito A, 2012, EXPERT REV MOL DIAGN, V12, P65, DOI 10.1586/ERM.11.82; HASSELSTROM K, 1988, SCAND J GASTROENTERO, V23, P103, DOI 10.3109/00365528809093857; Hazama H, 2000, J CLIN LAB ANAL, V14, P208, DOI 10.1002/1098-2825(2000)14:5<208::AID-JCLA2>3.0.CO;2-6; Hirschfield GM, 2018, GUT, V67, P1568, DOI 10.1136/gutjnl-2017-315259; Hirschfield GM, 2017, J HEPATOL, V67, P145, DOI 10.1016/j.jhep.2017.03.022; Hirschfield GM, 2015, GASTROENTEROLOGY, V148, P751, DOI 10.1053/j.gastro.2014.12.005; JORDE R, 1986, ACTA MED SCAND, V220, P241; Kikuchi K, 2009, HEPATOL RES, V39, P448, DOI 10.1111/j.1872-034X.2008.00474.x; Kisand KE, 1996, J MOL MED-JMM, V74, P269, DOI 10.1007/s001090050028; Komuro Osamu, 2004, Nihon Rinsho Meneki Gakkai Kaishi, V27, P322; Leung PSC, 2007, HEPATOLOGY, V46, P1436, DOI 10.1002/hep.21828; Leung PSC, 2005, SEMIN LIVER DIS, V25, P327, DOI 10.1055/s-2005-916324; Leuschner M, 2000, GUT, V46, P121, DOI 10.1136/gut.46.1.121; Leuschner Ulrich, 2003, Clin Liver Dis, V7, P741, DOI 10.1016/S1089-3261(03)00101-6; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Nakamura M, 2014, SEMIN LIVER DIS, V34, P334, DOI 10.1055/s-0034-1383732; Norman GL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00662; POUPON RE, 1991, NEW ENGL J MED, V324, P1548, DOI 10.1056/NEJM199105303242204; Rigopoulou EI, 2007, LIVER INT, V27, P1226, DOI 10.1111/j.1478-3231.2007.01586.x; RUEGG R, 1985, SCHWEIZ MED WSCHR, V115, P290; Samur S, 2017, HEPATOLOGY, V65, P920, DOI 10.1002/hep.28932; Tana MM, 2015, AM J CLIN PATHOL, V144, P601, DOI 10.1309/AJCPQV4A7QAEEFEV; Tanaka A, 2017, HEPATOL COMMUN, V1, P275, DOI 10.1002/hep4.1044; Tang LB, 2017, J GASTROEN HEPATOL, V32, P659, DOI 10.1111/jgh.13534; Yin YF, 2012, WORLD J GASTROENTERO, V18, P3938, DOI 10.3748/wjg.v18.i30.3938	39	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								869018	10.3389/fimmu.2022.869018	http://dx.doi.org/10.3389/fimmu.2022.869018			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V7QC	35663951	gold, Green Published			2022-12-18	WOS:000806278500001
J	Cheng, ML; Liu, HY; Zhou, C; Li, RT; Zheng, J; Qin, YH; Yang, N; Zhang, Y; Huang, JJ; Zhu, Z; Meng, QY; Wang, GQ; Zhao, H; Chen, Y; Bai, CQ; Qin, CF; Li, F				Cheng, Meng-Li; Liu, Hui-Ying; Zhou, Chao; Li, Rui-Ting; Zheng, Jing; Qin, Yan-Hong; Yang, Ning; Zhang, Yue; Huang, Juan-Juan; Zhu, Zhu; Meng, Qing-Yu; Wang, Guo-Qing; Zhao, Hui; Chen, Yun; Bai, Chang-Qing; Qin, Cheng-Feng; Li, Fan			Longitudinal Dynamics of Cellular Responses in Recovered COVID-19 Patients	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; cellular immunity; Th1 cytokines; interferon; SARS-CoV-2	CORONAVIRUS; PNEUMONIA; OUTBREAK	Safe and effective vaccines and therapeutics based on the understanding of antiviral immunity are urgently needed to end the COVID-19 pandemic. However, the understanding of these immune responses, especially cellular immune responses to SARS-CoV-2 infection, is limited. Here, we conducted a cohort study of COVID-19 patients who were followed and had blood collected to characterize the longitudinal dynamics of their cellular immune responses. Compared with healthy controls, the percentage of activation of SARS-CoV-2 S/N-specific T cells in recovered patients was significantly higher. And the activation percentage of S/N-specific CD8(+) T cells in recovered patients was significantly higher than that of CD4(+) T cells. Notably, SARS-CoV-2 specific T-cell responses were strongly biased toward the expression of Th1 cytokines, included the cytokines IFN gamma, TNF alpha and IL2. Moreover, the secreted IFN gamma and IL2 level in severe patients was higher than that in mild patients. Additionally, the number of IFN gamma-secreting S-specific T cells in recovered patients were higher than that of N-specific T cells. Overall, the SARS-CoV-2 S/N-specific T-cell responses in recovered patients were strong, and virus-specific immunity was present until 14-16 weeks after symptom onset. Our work provides a basis for understanding the immune responses and pathogenesis of COVID-19. It also has implications for vaccine development and optimization and speeding up the licensing of the next generation of COVID-19 vaccines.	[Cheng, Meng-Li; Huang, Juan-Juan; Meng, Qing-Yu; Wang, Guo-Qing; Li, Fan] Jilin Univ, Coll Basic Med Sci, Dept Pathogenobiol, Key Lab Zoonosis Res,Chinese Minist Educ, Changchun, Peoples R China; [Liu, Hui-Ying; Zheng, Jing; Qin, Yan-Hong; Yang, Ning; Zhang, Yue] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 5, Dept Resp & Crit Care Dis, Beijing, Peoples R China; [Zhou, Chao; Li, Rui-Ting; Zhu, Zhu; Zhao, Hui; Qin, Cheng-Feng] Acad Mil Med Sci, Beijing Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China; [Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing, Peoples R China; [Bai, Chang-Qing] Shenzhen Univ, Gen Hosp, Dept Resp & Crit Care Med, Shenzhen, Peoples R China; [Li, Fan] Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China	Jilin University; Academy of Military Medical Sciences - China; Beijing Institute of Microbiology & Epidemiology; Nanjing Medical University; Shenzhen University; Jilin University	Li, F (corresponding author), Jilin Univ, Coll Basic Med Sci, Dept Pathogenobiol, Key Lab Zoonosis Res,Chinese Minist Educ, Changchun, Peoples R China.; Qin, CF (corresponding author), Acad Mil Med Sci, Beijing Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Immune Microenvironm & Dis, Nanjing, Peoples R China.; Bai, CQ (corresponding author), Shenzhen Univ, Gen Hosp, Dept Resp & Crit Care Med, Shenzhen, Peoples R China.; Li, F (corresponding author), Jilin Univ, China Japan Union Hosp, Changchun, Peoples R China.	chenyun@njmu.edu.cn; baicq307@163.com; qincf@bmi.ac.cn; lifan@jlu.edu.cn	Qin, Cheng-Feng/I-6839-2019	Qin, Cheng-Feng/0000-0002-0632-2807	National Key Research and Development Project of China [2020YFC0842200, 2020YFA0707801]; National Natural Science Foundation [82041044]; National Science Fund for Distinguished Young Scholar [81925025]; NSFC [2019-I2M-5-049]; Innovation Fund for Medical Sciences [JK2020NC002]; Chinese Academy of Medical Sciences; AMS [81621005]	National Key Research and Development Project of China; National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Science Fund for Distinguished Young Scholar(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); NSFC(National Natural Science Foundation of China (NSFC)); Innovation Fund for Medical Sciences; Chinese Academy of Medical Sciences; AMS	This work was supported by the National Key Research and Development Project of China (2020YFC0842200, and 2020YFA0707801), the Special Grant from AMS (JK2020NC002), and the National Natural Science Foundation (No. 82041044). C-FQ was supported by the National Science Fund for Distinguished Young Scholar (No. 81925025), and the Innovative Research Group (No. 81621005) from the NSFC, and the Innovation Fund for Medical Sciences (No.2019-I2M-5-049) from the Chinese Academy of Medical Sciences.	Bertoletti A, 2021, CELL MOL IMMUNOL, V18, P2307, DOI 10.1038/s41423-021-00743-3; Bok K, 2021, IMMUNITY, V54, P1636, DOI 10.1016/j.immuni.2021.07.017; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6; Cheng ML, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00559-7; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Hsieh LE, 2022, J REPROD IMMUNOL, V149, DOI 10.1016/j.jri.2021.103464; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Johns Hopkins University, 2021, COR RES CTR; Krammer F, 2020, NATURE, V586, P516, DOI 10.1038/s41586-020-2798-3; Lederer K, 2022, CELL, V185, P1008, DOI 10.1016/j.cell.2022.01.027; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Reynolds CJ, 2021, SCIENCE, V372, P1418, DOI 10.1126/science.abh1282; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.21203/rs.3.rs-57112/v1, 10.1101/2020.08.11.20171843]; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Singh V, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.155145; Stephens DS, 2020, JAMA-J AM MED ASSOC, V324, P1279, DOI 10.1001/jama.2020.16656; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Wang C, 2020, LANCET, V395, P470, DOI 10.1016/S0140-6736(20)30185-9; Wang DW, 2020, J COASTAL RES, P1, DOI [10.1001/jama.2020.1585, 10.2112/JCR-SI109-001.1]; World Health Organization, 2021, NATURE, DOI DOI 10.1101/2020.06.17.156455; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Zhang F, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00263-y; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhou RH, 2020, IMMUNITY, V53, P864, DOI 10.1016/j.immuni.2020.07.026; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	32	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								911859	10.3389/fimmu.2022.911859	http://dx.doi.org/10.3389/fimmu.2022.911859			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V7ZM	35663993	Green Published, gold			2022-12-18	WOS:000806303500001
J	De Santis, F; Lopez, AB; Virtuoso, S; Poerio, N; Saccomandi, P; Olimpieri, T; Duca, L; De Angelis, LH; Aquilano, K; D'Andrea, MM; Aquaro, S; Borsetti, A; Ceccherini-Silberstein, F; Fraziano, M				De Santis, Federica; Lopez, Ana Borrajo; Virtuoso, Sara; Poerio, Noemi; Saccomandi, Patrizia; Olimpieri, Tommaso; Duca, Leonardo; De Angelis, Lucia Henrici; Aquilano, Katia; D'Andrea, Marco Maria; Aquaro, Stefano; Borsetti, Alessandra; Ceccherini-Silberstein, Francesca; Fraziano, Maurizio			Phosphatidylcholine Liposomes Down-Modulate CD4 Expression Reducing HIV Entry in Human Type-1 Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						host-directed therapy; liposome; phosphatidylcholine; macrophage; HIV entry	POLARIZATION; RESERVOIRS; PNEUMONIA; MEMBRANE; LIPIDS	A strategy adopted to combat human immunodeficiency virus type-1 (HIV-1) infection is based on interfering with virus entry into target cells. In this study, we found that phosphatidylcholine (PC) liposomes reduced the expression of the CD4 receptor in human primary type-1 macrophages but not in CD4(+) T cells. The down-regulation was specific to CD4, as any effect was not observed in CCR5 membrane expression. Moreover, the reduction of membrane CD4 expression required the Ca2+-independent protein kinase C (PKC), which in turn mediated serine phosphorylation in the intracytoplasmic tail of the CD4 receptor. Serine phosphorylation of CD4 was also associated with its internalization and degradation in acidic compartments. Finally, the observed CD4 downregulation induced by PC liposomes in human primary macrophages reduced the entry of both single-cycle replication and replication competent R5 tropic HIV-1. Altogether, these results show that PC liposomes reduce HIV entry in human macrophages and may impact HIV pathogenesis by lowering the viral reservoir.	[De Santis, Federica; Poerio, Noemi; Olimpieri, Tommaso; De Angelis, Lucia Henrici; Aquilano, Katia; D'Andrea, Marco Maria; Fraziano, Maurizio] Univ Roma Tor Vergata, Dipartimento Biol, Rome, Italy; [Lopez, Ana Borrajo; Saccomandi, Patrizia; Duca, Leonardo; Ceccherini-Silberstein, Francesca] Univ Roma Tor Vergata, Dipartimento Med Sperimentale, Rome, Italy; [Virtuoso, Sara; Borsetti, Alessandra] Ctr Nazl Ric HIV AIDS, Ist Super Sanita, Rome, Italy; [De Angelis, Lucia Henrici] Univ Siena, Dipartimento Biotecnol Med, Siena, Italy; [Aquaro, Stefano] Univ Calabria, Dipartimento Farm & Sci Salute & Nutr, Arcavacata Di Rende, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS); University of Siena; University of Calabria	Fraziano, M (corresponding author), Univ Roma Tor Vergata, Dipartimento Biol, Rome, Italy.	fraziano@bio.uniroma2.it	Aquaro, Stefano/GQY-7881-2022	Aquaro, Stefano/0000-0002-8417-2103; Henrici De Angelis, Lucia/0000-0003-0918-1584				Acchioni C, 2019, J VIROL, V93, DOI 10.1128/JVI.00495-19; Alteri C, 2019, J CLIN VIROL, V117, P61, DOI 10.1016/j.jcv.2019.06.004; Aquaro S, 2002, J MED VIROL, V68, P479, DOI 10.1002/jmv.10245; Aquaro S, 2020, VIRULENCE, V11, P400, DOI 10.1080/21505594.2020.1760443; Benoit M, 2008, J IMMUNOL, V181, P3733, DOI 10.4049/jimmunol.181.6.3733; Borrajo A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55060297; Cassol E, 2010, J LEUKOCYTE BIOL, V87, P599, DOI 10.1189/jlb.1009673; Chaudhuri S, 2018, ANTIVIR RES, V155, P76, DOI 10.1016/j.antiviral.2018.05.005; Costiniuk CT, 2014, REV MED VIROL, V24, P35, DOI 10.1002/rmv.1772; Cribbs SK, 2019, AM J MED SCI, V358, P376, DOI 10.1016/j.amjms.2019.09.010; Cribbs SK, 2020, PHYSIOL REV, V100, P603, DOI 10.1152/physrev.00039.2018; Cribbs SK, 2015, AIDS RES HUM RETROV, V31, P64, DOI [10.1089/aid.2014.0133, 10.1089/AID.2014.0133]; Curreli F, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12060609; De Santis F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213150; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; Dewhurst JA, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07101-2; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; ESCAMILLA R, 1993, EUR RESPIR J, V6, P1301; Esmail H, 2018, ANNU REV IMMUNOL, V36, P603, DOI 10.1146/annurev-immunol-042617-053420; Eyster KM, 2007, ADV PHYSIOL EDUC, V31, P5, DOI 10.1152/advan.00088.2006; Feikin DR, 2004, LANCET INFECT DIS, V4, P445, DOI 10.1016/S1473-3099(04)01060-6; Ganor Y, 2019, NAT MICROBIOL, V4, P633, DOI 10.1038/s41564-018-0335-z; Geldmacher C, 2012, TRENDS IMMUNOL, V33, P207, DOI 10.1016/j.it.2012.01.011; Hemelaar J, 2013, J INFECTION, V66, P391, DOI 10.1016/j.jinf.2012.10.026; Huang L, 2009, RESPIROLOGY, V14, P474, DOI 10.1111/j.1440-1843.2009.01534.x; Jambo KC, 2014, MUCOSAL IMMUNOL, V7, P1116, DOI 10.1038/mi.2013.127; Johnston SH, 2009, J VIROL, V83, P11016, DOI 10.1128/JVI.01242-09; Joint United Nations Programme on HIV/AIDS, 2021, GLOBAL AIDS UPDATE; Joseph SB, 2014, J VIROL, V88, P1858, DOI 10.1128/JVI.02477-13; Kruize Z, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02828; Kumar A, 2014, VIRUSES-BASEL, V6, P1837, DOI 10.3390/v6041837; Kumar N, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00168-19; Lodge R, 2017, CELL REP, V21, P141, DOI 10.1016/j.celrep.2017.09.030; Lynch GW, 2006, IMMUNOL CELL BIOL, V84, P154, DOI 10.1111/j.1440-1711.2005.01403.x; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Paoletti A, 2019, J IMMUNOL, V203, P1766, DOI 10.4049/jimmunol.1900386; Pau AK, 2014, INFECT DIS CLIN N AM, V28, P371, DOI 10.1016/j.idc.2014.06.001; Poerio N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.532225; Poerio N, 2017, SCI REP-UK, V7, DOI 10.1038/srep45120; Reece MD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.768695; Ridolfi B, 2004, AIDS RES HUM RETROV, V20, P723, DOI 10.1089/0889222041524652; Rodrigues V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01698; Rullo EV, 2019, MOL MED REP, V19, P1987, DOI 10.3892/mmr.2019.9840; Salpini R, 2019, J INFECT DIS, V220, P1935, DOI 10.1093/infdis/jiz411; Raposo RAS, 2011, J IMMUNOL, V187, P748, DOI 10.4049/jimmunol.1003678; Sattentau QJ, 2016, CELL HOST MICROBE, V19, P304, DOI 10.1016/j.chom.2016.02.013; Schmidt R, 2006, CRIT CARE MED, V34, P2370, DOI 10.1097/01.CCM.0000234036.19145.52; Shaik MM, 2019, NATURE, V565, P318, DOI 10.1038/s41586-018-0804-9; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Shen R, 2009, J VIROL, V83, P3258, DOI 10.1128/JVI.01796-08; SHIN J, 1990, EMBO J, V9, P425, DOI 10.1002/j.1460-2075.1990.tb08127.x; Stevenson M, 2003, NAT MED, V9, P853, DOI 10.1038/nm0703-853; Sunshine H, 2017, CURR OPIN LIPIDOL, V28, P408, DOI 10.1097/MOL.0000000000000443; Verreck FAW, 2006, J LEUKOCYTE BIOL, V79, P285, DOI 10.1189/jlb.0105015; Yao YL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00792; Yu JY, 2019, J VIROL, V93, DOI 10.1128/JVI.01866-18; Zhen A, 2014, J VIROL, V88, P9934, DOI 10.1128/JVI.00616-14; Zhu YT, 2021, BMC BIOL, V19, DOI 10.1186/s12915-021-01068-3	58	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								830788	10.3389/fimmu.2022.830788	http://dx.doi.org/10.3389/fimmu.2022.830788			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U6YJ	35663973	gold, Green Published			2022-12-18	WOS:000805555300001
J	Del Borrello, G; Miano, M; Micalizzi, C; Lupia, M; Ceccherini, I; Grossi, A; Cavalli, A; Gustincich, S; Rusmini, M; Faraci, M; Dell'Orso, G; Ramenghi, U; Mesini, A; Ricci, E; Schiavone, M; Di Iorgi, N; Dufour, C				Del Borrello, Giovanni; Miano, Maurizio; Micalizzi, Concetta; Lupia, Michela; Ceccherini, Isabella; Grossi, Alice; Cavalli, Andrea; Gustincich, Stefano; Rusmini, Marta; Faraci, Maura; Dell'Orso, Gianluca; Ramenghi, Ugo; Mesini, Alessio; Ricci, Erica; Schiavone, Maurizio; Di Iorgi, Natascia; Dufour, Carlo			Sirolimus Restores Erythropoiesis and Controls Immune Dysregulation in a Child With Cartilage-Hair Hypoplasia: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						sirolimus; bone marrow failure disorders; cartilage-hair hypoplasia (CHH); pure red cell aplasia (PRCA); whole-genome sequencing (WGS)	ANEMIA; HISTORY; RNA	Cartilage-hair hypoplasia (CHH) is a syndromic immunodeficiency characterized by metaphyseal dysplasia, cancer predisposition, and varying degrees of anemia. It may present as severe combined immunodeficiency in infancy, or slowly progress until fully manifesting in late adolescence/adulthood. No targeted treatment is currently available, and patients are usually managed with supportive measures, or are offered a bone marrow transplant if the clinical phenotype is severe and a suitable donor is available. We report the case of a young girl presenting with transfusion-dependent erythropoietic failure and immunological features resembling autoimmune lymphoproliferative syndrome who responded well to empirical sirolimus. She later developed a marked growth delay, which was ultimately attributed to metaphyseal dysplasia. A diagnosis of CHH was reached through whole-genome sequencing (WGS), after a less sensitive genetic diagnostic strategy failed. The patient eventually underwent a haploidentical bone marrow transplant due to progressive combined immunodeficiency manifested as cryptococcal meningoencephalitis. This case illustrates the potential role of sirolimus in correcting anemia and partially controlling the immune aberrations associated with CHH, and serves as a reminder of the invaluable role of WGS in diagnosing patients with complex and atypical presentations.	[Del Borrello, Giovanni; Miano, Maurizio; Micalizzi, Concetta; Lupia, Michela; Dufour, Carlo] Ist Ric & Cura Carattere Scintif IRCCS Ist Giannin, Hematol Unit, Genoa, Italy; [Ceccherini, Isabella; Grossi, Alice; Rusmini, Marta] Ist Ric & Cura Carattere Scintif IRCCS Ist Giannin, Unita Operativa Semplice Dipartimentale UOSD Genet, Genoa, Italy; [Cavalli, Andrea; Gustincich, Stefano] Italian Inst Technol IIT, Genoa, Italy; [Faraci, Maura; Dell'Orso, Gianluca] Ist Ric & Cura Carattere Scintif IRCCS Ist Giannin, Hematopoiet Stem Cell Transplantat Unit, Genoa, Italy; [Ramenghi, Ugo] Regina Margher Hosp, Haematol Unit, Turin, Italy; [Ramenghi, Ugo] Univ Turin, Sch Med, Dept Publ Hlth & Pediat, Turin, Italy; [Mesini, Alessio; Ricci, Erica] Covid Hosp, Ist Ric & Cura Carattere Scintif IRCCS Ist Giannin, Dipartimento Sci Pediatr, Unita Operat Malattie Infett, Genoa, Italy; [Schiavone, Maurizio] St Maria Annunziata Hosp, Pediat Unit, Taranto, Italy; [Di Iorgi, Natascia] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy; [Di Iorgi, Natascia] Ist Ric & Cura Carattere Scintif IRCCS Ist Giannin, Dept Pediat, Genoa, Italy	Istituto Italiano di Tecnologia - IIT; University of Turin; University of Genoa; University of Genoa	Dufour, C (corresponding author), Ist Ric & Cura Carattere Scintif IRCCS Ist Giannin, Hematol Unit, Genoa, Italy.		Miano, Maurizio/AAE-7960-2019; rusmini, marta/K-7042-2016	Miano, Maurizio/0000-0002-9816-1704; rusmini, marta/0000-0002-3109-413X; CAVALLI, ANDREA/0000-0002-6370-1176	ERG S.p.A.; Italian Ministry of Health (Ricerca Finalizzata) [RF-2018-12366314]	ERG S.p.A.; Italian Ministry of Health (Ricerca Finalizzata)(Ministry of Health, Italy)	We acknowledge ERG S.p.A., Rimorchiatori Riuniti (Genoa), Cambiaso Risso Marine (Genoa), Saar Depositi Oleari Portuali (Genoa), ONLUS Nicola Ferrari, and Ministero della Salute-Ricerca corrente 2021 for supporting the activity of Hematology Unit of IRCCS Istituto Giannina Gaslini. The whole-genome sequencing (WGS) analysis was supported by the Italian Ministry of Health (Ricerca Finalizzata RF-2018-12366314 to IC).	Acar M., 2020, BLOOD, V136, P17, DOI [10.1182/blood-2020-137392l72, DOI 10.1182/BLOOD-2020-137392L72]; Adams DM, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-3257; Bick D, 2019, J MED GENET, V56, P783, DOI 10.1136/jmedgenet-2019-106111; Biggs CM, 2017, J CLIN IMMUNOL, V37, P508, DOI 10.1007/s10875-017-0408-4; Bordon V, 2010, BLOOD, V116, P27, DOI 10.1182/blood-2010-01-259168; Bride KL, 2016, BLOOD, V127, P17, DOI 10.1182/blood-2015-07-657981; Cooper MA, 2021, J ALLER CL IMM-PRACT, V9, P628, DOI 10.1016/j.jaip.2020.11.055; Coulter TI, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02043; de la Fuente MA, 2011, J ALLERGY CLIN IMMUN, V128, P139, DOI 10.1016/j.jaci.2011.03.042; Dowdell KC, 2010, BLOOD, V115, P5164, DOI 10.1182/blood-2010-01-263145; Farrar JE, 2014, AM J HEMATOL, V89, P985, DOI 10.1002/ajh.23807; Goldfarbi KC, 2017, GENE DEV, V31, P59, DOI 10.1101/gad.286963.116; Grossi A, 2021, GENES-BASEL, V12, DOI 10.3390/genes12091299; JUVONEN E, 1995, EUR J PEDIATR, V154, P30, DOI 10.1007/BF01972969; MAKITIE O, 1993, EUR J PEDIATR, V152, P211, DOI 10.1007/BF01956147; Meienberg J, 2016, HUM GENET, V135, P359, DOI 10.1007/s00439-015-1631-9; Miano M, 2021, AM J HEMATOL, V96, P1077, DOI 10.1002/ajh.26242; Miano M, 2014, BRIT J HAEMATOL, V167, P571, DOI 10.1111/bjh.13010; Recasens-Alvarez C, 2021, NAT CELL BIOL, V23, P127, DOI 10.1038/s41556-020-00626-1; Vakkilainen S, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12913; Vakkilainen S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50334-6; Vakkilainen S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01581; Volkl S, 2016, BLOOD, V128, P227, DOI 10.1182/blood-2015-11-685024; Williams MS, 2005, AM J MED GENET A, V138A, P35, DOI 10.1002/ajmg.a.30902; Zhang X, 2014, AM J HEMATOL, V89, P954, DOI 10.1002/ajh.23786	25	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								893000	10.3389/fimmu.2022.893000	http://dx.doi.org/10.3389/fimmu.2022.893000			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V6MQ	35663969	gold, Green Published			2022-12-18	WOS:000806201900001
J	Hamedi, KR; Harmon, KA; Goodwin, RL; Arce, S				Hamedi, Kamron R.; Harmon, Katrina A.; Goodwin, Richard L.; Arce, Sergio			Autophagy and the Bone Marrow Microenvironment: A Review of Protective Factors in the Development and Maintenance of Multiple Myeloma	FRONTIERS IN IMMUNOLOGY			English	Review						multiple myeloma; autophagy; bone marrow microenvironment; unfolded protein response; plasma cells; drug-resistance	UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; PLASMA-CELL DIFFERENTIATION; NECROSIS-FACTOR-ALPHA; STROMAL CELLS; ER STRESS; BORTEZOMIB-RESISTANCE; MESSENGER-RNA; TRANSCRIPTION; FIBRONECTIN	The role of the unfolded protein response (UPR) in plasma cells (PC) and their malignant multiple myeloma (MM) counterparts is a well described area of research. The importance of autophagy in these cells, as well as the interplay between autophagy and the UPR system, has also been well studied. In this review, we will discuss the relationship between these two cellular responses and how they can be utilized in MM to account for the high levels of monoclonal immunoglobulin (Ig) protein synthesis that is characteristic of this disease. Interactions between MM cells and the bone marrow (BM) microenvironment and how MM cells utilize the UPR/autophagy pathway for their survival. These interacting pathways form the foundation for the mechanism of action for bortezomib, a proteasome inhibitor used to modify the progression of MM, and the eventual drug resistance that MM cells develop. One important resistance pathway implicated in MM progression is caspase 10 which attenuates autophagy to maintain its prosurvival function and avoid cell death. We lay a groundwork for future research including 3D in vitro models for better disease monitoring and personalized treatment. We also highlight pathways involved in MM cell survival and drug resistance that could be used as new targets for effective treatment.	[Hamedi, Kamron R.] Univ South Carolina, Sch Med Greenville, Greenville, SC 29208 USA; [Harmon, Katrina A.] Organogenesis, Res & Dev Dept, Birmingham, AL USA; [Goodwin, Richard L.; Arce, Sergio] Univ South Carolina, Sch Med Greenville, Biomed Sci, Greenville, SC USA; [Arce, Sergio] Prisma Hlth Canc Inst, Prisma Hlth Syst, Greenville, SC USA	Greenville Health System	Hamedi, KR (corresponding author), Univ South Carolina, Sch Med Greenville, Greenville, SC 29208 USA.	Khamedi@email.sc.edu	Arce, Sergio/J-9767-2019	Goodwin, Richard/0000-0002-2537-2535; Harmon, Katrina/0000-0002-2167-3816; Arce, Sergio/0000-0003-3605-6922				Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124; Baumann K., 2014, NAT REV MOL CELL BIO, V15, P5, DOI [10.1038/nrm3730, DOI 10.1038/NRM3730]; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Blagosklonny MV, 2013, AUTOPHAGY, V9, P260, DOI 10.4161/auto.22783; Bossen C, 2006, SEMIN IMMUNOL, V18, P263, DOI 10.1016/j.smim.2006.04.006; Carrasco DR, 2007, CANCER CELL, V11, P349, DOI 10.1016/j.ccr.2007.02.015; Carroll RG, 2013, CANCER CELL, V23, P425, DOI 10.1016/j.ccr.2013.04.001; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119; Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08; De Veirman K, 2014, CANCERS, V6, P1363, DOI 10.3390/cancers6031363; Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001; Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009; Epstein Joshua, 2003, Hematol J, V4, P310, DOI 10.1038/sj.thj.6200313; Frassanito MA, 2016, LEUKEMIA, V30, P640, DOI 10.1038/leu.2015.289; Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483; Garcia-Carmona Y, 2015, BLOOD, V125, P1749, DOI 10.1182/blood-2014-05-575845; Grootjans J, 2016, NAT REV IMMUNOL, V16, P469, DOI 10.1038/nri.2016.62; Gu JY, 2021, CYTOKINE, V138, DOI 10.1016/j.cyto.2020.155358; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Harmon KA, 2022, MICROSC MICROANAL, V28, P254, DOI 10.1017/S1431927621013805; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Hoang B, 2009, MOL CANCER THER, V8, P1974, DOI 10.1158/1535-7163.MCT-08-1177; Holt RU, 2005, HAEMATOLOGICA, V90, P479; Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200; Hu JS, 2012, DIS MODEL MECH, V5, P763, DOI 10.1242/dmm.008961; Ishikawa T, 2017, ELIFE, V6, DOI [10.7554/eLife.26845.001, 10.7554/eLife.26845]; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Jourdan M, 2014, LEUKEMIA, V28, P1647, DOI 10.1038/leu.2014.61; Jung G, 2015, ACTA HAEMATOL-BASEL, V134, P17, DOI 10.1159/000368848; Kaufman DM, 2017, CELL DEATH DIFFER, V24, P1730, DOI 10.1038/cdd.2017.101; Kawano Y, 2015, IMMUNOL REV, V263, P160, DOI 10.1111/imr.12233; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Khodadadi L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00721; Khongthong P, 2019, ENDOCR-RELAT CANCER, V26, pR369, DOI 10.1530/ERC-19-0087; Kim SG, 2013, MOL CELLS, V35, P463, DOI 10.1007/s10059-013-0138-2; Kopp MC, 2019, NAT STRUCT MOL BIOL, V26, P1053, DOI 10.1038/s41594-019-0324-9; Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017; Lee AH, 2005, EMBO J, V24, P4368, DOI 10.1038/sj.emboj.7600903; Levitin F, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100505; Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z; Malek MAYA, 2015, ONCOTARGET, V6, P3098; Masaki R, 2016, INT J MYELOMA, V6, P1; Mason CAE, 1999, FASEB J, V13, P1423, DOI 10.1096/fasebj.13.11.1423; Mateos Maria-Victoria, 2016, Cancer Treat Res, V169, P3; Michallet AS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025820; Milan E, 2016, J CLIN IMMUNOL, V36, pS18, DOI 10.1007/s10875-016-0254-9; Milan E, 2015, AUTOPHAGY, V11, P1161, DOI 10.1080/15548627.2015.1052928; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Murray MY, 2015, CELL CYCLE, V14, P2367, DOI 10.1080/15384101.2014.998067; Nihira K, 2014, CANCER SCI, V105, P568, DOI 10.1111/cas.12396; Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood-2003-06-2043; O'Blenes CAE, 2001, CIRC RES, V89, P26, DOI 10.1161/hh1301.093631; Oliva L, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00103; Park SM, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9070791; Pengo N, 2013, NAT IMMUNOL, V14, P298, DOI 10.1038/ni.2524; Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Romero-Ramirez L, 2004, CANCER RES, V64, P5943, DOI 10.1158/0008-5472.CAN-04-1606; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sprangers B., 2014, KIDNEY TRANSPLANTATI, P320; Tanida I, 2011, MICROBIOL IMMUNOL, V55, P1, DOI 10.1111/j.1348-0421.2010.00271.x; VanderVeldeZimmermann D, 1997, EXP CELL RES, V230, P111, DOI 10.1006/excr.1996.3405; Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101; Vincenz L, 2013, MOL CANCER THER, V12, P831, DOI 10.1158/1535-7163.MCT-12-0782; Wen XY, 1999, INT J ONCOL, V15, P173; Wirawan E, 2012, AUTOPHAGY, V8, P6, DOI 10.4161/auto.8.1.16645; Wols HAM, 2002, J IMMUNOL, V169, P4213, DOI 10.4049/jimmunol.169.8.4213; Yan YL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1172-5; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yu B, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00962-7; Yu Z, 2017, J CEREBR BLOOD F MET, V37, P1069, DOI 10.1177/0271678X16650218; Zeng R, 2012, ACTA PHARMACOL SIN, V33, P91, DOI 10.1038/aps.2011.143; Zhang WT, 2014, TISSUE ENG PART C-ME, V20, P663, DOI [10.1089/ten.TEC.2013.0490, 10.1089/ten.tec.2013.0490]; Zhang ZY, 2021, AUTOPHAGY, V17, P1841, DOI 10.1080/15548627.2020.1788889; Zhou Y, 2009, LEUKEMIA, V23, P1941, DOI 10.1038/leu.2009.160; Zismanov V, 2009, BRIT J CANCER, V101, P1402, DOI 10.1038/sj.bjc.6605291	84	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								889954	10.3389/fimmu.2022.889954	http://dx.doi.org/10.3389/fimmu.2022.889954			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U8DT	35663979	Green Published, gold			2022-12-18	WOS:000805637000001
J	Heinrich, B; Korangy, F				Heinrich, Bernd; Korangy, Firouzeh			Plasticity of Innate Lymphoid Cells in Cancer	FRONTIERS IN IMMUNOLOGY			English	Review						innate immunity; plasticity; tumor microenvironment; immunotherapy; cancer	FUNCTIONAL PLASTICITY; NK CELLS; T-BET; DIFFERENTIATION; IMMUNITY; FATE; HETEROGENEITY; INFLAMMATION; CYTOTOXICITY; HOMEOSTASIS	Innate lymphoid cells (ILCs) are a heterogenous population of the innate immune system, enriched at mucosal surfaces and are pivotal regulators of immune homeostasis. ILCs are the innate counterpart of T cells. Like T cells, ILC subsets are highly plastic with their composition and function controlled by alterations in their microenvironment. This plasticity allows for the trans-differentiation between the subsets to rapidly respond to their immune environment. The tumor microenvironment (TME) is a heterogeneous milieu characterized by different cytokines and growth factors. Through interaction with the tumor microenvironment, ILCs can transdifferentiate into different subsets resulting in pro or anti-tumor immunity. Thus, studying ILC plasticity might result in new therapeutic approaches for cancer therapy. In this review, we summarize current findings of the functional and plastic heterogeneity of ILCs in homeostasis as well as disease settings with a specific focus on cancer. We specifically highlight tumor-driven plasticity and how ILC-induced inflammation can impact the tumor microenvironment and anti-tumor immunity.	[Heinrich, Bernd; Korangy, Firouzeh] NCI, NIH, Ctr Canc Res, Thorac & Gastrointestinal Malignancies Branch, Bethesda, MD 20892 USA; [Heinrich, Bernd] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hannover Medical School	Korangy, F (corresponding author), NCI, NIH, Ctr Canc Res, Thorac & Gastrointestinal Malignancies Branch, Bethesda, MD 20892 USA.	Firouzeh.korangy@nih.gov			Intramural Research Program of the NIH; Intramural Research Program of NIH, NCI [ZIA BC 011345]	Intramural Research Program of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of NIH, NCI	This project was supported by the Intramural Research Program of the NIH, NCI (ZIA BC 011345).	Abt MC, 2015, CELL HOST MICROBE, V18, P27, DOI 10.1016/j.chom.2015.06.011; An ZW, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03111; Artis D, 2015, NATURE, V517, P293, DOI 10.1038/nature14189; Bal SM, 2020, NAT REV IMMUNOL, V20, P552, DOI 10.1038/s41577-020-0282-9; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bald T, 2019, SEMIN IMMUNOL, V41, DOI 10.1016/j.smim.2019.04.001; Bando JK, 2020, J EXP MED, V217, DOI 10.1084/jem.20191520; Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; Bernink JH, 2013, NAT IMMUNOL, V14, P221, DOI 10.1038/ni.2534; Bjorklund AK, 2016, NAT IMMUNOL, V17, P451, DOI 10.1038/ni.3368; Bruchard M, 2022, NAT IMMUNOL, V23, P262, DOI 10.1038/s41590-021-01120-y; Camelo A, 2017, BLOOD ADV, V1, P577, DOI 10.1182/bloodadvances.2016002352; Cella M, 2019, NAT IMMUNOL, V20, P980, DOI 10.1038/s41590-019-0425-y; Colonna M, 2018, IMMUNITY, V48, P1104, DOI 10.1016/j.immuni.2018.05.013; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; Cortez VS, 2015, CURR OPIN IMMUNOL, V32, P71, DOI 10.1016/j.coi.2015.01.004; Crome SQ, 2017, NAT MED, V23, P368, DOI 10.1038/nm.4278; Cuff AO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02180; Dadi S, 2016, CELL, V164, P365, DOI 10.1016/j.cell.2016.01.002; Diefenbach A, 2014, IMMUNITY, V41, P354, DOI 10.1016/j.immuni.2014.09.005; Ducimetiere L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02895; Duerr CU, 2016, CYTOKINE, V87, P1, DOI 10.1016/j.cyto.2016.01.018; DuPage M, 2016, NAT REV IMMUNOL, V16, P149, DOI 10.1038/nri.2015.18; Eberl G, 2015, SCIENCE, V348, DOI 10.1126/science.aaa6566; Eisenring M, 2010, NAT IMMUNOL, V11, P1030, DOI 10.1038/ni.1947; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Forkel M, 2019, J CROHNS COLITIS, V13, P67, DOI 10.1093/ecco-jcc/jjy119; Fuchs A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00104; Fuchs A, 2013, IMMUNITY, V38, P769, DOI 10.1016/j.immuni.2013.02.010; Galli SJ, 2011, NAT IMMUNOL, V12, P1035, DOI 10.1038/ni.2109; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Golebski K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09883-7; Gury-BenAri M, 2016, CELL, V166, P1231, DOI 10.1016/j.cell.2016.07.043; Hawke LG, 2020, J IMMUNOL, V204, P3171, DOI 10.4049/jimmunol.1900866; Hazenberg MD, 2014, BLOOD, V124, P700, DOI 10.1182/blood-2013-11-427781; Heinrich B, 2022, GUT, V71, P1161, DOI 10.1136/gutjnl-2021-325288; Hepworth MR, 2015, SCIENCE, V348, P1031, DOI 10.1126/science.aaa4812; Hochdorfer T, 2019, EUR J IMMUNOL, V49, P884, DOI 10.1002/eji.201848006; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Huang YF, 2018, SCIENCE, V359, P114, DOI 10.1126/science.aam5809; Huang YF, 2016, INT IMMUNOL, V28, P23, DOI 10.1093/intimm/dxv044; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Hughes T, 2014, CELL REP, V8, P150, DOI 10.1016/j.celrep.2014.05.042; Jiao YH, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00426; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Kumar V, 2020, J LEUKOCYTE BIOL, V108, P397, DOI 10.1002/JLB.4MIR0420-500RRR; Kumar V, 2021, INT REV IMMUNOL, V40, P217, DOI 10.1080/08830185.2021.1895145; Li N, 2018, J EXP MED, V215, P1383, DOI 10.1084/jem.20171934; Li Y, 2019, CELL MOL IMMUNOL, V16, P75, DOI 10.1038/s41423-018-0182-0; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Liu MF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00695; Liu YH, 2019, EBIOMEDICINE, V41, P333, DOI 10.1016/j.ebiom.2019.02.050; Maggi L, 2020, IMMUNOL LETT, V227, P109, DOI 10.1016/j.imlet.2020.08.004; Mchedlidze T, 2013, IMMUNITY, V39, P357, DOI 10.1016/j.immuni.2013.07.018; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moral JA, 2020, NATURE, V579, P130, DOI 10.1038/s41586-020-2015-4; Moreno-Nieves UY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101169118; Ohne Y, 2016, NAT IMMUNOL, V17, P646, DOI 10.1038/ni.3447; Park E, 2019, ELIFE, V8, DOI 10.7554/eLife.47605; Parker ME, 2020, J EXP MED, V217, DOI 10.1084/jem.20191030; Qi JJ, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100353; Qiu J, 2012, IMMUNITY, V36, P92, DOI 10.1016/j.immuni.2011.11.011; Rankin LC, 2013, NAT IMMUNOL, V14, P389, DOI 10.1038/ni.2545; Raykova A, 2017, BLOOD ADV, V1, P2679, DOI 10.1182/bloodadvances.2017008839; Ricardo-Gonzalez RR, 2018, NAT IMMUNOL, V19, P1093, DOI 10.1038/s41590-018-0201-4; Robinette ML, 2015, NAT IMMUNOL, V16, P306, DOI 10.1038/ni.3094; Salimi M, 2016, J IMMUNOL, V196, P45, DOI 10.4049/jimmunol.1501102; Sciume G, 2012, J EXP MED, V209, P2331, DOI 10.1084/jem.20122097; Scoville SD, 2019, CURR OPIN IMMUNOL, V56, P100, DOI 10.1016/j.coi.2018.11.003; Sheppard S, 2018, CELL REP, V22, P3385, DOI 10.1016/j.celrep.2018.03.023; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Simoni Y, 2017, IMMUNITY, V46, P148, DOI 10.1016/j.immuni.2016.11.005; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Teng F, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.110051; Tugues S, 2019, SEMIN IMMUNOL, V41, DOI 10.1016/j.smim.2019.03.002; Verrier T, 2016, J IMMUNOL, V196, P4731, DOI 10.4049/jimmunol.1502673; Vienne M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.768989; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vonarbourg C, 2010, IMMUNITY, V33, P736, DOI 10.1016/j.immuni.2010.10.017; Wang S, 2020, CELL RES, V30, P610, DOI 10.1038/s41422-020-0312-y; Wang S, 2017, CELL, V171, P201, DOI 10.1016/j.cell.2017.07.027; Weizman OE, 2017, CELL, V171, P795, DOI 10.1016/j.cell.2017.09.052; Xu XY, 2021, HEPATOLOGY, V74, P2526, DOI 10.1002/hep.31855; Yomogida K, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2117965118; Yuan XD, 2021, EUR J IMMUNOL, V51, P2188, DOI 10.1002/eji.202049033; Zeng BN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1540-2; Zhang KN, 2017, J IMMUNOL, V198, P1798, DOI 10.4049/jimmunol.1601421; Zhou L, 2022, NAT IMMUNOL, V23, P251, DOI 10.1038/s41590-021-01110-0; Zook EC, 2016, NAT IMMUNOL, V17, P775, DOI 10.1038/ni.3481	94	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								886520	10.3389/fimmu-13-886520	http://dx.doi.org/10.3389/fimmu-13-886520			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V7IV	35663967	Green Published, gold			2022-12-18	WOS:000806259600001
J	Herrada, AA; Olate-Briones, A; Lazo-Amador, R; Liu, CH; Hernandez-Rojas, B; Riadi, G; Escobedo, N				Herrada, Andres A.; Olate-Briones, Alexandra; Lazo-Amador, Rodrigo; Liu, Chaohong; Hernandez-Rojas, Bairon; Riadi, Gonzalo; Escobedo, Noelia			Lymph Leakage Promotes Immunosuppression by Enhancing Anti-Inflammatory Macrophage Polarization	FRONTIERS IN IMMUNOLOGY			English	Article						lymphatic vasculature; macrophages; inflammation; cancer; inflammatory bowel disease	PRIMARY INTESTINAL LYMPHANGIECTASIA; INFLAMMATORY-BOWEL-DISEASE; DYSFUNCTION; CANCER; VASCULATURE; METASTASIS; OBESITY; LYMPHANGIOGENESIS; INFILTRATION; INFECTION	Lymphatic vasculature is a network of capillaries and vessels capable of draining extracellular fluid back to blood circulation and to facilitate immune cell migration. Although the role of the lymphatic vasculature as coordinator of fluid homeostasis has been extensively studied, the consequences of abnormal lymphatic vasculature function and impaired lymph drainage have been mostly unexplored. Here, by using the Prox1(+/-) mice with defective lymphatic vasculature and lymphatic leakage, we provide evidence showing that lymph leakage induces an immunosuppressive environment by promoting anti-inflammatory M2 macrophage polarization in different inflammatory conditions. In fact, by using a mouse model of tail lymphedema where lymphatic vessels are thermal ablated leading to lymph accumulation, an increasing number of anti-inflammatory M2 macrophages are found in the lymphedematous tissue. Moreover, RNA-seq analysis from different human tumors shows that reduced lymphatic signature, a hallmark of lymphatic dysfunction, is associated with increased M2 and reduced M1 macrophage signatures, impacting the survival of the patients. In summary, we show that lymphatic vascular leakage promotes an immunosuppressive environment by enhancing anti-inflammatory macrophage differentiation, with relevance in clinical conditions such as inflammatory bowel diseases or cancer.	[Herrada, Andres A.; Olate-Briones, Alexandra; Lazo-Amador, Rodrigo; Escobedo, Noelia] Univ Autonoma Chile, Fac Ciencias Salud, Lymphat Vasculature & Inflammat Res Lab, Inst Ciencias Biomed, Talca, Chile; [Liu, Chaohong] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Basic Med, Dept Pathogen Biol, Wuhan, Peoples R China; [Hernandez-Rojas, Bairon] Univ Talca, Fac Engn, PhD Program Sci Ment Modeling Chem & Biol Syst, Talca, Chile; [Riadi, Gonzalo] Univ Talca, Fac Engn, Ctr Bioinformat Simulat & Modeling, Dept Bioinformat,Agencia Nacl Invest & Desarrollo, Talca, Chile	Universidad Autonoma de Chile; Huazhong University of Science & Technology; Universidad de Talca; Universidad de Talca	Herrada, AA; Escobedo, N (corresponding author), Univ Autonoma Chile, Fac Ciencias Salud, Lymphat Vasculature & Inflammat Res Lab, Inst Ciencias Biomed, Talca, Chile.				FONDECYT de inicio [11190253, 11160592]; ANID - Millennium Science Initiative Program [NCN19_168]; FONDEQUIP [EQM160063]; FONDECYT Regular [11140869, 1201562]; ANID - Doctoral Fellowship [21201090]; Pew Charitable Trusts	FONDECYT de inicio(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); ANID - Millennium Science Initiative Program; FONDEQUIP; FONDECYT Regular(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); ANID - Doctoral Fellowship; Pew Charitable Trusts	This work was funded by the following grants: FONDECYT de inicio No 11190253 (AH), ANID - Millennium Science Initiative Program NCN19_168, FONDEQUIP EQM160063 and FONDECYT Regular No 11140869 (GR), FONDECYT de inicio No 11160592 and FONDECYT Regular No 1201562 (NE), and ANID - Doctoral Fellowship No 21201090 (BH-R). AH is a Latin American Fellow in the Biomedical Sciences, supported by The Pew Charitable Trusts.	Aldrich MB, 2020, CANCERS, V12, DOI 10.3390/cancers12082280; Alexander JS, 2010, ANN NY ACAD SCI, V1207, pE75, DOI 10.1111/j.1749-6632.2010.05757.x; Aspelund A, 2014, J CLIN INVEST, V124, P3975, DOI 10.1172/JCI75395; Bain CC, 2013, MUCOSAL IMMUNOL, V6, P498, DOI 10.1038/mi.2012.89; Baird JB, 2002, AM J TROP MED HYG, V66, P163, DOI 10.4269/ajtmh.2002.66.163; Bhat M, 2011, GASTROINTEST ENDOSC, V74, P718, DOI 10.1016/j.gie.2010.09.019; Biswas SK, 2015, IMMUNITY, V43, P435, DOI 10.1016/j.immuni.2015.09.001; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Braune J, 2017, J IMMUNOL, V198, P2927, DOI 10.4049/jimmunol.1600476; Brouillard P, 2014, J CLIN INVEST, V124, P898, DOI 10.1172/JCI71614; Cao LL, 2019, CANCER MANAG RES, V11, P6125, DOI 10.2147/CMAR.S199832; Carlson JA, 2014, CLIN DERMATOL, V32, P599, DOI 10.1016/j.clindermatol.2014.04.007; Chakraborty S, 2013, MICROCIRCULATION, V20, P349, DOI 10.1111/micc.12031; Cheng HY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00421; D'Alessio S, 2014, J CLIN INVEST, V124, P3863, DOI 10.1172/JCI72189; Da Mesquita S., 2014, J CLIN INVEST, V124, P3975, DOI [10.1172/JCI75395, DOI 10.1172/JCI75395]; Dierselhuis MP, 2007, J PEDIATR GASTR NUTR, V44, P382, DOI 10.1097/01.mpg.0000233192.77521.2f; Dieterich LC, 2014, ANGIOGENESIS, V17, P359, DOI 10.1007/s10456-013-9406-1; Escobedo N, 2017, CELL METAB, V26, P598, DOI 10.1016/j.cmet.2017.07.020; Escobedo N, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85096; Escobedo N, 2016, ANNU REV CELL DEV BI, V32, P677, DOI 10.1146/annurev-cellbio-111315-124944; Fujiwara Nagatoshi, 2005, Current Drug Targets - Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024; Fukui S, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01958; Ghanta S, 2015, AM J PHYSIOL-HEART C, V308, pH1065, DOI 10.1152/ajpheart.00598.2014; Gousopoulos E, 2016, AM J PATHOL, V186, P2193, DOI 10.1016/j.ajpath.2016.04.006; Han XB, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.625423; Harvey NL, 2005, NAT GENET, V37, P1072, DOI 10.1038/ng1642; Herrada AA, 2020, LYMPHAT RES BIOL, V18, P136, DOI 10.1089/lrb.2019.0008; Hespe GE, 2016, J PHYSIOL-LONDON, V594, P4267, DOI 10.1113/JP271757; Hong JY, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-63; Horuluoglu BH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63143-z; Isaka N, 2004, CANCER RES, V64, P4400, DOI 10.1158/0008-5472.CAN-04-0752; Isidro RA, 2016, AM J PHYSIOL-GASTR L, V311, pG59, DOI 10.1152/ajpgi.00123.2016; Jackute J, 2018, BMC IMMUNOL, V19, DOI 10.1186/s12865-018-0241-4; Jha AK, 2015, IMMUNITY, V42, P419, DOI 10.1016/j.immuni.2015.02.005; Jiang XG, 2020, J ZHEJIANG UNIV-SC B, V21, P3, DOI 10.1631/jzus.B1800633; Ju AJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.709077; Jurisic G, 2013, INFLAMM BOWEL DIS, V19, P1983, DOI 10.1097/MIB.0b013e31829292f7; Karaman S, 2014, J CLIN INVEST, V124, P922, DOI 10.1172/JCI71606; Kataru RP, 2019, CANCER IMMUNOL RES, V7, P1345, DOI 10.1158/2326-6066.CIR-18-0337; Kerjaschki D, 2014, J CLIN INVEST, V124, P874, DOI 10.1172/JCI74854; Kimura T, 2015, ONCOTARGET, V6, P18081, DOI 10.18632/oncotarget.4018; Kowalczuk O, 2018, ONCOL LETT, V15, P6752, DOI 10.3892/ol.2018.8159; Kwon S, 2018, BIOMED OPT EXPRESS, V9, P4631, DOI 10.1364/BOE.9.004631; Kwon S, 2013, BIOMED OPT EXPRESS, V4, P967, DOI 10.1364/BOE.4.000967; Labonte AC, 2014, MOL CELLS, V37, P275, DOI 10.14348/molcells.2014.2374; Lane RS, 2018, J EXP MED, V215, P3057, DOI 10.1084/jem.20180654; Lee C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4457-8; Lee SJ, 2015, WORLD J GASTROENTERO, V21, P8467, DOI 10.3748/wjg.v21.i27.8467; Liu BL, 2018, EXP THER MED, V16, P5009, DOI 10.3892/etm.2018.6852; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mortimer PS, 2014, J CLIN INVEST, V124, P915, DOI 10.1172/JCI71608; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nielsen SR, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9624760; Nitti MD, 2016, J PHYSIOL-LONDON, V594, P7073, DOI 10.1113/JP273061; Nores GDG, 2016, INT J OBESITY, V40, P1582, DOI 10.1038/ijo.2016.96; Nores GDG, 2018, J INVEST DERMATOL, V138, P325, DOI 10.1016/j.jid.2017.09.011; Ohtsuka Y, 2003, PEDIATR RES, V53, P143, DOI 10.1203/01.PDR.0000041519.16507.06; Orecchioni M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01084; Oshi M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73624-w; Padera TP, 2002, SCIENCE, V296, P1883, DOI 10.1126/science.1071420; Podgrabinska S, 2014, MICROVASC RES, V95, P46, DOI 10.1016/j.mvr.2014.07.004; Rahier JF, 2013, INFLAMM BOWEL DIS, V19, P2084, DOI 10.1097/MIB.0b013e3182971cec; Randhawa PK, 2014, KOREAN J PHYSIOL PHA, V18, P279, DOI 10.4196/kjpp.2014.18.4.279; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Rehal S, 2018, AM J PHYSIOL-GASTR L, V314, pG408, DOI 10.1152/ajpgi.00340.2017; Rigamonti A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017637; Rockson SG, 2010, ANN NY ACAD SCI, V1207, pE2, DOI 10.1111/j.1749-6632.2010.05804.x; Roig J, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01036; Schulze H, 2018, HEALTH ECON REV, V8, DOI 10.1186/s13561-018-0194-6; Shen WS, 2019, INFLAMM BOWEL DIS, V25, P283, DOI 10.1093/ibd/izy306; Shimizu Y, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000438; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Smith P, 2007, J IMMUNOL, V178, P4557, DOI 10.4049/jimmunol.178.7.4557; Speer AL, 2013, J PEDIAT SURG CASE R, V1, P425, DOI 10.1016/j.epsc.2013.10.014; Stephens M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00557; Sugaya M, 2012, J INVEST DERMATOL, V132, P667, DOI 10.1038/jid.2011.349; Turner JD, 2009, J BIOL CHEM, V284, P22364, DOI 10.1074/jbc.M901528200; Van Kruiningen HJ, 2014, APMIS, V122, P1125, DOI 10.1111/apm.12268; van Tits LJH, 2011, ATHEROSCLEROSIS, V214, P345, DOI 10.1016/j.atherosclerosis.2010.11.018; Vignes S, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-5; Wang SW, 2019, J PHARMACOL EXP THER, V368, P391, DOI 10.1124/jpet.118.254516; Wei JC, 2017, CLIN CANCER RES, V23, P214, DOI 10.1158/1078-0432.CCR-16-0741; Weisser SB, 2012, JOVE-J VIS EXP, DOI 10.3791/4105; Weisser SB, 2011, J LEUKOCYTE BIOL, V90, P483, DOI 10.1189/jlb.0311124; Wu YF, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135121; Zampell JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049940; Zhang XL, 2019, J CELL PHYSIOL, V234, P6917, DOI 10.1002/jcp.27450; Zhu YJ, 2017, INT J MOL MED, V40, P281, DOI 10.3892/ijmm.2017.3022	91	0	0	9	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								841641	10.3389/fimmu.2022.841641	http://dx.doi.org/10.3389/fimmu.2022.841641			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V7LT	35663931	gold, Green Published			2022-12-18	WOS:000806267200001
J	Hioki, K; Hayashi, T; Natsume-Kitatani, Y; Kobiyama, K; Temizoz, B; Negishi, H; Kawakami, H; Fuchino, H; Kuroda, E; Coban, C; Kawahara, N; Ishii, KJ				Hioki, Kou; Hayashi, Tomoya; Natsume-Kitatani, Yayoi; Kobiyama, Kouji; Temizoz, Burcu; Negishi, Hideo; Kawakami, Hitomi; Fuchino, Hiroyuki; Kuroda, Etsushi; Coban, Cevayir; Kawahara, Nobuo; Ishii, Ken J.			Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; adjuvant; machine learning; herbal extracts; mouse; human	RED GINSENG EXTRACT; CYCLIC GMP-AMP; IMMUNOLOGICAL ADJUVANT; NASAL INFLUENZA; PLATYCODON-GRANDIFLORUM; IMMUNE-RESPONSES; INNATE IMMUNITY; ORAL ADJUVANT; PARTICLE-SIZE; R-PACKAGE	Adjuvants are important vaccine components, composed of a variety of chemical and biological materials that enhance the vaccine antigen-specific immune responses by stimulating the innate immune cells in both direct and indirect manners to produce a variety cytokines, chemokines, and growth factors. It has been developed by empirical methods for decades and considered difficult to choose a single screening method for an ideal vaccine adjuvant, due to their diverse biochemical characteristics, complex mechanisms of, and species specificity for their adjuvanticity. We therefore established a robust adjuvant screening strategy by combining multiparametric analysis of adjuvanticity in vivo and immunological profiles in vitro (such as cytokines, chemokines, and growth factor secretion) of various library compounds derived from hot-water extracts of herbal medicines, together with their diverse distribution of nano-sized physical particle properties with a machine learning algorithm. By combining multiparametric analysis with a machine learning algorithm such as rCCA, sparse-PLS, and DIABLO, we identified that human G-CSF and mouse RANTES, produced upon adjuvant stimulation in vitro, are the most robust biological parameters that can predict the adjuvanticity of various library compounds. Notably, we revealed a certain nano-sized particle population that functioned as an independent negative parameter to adjuvanticity. Finally, we proved that the two-step strategy pairing the negative and positive parameters significantly improved the efficacy of screening and a screening strategy applying principal component analysis using the identified parameters. These novel parameters we identified for adjuvant screening by machine learning with multiple biological and physical parameters may provide new insights into the future development of effective and safe adjuvants for human use.	[Hioki, Kou; Hayashi, Tomoya; Kobiyama, Kouji; Temizoz, Burcu; Negishi, Hideo; Ishii, Ken J.] Univ Tokyo IMSUT, Inst Med Sci, Int Vaccine Design Ctr vDesC, Dept Microbiol & Immunol,Div Vaccine Sci, Tokyo, Japan; [Hioki, Kou; Hayashi, Tomoya; Kobiyama, Kouji; Temizoz, Burcu; Ishii, Ken J.] Natl Inst Biomed Innovat, Ctr Vaccine & Adjuvant Res Ctr CVAR, Lab Mockup Vaccine, Osaka, Japan; [Natsume-Kitatani, Yayoi] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Artificial Intelligence Ctr Hlth & Biomed Res, Lab Bioinformat, Osaka, Japan; [Kawakami, Hitomi; Fuchino, Hiroyuki; Kawahara, Nobuo] Natl Inst Biomed Innovat Hlth & Nutr NIBIOHN, Res Ctr Med Plant Resources, Ibaraki, Japan; [Kuroda, Etsushi] Hyogo Coll Med, Dept Immunol, Nishinomiya, Hyogo, Japan; [Coban, Cevayir] Univ Tokyo IMSUT, Inst Med Sci, Int Vaccine Design Ctr vDesC, Dept Microbiol & Immunol, Tokyo, Japan; [Coban, Cevayir; Ishii, Ken J.] Osaka Univ, Immunol Frontier Res Ctr IFReC, Osaka, Japan	National Institute of Health Sciences - Japan; Hyogo College of Medicine; Osaka University	Ishii, KJ (corresponding author), Univ Tokyo IMSUT, Inst Med Sci, Int Vaccine Design Ctr vDesC, Dept Microbiol & Immunol,Div Vaccine Sci, Tokyo, Japan.; Ishii, KJ (corresponding author), Natl Inst Biomed Innovat, Ctr Vaccine & Adjuvant Res Ctr CVAR, Lab Mockup Vaccine, Osaka, Japan.; Ishii, KJ (corresponding author), Osaka Univ, Immunol Frontier Res Ctr IFReC, Osaka, Japan.	kenishii@ims.u-tokyo.ac.jp		Hioki, Kou/0000-0003-4945-1032; Kawakami, Hitomi/0000-0002-5039-2378				Alexyuk PG, 2019, ARCH VIROL, V164, P1793, DOI 10.1007/s00705-019-04273-2; An HZ, 2002, IMMUNOL LETT, V81, P165, DOI 10.1016/S0165-2478(02)00010-X; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Balunas MJ, 2005, LIFE SCI, V78, P431, DOI 10.1016/j.lfs.2005.09.012; Bochkov Denis V, 2012, J Chem Biol, V5, P5, DOI 10.1007/s12154-011-0064-8; Butler MS, 2004, J NAT PROD, V67, P2141, DOI 10.1021/np040106y; Choi HW, 2019, SLAS DISCOV, V24, P628, DOI 10.1177/2472555219834699; Chun H, 2010, J R STAT SOC B, V72, P3, DOI 10.1111/j.1467-9868.2009.00723.x; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Cook TM, 2021, ANAESTHESIA, V76, P608, DOI 10.1111/anae.15442; De Gregorio E, 2014, NAT REV IMMUNOL, V14, P505, DOI 10.1038/nri3694; den Haan JMM, 2014, IMMUNOL LETT, V162, P103, DOI 10.1016/j.imlet.2014.10.011; Desmet CJ, 2012, NAT REV IMMUNOL, V12, P479, DOI 10.1038/nri3247; El-Murr T, 2018, J IMMUNOL METHODS, V459, P55, DOI 10.1016/j.jim.2018.05.005; Estrada A, 2000, COMP IMMUNOL MICROB, V23, P27, DOI 10.1016/S0147-9571(99)00020-X; Ezoe S, 2020, VACCINE, V38, P7246, DOI 10.1016/j.vaccine.2020.09.056; Fan YP, 2016, INT J BIOL MACROMOL, V82, P264, DOI 10.1016/j.ijbiomac.2015.10.084; Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041; Garcia-Cordero JL, 2013, INTEGR BIOL-UK, V5, P650, DOI 10.1039/c3ib20263a; Gonzalez I, 2008, J STAT SOFTW, V23, P1; Hayashi M, 2016, VACCINE, V34, P306, DOI 10.1016/j.vaccine.2015.11.059; Hayashi T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02619; Honegr J, 2018, MOLECULES, V23, DOI 10.3390/molecules23010102; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Iitsuka H, 2018, BIOCHEM BIOPHYS REP, V16, P62, DOI 10.1016/j.bbrep.2018.08.004; Iyer V, 2015, HUM VACC IMMUNOTHER, V11, P1853, DOI 10.1080/21645515.2015.1046660; Jablonska K, 2021, PUBLIC HEALTH, V198, P230, DOI 10.1016/j.puhe.2021.07.037; Jin SY, 2021, ANGEW CHEM INT EDIT, V60, P961, DOI 10.1002/anie.202011604; Katare YK, 2005, INT J PHARMACEUT, V301, P149, DOI 10.1016/j.ijpharm.2005.05.028; Katselis GS, 2007, CAN J PHYSIOL PHARM, V85, P1184, DOI 10.1139/Y07-109; Kim J, 2013, PHYTOMEDICINE, V20, P951, DOI 10.1016/j.phymed.2013.04.008; Kobiyama K, 2014, P NATL ACAD SCI USA, V111, P3086, DOI 10.1073/pnas.1319268111; Kong XF, 2004, INT IMMUNOPHARMACOL, V4, P975, DOI 10.1016/j.intimp.2004.03.008; Kuroda E, 2013, INT REV IMMUNOL, V32, P209, DOI 10.3109/08830185.2013.773326; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Le Cao KA, 2009, BIOINFORMATICS, V25, P2855, DOI 10.1093/bioinformatics/btp515; Le Cao KA, 2008, STAT APPL GENET MOL, V7, DOI 10.2202/1544-6115.1390; Lee JS, 2014, J INTERF CYTOK RES, V34, P902, DOI 10.1089/jir.2013.0093; Lee MSJ, 2019, EUR J IMMUNOL, V49, P1433, DOI 10.1002/eji.201848084; Lee SO, 2019, J GINSENG RES, V43, P218, DOI 10.1016/j.jgr.2017.11.007; Li XR, 2011, EUR J PHARM BIOPHARM, V78, P107, DOI 10.1016/j.ejpb.2010.12.017; Ma N, 2020, PHARMACOL THERAPEUT, V216, DOI 10.1016/j.pharmthera.2020.107658; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Mao HH, 2020, ADV BIOCHEM ENG BIOT, V171, P155, DOI 10.1007/10_2019_107; Mishra T, 2010, J ETHNOPHARMACOL, V127, P341, DOI 10.1016/j.jep.2009.10.033; Moyer TJ, 2016, J CLIN INVEST, V126, P799, DOI 10.1172/JCI81083; Nagai T, 2002, INT IMMUNOPHARMACOL, V2, P1183, DOI 10.1016/S1567-5769(02)00086-3; Nagai T, 2001, VACCINE, V19, P4824, DOI 10.1016/S0264-410X(01)00215-8; Nagai T, 2010, INT IMMUNOPHARMACOL, V10, P655, DOI 10.1016/j.intimp.2010.03.004; Nanishi E, 2020, CURR OPIN PEDIATR, V32, P125, DOI 10.1097/MOP.0000000000000868; Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s; Ouyang K, 2012, IMMUNOPHARM IMMUNOT, V34, P126, DOI 10.3109/08923973.2011.586704; Pollard AJ, 2021, NAT REV IMMUNOL, V21, P83, DOI 10.1038/s41577-020-00479-7; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; R Development Core Team, 2018, R LANG ENV STAT COMP; Reed SG, 2013, NAT MED, V19, P1597, DOI 10.1038/nm.3409; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; Sarkar I, 2019, EXPERT REV VACCINES, V18, P505, DOI 10.1080/14760584.2019.1604231; Shah RR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47885-z; Shih AY, 2018, BIOPHYS J, V114, P32, DOI 10.1016/j.bpj.2017.10.027; Singh A, 2019, BIOINFORMATICS, V35, P3055, DOI 10.1093/bioinformatics/bty1054; Su F, 2012, VACCINE, V30, P4106, DOI 10.1016/j.vaccine.2012.03.052; Sun HX, 2011, INT IMMUNOPHARMACOL, V11, P2047, DOI 10.1016/j.intimp.2011.08.018; Sun HX, 2005, VACCINE, V23, P5533, DOI 10.1016/j.vaccine.2005.07.036; Sun HX, 2004, VACCINE, V22, P3882, DOI 10.1016/j.vaccine.2004.04.012; Sun LA, 2009, 21ST INTERNATIONAL JOINT CONFERENCE ON ARTIFICIAL INTELLIGENCE (IJCAI-09), PROCEEDINGS, P1230; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Sun YX, 2008, VACCINE, V26, P5911, DOI 10.1016/j.vaccine.2008.08.047; Tsuchiya Y, 2016, EBIOMEDICINE, V9, P87, DOI 10.1016/j.ebiom.2016.05.039; van der Vlist EJ, 2012, NAT PROTOC, V7, P1311, DOI 10.1038/nprot.2012.065; Wang MW, 2007, PHILOS T R SOC B, V362, P1093, DOI 10.1098/rstb.2007.2036; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Wu YJ, 2016, INT J BIOL MACROMOL, V91, P248, DOI 10.1016/j.ijbiomac.2016.05.046; Xie Y, 2009, VACCINE, V27, P757, DOI 10.1016/j.vaccine.2008.11.029; Xie Y, 2008, VACCINE, V26, P3937, DOI 10.1016/j.vaccine.2008.01.061; Xie Y, 2008, VACCINE, V26, P3452, DOI 10.1016/j.vaccine.2008.04.023; Xie Y, 2010, CHEM BIODIVERS, V7, P677, DOI 10.1002/cbdv.200900183; Xie Y, 2010, CHEM BIODIVERS, V7, P178, DOI 10.1002/cbdv.200900002; Xu ML, 2012, J GINSENG RES, V36, P396, DOI 10.5142/jgr.2012.36.4.396; Yang F, 2016, CARBOHYD POLYM, V145, P48, DOI 10.1016/j.carbpol.2016.03.024; Yang XY, 2010, VACCINE, V28, P737, DOI 10.1016/j.vaccine.2009.10.065; Yoo DG, 2012, J MED FOOD, V15, P855, DOI 10.1089/jmf.2012.0017; Zhou YF, 2020, J POULT SCI, V57, P160, DOI 10.2141/jpsa.0180089	83	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								847616	10.3389/fimmu.2022.847616	http://dx.doi.org/10.3389/fimmu.2022.847616			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U6ZJ	35663999	gold, Green Published			2022-12-18	WOS:000805557900001
J	Jalaleddine, N; Hachim, M; Al-Hroub, H; Sharif-Askari, NS; Senok, A; Elmoselhi, A; Mahboub, B; Kurien, NMS; Kandasamy, RK; Semreen, MH; Halwani, R; Soares, NC; Al Heialy, S				Jalaleddine, Nour; Hachim, Mahmood; Al-Hroub, Hamza; Sharif-Askari, Narjes Saheb; Senok, Abiola; Elmoselhi, Adel; Mahboub, Bassam; Kurien, Nimmi Moni Samuel; Kandasamy, Richard K.; Semreen, Mohammad H.; Halwani, Rabih; Soares, Nelson C.; Al Heialy, Saba			N6-Acetyl-L-Lysine and p-Cresol as Key Metabolites in the Pathogenesis of COVID-19 in Obese Patients	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; COVID-19; obesity; metabolomics; ultra-high-performance liquid chromatography-mass spectrometry	BODY-MASS INDEX; LYSINE ACETYLATION; HOMOARGININE; OUTBREAK; RISK; ACID	Despite the growing number of the vaccinated population, COVID-19, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global health burden. Obesity, a metabolic syndrome affecting one-third of the population, has proven to be a major risk factor for COVID-19 severe complications. Several studies have identified metabolic signatures and disrupted metabolic pathways associated with COVID-19, however there are no reports evaluating the role of obesity in the COVID-19 metabolic regulation. In this study we highlight the involvement of obesity metabolically in affecting SARS-CoV-2 infection and the consequent health complications, mainly cardiovascular disease. We measured one hundred and forty-four (144) metabolites using ultra high-performance liquid chromatography-quadrupole time of flight mass spectrometry (UHPLC-QTOF-MS) to identify metabolic changes in response to SARS-CoV-2 infection, in lean and obese COVID-19 positive (n=82) and COVID-19 negative (n=24) patients. The identified metabolites are found to be mainly correlating with glucose, energy and steroid metabolisms. Further data analysis indicated twelve (12) significantly yet differentially abundant metabolites associated with viral infection and health complications, in COVID-19 obese patients. Two of the detected metabolites, n6-acetyl-l-lysine and p-cresol, are detected only among the COVID-19 cohort, exhibiting significantly higher levels in COVID-19 obese patients when compared to COVID-19 lean patients. These metabolites have important roles in viral entry and could explain the increased susceptibility of obese patients. On the same note, a set of six metabolites associated with antiviral and anti-inflammatory functions displayed significantly lower abundance in COVID-19 obese patients. In conclusion, this report highlights the plasma metabolome of COVID-19 obese patients as a metabolic feature and signature to help improve clinical outcomes. We propose n6-acetyl-l-lysine and p-cresol as potential metabolic markers which warrant further investigations to better understand their involvement in different metabolic pathways in COVID-19.	[Jalaleddine, Nour; Hachim, Mahmood; Senok, Abiola; Kandasamy, Richard K.; Al Heialy, Saba] Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates; [Al-Hroub, Hamza; Sharif-Askari, Narjes Saheb; Elmoselhi, Adel; Mahboub, Bassam; Semreen, Mohammad H.; Halwani, Rabih; Soares, Nelson C.] Univ Sharjah, Sharjah Inst Med Res, Sharjah, U Arab Emirates; [Al-Hroub, Hamza; Semreen, Mohammad H.; Soares, Nelson C.] Univ Sharjah, Coll Pharm, Dept Med Chem, Sharjah, U Arab Emirates; [Mahboub, Bassam; Kurien, Nimmi Moni Samuel] Dubai Hlth Author, Rashid Hosp, Dept Pulm Med & Allergy & Sleep Med, Dubai, U Arab Emirates; [Kandasamy, Richard K.] Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res CEMIR, Trondheim, Norway; [Kandasamy, Richard K.] Norwegian Univ Sci & Technol, Dept Clin & Mol Med IKOM, Trondheim, Norway; [Halwani, Rabih] King Saud Univ, Fac Med, Prince Abdullah Ben Khaled Celiac Dis Res Chair, Dept Pediat, Riyadh, Saudi Arabia; [Halwani, Rabih] Univ Sharjah, Coll Med, Dept Clin Sci, Sharjah, U Arab Emirates; [Al Heialy, Saba] McGill Univ Hlth Ctr, Meakins Christie Labs, Res Inst, Montreal, PQ, Canada	University of Sharjah; University of Sharjah; Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); King Saud University; University of Sharjah; McGill University	Al Heialy, S (corresponding author), Mohammed Bin Rashid Univ Med & Hlth Sci, Coll Med, Dubai, U Arab Emirates.; Soares, NC (corresponding author), Univ Sharjah, Sharjah Inst Med Res, Sharjah, U Arab Emirates.; Soares, NC (corresponding author), Univ Sharjah, Coll Pharm, Dept Med Chem, Sharjah, U Arab Emirates.; Al Heialy, S (corresponding author), McGill Univ Hlth Ctr, Meakins Christie Labs, Res Inst, Montreal, PQ, Canada.			da Cruz Soares, Nelson/0000-0003-2331-8532; Saheb Sharif-Askari, Narjes/0000-0003-0482-6777	Mohammed Bin Rashid University of Medicine and Health Sciences Internal Research Grant [MBRU CMRG-2020-06]; University of Sharjah, UAE [COV19-0307]; Al Jalila Foundation Seed Grant [MBRU CMRG-2020-06]; King Saud University, Riyadh, Kingdom of Saudi Arabia;  [AJF202019]	Mohammed Bin Rashid University of Medicine and Health Sciences Internal Research Grant; University of Sharjah, UAE; Al Jalila Foundation Seed Grant; King Saud University, Riyadh, Kingdom of Saudi Arabia(King Saud University); 	Funding was provided by the Mohammed Bin Rashid University of Medicine and Health Sciences Internal Research Grant (MBRU-CM-RG2020-06) and by COVID-19 research grant (COV19-0307), University of Sharjah, UAE and Al Jalila Foundation Seed Grant (AJF202019) to RH; and by Prince Abdullah Ben Khalid Celiac Disease Research Chair, under the Vice Deanship of Research Chairs, King Saud University, Riyadh, Kingdom of Saudi Arabia.	Abu-Farha M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103544; Adams S, 2019, CURR PROTEIN PEPT SC, V20, P184, DOI 10.2174/1389203719666181026170049; Al Heialy S, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.555039; Al-Benna Sammy, 2020, Obes Med, V19, P100283, DOI 10.1016/j.obmed.2020.100283; Al-Salameh A, 2021, INT J OBESITY, V45, P700, DOI 10.1038/s41366-020-00721-1; Alam MA, 2016, NUTR METAB, V13, DOI 10.1186/s12986-016-0080-3; Alrob OA, 2014, CARDIOVASC RES, V103, P485, DOI 10.1093/cvr/cvu156; Annunziata G, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00240; Antonelli M, 2022, LANCET INFECT DIS, V22, P43, DOI 10.1016/S1473-3099(21)00460-6; Apovian Caroline M, 2016, Am J Manag Care, V22, ps176; Atzler D, 2015, CURR OPIN CLIN NUTR, V18, P83, DOI 10.1097/MCO.0000000000000123; Augusti PR, 2021, J NUTR BIOCHEM, V97, DOI 10.1016/j.jnutbio.2021.108787; Balaz M, 2019, CELL METAB, V29, P901, DOI 10.1016/j.cmet.2018.11.017; Blasco H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73966-5; Brunet P, 2003, ADV RENAL REPLACE TH, V10, P310, DOI 10.1053/j.arrt.2003.08.002; Butte NF, 2015, AM J CLIN NUTR, V102, P256, DOI 10.3945/ajcn.115.111872; Chang MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114446; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Cirulli ET, 2019, CELL METAB, V29, P488, DOI 10.1016/j.cmet.2018.09.022; Dietz W, 2020, OBESITY, V28, P1005, DOI 10.1002/oby.22818; Donath MY, 2019, NAT REV IMMUNOL, V19, P734, DOI 10.1038/s41577-019-0213-9; Dyavar SR, 2021, BIOMED PHARMACOTHER, V141, DOI 10.1016/j.biopha.2021.111794; Gabarre P, 2020, INTENS CARE MED, V46, P1339, DOI 10.1007/s00134-020-06153-9; Gao M, 2021, LANCET DIABETES ENDO, V9, P350, DOI 10.1016/S2213-8587(21)00089-9; Gibney MJ, 2005, AM J CLIN NUTR, V82, P497, DOI 10.1093/ajcn/82.3.497; Godarzi SM, 2020, NEFROLOGIA, V40, P311, DOI 10.1016/j.nefro.2019.10.003; Hamer HM, 2012, AM J PHYSIOL-GASTR L, V302, pG1, DOI 10.1152/ajpgi.00048.2011; Hatakeyama D, 2021, BIOCHEM BIOPH RES CO, V557, P273, DOI 10.1016/j.bbrc.2021.03.173; Hippisley-Cox J, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2244; Horton JL, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.84897; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hruby A, 2015, PHARMACOECONOMICS, V33, P673, DOI 10.1007/s40273-014-0243-x; Hu Yongwu, 2003, Genomics Proteomics & Bioinformatics, V1, P118; Iyer A, 2012, IMMUNOL CELL BIOL, V90, P39, DOI 10.1038/icb.2011.99; Jayanama K, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247023; Kimhofer T, 2020, J PROTEOME RES, V19, P4442, DOI 10.1021/acs.jproteome.0c00519; Kompaniyets L, 2021, MMWR-MORBID MORTAL W, V70, P355, DOI 10.15585/mmwr.mm7010e4; Kumboyono K, 2022, INFECT DRUG RESIST, V15, P821, DOI 10.2147/IDR.S348392; Law SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051149; Ley JP, 2002, J AGR FOOD CHEM, V50, P5897, DOI 10.1021/jf025667e; Li C, 2018, TRANSL RES, V191, P29, DOI 10.1016/j.trsl.2017.10.004; Li H, 2020, ATHEROSCLEROSIS, V315, pe182, DOI [10.1016/j.atherosclerosis.2020.10.566, DOI 10.1016/J.ATHEROSCLEROSIS.2020.10.566]; Liu JL, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872-021-02209-w; Marti JLG, 2021, J MED VIROL, V93, P2396, DOI 10.1002/jmv.26743; Masters RK, 2013, AM J EPIDEMIOL, V177, P431, DOI 10.1093/aje/kws325; Meijers BKI, 2008, KIDNEY INT, V73, P1174, DOI 10.1038/ki.2008.31; Nehme Z, 2020, HISTONE MODIFICATION, V20, P255, DOI [10.1016/B978-0-12-816422-8.00011-8, DOI 10.1016/B978-0-12-816422-8.00011-8]; Nicholson JK, 2008, NATURE, V455, P1054, DOI 10.1038/4551054a; Overmyer Katherine A, 2020, medRxiv, DOI 10.1101/2020.07.17.20156513; Painter SD, 2015, VACCINE, V33, P4422, DOI 10.1016/j.vaccine.2015.06.101; Park S, 2015, MOL CELLS, V38, P587, DOI 10.14348/molcells.2015.0126; Ponti G, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109859; Romanick SS, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180721; Sachdeva R, 2003, TEX HEART I J, V30, P308; Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659; Shao JH, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10040321; Su P, 2015, ANTI-CANCER AGENT ME, V15, P980, DOI 10.2174/1871520615666150130111120; Taylor LA, 2007, LIPIDS HEALTH DIS, V6, DOI 10.1186/1476-511X-6-17; Thomas T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.140327; Tsikas D, 2015, AMINO ACIDS, V47, P1697, DOI 10.1007/s00726-015-2055-5; Umar HI, 2021, J GENET ENG BIOTECHN, V19, DOI 10.1186/s43141-021-00120-7; Velavan TP, 2020, TROP MED INT HEALTH, V25, P278, DOI 10.1111/tmi.13383; Vukajlovic JM, 2020, RAPID COMMUN MASS SP, V34, DOI 10.1002/rcm.8595; Khanh VC, 2021, STEM CELLS DEV, V30, P758, DOI 10.1089/scd.2021.0065; Wang QJ, 2010, SCIENCE, V327, P1004, DOI 10.1126/science.1179687; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu D, 2020, INT J INFECT DIS, V94, P44, DOI 10.1016/j.ijid.2020.03.004; Xia JG, 2010, NUCLEIC ACIDS RES, V38, pW71, DOI 10.1093/nar/gkq329; Yang JR, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94256-8; Yeh YS, 2018, ISCIENCE, V9, P175, DOI 10.1016/j.isci.2018.10.019; Yosri N, 2021, FOODS, V10, DOI 10.3390/foods10081776; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	72	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								827603	10.3389/fimmu.2022.827603	http://dx.doi.org/10.3389/fimmu.2022.827603			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V8CE	35663953	Green Published, gold			2022-12-18	WOS:000806310600001
J	Li, X; Yang, B; Shi, CY; Wang, HB; Yu, RH; Li, Q; Liu, SK				Li, Xin; Yang, Ben; Shi, Chenyu; Wang, Hebing; Yu, Ruihai; Li, Qi; Liu, Shikai			Synergistic Interaction of Low Salinity Stress With Vibrio Infection Causes Mass Mortalities in the Oyster by Inducing Host Microflora Imbalance and Immune Dysregulation	FRONTIERS IN IMMUNOLOGY			English	Article						low salinity stress; Crassostrea gigas; Vibrio alginolyticus; digestive bacterial microbiota; immune response	EXTREME CLIMATIC EVENTS; GUT MICROBIOTA; CRASSOSTREA-GIGAS; PACIFIC OYSTER; OXIDATIVE STRESS; THERMAL-STRESS; DISEASE; INFLAMMATION; PATHOGENESIS; APOPTOSIS	A sudden drop in salinity following extreme precipitation events usually causes mass mortality of oysters exposed to pathogens in ocean environment. While how low salinity stress interacts with pathogens to cause mass mortality remains obscure. In this study, we performed an experiment by low salinity stress and pathogen infection with Vibrio alginolyticus to investigate their synergistic effect on the mortality of the Pacific oyster toward understanding of the interaction among environment, host, and pathogen. We showed that low salinity stress did not significantly affect proliferation and virulence of V. alginolyticus, but significantly altered microbial composition and immune response of infected oysters. Microbial community profiling by 16S rRNA amplicon sequencing revealed disrupted homeostasis of digestive bacterial microbiota with the abundance of several pathogenic bacteria being increased, which may affect the pathogenesis in infected oysters. Transcriptome profiling of infected oysters revealed that a large number of genes associated with apoptosis and inflammation were significantly upregulated under low salinity, suggesting that low salinity stress may have triggered immune dysregulation in infected oysters. Our results suggest that host-pathogen interactions are strongly affected by low salinity stress, which is of great significance for assessing future environmental risk of pathogenic diseases, decoding the interaction among environment, host genetics and commensal microbes, and disease surveillance in the oyster.	[Li, Xin; Yang, Ben; Shi, Chenyu; Wang, Hebing; Yu, Ruihai; Li, Qi; Liu, Shikai] Ocean Univ China, Coll Fisheries, Key Lab Mariculture, Minist Educ, Qingdao, Peoples R China; [Li, Qi; Liu, Shikai] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China	Ocean University of China; Qingdao National Laboratory for Marine Science & Technology	Liu, SK (corresponding author), Ocean Univ China, Coll Fisheries, Key Lab Mariculture, Minist Educ, Qingdao, Peoples R China.; Liu, SK (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China.	liushk@ouc.edu.cn	Liu, Shikai/D-4664-2013	Liu, Shikai/0000-0001-5777-489X				Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; BergogneBerezin E, 1996, CLIN MICROBIOL REV, V9, P148, DOI 10.1128/CMR.9.2.148; Biggs CR, 2018, BIOL LETTERS, V14, DOI 10.1098/rsbl.2018.0579; Burge CA, 2014, ANNU REV MAR SCI, V6, P249, DOI 10.1146/annurev-marine-010213-135029; Burger D, 2006, BEST PRACT RES CL RH, V20, P879, DOI 10.1016/j.berh.2006.06.004; Chaudhry A, 2013, J CLIN INVEST, V123, P939, DOI 10.1172/JCI57175; Choi K, 2013, J FISH DIS, V36, P389, DOI 10.1111/j.1365-2761.2012.01417.x; Coughlan BM, 2009, MAR POLLUT BULL, V58, P1680, DOI 10.1016/j.marpolbul.2009.06.020; Creeper JH, 2006, AUST VET J, V84, P408, DOI 10.1111/j.1751-0813.2006.00058.x; Croxatto A, 2007, ENVIRON MICROBIOL, V9, P370, DOI 10.1111/j.1462-2920.2006.01147.x; Dalli J, 2019, ADV EXP MED BIOL, V1161, P65, DOI 10.1007/978-3-030-21735-8_7; de Lorgeril J, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-6471-x; de Lorgeril J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06659-3; de Lorgeril J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023142; Deines P, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01610; Dinarello CA, 2002, CLIN EXP RHEUMATOL, V20, pS1; Donat MG, 2016, NAT CLIM CHANGE, V6, P508, DOI [10.1038/nclimate2941, 10.1038/NCLIMATE2941]; Du JB, 2021, SCI TOTAL ENVIRON, V774, DOI 10.1016/j.scitotenv.2021.145132; Duperthuy M, 2011, P NATL ACAD SCI USA, V108, P2993, DOI 10.1073/pnas.1015326108; Duperthuy M, 2010, ENVIRON MICROBIOL, V12, P951, DOI 10.1111/j.1462-2920.2009.02138.x; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Edye ME, 2013, J BIOL CHEM, V288, P30485, DOI 10.1074/jbc.M113.478941; EGIDIUS E, 1986, INT J SYST BACTERIOL, V36, P518, DOI 10.1099/00207713-36-4-518; Fasano A, 2005, NAT CLIN PRACT GASTR, V2, P416, DOI 10.1038/ncpgasthep0259; Festi D, 2014, WORLD J GASTROENTERO, V20, P16079, DOI 10.3748/wjg.v20.i43.16079; Ford SE, 2012, J MAR RES, V70, P253, DOI 10.1357/002224012802851850; Fuhrmann M, 2016, AQUACULT ENV INTERAC, V8, P543, DOI 10.3354/aei00197; Garnier M, 2007, MICROB ECOL, V53, P187, DOI 10.1007/s00248-006-9061-9; Gay M, 2004, DIS AQUAT ORGAN, V59, P49, DOI 10.3354/dao059049; Goncalves P, 2017, MOL ECOL, V26, P5974, DOI 10.1111/mec.14333; Green TJ, 2019, MICROB ECOL, V77, P736, DOI 10.1007/s00248-018-1242-9; He SX, 2017, SCI CHINA LIFE SCI, V60, P1260, DOI 10.1007/s11427-016-9072-6; He XC, 2011, FISH SHELLFISH IMMUN, V30, P870, DOI 10.1016/j.fsi.2011.01.009; He Y, 2015, FISH SHELLFISH IMMUN, V46, P131, DOI 10.1016/j.fsi.2015.05.023; Holmgren M, 2006, FRONT ECOL ENVIRON, V4, P87, DOI 10.1890/1540-9295(2006)004[0087:ECESAA]2.0.CO;2; Hu XY, 2018, ECOTOX ENVIRON SAFE, V164, P201, DOI 10.1016/j.ecoenv.2018.08.029; Jemaa M, 2014, J EXP BIOL, V217, P3067, DOI 10.1242/jeb.106575; Jin X, 2017, CHEMOSPHERE, V180, P259, DOI 10.1016/j.chemosphere.2017.03.130; Kim BM, 2017, MOL CELL TOXICOL, V13, P105, DOI 10.1007/s13273-017-0011-z; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; King WL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00473; King WL, 2019, MICROB ECOL, V77, P502, DOI 10.1007/s00248-018-1226-9; Kivistik C, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00683; Kong N, 2022, AQUACULTURE, V546, DOI 10.1016/j.aquaculture.2021.737365; Lai KP, 2020, ENVIRON MICROBIOL, V22, P3784, DOI 10.1111/1462-2920.15150; Lange K, 2016, DIGEST DIS, V34, P260, DOI 10.1159/000443360; Le Roux F, 2007, APPL ENVIRON MICROB, V73, P777, DOI 10.1128/AEM.02147-06; Lemire A, 2015, ISME J, V9, P1523, DOI 10.1038/ismej.2014.233; Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352; Li J, 2017, FRONT MAR SCI, V4, DOI 10.3389/fmars.2017.00112; Li K, 2007, J APPL MICROBIOL, V103, P675, DOI 10.1111/j.1365-2672.2007.03295.x; Li YX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.307; Li YQ, 2017, DEV COMP IMMUNOL, V71, P59, DOI 10.1016/j.dci.2017.01.024; Linkermann A, 2014, NAT REV IMMUNOL, V14, P759, DOI 10.1038/nri3743; Liu CX, 2003, FEMS MICROBIOL LETT, V222, P9, DOI 10.1016/S0378-1097(03)00296-9; Liu JJ, 2020, ECOTOX ENVIRON SAFE, V190, DOI 10.1016/j.ecoenv.2019.110127; Lokmer A, 2015, ISME J, V9, P670, DOI 10.1038/ismej.2014.160; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; Maynard CL, 2012, NATURE, V489, P231, DOI 10.1038/nature11551; Meng J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058563; Munroe D, 2013, ESTUAR COAST SHELF S, V135, P209, DOI 10.1016/j.ecss.2013.10.011; Natrah FMI, 2011, VET MICROBIOL, V154, P124, DOI 10.1016/j.vetmic.2011.06.024; Nie L, 2017, FISH SHELLFISH IMMUN, V68, P479, DOI 10.1016/j.fsi.2017.07.054; Park KS, 2004, INFECT IMMUN, V72, P6659, DOI 10.1128/IAI.72.11.6659-6665.2004; Patrick S, 2009, MICROBIOL-SGM, V155, P1039, DOI 10.1099/mic.0.025361-0; Perez T, 2010, MUCOSAL IMMUNOL, V3, P355, DOI 10.1038/mi.2010.12; Petton B, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00686; Pfahl S, 2017, NAT CLIM CHANGE, V7, P423, DOI [10.1038/nclimate3287, 10.1038/NCLIMATE3287]; Pita L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080307; Quast C, 2013, NUCLEIC ACIDS RES, V41, pD590, DOI 10.1093/nar/gks1219; Reid HI, 2003, DIS AQUAT ORGAN, V56, P249, DOI 10.3354/dao056249; Rey-Campos M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01894; Richard M, 2021, MAR ENVIRON RES, V165, DOI 10.1016/j.marenvres.2020.105251; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Rosani U, 2015, ENVIRON MICROBIOL, V17, P4200, DOI 10.1111/1462-2920.12706; Rosenberg E, 2007, NAT REV MICROBIOL, V5, P355, DOI 10.1038/nrmicro1635; Rupnik M, 2009, NAT REV MICROBIOL, V7, P526, DOI 10.1038/nrmicro2164; Salvi GE, 2005, J CLIN PERIODONTOL, V32, P108, DOI 10.1111/j.1600-051X.2005.00785.x; Saulnier D, 2010, MICROB ECOL, V59, P787, DOI 10.1007/s00248-009-9620-y; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schmitz M, 2016, FISH SHELLFISH IMMUN, V55, P550, DOI 10.1016/j.fsi.2016.06.031; Sehnal L, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.567408; Shi QX, 2019, SCI TOTAL ENVIRON, V659, P354, DOI 10.1016/j.scitotenv.2018.12.375; Simister R, 2012, ENVIRON MICROBIOL, V14, P3232, DOI 10.1111/1462-2920.12010; Sinha K, 2013, ARCH TOXICOL, V87, P1157, DOI 10.1007/s00204-013-1034-4; SMITH H, 1990, J GEN MICROBIOL, V136, P377, DOI 10.1099/00221287-136-3-377; Solomieu VB, 2015, J INVERTEBR PATHOL, V131, P2, DOI 10.1016/j.jip.2015.07.011; Soudant P, 2013, J INVERTEBR PATHOL, V114, P196, DOI 10.1016/j.jip.2013.06.001; Su JH, 2004, BBA-GENE STRUCT EXPR, V1678, P7, DOI 10.1016/j.bbaexp.2004.01.003; Thurber RV, 2009, ENVIRON MICROBIOL, V11, P2148, DOI 10.1111/j.1462-2920.2009.01935.x; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Travers MA, 2015, J INVERTEBR PATHOL, V131, P11, DOI 10.1016/j.jip.2015.07.010; Urbanczyk H, 2007, INT J SYST EVOL MICR, V57, P2823, DOI 10.1099/ijs.0.65081-0; Velez C, 2016, AQUAT TOXICOL, V176, P141, DOI 10.1016/j.aquatox.2016.04.016; Wang L, 2009, BIOL TRACE ELEM RES, V127, P53, DOI 10.1007/s12011-008-8223-7; Wegner KM, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-252; Wetz MS, 2013, MAR POLLUT BULL, V69, P7, DOI 10.1016/j.marpolbul.2013.01.020; Wojciechowski W, 2009, IMMUNITY, V30, P421, DOI 10.1016/j.immuni.2009.01.006; Xie W, 2022, FISH SHELLFISH IMMUN, V122, P316, DOI 10.1016/j.fsi.2022.02.001; Xiong JB, 2018, APPL MICROBIOL BIOT, V102, P7343, DOI 10.1007/s00253-018-9199-7; Xu F, 2011, MAR BIOL RES, V7, P796, DOI 10.1080/17451000.2011.569555; Yang B, 2021, AQUACULTURE, V535, DOI 10.1016/j.aquaculture.2021.736363; Zhang GF, 2012, NATURE, V490, P49, DOI 10.1038/nature11413; Zhao XL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046244; Zhou XH, 2013, CELL REP, V3, P1690, DOI 10.1016/j.celrep.2013.03.039; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	107	0	0	13	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								859975	10.3389/fimmu.2022.859975	http://dx.doi.org/10.3389/fimmu.2022.859975			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U7YK	35663972	gold, Green Published			2022-12-18	WOS:000805623100001
J	Liang, WZ; Li, XS; Wang, H; Nie, KC; Meng, QX; He, JL; Zheng, CF				Liang, Weizheng; Li, Xiushen; Wang, Hao; Nie, Kechao; Meng, Qingxue; He, Junli; Zheng, Chunfu			Puerarin: A Potential Therapeutic for SARS-CoV-2 and Hantavirus Co-Infection	FRONTIERS IN IMMUNOLOGY			English	Article						bioinformatics; puerarin; SARS-CoV-2; Hantavirus; co-infection; virus immunity	HEMORRHAGIC-FEVER; OXIDATIVE STRESS; MECHANISMS; INFLAMMATION; INFECTION; PROTECTS; INJURY; CELLS	Patients with Hantavirus-caused epidemic hemorrhagic fever (EHF) are at risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there is currently no validated EHF/SARS-CoV-2 strategy. Several studies have recently shown Puerarin, a natural product, has potent antiviral properties. The goal of present study was to determine the mechanism of puerarin in patients with EHF/COVID-19. We use network pharmacology and bioinformatics to investigate the possible pharmacological targets, bioactivities, and molecular mechanisms of puerarin in the treatment of patients with EHF/SARS-CoV-2. The study investigated the pathogenesis of COVID-19 and EHF and the signaling pathway impacted by puerarin. 68 common genes linked to puerarin and EHF/SARS-CoV-2 were discovered during the investigation. By using protein-protein interaction (PPI) network, we identified RELA, JUN, NF-B1, NF-B2, and FOS as potential therapeutic targets. The bioactivity and signaling pathways of puerarin have also been demonstrated in the treatment of EHF and COVID-19. According to present study, puerarin could reduce excessive immune responses and inflammation through the NF-B, TNF, and HIF-1 signaling pathways. This study explored the potential therapeutic targets and mechanisms of Puerarin in the treatment of EHF/COVID-19.	[Liang, Weizheng; Meng, Qingxue] Hebei North Univ, Cent Lab, Affiliated Hosp 1, Zhangjiakou, Peoples R China; [Liang, Weizheng; Zheng, Chunfu] Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou, Peoples R China; [Li, Xiushen; Wang, Hao] Shenzhen Univ Gen Hosp, Dept Obstet & Gynecol, Shenzhen, Peoples R China; [Li, Xiushen; Wang, Hao] Shenzhen Univ Hlth Sci Ctr, Sch Biomed Engn, Guangdong Key Lab Biomed Measurements & Ultrasound, Shenzhen, Peoples R China; [Li, Xiushen; Wang, Hao] Shenzhen Univ Gen Hosp, Shenzhen Key Lab, Shenzhen, Peoples R China; [Nie, Kechao] Cent South Univ, Xiangya Hosp 2, Dept Integrated Tradit Chinese & Western Internal, Changsha, Peoples R China; [He, Junli] Shenzhen Univ, Dept Pediat, Gen Hosp Shenzhen, Shenzhen, Guangdong, Peoples R China; [Zheng, Chunfu] Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada	Hebei North University; Fujian Medical University; Shenzhen University; Central South University; Shenzhen University; University of Calgary	Zheng, CF (corresponding author), Fujian Med Univ, Sch Basic Med Sci, Dept Immunol, Fuzhou, Peoples R China.; Zheng, CF (corresponding author), Univ Calgary, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada.		zheng, Chunfu/F-2404-2012	zheng, Chunfu/0000-0002-8797-1322	Shenzhen Key Laboratory Foundation [ZDSYS20200811143757022]	Shenzhen Key Laboratory Foundation	Funding The study was supported by Shenzhen Key Laboratory Foundation (ZDSYS20200811143757022).	Ahidjo BA, 2020, ACS INFECT DIS, V6, P1624, DOI 10.1021/acsinfecdis.0c00236; Ahmad B, 2020, CANCER MANAG RES, V12, P79, DOI 10.2147/CMAR.S233567; Araf Y, 2022, J MED VIROL, V94, P1825, DOI 10.1002/jmv.27588; Baldwin AS, 2012, IMMUNOL REV, V246, P327, DOI 10.1111/j.1600-065X.2012.01095.x; Brussow H, 2020, ENVIRON MICROBIOL, V22, P4895, DOI 10.1111/1462-2920.15302; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cartwright T, 2016, FEBS J, V283, P1812, DOI 10.1111/febs.13627; de las Heras N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090897; Giacomelli A, 2020, CLIN INFECT DIS, V71, P889, DOI 10.1093/cid/ciaa330; Giridharan S, 2018, J INFLAMM RES, V11, P407, DOI 10.2147/JIR.S140188; Grein J, 2020, NEW ENGL J MED, V382, P2327, DOI 10.1056/NEJMoa2007016; Guo J, 2017, J MED VIROL, V89, P1139, DOI 10.1002/jmv.24752; Hop HT, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00287; Hossain MG, 2022, J MED VIROL, V94, P1815, DOI 10.1002/jmv.27539; Iba T, 2022, THROMB HAEMOSTASIS, V122, P8, DOI 10.1055/a-1562-7599; Jayaweera M, 2020, ENVIRON RES, V188, DOI 10.1016/j.envres.2020.109819; Jiang H, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00001; Karki Rajendra, 2021, Cell, V184, P149, DOI [10.1101/2020.10.29.361048, 10.1016/j.cell.2020.11.025]; Khan M, 2021, MOLECULES, V26, DOI 10.3390/molecules26010039; Lauer SA, 2020, ANN INTERN MED, V172, P577, DOI 10.7326/M20-0504; Li Q, 2020, NEW ENGL J MED, V382, P1199, DOI 10.1056/NEJMoa2001316; Liu CM, 2016, CHEM-BIOL INTERACT, V243, P29, DOI 10.1016/j.cbi.2015.11.017; Liu W, 2021, INT J GEN MED, V14, P9873, DOI 10.2147/IJGM.S337025; Lorenz C, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101659; Malik S, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13080188; Marin BG, 2021, REV MED VIROL, V31, DOI 10.1002/rmv.2146; Martynenko AY, 2014, B EXP BIOL MED+, V156, P320, DOI 10.1007/s10517-014-2339-x; McEntire CRS, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.634827; Mediouni S, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0446-x; Noh JY, 2019, INFECT CHEMOTHER, V51, P405, DOI 10.3947/ic.2019.51.4.405; Prapty CNBS, 2022, REV MED VIROL, DOI 10.1002/rmv.2340; Riesenberg S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9755; Rocklov J, 2019, EMERG TOP LIFE SCI, V3, P133, DOI 10.1042/ETLS20180123; Saavedra-Velasco Marcos, 2020, Rev Fac Cien Med Univ Nac Cordoba, V77, P52, DOI 10.31053/1853.0605.v77.n1.28031; Salian VS, 2021, MOL PHARMACEUT, V18, P754, DOI 10.1021/acs.molpharmaceut.0c00608; Schonthaler HB, 2011, ANN RHEUM DIS, V70, pI109, DOI 10.1136/ard.2010.140533; Sohn KM, 2020, J KOREAN MED SCI, V35, DOI 10.3346/jkms.2020.35.e343; Strandin T, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-110; Suhail S, 2020, PROTEIN J, V39, P644, DOI 10.1007/s10930-020-09935-8; Tang F, 2014, MICROB DRUG RESIST, V20, P357, DOI 10.1089/mdr.2013.0104; van Doremalen N, 2020, NEW ENGL J MED, V382, P1564, DOI [10.1056/NEJMc2004973, 10.1101/2020.03.09.20033217]; Wang HX, 2021, PHYTOTHER RES, V35, P324, DOI 10.1002/ptr.6803; Wang L, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00560; West AP, 2006, ANNU REV CELL DEV BI, V22, P409, DOI 10.1146/annurev.cellbio.21.122303.115827; Yamamoto T, 2019, BIOCHEM BIOPH RES CO, V516, P626, DOI 10.1016/j.bbrc.2019.06.051; Yde P, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-115; Yu HT, 2012, VIRAL IMMUNOL, V25, P387, DOI 10.1089/vim.2012.0005; Zhang DZ, 2019, MOL MED REP, V20, P1017, DOI 10.3892/mmr.2019.10320; Zhang F, 2015, INT IMMUNOPHARMACOL, V28, P546, DOI 10.1016/j.intimp.2015.07.023; Zhou YX, 2014, PHYTOTHER RES, V28, P961, DOI 10.1002/ptr.5083	51	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								892350	10.3389/fimmu.2022.892350	http://dx.doi.org/10.3389/fimmu.2022.892350			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U8CW	35663983	gold, Green Published			2022-12-18	WOS:000805634700001
J	Pone, EJ; Hernandez-Davies, JE; Jan, SR; Silzel, E; Felgner, PL; Davies, DH				Pone, Egest J.; Hernandez-Davies, Jenny E.; Jan, Sharon; Silzel, Emily; Felgner, Philip L.; Davies, D. Huw			Multimericity Amplifies the Synergy of BCR and TLR4 for B Cell Activation and Antibody Class Switching	FRONTIERS IN IMMUNOLOGY			English	Article						multimericity; B cells; class switching; B cell receptor (BCR); Toll-like receptor (TLR); synergy; streptavidin; biotin	RECEPTOR NANOCLUSTERS; PATTERN-RECOGNITION; CROSS-REGULATION; DNA; CYTOKINES; AFFINITY; ADHESION; MODEL; IGM; ORGANIZATION	Sustained signaling through the B cell antigen receptor (BCR) is thought to occur only when antigen(s) crosslink or disperse multiple BCR units, such as by multimeric antigens found on the surfaces of viruses or bacteria. B cell-intrinsic Toll-like receptor (TLR) signaling synergizes with the BCR to induce and shape antibody production, hallmarked by immunoglobulin (Ig) class switch recombination (CSR) of constant heavy chains from IgM/IgD to IgG, IgA or IgE isotypes, and somatic hypermutation (SHM) of variable heavy and light chains. Full B cell differentiation is essential for protective immunity, where class switched high affinity antibodies neutralize present pathogens, memory B cells are held in reserve for future encounters, and activated B cells also serve as semi-professional APCs for T cells. But the rules that fine-tune B cell differentiation remain partially understood, despite their being essential for naturally acquired immunity and for guiding vaccine development. To address this in part, we have developed a cell culture system using splenic B cells from naive mice stimulated with several biotinylated ligands and antibodies crosslinked by streptavidin reagents. In particular, biotinylated lipopolysaccharide (LPS), a Toll-like receptor 4 (TLR4) agonist, and biotinylated anti-IgM were pre-assembled (multimerized) using streptavidin, or immobilized on nanoparticles coated with streptavidin, and used to active B cells in this precisely controlled, high throughput assay. Using B cell proliferation and Ig class switching as metrics for successful B cell activation, we show that the stimuli are both synergistic and dose-dependent. Crucially, the multimerized immunoconjugates are most active over a narrow concentration range. These data suggest that multimericity is an essential requirement for B cell BCR/TLRs ligands, and clarify basic rules for B cell activation. Such studies highlight the importance in determining the choice of single vs multimeric formats of antigen and PAMP agonists during vaccine design and development.	[Pone, Egest J.; Hernandez-Davies, Jenny E.; Jan, Sharon; Silzel, Emily; Felgner, Philip L.; Davies, D. Huw] Univ Calif Irvine, Vaccine Res & Dev Ctr, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Davies, DH (corresponding author), Univ Calif Irvine, Vaccine Res & Dev Ctr, Sch Med, Dept Physiol & Biophys, Irvine, CA 92697 USA.	ddavies@uci.edu						Altman MO, 2018, VIRAL IMMUNOL, V31, P142, DOI 10.1089/vim.2017.0129; Amendt T, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.709240; Amjad OA, 2017, LANGMUIR, V33, P1139, DOI 10.1021/acs.langmuir.6b03692; Andreeva L, 2017, NATURE, V549, P394, DOI 10.1038/nature23890; Arenas-Ramirez N, 2015, TRENDS IMMUNOL, V36, P763, DOI 10.1016/j.it.2015.10.003; Atcha H, 2021, CURR OPIN SOLID ST M, V25, DOI 10.1016/j.cossms.2021.100951; Bachmann MF, 2010, NAT REV IMMUNOL, V10, P787, DOI 10.1038/nri2868; Baumgarth N, 2021, ANNU REV IMMUNOL, V39, P103, DOI 10.1146/annurev-immunol-042718-041238; Bindslev N., 2008, DRUG ACCEPTOR INTERA; Boeglin E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025542; BRUNSWICK M, 1988, J IMMUNOL, V140, P3364; Cao XT, 2016, NAT REV IMMUNOL, V16, P35, DOI 10.1038/nri.2015.8; Cassese G, 2003, J IMMUNOL, V171, P1684, DOI 10.4049/jimmunol.171.4.1684; Chen ZG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.663443; Copeland RA, 2016, NAT REV DRUG DISCOV, V15, P87, DOI 10.1038/nrd.2015.18; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; DINTZIS HM, 1976, P NATL ACAD SCI USA, V73, P3671, DOI 10.1073/pnas.73.10.3671; Dirks RM, 2007, SIAM REV, V49, P65, DOI 10.1137/060651100; Erlendsson S, 2021, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.615565; Eslami M, 2021, CURR OPIN IMMUNOL, V71, P75, DOI 10.1016/j.coi.2021.06.009; Fan JP, 2015, NANOSCALE RES LETT, V10, DOI 10.1186/s11671-015-1130-x; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Frutiger A, 2021, CHEM REV, V121, P8095, DOI 10.1021/acs.chemrev.1c00044; Garcia-Parajo MF, 2014, J CELL SCI, V127, P4995, DOI 10.1242/jcs.146340; Gay NJ, 2014, NAT REV IMMUNOL, V14, P546, DOI 10.1038/nri3713; Gold MR, 2019, ANNU REV IMMUNOL, V37, P97, DOI 10.1146/annurev-immunol-042718-041704; Goodridge HS, 2011, NATURE, V472, P471, DOI 10.1038/nature10071; Handl HL, 2004, EXPERT OPIN THER TAR, V8, P565, DOI 10.1517/14728222.8.6.565; Hauser AE, 2010, SEMIN IMMUNOPATHOL, V32, P239, DOI 10.1007/s00281-010-0214-z; Hawkins ED, 2009, P NATL ACAD SCI USA, V106, P13457, DOI 10.1073/pnas.0905629106; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P465, DOI 10.1016/B978-0-12-382239-0.00011-X; Hinton HJ, 2008, CURR TOP MICROBIOL, V319, P1; Hornbeck Peter, 2017, Curr Protoc Immunol, V116, DOI 10.1002/cpim.18; Hu MM, 2018, ANNU REV CELL DEV BI, V34, P357, DOI 10.1146/annurev-cellbio-100617-062903; Hunter CA, 2009, ANGEW CHEM INT EDIT, V48, P7488, DOI 10.1002/anie.200902490; Ivashkiv LB, 2008, NAT REV IMMUNOL, V8, P816, DOI 10.1038/nri2396; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; Kagan JC, 2014, NAT REV IMMUNOL, V14, P821, DOI 10.1038/nri3757; Kelly HG, 2019, EXPERT REV VACCINES, V18, P269, DOI 10.1080/14760584.2019.1578216; Kieser KJ, 2017, NAT REV IMMUNOL, V17, P376, DOI 10.1038/nri.2017.25; Klasener K, 2014, ELIFE, V3, DOI 10.7554/eLife.02069; Kuraoka M, 2017, CELL REP, V18, P1627, DOI 10.1016/j.celrep.2017.01.050; Lechouane F, 2013, EUR J IMMUNOL, V43, P619, DOI 10.1002/eji.201242912; Li CH, 2014, P NATL ACAD SCI USA, V111, P14130, DOI 10.1073/pnas.1408628111; Li M, 2021, J CELL SCI, V134, DOI 10.1242/jcs.249318; Liu WL, 2016, TRENDS IMMUNOL, V37, P680, DOI 10.1016/j.it.2016.07.007; Macagno A, 2007, TRENDS IMMUNOL, V28, P227, DOI 10.1016/j.it.2007.03.008; Maity PC, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005887; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; MCINTYRE TM, 1995, J IMMUNOL, V154, P3156; Micoli F, 2021, NAT REV MICROBIOL, V19, P287, DOI 10.1038/s41579-020-00506-3; MOND JJ, 1995, CURR OPIN IMMUNOL, V7, P349, DOI 10.1016/0952-7915(95)80109-X; Mongini PKA, 1998, CELL IMMUNOL, V188, P137, DOI 10.1006/cimm.1998.1359; MONGINI PKA, 1992, J IMMUNOL, V148, P3892; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Morgunova E, 2017, CURR OPIN STRUC BIOL, V47, P1, DOI 10.1016/j.sbi.2017.03.006; Nussinov R, 2015, BIOL REV, V90, P587, DOI 10.1111/brv.12124; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Pageon SV, 2016, P NATL ACAD SCI USA, V113, pE5454, DOI 10.1073/pnas.1607436113; PARRY SL, 1994, J IMMUNOL, V152, P2821; Pone EJ, 2016, METHODS MOL BIOL, V1390, P229, DOI 10.1007/978-1-4939-3335-8_15; Pone EJ, 2015, AUTOIMMUNITY, V48, P1, DOI 10.3109/08916934.2014.993027; Pone EJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1769; Rawlings DJ, 2012, NAT REV IMMUNOL, V12, P282, DOI 10.1038/nri3190; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; ROES J, 1993, J EXP MED, V177, P45, DOI 10.1084/jem.177.1.45; Rui LX, 2006, J IMMUNOL, V177, P5337, DOI 10.4049/jimmunol.177.8.5337; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; SantaLucia J, 2004, ANNU REV BIOPH BIOM, V33, P415, DOI 10.1146/annurev.biophys.32.110601.141800; Seder RA, 2008, NAT REV IMMUNOL, V8, P247, DOI 10.1038/nri2274; Setz CS, 2019, EMBO J, V38, DOI 10.15252/embj.2018100249; Severinson E, 2003, SCAND J IMMUNOL, V58, P139, DOI 10.1046/j.1365-3083.2003.01295.x; Shaheen S, 2019, ADV IMMUNOL, V144, P23, DOI 10.1016/bs.ai.2019.08.003; Shen HM, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.110059; Smith DM, 2013, NAT REV IMMUNOL, V13, P592, DOI 10.1038/nri3488; Snapper CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00598; Speiser DE, 2017, CANCER DISCOV, V7, P1062, DOI 10.1158/2159-8290.CD-17-0858; Turner JS, 2020, IMMUNOL REV, V296, P9, DOI 10.1111/imr.12865; Turner ML, 2008, J IMMUNOL, V181, P374, DOI 10.4049/jimmunol.181.1.374; Turner ML, 2010, J IMMUNOL, V184, P6592, DOI 10.4049/jimmunol.0903437; Underhill DM, 2012, NAT REV IMMUNOL, V12, P492, DOI 10.1038/nri3244; Vijayashankar DP, 2021, EXP CELL RES, V405, DOI 10.1016/j.yexcr.2021.112650; Xiao Q, 2022, NAT REV IMMUNOL, V22, P188, DOI 10.1038/s41577-021-00572-5; Xu ZM, 2012, NAT REV IMMUNOL, V12, P517, DOI 10.1038/nri3216; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	85	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								882502	10.3389/fimmu.2022.882502	http://dx.doi.org/10.3389/fimmu.2022.882502			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U8CT	35663959	Green Published, gold			2022-12-18	WOS:000805634400001
J	Shah, AM; Zamora, R; Korff, S; Barclay, D; Yin, JL; El-Dehaibi, F; Billiar, TR; Vodovotz, Y				Shah, Ashti M.; Zamora, Ruben; Korff, Sebastian; Barclay, Derek; Yin, Jinling; El-Dehaibi, Fayten; Billiar, Timothy R.; Vodovotz, Yoram			Inferring Tissue-Specific, TLR4-Dependent Type 17 Immune Interactions in Experimental Trauma/Hemorrhagic Shock and Resuscitation Using Computational Modeling	FRONTIERS IN IMMUNOLOGY			English	Article						trauma; hemorrhagic shock; inflammation; systems biology; computational biology; Toll-like 4 receptor	TOLL-LIKE RECEPTOR-4; ACUTE LUNG INJURY; HEMORRHAGIC-SHOCK; SYSTEMIC INFLAMMATION; T-CELLS; TRAUMA; INNATE; TLR4; EXPRESSION; PATTERNS	Trauma/hemorrhagic shock followed by resuscitation (T/HS-R) results in multi-system inflammation and organ dysfunction, in part driven by binding of damage-associated molecular pattern molecules to Toll-like Receptor 4 (TLR4). We carried out experimental T/HS-R (pseudo-fracture plus 2 h of shock followed by 0-22 h of resuscitation) in C57BL/6 (wild type [WT]) and TLR4-null (TLR4(-/-)) mice, and then defined the dynamics of 20 protein-level inflammatory mediators in the heart, gut, lung, liver, spleen, kidney, and systemic circulation. Cross-correlation and Principal Component Analysis (PCA) on data from the 7 tissues sampled suggested that TLR4(-/-) samples express multiple inflammatory mediators in a small subset of tissue compartments as compared to the WT samples, in which many inflammatory mediators were localized non-specifically to nearly all compartments. We and others have previously defined a central role for type 17 immune cells in human trauma. Accordingly, correlations between IL-17A and GM-CSF (indicative of pathogenic Th17 cells); between IL-17A and IL-10 (indicative of non-pathogenic Th17 cells); and IL-17A and TNF (indicative of memory/effector T cells) were assessed across all tissues studied. In both WT and TLR4(-/-) mice, positive correlations were observed between IL-17A and GM-CSF, IL-10, and TNF in the kidney and gut. In contrast, the variable and dynamic presence of both pathogenic and non-pathogenic Th17 cells was inferred in the systemic circulation of TLR4(-/-) mice over time, suggesting a role for TLR4 in efflux of these cells into peripheral tissues. Hypergraph analysis - used to define dynamic, cross compartment networks - in concert with PCA-suggested that IL-17A was present persistently in all tissues at all sampled time points except for its absence in the plasma at 0.5h in the WT group, supporting the hypothesis that T/HS-R induces efflux of Th17 cells from the circulation and into specific tissues. These analyses suggest a complex, context-specific role for TLR4 and type 17 immunity following T/HS-R.	[Shah, Ashti M.; Zamora, Ruben; Korff, Sebastian; Barclay, Derek; Yin, Jinling; El-Dehaibi, Fayten; Billiar, Timothy R.; Vodovotz, Yoram] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; [Zamora, Ruben; Vodovotz, Yoram] McGowan Inst Regenerat Med, Ctr Inflammat & Regenerat Modeling, Pittsburgh, PA 15219 USA; [Vodovotz, Yoram] Univ Pittsburgh, Ctr Syst Immunol, Pittsburgh, PA 15260 USA; [Korff, Sebastian] Heidelberg Univ, Dept Orthoped & Traumatol, Heidelberg, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Ruprecht Karls University Heidelberg	Vodovotz, Y (corresponding author), Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA.; Vodovotz, Y (corresponding author), McGowan Inst Regenerat Med, Ctr Inflammat & Regenerat Modeling, Pittsburgh, PA 15219 USA.; Vodovotz, Y (corresponding author), Univ Pittsburgh, Ctr Syst Immunol, Pittsburgh, PA 15260 USA.	vodovotzy@upmc.edu			US Dept. of Energy [DE-AC05-76RL01830]	US Dept. of Energy(United States Department of Energy (DOE))	Funding AS: University of Pittsburgh School of Medicine Physician Scientist Training Program.	Abboud A, 2016, CRIT CARE MED, V44, pE1074, DOI 10.1097/CCM.0000000000001951; Abdul-Malak O, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7950374; Almahmoud K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217577; Almahmoud K, 2015, SHOCK, V44, P101, DOI 10.1097/SHK.0000000000000395; Almahmoud K, 2015, CRIT CARE MED, V43, P1395, DOI 10.1097/CCM.0000000000000964; Aral AM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.591154; Azhar N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88936-8; Barclay D, 2008, J CLIN LAB ANAL, V22, P278, DOI 10.1002/jcla.20253; Benhamou Y, 2009, CRIT CARE MED, V37, P1724, DOI 10.1097/CCM.0b013e31819da805; Bernal A, 2011, CURR COMPUT-AID DRUG, V7, P122; Beutler B, 2002, CURR TOP MICROBIOL, V270, P109; Billiar TR, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002342; Bonaroti J, 2021, ANTIOXID REDOX SIGN, V35, P1393, DOI 10.1089/ars.2021.0054; Brown D, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa3636; Chen TM, 2022, EBIOMEDICINE, V76, DOI 10.1016/j.ebiom.2022.103860; Chen TM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145108; Chong Jasmine, 2019, Curr Protoc Bioinformatics, V68, pe86, DOI 10.1002/cpbi.86; Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Cyr A, 2021, J AM COLL SURGEONS, V232, P276, DOI 10.1016/j.jamcollsurg.2020.12.022; Czura CJ, 2001, J ENDOTOXIN RES, V7, P315, DOI 10.1177/09680519010070041401; de Munter L, 2017, INJURY, V48, P221, DOI 10.1016/j.injury.2016.12.009; Deitch E A, 2001, Curr Opin Crit Care, V7, P92, DOI 10.1097/00075198-200104000-00007; Deng MH, 2013, J IMMUNOL, V190, P5152, DOI 10.4049/jimmunol.1300496; Ding N, 2014, CIRC-CARDIOVASC GENE, V7, P615, DOI 10.1161/CIRCGENETICS.113.000398; Ebbo M, 2017, NAT REV IMMUNOL, V17, P665, DOI 10.1038/nri.2017.86; Feng S, 2021, BMC BIOINFORMATICS, V22, DOI 10.1186/s12859-021-04197-2; Gao Y, 2022, IEEE T PATTERN ANAL, V44, P2548, DOI 10.1109/TPAMI.2020.3039374; Kaczorowski DJ, 2008, J LEUKOCYTE BIOL, V83, P546, DOI 10.1189/jlb.0607374; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Lamparello AJ, 2019, J AM COLL SURGEONS, V228, P148, DOI 10.1016/j.jamcollsurg.2018.10.019; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Liu YJ, 2009, J IMMUNOL, V182, P572, DOI 10.4049/jimmunol.182.1.572; Lord JM, 2014, LANCET, V384, P1455, DOI 10.1016/S0140-6736(14)60687-5; Lugo-Martinez J, 2021, BIOINFORMATICS, V37, P1000, DOI 10.1093/bioinformatics/btaa768; Lv TF, 2009, J TRAUMA, V66, P124, DOI 10.1097/TA.0b013e318181e555; Lyakh L, 2008, IMMUNOL REV, V226, P112, DOI 10.1111/j.1600-065X.2008.00700.x; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; McArthur MA, 2013, CLIN IMMUNOL, V146, P140, DOI 10.1016/j.clim.2012.12.003; Meng XZ, 2005, AM J PHYSIOL-REG I, V288, pR600, DOI 10.1152/ajpregu.00182.2004; Metukuri MR, 2009, AM J PHYSIOL-GASTR L, V296, pG499, DOI 10.1152/ajpgi.90526.2008; Mi Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019424; Mira JC, 2018, METHODS MOL BIOL, V1717, P1, DOI 10.1007/978-1-4939-7526-6_1; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Namas RA, 2016, J CRIT CARE, V36, P146, DOI 10.1016/j.jcrc.2016.07.002; Namas RA, 2015, ANTIOXID REDOX SIGN, V23, P1370, DOI 10.1089/ars.2015.6398; Namas RA, 2016, ANN SURG, V263, P191, DOI 10.1097/SLA.0000000000001001; Neal MD, 2006, J IMMUNOL, V176, P3070, DOI 10.4049/jimmunol.176.5.3070; Patel DD, 2015, IMMUNITY, V43, P1040, DOI 10.1016/j.immuni.2015.12.003; Peitzman A B, 1995, Curr Probl Surg, V32, P925, DOI 10.1016/S0011-3840(05)80008-5; Peters A, 2011, CURR OPIN IMMUNOL, V23, P702, DOI 10.1016/j.coi.2011.08.007; Pfeifer R, 2011, J ORTHOP RES, V29, P270, DOI 10.1002/jor.21214; Pierer M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023539; Prince JM, 2006, J AM COLL SURGEONS, V202, P407, DOI 10.1016/j.jamcollsurg.2005.11.021; Reino DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014829; Schimunek L, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589304; Seshadri A, 2017, CRIT CARE MED, V45, P1523, DOI 10.1097/CCM.0000000000002577; Sodhi CP, 2015, J IMMUNOL, V194, P4931, DOI 10.4049/jimmunol.1402490; Tang HQ, 2010, J IMMUNOL, V185, P2563, DOI 10.4049/jimmunol.0903664; Tian Z, 2009, BIOINFORMATICS, V25, P2831, DOI 10.1093/bioinformatics/btp467; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Ubeda C, 2012, J EXP MED, V209, P1445, DOI 10.1084/jem.20120504; van de Veerdonk FLV, 2010, J LEUKOCYTE BIOL, V88, P227, DOI 10.1189/jlb.0809550; Wang H, 2004, J INTERN MED, V255, P320, DOI 10.1111/j.1365-2796.2003.01302.x; Wang XF, 2013, HEPATOLOGY, V57, P373, DOI 10.1002/hep.25982; Watanabe H, 2004, SHOCK, V22, P460, DOI 10.1097/01.shk.0000142249.08135.e9; Weaver CT, 2007, ANNU REV IMMUNOL, V25, P821, DOI 10.1146/annurev.immunol.25.022106.141557; Wu JR, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100478; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Xu J, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002365; Yang R, 2002, AM J PHYSIOL-REG I, V283, pR1263, DOI 10.1152/ajpregu.00278.2002; Zaaqoq AM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02699; Zaaqoq AM, 2014, CRIT CARE MED, V42, P1487, DOI 10.1097/CCM.0000000000000248; Zamora R, 2021, MOL MED, V27, DOI 10.1186/s10020-021-00333-z; Zamora R, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006582; Zettel K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01672	76	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								908618	10.3389/fimmu.2022.908618	http://dx.doi.org/10.3389/fimmu.2022.908618			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U2PA	35663944	Green Published, gold			2022-12-18	WOS:000805258500001
J	Sundaram, S; Kim, EN; Jones, GM; Sivagnanam, S; Tripathi, M; Miremadi, A; Di Pietro, M; Coussens, LM; Fitzgerald, RC; Chang, YH; Zhuang, LZ				Sundaram, Srinand; Kim, Eun Na; Jones, Georgina M.; Sivagnanam, Shamilene; Tripathi, Monika; Miremadi, Ahmad; Di Pietro, Massimiliano; Coussens, Lisa M.; Fitzgerald, Rebecca C.; Chang, Young Hwan; Zhuang, Lizhe			Deciphering the Immune Complexity in Esophageal Adenocarcinoma and Pre-Cancerous Lesions With Sequential Multiplex Immunohistochemistry and Sparse Subspace Clustering Approach	FRONTIERS IN IMMUNOLOGY			English	Article						multiplex imaging; sparse subspace clustering; immune complexity; esophageal adenocarcinoma; Barrett's esophagus	TUMOR-ASSOCIATED MACROPHAGES; REGULATORY T-CELLS; BARRETTS-ESOPHAGUS; EXPRESSION; INFLAMMATION; ARCHITECTURE; REVEALS	Esophageal adenocarcinoma (EAC) develops from a chronic inflammatory environment across four stages: intestinal metaplasia, known as Barrett's esophagus, low- and high-grade dysplasia, and adenocarcinoma. Although the genomic characteristics of this progression have been well defined via large-scale DNA sequencing, the dynamics of various immune cell subsets and their spatial interactions in their tumor microenvironment remain unclear. Here, we applied a sequential multiplex immunohistochemistry (mIHC) platform with computational image analysis pipelines that allow for the detection of 10 biomarkers in one formalin-fixed paraffin-embedded (FFPE) tissue section. Using this platform and quantitative image analytics, we studied changes in the immune landscape during disease progression based on 40 normal and diseased areas from endoscopic mucosal resection specimens of chemotherapy treatment- naive patients, including normal esophagus, metaplasia, low- and high-grade dysplasia, and adenocarcinoma. The results revealed a steady increase of FOXP3(+) T regulatory cells and a CD163(+) myelomonocytic cell subset. In parallel to the manual gating strategy applied for cell phenotyping, we also adopted a sparse subspace clustering (SSC) algorithm allowing the automated cell phenotyping of mIHC-based single-cell data. The algorithm successfully identified comparable cell types, along with significantly enriched FOXP3 T regulatory cells and CD163(+) myelomonocytic cells as found in manual gating. In addition, SCC identified a new CSF1R(+)CD1C(+) myeloid lineage, which not only was previously unknown in this disease but also increases with advancing disease stages. This study revealed immune dynamics in EAC progression and highlighted the potential application of a new multiplex imaging platform, combined with computational image analysis on routine clinical FFPE sections, to investigate complex immune populations in tumor ecosystems.	[Sundaram, Srinand; Jones, Georgina M.; Tripathi, Monika; Miremadi, Ahmad; Di Pietro, Massimiliano; Fitzgerald, Rebecca C.; Zhuang, Lizhe] Univ Cambridge, Hutchison Med Res Council MRC Res Ctr, Med Res Council MRC Canc Unit, Cambridge, England; [Kim, Eun Na; Chang, Young Hwan] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA; [Sivagnanam, Shamilene; Coussens, Lisa M.] Oregon Hlth & Sci Univ, Dept Cell, Dev & Canc Biol, Portland, OR USA; [Coussens, Lisa M.; Chang, Young Hwan] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA	University of Cambridge; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Zhuang, LZ (corresponding author), Univ Cambridge, Hutchison Med Res Council MRC Res Ctr, Med Res Council MRC Canc Unit, Cambridge, England.; Chang, YH (corresponding author), Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97239 USA.; Chang, YH (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.	lz377@cam.ac.uk	Kim, Eun Na/GVU-5478-2022		CRUK-OHSU [C65718/A29808]; National Cancer Institute [U54CA209988]; National Institutes of Health [1U01 CA224012, U2C CA233280]; Knight Cancer Institute; OHSU-Brenden-Colson Center for Pancreatic Care; Medical Research Council [RG84369]	CRUK-OHSU; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Knight Cancer Institute; OHSU-Brenden-Colson Center for Pancreatic Care; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the CRUK-OHSU joint grant to YC and LZ (C65718/A29808) and was supported in part by the National Cancer Institute - U54CA209988. YC and LC acknowledges funding from the National Institutes of Health (1U01 CA224012, U2C CA233280), the Knight Cancer Institute, and the OHSU-Brenden-Colson Center for Pancreatic Care. The laboratory of RF is funded by a Core Programme Grant from the Medical Research Council (RG84369).	Abel EJ, 2014, HUM PATHOL, V45, P1092, DOI 10.1016/j.humpath.2014.01.008; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Banik G, 2020, METHOD ENZYMOL, V635, P1, DOI 10.1016/bs.mie.2019.05.039; Cappello F, 2005, BRIT J CANCER, V92, P888, DOI 10.1038/sj.bjc.6602415; Chang YH, 2017, IEEE ENG MED BIO, P4046, DOI 10.1109/EMBC.2017.8037744; Chang YH, 2017, IEEE ENG MED BIO, P672, DOI 10.1109/EMBC.2017.8036914; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crosby D, 2022, SCIENCE, V375, P1244, DOI 10.1126/science.aay9040; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018; Derks S, 2015, CANCER IMMUNOL RES, V3, P1123, DOI 10.1158/2326-6066.CIR-15-0046; Dong PP, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030320; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fitzgerald RC, 2002, GUT, V50, P451, DOI 10.1136/gut.50.4.451; Fitzgerald RC, 2020, LANCET, V396, P333, DOI 10.1016/S0140-6736(20)31099-0; Fitzgerald RC, 2014, GUT, V63, P7, DOI 10.1136/gutjnl-2013-305372; Galli F, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01586-y; Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/nmeth.2869, 10.1038/NMETH.2869]; Goltsev Y, 2018, CELL, V174, P968, DOI 10.1016/j.cell.2018.07.010; Grabsch HI., 2019, STANDARDS DATASETS R; Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001; Hou XX, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02018-z; Janssen LME, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0283-9; Jayasingam SD, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01512; Katikireddy KR, 2011, METHODS MOL BIOL, V784, P155, DOI 10.1007/978-1-61779-289-2_11; Klingen TA, 2017, HUM PATHOL, V69, P72, DOI 10.1016/j.humpath.2017.09.001; Lagisetty KH, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.143888; Lawlor KT, 2015, INT J MOL SCI, V16, P28098, DOI 10.3390/ijms161226078; Lin Jia-Ren, 2016, Curr Protoc Chem Biol, V8, P251, DOI 10.1002/cpch.14; Lind A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01375; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Mittal SK, 2015, J BIOL CHEM, V290, P27158, DOI 10.1074/jbc.M115.682708; Moons LMG, 2008, CARCINOGENESIS, V29, P926, DOI 10.1093/carcin/bgm241; Moons LMG, 2005, J PATHOL, V207, P269, DOI 10.1002/path.1847; Munch NS, 2019, GASTROENTEROLOGY, V157, P492, DOI 10.1053/j.gastro.2019.04.013; Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791; Nowicki-Osuch K, 2021, SCIENCE, V373, P760, DOI 10.1126/science.abd1449; Pan YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583084; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Quante M, 2012, CANCER CELL, V21, P36, DOI 10.1016/j.ccr.2011.12.004; Quatromoni JG, 2012, AM J TRANSL RES, V4, P376; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Romano M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01625; Ross-Innes CS, 2015, NAT GENET, V47, P1038, DOI 10.1038/ng.3357; Runge TM, 2015, GASTROENTEROL CLIN N, V44, P203, DOI 10.1016/j.gtc.2015.02.001; Schapiro D, 2017, NAT METHODS, V14, P873, DOI [10.1038/NMETH.4391, 10.1038/nmeth.4391]; Sivagnanam S., 2021, HTAN MULTIPLEX IHC I, DOI [10.17504/protocols.io.bsqjndun, DOI 10.17504/PROTOCOLS.IO.BSQJNDUN]; Somja J, 2013, AM J PATHOL, V182, P2168, DOI 10.1016/j.ajpath.2013.02.036; Sumitomo R, 2019, EXP THER MED, V18, P4490, DOI 10.3892/etm.2019.8068; Sun W, 2017, BRIT J CANCER, V117, P1631, DOI 10.1038/bjc.2017.329; Ternes L, 2022, COMMUN BIOL, V5, DOI 10.1038/s42003-022-03218-x; Tsujikawa T, 2017, CELL REP, V19, P203, DOI 10.1016/j.celrep.2017.03.037; Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592-019-0686-2; Visrodia K, 2016, ALIMENT PHARM THER, V44, P775, DOI 10.1111/apt.13783; Weaver JMJ, 2014, NAT GENET, V46, P837, DOI 10.1038/ng.3013; Yang CY, 2015, PR MACH LEARN RES, V37, P2463; Yoshimura K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.769534	57	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								874255	10.3389/fimmu.2022.874255	http://dx.doi.org/10.3389/fimmu.2022.874255			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V8AL	35663986	Green Published, gold			2022-12-18	WOS:000806306100001
J	Wang, WF; Ning, YP; Wang, YJ; Deng, GF; Pace, S; Barth, SA; Menge, C; Zhang, KH; Dai, YC; Cai, Y; Chen, XC; Werz, O				Wang, Wenfei; Ning, Yuping; Wang, Yejun; Deng, Guofang; Pace, Simona; Barth, Stefanie A.; Menge, Christian; Zhang, Kehong; Dai, Youchao; Cai, Yi; Chen, Xinchun; Werz, Oliver			Mycobacterium tuberculosis-Induced Upregulation of the COX-2/mPGES-1 Pathway in Human Macrophages Is Abrogated by Sulfasalazine	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; cyclooxygenase; sulfasalazine; macrophages; prostaglandin E-2	CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; INNATE IMMUNITY; MESSENGER-RNA; RECEPTOR EP2; KAPPA-B; ACTIVATION; CANCER; POLARIZATION; INHIBITION	Macrophages are the primary human host cells of intracellular Mycobacterium tuberculosis (M.tb) infection, where the magnitude of inflammatory reactions is crucial for determining the outcome of infection. Previously, we showed that the anti-inflammatory drug sulfasalazine (SASP) significantly reduced the M.tb bactericidal burden and histopathological inflammation in mice. Here, we asked which genes in human inflammatory macrophages are affected upon infection with M.tb and how would potential changes impact the functional state of macrophages. We used a flow cytometry sorting system which can distinguish the dead and alive states of M.tb harbored in human monocyte-derived macrophages (MDM). We found that the expression of cyclooxygenase-2 and microsomal prostaglandin E-2 synthase (mPGES)-1 increased significantly in tagRFP(+) MDM which were infected with alive M.tb. After exposure of polarized M1-MDM to M.tb (H37Rv strain)-conditioned medium (MTB-CM) or to the M.tb-derived 19-kD antigen, the production of PGE(2) and pro-inflammatory cytokines increased 3- to 4-fold. Upon treatment of M1-MDM with SASP, the MTB-CM-induced expression of COX-2 and the release of COX products and cytokines decreased. Elevation of PGE(2) in M1-MDM upon MTB-CM stimulation and modulation by SASP correlated with the activation of the NF-kappa B pathway. Together, infection of human macrophages by M.tb strongly induces COX-2 and mPGES-1 expression along with massive PGE(2) formation which is abrogated by the anti-inflammatory drug SASP.	[Wang, Wenfei; Ning, Yuping; Pace, Simona; Zhang, Kehong; Werz, Oliver] Friedrich Schiller Univ, Inst Pharm, Dept Pharmaceut Med Chem, Jena, Germany; [Wang, Wenfei; Ning, Yuping; Wang, Yejun; Zhang, Kehong; Dai, Youchao; Cai, Yi; Chen, Xinchun] Shenzhen Univ, Sch Med, Dept Pathogen Biol, Guangdong Prov Key Lab Reg Immun & Dis, Shenzhen, Peoples R China; [Deng, Guofang] Shenzhen Third Peoples Hosp, Guangdong Key Lab Emerging Infect Dis, Shenzhen, Peoples R China; [Barth, Stefanie A.; Menge, Christian] Fed Res Inst Anim Hlth, Inst Mol Pathogenesis, Friedrich Loeffler Inst, Jena, Germany	Friedrich Schiller University of Jena; Shenzhen University; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Friedrich Loeffler Institute	Werz, O (corresponding author), Friedrich Schiller Univ, Inst Pharm, Dept Pharmaceut Med Chem, Jena, Germany.; Chen, XC (corresponding author), Shenzhen Univ, Sch Med, Dept Pathogen Biol, Guangdong Prov Key Lab Reg Immun & Dis, Shenzhen, Peoples R China.		zhang, kehong/HGC-6351-2022; 张, 克宏/GRJ-9476-2022	Cai, Yi/0000-0002-1363-2328; Barth, Stefanie/0000-0003-4921-5056	National Natural Science Foundation [82070016]; Science and Technology Project of Shenzhen [JCYJ20180507182049853]; Deutsche Forschungsgemeinschaft (DFG) [SFB 1127, 239748522]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Science and Technology Project of Shenzhen; Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	This work was supported by the National Natural Science Foundation (grant number 82070016), the Science and Technology Project of Shenzhen (grant number JCYJ20180507182049853), and by the Deutsche Forschungsgemeinschaft (DFG), Collaborative Research Center SFB 1127 "ChemBioSys" (project number 239748522, project A04).	Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; [Anonymous], 1986, INFECT IMMUN, V51, P718; Augenstreich J, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.595029; Bai XY, 2016, RESPIROLOGY, V21, P951, DOI 10.1111/resp.12762; Bai XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061925; Behar SM, 2010, NAT REV MICROBIOL, V8, P668, DOI 10.1038/nrmicro2387; Bumann D, 2015, CELL HOST MICROBE, V17, P14, DOI 10.1016/j.chom.2014.12.006; Cai Y, 2016, ONCOTARGET, V7, P31001, DOI 10.18632/oncotarget.9052; Chen MJ, 2008, J EXP MED, V205, P2791, DOI 10.1084/jem.20080767; Cronstein BN, 1995, BRIT J RHEUMATOL, V34, P30; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Divangahi M, 2009, NAT IMMUNOL, V10, P899, DOI 10.1038/ni.1758; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; English JT, 2017, PROSTAG LEUKOTR ESS, V117, P17, DOI 10.1016/j.plefa.2017.01.004; Ferluga J, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2020.151951; Gan HT, 2005, J GASTROEN HEPATOL, V20, P1016, DOI 10.1111/j.1440-1746.2005.03862.x; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Jordan PM, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108247; Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029; Kaul V, 2012, J INFECT DIS, V206, P1816, DOI 10.1093/infdis/jis609; KHAN AKA, 1983, CLIN SCI, V64, P349, DOI 10.1042/cs0640349; Khan Z, 2011, CURR DRUG TARGETS, V12, P1082, DOI 10.2174/138945011795677764; Kim EH, 2018, CANCER LETT, V432, P180, DOI 10.1016/j.canlet.2018.06.018; Kolloli A, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00171; Kumar NP, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz257; Kumar P, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0119-0; Kunzmann AT, 2013, CANCER EPIDEM BIOMAR, V22, P1490, DOI 10.1158/1055-9965.EPI-13-0263; Liang L, 2016, INFECT GENET EVOL, V46, P23, DOI 10.1016/j.meegid.2016.10.016; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Luz RA, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/102160; MacMullan PA, 2016, CLIN RHEUMATOL, V35, P447, DOI 10.1007/s10067-014-2769-x; McClean CM, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw068; Miek L, 2022, IMMUNOLOGY, V166, P47, DOI 10.1111/imm.13449; Pellegrini JM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92667-1; Moideen K, 2020, CYTOKINE, V127, DOI 10.1016/j.cyto.2019.154929; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Mustafa A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010027; Nagano S, 2002, INT IMMUNOL, V14, P733, DOI 10.1093/intimm/dxf038; Nieminen R, 2006, INT IMMUNOPHARMACOL, V6, P987, DOI 10.1016/j.intimp.2006.01.009; Nore KG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579849; Organization World Health, 2021, INT J INFECT DIS; Price JV, 2014, IMMUNITY, V41, P685, DOI 10.1016/j.immuni.2014.10.015; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Romp E, 2020, CELL MOL LIFE SCI, V77, P3841, DOI 10.1007/s00018-019-03393-x; Schaible AM, 2013, BIOCHEM PHARMACOL, V86, P476, DOI 10.1016/j.bcp.2013.04.015; Seishinna R, 2016, CLIN RES HEPATOL GAS, V40, P487, DOI 10.1016/j.clinre.2015.11.007; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Sica A, 2015, CELL MOL LIFE SCI, V72, P4111, DOI 10.1007/s00018-015-1995-y; Smith WL, 2011, CHEM REV, V111, P5821, DOI 10.1021/cr2002992; Vynnycky E, 2000, AM J EPIDEMIOL, V152, P247, DOI 10.1093/aje/152.3.247; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wallis RS, 2015, NAT REV IMMUNOL, V15, P255, DOI 10.1038/nri3813; Werner M, 2019, FASEB J, V33, P6140, DOI 10.1096/fj.201802509R	53	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								849583	10.3389/fimmu.2022.849583	http://dx.doi.org/10.3389/fimmu.2022.849583			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V6LW	35663935	Green Published, gold			2022-12-18	WOS:000806199900001
J	Wu, HM; Zeng, LH; Ou, JX; Wang, TT; Chen, Y; Nandakumar, KS				Wu, Huimei; Zeng, Longhui; Ou, Jiaxin; Wang, Tingting; Chen, Yong; Nandakumar, Kutty Selva			Estrogen Acts Through Estrogen Receptor-beta to Promote Mannan-Induced Psoriasis-Like Skin Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						psoriasis; estrogen; estrogen receptor beta; gamma delta T cells; dendritic cells; IL-23/IL-17 axis	DELTA-T-CELLS; THERAPEUTIC TARGETS; MICRORNA EXPRESSION; GENE-EXPRESSION; GAMMA; IMMUNITY; WOMEN; SEX; DIFFERENTIATION; PROLIFERATION	Sex-bias is more obvious in several autoimmune disorders, but not in psoriasis. However, estrogen levels fluctuate during puberty, menstrual cycle, pregnancy, and menopause, which are related to variations in psoriasis symptoms observed in female patients. Estrogen has disease promoting or ameliorating functions based on the type of immune responses and tissues involved. To investigate the effects of estrogen on psoriasis, at first, we developed an innate immunity dependent mannan-induced psoriasis model, which showed a clear female preponderance in disease severity in several mouse strains. Next, we investigated the effects of endogenous and exogenous estrogen using ovariectomy and sham operated mice. 17-beta-estradiol (E2) alone promoted the skin inflammation and it also significantly enhanced mannan-induced skin inflammation. We also observed a prominent estrogen receptor-beta (ER-beta) expression in the skin samples, especially on keratinocytes. Subsequently, we confirmed the effects of E2 on psoriasis using ER-beta antagonist (PHTPP) and agonist (DPN). In addition, estrogen was found to affect the expression of certain genes (vgll3 and cebpb), microRNAs (miR146a and miR21), and immune cells (DCs and gamma delta T cells) as well as chemokines (CCL5 and CXCL10) and cytokines (TNF-alpha, IL-6, IL-22, IL-23, and IL-17 family), which promoted the skin inflammation. Thus, we demonstrate a pathogenic role for 17-beta-estradiol in promoting skin inflammation, which should be considered while designing new treatment strategies for psoriasis patients.	[Wu, Huimei; Ou, Jiaxin; Wang, Tingting; Nandakumar, Kutty Selva] Southern Med Univ, Karolinska Inst, Sch Pharmaceut Sci, United Med Inflammat Ctr, Guangzhou, Peoples R China; [Zeng, Longhui] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Orthoped, Guangzhou, Peoples R China; [Chen, Yong] Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Dept Rheumatol & Immunol,Clin Med Coll 2,Affiliate, Shenzhen, Peoples R China	Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Jinan University; Southern University of Science & Technology	Nandakumar, KS (corresponding author), Southern Med Univ, Karolinska Inst, Sch Pharmaceut Sci, United Med Inflammat Ctr, Guangzhou, Peoples R China.	nandakumar@smu.edu.cn	Nandakumar, Kutty Selva/D-5438-2011	Nandakumar, Kutty Selva/0000-0001-7790-8197	Southern Medical University, Guangzhou, China [C1034211, C1051004]	Southern Medical University, Guangzhou, China	This project was supported by "High-level talent introduction plan" project grants from Southern Medical University, Guangzhou, China (grant numbers C1034211, C1051004) given to KSN.	Albrecht ED, 2003, HUM REPROD, V18, P2039, DOI 10.1093/humrep/deg415; Andersson A, 2015, CLIN IMMUNOL, V161, P324, DOI 10.1016/j.clim.2015.09.014; Anipindi Varun C, 2019, Immunohorizons, V3, P317, DOI 10.4049/immunohorizons.1900040; Antonelli A, 2014, AUTOIMMUN REV, V13, P272, DOI 10.1016/j.autrev.2013.10.010; Antonini D, 2015, NUCLEIC ACIDS RES, V43, P862, DOI 10.1093/nar/gku1396; BAKER BS, 1992, BRIT J DERMATOL, V126, P105, DOI 10.1111/j.1365-2133.1992.tb07805.x; BRINCAT M, 1987, OBSTET GYNECOL, V70, P123; Buffa FM, 2011, CANCER RES, V71, P5635, DOI 10.1158/0008-5472.CAN-11-0489; Bupp MRG, 2015, CELL IMMUNOL, V294, P102, DOI 10.1016/j.cellimm.2015.02.002; Calippe B, 2010, J IMMUNOL, V185, P1169, DOI 10.4049/jimmunol.0902383; Campbell L, 2010, J EXP MED, V207, P1825, DOI 10.1084/jem.20100500; Castles CG, 1997, J STEROID BIOCHEM, V62, P155, DOI 10.1016/S0960-0760(97)00023-X; Chung HH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46485; Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488; Dragin N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08631-5; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Fry L, 2007, CLIN DERMATOL, V25, P606, DOI 10.1016/j.clindermatol.2007.08.015; Giannoni E, 2011, INFECT IMMUN, V79, P2690, DOI 10.1128/IAI.00076-11; Gudjonsson JE, 2009, J INVEST DERMATOL, V129, P2795, DOI 10.1038/jid.2009.173; Hagg D, 2017, AM J CLIN DERMATOL, V18, P583, DOI 10.1007/s40257-017-0274-0; Harding AT, 2022, CANCERS, V14, DOI 10.3390/cancers14040909; Iwano R, 2020, J APPL TOXICOL, V40, P1353, DOI 10.1002/jat.3988; Khan D, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00635; Khan D, 2010, EUR J IMMUNOL, V40, P2549, DOI 10.1002/eji.201040303; Khmaladze I, 2014, P NATL ACAD SCI USA, V111, pE3669, DOI 10.1073/pnas.1405798111; Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289; Knight J, 2012, HUM MOL GENET, V21, P5185, DOI 10.1093/hmg/dds344; Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549; Kovats S, 2015, CELL IMMUNOL, V294, P63, DOI 10.1016/j.cellimm.2015.01.018; Laffont S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00108; Lin X, 2016, J EUR ACAD DERMATOL, V30, P1085, DOI 10.1111/jdv.13661; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Ma HL, 2008, J CLIN INVEST, V118, P597, DOI 10.1172/JCI33263; Miyagawaa S, 2015, P NATL ACAD SCI USA, V112, P12986, DOI 10.1073/pnas.1513550112; Moulton VR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02279; Murase JE, 2005, ARCH DERMATOL, V141, P601, DOI 10.1001/archderm.141.5.601; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Naqvi S, 2019, SCIENCE, V365, P249, DOI 10.1126/science.aaw7317; Newcomb DC, 2015, J ALLERGY CLIN IMMUN, V136, P1025, DOI 10.1016/j.jaci.2015.05.046; Odhams CA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10106-2; Pagenkopf A, 2020, FEBS LETT, V594, P3371, DOI 10.1002/1873-3468.13911; Pantelyushin S, 2012, J CLIN INVEST, V122, P2252, DOI 10.1172/JCI61862; Polari L, 2018, INFLAMMATION, V41, P1157, DOI 10.1007/s10753-018-0763-1; Raghunath RS, 2015, CLIN EXP DERMATOL, V40, P111, DOI 10.1111/ced.12588; Selmi C, 2019, EXPERT REV CLIN IMMU, V15, P607, DOI 10.1080/1744666X.2019.1606714; Siersbaek R, 2020, CANCER CELL, V38, P412, DOI 10.1016/j.ccell.2020.06.007; Singh RP, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.725325; Son ED, 2005, J INVEST DERMATOL, V124, P1149, DOI 10.1111/j.0022-202X.2005.23736.x; Sperling T, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002833; STEVENS HP, 1993, BRIT J DERMATOL, V129, P458, DOI 10.1111/j.1365-2133.1993.tb03177.x; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Tillett W, 2017, RHEUMATOLOGY, V56, P2109, DOI 10.1093/rheumatology/kex323; Vaher H, 2020, EXP DERMATOL, V29, P51, DOI 10.1111/exd.14049; Wu SW, 2016, ACTA DERM-VENEREOL, V96, P927, DOI 10.2340/00015555-2312; Yan W, 2017, MOL NEUROBIOL, V54, P1631, DOI 10.1007/s12035-016-9769-6; Zhong JH, 2021, J INVEST DERMATOL, V141, P1765, DOI 10.1016/j.jid.2021.01.006; Zhong JH, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aas9864; Zhou T, 2016, CELL PHYSIOL BIOCHEM, V38, P959, DOI 10.1159/000443048	58	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								818173	10.3389/fimmu.2022.818173	http://dx.doi.org/10.3389/fimmu.2022.818173			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W0ZR	35663991	Green Published, gold			2022-12-18	WOS:000806510400001
J	Wu, YX; Zhang, HC; Meng, LX; Li, FS; Yu, CY				Wu, Yixin; Zhang, Huicong; Meng, Liuxian; Li, Fusheng; Yu, Changyuan			Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; protein vaccine; mRNA vaccine; IgG subclass antibodies; cellular immune response	CELL RESPONSES; FCR	After the outbreak of COVID-19, billions of vaccines with different types have been administrated, including recombinant protein vaccines and mRNA vaccines. Although both types of SARS-CoV-2 vaccine can protect people from viral infection, their differences in humoral and cellular immune responses are still not clearly understood. In this study, we made a head-to-head comparison between an mRNA vaccine candidate and a recombinant protein vaccine we developed previously. Results demonstrated that both vaccine candidates could elicit high specific binding and neutralizing antibody titers in BALB/c mice, but with bias towards different IgG subtypes. Besides, the mRNA vaccine candidate induces higher cellular immune responses than the recombinant protein vaccine. To date, this is the first reported study to directly compare the immune responses of both arms between SARS-CoV-2 mRNA and recombinant vaccines.	[Wu, Yixin; Meng, Liuxian; Yu, Changyuan] Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing, Peoples R China; [Zhang, Huicong; Li, Fusheng] Sysvax Inc, Res Dept, Beijing, Peoples R China; [Li, Fusheng] Sun Yat sen Biomed Inst Ltd, Vaccine Div, Hong Kong, Peoples R China	Beijing University of Chemical Technology	Yu, CY (corresponding author), Beijing Univ Chem Technol, Coll Life Sci & Technol, Beijing, Peoples R China.; Li, FS (corresponding author), Sysvax Inc, Res Dept, Beijing, Peoples R China.; Li, FS (corresponding author), Sun Yat sen Biomed Inst Ltd, Vaccine Div, Hong Kong, Peoples R China.	fushengli@sysvax.com; yucy@mail.buct.edu.cn			National Natural Science Foundation of China [82174531]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (Grant No. 82174531).	Bergmann CC, 2006, NAT REV MICROBIOL, V4, P121, DOI 10.1038/nrmicro1343; Cao YH, 2021, ECLINICALMEDICINE, V32, DOI 10.1016/j.eclinm.2021.100746; Elia U, 2021, NANO LETT, V21, P4774, DOI 10.1021/acs.nanolett.1c01284; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang Y, 2020, ACTA PHARMACOL SIN, V41, P1141, DOI 10.1038/s41401-020-0485-4; Huber VC, 2006, CLIN VACCINE IMMUNOL, V13, P981, DOI 10.1128/CVI.00156-06; KIPPS TJ, 1985, J EXP MED, V161, P1, DOI 10.1084/jem.161.1.1; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Nimmerjahn F, 2005, SCIENCE, V310, P1510, DOI 10.1126/science.1118948; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Park KS, 2021, ADV DRUG DELIVER REV, V169, P137, DOI 10.1016/j.addr.2020.12.008; Shin EC, 2016, NAT REV IMMUNOL, V16, P509, DOI 10.1038/nri.2016.69; Stern LJ, 2016, CURR OPIN IMMUNOL, V40, P70, DOI 10.1016/j.coi.2016.03.004; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Tang F, 2011, J IMMUNOL, V186, P7264, DOI 10.4049/jimmunol.0903490; Teo SP, 2022, J PHARM PRACT, V35, P947, DOI 10.1177/08971900211009650; Verbeke R, 2021, J CONTROL RELEASE, V333, P511, DOI 10.1016/j.jconrel.2021.03.043; Wadhwa A, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020102; Wang YF, 2021, J MED VIROL, V93, P892, DOI 10.1002/jmv.26320; Zhang NN, 2020, CELL, V182, P1271, DOI 10.1016/j.cell.2020.07.024	20	0	0	17	17	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								906457	10.3389/fimmu.2022.906457	http://dx.doi.org/10.3389/fimmu.2022.906457			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U7YO	35663946	Green Published, gold			2022-12-18	WOS:000805623500001
J	Xiao, Y; Ding, JH; Ma, DC; Chen, S; Li, X; Yu, KD				Xiao, Yi; Ding, Jiahan; Ma, Dachang; Chen, Sheng; Li, Xun; Yu, Keda			Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						trastuzumab; pertuzumab; predictive model; neoadjuvant treatment; HER2-amplified breast cancer	GROWTH-FACTOR RECEPTOR; PREOPERATIVE CHEMOTHERAPY; THERAPY; AMPLIFICATION; COMBINATION; NOMOGRAMS; LAPATINIB; SURVIVAL; EFFICACY; PLACEBO	BackgroundDual-targeted therapy is the standard treatment for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and effective biomarkers to predict the response to neoadjuvant trastuzumab and pertuzumab treatment need further investigation. Here, we developed a predictive model to evaluate the dual-targeted neoadjuvant treatment efficacy in HER2 gene-amplified breast cancer. MethodThis retrospective study included 159 HER2-amplified patients with locally advanced breast cancer who received neoadjuvant trastuzumab, pertuzumab, and chemotherapy. The correlation between clinicopathological factors and pathological complete response (pCR, in the breast and axilla) was evaluated. Patients were randomly assigned into the training set (n=110) and the testing set (n=49). We used an independent cohort (n=65) for external validation. We constructed our predictive nomogram model with the results of risk variables associated with pCR identified in the multivariate logistic analysis. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve, decision curve analysis, and calibration curves were employed to assess the nomogram's performance. ResultsWe revealed that the HER2/CEP17 ratio (p=0.001), CD8 levels (p=0.005), and histological grade (p=0.007) were independent indicators for pCR in dual-targeted neoadjuvant treatment after multivariate adjustment. The combined prediction efficacy of the three indicators was significantly higher than that of each single indicator alone. The AUCs were 0.819, 0.773, and 0.744 in the training, testing, and external validation sets, respectively. ConclusionsThe HER2/CEP17 ratio, CD8 levels, and histological grade were significantly correlated with pCR in dual-targeted neoadjuvant treatment. The combined model using these three markers provided a better predictive value for pCR than the HER2/CEP17 ratio, CD8 levels, and the histological grade alone, which showed that an immunological effect partially mediates the predictive impact of neoadjuvant treatment.	[Xiao, Yi; Ma, Dachang] Lanzhou Univ, Hosp 1, Dept Breast Surg, Lanzhou, Peoples R China; [Xiao, Yi; Li, Xun] Lanzhou Univ, Hosp 1, Dept Gen Surg, Lanzhou, Peoples R China; [Ding, Jiahan; Chen, Sheng; Yu, Keda] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China	Lanzhou University; Lanzhou University; Fudan University	Li, X (corresponding author), Lanzhou Univ, Hosp 1, Dept Gen Surg, Lanzhou, Peoples R China.; Yu, KD (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Shanghai, Peoples R China.	lixundr21@outlook.com; yukeda@fudan.edu.cn						Al-Saleh K, 2017, ONCOL LETT, V14, P337, DOI 10.3892/ol.2017.6144; Balachandran VP, 2015, LANCET ONCOL, V16, pE173, DOI 10.1016/S1470-2045(14)71116-7; Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206; Burstein HJ, 2014, J CLIN ONCOL, V32, P3959, DOI 10.1200/JCO.2014.56.7941; Choi JH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023053; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Denkert C, 2018, LANCET ONCOL, V19, P40, DOI 10.1016/S1470-2045(17)30904-X; Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370; Di Maio M, 2020, JAMA ONCOL, V6, P926, DOI 10.1001/jamaoncol.2020.0475; Finn RS, 2009, J CLIN ONCOL, V27, P3908, DOI 10.1200/JCO.2008.18.1925; Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9; Gown AM, 2008, MODERN PATHOL, V21, P1271, DOI 10.1038/modpathol.2008.83; Greenwell K, 2020, BREAST CANCER RES TR, V181, P249, DOI 10.1007/s10549-020-05599-1; Harbeck N, 2021, CANCERS, V13, DOI 10.3390/cancers13194884; Hurvitz SA, 2018, LANCET ONCOL, V19, P115, DOI 10.1016/S1470-2045(17)30716-7; Hwang HW, 2019, BREAST CANCER RES TR, V173, P255, DOI 10.1007/s10549-018-4981-x; Iqbal Nida, 2014, Mol Biol Int, V2014, P852748, DOI 10.1155/2014/852748; Jia LY, 2021, CLIN BREAST CANCER, V21, pE654, DOI 10.1016/j.clbc.2021.04.010; Katayama A, 2021, MODERN PATHOL, V34, P1271, DOI 10.1038/s41379-021-00738-5; Kogawa T, 2016, ONCOLOGIST, V21, P21, DOI 10.1634/theoncologist.2015-0101; Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491; Lee KH, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4832-5; Liu FF, 2011, BREAST CANCER RES TR, V130, P645, DOI 10.1007/s10549-011-1647-3; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Mao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115103; Masuda N, 2020, BREAST CANCER RES TR, V180, P135, DOI 10.1007/s10549-020-05524-6; McNamara KL, 2021, NAT CANCER, V2, P400, DOI 10.1038/s43018-021-00190-z; Metzger O, 2013, J CLIN ONCOL, V31, P3083, DOI 10.1200/JCO.2012.46.1574; Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957; Nami B, 2018, CANCERS, V10, DOI 10.3390/cancers10100342; Ogston KN, 2003, BREAST, V12, P320, DOI 10.1016/S0960-9776(03)00106-1; Perez EA, 2014, CANCER TREAT REV, V40, P276, DOI 10.1016/j.ctrv.2013.09.001; Perez EA, 2010, J CLIN ONCOL, V28, P4307, DOI 10.1200/JCO.2009.26.2154; Press MF, 1997, J CLIN ONCOL, V15, P2894, DOI 10.1200/JCO.1997.15.8.2894; Press MF, 2019, JAMA ONCOL, V5, P366, DOI 10.1001/jamaoncol.2018.6012; Rastogi P, 2008, J CLIN ONCOL, V26, P778, DOI 10.1200/JCO.2007.15.0235; Rouzier R, 2005, J CLIN ONCOL, V23, P8331, DOI 10.1200/JCO.2005.01.2898; Schneeweiss A, 2013, ANN ONCOL, V24, P2278, DOI 10.1093/annonc/mdt182; Stanton SE, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0165-6; Vu T, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00062; Wang K, 2016, ONCOTARGET, V7, P44288, DOI 10.18632/oncotarget.9988; Wolff AC, 2018, ARCH PATHOL LAB MED, V142, P1364, DOI [10.5858/arpa.2018-0902-SA, 10.1200/JCO.2018.77.8738]; Wu ZP, 2018, ONCOTARGETS THER, V11, P801, DOI 10.2147/OTT.S157634; Yamashita-Kashima Y, 2017, ONCOL LETT, V14, P4197, DOI 10.3892/ol.2017.6679; Yu KD, 2012, ONCOLOGIST, V17, P792, DOI 10.1634/theoncologist.2011-0381; Zhou ZR, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.08.63	46	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								877825	10.3389/fimmu.2022.877825	http://dx.doi.org/10.3389/fimmu.2022.877825			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U7YP	35663978	Green Published, gold			2022-12-18	WOS:000805623600001
J	Yu, K; Ji, YL; Liu, M; Shen, FG; Xiong, XX; Gu, LJ; Lu, TZ; Ye, YZ; Feng, S; He, JY				Yu, Kai; Ji, Yulong; Liu, Min; Shen, Fugeng; Xiong, Xiaoxing; Gu, Lijuan; Lu, Tianzhu; Ye, Yingze; Feng, Shi; He, Jianying			High Expression of CKS2 Predicts Adverse Outcomes: A Potential Therapeutic Target for Glioma	FRONTIERS IN IMMUNOLOGY			English	Article						glioma; cyclin-dependent kinases; bioinformatics; biomarkers; prognosis; immune related	TUMOR-INFILTRATING LYMPHOCYTES; GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; CANCER; CELLS; PROTEIN; IDENTIFICATION; PROLIFERATION; GLIOBLASTOMA; LANDSCAPE	Cyclin-dependent kinase regulatory subunit 2 (CKS2) is a potential prognostic marker and is overexpressed in various cancers. This study analyzed sequencing and clinical data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus, with external validation using the Chinese Glioma Genome Atlas (CGGA) data. CKS2 expression in the normal brain and tumor tissue was compared. cBioPortal and MethSurv were utilized to scrutinize the prognostic value of CKS2 methylation. Gene set enrichment examination and single-sample gene set enrichment analysis were employed to explore the potential biological functions of CKS2. Cell viability, colony formation, and transwell assays were conducted to evaluate the influence of CKS2 on glioma cell proliferation and invasion. Compared with normal brain tissue, the expression of CKS2 was upregulated in glioma samples (p < 0.001). Multivariate data analysis from TCGA and CGGA indicated that increased expression of CKS2 was an independent risk factor for the prognosis of overall survival in glioma patients. CKS2 methylation was negatively associated with CKS2 expression. Patients with CKS2 hypomethylation had worse overall survival compared with patients with CKS2 methylation, as suggested by the analysis of both TCGA and CGGA datasets. The expression level of CKS2 is closely related to tumor immunity, including the correlation of tumor immune cell infiltration, immune score, and co-expression of multiple immune-related genes. In addition, CKS2 is associated with several immune checkpoints and responses to the chemotherapy drug cisplatin. CKS2 knockdown impeded the expansion and aggression of glioma cell lines. The changes in CKS2 expression may provide a novel prognostic biomarker that can be used to improve patient overall survival rates.	[Yu, Kai; Xiong, Xiaoxing; Ye, Yingze; Feng, Shi] Wuhan Univ, Renmin Hosp, Dept Neurosurg, Wuhan, Peoples R China; [Ji, Yulong; Lu, Tianzhu] Nangchang Univ, Jiangxi Canc Hosp, Key Lab Translat Canc Res, Nanchang, Peoples R China; [Liu, Min] Poyang Cty Peoples Hosp, Dept Neurosurg, Shangrao, Peoples R China; [Shen, Fugeng] Shangli Cty Tradit Chinese Med Hosp, Bone Traumatol Dept, Pingxiang, Peoples R China; [Gu, Lijuan] Wuhan Univ, Renmin Hosp, Cent Lab, Wuhan, Peoples R China; [He, Jianying] JiangXi Prov Peoples Hosp, Affiliated Hosp 1, Nanchang Med Coll, Dept Orthoped, Nanchang, Peoples R China	Wuhan University; Nanchang University; Wuhan University	He, JY (corresponding author), JiangXi Prov Peoples Hosp, Affiliated Hosp 1, Nanchang Med Coll, Dept Orthoped, Nanchang, Peoples R China.	hejianyinglaoshi@163.com						Bao ZS, 2014, GENOME RES, V24, P1765, DOI 10.1101/gr.165126.113; Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; de Wit NJW, 2005, BRIT J CANCER, V92, P2249, DOI 10.1038/sj.bjc.6602612; Deorah Sundeep, 2006, Neurosurg Focus, V20, pE1, DOI 10.3171/foc.2006.20.4.E1; Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Goodenberger ML, 2012, CANCER GENET-NY, V205, P613, DOI 10.1016/j.cancergen.2012.10.009; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang T, 2016, CANCER LETT, V375, P263, DOI 10.1016/j.canlet.2016.01.024; Kawakami K, 2006, ONCOL REP, V16, P521; Kessler J, 2019, CANCERS, V11, DOI 10.3390/cancers11060889; Kouidhi S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00353; Lan YS, 2008, INT J CANCER, V123, P543, DOI 10.1002/ijc.23548; Lee HE, 2008, BRIT J CANCER, V99, P1704, DOI 10.1038/sj.bjc.6604738; Liberal V, 2012, P NATL ACAD SCI USA, V109, P2754, DOI 10.1073/pnas.1102434108; Lin CY, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1667; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lv ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067591; Mahadevan NR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051845; Martens C, 2021, CANCERS, V13, DOI 10.3390/cancers13102342; Martinsson-Ahlzen HS, 2008, MOL CELL BIOL, V28, P5698, DOI 10.1128/MCB.01833-07; Marwitz S, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0354-2; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Moya IM, 2012, DEV CELL, V22, P501, DOI 10.1016/j.devcel.2012.01.007; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; RICHARDSON HE, 1990, GENE DEV, V4, P1332, DOI 10.1101/gad.4.8.1332; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Shen DY, 2010, LIVER INT, V30, P119, DOI 10.1111/j.1478-3231.2009.02106.x; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Uchikado Y, 2006, INT J ONCOL, V29, P1337; Urbanowicz-Kachnowicz I, 1999, INT J CANCER, V82, P98, DOI 10.1002/(SICI)1097-0215(19990702)82:1<98::AID-IJC17>3.0.CO;2-A; Vivian J, 2017, NAT BIOTECHNOL, V35, P314, DOI 10.1038/nbt.3772; Wang YY, 2015, NEURO-ONCOLOGY, V17, P282, DOI 10.1093/neuonc/nou130; Wang YZ, 2013, J CLIN ONCOL, V31, P1188, DOI 10.1200/JCO.2012.41.5984; Wilson Taylor A, 2014, Surg Neurol Int, V5, P64, DOI 10.4103/2152-7806.132138; Wong YF, 2006, INT J CANCER, V118, P2461, DOI 10.1002/ijc.21660; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zanetti M, 2016, ONCOGENE, V35, P269, DOI 10.1038/onc.2015.108; Zhang H, 2019, J CANCER, V10, P4793, DOI 10.7150/jca.32475; Ziegler A, 2009, BLOOD, V113, P3494, DOI 10.1182/blood-2008-08-175109; Zirn B, 2005, ONCOGENE, V24, P5246, DOI 10.1038/sj.onc.1208725	48	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								881453	10.3389/fimmu.2022.881453	http://dx.doi.org/10.3389/fimmu.2022.881453			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U2TP	35663965	Green Published, gold			2022-12-18	WOS:000805270600001
J	Zhang, YX; Cai, MT; He, MX; Lu, YQ; Luo, X; Zhang, TY				Zhang, Yin-Xi; Cai, Meng-Ting; He, Ming-Xia; Lu, Yu-Qiang; Luo, Xiao; Zhang, Tian-Yi			Case Report: Neuromyelitis Optica Spectrum Disorder With Progressive Elevation of Cerebrospinal Fluid Cell Count and Protein Level Mimicking Infectious Meningomyelitis: A Diagnostic Challenge	FRONTIERS IN IMMUNOLOGY			English	Article						neuromyelitis optica spectrum disorder; aquaporin-4 antibody; infectious meningomyelitis; cerebrospinal fluid; longitudinally extensive transverse myelitis; area postrema syndrome	MENINGOENCEPHALITIS	Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune-mediated idiopathic inflammatory demyelinating disease with a typical clinical presentation of optic neuritis, acute myelitis, and area postrema syndrome. Most NMOSD patients are seropositive for disease-specific and pathogenic aquaporin-4 (AQP4) antibodies, which are key markers for the NMOSD diagnosis. Herein, we report an atypical case of a 41-year-old man who complained of intractable hiccups and vomiting at disease onset, followed by fever, headache, back pain, progressive paresthesia, and weakness of extremities later on. Magnetic resonance imaging revealed longitudinally extensive transverse myelitis. Cerebrospinal fluid analysis showed progressive increases in the white blood cell count and the protein level, which were accompanied by the deterioration of clinical manifestations. The patient was initially suspected of infectious meningomyelitis but was finally diagnosed with NMOSD. This case with distinct cerebrospinal fluid findings broadens the phenotypic spectrum of NMOSD. Furthermore, it also highlights the clinical value of AQP4 antibody test for early definitive diagnosis and proper treatment.	[Zhang, Yin-Xi; Cai, Meng-Ting] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Neurol, Hangzhou, Peoples R China; [He, Ming-Xia] Tongde Hosp Prov, Dept Hematol, Hangzhou, Zhejiang, Peoples R China; [Lu, Yu-Qiang; Zhang, Tian-Yi] Tongde Hosp, Dept Neurol, Hangzhou, Zhejiang, Peoples R China; [Luo, Xiao] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Radiol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University	Zhang, TY (corresponding author), Tongde Hosp, Dept Neurol, Hangzhou, Zhejiang, Peoples R China.	21718237@zju.edu.cn						Benedetti L, 2015, MULT SCLER J, V21, P246, DOI 10.1177/1352458514524294; Camara-Lemarroy CR, 2019, MULT SCLER J, V25, P325, DOI 10.1177/1352458518813105; Cortese R, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.679881; Deisenhammer F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00726; Dubey D, 2017, JAMA NEUROL, V74, P355, DOI 10.1001/jamaneurol.2016.5441; Jarius S, 2011, J NEUROL SCI, V306, P82, DOI 10.1016/j.jns.2011.03.038; Jarius S, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0214-9; Jarius S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-14; Kim HJ, 2015, NEUROLOGY, V84, P1165, DOI 10.1212/WNL.0000000000001367; Li L, 2022, J SPINAL CORD MED, V45, P148, DOI 10.1080/10790268.2020.1749475; Shi BX, 2020, MULT SCLER RELAT DIS, V41, DOI 10.1016/j.msard.2020.102013; Wang JY, 2013, MULT SCLER J, V19, P639, DOI 10.1177/1352458512459785; Wingerchuk DM, 2015, NEUROLOGY, V85, P177, DOI 10.1212/WNL.0000000000001729	13	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								864664	10.3389/fimmu.2022.864664	http://dx.doi.org/10.3389/fimmu.2022.864664			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V8DO	35663994	Green Published, gold			2022-12-18	WOS:000806314300001
J	Zhuang, Q; Huang, LQ; Zeng, Y; Wu, X; Qiao, G; Liu, MH; Wang, LL; Zhou, YJ; Xiong, YX				Zhuang, Qian; Huang, Liqiang; Zeng, Yue; Wu, Xu; Qiao, Gan; Liu, Minghua; Wang, Lulu; Zhou, Yejiang; Xiong, Yuxia			Dynamic Monitoring of Immunoinflammatory Response Identifies Immunoswitching Characteristics of Severe Acute Pancreatitis in Rats	FRONTIERS IN IMMUNOLOGY			English	Article						severe acute pancreatitis; intestinal mucosal immune function; inflammation; immunosuppression; immunoswitching	EARLY ENTERAL NUTRITION; PERSISTENT INFLAMMATION; IMMUNE FUNCTION; IMMUNOSUPPRESSION; BARRIER; INJURY; CELLS; AUTOPHAGY; RECEPTOR; PROTEIN	BackgroundImmune dysfunction is the main characteristic of severe acute pancreatitis (SAP), and the timing of immune regulation has become a major challenge for SAP treatment. Previous reports about the time point at which the immune status of SAP changed from excessive inflammatory response to immunosuppression (hypo-inflammatory response) are conflicting. PurposesThe aims of this study are to explore the immunological dynamic changes in SAP rats from the perspective of intestinal mucosal immune function, and to determine the immunoswitching point from excessive inflammatory response to immunosuppression. MethodsRetrograde injection of sodium taurocholate into the pancreaticobiliary duct was applied to establish a SAP model in rats. The survival rate and the activities of serum amylase and pancreatic lipase in SAP rats were measured at different time points after model construction. The pathological changes in the pancreas and small intestines were analyzed, and the levels of intestinal pro- and anti-inflammatory cytokines and the numbers of intestinal macrophages, dendritic cells, Th1, Th2, and T regulatory cells were assessed. Meanwhile, the SAP rats were challenged with Pseudomonas aeruginosa (PA) strains to simulate a second hit, and the levels of intestinal inflammatory cytokines and the numbers of immune cells were analyzed to confirm the immunoswitching point. ResultsThe time periods of 12-24 h and 48-72 h were the two death peaks in SAP rats. The pancreas of SAP rats showed self-limiting pathological changes, and the switching period of intestinal cytokines, and innate and adaptive immunity indexes occurred at 24-48 h. It was further confirmed that 48 h after SAP model construction was the immunoswitching point from excessive inflammatory response to immunosuppression. ConclusionThe SAP rats showed characteristics of intestinal mucosal immune dysfunction after model construction, and the 48th h was identified as the immunoswitching point from excessive inflammatory response to immunosuppression. The results are of great significance for optimizing the timing of SAP immune regulation.	[Zhuang, Qian; Huang, Liqiang; Zeng, Yue; Wu, Xu; Qiao, Gan; Liu, Minghua; Wang, Lulu; Xiong, Yuxia] Southwest Med Univ, Sch Pharm, Dept Pharmacol, Luzhou, Peoples R China; [Huang, Liqiang] Second Peoples Hosp Yibin, Inst Clin Trials Drugs, Yibin, Peoples R China; [Zhou, Yejiang] Southwest Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Luzhou, Peoples R China	Southwest Medical University; Southwest Medical University	Xiong, YX (corresponding author), Southwest Med Univ, Sch Pharm, Dept Pharmacol, Luzhou, Peoples R China.; Zhou, YJ (corresponding author), Southwest Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Luzhou, Peoples R China.	zyj7525@163.com; xyx_cell@swmu.edu.cn			Project of National Natural Science Foundation of China [81873067, 81102868]	Project of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This research was supported by the Project of National Natural Science Foundation of China (Nos. 81873067 and 81102868).	Cen ME, 2018, APOPTOSIS, V23, P377, DOI 10.1007/s10495-018-1464-9; Chen L, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12480; Chen ZL, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9682; CHIU CJ, 1970, ARCH SURG-CHICAGO, V101, P484; Cui YJ, 2021, TOXINS, V13, DOI 10.3390/toxins13090651; del Fresno C, 2018, SCIENCE, V362, P351, DOI 10.1126/science.aan8423; Deng DM, 2017, INT IMMUNOPHARMACOL, V42, P49, DOI 10.1016/j.intimp.2016.11.011; Fonteh P, 2018, ARCH IMMUNOL THER EX, V66, P199, DOI 10.1007/s00005-017-0495-1; Francozo MCS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51311-9; Garg PK, 2019, GASTROENTEROLOGY, V156, P2008, DOI 10.1053/j.gastro.2018.12.041; Gentile LF, 2012, J TRAUMA ACUTE CARE, V72, P1491, DOI 10.1097/TA.0b013e318256e000; Glaubitz J, 2020, PANCREATOLOGY, V20, DOI 10.1016/j.pan.2020.10.044; Guo JG, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021491; Hoque R, 2014, GASTROENTEROLOGY, V146, P1763, DOI 10.1053/j.gastro.2014.03.014; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Huang LQ, 2018, DIGEST DIS SCI, V63, P910, DOI 10.1007/s10620-018-4962-2; Huang SQ, 2021, WORLD J GASTROENTERO, V27, P815, DOI 10.3748/wjg.v27.i9.815; Huang ZW, 2021, J FOOD BIOCHEM, V45, DOI 10.1111/jfbc.13905; Hussein MMA, 2016, ENVIRON TOXICOL PHAR, V41, P14, DOI 10.1016/j.etap.2015.11.008; Jin WY, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/3909468; Jin Y, 2018, EUR REV MED PHARMACO, V22, P4018, DOI 10.26355/eurrev_201806_15288; Kylanpaa ML, 2010, WORLD J GASTROENTERO, V16, P2867, DOI 10.3748/wjg.v16.i23.2867; Lerch MM, 2013, GASTROENTEROLOGY, V144, P1180, DOI 10.1053/j.gastro.2012.12.043; Li Y, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2032057; Li ZQ, 2019, CYTOKINE GROWTH F R, V50, P1, DOI 10.1016/j.cytogfr.2019.11.001; Liu JB, 2019, CRIT REV MICROBIOL, V45, P539, DOI 10.1080/1040841X.2019.1621795; Liu YQ, 2021, FEBS OPEN BIO, V11, P1109, DOI 10.1002/2211-5463.13115; Lord RS, 2008, ALTERN MED REV, V13, P292; McBride MA, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.624272; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Munir F, 2020, IMMUNOL LETT, V217, P72, DOI 10.1016/j.imlet.2019.11.002; Pan LL, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801419; Pan LY, 2017, CELL PHYSIOL BIOCHEM, V44, P2395, DOI 10.1159/000486155; Pan LY, 2010, PANCREAS, V39, P633, DOI 10.1097/MPA.0b013e3181c79654; Peng C, 2021, INT J MED SCI, V18, P534, DOI 10.7150/ijms.51618; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; Rivas MN, 2019, IMMUNITY, V51, P508, DOI 10.1016/j.immuni.2019.05.021; Ruder B, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102162; Salminen A, 2018, BIOGERONTOLOGY, V19, P325, DOI 10.1007/s10522-018-9762-8; Sattler A, 2009, BLOOD, V113, P1948, DOI 10.1182/blood-2008-02-139147; Schmidt AI, 2017, PANCREATOLOGY, V17, P209, DOI 10.1016/j.pan.2017.02.011; SCHMIDT J, 1992, ANN SURG, V215, P44, DOI 10.1097/00000658-199201000-00007; Sendler M, 2020, GASTROENTEROLOGY, V158, P253, DOI 10.1053/j.gastro.2019.09.040; Shang SL, 2020, BRIT J PHARMACOL, V177, P4147, DOI 10.1111/bph.15158; Sharma D, 2017, DIGEST DIS SCI, V62, P3468, DOI 10.1007/s10620-017-4813-6; Shen S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00999; Shen YF, 2011, INFLAMMATION, V34, P36, DOI 10.1007/s10753-010-9205-4; Singh P, 2016, INDIAN J GASTROENTER, V35, P153, DOI 10.1007/s12664-016-0647-y; Song JB, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011871; Su SY, 2021, INT J MED SCI, V18, P3050, DOI 10.7150/ijms.45980; Sun JK, 2013, WORLD J GASTROENTERO, V19, P917, DOI 10.3748/wjg.v19.i6.917; Sun T, 2020, J IMMUNOL, V204, P1075, DOI 10.4049/jimmunol.1900710; Takahashi N, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0210-3; Tan Y, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420941765; Tang YS, 2021, DIGEST DIS SCI, V66, P4344, DOI 10.1007/s10620-020-06801-6; Thomson JE, 2018, PANCREATOLOGY, V18, P246, DOI 10.1016/j.pan.2018.01.007; Tian FM, 2020, CLIN CHIM ACTA, V510, P665, DOI 10.1016/j.cca.2020.08.029; Wang CY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01873; Wang LX, 2021, CELL MOL LIFE SCI, V78, P8209, DOI 10.1007/s00018-021-03970-z; Wen WW, 2017, CLIN RES HEPATOL GAS, V41, P703, DOI 10.1016/j.clinre.2017.03.007; Wiersinga WJ, 2014, VIRULENCE, V5, P36, DOI 10.4161/viru.25436; Wu JH, 2020, EBIOMEDICINE, V58, DOI 10.1016/j.ebiom.2020.102920; Xiong YX, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00075; Xu D, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2517-x; Xu X, 2020, GASTROENT RES PRACT, V2020, DOI 10.1155/2020/2549486; Yan YP, 2017, MOL MED REP, V16, P8471, DOI 10.3892/mmr.2017.7661; Yang N, 2017, J CRIT CARE, V42, P101, DOI 10.1016/j.jcrc.2017.07.013; Yang YZ, 2016, ASIAN PAC J TROP MED, V9, P1088, DOI 10.1016/j.apjtm.2016.09.001; Ye C, 2018, INT J OBESITY, V42, P1471, DOI 10.1038/s41366-018-0125-y; Yossipof TE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00979; Zhai ZX., 2017, J IMMUNOL, V33, P9, DOI [10.13431/j.cnki.immunol.j.20170162, DOI 10.13431/J.CNKI.IMMUNOL.J.20170162]; Zhang XP, 2009, J ZHEJIANG UNIV-SC B, V10, P493, DOI 10.1631/jzus.B0820265; Zheng YS, 2015, PANCREAS, V44, P500, DOI 10.1097/MPA.0000000000000294; Zou XP, 2010, JPEN-PARENTER ENTER, V34, P554, DOI 10.1177/0148607110362691	74	0	0	6	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 19	2022	13								876168	10.3389/fimmu.2022.876168	http://dx.doi.org/10.3389/fimmu.2022.876168			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V6KM	35663952	Green Published, gold			2022-12-18	WOS:000806196300001
J	Alphonse, N; Dickenson, RE; Alrehaili, A; Odendall, C				Alphonse, Noemie; Dickenson, Ruth E.; Alrehaili, Abrar; Odendall, Charlotte			Functions of IFN?s in Anti-Bacterial Immunity at Mucosal Barriers	FRONTIERS IN IMMUNOLOGY			English	Review						type III interferon; IFN?s; interferon signaling; epithelial barrier; bacterial infection; mucosal barrier	INTERFERON-STIMULATED GENES; I INTERFERON; INTESTINAL INFLAMMATION; ANTIVIRAL PROTECTION; DENDRITIC CELLS; LAMBDA; EXPRESSION; ALPHA; INDUCTION; ROLES	Type III interferons (IFNs), or IFN lambda s, are cytokines produced in response to microbial ligands. They signal through the IFN lambda receptor complex (IFNLR), which is located on epithelial cells and select immune cells at barrier sites. As well as being induced during bacterial or viral infection, type III IFNs are produced in response to the microbiota in the lung and intestinal epithelium where they cultivate a resting antiviral state. While the multiple anti-viral activities of IFN lambda s have been extensively studied, their roles in immunity against bacteria are only recently emerging. Type III IFNs increase epithelial barrier integrity and protect from infection in the intestine but were shown to increase susceptibility to bacterial superinfections in the respiratory tract. Therefore, the effects of IFN lambda can be beneficial or detrimental to the host during bacterial infections, depending on timing and biological contexts. This duality will affect the potential benefits of IFN lambda s as therapeutic agents. In this review, we summarize the current knowledge on IFN lambda induction and signaling, as well as their roles at different barrier sites in the context of anti-bacterial immunity.	[Alphonse, Noemie; Dickenson, Ruth E.; Alrehaili, Abrar; Odendall, Charlotte] Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London, England; [Alphonse, Noemie] Francis Crick Inst, Immunoregulat Lab, London, England	University of London; King's College London; Francis Crick Institute	Odendall, C (corresponding author), Kings Coll London, Sch Immunol & Microbial Sci, Dept Infect Dis, London, England.	Charlotte.odendall@kcl.ac.uk			King's College London/Francis Crick Institute - Cancer Research UK [FC001206]; UK Medical Research Council [FC001206, MR/N013700/1]; Wellcome Trust [FC001206, 206200/Z/17/Z]; Ministry of Higher Education in the Kingdom of Saudi Arabia; Royal Society	King's College London/Francis Crick Institute - Cancer Research UK; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); Ministry of Higher Education in the Kingdom of Saudi Arabia; Royal Society(Royal Society of London)	NA is supported by a studentship from the King's College London/Francis Crick Institute partnership which receives its core funding from Cancer Research UK (FC001206), the UK Medical Research Council (FC001206) and the Wellcome Trust (FC001206). RD is supported by a studentship from the UK Medical Research Council (MR/N013700/1). AA is supported by a studentship from the Ministry of Higher Education in the Kingdom of Saudi Arabia. CO is supported by a Sir Henry Dale Fellowship from the Royal Society and the Wellcome Trust (206200/Z/17/Z). For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.	Ahn D, 2019, AM J RESP CELL MOL, V60, P158, DOI 10.1165/rcmb.2018-0021OC; Alphonse N, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.624094; Ardanuy J, 2020, J IMMUNOL, V204, P2192, DOI 10.4049/jimmunol.1900912; Baldridge MT, 2017, J VIROL, V91, DOI 10.1128/JVI.02079-16; Baldridge MT, 2015, SCIENCE, V347, P266, DOI 10.1126/science.1258025; Barbalat R, 2009, NAT IMMUNOL, V10, P1200, DOI 10.1038/ni.1792; Barquero B, 2018, INT J RES UN MATH ED, V4, P8, DOI 10.1007/s40753-017-0067-0; Bhushal S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00671; Bierne H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039080; Blazek K, 2015, J EXP MED, V212, P845, DOI 10.1084/jem.20140995; Bolen CR, 2014, HEPATOLOGY, V59, P1262, DOI 10.1002/hep.26657; Boxx GM, 2016, CELL HOST MICROBE, V19, P760, DOI 10.1016/j.chom.2016.05.016; Bradley KC, 2019, CELL REP, V28, P245, DOI 10.1016/j.celrep.2019.05.105; Broad A, 2007, IMMUNOLOGY, V120, P103, DOI 10.1111/j.1365-2567.2006.02485.x; Broggi A, 2020, SCIENCE, V369, P706, DOI 10.1126/science.abc3545; Broggi A, 2017, NAT IMMUNOL, V18, P1084, DOI 10.1038/ni.3821; Broquet A, 2020, MOL IMMUNOL, V118, P52, DOI 10.1016/j.molimm.2019.12.003; Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429; Caine EA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07993-2; Chiriac MT, 2017, GASTROENTEROLOGY, V153, P123, DOI 10.1053/j.gastro.2017.03.015; Cohen D, 2019, NATURE, V574, P691, DOI 10.1038/s41586-019-1605-5; Das S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22344-4; Davidson S, 2016, EMBO MOL MED, V8, P1099, DOI 10.15252/emmm.201606413; Davies BW, 2012, CELL, V149, P358, DOI 10.1016/j.cell.2012.01.053; de Groen RA, 2015, J LEUKOCYTE BIOL, V98, P623, DOI 10.1189/jlb.3A0215-041RR; Dickson RP, 2017, MBIO, V8, DOI 10.1128/mBio.02287-16; Donnelly RP, 2010, J INTERF CYTOK RES, V30, P555, DOI 10.1089/jir.2010.0078; Durbin RK, 2013, IMMUNOL REV, V255, P25, DOI 10.1111/imr.12101; Dziarski R, 2004, MOL IMMUNOL, V40, P877, DOI 10.1016/j.molimm.2003.10.011; Espinosa V, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan5357; Finotti G, 2016, J LEUKOCYTE BIOL, V99, P107, DOI 10.1189/jlb.3VMA0415-144R; Galani IE, 2017, IMMUNITY, V46, P875, DOI 10.1016/j.immuni.2017.04.025; Gallagher G, 2010, J INTERF CYTOK RES, V30, P603, DOI 10.1089/jir.2010.0081; Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933; Helbig KJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52130-8; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Iversen MB, 2010, J VIROL, V84, P4579, DOI 10.1128/JVI.02591-09; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Jilg N, 2014, HEPATOLOGY, V59, P1250, DOI 10.1002/hep.26653; Jordan WJ, 2007, GENES IMMUN, V8, P254, DOI 10.1038/sj.gene.6364382; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461; Kim HJ, 2019, MICROBIOME, V7, DOI 10.1186/s40168-019-0691-9; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Kotenko SV, 2003, NAT IMMUNOL, V4, P69, DOI 10.1038/ni875; Krajmalnik-Brown R, 2012, NUTR CLIN PRACT, V27, P201, DOI 10.1177/0884533611436116; Krammer F, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/s41572-018-0002-y; Kreins AY, 2015, J EXP MED, V212, P1641, DOI 10.1084/jem.20140280; Kutsch M, 2020, EMBO J, V39, DOI 10.15252/embj.2020104926; Lan F, 2019, J ALLERGY CLIN IMMUN, V143, P1416, DOI 10.1016/j.jaci.2018.09.041; Lasfar A, 2006, CANCER RES, V66, P4468, DOI 10.1158/0008-5472.CAN-05-3653; Lauterbach H, 2010, J EXP MED, V207, P2703, DOI 10.1084/jem.20092720; Lazear HM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac6108; Lebreton A, 2011, SCIENCE, V331, P1319, DOI 10.1126/science.1200120; Lee SJ, 2012, INT J MOL MED, V30, P945, DOI 10.3892/ijmm.2012.1064; Levy DE, 2001, CYTOKINE GROWTH F R, V12, P143, DOI 10.1016/S1359-6101(00)00027-7; Li LZ, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-5494; Li P, 2017, NATURE, V551, P378, DOI 10.1038/nature24467; Li XD, 2013, SCIENCE, V341, P1390, DOI 10.1126/science.1244040; Love AC, 2014, INFECT IMMUN, V82, P2405, DOI 10.1128/IAI.01617-14; Major J, 2020, SCIENCE, V369, P712, DOI 10.1126/science.abc2061; Marcello T, 2006, GASTROENTEROLOGY, V131, P1887, DOI 10.1053/j.gastro.2006.09.052; McElrath C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22928-0; Mordstein M, 2010, J VIROL, V84, P5670, DOI 10.1128/JVI.00272-10; Morehouse BR, 2020, NATURE, V586, P429, DOI 10.1038/s41586-020-2719-5; Morrison MH, 2014, HUM IMMUNOL, V75, P996, DOI 10.1016/j.humimm.2014.06.016; Odendall C, 2017, J IMMUNOL, V199, P3270, DOI 10.4049/jimmunol.1700250; Odendall C, 2014, NAT IMMUNOL, V15, P717, DOI 10.1038/ni.2915; Peignier A, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00352-20; Perez J, 2020, NONCANONICAL ROLES O; Pervolaraki K, 2019, J INTERF CYTOK RES, V39, P650, DOI 10.1089/jir.2019.0040; Pervolaraki K, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007420; Pervolaraki K, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00459; Pietila TE, 2010, J LEUKOCYTE BIOL, V88, P665, DOI 10.1189/jlb.1009651; Piro AS, 2017, MBIO, V8, DOI 10.1128/mBio.01979-17; Planet PJ, 2016, MBIO, V7, DOI 10.1128/mBio.01939-15; Pott J, 2011, P NATL ACAD SCI USA, V108, P7944, DOI 10.1073/pnas.1100552108; Ramos HC, 2004, TRENDS MICROBIOL, V12, P509, DOI 10.1016/j.tim.2004.09.002; Ranjbar S, 2015, CELL REP, V13, P874, DOI 10.1016/j.celrep.2015.09.048; Rauch I, 2015, MOL CELL BIOL, V35, P2332, DOI 10.1128/MCB.01498-14; Read SA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02674; Rich HE, 2019, INFECT IMMUN, V87, DOI 10.1128/IAI.00114-19; Rojas JM, 2021, CELL MOL LIFE SCI, V78, P1423, DOI 10.1007/s00018-020-03671-z; Santer DM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008515; Santos JC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16889-z; Santos JC, 2018, EMBO J, V37, DOI 10.15252/embj.201798089; Savitsky D, 2010, CANCER IMMUNOL IMMUN, V59, P489, DOI 10.1007/s00262-009-0804-6; Schnepf D, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abd5318; Schoggins JW, 2014, CURR OPIN VIROL, V6, P40, DOI 10.1016/j.coviro.2014.03.006; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Siebler J, 2007, GASTROENTEROLOGY, V132, P358, DOI 10.1053/j.gastro.2006.10.028; Sommereyns C, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000017; Souza-Fonseca-Guimaraes F, 2015, P NATL ACAD SCI USA, V112, pE2376, DOI 10.1073/pnas.1424241112; Stack J, 2014, J IMMUNOL, V193, P6090, DOI 10.4049/jimmunol.1401605; Stockinger S, 2014, J IMMUNOL, V193, P4223, DOI 10.4049/jimmunol.1302708; Syedbasha M, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108211; Taylor KE, 2013, IMMUNOLOGY, V138, P190, DOI 10.1111/imm.12038; Van Winkle JA., 2021, ELIFE, V11, P1, DOI [10.1101/2021.06.02.446828, DOI 10.1101/2021.06.02.446828]; Wandel MP, 2020, NAT IMMUNOL, V21, P880, DOI 10.1038/s41590-020-0697-2; Wandel MP, 2017, CELL HOST MICROBE, V22, P507, DOI 10.1016/j.chom.2017.09.007; Wolk K, 2008, J LEUKOCYTE BIOL, V83, P1181, DOI 10.1189/jlb.0807525; Xu XQ, 2019, J INNATE IMMUN, V11, P29, DOI 10.1159/000490586; Yin ZW, 2012, J IMMUNOL, V189, P2735, DOI 10.4049/jimmunol.1102038; Yoon SI, 2010, STRUCTURE, V18, P638, DOI 10.1016/j.str.2010.02.009; Zanoni I, 2016, SCIENCE, V352, P1232, DOI 10.1126/science.aaf3036; Zhang SY, 2013, GASTROENTEROLOGY, V144, P414, DOI 10.1053/j.gastro.2012.10.034; Zhou JH, 2018, CELL PHYSIOL BIOCHEM, V51, P173, DOI 10.1159/000495172; Zhou ZL, 2007, J VIROL, V81, P7749, DOI 10.1128/JVI.02438-06	111	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								857639	10.3389/fimmu.2022.857639	http://dx.doi.org/10.3389/fimmu.2022.857639			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V9LK	35663961	gold, Green Published			2022-12-18	WOS:000806405100001
J	Amorim, CS; Moraes, JA; Magdalena, ID; Lopez, SG; Carneiro, ACD; Nunes, IKD; Pizzatti, L; Sardela, VF; Neto, FRA; Mirotti, LC; Pereira, HMG; Renovato-Martins, M				Amorim, Carolinne Souza; Moraes, Joao Alfredo; Magdalena, Ingrid de Jesus; Lopez, Sheila Gutierrez; Carneiro, Ana Carolina Dudenhoeffer; Nunes, Isabelle Karine da Costa; Pizzatti, Luciana; Sardela, Vinicius Figueiredo; Aquino Neto, Francisco Radler; Mirotti, Luciana Cristina; Pereira, Henrique Marcelo Gualberto; Renovato-Martins, Mariana			Extracellular Vesicles From Stored Red Blood Cells Convey Heme and Induce Spic Expression on Human Monocytes	FRONTIERS IN IMMUNOLOGY			English	Article						extracellular vesicles; monocytes; Spic; heme; red blood cells; autologous blood transfusion	GENE-EXPRESSION; MICROPARTICLES; OXYGENASE-1; STORAGE; TRANSFUSION; HEMOGLOBIN; ACTIVATION; BIOMARKERS; SPECTRUM; STRESS		[Amorim, Carolinne Souza; Magdalena, Ingrid de Jesus; Carneiro, Ana Carolina Dudenhoeffer; Nunes, Isabelle Karine da Costa; Sardela, Vinicius Figueiredo; Aquino Neto, Francisco Radler; Mirotti, Luciana Cristina; Pereira, Henrique Marcelo Gualberto; Renovato-Martins, Mariana] Univ Fed Rio Janeiro UFRJ, Lab Brasileiro Controle Dopagem, Lab Apoio Ao Desenvolvimento Tecnol, Inst Quim, Rio De Janeiro, Brazil; [Amorim, Carolinne Souza; Moraes, Joao Alfredo] Univ Fed Rio Janeiro, Lab Biol Redox, Programa Pesquisa Farmacol & Inflamacao, Inst Ciencias Biomed, Rio De Janeiro, Brazil; [Lopez, Sheila Gutierrez; Pizzatti, Luciana] Univ Fed Rio Janeiro UFRJ, Lab Biol Mol & Proteom Sangue, Lab Apoio Ao Desenvolvimento Tecnol, Inst Quim, Rio De Janeiro, Brazil; [Renovato-Martins, Mariana] Univ Fed Fluminense, Dept Biol Celular & Mol, Lab Inflamacao & Metab, Inst Biol, Niteroi, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal Fluminense	Renovato-Martins, M (corresponding author), Univ Fed Rio Janeiro UFRJ, Lab Brasileiro Controle Dopagem, Lab Apoio Ao Desenvolvimento Tecnol, Inst Quim, Rio De Janeiro, Brazil.; Renovato-Martins, M (corresponding author), Univ Fed Fluminense, Dept Biol Celular & Mol, Lab Inflamacao & Metab, Inst Biol, Niteroi, Brazil.	marianarenovato@id.uff.br	Moraes, João Alfredo A/E-3557-2017; Renovato-Martins, Mariana/V-1661-2019; Sardela, Vinícius F/D-9230-2018	Moraes, João Alfredo A/0000-0002-8563-6432; Renovato-Martins, Mariana/0000-0002-9860-5272; Sardela, Vinícius F/0000-0001-8481-3081; Pizzatti, Luciana/0000-0001-5513-782X				Akilesh HM, 2019, SCIENCE, V363, P142, DOI 10.1126/science.aao5213; Alam MZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00033; Alam Z, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107825; Almizraq RJ, 2016, TRANSFUS APHER SCI, V55, P281, DOI 10.1016/j.transci.2016.10.018; Ardoin SP, 2007, SCAND J IMMUNOL, V66, P159, DOI 10.1111/j.1365-3083.2007.01984.x; Ashenden M, 2002, HAEMATOLOGICA, V87, P225; Bain CC, 2014, NAT IMMUNOL, V15, P929, DOI 10.1038/ni.2967; Bebesi T, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-04915-7; Boyle JJ, 2011, ARTERIOSCL THROM VAS, V31, P2685, DOI 10.1161/ATVBAHA.111.225813; Camus SM, 2015, BLOOD, V125, P3805, DOI 10.1182/blood-2014-07-589283; Cardo LJ, 2008, TRANSFUS APHER SCI, V38, P117, DOI 10.1016/j.transci.2008.01.004; D'Alessandro A, 2019, BLOOD ADV, V3, P884, DOI 10.1182/bloodadvances.2018029629; da Guarda CC, 2017, EXPERT REV HEMATOL, V10, P533, DOI 10.1080/17474086.2017.1327809; Sardela PDD, 2019, FORENSIC TOXICOL, V37, P465, DOI 10.1007/s11419-019-00482-1; Donadee C, 2011, CIRCULATION, V124, P465, DOI 10.1161/CIRCULATIONAHA.110.008698; Donati F, 2018, CURR PHARM BIOTECHNO, V19, P124, DOI 10.2174/1389201019666180405165118; Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115; Duvigneau JC, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8100475; Fazeli PK, 2020, MOL METAB, V42, DOI 10.1016/j.molmet.2020.101082; Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200; Garcia-Roa M, 2017, BLOOD TRANSFUS-ITALY, V15, P222, DOI 10.2450/2017.0345-16; Gbotosho OT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01910; Guilliams M, 2014, NAT REV IMMUNOL, V14, P571, DOI 10.1038/nri3712; Haldar M, 2014, CELL, V156, P1223, DOI 10.1016/j.cell.2014.01.069; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Hess JR, 2010, TRANSFUS APHER SCI, V43, P51, DOI 10.1016/j.transci.2010.05.009; Jison ML, 2004, BLOOD, V104, P270, DOI 10.1182/blood-2003-08-2760; Kayama H, 2018, P NATL ACAD SCI USA, V115, P8418, DOI 10.1073/pnas.1808426115; Lang D, 2005, INT IMMUNOL, V17, P155, DOI 10.1093/intimm/dxh196; Lawrie AS, 2009, VOX SANG, V96, P206, DOI 10.1111/j.1423-0410.2008.01151.x; Lee JS, 2010, NAT MED, V16, P381, DOI 10.1038/nm0410-381; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Marrocco C, 2012, BLOOD TRANSFUS-ITALY, V10, pS71, DOI 10.2450/2012.011S; Martins R, 2016, NAT IMMUNOL, V17, P1361, DOI 10.1038/ni.3590; Meng FT, 2017, ANAL BIOCHEM, V521, P11, DOI 10.1016/j.ab.2017.01.002; Morkeberg J, 2013, HEMATOL-AM SOC HEMAT, P627, DOI 10.1182/asheducation-2013.1.627; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nader E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00454; NATH KA, 1995, KIDNEY INT, V47, P592, DOI 10.1038/ki.1995.75; Nyakundi BB, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/8929020; Paglia G, 2016, BLOOD, V128, pE43, DOI 10.1182/blood-2016-06-721688; Pottgiesser T, 2009, VOX SANG, V96, P333, DOI 10.1111/j.1423-0410.2009.01169.x; Renovato-Martins M, 2017, BBA-MOL BASIS DIS, V1863, P139, DOI 10.1016/j.bbadis.2016.09.016; Rubin O, 2010, BLOOD TRANSFUS-ITALY, V8, pS31, DOI 10.2450/2010.006S; Salzer U, 2008, TRANSFUSION, V48, P451, DOI 10.1111/j.1537-2995.2007.01549.x; Sardela VF, 2018, J MASS SPECTROM, V53, P476, DOI 10.1002/jms.4077; Singhal R, 2018, EUR J IMMUNOL, V48, P1285, DOI 10.1002/eji.201747449; Smith A, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00187; Tedesco S, 2015, IMMUNOBIOLOGY, V220, P545, DOI 10.1016/j.imbio.2014.12.008; Thomas RAB, 2016, TRANSPLANTATION, V100, P176, DOI 10.1097/TP.0000000000000770; Vijayan V, 2018, BIOCHEM PHARMACOL, V153, P159, DOI 10.1016/j.bcp.2018.02.010; Voss SC, 2017, DRUG TEST ANAL, V9, P1794, DOI 10.1002/dta.2212; Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456; Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034; Xue J, 2014, IMMUNITY, V40, P274, DOI 10.1016/j.immuni.2014.01.006; Zhong H, 2018, CURR OPIN HEMATOL, V25, P177, DOI 10.1097/MOH.0000000000000423	56	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								833286	10.3389/fimmu.2022.833286	http://dx.doi.org/10.3389/fimmu.2022.833286			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9BG	35663938	gold, Green Published			2022-12-18	WOS:000805018400001
J	Ben-Baruch, A				Ben-Baruch, Adit			Tumor Necrosis Factor alpha: Taking a Personalized Road in Cancer Therapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer; personalized therapy; tumor necrosis factor a/TNFa; TNFR1; TNFR2	TNF-ALPHA; BREAST-CANCER; RHEUMATOID-ARTHRITIS; MOLECULAR-CLONING; RECOMBINANT HUMAN; PHASE-II; CELL-DEATH; T-CELLS; EXPRESSION; RECEPTOR		[Ben-Baruch, Adit] Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel	Tel Aviv University	Ben-Baruch, A (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Shmunis Sch Biomed & Canc Res, Tel Aviv, Israel.	aditbb@tauex.tau.ac.il			DKFZ-MOST Cooperation in Cancer Research; Israel Cancer Research Fund; Federico Foundation; Israel Science Foundation	DKFZ-MOST Cooperation in Cancer Research; Israel Cancer Research Fund; Federico Foundation; Israel Science Foundation(Israel Science Foundation)	Studies in the Ben-Baruch laboratory on the TNF alpha-TNFR network in cancer were supported during the last three years by DKFZ-MOST Cooperation in Cancer Research, Israel Cancer Research Fund, Federico Foundation and Israel Science Foundation.	ADERKA D, 1992, J EXP MED, V175, P323, DOI 10.1084/jem.175.2.323; Antoon JW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00539; Askling J, 2005, ANN RHEUM DIS, V64, P1414, DOI 10.1136/ard.2004.033241; Baecklund E, 2004, CURR OPIN RHEUMATOL, V16, P254, DOI 10.1097/00002281-200405000-00014; BALKWILL FR, 1986, CANCER RES, V46, P3990; Balkwill F, 2009, NAT REV CANCER, V9, P361, DOI 10.1038/nrc2628; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Baram T, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061429; Baram T, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.614468; Bauer S, 2004, J IMMUNOL, V172, P3930, DOI 10.4049/jimmunol.172.6.3930; Baxevanis CN, 2000, EUR J IMMUNOL, V30, P1957, DOI 10.1002/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO;2-7; Ben-Baruch A, 2020, CANCER IMMUNOL IMMUN, V69, P263, DOI 10.1007/s00262-019-02435-4; Ben-Baruch A, 2012, CANCER MICROENVIRON, V5, P151, DOI 10.1007/s12307-011-0094-3; Bertazza LMS., 2012, TNF CANC FRIENDS AND; Bradley JR, 2020, FASEB BIOADV, V2, P126, DOI 10.1096/fba.2019-00071; BROUCKAERT PGG, 1986, INT J CANCER, V38, P763, DOI 10.1002/ijc.2910380521; Brown ER, 2008, ANN ONCOL, V19, P1340, DOI 10.1093/annonc/mdn054; BROWN TD, 1991, J IMMUNOTHER, V10, P376, DOI 10.1097/00002371-199110000-00010; Case K, 2020, J LEUKOCYTE BIOL, V107, P981, DOI 10.1002/JLB.5MA0420-375RRRRR; Chen X, 2007, J IMMUNOL, V179, P154, DOI 10.4049/jimmunol.179.1.154; Chen X, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal2328; Chen X, 2010, J IMMUNOL, V185, P174, DOI 10.4049/jimmunol.0903548; Chen YH, 2018, CYTOKINE, V101, P78, DOI 10.1016/j.cyto.2016.09.013; Coley W. B., 1910, P ROY SOC MED, V3, P1, DOI DOI 10.1177/003591571000301601; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; CREAGAN ET, 1988, CANCER, V62, P2467, DOI 10.1002/1097-0142(19881215)62:12<2467::AID-CNCR2820621202>3.0.CO;2-5; Cruceriu D, 2020, CELL ONCOL, V43, P1, DOI 10.1007/s13402-019-00489-1; Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105; Dadiani M, 2020, CANCER IMMUNOL IMMUN, V69, P1315, DOI 10.1007/s00262-020-02549-0; Egeblad M, 2000, INT J CANCER, V86, P617, DOI 10.1002/(SICI)1097-0215(20000601)86:5<617::AID-IJC3>3.3.CO;2-Q; Fischer R, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00401; Galdiero MR, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028662; Gong K, 2021, NEOPLASIA, V23, P189, DOI 10.1016/j.neo.2020.12.006; Gough P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585880; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; Grunhagen DJ, 2006, CANCER-AM CANCER SOC, V106, P1776, DOI 10.1002/cncr.21802; Gupta M, 2016, HUM PATHOL, V54, P82, DOI 10.1016/j.humpath.2016.03.006; Hamaguchi T, 2011, BIOCHEM BIOPH RES CO, V407, P525, DOI 10.1016/j.bbrc.2011.03.051; Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136; He J, 2019, PROG MOL BIOL TRANSL, V164, P101, DOI 10.1016/bs.pmbts.2019.03.010; He L, 2021, NEOPLASIA, V23, P197, DOI 10.1016/j.neo.2020.12.007; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; Hellgren K, 2021, RHEUMATOLOGY, V60, P3656, DOI 10.1093/rheumatology/keaa828; Huss V, 2022, RHEUMATOLOGY, V61, P1810, DOI 10.1093/rheumatology/keab570; Ji XM, 2017, CANCER LETT, V386, P24, DOI 10.1016/j.canlet.2016.10.031; Jiang MM, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108345; Kircheis R, 2002, CANCER GENE THER, V9, P673, DOI 10.1038/sj.cgt.7700487; Li YF, 2018, ONCOL LETT, V15, P6873, DOI 10.3892/ol.2018.8230; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Maccio A, 2012, CYTOKINE, V58, P133, DOI 10.1016/j.cyto.2012.01.015; Madhusudan S, 2004, CLIN CANCER RES, V10, P6528, DOI 10.1158/1078-0432.CCR-04-0730; Madhusudan S, 2005, J CLIN ONCOL, V23, P5950, DOI 10.1200/JCO.2005.04.127; MARMENOUT A, 1985, EUR J BIOCHEM, V152, P515, DOI 10.1111/j.1432-1033.1985.tb09226.x; Martinez-Reza I, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0398-9; Mercer LK, 2017, ANN RHEUM DIS, V76, P2025, DOI 10.1136/annrheumdis-2017-211623; Mercogliano MF, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00584; MILES DW, 1994, INT J CANCER, V56, P777, DOI 10.1002/ijc.2910560603; Montfort A, 2021, CLIN CANCER RES, V27, P1037, DOI 10.1158/1078-0432.CCR-20-3449; Montfort A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01818; Muthusami S, 2021, ENDOCR METAB IMMUNE, V21, P77, DOI 10.2174/1871530320666200909092908; Naude PJW, 2011, FEBS J, V278, P888, DOI 10.1111/j.1742-4658.2011.08017.x; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; Powell IJ, 2021, UROL ONCOL-SEMIN ORI, V39, P34, DOI 10.1016/j.urolonc.2020.08.019; Propper DJ, 2022, NAT REV CLIN ONCOL, V19, P237, DOI 10.1038/s41571-021-00588-9; Qu Y, 2022, INT J CANCER, V150, P1373, DOI 10.1002/ijc.33873; Qu Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01675; Raaschou P, 2018, ANN INTERN MED, V169, P291, DOI 10.7326/M17-2812; Roberts NJ, 2011, ONCOTARGET, V2, P739; Runbeck E, 2021, ANTIBODIES, V10, DOI 10.3390/antib10010010; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; Sethi G, 2008, FRONT BIOSCI-LANDMRK, V13, P5094, DOI 10.2741/3066; Seynhaeve ALB, 2007, CANCER RES, V67, P9455, DOI 10.1158/0008-5472.CAN-07-1599; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; Soria G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-130; Steeland S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051442; Torrey H, 2019, LEUKEMIA, V33, P1206, DOI 10.1038/s41375-018-0292-9; Torrey H, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aaf8608; Vanamee ES, 2017, TRENDS MOL MED, V23, P1037, DOI 10.1016/j.molmed.2017.09.007; VANZEE KJ, 1992, P NATL ACAD SCI USA, V89, P4845, DOI 10.1073/pnas.89.11.4845; Verhoef Cornelis, 2007, Curr Treat Options Oncol, V8, P417, DOI 10.1007/s11864-007-0044-y; Weiss T, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb2311; Weitzenfeld P, 2016, ONCOTARGET, V7, P81123, DOI 10.18632/oncotarget.13213; Weitzenfeld P, 2016, J LEUKOCYTE BIOL, V99, P1009, DOI 10.1189/jlb.3MA0815-373R; Yang FQ, 2017, MOL MED REP, V16, P2962, DOI 10.3892/mmr.2017.6898; Ye LL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00583; Yu MX, 2013, CANCER RES, V73, P4061, DOI 10.1158/0008-5472.CAN-12-3946; Zhang XZ, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003982; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; Ziffels B, 2018, IMMUNOTHERAPY-UK, V10, P177, DOI 10.2217/imt-2017-0119	91	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								903679	10.3389/fimmu.2022.903679	http://dx.doi.org/10.3389/fimmu.2022.903679			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V9KY	35663982	Green Published, gold			2022-12-18	WOS:000806403900001
J	Dong, BT; Chen, YP; Lyu, GR; Yang, XC				Dong, Bingtian; Chen, Yuping; Lyu, Guorong; Yang, Xiaocen			Aspartate Aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for Detecting Liver Fibrosis in Patients With Autoimmune Hepatitis: A Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune hepatitis; liver fibrosis; noninvasive methods; APRI; FIB-4	MAGNETIC-RESONANCE ELASTOGRAPHY; SIMPLE NONINVASIVE INDEX; TRANSIENT ELASTOGRAPHY; DIAGNOSTIC-ACCURACY; CIRRHOSIS; THERAPY; MARKERS; PREDICT; DISEASE	BackgroundAspartate aminotransferase-to-platelet ratio index (APRI) and fibrosis-4 index (FIB-4) are the two most widely studied noninvasive markers of liver fibrosis. We aimed to assess the diagnostic accuracy of APRI and FIB-4 for liver fibrosis in patients with autoimmune hepatitis (AIH) using liver biopsy as the reference standard. MethodsPubMed, EMBASE, Cochrane Library and Web of Science databases were searched for studies (published as of May 1st, 2021) that assessed the diagnostic performance of APRI and FIB-4 for liver fibrosis in AIH. The summary area under receiver operating characteristics curve (AUROC), sensitivity, specificity, diagnostic odds ratios were used to assess the diagnostic accuracy of APRI and FIB-4 for detecting liver fibrosis. ResultsFourteen studies (including 1015 patients) were selected with 13 studies each evaluating the use of APRI and FIB-4 for detecting different stages of fibrosis in AIH. For prediction of significant fibrosis, advanced fibrosis, and cirrhosis, the summary AUROC value was 0.66 [95% confidence interval (CI): 0.61-0.70], 0.71 (95% CI: 0.67-0.75), and 0.75 (95% CI: 0.71-0.79) for APRI, and the summary AUROC value was 0.75 (95% CI: 0.71-0.79), 0.73 (95% CI: 0.69-0.77) and 0.79 (95% CI: 0.75-0.82) for FIB-4, respectively. The summary sensitivity and specificity for diagnosis of significant fibrosis, advanced fibrosis, and cirrhosis were 90% and 36%, 78% and 55%, and 77% and 61% for APRI, and 70% and 70%, 65% and 70%, and 78% and 65% for FIB-4, respectively. ConclusionsAPRI and FIB-4 showed suboptimal diagnostic performance for identifying liver fibrosis in AIH with mediocre sensitivity and specificity.	[Dong, Bingtian; Lyu, Guorong] Fujian Med Univ, Dept Ultrasound, Affiliated Hosp 2, Quanzhou, Peoples R China; [Chen, Yuping] Fujian Med Univ, Dept Endocrinol, Affiliated Hosp 2, Quanzhou, Peoples R China; [Lyu, Guorong] Quanzhou Med Coll, Dept Clin Med, Quanzhou, Peoples R China; [Yang, Xiaocen] Xiamen Univ, Chenggong Hosp, Dept Ultrasound, Xiamen, Peoples R China	Fujian Medical University; Fujian Medical University; Xiamen University	Lyu, GR (corresponding author), Fujian Med Univ, Dept Ultrasound, Affiliated Hosp 2, Quanzhou, Peoples R China.; Lyu, GR (corresponding author), Quanzhou Med Coll, Dept Clin Med, Quanzhou, Peoples R China.	guoronglyu@fjmu.edu.cn						Abdo Ayman A, 2006, Saudi J Gastroenterol, V12, P73; Anastasiou OE, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.40737; Carbone M, 2014, J HEPATOL, V60, P210, DOI 10.1016/j.jhep.2013.09.020; Castera L, 2014, LIVER INT, V34, P91, DOI 10.1111/liv.12393; Czaja AJ, 2004, HEPATOLOGY, V39, P1631, DOI 10.1002/hep.20235; Dong BT, 2021, EXPERT REV GASTROENT, V15, P1077, DOI 10.1080/17474124.2021.1880894; Dong MH, 2018, LIVER INT, V38, P1562, DOI 10.1111/liv.13688; Doycheva I, 2019, LIVER INT, V39, P1002, DOI 10.1111/liv.14062; Duan WJ, 2020, J DIGEST DIS, V21, P519, DOI 10.1111/1751-2980.12924; Granito A, 2021, WORLD J GASTROENTERO, V27, DOI 10.3748/wjg.v27.i22.2994; Granito A, 2009, MINI-REV MED CHEM, V9, P847, DOI 10.2174/138955709788452676; Guo LW, 2017, MED SCI MONITOR, V23, P5106, DOI 10.12659/MSM.907300; Janik MK, 2021, LIVER INT, V41, P348, DOI 10.1111/liv.14726; Khare S, 2020, J CLIN TRANSL HEPATO, V8, P143, DOI 10.14218/JCTH.2020.00002; Kim WR, 2016, J HEPATOL, V64, P773, DOI 10.1016/j.jhep.2015.11.012; Komori A, 2021, CLIN MOL HEPATOL, V27, P58, DOI 10.3350/cmh.2020.0189; Li X, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.927946; Li Y, 2016, ALIMENT PHARM THER, V43, P458, DOI 10.1111/apt.13488; Liberal R, 2017, ALIMENT PHARM THER, V45, P723, DOI 10.1111/apt.13907; Liberati A, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Lin ZH, 2011, HEPATOLOGY, V53, P726, DOI 10.1002/hep.24105; Liu LY, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.22922; Lohse AW, 2015, J HEPATOL, V63, P971, DOI 10.1016/j.jhep.2015.06.030; Lu LG, 2020, J DIGEST DIS, V21, P127, DOI 10.1111/1751-2980.12854; Lv TT, 2019, J GASTROEN HEPATOL, V34, P1676, DOI 10.1111/jgh.14746; Mack CL, 2020, HEPATOLOGY, V72, P671, DOI 10.1002/hep.31065; Migita K, 2011, J GASTROENTEROL, V46, P56, DOI 10.1007/s00535-010-0337-y; Muratori P, 2005, WORLD J GASTROENTERO, V11, P1862, DOI 10.3748/wjg.v11.i12.1862; Nishikawa H, 2016, HEPATOL RES, V46, P613, DOI 10.1111/hepr.12596; Park DW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212771; Shaheen AAM, 2007, HEPATOLOGY, V46, P912, DOI 10.1002/hep.21835; Sheptulina A, 2016, J GASTROEN HEPATOL, V31, P1956, DOI 10.1111/jgh.13407; Sterling RK, 2006, HEPATOLOGY, V43, P1317, DOI 10.1002/hep.21178; Tanaka A, 2020, GUT LIVER, V14, P430, DOI 10.5009/gnl19261; Wai CT, 2003, HEPATOLOGY, V38, P518, DOI 10.1053/jhep.2003.50346; Wang HL, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021408; Wang J, 2017, WORLD J GASTROENTERO, V23, P859, DOI 10.3748/wjg.v23.i5.859; Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009; WHO, 2016, MYANM NATL SIMPL TRE; World Health Organization, 2009, HAND HYG WHY WHEN; Wu SS, 2019, HEPATOL INT, V13, P91, DOI 10.1007/s12072-018-9907-5; Xiao GQ, 2017, HEPATOLOGY, V66, P1486, DOI 10.1002/hep.29302; Xiao GQ, 2015, HEPATOLOGY, V61, P292, DOI 10.1002/hep.27382; Xing X, 2020, EXPERT REV GASTROENT, V14, P631, DOI 10.1080/17474124.2020.1779589; Xu QY, 2017, J GASTROEN HEPATOL, V32, P639, DOI 10.1111/jgh.13508; Xu XY, 2019, WORLD J CLIN CASES, V7, P2022, DOI 10.12998/wjcc.v7.i15.2022; Yuan XL, 2019, EUR J GASTROEN HEPAT, V31, P1467, DOI 10.1097/MEG.0000000000001437; Yunihastuti E, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05069-5; Zeng TT, 2018, CLIN CHIM ACTA, V486, P135, DOI 10.1016/j.cca.2018.07.030	49	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								892454	10.3389/fimmu.2022.892454	http://dx.doi.org/10.3389/fimmu.2022.892454			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V4XF	35663945	gold, Green Published			2022-12-18	WOS:000806093800001
J	Gao, ZW; Yang, L; Liu, C; Wang, X; Guo, WT; Zhang, HZ; Dong, K				Gao, Zhao-wei; Yang, Lan; Liu, Chong; Wang, Xi; Guo, Wen-tao; Zhang, Hui-zhong; Dong, Ke			Distinct Roles of Adenosine Deaminase Isoenzymes ADA1 and ADA2: A Pan-Cancer Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						ADA1; ADA2; cancer; prognosis; immune infiltration	GENE-THERAPY; CELLS; IMMUNODEFICIENCY; SERUM	ObjectiveAdenosine deaminase (ADA) plays an important role in immune response, which includes two isoenzymes: ADA1 and ADA2. This study aims to explore the roles of ADA1 and ADA2 in cancers. MethodsHuman Protein Atlas (HPA) and Gene Expression Profiling Interactive Analysis (GEPIA2) databases were used to analyze the mRNA expression of ADA1 and ADA2 in human normal cells and tumor tissues. The enzyme assay was used to detect the ADA1 and ADA2 activities in serum from cancer patients. The Kaplan-Meier (KM) plotter was used to analyze the prognostic value of ADA1 and ADA2. TIMER2.0 was used to explore how ADA1 and ADA2 correlate with immune infiltration and immune checkpoints. cBioPortal database was used to investigate the mutations of ADA1 and ADA2. LinkedOmics was used to screen the ADA1 and ADA2 expression-related genes. ResultsADA1 was significantly increased in several tumor tissues, including cholangiocarcinoma (CHOL), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), head and neck squamous cell carcinoma (HNSC), kidney renal clear cell carcinoma (KIRC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), thymoma (THYM), and uterine carcinosarcoma (UCS). ADA2 expression was significantly increased in esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), acute myeloid leukemia (LAML), OV, PAAD, skin cutaneous melanoma (SKCM), and stomach adenocarcinoma (STAD). There were no significant changes in serum ADA1 activities in most cancers, while serum ADA2 activities were increased in most cancers. For prognosis, high ADA1 expression was associated with the poor survival in several cancers, including esophageal squamous cell carcinoma (ESCC), HNSC, KIRC, kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), and uterine corpus endometrial carcinoma (UCEC). However, high ADA2 expression showed a favorable prognosis in breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), HNSC, KIRC, KIRP, LUAD, OV, PAAD, sarcoma, and THYM. ADA1 showed a moderate positive correlation with multiple infiltrating immune cells in most cancers. ADA2 was positively correlated with B cells, CD8 T cells, monocytes/macrophages, and dendritic cells (DCs) and was strongly negatively correlated with myeloid-derived suppressor cells. Function analysis showed that ADA1 expression-related genes were mainly enriched in cell division biological progression. However, ADA2-related genes were mainly associated with immune response. ConclusionAs isoenzymes, ADA1 and ADA2 showed opposite prognostic values and different correlative patterns with immune infiltrating. These data demonstrated the distinct roles of ADA1 and ADA2 in cancer. ADA2 might act as a protective factor in cancer.	[Gao, Zhao-wei; Yang, Lan; Liu, Chong; Wang, Xi; Guo, Wen-tao; Zhang, Hui-zhong; Dong, Ke] AF Med Univ, Tangdu Hosp, Dept Clin Lab, Xian, Peoples R China	Air Force Military Medical University	Dong, K (corresponding author), AF Med Univ, Tangdu Hosp, Dept Clin Lab, Xian, Peoples R China.	tdjyk3@fmmu.edu.cn			National Natural Science Foundation of China [81702732]; Tangdu Hospital [2021SHRC004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tangdu Hospital	This study was supported by the National Natural Science Foundation of China (81702732) and Scientist Fund of Tangdu Hospital (2021SHRC004).	Aghaei M, 2005, CLIN BIOCHEM, V38, P887, DOI 10.1016/j.clinbiochem.2005.05.015; Aghaei M, 2010, ARCH MED RES, V41, P14, DOI 10.1016/j.arcmed.2009.10.012; Apasov SG, 2001, J CLIN INVEST, V108, P131, DOI 10.1172/JCI200110360; Augustin RC, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-004089; Chiappori AA., 2022, CLIN CANCER RES, DOI [10.1158/1078-0432.CCR-21-2742, DOI 10.1158/1078-0432.CCR-21-2742]; Cicalese MP, 2016, BLOOD, V128, P45, DOI 10.1182/blood-2016-01-688226; Delemarre EM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.725447; Dell'Orso G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.754029; Gao ZW, 2020, HEPAT MON, V20, DOI 10.5812/hepatmon.98811; Gao ZW, 2022, ANN RHEUM DIS, V81, DOI 10.1136/annrheumdis-2020-217007; Gibson KM, 2019, ARTHRITIS RHEUMATOL, V71, P1747, DOI 10.1002/art.40913; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Johansson A, 2012, P NATL ACAD SCI USA, V109, P7841, DOI 10.1073/pnas.1118296109; Kaljas Y, 2017, CELL MOL LIFE SCI, V74, P555, DOI 10.1007/s00018-016-2357-0; Kohn DB, 2021, NEW ENGL J MED, V384, P2002, DOI 10.1056/NEJMoa2027675; LEE N, 1984, BRIT J HAEMATOL, V56, P107, DOI 10.1111/j.1365-2141.1984.tb01276.x; Lee PY, 2022, ANN RHEUM DIS, V81, DOI 10.1136/annrheumdis-2020-217055; Lee PY, 2020, ANN RHEUM DIS, V79, P225, DOI 10.1136/annrheumdis-2019-216030; Li R, 2022, CANCERS, V14, DOI 10.3390/cancers14051236; Moretti FA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02572-w; Nakajima Y, 2015, CELL PHYSIOL BIOCHEM, V35, P51, DOI 10.1159/000369674; Ortiz-Espinosa S, 2022, CANCER LETT, V529, P70, DOI 10.1016/j.canlet.2021.12.027; Pai SY, 2021, BLOOD, V138, P1287, DOI 10.1182/blood.2021012300; Pinto B, 2021, CLIN RHEUMATOL, V40, P3883, DOI 10.1007/s10067-021-05711-w; Saghiri R, 2012, RHEUMATOL INT, V32, P1633, DOI 10.1007/s00296-011-1836-8; SCHRADER WP, 1978, P NATL ACAD SCI USA, V75, P446, DOI 10.1073/pnas.75.1.446; Sun CF, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.837230; Utsugisawa T, 2021, TOHOKU J EXP MED, V255, P49, DOI 10.1620/tjem.255.49; Vijayan D, 2017, NAT REV CANCER, V17, P709, DOI 10.1038/nrc.2017.86; Wang L, 2021, CANCER RES, V81, P3319, DOI 10.1158/0008-5472.CAN-21-0340; Wu ZJ, 2022, J LEUKOCYTE BIOL, V111, P301, DOI 10.1002/JLB.5A0621-314R; Xue DY, 2022, SCI IMMUNOL, V7, DOI 10.1126/sciimmunol.abi6899; Yap JY, 2021, J CLIN IMMUNOL, V41, P1915, DOI 10.1007/s10875-021-01141-0; Zavialov AV, 2010, J LEUKOCYTE BIOL, V88, P279, DOI 10.1189/jlb.1109764; Zavialov AV, 2005, BIOCHEM J, V391, P51, DOI 10.1042/BJ20050683; Zhou Q, 2014, NEW ENGL J MED, V370, P911, DOI 10.1056/NEJMoa1307361; Zhou T, 2020, NATURE, V583, P609, DOI 10.1038/s41586-020-2422-6	37	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								903461	10.3389/fimmu.2022.903461	http://dx.doi.org/10.3389/fimmu.2022.903461			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5IF	35663977	gold, Green Published			2022-12-18	WOS:000806122400001
J	Hashai, K; Chapple, IL; Shapira, L; Assadi, W; Dadon, S; Polak, D				Hashai, Koren; Chapple, Ian L.; Shapira, Lior; Assadi, Walaa; Dadon, Stav; Polak, David			CD18 Mediates Neutrophil Imperviousness to the Aggregatibacter actinomycetemcomitans JP2 Clone in Molar-Incisor Pattern Periodontitis	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils (PMNs); periodontitis (inflammatory); CD18; oxidative stress; JP2 clone	PATHOGENESIS; LEUKOTOXIN; CLASSIFICATION; EPIDEMIOLOGY; EXPRESSION; GINGIVAL; THERAPY; STRAINS	IntroductionMolar-incisor pattern periodontitis (MIPP) in the absence of significant local risk factors or systemic disease, is a rare, early onset periodontal disease phenotype, with 0.5% to 2.5% global prevalence. The condition is characterized by impaired neutrophil function and persistent Aggregatibacter actinomycetemcomitans (JP2 clone) infection. The aim of this study was to characterize neutrophil functional responses to JP2 and to investigate the neutrophil receptors involved. Materials and MethodsNeutrophils were obtained from whole blood samples of periodontally healthy and MIPP subjects and incubated with the JP2 clone or a non-JP2 clone of A. actinomycetemcomitans. Bacterial survival was tested by blood agar culture; neutrophil death was tested with propidium iodide and flow cytometry; Reactive oxygen production (ROS) was measured with 2 ',7 '-dichlorofluorescein diacetate and a fluorescence plate reader; the cytokinome was analysed using an array profiler, ELISA and RT-PCR. Receptors binding to JP2 were isolated using a novel immunoprecipitation assay and validated functionally using specific blocking antibodies. ResultsJP2 and non-JP2 survival was comparable between all the neutrophil groups. Resistance to neutrophil necrosis following exposure to JP2 was significantly lower in the MIPP group, than in all the other groups (p<0.0001). Conversely, MIPP neutrophils showed lower levels of ROS production in response to JP2 infection compared with that of healthy neutrophils (p<0.001). Furthermore, significantly lower levels of cytokines, such as IL8, IL10 and TNF alpha, were observed during JP2 incubation with MIPP neutrophils than upon incubation with periodontally healthy neutrophils. Various proteins expressed on neutrophils bind to JP2. Of these, CD18 was found to mediate neutrophil necrosis. The CD18 receptor on MIPP neutrophils acts differently from that on periodontally healthy patients neutrophils, and appears to reflect differential neutrophil reactions to JP2. ConclusionThis study portrays a fundamental difference in neutrophil response to JP2 infection between periodontally healthy and MIPP patients. This was evident in the resistance to necrosis, and lower ROS and cytokine production, despite the persistent presence of viable JP2. Whilst in periodontally healthy neutrophils, JP2 binds to CD18 on cell surfaces, this is not the case in MIPP neutrophils, suggesting a potential role for CD18 in the periodontal susceptibility of MIPP patients.	[Hashai, Koren; Shapira, Lior; Dadon, Stav; Polak, David] Hebrew Univ Jerusalem, Fac Dent Med, Jerusalem, Israel; [Hashai, Koren; Shapira, Lior; Polak, David] Hadassah Med Ctr, Dept Periodont, Jerusalem, Israel; [Chapple, Ian L.] Univ Birmingham, Inst Clin Sci, Coll Med & Dent Sci, Sch Dent, Birmingham, Warwick, England; [Chapple, Ian L.] Birmingham Commun Hlthcare Natl Hlth Serv NHS Fdn, Birmingham, Warwick, England; [Assadi, Walaa] Rambam Med Ctr, Dept Orthodont, Hefa, Israel; [Dadon, Stav] Hadassah Med Ctr, Dept Orthodont, Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Birmingham; Rambam Health Care Campus; Technion Israel Institute of Technology; Hebrew University of Jerusalem; Hadassah University Medical Center	Polak, D (corresponding author), Hebrew Univ Jerusalem, Fac Dent Med, Jerusalem, Israel.; Polak, D (corresponding author), Hadassah Med Ctr, Dept Periodont, Jerusalem, Israel.	polak@mail.huji.ac.il	Chapple, Iain/T-2986-2017	Chapple, Iain/0000-0003-2697-7082				Bhansali Rahul S, 2013, J Indian Soc Periodontol, V17, P731, DOI 10.4103/0972-124X.124485; Burgess D, 2017, JDR Clin Trans Res, V2, P249, DOI 10.1177/2380084417695543; Burgess DK, 2017, J PERIODONTOL, V88, P1263, DOI 10.1902/jop.2017.170285; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Dagmar R., 1993, IMMUNOBIOLOGY, V187, P35; Fagerholm SC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00254; Fine DH, 2018, J CLIN PERIODONTOL, V45, pS95, DOI 10.1111/jcpe.12942; Finoti LS, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006932; Fredman G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024422; Gholizadeh P, 2017, MICROB PATHOGENESIS, V113, P303, DOI 10.1016/j.micpath.2017.11.001; Greenlee MC, 2008, CURR DRUG TARGETS, V9, P130; Haubek D, 2010, APMIS, V118, P1, DOI 10.1111/j.1600-0463.2010.02665.x; Herbert BA, 2016, MOL ORAL MICROBIOL, V31, P207, DOI 10.1111/omi.12119; Hirschfeld J, 2016, J ORAL MICROBIOL, V8, DOI 10.3402/jom.v8.33070; Hossen MJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep42995; Houshmand B, 2009, J PERIODONTAL RES, V44, P88, DOI 10.1111/j.1600-0765.2008.01092.x; Inanc N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82335-9; Johansson A, 2011, TOXINS, V3, P242, DOI 10.3390/toxins3030242; Kantarci A, 2003, J PERIODONTOL, V74, P66, DOI 10.1902/jop.2003.74.1.66; Kawada M, 2012, ONCOGENE, V31, P3111, DOI 10.1038/onc.2011.498; Kobayashi SD, 2018, J INNATE IMMUN, V10, P432, DOI 10.1159/000487756; Krueger E, 2020, MOL ORAL MICROBIOL, V35, P85, DOI 10.1111/omi.12284; Lai PC, 2015, J PERIODONTOL, V86, P155, DOI 10.1902/jop.2014.140183; Levy DH, 2019, J CLIN PERIODONTOL, V46, P62, DOI 10.1111/jcpe.13036; Li J, 2004, HUM MOL GENET, V13, P1715, DOI 10.1093/hmg/ddh182; Li Y, 2011, ONCOGENE, V30, P3887, DOI 10.1038/onc.2011.112; Mattiello Fabiano Dalla Lana, 2011, Braz. Dent. J., V22, P398, DOI 10.1590/S0103-64402011000500009; Mikolai C, 2021, J ORAL MICROBIOL, V13, DOI 10.1080/20002297.2020.1856565; Minguez M, 2016, CLIN ORAL INVEST, V20, P1809, DOI 10.1007/s00784-015-1653-7; Munksgaard PS, 2014, INFECT IMMUN, V82, P2219, DOI 10.1128/IAI.01647-14; Nemoto E, 1999, INFECT IMMUN, V67, P6225; Palmer LJ, 2016, J PERIODONTAL RES, V51, P70, DOI 10.1111/jre.12284; Permpanich P, 2006, CELL MICROBIOL, V8, P72, DOI 10.1111/j.1462-5822.2005.00601.x; Petes C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00256; Roberts HM., 2017, THESIS U BIRMINGHAM; Rudick CP, 2017, EXPERT REV CLIN IMMU, V13, P1189, DOI 10.1080/1744666X.2017.1392855; Sabharwal A, 2018, PERIODONTOL 2000, V78, P212, DOI 10.1111/prd.12226; Sempowski GD, 1997, J PERIODONTOL, V68, P284, DOI 10.1902/jop.1997.68.3.284; Shah Rucha, 2017, J Indian Soc Periodontol, V21, P180, DOI 10.4103/jisp.jisp_385_15; Shahabuddin Nishat, 2016, Int J Dent Oral Health, V2, DOI 10.16966/2378-7090.197; Silva LM, 2019, IMMUNOL REV, V287, P226, DOI 10.1111/imr.12724; SLOTS J, 1982, J CLIN MICROBIOL, V15, P606, DOI 10.1128/JCM.15.4.606-609.1982; Staples KJ, 2007, J IMMUNOL, V178, P4779, DOI 10.4049/jimmunol.178.8.4779; Susin C, 2014, PERIODONTOL 2000, V65, P27, DOI 10.1111/prd.12019; Tavakoli TT, 2022, J PERIODONTOL, V93, P392, DOI 10.1002/JPER.21-0143; Tonetti MS, 2018, J CLIN PERIODONTOL, V45, pS149, DOI [10.1111/jcpe.12945, 10.1002/JPER.18-0006]; Tong H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38632-5; Tsai CC, 2018, KAOHSIUNG J MED SCI, V34, P186, DOI 10.1016/j.kjms.2018.01.014; Velickovic M, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.638258; Yoshida A, 2021, JPN DENT SCI REV, V57, P20, DOI 10.1016/j.jdsr.2020.12.001; Zuccarino-Catania GV, 2014, NAT IMMUNOL, V15, P631, DOI 10.1038/ni.2914	52	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								847372	10.3389/fimmu.2022.847372	http://dx.doi.org/10.3389/fimmu.2022.847372			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5OE	35663998	gold, Green Published			2022-12-18	WOS:000806137900001
J	Lee, SY; Jr, JF; Dipasquale, J; Bastian, A; Tran, AM; Hong, DW; Chin, B; Nguyen-Lee, PJ; Mazal, S; Espinal, J; Thomas, T; Dou, HY				Lee, So Yoon; Fierro Jr, Javier; Dipasquale, Jake; Bastian, Anthony; Tran, An M.; Hong, Deawoo; Chin, Brandon; Nguyen-Lee, Paul J.; Mazal, Sarah; Espinal, Jamil; Thomas, Tima; Dou, Huanyu			Engineering Human Circulating Monocytes/Macrophages by Systemic Deliverable Gene Editing	FRONTIERS IN IMMUNOLOGY			English	Article						human circulating monocytes-derived macrophages; systemic deliverable gene-editing; IL-4; plasmid DNA; immune regulation	IN-VITRO; MACROPHAGES; NANOPARTICLES; DNA; POLYETHYLENIMINE; PLASMID; PEI; POLARIZATION; TRANSFECTION; INHIBITION	Delivery of plasmid DNA to transfect human primary macrophages is extremely difficult, especially for genetic engineering. Engineering macrophages is imperative for the treatment of many diseases including infectious diseases, cancer, neurological diseases, and aging. Unfortunately, plasmid does not cross the nuclear membranes of terminally differentiated macrophages to integrate the plasmid DNA (pDNA) into their genome. To address this issue, we have developed a core-shell nanoparticle (NP) using our newly created cationic lipid to deliver the anti-inflammatory cytokine IL-4 pDNA (IL-4pDNA-NPs). Human blood monocyte-derived macrophages (MDM) were effectively transfected with IL-4pDNA-NPs. IL-4pDNA-NPs were internalized in MDM within 30 minutes and delivered into the nucleus within 2 hours. Exogenous IL-4 expression was detected within 1 - 2 days and continued up to 30 days. Functional IL-4 expression led to M2 macrophage polarization in vitro and in an in vivo mouse model of inflammation. These data suggest that these NPs can protect pDNA from degradation by nucleases once inside the cell, and can transport pDNA into the nucleus to enhance gene delivery in macrophages in vitro and in vivo. In this research, we developed a new method to deliver plasmids into the nucleus of monocytes and macrophages for gene-editing. Introducing IL-4 pDNA into macrophages provides a new gene therapy solution for the treatment of various diseases.	[Lee, So Yoon; Fierro Jr, Javier; Dipasquale, Jake; Bastian, Anthony; Tran, An M.; Nguyen-Lee, Paul J.; Mazal, Sarah; Thomas, Tima; Dou, Huanyu] Texas Tech Univ Hlth Sci Ctr Paso, Dept Mol, El Paso, TX 79905 USA; [Hong, Deawoo; Chin, Brandon; Espinal, Jamil; Dou, Huanyu] Texas Tech Univ Hlth Sci Ctr Paso, Biomed Sci Grad Sch, El Paso, TX 79905 USA; [Lee, So Yoon; Fierro Jr, Javier; Dipasquale, Jake; Bastian, Anthony; Nguyen-Lee, Paul J.; Mazal, Sarah; Thomas, Tima; Dou, Huanyu] Texas Tech Univ Hlth Sci Ctr Paso, Translat Med Paul L Foster Sch Med, El Paso, TX 79905 USA		Dou, HY (corresponding author), Texas Tech Univ Hlth Sci Ctr Paso, Dept Mol, El Paso, TX 79905 USA.; Dou, HY (corresponding author), Texas Tech Univ Hlth Sci Ctr Paso, Biomed Sci Grad Sch, El Paso, TX 79905 USA.; Dou, HY (corresponding author), Texas Tech Univ Hlth Sci Ctr Paso, Translat Med Paul L Foster Sch Med, El Paso, TX 79905 USA.	huanyu.dou@ttuhsc.edu		DiPasquale, Jake/0000-0003-3756-5227				Bansal R, 2014, EUR J PHARM BIOPHARM, V87, P461, DOI 10.1016/j.ejpb.2014.05.001; Casper J, 2018, KIDNEY INT, V94, P993, DOI 10.1016/j.kint.2018.06.029; Champion JA, 2009, PHARM RES-DORDR, V26, P244, DOI 10.1007/s11095-008-9626-z; Chen LL, 2017, MAT SCI ENG C-MATER, V70, P418, DOI 10.1016/j.msec.2016.09.019; Chen QJ, 2020, J CONTROL RELEASE, V323, P179, DOI 10.1016/j.jconrel.2020.03.044; Chen T, 2018, CANCER IMMUNOL IMMUN, V67, P1635, DOI 10.1007/s00262-018-2233-x; Cheng CC, 2003, NUCLEIC ACIDS RES, V31, P2227, DOI 10.1093/nar/gkg323; Costa JP, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1342-y; da Silva RF, 2016, ATHEROSCLEROSIS, V248, P170, DOI 10.1016/j.atherosclerosis.2016.03.012; Dai MY, 2018, PROSTAG OTH LIPID M, V139, P36, DOI 10.1016/j.prostaglandins.2018.10.003; Dai Y, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201800445; Fernandes DC, 2019, FISH SHELLFISH IMMUN, V87, P51, DOI 10.1016/j.fsi.2018.12.074; Figueiredo CR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01132; Fukuda I, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/350580; Galarraga-Vinueza ME, 2020, J PERIODONTAL RES, V55, P821, DOI 10.1111/jre.12773; Gan ZS, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/8570818; Han J, 2018, ACS NANO, V12, P1959, DOI 10.1021/acsnano.7b09107; Hattori Y, 2004, BIOCHEM BIOPH RES CO, V317, P992, DOI 10.1016/j.bbrc.2004.03.141; He XY, 2018, NANOSCALE, V10, P15578, DOI 10.1039/c8nr05294h; Hong JW, 2004, J CONTROL RELEASE, V99, P167, DOI 10.1016/j.jconrel.2004.05.012; Jia XH, 2016, ONCOTARGET, V7, P20934, DOI 10.18632/oncotarget.8064; Jiang X, 2021, J CELL PHYSIOL, V236, P193, DOI 10.1002/jcp.29833; Lasch M, 2016, LAB INVEST, V96, P830, DOI 10.1038/labinvest.2016.62; Li XZ, 2018, BIOMED MATER, V13, DOI 10.1088/1748-605X/aabe33; Liu MC, 2018, CELL PHYSIOL BIOCHEM, V50, P1255, DOI 10.1159/000494585; Lyamina SV, 2012, B EXP BIOL MED+, V152, P548, DOI 10.1007/s10517-012-1572-4; Mairhofer J, 2008, MOL BIOTECHNOL, V39, P97, DOI 10.1007/s12033-008-9046-7; Martinez-Negro M, 2018, COLLOID SURFACE B, V161, P519, DOI 10.1016/j.colsurfb.2017.11.024; Melbourne JK, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106093; Midoux P, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170995; Nandakumar V, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00939-16; Okabe Y, 2014, CELL, V157, P832, DOI 10.1016/j.cell.2014.04.016; Poltavets AS, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061535; Qin LH, 2016, J BIOMED NANOTECHNOL, V12, P261, DOI 10.1166/jbn.2016.2155; Raja MAG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128963; Sato M, 2013, BIOTECHNOL J, V8, P1355, DOI 10.1002/biot.201300169; Souto EB, 2019, PHARM DEV TECHNOL, V24, P1181, DOI 10.1080/10837450.2019.1647235; Tan ZB, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4725-5; Tran TH, 2015, SCI REP-UK, V5, DOI 10.1038/srep16632; Wang D, 2019, NAT REV DRUG DISCOV, V18, P358, DOI 10.1038/s41573-019-0012-9; Wang D, 2018, MOL THER-METH CLIN D, V9, P234, DOI 10.1016/j.omtm.2018.03.004; Wang JP, 2019, BIOMATERIALS, V217, DOI 10.1016/j.biomaterials.2019.119296; Wang J, 2019, J MATER SCI-MATER M, V30, DOI 10.1007/s10856-019-6294-y; Wang KZ, 2017, CELL CYCLE, V16, P374, DOI 10.1080/15384101.2016.1269045; Wang W, 2015, MOL MED REP, V11, P2397, DOI 10.3892/mmr.2014.3018; Wei Weizhong, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P618; Wightman L, 2001, J GENE MED, V3, P362, DOI 10.1002/jgm.187; Wu YX, 2014, INT J MOL MED, V33, P1563, DOI 10.3892/ijmm.2014.1724; Xia WZ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02778-2; Yin Z, 2012, INT J NANOMED, V7, P4625, DOI 10.2147/IJN.S30671; Yong L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46765; Yu QR, 2020, INT J NANOMED, V15, P483, DOI 10.2147/IJN.S229858; Zhou X, 2020, NAT NEUROSCI, V23, P337, DOI 10.1038/s41593-020-0597-7; Zou L, 2018, J BIOMED NANOTECHNOL, V14, P1785, DOI 10.1166/jbn.2018.2620	54	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								754557	10.3389/fimmu.2022.754557	http://dx.doi.org/10.3389/fimmu.2022.754557			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9UI	35663976	Green Published, gold			2022-12-18	WOS:000805068100001
J	Li, M; Zhang, BB; Yin, YF; Wen, JA; Wang, JJ; He, YX; Jiang, QM; Loor, JJ; Wang, S; Yang, W; Xu, C				Li, Ming; Zhang, Bingbing; Yin, Yufeng; Wen, Jianan; Wang, Jingjing; He, Yuxin; Jiang, Qianming; Loor, Juan J.; Wang, Shuang; Yang, Wei; Xu, Chuang			Intracellular Ca2+ Signaling and Calcium Release-Activated Calcium Modulator ORAI1 Are Associated With CD4(+) T Lymphocytes in Dairy Cows	FRONTIERS IN IMMUNOLOGY			English	Article						SOCE; fatty acids; CD4(+) T cells; ketosis; ORAI1	NONESTERIFIED FATTY-ACIDS; BLOOD MONONUCLEAR-CELLS; CALF HEPATOCYTES; AUTOPHAGY; METABOLISM; EFFECTOR; KETOSIS; LIVER; DIFFERENTIATION; MITOCHONDRIA	The nutritional status of dairy cows and the metabolism of specific nutrients are critical regulators of immune cell function. Around the time of parturition, mobilization of body lipid and muscle helps compensate for the decrease in nutrient intake and the increased requirements of the mammary gland for lactation. An end-result of these processes is the marked increase in circulating concentrations of fatty acids (FA), which are a major risk factor for immune dysfunction. In food animal species such as dairy cows, any disturbance in nutritional or immunological homeostasis leads to deleterious feedback loops that can further risk health, efficiency of nutrient use, and compromise availability of safe and nutritious dairy foods for humans. Despite substantial progress with respect to regulation of innate immunity, such knowledge for adaptive immunity is scarce. To help bridge this gap in knowledge, we sought to study the role of calcium release-activated calcium modulator ORAI1 activation in T cells systemic immune function in vivo. CD4(+) T cells were isolated from peripheral blood of dairy cows diagnosed as healthy or with ketosis, a common metabolic disorder of FA metabolism. Results revealed that levels of intracellular Ca2+ and reactive oxygen species (ROS) along with the abundance of store-operated Ca2+ entry (SOCE) moiety increased during ketosis. Further, plasma concentrations of inflammatory cytokines were elevated, the balance of Th17/Treg cells was disrupted, mitochondrial function impaired, and the abundance of mitophagy-related proteins in CD4(+) T cells altered during ketosis. Molecular characterization of the direct effects of FA was evaluated in CD4(+) T cells isolated from the spleen of 1-day-old calves. Enhanced supply of FA increased intracellular Ca2+ and ROS concentrations, upregulated the abundance of proteins associated with mitochondrial dynamics and ORAI1. Intermediates of mitophagy accumulated and the balance of Th17/Treg cells also was affected by the supply of FA. These negative effects were attenuated by silencing or inhibition of ORAI1 in CD4(+) T cells. Together, data indicated that physiological states that lead to increases in systemic concentrations of FA could impact adaptive immunity negatively through ORAI1 regulated intracellular Ca2+, ROS balance, and increased effector functions of Th17 cells.	[Li, Ming; Yin, Yufeng; Wang, Shuang; Yang, Wei; Xu, Chuang] Heilongjiang Bayi Agr Univ, Coll Anim Sci & Vet Med, Daqing, Peoples R China; [Zhang, Bingbing; Wen, Jianan; Wang, Jingjing; He, Yuxin] Heilongjiang Bayi Agr Univ, Coll Life Sci & Technol, Daqing, Peoples R China; [Jiang, Qianming; Loor, Juan J.] Univ Illinois, Div Nutr Sci, Mammalian NutriPhysio Genom, Urbana, IL USA; [Jiang, Qianming; Loor, Juan J.] Univ Illinois, Dept Anim Sci, Mammalian NutriPhysio Genom, Urbana, IL USA	Heilongjiang Bayi Agricultural University; Heilongjiang Bayi Agricultural University; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Xu, C (corresponding author), Heilongjiang Bayi Agr Univ, Coll Anim Sci & Vet Med, Daqing, Peoples R China.	xuchuang7175@163.com						Abdelmagid SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116195; BAIRD GD, 1982, J DAIRY SCI, V65, P1, DOI 10.3168/jds.S0022-0302(82)82146-2; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERTICS SJ, 1992, J DAIRY SCI, V75, P1914, DOI 10.3168/jds.S0022-0302(92)77951-X; Bharath LP, 2020, CELL METAB, V32, P44, DOI 10.1016/j.cmet.2020.04.015; Buck MD, 2015, J EXP MED, V212, P1345, DOI 10.1084/jem.20151159; Burton JL, 2005, VET IMMUNOL IMMUNOP, V105, P197, DOI 10.1016/j.vetimm.2005.02.012; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Cheng Z, 2021, J DAIRY SCI, V104, P10059, DOI 10.3168/jds.2021-20136; Clarke AJ, 2015, ANN RHEUM DIS, V74, P912, DOI 10.1136/annrheumdis-2013-204343; Crookenden MA, 2019, J DAIRY SCI, V102, P7408, DOI 10.3168/jds.2019-16367; Drackley JK, 1999, J DAIRY SCI, V82, P2259, DOI 10.3168/jds.S0022-0302(99)75474-3; Du XL, 2018, J DAIRY SCI, V101, P3476, DOI 10.3168/jds.2017-13234; EMANUELSON U, 1993, J DAIRY SCI, V76, P2765, DOI 10.3168/jds.S0022-0302(93)77614-6; Endo Y, 2015, CELL REP, V12, P1042, DOI 10.1016/j.celrep.2015.07.014; Field CS, 2020, CELL METAB, V31, P422, DOI 10.1016/j.cmet.2019.11.021; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Gastaldello A, 2010, AUTOPHAGY, V6, P607, DOI 10.4161/auto.6.5.11964; Goff JP, 1997, J DAIRY SCI, V80, P1260, DOI 10.3168/jds.S0022-0302(97)76055-7; GRUMMER RR, 1995, J ANIM SCI, V73, P2820; Hahn O, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1187-1; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hermann-Kleiter N, 2010, BLOOD, V115, P2989, DOI 10.1182/blood-2009-10-233585; Itle AJ, 2015, J DAIRY SCI, V98, P128, DOI 10.3168/jds.2014-7932; Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540; Kaufmann U, 2019, CELL METAB, V29, P1104, DOI 10.1016/j.cmet.2019.01.019; Kaufmann U, 2016, J IMMUNOL, V196, P573, DOI 10.4049/jimmunol.1501406; Kim KD, 2014, J IMMUNOL, V192, P110, DOI 10.4049/jimmunol.1302586; Koentjoro B, 2017, SCI REP-UK, V7, DOI 10.1038/srep44373; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lacetera N, 2004, J DAIRY SCI, V87, P1012, DOI 10.3168/jds.S0022-0302(04)73246-4; Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730; Lee YK, 2016, BMB REP, V49, P424, DOI 10.5483/BMBRep.2016.49.8.081; Li M, 2021, J ANIM SCI, V99, DOI 10.1093/jas/skab184; Li P, 2013, CELL PHYSIOL BIOCHEM, V32, P1509, DOI 10.1159/000356588; Lian GJ, 2018, ELIFE, V7, DOI 10.7554/eLife.36158; Loor JJ, 2007, PHYSIOL GENOMICS, V32, P105, DOI 10.1152/physiolgenomics.00188.2007; Ma JA, 2010, EUR J IMMUNOL, V40, P3028, DOI 10.1002/eji.201040614; MacIver NJ, 2013, ANNU REV IMMUNOL, V31, P259, DOI 10.1146/annurev-immunol-032712-095956; OLTENACU PA, 1994, VET RES, V25, P208; Qiu YN, 2019, ECOTOX ENVIRON SAFE, V167, P178, DOI 10.1016/j.ecoenv.2018.08.050; Rimessi A, 2008, BBA-BIOENERGETICS, V1777, P808, DOI 10.1016/j.bbabio.2008.05.449; Scalia D, 2006, J DAIRY SCI, V89, P147, DOI 10.3168/jds.S0022-0302(06)72078-1; Schild L, 1997, BIOCHEM J, V328, P205, DOI 10.1042/bj3280205; SCHULTZ LH, 1968, J DAIRY SCI, V51, P1133, DOI 10.3168/jds.S0022-0302(68)87141-3; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Shaw Patrick J, 2012, Front Biosci (Elite Ed), V4, P2253; Ster C, 2012, J DAIRY SCI, V95, P708, DOI 10.3168/jds.2011-4695; Ureshino RP, 2014, ANTIOXID REDOX SIGN, V21, P123, DOI 10.1089/ars.2013.5777; Vicencio JM, 2009, CELL DEATH DIFFER, V16, P1006, DOI 10.1038/cdd.2009.34; Waldron RT, 2019, J PHYSIOL-LONDON, V597, P3085, DOI 10.1113/JP277856; Wang RN, 2012, NAT IMMUNOL, V13, P907, DOI 10.1038/ni.2386; Wu WW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132499; Wu ZZ, 2017, AM J CLIN EXP IMMUNO, V6, P1; YAMDAGNI S, 1970, J DAIRY SCI, V53, P1046, DOI 10.3168/jds.S0022-0302(70)86343-3; Yan Y, 2006, ACTA PHARMACOL SIN, V27, P821, DOI 10.1111/j.1745-7254.2006.00390.x; Yang L, 2018, ARTHRITIS RHEUMATOL, V70, P855, DOI 10.1002/art.40447; Zhang BB, 2020, J DAIRY SCI, V103, P11945, DOI 10.3168/jds.2020-18684; Zhang DF, 2019, IMMUNITY, V51, P671, DOI 10.1016/j.immuni.2019.08.001; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	60	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								835936	10.3389/fimmu.2022.835936	http://dx.doi.org/10.3389/fimmu.2022.835936			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9CR	35663942	gold, Green Published			2022-12-18	WOS:000805022200001
J	Liu, YL; Tao, XY; Tao, JH				Liu, Yaling; Tao, Xinyu; Tao, Jinhui			Strategies of Targeting Inflammasome in the Treatment of Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Review						inflammasome; treatment; systemic lupus erythematosus (SLE); target; strategy	NF-KAPPA-B; ATTENUATES MURINE LUPUS; INHIBITING NLRP3 INFLAMMASOME; I INTERFERON; ACTIVATION; NEPHRITIS; CELLS; AIM2; EXPRESSION; MICE	Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ dysfunction resulting from the production of multiple autoantibodies and adaptive immune system abnormalities involving T and B lymphocytes. In recent years, inflammasomes have been recognized as an important component of innate immunity and have attracted increasing attention because of their pathogenic role in SLE. In short, inflammasomes regulate the abnormal differentiation of immune cells, modulate pathogenic autoantibodies, and participate in organ damage. However, due to the clinical heterogeneity of SLE, the pathogenic roles of inflammasomes are variable, and thus, the efficacy of inflammasome-targeting therapies is uncertain. To provide a foundation for the development of such therapeutic strategies, in this paper, we review the role of different inflammasomes in the pathogenesis of SLE and their correlation with clinical phenotypes and propose some corresponding treatment strategies.	[Liu, Yaling; Tao, Jinhui] Univ Sci & Technol China, Affiliated Hosp 1, Dept Rheumatol & Immunol, Div Life Sci & Med, Hefei, Peoples R China; [Tao, Xinyu] Anhui Med Univ, Clin Coll 1, Dept Clin Med 5 3 Integrat, Hefei, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS; Anhui Medical University	Tao, JH (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Dept Rheumatol & Immunol, Div Life Sci & Med, Hefei, Peoples R China.		tao, jinhui/AAA-8818-2020		National Natural Science Foundation of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (81771774) and the Anhui Provincial Key Research and Development Plan (201904a07020103).	Alcocer-Gomez E, 2017, ADV PROTEIN CHEM STR, V108, P127, DOI 10.1016/bs.apcsb.2017.02.002; Ali MF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01504; An J, 2017, ARTHRITIS RHEUMATOL, V69, P800, DOI 10.1002/art.40002; Barsalou J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02162; Bonomini F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143466; Brightbill HD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02672-0; Camell CD, 2019, CELL METAB, V30, P1024, DOI 10.1016/j.cmet.2019.10.006; Chei S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58896-6; Chen JJ, 2017, ONCOTARGETS THER, V10, P811, DOI 10.2147/OTT.S125039; Chen KW, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6676; Chen SP, 2019, BRIT J PHARMACOL, V176, P1341, DOI 10.1111/bph.14639; Choubey D, 2020, CYTOKINE, V132, DOI 10.1016/j.cyto.2019.03.008; Choubey D, 2017, CLIN IMMUNOL, V176, P42, DOI 10.1016/j.clim.2016.12.011; Chu XQ, 2021, EXP EYE RES, V202, DOI 10.1016/j.exer.2020.108335; Clark KL, 2015, J AUTOIMMUN, V65, P38, DOI 10.1016/j.jaut.2015.08.005; Leal VNC, 2021, AIDS, V35, P899, DOI 10.1097/QAD.0000000000002833; Crow MK, 2014, J IMMUNOL, V192, P5459, DOI 10.4049/jimmunol.1002795; Curran CS, 2019, J AUTOIMMUN, V97, P1, DOI 10.1016/j.jaut.2018.10.025; da Cruz HLA, 2020, IMMUNOGENETICS, V72, P217, DOI 10.1007/s00251-020-01158-6; Davis LS, 2017, RHEUMATOLOGY, V56, P100, DOI 10.1093/rheumatology/kew417; Ding L, 2015, MED HYPOTHESES, V85, P846, DOI 10.1016/j.mehy.2015.09.026; Dong L, 2005, ARTHRITIS RHEUM-US, V52, P651, DOI 10.1002/art.20810; Dong L, 2020, INT J MED SCI, V17, P2200, DOI 10.7150/ijms.46962; Ehtesham N, 2021, LUPUS, V30, P1273, DOI 10.1177/09612033211014273; Enzler T, 2006, IMMUNITY, V25, P403, DOI 10.1016/j.immuni.2006.07.010; Evavold CL, 2018, J MOL BIOL, V430, P217, DOI 10.1016/j.jmb.2017.09.019; Fang RD, 2014, INFECT IMMUN, V82, P2310, DOI 10.1128/IAI.01572-14; Fousert E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040915; Frangou E, 2019, ANN RHEUM DIS, V78, P238, DOI 10.1136/annrheumdis-2018-213181; Fu R, 2019, ARTHRITIS RHEUMATOL, V71, P1308, DOI 10.1002/art.40863; Furini F, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00435; Furuya MY, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1685-x; Goropevsek A, 2017, CLIN REV ALLERG IMMU, V52, P164, DOI 10.1007/s12016-016-8550-y; Guarda G, 2011, IMMUNITY, V34, P213, DOI 10.1016/j.immuni.2011.02.006; Gulinello M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/207504; Guo CH, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.05.014; Guo HN, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/7304096; He JH, 2018, INNATE IMMUN-LONDON, V24, P307, DOI 10.1177/1753425918780985; Hu S, 2020, CLIN EXP RHEUMATOL, V38, P442; Huang N, 2018, TRENDS IMMUNOL, V39, P562, DOI 10.1016/j.it.2018.04.006; Huang T, 2020, CLIN EXP RHEUMATOL, V38, P680; Huang W, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-00318-7; Ip WKE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7931; Jeltsch-David H, 2014, AUTOIMMUN REV, V13, P963, DOI 10.1016/j.autrev.2014.08.015; Ji JJ, 2016, CLIN SCI, V130, P1453, DOI 10.1042/CS20160311; Kahlenberg JM, 2014, ARTHRITIS RHEUMATOL, V66, P152, DOI 10.1002/art.38225; Kahlenberg JM, 2013, J IMMUNOL, V190, P1217, DOI 10.4049/jimmunol.1202388; Kahlenberg JM, 2011, J IMMUNOL, V187, P6143, DOI 10.4049/jimmunol.1101284; Kato Y, 2018, ANN RHEUM DIS, V77, P1507, DOI 10.1136/annrheumdis-2018-212988; Katsuyama T, 2019, J CLIN INVEST, V129, P5411, DOI 10.1172/JCI127949; Kong FQ, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00369; Kong FQ, 2016, BIOMED PHARMACOTHER, V82, P167, DOI 10.1016/j.biopha.2016.04.043; Lee KH, 2017, AUTOIMMUN REV, V16, P1160, DOI 10.1016/j.autrev.2017.09.012; Lee KM, 2018, BIOCHEM BIOPH RES CO, V503, P116, DOI 10.1016/j.bbrc.2018.05.191; Lee S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218050; Li M, 2015, INT J CLIN EXP MED, V8, P17430; Li XJ, 2018, ACTA BIOCH BIOPH SIN, V50, P888, DOI 10.1093/abbs/gmy088; Li XJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.244; Li XZ, 2018, IMMUNOL RES, V66, P521, DOI 10.1007/s12026-018-9012-9; Li Y, 2018, BIOCHEM BIOPH RES CO, V501, P351, DOI 10.1016/j.bbrc.2018.03.148; Ling CB, 2019, EYE, V33, P777, DOI 10.1038/s41433-018-0318-6; Liu JH, 2017, ARTHRITIS RHEUMATOL, V69, P1840, DOI 10.1002/art.40166; Liu JL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03530-3; Liu LB, 2019, AM J TRANSL RES, V11, P806; Ma XX, 2018, ANN RHEUM DIS, V77, P1354, DOI 10.1136/annrheumdis-2017-212652; Marin-Aguilar F, 2020, AGING CELL, V19, DOI 10.1111/acel.13050; Mende R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01250; Migliorini P, 2010, EUR CYTOKINE NETW, V21, P264, DOI 10.1684/ecn.2010.0210; Molad Y, 2010, ANN RHEUM DIS, V69, P175, DOI 10.1136/ard.2008.102780; Yusoff FM, 2020, AUTOIMMUNITY, V53, P8, DOI 10.1080/08916934.2019.1693545; Niewold TB, 2011, J INTERF CYTOK RES, V31, P887, DOI 10.1089/jir.2011.0071; Noroozi S, 2017, MOL NEUROBIOL, V54, P3031, DOI 10.1007/s12035-016-9864-8; Okada M, 2014, J BIOL CHEM, V289, DOI 10.1074/jbc.M114.579961; Pan JY, 2018, BIOCHEM BIOPH RES CO, V498, P487, DOI 10.1016/j.bbrc.2018.03.005; Panchanathan R, 2015, MOL CELL ENDOCRINOL, V415, P45, DOI 10.1016/j.mce.2015.08.003; Panchanathan R, 2011, MOL IMMUNOL, V49, P273, DOI 10.1016/j.molimm.2011.08.022; Panchanathan R, 2009, J IMMUNOL, V183, P7031, DOI 10.4049/jimmunol.0802665; Pontillo A, 2015, AUTOIMMUNITY, V48, P434, DOI 10.3109/08916934.2015.1064399; Pontillo A, 2012, AUTOIMMUNITY, V45, P271, DOI 10.3109/08916934.2011.637532; Postal M, 2020, CURR OPIN IMMUNOL, V67, P87, DOI 10.1016/j.coi.2020.10.014; Pothlichet J, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003256; Qiu Q, 2020, EXP CELL RES, V386, DOI 10.1016/j.yexcr.2019.111737; Qiu YM, 2016, IUBMB LIFE, V68, P311, DOI 10.1002/iub.1491; Rozo C, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis-2016-209850; SATOH M, 1994, J EXP MED, V180, P2341, DOI 10.1084/jem.180.6.2341; Shi XL, 2019, PHYTOTHER RES, V33, P1413, DOI 10.1002/ptr.6332; Shin MS, 2019, ARTHRITIS RHEUMATOL, V71, P109, DOI 10.1002/art.40672; Shin MS, 2013, J IMMUNOL, V190, P1407, DOI 10.4049/jimmunol.1201195; Shin MS, 2012, J IMMUNOL, V188, P4769, DOI 10.4049/jimmunol.1103355; Skopelja-Gardner S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64865-w; Sollberger G, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6689; Spel L, 2020, IMMUNOL REV, V294, P48, DOI 10.1111/imr.12839; Su BF, 2018, LIFE SCI, V208, P26, DOI 10.1016/j.lfs.2018.07.009; Su WJ, 2017, BEHAV BRAIN RES, V322, P1, DOI 10.1016/j.bbr.2017.01.018; Sun LZ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101759; Tang LL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00882; Tavares RM, 2010, IMMUNITY, V33, P181, DOI 10.1016/j.immuni.2010.07.017; Teachey DT, 2008, BLOOD, V111, P705, DOI 10.1182/blood-2007-05-087353; Teichmann LL, 2013, IMMUNITY, V38, P528, DOI 10.1016/j.immuni.2012.11.017; Tian YX, 2020, DRUG DES DEV THER, V14, P2113, DOI 10.2147/DDDT.S251623; Varga Georg, 2018, Mol Cell Pediatr, V5, P5, DOI 10.1186/s40348-018-0083-4; Villanueva E, 2011, J IMMUNOL, V187, P538, DOI 10.4049/jimmunol.1100450; Voronov E, 2006, EUR CYTOKINE NETW, V17, P109; Wang H, 2020, J VASC RES, V57, P276, DOI 10.1159/000508077; Wang WB, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008335; Westerterp M, 2017, CELL METAB, V25, P1294, DOI 10.1016/j.cmet.2017.04.005; Wolf SJ, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.06.002; Wu CY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005037; Xie SH, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106066; Yan SS, 2018, J IMMUNOL, V200, P1016, DOI 10.4049/jimmunol.1701177; Yang CA, 2015, RHEUMATOLOGY, V54, P324, DOI 10.1093/rheumatology/keu318; Yang F, 2021, BIOCHEM CELL BIOL, V99, P313, DOI 10.1139/bcb-2020-0265; Yang FY, 2020, CLIN RHEUMATOL, V39, P425, DOI 10.1007/s10067-019-04751-7; Yang M, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00725-x; Yang QR, 2014, J RHEUMATOL, V41, P444, DOI 10.3899/jrheum.130310; Yin Q, 2013, CELL REP, V4, P327, DOI 10.1016/j.celrep.2013.06.024; Yu X, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07384-7; Yu YY, 2020, INNATE IMMUN-LONDON, V26, P294, DOI 10.1177/1753425919886643; Zahid A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02538; Zhang CJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04974-3; Zhang HL, 2021, EXPERT OPIN DRUG DIS, V16, P429, DOI 10.1080/17460441.2021.1844179; Zhang H, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0911-z; Zhang WJ, 2013, J CLIN IMMUNOL, V33, P925, DOI 10.1007/s10875-013-9881-6; Zhao JJ, 2019, INT IMMUNOPHARMACOL, V69, P213, DOI 10.1016/j.intimp.2019.01.046; Zhao JJ, 2013, ARTHRITIS RHEUM-US, V65, P3176, DOI 10.1002/art.38174; Zhao JJ, 2013, INT IMMUNOPHARMACOL, V17, P116, DOI 10.1016/j.intimp.2013.05.027; Zhao LD, 2017, CELL MOL IMMUNOL, V14, P842, DOI 10.1038/cmi.2016.47; Zhao WM, 2019, INT J BIOL SCI, V15, P1571, DOI 10.7150/ijbs.34211; Zwicker S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175153	129	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								894847	10.3389/fimmu.2022.894847	http://dx.doi.org/10.3389/fimmu.2022.894847			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8XP	35664004	Green Published, gold			2022-12-18	WOS:000805008900001
J	Lu, G; Zhou, JW; Yang, T; Li, J; Jiang, XR; Zhang, WJ; Gu, SS; Wang, J				Lu, Geng; Zhou, Jiawei; Yang, Ting; Li, Jin; Jiang, Xinrui; Zhang, Wenjun; Gu, Shuangshuang; Wang, Jun			Landscape of Metabolic Fingerprinting for Diagnosis and Risk Stratification of Sepsis	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; septic shock; biomarkers; metabolomics; risk score	5-OXOPROLINE; KYNURENINE; CRITERIA; DAMAGE; ACID	BackgroundSepsis and septic shock, a subset of sepsis with higher risk stratification, are hallmarked by high mortality rates and necessitated early and accurate biomarkers. MethodsUntargeted metabolomic analysis was performed to compare the metabolic features between the sepsis and control systemic inflammatory response syndrome (SIRS) groups in discovery cohort, and potential metabolic biomarkers were selected and quantified using multiple reaction monitoring based target metabolite detection method. ResultsDifferentially expressed metabolites including 46 metabolites in positive electrospray ionization (ESI) ion mode, 22 metabolites in negative ESI ion mode, and 4 metabolites with dual mode between sepsis and SIRS were identified and revealed. Metabolites 5-Oxoproline, L-Kynurenine and Leukotriene D4 were selected based on least absolute shrinkage and selection operator regularization logistic regression and differential expressed between sepsis and septic shock group in the training and test cohorts. Respective risk scores for sepsis and septic shock based on a 3-metabolite fingerprint classifier were established to distinguish sepsis from SIRS, septic shock from sepsis. Significant relationship between developed sepsis risk scores, septic shock risk scores and Sequential (sepsis-related) Organ Failure Assessment (SOFA), procalcitonin (PCT) and lactic acid were observed. ConclusionsCollectively, our findings demonstrated that the characteristics of plasma metabolites not only manifest phenotypic variation in sepsis onset and risk stratification of sepsis but also enable individualized treatment and improve current therapeutic strategies.	[Lu, Geng; Zhou, Jiawei; Li, Jin; Jiang, Xinrui; Gu, Shuangshuang; Wang, Jun] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Emergency, Affiliated Hosp,Med Sch, Nanjing, Peoples R China; [Yang, Ting] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Pharm, Affiliated Hosp,Med Sch, Nanjing, Peoples R China; [Zhang, Wenjun] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Lab Med, Affiliated Hosp,Med Sch, Nanjing, Peoples R China	Nanjing University; Nanjing University; Nanjing University	Gu, SS; Wang, J (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, Dept Emergency, Affiliated Hosp,Med Sch, Nanjing, Peoples R China.	guss2926@njglyy.com; wjgaogou@aliyun.com			Medical School of Nanjing University [2021-LCYJ-PY-22]; Key medical research project of Jiangsu Provincial Health Commission [ZDA2020021]; Key project of Medical and Technological Development Program of Nanjing [ZKX18013]	Medical School of Nanjing University; Key medical research project of Jiangsu Provincial Health Commission; Key project of Medical and Technological Development Program of Nanjing	Acknowledgments We thank all the patients who kindly donated blood and the staff at Nanjing Drum Tower Hospital, as well as American Journal Experts for proofreading the article. Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (2021-LCYJ-PY-22) to SG, and Key medical research project of Jiangsu Provincial Health Commission (ZDA2020021) and Key project of Medical and Technological Development Program of Nanjing (ZKX18013) to JW is gratefully acknowledged.	Ahn S, 2021, CLIN NUTR, V40, P3668, DOI 10.1016/j.clnu.2021.05.008; Baumgartner R, 2019, CYTOKINE, V122, DOI 10.1016/j.cyto.2017.09.004; Che NY, 2013, CLIN CHIM ACTA, V423, P5, DOI 10.1016/j.cca.2013.04.010; Cheng Y, 2012, J PROTEOME RES, V11, P1354, DOI 10.1021/pr201001a; Elmassry MM, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-01658-2; Emmett M, 2014, CLIN J AM SOC NEPHRO, V9, P191, DOI 10.2215/CJN.07730713; Evangelatos N, 2017, PUBLIC HEALTH GENOM, V20, P274, DOI 10.1159/000486362; Gao R, 2016, INFLAMMATION, V39, P550, DOI 10.1007/s10753-015-0279-x; Gotts JE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1585; Hao HP, 2017, CELL METAB, V25, P856, DOI 10.1016/j.cmet.2017.03.007; Horvatits T, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0272-7; Hotchkiss RS, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.45; Iro MA, 2020, CURR OPIN INFECT DIS, V33, P530, DOI 10.1097/QCO.0000000000000688; Izquierdo-Garcia JL, 2011, INTENS CARE MED, V37, P2023, DOI 10.1007/s00134-011-2359-1; Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25; Kaukonen KM, 2015, NEW ENGL J MED, V372, P1629, DOI 10.1056/NEJMoa1415236; Lambden S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2663-7; Lan XY, 2022, STEM CELL REV REP, V18, P585, DOI 10.1007/s12015-021-10178-y; Logters TT, 2009, SHOCK, V32, P29, DOI 10.1097/SHK.0b013e31819714fa; Lu JY, 2012, J PROTEOME RES, V11, P4705, DOI 10.1021/pr300523x; Mierzchala-Pasierb M, 2020, ARCH BIOCHEM BIOPHYS, V691, DOI 10.1016/j.abb.2020.108508; Nagar H, 2018, ACUTE CRIT CARE, V33, P65, DOI 10.4266/acc.2018.00157; Niederman MS, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03736-w; Pederzolli CD, 2010, METAB BRAIN DIS, V25, P145, DOI 10.1007/s11011-010-9190-1; Pierrakos C, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02993-5; Rocheteau P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10145; Ryoo SM, 2018, CRIT CARE MED, V46, pE489, DOI 10.1097/CCM.0000000000003030; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Seymour CW, 2016, JAMA-J AM MED ASSOC, V315, P762, DOI 10.1001/jama.2016.0288; Sforzini L, 2019, PSYCHOPHARMACOLOGY, V236, P2997, DOI 10.1007/s00213-019-05200-8; Stanski NL, 2020, NAT REV NEPHROL, V16, P20, DOI 10.1038/s41581-019-0199-3; Stocker M, 2021, CLIN INFECT DIS, V73, pE383, DOI 10.1093/cid/ciaa876; van der Pol A, 2018, CARDIOVASC RES, V114, P1871, DOI 10.1093/cvr/cvy187; Venkateswaran N, 2019, GENE DEV, V33, P1236, DOI 10.1101/gad.327056.119; Wang YT, 2010, NAT MED, V16, P279, DOI 10.1038/nm.2092; Wirz Y, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2125-7; Wray CJ, 2002, NUTRITION, V18, P971, DOI 10.1016/S0899-9007(02)00985-1	37	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								883628	10.3389/fimmu.2022.883628	http://dx.doi.org/10.3389/fimmu.2022.883628			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9SW	35663956	Green Published, gold			2022-12-18	WOS:000805064300001
J	Magoulopoulou, A; Qian, XY; Setiabudiawan, TP; Salas, SM; Yokota, C; Rottenberg, ME; Nilsson, M; Carow, B				Magoulopoulou, Anastasia; Qian, Xiaoyan; Setiabudiawan, Todia Pediatama; Salas, Sergio Marco; Yokota, Chika; Rottenberg, Martin E.; Nilsson, Mats; Carow, Berit			Spatial Resolution of Mycobacterium tuberculosis Bacteria and Their Surrounding Immune Environments Based on Selected Key Transcripts in Mouse Lungs	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; pathogen-host interaction (PHI); granuloma; in situ sequencing; automated bacteria identification; distance-based transcript analysis; automated tuberculous lesion identification; innate immune activation	NITRIC-OXIDE SYNTHASE; PROTECTIVE IMMUNITY; T-CELLS; GRANULOMA; INFECTION; EXPANSION; PATHOLOGY; LOCUS	Mycobacterium tuberculosis (Mtb) bacilli are the causative agent of tuberculosis (TB), a major killer of mankind. Although it is widely accepted that local interactions between Mtb and the immune system in the tuberculous granuloma determine whether the outcome of infection is controlled or disseminated, these have been poorly studied due to methodological constraints. We have recently used a spatial transcriptomic technique, in situ sequencing (ISS), to define the spatial distribution of immune transcripts in TB mouse lungs. To further contribute to the understanding of the immune microenvironments of Mtb and their local diversity, we here present two complementary automated bacteria-guided analysis pipelines. These position 33 ISS-identified immune transcripts in relation to single bacteria and bacteria clusters. The analysis was applied on new ISS data from lung sections of Mtb-infected C57BL/6 and C3HeB/FeJ mice. In lungs from C57BL/6 mice early and late post infection, transcripts that define inflammatory macrophages were enriched at subcellular distances to bacteria, indicating the activation of infected macrophages. In contrast, expression patterns associated to antigen presentation were enriched in non-infected cells at 12 weeks post infection. T-cell transcripts were evenly distributed in the tissue. In Mtb-infected C3HeB/FeJ mice, transcripts characterizing activated macrophages localized in apposition to small bacteria clusters, but not in organized granulomas. Despite differences in the susceptibility to Mtb, the transcript patterns found around small bacteria clusters of C3HeB/FeJ and C57BL/6 mice were similar. Altogether, the presented tools allow us to characterize in depth the immune cell populations and their activation that interact with Mtb in the infected lung.	[Magoulopoulou, Anastasia; Qian, Xiaoyan; Salas, Sergio Marco; Yokota, Chika; Nilsson, Mats] Stockholm Univ, Dept Biochem & Biophys, Sci Life Lab, Solna, Sweden; [Setiabudiawan, Todia Pediatama; Rottenberg, Martin E.; Carow, Berit] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Solna, Sweden; [Setiabudiawan, Todia Pediatama; Rottenberg, Martin E.; Carow, Berit] Karolinska Inst, Ctr TB Res, Solna, Sweden; [Carow, Berit] Novavax AB, Uppsala, Sweden	Stockholm University; Karolinska Institutet; Karolinska Institutet	Magoulopoulou, A (corresponding author), Stockholm Univ, Dept Biochem & Biophys, Sci Life Lab, Solna, Sweden.	anastasia.magoulopoulou@scilifelab.se	Setiabudiawan, Todia Pediatama/ABC-2518-2021	Setiabudiawan, Todia Pediatama/0000-0002-3252-1201; Rottenberg, Martin/0000-0003-0514-7434; Magoulopoulou, Anastasia/0000-0002-2175-7198				Ahmed M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay0233; Bucsan AN, 2019, PATHOG DIS, V77, DOI 10.1093/femspd/ftz037; Cadena AM, 2017, NAT REV IMMUNOL, V17, P691, DOI 10.1038/nri.2017.69; CANETTI G, 1956, AM REV TUBERC PULM, V74, P13; Carow B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09816-4; Carow B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003442; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Cohen SB, 2018, CELL HOST MICROBE, V24, P439, DOI 10.1016/j.chom.2018.08.001; Dar D, 2021, SCIENCE, V373, P758, DOI 10.1126/science.abi4882; Darwin KH, 2003, SCIENCE, V302, P1963, DOI 10.1126/science.1091176; Davis JM, 2009, CELL, V136, P37, DOI 10.1016/j.cell.2008.11.014; Driver ER, 2012, ANTIMICROB AGENTS CH, V56, P3181, DOI 10.1128/AAC.00217-12; Duncan SA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02431; Dunne PJ, 2009, J IMMUNOL, V183, P400, DOI 10.4049/jimmunol.0900169; Ehlers S, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00411; Elkington P, 2019, J INFECT DIS, V219, P1858, DOI 10.1093/infdis/jiz020; Ernst JD, 2018, CELL HOST MICROBE, V24, P34, DOI 10.1016/j.chom.2018.06.004; Gern BH, 2021, CELL HOST MICROBE, V29, P594, DOI 10.1016/j.chom.2021.02.005; Jamaati H, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02008; Kauffman KD, 2018, MUCOSAL IMMUNOL, V11, P462, DOI 10.1038/mi.2017.60; Kaufmann SHE, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4730; Ke RQ, 2013, NAT METHODS, V10, P857, DOI 10.1038/nmeth.2563; Kotze LA, 2021, MSPHERE, V6, DOI 10.1128/mSphere.00552-21; Kramnik I, 2016, SEMIN IMMUNOPATHOL, V38, P221, DOI 10.1007/s00281-015-0538-9; Lee H., 2022, SCI REP-UK, DOI [10.1038/s41598-022-11534-93367cf18-d1bb-4e0f-a8f7-5212a3339323, DOI 10.1038/S41598-022-11534-93367CF18-D1BB-4E0F-A8F7-5212A3339323]; Lin PL, 2014, NAT MED, V20, P75, DOI 10.1038/nm.3412; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Marakalala MJ, 2016, NAT MED, V22, P531, DOI 10.1038/nm.4073; McCaffrey EF, 2022, NAT IMMUNOL, V23, P318, DOI 10.1038/s41590-021-01121-x; Miller BH, 2004, INFECT IMMUN, V72, P2872, DOI 10.1128/IAI.72.5.2872-2878.2004; Moguche AO, 2015, J EXP MED, V212, P715, DOI 10.1084/jem.20141518; Nunes-Alves C, 2014, NAT REV MICROBIOL, V12, P289, DOI 10.1038/nrmicro3230; Pagan AJ, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a018499; Pan H, 2005, NATURE, V434, P767, DOI 10.1038/nature03419; Pichugin AV, 2009, AM J PATHOL, V174, P2190, DOI 10.2353/ajpath.2009.081075; Pisu D, 2021, J EXP MED, V218, DOI 10.1084/jem.20210615; Queval CJ, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02284; Ramakrishnan L, 2012, NAT REV IMMUNOL, V12, P352, DOI 10.1038/nri3211; Rhee KY, 2005, P NATL ACAD SCI USA, V102, P467, DOI 10.1073/pnas.0406133102; Satti I, 2019, EXPERT REV VACCINES, V18, P43, DOI 10.1080/14760584.2019.1552140; Schmok E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01537; Seiler P, 2003, J INFECT DIS, V188, P1326, DOI 10.1086/378563; Sheth RU, 2019, NAT BIOTECHNOL, V37, P877, DOI 10.1038/s41587-019-0183-2; Shi H, 2020, NATURE, V588, P676, DOI 10.1038/s41586-020-2983-4; Srivastava S, 2013, J IMMUNOL, V191, P1016, DOI 10.4049/jimmunol.1301236; Stoltzfus CR, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107523; Strell C, 2019, JNCI-J NATL CANCER I, V111, P983, DOI 10.1093/jnci/djy234; Strell C, 2019, FEBS J, V286, P1468, DOI 10.1111/febs.14435; Svedlund J, 2019, EBIOMEDICINE, V48, P212, DOI 10.1016/j.ebiom.2019.09.009; Volkman HE, 2010, SCIENCE, V327, P466, DOI 10.1126/science.1179663; Yan BS, 2007, J IMMUNOL, V179, P6919, DOI 10.4049/jimmunol.179.10.6919	51	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								876321	10.3389/fimmu.2022.876321	http://dx.doi.org/10.3389/fimmu.2022.876321			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9DP	35663950	Green Published, gold			2022-12-18	WOS:000805024600001
J	Nagafuchi, Y; Yanaoka, H; Fujio, K				Nagafuchi, Yasuo; Yanaoka, Haruyuki; Fujio, Keishi			Lessons From Transcriptome Analysis of Autoimmune Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						transcriptome; eQTL; autoimmune disease; immune cell; monocytes; macrophages; systemic lupus erythematosus; rheumatoid arthritis	SYSTEMIC-LUPUS-ERYTHEMATOSUS; GENE-EXPRESSION SIGNATURE; PERIPHERAL-BLOOD CELLS; RHEUMATOID-ARTHRITIS; OPEN-LABEL; INTERFERON; TOCILIZUMAB; RITUXIMAB; IDENTIFICATION; ANIFROLUMAB	Various immune cell types, including monocytes, macrophages, and adaptive immune T and B cells, play major roles in inflammation in systemic autoimmune diseases. However, the precise contribution of these cells to autoimmunity remains elusive. Transcriptome analysis has added a new dimension to biology and medicine. It enables us to observe the dynamics of gene expression in different cell types in patients with diverse diseases as well as in healthy individuals, which cannot be achieved with genomic information alone. In this review, we summarize how transcriptome analysis has improved our understanding of the pathological roles of immune cells in autoimmune diseases with a focus on the ImmuNexUT database we reported. We will also discuss the common experimental and analytical design of transcriptome analyses. Recently, single-cell RNA-seq analysis has provided atlases of infiltrating immune cells, such as pro-inflammatory monocytes and macrophages, peripheral helper T cells, and age or autoimmune-associated B cells in various autoimmune disease lesions. With the integration of genomic data, expression quantitative trait locus (eQTL) analysis can help identify candidate causal genes and immune cells. Finally, we also mention how the information obtained from these analyses can be used practically to predict patient prognosis.	[Nagafuchi, Yasuo; Fujio, Keishi] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan; [Nagafuchi, Yasuo] Univ Tokyo, Grad Sch Med, Dept Funct Genom & Immunol Dis, Tokyo, Japan; [Yanaoka, Haruyuki] St Lukes Int Univ, St Lukes Int Hosp, Immuno Rheumatol Ctr, Tokyo, Japan	University of Tokyo; University of Tokyo; St. Luke's International Hospital	Nagafuchi, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Tokyo, Japan.; Nagafuchi, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Funct Genom & Immunol Dis, Tokyo, Japan.	nagafuchi@g.ecc.u-tokyo.ac.jp	Nagafuchi, Yasuo/Y-9083-2019	Nagafuchi, Yasuo/0000-0002-1316-8035				Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Albert FW, 2015, NAT REV GENET, V16, P197, DOI 10.1038/nrg3891; Arazi A, 2019, NAT IMMUNOL, V20, P902, DOI 10.1038/s41590-019-0398-x; Baechler EC, 2003, P NATL ACAD SCI USA, V100, P2610, DOI 10.1073/pnas.0337679100; Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; Barrat FJ, 2019, NAT IMMUNOL, V20, P1574, DOI 10.1038/s41590-019-0466-2; Bave U, 2005, ARTHRITIS RHEUM-US, V52, P1185, DOI 10.1002/art.20998; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120; Chaussabel D, 2008, IMMUNITY, V29, P150, DOI 10.1016/j.immuni.2008.05.012; Chun S, 2017, NAT GENET, V49, P600, DOI 10.1038/ng.3795; de Berg PJV, 2008, CURR OPIN IMMUNOL, V20, P339, DOI 10.1016/j.coi.2008.03.007; DEAPEN D, 1992, ARTHRITIS RHEUM, V35, P311; Dennis G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4555; Denton CP, 2017, LANCET, V390, P1685, DOI 10.1016/S0140-6736(17)30933-9; Der E, 2019, NAT IMMUNOL, V20, P915, DOI 10.1038/s41590-019-0386-1; Donlin LT, 2019, NAT REV RHEUMATOL, V15, P327, DOI 10.1038/s41584-019-0217-7; Fairfax BP, 2014, SCIENCE, V343, P1118, DOI 10.1126/science.1246949; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404; Fonseka CY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq0305; Furie R, 2017, ARTHRITIS RHEUMATOL, V69, P376, DOI 10.1002/art.39962; Giladi A, 2018, CELL, V172, P14, DOI 10.1016/j.cell.2017.11.011; Higgs BW, 2011, ANN RHEUM DIS, V70, P2029, DOI 10.1136/ard.2011.150326; Humby F, 2021, LANCET, V397, P305, DOI 10.1016/S0140-6736(20)32341-2; Humby F, 2019, ANN RHEUM DIS, V78, P761, DOI 10.1136/annrheumdis-2018-214539; Ishigaki K, 2017, NAT GENET, V49, P1120, DOI 10.1038/ng.3885; Jenks SA, 2018, IMMUNITY, V49, P725, DOI 10.1016/j.immuni.2018.08.015; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Kobayashi S, 2022, RHEUMATOLOGY, V61, P4163, DOI 10.1093/rheumatology/keac031; Kobayashi S, 2021, J AUTOIMMUN, V116, DOI 10.1016/j.jaut.2020.102547; Kraan TCTMV, 2007, ANN RHEUM DIS, V66, P1008, DOI 10.1136/ard.2006.063412; Kuo D, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau8587; Lewis MJ, 2019, CELL REP, V28, P2455, DOI 10.1016/j.celrep.2019.07.091; Lin JX, 2019, ANNU REV IMMUNOL, V37, P295, DOI 10.1146/annurev-immunol-042718-041447; Lisnevskaia L, 2014, LANCET, V384, P1878, DOI 10.1016/S0140-6736(14)60128-8; Lubbers J, 2013, ANN RHEUM DIS, V72, P776, DOI 10.1136/annrheumdis-2012-202753; Lyons PA, 2010, ANN RHEUM DIS, V69, P1208, DOI 10.1136/ard.2009.108043; Ma WT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01140; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; McKinney EF, 2015, NATURE, V523, P612, DOI 10.1038/nature14468; Morand EF, 2020, NEW ENGL J MED, V382, P211, DOI 10.1056/NEJMoa1912196; Moreno-Moral A, 2018, ANN RHEUM DIS, V77, P596, DOI 10.1136/annrheumdis-2017-212454; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Munroe ME, 2016, ANN RHEUM DIS, V75, P2014, DOI 10.1136/annrheumdis-2015-208140; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; Navegantes KC, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1141-8; Nehar-Belaid D, 2020, NAT IMMUNOL, V21, P1094, DOI 10.1038/s41590-020-0743-0; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; Nishina N, 2014, ANN RHEUM DIS, V73, P945, DOI 10.1136/annrheumdis-2013-204137; Nombel A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.773352; Okada Y, 2014, NATURE, V506, P376, DOI 10.1038/nature12873; Orange DE, 2020, NEW ENGL J MED, V383, P218, DOI 10.1056/NEJMoa2004114; Ota M, 2021, CELL, V184, P3006, DOI 10.1016/j.cell.2021.03.056; Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76; Perez RK, 2022, SCIENCE, V376, P153, DOI 10.1126/science.abf1970; Plant D, 2019, ARTHRITIS RHEUMATOL, V71, P678, DOI 10.1002/art.40810; Rao DA, 2017, NATURE, V542, P110, DOI 10.1038/nature20810; Raterman HG, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3819; Sanayama Y, 2014, ARTHRITIS RHEUMATOL, V66, P1421, DOI 10.1002/art.38400; Sangaletti S, 2012, BLOOD, V120, P3007, DOI 10.1182/blood-2012-03-416156; Satoh T, 2017, NATURE, V541, P96, DOI 10.1038/nature20611; Schmiedel BJ, 2018, CELL, V175, P1701, DOI 10.1016/j.cell.2018.10.022; Scott MKD, 2019, LANCET RESP MED, V7, P497, DOI 10.1016/S2213-2600(18)30508-3; Sellam J, 2014, ARTHRITIS RHEUMATOL, V66, P2015, DOI 10.1002/art.38671; Skaug B, 2020, ANN RHEUM DIS, V79, P379, DOI 10.1136/annrheumdis-2019-215894; Takeuchi T, 2011, ANN RHEUM DIS, V70, P1208, DOI 10.1136/ard.2011.153023; Tyndall AJ, 2010, ANN RHEUM DIS, V69, P1809, DOI 10.1136/ard.2009.114264; Valenzi E, 2019, ANN RHEUM DIS, V78, P1379, DOI 10.1136/annrheumdis-2018-214865; Wang YF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21049-y; Wright HL, 2015, RHEUMATOLOGY, V54, P188, DOI 10.1093/rheumatology/keu299; Wu XY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25246-7; Yanaoka H, 2021, J AUTOIMMUN, V119, DOI 10.1016/j.jaut.2021.102617; Yazar S, 2022, SCIENCE, V376, P154, DOI 10.1126/science.abf3041; Ye CJ, 2014, SCIENCE, V345, P1311, DOI 10.1126/science.1254665; Yin XY, 2021, ANN RHEUM DIS, V80, P632, DOI 10.1136/annrheumdis-2020-219209; Yokoyama-Kokuryo W, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075-020-2137-y; Yusof MYM, 2017, ANN RHEUM DIS, V76, P1829, DOI 10.1136/annrheumdis-2017-211191; Yusof MYM, 2015, ANN RHEUM DIS, V74, P1734, DOI 10.1136/annrheumdis-2014-206496; Zhang F, 2021, GENOME MED, V13, DOI 10.1186/s13073-021-00881-3; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1; Zhang MJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01142; Zhao MM, 2021, CLIN REV ALLERG IMMU, V60, P68, DOI 10.1007/s12016-020-08813-6	84	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								857269	10.3389/fimmu.2022.857269	http://dx.doi.org/10.3389/fimmu.2022.857269			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8VZ	35663941	gold, Green Published			2022-12-18	WOS:000805004700001
J	Noack, L; Bundkirchen, K; Xu, BL; Gylstorff, S; Zhou, YZ; Koehler, K; Jantaree, P; Neunaber, C; Nowak, AJ; Relja, B				Noack, Laurens; Bundkirchen, Katrin; Xu, Baolin; Gylstorff, Severin; Zhou, Yuzhuo; Koehler, Kernt; Jantaree, Phatcharida; Neunaber, Claudia; Nowak, Aleksander J.; Relja, Borna			Acute Intoxication With Alcohol Reduces Trauma-Induced Proinflammatory Response and Barrier Breakdown in the Lung via the Wnt/beta-Catenin Signaling Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						femur fracture; hemorrhagic shock; inflammation; pulmonary; ethanol	ACTIVATION; PROTEIN; INJURY; ABUSE; INFLAMMATION; CONSUMPTION; INHIBITION; EXPRESSION; MORTALITY; ALPHA	BackgroundTrauma is the third leading cause of mortality worldwide. Upon admission, up to 50% of traumatized patients are acutely intoxicated with alcohol, which might lead to aberrant immune responses. An excessive and uncontrolled inflammatory response to injury is associated with damage to trauma-distant organs. We hypothesize that, along with inflammation-induced apoptosis, the activation of the Wnt/beta-catenin signaling pathway would cause breakdown of the lung barrier and the development of lung injury after trauma. It remains unclear whether ethanol intoxication (EI) prior to trauma and hemorrhagic shock will attenuate inflammation and organ injury. MethodsIn this study, 14 male C57BL/6J mice were randomly assigned to two groups and exposed either to EtOH or to NaCl as a control by an oral gavage before receiving a femur fracture (Fx) and hemorrhagic shock, followed by resuscitation (THFx). Fourteen sham animals received either EtOH or NaCl and underwent surgical procedures without THFx induction. After 24 h, oil red O staining of fatty vacuoles in the liver was performed. Histological lung injury score (LIS) was assessed to analyze the trauma-induced RLI. Gene expression of Cxcl1, Il-1 beta, Muc5ac, Tnf, and Tnfrsf10b as well as CXCL1, IL-1 beta, and TNF protein levels in the lung tissue and bronchoalveolar lavage fluid were determined by RT-qPCR, ELISA, and immunohistological analyses. Infiltrating polymorphonuclear leukocytes (PMNLs) were examined via immunostaining. Apoptosis was detected by activated caspase-3 expression in the lung tissue. To confirm active Wnt signaling after trauma, gene expression of Wnt3a and its inhibitor sclerostin (Sost) was determined. Protein expression of A20 and RIPK4 as possible modulators of the Wnt signaling pathway was analyzed via immunofluorescence. ResultsSignificant fatty changes in the liver confirmed the acute EI. Histopathology and decreased Muc5ac expression revealed an increased lung barrier breakdown and concomitant lung injury after THFx versus sham. EI prior trauma decreased lung injury. THFx increased not only the gene expression of pro-inflammatory markers but also the pulmonary infiltration with PMNL and apoptosis versus sham, while EI prior to THFx reduced those changes significantly. EI increased the THFx-reduced gene expression of Sost and reduced the THFx-induced expression of Wnt3a. While A20, RIPK4, and membranous beta-catenin were significantly reduced after trauma, they were enhanced upon EI. ConclusionThese findings suggest that acute EI alleviates the uncontrolled inflammatory response and lung barrier breakdown after trauma by suppressing the Wnt/beta-catenin signaling pathway.	[Noack, Laurens; Xu, Baolin; Gylstorff, Severin; Zhou, Yuzhuo; Nowak, Aleksander J.; Relja, Borna] Otto von Guericke Univ, Dept Radiol & Nucl Med, Expt Radiol, Magdeburg, Germany; [Bundkirchen, Katrin; Xu, Baolin; Zhou, Yuzhuo; Neunaber, Claudia] Hannover Med Sch, Trauma Dept, Hannover, Germany; [Koehler, Kernt] Justus Liebig Univ Giessen, Inst Vet Pathol, Giessen, Germany; [Jantaree, Phatcharida] Otto von Guericke Univ, Inst Expt Internal Med, Magdeburg, Germany	Otto von Guericke University; Hannover Medical School; Justus Liebig University Giessen; Otto von Guericke University	Relja, B (corresponding author), Otto von Guericke Univ, Dept Radiol & Nucl Med, Expt Radiol, Magdeburg, Germany.		Relja, Borna/B-6642-2016	Relja, Borna/0000-0002-5625-8823	German Research Foundation DFG [DFG RE 3304/9-1, NE 1932/1-3, 361210922/RTG 2408]	German Research Foundation DFG(German Research Foundation (DFG))	Funding This research was funded by the German Research Foundation DFG with grant numbers DFG RE 3304/9-1, NE 1932/1-3, and 361210922/RTG 2408.	Berkowitz DM, 2009, ALCOHOL CLIN EXP RES, V33, P1690, DOI 10.1111/j.1530-0277.2009.01005.x; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Bundkirchen K, 2018, J TRAUMA ACUTE CARE, V85, P359, DOI 10.1097/TA.0000000000001952; Bundkirchen K, 2017, CLIN ORTHOP RELAT R, V475, P2783, DOI 10.1007/s11999-017-5473-8; Burnham EL, 2009, ALCOHOL ALCOHOLISM, V44, P8, DOI 10.1093/alcalc/agn051; Chen L, 2019, BMC ANESTHESIOL, V19, DOI 10.1186/s12871-019-0698-6; Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249; Chertov O, 2000, IMMUNOL REV, V177, P68, DOI 10.1034/j.1600-065X.2000.17702.x; Czaja AJ, 2014, WORLD J GASTROENTERO, V20, P2515, DOI 10.3748/wjg.v20.i10.2515; DeBerge MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079340; Doggett TM, 2014, ALCOHOL CLIN EXP RES, V38, P2414, DOI 10.1111/acer.12525; Ehre C, 2012, P NATL ACAD SCI USA, V109, P16528, DOI 10.1073/pnas.1206552109; El-Guindy NBD, 2007, ALCOHOL, V41, P335, DOI 10.1016/j.alcohol.2007.07.002; Fan X, 2011, ALCOHOL CLIN EXP RES, V35, P1866, DOI 10.1111/j.1530-0277.2011.01531.x; Hiraoka Y, 2008, BIOCHEM BIOPH RES CO, V370, P154, DOI 10.1016/j.bbrc.2008.03.050; Howard BM, 2018, J TRAUMA ACUTE CARE, V84, P97, DOI 10.1097/TA.0000000000001716; Hu TM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/121786; Huang CK, 2015, J HEPATOL, V63, P191, DOI 10.1016/j.jhep.2015.02.030; Kapania EM, 2020, ANIM MODEL EXP MED, V3, P200, DOI 10.1002/ame2.12116; Kim J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19155-4; Lefaivre KA, 2010, J TRAUMA, V69, P1527, DOI 10.1097/TA.0b013e3181f8fa3b; Levy RS, 1996, J ORTHOP TRAUMA, V10, P21, DOI 10.1097/00005131-199601000-00004; Lichte P, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/132451; Liu B, 2013, J SURG RES, V185, P717, DOI 10.1016/j.jss.2013.06.031; Liu ZG, 2016, INT IMMUNOPHARMACOL, V35, P210, DOI 10.1016/j.intimp.2016.04.003; Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006; Ma Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep13595; Maraslioglu M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/808695; Matute-Bello G, 2011, AM J RESP CELL MOL, V44, P725, DOI 10.1165/rcmb.2009-0210ST; Mercer KE, 2014, CANCER PREV RES, V7, P675, DOI 10.1158/1940-6207.CAPR-13-0444-T; Mors K, 2017, CELL PHYSIOL BIOCHEM, V43, P17, DOI 10.1159/000480313; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Mors K, 2021, DIS MARKERS, V2021, DOI 10.1155/2021/6622701; Nakamura BN, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195893; Nelson S, 2002, NAT REV IMMUNOL, V2, P205, DOI 10.1038/nri744; Nowak AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249407; O'Keeffe T, 2009, J TRAUMA, V66, P495, DOI 10.1097/TA.0b013e31818234bf; Otis JS, 2008, ALCOHOL CLIN EXP RES, V32, P699, DOI 10.1111/j.1530-0277.2008.00626.x; Papayannopoulos V, 2018, IMMUNITY, V49, P992, DOI 10.1016/j.immuni.2018.12.006; Relja B, 2016, INJURY, V47, P640, DOI 10.1016/j.injury.2016.01.016; Relja B, 2012, BRIT J PHARMACOL, V165, P1188, DOI 10.1111/j.1476-5381.2011.01595.x; Relja B, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76499-z; Relja B, 2020, EUR J TRAUMA EMERG S, V46, P751, DOI 10.1007/s00068-019-01235-w; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; Rodriguez DA, 2004, ALCOHOL, V33, P9, DOI 10.1016/j.alcohol.2004.03.001; Ron D, 2013, CURR TOP BEHAV NEURO, V13, P87, DOI 10.1007/7854_2011_161; Sakran JV, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-64; Samuelson DR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006426; Santaolalla R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063298; Savola O, 2005, ALCOHOL ALCOHOLISM, V40, P269, DOI 10.1093/alcalc/agh159; Sawant DA, 2015, J TRAUMA ACUTE CARE, V79, P609, DOI 10.1097/TA.0000000000000807; Sawant KV, 2016, SCI REP-UK, V6, DOI 10.1038/srep33123; Sears BW, 2011, J BONE JOINT SURG AM, V93A, P739, DOI 10.2106/JBJS.J.00318; Secreto Frank J, 2009, Curr Osteoporos Rep, V7, P64; Smith P, 2019, ALCOHOL, V80, P81, DOI 10.1016/j.alcohol.2018.08.007; Soni D, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0056-3; Stormann P, 2017, PROSTAG LEUKOTR ESS, V127, P25, DOI 10.1016/j.plefa.2017.09.014; Sturm R, 2022, EUR J TRAUMA EMERG S, V48, P1569, DOI 10.1007/s00068-021-01666-4; Taieb J, 2002, J LEUKOCYTE BIOL, V72, P1142; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; von Maltzan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029890; Wagner N, 2019, INT J MOL MED, V44, P1127, DOI 10.3892/ijmm.2019.4259; Wand G, 2001, J NEUROSCI, V21, P5297, DOI 10.1523/JNEUROSCI.21-14-05297.2001; Warner DR, 2021, FASEB J, V35, DOI 10.1096/fj.202001202R; Wilson DF, 2020, MED HYPOTHESES, V140, DOI 10.1016/j.mehy.2020.109638; Xu BL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218181; Xu CQ, 2015, ALCOHOL CLIN EXP RES, V39, P969, DOI 10.1111/acer.12727; Xu P, 2013, J IMMUNOL, V190, P5247, DOI 10.4049/jimmunol.1203182; Zhang H, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/536435	69	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								866925	10.3389/fimmu.2022.866925	http://dx.doi.org/10.3389/fimmu.2022.866925			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9GV	35663960	Green Published, gold			2022-12-18	WOS:000805033000001
J	Wang, QH; Zhang, XY; Li, CC; Xiong, M; Bai, WX; Sun, S; Chen, C; Zhang, XX; Li, MY; Zhao, AM				Wang, Qiaohong; Zhang, Xinyang; Li, Congcong; Xiong, Miao; Bai, Wenxin; Sun, Si; Chen, Chao; Zhang, Xiaoxin; Li, Mingyang; Zhao, Aimin			Intracellular Lipid Accumulation Drives the Differentiation of Decidual Polymorphonuclear Myeloid-Derived Suppressor Cells via Arachidonic Acid Metabolism	FRONTIERS IN IMMUNOLOGY			English	Article						polymorphonuclear myeloid-derived suppressor cells; immune tolerance in pregnancy; unexplained recurrent pregnancy loss; arachidonic acid metabolism; PGE2 synthesis; fatty acid-binding protein 5	IMMUNE SUPPRESSION; TUMOR PROGRESSION; PREGNANCY LOSS; NEUTROPHILS; MECHANISMS; EXPRESSION; IMMUNOMETABOLISM; INFLAMMATION; MACROPHAGES; ACTIVATION	Decidual polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are essential to immune tolerance during pregnancy. A reduction in the number of these cells is associated with unexplained recurrent pregnancy loss (URPL). In our previous study, we reported that PMN-MDSCs are a group of mature neutrophils that are activated by the decidua microenvironment. In the present study, we show that the decidua microenvironment induces substantial lipid accumulation in neutrophils during their differentiation to PMN-MDSCs. Lower levels of lipid accumulation are detected in PMN-MDSCs from URPL patients, and the amount of lipid in the PMN-MDSCs is positively correlated with the proportion of PMN-MDSCs. Next, we demonstrate that decidua-derived IL6 with the presence of arachidonic acid upregulates fatty acid-binding protein 5 (FABP5) via the phosphorylation of signal transducer and activator of transcription 3 (STAT3). Fy -60ABP5 then continuously stimulates intracellular lipid accumulation. Increased intracellular lipid accumulation mediates arachidonic acid metabolism, a pathway that is significantly activated by the induction of the decidua microenvironment, to stimulate the synthesis of prostaglandin E2 (PGE2) and finally induce the differentiation of PMN-MDSCs. To summarize, decidua-derived IL6 facilitates the differentiation of PMN-MDSCs from neutrophils via the pSTAT3/FABP5/PGE2 pathway. Defects in the process may result in impaired differentiation and dysfunction of PMN-MDSCs in URPL. These findings enhance our understanding of the physiological mechanisms of immune tolerance in pregnancy and provide therapeutic options for URPL.	[Wang, Qiaohong; Zhang, Xinyang; Li, Congcong; Xiong, Miao; Bai, Wenxin; Sun, Si; Chen, Chao; Zhang, Xiaoxin; Li, Mingyang; Zhao, Aimin] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Obstet & Gynecol, Shanghai, Peoples R China; [Wang, Qiaohong; Zhang, Xinyang; Li, Congcong; Xiong, Miao; Bai, Wenxin; Sun, Si; Chen, Chao; Zhang, Xiaoxin; Li, Mingyang; Zhao, Aimin] Shanghai Key Lab Gynecol Oncol, Shanghai, Peoples R China; [Xiong, Miao] Shanghai Jiao Tong Univ, Dept Obstet & Gynecol, Sch Med, Affiliated Peoples Hosp 6, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Zhao, AM (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Obstet & Gynecol, Shanghai, Peoples R China.; Zhao, AM (corresponding author), Shanghai Key Lab Gynecol Oncol, Shanghai, Peoples R China.	zamzkh0526@126.com			National Natural Science Foundation of China [82071725, 81871179]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (No. 82071725) and the National Natural Science Foundation of China (No. 81871179).	Adachi Y, 2012, HISTOCHEM CELL BIOL, V138, P397, DOI 10.1007/s00418-012-0963-y; Ahmadi M, 2019, CELL IMMUNOL, V346, DOI 10.1016/j.cellimm.2019.103990; Al-Khami AA, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1344804; Al-Khami AA, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1200771; Arck PC, 2013, NAT MED, V19, P548, DOI 10.1038/nm.3160; Arruvito L, 2009, J REPROD IMMUNOL, V82, P158, DOI 10.1016/j.jri.2009.04.010; Bansal AS, 2010, AM J REPROD IMMUNOL, V64, P307, DOI 10.1111/j.1600-0897.2010.00864.x; Bleve A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165845; Bogdan D, 2018, J BIOL CHEM, V293, P5295, DOI 10.1074/jbc.RA118.001593; Bronte V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12150; Caetano MS, 2016, CANCER RES, V76, P3189, DOI 10.1158/0008-5472.CAN-15-2840; Cao W, 2011, CANCER RES, V71, DOI 10.1158/1538-7445.AM2011-3649; Clements VK, 2018, J LEUKOCYTE BIOL, V103, P395, DOI 10.1002/JLB.4HI0517-210R; Condamine T, 2011, TRENDS IMMUNOL, V32, P19, DOI 10.1016/j.it.2010.10.002; Corn KC, 2020, PROG LIPID RES, V80, DOI 10.1016/j.plipres.2020.101055; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; den Brok MH, 2018, TRENDS IMMUNOL, V39, P380, DOI 10.1016/j.it.2018.01.012; Field CS, 2020, CELL METAB, V31, P422, DOI 10.1016/j.cmet.2019.11.021; Furuhashi M, 2008, NAT REV DRUG DISCOV, V7, P489, DOI 10.1038/nrd2589; Giese MA, 2019, BLOOD, V133, P2159, DOI 10.1182/blood-2018-11-844548; Gnecco JS, 2019, HUM REPROD, V34, P702, DOI 10.1093/humrep/dez003; Gonzalez JM, 2013, J REPROD IMMUNOL, V97, P112, DOI 10.1016/j.jri.2012.07.008; Haggarty P, 2006, HUM REPROD, V21, P766, DOI 10.1093/humrep/dei385; Hossain F, 2015, CANCER IMMUNOL RES, V3, P1236, DOI 10.1158/2326-6066.CIR-15-0036; Jia HP, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.667525; Kang XM, 2016, MOL HUM REPROD, V22, P499, DOI 10.1093/molehr/gaw026; Kang XM, 2016, DNA CELL BIOL, V35, P358, DOI 10.1089/dna.2015.2962; Kobayashi S, 2022, INT J CANCER, V150, P152, DOI 10.1002/ijc.33777; Kostlin N, 2016, J IMMUNOL, V196, P1132, DOI 10.4049/jimmunol.1500340; Kostlin N, 2014, EUR J IMMUNOL, V44, P2582, DOI 10.1002/eji.201344200; Kostlin-Gille N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00161; Kwak-Kim J, 2009, J OBSTET GYNAECOL RE, V35, P609, DOI 10.1111/j.1447-0756.2009.01079.x; Li CC, 2020, HUM REPROD, V35, P2677, DOI 10.1093/humrep/deaa217; Li CC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01345; Li JJ, 2019, J CLIN ENDOCR METAB, V104, P5555, DOI 10.1210/jc.2019-00793; Li KL, 2018, FOOD FUNCT, V9, P1179, DOI 10.1039/c7fo01545c; Li SQ, 2020, EMBO REP, V21, DOI 10.15252/embr.201949425; Lim KJH, 2000, FERTIL STERIL, V73, P136, DOI 10.1016/S0015-0282(99)00457-4; Lindau R, 2018, HUM REPROD, V33, P588, DOI 10.1093/humrep/dey037; Liu FM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000501; Martin SA, 2016, J LIPID RES, V57, P1126, DOI 10.1194/jlr.R068072; Mohamed E, 2018, CELL MOL IMMUNOL, V15, P421, DOI 10.1038/s41423-018-0001-7; Nair RR, 2015, AM J REPROD IMMUNOL, V73, P479, DOI 10.1111/aji.12351; Niavarani SR, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6045-y; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; O'Sullivan SE, 2020, DRUG DISCOV TODAY, V25, P2056, DOI 10.1016/j.drudis.2020.09.018; Obermajer N, 2012, IMMUNOL INVEST, V41, P635, DOI 10.3109/08820139.2012.695417; Olenchock BA, 2017, IMMUNITY, V46, P703, DOI 10.1016/j.immuni.2017.04.013; Pan T, 2016, J LEUKOCYTE BIOL, V100, P499, DOI 10.1189/jlb.1A1015-481RR; Pan YD, 2017, NATURE, V543, P252, DOI 10.1038/nature21379; Peng XX, 2017, MOL PAIN, V13, DOI 10.1177/1744806917697007; Pillay J, 2013, CELL MOL LIFE SCI, V70, P3813, DOI 10.1007/s00018-013-1286-4; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; Porta C, 2018, FEBS J, V285, P717, DOI 10.1111/febs.14288; Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114; Ren JB, 2019, AM J REPROD IMMUNOL, V81, DOI 10.1111/aji.13099; Schindler M, 2017, HUM REPROD, V32, P1382, DOI 10.1093/humrep/dex087; Schwenk RW, 2010, PROSTAG LEUKOTR ESS, V82, P149, DOI 10.1016/j.plefa.2010.02.029; Senga S, 2018, BBA-MOL CELL BIOL L, V1863, P1057, DOI 10.1016/j.bbalip.2018.06.010; Seo J, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01367-5; Singel KL, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122311; Sinha P, 2007, CANCER RES, V67, P4507, DOI 10.1158/0008-5472.CAN-06-4174; Storch J, 2009, J LIPID RES, V50, pS126, DOI 10.1194/jlr.R800084-JLR200; Szczuko M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249628; Thiele K, 2018, SEMIN IMMUNOPATHOL, V40, P157, DOI 10.1007/s00281-017-0660-y; Trowsdale J, 2006, NAT IMMUNOL, V7, P241, DOI 10.1038/ni1317; Tsai JH, 2014, BIOL REPROD, V90, DOI 10.1095/biolreprod.113.113217; Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Veglia F, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-467; Velicky P, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007698; von Wolff M, 2000, MOL HUM REPROD, V6, P627; Vondra S, 2019, J LIPID RES, V60, P1922, DOI 10.1194/jlr.P093427; Vrachnis N, 2012, IN VIVO, V26, P799; Waight JD, 2013, J CLIN INVEST, V123, P4464, DOI 10.1172/JCI68189; Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075; Wang YA, 2018, J REPROD IMMUNOL, V127, P48, DOI 10.1016/j.jri.2018.05.002; Warning JC, 2011, REPRODUCTION, V141, P715, DOI 10.1530/REP-10-0360; Weber R, 2021, CELL IMMUNOL, V359, DOI 10.1016/j.cellimm.2020.104254; Weisblum Y, 2011, J VIROL, V85, P13204, DOI 10.1128/JVI.05749-11; Yan DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01399; Yan GF, 2018, CANCER RES, V78, P5586, DOI 10.1158/0008-5472.CAN-17-3962; Yan JW, 2020, TRENDS CELL BIOL, V30, P979, DOI 10.1016/j.tcb.2020.09.006; Zhang Y., 2021, HUM REPROD, V36, DOI [10.1093/humrep/deab130.367, DOI 10.1093/HUMREP/DEAB130.367]; Zhang YH, 2019, HUM REPROD, V34, P25, DOI 10.1093/humrep/dey347; Zhao AM, 2016, J REPROD IMMUNOL, V113, P35, DOI 10.1016/j.jri.2015.11.001; Zhou H, 2021, HUM REPROD, V36, P307; Zhou J, 2018, SEMIN IMMUNOL, V35, P19, DOI 10.1016/j.smim.2017.12.004; Zuo RJ, 2015, J BIOL CHEM, V290, P21280, DOI 10.1074/jbc.M115.656629	89	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								868669	10.3389/fimmu.2022.868669	http://dx.doi.org/10.3389/fimmu.2022.868669			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5OC	35664000	gold, Green Published			2022-12-18	WOS:000806137700001
J	Wu, XT; Wu, ZW; Ye, XQ; Pang, L; Sheng, YF; Wang, ZH; Zhou, YA; Zhu, JC; Hu, RM; Zhou, SC; Chen, JN; Wang, ZZ; Shi, M; Huang, JH; Chen, XX				Wu, Xiaotong; Wu, Zhiwei; Ye, Xiqian; Pang, Lan; Sheng, Yifeng; Wang, Zehua; Zhou, Yuenan; Zhu, Jiachen; Hu, Rongmin; Zhou, Sicong; Chen, Jiani; Wang, Zhizhi; Shi, Min; Huang, Jianhua; Chen, Xuexin			The Dual Functions of a Bracovirus C-Type Lectin in Caterpillar Immune Response Manipulation	FRONTIERS IN IMMUNOLOGY			English	Article						bracovirus; C-type lectin; immunosuppression; hemocytes proliferation; agglutination; hypoimmunity	CAMPOLETIS-SONORENSIS ICHNOVIRUS; POLYDNAVIRUS INDUCES APOPTOSIS; COTESIA-PLUTELLAE BRACOVIRUS; MANDUCA-SEXTA; HEMOCYTIC ENCAPSULATION; BANCHINE POLYDNAVIRUS; DOMAIN PROTEINS; BETA-INTEGRIN; GENE FAMILY; DROSOPHILA	Parasitoids are widespread in natural ecosystems and normally equipped with diverse viral factors to defeat host immune responses. On the other hand, parasitoids can enhance the antibacterial abilities and improve the hypoimmunity traits of parasitized hosts that may encounter pathogenic infections. These adaptive strategies guarantee the survival of parasitoid offspring, yet their underlying mechanisms are poorly understood. Here, we focused on Cotesia vestalis, an endoparasitoid of the diamondback moth Plutella xylostella, and found that C. vestalis parasitization decreases the number of host hemocytes, leading to disruption of the encapsulation reaction. We further found that one bracovirus C-type lectin gene, CvBV_28-1, is highly expressed in the hemocytes of parasitized hosts and participates in suppressing the proliferation rate of host hemocytes, which in turn reduces their population and represses the process of encapsulation. Moreover, CvBV_28-1 presents a classical bacterial clearance ability via the agglutination response in a Ca2+-dependent manner in response to gram-positive bacteria. Our study provides insights into the innovative strategy of a parasitoid-derived viral gene that has dual functions to manipulate host immunity for a successful parasitism.	[Wu, Xiaotong; Wu, Zhiwei; Ye, Xiqian; Pang, Lan; Sheng, Yifeng; Wang, Zehua; Zhou, Yuenan; Zhu, Jiachen; Hu, Rongmin; Zhou, Sicong; Chen, Jiani; Wang, Zhizhi; Shi, Min; Huang, Jianhua; Chen, Xuexin] Zhejiang Univ, Inst Insect Sci, Coll Agr & Biotechnol, Hangzhou, Peoples R China; [Wu, Xiaotong; Ye, Xiqian; Wang, Zhizhi; Shi, Min; Huang, Jianhua; Chen, Xuexin] Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China; [Wu, Xiaotong; Wu, Zhiwei; Ye, Xiqian; Pang, Lan; Sheng, Yifeng; Wang, Zehua; Zhou, Yuenan; Zhu, Jiachen; Hu, Rongmin; Zhou, Sicong; Chen, Jiani; Wang, Zhizhi; Shi, Min; Huang, Jianhua; Chen, Xuexin] Zhejiang Univ, Minist Agr Key Lab Mol Biol Crop Pathogens & Insec, Hangzhou, Peoples R China; [Wu, Xiaotong; Wu, Zhiwei; Ye, Xiqian; Pang, Lan; Sheng, Yifeng; Wang, Zehua; Zhou, Yuenan; Zhu, Jiachen; Hu, Rongmin; Zhou, Sicong; Chen, Jiani; Wang, Zhizhi; Shi, Min; Huang, Jianhua; Chen, Xuexin] Zhejiang Univ, Key Lab Biol Crop Pathogens & Insects Zhejiang Pro, Hangzhou, Peoples R China; [Shi, Min; Huang, Jianhua; Chen, Xuexin] Zhejiang Univ, State Key Lab Rice Biol, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Huang, JH; Chen, XX (corresponding author), Zhejiang Univ, Inst Insect Sci, Coll Agr & Biotechnol, Hangzhou, Peoples R China.; Huang, JH; Chen, XX (corresponding author), Guangdong Lab Lingnan Modern Agr, Guangzhou, Peoples R China.; Huang, JH; Chen, XX (corresponding author), Zhejiang Univ, Minist Agr Key Lab Mol Biol Crop Pathogens & Insec, Hangzhou, Peoples R China.; Huang, JH; Chen, XX (corresponding author), Zhejiang Univ, Key Lab Biol Crop Pathogens & Insects Zhejiang Pro, Hangzhou, Peoples R China.; Huang, JH; Chen, XX (corresponding author), Zhejiang Univ, State Key Lab Rice Biol, Hangzhou, Peoples R China.	jhhuang@zju.edu.cn; xxchen@zju.edu.cn	Wang, zz/HED-4408-2022; Chen, Xue-xin/D-1592-2010	Chen, Xue-xin/0000-0002-9109-8853	Key Project of Laboratory of Lingnan Modern Agriculture [NT2021003]; Key Program of National Natural Science Foundation of China [31630060]; National Key Research and Development Program of China [2019YFD0300104]; National Science Fund for Excellent Young Scholars [31622048]; National Science Foundation of China [32172467, 31672079]; Zhejiang Provincial Natural Science Foundation [LR18C140001]	Key Project of Laboratory of Lingnan Modern Agriculture; Key Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; National Science Fund for Excellent Young Scholars; National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation(Natural Science Foundation of Zhejiang Province)	This work was jointly supported by the Key Project of Laboratory of Lingnan Modern Agriculture (NT2021003), Key Program of National Natural Science Foundation of China (31630060), National Key Research and Development Program of China (2019YFD0300104) to XC, the National Science Fund for Excellent Young Scholars (31622048), and the National Science Foundation of China (32172467) to JH, and the National Science Foundation of China (31672079), and Zhejiang Provincial Natural Science Foundation (LR18C140001) to MS.	Anderl I, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005746; Banerjee U, 2019, GENETICS, V211, P367, DOI 10.1534/genetics.118.300223; Beck M, 2003, VIROLOGY, V314, P521, DOI 10.1016/S0042-6822(03)00463-X; Beck M, 2005, J VIROL, V79, P1861, DOI 10.1128/JVI.79.3.1861-1870.2005; Bitra K, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002722; BRAND AH, 1993, DEVELOPMENT, V118, P401; Chen YF, 2011, VIROLOGY, V414, P42, DOI 10.1016/j.virol.2011.03.009; Crozatier M, 2007, CELL MICROBIOL, V9, P1117, DOI 10.1111/j.1462-5822.2007.00930.x; Darboux I, 2019, CURR OPIN INSECT SCI, V32, P47, DOI 10.1016/j.cois.2018.10.007; Desjardins CA, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-12-r183; Djoumad A, 2013, J GEN VIROL, V94, P1888, DOI 10.1099/vir.0.052506-0; Djoumad A, 2013, J GEN VIROL, V94, P1134, DOI 10.1099/vir.0.049817-0; Doremus T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104072; Drezen JM, 2017, CURR OPIN VIROL, V25, P41, DOI 10.1016/j.coviro.2017.07.002; Drezen JM, 2014, CURR OPIN INSECT SCI, V6, P35, DOI 10.1016/j.cois.2014.09.008; Drickamer K, 1999, CURR OPIN STRUC BIOL, V9, P585, DOI 10.1016/S0959-440X(99)00009-3; Espagne E, 2004, SCIENCE, V306, P286, DOI 10.1126/science.1103066; Galindo I, 2000, VIROLOGY, V266, P340, DOI 10.1006/viro.1999.0080; Gao F, 2016, SCI REP-UK, V6, DOI 10.1038/srep26967; Gardiner EMM, 2000, ARCH INSECT BIOCHEM, V43, P147, DOI 10.1002/(SICI)1520-6327(200004)43:4&lt;147::AID-ARCH1&gt;3.0.CO;2-J; Gasmi L, 2018, ARCH INSECT BIOCHEM, V97, DOI 10.1002/arch.21432; Gasmi L, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005470; Gasmi L, 2017, BIOSENSORS-BASEL, V7, DOI 10.3390/bios7010012; Gill TA, 2013, INSECT MOL BIOL, V22, P341, DOI 10.1111/imb.12022; Glatz R, 2003, J BIOL CHEM, V278, P19743, DOI 10.1074/jbc.M301396200; Gueguen G, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003580; Hasegawa DK, 2017, J INSECT PHYSIOL, V98, P173, DOI 10.1016/j.jinsphys.2017.01.003; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Huang F, 2009, ARCH INSECT BIOCHEM, V70, P177, DOI 10.1002/arch.20284; Huang F, 2010, TISSUE CELL, V42, P360, DOI 10.1016/j.tice.2010.07.012; Hurtado C, 2004, VIROLOGY, V326, P160, DOI 10.1016/j.virol.2004.05.019; Ibrahim AMA, 2008, NATURWISSENSCHAFTEN, V95, P25, DOI 10.1007/s00114-007-0290-7; Irving P, 2005, CELL MICROBIOL, V7, P335, DOI 10.1111/j.1462-5822.2004.00462.x; Jakubowski P, 2013, TOXICOL APPL PHARM, V269, P34, DOI 10.1016/j.taap.2013.03.002; Jancek S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064432; Jung SH, 2005, DEVELOPMENT, V132, P2521, DOI 10.1242/dev.01837; Kilpatrick DC, 2002, BBA-GEN SUBJECTS, V1572, P187, DOI 10.1016/S0304-4165(02)00308-2; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim Y, 2005, ARCH INSECT BIOCHEM, V59, P230, DOI 10.1002/arch.20074; Kolde R, 2015, R PACKAGE; Krzemien J, 2007, NATURE, V446, P325, DOI 10.1038/nature05650; Kumar S, 2018, MOL BIOL EVOL, V35, P1547, DOI 10.1093/molbev/msy096; Nguyen LT, 2015, MOL BIOL EVOL, V32, P268, DOI 10.1093/molbev/msu300; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lanot R, 2001, DEV BIOL, V230, P243, DOI 10.1006/dbio.2000.0123; Lapointe R, 2005, J GEN VIROL, V86, P963, DOI 10.1099/vir.0.80834-0; Lapointe R, 2007, J VIROL, V81, P6491, DOI 10.1128/JVI.02702-06; Lee S, 2008, COMP BIOCHEM PHYS A, V149, P351, DOI 10.1016/j.cbpa.2008.01.007; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Letourneau M, 2016, FEBS LETT, V590, P4034, DOI 10.1002/1873-3468.12327; Letunic I, 2015, NUCLEIC ACIDS RES, V43, pD257, DOI 10.1093/nar/gku949; Li ZY, 2016, ANNU REV ENTOMOL, V61, P277, DOI 10.1146/annurev-ento-010715-023622; Ling EJ, 2008, MOL IMMUNOL, V45, P2598, DOI 10.1016/j.molimm.2007.12.021; Liu F, 2013, ISJ-INVERT SURVIV J, V10, P102; Lu YZ, 2020, INSECT BIOCHEM MOLEC, V126, DOI 10.1016/j.ibmb.2020.103451; Lu Z, 2008, J BIOL CHEM, V283, P21325, DOI 10.1074/jbc.M801593200; Lu ZQ, 2010, INSECT BIOCHEM MOLEC, V40, P497, DOI 10.1016/j.ibmb.2010.04.009; Luo KJ, 2006, ACTA BIOCH BIOPH SIN, V38, P577, DOI 10.1111/j.1745-7270.2006.00195.x; Makhijani K, 2011, DEVELOPMENT, V138, P5379, DOI 10.1242/dev.067322; Markus R, 2009, P NATL ACAD SCI USA, V106, P4805, DOI 10.1073/pnas.0801766106; Mistry J, 2021, NUCLEIC ACIDS RES, V49, pD412, DOI 10.1093/nar/gkaa913; Moreau SJM, 2015, TOXINS, V7, P2385, DOI 10.3390/toxins7072385; Moroy T, 2004, INT J BIOCHEM CELL B, V36, P1424, DOI 10.1016/S1357-2725(03)00432-1; Nalini M, 2008, J INSECT PHYSIOL, V54, P1125, DOI 10.1016/j.jinsphys.2008.04.023; Nardi JB, 2003, DEV GENES EVOL, V213, P477, DOI 10.1007/s00427-003-0352-6; Pennacchio F, 2006, ANNU REV ENTOMOL, V51, P233, DOI 10.1146/annurev.ento.51.110104.151029; Poulin R, 2000, Q REV BIOL, V75, P277, DOI 10.1086/393500; Pruijssers AJ, 2007, J VIROL, V81, P1209, DOI 10.1128/JVI.02189-06; Rao XJ, 2015, DEV COMP IMMUNOL, V53, P328, DOI 10.1016/j.dci.2015.07.005; Rao XJ, 2015, INSECT BIOCHEM MOLEC, V62, P75, DOI 10.1016/j.ibmb.2014.12.006; ROSS DR, 1989, DEV COMP IMMUNOL, V13, P205, DOI 10.1016/0145-305X(89)90001-3; Russo J, 1996, PARASITOLOGY, V112, P135, DOI 10.1017/S0031182000065173; Salvia R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11939-x; Sarray S, 2004, LAB INVEST, V84, P573, DOI 10.1038/labinvest.3700088; SHARON N, 1972, SCIENCE, V177, P949, DOI 10.1126/science.177.4053.949; Solovyev V, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-s1-s10; STOLTZ DB, 1984, INTERVIROLOGY, V21, P1, DOI 10.1159/000149497; Strand MR, 2008, INSECT IMMUNOLOGY, P25, DOI 10.1016/S0965-1748(02)00092-9; Strand MR, 2014, CURR OPIN INSECT SCI, V6, P68, DOI 10.1016/j.cois.2014.09.005; Strand MR, 2014, ANNU REV VIROL, V1, P333, DOI 10.1146/annurev-virology-031413-085451; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; STRAND MR, 1995, J GEN VIROL, V76, P283, DOI 10.1099/0022-1317-76-2-283; Suderman RJ, 2008, J GEN VIROL, V89, P1411, DOI 10.1099/vir.0.2008/000307-0; TALEKAR NS, 1993, ANNU REV ENTOMOL, V38, P275, DOI 10.1146/annurev.en.38.010193.001423; Tan J, 2013, J INSECT PHYSIOL, V59, P595, DOI 10.1016/j.jinsphys.2013.03.008; Tanaka K, 2007, VIROLOGY, V363, P26, DOI 10.1016/j.virol.2006.11.034; Teramato T, 2003, J INSECT PHYSIOL, V49, P463, DOI 10.1016/S0022-1910(03)00063-5; Tokusumi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006429; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Van Breedam W, 2014, FEMS MICROBIOL REV, V38, P598, DOI 10.1111/1574-6976.12052; von Bredow CR, 2021, DEV COMP IMMUNOL, V115, DOI 10.1016/j.dci.2020.103858; Wang P, 2017, INSECT BIOCHEM MOLEC, V86, P29, DOI 10.1016/j.ibmb.2017.05.005; Wang XW, 2014, J BIOL CHEM, V289, P2405, DOI 10.1074/jbc.M113.528885; Wang ZH, 2021, INSECT SCI, V28, P1567, DOI 10.1111/1744-7917.12883; Wang ZH, 2021, PLOS GENET, V17, DOI 10.1371/journal.pgen.1009751; Wang ZZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04504-1; Webb BA, 2006, VIROLOGY, V347, P160, DOI 10.1016/j.virol.2005.11.010; Wei SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059654; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Xia XF, 2018, DEV COMP IMMUNOL, V83, P70, DOI 10.1016/j.dci.2017.11.020; Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342; Ye XQ, 2018, DEV COMP IMMUNOL, V83, P124, DOI 10.1016/j.dci.2018.01.007; Yu DS, 2016, ARCH VIROL, V161, P3095, DOI 10.1007/s00705-016-2988-3; Yu XQ, 2005, INSECT BIOCHEM MOLEC, V35, P285, DOI 10.1016/j.ibmb.2005.01.004; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zhu YB, 2020, ADV EXP MED BIOL, V1204, P129, DOI 10.1007/978-981-15-1580-4_5	107	0	0	25	28	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								877027	10.3389/fimmu.2022.877027	http://dx.doi.org/10.3389/fimmu.2022.877027			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V5FZ	35663984	gold, Green Published			2022-12-18	WOS:000806116600001
J	Yang, J; Lin, S; Sun, HL; Chen, ZM; Yang, FL; Lin, X; Guo, LY; Wang, LL; Wen, A; Zhang, XD; Dai, YS; He, B; Cao, Y; Dong, HH; Liu, XB; Chen, B; Li, J; Zhao, Q; Lu, GW				Yang, Jing; Lin, Sheng; Sun, Honglu; Chen, Zimin; Yang, Fanli; Lin, Xi; Guo, Liyan; Wang, Lingling; Wen, Ao; Zhang, Xindan; Dai, Yushan; He, Bin; Cao, Yu; Dong, Haohao; Liu, Xianbo; Chen, Bo; Li, Jian; Zhao, Qi; Lu, Guangwen			A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; spike receptor-binding domain; nanobody; neutralization; structural basis	REVEALS; MODEL	The continuous spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) around the world has raised unprecedented challenges to the human society. Antibodies and nanobodies possessing neutralization activity represent promising drug candidates. In this study, we report the identification and characterization of a potent SARS-CoV-2 neutralizing nanobody that targets the viral spike receptor-binding domain (S-RBD). The nanobody, termed as Nb-007, engages SARS-CoV-2 S-RBD with the two-digit picomolar binding affinity and shows outstanding virus entry-inhibition activity. The complex structure of Nb-007 bound to SARS-CoV-2 S-RBD reveals an epitope that is partially overlapping with the binding site for the human receptor of angiotensin-converting enzyme 2 (ACE2). The nanobody therefore exerts neutralization by competing with ACE2 for S-RBD binding, which is further ascertained by our in-vitro biochemical analyses. Finally, we also show that Nb-007 reserves promising, though compromised, neutralization activity against the currently-circulating Delta variant and that fusion of the nanobody with Fc dramatically increases its entry-inhibition capacity. Taken together, these data have paved the way of developing Nb-007 as a drug-reserve for potential treatment of SARS-CoV-2 related diseases.	[Yang, Jing; Lin, Sheng; Sun, Honglu; Chen, Zimin; Yang, Fanli; Lin, Xi; Guo, Liyan; Wang, Lingling; Wen, Ao; Zhang, Xindan; Dai, Yushan; He, Bin; Cao, Yu; Lu, Guangwen] Sichuan Univ, West China Hosp Emergency Dept WCHED, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China; [Cao, Yu] Sichuan Univ, West China Hosp, Disaster Med Ctr, Chengdu, Peoples R China; [Dong, Haohao] Sichuan Univ, West China Hosp, Canc Ctr, Natl Clin Res Ctr Geriatr, Chengdu, Peoples R China; [Liu, Xianbo; Chen, Bo] CHENGDU NB BIOLAB CO LTD, Antibody R&D Dept, Chengdu, Peoples R China; [Li, Jian] Chengdu Univ, Sch Basic Med Sci, Chengdu, Peoples R China; [Zhao, Qi] Chengdu Univ, Coll Food & Biol Engn, Chengdu, Peoples R China	Sichuan University; Sichuan University; Sichuan University; Chengdu University; Chengdu University	Lu, GW (corresponding author), Sichuan Univ, West China Hosp Emergency Dept WCHED, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China.	lugw@scu.edu.cn	Lu, Guangwen/HCH-9193-2022					Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bannas P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01603; Brown CM, 2021, MMWR-MORBID MORTAL W, V70, P1059, DOI 10.15585/mmwr.mm7031e2; Deb Paroma, 2021, Biosaf Health, V3, P87, DOI 10.1016/j.bsheal.2021.02.001; Detalle L, 2016, ANTIMICROB AGENTS CH, V60, P6, DOI 10.1128/AAC.01802-15; Dong YT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00796-w; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Farinholt T, 2021, BMC MED, V19, DOI [10.1186/s12916-021-02103-4, 10.1101/2021.06.28.21258780]; Gulati S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04432-0; Hanke L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18174-5; Huo JD, 2020, NAT STRUCT MOL BIOL, V27, P846, DOI [10.1038/s41594-020-0469-6, 10.1038/s41594-020-00527-9]; Jin ZM, 2020, NATURE, V582, P289, DOI 10.1038/s41586-020-2223-y; Jovcevska I, 2020, BIODRUGS, V34, P11, DOI 10.1007/s40259-019-00392-z; Ju B, 2020, NATURE, V584, P115, DOI 10.1038/s41586-020-2380-z; Kreye J, 2020, CELL, V183, P1058, DOI 10.1016/j.cell.2020.09.049; Lei CH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16048-4; Li Ruiting, 2021, Biosaf Health, V3, P312, DOI 10.1016/j.bsheal.2021.08.003; Li Z, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5479762; Lin S, 2021, NUCLEIC ACIDS RES, V49, P5382, DOI 10.1093/nar/gkab320; Lin S, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00241-4; Liu William J, 2020, Biosaf Health, V2, P185, DOI 10.1016/j.bsheal.2020.11.005; Lu QZ, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00768-w; Mikszewski A, 2022, SCI TOTAL ENVIRON, V816, DOI 10.1016/j.scitotenv.2021.151499; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; Mlcochova P, 2021, NATURE, V599, P114, DOI 10.1038/s41586-021-03944-y; Mostaghimi D, 2022, LANCET INFECT DIS, V22, pE52, DOI 10.1016/S1473-3099(21)00472-2; Muhammed Yusuf, 2021, Biosaf Health, V3, P249, DOI 10.1016/j.bsheal.2021.07.003; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Nambulli S, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh0319; Newman JA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25166-6; Niu L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.647934; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Schoof M, 2020, SCIENCE, V370, P1473, DOI 10.1126/science.abe3255; Sofi Mohd Sharjeel, 2020, Biosaf Health, V2, P217, DOI 10.1016/j.bsheal.2020.11.002; Taylor PC, 2021, NAT REV IMMUNOL, V21, P382, DOI 10.1038/s41577-021-00542-x; Thoms M, 2020, SCIENCE, V369, P1249, DOI 10.1126/science.abc8665; Tu Z, 2020, IMMUNOLOGY, V161, P53, DOI 10.1111/imm.13224; Vanlandschoot P, 2011, ANTIVIR RES, V92, P389, DOI 10.1016/j.antiviral.2011.09.002; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang PF, 2021, NATURE, V593, P130, DOI 10.1038/s41586-021-03398-2; Wang QH, 2020, CELL, V181, P894, DOI 10.1016/j.cell.2020.03.045; Wang Q, 2020, CELL, V182, P417, DOI 10.1016/j.cell.2020.05.034; Wu Yuhan, 2021, Biosaf Health, V3, P202, DOI 10.1016/j.bsheal.2021.06.001; Xiang YF, 2020, SCIENCE, V370, P1479, DOI 10.1126/science.abe4747; Yang FL, 2020, CELL HOST MICROBE, V27, P441, DOI 10.1016/j.chom.2019.12.012; Yang HT, 2021, NAT REV MICROBIOL, V19, P685, DOI 10.1038/s41579-021-00630-8; Yang JY, 2020, NATURE, V586, P572, DOI 10.1038/s41586-020-2599-8; Yang Ren, 2020, Biosaf Health, V2, P226, DOI 10.1016/j.bsheal.2020.08.004; Yao HP, 2020, CELL, V183, P730, DOI 10.1016/j.cell.2020.09.018; Ye F, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00756-4; Yuan M, 2021, BIOCHEM BIOPH RES CO, V538, P192, DOI 10.1016/j.bbrc.2020.10.012; Zhang J, 2021, SCIENCE, V374, P1353, DOI [10.1101/2021.08.17.456689, 10.1126/science.abl9463]; Zhang ZY, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00302-0; Zhou Haiwei, 2021, Biosaf Health, V3, P238, DOI 10.1016/j.bsheal.2021.09.001; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017; Zhu YF, 2021, ASIAN J PHARM SCI, V16, P4, DOI 10.1016/j.ajps.2020.06.001	58	0	0	9	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								820336	10.3389/fimmu.2022.820336	http://dx.doi.org/10.3389/fimmu.2022.820336			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9BB	35663966	gold, Green Published			2022-12-18	WOS:000805017900001
J	Ye, Z; Wang, XK; Lv, YH; Wang, X; Cui, YC				Ye, Zhen; Wang, Xiao-kang; Lv, Yun-hui; Wang, Xin; Cui, Yong-chun			The Integrated Analysis Identifies Three Critical Genes as Novel Diagnostic Biomarkers Involved in Immune Infiltration in Atherosclerosis	FRONTIERS IN IMMUNOLOGY			English	Article						atherosclerosis; immune infiltration; diagnosis; biomarker; GEO datasets; machine learning	ADHESION MOLECULE-1; MECHANISMS	Atherosclerosis (AS), a chronic inflammatory disease of the blood vessels, is the primary cause of cardiovascular disease, the leading cause of death worldwide. This study aimed to identify possible diagnostic markers for AS and determine their correlation with the infiltration of immune cells in AS. In total, 10 serum samples from AS patients and 10 samples from healthy subjects were collected. The original gene expression profiles of GSE43292 and GSE57691 were downloaded from the Gene Expression Omnibus database. Least absolute shrinkage and selection operator regression model and support vector machine recursive feature elimination analyses were carried out to identify candidate markers. The diagnostic values of the identified biomarkers were determined using receiver operating characteristic assays. The compositional patterns of the 22 types of immune cell fraction in AS were estimated using CIBERSORT. RT-PCR was performed to further determine the expression of the critical genes. This study identified 17 differentially expressed genes (DEGs) in AS samples. The identified DEGs were mainly involved in non-small cell lung carcinoma, pulmonary fibrosis, polycystic ovary syndrome, glucose intolerance, and T-cell leukemia. FHL5, IBSP, and SCRG1 have been identified as the diagnostic genes in AS. The expression of SCRG1 and FHL5 was distinctly downregulated in AS samples, and the expression of IBSP was distinctly upregulated in AS samples, which was further confirmed using our cohort by RT-PCR. Moreover, immune assays revealed that FHL5, IBSP, and SCRG1 were associated with several immune cells, such as CD8 T cells, naive B cells, macrophage M0, activated memory CD4 T cells, and activated NK cells. Overall, future investigations into the occurrence and molecular mechanisms of AS may benefit from using the genes FHL5, IBSP, and SCRG1 as diagnostic markers for the condition.	[Ye, Zhen; Wang, Xiao-kang; Lv, Yun-hui; Wang, Xin; Cui, Yong-chun] Chinese Acad Med Sci, Fuwai Hosp, Ctr Cardiovasc Expt Study & Evaluat, Beijing, Peoples R China; [Ye, Zhen; Wang, Xiao-kang; Lv, Yun-hui; Wang, Xin; Cui, Yong-chun] Peking Union Med Coll, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Beijing Key Lab Preclin Res & Evaluat Cardiovasc I, Beijing, Peoples R China; [Ye, Zhen] Suqian First Hosp, Dept Pharm, Suqian, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College	Wang, X; Cui, YC (corresponding author), Chinese Acad Med Sci, Fuwai Hosp, Ctr Cardiovasc Expt Study & Evaluat, Beijing, Peoples R China.; Wang, X; Cui, YC (corresponding author), Peking Union Med Coll, Natl Ctr Cardiovasc Dis, State Key Lab Cardiovasc Dis, Beijing Key Lab Preclin Res & Evaluat Cardiovasc I, Beijing, Peoples R China.	wangxinfuwai@188.com; cuiyongchun@fuwai.com			National Natural Science Foundation of China [81970387, 81200213]; Natural Science Foundation of Beijing [7172181]; Natural Science Foundation of Suqian [K201918]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Beijing(Beijing Natural Science Foundation); Natural Science Foundation of Suqian	Funding This study was supported by the National Natural Science Foundation of China (81970387 and 81200213 to YC), Natural Science Foundation of Beijing (7172181 to YC), and Natural Science Foundation of Suqian (K201918 to ZY).	Alonso SG, 2018, J MED SYST, V42, DOI 10.1007/s10916-018-1018-2; Ayari H, 2013, J BIOSCIENCES, V38, P311, DOI 10.1007/s12038-013-9310-2; Barrington WT, 2017, NAT REV CARDIOL, V14, P699, DOI 10.1038/nrcardio.2017.169; Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721; Biros E, 2015, ONCOTARGET, V6, P12984, DOI 10.18632/oncotarget.3848; Cainzos-Achirica M, 2020, J AM COLL CARDIOL, V76, P2895, DOI 10.1016/j.jacc.2020.10.027; Chen Q, 2019, THERANOSTICS, V9, P6424, DOI 10.7150/thno.35528; Chen YK, 2021, J HEALTHC ENG, V2021, DOI 10.1155/2021/6402206; Frostegard J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-117; Guzik TJ, 2017, CARDIOVASC RES, V113, P1009, DOI 10.1093/cvr/cvx108; Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001; Huang TC, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.800833; Ito K, 2013, CPT-PHARMACOMET SYST, V2, DOI 10.1038/psp.2013.56; Jiang Z, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86374-0; Katsiki N, 2017, CURR OPIN LIPIDOL, V28, P347, DOI 10.1097/MOL.0000000000000431; Lechner K, 2020, EUR J PREV CARDIOL, V27, P394, DOI 10.1177/2047487319869400; Libby P, 2021, NATURE, V592, P524, DOI 10.1038/s41586-021-03392-8; Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146; Liu YZ, 2021, AGING-US, V13, P3080, DOI 10.18632/aging.202486; Preiss DJ, 2007, INT J CLIN PRACT, V61, P697, DOI 10.1111/j.1742-1241.2007.01330.x; Rocha VZ, 2009, NAT REV CARDIOL, V6, P399, DOI 10.1038/nrcardio.2009.55; Sanz H, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2451-4; Sasikala T, 2021, BIOMARK MED, V15, P121, DOI 10.2217/bmm-2020-0428; Schade DS, 2020, ENDOCR PRACT, V26, P1514, DOI 10.4158/EP-2020-0347; Schafer S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010037; Schaftenaar F, 2016, CURR OPIN LIPIDOL, V27, P209, DOI 10.1097/MOL.0000000000000302; Su WX, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.667690; Sun WC, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/4302425; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; Wagner N, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9112367; Wang SB, 2016, PHARMACOL RES, V111, P76, DOI 10.1016/j.phrs.2016.02.028; Williams JW, 2020, CIRC RES, V126, P1112, DOI 10.1161/CIRCRESAHA.119.315940; Wu JC, 2019, FASEB J, V33, P2105, DOI 10.1096/fj.201800098RR; Wu KR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25473-y; Wu TZ, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141; Xiao QQ, 2021, ACTA PHARM SIN B, V11, P941, DOI 10.1016/j.apsb.2020.12.018; Zhu F, 2021, BMC CARDIOVASC DISOR, V21, DOI 10.1186/s12872-021-02323-9	38	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 18	2022	13								905921	10.3389/fimmu.2022.905921	http://dx.doi.org/10.3389/fimmu.2022.905921			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T9FE	35663954	gold, Green Published			2022-12-18	WOS:000805028700001
J	Chen, CJ; Kajita, H; Takaya, K; Aramaki-Hattori, N; Sakai, S; Asou, T; Kishi, K				Chen, Cao-Jie; Kajita, Hiroki; Takaya, Kento; Aramaki-Hattori, Noriko; Sakai, Shigeki; Asou, Toru; Kishi, Kazuo			Single-Cell RNA-seq Analysis Reveals Cellular Functional Heterogeneity in Dermis Between Fibrotic and Regenerative Wound Healing Fates	FRONTIERS IN IMMUNOLOGY			English	Article						skin wound healing; fibrosis; regeneration; myofibroblast; macrophage; single-cell RNA sequencing		BackgroundFibrotic scars are common in both human and mouse skin wounds. However, wound-induced hair neogenesis in the murine wounding models often results in regenerative repair response. Herein, we aimed to uncover cellular functional heterogeneity in dermis between fibrotic and regenerative wound healing fates. MethodsThe expression matrix of single-cell RNA sequencing (scRNA-seq) data of fibrotic and regenerative wound dermal cells was filtered, normalized, and scaled; underwent principal components analysis; and further analyzed by Uniform Manifold Approximation and Projection (UMAP) for dimension reduction with the Seurat package. Cell types were annotated, and cell-cell communications were analyzed. The core cell population myofibroblast was identified and the biological functions of ligand and receptor genes between myofibroblast and macrophage were evaluated. Specific genes between fibrotic and regenerative myofibroblast and macrophage were identified. Temporal dynamics of myofibroblast and macrophage were reconstructed with the Monocle tool. ResultsAcross dermal cells, there were six cell types, namely, EN1-negative myofibroblasts, EN1-positive myofibroblasts, hematopoietic cells, macrophages, pericytes, and endothelial cells. Ligand and receptor genes between myofibroblasts and macrophages mainly modulated cell proliferation and migration, tube development, and the TGF-beta pathway. Specific genes that were differentially expressed in fibrotic compared to regenerative myofibroblasts or macrophages were separately identified. Specific genes between fibrotic and regenerative myofibroblasts were involved in the mRNA metabolic process and organelle organization. Specific genes between fibrotic and regenerative macrophages participated in regulating immunity and phagocytosis. We then observed the underlying evolution of myofibroblasts or macrophages. ConclusionCollectively, our findings reveal that myofibroblasts and macrophages may alter the skin wound healing fate through modulating critical signaling pathways.	[Chen, Cao-Jie; Kajita, Hiroki; Takaya, Kento; Aramaki-Hattori, Noriko; Sakai, Shigeki; Kishi, Kazuo] Keio Univ Sch Med, Dept Plast & Reconstruct Surg, Tokyo, Japan; [Asou, Toru] Tokyo Cosmet Surg Clin, Dept Plast Surg, Tokyo, Japan	Keio University	Kishi, K (corresponding author), Keio Univ Sch Med, Dept Plast & Reconstruct Surg, Tokyo, Japan.; Asou, T (corresponding author), Tokyo Cosmet Surg Clin, Dept Plast Surg, Tokyo, Japan.	mori@ideajapan.com; kkishi@a7.keio.jp			Japan China Sasakawa Medical Fellowship [2017816]	Japan China Sasakawa Medical Fellowship	Funding This work was supported in part by Japan China Sasakawa Medical Fellowship (2017816).	Aragona M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14684; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x; Chen H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.544; Chen TY, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120608; Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702; Gay D, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3704; Goss G, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.675080; Govindaraju P, 2019, MATRIX BIOL, V75-76, P314, DOI 10.1016/j.matbio.2018.06.004; Griffin DR, 2021, NAT MATER, V20, P560, DOI 10.1038/s41563-020-00844-w; Guerrero-Juarez CF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08247-x; Haensel D, 2020, CELL REP, V30, P3932, DOI 10.1016/j.celrep.2020.02.091; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Ishida Y, 2008, J IMMUNOL, V180, P569, DOI 10.4049/jimmunol.180.1.569; Lun ATL, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1662-y; Lynch MD, 2018, J CLIN INVEST, V128, P26, DOI 10.1172/JCI93555; Matejuk A, 2018, ARCH IMMUNOL THER EX, V66, P45, DOI 10.1007/s00005-017-0477-3; McCarthy DJ, 2017, BIOINFORMATICS, V33, P1179, DOI 10.1093/bioinformatics/btw777; Rajesh A, 2021, IMMUNOLOGY, V163, P98, DOI 10.1111/imm.13311; Ramilowski JA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8866; Rodrigues M, 2019, PHYSIOL REV, V99, P665, DOI 10.1152/physrev.00067.2017; Schmidt BA, 2013, DEVELOPMENT, V140, P1517, DOI 10.1242/dev.087593; Shook BA, 2018, SCIENCE, V362, P909, DOI 10.1126/science.aar2971; Sorkin M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14172-4; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Theocharidis G, 2020, DIABETES, V69, P2157, DOI 10.2337/db20-0188; Wei F, 2020, AGING-US, V12, P12002, DOI 10.18632/aging.103366; Xu JJ, 2020, IMMUNITY, V53, P371, DOI 10.1016/j.immuni.2020.06.023; Yamaguchi K, 2021, J INVEST DERMATOL, V141, P164, DOI 10.1016/j.jid.2020.04.030; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang T, 2020, BIOMED PHARMACOTHER, V129, DOI 10.1016/j.biopha.2020.110287; Zhou XJ, 2020, ACS NANO, V14, P12732, DOI 10.1021/acsnano.0c03064	32	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								875407	10.3389/fimmu.2022.875407	http://dx.doi.org/10.3389/fimmu.2022.875407			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T6GD	35664010	Green Published, gold			2022-12-18	WOS:000804824900001
J	Gao, YF; Yang, XM; Zhang, B				Gao, Yanfeng; Yang, Xuanming; Zhang, Bin			Editorial: Development and Potential Mechanisms of Low Molecular Weight Drugs for Cancer Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cancer immunotherapy; innate immunity; immune checkpoint; drug repositioning; small molecular inhibitor			[Gao, Yanfeng] Sun Yat sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen, Peoples R China; [Yang, Xuanming] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai, Peoples R China; [Zhang, Bin] Northwestern Univ Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL USA	Sun Yat Sen University; Shanghai Jiao Tong University; Northwestern University; Feinberg School of Medicine	Gao, YF (corresponding author), Sun Yat sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen, Peoples R China.	gaoyf29@mail.sysu.edu.cn			National Natural Science Foundation of China [U20A20369]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by grants from the National Natural Science Foundation of China (No. U20A20369).		0	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								920442	10.3389/fimmu.2022.920442	http://dx.doi.org/10.3389/fimmu.2022.920442			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V0ZP	35663988	Green Published, gold			2022-12-18	WOS:000805829100001
J	Gopalakrishnan, S; Hansen, MD; Skovdahl, HK; Roseth, IA; Granlund, AV; Ostvik, AE; Bakke, I; Sandvik, AK; Bruland, T				Gopalakrishnan, Shreya; Hansen, Marianne Dore; Skovdahl, Helene Kolstad; Roseth, Ingrid Aass; van Beelen Granlund, Atle; Ostvik, Ann Elisabet; Bakke, Ingunn; Sandvik, Arne Kristian; Bruland, Torunn			Tofacitinib Downregulates TNF and Poly(I:C)-Dependent MHC-II Expression in the Colonic Epithelium	FRONTIERS IN IMMUNOLOGY			English	Article						intestinal epithelium; organoids; tumor necrosis factor (TNF); polyinosinic; polycytidylic acid Poly(I; C); antigen presentation; major histocompatibility class II; tofacitinib; ulcerative colitis	INFLAMMATORY-BOWEL-DISEASE; HLA-DR ANTIGENS; ULCERATIVE-COLITIS; CELLS; INHIBITOR; BARRIER; DM; DISSOCIATION; LYMPHOCYTES; ACTIVATION	Major Histocompatibility Complex (MHC)-I and -II genes are upregulated in intestinal epithelial cells (IECs) during active inflammatory bowel diseases (IBD), but little is known about how IBD-relevant pro-inflammatory signals and IBD drugs can regulate their expression. We have previously shown that the synthetic analog of double-stranded RNA (dsRNA) Polyinosinic:polycytidylic acid (Poly(I:C)), induces interferon stimulated genes (ISGs) in colon organoids (colonoids). These ISGs may be involved in the induction of antigen presentation. In the present study, we applied colonoids derived from non-IBD controls and ulcerative colitis patients to identify induction and effects of IBD-drugs on antigen presentation in IECs in the context of Tumor Necrosis Factor (TNF)-driven inflammation. By RNA sequencing, we show that a combination of TNF and Poly(I:C) strongly induced antigen-presentation gene signatures in colonoids, including expression of MHC-II genes. MHC-I and -II protein expression was confirmed by immunoblotting and immunofluorescence. TNF+Poly(I:C)-dependent upregulation of MHC-II expression was associated with increased expression of Janus Kinases JAK1/2 as well as increased activation of transcription factor Signal transducer and activator of transcription 1 (STAT1). Accordingly, pre-treatment of colonoids with IBD-approved pan-Janus Kinase (JAK) inhibitor Tofacitinib led to the downregulation of TNF+Poly(I:C)-dependent MHC-II expression associated with the abrogation of STAT1 activation. Pre-treatment with corticosteroid Budesonide, commonly used in IBD, did not alter MHC-II expression. Collectively, our results identify a regulatory role for IBD-relevant pro-inflammatory signals on MHC-II expression that is influenced by Tofacitinib.	[Gopalakrishnan, Shreya; Hansen, Marianne Dore; Skovdahl, Helene Kolstad; Roseth, Ingrid Aass; van Beelen Granlund, Atle; Ostvik, Ann Elisabet; Bakke, Ingunn; Sandvik, Arne Kristian; Bruland, Torunn] NTNU Norwegian Univ Sci & Technol, Dept Clin & Mol Med IKOM, Trondheim, Norway; [Gopalakrishnan, Shreya; van Beelen Granlund, Atle; Ostvik, Ann Elisabet; Sandvik, Arne Kristian; Bruland, Torunn] St Olavs Univ Hosp, Dept Gastroenterol & Hepatol, Clin Med, Trondheim, Norway; [Hansen, Marianne Dore; Bakke, Ingunn] St Olavs Univ Hosp, Clin Lab Med, Trondheim, Norway; [Skovdahl, Helene Kolstad; van Beelen Granlund, Atle; Sandvik, Arne Kristian] NTNU Norwegian Univ Sci & Technol, Ctr Mol Inflammat Res CEMIR, Trondheim, Norway	Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU); Norwegian University of Science & Technology (NTNU)	Bruland, T (corresponding author), NTNU Norwegian Univ Sci & Technol, Dept Clin & Mol Med IKOM, Trondheim, Norway.; Bruland, T (corresponding author), St Olavs Univ Hosp, Dept Gastroenterol & Hepatol, Clin Med, Trondheim, Norway.	torunn.bruland@ntnu.no		Bakke, Ingunn/0000-0003-0356-6184	Faculty of Medicine and Health Sciences, NTNU; Liaison Committee; Central Norway Regional Health Authority; NTNU; St. Olav's University Hospital; Faculty of Medicine and Health Sciences at NTNU; Research Council of Norway [FRIPRO 262549]; Liaison Committee for Education, Research and Innovation in Central Norway [90545800]	Faculty of Medicine and Health Sciences, NTNU; Liaison Committee; Central Norway Regional Health Authority; NTNU; St. Olav's University Hospital; Faculty of Medicine and Health Sciences at NTNU; Research Council of Norway(Research Council of Norway); Liaison Committee for Education, Research and Innovation in Central Norway	This study was funded by the Faculty of Medicine and Health Sciences, NTNU (SG, HKS, IB, TB, AvBG and AKS), the Liaison Committee between the Central Norway Regional Health Authority and NTNU (SG, MDH, IAR, AvBG, AEO, IB, AKS, and TB), the Liaison committee between St. Olav's University Hospital and Faculty of Medicine and Health Sciences at NTNU (TB and AvBG), and the Research Council of Norway (AvBG, FRIPRO 262549). The authors work within the Clinical Academic Group for Precision Medicine in Inflammatory Bowel Disease (CAG-IBD https://www.ntnu.edu/cag-ibd/), which is supported by The Liaison Committee for Education, Research and Innovation in Central Norway (Project no. 90545800).	Bar F, 2013, CLIN EXP IMMUNOL, V172, P280, DOI 10.1111/cei.12047; Beyaz S, 2021, CELL STEM CELL, V28, P1922, DOI 10.1016/j.stem.2021.08.007; Bisping G, 2001, CLIN EXP IMMUNOL, V123, P15, DOI 10.1046/j.1365-2249.2001.01443.x; Biton M, 2018, CELL, V175, P1307, DOI 10.1016/j.cell.2018.10.008; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; Bruland T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910851; Choi J, 2018, LEUKEMIA, V32, P2483, DOI 10.1038/s41375-018-0123-z; De Vries LCS, 2017, J CROHNS COLITIS, V11, P885, DOI 10.1093/ecco-jcc/jjx003; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; Dotti I, 2017, GUT, V66, P2069, DOI 10.1136/gutjnl-2016-312609; FAIS S, 1987, CLIN EXP IMMUNOL, V68, P605; Granlund A, 2016, INFLAMM BOWEL DIS, V22, pS61, DOI 10.1097/01.MIB.0000480300.78972.da; Granlund AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056818; Heuberger C, 2021, IMMUNOLOGY, V162, P357, DOI 10.1111/imm.13270; HOANG P, 1992, GUT, V33, P1089, DOI 10.1136/gut.33.8.1089; Honap S, 2020, INFLAMM BOWEL DIS, V26, pE147, DOI 10.1093/ibd/izaa157; Honap S, 2020, J CROHNS COLITIS, V14, P1385, DOI 10.1093/ecco-jcc/jjaa075; HORIE Y, 1991, TOHOKU J EXP MED, V165, P87, DOI 10.1620/tjem.165.87; Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470; Kelsen Judith R, 2021, Inflamm Bowel Dis, V27, P256, DOI 10.1093/ibd/izaa145; Kiesler P, 2015, CELL MOL GASTROENTER, V1, P154, DOI 10.1016/j.jcmgh.2015.01.006; Koyama M, 2019, IMMUNITY, V51, P885, DOI 10.1016/j.immuni.2019.08.011; Kubinak JL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9642; Kubo S, 2014, ANN RHEUM DIS, V73, P2192, DOI 10.1136/annrheumdis-2013-203756; LAMB CA, 1992, J IMMUNOL, V148, P3478; Mahe MM, 2015, JOVE-J VIS EXP, DOI 10.3791/52483; Martini E, 2017, CELL MOL GASTROENTER, V4, P33, DOI 10.1016/j.jcmgh.2017.03.007; Moon S, 2021, J EXP MED, V218, DOI 10.1084/jem.20201665; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; Noben M, 2017, GUT, V66, P2193, DOI 10.1136/gutjnl-2016-313667; Okita R, 2021, THORAC CANCER, V12, P775, DOI 10.1111/1759-7714.13847; Ostvik AE, 2020, J CROHNS COLITIS, V14, P920, DOI 10.1093/ecco-jcc/jjaa022; Perez-Jeldres T, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00212; Peterson LW, 2014, NAT REV IMMUNOL, V14, P141, DOI 10.1038/nri3608; Pizarro TT, 2019, INFLAMM BOWEL DIS, V25, pS5, DOI 10.1093/ibd/izz075; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; Roland MM, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008558; Rosengren S, 2012, ANN RHEUM DIS, V71, P440, DOI 10.1136/ard.2011.150284; Saeterstad S, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0265189; Sandborn WJ, 2017, NEW ENGL J MED, V376, P1723, DOI 10.1056/NEJMoa1606910; Sandborn WJ, 2012, NEW ENGL J MED, V367, P616, DOI 10.1056/NEJMoa1112168; Sands BE, 2020, ALIMENT PHARM THER, V51, P271, DOI 10.1111/apt.15555; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Sayoc-Becerra A, 2020, INFLAMM BOWEL DIS, V26, P407, DOI 10.1093/ibd/izz266; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; SELBY WS, 1983, CLIN EXP IMMUNOL, V53, P614; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; Skovdahl HK, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.679741; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; Stephens WZ, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109916; Thelemann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086844; Wosen JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01970; Wosen JE, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02144	53	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								882277	10.3389/fimmu.2022.882277	http://dx.doi.org/10.3389/fimmu.2022.882277			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U0NP	35655783	gold, Green Published			2022-12-18	WOS:000805118200001
J	Kurtovic, T; Ravlic, S; Stimac, A; Lukacevic, SM; Hecimovic, A; Kazazic, S; Halassy, B				Kurtovic, Tihana; Ravlic, Sanda; Stimac, Adela; Lukacevic, Sanja Mateljak; Hecimovic, Ana; Kazazic, Sasa; Halassy, Beata			Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks	FRONTIERS IN IMMUNOLOGY			English	Article						convalescent plasma processing; polyclonal anti-COVID-19 IgG; IgG subclass; passive immunotherapy; wild-type SARS-CoV-2 neutralization assay; caprylic acid precipitation; ion-exchange chromatography; mass spectrometry	HUMAN-PLASMA; CAPRYLIC-ACID; LIQUID; IGM	During the pre-vaccine era of the COVID-19 pandemic convalescent plasma has once again emerged as a major potential therapeutic form of passive immunization that in specific cases still represents irreplaceable treatment option. There is a growing concern that variable concentration of neutralizing antibodies, present in convalescent plasma which originates from different donors, apparently affects its effectiveness. The drawback can be overcome through the downstream process of immunoglobulin fraction purification into a standardized product of improved safety and efficacy. All modern procedures are quite lengthy processes. They are also based on fractionation of large plasma quantities whose collection is not attainable during an epidemic. When outbreaks of infectious diseases are occurring more frequently, there is a great need for a more sustainable production approach that would be goal-oriented towards assuring easily and readily available immunoglobulin of therapeutic relevance. We propose a refinement strategy for the IgG preparation achieved through simplification and reduction of the processing steps. It was designed as a small but scalable process to offer an immediately available treatment option that would simultaneously be harmonized with an increased availability of convalescent plasma over the viral outbreak time-course. Concerning the ongoing pandemic status of the COVID-19, the proof of concept was demonstrated on anti-SARS-CoV-2 convalescent plasma but is likely applicable to any other type depending on the current needs. It was guided by the idea of persistent keeping of IgG molecules in the solution, so that protection of their native structure could be assured. Our manufacturing procedure provided a high-quality IgG product of above the average recovery whose composition profile was analyzed by mass spectrometry as quality control check. It was proved free from IgA and IgM as mediators of adverse transfusion reactions, as well as of any other residual impurities, since only IgG fragments were identified. The proportion of S protein-specific IgGs remained unchanged relative to the convalescent plasma. Undisturbed IgG subclass composition was accomplished as well. However, the fractionation principle affected the final product's capacity to neutralize wild-type SARS-CoV-2 infectivity, reducing it by half. Decrease in neutralization potency significantly correlated with the amount of IgM in the starting material.	[Kurtovic, Tihana; Ravlic, Sanda; Stimac, Adela; Lukacevic, Sanja Mateljak; Halassy, Beata] Univ Zagreb, Ctr Res & Knowledge Transfer Biotechnol, Zagreb, Croatia; [Kurtovic, Tihana; Ravlic, Sanda; Stimac, Adela; Lukacevic, Sanja Mateljak; Halassy, Beata] Ctr Excellence Virus Immunol & Vaccines, Zagreb, Croatia; [Hecimovic, Ana] Croatian Inst Transfus Med, Zagreb, Croatia; [Kazazic, Sasa] Rudjer Boskovic Inst, Div Phys Chem, Zagreb, Croatia	University of Zagreb; Rudjer Boskovic Institute	Kurtovic, T; Halassy, B (corresponding author), Univ Zagreb, Ctr Res & Knowledge Transfer Biotechnol, Zagreb, Croatia.; Kurtovic, T; Halassy, B (corresponding author), Ctr Excellence Virus Immunol & Vaccines, Zagreb, Croatia.	tkurtovi@unizg.hr; bhalassy@unizg.hr			Croatian Science Foundation [IP-CORONA-04-2053]; European Regional Development Fund [K.K.01.1.1.01.0006]; European Regional Development Fund - the Competitiveness and Cohesion Operational Programme project [K.K.01.1.1.04.0099]	Croatian Science Foundation; European Regional Development Fund(European Commission); European Regional Development Fund - the Competitiveness and Cohesion Operational Programme project	The research was funded by the Croatian Science Foundation (grant IP-CORONA-04-2053 to BH), by the European Regional Development Fund, grant number K.K.01.1.1.01.0006, "Strengthening the capacity of CerVirVac for research in virus immunology and vaccinology" and by the European Regional Development Fund - the Competitiveness and Cohesion Operational Programme project, grant number K.K.01.1.1.04.0099, "RAPTOVAX".	A.Nadas, 2020, medRxiv, DOI 10.1101/2020.08.18.20177303; Ali S, 2021, ECLINICALMEDICINE, V36, DOI 10.1016/j.eclinm.2021.100926; Ali S, 2021, IMMUNOTHERAPY-UK, V13, P397, DOI 10.2217/imt-2020-0263; Buchacher A, 2018, BIOPHARMACEUTICAL PROCESSING: DEVELOPMENT, DESIGN, AND IMPLEMENTATION OF MANUFACTURING PROCESSES, P857, DOI 10.1016/B978-0-08-100623-8.00043-8; Burnouf T, 2007, TRANSFUS MED REV, V21, P101, DOI 10.1016/j.tmrv.2006.11.001; Casadevall A, 2021, MBIO, V12, DOI 10.1128/mBio.03372-20; Casadevall A, 2021, CLIN INFECT DIS, V73, pE540, DOI 10.1093/cid/ciaa1213; Chua CL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171989; Dhingra N, 2012, VOX SANG, V103, P337, DOI 10.1111/j.1423-0410.2012.01630.x; Duan K, 2020, P NATL ACAD SCI USA, V117, P9490, DOI 10.1073/pnas.2004168117; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; El-Ekiaby M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003501; Focosi D, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13081594; Focosi D, 2021, LIFE-BASEL, V11, DOI 10.3390/life11020144; Halassy B, 2019, J PHARMACEUT BIOMED, V164, P276, DOI 10.1016/j.jpba.2018.10.020; Hurt AC, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040628; Khurana S, 2016, NAT MED, V22, P1439, DOI 10.1038/nm.4201; Klassen SA, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.684151; Lebing W, 2003, VOX SANG, V84, P193, DOI 10.1046/j.1423-0410.2003.00285.x; Libster R, 2021, NEW ENGL J MED, V384, P610, DOI 10.1056/NEJMoa2033700; Loveday EK, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13040562; Lukacevic SM, 2020, TOXINS, V12, DOI 10.3390/toxins12120798; Panch SR, 2019, NEW ENGL J MED, V381, P150, DOI 10.1056/NEJMra1802338; Parkkinen J, 2006, VOX SANG, V90, P97, DOI 10.1111/j.1423-0410.2005.00731.x; Perotti C, 2020, HAEMATOLOGICA, V105, P2834, DOI 10.3324/haematol.2020.261784; Price H., 2012, PRODUCTION PLASMA PR, P207; Radosevich M, 2010, VOX SANG, V98, P12, DOI 10.1111/j.1423-0410.2009.01226.x; Ravlic S, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.816159; Rnjak D, 2021, TRANSFUS CLIN BIOL, V28, P264, DOI 10.1016/j.tracli.2021.04.004; Salazar E, 2020, AM J PATHOL, V190, P2290, DOI 10.1016/j.ajpath.2020.08.001; Skountzou I, 2014, CLIN VACCINE IMMUNOL, V21, P1481, DOI 10.1128/CVI.00374-14; Stimac A, 2022, MOLECULES, V27, DOI 10.3390/molecules27051665; Stucki M, 2008, BIOLOGICALS, V36, P239, DOI 10.1016/j.biologicals.2008.01.004; Teschner W, 2007, VOX SANG, V92, P42, DOI 10.1111/j.1423-0410.2006.00846.x; Vandeberg P, 2021, TRANSFUSION, V61, P1705, DOI 10.1111/trf.16378; Vegivinti CTR, 2021, J CLIN APHERESIS, V36, P470, DOI 10.1002/jca.21881; WELLS JV, 1980, ANAESTH INTENS CARE, V8, P139, DOI 10.1177/0310057X8000800207; Wu YW, 2014, TRANSFUSION, V54, P169, DOI 10.1111/trf.12243; Yu H, 2003, TRANSFUS MED HEMOTH, V30, P214, DOI 10.1159/000074286	39	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								889736	10.3389/fimmu.2022.889736	http://dx.doi.org/10.3389/fimmu.2022.889736			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U0GQ	35655779	gold, Green Published			2022-12-18	WOS:000805100100001
J	Liu, JQ; Zhao, XL; Duan, XM; Zhang, WW; Li, CH				Liu, Jiqing; Zhao, Xuelin; Duan, Xuemei; Zhang, Weiwei; Li, Chenghua			CircRNA75 and CircRNA72 Function as the Sponge of MicroRNA-200 to Suppress Coelomocyte Apoptosis Via Targeting Tollip in Apostichopus japonicus (vol 12, 770055, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						Apostichopus japonicus; circRNA; miR-200; Tollip; apoptosis			[Liu, Jiqing; Zhao, Xuelin; Duan, Xuemei; Zhang, Weiwei; Li, Chenghua] Ningbo Univ, State Key Lab Qual & Safety Agroprod, Ningbo, Peoples R China; [Liu, Jiqing; Zhao, Xuelin; Duan, Xuemei; Zhang, Weiwei; Li, Chenghua] Ningbo Univ, Collaborat Innovat Ctr Zhejiang Marine High effici, Ningbo, Peoples R China; [Li, Chenghua] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China	Ningbo University; Ningbo University; Qingdao National Laboratory for Marine Science & Technology	Li, CH (corresponding author), Ningbo Univ, State Key Lab Qual & Safety Agroprod, Ningbo, Peoples R China.; Li, CH (corresponding author), Ningbo Univ, Collaborat Innovat Ctr Zhejiang Marine High effici, Ningbo, Peoples R China.; Li, CH (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China.	lichenghua@nbu.edu.cn						Liu JQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.770055	1	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								892511	10.3389/fimmu.2022.892511	http://dx.doi.org/10.3389/fimmu.2022.892511			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V8UI	35663934	gold, Green Published			2022-12-18	WOS:000806360100001
J	Qian, SY; Ding, MJ; Hou, HT; Wang, ZY; Zhang, JM; Zhang, Y; Dong, M; Zhu, LA; Wang, GN; Li, WC; Zhang, XD				Qian, Siyu; Ding, Mengjie; Hou, Huting; Wang, Zeyuan; Zhang, Jieming; Zhang, Yue; Dong, Meng; Zhu, Linan; Wang, Guannan; Li, Wencai; Zhang, Xudong			Clinical and Molecular Characteristics of 60 Patients With Human Immunodeficiency Virus-Negative Castleman Disease	FRONTIERS IN IMMUNOLOGY			English	Article						Castleman disease; classifications; prognosis; mTOR pathway; thrombocytopenia	TREATMENT GUIDELINES; TAFRO SYNDROME; MANAGEMENT; SPECTRUM	Castleman disease (CD) is a rare lymphoproliferative disorder. The mechanistic target of rapamycin (mTOR) pathway is a key regulator of various cellular functions, which may be related with the potential mechanisms of CD occurrence. We retrospectively collected the clinical information of 60 CD patients diagnosed in the First Affiliated Hospital of Zhengzhou University. And FFPE biopsy specimens were collected from 31 patients (12 unicentric CD patients and 19 multicentric CD patients) to detect the mTOR pathway protein expression. We are the first to demonstrate that thrombocytopenia and hypoalbuminemia are independent poor prognostic factors for CD. Moreover, mTOR activation was higher in CD compared to reactive lymphoid hyperplasia (used as a control group). This study offers some elucidation for the management and treatment of CD patients.	[Qian, Siyu; Ding, Mengjie; Hou, Huting; Wang, Zeyuan; Zhang, Jieming; Zhang, Yue; Dong, Meng; Zhu, Linan; Zhang, Xudong] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China; [Wang, Guannan; Li, Wencai] Zhengzhou Univ, Dept Pathol, Affiliated Hosp 1, Zhengzhou, Peoples R China	Zhengzhou University; Zhengzhou University	Zhang, XD (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China.; Li, WC (corresponding author), Zhengzhou Univ, Dept Pathol, Affiliated Hosp 1, Zhengzhou, Peoples R China.	Wencailizzu@126.com; fcczhangxd@zzu.edu.cn			National Natural Science Foundation of China [82070210]; Major Medicine Scientific and Technology Project of Henan Province [202001008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major Medicine Scientific and Technology Project of Henan Province	Funding The authors would like to thank the financial support provided by National Natural Science Foundation of China (82070210) and Major Medicine Scientific and Technology Project of Henan Province (NO.SBG 202001008).	Ara T, 2010, EUR J CANCER, V46, P1223, DOI 10.1016/j.ejca.2010.02.026; Arenas DJ, 2020, BLOOD, V135, P1673, DOI 10.1182/blood.2019002792; Barker R, 2009, EUR J NUCL MED MOL I, V36, P648, DOI 10.1007/s00259-008-0998-4; Boutboul D, 2019, BRIT J HAEMATOL, V186, P269, DOI 10.1111/bjh.15921; Bowne WB, 1999, CANCER, V85, P706, DOI 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7; Chen CH, 2009, J CARDIOTHORAC SURG, V4, DOI 10.1186/1749-8090-4-31; Dispenzieri A, 2019, AM J HEMATOL, V94, P812, DOI 10.1002/ajh.25495; Dispenzieri A, 2012, AM J HEMATOL, V87, P997, DOI 10.1002/ajh.23291; Dong YJ, 2015, BRIT J HAEMATOL, V169, P834, DOI 10.1111/bjh.13378; El-Osta HE, 2011, ONCOLOGIST, V16, P497, DOI 10.1634/theoncologist.2010-0212; Freedman A, 2018, AM J HEMATOL, V93, P296, DOI 10.1002/ajh.24937; Gonzalez-Garcia A, 2019, LEUKEMIA LYMPHOMA, V60, P3442, DOI 10.1080/10428194.2019.1639168; Hawkins JM, 2015, BLOOD, V126, P2163, DOI 10.1182/blood-2015-07-662122; INADA K, 1958, ANN SURG, V147, P409, DOI 10.1097/00000658-195803000-00018; Jiang Q, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.827461; Lan X, 2018, J CANCER RES CLIN, V144, P1265, DOI 10.1007/s00432-018-2647-z; Lee ES, 2013, CLIN NUCL MED, V38, P339, DOI 10.1097/RLU.0b013e3182816730; Li ZM, 2019, LEUKEMIA, V33, P1035, DOI 10.1038/s41375-018-0323-6; Liu AY, 2016, LANCET HAEMATOL, V3, pE163, DOI 10.1016/S2352-3026(16)00006-5; Lunning MA, 2018, BLOOD, V132, P2109, DOI 10.1182/blood-2018-09-875112; Mitsos S, 2018, ADV RESPIR MED, V86, P36, DOI 10.5603/ARM.2018.0008; Oksenhendler E, 2018, BRIT J HAEMATOL, V180, P206, DOI 10.1111/bjh.15019; Ostrowska B, 2021, LEUKEMIA LYMPHOMA, V62, P3031, DOI 10.1080/10428194.2021.1941926; Sakashita K, 2018, J BLOOD MED, V9, P15, DOI 10.2147/JBM.S127822; van Rhee F, 2020, BLOOD ADV, V4, P6039, DOI 10.1182/bloodadvances.2020003334; van Rhee F, 2018, BLOOD, V132, P2115, DOI 10.1182/blood-2018-07-862334; van Rhee F, 2014, LANCET ONCOL, V15, P966, DOI 10.1016/S1470-2045(14)70319-5; Williams SCP, 2013, NAT MED, V19, P1193, DOI 10.1038/nm1013-1193; Yu L, 2017, BLOOD, V129, P1658, DOI 10.1182/blood-2016-11-748855; Zhang L., 2016, SCI REP-UK, V2015, P2; Zhou N, 2012, J INT MED RES, V40, P1580, DOI 10.1177/147323001204000438	31	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								899073	10.3389/fimmu.2022.899073	http://dx.doi.org/10.3389/fimmu.2022.899073			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S5TT	35655778	Green Published, gold			2022-12-18	WOS:000804114500001
J	Shi, SJ; Bonaccorsi-Riani, E; Schurink, I; van den Bosch, T; Doukas, M; Lila, KA; Roest, HP; Xhema, D; Gianello, P; de Jonge, J; Verstegen, MMA; van der Laan, LJW				Shi, Shaojun; Bonaccorsi-Riani, Eliano; Schurink, Ivo; van den Bosch, Thierry; Doukas, Michael; Lila, Karishma A.; Roest, Henk P.; Xhema, Daela; Gianello, Pierre; de Jonge, Jeroen; Verstegen, Monique M. A.; van der Laan, Luc J. W.			Liver Ischemia and Reperfusion Induce Periportal Expression of Necroptosis Executor pMLKL Which Is Associated With Early Allograft Dysfunction After Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						ischemia-reperfusion injury; programmed cell death; non-parenchymal cell; myofibroblast; liver transplantation	HEPATIC ISCHEMIA; PRESERVATION; NECROSIS; APOPTOSIS; PROFILES; INJURY; DEATH	BackgroundEarly allograft dysfunction (EAD) following liver transplantation (LT) remains a major threat to the survival of liver grafts and recipients. In animal models, it is shown that hepatic ischemia-reperfusion injury (IRI) triggers phosphorylation of Mixed Lineage Kinase domain-like protein (pMLKL) inducing necroptotic cell death. However, the clinical implication of pMLKL-mediated cell death in human hepatic IRI remains largely unexplored. In this study, we aimed to investigate the expression of pMLKL in human liver grafts and its association with EAD after LT. MethodsThe expression of pMLKL was determined by immunohistochemistry in liver biopsies obtained from both human and rat LT. Human liver biopsies were obtained at the end of preservation (T0) and ~1 hour after reperfusion (T1). The positivity of pMLKL was quantified electronically and compared in rat and human livers and post-LT outcomes. Multiplex immunofluorescence staining was performed to characterize the pMLKL-expressing cells. ResultsIn the rat LT model, significant pMLKL expression was observed in livers after IRI as compared to livers of sham-operation animals. Similarly, the pMLKL score was highest after IRI in human liver grafts (in T1 biopsies). Both in rats and humans, the pMLKL expression is mostly observed in the portal triads. In grafts who developed EAD after LT (n=24), the pMLKL score at T1 was significantly higher as compared to non-EAD grafts (n=40). ROC curve revealed a high predictive value of pMLKL score at T1 (AUC 0.70) and the ratio of pMLKL score at T1 and T0 (pMLKL-index, AUC 0.82) for EAD. Liver grafts with a high pMLKL index (>1.64) had significantly higher levels of serum ALT, AST, and LDH 24 hours after LT compared to grafts with a low pMLKL index. Multivariate logistical regression analysis identified the pMLKL-index (Odds ratio=1.3, 95% CI 1.1-1.7) as a predictor of EAD development. Immunohistochemistry on serial sections and multiplex staining identified the periportal pMLKL-positive cells as portal fibroblasts, fibrocytes, and a minority of cholangiocytes. ConclusionPeriportal pMLKL expression increased significantly after IRI in both rat and human LT. The histological score of pMLKL is predictive of post-transplant EAD and is associated with early liver injury after LT. Periportal non-parenchymal cells (i.e. fibroblasts) appear most susceptible to pMLKL-mediated cell death during hepatic IRI.	[Shi, Shaojun; Schurink, Ivo; Roest, Henk P.; de Jonge, Jeroen; Verstegen, Monique M. A.; van der Laan, Luc J. W.] Univ Med Ctr, Erasmus MC Transplant Inst, Dept Surg, Rotterdam, Netherlands; [Bonaccorsi-Riani, Eliano] Catholic Univ Louvain, Abdominal Transplant Unit, Clin Univ St Luc, Brussels, Belgium; [Bonaccorsi-Riani, Eliano; Xhema, Daela; Gianello, Pierre] Catholic Univ Louvain, Pole Chirurg Expt & Transplantat Inst Rech Expt &, Brussels, Belgium; [van den Bosch, Thierry; Doukas, Michael; Lila, Karishma A.] Erasmus MC Univ Med Ctr, Dept Pathol, Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Transplant Institute; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Catholique Louvain; Erasmus University Rotterdam; Erasmus MC	van der Laan, LJW (corresponding author), Univ Med Ctr, Erasmus MC Transplant Inst, Dept Surg, Rotterdam, Netherlands.	l.vanderlaan@erasmusmc.nl		de Jonge, Jeroen/0000-0002-1131-027X	Medical Delta program grant (Regenerative Medicine 4D); TKI-LSH (Topconsortium Kennis en Innovatie-Life Sciences Health) [EMC-LSH19002]; China Scholarship Council [201706230252]	Medical Delta program grant (Regenerative Medicine 4D); TKI-LSH (Topconsortium Kennis en Innovatie-Life Sciences Health); China Scholarship Council(China Scholarship Council)	This study was partly funded by the Medical Delta program grant (Regenerative Medicine 4D) and TKI-LSH (Topconsortium Kennis en Innovatie-Life Sciences & Health) grant (RELOAD, EMC-LSH19002). SS is financially supported by the China Scholarship Council (No. 201706230252).	Agopian VG, 2018, JAMA SURG, V153, P436, DOI 10.1001/jamasurg.2017.5040; Argani P, 2010, AM J SURG PATHOL, V34, P1295, DOI 10.1097/PAS.0b013e3181e8ce5b; Ariyakhagorn V, 2009, J SURG RES, V153, P332, DOI 10.1016/j.jss.2008.04.003; Baidya R, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020212; Cao WX, 2018, APOPTOSIS, V23, P521, DOI 10.1007/s10495-018-1475-6; Clavien PA, 1998, HEPATOLOGY, V28, P281, DOI 10.1002/hep.510280201; Cursio R, 2010, HPB, V12, P1, DOI 10.1111/j.1477-2574.2009.00123.x; Dar WA, 2019, LIVER INT, V39, DOI 10.1111/liv.14091; Deschenes M, 2013, LIVER TRANSPLANT, V19, pS6, DOI 10.1002/lt.23746; Golse N, 2019, ANN SURG, V270, P131, DOI 10.1097/SLA.0000000000002726; Guicciardi ME, 2013, COMPR PHYSIOL, V3, P977, DOI 10.1002/cphy.c120020; Gujral JS, 2001, HEPATOLOGY, V33, P397, DOI 10.1053/jhep.2001.22002; Hirao H, 2021, HEPATOLOGY, V74, P2759, DOI 10.1002/hep.32030; Hong JM, 2016, TOXICOL APPL PHARM, V308, P1, DOI 10.1016/j.taap.2016.08.010; Howitt BE, 2016, JAMA ONCOL, V2, P518, DOI 10.1001/jamaoncol.2015.6326; Hudcova J, 2017, CLIN TRANSPLANT, V31, DOI 10.1111/ctr.12887; Kadono K, 2022, J HEPATOL, V76, P896, DOI 10.1016/j.jhep.2021.11.026; Katsumata LW, 2017, HEPATOL COMMUN, V1, P198, DOI 10.1002/hep4.1023; Klune JR, 2010, SURG CLIN N AM, V90, P665, DOI 10.1016/j.suc.2010.04.003; Konishi T, 2020, AM J PHYSIOL-GASTR L, V318, pG390, DOI 10.1152/ajpgi.00137.2019; Konishi T, 2019, AM J PHYSIOL-GASTR L, V316, pG323, DOI 10.1152/ajpgi.00154.2018; Kurian SM, 2015, AM J TRANSPLANT, V15, P1605, DOI 10.1111/ajt.13145; Kwon HM, 2019, LIVER INT, V39, P1545, DOI 10.1111/liv.14103; Lee DD, 2016, ANN HEPATOL, V15, P53, DOI 10.5604/16652681.1184212; Li CY, 2021, CELL DEATH DIFFER, V28, P1705, DOI 10.1038/s41418-020-00695-7; Li JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2437-9; Lua I, 2016, J HEPATOL, V64, P1137, DOI 10.1016/j.jhep.2016.01.010; Luedde T, 2014, GASTROENTEROLOGY, V147, P765, DOI 10.1053/j.gastro.2014.07.018; Moriwaki K, 2016, CELL MOL LIFE SCI, V73, P2325, DOI 10.1007/s00018-016-2203-4; Nishio T, 2019, J HEPATOL, V71, P573, DOI 10.1016/j.jhep.2019.04.012; Olthoff KM, 2010, LIVER TRANSPLANT, V16, P943, DOI 10.1002/lt.22091; Rosentreter D, 2015, SHOCK, V44, P72, DOI 10.1097/SHK.0000000000000371; Saeed WK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184752; Selten JW, 2017, LIVER TRANSPLANT, V23, P946, DOI 10.1002/lt.24766; Shi SJ, 2022, CELL MOL GASTROENTER, V13, P541, DOI 10.1016/j.jcmgh.2021.10.009; Shi SJ, 2019, LIVER TRANSPLANT, V25, P1091, DOI 10.1002/lt.25488; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Thomsen KL, 2019, J CLIN EXP HEPATOL, V9, P302, DOI 10.1016/j.jceh.2018.09.006; Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Verhoeven CJ, 2013, J HEPATOL, V59, P1231, DOI [10.1016/j.jhep.2013.07.034, 10.1016/j.jhep.2017.09.001]; Wang EM, 2020, FASEB J, V34, P16163, DOI 10.1096/fj.202000511RR; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Wang ZL, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03679-8; Wu HH, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051107; Yamada N, 2020, AM J TRANSPLANT, V20, P1606, DOI 10.1111/ajt.15773; Yang FJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2301903; Yang XY, 2021, IMMUNOL CELL BIOL, V99, P34, DOI 10.1111/imcb.12382; Zarrinpar A, 2013, NAT REV GASTRO HEPAT, V10, P434, DOI 10.1038/nrgastro.2013.88; Zhan CN, 2021, THERANOSTICS, V11, P4759, DOI 10.7150/thno.54072; Zhong WZ, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-2822; Zhu ZB, 2018, CLIN TRANSPLANT, V32, DOI 10.1111/ctr.13438	52	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								890353	10.3389/fimmu.2022.890353	http://dx.doi.org/10.3389/fimmu.2022.890353			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8PF	35655777	gold, Green Published			2022-12-18	WOS:000804987100001
J	Teuben, MPJ; Heeres, M; Blokhuis, T; Spijkerman, R; Knot, E; Vrisekoop, N; Pfeifer, R; Pape, HC; Koenderman, L; Leenen, LPH				Teuben, Michel P. J.; Heeres, Marjolein; Blokhuis, Taco; Spijkerman, Roy; Knot, Eric; Vrisekoop, Nienke; Pfeifer, Roman; Pape, Hans-Christoph; Koenderman, Leo; Leenen, Luke P. H.			Shift of Neutrophils From Blood to Bone Marrow Upon Extensive Experimental Trauma Surgery	FRONTIERS IN IMMUNOLOGY			English	Article						trauma; neutrophil; subsets; bone marrow; porcine model	SYSTEMIC INFLAMMATION; PERIPHERAL-BLOOD; SOCIAL-STATUS; MAJOR TRAUMA; KINETICS; STRESS; EXPRESSION; INJURY; CXCR4; MODEL	IntroductionExtensive trauma surgery evokes an immediate cellular immune response including altered circulatory neutrophil numbers. The concurrent bone marrow (BM) response however is currently unclear. We hypothesize that these BM changes include (1) a relative reduction of the bone marrow neutrophil fraction and (2) increasing heterogeneity of the bone marrow neutrophil pool due to (3) the appearance of aged/returning neutrophils from circulation into the BM-compartment. Materials and MethodsEight pigs were included in a standardized extensive trauma surgery model. Blood and bone marrow samples were collected at baseline and after 3 hours of ongoing trauma surgery. Leukocyte and subtype counts and cell surface receptor expression levels were studied by flow cytometry. ResultsAll animals survived the interventions. A significant drop in circulating neutrophil counts from 9.3 to 3.2x10(6) cells/ml (P=0.001) occurred after intervention, whereas circulatory neutrophil cell surface expression of CD11b increased. The concurrent bone marrow response included an increase of the BM neutrophil fraction from 63 +/- 3 to 71 +/- 3 percent (P<0.05). Simultaneously, the BM neutrophil pool became increasingly mature with a relative increase of a CXCR4(high)-neutrophil subtype that was virtually absent at baseline. ConclusionThe current study shows a shift in composition of the BM neutrophil pool during extensive trauma surgery that was associated with a relatively circulatory neutropenia. More specifically, under these conditions BM neutrophils were more mature than under homeostatic conditions and a CXCR4(high)-neutrophil subset became overrepresented possibly reflecting remigration of aged neutrophils to the BM. These findings may contribute to the development of novel interventions aimed to modify the trauma-induced immune response in the BM.	[Teuben, Michel P. J.; Heeres, Marjolein; Spijkerman, Roy; Knot, Eric; Leenen, Luke P. H.] Univ Med Ctr Utrecht, Dept Trauma, Utrecht, Netherlands; [Teuben, Michel P. J.; Heeres, Marjolein; Vrisekoop, Nienke; Koenderman, Leo] Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands; [Teuben, Michel P. J.; Pfeifer, Roman; Pape, Hans-Christoph] Univ Hosp Zurich, Dept Traumatol, Zurich, Switzerland; [Blokhuis, Taco] Maastricht Univ Med Ctr, Dept Surg, Maastricht, Netherlands; [Spijkerman, Roy; Vrisekoop, Nienke; Koenderman, Leo] Univ Med Ctr Utrecht, Dept Resp Med, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Zurich; University Zurich Hospital; Maastricht University; Maastricht University Medical Centre (MUMC); Utrecht University; Utrecht University Medical Center	Leenen, LPH (corresponding author), Univ Med Ctr Utrecht, Dept Trauma, Utrecht, Netherlands.	l.p.h.leenen@umcutrecht.nl		Pape, Hans-Christoph/0000-0002-2059-4980	University Medical Center Utrecht	University Medical Center Utrecht	MT is supported by the Alexandre Suerman Stipend from the University Medical Center Utrecht.	Altznauer F, 2004, J EXP MED, V199, P1343, DOI 10.1084/jem.20032033; AMOS RJ, 1990, J CLIN PATHOL, V43, P850, DOI 10.1136/jcp.43.10.850; ATHENS JW, 1963, ANNU REV PHYSIOL, V25, P195, DOI 10.1146/annurev.ph.25.030163.001211; Beery AK, 2018, CURR OPIN BEHAV SCI, V23, P143, DOI 10.1016/j.cobeha.2018.06.016; Benarafa C, 2011, J LEUKOCYTE BIOL, V90, P21, DOI 10.1189/jlb.0810461; BOTHA AJ, 1995, J TRAUMA, V39, P411; Botha AJ, 1997, INTENS CARE MED, V23, P504, DOI 10.1007/s001340050365; Brea D, 2012, BIOCHEM J, V447, P363, DOI 10.1042/BJ20120818; DANCEY JT, 1976, J CLIN INVEST, V58, P705, DOI 10.1172/JCI108517; De Filippo K, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12949; de Ruiter K, 2018, CYTOM PART A, V93A, P540, DOI 10.1002/cyto.a.23354; DUBREUIL P, 1993, CAN J ANIM SCI, V73, P241, DOI 10.4141/cjas93-026; Eash KJ, 2009, BLOOD, V113, P4711, DOI 10.1182/blood-2008-09-177287; Eighetany MT, 2004, J CLIN LAB ANAL, V18, P36, DOI 10.1002/jcla.20001; Fingerhut L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124523; Fuchs A, 2019, J IMMUNOL, V202, P3020, DOI 10.4049/jimmunol.1801456; Furze RC, 2008, IMMUNOLOGY, V125, P281, DOI 10.1111/j.1365-2567.2008.02950.x; Furze RC, 2008, FASEB J, V22, P3111, DOI 10.1096/fj.08-109876; GILLAN ER, 1994, BLOOD, V84, P1427; Gulack BC, 2015, J TRAUMA ACUTE CARE, V79, P437, DOI 10.1097/TA.0000000000000757; Hasjim Bima J, 2022, J Intensive Care Soc, V23, P117, DOI 10.1177/1751143720975316; Hesselink L, 2019, WORLD J EMERG SURG, V14, DOI 10.1186/s13017-019-0244-3; Hietbrink F, 2011, WORLD J EMERG SURG, V6, DOI 10.1186/1749-7922-6-34; Horst K, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/126060; Horst K, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03028; Jacobi CA, 1998, ARCH SURG-CHICAGO, V133, P258, DOI 10.1001/archsurg.133.3.258; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Lahoz-Beneytez J, 2016, BLOOD, V127, P3431, DOI 10.1182/blood-2016-03-700336; Lawrence YR, 2007, QJM-INT J MED, V100, P217, DOI 10.1093/qjmed/hcm006; Leitao L, 2019, FASEB J, V33, P857, DOI 10.1096/fj.201800610RR; Livingston DH, 2003, ANN SURG, V238, P748, DOI 10.1097/01.sla.0000094441.38807.09; Lord JM, 2014, LANCET, V384, P1455, DOI 10.1016/S0140-6736(14)60687-5; LUNDJOHANSEN F, 1993, J LEUKOCYTE BIOL, V54, P47, DOI 10.1002/jlb.54.1.47; Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022; Manz MG, 2014, NAT REV IMMUNOL, V14, P302, DOI 10.1038/nri3660; MARSH JC, 1967, J CLIN INVEST, V46, P1943, DOI 10.1172/JCI105684; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; MCGLONE JJ, 1993, J ANIM SCI, V71, P888, DOI 10.2527/1993.714888x; Nagase H, 2002, J LEUKOCYTE BIOL, V71, P711; Orr Y, 2007, AM J PHYSIOL-REG I, V292, pR1707, DOI 10.1152/ajpregu.00627.2006; Pallister I, 2002, CRIT CARE MED, V30, P1717, DOI 10.1097/00003246-200208000-00007; Pillay J, 2012, J CLIN INVEST, V122, P327, DOI 10.1172/JCI57990; Pillay J, 2010, BLOOD, V116, P625, DOI 10.1182/blood-2010-01-259028; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Rankin SM, 2010, J LEUKOCYTE BIOL, V88, P241, DOI 10.1189/jlb.0210112; RICHARDSON RP, 1989, ANN SURG, V210, P239, DOI 10.1097/00000658-198908000-00018; ROTHSTEIN G, 1987, BLOOD, V70, P1836; ROTONDO MF, 1993, J TRAUMA, V35, P375, DOI 10.1097/00005373-199309000-00008; Rovlias A, 2001, SURG NEUROL, V55, P190, DOI 10.1016/S0090-3019(01)00414-1; Schweinberger Monica H, 2007, J Foot Ankle Surg, V46, P411, DOI 10.1053/j.jfas.2007.05.009; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Summerfield A, 1997, J LEUKOCYTE BIOL, V62, P176, DOI 10.1002/jlb.62.2.176; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; Sutherland MA, 2006, J ANIM SCI, V84, P588, DOI 10.2527/2006.843588x; Teuben M, 2021, INJURY, V52, P426, DOI 10.1016/j.injury.2020.11.018; Tsukamoto T, 2009, SHOCK, V31, P3, DOI 10.1097/SHK.0b013e31817fdabf; van Lochem EG, 2004, CYTOM PART B-CLIN CY, V60B, P1, DOI 10.1002/cyto.b.20008; von Vietinghoff S, 2008, J IMMUNOL, V181, P5183, DOI 10.4049/jimmunol.181.8.5183; Waheed U, 2003, ANAESTHESIA, V58, P180, DOI 10.1046/j.1365-2044.2003.02964_5.x; Wengner A, 2008, BLOOD, V181, P51838, DOI 0.1182/blood-2007-07-0996481	60	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								883863	10.3389/fimmu.2022.883863	http://dx.doi.org/10.3389/fimmu.2022.883863			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8PE	35655784	Green Published, gold			2022-12-18	WOS:000804987000001
J	Zhang, RA; Zhang, XF; Chi, YH; Xu, YY; Chen, HY; Guo, ZX; Wei, TY				Zhang, Ruonan; Zhang, Xiao-Feng; Chi, Yunhua; Xu, Yuanyuan; Chen, Hongyan; Guo, Zhongxin; Wei, Taiyun			Nucleoprotein of a Rice Rhabdovirus Serves as the Effector to Attenuate Hemolymph Melanization and Facilitate Viral Persistent Propagation in its Leafhopper Vector	FRONTIERS IN IMMUNOLOGY			English	Article						rice stripe mosaic virus; melanization; leafhopper; prophenoloxidases (PPO); viral infection	ANTIMICROBIAL PEPTIDES; VIRUS; ACTIVATION; PROTEIN; PHAGOCYTOSIS; RESISTANCE; DROSOPHILA; HEMOCYTES; MECHANISM	Melanization in the hemolymph of arthropods is a conserved defense strategy against infection by invading pathogens. Numerous plant viruses are persistently transmitted by insect vectors, and must overcome hemolymph melanization. Here, we determine that the plant rhabdovirus rice stripe mosaic virus (RSMV) has evolved to evade the antiviral melanization response in the hemolymph in leafhopepr vectors. After virions enter vector hemolymph cells, viral nucleoprotein N is initially synthesized and directly interacts with prophenoloxidase (PPO), a core component of the melanization pathway and this process strongly activates the expression of PPO. Furthermore, such interaction could effectively inhibit the proteolytic cleavage of the zymogen PPO to active phenoloxidase (PO), finally suppressing hemolymph melanization. The knockdown of PPO expression or treatment with the PO inhibitor also suppresses hemolymph melanization and causes viral excessive accumulation, finally causing a high insect mortality rate. Consistent with this function, microinjection of N into leafhopper vectors attenuates melanization and promotes viral infection. These findings demonstrate that RSMV N serves as the effector to attenuate hemolymph melanization and facilitate viral persistent propagation in its insect vector. Our findings provide the insights in the understanding of ongoing arms race of insect immunity defense and viral counter-defense.	[Zhang, Ruonan; Zhang, Xiao-Feng; Chi, Yunhua; Xu, Yuanyuan; Chen, Hongyan; Guo, Zhongxin; Wei, Taiyun] Fujian Agr & Forestry Univ, Inst Plant Virol, State Key Lab Ecol Pest Control Fujian & Taiwan Cr, Fuzhou, Peoples R China	Fujian Agriculture & Forestry University	Wei, TY (corresponding author), Fujian Agr & Forestry Univ, Inst Plant Virol, State Key Lab Ecol Pest Control Fujian & Taiwan Cr, Fuzhou, Peoples R China.	weitaiyun@fafu.edu.cn		guo, zhongxin/0000-0001-7381-7765; Zhang, Xiao-Feng/0000-0002-1763-1154				An CJ, 2009, J BIOL CHEM, V284, P19716, DOI 10.1074/jbc.M109.007112; Cerenius L, 2008, TRENDS IMMUNOL, V29, P263, DOI 10.1016/j.it.2008.02.009; Chen XF, 2020, MBIO, V11, DOI 10.1128/mBio.01453-20; Clarke DK, 2006, SPRINGER SEMIN IMMUN, V28, P239, DOI 10.1007/s00281-006-0042-3; Dietzgen RG, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110303; Dimopoulos G, 2001, CURR OPIN IMMUNOL, V13, P79, DOI 10.1016/S0952-7915(00)00186-2; Eleftherianos I, 2021, IMMUNOLOGY, V164, P401, DOI 10.1111/imm.13390; Hillyer JF, 2003, J PARASITOL, V89, P62, DOI 10.1645/0022-3395(2003)089[0062:RPAMOB]2.0.CO;2; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; HULTMARK D, 1993, TRENDS GENET, V9, P178, DOI 10.1016/0168-9525(93)90165-E; Jaree P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02184; Khattar ZA, 2009, J BACTERIOL, V191, P7063, DOI 10.1128/JB.00892-09; Kingsolver MB, 2013, J MOL BIOL, V425, P4921, DOI 10.1016/j.jmb.2013.10.006; Lavine MD, 2003, INSECT MOL BIOL, V12, P441, DOI 10.1046/j.1365-2583.2003.00428.x; Lavine MD, 2001, J INSECT PHYSIOL, V47, P965, DOI 10.1016/S0022-1910(01)00071-3; Lefkowitz EJ, 2018, NUCLEIC ACIDS RES, V46, pD708, DOI 10.1093/nar/gkx932; Liu H, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M706113200; Liu WW, 2015, MOL CELL PROTEOMICS, V14, P2229, DOI 10.1074/mcp.M114.046763; Mavrouli MD, 2005, BBA-MOL CELL RES, V1744, P145, DOI 10.1016/j.bbamcr.2005.04.011; Prabu S, 2020, INT J BIOL MACROMOL, V153, P88, DOI 10.1016/j.ijbiomac.2020.03.003; Redinbaugh MG, 2005, CURR TOP MICROBIOL, V292, P143; RIZKI TM, 1985, MOL GEN GENET, V201, P7, DOI 10.1007/BF00397978; Saejeng A, 2010, J INSECT PHYSIOL, V56, P1232, DOI 10.1016/j.jinsphys.2010.03.025; Sangsuriya P, 2018, DEV COMP IMMUNOL, V86, P109, DOI 10.1016/j.dci.2018.05.005; Sutthangkul J, 2017, J GEN VIROL, V98, P769, DOI 10.1099/jgv.0.000729; Tassanakajon A, 2018, DEV COMP IMMUNOL, V80, P81, DOI 10.1016/j.dci.2017.05.009; Wang HT, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00513; Wang L, 2018, J ASIA-PAC ENTOMOL, V21, P864, DOI 10.1016/j.aspen.2018.06.008; Wang NF, 2016, FRONT MICROBIOL, V7, DOI [10.3389/fmicb.2016.01170, 10.3389/fmicb.2016.02140]; Wang QR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00785; Wang Y, 2017, INSECT MOL BIOL, V26, P552, DOI 10.1111/imb.12318; Wei J, 2018, CURR OPIN VIROL, V33, P18, DOI 10.1016/j.coviro.2018.07.005; Wei TY, 2006, J VIROL, V80, P8593, DOI 10.1128/JVI.00537-06; Yang X, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02457; Yuan CF, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006645; Zhang W, 2021, CELL SIGNAL, V83, DOI 10.1016/j.cellsig.2021.110003; Zhang XF, 2021, SCI CHINA LIFE SCI, V64, P1522, DOI 10.1007/s11427-020-1846-8; Zhao P, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03258	38	0	0	15	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 17	2022	13								904244	10.3389/fimmu.2022.904244	http://dx.doi.org/10.3389/fimmu.2022.904244			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S5SN	35655780	Green Published, gold			2022-12-18	WOS:000804111000001
J	Guan, RB; Hu, SR; Li, X; An, SH; Miao, XX; Li, HC				Guan, Ruobing; Hu, Shaoru; Li, Xiang; An, Shiheng; Miao, Xuexia; Li, Haichao			A TIL-Type Serine Protease Inhibitor Involved in Humoral Immune Response of Asian Corn Borer Ostrinia furnaculis	FRONTIERS IN IMMUNOLOGY			English	Article						Ostrinia furnacalis; serine protease; proteinase inhibitor; immune; melanization; antimicrobial peptides	BOMBYX-MORI; PROPHENOLOXIDASE ACTIVATION; TRYPSIN-INHIBITOR; EXPRESSION; HEMOLYMPH; SILKWORM; COMPONENTS; SEQUENCE; SYSTEM; PCR	To elucidate the application value of insect endogenous protease and its inhibitor genes in pest control, we analyzed in detail the transcriptome sequence of the Asian corn borer, Ostrinia furnacalis. We obtained 12 protease genes and 11 protease inhibitor genes, and comprehensively analyzed of their spatiotemporal expression by qRT-PCR. In which, a previous unstudied serine protease inhibitor gene attracted our attention. It belongs to the canonical serine proteinase inhibitor family, a trypsin inhibitor-like cysteine-rich domain (TIL)-type protease inhibitor, but its TIL domain lacks two cysteine residues, and it was named as ACB-TIL. Its expression level is relatively very low in the absence of pathogen stimulation, and can be up-regulated expression induced by Gram-negative bacteria (Escherichia coli), virus (BmNPV), and dsRNA (dsEGFP), but cannot be induced by fungus spores (Metarrhizium anisopliae). Prokaryotic expressed ACB-TIL protein can significantly inhibit the melanization in vitro. Injecting this protein into insect body can inhibit the production of antimicrobial peptides of attacin, lebocin and gloverin. Inhibition of ACB-TIL by RNAi can cause the responses of other immune-, protease- and inhibitor-related genes. ACB-TIL is primarily involved in Asian corn borer humoral immunity in responses to Gram-negative bacteria and viruses. This gene can be a potential target for pest control since this will mainly affect insect immune response.	[Guan, Ruobing; Li, Xiang; An, Shiheng; Li, Haichao] Henan Agr Univ, Coll Plant Protect, Henan Int Lab Green Pest Control, Zhengzhou, Peoples R China; [Guan, Ruobing; Miao, Xuexia; Li, Haichao] Chinese Acad Sci, Ctr Excellence Mol Plant Sci, Shanghai Inst Plant Physiol & Ecol, Key Lab Insect Dev & Evolutionary Biol, Shanghai, Peoples R China; [Hu, Shaoru] Shanghai Jiao Tong Univ, Biobank Peoples Hosp 9, Sch Med, Shanghai, Peoples R China	Henan Agricultural University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University	An, SH; Li, HC (corresponding author), Henan Agr Univ, Coll Plant Protect, Henan Int Lab Green Pest Control, Zhengzhou, Peoples R China.; Miao, XX; Li, HC (corresponding author), Chinese Acad Sci, Ctr Excellence Mol Plant Sci, Shanghai Inst Plant Physiol & Ecol, Key Lab Insect Dev & Evolutionary Biol, Shanghai, Peoples R China.							An CJ, 2010, INSECT BIOCHEM MOLEC, V40, P683, DOI 10.1016/j.ibmb.2010.07.001; Bania J, 1999, EUR J BIOCHEM, V262, P680, DOI 10.1046/j.1432-1327.1999.00406.x; Bao YY, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-507; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Cao XL, 2018, INSECT BIOCHEM MOLEC, V103, P53, DOI 10.1016/j.ibmb.2018.10.006; Cerenius L, 2010, ADV EXP MED BIOL, V708, P239; Chen RZ, 2016, ENVIRON ENTOMOL, V45, P207, DOI 10.1093/ee/nvv143; Chu Y, 2015, INSECT BIOCHEM MOLEC, V61, P53, DOI 10.1016/j.ibmb.2015.03.007; Cui L, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-016-3431-6; Edosa TT, 2020, INSECTS, V11, DOI 10.3390/insects11020105; EGUCHI M, 1994, J BIOCHEM-TOKYO, V115, P881, DOI 10.1093/oxfordjournals.jbchem.a124434; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gu QJ, 2019, J INSECT PHYSIOL, V116, P41, DOI 10.1016/j.jinsphys.2019.04.009; Guan RB, 2018, J BIOL CHEM, V293, P6011, DOI 10.1074/jbc.RA117.001553; Guo H, 2019, CHEMOSPHERE, V233, P796, DOI 10.1016/j.chemosphere.2019.06.025; Hua XT, 2018, J BIOL CHEM, V293, P11878, DOI 10.1074/jbc.RA117.000194; HUANG K, 1994, STRUCTURE, V2, P679, DOI 10.1016/S0969-2126(00)00068-X; Imler JL, 2014, DEV COMP IMMUNOL, V42, P3, DOI 10.1016/j.dci.2013.08.018; Ishii K, 2010, J BIOL CHEM, V285, P28635, DOI 10.1074/jbc.M110.138446; Jiang H, 2010, ADV EXP MED BIOL, V708, P181; Jiang WJ, 2020, INSECTS, V11, DOI 10.3390/insects11010036; Khorattanakulchai N, 2017, DEV COMP IMMUNOL, V77, P38, DOI 10.1016/j.dci.2017.07.016; Kurtz J, 2005, TRENDS IMMUNOL, V26, P186, DOI 10.1016/j.it.2005.02.001; Li B, 2017, GENE, V610, P64, DOI 10.1016/j.gene.2017.02.011; Li M, 2018, INSECT BIOCHEM MOLEC, V102, P21, DOI 10.1016/j.ibmb.2018.09.008; Li YS, 2016, PEPTIDES, V86, P13, DOI 10.1016/j.peptides.2016.09.013; Lin HL, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3583-z; Liu DR, 2015, DEV COMP IMMUNOL, V51, P22, DOI 10.1016/j.dci.2015.02.013; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Rosengren KJ, 2001, BIOCHEMISTRY-US, V40, P4601, DOI 10.1021/bi002623v; Shakeel M, 2020, EGYPT J BIOL PEST CO, V30, DOI 10.1186/s41938-020-0208-7; Shakeel M, 2019, ARCH INSECT BIOCHEM, V102, DOI 10.1002/arch.21556; Song GH, 2008, BIOCHEM BIOPH RES CO, V372, P191, DOI 10.1016/j.bbrc.2008.05.035; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tolstyko EA, 2021, BIOCHEMISTRY-MOSCOW+, V86, P1214, DOI 10.1134/S0006297921100059; Tong YR, 2005, J BIOL CHEM, V280, P14932, DOI 10.1074/jbc.M500532200; Wang XL, 2017, DEV COMP IMMUNOL, V69, P1, DOI 10.1016/j.dci.2016.11.022; Wang YB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018644; Xu LN, 2015, SCI REP-UK, V5, DOI 10.1038/srep15461; Xu Y, 2022, BIOLOGIA, V77, P261, DOI 10.1007/s11756-021-00931-6; Yang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16000-5; Zhang B, 2016, COMP BIOCHEM PHYS B, V192, P9, DOI 10.1016/j.cbpb.2015.11.004; Zhang SS, 2022, INSECT BIOCHEM MOLEC, V141, DOI 10.1016/j.ibmb.2021.103699; Zhang XL, 2021, INT J BIOL MACROMOL, V178, P63, DOI 10.1016/j.ijbiomac.2021.02.076	45	0	0	9	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								900129	10.3389/fimmu.2022.900129	http://dx.doi.org/10.3389/fimmu.2022.900129			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Q9VB	35651613	Green Published, gold			2022-12-18	WOS:000803027000001
J	Huang, J; Zhou, Q				Huang, Jing; Zhou, Qiong			Gene Biomarkers Related to Th17 Cells in Macular Edema of Diabetic Retinopathy: Cutting-Edge Comprehensive Bioinformatics Analysis and In Vivo Validation	FRONTIERS IN IMMUNOLOGY			English	Article						diabetic retinopathy; diabetic macular edema; Th17 cell; bioinformatic analysis; biomarker	RISK-FACTORS; RENAL-DISEASE; EXPRESSION; MIGRATION; ADHESION; NEOVASCULARIZATION; IDENTIFICATION; EPIDEMIOLOGY; NEPHROPATHY; PREVALENCE	BackgroundPrevious studies have shown that T-helper 17 (Th17) cell-related cytokines are significantly increased in the vitreous of proliferative diabetic retinopathy (PDR), suggesting that Th17 cells play an important role in the inflammatory response of diabetic retinopathy (DR), but its cell infiltration and gene correlation in the retina of DR, especially in diabetic macular edema (DME), have not been studied. MethodsThe dataset GSE160306 was downloaded from the Gene Expression Omnibus (GEO) database, which contains 9 NPDR samples and 10 DME samples. ImmuCellAI algorithm was used to estimate the abundance of Th17 cells in 24 kinds of infiltrating immune cells. The differentially expressed Th17 related genes (DETh17RGs) between NPDR and DME were documented by difference analysis and correlation analysis. Through aggregate analyses such as gene ontology (GO) and Kyoto Encyclopedia of Gene and Genome (KEGG) pathway enrichment analysis, a protein-protein interaction (PPI) network was constructed to analyze the potential function of DETh17RGs. CytoHubba plug-in algorithm, Lasso regression analysis and support vector machine recursive feature elimination (SVM-RFE) were implemented to comprehensively identify Hub DETh17RGs. The expression archetypes of Hub DETh17RGs were further verified in several other independent datasets related to DR. The Th17RG score was defined as the genetic characterization of six Hub DETh17RGs using the GSVA sample score method, which was used to distinguish early and advanced diabetic nephropathy (DN) as well as normal and diabetic nephropathy. Finally, real-time quantitative PCR (qPCR) was implemented to verify the transcription levels of Hub DETh17RGs in the STZ-induced DR model mice (C57BL/6J). Results238 DETh17RGs were identified, of which 212 genes were positively correlated while only 26 genes were negatively correlated. Six genes (CD44, CDC42, TIMP1, BMP7, RHOC, FLT1) were identified as Hub DETh17RGs. Because DR and DN have a strong correlation in clinical practice, the verification of multiple independent datasets related to DR and DN proved that Hub DETh17RGs can not only distinguish PDR patients from normal people, but also distinguish DN patients from normal people. It can also identify the initial and advanced stages of the two diseases (NPDR vs DME, Early DN vs Advanced DN). Except for CDC42 and TIMP1, the qPCR transcription levels and trends of other Hub DETh17RGs in STZ-induced DR model mice were consistent with the human transcriptome level in this study. ConclusionThis study will improve our understanding of Th17 cell-related molecular mechanisms in the progression of DME. At the same time, it also provides an updated basis for the molecular mechanism of Th17 cell crosstalk in the eye and kidney in diabetes.	[Huang, Jing; Zhou, Qiong] Nanchang Univ, Affiliated Hosp 1, Jiangxi Ctr Natl Ocular Dis Clin Res Ctr, Dept Ophthalmol, Nanchang, Peoples R China	Nanchang University	Zhou, Q (corresponding author), Nanchang Univ, Affiliated Hosp 1, Jiangxi Ctr Natl Ocular Dis Clin Res Ctr, Dept Ophthalmol, Nanchang, Peoples R China.	qiongzd06@126.com			Key research and development project in Jiangxi Province [20203BBG73058]; Central Government Guides Local Science and Technology Development Foundation [20211ZDG02003]	Key research and development project in Jiangxi Province; Central Government Guides Local Science and Technology Development Foundation	Funding This study was supported by the Key research and development project in Jiangxi Province, No. 20192BBGL70033; Key research and development project in Jiangxi Province, No. 20203BBG73058 and The Central Government Guides Local Science and Technology Development Foundation, No. 20211ZDG02003.	Abdel-Moneim A, 2018, BIOMED PHARMACOTHER, V101, P287, DOI 10.1016/j.biopha.2018.02.103; Abu El-Asrar AM, 2018, ACTA OPHTHALMOL, V96, pE27, DOI 10.1111/aos.13451; Ajoy MVK, 2011, INDIAN J OPHTHALMOL, V59, P207, DOI 10.4103/0301-4738.81029; Estua-Acosta GA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090979; Asadzadeh Z, 2017, CELL IMMUNOL, V322, P15, DOI 10.1016/j.cellimm.2017.10.015; Ashander LM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7945848; Bahrami B, 2017, ASIA-PAC J OPHTHALMO, V6, P535, DOI 10.22608/APO.2017350; Balaiya Sankarathi, 2017, Proteomics Insights, V8, p1178641816686078, DOI 10.1177/1178641816686078; Becker K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88698-3; Bek T, 2020, DIABETOLOGIA, V63, P2462, DOI 10.1007/s00125-020-05234-0; Benchoula K, 2021, ARCH BIOCHEM BIOPHYS, V698, DOI 10.1016/j.abb.2020.108743; Berezin A, 2019, DIABETES METAB SYND, V13, P3017, DOI 10.1016/j.dsx.2018.07.010; Bharadwaj AS, 2013, INVEST OPHTH VIS SCI, V54, P6917, DOI 10.1167/iovs.13-12058; Binet F, 2020, SCIENCE, V369, P934, DOI 10.1126/science.aay5356; Brockmann L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051033; Cao X, 2019, MED SCI MONITOR, V25, P6446, DOI 10.12659/MSM.915917; Cao YA, 2014, INVEST OPHTH VIS SCI, V55, P7321, DOI 10.1167/iovs.14-15167; Capone A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00348; Chen H, 2016, J INT MED RES, V44, P1403, DOI 10.1177/0300060516672369; Cho HY, 2020, CLIN EXP OPHTHALMOL, V48, P624, DOI 10.1111/ceo.13750; Choudhuri S, 2015, MOL CELL BIOCHEM, V405, P265, DOI 10.1007/s11010-015-2417-z; Conway EM, 2018, BLOOD COAGUL FIBRIN, V29, P243, DOI 10.1097/MBC.0000000000000720; Daruich A, 2018, PROG RETIN EYE RES, V63, P20, DOI 10.1016/j.preteyeres.2017.10.006; Diep TM, 2013, DIABETES RES CLIN PR, V100, P298, DOI 10.1016/j.diabres.2013.01.011; Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6; Elmasry K, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11040593; Eshaq RS, 2019, INVEST OPHTH VIS SCI, V60, P748, DOI 10.1167/iovs.18-25068; Everaert C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01617-3; Fan Y, 2019, DIABETES, V68, P2301, DOI 10.2337/db19-0204; Faselis C, 2020, CURR VASC PHARMACOL, V18, P117, DOI 10.2174/1570161117666190502103733; Forrester JV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583687; Gao BB, 2008, J PROTEOME RES, V7, P2516, DOI 10.1021/pr800112g; Guak H, 2020, IMMUNOLOGY, V161, P200, DOI 10.1111/imm.13260; Hanson S.R., 2020, BIOMATER SCI-UK, V4, P801, DOI DOI 10.1016/B978-0-12-816137-1.00052-0; He F, 2013, DIABETOLOGIA, V56, P457, DOI 10.1007/s00125-012-2796-6; Hoeppner LH, 2015, J CELL SCI, V128, P3556, DOI 10.1242/jcs.167601; Huang QY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010179; Ishikawa K, 2015, INVEST OPHTH VIS SCI, V56, P932, DOI 10.1167/iovs.14-15589; Jiang SM, 2019, OPHTHALMIC RES, V62, P68, DOI 10.1159/000500833; Jonas JB, 2019, FRONT DIABETES, V27, P20, DOI 10.1159/000486262; Kim Chang H., 2009, Inflammation & Allergy Drug Targets, V8, P221; Kitzing TM, 2010, ONCOGENE, V29, P2441, DOI 10.1038/onc.2009.515; Koo Nam Kyun, 2013, Korean J Ophthalmol, V27, P98, DOI 10.3341/kjo.2013.27.2.98; Lam JD, 2017, DIABETES, V66, P1950, DOI 10.2337/db16-1035; Li YP, 2019, INVEST OPHTH VIS SCI, V60, P4084, DOI 10.1167/iovs.19-26767; Lim RR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030899; Lin HT, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030509; Liu CY, 2021, IUBMB LIFE, V73, P1307, DOI 10.1002/iub.2544; Liu SL, 2016, EXP THER MED, V11, P257, DOI 10.3892/etm.2015.2877; Loukovaara S, 2015, J PROTEOME RES, V14, P5131, DOI 10.1021/acs.jproteome.5b00900; Lu JY, 2019, J DIABETES INVEST, V10, P753, DOI 10.1111/jdi.12957; Ma LL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2370-y; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Mizukawa B, 2017, BLOOD, V130, P1336, DOI 10.1182/blood-2016-12-758458; Nakagawa T, 2009, DIABETES, V58, P1471, DOI 10.2337/db09-0119; Nalbant A, 2019, J INTERF CYTOK RES, V39, P56, DOI 10.1089/jir.2018.0057; Volpe CMO, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0135-z; Olsen TW, 2020, OPHTHALMOLOGY, V127, pP66, DOI 10.1016/j.ophtha.2019.09.025; Park HC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220506; Park JH, 2016, EXP CLIN ENDOCR DIAB, V124, P557, DOI 10.1055/s-0042-101792; Paul S, 2020, J DIABETES COMPLICAT, V34, DOI 10.1016/j.jdiacomp.2020.107613; Perera N, 2020, ACS PHARMACOL TRANSL, V3, P11, DOI 10.1021/acsptsci.9b00064; Rafail S, 2015, J IMMUNOL, V194, P1285, DOI 10.4049/jimmunol.1402354; Raman R, 2012, J DIABETES COMPLICAT, V26, P123, DOI 10.1016/j.jdiacomp.2012.02.001; Ramos CJ, 2018, J BIOL CHEM, V293, P717, DOI 10.1074/jbc.M117.815381; Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011; Reddy PNG, 2016, BLOOD, V127, P1967, DOI 10.1182/blood-2016-01-693572; Sakimoto S, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89906; Sandquist Ivy, 2018, F1000Res, V7, P205, DOI 10.12688/f1000research.13020.1; Saucedo L, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/9811361; Schimmel Lilian, 2020, Small GTPases, V11, P225, DOI 10.1080/21541248.2017.1377815; Shabgah AG, 2014, POSTEP DERM ALERGOL, V31, P256, DOI 10.5114/pdia.2014.40954; Shi JS, 2018, CHINESE MED J-PEKING, V131, P2886, DOI 10.4103/0366-6999.246063; Shibuya M, 2015, ENDOCR METAB IMMUNE, V15, P135, DOI 10.2174/1871530315666150316121956; Song KH, 2019, J DIABETES INVEST, V10, P745, DOI 10.1111/jdi.12953; Taguchi M, 2020, EXP EYE RES, V198, DOI 10.1016/j.exer.2020.108155; Takeuchi M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178230; Takeuchi M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137358; Temkar S, 2018, INT OPHTHALMOL, V38, P1043, DOI 10.1007/s10792-017-0557-8; Thomas RL, 2019, DIABETES RES CLIN PR, V157, DOI 10.1016/j.diabres.2019.107840; Uemura A, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100954; Van Geest RJ, 2013, J CELL COMMUN SIGNAL, V7, P1, DOI 10.1007/s12079-012-0178-y; Wang LZY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03076; Wolf G, 2007, CLIN NEPHROL, V68, P81; Wong TY, 2020, OPHTHALMOLOGICA, V243, P9, DOI 10.1159/000502387; Woroniecka KI, 2011, DIABETES, V60, P2354, DOI 10.2337/db10-1181; Yao X, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96438-w; Yasuda K, 2019, SEMIN IMMUNOPATHOL, V41, P283, DOI 10.1007/s00281-019-00733-8; Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909; You JX, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.923146; Zhang J, 2015, CELL SIGNAL, V27, P1703, DOI 10.1016/j.cellsig.2015.05.009; Zhang JL, 2018, RENAL FAILURE, V40, P243, DOI 10.1080/0886022X.2018.1456453; Zhao LJ, 2020, ENDOCR PRACT, V26, P429, DOI 10.4158/EP-2019-0512; Zhao ZY, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15166; Zheng YF, 2012, INDIAN J OPHTHALMOL, V60, P428, DOI 10.4103/0301-4738.100542; Zhou T, 2021, GLIA, V69, P2644, DOI 10.1002/glia.24063	96	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								858972	10.3389/fimmu.2022.858972	http://dx.doi.org/10.3389/fimmu.2022.858972			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Q9VQ	35651615	gold, Green Published			2022-12-18	WOS:000803028500001
J	Jin, Z; Dong, YT; Liu, S; Liu, J; Qiu, XR; Zhang, Y; Zong, H; Hou, WT; Guo, SY; Sun, YF; Chen, SM; Dong, HQ; Li, YY; An, MM; Shen, H				Jin, Zhao; Dong, Yi-Ting; Liu, Shuang; Liu, Jie; Qiu, Xi-Ran; Zhang, Yu; Zong, Hui; Hou, Wei-Tong; Guo, Shi-Yu; Sun, Yu-Fang; Chen, Si-Min; Dong, Hai-Qing; Li, Yong-Yong; An, Mao-Mao; Shen, Hui			Potential of Polyethyleneimine as an Adjuvant To Prepare Long-Term and Potent Antifungal Nanovaccine	FRONTIERS IN IMMUNOLOGY			English	Article						polyethylenimine; nanoparticles; fungal infections; long-lived plasma cell; long-term protection	SODIUM DODECYL-SULFATE; RECOMBINANT ANTIBODIES; SEROLOGICAL RESPONSE; VACCINE; CELL; SDS; POLYSACCHARIDE; ENHANCEMENT; PROTECTION; EFFECTOR	BackgroundCandida albicans infections are particularly prevalent in immunocompromised patients. Even with appropriate treatment with current antifungal drugs, the mortality rate of invasive candidiasis remains high. Many positive results have been achieved in the current vaccine development. There are also issues such as the vaccine's protective effect is not persistent. Considering the functionality and cost of the vaccine, it is important to develop safe and efficient new vaccines with long-term effects. In this paper, an antifungal nanovaccine with Polyethyleneimine (PEI) as adjuvant was constructed, which could elicit more effective and long-term immunity via stimulating B cells to differentiate into long-lived plasma cells. Materials and MethodsHsp90-CTD is an important target for protective antibodies during disseminated candidiasis. Hsp90-CTD was used as the antigen, then introduced SDS to "charge" the protein and added PEI to form the nanovaccine. Dynamic light scattering and transmission electron microscope were conducted to identify the size distribution, zeta potential, and morphology of nanovaccine. The antibody titers in mice immunized with the nanovaccine were measured by ELISA. The activation and maturation of long-lived plasma cells in bone marrow by nanovaccine were also investigated via flow cytometry. Finally, the kidney of mice infected with Candida albicans was stained with H&E and PAS to evaluate the protective effect of antibody in serum produced by immunized mice. ResultsNanoparticles (NP) formed by Hsp90-CTD and PEI are small, uniform, and stable. NP had an average size of 116.2 nm with a PDI of 0.13. After immunizing mice with the nanovaccine, it was found that the nano-group produced antibodies faster and for a longer time. After 12 months of immunization, mice still had high and low levels of antibodies in their bodies. Results showed that the nanovaccine could promote the differentiation of B cells into long-lived plasma cells and maintain the long-term existence of antibodies in vivo. After immunization, the antibodies in mice could protect the mice infected by C. albicans. ConclusionAs an adjuvant, PEI can promote the differentiation of B cells into long-lived plasma cells to maintain long-term antibodies in vivo. This strategy can be adapted for the future design of vaccines.	[Jin, Zhao; Dong, Yi-Ting; Liu, Shuang; Liu, Jie; Qiu, Xi-Ran; Zhang, Yu; Zong, Hui; Hou, Wei-Tong; Guo, Shi-Yu; Sun, Yu-Fang; Chen, Si-Min; Dong, Hai-Qing; Li, Yong-Yong; An, Mao-Mao] Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Pharmacol, Shanghai, Peoples R China; [Shen, Hui] Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai, Peoples R China	Tongji University; Tongji University	Li, YY; An, MM (corresponding author), Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Pharmacol, Shanghai, Peoples R China.; Shen, H (corresponding author), Tongji Univ Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai, Peoples R China.				National Key Research and Development Program of China [2021YFC2300400]; Shanghai Natural Science Foundation [20ZR1459500]; National Natural Science Foundation of China [82173864, 81601745, 81671989]	National Key Research and Development Program of China; Shanghai Natural Science Foundation(Natural Science Foundation of Shanghai); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by he National Key Research and Development Program of China (2021YFC2300400), the Shanghai Natural Science Foundation (20ZR1459500) and the National Natural Science Foundation of China (82173864, 81601745, 81671989).	Bar E, 2012, J IMMUNOL, V188, P5636, DOI 10.4049/jimmunol.1200594; Bonin CRB, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03845-3; Billig EMW, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-64; Bouassida M, 2018, ENG LIFE SCI, V18, P70, DOI 10.1002/elsc.201700152; Brynjolfsson SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02673; Burnie J, 2004, EXPERT OPIN BIOL TH, V4, P233, DOI 10.1517/14712598.4.2.233; Burnie J, 2003, DRUG NEWS PERSPECT, V16, P205, DOI 10.1358/dnp.2003.16.4.829331; Canete PF, 2019, J EXP MED, V216, P1843, DOI 10.1084/jem.20190493; Cassone A, 2015, BJOG-INT J OBSTET GY, V122, P785, DOI 10.1111/1471-0528.12994; Chin VK, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101643; Dong X, 2018, ACS APPL MATER INTER, V10, P21861, DOI 10.1021/acsami.8b04867; Edwards JE, 2012, J MED MICROBIOL, V61, P895, DOI 10.1099/jmm.0.041665-0; Fu Y, 2002, MOL MICROBIOL, V44, P61, DOI 10.1046/j.1365-2958.2002.02873.x; Giancola C, 1997, INT J BIOL MACROMOL, V20, P193, DOI 10.1016/S0141-8130(97)01159-8; Grant EV, 2012, EUR J IMMUNOL, V42, P2937, DOI 10.1002/eji.201242410; Hendricks DW, 2011, BLOOD, V117, P1239, DOI 10.1182/blood-2010-07-299263; Herrera E, 2000, EMBO J, V19, P472, DOI 10.1093/emboj/19.3.472; Jangalwe S, 2016, IMMUN INFLAMM DIS, V4, P427, DOI 10.1002/iid3.124; Kachuk C, 2018, J PROTEOMICS, V175, P75, DOI 10.1016/j.jprot.2017.03.002; Kaspersen JD, 2017, BIOPHYS J, V112, P1609, DOI 10.1016/j.bpj.2017.03.013; Kotsmar C, 2009, ADV COLLOID INTERFAC, V150, P41, DOI 10.1016/j.cis.2009.05.002; Ling HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035688; Liu RY, 2012, ACTA CRYSTALLOGR D, V68, P497, DOI 10.1107/S0907444912002740; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; Martin-Manso G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048775; MATTHEWS R, 1989, FEMS MICROBIOL LETT, V60, P25, DOI 10.1016/0378-1097(89)90071-2; Matthews RC, 2004, VACCINE, V22, P865, DOI 10.1016/j.vaccine.2003.11.032; MATTHEWS RC, 1987, J CLIN MICROBIOL, V25, P230, DOI 10.1128/JCM.25.2.230-237.1987; MATTHEWS RC, 1984, LANCET, V2, P1415; Moura APV, 2017, ACS CENTRAL SCI, V3, P1026, DOI 10.1021/acscentsci.7b00311; Naglik J, 2004, CELL MICROBIOL, V6, P915, DOI 10.1111/j.1462-5822.2004.00439.x; Negandaripour M, 2017, BIOTECHNOL ADV, V35, P575, DOI 10.1016/j.biotechadv.2017.05.002; Ooi JD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11255-0; Quemeneur L, 2008, BLOOD, V111, P2714, DOI 10.1182/blood-2007-07-102822; Ramani K, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98241; Randez-Gil F, 1998, MOL CELL BIOL, V18, P2940, DOI 10.1128/MCB.18.5.2940; Rydyznski C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7375; Saville SP, 2008, INFECT IMMUN, V76, P97, DOI 10.1128/IAI.00982-07; Shen C, 2017, INT J NANOMED, V12, P5443, DOI 10.2147/IJN.S137980; Sheppard DC, 2004, J BIOL CHEM, V279, P30480, DOI 10.1074/jbc.M401929200; Slifka MK, 2014, VACCINE, V32, P2948, DOI 10.1016/j.vaccine.2014.03.078; Su QP, 2010, DIAGN MICR INFEC DIS, V68, P382, DOI 10.1016/j.diagmicrobio.2010.07.009; Sumiyoshi M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74749-8; Takatsuka S, 2018, NAT IMMUNOL, V19, P1025, DOI 10.1038/s41590-018-0177-0; Thomas DP, 2006, PROTEOMICS, V6, P6033, DOI 10.1002/pmic.200600321; Travassos LR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00224; Tsai DY, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0558-1; Tso GHW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00897; Vaughan AM, 2012, CURR OPIN IMMUNOL, V24, P324, DOI 10.1016/j.coi.2012.03.009; Wang XJ, 2015, VIRULENCE, V6, P309, DOI 10.4161/21505594.2014.983015; Wang YC, 2014, HUM VACC IMMUNOTHER, V10, P1057, DOI 10.4161/hv.27714; Wang YH, 2008, J CLIN INVEST, V118, P2896, DOI 10.1172/JCI35618; Waninge R, 1998, INT DAIRY J, V8, P141, DOI 10.1016/S0958-6946(98)00031-4; Wegmann F, 2012, NAT BIOTECHNOL, V30, P883, DOI 10.1038/nbt.2344; Xin H, 2008, P NATL ACAD SCI USA, V105, P13526, DOI 10.1073/pnas.0803195105; Yang F, 2016, CARBOHYD POLYM, V145, P48, DOI 10.1016/j.carbpol.2016.03.024; Yang HM, 2014, CARBOHYD POLYM, V109, P77, DOI 10.1016/j.carbpol.2014.03.054	57	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								843684	10.3389/fimmu.2022.843684	http://dx.doi.org/10.3389/fimmu.2022.843684			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1R8FJ	35651617	Green Published, gold			2022-12-18	WOS:000803599400001
J	Oudinet, C; Zhang, XF; Puget, N; Kyritsis, N; Leduc, C; Braikia, FZ; Dauba, A; Alt, FW; Khamlichi, AA				Oudinet, Chloe; Zhang, Xuefei; Puget, Nadine; Kyritsis, Nia; Leduc, Claire; Braikia, Fatima-Zohra; Dauba, Audrey; Alt, Frederick W.; Khamlichi, Ahmed Amine			Switch Tandem Repeats Influence the Choice of the Alternative End-Joining Pathway in Immunoglobulin Class Switch Recombination	FRONTIERS IN IMMUNOLOGY			English	Article						B lymphocyte; class switch recombination; switch sequence; alternative end-joining; enhancer	IGH CLASS SWITCH; CYTIDINE DEAMINASE AID; DOUBLE-STRAND BREAKS; REGION RECOMBINATION; SOMATIC HYPERMUTATION; DNA RESECTION; ACTIVATION; REPAIR; MU; MECHANISM	Immunoglobulin class switch recombination (CSR) plays an important role in humoral imm\une responses by changing the effector functions of antibodies. CSR occurs between highly repetitive switch (S) sequences located upstream of immunoglobulin constant gene exons. Switch sequences differ in size, the nature of their repeats, and the density of the motifs targeted by the activation-induced cytidine deaminase (AID), the enzyme that initiates CSR. CSR involves double-strand breaks (DSBs) at the universal S mu donor region and one of the acceptor S regions. The DSBs ends are fused by the classical non-homologous end-joining (C-NHEJ) and the alternative-NHEJ (A-NHEJ) pathways. Of the two pathways, the A-NHEJ displays a bias towards longer junctional micro-homologies (MHs). The S mu region displays features that distinguish it from other S regions, but the molecular basis of S mu specificity is ill-understood. We used a mouse line in which the downstream S gamma 3 region was put under the control of the E mu enhancer, which regulates S mu, and analyzed its recombination activity by CSR-HTGTS. Here, we show that provision of E mu enhancer to S gamma 3 is sufficient to confer the recombinational features of S mu to S gamma 3, including efficient AID recruitment, enhanced internal deletions and robust donor function in CSR. Moreover, junctions involving S gamma 3 display a bias for longer MH irrespective of sequence homology with switch acceptor sites. The data suggest that the propensity for increased MH usage is an intrinsic property of S gamma 3 sequence, and that the tandem repeats of the donor site influence the choice of the A-NHEJ.	[Oudinet, Chloe; Puget, Nadine; Leduc, Claire; Braikia, Fatima-Zohra; Dauba, Audrey; Khamlichi, Ahmed Amine] Univ Toulouse, Univ Paul Sabatier, Inst Pharmacol & Biol Struct, IPBS,CNRS, Toulouse, France; [Zhang, Xuefei; Kyritsis, Nia; Alt, Frederick W.] Boston Childrens Hosp, Howard Hughes Med Inst, Harvard Med Sch, Dept Genet,Program Cellular & Mol Med, Boston, MA USA; [Puget, Nadine] Univ Toulouse, Univ Paul Sabatier UPS, Ctr Biol Integrat CBI, Unite Biol Mol Cellulaire & Dev MCD, Toulouse, France; [Zhang, Xuefei] Peking Univ, Biomed Pioneering Innovat Ctr, Innovat Ctr Genom, Beijing, Peoples R China	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Peking University	Khamlichi, AA (corresponding author), Univ Toulouse, Univ Paul Sabatier, Inst Pharmacol & Biol Struct, IPBS,CNRS, Toulouse, France.	ahmed.khamlichi@ipbs.fr			Agence Nationale de la Recherche [ANR-21-CE15-0019]; Institut National du Cancer [INCA_9363, PLBIO15-134]; Fondation ARC pour la Recherche sur le Cancer [PJA 20191209515]; Ligue Contre le Cancer; Fondation pour la Recherche Medicale; ITMO Cancer Aviesan (National Alliance for Life Science and Health)	Agence Nationale de la Recherche(French National Research Agency (ANR)); Institut National du Cancer(Institut National du Cancer (INCA) France); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); ITMO Cancer Aviesan (National Alliance for Life Science and Health)	This work was supported by the Agence Nationale de la Recherche [ANR-21-CE15-0019], the Institut National du Cancer [INCA_9363, PLBIO15-134], the Fondation ARC pour la Recherche sur le Cancer [PJA 20191209515], the Ligue Contre le Cancer (Ligue Regionale : comites de lEx Region Midi-Pyrenees). FA is an investigator of the Howard Hughes Medical Institute. CO was a fellow of the Ministry of Higher Education & Research and recipient of a fellowship from the "Fondation pour la Recherche Medicale". TRI- IPBS has the financial support of ITMO Cancer Aviesan (National Alliance for Life Science and Health) within the framework of Cancer Plan.	ALT FW, 1982, NATURE, V296, P325, DOI 10.1038/296325a0; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Boboila C, 2012, ADV IMMUNOL, V116, P1, DOI 10.1016/B978-0-12-394300-2.00001-6; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Boboila C, 2010, J EXP MED, V207, P417, DOI 10.1084/jem.20092449; Bothmer A, 2010, J EXP MED, V207, P855, DOI 10.1084/jem.20100244; Braikia FZ, 2017, P NATL ACAD SCI USA, V114, P6092, DOI 10.1073/pnas.1701631114; Casellas R, 1998, EMBO J, V17, P2404, DOI 10.1093/emboj/17.8.2404; Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Cortizas EM, 2013, J IMMUNOL, V191, P5751, DOI 10.4049/jimmunol.1301300; Crowe JL, 2018, P NATL ACAD SCI USA, V115, P8615, DOI 10.1073/pnas.1808490115; Dempsey LA, 1999, J BIOL CHEM, V274, P1066, DOI 10.1074/jbc.274.2.1066; Deriano L, 2013, ANNU REV GENET, V47, P433, DOI 10.1146/annurev-genet-110711-155540; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Di Virgilio M, 2013, SCIENCE, V339, P711, DOI 10.1126/science.1230624; Dong JC, 2015, NATURE, V525, P134, DOI 10.1038/nature14970; Dudley DD, 2002, P NATL ACAD SCI USA, V99, P9984, DOI 10.1073/pnas.152333499; DUNNICK W, 1993, NUCLEIC ACIDS RES, V21, P365, DOI 10.1093/nar/21.3.365; Feng YQ, 2020, TRENDS IMMUNOL, V41, P586, DOI 10.1016/j.it.2020.04.009; Franco S, 2008, J EXP MED, V205, P557, DOI 10.1084/jem.20080044; Hackney JA, 2009, ADV IMMUNOL, V101, P163, DOI 10.1016/S0065-2776(08)01005-5; Han L, 2011, P NATL ACAD SCI USA, V108, P11584, DOI 10.1073/pnas.1018726108; Hu JZ, 2016, NAT PROTOC, V11, P853, DOI 10.1038/nprot.2016.043; Jung D, 2006, ANNU REV IMMUNOL, V24, P541, DOI 10.1146/annurev.immunol.23.021704.115830; Khamlichi AA, 2018, TRENDS GENET, V34, P954, DOI 10.1016/j.tig.2018.08.005; Laffleur B, 2021, NAT GENET, V53, P230, DOI 10.1038/s41588-020-00772-0; Larson ED, 2005, CURR BIOL, V15, P470, DOI 10.1016/j.cub.2004.12.077; LI SC, 1994, INT IMMUNOL, V6, P491, DOI 10.1093/intimm/6.4.491; Ling AK, 2018, P NATL ACAD SCI USA, V115, P2800, DOI 10.1073/pnas.1720962115; Lumsden JM, 2004, J EXP MED, V200, P1111, DOI 10.1084/jem.20041074; MANDLER R, 1993, J IMMUNOL, V150, P407; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Oudinet C, 2020, ADV IMMUNOL, V147, P89, DOI 10.1016/bs.ai.2020.06.003; Pan Q, 1998, J IMMUNOL, V161, P3520; Pan Q, 2002, EUR J IMMUNOL, V32, P1300, DOI 10.1002/1521-4141(200205)32:5<1300::AID-IMMU1300>3.0.CO;2-L; Pan-Hammarstrom Q, 2005, J EXP MED, V201, P189, DOI 10.1084/jem.20040772; Panchaksharia RA, 2018, P NATL ACAD SCI USA, V115, P762, DOI 10.1073/pnas.1719988115; Pinaud E, 2011, ADV IMMUNOL, V110, P27, DOI 10.1016/B978-0-12-387663-8.00002-8; Puget N, 2015, MOL CELL BIOL, V35, P2231, DOI 10.1128/MCB.00294-15; Rajagopal D, 2009, J EXP MED, V206, P1237, DOI 10.1084/jem.20082514; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reina-San-Martin B, 2003, J EXP MED, V197, P1767, DOI 10.1084/jem.20030569; Reina-San-Martin B, 2007, EUR J IMMUNOL, V37, P235, DOI 10.1002/eji.200636789; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; Shinkura R, 2003, NAT IMMUNOL, V4, P435, DOI 10.1038/ni918; Shukla V, 2020, MOL CELL, V77, P384, DOI 10.1016/j.molcel.2019.10.031; So CC, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008101; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Stavnezer J, 2010, ADV IMMUNOL, V108, P45, DOI 10.1016/S0065-2776(10)08003_X; Vaidyanathan B, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00405; Wang XS, 2020, P NATL ACAD SCI USA, V117, P25700, DOI 10.1073/pnas.2010972117; Wesemann DR, 2011, J EXP MED, V208, P2733, DOI 10.1084/jem.20111155; Wu YL, 2017, J EXP MED, V214, P183, DOI 10.1084/jem.20161056; Wuerffe R, 2007, IMMUNITY, V27, P711, DOI 10.1016/j.immuni.2007.09.007; Yan CT, 2007, NATURE, V449, P478, DOI 10.1038/nature06020; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829; Yu KF, 2019, CRIT REV BIOCHEM MOL, V54, P333, DOI 10.1080/10409238.2019.1659227; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; Zan H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14244; Zarrin AA, 2005, P NATL ACAD SCI USA, V102, P2466, DOI 10.1073/pnas.0409847102; Zarrin AA, 2004, NAT IMMUNOL, V5, P1275, DOI 10.1038/ni1137; Zhang TT, 2010, P NATL ACAD SCI USA, V107, P3040, DOI 10.1073/pnas.0915072107; Zhang XF, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024392118; Zhang XF, 2019, NATURE, V575, P385, DOI 10.1038/s41586-019-1723-0	67	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								870933	10.3389/fimmu.2022.870933	http://dx.doi.org/10.3389/fimmu.2022.870933			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T2MF	35651614	gold, Green Published			2022-12-18	WOS:000804568800001
J	Patil, NK; Bohannon, JK; Vachharajani, V; McCall, CE				Patil, Naeem K.; Bohannon, Julia K.; Vachharajani, Vidula; McCall, Charles E.			Editorial: The Roles of Mitochondria in Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mitochondria; immunity; TCA cycle; itaconate; oxidative stress; inflammation	SUCCINATE-DEHYDROGENASE; OXIDATIVE STRESS; ITACONATE; TAURINE; METABOLITE; PATHWAY; GENE-1		[Patil, Naeem K.; Bohannon, Julia K.] Vanderbilt Univ Sch Med, Dept Anesthesiol, Nashville, TN USA; [Bohannon, Julia K.] Vanderbilt Univ Sch Med, Dept Pathol Microbiol & Immunol, Nashville, TN USA; [Vachharajani, Vidula] Clin Lerner Coll Med Case Western Reserve Univ, Dept Crit Care Med & Inflammat & Immun, Cleveland, OH USA; [McCall, Charles E.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27101 USA	Vanderbilt University; Vanderbilt University; Wake Forest University	McCall, CE (corresponding author), Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC 27101 USA.	chmccall@wakehealth.edu			NIH [5R35 GM126922, 5R35 GM141927]; NIAAA [5R35 GM126922]; NIGMS [5R35 GM126922]; Vanderbilt Faculty Research Scholars Award; Shock Society Faculty Research Award;  [R01AA028763];  [R01GM099807]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAAA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Vanderbilt Faculty Research Scholars Award; Shock Society Faculty Research Award; ; 	CM is supported by NIH 5R35 GM126922, VV is supported by R01AA028763 (NIAAA) and R01GM099807 (NIGMS), JB is supported by NIH 5R35 GM141927, and NP was supported by Vanderbilt Faculty Research Scholars Award and the Shock Society Faculty Research Award.	Carre J, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0291-8; Chen MX, 2020, SCIENCE, V369, P450, DOI 10.1126/science.aaz1333; Cordes T, 2016, J BIOL CHEM, V291, P14274, DOI 10.1074/jbc.M115.685792; Dominguez-Gutierrez PR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01863; Feichtinger RG, 2017, AM J HUM GENET, V101, P525, DOI 10.1016/j.ajhg.2017.08.015; Galley HF, 2011, BRIT J ANAESTH, V107, P57, DOI 10.1093/bja/aer093; Hooftman A, 2020, CELL METAB, V32, P468, DOI 10.1016/j.cmet.2020.07.016; Idelchik MDS, 2017, SEMIN CANCER BIOL, V47, P57, DOI 10.1016/j.semcancer.2017.04.005; Jha AK, 2015, IMMUNITY, V42, P419, DOI 10.1016/j.immuni.2015.02.005; Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68; Kumar P., 2018, FRONT IMMUNOL, V12, DOI [10.3389/fimmu.2018.01863, DOI 10.3389/FIMMU.2018.01863]; Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004; Li XB, 2017, P NATL ACAD SCI USA, V114, pE9655, DOI 10.1073/pnas.1712465114; Luan HH, 2016, CELL METAB, V24, P379, DOI 10.1016/j.cmet.2016.08.013; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; McBride MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01043; Michelucci A, 2013, P NATL ACAD SCI USA, V110, P7820, DOI 10.1073/pnas.1218599110; Mills E, 2014, TRENDS CELL BIOL, V24, P313, DOI 10.1016/j.tcb.2013.11.008; Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986; Missiroli S, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030740; Ohama T, 2010, J BIOL CHEM, V285, P8711, DOI 10.1074/jbc.M109.099788; Patil NK, 2014, AM J PHYSIOL-RENAL, V306, pF734, DOI 10.1152/ajprenal.00643.2013; Pizzino G, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8416763; Rashid K, 2013, FOOD CHEM TOXICOL, V51, P317, DOI 10.1016/j.fct.2012.10.007; Schaffer S, 2018, BIOMOL THER, V26, P225, DOI 10.4062/biomolther.2017.251; Schwaderer AL, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.11.73; Schwartz L, 2008, AM J PHYSIOL-GASTR L, V295, pG934, DOI 10.1152/ajpgi.90296.2008; Sharifi-Rad M, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00694; Suliman HB, 2016, PHARMACOL REV, V68, P20, DOI 10.1124/pr.115.011502; Swain A, 2020, NAT METAB, V2, P594, DOI 10.1038/s42255-020-0210-0; Tan YX, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01959-x; Williams J, 2016, UROLOGY, V93, DOI 10.1016/j.urology.2016.03.004; Williams NC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00141; Yan MZ, 2018, REDOX BIOL, V17, P274, DOI 10.1016/j.redox.2018.04.019; Zhu XW, 2019, J LEUKOCYTE BIOL, V105, P215, DOI 10.1002/JLB.3HI0918-373R	36	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								914639	10.3389/fimmu.2022.914639	http://dx.doi.org/10.3389/fimmu.2022.914639			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U8FU	35651600	Green Published, gold			2022-12-18	WOS:000805642300001
J	Pieren, DKJ; Smits, NAM; Postel, RJ; Kandiah, V; de Wit, J; van Beek, J; van Baarle, D; Guichelaar, T				Pieren, Daan K. J.; Smits, Noortje A. M.; Postel, Rimke J.; Kandiah, Vinitha; de Wit, Jelle; van Beek, Josine; van Baarle, Debbie; Guichelaar, Teun			Co-Expression of TIGIT and Helios Marks Immunosenescent CD8(+) T Cells During Aging	FRONTIERS IN IMMUNOLOGY			English	Article						CD8+T cells; aging; TIGIT; Helios; influenza; immunosenescence; CD28; CD27	INFLUENZA; VIRUS; LYMPHOCYTES; ACTIVATION; EXHAUSTION; EXPRESSION; PROTECTION; ANTITUMOR; IMMUNITY	Aging leads to alterations in the immune system that result in ineffective responsiveness against pathogens. Features of this process, collectively known as immunosenescence, accumulate in CD8(+) T cells with age and have been ascribed to differentiation of these cells during the course of life. Here we aimed to identify novel markers in CD8(+) T cells associated with immunosenescence. Furthermore, we assessed how these markers relate to the aging-related accumulation of highly differentiated CD27(-)CD28(-) cells. We found that co-expression of the transcription factor Helios and the aging-related marker TIGIT identifies CD8(+) T cells that fail to proliferate and show impaired induction of activation markers CD69 and CD25 in response to stimulation in vitro. Despite this, in blood of older adults we found TIGIT(+)Helios(+) T cells to become highly activated during an influenza-A virus infection, but these higher frequencies of activated TIGIT(+)Helios(+) T cells associate with longer duration of coughing. Moreover, in healthy individuals, we found that TIGIT(+)Helios(+) CD8(+) T cells accumulate with age in the highly differentiated CD27(-)CD28(-) population. Interestingly, TIGIT(+)Helios(+) CD8(+) T cells also accumulate with age among the less differentiated CD27(+)CD28(-) T cells before their transit into the highly differentiated CD27(-)CD28(-) stage. This finding suggests that T cells with immunosenescent features become prominent at old age also within the earlier differentiation states of these cells. Our findings show that co-expression of TIGIT and Helios refines the definition of immunosenescent CD8(+) T cells and challenge the current dogma of late differentiation stage as proxy for T-cell immunosenescence.	[Pieren, Daan K. J.; Smits, Noortje A. M.; Postel, Rimke J.; Kandiah, Vinitha; de Wit, Jelle; van Beek, Josine; van Baarle, Debbie; Guichelaar, Teun] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands; [van Baarle, Debbie] Univ Utrecht, Univ Med Ctr Utrecht, Ctr Translat Immunol, Utrecht, Netherlands; [Pieren, Daan K. J.] Vall Hebron Res Inst VHIR, Infect Dis Dept, Barcelona, Spain; [van Baarle, Debbie] Univ Med Ctr Groningen, Dept Med Microbiol & Infect Prevent, Groningen, Netherlands	Netherlands National Institute for Public Health & the Environment; Utrecht University; Utrecht University Medical Center; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); University of Groningen	Guichelaar, T (corresponding author), Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, Bilthoven, Netherlands.	Teun.guichelaar@rivm.nl	Guichelaar, Teun/AEQ-7065-2022	Guichelaar, Teun/0000-0002-5112-8923; Pieren, Daan/0000-0003-0461-5064	Dutch Ministry of Health, Welfare and Sport	Dutch Ministry of Health, Welfare and Sport	This study was supported by the Dutch Ministry of Health, Welfare and Sport.	Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Beltra JC, 2016, P NATL ACAD SCI USA, V113, pE5444, DOI 10.1073/pnas.1604256113; Bengsch B, 2018, IMMUNITY, V48, P1029, DOI 10.1016/j.immuni.2018.04.026; Bin Dhuban K, 2015, J IMMUNOL, V194, P3687, DOI 10.4049/jimmunol.1401803; Chew GM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005349; Dennett NS, 2002, EXP GERONTOL, V37, P271, DOI 10.1016/S0531-5565(01)00193-0; Fuhrman CA, 2015, J IMMUNOL, V195, P145, DOI 10.4049/jimmunol.1402381; GOTCH F, 1987, NATURE, V326, P881, DOI 10.1038/326881a0; Guillerey C, 2018, BLOOD, V132, P1689, DOI 10.1182/blood-2018-01-825265; Henson SM, 2015, EUR J IMMUNOL, V45, P1441, DOI 10.1002/eji.201445312; Henson SM, 2014, J CLIN INVEST, V124, P4004, DOI 10.1172/JCI75051; Henson SM, 2012, IMMUNOLOGY, V135, P355, DOI 10.1111/j.1365-2567.2011.03550.x; Henson SM, 2009, BLOOD, V113, P6619, DOI 10.1182/blood-2009-01-199588; Hijano DR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220908; Huber SKR, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03103; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Kaaijk P, 2022, VIRUSES-BASEL, V14, DOI 10.3390/v14040797; Khan N, 2002, J IMMUNOL, V169, P1984, DOI 10.4049/jimmunol.169.4.1984; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Kong YX, 2016, CLIN CANCER RES, V22, P3057, DOI 10.1158/1078-0432.CCR-15-2626; Lio D, 1996, MECH AGEING DEV, V89, P51, DOI 10.1016/0047-6374(96)01726-5; Machicote A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02788; MCMICHAEL AJ, 1983, NEW ENGL J MED, V309, P13, DOI 10.1056/NEJM198307073090103; Ng TP, 2015, NPJ AGING MECH DIS, V1, DOI 10.1038/npjamd.2015.5; Nikolich-Zugich J, 2018, NAT IMMUNOL, V19, P10, DOI 10.1038/s41590-017-0006-x; Pel J.Z.S., 1965, HUISARTS WETENSCHAP, V86, P321; Pieren DKJ, 2021, AGING CELL, V20, DOI 10.1111/acel.13372; Pieren DKJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42120-1; Plunkett FJ, 2007, J IMMUNOL, V178, P7710, DOI 10.4049/jimmunol.178.12.7710; Schindowski K, 2002, MECH AGEING DEV, V123, P375, DOI 10.1016/S0047-6374(01)00396-7; Schmidt ME, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00678; Schorer M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15025-1; Slutter B, 2013, IMMUNITY, V39, P939, DOI 10.1016/j.immuni.2013.09.013; Song YZ, 2018, AGING CELL, V17, DOI 10.1111/acel.12716; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; St Paul M, 2020, TRENDS CELL BIOL, V30, P695, DOI 10.1016/j.tcb.2020.06.003; Suzuki J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05854-6; Tarazona R, 2000, MECH AGEING DEV, V121, P77; Tcherniaeva I, 2018, J IMMUNOL METHODS, V462, P1, DOI 10.1016/j.jim.2018.07.003; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; van Beek J, 2017, J INFECT DIS, V216, P415, DOI 10.1093/infdis/jix268; van den Berg SPH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00082; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Weng NP, 2009, TRENDS IMMUNOL, V30, P306, DOI 10.1016/j.it.2009.03.013; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	48	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								833531	10.3389/fimmu.2022.833531	http://dx.doi.org/10.3389/fimmu.2022.833531			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S6YF	35651622	gold, Green Published			2022-12-18	WOS:000804194000001
J	Sadeghirad, H; Monkman, J; Mehdi, AM; Ladwa, R; O'Byrne, K; Hughes, BGM; Kulasinghe, A				Sadeghirad, Habib; Monkman, James; Mehdi, Ahmed M.; Ladwa, Rahul; O'Byrne, Ken; Hughes, Brett G. M.; Kulasinghe, Arutha			Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas	FRONTIERS IN IMMUNOLOGY			English	Article						oropharangeal cancer; spatial proteomics; head and neck cancer; metastasis; lymph node metastasis; digital spatial profiling	HEAD; CANCER; BREAKS	Head and neck squamous cell carcinoma (HNSCC) often presents with locoregional or distant disease, despite multimodal therapeutic approaches, which include surgical resection, chemoradiotherapy, and more recently, immunotherapy for metastatic or recurrent HNSCC. Therapies often target the primary and nodal regional HNSCC sites, and their efficacy at controlling occult distant sites remains poor. While our understanding of the tumor microenvironment conducive to effective therapies is increasing, the biology underpinning locoregional sites remains unclear. Here, we applied targeted spatial proteomic approaches to primary and lymph node metastasis from an oropharyngeal SCC (OPSCC) cohort to understand the expression of proteins within tumors, and stromal compartments of the respective sites in samples of both matched and unmatched patients. In unmatched analyses of n = 43 primary and 11 nodal metastases, our data indicated that tumor cells in nodal metastases had higher levels of Ki-67, PARP, BAD, and cleaved caspase 9, suggesting a role for increased proliferation, DNA repair, and apoptosis within these metastatic cells. Conversely, in matched analyses (n = 7), pro-apoptotic markers BIM and BAD were enriched in the stroma of primary tumors. Univariate, overall survival (OS) analysis indicated CD25 in tumor regions of primary tumors to be associated with reduced survival (HR = 3.3, p = 0.003), while progesterone receptor (PR) was associated with an improved OS (HR = 0.33, p = 0.015). This study highlights the utility of spatial proteomics for delineating the tumor and stromal compartment composition, and utility toward understanding these properties in locoregional metastasis. These findings indicate unique biological properties of lymph node metastases that may elucidate further understanding of distant metastatic in OPSCC.	[Sadeghirad, Habib; Monkman, James; Mehdi, Ahmed M.; Kulasinghe, Arutha] Univ Queensland, Univ Queensland Diamantina Inst, Woolloongabba, Qld, Australia; [Mehdi, Ahmed M.] Queensland Cyber Infrastructure Fdn Ltd, QCIF Facil Adv Bioinformat, Brisbane, Qld, Australia; [Ladwa, Rahul; O'Byrne, Ken] Princess Alexandra Hosp, Woolloongabba, Qld, Australia; [Ladwa, Rahul; Hughes, Brett G. M.; Kulasinghe, Arutha] Univ Queensland, Fac Med, Herston, Qld, Australia; [Hughes, Brett G. M.] Royal Brisbane & Womens Hosp, Canc Care Serv, Herston, Qld, Australia	University of Queensland; University of Queensland; Royal Brisbane & Women's Hospital	Kulasinghe, A (corresponding author), Univ Queensland, Univ Queensland Diamantina Inst, Woolloongabba, Qld, Australia.; Kulasinghe, A (corresponding author), Univ Queensland, Fac Med, Herston, Qld, Australia.	Arutha.kulasinghe@uq.edu.au		Kulasinghe, Arutha/0000-0003-3224-7350; O'Byrne, Kenneth/0000-0002-6754-5633; Hughes, Brett/0000-0002-1811-0537				Ampil FL, 2012, ORAL ONCOL, V48, P325, DOI 10.1016/j.oraloncology.2011.11.016; Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X; Bansal N, 2012, J GYNECOL ONCOL, V23, P35, DOI 10.3802/jgo.2012.23.1.35; Boac BM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53695-0; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Chen TC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57177-1; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Cohen EEW, 2019, LANCET, V393, P156, DOI 10.1016/S0140-6736(18)31999-8; De Silva RK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201755; ElTanbouly MA, 2019, SEMIN IMMUNOL, V42, DOI 10.1016/j.smim.2019.101308; Eustermann S, 2015, MOL CELL, V60, P742, DOI 10.1016/j.molcel.2015.10.032; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Flynn MJ, 2017, BRIT J HAEMATOL, V179, P20, DOI 10.1111/bjh.14770; Grimm SL, 2016, J MOL BIOL, V428, P3831, DOI 10.1016/j.jmb.2016.06.020; Ishikawa H, 2008, NATURE, V455, P674, DOI 10.1038/nature07317; Johnson DE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00224-3; Kann BH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32441-y; Kulasinghe A, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.607349; Kuwahara D, 2003, AURIS NASUS LARYNX, V30, pS85; Langelier MF, 2014, NUCLEIC ACIDS RES, V42, P7762, DOI 10.1093/nar/gku474; Liebl MC, 2019, J EUR ACAD DERMATOL, V33, P52, DOI 10.1111/jdv.15992; Lines JL, 2014, CANCER RES, V74, P1924, DOI 10.1158/0008-5472.CAN-13-1504; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Luo LQ, 2004, J IMMUNOL, V173, P5445, DOI 10.4049/jimmunol.173.9.5445; Marchion DC, 2011, CLIN CANCER RES, V17, P6356, DOI 10.1158/1078-0432.CCR-11-0735; Molania R, 2019, NUCLEIC ACIDS RES, V47, P6073, DOI 10.1093/nar/gkz433; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Rajapakshe RMAR, 2015, CANCER EPIDEMIOL, V39, P360, DOI 10.1016/j.canep.2015.02.011; Risso D, 2014, NAT BIOTECHNOL, V32, P896, DOI 10.1038/nbt.2931; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rohart F, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005752; RStudio Team, 2021, RSTUDIO INT DEV ENV; Sabatini ME, 2020, BRIT J CANCER, V122, P306, DOI 10.1038/s41416-019-0602-7; Rad HS, 2021, MED RES REV, V41, P1474, DOI 10.1002/med.21765; Rad HS, 2020, CLIN TRANSL IMMUNOL, V9, DOI 10.1002/cti2.1215; SHAH JP, 1990, AM J SURG, V160, P405, DOI 10.1016/S0002-9610(05)80554-9; Shukla S, 2017, EUR J CELL BIOL, V96, P728, DOI 10.1016/j.ejcb.2017.09.002; Sohn B, 2016, ACTA RADIOL, V57, P1352, DOI 10.1177/0284185115587544; Starzer Angelika M, 2020, ESMO Open, V4, pe000629, DOI 10.1136/esmoopen-2019-000629; Stern PL, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071234; Sun XM, 2018, CHROMOSOMA, V127, P175, DOI 10.1007/s00412-018-0659-8; Tai SK, 2013, AM J SURG PATHOL, V37, P1164, DOI 10.1097/PAS.0b013e318285f684; Therneau T., 2021, PACKAGE SURVIVAL ANA; Thomas R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00947; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								895513	10.3389/fimmu.2022.895513	http://dx.doi.org/10.3389/fimmu.2022.895513			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Q9YC	35651606	gold, Green Published			2022-12-18	WOS:000803035000001
J	Serran, MG; Vernengo, FF; Almada, L; Beccaria, CG; Gazzoni, Y; Canete, PF; Roco, JA; Boari, JT; Ramello, MC; Wehrens, E; Cai, YP; Zuniga, EI; Montes, CL; Cockburn, IA; Rodriguez, EVA; Vinuesa, CG; Gruppi, A				Serran, Melisa Gorosito; Vernengo, Facundo Fiocca; Almada, Laura; Beccaria, Cristian G.; Gazzoni, Yamila; Canete, Pablo F.; Roco, Jonathan A.; Boari, Jimena Tosello; Ramello, Maria Cecilia; Wehrens, Ellen; Cai, Yeping; Zuniga, Elina I.; Montes, Carolina L.; Cockburn, Ian A.; Rodriguez, Eva V. Acosta; Vinuesa, Carola G.; Gruppi, Adriana			Extrafollicular Plasmablasts Present in the Acute Phase of Infections Express High Levels of PD-L1 and Are Able to Limit T Cell Response	FRONTIERS IN IMMUNOLOGY			English	Article						plasmablasts; plasma cells; B cell; PD-L1; Trypanosoma cruzi; Plasmodium; LCMV; immunosuppression; microorganism evasion	TRYPANOSOMA-CRUZI; REGULATORY FUNCTION; DENDRITIC CELLS; B-CELLS; PROLIFERATION; AUTOIMMUNE; CYTOKINES; IMMUNITY; BLOCKADE; SIGNALS	During infections with protozoan parasites or some viruses, T cell immunosuppression is generated simultaneously with a high B cell activation. It has been described that, as well as producing antibodies, plasmablasts, the differentiation product of activated B cells, can condition the development of protective immunity in infections. Here, we show that, in T. cruzi infection, all the plasmablasts detected during the acute phase of the infection had higher surface expression of PD-L1 than other mononuclear cells. PD-L1(hi) plasmablasts were induced in vivo in a BCR-specific manner and required help from Bcl-6(+)CD4(+)T cells. PD-L1(hi) expression was not a characteristic of all antibody-secreting cells since plasma cells found during the chronic phase of infection expressed PD-L1 but at lower levels. PD-L1(hi) plasmablasts were also present in mice infected with Plasmodium or with lymphocytic choriomeningitis virus, but not in mice with autoimmune disorders or immunized with T cell-dependent antigens. In vitro experiments showed that PD-L1(hi) plasmablasts suppressed the T cell response, partially via PD-L1. Thus, this study reveals that extrafollicular PD-L1(hi) plasmablasts, whose peaks of response precede the peak of germinal center response, may have a modulatory function in infections, thus influencing T cell response.	[Serran, Melisa Gorosito; Vernengo, Facundo Fiocca; Almada, Laura; Beccaria, Cristian G.; Gazzoni, Yamila; Boari, Jimena Tosello; Ramello, Maria Cecilia; Montes, Carolina L.; Rodriguez, Eva V. Acosta; Gruppi, Adriana] Univ Nacl Cordoba, Fac Ciencias Quim, Ctr Invest Bioquim Clin Inmunol CIBICI, Consejo Nacl Invest Cient CONICET, Cordoba, Argentina; [Canete, Pablo F.; Roco, Jonathan A.; Cai, Yeping; Cockburn, Ian A.; Vinuesa, Carola G.] Australian Natl Univ, John Curtin Sch Med Res, Dept Immunol & Infect Dis, Canberra, ACT, Australia; [Wehrens, Ellen; Zuniga, Elina I.] Univ Calif San Diego, Div Biol Sci, San Diego, CA USA; [Vinuesa, Carola G.] Shanghai Jiao Tong Univ, Shanghai Renji Hosp, China Australia Ctr Personalised Immunol, Shanghai, Peoples R China	National University of Cordoba; Australian National University; John Curtin School of Medical Research; University of California System; University of California San Diego; Shanghai Jiao Tong University	Gruppi, A (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Ctr Invest Bioquim Clin Inmunol CIBICI, Consejo Nacl Invest Cient CONICET, Cordoba, Argentina.	agruppi@fcq.unc.edu.ar	Canete, Pablo/HGB-5944-2022; Montes, Carolina/GZG-5187-2022	Cockburn, Ian/0000-0001-8220-9294; Beccaria, Cristian Gabriel/0000-0001-9682-4415; Fiocca Vernengo, Facundo/0000-0003-2293-5598				AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; Akhmetzyanova I, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005224; Arocena AR, 2014, EUR J IMMUNOL, V44, P184, DOI 10.1002/eji.201343606; Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444; Bermejo DA, 2013, NAT IMMUNOL, V14, P514, DOI 10.1038/ni.2569; Bermejo DA, 2011, IMMUNOLOGY, V132, P123, DOI 10.1111/j.1365-2567.2010.03347.x; Butler NS, 2012, NAT IMMUNOL, V13, P188, DOI 10.1038/ni.2180; Cardillo F, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv082; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Doi T, 2012, BIOCHEM BIOPH RES CO, V425, P918, DOI 10.1016/j.bbrc.2012.08.010; Dong HD, 1999, NAT MED, V5, P1365; DosReis GA, 2011, BRAZ J MED BIOL RES, V44, P84, DOI 10.1590/S0100-879X2011000200001; Dyck L, 2017, EUR J IMMUNOL, V47, P765, DOI 10.1002/eji.201646875; Vernengo FF, 2020, MBIO, V11, DOI 10.1128/mBio.00447-20; Funaki S, 2017, ONCOL REP, V38, P2277, DOI 10.3892/or.2017.5894; Gaya M, 2018, CELL, V172, P517, DOI 10.1016/j.cell.2017.11.036; Geiger A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00212; Serran MG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01548; Greczmiel U, 2020, EUR J IMMUNOL, V50, P396, DOI 10.1002/eji.201948286; Gutierrez FRS, 2011, INFECT IMMUN, V79, P1873, DOI 10.1128/IAI.01047-10; Ha SJ, 2008, J EXP MED, V205, P543, DOI 10.1084/jem.20071949; Hollister K, 2013, J IMMUNOL, V191, P3705, DOI 10.4049/jimmunol.1300378; Jellison ER, 2007, EUR J IMMUNOL, V37, P119, DOI 10.1002/eji.200636516; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Lee SK, 2011, J EXP MED, V208, P1377, DOI 10.1084/jem.20102065; Lee-Chang C, 2019, CANCER IMMUNOL RES, V7, P1928, DOI 10.1158/2326-6066.CIR-19-0240; Lopez-Medina M, 2015, IMMUNOBIOLOGY, V220, P1369, DOI 10.1016/j.imbio.2015.07.005; Matsumoto M, 2014, IMMUNITY, V41, P1040, DOI 10.1016/j.immuni.2014.10.016; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; Merluzzi S, 2010, BLOOD, V115, P2810, DOI 10.1182/blood-2009-10-250126; MINOPRIO P, 1988, SCAND J IMMUNOL, V28, P553, DOI 10.1111/j.1365-3083.1988.tb01487.x; Moran-Utrera Y, 2012, J TROP MED-US, V2012, DOI 10.1155/2012/829139; Norris KA, 1997, INFECT IMMUN, V65, P349, DOI 10.1128/IAI.65.2.349-357.1997; Patil NK, 2018, J LEUKOCYTE BIOL, V103, P23, DOI 10.1002/JLB.5HI0917-360R; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Poncini CV, 2010, MOL IMMUNOL, V47, P1981, DOI 10.1016/j.molimm.2010.04.016; Shalapour S, 2015, NATURE, V521, P94, DOI 10.1038/nature14395; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Song SS, 2014, INT IMMUNOPHARMACOL, V20, P117, DOI 10.1016/j.intimp.2014.02.027; Souza PEA, 2007, INFECT IMMUN, V75, P1886, DOI 10.1128/IAI.01931-06; Trivedi N, 2019, IMMUNITY, V51, P1088, DOI 10.1016/j.immuni.2019.10.004; Vijay R, 2020, NAT IMMUNOL, V21, P790, DOI 10.1038/s41590-020-0678-5; Waghabi MC, 2009, ANTIMICROB AGENTS CH, V53, P4694, DOI 10.1128/AAC.00580-09; Wang X, 2017, IMMUNOL LETT, V184, P7, DOI 10.1016/j.imlet.2017.02.006; West EE, 2013, J CLIN INVEST, V123, P2604, DOI 10.1172/JCI67008; Wherry EJ, 2003, J VIROL, V77, P4911, DOI 10.1128/JVI.77.8.4911-4927.2003; Wilmore JR, 2013, J IMMUNOL, V191, P4731, DOI 10.4049/jimmunol.1301450; Zacca ER, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02241; Zuniga EI, 2015, ANNU REV VIROL, V2, P573, DOI 10.1146/annurev-virology-100114-055226	50	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 16	2022	13								828734	10.3389/fimmu.2022.828734	http://dx.doi.org/10.3389/fimmu.2022.828734			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Q9VC	35651611	gold, Green Published			2022-12-18	WOS:000803027100001
J	Alam, I; Batool, K; Idris, AL; Tan, WL; Guan, X; Zhang, LL				Alam, Intikhab; Batool, Khadija; Idris, Aisha Lawan; Tan, Weilong; Guan, Xiong; Zhang, Lingling			Role of Lectin in the Response of Aedes aegypti Against Bt Toxin	FRONTIERS IN IMMUNOLOGY			English	Review						Bacillus thuringiensis; Aedes aegypti; lectin; toxicity; mechanism	C-TYPE LECTIN; THURINGIENSIS SUBSP ISRAELENSIS; SEXTA AMINOPEPTIDASE-N; BACILLUS-THURINGIENSIS; ALKALINE-PHOSPHATASE; CRYSTAL-STRUCTURE; MANDUCA-SEXTA; ZIKA VIRUS; BIOLOGICAL-CONTROL; CRY11AA TOXIN	Aedes aegypti is one of the world's most dangerous mosquitoes, and a vector of diseases such as dengue fever, chikungunya virus, yellow fever, and Zika virus disease. Currently, a major global challenge is the scarcity of antiviral medicine and vaccine for arboviruses. Bacillus thuringiensis var israelensis (Bti) toxins are used as biological mosquito control agents. Endotoxins, including Cry4Aa, Cry4Ba, Cry10Aa, Cry11Aa, and Cyt1Aa, are toxic to mosquitoes. Insect eradication by Cry toxin relies primarily on the interaction of cry toxins with key toxin receptors, such as aminopeptidase (APN), alkaline phosphatase (ALP), cadherin (CAD), and ATP-binding cassette transporters. The carbohydrate recognition domains (CRDs) of lectins and domains II and III of Cry toxins share similar structural folds, suggesting that midgut proteins, such as C-type lectins (CTLs), may interfere with interactions among Cry toxins and receptors by binding to both and alter Cry toxicity. In the present review, we summarize the functional role of C-type lectins in Ae. aegypti mosquitoes and the mechanism underlying the alteration of Cry toxin activity by CTLs. Furthermore, we outline future research directions on elucidating the Bti resistance mechanism. This study provides a basis for understanding Bti resistance, which can be used to develop novel insecticides.	[Alam, Intikhab; Batool, Khadija; Idris, Aisha Lawan; Guan, Xiong; Zhang, Lingling] Fujian Agr & Forestry Univ, Coll Life Sci, State Key Lab Ecol Pest Control Fujian & Taiwan Cr, Fuzhou, Peoples R China; [Alam, Intikhab; Batool, Khadija; Idris, Aisha Lawan; Guan, Xiong; Zhang, Lingling] Fujian Agr & Forestry Univ, Key Lab Biopesticides & Chem Biol, MOE, Fuzhou, Peoples R China; [Alam, Intikhab] South China Agr Univ, Coll Life Sci, Guangzhou, Peoples R China; [Tan, Weilong] Nanjing Bioengn Gene Technol Ctr Med, Nanjing, Peoples R China	Fujian Agriculture & Forestry University; Fujian Agriculture & Forestry University; South China Agricultural University	Zhang, LL (corresponding author), Fujian Agr & Forestry Univ, Coll Life Sci, State Key Lab Ecol Pest Control Fujian & Taiwan Cr, Fuzhou, Peoples R China.; Zhang, LL (corresponding author), Fujian Agr & Forestry Univ, Key Lab Biopesticides & Chem Biol, MOE, Fuzhou, Peoples R China.	lingling00264@163.com	zhang, lingling/HDM-2189-2022		National Program of China [2017YFE0121700, 2017YFE0122000]; United Fujian Provincial Health and Education Project for Tackling Key Research [2019-WJ-29]; Natural Science Foundation of Fujian Province [2020J01550, 2020I0031]; Special Fund for Scientific and Technological Innovation of Fujian Agriculture and Forestry University [KFA20124A]	National Program of China; United Fujian Provincial Health and Education Project for Tackling Key Research; Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); Special Fund for Scientific and Technological Innovation of Fujian Agriculture and Forestry University	Funding This work was funded by the National Program of China (Grant Numbers 2017YFE0121700 and 2017YFE0122000); the United Fujian Provincial Health and Education Project for Tackling Key Research (Grant No. 2019-WJ-29); Natural Science Foundation of Fujian Province (Grant No. 2020J01550 and 2020I0031); the Special Fund for Scientific and Technological Innovation of Fujian Agriculture and Forestry University (KFA20124A).	Abd-Jamil J, 2020, J TROP MED-US, V2020, DOI 10.1155/2020/1019238; Adang MJ, 2014, ADV INSECT PHYSIOL, V47, P39, DOI 10.1016/B978-0-12-800197-4.00002-6; Adelman ZN, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070367; Ahmad S, 2021, SAUDI J BIOMED RES, V6, P85, DOI [10.36348/sjbr.2021.v06i05.002, DOI 10.36348/SJBR.2021.V06I05.002]; Ahmed H., 2008, ANIMAL LECTINS FUNCT, DOI [10.1201/9781420006971, DOI 10.1201/9781420006971]; de Almeida JP, 2021, CURR OPIN VIROL, V49, P7, DOI 10.1016/j.coviro.2021.04.002; Fiorentino MA, 2018, OPEN VET J, V8, P57, DOI 10.4314/ovj.v8i1.10; Antonova Y, 2009, INSECT BIOCHEM MOLEC, V39, P303, DOI 10.1016/j.ibmb.2009.01.007; Barrett ADT, 2007, ANNU REV ENTOMOL, V52, P209, DOI 10.1146/annurev.ento.52.110405.091454; Batool K, 2019, J AGR FOOD CHEM, V67, P8896, DOI 10.1021/acs.jafc.9b01840; Batool K, 2018, TOXINS, V10, DOI 10.3390/toxins10100390; Ben-Dov E, 2014, TOXINS, V6, P1222, DOI 10.3390/toxins6041222; Bennett KL, 2016, MOL ECOL, V25, P4337, DOI 10.1111/mec.13762; Berry C, 2002, APPL ENVIRON MICROB, V68, P5082, DOI 10.1128/AEM.68.10.5082-5095.2002; Bhatt S, 2013, NATURE, V496, P504, DOI 10.1038/nature12060; Bi J, 2019, INSECT MOL BIOL, V28, P649, DOI 10.1111/imb.12582; Boonserm P, 2005, J MOL BIOL, V348, P363, DOI 10.1016/j.jmb.2005.02.013; Bourne Y, 2004, J BIOL CHEM, V279, P527, DOI 10.1074/jbc.M308218200; Bovay A, 2021, HUM VACC IMMUNOTHER, V17, P2471, DOI 10.1080/21645515.2021.1891752; Braga IA, 2007, EPIDEMIOL SERV SAUDE, V16, P295; Bravo A, 2007, TOXICON, V49, P423, DOI 10.1016/j.toxicon.2006.11.022; Briegel H, 2003, J VECTOR ECOL, V28, P1; Brown JE, 2011, P ROY SOC B-BIOL SCI, V278, P2446, DOI 10.1098/rspb.2010.2469; Brown JE, 2014, EVOLUTION, V68, P514, DOI 10.1111/evo.12281; Burt FJ, 2012, LANCET, V379, P662, DOI 10.1016/S0140-6736(11)60281-X; Burton SL, 1999, J MOL BIOL, V287, P1011, DOI 10.1006/jmbi.1999.2649; Cabiaux V, 1997, INT J BIOL MACROMOL, V21, P285, DOI 10.1016/S0141-8130(97)00078-0; Calvez E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004374; Carneiro DC, 2022, J APPL MICROBIOL, V132, P841, DOI 10.1111/jam.15263; Carod-Artal FJ, 2016, REV NEUROLOGIA, V62, P317, DOI 10.33588/rn.6207.2016152; Carvalho KD, 2021, PARASITE VECTOR, V14, DOI 10.1186/s13071-021-04880-6; Chen HL, 2021, BIOCHEM BIOPH RES CO, V566, P155, DOI 10.1016/j.bbrc.2021.05.092; Chen JW, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0007948; Chen JW, 2013, INSECT BIOCHEM MOLEC, V43, P1201, DOI 10.1016/j.ibmb.2013.09.007; Chen JW, 2009, BIOCHEM J, V424, P191, DOI 10.1042/BJ20090730; Chen JW, 2009, INSECT BIOCHEM MOLEC, V39, P688, DOI 10.1016/j.ibmb.2009.08.003; Chen RB, 2011, VIRUSES-BASEL, V3, P1562, DOI 10.3390/v3091562; Cheng G, 2010, CELL, V142, P714, DOI 10.1016/j.cell.2010.07.038; Cheng L, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640367; CHILCOTT CN, 1988, J GEN MICROBIOL, V134, P2551; Chouin-Carneiro T, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004543; Christophers S., 1960, YELLOW FEVER MOSQUIT; Christophides GK, 2002, SCIENCE, V298, P159, DOI 10.1126/science.1077136; Clements A., 1992, BIOL MOSQUITOES DEV, V1; Clements AN., 1999, SENSORY RECEPTION BE; Crawford JE, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0351-0; Daborn PJ, 2007, INSECT BIOCHEM MOLEC, V37, P512, DOI 10.1016/j.ibmb.2007.02.008; Dambuza IM, 2015, CURR OPIN IMMUNOL, V32, P21, DOI 10.1016/j.coi.2014.12.002; Davis J, 2021, J VECTOR ECOL, V46, P30, DOI 10.52707/1081-1710-46.1.30; de Maagd RA, 2003, ANNU REV GENET, V37, P409, DOI 10.1146/annurev.genet.37.110801.143042; de Oliveira R M, 1998, Cad Saude Publica, V14 Suppl 2, P69, DOI 10.1590/S0102-311X1998000600006; Dhania NK, 2021, COMP BIOCHEM PHYS B, V255, DOI 10.1016/j.cbpb.2021.110600; Dillon RJ, 2004, ANNU REV ENTOMOL, V49, P71, DOI 10.1146/annurev.ento.49.061802.123416; do Nascimento J, 2022, BIOL CONTROL, V165, DOI 10.1016/j.biocontrol.2021.104792; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; Doloi Dipika, 2021, International Journal of Mosquito Research, V8, P31, DOI 10.22271/23487941.2021.v8.i1a.497; Dong YM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000423; Dorsch MA, 2019, J COMP PATHOL, V166, P45, DOI 10.1016/j.jcpa.2018.10.172; Eleftherianos I, 2021, INT J BIOL MACROMOL, V191, P277, DOI 10.1016/j.ijbiomac.2021.09.082; Canton PE, 2011, PEPTIDES, V32, P595, DOI 10.1016/j.peptides.2010.06.005; Fauci AS, 2016, NEW ENGL J MED, V374, P601, DOI 10.1056/NEJMp1600297; Federici BA, 1998, APPL ENVIRON MICROB, V64, P4368; Feng DM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136430; Fernandez LE, 2006, BIOCHEM J, V394, P77, DOI 10.1042/BJ20051517; Fernandez LE, 2009, BIOCHEMISTRY-US, V48, P8899, DOI 10.1021/bi900979b; Ferreira PG, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00901; Flores-Escobar B, 2013, APPL ENVIRON MICROB, V79, P4543, DOI 10.1128/AEM.01062-13; Foster Woodbridge A., 2002, P203, DOI 10.1016/B978-012510451-7/50014-1; Gabrieli P, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.630438; Gahan LJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001248; Gloria-Soria A, 2016, MOL ECOL, V25, P5377, DOI 10.1111/mec.13866; Gloria-Soria A, 2021, AM J TROP MED HYG, V104, P1123, DOI 10.4269/ajtmh.20-0874; Gomez I, 2007, PEPTIDES, V28, P169, DOI 10.1016/j.peptides.2006.06.013; Gomez I, 2002, FEBS LETT, V513, P242, DOI 10.1016/S0014-5793(02)02321-9; Griffitts JS, 2005, SCIENCE, V307, P922, DOI 10.1126/science.1104444; GROCHULSKI P, 1995, J MOL BIOL, V254, P447, DOI 10.1006/jmbi.1995.0630; Gubler DJ, 2001, ENVIRON HEALTH PERSP, V109, P223, DOI 10.2307/3435012; Gubler DJ, 1998, EMERG INFECT DIS, V4, P442, DOI 10.3201/eid0403.980326; Gubler DJ, 1998, CLIN MICROBIOL REV, V11, P480, DOI 10.1128/CMR.11.3.480; Gubler Duane J., 2002, Trends in Microbiology, V10, P100, DOI 10.1016/S0966-842X(01)02288-0; Guerchicoff A, 2001, APPL ENVIRON MICROB, V67, P1090, DOI 10.1128/AEM.67.3.1090-1096.2001; Gney G, 2021, ARCH INSECT BIOCHEM, V108, DOI 10.1002/arch.21834; Guo SY, 2015, J IND MICROBIOL BIOT, V42, P925, DOI 10.1007/s10295-015-1612-y; Guo ZJ, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009917; Guzman MG, 2010, NAT REV MICROBIOL, pS7, DOI 10.1038/nrmicro2460; Hawkes FM., 2021, MOSQUITOPIA, P16, DOI [10.4324/9781003056034-2, DOI 10.4324/9781003056034-2]; Heckel DG, 2021, INSECTS, V12, DOI 10.3390/insects12050389; Herrero S, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-96; Hu XH, 2020, PESTIC BIOCHEM PHYS, V162, P96, DOI 10.1016/j.pestbp.2019.09.010; Iborra S, 2015, IMMUNOBIOLOGY, V220, P175, DOI 10.1016/j.imbio.2014.09.013; Idowu PA, 2021, ANIMALS-BASEL, V11, DOI 10.3390/ani11030787; Janisiewicz WJ, 2002, ANNU REV PHYTOPATHOL, V40, P411, DOI 10.1146/annurev.phyto.40.120401.130158; Jenkins JL, 1999, FEBS LETT, V462, P373, DOI 10.1016/S0014-5793(99)01559-8; Jimenez AI, 2012, INSECT BIOCHEM MOLEC, V42, P683, DOI 10.1016/j.ibmb.2012.06.001; Jurat-Fuentes JL, 2004, BIOCHEMISTRY-US, V43, P14299, DOI 10.1021/bi048500i; Jurat-Fuentes JL, 2004, EUR J BIOCHEM, V271, P3127, DOI 10.1111/j.1432-1033.2004.04238.x; Kamei R, 2020, CURR PHARM BIOTECHNO, V21, P1444, DOI 10.2174/1389201021666200730123330; Kanagawa M, 2011, BIOCHEM BIOPH RES CO, V404, P201, DOI 10.1016/j.bbrc.2010.11.093; Kefi M, 2021, BMC GENOMICS, V22, DOI 10.1186/s12864-021-08205-w; KNIGHT PJK, 1995, J BIOL CHEM, V270, P17765, DOI 10.1074/jbc.270.30.17765; KNOWLES BH, 1991, P ROY SOC B-BIOL SCI, V245, P31, DOI 10.1098/rspb.1991.0084; Koizumi N, 1999, FEBS LETT, V443, P139, DOI 10.1016/S0014-5793(98)01701-3; Kraemer MUG, 2019, NAT MICROBIOL, V4, P854, DOI 10.1038/s41564-019-0376-y; Lee SB, 2015, PEPTIDES, V68, P140, DOI 10.1016/j.peptides.2014.07.015; Lee SB, 2014, INSECT BIOCHEM MOLEC, V54, P112, DOI 10.1016/j.ibmb.2014.09.004; Lees RS, 2021, STERILE INSECT TECHNIQUE, 2 EDITION, P1081; Lemaitre B, 2007, ANNU REV IMMUNOL, V25, P697, DOI 10.1146/annurev.immunol.25.022106.141615; Li H, 2021, INSECTS, V12, DOI 10.3390/insects12060559; Li HH, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101486; Li J, 2021, INSECT MOL BIOL, V30, P90, DOI 10.1111/imb.12680; LI JD, 1991, NATURE, V353, P815, DOI 10.1038/353815a0; Li JY, 2021, J INTEGR AGR, V20, P3240, DOI 10.1016/S2095-3119(21)63650-X; Li M, 2014, DEV COMP IMMUNOL, V46, P231, DOI 10.1016/j.dci.2014.04.014; Likitvivatanavong S, 2011, J AGR FOOD CHEM, V59, P2829, DOI 10.1021/jf1036189; Likitvivatanavong S, 2011, APPL ENVIRON MICROB, V77, P24, DOI 10.1128/AEM.01852-10; Lindenwald DL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145122; Ling EJ, 2008, MOL IMMUNOL, V45, P2598, DOI 10.1016/j.molimm.2007.12.021; Liu FF, 2022, DEV COMP IMMUNOL, V127, DOI 10.1016/j.dci.2021.104309; Liu K, 2017, J VIROL, V91, DOI [10.1128/JVI.01348-16, 10.1128/jvi.01348-16]; Lopez-Molina S, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009199; Lounibos LP, 2002, ANNU REV ENTOMOL, V47, P233, DOI 10.1146/annurev.ento.47.091201.145206; Lu YZ, 2020, INSECT BIOCHEM MOLEC, V126, DOI 10.1016/j.ibmb.2020.103451; Ma XL, 2022, INSECT BIOCHEM MOLEC, V140, DOI 10.1016/j.ibmb.2021.103678; Mack RN, 2000, ECOL APPL, V10, P689, DOI 10.1890/1051-0761(2000)010[0689:BICEGC]2.0.CO;2; McConnell MT, 2015, PEERJ, V3, DOI 10.7717/peerj.1206; Meagher JL, 2005, GLYCOBIOLOGY, V15, P1033, DOI 10.1093/glycob/cwi088; Meister S, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000542; Morand S, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.661063; Nair K, 2021, ECOTOX ENVIRON SAFE, V228, DOI 10.1016/j.ecoenv.2021.112975; Naithani S, 2021, J PLANT PHYSIOL, V266, DOI 10.1016/j.jplph.2021.153531; Nunes C, 2021, FEBS J, V288, P3928, DOI 10.1111/febs.15581; Palma L, 2014, TOXINS, V6, P3296, DOI 10.3390/toxins6123296; Pandian GN, 2008, APPL ENVIRON MICROB, V74, P1324, DOI 10.1128/AEM.01901-07; Pang XJ, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.23, 10.1038/NMICROBIOL.2016.23]; Pardo-Lopez L, 2013, FEMS MICROBIOL REV, V37, P3, DOI 10.1111/j.1574-6976.2012.00341.x; Park Y, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-46; Pigott CR, 2007, MICROBIOL MOL BIOL R, V71, P255, DOI 10.1128/MMBR.00034-06; Pinheiro Fransisco P., 1997, World Health Statistics Quarterly, V50, P161; Pisa L, 2021, ENVIRON SCI POLLUT R, V28, P11749, DOI 10.1007/s11356-017-0341-3; Poopathi S, 2002, J INVERTEBR PATHOL, V79, P132, DOI 10.1016/S0022-2011(02)00017-4; Puntasecca CJ, 2021, PLOS NEGLECT TROP D, V15, DOI 10.1371/journal.pntd.0009055; Qiu WL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.661823; Quimbayo M, 2014, BIOMEDICA, V34, P473, DOI [10.7705/biomedica.v34i3.2146, 10.1590/S0120-41572014000300016]; Ramirez JL, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001561; Rao P., 2021, ENV SUSTAIN, V4, P23, DOI [10.1007/s42398-020-00151-9, DOI 10.1007/S42398-020-00151-9]; Rao XJ, 2015, INSECT BIOCHEM MOLEC, V62, P75, DOI 10.1016/j.ibmb.2014.12.006; Rausell C, 2000, APPL ENVIRON MICROB, V66, P1553, DOI 10.1128/AEM.66.4.1553-1558.2000; Rebelo J M, 1999, Cad Saude Publica, V15, P477, DOI 10.1590/S0102-311X1999000300004; Rees JS, 2009, J INVERTEBR PATHOL, V100, P139, DOI 10.1016/j.jip.2009.01.002; Ritchie SA, 2021, ECOL CONT VECTOR-BOR, V6, P59, DOI 10.3920/978-90-8686-895-7_4; ROBINSON M C, 1955, Trans R Soc Trop Med Hyg, V49, P28, DOI [10.1016/0035-9203(55)90080-8, 10.1016/0035-9203(57)90022-6]; Rodriguez-Almazan C, 2012, BIOCHEM J, V443, P711, DOI 10.1042/BJ20111579; Rose NH, 2020, CURR BIOL, V30, P3570, DOI 10.1016/j.cub.2020.06.092; Sabir MJ, 2021, SAUDI J BIOL SCI, V28, P5074, DOI 10.1016/j.sjbs.2021.05.023; Schnitger AKD, 2009, J BIOL CHEM, V284, P17616, DOI 10.1074/jbc.M808298200; Da Silva IHS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207789; Shao ES, 2016, SCI REP-UK, V6, DOI 10.1038/srep20106; Shin SW, 2003, P NATL ACAD SCI USA, V100, P2616, DOI 10.1073/pnas.0537347100; Shrinet J, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-100; Sieiro C., 2021, DEVELOPMENTAL BIOL P, P125, DOI [10.1007/978-3-030-77595-7_4, DOI 10.1007/978-3-030-77595-7_4]; Silva-Filha MHNL, 2021, TOXINS, V13, DOI 10.3390/toxins13080523; Speakman EA, 2020, TRENDS IMMUNOL, V41, P61, DOI 10.1016/j.it.2019.11.007; Stalinski R, 2016, ENVIRON MICROBIOL, V18, P1022, DOI 10.1111/1462-2920.13186; Teixeira MG, 2016, AM J PUBLIC HEALTH, V106, P601, DOI 10.2105/AJPH.2016.303113; Torres-Quintero MC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22740-9; Vachon V, 2012, J INVERTEBR PATHOL, V111, P1, DOI 10.1016/j.jip.2012.05.001; Valaitis AP, 2013, J INVERTEBR PATHOL, V112, P1, DOI 10.1016/j.jip.2012.10.002; Valtierra-de-Luis D, 2020, TOXINS, V12, DOI 10.3390/toxins12060355; Van Damme EJM, 2022, GLYCOCONJUGATE J, V39, P83, DOI 10.1007/s10719-021-10015-x; van Frankenhuyzen K, 2013, J INVERTEBR PATHOL, V114, P76, DOI 10.1016/j.jip.2013.05.010; van Frankenhuyzen K, 2009, J INVERTEBR PATHOL, V101, P1, DOI 10.1016/j.jip.2009.02.009; Vasconcelos PFC, 2015, REV PANAMAZ SAUDE, V6, P9, DOI DOI 10.5123/S2176-62232015000200001; Vila M, 2021, BIOSCIENCE, V71, P722, DOI 10.1093/biosci/biab047; Vilarinhos P, 1998, PIRACICABA LUIZ QUEI, V20, P447, DOI [10.1016/j.rbe.2017.11.004, DOI 10.1016/J.RBE.2017.11.004]; Vorou R, 2016, INT J INFECT DIS, V48, P85, DOI 10.1016/j.ijid.2016.05.014; Wang JX, 2021, INSECTS, V12, DOI 10.3390/insects12030223; Wang SF, 2016, EMERG MICROBES INFEC, V5, DOI 10.1038/emi.2016.124; Wang WW, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008901; Wang XW, 2014, J BIOL CHEM, V289, P11779, DOI 10.1074/jbc.M114.552307; Waterhouse RM, 2007, SCIENCE, V316, P1738, DOI 10.1126/science.1139862; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WHO, 2013, AL GLOB RESP GAR IMP; Wirth MC., 2010, OPEN TOXICOLOGY J, V3, P126, DOI [10.2174/1875414701003010126, DOI 10.2174/1875414701003010126]; Wu JY, 2021, ACTA TROP, V223, DOI 10.1016/j.actatropica.2021.106088; Xia XF, 2018, DEV COMP IMMUNOL, V83, P70, DOI 10.1016/j.dci.2017.11.020; Xiong G., 2006, REV CHINA AGR SCI TE, V8, P5; Yang XR, 2021, J TRAVEL MED, V28, DOI 10.1093/jtm/taab146; Yang YJ, 2021, J INTEGR AGR, V20, P2195, DOI 10.1016/S2095-3119(20)63316-0; Yapa BMCRW, 2019, EMERG MICROBES INFEC, V8, P70, DOI 10.1080/22221751.2018.1559708; Yu XQ, 2004, DEV COMP IMMUNOL, V28, P891, DOI 10.1016/j.dci.2004.02.005; Yu XQ, 2003, DEV COMP IMMUNOL, V27, P189, DOI 10.1016/S0145-305X(02)00099-X; Yu XQ, 1999, INSECT BIOCHEM MOLEC, V29, P585, DOI 10.1016/S0965-1748(99)00036-3; Yu XQ, 2002, INSECT BIOCHEM MOLEC, V32, P1287, DOI 10.1016/S0965-1748(02)00091-7; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zhang LL, 2018, J AGR FOOD CHEM, V66, P13435, DOI 10.1021/acs.jafc.8b04665; Zhang LL, 2013, J ECON ENTOMOL, V106, P1098, DOI 10.1603/EC12308; Zhang RN, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103021118; Zhang XF, 2015, INSECT BIOCHEM MOLEC, V62, P38, DOI 10.1016/j.ibmb.2015.02.001	198	0	0	8	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								898198	10.3389/fimmu.2022.898198	http://dx.doi.org/10.3389/fimmu.2022.898198			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N4FG	35634312	Green Published, gold			2022-12-18	WOS:000800612400001
J	Han, YL; Yang, JX; He, DS; Feng, Y; Liu, XM; Min, Y; Fan, SH; Yin, GB; Hu, DX				Han, Yuling; Yang, Jiaxin; He, Danshuang; Feng, Yang; Liu, Xiaoman; Min, Yu; Fan, Shenghao; Yin, Guobing; Hu, Daixing			Safety and Immunogenicity of Inactivated and Recombinant Protein SARS-CoV-2 Vaccines in Patients With Thyroid Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						Coronavirus disease 2019 (COVID-19); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); inactivated SARS-CoV-2 vaccine; immunogenicity; safety	COVID-19 VACCINES; SEX-DIFFERENCES; VACCINATION	BackgroundThis study aimed at assessing the safety and immunogenicity of SARS-CoV-2 vaccines in patients with thyroid cancer. MethodsThis observational study included thyroid cancer patients between April 1, 2021, and November 31, 2021, in the Second Affiliated Hospital of Chongqing Medical University. All participants received at least one dose of the SARS-CoV-2 vaccine. SARS-CoV-2 IgG was tested, and the interval time between the last dose and humoral response test ranged from ResultsA total of 115 participants at least received one dose of SARS-CoV-2 vaccines with a 67.0% IgG-positive rate. Among them, 98 cases had completed vaccination, and the positivity of SARS-CoV-2 IgG antibodies was 96% (24/25) with three doses of ZF2001. SARS-CoV-2 IgG antibodies' positivity was 63.0% (46/73) of two doses of CoronaVac or BBIBP-CorV vaccine. Additionally, after 4 months of the last-dose vaccination, the IgG-positive rate (31.6%, 6/19) significantly decreased in thyroid cancer patients. The IgG-positive rate (81.0%, 64/79) was satisfactory within 3 months of the last-dose vaccination. Ten (10.2%) patients had side effects after SARS-CoV-2 vaccination. Among them, two (2.0%) patients had a fever, five (5.1%) patients had injection site pain, one (1.0%) patient felt dizzy, and one patient felt dizzy and had injection site pain at the same time. ConclusionSARS-CoV-2 vaccines (CoronaVac, BBIBP-CorV, and ZF2001) are safe in thyroid cancer patients. The regression time of SARS-CoV-2 IgG is significantly shorter in thyroid cancer patients than in healthy adults. Therefore, a booster vaccination dose may be earlier than the systematic strategy for thyroid cancer patients.	[Han, Yuling; Yang, Jiaxin; He, Danshuang; Feng, Yang; Liu, Xiaoman; Min, Yu; Fan, Shenghao; Yin, Guobing; Hu, Daixing] Chongqing Med Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 2, Chongqing, Peoples R China	Chongqing Medical University	Fan, SH; Yin, GB; Hu, DX (corresponding author), Chongqing Med Univ, Dept Breast & Thyroid Surg, Affiliated Hosp 2, Chongqing, Peoples R China.	18173755@qq.com; yinguobing@cqmu.edu.cn; hudaixing523@163.com			National Natural Science Foundation of China [81972460]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (NSFC No. 81972460) for GY.	Ariamanesh M, 2022, CANCER INVEST, V40, P26, DOI 10.1080/07357907.2021.1992420; Fischinger S, 2019, SEMIN IMMUNOPATHOL, V41, P239, DOI 10.1007/s00281-018-0726-5; Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]; Haque A, 2022, J AUTOIMMUN, V127, DOI 10.1016/j.jaut.2021.102792; Javadinia Seyed Alireza, 2021, Asian Pac J Cancer Prev, V22, P3053, DOI 10.31557/APJCP.2021.22.10.3053; Javadinia SA, 2022, CANCER INVEST, V40, P115, DOI 10.1080/07357907.2021.1995742; Joudi M, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.798975; Massarweh A, 2021, JAMA ONCOL, V7, P1133, DOI 10.1001/jamaoncol.2021.2155; Motlagh A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02692-3; Rai GK, 2022, LANCET INFECT DIS, V22, P529, DOI 10.1016/S1473-3099(21)00455-2; Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015; Rosenberg ES, 2022, NEW ENGL J MED, V386, P116, DOI 10.1056/NEJMoa2116063; Saure D, 2022, LANCET INFECT DIS, V22, P56, DOI 10.1016/S1473-3099(21)00479-5; Shmueli ES, 2021, EUR J CANCER, V157, P124, DOI 10.1016/j.ejca.2021.08.007; Soroosh D, 2020, INT J CANCER MANAG, V13, DOI 10.5812/ijcm.103283; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943; Swift MD, 2021, CLIN INFECT DIS, V73, pE1376, DOI 10.1093/cid/ciab361; Taghizadeh-Hesary F, 2021, INT J CANCER MANAG, V14, DOI 10.5812/ijcm.110907; Tali SHS, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00228-20; Tanriover MD, 2021, LANCET, V398, P213, DOI 10.1016/S0140-6736(21)01429-X; Thomas N, 2021, ADV EXP MED BIOL, V1327, P79, DOI 10.1007/978-3-030-71697-4_6; Thomas Stephen J, 2021, N Engl J Med, V385, P1761, DOI 10.1056/NEJMoa2110345; Vaccarella S, 2015, THYROID, V25, P1127, DOI 10.1089/thy.2015.0116; Xia SL, 2022, LANCET INFECT DIS, V22, P196, DOI 10.1016/S1473-3099(21)00462-X; Xia SL, 2021, LANCET INFECT DIS, V21, P39, DOI 10.1016/S1473-3099(20)30831-8; Yang SL, 2021, LANCET INFECT DIS, V21, P1107, DOI 10.1016/S1473-3099(21)00127-4; Yek C, 2022, MMWR-MORBID MORTAL W, V71, P19, DOI [10.15585/mmwr.mm7101a4, 10.1101/2021.07.08.21259776v1]; Zeng G, 2022, LANCET INFECT DIS, V22, P483, DOI 10.1016/S1473-3099(21)00681-2	28	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								855311	10.3389/fimmu.2022.855311	http://dx.doi.org/10.3389/fimmu.2022.855311			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V4JD	35634276	gold, Green Published			2022-12-18	WOS:000806057200001
J	Huang, W; Xie, WD; Zhong, HH; Cai, SM; Huang, QB; Liu, YT; Zeng, ZH; Liu, YA				Huang, Wei; Xie, Weidang; Zhong, Hanhui; Cai, Shumin; Huang, Qiaobing; Liu, Youtan; Zeng, Zhenhua; Liu, Yanan			Cytosolic p53 Inhibits Parkin-Mediated Mitophagy and Promotes Acute Liver Injury Induced by Heat Stroke	FRONTIERS IN IMMUNOLOGY			English	Article						mitophagy; acute liver injury; p53; Parkin; apoptosis	MITOCHONDRIAL QUALITY-CONTROL; AUTOPHAGY; PINK1	Heat stroke (HS) is a severe condition characterized by increased morbidity and high mortality. Acute liver injury (ALI) is a well-documented complication of HS. The tumor suppressor p53 plays an important role in regulation of mitochondrial integrity and mitophagy in several forms of ALI. However, the role of p53-regulated mitophagy in HS-ALI remains unclear. In our study, we discovered the dynamic changes of mitophagy in hepatocytes and demonstrated the protective effects of mitophagy activation on HS-ALI. Pretreatment with 3-MA or Mdivi-1 significantly exacerbated ALI by inhibiting mitophagy in HS-ALI mice. Consistent with the animal HS-ALI model results, silencing Parkin aggravated mitochondrial damage and apoptosis by inhibiting mitophagy in HS-treated normal human liver cell line (LO2 cells). Moreover, we described an increase in the translocation of p53 from the nucleus to the cytoplasm, and cytosolic p53 binds to Parkin in LO2 cells following HS. p53 overexpression using a specific adenovirus or Tenovin-6 exacerbated HS-ALI through Parkin-dependent mitophagy both in vivo and in vitro, whereas inhibition of p53 using siRNA or PFT-alpha effectively reversed this process. Our results demonstrate that cytosolic p53 binds to Parkin and inhibits mitophagy by preventing Parkin's translocation from the cytosol to the mitochondria, which decreases mitophagy activation and leads to hepatocyte apoptosis in HS-ALI. Overall, pharmacologic induction of mitophagy by inhibiting p53 may be a promising therapeutic approach for HS-ALI treatment.	[Huang, Wei; Xie, Weidang; Cai, Shumin; Zeng, Zhenhua; Liu, Yanan] Southern Med Univ, Nanfang Hosp, Dept Crit Care Med, Guangzhou, Peoples R China; [Huang, Wei] Southern Med Univ, Sch Clin Med 1, Guangzhou, Peoples R China; [Zhong, Hanhui] Affiliated Hosp Guangdong Med Univ, Dept Anesthesiol, Zhanjiang, Peoples R China; [Huang, Qiaobing] Southern Med Univ, Dept Pathophysiol, Guangdong Prov Key Lab Shock & Microcirculat, Guangzhou, Peoples R China; [Liu, Youtan] Southern Med Univ, Shenzhen Hosp, Dept Anesthesiol, Shenzhen, Peoples R China	Southern Medical University - China; Southern Medical University - China; Guangdong Medical University; Southern Medical University - China; Southern Medical University - China	Zeng, ZH; Liu, YA (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Crit Care Med, Guangzhou, Peoples R China.	zhenhuazeng.2008@163.com; lyn21100145@i.smu.edu.cn			National Natural Science Foundation of China [81701955, 81871604, 82172181]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by grants from the National Natural Science Foundation of China (81701955, 81871604, and 82172181).	Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Agarwal S, 2022, CURR OPIN NEUROBIOL, V72, P111, DOI 10.1016/j.conb.2021.09.005; Alele FO, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17197037; Bader V, 2020, BIOL CHEM, V401, P891, DOI 10.1515/hsz-2020-0135; Banfi F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24391-3; Bi X, 2020, HEPATOLOGY, V71, P1122, DOI 10.1002/hep.30938; Bouchama A, 2002, NEW ENGL J MED, V346, P1978, DOI 10.1056/NEJMra011089; Carlsen L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111828; Chen YF, 2021, NEUROSCIENCE, V476, P12, DOI 10.1016/j.neuroscience.2021.09.010; Chen YF, 2020, J CARDIOVASC TRANSL, V13, P928, DOI 10.1007/s12265-020-10003-w; Choudhury FK, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10111838; Deshwal S, 2020, ANNU REV BIOCHEM, V89, P501, DOI 10.1146/annurev-biochem-062917-012739; Dokladny K, 2015, AUTOPHAGY, V11, P200, DOI 10.1080/15548627.2015.1009776; Elias J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910590; Ezhilarasan D, 2021, HEPATOB PANCREAT DIS, V20, P315, DOI 10.1016/j.hbpd.2021.04.010; Fu XM, 2020, PROTEIN CELL, V11, P71, DOI 10.1007/s13238-019-00665-x; Geng Y, 2015, J HEPATOL, V63, P622, DOI 10.1016/j.jhep.2015.04.010; Goiran T, 2018, CELL DEATH DIFFER, V25, P873, DOI 10.1038/s41418-017-0016-0; Hirao H, 2022, NAT REV GASTRO HEPAT, V19, P239, DOI 10.1038/s41575-021-00549-8; Hoshino A, 2014, P NATL ACAD SCI USA, V111, P3116, DOI 10.1073/pnas.1318951111; Hoshino A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3308; Jung YY, 2017, REDOX BIOL, V12, P666, DOI 10.1016/j.redox.2017.04.007; Ke PY, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040831; Kouroumalis E, 2021, WORLD J HEPATOL, V13, DOI 10.4254/wjh.v13.i1.6; Li L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1316-8; Li RB, 2020, AGING-US, V12, P6467, DOI 10.18632/aging.102972; Li Y, 2018, INT J MOL MED, V41, P3517, DOI 10.3892/ijmm.2018.3555; Lin QS, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101254; Liu ZF, 2019, J CELL PHYSIOL, V234, P10761, DOI 10.1002/jcp.27750; Ma XW, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040837; Manzella N, 2018, AGING CELL, V17, DOI 10.1111/acel.12811; Mehta S, 2021, EMBO REP, V22, DOI 10.15252/embr.202153085; Saleem S, 2021, NEUROSCIENCE, V469, P162, DOI 10.1016/j.neuroscience.2021.06.023; Samaiya PK, 2021, MOL CELL BIOCHEM, V476, P4421, DOI 10.1007/s11010-021-04253-8; Schank M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03238-7; Shi T, 2020, ANTIOXID REDOX SIGN, V33, P839, DOI 10.1089/ars.2020.8074; Song YM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010122; Song YJ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/3960773; Sun MM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685523; Suzuki N, 2021, AUTOPHAGY, V17, P3776, DOI 10.1080/15548627.2021.1897961; Tan QH, 2020, ARCH TOXICOL, V94, P2925, DOI 10.1007/s00204-020-02780-9; Tang CY, 2019, PHARMACOL THERAPEUT, V195, P5, DOI 10.1016/j.pharmthera.2018.10.013; Thangaraj A, 2020, AUTOPHAGY, V16, P289, DOI 10.1080/15548627.2019.1607686; Tian S, 2017, MOLECULES, V22, DOI 10.3390/molecules22111886; Venderova K, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a009365; VESCIA FG, 1962, GASTROENTEROLOGY, V43, P340; Wang SY, 2021, ACTA PHARM SIN B, V11, P3508, DOI 10.1016/j.apsb.2021.07.006; Williams JA, 2015, PHARMACOL RES, V102, P264, DOI 10.1016/j.phrs.2015.09.020; Xu M, 2021, CELL MOL GASTROENTER, V12, P567, DOI 10.1016/j.jcmgh.2021.03.007; Xuan Biao, 2021, G3 (Bethesda), V11, DOI 10.1093/g3journal/jkab147; Youle RJ, 2019, SCIENCE, V365, P655, DOI 10.1126/science.aaw9855; Zhang F, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2238-1; Zhang S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.851832	53	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								859231	10.3389/fimmu.2022.859231	http://dx.doi.org/10.3389/fimmu.2022.859231			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V4KR	35634298	gold, Green Published			2022-12-18	WOS:000806061200001
J	Kangethe, RT; Winger, EM; Settypalli, TBK; Datta, S; Wijewardana, V; Lamien, CE; Unger, H; Coetzer, THT; Cattoli, G; Diallo, A				Kangethe, Richard T.; Winger, Eva M.; Settypalli, Tirumala Bharani K.; Datta, Sneha; Wijewardana, Viskam; Lamien, Charles E.; Unger, Hermann; Coetzer, Theresa H. T.; Cattoli, Giovanni; Diallo, Adama			Low Dose Gamma Irradiation of Trypanosoma evansi Parasites Identifies Molecular Changes That Occur to Repair Radiation Damage and Gene Transcripts That May Be Involved in Establishing Disease in Mice Post-Irradiation	FRONTIERS IN IMMUNOLOGY			English	Article						Trypanosoma evansi; gamma irradiation; TryMS array; vaccine; surra	CD5(+) B-CELLS; AFRICAN TRYPANOSOMES; EXPERIMENTAL INFECTIONS; ANTIBODY-RESPONSES; OLIGOPEPTIDASE-B; BETA-TUBULIN; IMMUNIZATION; BRUCEI; IMMUNITY; CATTLE	The protozoan parasite Trypanosoma evansi is responsible for causing surra in a variety of mammalian hosts and is spread by many vectors over a wide geographical area making it an ideal target for irradiation as a tool to study the initial events that occur during infection. Parasites irradiated at the representative doses 100Gy, 140Gy, and 200Gy were used to inoculate BALB/c mice revealing that parasites irradiated at 200Gy were unable to establish disease in all mice. Cytokine analysis of mice inoculated with 200Gy of irradiated parasites showed significantly lower levels of interleukins when compared to mice inoculated with non-irradiated and 100Gy irradiated parasites. Irradiation also differentially affected the abundance of gene transcripts in a dose-dependent trend measured at 6- and 20-hours post-irradiation with 234, 325, and 484 gene transcripts affected 6 hours post-irradiation for 100Gy-, 140Gy- and 200Gy-irradiated parasites, respectively. At 20 hours post-irradiation, 422, 381, and 457 gene transcripts were affected by irradiation at 100Gy, 140Gy, and 200Gy, respectively. A gene ontology (GO) term analysis was carried out for the three representative doses at 6 hours and 20 hours post-irradiation revealing different processes occurring at 20 hours when compared to 6 hours for 100Gy irradiation. The top ten most significant processes had a negative Z score. These processes fall in significance at 140Gy and even further at 200Gy, revealing that they were least likely to occur at 200Gy, and thus may have been responsible for infection in mice by 100Gy and 140Gy irradiated parasites. When looking at 100Gy irradiated parasites 20 hours post-irradiation processes with a positive Z score, we identified genes that were involved in multiple processes and compared their fold change values at 6 hours and 20 hours. We present these genes as possibly necessary for repair from irradiation damage at 6 hours and suggestive of being involved in the establishment of disease in mice at 20 hours post-irradiation. A potential strategy using this information to develop a whole parasite vaccine is also postulated.	[Kangethe, Richard T.; Winger, Eva M.; Settypalli, Tirumala Bharani K.; Datta, Sneha; Wijewardana, Viskam; Lamien, Charles E.; Unger, Hermann; Cattoli, Giovanni; Diallo, Adama] Anim Prod & Hlth Lab, IAEA Agr & Biotechnol Lab, IAEA Labs Seibersdorf, Int Atom Energy Agcy IAEA, Vienna, Austria; [Coetzer, Theresa H. T.] Univ KwaZulu Natal, Sch Life Sci, Biochem, Pietermaritzburg, South Africa; [Diallo, Adama] UMR CIRAD INRA, Anim, Montpellier, France	International Atomic Energy Agency; University of Kwazulu Natal; CIRAD; INRAE	Kangethe, RT (corresponding author), Anim Prod & Hlth Lab, IAEA Agr & Biotechnol Lab, IAEA Labs Seibersdorf, Int Atom Energy Agcy IAEA, Vienna, Austria.	R.T.Kangethe@iaea.org	Kangethe, Richard/GWZ-3122-2022	Kangethe, Richard/0000-0002-2598-9324				Antoine-Moussiaux N, 2008, TRENDS PARASITOL, V24, P411, DOI 10.1016/j.pt.2008.05.010; Antoine-Moussiaux N, 2009, INFECT IMMUN, V77, P1276, DOI 10.1128/IAI.01185-08; Aregawi WG, 2019, PARASITE VECTOR, V12, DOI 10.1186/s13071-019-3311-4; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Athar A, 2019, NUCLEIC ACIDS RES, V47, pD711, DOI 10.1093/nar/gky964; Autheman D, 2021, NATURE, V595, P96, DOI 10.1038/s41586-021-03597-x; Authie E, 2001, INT J PARASITOL, V31, P1429, DOI 10.1016/S0020-7519(01)00266-1; Auty H, 2015, REV SCI TECH OIE, V34, P587, DOI 10.20506/rst.34.2.2382; Awuoche EO, 2018, PARASITE VECTOR, V11, DOI 10.1186/s13071-018-2964-8; Bain RK, 1999, INT J PARASITOL, V29, P185, DOI 10.1016/S0020-7519(98)00187-8; Baral TN, 2007, J INFECT DIS, V195, P1513, DOI 10.1086/515577; Boulange AF, 2011, PROTEIN EXPRES PURIF, V75, P95, DOI 10.1016/j.pep.2010.09.002; Brenndorfer M, 2010, MOL BIOCHEM PARASIT, V172, P52, DOI 10.1016/j.molbiopara.2010.03.007; Carnes J, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003404; Cerqueira PG, 2017, MOL BIOCHEM PARASIT, V212, P55, DOI 10.1016/j.molbiopara.2017.01.005; Cerveny L, 2013, INFECT IMMUN, V81, P629, DOI 10.1128/IAI.01035-12; Claes F, 2003, PARASITOLOGY, V126, P425, DOI 10.1017/S0031182003002968; Clayton C, 2007, MOL BIOCHEM PARASIT, V156, P93, DOI 10.1016/j.molbiopara.2007.07.007; Clayton C, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.190072; Coen PG, 2001, EPIDEMIOL INFECT, V126, P111, DOI 10.1017/S0950268801004964; Coetzer THT, 2008, BIOCHIMIE, V90, P336, DOI 10.1016/j.biochi.2007.10.011; Daley JM, 2014, NUCLEIC ACIDS RES, V42, P11083, DOI 10.1093/nar/gku803; Dargantes AP, 2009, INT J PARASITOL, V39, P1109, DOI 10.1016/j.ijpara.2009.02.012; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; de Menezes VT, 2004, PARASITOL RES, V94, P193, DOI 10.1007/s00436-004-1207-4; Desquesnes M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/194176; Desquesnes M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/321237; DUXBURY RE, 1975, T ROY SOC TROP MED H, V69, P484, DOI 10.1016/0035-9203(75)90104-2; DUXBURY RE, 1972, EXP PARASITOL, V32, P527, DOI 10.1016/0014-4894(72)90071-9; DUXBURY RE, 1973, T ROY SOC TROP MED H, V67, P266, DOI 10.1016/0035-9203(73)90172-7; DUXBURY RE, 1972, T ROY SOC TROP MED H, V66, P349, DOI 10.1016/0035-9203(72)90237-4; DUXBURY RE, 1972, AM J TROP MED HYG, V21, P885, DOI 10.4269/ajtmh.1972.21.885; DUXBURY RE, 1969, J PARASITOL, V55, P859, DOI 10.2307/3277231; El Ridi R, 2015, J ADV RES, V6, P255, DOI 10.1016/j.jare.2014.10.002; Ferreira LG, 2017, PHARMACOL THERAPEUT, V180, P49, DOI 10.1016/j.pharmthera.2017.06.004; Finelle P., 1983, FAO Animal Production and Health Paper, P1; Grynberg P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029596; HERBERT WJ, 1976, EXP PARASITOL, V40, P427, DOI 10.1016/0014-4894(76)90110-7; Hewitson JP, 2005, PARASITE IMMUNOL, V27, P271, DOI 10.1111/j.1365-3024.2005.00764.x; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; Hoare CA, 1973, MED J AUSTRALIA, V1, P140, DOI [10.5694/j.1326-5377.1973.tb119667.x, DOI 10.5694/J.1326-5377.1973.TB119667.X]; HOARE CECIL A., 1965, ACTA TROP, V22, P204; Hoffman SL, 2002, J INFECT DIS, V185, P1155, DOI 10.1086/339409; Hoffman SL, 2010, HUM VACCINES, V6, P97, DOI 10.4161/hv.6.1.10396; Holland WG, 2003, VET PARASITOL, V111, P115, DOI 10.1016/S0304-4017(02)00363-1; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Kangethe RT, 2012, MOL BIOCHEM PARASIT, V182, P7, DOI 10.1016/j.molbiopara.2011.11.007; Kolev NG, 2012, SCIENCE, V338, P1352, DOI 10.1126/science.1229641; Kurup SP, 2012, VET PARASITOL, V187, P9, DOI 10.1016/j.vetpar.2012.01.009; Li SQ, 2007, PARASITE IMMUNOL, V29, P191, DOI 10.1111/j.1365-3024.2006.00933.x; Lubega GW, 2002, EXP PARASITOL, V102, P9, DOI 10.1016/S0014-4894(02)00140-6; Luke TC, 2003, J EXP BIOL, V206, P3803, DOI 10.1242/jeb.00644; Magez S, 2002, MICROBES INFECT, V4, P999, DOI 10.1016/S1286-4579(02)01617-9; Magez S, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10081050; Magez S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00382; Magez S, 2010, PARASITOLOGY, V137, P2017, DOI 10.1017/S0031182010000223; Mansfield JM, 2005, PARASITE IMMUNOL, V27, P361, DOI 10.1111/j.1365-3024.2005.00791.x; Morrison LJ, 2016, TRENDS PARASITOL, V32, P599, DOI 10.1016/j.pt.2016.04.012; MORRISON WI, 1982, PARASITE IMMUNOL, V4, P395, DOI 10.1111/j.1365-3024.1982.tb00451.x; Moss CX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123241; Mugo E, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006560; Namangala B, 2011, PARASITE IMMUNOL, V33, P430, DOI 10.1111/j.1365-3024.2011.01280.x; Namangala B, 2001, J INFECT DIS, V183, P1794, DOI 10.1086/320731; Chau NVV, 2016, CLIN INFECT DIS, V62, P1002, DOI 10.1093/cid/ciw052; Ohta K, 1998, P NATL ACAD SCI USA, V95, P646, DOI 10.1073/pnas.95.2.646; Onah DN, 1999, PARASITOL RES, V85, P263, DOI 10.1007/s004360050545; Onah DN, 1998, PARASITE IMMUNOL, V20, P121, DOI 10.1111/j.1365-3024.1998.00125.x; Onah DN, 1998, VET IMMUNOL IMMUNOP, V63, P209, DOI 10.1016/S0165-2427(97)00147-5; Papatpremsiri A, 2016, J HELMINTHOL, V90, P39, DOI 10.1017/S0022149X14000741; Paulnock DM, 2010, PARASITOLOGY, V137, P2051, DOI 10.1017/S0031182010001460; Plowe CV, 2009, J INFECT DIS, V200, P1646, DOI 10.1086/646613; Powell SN, 2002, MOL CELL, V10, P1262, DOI 10.1016/S1097-2765(02)00789-X; Radwanska M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02253; Regis-Da-Silva CG, 2006, MOL BIOCHEM PARASIT, V149, P191, DOI 10.1016/j.molbiopara.2006.05.012; SADUN EH, 1973, AM J TROP MED HYG, V22, P323, DOI 10.4269/ajtmh.1973.22.323; Salah AA, 2015, TROP ANIM HEALTH PRO, V47, P707, DOI 10.1007/s11250-015-0780-0; Vieira HGS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097526; SEED JR, 1993, J PARASITOL, V79, P226, DOI 10.2307/3283512; Shi HF, 2018, MOL BIOCHEM PARASIT, V224, P50, DOI 10.1016/j.molbiopara.2018.07.011; Singleton EV, 2020, J RADIAT RES, V61, P886, DOI 10.1093/jrr/rraa076; Stijlemans B, 2007, J IMMUNOL, V179, P4003, DOI 10.4049/jimmunol.179.6.4003; Stijlemans B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00233; Sumba AL, 1998, MED VET ENTOMOL, V12, P417, DOI 10.1046/j.1365-2915.1998.00131.x; TIZARD I, 1978, MICROBIOL REV, V42, P661, DOI 10.1128/MMBR.42.4.664-681.1978; Toh JY, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85225-2; Truc P, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002256; UCHE UE, 1994, VET PARASITOL, V52, P21, DOI 10.1016/0304-4017(94)90032-9; UCHE UE, 1993, J COMP PATHOL, V109, P1, DOI 10.1016/S0021-9975(08)80235-6; Urbina JA, 2002, MOL BIOCHEM PARASIT, V125, P35, DOI 10.1016/S0166-6851(02)00206-2; Vasquez JJ, 2014, NUCLEIC ACIDS RES, V42, P3623, DOI 10.1093/nar/gkt1386; Vickerman K., 1993, Immunology and molecular biology of parasitic infections., P170; Vinet L, 2011, J PHYS A-MATH THEOR, V44, DOI 10.1088/1751-8113/44/8/085201; Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300; WELLDE BT, 1973, EXP PARASITOL, V34, P62, DOI 10.1016/0014-4894(73)90063-5; WELLDE BT, 1975, EXP PARASITOL, V37, P125, DOI 10.1016/0014-4894(75)90060-0	95	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								852091	10.3389/fimmu.2022.852091	http://dx.doi.org/10.3389/fimmu.2022.852091			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W1ZW	35634275	Green Published, gold			2022-12-18	WOS:000806578800001
J	Rodriguez-Hernandez, MA; Carneros, D; Nunez-Nunez, M; Coca, R; Baena, R; Lopez-Ruiz, GM; Cano-Serrano, ME; Martinez-Telleria, A; Fuentes-Lopez, A; Praena-Fernandez, JM; Garbers, C; Hernandez-Quero, J; Garcia, F; Rose-John, S; Bustos, M				Rodriguez-Hernandez, Maria Angeles; Carneros, David; Nunez-Nunez, Maria; Coca, Ramon; Baena, Rosario; Lopez-Ruiz, Gema M.; Cano-Serrano, Maria Elena; Martinez-Telleria, Alberto; Fuentes-Lopez, Ana; Praena-Fernandez, Juan Manuel; Garbers, Christoph; Hernandez-Quero, Jose; Garcia, Federico; Rose-John, Stefan; Bustos, Matilde			Identification of IL-6 Signalling Components as Predictors of Severity and Outcome in COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; IL-6; soluble receptors; soluble IL-6 receptor (sIL-6R); soluble gp130 (sgp130); IL-6 trans-signalling	SOLUBLE IL-6R; CUTTING EDGE; CYTOKINE; GP130; INHIBITOR; BLOCKADE; SEPSIS; LIVER	IL-6 is one of the major mediators of the hyper-inflammatory responses with complex biological functions as it can signal via different modes of action. IL-6 by classical signalling has anti-inflammatory and antibacterial activities, while trans-signalling mediates pro-inflammatory effects. The net biological effect of IL-6 is established by multiple factors beyond its absolute concentration. Here, we assess the relationship between IL-6 signalling variables [IL-6, soluble IL-6R (sIL-6R) and soluble gp130 (sgp130)] and outcomes in a cohort of 366 COVID-19 patients. The potential trans-signalling was evaluated by a ratio between the pro-inflammatory binary IL-6:sIL-6R complex and the inactive ternary IL-6:sIL-6R:sgp130 complex (binary/ternary complex) and the fold molar excess of sgp130 over sIL-6R (FME). Our data provide new evidence that high levels of IL-6, sIL-6R, sgp130, binary/ternary complex ratio, and low FME are independent predictors of COVID-19 severity in survivor patients (without death), and the combination of IL-6 + sIL-6R + sgp130 exhibited the most robust classification capacity. Conversely, in a subgroup of patients with a very poor prognosis, we found that high levels of IL-6 and low levels of sIL-6R, sgp130, and binary/ternary complex ratio were predictors of death. In this context, the highest predictive capacity corresponded to the combined analysis of IL-6 + FME + lymphopenia + creatinine. Herein, we present IL-6 signalling variables as a helpful tool for the early identification and stratification of patients with clear implications for treatment and clinical decision-making.	[Rodriguez-Hernandez, Maria Angeles; Carneros, David; Lopez-Ruiz, Gema M.; Bustos, Matilde] Univ Seville US, Inst Biomed Seville IBIS, Spanish Natl Res Council CSIC,Virgen Rocio Univ Ho, Area Liver, Seville, Spain; [Nunez-Nunez, Maria] San Cecilio Univ Hosp, Dept Pharm, Granada, Spain; [Nunez-Nunez, Maria; Hernandez-Quero, Jose] San Cecilio Univ Hosp, Infect Dis Unit, Granada, Spain; [Nunez-Nunez, Maria; Garcia, Federico] Biosanit Res Inst Granada Ibs Granada, Granada, Spain; [Coca, Ramon] Virgen Nieves Univ Hosp, Dept Clin Anal, Granada, Spain; [Baena, Rosario] Univ Navarra, Dept Pharmaceut Technol & Chem, Pamplona, Spain; [Cano-Serrano, Maria Elena] San Cecilio Univ Hosp, Dept Anaesthesiol, Granada, Spain; [Martinez-Telleria, Alberto] Virgen Nieves Univ Hosp, Dept Anaesthesiol, Granada, Spain; [Fuentes-Lopez, Ana; Garcia, Federico] San Cecilio Univ Hosp, Dept Microbiol, Granada, Spain; [Praena-Fernandez, Juan Manuel] Univ Granada, Sci Fac, Dept Stat, Granada, Spain; [Garbers, Christoph] Otto von Guericke Univ, Med Fac, Dept Pathol, Magdeburg, Germany; [Garcia, Federico] Ctr Invest Biomed Red Enfermedades Infecciosas CIB, ISCIII, Madrid, Spain; [Rose-John, Stefan] Univ Kiel, Inst Biochem, Kiel, Germany	Consejo Superior de Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS); Hospital Universitario San Cecilio; Hospital Universitario San Cecilio; Hospital Universitario Virgen de las Nieves; University of Navarra; Hospital Universitario San Cecilio; Hospital Universitario Virgen de las Nieves; Hospital Universitario San Cecilio; University of Granada; Otto von Guericke University; Instituto de Salud Carlos III; University of Kiel	Rodriguez-Hernandez, MA; Bustos, M (corresponding author), Univ Seville US, Inst Biomed Seville IBIS, Spanish Natl Res Council CSIC,Virgen Rocio Univ Ho, Area Liver, Seville, Spain.	marodriguez-ibis@us.es; mbustos-ibis@us.es	PRAENA-FERNANDEZ, J M/GON-7040-2022; Garbers, Christoph/D-9932-2015; Rodríguez-Hernández, Ángeles/K-9717-2015	PRAENA-FERNANDEZ, J M/0000-0001-5728-1024; Garbers, Christoph/0000-0003-4939-6950; Rodríguez-Hernández, Ángeles/0000-0003-1846-0606				Aparicio-Siegmund S, 2019, AM J PHYSIOL-ENDOC M, V317, pE411, DOI 10.1152/ajpendo.00166.2019; Arunachalam PS, 2020, SCIENCE, V369, P1210, DOI 10.1126/science.abc6261; Azkur AK, 2020, ALLERGY, V75, P1564, DOI 10.1111/all.14364; Biran N, 2020, LANCET RHEUMATOL, V2, pE603, DOI 10.1016/S2665-9913(20)30277-0; Bonnet B, 2021, EBIOMEDICINE, V73, DOI 10.1016/j.ebiom.2021.103622; Boomer JS, 2011, JAMA-J AM MED ASSOC, V306, P2594, DOI 10.1001/jama.2011.1829; Briso EM, 2008, J IMMUNOL, V180, P7102, DOI 10.4049/jimmunol.180.11.7102; Calis J, 2013, NEW ENGL J MED, V369, P2062, DOI [10.1056/NEJMc1312359, 10.1056/NEJMra1208623]; Cavalli G, 2020, LANCET RHEUMATOL, V2, pE325, DOI 10.1016/S2665-9913(20)30127-2; Dimopoulos G, 2020, CELL HOST MICROBE, V28, P117, DOI 10.1016/j.chom.2020.05.007; Ding LL, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.733274; Dominitzki S, 2007, J IMMUNOL, V179, P2041, DOI 10.4049/jimmunol.179.4.2041; Ferrari F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217424; Fujino M, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11081327; Garbers C, 2018, NAT REV DRUG DISCOV, V17, P395, DOI 10.1038/nrd.2018.45; Guaraldi G, 2020, LANCET RHEUMATOL, V2, pE474, DOI 10.1016/S2665-9913(20)30173-9; Gupta S, 2021, JAMA INTERN MED, V181, P41, DOI 10.1001/jamainternmed.2020.6252; Hermine O, 2021, JAMA INTERN MED, V181, P32, DOI 10.1001/jamainternmed.2020.6820; Herold T, 2020, J ALLERGY CLIN IMMUN, V146, P128, DOI 10.1016/j.jaci.2020.05.008; Huet T, 2020, LANCET RHEUMATOL, V2, pE393, DOI 10.1016/S2665-9913(20)30164-8; Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153; Jostock T, 2001, EUR J BIOCHEM, V268, P160, DOI 10.1046/j.1432-1327.2001.01867.x; Kang SJ, 2020, P NATL ACAD SCI USA, V117, P22351, DOI 10.1073/pnas.2010229117; Koutsakos M, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100208; Kox M, 2020, JAMA-J AM MED ASSOC, V324, P1565, DOI 10.1001/jama.2020.17052; Leisman DE, 2020, LANCET RESP MED, V8, P1233, DOI 10.1016/S2213-2600(20)30404-5; McConnell MJ, 2021, J HEPATOL, V75, P647, DOI 10.1016/j.jhep.2021.04.050; McElvaney OJ, 2021, LANCET RESP MED, V9, P643, DOI 10.1016/S2213-2600(21)00103-X; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Miri Y, 2021, OPEN HEART, V8, DOI 10.1136/openhrt-2021-001694; Monneret G, 2021, J MED VIROL, V93, P197, DOI 10.1002/jmv.26317; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Muller-Newen G, 1998, J IMMUNOL, V161, P6347; Osuchowski MF, 2021, LANCET RESP MED, V9, P622, DOI 10.1016/S2213-2600(21)00218-6; Parr JB, 2021, JAMA INTERN MED, V181, P12, DOI 10.1001/jamainternmed.2020.6557; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Salvarani C, 2021, JAMA INTERN MED, V181, P24, DOI 10.1001/jamainternmed.2020.6615; Schmidt-Arras D, 2016, J HEPATOL, V64, P1403, DOI 10.1016/j.jhep.2016.02.004; Schuett H, 2012, ARTERIOSCL THROM VAS, V32, P281, DOI 10.1161/ATVBAHA.111.229435; Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313; Somers EC, 2021, CLIN INFECT DIS, V73, pE445, DOI [10.1093/cid/ciaa954, 10.1101/2020.05.29.20117358]; Sommer J, 2014, J BIOL CHEM, V289, P22140, DOI 10.1074/jbc.M114.560938; Stone JH, 2020, NEW ENGL J MED, V383, P2333, DOI 10.1056/NEJMoa2028836; Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0; Wei, 2021, MOL BIOMED, V2, P1, DOI [10.1186/s43556-020-00015-y, DOI 10.1186/S43556-020-00015-Y]; Wolf J, 2016, J BIOL CHEM, V291, P16186, DOI 10.1074/jbc.M116.718551; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Ziegler L, 2019, CARDIOVASC RES, V115, P213, DOI 10.1093/cvr/cvy191	49	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								891456	10.3389/fimmu.2022.891456	http://dx.doi.org/10.3389/fimmu.2022.891456			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P1QY	35634332	Green Published, gold			2022-12-18	WOS:000801793400001
J	Sijmons, D; Guy, AJ; Walduck, AK; Ramsland, PA				Sijmons, Daniel; Guy, Andrew J.; Walduck, Anna K.; Ramsland, Paul A.			Helicobacter pylori and the Role of Lipopolysaccharide Variation in Innate Immune Evasion	FRONTIERS IN IMMUNOLOGY			English	Review						H; pylori; innate immunity; lipopolysaccharide; dendritic cells; Lewis system antigens; molecular mimicry; adhesion; inflammation	NEUTROPHIL-ACTIVATING PROTEIN; GASTRIC EPITHELIAL-CELLS; PHASE VARIATION; EXPERIMENTAL-INFECTION; VACUOLATING CYTOTOXIN; DENDRITIC CELL; IV SECRETION; T-CELLS; DC-SIGN; LEWIS-B	Helicobacter pylori is an important human pathogen that infects half the human population and can lead to significant clinical outcomes such as acute and chronic gastritis, duodenal ulcer, and gastric adenocarcinoma. To establish infection, H. pylori employs several mechanisms to overcome the innate and adaptive immune systems. H. pylori can modulate interleukin (IL) secretion and innate immune cell function by the action of several virulence factors such as VacA, CagA and the type IV secretion system. Additionally, H. pylori can modulate local dendritic cells (DC) negatively impacting the function of these cells, reducing the secretion of immune signaling molecules, and influencing the differentiation of CD4(+) T helper cells causing a bias to Th1 type cells. Furthermore, the lipopolysaccharide (LPS) of H. pylori displays a high degree of phase variation and contains human blood group carbohydrate determinants such as the Lewis system antigens, which are proposed to be involved in molecular mimicry of the host. Lastly, the H. pylori group of outer membrane proteins such as BabA play an important role in attachment and interaction with host Lewis and other carbohydrate antigens. This review examines the various mechanisms that H. pylori utilises to evade the innate immune system as well as discussing how the structure of the H. pylori LPS plays a role in immune evasion.	[Sijmons, Daniel; Guy, Andrew J.; Walduck, Anna K.; Ramsland, Paul A.] RMIT Univ, Sch Sci, Melbourne, Vic, Australia; [Guy, Andrew J.] ZiP Diagnost, Collingwood, Vic, Australia; [Ramsland, Paul A.] Monash Univ, Dept Immunol, Melbourne, Vic, Australia; [Ramsland, Paul A.] Univ Melbourne, Dept Surg, Austin Hlth, Heidelberg, Vic, Australia	Royal Melbourne Institute of Technology (RMIT); Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne	Ramsland, PA (corresponding author), RMIT Univ, Sch Sci, Melbourne, Vic, Australia.; Ramsland, PA (corresponding author), Monash Univ, Dept Immunol, Melbourne, Vic, Australia.; Ramsland, PA (corresponding author), Univ Melbourne, Dept Surg, Austin Hlth, Heidelberg, Vic, Australia.	paul.ramsland@rmit.edu.au		Walduck, Anna/0000-0002-9624-4370	Research Training Program Stipend Scholarship from the Australian Government, Department of Education and Training	Research Training Program Stipend Scholarship from the Australian Government, Department of Education and Training	DS is supported by a Research Training Program Stipend Scholarship from the Australian Government, Department of Education and Training.	Abadi ATB, 2017, WORLD J GASTROENTERO, V23, P2870, DOI 10.3748/wjg.v23.i16.2870; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Al-Maleki AR, 2017, CELL MICROBIOL, V19, DOI 10.1111/cmi.12771; Alberts B., 2014, MOL BIOL CELL; Altobelli A, 2019, MBIO, V10, DOI 10.1128/mBio.00261-19; Amedei A, 2006, J CLIN INVEST, V116, P1092, DOI 10.1172/JCI27177; Ansari S, 2017, WORLD J GASTROENTERO, V23, P4158, DOI 10.3748/wjg.v23.i23.4158; Appelmelk BJ, 2000, INFECT IMMUN, V68, P5928, DOI 10.1128/IAI.68.10.5928-5932.2000; Araujo GRL, 2022, WORLD J GASTROENTERO, V28, P402, DOI 10.3748/wjg.v28.i4.402; Backert S, 2018, CURR TOP MICROBIOL, V413, P187, DOI 10.1007/978-3-319-75241-9_8; Backert S, 2010, TRENDS MICROBIOL, V18, P479, DOI 10.1016/j.tim.2010.08.003; Backstrom A, 2004, P NATL ACAD SCI USA, V101, P16923, DOI 10.1073/pnas.0404817101; Baj J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010027; Benktander J, 2018, VIRULENCE, V9, P738, DOI 10.1080/21505594.2018.1440171; Bergman MP, 2004, J EXP MED, V200, P979, DOI 10.1084/jem.20041061; Blanchard TG, 1999, CAN J GASTROENTEROL, V13, P591, DOI 10.1155/1999/142457; Blaser N, 2019, ADV EXP MED BIOL, V1149, P77, DOI 10.1007/5584_2019_360; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; Borlace GN, 2008, HELICOBACTER, V13, P380, DOI 10.1111/j.1523-5378.2008.00625.x; Carrillo JLM., 2017, PHYSL PATHOLOGY IMMU, DOI [10.5772/intechopen.70556, DOI 10.5772/INTECHOPEN.70556]; Cheok YY, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9122502; Chevalier C, 1999, MOL MICROBIOL, V31, P1359, DOI 10.1046/j.1365-2958.1999.01271.x; COVER TL, 1992, J INFECT DIS, V166, P1073, DOI 10.1093/infdis/166.5.1073; Crabtree JE, 1999, J CLIN PATHOL, V52, P653, DOI 10.1136/jcp.52.9.653; Cullen TW, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002454; D'Elios MM, 2007, FEMS IMMUNOL MED MIC, V50, P157, DOI 10.1111/j.1574-695X.2007.00258.x; Darwin P E, 1996, Helicobacter, V1, P20, DOI 10.1111/j.1523-5378.1996.tb00004.x; de Bernard M, 2010, TOXICON, V56, P1186, DOI 10.1016/j.toxicon.2009.09.020; Mattos Luiz Carlos de, 2016, Rev. Bras. Hematol. Hemoter., V38, P331, DOI 10.1016/j.bjhh.2016.07.005; de Melo FF, 2012, MICROBES INFECT, V14, P341, DOI 10.1016/j.micinf.2011.11.008; Diacovich L, 2010, NAT REV MICROBIOL, V8, P117, DOI 10.1038/nrmicro2295; Doohan D, 2021, TOXINS, V13, DOI 10.3390/toxins13070485; Dunne C, 2014, WORLD J GASTROENTERO, V20, P5610, DOI 10.3748/wjg.v20.i19.5610; Fan XJ, 2000, J IMMUNOL, V165, P1918, DOI 10.4049/jimmunol.165.4.1918; Farzi N, 2018, INFECT GENET EVOL, V60, P26, DOI 10.1016/j.meegid.2018.02.017; Forstneric V, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006574; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Fujimoto Y, 2012, CARBOHYD RES, V356, P37, DOI 10.1016/j.carres.2012.03.013; Gobert AP, 2019, MBIO, V10, DOI 10.1128/mBio.02174-19; Gonciarz W, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0515-z; Goodwin AC, 2008, MICROBIOL-SGM, V154, P2231, DOI 10.1099/mic.0.2007/016055-0; Gorrell RJ, 2013, INFECT IMMUN, V81, P3880, DOI 10.1128/IAI.01424-12; Grubman A, 2010, CELL MICROBIOL, V12, P626, DOI 10.1111/j.1462-5822.2009.01421.x; Guo HT, 2015, NAT MED, V21, P677, DOI 10.1038/nm.3893; Guo Y, 2004, NAT STRUCT MOL BIOL, V11, P591, DOI 10.1038/nsmb784; Hatakeyama M, 2017, P JPN ACAD B-PHYS, V93, P196, DOI 10.2183/pjab.93.013; Horridge DN, 2017, PATHOG DIS, V75, DOI 10.1093/femspd/ftx113; Huang Y, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00159; Ilver D, 1998, SCIENCE, V279, P373, DOI 10.1126/science.279.5349.373; Imai S, 2021, CELL HOST MICROBE, V29, P941, DOI 10.1016/j.chom.2021.04.006; Ishijima N, 2011, J BIOL CHEM, V286, P25256, DOI 10.1074/jbc.M111.233601; Junaid M, 2016, TOXICON, V118, P27, DOI 10.1016/j.toxicon.2016.04.037; Kaneko T, 2000, VIRCHOWS ARCH, V437, P514, DOI 10.1007/s004280000285; Kim JM, 2011, CLIN EXP IMMUNOL, V166, P34, DOI 10.1111/j.1365-2249.2011.04447.x; Kusters JG, 2006, CLIN MICROBIOL REV, V19, P449, DOI 10.1128/CMR.00054-05; Kwok T, 2007, NATURE, V449, P862, DOI 10.1038/nature06187; Lamarque D, 2000, BRIT J PHARMACOL, V130, P1531, DOI 10.1038/sj.bjp.0703468; Lamb A, 2013, J CELL BIOCHEM, V114, P491, DOI 10.1002/jcb.24389; Lamb A, 2009, EMBO REP, V10, P1242, DOI 10.1038/embor.2009.210; Latour YL, 2020, AMINO ACIDS, V52, P151, DOI 10.1007/s00726-019-02719-0; Lekmeechai S, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01837; Li H, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008497; Li H, 2018, TOXINS, V10, DOI 10.3390/toxins10090364; Li H, 2016, HELICOBACTER, V21, P445, DOI 10.1111/hel.12301; Li NS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0962-5; Lim SH, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-104; Lina TT, 2014, WORLD J GASTROENTERO, V20, P12753, DOI 10.3748/wjg.v20.i36.12753; Linden S, 2002, GASTROENTEROLOGY, V123, P1923, DOI 10.1053/gast.2002.37076; Ling SSM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131460; Liu AN, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10010145; Lozniewski A, 2003, INFECT IMMUN, V71, P2902, DOI 10.1128/IAI.71.5.2902-2906.2003; Luo Y, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00604; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Malfertheiner P, 2017, GUT, V66, P6, DOI 10.1136/gutjnl-2016-312288; Manojlovic N, 2004, HEPATO-GASTROENTEROL, V51, P282; Matteo MJ, 2011, INT J MOL EPIDEMIOL, V2, P286; Maverakis E, 2015, J AUTOIMMUN, V57, P1, DOI 10.1016/j.jaut.2014.12.002; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Miszczyk E, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/206463; Mitchell P, 2007, INFECT IMMUN, V75, P810, DOI 10.1128/IAI.00228-06; Monteiro MA, 2000, EUR J BIOCHEM, V267, P305, DOI 10.1046/j.1432-1327.2000.01007.x; Moonens K, 2016, CELL HOST MICROBE, V19, P55, DOI 10.1016/j.chom.2015.12.004; Moran AP, 2007, INT J MED MICROBIOL, V297, P307, DOI 10.1016/j.ijmm.2007.03.008; Moran AP, 1996, ALIMENT PHARM THER, V10, P39, DOI 10.1046/j.1365-2036.1996.22164004.x; Moran AP, 2002, J BIOL CHEM, V277, P5785, DOI 10.1074/jbc.M108574200; Moyat M, 2014, WORLD J GASTROENTERO, V20, P5583, DOI 10.3748/wjg.v20.i19.5583; Mungazi SG, 2018, ANN MED SURG, V35, P153, DOI 10.1016/j.amsu.2018.09.040; MUOTIALA A, 1992, INFECT IMMUN, V60, P1714, DOI 10.1128/IAI.60.4.1714-1716.1992; Negrini R, 1996, GASTROENTEROLOGY, V111, P655, DOI 10.1053/gast.1996.v111.pm8780570; NIELSEN H, 1994, J INFECT DIS, V170, P135, DOI 10.1093/infdis/170.1.135; Nilsson C, 2006, P NATL ACAD SCI USA, V103, P2863, DOI 10.1073/pnas.0511119103; Nilsson C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003811; O'Keeffe J, 2008, HELICOBACTER, V13, P1, DOI 10.1111/j.1523-5378.2008.00559.x; Obonyo M, 2007, INFECT IMMUN, V75, P2408, DOI 10.1128/IAI.01794-06; Oertli M, 2012, J CLIN INVEST, V122, P1082, DOI 10.1172/JCI61029; Olivera-Severo D, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01883; Ottemann KM, 2002, INFECT IMMUN, V70, P1984, DOI 10.1128/IAI.70.4.1984-1990.2002; Pachathundikandi SK, 2020, CANCERS, V12, DOI 10.3390/cancers12040803; Pachathundikandi SK, 2018, INNATE IMMUN-LONDON, V24, P11, DOI 10.1177/1753425917738043; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pasupuleti M, 2012, CRIT REV BIOTECHNOL, V32, P143, DOI 10.3109/07388551.2011.594423; Pece S, 1995, J ENDOTOXIN RES, V2, P455, DOI 10.1177/096805199600200609; Pece Salvatore, 1997, Recenti Progressi in Medicina, V88, P237; Perepelov AV, 2020, BIOCHEMISTRY-MOSCOW+, V85, P234, DOI 10.1134/S0006297920020108; Prashar A, 2022, ANNU REV PHYSIOL, V84, P485, DOI 10.1146/annurev-physiol-061121-035930; Raghwan, 2014, HELICOBACTER, V19, P17, DOI 10.1111/hel.12087; Ramachandra L, 2009, CURR OPIN IMMUNOL, V21, P98, DOI 10.1016/j.coi.2009.01.001; Ramarao N, 2001, INFECT IMMUN, V69, P2604, DOI 10.1128/IAI.69.4.2604-2611.2001; Ren ZG, 2001, J GASTROEN HEPATOL, V16, P142, DOI 10.1046/j.1440-1746.2001.02385.x; Roszczenko-Jasinska P, 2020, APPL MICROBIOL BIOT, V104, P9891, DOI 10.1007/s00253-020-10945-w; Salcedo SP, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040021; Sanders CJ, 2006, J IMMUNOL, V177, P2810, DOI 10.4049/jimmunol.177.5.2810; Sarajlic M, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00655-1; Semper RP, 2014, J IMMUNOL, V193, P3566, DOI 10.4049/jimmunol.1400362; Sharndama HC, 2022, BRAZ J MICROBIOL, V53, P33, DOI 10.1007/s42770-021-00675-0; SHERBURNE R, 1995, INFECT IMMUN, V63, P4564, DOI 10.1128/IAI.63.12.4564-4568.1995; Sheu BS, 2010, J GASTROEN HEPATOL, V25, P26, DOI 10.1111/j.1440-1746.2009.06141.x; Shimoyama A, 2011, CHEM-EUR J, V17, P14464, DOI 10.1002/chem.201003581; Smith Sinead M, 2014, World J Gastrointest Pathophysiol, V5, P133, DOI 10.4291/wjgp.v5.i3.133; Solnick JV, 2004, P NATL ACAD SCI USA, V101, P2106, DOI 10.1073/pnas.0308573100; Styer CM, 2010, INFECT IMMUN, V78, P1593, DOI 10.1128/IAI.01297-09; Sugimoto M, 2011, J GASTROEN HEPATOL, V26, P1677, DOI 10.1111/j.1440-1746.2011.06817.x; Tafreshi M, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00022; Talarico S, 2012, MOL MICROBIOL, V84, P1050, DOI 10.1111/j.1365-2958.2012.08073.x; Tanaka H, 2010, ARCH BIOCHEM BIOPHYS, V498, P35, DOI 10.1016/j.abb.2010.03.021; Tegtmeyer N, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108159; Testerman TL, 2014, WORLD J GASTROENTERO, V20, P12781, DOI 10.3748/wjg.v20.i36.12781; Toyoshima O, 2018, WORLD J GASTROENTERO, V24, P4061, DOI 10.3748/wjg.v24.i35.4061; Tran LS, 2017, MICROBES INFECT, V19, P449, DOI 10.1016/j.micinf.2017.06.005; Tshibangu-Kabamba E, 2021, NAT REV GASTRO HEPAT, V18, P613, DOI 10.1038/s41575-021-00449-x; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; Van den Brink GR, 2000, GUT, V46, P601, DOI 10.1136/gut.46.5.601; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Venerito M, 2019, HELICOBACTER, V24, DOI 10.1111/hel.12643; Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131; Wang SK, 2007, WORLD J GASTROENTERO, V13, P2923, DOI 10.3748/wjg.v13.i21.2923; Xu CJ, 2020, EUR J CLIN MICROBIOL, V39, P1821, DOI 10.1007/s10096-020-03948-y; Xue J, 2020, J REPROD IMMUNOL, V137, DOI 10.1016/j.jri.2019.103079; Yamaji Y, 2002, SCAND J GASTROENTERO, V37, P148, DOI 10.1080/003655202753416795; Yamaoka Y, 2000, P NATL ACAD SCI USA, V97, P7533, DOI 10.1073/pnas.130079797; Yamaoka Y, 2008, WORLD J GASTROENTERO, V14, P4265, DOI 10.3748/wjg.14.4265; Yokoyama K, 2005, P NATL ACAD SCI USA, V102, P9661, DOI 10.1073/pnas.0502529102; Zhang HX, 2020, INT J MED MICROBIOL, V310, DOI 10.1016/j.ijmm.2019.151356; Zhang L, 2018, J PATHOL, V244, P432, DOI 10.1002/path.5033	144	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								868225	10.3389/fimmu.2022.868225	http://dx.doi.org/10.3389/fimmu.2022.868225			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W1UD	35634347	gold, Green Published			2022-12-18	WOS:000806563800001
J	Thorel, M; Mateos-Hernandez, L; Mulot, B; Azzouni, MN; Hodzic, A; Gaillot, H; Ruel, Y; Desoubeaux, G; Delaye, JB; Obregon, D; Wu-Chuang, A; de la Fuente, J; Bermudez-Humaran, LG; Risco-Castillo, V; Leclerc, A; Cabezas-Cruz, A				Thorel, Milan; Mateos-Hernandez, Lourdes; Mulot, Baptiste; Azzouni, Mouna Naila; Hodzic, Adnan; Gaillot, Hugues; Ruel, Yannick; Desoubeaux, Guillaume; Delaye, Jean-Baptiste; Obregon, Dasiel; Wu-Chuang, Alejandra; de la Fuente, Jose; Bermudez-Humaran, Luis G.; Risco-Castillo, Veronica; Leclerc, Antoine; Cabezas-Cruz, Alejandro			Assessment of the Safety and Efficacy of an Oral Probiotic-Based Vaccine Against Aspergillus Infection in Captive-Bred Humboldt Penguins (Spheniscus humboldti)	FRONTIERS IN IMMUNOLOGY			English	Article						alpha-Gal Vaccine; aspergillosis; Aspergillus fumigatus; probiotics; E. coli Nissle 1917; penguins; Spheniscus humboldti; zoo	PLASMA-PROTEIN ELECTROPHORESIS; ALPHA-GAL; COMPUTED-TOMOGRAPHY; RESPIRATORY SYSTEM; PSITTACINE BIRDS; PYGOSCELIS-PAPUA; IMMUNE-RESPONSE; ANTIBODIES; DIAGNOSIS; DEMERSUS	Aspergillosis is a fungal infection caused mainly by Aspergillus fumigatus that often results in respiratory disease in birds. Aspergillosis is a major cause of morbidity and mortality in captive-bred penguin species. Currently, there is no registered vaccine to prevent aspergillosis. Recent research demonstrated that oral administration of gram-negative bacteria expressing high levels of galactose-alpha-1,3-galactose (alpha-Gal) modulates anti-alpha-Gal immunity and protects turkeys from clinical aspergillosis caused by experimental A. fumigatus infection. The role of anti-alpha-Gal immunity in penguins has not been studied. Here, we tested the distribution of alpha-1,3-galactosyltransferase (alpha 1,3GT) genes in the fecal microbiome of Humboldt penguins (Spheniscus humboldti). The occurrence of natural anti-alpha-Gal antibodies (Abs) in sera and eggs of healthy Humboldt penguins was also assessed. A trial was then conducted to test whether oral administration of Escherichia coli Nissle, expressing high alpha-Gal levels, modulates anti-alpha-Gal immunity in a colony of Humboldt penguins. Animals in the vaccination and placebo groups were evaluated before the trial and followed for one year for aspergillosis detection using a diagnostic panel including computed tomography scans, capillary zone electrophoresis, 3-hydroxybutyrate levels, and anti-A. fumigatus Abs. Anti-alpha-Gal Abs were detected in sera (IgM and IgY) and eggs (IgY) of healthy penguins. Microbiota analysis and functional predictions revealed the presence of alpha 1,3GT genes in the microbiota of Humboldt penguins and other penguin species. A strong decrease in anti-alpha-Gal IgM levels was observed in all animals in the placebo group three months after vaccination protocol. This decrease was not observed in E. coli Nissle-treated penguins. After the vaccination protocol, we found a positive correlation between anti-E. coli IgY and anti-alpha-Gal IgY in the E. coli Nissle group, suggesting a correlation between the presence of the bacteria and these Abs. During the study period, three penguins exhibited respiratory signs consistent with aspergillosis. Two were from the placebo group whose symptoms resolved with specific treatments, while a single vaccinated individual developed fatal respiratory aspergillosis eight months after the trial. We conclude that E. coli Nissle represents a safe potential probiotic with a protective effect against aspergillosis in Humboldt penguins that deserves to be further explored for therapeutic uses in these animals.	[Thorel, Milan; Mulot, Baptiste; Leclerc, Antoine] ZooParc Beauval & Beauval Nat, St Aignan Sur Cher, France; [Mateos-Hernandez, Lourdes; Azzouni, Mouna Naila; Wu-Chuang, Alejandra; Cabezas-Cruz, Alejandro] Ecole Natl Vet Alfort, Anses, INRAE, UMR BIPAR,Lab Sante Anim, Maisons Alfort, France; [Hodzic, Adnan] Univ Vet Med Vienna, Inst Parasitol, Dept Pathobiol, Vienna, Austria; [Gaillot, Hugues; Ruel, Yannick] ADVETIA Vet Hosp Ctr, Velizy Villacoublay, France; [Desoubeaux, Guillaume] CHU Tours, Serv Parasitol Mycol Med Trop, Tours, France; [Desoubeaux, Guillaume] Univ Tours, Fac Med, Ctr Etud Pathol Resp, Inserm U1100, Tours, France; [Delaye, Jean-Baptiste] CHU Tours, Lab Med Nucl Vitro Ctr Regpistage Neonatal, Pole Biol Med, Tours, France; [Obregon, Dasiel] Univ Guelph, Sch Environm Sci, Guelph, ON, Canada; [de la Fuente, Jose] CSIC, SaBio, Inst Deinvest Recursos Cineget IREC, UCLM,JCCM, Ciudad Real, Spain; [de la Fuente, Jose] Oklahoma State Univ, Ctr Vet Hlth Sci, Dept Vet Pathobiol, Stillwater, OK USA; [Bermudez-Humaran, Luis G.] Univ Paris Saclay, Micalis Inst, INRAE, AgroParisTech, Jouy En Josas, France; [Risco-Castillo, Veronica] Univ Paris Est, Ecole Natl Vet Alfort, EA Dynamyc 7380, UPEC,USC,ANSES, Maisons Alfort, France	Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES); Laboratoire de Sante Animale de Maisons-Alfort; Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE; University of Veterinary Medicine Vienna; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Tours; University of Guelph; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Castilla-La Mancha; Oklahoma State University System; Oklahoma State University - Stillwater; AgroParisTech; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Agence Nationale de Securite Sanitaire de l'Alimentation, de l'Environnement du Travail (ANSES); Ecole Nationale Veterinaire d'Alfort (ENVA); Universite Paris-Est-Creteil-Val-de-Marne (UPEC)	Thorel, M (corresponding author), ZooParc Beauval & Beauval Nat, St Aignan Sur Cher, France.; Cabezas-Cruz, A (corresponding author), Ecole Natl Vet Alfort, Anses, INRAE, UMR BIPAR,Lab Sante Anim, Maisons Alfort, France.	milan.thorel59@gmail.com; alejandro.cabezas@vet-alfort.fr	Cabezas-Cruz, Alejandro/P-2755-2017; Obregon Alvarez, Dasiel/E-6401-2016	Cabezas-Cruz, Alejandro/0000-0002-8660-730X; Obregon Alvarez, Dasiel/0000-0002-5786-1114	French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" [ANR-10-LABX-62-IBEID]; Programa Nacional de Becas de Postgrado en el Exterior "Don Carlos Antonio Lopez" [205/2018]	French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases"(French National Research Agency (ANR)); Programa Nacional de Becas de Postgrado en el Exterior "Don Carlos Antonio Lopez"	UMR BIPAR is supported by the French Government's Investissement d'Avenir program, Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (grant no. ANR-10-LABX-62-IBEID). AW-C is supported by Programa Nacional de Becas de Postgrado en el Exterior "Don Carlos Antonio Lopez" (grant no. 205/2018).	Allaire J.J, 2017, NETWORKD3 D3 JAVASCR; ALMEIDA IC, 1991, J IMMUNOL, V146, P2394; ALMEIDA IC, 1994, BIOCHEM J, V304, P793, DOI 10.1042/bj3040793; Alvarez-Perez S, 2010, VET MICROBIOL, V144, P444, DOI 10.1016/j.vetmic.2010.02.026; Arne P, 2021, J FUNGI, V7, DOI 10.3390/jof7030241; Barber AE, 2020, MED MYCOL, V58, P1187, DOI 10.1093/mmy/myaa045; Bechert U, 2010, J ZOO WILDLIFE MED, V41, P263, DOI 10.1638/2009-0211R.1; Beernaert LA, 2010, AVIAN PATHOL, V39, P325, DOI 10.1080/03079457.2010.506210; Bello-Gil D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00342; Bokulich NA, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0470-z; Bolyen E, 2019, NAT BIOTECHNOL, V37, P852, DOI 10.1038/s41587-019-0209-9; Bong JH, 2019, BIOSENS BIOELECTRON, V126, P518, DOI 10.1016/j.bios.2018.10.036; BORISH L, 1992, INFLAMMATION, V16, P471, DOI 10.1007/BF00918973; Bouhours JF, 1998, GLYCOCONJUGATE J, V15, P93, DOI 10.1023/A:1006903919461; Bunting EM, 2009, J ZOO WILDLIFE MED, V40, P508, DOI 10.1638/2009-0045.1; Cabana AL, 2019, BRAZ J BIOL, V79, P169, DOI 10.1590/1519-6984.171140; Cabana AL, 2015, PESQUI VET BRASIL, V35, P573, DOI 10.1590/S0100-736X2015000600015; Cabezas-Cruz A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01733; Cabezas-Cruz A, 2017, ACS CENTRAL SCI, V3, P1140, DOI 10.1021/acscentsci.7b00517; Cabezas-Cruz A, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2016.164; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/nmeth.3869, 10.1038/NMETH.3869]; Cook CL, 2001, J BIOSCI BIOENG, V91, P305, DOI 10.1016/S1389-1723(01)80139-0; Cray C, 2009, AVIAN DIS, V53, P491, DOI 10.1637/8673-030209-Reg.1; Cray C, 2009, J AVIAN MED SURG, V23, P125, DOI 10.1647/2007-041.1; Cray C, 2009, J ZOO WILDLIFE MED, V40, P64, DOI 10.1638/2007-0138.1; Cruz AC, 2016, EXPERT REV VACCINES, V15, P953, DOI 10.1080/14760584.2016.1181547; da Silva RP, 2015, J ZOO WILDLIFE MED, V46, P667, DOI 10.1638/2013-0092.1; Desoubeaux G, 2018, J ZOO WILDLIFE MED, V49, P696, DOI 10.1638/2017-0172.1; Dewar ML, 2013, MICROBIOLOGYOPEN, V2, P195, DOI 10.1002/mbo3.66; Douglas GM, 2020, NAT BIOTECHNOL, V38, P685, DOI 10.1038/s41587-020-0548-6; Fischer D, 2014, AVIAN DIS, V58, P587, DOI 10.1637/10831-032714-Reg; Fischer D, 2015, J EXOT PET MED, V24, P283, DOI 10.1053/j.jepm.2015.06.016; FLACH EJ, 1990, VET REC, V126, P81; Fryer J, 1999, XENOTRANSPLANTATION, V6, P98, DOI 10.1034/j.1399-3089.1999.00015.x; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; German AC, 2002, VET REC, V150, P513, DOI 10.1136/vr.150.16.513; Gonzalez J, 1995, Bol Chil Parasitol, V50, P3; Graczyk TK, 1995, MYCOPATHOLOGIA, V131, P179, DOI 10.1007/BF01102898; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Hasselquist D, 2009, PHILOS T R SOC B, V364, P51, DOI 10.1098/rstb.2008.0137; Hodzic A, 2020, TRENDS PARASITOL, V36, P992, DOI 10.1016/j.pt.2020.08.001; Hyatt MW, 2015, J ZOO WILDLIFE MED, V46, P880, DOI 10.1638/2015-0128.1; Iniguez E, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0006039; Itoh M, 2020, J VET MED SCI, V82, P1260, DOI 10.1292/jvms.20-0129; Ivey ES, 2000, J AVIAN MED SURG, V14, P103, DOI 10.1647/1082-6742(2000)014[0103:SAPPEF]2.0.CO;2; Jones MP, 2000, SEMIN AVIAN EXOT PET, V9, P52, DOI 10.1053/AX.2000.4619; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kostka V., 2013, P 1 ICARE C; Krol L, 2020, ZOO BIOL, V39, P405, DOI 10.1002/zoo.21561; Kummrow M, 2012, J AVIAN MED SURG, V26, P213, DOI 10.1647/2011-006R1.1; Lee CC, 2019, J IMMUNOL, V202, P991, DOI 10.4049/jimmunol.1800736; Leinonen R, 2011, NUCLEIC ACIDS RES, V39, pD19, DOI 10.1093/nar/gkq1019; LEUNG KH, 1982, IMMUNOPHARMACOLOGY, V4, P55, DOI 10.1016/0162-3109(82)90025-X; Luo Y, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00374; Mach N, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.583600; Manez R, 2001, XENOTRANSPLANTATION, V8, P15, DOI 10.1034/j.1399-3089.2001.00082.x; Mateos-Hernandez L, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020285; Melo AM, 2021, MED MYCOL, V59, P1076, DOI 10.1093/mmy/myab040; Meredith A., 1997, 4 C EUROPEAN COMMITT, p227s; Montassier E, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03000; Mota MS., 2021, P JOINT AAZVEAZWV, P108; NAKEEB SM, 1981, J ZOO ANIM MED, V12, P51, DOI 10.2307/20094516; Naylor AD, 2017, VET CLIN PATH, V46, P605, DOI 10.1111/vcp.12527; Nevitt BN, 2014, AM J VET RES, V75, P739, DOI 10.2460/ajvr.75.8.739; Pacheco I, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14070635; Palinauskas V, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.807682; Posekany KJ, 2002, INFECT IMMUN, V70, P6215, DOI 10.1128/IAI.70.11.6215-6222.2002; Redig Patrick T., 1993, P178; Redig PT., 2016, AVIAN MED 3 EDITION, P460; Reed K, 2020, J ZOO WILDLIFE MED, V51, P591, DOI 10.1638/2019-0160; RICHARD JL, 1991, AVIAN DIS, V35, P93, DOI 10.2307/1591300; Rivas AE, 2019, J ZOO WILDLIFE MED, V50, P396, DOI 10.1638/2018-0189; Rivas AE, 2019, J ZOO WILDLIFE MED, V50, P427, DOI 10.1638/2018-0190; Rivas AE, 2018, J ZOO WILDLIFE MED, V49, P542, DOI 10.1638/2017-0119.1; RStudio Team, 2020, RSTUDIO INT DEV R RS; Smith JA, 2010, J ZOO WILDLIFE MED, V41, P487, DOI 10.1638/2010-0019.1; SPRINGER GF, 1969, J CLIN INVEST, V48, P1280, DOI 10.1172/JCI106094; SPRINGER GF, 1959, J EXP MED, V110, P221, DOI 10.1084/jem.110.2.221; Stidworthy MF, 2018, PATHOLOGY OF WILDLIFE AND ZOO ANIMALS, P653, DOI 10.1016/B978-0-12-805306-5.00027-4; Thompson R., 2013, UNDERSTANDING DIAGNO; Trumpp K, 2021, J ZOO WILDLIFE MED, V52, P1135, DOI 10.1638/2020-0224; Valdivia AO, 2020, ACS OMEGA, V5, P33280, DOI 10.1021/acsomega.0c04983; Wallace RS., 2015, FOWLERS ZOO WILD ANI, P82; Walsh WE, 2000, IMMUNOLOGY, V101, P467, DOI 10.1046/j.1365-2567.2000.00136.x; Westendorf AM, 2005, FEMS IMMUNOL MED MIC, V43, P373, DOI 10.1016/j.femsim.2004.10.023; Wieczorek E, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071768; Xavier MO, 2007, BRAZ J MICROBIOL, V38, P480, DOI 10.1590/S1517-83822007000300018; Yamada K, 2020, J VET MED SCI, V82, P373, DOI 10.1292/jvms.19-0431; Yan L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32959-1; Yarza P, 2014, NAT REV MICROBIOL, V12, P635, DOI 10.1038/nrmicro3330; Yilmaz B, 2014, CELL, V159, P1277, DOI 10.1016/j.cell.2014.10.053; Zalesak SM, 2020, J AVIAN MED SURG, V34, P52, DOI 10.1647/1082-6742-34.1.52	92	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								897223	10.3389/fimmu.2022.897223	http://dx.doi.org/10.3389/fimmu.2022.897223			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T7TS	35634323	Green Submitted, Green Published, gold			2022-12-18	WOS:000804931100001
J	Ye, XL; Liu, LH; Chen, LA; Nie, XH; Huang, L; Ye, DH; Zeng, JF; Li, T; Li, B; Xu, M; Chen, LM				Ye, Xianlin; Liu, Lihua; Chen, Lina; Nie, Xianghui; Huang, Lu; Ye, Denghuang; Zeng, Jinfeng; Li, Tong; Li, Bin; Xu, Min; Chen, Limin			High-Frequency Notable HBV Mutations Identified in Blood Donors With Occult Hepatitis B Infection From Heyuan City of Southern China	FRONTIERS IN IMMUNOLOGY			English	Article						occult hepatitis B virus infection (OBI); blood donors; gene mutations; mini pool (MP); nucleic acid testing (NAT)	NUCLEIC-ACID TEST; VIRUS INFECTION; TESTING ALGORITHM; C-VIRUS; TRANSMISSION; DONATIONS; RISK; EXPERIENCE	BackgroundAll Chinese blood centers have implemented mini pool (MP) HBV nucleic acid testing (NAT) together with HBsAg ELISA in routine donor screening since 2015. The prevalence of occult hepatitis B virus infection (OBI) in donors from different regions varies, and the molecular characterization of the HBV DNA and clinical outcomes of these OBIs remain largely unexplored. MethodsBlood donations from Heyuan city in Southern China were screened by HBsAg ELISA and HBV MP8 NAT. Donations with HBsAg-/HBV DNA+ were collected for this study. Molecular characterizations of HBV DNAs were further analyzed by various DNA amplification assays including quantitative PCR (qPCR) and nested PCR, amplifying the basic core and pre-core promoter regions (BCP/PC). The HBsAg (S) region from HBV DNA was isolated by high-volume nucleic acid extraction. Notable mutations were identified by comparison to the HBV reference sequences. The clinical outcomes of the donors with OBIs were further followed for nearly 3 years. ResultsSeventy OBIs from 44,592 donations (0.15%) that we identified and reported previously were enrolled for this current study. HBV sequences were obtained from 44/70 OBIs, and genotyping analysis showed that 42/44 (95.2%) OBIs were genotype B, and 2/44 (4.8%) were genotype C. Interestingly, mutation analysis revealed that various mutations including M133L/T, F134L, P142L, V168A, R169H, S174N, L175S, and V177A of HBV DNA affecting HBsAg detection were observed in genotype B OBIs. Two notable mutations, T47K and L53S, were identified in genotype C OBIs. Follow-up studies showed that 3/31 (9.7%) OBIs converted to HBsAg+ as chronic infections while 1/31 (3.2%) HBV DNA was undetectable (classified as recovery) and 27/31 (87.1%) remained as OBIs. ConclusionVarious notable mutations affecting HBsAg detection were observed in blood donors with OBIs in Heyuan city of Southern China. Follow-up studies showed that most OBIs remained as OBIs with fluctuating or low viral loads. Higher sensitive HBV ID NAT is recommended for donor screening to further reduce the transmission risk of OBIs.	[Ye, Xianlin; Zeng, Jinfeng; Li, Tong] Shenzhen Blood Ctr, Dept Lab, Shenzhen, Peoples R China; [Liu, Lihua; Chen, Lina; Nie, Xianghui; Huang, Lu; Ye, Denghuang] Heyuan Blood Ctr, Dept Lab, Heyuan, Peoples R China; [Li, Bin; Chen, Limin] Chinese Acad Med Sci, Joint Lab Transfus Transmitted Dis TTDs, Inst Blood Transfus, Nanning, Peoples R China; [Li, Bin; Chen, Limin] Nanning Blood Ctr, Nanning, Peoples R China; [Xu, Min; Chen, Limin] Chinese Acad Med Sci CAMS & Peking Union Med Coll, Inst Blood Transfus, Prov Key Lab Transfus Transmitted Dis, Chengdu, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Blood Transfusion - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Blood Transfusion - CAMS	Li, B; Chen, LM (corresponding author), Chinese Acad Med Sci, Joint Lab Transfus Transmitted Dis TTDs, Inst Blood Transfus, Nanning, Peoples R China.; Li, B; Chen, LM (corresponding author), Nanning Blood Ctr, Nanning, Peoples R China.; Xu, M; Chen, LM (corresponding author), Chinese Acad Med Sci CAMS & Peking Union Med Coll, Inst Blood Transfus, Prov Key Lab Transfus Transmitted Dis, Chengdu, Peoples R China.	leo_li2323@163.com; xumin999@foxmail.com; limin_chen_99@126.com			Nature and Science Fund of Shenzhen and Guangdong [JCYJ20190806112201646, 2021A1515010979]; Shenzhen Key Medical Discipline Construction Fund [SZXK070]; CAMS Initiative for Innovative Medicine [CAMS-2016-I2M-3-025, CAMS-2017-I2M-BR-15]; National Key Research and Development Program [2018YFE0107500]; Science and Technology Partnership Program; Ministry of Science and Technology of China [KY201904011]	Nature and Science Fund of Shenzhen and Guangdong; Shenzhen Key Medical Discipline Construction Fund; CAMS Initiative for Innovative Medicine; National Key Research and Development Program; Science and Technology Partnership Program; Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by the Nature and Science Fund of Shenzhen and Guangdong (JCYJ20190806112201646 and 2021A1515010979) and Shenzhen Key Medical Discipline Construction Fund (SZXK070) to XY and CAMS Initiative for Innovative Medicine (CAMS-2016-I2M-3-025 and CAMS-2017-I2M-B & R-15), the National Key Research and Development Program (2018YFE0107500), and Science and Technology Partnership Program, Ministry of Science and Technology of China (KY201904011) to LC.	Allain JP, 2015, OCCULT HEPATITIS B I, P190; Candotti D, 2009, J HEPATOL, V51, P798, DOI 10.1016/j.jhep.2009.05.020; Chan HLY, 2004, GUT, V53, P1494, DOI 10.1136/gut.2003.033324; Chen JH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155654; Dickson RC, 1997, GASTROENTEROLOGY, V113, P1668, DOI 10.1053/gast.1997.v113.pm9352871; Dodd RY, 2018, TRANSFUSION, V58, P2166, DOI 10.1111/trf.14784; Echevarria JM, 2006, J MED VIROL, V78, pS36, DOI 10.1002/jmv.20605; Enjalbert F, 2014, TRANSFUSION, V54, P2485, DOI 10.1111/trf.12653; Gerlich WH, 2006, J CLIN VIROL, V36, pS18, DOI 10.1016/S1386-6532(06)80004-1; Gish RG, 2014, J VIRAL HEPATITIS, V21, P905, DOI 10.1111/jvh.12257; Gou HN, 2015, TRANSFUSION, V55, P2272, DOI 10.1111/trf.13135; Hoshi Y, 2019, TRANSFUSION, V59, P2602, DOI 10.1111/trf.15393; Hourfar MK, 2008, TRANSFUSION, V48, P1558, DOI 10.1111/j.1537-2995.2008.01718.x; Levicnik-Stezinar S, 2008, J HEPATOL, V48, P1022, DOI 10.1016/j.jhep.2008.02.016; Li HM, 2015, WORLD J GASTROENTERO, V21, P6684, DOI 10.3748/wjg.v21.i21.6684; Li L, 2008, TRANSFUSION, V48, P1198, DOI 10.1111/j.1537-2995.2008.01672.x; Liang J., 2011, S CHINA J PREV MED I, V37, P40; Liang XF, 2009, VACCINE, V27, P6550, DOI 10.1016/j.vaccine.2009.08.048; Liu L., 2019, CHINA MED PHARM, V9, P196, DOI [10.3969/j.issn.1671-7414.2020.04.009, DOI 10.3969/J.ISSN.1671-7414.2020.04.009]; Liu LiHua, 2020, Journal of Modern Laboratory Medicine, V35, P32, DOI 10.3969/j.issn.1671-7414.2020.04.008; Louisirirotchanakul S, 2011, TRANSFUSION, V51, P1532, DOI 10.1111/j.1537-2995.2010.03023.x; Mak LY, 2020, J HEPATOL, V73, P952, DOI 10.1016/j.jhep.2020.05.042; McMahon BJ, 2021, HEPATOLOGY, V74, P2965, DOI 10.1002/hep.32065; Niazi SK, 2015, TRANSFUSION, V55, P1803, DOI 10.1111/trf.13017; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; Ponde RAA, 2013, EUR J CLIN MICROBIOL, V32, P461, DOI 10.1007/s10096-012-1781-9; Raimondi S, 2010, J HEPATOL, V52, P441, DOI 10.1016/j.jhep.2009.12.014; Raimondo G, 2019, J HEPATOL, V71, P397, DOI 10.1016/j.jhep.2019.03.034; Seed CR, 2017, VOX SANG, V112, P3, DOI 10.1111/vox.12446; Seed CR, 2019, VOX SANG, V114, P397, DOI 10.1111/vox.12744; Stolz M, 2019, TRANSFUS MED HEMOTH, V46, P104, DOI 10.1159/000499166; Svicher V, 2012, ANTIVIR RES, V93, P86, DOI 10.1016/j.antiviral.2011.10.022; Tong SP, 2005, J CLIN VIROL, V34, pS134, DOI 10.1016/S1386-6532(05)80023-X; Tsoi WC, 2013, TRANSFUSION, V53, P2477, DOI 10.1111/trf.12165; Wang H, 2020, J VIRAL HEPATITIS, V27, P915, DOI 10.1111/jvh.13309; Wang J, 2017, VACCINE, V35, P5808, DOI 10.1016/j.vaccine.2017.09.030; Wang LN, 2015, TRANSFUSION, V55, P395, DOI 10.1111/trf.12818; Weusten J, 2011, TRANSFUSION, V51, P203, DOI 10.1111/j.1537-2995.2010.02804.x; Yang ZS, 2013, TRANSFUSION, V53, P2538, DOI 10.1111/trf.12159; Ye XL, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4215-9; Ye XL, 2017, BLOOD TRANSFUS-ITALY, V15, P6, DOI 10.2450/2016.0268-15; Ye XL, 2013, TRANSFUS APHER SCI, V49, P318, DOI 10.1016/j.transci.2013.08.005; Yuan Q, 2010, J CLIN MICROBIOL, V48, P357, DOI 10.1128/JCM.01781-09; Zeng FF, 2016, SCI REP-UK, V6, DOI 10.1038/srep36186; Zheng X, 2015, TRANSFUSION, V55, P890, DOI 10.1111/trf.12902; Zheng X, 2011, J CLIN MICROBIOL, V49, P1730, DOI 10.1128/JCM.00145-11	46	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 13	2022	13								754383	10.3389/fimmu.2022.754383	http://dx.doi.org/10.3389/fimmu.2022.754383			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1W2AJ	35634299	gold, Green Published			2022-12-18	WOS:000806580100001
J	Aubrey, M; Warburg, ZJ; Murre, C				Aubrey, Megan; Warburg, Zachary J.; Murre, Cornelis			Helix-Loop-Helix Proteins in Adaptive Immune Development	FRONTIERS IN IMMUNOLOGY			English	Review						HLH; E proteins; Id proteins; VDJ recombination; lymphopoiesis; hematopoiesis; T cell development; B cell development	TRANSCRIPTION FACTORS E2A; ADULT HEMATOPOIETIC STEM; B-CELL DEVELOPMENT; RECOMBINATION ACTIVATING GENE; LIGHT-CHAIN RECOMBINATION; HEAVY-CHAIN; V(D)J RECOMBINATION; ALPHA-BETA; GERMINAL CENTER; DNA-BINDING	The E/ID protein axis is instrumental for defining the developmental progression and functions of hematopoietic cells. The E proteins are dimeric transcription factors that activate gene expression programs and coordinate changes in chromatin organization. Id proteins are antagonists of E protein activity. Relative levels of E/Id proteins are modulated throughout hematopoietic development to enable the progression of hematopoietic stem cells into multiple adaptive and innate immune lineages including natural killer cells, B cells and T cells. In early progenitors, the E proteins promote commitment to the T and B cell lineages by orchestrating lineage specific programs of gene expression and regulating VDJ recombination of antigen receptor loci. In mature B cells, the E/Id protein axis functions to promote class switch recombination and somatic hypermutation. E protein activity further regulates differentiation into distinct CD4+ and CD8+ T cells subsets and instructs mature T cell immune responses. In this review, we discuss how the E/Id proteins define the adaptive immune system lineages, focusing on their role in directing developmental gene programs.	[Aubrey, Megan; Warburg, Zachary J.; Murre, Cornelis] Univ Calif San Diego, Div Biol Sci, Sect Mol Biol, San Diego, CA USA	University of California System; University of California San Diego	Murre, C (corresponding author), Univ Calif San Diego, Div Biol Sci, Sect Mol Biol, San Diego, CA USA.	cmurre@ucsd.edu		Warburg, Zachary/0000-0003-3115-497X				Agata Y, 2001, J EXP MED, V193, P873, DOI 10.1084/jem.193.7.873; Agata Y, 2007, IMMUNITY, V27, P871, DOI 10.1016/j.immuni.2007.11.015; ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Bain G, 1999, J EXP MED, V189, P289, DOI 10.1084/jem.189.2.289; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Bain G, 1998, SEMIN IMMUNOL, V10, P143, DOI 10.1006/smim.1998.0116; Baker JE, 1998, IMMUNITY, V9, P159, DOI 10.1016/S1074-7613(00)80598-1; Barndt R, 1999, J IMMUNOL, V163, P3331; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; Beck K, 2009, J EXP MED, V206, P2271, DOI 10.1084/jem.20090756; Blom B, 1999, EMBO J, V18, P2793, DOI 10.1093/emboj/18.10.2793; Blume J, 2019, EUR J IMMUNOL, V49, P121, DOI 10.1002/eji.201847660; Borghesi L, 2005, J EXP MED, V202, P1669, DOI 10.1084/jem.20051190; Bories JC, 1996, P NATL ACAD SCI USA, V93, P7871, DOI 10.1073/pnas.93.15.7871; Bossen C, 2015, NAT IMMUNOL, V16, P775, DOI 10.1038/ni.3170; Bouderlique T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00455; Bouvier G, 1996, P NATL ACAD SCI USA, V93, P7877, DOI 10.1073/pnas.93.15.7877; Bradney C, 2003, J BIOL CHEM, V278, P2370, DOI 10.1074/jbc.M211464200; Braunstein M, 2011, MOL CELL BIOL, V31, P971, DOI 10.1128/MCB.01034-10; Braunstein M, 2010, EUR J IMMUNOL, V40, P3173, DOI 10.1002/eji.201040360; Cannarile MA, 2006, NAT IMMUNOL, V7, P1317, DOI 10.1038/ni1403; CAPONE M, 1993, EMBO J, V12, P4335, DOI 10.1002/j.1460-2075.1993.tb06118.x; Chapple RH, 2018, BLOOD ADV, V2, P1220, DOI 10.1182/bloodadvances.2018016295; Chen SW, 2016, MOL CELL BIOL, V36, P2543, DOI 10.1128/MCB.00150-16; CHIEN YH, 1987, NATURE, V330, P722, DOI 10.1038/330722a0; Choi JK, 1996, EMBO J, V15, P5014, DOI 10.1002/j.1460-2075.1996.tb00881.x; Chu C, 2001, J BIOL CHEM, V276, P8524, DOI 10.1074/jbc.M008371200; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; D'Cruz LM, 2014, J IMMUNOL, V192, P2227, DOI 10.4049/jimmunol.1302904; D'Cruz LM, 2012, EUR J IMMUNOL, V42, P2031, DOI 10.1002/eji.201242497; D'Cruz LM, 2010, NAT IMMUNOL, V11, P240, DOI 10.1038/ni.1845; Decker T, 2009, IMMUNITY, V30, P508, DOI 10.1016/j.immuni.2009.01.012; del Blanco B, 2015, P NATL ACAD SCI USA, V112, pE1744, DOI 10.1073/pnas.1406551112; del Blanco B, 2012, J IMMUNOL, V188, P3278, DOI 10.4049/jimmunol.1100271; Denholtz M, 2020, GENE DEV, V34, P149, DOI 10.1101/gad.333708.119; Dias S, 2008, IMMUNITY, V29, P217, DOI 10.1016/j.immuni.2008.05.015; Dinesh RK, 2020, EUR J IMMUNOL, V50, P380, DOI 10.1002/eji.201948357; Ebert A, 2011, IMMUNITY, V34, P175, DOI 10.1016/j.immuni.2011.02.005; Emmanuel AO, 2018, NAT IMMUNOL, V19, P1366, DOI 10.1038/s41590-018-0254-4; Engel I, 2004, EMBO J, V23, P202, DOI 10.1038/sj.emboj.7600017; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Fahl SP., 2017, SIGNALING MECH REGUL, V476, P85; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; Frias AB, 2019, J IMMUNOL, V203, P658, DOI 10.4049/jimmunol.1900358; Fuxa M, 2004, GENE DEV, V18, P411, DOI 10.1101/gad.291504; Gloury R, 2016, J EXP MED, V213, P1095, DOI 10.1084/jem.20152003; Goldfarb AN, 1996, MOL IMMUNOL, V33, P947, DOI 10.1016/S0161-5890(96)00047-8; Gonda H, 2003, J EXP MED, V198, P1427, DOI 10.1084/jem.20030802; Gorman JR, 1996, IMMUNITY, V5, P241, DOI 10.1016/S1074-7613(00)80319-2; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Grundstrom C, 2018, EUR J IMMUNOL, V48, P1687, DOI 10.1002/eji.201847625; Haks MC, 2005, IMMUNITY, V22, P595, DOI 10.1016/j.immuni.2005.04.003; Hauser J, 2008, P NATL ACAD SCI USA, V105, P1267, DOI 10.1073/pnas.0708220105; Hauser J, 2016, MOL IMMUNOL, V80, P78, DOI 10.1016/j.molimm.2016.10.014; Hauser J, 2013, MOL IMMUNOL, V54, P247, DOI 10.1016/j.molimm.2012.12.002; Hauser J, 2010, MOL IMMUNOL, V47, P1031, DOI 10.1016/j.molimm.2009.11.015; Hayes SM, 2005, IMMUNITY, V22, P583, DOI 10.1016/j.immuni.2005.03.014; Hodawadekar S, 2012, J IMMUNOL, V188, P2276, DOI 10.4049/jimmunol.1102239; Hosokawa H, 2018, NAT IMMUNOL, V19, P1427, DOI 10.1038/s41590-018-0238-4; Hsu LY, 2003, IMMUNITY, V19, P105, DOI 10.1016/S1074-7613(03)00181-X; Hu TS, 2013, J IMMUNOL, V191, P5065, DOI 10.4049/jimmunol.1301546; Huang ZF, 2006, J IMMUNOL, V176, P4880, DOI 10.4049/jimmunol.176.8.4880; Igarashi H, 2002, IMMUNITY, V17, P117, DOI 10.1016/S1074-7613(02)00366-7; Ikawa T, 2004, IMMUNITY, V20, P349, DOI 10.1016/S1074-7613(04)00049-4; Ikawa T, 2015, STEM CELL REP, V5, P716, DOI 10.1016/j.stemcr.2015.09.012; Ikawa T, 2006, J EXP MED, V203, P1329, DOI 10.1084/jem.20060268; Ikawa T, 2010, SCIENCE, V329, P93, DOI 10.1126/science.1188995; Inlay MA, 2004, J EXP MED, V200, P1205, DOI 10.1084/jem.20041135; Inlay MA, 2009, GENE DEV, V23, P2376, DOI 10.1101/gad.1836009; Ioannidis V, 2001, NAT IMMUNOL, V2, P691, DOI 10.1038/90623; Isoda T, 2017, CELL, V171, P103, DOI 10.1016/j.cell.2017.09.001; IWASHIMA M, 1988, P NATL ACAD SCI USA, V85, P8161, DOI 10.1073/pnas.85.21.8161; Jaleco AC, 1999, BLOOD, V94, P2637, DOI 10.1182/blood.V94.8.2637.420k22_2637_2646; Jensen CT, 2018, J EXP MED, V215, P1947, DOI 10.1084/jem.20171384; Jhunjhunwala S, 2008, CELL, V133, P265, DOI 10.1016/j.cell.2008.03.024; Jia JQ, 2008, EUR J IMMUNOL, V38, P2806, DOI 10.1002/eji.200838144; Johnson K, 2008, IMMUNITY, V28, P335, DOI 10.1016/j.immuni.2007.12.019; Jones-Mason ME, 2012, IMMUNITY, V36, P348, DOI 10.1016/j.immuni.2012.02.010; Kadakia T, 2019, J EXP MED, V216, P1749, DOI 10.1084/jem.20182285; Karki S, 2018, CELL REP, V24, P2443, DOI 10.1016/j.celrep.2018.07.091; Kee BL, 2001, NAT IMMUNOL, V2, P242, DOI 10.1038/85303; Kee BL, 2002, EMBO J, V21, P103, DOI 10.1093/emboj/21.1.103; Kleiman E, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02074; Knell J, 2013, J IMMUNOL, V190, P1501, DOI 10.4049/jimmunol.1200750; Kosak ST, 2002, SCIENCE, V296, P158, DOI 10.1126/science.1068768; Krangel MS, 2009, CURR OPIN IMMUNOL, V21, P133, DOI 10.1016/j.coi.2009.03.009; Kwon K, 2008, IMMUNITY, V28, P751, DOI 10.1016/j.immuni.2008.04.014; Langerak AW, 2001, BLOOD, V98, P2456, DOI 10.1182/blood.V98.8.2456; Lauritsen JPH, 2009, IMMUNITY, V31, P565, DOI 10.1016/j.immuni.2009.07.010; Lazorchak AS, 2006, MOL CELL BIOL, V26, P810, DOI 10.1128/MCB.26.3.810-821.2006; Li J, 2013, J IMMUNOL, V191, P5052, DOI 10.4049/jimmunol.1301252; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; Lin YC, 2012, NAT IMMUNOL, V13, P1196, DOI 10.1038/ni.2432; Lin YC, 2010, NAT IMMUNOL, V11, P635, DOI 10.1038/ni.1891; Lio CW, 2016, ELIFE, V5, DOI 10.7554/eLife.18290; Longabaugh WJR, 2017, P NATL ACAD SCI USA, V114, P5800, DOI 10.1073/pnas.1610617114; Majumder K, 2015, ADV IMMUNOL, V128, P273, DOI 10.1016/bs.ai.2015.07.001; Mandal M, 2009, NAT IMMUNOL, V10, P1110, DOI 10.1038/ni.1785; Manoharan A, 2015, EUR J IMMUNOL, V45, P2343, DOI 10.1002/eji.201445035; Mansson R, 2012, P NATL ACAD SCI USA, V109, P21028, DOI 10.1073/pnas.1211427109; Mansson R, 2010, BLOOD, V115, P2601, DOI 10.1182/blood-2009-08-236398; Masson F, 2013, J IMMUNOL, V190, P4585, DOI 10.4049/jimmunol.1300099; Mercer EM, 2011, IMMUNITY, V35, P413, DOI 10.1016/j.immuni.2011.06.013; Michael N, 2003, IMMUNITY, V19, P235, DOI 10.1016/S1074-7613(03)00204-8; Milner JJ, 2020, IMMUNITY, V52, P808, DOI 10.1016/j.immuni.2020.04.007; Miyazaki K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.659761; Miyazaki K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1455; Miyazaki M, 2017, IMMUNITY, V46, P818, DOI 10.1016/j.immuni.2017.04.022; Miyazaki M, 2015, GENE DEV, V29, P409, DOI 10.1101/gad.255331.114; Miyazaki M, 2014, NAT IMMUNOL, V15, P767, DOI 10.1038/ni.2928; Miyazaki M, 2011, NAT IMMUNOL, V12, P992, DOI 10.1038/ni.2086; Monticelli LA, 2009, P NATL ACAD SCI USA, V106, P19461, DOI 10.1073/pnas.0908249106; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nagulapalli S, 2002, MOL CELL BIOL, V22, P7337, DOI 10.1128/MCB.22.20.7337-7350.2002; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; Naik AK, 2019, J EXP MED, V216, P231, DOI 10.1084/jem.20181402; Nazaraliyev A, 2020, CURR OPIN HEMATOL, V27, P241, DOI 10.1097/MOH.0000000000000587; Nozaki M, 2011, INT IMMUNOL, V23, P297, DOI 10.1093/intimm/dxr005; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Omilusik KD, 2018, J EXP MED, V215, P773, DOI 10.1084/jem.20171584; Omilusik KD, 2013, CURR OPIN IMMUNOL, V25, P660, DOI 10.1016/j.coi.2013.09.004; Petersson K, 2002, EUR J IMMUNOL, V32, P911, DOI 10.1002/1521-4141(200203)32:3<911::AID-IMMU911>3.0.CO;2-H; Pilzecker B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00438; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Quong MW, 2004, J EXP MED, V199, P1101, DOI 10.1084/jem.20031180; Quong MW, 1999, EMBO J, V18, P6307, DOI 10.1093/emboj/18.22.6307; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Roldan E, 2005, NAT IMMUNOL, V6, P31, DOI 10.1038/ni1150; Romanow WJ, 2000, MOL CELL, V5, P343, DOI 10.1016/S1097-2765(00)80429-3; Roy S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00042; Sakamoto S, 2012, J IMMUNOL, V188, P5547, DOI 10.4049/jimmunol.1002346; SAWADA S, 1993, MOL CELL BIOL, V13, P5620, DOI 10.1128/MCB.13.9.5620; Sayegh C, 2005, GENE DEV, V19, P322, DOI 10.1101/gad.1254305; Sayegh CE, 2003, NAT IMMUNOL, V4, P586, DOI 10.1038/ni923; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schauder DM, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2013452118; Schebesta M, 2002, IMMUNITY, V17, P473, DOI 10.1016/S1074-7613(02)00418-1; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; Schotte R, 2010, J IMMUNOL, V184, P6670, DOI 10.4049/jimmunol.0901508; Schwartz R, 2006, P NATL ACAD SCI USA, V103, P9976, DOI 10.1073/pnas.0603728103; Seet CS, 2004, J EXP MED, V199, P1689, DOI 10.1084/jem.20032202; Semerad CL, 2009, P NATL ACAD SCI USA, V106, P1930, DOI 10.1073/pnas.0808866106; Sharma A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115803; Shaw LA, 2016, NAT IMMUNOL, V17, P834, DOI 10.1038/ni.3461; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; Shih HY, 2012, P NATL ACAD SCI USA, V109, pE3493, DOI 10.1073/pnas.1214131109; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; Singh SK, 2018, CELL STEM CELL, V23, P252, DOI 10.1016/j.stem.2018.06.001; Sleckman BP, 2000, P NATL ACAD SCI USA, V97, P7975, DOI 10.1073/pnas.130190597; Souroullas GP, 2009, CELL STEM CELL, V4, P180, DOI 10.1016/j.stem.2009.01.001; Stadhouders R, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001791; Sugai M, 2003, NAT IMMUNOL, V4, P25, DOI 10.1038/ni874; Sullivan JM, 2019, J IMMUNOL, V202, P31, DOI 10.4049/jimmunol.1800917; Tanaka A, 2010, J EXP MED, V207, P405, DOI 10.1084/jem.20090821; Tripathi RK, 2000, MOL CELL BIOL, V20, P42, DOI 10.1128/MCB.20.1.42-53.2000; Ueda-Hayakawa I, 2009, J IMMUNOL, V182, P5306, DOI 10.4049/jimmunol.0804249; van der Stoep N, 1998, IMMUNITY, V8, P743, DOI 10.1016/S1074-7613(00)80579-8; Verma-Gaur J, 2012, J IMMUNOL, V188, P6175, DOI 10.4049/jimmunol.1103105; Verykokakis M, 2013, J IMMUNOL, V191, P5973, DOI 10.4049/jimmunol.1301521; Verykokakis M, 2010, IMMUNITY, V33, P203, DOI 10.1016/j.immuni.2010.07.013; Verykokakis M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009303; Wang DC, 2006, J IMMUNOL, V177, P109, DOI 10.4049/jimmunol.177.1.109; Welinder E, 2011, P NATL ACAD SCI USA, V108, P17402, DOI 10.1073/pnas.1111766108; Wikstrom I, 2006, J IMMUNOL, V177, P6723, DOI 10.4049/jimmunol.177.10.6723; WILSON A, 1994, J EXP MED, V179, P1355, DOI 10.1084/jem.179.4.1355; Wohner M, 2016, J EXP MED, V213, P1201, DOI 10.1084/jem.20152002; Wojciechowski J, 2007, J IMMUNOL, V178, P5717, DOI 10.4049/jimmunol.178.9.5717; Xiong N, 2004, P NATL ACAD SCI USA, V101, P260, DOI 10.1073/pnas.0303738101; Xiong N, 2002, IMMUNITY, V16, P453, DOI 10.1016/S1074-7613(02)00285-6; Xiong N, 2008, J EXP MED, V205, P929, DOI 10.1084/jem.20071275; Xu Y, 1996, IMMUNITY, V4, P377, DOI 10.1016/S1074-7613(00)80251-4; Xu ZM, 2012, NAT REV IMMUNOL, V12, P517, DOI 10.1038/nri3216; Yabuki M, 2009, J IMMUNOL, V182, P408, DOI 10.4049/jimmunol.182.1.408; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yang CY, 2011, NAT IMMUNOL, V12, P1221, DOI 10.1038/ni.2158; Yannoutsos N, 2004, NAT IMMUNOL, V5, P443, DOI 10.1038/ni1053; Zhang BJ, 2018, J IMMUNOL, V201, P1452, DOI 10.4049/jimmunol.1800106; Zhang BJ, 2014, J IMMUNOL, V192, P1055, DOI 10.4049/jimmunol.1302694; Zhang ZX, 2006, NAT IMMUNOL, V7, P616, DOI 10.1038/ni1339; Zhou Y, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abm0819; Zhu YN, 2021, GENE DEV, V35, P65, DOI 10.1101/gad.343475.120; Zhu YN, 2017, GENE DEV, V31, P141, DOI 10.1101/gad.293910.116; Zhuang Y, 1996, MOL CELL BIOL, V16, P2898	187	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								881656	10.3389/fimmu.2022.881656	http://dx.doi.org/10.3389/fimmu.2022.881656			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Q4HB	35634342	Green Published, gold			2022-12-18	WOS:000802649500001
J	Bai, RL; Cui, JW				Bai, Rilan; Cui, Jiuwei			Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy	FRONTIERS IN IMMUNOLOGY			English	Review						tumor; immune checkpoint inhibitor; natural killer cell; programmed death receptor-1; programmed death-ligand 1	NK CELLS; T-CELLS; PD-L1 EXPRESSION; HODGKIN LYMPHOMA; TGF-BETA; PROSTATE-CANCER; IFN-GAMMA; MOUSE NK; ANTIBODY; IMMUNITY	Antibodies targeting programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) have been considered breakthrough therapies for a variety of solid and hematological malignancies. Although cytotoxic T cells play an important antitumor role during checkpoint blockade, they still show a potential killing effect on tumor types showing loss of/low major histocompatibility complex (MHC) expression and/or low neoantigen load; this knowledge has shifted the focus of researchers toward mechanisms of action other than T cell-driven immune responses. Evidence suggests that the blockade of the PD-1/PD-L1 axis may also improve natural killer (NK)-cell function and activity through direct or indirect mechanisms, which enhances antitumor cytotoxic effects; although important, this topic has been neglected in previous studies. Recently, some studies have reported evidence of PD-1 and PD-L1 expression in human NK cells, performed exploration of the intrinsic mechanism by which PD-1/PD-L1 blockade enhances NK-cell responses, and made some progress. This article summarizes the recent advances regarding the expression of PD-1 and PD-L1 molecules on the surface of NK cells as well as the interaction between anti-PD-1/PD-L1 drugs and NK cells and associated molecular mechanisms in the tumor microenvironment.	[Bai, Rilan; Cui, Jiuwei] First Hosp Jilin Univ, Canc Ctr, Changchun, Peoples R China	Jilin University	Cui, JW (corresponding author), First Hosp Jilin Univ, Canc Ctr, Changchun, Peoples R China.	cuijw@jlu.edu.cn			Jilin Provincial Department of Science and Technology Project [20190303146SF]; Jilin Provincial Department of Finance Project [JLSWSRCZX2020-0023]; Jilin Province Biotherapeutic Science and Technology Innovation Center Project [20200602032ZP]	Jilin Provincial Department of Science and Technology Project; Jilin Provincial Department of Finance Project; Jilin Province Biotherapeutic Science and Technology Innovation Center Project	Funding This work was supported by grants from Jilin Provincial Department of Science and Technology Project (20190303146SF); Jilin Provincial Department of Finance Project (JLSWSRCZX2020-0023); Jilin Province Biotherapeutic Science and Technology Innovation Center Project (20200602032ZP).	Alvarez IB, 2010, J INFECT DIS, V202, P524, DOI 10.1086/654932; Alvarez M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00007; Alvarez M, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127729; Alvarez M, 2014, J IMMUNOL, V193, P1709, DOI 10.4049/jimmunol.1400034; An LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep33346; Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Ansell SM, 2016, AM J HEMATOL, V91, P109, DOI 10.1002/ajh.24226; Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087; Antonangeli F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584626; Ardolino M, 2014, J CLIN INVEST, V124, P4781, DOI 10.1172/JCI74337; Barry KC, 2018, NAT MED, V24, P1178, DOI 10.1038/s41591-018-0085-8; Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992; Beldi-Ferchiou A, 2016, ONCOTARGET, V7, P72961, DOI 10.18632/oncotarget.12150; Bellucci R, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008824; Boyerinas B, 2015, CANCER IMMUNOL RES, V3, P1148, DOI 10.1158/2326-6066.CIR-15-0059; Brunner-Weinzierl MC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02737; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239; Cader FZ, 2018, BLOOD, V132, P825, DOI 10.1182/blood-2018-04-843714; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chan CJ, 2014, NAT IMMUNOL, V15, P431, DOI 10.1038/ni.2850; Chen YJ, 2011, CYTOKINE, V56, P231, DOI 10.1016/j.cyto.2011.06.004; Choi B, 2020, CANCER LETT, V478, P56, DOI 10.1016/j.canlet.2020.02.042; Cichocki F, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5618; Concha-Benavente F, 2018, CANCER IMMUNOL RES, V6, P1548, DOI 10.1158/2326-6066.CIR-18-0062; Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590-020-0620-x; Dong WJ, 2019, CANCER DISCOV, V9, P1422, DOI 10.1158/2159-8290.CD-18-1259; Fu BQ, 2014, IMMUNOLOGY, V141, P483, DOI 10.1111/imm.12224; Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511; Giuliani M, 2017, ONCOTARGET, V8, P24031, DOI 10.18632/oncotarget.15234; Godal R, 2010, BIOL BLOOD MARROW TR, V16, P612, DOI 10.1016/j.bbmt.2010.01.019; Hassan R, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.8503; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Hicks KC, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1466018; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Keskin DB, 2007, P NATL ACAD SCI USA, V104, P3378, DOI 10.1073/pnas.0611098104; Koirala P, 2016, SCI REP-UK, V6, DOI 10.1038/srep30093; KOS FJ, 1995, J IMMUNOL, V155, P578; Li HJ, 2018, GUT, V67, P2035, DOI 10.1136/gutjnl-2017-314098; Lieberman NAP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00150; Lin M, 2020, J CLIN INVEST, V130, P2560, DOI 10.1172/JCI132712; Liu Y, 2017, ONCOGENE, V36, P6143, DOI 10.1038/onc.2017.209; Lopez-Verges S, 2010, BLOOD, V116, P3865, DOI 10.1182/blood-2010-04-282301; MacFarlane AW, 2014, CANCER IMMUNOL RES, V2, P320, DOI 10.1158/2326-6066.CIR-13-0133; Mak P, 2015, ONCOTARGET, V6, P40247, DOI 10.18632/oncotarget.5377; Makowska A, 2021, CANCER IMMUNOL IMMUN, V70, P323, DOI 10.1007/s00262-020-02681-x; Makowska A, 2019, TRANSL ONCOL, V12, P1237, DOI 10.1016/j.tranon.2019.04.017; Mandai M, 2016, CLIN CANCER RES, V22, P2329, DOI 10.1158/1078-0432.CCR-16-0224; Marcoe JP, 2012, NAT IMMUNOL, V13, P843, DOI 10.1038/ni.2388; Mariotti FR, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1557030; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Mishima Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6872; Mishima Y, 2011, BLOOD, V118, P2443, DOI 10.1182/blood-2011-01-331892; Moretta L, 2014, INT ARCH ALLERGY IMM, V164, P253, DOI 10.1159/000365632; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Norris S, 2012, VIRAL IMMUNOL, V25, P329, DOI 10.1089/vim.2011.0096; Oyer JL, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1509819; Park IH, 2017, ONCOTARGET, V8, P32722, DOI 10.18632/oncotarget.16281; Park JE, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000873; Julia EP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02140; Pesce S, 2017, J ALLERGY CLIN IMMUN, V139, P335, DOI 10.1016/j.jaci.2016.04.025; Porichis F, 2018, J IMMUNOL, V201, P971, DOI 10.4049/jimmunol.1701551; Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904; Iraolagoitia XLR, 2016, J IMMUNOL, V197, P953, DOI 10.4049/jimmunol.1502291; Ritprajak P, 2015, ORAL ONCOL, V51, P221, DOI 10.1016/j.oraloncology.2014.11.014; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Romagne F, 2009, BLOOD, V114, P2667, DOI 10.1182/blood-2009-02-206532; Sheffer M, 2021, NAT GENET, V53, P1196, DOI 10.1038/s41588-021-00889-w; Shen MJ, 2017, ONCOTARGET, V8, P80506, DOI 10.18632/oncotarget.19193; Sitrin J, 2013, J EXP MED, V210, P1153, DOI 10.1084/jem.20122248; Sivori S, 2019, CELL MOL IMMUNOL, V16, P430, DOI 10.1038/s41423-019-0206-4; Stojanovic A, 2014, J IMMUNOL, V192, P4184, DOI 10.4049/jimmunol.1302091; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Sun R, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100825; Tato CM, 2006, INT IMMUNOL, V18, P505, DOI 10.1093/intimm/dxh391; Taylor S, 2017, J EXP MED, V214, P1663, DOI 10.1084/jem.20161653; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; Trzonkowski P, 2004, CLIN IMMUNOL, V112, P258, DOI 10.1016/j.clim.2004.04.003; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vari F, 2018, BLOOD, V131, P1809, DOI 10.1182/blood-2017-07-796342; Villegas FR, 2002, LUNG CANCER-J IASLC, V35, P23, DOI 10.1016/S0169-5002(01)00292-6; Waggoner SN, 2014, J VIROL, V88, P1953, DOI 10.1128/JVI.03002-13; Wagtmann N, 1995, IMMUNITY, V3, P801, DOI 10.1016/1074-7613(95)90069-1; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Wan CX, 2021, CANCER RES, V81, P158, DOI 10.1158/0008-5472.CAN-20-1674; Wang W, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00368; Wang XY, 2017, CELL BIOL INT, V41, P177, DOI 10.1002/cbin.10716; Wang X, 2017, IMMUNOL LETT, V184, P7, DOI 10.1016/j.imlet.2017.02.006; White ME, 2019, CELL IMMUNOL, V337, P48, DOI 10.1016/j.cellimm.2019.02.001; Xu HFC, 2017, CELL REP, V21, P2528, DOI 10.1016/j.celrep.2017.11.001; Xu LJ, 2018, MOL ONCOL, V12, P269, DOI 10.1002/1878-0261.12135; Yao G, 2015, ONCOTARGET, V6, P30251, DOI 10.18632/oncotarget.4943; Zhai LJ, 2018, CELL MOL IMMUNOL, V15, P447, DOI 10.1038/cmi.2017.143; Zheng GX, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00629-w; Zhou J, 2019, IMMUNITY, V50, P403, DOI 10.1016/j.immuni.2018.12.024; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032; Zou WP, 2018, CELL MOL IMMUNOL, V15, P419, DOI 10.1038/s41423-018-0011-5	99	0	0	7	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								886931	10.3389/fimmu.2022.886931	http://dx.doi.org/10.3389/fimmu.2022.886931			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S6AO	35634343	Green Published, gold			2022-12-18	WOS:000804132200001
J	Bhattacharyya, A; Torre, P; Yadav, P; Boostanpour, K; Chen, TY.; Tsukui, T; Sheppard, D; Muramatsu, R; Seed, RI; Nishimura, SL; Jung, JB; Tang, XZ; Allen, CDC; Bhattacharya, M				Bhattacharyya, Aritra; Torre, Paola; Yadav, Preeti; Boostanpour, Kaveh; Chen, Tian Y.; Tsukui, Tatsuya; Sheppard, Dean; Muramatsu, Rieko; Seed, Robert I.; Nishimura, Stephen L.; Jung, James B.; Tang, Xin-Zi; Allen, Christopher D. C.; Bhattacharya, Mallar			Macrophage Cx43 Is Necessary for Fibroblast Cytosolic Calcium and Lung Fibrosis After Injury	FRONTIERS IN IMMUNOLOGY			English	Article						P2RX4; lung fibrosis; fibroblast; macrophage; calcium imaging	EXPRESSION; CELLS	Macrophages are paracrine signalers that regulate tissular responses to injury through interactions with parenchymal cells. Connexin hemichannels have recently been shown to mediate efflux of ATP by macrophages, with resulting cytosolic calcium responses in adjacent cells. Here we report that lung macrophages with deletion of connexin 43 (Mac(Delta Cx43)) had decreased ATP efflux into the extracellular space and induced a decreased cytosolic calcium response in co-cultured fibroblasts compared to WT macrophages. Furthermore, Mac(Delta Cx43) mice had decreased lung fibrosis after bleomycin-induced injury. Interrogating single cell data for human and mouse, we found that P2rx4 was the most highly expressed ATP receptor and calcium channel in lung fibroblasts and that its expression was increased in the setting of fibrosis. Fibroblast-specific deletion of P2rx4 in mice decreased lung fibrosis and collagen expression in lung fibroblasts in the bleomycin model. Taken together, these studies reveal a Cx43-dependent profibrotic effect of lung macrophages and support development of fibroblast P2rx4 as a therapeutic target for lung fibrosis.	[Bhattacharyya, Aritra; Torre, Paola; Yadav, Preeti; Boostanpour, Kaveh; Chen, Tian Y.; Tsukui, Tatsuya; Sheppard, Dean; Bhattacharya, Mallar] Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Allergy,and Sleep, San Francisco, CA USA; [Bhattacharyya, Aritra; Torre, Paola; Yadav, Preeti; Boostanpour, Kaveh; Chen, Tian Y.; Jung, James B.; Tang, Xin-Zi; Allen, Christopher D. C.; Bhattacharya, Mallar] Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, San Francisco, CA USA; [Tsukui, Tatsuya; Sheppard, Dean; Jung, James B.; Tang, Xin-Zi; Allen, Christopher D. C.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA USA; [Muramatsu, Rieko] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Pharmacol, Kodaira, Japan; [Seed, Robert I.; Nishimura, Stephen L.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA; [Allen, Christopher D. C.] Univ Calif San Francisco, Dept Anat, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Center for Neurology & Psychiatry - Japan; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bhattacharya, M (corresponding author), Univ Calif San Francisco, Dept Med, Div Pulm Crit Care Allergy,and Sleep, San Francisco, CA USA.; Bhattacharya, M (corresponding author), Univ Calif San Francisco, Sandler Asthma Basic Res Ctr, San Francisco, CA USA.	mallar.bhattacharya@ucsf.edu		Allen, Christopher/0000-0002-1879-9047; Tang, Xin-Zi/0000-0001-6064-8624	US Department of Defense	US Department of Defense(United States Department of Defense)	Funding This work was supported by the US Department of Defense (W81XWH2110417 to MB), the National Heart, Lung, And Blood Institute (DP2HL117752 to CA), the National Institute Of Allergy And Infectious Diseases (R21AI130495 to CA), the UCSF Cardiovascular Research Institute, and the UCSF Sandler Asthma Basic Research Center.	Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Bhattacharyya A, 2022, AM J PHYSIOL-LUNG C, V322, pL495, DOI 10.1152/ajplung.00458.2021; Blackwell TS, 2014, AM J RESP CRIT CARE, V189, P214, DOI 10.1164/rccm.201306-1141WS; Braganca B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145005; Dong TX, 2017, ELIFE, V6, DOI 10.7554/eLife.32417; Dosch M, 2019, ELIFE, V8, DOI 10.7554/eLife.42670; Fidler TP, 2021, NATURE, V592, P296, DOI 10.1038/s41586-021-03341-5; Finkbeiner WE., 1997, LUNG SCI FDN, P415; Foo SS, 2006, CELL, V124, P161, DOI 10.1016/j.cell.2005.10.034; Ginhoux F, 2016, NAT IMMUNOL, V17, P34, DOI 10.1038/ni.3324; Guilliams M, 2020, IMMUNITY, V52, P434, DOI 10.1016/j.immuni.2020.02.015; He LJ, 2017, J CLIN INVEST, V127, P2968, DOI 10.1172/JCI93868; Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085; Janssen LJ, 2009, INT J BIOCHEM CELL B, V41, P2477, DOI 10.1016/j.biocel.2009.08.004; Kang J, 2008, J NEUROSCI, V28, P4702, DOI 10.1523/JNEUROSCI.5048-07.2008; Larson-Casey JL, 2016, IMMUNITY, V44, P582, DOI 10.1016/j.immuni.2016.01.001; Le Guilcher C, 2018, J HEPATOL, V69, P644, DOI 10.1016/j.jhep.2018.05.020; Lembong J, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0140; Li W, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18452-1; Misharin AV, 2017, J EXP MED, V214, P2387, DOI 10.1084/jem.20162152; Molawi K, 2014, J EXP MED, V211, P2151, DOI 10.1084/jem.20140639; Mulder K, 2021, IMMUNITY, V54, P1883, DOI 10.1016/j.immuni.2021.07.007; Ovchinnikov DA, 2008, J LEUKOCYTE BIOL, V83, P430, DOI 10.1189/jlb.0807585; Ozaki T, 2016, SCI REP-UK, V6, DOI 10.1038/srep25893; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Satoh T, 2017, NATURE, V541, P96, DOI 10.1038/nature20611; Scott MKD, 2019, LANCET RESP MED, V7, P497, DOI 10.1016/S2213-2600(18)30508-3; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Taylor SC, 2013, MOL BIOTECHNOL, V55, P217, DOI 10.1007/s12033-013-9672-6; Trang T, 2009, J NEUROSCI, V29, P3518, DOI 10.1523/JNEUROSCI.5714-08.2009; Tsukui T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15647-5; Zhou X, 2018, CELL, V172, P744, DOI 10.1016/j.cell.2018.01.015; Zumerle S, 2019, CELL REP, V27, P1, DOI 10.1016/j.celrep.2019.03.011	33	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								880887	10.3389/fimmu.2022.880887	http://dx.doi.org/10.3389/fimmu.2022.880887			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M9RK	35634278	gold, Green Published			2022-12-18	WOS:000800301900001
J	Chen, P; Zhou, YK; Han, CS; Chen, LJ; Wang, YM; Zhuang, ZM; Lin, S; Zhou, YH; Jiang, JH; Yang, RL				Chen, Peng; Zhou, Yi-kun; Han, Chun-shan; Chen, Liu-jing; Wang, Yi-ming; Zhuang, Zi-meng; Lin, Shuai; Zhou, Yan-heng; Jiang, Jiu-hui; Yang, Rui-li			Stem Cells From Human Exfoliated Deciduous Teeth Alleviate Liver Cirrhosis via Inhibition of Gasdermin D-Executed Hepatocyte Pyroptosis	FRONTIERS IN IMMUNOLOGY			English	Article						liver cirrhosis; stem cells from human exfoliated deciduous teeth; NLRP3; GSDMD; pyroptosis	BONE-MARROW; IN-VITRO; FIBROSIS; TRANSPLANTATION; MECHANISM; CASPASES; DEATH; GSDMD	Liver cirrhosis represents a type of end-stage liver disease with few effective therapies, which was characterized by damaged functional liver tissue due to long-term inflammation. Gasdermin D (GSDMD)-executed programmed necrosis is reported to be involved in inflammation. However, the role of GSDMD in liver cirrhosis remains unclear. In this study, we used a CCl4-induced cirrhosis model and found stem cells from human exfoliated deciduous teeth (SHED) infusion showed profound therapeutic effects for liver cirrhosis. Mechanistically, NLRP3 inflammasome-activated GSDMD and its pyroptosis were upregulated in liver cirrhosis, while SHED infusion could suppress the expression of GSDMD and Caspase-1, resulting in reduced hepatocyte pyroptosis and inflammatory cytokine IL-1 beta release. Consistently, SHED could inhibit the elevated expression of NLRP3, GSDMD and Caspase-1 induced by CCl4 treatment in vitro co-culture system, which was mediated by decreasing reactive oxygen species (ROS) generation. Moreover, the pyroptosis inhibitor disulfiram showed similar therapeutic effects for liver cirrhosis as SHED. In conclusion, SHED alleviates CCl4-induced liver cirrhosis via inhibition of hepatocytes pyroptosis. Our findings could provide a potential treatment strategy and novel target for liver cirrhosis.	[Chen, Peng; Zhou, Yi-kun; Han, Chun-shan; Chen, Liu-jing; Wang, Yi-ming; Zhuang, Zi-meng; Lin, Shuai; Zhou, Yan-heng; Jiang, Jiu-hui; Yang, Rui-li] Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, Beijing, Peoples R China; [Chen, Peng; Zhou, Yi-kun; Han, Chun-shan; Chen, Liu-jing; Wang, Yi-ming; Zhuang, Zi-meng; Lin, Shuai; Zhou, Yan-heng; Jiang, Jiu-hui; Yang, Rui-li] Natl Clin Res Ctr Oral Dis, Beijing, Peoples R China; [Chen, Peng; Zhou, Yi-kun; Han, Chun-shan; Chen, Liu-jing; Wang, Yi-ming; Zhuang, Zi-meng; Lin, Shuai; Zhou, Yan-heng; Jiang, Jiu-hui; Yang, Rui-li] Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China; [Chen, Peng; Zhou, Yi-kun; Han, Chun-shan; Chen, Liu-jing; Wang, Yi-ming; Zhuang, Zi-meng; Lin, Shuai; Zhou, Yan-heng; Jiang, Jiu-hui; Yang, Rui-li] Beijing Key Lab Digital Stomatol, Beijing, Peoples R China	Peking University	Jiang, JH; Yang, RL (corresponding author), Peking Univ, Dept Orthodont, Sch & Hosp Stomatol, Beijing, Peoples R China.; Jiang, JH; Yang, RL (corresponding author), Natl Clin Res Ctr Oral Dis, Beijing, Peoples R China.; Jiang, JH; Yang, RL (corresponding author), Natl Engn Lab Digital & Mat Technol Stomatol, Beijing, Peoples R China.; Jiang, JH; Yang, RL (corresponding author), Beijing Key Lab Digital Stomatol, Beijing, Peoples R China.	drjiangw@163.com; ruiliyang@bjmu.edu.cn			National Natural Science Foundation of China [81970940]; Ten-thousand Talents Program [QNBJ-2020 (R-lY)]; National Science and Technology Major Project of the Ministry of Science and Technology of China [2018ZX10302207]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ten-thousand Talents Program; National Science and Technology Major Project of the Ministry of Science and Technology of China	This work was supported by the National Natural Science Foundation of China No. 81970940 (R-lY), Ten-thousand Talents Program QNBJ-2020 (R-lY), and the National Science and Technology Major Project of the Ministry of Science and Technology of China No. 2018ZX10302207.	Akiyama K, 2012, CELL STEM CELL, V10, P544, DOI 10.1016/j.stem.2012.03.007; Amir M, 2018, HEPATOLOGY, V67, P479, DOI 10.1002/hep.29491; An  P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16092-0; Beckwith KS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16143-6; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Cai GF, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-020-02030-w; Choi JS, 2019, BIOMATER SCI-UK, V7, P1078, DOI 10.1039/c8bm01347k; Das S, 2016, P NATL ACAD SCI USA, V113, P13132, DOI 10.1073/pnas.1610433113; Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940; Evavold CL, 2021, CELL, V184, P4495, DOI 10.1016/j.cell.2021.06.028; Fang SB, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1723260; FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83; FULLER RK, 1986, JAMA-J AM MED ASSOC, V256, P1449, DOI 10.1001/jama.256.11.1449; Galleu A, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aam7828; Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797; HAYASAKA A, 1991, J HEPATOL, V13, P328, DOI 10.1016/0168-8278(91)90077-O; Hirsova P, 2015, CELL MOL GASTROENTER, V1, P17, DOI 10.1016/j.jcmgh.2014.11.005; Hough KP, 2018, REDOX BIOL, V18, P54, DOI 10.1016/j.redox.2018.06.009; Hu JJ, 2020, NAT IMMUNOL, V21, P736, DOI 10.1038/s41590-020-0669-6; Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004-0021; Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558; Khanova E, 2018, HEPATOLOGY, V67, P1737, DOI 10.1002/hep.29645; Koh EH, 2021, GUT, V70, P1954, DOI 10.1136/gutjnl-2020-322509; Kovacs SB, 2017, TRENDS CELL BIOL, V27, P673, DOI 10.1016/j.tcb.2017.05.005; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Li S, 2019, J EXP MED, V216, P2562, DOI 10.1084/jem.20190377; Li X, 2018, J ALLERGY CLIN IMMUN, V141, P1634, DOI 10.1016/j.jaci.2017.08.017; Li YS, 2021, CELL DEATH DIFFER, V28, P2333, DOI 10.1038/s41418-021-00755-6; Li YY, 2019, CELL METAB, V30, P477, DOI 10.1016/j.cmet.2019.06.016; Man SM, 2014, P NATL ACAD SCI USA, V111, P17588, DOI 10.1073/pnas.1419925111; Moreno-Moral A, 2018, ANN RHEUM DIS, V77, P596, DOI 10.1136/annrheumdis-2017-212454; Murray KF, 2005, HEPATOLOGY, V41, P1407, DOI 10.1002/hep.20704; Parekkadan B, 2007, BIOCHEM BIOPH RES CO, V363, P247, DOI 10.1016/j.bbrc.2007.05.150; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Petrou P, 2020, BRAIN, V143, P3574, DOI 10.1093/brain/awaa333; Saeki N., 2012, ENDOTHELIUM EPITHELI, P193; Sakaida I, 2004, HEPATOLOGY, V40, P1304, DOI 10.1002/hep.20452; Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140-6736(04)16627-0; Sepanlou SG., 2020, LANCET GASTROENTEROL, V5, P245, DOI [10.1016/S2468-1253(19)30349-8, DOI 10.1016/S2468-1253(19)30349-8]; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Wang DY, 2020, CELL DEATH DIFFER, V27, P466, DOI 10.1038/s41418-019-0366-x; Wang HY, 2020, J CELL PHYSIOL, V235, P2722, DOI 10.1002/jcp.29176; Wang K, 2020, CELL, V180, P941, DOI 10.1016/j.cell.2020.02.002; Xi RH, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026307118; Xia SY, 2021, NATURE, V593, P607, DOI 10.1038/s41586-021-03478-3; Xie J, 2019, Beijing Da Xue Xue Bao Yi Xue Ban, V51, P900; Xu B, 2018, J HEPATOL, V68, P773, DOI 10.1016/j.jhep.2017.11.040; Yamaguchi S, 2015, SCI REP-UK, V5, DOI 10.1038/srep16295; Yamaza T, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0154-6; Yang Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0257-0; Yokoyama T, 2019, HUM CELL, V32, P125, DOI 10.1007/s13577-018-00234-0; Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663; Zhou YK, 2020, WORLD J STEM CELLS, V12, P1623, DOI 10.4252/wjsc.v12.i12.1623; Zhu RJ, 2021, CELL RES, V31, P1244, DOI 10.1038/s41422-021-00573-y	56	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								860225	10.3389/fimmu.2022.860225	http://dx.doi.org/10.3389/fimmu.2022.860225			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P7IZ	35634294	Green Published, gold			2022-12-18	WOS:000802179800001
J	Crotty, KM; Yeligar, SM				Crotty, Kathryn M.; Yeligar, Samantha M.			Hyaladherins May be Implicated in Alcohol-Induced Susceptibility to Bacterial Pneumonia	FRONTIERS IN IMMUNOLOGY			English	Review						hyaluronan; alcohol use disorder; pneumonia; hyaladherin; immunity	RESPIRATORY-DISTRESS-SYNDROME; EPITHELIAL BARRIER FUNCTION; HYALURONAN HYALURONIC-ACID; LUNG INJURY; BINDING-PROTEIN; AIRWAY HYPERRESPONSIVENESS; EXTRACELLULAR-MATRIX; CD44 DEFICIENCY; RECEPTOR RHAMM; NADPH OXIDASE	Although the epidemiology of bacterial pneumonia and excessive alcohol use is well established, the mechanisms by which alcohol induces risk of pneumonia are less clear. Patterns of alcohol misuse, termed alcohol use disorders (AUD), affect about 15 million people in the United States. Compared to otherwise healthy individuals, AUD increase the risk of respiratory infections and acute respiratory distress syndrome (ARDS) by 2-4-fold. Levels and fragmentation of hyaluronic acid (HA), an extracellular glycosaminoglycan of variable molecular weight, are increased in chronic respiratory diseases, including ARDS. HA is largely involved in immune-assisted wound repair and cell migration. Levels of fragmented, low molecular weight HA are increased during inflammation and decrease concomitant with leukocyte levels following injury. In chronic respiratory diseases, levels of fragmented HA and leukocytes remain elevated, inflammation persists, and respiratory infections are not cleared efficiently, suggesting a possible pathological mechanism for prolonged bacterial pneumonia. However, the role of HA in alcohol-induced immune dysfunction is largely unknown. This mini literature review provides insights into understanding the role of HA signaling in host immune defense following excessive alcohol use. Potential therapeutic strategies to mitigate alcohol-induced immune suppression in bacterial pneumonia and HA dysregulation are also discussed.	[Crotty, Kathryn M.; Yeligar, Samantha M.] Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA; [Crotty, Kathryn M.; Yeligar, Samantha M.] Atlanta Vet Affairs Hlth Care Syst, Decatur, GA 30033 USA	Emory University	Yeligar, SM (corresponding author), Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep Med, Atlanta, GA 30322 USA.; Yeligar, SM (corresponding author), Atlanta Vet Affairs Hlth Care Syst, Decatur, GA 30033 USA.	syeliga@emory.edu						Al-Kubaisy W, 2012, PROCD SOC BEHV, V38, P59, DOI 10.1016/j.sbspro.2012.03.324; American Psychiatric Association, 2013, DSM 5 TASK FORCE DIA, V5th, DOI DOI 10.1176/APPI.BOOKS.9780890425596; [Anonymous], 2021, CTR DIS CONTROL PREV; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Assmann V, 1999, J CELL SCI, V112, P3943; Bailey KL, 2019, ALCOHOL, V80, P131, DOI 10.1016/j.alcohol.2018.11.002; Baker R C, 1993, Recent Dev Alcohol, V11, P249; Balhara J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641311; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BAUGHMAN RP, 1987, ALCOHOL CLIN EXP RES, V11, P261, DOI 10.1111/j.1530-0277.1987.tb01303.x; Bollyky PL, 2007, J IMMUNOL, V179, P744, DOI 10.4049/jimmunol.179.2.744; Bottazzi B, 2006, J LEUKOCYTE BIOL, V79, P909, DOI 10.1189/jlb.1005557; Brown SD, 2012, ALCOHOL CLIN EXP RES, V36, P1952, DOI 10.1111/j.1530-0277.2012.01825.x; Buonpensiero P, 2010, ADV THER, V27, P870, DOI 10.1007/s12325-010-0076-8; Burnham EL, 2003, ALCOHOL CLIN EXP RES, V27, P1167, DOI 10.1097/01.ALC.0000075821.34270.98; Byskov K, 2020, THROMB RES, V188, P74, DOI 10.1016/j.thromres.2020.02.010; CANTIN AM, 1990, AM J RESP CELL MOL, V3, P79, DOI 10.1165/ajrcmb/3.1.79; Cantor J, 2017, INT J CHRONIC OBSTR, V12, P2747, DOI 10.2147/COPD.S142156; Chang MY, 2017, AM J PHYSIOL-LUNG C, V313, pL1069, DOI 10.1152/ajplung.00353.2017; Chang MY, 2014, MATRIX BIOL, V34, P1, DOI 10.1016/j.matbio.2014.01.011; CULTY M, 1994, J LEUKOCYTE BIOL, V56, P605, DOI 10.1002/jlb.56.5.605; CULTY M, 1992, J CELL BIOL, V116, P1055, DOI 10.1083/jcb.116.4.1055; Currie AJ, 2004, J PEDIATR-US, V144, P512, DOI 10.1016/j.jpeds.2003.10.034; Deban L, 2011, CELL TISSUE RES, V343, P237, DOI 10.1007/s00441-010-1018-0; Dela Cruz CS, 2012, CELL HOST MICROBE, V12, P34, DOI 10.1016/j.chom.2012.05.017; Dong Y, 2018, MUCOSAL IMMUNOL, V11, P601, DOI 10.1038/mi.2017.83; DSOUZA M, 1985, BIOCHEM INT, V10, P43; Elibol B, 2020, AM J DRUG ALCOHOL AB, V46, P718, DOI 10.1080/00952990.2020.1780601; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Esposito AJ, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1895-7; Evanko SP, 2009, J HISTOCHEM CYTOCHEM, V57, P1041, DOI 10.1369/jhc.2009.953802; Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09; Garantziotis S, 2010, AM J RESP CRIT CARE, V181, P666, DOI 10.1164/rccm.200903-0381OC; Garantziotis S, 2009, J BIOL CHEM, V284, P11309, DOI 10.1074/jbc.M802400200; Gebe JA, 2017, AM J RESP CELL MOL, V56, P109, DOI 10.1165/rcmb.2016-0111OC; Geng B, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0876-2; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Greenberg SS, 1999, ALCOHOL CLIN EXP RES, V23, P735, DOI 10.1097/00000374-199904000-00021; Hallgren O, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-55; HALLGREN R, 1989, AM REV RESPIR DIS, V139, P682; Haserodt S, 2011, GLYCOBIOLOGY, V21, P175, DOI 10.1093/glycob/cwq145; Jackson DG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00471; Jha BK, 2004, J BIOL CHEM, V279, P23061, DOI 10.1074/jbc.M310676200; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jiang D, 2007, ANNU REV CELL DEV BI, V23, P435, DOI 10.1146/annurev.cellbio.23.090506.123337; Jiang DH, 2011, PHYSIOL REV, V91, P221, DOI 10.1152/physrev.00052.2009; Jimenez VM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218147; Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1; Johnson CG, 2018, AM J PHYSIOL-LUNG C, V315, pL787, DOI 10.1152/ajplung.00009.2018; Johnson LA, 2017, NAT IMMUNOL, V18, P762, DOI 10.1038/ni.3750; Johnson P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02787; Jourdain M, 1997, CRIT CARE MED, V25, P452, DOI 10.1097/00003246-199703000-00014; Kager LM, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002306; Kang I, 2017, J BIOL CHEM, V292, P51, DOI 10.1074/jbc.M116.753186; Kaphalia L, 2013, TOXICOL LETT, V222, P171, DOI 10.1016/j.toxlet.2013.07.016; Kasuda S, 2017, ALCOHOL, V64, P1, DOI 10.1016/j.alcohol.2017.04.003; Kohda D, 1996, CELL, V86, P767, DOI 10.1016/S0092-8674(00)80151-8; Kronborg G, 2002, SCAND J INFECT DIS, V34, P323, DOI 10.1080/00365540110080233; Lazrak A, 2015, AM J PHYSIOL-LUNG C, V308, pL891, DOI 10.1152/ajplung.00377.2014; Lee DH, 2019, METABOLISM, V95, P46, DOI 10.1016/j.metabol.2019.03.010; Li ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027137; Liang JR, 2016, NAT MED, V22, P1285, DOI 10.1038/nm.4192; Liang JR, 2011, J ALLERGY CLIN IMMUN, V128, P403, DOI 10.1016/j.jaci.2011.04.006; Liang Y, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/371593; Liang Y, 2013, FREE RADICAL BIO MED, V65, P1427, DOI 10.1016/j.freeradbiomed.2013.10.010; Liang Y, 2012, SCI WORLD J, DOI 10.1100/2012/740308; Lynn BD, 2001, J NEUROSCI RES, V65, P6, DOI 10.1002/jnr.1122; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; Mambetsariev N, 2010, ARTERIOSCL THROM VAS, V30, P483, DOI 10.1161/ATVBAHA.109.200451; Mandi Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01406; McKallip RJ, 2015, INFLAMMATION, V38, P1250, DOI 10.1007/s10753-014-0092-y; Milner CM, 2007, BIOCHEM SOC T, V35, P672, DOI 10.1042/BST0350672; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; Moraes TJ, 2008, AM J PHYSIOL-LUNG C, V294, pL368, DOI 10.1152/ajplung.00036.2007; Morris NL, 2021, ALCOHOL, V90, P27, DOI 10.1016/j.alcohol.2020.11.004; Moss M, 2003, CRIT CARE MED, V31, P869, DOI 10.1097/01.CCM.0000055389.64497.11; Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; Nedvetzki S, 2004, P NATL ACAD SCI USA, V101, P18081, DOI 10.1073/pnas.0407378102; NETTELBLADT O, 1989, AM REV RESPIR DIS, V140, P1028, DOI 10.1164/ajrccm/140.4.1028; Nishikawa KC, 2003, EXP CELL RES, V287, P79, DOI 10.1016/S0014-4827(03)00069-7; Noble Paul W, 2006, Proc Am Thorac Soc, V3, P401, DOI 10.1513/pats.200604-097AW; Nojgaard C, 2003, J HEPATOL, V39, P179, DOI 10.1016/S0168-8278(03)00184-3; Nordenbaek C, 1999, J INFECT DIS, V180, P1722, DOI 10.1086/315050; Ostergaard C, 2002, CLIN DIAGN LAB IMMUN, V9, P598, DOI 10.1128/CDLI.9.3.598-604.2002; Papakonstantinou E, 2015, CHEST, V148, P1497, DOI 10.1378/chest.15-0153; Pelaez A, 2004, AM J PHYSIOL-LUNG C, V286, pL106, DOI 10.1152/ajplung.00148.2003; Petrey AC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00101; Presta M, 2007, J CELL MOL MED, V11, P723, DOI 10.1111/j.1582-4934.2007.00061.x; Price ME, 2019, ALCOHOL, V80, P91, DOI 10.1016/j.alcohol.2018.09.010; Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056; SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749; Savani RC, 2000, AM J RESP CELL MOL, V23, P475, DOI 10.1165/ajrcmb.23.4.3944; Schouten M, 2012, CRIT CARE, V16, DOI 10.1186/cc11910; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Snyder JM, 2015, J HISTOCHEM CYTOCHEM, V63, P952, DOI 10.1369/0022155415610383; Sokolowska M, 2014, J BIOL CHEM, V289, P4470, DOI 10.1074/jbc.M113.515106; Stern R, 2006, EUR J CELL BIOL, V85, P699, DOI 10.1016/j.ejcb.2006.05.009; Stober VP, 2017, J BIOL CHEM, V292, P20845, DOI 10.1074/jbc.M116.756627; Sueblinvong V, 2014, ALCOHOL CLIN EXP RES, V38, P2731, DOI 10.1111/acer.12563; Sueblinvong V, 2014, ALCOHOL CLIN EXP RES, V38, P336, DOI 10.1111/acer.12232; Sunderhauf A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.575854; Sumiya J, 1997, J BIOCHEM-TOKYO, V122, P983; Sun YJ, 2022, NEOPLASMA, V69, P155, DOI 10.4149/neo_2021_210904N1271; Swaidani S, 2013, J BIOL CHEM, V288, P412, DOI 10.1074/jbc.M112.389874; Szabo G, 1996, ALCOHOL CLIN EXP RES, V20, P900, DOI 10.1111/j.1530-0277.1996.tb05269.x; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Tseng V, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57147-7; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL CB, 1993, DEV BIOL, V155, P324, DOI 10.1006/dbio.1993.1032; Vaday GG, 2001, J LEUKOCYTE BIOL, V69, P885; van der Windt GJW, 2010, AM J PATHOL, V177, P2483, DOI 10.2353/ajpath.2010.100562; Vistejnova L, 2014, CYTOKINE, V70, P97, DOI 10.1016/j.cyto.2014.07.006; Wagner MC, 2012, ALCOHOL CLIN EXP RES, V36, P197, DOI 10.1111/j.1530-0277.2011.01599.x; Wang Q, 2002, AM J PATHOL, V161, P2219, DOI 10.1016/S0002-9440(10)64498-7; Wang W, 2009, ARCH MED RES, V40, P321, DOI 10.1016/j.arcmed.2009.04.005; Wight TN, 2017, CELL IMMUNOL, V312, P1, DOI 10.1016/j.cellimm.2016.12.003; Wight TN, 2014, MATRIX BIOL, V35, P152, DOI 10.1016/j.matbio.2014.01.015; Wyatt TA, 2004, ALCOHOL CLIN EXP RES, V28, P998, DOI 10.1097/01.ALC.0000130805.75641.F4; Wygrecka M, 2007, THORAX, V62, P880, DOI 10.1136/thx.2006.069658; Yadav G, 2009, J BIOL CHEM, V284, P3897, DOI 10.1074/jbc.M804246200; Yagi M, 2012, NUCLEIC ACIDS RES, V40, P9717, DOI 10.1093/nar/gks774; YANG BH, 1993, J BIOL CHEM, V268, P8617; Yeligar SM, 2021, J IMMUNOL, V207, P483, DOI 10.4049/jimmunol.2000565; Yeligar SM, 2016, ALCOHOL, V55, P51, DOI 10.1016/j.alcohol.2016.08.005; Yeligar SM, 2016, AM J RESP CELL MOL, V55, P35, DOI 10.1165/rcmb.2015-0077OC; Yeligar SM, 2014, AM J PHYSIOL-LUNG C, V306, pL429, DOI 10.1152/ajplung.00159.2013; Zaman A, 2005, AM J RESP CELL MOL, V33, P447, DOI 10.1165/rcmb.2004-0333OC; Zhang ZW, 2012, INT J MOL SCI, V13, P6873, DOI 10.3390/ijms13066873; Zhao T, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00303-7; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	132	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								865522	10.3389/fimmu.2022.865522	http://dx.doi.org/10.3389/fimmu.2022.865522			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1R8YZ	35634317	gold, Green Published			2022-12-18	WOS:000803650600001
J	De Beck, L; Awad, RM; Basso, V; Casares, N; De Ridder, K; De Vlaeminck, Y; Gnata, A; Goyvaerts, C; Lecocq, Q; San Jose-Eneriz, E; Verhulst, S; Maes, K; Vanderkerken, K; Agirre, X; Prosper, F; Lasarte, JJ; Mondino, A; Breckpot, K				De Beck, Lien; Awad, Robin Maximilian; Basso, Veronica; Casares, Noelia; De Ridder, Kirsten; De Vlaeminck, Yannick; Gnata, Alessandra; Goyvaerts, Cleo; Lecocq, Quentin; San Jose-Eneriz, Edurne; Verhulst, Stefaan; Maes, Ken; Vanderkerken, Karin; Agirre, Xabier; Prosper, Felipe; Lasarte, Juan Jose; Mondino, Anna; Breckpot, Karine			Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma	FRONTIERS IN IMMUNOLOGY			English	Article						melanoma; cancer vaccination; dendritic cell vaccination; adoptive T cell therapies; epigenetic targeted therapy; histone and DNA methylation; demethylation; histone methyltransferase G9a; DNA methyltransferase (DNMT)	EPIGENETIC REGULATION; EXPRESSION; CELLS; G9A; PROGRESSION; PROTEINS; BLOCKADE; SURVIVAL; PATHWAY; ANTIGEN	Immunotherapy has improved the treatment of malignant skin cancer of the melanoma type, yet overall clinical response rates remain low. Combination therapies could be key to meet this cogent medical need. Because epigenetic hallmarks represent promising combination therapy targets, we studied the immunogenic potential of a dual inhibitor of histone methyltransferase G9a and DNA methyltransferases (DNMTs) in the preclinical B16-OVA melanoma model. Making use of tumor transcriptomic and functional analyses, methylation-targeted epigenetic reprogramming was shown to induce tumor cell cycle arrest and apoptosis in vitro coinciding with transient tumor growth delay and an IFN-I response in immune-competent mice. In consideration of a potential impact on immune cells, the drug was shown not to interfere with dendritic cell maturation or T-cell activation in vitro. Notably, the drug promoted dendritic cell and, to a lesser extent, T-cell infiltration in vivo, yet failed to sensitize tumor cells to programmed cell death-1 inhibition. Instead, it increased therapeutic efficacy of TCR-redirected T cell and dendritic cell vaccination, jointly increasing overall survival of B16-OVA tumor-bearing mice. The reported data confirm the prospect of methylation-targeted epigenetic reprogramming in melanoma and sustain dual G9a and DNMT inhibition as a strategy to tip the cancer-immune set-point towards responsiveness to active and adoptive vaccination against melanoma.	[De Beck, Lien; Awad, Robin Maximilian; De Ridder, Kirsten; De Vlaeminck, Yannick; Goyvaerts, Cleo; Lecocq, Quentin; Breckpot, Karine] Vrije Univ Brussel VUB, Dept Biomed Sci, Lab Mol & Cellular Therapy, Brussels, Belgium; [De Beck, Lien; Maes, Ken; Vanderkerken, Karin] Vrije Univ Brussel VUB, Dept Biomed Sci, Lab Hematol & Immunol, Brussels, Belgium; [Basso, Veronica; Gnata, Alessandra; Mondino, Anna] IRCCS Osped San Raffaele, Div Immunol Transplantat & Infect Dis, Lymphocyte Activat Unit, Milan, Italy; [Casares, Noelia; Lasarte, Juan Jose] Ctr Invest Med Aplicada CIMA, Immunol & Immunotherapy Program, Inst Invest Sanit Navarra IdiSNA, Pamplona, Spain; [San Jose-Eneriz, Edurne; Agirre, Xabier; Prosper, Felipe] Univ Navarra, Ctr Invest Med Aplicada CIMA, Hemato Oncol Program, Inst Invest Sanitaria deNavarra IdiSNA, Pamplona, Spain; [Verhulst, Stefaan] Vrije Univ Brussel VUB, Dept Biomed Sci, Liver Cell Biol Res Grp, Brussels, Belgium; [Maes, Ken] Vrije Univ Brussel VUB, Universitair Ziekenhuis Brussel UZ Brussel, Ctr Med Genet, Brussels, Belgium; [Agirre, Xabier; Prosper, Felipe] Ctr Invest Biomed Red Canc CIBERONC, Lab Canc Epigenet, Madrid, Spain; [Prosper, Felipe] Univ Navarra, Clin Universidadde Navarra, Hematol & Cell Therapy Dept, Pamplona, Spain	Vrije Universiteit Brussel; Vrije Universiteit Brussel; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Navarra; Vrije Universiteit Brussel; Vrije Universiteit Brussel; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; University of Navarra	Breckpot, K (corresponding author), Vrije Univ Brussel VUB, Dept Biomed Sci, Lab Mol & Cellular Therapy, Brussels, Belgium.	karine.breckpot@vub.be	; Goyvaerts, Cleo/G-1591-2019; mondino, anna/K-9434-2016	De Ridder, Kirsten/0000-0003-1482-1742; De Beck, Lien/0000-0002-8445-0441; Awad, Robin Maximilian/0000-0001-5434-494X; Verhulst, Stefaan/0000-0001-6566-6071; Goyvaerts, Cleo/0000-0002-1725-7772; Lecocq, Quentin/0000-0002-2627-0880; mondino, anna/0000-0003-0833-6927; De Vlaeminck, Yannick/0000-0002-1882-4740; Maes, Ken/0000-0001-8906-2790				Al Emran A, 2019, TRENDS IMMUNOL, V40, P328, DOI 10.1016/j.it.2019.02.004; Albershardt TC, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-0201-x; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Angioni R, 2021, CANCERS, V13, DOI 10.3390/cancers13030401; [Anonymous], 2020, CANC TOM EST NUMB NE; Bald T, 2014, CANCER DISCOV, V4, P674, DOI 10.1158/2159-8290.CD-13-0458; Barcena-Varela M, 2019, HEPATOLOGY, V69, P587, DOI 10.1002/hep.30168; Benci JL, 2016, CELL, V167, P1540, DOI 10.1016/j.cell.2016.11.022; Bhattacharya Arjun, 2021, Brief Bioinform, V22, DOI 10.1093/bib/bbaa163; Bishop DT, 2002, J NATL CANCER I, V94, P894, DOI 10.1093/jnci/94.12.894; Breckpot K, 2003, J GENE MED, V5, P654, DOI 10.1002/jgm.400; Budhwani M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00322; Cannuyer J, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0147-4; Chen C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00187; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011; Danaher P, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0215-8; Dang NN, 2020, AGING-US, V12, P2393, DOI 10.18632/aging.102750; Daver N, 2019, CANCER DISCOV, V9, P370, DOI 10.1158/2159-8290.CD-18-0774; Davis LE, 2019, CANCER BIOL THER, V20, P1366, DOI 10.1080/15384047.2019.1640032; de Witte MA, 2006, BLOOD, V108, P870, DOI 10.1182/blood-2005-08-009357; Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Erdag G, 2012, CANCER RES, V72, P1070, DOI 10.1158/0008-5472.CAN-11-3218; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Falahat R, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2013598118; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; Fenton SE, 2021, CANCERS, V13, DOI 10.3390/cancers13051037; Gassenmaier M, 2020, AM J PATHOL, V190, P2155, DOI 10.1016/j.ajpath.2020.07.002; Gato-Canas M, 2017, CELL REP, V20, P1818, DOI 10.1016/j.celrep.2017.07.075; Giunta EF, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082048; Gomes F, 2018, FUTURE ONCOL, V14, P1241, DOI 10.2217/fon-2017-0484; Hoechst B, 2011, BLOOD, V117, P6532, DOI 10.1182/blood-2010-11-317321; Itakura E, 2011, MODERN PATHOL, V24, P801, DOI 10.1038/modpathol.2011.5; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Joruiz SM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026039; Kato S, 2020, CANCER DISCOV, V10, P980, DOI 10.1158/2159-8290.CD-19-0532; Kelly GM, 2021, CLIN CANCER RES, V27, P2624, DOI 10.1158/1078-0432.CCR-20-3463; Krohn IK, 2022, ALLERGY, V77, P827, DOI 10.1111/all.15104; Kunert A, 2016, J IMMUNOL, V197, P2541, DOI 10.4049/jimmunol.1502024; Lamberti MJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02614; Leick KM, 2019, CANCER IMMUNOL IMMUN, V68, P1121, DOI 10.1007/s00262-019-02345-5; Li W, 2006, PATHOLOGY, V38, P287, DOI 10.1080/00313020600817951; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lucarini V, 2021, CANCERS, V13, DOI 10.3390/cancers13030433; Manzo T, 2017, CANCER RES, V77, P658, DOI 10.1158/0008-5472.CAN-16-0725; Maric H, 2019, MELANOMA RES, V29, P596, DOI 10.1097/CMR.0000000000000612; Maurer DM, 2019, MELANOMA RES, V29, P109, DOI 10.1097/CMR.0000000000000535; Melnikova VO, 2004, ONCOGENE, V23, P2347, DOI 10.1038/sj.onc.1207405; Micevic G, 2016, CELL REP, V14, P2180, DOI 10.1016/j.celrep.2016.02.010; Mitra S, 2020, MOL ONCOL, V14, P933, DOI 10.1002/1878-0261.12663; Molognoni F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081937; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mpakali A, 2021, CANCERS, V13, DOI 10.3390/cancers13010134; Murgaski A, 2019, CANCERS, V11, DOI 10.3390/cancers11050670; Nakahara T, 2016, J INVEST DERMATOL, V136, P146, DOI 10.1038/JID.2015.359; Newton-Bishop JA, 1999, BRIT J CANCER, V80, P295, DOI 10.1038/sj.bjc.6690354; Nguyen LT, 2019, CANCER IMMUNOL IMMUN, V68, P773, DOI 10.1007/s00262-019-02307-x; Oba T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19192-z; Oh E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111387; Padron A, 2018, EXP GERONTOL, V105, P146, DOI 10.1016/j.exger.2017.12.025; Plesca D, 2008, METHOD ENZYMOL, V446, P107, DOI 10.1016/S0076-6879(08)01606-6; Punt S, 2021, CANCER IMMUNOL IMMUN, V70, P1101, DOI 10.1007/s00262-020-02748-9; Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9; Romano G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112354; Ruffell B, 2014, CANCER CELL, V26, P623, DOI 10.1016/j.ccell.2014.09.006; Jose-Eneriz ES, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15424; Segovia C, 2019, NAT MED, V25, P1073, DOI 10.1038/s41591-019-0499-y; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tan YH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5619; Taylor RC, 2007, J CLIN ONCOL, V25, P869, DOI 10.1200/JCO.2006.08.9755; Teixeira AF, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00605; Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105; Tsukamoto H, 2018, CANCER RES, V78, P5011, DOI 10.1158/0008-5472.CAN-18-0118; Ueha S, 2015, CANCER IMMUNOL RES, V3, P631, DOI 10.1158/2326-6066.CIR-14-0190; Uzdensky A, 2014, TUMOR BIOL, V35, P8225, DOI 10.1007/s13277-014-2098-3; Venza M, 2016, ONCOL REP, V35, P2451, DOI 10.3892/or.2016.4618; Venza M, 2015, BBA-GENE REGUL MECH, V1849, P247, DOI 10.1016/j.bbagrm.2014.12.004; Wang L, 2015, CANCER IMMUNOL RES, V3, P1030, DOI 10.1158/2326-6066.CIR-15-0073; Wilgenhof S, 2011, J IMMUNOTHER, V34, P448, DOI 10.1097/CJI.0b013e31821dcb31; Yu GJ, 2019, CELL MOL IMMUNOL, V16, P401, DOI 10.1038/s41423-018-0026-y; Yu HZ, 2016, BIOCHEM BIOPH RES CO, V476, P400, DOI 10.1016/j.bbrc.2016.05.133; Zhao B, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920937612	85	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								799636	10.3389/fimmu.2022.799636	http://dx.doi.org/10.3389/fimmu.2022.799636			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Q4MX	35634329	Green Published, gold			2022-12-18	WOS:000802664700001
J	Elkoshi, Z				Elkoshi, Zeev			On the Prognostic Power of Tumor-Infiltrating Lymphocytes - A Critical Commentary	FRONTIERS IN IMMUNOLOGY			English	Article						tumor-infiltrating lymphocytes; regulatory T cells; CD8+T cells; cancer prognosis; CD8; Treg	REGULATORY T-CELLS; CANCER; SURVIVAL; CD8(+); RATIO; PERFORIN; LIVER	Tumor-infiltrating lymphocytes are extensively used as prognostic biomarkers in cancer. Regulatory T cells (Tregs) or CD8+ T cells frequencies in tumor site, or their ratio, are the most common markers used to assess prognosis. This work offers a possible explanation for the opposite correlations between intra-tumoral Tregs and survival, associated with different types of cancer. The complexity involved with the selection of a preferred marker, including the effect of variability, is presented and discussed. The lymphocytes frequency ratio is proposed as the marker of choice in most types of cancer. The ratio correlates directly with survival, irrespective of cancer type and is also less variable than the frequencies of each of the two lymphocytes, if these frequencies correlate with each other in the tumor microenvironment. However, if the frequency of one of the two lymphocytes is highly variable, abandoning the ratio in favor of the lymphocyte with less variable frequency will improve correlation with survival, especially when the intra-tumoral frequencies of the two species are inversely correlated. It is plausible, that the best prognostic marker selected this way, will be also be the best predictor of checkpoint inhibitor therapy success.	[Elkoshi, Zeev] Taro Pharmaceut Ind Ltd, Res & Dev Dept, H_efa, Israel		Elkoshi, Z (corresponding author), Taro Pharmaceut Ind Ltd, Res & Dev Dept, H_efa, Israel.							Adams SF, 2009, CANCER-AM CANCER SOC, V115, P2891, DOI 10.1002/cncr.24317; An N, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-02160-7; Cao XF, 2007, IMMUNITY, V27, P635, DOI 10.1016/j.immuni.2007.08.014; de Jong RA, 2009, GYNECOL ONCOL, V114, P105, DOI 10.1016/j.ygyno.2009.03.022; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; Ding W, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013301; Echarti A, 2019, CANCERS, V11, DOI 10.3390/cancers11091398; Elkoshi Z, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.821598; Frey DM, 2010, INT J CANCER, V126, P2635, DOI 10.1002/ijc.24989; Fu JL, 2007, GASTROENTEROLOGY, V132, P2328, DOI 10.1053/j.gastro.2007.03.102; Ganesan AP, 2013, J IMMUNOL, V191, P2009, DOI 10.4049/jimmunol.1301317; Han S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00279; Hu LY, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957-021-02420-1; Huang Y, 2012, DIGESTION, V86, P329, DOI 10.1159/000342801; Jackute J, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0108-x; Jordanova ES, 2008, CLIN CANCER RES, V14, P2028, DOI 10.1158/1078-0432.CCR-07-4554; Kawashima A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63060-1; Kumagai S, 2020, NAT IMMUNOL, V21, P1346, DOI 10.1038/s41590-020-0769-3; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Lee WS, 2013, ANN SURG ONCOL, V20, P697, DOI 10.1245/s10434-012-2752-1; Leffers N, 2009, CANCER IMMUNOL IMMUN, V58, P449, DOI 10.1007/s00262-008-0583-5; Li CX, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01234-1; Li J, 2017, ONCOTARGET, V8, P15621, DOI 10.18632/oncotarget.14919; Ling A, 2014, BRIT J CANCER, V110, P2551, DOI 10.1038/bjc.2014.161; Loddenkemper C, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-52; Mathai AM, 2012, AM J SURG PATHOL, V36, P980, DOI 10.1097/PAS.0b013e31824e9b7c; Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412; Oh DY, 2021, IMMUNITY, V54, P2701, DOI 10.1016/j.immuni.2021.11.015; Patel MV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.657326; Peng GL, 2019, AM J TRANSL RES, V11, P5039; Preston CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080063; Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Shah W, 2011, CELL MOL IMMUNOL, V8, P59, DOI 10.1038/cmi.2010.56; Shang B, 2015, SCI REP-UK, V5, DOI 10.1038/srep15179; Sideras K, 2018, J SURG ONCOL, V118, P68, DOI 10.1002/jso.25091; Stuart A., 1987, KENDALLS ADV THEORY, V1; Suzuki H, 2010, CANCER IMMUNOL IMMUN, V59, P653, DOI 10.1007/s00262-009-0781-9; Tang YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091551; vandenBroek MF, 1996, J EXP MED, V184, P1781, DOI 10.1084/jem.184.5.1781; Wang J, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07234-0; Yamagami W, 2011, INT J GYNECOL CANCER, V21, P1628, DOI 10.1097/IGC.0b013e31822c271f	42	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								892543	10.3389/fimmu.2022.892543	http://dx.doi.org/10.3389/fimmu.2022.892543			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U0QA	35634289	Green Published, gold			2022-12-18	WOS:000805124500001
J	Germano, MJ; Mackern-Oberti, JP; Vitorio, JG; Duarte, MC; Pimenta, DC; Sanchez, MV; Bruna, FA; Lozano, ES; Fernandes, AP; Cargnelutti, DE				Germano, Maria Jose; Mackern-Oberti, Juan Pablo; Vitorio, Jessica Gardone; Duarte, Mariana Costa; Pimenta, Daniel Carvalho; Sanchez, Maria Victoria; Bruna, Flavia Alejandra; Lozano, Esteban Sebastian; Fernandes, Ana Paula; Cargnelutti, Diego Esteban			Identification of Immunodominant Antigens From a First-Generation Vaccine Against Cutaneous Leishmaniasis	FRONTIERS IN IMMUNOLOGY			English	Article						L; amazonensis; immunoproteomic analysis; vaccines; American tegumentary leishmaniasis; neglected tropical disease (NTD)	CYTOSOLIC TRYPAREDOXIN; PROTEINS; INFECTION; DONOVANI; IMMUNOPROTEOMICS; PROLIFERATION; IMMUNIZATION; INDUCTION; RESPONSES; SURVIVAL	Leishmaniasis is a neglected tropical disease (NTD) caused by parasites belonging to the Leishmania genus for which there is no vaccine available for human use. Thus, the aims of this study are to evaluate the immunoprotective effect of a first-generation vaccine against L. amazonensis and to identify its immunodominant antigens. BALB/c mice were inoculated with phosphate buffer sodium (PBS), total L. amazonensis antigens (TLAs), or TLA with Poly (I:C) and Montanide ISA 763. The humoral and cellular immune response was evaluated before infection. IgG, IgG1, and IgG2a were measured on serum, and IFN-gamma, IL-4, and IL-10 cytokines as well as cell proliferation were measured on a splenocyte culture from vaccinated mice. Immunized mice were challenged with 10(4) infective parasites of L. amazonensis on the footpad. After infection, the protection provided by the vaccine was analyzed by measuring lesion size, splenic index, and parasite load on the footpad and spleen. To identify immunodominant antigens, total proteins of L. amazonensis were separated on 2D electrophoresis gel and transferred to a membrane that was incubated with serum from immunoprotected mice. The antigens recognized by the serum were analyzed through a mass spectrometric assay (LC-MS/MS-IT-TOF) to identify their protein sequence, which was subjected to bioinformatic analysis. The first-generation vaccine induced higher levels of antibodies, cytokines, and cell proliferation than the controls after the second dose. Mice vaccinated with TLA + Poly (I:C) + Montanide ISA 763 showed less footpad swelling, a lower splenic index, and a lower parasite load than the control groups (PBS and TLA). Four immunodominant proteins were identified by mass spectrometry: cytosolic tryparedoxin peroxidase, an uncharacterized protein, a kinetoplast-associated protein-like protein, and a putative heat-shock protein DNAJ. The identified proteins showed high levels of conserved sequence among species belonging to the Leishmania genus and the Trypanosomatidae family. These proteins also proved to be phylogenetically divergent to human and canine proteins. TLA + Poly (I:C) + Montanide ISA 763 could be used as a first-generation vaccine against leishmaniasis. The four proteins identified from the whole-protein vaccine could be good antigen candidates to develop a new-generation vaccine against leishmaniasis.	[Germano, Maria Jose; Mackern-Oberti, Juan Pablo; Sanchez, Maria Victoria; Bruna, Flavia Alejandra; Lozano, Esteban Sebastian; Cargnelutti, Diego Esteban] Univ Nacl Cuyo UNCuyo, Consejo Nacl Invest Cient & Tecn CONICET, Inst Med & Biol Expt Cuyo IMBECU, Mendoza, Argentina; [Mackern-Oberti, Juan Pablo; Lozano, Esteban Sebastian; Cargnelutti, Diego Esteban] Univ Nacl Cuyo UNCuyo, Fac Ciencias Med FCM, Mendoza, Argentina; [Vitorio, Jessica Gardone; Duarte, Mariana Costa; Fernandes, Ana Paula] Univ Fed Minas Gerais, Fac Farm, Dept Anal Clin & Toxicol, Belo Horizonte, Brazil; [Pimenta, Daniel Carvalho] Inst Butantan, Lab Bioquim & Biofis, Sao Paulo, Brazil	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza; Universidade Federal de Minas Gerais; Instituto Butantan	Cargnelutti, DE (corresponding author), Univ Nacl Cuyo UNCuyo, Consejo Nacl Invest Cient & Tecn CONICET, Inst Med & Biol Expt Cuyo IMBECU, Mendoza, Argentina.; Cargnelutti, DE (corresponding author), Univ Nacl Cuyo UNCuyo, Fac Ciencias Med FCM, Mendoza, Argentina.	diegocargnelutti@hotmail.com	Pimenta, Daniel C/B-4361-2008	Pimenta, Daniel C/0000-0003-2406-0860; Sanchez, Maria/0000-0003-2252-959X; Lozano, Esteban/0000-0002-9229-2439	Universidad Nacional de Cuyo (UNCuyo ) [SIIP 06/J499, SIIP J082/2019]; Consejo Nacional de Investigaciones Cientiificas y Tecnicas (CONICET) [PIP 11220150100210, PIP 0081-2015]; Agencia Nacional de Promocion Cientifica y Tecnologica (AGENCIA) [PICT 2018-01511, PICT-2015-0271, PICT 2015-1052, PICT 2018-2642, PICT 2019-01762]; Universidad del Aconcagua (CIUDA 2021); Instituto Nacional de Ciencia e Tecnologia em Vacinas (INCTV)/CNPq [465293/2014-0]; Rede Mineira de Biomoleculas (FAPEMIG) [red001214]; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil); Coordenacao de Aperfeicoamento dePessoal de Nivel Superior (CAPES, Brazil)	Universidad Nacional de Cuyo (UNCuyo ); Consejo Nacional de Investigaciones Cientiificas y Tecnicas (CONICET); Agencia Nacional de Promocion Cientifica y Tecnologica (AGENCIA)(ANPCyT); Universidad del Aconcagua (CIUDA 2021); Instituto Nacional de Ciencia e Tecnologia em Vacinas (INCTV)/CNPq; Rede Mineira de Biomoleculas (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento dePessoal de Nivel Superior (CAPES, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by Universidad Nacional de Cuyo ( UNCuyo SIIP 06/J499; UNCuyo SIIP J082/2019), Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) (PIP 11220150100210Co 2015-2017 and PIP 0081-2015), Agencia Nacional de Promocion Cientifica y Tecnologica (AGENCIA) (PICT 2018-01511, PICT-2015-0271, PICT 2015-1052, PICT 2018-2642, and PICT 2019-01762), Universidad del Aconcagua (CIUDA 2021). Instituto Nacional de Ciencia e Tecnologia em Vacinas (INCTV)/CNPq (grant no 465293/2014-0), and Rede Mineira de Biomoleculas (FAPEMIG grant no red001214). Authors received research and students fellowships from Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq, Brazil) andCoordenacao de Aperfeicoamento dePessoal de Nivel Superior (CAPES, Brazil), respectively.	Akhoundi M, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004349; Akilov OE, 2007, INT J DERMATOL, V46, P132, DOI 10.1111/j.1365-4632.2007.03154.x; Almeida APMM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00465; Andrade JM, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-406; Antinori S, 2012, EUR J CLIN MICROBIOL, V31, P109, DOI 10.1007/s10096-011-1276-0; Aucouturier J, 2001, VACCINE, V19, P2666, DOI 10.1016/S0264-410X(00)00498-9; Avliyakulov NK, 2004, EUKARYOT CELL, V3, P518, DOI 10.1128/EC.3.2.518-526.2004; Baldwin TM, 2003, INFECT IMMUN, V71, P6830, DOI 10.1128/IAI.71.12.6830-6834.2003; Bogdan C, 2019, METHODS MOL BIOL, V1971, P315, DOI 10.1007/978-1-4939-9210-2_18; Bolhassani A, 2008, EXPERT REV VACCINES, V7, P1185, DOI 10.1586/14760584.7.8.1185; Brotherton MC, 2010, J PROTEOME RES, V9, P3842, DOI 10.1021/pr100048m; Christensen SM, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007152; Coelho VTS, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001430; Costa MM, 2011, J PROTEOME RES, V10, P2172, DOI 10.1021/pr101286y; Cunningham AL, 2016, VACCINE, V34, P6655, DOI 10.1016/j.vaccine.2016.10.016; de Lima CMF, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.652956; de Souza SSA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187516; Dennehy R, 2012, CURR PROTEIN PEPT SC, V13, P807, DOI 10.2174/138920312804871184; Duarte MC, 2015, CLIN VACCINE IMMUNOL, V22, P1187, DOI 10.1128/CVI.00465-15; Cargnelutti DE, 2016, J MICROBIOL IMMUNOL, V49, P24, DOI 10.1016/j.jmii.2014.01.006; Falisse-Poirrier N, 2006, J MICROBIOL METH, V67, P593, DOI 10.1016/j.mimet.2006.05.002; de Mendonca SCF, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00524; Gardinassi LG, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1669-0; Hafner AM, 2013, ADV DRUG DELIVER REV, V65, P1386, DOI 10.1016/j.addr.2013.05.013; Iborra S, 2018, EXPERT REV VACCINES, V17, P323, DOI 10.1080/14760584.2018.1459191; Iyer JP, 2008, MOL MICROBIOL, V68, P372, DOI 10.1111/j.1365-2958.2008.06154.x; Jara M, 2013, J CLIN MICROBIOL, V51, P1826, DOI 10.1128/JCM.00208-13; Krober-Boncardo C GJ., 2020, LEISHMANIA PARASITES, P1; Lage DP, 2020, NPJ VACCINES, V5, DOI 10.1038/s41541-020-00224-0; Lagerqvist N, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-6; Maria JG, 2019, ASIAN PAC J TROP MED, V12, P300, DOI 10.4103/1995-7645.262073; Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085; Martins VT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137683; Mehravaran A, 2019, INFECT GENET EVOL, V70, P27, DOI 10.1016/j.meegid.2019.01.005; Mohebali M, 2019, ACTA TROP, V200, DOI 10.1016/j.actatropica.2019.105173; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mutiso JM., 2009, INT J INTEG BIOL, V7, P107; Mutiso JM, 2010, REV INST MED TROP SP, V52, P95, DOI 10.1590/S0036-46652010000200006; Pavlick A, 2020, CANCER IMMUNOL RES, V8, P70, DOI 10.1158/2326-6066.CIR-19-0545; de Souza FSP, 2010, MOL BIOCHEM PARASIT, V172, P90, DOI 10.1016/j.molbiopara.2010.03.014; Rosenzweig D, 2008, PROTEOMICS, V8, P1843, DOI 10.1002/pmic.200701043; Rossi M, 2018, INT IMMUNOL, V30, P103, DOI 10.1093/intimm/dxx075; Rostamian M, 2020, ASIAN PAC J TROP BIO, V10, P532, DOI 10.4103/2221-1691.297052; Salari S, 2020, PARASITE VECTOR, V13, DOI 10.1186/s13071-020-04289-7; Salem ML, 2006, VACCINE, V24, P5119, DOI 10.1016/j.vaccine.2006.04.010; Sanchez MV, 2017, PARASITE IMMUNOL, V39, DOI 10.1111/pim.12491; Shokri M, 2016, MOL IMMUNOL, V76, P108, DOI 10.1016/j.molimm.2016.06.010; Skwarczynski M, 2016, CHEM SCI, V7, P842, DOI 10.1039/c5sc03892h; Srivastava S, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1553-y; Suman SS, 2016, BIOCHIMIE, V121, P312, DOI 10.1016/j.biochi.2015.12.017; Suman SS, 2018, CYTOKINE, V108, P1, DOI 10.1016/j.cyto.2018.03.010; Sundar S, 2014, EXPERT REV VACCINES, V13, P489, DOI 10.1586/14760584.2014.894467; Teixeira PC, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003411; Thompson EA, 2017, CURR OPIN IMMUNOL, V47, P1, DOI 10.1016/j.coi.2017.06.006; Velez R, 2020, TROP MED INT HEALTH, V25, P540, DOI 10.1111/tmi.13382; Wang JY, 2014, EUKARYOT CELL, V13, P919, DOI 10.1128/EC.00260-13; WHO, 2010, WHO TECH REP SER, V949, P1; Xin LJ, 2007, INFECT IMMUN, V75, P5018, DOI 10.1128/IAI.00499-07	59	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								825007	10.3389/fimmu.2022.825007	http://dx.doi.org/10.3389/fimmu.2022.825007			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P7II	35634280	gold, Green Published			2022-12-18	WOS:000802178100001
J	Gottschalk, TA; Hall, P; Tsantikos, E; L'Estrange-Stranieri, E; Hickey, MJ; Hibbs, ML				Gottschalk, Timothy A.; Hall, Pamela; Tsantikos, Evelyn; L'Estrange-Stranieri, Elan; Hickey, Michael J.; Hibbs, Margaret L.			Loss of CD11b Accelerates Lupus Nephritis in Lyn-Deficient Mice Without Disrupting Glomerular Leukocyte Trafficking	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; glomerulonephritis; inflammation; myeloid cells; immune cell trafficking; Lyn tyrosine kinase; leukocyte integrin CD11b	COMPLEMENT RECEPTOR-3; INTEGRIN; ITGAM; MAC-1; ERYTHEMATOSUS; ACTIVATION; ADHESION; ASSOCIATION; EMIGRATION; MONOCYTES	Systemic lupus erythematosus (SLE) is a complex, heterogeneous autoimmune disease. A common manifestation, lupus nephritis, arises from immune complex deposition in the kidney microvasculature promoting leukocyte activation and infiltration, which triggers glomerular damage and renal dysfunction. CD11b is a leukocyte integrin mainly expressed on myeloid cells, and aside from its well-ascribed roles in leukocyte trafficking and phagocytosis, it can also suppress cytokine production and autoreactivity. Genome-wide association studies have identified loss-of-function polymorphisms in the CD11b-encoding gene ITGAM that are strongly associated with SLE and lupus nephritis; however, it is not known whether these polymorphisms act alone to induce disease or in concert with other risk alleles. Herein we show using Itgam(-/-) mice that loss of CD11b led to mild inflammatory traits, which were insufficient to trigger autoimmunity or glomerulonephritis. However, deficiency of CD11b in autoimmune-prone Lyn-deficient mice (Lyn(-/-)Itgam(-/-)) accelerated lupus-like disease, driving early-onset immune cell dysregulation, autoantibody production and glomerulonephritis, impacting survival. Migration of leukocytes to the kidney in Lyn(-/-) mice was unhindered by lack of CD11b. Indeed, kidney inflammatory macrophages were further enriched, neutrophil retention in glomerular capillaries was increased and kidney inflammatory cytokine responses were enhanced in Lyn(-/-)Itgam(-/-) mice. These findings indicate that ITGAM is a non-monogenic autoimmune susceptibility gene, with loss of functional CD11b exacerbating disease without impeding glomerular leukocyte trafficking when in conjunction with other pre-disposing genetic mutations. This highlights a primarily protective role for CD11b in restraining inflammation and autoimmune disease and provides a potential therapeutic avenue for lupus treatment.	[Gottschalk, Timothy A.; Tsantikos, Evelyn; L'Estrange-Stranieri, Elan; Hibbs, Margaret L.] Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Leukocyte Signalling Lab, Melbourne, VIC, Australia; [Hall, Pamela; Hickey, Michael J.] Monash Univ, Ctr Inflammatory Dis, Monash Med Ctr, Dept Med, Clayton, VIC, Australia	Monash University; Monash University	Hibbs, ML (corresponding author), Monash Univ, Cent Clin Sch, Dept Immunol & Pathol, Leukocyte Signalling Lab, Melbourne, VIC, Australia.	Margaret.Hibbs@monash.edu			National Health and Medical Research Council of Australia [1080274, 1124459]; Central Clinical School, Monash University; Australian Postgraduate Award for doctoral studies; National Health and Medical Research Council Australia [1135971]	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Central Clinical School, Monash University; Australian Postgraduate Award for doctoral studies; National Health and Medical Research Council Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by funding from the National Health and Medical Research Council of Australia [1080274 to MLH, 1124459 to MJH] and the Central Clinical School, Monash University. TG was a recipient of an Australian Postgraduate Award for doctoral studies, and MJH held a fellowship from the National Health and Medical Research Council Australia [1135971].	Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; De Filippo K, 2008, J IMMUNOL, V180, P4308, DOI 10.4049/jimmunol.180.6.4308; Devi S, 2013, NAT MED, V19, P107, DOI 10.1038/nm.3024; Ding CL, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3813; Ehlers MRW, 2000, MICROBES INFECT, V2, P289, DOI 10.1016/S1286-4579(00)00299-9; Faridi MH, 2017, J CLIN INVEST, V127, P1271, DOI 10.1172/JCI88442; Finsterbusch M, 2016, P NATL ACAD SCI USA, V113, pE5172, DOI 10.1073/pnas.1606253113; Ghodke-Puranik Y, 2015, J AUTOIMMUN, V64, P125, DOI 10.1016/j.jaut.2015.08.004; Gottschalk TA, 2021, IMMUN INFLAMM DIS, V9, P758, DOI 10.1002/iid3.430; Gottschalk TA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00550; Han CF, 2010, NAT IMMUNOL, V11, P734, DOI 10.1038/ni.1908; Harley JB, 2008, NAT GENET, V40, P204, DOI 10.1038/ng.81; HIBBS ML, 1995, CELL, V83, P301, DOI 10.1016/0092-8674(95)90171-X; Hom G, 2008, NEW ENGL J MED, V358, P900, DOI 10.1056/NEJMoa0707865; Hua ZL, 2014, J IMMUNOL, V192, P875, DOI 10.4049/jimmunol.1300683; Kevil CG, 2004, AM J PATHOL, V165, P609, DOI 10.1016/S0002-9440(10)63325-1; Khan SQ, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00045; Lamagna C, 2014, J IMMUNOL, V192, P919, DOI 10.4049/jimmunol.1301979; Lin SL, 2009, J IMMUNOL, V183, P6733, DOI 10.4049/jimmunol.0901473; Lu HF, 1997, J CLIN INVEST, V99, P1340, DOI 10.1172/JCI119293; Ma KY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236021; Maiguel D, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001811; Martinez L, 2020, J IMMUNOL, V205, P2545, DOI 10.4049/jimmunol.1901402; Maxwell MJ, 2012, J AUTOIMMUN, V38, P381, DOI 10.1016/j.jaut.2012.04.001; Nath SK, 2008, NAT GENET, V40, P152, DOI 10.1038/ng.71; Overbergh L, 2003, J Biomol Tech, V14, P33; Parikh SV, 2020, AM J KIDNEY DIS, V76, P265, DOI 10.1053/j.ajkd.2019.10.017; Phillipson M, 2006, J EXP MED, V203, P2569, DOI 10.1084/jem.20060925; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Rhodes B, 2012, ANN RHEUM DIS, V71, P2028, DOI 10.1136/annrheumdis-2012-201390; Rosetti F, 2016, IMMUNOL REV, V269, P175, DOI 10.1111/imr.12373; Rosetti F, 2012, J IMMUNOL, V189, P3714, DOI 10.4049/jimmunol.1201594; Ross GD, 2002, IMMUNOL RES, V25, P219, DOI 10.1385/IR:25:3:219; Ruiz-Villalba A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00043-9; Saggu G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07506-1; Tang T, 1997, J EXP MED, V186, P1853, DOI 10.1084/jem.186.11.1853; Tsantikos E., 2014, INT J CLIN RHEUMATOL, V9, P519, DOI [10.2217/ijr.14.44, DOI 10.2217/IJR.14.44]; Tsantikos E, 2010, J IMMUNOL, V184, P1348, DOI 10.4049/jimmunol.0901878; Vincent FB., 2021, PATHOGENESIS SYSTEMI, P9; Wagner C, 2001, EUR J IMMUNOL, V31, P1173, DOI 10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9; Wang L, 2010, IMMUNITY, V32, P518, DOI 10.1016/j.immuni.2010.03.014; Xu YK, 2005, IMMUNITY, V22, P9, DOI 10.1016/j.immuni.2004.12.004; Yeung L, 2021, IMMUNOL CELL BIOL, V99, P1053, DOI 10.1111/imcb.12501; Zhang L, 1999, CELL RES, V9, P171, DOI 10.1038/sj.cr.7290015; Zhang QR, 2018, EXP MOL MED, V50, DOI 10.1038/emm.2017.256; Zhou YB, 2013, ARTHRITIS RHEUM-US, V65, P2907, DOI 10.1002/art.38117	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								875359	10.3389/fimmu.2022.875359	http://dx.doi.org/10.3389/fimmu.2022.875359			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1Q3KC	35634296	gold, Green Published			2022-12-18	WOS:000802589800001
J	Guo, F; Hancock, B; Griffith, A; Lin, H; Howard, K; Keegan, J; Zhang, F; Chicoine, A; Cahill, L; Ng, J; Lederer, J				Guo, Fei; Hancock, Brandon; Griffith, Alec; Lin, Hui; Howard, Kaitlyn; Keegan, Joshua; Zhang, Fan; Chicoine, Adam; Cahill, Laura; Ng, Julie; Lederer, James			Distinct Injury Responsive Regulatory T Cells Identified by Multi-Dimensional Phenotyping	FRONTIERS IN IMMUNOLOGY			English	Article						Tregs; trauma immunology; CyTOF; T cell receptor diversity; single-cell RNA sequencing	CYTOMETRY DATA; TRAUMA; MECHANISMS; TOLERANCE; EXPANSION; DEFECTS; REVEALS; MEMORY	CD4(+) regulatory T cells (Tregs) activate and expand in response to different types of injuries, suggesting that they play a critical role in controlling the immune response to tissue and cell damage. This project used multi-dimensional profiling techniques to comprehensively characterize injury responsive Tregs in mice. We show that CD44(high) Tregs expand in response to injury and were highly suppressive when compared to CD44(low) Tregs. T cell receptor (TCR) repertoire analysis revealed that the CD44(high) Treg population undergo TCR alpha beta clonal expansion as well as increased TCR CDR3 diversity. Bulk RNA sequencing and single-cell RNA sequencing with paired TCR clonotype analysis identified unique differences between CD44(high) and CD44(low) Tregs and specific upregulation of genes in Tregs with expanded TCR clonotypes. Gene ontology analysis for molecular function of RNA sequencing data identified chemokine receptors and cell division as the most enriched functional terms in CD44(high) Tregs versus CD44(low) Tregs. Mass cytometry (CyTOF) analysis of Tregs from injured and uninjured mice verified protein expression of these genes on CD44(high) Tregs, with injury-induced increases in Helios, Galectin-3 and PYCARD expression. Taken together, these data indicate that injury triggers the expansion of a highly suppressive CD44(high) Treg population that is transcriptionally and phenotypically distinct from CD44(low) Tregs suggesting that they actively participate in controlling immune responses to injury and tissue damage.	[Guo, Fei; Hancock, Brandon; Griffith, Alec; Lin, Hui; Howard, Kaitlyn; Keegan, Joshua; Zhang, Fan; Cahill, Laura; Lederer, James] Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Boston, MA USA; [Guo, Fei] Ningbo Univ, Ningbo Med Ctr Lihuili Hosp, Ningbo, Peoples R China; [Lin, Hui] Nanchang Univ, Sch Basic Med Sci, Dept Pathophysiol, Nanchang, Peoples R China; [Zhang, Fan] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Crit Care Med, Jinan, Peoples R China; [Chicoine, Adam] Brigham & Womens Hosp, Human Immunol Ctr, Boston, MA USA; [Ng, Julie] Brighamand Womens Hosp, Dept Med, Div Pulm & Crit Care Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Ningbo University; Nanchang University; Shandong University; Harvard University; Brigham & Women's Hospital	Lederer, J (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Surg, Boston, MA USA.	jlederer@bwh.harvard.edu		Zhang, Fan/0000-0001-7686-1155				Adeegbe D, 2019, J THORAC ONCOL, V14, pS453, DOI 10.1016/j.jtho.2019.08.938; Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bacher P, 2016, CELL, V167, P1067, DOI 10.1016/j.cell.2016.09.050; Bloemsma GC, 2008, BURNS, V34, P1103, DOI 10.1016/j.burns.2008.02.010; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Carbon S, 2021, NUCLEIC ACIDS RES, V49, pD325, DOI 10.1093/nar/gkaa1113; Chiffelle J, 2020, CURR OPIN BIOTECH, V65, P284, DOI 10.1016/j.copbio.2020.07.010; Cho J, 2019, P NATL ACAD SCI USA, V116, P26727, DOI 10.1073/pnas.1914848116; Cornwell M, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2139-9; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; Curran CS, 2018, AM J RESP CRIT CARE, V197, P708, DOI 10.1164/rccm.201705-1043SO; Dalessandri T, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00347; Finck R, 2013, CYTOM PART A, V83A, P483, DOI 10.1002/cyto.a.22271; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fujimi S, 2009, J LEUKOCYTE BIOL, V85, P862, DOI 10.1189/jlb.0408257; Galvan-Pena S, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2111315118; Guo XY, 2018, NAT MED, V24, P978, DOI 10.1038/s41591-018-0045-3; Gupta DL, 2016, CYTOKINE, V88, P214, DOI 10.1016/j.cyto.2016.09.010; Hanschen M, 2011, SHOCK, V35, P252, DOI 10.1097/SHK.0b013e3181f489c5; Hasib L, 2016, J INTERN MED, V279, P63, DOI 10.1111/joim.12398; Hoover L, 2006, J TRAUMA, V61, P310, DOI 10.1097/01.ta.0000229052.75460.c2; Johnson BZ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01481; Kelly JL, 1997, SURGERY, V122, P146, DOI 10.1016/S0039-6060(97)90003-9; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Koo TY, 2017, KIDNEY INT, V92, P415, DOI 10.1016/j.kint.2017.01.031; Kornete M, 2017, AUTOIMMUNITY, V50, P354, DOI 10.1080/08916934.2017.1364368; Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53; Lachiewicz AM, 2017, CLIN INFECT DIS, V65, P2130, DOI 10.1093/cid/cix682; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; MacConmara MP, 2006, ANN SURG, V244, P514, DOI 10.1097/01.sla.0000239031.06906.1f; Mack VE, 1996, ARCH SURG-CHICAGO, V131, P1303; Mhanna V, 2021, DIABETES, V70, P976, DOI 10.2337/db20-0896; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Miyara M, 2007, TRENDS MOL MED, V13, P108, DOI 10.1016/j.molmed.2007.01.003; Ni Choileain N, 2006, J IMMUNOL, V176, P225; Paterson HM, 2003, J IMMUNOL, V171, P1473, DOI 10.4049/jimmunol.171.3.1473; Patterson SJ, 2016, J CLIN INVEST, V126, P1039, DOI 10.1172/JCI83987; Qiu P, 2011, NAT BIOTECHNOL, V29, P886, DOI 10.1038/nbt.1991; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Sauaia A, 1996, WORLD J SURG, V20, P392, DOI 10.1007/s002689900062; Schubert Mikkel, 2016, BMC Res Notes, V9, P88, DOI 10.1186/s13104-016-1900-2; Schwacha MG, 1999, J BURN CARE REHABIL, V20, P37, DOI 10.1097/00004630-199901001-00007; Shen KL, 2020, WORLD J PEDIATR, V16, P232, DOI 10.1007/s12519-020-00362-4; Siegmund K, 2005, BLOOD, V106, P3097, DOI 10.1182/blood-2005-05-1864; Son J, 2020, CANCER IMMUNOL RES, V8, P1393, DOI 10.1158/2326-6066.CIR-19-0828; Stoecklein VM, 2012, J LEUKOCYTE BIOL, V92, P539, DOI 10.1189/jlb.0212072; Stremska ME, 2019, J AUTOIMMUN, V102, P133, DOI 10.1016/j.jaut.2019.05.005; Sun ZR, 2019, J CELL PHYSIOL, V234, P4608, DOI 10.1002/jcp.27245; van der Veeken J, 2016, CELL, V166, P977, DOI 10.1016/j.cell.2016.07.006; Vasanthakumar A, 2020, NATURE, V579, P581, DOI 10.1038/s41586-020-2040-3; Venken K, 2008, J IMMUNOL, V180, P6411, DOI 10.4049/jimmunol.180.9.6411; Wang CL, 2010, P NATL ACAD SCI USA, V107, P1518, DOI 10.1073/pnas.0913939107; Wang YZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.595355; Wanke-Jellinek L, 2016, J IMMUNOL, V196, P767, DOI 10.4049/jimmunol.1500597; Xie MX, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00676; Yamakawa K, 2021, J LEUKOCYTE BIOL, V109, P645, DOI 10.1002/JLB.4A0520-122R; Yang D, 2017, IMMUNOL REV, V280, P41, DOI 10.1111/imr.12577; Yang Y, 2015, ELIFE, V4, DOI 10.7554/eLife.09083; Zedler S, 1997, J TRAUMA, V42, P872, DOI 10.1097/00005373-199705000-00018; Zhang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070056; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6; Zunder ER, 2015, NAT PROTOC, V10, P316, DOI 10.1038/nprot.2015.020	64	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								833100	10.3389/fimmu.2022.833100	http://dx.doi.org/10.3389/fimmu.2022.833100			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N0EX	35634302	Green Published, gold			2022-12-18	WOS:000800338200001
J	Honda, T; Keith, YH				Honda, Tetsuya; Keith, Yuki Honda			Novel Insights Into the Immune-Regulatory Functions of Mast Cells in the Cutaneous Immune Response	FRONTIERS IN IMMUNOLOGY			English	Review						mast cell; IL-10; PD-1; regulatory T cells (Tregs); regulatory B cells (Bregs)	CONTACT-DERMATITIS; DENDRITIC CELLS; SKIN PATHOLOGY; ELICITATION; EXPRESSION; MATURATION; TOLERANCE; GROWTH	Skin is a frontline organ that is continuously exposed to external stimuli, including pathogens. Various immune cells reside in the skin under physiological conditions and protect the body from the entry of pathogens/antigens by interacting with each other and orchestrating diverse cutaneous immune responses. To avoid unnecessary inflammation and tissue damage during the elimination of external pathogens and antigens, skin possesses regulatory systems that fine-tune these immune reactions. Mast cells (MCs) are one of the skin-resident immune cell populations that play both effector and regulatory functions in the cutaneous immune response. So far, the interleukin-10-mediated mechanisms have mostly been investigated as the regulatory mechanisms of MCs. Recent studies have elucidated other regulatory mechanisms of MCs, such as the maintenance of regulatory T/B cells and the programmed cell death protein-1/programmed cell death-ligand 1-mediated inhibitory pathway. These regulatory pathways of MCs have been suggested to play important roles in limiting the excessive inflammation in inflammatory skin diseases, such as contact and atopic dermatitis. The regulatory functions of MCs may also be involved in the escape mechanisms of antitumor responses in skin cancers, such as melanoma. Understanding and controlling the regulatory functions of skin MCs may lead to novel therapeutic strategies for inflammatory skin diseases and skin cancers.	[Honda, Tetsuya] Hamamatsu Univ, Dept Dermatol, Sch Med, Hamamatsu, Japan; [Keith, Yuki Honda] Kyoto Univ, Dept Dermatol, Grad Sch Med, Kyoto, Japan	Hamamatsu University School of Medicine; Kyoto University	Honda, T (corresponding author), Hamamatsu Univ, Dept Dermatol, Sch Med, Hamamatsu, Japan.	hontetsu@hama-med.ac.jp			Japan Society for the Promotion of Science KAKENHI [JP19K08790, JP15H05906]; Japan Science, Japan Agency for Medical Research and Development (AMED) [19ek0410062s0201]; Kose Cosmetology Research Foundation; Lydia O'leary Memorial Pias Dermatological Foundation	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Japan Science, Japan Agency for Medical Research and Development (AMED); Kose Cosmetology Research Foundation; Lydia O'leary Memorial Pias Dermatological Foundation	This work was supported by the Japan Society for the Promotion of Science KAKENHI (JP19K08790, JP15H05906 [T.H.], Japan Science, Japan Agency for Medical Research and Development (AMED) (19ek0410062s0201) [T.H.], Kose Cosmetology Research Foundation [T.H.], Lydia O'leary Memorial Pias Dermatological Foundation [T.H.]	Ando T, 2013, J INVEST DERMATOL, V133, P2695, DOI 10.1038/jid.2013.250; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Biggs L, 2010, J EXP MED, V207, P455, DOI 10.1084/jem.20091725; Biswas A, 2014, INT J DERMATOL, V53, P806, DOI 10.1111/j.1365-4632.2012.05745.x; Curti BD, 2021, NEW ENGL J MED, V384, P2229, DOI 10.1056/NEJMra2034861; Derakhshan T, 2021, J EXP MED, V218, DOI 10.1084/jem.20200321; Dudeck A, 2011, IMMUNITY, V34, P973, DOI 10.1016/j.immuni.2011.03.028; Dudeck J, 2017, J EXP MED, V214, P3791, DOI 10.1084/jem.20160783; Dwyer DF, 2016, NAT IMMUNOL, V17, P878, DOI 10.1038/ni.3445; Galli SJ, 2020, ANNU REV IMMUNOL, V38, P49, DOI 10.1146/annurev-immunol-071719-094903; Gaudenzio N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01275; Gentek R, 2018, IMMUNITY, V48, P1160, DOI 10.1016/j.immuni.2018.04.025; Gimenez-Rivera VA, 2016, J IMMUNOL, V197, P4240, DOI 10.4049/jimmunol.1600236; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Hallgren J, 2007, IMMUNOL REV, V217, P8, DOI 10.1111/j.1600-065X.2007.00502.x; Hershko AY, 2011, IMMUNITY, V35, P562, DOI 10.1016/j.immuni.2011.07.013; Hirano T, 2021, J ALLERGY CLIN IMMUN, V148, P563, DOI 10.1016/j.jaci.2020.12.654; Honda T, 2020, J ALLERGY CLIN IMMUN, V145, P1136, DOI 10.1016/j.jaci.2020.02.008; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; Honda Y, 2019, J ALLERGY CLIN IMMUN, V144, P617, DOI 10.1016/j.jaci.2019.05.011; Kabashima K, 2019, NAT REV IMMUNOL, V19, P19, DOI 10.1038/s41577-018-0084-5; Kaesler S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125057; Kawakami Yuko, 2007, Allergol Int, V56, P403, DOI 10.2332/allergolint.O-07-486; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kim HS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav8152; Kitagaki H, 1997, J IMMUNOL, V159, P2484; KITAMURA Y, 1977, NATURE, V268, P442, DOI 10.1038/268442a0; Komi DEA, 2020, CLIN REV ALLERG IMMU, V58, P342, DOI 10.1007/s12016-019-08769-2; Li HZ, 2022, CANCER CELL, V40, P36, DOI 10.1016/j.ccell.2021.11.002; Li ZQ, 2018, IMMUNITY, V49, P640, DOI 10.1016/j.immuni.2018.09.023; Moniaga CS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15319; Morgenstern NB, 2022, J ALLERGY CLIN IMMUN, V149, P2062, DOI 10.1016/j.jaci.2022.02.025; Motakis E, 2014, BLOOD, V123, pE58, DOI 10.1182/blood-2013-02-483792; Nagata K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094972; Norman MU, 2008, AM J PATHOL, V172, P1638, DOI 10.2353/ajpath.2008.070559; Otsuka A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025538; Reber LL, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92900; RENNICK D, 1995, BLOOD, V85, P57, DOI 10.1182/blood.V85.1.57.bloodjournal85157; Ribatti D, 2003, EUR J CLIN INVEST, V33, P420, DOI 10.1046/j.1365-2362.2003.01152.x; Ribatti D, 2003, EUR J CANCER, V39, P666, DOI 10.1016/S0959-8049(02)00150-8; Serhan N, 2019, NAT IMMUNOL, V20, P1435, DOI 10.1038/s41590-019-0493-z; Siiskonen H, 2015, MELANOMA RES, V25, P479, DOI 10.1097/CMR.0000000000000192; Skokos D, 2003, J IMMUNOL, V170, P3037, DOI 10.4049/jimmunol.170.6.3037; Somasundaram R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20600-7; SONODA T, 1982, AM J PATHOL, V106, P312; Svanberg S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176311; Tokura Y, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.618897; van de Veen W, 2016, J ALLERGY CLIN IMMUN, V138, P654, DOI 10.1016/j.jaci.2016.07.006; Voss M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094589; Weber FC, 2015, J EXP MED, V212, P15, DOI 10.1084/jem.20130062; Weitzmann A, 2020, J INVEST DERMATOL, V140, P2433, DOI 10.1016/j.jid.2020.03.963; Zhang ZW, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071615	52	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								898419	10.3389/fimmu.2022.898419	http://dx.doi.org/10.3389/fimmu.2022.898419			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M9OO	35634300	Green Published, gold			2022-12-18	WOS:000800294500001
J	Kim, JY; Kim, J; Huang, M; Kosonen, R; Lee, JE				Kim, Jong Youl; Kim, Jiwon; Huang, Meiying; Kosonen, Renee; Lee, Jong Eun			CCR4 and CCR5 Involvement in Monocyte-Derived Macrophage Migration in Neuroinflammation	FRONTIERS IN IMMUNOLOGY			English	Article						neuroinflammation; microglia; monocyte-derived macrophage; CCR4; CCR5	INFLAMMATORY RESPONSES; CEREBRAL-ISCHEMIA; CHEMOKINE; MICROGLIA; STROKE; INNATE; MECHANISMS; EXPRESSION; SIGNALS; TARGET	Microglia, resident macrophages in the brain, play major roles in neuroinflammation after an acute many neurological diseases, including stroke. Our recent animal stroke model showed that interleukin (IL)-4 and IL-13 released by microglia are converted into monocyte-derived macrophages. However, the correlation with the migration mechanism of these cells is still unclear. This study aimed to clarify the effect of these cells on their migration and to identify potential targets that influence neuroinflammatory conditions. Inflammatory conditions were induced by lipopolysaccharide (LPS) treatment in in vitro and in vivo models. Cell migration was observed using transwell assay, and target chemokines were screened using the proteome profiler array in the in vitro model. Intravital, IVIS, and CLARITY imaging were used in the in vivo model. After LPS (1 ng/ml) treatment in BV2 (microglia cell line) and J774 (monocyte/macrophage cell line) cells, BV2 migration was approximately two-fold more enhanced compared to J774 migration. Overall, six types of chemokine C-C motif ligands (CCLs) were detected from the BV2 conditioned medium with LPS. These CCLs were related to C-C motif receptor (CCR)4 and CCR5. In the in vivo model, CCR4 and CCR5 antagonist significantly inhibited the migration of monocyte-derived macrophages to brain tissue following LPS (5 mu g) treatment. In conclusion, the chemokines released by microglia may influence migration of monocyte-derived macrophages in necroinflammation conditions inducted by microglial activation. CCR4 and CCR5 expressed on monocyte-derived macrophages interacted with these chemokines and induced migration. Therefore, CCR4 and CCR5 may be explored as new therapeutic targets for neuroinflammation.	[Kim, Jong Youl; Kim, Jiwon; Huang, Meiying; Kosonen, Renee; Lee, Jong Eun] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea; [Kim, Jiwon; Huang, Meiying; Kosonen, Renee; Lee, Jong Eun] Yonsei Univ, Coll Med, Grad Sch Med Sci, Brain Korea Project 21, Seoul, South Korea; [Lee, Jong Eun] Yonsei Univ, Coll Med, Brain Res Inst, Seoul, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Lee, JE (corresponding author), Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea.; Lee, JE (corresponding author), Yonsei Univ, Coll Med, Grad Sch Med Sci, Brain Korea Project 21, Seoul, South Korea.; Lee, JE (corresponding author), Yonsei Univ, Coll Med, Brain Res Inst, Seoul, South Korea.	jelee@yuhs.ac		Lee, Jong Eun/0000-0001-6203-7413; Kim, Jong Youl/0000-0002-8340-2894	National Research Foundation of Korea (NRF) - Ministry of Science, ICT, and Future Planning [NRF-2016M3C7A1905098]; NRF - Korea government (MSIT) [NRF-2021R1A2C2008034]; NRF - Ministry of Education [NRF-2020R1I1A1A01064803]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT, and Future Planning(National Research Foundation of Korea); NRF - Korea government (MSIT)(National Research Foundation of Korea); NRF - Ministry of Education(National Research Foundation of Korea)	This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, ICT, and Future Planning (NRF-2016M3C7A1905098 to JEL), the NRF grant funded by the Korea government (MSIT) (NRF-2021R1A2C2008034 to JEL), and NRF funded by the Ministry of Education (NRF-2020R1I1A1A01064803 to JYK).	Appel S H, 2011, Acta Myol, V30, P4; Castanheira FVES, 2019, SHOCK, V52, pE100, DOI 10.1097/SHK.0000000000001301; Chen C, 2019, CELL MOL NEUROBIOL, V39, P651, DOI 10.1007/s10571-019-00669-5; Chung Wen-Hung, 2010, Allergology International, V59, P325, DOI 10.2332/allergolint.10-RAI-0261; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; Cowan JE, 2014, J IMMUNOL, V193, P1204, DOI 10.4049/jimmunol.1400993; Fantuzzi L, 2019, CELL MOL LIFE SCI, V76, P4869, DOI 10.1007/s00018-019-03255-6; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Huang WC, 2010, ANAT CELL BIOL, V43, P325, DOI 10.5115/acb.2010.43.4.325; Iadecola C, 2011, NAT MED, V17, P796, DOI 10.1038/nm.2399; Ishikawa M, 2004, FRONT BIOSCI-LANDMRK, V9, P1339, DOI 10.2741/1330; Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004; Kawabori M, 2015, METAB BRAIN DIS, V30, P381, DOI 10.1007/s11011-014-9531-6; Kim JY, 2014, CURR MED CHEM, V21, P2076, DOI 10.2174/0929867321666131228205146; Kim JY, 2016, EXP NEUROBIOL, V25, P241, DOI 10.5607/en.2016.25.5.241; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kronenberg G, 2018, ACTA NEUROPATHOL, V135, P551, DOI 10.1007/s00401-017-1795-6; Lai AY, 2006, CAN J PHYSIOL PHARM, V84, P49, DOI 10.1139/y05-143; Mahad DJ, 2004, J NEUROPATH EXP NEUR, V63, P262, DOI 10.1093/jnen/63.3.262; Murphy PM, 2000, PHARMACOL REV, V52, P145; Ness TL, 2006, J IMMUNOL, V177, P7531, DOI 10.4049/jimmunol.177.11.7531; Oppermann M, 2004, CELL SIGNAL, V16, P1201, DOI 10.1016/j.cellsig.2004.04.007; Park J, 2021, TRANSL STROKE RES, V12, P879, DOI 10.1007/s12975-020-00878-x; Perego C, 2016, NEUROBIOL DIS, V96, P284, DOI 10.1016/j.nbd.2016.09.017; POWER CA, 1995, CYTOKINE, V7, P479, DOI 10.1006/cyto.1995.0065; Proudfoot AEI, 1999, J BIOL CHEM, V274, P32478, DOI 10.1074/jbc.274.45.32478; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Seki E, 2009, J CLIN INVEST, V119, P1858, DOI 10.1172/JCI37444; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016; Weston RM, 2007, J CEREBR BLOOD F MET, V27, P100, DOI 10.1038/sj.jcbfm.9600324; WOOD PL, 1995, NEUROL RES, V17, P242, DOI 10.1080/01616412.1995.11740321; Yilmaz G, 2008, NEUROL RES, V30, P783, DOI 10.1179/174313208X341085; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	34	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								876033	10.3389/fimmu.2022.876033	http://dx.doi.org/10.3389/fimmu.2022.876033			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1U0RT	35634277	Green Published, gold			2022-12-18	WOS:000805129000001
J	Kuijpers, Y; Chu, XJ; Jaeger, M; Moorlag, SJCFM; Koeken, VACM; Zhang, BW; de Nooijer, A; Grondman, I; Gupta, MK; Janssen, N; Mourits, VP; de Bree, LCJ; de Mast, Q; van de Veerdonk, FL; Joosten, LAB; Li, Y; Netea, MG; Xu, CJ				Kuijpers, Yunus; Chu, Xiaojing; Jaeger, Martin; Moorlag, Simone J. C. F. M.; Koeken, Valerie A. C. M.; Zhang, Bowen; de Nooijer, Aline; Grondman, Inge; Gupta, Manoj Kumar; Janssen, Nico; Mourits, Vera P.; de Bree, L. Charlotte J.; de Mast, Quirijn; van de Veerdonk, Frank L.; Joosten, Leo A. B.; Li, Yang; Netea, Mihai G.; Xu, Cheng-Jian			The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						genome-wide association studies; COVID-19; genotyping; cytokine; single-cell	ABO BLOOD-GROUP; CYTOKINE PRODUCTION; DISEASE SEVERITY; INNATE	Recent genome-wide association studies (GWASs) of COVID-19 patients of European ancestry have identified genetic loci significantly associated with disease severity. Here, we employed the detailed clinical, immunological and multi-omics dataset of the Human Functional Genomics Project (HFGP) to explore the physiological significance of the host genetic variants that influence susceptibility to severe COVID-19. A genomics investigation intersected with functional characterization of individuals with high genetic risk for severe COVID-19 susceptibility identified several major patterns: i. a large impact of genetically determined innate immune responses in COVID-19, with ii. increased susceptibility for severe disease in individuals with defective cytokine production; iii. genetic susceptibility related to ABO blood groups is probably mediated through the von Willebrand factor (VWF) and endothelial dysfunction. We further validated these identified associations at transcript and protein levels by using independent disease cohorts. These insights allow a physiological understanding of genetic susceptibility to severe COVID-19, and indicate pathways that could be targeted for prevention and therapy.	[Kuijpers, Yunus; Chu, Xiaojing; Koeken, Valerie A. C. M.; Zhang, Bowen; Gupta, Manoj Kumar; Li, Yang; Xu, Cheng-Jian] Ctr Individualised Infect Med CiiM, Joint venture Hannover Med Sch & Helmholtz Ctr Inf, Hannover, Germany; [Kuijpers, Yunus; Chu, Xiaojing; Koeken, Valerie A. C. M.; Zhang, Bowen; Gupta, Manoj Kumar; Li, Yang; Xu, Cheng-Jian] WINCORE, Joint venture Hannover Med Sch & Helmholtz Ctr Inf, Ctr Expt & Clin Infect Res, Hannover, Germany; [Chu, Xiaojing] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Groningen, Netherlands; [Jaeger, Martin; Moorlag, Simone J. C. F. M.; Koeken, Valerie A. C. M.; de Nooijer, Aline; Grondman, Inge; Janssen, Nico; Mourits, Vera P.; de Bree, L. Charlotte J.; de Mast, Quirijn; van de Veerdonk, Frank L.; Joosten, Leo A. B.; Li, Yang; Netea, Mihai G.; Xu, Cheng-Jian] Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands; [Jaeger, Martin; Moorlag, Simone J. C. F. M.; Koeken, Valerie A. C. M.; de Nooijer, Aline; Grondman, Inge; Janssen, Nico; Mourits, Vera P.; de Bree, L. Charlotte J.; de Mast, Quirijn; van de Veerdonk, Frank L.; Joosten, Leo A. B.; Li, Yang; Netea, Mihai G.; Xu, Cheng-Jian] Radboud Univ Nijmegen Med Ctr, Radboud Inst Ctr Infect Dis, Nijmegen, Netherlands; [Joosten, Leo A. B.] Fac Policia Mil FPM Estado Goias, Nucleo Pesquisa, Goiania, Brazil; [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst LIMES, Dept Genom & Immunoregulat, Bonn, Germany; [Xu, Cheng-Jian] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany	University of Groningen; Radboud University Nijmegen; Radboud University Nijmegen; University of Bonn; Hannover Medical School	Xu, CJ (corresponding author), Ctr Individualised Infect Med CiiM, Joint venture Hannover Med Sch & Helmholtz Ctr Inf, Hannover, Germany.; Xu, CJ (corresponding author), WINCORE, Joint venture Hannover Med Sch & Helmholtz Ctr Inf, Ctr Expt & Clin Infect Res, Hannover, Germany.; Netea, MG; Xu, CJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Dept Internal Med, Nijmegen, Netherlands.; Netea, MG; Xu, CJ (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Inst Ctr Infect Dis, Nijmegen, Netherlands.; Netea, MG (corresponding author), Univ Bonn, Life & Med Sci Inst LIMES, Dept Genom & Immunoregulat, Bonn, Germany.; Xu, CJ (corresponding author), Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany.	Mihai.Netea@radboudumc.nl; Xu.Chengjian@mh-hannover.de	Xu, Cheng-Jian/G-9144-2018; Li, Yang/HGT-8446-2022; Koeken, Valerie/P-8454-2015	Xu, Cheng-Jian/0000-0003-1586-4672; Li, Yang/0000-0003-4022-7341; Koeken, Valerie/0000-0002-5783-9013; Chu, Xiaojing/0000-0002-9882-2912	ERC [833247, 948207]; Netherlands Organization for Scientific Research; Radboud University Medical Centre; Helmholtz Initiative and Networking Fund [1800167]; German Federal Ministry of Education and Research [01KX2021]	ERC(European Research Council (ERC)European Commission); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Radboud University Medical Centre; Helmholtz Initiative and Networking Fund(Helmholtz Association); German Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF))	MN was supported by an ERC Advanced Grant (833247) and a Spinoza Grant of the Netherlands Organization for Scientific Research. YL was supported by an ERC starting Grant (948207) and a Radboud University Medical Centre Hypatia Grant (2018). C-JX was supported by Helmholtz Initiative and Networking Fund (1800167). This work was also partly supported by the German Federal Ministry of Education and Research, NaFoUniMedCovid19"-COVIM [01KX2021].	Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; [Аксёнова Анна Юрьевна Aksenova Anna Yu.], 2020, [Экологическая генетика, Ecological Genetics, Ekologicheskaya genetika], V18, P135, DOI 10.17816/ecogen33973; Assarsson E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095192; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; de Moura MC, 2021, EBIOMEDICINE, V66, DOI 10.1016/j.ebiom.2021.103339; Chen G, 2020, J CLIN INVEST, V130, P2620, DOI 10.1172/JCI137244; Chen ZY, 2020, NAT REV IMMUNOL, V20, P529, DOI 10.1038/s41577-020-0402-6; Choi SW, 2020, NAT PROTOC, V15, P2759, DOI 10.1038/s41596-020-0353-1; Chu XJ, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02413-z; Dai YL, 2021, HUM GENET, V140, P1313, DOI 10.1007/s00439-021-02305-z; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Dzik S, 2020, TRANSFUSION, V60, P1883, DOI 10.1111/trf.15946; Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; Franchini Massimo, 2007, Thromb J, V5, P14; Giamarellos-Bourboulis EJ, 2020, CELL HOST MICROBE, V27, P992, DOI 10.1016/j.chom.2020.04.009; Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383; Goligher EC, 2021, NEW ENGL J MED, V385, P777, DOI [10.1056/NEJMoa2100433, 10.1056/NEJMoa2103417]; Goshua G, 2020, LANCET HAEMATOL, V7, pE575, DOI 10.1016/S2352-3026(20)30216-7; Hoiland RL, 2020, BLOOD ADV, V4, P4981, DOI 10.1182/bloodadvances.2020002623; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Horowitz JE, 2022, NAT GENET, V54, P382, DOI 10.1038/s41588-021-01006-7; Huang I, 2020, J INTENSIVE CARE, V8, DOI 10.1186/s40560-020-00453-4; Hultstrom M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03223-8; Janssen NAF, 2021, J INFECT DIS, V223, P1322, DOI 10.1093/infdis/jiab065; Kasela S, 2021, GENOME BIOL, V22, DOI [10.1186/s13059-021-02454-4, 10.1101/2021.04.09.21255184]; Kawecki C, 2017, J THROMB HAEMOST, V15, P1285, DOI 10.1111/jth.13696; Khera AV, 2018, NAT GENET, V50, P1219, DOI 10.1038/s41588-018-0183-z; Koeken VACM, 2020, J CLIN INVEST, V130, P5591, DOI 10.1172/JCI133935; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Kyriazopoulou E, 2021, NAT MED, V27, P1752, DOI 10.1038/s41591-021-01499-z; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Li Y, 2016, CELL, V167, P1099, DOI 10.1016/j.cell.2016.10.017; Loh PR, 2016, NAT GENET, V48, P1443, DOI 10.1038/ng.3679; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Mourits VP, 2020, IMMUNOLOGY, V159, P289, DOI 10.1111/imm.13145; Netea MG, 2020, CELL, V181, P969, DOI 10.1016/j.cell.2020.04.042; Niemi MEK, 2021, NATURE, V600, P472, DOI 10.1038/s41586-021-03767-x; O'Sullivan JM, 2020, BRIT J HAEMATOL, V190, P27, DOI 10.1111/bjh.16845; Pairo-Castineira E, 2021, NATURE, V591, P92, DOI 10.1038/s41586-020-03065-y; Rapkiewicz AV, 2020, ECLINICALMEDICINE, V24, DOI 10.1016/j.eclinm.2020.100434; Robba C, 2020, EXPERT REV RESP MED, V14, P865, DOI 10.1080/17476348.2020.1778470; Roberts CM, 2020, BRIT J ANAESTH, V125, P238, DOI 10.1016/j.bja.2020.06.013; Salama C, 2021, NEW ENGL J MED, V384, P20, DOI 10.1056/NEJMoa2030340; Schirmer M, 2016, CELL, V167, P1125, DOI 10.1016/j.cell.2016.10.020; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Shabalin AA, 2012, BIOINFORMATICS, V28, P1353, DOI 10.1093/bioinformatics/bts163; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Sun JT, 2020, FRONT CARDIOVASC MED, V7, DOI 10.3389/fcvm.2020.584987; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; ter Horst R, 2016, CELL, V167, P1111, DOI 10.1016/j.cell.2016.10.018; Tian WM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19706-9; Tunjungputri RN, 2018, THROMB HAEMOSTASIS, V118, P2112, DOI 10.1055/s-0038-1675603; Valeri M, 2016, PATHOG DIS, V74, DOI 10.1093/femspd/ftw111; van der Made CI, 2020, JAMA-J AM MED ASSOC, V324, P663, DOI 10.1001/jama.2020.13719; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Watanabe K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01261-5; Wei LL, 2020, J MED VIROL, V92, P2768, DOI 10.1002/jmv.26181; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Wu YQ, 2020, CLIN CHIM ACTA, V509, P220, DOI 10.1016/j.cca.2020.06.026; Xie LX, 2021, VIRAL IMMUNOL, V34, P416, DOI 10.1089/vim.2020.0320; Yao Y, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00519-1; Zeberg H, 2020, NATURE, V587, P610, DOI 10.1038/s41586-020-2818-3; Zhang Q, 2022, NATURE, V603, P587, DOI [10.1038/s41586-022-04447-0, 10.1159/000524200]; Zhang XN, 2020, NATURE, V583, P437, DOI [10.1038/s41586-020-2355-0, 10.1007/s00521-020-05117-w]; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhou SR, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01281-1	67	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								859387	10.3389/fimmu.2022.859387	http://dx.doi.org/10.3389/fimmu.2022.859387			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T7RM	35634344	Green Published, gold			2022-12-18	WOS:000804925300001
J	Mishra, A; Singh, VK; Jagannath, C; Subbian, S; Restrepo, BI; Gauduin, MC; Khan, A				Mishra, Abhishek; Singh, Vipul K.; Jagannath, Chinnaswamy; Subbian, Selvakumar; Restrepo, Blanca I.; Gauduin, Marie-Claire; Khan, Arshad			Human Macrophages Exhibit GM-CSF Dependent Restriction of Mycobacterium tuberculosis Infection via Regulating Their Self-Survival, Differentiation and Metabolism	FRONTIERS IN IMMUNOLOGY			English	Article						macrophages; Mycobacterium tuberculosis; tuberculosis; granulocyte macrophage colony-stimulating factor; cell death; antigen presentation; autophagy; cellular metabolism	COLONY-STIMULATING FACTOR; INNATE IMMUNITY; CELL; DIVERSITY; CYTOKINES; RESPONSES; FEATURES	GM-CSF is an important cytokine that regulates the proliferation of monocytes/macrophages and its various functions during health and disease. Although growing evidences support the notion that GM-CSF could play a major role in immunity against tuberculosis (TB) infection, the mechanism of GM-CSF mediated protective effect against TB remains largely unknown. Here in this study we examined the secreted levels of GM-CSF by human macrophages from different donors along with the GM-CSF dependent cellular processes that are critical for control of M. tuberculosis infection. While macrophage of different donors varied in their ability to produce GM-CSF, a significant correlation was observed between secreted levels of GM-CSF, survial of macrophages and intra-macrophage control of Mycobacterium tuberculosis bacilli. GM-CSF levels secreted by macrophages negatively correlated with the intra-macrophage M. tuberculosis burden, survival of infected host macrophages positively correlated with their GM-CSF levels. GM-CSF-dependent prolonged survival of human macrophages also correlated with significantly decreased bacterial burden and increased expression of self-renewal/cell-survival associated genes such as BCL-2 and HSP27. Antibody-mediated depletion of GM-CSF in macrophages resulted in induction of significantly elevated levels of apoptotic/necrotic cell death and a simultaneous decrease in autophagic flux. Additionally, protective macrophages against M. tuberculosis that produced more GM-CSF, induced a stronger granulomatous response and produced significantly increased levels of IL-1 beta, IL-12 and IL-10 and decreased levels of TNF-alpha and IL-6. In parallel, macrophages isolated from the peripheral blood of active TB patients exhibited reduced capacity to control the intracellular growth of M. tuberculosis and produced significantly lower levels of GM-CSF. Remarkably, as compared to healthy controls, macrophages of active TB patients exhibited significantly altered metabolic state correlating with their GM-CSF secretion levels. Altogether, these results suggest that relative levels of GM-CSF produced by human macrophages plays a critical role in preventing cell death and maintaining a protective differentiation and metabolic state of the host cell against M. tuberculosis infection.	[Mishra, Abhishek; Singh, Vipul K.; Jagannath, Chinnaswamy; Khan, Arshad] Houston Methodist Res Inst, Dept Pathol & Genom Med, Houston, TX USA; [Subbian, Selvakumar] Publ Hlth Res Inst, New Jersey Med Sch, Dept Med, Newark, NJ USA; [Restrepo, Blanca I.] Univ Texas Sch Publ Hlth, Brownsville, TX USA; [Gauduin, Marie-Claire] Texas Biomed Res Inst, Dis Intervent & Prevent, San Antonio, TX USA	The Methodist Hospital System; The Methodist Hospital - Houston; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Texas Biomedical Research Institute	Khan, A (corresponding author), Houston Methodist Res Inst, Dept Pathol & Genom Med, Houston, TX USA.		Mishra, Abhishek/I-5362-2019	Mishra, Abhishek/0000-0003-2077-0937				Barr DA, 2020, LANCET INFECT DIS, V20, P742, DOI 10.1016/S1473-3099(19)30695-4; Benmerzoug S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26984-3; Bergeron A, 1997, J IMMUNOL, V159, P3034; Berrington WR, 2007, IMMUNOL REV, V219, P167, DOI 10.1111/j.1600-065X.2007.00545.x; Bhatt K, 2015, CLIN VACCINE IMMUNOL, V22, P258, DOI 10.1128/CVI.00721-14; Bryson BD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10065-8; Cadena AM, 2016, MBIO, V7, DOI 10.1128/mBio.00342-16; Cho JE, 2013, BMB REP, V46, P213, DOI 10.5483/BMBRep.2013.46.4.200; CROWLE AJ, 1990, INFECT IMMUN, V58, P632, DOI 10.1128/IAI.58.3.632-638.1990; DENIS M, 1990, IMMUNOL LETT, V24, P203, DOI 10.1016/0165-2478(90)90049-V; Deretic V, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a018481; Gallegos AM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002052; Glaziou P, 2015, CSH PERSPECT MED, V5, DOI [10.1101/cshperspect.a017798, 10.1055/s-0038-1651492]; Gonzalez-Juarrero M, 2005, J LEUKOCYTE BIOL, V77, P914, DOI 10.1189/jlb.1204723; Guirado E, 2015, MBIO, V6, DOI 10.1128/mBio.02537-14; Harding CV, 2010, NAT REV MICROBIOL, V8, P296, DOI 10.1038/nrmicro2321; Khan A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100372; Khan A, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0122-8; Khan A, 2019, J LEUKOCYTE BIOL, V106, P275, DOI 10.1002/JLB.MR0318-095RR; Kratz M, 2014, CELL METAB, V20, P614, DOI 10.1016/j.cmet.2014.08.010; Kumar R, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00105; LAN HY, 1995, AM J PATHOL, V147, P1214; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Liu CH, 2017, CELL MOL IMMUNOL, V14, P963, DOI 10.1038/cmi.2017.88; Liu Jianguo, 2005, Curr Immunol Rev, V1, P119, DOI 10.2174/1573395054065115; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Marakalala MJ, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01028; Mendez-Samperio P, 2010, INT J INFECT DIS, V14, pE366, DOI 10.1016/j.ijid.2009.06.022; Mishra A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01599; Mootoo Amanda, 2009, Inflammation & Allergy Drug Targets, V8, P53; Pieters J, 2008, CELL HOST MICROBE, V3, P399, DOI 10.1016/j.chom.2008.05.006; Rothchild AC, 2017, MBIO, V8, DOI [10.1128/mBio.01514-17, 10.1128/mbio.01514-17]; Sakai S, 2014, CURR OPIN IMMUNOL, V29, P137, DOI 10.1016/j.coi.2014.06.003; Shibata Y, 2001, IMMUNITY, V15, P557, DOI 10.1016/S1074-7613(01)00218-7; Sia JK, 2019, MICROBIOL SPECTR, V7, DOI 10.1128/microbiolspec.GPP3-0022-2018; Srivastava S, 2014, IMMUNOL REV, V262, P179, DOI 10.1111/imr.12217; Szeliga J, 2008, TUBERCULOSIS, V88, P7, DOI 10.1016/j.tube.2007.08.009; Thomas BE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147397; Torres M, 2006, INFECT IMMUN, V74, P1621, DOI 10.1128/IAI.74.3.1621-1630.2006; Ushach I, 2016, J LEUKOCYTE BIOL, V100, P481, DOI 10.1189/jlb.3RU0316-144R; van Crevel R, 2002, CLIN MICROBIOL REV, V15, P294, DOI 10.1128/CMR.15.2.294-309.2002; Wilson JL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02265; Wynn AA, 2001, AM J PATHOL, V158, P131, DOI 10.1016/S0002-9440(10)63951-X; Yonekawa T, 2013, ESSAYS BIOCHEM, V55, P105, DOI [10.1042/BSE0550105, 10.1042/bse0550105]; Zeng GC, 2018, CELL MOL IMMUNOL, V15, P206, DOI 10.1038/cmi.2017.113	45	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								859116	10.3389/fimmu.2022.859116	http://dx.doi.org/10.3389/fimmu.2022.859116			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M9TA	35634283	Green Published, gold			2022-12-18	WOS:000800306100001
J	Quintana, FJ; Pozo, D				Quintana, Francisco J.; Pozo, David			Editorial: Nanoparticle-Mediated Signaling Rewiring and Reprogramming of Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						cell signalling; autoimmunity; inflammation; reprogramming; personalized medicine; immunotherapy; nanoparticles; immunoregulation			[Quintana, Francisco J.] Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA; [Quintana, Francisco J.] Broad Inst Massachusetts Inst Technol MIT & Harvar, Cambridge, MA 02142 USA; [Pozo, David] Univ Seville, Dept Med Biochem Mol Biol & Immunol, Sch Med, Seville, Spain; [Pozo, David] Univ Seville, Seville Univ Pablo de Olavide UPO, Andalusian Ctr Mol Biol & Regenerat Med, Consejo Super Invest Cient CSIC, Seville, Spain	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER)	Quintana, FJ (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Ann Romney Ctr Neurol Dis, Boston, MA 02115 USA.; Quintana, FJ (corresponding author), Broad Inst Massachusetts Inst Technol MIT & Harvar, Cambridge, MA 02142 USA.; Pozo, D (corresponding author), Univ Seville, Dept Med Biochem Mol Biol & Immunol, Sch Med, Seville, Spain.; Pozo, D (corresponding author), Univ Seville, Seville Univ Pablo de Olavide UPO, Andalusian Ctr Mol Biol & Regenerat Med, Consejo Super Invest Cient CSIC, Seville, Spain.	fquintana@bwh.harvard.edu; david.pozo@cabimer.es			Regional Ministry of Transformacion Economica, Industria, Conocimiento y Universidades [PAID2020, CTS677]; Spanish Government Ministry of Science and Innovation of Spain [RTI2018-098432-B-I00]; European Regional Development Fund (ERDF); National Institutes of Health; Progressive Multiple Sclerosis Alliance; National Multiple Sclerosis Society	Regional Ministry of Transformacion Economica, Industria, Conocimiento y Universidades; Spanish Government Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)); European Regional Development Fund (ERDF)(European Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Progressive Multiple Sclerosis Alliance; National Multiple Sclerosis Society(National Multiple Sclerosis Society)	DP is supported by the Regional Ministry of Transformacion Economica, Industria, Conocimiento y Universidades, PAID2020, CTS677 to DP) and the Spanish Government Ministry of Science and Innovation of Spain [RTI2018-098432-B-I00, co-funded by the European Regional Development Fund (ERDF), a way to build Europe]. FQ is supported by the National Institutes of Health, the Progressive Multiple Sclerosis Alliance and the National Multiple Sclerosis Society.	Heim CE, 2020, NAT MICROBIOL, V5, P1271, DOI 10.1038/s41564-020-0756-3; Italiani P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.566309; Kenison JE, 2020, P NATL ACAD SCI USA, V117, P32017, DOI 10.1073/pnas.2016451117; Krienke Christina, 2021, Science, V371, P145, DOI 10.1126/science.aay3638; Leal-Lasarte M, 2021, IMMUNOLOGY, V164, P358, DOI 10.1111/imm.13377; Lee HG, 2022, NAT REV DRUG DISCOV, V21, P339, DOI 10.1038/s41573-022-00390-x; Park J, 2019, P NATL ACAD SCI USA, V116, P14947, DOI 10.1073/pnas.1820276116; Serra P, 2019, NAT BIOTECHNOL, V37, P238, DOI 10.1038/s41587-019-0015-4; Shemesh CS, 2021, MOL THER, V29, P555, DOI 10.1016/j.ymthe.2020.09.038; Swartzwelter BJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249695; Wang H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19540-z; Wang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.288; Yeste A, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad0612	13	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								927733	10.3389/fimmu.2022.927733	http://dx.doi.org/10.3389/fimmu.2022.927733			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T0LD	35634330	Green Published, gold			2022-12-18	WOS:000804430600001
J	Wang, CH; Lo, CY; Huang, HY; Wang, TY; Weng, CM; Chen, CJ; Huang, YC; Chung, FT; Lin, CW; Chung, KF; Kuo, HP				Wang, Chun-Hua; Lo, Chun-Yu; Huang, Hung-Yu; Wang, Tsai-Yu; Weng, Chih-Ming; Chen, Chih-Jung; Huang, Yu-Chen; Chung, Fu-Tsai; Lin, Chang-Wei; Chung, Kian Fan; Kuo, Han-Pin			Oxygen Desaturation Is Associated With Fibrocyte Activation via Epidermal Growth Factor Receptor/Hypoxia- Inducible Factor-1a Axis in Chronic Obstructive Pulmonary Disease	FRONTIERS IN IMMUNOLOGY			English	Article						chronic obstructive pulmonary disease (COPD); fibrocyte; epidermal growth factor receptor (EGFR); hypoxia-inducible factor-1 alpha (HIF-1 alpha); desaturation	HYPOXIA-INDUCED PROLIFERATION; CIRCULATING FIBROCYTES; MAMMALIAN TARGET; UP-REGULATION; EXPRESSION; ASTHMA; DIFFERENTIATION; MODULATION; CELLS	Fibrocytes are bloodborne mesenchymal progenitors which accumulate and differentiate at the disease site. We investigated whether hypoxemia activates fibrocytes, accelerating airflow limitation and exercise intolerance in chronic obstructive pulmonary disease (COPD) patients. Flow cytometry was used to determine collagen I+/CD45(+) fibrocytes and a-smooth muscle actin+ differentiating fibrocytes within peripheral blood and cultured cells, as well as the expression of CXC chemokine receptor 4 (CXCR4), epidermal growth factor receptor (EGFR), connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF)-1a. Fibrocytes in lung specimens were identified by confocal microscopy. Compared to non-desaturators, COPD desaturators (peripheral blood oxygen saturation <= 88% during exercise) had greater number of fibrocytes in peripheral blood and lung specimens, paralleled with faster yearly lung function decline and a 6-minute walk distance. Fibrocytes from desaturators expressed more EGFR, CXCR4, CTGF, and HIF-1 alpha, with a higher capacity of proliferation and myofibroblastic differentiation. Hypoxia (5% oxygen) increased the expression of EGFR, CXCR4, CTGF, and HIF-1a, the number and differentiation in fibrocytes. These efects were attenuated by EGFR inhibitor gefitinib, HIF-1a gene silencing, and anti-CTGF antibody. These data elucidate that hypoxemia triggers fibrocyte activation through the EGFR/HIF-1a axis, aggravating airflow obstruction in COPD.	[Wang, Chun-Hua; Lo, Chun-Yu; Huang, Hung-Yu; Wang, Tsai-Yu; Huang, Yu-Chen; Chung, Fu-Tsai; Lin, Chang-Wei] Chang Gung Mem Hosp, Dept Thorac Med, Taipei, Taiwan; [Wang, Chun-Hua; Lo, Chun-Yu; Huang, Hung-Yu; Wang, Tsai-Yu; Huang, Yu-Chen; Chung, Fu-Tsai; Lin, Chang-Wei] ChangGung Univ, Coll Med, Taoyuan, Taiwan; [Weng, Chih-Ming] Taipei Med Univ, Sch Resp Therapy, Taipei, Taiwan; [Chen, Chih-Jung] Taichung Vet Gen Hosp, Dept Pathol, Taichung, Taiwan; [Chen, Chih-Jung] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Chung, Fu-Tsai] New Taipei Municipal TuCheng Hosp, Dept Thorac Med, New Taipei, Taiwan; [Chung, Kian Fan] Natl Heart & Lung Inst, Imperial Coll London, Airway Dis Sect, London, England; [Chung, Kian Fan] Royal Brompton Hosp, Biomed Res Unit, London, England; [Kuo, Han-Pin] Taipei Med Univ Hosp, Dept Thorac Med, Taipei, Taiwan; [Kuo, Han-Pin] Taipei Med Univ, Sch Med, Taipei, Taiwan	Chang Gung Memorial Hospital; Taipei Medical University; Taichung Veterans General Hospital; Chung Shan Medical University; Imperial College London; Royal Brompton Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University	Wang, CH (corresponding author), Chang Gung Mem Hosp, Dept Thorac Med, Taipei, Taiwan.; Wang, CH (corresponding author), ChangGung Univ, Coll Med, Taoyuan, Taiwan.; Kuo, HP (corresponding author), Taipei Med Univ Hosp, Dept Thorac Med, Taipei, Taiwan.; Kuo, HP (corresponding author), Taipei Med Univ, Sch Med, Taipei, Taiwan.	wchunhua@ms7.hinet.net; hpk8828@gmail.com	Huang, Hung-Yu/ABA-5638-2021	Wang, Chun-Hua/0000-0002-3514-9353	National Medical Research Program (NMRP) [99-2314-B-182-043-MY3, 108-2314-B-182A-128-MY2]; Chang Gung Medical Research Project (CMRP) [CMRPG390041-2]	National Medical Research Program (NMRP); Chang Gung Medical Research Project (CMRP)	This work was supported by the National Medical Research Program (NMRP) grant 99-2314-B-182-043-MY3, 108-2314-B-182A-128-MY2 and the Chang Gung Medical Research Project (CMRP) grant CMRPG390041-2.	Andrianopoulos V, 2014, RESP PHYSIOL NEUROBI, V190, P40, DOI 10.1016/j.resp.2013.10.002; Banks MF, 2005, J APPL PHYSIOL, V98, P732, DOI 10.1152/japplphysiol.00821.2004; Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172; BUCALA R, 1994, MOL MED, V1, P71, DOI 10.1007/bf03403533; Cheng Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160593; Doring Y, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00212; Dupin I, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.02173-2018; Dupin I, 2016, J ALLERGY CLIN IMMUN, V137, P1036, DOI 10.1016/j.jaci.2015.08.043; Franovic A, 2007, P NATL ACAD SCI USA, V104, P13092, DOI 10.1073/pnas.0702387104; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Huang HY, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040562; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Kent BD, 2011, INT J CHRONIC OBSTR, V6, P199, DOI 10.2147/COPD.S10611; Kim C, 2013, RESPIRATION, V86, P109, DOI 10.1159/000342891; Kim Victor, 2008, Proc Am Thorac Soc, V5, P513, DOI 10.1513/pats.200708-124ET; Lo CY, 2015, J ALLERGY CLIN IMMUN, V135, P1186, DOI 10.1016/j.jaci.2014.10.031; Nishi H, 2002, CANCER RES, V62, P827; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Rho JK, 2009, ONCOL REP, V21, P801, DOI 10.3892/or_00000287; Roche O, 2016, NUCLEIC ACIDS RES, V44, P9315, DOI 10.1093/nar/gkw811; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019; Toby IT, 2010, AM J PHYSIOL-LUNG C, V298, pL600, DOI 10.1152/ajplung.00122.2009; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Waatevik M, 2016, EUR RESPIR J, V48, P82, DOI 10.1183/13993003.00975-2015; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Wang CH, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.congress-2019.PA1670; Wang CH, 2015, J ALLERGY CLIN IMMUN, V135, P1154, DOI 10.1016/j.jaci.2014.09.011; Wang CH, 2012, J ALLERGY CLIN IMMUN, V129, P1367, DOI 10.1016/j.jaci.2012.01.038; Weng CM, 2013, AM J RESP CRIT CARE, V188, P298, DOI 10.1164/rccm.201301-0132OC; Zhong H, 2000, CANCER RES, V60, P1541	34	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 12	2022	13								852713	10.3389/fimmu.2022.852713	http://dx.doi.org/10.3389/fimmu.2022.852713			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8MI	35634326	Green Published, gold			2022-12-18	WOS:000804979600001
J	Chen, L; Jin, SJ; Yang, M; Gui, CM; Yuan, YP; Dong, GT; Zeng, WZ; Zeng, J; Hu, GX; Qiao, LJ; Wang, JH; Xi, YL; Sun, J; Wang, N; Wang, MM; Xing, LF; Yang, Y; Teng, Y; Hou, JX; Bi, QJ; Cai, HB; Zhang, GS; Hong, YC; Zhang, ZH				Chen, Lin; Jin, Senjun; Yang, Min; Gui, Chunmei; Yuan, Yingpu; Dong, Guangtao; Zeng, Weizhong; Zeng, Jing; Hu, Guoxin; Qiao, Lujun; Wang, Jinhua; Xi, Yonglin; Sun, Jian; Wang, Nan; Wang, Minmin; Xing, Lifeng; Yang, Yi; Teng, Yan; Hou, Junxia; Bi, Qiaojie; Cai, Huabo; Zhang, Gensheng; Hong, Yucai; Zhang, Zhongheng			Integrated Single Cell and Bulk RNA-Seq Analysis Revealed Immunomodulatory Effects of Ulinastatin in Sepsis: A Multicenter Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; single cell; ulinastatin; RNA-seq; immunosuppression	EXPRESSION; RECONSTRUCTION; READS	Sepsis is a leading cause of morbidity and mortality in the intensive care unit, which is caused by unregulated inflammatory response leading to organ injuries. Ulinastatin (UTI), an immunomodulatory agent, is widely used in clinical practice and is associated with improved outcomes in sepsis. But its underlying mechanisms are largely unknown. Our study integrated bulk and single cell RNA-seq data to systematically explore the potential mechanisms of the effects of UTI in sepsis. After adjusting for potential confounders in the negative binomial regression model, there were more genes being downregulated than being upregulated in the UTI group. These down-regulated genes were enriched in the neutrophil involved immunity such as neutrophil activation and degranulation, indicating the immunomodulatory effects of UTI is mediated via regulation of neutrophil activity. By deconvoluting the bulk RNA-seq samples to obtain fractions of cell types, the Myeloid-derived suppressor cells (MDSC) were significantly expanded in the UTI treated samples. Further cell-cell communication analysis revealed some signaling pathways such as ANEEXIN, GRN and RESISTIN that might be involved in the immunomodulatory effects of UTI. The study provides a comprehensive reference map of transcriptional states of sepsis treated with UTI, as well as a general framework for studying UTI-related mechanisms.	[Chen, Lin] Zhejiang Univ, Affiliated Jinhua Hosp, Dept Crit Care Med, Sch Med, Jinhua, Peoples R China; [Jin, Senjun] Zhejiang Prov Peoples Hosp, Peoples Hosp, Dept Emergency, Hangzhou Med Coll, Hangzhou, Peoples R China; [Yang, Min] Anhui Med Univ, Dept Intens Care Unit 2, Affiliated Hosp 2, Hefei, Peoples R China; [Gui, Chunmei; Yuan, Yingpu] First Peoples Hosp Changde City, Dept Crit Care Med, Changde, Peoples R China; [Dong, Guangtao] Harbin Med Univ, Dept Emergency Med, Affiliated Hosp 1, Harbin, Peoples R China; [Zeng, Weizhong; Zeng, Jing] Zhuzhou Cent Hosp, Dept Crit Care Med, Zhuzhou, Peoples R China; [Hu, Guoxin; Qiao, Lujun] Shengli Oilfield Cent Hosp, Emergency Dept, Dongying, Peoples R China; [Wang, Jinhua; Xi, Yonglin] Xian Med Univ, Dept Crit Care Med, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China; [Sun, Jian] Lishui Ctr Hosp, Dept Crit Care Med, Lishui, Peoples R China; [Wang, Nan; Wang, Minmin] Anhui Med Univ, Anhui Med Univ, Dept Crit Care Med, Affiliated Hosp 4, Hefei, Peoples R China; [Xing, Lifeng; Cai, Huabo] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Emergency Med, Sch Med, Hangzhou, Peoples R China; [Yang, Yi] Second Hosp Jiaxing, Dept Emergency Med, Jiaxing, Peoples R China; [Teng, Yan; Hou, Junxia] Xi An Jiao Tong Univ, Dept Crit Care Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China; [Bi, Qiaojie] Qing Dao Univ, Qingdao Municipal Hosp, Dept Emergency, Sch Med, Qingdao, Peoples R China; [Zhang, Gensheng] Zhejiang Univ Sch Med, Affiliated Hosp 2, Dept Crit Care Med, Hangzhou, Peoples R China; [Hong, Yucai; Zhang, Zhongheng] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Emergency Med, Key Lab Precis Med Diag & Monitoring Res Zhejiang, Hangzhou, Peoples R China	Zhejiang University; Hangzhou Medical College; Zhejiang Provincial People's Hospital; Anhui Medical University; Harbin Medical University; Xi'an Medical University; Anhui Medical University; Zhejiang University; Xi'an Jiaotong University; Qingdao Municipal Hospital; Qingdao University; Zhejiang University	Zhang, GS (corresponding author), Zhejiang Univ Sch Med, Affiliated Hosp 2, Dept Crit Care Med, Hangzhou, Peoples R China.; Hong, YC; Zhang, ZH (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Emergency Med, Key Lab Precis Med Diag & Monitoring Res Zhejiang, Hangzhou, Peoples R China.	genshengzhang@zju.edu.cn; 3416234@zju.edu.cn; zh_zhang1984@zju.edu.cn	Wang, Jin/GYA-2019-2022; Zhang, Zhongheng/E-1282-2011; zhang, zh/GWV-4677-2022	Zhang, Zhongheng/0000-0002-2336-5323; 	Health Science and Technology Plan of Zhejiang Province [2021KY745]; National Natural Science Foundation of China [81901929]; Key Research & Development project of Zhejiang Province [2021C03071]; Zhejiang Provincial Project of Medical and Health Technology [2022PY099]; Youth Foundation of Jinhua Municipal Central Hospital [JY2020-2-10]; Key Project of Jinhua City [2021-3-037]; Key Laboratory of Emergency and Trauma (Hainan Medical University), Ministry of Education [KLET-202118]; Techpool Bio-Pharma Co., Ltd.	Health Science and Technology Plan of Zhejiang Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research & Development project of Zhejiang Province; Zhejiang Provincial Project of Medical and Health Technology; Youth Foundation of Jinhua Municipal Central Hospital; Key Project of Jinhua City; Key Laboratory of Emergency and Trauma (Hainan Medical University), Ministry of Education; Techpool Bio-Pharma Co., Ltd.	The study was supported by Health Science and Technology Plan of Zhejiang Province (2021KY745), National Natural Science Foundation of China (81901929) and Key Research & Development project of Zhejiang Province (2021C03071). LC received funding from Zhejiang Provincial Project of Medical and Health Technology (2022PY099), Youth Foundation of Jinhua Municipal Central Hospital (JY2020-2-10) and Key Project of Jinhua City (2021-3-037) and Key Laboratory of Emergency and Trauma (Hainan Medical University), Ministry of Education (Grant No. KLET-202118). Ulinastatin was provided by the Techpool Bio-Pharma Co., Ltd.	Aarts CEM, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12989; Agrati C, 2020, CELL DEATH DIFFER, V27, P3196, DOI 10.1038/s41418-020-0572-6; Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; Bauer M, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02950-2; Bonaventura A, 2020, EUR J CLIN INVEST, V50, DOI 10.1111/eci.13333; Brandes F, 2021, INTENS CARE MED EXP, V9, DOI 10.1186/s40635-021-00406-7; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cohen J, 2021, INTENS CARE MED, V47, P974, DOI 10.1007/s00134-021-06464-5; Diao N, 2016, SCI REP-UK, V6, DOI 10.1038/srep34672; Evans L, 2021, CRIT CARE MED, V49, pE1063, DOI 10.1097/CCM.0000000000005337; Fang MY, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10091333; Flores R, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00566; Huang H, 2022, EXP THER MED, V23, DOI 10.3892/etm.2021.11044; Huang Shun-wei, 2006, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V18, P653; Jang JC, 2017, P NATL ACAD SCI USA, V114, pE10399, DOI 10.1073/pnas.1716015114; Janols H, 2014, J LEUKOCYTE BIOL, V96, P685, DOI 10.1189/jlb.5HI0214-074R; Jiang JY, 2021, J RECEPT SIG TRANSD, V41, P457, DOI 10.1080/10799893.2020.1825490; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Kechin A, 2017, J COMPUT BIOL, V24, P1138, DOI 10.1089/cmb.2017.0096; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kumar S, 2021, CLIN CHIM ACTA, V523, P152, DOI 10.1016/j.cca.2021.09.012; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liu DD, 2017, J CRIT CARE, V39, P259, DOI 10.1016/j.jcrc.2016.12.013; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Marais C, 2021, ANN INTENSIVE CARE, V11, DOI 10.1186/s13613-021-00896-4; Meng C, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000023361; Meng WT, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00273; Mui L, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.735472; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Pan WY, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105835; Patil I., 2021, J OPEN SOURCE SOFTW, V6, P3167, DOI 10.21105/joss.03167; Pertea Geo, 2020, F1000Res, V9, P304, DOI 10.12688/f1000research.23297.1; Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122; Ru YB, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku631; Saiga H, 2022, INT IMMUNOL, V34, P159, DOI 10.1093/intimm/dxab103; Satija R, 2015, NAT BIOTECHNOL, V33, P495, DOI 10.1038/nbt.3192; Seymour CW, 2019, JAMA-J AM MED ASSOC, V321, P2003, DOI 10.1001/jama.2019.5791; Sim H, 2021, IMMUNE NETW, V21, DOI 10.4110/in.2021.21.e13; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Stark R, 2019, NAT REV GENET, V20, P631, DOI 10.1038/s41576-019-0150-2; Steen CB, 2020, METHODS MOL BIOL, V2117, P135, DOI 10.1007/978-1-0716-0301-7_7; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Terryn J, 2021, FRONT MOL NEUROSCI, V14, DOI 10.3389/fnmol.2021.713031; Tian G, 2020, INT IMMUNOPHARMACOL, V79, DOI 10.1016/j.intimp.2019.106090; Toufiq M, 2020, IMMUNOLOGY, V161, P291, DOI 10.1111/imm.13239; Trikha P, 2014, BBA-REV CANCER, V1846, P55, DOI 10.1016/j.bbcan.2014.04.003; Wang JY, 2020, J INFLAMM RES, V13, P109, DOI 10.2147/JIR.S234122; Wang QL, 2021, MOL IMMUNOL, V138, P99, DOI 10.1016/j.molimm.2021.07.022; Wu TZ, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141; Wu YM, 2021, FASEB J, V35, DOI 10.1096/fj.202100981RR; Zhang JX, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.108264; Zhang ZH, 2020, EBIOMEDICINE, V62, DOI 10.1016/j.ebiom.2020.103081; Zhang ZH, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2279-3	54	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								882774	10.3389/fimmu.2022.882774	http://dx.doi.org/10.3389/fimmu.2022.882774			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N2JR	35634310	Green Published, gold			2022-12-18	WOS:000800488000001
J	Ismail, IH; Kanegane, H; Zhao, XD				Ismail, Intan Hakimah; Kanegane, Hirokazu; Zhao, Xiaodong			Editorial: Creating Awareness for Primary Immunodeficiencies in the Southeast and East Asia Regions	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						primary immunodeificiency; southeast asia; East Asia; immunology; Nationwide survey; Clinical Immunology			[Ismail, Intan Hakimah] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Paediat, Serdang, Malaysia; [Kanegane, Hirokazu] Tokyo Med & Dent Univ TMDU, Dept Child Hlth & Dev, Tokyo, Japan; [Zhao, Xiaodong] Chongqing Med Univ, Dept Rheumatol & Immunol, Chongqing, Peoples R China	Universiti Putra Malaysia; Tokyo Medical & Dental University (TMDU); Chongqing Medical University	Kanegane, H (corresponding author), Tokyo Med & Dent Univ TMDU, Dept Child Hlth & Dev, Tokyo, Japan.	hkanegane.ped@tmd.ac.jp							0	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								920819	10.3389/fimmu.2022.920819	http://dx.doi.org/10.3389/fimmu.2022.920819			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8JP	35634327	Green Published, gold			2022-12-18	WOS:000804972500001
J	Lill, JR; Bassani-Sternberg, M				Lill, Jennie R.; Bassani-Sternberg, Michal			Editorial: Immunopeptidomic Approaches for the Identification of Tumor (neo)Antigens	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						immunopeptidome; mass spectrometry; proteomics; cancer immunology; major histocompability complex			[Lill, Jennie R.] Genentech Inc, Dept Microchem Prote Lipid & Next Generat Sequenci, South San Francisco, CA 94080 USA; [Bassani-Sternberg, Michal] Agora Res Ctr, Ludwig Inst Canc Res, Lausanne, Switzerland	Roche Holding; Genentech; Ludwig Institute for Cancer Research	Lill, JR (corresponding author), Genentech Inc, Dept Microchem Prote Lipid & Next Generat Sequenci, South San Francisco, CA 94080 USA.; Bassani-Sternberg, M (corresponding author), Agora Res Ctr, Ludwig Inst Canc Res, Lausanne, Switzerland.	jlill@gene.com; Michal.Bassani@chuv.ch						CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; Ehx G, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0642-x; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JOYCE S, 1994, CURR OPIN IMMUNOL, V6, P24, DOI 10.1016/0952-7915(94)90029-9; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001	5	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								923776	10.3389/fimmu.2022.923776	http://dx.doi.org/10.3389/fimmu.2022.923776			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1R9SU	35634286	Green Published, gold			2022-12-18	WOS:000803702400001
J	Morris, NL; Michael, DN; Crotty, KM; Chang, SS; Yeligar, SM				Morris, Niya L.; Michael, David N.; Crotty, Kathryn M.; Chang, Sarah S.; Yeligar, Samantha M.			Alcohol-Induced Glycolytic Shift in Alveolar Macrophages Is Mediated by Hypoxia-Inducible Factor-1 Alpha	FRONTIERS IN IMMUNOLOGY			English	Article						ethanol; hypoxia-inducible factor-1 alpha; alveolar macrophage; energy metabolism; glycolysis	ACUTE LUNG INJURY; OXIDATIVE STRESS; NADPH OXIDASE; ETHANOL; HIF-1-ALPHA; INFLAMMATION; DYSFUNCTION; APOPTOSIS; SEPSIS	Excessive alcohol use increases the risk of developing respiratory infections partially due to impaired alveolar macrophage (AM) phagocytic capacity. Previously, we showed that chronic ethanol (EtOH) exposure led to mitochondrial derangements and diminished oxidative phosphorylation in AM. Since oxidative phosphorylation is needed to meet the energy demands of phagocytosis, EtOH mediated decreases in oxidative phosphorylation likely contribute to impaired AM phagocytosis. Treatment with the peroxisome proliferator-activated receptor gamma (PPAR gamma) ligand, pioglitazone (PIO), improved EtOH-mediated decreases in oxidative phosphorylation. In other models, hypoxia-inducible factor-1 alpha (HIF-1 alpha) has been shown to mediate the switch from oxidative phosphorylation to glycolysis; however, the role of HIF-1 alpha in chronic EtOH mediated derangements in AM has not been explored. We hypothesize that AM undergo a metabolic shift from oxidative phosphorylation to a glycolytic phenotype in response to chronic EtOH exposure. Further, we speculate that HIF-1 alpha is a critical mediator of this metabolic switch. To test these hypotheses, primary mouse AM (mAM) were isolated from a mouse model of chronic EtOH consumption and a mouse AM cell line (MH-S) were exposed to EtOH in vitro. Expression of HIF-1 alpha, glucose transporters (Glut1 and 4), and components of the glycolytic pathway (Pfkfb3 and PKM2), were measured by qRT-PCR and western blot. Lactate levels (lactate assay), cell energy phenotype (extracellular flux analyzer), glycolysis stress tests (extracellular flux analyzer), and phagocytic function (fluorescent microscopy) were conducted. EtOH exposure increased expression of HIF-1 alpha, Glut1, Glut4, Pfkfb3, and PKM2 and shifted AM to a glycolytic phenotype. Pharmacological stabilization of HIF-1 alpha via cobalt chloride treatment in vitro mimicked EtOH-induced AM derangements (increased glycolysis and diminished phagocytic capacity). Further, PIO treatment diminished HIF-1 alpha levels and reversed glycolytic shift following EtOH exposure. These studies support a critical role for HIF-1 alpha in mediating the glycolytic shift in energy metabolism of AM during excessive alcohol use.	[Morris, Niya L.; Michael, David N.; Crotty, Kathryn M.; Chang, Sarah S.; Yeligar, Samantha M.] Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep, Atlanta, GA 30322 USA; [Morris, Niya L.; Michael, David N.; Crotty, Kathryn M.; Chang, Sarah S.; Yeligar, Samantha M.] Atlanta Vet Affairs Hlth Care Syst, Decatur, GA 30033 USA	Emory University	Yeligar, SM (corresponding author), Emory Univ, Dept Med, Div Pulm Allergy Crit Care & Sleep, Atlanta, GA 30322 USA.; Yeligar, SM (corresponding author), Atlanta Vet Affairs Hlth Care Syst, Decatur, GA 30033 USA.	syeliga@emory.edu			National Institute on Alcohol Abuse and Alcoholism [R01AA026086, 0000-0001-9309-0233]; National Heart, Lung, and Blood Institute [T32HL116271]	National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported in part by grants from the National Institute on Alcohol Abuse and Alcoholism (R01AA026086) to SMY (ORCID ID: 0000-0001-9309-0233) and the National Heart, Lung, and Blood Institute (T32HL116271) to David M. Guidot, Lou Ann S. Brown, and C. Michael Hart. The contents of this report do not represent the views of the Department of Veterans Affairs or the US Government.	Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; [Anonymous], NATL I ALCOHOL ABUSE; BLOMSTRAND R, 1973, LIFE SCI, V13, P1131, DOI 10.1016/0024-3205(73)90380-9; Blum JI, 2016, AM J MED SCI, V352, P71, DOI 10.1016/j.amjms.2016.03.019; Brown LAS, 2004, ALCOHOL, V33, P191, DOI 10.1016/j.alcohol.2004.08.002; Cho SJ, 2017, AM J RESP CELL MOL, V56, P521, DOI 10.1165/rcmb.2016-0225OC; Correnti JM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31025-0; Del Rey MJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03921-4; Fischer M, 2003, J BIOL CHEM, V278, P27997, DOI 10.1074/jbc.M302140200; Gong YQ, 2017, BIOCHEM BIOPH RES CO, V491, P522, DOI 10.1016/j.bbrc.2017.05.173; He Z, 2015, BRIT J NUTR, V113, P1355, DOI 10.1017/S000711451500077X; Herold S, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00065; Hu K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00426; Kang H, 2021, LAB INVEST, V101, P1225, DOI 10.1038/s41374-021-00599-1; Katada R, 2012, AM J PATHOL, V180, P17, DOI 10.1016/j.ajpath.2011.09.011; Lee KS, 2006, J ALLERGY CLIN IMMUN, V118, P120, DOI 10.1016/j.jaci.2006.03.021; Liu Wei, 2012, Int J Biochem Mol Biol, V3, P165; Mehta AJ, 2013, AM J RESP CRIT CARE, V188, P716, DOI 10.1164/rccm.201301-0061OC; Mehta AJ, 2012, AM J MED SCI, V343, P244, DOI 10.1097/MAJ.0b013e31823ede77; Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029; Morris NL, 2021, ALCOHOL, V90, P27, DOI 10.1016/j.alcohol.2020.11.004; Moss M, 2005, CLIN INFECT DIS, V41, pS490, DOI 10.1086/432003; Nag S, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13531; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8; Sutliff Roy L, 2010, Ther Adv Respir Dis, V4, P143, DOI 10.1177/1753465809369619; Varacallo M, 2018, BIOCH GLYCOLYSIS; Wagner MC, 2012, ALCOHOL CLIN EXP RES, V36, P197, DOI 10.1111/j.1530-0277.2011.01599.x; Wang T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/9029327; Woods PS, 2020, AM J RESP CELL MOL, V62, P243, DOI 10.1165/rcmb.2019-0244OC; Wu G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01667; Yeligar SM, 2021, J IMMUNOL, V207, P483, DOI 10.4049/jimmunol.2000565; Yeligar SM, 2018, AM J RESP CELL MOL, V58, P648, DOI 10.1165/rcmb.2016-0293OC; Yeligar SM, 2016, AM J RESP CELL MOL, V55, P35, DOI 10.1165/rcmb.2015-0077OC; Yeligar SM, 2014, AM J PHYSIOL-LUNG C, V306, pL429, DOI 10.1152/ajplung.00159.2013; Yeligar SM, 2012, J IMMUNOL, V188, P3648, DOI 10.4049/jimmunol.1101278; Yeligar SM, 2010, J BIOL CHEM, V285, P35359, DOI 10.1074/jbc.M110.138636; Yuan Y, 2003, J BIOL CHEM, V278, P15911, DOI 10.1074/jbc.M300463200; Yun JW, 2014, FREE RADICAL BIO MED, V77, P183, DOI 10.1016/j.freeradbiomed.2014.08.030	39	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								865492	10.3389/fimmu.2022.865492	http://dx.doi.org/10.3389/fimmu.2022.865492			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N2HY	35634337	Green Published, gold			2022-12-18	WOS:000800483400001
J	Patel, SR; Lundgren, TS; Baldwin, WH; Cox, C; Parker, ET; Healey, JF; Jajosky, RP; Zerra, PE; Josephson, CD; Doering, CB; Stowell, SR; Meeks, SL				Patel, Seema R.; Lundgren, Taran S.; Baldwin, Wallace Hunter; Cox, Courtney; Parker, Ernest T.; Healey, John F.; Jajosky, Ryan P.; Zerra, Patricia E.; Josephson, Cassandra D.; Doering, Christopher B.; Stowell, Sean R.; Meeks, Shannon L.			Neutralizing Antibodies Against Factor VIII Can Occur Through a Non-Germinal Center Pathway	FRONTIERS IN IMMUNOLOGY			English	Article						hemophilia A; germinal center; B cells; neutralizing antibodies (inhibitors); extrafollicular pathway	MEMORY B-CELLS; SEVERE HEMOPHILIA-A; SHORT-LIVED PLASMABLASTS; INHIBITOR DEVELOPMENT; IMMUNE-RESPONSE; MOUSE STRAINS; HIGH-AFFINITY; CLASS-II; GENE; FVIII	Humoral immunity to factor VIII (FVIII) represents a significant challenge for the treatment of patients with hemophilia A. Current paradigms indicate that neutralizing antibodies against FVIII (inhibitors) occur through a classical CD4 T cell, germinal center (GC) dependent process. However, clinical observations suggest that the nature of the immune response to FVIII may differ between patients. While some patients produce persistent low or high inhibitor titers, others generate a transient response. Moreover, FVIII reactive memory B cells are only detectable in some patients with sustained inhibitor titers. The determinants regulating the type of immune response a patient develops, let alone how the immune response differs in these patients remains incompletely understood. One hypothesis is that polymorphisms within immunoregulatory genes alter the underlying immune response to FVIII, and thereby the inhibitor response. Consistent with this, studies report that inhibitor titers to FVIII differ in animals with the same F8 pathogenic variant but completely distinct backgrounds; though, how these genetic disparities affect the immune response to FVIII remains to be investigated. Given this, we sought to mechanistically dissect how genetics impact the underlying immune response to FVIII. In particular, as the risk of producing inhibitors is weakly associated with differences in HLA, we hypothesized that genetic factors other than HLA influence the immune response to FVIII and downstream inhibitor formation. Our data demonstrate that FVIII deficient mice encoding the same MHC and F8 variant produce disparate inhibitor titers, and that the type of inhibitor response formed associates with the ability to generate GCs. Interestingly, the formation of antibodies through a GC or non-GC pathway does not appear to be due to differences in CD4 T cell immunity, as the CD4 T cell response to an immunodominant epitope in FVIII was similar in these mice. These results indicate that genetics can impact the process by which inhibitors develop and may in part explain the apparent propensity of patients to form distinct inhibitor responses. Moreover, these data highlight an underappreciated immunological pathway of humoral immunity to FVIII and lay the groundwork for identification of biomarkers for the development of approaches to tolerize against FVIII.	[Patel, Seema R.; Lundgren, Taran S.; Baldwin, Wallace Hunter; Cox, Courtney; Parker, Ernest T.; Healey, John F.; Zerra, Patricia E.; Josephson, Cassandra D.; Doering, Christopher B.; Meeks, Shannon L.] Emory Univ, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, Sch Med, Atlanta, GA 30322 USA; [Lundgren, Taran S.] Emory Univ, Laney Grad Sch, Grad Program Mol & Syst Pharmacol, Sch Med, Atlanta, GA USA; [Jajosky, Ryan P.; Stowell, Sean R.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA; [Zerra, Patricia E.] Emory Univ, Ctr Transfus Med & Cellular Therapies, Dept Lab Med & Pathol, Sch Med, Atlanta, GA USA	Children's Healthcare of Atlanta (CHOA); Emory University; Emory University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Emory University	Meeks, SL (corresponding author), Emory Univ, Aflac Canc & Blood Disorders Ctr, Childrens Healthcare Atlanta, Sch Med, Atlanta, GA 30322 USA.	smeeks@emory.edu			Pediatrics/Winship Flow Cytometry Core of Winship Cancer Institute of Emory University; Children's Healthcare of Atlanta; NIH/NCI [P30CA138292]; Hemophilia of Georgia; Judith Graham Pool Postdoctoral Award;  [HL141335];  [HL141981]	Pediatrics/Winship Flow Cytometry Core of Winship Cancer Institute of Emory University; Children's Healthcare of Atlanta; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Hemophilia of Georgia; Judith Graham Pool Postdoctoral Award; ; 	Research reported in this study was supported in part by the Pediatrics/Winship Flow Cytometry Core of Winship Cancer Institute of Emory University, Children's Healthcare of Atlanta and NIH/NCI under the award P30CA138292. This study was supported by funding from the R01 (HL141335) and U54 (HL141981), as well as Hemophilia of Georgia awarded to SLM and the Judith Graham Pool Postdoctoral Award to SP.	Abbott RK, 2018, IMMUNITY, V48, P133, DOI 10.1016/j.immuni.2017.11.023; Antun A, 2015, J THROMB HAEMOST, V13, P1980, DOI 10.1111/jth.13143; Astermark J, 2007, J THROMB HAEMOST, V5, P263, DOI 10.1111/j.1538-7836.2007.02290.x; Astermark J, 2006, BLOOD, V107, P3167, DOI 10.1182/blood-2005-09-3918; Astermark J, 2006, BLOOD, V108, P3739, DOI 10.1182/blood-2006-05-024711; Astermark J, 2005, HAEMATOLOGICA, V90, P924; Astermark J, 2013, BLOOD, V121, P1446, DOI 10.1182/blood-2012-06-434803; Barrow RT, 2006, J THROMB HAEMOST, V4, P2223, DOI 10.1111/j.1538-7836.2006.02135.x; Batsuli G, 2016, BLOOD, V128, P2055, DOI 10.1182/blood-2016-02-701805; BEREK C, 1991, CELL, V67, P1121, DOI 10.1016/0092-8674(91)90289-B; BI L, 1995, NAT GENET, V10, P119, DOI 10.1038/ng0595-119; BRAY GL, 1993, AM J HEMATOL, V42, P375, DOI 10.1002/ajh.2830420408; Chao BN, 2016, J THROMB HAEMOST, V14, P346, DOI 10.1111/jth.13202; Chappell CP, 2012, J EXP MED, V209, P1825, DOI 10.1084/jem.20120774; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Cyster JG, 2019, CELL, V177, P524, DOI 10.1016/j.cell.2019.03.016; Dal Porto JM, 1998, J IMMUNOL, V161, P5373; Dal Porto JM, 2002, J EXP MED, V195, P1215, DOI 10.1084/jem.20011550; Di Niro R, 2015, IMMUNITY, V43, P120, DOI 10.1016/j.immuni.2015.06.013; Dimichele D, 2002, HAEMOPHILIA, V8, P280, DOI 10.1046/j.1365-2516.2002.00626.x; Eckhardt CL, 2013, BLOOD, V122, P1954, DOI 10.1182/blood-2013-02-483263; Elsner RA, 2020, IMMUNITY, V53, P1136, DOI 10.1016/j.immuni.2020.11.006; Franchini M, 2013, BLOOD REV, V27, P179, DOI 10.1016/j.blre.2013.06.002; Gouw SC, 2012, BLOOD, V119, P2922, DOI 10.1182/blood-2011-09-379453; Gringeri A, 2003, BLOOD, V102, P2358, DOI 10.1182/blood-2003-03-0941; Guler ML, 1997, J IMMUNOL, V159, P1767; Hamilton JA, 2015, J IMMUNOL, V194, P5022, DOI 10.4049/jimmunol.1402335; Hartmann W, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79477-7; Hay CRM, 2012, BLOOD, V119, P1335, DOI 10.1182/blood-2011-08-369132; Hay CRM, 1997, THROMB HAEMOSTASIS, V77, P234; Healey JF, 2007, J THROMB HAEMOST, V5, P512, DOI 10.1111/j.1538-7836.2007.02373.x; Hofbauer CJ, 2015, BLOOD, V125, P1180, DOI 10.1182/blood-2014-09-598268; Hoyer BF, 2004, J EXP MED, V199, P1577, DOI 10.1084/jem.20040168; Jenks SA, 2019, IMMUNOL REV, V288, P136, DOI 10.1111/imr.12741; Jing WQ, 2019, BLOOD ADV, V3, P3099, DOI 10.1182/bloodadvances.2019000650; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; KASPER CK, 1975, THROMB DIATH HAEMOST, V34, P612; Kempton CL, 2014, BLOOD, V124, P3365, DOI 10.1182/blood-2014-05-577643; Krautler NJ, 2017, J EXP MED, V214, P1259, DOI 10.1084/jem.20161533; Krishnamurty AT, 2016, IMMUNITY, V45, P402, DOI 10.1016/j.immuni.2016.06.014; Kuroda E, 2000, J IMMUNOL, V164, P2386, DOI 10.4049/jimmunol.164.5.2386; Lee SK, 2011, J EXP MED, V208, P1377, DOI 10.1084/jem.20102065; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; LOLLAR P, 1988, BLOOD, V71, P137; MacLennan ICM, 2003, IMMUNOL REV, V194, P8, DOI 10.1034/j.1600-065X.2003.00058.x; Malkiel S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00427; MARIANI G, 1994, THROMB HAEMOSTASIS, V72, P155; Meeks SL, 2016, HEMATOL-AM SOC HEMAT, P657, DOI 10.1182/asheducation-2016.1.657; Meeks SL, 2012, BLOOD, V120, P2512, DOI 10.1182/blood-2012-02-412361; Mei BS, 2010, BLOOD, V116, P270, DOI 10.1182/blood-2009-11-254755; Mesin L, 2016, IMMUNITY, V45, P471, DOI 10.1016/j.immuni.2016.09.001; Navarrete A, 2009, J THROMB HAEMOST, V7, P1816, DOI 10.1111/j.1538-7836.2009.03571.x; Nichols TC, 2016, J THROMB HAEMOST, V14, P894, DOI 10.1111/jth.13301; Nurieva RI, 2009, SCIENCE, V325, P1001, DOI 10.1126/science.1176676; Nutt SL, 2015, NAT REV IMMUNOL, V15, P160, DOI 10.1038/nri3795; Odegard JM, 2008, J EXP MED, V205, P2873, DOI 10.1084/jem.20080840; Oldenburg J, 1997, THROMB HAEMOSTASIS, V77, P238; Pape KA, 2018, IMMUNITY, V48, P1135, DOI 10.1016/j.immuni.2018.04.019; Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730; Paus D, 2006, J EXP MED, V203, P1081, DOI 10.1084/jem.20060087; Pavlova A, 2009, J THROMB HAEMOST, V7, P2006, DOI 10.1111/j.1538-7836.2009.03636.x; Peyvandi F, 2016, NEW ENGL J MED, V374, P2054, DOI 10.1056/NEJMoa1516437; Phan TG, 2005, J IMMUNOL, V174, P4567, DOI 10.4049/jimmunol.174.8.4567; Price PW, 2009, J IMMUNOL METHODS, V343, P28, DOI 10.1016/j.jim.2009.01.005; Qadura M, 2011, HAEMOPHILIA, V17, P288, DOI 10.1111/j.1365-2516.2010.02397.x; Qian JH, 2000, EUR J IMMUNOL, V30, P2548, DOI 10.1002/1521-4141(200009)30:9<2548::AID-IMMU2548>3.0.CO;2-H; Qian JJ, 1999, THROMB HAEMOSTASIS, V81, P240, DOI 10.1055/s-0037-1614450; RAGNI MV, 1989, TRANSFUSION, V29, P447, DOI 10.1046/j.1537-2995.1989.29589284147.x; Reipert BM, 2020, BLOOD ADV, V4, P5785, DOI 10.1182/bloodadvances.2020002731; Reipert BM, 2010, HAEMOPHILIA, V16, P25, DOI 10.1111/j.1365-2516.2008.01962.x; Reipert BM, 2001, THROMB HAEMOSTASIS, V86, P1345, DOI 10.1055/s-0037-1616733; Sack BK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037671; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Sellers RS, 2012, VET PATHOL, V49, P32, DOI 10.1177/0300985811429314; Shih TAY, 2002, NAT IMMUNOL, V3, P570, DOI 10.1038/ni803; Shlomchik MJ, 2008, IMMUNITY, V28, P18, DOI 10.1016/j.immuni.2007.12.004; Stebegg M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02469; Steinitz KN, 2012, BLOOD, V119, P4073, DOI 10.1182/blood-2011-08-374645; Taylor JJ, 2012, J EXP MED, V209, P2065, DOI 10.1084/jem.20112272; Taylor JJ, 2012, J EXP MED, V209, P597, DOI 10.1084/jem.20111696; Van Helden PMW, 2007, J THROMB HAEMOST, V5, P2306, DOI 10.1111/j.1538-7836.2007.02736.x; Van Helden PMW, 2010, HAEMOPHILIA, V16, P35, DOI 10.1111/j.1365-2516.2010.02215.x; VERBRUGGEN B, 1995, THROMB HAEMOSTASIS, V73, P247; Walsh CE, 2015, AM J HEMATOL, V90, P400, DOI 10.1002/ajh.23957; Webb LMC, 2017, IMMUNOLOGY, V152, P185, DOI 10.1111/imm.12778; Weisel F, 2017, ANNU REV IMMUNOL, V35, P255, DOI 10.1146/annurev-immunol-041015-055531; Whelan SFJ, 2013, BLOOD, V121, P1039, DOI 10.1182/blood-2012-07-444877; William J, 2005, J IMMUNOL, V174, P6879, DOI 10.4049/jimmunol.174.11.6879; Woodruff MC, 2020, NAT IMMUNOL, V21, P1506, DOI 10.1038/s41590-020-00814-z; Wu HY, 2001, THROMB HAEMOSTASIS, V85, P125, DOI 10.1055/s-0037-1612915; Yu D, 2009, IMMUNITY, V31, P457, DOI 10.1016/j.immuni.2009.07.002; Zerra PE, 2021, BLOOD, V138, P706, DOI 10.1182/blood.2020009376; Zerra PE, 2017, BLOOD, V130, P2559, DOI 10.1182/blood-2017-05-782912	93	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								880829	10.3389/fimmu.2022.880829	http://dx.doi.org/10.3389/fimmu.2022.880829			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T6NH	35634288	gold, Green Published			2022-12-18	WOS:000804845800001
J	Polvere, I; Parrella, A; Zerillo, L; Voccola, S; Cardinale, G; D'Andrea, S; Madera, JR; Stilo, R; Vito, P; Zotti, T				Polvere, Immacolata; Parrella, Alfredina; Zerillo, Lucrezia; Voccola, Serena; Cardinale, Gaetano; D'Andrea, Silvia; Madera, Jessica Raffaella; Stilo, Romania; Vito, Pasquale; Zotti, Tiziana			Humoral Immune Response Diversity to Different COVID-19 Vaccines: Implications for the "Green Pass" Policy	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; neutralizing antibodies; anti-RBD antibody titer; SARS-CoV-2; humoral immune response; Green Pass Policy	STANDARD	In the COVID-19 pandemic year 2021, several countries have implemented a vaccine certificate policy, the "Green Pass Policy" (GPP), to reduce virus spread and to allow safe relaxation of COVID-19 restrictions and reopening of social and economic activities. The rationale for the GPP is based on the assumption that vaccinated people should maintain a certain degree of immunity to SARS-CoV-2. Here we describe and compare, for the first time, the humoral immune response to mRNA-1273, BNT162b2, Ad26.COV2.S, and ChAdOx1 nCoV-19 vaccines in terms of antibody titer elicited, neutralizing activity, and epitope reactogenicity among 369 individuals aged 19 to 94 years. In parallel, we also considered the use of a rapid test for the determination of neutralizing antibodies as a tool to guide policymakers in defining booster vaccination strategies and eligibility for Green Pass. Our analysis demonstrates that the titer of antibodies directed towards the receptor-binding domain (RBD) of SARS-CoV-2 Spike is significantly associated with age and vaccine type. Moreover, natural COVID-19 infection combined with vaccination results, on average, in higher antibody titer and higher neutralizing activity as compared to fully vaccinated individuals without prior COVID-19. We also found that levels of anti-Spike RBD antibodies are not always strictly associated with the extent of inhibition of RBD-ACE2 binding, as we could observe different neutralizing activities in sera with similar anti-RBD concentrations. Finally, we evaluated the reactivity to four synthetic peptides derived from Spike protein on a randomly selected serum sample and observed that similar to SARS-CoV-2 infection, vaccination elicits a heterogeneous antibody response with qualitative individual features. On the basis of our results, the use of rapid devices to detect the presence of neutralizing antibodies, even on a large scale and repeatedly over time, appears helpful in determining the duration of the humoral protection elicited by vaccination. These aspects and their implications for the GPP are discussed.	[Polvere, Immacolata; Zerillo, Lucrezia; D'Andrea, Silvia; Madera, Jessica Raffaella; Stilo, Romania; Vito, Pasquale; Zotti, Tiziana] Univ Sannio, Dept Sci & Technol, Benevento, Italy; [Parrella, Alfredina; Voccola, Serena; Cardinale, Gaetano] Consorzio Sannio Tech, Apollosa, Italy; [Parrella, Alfredina; Cardinale, Gaetano] Tecno Bios Srl, Apollosa, Italy; [Zerillo, Lucrezia; Voccola, Serena; D'Andrea, Silvia; Vito, Pasquale; Zotti, Tiziana] Univ Sannio, Genus Biotech Srls, Benevento, Italy	University of Sannio; University of Sannio	Vito, P; Zotti, T (corresponding author), Univ Sannio, Dept Sci & Technol, Benevento, Italy.; Vito, P; Zotti, T (corresponding author), Univ Sannio, Genus Biotech Srls, Benevento, Italy.	vito@unisannio.it; tzotti@unisannio.it						Alter G, 2021, NATURE, V596, P268, DOI 10.1038/s41586-021-03681-2; Barbeau DJ., 2021, COMP ANAL HUMAN IMMU, V09, DOI [10.1101/2021.09.21.21262927, DOI 10.1101/2021.09.21.21262927]; Barrett JR, 2021, NAT MED, V27, P279, DOI 10.1038/s41591-020-01179-4; Bewley KR, 2021, NAT PROTOC, V16, P3114, DOI 10.1038/s41596-021-00536-y; Brown L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86008-5; Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1; Criscuolo E, 2021, J MED VIROL, V93, P2160, DOI 10.1002/jmv.26605; Dashdorj NJ, 2021, CELL HOST MICROBE, V29, P1738, DOI 10.1016/j.chom.2021.11.004; Dolscheid-Pommerich R, 2022, J MED VIROL, V94, P388, DOI 10.1002/jmv.27287; Dong YT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00796-w; Doria-Rose N, 2021, NEW ENGL J MED, V384, P2259, DOI 10.1056/NEJMc2103916; Dupont L, 2021, NAT MICROBIOL, V6, P1433, DOI 10.1038/s41564-021-00974-0; European Commission, EU DIG COVID CERT; European Medicines Agency, AUTH COVID 19 VACC; Feng S, 2021, NAT MED, V27, P2032, DOI 10.1038/s41591-021-01540-1; Food and Drug Administration, COVID 19 VACC AUTH E; Garcia-Beltran WF, 2021, CELL, V184, P2372, DOI [10.1016/j.cell.2021.03.013, 10.1016/j.cell.2021.04.006]; Gilbert PB, 2022, SCIENCE, V375, P43, DOI 10.1126/science.abm3425; Gray AN, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259703; Hassine IH, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2313; Ho TC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101163; Hu J, 2022, CELL MOL IMMUNOL, V19, P293, DOI [10.1038/s41423-021-00836-z, 10.1080/08164622.2022.2106779]; Israel A, 2022, VACCINES-BASEL, V10, DOI [10.3390/vaccines10010064, 10.1101/2021.08.19.21262111]; Jochum S, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.798117; Jung BK, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11122193; Khoury DS, 2021, NAT MED, V27, P1205, DOI 10.1038/s41591-021-01377-8; Kristiansen PA, 2021, LANCET, V397, P1347, DOI 10.1016/S0140-6736(21)00527-4; Lake DF, 2021, J CLIN VIROL, V145, DOI 10.1016/j.jcv.2021.105024; Payne RP, 2021, CELL, V184, P5699, DOI 10.1016/j.cell.2021.10.011; Pegu A, 2021, SCIENCE, V373, P1372, DOI 10.1126/science.abj4176; Polvere I, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9090987; Polvere I, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11030483; Polvere I, 2022, GENES DIS, V9, P275, DOI 10.1016/j.gendis.2021.01.008; Powelson I, 2022, J HAND SURG-AM, V47, P79, DOI 10.1016/j.jhsa.2021.07.002; Premkumar L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abc8413; Roche Diagnostics GmbH 2021; Elecsys&REG;, ANTI SARS COV 2 S AS; Shang J, 2020, P NATL ACAD SCI USA, V117, P11727, DOI 10.1073/pnas.2003138117; Steensels D, 2021, JAMA-J AM MED ASSOC, V326, P1533, DOI 10.1001/jama.2021.15125; Szczepanek J, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10010099; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Van Tilbeurgh M, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060579; Wang JFJ, 2021, EXPERT REV MOL DIAGN, V21, P363, DOI 10.1080/14737159.2021.1913123; Yu SC, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060588; Zheng JX, 2022, CELL MOL IMMUNOL, V19, P150, DOI 10.1038/s41423-021-00774-w	44	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								833085	10.3389/fimmu.2022.833085	http://dx.doi.org/10.3389/fimmu.2022.833085			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M5QV	35634315	gold, Green Published			2022-12-18	WOS:000800024500001
J	Principe, N; Aston, WJ; Hope, DE; Tilsed, CM; Fisher, SA; Boon, L; Dick, IM; Chin, WL; McDonnell, AM; Nowak, AK; Lake, RA; Chee, J; Lesterhuis, WJ				Principe, Nicola; Aston, Wayne J.; Hope, Danika E.; Tilsed, Caitlin M.; Fisher, Scott A.; Boon, Louis; Dick, Ian M.; Chin, Wee Loong; McDonnell, Alison M.; Nowak, Anna K.; Lake, Richard A.; Chee, Jonathan; Lesterhuis, Willem Joost			Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations	FRONTIERS IN IMMUNOLOGY			English	Article						chemo-immunotherapy combinations; immune checkpoint blockade (ICB) therapy; T cells; proinflammatory cytokine; TNFa = tumor necrosis factor-a; IL-1b; fluorouracil (5-FU); cisplatin	SUPPRESSOR-CELLS; CROSS-PRESENTATION; CTLA-4 BLOCKADE; T-CELLS; TUMOR; CISPLATIN; THERAPY; SYNERGY	Antibodies that target immune checkpoints such as cytotoxic T lymphocyte antigen 4 (CTLA-4) and the programmed cell death protein 1/ligand 1 (PD-1/PD-L1) are now a treatment option for multiple cancer types. However, as a monotherapy, objective responses only occur in a minority of patients. Chemotherapy is widely used in combination with immune checkpoint blockade (ICB). Although a variety of isolated immunostimulatory effects have been reported for several classes of chemotherapeutics, it is unclear which chemotherapeutics provide the most benefit when combined with ICB. We investigated 10 chemotherapies from the main canonical classes dosed at the clinically relevant maximum tolerated dose in combination with anti-CTLA-4/anti-PD-L1 ICB. We screened these chemo-immunotherapy combinations in two murine mesothelioma models from two different genetic backgrounds, and identified chemotherapies that produced additive, neutral or antagonistic effects when combined with ICB. Using flow cytometry and bulk RNAseq, we characterized the tumor immune milieu in additive chemo-immunotherapy combinations. 5-fluorouracil (5-FU) or cisplatin were additive when combined with ICB while vinorelbine and etoposide provided no additional benefit when combined with ICB. The combination of 5-FU with ICB augmented an inflammatory tumor microenvironment with markedly increased CD8(+) T cell activation and upregulation of IFN gamma, TNF alpha and IL-1 beta signaling. The effective anti-tumor immune response of 5-FU chemo-immunotherapy was dependent on CD8(+) T cells but was unaffected when TNF alpha or IL-1 beta cytokine signaling pathways were blocked. Our study identified additive and non-additive chemotherapy/ICB combinations and suggests a possible role for increased inflammation in the tumor microenvironment as a basis for effective combination therapy.	[Principe, Nicola; Aston, Wayne J.; Hope, Danika E.; Tilsed, Caitlin M.; Fisher, Scott A.; Dick, Ian M.; Chin, Wee Loong; Nowak, Anna K.; Lake, Richard A.; Chee, Jonathan; Lesterhuis, Willem Joost] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia; [Principe, Nicola; Tilsed, Caitlin M.; Fisher, Scott A.; Lake, Richard A.; Chee, Jonathan; Lesterhuis, Willem Joost] Univ Western Australia, Sch Biomed Sci, Crawley, WA, Australia; [Principe, Nicola; Tilsed, Caitlin M.; Fisher, Scott A.; Dick, Ian M.; Nowak, Anna K.; Lake, Richard A.; Chee, Jonathan; Lesterhuis, Willem Joost] Inst Resp Hlth, Perth, WA, Australia; [Boon, Louis] JJP Biol, Warsaw, Poland; [Chin, Wee Loong; McDonnell, Alison M.; Lesterhuis, Willem Joost] Telethon Kids Inst, Perth, WA, Australia; [Chin, Wee Loong; Nowak, Anna K.] Univ Western Australia, Med Sch, Crawley, WA, Australia	University of Western Australia; University of Western Australia; Telethon Kids Institute; University of Western Australia	Chee, J; Lesterhuis, WJ (corresponding author), Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia.; Chee, J; Lesterhuis, WJ (corresponding author), Univ Western Australia, Sch Biomed Sci, Crawley, WA, Australia.; Chee, J; Lesterhuis, WJ (corresponding author), Inst Resp Hlth, Perth, WA, Australia.; Lesterhuis, WJ (corresponding author), Telethon Kids Inst, Perth, WA, Australia.	jonathan.chee@uwa.edu.au; joost.lesterhuis@telethonkids.org.au	Tilsed, Caitlin M/AFU-2305-2022; Boon, Laurence/HCI-3629-2022; Nowak, Anna/B-2487-2013; Chee, Jonathan/D-4634-2017; Fisher, Scott/H-9187-2014	Tilsed, Caitlin M/0000-0002-9066-5182; Hope, Danika/0000-0001-5312-4355; Boon, Louis/0000-0002-0937-9171; Nowak, Anna/0000-0002-9317-9526; Principe, Nicola/0000-0001-6458-2482; Chee, Jonathan/0000-0002-7986-2708; Lesterhuis, Willem Joost/0000-0002-2718-276X; Fisher, Scott/0000-0003-1551-5579	NHMRC [1067113]; UWA Richard Walter Gibbon Medical Research; Cancer Council WA; UWA Raine Foundation, Cancer Council WA, WA Department of Health; iCare Dust Diseases Board; Simon Lee Foundation; National Centre for Asbestos Related Diseases	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); UWA Richard Walter Gibbon Medical Research; Cancer Council WA(Cancer Council Western Australia); UWA Raine Foundation, Cancer Council WA, WA Department of Health; iCare Dust Diseases Board; Simon Lee Foundation; National Centre for Asbestos Related Diseases	This work was funded by NHMRC grant 1067113. NP was supported by UWA Richard Walter Gibbon Medical Research and Cancer Council WA scholarships. JC was supported by grants and fellowship from the UWA Raine Foundation, Cancer Council WA, WA Department of Health, and iCare Dust Diseases Board. WL was supported by fellowships from the Simon Lee Foundation, NHMRC and Cancer Council WA. The National Centre for Asbestos Related Diseases receive funding through the NHMRC Centres of Research Excellence scheme.	Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Aston WJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3677-7; Bae SH, 2007, CLIN CANCER RES, V13, P341, DOI 10.1158/1078-0432.CCR-06-1838; Bray NL, 2016, NAT BIOTECHNOL, V34, P525, DOI 10.1038/nbt.3519; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Cook AM, 2016, CURR OPIN IMMUNOL, V39, P23, DOI 10.1016/j.coi.2015.12.003; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Cui SJ, 2017, MED SCI MONITOR, V23, P3360, DOI 10.12659/MSM.902426; DAVIS MR, 1992, INT J CANCER, V52, P881, DOI 10.1002/ijc.2910520609; de Mutsert R, 2009, KIDNEY INT, V75, P677, DOI 10.1038/ki.2008.645; Fear VS, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1494111; Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z; Harada K, 2016, INT J ONCOL, V49, P276, DOI 10.3892/ijo.2016.3523; He XR, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000807; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Iida Y, 2017, CANCER SCI, V108, P1974, DOI 10.1111/cas.13337; Jackaman C, 2003, J IMMUNOL, V171, P5051, DOI 10.4049/jimmunol.171.10.5051; Jure-Kunkel M, 2013, CANCER IMMUNOL IMMUN, V62, P1533, DOI 10.1007/s00262-013-1451-5; Kang JH, 2021, TRENDS IMMUNOL, V42, P293, DOI 10.1016/j.it.2021.02.006; Kaplanov I, 2019, P NATL ACAD SCI USA, V116, P1361, DOI 10.1073/pnas.1812266115; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836; Lequeux A, 2021, ONCOGENE, V40, P4725, DOI 10.1038/s41388-021-01846-x; Lesterhuis WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061895; Lesterhuis WJ, 2011, J CLIN INVEST, V121, P3100, DOI 10.1172/JCI43656; Liu F, 2016, ONCOTARGETS THER, V9, P5999, DOI 10.2147/OTT.S109342; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Magkouta Sophia, 2018, Oncotarget, V9, P21783, DOI 10.18632/oncotarget.25004; McDonnell AM, 2015, EUR J IMMUNOL, V45, P49, DOI 10.1002/eji.201444722; Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905; Nowak AK, 2020, LANCET ONCOL, V21, P1213, DOI 10.1016/S1470-2045(20)30462-9; Orecchioni S, 2018, BRIT J CANCER, V118, P1329, DOI 10.1038/s41416-018-0076-z; Park SJ, 2019, ORAL ONCOL, V95, P127, DOI 10.1016/j.oraloncology.2019.06.016; Parra K, 2017, BRIT J CANCER, V116, P324, DOI 10.1038/bjc.2016.429; Patsoukis N, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7692; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Paz-Ares L, 2019, LANCET, V394, P1929, DOI 10.1016/S0140-6736(19)32222-6; Perez-Ruiz E, 2019, NATURE, V569, P428, DOI 10.1038/s41586-019-1162-y; Pircher A, 2014, LUNG CANCER, V85, P81, DOI 10.1016/j.lungcan.2014.04.001; Ramakrishnan R, 2010, J CLIN INVEST, V120, P1111, DOI 10.1172/JCI40269; Rettig L, 2011, INT J CANCER, V129, P832, DOI 10.1002/ijc.25756; Robinson C, 2014, LUNG CANCER MANAG, V3, P397, DOI 10.2217/LMT.14.27; Saint-Jean M, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021329; Schmidt EV, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2019.20833; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Suzuki E, 2005, CLIN CANCER RES, V11, P6713, DOI 10.1158/1078-0432.CCR-05-0883; Tang WD, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2019.115235; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Wei HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084927; Wu YH, 2016, BMC IMMUNOL, V17, DOI 10.1186/s12865-016-0167-7; Xie Zhuorui, 2021, Curr Protoc, V1, pe90, DOI 10.1002/cpz1.90; Zemek RM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav7816; Zhao XD, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101056	54	0	0	3	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								872295	10.3389/fimmu.2022.872295	http://dx.doi.org/10.3389/fimmu.2022.872295			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P0YC	35634282	gold, Green Published			2022-12-18	WOS:000801744400001
J	Sabatini, A; Guerrera, G; Corsetti, M; Ruocco, G; De Bardi, M; Renzi, S; Cavalieri, D; Battistini, L; Angelini, DF; Volpe, E				Sabatini, Andrea; Guerrera, Gisella; Corsetti, Marta; Ruocco, Gabriella; De Bardi, Marco; Renzi, Sonia; Cavalieri, Duccio; Battistini, Luca; Angelini, Daniela Francesca; Volpe, Elisabetta			Human Conventional and Plasmacytoid Dendritic Cells Differ in Their Ability to Respond to Saccharomyces cerevisiae	FRONTIERS IN IMMUNOLOGY			English	Article						microbiota; dendritic cells; Saccharomyces cerevisiae; T helper polarization; fungi	REGULATORY T-CELLS; HOST-DEFENSE; PROTECTIVE IMMUNITY; DEOXYNUCLEIC ACIDS; CANDIDA-ALBICANS; FUNGAL RNA; INDUCE; RECOGNITION; ACTIVATION; MICROBIOTA	Saccharomyces cerevisiae is a commensal yeast colonizer of mucosal surfaces and an emerging opportunistic pathogen in the mucosa and bloodstream. The role of S. cerevisiae has been largely characterized in peripheral blood mononuclear cells and monocyte-derived dendritic cells, where yeast cells induce the production of inflammatory cytokines through the interaction with mannose receptors, chitin receptors, DC SIGN, and dectin1. However, the response of blood-circulating dendritic cells (DCs) to S. cerevisiae has never been investigated. Among blood DCs, conventional DCs (cDCs) are producers of inflammatory cytokines, while plasmacytoid DCs (pDCs) are a specialized population producing a large amount of interferon (IFN)-alpha, which is involved in the antiviral immune response. Here we report that both human DC subsets are able to sense S. cerevisiae. In particular, cDCs produce interleukin (IL)-6, express activation markers, and promotes T helper 17 cell polarization in response to yeasts, behaving similarly to monocyte-derived DCs as previously described. Interestingly, pDCs, not cDCs, sense fungal nucleic acids, leading to the generation of P1-pDCs (PD-L1(+)CD80(-)), a pDC subset characterized by the production of IFN-alpha and the induction of a Th profile producing IL-10. These results highlight a novel role of pDCs in response to S. cerevisiae that could be important for the regulation of the host microbiota-immune system balance and of anti-fungal immune response.	[Sabatini, Andrea; Corsetti, Marta; Ruocco, Gabriella; Volpe, Elisabetta] Ist Ricovero & Cura Carattere Sci IRCCS Fdn St Luc, Mol Neuroimmunol Unit, Rome, Italy; [Sabatini, Andrea] Sapienza Univ, Dept Biol & Biotechnol Charles Darwin, Rome, Italy; [Guerrera, Gisella; De Bardi, Marco; Battistini, Luca; Angelini, Daniela Francesca] Ist Ricovero & Cura Carattere Sci IRCCS St Lucia F, Neuroimmunol Unit, Rome, Italy; [Renzi, Sonia; Cavalieri, Duccio] Univ Florence, Dept Biol, Florence, Italy	Sapienza University Rome; University of Florence	Volpe, E (corresponding author), Ist Ricovero & Cura Carattere Sci IRCCS Fdn St Luc, Mol Neuroimmunol Unit, Rome, Italy.; Battistini, L (corresponding author), Ist Ricovero & Cura Carattere Sci IRCCS St Lucia F, Neuroimmunol Unit, Rome, Italy.	l.battistini@hsantalucia.it; e.volpe@hsantalucia.it	De Bardi, Marco/AAD-2007-2019; Angelini, Daniela F/J-8001-2018	De Bardi, Marco/0000-0001-8217-970X; Angelini, Daniela F/0000-0003-4552-9226; Renzi, Sonia/0000-0002-0450-106X; Guerrera, Gisella/0000-0002-3467-6469				Alculumbre S, 2019, SEMIN CELL DEV BIOL, V86, P24, DOI 10.1016/j.semcdb.2018.02.014; Alculumbre SG, 2018, NAT IMMUNOL, V19, P63, DOI 10.1038/s41590-017-0012-z; Bacci A, 2002, J IMMUNOL, V168, P2904, DOI 10.4049/jimmunol.168.6.2904; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Belkaid Y, 2014, CELL, V157, P121, DOI 10.1016/j.cell.2014.03.011; Biondo C, 2012, EUR J IMMUNOL, V42, P2632, DOI 10.1002/eji.201242532; Bode C, 2016, EUR J IMMUNOL, V46, P1615, DOI 10.1002/eji.201546113; Bozza S, 2003, BLOOD, V102, P3807, DOI 10.1182/blood-2003-03-0748; Cappuccio A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7847; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; de Llanos R, 2006, ANTON LEEUW INT J G, V90, P221, DOI 10.1007/s10482-006-9077-7; Di Paola M, 2020, J TRANSL AUTOIMMUN, V3, DOI 10.1016/j.jtauto.2020.100036; Gilliet M, 2002, HUM IMMUNOL, V63, P1149, DOI 10.1016/S0198-8859(02)00753-X; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Guiducci C, 2006, J EXP MED, V203, P1999, DOI 10.1084/jem.20060401; Hallen-Adams HE, 2017, VIRULENCE, V8, P352, DOI 10.1080/21505594.2016.1247140; Herbrecht R, 2005, CLIN INFECT DIS, V40, P1635, DOI 10.1086/429926; Hori S, 2002, EUR J IMMUNOL, V32, P1282, DOI 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jaeger M, 2015, EUR J CLIN MICROBIOL, V34, P963, DOI 10.1007/s10096-014-2309-2; Kerkmann M, 2005, J BIOL CHEM, V280, P8086, DOI 10.1074/jbc.M410868200; Kim T, 2010, P NATL ACAD SCI USA, V107, P15181, DOI 10.1073/pnas.1006539107; Levings MK, 2001, J IMMUNOL, V166, P5530, DOI 10.4049/jimmunol.166.9.5530; Miyazato A, 2009, INFECT IMMUN, V77, P3056, DOI 10.1128/IAI.00840-08; Montagnoli C, 2002, J IMMUNOL, V169, P6298, DOI 10.4049/jimmunol.169.11.6298; Montagnoli C, 2001, IMMUNOBIOLOGY, V204, P582, DOI 10.1078/0171-2985-00095; Nakamura K, 2008, J IMMUNOL, V180, P4067, DOI 10.4049/jimmunol.180.6.4067; ODOHERTY U, 1994, IMMUNOLOGY, V82, P487; Piarroux R, 1999, LANCET, V353, P1851, DOI 10.1016/S0140-6736(99)02001-2; Prakash S, 2011, BIOL-TARGETS THER, V5, P71, DOI 10.2147/BTT.S19099; Ramirez-Ortiz ZG, 2008, INFECT IMMUN, V76, P2123, DOI 10.1128/IAI.00047-08; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Rizzetto L, 2016, J BIOL CHEM, V291, P7961, DOI 10.1074/jbc.M115.699645; Rizzetto L, 2010, J IMMUNOL, V184, P4258, DOI 10.4049/jimmunol.0902972; Romani L, 2011, NAT REV IMMUNOL, V11, P275, DOI 10.1038/nri2939; Ruocco G, 2015, CLIN SCI, V129, P291, DOI 10.1042/CS20140608; See P, 2017, SCIENCE, V356, DOI 10.1126/science.aag3009; Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Stefanini I, 2012, P NATL ACAD SCI USA, V109, P13398, DOI 10.1073/pnas.1208362109; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; TAYLOR GD, 1994, MYCOSES, V37, P187, DOI 10.1111/j.1439-0507.1994.tb00298.x; van de Veerdonk FL, 2008, IMMUNOBIOLOGY, V213, P613, DOI 10.1016/j.imbio.2008.05.002; Wang X, 2020, J IMMUNOL, V205, P3058, DOI 10.4049/jimmunol.2000802; Zelante T, 2007, ADV EXP MED BIOL, V590, P209	48	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								850404	10.3389/fimmu.2022.850404	http://dx.doi.org/10.3389/fimmu.2022.850404			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M5VI	35634316	Green Published, gold			2022-12-18	WOS:000800036300001
J	Schubert, N; Schumann, T; Daum, E; Flade, K; Ge, Y; Hagedorn, L; Edelmann, W; Mueller, L; Schmitz, M; Kuut, G; Hornung, V; Behrendt, R; Roers, A				Schubert, Nadja; Schumann, Tina; Daum, Elena; Flade, Karolin; Ge, Yan; Hagedorn, Lara; Edelmann, Winfried; Mueller, Luise; Schmitz, Marc; Kuut, Gunnar; Hornung, Veit; Behrendt, Rayk; Roers, Axel			Genome Replication Is Associated With Release of Immunogenic DNA Waste	FRONTIERS IN IMMUNOLOGY			English	Article						Trex1; type I interferon; Exo1; replication; cytosolic DNA; interferonopathy	NUCLEOTIDE EXCISION-REPAIR; AICARDI-GOUTIERES-SYNDROME; REVERSE-TRANSCRIPTASE INHIBITORS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; EXONUCLEASE TREX1; I INTERFERON; MICE LACKING; CGAS; MUTATIONS; ACTIVATION	Innate DNA sensors detect foreign and endogenous DNA to induce responses to infection and cellular stress or damage. Inappropriate activation by self-DNA triggers severe autoinflammatory conditions, including Aicardi-Goutieres syndrome (AGS) that can be caused by defects of the cytosolic DNase 3'repair exonuclease 1 (TREX1). TREX1 loss-of-function alleles are also associated with systemic lupus erythematosus (SLE). Chronic activation of innate antiviral immunity in TREX1-deficient cells depends on the DNA sensor cGAS, implying that accumulating TREX1 DNA substrates cause the inflammatory pathology. Retrotransposon-derived cDNAs were shown to activate cGAS in TREX1-deficient neuronal cells. We addressed other endogenous sources of cGAS ligands in cells lacking TREX1. We find that induced loss of TREX1 in primary cells induces a rapid IFN response that requires ongoing proliferation. The inflammatory phenotype of Trex1(-/-) mice was partially rescued by additional knock out of exonuclease 1, a multifunctional enzyme providing 5' flap endonuclease activity for Okazaki fragment processing and postreplicative ribonucleotide excision repair. Our data imply genome replication as a source of DNA waste with pathogenic potential that is efficiently degraded by TREX1.	[Schubert, Nadja; Schumann, Tina; Daum, Elena; Flade, Karolin; Ge, Yan; Hagedorn, Lara; Mueller, Luise; Schmitz, Marc; Behrendt, Rayk; Roers, Axel] Univ Technol TU Dresden, Inst Immunol, Med Fac Carl Gustav Carus, Dresden, Germany; [Edelmann, Winfried] Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY USA; [Schmitz, Marc] Univ Technol TU Dresden, Univ Hosp Carl Gustav Carus, Natl Ctr Tumor Dis NCT, Dresden, Germany; [Schmitz, Marc] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Schmitz, Marc; Kuut, Gunnar; Hornung, Veit] Ludwig Maximilians Univ Munchen, Gene Ctr, Dept Biochem, Munich, Germany; [Behrendt, Rayk] Univ Hosp Bonn, Inst Clin Chem & Clin Pharmacol, Bonn, Germany; [Roers, Axel] Univ Hosp Heidelberg, Inst Immunol, Heidelberg, Germany; German Canc Res Ctr, Heidelberg, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Yeshiva University; Albert Einstein College of Medicine; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; University of Bonn; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Roers, A (corresponding author), Univ Technol TU Dresden, Inst Immunol, Med Fac Carl Gustav Carus, Dresden, Germany.; Roers, A (corresponding author), Univ Hosp Heidelberg, Inst Immunol, Heidelberg, Germany.	axel.roers@uni-heidelberg.de		Rupp, Luise/0000-0002-6610-326X				Ablasser A, 2019, SCIENCE, V363, P1055, DOI 10.1126/science.aat8657; Ablasser A, 2014, J IMMUNOL, V192, P5993, DOI 10.4049/jimmunol.1400737; Achleitner M, 2017, J IMMUNOL, V199, P2261, DOI 10.4049/jimmunol.1700714; Ahn J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6166; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Baillie JK, 2011, NATURE, V479, P534, DOI 10.1038/nature10531; Balmus G, 2015, NAT PROTOC, V10, P205, DOI 10.1038/nprot.2015.010; Beck-Engeser GB, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-91; Bennett L, 2003, J EXP MED, V197, P711, DOI 10.1084/jem.20021553; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; Burgers PMJ, 2017, ANNU REV BIOCHEM, V86, P417, DOI 10.1146/annurev-biochem-061516-044709; CHITRABAMRUNG S, 1981, RHEUMATOL INT, V1, P55, DOI 10.1007/BF00541153; Crow YJ, 2022, NAT REV IMMUNOL, V22, P471, DOI 10.1038/s41577-021-00633-9; Crow YJ, 2006, NAT GENET, V38, P910, DOI 10.1038/ng1842; Crow YJ, 2006, NAT GENET, V38, P917, DOI 10.1038/ng1845; Crow YJ, 2015, AM J MED GENET A, V167, P296, DOI 10.1002/ajmg.a.36887; de Koning APJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002384; Mann CCD, 2021, EMBO J, V40, DOI 10.15252/embj.2021108293; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Du MJ, 2018, SCIENCE, V361, P704, DOI 10.1126/science.aat1022; Erdal E, 2017, GENE DEV, V31, P353, DOI 10.1101/gad.289769.116; Flynn PJ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103585118; Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gall A, 2012, IMMUNITY, V36, P120, DOI 10.1016/j.immuni.2011.11.018; Grieves JL, 2015, P NATL ACAD SCI USA, V112, P5117, DOI 10.1073/pnas.1423804112; Guan JH, 2021, CANCER CELL, V39, P109, DOI 10.1016/j.ccell.2020.11.004; Haig D, 2016, BIOESSAYS, V38, P1158, DOI 10.1002/bies.201600125; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Harding SM, 2017, NATURE, V548, P466, DOI 10.1038/nature23470; Herzner AM, 2015, NAT IMMUNOL, V16, P1025, DOI 10.1038/ni.3267; Hiller B, 2018, CANCER RES, V78, P5917, DOI 10.1158/0008-5472.CAN-18-1099; Ho SSW, 2016, IMMUNITY, V44, P1177, DOI 10.1016/j.immuni.2016.04.010; Hopfner KP, 2020, NAT REV MOL CELL BIO, V21, P501, DOI 10.1038/s41580-020-0244-x; Howe KL, 2020, NUCLEIC ACIDS RES, V48, pD689, DOI 10.1093/nar/gkz890; Huang CRL, 2012, ANNU REV GENET, V46, P651, DOI 10.1146/annurev-genet-110711-155616; Hyka-Nouspikel N, 2011, BLOOD, V117, P6277, DOI 10.1182/blood-2010-12-326637; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kahli M, 2019, NUCLEIC ACIDS RES, V47, P1814, DOI 10.1093/nar/gky1242; Kato M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04132-9; Keijzers G, 2016, CRIT REV BIOCHEM MOL, V51, P440, DOI 10.1080/10409238.2016.1215407; Kenny EF, 2019, EUR J IMMUNOL, V49, P590, DOI 10.1002/eji.201847875; Kim SH., 2022, NUCLEIC ACIDS RES, V34; Kubota S, 2014, J BIOL CHEM, V289, P5730, DOI 10.1074/jbc.M113.546655; Laguette N, 2014, CELL, V156, P134, DOI 10.1016/j.cell.2013.12.011; Lan YY, 2014, CELL REP, V9, P180, DOI 10.1016/j.celrep.2014.08.074; Lee-Kirsch MA, 2007, NAT GENET, V39, P1065, DOI 10.1038/ng2091; Li T, 2018, J EXP MED, V215, P1287, DOI 10.1084/jem.20180139; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549; Mankan AK, 2014, EMBO J, V33, P2937, DOI 10.15252/embj.201488726; Marteijn JA, 2014, NAT REV MOL CELL BIO, V15, P465, DOI 10.1038/nrm3822; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; Mohr L, 2021, MOL CELL, V81, P724, DOI 10.1016/j.molcel.2020.12.037; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morita M, 2004, MOL CELL BIOL, V24, P6719, DOI 10.1128/MCB.24.15.6719-6727.2004; Naim V, 2013, NAT CELL BIOL, V15, P1008, DOI 10.1038/ncb2793; Napirei M, 2000, NAT GENET, V25, P177, DOI 10.1038/76032; Nehar-Belaid D, 2020, NAT IMMUNOL, V21, P1094, DOI 10.1038/s41590-020-0743-0; Okabe Y, 2005, J EXP MED, V202, P1333, DOI 10.1084/jem.20051654; Padeken J, 2015, CURR OPIN GENET DEV, V31, P12, DOI 10.1016/j.gde.2015.03.009; Peschke K, 2016, J IMMUNOL, V197, P2157, DOI 10.4049/jimmunol.1600722; Ramantani G, 2010, ARTHRITIS RHEUM-US, V62, P1469, DOI 10.1002/art.27367; Reijns MAM, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.011; Rice GI, 2018, NEW ENGL J MED, V379, P2275, DOI 10.1056/NEJMc1810983; Rice GI, 2013, LANCET NEUROL, V12, P1159, DOI 10.1016/S1474-4422(13)70258-8; Roberts A, 2013, NAT METHODS, V10, P71, DOI [10.1038/NMETH.2251, 10.1038/nmeth.2251]; Rodero MP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01932-3; Rodero MP, 2016, J EXP MED, V213, P2527, DOI 10.1084/jem.20161596; Roers A, 2016, IMMUNITY, V44, P739, DOI 10.1016/j.immuni.2016.04.002; Schaetzlein S, 2013, P NATL ACAD SCI USA, V110, pE2470, DOI 10.1073/pnas.1308512110; Schlee M, 2016, NAT REV IMMUNOL, V16, P566, DOI 10.1038/nri.2016.78; Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862; Schwartz EK, 2011, CHROMOSOMA, V120, P109, DOI 10.1007/s00412-010-0304-7; Shen YJ, 2015, CELL REP, V11, P460, DOI 10.1016/j.celrep.2015.03.041; Smith DJ, 2012, NATURE, V483, P434, DOI 10.1038/nature10895; Sparks JL, 2012, MOL CELL, V47, P980, DOI 10.1016/j.molcel.2012.06.035; Stetson DB, 2008, CELL, V134, P587, DOI 10.1016/j.cell.2008.06.032; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Symington LS, 2011, ANNU REV GENET, V45, P247, DOI 10.1146/annurev-genet-110410-132435; Takahashi A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03555-8; Thomas CA, 2017, CELL STEM CELL, V21, P319, DOI 10.1016/j.stem.2017.07.009; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Uggenti C, 2020, NAT GENET, V52, P1364, DOI 10.1038/s41588-020-00737-3; Uggenti C, 2019, ANNU REV IMMUNOL, V37, P247, DOI 10.1146/annurev-immunol-042718-041257; Upton KR, 2015, CELL, V161, P228, DOI 10.1016/j.cell.2015.03.026; Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618; Volkman HE, 2019, ELIFE, V8, DOI 10.7554/eLife.47491; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wolf C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11752; Yan N, 2010, NAT IMMUNOL, V11, P1005, DOI 10.1038/ni.1941; Yang YG, 2007, CELL, V131, P873, DOI 10.1016/j.cell.2007.10.017; Yasutomo K, 2001, NAT GENET, V28, P313, DOI 10.1038/91070; Zhang XW, 2020, IMMUNITY, V53, P43, DOI 10.1016/j.immuni.2020.05.013	95	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								880413	10.3389/fimmu.2022.880413	http://dx.doi.org/10.3389/fimmu.2022.880413			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P8YF	35634291	Green Published, gold			2022-12-18	WOS:000802288400001
J	Vieira, VA; Herbert, N; Cromhout, G; Adland, E; Goulder, P				Vieira, Vinicius A.; Herbert, Nicholas; Cromhout, Gabriela; Adland, Emily; Goulder, Philip			Role of Early Life Cytotoxic T Lymphocyte and Natural Killer Cell Immunity in Paediatric HIV Cure/Remission in the Anti-Retroviral Therapy Era	FRONTIERS IN IMMUNOLOGY			English	Review						HIV; innate immunity; CTL; NK cell; paediatric	PLASMACYTOID DENDRITIC CELLS; NK CELLS; HLA-B; CHILD TRANSMISSION; GENDER-DIFFERENCES; MEDIATED RESPONSE; INFECTED INFANTS; SEX-DIFFERENCES; CD8(+); ACTIVATION	Only three well-characterised cases of functional cure have been described in paediatric HIV infection over the past decade. This underlines the fact that early initiation of combination antiretroviral therapy (cART), whilst minimising the size of the viral reservoir, is insufficient to achieve cure, unless other factors contribute. In this review, we consider these additional factors that may facilitate functional cure in paediatric infection. Among the early life immune activity, these include HIV-specific cytotoxic T-lymphocyte (CTL) and natural killer (NK) cell responses. The former have less potent antiviral efficacy in paediatric compared with adult infection, and indeed, in early life, NK responses have greater impact in suppressing viral replication than CTL. This fact may contribute to a greater potential for functional cure to be achieved in paediatric versus adult infection, since post-treatment control in adults is associated less with highly potent CTL activity, and more with effective antiviral NK cell responses. Nonetheless, antiviral CTL responses can play an increasingly effective role through childhood, especially in individuals expressing then 'protective' HLA-I molecules HLA-B*27/57/58:01/8101. The role of the innate system on preventing infection, in shaping the particular viruses transmitted, and influencing outcome is discussed. The susceptibility of female fetuses to in utero mother-to-child transmission, especially in the setting of recent maternal infection, is a curiosity that also provides clues to mechanisms by which cure may be achieved, since initial findings are that viral rebound is less frequent among males who interrupt cART. The potential of broadly neutralising antibody therapy to facilitate cure in children who have received early cART is discussed. Finally, we draw attention to the impact of the changing face of the paediatric HIV epidemic on cure potential. The effect of cART is not limited to preventing AIDS and reducing the risk of transmission. cART also affects which mothers transmit. No longer are mothers who transmit those who carry genes associated with poor immune control of HIV. In the cART era, a high proportion (>70% in our South African study) of transmitting mothers are those who seroconvert in pregnancy or who for social reasons are diagnosed late in pregnancy. As a result, now, genes associated with poor immune control of HIV are not enriched in mothers who transmit HIV to their child. These changes will likely influence the effectiveness of HLA-associated immune responses and therefore cure potential among children.	[Vieira, Vinicius A.; Adland, Emily; Goulder, Philip] Univ Oxford, Dept Paediat, Peter Medawar Bldg Pathogen Res, Oxford, Oxon, England; [Herbert, Nicholas; Goulder, Philip] Afr Hlth Res Inst AHRI, Nelson Mandela Sch Med R, Durban, South Africa; [Cromhout, Gabriela; Goulder, Philip] Univ KwaZulu Natal, Doris Duke Med Res Inst, Nelson Mandela Sch Med R, HIV Pathogenesis Programme, Durban, South Africa	University of Oxford; Africa Health Research Institute; University of Kwazulu Natal	Goulder, P (corresponding author), Univ Oxford, Dept Paediat, Peter Medawar Bldg Pathogen Res, Oxford, Oxon, England.; Goulder, P (corresponding author), Afr Hlth Res Inst AHRI, Nelson Mandela Sch Med R, Durban, South Africa.; Goulder, P (corresponding author), Univ KwaZulu Natal, Doris Duke Med Res Inst, Nelson Mandela Sch Med R, HIV Pathogenesis Programme, Durban, South Africa.			Herbert, Nicholas/0000-0002-3708-694X	Wellcome Trust [WT104748MA]; National Institutes of Health [PG RO1-AI133673, 1UM1AI164566-01]; EPIICAL Project (Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies); ViiV Healthcare UK	Wellcome Trust(Wellcome Trust); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EPIICAL Project (Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies); ViiV Healthcare UK	This work was supported by the Wellcome Trust (PG WTIA Grant WT104748MA), the National Institutes of Health (PG RO1-AI133673, 1UM1AI164566-01) and by a grant to PG through the EPIICAL Project (Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies). The EPIICAL Project is funded through an independent grant by ViiV Healthcare UK.	Abbas M., 2022, STATPEARLS; Adland E, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-15632-y, 10.1038/s41467-020-16215-7]; Adland E, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004954; Ahmed R, 2007, NAT IMMUNOL, V8, P1188, DOI 10.1038/ni1530; Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115; Allen TM, 2008, J EXP MED, V205, P1003, DOI 10.1084/jem.20080569; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Alter G, 2007, J INFECT DIS, V195, P1452, DOI 10.1086/513878; Ananworanich J, 2010, J ALLERGY CLIN IMMUN, V126, P1294, DOI 10.1016/j.jaci.2010.09.038; [Anonymous], 2021, PAED CAR TREATM; [Anonymous], 2008, NEW ENGL J MED, DOI DOI 10.1056/NEJM199908053410602; [Anonymous], CHANGING CLIN EPIDEM; [Anonymous], 2020, GEND HIV AIDS; [Anonymous], 2021, GLOB HIV AIDS STAT F; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Berger CT, 2011, J VIROL, V85, P9334, DOI 10.1128/JVI.00460-11; Bertagnolli LN, 2020, P NATL ACAD SCI USA, V117, P32066, DOI 10.1073/pnas.2020617117; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Boesch AW, 2015, IMMUNOL REV, V268, P296, DOI 10.1111/imr.12339; Borducchi EN, 2018, NATURE, V563, P360, DOI 10.1038/s41586-018-0600-6; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Carlson JM, 2014, SCIENCE, V345, DOI 10.1126/science.1254031; Carlson JM, 2012, J VIROL, V86, P5230, DOI 10.1128/JVI.06728-11; Cella M, 1999, NAT MED, V5, P919, DOI 10.1038/11360; Chistiakov DA, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00279; Choudhary SK, 2007, J VIROL, V81, P8838, DOI 10.1128/JVI.02663-06; Claiborne DT, 2015, P NATL ACAD SCI USA, V112, pE1480, DOI 10.1073/pnas.1421607112; Costa-Garcia M, 2015, J IMMUNOL, V194, P2715, DOI 10.4049/jimmunol.1402281; Cromhout GZL., REDUCED SELECTION UN; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; De Cock KM, 2000, JAMA-J AM MED ASSOC, V283, P1175, DOI 10.1001/jama.283.9.1175; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Dong YH, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1043; Edwards BH, 2002, J VIROL, V76, P2298, DOI 10.1128/JVI.76.5.2298-2305.2002; Estes JD, 2008, J IMMUNOL, V181, P2934, DOI 10.4049/jimmunol.181.4.2934; Feeney ME, 2005, J IMMUNOL, V174, P7524, DOI 10.4049/jimmunol.174.12.7524; Fellay J, 2007, SCIENCE, V317, P944, DOI 10.1126/science.1143767; Fenton-May AE, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-146; Ferguson AL, 2013, IMMUNITY, V38, P606, DOI 10.1016/j.immuni.2012.11.022; Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718; Frange P, 2016, LANCET HIV, V3, pE49, DOI 10.1016/S2352-3018(15)00232-5; Gandhi M, 2002, CLIN INFECT DIS, V35, P313, DOI 10.1086/341249; Garcia-Broncano P, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7350; Goga AE, 2020, J EPIDEMIOL COMMUN H, V74, P1069, DOI 10.1136/jech-2019-213453; Gondim MVP, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd8179; Goodier MR, 2018, EUR J IMMUNOL, V48, P50, DOI 10.1002/eji.201646762; Gottlieb MS., 2006, PNEUMOCYSTIS PNEUMON, P980, DOI [10.2105/AJPH.96.6.980, DOI 10.2105/AJPH.96.6.980]; Goulder PJ, 2016, NAT REV IMMUNOL, V16, P259, DOI 10.1038/nri.2016.19; Goulder PJR, 2001, NATURE, V412, P334, DOI 10.1038/35085576; Gupta P, 2015, PLANT METHODS, V11, DOI 10.1186/s13007-015-0051-0; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Havers FP, 2021, MMWR-MORBID MORTAL W, V70, P851, DOI 10.15585/mmwr.mm7023e1; Hogarth PM, 2012, NAT REV DRUG DISCOV, V11, P311, DOI 10.1038/nrd2909; Horowitz A, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1672; Huang SH, 2008, J IMMUNOL, V181, P8103, DOI 10.4049/jimmunol.181.11.8103; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Hurst J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9495; Iyer SS, 2017, P NATL ACAD SCI USA, V114, pE590, DOI 10.1073/pnas.1620144114; Jaspan HB, 2006, AIDS, V20, P483, DOI 10.1097/01.aids.0000210602.40267.60; Jilg N, 2019, INFECT DIS CLIN N AM, V33, P857, DOI 10.1016/j.idc.2019.04.007; Kaye S, 2008, J INFECT DIS, V197, P1307, DOI 10.1086/586715; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Kiepiela P, 2007, NAT MED, V13, P46, DOI 10.1038/nm1520; Klatt NR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004345; Klatt NR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007153; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Knipe D., 2001, FIELDS VIROLOGY, P2675; Kollmann TR, 2009, J IMMUNOL, V183, P7150, DOI 10.4049/jimmunol.0901481; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; Kourtis AP, 2001, JAMA-J AM MED ASSOC, V285, P709, DOI 10.1001/jama.285.6.709; Kramski M, 2013, CURR HIV RES, V11, P388, DOI 10.2174/15701; Kuhn L, 2020, ECLINICALMEDICINE, V18, DOI 10.1016/j.eclinm.2019.100241; Lanese NA., 2022, 3 PERSON HAS BEEN CU; Langford C, 2002, MED HIST, V46, P1; Leitman EM, 2017, J EXP MED, V214, P3239, DOI 10.1084/jem.20162123; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Leslie A, 2010, J VIROL, V84, P9879, DOI 10.1128/JVI.00320-10; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Lisovsky I, 2015, J VIROL, V89, P9909, DOI 10.1128/JVI.01546-15; Lisziewicz J, 1999, NEW ENGL J MED, V340, P1683, DOI 10.1056/NEJM199905273402114; Lohman BL, 2005, J VIROL, V79, P8121, DOI 10.1128/JVI.79.13.8121-8130.2005; Lopez M, 2011, AIDS RES HUM RETROV, V27, P157, DOI 10.1089/aid.2010.0107; Lopez-Vazquez A, 2005, HUM IMMUNOL, V66, P285, DOI 10.1016/j.humimm.2005.01.001; Lu LL, 2018, NAT REV IMMUNOL, V18, P46, DOI 10.1038/nri.2017.106; Lynch JB, 2011, J VIROL, V85, P5252, DOI 10.1128/JVI.02216-10; Madec Yoann, 2013, AIDS, V27, P2451, DOI 10.1097/01.aids.0000431945.72365.01; Marsh SGE., HLA FACTSBOOK HLA FA; Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035; Martin MP, 2018, J CLIN INVEST, V128, P1903, DOI 10.1172/JCI98463; Martinez-Picado J, 2005, J VIROL, V79, P5907, DOI 10.1128/JVI.79.10.5907-5913.2005; Mast EE, 2005, J INFECT DIS, V192, P1880, DOI 10.1086/497701; Matthews PC, 2008, J VIROL, V82, P8548, DOI 10.1128/JVI.00580-08; Matthews PC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047799; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; McLean MR, 2017, J IMMUNOL, V199, P816, DOI 10.4049/jimmunol.1602161; Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004; Merino AM, 2013, CLIN EXP IMMUNOL, V174, P414, DOI 10.1111/cei.12187; Migueles SA, 2002, NAT IMMUNOL, V3, P1061, DOI 10.1038/ni845; Millar JR, 2021, J INFECT DIS, V224, P1925, DOI 10.1093/infdis/jiab223; Millar JR, 2021, AIDS, V35, P1597, DOI 10.1097/QAD.0000000000002915; Millar JR, 2020, ECLINICALMEDICINE, V22, DOI 10.1016/j.eclinm.2020.100344; Milligan C, 2015, CELL HOST MICROBE, V17, P500, DOI 10.1016/j.chom.2015.03.002; Mphatswe W, 2007, AIDS, V21, P1253, DOI 10.1097/QAD.0b013e3281a3bec2; Muenchhoff M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1048; Murphy TL, 2016, ANNU REV IMMUNOL, V34, P93, DOI 10.1146/annurev-immunol-032713-120204; Naidoo VL, 2017, J VIROL, V91, DOI 10.1128/JVI.00518-17; Namazi G, 2018, J INFECT DIS, V218, P1954, DOI 10.1093/infdis/jiy479; Ndhlovu ZM, 2015, J VIROL, V89, P10735, DOI 10.1128/JVI.01527-15; Ndhlovu ZM, 2015, IMMUNITY, V43, P591, DOI 10.1016/j.immuni.2015.08.012; Neidich SD, 2019, J CLIN INVEST, V129, P4838, DOI 10.1172/JCI126391; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Nishimura Y, 2017, NATURE, V543, P559, DOI 10.1038/nature21435; Obar JJ, 2010, INT IMMUNOL, V22, P619, DOI 10.1093/intimm/dxq053; Palma P, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-2092-z; PAREKH BS, 1993, AIDS RES HUM RETROV, V9, P907, DOI 10.1089/aid.1993.9.907; Payne H, 2021, AIDS RES THER, V18, DOI 10.1186/s12981-021-00389-1; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Persaud D, 2013, NEW ENGL J MED, V369, P1828, DOI 10.1056/NEJMoa1302976; Prendergast A, 2011, AIDS, V25, P1329, DOI 10.1097/QAD.0b013e3283478575; Prince JL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1003041; Ramsuran V, 2018, SCIENCE, V359, P86, DOI 10.1126/science.aam8825; Rankin DA, 2021, CURR OPIN PEDIATR, V33, P114, DOI 10.1097/MOP.0000000000000971; Reizis B, 2019, IMMUNITY, V50, P37, DOI 10.1016/j.immuni.2018.12.027; Reizis B, 2011, NAT REV IMMUNOL, V11, P558, DOI 10.1038/nri3027; Robb ML, 2016, NEW ENGL J MED, V374, P2120, DOI 10.1056/NEJMoa1508952; Rodger AJ, 2019, LANCET, V393, P2428, DOI 10.1016/S0140-6736(19)30418-0; Rotger M, 2011, J CLIN INVEST, V121, P2391, DOI 10.1172/JCI45235; Rouzioux C, 1995, AM J EPIDEMIOL, V142, P1330, DOI 10.1093/oxfordjournals.aje.a117601; Rutishauser RL, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.136648; Rutishauser RL, 2017, AIDS RES HUM RETROV, V33, P658, DOI [10.1089/aid.2016.0324, 10.1089/AID.2016.0324]; Saez-Cirion A., 2019, IAS 2019 10 INT C HI; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Sawai CM, 2013, J EXP MED, V210, P2151, DOI 10.1084/jem.20130443; Scheid JF, 2016, NATURE, V535, P556, DOI 10.1038/nature18929; Scott ZA, 2001, J IMMUNOL, V167, P7134, DOI 10.4049/jimmunol.167.12.7134; Shah SV, 2018, CELL REP, V25, P2766, DOI 10.1016/j.celrep.2018.11.020; Shalekoff S, 2009, AIDS, V23, P789, DOI 10.1097/QAD.0b013e328329c784; Siberry GK, 2014, PEDIATR REV, V35, P268, DOI 10.1542/pir.35-7-268; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Singh KK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151364; Sunshine J, 2014, J VIROL, V88, P1354, DOI 10.1128/JVI.02361-13; Taha TE, 2005, PEDIATRICS, V115, pE167, DOI 10.1542/peds.2004-1590; Thobakgale CF, 2007, J VIROL, V81, P12775, DOI 10.1128/JVI.00624-07; Thomas AS, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100412; Thorne C, 2004, AIDS, V18, P2337, DOI 10.1097/00002030-200411190-00019; Tomescu C, 2012, AIDS, V26, P1869, DOI 10.1097/QAD.0b013e32835861b0; Tovo PA, 2005, J INFECT DIS, V192, P1872, DOI 10.1086/497695; Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482; Turk G, 2013, J VIROL, V87, P7445, DOI 10.1128/JVI.00865-13; Van Zyl GU, 2017, J CLIN INVEST, V127, P3827, DOI [10.1172/jci94582, 10.1172/JCI94582]; Veldsman KA, 2018, AIDS, V32, P629, DOI [10.1097/QAD.0000000000001739, 10.1097/qad.0000000000001739]; Vieira V., EARLY PD 1 EXPRESSIO; Vieira VA, 2022, J VIROL, V96, DOI 10.1128/JVI.01535-21; Vieira VA, 2022, AIDS, V36, P95, DOI 10.1097/QAD.0000000000003078; Vieira VA, 2019, AIDS, V33, P67, DOI 10.1097/QAD.0000000000002043; Vieira VA, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1010090; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Violari A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08311-0; Vreeman RC, 2015, J INT AIDS SOC, V18, P53, DOI 10.7448/IAS.18.7.20258; Whitmire JK, 2005, J EXP MED, V201, P1053, DOI 10.1084/jem.20041463; Yaffe ZA, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100254; Yang OO, 2017, AIDS, V31, P1090, DOI 10.1097/QAD.0000000000001443; Zacharopoulou P, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-021-04212-9	165	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								886562	10.3389/fimmu.2022.886562	http://dx.doi.org/10.3389/fimmu.2022.886562			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S3ZM	35634290	Green Published, gold			2022-12-18	WOS:000803992400001
J	Viola, NT; Glassbrook, JE; Kalluri, JR; Hackett, JB; Wicker, MN; Sternberg, J; Gibson, HM				Viola, Nerissa T.; Glassbrook, James E.; Kalluri, Jhansi R.; Hackett, Justin B.; Wicker, Madison N.; Sternberg, Joshua; Gibson, Heather M.			Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses	FRONTIERS IN IMMUNOLOGY			English	Article						Interleukin-12; PET imaging; immunotherapy; inflammation; radioactive tracer	INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; INTERFERON-GAMMA; T-CELLS; IMMUNOREGULATORY FUNCTIONS; MAINTENANCE THERAPY; INNATE RESISTANCE; DOUBLE-BLIND; USTEKINUMAB; CYTOKINE; TRIAL	The immune cytokine interleukin-12 (IL-12) is involved in cancer initiation and progression, autoimmunity, as well as graft versus host disease. The ability to monitor IL-12 via imaging may provide insight into various immune processes, including levels of antitumor immunity, inflammation, and infection due to its functions in immune signaling. Here, we report the development and preclinical evaluation of an antibody-based IL-12-specific positron emission tomography (PET) tracer. To mimic localized infection and stimulate IL-12 production, BALB/c mice were administered lipopolysaccharide (LPS) intramuscularly. [Zr-89]Zr-DFO-alpha IL12 tracer was given one hour post LPS administration and PET images were taken after 5, 24, 48, and 72 hours. We observed significantly higher uptake in LPS-treated mice as compared to controls. Biodistribution of the tracer was evaluated in a separate cohort of mice, where tracer uptake was elevated in muscle, spleen, lymph nodes, and intestines after LPS administration. To evaluate the utility of [Zr-89]Zr-DFO-alpha IL12 as an indicator of antigen presenting cell activation after cancer immunotherapy, we compared PET imaging with and without intratumoral delivery of oncolytic adenovirus expressing granulocyte-macrophage colony-stimulating factor (Adv/GM-CSF), which we have shown promotes anti-tumor immunity. BALB/c mice were inoculated orthotopically with the mouse mammary carcinoma line TUBO. Once TUBO tumors reached a volume of ~50 mm(3), mice were treated with either three intratumoral injections of 10(8) PFU Adv/GM-CSF or vehicle control, given every other day. Upon the last dose, [Zr-89]Zr-DFO-alpha IL12 was injected intravenously and 72 hours later all mice were imaged via PET. Tumor-specific uptake of [Zr-89]Zr-DFO-alpha IL12 was higher in Adv/GM-CSF treated mice versus controls. Tissues were harvested after imaging, and elevated levels of macrophages and CD8(+) T-c cells were detected in Adv/GM-CSF treated tumors by immunohistochemistry. We validated that IL-12 expression was induced after Adv/GM-CSF by qRT-PCR. Importantly, expression of genes activated by IL-12 (IFN gamma, TNF alpha, and IL-18) were unaffected after IL-12 imaging relative to mice receiving an IgG control tracer, suggesting the tracer antibody does not significantly disrupt signaling. Our results indicate that targeting soluble cytokines such as IL-12 by PET imaging with antibody tracers may serve as a noninvasive method to evaluate the function of the immune milieu in situ.	[Viola, Nerissa T.; Glassbrook, James E.; Kalluri, Jhansi R.; Wicker, Madison N.; Sternberg, Joshua; Gibson, Heather M.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48202 USA; [Glassbrook, James E.] Wayne State Univ, Dept Biochem Microbiol & Immunol, Detroit, MI USA; [Hackett, Justin B.] Wayne State Univ, Sch Med, Canc Biol Grad Program, Detroit, MI USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Wayne State University	Viola, NT; Gibson, HM (corresponding author), Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48202 USA.	Violan@karmanos.org; Gibsonh@karmanos.org	Pisaneschi, Federica/GYU-7470-2022; Gibson, Heather/GLV-4595-2022; Pisaneschi, Federica/GYU-7584-2022	Pisaneschi, Federica/0000-0002-1989-4417; Gibson, Heather/0000-0003-2652-8252; Pisaneschi, Federica/0000-0002-1989-4417	National Institutes of Health (NIH) [P30 CA022453]; Karmanos Cancer Institute at Wayne State University; National Cancer Institute under the NIH; Ruth L. Kirschstein National Research Service Award [P30 CA022453];  [R37 CA220482];  [T32-CA009531]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Karmanos Cancer Institute at Wayne State University; National Cancer Institute under the NIH; Ruth L. Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; 	The authors acknowledge the Microscopy, Imaging and Cytometry Resources Core, which is supported in part by the National Institutes of Health (NIH) grant P30 CA022453 to the Karmanos Cancer Institute at Wayne State University. Research was funded in part by the National Cancer Institute under the NIH. Award numbers include R37 CA220482 (NV and HG), and the Ruth L. Kirschstein National Research Service Award T32-CA009531 (JG).	Arganda-Carreras I, 2017, BIOINFORMATICS, V33, P2424, DOI 10.1093/bioinformatics/btx180; Bastian D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00988; Caruso M, 1996, P NATL ACAD SCI USA, V93, P11302, DOI 10.1073/pnas.93.21.11302; Castro-Mejia J, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/4953120; Chan YH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00894; Chargari C, 2013, ANTI-CANCER DRUG, V24, P324, DOI 10.1097/CAD.0b013e32835dbaaf; Chinnasamy D, 2012, CLIN CANCER RES, V18, P1672, DOI 10.1158/1078-0432.CCR-11-3050; Deepak P, 2016, DRUG DES DEV THER, V10, P3685, DOI 10.2147/DDDT.S102141; Diaz-Montero CM, 2008, CANCER IMMUNOL IMMUN, V57, P563, DOI 10.1007/s00262-007-0394-0; Dmochowska N, 2019, J NUCL MED, V60, P858, DOI 10.2967/jnumed.118.219287; Feagan BG, 2016, NEW ENGL J MED, V375, P1946, DOI 10.1056/NEJMoa1602773; Fleetwood AJ, 2007, J IMMUNOL, V178, P5245, DOI 10.4049/jimmunol.178.8.5245; Gibson H, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.984523; Gibson HM, 2018, CANCER RES, V78, P5706, DOI 10.1158/0008-5472.CAN-18-0253; Goriely S, 2008, NAT REV IMMUNOL, V8, P81, DOI 10.1038/nri2225; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; HENDRZAK JA, 1995, LAB INVEST, V72, P619; Hino A, 2000, CYTOKINE, V12, P12, DOI 10.1006/cyto.1999.0515; Kerkar SP, 2010, CANCER RES, V70, P6725, DOI 10.1158/0008-5472.CAN-10-0735; Kieper WC, 2001, J IMMUNOL, V166, P5515, DOI 10.4049/jimmunol.166.9.5515; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Kung BT, 2019, AM J NUCL MED MOLEC, V9, P255; Larimer BM, 2017, CANCER RES, V77, P2318, DOI 10.1158/0008-5472.CAN-16-3346; Leonard JP, 1997, BLOOD, V90, P2541; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Li JY, 2020, CELL IMMUNOL, V349, DOI 10.1016/j.cellimm.2020.104042; Luo Q, 2004, J BIOL CHEM, V279, P18451, DOI 10.1074/jbc.M400320200; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Mirlekar B, 2021, CANCERS, V13, DOI 10.3390/cancers13020167; Monteleone G, 1999, CLIN EXP IMMUNOL, V117, P469; Motzer RJ, 2001, J INTERF CYTOK RES, V21, P257, DOI 10.1089/107999001750169934; Munnink THO, 2011, J NUCL MED, V52, P2001, DOI 10.2967/jnumed.111.092809; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Pijl JP, 2021, SEMIN NUCL MED, V51, P633, DOI 10.1053/j.semnuclmed.2021.06.008; Reich K, 2011, NEW ENGL J MED, V365, P1586, DOI 10.1056/NEJMoa1010858; Roberts J, 2018, IMMUNOTHERAPY-UK, V10, P361, DOI 10.2217/imt-2017-0149; Sands BE, 2019, NEW ENGL J MED, V381, P1201, DOI 10.1056/NEJMoa1900750; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Shah NN, 2018, CYTOTHERAPY, V20, P1415, DOI 10.1016/j.jcyt.2018.10.003; Steding CE, 2011, IMMUNOLOGY, V133, P221, DOI 10.1111/j.1365-2567.2011.03429.x; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.iy.13.040195.001343; TRINCHIERI G, 1994, BLOOD, V84, P4008, DOI 10.1182/blood.V84.12.4008.bloodjournal84124008; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Ullrich KAM, 2020, EXCLI J, V19, P1563, DOI 10.17179/excli2020-3104; Vacaflores A, 2017, MOL IMMUNOL, V81, P1, DOI 10.1016/j.molimm.2016.11.008; Vacaflores A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157175; Viola-Villegas NT, 2014, MOL PHARMACEUT, V11, P3965, DOI 10.1021/mp500164r; Viola-Villegas NT, 2013, J NUCL MED, V54, P1876, DOI 10.2967/jnumed.113.119867; Warren HS, 2010, J INFECT DIS, V201, P223, DOI 10.1086/649557; Watkins SK, 2007, J IMMUNOL, V178, P1357, DOI 10.4049/jimmunol.178.3.1357; Wojno EDT, 2019, IMMUNITY, V50, P851, DOI 10.1016/j.immuni.2019.03.011; Wysocka M, 2001, J IMMUNOL, V166, P7504, DOI 10.4049/jimmunol.166.12.7504; Xu M, 2015, J IMMUNOL, V194, P4997, DOI 10.4049/jimmunol.1402603	53	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								870110	10.3389/fimmu.2022.870110	http://dx.doi.org/10.3389/fimmu.2022.870110			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S4EO	35634303	gold, Green Published			2022-12-18	WOS:000804005700001
J	Wang, N; Li, JH; Wang, YJ; Wang, YY; Zhang, DF; Shi, CB; Li, YY; Bergmann, SM; Mo, XB; Yin, JY; Wang, Q				Wang, Nan; Li, Jiahao; Wang, Yajun; Wang, Yingying; Zhang, Defeng; Shi, Cunbin; Li, Yingying; Bergmann, Sven M.; Mo, Xubing; Yin, Jiyuan; Wang, Qing			Recombinant Lactococcus lactis Expressing Grass Carp Reovirus VP6 Induces Mucosal Immunity Against Grass Carp Reovirus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						grass carp reovirus; Lactococcus lactis; oral vaccine; VP6; mucosal immune protection	COMPLETE GENOME SEQUENCE; DIFFERENT GENOTYPES; ORAL IMMUNIZATION; ESCHERICHIA-COLI; RAINBOW-TROUT; VACCINES; PROTEIN; GCRV; RESPONSES; STRAINS	Grass carp haemorrhagic disease caused by grass carp reovirus II is a serious disease of the aquaculture industry and vaccination is the only effective method of GCRV protection. In this study, Lactococcus lactis was used as oral vaccine delivery to express the GCRV II VP6 protein. We evaluated the protective efficacy of the live vaccine strain to induce mucosal immune protection. After oral administration, the recombinant strains remained in the hindgut for antigen presentation and increased the survival rate 46.7% and the relative percent survival 42.9%, respectively versus control vaccination. Though L. lactis alone can induce the inflammatory response by stimulating the mucosal immune system, the recombinant L. lactis expressing VP6 greatly enhanced nonspecific immune responses via expression of immune related genes of the fish. Furthermore, both systemic and mucosal immunity was elicited following oral immunization with the recombinant strain and this strain also elicited an inflammatory response and cellular immunity to enhance the protective effect. L. lactis can therefore be utilized as a mucosal immune vector to trigger high levels of immune protection in fish at both the systemic and mucosal levels. L. lactis is a promising candidate for oral vaccine delivery.	[Wang, Nan; Li, Jiahao; Wang, Yajun; Wang, Yingying; Zhang, Defeng; Shi, Cunbin; Li, Yingying; Mo, Xubing; Yin, Jiyuan; Wang, Qing] Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Key Lab Fishery Drug Dev, Key Lab Aquat Anim ImmuneTechnol Guangdong Prov,Mi, Guangzhou, Peoples R China; [Bergmann, Sven M.] Fed Res Inst Anim Hlth, Inst Infectol, Friedrich Loffler Inst FLI, Greifswald, Germany	Chinese Academy of Fishery Sciences; Pearl River Fisheries Research Institute, CAFS	Yin, JY; Wang, Q (corresponding author), Chinese Acad Fishery Sci, Pearl River Fisheries Res Inst, Key Lab Fishery Drug Dev, Key Lab Aquat Anim ImmuneTechnol Guangdong Prov,Mi, Guangzhou, Peoples R China.	yinjiyuan@prfri.ac.cn; sunny_929@163.com	wang, yi/GVT-8516-2022; wang, yan/GSE-6489-2022; wang, yingying/GRS-3058-2022					Abualrous ET, 2021, CURR OPIN IMMUNOL, V70, P95, DOI 10.1016/j.coi.2021.04.009; Cano-Lozano JA, 2022, J BIOSCI BIOENG, V133, P187, DOI [10.1016/j.jbiosc.2021.11.004, 10.1016/jbiosc.2021.11.004]; Aoki T, 2013, FISH SHELLFISH IMMUN, V35, P1689, DOI 10.1016/j.fsi.2013.02.005; Bahey-El-Din M, 2012, VACCINE, V30, P685, DOI 10.1016/j.vaccine.2011.11.098; Bahey-El-Din M, 2011, HUM VACCINES, V7, P106, DOI 10.4161/hv.7.1.13631; Barrera C, 2002, HUM IMMUNOL, V63, P384, DOI 10.1016/S0198-8859(02)00386-5; Brudeseth BE, 2013, FISH SHELLFISH IMMUN, V35, P1759, DOI 10.1016/j.fsi.2013.05.029; Cai YZ, 2020, AQUACULT REP, V18, DOI 10.1016/j.aqrep.2020.100538; Cao LP, 2021, AQUAT TOXICOL, V239, DOI 10.1016/j.aquatox.2021.105956; Cao P, 2022, COMPOS PART B-ENG, V236, DOI 10.1016/j.compositesb.2022.109826; Chen DD, 2019, AQUACULTURE, V504, P88, DOI 10.1016/j.aquaculture.2019.01.055; Chen JM, 2021, FISH SHELLFISH IMMUN, V117, P53, DOI 10.1016/j.fsi.2021.07.014; Chen JM, 2021, AQUACULTURE, V533, DOI 10.1016/j.aquaculture.2020.736133; Chen XP, 2022, POULTRY SCI, V101, DOI 10.1016/j.psj.2021.101651; Hao K, 2018, FISH SHELLFISH IMMUN, V72, P199, DOI 10.1016/j.fsi.2017.10.060; Lee SH, 2021, FISH SHELLFISH IMMUN, V114, P253, DOI 10.1016/j.fsi.2021.05.007; Li XY, 2017, FISH SHELLFISH IMMUN, V70, P1, DOI 10.1016/j.fsi.2017.08.042; Liao ZW, 2021, DEV COMP IMMUNOL, V122, DOI 10.1016/j.dci.2021.104131; Liu JK, 2009, APPL ENVIRON MICROB, V75, P4491, DOI 10.1128/AEM.02672-08; Magadan S, 2015, RESULTS PROBL CELL D, V57, P235, DOI 10.1007/978-3-319-20819-0_10; Marchler-Bauer A, 2017, NUCLEIC ACIDS RES, V45, pD200, DOI 10.1093/nar/gkw1129; Nazifi N, 2019, BMC VET RES, V15, DOI 10.1186/s12917-019-2074-7; OBST M, 1992, FEMS MICROBIOL LETT, V97, P209, DOI 10.1111/j.1574-6968.1992.tb05465.x; Qiao YT, 2022, FOOD SCI HUM WELL, V11, P238, DOI 10.1016/j.fshw.2021.11.008; Qin SK, 2022, MICROB PATHOGENESIS, V165, DOI 10.1016/j.micpath.2021.105216; Qiu DK, 2021, AQUACULTURE, V533, DOI 10.1016/j.aquaculture.2020.736152; Qiu DK, 2021, AQUACULTURE, V530, DOI 10.1016/j.aquaculture.2020.735948; REED L. J., 1938, AMER JOUR HYG, V27, P493; Ribeiro LA, 2002, APPL ENVIRON MICROB, V68, P910, DOI 10.1128/AEM.68.2.910-916.2002; Saez D, 2012, VACCINE, V30, P1283, DOI 10.1016/j.vaccine.2011.12.088; Sholichah L., 2016, INDONESIAN AQUACULTU, V11, P41, DOI [10.15578/iaj.11.1.2016.41-47, DOI 10.15578/IAJ.11.1.2016.41-47]; Sigh J, 2004, FISH SHELLFISH IMMUN, V17, P75, DOI 10.1016/j.fsi.2003.12.005; Song SS, 2019, VACCINE, V37, P4364, DOI 10.1016/j.vaccine.2019.06.026; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; [汤亚方 Tang Yafang], 2018, [淡水渔业, Freshwater Fisheries], V48, P9; Tian YY, 2013, FISH SHELLFISH IMMUN, V35, P351, DOI 10.1016/j.fsi.2013.04.022; Utke K, 2008, DEV COMP IMMUNOL, V32, P239, DOI 10.1016/j.dci.2007.05.010; Wang Nan, 2021, South China Fisheries Science, V17, P74, DOI 10.12131/20210039; Wang Q, 2012, J VIROL, V86, P12466, DOI 10.1128/JVI.02333-12; Wegmann U, 2007, J BACTERIOL, V189, P3256, DOI 10.1128/JB.01768-06; Xue RY, 2013, FISH SHELLFISH IMMUN, V34, P348, DOI 10.1016/j.fsi.2012.11.024; Yan Xiuying, 2018, Aquaculture and Fisheries, V3, P184, DOI 10.1016/j.aaf.2018.07.005; Yin JY, 2016, APPL MICROBIOL BIOT, V100, P9593, DOI 10.1007/s00253-016-7779-y; Zeng WW, 2016, FISH SHELLFISH IMMUN, V54, P473, DOI 10.1016/j.fsi.2016.04.133; Zheng YY, 2021, AQUACULTURE, V534, DOI 10.1016/j.aquaculture.2020.736197; Zhu B, 2015, FISH SHELLFISH IMMUN, V42, P325, DOI 10.1016/j.fsi.2014.11.026	46	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								914010	10.3389/fimmu.2022.914010	http://dx.doi.org/10.3389/fimmu.2022.914010			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6BO	35634331	Green Published, gold			2022-12-18	WOS:000800052600001
J	Wang, YB; Liu, XY; Xia, PP; Li, ZW; FuChen, X; Shen, YF; Yu, P; Zhang, J				Wang, Yongbo; Liu, Xingyu; Xia, Panpan; Li, Zhangwang; FuChen, Xinxi; Shen, Yunfeng; Yu, Peng; Zhang, Jing			The Regulatory Role of MicroRNAs on Phagocytes: A Potential Therapeutic Target for Chronic Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						chronic disease; miRNA; immunity; neutrophils; macrophages	NEUTROPHIL EXTRACELLULAR TRAPS; PATTERN-RECOGNITION RECEPTORS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; T-CELL-ACTIVATION; MACROPHAGE ACTIVATION; IN-VIVO; RHEUMATOID-ARTHRITIS; CHRONIC INFLAMMATION; APOPTOTIC NEUTROPHILS; IMMUNE-RESPONSE	An effective acute inflammatory response results in the elimination of infectious microorganisms, followed by a smooth transition to resolution and repair. During the inflammatory response, neutrophils play a crucial role in antimicrobial defense as the first cells to reach the site of infection damage. However, if the neutrophils that have performed the bactericidal effect are not removed in time, the inflammatory response will not be able to subside. Anti-inflammatory macrophages are the main scavengers of neutrophils and can promote inflammation towards resolution. MicroRNAs (miRNAs) have great potential as clinical targeted therapy and have attracted much attention in recent years. This paper summarizes the involvement of miRNAs in the process of chronic diseases such as atherosclerosis, rheumatoid arthritis and systemic lupus erythematosus by regulating lipid metabolism, cytokine secretion, inflammatory factor synthesis and tissue repair in two types of cells. This will provide a certain reference for miRNA-targeted treatment of chronic diseases.	[Wang, Yongbo; Liu, Xingyu; Xia, Panpan; FuChen, Xinxi; Shen, Yunfeng; Yu, Peng] Nanchang Univ, Dept Metab & Endocrinol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China; [Wang, Yongbo; Liu, Xingyu; Li, Zhangwang] Nanchang Univ, Affiliated Hosp 2, Clin Med Coll 2, Nanchang, Jiangxi, Peoples R China; [Zhang, Jing] Nanchang Univ, Dept Anesthesiol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China	Nanchang University; Nanchang University; Nanchang University	Yu, P (corresponding author), Nanchang Univ, Dept Metab & Endocrinol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.; Zhang, J (corresponding author), Nanchang Univ, Dept Anesthesiol, Affiliated Hosp 2, Nanchang, Jiangxi, Peoples R China.				Key Science and Technology Research Project of Education Department of Jiangxi Province [GJJ180004]	Key Science and Technology Research Project of Education Department of Jiangxi Province	Funding This research was supported by grants from the Key Science and Technology Research Project of Education Department of Jiangxi Province (GJJ180004).	Abdullah A, 2018, EUR J CELL BIOL, V97, P359, DOI 10.1016/j.ejcb.2018.05.002; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Adlakha YK, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.301; Alexander M, 2015, BIOESSAYS, V37, P1005, DOI 10.1002/bies.201500054; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; An JH, 2019, EUR REV MED PHARMACO, V23, P8665, DOI 10.26355/eurrev_201910_19184; Ariel A, 2006, NAT IMMUNOL, V7, P1209, DOI 10.1038/ni1392; Arroyo AB, 2021, THROMB HAEMOSTASIS, V121, P1138, DOI 10.1055/a-1342-3648; Arroyo AB, 2021, HAEMATOLOGICA, V106, P1636, DOI 10.3324/haematol.2019.240226; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bala S, 2016, J HEPATOL, V64, P1378, DOI 10.1016/j.jhep.2016.01.035; Bashir S, 2016, INFLAMM RES, V65, P1, DOI 10.1007/s00011-015-0874-1; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Bjerregaard MD, 2003, BLOOD, V101, P4322, DOI 10.1182/blood-2002-03-0835; Blanco LP, 2021, ARTHRITIS RHEUMATOL, V73, P2282, DOI 10.1002/art.41796; Borregaard N, 2010, IMMUNITY, V33, P657, DOI 10.1016/j.immuni.2010.11.011; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bracken CP, 2015, CANCER RES, V75, P2594, DOI 10.1158/0008-5472.CAN-15-0287; Braga TT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00602; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009; Buckley CD, 2013, NAT REV IMMUNOL, V13, P59, DOI 10.1038/nri3362; Butin-Israeli V, 2019, J CLIN INVEST, V129, P712, DOI 10.1172/JCI122085; Bystrom J, 2008, BLOOD, V112, P4117, DOI 10.1182/blood-2007-12-129767; Cai X, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02492-6; Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530; Castrillo A, 2001, J EXP MED, V194, P1231, DOI 10.1084/jem.194.9.1231; Chen BZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653344; Chistiakov DA, 2015, INT J CARDIOL, V184, P436, DOI 10.1016/j.ijcard.2015.03.055; Chung HY, 2019, AGING DIS, V10, P367, DOI 10.14336/AD.2018.0324; Clark SR, 2007, NAT MED, V13, P463, DOI 10.1038/nm1565; Curtale G, 2013, P NATL ACAD SCI USA, V110, P11499, DOI 10.1073/pnas.1219852110; Das A, 2015, AM J PATHOL, V185, P2596, DOI 10.1016/j.ajpath.2015.06.001; de la Rosa IA, 2020, HAEMATOLOGICA, V105, P2250, DOI 10.3324/haematol.2018.205047; De Melo P, 2021, J IMMUNOL, V207, P902, DOI 10.4049/jimmunol.2001251; Deng FH, 2021, J CROHNS COLITIS, V15, P665, DOI 10.1093/ecco-jcc/jjaa214; Dennis EA, 2015, NAT REV IMMUNOL, V15, P511, DOI 10.1038/nri3859; Ding JL, 2021, THERANOSTICS, V11, P5813, DOI 10.7150/thno.58731; Donate PB, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017120118; Dooley J, 2012, EUR J IMMUNOL, V42, P1073, DOI 10.1002/eji.201142305; Dufey E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15694-y; Durcan L, 2019, LANCET, V393, P2332, DOI 10.1016/S0140-6736(19)30237-5; Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005; Epelman S, 2014, IMMUNITY, V41, P21, DOI 10.1016/j.immuni.2014.06.013; Escate R, 2018, FASEB J, V32, P601, DOI [10.1096/fj.201700476R, 10.1096/fj.201700476RR]; Fafian-Labora JA, 2020, TRENDS CELL BIOL, V30, P628, DOI 10.1016/j.tcb.2020.05.003; FALLOON J, 1986, J ALLERGY CLIN IMMUN, V77, P653, DOI 10.1016/0091-6749(86)90404-5; Feehan KT, 2019, TRENDS MOL MED, V25, P198, DOI 10.1016/j.molmed.2019.01.006; Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2; Firestein GS, 2017, IMMUNITY, V46, P183, DOI 10.1016/j.immuni.2017.02.006; Fox S, 2010, J INNATE IMMUN, V2, P216, DOI 10.1159/000284367; Fu MM, 2021, BIOENGINEERED, V12, P2550, DOI 10.1080/21655979.2021.1935405; Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39; Funes SC, 2018, IMMUNOLOGY, V154, P186, DOI 10.1111/imm.12910; Gajeton J, 2021, J CELL MOL MED, V25, P2549, DOI 10.1111/jcmm.16224; Gomez I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14043-y; Gomez JL, 2020, AM J RESP CRIT CARE, V202, P51, DOI 10.1164/rccm.201912-2360OC; Gonzalez-Quiroz M, 2020, TRENDS CELL BIOL, V30, P881, DOI 10.1016/j.tcb.2020.09.002; Goodwin AJ, 2020, AM J PHYSIOL-LUNG C, V318, pL1261, DOI 10.1152/ajplung.00494.2019; Gordon S, 2017, BMC BIOL, V15, DOI 10.1186/s12915-017-0392-4; Greenlee-Wacker MC, 2014, J IMMUNOL, V192, P4709, DOI 10.4049/jimmunol.1302692; Grolleau-Julius A, 2010, CLIN REV ALLERG IMMU, V39, P42, DOI 10.1007/s12016-009-8169-3; Guo F, 2018, J CELL MOL MED, V22, P5062, DOI 10.1111/jcmm.13790; Haynes L, 2006, IMMUNITY, V24, P663, DOI 10.1016/j.immuni.2006.06.003; Headland SE, 2015, SEMIN IMMUNOL, V27, P149, DOI 10.1016/j.smim.2015.03.014; Hegewald AB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585282; Heward JA, 2014, TRENDS IMMUNOL, V35, P408, DOI 10.1016/j.it.2014.07.005; Hidalgo A, 2019, TRENDS IMMUNOL, V40, P584, DOI 10.1016/j.it.2019.04.013; Hilhorst M, 2015, J AM SOC NEPHROL, V26, P2314, DOI 10.1681/ASN.2014090903; Hook M, 2018, BBA-MOL BASIS DIS, V1864, P2718, DOI 10.1016/j.bbadis.2018.01.026; Hsu AY, 2019, P NATL ACAD SCI USA, V116, P18561, DOI 10.1073/pnas.1905221116; Huang YL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193502; Ivanovska I, 2008, CELL CYCLE, V7, P3137, DOI 10.4161/cc.7.20.6923; Ivashkiv LB, 2013, TRENDS IMMUNOL, V34, P216, DOI 10.1016/j.it.2012.11.001; Jeannin P, 2008, CURR OPIN IMMUNOL, V20, P530, DOI 10.1016/j.coi.2008.04.013; Jetten N, 2014, ANGIOGENESIS, V17, P109, DOI 10.1007/s10456-013-9381-6; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Jones HR, 2016, SEMIN IMMUNOL, V28, P137, DOI 10.1016/j.smim.2016.03.007; Jorch SK, 2017, NAT MED, V23, P279, DOI 10.1038/nm.4294; Kadota T, 2018, MOL ASPECTS MED, V60, P92, DOI 10.1016/j.mam.2017.11.005; Kambara H, 2018, CELL REP, V22, P2924, DOI 10.1016/j.celrep.2018.02.067; Karshovska E, 2020, ARTERIOSCL THROM VAS, V40, P583, DOI 10.1161/ATVBAHA.119.313290; Kessenbrock K, 2009, NAT MED, V15, P623, DOI 10.1038/nm.1959; Kim C, 2018, CELL REP, V25, P2148, DOI 10.1016/j.celrep.2018.10.074; Kim MH, 2011, BLOOD, V117, P3343, DOI 10.1182/blood-2010-07-296970; Kingsley SMK, 2017, INT REV IMMUNOL, V36, P154, DOI 10.1080/08830185.2017.1284212; Kitching AR, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0204-y; Klausen P, 2004, J LEUKOCYTE BIOL, V75, P569, DOI 10.1189/jlb.1003474; Knight JS, 2012, CURR OPIN RHEUMATOL, V24, P441, DOI 10.1097/BOR.0b013e3283546703; Kobayashi H, 2014, MOL MED REP, V9, P9, DOI 10.3892/mmr.2013.1755; Kolaczkowska E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7673; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kong XH, 2021, J BIOL REG HOMEOS AG, V35, P921, DOI 10.23812/20-604-A; Kotas ME, 2015, CELL, V160, P816, DOI 10.1016/j.cell.2015.02.010; Kreiner E, 2017, J ALLERGY CLIN IMMUN, V140, P771, DOI 10.1016/j.jaci.2016.10.055; Kuznetsova T, 2020, NAT REV CARDIOL, V17, P216, DOI 10.1038/s41569-019-0265-3; Lawrence SM, 2020, TRENDS IMMUNOL, V41, P531, DOI 10.1016/j.it.2020.03.008; Lee JW, 2019, AUTOPHAGY, V15, P753, DOI 10.1080/15548627.2018.1556946; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; Lee KH, 2017, AUTOIMMUN REV, V16, P1160, DOI 10.1016/j.autrev.2017.09.012; Leuti A, 2020, ADV DRUG DELIVER REV, V159, P133, DOI 10.1016/j.addr.2020.06.028; Ley K, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat4579; Li B, 2018, CELL MOL IMMUNOL, V15, P595, DOI 10.1038/cmi.2018.7; Liao TL, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95028-0; Liechty C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093328; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; Lin CM, 2021, EUR J NUTR, V60, P4345, DOI 10.1007/s00394-021-02593-1; Linhares-Lacerda L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59486-2; Liu CH, 2017, NAT IMMUNOL, V18, P1175, DOI 10.1038/ni.3828; Locati M, 2020, ANNU REV PATHOL-MECH, V15, P123, DOI 10.1146/annurev-pathmechdis-012418-012718; Madsen CM, 2017, EUR HEART J, V38, P2478, DOI 10.1093/eurheartj/ehx163; Maes T, 2016, J ALLERGY CLIN IMMUN, V137, P1433, DOI 10.1016/j.jaci.2016.02.018; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; de los Reyes-Garcia AM, 2019, BIOMED REP, V10, P195, DOI 10.3892/br.2019.1187; Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166; Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107; Mayne K, 2020, FRONT AGING NEUROSCI, V12, DOI 10.3389/fnagi.2020.572090; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Megens RTA, 2012, THROMB HAEMOSTASIS, V107, P597, DOI 10.1160/TH11-09-0650; Meiler S, 2015, ARTERIOSCL THROM VAS, V35, P323, DOI 10.1161/ATVBAHA.114.304878; Merx MW, 2007, CIRCULATION, V116, P793, DOI 10.1161/CIRCULATIONAHA.106.678359; Metzemaekers M, 2020, CELL MOL IMMUNOL, V17, P433, DOI 10.1038/s41423-020-0412-0; Mills KHG, 2011, NAT REV IMMUNOL, V11, P807, DOI 10.1038/nri3095; Lopes TCM, 2020, INFLAMM RES, V69, P1163, DOI 10.1007/s00011-020-01398-y; Muller PA, 2014, CELL, V158, P300, DOI 10.1016/j.cell.2014.04.050; Munoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Mussbacher M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00085; Nakano H, 2009, NAT IMMUNOL, V10, P394, DOI 10.1038/ni.1707; Natoli G, 2011, GENE DEV, V25, P101, DOI 10.1101/gad.2018811; Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716; Netea MG, 2021, NAT IMMUNOL, V22, P254, DOI 10.1038/s41590-020-00846-5; Newson J, 2017, CELL REP, V20, P3162, DOI 10.1016/j.celrep.2017.08.098; Nguyen GT, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00373; Ni J, 2017, NAT REV GASTRO HEPAT, V14, P573, DOI 10.1038/nrgastro.2017.88; Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Onali S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040344; Pan Y, 2019, J CLIN INVEST, V129, P834, DOI 10.1172/JCI123069; Parihar SP, 2018, MUCOSAL IMMUNOL, V11, P496, DOI 10.1038/mi.2017.68; Parkhurst CN, 2013, CELL, V155, P1596, DOI 10.1016/j.cell.2013.11.030; Pasca S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00625; Pashangzadeh S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.669382; Peake JM, 2007, J NUTR BIOCHEM, V18, P357, DOI 10.1016/j.jnutbio.2006.10.005; Pillay J, 2010, BLOOD, V116, P625, DOI 10.1182/blood-2010-01-259028; Poznyak A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051835; Prattichizzo F, 2021, CYTOKINE GROWTH F R, V58, P141, DOI 10.1016/j.cytogfr.2020.07.013; Quero L, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03087; Ray Katrina, 2012, Nat Rev Rheumatol, V8, P501, DOI 10.1038/nrrheum.2012.123; Remmerie A, 2018, CELL IMMUNOL, V330, P27, DOI 10.1016/j.cellimm.2018.01.020; Ren BD, 2019, APOPTOSIS, V24, P892, DOI 10.1007/s10495-019-01567-3; Roffel MP, 2021, AM J PHYSIOL-LUNG C, V321, pL1091, DOI 10.1152/ajplung.00252.2021; Schmid-Schonbein GW, 2006, ANNU REV BIOMED ENG, V8, P93, DOI 10.1146/annurev.bioeng.8.061505.095708; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429; Sherer Y, 2004, SEMIN ARTHRITIS RHEU, V34, P501, DOI 10.1016/j.semarthrit.2004.07.002; Shi ZG, 2019, EUR REV MED PHARMACO, V23, P5432, DOI 10.26355/eurrev_201906_18212; Sica A, 2014, HEPATOLOGY, V59, P2034, DOI 10.1002/hep.26754; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Silvestre-Roig C, 2020, NAT REV CARDIOL, V17, P327, DOI 10.1038/s41569-019-0326-7; Silvestre-Roig C, 2016, BLOOD, V127, P2173, DOI 10.1182/blood-2016-01-688887; Smith E, 2008, J IMMUNOL, V181, P1357, DOI 10.4049/jimmunol.181.2.1357; Smith S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120798; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Sockrider M, 2020, AM J RESP CRIT CARE, V202, pP25, DOI 10.1164/rccm.2029P25; Soehnlein O, 2017, NAT REV IMMUNOL, V17, P248, DOI 10.1038/nri.2017.10; Spengler J, 2015, ARTHRITIS RHEUMATOL, V67, P3135, DOI 10.1002/art.39313; Stark MA, 2005, IMMUNITY, V22, P285, DOI 10.1016/j.immuni.2005.01.011; Stewart AG, 2016, BRIT J PHARMACOL, V173, P631, DOI 10.1111/bph.13389; Su SC, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9523; Summers C, 2010, TRENDS IMMUNOL, V31, P318, DOI 10.1016/j.it.2010.05.006; Sun Y, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108576; Suzuki K, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9060223; Tabas I, 2020, CIRC RES, V126, P1209, DOI 10.1161/CIRCRESAHA.119.315939; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tajbakhsh A, 2019, TRENDS ENDOCRIN MET, V30, P672, DOI 10.1016/j.tem.2019.07.006; Takeuch O, 2011, EUR J IMMUNOL, V41, P2490, DOI 10.1002/eji.201141792; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Talari M, 2017, MOL IMMUNOL, V82, P1, DOI 10.1016/j.molimm.2016.12.014; Tian F, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/6894684; Tiedt S, 2017, CIRC RES, V121, P970, DOI 10.1161/CIRCRESAHA.117.311572; Tofts PS, 2011, BLOOD, V117, P6050, DOI 10.1182/blood-2010-10-310532; Uderhardt S, 2012, IMMUNITY, V36, P834, DOI 10.1016/j.immuni.2012.03.010; Van den Bossche J, 2014, CURR OPIN LIPIDOL, V25, P367, DOI 10.1097/MOL.0000000000000109; Van Roosbroeck K, 2017, ADV CANCER RES, V135, P119, DOI 10.1016/bs.acr.2017.06.002; Varela ML, 2018, INFLAMMATION, V41, P1115, DOI 10.1007/s10753-018-0739-1; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Vergadi E, 2014, J IMMUNOL, V192, P394, DOI 10.4049/jimmunol.1300959; von Bruhl ML, 2012, J EXP MED, V209, P819, DOI 10.1084/jem.20112322; Wakim LM, 2011, NATURE, V471, P629, DOI 10.1038/nature09863; Wang DL, 2018, CARDIOVASC RES, V114, P1794, DOI 10.1093/cvr/cvy132; Wang JK, 2019, CANCER LETT, V454, P134, DOI 10.1016/j.canlet.2019.04.015; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Wang Z, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115855; Wei YY, 2018, CIRCULATION, V138, P2007, DOI 10.1161/CIRCULATIONAHA.117.031589; Wei YY, 2016, CELL MOL LIFE SCI, V73, P3473, DOI 10.1007/s00018-016-2254-6; Wei YY, 2015, ARTERIOSCL THROM VAS, V35, P796, DOI 10.1161/ATVBAHA.114.304723; Wei YY, 2013, CIRCULATION, V127, P1609, DOI 10.1161/CIRCULATIONAHA.112.000736; Weindel CG, 2015, AUTOPHAGY, V11, P1010, DOI 10.1080/15548627.2015.1052206; Wu ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072593; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Xu DH, 2019, J CELL PHYSIOL, V234, P1502, DOI 10.1002/jcp.27014; Xu WJ, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01374-4; Xu YY, 2020, MOL THER, V28, P202, DOI 10.1016/j.ymthe.2019.09.008; Yang BB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.756825; Yang HX, 2020, EUR REV MED PHARMACO, V24, P9139, DOI 10.26355/eurrev_202009_22861; Yin C, 2018, CELL TISSUE RES, V371, P455, DOI 10.1007/s00441-017-2731-8; Ying HJ, 2015, J IMMUNOL, V194, P1239, DOI 10.4049/jimmunol.1402088; Ying W, 2021, CELL METAB, V33, P781, DOI 10.1016/j.cmet.2020.12.019; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhang FX, 2018, BIOMED PHARMACOTHER, V104, P645, DOI 10.1016/j.biopha.2018.05.068; Zhang L, 2020, J AUTOIMMUN, V109, DOI 10.1016/j.jaut.2020.102438; Zhang Q, 2021, GENES-BASEL, V12, DOI 10.3390/genes12050760; Zhang YG, 2019, CELL CYCLE, V18, P2674, DOI 10.1080/15384101.2019.1654797; Zhong Y, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160105; Zhu JM, 2019, THERANOSTICS, V9, P6901, DOI 10.7150/thno.37357; Zhu YH, 2017, CELL DEATH DIFFER, V24, P2199, DOI 10.1038/cdd.2017.151; Zigmond E, 2013, TRENDS IMMUNOL, V34, P162, DOI 10.1016/j.it.2013.02.001	226	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								901166	10.3389/fimmu.2022.901166	http://dx.doi.org/10.3389/fimmu.2022.901166			20	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M3LR	35634335	gold, Green Published			2022-12-18	WOS:000799875000001
J	Zhang, BB; Zhao, JA; Jiang, MJ; Peng, DD; Dou, XB; Song, Y; Shi, JP				Zhang, Binbin; Zhao, Jianan; Jiang, Minjie; Peng, Dandan; Dou, Xiaobing; Song, Yu; Shi, Junping			The Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment	FRONTIERS IN IMMUNOLOGY			English	Review						metabolic-associated fatty liver disease; gut microbial-derived exosomes; therapeutic approaches; insulin resistance; intestinal barrier; inflammatory response; lipid metabolism; liver fibrosis	OUTER-MEMBRANE VESICLES; EXTRACELLULAR VESICLES; COMMUNICATION; BACTERIA; CANCER; CELLS; TRANSLOCATION; INFLAMMATION; INHIBITION; EXPRESSION	The prevalence and incidence of metabolic-associated fatty liver disease (MAFLD), a clinically heterogeneous disease whose primary clinical therapies include dietary control and exercise therapy, is increasing worldwide and constitutes a significant medical burden. Gut microbes influence the physiopathological processes of the liver through different mechanisms based on the gut-liver axis. Exosomes are essential carriers of intercellular communication. Most previous studies have focused on adipocyte- and hepatocyte-derived exosomes, while the critical role of microbial-derived exosomes and the molecular mechanisms behind them in MAFLD have received little attention. Therefore, we searched and screened the latest relevant studies in the PubMeb database to elucidate the link between microbial-derived exosomes and the pathogenesis of MAFLD, mainly in terms of insulin resistance, intestinal barrier, inflammatory response, lipid metabolism, and liver fibrosis. The aim was to provide a theoretical framework and support for clinical protocols and innovative drug development.	[Zhang, Binbin; Peng, Dandan; Shi, Junping] Hangzhou Normal Univ, Dept Translat Med Platform, Affiliated Hosp, Hangzhou, Peoples R China; [Zhang, Binbin; Jiang, Minjie; Dou, Xiaobing; Song, Yu] Zhejiang Univ Tradit Chinese Med, Hangzhou, Peoples R China; [Zhao, Jianan] Shanghai Univ Tradit Chinese Med, Guanghua Clin Med Coll, Shanghai, Peoples R China; [Zhao, Jianan] Shanghai Univ Tradit Chinese Med, Shanghai Guanghua Hosp, Dept Rheumatol, Shanghai, Peoples R China; [Zhao, Jianan] Shanghai Acad Tradit Chinese Med, Inst Arthrit Res Integrat Med, Shanghai, Peoples R China; [Shi, Junping] Hangzhou Normal Univ, Affiliated Hosp, Metab Dis Ctr, Dept Infect & Hepatol Dis, Hangzhou, Peoples R China	Hangzhou Normal University; Zhejiang Chinese Medical University; Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine; Hangzhou Normal University	Shi, JP (corresponding author), Hangzhou Normal Univ, Dept Translat Med Platform, Affiliated Hosp, Hangzhou, Peoples R China.; Dou, XB; Song, Y (corresponding author), Zhejiang Univ Tradit Chinese Med, Hangzhou, Peoples R China.; Shi, JP (corresponding author), Hangzhou Normal Univ, Affiliated Hosp, Metab Dis Ctr, Dept Infect & Hepatol Dis, Hangzhou, Peoples R China.	xbdou77@163.com; songyu@zcmu.edu.cn; 20131004@hznu.edu.cn	Zhao, Jianan/GHS-3389-2022; Zhao, Jianan/GNW-6751-2022	Zhao, Jianan/0000-0002-8439-1082; 	National Natural Science Funds of China [81570524]; Zhejiang Provincial Basic Public Welfare Research Project [GF20H030035]; Major Projects of Hangzhou Medical and Health Science and Technology Program [0020191059]	National Natural Science Funds of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Basic Public Welfare Research Project; Major Projects of Hangzhou Medical and Health Science and Technology Program	Funding This work was funded by the National Natural Science Funds of China (81570524), Zhejiang Provincial Basic Public Welfare Research Project (GF20H030035), Major Projects of Hangzhou Medical and Health Science and Technology Program (0020191059).	Amar J, 2011, EMBO MOL MED, V3, P559, DOI 10.1002/emmm.201100159; Badi SA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01610; Bittel M, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12159; Blasco-Baque V, 2017, DIABETOLOGIA, V60, P690, DOI 10.1007/s00125-017-4209-3; Brown L, 2015, NAT REV MICROBIOL, V13, P620, DOI 10.1038/nrmicro3480; Chang CS, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0554-5; Chatterjee D, 2013, J BIOL CHEM, V288, P4299, DOI 10.1074/jbc.M112.408302; Chen Y, 2019, BIOCHEM BIOPH RES CO, V509, P767, DOI 10.1016/j.bbrc.2018.12.180; Choi Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep15878; Couzin J, 2005, SCIENCE, V308, P1862, DOI 10.1126/science.308.5730.1862; Dalmasso G, 2010, DIFFERENTIATION, V80, P147, DOI 10.1016/j.diff.2010.06.005; Davani-Davari D, 2019, FOODS, V8, DOI 10.3390/foods8030092; Deng LL, 2020, MICROB PATHOGENESIS, V147, DOI 10.1016/j.micpath.2020.104353; Depommier C, 2020, GUT MICROBES, V11, P1231, DOI 10.1080/19490976.2020.1737307; Depommier C, 2019, NAT MED, V25, P1096, DOI 10.1038/s41591-019-0495-2; Devhare PB, 2018, MOL ASPECTS MED, V60, P115, DOI 10.1016/j.mam.2017.11.001; Di Ciaula A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082648; Dorairaj V, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111494; El Kaoutari A, 2013, NAT REV MICROBIOL, V11, P497, DOI 10.1038/nrmicro3050; Ellis TN, 2010, MICROBIOL MOL BIOL R, V74, P81, DOI 10.1128/MMBR.00031-09; Erridge C, 2007, AM J CLIN NUTR, V86, P1286, DOI 10.1093/ajcn/86.5.1286; Eslam M, 2020, J HEPATOL, V73, P202, DOI 10.1016/j.jhep.2020.03.039; Felli C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091907; Gao H, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28239-2; Gu L, 2019, SHOCK, V51, P256, DOI 10.1097/SHK.0000000000001129; Hirsova P, 2016, HEPATOLOGY, V64, P2219, DOI 10.1002/hep.28814; Hou X, 2021, HEPATOLOGY, V74, P116, DOI 10.1002/hep.31658; Hughes DT, 2008, NAT REV MICROBIOL, V6, P111, DOI 10.1038/nrmicro1836; Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029; Jia L, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4878; Jones EJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00057; Fabrega MJ, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00705; Kaparakis-Liaskos M, 2015, NAT REV IMMUNOL, V15, P375, DOI 10.1038/nri3837; Lakshmi S, 2021, EUR J CANCER, V144, P252, DOI 10.1016/j.ejca.2020.11.033; Lee EY, 2007, PROTEOMICS, V7, P3821, DOI 10.1002/pmic.200790083; Leti F, 2015, TRANSL RES, V166, P304, DOI 10.1016/j.trsl.2015.04.014; Li CJ, 2020, THERANOSTICS, V10, P7422, DOI 10.7150/thno.42167; Li DT, 2016, BIOTECHNOL ADV, V34, P1210, DOI 10.1016/j.biotechadv.2016.08.003; Li L, 2011, HEPATOLOGY, V54, P1620, DOI 10.1002/hep.24552; Li S, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-018-0263-x; Lin X, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116582; Lindenmeyer CC, 2018, CLIN LIVER DIS, V22, P11, DOI 10.1016/j.cld.2017.08.003; Liu HP, 2015, EUR J IMMUNOL, V45, P1010, DOI 10.1002/eji.201444726; Luo ZL, 2021, GASTROENTEROLOGY, V160, P863, DOI 10.1053/j.gastro.2020.10.042; Macia L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010107; Malaguarnera M, 2012, DIGEST DIS SCI, V57, P545, DOI 10.1007/s10620-011-1887-4; Mendez-Sanchez N, 2021, LANCET GASTROENTEROL, V6, P65, DOI [10.1016/S2468-1253(20)30340-X, 10.1016/S2468-1253(20)30340-x]; Morad G, 2019, ACS NANO, V13, P13853, DOI 10.1021/acsnano.9b04397; Mouries J, 2019, J HEPATOL, V71, P1216, DOI 10.1016/j.jhep.2019.08.005; Nabavi S, 2014, J DAIRY SCI, V97, P7386, DOI 10.3168/jds.2014-8500; Nah G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56662-x; Ni YQ, 2020, AGING DIS, V11, P164, DOI 10.14336/AD.2019.0402; Nikoopour E, 2015, CYTOKINE, V74, P35, DOI 10.1016/j.cyto.2014.09.007; Olsen I, 2015, J ORAL MICROBIOL, V7, DOI 10.3402/jom.v7.27468; Ortiz S, 2014, J CLIN ENDOCR METAB, V99, P2575, DOI 10.1210/jc.2013-4483; Pant K, 2017, REDOX BIOL, V12, P340, DOI 10.1016/j.redox.2017.03.006; Portincasa P, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10010083; Povero D, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004512; Raftar SKA, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00484-21; Rahman K, 2016, GASTROENTEROLOGY, V151, P733, DOI 10.1053/j.gastro.2016.06.022; Riley DR, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003107; Rivera CA, 2007, J HEPATOL, V47, P571, DOI 10.1016/j.jhep.2007.04.019; Roden M, 2004, NEWS PHYSIOL SCI, V19, P92, DOI 10.1152/nips.01459.2003; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Rowland I, 2018, EUR J NUTR, V57, P1, DOI 10.1007/s00394-017-1445-8; Safdar A, 2016, NAT REV ENDOCRINOL, V12, P504, DOI 10.1038/nrendo.2016.76; Sanjabi S, 2009, CURR OPIN PHARMACOL, V9, P447, DOI 10.1016/j.coph.2009.04.008; Schertzer JW, 2013, J MOL MICROB BIOTECH, V23, P118, DOI 10.1159/000346770; Schnabl B, 2014, GASTROENTEROLOGY, V146, P1513, DOI 10.1053/j.gastro.2014.01.020; Schneeberger M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16643; Seeger T, 2014, OBESITY, V22, P2352, DOI 10.1002/oby.20852; Shen Y, 2012, CELL HOST MICROBE, V12, P509, DOI 10.1016/j.chom.2012.08.004; Shiha G, 2021, LANCET GASTROENTEROL, V6, P73, DOI 10.1016/S2468-1253(20)30294-6; Shiha G, 2021, LANCET GASTROENTEROL, V6, P57, DOI 10.1016/S2468-1253(20)30213-2; Singh N, 2012, INT J BIOL SCI, V8, P171, DOI 10.7150/ijbs.8.171; Soderblom T, 2005, CELL MICROBIOL, V7, P779, DOI 10.1111/j.1462-5822.2005.00510.x; Sumida Y, 2018, J GASTROENTEROL, V53, P362, DOI 10.1007/s00535-017-1415-1; Toyofuku M, 2019, NAT REV MICROBIOL, V17, P13, DOI 10.1038/s41579-018-0112-2; Tulkens J, 2020, NAT PROTOC, V15, P40, DOI 10.1038/s41596-019-0236-5; Tulkens J, 2020, GUT, V69, P191, DOI 10.1136/gutjnl-2018-317726; Wang SH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0625-1; Wang W, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00581-2; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yang XY, 2020, INT J BIOL SCI, V16, P2357, DOI 10.7150/ijbs.46405; Yu YJ, 2018, ACTA PHARMACOL SIN, V39, P514, DOI 10.1038/aps.2017.82; Zhang J, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abh1541; Zhang J, 2015, CANCER RES, V75, P1859, DOI 10.1158/0008-5472.CAN-14-1254; Zhang L, 2019, BBA-REV CANCER, V1871, P455, DOI 10.1016/j.bbcan.2019.04.004; Zhao JA, 2021, CELL MOL BIOL LETT, V26, DOI 10.1186/s11658-021-00254-z; Zimmermann M, 2019, NATURE, V570, P462, DOI 10.1038/s41586-019-1291-3	90	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 11	2022	13								893617	10.3389/fimmu.2022.893617	http://dx.doi.org/10.3389/fimmu.2022.893617			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6BX	35634340	Green Published, gold			2022-12-18	WOS:000800053500001
J	Banham, GD; Lee, CYC; Ferdinand, JR; Matthews, RJ; Jing, CZ; Smithers, N; Prinjha, RK; Clatworthy, MR				Banham, Gemma D.; Lee, Colin Y. C.; Ferdinand, John R.; Matthews, Rebeccah J.; Jing, Chenzhi; Smithers, Nicholas; Prinjha, Rab K.; Clatworthy, Menna R.			Bromodomain Inhibitors Modulate Fc?R-Mediated Mononuclear Phagocyte Activation and Chemotaxis	FRONTIERS IN IMMUNOLOGY			English	Article						BET inhibitors; systemic lupus erythematosus (SLE); Fc gamma-receptor; dendritic cell chemotaxis; antibody-mediated inflammation	SYSTEMIC-LUPUS-ERYTHEMATOSUS; DENDRITIC CELL-MIGRATION; TUMOR-NECROSIS-FACTOR; GAMMA-RIIB; EFFICIENT PRESENTATION; SOLUBLE-ANTIGEN; BET PROTEIN; RECEPTOR; CLEARANCE; MACROPINOCYTOSIS	IgG antibodies form immune complexes (IC) that propagate inflammation and tissue damage in autoimmune diseases such as systemic lupus erythematosus. IgG IC engage Fc gamma receptors (Fc gamma R) on mononuclear phagocytes (MNP), leading to widespread changes in gene expression that mediate antibody effector function. Bromodomain and extra-terminal domain (BET) proteins are involved in governing gene transcription. We investigated the capacity of BET protein inhibitors (iBET) to alter IgG Fc gamma R-mediated MNP activation. We found that iBET dampened IgG IC-induced pro-inflammatory gene expression and decreased activating Fc gamma R expression on MNPs, reducing their ability to respond to IgG IC. Despite Fc gamma R downregulation, iBET-treated macrophages demonstrated increased phagocytosis of protein antigen, IgG IC, and apoptotic cells. iBET also altered cell morphology, generating more amoeboid MNPs with reduced adhesion. iBET treatment impaired chemotaxis towards a CCL19 gradient in IC-stimulated dendritic cells (DC) in vitro, and inhibited IC-induced DC migration to draining lymph nodes in vivo, in a DC-intrinsic manner. Altogether, our data show that iBET modulates Fc gamma R-mediated MNP activation and migration, revealing the therapeutic potential of BET protein inhibition in antibody-mediated diseases.	[Banham, Gemma D.; Lee, Colin Y. C.; Ferdinand, John R.; Matthews, Rebeccah J.; Jing, Chenzhi; Clatworthy, Menna R.] Univ Cambridge, Med Res Council, Dept Med, Mol Immun Unit,Lab Mol Biol, Cambridge, England; [Lee, Colin Y. C.; Clatworthy, Menna R.] Wellcome Sanger Inst, Cellular Genet, Cambridge, England; [Smithers, Nicholas; Prinjha, Rab K.] GlaxoSmithKline, Immuno Inflammat Ctr Excellence Drug Discovery, Med Res Ctr, Epinova DPU, Stevenage, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Cambridge; Wellcome Trust Sanger Institute; GlaxoSmithKline	Clatworthy, MR (corresponding author), Univ Cambridge, Med Res Council, Dept Med, Mol Immun Unit,Lab Mol Biol, Cambridge, England.; Clatworthy, MR (corresponding author), Wellcome Sanger Inst, Cellular Genet, Cambridge, England.	mrc38@cam.ac.uk		Lee, Colin/0000-0001-8380-4917	GSK; Wellcome Translational Medicine and Therapeutics [102728/z/13/z]; Gates Cambridge scholarship; University of Cambridge School of Clinical Medicine; National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre; NIHR Blood and Transplant Research Unit in Organ Donation [NIHR BTRU-2014-10027]; Medical Research Council New Investigator Research [MR/N024907/1]; Arthritis Research UK Cure Challenge Research [21777]	GSK(GlaxoSmithKline); Wellcome Translational Medicine and Therapeutics; Gates Cambridge scholarship; University of Cambridge School of Clinical Medicine; National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre(National Institute for Health Research (NIHR)); NIHR Blood and Transplant Research Unit in Organ Donation; Medical Research Council New Investigator Research(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Arthritis Research UK Cure Challenge Research	This study received funding from GSK for RNA sequencing experiments. GSK was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. GB was funded by a Wellcome Translational Medicine and Therapeutics PhD grant (102728/z/13/z). CL was funded by the Gates Cambridge scholarship and University of Cambridge School of Clinical Medicine. JF, RM, CJ, and MC were supported by the National Institute of Health Research (NIHR) Cambridge Biomedical Research Centre and the NIHR Blood and Transplant Research Unit in Organ Donation (NIHR BTRU-2014-10027), and MC by a Medical Research Council New Investigator Research Grant (MR/N024907/1) and an Arthritis Research UK Cure Challenge Research Grant (21777).	Andrieu G, 2016, CANCER RES, V76, P6555, DOI 10.1158/0008-5472.CAN-16-0559; Aronin CEP, 2017, IMMUNITY, V47, P862, DOI 10.1016/j.immuni.2017.10.020; Bagley JA, 2014, GENE DEV, V28, P1940, DOI 10.1101/gad.239962.114; Bakdash G, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00053; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bandukwala HS, 2012, P NATL ACAD SCI USA, V109, P14532, DOI 10.1073/pnas.1212264109; Belkina AC, 2013, J IMMUNOL, V190, P3670, DOI 10.4049/jimmunol.1202838; Berry MR, 2017, CELL, V170, P860, DOI 10.1016/j.cell.2017.07.022; Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; Bolland S, 2000, IMMUNITY, V13, P277, DOI 10.1016/S1074-7613(00)00027-3; Boross P, 2011, J IMMUNOL, V187, P1304, DOI 10.4049/jimmunol.1101194; Brown CC, 2019, CELL, V179, P846, DOI 10.1016/j.cell.2019.09.035; Brownlie RJ, 2008, J EXP MED, V205, P883, DOI 10.1084/jem.20072565; Burgdorf S, 2008, CURR OPIN IMMUNOL, V20, P89, DOI 10.1016/j.coi.2007.12.002; Chan CH, 2015, EUR J IMMUNOL, V45, P287, DOI 10.1002/eji.201444862; Clatworthy MR, 2014, NAT MED, V20, P1458, DOI 10.1038/nm.3709; Clatworthy MR, 2004, J EXP MED, V199, P717, DOI 10.1084/jem.20032197; Crispin JC, 2012, CLIN IMMUNOL, V143, P45, DOI 10.1016/j.clim.2011.12.004; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; Dalby E, 2020, J IMMUNOL, V205, P102, DOI 10.4049/jimmunol.1901382; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Decker P, 2006, RHEUMATOLOGY, V45, P1087, DOI 10.1093/rheumatology/kel061; Ding DC, 2006, J IMMUNOL, V177, P5878, DOI 10.4049/jimmunol.177.9.5878; Duan QM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aah5084; Filippakopoulos P, 2020, SCIENCE, V368, P367, DOI 10.1126/science.abb5060; Floto RA, 2005, NAT MED, V11, P1056, DOI 10.1038/nm1288; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Fu WX, 2014, ELIFE, V3, DOI 10.7554/eLife.04631; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Gaipl US, 2007, J AUTOIMMUN, V28, P114, DOI 10.1016/j.jaut.2007.02.005; Gerl V, 2010, ANN RHEUM DIS, V69, P1370, DOI 10.1136/ard.2009.111021; Haessler U, 2011, P NATL ACAD SCI USA, V108, P5614, DOI 10.1073/pnas.1014920108; Harada Y, 2012, BLOOD, V119, P4451, DOI 10.1182/blood-2012-01-407098; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Huang MC, 2017, BRIT J PHARMACOL, V174, P101, DOI 10.1111/bph.13657; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Jing CZ, 2020, P NATL ACAD SCI USA, V117, P15160, DOI 10.1073/pnas.2000943117; Jung KH, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0260-5; Junker F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01393; Kibbie J, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005808; Kono H, 2005, HUM MOL GENET, V14, P2881, DOI 10.1093/hmg/ddi320; Leroy G, 2008, MOL CELL, V30, P51, DOI 10.1016/j.molcel.2008.01.018; Licht R, 1999, J IMMUNOL METHODS, V223, P237, DOI 10.1016/S0022-1759(98)00212-9; Lim JP, 2011, IMMUNOL CELL BIOL, V89, P836, DOI 10.1038/icb.2011.20; Lucas M, 2005, J IMMUNOL, V175, P469, DOI 10.4049/jimmunol.175.1.469; Morgado-Pascual JL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01315; Maier B, 2020, NATURE, V580, P257, DOI 10.1038/s41586-020-2134-y; Mele DA, 2013, J EXP MED, V210, P2181, DOI 10.1084/jem.20130376; Middleton SA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35653-4; Munoz LE, 2005, RHEUMATOLOGY, V44, P1101, DOI 10.1093/rheumatology/keh693; Munoz LE, 2010, NAT REV RHEUMATOL, V6, P280, DOI 10.1038/nrrheum.2010.46; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Nimmerjahn F, 2007, ADV IMMUNOL, V96, P179, DOI 10.1016/S0065-2776(07)96005-8; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Prinjha RK, 2012, TRENDS PHARMACOL SCI, V33, P146, DOI 10.1016/j.tips.2011.12.002; Rahman A, 2008, NEW ENGL J MED, V358, P929, DOI 10.1056/NEJMra071297; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Scheinecker C, 2001, ARTHRITIS RHEUM, V44, P856, DOI 10.1002/1529-0131(200104)44:4<856::AID-ANR142>3.0.CO;2-A; Schilderink R, 2016, MOL IMMUNOL, V79, P66, DOI 10.1016/j.molimm.2016.09.010; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; Seal J, 2012, BIOORG MED CHEM LETT, V22, P2968, DOI 10.1016/j.bmcl.2012.02.041; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002; Sun YL, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.621093; Tal O, 2011, J EXP MED, V208, P2141, DOI 10.1084/jem.20102392; Toniolo PA, 2015, J IMMUNOL, V194, P3180, DOI 10.4049/jimmunol.1401635; van Montfoort N, 2012, J IMMUNOL, V189, P92, DOI 10.4049/jimmunol.1103703; Wang LM, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0124-9; Wang N, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00384-4; Willcocks LC, 2010, P NATL ACAD SCI USA, V107, P7881, DOI 10.1073/pnas.0915133107; Zhong Q, 2018, J IMMUNOL, V200, P3913, DOI 10.4049/jimmunol.1701756; Zinselmeyer BH, 2008, INFLAMM RES, V57, P93, DOI 10.1007/s00011-007-7195-y	80	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								885101	10.3389/fimmu.2022.885101	http://dx.doi.org/10.3389/fimmu.2022.885101			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8GH	35619690	Green Published, gold			2022-12-18	WOS:000804963900001
J	Cariaco, Y; Almeida, MPO; Araujo, ECB; Briceno, MPP; Duran-Rodriguez, AT; Franco, RR; Espindola, FS; Silva, NM				Cariaco, Yusmaris; Almeida, Marcos Paulo Oliveira; Araujo, Ester Cristina Borges; Briceno, Marisol Patricia Pallete; Duran-Rodriguez, Andrea Tatiana; Franco, Rodrigo Rodrigues; Espindola, Foued Salmen; Silva, Neide Maria			Inhibition of Heme Oxygenase-1 by Zinc Protoporphyrin IX Improves Adverse Pregnancy Outcomes in Malaria During Early Gestation	FRONTIERS IN IMMUNOLOGY			English	Article						HO-1; malaria; pregnancy; uterine natural killer cells; iron overload; ferroptosis; ZnPPIX	NATURAL-KILLER-CELLS; MATERNAL-FETAL INTERFACE; EXPRESSION; IRON; QUANTITATION; PROTECTION; INFECTION; DEATH; GPX4	The enzyme heme oxygenase-1 (HO-1) has cytoprotective effects by catalyzing the degradation of heme to produce carbon monoxide, iron and biliverdin. Furthermore, HO-1 activity has been associated with successful pregnancy. On the other hand, in the context of certain inflammatory conditions, HO-1 can induce iron overload and cell death. To investigate the role of HO-1 in gestational malaria, pregnant BALB/c mice were infected with Plasmodium berghei ANKA in early, mid and late gestation. We found that malaria affected the pregnancy outcome in the three periods evaluated. However, only poor pregnancy outcomes in early pregnancy were related to HO-1 upregulation, iron overload, lipid peroxidation and necrosis of the decidua, which were prevented by HO-1 inhibition. In conclusion, HO-1 expression must be finely tuned in gestational malaria to avoid the deleterious effect of increased enzyme activity.	[Cariaco, Yusmaris; Almeida, Marcos Paulo Oliveira; Araujo, Ester Cristina Borges; Briceno, Marisol Patricia Pallete; Duran-Rodriguez, Andrea Tatiana; Silva, Neide Maria] Univ Fed Uberlandia, Inst Biomed Sci, Lab Immunopathol, Uberlandia, Brazil; [Franco, Rodrigo Rodrigues; Espindola, Foued Salmen] Univ Fed Uberlandia, Inst Biotechnol, Lab Biochem & Mol Biol, Uberlandia, Brazil	Universidade Federal de Uberlandia; Universidade Federal de Uberlandia	Silva, NM (corresponding author), Univ Fed Uberlandia, Inst Biomed Sci, Lab Immunopathol, Uberlandia, Brazil.	nmsilva@ufu.br	Almeida, Marcos/GVT-3119-2022; Pallete, Marisol/GPG-1554-2022	Almeida, Marcos/0000-0003-3835-1925; Pallete Briceno, Marisol/0000-0002-7875-1686; Borges Araujo, Ester Cristina/0000-0001-7053-6757; Cariaco, Yusmaris/0000-0003-3473-3555	Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES) [001]	Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG), and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). In addition, this study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES), Finance Code 001. N.M. Silva is research fellow from CNPq.	Abrams ET, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-39; Akanbi O M, 2010, Afr J Reprod Health, V14, P209; Ali AA, 2011, PARASITE VECTOR, V4, DOI 10.1186/1756-3305-4-88; Amaral EP, 2019, J EXP MED, V216, P556, DOI 10.1084/jem.20181776; [Anonymous], 2012, MALARIA J, DOI DOI 10.1186/1475-2875-11-112; Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5; Barateiro A, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01369; Barber EM, 2003, J IMMUNOL, V171, P37, DOI 10.4049/jimmunol.171.1.37; Bolon B., 2014, GUIDE INVESTIGATION, P175, DOI 10.1016/B978-0-12-394445-0.00014-X; Boonyapranai K, 2021, J PARASITOL RES, V2021, DOI 10.1155/2021/1896997; Botelho-Nevers E, 2005, ANN TROP MED PARASIT, V99, P715, DOI 10.1179/136485905X65099; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brigelius-Flohe R, 2013, BBA-GEN SUBJECTS, V1830, P3289, DOI 10.1016/j.bbagen.2012.11.020; BROSENS I, 1967, J PATHOL BACTERIOL, V93, P569, DOI 10.1002/path.1700930218; Campbell NK, 2021, NAT REV IMMUNOL, V21, P411, DOI 10.1038/s41577-020-00491-x; Cartwright JE, 2010, REPRODUCTION, V140, P803, DOI 10.1530/REP-10-0294; Chaiyaroj SC, 2004, ACTA TROP, V89, P319, DOI 10.1016/j.actatropica.2003.10.010; Costa DL, 2021, MUCOSAL IMMUNOL, V14, P253, DOI 10.1038/s41385-020-00342-x; De Beaudrap P, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-139; de Lima JP, 2021, J ETHNOPHARMACOL, V268, DOI 10.1016/j.jep.2020.113667; Deroost K, 2016, FEMS MICROBIOL REV, V40, P208, DOI 10.1093/femsre/fuv046; Desai M, 2007, LANCET INFECT DIS, V7, P93, DOI 10.1016/S1473-3099(07)70021-X; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dutra FF, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00115; Duvigneau JC, 2008, LAB INVEST, V88, P70, DOI 10.1038/labinvest.3700691; Duvigneau JC, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8100475; Erlebacher A., 2014, GUIDE INVESTIGATION, P227, DOI [10.1016/B978-0-12-394445-0.00019-9, DOI 10.1016/B978-0-12-394445-0.00019-9]; Fernandez-Mendivil C, 2021, REDOX BIOL, V38, DOI 10.1016/j.redox.2020.101789; FINN CA, 1967, J REPROD FERTIL, V13, P259; Fisher AL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24333-z; GABAY T, 1993, EXP PARASITOL, V77, P261, DOI 10.1006/expr.1993.1084; Gallardo V, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2019.07.016; Gomez-Lopez N, 2010, J LEUKOCYTE BIOL, V88, P625, DOI 10.1189/jlb.1209796; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Hirschhorn T, 2019, FREE RADICAL BIO MED, V133, P130, DOI 10.1016/j.freeradbiomed.2018.09.043; Hunt NH, 2007, NAT MED, V13, P667, DOI 10.1038/nm0607-667; Huy NT, 2005, ANAL BIOCHEM, V344, P289, DOI 10.1016/j.ab.2005.06.022; Imai H, 2003, BIOCHEM BIOPH RES CO, V305, P278, DOI 10.1016/S0006-291X(03)00734-4; Imai H, 2017, CURR TOP MICROBIOL, V403, P143, DOI 10.1007/82_2016_508; Iyer JK, 2003, MOL MED, V9, P175, DOI 10.1007/BF03402182; Kaislasuo J, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13195; Kieckbusch J, 2015, CELL REP, V13, P2817, DOI 10.1016/j.celrep.2015.11.050; Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162; Latchoumycandane C, 2012, J BIOL CHEM, V287, P17693, DOI 10.1074/jbc.M111.300012; Li C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01120; Linzke N, 2014, HYPERTENSION, V63, P580, DOI 10.1161/HYPERTENSIONAHA.113.02403; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; Maurya VK, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.640907; Meyer N, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00711; Meyer N, 2017, SCI REP-UK, V7, DOI 10.1038/srep45106; Moffett-King A, 2002, NAT REV IMMUNOL, V2, P656, DOI 10.1038/nri886; Mu JW, 2008, REPROD BIOL ENDOCRIN, V6, DOI 10.1186/1477-7827-6-34; Najjar N, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12614; Neres R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001608; Almeida MPO, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.659028; Ordi J, 2001, J INFECT DIS, V183, P1100, DOI 10.1086/319295; Othoro C, 2008, INFECT IMMUN, V76, P1678, DOI 10.1128/IAI.01420-07; Padua TA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01835; Paffaro VA, 2003, PLACENTA, V24, P479, DOI 10.1053/plac.2002.0919; Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586; Pang SC., 2014, GUIDE INVESTIGATION, P3, DOI [10.1016/B978-0-12-394445-0.00001-1, DOI 10.1016/B978-0-12-394445-0.00001-1]; Pawlak JB, 2019, J CLIN INVEST, V129, P4912, DOI 10.1172/JCI120446; Penha-Goncalves C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00155; Pereira MLM, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4158698; Salifu Hassana, 2016, SOJ Microbiol Infect Dis, V4, DOI 10.15226/sojmid/4/2/00154; Sarr Demba, 2017, Immunohorizons, V1, P29, DOI 10.4049/immunohorizons.1700002; Sartelet H, 2005, PLACENTA, V26, P505, DOI 10.1016/j.placenta.2004.08.006; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schmiegelow C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053794; Schumacher A, 2015, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00288; Sharma L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032694; Simmons DG., 2014, GUIDE INVESTIGATION, P143; SLATER AFG, 1992, EXP PARASITOL, V74, P362, DOI 10.1016/0014-4894(92)90162-4; Smith CDM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55588-8; St-Germain LE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113776; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; Suttner DM, 1999, FASEB J, V13, P1800, DOI 10.1096/fasebj.13.13.1800; Tachibana M, 2008, MICROB PATHOGENESIS, V45, P105, DOI 10.1016/j.micpath.2008.04.002; Tachibana M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025046; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Terry CM, 1998, AM J PHYSIOL-HEART C, V274, pH883, DOI 10.1152/ajpheart.1998.274.3.H883; Tseng AM, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201800252; Vento-Tormo R, 2018, NATURE, V563, P347, DOI 10.1038/s41586-018-0698-6; Wang WJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02025; WHO, 2018, WORLD MAL REP 2018; Woods L, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00570; Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014; Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010; Yant LJ, 2003, FREE RADICAL BIO MED, V34, P496, DOI 10.1016/S0891-5849(02)01360-6; Zenclussen AC, 2005, INT IMMUNOPHARMACOL, V5, P41, DOI 10.1016/j.intimp.2004.09.011; Zenclussen Ana Claudia, 2007, Expert Reviews in Molecular Medicine, V9, DOI 10.1017/S1462399407000294; Zenclussen ML, 2015, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00291; Zenclussen ML, 2011, J PATHOL, V225, P293, DOI 10.1002/path.2946; Zhao H, 2009, PLACENTA, V30, P861, DOI 10.1016/j.placenta.2009.07.012; Zhao H, 2011, BIOL REPROD, V85, P1005, DOI 10.1095/biolreprod.111.093039	96	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								879158	10.3389/fimmu.2022.879158	http://dx.doi.org/10.3389/fimmu.2022.879158			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S3DE	35619717	gold, Green Published			2022-12-18	WOS:000803934100001
J	Chang, CM; Peng, KY; Chan, CK; Lin, YF; Liao, HW; Chang, JG; Wu, MS; Wu, VC; Chang, WC				Chang, Che-Mai; Peng, Kang-Yung; Chan, Chieh-Kai; Lin, Yu-Feng; Liao, Hung-Wei; Chang, Jan-Gowth; Wu, Mai-Szu; Wu, Vin-Cent; Chang, Wei-Chiao			Divergent Characteristics of T-Cell Receptor Repertoire Between Essential Hypertension and Aldosterone-Producing Adenoma	FRONTIERS IN IMMUNOLOGY			English	Article						hypertension; aldosterone-producing adenoma (APA); high-throughput sequencing; T-cell receptor (TCR); TCR repertoire; Taiwan Primary Aldosteronism Investigation (TAIPAI)	SOMATIC MUTATIONS; INFLAMMATION; DIAGNOSIS; ATP1A1; HEART	Aldosterone-producing adenoma (APA) is a benign adrenal tumor that results in persistent hyperaldosteronism. As one major subtype of primary aldosteronism, APA leads to secondary hypertension that is associated with immune dysregulation. However, how the adaptive immune system, particularly the T-cell population, is altered in APA patients remains largely unknown. Here, we performed TCR sequencing to characterize the TCR repertoire between two age-matched groups of patients: one with APA and the other one with essential hypertension (EH). Strikingly, we found a significant reduction of TCR repertoire diversity in the APA group. Analyses on TCR clustering and antigen annotation further showed that the APA group possessed lower diversity in TCR clonotypes with non-common antigen-specific features, compared with the EH group. In addition, our results indicated that the strength of correlation between generation probabilities and frequencies of TCR clonotypes was significantly higher in the APA group than that in the EH group. Finally, we observed that clinical features, including plasma aldosterone level, aldosterone-renin ratio, and blood sodium level, were positively associated with the strength of correlation between generation and abundance of TCR clonotypes in the APA group. Our findings unveiled the correlation between T-cell immune repertoire and APA, suggesting a critical role of such adrenal adenoma in the T-cell immunity of patients with hypertension.	[Chang, Che-Mai] Taipei Med Univ, Coll Med Sci & Technol, Ph D Program Med Biotechnol, Taipei, Taiwan; [Peng, Kang-Yung; Chan, Chieh-Kai; Lin, Yu-Feng; Wu, Vin-Cent] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan; [Peng, Kang-Yung; Wu, Vin-Cent] Taiwan Primary Aldosteronism Invest TAIPAI Study G, TAIPAI, Taipei, Taiwan; [Liao, Hung-Wei] Dept Nephrol, Chinru Clin, Taipei, Taiwan; [Chang, Jan-Gowth] China Med Univ Hosp, Epigenome Res Ctr, Taichung, Taiwan; [Chang, Jan-Gowth] China Med Univ, Sch Med, Taichung, Taiwan; [Wu, Mai-Szu] Taipei Med Univ Shuang HoHospital, Dept Internal Med, Div Nephrol, New Taipei City, Taiwan; [Wu, Mai-Szu] Taipei Med Univ, Coll Med, Sch Med, Dept Internal Med, Taipei, Taiwan; [Wu, Mai-Szu] Taipei Med Univ, Res Ctr Urol & Kidney TMU RCUK, TMU, Taipei, Taiwan; [Wu, Vin-Cent] Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei, Taipei, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Wanfang Hosp, Integrat Res Ctr Crit Care, Dept Pharm, Taipei, Taiwan; [Chang, Wei-Chiao] Taipei Med Univ, Shuang Ho Hosp, Dept Med Res, New Taipei City, Taiwan	Taipei Medical University; National Taiwan University; National Taiwan University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Taipei Medical University; Taipei Medical University; National Taiwan University; National Taiwan University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Municipal WanFang Hospital; Taipei Medical University	Wu, VC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan.; Wu, VC (corresponding author), Taiwan Primary Aldosteronism Invest TAIPAI Study G, TAIPAI, Taipei, Taiwan.; Wu, VC (corresponding author), Natl Taiwan Univ Hosp, Dept Internal Med, Div Nephrol, Taipei, Taiwan.; Chang, WC (corresponding author), Taipei Med Univ, Sch Pharm, Master Program Clin Pharmacogen & Pharmacoprote, Taipei, Taiwan.; Chang, WC (corresponding author), Taipei Med Univ, Sch Pharm, Dept Clin Pharm, Taipei, Taipei, Taiwan.; Chang, WC (corresponding author), Taipei Med Univ, Wanfang Hosp, Integrat Res Ctr Crit Care, Dept Pharm, Taipei, Taiwan.; Chang, WC (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Dept Med Res, New Taipei City, Taiwan.	q91421028@ntu.edu.tw; wcc@tmu.edu.tw		Chan, Chieh-Kai/0000-0003-4529-3161	Ministry of Science and Technology, Taiwan [106-2314-B-002-166-MY3, 107-2314-B-002-026-MY3, 106-2321-B-182-002, 105-2628-B-038-001-MY4, 109-2628-B-038-012, MOST 110-2321-B-038-002]; National Taiwan University Hospital [105-S3061, 107-S3809, UN103-082, UN106-014, 105-P05, 106-P02, 107-T02]	Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, TaiwanMinistry of Science, ICT & Future Planning, Republic of Korea); National Taiwan University Hospital(National Taiwan University)	This work was supported by grants from the Ministry of Science and Technology, Taiwan (106-2314-B-002-166-MY3, 107-2314-B-002-026-MY3, 106-2321-B-182-002, 105-2628-B-038-001-MY4, 109-2628-B-038-012, MOST 110-2321-B-038-002 - Establishing A Translational Female Cancer Biomedical Big Data Bank and Developing Precision Medicine Healthcare System), and National Taiwan University Hospital (105-S3061, 107-S3809, UN103-082, UN106-014, 105-P05, 106-P02, 107-T02).	Azizan EAB, 2013, NAT GENET, V45, P1055, DOI 10.1038/ng.2716; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Beuschlein F, 2013, NAT GENET, V45, P440, DOI 10.1038/ng.2550; Bolen CR, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1556-5; Byrd JB, 2018, CIRCULATION, V138, P823, DOI 10.1161/CIRCULATIONAHA.118.033597; Catena C, 2008, ARCH INTERN MED, V168, P80, DOI 10.1001/archinternmed.2007.33; Chan CK, 2019, SURGERY, V166, P362, DOI 10.1016/j.surg.2019.05.001; Chan CK, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2239-y; Chang CM, 2021, J CLIN IMMUNOL, V41, P1131, DOI 10.1007/s10875-021-01045-z; Chang CM, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.136; Fagugli RM, 2011, INT J HYPERTENS, V2011, DOI 10.4061/2011/162804; Fernandes-Rosa FL, 2020, TRENDS MOL MED, V26, P819, DOI 10.1016/j.molmed.2020.05.005; Fernandes-Rosa FL, 2014, HYPERTENSION, V64, P354, DOI 10.1161/HYPERTENSIONAHA.114.03419; Ferreira NS, 2021, AM J HYPERTENS, V34, P15, DOI 10.1093/ajh/hpaa137; Glanville J, 2017, NATURE, V547, P94, DOI 10.1038/nature22976; Greene EL, 1996, J CLIN INVEST, V98, P1063, DOI 10.1172/JCI118867; Guo LP, 2020, J PATHOL, V251, P26, DOI 10.1002/path.5396; Herrada AA, 2011, J HYPERTENS, V29, P1684, DOI 10.1097/HJH.0b013e32834a4c75; Herrada AA, 2010, J IMMUNOL, V184, P191, DOI 10.4049/jimmunol.0802886; Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4; Kasal DA, 2012, HYPERTENSION, V59, P324, DOI 10.1161/HYPERTENSIONAHA.111.181123; Kotlyar E, 2006, J CARD FAIL, V12, P122, DOI 10.1016/j.cardfail.2005.08.005; Krysan K, 2019, CANCER RES, V79, P5022, DOI 10.1158/0008-5472.CAN-19-0153; Krysiak R, 2012, HYPERTENS RES, V35, P123, DOI 10.1038/hr.2011.142; Marney AM, 2007, CLIN SCI, V113, P267, DOI 10.1042/CS20070123; Minervina AA, 2021, ELIFE, V10, DOI 10.7554/eLife.63502; Monticone S, 2018, LANCET DIABETES ENDO, V6, P41, DOI 10.1016/S2213-8587(17)30319-4; Monticone S, 2017, J AM COLL CARDIOL, V69, P1811, DOI 10.1016/j.jacc.2017.01.052; Munoz-Durango N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/652738; Nanba K, 2018, J CLIN ENDOCR METAB, V103, P3869, DOI 10.1210/jc.2018-01004; Peng KY, 2020, HYPERTENSION, V76, P1537, DOI 10.1161/HYPERTENSIONAHA.120.15328; Pogorelyy MV, 2018, P NATL ACAD SCI USA, V115, P12704, DOI 10.1073/pnas.1809642115; Reincke M, 2012, HYPERTENSION, V60, P618, DOI 10.1161/HYPERTENSIONAHA.112.197111; Scholl UI, 2015, CLIN ENDOCRINOL, V83, P779, DOI 10.1111/cen.12873; Seidel E, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0337-9; Sethna Z, 2019, BIOINFORMATICS, V35, P2974, DOI 10.1093/bioinformatics/btz035; Sun Y, 2002, AM J PATHOL, V161, P1773, DOI 10.1016/S0002-9440(10)64454-9; Tauber P, 2016, ENDOCRINOLOGY, V157, P2489, DOI 10.1210/en.2015-2029; Wong HSC, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0349-5; Wu VC, 2017, J FORMOS MED ASSOC, V116, P993, DOI 10.1016/j.jfma.2017.06.004; Wu VC, 2015, SCI REP-UK, V5, DOI 10.1038/srep11396; Xanthakis V, 2013, CURR HYPERTENS REP, V15, P102, DOI 10.1007/s11906-013-0330-y	42	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								853403	10.3389/fimmu.2022.853403	http://dx.doi.org/10.3389/fimmu.2022.853403			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M9IF	35619691	Green Published, gold			2022-12-18	WOS:000800278000001
J	Feng, RY; Lu, MN; Liu, L; Xu, K; Xu, P				Feng, Ruoyang; Lu, Mengnan; Liu, Lin; Xu, Ke; Xu, Peng			Transcriptome-Wide Association Studies and Integration Analysis of mRNA Expression Profiles Identify Candidate Genes and Pathways Associated With Ankylosing Spondylitis	FRONTIERS IN IMMUNOLOGY			English	Article						ankylosing spondylitis; genome-wide association study (GWAS); transcriptome-wide association study (TWAS); mRNA expression profile; susceptibility genes	INDUCTION; HLA-B27	This study aimed to identify susceptibility genes and pathways associated with ankylosing spondylitis (AS) by integrating whole transcriptome-wide association study (TWAS) analysis and mRNA expression profiling data. AS genome-wide association study (GWAS) summary data from the large GWAS database were used. This included data of 1265 AS patients and 452264 controls. A TWAS of AS was conducted using these data. The analysis software used was FUSION, and Epstein-Barr virus-transformed lymphocytes, transformed fibroblasts, peripheral blood, and whole blood were used as gene expression references. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed for the important genes identified via TWAS. Protein-protein interaction (PPI) network analysis based on the STRING database was also performed to detect genes shared by TWAS and mRNA expression profiles in AS. TWAS identified 920 genes (P <0.05) and analyzed mRNA expression profiles to obtain 1183 differential genes. Following comparison of the TWAS results and mRNA expression characteristics, we obtained 70 overlapping genes and performed GO and KEGG enrichment analyses of these genes to obtain 16 pathways. Via PPI network analysis, we obtained the protein interaction network and performed MCODE analysis to acquire the HUB genes. Similarly, we performed GO and KEGG analyses on the genes identified by TWAS, obtained 98 pathways after screening, and analyzed protein interactions via the PPI network. Through the integration of TWAS and mRNA expression analysis, genes related to AS and GO and KEGG terms were determined, providing new evidence and revealing the pathogenesis of AS. Our AS TWAS work identified novel genes associated with AS, as well as suggested potential tissues and pathways of action for these TWAS AS genes, providing a new direction for research into the pathogenesis of AS.	[Feng, Ruoyang; Liu, Lin; Xu, Ke; Xu, Peng] Xi An Jiao Tong Univ, Hong Hui Hosp, Dept Joint Surg, Xian, Peoples R China; [Lu, Mengnan] Xi An Jiao Tong Univ, Dept Pediat, Affiliated Hosp 2, Xian, Peoples R China	Xi'an Jiaotong University; Xi'an Jiaotong University	Xu, P (corresponding author), Xi An Jiao Tong Univ, Hong Hui Hosp, Dept Joint Surg, Xian, Peoples R China.	sousou369@163.com			National Natural Scientific Foundation	National Natural Scientific Foundation(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Scientific Foundation of China (82072432, 81772410).	Alessandri C, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1385-y; Arends S, 2011, OSTEOPOROSIS INT, V22, P1431, DOI 10.1007/s00198-010-1338-7; Bhattacharya A, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1942-6; Canela-Xandri O, 2018, NAT GENET, V50, P1593, DOI 10.1038/s41588-018-0248-z; Canver MC, 2017, NAT GENET, V49, P625, DOI 10.1038/ng.3793; Collado-Torres L, 2019, NEURON, V103, P203, DOI 10.1016/j.neuron.2019.05.013; Cronan JE, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00510; de Winter JJ, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1093-z; Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873; Glossop JR, 2017, EPIGENOMICS-UK, V9, P419, DOI [10.2217/epi-2016-0042, 10.2217/epi-2016-0144]; Guo Li, 2011, Chin J Cancer, V30, P336; Gusev A, 2019, NAT GENET, V51, P815, DOI 10.1038/s41588-019-0395-x; Gusev A, 2018, NAT GENET, V50, P538, DOI 10.1038/s41588-018-0092-1; Gusev A, 2016, NAT GENET, V48, P245, DOI 10.1038/ng.3506; Hua LQ, 2013, J VIROL, V87, P11884, DOI 10.1128/JVI.01461-13; Inoue T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-98865-1; Jensen LJ, 2009, NUCLEIC ACIDS RES, V37, pD412, DOI 10.1093/nar/gkn760; Kucuksezer UC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.622306; Kuhne M, 2009, ARTHRITIS RHEUM-US, V60, P1635, DOI 10.1002/art.24549; Lee SH, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2071; Li LL, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018-020-02064-z; Li ZX, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008038; Lin ZM, 2012, NAT GENET, V44, P73, DOI 10.1038/ng.1005; Ma H, 2020, CANCER MED-US, V9, P5258, DOI 10.1002/cam4.3148; Ma M, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.663080; Nancy Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.624632; Paladini F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00035; Porcu E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10936-0; Qian HY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.559593; Reveille JD, 2010, NAT GENET, V42, P123, DOI 10.1038/ng.513; Santos SG, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2492; Scoville SD, 2016, IMMUNITY, V44, P1140, DOI 10.1016/j.immuni.2016.04.007; Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140-6736(16)31591-4; Simone D, 2018, RHEUMATOLOGY, V57, P4, DOI 10.1093/rheumatology/key001; Sun B, 2020, BRIEF BIOINFORM, V21, P1756, DOI 10.1093/bib/bbz097; Wang CM, 2021, J PERS MED, V11, DOI 10.3390/jpm11060564; Wendling D, 2019, EXPERT OPIN BIOL TH, V19, P55, DOI 10.1080/14712598.2019.1554053; Wu C, 2020, HUM GENET, V139, P199, DOI 10.1007/s00439-019-02098-2; Wu CY, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02419-9; Wu L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17673-9; Xie JM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02151; Xu JW, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02458-2; Ye GW, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02993-x; Zhai Y, 2018, AUTOPHAGY, V14, P1629, DOI 10.1080/15548627.2018.1458804; Zhang J, 2018, EUR J IMMUNOL, V48, P738, DOI 10.1002/eji.201747299; Zhang PY, 2021, CURR PHARM BIOTECHNO, V22, P305, DOI 10.2174/1389201021666200302104418	46	0	0	9	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								814303	10.3389/fimmu.2022.814303	http://dx.doi.org/10.3389/fimmu.2022.814303			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P8SD	35619696	gold, Green Published			2022-12-18	WOS:000802272600001
J	He, D; Liu, LY; Shen, DC; Zou, P; Cui, LY				He, Di; Liu, Liyang; Shen, Dongchao; Zou, Peng; Cui, Liying			The Effect of Peripheral Immune Cell Counts on the Risk of Multiple Sclerosis: A Mendelian Randomization Study	FRONTIERS IN IMMUNOLOGY			English	Article						multiple sclerosis; mendelian randomization (MR); genome wide association study (GWAS); peripheral immune cell count; NKT cell	KILLER T-CELLS; ANTIGEN PRESENTATION; CAUSAL INFERENCE; INNATE IMMUNITY; AUTOIMMUNITY; INSTRUMENTS; MECHANISMS; TRAITS; ROBUST	ObjectivesMultiple sclerosis (MS) is a complex central nervous system (CNS) demyelinating disease, the etiology of which involves the interplay between genetic and environmental factors. We aimed to determine whether genetically predicted peripheral immune cell counts may have a causal effect on MS. MethodsWe used genetic variants strongly associated with cell counts of circulating leukocyte, lymphocyte, monocyte, neutrophil, eosinophil, and basophil, in addition to some subpopulations of T and B lymphocyte, as instrumental variables (IVs) to perform Mendelian randomization (MR) analyses. The effect of immune cell counts on MS risk was measured using the summary statistics from the International Multiple Sclerosis Genetics Consortium (IMSGC) genome-wide association studies (GWAS). ResultsOur findings indicated that higher leucocyte count [odds ratio (OR), 1.24; 95% confidence interval (CI), 1.07 - 1.43; p = 0.0039] and lymphocyte count (OR, 1.17; 95% CI, 1.01 - 1.35; p = 0.0317) were causally associated with MS susceptibility. In addition, we also found that increase of genetically predicted natural killer T (NKT) cell count is also associated with an increase MS risk (OR, 1.24; 95% CI, 1.06 - 1.45; p = 0.0082). ConclusionsThese findings show that the genetic predisposition to higher peripheral immune cell counts can exert a causal effect on MS risk, which confirms the crucial role played by peripheral immunity in MS. Particularly, the causal association between NKT cell count and MS underscores the relevance of exploring the functional roles of NKT cells in disease pathogenesis in future.	[He, Di; Shen, Dongchao; Cui, Liying] Chinese Acad Med Sci Peking Union Med Coll CAMS &, Peking Union Med Coll Hosp PUMCH, Dept Neurol, Beijing, Peoples R China; [Liu, Liyang] Peking Union Med Coll, Peking Union Md Coll M D Program, Beijing, Peoples R China; [Zou, Peng] Beijing Tsinghua Changgung Hosp, Dept Cardiac Surg, Beijing, Peoples R China; [Cui, Liying] Chinese Acad Med Sci Peking Union Med Coll CAMS, Neurosci Ctr, Beijing, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	He, D; Cui, LY (corresponding author), Chinese Acad Med Sci Peking Union Med Coll CAMS &, Peking Union Med Coll Hosp PUMCH, Dept Neurol, Beijing, Peoples R China.; Cui, LY (corresponding author), Chinese Acad Med Sci Peking Union Med Coll CAMS, Neurosci Ctr, Beijing, Peoples R China.	hedi@pumch.cn; pumchcuily@yahoo.com	Liu, Liyang/GQA-4875-2022	Liu, Li-Yang/0000-0001-5352-6258				Baecher-Allan C, 2018, NEURON, V97, P742, DOI 10.1016/j.neuron.2018.01.021; Bowden J, 2017, STAT MED, V36, P1783, DOI 10.1002/sim.7221; Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965; Brownlee WJ, 2017, LANCET, V389, P1336, DOI 10.1016/S0140-6736(16)30959-X; Burgess Stephen, 2019, Wellcome Open Res, V4, P186, DOI 10.12688/wellcomeopenres.15555.1; Burgess S, 2017, EUR J EPIDEMIOL, V32, P377, DOI 10.1007/s10654-017-0255-x; Burgess S, 2017, EPIDEMIOLOGY, V28, P30, DOI 10.1097/EDE.0000000000000559; Carrion B, 2021, NEUROL-NEUROIMMUNOL, V8, DOI 10.1212/NXI.0000000000001065; Casetti R, 2008, CELL MOL IMMUNOL, V5, P161, DOI 10.1038/cmi.2008.20; Chiang CWK, 2018, NAT GENET, V50, P1426, DOI 10.1038/s41588-018-0215-8; Comi G, 2017, LANCET, V389, P1347, DOI 10.1016/S0140-6736(16)32388-1; Cotsapas C, 2018, CELL, V175, P1679, DOI 10.1016/j.cell.2018.09.049; Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328; Dendrou CA, 2015, NAT REV IMMUNOL, V15, P545, DOI 10.1038/nri3871; Dhodapkar MV, 2017, J IMMUNOL, V198, P1015, DOI 10.4049/jimmunol.1601399; Emdin CA, 2017, JAMA-J AM MED ASSOC, V318, P1925, DOI 10.1001/jama.2017.17219; Farh KKH, 2015, NATURE, V518, P337, DOI 10.1038/nature13835; Galvez NMS, 2021, CLIN MICROBIOL REV, V34, DOI 10.1128/CMR.00232-20; Gigli G, 2007, IMMUNOLOGY, V122, P409, DOI 10.1111/j.1365-2567.2007.02655.x; Gutierrez-Arcelus M, 2016, NAT REV GENET, V17, P160, DOI 10.1038/nrg.2015.33; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2020, NEW ENGL J MED, V383, P546, DOI 10.1056/NEJMoa1917246; Hemani G, 2018, HUM MOL GENET, V27, pR195, DOI 10.1093/hmg/ddy163; Illes Z, 2000, J IMMUNOL, V164, P4375, DOI 10.4049/jimmunol.164.8.4375; Jahng A, 2004, J EXP MED, V199, P947, DOI 10.1084/jem.20031389; Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034; Lazaridis I, 2014, NATURE, V513, P409, DOI 10.1038/nature13673; Leadbetter EA, 2021, MOL IMMUNOL, V130, P49, DOI 10.1016/j.molimm.2020.12.005; Lee DSW, 2021, NAT REV DRUG DISCOV, V20, P179, DOI 10.1038/s41573-020-00092-2; Lee YJ, 2013, NAT IMMUNOL, V14, P1146, DOI 10.1038/ni.2731; Lu H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.647588; Madireddy L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09773-y; Miyamoto K, 2001, NATURE, V413, P531, DOI 10.1038/35097097; Mokry LE, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002053; Mokry LE, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001866; Olsson T, 2017, NAT REV NEUROL, V13, P25, DOI 10.1038/nrneurol.2016.187; Orru V, 2020, NAT GENET, V52, P1036, DOI 10.1038/s41588-020-0684-4; Patsopoulos NA, 2019, SCIENCE, V365, P1417, DOI 10.1126/science.aav7188; Sawcer S, 2014, LANCET NEUROL, V13, P700, DOI 10.1016/S1474-4422(14)70041-9; Sawcer S, 2011, NATURE, V476, P214, DOI 10.1038/nature10251; Shamshiev A, 1999, EUR J IMMUNOL, V29, P1667, DOI 10.1002/(SICI)1521-4141(199905)29:05<1667::AID-IMMU1667>3.0.CO;2-U; Singh AK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01969; Smets I, 2018, BRAIN, V141, P786, DOI 10.1093/brain/awx372; Steri M, 2017, NEW ENGL J MED, V376, P1615, DOI 10.1056/NEJMoa1610528; Thompson AJ, 2018, LANCET, V391, P1622, DOI 10.1016/S0140-6736(18)30481-1; Van Kaer L, 2015, IMMUNOLOGY, V146, P1, DOI 10.1111/imm.12485; Vandebergh M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.834644; Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7; Vuckovic D, 2020, CELL, V182, P1214, DOI 10.1016/j.cell.2020.08.008; Wang RX, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-021-03205-6; Xue HR, 2021, AM J HUM GENET, V108, P1251, DOI 10.1016/j.ajhg.2021.05.014; Yuan S, 2021, J NEUROL, V268, P114, DOI 10.1007/s00415-020-10119-8; Zamvil SS, 2021, NEW ENGL J MED, V384, P378, DOI 10.1056/NEJMcibr2032177; Zarobkiewicz MK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179520; Zenewicz LA, 2010, CELL, V140, P791, DOI 10.1016/j.cell.2010.03.003; Zeng P, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1448-9	56	0	0	2	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								867693	10.3389/fimmu.2022.867693	http://dx.doi.org/10.3389/fimmu.2022.867693			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M0NS	35619713	gold, Green Published			2022-12-18	WOS:000799675500001
J	Lellouch, AG; Andrews, AR; Saviane, G; Ng, ZY; Schol, IM; Goutard, M; Gama, AR; Rosales, IA; Colvin, RB; Lantieri, LA; Randolph, MA; Benichou, G; Jr, CCL				Lellouch, Alexandre G.; Andrews, Alec R.; Saviane, Gaelle; Ng, Zhi Yang; Schol, Ilse M.; Goutard, Marion; Gama, Amon-Ra; Rosales, Ivy A.; Colvin, Robert B.; Lantieri, Laurent A.; Randolph, Mark A.; Benichou, Gilles; Cetrulo Jr, Curtis L.			Tolerance of a Vascularized Composite Allograft Achieved in MHC Class-I-mismatch Swine via Mixed Chimerism	FRONTIERS IN IMMUNOLOGY			English	Article						Vascularized composite allotransplantation (VCA); bone marrow transplantation; mixed chimerism; co-stimulatory blockade; skin tolerance; MHC class I	TRANSPLANTATION; RECIPIENTS; INDUCTION; INFECTION; ANTIGEN; KIDNEY; HAND	BackgroundVascularized composite allografts (VCAs) allow reconstruction of devastating injuries and amputations, yet require lifelong immunosuppression that is associated with significant morbidity. Induction of immune tolerance of VCAs would permit widespread use of these procedures. VCAs are acquired from deceased donors most likely to be fully-MHC-mismatched (in contrast to living-related renal transplant donor-recipient pairs matched at one MHC haplotype). After achieving VCA tolerance in a swine model equivalent to clinical living-related renal transplants (single-haplotype MHC mismatches: e.g., "mother-daughter"/haploidentical), we tested our protocol in MHC class I, class II, and fully-MHC-mismatched pairs. Although class II mismatched swine demonstrated similar results as the haploidentical scenario (stable mixed chimerism and tolerance), our protocol failed to prevent rejection of class I and full mismatch VCAs. Here, we describe a new adapted conditioning protocol that successfully achieved tolerance across MHC class-I-mismatch barriers in swine. MethodsSwine were treated with non-myeloablative total body and thymic irradiation two days prior to infusion of bone marrow cells from an MHC class I-mismatched donor. They also received a short-term treatment with CTLA4-Ig (Belatacept (R)) and anti-IL6R mAb (Tociluzimab (R)) and were transplanted with an osteomyocutaneous VCA from the same donor. ResultsStable mixed chimerism and tolerance of MHC class-I-mismatched VCAs was achieved in 3 recipients. Allograft tolerance was associated with a sustained lack of anti-donor T cell response and a concomitant expansion of double negative CD4(-)CD8(-) T cells producing IL-10. ConclusionsThis study demonstrates the first successful mixed chimerism-induced VCA tolerance in a large animal model across a MHC class-I-mismatch. Future studies aimed at fully-mismatched donor-recipient pairs are under investigation with this protocol.	[Lellouch, Alexandre G.; Andrews, Alec R.; Ng, Zhi Yang; Schol, Ilse M.; Goutard, Marion; Randolph, Mark A.; Cetrulo Jr, Curtis L.] Harvard Med Sch, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02115 USA; [Lellouch, Alexandre G.; Andrews, Alec R.; Saviane, Gaelle; Ng, Zhi Yang; Schol, Ilse M.; Goutard, Marion; Gama, Amon-Ra; Randolph, Mark A.; Cetrulo Jr, Curtis L.] Harvard Med Sch, Ctr Transplantat Sci, Massachusetts Gen Hosp, Vascularized Composite Allotransplantat Lab, Boston, MA 02115 USA; [Lellouch, Alexandre G.; Goutard, Marion; Lantieri, Laurent A.] Univ Paris 05, Assistance Publ Hop Paris APHP, Hop Europe Georges Pompidou, Serv Chirurg Plast, Paris, France; [Lellouch, Alexandre G.; Andrews, Alec R.; Saviane, Gaelle; Goutard, Marion; Randolph, Mark A.; Cetrulo Jr, Curtis L.] Harvard Med Sch, Shriners Hosp Children, Boston, MA 02115 USA; [Saviane, Gaelle; Rosales, Ivy A.; Colvin, Robert B.; Benichou, Gilles; Cetrulo Jr, Curtis L.] Harvard Med Sch, Ctr Transplantat Sci, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Jr, CCL (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Div Plast & Reconstruct Surg, Boston, MA 02115 USA.; Jr, CCL (corresponding author), Harvard Med Sch, Ctr Transplantat Sci, Massachusetts Gen Hosp, Vascularized Composite Allotransplantat Lab, Boston, MA 02115 USA.; Jr, CCL (corresponding author), Harvard Med Sch, Shriners Hosp Children, Boston, MA 02115 USA.; Jr, CCL (corresponding author), Harvard Med Sch, Ctr Transplantat Sci, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA.	ccetrulo@mgh.harvard.edu	Ng, Zhi Yang/N-8251-2018	Ng, Zhi Yang/0000-0003-0538-3066	Sundry Fund of the Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital; Shriners Hospitals for Children Boston; Musculoskeletal Transplant Foundation; Office of the Assistant Secretary of Defense for Health Affairs; Defense Health Agency, Research, Development and Acquisition Directorate through the Reconstructive Transplant Research Consortium [W81XWH-13-2-0060, W81XWH- 16-1-0702, W81XWH-17-1-0680]	Sundry Fund of the Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital; Shriners Hospitals for Children Boston; Musculoskeletal Transplant Foundation; Office of the Assistant Secretary of Defense for Health Affairs; Defense Health Agency, Research, Development and Acquisition Directorate through the Reconstructive Transplant Research Consortium	This work was supported by the Sundry Fund of the Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Shriners Hospitals for Children Boston, Musculoskeletal Transplant Foundation, and the Office of the Assistant Secretary of Defense for Health Affairs and the Defense Health Agency, Research, Development and Acquisition Directorate through the Reconstructive Transplant Research Consortium under Award No. (W81XWH-13-2-0060, W81XWH- 16-1-0702 and W81XWH-17-1-0680). Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the DoD.	Ahmed EB, 2011, AM J TRANSPLANT, V11, P936, DOI 10.1111/j.1600-6143.2011.03476.x; Berendsen TA, 2014, NAT MED, V20, P790, DOI 10.1038/nm.3588; Brannstrom M, 2015, LANCET, V385, P2352, DOI 10.1016/S0140-6736(15)61098-4; Cendales LC, 2008, AM J TRANSPLANT, V8, P1396, DOI 10.1111/j.1600-6143.2008.02243.x; Conrad A, 2019, TRANSPL INT, V32, P693, DOI 10.1111/tri.13399; Cooke KR, 2000, TRANSPLANTATION, V70, P272, DOI 10.1097/00007890-200007270-00006; Dubernard JM, 1999, LANCET, V353, P1315, DOI 10.1016/S0140-6736(99)02062-0; Elias N, 2015, CURR OPIN ORGAN TRAN, V20, P406, DOI 10.1097/MOT.0000000000000211; Fuchimoto Y, 1999, TISSUE ANTIGENS, V54, P43, DOI 10.1034/j.1399-0039.1999.540105.x; Hettiaratchy S, 2004, TRANSPLANTATION, V77, P514, DOI 10.1097/01.TP.0000113806.52063.42; Kawai T, 2014, AM J TRANSPLANT, V14, P1599, DOI 10.1111/ajt.12731; Kawai T, 2013, NEW ENGL J MED, V368, P1850, DOI 10.1056/NEJMc1213779; Lantieri L, 2020, LANCET, V396, P1758, DOI 10.1016/S0140-6736(20)32438-7; Leonard DA, 2014, AM J TRANSPLANT, V14, P343, DOI 10.1111/ajt.12560; Leto Barone AA, 2015, VASC COMPOS ALLOTRAN, V2, P1, DOI [10.1080/23723505.2015, DOI 10.1080/23723505.2015.1039692]; Miller ML, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8566; Petruzzo P, 2017, CURR TRANSPL REP, V4, P294, DOI DOI 10.1007/S40472-017-0168-3; Rifkin WJ, 2021, J SURG RES, V258, P17, DOI 10.1016/j.jss.2020.08.006; SACHS DH, 1976, TRANSPLANTATION, V22, P559, DOI 10.1097/00007890-197612000-00004; Shanmugarajah K, 2017, AM J TRANSPLANT, V17, P1729, DOI 10.1111/ajt.14189; Su Charles A, 2014, Curr Transplant Rep, V1, P137; THISTLETHWAITE JR, 1984, J IMMUNOGENET, V11, P9; Tizon R, 2012, BONE MARROW TRANSPL, V47, P1332, DOI 10.1038/bmt.2011.260; van der Merwe A, 2017, LANCET, V390, P1038, DOI 10.1016/S0140-6736(17)31807-X; Wang T, 2010, AM J TRANSPLANT, V10, P1524, DOI 10.1111/j.1600-6143.2010.03066.x	25	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								829406	10.3389/fimmu.2022.829406	http://dx.doi.org/10.3389/fimmu.2022.829406			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S3US	35619720	gold, Green Published			2022-12-18	WOS:000803980000001
J	Liu, WJ; Xing, J; Tang, XQ; Sheng, XZ; Chi, H; Zhan, WB				Liu, Wenjing; Xing, Jing; Tang, Xiaoqian; Sheng, Xiuzhen; Chi, Heng; Zhan, Wenbin			Characterization of Co-Stimulatory Ligand CD80/86 and Its Effect as a Molecular Adjuvant on DNA Vaccine Against Vibrio anguillarum in Flounder (Paralichthys olivaceus)	FRONTIERS IN IMMUNOLOGY			English	Article						CD80; 86; lymphocytes; adaptive immune; adjuvants; flounder	RECOMBINANT PROTEINS; ADAPTIVE IMMUNITY; FISH; CD28; CD86; CONSERVATION; INSIGHTS; FEATURES; ORIGIN; SYSTEM	The CD80/86 molecule is one of the important co-stimulatory ligands and involves antigen-specific immune responses by ligating with CD28 and then delivering the required second signal to T-cell activation. In this study, a CD80/86 homolog was identified, and its expression characteristics were studied in flounder (Paralichthys olivaceus). The open reading frame (ORF) of CD80/86 is 906 bp, encoding 301 aa, and the extracellular amino acid sequence encoded two IgV- and IgC-like structural domains; fCD80/86 is highly expressed in head kidney, peripheral blood leukocytes (PBLs), and spleen, and has relatively high expression in muscle. Antibodies specific for CD80/86 were produced, and CD80/86 was colocalized with MHCII+, CD40+, and CD83+ leukocytes but not with IgM+, CD3+, or CD4+ lymphocytes. The cloned CD80/86 in flounder shares conserved structural features with its mammalian counterparts and is mainly distributed on antigen-presenting cells. Based on these data, CD80/86 as an adjuvant to enhance the immune response of DNA vaccine was investigated. A bicistronic DNA vaccine expressing both CD80/86 and the outer membrane protein (OmpK) of Vibrio anguillarum (p-OmpK-CD80/86) was successfully constructed. After immunization, p-OmpK-CD80/86 could induce the upregulation of the proportion of IgM+ and CD4+ cells in flounder, compared to the p-OmpK- or p-CD80/86-immunized group; CD28 genes were significantly induced in the p-CD80/86 and p-OmpK-CD80/86 groups. Compared to the p-OmpK group, the higher expression of CD83, MHCI, CD4, CD8, and IL-2 was detected at the injection site. The relative percent survival (RPS) produced by p-OmpK-CD80/86 is 66.11% following the V. anguillarum challenge, while the RPS of p-OmpK or p-CD80/86 is 46.30% and 5.56%, respectively. The results revealed that CD80/86 is mainly found in antigen-presenting cells, and could help elicit humoral immune responses in teleost through the CD80/86-CD28 signaling pathway involving CD4+ lymphocytes.	[Liu, Wenjing; Xing, Jing; Tang, Xiaoqian; Sheng, Xiuzhen; Chi, Heng; Zhan, Wenbin] Ocean Univ China, Lab Pathol & Immunol Aquat Anim, Key Lab Mariculture, Minist Educ KLMME, Qingdao, Peoples R China; [Xing, Jing; Tang, Xiaoqian; Zhan, Wenbin] Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China	Ocean University of China; Qingdao National Laboratory for Marine Science & Technology	Xing, J (corresponding author), Ocean Univ China, Lab Pathol & Immunol Aquat Anim, Key Lab Mariculture, Minist Educ KLMME, Qingdao, Peoples R China.; Xing, J (corresponding author), Qingdao Natl Lab Marine Sci & Technol, Lab Marine Fisheries Sci & Food Prod Proc, Qingdao, Peoples R China.	xingjing@ouc.edu.cn			National Key Research and Development Program of China [2018YFD0900503]; National Natural Science Foundation of China [32173005, 31730101, 31672684]; Shandong Provincial Natural Science Foundation [ZR2020KC025]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province)	Funding This work was supported by the National Key Research and Development Program of China (2018YFD0900503), the National Natural Science Foundation of China (32173005, 31730101, 31672684) and the Shandong Provincial Natural Science Foundation (ZR2020KC025).	Awate S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00114; Baliga P, 2018, CURR MICROBIOL, V75, P368, DOI 10.1007/s00284-017-1390-z; Beyersdorf N, 2015, IMMUNOTARGETS THER, V4, P111, DOI 10.2147/ITT.S61647; Bhatia S, 2006, IMMUNOL LETT, V104, P70, DOI 10.1016/j.imlet.2005.11.019; Biller-Takahashi JD, 2014, AN ACAD BRAS CIENC, V86, P1483, DOI 10.1590/0001-3765201420130159; Bour-Jordan H, 2002, J CLIN IMMUNOL, V22, P1, DOI 10.1023/A:1014256417651; Cao YS, 2017, ONCOTARGET, V8, P112222, DOI 10.18632/oncotarget.23095; Chen YT, 2020, CELL IMMUNOL, V352, DOI 10.1016/j.cellimm.2020.104077; Collins C, 2019, FISH SHELLFISH IMMUN, V85, P106, DOI 10.1016/j.fsi.2018.07.012; Collins M, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-6-223; Dalmo RA, 2018, J FISH DIS, V41, P1, DOI 10.1111/jfd.12727; de Haan N, 2020, GLYCOBIOLOGY, V30, P226, DOI 10.1093/glycob/cwz048; Dong Fujing, 2021, Fish Shellfish Immunol Rep, V2, P100030, DOI 10.1016/j.fsirep.2021.100030; Du Xiaogang, 2009, Weishengwu Xuebao, V49, P357; Flajnik MF, 2010, NAT REV GENET, V11, P47, DOI 10.1038/nrg2703; Frans I, 2011, J FISH DIS, V34, P643, DOI 10.1111/j.1365-2761.2011.01279.x; Gong YF, 2009, J IMMUNOL, V182, P7749, DOI 10.4049/jimmunol.0804370; Grunwald T, 2015, CLIN EXP VACCINE RES, V4, P1, DOI 10.7774/cevr.2015.4.1.1; Hansen JD, 2009, MOL IMMUNOL, V46, P457, DOI 10.1016/j.molimm.2008.10.007; Holvold LB, 2014, VET RES, V45, DOI 10.1186/1297-9716-45-21; Hosseini A, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106221; Huang Y, 2018, FISH SHELLFISH IMMUN, V72, P95, DOI 10.1016/j.fsi.2017.10.008; Iiyama M, 2021, MOL IMMUNOL, V131, P51, DOI 10.1016/j.molimm.2020.12.002; Jazayeri SD, 2019, VET RES, V50, DOI 10.1186/s13567-019-0698-z; Kutzler MA, 2008, NAT REV GENET, V9, P776, DOI 10.1038/nrg2432; Lankipalli S, 2021, PROTEIN SCI, V30, P1958, DOI 10.1002/pro.4151; Lee J, 2018, ACTA BIOMATER, V80, P31, DOI 10.1016/j.actbio.2018.08.033; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li HL, 2022, J OCEANOL LIMNOL, V40, P786, DOI 10.1007/s00343-021-1092-z; Li L, 2016, EXPERT REV VACCINES, V15, P313, DOI 10.1586/14760584.2016.1124762; Li Q, 2007, FISH SHELLFISH IMMUN, V23, P982, DOI 10.1016/j.fsi.2007.03.008; Loudon PT, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011021; Magee CN, 2012, AM J TRANSPLANT, V12, P2588, DOI 10.1111/j.1600-6143.2012.04180.x; Maiti B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01362; Marino M, 2011, GENE THER, V18, P109, DOI 10.1038/gt.2010.124; Mir M.A., 2015, DEV COSTIMULATORY MO, P1, DOI [10.1016/b978-0-12-802585-7.00001-7, DOI 10.1016/B978-0-12-802585-7.00001-7]; Mo ZQ, 2017, FISH SHELLFISH IMMUN, V67, P467, DOI 10.1016/j.fsi.2017.05.064; Rauta PR, 2012, IMMUNOL LETT, V148, P23, DOI 10.1016/j.imlet.2012.08.003; Rogeri PS, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.582258; Sansom DM, 2003, TRENDS IMMUNOL, V24, P314, DOI 10.1016/S1471-4906(03)00111-X; Shao T, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01204; Shao T, 2015, DEV COMP IMMUNOL, V49, P38, DOI 10.1016/j.dci.2014.11.010; SHARPE AH, 1995, CURR OPIN IMMUNOL, V7, P389, DOI 10.1016/0952-7915(95)80115-4; Smith NC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02292; Sohn Hanchang, 2019, Fisheries and Aquatic Sciences, V22, P14, DOI 10.1186/s41240-019-0129-0; Subauste CS, 1998, J IMMUNOL, V160, P1831; Tai Y, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00642; Tsuji T, 1997, EUR J IMMUNOL, V27, P782, DOI 10.1002/eji.1830270329; Valenzuela CA, 2017, DEV COMP IMMUNOL, V73, P1, DOI 10.1016/j.dci.2017.03.004; Vasu C, 2003, INT IMMUNOL, V15, P167, DOI 10.1093/intimm/dxg017; Wang H, 2020, FISH SHELLFISH IMMUN, V102, P228, DOI 10.1016/j.fsi.2020.04.026; Wells AD, 2009, J IMMUNOL, V182, P7331, DOI 10.4049/jimmunol.0803917; Xing J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.765036; Xing J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69542-6; Xing J, 2018, MOL IMMUNOL, V104, P79, DOI 10.1016/j.molimm.2018.11.001; Xing J, 2017, VACCINE, V35, P3196, DOI 10.1016/j.vaccine.2017.04.071; Xing J, 2017, MICROB PATHOGENESIS, V107, P155, DOI 10.1016/j.micpath.2017.03.027; Xu G., 2018, BMC INFECT DIS, V18, P1, DOI [10.1186/S12879-018-3258-7/FIGURES/4, DOI 10.1186/S12879-018-3258-7/FIGURES/4]; Xu HS, 2020, DEV COMP IMMUNOL, V103, DOI 10.1016/j.dci.2019.103492; Zhang MM, 2017, ACS BIOMATER SCI ENG, V3, P108, DOI 10.1021/acsbiomaterials.6b00418; Zhang XJ, 2018, DEV COMP IMMUNOL, V89, P73, DOI 10.1016/j.dci.2018.08.007; Zhang YA, 2009, J IMMUNOL, V183, P83, DOI 10.4049/jimmunol.0900605; Zheng Y, 2004, J IMMUNOL, V172, P2778, DOI 10.4049/jimmunol.172.5.2778; Zhu LY, 2014, J IMMUNOL, V192, P2699, DOI 10.4049/jimmunol.1301312	64	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								881753	10.3389/fimmu.2022.881753	http://dx.doi.org/10.3389/fimmu.2022.881753			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P8OU	35619706	gold, Green Published			2022-12-18	WOS:000802263900001
J	Liu, ZB; Liu, Y; Liu, MM; Gong, QJ; Shi, AJ; Li, XH; Bai, X; Guan, XY; Hao, B; Liu, FL; Zhou, X; Yuan, HF				Liu, Zhibin; Liu, Yao; Liu, Mingming; Gong, Qingjia; Shi, Anjie; Li, Xiuhong; Bai, Xu; Guan, Xiaoyue; Hao, Bing; Liu, Feila; Zhou, Xing; Yuan, Hongfeng			PD-L1 Inhibits T Cell-Induced Cytokines and Hyaluronan Expression via the CD40-CD40L Pathway in Orbital Fibroblasts From Patients With Thyroid Associated Ophthalmopathy	FRONTIERS IN IMMUNOLOGY			English	Article						PD-L1; T cell; orbital fibroblast; CD40; thyroid associated ophthalmopathy	GRAVES-DISEASE; SYNTHASE 2; NF-B; CD40; PATHOGENESIS; ACTIVATION; PD-1/PD-L1; INDUCTION; SECRETION; PROLIFERATION	Thyroid associated ophthalmopathy (TAO), characterized by T cell infiltration and orbital fibroblast activation, is an organ-specific autoimmune disease which is still short of effective and safety therapeutic drugs. The PD-1/PD-L1 pathway has been reported hindering the progression of Graves' disease to some extent by inhibiting T cell activity, and tumor therapy with a PD-1 inhibitor caused some adverse effects similar to the symptoms of TAO. These findings suggest that the PD-1/PD-L1 pathway may be associated with the pathogenesis of TAO. However, it remains unknown whether the PD-1/PD-L1 pathway is involved in orbital fibroblast activation. Here, we show that orbital fibroblasts from patients with TAO do not express PD-L1. Based on in vitro OF-T cell co-culture system, exogenous PD-L1 weakens T cell-induced orbital fibroblast activation by inhibiting T cell activity, resulting in reduced production of sICAM-1, IL-6, IL-8, and hyaluronan. Additionally, exogenous PD-L1 treatment also inhibits the expression of CD40 and the phosphorylation levels of MAPK and NF-kappa B pathways in orbital fibroblasts of the OF-T cell co-culture system. Knocking down CD40 with CD40 siRNA or down-regulating the phosphorylation levels of MAPK and NF-kappa B pathways with SB203580, PD98059, SP600125, and PDTC can both reduce the expression of these cytokines and hyaluronan. Our study demonstrates that the orbital immune tolerance deficiency caused by the lack of PD-L1 in orbital fibroblasts may be one of the causes for the active orbital inflammation in TAO patients, and the utilization of exogenous PD-L1 to reconstruct the orbital immune tolerance microenvironment may be a potential treatment strategy for TAO.	[Liu, Zhibin; Liu, Yao; Liu, Mingming; Gong, Qingjia; Shi, Anjie; Li, Xiuhong; Bai, Xu; Guan, Xiaoyue; Hao, Bing; Yuan, Hongfeng] Army Med Univ, Daping Hosp, Dept Ophthalmol, Chongqing, Peoples R China; [Li, Xiuhong; Yuan, Hongfeng] Chongqing Aier Hosp, Dept Ortibal Surg, Chongqing, Peoples R China; [Liu, Feila; Zhou, Xing] Chongqing Univ Technol, Sch Pharm & Bioengn, Chongqing, Peoples R China; [Zhou, Xing] Chongqing Hosp Tradit Chinese Med, Dept Pharm, Chongqing, Peoples R China; [Zhou, Xing] Chongqing Univ Technol, Chongqing Key Lab Med Chem & Mol Pharmacol, Chongqing, Peoples R China	Army Medical University; Chongqing University of Technology; Chongqing University of Technology	Yuan, HF (corresponding author), Army Med Univ, Daping Hosp, Dept Ophthalmol, Chongqing, Peoples R China.; Yuan, HF (corresponding author), Chongqing Aier Hosp, Dept Ortibal Surg, Chongqing, Peoples R China.; Zhou, X (corresponding author), Chongqing Univ Technol, Sch Pharm & Bioengn, Chongqing, Peoples R China.; Zhou, X (corresponding author), Chongqing Hosp Tradit Chinese Med, Dept Pharm, Chongqing, Peoples R China.; Zhou, X (corresponding author), Chongqing Univ Technol, Chongqing Key Lab Med Chem & Mol Pharmacol, Chongqing, Peoples R China.	diszhou@cqut.edu.cn; yhf871@sina.com	Zhou, Xing/X-3497-2019	Zhou, Xing/0000-0003-0852-0687	Chongqing Science and Technology Program [30119-2961]; Talent Innovation Capacity Development Program of Army Medical Center [5012002-3519]; Science and Technology Research Program of Chongqing Municipal Education Commission [KJQN201901138]	Chongqing Science and Technology Program; Talent Innovation Capacity Development Program of Army Medical Center; Science and Technology Research Program of Chongqing Municipal Education Commission	Supported by the Chongqing Science and Technology Program (Grant No. 30119-2961), the Talent Innovation Capacity Development Program of Army Medical Center (Grant No. 5012002-3519) and the Science and Technology Research Program of Chongqing Municipal Education Commission (Grant No. KJQN201901138).	Alvarez-Sierra D, 2019, J AUTOIMMUN, V103, DOI 10.1016/j.jaut.2019.05.013; Banga JP, 2015, HORM METAB RES, V47, P797, DOI 10.1055/s-0035-1555956; Boboridis KG, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007630.pub2; Cao HJ, 1998, J BIOL CHEM, V273, P29615, DOI 10.1074/jbc.273.45.29615; Caon I, 2020, J BIOL CHEM, V295, P3485, DOI 10.1074/jbc.RA119.011982; Chen BL, 2005, J IMMUNOL, V175, P1310, DOI 10.4049/jimmunol.175.2.1310; Cui X, 2020, ELIFE, V9, DOI 10.7554/eLife.52253; Del Prete Gianfranco, 1994, Trends in Microbiology, V2, P4, DOI 10.1016/0966-842X(94)90336-0; Douglas RS, 2010, J CLIN ENDOCR METAB, V95, P430, DOI 10.1210/jc.2009-1614; Feldon SE, 2005, INVEST OPHTH VIS SCI, V46, P3913, DOI 10.1167/iovs.05-0605; Ferrara R, 2018, JAMA ONCOL, V4, P1543, DOI 10.1001/jamaoncol.2018.3676; Fu WY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12321-3; Gillespie EF, 2012, INVEST OPHTH VIS SCI, V53, P7746, DOI 10.1167/iovs.12-9861; Han H, 2020, J TOXICOL SCI, V45, P701, DOI 10.2131/jts.45.701; Han R, 2006, ENDOCRINOLOGY, V147, P13, DOI 10.1210/en.2005-1018; Harigai M, 2004, ARTHRITIS RHEUM-US, V50, P2167, DOI 10.1002/art.20340; Hwang CJ, 2009, INVEST OPHTH VIS SCI, V50, P2262, DOI 10.1167/iovs.08-2328; Kahaly GJ, 2011, J CLIN ENDOCR METAB, V96, P422, DOI 10.1210/jc.2010-1424; Kao JJ, 2006, EXP GERONTOL, V41, P641, DOI 10.1016/j.exger.2006.04.003; Khong JJ, 2016, BRIT J OPHTHALMOL, V100, P142, DOI 10.1136/bjophthalmol-2015-307399; Konstantinidou M, 2018, ANGEW CHEM INT EDIT, V57, P4840, DOI 10.1002/anie.201710407; Kuol N, 2018, IMMUNOTHERAPY-UK, V10, P149, DOI 10.2217/imt-2017-0120; Li H, 2016, MOL MED REP, V14, P2799, DOI 10.3892/mmr.2016.5570; Li YY, 2018, J CELL PHYSIOL, V233, P2590, DOI 10.1002/jcp.26134; Lu S, 2019, JAMA ONCOL, V5, P1195, DOI 10.1001/jamaoncol.2019.1549; Minakaran N, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009226.pub2; Nagayama Y, 2015, CURR OPIN ENDOCRINOL, V22, P381, DOI 10.1097/MED.0000000000000186; Pluvinet R, 2008, BLOOD, V112, P3624, DOI 10.1182/blood-2008-03-143305; Postow MA, 2015, J CLIN ONCOL, V33, P1974, DOI 10.1200/JCO.2014.59.4358; Pyzik A, 2017, MOL CELL ENDOCRINOL, V448, P28, DOI 10.1016/j.mce.2017.03.006; Ruchala M, 2016, EXPERT REV CLIN PHAR, V9, P981, DOI 10.1586/17512433.2016.1165606; Sagiv O, 2019, OPHTHAL PLAST RECONS, V35, P50, DOI 10.1097/IOP.0000000000001161; Sempowski GD, 1998, AM J PHYSIOL-CELL PH, V274, pC707, DOI 10.1152/ajpcell.1998.274.3.C707; Smith TJ, 2019, ENDOCR REV, V40, P236, DOI 10.1210/er.2018-00066; Smith TJ, 2019, ANNU REV PHARMACOL, V59, P129, DOI 10.1146/annurev-pharmtox-010617-052509; St Paul M, 2020, TRENDS CELL BIOL, V30, P695, DOI 10.1016/j.tcb.2020.06.003; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Taylor PN, 2020, NAT REV ENDOCRINOL, V16, P104, DOI 10.1038/s41574-019-0305-4; Terazawa S, 2020, J BIOL CHEM, V295, P7274, DOI 10.1074/jbc.RA119.011139; Ungerer M, 2017, CLIN REV ALLERG IMMU, V52, P182, DOI 10.1007/s12016-016-8562-7; van Steensel L, 2010, INVEST OPHTH VIS SCI, V51, P1002, DOI 10.1167/iovs.09-4338; Vigetti D, 2010, J BIOL CHEM, V285, P24639, DOI 10.1074/jbc.M110.134536; Virakul S, 2016, EXP EYE RES, V147, P85, DOI 10.1016/j.exer.2016.05.005; Vogel JD, 2004, GASTROENTEROLOGY, V126, P63, DOI 10.1053/j.gastro.2003.10.046; Wang X, 2019, CRIT REV CL LAB SCI, V56, P18, DOI 10.1080/10408363.2018.1522292; Watanabe M, 2004, CLIN EXP IMMUNOL, V136, P555, DOI 10.1111/j.1365-2249.2004.02482.x; Wiersinga WM, 2017, LANCET DIABETES ENDO, V5, P134, DOI 10.1016/S2213-8587(16)30046-8; Wu XM, 2019, COMPUT STRUCT BIOTEC, V17, P661, DOI 10.1016/j.csbj.2019.03.006; Xia N, 2006, INT J MOL MED, V17, P911; Yang MG, 2020, TISSUE CELL, V64, DOI 10.1016/j.tice.2020.101343; Zhang C, 2012, ENDOCRINE, V41, P248, DOI 10.1007/s12020-012-9600-8; Zhang L, 2012, J CLIN ENDOCR METAB, V97, P653, DOI 10.1210/jc.2011-1299; Zhao LQ, 2010, INVEST OPHTH VIS SCI, V51, P4652, DOI 10.1167/iovs.09-3789; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	54	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								849480	10.3389/fimmu.2022.849480	http://dx.doi.org/10.3389/fimmu.2022.849480			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N0KA	35619700	Green Published, gold			2022-12-18	WOS:000800351900001
J	Marzella, DF; Parizi, FM; Van Tilborg, D; Renaud, N; Sybrandi, D; Buzatu, R; Rademaker, DT; 't Hoen, PAC; Xue, LC				Marzella, Dario F.; Parizi, Farzaneh M.; Van Tilborg, Derek; Renaud, Nicolas; Sybrandi, Daan; Buzatu, Rafaella; Rademaker, Daniel T.; 't Hoen, Peter A. C.; Xue, Li C.			PANDORA: A Fast, Anchor-Restrained Modelling Protocol for Peptide: MHC Complexes	FRONTIERS IN IMMUNOLOGY			English	Article						peptide:MHC; integrative modelling; computational structural biology; large-scale 3D-modelling; computational immunology	ANTIGEN PRESENTATION; DATABASE; PREDICTION; IPD; IMGT/3DSTRUCTURE-DB; ACCURACY; DOCKING; CELLS; TOOL	Deeper understanding of T-cell-mediated adaptive immune responses is important for the design of cancer immunotherapies and antiviral vaccines against pandemic outbreaks. T-cells are activated when they recognize foreign peptides that are presented on the cell surface by Major Histocompatibility Complexes (MHC), forming peptide:MHC (pMHC) complexes. 3D structures of pMHC complexes provide fundamental insight into T-cell recognition mechanism and aids immunotherapy design. High MHC and peptide diversities necessitate efficient computational modelling to enable whole proteome structural analysis. We developed PANDORA, a generic modelling pipeline for pMHC class I and II (pMHC-I and pMHC-II), and present its performance on pMHC-I here. Given a query, PANDORA searches for structural templates in its extensive database and then applies anchor restraints to the modelling process. This restrained energy minimization ensures one of the fastest pMHC modelling pipelines so far. On a set of 835 pMHC-I complexes over 78 MHC types, PANDORA generated models with a median RMSD of 0.70 angstrom and achieved a 93% success rate in top 10 models. PANDORA performs competitively with three pMHC-I modelling state-of-the-art approaches and outperforms AlphaFold2 in terms of accuracy while being superior to it in speed. PANDORA is a modularized and user-configurable python package with easy installation. We envision PANDORA to fuel deep learning algorithms with large-scale high-quality 3D models to tackle long-standing immunology challenges.	[Marzella, Dario F.; Parizi, Farzaneh M.; Van Tilborg, Derek; Buzatu, Rafaella; Rademaker, Daniel T.; 't Hoen, Peter A. C.; Xue, Li C.] Radboud Inst Mol Life Sci, Ctr Mol & Biomol Informat, Radboudumc, Nijmegen, Netherlands; [Parizi, Farzaneh M.] Univ Tehran, Inst Biochem & Biophys, Tehran, Iran; [Van Tilborg, Derek] Eindhoven Univ Technol, Inst Complex Mol Syst, Dept Biomed Engn, Eindhoven, Netherlands; [Renaud, Nicolas] Nat Sci & Engn Sect, Netherlands Esci Ctr, Amsterdam, Netherlands; [Sybrandi, Daan] Univ Utrecht, Fac Sci Chem, Bijvoet Ctr Biomol Res, Utrecht, Netherlands	Radboud University Nijmegen; University of Tehran; Eindhoven University of Technology; Utrecht University	Xue, LC (corresponding author), Radboud Inst Mol Life Sci, Ctr Mol & Biomol Informat, Radboudumc, Nijmegen, Netherlands.	me.lixue@gmail.com		Rademaker, Daniel-Tobias/0000-0003-1959-1317	Radboudumc [Rv819.52706]; Department of Scholarships and Student's Affairs Abroad, Ministry of Science, Research and Technology, Iran	Radboudumc; Department of Scholarships and Student's Affairs Abroad, Ministry of Science, Research and Technology, Iran	This project is supported by the Hypatia Fellowship from Radboudumc (Rv819.52706). FP acknowledges a visiting scholarship from Department of Scholarships and Students' Affairs Abroad, Ministry of Science, Research and Technology, Iran.	Abelin JG, 2019, IMMUNITY, V51, P766, DOI 10.1016/j.immuni.2019.08.012; Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Abella JR, 2019, MOLECULES, V24, DOI 10.3390/molecules24050881; Agrawal P, 2019, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2449-y; Antunes DA, 2020, JCO CLIN CANCER INFO, V4, P623, DOI 10.1200/CCI.19.00123; Antunes DA, 2018, CURR TOP MED CHEM, V18, P2239, DOI 10.2174/1568026619666181224101744; Antunes DA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22173-4; Baek M, 2021, SCIENCE, V373, P871, DOI 10.1126/science.abj8754; Chys P, 2013, J CHEM THEORY COMPUT, V9, P1821, DOI 10.1021/ct300977f; Cock PJA, 2009, BIOINFORMATICS, V25, P1422, DOI 10.1093/bioinformatics/btp163; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Ehrenmann F, 2010, NUCLEIC ACIDS RES, V38, pD301, DOI 10.1093/nar/gkp946; Fisette O, 2020, P NATL ACAD SCI USA, V117, P20597, DOI 10.1073/pnas.2004445117; Garstka MA, 2015, P NATL ACAD SCI USA, V112, P1505, DOI 10.1073/pnas.1416543112; Guillaume P, 2018, P NATL ACAD SCI USA, V115, P5083, DOI 10.1073/pnas.1717277115; Huber SR, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00171; HULL P, 1970, HEREDITY, V25, P461, DOI 10.1038/hdy.1970.47; Johansson-┼khe I., 2021, BIORXIV, DOI [10.1101/2021.11.16.468810, DOI 10.1101/2021.11.16.468810]; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Kaas Q, 2004, NUCLEIC ACIDS RES, V32, pD208, DOI 10.1093/nar/gkh042; Kaufman J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.601089; Kaufmana J, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2122079119; Khan Javed Mohammed, 2010, Immunome Res, V6 Suppl 1, pS2, DOI 10.1186/1745-7580-6-S1-S2; Ko J., 2021, ALPHAFOLD2 PREDICT P, p20210727453972, DOI [10.1101/2021.07.27.453972v2, DOI 10.1101/2021.07.27.453972V2]; Kyeong HH, 2018, BIOINFORMATICS, V34, P469, DOI 10.1093/bioinformatics/btx589; La Gruta NL, 2018, NAT REV IMMUNOL, V18, P467, DOI 10.1038/s41577-018-0007-5; Laidlaw BJ, 2016, NAT REV IMMUNOL, V16, P102, DOI 10.1038/nri.2015.10; Lensink MF, 2020, PROTEINS, V88, P916, DOI 10.1002/prot.25870; Liu J., 2011, MAJOR HISTOCOMPATIBI, DOI DOI 10.1002/9780470015902.A0000922.PUB2; Liu TF, 2014, J CHEM INF MODEL, V54, P2233, DOI 10.1021/ci500393h; Maccari G, 2017, NUCLEIC ACIDS RES, V45, pD860, DOI 10.1093/nar/gkw1050; Macdonald IK, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001149; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.immunol.13.1.587; Mage MG, 2012, J IMMUNOL, V189, P1391, DOI 10.4049/jimmunol.1200831; Matzaraki V, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1207-1; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Mendez R, 2003, PROTEINS, V52, P51, DOI 10.1002/prot.10393; Mirdita Milot, 2021, Zenodo, DOI [10.1038/s41592-022-01488-1, 10.5281/ZENODO.5123297]; Munoz V, 1997, BIOPOLYMERS, V41, P495, DOI 10.1002/(SICI)1097-0282(19970415)41:5<495::AID-BIP2>3.3.CO;2-6; O'Donnell TJ, 2020, CELL SYST, V11, P42, DOI 10.1016/j.cels.2020.06.010; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Reau, 2021, BIORXIV, DOI [10.1101/2021.12.08.471762, DOI 10.1101/2021.12.08.471762]; Renaud N, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27396-0; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Rigo MM, 2015, SCI REP-UK, V5, DOI 10.1038/srep18413; Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950; Robinson J, 2015, NUCLEIC ACIDS RES, V43, pD423, DOI 10.1093/nar/gku1161; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Sercinoglu O, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232849; Shen YM, 2014, J CHEM THEORY COMPUT, V10, P4745, DOI 10.1021/ct500592m; Shiina T, 2009, J HUM GENET, V54, P15, DOI 10.1038/jhg.2008.5; Tsaban Tomer, 2022, Nat Commun, V13, P176, DOI 10.1038/s41467-021-27838-9; Tunyasuvunakool K, 2021, NATURE, V596, P590, DOI 10.1038/s41586-021-03828-1; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Wang PY, 2021, J IMMUNOL, V207, P2167, DOI 10.4049/jimmunol.2100350; Webb B, 2017, METHODS MOL BIOL, V1654, P39, DOI 10.1007/978-1-4939-7231-9_4; Wieczorek M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00292; Wu YN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.621153; Wu YA, 2021, J IMMUNOL, V207, P308, DOI 10.4049/jimmunol.2001165; Yao SG, 2016, J IMMUNOL, V196, P1943, DOI 10.4049/jimmunol.1501352; Yassai M, 2002, J IMMUNOL, V168, P1281, DOI 10.4049/jimmunol.168.3.1281; Zacharias M, 2004, BIOPHYS J, V87, P2203, DOI 10.1529/biophysj.104.044743	63	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								878762	10.3389/fimmu.2022.878762	http://dx.doi.org/10.3389/fimmu.2022.878762			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N2AG	35619705	Green Submitted, Green Published, gold			2022-12-18	WOS:000800463200001
J	Simon, R; Martin-Martin, A; Morel, E; Diaz-Rosales, P; Tafalla, C				Simon, Rocio; Martin-Martin, Alba; Morel, Esther; Diaz-Rosales, Patricia; Tafalla, Carolina			Functional and Phenotypic Characterization of B Cells in the Teleost Adipose Tissue	FRONTIERS IN IMMUNOLOGY			English	Article						teleost fish; rainbow trout; adipose tissue; B cells; peritoneal antigens; IgM	IMMUNE GENE-EXPRESSION; RAINBOW-TROUT; PLASMA-CELLS; IDENTIFICATION; LYMPHOCYTES; RESPONSES; ANTIGEN; ABSENCE; IGD	The immune response of the adipose tissue (AT) has been neglected in most animal models until investigations in human and mice linked obesity to chronic inflammation, highlighting the immune nature of this tissue. Despite this, in teleost fish, only a few studies have addressed the immune role of the AT. These studies have mostly focused on reporting transcriptional changes in the AT in response to diverse intraperitoneally delivered stimuli. Although the presence of B cells within the AT was also previously revealed, these cells have never been phenotypically or functionally characterized and this is what we have addressed in the current study. Initially, the B cell populations present in the rainbow trout (Oncorhynchus mykiss) AT were characterized in comparison to B cells from other sources. As occurs in other rainbow trout tissues, IgM(+)IgD(+), IgM(+)IgD(-) and IgD(+)IgM(-) B cell subsets were identified in the AT. Interestingly, AT IgM(+)IgD(-) B cells showed a transcriptional profile that agrees with that of cells that have committed to plasmablasts/plasma cells, being this profile much more pronounced towards a differentiation state than that of blood IgM(+)IgD(-) B cells. Accordingly, the IgM-secreting capacity of AT B cells is significantly higher than that of blood B cells. Additionally, AT IgM(+)IgD(+) B cells also showed specific phenotypic traits when compared to their counterparts in other tissues. Finally, we established how these B cell subsets responded when rainbow trout were intraperitoneally injected with a model antigen. Our results demonstrate that the AT hosts plasmablasts/plasma cells that secrete specific IgMs, as happens in the peritoneal cavity and systemic immune tissues. Although the presence of these antigen-specific IgM-secreting cells was more abundant in the peritoneal cavity, these specific differentiated B cells were detected in the AT for long time periods at levels similar to those of spleen and head kidney. Our results provide new evidence regarding the immune role of the teleost AT, indicating that it functions as a secondary lymphoid organ that promotes immunity to peritoneal antigens.	[Simon, Rocio; Martin-Martin, Alba; Morel, Esther; Diaz-Rosales, Patricia; Tafalla, Carolina] Consejo Super Invest Cient CISA INIA CSIC, Anim Hlth Res Ctr, Inst Nacl Invest & Tecnol Agr & Alimentaria, Madrid, Spain	Instituto Nacional Investigacion Tecnologia Agraria Alimentaria (INIA)	Tafalla, C (corresponding author), Consejo Super Invest Cient CISA INIA CSIC, Anim Hlth Res Ctr, Inst Nacl Invest & Tecnol Agr & Alimentaria, Madrid, Spain.	tafalla@inia.csic.es	Simón, Rocío/CAJ-5686-2022; Díaz-Rosales, Patricia/GPG-6820-2022	Simón, Rocío/0000-0001-6584-5141; Martin-Martin, Alba/0000-0003-3092-2893				Abos B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01203; Abos B, 2018, J IMMUNOL, V201, P465, DOI 10.4049/jimmunol.1701546; Abos B, 2016, SCI REP-UK, V6, DOI 10.1038/srep30004; Ansel KM, 2002, IMMUNITY, V16, P67, DOI 10.1016/S1074-7613(01)00257-6; Ballesteros NA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066118; Baumgarth N, 2004, METHOD CELL BIOL, V75, P643; Bohannon C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11826; Boothby MR, 2019, GENE DEV, V33, P26, DOI 10.1101/gad.320192.118; Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797; Carlow DA, 2009, J IMMUNOL, V183, P1155, DOI 10.4049/jimmunol.0900409; Castro R, 2015, DEV COMP IMMUNOL, V51, P116, DOI 10.1016/j.dci.2015.03.002; Cerutti A, 2011, TRENDS IMMUNOL, V32, P202, DOI 10.1016/j.it.2011.02.004; DELUCA D, 1983, EUR J IMMUNOL, V13, P546, DOI 10.1002/eji.1830130706; Edholm ES, 2010, J IMMUNOL, V185, P4082, DOI 10.4049/jimmunol.1000631; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; Granja AG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02902; Granja AG, 2019, FISH SHELLFISH IMMUN, V85, P9, DOI 10.1016/j.fsi.2017.10.003; Granja AG, 2015, J IMMUNOL, V195, P1825, DOI 10.4049/jimmunol.1500322; Gutzeit C, 2018, EUR J IMMUNOL, V48, P1101, DOI 10.1002/eji.201646547; Ha SA, 2006, J EXP MED, V203, P2541, DOI 10.1084/jem.20061041; Hamel KM, 2012, AUTOIMMUNITY, V45, P333, DOI 10.3109/08916934.2012.665524; Jenberie S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01682; John BJ, 2006, ALIMENT PHARM THER, V23, P1511, DOI 10.1111/j.1365-2036.2006.02915.x; Kaminski DA, 2010, TRENDS IMMUNOL, V31, P384, DOI 10.1016/j.it.2010.08.001; Ma CY, 2013, EUR J IMMUNOL, V43, P360, DOI 10.1002/eji.201242570; Martin F, 2001, CURR OPIN IMMUNOL, V13, P195, DOI 10.1016/S0952-7915(00)00204-1; Martin-Martin A, 2020, DEV COMP IMMUNOL, V109, DOI 10.1016/j.dci.2020.103715; Mathis D, 2013, CELL METAB, V17, P851, DOI 10.1016/j.cmet.2013.05.008; MIYACHI K, 1978, J IMMUNOL, V121, P2228; Parra D, 2012, J LEUKOCYTE BIOL, V91, P525, DOI 10.1189/jlb.0711372; Pelletier N, 2010, NAT IMMUNOL, V11, P1110, DOI 10.1038/ni.1954; Perdiguero P, 2019, CELL REP, V29, P4223, DOI 10.1016/j.celrep.2019.11.101; Pignatelli J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110920; Ramirez-Gomez F, 2012, J IMMUNOL, V188, P1341, DOI 10.4049/jimmunol.1101938; Rangel-Moreno J, 2009, IMMUNITY, V30, P731, DOI 10.1016/j.immuni.2009.03.014; Salmeron C, 2018, J EXP BIOL, V221, DOI 10.1242/jeb.161588; Savage HP, 2017, J EXP MED, V214, P2777, DOI 10.1084/jem.20161122; Scapigliati G, 2018, FRONT IMMUNOL, V9, DOI [10.3389/fimmu.2018.00971, 10.3389/fimmu.0018.00971]; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Srikakulapu P, 2020, ARTERIOSCL THROM VAS, V40, P1110, DOI 10.1161/ATVBAHA.119.312467; Sunyer J. Oriol, 2012, Infectious Disorders - Drug Targets, V12, P200; Tafalla C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00295; van der Wal YA, 2021, DEV COMP IMMUNOL, V123, DOI 10.1016/j.dci.2021.104125; Vaughan AT, 2011, INT J BIOCHEM CELL B, V43, P280, DOI 10.1016/j.biocel.2010.12.005; Veenstra KA, 2019, FISH SHELLFISH IMMUN, V87, P559, DOI 10.1016/j.fsi.2019.02.001; Veenstra KA, 2018, DEV COMP IMMUNOL, V81, P83, DOI 10.1016/j.dci.2017.11.001; Veenstra KA, 2017, MOL IMMUNOL, V88, P89, DOI 10.1016/j.molimm.2017.05.026; Ye JM, 2011, DEV COMP IMMUNOL, V35, P1273, DOI 10.1016/j.dci.2011.03.005; Zhang YA, 2010, NAT IMMUNOL, V11, P827, DOI 10.1038/ni.1913	49	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								868551	10.3389/fimmu.2022.868551	http://dx.doi.org/10.3389/fimmu.2022.868551			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1L3SI	35619704	Green Published, gold			2022-12-18	WOS:000799211400001
J	van Baardwijk, M; Cristoferi, I; Ju, J; Varol, H; Minnee, RC; Reinders, MEJ; Li, YL; Stubbs, AP; Groningen, MCVC				van Baardwijk, Myrthe; Cristoferi, Iacopo; Ju, Jie; Varol, Hilal; Minnee, Robert C.; Reinders, Marlies E. J.; Li, Yunlei; Stubbs, Andrew P.; Clahsen-van Groningen, Marian C.			A Decentralized Kidney Transplant Biopsy Classifier for Transplant Rejection Developed Using Genes of the Banff-Human Organ Transplant Panel	FRONTIERS IN IMMUNOLOGY			English	Article						kidney transplantation; gene expression; graft rejection; diagnosis; pathology; transcriptomics; bioinformatics; machine learning	INTERNATIONAL VARIATION	Introduction A decentralized and multi-platform-compatible molecular diagnostic tool for kidney transplant biopsies could improve the dissemination and exploitation of this technology, increasing its clinical impact. As a first step towards this molecular diagnostic tool, we developed and validated a classifier using the genes of the Banff-Human Organ Transplant (B-HOT) panel extracted from a historical Molecular Microscope(R) Diagnostic system microarray dataset. Furthermore, we evaluated the discriminative power of the B-HOT panel in a clinical scenario. Materials and Methods Gene expression data from 1,181 kidney transplant biopsies were used as training data for three random forest models to predict kidney transplant biopsy Banff categories, including non-rejection (NR), antibody-mediated rejection (ABMR), and T-cell-mediated rejection (TCMR). Performance was evaluated using nested cross-validation. The three models used different sets of input features: the first model (B-HOT Model) was trained on only the genes included in the B-HOT panel, the second model (Feature Selection Model) was based on sequential forward feature selection from all available genes, and the third model (B-HOT+ Model) was based on the combination of the two models, i.e. B-HOT panel genes plus highly predictive genes from the sequential forward feature selection. After performance assessment on cross-validation, the best-performing model was validated on an external independent dataset based on a different microarray version. Results The best performances were achieved by the B-HOT+ Model, a multilabel random forest model trained on B-HOT panel genes with the addition of the 6 most predictive genes of the Feature Selection Model (ST7, KLRC4-KLRK1, TRBC1, TRBV6-5, TRBV19, and ZFX), with a mean accuracy of 92.1% during cross-validation. On the validation set, the same model achieved Area Under the ROC Curve (AUC) of 0.965 and 0.982 for NR and ABMR respectively. Discussion This kidney transplant biopsy classifier is one step closer to the development of a decentralized kidney transplant biopsy classifier that is effective on data derived from different gene expression platforms. The B-HOT panel proved to be a reliable highly-predictive panel for kidney transplant rejection classification. Furthermore, we propose to include the aforementioned 6 genes in the B-HOT panel for further optimization of this commercially available panel.	[van Baardwijk, Myrthe; Cristoferi, Iacopo; Ju, Jie; Varol, Hilal; Li, Yunlei; Stubbs, Andrew P.; Clahsen-van Groningen, Marian C.] Univ Med Ctr Rotterdam, Dept Pathol & Clin Bioinformat, Erasmus MC, Rotterdam, Netherlands; [van Baardwijk, Myrthe; Cristoferi, Iacopo; Minnee, Robert C.] Univ Med Ctr Rotterdam, Dept Surg, Div HPB & Transplant Surg, Erasmus MC, Rotterdam, Netherlands; [van Baardwijk, Myrthe; Cristoferi, Iacopo; Varol, Hilal; Minnee, Robert C.; Reinders, Marlies E. J.; Clahsen-van Groningen, Marian C.] Univ Med Ctr Rotterdam, Erasmus MC Transplant Inst, Erasmus MC, Rotterdam, Netherlands; [van Baardwijk, Myrthe] Omnigen BV, Compan Diagnost & Personalised Healthcare, Delft, Netherlands; [Reinders, Marlies E. J.] Univ Med Ctr Rotterdam, Dept Internal Med, Erasmus MC, Rotterdam, Netherlands; [Clahsen-van Groningen, Marian C.] Rheinish Westphalian Tech Univ Aachen Univ RWTH, Inst Expt Med & Syst Biol, Aachen, Germany	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Transplant Institute; Erasmus University Rotterdam; Erasmus MC	van Baardwijk, M (corresponding author), Univ Med Ctr Rotterdam, Dept Pathol & Clin Bioinformat, Erasmus MC, Rotterdam, Netherlands.; van Baardwijk, M (corresponding author), Univ Med Ctr Rotterdam, Dept Surg, Div HPB & Transplant Surg, Erasmus MC, Rotterdam, Netherlands.; van Baardwijk, M (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC Transplant Inst, Erasmus MC, Rotterdam, Netherlands.; van Baardwijk, M (corresponding author), Omnigen BV, Compan Diagnost & Personalised Healthcare, Delft, Netherlands.	m.vanbaardwijk@erasmusmc.nl						Blighe K., 2021, PCATOOLS EVERYTHING; Furness PN, 2003, AM J SURG PATHOL, V27, P805, DOI 10.1097/00000478-200306000-00012; Furness PN, 2001, KIDNEY INT, V60, P1998, DOI 10.1046/j.1523-1755.2001.00030.x; Galan-Caridad JM, 2007, CELL, V129, P345, DOI 10.1016/j.cell.2007.03.014; Halloran PF, 2017, AM J TRANSPLANT, V17, P2851, DOI 10.1111/ajt.14329; Halloran PF, 2016, NAT REV NEPHROL, V12, P534, DOI 10.1038/nrneph.2016.85; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Kolbert CP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052517; Loupy A, 2020, AM J TRANSPLANT, V20, P2318, DOI 10.1111/ajt.15898; Mengel M, 2020, AM J TRANSPLANT, V20, P2305, DOI 10.1111/ajt.16059; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; Pedregosa F., 2011, J MACH LEARN RES, V12, P2825; R Core Team, 2021, COMPUTER SOFTWARE; Reeve J, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94197; Rowen L, 1996, SCIENCE, V272, P1755, DOI 10.1126/science.272.5269.1755; Smith RN, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920-021-00891-5; Van Loon E, 2019, EBIOMEDICINE, V46, P463, DOI 10.1016/j.ebiom.2019.07.028; Van Rossum G., 1995, PYTHON TUTORIAL, V620; Wolski W., 2018, SRMSERVICE R PACKAGE; Zapf A, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882-015-0146-x; Zhang L, 2021, J IMMUNOL METHODS, V494, DOI 10.1016/j.jim.2021.113041	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								841519	10.3389/fimmu.2022.841519	http://dx.doi.org/10.3389/fimmu.2022.841519			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S3RO	35619722	Green Published, gold			2022-12-18	WOS:000803971700001
J	Zeng, L; Li, SH; Xu, SY; Chen, K; Qin, LJ; Liu, XY; Wang, F; Fu, S; Deng, L; Wang, FH; Miao, L; Li, L; Liu, N; Wang, R; Wang, HY				Zeng, Liang; Li, Shu-Hua; Xu, Shuo-Yu; Chen, Kai; Qin, Liang-Jun; Liu, Xiao-Yun; Wang, Fang; Fu, Sha; Deng, Ling; Wang, Feng-Hua; Miao, Lei; Li, Le; Liu, Na; Wang, Ran; Wang, Hai-Yun			Clinical Significance of a CD3/CD8-Based Immunoscore in Neuroblastoma Patients Using Digital Pathology	FRONTIERS IN IMMUNOLOGY			English	Article						neuroblastoma; prognosis; immunology; digital pathology; CD3; CD8 T cells	TUMOR-INFILTRATING LYMPHOCYTES; NEGATIVE BREAST-CANCER; FREE SURVIVAL; CELLS; TRASTUZUMAB; SYSTEM	BackgroundInfiltrating immune cells have been reported as prognostic markers in many cancer types. We aimed to evaluate the prognostic role of tumor-infiltrating lymphocytes, namely CD3+ T cells, CD8+ cytotoxic T cells and memory T cells (CD45RO+), in neuroblastoma. Patients and MethodsImmunohistochemistry was used to determine the expression of CD3, CD8 and CD45RO in the tumor samples of 244 neuroblastoma patients. We then used digital pathology to calculate the densities of these markers and derived an immunoscore based on such densities. ResultsDensities of CD3+ and CD8+ T cells in tumor were positively associated with the overall survival (OS) and event-free survival (EFS), whereas density of CD45RO+ T cells in tumor was negatively associated with OS but not EFS. An immunoscore with low density of CD3 and CD8 (CD3-CD8-) was indictive of a greater risk of death (hazard ratio 6.39, 95% confidence interval 3.09-13.20) and any event (i.e., relapse at any site, progressive disease, second malignancy, or death) (hazard ratio 4.65, 95% confidence interval 2.73-7.93). Multivariable analysis revealed that the CD3-CD8- immunoscore was an independent prognostic indicator for OS, even after adjusting for other known prognostic indicators. ConclusionsThe new immunoscore based on digital pathology evaluated densities of tumor-infiltrating CD3+ and CD8+ T cells contributes to the prediction of prognosis in neuroblastoma patients.	[Zeng, Liang; Chen, Kai; Qin, Liang-Jun; Wang, Hai-Yun] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Natl Childrens Med Ctr South Cent Reg, Dept Pathol, Guangzhou, Peoples R China; [Li, Shu-Hua] Sun Yat Sen Univ, Affiliated Hosp 1, Mol Diag & Gene Testing Ctr, Guangzhou, Peoples R China; [Xu, Shuo-Yu] Biototem Pte Ltd, Foshan, Peoples R China; [Xu, Shuo-Yu] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Peoples R China; [Liu, Xiao-Yun; Wang, Fang; Deng, Ling] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Fu, Sha] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Cellular & Mol Diagnost Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou, Peoples R China; [Wang, Feng-Hua; Li, Le] Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Natl Childrens Med Ctr South Cent Reg, Dept Thorac Surg, Guangzhou, Peoples R China; [Miao, Lei; Wang, Hai-Yun] Guangzhou Med Univ, Guangzhou Inst Pediat, Guangzhou Women & Childrens Med Ctr, Natl Childrens Med Ctr South Cent Reg,Dept Pediat, Guangzhou, Peoples R China; [Liu, Na] Sun Yat Sen Univ Canc Ctr, CollaborativeInnovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol Southern China,Guangdong Key L, Guangzhou, Peoples R China; [Wang, Ran] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Peoples R China	Guangzhou Medical University; Sun Yat Sen University; Southern Medical University - China; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Guangzhou Medical University; Guangzhou Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University	Wang, HY (corresponding author), Guangzhou Med Univ, Guangzhou Women & Childrens Med Ctr, Natl Childrens Med Ctr South Cent Reg, Dept Pathol, Guangzhou, Peoples R China.; Wang, HY (corresponding author), Guangzhou Med Univ, Guangzhou Inst Pediat, Guangzhou Women & Childrens Med Ctr, Natl Childrens Med Ctr South Cent Reg,Dept Pediat, Guangzhou, Peoples R China.; Liu, N (corresponding author), Sun Yat Sen Univ Canc Ctr, CollaborativeInnovat Ctr Canc Med, Dept Expt Res, State Key Lab Oncol Southern China,Guangdong Key L, Guangzhou, Peoples R China.; Wang, R (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou, Peoples R China.	liun1@sysucc.org.cn; wangr55@mail.sysu.edu.cn; wanghy29@mail3.sysu.edu.cn	wang, fang/GYD-4295-2022		Guangzhou Women and Children's Medical Center [3001151-04]; National Natural Science Foundation of China [81602468]	Guangzhou Women and Children's Medical Center; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was partially supported by the start-up program of Guangzhou Women and Children's Medical Center (No. 3001151-04) and the National Natural Science Foundation of China (81602468).	Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004; Anitei MG, 2014, CLIN CANCER RES, V20, P1891, DOI 10.1158/1078-0432.CCR-13-2830; Bao RY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002417; Baxi V, 2022, MODERN PATHOL, V35, P23, DOI 10.1038/s41379-021-00919-2; Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168; Brambilla E, 2016, J CLIN ONCOL, V34, P1223, DOI 10.1200/JCO.2015.63.0970; Davis KL, 2020, LANCET ONCOL, V21, P541, DOI 10.1016/S1470-2045(20)30023-1; Donnem T, 2016, ANN ONCOL, V27, P226, DOI 10.1093/annonc/mdv560; Fu CM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03059; Gabrielson A, 2016, CANCER IMMUNOL RES, V4, P419, DOI 10.1158/2326-6066.CIR-15-0110; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Grobner SN, 2018, NATURE, V555, P321, DOI 10.1038/nature25480; Heindl A, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx137; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Irwin MS, 2021, J CLIN ONCOL, V39, P3229, DOI 10.1200/JCO.21.00278; Jung Hwejin, 2019, BMC Biomed Eng, V1, P24, DOI 10.1186/s42490-019-0026-8; Kang BW, 2016, ANN ONCOL, V27, P494, DOI 10.1093/annonc/mdv610; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Loi S, 2014, ANN ONCOL, V25, P1544, DOI 10.1093/annonc/mdu112; Luen SJ, 2017, LANCET ONCOL, V18, P52, DOI [10.1016/S1470-2045(16)30631-3, 10.1016/s1470-2045(16)30631-3]; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Maris JM, 2010, NEW ENGL J MED, V362, P2202, DOI 10.1056/NEJMra0804577; McShane LM, 2005, JNCI-J NATL CANCER I, V97, P1180, DOI 10.1093/jnci/dji237; Mina M, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1019981; Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425; Monclair T, 2009, J CLIN ONCOL, V27, P298, DOI 10.1200/JCO.2008.16.6876; Orrego Enrique, 2018, CNS Oncol, V7, pCNS21, DOI 10.2217/cns-2017-0037; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Park JR, 2019, JAMA-J AM MED ASSOC, V322, P746, DOI 10.1001/jama.2019.11642; Peifer M, 2015, NATURE, V526, P700, DOI 10.1038/nature14980; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Ruifrok AC, 2003, APPL IMMUNOHISTO M M, V11, P85, DOI 10.1097/00022744-200303000-00014; Telli ML, 2020, CLIN CANCER RES, V26, P2704, DOI 10.1158/1078-0432.CCR-19-0664; Van de Velde LA, 2021, CANCER RES, V81, P5047, DOI 10.1158/0008-5472.CAN-21-0691; Wang HY, 2011, J CLIN ONCOL, V29, P4516, DOI 10.1200/JCO.2010.33.7741; Wang YQ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000334; Wen T, 2017, CANCER IMMUNOL RES, V5, P524, DOI 10.1158/2326-6066.CIR-16-0381	43	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								878457	10.3389/fimmu.2022.878457	http://dx.doi.org/10.3389/fimmu.2022.878457			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N0KL	35619699	Green Published, gold			2022-12-18	WOS:000800353000001
J	Zha, SY; Yu, X; Wang, XX; Gu, Y; Tan, YD; Lu, Y; Yao, ZR				Zha, Siyuan; Yu, Xia; Wang, Xiaoxiao; Gu, Yan; Tan, Yidong; Lu, Ying; Yao, Zhirong			Topical Simvastatin Improves Lesions of Diffuse Normolipemic Plane Xanthoma by Inhibiting Foam Cell Pyroptosis	FRONTIERS IN IMMUNOLOGY			English	Article						diffuse plane xanthoma; foam cells; oxidized-LDL; pyroptosis; simvastatin	ADIPOSE-TISSUE INFLAMMATION; GASDERMIN D; INSULIN-RESISTANCE; THERAPY; ASSOCIATION; CASPASES; CLEAVAGE; GSDMD	Xanthoma pathogenesis is speculated to be associated with oxidized low-density lipoprotein (ox-LDL) deposition, although this remains unclear. Most patients with diffuse plane xanthomas present elevated blood lipid levels, and they benefit from treatment with oral lipid-lowering agents. However, there is no available treatment for diffuse normolipemic plane xanthoma (DNPX). In this study, for the first time, we used a topical simvastatin ointment to treat DNPX in three pediatric patients and observed favorable results. Immunofluorescence staining showed that the pyroptotic pathway was significantly attenuated after topical simvastatin application on the skin lesions of the patients. As ox-LDL deposition was observed in the lesions, we used ox-LDL to build a foam cell model in vitro. In the ox-LDL-induced foam cell formation, simvastatin consistently inhibited pyroptotic activation and inflammation in the macrophages. Additionally, the overexpression of nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) or 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase (HMGCR), the known target of statins, reversed the effects of simvastatin. Moreover, gasdermin D (GSDMD) or HMGCR knockdown inhibited ox-LDL-induced pyroptosis. Furthermore, the immunoprecipitation results confirmed the interaction between NLRP3 and HMGCR, and this interaction was inhibited by simvastatin. In conclusion, we demonstrated that topical application of simvastatin ointment might be a promising treatment for DNPX skin lesions and that this therapeutic effect may be related to pyroptosis inhibition via HMGCR inhibition in foam cells. Moreover, xanthoma pathogenesis might be associated with ox-LDL deposition and inflammation.	[Zha, Siyuan; Yu, Xia; Wang, Xiaoxiao; Gu, Yan; Tan, Yidong; Lu, Ying; Yao, Zhirong] Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Dermatol, Shanghai, Peoples R China; [Zha, Siyuan; Yu, Xia; Wang, Xiaoxiao; Gu, Yan; Tan, Yidong; Lu, Ying; Yao, Zhirong] Shanghai Jiao Tong Univ, Inst Dermatol, Sch Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Lu, Y; Yao, ZR (corresponding author), Shanghai Jiao Tong Univ, Xinhua Hosp, Sch Med, Dept Dermatol, Shanghai, Peoples R China.; Lu, Y; Yao, ZR (corresponding author), Shanghai Jiao Tong Univ, Inst Dermatol, Sch Med, Shanghai, Peoples R China.	stove@shsmu.edu.cn; yaozhirong@xinhuamed.com.cn						Aljenedil S, 2018, J CLIN LIPIDOL, V12, P872, DOI 10.1016/j.jacl.2018.03.087; Booken N, 2009, DERMATOLOGY, V219, P91, DOI 10.1159/000165626; Braga JAF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02137; Bulek K, 2020, J CLIN INVEST, V130, P4218, DOI 10.1172/JCI138103; Souza MCC, 2020, AN BRAS DERMATOL, V95, P261, DOI 10.1016/j.abd.2019.08.026; Cohen Yoon K, 2015, Dermatol Pract Concept, V5, P65, DOI 10.5826/dpc.0504a16; Cota C, 2020, AM J DERMATOPATH, V42, pE167, DOI 10.1097/DAD.0000000000001757; Duner P, 2009, J INTERN MED, V265, P593, DOI 10.1111/j.1365-2796.2008.02067.x; Falk E, 2006, J AM COLL CARDIOL, V47, pC7, DOI 10.1016/j.jacc.2005.09.068; He MY, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0490-8; Henderson R, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0256-1; Hot A, 2013, ANN RHEUM DIS, V72, P754, DOI 10.1136/annrheumdis-2012-201887; Humphries F, 2020, SCIENCE, V369, P1633, DOI 10.1126/science.abb9818; Kumar S, 2021, AUTOPHAGY, V17, P2273, DOI 10.1080/15548627.2020.1822088; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Longo J, 2020, CLIN CANCER RES, V26, P5791, DOI 10.1158/1078-0432.CCR-20-1967; Lopez-Trujillo E, 2020, AUSTRALAS J DERMATOL, V61, pE245, DOI 10.1111/ajd.13198; Luo J, 2020, NAT REV MOL CELL BIO, V21, P225, DOI 10.1038/s41580-019-0190-7; Luo YT, 2017, CELL RES, V27, P352, DOI 10.1038/cr.2017.8; Marcoval J, 1998, J AM ACAD DERMATOL, V39, P439, DOI 10.1016/S0190-9622(98)70321-4; Matsui S, 2019, EUR HEART J, V40, P2831, DOI 10.1093/eurheartj/ehy827; Maxit MJ, 2001, MEDICINA-BUENOS AIRE, V61, P187; Miyagi Y, 2016, J ATHEROSCLER THROMB, V23, P112, DOI 10.5551/jat.31666; Momen S, 2017, J EUR ACAD DERMATOL, V31, pE450, DOI 10.1111/jdv.14290; Negre-Salvayre A, 2017, FREE RADICAL BIO MED, V111, P127, DOI 10.1016/j.freeradbiomed.2016.12.038; Ohshiro T, 2009, J ATHEROSCLER THROMB, V16, P698, DOI 10.5551/jat.No810; Onishi R, 2013, INT J DERMATOL, V52, P1456, DOI 10.1111/j.1365-4632.2011.05321.x; Oosterveer DM, 2009, ATHEROSCLEROSIS, V206, P223, DOI 10.1016/j.atherosclerosis.2009.02.019; Peng YJ, 2018, AGING CELL, V17, DOI 10.1111/acel.12820; Perry RJ, 2015, CELL, V160, P745, DOI 10.1016/j.cell.2015.01.012; Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514; SMITH CH, 1995, BRIT J DERMATOL, V132, P286; Sowa Y, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030605; Takei A, 2020, DIABETES, V69, P158, DOI 10.2337/db19-0076; Tall AR, 2019, J LIPID RES, V60, P721, DOI 10.1194/jlr.S091280; Tulbah AS, 2016, EXPERT OPIN DRUG DEL, V13, P1407, DOI 10.1080/17425247.2016.1193150; Van der Donckt C, 2015, NEUROSCIENCE, V295, P11, DOI 10.1016/j.neuroscience.2015.03.023; Varghese JF, 2019, CELL SIGNAL, V53, P316, DOI 10.1016/j.cellsig.2018.10.020; Wang DY, 2020, CELL DEATH DIFFER, V27, P466, DOI 10.1038/s41418-019-0366-x; Wang K, 2020, CELL, V180, P941, DOI 10.1016/j.cell.2020.02.002; Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393; Yao YG, 2016, CELL PHYSIOL BIOCHEM, V38, P415, DOI 10.1159/000438640; Yu X, 2021, J DERMATOL, V48, P223, DOI 10.1111/1346-8138.15649; Zak A, 2014, BIOMED PAP, V158, P181, DOI 10.5507/bp.2014.016; Zhang Y, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12449	45	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 10	2022	13								865704	10.3389/fimmu.2022.865704	http://dx.doi.org/10.3389/fimmu.2022.865704			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M0MX	35619689	gold, Green Published			2022-12-18	WOS:000799673400001
J	Chen, YH; Qin, CC; Chang, JB; Liu, YX; Zhang, QH; Ye, ZJ; Li, ZJ; Tian, FX; Ma, WB; Wei, JJ; Feng, M; Chen, SP; Yao, JH; Wang, RZ				Chen, Yihao; Qin, Chenchen; Chang, Jianbo; Liu, Yixun; Zhang, Qinghua; Ye, Zeju; Li, Zhaojian; Tian, Fengxuan; Ma, Wenbin; Wei, Junji; Feng, Ming; Chen, Shengpan; Yao, Jianhua; Wang, Renzhi			Defining Delayed Perihematomal Edema Expansion in Intracerebral Hemorrhage: Segmentation, Time Course, Risk Factors and Clinical Outcome	FRONTIERS IN IMMUNOLOGY			English	Article						intracerebral hemorrhage; delayed perihematomal edema expansion; time course; prognosis; deep learning	PERIHEMORRHAGIC EDEMA; NATURAL-HISTORY; DEEP; RATS	We attempt to generate a definition of delayed perihematomal edema expansion (DPE) and analyze its time course, risk factors, and clinical outcomes. A multi-cohort data was derived from the Chinese Intracranial Hemorrhage Image Database (CICHID). A non-contrast computed tomography (NCCT) -based deep learning model was constructed for fully automated segmentation hematoma and perihematomal edema (PHE). Time course of hematoma and PHE evolution correlated to initial hematoma volume was volumetrically assessed. Predictive values for DPE were calculated through receiver operating characteristic curve analysis and were tested in an independent cohort. Logistic regression analysis was utilized to identify risk factors for DPE formation and poor outcomes. The test cohort's Dice scores of lesion segmentation were 0.877 and 0.642 for hematoma and PHE, respectively. Overall, 1201 patients were enrolled for time-course analysis of ICH evolution. A total of 312 patients were further selected for DPE analysis. Time course analysis showed the growth peak of PHE approximately concentrates in 14 days after onset. The best cutoff for DPE to predict poor outcome was 3.34 mL of absolute PHE expansion from 4-7 days to 8-14 days (AUC=0.784, sensitivity=72.2%, specificity=81.2%), and 3.78 mL of absolute PHE expansion from 8-14 days to 15-21 days (AUC=0.682, sensitivity=59.3%, specificity=92.1%) in the derivation sample. Patients with DPE was associated with worse outcome (OR: 12.340, 95%CI: 6.378-23.873, P<0.01), and the larger initial hematoma volume (OR: 1.021, 95%CI: 1.000-1.043, P=0.049) was the significant risk factor for DPE formation. This study constructed a well-performance deep learning model for automatic segmentations of hematoma and PHE. A new definition of DPE was generated and is confirmed to be related to poor outcomes in ICH. Patients with larger initial hematoma volume have a higher risk of developing DPE formation.	[Chen, Yihao; Chang, Jianbo; Ma, Wenbin; Wei, Junji; Feng, Ming; Wang, Renzhi] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Neurosurg, Beijing, Peoples R China; [Qin, Chenchen; Liu, Yixun; Yao, Jianhua] Tencent AI Lab, Shenzhen, Peoples R China; [Zhang, Qinghua] Shenzhen Nanshan Hosp, Dept Neurosurg, Shenzhen, Peoples R China; [Ye, Zeju] Dongguan Peoples Hosp, Dept Neurosurg, Dongguan, Peoples R China; [Li, Zhaojian] Qingdao Univ, Affiliated Hosp, Dept Neurosurg, Qingdao, Peoples R China; [Li, Zhaojian] Qingdao Univ, Dept Med, Qingdao, Peoples R China; [Tian, Fengxuan] Qinghai Prov Peoples Hosp, Dept Neurosurg, Xining, Peoples R China; [Chen, Shengpan] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Inst Neurosci, Dept Neurosurg, Guangzhou, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Peking Union Medical College Hospital; Tencent; Qingdao University; Qingdao University; Guangdong Academy of Medical Sciences & Guangdong General Hospital	Wang, RZ (corresponding author), Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Neurosurg, Beijing, Peoples R China.; Yao, JH (corresponding author), Tencent AI Lab, Shenzhen, Peoples R China.; Chen, SP (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Inst Neurosci, Dept Neurosurg, Guangzhou, Peoples R China.	doctor_chensp@163.com; Jianhua.yao@gmail.com; wangrz@126.com	Yao, Jianhua/GQZ-6627-2022	Yao, Jianhua/0000-0001-9157-9596	National Key R&D Program of China [2018YFA0108603]; Beijing Tianjin Hebei basic research cooperation project [19JCZDJC64600(Z)]; CAMS Innovation Fund for medical sciences (CIFMS) [2020-I2M-CT-B-028]; National Natural Science Foundation of China [82001389]	National Key R&D Program of China; Beijing Tianjin Hebei basic research cooperation project; CAMS Innovation Fund for medical sciences (CIFMS); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Key R&D Program of China (2018YFA0108603), the Beijing Tianjin Hebei basic research cooperation project (19JCZDJC64600(Z)), the CAMS Innovation Fund for medical sciences (CIFMS) (2020-I2M-C&T-B-028), the National Natural Science Foundation of China (82001389).	Bodmer D, 2012, TRANSL STROKE RES, V3, pS52, DOI 10.1007/s12975-012-0162-0; Carlsson M, 2021, STROKE, V52, P3883, DOI 10.1161/STROKEAHA.120.032750; Chen YH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740632; Dhar R, 2020, STROKE, V51, P648, DOI 10.1161/STROKEAHA.119.027657; Dowlatshahi D, 2011, NEUROLOGY, V76, P1238, DOI 10.1212/WNL.0b013e3182143317; Grunwald Z, 2017, NEUROCRIT CARE, V26, P205, DOI 10.1007/s12028-016-0321-3; Haque ME, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00888; Inaji M, 2003, ACTA NEUROCHIR SUPPL, V86, P445; Li N, 2013, STROKE, V44, P658, DOI 10.1161/STROKEAHA.112.673590; Loan JJM, 2021, INT J STROKE, V16, P828, DOI 10.1177/1747493020974282; Lv XN, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6249509; Murthy SB, 2016, J NEUROL NEUROSUR PS, V87, P1169, DOI 10.1136/jnnp-2016-313653; Murthy SB, 2015, STROKE, V46, P3088, DOI 10.1161/STROKEAHA.115.010054; Nicholas E., 2016, LANCET NEUROL, V18, P88; Peng WJ, 2019, CNS NEUROSCI THER, V25, P1189, DOI 10.1111/cns.13219; Perkins NJ, 2006, AM J EPIDEMIOL, V163, P670, DOI 10.1093/aje/kwj063; Rodriguez-Luna D, 2016, STROKE, V47, P350, DOI 10.1161/STROKEAHA.115.011295; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Sprugel MI, 2019, NEUROLOGY, V93, pE1159, DOI 10.1212/WNL.0000000000008129; Staykov D, 2011, STROKE, V42, P2625, DOI 10.1161/STROKEAHA.111.618611; Sun WP, 2013, NEUROCRIT CARE, V19, P299, DOI 10.1007/s12028-013-9894-2; Urday S, 2016, CRIT CARE MED, V44, P790, DOI 10.1097/CCM.0000000000001553; Urday S, 2015, STROKE, V46, P1116, DOI 10.1161/STROKEAHA.114.007565; Urday S, 2015, NAT REV NEUROL, V11, P111, DOI 10.1038/nrneurol.2014.264; van Asch CJJ, 2010, LANCET NEUROL, V9, P167, DOI 10.1016/S1474-4422(09)70340-0; Venkatasubramanian C, 2011, STROKE, V42, P73, DOI 10.1161/STROKEAHA.110.590646; Volbers B, 2016, NEUROCRIT CARE, V24, P404, DOI 10.1007/s12028-015-0185-y; Volbers B, 2011, EUR J NEUROL, V18, P1323, DOI 10.1111/j.1468-1331.2011.03395.x; WAHL F, 1994, J NEUROCHEM, V63, P1003; Wu H, 2010, NEUROCHEM INT, V57, P248, DOI 10.1016/j.neuint.2010.06.002; Wu TY, 2017, STROKE, V48, P873, DOI 10.1161/STROKEAHA.116.014416; Yang J, 2015, STROKE, V46, P1009, DOI 10.1161/STROKEAHA.114.007154; Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015; Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167; Zhao XJ, 2021, EUR RADIOL, V31, P5012, DOI 10.1007/s00330-020-07558-2; Ziai WC, 2013, STROKE, V44, pS74, DOI 10.1161/STROKEAHA.111.000662	36	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								911207	10.3389/fimmu.2022.911207	http://dx.doi.org/10.3389/fimmu.2022.911207			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S2VL	35615357	gold, Green Published			2022-12-18	WOS:000803913900001
J	Faierstein, K; Shilo, N; Levartovsky, A; Raphael, R; Givon, A; Agmon-Levin, N; Mayan, H				Faierstein, Kobi; Shilo, Noya; Levartovsky, Asaf; Raphael, Roy; Givon, Amir; Agmon-Levin, Nancy; Mayan, Haim			Autoimmune Neutropenia Associated With HHV-6 Virus Infection: A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						secondary autoimmune neutropenia (AIN); human herpesvirus 6 (HHV-6); granulocyte immunofluorescence test (GIFT); agranulocitosis; neutropenic fever		BackgroundAutoimmune neutropenia (AIN) is divided into primary and secondary forms. The former is more prevalent in children and is usually a self-limiting disease. Secondary AIN is more common in adults and often occurs in the setting of another autoimmune disorder or secondary to infections, malignancies or medications. Several viral and bacterial pathogens were described to trigger AIN. Here we report a case of AIN in an adult woman associated with human herpesvirus-6 (HHV-6) infection. Case PresentationWe report a case of AIN in an adult woman associated with HHV-6 infection. The patient presented to the emergency department with fever and painful genital ulcers. Upon arrival, her laboratory workup demonstrated severe neutropenia and elevated inflammatory markers. She was hospitalized and underwent a thorough infectious, hematological, autoimmune and inflammatory workup. Malignancy was also excluded using an advanced whole body radiological scan. Serological tests confirmed the presence of both acute and chronic types of HHV-6 antibodies, at very high titers. Polymerase chain reaction demonstrated a numerous copies of the virus in the patient's blood. Specific immunofluorescence test confirmed the diagnosis of autoimmune neutropenia. ConclusionSecondary AIN is a rare disease that may affect all range of ages. The adult type is a challenging disorder that has different etiologies and may be triggered by a variable infectious pathogen. The finding of HHV-6 as a possible culprit pathogen may warrant physicians into widening the evaluation and include HHV-6 in the analysis.	[Faierstein, Kobi; Shilo, Noya; Levartovsky, Asaf; Raphael, Roy; Givon, Amir; Mayan, Haim] Chaim Sheba Med Ctr, Dept Med E, Ramat Gan, Israel; [Faierstein, Kobi; Shilo, Noya; Levartovsky, Asaf; Raphael, Roy; Givon, Amir; Agmon-Levin, Nancy; Mayan, Haim] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Agmon-Levin, Nancy] Sheba Med Ctr, Ctr Autoimmune Dis, Clin Immunol Angioedema & Allergy Unit, Ramat Gan, Israel	Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center	Faierstein, K (corresponding author), Chaim Sheba Med Ctr, Dept Med E, Ramat Gan, Israel.; Faierstein, K (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.	faierstein10@gmail.com						Ablashi D, 2014, ARCH VIROL, V159, P863, DOI 10.1007/s00705-013-1902-5; Afzal W, 2017, SOUTH MED J, V110, P300, DOI 10.14423/SMJ.0000000000000637; Agut H, 2015, CLIN MICROBIOL REV, V28, P313, DOI 10.1128/CMR.00122-14; Akhtari M, 2009, AUTOIMMUN REV, V9, P62, DOI 10.1016/j.autrev.2009.03.006; BOXER LA, 1975, NEW ENGL J MED, V293, P748, DOI 10.1056/NEJM197510092931505; Boxer LA, 2012, HEMATOL-AM SOC HEMAT, P174, DOI 10.1182/asheducation-2012.1.174; Hill JA, 2019, CURR OPIN INFECT DIS, V32, P584, DOI 10.1097/QCO.0000000000000592; Peddu V, 2020, J VIROL, V94, DOI 10.1128/JVI.01418-19; Tokushima-Imayoshi M, 2006, INT J HEMATOL, V84, P151, DOI 10.1532/IJH97.06064; Yagasaki H, 2011, ANN HEMATOL, V90, P851, DOI 10.1007/s00277-010-1095-x	10	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								880016	10.3389/fimmu.2022.880016	http://dx.doi.org/10.3389/fimmu.2022.880016			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1L5UY	35615353	gold, Green Published			2022-12-18	WOS:000799354200001
J	Garantziotis, P; Nikolakis, D; Doumas, S; Frangou, E; Sentis, G; Filia, A; Fanouriakis, A; Bertsias, G; Boumpas, DT				Garantziotis, Panagiotis; Nikolakis, Dimitrios; Doumas, Stavros; Frangou, Eleni; Sentis, George; Filia, Anastasia; Fanouriakis, Antonis; Bertsias, George; Boumpas, Dimitrios T.			Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs	FRONTIERS IN IMMUNOLOGY			English	Article						molecular taxonomy; drug response prediction; systemic lupus erythematosus; drug repurposing; endotypes	MRL/LPR MOUSE MODEL; RENAL-DISEASE; INHIBITION; KINASE; DAMAGE; EXPRESSION; SIGNATURES; NETWORKS; INDEX	ObjectivesTreatment of Systemic Lupus Erythematosus (SLE) is characterized by a largely empirical approach and relative paucity of novel compound development. We sought to stratify SLE patients based on their molecular phenotype and identify putative therapeutic compounds for each molecular fingerprint. MethodsBy the use of whole blood RNA-seq data from 120 SLE patients, and in a data-driven, clinically unbiased manner, we established modules of commonly regulated genes (molecular endotypes) and re-stratified patients through hierarchical clustering. Disease activity and severity were assessed using SLEDAI-2K and Lupus Severity Index, respectively. Through an in silico drug prediction pipeline, we investigated drugs currently in use, tested in lupus clinical trials, and listed in the iLINCS prediction databases, for their ability to reverse the gene expression signatures in each molecular endotype. Drug repurposing analysis was also performed to identify perturbagens that counteract group-specific SLE signatures. ResultsMolecular taxonomy identified five lupus endotypes, each characterized by a unique gene module enrichment pattern. Neutrophilic signature group consisted primarily of patients with active lupus nephritis, while the B-cell expression group included patients with constitutional features. Patients with moderate severity and serologic activity exhibited a signature enriched for metabolic processes. Mild disease was distributed in two groups, exhibiting enhanced basic cellular functions, myelopoiesis, and autophagy. Bortezomib was predicted to reverse disturbances in the "neutrophilic" cluster, azathioprine and ixazomib in the "B-cell" cluster, and fostamatinib in the "metabolic" patient subgroup. ConclusionThe clinical spectrum of SLE encompasses distinct molecular endotypes, each defined by unique pathophysiologic aberrancies potentially reversible by distinct compounds.	[Garantziotis, Panagiotis; Doumas, Stavros; Frangou, Eleni; Sentis, George; Filia, Anastasia; Fanouriakis, Antonis; Boumpas, Dimitrios T.] Biomed Res Fdn Acad Athens, Lab Autoimmun & Inflammat, Athens, Greece; [Garantziotis, Panagiotis] Hannover Med Sch, Rheumatol & Immunol, Hannover, Germany; [Nikolakis, Dimitrios] Univ Amsterdam, Amsterdam Inst Gastroenterol Endocrinol & Metab, Acad Med Ctr, Dept Gastroenterol, Amsterdam, Netherlands; [Nikolakis, Dimitrios] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam, Netherlands; [Nikolakis, Dimitrios] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Inst Infect & Immun, Dept Rheumatol & Clin Immunol, Amsterdam, Netherlands; [Nikolakis, Dimitrios] Acad Med Ctr, Amsterdam Rheumatol & Immunol Ctr ARC, Amsterdam, Netherlands; [Nikolakis, Dimitrios] Univ Amsterdam, Amsterdam Univ Med Ctr UMC, Amsterdam Inst Infect & Immun, Dept Expt Immunol, Amsterdam, Netherlands; [Doumas, Stavros] MedStar Georgetown Univ Hosp, Dept Med, Washington, DC USA; [Frangou, Eleni] Limassol Gen Hosp, Dept Nephrol, Limassol, Cyprus; [Fanouriakis, Antonis] Natl Kapodistrian Univ, Dept Propaedeut & Internal Med 1, Rheumatol Unit, Athens Med Sch, Athens, Greece; [Fanouriakis, Antonis; Boumpas, Dimitrios T.] Attikon Univ Hosp, Dept Internal Med 4, Athens, Greece; [Fanouriakis, Antonis; Boumpas, Dimitrios T.] Natl & Kapodistrian Univ Athens, Med Sch, Joint Rheumatol Program, Athens, Greece; [Bertsias, George] Univ Crete, Dept Rheumatol, ClinicalImmunol & Allergy, Sch Med, Iraklion, Greece; [Bertsias, George] Fdn Res & Technol Hellas FORTH, Inst Mol Biol & Biotechnol, Iraklion, Greece	Academy of Athens; Hannover Medical School; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; University of Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Georgetown University; National & Kapodistrian University of Athens; University Hospital Attikon; National & Kapodistrian University of Athens; University of Crete	Boumpas, DT (corresponding author), Biomed Res Fdn Acad Athens, Lab Autoimmun & Inflammat, Athens, Greece.; Boumpas, DT (corresponding author), Attikon Univ Hosp, Dept Internal Med 4, Athens, Greece.; Boumpas, DT (corresponding author), Natl & Kapodistrian Univ Athens, Med Sch, Joint Rheumatol Program, Athens, Greece.	boumpasd@uoc.gr	Garantziotis, Panagiotis/GYJ-1697-2022	Doumas, Stavros Alexandros Petros/0000-0003-3903-0920	EU [733100]; ERC [742390]; Foundation for Research in Rheumatology (FOREUM)	EU(European Commission); ERC(European Research Council (ERC)European Commission); Foundation for Research in Rheumatology (FOREUM)	Funding This work was supported by grants from EU (SYSCID grant agreement number 733100), ERC (LUPUSCARE grant agreement number 742390) and the Foundation for Research in Rheumatology (FOREUM)all to DB.	Akesson K, 2018, LUPUS SCI MED, V5, DOI 10.1136/lupus-2017-000254; Alexander T, 2015, ANN RHEUM DIS, V74, P1474, DOI 10.1136/annrheumdis-2014-206016; Alunno A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080898; Banchereau R, 2016, CELL, V165, P551, DOI 10.1016/j.cell.2016.03.008; Bello GA, 2016, LUPUS SCI MED, V3, DOI 10.1136/lupus-2015-000136; Besliu Alina Nicoleta, 2009, Roum Arch Microbiol Immunol, V68, P69; Bortoluzzi A, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1089-8; Chalmers SA, 2019, J AUTOIMMUN, V98, P33, DOI 10.1016/j.jaut.2018.11.004; Clarke AJ, 2015, ANN RHEUM DIS, V74, P912, DOI 10.1136/annrheumdis-2013-204343; Deng GM, 2010, ARTHRITIS RHEUM-US, V62, P2086, DOI 10.1002/art.27452; Domeier PP, 2018, CELL REP, V24, P406, DOI 10.1016/j.celrep.2018.06.046; Fanouriakis A, 2019, ANN RHEUM DIS, V78, P736, DOI 10.1136/annrheumdis-2019-215089; Feng X, 2017, LUPUS, V26, P62, DOI 10.1177/0961203316651738; Fernandez D, 2010, DISCOV MED, V9, P173; Furie R, 2020, NEW ENGL J MED, V383, P1117, DOI 10.1056/NEJMoa2001180; Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303; Grammatikos AP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074550; Grammer AC, 2016, LUPUS, V25, P1150, DOI 10.1177/0961203316657437; Grammer AC, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4667; Hage-Sleiman R, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/348798; Hsieh SC, 2008, RHEUMATOLOGY, V47, P150, DOI 10.1093/rheumatology/kem320; Huang CM, 2004, LUPUS, V13, P773, DOI 10.1191/0961203304lu1081oa; Hubel J, 2015, BIOMEDICINES, V3, P138, DOI 10.3390/biomedicines3010138; Jin N, 2011, INT IMMUNOPHARMACOL, V11, P1319, DOI 10.1016/j.intimp.2011.04.015; Karatzas E, 2019, COMPUT STRUCT BIOTEC, V17, P939, DOI 10.1016/j.csbj.2019.05.010; Keenan AB, 2018, CELL SYST, V6, P13, DOI 10.1016/j.cels.2017.11.001; Kim SC, 2015, ANN RHEUM DIS, V74, P1968, DOI 10.1136/annrheumdis-2014-205216; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lipinski CA, 1997, ADV DRUG DELIVER REV, V23, P3, DOI 10.1016/S0169-409X(96)00423-1; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mishra N, 2003, J CLIN INVEST, V111, P539, DOI 10.1172/JC1200316153; Okon L, 2014, J AM ACAD DERMATOL, V70, P583, DOI 10.1016/j.jaad.2013.11.007; Owen KA, 2020, AM J HUM GENET, V107, P864, DOI 10.1016/j.ajhg.2020.09.007; Panousis NI, 2019, ANN RHEUM DIS, V78, P1079, DOI 10.1136/annrheumdis-2018-214379; Qin SP, 2016, INFLAMMATION, V39, P503, DOI 10.1007/s10753-015-0273-3; Regna NL, 2014, CLIN IMMUNOL, V151, P29, DOI 10.1016/j.clim.2014.01.002; Rovin BH, 2021, LANCET, V397, P2070, DOI 10.1016/S0140-6736(21)00578-X; Saavedra-Garcia P, 2020, AM J PHYSIOL-CELL PH, V318, pC451, DOI 10.1152/ajpcell.00286.2019; Shimp SK, 2012, CELL MOL IMMUNOL, V9, P255, DOI 10.1038/cmi.2012.5; Toro-Dominguez D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51616-9; Toro-Dominguez D, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1263-7; Ugarte-Gil MF, 2015, ANN RHEUM DIS, V74, P1019, DOI 10.1136/annrheumdis-2013-204620; Uribe AG, 2004, J RHEUMATOL, V31, P1934; Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n; Waibel M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7838; Wallace DJ, 2018, LANCET, V392, P222, DOI 10.1016/S0140-6736(18)31363-1; Wang YF, 2018, ANN RHEUM DIS, V77, P1078, DOI 10.1136/annrheumdis-2018-213093; Whartenby KA, 2008, EXPERT OPIN INV DRUG, V17, P1685, DOI [10.1517/13543784.17.11.1685, 10.1517/13543784.17.11.1685 ]; Xi JJ, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111646; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zen M, 2015, ANN RHEUM DIS, V74, P2117, DOI 10.1136/annrheumdis-2015-207347; Zhao JJ, 2015, ARTHRITIS RHEUMATOL, V67, P1036, DOI 10.1002/art.38993; Zhao W, 2018, INFLAMMATION, V41, P1717, DOI 10.1007/s10753-018-0815-6; Zou YL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01950; 2016, bioRxiv, DOI 10.1101/060012	55	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								860726	10.3389/fimmu.2022.860726	http://dx.doi.org/10.3389/fimmu.2022.860726			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1L0CF	35615355	Green Published, gold			2022-12-18	WOS:000798959900001
J	Kny, M; Fielitz, J				Kny, Melanie; Fielitz, Jens			Hidden Agenda-The Involvement of Endoplasmic Reticulum Stress and Unfolded Protein Response in Inflammation-Induced Muscle Wasting	FRONTIERS IN IMMUNOLOGY			English	Review						endoplasmic reticulum stress; inflammation; intensive care unit acquired weakness; unfolded protein response; sepsis	INTENSIVE-CARE-UNIT; TYROSINE-PHOSPHATASE 1B; SMALL-MOLECULE INHIBITION; CRITICAL ILLNESS MYOPATHY; CRITICALLY-ILL PATIENTS; ER QUALITY-CONTROL; SKELETAL-MUSCLE; INSULIN-RESISTANCE; TRANSCRIPTIONAL INDUCTION; TRANSLATIONAL CONTROL	Critically ill patients at the intensive care unit (ICU) often develop a generalized weakness, called ICU-acquired weakness (ICUAW). A major contributor to ICUAW is muscle atrophy, a loss of skeletal muscle mass and function. Skeletal muscle assures almost all of the vital functions of our body. It adapts rapidly in response to physiological as well as pathological stress, such as inactivity, immobilization, and inflammation. In response to a reduced workload or inflammation muscle atrophy develops. Recent work suggests that adaptive or maladaptive processes in the endoplasmic reticulum (ER), also known as sarcoplasmic reticulum, contributes to this process. In muscle cells, the ER is a highly specialized cellular organelle that assures calcium homeostasis and therefore muscle contraction. The ER also assures correct folding of proteins that are secreted or localized to the cell membrane. Protein folding is a highly error prone process and accumulation of misfolded or unfolded proteins can cause ER stress, which is counteracted by the activation of a signaling network known as the unfolded protein response (UPR). Three ER membrane residing molecules, protein kinase R-like endoplasmic reticulum kinase (PERK), inositol requiring protein 1a (IRE1a), and activating transcription factor 6 (ATF6) initiate the UPR. The UPR aims to restore ER homeostasis by reducing overall protein synthesis and increasing gene expression of various ER chaperone proteins. If ER stress persists or cannot be resolved cell death pathways are activated. Although, ER stress-induced UPR pathways are known to be important for regulation of skeletal muscle mass and function as well as for inflammation and immune response its function in ICUAW is still elusive. Given recent advances in the development of ER stress modifying molecules for neurodegenerative diseases and cancer, it is important to know whether or not therapeutic interventions in ER stress pathways have favorable effects and these compounds can be used to prevent or treat ICUAW. In this review, we focus on the role of ER stress-induced UPR in skeletal muscle during critical illness and in response to predisposing risk factors such as immobilization, starvation and inflammation as well as ICUAW treatment to foster research for this devastating clinical problem.	[Kny, Melanie] Charite Univ Med Berlin, Expt & Clin Res Ctr ECRC, Max Delbruck Ctr MDC Mol Med, Helmholtz Assoc, Berlin, Germany; [Fielitz, Jens] DZHK German Ctr Cardiovasc Res, Dept Mol Cardiol, Partner Site, Greifswald, Germany; [Fielitz, Jens] Univ Med Greifswald, Dept Internal Med B, Cardiol, Greifswald, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; German Centre for Cardiovascular Research; Greifswald Medical School	Fielitz, J (corresponding author), DZHK German Ctr Cardiovasc Res, Dept Mol Cardiol, Partner Site, Greifswald, Germany.; Fielitz, J (corresponding author), Univ Med Greifswald, Dept Internal Med B, Cardiol, Greifswald, Germany.	jens.fielitz@uni-greifswald.de			Deutsche Forschungsgemeinschaft [FI 965/5-1, FI 965/5-2, FI 965/9-1, FI 965/10-1]; German Center for Cardiovascular Research [DZHK 81Z5400153]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); German Center for Cardiovascular Research	This study was supported by the Deutsche Forschungsgemeinschaft (FI 965/5-1, FI 965/5-2, FI 965/9-1, FI 965/10-1 (to JF)) and the German Center for Cardiovascular Research, partner site Greifswald [DZHK 81Z5400153 (to JF)].	Acosta-Alvear D, 2007, MOL CELL, V27, P53, DOI 10.1016/j.molcel.2007.06.011; Adams V, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102272; Afzali AM, 2018, AUTOIMMUN REV, V17, P518, DOI 10.1016/j.autrev.2017.12.005; Alibegovic AC, 2010, AM J PHYSIOL-ENDOC M, V299, pE752, DOI 10.1152/ajpendo.00590.2009; Alter J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029498; Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Arumugam S, 2012, FREE RADICAL RES, V46, P154, DOI 10.3109/10715762.2011.647010; Asami Y, 2018, INT J MED SCI, V15, P628, DOI 10.7150/ijms.22723; Aweida D, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010110; Baehr LM, 2016, AGING-US, V8, P127, DOI 10.18632/aging.100879; Barnes T, 2018, CHEST, V154, P185, DOI 10.1016/j.chest.2017.11.010; Barreiro E, 2019, J CELL PHYSIOL, V234, P11315, DOI 10.1002/jcp.27789; Bazzucchi I, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010205; Bein T, 2015, ANAESTHESIST, V64, pS1, DOI 10.1007/s00101-015-0071-1; Beltrami M, 2021, WORLD J CARDIOL, V13, P1, DOI 10.4330/wjc.v13.i1.1; Bentzinger CF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008342; Berek K, 1996, INTENS CARE MED, V22, P849; Bierbrauer J, 2012, CRIT CARE MED, V40, P647, DOI 10.1097/CCM.0b013e31823295e6; Blais A, 2005, GENE DEV, V19, P553, DOI 10.1101/gad.1281105; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Bogaerts A, 2007, J GERONTOL A-BIOL, V62, P630, DOI 10.1093/gerona/62.6.630; Bohnert KR, 2018, J CELL PHYSIOL, V233, P67, DOI 10.1002/jcp.25852; Bohnert KR, 2016, FASEB J, V30, P3053, DOI 10.1096/fj.201600250RR; Bowen TS, 2017, J CACHEXIA SARCOPENI, V8, P939, DOI 10.1002/jcsm.12233; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Bravo R, 2011, J CELL SCI, V124, P2143, DOI 10.1242/jcs.080762; Bruss MD, 2005, DIABETES, V54, P41, DOI 10.2337/diabetes.54.1.41; Busch K, 2021, J CACHEXIA SARCOPENI, V12, P1653, DOI 10.1002/jcsm.12763; CALDWELL CJ, 1990, NEUROPATH APPL NEURO, V16, P225, DOI 10.1111/j.1365-2990.1990.tb01159.x; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chaudhary P, 2012, MOL CELL BIOCHEM, V364, P101, DOI 10.1007/s11010-011-1210-x; Chen C, 2020, MOLECULES, V25, DOI 10.3390/molecules25143267; Chen LY, 2020, DIABET METAB SYND OB, V13, P4561, DOI 10.2147/DMSO.S275301; Chipurupalli S, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.758311; Cho DS, 2020, J CACHEXIA SARCOPENI, V11, P1351, DOI 10.1002/jcsm.12596; Choi SE, 2008, ARCH BIOCHEM BIOPHYS, V475, P109, DOI 10.1016/j.abb.2008.04.015; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Connolly B, 2016, THORAX, V71, P881, DOI 10.1136/thoraxjnl-2015-208273; COUTEAUX R, 1988, BIOL CELL, V62, P171, DOI 10.1016/0248-4900(88)90034-2; da Silva MH, 2017, LIFE SCI, V179, P98, DOI 10.1016/j.lfs.2017.05.004; De Jonghe B, 1998, INTENS CARE MED, V24, P1242, DOI 10.1007/s001340050757; De Jonghe B, 2007, CRIT CARE MED, V35, P2007, DOI 10.1097/01.ccm.0000281450.01881.d8; Theije CC, 2018, ENDOCRINOLOGY, V159, P519, DOI 10.1210/en.2017-00603; De Waele E, 2021, CURR OPIN CRIT CARE, V27, P334, DOI 10.1097/MCC.0000000000000844; Deldicque L, 2013, J PHYSIOL BIOCHEM, V69, P215, DOI 10.1007/s13105-012-0204-9; Denehy L, 2013, CRIT CARE, V17, DOI 10.1186/cc12835; Ding BX, 2016, SCI REP-UK, V6, DOI 10.1038/srep22538; Ding K, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/6614985; dos Santos C, 2016, AM J RESP CRIT CARE, V194, P821, DOI 10.1164/rccm.201512-2344OC; Du Bois P, 2015, CIRC RES, V117, P424, DOI 10.1161/CIRCRESAHA.114.305393; Du KY, 2003, SCIENCE, V300, P1574, DOI 10.1126/science.1079817; Ebert SM, 2015, J BIOL CHEM, V290, P25497, DOI 10.1074/jbc.M115.681445; Ebert SM, 2012, J BIOL CHEM, V287, P27290, DOI 10.1074/jbc.M112.374777; Ebert SM, 2010, MOL ENDOCRINOL, V24, P790, DOI 10.1210/me.2009-0345; Eisner V., 2013, INTERACTIONS SARCO E; Eisner V, 2013, J CELL SCI, V126, P2965, DOI 10.1242/jcs.093609; Elke G, 2019, CLIN NUTR ESPEN, V33, P220, DOI 10.1016/j.clnesp.2019.05.002; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Emanuele E, 2016, NEUROENDOCRINOL LETT, V37, P213; Eyers PA, 2017, TRENDS CELL BIOL, V27, P284, DOI 10.1016/j.tcb.2016.11.002; Fan E, 2014, AM J RESP CRIT CARE, V190, P1437, DOI 10.1164/rccm.201411-2011ST; Fang PH, 2018, LIFE SCI, V196, P156, DOI 10.1016/j.lfs.2018.01.022; Fielitz J, 2007, J CLIN INVEST, V117, P2486, DOI 10.1172/JCI32827; Fossat G, 2018, JAMA-J AM MED ASSOC, V320, P368, DOI 10.1001/jama.2018.9592; Fox DK, 2014, AM J PHYSIOL-ENDOC M, V307, pE245, DOI 10.1152/ajpendo.00010.2014; Gallot YS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052567; Gerovasili V, 2009, CRIT CARE, V13, DOI 10.1186/cc8123; Gerovasili V, 2009, CHEST, V136, P1249, DOI 10.1378/chest.08-2888; Giordani L, 2019, MOL CELL, V74, P609, DOI 10.1016/j.molcel.2019.02.026; Gong N, 2015, GENET MOL RES, V14, P12377, DOI 10.4238/2015.October.16.4; Goodman CA, 2011, CELL SIGNAL, V23, P1896, DOI 10.1016/j.cellsig.2011.07.013; Gordaliza-Alaguero I, 2019, EMBO REP, V20, DOI 10.15252/embr.201947928; Grande V, 2018, HUM MOL GENET, V27, P2477, DOI 10.1093/hmg/ddy152; Gu F, 2004, J BIOL CHEM, V279, P49689, DOI 10.1074/jbc.C400261200; Gu N, 2015, BIOCHEM BIOPH RES CO, V467, P521, DOI 10.1016/j.bbrc.2015.10.005; Gu RC, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01198; Guo R, 2015, INT J CARDIOL, V191, P36, DOI 10.1016/j.ijcard.2015.04.245; Haberecht-Muller S, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11091327; Hahn A, 2020, J CACHEXIA SARCOPENI, V11, P103, DOI 10.1002/jcsm.12491; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hayashi T, 2000, DIABETES, V49, P527, DOI 10.2337/diabetes.49.4.527; Herridge MS, 2011, NEW ENGL J MED, V364, P1293, DOI 10.1056/NEJMoa1011802; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hetz C, 2020, NAT REV MOL CELL BIO, V21, P421, DOI 10.1038/s41580-020-0250-z; Hetz C, 2019, NAT CHEM BIOL, V15, P764, DOI 10.1038/s41589-019-0326-2; Hill A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082851; Hodgson CL, 2017, J PHYSIOTHER, V63, P4, DOI 10.1016/j.jphys.2016.10.011; Hollien J, 2009, J CELL BIOL, V186, P323, DOI 10.1083/jcb.200903014; Hu HL, 2014, CELL PHYSIOL BIOCHEM, V33, P1899, DOI 10.1159/000362967; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Huang N, 2017, INTENS CARE MED EXP, V5, DOI 10.1186/s40635-016-0115-0; Hunter RB, 2001, AM J PHYSIOL-CELL PH, V281, pC1285, DOI 10.1152/ajpcell.2001.281.4.C1285; Hwang SL, 2013, BRIT J PHARMACOL, V169, P69, DOI 10.1111/bph.12124; Isaac ST, 2016, CURR DRUG TARGETS, V17, P1140, DOI 10.2174/1389450116666150416115721; Islam MA, 2022, ANIM BIOSCI, V35, P22, DOI 10.5713/ab.21.0140; Jaitovich A, 2015, J BIOL CHEM, V290, P9183, DOI 10.1074/jbc.M114.625715; Jespersen JG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018090; Karatzanos E, 2012, CRIT CARE RES PRACT, V2012, DOI 10.1155/2012/432752; Kars M, 2010, DIABETES, V59, P1899, DOI 10.2337/db10-0308; Kedar V, 2004, P NATL ACAD SCI USA, V101, P18135, DOI 10.1073/pnas.0404341102; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; Khan MM, 2015, SHOCK, V44, P294, DOI 10.1097/SHK.0000000000000425; Kim N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120104; Kim Y, 2018, J MED FOOD, V21, P551, DOI 10.1089/jmf.2017.4108; Koch S, 2014, MUSCLE NERVE, V50, P431, DOI 10.1002/mus.24175; Koh HJ, 2006, MOL CELL BIOL, V26, P8217, DOI 10.1128/MCB.00979-06; Koh HJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2851; Kohno K, 2007, ANTIOXID REDOX SIGN, V9, P2295, DOI 10.1089/ars.2007.1819; Koncarevic A, 2007, FASEB J, V21, P427, DOI 10.1096/fj.06-6665com; Korponay TC, 2020, AM J RESP CELL MOL, V62, P74, DOI 10.1165/rcmb.2019-0061OC; Koyama S, 2008, J MOL BIOL, V376, P1224, DOI 10.1016/j.jmb.2007.11.049; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; Kryvenko V, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.735580; Kumar V, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020173; Kunze M, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00259; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Kwak HJ, 2016, CELL SIGNAL, V28, P788, DOI 10.1016/j.cellsig.2016.03.015; Kwon SJ, 2005, CLIN CANCER RES, V11, P7607, DOI 10.1158/1078-0432.CCR-05-0981; Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745; Langen RCJ, 2013, INT J BIOCHEM CELL B, V45, P2245, DOI 10.1016/j.biocel.2013.06.015; Langhans C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092048; Le NH, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/834294; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Lee CS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14659; Lee S, 2016, HUM EXP TOXICOL, V35, P501, DOI 10.1177/0960327115595683; Lee SJ, 2014, BIOCHEM BIOPH RES CO, V455, P147, DOI 10.1016/j.bbrc.2014.10.115; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Li CG, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01409; Li YP, 2016, ACTA PHARMACOL SIN, V37, P344, DOI 10.1038/aps.2015.130; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Ma L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186128; Machado A, 2010, SCAND J MED SCI SPOR, V20, P200, DOI 10.1111/j.1600-0838.2009.00919.x; Malerba A, 2019, HUM MOL GENET, V28, P1694, DOI 10.1093/hmg/ddz007; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Manas-Garcia L, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092436; Marciniak SJ, 2004, GENE DEV, V18, P3066, DOI 10.1101/gad.1250704; Martina JA, 2016, EMBO J, V35, P479, DOI 10.15252/embj.201593428; Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; McElhinny AS, 2002, J CELL BIOL, V157, P125, DOI 10.1083/jcb.200108089; Menu P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.132; Milan G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7670; Millay DP, 2013, NATURE, V499, P301, DOI 10.1038/nature12343; Moon JY, 2020, CELL BIOL INT, V44, P1831, DOI 10.1002/cbin.11377; Morris PE, 2016, JAMA-J AM MED ASSOC, V315, P2694, DOI 10.1001/jama.2016.7201; Morris PE, 2011, AM J MED SCI, V341, P373, DOI 10.1097/MAJ.0b013e31820ab4f6; Mukai R, 2016, J NUTR BIOCHEM, V31, P67, DOI 10.1016/j.jnutbio.2016.02.001; Mukai R, 2010, J NAT PROD, V73, P1708, DOI 10.1021/np100240y; Murlasits Z, 2007, MED SCI SPORT EXER, V39, P1522, DOI 10.1249/mss.0b013e3180cc25c7; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nakanishi K, 2005, J CELL BIOL, V169, P555, DOI 10.1083/jcb.200412024; Nakanishi K, 2007, FASEB J, V21, P2994, DOI 10.1096/fj.06-6408com; Nishikawa S, 2005, J BIOCHEM, V137, P551, DOI 10.1093/jb/mvi068; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Nowak M, 2019, J CELL SCI, V132, DOI 10.1242/jcs.233395; Oberg AI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022510; Ochala J, 2008, EXP PHYSIOL, V93, P486, DOI 10.1113/expphysiol.2007.041798; Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294; Ogborn DI, 2014, AM J PHYSIOL-REG I, V307, pR664, DOI 10.1152/ajpregu.00511.2013; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160; Tortola CP, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.550506; Pan YT, 2019, MOL MED REP, V20, P709, DOI 10.3892/mmr.2019.10298; Panzhinskiy E, 2013, CURR MED CHEM, V20, P2609, DOI 10.2174/0929867311320210001; Panzhinskiy E, 2013, DIABETOLOGIA, V56, P598, DOI 10.1007/s00125-012-2782-z; Panzhinskiy E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077228; Parveen A, 2021, FASEB J, V35, DOI 10.1096/fj.202100777RR; Patsaki I, 2017, J CRIT CARE, V40, P76, DOI 10.1016/j.jcrc.2017.03.014; Paul PK, 2012, MOL CELL BIOL, V32, P1248, DOI 10.1128/MCB.06351-11; Paul PK, 2010, J CELL BIOL, V191, P1395, DOI 10.1083/jcb.201006098; Paval DR, 2022, J CACHEXIA SARCOPENI, V13, P824, DOI 10.1002/jcsm.12912; Peris-Moreno D, 2021, MOLECULES, V26, DOI 10.3390/molecules26020407; Perner A, 2016, INTENS CARE MED, V42, P1958, DOI 10.1007/s00134-016-4577-z; Polge C, 2018, J CACHEXIA SARCOPENI, V9, P129, DOI 10.1002/jcsm.12249; Polge C, 2011, FASEB J, V25, P3790, DOI 10.1096/fj.11-180968; Puthucheary ZA, 2013, JAMA-J AM MED ASSOC, V310, P1591, DOI 10.1001/jama.2013.278481; Qu JY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041526; Quinn ME, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15665; Raciti GA, 2010, DIABETOLOGIA, V53, P955, DOI 10.1007/s00125-010-1676-1; Rashid T, 2019, EMBO J, V38, DOI 10.15252/embj.201899576; Rawat R, 2010, AM J PATHOL, V176, P2891, DOI 10.2353/ajpath.2010.090058; Read A, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10050384; Relaix F, 2012, DEVELOPMENT, V139, P2845, DOI 10.1242/dev.069088; Ren J, 2021, NAT REV CARDIOL, V18, P499, DOI 10.1038/s41569-021-00511-w; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Rieusset J, 2012, BIOCHEM BIOPH RES CO, V417, P439, DOI 10.1016/j.bbrc.2011.11.135; Robert F, 2006, MOL BIOL CELL, V17, P4632, DOI 10.1091/mbc.E06-06-0478; Rocheteau P, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10145; Routsi C, 2010, CRIT CARE, V14, DOI 10.1186/cc8987; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; Sakr Y, 2018, OPEN FORUM INFECT DI, V5, DOI 10.1093/ofid/ofy313; Samuel VT, 2012, CELL, V148, P852, DOI 10.1016/j.cell.2012.02.017; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Saveljeva S, 2016, ONCOTARGET, V7, P12254, DOI 10.18632/oncotarget.7601; Schaller SJ, 2016, LANCET, V388, P1377, DOI 10.1016/S0140-6736(16)31637-3; Schefold JC, 2020, J CACHEXIA SARCOPENI, V11, P1399, DOI 10.1002/jcsm.12620; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schiaffino S, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0046-6; Schmidt F, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0545-6; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040; Schroder M, 2005, MUTAT RES-FUND MOL M, V569, P29, DOI 10.1016/j.mrfmmm.2004.06.056; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Schweickert WD, 2007, CHEST, V131, P1541, DOI 10.1378/chest.06-2065; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Sepulveda-Loyola W, 2020, J CACHEXIA SARCOPENI, V11, P1164, DOI 10.1002/jcsm.12600; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Sharshar T, 2009, CRIT CARE MED, V37, P3047, DOI 10.1097/CCM.0b013e3181b027e9; Shen MZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088389; Shi T, 2020, J LEUKOCYTE BIOL, V108, P1829, DOI 10.1002/JLB.3AB0820-576RRR; Shu XY, 2022, J CACHEXIA SARCOPENI, V13, P145, DOI 10.1002/jcsm.12890; Sidrauski C, 1996, CELL, V87, P405, DOI 10.1016/S0092-8674(00)81361-6; Slade L, 2017, MOL CANCER RES, V15, P1637, DOI 10.1158/1541-7786.MCR-17-0320; SLOT JW, 1991, P NATL ACAD SCI USA, V88, P7815, DOI 10.1073/pnas.88.17.7815; Smith JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00422; Son YH, 2017, BIOMED PHARMACOTHER, V95, P1486, DOI 10.1016/j.biopha.2017.09.002; Sun LJ, 2017, BIOCHEM BIOPH RES CO, V487, P83, DOI 10.1016/j.bbrc.2017.04.022; Tanaka K, 2009, P JPN ACAD B-PHYS, V85, P12, DOI [10.2183/pjab.85.12, 10.2183/pjab/85.12]; Tezze C, 2017, CELL METAB, V25, P1374, DOI 10.1016/j.cmet.2017.04.021; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Van Aerde N, 2020, INTENS CARE MED, V46, P1184, DOI 10.1007/s00134-020-05927-5; van Vliet AR, 2018, CURR TOP MICROBIOL, V414, P73, DOI 10.1007/82_2017_2; van Zanten ARH, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2657-5; Vincent JL, 2018, INTENS CARE MED, V44, P337, DOI 10.1007/s00134-017-5043-2; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Walsh CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep29334; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; Wang BJ, 2020, BIOL OPEN, V9, DOI 10.1242/bio.054296; Wang BH, 2018, NEUROUROL URODYNAM, V37, P699, DOI 10.1002/nau.23380; Wang DT, 2014, INT IMMUNOPHARMACOL, V19, P206, DOI 10.1016/j.intimp.2014.02.002; Wang HL, 2010, DIABETES, V59, P1879, DOI 10.2337/db10-0207; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Weber-Carstens S, 2013, AM J RESP CRIT CARE, V187, P387, DOI 10.1164/rccm.201209-1649OC; Weber-Carstens S, 2009, CRIT CARE MED, V37, P2632, DOI 10.1097/CCM.0b013e3181a92f28; Wei XC, 1998, ACTA ORTHOP SCAND, V69, P633, DOI 10.3109/17453679808999270; WILKINSON KD, 1980, J BIOL CHEM, V255, P7529; Witt SH, 2005, J MOL BIOL, V350, P713, DOI 10.1016/j.jmb.2005.05.021; Wolf DH, 2004, BBA-MOL CELL RES, V1695, P19, DOI 10.1016/j.bbamcr.2004.10.007; Wollersheim T, 2019, J CACHEXIA SARCOPENI, V10, P734, DOI 10.1002/jcsm.12428; Wollersheim T, 2017, CRIT CARE, V21, DOI 10.1186/s13054-016-1576-y; Wollersheim T, 2014, INTENS CARE MED, V40, P528, DOI 10.1007/s00134-014-3224-9; Wu J, 2011, CELL METAB, V13, P160, DOI 10.1016/j.cmet.2011.01.003; Xu ZQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep37709; Yamamoto K, 2007, DEV CELL, V13, P365, DOI 10.1016/j.devcel.2007.07.018; Yamamoto K, 2010, MOL BIOL CELL, V21, P2975, DOI 10.1091/mbc.E09-02-0133; Yang J, 2017, BIOMED PHARMACOTHER, V93, P1343, DOI 10.1016/j.biopha.2017.06.086; Yang T, 2018, ACTA NEUROL SCAND, V138, P104, DOI 10.1111/ane.12964; Yang XF, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04094-9; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yin XL, 2011, AM J CHINESE MED, V39, P853, DOI 10.1142/S0192415X11009251; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Yoshida H, 2007, ANTIOXID REDOX SIGN, V9, P2323, DOI 10.1089/ars.2007.1800; Yu YT, 2021, CRIT CARE, V25, DOI 10.1186/s13054-021-03774-4; Yu ZG, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002321; Zanders L, 2022, J CACHEXIA SARCOPENI, V13, P713, DOI 10.1002/jcsm.12867; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848; Zhang PC, 2002, MOL CELL BIOL, V22, P3864, DOI 10.1128/MCB.22.11.3864-3874.2002; Zhang Z, 2020, DIABET METAB SYND OB, V13, P1417, DOI 10.2147/DMSO.S243024; Zhao GL, 2016, ACTA PHARMACOL SIN, V37, P354, DOI 10.1038/aps.2015.136; Zhu XX, 2017, CRIT CARE MED, V45, pE169, DOI 10.1097/CCM.0000000000002056; Zismanov V, 2016, CELL STEM CELL, V18, P79, DOI 10.1016/j.stem.2015.09.020; Zusman O, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1538-4	265	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								878755	10.3389/fimmu.2022.878755	http://dx.doi.org/10.3389/fimmu.2022.878755			26	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S2WF	35615361	Green Accepted, gold, Green Published			2022-12-18	WOS:000803915900001
J	Mueller, M; Reguzova, A; Loeffler, MW; Amann, R				Mueller, Melanie; Reguzova, Alena; Loeffler, Markus W.; Amann, Ralf			Orf Virus-Based Vectors Preferentially Target Professional Antigen-Presenting Cells, Activate the STING Pathway and Induce Strong Antigen-Specific T Cell Responses	FRONTIERS IN IMMUNOLOGY			English	Article						parapoxvirus; ORFV; viral vector; vaccine; antigen-presenting cell; STING pathway; T cell response	DENDRITIC CELLS; INDEPENDENT PRODUCTION; MACROPINOCYTOSIS; PARAPOXVIRUSES; INFECTION; RECEPTOR; DNA; INTERFERON; EXPRESSION; GENERATION	BackgroundOrf virus (ORFV)-based vectors are attractive for vaccine development as they enable the induction of potent immune responses against specific transgenes. Nevertheless, the precise mechanisms of immune activation remain unknown. This study therefore aimed to characterize underlying mechanisms in human immune cells. MethodsPeripheral blood mononuclear cells were infected with attenuated ORFV strain D1701-VrV and analyzed for ORFV infection and activation markers. ORFV entry in susceptible cells was examined using established pharmacological inhibitors. Using the THP1-Dual (TM) reporter cell line, activation of nuclear factor-kappa B and interferon regulatory factor pathways were simultaneously evaluated. Infection with an ORFV recombinant encoding immunogenic peptides (PepTrio-ORFV) was used to assess the induction of antigen-specific CD8+ T cells. ResultsORFV was found to preferentially target professional antigen-presenting cells (APCs) in vitro, with ORFV uptake mediated primarily by macropinocytosis. ORFV-infected APCs exhibited an activated phenotype, required for subsequent lymphocyte activation. Reporter cells revealed that the stimulator of interferon genes pathway is a prerequisite for ORFV-mediated cellular activation. PepTrio-ORFV efficiently induced antigen-specific CD8+ T cell recall responses in a dose-dependent manner. Further, activation and expansion of naive antigen-specific CD8+ T cells was observed in response. DiscussionOur findings confirm that ORFV induces a strong antigen-specific immune response dependent on APC uptake and activation. These data support the notion that ORFV D1701-VrV is a promising vector for vaccine development and the design of innovative immunotherapeutic applications.	[Mueller, Melanie; Reguzova, Alena; Loeffler, Markus W.; Amann, Ralf] Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Tubingen, Germany; [Loeffler, Markus W.] Univ Hosp Tubingen, Dept Gen, Visceral & Transplant Surg, Tubingen, Germany; [Loeffler, Markus W.] Univ Hosp Tubingen, Dept Clin Pharmacol, Tubingen, Germany; [Loeffler, Markus W.] Univ Tubingen, Cluster Excellence iFIT EXC2180 mage Guided & Fun, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen	Loeffler, MW; Amann, R (corresponding author), Univ Tubingen, Interfac Inst Cell Biol, Dept Immunol, Tubingen, Germany.; Loeffler, MW (corresponding author), Univ Hosp Tubingen, Dept Gen, Visceral & Transplant Surg, Tubingen, Germany.; Loeffler, MW (corresponding author), Univ Hosp Tubingen, Dept Clin Pharmacol, Tubingen, Germany.; Loeffler, MW (corresponding author), Univ Tubingen, Cluster Excellence iFIT EXC2180 mage Guided & Fun, Tubingen, Germany.	markus.loeffler@uni-tuebingen.de; ralf.amann@ifiz.uni-tuebingen.de	Löffler, Markus/K-2239-2014	Löffler, Markus/0000-0003-2513-1317	Institutional Strategy of the University of Tuebingen; EXIST Forschungstransfer of the German Ministry for Economic Affairs and Energy; European Social Fund; University of Tuebingen	Institutional Strategy of the University of Tuebingen; EXIST Forschungstransfer of the German Ministry for Economic Affairs and Energy; European Social Fund(European Social Fund (ESF)); University of Tuebingen	This research was supported in part by the Institutional Strategy of the University of Tuebingen (Deutsche Forschungsgemeinschaft ZUK63), the EXIST Forschungstransfer of the German Ministry for Economic Affairs and Energy, which is co-financed by the European Social Fund. We acknowledge support by Open Access Publishing Fund of the University of Tuebingen.	Al-Salam S, 2008, J CUTAN PATHOL, V35, P603, DOI 10.1111/j.1600-0560.2007.00857.x; Altenburg AF, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08719-y; Amann R, 2013, J VIROL, V87, P1618, DOI 10.1128/JVI.02470-12; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Barbalat R, 2009, NAT IMMUNOL, V10, P1200, DOI 10.1038/ni.1792; Buttner M, 2002, J VET MED B, V49, P7, DOI 10.1046/j.1439-0450.2002.00539.x; Cubells JRE, 2016, DERMATOPATHOLOGY, V3, P55, DOI 10.1159/000447125; Dutta Dipannita, 2012, Cell Logist, V2, P203; El-Jesr M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.568412; Flechsig C, 2011, CYTOTHERAPY, V13, P739, DOI 10.3109/14653249.2010.549123; Georgana I, 2018, J VIROL, V92, DOI 10.1128/JVI.02145-17; Guerra S, 2007, J VIROL, V81, P8707, DOI 10.1128/JVI.00444-07; Henkel M, 2005, J VIROL, V79, P314, DOI 10.1128/JVI.79.1.314-325.2005; Kieser Q, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228028; Lam E, 2014, J VIROL, V88, P974, DOI 10.1128/JVI.02702-13; Liu L, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-15; MAYR A, 1981, ZBL VET MED B, V28, P535; MERCER AA, 1987, VIROLOGY, V157, P1, DOI 10.1016/0042-6822(87)90307-2; Mercer J, 2009, NAT CELL BIOL, V11, P510, DOI 10.1038/ncb0509-510; Norbury CC, 1997, EUR J IMMUNOL, V27, P280, DOI 10.1002/eji.1830270141; Quemin ER, 2018, J MOL BIOL, V430, P1714, DOI 10.1016/j.jmb.2018.04.019; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Reguzova A, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9121862; Reguzova A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020295; Rohde J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083802; Rohde J, 2011, VACCINE, V29, P9256, DOI 10.1016/j.vaccine.2011.09.121; Rziha HJ, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11020127; Rziha HJ, 2016, METHODS MOL BIOL, V1349, P177, DOI 10.1007/978-1-4939-3008-1_12; Rziha HJ, 1999, J BIOTECHNOL, V73, P235, DOI 10.1016/S0168-1656(99)00141-8; Rziha HJ, 2000, J BIOTECHNOL, V83, P137, DOI 10.1016/S0168-1656(00)00307-2; Rziha HJ., 2021, ENCY VIROLOGY, P666; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sandgren KJ, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000866; Sarkar K, 2005, IMMUNOLOGY, V116, P513, DOI 10.1111/j.1365-2567.2005.02253.x; Schneider M, 2020, J VIROL, V94, DOI 10.1128/JVI.00398-20; Siegemund S, 2009, J VIROL, V83, P9411, DOI 10.1128/JVI.02362-08; van Rooij EMA, 2010, VACCINE, V28, P1808, DOI 10.1016/j.vaccine.2009.12.004; Voigt H, 2007, VACCINE, V25, P5915, DOI 10.1016/j.vaccine.2007.05.035; von Buttlar H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106188; Wang RX, 2019, REV MED VIROL, V29, DOI 10.1002/rmv.2013; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Xiao TS, 2013, MOL CELL, V51, P135, DOI 10.1016/j.molcel.2013.07.004; Zhu JG, 2007, BLOOD, V109, P619, DOI 10.1182/blood-2006-06-027136	43	0	0	6	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								873351	10.3389/fimmu.2022.873351	http://dx.doi.org/10.3389/fimmu.2022.873351			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S2OX	35615366	Green Published, gold			2022-12-18	WOS:000803896800001
J	Peng, B; Sun, L; Zhang, M; Yan, HC; Shi, GC; Xia, ZW; Dai, RR; Tang, W				Peng, Bo; Sun, Lin; Zhang, Meng; Yan, Huacheng; Shi, Guochao; Xia, Zhenwei; Dai, Ranran; Tang, Wei			Role of IL-25 on Eosinophils in the Initiation of Th2 Responses in Allergic Asthma	FRONTIERS IN IMMUNOLOGY			English	Article						IL-25; eosinophil; APC; allergic asthma; Th2 response	DENDRITIC CELLS; RECEPTOR EXPRESSION; IMMUNE-RESPONSES; ANTIGEN PRESENTATION; T-CELLS; INFLAMMATION; DISEASE; AIRWAYS; INTERLEUKIN-25; ACTIVATION	BackgroundEosinophils act as a secondary antigen-presenting cell (APC) to stimulate Th cell responses against antigens. IL-25 plays a significant role in eosinophil activation in allergic asthma. The role of IL-25 on the classic APC functions of dendritic cells has been elucidated. However, whether IL-25 facilitates eosinophils for antigen presentation is unknown. ObjectiveTo elucidate the role of IL-25 on eosinophils antigen presenting function during allergic asthma and its related mechanism. MethodsEosinophils from allergic asthma subjects were cultured with IL-25 and HDM to identify the co-stimulator molecules expression. Co-cultures of patient eosinophils and autologous naive CD4(+) T cells in the same culture system were to explore whether eosinophils had the capacity to promote Th cell differentiation in response to IL-25 engagement. In asthma mouse model, IL-25(-/-) mice were exposed to HDM to investigate the effect of IL-25 on eosinophils during the sensitization phase. The impact of IL-25 on the capacity for eosinophils taking up antigens was evaluated. Mouse bone marrow derived eosinophils (BmEOS) were co-cultured with naive CD4(+)T cells sorted from spleens under HDM and IL-25 stimulation to identify T cell differentiation. ResultsIL-25 upregulated HLA-DR, PD-L1, and OX-40L expression on eosinophils from allergic asthma patients. IL-25 and HDM co-sensitized eosinophils promoted Th2 differentiation. In mouse model, IL-25(-/-) mice experienced restrained allergic pulmonary inflammation and reduced eosinophils recruitment and antigen uptake capacity during the early sensitization phase. In vitro, IL-25 promoted antigen uptake by eosinophils. In BmEOS and naive CD4(+)T cells co-culture, IL-25 accreted the proportion of CD4(+)Th2 cells, which was absent in CD4(+)T cells culture alone. ConclusionOur data identify a novel role of IL-25 in enhancing eosinophils antigen uptake and co-stimulator molecules expression to induce Th2 priming in the context of allergic inflammation.	[Peng, Bo; Sun, Lin; Yan, Huacheng; Shi, Guochao; Dai, Ranran; Tang, Wei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China; [Peng, Bo; Sun, Lin; Yan, Huacheng; Shi, Guochao; Dai, Ranran; Tang, Wei] Shanghai Jiao Tong Univ, Sch Med, Inst Resp Dis, Shanghai, Peoples R China; [Peng, Bo; Sun, Lin; Yan, Huacheng; Shi, Guochao; Dai, Ranran; Tang, Wei] Shanghai Key Lab Emergency Prevent, Diag & Treatment Resp Infect Dis, Shanghai, Peoples R China; [Zhang, Meng; Xia, Zhenwei] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pediat, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Dai, RR; Tang, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pulm & Crit Care Med, Shanghai, Peoples R China.; Dai, RR; Tang, W (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Resp Dis, Shanghai, Peoples R China.; Dai, RR; Tang, W (corresponding author), Shanghai Key Lab Emergency Prevent, Diag & Treatment Resp Infect Dis, Shanghai, Peoples R China.; Xia, ZW (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Pediat, Shanghai, Peoples R China.	xzw10484@rjh.com.cn; drrcyy@msn.com; tina_tangwei@163.com						Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Angkasekwinai P, 2010, NAT IMMUNOL, V11, P250, DOI 10.1038/ni.1846; Cheung PFY, 2006, ALLERGY, V61, P878, DOI 10.1111/j.1398-9995.2006.01102.x; Claudio E, 2019, J IMMUNOL, V203, P2319, DOI 10.4049/jimmunol.1900254; Claudio E, 2015, J IMMUNOL, V195, P3525, DOI 10.4049/jimmunol.1500436; Corrigan CJ, 2011, J ALLERGY CLIN IMMUN, V128, P116, DOI 10.1016/j.jaci.2011.03.043; DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919; Di CX, 2015, J BIOL CHEM, V290, P12523, DOI 10.1074/jbc.M115.642637; Duez C, 2004, J ALLERGY CLIN IMMUN, V114, P820, DOI 10.1016/j.jaci.2004.08.011; Dyer KD, 2008, J IMMUNOL, V181, P4004, DOI 10.4049/jimmunol.181.6.4004; Farhan RK, 2016, IMMUNOLOGY, V149, P413, DOI 10.1111/imm.12658; Gregory LG, 2013, THORAX, V68, P82, DOI 10.1136/thoraxjnl-2012-202003; Hammad H, 2021, CELL, V184, P1469, DOI 10.1016/j.cell.2021.02.016; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hogan SP, 2008, CLIN EXP ALLERGY, V38, P709, DOI 10.1111/j.1365-2222.2008.02958.x; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jacobsen EA, 2011, J IMMUNOL, V187, P6059, DOI 10.4049/jimmunol.1102299; Kaiko GE, 2010, J IMMUNOL, V185, P4681, DOI 10.4049/jimmunol.1001758; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Li HJ, 2014, INFLAMMATION, V37, P1070, DOI 10.1007/s10753-014-9830-4; Li J, 2009, ALLERGY, V64, P1083, DOI 10.1111/j.1398-9995.2009.01967.x; Lu Thomas X, 2014, Bio Protoc, V4; Lucas ED, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108258; MacKenzie JR, 2001, J IMMUNOL, V167, P3146, DOI 10.4049/jimmunol.167.6.3146; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1; Schuijs MJ, 2019, TRENDS IMMUNOL, V40, P22, DOI 10.1016/j.it.2018.11.001; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shi HZ, 2004, ALLERGY, V59, P428, DOI 10.1046/j.1398-9995.2003.00405.x; Tang W, 2018, CLIN TRANSL ALLERGY, V8, DOI 10.1186/s13601-018-0190-2; Tang W, 2016, INT ARCH ALLERGY IMM, V170, P234, DOI 10.1159/000449248; Tang W, 2014, INT ARCH ALLERGY IMM, V163, P5, DOI 10.1159/000355331; Tworek D, 2016, AM J RESP CRIT CARE, V193, P957, DOI 10.1164/rccm.201509-1751OC; von Garnier C, 2007, J IMMUNOL, V179, P5748, DOI 10.4049/jimmunol.179.9.5748; Wang HB, 2007, J IMMUNOL, V179, P7585, DOI 10.4049/jimmunol.179.11.7585; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Weller PF, 2017, NAT REV IMMUNOL, V17, P746, DOI 10.1038/nri.2017.95; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; Wong CK, 2005, AM J RESP CELL MOL, V33, P186, DOI 10.1165/rcmb.2005-0034OC; Xu M, 2018, IMMUNITY, V48, P787, DOI 10.1016/j.immuni.2018.03.019; Xu M, 2017, IMMUNOL REV, V278, P185, DOI 10.1111/imr.12558	43	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								842500	10.3389/fimmu.2022.842500	http://dx.doi.org/10.3389/fimmu.2022.842500			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K9VS	35615348	gold, Green Published			2022-12-18	WOS:000798942900001
J	Peng, YJ; Wu, QY; Zhou, Q; Yang, ZL; Yin, F; Wang, LX; Chen, Q; Feng, C; Ren, XW; Liu, TY				Peng, Yaojun; Wu, Qiyan; Zhou, Qing; Yang, Zhanglin; Yin, Fan; Wang, Lingxiong; Chen, Qi; Feng, Cong; Ren, Xuewen; Liu, Tianyi			Identification of Immune-Related Genes Concurrently Involved in Critical Illnesses Across Different Etiologies: A Data-Driven Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						critical illness; trauma; sepsis; WGCNA; data-driven analysis; immune response	SEPSIS; BIOMARKERS; GENOMICS; TRAUMA; CELLS	Severe trauma and sepsis can lead to multiple organ dysfunction syndrome, which is a leading cause of death in intensive care units with mortality rates in excess of 50%. In addition to infection, the degree of immuno-inflammatory response also influences the outcome. The genomic changes observed after a variety of pathophysiological insults, such as trauma, sepsis, burns are similar, and consist of innate immune activation and adaptive immunity suppression. However, the characteristics of the shared mechanisms of aforementioned critical illnesses and the clinical relevance remain less explored. In the present study, we performed a data analysis to identify functional genes concurrently involved in critical illnesses across differing etiologies (trauma and sepsis derived from community-acquired pneumonia/abdominal source) and explored the shared signaling pathways these common genes involved in to gain insight into the underlying molecular mechanisms. A number of immune-related biological functions were found to be dysregulated in both trauma and sepsis in the present study, so we continued to identify immune-related common genes, profiled the immune cell proportion, and explored the relationships between them. The diagnostic and prognostic value of the immune-related common genes was also evaluated to address their potential clinical utilization as novel biomarkers. Notably, we identified a list of 14 immune-related genes concurrently dysregulated in trauma and sepsis showing favorable diagnostic value, among which S100P can predict prognosis of sepsis patients. Moreover, a spectrum of immune cell subsets including naive B cells, CD8+ T cells, CD4+ memory resting T cells, activated NK cells, resting dendritic cells, plasma cells, Tregs, macrophages M0 and macrophages M1 was found to be concurrently dysregulated in both trauma and sepsis, and a close relation between above identified immune-related genes and immune cell subsets was observed. Our data-driven findings lay a foundation for future research to elucidate the pathophysiology regarding the aspect of inflammatory and immune response in critical illnesses, and suggest future studies focus on interpreting the function roles of the identified immune-related genes, as well as the reactive immune cell subsets.	[Peng, Yaojun; Yang, Zhanglin; Feng, Cong; Ren, Xuewen] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Emergency, Beijing, Peoples R China; [Wu, Qiyan; Wang, Lingxiong; Liu, Tianyi] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Inst Oncol, Beijing, Peoples R China; [Zhou, Qing] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Gastroenterol, Beijing, Peoples R China; [Yin, Fan] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Oncol, Beijing, Peoples R China; [Yin, Fan] Chinese Peoples Liberat Army PLA Gen Hosp, Natl Clin Res Ctr Geriatr Dis, Beijing, Peoples R China; [Chen, Qi] Chinese Peoples Liberat Army PLA Gen Hosp, Dept Tradit Chinese Med, Med Ctr 1, Beijing, Peoples R China		Feng, C; Ren, XW (corresponding author), Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Emergency, Beijing, Peoples R China.; Liu, TY (corresponding author), Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Inst Oncol, Beijing, Peoples R China.	fc194@163.com; rxw2007@126.com; tianyiliu08@hotmail.com			National Natural Science Foundation of China [82072200]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (No. 82072200). The funding organizations had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation and approval of the manuscript.	Bergmann CB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.622601; Brown KA, 2006, LANCET, V368, P157, DOI 10.1016/S0140-6736(06)69005-3; Brumann M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/749175; Burnham KL, 2017, AM J RESP CRIT CARE, V196, P328, DOI 10.1164/rccm.201608-1685OC; Cecconi M, 2018, LANCET, V392, P75, DOI 10.1016/S0140-6736(18)30696-2; Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12; Conway-Morris A, 2018, CRIT CARE CLIN, V34, P29, DOI 10.1016/j.ccc.2017.08.002; Edsparr K, 2010, J IMMUNOTHER, V33, P475, DOI 10.1097/CJI.0b013e3181d372a0; El-Menyar A, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/5374419; Gao YL, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.829210; Gilbert JA, 2018, LANCET RESP MED, V6, P821, DOI 10.1016/S2213-2600(18)30362-X; Kumar V, 2018, EUR J CELL BIOL, V97, P379, DOI 10.1016/j.ejcb.2018.05.001; Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559; Li JY, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.741015; Lord JM, 2014, LANCET, V384, P1455, DOI 10.1016/S0140-6736(14)60687-5; Lu JY, 2020, AM J TRANSL RES, V12, P2749; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Parker HS, 2014, BIOINFORMATICS, V30, P2757, DOI 10.1093/bioinformatics/btu375; Peng F, 2022, J INTENSIVE CARE MED, V37, P352, DOI 10.1177/0885066621993423; Peng F, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01480-3; Peng YP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-738; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Scicluna BP, 2018, AM J RESP CRIT CARE, V197, P1070, DOI 10.1164/rccm.201707-1339LE; Scicluna BP, 2015, AM J RESP CRIT CARE, V192, P826, DOI 10.1164/rccm.201502-0355OC; Stanski NL, 2020, NAT REV NEPHROL, V16, P20, DOI 10.1038/s41581-019-0199-3; Tompkins RG, 2015, J TRAUMA ACUTE CARE, V78, P671, DOI 10.1097/TA.0000000000000568; van der Poll T, 2021, IMMUNITY, V54, P2450, DOI 10.1016/j.immuni.2021.10.012; van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36; van Engelen TSR, 2018, CRIT CARE CLIN, V34, P139, DOI 10.1016/j.ccc.2017.08.010; Warren HS, 2009, MOL MED, V15, P220, DOI 10.2119/molmed.2009.00027; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354; Yang YX, 2017, EXP THER MED, V13, P1689, DOI 10.3892/etm.2017.4178; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								858864	10.3389/fimmu.2022.858864	http://dx.doi.org/10.3389/fimmu.2022.858864			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K6AA	35615364	gold, Green Published			2022-12-18	WOS:000798679900001
J	Quevedo-Abeledo, JC; Martin-Gonzalez, C; Ferrer-Moure, C; de Armas-Rillo, L; Hernandez-Hernandez, MV; Gonzalez-Gay, MA; Ferraz-Amaro, I				Quevedo-Abeledo, Juan Carlos; Martin-Gonzalez, Candelaria; Ferrer-Moure, Carmen; de Armas-Rillo, Laura; Hernandez-Hernandez, Maria Vanesa; Gonzalez-Gay, Miguel A.; Ferraz-Amaro, Ivan			Key Molecules of Triglycerides Pathway Metabolism Are Disturbed in Patients With Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; dyslipidemia; lipoprotein lipase; angiopoietin-like protein 4; apolipoprotein C3	LIPOPROTEIN-LIPASE; DISEASE; INDEX; ATHEROSCLEROSIS; DYSLIPIDEMIA; C3	BackgroundElevated triglycerides or triglyceride-rich lipoproteins are an additional cause of cardiovascular (CV) disease. Given that patients with systemic lupus erythematosus (SLE) have a high prevalence of premature CV disease and show an altered lipid profile, our objective was to study whether three molecules that play a central role in the triglyceride metabolism: apolipoprotein C-III (ApoC3), angiopoietin-like protein 4 (ANGPLT4), and lipoprotein lipase (LPL) differ between SLE patients and controls, and how they are related to disease characteristics, including disease damage. MethodsCross-sectional study that included 347 women, 185 of them diagnosed with SLE and 162 age-matched controls. ANGPTL4, ApoC3 and LPL, and standard lipid profiles were analyzed in SLE patients and controls. A multivariable analysis was performed to assess whether ANGPTL4, ApoC3 and LPL molecules differ between patients and controls and to study their relationship with SLE disease damage. ResultsAfter fully multivariable analysis that included classic CV risk factors, and the modifications that the disease itself produces over the lipid profile, it was found that ApoC3 was significantly lower (beta coef. -1.2 [95%CI -1.6- -0.8) mg/dl, <0.001), and ANGPTL4 (beta coef. 63 [95%CI 35-90] ng/ml, <0.001) and LPL (beta coef. 79 [95%CI 30-128] ng/ml, p=0.002) significantly higher in patients with SLE compared to controls. Disease damage score was significantly and independently associated with higher serum levels of LPL (beta coef. 23 [95%CI 10-35] ng/ml, p=0.001). Mediation analysis suggested that the relationship between disease damage and LPL was direct and not mediated by ApoC3 or ANGPLT4. ConclusionThe ApoC3, ANGPLT4 and LPL axis is disrupted in patients with SLE. Disease damage explains this disturbance.	[Quevedo-Abeledo, Juan Carlos] Hosp Doctor Negrin, Div Rheumatol, Las Palmas Gran Canaria, Spain; [Martin-Gonzalez, Candelaria] Hosp Univ Canarias, Div Internal Med, Tenerife, Spain; [Martin-Gonzalez, Candelaria; Ferraz-Amaro, Ivan] Univ Laguna, Internal Med Dept, Tenerife, Spain; [Ferrer-Moure, Carmen] Hosp Univ Canarias, Div Cent Lab, Tenerife, Spain; [de Armas-Rillo, Laura] Univ Europea Canarias, Div Hlth Sci, Tenerife, Spain; [Hernandez-Hernandez, Maria Vanesa; Ferraz-Amaro, Ivan] Hosp Univ Canarias, Div Rheumatol, Tenerife, Spain; [Gonzalez-Gay, Miguel A.] Hosp Univ Marques Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Genet & Atherosclerosis Res Grp Syst Inflammatory, Epidemiol, Santander, Spain; [Gonzalez-Gay, Miguel A.] Univ Cantabria, Hosp Univ Marques Valdecilla, Div Rheumatol, Santander, Spain; [Gonzalez-Gay, Miguel A.] Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Johannesburg, South Africa	Universidad de la Laguna; Universidad de la Laguna; Universidad de la Laguna; Universidad de la Laguna; Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV); Universidad de Cantabria; University of Witwatersrand	Ferraz-Amaro, I (corresponding author), Univ Laguna, Internal Med Dept, Tenerife, Spain.; Ferraz-Amaro, I (corresponding author), Hosp Univ Canarias, Div Rheumatol, Tenerife, Spain.; Gonzalez-Gay, MA (corresponding author), Hosp Univ Marques Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Genet & Atherosclerosis Res Grp Syst Inflammatory, Epidemiol, Santander, Spain.; Gonzalez-Gay, MA (corresponding author), Univ Cantabria, Hosp Univ Marques Valdecilla, Div Rheumatol, Santander, Spain.; Gonzalez-Gay, MA (corresponding author), Univ Witwatersrand, Fac Hlth Sci, Sch Physiol, Cardiovasc Pathophysiol & Genom Res Unit, Johannesburg, South Africa.	miguelaggay@hotmail.com; iferrazamaro@hotmail.com	Martín-González, Candelaria/G-3629-2016; Gonzalez-Gay, Miguel/B-2306-2008	Gonzalez-Gay, Miguel/0000-0002-7924-7406	Spanish Ministry of Health; Fondo Europeo de Desarrollo Regional - FEDER - (Fondo de Investigaciones Sanitarias) [PI17/00083]	Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Fondo Europeo de Desarrollo Regional - FEDER - (Fondo de Investigaciones Sanitarias)	This work was supported by a grant to IF-A from the Spanish Ministry of Health, Subdireccion General de Evaluacion y Fomento de la Investigacion, Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion 2013-2016 and by Fondo Europeo de Desarrollo Regional - FEDER - (Fondo de Investigaciones Sanitarias, PI17/00083).	Akoumianakis I, 2021, CURR ATHEROSCLER REP, V23, DOI 10.1007/s11883-021-00914-7; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Beigneux AP, 2019, P NATL ACAD SCI USA, V116, P6319, DOI 10.1073/pnas.1900983116; de Carvalho JF, 2008, AUTOIMMUN REV, V7, P246, DOI 10.1016/j.autrev.2007.11.016; Fernandez-Nebro A, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001183; Ganjali S, 2020, SEMIN ARTHRITIS RHEU, V50, P769, DOI 10.1016/j.semarthrit.2020.05.011; Gladman D, 1996, ARTHRITIS RHEUM, V39, P363, DOI 10.1002/art.1780390303; Gladman DD, 2002, J RHEUMATOL, V29, P288; Hage MP, 2014, THER ADV ENDOCRINOL, V5, P77, DOI 10.1177/2042018814547204; Hertle E, 2014, MOL IMMUNOL, V61, P135, DOI 10.1016/j.molimm.2014.06.031; Hirano T, 2004, METABOLISM, V53, P526, DOI 10.1016/j.metabol.2003.10.021; Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928; KATZ JD, 1993, LUPUS, V2, P119, DOI 10.1177/096120339300200210; Kiani AN, 2015, ARTHRIT CARE RES, V67, P442, DOI 10.1002/acr.22430; Kim SY, 2020, ARTHRITIS RHEUMATOL, V72, P20, DOI 10.1002/art.41059; Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726; Morgan PE, 2007, FREE RADICAL RES, V41, P1301, DOI 10.1080/10715760701684809; Mosca M, 2006, CLIN EXP RHEUMATOL, V24, pS100; Nordestgaard BG, 2014, LANCET, V384, P626, DOI 10.1016/S0140-6736(14)61177-6; Persson L, 2004, ARTERIOSCL THROM VAS, V24, P1062, DOI 10.1161/01.ATV.0000127302.24266.40; Reichlin M, 2002, ARTHRITIS RHEUM, V46, P2957, DOI 10.1002/art.10624; Romeo S, 2009, J CLIN INVEST, V119, P70, DOI 10.1172/JCI37118; Sanchez-Perez H, 2020, THER ADV MUSCULOSKEL, V12, DOI 10.1177/1759720X20975904; Sanchez-Perez H, 2020, RHEUMATOLOGY, V59, P2847, DOI 10.1093/rheumatology/keaa038; Tselios K, 2016, SEMIN ARTHRITIS RHEU, V45, P604, DOI 10.1016/j.semarthrit.2015.10.010; Valeri L, 2013, PSYCHOL METHODS, V18, P137, DOI 10.1037/a0031034; Xin Y, 2021, J CLIN LIPIDOL, V15, P311, DOI 10.1016/j.jacl.2021.01.011; Zheng CY, 2010, CIRCULATION, V121, P1722, DOI 10.1161/CIRCULATIONAHA.109.875807	28	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								827355	10.3389/fimmu.2022.827355	http://dx.doi.org/10.3389/fimmu.2022.827355			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1L0JF	35615358	gold, Green Published			2022-12-18	WOS:000798978100001
J	Rong, H; Qi, M; Pan, JD; Sun, YH; Gao, JW; Zhang, XW; Li, W; Zhang, B; Zhang, XE; Cui, ZQ				Rong, Heng; Qi, Mi; Pan, Jingdi; Sun, Yuhan; Gao, Jiawang; Zhang, Xiaowei; Li, Wei; Zhang, Bo; Zhang, Xian-En; Cui, Zongqiang			Self-Assembling Nanovaccine Confers Complete Protection Against Zika Virus Without Causing Antibody-Dependent Enhancement	FRONTIERS IN IMMUNOLOGY			English	Article						zika virus; nanovaccine; ferritin; ZIKV envelop protein domain III; antibody-dependent enhancement	IMMUNE-RESPONSES; DOMAIN III; INFECTION; VACCINES; DENGUE; IMMUNOGENICITY; IMMUNIZATION; SARS-COV-2	The Zika virus (ZIKV) epidemic poses a substantial threat to the public, and the development of safe and effective vaccines is a demanding challenge. In this study, we constructed a kind of self-assembling nanovaccine which confers complete protection against ZIKV infection. The ZIKV envelop protein domain III (zEDIII) was presented on recombinant human heavy chain ferritin (rHF) to form the zEDIII-rHF nanoparticle. Immunization of mice with zEDIII-rHF nanoparticle in the absence of an adjuvant induced robust humoral and cellular immune responses. zEDIII-rHF vaccination conferred complete protection against lethal infection with ZIKV and eliminated pathological symptoms in the brain. Importantly, the zEDIII-rHF nanovaccine induced immune response did not cross-react with dengue virus-2, overcoming the antibody-dependent enhancement (ADE) problem that is a safety concern for ZIKV vaccine development. Our constructed zEDIII-rHF nanovaccine, with superior protective performance and avoidance of ADE, provides an effective and safe vaccine candidate against ZIKV.	[Rong, Heng; Qi, Mi; Pan, Jingdi; Sun, Yuhan; Gao, Jiawang; Zhang, Xiaowei; Li, Wei; Zhang, Bo; Cui, Zongqiang] Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, State Key Lab Virol, Wuhan, Peoples R China; [Rong, Heng; Qi, Mi; Pan, Jingdi; Sun, Yuhan; Gao, Jiawang; Cui, Zongqiang] Univ Chinese Acad Sci, Beijing, Peoples R China; [Zhang, Xian-En] Chinese Acad Sci, Shenzhen Inst Adv Technol, Fac Synthet Biol, Shenzhen, Peoples R China	Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; Shenzhen Institute of Advanced Technology, CAS	Cui, ZQ (corresponding author), Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, State Key Lab Virol, Wuhan, Peoples R China.; Cui, ZQ (corresponding author), Univ Chinese Acad Sci, Beijing, Peoples R China.	czq@wh.iov.cn	zhang, xiaowei/GQH-5387-2022		Strategic Priority Research Program of the Chinese Academy of Sciences [XDB29050201]; National Natural Science Foundation of China [31925025, 91743108, 21727816]; Key Research Project of Frontier Science of the Chinese Academy of Sciences	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research Project of Frontier Science of the Chinese Academy of Sciences	This work was supported by the Strategic Priority Research Program of the Chinese Academy of Sciences (No. XDB29050201)?the National Natural Science Foundation of China (Nos. 31925025, 91743108, and 21727816) and the Key Research Project of Frontier Science of the Chinese Academy of Sciences.	Abbink P, 2016, SCIENCE, V353, P1129, DOI 10.1126/science.aah6157; Bento D, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11020072; Bessa J, 2008, EUR J IMMUNOL, V38, P114, DOI 10.1002/eji.200636959; Bhushan B, 2014, J BIOMED NANOTECHNOL, V10, P2950, DOI 10.1166/jbn.2014.1980; Bonheur AN, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06482-0; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; Chareonsirisuthigul T, 2007, J GEN VIROL, V88, P365, DOI 10.1099/vir.0.82537-0; Chen HX, 2015, J MOL DIAGN, V17, P722, DOI 10.1016/j.jmoldx.2015.06.008; Cox F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202820; Dai LP, 2021, NAT IMMUNOL, V22, P958, DOI 10.1038/s41590-021-00966-6; Deng CL, 2016, VIROL SIN, V31, P176, DOI 10.1007/s12250-016-3778-5; Gaudinski MR, 2018, LANCET, V391, P552, DOI 10.1016/S0140-6736(17)33105-7; Haque A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040739; He LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12041; Heinz FX, 2017, MICROBIOL MOL BIOL R, V81, DOI [10.1128/MMBR.00055-16, 10.1128/mmbr.00055-16]; Hoen B, 2018, NEW ENGL J MED, V378, P985, DOI 10.1056/NEJMoa1709481; Huang HR, 2017, J VIROL, V91, DOI [10.1128/JVI.00900-17, 10.1128/jvi.00900-17]; Jearanaiwitayakul T, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13112202; Kanekiyo M, 2013, NATURE, V499, P102, DOI 10.1038/nature12202; Kotaki T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-92403-9; Langerak T, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007640; Li AZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05276-4; Li PH, 2018, J VIROL, V92, DOI [10.1128/JVI.00701-18, 10.1128/jvi.00701-18]; Lin HH, 2018, BIOTECHNOL ADV, V36, P47, DOI 10.1016/j.biotechadv.2017.09.004; Lopez-Camacho C, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020307; Lucas CGO, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05519-4; Mamo T, 2012, VACCINE, V30, P6609, DOI 10.1016/j.vaccine.2012.08.023; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Musso D, 2018, LANCET INFECT DIS, V18, pE172, DOI 10.1016/S1473-3099(17)30446-2; Ngono AE, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb2154; Perez P, 2021, EMERG MICROBES INFEC, V10, P1441, DOI 10.1080/22221751.2021.1951624; Perez P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35724-6; Powell AE, 2021, ACS CENTRAL SCI, V7, P183, DOI 10.1021/acscentsci.0c01405; Qi JM, 2021, BIOCONJUGATE CHEM, V32, P328, DOI 10.1021/acs.bioconjchem.0c00700; Qi M, 2018, SMALL, V14, DOI 10.1002/smll.201703207; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Shan C, 2017, NAT MED, V23, P763, DOI 10.1038/nm.4322; Shi Y, 2018, ADV EXP MED BIOL, V1062, P77, DOI 10.1007/978-981-10-8727-1_6; Shukla R, 2020, EBIOMEDICINE, V54, DOI 10.1016/j.ebiom.2020.102738; Slavov SN, 2016, BRAZ J MED BIOL RES, V49, DOI 10.1590/1414-431X20165420; Sliepen K, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0210-4; Slon-Campos JL, 2019, NAT IMMUNOL, V20, P1291, DOI 10.1038/s41590-019-0477-z; Song BH, 2017, J NEUROIMMUNOL, V308, P50, DOI 10.1016/j.jneuroim.2017.03.001; Stettler K, 2016, SCIENCE, V353, P823, DOI 10.1126/science.aaf8505; Sumathy K, 2017, SCI REP-UK, V7, DOI 10.1038/srep46375; Tai WB, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-017-0007-8; Tirado SMC, 2003, VIRAL IMMUNOL, V16, P69, DOI 10.1089/088282403763635465; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Wen JS, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107566; Wen JS, 2017, J INTERF CYTOK RES, V37, P475, DOI 10.1089/jir.2017.0106; Wilder-Smith A, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1067-x; Wollner CJ, 2021, J VIROL, V95, DOI 10.1128/JVI.02482-20; Xu MY, 2016, J VIROL METHODS, V236, P93, DOI 10.1016/j.jviromet.2016.07.014; Yang M, 2017, VACCINE, V35, P4287, DOI 10.1016/j.vaccine.2017.04.052; Zhang NR, 2015, MICROBES INFECT, V17, P123, DOI 10.1016/j.micinf.2014.12.006; Zhao K, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00983-5	56	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								905431	10.3389/fimmu.2022.905431	http://dx.doi.org/10.3389/fimmu.2022.905431			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S2VF	35615356	gold, Green Published			2022-12-18	WOS:000803913300001
J	Wu, ML; Zhao, HD; Tang, XQ; Zhao, WX; Yi, XH; Li, Q; Sun, XZ				Wu, Mingli; Zhao, Haidong; Tang, Xiaoqin; Zhao, Wanxia; Yi, Xiaohua; Li, Qi; Sun, Xiuzhu			Organization and Complexity of the Yak (Bos Grunniens) Immunoglobulin Loci	FRONTIERS IN IMMUNOLOGY			English	Article						yak; IgH; Ig lambda; Ig kappa; structure of the genomic; diversity of expression	ANTIBODY REPERTOIRE DEVELOPMENT; CLASS SWITCH RECOMBINATION; EXCEPTIONALLY LONG CDR3H; HEAVY-CHAIN; V(D)J RECOMBINATION; B-CELL; EXPRESSION; DNA; MECHANISM; GERMLINE	As important livestock in Qinghai-Tibet Plateau, yak provides meat and other necessities for Tibetans living. Plateau yak has resistance to diseases and stress, yet is nearly unknown in the structure and expression mechanism of yak immunoglobulin loci. Based on the published immunoglobulin genes of bovids (cattle, sheep and goat), the genomic organization of the yak immunoglobulin heavy chain (IgH) and immunoglobulin light chain (IgL) were described. The assemblage diversity of IgH, Ig lambda and Ig kappa in yak was similar to that in bovids, and contributes little to the antibody lineage compared with that in humans and mice. Somatic hypermutation (SHM) had a greater effect on immunoglobulin diversity in yak than in goat and sheep, and in addition to the complementarity-determining region (CDR), some loci in the framework region (FR) also showed high frequency mutations. CDR3 diversity showed that immunological lineages in yak were overwhelmingly generated through linkage diversity in IgH rearrangements. The emergence of new high-throughput sequencing technologies and the yak whole genome (2019) publication have greatly improved our understanding of the immune response in yaks. We had a more comprehensive analysis of yak immunoglobulin expression diversity by PE300, which avoided the disadvantage of missing low-frequency recombination in traditional Sanger sequencing. In summary, we described the schematic structure of the genomic organization of yak IgH loci and IgL loci. The analysis of immunoglobulin expression diversity showed that yak made up for the deficiency of V(D)J recombinant diversity by junctional diversity and CDR3 diversity. In addition, yak, like cattle, also had the same ultra-long IgH CDR3 (CDR3H), which provided more contribution to the diverse expression of yak immunoglobulin. These findings might provide a theoretical basis for disease resistance breeding and vaccine development in yak.	[Wu, Mingli; Zhao, Haidong; Tang, Xiaoqin; Zhao, Wanxia; Yi, Xiaohua; Li, Qi; Sun, Xiuzhu] Northwest A&F Univ, Coll Anim Sci & Technol, Yangling, Peoples R China; [Sun, Xiuzhu] Northwest A&F Univ, Coll Grassland Agr, Yangling, Peoples R China	Northwest A&F University - China; Northwest A&F University - China	Sun, XZ (corresponding author), Northwest A&F Univ, Coll Anim Sci & Technol, Yangling, Peoples R China.; Sun, XZ (corresponding author), Northwest A&F Univ, Coll Grassland Agr, Yangling, Peoples R China.	sunxiuzhu@nwafu.edu.cn			National Natural Science Foundation of China [31972557]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Project supported by National Natural Science Foundation of China (31972557).	Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; Arakawa H, 2002, J IMMUNOL, V169, P818, DOI 10.4049/jimmunol.169.2.818; Azhar A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9101050; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Briney BS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036750; Butler JE, 2017, ANNU REV ANIM BIOSCI, V5, P255, DOI 10.1146/annurev-animal-022516-022818; Butler JE, 2013, MOL IMMUNOL, V55, P329, DOI 10.1016/j.molimm.2013.03.011; Carmona LM, 2017, FEBS J, V284, P1590, DOI 10.1111/febs.13990; Charlton KA, 2000, J IMMUNOL, V164, P6221, DOI 10.4049/jimmunol.164.12.6221; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chen LM, 2008, VET IMMUNOL IMMUNOP, V124, P284, DOI 10.1016/j.vetimm.2008.04.012; Cheng G, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2317; Chi XY, 2020, IMMUNOLOGY, V160, P233, DOI 10.1111/imm.13176; Danilova N, 2005, NAT IMMUNOL, V6, P295, DOI 10.1038/ni1166; Deiss TC, 2019, CELL MOL IMMUNOL, V16, P53, DOI 10.1038/cmi.2017.117; Dong JH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00558; Du LJ, 2018, IMMUNOBIOLOGY, V223, P599, DOI 10.1016/j.imbio.2018.07.005; Elemento O, 2003, DEV COMP IMMUNOL, V27, P763, DOI 10.1016/S0145-305X(03)00078-8; Fugmann SD, 2000, ANNU REV IMMUNOL, V18, P495, DOI 10.1146/annurev.immunol.18.1.495; Guan XX, 2016, DEV COMP IMMUNOL, V60, P167, DOI 10.1016/j.dci.2016.02.029; Haakenson JK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01262; Haire RN, 1996, J IMMUNOL, V157, P1544; Heilig R, 2003, NATURE, V421, P601, DOI 10.1038/nature01348; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Hsu E, 2016, J IMMUNOL, V196, P3517, DOI 10.4049/jimmunol.1600164; Hu XH, 2019, NAT GENET, V51, P560, DOI 10.1038/s41588-018-0339-x; Jenne CN, 2006, DEV COMP IMMUNOL, V30, P165, DOI 10.1016/j.dci.2005.06.009; Jiang ZX, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01067; Johnston CM, 2006, J IMMUNOL, V176, P4221, DOI 10.4049/jimmunol.176.7.4221; Koti M, 2008, DEV BIOLOGICALS, V132, P307, DOI 10.1159/000317176; Koti M, 2010, MOL IMMUNOL, V47, P2119, DOI 10.1016/j.molimm.2010.02.014; Kumar S, 2016, MOL BIOL EVOL, V33, P1870, DOI [10.1093/molbev/msv279, 10.1093/molbev/msw054]; Lee SS, 2002, IMMUNITY, V16, P571, DOI 10.1016/S1074-7613(02)00300-X; Lefranc MP, 2003, DEV COMP IMMUNOL, V27, P55, DOI 10.1016/S0145-305X(02)00039-3; Liljavirta J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099808; Ma L, 2016, THESIS CHINA AGR U B; Ma L, 2016, J IMMUNOL, V196, P4358, DOI 10.4049/jimmunol.1600158; Mage RG, 2006, DEV COMP IMMUNOL, V30, P137, DOI 10.1016/j.dci.2005.06.017; MEEK KD, 1989, J EXP MED, V170, P39, DOI 10.1084/jem.170.1.39; Nguyen VK, 2000, EMBO J, V19, P921, DOI 10.1093/emboj/19.5.921; Pasman Y, 2010, VET IMMUNOL IMMUNOP, V135, P306, DOI 10.1016/j.vetimm.2009.12.012; Qin T, 2008, DEV COMP IMMUNOL, V32, P156, DOI 10.1016/j.dci.2007.05.007; Qin T, 2015, IMMUNOL LETT, V168, P313, DOI 10.1016/j.imlet.2015.10.010; Rawlings DJ, 2017, NAT REV IMMUNOL, V17, P421, DOI 10.1038/nri.2017.24; Rio D.C., 2010, COLD SPRING HARB PRO, V2010, ppdb.prot5439, DOI [10.1101/pdb.prot5439, DOI 10.1101/PDB.PROT5439]; Saeed U., 2019, BIOL SEQUENCE ANAL; Safonova Y, 2020, GENOME RES, V30, P1547, DOI 10.1101/gr.259598.119; Saini SS, 1999, EUR J IMMUNOL, V29, P2420, DOI 10.1002/(SICI)1521-4141(199908)29:08&lt;2420::AID-IMMU2420&gt;3.0.CO;2-A; Schroeder HW, 2010, J ALLERGY CLIN IMMUN, V125, pS41, DOI 10.1016/j.jaci.2009.09.046; Schroeder HW, 2006, DEV COMP IMMUNOL, V30, P119, DOI 10.1016/j.dci.2005.06.006; Stanfield RL, 2018, ADV IMMUNOL, V137, P135, DOI 10.1016/bs.ai.2017.12.004; Stanfield RL, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf7962; Sun Y, 2010, DEV COMP IMMUNOL, V34, P1009, DOI 10.1016/j.dci.2010.05.003; Tomana M, 2002, IMMUNOGENETICS, V54, P120, DOI 10.1007/s00251-002-0447-7; Townsend CL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00388; Vlasova AN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.643206; Walther S, 2015, DEV COMP IMMUNOL, V53, P303, DOI 10.1016/j.dci.2015.07.017; Walther S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064234; Wang F, 2013, CELL, V153, P1379, DOI 10.1016/j.cell.2013.04.049; Wang ZP, 2015, FISH SHELLFISH IMMUN, V44, P283, DOI 10.1016/j.fsi.2015.02.030; Weber J, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.23; Wu Q, 2010, DEV COMP IMMUNOL, V34, P579, DOI 10.1016/j.dci.2009.12.019; YAMAWAKIKATAOKA Y, 1987, NUCLEIC ACIDS RES, V15, P5888, DOI 10.1093/nar/15.14.5888; Yu KF, 2019, CRIT REV BIOCHEM MOL, V54, P333, DOI 10.1080/10409238.2019.1659227; Yu XH, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.11.024; Zhang M, 2020, J IMMUNOL, V205, P2137, DOI 10.4049/jimmunol.1901483; Zhao YF, 2003, J BIOL CHEM, V278, P35024, DOI 10.1074/jbc.M301337200; Zhuang Y, 2007, INFECT IMMUN, V75, P5185, DOI 10.1128/IAI.00913-07	68	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 9	2022	13								876509	10.3389/fimmu.2022.876509	http://dx.doi.org/10.3389/fimmu.2022.876509			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1T8DE	35615368	gold, Green Published			2022-12-18	WOS:000804955800001
J	Chen, F; Wang, JP; Zhang, PL; Zuo, Y; Ye, LF; Wang, GC; Shu, XM				Chen, Fang; Wang, Jinping; Zhang, Puli; Zuo, Yu; Ye, Lifang; Wang, Guochun; Shu, Xiaoming			Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort	FRONTIERS IN IMMUNOLOGY			English	Article						negative myositis autoantibody; interstitial lung disease; RPILD; dermatomyositis; myositis specific autoantibody; myositis associated autoantibody	ANTIBODY; CLASSIFICATION	ObjectiveThe clinical features of interstitial lung disease (ILD) in patients with dermatomyositis (DM) and negative myositis autoantibodies had not been exactly demonstrated previously. This study aimed to describe and expand the phenotype of interstitial lung disease (ILD) in this cohort of patients. MethodsA total of 1125 consecutive Chinese patients with idiopathic inflammatory myopathies (IIM) between 2006 and 2020 were screened retrospectively. All proven cases of isolated ILD with both negative myositis-specific autoantibodies (MSA) and negative myositis-associated autoantibodies (MAA) were selected for inclusion. The clinical features and outcome among this group, MDA5(+)DM (DM patients with positive anti-MDA5 antibody) and ASS (patients with positive anti-aminoacyl tRNA synthetases antibodies were recorded and compared. ResultsOf 1125 IIM patients with an average follow-up of 6 years, 154 DM patients with negative MSA and MAA (MSA/MAA) were identified, with an ILD incidence of 46.8%. DM-ILD Patients with negative MSA/MAA presented younger age at onset (p<0.001), lower incidence of elevated CA153 (p=0.03) and fever (p=0.04)than those ILD patients with MDA5(+)DM and ASS.The estimated high-resolution computed tomography patterns of ILD showed non-specific interstitial pneumonia (66.6%), followed by organizing pneumonia in patients with negative MSA/MAA. OP pattern was more common in patients with MDA5(+)DM (69.7%), and the ratios of the OP (48.7%) and NSIP (51.3%) patterns were almost equal in patients with ASS. Of these DM-ILD patients with negative MSA/MAA, 25% developed rapidly progressive interstitial lung disease (RP-ILD). Patients with RP-ILD had a shorter disease duration (p=0.002), higher percentage of positive ANA(p=0.01) and organizing pneumonia patterns (p=0.04), elevated CYFRA211(p=0.04) and decreased FiO2/PaO2 (p<0.001) than those with chronic progressive ILD. The incidence of OP pattern in RP-ILD patients with negative MSA/MAA was lower than in those RPILD patients with MDA5(+) DM (75%) and ASS (89%) (p=0.006). The cumulative 5- and 10-year survival rates in the DM-ILD patients with negative MSA/MAA were 91% and 88%, respectively, during the long-term follow-up study. And they had more favorable survival rate compared with ILD patients with MDA5(+)DM and ASS (p<0.001). An independent prognostic factor was identified as decreased PaO2/FiO2 (hazard ratio, 0.97; p=0.004]. ConclusionsThis study indicates DM-ILD patients with negative MSA/MAA had favorable long-term outcomes. Decreased baseline PaO2/FiO2 acted as an independent prognostic factor for this group of patients.	[Shu, Xiaoming] Key Lab Myositis, Dept Rheumatol, Beijing, Peoples R China; China Japan Friendship Hosp, Beijing Key Lab Immune Mediated Inflammatory Dis, Beijing, Peoples R China	China-Japan Friendship Hospital	Shu, XM (corresponding author), Key Lab Myositis, Dept Rheumatol, Beijing, Peoples R China.	sxm992283@hotmail.com			Fundamental Research Funds for the Central Universities [3332020074]; Elite Medical Professionals project of China-Japan Friendship Hospital	Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Elite Medical Professionals project of China-Japan Friendship Hospital	Funding This study was funded by the Fundamental Research Funds for the Central Universities (No. 3332020074) and Elite Medical Professionals project of China-Japan Friendship Hospital(No.ZRJY2021-GG14).	Allenbach Y, 2020, NEUROLOGY, V95, pE70, DOI 10.1212/WNL.0000000000009727; Bao YQ, 2021, INT J GEN MED, V14, P2553, DOI 10.2147/IJGM.S310917; Chen F, 2019, RESP MED, V155, P127, DOI 10.1016/j.rmed.2019.07.020; Chen F, 2012, RHEUMATOL INT, V32, P3909, DOI 10.1007/s00296-011-2323-y; Gono T, 2016, NAT REV RHEUMATOL, V12, pP504, DOI 10.1038/nrrheum.2016.120; Gono T, 2010, RHEUMATOLOGY, V49, P1713, DOI 10.1093/rheumatology/keq149; Gui XH, 2021, RHEUMATOLOGY, V60, P3913, DOI 10.1093/rheumatology/keaa843; Huang HL, 2021, NEUROL SCI, V42, P2855, DOI 10.1007/s10072-020-04911-7; Huang WH, 2020, RHEUMATOLOGY, V59, P3886, DOI 10.1093/rheumatology/keaa266; Lian XY, 2020, CHEST, V158, P1535, DOI 10.1016/j.chest.2020.04.057; Mammen AL, 2020, NEUROMUSCULAR DISORD, V30, P70, DOI 10.1016/j.nmd.2019.10.005; Motegi S, 2019, EUR J DERMATOL, V29, P511, DOI 10.1684/ejd.2019.3634; Nakashima R, 2010, INT J CLIN RHEUMATOL, V5, P523, DOI DOI 10.2217/IJR.10.48; Sabbagh S, 2019, ANN RHEUM DIS, V78, P988, DOI 10.1136/annrheumdis-2018-215004; Satoh M, 2017, CLIN REV ALLERG IMMU, V52, P1, DOI 10.1007/s12016-015-8510-y; Selva-O'Callaghan A, 2018, LANCET NEUROL, V17, P816, DOI 10.1016/S1474-4422(18)30254-0; Shi JL, 2017, J RHEUMATOL, V44, P1051, DOI 10.3899/jrheum.161480; Travis WD, 2013, AM J RESP CRIT CARE, V188, P733, DOI 10.1164/rccm.201308-1483ST; Yamasaki Y, 2016, MOD RHEUMATOL, V26, P403, DOI 10.3109/14397595.2015.1091155; Zhu DX, 2021, RHEUMATOLOGY, V60, P3896, DOI 10.1093/rheumatology/keaa819; Zuo Y, 2020, RHEUMATOLOGY, V59, P2829, DOI 10.1093/rheumatology/keaa034	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								879266	10.3389/fimmu.2022.879266	http://dx.doi.org/10.3389/fimmu.2022.879266			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6SY	35603153	Green Published, gold			2022-12-18	WOS:000800100600001
J	de Haas, P; de Jonge, MI; Koenen, HJPM; Joosten, B; Janssen, MCH; de Boer, L; Hendriks, WJAJ; Lefeber, DJ; Cambi, A				de Haas, Paola; de Jonge, Marien I.; Koenen, Hans J. P. M.; Joosten, Ben; Janssen, Mirian C. H.; de Boer, Lonneke; Hendriks, Wiljan J. A. J.; Lefeber, Dirk J.; Cambi, Alessandra			Evaluation of Cell Models to Study Monocyte Functions in PMM2 Congenital Disorders of Glycosylation	FRONTIERS IN IMMUNOLOGY			English	Article						glycosylation; monocytes; congenital disorders of glycosylation; immune cells; phosphomannomutase 2	DEFICIENT GLYCOPROTEIN SYNDROME; PHOSPHOMANNOMUTASE 2; ER-STRESS; EXPRESSION; MUTATIONS; RECEPTOR; CDG; DIFFERENTIATION; RECOGNITION; ACTIVATION	Congenital disorders of glycosylation (CDG) are inherited metabolic diseases characterized by mutations in enzymes involved in different steps of protein glycosylation, leading to aberrant synthesis, attachment or processing of glycans. Recently, immunological dysfunctions in several CDG types have been increasingly documented. Despite these observations, detailed studies on immune cell dysfunction in PMM2-CDG and other CDG types are still scarce. Studying PMM2-CDG patient immune cells is challenging due to limited availability of patient material, which is a result of the low incidence of the disease and the often young age of the subjects. Dedicated immune cell models, mimicking PMM2-CDG, could circumvent many of these problems and facilitate research into the mechanisms of immune dysfunction. Here we provide initial observations about the immunophenotype and the phagocytic function of primary PMM2-CDG monocytes. Furthermore, we assessed the suitability of two different glycosylation-impaired human monocyte models: tunicamycin-treated THP-1 monocytes and PMM2 knockdown THP-1 monocytes induced by shRNAs. We found no significant differences in primary monocyte subpopulations of PMM2-CDG patients as compared to healthy individuals but we did observe anomalous surface glycosylation patterns in PMM2-CDG patient monocytes as determined using fluorescent lectin binding. We also looked at the capacity of monocytes to bind and internalize fungal particles and found a slightly increased uptake of C. albicans by PMM2-CDG monocytes as compared to healthy monocytes. Tunicamycin-treated THP-1 monocytes showed a highly decreased uptake of fungal particles, accompanied by a strong decrease in glycosylation levels and a high induction of ER stress. In contrast and despite a drastic reduction of the PMM2 enzyme activity, PMM2 knockdown THP-1 monocytes showed no changes in global surface glycosylation levels, levels of fungal particle uptake similar to control monocytes, and no ER stress induction. Collectively, these initial observations suggest that the absence of ER stress in PMM2 knockdown THP-1 cells make this model superior over tunicamycin-treated THP-1 cells and more comparable to primary PMM2-CDG monocytes. Further development and exploitation of CDG monocyte models will be essential for future in-depth studies to ultimately unravel the mechanisms of immune dysfunction in CDG.	[de Haas, Paola; Joosten, Ben; Hendriks, Wiljan J. A. J.; Cambi, Alessandra] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Cell Biol, Nijmegen, Netherlands; [de Jonge, Marien I.; Koenen, Hans J. P. M.] Radboud Univ Nijmegen Med Ctr, Dept Lab Med, Lab Med Immunol, Nijmegen, Netherlands; [Janssen, Mirian C. H.] Radboud Univ Nijmegen Med Ctr, Radboud Ctr Mitochondrial Med, Dept Rehabil, Nijmegen, Netherlands; [Janssen, Mirian C. H.] Radboud Univ Nijmegen Med Ctr, Radboud Ctr Mitochondrial Med, Dept Internal Med, Nijmegen, Netherlands; [de Boer, Lonneke] Radboudumc Amalia Childrens Hosp, Dept Paediat, Nijmegen, Netherlands; [Lefeber, Dirk J.] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Lab Med, Translat Metab Lab, Nijmegen, Netherlands; [Lefeber, Dirk J.] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Cambi, A (corresponding author), Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Dept Cell Biol, Nijmegen, Netherlands.	alessandra.cambi@radboudumc.nl	Hendriks, Wiljan J.A.J./A-5214-2013; Cambi, Alessandra/L-4242-2015	Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Cambi, Alessandra/0000-0003-1597-1582	Radboudumc Intramural grant; Stofwisselkracht [R0005003]	Radboudumc Intramural grant; Stofwisselkracht	Research described in this study was financially supported by a Radboudumc Intramural grant (to AC) and by Stofwisselkracht grant R0005003 (to AC and PH).	Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053; Bakar NA., 2022, J INHERITED METAB DI, P1, DOI [10.1002/jimd.12496, DOI 10.1002/JIMD.12496]; Baker PJ, 2018, METHODS MOL BIOL, V1714, P41, DOI 10.1007/978-1-4939-7519-8_3; Benicky J, 2019, J BIOL CHEM, V294, P16816, DOI 10.1074/jbc.RA119.009989; Berges C, 2005, BIOCHEM BIOPH RES CO, V333, P896, DOI 10.1016/j.bbrc.2005.05.171; Bergmann M, 1998, GLYCOBIOLOGY, V8, P963, DOI 10.1093/glycob/8.10.963; Blank C, 2006, J INHERIT METAB DIS, V29, P592, DOI 10.1007/s10545-006-0275-2; Bosshart H, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.53; Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002; Clark MC, 2012, ANN NY ACAD SCI, V1253, P58, DOI 10.1111/j.1749-6632.2011.06304.x; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; de la Morena-Barrio ME, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-170; de Lonlay P, 2001, J MED GENET, V38, P14, DOI 10.1136/jmg.38.1.14; Esteban A, 2011, P NATL ACAD SCI USA, V108, P14270, DOI 10.1073/pnas.1111415108; Fischer M, 2017, EUR J IMMUNOL, V47, P848, DOI 10.1002/eji.201646849; Foufelle F, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.211; Francisco R, 2019, MOL GENET METAB, V126, P1, DOI 10.1016/j.ymgme.2018.11.003; Francisco R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072092; Freeman SA, 2018, CELL, V172, P305, DOI 10.1016/j.cell.2017.12.023; Freund EC, 2020, J EXP MED, V217, DOI 10.1084/jem.20191692; Garcia-Lopez R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158863; Gazit Y, 2010, J CLIN IMMUNOL, V30, P308, DOI 10.1007/s10875-009-9354-0; Geisler C, 2011, GLYCOBIOLOGY, V21, P988, DOI 10.1093/glycob/cwr080; Gudde AEEG, 2017, BBA-GENE REGUL MECH, V1860, P740, DOI 10.1016/j.bbagrm.2017.04.002; Vega AI, 2011, J INHERIT METAB DIS, V34, P929, DOI 10.1007/s10545-011-9328-2; Izquierdo-Serra M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020619; Jaeken J, 1997, J INHERIT METAB DIS, V20, P447, DOI 10.1023/A:1005331523477; Jain A, 2017, P NATL ACAD SCI USA, V114, P11199, DOI 10.1073/pnas.1706193114; Kapellos TS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02035; Kato Y, 2006, BIOL PHARM BULL, V29, P1580, DOI 10.1248/bpb.29.1580; Kim SY, 2013, EUR J PHARMACOL, V721, P294, DOI 10.1016/j.ejphar.2013.09.022; Kjaergaard S, 1998, EUR J HUM GENET, V6, P331, DOI 10.1038/sj.ejhg.5200194; Komura T, 2010, DIABETES, V59, P634, DOI 10.2337/db09-0659; Li ZH, 2017, MOL MED REP, V16, P8380, DOI 10.3892/mmr.2017.7625; Lipinski P, 2021, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.715151; Matthijs G, 1998, AM J HUM GENET, V62, P542, DOI 10.1086/301763; Monin ML, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0207-4; Monticelli M, 2016, J INHERIT METAB DIS, V39, P765, DOI 10.1007/s10545-016-9954-9; Netea MG, 2008, NAT REV MICROBIOL, V6, P67, DOI 10.1038/nrmicro1815; Ondruskova N, 2021, BBA-GEN SUBJECTS, V1865, DOI 10.1016/j.bbagen.2020.129751; Ong BB, 2009, FORENSIC SCI MED PAT, V5, P307, DOI 10.1007/s12024-009-9108-6; Oslowski CM, 2011, METHOD ENZYMOL, V490, P71, DOI 10.1016/B978-0-12-385114-7.00004-0; Papazoglu G.M., 2021, J. inborn errors metab. screen., V9, pe20200030, DOI 10.1590/2326-4594-jiems-2020-0030; Parrado A, 2022, GLYCOBIOLOGY, V32, P84, DOI 10.1093/glycob/cwab087; Peanne R, 2018, EUR J MED GENET, V61, P643, DOI 10.1016/j.ejmg.2017.10.012; Polet F, 2016, ONCOTARGET, V7, P46371, DOI 10.18632/oncotarget.10131; Ravell JC, 2020, J CLIN INVEST, V130, P507, DOI 10.1172/JCI131116; Rowland R, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.01199-21; Sassi A, 2014, J ALLERGY CLIN IMMUN, V133, P1410, DOI 10.1016/j.jaci.2014.02.025; Sato M, 2003, J IMMUNOL, V171, P417, DOI 10.4049/jimmunol.171.1.417; Schibler J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167323; Schollen E, 2000, EUR J HUM GENET, V8, P367, DOI 10.1038/sj.ejhg.5200470; Thiesler CT, 2016, MOL CELL PROTEOMICS, V15, P1435, DOI 10.1074/mcp.M115.054122; Thompson A, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007850; Vals MA, 2018, JIMD REP, V39, P13, DOI 10.1007/8904_2017_41; van de Kamp JM, 2007, J MED GENET, V44, P277, DOI 10.1136/jmg.2006.044735; VanSchaftingen E, 1995, FEBS LETT, V377, P318, DOI 10.1016/0014-5793(95)01357-1; Vijayan D, 2012, IMMUNOL CELL BIOL, V90, P889, DOI 10.1038/icb.2012.24; Wang HB, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1327494; Weber ANR, 2004, J BIOL CHEM, V279, P34589, DOI 10.1074/jbc.M403830200; Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404; Witters P, 2019, GENET MED, V21, P1181, DOI 10.1038/s41436-018-0301-4; Yuste-Checa P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179456; Zhang WY, 2016, CLIN CHEM, V62, P208, DOI 10.1373/clinchem.2015.243279	64	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								869031	10.3389/fimmu.2022.869031	http://dx.doi.org/10.3389/fimmu.2022.869031			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P2YJ	35603178	Green Published, gold			2022-12-18	WOS:000801880300001
J	DiGiacomo, DV; Shay, JE; Crotty, R; Yang, NY; Bloom, P; Corey, K; Barmettler, S; Farmer, JR				DiGiacomo, Daniel V.; Shay, Jessica E.; Crotty, Rory; Yang, Nancy; Bloom, Patricia; Corey, Kathleen; Barmettler, Sara; Farmer, Jocelyn R.			Liver Stiffness by Transient Elastography Correlates With Degree of Portal Hypertension in Common Variable Immunodeficiency Patients With Nodular Regenerative Hyperplasia	FRONTIERS IN IMMUNOLOGY			English	Article						common variable immunodeficiency (CVID); nodular regenerative hyperplasia (NRH); transient elastography (TE); fibroscan (c); liver disease; liver biopsy	IMMUNE-DEFICIENCY; DIAGNOSIS; DISEASE; ASSOCIATION; MANAGEMENT; FIBROSCAN; CIRRHOSIS	Nodular regenerative hyperplasia (NRH) is associated with high morbidity and mortality in patients with common variable immunodeficiency (CVID). While liver biopsy is the gold standard for NRH diagnosis, a non-invasive technique could facilitate early disease recognition, monitoring, and/or immune intervention. We performed a cross-sectional analysis of ultrasound-based transient elastography (TE) in patients with CVID to evaluate liver stiffness and compared this between patients with (N = 12) and without (N = 6) biopsy-proven NRH. Additionally, these data were compared to a cohort followed at our institution for non-alcoholic fatty liver disease (NAFLD) (N = 527), a disease for which TE has routine diagnostic use. Clinical and pathologic features of NRH were evaluated as correlates of liver stiffness, and receiver operating characteristic curves were used to define a liver stiffness cutoff with diagnostic utility for NRH among CVID patients. CVID patients with NRH had a more severe disease presentation compared to those without. This included increased autoinflammatory disease comorbidities, combined B-cell and T-cell dysfunction, and abnormal liver biochemistries (specifically an increased mean alkaline phosphatase level [proximal to TE, 250 vs. 100 U/L; p = 0.03; peak, 314 vs. 114 U/L; p = 0.02). Results of TE demonstrated a significantly elevated liver stiffness in CVID patients with NRH (mean 13.2 +/- 6.2 kPa) as compared to both CVID patients without NRH (mean 4.6 +/- 0.9 kPa) and non-CVID patients with NAFLD (mean 6.9 +/- 5.5 kPa) (p < 0.01). No single or composite histopathologic feature of NRH correlated with liver stiffness including nodule size, nodule density, sinusoidal dilation, fibrosis, and/or lymphocytosis. In contrast, liver stiffness by TE was significantly correlated with clinical parameters of portal hypertension, including an elevated hepatic venous pressure gradient, an increased splenic longitudinal diameter, presence of varices, and presence of peripheral edema. A liver stiffness of greater than or equal to 6.2 kPa was a clinically significant cutoff for NRH in CVID patients. We propose that TE has diagnostic utility in CVID, particularly in the presence of immunophenotypic features such as combined B-cell and T-cell dysfunction, autoinflammatory comorbidities, and/or abnormal liver tests. Elevated liver stiffness by TE should raise suspicion for NRH in patients with CVID and prompt expedited evaluation by hepatology.	[DiGiacomo, Daniel V.; Yang, Nancy; Barmettler, Sara; Farmer, Jocelyn R.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; [Shay, Jessica E.; Corey, Kathleen] Massachusetts Gen Hosp, Dept Med, Div Gastroenterol, Boston, MA USA; [Crotty, Rory] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; [Bloom, Patricia] Univ Michigan, Dept Med, Div Gastroenterol, Ann Arbor, MI USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; University of Michigan System; University of Michigan	DiGiacomo, DV (corresponding author), Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.	ddigiacomo@mgh.harvard.edu			National Institute of Allergy and Infectious Diseases of the National Institutes of Health [K23AI163350]	National Institute of Allergy and Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	SB is supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number K23AI163350.	Azzu V, 2019, J ALLER CL IMM-PRACT, V7, P2484, DOI 10.1016/j.jaip.2019.04.016; Azzu V, 2018, LIVER TRANSPLANT, V24, P171, DOI 10.1002/lt.24979; Bochnakova Teodora, 2021, Clin Liver Dis (Hoboken), V17, P144, DOI 10.1002/cld.1031; Bonilla FA, 2016, J ALLER CL IMM-PRACT, V4, P38, DOI 10.1016/j.jaip.2015.07.025; Bonilla FA, 2015, J ALLERGY CLIN IMMUN, V136, P1186, DOI 10.1016/j.jaci.2015.04.049; Chalasani N, 2018, HEPATOLOGY, V67, P328, DOI 10.1002/hep.29367; Crescenzi L, 2019, DIGEST LIVER DIS, V51, P1599, DOI 10.1016/j.dld.2019.05.016; Crotty R, 2020, AM J SURG PATHOL, V44, P617, DOI 10.1097/PAS.0000000000001452; Eddowes PJ, 2019, GASTROENTEROLOGY, V156, P1717, DOI 10.1053/j.gastro.2019.01.042; Farmer JR, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01740; Foucher J, 2006, GUT, V55, P403, DOI 10.1136/gut.2005.069153; Fuss IJ, 2013, J CLIN IMMUNOL, V33, P748, DOI 10.1007/s10875-013-9873-6; Gereige JD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02753; Hartleb M, 2011, WORLD J GASTROENTERO, V17, P1400, DOI 10.3748/wjg.v17.i11.1400; Hashemi SA, 2016, CASP J INTERN MED, V7, P242; Jharap B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120299; Laharie D, 2010, EUR J GASTROEN HEPAT, V22, P487, DOI 10.1097/MEG.0b013e328334098f; Lim JK, 2017, GASTROENTEROLOGY, V152, P1536, DOI 10.1053/j.gastro.2017.03.017; Malamut G, 2008, J HEPATOL, V48, P74, DOI 10.1016/j.jhep.2007.08.011; Mayor PC, 2018, J ALLERGY CLIN IMMUN, V141, P1028, DOI 10.1016/j.jaci.2017.05.024; OPHIR J, 1991, ULTRASONIC IMAGING, V13, P111, DOI 10.1016/0161-7346(91)90079-W; Pecoraro A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00338; Resnick ES, 2012, BLOOD, V119, P1650, DOI 10.1182/blood-2011-09-377945; Robertson F, 2001, EUR RADIOL, V11, P80, DOI 10.1007/s003300000528; Tranah TH., 2021, J LIVER TRANSPL, V4, DOI DOI 10.1016/J.LIVER.2021.100038; von Spee-Mayer C, 2021, J ALLER CL IMM-PRACT, V9, P760, DOI 10.1016/j.jaip.2020.10.028; WANLESS IR, 1990, HEPATOLOGY, V11, P787, DOI 10.1002/hep.1840110512; Ward C, 2008, CLIN EXP IMMUNOL, V153, P331, DOI 10.1111/j.1365-2249.2008.03711.x; Wong VWS, 2010, HEPATOLOGY, V51, P454, DOI 10.1002/hep.23312	29	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								864550	10.3389/fimmu.2022.864550	http://dx.doi.org/10.3389/fimmu.2022.864550			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S0MY	35603209	Green Published, gold			2022-12-18	WOS:000803755000001
J	Dong, RY; Zhang, YX; Xiao, HW; Zeng, X				Dong, Ruoyu; Zhang, Yixi; Xiao, Haowen; Zeng, Xun			Engineering gamma delta T Cells: Recognizing and Activating on Their Own Way	FRONTIERS IN IMMUNOLOGY			English	Review						gamma delta T cells; engineering; stimulation; dual recognition; tumor	INDUCED CONFORMATIONAL-CHANGE; CYTOTOXICITY RECEPTOR NKP30; NKG2D TRIGGERS CYTOTOXICITY; ALPHA-BETA; ANTIGEN RECEPTOR; TUMOR-CELLS; IL-17 PRODUCTION; CYTOKINE PRODUCTION; ANTITUMOR-ACTIVITY; CO-STIMULATION	Adoptive cell therapy (ACT) with engineered T cells has emerged as a promising strategy for the treatment of malignant tumors. Among them, there is great interest in engineered gamma delta T cells for ACT. With both adaptive and innate immune characteristics, gamma delta T cells can be activated by gamma delta TCRs to recognize antigens in a MHC-independent manner, or by NK receptors to recognize stress-induced molecules. The dual recognition system enables gamma delta T cells with unique activation and cytotoxicity profiles, which should be considered for the design of engineered gamma delta T cells. However, the current designs of engineered gamma delta T cells mostly follow the strategies that used in alpha beta T cells, but not making good use of the specific characteristics of gamma delta T cells. Therefore, it is no surprising that current engineered gamma delta T cells in preclinical or clinical trials have limited efficacy. In this review, we summarized the patterns of antigen recognition of gamma delta T cells and the features of signaling pathways for the functions of gamma delta T cells. This review will additionally discuss current progress in engineered gamma delta T cells and provide insights in the design of engineered gamma delta T cells based on their specific characteristics.	[Dong, Ruoyu; Xiao, Haowen] Zhejiang Univ Sch Med, Sir Run Run Shaw Hosp, Dept Hematol, Hangzhou, Peoples R China; [Zhang, Yixi; Zeng, Xun] Zhejiang Univ Sch Med, Affiliated Hosp 1, Natl Clin Res Ctr Infect Dis, Natl Med Ctr Infect Dis,Collaborat Innovat Ctr Dia, Hangzhou, Peoples R China	Zhejiang University	Xiao, HW (corresponding author), Zhejiang Univ Sch Med, Sir Run Run Shaw Hosp, Dept Hematol, Hangzhou, Peoples R China.; Zeng, X (corresponding author), Zhejiang Univ Sch Med, Affiliated Hosp 1, Natl Clin Res Ctr Infect Dis, Natl Med Ctr Infect Dis,Collaborat Innovat Ctr Dia, Hangzhou, Peoples R China.	haowenxiaoxiao@zju.edu.cn; xunzeng@zju.edu.cn	Zeng, Xun/HHM-7791-2022		National Natural Science Foundation of China [31870899, 32070899, 81870136, 82170141]; Natural Science Foundation of Zhejiang Province [LXZ22H080001]; Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases [2022zz16]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases	Funding This work was supported by the National Natural Science Foundation of China (No. 31870899 and 32070899 to XZ, No. 81870136 and 82170141 to HX), Natural Science Foundation of Zhejiang Province (No. LXZ22H080001), and the Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases (No.2022zz16).	Acuto O, 2003, NAT REV IMMUNOL, V3, P939, DOI 10.1038/nri1248; Alnaggar M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0501-8; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bendle GM, 2010, NAT MED, V16, P565, DOI 10.1038/nm.2128; Bessoles S, 2011, EUR J IMMUNOL, V41, P1619, DOI 10.1002/eji.201041230; Billadeau DD, 2003, NAT IMMUNOL, V4, P557, DOI 10.1038/ni929; Breuning J, 2019, IMMUNOLOGY, V156, P130, DOI 10.1111/imm.13009; Campoli MR, 2004, CRIT REV IMMUNOL, V24, P267, DOI 10.1615/CritRevImmunol.v24.i4.40; Capsomidis A, 2018, MOL THER, V26, P354, DOI 10.1016/j.ymthe.2017.12.001; Chabab G, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061537; Cheadle EJ, 2012, GENE THER, V19, P1114, DOI 10.1038/gt.2011.192; Cheng HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063746; Cimini E, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7090350; Correia DV, 2011, BLOOD, V118, P992, DOI 10.1182/blood-2011-02-339135; Crowther MD, 2020, NAT IMMUNOL, V21, P178, DOI 10.1038/s41590-019-0578-8; da Mota JB, 2020, J LEUKOCYTE BIOL, V108, P1239, DOI 10.1002/JLB.4MA0420-568R; Dadi HK, 2003, NEW ENGL J MED, V349, P1821, DOI 10.1056/NEJMoa031178; Das H, 2001, IMMUNITY, V15, P83, DOI 10.1016/S1074-7613(01)00168-6; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DAVIGNON D, 1981, J IMMUNOL, V127, P590; de Saint Basile G, 2004, J CLIN INVEST, V114, P1512, DOI 10.1172/JCI200422588; deBarros A, 2011, EUR J IMMUNOL, V41, P195, DOI 10.1002/eji.201040905; Delgado P, 2000, NATURE, V406, P426, DOI 10.1038/35019102; Deniger DC, 2013, MOL THER, V21, P638, DOI 10.1038/mt.2012.267; Deseke M, 2020, CELL MOL IMMUNOL, V17, P914, DOI 10.1038/s41423-020-0503-y; Di Lorenzo B, 2019, CANCER IMMUNOL RES, V7, P552, DOI 10.1158/2326-6066.CIR-18-0647; Diefenbach A, 2002, NAT IMMUNOL, V3, P1142, DOI 10.1038/ni858; Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008-5472.CAN-07-0199; Dorrie J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109944; DOHERTY PC, 1991, SPRINGER SEMIN IMMUN, V13, P11, DOI 10.1007/BF01225275; Domae E, 2017, ONCOTARGET, V8, P45928, DOI 10.18632/oncotarget.17498; Dopfer EP, 2014, CELL REP, V7, P1704, DOI 10.1016/j.celrep.2014.04.049; Duault C, 2017, EUR J IMMUNOL, V47, P2137, DOI 10.1002/eji.201747093; Fisher J, 2017, MOL THER, V25, P1234, DOI 10.1016/j.ymthe.2017.03.002; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Garcia VE, 1998, J IMMUNOL, V160, P4322; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gherardin NA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22130-1; Gil D, 2002, CELL, V109, P901, DOI 10.1016/S0092-8674(02)00799-7; Gilfillan S, 2002, NAT IMMUNOL, V3, P1150, DOI 10.1038/ni857; Girlanda S, 2005, CANCER RES, V65, P7502, DOI 10.1158/0008-5472.CAN-05-0731; Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500; Grant EJ, 2017, CURR OPIN VIROL, V22, P77, DOI 10.1016/j.coviro.2016.12.001; Gu SY, 2017, P NATL ACAD SCI USA, V114, pE7311, DOI 10.1073/pnas.1707547114; Halary F, 1997, EUR J IMMUNOL, V27, P2812, DOI 10.1002/eji.1830271111; Harly C, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.aba9010; Harly C, 2012, BLOOD, V120, P2269, DOI 10.1182/blood-2012-05-430470; Harrer DC, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3539-3; Hassan NJ, 2004, EUR J IMMUNOL, V34, P930, DOI 10.1002/eji.200424856; Hayes SM, 2002, IMMUNITY, V16, P827, DOI 10.1016/S1074-7613(02)00320-5; He KX, 2016, MOL MED, V22, P519, DOI 10.2119/molmed.2016.00023; Hou LF, 2013, J IMMUNOL, V190, P621, DOI 10.4049/jimmunol.1201970; Hudecek R, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.752646; Ibusuki A, 2014, J INVEST DERMATOL, V134, P396, DOI 10.1038/jid.2013.353; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Jiang XT, 2019, CANCER LETT, V462, P23, DOI 10.1016/j.canlet.2019.07.017; Johanna I, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0558-4; Kabelitz D, 2020, CELL MOL IMMUNOL, V17, P925, DOI 10.1038/s41423-020-0504-x; Kailayangiri S, 2012, BRIT J CANCER, V106, P1123, DOI 10.1038/bjc.2012.57; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Karunakaran MM, 2020, IMMUNITY, V52, P487, DOI 10.1016/j.immuni.2020.02.014; Kato Y, 2006, J IMMUNOL, V177, P877, DOI 10.4049/jimmunol.177.2.877; Kierkels GJJ, 2019, BLOOD ADV, V3, P2870, DOI 10.1182/bloodadvances.2019032409; Kobayashi H, 2011, CANCER IMMUNOL IMMUN, V60, P1075, DOI 10.1007/s00262-011-1021-7; Kong Y, 2009, BLOOD, V114, P310, DOI 10.1182/blood-2008-12-196287; Kuhns MS, 2006, IMMUNITY, V24, P133, DOI 10.1016/j.immuni.2006.01.006; Lafont V, 2000, J BIOL CHEM, V275, P19282, DOI 10.1074/jbc.M910487199; Laird RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063178; Lalor SJ, 2011, J IMMUNOL, V186, P5738, DOI 10.4049/jimmunol.1003597; Lanier LL, 2015, CANCER IMMUNOL RES, V3, P575, DOI 10.1158/2326-6066.CIR-15-0098; Lanier LL, 2001, NAT IMMUNOL, V2, P23, DOI 10.1038/83130; Le Nours J, 2019, SCIENCE, V366, P1522, DOI 10.1126/science.aav3900; Lee SJ, 2013, EUR J IMMUNOL, V43, P1839, DOI 10.1002/eji.201242842; Lepore M, 2014, J EXP MED, V211, P1360, DOI 10.1084/jem.20140410; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; Li JQ, 2009, J IMMUNOL, V182, P8118, DOI 10.4049/jimmunol.0900101; Li W, 2010, J IMMUNOTHER, V33, P287, DOI 10.1097/CJI.0b013e3181c80ffa; Li YL, 2011, J EXP MED, V208, P703, DOI 10.1084/jem.20102548; Liang YJ, 2015, EUR J IMMUNOL, V45, P3052, DOI 10.1002/eji.201545696; Liu ZY, 2008, J IMMUNOL, V180, P6044, DOI 10.4049/jimmunol.180.9.6044; Lockhart E, 2006, J IMMUNOL, V177, P4662, DOI 10.4049/jimmunol.177.7.4662; Marcu-Malina V, 2011, BLOOD, V118, P50, DOI 10.1182/blood-2010-12-325993; Marlin R, 2017, P NATL ACAD SCI USA, V114, P3163, DOI 10.1073/pnas.1621052114; Mei Z, 2020, CANCER MED-US, V9, P640, DOI 10.1002/cam4.2733; Michel ML, 2012, P NATL ACAD SCI USA, V109, P17549, DOI 10.1073/pnas.1204327109; Mikulak J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125884; Minguet S, 2007, IMMUNITY, V26, P43, DOI 10.1016/j.immuni.2006.10.019; Nedellec S, 2010, J IMMUNOL, V185, P55, DOI 10.4049/jimmunol.1000373; Nicolas L, 2001, CLIN IMMUNOL, V98, P358, DOI 10.1006/clim.2000.4978; Nitahara A, 2006, J INVEST DERMATOL, V126, P1052, DOI 10.1038/sj.jid.5700112; OHTEKI T, 1993, EUR J IMMUNOL, V23, P1251, DOI 10.1002/eji.1830230609; Pei YJ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0174-2; Perez C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583716; Pitcher LA, 2005, EUR J IMMUNOL, V35, P3643, DOI 10.1002/eji.200535136; Rakasz E, 1997, INT IMMUNOL, V9, P161, DOI 10.1093/intimm/9.1.161; Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445; Reijneveld JF, 2020, P NATL ACAD SCI USA, V117, P22944, DOI 10.1073/pnas.2010545117; Ribot JC, 2012, J IMMUNOL, V189, P1202, DOI 10.4049/jimmunol.1200268; Ribot JC, 2010, J IMMUNOL, V185, P6421, DOI 10.4049/jimmunol.1002283; Ribot JC, 2009, NAT IMMUNOL, V10, P427, DOI 10.1038/ni.1717; Rigau M, 2020, SCIENCE, V367, P642, DOI 10.1126/science.aay5516; Rincon-Orozco B, 2005, J IMMUNOL, V175, P2144, DOI 10.4049/jimmunol.175.4.2144; Rischer M, 2004, BRIT J HAEMATOL, V126, P583, DOI 10.1111/j.1365-2141.2004.05077.x; Roberts AI, 2001, J IMMUNOL, V167, P5527, DOI 10.4049/jimmunol.167.10.5527; Roy S, 2016, J IMMUNOL, V196, P1933, DOI 10.4049/jimmunol.1502202; Rozenbaum M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01347; Ruth JH, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.145662; Salim M, 2017, ACS CHEM BIOL, V12, P2631, DOI 10.1021/acschembio.7b00694; Sandstrom A, 2014, IMMUNITY, V40, P490, DOI 10.1016/j.immuni.2014.03.003; Scheffer GL, 2002, EUR J CANCER, V38, P1535, DOI 10.1016/S0959-8049(02)00108-9; Schilbach K, 2020, CANCERS, V12, DOI 10.3390/cancers12010130; Sebestyen Z, 2020, NAT REV DRUG DISCOV, V19, P169, DOI 10.1038/s41573-019-0038-z; Shimizu K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131477; Siegers GM, 2007, J EXP MED, V204, P2537, DOI 10.1084/jem.20070782; Silva-Santos B, 2019, NAT REV CANCER, V19, P392, DOI 10.1038/s41568-019-0153-5; Silva-Santos B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00851; Singh AK, 2020, LANCET ONCOL, V21, pE168, DOI 10.1016/S1470-2045(19)30823-X; Song DG, 2012, BLOOD, V119, P696, DOI 10.1182/blood-2011-03-344275; Spada FM, 2000, J EXP MED, V191, P937, DOI 10.1084/jem.191.6.937; SPERLING AI, 1993, J IMMUNOL, V151, P6043; Stojanovic A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00827; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Swamy M, 2016, IMMUNITY, V44, P1091, DOI 10.1016/j.immuni.2016.04.011; TESTI R, 1989, EUR J IMMUNOL, V19, P185, DOI 10.1002/eji.1830190129; Thedrez A, 2009, J IMMUNOL, V182, P3423, DOI 10.4049/jimmunol.0803068; Tosolini M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284723; Uldrich AP, 2013, NAT IMMUNOL, V14, P1137, DOI 10.1038/ni.2713; van der Veken LT, 2009, J IMMUNOL, V182, P164, DOI 10.4049/jimmunol.182.1.164; van der Veken LT, 2006, CANCER RES, V66, P3331, DOI 10.1158/0008-5472.CAN-05-4190; VANDEWIELVANKEMENADE E, 1992, EUR J IMMUNOL, V22, P1467; von Lilienfeld-Toal M, 2006, CLIN EXP IMMUNOL, V144, P528, DOI 10.1111/j.1365-2249.2006.03078.x; Wang F, 2016, NAT IMMUNOL, V17, P844, DOI 10.1038/ni.3462; Wang P, 2000, MOL MED, V6, P196, DOI 10.1007/BF03402114; Wang Q, 2020, EXP THER MED, V20, DOI 10.3892/etm.2020.9354; Wen T, 2002, J IMMUNOL, V168, P4897, DOI 10.4049/jimmunol.168.10.4897; Wesch D, 2011, CELL MOL LIFE SCI, V68, P2357, DOI 10.1007/s00018-011-0699-1; WESSELBORG S, 1991, J EXP MED, V173, P297, DOI 10.1084/jem.173.2.297; Willcox CR, 2012, NAT IMMUNOL, V13, P872, DOI 10.1038/ni.2394; Wrobel P, 2007, SCAND J IMMUNOL, V66, P320, DOI 10.1111/j.1365-3083.2007.01963.x; Xiang Z, 2014, CANCER CELL, V26, P565, DOI 10.1016/j.ccr.2014.07.026; Xu YY, 2018, CELL DISCOV, V4, DOI 10.1038/s41421-018-0066-6; Yamaguchi T, 1998, CANCER IMMUNOL IMMUN, V47, P97, DOI 10.1007/s002620050509; Zeng X, 2014, ELIFE, V3, DOI 10.7554/eLife.03609; Zeng X, 2012, IMMUNITY, V37, P524, DOI 10.1016/j.immuni.2012.06.011; Zhai XC, 2021, AM J CANCER RES, V11, P79; Zhang BF, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01474-1; Zhang C, 2021, CELL MOL IMMUNOL, V18, P2083, DOI 10.1038/s41423-021-00732-6; Zhang H, 2007, J IMMUNOL, V179, P4910, DOI 10.4049/jimmunol.179.7.4910; Zhang T, 2004, CANCER GENE THER, V11, P487, DOI 10.1038/sj.cgt.7700703; Zhao H, 2012, CELL MOL IMMUNOL, V9, P147, DOI 10.1038/cmi.2011.28; Zompi S, 2003, NAT IMMUNOL, V4, P565, DOI 10.1038/ni930	151	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								889051	10.3389/fimmu.2022.889051	http://dx.doi.org/10.3389/fimmu.2022.889051			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K4IB	35603176	gold, Green Published			2022-12-18	WOS:000798565400001
J	Fuentes, R; Aguinagalde, L; Pifferi, C; Plata, A; Sacristan, N; Castellana, D; Anguita, J; Fernandez-Tejada, A				Fuentes, Roberto; Aguinagalde, Leire; Pifferi, Carlo; Plata, Adrian; Sacristan, Nagore; Castellana, Donatello; Anguita, Juan; Fernandez-Tejada, Alberto			Novel Oxime-Derivatized Synthetic Triterpene Glycosides as Potent Saponin Vaccine Adjuvants	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine adjuvants; synthetic saponins; carbohydrates; immune responses; immunological evaluation	IMMUNOLOGICAL EVALUATION; ANTICANCER VACCINES; QUILLAJA-SAPONARIA; QS-21; DESIGN; MECHANISMS; VARIANTS; EFFICACY; SYSTEM; SAFETY	Vaccine adjuvants are key for optimal vaccine efficacy, increasing the immunogenicity of the antigen and potentiating the immune response. Saponin adjuvants such as the carbohydrate-based QS-21 natural product are among the most promising candidates in vaccine formulations, but suffer from inherent drawbacks that have hampered their use and approval as stand-alone adjuvants. Despite the recent development of synthetic derivatives with improved properties, their full potential has not yet been reached, allowing the prospect of discovering further optimized saponin variants with higher potency. Herein, we have designed, chemically synthesized, and immunologically evaluated novel oxime-derivatized saponin adjuvants with targeted structural modifications at key triterpene functionalities. The resulting analogues have revealed important findings into saponin structure-activity relationships, including adjuvant mechanistic insights, and have shown superior adjuvant activity in terms of significantly increased antibody response augmentation compared to our previous saponin leads. These newly identified saponin oximes emerge as highly promising synthetic adjuvants for further preclinical development towards potential next generation immunotherapeutics for future vaccine applications.	[Fuentes, Roberto; Aguinagalde, Leire; Pifferi, Carlo; Plata, Adrian; Sacristan, Nagore; Fernandez-Tejada, Alberto] Ctr Cooperat Res Biosci CIC bioGUNE, Chem Immunol Lab, Basque Res & Technol Alliance BRTA, Derio, Spain; [Castellana, Donatello] Ctr Cooperat Res Biosci C bioGUNE, Res & Dev, Basque Res & Technol Alliance BRTA, Derio, Spain; [Anguita, Juan] Ctr Cooperat Res Biosci CIC bioGUNE, Inflammat & Macrophage Plast Lab, Basque Res & Technol Alliance BRTA, Derio, Spain; [Anguita, Juan; Fernandez-Tejada, Alberto] Ikerbasque, Basque Fdn Sci, Bilbao, Spain	CIC bioGUNE; CIC bioGUNE; Basque Foundation for Science	Fernandez-Tejada, A (corresponding author), Ikerbasque, Basque Fdn Sci, Bilbao, Spain.	afernandeztejada@cicbiogune.es	Anguita, Juan/D-5432-2011	Anguita, Juan/0000-0003-2061-7182; Plata-Ruiz, Adrian/0000-0002-6963-0102				Adams MM, 2010, J AM CHEM SOC, V132, P1939, DOI 10.1021/ja9082842; [Anonymous], SHINGLES; Bednarczyk-Cwynar B, 2013, J MOL STRUCT, V1053, P115, DOI 10.1016/j.molstruc.2013.09.006; Chea EK, 2012, J AM CHEM SOC, V134, P13448, DOI 10.1021/ja305121q; Chen H, 1996, J MOL MED, V74, P497; Cleland JL, 1996, J PHARM SCI, V85, P22, DOI 10.1021/js9503136; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; Didierlaurent AM, 2017, EXPERT REV VACCINES, V16, P55, DOI 10.1080/14760584.2016.1213632; Emirdag-Ozturk S, 2014, EUR J MED CHEM, V82, P565, DOI 10.1016/j.ejmech.2014.05.084; Fernandez-Tejada A, 2017, PURE APPL CHEM, V89, P1359, DOI 10.1515/pac-2016-1213; Fernandez-Tejada A, 2017, METHODS MOL BIOL, V1494, P45, DOI 10.1007/978-1-4939-6445-1_4; Fernandez-Tejada A, 2016, ACCOUNTS CHEM RES, V49, P1741, DOI 10.1021/acs.accounts.6b00242; Fernandez-Tejada A, 2015, CHEM COMMUN, V51, P13949, DOI 10.1039/c5cc05244k; Fernandez-Tejada A, 2014, BIOORGAN MED CHEM, V22, P5917, DOI 10.1016/j.bmc.2014.09.016; Fernandez-Tejada A, 2014, NAT CHEM, V6, P636, DOI [10.1038/NCHEM.1963, 10.1038/nchem.1963]; Fuentes R, 2021, CHEM-EUR J, V27, P4731, DOI 10.1002/chem.202004705; Galonic DP, 2007, NATURE, V446, P1000, DOI 10.1038/nature05813; Ghirardello M, 2020, CHEM COMMUN, V56, P719, DOI 10.1039/c9cc07781b; Kensil C R, 1998, Expert Opin Investig Drugs, V7, P1475, DOI 10.1517/13543784.7.9.1475; KENSIL CR, 1991, J IMMUNOL, V146, P431; Kite GC, 2004, RAPID COMMUN MASS SP, V18, P2859, DOI 10.1002/rcm.1698; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; Li WH, 2020, CHEM REV, V120, P11420, DOI 10.1021/acs.chemrev.9b00833; Marciani DJ, 2018, TRENDS PHARMACOL SCI, V39, P573, DOI 10.1016/j.tips.2018.03.005; Marciani DJ, 2003, DRUG DISCOV TODAY, V8, P934, DOI 10.1016/S1359-6446(03)02864-2; Nico D, 2007, VACCINE, V25, P649, DOI 10.1016/j.vaccine.2006.08.035; Nico D, 2012, VACCINE, V30, P3169, DOI 10.1016/j.vaccine.2012.03.006; Paston SJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.627932; Pifferi C., 2021, EUROPEAN PATENT APPL; Pifferi C, 2021, NAT REV CHEM, V5, P197, DOI 10.1038/s41570-020-00244-3; Pifferi C, 2020, CHEM SCI, V11, P4488, DOI 10.1039/d0sc00544d; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Ragupathi G, 2011, EXPERT REV VACCINES, V10, P463, DOI [10.1586/erv.11.18, 10.1586/ERV.11.18]; RHODES J, 1995, NATURE, V377, P71, DOI 10.1038/377071a0; SOLTYSIK S, 1995, VACCINE, V13, P1403, DOI 10.1016/0264-410X(95)00077-E; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Waite DC, 2001, VACCINE, V19, P3957, DOI 10.1016/S0264-410X(01)00142-6; Wang H, 2015, EUR J MED CHEM, V102, P594, DOI 10.1016/j.ejmech.2015.08.034; Wang PF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030222; Wilson RM, 2013, J AM CHEM SOC, V135, P14462, DOI 10.1021/ja405932r; Zhu JL, 2009, EXPERT REV VACCINES, V8, P1399, DOI 10.1586/ERV.09.95	41	0	0	12	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								865507	10.3389/fimmu.2022.865507	http://dx.doi.org/10.3389/fimmu.2022.865507			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P8AI	35603193	Green Published, gold			2022-12-18	WOS:000802226000001
J	Goncalves, JIB; Borges, TJ; de Souza, APD				Goncalves, Joao I. B.; Borges, Thiago J.; de Souza, Ana Paula Duarte			Microbiota and the Response to Vaccines Against Respiratory Virus	FRONTIERS IN IMMUNOLOGY			English	Review						virus; microbiota; vaccine; respiratory virus; immune response	CHAIN FATTY-ACIDS; T-CELLS SHAPE; INFLUENZA VACCINATION; GUT MICROBIOTA; DOUBLE-BLIND; ANTIBODY-RESPONSE; INTESTINAL MICROBIOTA; IMMUNE-RESPONSE; HOST-DEFENSE; LACTOBACILLUS	This mini review describes the role of gut and lung microbiota during respiratory viral infection and discusses the implication of the microbiota composition on the immune responses generated by the vaccines designed to protect against these pathogens. This is a growing field and recent evidence supports that the composition and function of the microbiota can modulate the immune response of vaccination against respiratory viruses such as influenza and SARS-CoV-2. Recent studies have highlighted that molecules derived from the microbiome can have systemic effects, acting in distant organs. These molecules are recognized by the immune cells from the host and can trigger or modulate different responses, interfering with vaccination protection. Modulating the microbiota composition has been suggested as an approach to achieving more efficient protective immune responses. Studies in humans have reported associations between a better vaccine response and specific bacterial taxa. These associations vary among different vaccine strategies and are likely to be context-dependent. The use of prebiotics and probiotics in conjunction with vaccination demonstrated that bacterial components could act as adjuvants. Future microbiota-based interventions may potentially improve and optimize the responses of respiratory virus vaccines.	[Goncalves, Joao I. B.; de Souza, Ana Paula Duarte] Pontif Catholic Univ Rio Grande do Sul PUCRS, Hlth & Life Sci Sch, Lab Clin & Expt Immunol, Porto Alegre, Brazil; [Goncalves, Joao I. B.; Borges, Thiago J.] Massachusetts Gen Hosp, Ctr Transplantat Sci, Harvard Med Sch, Dept Surg, Boston, MA USA	Pontificia Universidade Catolica Do Rio Grande Do Sul; Harvard University; Harvard Medical School; Massachusetts General Hospital	de Souza, APD (corresponding author), Pontif Catholic Univ Rio Grande do Sul PUCRS, Hlth & Life Sci Sch, Lab Clin & Expt Immunol, Porto Alegre, Brazil.	ana.duarte@pucrs.br		Borges, Thiago J/0000-0002-6554-0169; Souza, Ana Paula/0000-0002-6021-5068				Dang AT, 2019, MUCOSAL IMMUNOL, V12, P843, DOI 10.1038/s41385-019-0160-6; [Anonymous], 2022, GUT MICROBIOTA PROFI; Ansaldo E, 2021, ANNU REV IMMUNOL, V39, P449, DOI 10.1146/annurev-immunol-093019-112348; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arrieta MC, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab2271; Bachem A, 2019, IMMUNITY, V51, P285, DOI 10.1016/j.immuni.2019.06.002; Balmer ML, 2020, CELL METAB, V32, P457, DOI 10.1016/j.cmet.2020.07.004; Balmer ML, 2016, IMMUNITY, V44, P1312, DOI 10.1016/j.immuni.2016.03.016; Bansal T, 2010, P NATL ACAD SCI USA, V107, P228, DOI 10.1073/pnas.0906112107; Bassis CM, 2015, MBIO, V6, DOI 10.1128/mBio.00037-15; Blacher E, 2017, J IMMUNOL, V198, P572, DOI 10.4049/jimmunol.1601247; Boge T, 2009, VACCINE, V27, P5677, DOI 10.1016/j.vaccine.2009.06.094; Bosch M, 2012, NUTR HOSP, V27, P504, DOI [10.3305/nh.2012.27.2.5519, 10.1590/S0212-16112012000200023]; CDC, 1999, MMWR MORB MORTAL WKL, V48, P243; Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111; Charbonneau MR, 2016, CELL, V164, P859, DOI 10.1016/j.cell.2016.01.024; Chen LW, 2011, SHOCK, V36, P67, DOI 10.1097/SHK.0b013e3182184ee7; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Correa RO, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.17; Cox AJ, 2010, BRIT J SPORT MED, V44, P222, DOI 10.1136/bjsm.2007.044628; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; de Vrese M, 2005, CLIN NUTR, V24, P481, DOI 10.1016/j.clnu.2005.02.006; Dickson RP, 2016, ANNU REV PHYSIOL, V78, P481, DOI 10.1146/annurev-physiol-021115-105238; Dilantika C, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-3; Doi H, 2021, VACCINE, V39, P5224, DOI 10.1016/j.vaccine.2021.07.017; Dong FC, 2020, GUT MICROBES, V12, DOI 10.1080/19490976.2020.1859812; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Enaud R, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00009; Ewaschuk JB, 2008, AM J PHYSIOL-GASTR L, V295, pG1025, DOI 10.1152/ajpgi.90227.2008; Fujimura KE, 2016, NAT MED, V22, P1187, DOI 10.1038/nm.4176; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gluck U, 2003, AM J CLIN NUTR, V77, P517; Groves HT, 2020, MBIO, V11, DOI 10.1128/mBio.03236-19; Groves HT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00182; Gu SL, 2020, CLIN INFECT DIS, V71, P2669, DOI 10.1093/cid/ciaa709; Hagan T, 2019, CELL, V178, P1313, DOI 10.1016/j.cell.2019.08.010; Hao QK, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006895.pub3; Harding JN, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-01816-5; Hill C, 2014, NAT REV GASTRO HEPAT, V11, P506, DOI 10.1038/nrgastro.2014.66; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Jespersen L, 2015, AM J CLIN NUTR, V101, P1188, DOI 10.3945/ajcn.114.103531; JOHN TJ, 1972, AM J EPIDEMIOL, V96, P263, DOI 10.1093/oxfordjournals.aje.a121457; JOHN TJ, 1976, BRIT MED J, V1, P812, DOI 10.1136/bmj.1.6013.812; Jung YJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17487-8; Karl JP, 2021, MIL MED, V186, pE310, DOI 10.1093/milmed/usaa261; Kekkonen RA, 2007, INT J SPORT NUTR EXE, V17, P352, DOI 10.1123/ijsnem.17.4.352; Kim CH, 2021, CELL MOL IMMUNOL, V18, P1161, DOI 10.1038/s41423-020-00625-0; Kim D, 2016, NAT MED, V22, P524, DOI 10.1038/nm.4075; Kim S, 2014, BMB REP, V47, P173, DOI 10.5483/BMBRep.2014.47.3.272; King S, 2014, BRIT J NUTR, V112, P41, DOI 10.1017/S0007114514000075; Kurupati R, 2016, ONCOTARGET, V7, P62898, DOI 10.18632/oncotarget.11704; Laidlaw BJ, 2015, NAT IMMUNOL, V16, P871, DOI 10.1038/ni.3224; Langkamp-Henken B, 2004, J AM GERIATR SOC, V52, P3, DOI 10.1111/j.1532-5415.2004.52003.x; Lavelle A, 2020, NAT REV GASTRO HEPAT, V17, P223, DOI 10.1038/s41575-019-0258-z; Lee JS, 2012, NAT IMMUNOL, V13, P144, DOI 10.1038/ni.2187; Lee JE, 2020, VET RES, V51, DOI 10.1186/s13567-020-00788-8; Lee JS, 2006, J VIROL, V80, P4079, DOI 10.1128/JVI.80.8.4079-4087.2006; Lei WT, 2017, NUTRIENTS, V9, DOI 10.3390/nu9111175; Levy M, 2017, CURR OPIN MICROBIOL, V35, P8, DOI 10.1016/j.mib.2016.10.003; Levy M, 2017, NAT REV IMMUNOL, V17, P219, DOI 10.1038/nri.2017.7; Lindner C, 2012, J EXP MED, V209, P365, DOI 10.1084/jem.20111980; Lousada-Dietrich S, 2011, VACCINE, V29, P3284, DOI 10.1016/j.vaccine.2011.02.022; Lynn DJ, 2022, NAT REV IMMUNOL, V22, P33, DOI 10.1038/s41577-021-00554-7; Machado MG, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.773261; Maruyama M, 2016, INT J FOOD SCI NUTR, V67, P67, DOI 10.3109/09637486.2015.1126564; Mathieu E, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01168; McElhaney JE, 1998, VACCINE, V16, P1742, DOI 10.1016/S0264-410X(98)00133-9; MCELHANEY JE, 1992, J GERONTOL, V47, pM3, DOI 10.1093/geronj/47.1.M3; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Mezhenskaya D, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111515; Muhlebach MS, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006798; Nagafuchi S, 2015, PHARMACEUTICALS, V8, P351, DOI 10.3390/ph8020351; Nakaya HI, 2015, IMMUNITY, V43, P1186, DOI 10.1016/j.immuni.2015.11.012; Ng SC, 2022, GUT, V71, P1106, DOI 10.1136/gutjnl-2021-326563; Oh JZ, 2014, IMMUNITY, V41, P478, DOI 10.1016/j.immuni.2014.08.009; Pannaraj PS, 2017, JAMA PEDIATR, V171, P647, DOI 10.1001/jamapediatrics.2017.0378; Pattaroni C, 2018, CELL HOST MICROBE, V24, P857, DOI 10.1016/j.chom.2018.10.019; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Riede L, 2013, CURR MED RES OPIN, V29, P251, DOI 10.1185/03007995.2013.765837; Rizzardini G, 2012, BRIT J NUTR, V107, P876, DOI 10.1017/S000711451100420X; Rooks MG, 2016, NAT REV IMMUNOL, V16, P341, DOI 10.1038/nri.2016.42; Ruff WE, 2020, NAT REV MICROBIOL, V18, P521, DOI 10.1038/s41579-020-0367-2; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Schuijt TJ, 2016, GUT, V65, P575, DOI 10.1136/gutjnl-2015-309728; Schulthess J, 2019, IMMUNITY, V50, P432, DOI 10.1016/j.immuni.2018.12.018; Sela DA, 2010, TRENDS MICROBIOL, V18, P298, DOI 10.1016/j.tim.2010.03.008; Sencio V, 2021, MUCOSAL IMMUNOL, V14, P296, DOI 10.1038/s41385-020-00361-8; Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533; Sepahi A, 2021, MUCOSAL IMMUNOL, V14, P317, DOI 10.1038/s41385-020-0312-8; Skelly AN, 2019, NAT REV IMMUNOL, V19, P305, DOI 10.1038/s41577-019-0144-5; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Tan J, 2014, ADV IMMUNOL, V121, P91, DOI 10.1016/B978-0-12-800100-4.00003-9; Tanaka M, 2017, ALLERGOL INT, V66, P515, DOI 10.1016/j.alit.2017.07.010; Tao Wanyin, 2020, Med Microecol, V5, P100023, DOI 10.1016/j.medmic.2020.100023; Tiollier E, 2007, MIL MED, V172, P1006, DOI 10.7205/MILMED.172.9.1006; Trompette A, 2018, IMMUNITY, V48, P992, DOI 10.1016/j.immuni.2018.04.022; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; van Best N, 2015, BIRTH DEFECTS RES C, V105, P240, DOI 10.1002/bdrc.21113; van Puyenbroeck K, 2012, AM J CLIN NUTR, V95, P1165, DOI 10.3945/ajcn.111.026831; de Oliveira GLV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.635471; Villena J, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9040683; Vinolo MAR, 2011, J NUTR BIOCHEM, V22, P849, DOI 10.1016/j.jnutbio.2010.07.009; Wei B, 2008, EUR J IMMUNOL, V38, P3411, DOI 10.1002/eji.200838432; Wu S, 2013, CURR MICROBIOL, V67, P414, DOI 10.1007/s00284-013-0380-z; Wu W, 2017, MUCOSAL IMMUNOL, V10, P946, DOI 10.1038/mi.2016.114; Wypych TP, 2019, NAT IMMUNOL, V20, P1279, DOI 10.1038/s41590-019-0451-9; Xavier-Santos D, 2022, TRENDS FOOD SCI TECH, V120, P174, DOI 10.1016/j.tifs.2021.12.033; Xu JQ, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.789242; Yeh TL, 2018, DRUG DES DEV THER, V12, P217, DOI 10.2147/DDDT.S155110; Yeoh YK, 2021, GUT, V70, P698, DOI 10.1136/gutjnl-2020-323020; Zaman K, 2010, LANCET, V376, P615, DOI 10.1016/S0140-6736(10)60755-6; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003; Zimmermann P, 2019, CLIN MICROBIOL REV, V32, DOI 10.1128/CMR.00084-18; Zuo T, 2020, GASTROENTEROLOGY, V159, P944, DOI 10.1053/j.gastro.2020.05.048	116	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								889945	10.3389/fimmu.2022.889945	http://dx.doi.org/10.3389/fimmu.2022.889945			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6YL	35603203	Green Published, gold			2022-12-18	WOS:000800115200001
J	Gutierrez, C; Vilas, CK; Wu, CJ; Al'Khafaji, AM				Gutierrez, Catherine; Vilas, Caroline K.; Wu, Catherine J.; Al'Khafaji, Aziz M.			Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						tumor heterogeneity; clonal dynamics; clonal evolution; drug resistance; homogenization; cellular plasticity; functionalized lineage tracing; DNA barcoding	COLLATERAL SENSITIVITY; CLONAL EVOLUTION; INTRATUMOR HETEROGENEITY; GENETIC-HETEROGENEITY; CROSS-RESISTANCE; CELL-LINES; INHIBITION; MECHANISMS; PLASTICITY; DYNAMICS	The therapeutic landscape across many cancers has dramatically improved since the introduction of potent targeted agents and immunotherapy. Nonetheless, success of these approaches is too often challenged by the emergence of therapeutic resistance, fueled by intratumoral heterogeneity and the immense evolutionary capacity inherent to cancers. To date, therapeutic strategies have attempted to outpace the evolutionary tempo of cancer but frequently fail, resulting in lack of tumor response and/or relapse. This realization motivates the development of novel therapeutic approaches which constrain evolutionary capacity by reducing the degree of intratumoral heterogeneity prior to treatment. Systematic development of such approaches first requires the ability to comprehensively characterize heterogeneous populations over the course of a perturbation, such as cancer treatment. Within this context, recent advances in functionalized lineage tracing approaches now afford the opportunity to efficiently measure multimodal features of clones within a tumor at single cell resolution, enabling the linkage of these features to clonal fitness over the course of tumor progression and treatment. Collectively, these measurements provide insights into the dynamic and heterogeneous nature of tumors and can thus guide the design of homogenization strategies which aim to funnel heterogeneous cancer cells into known, targetable phenotypic states. We anticipate the development of homogenization therapeutic strategies to better allow for cancer eradication and improved clinical outcomes.	[Gutierrez, Catherine; Wu, Catherine J.] Harvard Med Sch, Dept Med, Boston, MA USA; [Gutierrez, Catherine; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; [Vilas, Caroline K.] Univ Texas Austin, Dept Mol Biosci, Austin, TX USA; [Vilas, Caroline K.] Univ Texas Austin, Coll Pharm, Div Chem Biol & Med Chem, Austin, TX USA; [Wu, Catherine J.] Brigham & Womens Hosp, Dept Med, Boston, MA USA; [Wu, Catherine J.; Al'Khafaji, Aziz M.] MIT & Harvard, Broad Inst, Cambridge, MA USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Al'Khafaji, AM (corresponding author), MIT & Harvard, Broad Inst, Cambridge, MA USA.	aalkhafa@broadinstitute.org		Vilas, Caroline/0000-0002-8080-3035	Dana-Farber Cancer Institute	Dana-Farber Cancer Institute	Funding CG is supported by the Dana-Farber Cancer Institute Fellowship, the American Society of Hematology Minority Medical Student Award Program and the NIH Ruth L. Kirschstein NRSA Individual Predoctoral Fellowship F31 Award (1F31CA239443-01). CKV is supported by the NIH Ruth L. Kirschstein NRSA Individual Predoctoral Fellowship F31 Award (5F31CA243349-03) CJW is the Lavine Family Chair for Preventative Cancer Therapies at DFCI. AMA is supported by the Broad Institute IGNITE award.	Alfarouk KO, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0221-1; An X, 2010, LEUKEMIA RES, V34, P1255, DOI 10.1016/j.leukres.2010.04.016; Andor N, 2016, NAT MED, V22, P105, DOI 10.1038/nm.3984; [Anonymous], BRAF INHIBITORS INDU; Askary A, 2020, NAT BIOTECHNOL, V38, P66, DOI 10.1038/s41587-019-0299-4; Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bell CC, 2020, BRIT J CANCER, V122, P465, DOI 10.1038/s41416-019-0648-6; Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841; Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416; Blakemore SJ, 2020, LEUKEMIA, V34, P1760, DOI 10.1038/s41375-020-0723-2; Boot A, 2018, GENOME RES, V28, P654, DOI 10.1101/gr.230219.117; Bowling S, 2020, CELL, V181, P1410, DOI 10.1016/j.cell.2020.04.048; Brown R, 2014, NAT REV CANCER, V14, P747, DOI 10.1038/nrc3819; Bukowski K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093233; Chang MT, 2022, NAT BIOTECHNOL, V40, P86, DOI 10.1038/s41587-021-01005-3; Chen GB, 2015, CELL, V160, P771, DOI 10.1016/j.cell.2015.01.026; Chow KHK, 2021, SCIENCE, V372, P145, DOI 10.1126/science.abb3099; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Darini C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10138-8; Davis A, 2017, BBA-REV CANCER, V1867, P151, DOI 10.1016/j.bbcan.2017.01.003; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Emert BL, 2021, NAT BIOTECHNOL, V39, P865, DOI 10.1038/s41587-021-00837-3; Faltas BM, 2016, NAT GENET, V48, P1490, DOI 10.1038/ng.3692; Feldman D, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00911-3; Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380; Frede J, 2021, NAT CELL BIOL, V23, P1199, DOI 10.1038/s41556-021-00766-y; Galluzzi L, 2018, NAT REV MOL CELL BIO, V19, P731, DOI 10.1038/s41580-018-0068-0; Goldman A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7139; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Gunnarsson EB, 2020, J THEOR BIOL, V490, DOI 10.1016/j.jtbi.2020.110162; Guo CE, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1699-y; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gutierrez C, 2021, NAT CANCER, V2, P758, DOI 10.1038/s43018-021-00222-8; Gutierrez C, 2019, BLOOD ADV, V3, P3759, DOI 10.1182/bloodadvances.2019000367; Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040; Herencias C, 2021, ELIFE, V10, DOI 10.7554/eLife.65130; HILL BT, 1986, DRUG EXP CLIN RES, V12, P293; Howlader N., 2020, NATL CANC I; Jensen PB, 1997, BRIT J CANCER, V75, P869, DOI 10.1038/bjc.1997.154; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Klempner SJ, 2013, CANCER DISCOV, V3, P1345, DOI 10.1158/2159-8290.CD-13-0063; Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501; Landau DA, 2015, NATURE, V526, P525, DOI 10.1038/nature15395; Lee JW, 2020, NAT COMMUN, V11, DOI [10.1038/s41467-020-14512-9, 10.1038/s41467-020-15726-7]; Lin KH, 2020, NAT GENET, V52, P408, DOI 10.1038/s41588-020-0590-9; Ling SP, 2015, P NATL ACAD SCI USA, V112, pE6496, DOI 10.1073/pnas.1519556112; Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015; Loveless TB, 2021, NAT CHEM BIOL, V17, P739, DOI 10.1038/s41589-021-00769-8; Ludwig LS, 2019, CELL, V176, P1325, DOI 10.1016/j.cell.2019.01.022; Marine JC, 2020, NAT REV CANCER, V20, P743, DOI 10.1038/s41568-020-00302-4; Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007; McGrail DJ, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abe6201; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Menon DR, 2015, ONCOGENE, V34, P4448, DOI 10.1038/onc.2014.372; Miller TE, 2022, NAT BIOTECHNOL, DOI 10.1038/s41587-022-01210-8; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Moss TJ, 2017, EUR UROL, V72, P641, DOI 10.1016/j.eururo.2017.05.048; Mroz EA, 2013, ORAL ONCOL, V49, P211, DOI 10.1016/j.oraloncology.2012.09.007; Nam AS, 2021, NAT REV GENET, V22, P3, DOI 10.1038/s41576-020-0265-5; Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024; O'Hare T, 2012, NAT REV CANCER, V12, P513, DOI 10.1038/nrc3317; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oren Y, 2021, NATURE, V596, P576, DOI 10.1038/s41586-021-03796-6; Ouzon-Shubeita H, 2020, BIOCHEM J, V477, P937, DOI 10.1042/BCJ20190906; Pearson A, 2016, CANCER DISCOV, V6, P838, DOI 10.1158/2159-8290.CD-15-1246; Pei WK, 2017, NATURE, V548, P456, DOI 10.1038/nature23653; Pirozzi G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021548; Pisco AO, 2015, BRIT J CANCER, V112, P1725, DOI 10.1038/bjc.2015.146; Pisco AO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3467; Quinn JJ, 2021, SCIENCE, V371, P909, DOI 10.1126/science.abc1944; Raghavan S, 2021, CELL, V184, P6119, DOI 10.1016/j.cell.2021.11.017; Raj B, 2018, NAT BIOTECHNOL, V36, P442, DOI 10.1038/nbt.4103; Reich S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16747-y; Robasky K, 2014, NAT REV GENET, V15, P56, DOI 10.1038/nrg3655; Russo M, 2019, SCIENCE, V366, P1473, DOI 10.1126/science.aav4474; Schwarz RF, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001789; Scott J, 2017, BBA-REV CANCER, V1867, P139, DOI 10.1016/j.bbcan.2017.01.006; Shaw AT, 2016, NEW ENGL J MED, V374, P54, DOI 10.1056/NEJMoa1508887; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Singleton KR, 2017, CELL REP, V21, P2796, DOI 10.1016/j.celrep.2017.11.022; Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214; Sun CY, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5148; SUZUKI H, 1994, BIOL PHARM BULL, V17, P222; Szikriszt B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0963-7; Tang L, 2020, NAT METHODS, V17, P359, DOI 10.1038/s41592-020-0802-3; Tong MY, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0287-y; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; Valent P, 2007, BIOL-TARGETS THER, V1, P433; Vander Velde R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16212-w; VanHorn S, 2021, DEV CELL, V56, P7, DOI 10.1016/j.devcel.2020.10.021; Voss MH, 2014, CLIN CANCER RES, V20, P1955, DOI 10.1158/1078-0432.CCR-13-2345; Wang LQ, 2018, CELL, V173, P1413, DOI 10.1016/j.cell.2018.04.012; Weinreb C, 2020, SCIENCE, V367, DOI 10.1126/science.aaw3381; Xu J, 2019, ELIFE, V8, DOI 10.7554/eLife.45105; Yang D., 2021, LINEAGE RECORDING RE, DOI [10.1101/2021.10.12.464111, DOI 10.1101/2021.10.12.464111]; Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhang JJ, 2014, SCIENCE, V346, P256, DOI 10.1126/science.1256930; Zhao BY, 2016, CELL, V165, P234, DOI 10.1016/j.cell.2016.01.045; Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00572-w	102	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								859032	10.3389/fimmu.2022.859032	http://dx.doi.org/10.3389/fimmu.2022.859032			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6XN	35603167	gold, Green Published			2022-12-18	WOS:000800112800001
J	He, CF; Malone, MJ; Wendel, BS; Ma, KY; Del Alcazar, D; Weiner, DB; De Jager, PL; Del Rio-Estrada, PM; Ablanedo-Terrazas, Y; Reyes-Teran, G; Su, LF; Jiang, N				He, Chenfeng; Malone, Michael J.; Wendel, Ben S.; Ma, Ke-Yue; Del Alcazar, Daniel; Weiner, David B.; De Jager, Philip L.; Del Rio-Estrada, Perla M.; Ablanedo-Terrazas, Yuria; Reyes-Teran, Gustavo; Su, Laura F.; Jiang, Ning			Transcriptome and TCR Repertoire Measurements of CXCR3(+) T Follicular Helper Cells Within HIV-Infected Human Lymph Nodes	FRONTIERS IN IMMUNOLOGY			English	Article						CXCR3; follicular-helper T cells (T-FH); TCR repertoire; RNA-seq; HIV	TFH CELLS; SERUM IMMUNOGLOBULIN; CXCR5(+); BLOOD; REPLICATION; INDUCTION; RESPONSES; IMMUNITY; TONSILS; MALARIA	Follicular-helper T cells (T-FH) are an essential arm of the adaptive immune system. Although T-FH were first discovered through their ability to contribute to antibody affinity maturation through co-stimulatory interactions with B cells, new light has been shed on their ability to remain a complex and functionally plastic cell type. Due to a lack sample availability, however, many studies have been limited to characterizing T-FH in mice or non-canonical tissue types, such as peripheral blood. Such constraints have resulted in a limited, and sometimes contradictory, understanding of this fundamental cell type. One subset of T-FH receiving attention in chronic infection are CXCR3-expressing T-FH cells (CXCR3(+)T(FH)) due to their abnormal accumulation in secondary lymphoid tissues. Their function and clonal relationship with other T-FH subsets in lymphoid tissues during infection, however, remains largely unclear. We thus systematically investigated this and other subsets of T-FH within untreated HIV-infected human lymph nodes using Mass CyTOF and a combination of RNA and TCR repertoire sequencing. We show an inflation of the CXCR3(+)T(FH) compartment during HIV infection that correlates with a lower HIV burden. Deeper analysis into this population revealed a functional shift of CXCR3(+)T(FH) away from germinal center T-FH (GC-T-FH), including the altered expression of several important transcription factors and cytokines. CXCR3(+)T(FH) also upregulated cell migration transcriptional programs and were clonally related to peripheral T-FH populations. In combination, these data suggest that CXCR3(+)T(FH) have a greater tendency to enter circulation than their CXCR3(-) counterparts, potentially functioning through distinct modalities that may lead to enhanced defense.	[He, Chenfeng; Wendel, Ben S.; Jiang, Ning] Univ Texas Austin, Cockrell Sch Engn, Dept Biomed Engn, Austin 78712, TX USA; [Malone, Michael J.; Jiang, Ning] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Malone, Michael J.; Ma, Ke-Yue; Jiang, Ning] Univ Texas Austin, Interdisciplinary Life Sci Grad Program, Austin, TX 78712 USA; [Wendel, Ben S.] Univ Texas Austin, Cockrell Sch Engn, McKetta Dept Chem Engn, Austin, TX USA; [Del Alcazar, Daniel; Su, Laura F.] Univ Penn, Inst Immunol, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Del Alcazar, Daniel; Su, Laura F.] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA 19104 USA; [Weiner, David B.] Wistar Inst Anat & Biol, Vaccine & Immunotherapy Ctr, Philadelphia, PA USA; [De Jager, Philip L.] Columbia Univ Med Ctr, Ctr Translat & Computat Neuroimmunol, New York, NY USA; [Del Rio-Estrada, Perla M.; Ablanedo-Terrazas, Yuria] Inst Nacl Enfermedades Respiratorias, Dept Invest Enfermedades Infecciosas, Mexico City, Mexico; [Reyes-Teran, Gustavo] Hosp Alta Especial, Comis Coordinadora Inst Nacl Salud, Secretaria Salud, Mexico City, Mexico; [Jiang, Ning] Univ Penn Perelman, Sch Med, Inst Immunol, Philadelphia, PA 19104 USA	University of Texas System; University of Texas Austin; University of Pennsylvania; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Pennsylvania; Pennsylvania Medicine; The Wistar Institute; Columbia University; University of Pennsylvania	Jiang, N (corresponding author), Univ Texas Austin, Cockrell Sch Engn, Dept Biomed Engn, Austin 78712, TX USA.; Jiang, N (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.; Jiang, N (corresponding author), Univ Texas Austin, Interdisciplinary Life Sci Grad Program, Austin, TX 78712 USA.; Su, LF (corresponding author), Univ Penn, Inst Immunol, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA.; Su, LF (corresponding author), Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.; Jiang, N (corresponding author), Univ Penn Perelman, Sch Med, Inst Immunol, Philadelphia, PA 19104 USA.	laurasu@upenn.edu; jnjiang@upenn.edu	Ma, Kevin/ABB-9237-2020		NIH [S10OD020072, R56AG064801, R01AI134879]; NIH IPCAVD [U19 Al109646-04]; Chan Zuckerberg Initiative Neurodegeneration Challenge Network Ben Barres Early Career Acceleration Awards [191856]; VA Merit Award [IMMA-020-15F]; NIH/NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) [75N93019C00051]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH IPCAVD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chan Zuckerberg Initiative Neurodegeneration Challenge Network Ben Barres Early Career Acceleration Awards; VA Merit Award(US Department of Veterans Affairs); NIH/NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs)	This work was supported by NIH grants S10OD020072 (NJ), R56AG064801 (NJ), R01AI134879 (LFS), NIH IPCAVD grant U19 Al109646-04(DBW), Chan Zuckerberg Initiative Neurodegeneration Challenge Network Ben Barres Early Career Acceleration Awards 191856 (NJ), VA Merit Award IMMA-020-15F (LFS), NIH/NIAID Collaborative Influenza Vaccine Innovation Centers (CIVICs) contract 75N93019C00051(DBW). DBW is the W.W. Smith Charitable Trust Professor at the Wistar Institute.	Aid M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00895; AUCOUTURIER P, 1986, CLIN EXP IMMUNOL, V63, P234; Baiyegunhi O, 2018, J VIROL, V92, DOI 10.1128/JVI.00659-18; Bentebibel SE, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005191; Bhattacharyya A., 1943, BULL CALCUTTA MATH S, V35, P99; Boritz EA, 2016, CELL, V166, P1004, DOI 10.1016/j.cell.2016.06.039; BOWEN MB, 1991, HUM IMMUNOL, V31, P67, DOI 10.1016/0198-8859(91)90050-J; Bowyer G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01660; Brenna E, 2020, CELL REP, V30, P137, DOI 10.1016/j.celrep.2019.12.016; Chang ST, 2011, MBIO, V2, DOI 10.1128/mBio.00134-11; Crotty S, 2019, IMMUNITY, V50, P1132, DOI 10.1016/j.immuni.2019.04.011; Crotty S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a032102; Crotty S, 2014, IMMUNITY, V41, P529, DOI 10.1016/j.immuni.2014.10.004; Del Alcazar D, 2019, CELL REP, V28, P3047, DOI 10.1016/j.celrep.2019.08.037; Dhillon AK, 2007, J VIROL, V81, P6548, DOI 10.1128/JVI.02749-06; Giroux M, 2011, BLOOD, V117, P1734, DOI 10.1182/blood-2010-05-287649; Goel RR, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abi6950; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Havenar-Daughton C, 2017, IMMUNOL REV, V275, P49, DOI 10.1111/imr.12512; He J, 2013, IMMUNITY, V39, P770, DOI 10.1016/j.immuni.2013.09.007; Hong JJ, 2012, J IMMUNOL, V188, P3247, DOI 10.4049/jimmunol.1103138; Hufert FT, 1997, AIDS, V11, P849, DOI 10.1097/00002030-199707000-00003; Jiang N, 2014, NAT BIOTECHNOL, V32, P639, DOI 10.1038/nbt.2953; Kim CH, 2001, J EXP MED, V193, P1373, DOI 10.1084/jem.193.12.1373; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim JR, 2005, BMC IMMUNOL, V6, DOI 10.1186/1471-2172-6-3; Kolde R, 2012, PACKAGE PHEATMAP; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liang HB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11754-0; Lindqvist M, 2012, J CLIN INVEST, V122, P3271, DOI 10.1172/JCI64314; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Ma KY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00033; Manzotti CN, 2002, EUR J IMMUNOL, V32, P2888, DOI 10.1002/1521-4141(2002010)32:10<2888::AID-IMMU2888>3.0.CO;2-F; Martin-Gayo E, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89574; Matsumine A, 1996, J BIOL CHEM, V271, P10341, DOI 10.1074/jbc.271.17.10341; McDavid A, 2013, BIOINFORMATICS, V29, P461, DOI 10.1093/bioinformatics/bts714; McGowan JP, 2006, MED SCI MONITOR, V12, pCR11; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Obeng-Adjei N, 2015, CELL REP, V13, P425, DOI 10.1016/j.celrep.2015.09.004; Oh DY, 2020, CELL, V181, P1612, DOI 10.1016/j.cell.2020.05.017; Painter MM, 2021, IMMUNITY, V54, P2133, DOI 10.1016/j.immuni.2021.08.001; Pallikkuth S, 2016, J VIROL, V90, P2718, DOI 10.1128/JVI.02883-15; Perreau M, 2013, J EXP MED, V210, P143, DOI 10.1084/jem.20121932; Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006; Quinn JL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00382; Ryg-Cornejo V, 2016, CELL REP, V14, P68, DOI 10.1016/j.celrep.2015.12.006; Schillie S, 2013, MMWR RECOMM REP, V62, P1; Sergushichev AA, ALGORITHM FAST PRERA, DOI 10.1101/060012v1; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; Shugay M, 2014, NAT METHODS, V11, P653, DOI [10.1038/nmeth.2960, 10.1038/NMETH.2960]; Song WZ, 2019, IMMUNOL REV, V288, P85, DOI 10.1111/imr.12740; Stone EL, 2015, IMMUNITY, V42, P239, DOI 10.1016/j.immuni.2015.01.017; Trub M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00489; Vanderleyden I, 2020, CELL REP, V30, P611, DOI 10.1016/j.celrep.2019.12.076; Velu V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01272; Velu V, 2016, J IMMUNOL, V197, P1832, DOI 10.4049/jimmunol.1600143; Wendel BS, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aan8884; Wilson EB, 2011, CURR TOP MICROBIOL, V350, P39, DOI 10.1007/82_2010_96; Wong MT, 2015, CELL REP, V11, P1822, DOI 10.1016/j.celrep.2015.05.022; Wu D, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks461; Yamamoto T, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3964; Zhang J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46533-w; Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	67	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								859070	10.3389/fimmu.2022.859070	http://dx.doi.org/10.3389/fimmu.2022.859070			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S3QU	35619703	Green Published, gold			2022-12-18	WOS:000803969700001
J	Hensen, L; Illing, PT; Rowntree, LC; Davies, J; Miller, A; Tong, SYC; Habel, JR; van de Sandt, CE; Flanagan, KL; Purcell, AW; Kedzierska, K; Clemens, EB				Hensen, Luca; Illing, Patricia T.; Rowntree, Louise C.; Davies, Jane; Miller, Adrian; Tong, Steven Y. C.; Habel, Jennifer R.; van de Sandt, Carolien E.; Flanagan, Katie L.; Purcell, Anthony W.; Kedzierska, Katherine; Clemens, E. Bridie			T Cell Epitope Discovery in the Context of Distinct and Unique Indigenous HLA Profiles	FRONTIERS IN IMMUNOLOGY			English	Review						CD8(+) T cell epitopes; Human Leucocyte Antigen (HLA); influenza; SARS-CoV-2; Indigenous populations; epitope discovery; antigen presentation; immunopeptidome	INFLUENZA-A-VIRUS; CLASS-I HLA; GENOME-WIDE ASSOCIATION; COVID-19 INCREASED RISK; PEPTIDOME DECONVOLUTION; ETHNIC DISPARITIES; PERIPHERAL-BLOOD; ANTIGENIC DRIFT; MHC REGION; B-CELLS	CD8(+) T cells are a pivotal part of the immune response to viruses, playing a key role in disease outcome and providing long-lasting immunity to conserved pathogen epitopes. Understanding CD8(+) T cell immunity in humans is complex due to CD8(+) T cell restriction by highly polymorphic Human Leukocyte Antigen (HLA) proteins, requiring T cell epitopes to be defined for different HLA allotypes across different ethnicities. Here we evaluate strategies that have been developed to facilitate epitope identification and study immunogenic T cell responses. We describe an immunopeptidomics approach to sequence HLA-bound peptides presented on virus-infected cells by liquid chromatography with tandem mass spectrometry (LC-MS/MS). Using antigen presenting cell lines that stably express the HLA alleles characteristic of Indigenous Australians, this approach has been successfully used to comprehensively identify influenza-specific CD8(+) T cell epitopes restricted by HLA allotypes predominant in Indigenous Australians, including HLA-A*24:02 and HLA-A*11:01. This is an essential step in ensuring high vaccine coverage and efficacy in Indigenous populations globally, known to be at high risk from influenza disease and other respiratory infections.	[Hensen, Luca; Rowntree, Louise C.; Habel, Jennifer R.; van de Sandt, Carolien E.; Kedzierska, Katherine; Clemens, E. Bridie] Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia; [Illing, Patricia T.; Purcell, Anthony W.] Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol & Infect & Immun Program, Clayton, Vic, Australia; [Davies, Jane; Tong, Steven Y. C.] Menzies Sch Hlth Res, Darwin, NT, Australia; [Miller, Adrian] CQ Univ, Indigenous Engagement, Townsville, Qld, Australia; [Tong, Steven Y. C.] Royal Melbourne Hosp, Victorian Infect Dis Serv, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [Tong, Steven Y. C.] Univ Melbourne, Dept Infect Dis, Peter Doherty Inst Infect & Immun, Melbourne, Vic, Australia; [van de Sandt, Carolien E.] Univ Amsterdam, Dept Hematopoiesis, Sanquin Res & Landsteiner Lab, AmsterdamUMC, Amsterdam, Netherlands; [Flanagan, Katie L.] Launceston Gen Hosp, Dept Infect Dis, Launceston, Tas, Australia; [Flanagan, Katie L.] Launceston Gen Hosp, Tasmanian Vaccine Trial Ctr, Launceston, Tas, Australia; [Flanagan, Katie L.] Univ Tasmania, Sch Hlth Sci, Sch Med, Launceston, Tas, Australia; [Flanagan, Katie L.] Monash Univ, Dept Immunol & Pathol, Melbourne, Vic, Australia	University of Melbourne; Monash University; Charles Darwin University; Menzies School of Health Research; Central Queensland University; Royal Melbourne Hospital; University of Melbourne; University of Amsterdam; University of Tasmania; Monash University	Kedzierska, K (corresponding author), Univ Melbourne, Peter Doherty Inst Infect & Immun, Dept Microbiol & Immunol, Parkville, Vic, Australia.	kkedz@unimelb.edu.au	Tong, Steven/N-2353-2013	Tong, Steven/0000-0002-1368-8356; Miller, Adrian/0000-0001-9735-6609	Melbourne International Research Scholarship (MIRS); University of Melbourne; Melbourne Research Scholarship from the University of Melbourne; European Union [792532]; Clifford Craig Foundation [145]; NHMRC Principal Research Fellowship [1137739]; NHMRC Project [1085018, 1071916, 1091516]; NHMRC Senior Research Fellowship [1102792]; NHMRC Program [1071916]; NHMRC Investigator Grant [1173871]; NHMRC Career Development Fellow [1145033]; NHMRC Peter Doherty Fellow [1122524]	Melbourne International Research Scholarship (MIRS); University of Melbourne(University of Melbourne); Melbourne Research Scholarship from the University of Melbourne; European Union(European Commission); Clifford Craig Foundation; NHMRC Principal Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Project(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Program(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Investigator Grant(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Career Development Fellow(National Health and Medical Research Council (NHMRC) of Australia); NHMRC Peter Doherty Fellow(National Health and Medical Research Council (NHMRC) of Australia)	LH received funding from a Melbourne International Research Scholarship (MIRS) and Melbourne International Fee Remission Scholarship (MIFRS) from The University of Melbourne. ST is a NHMRC Career Development Fellow (#1145033). JH is supported by a Melbourne Research Scholarship from the University of Melbourne. CS has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement (#792532). KF received funding from a Clifford Craig Foundation Grant (#145). AP is supported by an NHMRC Principal Research Fellowship (#1137739) and NHMRC Project Grant (#1085018). EC is a NHMRC Peter Doherty Fellow (#1091516). KK is supported by a NHMRC Senior Research Fellowship (#1102792), NHMRC Program Grant (#1071916), NHMRC Investigator Grant (#1173871) and NHMRC Project Grant (#1122524) to KK, ST, AM, and AP.	Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007; Ahmed R, 2007, NAT IMMUNOL, V8, P1188, DOI 10.1038/ni1530; Ahmed SF, 2020, NAT PROTOC, V15, P2141, DOI 10.1038/s41596-020-0358-9; Ahmed SF, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030254; Alexander J, 1997, J IMMUNOL, V159, P4753; Alexander J, 2010, HUM IMMUNOL, V71, P468, DOI 10.1016/j.humimm.2010.02.014; Alvarez B, 2019, MOL CELL PROTEOMICS, V18, P2459, DOI 10.1074/mcp.TIR119.001658; AMP Research Lab, 2021, COL COR COVID 19 DEA; Andreatta M, 2017, NUCLEIC ACIDS RES, V45, pW458, DOI 10.1093/nar/gkx248; Antunes RD, 2018, J CLIN INVEST, V128, P3853, DOI 10.1172/JCI121309; Assarsson E, 2008, J VIROL, V82, P12241, DOI 10.1128/JVI.01563-08; Bancroft T, 2016, CELL IMMUNOL, V304, P35, DOI 10.1016/j.cellimm.2016.05.002; Bao YM, 2008, J VIROL, V82, P596, DOI 10.1128/JVI.02005-07; Bassani-Sternberet M, 2016, J IMMUNOL, V197, P2492, DOI 10.4049/jimmunol.1600808; Bassani-Sternberg M, 2010, P NATL ACAD SCI USA, V107, P18769, DOI 10.1073/pnas.1008501107; Ben Shachar S, 2021, J CLIN IMMUNOL, V41, P1154, DOI 10.1007/s10875-021-01071-x; Berkhoff EGM, 2004, J VIROL, V78, P5216, DOI 10.1128/JVI.78.10.5216-5222.2004; Boggild AK, 2011, CAN J PUBLIC HEALTH, V102, P345, DOI 10.1007/BF03404174; Briscoe G., 1996, THESIS AUST NATL U; BURGERT HG, 1985, CELL, V41, P987, DOI 10.1016/S0092-8674(85)80079-9; Castelli EC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.742881; Castrodale L., 2009, Morbidity and Mortality Weekly Report, V58, P1341; Chang CXL, 2013, EUR J IMMUNOL, V43, P1109, DOI 10.1002/eji.201243088; Chapiro J, 2006, J IMMUNOL, V176, P1053, DOI 10.4049/jimmunol.176.2.1053; Chen D, 2015, HUM MOL GENET, V24, P2681, DOI 10.1093/hmg/ddv015; Clemens EB, 2016, IMMUNOL CELL BIOL, V94, P367, DOI 10.1038/icb.2015.93; Croft NP, 2019, P NATL ACAD SCI USA, V116, P3112, DOI 10.1073/pnas.1815239116; Croft NP, 2015, MOL IMMUNOL, V68, P77, DOI 10.1016/j.molimm.2015.06.010; Dejnirattisai W, 2021, CELL, V184, P2939, DOI 10.1016/j.cell.2021.03.055; Dolton G., 2021, MEDRXIV, p2021.2006.2021.21259010, DOI [10.1101/2021.06.21.21259010, DOI 10.1101/2021.06.21.21259010]; Dougan SK, 2013, NATURE, V503, P406, DOI 10.1038/nature12637; Douillard V, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.774922; Duggal P, 2013, ANN INTERN MED, V158, P235, DOI 10.7326/0003-4819-158-4-201302190-00003; Escobar H, 2008, J IMMUNOL, V181, P4874, DOI 10.4049/jimmunol.181.7.4874; Ewer KJ, 2021, NAT MED, V27, P270, DOI 10.1038/s41591-020-01194-5; Falfan-Valencia R, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/3174868; Fridman A, 2012, ONCOIMMUNOLOGY, V1, P1258, DOI 10.4161/onci.21355; Fritsche J, 2021, MOL CELL PROTEOMICS, V20, DOI 10.1016/j.mcpro.2021.100110; Gangaev A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22811-y; Gao XJ, 2000, MAJOR HISTOCOMPATIBILITY COMPLEX, P446; Garcia-Medel N, 2012, MOL CELL PROTEOMICS, V11, P1416, DOI 10.1074/mcp.M112.019588; Geldmacher C, 2009, BLOOD, V114, P1553, DOI 10.1182/blood-2009-02-206193; Gfeller D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01716; Gianfrani C, 2000, HUM IMMUNOL, V61, P438, DOI 10.1016/S0198-8859(00)00105-1; Goncalves G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645770; Gonzalez-Galarza FF, 2020, NUCLEIC ACIDS RES, V48, pD783, DOI 10.1093/nar/gkz1029; Grant E, 2013, IMMUNOL CELL BIOL, V91, P184, DOI 10.1038/icb.2012.78; Gras S, 2010, P NATL ACAD SCI USA, V107, P12599, DOI 10.1073/pnas.1007270107; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grifoni A, 2020, CELL HOST MICROBE, V27, P671, DOI 10.1016/j.chom.2020.03.002; Gutierrez-Achury J, 2015, NAT GENET, V47, P577, DOI 10.1038/ng.3268; Gutierrez-Bautista JF, 2022, J MICROBIOL IMMUNOL, V55, P421, DOI 10.1016/j.jmii.2021.08.009; Habel J, 2022, PLOS PATHOG, V18, DOI 10.1371/journal.ppat.1010337; Habel JR, 2020, P NATL ACAD SCI USA, V117, P24384, DOI 10.1073/pnas.2015486117; Hayward AC, 2015, AM J RESP CRIT CARE, V191, P1422, DOI 10.1164/rccm.201411-1988OC; Hensen L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23212-x; Herda PS, 2000, NEW ZEAL J HIST, V34, P133; Hertz T, 2013, P NATL ACAD SCI USA, V110, P13492, DOI 10.1073/pnas.1221555110; Hickman HD, 2004, J IMMUNOL, V172, P2944, DOI 10.4049/jimmunol.172.5.2944; Holst J, 2006, NAT METHODS, V3, P191, DOI 10.1038/nmeth858; Howson JMM, 2009, DIABETES OBES METAB, V11, P31, DOI 10.1111/j.1463-1326.2008.01001.x; Hu C, 2022, GENES DIS, V9, P216, DOI 10.1016/j.gendis.2021.05.006; Hu XL, 2015, NAT GENET, V47, P898, DOI 10.1038/ng.3353; Hui KPY, 2018, LANCET RESP MED, V6, P846, DOI 10.1016/S2213-2600(18)30236-4; Illing PT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07109-w; Iturrieta-Zuazo I, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108572; Iuliano AD, 2018, LANCET, V391, P1285, DOI 10.1016/S0140-6736(17)33293-2; Jafarpour R, 2021, PATHOL RES PRACT, V228, P1, DOI 10.1016/j.prp.2021.153647; Javitt A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00141; Jester B, 2019, VIROLOGY, V527, P32, DOI 10.1016/j.virol.2018.10.019; Johnson NPAS, 2002, B HIST MED, V76, P105, DOI 10.1353/bhm.2002.0022; Juno JA, 2020, NAT MED, V26, DOI 10.1038/s41591-020-0995-0; Karlsson AC, 2003, J IMMUNOL METHODS, V283, P141, DOI 10.1016/j.jim.2003.09.001; Kaushansky N, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00280; Kelly H, 2009, EUROSURVEILLANCE, V14, P6; Kelm M., 1999, BR COLUMBIAN Q SUM, V122; Khor CC, 2011, NAT GENET, V43, P1139, DOI 10.1038/ng.960; Kloverpris HN, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0149-5; Komov L, 2018, PROTEOMICS, V18, DOI 10.1002/pmic.201700248; Koutsakos M, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100208; Koutsakos M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01158; Koutsakos M, 2019, NAT IMMUNOL, V20, P613, DOI 10.1038/s41590-019-0320-6; Kundu Rhia, 2022, Nat Commun, V13, P80, DOI 10.1038/s41467-021-27674-x; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Lee ACY, 2017, J GEN VIROL, V98, P922, DOI 10.1099/jgv.0.000751; Lee Chloe H, 2020, F1000Res, V9, P145, DOI 10.12688/f1000research.22507.2; Lee K, 2009, GLOB INST, P1; Leffell MS, 2002, HUM IMMUNOL, V63, P614, DOI 10.1016/S0198-8859(02)00415-9; Lersritwimanmaen P, 2015, BIOCHEM BIOPH RES CO, V464, P888, DOI 10.1016/j.bbrc.2015.07.061; Liepe J, 2016, SCIENCE, V354, P354, DOI 10.1126/science.aaf4384; Lin Marie, 2003, BMC Med Genet, V4, P9, DOI 10.1186/1471-2350-4-9; Liu J, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00249-2; Liu J, 2012, J VIROL, V86, P13281, DOI 10.1128/JVI.01841-12; Liu WJ, 2016, J INFECT DIS, V214, P1937, DOI 10.1093/infdis/jiw471; Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8; Lubke M, 2020, J EXP MED, V217, DOI 10.1084/jem.20191164; MacDonald KS, 2000, J INFECT DIS, V181, P1581, DOI 10.1086/315472; Macdonald WA, 2003, J EXP MED, V198, P679, DOI 10.1084/jem.20030066; Machkovech HM, 2015, J VIROL, V89, P11275, DOI 10.1128/JVI.01571-15; Malaker SA, 2017, J PROTEOME RES, V16, P228, DOI 10.1021/acs.jproteome.6b00496; Mathur R, 2021, LANCET, V398, P390, DOI 10.1016/S0140-6736(21)01424-0; Mathur R, 2021, LANCET, V397, P1711, DOI 10.1016/S0140-6736(21)00634-6; Mathur R, 2020, LANCET, V396, P1866, DOI 10.1016/S0140-6736(20)32465-X; Matzaraki V, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1207-1; McMurtrey C, 2016, ELIFE, V5, DOI 10.7554/eLife.12556; Mei ST, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa415; Mifsud NA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.653710; Miki D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084226; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Mousseau M, 2013, INT INDIG POLICY J, V4, DOI 10.18584/iipj.2013.4.2.4; Nagler A, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109305; Nakiboneka R, 2019, VACCINE, V37, P113, DOI 10.1016/j.vaccine.2018.11.024; Nelde A, 2021, NAT IMMUNOL, V22, P74, DOI 10.1038/s41590-020-00808-x; Ng OW, 2016, VACCINE, V34, P2008, DOI 10.1016/j.vaccine.2016.02.063; Nguyen AT, 2021, BIOCHEM SOC T, V49, P2319, DOI 10.1042/BST20210410; Nguyen A, 2020, J VIROL, V94, DOI 10.1128/JVI.00510-20; Nguyen THO, 2021, IMMUNITY, V54, P1066, DOI 10.1016/j.immuni.2021.04.009; Nguyen THO, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23018-x; Nicastri A, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.201900401; Nicholas B, 2022, PLOS PATHOG, V18, DOI 10.1371/journal.ppat.1009894; Nuwarda RF, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9091032; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Ovsyannikova IG, 2020, IMMUNOL REV, V296, P205, DOI 10.1111/imr.12897; Pan D, 2021, LANCET, V398, P389, DOI 10.1016/S0140-6736(21)01428-8; Pan D, 2020, ECLINICALMEDICINE, V23, DOI 10.1016/j.eclinm.2020.100404; Pandey K, 2020, MOL IMMUNOL, V123, P7, DOI 10.1016/j.molimm.2020.04.008; Parker Robert, 2021, Mol Cell Proteomics, V20, P100124, DOI 10.1016/j.mcpro.2021.100124; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Perez-Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Poland GA, 2008, VACCINE, V26, pD35, DOI 10.1016/j.vaccine.2008.07.065; Prilliman K, 1997, IMMUNOGENETICS, V45, P379, DOI 10.1007/s002510050219; Purcell AW, 2019, NAT PROTOC, V14, P1687, DOI 10.1038/s41596-019-0133-y; Pymm P, 2017, NAT STRUCT MOL BIOL, V24, P387, DOI 10.1038/nsmb.3381; Quadeer AA, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100312; Quinones-Parra S, 2014, P NATL ACAD SCI USA, V111, P1049, DOI 10.1073/pnas.1322229111; Ramirez JD, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008686; Randall DA, 2018, MED J AUSTRALIA, V209, P19, DOI 10.5694/mja17.00878; Ranga V, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030408; Reiss S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186998; Requena D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02008; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Ritz D, 2016, PROTEOMICS, V16, P1570, DOI 10.1002/pmic.201500445; Robinson J, 2020, NUCLEIC ACIDS RES, V48, pD948, DOI 10.1093/nar/gkz950; Rowntree LC, 2021, IMMUNOL CELL BIOL, V99, P990, DOI 10.1111/imcb.12482; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Saini SK, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf7550; Santos VS, 2021, J PUBLIC HEALTH-UK, V43, pE250, DOI 10.1093/pubmed/fdaa176; Sarkizova S, 2020, NAT BIOTECHNOL, V38, P199, DOI 10.1038/s41587-019-0322-9; Schittenhelm RB, 2014, TISSUE ANTIGENS, V83, P174, DOI 10.1111/tan.12282; Schittenhelm RB, 2016, MOL CELL PROTEOMICS, V15, P1867, DOI 10.1074/mcp.M115.056358; Schulien I, 2021, NAT MED, V27, P78, DOI 10.1038/s41591-020-01143-2; Schuren ABC, 2016, CURR OPIN IMMUNOL, V40, P43, DOI 10.1016/j.coi.2016.02.007; Scull KE, 2012, MOL IMMUNOL, V51, P136, DOI 10.1016/j.molimm.2012.02.117; Sesma L, 2003, J BIOL CHEM, V278, P46461, DOI 10.1074/jbc.M308816200; Sidney J, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-1; Singh SK, 2012, CANCER IMMUNOL IMMUN, V61, P1953, DOI 10.1007/s00262-012-1251-3; Snyder Thomas M, 2020, medRxiv, DOI 10.1101/2020.07.31.20165647; Sohail MS, 2021, ADV DRUG DELIVER REV, V171, P29, DOI 10.1016/j.addr.2021.01.007; Sridhar S, 2013, NAT MED, V19, P1305, DOI 10.1038/nm.3350; Stephens HAF, 2002, TISSUE ANTIGENS, V60, P309, DOI 10.1034/j.1399-0039.2002.600405.x; STORKUS WJ, 1989, P NATL ACAD SCI USA, V86, P2361, DOI 10.1073/pnas.86.7.2361; Stranzl T, 2010, IMMUNOGENETICS, V62, P357, DOI 10.1007/s00251-010-0441-4; Suh S, 2022, BMC INFECT DIS, V22, DOI 10.1186/s12879-022-07034-w; Summers JA, 2018, NEW ZEAL MED J, V131, P54; Sveinbjornsson G, 2016, NAT GENET, V48, P318, DOI 10.1038/ng.3498; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100204; United Nations Department of Economic and Social Affairs: Division for Social Policy and Development, 2009, STAT WORLDS IND PEOP; Valkenburg SA, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3663; van de Sandt CE, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13346-4; van de Weijer ML, 2015, SEMIN IMMUNOL, V27, P125, DOI 10.1016/j.smim.2015.03.010; Verrall A, 2010, EMERG INFECT DIS, V16, P100, DOI 10.3201/eid1601.090994; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Voeten JTM, 2000, J VIROL, V74, P6800, DOI 10.1128/JVI.74.15.6800-6807.2000; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wahl A, 2009, P NATL ACAD SCI USA, V106, P540, DOI 10.1073/pnas.0811271106; Wang Mingjun, 2014, Methods Mol Biol, V1184, P309, DOI 10.1007/978-1-4939-1115-8_17; Wang ZF, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7833; Wilkinson TM, 2012, NAT MED, V18, P274, DOI 10.1038/nm.2612; Woods K, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0111-7; Woolthuis RG, 2016, SCI REP-UK, V6, DOI 10.1038/srep33334; World Health Organization (WHO), 2021, AV INFL WEEKL UPD NU; Wu T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10661-8; Yaciuk JC, 2014, J VIROL, V88, P12992, DOI 10.1128/JVI.01914-14; Yewdell JW, 2021, IMMUNITY, V54, P2681, DOI 10.1016/j.immuni.2021.11.016; Yu K, 2002, MOL MED, V8, P137, DOI 10.1007/BF03402006; Yuen TJ, 2010, J VIROL, V84, P10220, DOI 10.1128/JVI.01281-10; Zarling AL, 2000, J EXP MED, V192, P1755, DOI 10.1084/jem.192.12.1755; Zaunders JJ, 2009, J IMMUNOL, V183, P2827, DOI 10.4049/jimmunol.0803548; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zhao WL, 2018, PLOS COMPUT BIOL, V14, DOI 10.1371/journal.pcbi.1006457; Zheng JZ, 2021, AGING-US, V13, P14372, DOI 10.18632/aging.203053	193	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								812393	10.3389/fimmu.2022.812393	http://dx.doi.org/10.3389/fimmu.2022.812393			23	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K6GR	35603215	Green Published, gold			2022-12-18	WOS:000798697300001
J	Hidaka, R; Miyazaki, K; Miyazaki, M				Hidaka, Reiko; Miyazaki, Kazuko; Miyazaki, Masaki			The E-Id Axis Instructs Adaptive Versus Innate Lineage Cell Fate Choice and Instructs Regulatory T Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Review						T cell versus ILCs; Rag gene expression; E-Id axis; T-lineage commitment; Treg differentiation	LOOP-HELIX PROTEINS; RECOMBINATION ACTIVATING GENE; TRANSCRIPTION FACTOR GATA3; DELTA-LIKE 4; DNA-BINDING; LYMPHOCYTE DEVELOPMENT; THYMOCYTE DEVELOPMENT; ILC2 DIFFERENTIATION; SUPER-ENHANCERS; FACTOR E2-2	Immune responses are primarily mediated by adaptive and innate immune cells. Adaptive immune cells, such as T and B cells, evoke antigen-specific responses through the recognition of specific antigens. This antigen-specific recognition relies on the V(D)J recombination of immunoglobulin (Ig) and T cell receptor (TCR) genes mediated by recombination-activating gene (Rag)1 and Rag2 (Rag1/2). In addition, T and B cells employ cell type-specific developmental pathways during their activation processes, and the regulation of these processes is strictly regulated by the transcription factor network. Among these factors, members of the basic helix-loop-helix (bHLH) transcription factor mammalian E protein family, including E12, E47, E2-2, and HEB, orchestrate multiple adaptive immune cell development, while their antagonists, Id proteins (Id1-4), function as negative regulators. It is well established that a majority of T and B cell developmental trajectories are regulated by the transcriptional balance between E and Id proteins (the E-Id axis). E2A is critically required not only for B cell but also for T cell lineage commitment, whereas Id2 and Id3 enforce the maintenance of naive T cells and naive regulatory T (Treg) cells. Here, we review the current knowledge of E- and Id-protein function in T cell lineage commitment and Treg cell differentiation.	[Hidaka, Reiko; Miyazaki, Kazuko; Miyazaki, Masaki] Kyoto Univ, Inst Life & Med Sci, Lab Immunol, Kyoto, Japan	Kyoto University	Miyazaki, M (corresponding author), Kyoto Univ, Inst Life & Med Sci, Lab Immunol, Kyoto, Japan.	mmiyazaki@infront.kyoto-u.ac.jp						Ali N, 2017, CELL, V169, P1119, DOI 10.1016/j.cell.2017.05.002; Amin RH, 2008, NAT IMMUNOL, V9, P613, DOI 10.1038/ni.1612; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Bain G, 2001, NAT IMMUNOL, V2, P165, DOI 10.1038/84273; Belle I, 2014, CURR TOP DEV BIOL, V110, P153, DOI [10.1016/B978-0-12-405943-6.00003-4-X, 10.1016/B978-0-12-405943-6.00004-X]; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; Bradney C, 2003, J BIOL CHEM, V278, P2370, DOI 10.1074/jbc.M211464200; Braunstein M, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/678705; Braunstein M, 2011, MOL CELL BIOL, V31, P971, DOI 10.1128/MCB.01034-10; Califano D, 2015, IMMUNITY, V43, P354, DOI 10.1016/j.immuni.2015.07.005; Capone M, 1998, P NATL ACAD SCI USA, V95, P12522, DOI 10.1073/pnas.95.21.12522; Chea S, 2016, CELL REP, V14, P1500, DOI 10.1016/j.celrep.2016.01.015; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cherrier DE, 2018, IMMUNITY, V48, P1091, DOI 10.1016/j.immuni.2018.05.010; Chung Y, 2011, NAT MED, V17, P983, DOI 10.1038/nm.2426; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Cisse B, 2008, CELL, V135, P37, DOI 10.1016/j.cell.2008.09.016; Constantinides MG, 2014, NATURE, V508, P397, DOI 10.1038/nature13047; Constantinides MG, 2013, CURR OPIN IMMUNOL, V25, P161, DOI 10.1016/j.coi.2013.01.003; Cretney E, 2013, TRENDS IMMUNOL, V34, P74, DOI 10.1016/j.it.2012.11.002; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; D'Cruz LM, 2012, EUR J IMMUNOL, V42, P2031, DOI 10.1002/eji.201242497; D'Cruz LM, 2010, NAT IMMUNOL, V11, P240, DOI 10.1038/ni.1845; Delacher M, 2020, IMMUNITY, V52, P295, DOI 10.1016/j.immuni.2019.12.002; Dengler HS, 2008, NAT IMMUNOL, V9, P1388, DOI 10.1038/ni.1667; Dias S, 2008, IMMUNITY, V29, P217, DOI 10.1016/j.immuni.2008.05.015; Ebihara T, 2015, NAT IMMUNOL, V16, P1124, DOI 10.1038/ni.3272; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Engel I, 2001, NAT REV IMMUNOL, V1, P193, DOI 10.1038/35105060; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Fahl SP, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108716; Ferreira ACF, 2021, NAT IMMUNOL, V22, P166, DOI 10.1038/s41590-020-00833-w; Frias AB, 2019, J IMMUNOL, V203, P658, DOI 10.4049/jimmunol.1900358; Gao P, 2014, J EXP MED, V211, P2651, DOI 10.1084/jem.20132681; Ghosh HS, 2010, IMMUNITY, V33, P905, DOI 10.1016/j.immuni.2010.11.023; Grajkowska LT, 2017, IMMUNITY, V46, P65, DOI 10.1016/j.immuni.2016.11.006; Han XJ, 2019, P NATL ACAD SCI USA, V116, P4471, DOI 10.1073/pnas.1800494116; Hao B, 2015, J EXP MED, V212, P809, DOI 10.1084/jem.20142207; Harly C, 2018, J EXP MED, V215, P249, DOI 10.1084/jem.20170832; He R, 2016, NATURE, V537, P412, DOI 10.1038/nature19317; Hnisz D, 2017, CELL, V169, P13, DOI 10.1016/j.cell.2017.02.007; Hnisz D, 2013, CELL, V155, P934, DOI 10.1016/j.cell.2013.09.053; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hosokawa H, 2021, BIOESSAYS, V43, DOI 10.1002/bies.202000345; Hosokawa H, 2021, NAT REV IMMUNOL, V21, P162, DOI 10.1038/s41577-020-00426-6; Hosokawa H, 2020, J EXP MED, V217, DOI 10.1084/jem.20190972; Hosokawa H, 2018, NAT IMMUNOL, V19, P1427, DOI 10.1038/s41590-018-0238-4; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hozumi K, 2008, J EXP MED, V205, P2507, DOI 10.1084/jem.20080134; Hsu LY, 2003, IMMUNITY, V19, P105, DOI 10.1016/S1074-7613(03)00181-X; Hwang SM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07254-2; Ikawa T, 2006, J EXP MED, V203, P1329, DOI 10.1084/jem.20060268; Ito M, 2019, NATURE, V565, P246, DOI 10.1038/s41586-018-0824-5; Jones ME, 2007, IMMUNITY, V27, P860, DOI 10.1016/j.immuni.2007.10.014; Jones R, 2018, EUR J IMMUNOL, V48, P1481, DOI 10.1002/eji.201847511; Kee BL, 2009, NAT REV IMMUNOL, V9, P175, DOI 10.1038/nri2507; Kernfeld EM, 2018, IMMUNITY, V48, P1258, DOI 10.1016/j.immuni.2018.04.015; Klein L, 2014, NAT REV IMMUNOL, V14, P377, DOI 10.1038/nri3667; Klose CSN, 2016, NAT IMMUNOL, V17, P765, DOI 10.1038/ni.3489; Klose CSN, 2014, CELL, V157, P340, DOI 10.1016/j.cell.2014.03.030; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Koga S, 2018, J EXP MED, V215, P1609, DOI 10.1084/jem.20172310; Koltsova EK, 2007, J IMMUNOL, V179, P4694, DOI 10.4049/jimmunol.179.7.4694; Krangel MS, 2009, CURR OPIN IMMUNOL, V21, P133, DOI 10.1016/j.coi.2009.03.009; Kreslavsky T, 2010, CURR OPIN IMMUNOL, V22, P185, DOI 10.1016/j.coi.2009.12.006; Kuo TC, 2009, CURR OPIN IMMUNOL, V21, P173, DOI 10.1016/j.coi.2009.03.008; Lauritsen JPH, 2009, IMMUNITY, V31, P565, DOI 10.1016/j.immuni.2009.07.010; Liang JJ, 2021, J BIOL RES-THESSALON, V28, DOI 10.1186/s40709-021-00146-5; Lin YC, 2012, NAT IMMUNOL, V13, P1196, DOI 10.1038/ni.2432; Lin YC, 2010, NAT IMMUNOL, V11, P635, DOI 10.1038/ni.1891; Linterman MA, 2011, NAT MED, V17, P975, DOI 10.1038/nm.2425; Lio CW, 2016, ELIFE, V5, DOI 10.7554/eLife.18290; Lio CWJ, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau7523; Liu C, 2014, J IMMUNOL, V193, P663, DOI 10.4049/jimmunol.1302554; Liu XD, 2014, NATURE, V507, P513, DOI 10.1038/nature12910; Maruyama T, 2011, NAT IMMUNOL, V12, P86, DOI 10.1038/ni.1965; Massari ME, 1999, MOL CELL, V4, P63, DOI 10.1016/S1097-2765(00)80188-4; Milner JJ, 2020, IMMUNITY, V52, P808, DOI 10.1016/j.immuni.2020.04.007; Miyazaki K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.659761; Miyazaki K, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1455; Miyazaki K, 2014, TRENDS IMMUNOL, V35, P205, DOI 10.1016/j.it.2014.02.009; Miyazaki M, 2017, IMMUNITY, V46, P818, DOI 10.1016/j.immuni.2017.04.022; Miyazaki M, 2015, GENE DEV, V29, P409, DOI 10.1101/gad.255331.114; Miyazaki M, 2014, NAT IMMUNOL, V15, P767, DOI 10.1038/ni.2928; Miyazaki M, 2011, NAT IMMUNOL, V12, P992, DOI 10.1038/ni.2086; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mowel WK, 2017, IMMUNITY, V47, P435, DOI 10.1016/j.immuni.2017.08.012; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; Murre C, 2019, GENE DEV, V33, P6, DOI 10.1101/gad.320663.118; Naik AK, 2019, J EXP MED, V216, P231, DOI 10.1084/jem.20181402; Napier RJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00344; Ohkura N, 2020, CELL RES, V30, P465, DOI 10.1038/s41422-020-0324-7; Omilusik KD, 2018, J EXP MED, V215, P773, DOI 10.1084/jem.20171584; Pan LH, 2002, J IMMUNOL, V168, P3923, DOI 10.4049/jimmunol.168.8.3923; Qian LY, 2019, J EXP MED, V216, P884, DOI 10.1084/jem.20182100; Qiu Y, 1998, MOL CELL BIOL, V18, P2957, DOI 10.1128/MCB.18.5.2957; Rauch KS, 2016, CELL REP, V17, P2827, DOI 10.1016/j.celrep.2016.11.045; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Rothenberg EV, 2019, GENE DEV, V33, P1117, DOI 10.1101/gad.327163.119; Rowley MJ, 2018, NAT REV GENET, V19, P789, DOI 10.1038/s41576-018-0060-8; Roy S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00042; Schatz DG, 2011, NAT REV IMMUNOL, V11, P251, DOI 10.1038/nri2941; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; Schulz D, 2012, J EXP MED, V209, P187, DOI 10.1084/jem.20110645; Seehus CR, 2015, NAT IMMUNOL, V16, P599, DOI 10.1038/ni.3168; Seillet C, 2014, J EXP MED, V211, P1733, DOI 10.1084/jem.20140145; Serafini N, 2015, NAT REV IMMUNOL, V15, P415, DOI 10.1038/nri3855; Shaw LA, 2016, NAT IMMUNOL, V17, P834, DOI 10.1038/ni.3461; Shin SB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.681110; Shin SB, 2020, BLOOD ADV, V4, P5362, DOI 10.1182/bloodadvances.2020002758; Smigiel KS, 2014, J EXP MED, V211, P121, DOI 10.1084/jem.20131142; Sullivan JM, 2019, J IMMUNOL, V202, P31, DOI 10.4049/jimmunol.1800917; Taniuchi I, 2018, ANNU REV IMMUNOL, V36, P579, DOI 10.1146/annurev-immunol-042617-053411; Teachenor R, 2012, MOL CELL BIOL, V32, P1671, DOI 10.1128/MCB.06452-11; Timblin GA, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00437-16; Verykokakis M, 2014, IMMUNOL REV, V261, P177, DOI 10.1111/imr.12203; Verykokakis M, 2010, IMMUNITY, V33, P203, DOI 10.1016/j.immuni.2010.07.013; Wang HC, 2017, J IMMUNOL, V198, P3149, DOI 10.4049/jimmunol.1602009; Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035; WILSON A, 1994, J EXP MED, V179, P1355, DOI 10.1084/jem.179.4.1355; Wing JB, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01910; Wing JB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00178; Wojciechowski J, 2007, J IMMUNOL, V178, P5717, DOI 10.4049/jimmunol.178.9.5717; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Xu W, 2015, CELL REP, V10, P2043, DOI 10.1016/j.celrep.2015.02.057; Xu W, 2013, BLOOD, V121, P1534, DOI 10.1182/blood-2012-08-449447; Yagi RJ, 2014, IMMUNITY, V40, P378, DOI 10.1016/j.immuni.2014.01.012; Yang CY, 2011, NAT IMMUNOL, V12, P1221, DOI 10.1038/ni.2158; Yang Q, 2015, NAT IMMUNOL, V16, P1044, DOI 10.1038/ni.3248; Yannoutsos N, 2004, NAT IMMUNOL, V5, P443, DOI 10.1038/ni1053; Yoshikawa G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115888; Zhu YN, 2021, GENE DEV, V35, P65, DOI 10.1101/gad.343475.120	133	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								890056	10.3389/fimmu.2022.890056	http://dx.doi.org/10.3389/fimmu.2022.890056			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K1KK	35603170	gold, Green Published			2022-12-18	WOS:000798367900001
J	Hu, CQ; Dai, Z; Xu, J; Zhao, LY; Xu, YP; Li, ML; Yu, JH; Zhang, L; Deng, H; Liu, LJ; Zhang, MY; Huang, JR; Wu, LP; Chen, GX				Hu, Congqi; Dai, Zhao; Xu, Jia; Zhao, Lianyu; Xu, Yanping; Li, Meilin; Yu, Jiahui; Zhang, Lu; Deng, Hui; Liu, Lijuan; Zhang, Mingying; Huang, Jiarong; Wu, Linping; Chen, Guangxing			Proteome Profiling Identifies Serum Biomarkers in Rheumatoid Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						rheumatoid arthritis; biomarker; proteomics; ORM1; serum	BINDING SITE; FIBRONECTIN; HAPTOGLOBIN; LANDSCAPE	Rheumatoid arthritis (RA) causes serious disability and productivity loss, and there is an urgent need for appropriate biomarkers for diagnosis, treatment assessment, and prognosis evaluation. To identify serum markers of RA, we performed mass spectrometry (MS)-based proteomics, and we obtained 24 important markers in normal and RA patient samples using a random forest machine learning model and 11 protein-protein interaction (PPI) network topological analysis methods. Markers were reanalyzed using additional proteomics datasets, immune infiltration status, tissue specificity, subcellular localization, correlation analysis with disease activity-based diagnostic indications, and diagnostic receiver-operating characteristic analysis. We discovered that ORM1 in serum is significantly differentially expressed in normal and RA patient samples, which is positively correlated with disease activity, and is closely related to CD56dim natural killer cell, effector memory CD8(+)T cell, and natural killer cell in the pathological mechanism, which can be better utilized for future research on RA. This study supplies a comprehensive strategy for discovering potential serum biomarkers of RA and provides a different perspective for comprehending the pathological mechanism of RA, identifying potential therapeutic targets, and disease management.	[Hu, Congqi; Liu, Lijuan; Zhang, Mingying; Chen, Guangxing] Guangzhou Univ Chinese Med, Dept Rheumatol, Affiliated Hosp 1, Guangzhou, Peoples R China; [Dai, Zhao; Xu, Jia; Zhao, Lianyu; Li, Meilin; Yu, Jiahui; Zhang, Lu; Deng, Hui] Guangzhou Univ Chinese Med, Clin Med Sch 1, Guangzhou, Peoples R China; [Xu, Yanping; Chen, Guangxing] Guangzhou Univ Chinese Med, Baiyun Hosp, Affiliated Hosp 1, Guangzhou, Peoples R China; [Huang, Jiarong; Wu, Linping] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Ctr Chem Biol & Drug Discovery, Guangzhou, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Chen, GX (corresponding author), Guangzhou Univ Chinese Med, Dept Rheumatol, Affiliated Hosp 1, Guangzhou, Peoples R China.; Chen, GX (corresponding author), Guangzhou Univ Chinese Med, Baiyun Hosp, Affiliated Hosp 1, Guangzhou, Peoples R China.; Wu, LP (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Ctr Chem Biol & Drug Discovery, Guangzhou, Peoples R China.	wu_linping@gibh.ac.cn; cgx02@gzucm.edu.cn		WU, Linping/0000-0001-7579-2987	Guangzhou Science Technology and Innovation Commission Technology Research Projects [201904010336]; Innovative and Strong Hospital Project of The First Affiliated Hospital of Guangzhou University of Chinese Medicine [211010010705]	Guangzhou Science Technology and Innovation Commission Technology Research Projects; Innovative and Strong Hospital Project of The First Affiliated Hospital of Guangzhou University of Chinese Medicine	Funding This study was funded by the Guangzhou Science Technology and Innovation Commission Technology Research Projects (No. 201904010336) and the Innovative and Strong Hospital Project of The First Affiliated Hospital of Guangzhou University of Chinese Medicine (No. 211010010705).	AKIYAMA SK, 1995, CANCER METAST REV, V14, P173, DOI 10.1007/BF00690290; Aslan C, 2019, J CELL PHYSIOL, V234, P16885, DOI 10.1002/jcp.28374; Cheng YJ, 2014, INFLAMMATION, V37, P1459, DOI 10.1007/s10753-014-9871-8; de Kleijn DPV, 2002, FASEB J, V16, P1123, DOI 10.1096/fj.02-0019fje; Dobryszycka W, 1997, EUR J CLIN CHEM CLIN, V35, P647; Generali E, 2021, CLIN EXP RHEUMATOL, V39, P38, DOI 10.55563/clinexprheumatol/skp9ff; Getz GS, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00536; Glick EN, 1980, J R SOC MED, V73, P80, DOI [10.1177/014107688007300129, DOI 10.1177/014107688007300129]; Jang WY, 2017, BRAIN RES, V1654, P55, DOI 10.1016/j.brainres.2016.09.003; Kawelke N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028181; Kopylov AT, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76689-9; Kroot EJJA, 2000, ARTHRITIS RHEUM, V43, P1831, DOI 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6; Lourido L, 2017, EXPERT REV PROTEOMIC, V14, P431, DOI 10.1080/14789450.2017.1321481; Luo Ming-Zhi, 2010, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V26, P1210; Luo ZM, 2015, J PHYSIOL BIOCHEM, V71, P329, DOI 10.1007/s13105-015-0389-9; Midwood KS, 2006, J INVEST DERM SYMP P, V11, P73, DOI 10.1038/sj.jidsymp.5650005; Mun S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184368; Ohkuro M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04420-4; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; Park YJ, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.120; Petersen HH, 2004, VET RES, V35, P163, DOI 10.1051/vetres:2004002; Pincus T, 2014, CLIN EXP RHEUMATOL, V32, pS1; ROSTAGNO A, 1994, J BIOL CHEM, V269, P31938; Ruhlmann C, 2016, AGING-US, V8, P2777, DOI 10.18632/aging.101086; RUOSLAHTI E, 1984, CANCER METAST REV, V3, P43, DOI 10.1007/BF00047692; Shi MJ, 2021, CARDIOVASC TOXICOL, V21, P387, DOI 10.1007/s12012-020-09631-0; Smeets MB, 2003, INT J EXP PATHOL, V84, P69, DOI 10.1046/j.1365-2613.2003.00336.x; THOMPSON S, 1989, CLIN CHIM ACTA, V184, P251, DOI 10.1016/0009-8981(89)90058-2; Tobon GJ, 2010, J AUTOIMMUN, V35, P10, DOI 10.1016/j.jaut.2009.12.009; van Nies JAB, 2014, ANN RHEUM DIS, V73, P861, DOI 10.1136/annrheumdis-2012-203130; Wan JJ, 2019, J CELL PHYSIOL, V234, P20533, DOI 10.1002/jcp.28653; Wang WY, 2019, BIOMED PHARMACOTHER, V109, P1772, DOI 10.1016/j.biopha.2018.11.055; Wells G, 2008, ANN RHEUM DIS, V67, P260, DOI 10.1136/ard.2007.069690; Yamada T, 2001, ANN RHEUM DIS, V60, P124, DOI 10.1136/ard.60.2.124; Zhang XF, 2018, NAT PROTOC, V13, P530, DOI 10.1038/nprot.2017.147; Zhang XF, 2017, MOL CELL, V65, P941, DOI 10.1016/j.molcel.2017.01.004; Zollinger AJ, 2017, MATRIX BIOL, V60-61, P27, DOI 10.1016/j.matbio.2016.07.011	37	0	0	13	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								865425	10.3389/fimmu.2022.865425	http://dx.doi.org/10.3389/fimmu.2022.865425			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J8RP	35603148	Green Published, gold			2022-12-18	WOS:000798180900001
J	Humbel, M; Bellanger, F; Horisberger, A; Suffiotti, M; Fluder, N; Makhmutova, M; Mathias, A; Du Pasquier, R; Fenwick, C; Ribi, C; Comte, D				Humbel, Morgane; Bellanger, Florence; Horisberger, Alice; Suffiotti, Madeleine; Fluder, Natalia; Makhmutova, Mariko; Mathias, Amandine; Du Pasquier, Renaud; Fenwick, Craig; Ribi, Camillo; Comte, Denis			SLAMF Receptor Expression Identifies an Immune Signature That Characterizes Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						SLE; systemic lupus erythematosus; SLAMF; autoimmunity; immune signature; biomarker	ALTERED EXPRESSION; ACTIVATION; MOLECULE; CELLS; ENGAGEMENT; CLASSIFICATION; CRITERIA; CD319; CD244	Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology, linked to alterations in both the innate and the adaptive immune system. Due to the heterogeneity of the clinical presentation, the diagnosis of SLE remains complicated and is often made years after the first symptoms manifest, delaying treatment, and worsening the prognosis. Several studies have shown that signaling lymphocytic activation molecule family (SLAMF) receptors are aberrantly expressed and dysfunctional in SLE immune cells, contributing to the altered cellular function observed in these patients. The aim of this study was to determine whether altered co-/expression of SLAMF receptors on peripheral blood mononuclear cells (PBMC) identifies SLE characteristic cell populations. To this end, single cell mass cytometry and bioinformatic analysis were exploited to compare SLE patients to healthy and autoimmune diseases controls. First, the expression of each SLAMF receptor on all PBMC populations was investigated. We observed that SLAMF1+ B cells (referred to as SLEB1) were increased in SLE compared to controls. Furthermore, the frequency of SLAMF4+ monocytes and SLAMF4+ NK were inversely correlated with disease activity, whereas the frequency SLAMF1+ CD4+ TDEM cells were directly correlated with disease activity. Consensus clustering analysis identified two cell clusters that presented significantly increased frequency in SLE compared to controls: switch memory B cells expressing SLAMF1, SLAMF3, SLAMF5, SLAMF6 (referred to as SLESMB) and circulating T follicular helper cells expressing the same SLAMF receptors (referred to as SLEcTFH). Finally, the robustness of the identified cell populations as biomarkers for SLE was evaluated through ROC curve analysis. The combined measurement of SLEcTFH and SLEB1 or SLESMB cells identified SLE patients in 90% of cases. In conclusion, this study identified an immune signature for SLE based on the expression of SLAMF receptors on PBMC, further highlighting the involvement of SLAMF receptors in the pathogenesis of SLE.	[Humbel, Morgane; Bellanger, Florence; Horisberger, Alice; Suffiotti, Madeleine; Fluder, Natalia; Fenwick, Craig; Ribi, Camillo; Comte, Denis] Lausanne Univ Hosp, Dept Med, Serv Immunol & Allergy, Lausanne, Switzerland; [Humbel, Morgane; Bellanger, Florence; Horisberger, Alice; Suffiotti, Madeleine; Fluder, Natalia; Mathias, Amandine; Du Pasquier, Renaud; Fenwick, Craig; Ribi, Camillo; Comte, Denis] Univ Lausanne, Lausanne, Switzerland; [Makhmutova, Mariko] Swiss Fed Inst Technol Lausanne, Machine Learning & Optimizat Lab, Lausanne, Switzerland; [Mathias, Amandine; Du Pasquier, Renaud] Univ Hosp Lausanne, Dept Clin Neurosci, Serv Neurol, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Comte, D (corresponding author), Lausanne Univ Hosp, Dept Med, Serv Immunol & Allergy, Lausanne, Switzerland.; Comte, D (corresponding author), Univ Lausanne, Lausanne, Switzerland.	denis.comte@chuv.ch	Comte, Denis/ABF-4743-2020	Comte, Denis/0000-0002-6605-1498				Arriens C, 2017, RHEUMATOLOGY, V56, P32, DOI 10.1093/rheumatology/kew407; Capecchi R, 2020, RHEUMATOLOGY, V59, P12, DOI 10.1093/rheumatology/keaa484; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Chatterjee M, 2011, AUTOIMMUNITY, V44, P211, DOI 10.3109/08916934.2010.530627; Comte D, 2017, ARTHRITIS RHEUMATOL, V69, P1035, DOI 10.1002/art.40038; Comte D, 2016, P NATL ACAD SCI USA, V113, P9321, DOI 10.1073/pnas.1605081113; de Salort J, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00225; Dragovich MA, 2018, AUTOIMMUN REV, V17, P674, DOI 10.1016/j.autrev.2018.01.018; Gadalla R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00415; Hagberg N, 2013, J IMMUNOL, V191, P2989, DOI 10.4049/jimmunol.1301022; Humbel M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.645478; Karampetsou MP, 2019, ARTHRITIS RHEUMATOL, V71, P99, DOI 10.1002/art.40682; Karampetsou MP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186073; Kim JR, 2010, CLIN EXP IMMUNOL, V160, P348, DOI 10.1111/j.1365-2249.2010.04116.x; Kis-Toth K, 2016, ARTHRITIS RHEUMATOL, V68, P164, DOI 10.1002/art.39410; Kis-Toth K, 2014, J IMMUNOL, V192, P4436, DOI 10.4049/jimmunol.1302909; Linan-Rico L, 2015, LUPUS, V24, P1184, DOI 10.1177/0961203315584412; Mak A, 2018, CLIN RHEUMATOL, V37, P811, DOI 10.1007/s10067-017-3698-2; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Meyer Aurore, 2020, Lupus Sci Med, V7, DOI 10.1136/lupus-2020-000399; Morris DL, 2016, NAT GENET, V48, P940, DOI 10.1038/ng.3603; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; Ribi C, 2014, SWISS MED WKLY, V144, DOI 10.4414/smw.2014.13990; RIVERO SJ, 1978, ARTHRITIS RHEUM, V21, P295, DOI 10.1002/art.1780210302; Spitzer MH, 2016, CELL, V165, P780, DOI 10.1016/j.cell.2016.04.019; Stratigou V, 2017, RHEUMATOLOGY, V56, P1206, DOI 10.1093/rheumatology/kex078; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tsokos GC, 2011, NEW ENGL J MED, V365, P2110, DOI 10.1056/NEJMra1100359; Wang NH, 2016, CLIN IMMUNOL, V173, P19, DOI 10.1016/j.clim.2016.06.009; Wang NH, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00158	32	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								843059	10.3389/fimmu.2022.843059	http://dx.doi.org/10.3389/fimmu.2022.843059			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K2VW	35603218	Green Published, gold			2022-12-18	WOS:000798466000001
J	Iwamoto, N; Araki, T; Umetsu, A; Takatani, A; Aramaki, T; Ichinose, K; Terada, K; Hirakata, N; Ueki, Y; Kawakami, A; Eguchi, K				Iwamoto, Naoki; Araki, Takeshi; Umetsu, Ayaka; Takatani, Ayuko; Aramaki, Toshiyuki; Ichinose, Kunihiro; Terada, Kaoru; Hirakata, Naoyuki; Ueki, Yukitaka; Kawakami, Atsushi; Eguchi, Katsumi			The Association of Increase of Human T-Cell Leukemia Virus Type-1 (HTLV-1) Proviral Load (PVL) With Infection in HTLV-1-Positive Patients With Rheumatoid Arthritis: A Longitudinal Analysis of Changes in HTLV-1 PVLs in a Single Center Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						rheumatoid arthritis; human T-cell leukemia virus type 1; proviral load; infection; molecular-targeted therapy	LEUKEMIA/LYMPHOMA; LYMPHOCYTES; MANAGEMENT; CARRIERS	ObjectiveWe evaluated changes of HTLV-1 proviral loads (PVLs) during treatment for rheumatoid arthritis (RA) and investigated whether these changes affect the clinical course in HTLV-1-positive RA patients. MethodsA total of 41 HTLV-1-positive RA patients were analyzed. Their clinical picture including disease activity [Disease Activity Score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR), DAS28-CRP, simplified disease activity index (SDAI), and clinical disease activity index (CDAI)] and comorbidity were evaluated over a 2-year period. PVLs from peripheral blood mononuclear cells were investigated by real-time polymerase chain reaction (PCR). We investigated whether HTLV-1 PVLs is altered, or which clinical characteristics affect changes of HTLV1-PVLs during 2-year treatment. ResultsClinical disease activity was not changed during the 2-year observational period. The mean HTLV-1 PVL value change from baseline to 2 years was -1.2 copies/1000 PBMCs, which was not statistically significant. No baseline clinical characteristics influenced changes in HTLV-1 PVL. However, a numerical change of HTLV-1 PVLs was increased in 4 patients initiating the new biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) at 2-10 months after starting the new b/ts DMARDs (numerical increase was 24.87 copies/1000 PBMCs). Infection occurred in 4 patients, and 3 of those patients showed an increased HTLV-1 PVL. Univariate analysis revealed an association between increase of HTLV-1 PVL and incidence of infection. ConclusionsOver 2 years, HTLV-1 PVL did not significantly change in our HTLV-1-positive RA patients. Individual changes in HTLV-1 PVL were correlated with incidence of infection but not disease activity which indicate that we may take precaution toward infection at the uptick of HTLV-1 PVL in HTLV-1-positive RA patients.	[Iwamoto, Naoki; Ichinose, Kunihiro; Kawakami, Atsushi] Nagasaki Univ, Dept Immunol & Rheumatol, Div Adv Prevent Med Sci, Grad Sch Biomed Sci, Nagasaki, Japan; [Iwamoto, Naoki; Araki, Takeshi; Umetsu, Ayaka; Takatani, Ayuko; Aramaki, Toshiyuki; Ichinose, Kunihiro; Terada, Kaoru; Hirakata, Naoyuki; Ueki, Yukitaka; Eguchi, Katsumi] Sasebo Chuo Hosp, Dept Rheumatol, Sasebo, Japan	Nagasaki University	Iwamoto, N (corresponding author), Nagasaki Univ, Dept Immunol & Rheumatol, Div Adv Prevent Med Sci, Grad Sch Biomed Sci, Nagasaki, Japan.; Iwamoto, N; Eguchi, K (corresponding author), Sasebo Chuo Hosp, Dept Rheumatol, Sasebo, Japan.	naoki-iwa@nagasaki-u.ac.jp; keguchi0630@yahoo.co.jp						Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Araya N, 2014, J CLIN INVEST, V124, P3431, DOI 10.1172/JCI75250; Ashida C, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-05195-0; Bangham CRM, 2018, ANNU REV IMMUNOL, V36, P43, DOI 10.1146/annurev-immunol-042617-053222; Eguchi K, 2020, MOD RHEUMATOL, V30, P471, DOI 10.1080/14397595.2019.1602931; Endo Y, 2021, MOD RHEUMATOL, V31, P972, DOI 10.1080/14397595.2020.1847802; Espindola OD, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10102514; Fukui S, 2017, BMC IMMUNOL, V18, DOI 10.1186/s12865-017-0191-2; Hashiba Y, 2022, MOD RHEUMATOL, V32, P866, DOI 10.1093/mr/roab077; Iwanaga M, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01124; Iwanaga M, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00322; Kawano N, 2019, J CLIN EXP HEMATOP, V59, P156, DOI 10.3960/jslrt.18032; Kawano N, 2018, J CLIN EXP HEMATOP, V58, P107, DOI 10.3960/jslrt.18011; Kogure Y, 2017, CANCER SCI, V108, P1719, DOI 10.1111/cas.13303; Matsumoto C, 2017, J MED VIROL, V89, P1469, DOI 10.1002/jmv.24802; MITSUYA H, 1984, SCIENCE, V225, P1484, DOI 10.1126/science.6206569; Montes M, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000456; Nakamura H, 2013, INTERNAL MED, V52, P1983, DOI 10.2169/internalmedicine.52.0468; Okamoto M, 2019, MOD RHEUMATOL CASE, V3, P87, DOI 10.1080/24725625.2018.1549932; Proietti FA, 2005, ONCOGENE, V24, P6058, DOI 10.1038/sj.onc.1208968; SAKAI M, 1993, J CLIN INVEST, V92, P1957, DOI 10.1172/JCI116789; Satake M, 2015, LEUKEMIA LYMPHOMA, V56, P1806, DOI 10.3109/10428194.2014.964700; Schierhout G, 2020, LANCET INFECT DIS, V20, P133, DOI 10.1016/S1473-3099(19)30402-5; Shiraishi Tomoko, 2017, Journal of UOEH, V39, P55, DOI 10.7888/juoeh.39.55; Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715; Suzuki T, 2018, ARTHRITIS RHEUMATOL, V70, P1014, DOI 10.1002/art.40461; Takajo I, 2018, INTERNAL MED, V57, P2071, DOI 10.2169/internalmedicine.0308-17; Tanaka T, 2015, CASE REP HEMATOL, V2015, DOI 10.1155/2015/943867; Umekita K, 2019, MOD RHEUMATOL, V29, P795, DOI 10.1080/14397595.2018.1519890; Verdonck K, 2007, LANCET INFECT DIS, V7, P266, DOI 10.1016/S1473-3099(07)70081-6; Yamauchi J, 2019, NEW ENGL J MED, V380, P296, DOI 10.1056/NEJMc1809779; Yanagihara T, 2018, ANN HEMATOL, V97, P359, DOI 10.1007/s00277-017-3146-z; Yasunaga J, 2001, BLOOD, V97, P3177, DOI 10.1182/blood.V97.10.3177	33	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								887783	10.3389/fimmu.2022.887783	http://dx.doi.org/10.3389/fimmu.2022.887783			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6WI	35603142	gold, Green Published			2022-12-18	WOS:000800109700001
J	Li, BH; Duan, H; Wang, S; Wu, JJ; Li, YZ				Li, Bohan; Duan, Hua; Wang, Sha; Wu, Jiajing; Li, Yazhu			Gradient Boosting Machine Learning Model for Defective Endometrial Receptivity Prediction by Macrophage-Endometrium Interaction Modules	FRONTIERS IN IMMUNOLOGY			English	Article						immune infiltration; defective endometrial receptivity; infertility; Xgboost; machine learning	NETWORK ANALYSIS; CELLS	BackgroundA receptive endometrium is a prerequisite for successful embryo implantation. Mounting evidence shows that nearly one-third of infertility and implantation failures are caused by defective endometrial receptivity. This study pooled 218 subjects from multiple datasets to investigate the association of the immune infiltration level with reproductive outcome. Additionally, macrophage-endometrium interaction modules were constructed to explore an accurate and cost-effective approach to endometrial receptivity assessment. MethodsImmune-infiltration levels in 4 GEO datasets (n=218) were analyzed and validated through meta-analysis. Macrophage-endometrium interaction modules were selected based on the weighted gene co-expression network in GSE58144 and differentially expressed genes dominated by GSE19834 dataset. Xgboost, random forests, and regression algorithms were applied to predictive models. Subsequently, the efficacy of the models was compared and validated in the GSE165004 dataset. Forty clinical samples (RT-PCR and western blot) were performed for expression and model validation, and the results were compared to those of endometrial thickness in clinical pregnancy assessment. ResultsAltered levels of M phi s infiltration were shown to critically influence embryo implantation. The three selected modules, manifested as macrophage-endometrium interactions, were enrichment in the immunoreactivity, decidualization, and signaling functions and pathways. Moreover, hub genes within the modules exerted significant reproductive prognostic effects. The xgboost algorithm showed the best performance among the machine learning models, with AUCs of 0.998 (95% CI 0.994-1) and 0.993 (95% CI 0.979-1) in GSE58144 and GSE165004 datasets, respectively. These results were significantly superior to those of the other two models (random forest and regression). Similarly, the model was significantly superior to ultrasonography (endometrial thickness) with a better cost-benefit ratio in the population. ConclusionSuccessful embryo implantation is associated with infiltration levels of M phi s, manifested in genetic modules involved in macrophage-endometrium interactions. Therefore, utilizing the hub genes in these modules can provide a platform for establishing excellent machine learning models to predict reproductive outcomes in patients with defective endometrial receptivity.	[Li, Bohan; Duan, Hua; Wang, Sha; Li, Yazhu] Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing Maternal & Child Hlth Care Hosp, Dept Minimally Invas Gynecol Ctr, Beijing, Peoples R China; [Wu, Jiajing] Capital Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Beijing, Peoples R China	Capital Medical University; Capital Medical University	Duan, H (corresponding author), Capital Med Univ, Beijing Obstet & Gynecol Hosp, Beijing Maternal & Child Hlth Care Hosp, Dept Minimally Invas Gynecol Ctr, Beijing, Peoples R China.	duanhua@ccmu.edu.cn	Li, Bohan/GRR-3628-2022	Li, Bohan/0000-0001-7686-8605	National Key Research and Development Program of China [Z211100002921015]; Beijing Municipal Science & Technology Commission [2018YFC1004803]	National Key Research and Development Program of China; Beijing Municipal Science & Technology Commission(Beijing Municipal Science & Technology Commission)	This study was financially supported by the National Key Research and Development Program of China (2018YFC1004803) and Beijing Municipal Science & Technology Commission (No.Z211100002921015).	Abrahams VM, 2011, J REPROD IMMUNOL, V88, P112, DOI 10.1016/j.jri.2010.12.003; Ariza ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069827; Bloch DB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094784; Cardenas I, 2010, J IMMUNOL, V185, P1248, DOI 10.4049/jimmunol.1000289; Carruba G, 2003, J CELL BIOCHEM, V90, P187, DOI 10.1002/jcb.10607; Craciunas L, 2019, HUM REPROD UPDATE, V25, P202, DOI 10.1093/humupd/dmy044; Diamond MP, 2015, NEW ENGL J MED, V373, P1230, DOI 10.1056/NEJMoa1414827; Diao LH, 2020, PLACENTA, V99, P180, DOI 10.1016/j.placenta.2020.07.025; Diaz-Gimeno P, 2011, FERTIL STERIL, V95, P50, DOI 10.1016/j.fertnstert.2010.04.063; Ghazalpour A, 2006, PLOS GENET, V2, P1182, DOI 10.1371/journal.pgen.0020130; Guo PF, 2010, BLOOD, V116, P2061, DOI 10.1182/blood-2009-11-252940; Hartaigh BO, 2018, JACC-CARDIOVASC IMAG, V11, P450, DOI 10.1016/j.jcmg.2017.03.018; Hunt JS, 2006, IMMUNOL REV, V213, P36, DOI 10.1111/j.1600-065X.2006.00436.x; Jena MK, 2019, ARCH IMMUNOL THER EX, V67, P295, DOI 10.1007/s00005-019-00552-7; Keenihan SNH, 2004, BIOL REPROD, V70, P1562, DOI 10.1095/biolreprod.103.024794; Lessey BA, 2011, FERTIL STERIL, V96, P522, DOI 10.1016/j.fertnstert.2011.07.1095; Li BH, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10020139; Li BH, 2021, REPROD BIOMED ONLINE, V42, P429, DOI 10.1016/j.rbmo.2020.10.005; Li TC, 2002, HUM REPROD UPDATE, V8, P43, DOI 10.1093/humupd/8.1.43; Lucas ES, 2016, STEM CELLS, V34, P346, DOI 10.1002/stem.2222; Lv ZL, 2019, MUCOSAL IMMUNOL, V12, P1164, DOI 10.1038/s41385-019-0184-y; Madhukaran SP, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00053; NCBI Resource Coordinators, 2015, NUCLEIC ACIDS RES, V43, P17; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Ning F, 2016, AM J REPROD IMMUNOL, V75, P298, DOI 10.1111/aji.12477; Alvarado-Diaz CP, 2015, FERTIL STERIL, V103, P439, DOI 10.1016/j.fertnstert.2014.10.046; Perez-Deben S, 2019, J PROTEOMICS, V203, DOI 10.1016/j.jprot.2019.103381; Ruiz-Alonso M, 2013, FERTIL STERIL, V100, P818, DOI 10.1016/j.fertnstert.2013.05.004; Salamonsen LA, 2000, HUM REPROD UPDATE, V6, P16, DOI 10.1093/humupd/6.1.16; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Szekeres-Bartho J, 2009, J REPROD IMMUNOL, V83, P60, DOI 10.1016/j.jri.2009.06.262; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Yang ZY, 2011, INT IMMUNOPHARMACOL, V11, P1442, DOI 10.1016/j.intimp.2011.04.024; Young OM, 2015, AM J REPROD IMMUNOL, V73, P22, DOI 10.1111/aji.12336; Zhang YH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00120	35	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								842607	10.3389/fimmu.2022.842607	http://dx.doi.org/10.3389/fimmu.2022.842607			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K1EQ	35603216	gold, Green Published			2022-12-18	WOS:000798352900001
J	Li, LQ; Wang, Y; He, XH; Li, ZZ; Lu, MX; Gong, TJ; Chang, Q; Lin, JQ; Liu, C; Luo, Y; Min, L; Zhou, Y; Tu, CQ				Li, Longqing; Wang, Yang; He, Xuanhong; Li, Zhuangzhuang; Lu, Minxun; Gong, Taojun; Chang, Qing; Lin, Jingqi; Liu, Chuang; Luo, Yi; Min, Li; Zhou, Yong; Tu, Chongqi			Hematological Prognostic Scoring System Can Predict Overall Survival and Can Indicate Response to Immunotherapy in Patients With Osteosarcoma	FRONTIERS IN IMMUNOLOGY			English	Article						osteosarcoma; hematological; prognostic; inflammation; immunotherapy	CELL LUNG-CANCER; C-REACTIVE PROTEIN; LACTATE-DEHYDROGENASE; GROWTH-FACTOR; OPEN-LABEL; EXPRESSION; FIBRINOGEN; OUTCOMES; PD-L1; RATIO	Osteosarcoma is the most common primary malignant bone tumor with a high metastatic potential. Nowadays, there is a lack of new markers to identify prognosis of osteosarcoma patients with response to medical treatment. Recent studies have shown that hematological markers can reflect to some extent the microenvironment of an individual with the potential to predict patient prognosis. However, most of the previous studies have studied the prognostic value of a single hematological index, and it is difficult to comprehensively reflect the tumor microenvironment of patients. Here, we comprehensively collected 16 hematological markers and constructed a hematological prognostic scoring system (HPSS) using LASSO cox regression analysis. HPSS contains many indicators such as immunity, inflammation, coagulation and nutrition. Our results suggest that HPSS is an independent prognostic factor for overall survival in osteosarcoma patients and is an optimal addition to clinical characteristics and well suited to further identify high-risk patients from clinically low-risk patients. HPSS-based nomograms have good predictive ability. Finally, HPSS also has some hints for immunotherapy response in osteosarcoma patients.	[Li, Longqing; Wang, Yang; He, Xuanhong; Li, Zhuangzhuang; Lu, Minxun; Gong, Taojun; Chang, Qing; Lin, Jingqi; Luo, Yi; Min, Li; Zhou, Yong; Tu, Chongqi] Sichuan Univ, West China Hosp, Orthopaed Res Inst, Dept Orthoped, Chengdu, Peoples R China; [Li, Longqing; Wang, Yang; He, Xuanhong; Li, Zhuangzhuang; Lu, Minxun; Gong, Taojun; Luo, Yi; Min, Li; Zhou, Yong; Tu, Chongqi] Sichuan Univ, West China Hosp, Dept Orthoped, Printing & Biomech Lab, Chengdu, Peoples R China; [Liu, Chuang] Yinfeng Gene Technol Co Ltd, Inst Jinan Yinfeng Med Lab, Jinan, Peoples R China	Sichuan University; Sichuan University	Zhou, Y; Tu, CQ (corresponding author), Sichuan Univ, West China Hosp, Orthopaed Res Inst, Dept Orthoped, Chengdu, Peoples R China.; Zhou, Y; Tu, CQ (corresponding author), Sichuan Univ, West China Hosp, Dept Orthoped, Printing & Biomech Lab, Chengdu, Peoples R China.	zhouyonggk@163.com; tucq@scu.edu.cn			Science and Technology Research Program of Sichuan Province [2020YFS0036]; Chengdu Science and Technology Project [2017-CY02-00032-GX]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYJC18036]; Fundamental Research Funds for the Central Universities [20826041E4071]; Post-Docter Research Project, West China Hospital, Sichuan University [20HXBH136]; China Postdoctoral Science Foundation [2021M702342]	Science and Technology Research Program of Sichuan Province; Chengdu Science and Technology Project; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Post-Docter Research Project, West China Hospital, Sichuan University; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	The institution of one ormore of the authors (ML, LM, YZ, CT) has received, during the study period, funding from the Science and Technology Research Programof Sichuan Province (2020YFS0036), the Chengdu Science and Technology Project (2017-CY02-00032-GX), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (ZYJC18036), the Fundamental Research Funds for the Central Universities (20826041E4071), Post-Docter Research Project, West China Hospital, Sichuan University (20HXBH136), and Project funded by China Postdoctoral Science Foundation (2021M702342).	Adashek JJ, 2021, TRENDS CANCER, V7, P15, DOI 10.1016/j.trecan.2020.08.009; Aljubran AH, 2009, ANN ONCOL, V20, P1136, DOI 10.1093/annonc/mdn731; Bacci G, 2005, EUR J CANCER, V41, P2836, DOI 10.1016/j.ejca.2005.08.026; Boye K, 2021, CANCER IMMUNOL IMMUN, V70, P2617, DOI 10.1007/s00262-021-02876-w; Charrier M, 2019, EUR J CANCER, V108, P88, DOI 10.1016/j.ejca.2018.12.017; Chen PX, 2017, ONCOTARGETS THER, V10, P3107, DOI 10.2147/OTT.S138854; Cupp MA, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01817-1; D'Angelo SP, 2018, LANCET ONCOL, V19, P416, DOI 10.1016/S1470-2045(18)30006-8; Diem S, 2016, BRIT J CANCER, V114, P256, DOI 10.1038/bjc.2015.467; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Fornarini G, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100118; Forrest SJ, 2018, CURR OPIN PEDIATR, V30, P17, DOI 10.1097/MOP.0000000000000570; Galon J, 2020, IMMUNITY, V52, P55, DOI 10.1016/j.immuni.2019.12.018; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Gorlick R, 2013, PEDIATR BLOOD CANCER, V60, P1009, DOI 10.1002/pbc.24429; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao H, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12536; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu HZ, 2020, ONCOTARGETS THER, V13, P12673, DOI 10.2147/OTT.S287192; Huang X, 2018, J CANCER, V9, P2525, DOI 10.7150/jca.25011; Inomata M, 2016, MOL CLIN ONCOL, V4, P774, DOI 10.3892/mco.2016.779; Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895; Kager L, 2017, FUTURE ONCOL, V13, P357, DOI 10.2217/fon-2016-0261; Kempf-Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063; Lee AY, 2002, CANCER TREAT REV, V28, P137, DOI 10.1016/S0305-7372(02)00044-0; Li LQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00030; Li XY, 2021, CANCER MED-US, V10, P4228, DOI 10.1002/cam4.3878; Li YJ, 2017, ONCOTARGETS THER, V10, P5255, DOI 10.2147/OTT.S140560; Liang YJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-07841-5; Liu BJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep39862; Liu J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1746112; Liu T, 2015, FEBS OPEN BIO, V5, P682, DOI 10.1016/j.fob.2015.08.002; Mao MJ, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820915520; Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031; Mirabello L, 2009, CANCER-AM CANCER SOC, V115, P1531, DOI 10.1002/cncr.24121; Miura K, 2017, LUNG CANCER, V111, P88, DOI 10.1016/j.lungcan.2017.07.003; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Mori S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136897; Petrelli F, 2015, ACTA ONCOL, V54, P961, DOI 10.3109/0284186X.2015.1043026; Powell DR, 2016, TRENDS IMMUNOL, V37, P41, DOI 10.1016/j.it.2015.11.008; Qiao YF, 2021, ONCOTARGETS THER, V14, P1101, DOI 10.2147/OTT.S278831; Sahni A, 2008, J THROMB HAEMOST, V6, P176; Sanchez-Gastaldo A, 2021, TRANSL LUNG CANCER R, V10, P2509, DOI 10.21037/tlcr-21-156; Saraf AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00004; SMALE BF, 1981, CANCER, V47, P2375, DOI 10.1002/1097-0142(19810515)47:10<2375::AID-CNCR2820471009>3.0.CO;2-I; Strauss SJ, 2018, CURR OPIN ONCOL, V30, P252, DOI 10.1097/CCO.0000000000000456; Suazo-Zepeda E, 2021, CANCER IMMUNOL IMMUN, V70, P3069, DOI 10.1007/s00262-021-02996-3; Sundara YT, 2017, CANCER IMMUNOL IMMUN, V66, P119, DOI 10.1007/s00262-016-1925-3; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; Valery PC, 2015, CANCER CAUSE CONTROL, V26, P1127, DOI [10.1007/s10552-015-0607-3, 10]; Verheul HMW, 2010, UROLOGY, V75, P608, DOI 10.1016/j.urology.2009.05.075; Wang PF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00886; Wang SN, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.654452; Whelan JS, 2018, J CLIN ONCOL, V36, P188, DOI 10.1200/JCO.2017.75.1743; Xie L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000798; Xu ZS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163719; Zhang LH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020920; Zhang L, 2020, CANCER MANAG RES, V12, P5373, DOI 10.2147/CMAR.S246695	60	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								879560	10.3389/fimmu.2022.879560	http://dx.doi.org/10.3389/fimmu.2022.879560			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K6OV	35603156	Green Published, gold			2022-12-18	WOS:000798718500001
J	Li, Y; Ji, MH; Yang, JJ				Li, Ying; Ji, Muhuo; Yang, Jianjun			Current Understanding of Long-Term Cognitive Impairment After Sepsis	FRONTIERS IN IMMUNOLOGY			English	Review						sepsis; cognitive impairment; BBB dysregulation; neuroinflammation; neurotransmitter dysfunction; neuronal loss	NF-KAPPA-B; BLOOD-BRAIN-BARRIER; LOCUS-COERULEUS; ACUTE NEUROINFLAMMATION; NEURONAL LOSS; TNF-ALPHA; DYSFUNCTION; ACTIVATION; LIPOPOLYSACCHARIDE; RECEPTORS	Sepsis is recognized as a life-threatening multi-organ dysfunction resulting from a dysregulated host response to infection. Although the incidence and mortality of sepsis decrease significantly due to timely implementation of anti-infective and support therapies, accumulating evidence suggests that a great proportion of survivors suffer from long-term cognitive impairment after hospital discharge, leading to decreased life quality and substantial caregiving burdens for family members. Several mechanisms have been proposed for long-term cognitive impairment after sepsis, which are not mutually exclusive, including blood-brain barrier disruption, neuroinflammation, neurotransmitter dysfunction, and neuronal loss. Targeting these critical processes might be effective in preventing and treating long-term cognitive impairment. However, future in-depth studies are required to facilitate preventive and/or treatment strategies for long-term cognitive impairment after sepsis.	[Li, Ying] Southeast Univ, Jiangyin Hosp, Dept Anesthesiol, Med Sch, Jiangyin, Peoples R China; [Ji, Muhuo] Nanjing Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Nanjing, Peoples R China; [Yang, Jianjun] Zhengzhou Univ, Dept Anesthesiol Pain & Perioperat Med, Affiliated Hosp 1, Zhengzhou, Peoples R China	Southeast University - China; Nanjing Medical University; Zhengzhou University	Ji, MH (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Dept Anesthesiol, Nanjing, Peoples R China.; Yang, JJ (corresponding author), Zhengzhou Univ, Dept Anesthesiol Pain & Perioperat Med, Affiliated Hosp 1, Zhengzhou, Peoples R China.							Alverdy JC, 2020, INFECT IMMUN, V88, DOI 10.1128/IAI.00942-19; Andonegui G, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99364; Barichello T, 2019, MOL NEUROBIOL, V56, P186, DOI 10.1007/s12035-018-1048-2; Barichello T, 2012, METAB BRAIN DIS, V27, P587, DOI 10.1007/s11011-012-9315-9; Barter J, 2019, MOL NEUROBIOL, V56, P8557, DOI 10.1007/s12035-019-01681-y; Beyer MMS, 2020, J NEUROSCI, V40, P5480, DOI 10.1523/JNEUROSCI.0200-20.2020; Bluemel P, 2021, EXP NEUROL, V338, DOI 10.1016/j.expneurol.2020.113591; Bortolato B, 2015, CURR NEUROPHARMACOL, V13, P558, DOI 10.2174/1570159X13666150630171433; Bruck E, 2018, J INTENSIVE CARE, V6, DOI 10.1186/s40560-017-0272-6; Brummel NE, 2017, AM J RESP CRIT CARE, V196, P64, DOI 10.1164/rccm.201605-0939OC; Calsavara AJC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22754-3; Cardoso FL, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0299-3; Carita AC, 2020, NANOMED-NANOTECHNOL, V24, DOI 10.1016/j.nano.2019.102117; Cerullo G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.574029; Chavan SS, 2012, MOL MED, V18, P930, DOI 10.2119/molmed.2012.00195; Comim CM, 2013, MOL NEUROBIOL, V47, P394, DOI 10.1007/s12035-012-8354-x; Cooper KF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4701275; Danielski LG, 2018, MOL NEUROBIOL, V55, P5255, DOI 10.1007/s12035-017-0706-0; Deczkowska A, 2018, CELL, V173, P1073, DOI 10.1016/j.cell.2018.05.003; Della Giustina A, 2020, NUTRITION, V70, DOI 10.1016/j.nut.2018.12.003; Della Giustina A, 2017, NEUROCHEM INT, V108, P436, DOI 10.1016/j.neuint.2017.06.003; Erikson K, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03101-3; Angelo MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107901; Franke K, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00789; Fu Q, 2019, INFLAMMATION, V42, P306, DOI 10.1007/s10753-018-0894-4; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Goodenough DA, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002576; Gorina R, 2011, GLIA, V59, P242, DOI 10.1002/glia.21094; Gu M, 2021, NEUROTOX RES, V39, P489, DOI 10.1007/s12640-020-00270-5; Gunther ML, 2012, CRIT CARE MED, V40, P2022, DOI 10.1097/CCM.0b013e318250acc0; Guo JN, 2017, NEURAL REGEN RES, V12, P1832, DOI 10.4103/1673-5374.219044; Guo R, 2021, MEDIAT INFLAMM, V2021, DOI 10.1155/2021/9925059; Haam J, 2017, J NEUROCHEM, V142, P111, DOI 10.1111/jnc.14052; Hamilton NB, 2010, NAT REV NEUROSCI, V11, P227, DOI 10.1038/nrn2803; Haslund-Vinding J, 2017, BRIT J PHARMACOL, V174, P1733, DOI 10.1111/bph.13425; He W, 2020, BRAIN RES BULL, V165, P90, DOI 10.1016/j.brainresbull.2020.09.012; Hennessy E, 2017, BRAIN BEHAV IMMUN, V59, P233, DOI 10.1016/j.bbi.2016.09.011; Hernandes MS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-36; Herskovits AZ, 2014, NEURON, V81, P471, DOI 10.1016/j.neuron.2014.01.028; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Hoogland ICM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0332-6; Hu JJ, 2020, NAT IMMUNOL, V21, P736, DOI 10.1038/s41590-020-0669-6; Hu M, 2016, KOREAN J PHYSIOL PHA, V20, P325, DOI 10.4196/kjpp.2016.20.4.325; Hu YY, 2013, INT IMMUNOPHARMACOL, V16, P108, DOI 10.1016/j.intimp.2013.03.019; Huang L, 2019, BIOCHEM BIOPH RES CO, V517, P221, DOI 10.1016/j.bbrc.2019.07.045; Huerta Patricio T, 2016, Mol Med, V22, P789, DOI 10.2119/molmed.2015.00201; Hughes CG, 2018, INTENS CARE MED, V44, P345, DOI 10.1007/s00134-018-5120-1; Hung SY, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0355-7; Ince C, 2016, SHOCK, V45, P259, DOI 10.1097/SHK.0000000000000473; Iwashyna TJ, 2010, JAMA-J AM MED ASSOC, V304, P1787, DOI 10.1001/jama.2010.1553; Ji MH, 2020, BEHAV BRAIN RES, V383, DOI 10.1016/j.bbr.2020.112509; Ji MH, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0401-x; Ji MH, 2020, AGING-US, V12, P2471, DOI 10.18632/aging.102755; Jiang Y, 2020, EXP BRAIN RES, V238, P2897, DOI 10.1007/s00221-020-05950-4; Jiao FZ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6782872; Kim HJ, 2011, MOL PHARMACOL, V80, P357, DOI 10.1124/mol.111.071647; Lemstra AW, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-4; Li F, 2020, BRAIN RES, V1737, DOI 10.1016/j.brainres.2020.146780; Li Yi, 2021, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V37, P961; Lima CX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132336; Liu SF, 2006, AM J PHYSIOL-LUNG C, V290, pL622, DOI 10.1152/ajplung.00477.2005; Liu WY, 2017, CELL MOL NEUROBIOL, V37, P1195, DOI 10.1007/s10571-016-0449-x; Lochhead JJ, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00914; Lorne E, 2010, INTENS CARE MED, V36, P1826, DOI 10.1007/s00134-010-1983-5; Mahmoud S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020184; Manfredini A, 2019, CLIN SCI, V133, P1993, DOI 10.1042/CS20190351; Mather M, 2016, TRENDS COGN SCI, V20, P214, DOI 10.1016/j.tics.2016.01.001; Mi T, 2019, J CELL BIOCHEM, V120, P7101, DOI 10.1002/jcb.27983; Michels M, 2015, MOL MED, V21, P219, DOI 10.2119/molmed.2015.00070; Michels M, 2015, BRAIN BEHAV IMMUN, V43, P54, DOI 10.1016/j.bbi.2014.07.002; Mina F, 2014, MOL NEUROBIOL, V49, P1069, DOI 10.1007/s12035-013-8581-9; Mishra A, 2012, J NEUROIMMUNE PHARM, V7, P571, DOI 10.1007/s11481-012-9342-7; Mithaiwala MN, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061548; Moraes CA, 2015, MOL NEUROBIOL, V52, P653, DOI 10.1007/s12035-014-8868-5; Moraes CA, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14050416; Murray AJ, 2011, NAT NEUROSCI, V14, P297, DOI 10.1038/nn.2751; Ngo B, 2019, NAT REV CANCER, V19, P271, DOI 10.1038/s41568-019-0135-7; Nwafor DC, 2019, J CENT NERV SYST DIS, V11, DOI 10.1177/1179573519840652; Ognjanovski N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15039; Orhun G, 2020, NEUROCRIT CARE, V32, P459, DOI 10.1007/s12028-019-00759-8; Orhun G, 2019, NEUROCRIT CARE, V30, P106, DOI 10.1007/s12028-018-0581-1; Orihuela CJ, 2006, INFECT IMMUN, V74, P3783, DOI 10.1128/IAI.00022-06; Otto SL, 2019, BRAIN STRUCT FUNCT, V224, P829, DOI 10.1007/s00429-018-1799-6; Padayatty SJ, 2003, J AM COLL NUTR, V22, P18, DOI 10.1080/07315724.2003.10719272; Pan SW, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00267; Petronilho F, 2012, BRAIN BEHAV IMMUN, V26, P904, DOI 10.1016/j.bbi.2012.03.007; Prescott HC, 2018, JAMA-J AM MED ASSOC, V319, P62, DOI 10.1001/jama.2017.17687; Qian LR, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/3917393; Qin LH, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/120641; Radeva MY, 2018, ACTA PHYSIOL, V222, DOI 10.1111/apha.12860; Reis PA, 2017, BRAIN BEHAV IMMUN, V60, P293, DOI 10.1016/j.bbi.2016.11.006; Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963; Rengel KF, 2019, ANESTH ANALG, V128, P772, DOI 10.1213/ANE.0000000000004066; Saidu NEB, 2019, MED RES REV, V39, P1923, DOI 10.1002/med.21567; Sara SJ, 2009, NAT REV NEUROSCI, V10, P211, DOI 10.1038/nrn2573; Schaeffer S, 2021, NAT NEUROSCI, V24, P1198, DOI 10.1038/s41593-021-00904-7; Schwarz LA, 2015, CURR BIOL, V25, pR1051, DOI 10.1016/j.cub.2015.09.039; Seidel G, 2020, EUR J NEUROSCI, V52, P4395, DOI 10.1111/ejn.14850; Semmler A, 2007, EXP NEUROL, V204, P733, DOI 10.1016/j.expneurol.2007.01.003; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Shamim D, 2017, J CENT NERV SYST DIS, V9, DOI 10.1177/1179573517722512; Sheth P, 2007, AM J PHYSIOL-GASTR L, V293, pG308, DOI 10.1152/ajpgi.00582.2006; Shulyatnikova T, 2020, NEUROCHEM RES, V45, P83, DOI 10.1007/s11064-019-02743-2; Sorce S, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004531; Stamatovic SM, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1154641; Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0; Sweeney MD, 2019, PHYSIOL REV, V99, P21, DOI 10.1152/physrev.00050.2017; Switon K, 2017, NEUROSCIENCE, V341, P112, DOI 10.1016/j.neuroscience.2016.11.017; Tang CZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1522-4; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tchessalova D, 2019, NEUROBIOL LEARN MEM, V158, P60, DOI 10.1016/j.nlm.2019.01.003; Terrando N, 2014, MOL MED, V20, P667, DOI 10.2119/molmed.2014.00143; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; Tian JM, 2020, CELL MOL NEUROBIOL, V40, P521, DOI 10.1007/s10571-019-00750-z; Totland MZ, 2020, CELL MOL LIFE SCI, V77, P573, DOI 10.1007/s00018-019-03285-0; Tsujimoto H, 2008, SHOCK, V29, P315, DOI [10.1097/SHK.0b013e318157ee55, 10.1097/shk.0b013e318157ee55]; Verdonk F, 2019, BRAIN BEHAV IMMUN, V81, P361, DOI 10.1016/j.bbi.2019.06.033; Wang GB, 2014, MOL CELL BIOCHEM, V385, P125, DOI 10.1007/s11010-013-1821-5; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Wang Y, 2020, J INT MED RES, V48, DOI 10.1177/0300060520949767; Williams LM, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00104-20; Wu XX, 2019, INFLAMMATION, V42, P2215, DOI 10.1007/s10753-019-01085-z; Xu JT, 2021, MBIO, V12, DOI 10.1128/mBio.01076-21; Xuemei Ma FX., 2015, BRAIN DISORD THER, V04, P154, DOI [10.4172/2168-975X.1000154, DOI 10.4172/2168-975X.1000154, 10.4172/2168-975X, DOI 10.4172/2168-975X]; Yan ZB, 2016, ARTERIOSCL THROM VAS, V36, P339, DOI 10.1161/ATVBAHA.115.306549; Yang H, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0081-6; Yin X, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01071; Yu Y, 2020, INT IMMUNOPHARMACOL, V85, DOI 10.1016/j.intimp.2020.106585; Zaghloul N, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02031-9; Zarbato GF, 2018, NEUROTOX RES, V34, P418, DOI 10.1007/s12640-018-9900-8; Zeng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep20931; Zhang N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93861-x; [张雪艳 Zhang Xueyan], 2016, [中华危重病急救医学, Chinese Critical Care Medicine], V28, P127; Zhang Y, 2014, J NEUROSCI, V34, P11929, DOI [10.1523/JNEUROSCI.1860-14.2014, 10.11772/j.issn.1001-9081.2014.07.1929]; Zhao JY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42286-8; Zhou RX, 2020, CNS NEUROSCI THER, V26, P177, DOI 10.1111/cns.13229; Zhu YR, 2019, TOXICOL APPL PHARM, V363, P34, DOI 10.1016/j.taap.2018.10.013; Zujalovic B, 2020, BMC ANESTHESIOL, V20, DOI 10.1186/s12871-020-01204-6	139	0	0	6	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								855006	10.3389/fimmu.2022.855006	http://dx.doi.org/10.3389/fimmu.2022.855006			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M5XL	35603184	Green Published, gold			2022-12-18	WOS:000800041800001
J	Li, Y; Liu, YH; Qu, YC; Chen, X; Qu, X; Ye, YS; Du, XH; Cheng, Y; Xu, M; Zhang, HB				Li, Yong; Liu, Yihong; Qu, Yanchun; Chen, Xian; Qu, Xin; Ye, Yongsong; Du, Xiaohua; Cheng, Ying; Xu, Mian; Zhang, Haibo			Case Report: Two Cases of Soft-Tissue Sarcomas: High TMB as a Potential Predictive Biomarker for Anlotinib Combined With Toripalimab Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						soft-tissue sarcomas; tumor mutational burden (TMB); immune checkpoint inhibitors; anlotinib; toripalimab	PART SARCOMA; DOUBLE-BLIND; OPEN-LABEL; PAZOPANIB; EFFICACY; CANCER; SAFETY; BURDEN	Soft-tissue sarcomas (STS), with over 100 different histologic subtypes, are rare tumors that account for 1% of all adult malignancies. Immune checkpoint inhibitors (ICIs) display certain benefits in some subtypes, especially in undifferentiated pleomorphic sarcoma (UPS), alveolar soft part sarcoma (ASPS), and leiomyosarcoma (LMS). However, efficacy is difficult to predict. High tumor mutational burden (TMB-H) and programmed death-ligand 1 (PD-L1) expression are the strongest features associated with the efficacy of immunotherapy, although they are rarely found in STS patients. Until now, whether or not PD-L1 expression and TMB are related to the efficacy of immunotherapy has not been determined. In this study, we report data obtained from two STS patients, one ASPS and one UPS with a high TMB, that benefited from anlotinib combined with toripalimab following resistance to anlotinib monotherapy. A 26 year-old female patient was diagnosed with ASPS. PD-L1 was negative. Next generation sequencing (NSG) revealed ASPSCR1-TFE3 fusion and TMB-H. Following eight months of anlotinib monotherapy, the patient's disease progressed but continued to benefit from subsequent use of anlotinib combined with toripalimab for 19 months. Another 63 year-old male patient was diagnosed with UPS. PD-L1 was positive and NGS revealed TMB-H. Following 19 months of anlotinib monotherapy, the patient's disease progressed but continued to benefit from subsequent use of anlotinib combined with toripalimab. DFS is 23 months to follow-up time. The results presented are the first to report the relationship between TMB and the efficacy of immunotherapy in STS. Based on our results, we hypothesis that anlotinib combined with toripalimab is effective for the treatment of some advanced ASPS or UPS. TMB may be a potential predictive biomarker for ICI treatment and deserves additional study.	[Li, Yong; Liu, Yihong; Qu, Yanchun; Chen, Xian; Qu, Xin; Ye, Yongsong; Zhang, Haibo] Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou, Peoples R China; [Du, Xiaohua] Guangdong Prov Hosp Chinese Med, Dept Pathol, Guangzhou, Peoples R China; [Cheng, Ying; Xu, Mian] Shanghai OrigiMed Co Ltd, Dept Med, Shanghai, Peoples R China	Guangzhou University of Chinese Medicine; Guangzhou University of Chinese Medicine	Li, Y; Zhang, HB (corresponding author), Guangdong Prov Hosp Chinese Med, Dept Oncol, Guangzhou, Peoples R China.	yongjie88net@163.com; haibozh@aliyun.com						Burgess MA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11008; Cao DD, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1629258; Cao JY, 2019, ONCOLOGIST, V24, pE1294, DOI 10.1634/theoncologist.2019-0236; Casey DL, 2020, CLIN CANCER RES, V26, P1135, DOI 10.1158/1078-0432.CCR-19-2631; Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2; Cheung LS, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002345; Chi YHBL, 2018, CLIN CANCER RES, V24, P5233, DOI 10.1158/1078-0432.CCR-17-3766; Clark MA, 2005, NEW ENGL J MED, V353, P701, DOI 10.1056/NEJMra041866; Conley Anthony P, 2018, J Glob Oncol, V4, P1, DOI 10.1200/JGO.2017.009993; Coyne GO, 2018, 2018 CTOS ANN M NOV; D'Angelo SP, 2018, LANCET ONCOL, V19, P416, DOI 10.1016/S1470-2045(18)30006-8; D'Angelo SP, 2015, HUM PATHOL, V46, P357, DOI 10.1016/j.humpath.2014.11.001; Duffy MJ, 2019, CLIN CHEM, V65, P1228, DOI 10.1373/clinchem.2019.303644; Groisberg R, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0301-y; He M, 2020, HUM PATHOL, V100, P15, DOI 10.1016/j.humpath.2020.04.007; Kim H, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835921992992; Kim JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082870; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Luo Y, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025262; Mir O, 2016, LANCET ONCOL, V17, P1732, DOI 10.1016/S1470-2045(16)30507-1; Monga V, 2020, CANCERS, V12, DOI 10.3390/cancers12071873; Penel N, 2018, CANCER-AM CANCER SOC, V124, P1179, DOI 10.1002/cncr.31176; Pollack SM, 2017, CANCER-AM CANCER SOC, V123, P3291, DOI 10.1002/cncr.30726; Portera CA, 2001, CANCER, V91, P585, DOI 10.1002/1097-0142(20010201)91:3<585::AID-CNCR1038>3.0.CO;2-0; Reichardt P, 2003, EUR J CANCER, V39, P1511, DOI 10.1016/S0959-8049(03)00264-8; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Sheng XN, 2019, J CLIN ONCOL, V37, P2987, DOI 10.1200/JCO.19.00210; Stacchiotti S, 2011, ANN ONCOL, V22, P1682, DOI 10.1093/annonc/mdq644; Stacchiotti S, 2018, ONCOLOGIST, V23, P62, DOI 10.1634/theoncologist.2017-0161; Stockwin LH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-22; Su H, 2021, INVEST NEW DRUG, V39, P1411, DOI 10.1007/s10637-021-01105-6; Tawbi HA, 2017, LANCET ONCOL, V18, P1493, DOI 10.1016/S1470-2045(17)30624-1; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; Vieira AC, 2020, OXF MED CASE REP, P21, DOI 10.1093/omcr/omz138; Wilky BA, 2019, LANCET ONCOL, V20, P837, DOI 10.1016/S1470-2045(19)30153-6; Xu LB, 2020, INT J BIOL MARKER, V35, P14, DOI 10.1177/1724600820925095; Xu LB, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12614; Xu Z, 2021, ANN PALLIAT MED, V10, P785, DOI 10.21037/apm-20-2275; Yang JL, 2020, EUR J CANCER, V130, P182, DOI 10.1016/j.ejca.2020.01.028; Yang S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.11572; Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444; Zheng SE, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.625226	43	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								832593	10.3389/fimmu.2022.832593	http://dx.doi.org/10.3389/fimmu.2022.832593			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P8AF	35603147	gold, Green Published			2022-12-18	WOS:000802225700001
J	Mao, ZY; Jia, XH; Jiang, PP; Wang, QY; Zhang, YJ; Li, YL; Fu, XL; Jiao, M; Jiang, LL; Liu, ZY; Guo, H				Mao, Ziyang; Jia, Xiaohui; Jiang, Panpan; Wang, Qinyang; Zhang, Yajuan; Li, Yanlin; Fu, Xiaolan; Jiao, Min; Jiang, Lili; Liu, Zhiyan; Guo, Hui			Effect of Concomitant Use of Analgesics on Prognosis in Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis	FRONTIERS IN IMMUNOLOGY			English	Review						immune checkpoint inhibitors; analgesics; drug-drug interactions; prognosis; meta-analysis	CANCER; NIVOLUMAB; GROWTH; MECHANISMS; MELANOMA; THERAPY	Background: Drug-drug interactions (DDIs) pose new challenges beyond traditional pharmacodynamics in the context of optimizing the treatment options with immune checkpoint inhibitors (ICIs). To alleviate cancer-related pain, analgesics are of absolute vital importance as chronic medications used by cancer patients. However, the possible outcome of ICI treatment concomitant with analgesics remains unclear. Methods: Original articles describing the possible influence of analgesics use on ICI treatment published before December 1, 2021 were retrieved from PubMed, Embase, and the Cochrane Library. Odds ratio (OR) with 95% confidence interval (CI) for objective response rate (ORR), hazard ratio (HR) with 95% CI for progression-free survival (PFS), and overall survival (OS) were calculated using the random-effects or fixed-effects model, and heterogeneity was assessed using the chi(2)-based Q-test. Publication bias was examined by funnel plot analysis. Results: A total of 11 studies involving 4,404 patients were included. The pooled OR showed that opioid use decreased the response of opioid users to ICIs compared to non-opioid users (OR = 0.49, 95% CI = 0.37-0.65, p < 0.001). Compared to patients who did not receive opioids, opioid users had an increased risk of progression and mortality (HR = 1.61, 95% CI = 1.37-1.89, p < 0.001; HR = 1.67, 95% CI =1.30-2.14, p < 0.001, respectively). Furthermore, the concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) was not significantly associated with differences in ORR, PFS, and OS in patients treated with ICIs (OR = 1.40, 95% CI = 0.84-2.32, p = 0.190; HR = 0.90, 95% CI = 0.77-1.06, p = 0.186; HR = 0.90, 95% CI = 0.71-1.14, p = 0.384, respectively). Conclusion: The concomitant use of opioids during ICI treatment has an adverse effect on patient prognosis, while the use of NSAIDs is not significantly associated with the prognosis in patients treated with ICIs.	[Mao, Ziyang; Jia, Xiaohui; Jiang, Panpan; Wang, Qinyang; Zhang, Yajuan; Li, Yanlin; Fu, Xiaolan; Jiao, Min; Jiang, Lili; Guo, Hui] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Peoples R China; [Liu, Zhiyan] Northwest Univ, Affiliated Hosp, Xian Hosp 3, Dept Resp & Crit Care Med,Resp & Crit Care Med, Xian, Peoples R China; [Guo, Hui] Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian, Peoples R China; [Guo, Hui] Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Minist Educ China, Xian, Peoples R China	Xi'an Jiaotong University; Northwest University Xi'an; Xi'an Jiaotong University; Ministry of Education, China; Xi'an Jiaotong University	Guo, H (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian, Peoples R China.; Liu, ZY (corresponding author), Northwest Univ, Affiliated Hosp, Xian Hosp 3, Dept Resp & Crit Care Med,Resp & Crit Care Med, Xian, Peoples R China.; Guo, H (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Ctr Translat Med, Xian, Peoples R China.; Guo, H (corresponding author), Xi An Jiao Tong Univ, Key Lab Environm & Genes Related Dis, Minist Educ China, Xian, Peoples R China.	1441999403@qq.com; guohui@xjtufh.edu.cn	Jia, Xiaohui/GWV-1174-2022; Zhang, Yajuan/ABD-7639-2022					Al-Hasani R, 2011, ANESTHESIOLOGY, V115, P1363, DOI 10.1097/ALN.0b013e318238bba6; Anekar A. A., 2021, STATPEARLS; Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741; Banerjee S, 2016, MUCOSAL IMMUNOL, V9, P1418, DOI 10.1038/mi.2016.9; Barbi J, 2014, IMMUNOL REV, V259, P115, DOI 10.1111/imr.12172; Bazzani L, 2017, ONCOTARGET, V8, P31270, DOI 10.18632/oncotarget.16116; Beagles K, 2004, MOL PHARMACOL, V65, P437, DOI 10.1124/mol.65.2.437; Borner C, 2009, J IMMUNOL, V183, P882, DOI 10.4049/jimmunol.0802763; Bottcher JP, 2018, CELL, V172, P1022, DOI 10.1016/j.cell.2018.01.004; Borst P, 2020, IUBMB LIFE, V72, P2241, DOI 10.1002/iub.2367; Botticelli A, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02784-8; Cantini L, 2021, EUR J CANCER, V144, P41, DOI 10.1016/j.ejca.2020.10.031; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Cornwell WD, 2013, J NEUROIMMUNOL, V265, P43, DOI 10.1016/j.jneuroim.2013.09.013; Cortellini A, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002421; Cortellini A, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001361; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Failing JJ, 2016, MELANOMA RES, V26, P609, DOI 10.1097/CMR.0000000000000299; Ferrer MD, 2019, CURR MED CHEM, V26, P3225, DOI 10.2174/0929867325666180514112124; Franco F, 2018, IMMUNITY, V49, P987, DOI 10.1016/j.immuni.2018.12.002; Fujino H, 2011, BIOCHEM PHARMACOL, V81, P379, DOI 10.1016/j.bcp.2010.11.001; Fujioka N, 2011, ANESTH ANALG, V113, P1353, DOI 10.1213/ANE.0b013e318232b35a; Fundytus A, 2021, ANN ONCOL, V32, P833, DOI 10.1016/j.annonc.2021.03.208; Gach K, 2009, CHEM BIOL DRUG DES, V74, P390, DOI 10.1111/j.1747-0285.2009.00875.x; Gaucher L, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/17588359211000591; Gong L, 2014, INT J CLIN EXP PATHO, V7, P7708; Gupta K, 2002, CANCER RES, V62, P4491; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Humphries A, 2018, HUM VACC IMMUNOTHER, V14, P2178, DOI 10.1080/21645515.2018.1442970; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Iglesias-Santamaria A, 2020, CLIN TRANSL ONCOL, V22, P1481, DOI 10.1007/s12094-019-02282-w; Jiao SP, 2019, CELL, V179, P1177, DOI 10.1016/j.cell.2019.10.029; Kanai O, 2021, THORAC CANCER, V12, P949, DOI 10.1111/1759-7714.13845; Li MY, 2020, INT IMMUNOPHARMACOL, V88, DOI 10.1016/j.intimp.2020.106972; Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9; Meng JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054040; Meriggi F, 2021, CANCER IMMUNOL IMMUN, V70, P1511, DOI 10.1007/s00262-020-02786-3; Miura K, 2021, THORAC CANCER, V12, P1983, DOI 10.1111/1759-7714.14001; Ni W, 2021, MOL THER, V29, P2995, DOI 10.1016/j.ymthe.2021.05.012; Pan JS, 2016, SCI REP-UK, V6, DOI 10.1038/srep33823; Petrelli F, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051458; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Scripture CD, 2006, NAT REV CANCER, V6, P546, DOI 10.1038/nrc1887; Svaton M, 2020, ANTICANCER RES, V40, P2209, DOI 10.21873/anticanres.14182; Taniguchi Yoshihiko, 2020, BMJ Support Palliat Care, DOI 10.1136/bmjspcare-2020-002480; Tian M., 2021, ANTI-CANCER AGENT ME, DOI [10.1080/21645515.2018.1442970, DOI 10.1080/21645515.2018.1442970]; Wang DY, 2020, ONCOLOGIST, V25, pE602, DOI 10.1634/theoncologist.2019-0518; Wang FY, 2017, TOXICOL PATHOL, V45, P150, DOI 10.1177/0192623316679898; Wang SJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000889; Weber JS, 2015, LANCET ONCOL, V16, P375, DOI 10.1016/S1470-2045(15)70076-8; Wells G., 2000, NEWCASTLE OTTAWA SCA; Wiffen PJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012592.pub2; Yan GF, 2018, CANCER RES, V78, P5586, DOI 10.1158/0008-5472.CAN-17-3962; Zajaczkowska R, 2018, PAIN RES MANAG, V2018, DOI 10.1155/2018/9293704	54	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								861723	10.3389/fimmu.2022.861723	http://dx.doi.org/10.3389/fimmu.2022.861723			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1S0PA	35603146	gold, Green Published			2022-12-18	WOS:000803760400001
J	Ondigo, BN; Hamilton, RE; Magomere, EO; Onkanga, IO; Mwinzi, PN; Odiere, MR; Ganley-Leal, L				Ondigo, Bartholomew N.; Hamilton, Rachael E.; Magomere, Edwin O.; Onkanga, Isaac O.; Mwinzi, Pauline N.; Odiere, Maurice R.; Ganley-Leal, Lisa			Potential Utility of Systemic Plasma Biomarkers for Evaluation of Pediatric Schistosomiasis in Western Kenya	FRONTIERS IN IMMUNOLOGY			English	Article						biomarkers; schistosomiasis; infection; intensity; diagnosis	MANSONI INFECTION; MYELOID CELLS-1; PREVALENCE; TREM-1; IGE; SANITATION; DIAGNOSIS; CHILDREN; HYGIENE; WATER	IntroductionCurrent diagnostic tools for schistosomiasis are limited, and new tests are necessary to enhance disease diagnosis and surveillance. Identification of novel disease-specific biomarkers may facilitate the development of such tests. We evaluated a panel of biomarkers used in sepsis and parasitic diseases for their potential suitability in the diagnosis of schistosomiasis. ObjectiveThe study evaluated the levels of systemic plasma biomarkers in relation to Schistosoma mansoni infection and parasite burden. MethodsSix biomarkers were measured in the plasma of children from schistosomiasis-endemic regions using ELISA. The concentration of soluble CD23 (sCD23) and lipopolysaccharide (LPS) was tested in 199 and 124 plasma samples, respectively, while interleukin-6 (IL-6), soluble triggering receptor expressed on myeloid (sTREM) cells, eotaxin-1, and fatty acid-binding protein (FABP) concentrations were tested in 30 plasma samples. ResultsThe concentration of IL-6, eotaxin-1, FABP, and LPS was similar between schistosome-infected and uninfected children. The schistosome-infected children had higher median levels of sTREM and sCD23 as compared to uninfected children, 119.0 (29.9-208.9) versus 10.7 (0.0-73.4) (p = 0.046) and 2,549.0 (1,899.0-3,356.0) vs. 2,035.0 (1,448.0-2,939.0) (p = 0.05), respectively. In addition, sTREM was positively correlated with egg density (p = 0.017). ConclusionOur data show that active schistosomiasis per se is associated with elevated levels of sTREM and sCD23. sTREM has potential diagnostic and prognostic values. However, these biomarkers did not distinguish between children with low egg burden and uninfected children.	[Ondigo, Bartholomew N.; Magomere, Edwin O.] Egerton Univ, Fac Sci, Dept Biochem & Mol Biol, Egerton, Kenya; [Hamilton, Rachael E.] Boston Univ, Sch Publ Hlth, Boston, MA USA; [Hamilton, Rachael E.; Ganley-Leal, Lisa] Global Dev, Elegance Biotechnol, Wayne, PA USA; [Onkanga, Isaac O.; Odiere, Maurice R.] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya; [Mwinzi, Pauline N.] WHO, Reg Off Africa, Brazzaville, Rep Congo	Egerton University; Boston University; Kenya Medical Research Institute; World Health Organization	Ondigo, BN (corresponding author), Egerton Univ, Fac Sci, Dept Biochem & Mol Biol, Egerton, Kenya.	ondigo2002@gmail.com		Ondigo, Bartholomew/0000-0003-3607-9964; Magomere, Edwin/0000-0002-7735-1576	National Institutes of Allergy and Infectious Diseases [R01AI116593]	National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was supported by the National Institutes of Allergy and Infectious Diseases (R01AI116593) awarded to LG-L.	Aly IR, 2012, KOREAN J PARASITOL, V50, P37, DOI 10.3347/kjp.2012.50.1.37; Bomfim LGS, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02265; Borsini A, 2020, INT J NEUROPSYCHOPH, V23, P738, DOI 10.1093/ijnp/pyaa055; Bouchon A, 2000, J IMMUNOL, V164, P4991, DOI 10.4049/jimmunol.164.10.4991; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Castro VN, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02975; Chadeka EA, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005872; Cheng PC, 2011, PARASITE IMMUNOL, V33, P276, DOI 10.1111/j.1365-3024.2011.01284.x; Colonna M, 2003, J INFECT DIS, V187, pS397, DOI 10.1086/374754; Cooper AM, 2012, J IMMUNOL, V188, P3199, DOI 10.4049/jimmunol.1102689; Coufal S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5727312; de Dood CJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02635; Duramaz BB, 2021, ARCH PEDIATRIE, V28, P567, DOI 10.1016/j.arcped.2021.06.001; Engeroff P, 2021, ALLERGY, V76, P1981, DOI 10.1111/all.14724; Ezeamama AE, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0005524; Francois B, 2020, INTENS CARE MED, V46, P1425, DOI 10.1007/s00134-020-06109-z; French MD, 2018, PLOS NEGLECT TROP D, V12, DOI 10.1371/journal.pntd.0006484; Geiger SM, 2013, TROP MED INT HEALTH, V18, P750, DOI 10.1111/tmi.12095; Gunda DW, 2020, TROP MED INFECT DIS, V5, DOI 10.3390/tropicalmed5010020; Hailu T, 2020, IRAN J PARASITOL, V15, P124; Jolly L, 2021, CELL MOL IMMUNOL, V18, P2054, DOI 10.1038/s41423-021-00733-5; Kardoush MI, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154465; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Klemperer KM, 2020, AM J TROP MED HYG, V102, P1382, DOI 10.4269/ajtmh.19-0875; Lemarie J, 2020, CRIT CARE CLIN, V36, P41, DOI 10.1016/j.ccc.2019.08.004; Mulopo C, 2021, J WATER SANIT HYG DE, V11, P255, DOI 10.2166/washdev.2021.182; Mwinzi PNM, 2009, J INFECT DIS, V199, P272, DOI 10.1086/595792; Nakagawa Hiroko, 2014, BMC Hematol, V14, P6, DOI 10.1186/2052-1839-14-6; Odiere MR, 2012, PARASITE VECTOR, V5, DOI 10.1186/1756-3305-5-278; Onguru, 2016, EXPRESSION CD23 SCHI; Onguru D, 2011, AM J TROP MED HYG, V84, P321, DOI 10.4269/ajtmh.2011.10-0397; Onkanga IO, 2016, INT J PARASITOL, V46, P439, DOI 10.1016/j.ijpara.2016.01.006; Prussin Calman, 2003, Journal of Allergy and Clinical Immunology, V111, pS486; Purdue MP, 2015, LEUKEMIA, V29, P1429, DOI 10.1038/leu.2015.2; Rujeni N, 2013, INT ARCH ALLERGY IMM, V161, P333, DOI 10.1159/000346545; Sang HC, 2014, PARASITE VECTOR, V7, DOI 10.1186/1756-3305-7-125; Song XF, 2017, SURG INFECT, V18, P577, DOI 10.1089/sur.2016.174; Tessarz AAS, 2008, IMMUNOL LETT, V116, P111, DOI 10.1016/j.imlet.2007.11.021; Vicente B, 2016, PARASITE VECTOR, V9, DOI 10.1186/s13071-016-1500-y; Wami WM, 2014, PARASITOLOGY, V141, P1962, DOI 10.1017/S0031182014000213; Weerakoon KGAD, 2015, CLIN MICROBIOL REV, V28, P939, DOI 10.1128/CMR.00137-14; World Health Organization, 2019, Weekly Epidemiological Record, V94, P425	42	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								887213	10.3389/fimmu.2022.887213	http://dx.doi.org/10.3389/fimmu.2022.887213			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K6BV	35603171	Green Published, gold			2022-12-18	WOS:000798684600001
J	Qian, LW; Lai, XJ; Gu, BX; Sun, XA				Qian, Liwen; Lai, Xiaojing; Gu, Benxing; Sun, Xiaonan			An Immune-Related Gene Signature for Predicting Neoadjuvant Chemoradiotherapy Efficacy in Rectal Carcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						rectal carcinoma; neoadjuvant chemoradiotherapy; immune-related genes; Bioinformatics analysis; prognosis	PREOPERATIVE CHEMORADIOTHERAPY; CLINICAL-PRACTICE; TUMOR-CELLS; CANCER; EXPRESSION; IMMUNOSCORE; TAP; RADIOTHERAPY; RECOGNITION; PEPTIDES	BackgroundLocally advanced rectal cancers (LARC) show a highly variable response to neoadjuvant chemoradiotherapy (nCRT), and the impact of the tumor immune response in this process is poorly understood. This study aimed to characterize the immune-related gene expression profiles (GEP), pathways, and cell types associated with response or resistance to neoadjuvant chemoradiotherapy. MethodsThe transcriptomic and clinical data of Rectal carcinoma from the Gene Expression Omnibus database and Immune-related genes (IRGs) from ImmPort were downloaded to identify the differentially expressed immune-related genes (DEIRGs) between responder and non-responder to neoadjuvant chemoradiotherapy. Gene set enrichment analyses were performed to uncover significantly enriched GO terms and KEGG pathways. Immune cell infiltration was estimated from RNA-sequencing data using ImmuCellAI. Afterward, we constructed an immune-related gene-based predictive model (IRGPM) by Support Vector Machine and validated it in an external cohort. ResultA 15-gene signature (HLA-DPB1, HLA-DQA1, CXCL9, CXCL10, TAP2, INHBB, BMP2, CD74, IL33, CCL11, CXCL11, DEFB1, HLA-DPA1, CCN3, STAT1) was identified as DEIRGs and found to be significantly associated with nCRT outcomes. Gene set enrichment analyses indicated that the 15 genes play active roles in inflammation-related biological processes. In addition, ImmuCellAI revealed that CD4 naive T cells, Tex, Th1 were significantly up-regulated (p=0.035, p=0.02, p=0.0086, respectively), while Tfh were significantly down-regulated (p=0.015) in responder subgroup. Finally, a novel predictive model was developed by SVM based on DEIRGs with an AUC of 80% (internal validation) and 73.5% (external validation). ConclusionOur team conducted a genomic study of the relationship between gene expression profile and response to nCRT in LARC. Our data suggested that the DEIRGs signature could help predict the efficacy of nCRT. And a DEIRGs-based SVM model was developed to monitor the outcomes of nCRT in LARC.	[Qian, Liwen; Lai, Xiaojing; Gu, Benxing; Sun, Xiaonan] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China	Zhejiang University	Sun, XA (corresponding author), Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Radiat Oncol, Hangzhou, Peoples R China.	sunxiaonan@zju.edu.cn						Abele R, 2004, PHYSIOLOGY, V19, P216, DOI 10.1152/physiol.00002.2004; Agostini M, 2015, CANCER BIOL THER, V16, P1160, DOI 10.1080/15384047.2015.1046652; Ajani JA, 2008, JAMA-J AM MED ASSOC, V299, P1914, DOI 10.1001/jama.299.16.1914; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Benson A, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061; Bhattacharya S, 2014, IMMUNOL RES, V58, P234, DOI 10.1007/s12026-014-8516-1; Bonamy C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36387-z; Cercek A, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0071; Chang CC, 2014, WORLD J GASTROENTERO, V20, P6826, DOI 10.3748/wjg.v20.i22.6826; Dayde D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030573; Durgeau A, 2011, J IMMUNOL, V187, P5532, DOI 10.4049/jimmunol.1102060; Ekmekcioglu S, 2016, CLIN CANCER RES, V22, P3016, DOI 10.1158/1078-0432.CCR-15-2226; El Hage F, 2013, ANN NY ACAD SCI, V1283, P75, DOI 10.1111/j.1749-6632.2012.06777.x; El Sissy C, 2020, CLIN CANCER RES, V26, P5198, DOI 10.1158/1078-0432.CCR-20-0337; Fang M, 2017, CANCER RES, V77, P2735, DOI 10.1158/0008-5472.CAN-16-1602; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Gim J, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0623-9; Guo Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep36935; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hu Y, 2018, GENE CHROMOSOME CANC, V57, P140, DOI 10.1002/gcc.22512; Huang SJ, 2018, CANCER GENOM PROTEOM, V15, P41, DOI 10.21873/cgp.20063; Ivashkiv LB, 2018, NAT REV IMMUNOL, V18, P545, DOI 10.1038/s41577-018-0029-z; Kamran SC, 2019, CLIN CANCER RES, V25, P5561, DOI 10.1158/1078-0432.CCR-19-0908; Korbecki J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218412; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Miao YR, 2020, ADV SCI, V7, DOI 10.1002/advs.201902880; Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025; Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329; Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI 10.1200/JCO.2009.22.0467; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taube JM, 2018, MODERN PATHOL, V31, P214, DOI 10.1038/modpathol.2017.156; Teng FF, 2015, TRANSL RES, V166, P721, DOI 10.1016/j.trsl.2015.06.019; van Gijn W, 2011, LANCET ONCOL, V12, P575, DOI 10.1016/S1470-2045(11)70097-3; Verhoeven Y, 2020, SEMIN CANCER BIOL, V60, P41, DOI 10.1016/j.semcancer.2019.10.002; Watanabe T, 2014, DIS COLON RECTUM, V57, P23, DOI 10.1097/01.dcr.0000437688.33795.9d; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yuki S, 2020, J CLIN ONCOL, V38; Zeitounu G, 2019, CHIRURGIA-BUCHAREST, V114, P152, DOI 10.21614/chirurgia.114.2.152	44	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								784479	10.3389/fimmu.2022.784479	http://dx.doi.org/10.3389/fimmu.2022.784479			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1P7MK	35603163	Green Published, gold			2022-12-18	WOS:000802188900001
J	Shamriz, O; Zahalka, N; Simon, AJ; Lev, A; Barel, O; Mor, N; Tal, Y; Segel, MJ; Somech, R; Yonath, H; Toker, O				Shamriz, Oded; Zahalka, Naseem; Simon, Amos J.; Lev, Atar; Barel, Ortal; Mor, Nofar; Tal, Yuval; Segel, Michael J.; Somech, Raz; Yonath, Hagith; Toker, Ori			GATA2 Deficiency in Adult Life Is Characterized by Phenotypic Diversity and Delayed Diagnosis	FRONTIERS IN IMMUNOLOGY			English	Article						GATA2; exome; primary immune deficiency (PID); hematopoietic; diagnosis	MUTATIONS	The transcription factor GATA2 plays a key role in the survival and self-renewal of hematopoietic stem and progenitor cells. Autosomal dominant variants in GATA2 cause a broad spectrum of heterogeneous phenotypes. Here, we present our experience with GATA2 deficiency in a retrospective multicenter analysis of computerized medical records of adult patients (age >= 18 years) treated between 2018 and 2022 at Shaare Zedek Medical Center in Jerusalem and Sheba Tel-Hashomer Medical Center in Ramat Gan, Israel. Two male and two female patients with GATA2 deficiency were identified. Three of the patients presented with symptoms in adult life and all patients were diagnosed as adults. Age at presentation was 10.5-36 years and age at diagnosis 24-47 years. Diagnosis was delayed in all patients by 1-24.5 years. The phenotypic diversity was notable. Patients presented with myelodysplastic syndrome (n=2), pulmonary alveolar proteinosis (n=1), and recurrent viral (n=1), bacterial (n=3), and mycobacterial (n=1) infections. Bone marrow biopsy revealed cytogenetic abnormalities in one patient (monosomy 7). Patients were diagnosed by exome sequencing (n=3) and Sanger sequencing of the coding exons in GATA2 (n=1). Novel heterozygous GATA2 variants (c.177C>A, p.Y59* and c.610dup, p.R204Pfs*78) were identified in two patients. Immune workup revealed B cell lymphopenia and monocytopenia in all tested patients. One patient died from overwhelming sepsis despite all patients being treated with antibiotics and anti-mycobacterials. Our cohort highlights the phenotypic diversity, late presentation, and delayed diagnosis of GATA2 deficiency. Increased awareness of this primary immune deficiency presenting in adult life is needed and should involve a high index of suspicion.	[Shamriz, Oded] Hebrew Univ Jerusalem, Dept Med, Allergy & Clin Immunol Unit, Hadassah Med Org, Jerusalem, Israel; [Shamriz, Oded] Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Lautenberg Ctr Immunol & Canc Res, Fac Med, Jerusalem, Israel; [Zahalka, Naseem] Sheba Med Ctr, Internal Med, Ramat Gan, Israel; [Zahalka, Naseem] Sheba Med Ctr, Sheba Canc Res Ctr, Ramat Gan, Israel; [Zahalka, Naseem] Sheba Med Ctr, Inst Hematol, Ramat Gan, Israel; [Lev, Atar; Somech, Raz] Tel Aviv Univ, Edmond & Lily Safra Childrens Hosp, Sackler Fac Med, Pediat Dept & Immunol Serv, Tel Aviv, Israel; [Lev, Atar; Somech, Raz] Jeffrey Modell Fdn Israeli Network Primary Immuno, New York, NY USA; [Barel, Ortal; Mor, Nofar] Sheba Med Ctr, Genom Unit, Sheba Canc Res Ctr, Ramat Gan, Israel; [Lev, Atar; Barel, Ortal] Sheba Med Ctr, Wohl Inst Translat Med, Ramat Gan, Israel; [Segel, Michael J.] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel; [Segel, Michael J.] Sheba Med Ctr, Dept Pulmonol, Ramat Gan, Israel; [Yonath, Hagith] Sheba Med Ctr, Danek Gertner Inst Human Genet, Ramat Gan, Israel; [Toker, Ori] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Allergy & Clin Immunol Unit, Fac Med, Jerusalem, Israel	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center; Chaim Sheba Medical Center; Hebrew University of Jerusalem; Shaare Zedek Medical Center	Shamriz, O (corresponding author), Hebrew Univ Jerusalem, Dept Med, Allergy & Clin Immunol Unit, Hadassah Med Org, Jerusalem, Israel.; Shamriz, O (corresponding author), Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Lautenberg Ctr Immunol & Canc Res, Fac Med, Jerusalem, Israel.; Toker, O (corresponding author), Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Allergy & Clin Immunol Unit, Fac Med, Jerusalem, Israel.	oded.shamriz@mail.huji.ac.il; oritoker@szmc.org.il	toker, ori/CAG-3660-2022					Abdelfattah A, 2021, BLOOD ADV, V5, P4285, DOI 10.1182/bloodadvances.2021004726; Apoil PA, 2017, DATA BRIEF, V12, P400, DOI 10.1016/j.dib.2017.04.019; Bortnick R, 2021, BONE MARROW TRANSPL, V56, P2732, DOI 10.1038/s41409-021-01374-y; Donadieu J, 2018, HAEMATOLOGICA, V103, P1278, DOI 10.3324/haematol.2017.181909; Garrison E., 2012, ARXIV12073907; Hirabayashi S, 2017, INT J HEMATOL, V106, P175, DOI 10.1007/s12185-017-2285-2; Hsu AP, 2013, BLOOD, V121, P3830, DOI 10.1182/blood-2012-08-452763; Jorgensen SF, 2022, J CLIN IMMUNOL, V42, P404, DOI 10.1007/s10875-021-01189-y; Koyunlar Cansu, 2020, Front Genome Ed, V2, P602182, DOI 10.3389/fgeed.2020.602182; Li MX, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx019; Marciano BE, 2021, CHEST, V160, P1350, DOI 10.1016/j.chest.2021.05.046; Mardahl M, 2019, BRIT J HAEMATOL, V186, P471, DOI 10.1111/bjh.15947; Oleaga-Quintas C, 2021, J CLIN IMMUNOL, V41, P639, DOI 10.1007/s10875-020-00930-3; Pasquet M, 2013, BLOOD, V121, P822, DOI 10.1182/blood-2012-08-447367; Poplin R., 2018, BIORXIV, DOI [10.1101/201178, DOI 10.1101/201178, 10.1101/201178v3]; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Spinner MA, 2014, BLOOD, V123, P809, DOI 10.1182/blood-2013-07-515528; Svobodova T, 2015, BMC PULM MED, V15, DOI 10.1186/s12890-015-0006-2; van Lier YF, 2020, CLIN IMMUNOL, V218, DOI 10.1016/j.clim.2020.108522; West RR, 2022, BLOOD ADV, V6, P793, DOI 10.1182/bloodadvances.2021005065; Zhang MY, 2015, HAEMATOLOGICA, V100, P42, DOI 10.3324/haematol.2014.113456	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								886117	10.3389/fimmu.2022.886117	http://dx.doi.org/10.3389/fimmu.2022.886117			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K6UL	35603181	gold, Green Published			2022-12-18	WOS:000798733100001
J	Simoes, AM; Holmstrom, MO; Aehnlich, P; Rahbech, A; Radziwon-Balicka, A; Zamora, C; Klausen, TW; Skov, V; Kjaer, L; Ellervik, C; El Fassi, D; Vidal, S; Hasselbalch, HC; Andersen, MH; Straten, PT				Simoes, Ana MicaelaCarnaz; Holmstrom, Morten Orebo; Aehnlich, Pia; Rahbech, Anne; Radziwon-Balicka, Aneta; Zamora, Carlos; Wirenfeldt Klausen, Tobias; Skov, Vibe; Kjaer, Lasse; Ellervik, Christina; El Fassi, Daniel; Vidal, Silvia; Hasselbalch, Hans Carl; Andersen, Mads Hald; Straten, Per Thor			Patients With Myeloproliferative Neoplasms Harbor High Frequencies of CD8 T Cell-Platelet Aggregates Associated With T Cell Suppression	FRONTIERS IN IMMUNOLOGY			English	Article						platelets; platelet-bound T cells; platelet-T cell aggregates; Myeloproliferative Neoplasms (MPN); CALR mutation; JAK2 mutation	CALR EXON-9 MUTATIONS; NATURAL-KILLER-CELLS; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; JAK2V617F MUTATION; INTERFERON-ALPHA; CLASS-I; LYMPHOCYTE; LEUKOCYTE; ELIMINATION	Myeloproliferative neoplasms (MPN) are chronic cancers of the hematopoietic stem cells in the bone marrow, and patients often harbor elevated numbers of circulating platelets (PLT). We investigated the frequencies of circulating PLT-lymphocyte aggregates in MPN patients and the effect of PLT-binding on CD8 T cell function. The phenotype of these aggregates was evaluated in 50 MPN patients and 24 controls, using flow cytometry. In vitro studies compared the proliferation, cytokine release, and cytoxicity of PLT-bound and PLT-free CD8 T cells. Frequencies of PLT-CD8 T cell aggregates, were significantly elevated in MPN patients. Advanced disease stage and CALR mutation associated with the highest aggregate frequencies with a predominance of PLT-binding to antigen-experienced CD8 T cells. PLT-bound CD8 T cells showed reduction in proliferation and cytotoxic capacity. Our data suggest that CD8 T cell responses are jeopardized in MPN patients. JAK2 and CALR exon 9 mutations - the two predominant driver mutations in MPN - are targets for natural T cell responses in MPN patients. Moreover, MPN patients have more infections compared to background. Thus, PLT binding to antigen experienced CD8 T cells could play a role in the inadequacy of the immune system to control MPN disease progression and prevent recurrent infections.	[Simoes, Ana MicaelaCarnaz; Holmstrom, Morten Orebo; Aehnlich, Pia; Rahbech, Anne; Radziwon-Balicka, Aneta; Wirenfeldt Klausen, Tobias; Andersen, Mads Hald; Straten, Per Thor] Herlev Univ Hosp, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark; [Zamora, Carlos; Vidal, Silvia] Hosp Sant Creu & St Pau, IIB Sant Pau Inst Rec, Barcelona, Spain; [Skov, Vibe; Kjaer, Lasse; Hasselbalch, Hans Carl] Zealand Univ Hosp, Dept Hematol, Roskilde, Denmark; [Ellervik, Christina; El Fassi, Daniel] Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark; [Ellervik, Christina] Boston Childrens Hosp, Harvard Med Sch, Dept Lab Med, Boston, MA USA; [Ellervik, Christina] Dept Data & Innovat Support, Soro, Region Zealand, Denmark; [El Fassi, Daniel] Univ Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark; [Andersen, Mads Hald; Straten, Per Thor] Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen, Denmark	University of Copenhagen; Herlev & Gentofte Hospital; University of Copenhagen; Harvard University; Boston Children's Hospital; Harvard Medical School; Rigshospitalet; University of Copenhagen; University of Copenhagen	Straten, PT (corresponding author), Herlev Univ Hosp, Natl Ctr Canc Immune Therapy CCIT DK, Dept Oncol, Herlev, Denmark.; Straten, PT (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Dept Immunol & Microbiol, Copenhagen, Denmark.	per.thor.straten@regionh.dk		Andersen, Mads Hald/0000-0002-2914-9605; El Fassi, Daniel/0000-0001-8226-1658; thor Straten, Per/0000-0002-4731-4969				Alvarez-Larran A, 2008, ANN HEMATOL, V87, P269, DOI 10.1007/s00277-007-0386-3; Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Barosi G, 2014, CURR HEMATOL MALIG R, V9, P331, DOI 10.1007/s11899-014-0227-0; Catani MV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030788; Cervantes F, 2000, EUR J HAEMATOL, V65, P104, DOI 10.1034/j.1600-0609.2000.90262.x; Cordua S, 2019, BLOOD, V134, P469, DOI 10.1182/blood.2019001113; Costa-Brito AR, 2015, BLOOD CELL MOL DIS, V55, P208, DOI 10.1016/j.bcmd.2015.06.005; Falanga A, 2005, EXP HEMATOL, V33, P523, DOI 10.1016/j.exphem.2005.01.015; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Guo L, 2021, BLOOD, V138, P401, DOI 10.1182/blood.2020008958; Hasselbalch HC, 2019, SEMIN IMMUNOPATHOL, V41, P5, DOI 10.1007/s00281-018-0700-2; Hasselbalch HC, 2014, LEUKEMIA RES, V38, P1230, DOI 10.1016/j.leukres.2014.07.006; Holmstrom MO, 2018, LEUKEMIA, V32, P429, DOI 10.1038/leu.2017.214; Holmstrom MO, 2017, LEUKEMIA, V31, P495, DOI 10.1038/leu.2016.290; Holmstrom MO, 2016, LEUKEMIA, V30, P2413, DOI 10.1038/leu.2016.233; Holmstrom MO, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-018-0166-4; Holmstrom MO, 2020, CANCERS, V12, DOI 10.3390/cancers12071763; Holmstrom MO, 2020, CANCER IMMUNOL IMMUN, V69, P315, DOI 10.1007/s00262-019-02473-y; Idorn M, 2014, CANCER IMMUNOL IMMUN, V63, P1177, DOI 10.1007/s00262-014-1591-2; Kiladjian JJ, 2016, LEUKEMIA, V30, P776, DOI 10.1038/leu.2015.326; Kjaer L, 2018, LEUKEMIA LYMPHOMA, V59, P973, DOI 10.1080/10428194.2017.1359743; Kovacsovics-Bankowski M, 2016, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-016-0057-y; Langabeer Stephen E, 2016, JAKSTAT, V5, pe1248011, DOI 10.1080/21623996.2016.1248011; Larsen TS, 2007, BRIT J HAEMATOL, V136, P745, DOI 10.1111/j.1365-2141.2007.06497.x; Li N, 2006, J THROMB HAEMOST, V4, P874, DOI 10.1111/j.1538-7836.2006.01817.x; Matsumoto M, 2009, J IMMUNOL, V183, P7204, DOI 10.4049/jimmunol.0902173; McLornan DP, 2015, CURR HEMATOL MALIG R, V10, P370, DOI 10.1007/s11899-015-0284-z; Meikle CK, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236966; Nangalia J, 2017, BLOOD, V130, P2475, DOI 10.1182/blood-2017-06-782037; Nieswandt B, 1999, CANCER RES, V59, P1295; Palumbo JS, 2005, BLOOD, V105, P178, DOI 10.1182/blood-2004-06-2272; Placke T, 2012, CANCER RES, V72, P440, DOI 10.1158/0008-5472.CAN-11-1872; Pourcelot E, 2014, EXP HEMATOL, V42, P360, DOI 10.1016/j.exphem.2014.01.006; Rachidi S, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aai7911; Riley CH, 2016, EUR J HAEMATOL, V97, P83, DOI 10.1111/ejh.12687; Riley CH, 2015, EUR J HAEMATOL, V94, P227, DOI 10.1111/ejh.12420; Saini SK, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aau9039; Skov V, 2013, LEUKEMIA LYMPHOMA, V54, P2269, DOI 10.3109/10428194.2013.764417; Starossom SC, 2015, CIRC RES, V117, P779, DOI 10.1161/CIRCRESAHA.115.306847; Tefferi A, 2011, J CLIN ONCOL, V29, P1356, DOI 10.1200/JCO.2010.32.9490; Tinoco R, 2016, IMMUNITY, V44, P1190, DOI 10.1016/j.immuni.2016.04.015; Vaidya R, 2012, AM J HEMATOL, V87, P1003, DOI 10.1002/ajh.23295; Vainchenker W, 2017, BLOOD, V129, P667, DOI 10.1182/blood-2016-10-695940; VARGAS JR, 1982, PROSTAGLANDINS, V23, P929, DOI 10.1016/0090-6980(82)90135-6; Wang JC, 2016, LEUKEMIA RES, V43, P39, DOI 10.1016/j.leukres.2016.02.004; Zamora C, 2017, J IMMUNOL, V198, P3099, DOI 10.4049/jimmunol.1601708; Zamora C, 2013, J LEUKOCYTE BIOL, V94, P521, DOI 10.1189/jlb.0213074	47	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								866610	10.3389/fimmu.2022.866610	http://dx.doi.org/10.3389/fimmu.2022.866610			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6FU	35603202	gold, Green Published			2022-12-18	WOS:000800063900001
J	Tanaka, T; Shiba, T; Honda, Y; Izawa, K; Yasumi, T; Saito, MK; Nishikomori, R				Tanaka, Takayuki; Shiba, Takeshi; Honda, Yoshitaka; Izawa, Kazushi; Yasumi, Takahiro; Saito, Megumu K.; Nishikomori, Ryuta			Induced Pluripotent Stem Cell-Derived Monocytes/Macrophages in Autoinflammatory Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						autoinflammatory diseases; induced pluripotent stem cells; disease modeling; drug screening; monocytes; macrophages	NF-KAPPA-B; ANHIDROTIC ECTODERMAL DYSPLASIA; MEDITERRANEAN FEVER MUTATIONS; CYCLIC GMP-AMP; BLAU SYNDROME; SOMATIC MOSAICISM; CIAS1 MUTATIONS; NLRP3 INFLAMMASOME; ARTICULAR SYNDROME; HUMAN MONOCYTE	The concept of autoinflammation, first proposed in 1999, refers to a seemingly unprovoked episode of sterile inflammation manifesting as unexplained fever, skin rashes, and arthralgia. Autoinflammatory diseases are caused mainly by hereditary abnormalities of innate immunity, without the production of autoantibodies or autoreactive T cells. The revolutionary discovery of induced pluripotent stem cells (iPSCs), whereby a patient's somatic cells can be reprogrammed into an embryonic pluripotent state by forced expression of a defined set of transcription factors, has the transformative potential to enable in vitro disease modeling and drug candidate screening, as well as to provide a resource for cell replacement therapy. Recent reports demonstrate that recapitulating a disease phenotype in vitro is feasible for numerous monogenic diseases, including autoinflammatory diseases. In this review, we provide a comprehensive overview of current advances in research into autoinflammatory diseases involving iPSC-derived monocytes/macrophages. This review may aid in the planning of new studies of autoinflammatory diseases.	[Tanaka, Takayuki; Izawa, Kazushi; Yasumi, Takahiro] Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan; [Tanaka, Takayuki] Japanese Red Cross Otsu Hosp, Dept Pediat, Otsu, Japan; [Shiba, Takeshi] Imagine Inst, Lab Lymphocyte Activat & Susceptibil EBV Infect, INSERM, UMR 1163, Paris, France; [Honda, Yoshitaka] Kyoto Univ, Inst Adv Study Human Biol ASHBi, Kyoto, Japan; [Honda, Yoshitaka] Kyoto Univ, Grad Sch Med, Dept Immunol, Kyoto, Japan; [Saito, Megumu K.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Clin Applicat, Kyoto, Japan; [Nishikomori, Ryuta] Kurume Univ, Sch Med, Dept Pediat & Child Hlth, Kurume, Japan	Kyoto University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Kyoto University; Kyoto University; Kyoto University; Kurume University	Tanaka, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pediat, Kyoto, Japan.; Tanaka, T (corresponding author), Japanese Red Cross Otsu Hosp, Dept Pediat, Otsu, Japan.	tatanaka@kuhp.kyoto-u.ac.jp		Yasumi, Takahiro/0000-0003-3257-5071	 [JP19K08320]		Funding This research was supported by the following grant: Grants-in-Aids for Scientific Research (C) (grant JP19K08320 to T.T.).	Ablasser A, 2019, SCIENCE, V363, P1055, DOI 10.1126/science.aat8657; Abyzov A, 2012, NATURE, V492, P438, DOI 10.1038/nature11629; Aksentijevich I, 2002, ARTHRITIS RHEUM-US, V46, P3340, DOI 10.1002/art.10688; Aksentijevich I, 2007, ARTHRITIS RHEUM-US, V56, P1273, DOI 10.1002/art.22491; Alagoz M, 2020, INT J MOL MED, V46, P521, DOI 10.3892/ijmm.2020.4609; Alasoo K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12524; Aldea A, 2004, AM J MED GENET A, V124A, P67, DOI 10.1002/ajmg.a.20296; Arima K, 2011, P NATL ACAD SCI USA, V108, P14914, DOI 10.1073/pnas.1106015108; Badran YR, 2017, J EXP MED, V214, P1937, DOI 10.1084/jem.20160724; Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919; Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613; Ben-Chetrit E, 2018, ANN RHEUM DIS, V77, P1558, DOI 10.1136/annrheumdis-2017-212515; Bernot A, 1997, NAT GENET, V17, P25; Bjornson-Hooper Zachary B, 2022, Front Immunol, V13, P867015, DOI 10.3389/fimmu.2022.867015; BLAU EB, 1985, J PEDIATR-US, V107, P689, DOI 10.1016/S0022-3476(85)80394-2; BOGDAN C, 1991, J EXP MED, V174, P1549, DOI 10.1084/jem.174.6.1549; Boisson B, 2019, J CLIN INVEST, V129, P583, DOI 10.1172/JCI124011; Bosshart H, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.53; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; BRUGGER W, 1991, J LEUKOCYTE BIOL, V49, P483, DOI 10.1002/jlb.49.5.483; Buchrieser J, 2017, STEM CELL REP, V8, P334, DOI 10.1016/j.stemcr.2016.12.020; Chae JJ, 2011, IMMUNITY, V34, P755, DOI 10.1016/j.immuni.2011.02.020; CHEBATH J, 1987, NATURE, V330, P587, DOI 10.1038/330587a0; Chen J, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2017-5; CLEMENS MJ, 1978, CELL, V13, P565, DOI 10.1016/0092-8674(78)90329-X; Cuchet-Lourenco D, 2018, SCIENCE, V361, P810, DOI 10.1126/science.aar2641; Cui D, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.656867; De Benedetti F, 2018, NEW ENGL J MED, V378, P1908, DOI 10.1056/NEJMoa1706314; de Jesus AA, 2015, ANNU REV IMMUNOL, V33, P823, DOI 10.1146/annurev-immunol-032414-112227; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Dong CS, 2013, GENE, V519, P279, DOI 10.1016/j.gene.2013.02.015; Dugan J, 2015, J IMMUNOL, V194, P349, DOI 10.4049/jimmunol.1402330; Feldmann J, 2002, AM J HUM GENET, V71, P198, DOI 10.1086/341357; Fremond ML, 2021, J CLIN IMMUNOL, V41, P501, DOI 10.1007/s10875-021-00974-z; Fujimaki Y, 2021, PEDIATR INT, V63, P982, DOI 10.1111/ped.14526; Fujisawa A, 2007, BLOOD, V109, P2903, DOI 10.1182/blood-2006-07-033597; Fusco F, 2008, HUM MUTAT, V29, P595, DOI 10.1002/humu.20739; Gaidt MM, 2016, IMMUNITY, V44, P833, DOI 10.1016/j.immuni.2016.01.012; Gangemi S, 2018, CLIN GENET, V94, P81, DOI 10.1111/cge.13223; Gattorno M, 2007, ARTHRITIS RHEUM, V56, P3138, DOI 10.1002/art.22842; Ghonime MG, 2014, J IMMUNOL, V192, P3881, DOI 10.4049/jimmunol.1301974; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Han YC, 2014, SCIENCE, V343, P1244, DOI 10.1126/science.1249845; Heilig R, 2018, EUR J IMMUNOL, V48, P230, DOI 10.1002/eji.201746947; Hill DA, 2018, P NATL ACAD SCI USA, V115, pE5096, DOI 10.1073/pnas.1802611115; Honda Y, 2021, J CLIN IMMUNOL, V41, P1187, DOI 10.1007/s10875-021-01021-7; Honda-Ozaki F, 2018, STEM CELL REP, V10, P1835, DOI 10.1016/j.stemcr.2018.04.004; Igaz P, 2001, INFLAMM RES, V50, P435, DOI 10.1007/PL00000267; Jamilloux Y, 2018, RHEUMATOLOGY, V57, P100, DOI 10.1093/rheumatology/kex373; Janssen CEI, 2012, J ALLERGY CLIN IMMUN, V129, P1076, DOI 10.1016/j.jaci.2012.02.004; Jarosz-Griffiths HH, 2019, INT IMMUNOL, V31, P639, DOI 10.1093/intimm/dxz024; Jeremiah N, 2014, J CLIN INVEST, V124, P5516, DOI 10.1172/JCI79100; Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972; Karlsson KR, 2008, EXP HEMATOL, V36, P1167, DOI 10.1016/j.exphem.2008.04.009; Kase N, 2021, STEM CELL TRANSL MED, V10, P455, DOI 10.1002/sctm.20-0198; Kawai T, 2012, ALLERGOL INT, V61, P207, DOI 10.2332/allergolint.12-RAI-0446; Kawasaki Y, 2017, ARTHRITIS RHEUMATOL, V69, P447, DOI 10.1002/art.39960; Kim H, 2016, J MOL MED, V94, P1111, DOI 10.1007/s00109-016-1465-5; Kitagawa Y, 2022, J ALLERGY CLIN IMMUN, V149, P176, DOI 10.1016/j.jaci.2021.05.030; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lee CZW, 2018, NAT REV IMMUNOL, V18, P716, DOI 10.1038/s41577-018-0054-y; Lee KH, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.410027; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu Y, 2014, NEW ENGL J MED, V371, P507, DOI 10.1056/NEJMoa1312625; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; Lu L, 2018, SEMIN ARTHRITIS RHEU, V47, P727, DOI 10.1016/j.semarthrit.2017.09.010; Lyadova I, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.640703; Magg T, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abf9564; Magnotti F, 2021, ANN RHEUM DIS, V80, P128, DOI 10.1136/annrheumdis-2020-218366; Magnotti F, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910547; Magupalli VG, 2020, SCIENCE, V369, P1448, DOI 10.1126/science.aas8995; Masters SL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1471; Matsuda T, 2020, ANN RHEUM DIS, V79, P1492, DOI 10.1136/annrheumdis-2020-217320; Mayor A, 2007, NAT IMMUNOL, V8, P497, DOI 10.1038/ni1459; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Moghaddas F, 2017, ANN RHEUM DIS, V76, P2085, DOI 10.1136/annrheumdis-2017-211473; Mukherjee C, 2018, METHODS MOL BIOL, V1784, P13, DOI 10.1007/978-1-4939-7837-3_2; Mukhopadhyay S, 2020, J EXP MED, V217, DOI 10.1084/jem.20180649; Munn C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250107; Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109; Nagakura T, 2017, J RHEUMATOL, V44, P536, DOI 10.3899/jrheum.160672; Nakagawa K, 2015, ANN RHEUM DIS, V74, P603, DOI 10.1136/annrheumdis-2013-204361; Nakaseko H, 2019, RHEUMATOLOGY, V58, P182, DOI 10.1093/rheumatology/key283; Nishitani-Isa M, 2022, J EXP MED, V219, DOI 10.1084/jem.20211889; Okano T., 2022, ENSHOTOMENEKI, V30, P159; Otsubo Y, 2017, MOD RHEUMATOL, V27, P169, DOI 10.3109/14397595.2014.964388; Ozaki E, 2015, J INFLAMM RES, V8, P15, DOI 10.2147/JIR.S51250; Ozen S, 2016, ANN RHEUM DIS, V75, P644, DOI 10.1136/annrheumdis-2015-208690; Park YH, 2016, NAT IMMUNOL, V17, P914, DOI 10.1038/ni.3457; Picard C, 2011, CLIN MICROBIOL REV, V24, P490, DOI 10.1128/CMR.00001-11; Rodell CB, 2019, THERANOSTICS, V9, P7714, DOI 10.7150/thno.34421; Rosenstiel P, 2003, GASTROENTEROLOGY, V124, P1001, DOI 10.1053/gast.2003.50157; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rowczenio DM, 2020, RHEUMATOLOGY, V59, P554, DOI 10.1093/rheumatology/kez334; Saito M, 2005, ARTHRITIS RHEUM-US, V52, P3579, DOI 10.1002/art.21404; Saito M, 2008, BLOOD, V111, P2132, DOI 10.1182/blood-2007-06-094201; Sanchez GAM, 2018, J CLIN INVEST, V128, P3041, DOI 10.1172/JCI98814; Seki R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237030; Shi XY, 2019, J DERMATOL, V46, pE160, DOI 10.1111/1346-8138.14679; Shiba T, 2019, J ALLERGY CLIN IMMUN, V144, P1438, DOI 10.1016/j.jaci.2019.07.039; Simonini G, 2013, ARTHRITIS RHEUM-US, V65, P513, DOI 10.1002/art.37776; Smahi A, 2000, NATURE, V405, P466; Stoffels M, 2014, ANN RHEUM DIS, V73, P455, DOI 10.1136/annrheumdis-2012-202580; Sun KW, 2021, FUTURE MED CHEM, V13, P839, DOI 10.4155/fmc-2020-0376; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Takada S, 2018, J ALLERGY CLIN IMMUN, V141, P339, DOI 10.1016/j.jaci.2017.04.013; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takata K, 2017, IMMUNITY, V47, P183, DOI 10.1016/j.immuni.2017.06.017; Tan EEK, 2020, J CLIN INVEST, V130, P5817, DOI 10.1172/JCI98882; Tanaka N, 2011, ARTHRITIS RHEUM-US, V63, P3625, DOI 10.1002/art.30512; Tanaka T, 2012, BLOOD, V120, P1299, DOI 10.1182/blood-2012-03-417881; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Tasnim F, 2019, BIOMATERIALS, V192, P377, DOI 10.1016/j.biomaterials.2018.11.016; Torrelo A, 2017, J EUR ACAD DERMATOL, V31, P536, DOI 10.1111/jdv.13858; Totemeyer S, 2006, J IMMUNOL, V176, P4804, DOI 10.4049/jimmunol.176.8.4804; Ueda N, 2018, STEM CELL REP, V10, P1935, DOI 10.1016/j.stemcr.2018.04.025; Van Gijn ME, 2018, J MED GENET, V55, P530, DOI 10.1136/jmedgenet-2017-105216; Van Gorp H, 2020, ANN RHEUM DIS, V79, P960, DOI 10.1136/annrheumdis-2019-216701; Van Gorp H, 2016, P NATL ACAD SCI USA, V113, P14384, DOI 10.1073/pnas.1613156113; Verhoeven D, 2022, J ALLERGY CLIN IMMUN, V149, P1120, DOI 10.1016/j.jaci.2021.07.039; Vigano E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9761; von Bernuth H, 2008, SCIENCE, V321, P691, DOI 10.1126/science.1158298; Wang C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05033-5; Weise G, 2012, J CLIN NEUROSCI, V19, P1312, DOI 10.1016/j.jocn.2011.11.026; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yeung ATY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15013; Yokoyama K, 2015, ARTHRITIS RHEUMATOL, V67, P302, DOI 10.1002/art.38912; Zhang HR, 2015, CIRC RES, V117, P17, DOI 10.1161/CIRCRESAHA.117.305860; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	132	0	0	6	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								870535	10.3389/fimmu.2022.870535	http://dx.doi.org/10.3389/fimmu.2022.870535			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1M6XQ	35603217	Green Published, gold			2022-12-18	WOS:000800113100001
J	Yan, HH; Li, BC; Su, R; Gao, C; Li, XF; Wang, CH				Yan, Huanhuan; Li, Baochen; Su, Rui; Gao, Chong; Li, Xiaofeng; Wang, Caihong			Preliminary Study on the Imbalance Between Th17 and Regulatory T Cells in Antiphospholipid Syndrome	FRONTIERS IN IMMUNOLOGY			English	Article						primary antiphospholipid syndrome (PAPS); secondary antiphospholipid syndrome (SAPS); T helper 17(Th17) cells; regulatory T(Treg) cells; cytokines	SYSTEMIC-LUPUS-ERYTHEMATOSUS; AUTOIMMUNE; INTERLEUKIN-2; RESPONSES; AUTOANTIBODIES; EPIDEMIOLOGY; ACTIVATION; DISTINCT; UPDATE; TREG	ObjectivePatients with antiphospholipid syndrome (APS) have immune cell abnormalities that remain poorly understood. This study compared primary APS (PAPS) and secondary APS (SAPS) patients with healthy controls with respect to peripheral blood lymphocytes, CD4+T cell subsets, and cytokine levels. The correlation between antiphospholipid antibody titres and T helper 17 (Th17) and T regulatory (Treg) cell subsets was also analyzed, together with the correlations between cytokine profiles and the clinical characteristics of APS patients. MethodsThe retrospective study population consisted of 67 APS patients (12 with PAPS, 55 with SAPS) and 40 healthy controls. Absolute numbers of peripheral blood lymphocyte subsets and CD4+ T cell subsets were detected by flow cytometry, and serum cytokine levels by flow cytometry bead array. ResultsPatients with SAPS had lower absolute values of T, B and CD4+T cells than the healthy control group, while only natural killer (NK) cell levels were decreased in patients with PAPS. Absolute numbers of T, B, NK, and CD4+T cells were significantly higher in the PAPS than SAPS group. The trends in CD4+T cell subsets were the same in PAPS and SAPS patients as in healthy controls, with increased Th1, decreased Th2, and decreased Treg levels, and thus an increased Th17/Treg ratio. Th2, Th17, and Treg cell counts were higher in the PAPS than SAPS group. Cytokine analysis showed that only IL-10 levels differed between the two APS groups. However, the levels of all of the studied cytokines were higher in APS patients than healthy controls, and correlated with the clinical characteristics of the patients. In the PAPS group, the titres of two autoantibodies correlated positively with the Th17/Treg ratio and negatively with the levels of D-dimer and Treg subsets. ConclusionsOur study clearly showed that APS patients have immune disturbances, the most prominent of which is an increase in the Th17/Treg ratio, due to a decrease in the number of Treg cells. These abnormalities may be involved in the occurrence and progression of APS. An additional finding was a higher level of peripheral blood lymphocytes in PAPS than SAPS patients, which may be related to the immunosuppressive treatment of SAPS patients.	[Yan, Huanhuan; Li, Baochen; Su, Rui; Li, Xiaofeng; Wang, Caihong] Second Hosp Shanxi Med Univ, Dept Rheumatol, Taiyuan, Peoples R China; [Gao, Chong] Brigham & Womens Hosp, Childrens Hosp, Harvard Med Sch, Joint Program Transfus Med, Boston, MA USA	Shanxi Medical University; Harvard University; Boston Children's Hospital; Brigham & Women's Hospital; Harvard Medical School	Wang, CH (corresponding author), Second Hosp Shanxi Med Univ, Dept Rheumatol, Taiyuan, Peoples R China.		Yan, Huanhuan/GWV-7978-2022; li, xiaofeng/GXF-9442-2022		National Natural Science Foundation of China [81971543, 81471618]; Key Research and Development (R&D) Projects of Shanxi Province [201803D31119]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development (R&D) Projects of Shanxi Province	Funding This work was supported by National Natural Science Foundation of China (No. 81971543, No. 81471618); Key Research and Development (R&D) Projects of Shanxi Province (201803D31119).	Abbas AK, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aat1482; Abd el-Moniem G, 2020, CURR RHEUMATOL REV, V16, P304, DOI 10.2174/1573397116666200116095734; Abrahams VM, 2017, ARTHRITIS RHEUMATOL, V69, P1710, DOI 10.1002/art.40136; Alvarez-Rodriguez L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00391; Alvarez-Rodriguez L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020589; Banuelos J, 2016, CYTOKINE GROWTH F R, V31, P27, DOI 10.1016/j.cytogfr.2016.05.002; Boardman DA, 2022, J ALLERGY CLIN IMMUN, V149, P1, DOI 10.1016/j.jaci.2021.11.007; Boyman O, 2012, NAT REV IMMUNOL, V12, P180, DOI 10.1038/nri3156; Buckner JH, 2022, TRENDS IMMUNOL, V43, P167, DOI 10.1016/j.it.2022.01.005; Santacruz JC, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.21090; Carbone J, 2009, J RHEUMATOL, V36, P1217, DOI 10.3899/jrheum.081079; Cervera R, 2017, THROMB RES, V151, pS43, DOI 10.1016/S0049-3848(17)30066-X; Cheng S, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/1719720; Cheng S, 2016, MOL IMMUNOL, V71, P78, DOI 10.1016/j.molimm.2016.01.012; Dabit JY, 2021, CURR RHEUMATOL REP, V23, DOI 10.1007/s11926-021-01038-2; Deng JS, 2010, CIRCULATION, V121, P906, DOI 10.1161/CIRCULATIONAHA.109.872903; Duarte-Garca A, 2019, ARTHRITIS RHEUMATOL, V71, P1545, DOI 10.1002/art.40901; Giganti G, 2021, EUR J IMMUNOL, V51, P39, DOI 10.1002/eji.201948131; Goschl L, 2019, SEMIN IMMUNOPATHOL, V41, P301, DOI 10.1007/s00281-019-00741-8; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Hisada R, 2017, J THROMB HAEMOST, V15, P1782, DOI 10.1111/jth.13763; Inamo J, 2021, CLIN RHEUMATOL, V40, P3615, DOI 10.1007/s10067-021-05602-0; Jakiela B, 2016, LUPUS, V25, P389, DOI 10.1177/0961203315618267; Johnston LR, 2015, ATHEROSCLEROSIS, V239, P283, DOI 10.1016/j.atherosclerosis.2015.01.006; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Kaluzna A, 2022, J CLIN MED, V11, DOI 10.3390/jcm11020400; Klatzmann D, 2015, NAT REV IMMUNOL, V15, P283, DOI 10.1038/nri3823; Knight JS, 2022, SEMIN IMMUNOPATHOL, V44, P347, DOI 10.1007/s00281-022-00916-w; Kolitz T, 2019, LUPUS, V28, P1712, DOI 10.1177/0961203319887229; Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730; Li XY, 2021, CLIN RHEUMATOL, V40, P193, DOI 10.1007/s10067-020-05203-3; Liu C, 2018, ARTHRITIS RHEUMATOL, V70, P711, DOI 10.1002/art.40430; Liu C, 2018, INT IMMUNOPHARMACOL, V56, P261, DOI 10.1016/j.intimp.2018.01.038; Lopez-Pedrera C, 2016, RHEUMATOLOGY, V55, P2096, DOI 10.1093/rheumatology/kew054; Man YL, 2022, BRAIN SCI, V12, DOI 10.3390/brainsci12010091; McDonnell T, 2020, BLOOD REV, V39, DOI 10.1016/j.blre.2019.100610; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Mormile I, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020132; Ohue Y, 2019, CANCER SCI, V110, P2080, DOI 10.1111/cas.14069; Peng Q, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.737334; Popovic-Kuzmanovic D, 2013, IMMUNOBIOLOGY, V218, P186, DOI 10.1016/j.imbio.2012.03.002; Dal Ben ERR, 2014, REV BRAS REUMATOL, V54, P241, DOI 10.1016/j.rbre.2013.09.001; Dal Ben ERR, 2013, J CLIN IMMUNOL, V33, P876, DOI 10.1007/s10875-012-9857-y; Ruffatti A, 2019, EXPERT REV CLIN IMMU, V15, P347, DOI 10.1080/1744666X.2019.1565995; Sammaritano LR, 2020, BEST PRACT RES CL RH, V34, DOI 10.1016/j.berh.2019.101463; Sangli SS, 2021, JCR-J CLIN RHEUMATOL, V27, pE297, DOI 10.1097/RHU.0000000000001358; Schnell A, 2021, CELL, V184, P6281, DOI 10.1016/j.cell.2021.11.018; Serrano R, 2020, LUPUS, V29, P1050, DOI 10.1177/0961203320933009; Shahneh F, 2021, BLOOD, V137, P1517, DOI 10.1182/blood.2020005407; Shoenfeld Y, 2006, AM J REPROD IMMUNOL, V56, P337, DOI 10.1111/j.1600-0897.2006.00434.x; Simonin L, 2017, CLIN REV ALLERG IMMU, V53, P14, DOI 10.1007/s12016-016-8568-1; Tabacco S, 2019, LUPUS, V28, P1503, DOI 10.1177/0961203319882507; Ticconi C, 2016, AM J REPROD IMMUNOL, V76, P396, DOI 10.1111/aji.12560; von Spee-Mayer C, 2016, ANN RHEUM DIS, V75, P1407, DOI 10.1136/annrheumdis-2015-207776; Wagner A, 2021, CELL, V184, P4168, DOI 10.1016/j.cell.2021.05.045; Xourgia E, 2021, CURR RHEUMATOL REP, V23, DOI 10.1007/s11926-021-01051-5; Yan JB, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8813558; Yasuda K, 2019, SEMIN IMMUNOPATHOL, V41, P283, DOI 10.1007/s00281-019-00733-8; Yin QM, 2021, IMMUNOL RES, V69, P398, DOI 10.1007/s12026-021-09211-6; Youinou P, 2004, THROMB RES, V114, P363, DOI 10.1016/j.thromres.2004.06.019	60	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 6	2022	13								873644	10.3389/fimmu.2022.873644	http://dx.doi.org/10.3389/fimmu.2022.873644			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1K2ZT	35603166	gold, Green Published			2022-12-18	WOS:000798476100001
J	Antunes, KH; Cassao, G; Santos, LD; Borges, SG; Poppe, J; Goncalves, JB; Nunes, ED; Recacho, GF; Sousa, VB; Da Silva, GS; Mansur, D; Stein, RT; Pasquali, C; De Souza, APD				Antunes, Krist Helen; Cassao, Gisele; Santos, Leonardo Duarte; Borges, Sofia Giacomet; Poppe, Juliana; Goncalves, Joao Budelon; Nunes, Eduarda da Silva; Recacho, Guilherme Fernando; Sousa, Vitoria Barbosa; Da Silva, Gabriela Souza; Mansur, Daniel; Stein, Renato T.; Pasquali, Christian; De Souza, Ana Paula Duarte			Airway Administration of Bacterial Lysate OM-85 Protects Mice Against Respiratory Syncytial Virus Infection	FRONTIERS IN IMMUNOLOGY			English	Article						respiratory syncytial virus; OM-85; postbiotic; antiviral response; lung microbiota	PUBLIC-HEALTH MEASURES; ALVEOLAR MACROPHAGES; RIG-I; RSV; CELLS; CHILDREN; RESURGENCE; INFLUENZA; STRATEGY; INFANTS	Respiratory syncytial virus (RSV) is a seasonal pathogen responsible for the highest percentage of viral bronchiolitis in pediatric patients. There are currently no vaccine available and therapeutic methods to mitigate the severity of RSV bronchiolitis are limited. OM-85, an oral standardized bacterial lysate isolated from human respiratory strains and widely used to prevent recurrent infections and/or exacerbations in populations at risk, has been shown to be effective and safe in children and adults. Here, we demonstrate that airway administration of OM-85 in Balb/c mice prior to infection prevents RSV-induced disease, resulting in inhibition of viral replication associated with less perivascular and peribronchial inflammation in the lungs. These protective effects are dose and time-dependent with complete protection using 1mg dose of OM-85 only four times intranasally. Mechanistic insights using this topical route in the airways revealed increased alveolar macrophages, a selective set of tolerogenic DCs, Treg and Th1 expansion in the lung, even in the absence of infection, contributing to a better Th1/Th2 balance and preventing ILC2 recruitment in the airways and associated inflammatory sequelae. OM-85 preventive treatment also improved antiviral response by increasing IFN beta and its responsive genes in the lung. In vitro, OM-85 protects against RSV infection in a type I interferon pathway. Our animal model data suggest that intranasal use of OM-85 should be considered as a potential prophylactic product to prevent RSV bronchiolitis once human studies confirm these findings.	[Antunes, Krist Helen; Cassao, Gisele; Santos, Leonardo Duarte; Borges, Sofia Giacomet; Poppe, Juliana; Goncalves, Joao Budelon; Nunes, Eduarda da Silva; Recacho, Guilherme Fernando; Sousa, Vitoria Barbosa; Da Silva, Gabriela Souza; De Souza, Ana Paula Duarte] Pontifical Catholic Univ Rio Grande Sul PUCRS, Sch Hlth & Life Sci, Lab Clin & Expt Immunol, Porto Alegre, Brazil; [Mansur, Daniel] Univ Fed Santa Catarina, Dept Microbiol, Lab Imunobiol, Immunol & Parasitol, Florianopolis, Brazil; [Stein, Renato T.] Pontifical Catholic Univ Rio Grande Sul PUCRS, Sao Lucas Hosp PUCRS, Sch Med, Dept Pediat, Porto Alegre, Brazil; [Pasquali, Christian] OM Pharm SA, Dept Preclin Res, Meyrin, Switzerland	Pontificia Universidade Catolica Do Rio Grande Do Sul; Universidade Federal de Santa Catarina (UFSC); Pontificia Universidade Catolica Do Rio Grande Do Sul	De Souza, APD (corresponding author), Pontifical Catholic Univ Rio Grande Sul PUCRS, Sch Hlth & Life Sci, Lab Clin & Expt Immunol, Porto Alegre, Brazil.	ana.duarte@pucrs.br	sousa, vitoria/GRE-6585-2022	Antunes, Krist/0000-0002-1525-6581; Souza, Ana Paula/0000-0002-6021-5068				Ahmad A, 2022, NEW ENGL J MED, V386, P655, DOI 10.1056/NEJMoa2108903; Antunes KH, 2022, EBIOMEDICINE, V77, DOI 10.1016/j.ebiom.2022.103891; Antunes KH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11152-6; Aranda SS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01006; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Becker Y, 2006, VIRUS GENES, V33, P235, DOI 10.1007/s11262-006-0064-x; Breese C, 2013, PEDIATRICS, V132, pE341, DOI 10.1542/peds.2013-0303; Buendia JA, 2021, TURKISH J PEDIATR, V63, P673, DOI 10.24953/turkjped.2021.04.015; Byrne AJ, 2015, THORAX, V70, P1189, DOI 10.1136/thoraxjnl-2015-207020; Dang AT, 2017, SCI REP-UK, V7, DOI 10.1038/srep43844; de Jong E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.699633; Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538; DeVincenzo JP, 2015, NEW ENGL J MED, V373, P2048, DOI 10.1056/NEJMoa1413275; Dickson RP, 2021, NAT MICROBIOL, V6, P1217, DOI 10.1038/s41564-021-00969-x; Duerr CU, 2016, NAT IMMUNOL, V17, P65, DOI 10.1038/ni.3308; Dumas A, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12966; Esposito S, 2018, CURR OPIN ALLERGY CL, V18, P198, DOI 10.1097/ACI.0000000000000433; Fang L, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111544; Foley DA, 2022, ARCH DIS CHILD, V107, DOI 10.1136/archdischild-2021-322507; Fonseca W, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.675169; Fourgeaud J, 2021, EUR J CLIN MICROBIOL, V40, P2389, DOI 10.1007/s10096-021-04323-1; Garcia-Castillo V, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.568636; Goritzka M, 2015, J EXP MED, V212, P699, DOI 10.1084/jem.20140825; Graham BS, 2013, CURR TOP MICROBIOL, V372, P391, DOI 10.1007/978-3-642-38919-1_20; Groeger D, 2020, EBIOMEDICINE, V60, DOI 10.1016/j.ebiom.2020.102981; Hu XY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15471-w; Idoyaga J, 2013, J CLIN INVEST, V123, P844, DOI 10.1172/JCI65260; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI [10.1056/NEJMoa1500245, 10.1056/NEJMc1511751]; Jung HE, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010102; Kanmani P, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01613; Kolli D, 2014, AM J RESP CELL MOL, V51, P502, DOI 10.1165/rcmb.2013-0414OC; Lavoie PM, 2021, CAN MED ASSOC J, V193, pE1140, DOI 10.1503/cmaj.210919; Li Y, 2021, LANCET INFECT DIS, V21, P1303, DOI 10.1016/S1473-3099(20)30703-9; Liu YL, 2017, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00662; Makino A, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103201; Makris S, 2016, J INNATE IMMUN, V8, P452, DOI 10.1159/000446824; Man WH, 2017, NAT REV MICROBIOL, V15, P259, DOI 10.1038/nrmicro.2017.14; Marr N, 2014, J IMMUNOL, V192, P948, DOI 10.4049/jimmunol.1302007; Mathieu E, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01168; Nair H, 2010, LANCET, V375, P1545, DOI 10.1016/S0140-6736(10)60206-1; Parry MF, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofaa511; Pasquali C, 2014, FRONT MED, V1, DOI 10.3389/fmed.2014.00041; Piters WAAD, 2020, CELL HOST MICROBE, V28, P223, DOI 10.1016/j.chom.2020.07.004; Pivniouk V, 2022, J ALLERGY CLIN IMMUN, V149, P923, DOI 10.1016/j.jaci.2021.11.019; Pivniouk V, 2022, J ALLERGY CLIN IMMUN, V149, P943, DOI 10.1016/j.jaci.2021.09.013; Porto BN, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13101960; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Rodgers L, 2021, CLIN INFECT DIS, V73, pS110, DOI 10.1093/cid/ciab311; Rossi GA., 2019, EUR RESPIR PULMONARY, V15, P17, DOI [10.17925/ERPD.2019.5.1.17, DOI 10.17925/ERPD.2019.5.1.17]; Rossi GA, 2018, ITAL J PEDIATR, V44, DOI 10.1186/s13052-018-0569-7; Roth M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188010; Ruckwardt TJ, 2018, MUCOSAL IMMUNOL, V11, P186, DOI 10.1038/mi.2017.28; Salminen S, 2021, NAT REV GASTRO HEPAT, V18, P649, DOI 10.1038/s41575-021-00440-6; Salzmann M, 2021, J INNATE IMMUN, DOI 10.1159/000519699; Santos LD, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.03764-2020; Schaad UB, 2002, CHEST, V122, P2042, DOI 10.1378/chest.122.6.2042; Sedeyn K, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007984; Shirey KA, 2014, MUCOSAL IMMUNOL, V7, P549, DOI 10.1038/mi.2013.71; Spacova I, 2021, TRENDS MOL MED, V27, P538, DOI 10.1016/j.molmed.2021.03.009; Strickland DH, 2011, MUCOSAL IMMUNOL, V4, P43, DOI 10.1038/mi.2010.43; Suarez N, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00545; Sun MM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05901-2; Tan JY, 2020, J HOSP INFECT, V106, P387, DOI 10.1016/j.jhin.2020.07.023; Tomosada Y, 2013, BMC IMMUNOL, V14, DOI 10.1186/1471-2172-14-40; Topping DL, 2001, PHYSIOL REV, V81, P1031, DOI 10.1152/physrev.2001.81.3.1031; Trompette A, 2018, IMMUNITY, V48, P992, DOI 10.1016/j.immuni.2018.04.022; Ujiie M, 2021, EMERG INFECT DIS, V27, P2969, DOI 10.3201/eid2711.211565; Vieira RD, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00067; Vu LD, 2019, AM J RESP CRIT CARE, V200, P1414, DOI 10.1164/rccm.201812-2366OC; Wu BG, 2017, MICROBIOL SPECTR, V5, DOI 10.1128/microbiolspec.BAD-0005-2016; Wu YH, 2020, ALLERGY, V75, P818, DOI 10.1111/all.14091; Yeoh Daniel K, 2021, Clin Infect Dis, V72, P2199, DOI 10.1093/cid/ciaa1475; Zhang Liwen, 2021, J Immunol Res, V2021, P6625551, DOI 10.1155/2021/6625551	73	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 5	2022	13								867022	10.3389/fimmu.2022.867022	http://dx.doi.org/10.3389/fimmu.2022.867022			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J5WU	35603159	gold, Green Published			2022-12-18	WOS:000797990000001
J	Yang, B; Yang, C; Wang, Y				Yang, Bin; Yang, Cheng; Wang, Ying			Editorial: Innate Immunity in Kidney Injury, Repair and Fibrosis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						fibrosis; inflammation; innate immunity; kidney injury; macrophage; phagocytosis; repair and tubular epithelial cell	PEPTIDE		[Yang, Bin] Univ Leicester, Univ Hosp Leicester Natl Hlth Serv NHS Trust, Coll Life Sci, Dept Cardiovasc Sci, Leicester, Leics, England; [Yang, Bin] Affiliated Hosp Nantong Univ, Nantong Leicester Joint Inst Kidney Sci, Dept Nephrol, Nantong, Peoples R China; [Yang, Cheng] Fudan Univ, Zhongshan Hosp, Dept Urol, Shanghai, Peoples R China; [Yang, Cheng] Shanghai Key Lab Organ Transplantat, Shanghai, Peoples R China; [Yang, Cheng] Zhangjiang Inst Fudan Univ, Shanghai, Peoples R China; [Wang, Ying] Chinese Acad Sci, Shanghai Inst Nutr & Hlth, Chinese Acad Sci CAS Key Lab Tissue Microenvironm, Shanghai, Peoples R China	University Hospitals of Leicester NHS Trust; University of Leicester; Nantong University; Fudan University; Chinese Academy of Sciences; Shanghai Institute of Nutrition & Health, CAS	Yang, B (corresponding author), Univ Leicester, Univ Hosp Leicester Natl Hlth Serv NHS Trust, Coll Life Sci, Dept Cardiovasc Sci, Leicester, Leics, England.; Yang, B (corresponding author), Affiliated Hosp Nantong Univ, Nantong Leicester Joint Inst Kidney Sci, Dept Nephrol, Nantong, Peoples R China.	by5@le.ac.uk						De Chiara L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011093; Mehta RL, 2015, LANCET, V385, P2616, DOI 10.1016/S0140-6736(15)60126-X; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Wu YY, 2020, J PHARMACOL EXP THER, V375, P92, DOI 10.1124/jpet.120.000092; Yang C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.338; Zwaini Z, 2017, CURR GENE THER, V17, P411, DOI 10.2174/1566523218666180214093043	6	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 5	2022	13								909654	10.3389/fimmu.2022.909654	http://dx.doi.org/10.3389/fimmu.2022.909654			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J9QV	35603199	Green Published, gold			2022-12-18	WOS:000798247200001
J	Betzler, AC; Ezic, J; Abou Kors, T; Hoffmann, TK; Wirth, T; Brunner, C				Betzler, Annika C.; Ezic, Jasmin; Abou Kors, Tsima; Hoffmann, Thomas K.; Wirth, Thomas; Brunner, Cornelia			T Cell Specific BOB.1/OBF.1 Expression Promotes Germinal Center Response and T Helper Cell Differentiation	FRONTIERS IN IMMUNOLOGY			English	Article						BOB.1/OBF.1; germinal center; T cell differentiation; follicular T helper cells; humoral immunity; transcriptional co-activator; Pou2af1	TRANSCRIPTIONAL COACTIVATOR BOB1; FOLLICULAR REGULATORY CELLS; OCA-B; MICE LACKING; DNA-BINDING; PROTEIN; IL-21; PHOSPHORYLATION; SUPPRESSES; ACTIVATION	The transcriptional co-activator BOB.1/OBF.1 is expressed in both B and T cells. The main characteristic of conventional BOB.1/OBF.1 deficient mice is the complete absence of germinal centers (GCs). This defect was mainly attributed to the defective B cell compartment. However, it is unknown whether and how BOB.1/OBF.1 expression in T cells contributes to the GC reaction. To finally clarify this question, we studied the in vivo function of BOB.1/OBF.1 in CD4(+) T and follicular T helper (TFH) cell subpopulations by conditional mutagenesis, in the presence of immunocompetent B lymphocytes. BOB.1/OBF.1 deletion in CD4(+) T as well as TFH cells resulted in impaired GC formation demonstrating that the impaired GC reaction described for conventional BOB.1/OBF.1-deficient mice cannot exclusively be traced back to the B cell compartment. Furthermore, we show a requirement of BOB.1/OBF.1 for T helper (TH) cell subsets, particularly for TFH cell differentiation.	[Betzler, Annika C.; Ezic, Jasmin; Abou Kors, Tsima; Hoffmann, Thomas K.; Brunner, Cornelia] Ulm Univ Med Ctr, Dept Oto Rhino Laryngol, Ulm, Germany; [Wirth, Thomas] Ulm Univ, Dept Physiol Chem, Ulm, Germany	Ulm University; Ulm University	Brunner, C (corresponding author), Ulm Univ Med Ctr, Dept Oto Rhino Laryngol, Ulm, Germany.	cornelia.brunner@uniklinik-ulm.de	Brunner, Cornelia/H-8893-2018	Brunner, Cornelia/0000-0002-6456-5508	German Research Foundation (DFG) [BR 2891/8-1]	German Research Foundation (DFG)(German Research Foundation (DFG))	This work was supported by a grant from the German Research Foundation (DFG) to CB (BR 2891/8-1).	Betzler AC, 2022, EUR J IMMUNOL, V52, P404, DOI 10.1002/eji.202149333; Betzler AC, 2021, EUR J IMMUNOL, V51, P1860, DOI 10.1002/eji.202048578; Boding L, 2014, EUR J IMMUNOL, V44, P3109, DOI 10.1002/eji.201344388; Brunner C, 2007, EMBO J, V26, P3191, DOI 10.1038/sj.emboj.7601742; Brunner Cornelia, 2006, Current Immunology Reviews, V2, P3, DOI 10.2174/157339506775471901; Caza TN, 2014, ANN RHEUM DIS, V73, P1888, DOI 10.1136/annrheumdis-2013-203794; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Chasman D, 1999, GENE DEV, V13, P2650, DOI 10.1101/gad.13.20.2650; Chevrier S, 2014, IMMUNOL CELL BIOL, V92, P12, DOI 10.1038/icb.2013.71; Choi YS, 2015, NAT IMMUNOL, V16, P980, DOI 10.1038/ni.3226; Chtanova T, 2004, J IMMUNOL, V173, P68, DOI 10.4049/jimmunol.173.1.68; Coquet JM, 2007, J IMMUNOL, V178, P2827, DOI 10.4049/jimmunol.178.5.2827; De Silva NS, 2015, NAT REV IMMUNOL, V15, P137, DOI 10.1038/nri3804; FALKNER FG, 1984, NATURE, V310, P71, DOI 10.1038/310071a0; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Hess J, 2001, MOL CELL BIOL, V21, P1531, DOI 10.1128/MCB.21.5.1531-1539.2001; Ikegami I, 2019, BIOCHEM BIOPH RES CO, V514, P1167, DOI 10.1016/j.bbrc.2019.05.057; Karnowski A, 2012, J EXP MED, V209, P2049, DOI 10.1084/jem.20111504; Kim H, 2021, J EXP MED, V218, DOI 10.1084/jem.20200533; Kury P, 2021, J ALLERGY CLIN IMMUN, V147, P1977, DOI 10.1016/j.jaci.2021.01.027; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Lee PP, 2001, IMMUNITY, V15, P763, DOI 10.1016/S1074-7613(01)00227-8; Levels MJ, 2017, ARTHRITIS RHEUMATOL, V69, P750, DOI 10.1002/art.39993; Locci M, 2013, IMMUNITY, V39, P758, DOI 10.1016/j.immuni.2013.08.031; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Mahnke J, 2016, SCI REP-UK, V6, DOI 10.1038/srep35521; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Metenou S, 2014, EUR J IMMUNOL, V44, P2036, DOI 10.1002/eji.201444452; Moriuchi M, 2001, J BIOL CHEM, V276, P8639, DOI 10.1074/jbc.M008391200; Mueller K, 2013, NUCLEIC ACIDS RES, V41, P2138, DOI 10.1093/nar/gks1349; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Nurieva RI, 2008, IMMUNITY, V29, P138, DOI 10.1016/j.immuni.2008.05.009; O'Connor MH, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02079-0; PARSLOW TG, 1984, P NATL ACAD SCI-BIOL, V81, P2650, DOI 10.1073/pnas.81.9.2650; Pevzner V, 2000, BIOCHEM J, V347, P29, DOI 10.1042/0264-6021:3470029; Placek K, 2017, NAT IMMUNOL, V18, P1035, DOI 10.1038/ni.3812; Qin XF, 1998, EMBO J, V17, P5066, DOI 10.1093/emboj/17.17.5066; Samardzic T, 2002, MOL CELL BIOL, V22, P8320, DOI 10.1128/MCB.22.23.8320-8331.2002; Samardzic T, 2002, EUR J IMMUNOL, V32, P2481, DOI 10.1002/1521-4141(200209)32:9<2481::AID-IMMU2481>3.0.CO;2-C; Sauter P, 1998, MOL CELL BIOL, V18, P7397, DOI 10.1128/MCB.18.12.7397; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Shakya A, 2015, J EXP MED, V212, P2115, DOI 10.1084/jem.20150363; Song S, 2021, BLOOD, V137, P2920, DOI 10.1182/blood.2020010175; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; Stauss D, 2016, EMBO J, V35, P881, DOI 10.15252/embj.201591459; Sun ZW, 2005, CELL IMMUNOL, V236, P146, DOI 10.1016/j.cellimm.2005.08.021; Trockenbacher A, 2001, NAT GENET, V29, P287, DOI 10.1038/ng762; Vanderleyden I, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0471-7; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; Wang F, 2007, TISSUE ANTIGENS, V69, P62, DOI 10.1111/j.1399-0039.2006.00706.x; Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200; Westendorf K, 2016, J IMMUNOL METHODS, V436, P54, DOI 10.1016/j.jim.2016.06.005; Wichner K, 2016, FASEB J, V30, P761, DOI 10.1096/fj.15-274001; Wing JB, 2017, P NATL ACAD SCI USA, V114, pE6400, DOI 10.1073/pnas.1705551114; Wolf I, 1998, J BIOL CHEM, V273, P28831, DOI 10.1074/jbc.273.44.28831; Yamada Akiko, 2017, Front Immunol, V8, P403, DOI 10.3389/fimmu.2017.00403; Yamashita K, 2016, EUR J IMMUNOL, V46, P1361, DOI 10.1002/eji.201545499; Yeremenko N, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102833; Yosef N, 2013, NATURE, V496, P461, DOI 10.1038/nature11981; Yu X, 2001, IMMUNITY, V14, P157, DOI 10.1016/S1074-7613(09)00090-9; Zhu AQ, 2019, BIOINFORMATICS, V35, P2084, DOI 10.1093/bioinformatics/bty895; Zhu YY, 2016, INT IMMUNOL, V28, P173, DOI 10.1093/intimm/dxv079; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	65	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								889564	10.3389/fimmu.2022.889564	http://dx.doi.org/10.3389/fimmu.2022.889564			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J4ED	35603192	Green Published, gold			2022-12-18	WOS:000797870000001
J	Dou, YF; Xie, Y; Zhang, LY; Liu, S; Xu, DD; Wei, YY; Li, YS; Zhang, XL				Dou, Yafeng; Xie, Yan; Zhang, Lingyun; Liu, Sheng; Xu, Dandan; Wei, Yuying; Li, Yongshuai; Zhang, Xiao-Lian			Host MKRN1-Mediated Mycobacterial PPE Protein Ubiquitination Suppresses Innate Immune Response	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis; PPE68; MKRN1; ubiquitination; innate immune response	PATTERN-RECOGNITION RECEPTORS; NITRIC-OXIDE; TUBERCULOSIS; ACTIVATION; EXPRESSION; CONTRIBUTES; MACROPHAGES; SECRETION; VIRULENCE; CYTOKINES	Mycobacterium tuberculosis (Mtb), as an important intracellular pathogen, can invade and survive in macrophages and is capable of escaping the clearance of immune system. Despite decades of research efforts, the precise mechanism of immune escape and the virulence factors encoded by Mtb involved remain to be explored. Mtb-specific genomic regions of deletion (RD)-encoded proteins and PE/PPE family proteins have been implicated in immune evasion. Here, we screened more than forty RD-encoded proteins which might be involved in facilitating bacterial survival in macrophages, and found that a Mtb PPE68/Rv3873 protein, encoded by Mtb-RD1, is essential for efficient Mtb intracellular survival in macrophages. In terms of mechanism, we found that the ubiquitin ligase (E3) Makorin Ring Finger Protein 1 (MKRN1) of macrophage interacted with PPE68 and promoted the attachment of lysine (K)-63-linked ubiquitin chains to the K166 site of PPE68. K63-ubiquitination of PPE68 further bound src homology 2 domain-containing protein tyrosine phosphatase 1 (SHP1) to suppress K63-linked polyubiquitin chains of tumor necrosis factor receptor-associated factor 6 (TRAF6), and then remarkably suppressed TRAF6-driven NF-kappa B and AP-1 signaling and TNF-alpha, IL-6 and NO production. We demonstrate that the K63-linked ubiquitination of PPE68 by MKRN1 contributed to the PPE68-mediated mycobacterial immune escape. Our finding identifies a previously unrecognized mechanism by which host MKRN1-mediated-ubiquitination of mycobacterial PPE protein suppresses innate immune responses. Disturbing the interaction between host MKRN1 ubiquitin system and mycobacterial PPE protein might be a potential therapeutic target for tuberculosis.	[Dou, Yafeng; Xie, Yan; Zhang, Lingyun; Liu, Sheng; Xu, Dandan; Wei, Yuying; Li, Yongshuai; Zhang, Xiao-Lian] Wuhan Univ TaiKang Med Sch, Sch Basic Med Sci, Dept Immunol, Hubei Prov Key Lab Allergy & Immunol, Wuhan, Peoples R China; [Zhang, Xiao-Lian] Wuhan Univ, Dept Allergy Zhongnan Hosp, Sch Med, Wuhan, Peoples R China; [Zhang, Xiao-Lian] Wuhan Univ, Frontier Sci Ctr Immunol & Metab, State Key Lab Virol, Wuhan, Peoples R China	Wuhan University; Wuhan University	Zhang, XL (corresponding author), Wuhan Univ TaiKang Med Sch, Sch Basic Med Sci, Dept Immunol, Hubei Prov Key Lab Allergy & Immunol, Wuhan, Peoples R China.; Zhang, XL (corresponding author), Wuhan Univ, Dept Allergy Zhongnan Hosp, Sch Med, Wuhan, Peoples R China.; Zhang, XL (corresponding author), Wuhan Univ, Frontier Sci Ctr Immunol & Metab, State Key Lab Virol, Wuhan, Peoples R China.	zhangxiaolian@whu.edu.cn			National Grand Program on Key Infectious Disease of China [2017ZX10201301-006, 2012ZX10003002-015]; National Key R&D Program of China [2018YFA0507603]; National Natural Science Foundation of China [91740120, 22077097]; National Outstanding Youth Foundation of China [81025008]; Hubei Province's Outstanding Medical Academic Leader Program [523-276003]; Hubei Province Key RD Program [2020BCB020]; Research and Innovation Team Project of Hubei Provincial Health Commission [WJ2021C002]; Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University [TFJC 2018002]; Fundamental Research Funds for the Central Universities; Foundation Committee Innovation Group Project [21721005]	National Grand Program on Key Infectious Disease of China; National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Outstanding Youth Foundation of China; Hubei Province's Outstanding Medical Academic Leader Program; Hubei Province Key RD Program; Research and Innovation Team Project of Hubei Provincial Health Commission; Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Foundation Committee Innovation Group Project	This project was supported by grants from the National Grand Program on Key Infectious Disease of China (2017ZX10201301-006 and 2012ZX10003002-015), the National Key R&D Program of China (2018YFA0507603), the National Natural Science Foundation of China (91740120 and 22077097), the National Outstanding Youth Foundation of China (81025008), Hubei Province's Outstanding Medical Academic Leader Program (523-276003), Hubei Province Key R&D Program (2020BCB020), Research and Innovation Team Project of Hubei Provincial Health Commission (WJ2021C002), the Medical Science Advancement Program (Basic Medical Sciences) of Wuhan University (TFJC 2018002), the Fundamental Research Funds for the Central Universities and Foundation Committee Innovation Group Project (21721005).	An HZ, 2008, NAT IMMUNOL, V9, P542, DOI 10.1038/ni.1604; Asaad M, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2020.107363; Ashida H, 2010, NAT CELL BIOL, V12, P66, DOI 10.1038/ncb2006; Bao YQ, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071645; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Beltan E, 2000, MICROB PATHOGENESIS, V28, P313, DOI 10.1006/mpat.1999.0345; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; Bhoj VG, 2009, NATURE, V458, P430, DOI 10.1038/nature07959; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Chai QY, 2020, CELL MOL IMMUNOL, V17, P901, DOI 10.1038/s41423-020-0502-z; Chai QY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09955-8; Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x; Chinta KC, 2016, NITRIC OXIDE-BIOL CH, V59, P28, DOI 10.1016/j.niox.2016.06.009; Chow A, 2011, J EXP MED, V208, P261, DOI 10.1084/jem.20101688; Collins CA, 2010, TRENDS CELL BIOL, V20, P205, DOI 10.1016/j.tcb.2010.01.002; Converse SE, 2005, J BACTERIOL, V187, P1238, DOI 10.1128/JB.187.4.1238-1245.2005; Daim S, 2011, J MED MICROBIOL, V60, P582, DOI 10.1099/jmm.0.026047-0; Damen MPM, 2020, J BIOL CHEM, V295, P5960, DOI 10.1074/jbc.RA119.011682; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Deng WY, 2014, CELL PHYSIOL BIOCHEM, V33, P273, DOI 10.1159/000356668; Fishbein S, 2015, MOL MICROBIOL, V96, P901, DOI 10.1111/mmi.12981; Franco LH, 2017, CELL HOST MICROBE, V21, P59, DOI [10.1016/j.chom.2016.11.002, 10.1016/j.chom.2017.08.005]; Gray TA, 2000, GENOMICS, V66, P76, DOI 10.1006/geno.2000.6199; Hansen JM, 2014, J INFECT DIS, V209, P1045, DOI 10.1093/infdis/jit622; He H, 2021, J IMMUNOL, V206, P1161, DOI 10.4049/jimmunol.2000234; Houben D, 2012, CELL MICROBIOL, V14, P1287, DOI 10.1111/j.1462-5822.2012.01799.x; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Kaufmann E, 2018, CELL, V172, P176, DOI 10.1016/j.cell.2017.12.031; Kim JH, 2014, CELL DEATH DIFFER, V21, P594, DOI 10.1038/cdd.2013.181; Kim JH, 2005, GENE DEV, V19, P776, DOI 10.1101/gad.1289405; Kim SY, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012497; Kinsella S, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0099-15.2016; Koster S, 2017, P NATL ACAD SCI USA, V114, pE8711, DOI 10.1073/pnas.1707792114; Lee JW, 2017, APPL ENVIRON MICROB, V83, DOI 10.1128/AEM.02289-16; Lee JY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01477; Lee MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8769; Leemans JC, 2003, J CLIN INVEST, V111, P681, DOI 10.1172/JCI200316936; Manzanillo PS, 2013, NATURE, V501, P512, DOI 10.1038/nature12566; Martinez AN, 2013, J INFECT DIS, V207, P1253, DOI 10.1093/infdis/jit037; Meenu S, 2016, MED MICROBIOL IMMUN, V205, P163, DOI 10.1007/s00430-015-0432-z; Mehta M, 2019, FREE RADICAL BIO MED, V131, P50, DOI 10.1016/j.freeradbiomed.2018.11.032; Mustafa A, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010027; Nandan D, 1999, INFECT IMMUN, V67, P4055, DOI 10.1128/IAI.67.8.4055-4063.1999; Nikitushkin VD, 2020, METABOLOMICS, V16, DOI 10.1007/s11306-020-1645-8; Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x; Peddireddy V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00084; Qu ZL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba4733; Raghavan S, 2008, NATURE, V454, P717, DOI 10.1038/nature07219; Rytkonen A, 2007, P NATL ACAD SCI USA, V104, P3502, DOI 10.1073/pnas.0610095104; Santosuosso M, 2007, J IMMUNOL, V178, P2387, DOI 10.4049/jimmunol.178.4.2387; Shin Dong-Min, 2011, Immune Netw, V11, P245, DOI 10.4110/in.2011.11.5.245; Singer AU, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003121; Subrahmanian M, 2020, BIOTECHNOL LETT, V42, P1527, DOI 10.1007/s10529-020-02873-6; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tiwari B, 2014, FEBS J, V281, P1556, DOI 10.1111/febs.12723; Wadekar HB, 2013, PLANTA, V237, P1083, DOI 10.1007/s00425-012-1828-2; Wang J, 2015, NAT IMMUNOL, V16, P237, DOI 10.1038/ni.3096; Wang L, 2020, NATURE, V577, P682, DOI 10.1038/s41586-019-1915-7; WHO, 2021, GLOBAL TUBERCULOSIS; Wieland CW, 2008, IMMUNOLOGY, V125, P272, DOI 10.1111/j.1365-2567.2008.02840.x; Yan DP, 2012, NAT IMMUNOL, V13, P1063, DOI 10.1038/ni.2417; Yuan CH, 2019, ISCIENCE, V11, P13, DOI 10.1016/j.isci.2018.11.039; Zhang Q, 2005, P NATL ACAD SCI USA, V102, P6948, DOI 10.1073/pnas.0501959102; Zulauf KE, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007011	64	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								880315	10.3389/fimmu.2022.880315	http://dx.doi.org/10.3389/fimmu.2022.880315			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J4XC	35603194	gold, Green Published			2022-12-18	WOS:000797922000001
J	Eckert, D; Rapp, F; Tsedeke, AT; Kraft, D; Wente, I; Molendowska, J; Basheer, S; Langhans, M; Meckel, T; Friedrich, T; Donaubauer, AJ; Becker, I; Frey, B; Fournier, C				Eckert, Denise; Rapp, Felicitas; Tsedeke, Ayele Taddese; Kraft, Daniela; Wente, Isabell; Molendowska, Jessica; Basheer, Sidra; Langhans, Markus; Meckel, Tobias; Friedrich, Thomas; Donaubauer, Anna-Jasmina; Becker, Ina; Frey, Benjamin; Fournier, Claudia			Modulation of Differentiation and Bone Resorbing Activity of Human (Pre-) Osteoclasts After X-Ray Exposure	FRONTIERS IN IMMUNOLOGY			English	Article						osteoclastogenesis; inflammation; musculo- skeletal disorders; low-dose radiotherapy; x-ray; NFATc-1; chronic degenerative and inflammatory diseases	IMMUNE-SYSTEM; RHEUMATOID-ARTHRITIS; IONIZING-RADIATION; PROGENITOR CELLS; CANCER-TREATMENT; IRRADIATION; THERAPY; MECHANISMS; DISEASES	Low-dose radiotherapy (LD-RT) is a local treatment option for patients with chronic degenerative and inflammatory diseases, in particular musculoskeletal diseases. Despite reported analgesic and anti-inflammatory effects, cellular and molecular mechanisms related to osteoimmunological effects are still elusive. Here we test the hypothesis that X-irradiation inhibits the differentiation of precursor osteoclasts into mature osteoclasts (mOC) and their bone resorbing activity. Circulating monocytes from healthy donors were isolated and irradiated after attachment with single or fractionated X-ray doses, comparable to an LD-RT treatment scheme. Then monocytes underwent ex vivo differentiation into OC during cultivation up to 21 days, under conditions mimicking the physiological microenvironment of OC on bone. After irradiation, apoptotic frequencies were low, but the total number of OC precursors and mOC decreased up to the end of the cultivation period. On top, we observed an impairment of terminal differentiation, i.e. a smaller fraction of mOC, reduced resorbing activity on bone, and release of collagen fragments. We further analyzed the effect of X-irradiation on multinucleation, resulting from the fusion of precursor OC, which occurs late during OC differentiation. At 21 days after exposure, the observation of smaller cellular areas and a reduced number of nuclei per mOC suggest an impaired fusion of OC precursors to form mOC. Before, at 14 days, the nuclear translocation of Nuclear Factor Of Activated T Cells 1 (NFATc1), a master regulator of osteoclast differentiation and fusion, was decreased. In first results, obtained in the frame of a longitudinal LD-RT study, we previously reported a pain-relieving effect in patients. However, in a subgroup of patients suffering from Calcaneodynia or Achillodynia, we did not observe a consistent decrease of established blood markers for resorption and formation of bone, or modified T cell subtypes involved in regulating these processes. To assess the relevance of changes in bone metabolism for other diseases treated with LD-RT will be subject of further studies. Taken together, we observed that in vitro X-irradiation of monocytes results in an inhibition of the differentiation into bone-resorbing OC and a concomitant reduction of resorbing activity. The detected reduced NFATc1 signaling could be one underlying mechanism.	[Eckert, Denise; Rapp, Felicitas; Tsedeke, Ayele Taddese; Kraft, Daniela; Wente, Isabell; Molendowska, Jessica; Basheer, Sidra; Friedrich, Thomas; Fournier, Claudia] Gesell Schwerionenforsch GSI Helmholtzzent Schweri, Dept Biophys, Darmstadt, Germany; [Langhans, Markus; Meckel, Tobias] Tech Univ Darmstadt, Dept Macromol & Paper Chem & Membrane Dynam, Darmstadt, Germany; [Donaubauer, Anna-Jasmina; Becker, Ina; Frey, Benjamin] Univ Klinikum Erlangen, Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Radiat Oncol, Translat Radiobiol, Erlangen, Germany; [Donaubauer, Anna-Jasmina; Becker, Ina; Frey, Benjamin] Univ Klinikum Erlangen, Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Radiat Oncol, Erlangen, Germany; [Rapp, Felicitas] Heidelberg Univ, Med Fac Mannheim, Dept Hematol & Oncol, Mannheim, Germany	Technical University of Darmstadt; University of Erlangen Nuremberg; University of Erlangen Nuremberg; Ruprecht Karls University Heidelberg	Fournier, C (corresponding author), Gesell Schwerionenforsch GSI Helmholtzzent Schweri, Dept Biophys, Darmstadt, Germany.	c.fournier@gsi.de			Bundesministerium fuer Bildung und Forschung (BMBF) [02NUK050A, 02NUK050E]; Department of Radiation Oncology at Universitaetsklinikum Erlangen	Bundesministerium fuer Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); Department of Radiation Oncology at Universitaetsklinikum Erlangen	This work was in part funded by the Bundesministerium fuer Bildung und Forschung (BMBF; GREWIS-alpha, 02NUK050A and 02NUK050E). The IMMO-LDRT01 trial is funded by Department of Radiation Oncology at Universitaetsklinikum Erlangen.	Becker D, 2009, INT J RADIAT BIOL, V85, P1051, DOI 10.3109/09553000903232850; Bindu S, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114147; Chen M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104016; Cucu A, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00882; Cummings Brian S, 2004, Curr Protoc Pharmacol, VChapter 12, DOI 10.1002/0471141755.ph1208s25; D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003; de Vries TJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00505; Deloch L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103197; Deloch L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01834; Donaubauer AJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.740742; Donaubauer AJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165854; Ehnert S, 2021, WORLD J STEM CELLS, V13, P1667, DOI 10.4252/wjsc.v13.i11.1667; Falcke SE, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113574; Fardellone P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/484280; Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003; Feng X, 2011, ANNU REV PATHOL-MECH, V6, P121, DOI 10.1146/annurev-pathol-011110-130203; Florencio-Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746; Frey B, 2015, CANCER LETT, V368, P230, DOI 10.1016/j.canlet.2015.04.010; Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859; Gevorgyan A, 2007, J CRANIOFAC SURG, V18, P1001, DOI 10.1097/scs.0b013e31812f7584; Ginaldi L, 2016, CURR MED CHEM, V23, P3754, DOI 10.2174/0929867323666160907162546; Handforth C, 2018, CALCIFIED TISSUE INT, V102, P251, DOI 10.1007/s00223-017-0369-x; Hildebrandt G, 2003, INT J RADIAT BIOL, V79, P993, DOI 10.1080/09553000310001636639; Hopewell JW, 2003, MED PEDIATR ONCOL, V41, P208, DOI 10.1002/mpo.10338; Jiang C, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.684007; Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007-0237; Kirkpatrick J, 2017, J ANAT, V230, P743, DOI 10.1111/joa.12607; Kleinhans C, 2015, J BIOTECHNOL, V205, P101, DOI 10.1016/j.jbiotec.2014.11.039; Large M, 2014, RADIAT ONCOL, V9, DOI 10.1186/1748-717X-9-80; Lees RL, 2001, BONE, V28, P187, DOI 10.1016/S8756-3282(00)00433-6; Lima F, 2017, RADIAT RES, V188, P433, DOI 10.1667/RR14414.1; Lucatto SC, 2011, ACTA CIR BRAS, V26, P475, DOI 10.1590/S0102-86502011000600012; Ma QY, 2021, BONE RES, V9, DOI 10.1038/s41413-020-00121-1; Marchev AS, 2017, ANN NY ACAD SCI, V1401, P114, DOI 10.1111/nyas.13407; Mei LW, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.734774; Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101; Nakamura H, 2014, BIOCHEM BIOPH RES CO, V455, P305, DOI 10.1016/j.bbrc.2014.11.009; Nakatsukasa H, 2008, J RADIAT RES, V49, P381, DOI 10.1269/jrr.08002; Oest ME, 2015, J ORTHOP RES, V33, P334, DOI 10.1002/jor.22761; Okamoto K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3323; Ott OJ, 2019, STRAHLENTHER ONKOL, V195, P285, DOI 10.1007/s00066-018-1412-1; Rajpura A, 2011, HIP INT, V21, P385, DOI 10.5301/HIP.2011.8538; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Rodel F, 2007, INT J RADIAT BIOL, V83, P357, DOI 10.1080/09553000701317358; Ruhle PF, 2017, AUTOIMMUNITY, V50, P133, DOI 10.1080/08916934.2017.1284819; Sawajiri M, 2003, RADIAT ENVIRON BIOPH, V42, P219, DOI 10.1007/s00411-003-0204-9; Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2166; Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110; Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153; Seegenschmiedt MH, 2004, STRAHLENTHER ONKOL, V180, P718, DOI 10.1007/s00066-004-9197-9; Simoniello P, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00294; Singh JA, 2015, LANCET, V386, P258, DOI 10.1016/S0140-6736(14)61704-9; Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852; Takayanagi H, 2009, NAT REV RHEUMATOL, V5, P667, DOI 10.1038/nrrheum.2009.217; Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; Vesprey Alexander, 2016, Bio Protoc, V6, DOI 10.21769/BioProtoc.1836; Vlot MC, 2018, BONE, V114, P215, DOI 10.1016/j.bone.2018.06.011; Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036; Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1; Wu XJ, 2005, J BIOL CHEM, V280, P29964, DOI 10.1074/jbc.M500710200; Xian YS, 2021, BIOCHEM PHARMACOL, V193, DOI 10.1016/j.bcp.2021.114761; Yavropoulou M. P., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P204; Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138; Zhai JL, 2019, INT J MOL MED, V44, P2265, DOI 10.3892/ijmm.2019.4369; Zhang J, 2017, J RADIAT RES, V58, P791, DOI 10.1093/jrr/rrx026; Zhou XZ, 2009, ARCH ORTHOP TRAUM SU, V129, P125, DOI 10.1007/s00402-008-0634-6	67	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								817281	10.3389/fimmu.2022.817281	http://dx.doi.org/10.3389/fimmu.2022.817281			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J3PR	35603191	Green Published, gold, Green Submitted			2022-12-18	WOS:000797832300001
J	Fovet, CM; Pimienta, C; Galhaut, M; Relouzat, F; Nunez, N; Cavarelli, M; Sconosciuti, Q; Dhooge, N; Marzinotto, I; Lampasona, V; Tolazzi, M; Scarlatti, G; Fang, RHT; Naninck, T; Dereuddre-Bosquet, N; Van Wassenhove, J; Gallouet, AS; Maisonnasse, P; Le Grand, R; Menu, E; Seddiki, N				Fovet, Claire-Maelle; Pimienta, Camille; Galhaut, Mathilde; Relouzat, Francis; Nunez, Natalia; Cavarelli, Mariangela; Sconosciuti, Quentin; Dhooge, Nina; Marzinotto, Ilaria; Lampasona, Vito; Tolazzi, Monica; Scarlatti, Gabriella; Fang, Raphael Ho Tsong; Naninck, Thibaut; Dereuddre-Bosquet, Nathalie; Van Wassenhove, Jerome; Gallouet, Anne-Sophie; Maisonnasse, Pauline; Le Grand, Roger; Menu, Elisabeth; Seddiki, Nabila			A Case Study to Dissect Immunity to SARS-CoV-2 in a Neonate Nonhuman Primate Model	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; innate immunity; type-I IFN; pediatric; neonate; children; COVID-19; nonhuman primate; microbiota	GUT MICROBIOTA; CORONAVIRUS; MACAQUES; RESPONSES; CHILDREN; DISEASE	Most children are less severely affected by coronavirus-induced disease 2019 (COVID-19) than adults, and thus more difficult to study progressively. Here, we provide a neonatal nonhuman primate (NHP) deep analysis of early immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in blood and mucosal tissues. In addition, we provide a comparison with SARS-CoV-2-infected adult NHP. Infection of the neonate resulted in a mild disease compared with adult NHPs that develop, in most cases, moderate lung lesions. In concomitance with the viral RNA load increase, we observed the development of an early innate response in the blood, as demonstrated by RNA sequencing, flow cytometry, and cytokine longitudinal data analyses. This response included the presence of an antiviral type-I IFN gene signature, a persistent and lasting NKT cell population, a balanced peripheral and mucosal IFN-gamma/IL-10 cytokine response, and an increase in B cells that was accompanied with anti-SARS-CoV-2 antibody response. Viral kinetics and immune responses coincided with changes in the microbiota profile composition in the pharyngeal and rectal mucosae. In the mother, viral RNA loads were close to the quantification limit, despite the very close contact with SARS-CoV-2-exposed neonate. This pilot study demonstrates that neonatal NHPs are a relevant model for pediatric SARS-CoV-2 infection, permitting insights into the early steps of anti-SARS-CoV-2 immune responses in infants.	[Fovet, Claire-Maelle; Pimienta, Camille; Galhaut, Mathilde; Relouzat, Francis; Cavarelli, Mariangela; Sconosciuti, Quentin; Dhooge, Nina; Fang, Raphael Ho Tsong; Naninck, Thibaut; Dereuddre-Bosquet, Nathalie; Van Wassenhove, Jerome; Gallouet, Anne-Sophie; Maisonnasse, Pauline; Le Grand, Roger; Menu, Elisabeth; Seddiki, Nabila] Univ Paris Saclay, INSERM, CEA, Ctr Immunol Viral Autoimmune Hematol & Bacterial, Fontenay Aux Roses, France; [Nunez, Natalia] Life & Soft, Fontenay Aux Roses, France; [Marzinotto, Ilaria; Lampasona, Vito] IRCCS Osped San Raffaele, Diabet Res Inst, Milan, Italy; [Tolazzi, Monica; Scarlatti, Gabriella] IRCCS Osped San Raffaele, Div Immunol Transplantat & Infect Dis, Viral Evolut & Transmiss Unit, Milan, Italy; [Menu, Elisabeth] Inst Pasteur, Dept Virol, MISTIC Grp, Paris, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Seddiki, N (corresponding author), Univ Paris Saclay, INSERM, CEA, Ctr Immunol Viral Autoimmune Hematol & Bacterial, Fontenay Aux Roses, France.	nabila.seddiki@cea.fr		Galhaut, Mathilde/0000-0002-2607-4855; Seddiki, Nabila/0000-0002-0379-8527; CAVARELLI, MARIANGELA/0000-0002-8468-0263; Scarlatti, Gabriella/0000-0003-2316-2689				Adeli K, 2017, CRIT REV CL LAB SCI, V54, P358, DOI 10.1080/10408363.2017.1379945; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Bai L, 2013, P NATL ACAD SCI USA, V110, P16097, DOI 10.1073/pnas.1303218110; Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4; Bohn MK, 2020, INT J LAB HEMATOL, V42, P750, DOI 10.1111/ijlh.13306; Brody Irene Bukh, 2019, Pathog Immun, V4, P1, DOI 10.20411/pai.v4i1.241; Brouwer PJM, 2021, CELL, V184, P1188, DOI 10.1016/j.cell.2021.01.035; Burbelo PD, 2005, BMC BIOTECHNOL, V5, DOI 10.1186/1472-6750-5-22; Castagnoli R, 2020, JAMA PEDIATR, V174, P882, DOI 10.1001/jamapediatrics.2020.1467; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Chen YX, 2008, VIROLOGY, V381, P89, DOI 10.1016/j.virol.2008.08.016; Chen ZL, 2018, J IMMUNOL, V200, P3117, DOI 10.4049/jimmunol.1701026; Cotugno N, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108852; Cui YF, 2019, ZOOL RES, V40, P89, DOI 10.24272/j.issn.2095-8137.2018.061; de Wit E, 2020, P NATL ACAD SCI USA, V117, P6771, DOI 10.1073/pnas.1922083117; Dispinseri S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22958-8; Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702; Dowell AC, 2022, NAT IMMUNOL, V23, P40, DOI 10.1038/s41590-021-01089-8; Duncan CJA, 2021, J CLIN IMMUNOL, V41, P1446, DOI 10.1007/s10875-021-01118-z; Escudie F, 2018, BIOINFORMATICS, V34, P1287, DOI 10.1093/bioinformatics/btx791; Fenyo EM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004505; Fouchier RAM, 2003, NATURE, V423, P240, DOI 10.1038/423240a; Gilbert C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.750279; Haagmans BL, 2006, PLOS MED, V3, P598, DOI 10.1371/journal.pmed.0030194; Heald-Sargent T, 2020, JAMA PEDIATR, V174, P902, DOI 10.1001/jamapediatrics.2020.3651; Heinonen S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw0268; Huang RL, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00445; Koo BS, 2019, LAB ANIM RES, V35, DOI 10.1186/s42826-019-0006-0; Krogh AKH, 2014, J ZOO WILDLIFE MED, V45, P306, DOI 10.1638/2013-0153R.1; Kuiken T, 2003, LANCET, V362, P263, DOI 10.1016/S0140-6736(03)13967-0; Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377; Lang ML, 2009, EXPERT REV VACCINES, V8, P1109, DOI [10.1586/erv.09.56, 10.1586/ERV.09.56]; Li H, 2018, BIOINFORMATICS, V34, P3094, DOI 10.1093/bioinformatics/bty191; Liu L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.123158; Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344; Loske J, 2022, NAT BIOTECHNOL, V40, P319, DOI 10.1038/s41587-021-01037-9; Love HC, 2014, IEEE ENG MED BIO, P5667, DOI 10.1109/EMBC.2014.6944913; Ludvigsson JF, 2020, ACTA PAEDIATR, V109, P1088, DOI 10.1111/apa.15270; Luo F, 2018, VIROL SIN, V33, P201, DOI 10.1007/s12250-018-0009-2; Maisonnasse P, 2020, NATURE, V585, P584, DOI 10.1038/s41586-020-2558-4; Mallapaty S, 2021, NATURE, V597, P166, DOI 10.1038/d41586-021-02423-8; Merino KM, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00388; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; Nunez N, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060584; Pan F, 2020, RADIOLOGY, V295, P715, DOI 10.1148/radiol.2020200370; Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197; Pierce CA., 2021, JCI INSIGHT, V6, DOI [10.1172/jci.insight.148694, DOI 10.1172/JCI.INSIGHT.148694, DOI 10.1172/jci.insight.148694]; Pierce CA, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abd5487; Qiu HY, 2020, LANCET INFECT DIS, V20, P689, DOI 10.1016/S1473-3099(20)30198-5; Roberts A, 2008, VIRUS RES, V133, P20, DOI 10.1016/j.virusres.2007.03.025; Rockx B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018558; Rognes T, 2016, PEERJ, V4, DOI 10.7717/peerj.2584; Secchi M, 2020, J CLIN INVEST, V130, P6366, DOI 10.1172/JCI142804; Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4; Smet A, 2011, HELICOBACTER, V16, P70, DOI 10.1111/j.1523-5378.2011.00884.x; Sokol H, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1893113; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; Tanaka M, 2017, ALLERGOL INT, V66, P515, DOI 10.1016/j.alit.2017.07.010; Thapa S, 2020, PEDIATR INFECT DIS J, V39, pE226, DOI 10.1097/INF.0000000000002703; Trottein F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01750; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Vodnar DC, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.575559; Vono M, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109773; Weatherhead JE, 2020, J CLIN INVEST, V130, P6194, DOI 10.1172/JCI145301; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xie Zhuorui, 2021, Curr Protoc, V1, pe90, DOI 10.1002/cpz1.90; Yonker LM, 2021, J INFECT DIS, V224, P1821, DOI [10.1093/infdis/jiab509, 10.1101/2021.05.30.21258086]; Zhang Z, 2021, CLIN INFECT DIS, V73, pE4154, DOI 10.1093/cid/ciaa1911	69	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								855230	10.3389/fimmu.2022.855230	http://dx.doi.org/10.3389/fimmu.2022.855230			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8NM	35603150	gold, Green Published			2022-12-18	WOS:000797483600001
J	Huan, C; Qu, XL; Li, ZL				Huan, Chen; Qu, Xinglong; Li, Zhaolong			Host Restrictive Factors Are the Emerging Storm Troopers Against Enterovirus: A Mini-Review	FRONTIERS IN IMMUNOLOGY			English	Review						host restrictive factors; enteroviruses; virus-host interplay; antiviral; arms race	HEPATITIS-B-VIRUS; ENZYME REPLACEMENT THERAPY; AICARDI-GOUTIERES SYNDROME; HIV-1 RESTRICTION; 3C PROTEASE; RESISTANT MUTATIONS; GAUCHER-DISEASE; RNA REPLICATION; FACTOR SAMHD1; 2C PROTEIN	Enterovirus infection continues to be a global health problem. The lack of specific drugs and broad-spectrum vaccines means an urgent need to develop effective strategies against enteroviruses. Host restrictive factors are a class of intrinsic host antiviral factors that have been broadly defined and investigated during HIV infections and have great significance for drug development and treatment design. In recent years, the essential role of host restrictive factors in regulating enteroviral infections has been gradually recognized and investigated. An increasing number of studies have shown that host-restrictive factors regulate multiple steps in the life cycle of enteroviruses. This mini-review discusses the restrictive factors against enteroviruses, their antiviral mechanism, and the arms race between them and enteroviruses. We also summarise the pathways that enteroviruses use to impair host antiviral signals. This mini-review characterizes the essential role of host restriction factors in enterovirus infections, which provides ideas and potential targets for antiviral drug design by regulating host restrictive factors. It also reveals potential future research on the interplay between host restrictive factors and enteroviruses.	[Huan, Chen; Li, Zhaolong] First Hosp Jilin Univ, Inst Virol & AIDS Res, Ctr Infect Dis & Pathogen Biol, Key Lab Organ Regenerat & Transplantat,Minist Educ, Changchun, Peoples R China; [Qu, Xinglong] First Hosp Jilin Univ, Resp Dept, Changchun, Peoples R China	Jilin University; Jilin University	Li, ZL (corresponding author), First Hosp Jilin Univ, Inst Virol & AIDS Res, Ctr Infect Dis & Pathogen Biol, Key Lab Organ Regenerat & Transplantat,Minist Educ, Changchun, Peoples R China.	lizhaolong@jlu.edu.cn			National Natural Science Foundation of China [81701987, 81801994]; Science and Technology Department of Jilin Province [20210101300JC]; China Postdoctoral Science Foundation [2020M670826]; Education Department of Jilin Province [JJKH20211141KJ]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Jilin Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Education Department of Jilin Province	Funding This work was supported in part by funding from the National Natural Science Foundation of China (81701987 to ZL and 81801994 to CH), the Science and Technology Department of Jilin Province (20210101300JC), China Postdoctoral Science Foundation (2020M670826), and the Education Department of Jilin Province (JJKH20211141KJ).	AEBI M, 1989, MOL CELL BIOL, V9, P5062, DOI 10.1128/MCB.9.11.5062; Antonucci JM, 2016, NAT MED, V22, P1072, DOI 10.1038/nm.4163; Baggen J, 2018, NAT REV MICROBIOL, V16, P368, DOI 10.1038/s41579-018-0005-4; Ballana E, 2015, TRENDS MICROBIOL, V23, P680, DOI 10.1016/j.tim.2015.08.002; Beloglazova N, 2013, J BIOL CHEM, V288, P8101, DOI 10.1074/jbc.M112.431148; Bian LL, 2015, EXPERT REV ANTI-INFE, V13, P1061, DOI 10.1586/14787210.2015.1058156; Bonvin M, 2006, HEPATOLOGY, V43, P1364, DOI 10.1002/hep.21187; Boparai JK, 2020, PROTEIN PEPTIDE LETT, V27, P4, DOI 10.2174/0929866526666190822165812; Caligiuri P, 2016, WORLD J GASTROENTERO, V22, P145, DOI 10.3748/wjg.v22.i1.145; Charrow J, 2004, J PEDIATR-US, V144, P112, DOI 10.1016/j.jpeds.2003.10.067; Chen ZM, 2014, BIOCHEM BIOPH RES CO, V450, P1462, DOI 10.1016/j.bbrc.2014.07.023; Choi J, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0174-4; D'Urbano V, 2021, NEW MICROBIOL, V44, P95; Davies EH, 2007, J INHERIT METAB DIS, V30, P935, DOI 10.1007/s10545-007-0577-z; Du HW, 2015, SCI REP-UK, V5, DOI 10.1038/srep14302; Dyda A, 2018, EUROSURVEILLANCE, V23, P16, DOI 10.2807/1560-7917.ES.2018.23.3.17-00310; Fan WC, 2021, CELL, V184, P3410, DOI 10.1016/j.cell.2021.04.047; Feng Q, 2014, J VIROL, V88, P3369, DOI 10.1128/JVI.02712-13; Fu XM, 2020, VIROL SIN, V35, P21, DOI 10.1007/s12250-019-00169-2; Goldstone DC, 2011, NATURE, V480, P379, DOI 10.1038/nature10623; Han Y, 2016, J CELL SCI, V129, P4534, DOI 10.1242/jcs.193698; Hixon AM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11090821; Ho HY, 2008, J GEN VIROL, V89, P2080, DOI 10.1099/vir.0.2008/001404-0; Hollenbaugh JA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003481; Holm-Hansen CC, 2016, LANCET INFECT DIS, V16, pE64, DOI 10.1016/S1473-3099(15)00543-5; Hrecka K, 2011, NATURE, V474, P658, DOI 10.1038/nature10195; Hung HC, 2011, J INFECT DIS, V203, P1784, DOI 10.1093/infdis/jir174; Jimenez VC, 2012, SCI REP-UK, V2, DOI 10.1038/srep00763; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Laguette N, 2011, NATURE, V474, P654, DOI 10.1038/nature10117; Lahouassa H, 2012, NAT IMMUNOL, V13, P223, DOI 10.1038/ni.2236; Lei XB, 2014, J VIROL, V88, P9830, DOI 10.1128/JVI.01425-14; Lei XB, 2013, J VIROL, V87, P1690, DOI 10.1128/JVI.01855-12; Lei XB, 2011, J VIROL, V85, P8811, DOI 10.1128/JVI.00447-11; Lei XB, 2010, J VIROL, V84, P8051, DOI 10.1128/JVI.02491-09; Li HY, 2020, J CELL BIOCHEM, V121, P4321, DOI 10.1002/jcb.29628; Li L, 2019, ANTIVIR RES, V161, P70, DOI 10.1016/j.antiviral.2018.10.010; Li Q, 2016, J VIROL, V90, P5141, DOI 10.1128/JVI.03021-15; Li ZL, 2022, J VIROL, V96, DOI 10.1128/JVI.01708-21; Li ZL, 2020, EMBO REP, V21, DOI 10.15252/embr.201847528; Li ZL, 2018, NUCLEIC ACIDS RES, V46, P11514, DOI 10.1093/nar/gky840; Li ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep20839; Li ZR, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01725-7; Liang BY, 2017, MICROB DRUG RESIST, V23, P285, DOI 10.1089/mdr.2015.0347; Lin JY, 2008, J GEN VIROL, V89, P2540, DOI 10.1099/vir.0.2008/003673-0; Lin JY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140291; Lin JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103827; Lin JY, 2009, J VIROL, V83, P6106, DOI 10.1128/JVI.02476-08; Liu Y, 2007, J VIROL, V81, P5669, DOI 10.1128/JVI.02350-06; Luo Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087491; Ma J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067606; Mohanram V, 2013, J IMMUNOL, V190, P3346, DOI 10.4049/jimmunol.1201184; Morasco BJ, 2003, J VIROL, V77, P5136, DOI 10.1128/JVI.77.9.5136-5144.2003; Nakata K, 2017, J GEN VIROL, V98, P643, DOI 10.1099/jgv.0.000723; Nguyen TT, 2002, J INTERF CYTOK RES, V22, P899, DOI 10.1089/107999002760274926; Passos V, 2019, J VIROL, V93, DOI 10.1128/JVI.01221-19; Pfister T, 2000, J VIROL, V74, P334, DOI 10.1128/JVI.74.1.334-343.2000; Powell RD, 2011, J BIOL CHEM, V286, P43596, DOI 10.1074/jbc.C111.317628; Razonable RR, 2018, CURR OPIN ORGAN TRAN, V23, P388, DOI 10.1097/MOT.0000000000000541; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Ryoo J, 2014, NAT MED, V20, P936, DOI 10.1038/nm.3626; Sarkis PTN, 2006, J IMMUNOL, V177, P4530, DOI 10.4049/jimmunol.177.7.4530; Schein CH, 2006, PEPTIDES, V27, P1676, DOI 10.1016/j.peptides.2006.01.018; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Sheppard P, 2003, NAT IMMUNOL, V4, P63, DOI 10.1038/ni873; Simon V, 2015, NAT IMMUNOL, V16, P546, DOI 10.1038/ni.3156; Sun YN, 2012, J VIROL, V86, P13662, DOI 10.1128/JVI.01712-12; Takaoka A, 2006, CELL MICROBIOL, V8, P907, DOI 10.1111/j.1462-5822.2006.00716.x; Tan JZ, 2013, J VIROL, V87, P4339, DOI 10.1128/JVI.01123-12; Tang WF, 2007, J BIOL CHEM, V282, P5888, DOI 10.1074/jbc.M611145200; Ullmer W, 2018, MBIO, V9, DOI 10.1128/mBio.01669-18; Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201; Wang B, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003231; Wang CY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152177; Wang HB, 2015, CELL REP, V12, P42, DOI 10.1016/j.celrep.2015.05.047; Wang HQ, 2019, ANTIVIR RES, V165, P23, DOI 10.1016/j.antiviral.2019.03.005; Wang LY, 2015, MOLECULES, V20, P16320, DOI 10.3390/molecules200916320; Wang SH, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.615965; Weinreb NJ, 2005, AM J HEMATOL, V80, P223, DOI 10.1002/ajh.20504; Wen WH, 2020, CURR MICROBIOL, V77, P1968, DOI 10.1007/s00284-020-02082-4; Wu S, 2014, VIRUS RES, V192, P52, DOI 10.1016/j.virusres.2014.08.003; Xia HJ, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005067; Xiang ZC, 2016, J VIROL, V90, P1613, DOI 10.1128/JVI.02395-15; Xiao HM, 2021, VIROL SIN, V36, P1363, DOI 10.1007/s12250-021-00410-x; Xue YC, 2021, J VIROL, V95, DOI 10.1128/JVI.00304-21; Yamayoshi S, 2009, NAT MED, V15, P798, DOI 10.1038/nm.1992; Yin FF, 2015, J GEN VIROL, V96, P3302, DOI 10.1099/jgv.0.000285; Ying SC, 2007, ACTA BIOCH BIOPH SIN, V39, P297, DOI 10.1111/j.1745-7270.2007.00275.x; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yu AM, 2020, PHARMACOL REV, V72, P862, DOI 10.1124/pr.120.019554; Zhang C, 2015, EMERG MICROBES INFEC, V4, DOI 10.1038/emi.2015.12; Zhao TS, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2087; Zhao ZL, 2021, J VIROL, V95, DOI 10.1128/JVI.00620-21; Zheng ZH, 2011, J IMMUNOL, V187, P2202, DOI 10.4049/jimmunol.1100285	94	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								910780	10.3389/fimmu.2022.910780	http://dx.doi.org/10.3389/fimmu.2022.910780			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I4YR	35603180	Green Published, gold			2022-12-18	WOS:000797236500001
J	Hulsebus, HJ; Najarro, KM; McMahan, RH; Boe, DM; Orlicky, DJ; Kovacs, EJ				Hulsebus, Holly J.; Najarro, Kevin M.; McMahan, Rachel H.; Boe, Devin M.; Orlicky, David J.; Kovacs, Elizabeth J.			Ethanol Intoxication Impairs Respiratory Function and Bacterial Clearance and Is Associated With Neutrophil Accumulation in the Lung After Streptococcus pneumoniae Infection	FRONTIERS IN IMMUNOLOGY			English	Article						alcohol; inflammation; innate immunity; lung function; macrophage; leukocyte	COLONY-STIMULATING FACTOR; ALCOHOL-CONSUMPTION; INFLAMMATORY RESPONSE; PNEUMOCOCCAL PNEUMONIA; PULMONARY INFLAMMATION; KLEBSIELLA-PNEUMONIAE; G-CSF; SUPPRESSES; EXPOSURE; RATS	Alcohol consumption is commonplace in the United States and its prevalence has increased in recent years. Excessive alcohol use is linked to an increased risk of infections including pneumococcal pneumonia, mostly commonly caused by Streptococcus pneumoniae. In addition, pneumonia patients with prior alcohol use often require more intensive treatment and longer hospital stays due to complications of infection. The initial respiratory tract immune response to S. pneumoniae includes the production of pro-inflammatory cytokines and chemokines by resident cells in the upper and lower airways which activate and recruit leukocytes to the site of infection. However, this inflammation must be tightly regulated to avoid accumulation of toxic by-products and subsequent tissue damage. A majority of previous work on alcohol and pneumonia involve animal models utilizing high concentrations of ethanol or chronic exposure and offer conflicting results about how ethanol alters immunity to pathogens. Further, animal models often employ a high bacterial inoculum which may overwhelm the immune system and obscure results, limiting their applicability to the course of human infection. Here, we sought to determine how a more moderate ethanol exposure paradigm affects respiratory function and innate immunity in mice after intranasal infection with 10(4) colony forming units of S. pneumoniae. Ethanol-exposed mice displayed respiratory dysfunction and impaired bacterial clearance after infection compared to their vehicle-exposed counterparts. This altered response was associated with increased gene expression of neutrophil chemokines Cxcl1 and Cxcl2 in whole lung homogenates, elevated concentrations of circulating granulocyte-colony stimulating factor (G-CSF), and higher neutrophil numbers in the lung 24 hours after infection. Taken together, these findings suggest that even a more moderate ethanol consumption pattern can dramatically modulate the innate immune response to S. pneumoniae after only 3 days of ethanol exposure and provide insight into possible mechanisms related to the compromised respiratory immunity seen in alcohol consumers with pneumonia.	[Hulsebus, Holly J.; Najarro, Kevin M.; McMahan, Rachel H.; Boe, Devin M.; Kovacs, Elizabeth J.] Univ Colorado Anschutz Med Campus, Dept Surg, Div GI Trauma & Endocrine Surg, Aurora, CO USA; [Hulsebus, Holly J.; Boe, Devin M.; Kovacs, Elizabeth J.] Univ Colorado Anschutz Med Campus, Immunol Grad Program, Aurora, CO USA; [Orlicky, David J.] Univ Colorado Anschutz Med Campus, Dept Pathol, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Kovacs, EJ (corresponding author), Univ Colorado Anschutz Med Campus, Dept Surg, Div GI Trauma & Endocrine Surg, Aurora, CO USA.; Kovacs, EJ (corresponding author), Univ Colorado Anschutz Med Campus, Immunol Grad Program, Aurora, CO USA.							Aggarwal A, 2017, CHEST, V152, p956A, DOI 10.1016/j.chest.2017.08.991; Akhtar S, 2011, MOL MED, V17, P88, DOI 10.2119/molmed.2010.00080; Assiri MA, 2017, ALCOHOL CLIN EXP RES, V41, P1705, DOI 10.1111/acer.13473; Bagby GJ, 1998, ALCOHOL CLIN EXP RES, V22, P1740, DOI 10.1097/00000374-199811000-00017; Boe DM, 2010, ALCOHOL CLIN EXP RES, V34, P1723, DOI 10.1111/j.1530-0277.2010.01259.x; Boe DM, 2001, J INFECT DIS, V184, P1134, DOI 10.1086/323661; Booyse FM, 2001, THROMB HAEMOSTASIS, V86, P517; Bordon J, 2013, INT J INFECT DIS, V17, pE76, DOI 10.1016/j.ijid.2012.06.006; Centers for Disease Control and Prevention, ALCOHOL PUBLIC HLTH; Chen MM, 2014, EXP GERONTOL, V54, P42, DOI 10.1016/j.exger.2013.12.010; Chen MM, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/971481; Curtis BJ, 2019, ALCOHOL, V80, P139, DOI 10.1016/j.alcohol.2018.09.001; Curtis BJ, 2019, SHOCK, V51, P625, DOI 10.1097/SHK.0000000000001188; de Hennezel L, 2001, EUR RESPIR J, V17, P94; de Roux A, 2006, CHEST, V129, P1219, DOI 10.1378/chest.129.5.1219; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Donkor ES, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00007; Fox S, 2010, J INNATE IMMUN, V2, P216, DOI 10.1159/000284367; Fukushi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021207; Gandhi JA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095707; Garvy BA, 1996, INFLAMMATION, V20, P499, DOI 10.1007/BF01487042; Ghanem ENB, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005126; Goral J, 2005, J IMMUNOL, V174, P456, DOI 10.4049/jimmunol.174.1.456; Goto Y, 2004, AM J RESP CELL MOL, V30, P620, DOI 10.1165/rcmb.2003-0312OC; Gregory AD, 2007, BLOOD, V109, P3235, DOI 10.1182/blood-2005-01-015081; Grommes J, 2011, MOL MED, V17, P293, DOI 10.2119/molmed.2010.00138; Guo FF, 2018, ALCOHOL CLIN EXP RES, V42, P1828, DOI 10.1111/acer.13840; Gupta NM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.5172; Gustot T, 2014, J HEPATOL, V60, P267, DOI 10.1016/j.jhep.2013.09.011; H R YO, 2022, COMMUNITY ACQUIRED P; Happel KI, 2007, ALCOHOL, V41, P325, DOI 10.1016/j.alcohol.2007.06.002; Happel KI, 2006, ALCOHOL CLIN EXP RES, V30, P1200, DOI 10.1111/j.1530-0277.2006.00144.x; Hardy RD, 2001, INFECT IMMUN, V69, P3869, DOI 10.1128/IAI.69.6.3869-3876.2001; Hubel K, 2002, J INFECT DIS, V185, P1490, DOI 10.1086/340221; Imhof A, 2008, DIABETES VASC DIS RE, V5, P48, DOI 10.3132/dvdr.2008.009; Isles HM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01784; Jeyaseelan S, 2006, J IMMUNOL, V177, P538, DOI 10.4049/jimmunol.177.1.538; Jin LL, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006637; Johansson N, 2010, CLIN INFECT DIS, V50, P202, DOI 10.1086/648678; Joshi PC, 2005, J IMMUNOL, V175, P6837, DOI 10.4049/jimmunol.175.10.6837; Karavitis J, 2008, J INTERF CYTOK RES, V28, P413, DOI 10.1089/jir.2007.0111; Karavitis J, 2012, CELL IMMUNOL, V274, P61, DOI 10.1016/j.cellimm.2012.02.002; Karavitis J, 2011, J LEUKOCYTE BIOL, V90, P1065, DOI 10.1189/jlb.0311114; Koppe U, 2012, CELL MICROBIOL, V14, P460, DOI 10.1111/j.1462-5822.2011.01746.x; Kuntsche E, 2005, CLIN PSYCHOL REV, V25, P841, DOI 10.1016/j.cpr.2005.06.002; Lee KMC, 2020, IMMUNOTARGETS THER, V9, P225, DOI 10.2147/ITT.S262566; Lim R, 2014, JOVE-J VIS EXP, DOI 10.3791/51755; Livy DJ, 2003, ALCOHOL, V29, P165, DOI 10.1016/S0741-8329(03)00025-9; Lujan M, 2010, EUR RESPIR J, V36, P1073, DOI 10.1183/09031936.00176309; Maus UA, 2003, J IMMUNOL, V170, P3273, DOI 10.4049/jimmunol.170.6.3273; Mehta AJ, 2013, AM J RESP CRIT CARE, V188, P716, DOI 10.1164/rccm.201301-0061OC; Menachery VD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131451; Milton PL, 2012, RESPIRATION, V83, P253, DOI 10.1159/000330586; Mitzner W, 1998, AM J RESP CRIT CARE, V158, P340, DOI 10.1164/ajrccm.158.1.let1; Mohawk JA, 2007, PHYSIOL BEHAV, V92, P800, DOI 10.1016/j.physbeh.2007.06.009; Molina PE, 2010, ALCOHOL RES HEALTH, V33, P97; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; National Institute on Alcohol Abuse and Alcoholism, ALC SAL COVID 19 PAN; National Institute on Alcohol Abuse and Alcoholism, 2021, UND ALC US DIS; National Institute on Alcohol Abuse and Alcoholism, DRINK LEV DEF; Opitz B, 2010, AM J RESP CRIT CARE, V181, P1294, DOI 10.1164/rccm.200909-1427SO; Patel PJ, 1999, AM J RESP CELL MOL, V20, P1229, DOI 10.1165/ajrcmb.20.6.3491; Plunk AD, 2014, ALCOHOL CLIN EXP RES, V38, P471, DOI 10.1111/acer.12250; Puchta A, 2014, JOVE-J VIS EXP, DOI 10.3791/50490; Quinton LJ, 2002, J INFECT DIS, V185, P1476, DOI 10.1086/340504; Raasch CE, 2010, ALCOHOL CLIN EXP RES, V34, P2035, DOI 10.1111/j.1530-0277.2010.01291.x; Roberts AW, 2005, GROWTH FACTORS, V23, P33, DOI 10.1080/08977190500055836; Rydell-Tormanen K, 2006, EUR RESPIR J, V28, P268, DOI 10.1183/09031936.06.00126905; Sahoo M, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004327; Samokhvalov AV, 2010, EPIDEMIOL INFECT, V138, P1789, DOI 10.1017/S0950268810000774; Samuelson DR, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02524-0; Samuelson DR, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006426; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shults JA, 2016, J LEUKOCYTE BIOL, V100, P1037, DOI 10.1189/jlb.3MA0316-111R; Shults JA, 2015, ALCOHOL, V49, P713, DOI 10.1016/j.alcohol.2015.06.006; Simet SM, 2015, ALCOHOL RES-CURR REV, V37, P199; Simou E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022344; Skloot GS, 2021, J APPL PHYSIOL, V130, P80, DOI 10.1152/japplphysiol.00556.2020; Malacco NLSD, 2020, ELIFE, V9, DOI 10.7554/eLife.58855; Substance Abuse and Mental Health Services Administration, 2021, 2020 NSDUH DET TABL; Tateda K, 2001, INFECT IMMUN, V69, P2017, DOI 10.1128/IAI.69.4.2017-2024.2001; Taut K, 2008, AM J RESP CELL MOL, V38, P105, DOI 10.1165/rcmb.2007-0132OC; Trevejo-Nunez G, 2015, INFECT IMMUN, V83, P2082, DOI 10.1128/IAI.02869-14; Vergis N, 2017, GASTROENTEROLOGY, V152, P1068, DOI 10.1053/j.gastro.2016.12.019; Verheijden KAT, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00190; Wang JJ, 2008, ACTA CARDIOL, V63, P65, DOI 10.2143/AC.63.1.2025334; White AM, 2022, JAMA-J AM MED ASSOC, V327, P1704, DOI 10.1001/jama.2022.4308; Xi B, 2017, J AM COLL CARDIOL, V70, P913, DOI 10.1016/j.jacc.2017.06.054; Xu JG, 2007, AM J RESP CELL MOL, V37, P291, DOI 10.1165/rcmb.2006-0187OC; Zhang P, 1997, ALCOHOL CLIN EXP RES, V21, P773, DOI 10.1097/00000374-199708000-00002; Zhang P, 1998, ALCOHOL CLIN EXP RES, V22, P135, DOI 10.1111/j.1530-0277.1998.tb03629.x	91	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								884719	10.3389/fimmu.2022.884719	http://dx.doi.org/10.3389/fimmu.2022.884719			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8NG	35603143	Green Published, gold			2022-12-18	WOS:000797483000001
J	Jaiswal, SR; Arunachalam, J; Saifullah, A; Lakhchaura, R; Tailor, D; Mehta, A; Bhagawati, G; Aiyer, H; Khamar, B; Malhotra, SV; Chakrabarti, S				Jaiswal, Sarita Rani; Arunachalam, Jaganath; Saifullah, Ashraf; Lakhchaura, Rohit; Tailor, Dhanir; Mehta, Anupama; Bhagawati, Gitali; Aiyer, Hemamalini; Khamar, Bakulesh; Malhotra, Sanjay V.; Chakrabarti, Suparno			Impact of an Immune Modulator Mycobacterium-w on Adaptive Natural Killer Cells and Protection Against COVID-19	FRONTIERS IN IMMUNOLOGY			English	Article						Mw for COVID-19 Mycobacterium w (Mw); COVID-19; SARS-CoV-2; innate immunity; NKG2C; adaptive NK cells; NKG2A; ADCC	NK CELLS; EFFECTOR FUNCTIONS; EXPANSION; ACTIVATION; LEUKEMIA; SUBSET; INNATE	The kinetics of NKG2C(+) adaptive natural killer (ANK) cells and NKG2A(+)inhibitory NK (iNK) cells with respect to the incidence of SARS-CoV-2 infection were studied for 6 months in a cohort of healthcare workers following the administration of the heat-killed Mycobacterium w (Mw group) in comparison to a control group. In both groups, corona virus disease 2019 (COVID-19) correlated with lower NKG2C(+)ANK cells at baseline. There was a significant upregulation of NKG2C expression and IFN-gamma release in the Mw group (p=0.0009), particularly in those with a lower baseline NKG2C expression, along with the downregulation of iNK cells (p<0.0001). This translated to a significant reduction in the incidence and severity of COVID-19 in the Mw group (incidence risk ratio-0.15, p=0.0004). RNA-seq analysis at 6 months showed an upregulation of the ANK pathway genes and an enhanced ANK-mediated antibody-dependent cellular cytotoxicity (ADCC) signature. Thus, Mw was observed to have a salutary impact on the ANK cell profile and a long-term upregulation of ANK-ADCC pathways, which could have provided protection against COVID-19 in a non-immune high-risk population.	[Jaiswal, Sarita Rani; Arunachalam, Jaganath; Chakrabarti, Suparno] Manashi Chakrabarti Fdn, Cellular Therapy & Immunol, New Delhi, India; [Jaiswal, Sarita Rani; Saifullah, Ashraf; Lakhchaura, Rohit; Mehta, Anupama; Chakrabarti, Suparno] Dharamshila Narayana Superspecial Hosp, Dept Blood & MarrowTransplantat, New Delhi, India; [Jaiswal, Sarita Rani] Amity Univ, Amity Inst Mol Med & Stem Cell Res, Noida, India; [Tailor, Dhanir; Malhotra, Sanjay V.] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR USA; [Bhagawati, Gitali; Aiyer, Hemamalini] Dharamshila Narayana Superspecial Hosp, Dept Pathol & Microbiol, New Delhi, India; [Khamar, Bakulesh] Cadila Pharmaceut Ltd, Res & Dev, Ahmadabad, India; [Tailor, Dhanir; Malhotra, Sanjay V.] Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Expt Therapeut, Portland, OR USA	Amity University Noida; Oregon Health & Science University; Oregon Health & Science University	Chakrabarti, S (corresponding author), Manashi Chakrabarti Fdn, Cellular Therapy & Immunol, New Delhi, India.; Chakrabarti, S (corresponding author), Dharamshila Narayana Superspecial Hosp, Dept Blood & MarrowTransplantat, New Delhi, India.; Malhotra, SV (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR USA.; Malhotra, SV (corresponding author), Oregon Hlth & Sci Univ, Knight Canc Inst, Ctr Expt Therapeut, Portland, OR USA.	malhotsa@ohsu.edu; foundationforcure@gmail.com		ARUNACHALAM, JAGANATH/0000-0001-8817-7764				Abebe F, 2021, CLIN EXP IMMUNOL, V204, P32, DOI 10.1111/cei.13565; Beziat V, 2011, BLOOD, V117, P4394, DOI 10.1182/blood-2010-11-319194; Beziat V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011966; Bjorkstrom NK, 2011, J EXP MED, V208, P13, DOI 10.1084/jem.20100762; Blumenthal D, 2020, NEW ENGL J MED, V383, P1483, DOI 10.1056/NEJMsb2021088; Bortolotti D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091975; Chen XM, 2021, VIROLOGY, V559, P1, DOI 10.1016/j.virol.2021.03.009; Cichocki F, 2016, LEUKEMIA, V30, P456, DOI 10.1038/leu.2015.260; Cichocki F, 2018, J EXP MED, V215, P2379, DOI 10.1084/jem.20172168; Covian C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02806; Das S, 2016, TUBERCULOSIS, V101, P201, DOI 10.1016/j.tube.2016.09.027; Della Chiesa M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00573; Escobar LE, 2020, P NATL ACAD SCI USA, V117, P17720, DOI 10.1073/pnas.2008410117; Esteso G, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.622995; Fendler A., 2021, NAT CANCER, V2, P1321, DOI [10.1038/s43018-021-00274-w, DOI 10.1038/S43018-021-00274-W]; Gupta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039215; Hart GT, 2019, J EXP MED, V216, P1280, DOI 10.1084/jem.20181681; Holmes TD, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abc9801; Hwang I, 2012, INT IMMUNOL, V24, P793, DOI 10.1093/intimm/dxs080; Jaiswal SR, 2022, CLIN TRANSL IMMUNOL, V11, DOI 10.1002/cti2.1359; Jaiswal SR, 2021, TRANSPL CELL THER, V27, P144, DOI 10.1016/j.jtct.2020.10.005; Jaiswal SR, 2021, BONE MARROW TRANSPL, V56, P185, DOI 10.1038/s41409-020-01002-1; Jaiswal SR, 2020, MEDITERR J HEMATOL I, V12, DOI 10.4084/MJHID.2020.047; Jaiswal SR, 2020, TRANSPLANTATION, V104, pE23, DOI 10.1097/TP.0000000000002941; Jaiswal SR, 2019, IMMUNOTHERAPY-UK, V11, P1221, DOI 10.2217/imt-2019-0037; Kamal R, 2017, BRIT J DERMATOL, V176, P1388, DOI 10.1111/bjd.14971; Kaushal J, 2021, CITIES, V111, DOI 10.1016/j.cities.2020.103097; Kleinnijenhuis J, 2014, CLIN IMMUNOL, V155, P213, DOI 10.1016/j.clim.2014.10.005; Kumar P, 2015, J LEUKOCYTE BIOL, V97, P511, DOI 10.1189/jlb.1A0714-361R; Lanier LL, 2013, NAT REV IMMUNOL, V13, P73, DOI 10.1038/nri3389; Levin EG, 2021, NEW ENGL J MED, V385, pE84, DOI 10.1056/NEJMoa2114583; Liu WR, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101709; Lopez-Verges S, 2011, P NATL ACAD SCI USA, V108, P14725, DOI 10.1073/pnas.1110900108; Mele D, 2021, HEPATOLOGY, V73, P79, DOI 10.1002/hep.31273; Miyashita R, 2004, INT IMMUNOL, V16, P163, DOI 10.1093/intimm/dxh013; Moretta L, 2011, FEBS LETT, V585, P1563, DOI 10.1016/j.febslet.2011.04.061; Muccio L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01050; Nattermann J, 2005, ANTIVIR THER, V10, P95; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Pandey RK, 2012, VACCINE, V30, P5748, DOI 10.1016/j.vaccine.2012.07.002; Riese P, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8020281; Rolle A, 2018, CELL REP, V24, P1967, DOI 10.1016/j.celrep.2018.07.069; Sattler A, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI150175; Schlums H, 2015, IMMUNITY, V42, P443, DOI 10.1016/j.immuni.2015.02.008; Sehgal IS, 2021, ERJ OPEN RES, V7, DOI 10.1183/23120541.00059-2021; Sehgal IS, 2015, J CRIT CARE, V30, P85, DOI 10.1016/j.jcrc.2014.08.012; Subramaniam M, 2016, SCI REP-UK, V6, DOI 10.1038/srep19833; Sun JC, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029538; Sun JC, 2009, EUR J IMMUNOL, V39, P2059, DOI 10.1002/eji.200939435; Thomas R, 2012, AIDS RES HUM RETROV, V28, P844, DOI [10.1089/aid.2011.0253, 10.1089/AID.2011.0253]; Vietzen H, 2021, GENET MED, V23, P963, DOI 10.1038/s41436-020-01077-7; Voysey M, 2021, LANCET, V397, P99, DOI 10.1016/S0140-6736(20)32661-1; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Zhang RJ, 2007, AIDS, V21, pS9, DOI 10.1097/01.aids.0000304691.32014.19	54	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								887230	10.3389/fimmu.2022.887230	http://dx.doi.org/10.3389/fimmu.2022.887230			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8QT	35603154	Green Submitted, gold, Green Published			2022-12-18	WOS:000797492400001
J	Li, RF; Zhu, XJ; Zhou, P; Qiao, YH; Li, YQ; Xu, YC; Shi, X				Li, Rifei; Zhu, Xinjie; Zhou, Peng; Qiao, Yuehua; Li, Yinqian; Xu, Yice; Shi, Xi			Generation of a High-Affinity Nanobody Against CD147 for Tumor Targeting and Therapeutic Efficacy Through Conjugating Doxorubicin	FRONTIERS IN IMMUNOLOGY			English	Article						tumor targeting; nanobody; CD147; phage display; DOX-11-1	MATRIX METALLOPROTEINASE INDUCER; HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODIES; POOR-PROGNOSIS; CANCER-CELLS; METASTASIS; CHEMOTHERAPY; HAB18G/CD147; RESISTANCE; INVASION	CD147, a glycosylated transmembrane protein in the immunoglobulin superfamily, is overexpressed on the surfaces of various tumor cells and promotes cancer cell proliferation, invasion, and metastasis. Nanobodies, characterized by small sizes, high affinities and specificities, and low immunogenicities, are promising diagnostic and therapeutic tools. However, there are few reports on nanobodies that specifically target CD147. In this work, a specific anti-CD147 nanobody has been successfully identified using phage display technology. The tumor target and antitumor effects have also been detected in different CD147-positive tumors in in vitro and in vivo assays, respectively. Meanwhile, it has a synergistic effect for inhibiting 4T1-bearing mice through conjugating doxorubicin. It may afford new strategies for cancer therapies.	[Li, Rifei; Li, Yinqian] Northwest A&F Univ, Coll Vet Med, Yangling, Peoples R China; [Zhu, Xinjie] Hainan Univ, Sch Pharmaceut Sci, Key Lab Trop Biol Resources Minist Educ, Haikou, Peoples R China; [Zhu, Xinjie; Zhou, Peng] Peking Univ, Coll Chem & Mol Engn, Synthet & Funct Biomol Ctr, Beijing, Peoples R China; [Qiao, Yuehua; Shi, Xi] Xuzhou Med Univ, Artificial Auditory Lab Jiangsu Prov, Xuzhou, Peoples R China; [Xu, Yice] Wuhan Univ Sci & Technol, Dept Otolaryngol Head & Neck Surg, Xiaogan Hosp, Xiaogan, Peoples R China	Northwest A&F University - China; Hainan University; Peking University; Xuzhou Medical University; Wuhan University of Science & Technology	Zhu, XJ (corresponding author), Hainan Univ, Sch Pharmaceut Sci, Key Lab Trop Biol Resources Minist Educ, Haikou, Peoples R China.; Zhu, XJ (corresponding author), Peking Univ, Coll Chem & Mol Engn, Synthet & Funct Biomol Ctr, Beijing, Peoples R China.; Shi, X (corresponding author), Xuzhou Med Univ, Artificial Auditory Lab Jiangsu Prov, Xuzhou, Peoples R China.; Xu, YC (corresponding author), Wuhan Univ Sci & Technol, Dept Otolaryngol Head & Neck Surg, Xiaogan Hosp, Xiaogan, Peoples R China.	zhuxj@hainanu.edu.cn; xuyice101@126.com; shixi19850112@163.com						Ahler E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064561; Als AB, 2007, CLIN CANCER RES, V13, P4407, DOI 10.1158/1078-0432.CCR-07-0109; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bernard SC, 2014, NAT MED, V20, P725, DOI 10.1038/nm.3563; BHATTACHARYA M, 1982, CANCER RES, V42, P1650; Bi XC, 2012, CLIN TRANSL ONCOL, V14, P190, DOI 10.1007/s12094-012-0783-5; Bougatef F, 2009, BLOOD, V114, P5547, DOI 10.1182/blood-2009-04-217380; Chames P, 2009, M S-MED SCI, V25, P1159, DOI 10.1051/medsci/200925121159; Chen ZN, 2006, INT J RADIAT ONCOL, V65, P435, DOI 10.1016/j.ijrobp.2005.12.034; de Marco A, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-44; Ding PF, 2017, ONCOTARGET, V8, P51151, DOI 10.18632/oncotarget.17712; Eichner R, 2016, NAT MED, V22, P735, DOI 10.1038/nm.4128; Fenizia C, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061434; Gallagher SM, 2007, CANCER RES, V67, P4182, DOI 10.1158/0008-5472.CAN-06-3184; Gao J, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0920-9; Grass GD, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20150256; Gu XJ, 2019, NANO LETT, V19, P3344, DOI 10.1021/acs.nanolett.9b01065; Guan XW, 2019, AAPS J, V21, DOI 10.1208/s12248-018-0261-2; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; Harmsen MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00960; Hellmann I, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02490; Hu YZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01442; Hu ZH, 2016, ONCOTARGET, V7, P82921, DOI 10.18632/oncotarget.13289; Huang P, 2015, INT J CLIN EXP PATHO, V8, P309; Iacono KT, 2007, EXP MOL PATHOL, V83, P283, DOI 10.1016/j.yexmp.2007.08.014; Jia L, 2006, IUBMB LIFE, V58, P209, DOI 10.1080/15216540600719580; Jiang JL, 2001, J BIOL CHEM, V276, P46870, DOI 10.1074/jbc.M108291200; Jin SJ, 2018, PROTEIN CELL, V9, P310, DOI 10.1007/s13238-017-0443-1; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Ke X, 2012, ONCOL LETT, V3, P1249, DOI 10.3892/ol.2012.658; Kijanka M, 2015, NANOMEDICINE-UK, V10, P161, DOI 10.2217/nnm.14.178; Kijanka M, 2013, EUR J NUCL MED MOL I, V40, P1718, DOI 10.1007/s00259-013-2471-2; Krzyscik MA, 2019, MOL PHARMACEUT, V16, P3588, DOI 10.1021/acs.molpharmaceut.9b00434; Ku XM, 2007, SCAND J IMMUNOL, V65, P435, DOI 10.1111/j.1365-3083.2007.01930.x; Kuang YH, 2009, CANCER LETT, V276, P189, DOI 10.1016/j.canlet.2008.11.010; Landras A, 2019, CANCERS, V11, DOI 10.3390/cancers11111803; Li JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35210; Li Y, 2009, HISTOPATHOLOGY, V54, P677, DOI 10.1111/j.1365-2559.2009.03280.x; Maldonado-Baez L, 2013, J CELL BIOL, V201, P233, DOI 10.1083/jcb.201208172; Marcucci F, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00167; Papoutsi M, 2000, HISTOCHEM CELL BIOL, V113, P105, DOI 10.1007/s004180050013; Piao SL, 2012, J CANCER RES CLIN, V138, P627, DOI 10.1007/s00432-011-1142-6; Tang J, 2008, CELL MOL LIFE SCI, V65, P2933, DOI 10.1007/s00018-008-8315-8; Tseng HC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18444-2; Van Audenhove I, 2016, EBIOMEDICINE, V8, P40, DOI 10.1016/j.ebiom.2016.04.028; van der Meel R, 2012, J CONTROL RELEASE, V159, P281, DOI 10.1016/j.jconrel.2011.12.027; Wang K, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00426-x; Wang P, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.571181; Xiong LJ, 2014, INT J MOL SCI, V15, P17411, DOI 10.3390/ijms151017411; Xu JL, 2021, NATURE, V595, P278, DOI 10.1038/s41586-021-03676-z; Xu J, 2007, MOL CANCER RES, V5, P605, DOI 10.1158/1541-7786.MCR-06-0286; Xu RZ, 2011, BIOCONJUGATE CHEM, V22, P870, DOI 10.1021/bc1002295; Yang JM, 2006, J BIOL CHEM, V281, P9719, DOI 10.1074/jbc.M508421200; Yin HY, 2017, NEUROL SCI, V38, P129, DOI 10.1007/s10072-016-2727-2; Zeng HZ, 2011, NEOPLASMA, V58, P449, DOI 10.4149/neo_2011_05_449; Zhong XW, 2013, ANN SURG ONCOL, V20, P1044, DOI 10.1245/s10434-012-2377-4; Zhu LC, 2015, AM J CANCER RES, V5, P830; Zhu M, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0352-5; Zhu XJ, 2019, SMALL, V15, DOI 10.1002/smll.201803428; Zimmermann K, 2017, INT J HYPERTHER, V33, P178, DOI 10.1080/02656736.2016.1230233	60	0	0	10	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								852700	10.3389/fimmu.2022.852700	http://dx.doi.org/10.3389/fimmu.2022.852700			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8PV	35603157	Green Published, gold			2022-12-18	WOS:000797490000001
J	Liang, Y; Cui, L; Xiao, L; Liu, X; Yang, YR; Ling, YB; Wang, T; Wang, L; Wang, J; Wu, XQ				Liang, Yan; Cui, Lei; Xiao, Li; Liu, Xiao; Yang, Yourong; Ling, Yanbo; Wang, Tong; Wang, Lan; Wang, Jie; Wu, Xueqiong			Immunotherapeutic Effects of Different Doses of Mycobacterium tuberculosis ag85a/b DNA Vaccine Delivered by Electroporation	FRONTIERS IN IMMUNOLOGY			English	Article						DNA vaccine; ag85a; b DNA; immunotherapy; Mycobacterium tuberculosis; electroporation	IN-VIVO ELECTROPORATION; REGULATORY T-CELLS; IMMUNE-RESPONSES; TUBERCULOSIS; MICE; IMMUNOGENICITY; IMMUNIZATION; STRATEGIES; PROTECTION; THERAPY	BackgroundTuberculosis (TB) is a major global public health problem. New treatment methods on TB are urgently demanded. MethodsNinety-six female BALB/c mice were challenged with 2x10(4) colony-forming units (CFUs) of MTB H(37)Rv through tail vein injection, then was treated with 10 mu g, 50 mu g, 100 mu g, and 200 mu g of Mycobacterium tuberculosis (MTB) ag85a/b chimeric DNA vaccine delivered by intramuscular injection (IM) and electroporation (EP), respectively. The immunotherapeutic effects were evaluated immunologically, bacteriologically, and pathologically. ResultsCompared with the phosphate-buffered saline (PBS) group, the CD4(+)IFN-gamma(+) T cells% in whole blood from 200 mu g DNA IM group and four DNA EP groups increased significantly (P<0.05), CD8(+)IFN-gamma(+) T cells% (in 200 mu g DNA EP group), CD4(+)IL-4(+) T cells% (50 mu g DNA IM group) and CD8(+)IL-4(+) T cells% (50 mu g and 100 mu g DNA IM group, 100 mu g and 200 mu g DNA EP group) increased significantly only in a few DNA groups (P< 0.05). The CD4(+)CD25(+) Treg cells% decreased significantly in all DNA vaccine groups (P<0.01). Except for the 10 mu g DNA IM group, the lung and spleen colony-forming units (CFUs) of the other seven DNA immunization groups decreased significantly (P<0.001, P<0.01), especially the 100 mu g DNA IM group and 50 mu g DNA EP group significantly reduced the pulmonary bacterial loads and lung lesions than the other DNA groups. ConclusionsAn MTB ag85a/b chimeric DNA vaccine could induce Th1-type cellular immune reactions. DNA immunization by EP could improve the immunogenicity of the low-dose DNA vaccine, reduce DNA dose, and produce good immunotherapeutic effects on the mouse TB model, to provide the basis for the future human clinical trial of MTB ag85a/b chimeric DNA vaccine.	[Liang, Yan; Cui, Lei; Xiao, Li; Liu, Xiao; Yang, Yourong; Ling, Yanbo; Wang, Tong; Wang, Lan; Wang, Jie; Wu, Xueqiong] Eighth Med Ctr PLA Gen Hosp, Sr Dept TB, TB Prevent & Control Key Lab, Beijing Key Lab New Tech TB Diagnosisand Treatment, Beijing, Peoples R China		Wu, XQ (corresponding author), Eighth Med Ctr PLA Gen Hosp, Sr Dept TB, TB Prevent & Control Key Lab, Beijing Key Lab New Tech TB Diagnosisand Treatment, Beijing, Peoples R China.	xueqiongwu@139.com			Serious Infectious Diseases Special Foundation [2012ZX10003008-002, 2018ZX10731301-005]; Special Key Project of the Medical Innovation Project of China [18CXZ028]	Serious Infectious Diseases Special Foundation; Special Key Project of the Medical Innovation Project of China	This project was supported by the grant from the Serious Infectious Diseases Special Foundation (2012ZX10003008-002, 2018ZX10731301-005), the Special Key Project of the Medical Innovation Project of China (18CXZ028).	Babiuk S, 2002, VACCINE, V20, P3399, DOI 10.1016/S0264-410X(02)00269-4; Barbon CM, 2010, VACCINE, V28, P7852, DOI 10.1016/j.vaccine.2010.09.078; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Cardona P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02139; Cohen J, 2002, SCIENCE, V295, P1616, DOI 10.1126/science.295.5560.1616; Cui ZR, 2003, CRIT REV THER DRUG, V20, P103, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i23.10; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; Fedatto PF, 2012, IMMUNOLOGY, V137, P239, DOI 10.1111/imm.12006; Gregoriadis G, 1997, FEBS LETT, V402, P107, DOI 10.1016/S0014-5793(96)01507-4; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Kalat M, 2002, CANCER RES, V62, P5489; Kaufmann SHE, 2006, NAT REV IMMUNOL, V6, P699, DOI 10.1038/nri1920; Kim HJ, 2011, KOREAN J PARASITOL, V49, P85, DOI 10.3347/kjp.2011.49.1.85; KLENCHIN VA, 1991, BIOPHYS J, V60, P804, DOI 10.1016/S0006-3495(91)82115-4; Li Ding-feng, 2006, Zhonghua Weishengwuxue He Mianyixue Zazhi, V26, P1038; Li ZM, 2006, VACCINE, V24, P4565, DOI 10.1016/j.vaccine.2005.08.021; Liang Y., 2014, CHIN J ANTITUBERC, V36, P424, DOI [10.3969/j.issn.1000-6621.2014.06.004, DOI 10.3969/J.ISSN.1000-6621.2014.06.004]; Liang Y, 2016, CURR GENE THER, V16, P249, DOI 10.2174/1566523216666161102170123; [梁艳 Liang Yan], 2014, [中华微生物学和免疫学杂志, Chinese Journal of Microbiology and Immunology], V34, P673; Liang Y, 2012, FEMS IMMUNOL MED MIC, V66, P419, DOI 10.1111/1574-695X.12008; Lin F, 2011, VACCINE, V29, P6771, DOI 10.1016/j.vaccine.2010.12.057; Liu KH, 2011, J VIROL, V85, P4853, DOI 10.1128/JVI.02437-10; Liu MA, 1997, VACCINE, V15, P909, DOI 10.1016/S0264-410X(96)00280-0; Liu MA, 2005, ADV GENET, V55, P25, DOI 10.1016/S0065-2660(05)55002-8; Lowrie DB, 1999, NATURE, V400, P269, DOI 10.1038/22326; Luckay A, 2007, J VIROL, V81, P5257, DOI 10.1128/JVI.00055-07; Luxembourg A, 2006, VACCINE, V24, P4490, DOI 10.1016/j.vaccine.2005.08.014; MacGregor RR, 1998, J INFECT DIS, V178, P92, DOI 10.1086/515613; Mu JY, 2009, MOL THER, V17, P1093, DOI 10.1038/mt.2009.60; Pasquini S, 1997, IMMUNOL CELL BIOL, V75, P397, DOI 10.1038/icb.1997.62; Prazeres DMF, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.PLAS-0022-2014; Roy E, 2008, TUBERCULOSIS, V88, P197, DOI [10.1016/j.tube.2007.11.005, 10.1016/S1472-9792(08)70011-8]; Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008; Sheng ZY, 2019, VIROL SIN, V34, P88, DOI 10.1007/s12250-019-00090-8; Shirota H, 2007, J IMMUNOL, V179, P329, DOI 10.4049/jimmunol.179.1.329; Suschak JJ, 2018, J INFECT DIS, V218, pS519, DOI 10.1093/infdis/jiy378; Tacket CO, 1999, VACCINE, V17, P2826, DOI 10.1016/S0264-410X(99)00094-8; Tang JS, 2018, TUBERCULOSIS, V113, P65, DOI 10.1016/j.tube.2018.07.003; Tollefsen S, 2003, SCAND J IMMUNOL, V57, P229, DOI 10.1046/j.1365-3083.2003.01218.x; Tollefsen S, 2002, VACCINE, V20, P3370, DOI 10.1016/S0264-410X(02)00289-X; Villarreal DO, 2014, HUM VACC IMMUNOTHER, V10, P2188, DOI 10.4161/hv.29574; Villarreal DO, 2013, EXPERT REV VACCINES, V12, P537, DOI [10.1586/erv.13.33, 10.1586/ERV.13.33]; Weiland O, 2013, MOL THER, V21, P1796, DOI 10.1038/mt.2013.119; Winslow GM, 2008, IMMUNOL REV, V225, P284, DOI 10.1111/j.1600-065X.2008.00693.x; World Health Organization, GLOBAL TUBERCULOSIS; Wu XQ., 2006, CELL MOL IMMUNOL, V22, P883, DOI [10.1007/s00034-004-1208-7, DOI 10.1007/S00034-004-1208-7]; Yan J., 2010, MOL THER, V18, pS184, DOI [10.1016/S1525-0016(16)37918-7, DOI 10.1016/S1525-0016(16)37918-7]; Zhang XZ, 2007, VACCINE, V25, P1342, DOI 10.1016/j.vaccine.2006.09.089; Zucchelli S, 2000, J VIROL, V74, P11598, DOI 10.1128/JVI.74.24.11598-11607.2000; Zupanic A, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-66	52	0	0	3	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								876579	10.3389/fimmu.2022.876579	http://dx.doi.org/10.3389/fimmu.2022.876579			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J1NP	35603155	Green Published, gold			2022-12-18	WOS:000797691300001
J	Matsuda, KM; Yoshizaki, A; Yamaguchi, K; Fukuda, E; Okumura, T; Ogawa, K; Ono, C; Norimatsu, Y; Kotani, H; Hisamoto, T; Kawanabe, R; Kuzumi, A; Fukasawa, T; Ebata, S; Miyagawa, T; Yoshizaki-Ogawa, A; Goshima, N; Sato, S				Matsuda, Kazuki M.; Yoshizaki, Ayumi; Yamaguchi, Kei; Fukuda, Eriko; Okumura, Taishi; Ogawa, Koji; Ono, Chihiro; Norimatsu, Yuta; Kotani, Hirohito; Hisamoto, Teruyoshi; Kawanabe, Ruriko; Kuzumi, Ai; Fukasawa, Takemichi; Ebata, Satoshi; Miyagawa, Takuya; Yoshizaki-Ogawa, Asako; Goshima, Naoki; Sato, Shinichi			Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status	FRONTIERS IN IMMUNOLOGY			English	Article						autoantibody; protein array; autoimmunity; inflammatory disease; malignancy	SYSTEMIC-SCLEROSIS; CLASSIFICATION CRITERIA; PSORIATIC-ARTHRITIS; SEQUENCE	Autoantibodies are found in various pathological conditions such as autoimmune diseases, infectious diseases, and malignant tumors. However their clinical implications have not yet been fully elucidated. Herein, we conducted proteome-wide autoantibody screening and quantification with wet protein arrays consisting of proteins synthesized from proteome-wide human cDNA library (HuPEX) maintaining their three-dimensional structure. A total of 565 autoantibodies were identified from the sera of three representative inflammatory disorders (systemic sclerosis, psoriasis, and cutaneous arteritis). Each autoantibody level either positively or negatively correlated with serum levels of C-reactive protein, the best-recognized indicator of inflammation. In particular, we discovered total levels of a subset of autoantibodies correlates with the severity of clinical symptoms. From the sera of malignant melanoma, 488 autoantibodies were detected. Notably, patients with metastases had increased overall autoantibody production compared to those with tumors limiting to the primary site. Collectively, proteome-wide screening of autoantibodies using the in vitro proteome can reveal the "autoantibody landscape" of human subjects and may provide novel clinical biomarkers.	[Matsuda, Kazuki M.; Yoshizaki, Ayumi; Norimatsu, Yuta; Kotani, Hirohito; Hisamoto, Teruyoshi; Kawanabe, Ruriko; Kuzumi, Ai; Fukasawa, Takemichi; Ebata, Satoshi; Miyagawa, Takuya; Yoshizaki-Ogawa, Asako; Sato, Shinichi] Univ Tokyo Grad Sch Med, Dept Dermatol, Tokyo, Japan; [Yamaguchi, Kei; Okumura, Taishi; Ogawa, Koji; Ono, Chihiro; Goshima, Naoki] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery, Tokyo, Japan; [Yamaguchi, Kei; Okumura, Taishi; Ogawa, Koji; Ono, Chihiro; Goshima, Naoki] ProteoBridge Corp, Tokyo, Japan; [Fukuda, Eriko] Cellular & Mol Biotechnol Res Inst, Natl Inst Adv Ind Sci & Technol, Tokyo, Japan	University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Yoshizaki, A; Sato, S (corresponding author), Univ Tokyo Grad Sch Med, Dept Dermatol, Tokyo, Japan.	ayuyoshi@me.com; satos-der@h.u-tokyo.ac.jp	深澤, 毅倫/AAB-8559-2021; Ebata, Satoshi/GLU-7664-2022	深澤, 毅倫/0000-0002-6093-1881; Ebata, Satoshi/0000-0001-5606-1513				Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776; Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Caron M, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0102-2017; Chaplin DD, 2010, J ALLERGY CLIN IMMUN, V125, pS3, DOI 10.1016/j.jaci.2009.12.980; CLEMENTS PJ, 1990, ARTHRITIS RHEUM, V33, P1256, DOI 10.1002/art.1780330828; DALE JB, 1986, J EXP MED, V164, P1785, DOI 10.1084/jem.164.5.1785; Didier K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00541; Endo Y, 2006, CURR OPIN BIOTECH, V17, P373, DOI 10.1016/j.copbio.2006.06.009; Fukuda E, 2021, GENES CELLS, V26, P180, DOI 10.1111/gtc.12832; Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49; Goshima N, 2008, NAT METHODS, V5, P1011, DOI 10.1038/nmeth.1273; Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313; Hamaguchi Y, 2008, BRIT J DERMATOL, V158, P487, DOI 10.1111/j.1365-2133.2007.08392.x; Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000; Jeong JS, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.016253; Khamashta M, 2016, ANN RHEUM DIS, V75, P1909, DOI 10.1136/annrheumdis-2015-208562; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LEROY EC, 1988, J RHEUMATOL, V15, P202; Ludwig RJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00603; Matsuda KM, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1919-6; Matsuda KM, 2021, J DERMATOL, V48, P1021, DOI 10.1111/1346-8138.15868; Menter A, 2008, J AM ACAD DERMATOL, V58, P826, DOI 10.1016/j.jaad.2008.02.039; Morimoto AM, 2011, ARTHRITIS RHEUM-US, V63, P2407, DOI 10.1002/art.30399; Nakamura T, 2009, ARCH DERMATOL RES, V301, P117, DOI 10.1007/s00403-008-0898-2; Ota M, 2021, CELL, V184, P3006, DOI 10.1016/j.cell.2021.03.056; Rubio-Rivas M, 2014, SEMIN ARTHRITIS RHEU, V44, P208, DOI 10.1016/j.semarthrit.2014.05.010; Sawasaki T, 2002, P NATL ACAD SCI USA, V99, P14652, DOI 10.1073/pnas.232580399; Sawasaki T, 2002, FEBS LETT, V514, P102, DOI 10.1016/S0014-5793(02)02329-3; Schwartz RH, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006908; Taylor W, 2006, ARTHRITIS RHEUM, V54, P2665, DOI 10.1002/art.21972; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321; van den Hoogen F, 2013, ANN RHEUM DIS, V72, P1747, DOI [10.1136/annrheumdis-2013-204424, 10.1002/art.38098]; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wang Eric Y, 2022, Cell Rep Methods, V2, DOI 10.1016/j.crmeth.2022.100172; Wang EY, 2021, NATURE, V595, P283, DOI [10.1038/s41586-021-03631-y, 10.1101/2020.12.10.20247205]; Yuan YL, 2019, ARTHRITIS RHEUMATOL, V71, P941, DOI 10.1002/art.40830	39	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								893086	10.3389/fimmu.2022.893086	http://dx.doi.org/10.3389/fimmu.2022.893086			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8RH	35603173	gold, Green Published			2022-12-18	WOS:000797493800001
J	Pompura, SL; Hafler, DA; Dominguez-Villar, M				Pompura, Saige L.; Hafler, David A.; Dominguez-Villar, Margarita			Fatty Acid Metabolism and T Cells in Multiple Sclerosis	FRONTIERS IN IMMUNOLOGY			English	Review						T cell; multiple sclerosis; immunometabolism; fatty acids; T regulatory (Treg) cell	PROMOTE IMMUNE HOMEOSTASIS; TH1-LIKE TREG GENERATION; VISCERAL ADIPOSE-TISSUE; GAMMA PPAR-GAMMA; REGULATORY T; TH17 CELLS; HELPER 17; DOCOSAHEXAENOIC ACID; PROTEIN-KINASE; T(H)17 CELLS	Cellular metabolic remodeling is intrinsically linked to the development, activation, differentiation, function, and survival of T cells. T cells transition from a catabolic, naive state to an anabolic effector state upon T cell activation. Subsequently, specialization of T cells into T helper (Th) subsets, including regulatory T cells (T-reg), requires fine-tuning of metabolic programs that better support and optimize T cell functions for that particular environment. Increasingly, studies have shown that changes in nutrient availability at both the cellular and organismal level during disease states can alter T cell function, highlighting the importance of better characterizing metabolic-immune axes in both physiological and disease settings. In support of these data, a growing body of evidence is emerging that shows specific lipid species are capable of altering the inflammatory functional phenotypes of T cells. In this review we summarize the metabolic programs shown to support naive and effector T cells, and those driving Th subsets. We then discuss changes to lipid profiles in patients with multiple sclerosis, and focus on how the presence of specific lipid species can alter cellular metabolism and function of T cells.	[Pompura, Saige L.; Hafler, David A.] Yale Sch Med, Dept Neurol & Immunobiol, New Haven, CT USA; [Dominguez-Villar, Margarita] Imperial Coll London, Fac Med, London, England	Yale University; Imperial College London	Dominguez-Villar, M (corresponding author), Imperial Coll London, Fac Med, London, England.				NIH [U19 AI089992, R25 NS079193, P01 AI073748, U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, R01 CA227473]; National Multiple Sclerosis Society (NMSS) [CA 1061- A-18, RG-1802-30153]; Nancy Taylor Foundation for Chronic Diseases; Race to Erase MS.	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society (NMSS)(National Multiple Sclerosis Society); Nancy Taylor Foundation for Chronic Diseases; Race to Erase MS.	This work was supported by grants to DAH from the NIH (U19 AI089992, R25 NS079193, P01 AI073748, U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, and R01 CA227473); the National Multiple Sclerosis Society (NMSS) (CA 1061- A-18, RG-1802-30153); the Nancy Taylor Foundation for Chronic Diseases; and Race to Erase MS.	Adams WC, 2016, CELL REP, V17, P3142, DOI 10.1016/j.celrep.2016.11.065; Aires V, 2003, BRIT J PHARMACOL, V140, P1217, DOI 10.1038/sj.bjp.0705563; Angela M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13683; Angelin A, 2017, CELL METAB, V25, P1282, DOI 10.1016/j.cmet.2016.12.018; Apostolidis SA, 2016, NAT IMMUNOL, V17, P556, DOI 10.1038/ni.3390; Asanuma S, 2011, ANN HEMATOL, V90, P617, DOI 10.1007/s00277-010-1121-z; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bailis W, 2019, NATURE, V571, P403, DOI 10.1038/s41586-019-1311-3; Basu S, 2015, J LEUKOCYTE BIOL, V97, P279, DOI 10.1189/jlb.2AB0514-273RR; Batten M, 2010, J EXP MED, V207, P2895, DOI 10.1084/jem.20100064; Berod L, 2014, NAT MED, V20, P1327, DOI 10.1038/nm.3704; Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655; Bhargava P, 2016, MULT SCLER J, V22, P451, DOI 10.1177/1352458515622827; Blagih J, 2015, IMMUNITY, V42, P41, DOI 10.1016/j.immuni.2014.12.030; BODY DR, 1988, PROG LIPID RES, V27, P39, DOI 10.1016/0163-7827(88)90004-5; Bonin A, 2000, J LIPID RES, V41, P277; Brucklacher-Waldert V, 2009, BRAIN, V132, P3329, DOI 10.1093/brain/awp289; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Calder PC, 2010, NUTRIENTS, V2, P355, DOI 10.3390/nu2030355; Cantuti-Castelvetri L, 2018, SCIENCE, V359, P684, DOI 10.1126/science.aan4183; Carrillo C, 2012, NUTR HOSP, V27, P978, DOI 10.3305/nh.2012.27.4.5783; Cham CM, 2008, EUR J IMMUNOL, V38, P2438, DOI 10.1002/eji.200838289; Cham CM, 2005, J IMMUNOL, V174, P4670, DOI 10.4049/jimmunol.174.8.4670; Chang CH, 2013, CELL, V153, P1239, DOI 10.1016/j.cell.2013.05.016; Chapman NM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04392-5; Chen T, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal5196; Choi JM, 2012, MOL CELLS, V33, P217, DOI 10.1007/s10059-012-2297-y; Chornoguz O, 2017, J IMMUNOL, V198, P3939, DOI 10.4049/jimmunol.1601078; CHOW SC, 1990, J BIOL CHEM, V265, P902; Christensen JR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057820; Chung Y, 2009, IMMUNITY, V30, P576, DOI 10.1016/j.immuni.2009.02.007; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; Corsetto PA, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-73; Cury-Boaventura MF, 2006, LIFE SCI, V78, P1448, DOI 10.1016/j.lfs.2005.07.038; de Carvalho Jozelio Freire, 2009, Front Biosci (Elite Ed), V1, P501; de Jong AJ, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00483; De Rosa V, 2015, NAT IMMUNOL, V16, P1174, DOI 10.1038/ni.3269; Delgoffe GM, 2009, IMMUNITY, V30, P832, DOI 10.1016/j.immuni.2009.04.014; Denys A, 2002, MOL CELL BIOCHEM, V232, P143, DOI 10.1023/A:1014806122510; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Domingues HS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015531; Dominguez-Villar M, 2011, NAT MED, V17, P673, DOI 10.1038/nm.2389; Dos Passos GR, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/5314541; Endo Y, 2015, CELL REP, V12, P1042, DOI 10.1016/j.celrep.2015.07.014; Farini A, 2007, J PATHOL, V213, P229, DOI 10.1002/path.2213; Ferreira HB, 2021, ARCH BIOCHEM BIOPHYS, V697, DOI 10.1016/j.abb.2020.108672; Feuerer M, 2009, NAT MED, V15, P930, DOI 10.1038/nm.2002; FIELD CJ, 1984, NUTR RES, V4, P743, DOI 10.1016/S0271-5317(84)80050-0; Fletcher JM, 2010, CLIN EXP IMMUNOL, V162, P1, DOI 10.1111/j.1365-2249.2010.04143.x; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Franchi L, 2017, J IMMUNOL, V198, P2735, DOI 10.4049/jimmunol.1600810; Frauwirth KA, 2002, IMMUNITY, V16, P769, DOI 10.1016/S1074-7613(02)00323-0; Frischer JM, 2009, BRAIN, V132, P1175, DOI 10.1093/brain/awp070; Gaublomme JT, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.009; Gerriets VA, 2016, NAT IMMUNOL, V17, P1459, DOI 10.1038/ni.3577; Gerriets VA, 2015, J CLIN INVEST, V125, P194, DOI 10.1172/JCI76012; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Giri S., 2014, J IMMUNOL, V192, P10; Gocke AR, 2009, J IMMUNOL, V182, P4479, DOI 10.4049/jimmunol.0713927; Grassi S, 2020, J LIPID RES, V61, P636, DOI 10.1194/jlr.TR119000427; Gualdoni GA, 2016, FASEB J, V30, P3800, DOI 10.1096/fj.201600522R; Gubser PM, 2013, NAT IMMUNOL, V14, P1064, DOI 10.1038/ni.2687; Guma M, 2016, NAT REV RHEUMATOL, V12, P269, DOI 10.1038/nrrheum.2016.1; Haghikia A, 2015, IMMUNITY, V43, P817, DOI 10.1016/j.immuni.2015.09.007; Hammer A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0954-y; Han JM, 2015, J IMMUNOL, V194, P4777, DOI 10.4049/jimmunol.1500020; Harbour SN, 2015, P NATL ACAD SCI USA, V112, P7061, DOI 10.1073/pnas.1415675112; Hedstrom AK, 2012, MULT SCLER J, V18, P1334, DOI 10.1177/1352458512436596; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heikamp EB, 2014, NAT IMMUNOL, V15, P457, DOI 10.1038/ni.2867; Heink S, 2017, NAT IMMUNOL, V18, P74, DOI 10.1038/ni.3632; Hernandez AL, 2015, J CLIN INVEST, V125, P4212, DOI 10.1172/JCI81151; Hosios AM, 2016, DEV CELL, V36, P540, DOI 10.1016/j.devcel.2016.02.012; Howie D, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01949; Howie D, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89160; Hu X, 2015, NAT CHEM BIOL, V11, P141, DOI [10.1038/NCHEMBIO.1714, 10.1038/nchembio.1714]; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; Hubler Z, 2018, NATURE, V560, P372, DOI 10.1038/s41586-018-0360-3; Huynh A, 2015, NAT IMMUNOL, V16, P188, DOI 10.1038/ni.3077; Innes JK, 2018, PROSTAG LEUKOTR ESS, V132, P41, DOI 10.1016/j.plefa.2018.03.004; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jackson SH, 2004, NAT IMMUNOL, V5, P818, DOI 10.1038/ni1096; Jacobs SR, 2008, J IMMUNOL, V180, P4476, DOI 10.4049/jimmunol.180.7.4476; Jain R, 2016, IMMUNITY, V44, P131, DOI 10.1016/j.immuni.2015.11.009; Kambe T, 1999, FEBS LETT, V453, P81, DOI 10.1016/S0014-5793(99)00702-4; Kaskow BJ, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029025; Kebir H, 2009, ANN NEUROL, V66, P390, DOI 10.1002/ana.21748; Kidani Y, 2013, NAT IMMUNOL, V14, P489, DOI 10.1038/ni.2570; Kim W, 2014, BRIT J NUTR, V111, P254, DOI 10.1017/S0007114513002444; Kinnaird A, 2016, NAT REV CANCER, V16, P694, DOI 10.1038/nrc.2016.82; Kishore M, 2017, IMMUNITY, V47, P875, DOI 10.1016/j.immuni.2017.10.017; Kitz A, 2017, CELL MOL LIFE SCI, V74, P4059, DOI 10.1007/s00018-017-2569-y; Kitz A, 2016, EMBO REP, V17, P1169, DOI 10.15252/embr.201541905; Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868; Klocperk A, 2014, J CLIN IMMUNOL, V34, P864, DOI 10.1007/s10875-014-0071-y; Klotz L, 2009, J EXP MED, V206, P2079, DOI 10.1084/jem.20082771; Klysz D, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab2610; Kolodin D, 2015, CELL METAB, V21, P543, DOI 10.1016/j.cmet.2015.03.005; Kopf H, 2007, INT IMMUNOPHARMACOL, V7, P1819, DOI 10.1016/j.intimp.2007.08.027; La Rocca C, 2017, METABOLISM, V77, P39, DOI 10.1016/j.metabol.2017.08.011; Lee SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135858; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Leung S, 2010, CELL MOL IMMUNOL, V7, P182, DOI 10.1038/cmi.2010.22; Lewkowicz N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080786; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Linterman MA, 2010, J EXP MED, V207, P353, DOI 10.1084/jem.20091738; Lochner M, 2015, TRENDS IMMUNOL, V36, P81, DOI 10.1016/j.it.2014.12.005; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MacIver NJ, 2011, J IMMUNOL, V187, P4187, DOI 10.4049/jimmunol.1100367; Mailer RKW, 2015, SCI REP-UK, V5, DOI 10.1038/srep14674; Martin F, 2012, TRENDS MOL MED, V18, P742, DOI 10.1016/j.molmed.2012.09.007; Mauro C, 2017, CELL METAB, V25, P593, DOI 10.1016/j.cmet.2017.01.008; McClymont SA, 2011, J IMMUNOL, V186, P3918, DOI 10.4049/jimmunol.1003099; Mendoza A, 2017, NATURE, V546, P158, DOI 10.1038/nature22352; Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613; Morita R, 2011, IMMUNITY, V34, P108, DOI 10.1016/j.immuni.2010.12.012; Munz C, 2009, NAT REV IMMUNOL, V9, P246, DOI 10.1038/nri2527; Munger KL, 2009, NEUROLOGY, V73, P1543, DOI 10.1212/WNL.0b013e3181c0d6e0; Nogueras L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47906-x; Palomer X, 2016, BBA-MOL CELL BIOL L, V1861, P1569, DOI 10.1016/j.bbalip.2016.01.019; Peeters LM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01160; Peng M, 2016, SCIENCE, V354, P481, DOI 10.1126/science.aaf6284; Pfeifle R, 2017, NAT IMMUNOL, V18, P104, DOI 10.1038/ni.3579; Poisson LM, 2015, J BIOL CHEM, V290, P30697, DOI 10.1074/jbc.M115.679068; Polak PE, 2005, J NEUROIMMUNOL, V168, P65, DOI 10.1016/j.jneuroim.2005.07.006; Pollizzi KN, 2015, J CLIN INVEST, V125, P2090, DOI 10.1172/JCI77746; Pompura SL, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI138519; Procaccini C, 2016, IMMUNITY, V44, P712, DOI 10.1016/j.immuni.2016.02.022; Procaccini C, 2010, IMMUNITY, V33, P929, DOI 10.1016/j.immuni.2010.11.024; Radzikowska U, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122990; RAINE CS, 1994, ANN NEUROL, V36, pS61, DOI 10.1002/ana.410360716; Raud B, 2018, CELL METAB, V28, P504, DOI 10.1016/j.cmet.2018.06.002; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Rueda CM, 2017, J LIPID RES, V58, P1514, DOI 10.1194/jlr.M072835; Santori FR, 2015, CELL METAB, V21, P286, DOI 10.1016/j.cmet.2015.01.004; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Scharping NE, 2016, IMMUNITY, V45, P374, DOI [10.1016/j.immuni.2016.07.009, 10.1016/j.immuni.2016.08.009]; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Sena LA, 2013, IMMUNITY, V38, P225, DOI 10.1016/j.immuni.2012.10.020; Seumois G, 2016, J IMMUNOL, V197, P655, DOI 10.4049/jimmunol.1600397; Sharma MD, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500845; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Sie C, 2014, EXP NEUROL, V262, P18, DOI 10.1016/j.expneurol.2014.03.009; Siska PJ, 2015, TRENDS IMMUNOL, V36, P257, DOI 10.1016/j.it.2015.02.007; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Spann NJ, 2013, NAT IMMUNOL, V14, P893, DOI 10.1038/ni.2681; SPECTOR AA, 1984, CLIN PHYSIOL BIOCH, V2, P123; Stentz FB, 2006, BIOCHEM BIOPH RES CO, V346, P721, DOI 10.1016/j.bbrc.2006.05.159; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Sun YF, 2016, J NEUROIMMUNOL, V292, P58, DOI 10.1016/j.jneuroim.2016.01.014; SZAMEL M, 1989, J IMMUNOL, V143, P2806; Takahashi HK, 2012, J CELL PHYSIOL, V227, P339, DOI 10.1002/jcp.22740; Tamas P, 2006, J EXP MED, V203, P1665, DOI 10.1084/jem.20052469; Tan J, 2016, CELL REP, V15, P2809, DOI 10.1016/j.celrep.2016.05.047; Tarasenko TN, 2017, CELL METAB, V25, P1254, DOI 10.1016/j.cmet.2017.05.007; Tauhid S, 2014, J NEUROL SCI, V346, P250, DOI 10.1016/j.jns.2014.08.047; Terada S, 2001, MICROBIOL IMMUNOL, V45, P473, DOI 10.1111/j.1348-0421.2001.tb02647.x; Travis MA, 2014, ANNU REV IMMUNOL, V32, P51, DOI 10.1146/annurev-immunol-032713-120257; Tzartos JS, 2011, AM J PATHOL, V178, P794, DOI 10.1016/j.ajpath.2010.10.043; Uchiyama R, 2017, J IMMUNOL, V199, P1122, DOI 10.4049/jimmunol.1601373; Uher T, 2017, J LIPID RES, V58, P403, DOI 10.1194/jlr.M072751; Ustun C, 2011, BLOOD, V118, P5084, DOI 10.1182/blood-2011-07-365817; van de Kraats C, 2014, MULT SCLER J, V20, P412, DOI 10.1177/1352458513499421; Vasanthakumar A, 2015, NAT IMMUNOL, V16, P544, DOI 10.1038/ni0515-544d; Verstappen GM, 2018, J AUTOIMMUN, V87, P16, DOI 10.1016/j.jaut.2017.11.003; Wang C, 2015, CELL, V163, DOI 10.1016/j.cell.2015.10.068; Wang RN, 2011, IMMUNITY, V35, P871, DOI 10.1016/j.immuni.2011.09.021; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weinberg SE, 2019, NATURE, V565, P495, DOI 10.1038/s41586-018-0846-z; Wells H. F., 2008, Economic Information Bulletin - USDA Economic Research Service; Wohlfert EA, 2007, J IMMUNOL, V178, P4129, DOI 10.4049/jimmunol.178.7.4129; Xia MC, 2014, J ALLERGY CLIN IMMUN, V134, P634, DOI 10.1016/j.jaci.2014.03.010; Xie M, 2006, P NATL ACAD SCI USA, V103, P17378, DOI 10.1073/pnas.0604708103; Xu S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.331; Yang JQ, 2016, J ALLERGY CLIN IMMUN, V137, P231, DOI 10.1016/j.jaci.2015.05.004; Yang K, 2011, NAT IMMUNOL, V12, P888, DOI 10.1038/ni.2068; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Ye J, 2013, AM J PATHOL, V182, P10, DOI 10.1016/j.ajpath.2012.08.041; Yin YM, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa0835; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158; Zeng H, 2013, NATURE, V499, P485, DOI 10.1038/nature12297; Zeng H, 2013, CURR OPIN IMMUNOL, V25, P347, DOI 10.1016/j.coi.2013.05.002; Zhang J, 1992, Int Rev Immunol, V9, P183, DOI 10.3109/08830189209061790; ZHANG JW, 1994, J EXP MED, V179, P973, DOI 10.1084/jem.179.3.973; Zhang X, 2013, EUR J IMMUNOL, V43, P281, DOI 10.1002/eji.201242566; Zhang X, 2011, J IMMUNOL, V187, P3431, DOI 10.4049/jimmunol.1100580; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zhou T, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1791-y; Zielinski CE, 2012, NATURE, V484, P514, DOI 10.1038/nature10957; Zurier RB, 1999, PROSTAG LEUKOTR ESS, V60, P371, DOI 10.1016/S0952-3278(99)80015-5	190	0	0	4	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								869197	10.3389/fimmu.2022.869197	http://dx.doi.org/10.3389/fimmu.2022.869197			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J3RZ	35603182	Green Published, gold			2022-12-18	WOS:000797838300001
J	Sudan, R; Fernandes, S; Srivastava, N; Pedicone, C; Meyer, ST; Chisholm, JD; Engelman, RW; Kerr, WG				Sudan, Raki; Fernandes, Sandra; Srivastava, Neetu; Pedicone, Chiara; Meyer, Shea T.; Chisholm, John D.; Engelman, Robert W.; Kerr, William G.			LRBA Deficiency Can Lead to Lethal Colitis That Is Diminished by SHIP1 Agonism	FRONTIERS IN IMMUNOLOGY			English	Article						LRBA deficiency; SHIP1; src homology 2 domain-containing inositol phosphatase 1; colitis; ILC3 cytokines	REGULATORY T-CELLS; DENDRITIC CELLS; MOUSE MODEL; DISEASE; LIPOPOLYSACCHARIDE; GENE; IDENTIFICATION; INFLAMMATION; EXPRESSION; TOLERANCE	Humans homozygous for inactivating LRBA (lipopolysaccharide (LPS)-responsive beige-like anchor) mutations or with compound heterozygous mutations exhibit a spectrum of immune-related pathologies including inflammatory bowel disease (IBD). The cause of this pathology remains undefined. Here we show that disruption of the colon epithelial barrier in LRBA-deficient mice by dextran sulfate sodium (DSS) consumption leads to severe and uniformly lethal colitis. Analysis of bone marrow (BM) chimeras showed that susceptibility to lethal colitis is primarily due to LRBA deficiency in the immune compartment and not the gut epithelium. Further dissection of the immune defect in LRBA-deficient hosts showed that LRBA is essential for the expression of CTLA4 by Treg cells and IL22 and IL17 expression by ILC3 cells in the large intestine when the gut epithelium is compromised by DSS. We further show that SHIP1 agonism partially abrogates the severity and lethality of DSS-mediated colitis. Our findings indicate that enteropathy induced by LRBA deficiency has multiple causes and that SHIP1 agonism can partially abrogate the inflammatory milieu in the gut of LRBA-deficient hosts.	[Sudan, Raki; Fernandes, Sandra; Srivastava, Neetu; Pedicone, Chiara; Kerr, William G.] SUNY Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY USA; [Meyer, Shea T.; Chisholm, John D.; Kerr, William G.] Syracuse Univ, Dept Chem, Syracuse, NY USA; [Engelman, Robert W.] Univ S Florida, Dept Pathol & Cell Biol, Tampa, FL USA; [Engelman, Robert W.] Univ S Florida, Dept Pediat, Tampa, FL USA; [Engelman, Robert W.] Univ S Florida, H Lee Moffitt Comprehens Canc Ctr, Tampa, FL USA; [Engelman, Robert W.] Univ S Florida, Res Inst, Tampa, FL USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Syracuse University; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Kerr, WG (corresponding author), SUNY Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY USA.; Kerr, WG (corresponding author), Syracuse Univ, Dept Chem, Syracuse, NY USA.	kerrw@upstate.edu	Sudan, Raki/AFK-6979-2022; Srivastava, Neetu/HDM-9431-2022	Fernandes Denney, Sandra/0000-0003-0919-8925	NIH [RO1 AG059717]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding This work was supported in part by NIH grant RO1 AG059717 to WK.	Alangari A, 2012, J ALLERGY CLIN IMMUN, V130, P481, DOI 10.1016/j.jaci.2012.05.043; Alroqi FJ, 2018, J ALLERGY CLIN IMMUN, V141, P1050, DOI 10.1016/j.jaci.2017.05.022; Andres SA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-326; Azizi G, 2017, EUR ANN ALLERGY CLIN, V49, P235, DOI 10.23822/EurAnnACI.1764-1489.22; Barnes MJ, 2009, IMMUNITY, V31, P401, DOI 10.1016/j.immuni.2009.08.011; Bishop JL, 2014, MUCOSAL IMMUNOL, V7, P405, DOI 10.1038/mi.2013.60; Blanco-Menendez N, 2015, J IMMUNOL, V195, P4466, DOI 10.4049/jimmunol.1402874; Blander JM, 2017, NAT IMMUNOL, V18, P851, DOI 10.1038/ni.3780; Burnett DL, 2017, IMMUNOL CELL BIOL, V95, P775, DOI 10.1038/icb.2017.50; Burns SO, 2012, J ALLERGY CLIN IMMUN, V130, P1428, DOI 10.1016/j.jaci.2012.07.035; de Souza N, 2007, DEVELOPMENT, V134, P691, DOI 10.1242/dev.02767; Gabhann JN, 2010, J IMMUNOL, V184, P2314, DOI 10.4049/jimmunol.0902589; Gamez-Diaz L, 2017, IMMUNOL CELL BIOL, V95, P789, DOI 10.1038/icb.2017.52; Gamez-Diaz L, 2016, J ALLERGY CLIN IMMUN, V137, P223, DOI 10.1016/j.jaci.2015.09.025; Hayashi T, 2009, P NATL ACAD SCI USA, V106, P2764, DOI 10.1073/pnas.0813037106; Jamee M, 2021, CLIN EXP IMMUNOL, V205, P28, DOI 10.1111/cei.13600; Keir ME, 2020, J EXP MED, V217, DOI 10.1084/jem.20192195; Kerr WG, 1996, P NATL ACAD SCI USA, V93, P3947, DOI 10.1073/pnas.93.9.3947; Kerr WG, 2011, ANN NY ACAD SCI, V1217, P1, DOI 10.1111/j.1749-6632.2010.05869.x; Kerr WG, 2011, GUT, V60, P177, DOI 10.1136/gut.2009.202283; Kurtenbach S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08543-4; Lee JS, 2015, IMMUNITY, V43, P727, DOI 10.1016/j.immuni.2015.09.003; Li SY, 2016, IMMUNITY, V45, P185, DOI 10.1016/j.immuni.2016.06.027; Lind EF, 2015, J IMMUNOL, V195, P4632, DOI 10.4049/jimmunol.1302941; Liu HY, 2003, J IMMUNOL, V171, P5012, DOI 10.4049/jimmunol.171.10.5012; Lo B, 2015, SCIENCE, V349, P436, DOI 10.1126/science.aaa1663; Lopez-Herrera G, 2012, AM J HUM GENET, V90, P986, DOI 10.1016/j.ajhg.2012.04.015; McGeachy MJ, 2019, IMMUNITY, V50, P892, DOI 10.1016/j.immuni.2019.03.021; Meimetis LG, 2012, EUR J ORG CHEM, V2012, P5195, DOI 10.1002/ejoc.201200631; Ong CJ, 2007, BLOOD, V110, P1942, DOI 10.1182/blood-2007-03-079699; Park MY, 2014, MUCOSAL IMMUNOL, V7, P1429, DOI 10.1038/mi.2014.32; Park MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep36568; Pauls SD, 2017, EUR J IMMUNOL, V47, P932, DOI 10.1002/eji.201646795; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Read S, 2006, J IMMUNOL, V177, P4376, DOI 10.4049/jimmunol.177.7.4376; Sawa S, 2011, NAT IMMUNOL, V12, P320, DOI 10.1038/ni.2002; Saz-Leal P, 2018, CELL REP, V25, P1118, DOI 10.1016/j.celrep.2018.09.092; Sly LM, 2009, BLOOD, V113, P2945, DOI 10.1182/blood-2008-06-166082; Sugimoto K, 2008, J CLIN INVEST, V118, P534, DOI [10.1172/JC133194, 10.1172/JCI33194]; Tesch VK, 2020, J ALLERGY CLIN IMMUN, V145, P1452, DOI 10.1016/j.jaci.2019.12.896; Tozlu S, 2006, ENDOCR-RELAT CANCER, V13, P1109, DOI 10.1677/erc.1.01120; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Wang JW, 2001, J IMMUNOL, V166, P4586, DOI 10.4049/jimmunol.166.7.4586; Wang KW, 2019, P NATL ACAD SCI USA, V116, P11380, DOI 10.1073/pnas.1901407116; Watanabe K, 2008, INFECT IMMUN, V76, P5834, DOI 10.1128/IAI.00542-08	45	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								830961	10.3389/fimmu.2022.830961	http://dx.doi.org/10.3389/fimmu.2022.830961			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8ZT	35603158	Green Published, gold			2022-12-18	WOS:000797516500001
J	Szczesny, P; Barsotti, S; Nennesmo, I; Danielsson, O; Dastmalchi, M				Szczesny, Piotr; Barsotti, Simone; Nennesmo, Inger; Danielsson, Olof; Dastmalchi, Maryam			Screening for Anti-HMGCR Antibodies in a Large Single Myositis Center Reveals Infrequent Exposure to Statins and Diversiform Presentation of the Disease	FRONTIERS IN IMMUNOLOGY			English	Article						immune-mediated necrotizing myopathy (IMNM); anti-HMGCR; statin; dermatomyositis; idiopathic inflammatory myopathy	IDIOPATHIC INFLAMMATORY MYOPATHIES; NECROTIZING MYOPATHIES; CLASSIFICATION; ADULT	BackgroundThe objective of this study is to assess the frequency of autoantibodies against 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) in a single center myositis cohort and to analyze associations with statin exposure, clinical features, and outcome of disease course. MethodsA total of 312 patients with idiopathic inflammatory myopathies (IIMs) followed at the rheumatology clinic, Karolinska University Hospital, were identified in the Euromyositis registry between 1988 and 2014 and were classified according to the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology (EULAR/ACR) criteria. Available serum samples were analyzed for anti-HMGCR autoantibodies by ELISA. Positive sera were confirmed by immunoprecipitation. Clinical data were extracted from Euromyositis registry and medical records. Muscle samples were examined by two pathologists blinded to the subjects' autoantibody status. ResultsOf 312 patients, 13 (4.3%) were positive for anti-HMGCR. Two of the 13 (15%) anti-HMGCR-positive patients had histories of statin use versus 12 (4.2%) in the anti-HMGCR-negative group. In the anti-HMGCR-positive group, five (38%) had a clinical phenotype compatible with dermatomyositis. Muscle biopsies of patients with HMGCR autoantibodies showed findings consistent with immune-mediated necrotizing myopathy in all cases except for one. Five (38%) patients required treatment with intravenous immunoglobulin compared to seven (2.3%) without this antibody. At the last visit, seven patients had chronic, active disease course, and five of 13 patients were in remission, including three without treatment. ConclusionsPatients with IIM related to anti-HMGCR autoantibodies may present with a wide range of symptoms, more than previously anticipated. When a broad approach to screening for these antibodies is applied, only a minority of patients was found to have previous statin exposure. The results of this study justify the addition of anti-HMGCR autoantibodies to routine diagnostic procedures in patients with myositis.	[Szczesny, Piotr] Natl Inst Geriatr Rheumatol & Rehabil, Dept Rheumatol, Warsaw, Poland; [Barsotti, Simone] Univ Pisa, Dept Clin & Expt Med, Rheumatol Unit, Pisa, Italy; [Barsotti, Simone] Livorno Hosp, Rheumatol Outpatient Clin, Livorno, Italy; [Nennesmo, Inger] Karolinska Inst, Dept Lab Med, Stockholm, Sweden; [Danielsson, Olof] Linkoping Univ, Fac Med & Hlth Sci, Dept Biomed & Clin Sci, Div Neurol, Linkoping, Sweden; [Dastmalchi, Maryam] Karolinska Inst, Dept Med, Div Rheumatol, Solna, Sweden; [Dastmalchi, Maryam] Karolinska Univ Hosp, Div Rheumatol, Stockholm, Sweden; [Dastmalchi, Maryam] Karolinska Inst, Ctr Mol Med, Stockholm, Sweden	National Institute of Geriatrics, Rheumatology & Rehabilitation; University of Pisa; Karolinska Institutet; Linkoping University; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Szczesny, P (corresponding author), Natl Inst Geriatr Rheumatol & Rehabil, Dept Rheumatol, Warsaw, Poland.	piotr.szczesny@spartanska.pl						Allenbach Y, 2018, NEUROLOGY, V90, pE507, DOI 10.1212/WNL.0000000000004923; Allenbach Y, 2018, NEUROMUSCULAR DISORD, V28, P87, DOI 10.1016/j.nmd.2017.09.016; Arouche-Delaperche L, 2017, ANN NEUROL, V81, P538, DOI 10.1002/ana.24902; Bergua C, 2019, ANN RHEUM DIS, V78, P131, DOI 10.1136/annrheumdis-2018-213518; Christopher-Stine L, 2010, ARTHRITIS RHEUM-US, V62, P2757, DOI 10.1002/art.27572; Connors GR, 2010, CHEST, V138, P1464, DOI 10.1378/chest.10-0180; Ge YP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141616; Hou Y, 2022, J NEUROL, V269, P280, DOI 10.1007/s00415-021-10621-7; Lundberg IE, 2017, ANN RHEUM DIS, V76, P1955, DOI 10.1136/annrheumdis-2017-211468; Mammen AL, 2012, ARTHRIT CARE RES, V64, P1233, DOI 10.1002/acr.21671; Rider LG, 2011, ARTHRIT CARE RES, V63, pS118, DOI 10.1002/acr.20532; Tiniakou E, 2017, RHEUMATOLOGY, V56, P787, DOI 10.1093/rheumatology/kew470; Watanabe Y, 2016, J NEUROL NEUROSUR PS, V87, P1038, DOI 10.1136/jnnp-2016-313166; Werner JL, 2012, ARTHRITIS RHEUM-US, V64, P4087, DOI 10.1002/art.34673; Williams B, 2021, J AUTOIMMUN, V123, DOI 10.1016/j.jaut.2021.102691	15	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								866701	10.3389/fimmu.2022.866701	http://dx.doi.org/10.3389/fimmu.2022.866701			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8NE	35603214	Green Published, gold			2022-12-18	WOS:000797482800001
J	Ye, ZL; Zeng, DQ; Zhou, R; Shi, M; Liao, WJ				Ye, Zilan; Zeng, Dongqiang; Zhou, Rui; Shi, Min; Liao, Wangjun			Tumor Microenvironment Evaluation for Gastrointestinal Cancer in the Era of Immunotherapy and Machine Learning	FRONTIERS IN IMMUNOLOGY			English	Review						tumor microenvironment; gastrointestinal cancer; immunotherapy; chemotherapy; machine learning	GASTRIC-CANCER; IMMUNE CELLS; IMMUNOSCORE; PROGNOSIS; SUBTYPES; HETEROGENEITY; IMMUNOLOGY	A dynamic and mutualistic interplay between tumor cells and the surrounding tumor microenvironment (TME) triggered the initiation, progression, metastasis, and therapy response of solid tumors. Recent clinical breakthroughs in immunotherapy for gastrointestinal cancer conferred considerable attention to the estimation of TME, and the maturity of next-generation sequencing (NGS)-based technology contributed to the availability of increasing datasets and computational toolbox for deciphering TME compartments. In the current review, we demonstrated the components of TME, multiple methodologies involved in TME detection, and prognostic and predictive TME signatures derived from corresponding methods for gastrointestinal cancer. The TME evaluation comprises traditional, radiomics, and NGS-based high-throughput methodologies, and the computational algorithms are comprehensively discussed. Moreover, we systemically elucidated the existing TME-relevant signatures in the prognostic, chemotherapeutic, and immunotherapeutic settings. Collectively, we highlighted the clinical and technological advances in TME estimation for clinical translation and anticipated that TME-associated biomarkers may be promising in optimizing the future precision treatment for gastrointestinal cancer.	[Ye, Zilan; Zeng, Dongqiang; Zhou, Rui; Shi, Min; Liao, Wangjun] Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Peoples R China	Southern Medical University - China	Liao, WJ (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Oncol, Guangzhou, Peoples R China.	nfyyliaowj@163.com	Zeng, Dongqiang/C-3828-2019	Zeng, Dongqiang/0000-0001-9724-8325	National Natural Science Foundation of China [82073303, 81772580]; Guangzhou Planned Project of Science and Technology [201803010070]; Guangdong-Macao Science and Technology Innovation Joint Fund Project and Hong Kong-Macao Science and Technology Achievement Transformation Project in Guangdong [2020A0505090007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangzhou Planned Project of Science and Technology; Guangdong-Macao Science and Technology Innovation Joint Fund Project and Hong Kong-Macao Science and Technology Achievement Transformation Project in Guangdong	This work was supported by the National Natural Science Foundation of China (Nos. 82073303 and 81772580), the Guangzhou Planned Project of Science and Technology (No. 201803010070), and the Guangdong-Macao Science and Technology Innovation Joint Fund Project and Hong Kong-Macao Science and Technology Achievement Transformation Project in Guangdong (No. 2020A0505090007) for data collection and interpretation.	Ahn J, 2013, BIOINFORMATICS, V29, P1865, DOI 10.1093/bioinformatics/btt301; Ali HR, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002194; Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004; Aran D, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1349-1; Argiles G, 2020, ANN ONCOL, V31, P1291, DOI 10.1016/j.annonc.2020.06.022; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05570-1; Charoentong P, 2017, CELL REP, V18, P248, DOI 10.1016/j.celrep.2016.12.019; Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166; Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126; Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6; Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287; Gao SW, 2016, JAMA ONCOL, V2, P37, DOI 10.1001/jamaoncol.2015.3413; Gawad C, 2016, NAT REV GENET, V17, P175, DOI 10.1038/nrg.2015.16; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Gold JS, 2009, LANCET ONCOL, V10, P1045, DOI 10.1016/S1470-2045(09)70242-6; Hackl H, 2016, NAT REV GENET, V17, P441, DOI 10.1038/nrg.2016.67; Huang AC, 2019, NAT MED, V25, P454, DOI 10.1038/s41591-019-0357-y; Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Jiang Y, 2020, ANN ONCOL, V31, P760, DOI 10.1016/j.annonc.2020.03.295; Jiang YM, 2021, LANCET DIGIT HEALTH, V3, pE371, DOI 10.1016/S2589-7500(21)00065-0; Jiang YM, 2018, CLIN CANCER RES, V24, P5574, DOI 10.1158/1078-0432.CCR-18-0848; Jiang YM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.1087; Jiang YM, 2018, ANN SURG, V267, P504, DOI 10.1097/SLA.0000000000002116; Kargl J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14381; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Kitano Y, 2018, BRIT J CANCER, V118, P171, DOI 10.1038/bjc.2017.401; Klein AM, 2015, CELL, V161, P1187, DOI 10.1016/j.cell.2015.04.044; Kuhn A, 2011, NAT METHODS, V8, P945, DOI [10.1038/NMETH.1710, 10.1038/nmeth.1710]; Lau D, 2019, TRENDS CANCER, V5, P149, DOI 10.1016/j.trecan.2019.02.006; Lee H, 2020, ANN ONCOL, V31, P487, DOI 10.1016/j.annonc.2020.01.011; Li B, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1028-7; Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818; Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307; Liebner DA, 2014, BIOINFORMATICS, V30, P682, DOI 10.1093/bioinformatics/btt566; Lin SH, 2019, EPIGENOMICS-UK, V11, P1251, DOI 10.2217/epi-2019-0151; Lu ZH, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000631; Lu ZH, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000374; Mahajan UM, 2018, GASTROENTEROLOGY, V155, P1625, DOI 10.1053/j.gastro.2018.08.009; Mlecnik B, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6352; Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587-019-0114-2; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Ngambenjawong C, 2017, ADV DRUG DELIVER REV, V114, P206, DOI 10.1016/j.addr.2017.04.010; Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5; Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X; Panda Anshuman, 2018, J Natl Cancer Inst, V110, P316, DOI 10.1093/jnci/djx213; Racle J, 2017, ELIFE, V6, DOI 10.7554/eLife.26476; Razzak Mina, 2014, Nat Rev Gastroenterol Hepatol, V11, P577, DOI 10.1038/nrgastro.2014.146; Saeys Y, 2016, NAT REV IMMUNOL, V16, P449, DOI 10.1038/nri.2016.56; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Sturm G, 2019, BIOINFORMATICS, V35, pI436, DOI 10.1093/bioinformatics/btz363; Sun R, 2018, LANCET ONCOL, V19, P1180, DOI 10.1016/S1470-2045(18)30413-3; Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151; Tappeiner E, 2017, BIOINFORMATICS, V33, P3140, DOI 10.1093/bioinformatics/btx377; Taube JM, 2018, MODERN PATHOL, V31, P214, DOI 10.1038/modpathol.2017.156; Tauriello DVF, 2016, TRENDS CANCER, V2, P495, DOI 10.1016/j.trecan.2016.08.001; Turley SJ, 2015, NAT REV IMMUNOL, V15, P669, DOI 10.1038/nri3902; van der Leun AM, 2020, NAT REV CANCER, V20, P218, DOI 10.1038/s41568-019-0235-4; Wang Y, 2018, CANCER IMMUNOL IMMUN, V67, P435, DOI 10.1007/s00262-017-2094-8; Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Zeng D, 2018, BRIT J SURG, V105, P1338, DOI 10.1002/bjs.10871; Zeng DQ, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002467; Zeng DQ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687975; Zeng DQ, 2020, THERANOSTICS, V10, P7002, DOI 10.7150/thno.46176; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436; Zhang Q, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1347; Zhang Zicheng, 2021, Brief Bioinform, V22, DOI 10.1093/bib/bbaa075; Zhong Y, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-89; Zhou R, 2019, EBIOMEDICINE, V42, P420, DOI 10.1016/j.ebiom.2019.03.043; Zhou R, 2019, CANCER IMMUNOL IMMUN, V68, P433, DOI 10.1007/s00262-018-2289-7	77	0	0	10	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								819807	10.3389/fimmu.2022.819807	http://dx.doi.org/10.3389/fimmu.2022.819807			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J3HZ	35603201	Green Published, gold			2022-12-18	WOS:000797812200001
J	Zhang, M; Wu, LL; Deng, YY; Peng, F; Wang, TT; Zhao, YH; Chen, P; Liu, JA; Cai, GY; Wang, LQ; Wu, J; Chen, XM				Zhang, Min; Wu, Lingling; Deng, Yiyao; Peng, Fei; Wang, Tiantian; Zhao, Yinghua; Chen, Pu; Liu, Jiaona; Cai, Guangyan; Wang, Liqiang; Wu, Jie; Chen, Xiangmei			Single Cell Dissection of Epithelial-Immune Cellular Interplay in Acute Kidney Injury Microenvironment	FRONTIERS IN IMMUNOLOGY			English	Article						acute kidney injury; renal tubular epithelial cells; microenvironment; intercellular crosstalk; trajectory analysis	REVEALS; MACROPHAGE	BackgroundUnderstanding the acute kidney injury (AKI) microenvironment changes and the complex cellular interaction is essential to elucidate the mechanisms and develop new targeted therapies for AKI. MethodsWe employed unbiased single-cell RNA sequencing to systematically resolve the cellular atlas of kidney tissue samples from mice at 1, 2 and 3 days after ischemia-reperfusion AKI and healthy control. The single-cell transcriptome findings were validated using multiplex immunostaining, western blotting, and functional experiments. ResultsWe constructed a systematic single-cell transcriptome atlas covering different AKI timepoints with immune cell infiltration increasing with AKI progression. Three new proximal tubule cells (PTCs) subtypes (PTC-S1-new/PTC-S2-new/PTC-S3-new) were identified, with upregulation of injury and repair-regulated signatures such as Sox9, Vcam1, Egr1, and Klf6 while with downregulation of metabolism. PTC-S1-new exhibited pro-inflammatory and pro-fibrotic signature compared to normal PTC, and trajectory analysis revealed that proliferating PTCs were the precursor cell of PTC-S1-new, and part of PTC-S1-new cells may turn into PTC-injured and then become fibrotic. Cellular interaction analysis revealed that PTC-S1-new and PTC-injured interacted closely with infiltrating immune cells through CXCL and TNF signaling pathways. Immunostaining validated that injured PTCs expressed a high level of TNFRSF1A and Kim-1, and functional experiments revealed that the exogenous addition of TNF-alpha promoted kidney inflammation, dramatic injury, and specific depletion of TNFRSF1A would abrogate the injury. ConclusionsThe single-cell profiling of AKI microenvironment provides new insight for the deep understanding of molecular changes of AKI, and elucidates the mechanisms and developing new targeted therapies for AKI.	[Zhang, Min; Wu, Lingling; Peng, Fei; Wang, Tiantian; Zhao, Yinghua; Chen, Pu; Liu, Jiaona; Cai, Guangyan; Wu, Jie; Chen, Xiangmei] China Gen Hosp, Nephrol Inst Chinese Peoples Liberat Army, Natl Clin Res Ctr Kidney Dis, Dept Nephrol,State Key Lab Kidney Dis,Beijing Key, Beijing, Peoples R China; [Deng, Yiyao] Guizhou Prov Peoples Hosp, Dept Nephrol, Guiyang, Peoples R China; [Wang, Liqiang] Gen Hosp Chinese Peoples Liberat Army PLA China, Dept Ophthalmol, Ophthalmol & Visual Sci Key Lab Peoples Liberat Ar, Beijing, Peoples R China		Wu, J; Chen, XM (corresponding author), China Gen Hosp, Nephrol Inst Chinese Peoples Liberat Army, Natl Clin Res Ctr Kidney Dis, Dept Nephrol,State Key Lab Kidney Dis,Beijing Key, Beijing, Peoples R China.; Wang, LQ (corresponding author), Gen Hosp Chinese Peoples Liberat Army PLA China, Dept Ophthalmol, Ophthalmol & Visual Sci Key Lab Peoples Liberat Ar, Beijing, Peoples R China.	liqiangw301@163.com; wujie301@126.com; xmchen301@126.com	Wu, Ling/GZN-2235-2022		National Key R&D Program of China [2018YFA0108803]; National Natural Science Foundation of China [82030025]; Military Medical Key Projects [BLB19J009]	National Key R&D Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Military Medical Key Projects	Funding This work was supported by National Key R&D Program of China (2017YFA0103203, 2017YFA0103200), National Natural Science Foundation of China (82030025), Military Medical Key Projects (BLB19J009), and the National Key R&D Program of China (2018YFA0108803).	Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/NMETH.4463, 10.1038/nmeth.4463]; Bellomo R, 2012, LANCET, V380, P756, DOI 10.1016/S0140-6736(11)61454-2; Bolisetty S, 2015, KIDNEY INT, V88, P95, DOI 10.1038/ki.2015.102; Brandt S, 2020, J AM SOC NEPHROL, V31, P2589, DOI 10.1681/ASN.2019121289; Chang-Panesso M, 2017, NAT REV NEPHROL, V13, P39, DOI 10.1038/nrneph.2016.169; Chen JW, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00411; Conway BR, 2020, J AM SOC NEPHROL, V31, P2833, DOI 10.1681/ASN.2020060806; Duraes FD, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.130651; Fahling M, 2017, NAT REV NEPHROL, V13, P169, DOI 10.1038/nrneph.2016.196; Ferreira RM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.147703; Fu J, 2019, J AM SOC NEPHROL, V30, P533, DOI 10.1681/ASN.2018090896; Fu ZJ, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101671; Gerhardt LMS, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026684118; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Huang LH, 2011, KIDNEY INT, V79, P613, DOI 10.1038/ki.2010.469; Huang YH, 2020, THERANOSTICS, V10, P7384, DOI 10.7150/thno.45455; Inoue T, 2019, KIDNEY INT, V95, P563, DOI 10.1016/j.kint.2018.09.020; Jiang XX, 2019, J CELL BIOCHEM, V120, P16273, DOI 10.1002/jcb.28909; Jin HY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0616-8; Jin SQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21246-9; Kieran NE, 2003, KIDNEY INT, V64, P480, DOI 10.1046/j.1523-1755.2003.00106.x; Kirita Y, 2020, P NATL ACAD SCI USA, V117, P15874, DOI 10.1073/pnas.2005477117; Kumar S, 2014, SEMIN NEPHROL, V34, P404, DOI 10.1016/j.semnephrol.2014.06.007; Kusaba T, 2014, P NATL ACAD SCI USA, V111, P1527, DOI 10.1073/pnas.1310653110; Lee S, 2011, J AM SOC NEPHROL, V22, P317, DOI 10.1681/ASN.2009060615; Liao JL, 2020, SCI DATA, V7, DOI 10.1038/s41597-019-0351-8; Liu J, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.94716; Liu P, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109693; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; Nguan CYC, 2014, AM J PHYSIOL-RENAL, V306, pF724, DOI 10.1152/ajprenal.00410.2013; Park J, 2018, SCIENCE, V360, P758, DOI 10.1126/science.aar2131; Peerapornratana S, 2019, KIDNEY INT, V96, P1083, DOI 10.1016/j.kint.2019.05.026; Piret SE, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024414118; Potter SS, 2018, NAT REV NEPHROL, V14, P479, DOI 10.1038/s41581-018-0021-7; Rao DA, 2020, NAT REV NEPHROL, V16, P238, DOI 10.1038/s41581-019-0232-6; Rossaint J, 2016, MINERVA UROL NEFROL, V68, P49; Rudman-Melnick V, 2020, J AM SOC NEPHROL, V31, P2793, DOI 10.1681/ASN.2020010052; Speeckaert MM, 2012, AM J NEPHROL, V36, P261, DOI 10.1159/000342333; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Supavekin S, 2003, KIDNEY INT, V63, P1714, DOI 10.1046/j.1523-1755.2003.00928.x; Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859; Wen Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.681748; Wen Y, 2019, J AM SOC NEPHROL, V30, P1925, DOI 10.1681/ASN.2019020111; Wu HJ, 2019, J AM SOC NEPHROL, V30, P23, DOI 10.1681/ASN.2018090912; Xu C, 2014, KIDNEY INT, V85, P72, DOI 10.1038/ki.2013.286; Xu LN, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118505; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Zhou XN, 2021, CANCER RES, V81, P2690, DOI 10.1158/0008-5472.CAN-20-2930	48	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								857025	10.3389/fimmu.2022.857025	http://dx.doi.org/10.3389/fimmu.2022.857025			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8TB	35603220	Green Published, gold			2022-12-18	WOS:000797498500001
J	Zhu, MC; Zeng, QP; Fan, T; Lei, YY; Wang, F; Zheng, SF; Wang, XF; Zeng, H; Tan, FW; Sun, N; Xue, Q; He, J				Zhu, Mingchuang; Zeng, Qingpeng; Fan, Tao; Lei, Yuanyuan; Wang, Feng; Zheng, Sufei; Wang, Xinfeng; Zeng, Hui; Tan, Fengwei; Sun, Nan; Xue, Qi; He, Jie			Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis (vol 13, 783495, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						lipid metabolism; early-stage lung adenocarcinoma (LUAD); recurrence; immune checkpoints(ICP); signature			[Zhu, Mingchuang; Fan, Tao; He, Jie] Wuhan Univ, Dept Oncol, Renmin Hosp, Wuhan, Peoples R China; [Zeng, Qingpeng; Lei, Yuanyuan; Wang, Feng; Zheng, Sufei; Wang, Xinfeng; Zeng, Hui; Tan, Fengwei; Sun, Nan; Xue, Qi; He, Jie] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China	Wuhan University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College	He, J (corresponding author), Wuhan Univ, Dept Oncol, Renmin Hosp, Wuhan, Peoples R China.; He, J (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China.							Zhu MC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.783495	1	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 4	2022	13								909105	10.3389/fimmu.2022.909105	http://dx.doi.org/10.3389/fimmu.2022.909105			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J4FU	35603152	Green Published, gold			2022-12-18	WOS:000797874500001
J	Adler, A; Manivel, VA; Fromell, K; Teramura, Y; Ekdahl, KN; Nilsson, B				Adler, Anna; Manivel, Vivek Anand; Fromell, Karin; Teramura, Yuji; Ekdahl, Kristina N.; Nilsson, Bo			A Robust Method to Store Complement C3 With Superior Ability to Maintain the Native Structure and Function of the Protein	FRONTIERS IN IMMUNOLOGY			English	Article						C3; C3(H2O); thioester; storage; freezing	INTRACELLULAR COMPLEMENT; MONOCLONAL-ANTIBODIES; ALTERNATIVE PATHWAY; PUTATIVE THIOESTER; C-3; BOND; ACQUISITION; GENERATION; ACTIVATION; COMPONENT	Complement components have a reputation to be very labile. One of the reasons for this is the spontaneous hydrolysis of the internal thioester that is found in both C3 and C4 (but not in C5). Despite the fact that approximate to 20,000 papers have been published on human C3 there is still no reliable method to store the protein without generating C3(H2O), a fact that may have affected studies of the conformation and function of C3, including recent studies on intracellular C3(H2O). The aim of this work was to define the conditions for storage of native C3 and to introduce a robust method that makes C3 almost resistant to the generation of C3(H2O). Here, we precipitated native C3 at the isoelectric point in low ionic strength buffer before freezing the protein at -80 degrees C. The formation of C3(H2O) was determined using cation exchange chromatography and the hemolytic activity of the different C3 preparations was determined using a hemolytic assay for the classical pathway. We show that freezing native C3 in the precipitated form is the best method to avoid loss of function and generation of C3(H2O). By contrast, the most efficient way to consistently generate C3(H2O) was to incubate native C3 in a buffer at pH 11.0. We conclude that we have defined the optimal storage conditions for storing and maintaining the function of native C3 without generating C3(H2O) and also the conditions for consistently generating C3(H2O).	[Adler, Anna; Manivel, Vivek Anand; Fromell, Karin; Teramura, Yuji; Ekdahl, Kristina N.; Nilsson, Bo] Uppsala Univ, Dept Immunol Genet & Pathol IGP, Rudbeck Lab, Uppsala, Sweden; [Teramura, Yuji] Cellular & Mol Biotechnol Res Inst CMB, Natl Inst Adv Ind Sci andTechnol AIST, Tsukuba, Japan; [Ekdahl, Kristina N.] Linnaeus Univ, Linnaeus Ctr Biomat Chem, Kalmar, Sweden	Uppsala University; Linnaeus University	Nilsson, B (corresponding author), Uppsala Univ, Dept Immunol Genet & Pathol IGP, Rudbeck Lab, Uppsala, Sweden.	bo.nilsson@igp.uu.se		Fromell, Karin/0000-0001-8905-8791	Swedish Research Council [2016-01060, 2016-04519, 2020-05762, 2021-02252]	Swedish Research Council(Swedish Research CouncilEuropean Commission)	Funding The Swedish Research Council grants 2016-01060, 2016-04519, 2020-05762, and 2021-02252.	Arborea G, 2017, MOL IMMUNOL, V89, P2, DOI 10.1016/j.molimm.2017.05.012; EKDAHL KN, 1992, SCAND J IMMUNOL, V35, P85, DOI 10.1111/j.1365-3083.1992.tb02837.x; Ekdahl KN, 2019, MOL IMMUNOL, V114, P353, DOI 10.1016/j.molimm.2019.07.032; Elvington M, 2017, J CLIN INVEST, V127, P970, DOI 10.1172/JCI89412; Fromell K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00530; Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231; HACK CE, 1990, J IMMUNOL, V144, P4249; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; ISENMAN DE, 1981, BIOCHEMISTRY-US, V20, P4458, DOI 10.1021/bi00518a034; ISENMAN DE, 1983, ANN NY ACAD SCI, V421, P277, DOI 10.1111/j.1749-6632.1983.tb18115.x; Johnstone A, 1996, IMMUNOCHEMISTRY PRAC; LAW SKA, 1990, BIOCHEM SOC T, V18, P1155; MULLEREBERHARD HJ, 1960, J EXP MED, V111, P201, DOI 10.1084/jem.111.2.201; NILSSON B, 1990, BIOCHEM J, V268, P55, DOI 10.1042/bj2680055; NILSSON B, 1986, SCAND J IMMUNOL, V23, P357, DOI 10.1111/j.1365-3083.1986.tb01976.x; NILSSON B, 1987, MOL IMMUNOL, V24, P487, DOI 10.1016/0161-5890(87)90023-X; NILSSON B, 1992, BIOCHEM J, V282, P715, DOI 10.1042/bj2820715; NILSSON UR, 1984, J IMMUNOL METHODS, V72, P49, DOI 10.1016/0022-1759(84)90432-0; PANGBURN MK, 1992, J BIOL CHEM, V267, P8584; PANGBURN MK, 1980, J EXP MED, V152, P1102, DOI 10.1084/jem.152.4.1102; PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856; TACK BF, 1980, P NATL ACAD SCI-BIOL, V77, P5764, DOI 10.1073/pnas.77.10.5764	22	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								891994	10.3389/fimmu.2022.891994	http://dx.doi.org/10.3389/fimmu.2022.891994			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1J4WT	35592325	gold, Green Published			2022-12-18	WOS:000797921100001
J	Chao, YH; Liu, CH; Pan, YA; Yen, FS; Chiou, JY; Wei, JCC				Chao, Yung-Hsiang; Liu, Chin-Hsiu; Pan, Yu-An; Yen, Fu-Shun; Chiou, Jeng-Yuan; Wei, James Cheng-Chung			Association Between Endometriosis and Subsequent Risk of Sjogren's Syndrome: A Nationwide Population-Based Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						Sjogren's syndrome; autoimmune disease; endometriosis; epidemiology; cohort	SYSTEMIC-LUPUS-ERYTHEMATOSUS; WOMEN; PREVALENCE; ARTHRITIS	ObjectiveThe relationship between endometriosis and the ensuing risk of Sjogren's syndrome has remained unclear. This study aims to present epidemiological evidence for this connection. MethodsThis is a retrospective cohort study of endometriosis patients (ICD-9-CM 617.0-617.9 and 621.3) and matched comparison group between 2000 and 2012 in the National Taiwan Insurance Research Database. After age matching, we analyzed the association between endometriosis and Sjogren's syndrome (ICD-9-CM 710.2). We used the Cox proportional hazard model to examine the hazard ratio of incidental Sjogren's syndrome. Subgroup analyses on age, comorbidities, and disease duration were also performed. ResultsA total of 73,665 individuals were included in this study. We identified 14733 newly diagnosed endometriosis patients and 58,932 non-endometriosis comparison group. The adjusted hazard ratio (HR) for incidental Sjogren's syndrome was 1.45 (95% confidence interval CI=1.27-1.65) in the endometriosis group, compared to the non-endometriosis comparison group. In subgroup analysis, the adjusted HR was 1.53 (95% CI=1.25-1.88) in the age group of 20-39 and 1.41 (95% CI =1.18-1.68) in the age of 40-64. Time-vary analysis showed that endometriosis who have a follow-up time of fewer than five years (adjusted HR=1.57, 95% CI=1.32-1.87) have a significantly highest risk of having subsequent Sjogren's syndrome. ConclusionThis population-based cohort study indicated that having a history of endometriosis puts patients at an increased risk of getting Sjogren's syndrome afterward, especially in the age group of 20-39 and within the first five years after the diagnosis of endometriosis. Clinicians should recognize this possible association in managing endometriosis or Sjogren's syndrome patients.	[Chao, Yung-Hsiang; Wei, James Cheng-Chung] Chung Shan Med Univ, Inst Med, Taichung, Taiwan; [Liu, Chin-Hsiu; Wei, James Cheng-Chung] Chung Shan Med Univ Hosp, Dept Allergy, Immunol & Rheumatol, Taichung, Taiwan; [Liu, Chin-Hsiu] China Med Univ Hosp, China Med Univ, Rheumatol & Immunol Ctr, Taichung, Taiwan; [Liu, Chin-Hsiu; Pan, Yu-An] Columbia Univ, Mailman Sch Publ Hlth, Dept Sociomed Sci, New York, NY USA; [Chao, Yung-Hsiang; Yen, Fu-Shun] Dr Yens Clin, Taoyuan, Taiwan; [Yen, Fu-Shun; Chiou, Jeng-Yuan] Chung Shan Med Univ, Sch Hlth Policy & Management, Taichung, Taiwan; [Chiou, Jeng-Yuan; Wei, James Cheng-Chung] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan; [Wei, James Cheng-Chung] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan; China Med Univ, Coll Med, Taichung, Taiwan	Chung Shan Medical University; Chung Shan Medical University; Chung Shan Medical University Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan; Columbia University; Chung Shan Medical University; China Medical University Taiwan; Taichung Veterans General Hospital; China Medical University Taiwan	Wei, JCC (corresponding author), Chung Shan Med Univ, Inst Med, Taichung, Taiwan.; Wei, JCC (corresponding author), Chung Shan Med Univ Hosp, Dept Allergy, Immunol & Rheumatol, Taichung, Taiwan.; Wei, JCC (corresponding author), China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan.; Wei, JCC (corresponding author), Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.	wei3228@gmail.com	Liu, Chin-Hsiu/GRE-7887-2022	Liu, Chin-Hsiu/0000-0002-2564-1133				Bedaiwy MA, 2002, HUM REPROD, V17, P426, DOI 10.1093/humrep/17.2.426; Bulun SE, 2009, NEW ENGL J MED, V360, P268, DOI 10.1056/NEJMra0804690; Burney RO, 2019, FERTIL STERIL, V112, pE153, DOI 10.1016/j.fertnstert.2019.08.083; Chen Chia-Lun, 2021, Front Med (Lausanne), V8, P796324, DOI 10.3389/fmed.2021.796324; Chen HH, 2019, SEMIN ARTHRITIS RHEU, V48, P895, DOI 10.1016/j.semarthrit.2018.06.007; Eisenberg VH, 2018, BJOG-INT J OBSTET GY, V125, P55, DOI 10.1111/1471-0528.14711; Eisenberg VH, 2012, AUTOIMMUN REV, V11, P806, DOI 10.1016/j.autrev.2012.01.005; Fan YH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79954-z; Gau SY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.640618; Giudice LC, 2010, NEW ENGL J MED, V362, P2389, DOI 10.1056/NEJMcp1000274; Greenbaum H, 2019, AM J REPROD IMMUNOL, V81, DOI 10.1111/aji.13095; Helmick CG, 2008, ARTHRITIS RHEUM-US, V58, P15, DOI 10.1002/art.23177; Hwang SH, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02343-7; Joseph S, 2019, DATABASE-OXFORD, DOI 10.1093/database/baz062; Kvaskoff M, 2021, HUM REPROD UPDATE, V27, P393, DOI 10.1093/humupd/dmaa045; Kyama Cleophas M, 2003, Reprod Biol Endocrinol, V1, P123, DOI 10.1186/1477-7827-1-123; Ma K., 2020, ORAL SURG ORAL MED O, V129, pe192, DOI [10.1016/j.oooo.2019.07.044, DOI 10.1016/J.OOOO.2019.07.044]; Matorras R, 2007, LUPUS, V16, P736, DOI 10.1177/0961203307081339; Nielsen NM, 2011, HUM REPROD, V26, P1555, DOI 10.1093/humrep/der105; Porpora MG, 2020, GYNECOL ENDOCRINOL, V36, P356, DOI 10.1080/09513590.2019.1655727; Prescott J, 2016, HUM REPROD, V31, P1475, DOI 10.1093/humrep/dew085; Qin BD, 2015, ANN RHEUM DIS, V74, P1983, DOI 10.1136/annrheumdis-2014-205375; Rios-Rios WD, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111539; Santoro L, 2012, HUM REPROD, V27, P1320, DOI 10.1093/humrep/des062; Shigesi N, 2019, HUM REPROD UPDATE, V25, P486, DOI 10.1093/humupd/dmz014; Sinaii N, 2002, HUM REPROD, V17, P2715, DOI 10.1093/humrep/17.10.2715; van Nimwegen JF, 2020, RHEUMATOLOGY, V59, P2806, DOI 10.1093/rheumatology/keaa017; Wei CH, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.619664; Wu MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175836; Wu XF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19580-y; Xue YH, 2021, RHEUMATOLOGY, V60, P3326, DOI 10.1093/rheumatology/keaa784; Yao Y, 2021, CLIN REV ALLERG IMMU, V60, P111, DOI 10.1007/s12016-020-08793-7; Yu MC, 2014, J ETHNOPHARMACOL, V155, P435, DOI 10.1016/j.jep.2014.05.049	33	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								845944	10.3389/fimmu.2022.845944	http://dx.doi.org/10.3389/fimmu.2022.845944			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1HJ	35592328	gold, Green Published			2022-12-18	WOS:000796986900001
J	Castro, ACE; Maia, R; Batalha, S; Freixo, JP; Martins, C; Neves, C; Cordeiro, AI; Neves, JF				Costa e Castro, Ana; Maia, Raquel; Batalha, Sara; Freixo, Joao Parente; Martins, Catarina; Neves, Conceicao; Cordeiro, Ana Isabel; Neves, Joao Farela			Case Report: Wide Spectrum of Manifestations of Ligase IV Deficiency: Report of 3 Cases	FRONTIERS IN IMMUNOLOGY			English	Article						ligase iv; immunodeficiency; bone marrow failure; case report; hypopigmentation; lymphopenia	MUTATION; IMPACT; MODEL	DNA ligase IV deficiency is a rare autosomal recessive disorder associated with impaired DNA repair mechanisms. Most patients with DNA repair defects present with neurologic deficits, combined immunodeficiency, bone marrow failure, and/or hematologic neoplasia. We present 3 unrelated cases of ligase IV deficiency with different clinical presentations. Patient 1 presented at the age of 5 with bone marrow failure, dysmorphic features, and T and B lymphopenia. A compound heterozygous variant L19W/K635fs in the LIG4 gene was identified. Patient 2 presented at the age of 16 with recurrent infections. He had agammaglobulinemia and absent B cells. A homozygous R278H in the LIG4 gene was identified. Patient 3 was referred for vitiligo and B-cell lymphopenia (low class-switched B cells) and hypogammaglobulinemia. Homozygous R278H in LIG4 was also identified. In the last few years, the spectrum of clinical manifestations caused by ligase IV deficiency has widened, making it very difficult to establish an accurate clinical diagnosis. The use of NGS allows a proper diagnosis and provides a better prognosis and adequate family counseling.	[Costa e Castro, Ana] Ctr Hosp Univ Lisboa Cent CHULC, Pediat, Hosp Dona Estefania, Lisbon, Portugal; [Maia, Raquel; Batalha, Sara] Ctr Hosp Univ Lisboa Cent CHULC, Pediat Hematol Unit, Hosp Dona Estefania, Lisbon, Portugal; [Freixo, Joao Parente] Ctr Genet Preditiva & Preventiva, Inst Biol Mol & Celular, Inst Invest & Inovacaao Saude, Porto, Portugal; [Martins, Catarina; Neves, Joao Farela] Nova Univ Lisbon, NOVA Med Sch, Comprehens Hlth Res Ctr CHRC, Lisbon, Portugal; [Martins, Catarina; Cordeiro, Ana Isabel; Neves, Joao Farela] Nova Univ Lisbon, NOVA Med Sch, Chron Dis Res Ctr CEDOC, Lisbon, Portugal; [Neves, Conceicao; Neves, Joao Farela] Ctr Hosp Univ Lisboa Cent, Hosp Dona Estefania, Primary Immunodeficiencies Unit, Lisbon, Portugal	Universidade do Porto; Universidade Nova de Lisboa; Universidade Nova de Lisboa	Neves, JF (corresponding author), Nova Univ Lisbon, NOVA Med Sch, Comprehens Hlth Res Ctr CHRC, Lisbon, Portugal.; Neves, JF (corresponding author), Nova Univ Lisbon, NOVA Med Sch, Chron Dis Res Ctr CEDOC, Lisbon, Portugal.; Neves, JF (corresponding author), Ctr Hosp Univ Lisboa Cent, Hosp Dona Estefania, Primary Immunodeficiencies Unit, Lisbon, Portugal.	joao.farelaneves@chlc.min-saude.pt		Farela Neves, Joao/0000-0003-4740-6094	Fundacao Ciencia e Tecnologia [UIDP/04923/2020]	Fundacao Ciencia e Tecnologia(Portuguese Foundation for Science and Technology)	& nbsp;The present publication was funded by Fundacao Ciencia e Tecnologia, IP national support through CHRC (UIDP/04923/2020).	Altmann T, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0520-1; Brunet BA, 2017, ANN ALLERG ASTHMA IM, V119, P379, DOI 10.1016/j.anai.2017.07.017; Chadha Priyal, 2021, Radiol Case Rep, V16, P2890, DOI 10.1016/j.radcr.2021.07.002; Chistiakov DA, 2009, EUR J MED GENET, V52, P373, DOI 10.1016/j.ejmg.2009.05.009; Felgentreff K, 2016, J CLIN IMMUNOL, V36, P341, DOI 10.1007/s10875-016-0266-5; Gerasimou P., 2020, HUM PATHOL CASE REP, V22, DOI [10.1016/j.ehpc.2020.200442, DOI 10.1016/J.EHPC.2020.200442]; Girard PM, 2004, HUM MOL GENET, V13, P2369, DOI 10.1093/hmg/ddh274; Jspeert HI, 2013, HUM MUTAT, V34, P1611, DOI 10.1002/humu.22436; Luo XZ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.695993; Madhu R, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.103974; Matsumoto K, 2020, J CLIN IMMUNOL, V40, P1187, DOI 10.1007/s10875-020-00831-5; Murray JE, 2014, HUM MUTAT, V35, P76, DOI 10.1002/humu.22461; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; PLOWMAN PN, 1990, BRIT J RADIOL, V63, P624, DOI 10.1259/0007-1285-63-752-624; Riballo E, 1999, CURR BIOL, V9, P699, DOI 10.1016/S0960-9822(99)80311-X; Riballo E, 2001, J BIOL CHEM, V276, P31124, DOI 10.1074/jbc.M103866200; Rucci F, 2010, P NATL ACAD SCI USA, V107, P3024, DOI 10.1073/pnas.0914865107; Schober S, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1724-z; Scully R, 2019, NAT REV MOL CELL BIO, V20, P698, DOI 10.1038/s41580-019-0152-0; Sharma R, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.570084; Slatter MA, 2020, CURR ALLERGY ASTHM R, V20, DOI 10.1007/s11882-020-00955-z; Boone ATS, 2019, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00426; Sun BJ, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01411-x; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Tilgner K, 2013, CELL DEATH DIFFER, V20, P1089, DOI 10.1038/cdd.2013.44; Tomkinson AE, 2020, MUTAGENESIS, V35, P51, DOI 10.1093/mutage/gez026	26	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								869728	10.3389/fimmu.2022.869728	http://dx.doi.org/10.3389/fimmu.2022.869728			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I7HL	35592332	Green Published, gold			2022-12-18	WOS:000797398100001
J	Fox, A; Liu, XM; Zolla-Pazner, S; Powell, RL				Fox, Alisa; Liu, Xiaomei; Zolla-Pazner, Susan; Powell, Rebecca L.			Impact of IgG Isotype on the Induction of Antibody-Dependent Cellular Phagocytosis of HIV by Human Milk Leukocytes	FRONTIERS IN IMMUNOLOGY			English	Article						human milk; lactation; ADCP; phagocytosis; mother-to-child HIV transmission; HIV; IgG; phagocytes	FC-GAMMA RECEPTORS; TO-CHILD TRANSMISSION; BREAST-MILK; B-CELLS; MONOCLONAL-ANTIBODIES; REDUCED RISK; MUCOSAL IGA; AFFINITY; SPECIFICITY; ASSOCIATION	Approximately 100,000 mother-to-child transmission (MTCT) events of HIV via human milk feeding occur each year. However, only about 15% of infants milk-fed by untreated HIV+ mothers become infected, suggesting a protective effect of the milk itself. Infants ingest 10(5)-10(8) maternal leukocytes daily via milk, which remain functional beyond ingestion. Such function may be elicited by maternal milk antibody (Ab). Though IgA is dominant in milk, most HIV-specific milk Abs are of the IgG subclass, highlighting the importance of investigating the function of each IgG isotype in the milk context. Though Ab effector function mediated by the constant (Fc) domain via interaction with Fc Receptors (FcRs), such as Ab-dependent cellular phagocytosis (ADCP), are critical in protecting against HIV infection, ADCP is largely unexplored as it relates to mitigation of MTCT. Presently we report the ADCP activity of milk leukocytes against HIV particles and immune complexes (ICs), using 57 unique samples from 34 women, elicited by IgG1/2/3/4 of monoclonal (m)Ab 246-D. Granulocyte ADCP of HIV was most potent compared to other phagocytes when elicited by IgG1/3/4. IgG1/3 activated granulocytes similarly, exhibiting 1.6x-4.4x greater activity compared to IgG2/4, and a preference for virus compared to ICs. Notably, CD16- monocyte ADCP of a given target were unaffected by isotype, and CD16+ monocytes were poorly stimulated by IgG1. IgG2/4 elicited potent IC ADCP, and in terms of total leukocyte IC ADCP, IgG4 and IgG3 exhibited similar function, with IgG4 eliciting 1.6x-2.1x greater activity compared to IgG1/IgG2, and CD16+ monocytes most stimulated by IgG2. These data contribute to a more comprehensive understanding of Fc-mediated functionality of milk leukocytes, which is critical in order to develop therapeutic approaches to eliminating this route of MTCT, including mucosal administration of mAbs and/or a maternal vaccination aimed to elicit a potent milk Ab response.	[Fox, Alisa; Liu, Xiaomei; Zolla-Pazner, Susan; Powell, Rebecca L.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY USA	Icahn School of Medicine at Mount Sinai	Powell, RL (corresponding author), Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY USA.	rebecca.powell@mssm.edu						Ackerman M., 2014, ANTIBODY FC, V1st ed; Ackerman ME, 2013, J VIROL, V87, P5468, DOI 10.1128/JVI.03403-12; Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Arsenault JE, 2010, J INFECT DIS, V202, P370, DOI 10.1086/653706; Autissier P, 2010, CYTOM PART A, V77A, P410, DOI 10.1002/cyto.a.20859; Bode L, 2012, AM J CLIN NUTR, V96, P831, DOI 10.3945/ajcn.112.039503; Bournazos S, 2020, NAT REV IMMUNOL, V20, P633, DOI 10.1038/s41577-020-00410-0; BUTTE NF, 1984, AM J CLIN NUTR, V39, P296, DOI 10.1093/ajcn/39.2.296; Cabinian A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156762; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; de Taeye SW, 2019, ANTIBODIES, V8, DOI 10.3390/antib8020030; DEWEY KG, 1984, J PEDIATR GASTR NUTR, V3, P713, DOI 10.1097/00005176-198411000-00014; DUCHEMIN AM, 1994, J BIOL CHEM, V269, P12111; Duchemin M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01141; Eudailey JA, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00505-17; Faucher JL, 2007, CYTOM PART A, V71A, P934, DOI 10.1002/cyto.a.20457; Filias A, 2011, BMC PEDIATR, V11, DOI 10.1186/1471-2431-11-29; Forthal DN, 2007, J IMMUNOL, V179, P7916, DOI 10.4049/jimmunol.179.11.7916; Fowler MG, 2007, AM J OBSTET GYNECOL, V197, pS3, DOI 10.1016/j.ajog.2007.06.048; Franca EL, 2011, APMIS, V119, P710, DOI 10.1111/j.1600-0463.2011.02789.x; Friedman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037648; Gach JS, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006793; GORNY MK, 1991, P NATL ACAD SCI USA, V88, P3238, DOI 10.1073/pnas.88.8.3238; Groot F, 2005, J VIROL, V79, P3009, DOI 10.1128/JVI.79.5.3009-3015.2005; Guilliams M, 2014, NAT REV IMMUNOL, V14, P94, DOI 10.1038/nri3582; Habte HH, 2008, NEONATOLOGY, V93, P162, DOI 10.1159/000108414; Hanson LA, 2000, ACTA PAEDIATR, V89, P252, DOI 10.1080/080352500750028339; Hassiotou F, 2015, ADV NUTR, V6, P267, DOI 10.3945/an.114.007377; Hassiotou F, 2013, J HUM LACT, V29, P171, DOI 10.1177/0890334413477242; Hayes JM, 2016, J INFLAMM RES, V9, P209, DOI 10.2147/JIR.S121233; Hioe CE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010254; Hubner W, 2007, J VIROL, V81, P12596, DOI 10.1128/JVI.01088-07; JAIN L, 1989, ARCH DIS CHILD-FETAL, V64, P930, DOI 10.1136/adc.64.7_Spec_No.930; Kuhn L, 2005, JAIDS-J ACQ IMM DEF, V39, P138; Lonnerdal B, 2003, AM J CLIN NUTR, V77, p1537S; Mabuka J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002739; Monteiro RC, 2003, ANNU REV IMMUNOL, V21, P177, DOI 10.1146/annurev.immunol.21.120601.141011; Musich T, 2017, J VIROL, V91, DOI [10.1128/JVI.02325-16, 10.1128/jvi.02325-16]; Musich T, 2015, CLIN IMMUNOL, V158, P127, DOI 10.1016/j.clim.2015.03.020; Nelson CS, 2016, J VIROL, V90, P4951, DOI 10.1128/JVI.00335-16; Permar SR, 2010, J VIROL, V84, P8209, DOI 10.1128/JVI.00656-10; Pollara J, 2015, J VIROL, V89, P9952, DOI 10.1128/JVI.01560-15; Powell RLR, 2019, JOVE-J VIS EXP, DOI 10.3791/60149; Powell RLR, 2019, BREASTFEED MED, V14, P185, DOI 10.1089/bfm.2018.0232; Rerks-Ngarm S, 2009, NEW ENGL J MED, V361, P2209, DOI 10.1056/NEJMoa0908492; Sacha CR, 2015, MUCOSAL IMMUNOL, V8, P316, DOI 10.1038/mi.2014.69; Sips M, 2016, MUCOSAL IMMUNOL, V9, P1584, DOI 10.1038/mi.2016.12; Tay MZ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00332; Tay MZ, 2019, J VIROL, V93, DOI 10.1128/JVI.02084-18; Tay MZ, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005817; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Trend S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135580; Tuaillon E, 2009, J IMMUNOL, V182, P7155, DOI 10.4049/jimmunol.0803107; Tuboly S, 2002, ADV EXP MED BIOL, V503, P107; Villamor E, 2007, AM J CLIN NUTR, V86, P682, DOI 10.1093/ajcn/86.3.682; Wahl A, 2015, J VIROL, V89, P10868, DOI 10.1128/JVI.01702-15; Wahl A, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002732; Walter J, 2009, J INFECT DIS, V200, P1498, DOI 10.1086/644603; Weaver LT, 1998, ARCH DIS CHILD, V78, P235, DOI 10.1136/adc.78.3.235; WIRT DP, 1992, CYTOMETRY, V13, P282, DOI 10.1002/cyto.990130310; World Health Organization, 2016, WHO GUID GUID APPR G; Yates NL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007730; Zhou L, 2000, IMMUNOLOGY, V101, P570, DOI 10.1046/j.1365-2567.2000.00144.x; Zhu HQ, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/431896	65	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								831767	10.3389/fimmu.2022.831767	http://dx.doi.org/10.3389/fimmu.2022.831767			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1ES	35592337	Green Published, gold, Green Submitted			2022-12-18	WOS:000796980000001
J	Hoang, Y; Gryzik, S; Hoppe, I; Rybak, A; Schaedlich, M; Kadner, I; Walther, D; Vera, J; Radbruch, A; Groth, D; Baumgart, S; Baumgrass, R				Hoang, Yen; Gryzik, Stefanie; Hoppe, Ines; Rybak, Alexander; Schaedlich, Martin; Kadner, Isabelle; Walther, Dirk; Vera, Julio; Radbruch, Andreas; Groth, Detlef; Baumgart, Sabine; Baumgrass, Ria			PRI: Re-Analysis of a Public Mass Cytometry Dataset Reveals Patterns of Effective Tumor Treatments	FRONTIERS IN IMMUNOLOGY			English	Article						multi-parametric analysis; re-analysis; combinatorial protein expression; high-dimensional cytometry data; mass cytometry data; pattern perception	FLOW-CYTOMETRY; HETEROGENEITY; VISUALIZATION; FUTURE; CELLS	Recently, mass cytometry has enabled quantification of up to 50 parameters for millions of cells per sample. It remains a challenge to analyze such high-dimensional data to exploit the richness of the inherent information, even though many valuable new analysis tools have already been developed. We propose a novel algorithm "pattern recognition of immune cells (PRI)" to tackle these high-dimensional protein combinations in the data. PRI is a tool for the analysis and visualization of cytometry data based on a three or more-parametric binning approach, feature engineering of bin properties of multivariate cell data, and a pseudo-multiparametric visualization. Using a publicly available mass cytometry dataset, we proved that reproducible feature engineering and intuitive understanding of the generated bin plots are helpful hallmarks for re-analysis with PRI. In the CD4(+)T cell population analyzed, PRI revealed two bin-plot patterns (CD90/CD44/CD86 and CD90/CD44/CD27) and 20 bin plot features for threshold-independent classification of mice concerning ineffective and effective tumor treatment. In addition, PRI mapped cell subsets regarding co-expression of the proliferation marker Ki67 with two major transcription factors and further delineated a specific Th1 cell subset. All these results demonstrate the added insights that can be obtained using the non-cluster-based tool PRI for re-analyses of high-dimensional cytometric data.	[Hoang, Yen; Gryzik, Stefanie; Hoppe, Ines; Rybak, Alexander; Schaedlich, Martin; Kadner, Isabelle; Radbruch, Andreas; Baumgart, Sabine; Baumgrass, Ria] Leibniz Inst, German Rheumatism Res Ctr DRFZ, Berlin, Germany; [Rybak, Alexander; Schaedlich, Martin; Kadner, Isabelle; Groth, Detlef; Baumgrass, Ria] Univ Potsdam, Inst Biochem & Biol, Bioinformat, Potsdam, Germany; [Walther, Dirk] Max Planck Inst Mol Plant Physiol, Bioinformat, Potsdam, Germany; [Vera, Julio] Friedrich Alexander Univ Erlangen Nurnberg FAU, Lab Syst Tumor Immunol, Erlangen, Germany; [Vera, Julio; Radbruch, Andreas] Charite Campus Berlin Mitte, Dept Rheumatol & Clin Immunol, Berlin, Germany; [Baumgart, Sabine] Univ Hosp Jena, Inst Immunol, Core Facil Cytometry, Jena, Germany; Univ klinikum Erlangen, Erlangen, Germany	Deutsches Rheuma-Forschungszentrum (DRFZ); University of Potsdam; Max Planck Society; University of Erlangen Nuremberg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Friedrich Schiller University of Jena; University of Erlangen Nuremberg	Baumgrass, R (corresponding author), Leibniz Inst, German Rheumatism Res Ctr DRFZ, Berlin, Germany.; Baumgrass, R (corresponding author), Univ Potsdam, Inst Biochem & Biol, Bioinformat, Potsdam, Germany.							Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Bruggner RV, 2014, P NATL ACAD SCI USA, V111, pE2770, DOI 10.1073/pnas.1408792111; Cariou B, 2020, DIABETOLOGIA, V63, P1500, DOI 10.1007/s00125-020-05180-x; Cheng Y, 2016, J IMMUNOL, V196, P924, DOI 10.4049/jimmunol.1501928; Ellis B, 2017, FLOWCORE BASIC STRUC, DOI [10.18129/B9.bioc.flowCore, DOI 10.18129/B9.BIOC.FLOWCORE]; Finak G, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-546; Galili T, 2015, BIOINFORMATICS, V31, P3718, DOI 10.1093/bioinformatics/btv428; Gryzik S, 2020, ELIFE, V9, DOI 10.7554/eLife.53226; Kotecha Nikesh, 2010, Curr Protoc Cytom, VChapter 10, DOI 10.1002/0471142956.cy1017s53; Levine JH, 2015, CELL, V162, P184, DOI 10.1016/j.cell.2015.05.047; Liechti T, 2021, NAT IMMUNOL, V22, P1190, DOI 10.1038/s41590-021-01006-z; Lugli E, 2010, CYTOM PART A, V77A, P705, DOI 10.1002/cyto.a.20901; Mair F, 2019, CYTOM PART A, V95A, P147, DOI 10.1002/cyto.a.23700; Mair F, 2016, EUR J IMMUNOL, V46, P34, DOI 10.1002/eji.201545774; Montante S, 2019, INT J LAB HEMATOL, V41, P56, DOI 10.1111/ijlh.13016; Newell EW, 2016, NAT IMMUNOL, V17, P890, DOI 10.1038/ni.3485; R Core Team, 2018, R LANG ENV STAT COMP, P10, DOI [DOI 10.1038/SJ.HDY.6800737, 10.1108/eb003648]; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Saeys Y, 2016, NAT REV IMMUNOL, V16, P449, DOI 10.1038/nri.2016.56; Spitzer MH, 2017, CELL, V168, P487, DOI 10.1016/j.cell.2016.12.022; Spitzer MH, 2016, CELL, V165, P780, DOI 10.1016/j.cell.2016.04.019; Van Gassen S, 2015, CYTOM PART A, V87A, P636, DOI 10.1002/cyto.a.22625; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1	25	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								849329	10.3389/fimmu.2022.849329	http://dx.doi.org/10.3389/fimmu.2022.849329			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I0ZX	35592315	Green Submitted, Green Published, gold			2022-12-18	WOS:000796967400001
J	Lambert, N; El Moussaoui, M; Ritacco, C; Moise, M; Paulus, A; Delvenne, P; Baron, F; Sadzot, B; Maquet, P				Lambert, Nicolas; El Moussaoui, Majdouline; Ritacco, Caroline; Moise, Martin; Paulus, Astrid; Delvenne, Philippe; Baron, Frederic; Sadzot, Bernard; Maquet, Pierre			Killing Two Birds With One Stone: Effective Control of Both Non-Small Cell Lung Cancer and Progressive Multifocal Leukoencephalopathy With Atezolizumab, A Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						PML; progressive multifocal leucoencephalopathy; JC virus (JCV); immune checkpoint inhibitors (ICI); immunotherapy; atezolizumab; PD1 and PDL1; non small cell lung cancer (NSCLC); lung adecarcinoma		Treating patients with cancer complicated by severe opportunistic infections is particularly challenging since classical cancer treatments, such as chemotherapy, often induce profound immune suppression and, as a result, may favor infection progression. Little is known about the potential place of immune checkpoint inhibitors in these complex situations. Here, we report a 66-year-old man who was concomitantly diagnosed with non-small cell lung cancer and progressive multifocal leukoencephalopathy. The patient was treated with anti-PD-L1 antibody atezolizumab, which allowed effective control of both lung cancer and progressive multifocal leukoencephalopathy, as demonstrated by the patient's remarkable neurologic clinical improvement, JC viral load reduction in his cerebrospinal fluid, regression of the brain lesions visualized through MRI, and the strict radiological stability of his cancer. In parallel, treatment with atezolizumab was associated with biological evidence of T-cell reinvigoration. Hence, our data suggest that immune checkpoint inhibitors may constitute a treatment option for patients with cancer complicated by severe opportunistic infections.	[Lambert, Nicolas; Sadzot, Bernard; Maquet, Pierre] Univ Hosp Liege, Dept Neurol, Liege, Belgium; [Lambert, Nicolas; Moise, Martin] Univ Liege, Lab Mol Regulat Neurogenesis, GIGA Stem Cells & GIGA Neurosci, Interdisciplinary Cluster Appl Genoprote GIGA R, Liege, Belgium; [El Moussaoui, Majdouline] Univ Hosp Liege, Dept Infect Dis & Gen Internal Med, Liege, Belgium; [Ritacco, Caroline; Baron, Frederic] Univ Liege, Hematol Res Unit, Interdisciplinary Cluster Appl Genoprote GIGA R, GIGA-I3, Liege, Belgium; [Moise, Martin] Univ Hosp Liege, Dept Radiol, Liege, Belgium; [Paulus, Astrid] Univ Hosp Liege, Dept Pneumol, Liege, Belgium; [Delvenne, Philippe] Univ Hosp Liege, Dept Anatomopathol, Liege, Belgium; [Baron, Frederic] Univ Hosp Liege, Dept Hematol, Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Lambert, N (corresponding author), Univ Hosp Liege, Dept Neurol, Liege, Belgium.; Lambert, N (corresponding author), Univ Liege, Lab Mol Regulat Neurogenesis, GIGA Stem Cells & GIGA Neurosci, Interdisciplinary Cluster Appl Genoprote GIGA R, Liege, Belgium.	nicolas.lambert@chuliege.be		Moise, Martin/0000-0003-3874-2213				Banck JC, 2021, HEMASPHERE, V5, DOI 10.1097/HS9.0000000000000530; Beck ES, 2020, CURR OPIN VIROL, V40, P19, DOI 10.1016/j.coviro.2020.02.005; Berger JR, 2013, NEUROLOGY, V80, P1430, DOI 10.1212/WNL.0b013e31828c2fa1; Cortese I, 2021, NAT REV NEUROL, V17, P37, DOI 10.1038/s41582-020-00427-y; Cortese I, 2019, NEW ENGL J MED, V380, P1597, DOI 10.1056/NEJMoa1815039; Grimaldi D, 2017, LANCET INFECT DIS, V17, P18, DOI 10.1016/S1473-3099(16)30541-2; Lambert N, 2022, EMERG INFECT DIS, V28, P253, DOI 10.3201/eid2801.204809; Lambert N, 2021, EUR J NEUROL, V28, P3814, DOI 10.1111/ene.15021; Locati LD, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.799453; Pawlitzki M, 2019, NEUROL-NEUROIMMUNOL, V6, DOI 10.1212/NXI.0000000000000627; Siegel Rebecca L, 2019, CA Cancer J Clin, V69, P7, DOI 10.3322/caac.21551; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862	12	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								889148	10.3389/fimmu.2022.889148	http://dx.doi.org/10.3389/fimmu.2022.889148			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1GY	35592313	gold, Green Published			2022-12-18	WOS:000796985800001
J	Leonhard, J; Schaier, M; Kaelble, F; Eckstein, V; Zeier, M; Steinborn, A				Leonhard, Jonas; Schaier, Matthias; Kaelble, Florian; Eckstein, Volker; Zeier, Martin; Steinborn, Andrea			Chronic Kidney Failure Provokes the Enrichment of Terminally Differentiated CD8(+) T Cells, Impairing Cytotoxic Mechanisms After Kidney Transplantation	FRONTIERS IN IMMUNOLOGY			English	Article						chronic kidney failure; dialysis treatment; kidney transplantation; CD8(+) T cell differentiation; CD8(+) regulatory T cells; cytotoxic mechanisms; CD8(+) TEMRA cells	2 SUBSETS; RECIPIENTS; DIALYSIS; NAIVE	Chronic kidney failure (KF) provokes the development of immune senescent CD8(+) cytotoxic T cells, affecting the occurrence of graft rejection, viral infections, and malignancies after kidney transplantation. In this study, we analyzed the impact of KF, subsequent dialysis treatment, and kidney transplantation on the differentiation of CD8(+)CD31(+)CD45RA(+)CCR7(+) recent thymic emigrant (CCR7(+) RTE) Tregs/Tresps into CD8(+)CD31(-)CD45RA(-) memory (CD31(-) memory) Tregs/Tresps and its effect on the release of cytokines, Fas receptor, Fas ligand as well as cytotoxic mediators by naive, central memory (CM), effector memory (EM), and terminally differentiated effector memory (TEMRA) Tresps. We found that normal age-dependent differentiation of CD8(+) Tregs/Tresps generally differs in the way that TEMRA cells only arise in Tresps. Compared to healthy controls, KF patients revealed an age-independently decreased frequency of CCR7(+) RTE Tregs/Tresps, but increased frequencies of CCR7(+) MN Tregs/Tresps and CD31(-) memory Tregs/Tresps, suggesting an increased differentiation via CD31(+)CD45RA(-) memory (CD31(+) memory) Tregs/Tresps into CD31(-) memory Tregs/Tresps. Intensified differentiation via CD31(+) memory Tresps increased the emergence of apoptosis-resistant CM Tresps with strong Fas ligand-mediated cytotoxicity. CCR7(+) RTE Tresp proliferation generated TEMRA Tresps, secreting high levels of cytotoxic mediators. In dialysis and transplant patients, CD31(+) TEMRA Tregs/Tresps accumulated, proposing an impaired CCR7(+) RTE Treg/Tresp differentiation via CD31(+) memory Tregs/Tresps into CD31(-) memory Tregs/Tresps. Increased percentages of CD31(-) TEMRA Tresps, but not of CD31(-) TEMRA Tregs, were observed in all patient groups, indicating impaired proliferation of CCR7(+) RTE Tresps, but not of CCR7(+) RTE Tregs, into CD31(-) memory Tregs/Tresps. In transplant patients, CCR7(+) RTE Tregs accumulated, while frequencies of CCR7(+) RTE Tresps were decreased, suggesting that the immunosuppressive therapy only prevented excessive CCR7(+) RTE Treg differentiation but not that of CCR7(+) RTE Tresps. Presumably, this caused the accumulation of TEMRA Tresps with decreased release of cytotoxic mediators, such as perforin. In conclusion, we propose that chronic KF affects both the differentiation of CD8(+) Tregs and CD8(+) Tresps. However, the immunosuppressive therapy after transplantation may successfully prevent excessive Treg differentiation, but not as suffciently that of Tresps. Therefore, the risk for graft rejection may be reduced, while the susceptibility for infections and malignancies may be increased in these patients.	[Leonhard, Jonas; Steinborn, Andrea] Heidelberg Univ, Dept Obstet & Gynecol, Heidelberg, Germany; [Leonhard, Jonas; Schaier, Matthias; Kaelble, Florian; Zeier, Martin] Heidelberg Univ, Dept Nephrol, Heidelberg, Germany; [Eckstein, Volker] Heidelberg Univ, Dept Internal Med Hematol 5, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Steinborn, A (corresponding author), Heidelberg Univ, Dept Obstet & Gynecol, Heidelberg, Germany.	andrea.steinborn-kroehl@med.uni-heidelberg.de			Kidney Center Heidelberg research grant; Department of Nephrology, University of Heidelberg, Germany	Kidney Center Heidelberg research grant; Department of Nephrology, University of Heidelberg, Germany	This work was supported by a Kidney Center Heidelberg research grant. The project was financed with funds from the research budget of the Department of Nephrology, University of Heidelberg, Germany.	Betjes MGH, 2020, TOXINS, V12, DOI 10.3390/toxins12040224; Betjes MGH, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228096; Betjes MGH, 2013, BLOOD PURIFICAT, V36, P173, DOI 10.1159/000356084; Betjes MGH, 2013, NAT REV NEPHROL, V9, P255, DOI 10.1038/nrneph.2013.44; Betjes MGH, 2012, J NEPHROL, V25, P183, DOI 10.5301/jn.5000057; Betjes MGH, 2011, KIDNEY INT, V80, P209, DOI 10.1038/ki.2011.110; Bottomley MJ, 2016, J AM SOC NEPHROL, V27, P1505, DOI 10.1681/ASN.2015030250; Callender LA, 2018, AGING CELL, V17, DOI 10.1111/acel.12675; Carroll RP, 2010, J AM SOC NEPHROL, V21, P713, DOI 10.1681/ASN.2009060669; Chiu YL, 2018, IMMUN AGEING, V15, DOI 10.1186/s12979-018-0131-x; Cohen G, 2020, TOXINS, V12, DOI 10.3390/toxins12070439; Courivaud C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01653; Crepin T, 2016, TRANSPL INFECT DIS, V18, P415, DOI 10.1111/tid.12534; Crepin T, 2020, NEPHROL DIAL TRANSPL, V35, P624, DOI 10.1093/ndt/gfy276; Dedeoglu B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150826; Flippe L, 2019, IMMUNOL REV, V292, P209, DOI 10.1111/imr.12812; Fribourg M, 2019, KIDNEY INT, V96, P436, DOI 10.1016/j.kint.2019.01.040; Hartzell S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583702; Jacquemont L, 2020, J AM SOC NEPHROL, V31, P876, DOI 10.1681/ASN.2019080847; Kim HY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03130-z; Kim KW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27141-6; Kimmig S, 2002, J EXP MED, V195, P789, DOI 10.1084/jem.20011756; Ko EJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0234323; Levey AS, 2020, KIDNEY INT, V97, P1117, DOI 10.1016/j.kint.2020.02.010; Litjens NHR, 2008, J AM SOC NEPHROL, V19, P1483, DOI 10.1681/ASN.2007090971; Meijers RWJ, 2014, TRANSPL INT, V27, P1272, DOI 10.1111/tri.12416; Nian YQ, 2019, TRANSPLANTATION, V103, P2227, DOI 10.1097/TP.0000000000002786; Oniscu GC, 2005, J AM SOC NEPHROL, V16, P1859, DOI 10.1681/ASN.2004121092; Ortiz A, 2014, LANCET, V383, P1831, DOI 10.1016/S0140-6736(14)60384-6; Rufer N, 2003, BLOOD, V102, P1779, DOI 10.1182/blood-2003-02-0420; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schaier M, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075-018-1778-6; Schaier M, 2018, IMMUNOLOGY, V155, P211, DOI 10.1111/imm.12947; Schaier M, 2017, IMMUNOL CELL BIOL, V95, P895, DOI 10.1038/icb.2017.57; Stewart JH, 2009, NEPHROL DIAL TRANSPL, V24, P3225, DOI 10.1093/ndt/gfp331; Verma K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177405; Wolfe RA, 1999, NEW ENGL J MED, V341, P1725, DOI 10.1056/NEJM199912023412303; Xiang FF, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.00178; Yap M, 2014, J AM SOC NEPHROL, V25, P1856, DOI 10.1681/ASN.2013080848; Yoon JW, 2006, KIDNEY INT, V70, P371, DOI 10.1038/sj.ki.5001550; Zhang SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062154	41	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								752570	10.3389/fimmu.2022.752570	http://dx.doi.org/10.3389/fimmu.2022.752570			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I7KD	35592311	Green Published, gold			2022-12-18	WOS:000797405200001
J	Li, D; Wang, XZ; Liao, YZ; Wang, SC; Shan, JJ; Ji, JJ				Li, Dan; Wang, Xianzheng; Liao, Yingzhao; Wang, Shouchuan; Shan, Jinjun; Ji, Jianjian			Insights Gained Into the Treatment of COVID19 by Pulmonary Surfactant and Its Components	FRONTIERS IN IMMUNOLOGY			English	Article						pulmonary surfactant; COVID-19; ARDS; therapeutic applications; respiratory viral infections	RESPIRATORY-DISTRESS-SYNDROME; SYNCYTIAL VIRUS PNEUMONIA; EXOGENOUS SURFACTANT; INFLUENZA-VIRUS; LIPID RAFTS; PROTEIN-A; ENTRY; INFECTION; ENHANCEMENT; CHOLESTEROL	Pulmonary surfactant constitutes an important barrier that pathogens must cross to gain access to the rest of the organism via the respiratory surface. The presence of pulmonary surfactant prevents the dissemination of pathogens, modulates immune responses, and optimizes lung biophysical activity. Thus, the application of pulmonary surfactant for the treatment of respiratory diseases provides an effective strategy. Currently, several clinical trials are investigating the use of surfactant preparations to treat patients with coronavirus disease 2019 (COVID-19). Some factors have been considered in the application of pulmonary surfactant for the treatment COVID-19, such as mechanical ventilation strategy, timing of treatment, dose delivered, method of delivery, and preparation utilized. This review supplements this list with two additional factors: accurate measurement of surfactants in patients and proper selection of pulmonary surfactant components. This review provides a reference for ongoing exogenous surfactant trials involving patients with COVID-19 and provides insight for the development of surfactant preparations for the treatment of viral respiratory infections.	[Li, Dan; Wang, Xianzheng; Wang, Shouchuan; Shan, Jinjun; Ji, Jianjian] Nanjing Univ Chinese Med, Inst Pediat, Jiangsu Key Lab Pediat Resp Dis, Nanjing, Peoples R China; [Li, Dan] Nanjing Univ Chinese Med, Dept Immunol, Nanjing, Peoples R China; [Liao, Yingzhao] Shenzhen Tradit Chinese Med Hosp, Pediat Tradit Chinese Med, Shenzhen, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Wang, SC; Shan, JJ; Ji, JJ (corresponding author), Nanjing Univ Chinese Med, Inst Pediat, Jiangsu Key Lab Pediat Resp Dis, Nanjing, Peoples R China.	wscnj@njucm.edu.cn; jijj@njucm.edu.cn; jshan@njucm.edu.cn			National Natural Science Foundation of China [82004204, 81774156]; Qinglan Project of Jiangsu Province of China; Natural Science Foundation of Jiangsu Province of China [BK20210681]; Colleges and universities in Jiangsu Province Natural Science Research [21KJB310007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Qinglan Project of Jiangsu Province of China; Natural Science Foundation of Jiangsu Province of China(Natural Science Foundation of Jiangsu Province); Colleges and universities in Jiangsu Province Natural Science Research	Funding This work was sponsored by the National Natural Science Foundation of China (82004204, 81774156), Qinglan Project of Jiangsu Province of China, Natural Science Foundation of Jiangsu Province of China (BK20210681), and Colleges and universities in Jiangsu Province Natural Science Research (21KJB310007).	[Anonymous], 2020, LANCET INFECT DIS, V20, P261, DOI 10.1016/S1473-3099(20)30072-4; Autilio C, 2019, ARCH DIS CHILD-FETAL, V104, pF443, DOI 10.1136/archdischild-2018-315413; Ballard PL, 2019, PEDIATR RES, V85, P305, DOI 10.1038/s41390-018-0144-3; Belov GA, 2015, VIRUSES-BASEL, V7, P3500, DOI 10.3390/v7072784; BENNE CA, 1995, J INFECT DIS, V171, P335, DOI 10.1093/infdis/171.2.335; Bos LDJ, 2021, LANCET RESP MED, V9, P1377, DOI 10.1016/S2213-2600(21)00365-9; Calabrese F, 2020, VIRCHOWS ARCH, V477, P359, DOI 10.1007/s00428-020-02886-6; Choi KS, 2005, J VIROL, V79, P9862, DOI 10.1128/JVI.79.15.9862-9871.2005; Coil DA, 2005, J VIROL, V79, P11496, DOI 10.1128/JVI.79.17.11496-11500.2005; Curstedt Tore, 2005, Biol Neonate, V87, P332, DOI 10.1159/000084881; Deng YR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.630242; Dushianthan A, 2012, CRIT CARE, V16, DOI 10.1186/cc11512; Fessler MB, 2016, AM J RESP CELL MOL, V54, P624, DOI 10.1165/rcmb.2016-0011PS; Funk CJ, 2012, J GEN VIROL, V93, P494, DOI 10.1099/vir.0.038414-0; Gerosa C, 2021, EUR REV MED PHARMACO, V25, P4639, DOI 10.26355/eurrev_202107_26257; Guo HC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170123; Han S, 2015, ANN AM THORAC SOC, V12, P765, DOI 10.1513/AnnalsATS.201411-507FR; Hartshorn KL, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-65; Heching M, 2021, CHEST, V160, pE9, DOI 10.1016/j.chest.2021.01.028; Heiring C, 2020, ACTA PAEDIATR, V109, P285, DOI 10.1111/apa.14831; Hsieh MH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.641360; Islam AMMK, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76404-8; Jeon JH, 2018, ARCH VIROL, V163, P3119, DOI 10.1007/s00705-018-3967-7; Ji JJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.730022; Katsiki N, 2020, ARCH MED SCI, V16, P485, DOI 10.5114/aoms.2020.94503; Koumbourlis AC, 2020, AM J RESP CRIT CARE, V202, P624, DOI 10.1164/rccm.202004-1471LE; Lee JW, 2021, NAT STRUCT MOL BIOL, V28, P181, DOI 10.1038/s41594-020-00548-4; Leist SR, 2020, CELL, V183, P1070, DOI 10.1016/j.cell.2020.09.050; Leth-Larsen R, 2007, IMMUNOBIOLOGY, V212, P201, DOI 10.1016/j.imbio.2006.12.001; LeVine AM, 2004, AM J RESP CELL MOL, V31, P193, DOI 10.1165/rcmb.2003-0107OC; LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849; Lewis JE, 2003, ANNU REV PHYSIOL, V65, P613, DOI 10.1146/annurev.physiol.65.092101.142434; Liao MF, 2020, NAT MED, V26, P842, DOI 10.1038/s41591-020-0901-9; Lu YN, 2008, BIOCHEM BIOPH RES CO, V369, P344, DOI 10.1016/j.bbrc.2008.02.023; Madan T, 2021, AM J RESP CELL MOL, V65, P41, DOI 10.1165/rcmb.2021-0005OC; Madsen J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059047; Mazur W, 2011, EUR RESPIR J, V38, P277, DOI 10.1183/09031936.00110510; Merad M, 2022, SCIENCE, V375, P1122, DOI 10.1126/science.abm8108; Mercer J, 2008, SCIENCE, V320, P531, DOI 10.1126/science.1155164; Numata M, 2022, BBA-MOL CELL BIOL L, V1867, DOI 10.1016/j.bbalip.2022.159139; Numata M, 2020, J BIOL CHEM, V295, P1704, DOI 10.1074/jbc.RA119.012053; Numata M, 2015, J LIPID RES, V56, P578, DOI 10.1194/jlr.M055723; Numata M, 2013, J LIPID RES, V54, P2133, DOI 10.1194/jlr.M037077; Numata M, 2012, AM J RESP CELL MOL, V46, P479, DOI 10.1165/rcmb.2011-0194OC; Numata M, 2010, P NATL ACAD SCI USA, V107, P320, DOI 10.1073/pnas.0909361107; Piva S, 2021, RESP RES, V22, DOI 10.1186/s12931-020-01603-w; Radenkovic D, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061909; Rendeiro AF, 2021, NATURE, V593, P564, DOI 10.1038/s41586-021-03475-6; Rose F, 1999, AM J RESP CRIT CARE, V160, P846, DOI 10.1164/ajrccm.160.3.9812155; Sanaki T, 2019, FASEB J, V33, P13866, DOI 10.1096/fj.201901095RR; Scendoni R, 2022, CLIN PATHOL, V15, DOI 10.1177/2632010X221083223; Schousboe P, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-07944-4; Schousboe P, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03268-9; Schulte-Schrepping J, 2020, CELL, V182, P1419, DOI 10.1016/j.cell.2020.08.001; Shan JJ, 2018, RSC ADV, V8, P29368, DOI 10.1039/c8ra05640d; Stoeck IK, 2018, J VIROL, V92, DOI 10.1128/JVI.01196-17; Sun XJ, 2003, J VIROL, V77, P12543, DOI 10.1128/JVI.77.23.12543-12551.2003; Suresh Gautham K, 2002, Paediatr Drugs, V4, P485, DOI 10.2165/00128072-200204080-00001; Takano H, 2020, MED HYPOTHESES, V144, DOI 10.1016/j.mehy.2020.110020; Ujma S, 2019, PATHOGENS, V8, DOI 10.3390/pathogens8040288; Veldhuizen RAW, 2021, EXPERT REV RESP MED, V15, P597, DOI 10.1080/17476348.2021.1865809; Vento G, 2021, LANCET RESP MED, V9, P159, DOI 10.1016/S2213-2600(20)30179-X; Voelker DR, 2019, J BIOL CHEM, V294, P4282, DOI 10.1074/jbc.AW118.003229; Vos GD, 1996, PEDIATR PULM, V22, P412, DOI 10.1002/(SICI)1099-0496(199612)22:6<412::AID-PPUL11>3.0.CO;2-C; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Wang EY, 2021, NATURE, V595, P283, DOI [10.1038/s41586-021-03631-y, 10.1101/2020.12.10.20247205]; Wang SG, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.698905; Watson A, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622598; Woods PS, 2016, AM J PHYSIOL-LUNG C, V311, pL1160, DOI 10.1152/ajplung.00339.2016; Xu K, 2015, P NATL ACAD SCI USA, V112, pE1782, DOI 10.1073/pnas.1418971112; Zhang HJ, 2020, AM J RESP CRIT CARE, V202, P219, DOI 10.1164/rccm.202003-0541OC; Zhang Q, 2020, SCIENCE, V370, DOI 10.1126/science.abd4570; Zhou RH, 2020, IMMUNITY, V53, P864, DOI 10.1016/j.immuni.2020.07.026; Zuo YY, 2008, BBA-BIOMEMBRANES, V1778, P1947, DOI 10.1016/j.bbamem.2008.03.021	74	0	0	4	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								842453	10.3389/fimmu.2022.842453	http://dx.doi.org/10.3389/fimmu.2022.842453			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1FX	35592339	Green Published, gold			2022-12-18	WOS:000796983100001
J	Li, ZH; Luo, ZT; Shi, XQ; Pang, BS; Ma, YM; Jin, JW				Li, Zhaohong; Luo, Zengtao; Shi, Xiaoqian; Pang, Baosen; Ma, Yingmin; Jin, Jiawei			The Levels of Oxidized Phospholipids in High-Density Lipoprotein During the Course of Sepsis and Their Prognostic Value	FRONTIERS IN IMMUNOLOGY			English	Article						sepsis; high-density lipoprotein (HDL); oxidized phospholipids; 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-phosphatidylcholine (POVPC); 1-palmitoyl-2glutaroyl-sn-glycero-phosphatidylcholine (PGPC)	OXIDATION-PRODUCTS; CHOLESTEROL EFFLUX; SEPTIC SHOCK; HDL; DYSFUNCTION; PARTICLES; POVPC; LDL	PurposeTo examine the levels of 1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero phosphatidylcholine (POVPC) and 1-palmitoyl-2-glutaroyl-sn-glycero-phosphatidylcholine (PGPC) (the oxidized phosphatidylcholines) in HDL during the course of sepsis and to evaluate their prognostic value. Materials and MethodsThis prospective cohort pilot study enrolled 25 septic patients and 10 healthy subjects from 2020 to 2021. The HDLs were extracted from patient plasmas at day 1, 3 and 7 after sepsis onset and from healthy plasmas (total 81 plasma samples). These HDLs were then subjected to examining POVPC and PGPC by using an ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS) system. We further measured the levels of 38 plasma cytokines by Luminex and evaluated the correlation of HDL-POVPC level with these cytokines. Patients were further stratified into survivors and non-survivors to analyze the association of HDL-POVPC level with 28-day mortality. ResultsSeptic patients exhibited significant increase of HDL-POVPC at day 1, 3 and 7 after sepsis onset (POVPC-D1, p=0.0004; POVPC-D3, p=0.033; POVPC-D7, p=0.004, versus controls). HDL-PGPC was detected only in some septic patients (10 of 25) but not in healthy controls. Septic patients showed a significant change of the plasma cytokines profile. The correlation assay showed that IL-15 and IL-18 levels were positively correlated with HDL-POVPC level, while the macrophage-derived chemokine (MDC) level was negatively correlated with HDL-POVPC level. Furthermore, HDL-POVPC level in non-survivors was significantly increased versus survivors at day 1 and 3 (POVPC-D1, p=0.002; POVPC-D3, p=0.003). Area under ROC curves of POVPC-D1 and POVPC-D3 in predicting 28-day mortality were 0.828 and 0.851. POVPC-D1and POVPC-D3 were the independent risk factors for the death of septic patients (p=0.046 and 0.035). ConclusionsHDL-POVPC was persistently increased in the course of sepsis. POVPC-D1 and POVPC-D3 were significantly correlated with 28-mortality and might be valuable to predict poor prognosis.	[Li, Zhaohong; Luo, Zengtao; Ma, Yingmin; Jin, Jiawei] Capital Med Univ, Beijing Chaoyang Hosp, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing, Peoples R China; [Li, Zhaohong; Luo, Zengtao; Shi, Xiaoqian; Pang, Baosen; Jin, Jiawei] Capital Med Univ, Beijing Chaoyang Hosp, Clin Res Ctr, Beijing, Peoples R China; [Li, Zhaohong; Luo, Zengtao; Ma, Yingmin] Capital Med Univ, Beijing Youan Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China	Capital Medical University; Capital Medical University; Capital Medical University	Ma, YM; Jin, JW (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Beijing Inst Resp Med, Dept Resp & Crit Care Med, Beijing, Peoples R China.; Jin, JW (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Clin Res Ctr, Beijing, Peoples R China.; Ma, YM (corresponding author), Capital Med Univ, Beijing Youan Hosp, Dept Resp & Crit Care Med, Beijing, Peoples R China.	ma.yingmin@163.com; jiaweijin@ccmu.edu.cn			Reform and Development Program of Beijing Institute of Respiratory Medicine (2021)	Reform and Development Program of Beijing Institute of Respiratory Medicine (2021)	This work was supported by Reform and Development Program of Beijing Institute of Respiratory Medicine (2021).	Amunugama K, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100090; Bavunoglu I, 2016, J INFECT DEV COUNTR, V10, P1045, DOI 10.3855/jidc.7585; Behnes M, 2008, J CRIT CARE, V23, P537, DOI 10.1016/j.jcrc.2008.09.002; Berliner JA, 2009, J LIPID RES, V50, pS207, DOI 10.1194/jlr.R800074-JLR200; Birukova AA, 2013, TRANSL RES, V161, P495, DOI 10.1016/j.trsl.2012.12.008; BRONZERT TJ, 1977, CLIN CHEM, V23, P2089; Camont L, 2013, ARTERIOSCL THROM VAS, V33, P2715, DOI 10.1161/ATVBAHA.113.301468; Chien JY, 2005, CRIT CARE MED, V33, P1688, DOI 10.1097/01.CCM.0000171183.79525.6B; Chien YF, 2015, J CRIT CARE, V30, P506, DOI 10.1016/j.jcrc.2015.01.001; Chiesa ST, 2019, CARDIOVASC DRUG THER, V33, P207, DOI 10.1007/s10557-018-06846-w; Cirstea M, 2017, J CRIT CARE, V38, P289, DOI 10.1016/j.jcrc.2016.11.041; Cohen J, 2015, LANCET INFECT DIS, V15, P581, DOI 10.1016/S1473-3099(15)70112-X; Deng LS, 2020, J INFECTION, V81, pE1, DOI 10.1016/j.jinf.2020.03.002; Eidt MV, 2016, CLIN CHIM ACTA, V453, P100, DOI 10.1016/j.cca.2015.12.009; Fruhwirth GO, 2006, BBA-MOL CELL BIOL L, V1761, P1060, DOI 10.1016/j.bbalip.2006.06.001; Fu PF, 2009, TRANSL RES, V153, P166, DOI 10.1016/j.trsl.2008.12.005; Gao DT, 2020, J BIOL CHEM, V295, P1973, DOI 10.1074/jbc.RA119.008445; Guirgis FW, 2017, SHOCK, V48, P539, DOI 10.1097/SHK.0000000000000887; Huang Y, 2014, NAT MED, V20, P193, DOI 10.1038/nm.3459; Kahn JM, 2019, JAMA-J AM MED ASSOC, V322, P240, DOI 10.1001/jama.2019.9021; Karki P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040981; Kataria Y, 2021, METHODS MOL BIOL, V2321, P177, DOI 10.1007/978-1-0716-1488-4_16; Ke YB, 2019, FASEB J, V33, P3887, DOI 10.1096/fj.201800981R; Kontush A, 2003, ARTERIOSCL THROM VAS, V23, P1881, DOI 10.1161/01.ATV.0000091338.93223.E8; Lee S, 2012, CIRC RES, V111, P778, DOI 10.1161/CIRCRESAHA.111.256859; Li Y, 2021, J LIPID RES, V62, DOI 10.1016/j.jlr.2021.100066; Martin SS, 2014, TRENDS ENDOCRIN MET, V25, P329, DOI 10.1016/j.tem.2014.05.005; Matsukawa A, 2000, J IMMUNOL, V164, P5362, DOI 10.4049/jimmunol.164.10.5362; Mecatti GC, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-020-01246-2; Navab M, 2001, ARTERIOSCL THROM VAS, V21, P481, DOI 10.1161/01.ATV.21.4.481; Nie J, 2020, MOL ASPECTS MED, V76, DOI 10.1016/j.mam.2020.100909; Que XC, 2018, NATURE, V558, P301, DOI 10.1038/s41586-018-0198-8; Rhee C, 2017, JAMA-J AM MED ASSOC, V318, P1241, DOI 10.1001/jama.2017.13836; Rohatgi A, 2014, NEW ENGL J MED, V371, P2383, DOI 10.1056/NEJMoa1409065; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Stamenkovic A, 2019, CAN J PHYSIOL PHARM, V97, P473, DOI 10.1139/cjpp-2018-0490; Subbanagounder G, 2000, ARTERIOSCL THROM VAS, V20, P2248, DOI 10.1161/01.ATV.20.10.2248; Tanaka S, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02860-3; Tanaka S, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0541-8; Tanaka S, 2017, ANN INTENSIVE CARE, V7, DOI 10.1186/s13613-017-0284-3; Wu QH, 2019, POSTGRAD MED J, V95, P240, DOI 10.1136/postgradmedj-2018-136371; Yan FX, 2017, J MOL CELL CARDIOL, V112, P40, DOI 10.1016/j.yjmcc.2017.08.016; Yang L, 2020, RESP RES, V21, DOI 10.1186/s12931-020-01553-3; Zou BK, 2021, ELIFE, V10, DOI [10.7554/eLife.70938, 10.7554/eLife.70938.sa0, 10.7554/eLife.70938.sa1, 10.7554/eLife.70938.sa2]	44	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								893929	10.3389/fimmu.2022.893929	http://dx.doi.org/10.3389/fimmu.2022.893929			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I7ES	35592322	Green Published, gold			2022-12-18	WOS:000797390800001
J	Liu, C; Li, FL; Liu, S; Chen, Q; Sang, HF; Yang, QW; Zhou, K; Zi, WJ				Liu, Chang; Li, Fengli; Liu, Shuai; Chen, Qiong; Sang, Hongfei; Yang, Qingwu; Zhou, Kai; Zi, Wenji			Neutrophil Count Predicts Malignant Cerebellar Edema and Poor Outcome in Acute Basilar Artery Occlusion Receiving Endovascular Treatment: A Nationwide Registry-Based Study	FRONTIERS IN IMMUNOLOGY			English	Article						acute basilar artery occlusion; endovascular treatment; malignant cerebellar edema; neutrophil count; outcome	STROKE; THROMBOLYSIS; ISCHEMIA; THERAPY; IMPACT; SCORE	BackgroundAcute basilar artery occlusion (ABAO) is known to have a poor outcome with a high rate of morbidity and mortality despite endovascular treatment (EVT), highlighting the necessities of exploring factors to limit the efficacy of EVT in these patients. Cerebellar infarctions in ABAO might progress to malignant cerebellar edema (MCE), a life-threatening complication after reperfusion, posing a secondary injury to the brainstem by mass effects. Therefore, the present research aimed to explore the impacts of MCE on a long-term outcome and investigate the prognostic factors for MCE among ABAO after EVT. MethodsIn the national BASILAR registry, a total of 329 ABO patients with cerebellar infarctions treated by EVT met the inclusion criteria. The presence of MCE defined by the Jauss scale >= 4 points, was evaluated on the computed tomography performed 72 h after EVT. The adjusted odds ratio and 95% CI were obtained by logistic regression models. A favorable outcome was defined as a 90-day modified Rankin Scale score of 0-3. ResultsMCE was statistically associated with the decreased incidence of a favorable outcome [adjusted odds ratio, 0.35(95% CI, 0.18-0.68), P=0.002]. The baseline National Institutes of Health Stroke Scale score, collateral circulation, neutrophil count at admission, and recanalization status were predictors for MCE and a favorable functional status at 90 days (all P<0.05). Among all inflammatory factors, the neutrophil count achieved the highest accuracy, sensitivity, and specificity for MCE. Adding the neutrophil count status into the baseline model obviously enhanced its prediction ability for MCE and favorable outcome by increasing the area under curve and achieving both net reclassification and integrated discrimination improvement (all P<0.05). Mediation analysis indicated that MCE mediated the association between the increased neutrophil count and worse functional outcome (P=0.026). DiscussionMCE acted essential roles in worsening prognosis for ABAO after EVT. A high neutrophil count at admission was linked to MCE and a poor outcome among ABAO patients, which could be further incorporated into the clinical decision-making system and guide immunomodulation therapy.	[Liu, Chang; Li, Fengli; Liu, Shuai; Chen, Qiong; Sang, Hongfei; Yang, Qingwu; Zhou, Kai; Zi, Wenji] Army Med Univ, Mil Med Univ 3, Dept Neurol, Xinqiao Hosp, Chongqing, Peoples R China; [Liu, Chang; Li, Fengli; Liu, Shuai; Chen, Qiong; Sang, Hongfei; Yang, Qingwu; Zhou, Kai; Zi, Wenji] Army Med Univ, Mil Med Univ 3, Affiliated Hosp 2, Chongqing, Peoples R China; [Sang, Hongfei] Zhejiang Univ, Affiliated Hangzhou First Peoples Hosp, Dept Neurol, Sch Med, Hangzhou, Peoples R China	Army Medical University; Army Medical University; Zhejiang University	Yang, QW; Zhou, K; Zi, WJ (corresponding author), Army Med Univ, Mil Med Univ 3, Dept Neurol, Xinqiao Hosp, Chongqing, Peoples R China.; Yang, QW; Zhou, K; Zi, WJ (corresponding author), Army Med Univ, Mil Med Univ 3, Affiliated Hosp 2, Chongqing, Peoples R China.	yangqwmlys@163.com; mfksx319@163.com; ziwenjie@126.com			National Natural Science Foundation of China [82001264, 82071323, 82001265, 81901236]; Chongqing Natural Science Foundation [cstc2020jcyj-msxmX0926]; Clinical Medical Research Talent Training Program of Army Medical University [2019XLC2008, 2019XLC3016]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chongqing Natural Science Foundation(Natural Science Foundation of Chongqing); Clinical Medical Research Talent Training Program of Army Medical University	Funding This work was supported by National Natural Science Foundation of China (No. 82001264, 82071323, 82001265, 81901236), Chongqing Natural Science Foundation (No. cstc2020jcyj-msxmX0926), Clinical Medical Research Talent Training Program of Army Medical University (No. 2019XLC2008 and 2019XLC3016).	Al-Dasuqi K, 2020, STROKE, V51, pE193, DOI 10.1161/STROKEAHA.120.029892; Boisseau W, 2019, NEUROLOGY, V93, pE467, DOI 10.1212/WNL.0000000000007859; Broocks G, 2021, NEUROSURGERY, V88, P531, DOI 10.1093/neuros/nyaa438; Cai W, 2020, TRANSL STROKE RES, V11, P108, DOI 10.1007/s12975-019-00694-y; Chen C, 2021, J CEREBR BLOOD F MET, V41, P2150, DOI 10.1177/0271678X211000137; Cheng B, 2014, STROKE, V45, P1695, DOI 10.1161/STROKEAHA.114.005152; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Enzmann G, 2018, THER ADV NEUROL DISO, V11, DOI 10.1177/1756286418794184; Fabritius MP, 2017, STROKE, V48, P2597, DOI 10.1161/STROKEAHA.117.018237; Ferro D, 2021, STROKE, V52, P859, DOI 10.1161/STROKEAHA.120.032130; Jauss M, 2001, J NEUROIMAGING, V11, P268, DOI 10.1111/j.1552-6569.2001.tb00045.x; Langezaal LCM, 2021, NEW ENGL J MED, V384, P1910, DOI 10.1056/NEJMoa2030297; Liu XF, 2020, LANCET NEUROL, V19, P115, DOI 10.1016/S1474-4422(19)30395-3; Ludewig P, 2013, CIRC RES, V113, P1013, DOI 10.1161/CIRCRESAHA.113.301207; Maestrini I, 2015, NEUROLOGY, V85, P1408, DOI 10.1212/WNL.0000000000002029; Mattle HP, 2011, LANCET NEUROL, V10, P1002, DOI 10.1016/S1474-4422(11)70229-0; Mourand I, 2014, AM J NEURORADIOL, V35, P1117, DOI 10.3174/ajnr.A3870; Mourand I, 2021, J NEUROINTERV SURG, V13, P995, DOI 10.1136/neurintsurg-2020-016804; Qiu YM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.678744; Reinhard M, 2012, STROKE, V43, P987, DOI 10.1161/STROKEAHA.111.644674; Rexrode KM, 2022, CIRC RES, V130, P512, DOI 10.1161/CIRCRESAHA.121.319915; Silwedel C, 2006, J NEUROIMMUNOL, V179, P37, DOI 10.1016/j.jneuroim.2006.06.019; Soehnlein O, 2017, NAT REV IMMUNOL, V17, P248, DOI 10.1038/nri.2017.10; Strbian D, 2013, ANN NEUROL, V73, P688, DOI 10.1002/ana.23904; van der Hoeven EJRJ, 2016, INT J STROKE, V11, P768, DOI 10.1177/1747493016641951; von Kummer R, 2015, STROKE, V46, P2981, DOI 10.1161/STROKEAHA.115.010049; Wang PP, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00312; Wanrooy BJ, 2021, IMMUNOL CELL BIOL, V99, P924, DOI 10.1111/imcb.12463; Yoon W, 2021, J NEUROINTERV SURG, V13, DOI 10.1136/neurintsurg-2020-015930; Zhang SPR, 2021, TRENDS PHARMACOL SCI, V42, P96, DOI 10.1016/j.tips.2020.11.010; Zi WJ, 2020, JAMA NEUROL, V77, P561, DOI 10.1001/jamaneurol.2020.0156	31	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								835915	10.3389/fimmu.2022.835915	http://dx.doi.org/10.3389/fimmu.2022.835915			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1AH	35592334	Green Published, gold			2022-12-18	WOS:000796968400001
J	Maglie, R; Baffa, ME; Montefusco, F; Pipito, C; Senatore, S; Capassoni, M; Maio, V; Cerinic, MM; Antiga, E; Guiducci, S				Maglie, Roberto; Baffa, Maria Efenesia; Montefusco, Francesca; Pipito, Carlo; Senatore, Stefano; Capassoni, Marco; Maio, Vincenza; Cerinic, Marco Matucci; Antiga, Emiliano; Guiducci, Serena			Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?	FRONTIERS IN IMMUNOLOGY			English	Article						bullous pemphigoid; morphea; lichen sclerosus; BP180; autoantigen	AUTOANTIBODIES; COEXISTENCE; SERIES; BP180; NC16A	Bullous pemphigoid (BP) represents the most common autoimmune bullous disease and is characterized by IgG autoantibodies targeting collagen XVII (BP180). BP has reportedly been occurred in association with other inflammatory skin diseases. Here, we describe the unusual occurrence of BP in a female patient with a concomitant history of generalized morphea (localized scleroderma, LoS) and cutaneous and genital lichen sclerosus (LiS). The occurrence of BP was associated with elevated serum levels of anti-BP180 IgG autoantibodies, which decreased upon clinical remission. Autoimmune bullous diseases and sclerosing dermatitis are immunologically distinct entities, whose association has been rarely described. In this study, we provide a literature review on cases of BP developed in patients with either LoS or LiS. Further, we discussed immunological mechanisms which may have favored the emergence of BP in our patient.	[Maglie, Roberto; Baffa, Maria Efenesia; Montefusco, Francesca; Pipito, Carlo; Senatore, Stefano; Antiga, Emiliano] Univ Florence, Dept Hlth Sci, Sect Dermatol, Florence, Italy; [Capassoni, Marco; Cerinic, Marco Matucci; Guiducci, Serena] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Capassoni, Marco; Cerinic, Marco Matucci; Guiducci, Serena] Dept Geriatr Med, Div Rheumatol, Scleroderma Unit Azienda Ospedaliera Universitaria, Florence, Italy; [Maio, Vincenza] Univ Florence, Dept Hlth Sci, Div Pathol Anat, Florence, Italy	University of Florence; University of Florence; University of Florence	Antiga, E (corresponding author), Univ Florence, Dept Hlth Sci, Sect Dermatol, Florence, Italy.	emiliano.antiga@unifi.it						Aromolo IF, 2022, INT J DERMATOL, V61, P1353, DOI 10.1111/ijd.16045; Baldo M, 2010, CLIN EXP DERMATOL, V35, P543, DOI 10.1111/j.1365-2230.2010.03827.x; Baldo M, 2010, J EUR ACAD DERMATOL, V24, P186, DOI 10.1111/j.1468-3083.2009.03375.x; BERNSTEIN JE, 1981, ARCH DERMATOL, V117, P725, DOI 10.1001/archderm.117.11.725; Bieber K, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591971; Chouchane K, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-03192-8; Danescu S, 2016, J DERMATOL, V43, P134, DOI 10.1111/1346-8138.13031; Di Zenzo G, 2008, CLIN IMMUNOL, V128, P415, DOI 10.1016/j.clim.2008.04.012; Edwards G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01477; Eyerich K, 2018, J EUR ACAD DERMATOL, V32, P692, DOI 10.1111/jdv.14673; Farrell AM, 2000, BRIT J DERMATOL, V143, P598; Felton S, 2012, OSTOMY WOUND MANAG, V58, P34; Freire PC, 2019, J INVEST DERMATOL, V139, P2417, DOI 10.1016/j.jid.2019.04.025; Gambichler T, 2022, BRIT J DERMATOL, V186, P728, DOI 10.1111/bjd.20890; Gambichler T, 2011, J EUR ACAD DERMATOL, V25, P369, DOI 10.1111/j.1468-3083.2010.03739.x; Granel B, 2006, IMMUNOGENETICS, V58, P693, DOI 10.1007/s00251-006-0135-0; Hashimoto T, 2020, J AM ACAD DERMATOL, V83, P53, DOI 10.1016/j.jaad.2019.07.060; Ho YH, 2019, J DERMATOL, V46, P604, DOI 10.1111/1346-8138.14902; Howard Anne, 2004, Australas J Dermatol, V45, P12, DOI 10.1111/j.1440-0960.2004.00026.x; IHN H, 1995, ARCH DERMATOL RES, V287, P193, DOI 10.1007/BF01262331; Iskandarli M, 2016, GIORN ITAL DERMAT V, V151, P562; Kassamali Bina, 2021, JAAD Case Rep, V17, P7, DOI 10.1016/j.jdcr.2021.08.018; Kreuter A, 2012, J AM ACAD DERMATOL, V67, P1157, DOI 10.1016/j.jaad.2012.04.003; Kridin K, 2022, DERMATITIS, V33, P268, DOI 10.1097/DER.0000000000000792; Lutz V, 2012, ARCH DERMATOL, V148, P24, DOI 10.1001/archdermatol.2011.305; Maglie R, 2022, J AM ACAD DERMATOL, V87, P761, DOI 10.1016/j.jaad.2021.07.007; Maglie R, 2020, AM J CLIN DERMATOL, V21, P833, DOI 10.1007/s40257-020-00553-9; Maglie R, 2019, CURR OPIN PHARMACOL, V46, P34, DOI 10.1016/j.coph.2018.12.007; Makita E, 2021, J INVEST DERMATOL, V141, P1167, DOI 10.1016/j.jid.2020.08.031; Montagnon CM, 2021, J AM ACAD DERMATOL, V85, P1, DOI 10.1016/j.jaad.2020.11.076; Patsatsi A, 2014, ACTA DERM-VENEREOL, V94, P711, DOI 10.2340/00015555-1851; Sacher C, 2001, DERMATOLOGY, V202, P54, DOI 10.1159/000051588; Schmidt T, 2018, J ALLERGY CLIN IMMUN, V142, P669, DOI 10.1016/j.jaci.2018.02.044; Solimani F, 2019, J EUR ACAD DERMATOL, V33, P735, DOI 10.1111/jdv.15170; Solimani F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01413; Varpuluoma O, 2019, J INVEST DERMATOL, V139, P600, DOI 10.1016/j.jid.2018.10.010; Walsh ML, 2012, J LOW GENIT TRACT DI, V16, P468, DOI 10.1097/LGT.0b013e31825e9b18; Wang YM, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.824110; Yoshifuku A, 2018, INDIAN J DERMATOL, V63, P427, DOI 10.4103/ijd.IJD_127_18; Zakka LR, 2011, AUTOIMMUN REV, V11, P40, DOI 10.1016/j.autrev.2011.07.002; Zhang XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.731774	41	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								887279	10.3389/fimmu.2022.887279	http://dx.doi.org/10.3389/fimmu.2022.887279			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I7OL	35592319	gold, Green Published			2022-12-18	WOS:000797416600001
J	Meghnem, D; Maillasson, M; Barbieux, I; Morisseau, S; Keita, D; Jacques, Y; Quemener, A; Mortier, E				Meghnem, Dihia; Maillasson, Mike; Barbieux, Isabelle; Morisseau, Sebastien; Keita, Dalloba; Jacques, Yannick; Quemener, Agnes; Mortier, Erwan			Selective Targeting of IL-15R alpha Is Sufficient to Reduce Inflammation	FRONTIERS IN IMMUNOLOGY			English	Article						interleukin; receptor; IL-2; inhibition; homeostasis	RECEPTOR-ALPHA-CHAIN; NATURAL-KILLER-CELLS; T-CELLS; IL-15 RECEPTOR; TRANS-PRESENTATION; BETA-CHAIN; FUNCTIONAL-CHARACTERIZATION; INTERLEUKIN-15 IL-15; INDUCED ARTHRITIS; GAMMA-CHAIN	Cytokines are crucial molecules for maintaining the proper functioning of the immune system. Nevertheless, a dysregulation of cytokine expression could be involved in the pathogenesis of autoimmune diseases. Interleukin (IL)-15 is a key factor for natural killer cells (NK) and CD8 T cells homeostasis, necessary to fight cancer and infections but could also be considered as a pro-inflammatory cytokine involved in autoimmune inflammatory disease, including rheumatoid arthritis, psoriasis, along with tumor necrosis factor alpha (TNF-alpha), IL-6, and IL-1 beta. The molecular mechanisms by which IL-15 exerts its inflammatory function in these diseases are still unclear. In this study, we generated an IL-15-derived molecule called NANTIL-15 (New ANTagonist of IL-15), designed to selectively inhibit the action of IL-15 through the high-affinity trimeric IL-15R alpha/IL-2R beta/gamma c receptor while leaving IL-15 signaling through the dimeric IL-2R beta/gamma c receptor unaffected. Administrating of NANTIL-15 in healthy mice did not affect the IL-15-dependent cell populations such as NK and CD8 T cells. In contrast, we found that NANTIL-15 efficiently reduced signs of inflammation in a collagen-induced arthritis model. These observations demonstrate that the inflammatory properties of IL-15 are linked to its action through the trimeric IL-15R alpha/IL-2R beta/gamma c receptor, highlighting the interest of selectively targeting this receptor.	[Meghnem, Dihia; Maillasson, Mike; Barbieux, Isabelle; Morisseau, Sebastien; Keita, Dalloba; Jacques, Yannick; Quemener, Agnes; Mortier, Erwan] Nantes Univ, CNRS, Inserm, CRCI2NA, Nantes, France; [Meghnem, Dihia; Maillasson, Mike; Barbieux, Isabelle; Morisseau, Sebastien; Keita, Dalloba; Jacques, Yannick; Quemener, Agnes; Mortier, Erwan] Immuno Onco Greffe, LabEX IGO, Nantes, France; [Maillasson, Mike; Mortier, Erwan] Nantes Univ, Ctr Hosp Univ CHU Nantes, Inserm, CNRS, Nantes, France; [Morisseau, Sebastien] Nantes Hosp, Ctr Hosp Univ CHU, Nantes, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Mortier, E (corresponding author), Nantes Univ, CNRS, Inserm, CRCI2NA, Nantes, France.; Mortier, E (corresponding author), Immuno Onco Greffe, LabEX IGO, Nantes, France.; Mortier, E (corresponding author), Nantes Univ, Ctr Hosp Univ CHU Nantes, Inserm, CNRS, Nantes, France.	erwan.mortier@cnrs.fr			Inserm Transfert [R13079NS]; Region des Pays de la Loire (PIRAMID project) [2015-08206]; Fondation pour la Recherche Medicale as "equipe labellisee" [DEQ20170839118]; Janssen Innovation; Centre National de la Recherche Scientifique (CNRS), Inserm, Nantes, University; European Center of Transplantation and Immunotherapy Sciences (IHU-Cesti) [ANR-10-IBHU-005]; French government; Nantes Metropole; Region Pays de la Loire	Inserm Transfert; Region des Pays de la Loire (PIRAMID project); Fondation pour la Recherche Medicale as "equipe labellisee"; Janssen Innovation; Centre National de la Recherche Scientifique (CNRS), Inserm, Nantes, University; European Center of Transplantation and Immunotherapy Sciences (IHU-Cesti); French government; Nantes Metropole(Region Pays de la Loire); Region Pays de la Loire(Region Pays de la Loire)	We would like to thank the members of the Mocka lab for helpful discussions and Impact Platform, the 'Unite Therapeutique Experimentale' and CytoCell facilities for technical assistance (SFR Sante, Bonamy, Nantes). This work was included in the LabEx IGO, Immunotherapy, Graft, Oncology program. This research was funded by Inserm Transfert (R13079NS), the Region des Pays de la Loire (PIRAMID project, 2015-08206), through a "Dynamiques Scientifiques" grant, the Fondation pour la Recherche Medicale as "equipe labellisee" (DEQ20170839118), and Janssen Innovation. This work was also supported by the Centre National de la Recherche Scientifique (CNRS), Inserm, Nantes, University and realized in the context of the Nantes project of European Center of Transplantation and Immunotherapy Sciences (IHU-Cesti) through the ANR-10-IBHU-005 project, which received French government financial support managed by the Agence Nationale de la Recherche (ANR) and supported by Nantes Metropole and Region Pays de la Loire.	Abadie V, 2020, NATURE, V578, P600, DOI 10.1038/s41586-020-2003-8; Agostini C, 1999, AM J PHYSIOL-LUNG C, V277, pL240, DOI 10.1152/ajplung.1999.277.2.L240; Allard-Chamard H, 2020, CYTOKINE, V136, DOI 10.1016/j.cyto.2020.155258; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Aringer M, 2001, RHEUMATOLOGY, V40, P876, DOI 10.1093/rheumatology/40.8.876; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; Badolato R, 1997, BLOOD, V90, P2804, DOI 10.1182/blood.V90.7.2804.2804_2804_2809; Bergamaschi C, 2012, BLOOD, V120, pE1, DOI 10.1182/blood-2011-10-384362; Bernard J, 2004, J BIOL CHEM, V279, P24313, DOI 10.1074/jbc.M312458200; Bouchaud G, 2013, J EXP MED, V210, P2105, DOI 10.1084/jem.20130291; Bouchaud G, 2010, GASTROENTEROLOGY, V138, P2378, DOI 10.1053/j.gastro.2010.02.044; Burkett PR, 2004, J EXP MED, V200, P825, DOI 10.1084/jem.20041389; Burkett PR, 2003, P NATL ACAD SCI USA, V100, P4724, DOI 10.1073/pnas.0737048100; Chen J, 2013, P NATL ACAD SCI USA, V110, P13534, DOI 10.1073/pnas.1312911110; Chen XL, 2014, CELL MOL IMMUNOL, V11, P387, DOI 10.1038/cmi.2014.13; Ciszewski C, 2020, GASTROENTEROLOGY, V158, P625, DOI 10.1053/j.gastro.2019.10.006; Dubois S, 2002, IMMUNITY, V17, P537, DOI 10.1016/S1074-7613(02)00429-6; Ferrari-Lacraz S, 2004, J IMMUNOL, V173, P5818, DOI 10.4049/jimmunol.173.9.5818; FRANCOIS C, 1995, INT IMMUNOL, V7, P1173, DOI 10.1093/intimm/7.8.1173; Frohna PA, 2020, J CLIN PHARMACOL, V60, P264, DOI 10.1002/jcph.1522; Girard D, 1996, BLOOD, V88, P3176, DOI 10.1182/blood.V88.8.3176.bloodjournal8883176; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; KALUZA B, 1991, GENE, V107, P297, DOI 10.1016/0378-1119(91)90330-E; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kim YS, 1998, J IMMUNOL, V160, P5742; Koka R, 2003, J EXP MED, V197, P977, DOI 10.1084/jem.20021836; Kurowska M, 2002, J IMMUNOL, V169, P1760, DOI 10.4049/jimmunol.169.4.1760; Lee TL, 2015, J INVEST DERMATOL, V135, P1329, DOI 10.1038/jid.2015.17; Lin JX, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028449; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Losy J, 2002, FOLIA NEUROPATHOL, V40, P151; Ma A, 2006, ANNU REV IMMUNOL, V24, P657, DOI 10.1146/annurev.immunol.24.021605.090727; Malamut G, 2010, J CLIN INVEST, V120, P2131, DOI 10.1172/JCI41344; Massoud R, 2015, P NATL ACAD SCI USA, V112, P11030, DOI 10.1073/pnas.1412626112; McInnes IB, 1997, NAT MED, V3, P189, DOI 10.1038/nm0297-189; McInnes IB, 1996, NAT MED, V2, P175, DOI 10.1038/nm0296-175; Meghnem D, 2017, J IMMUNOL, V198, P4563, DOI 10.4049/jimmunol.1700046; Mention JJ, 2003, GASTROENTEROLOGY, V125, P730, DOI 10.1016/S0016-5085(03)01047-3; Mortier E, 2004, J IMMUNOL, V173, P1681, DOI 10.4049/jimmunol.173.3.1681; Mortier E, 2008, J EXP MED, V205, P1213, DOI 10.1084/jem.20071913; Mortier E, 2009, IMMUNITY, V31, P811, DOI 10.1016/j.immuni.2009.09.017; Muro S, 2001, J ALLERGY CLIN IMMUN, V108, P970, DOI 10.1067/mai.2001.119556; Nata T, 2015, J BIOL CHEM, V290, P22338, DOI 10.1074/jbc.M115.661074; Perdreau H, 2010, EUR CYTOKINE NETW, V21, P297, DOI 10.1684/ecn.2010.0207; Pettit DK, 1997, J BIOL CHEM, V272, P2312; Pilson RS, 1997, J IMMUNOL, V159, P1543; Purton JF, 2007, J EXP MED, V204, P951, DOI 10.1084/jem.20061805; Quemener A, 2020, J CELL SCI, V133, DOI 10.1242/jcs.236802; Quemener A, 2017, J MED CHEM, V60, P6249, DOI 10.1021/acs.jmedchem.7b00485; Ratthe C, 2004, J LEUKOCYTE BIOL, V76, P162, DOI 10.1189/jlb.0605298; Rentzos M, 2006, J NEUROL SCI, V241, P25, DOI 10.1016/j.jns.2005.10.003; Richmond JM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aam7710; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; Rodriguez-Alvarez Y, 2021, J PEPT SCI, V27, DOI 10.1002/psc.3293; Ruchatz H, 1998, J IMMUNOL, V160, P5654; Ruckert R, 2005, J IMMUNOL, V174, P5507, DOI 10.4049/jimmunol.174.9.5507; Ruckert R, 2009, IMMUNOLOGY, V126, P63, DOI 10.1111/j.1365-2567.2008.02878.x; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Savio AS, 2012, J PEPT SCI, V18, P25, DOI 10.1002/psc.1411; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; Smadja J, 2021, BIOORGAN MED CHEM, V39, DOI 10.1016/j.bmc.2021.116161; Tamzalit F, 2014, P NATL ACAD SCI USA, V111, P8565, DOI 10.1073/pnas.1405514111; Tan X, 2006, GENES IMMUN, V7, P407, DOI 10.1038/sj.gene.6364314; Thurkow EW, 1997, J PATHOL, V181, P444; TSUDO M, 1989, P NATL ACAD SCI USA, V86, P1982, DOI 10.1073/pnas.86.6.1982; Verri WA, 2007, EUR J IMMUNOL, V37, P3373, DOI 10.1002/eji.200737488; Villadsen LS, 2003, J CLIN INVEST, V112, P1571, DOI 10.1172/JCI200318986; Waldmann Thomas A, 2013, J Investig Dermatol Symp Proc, V16, pS28, DOI 10.1038/jidsymp.2013.8; Walzer T, 2007, CURR OPIN IMMUNOL, V19, P365, DOI 10.1016/j.coi.2007.04.004; Walzer T, 2007, P NATL ACAD SCI USA, V104, P3384, DOI 10.1073/pnas.0609692104; WILLERFORD DM, 1995, IMMUNITY, V3, P521, DOI 10.1016/1074-7613(95)90180-9; Xing LZ, 2014, NAT MED, V20, P1043, DOI 10.1038/nm.3645; Yang XK, 2015, HUM IMMUNOL, V76, P812, DOI 10.1016/j.humimm.2015.09.041; Yokoyama S, 2009, P NATL ACAD SCI USA, V106, P15849, DOI 10.1073/pnas.0908834106; Yoshihara K, 2006, GUT, V55, P334, DOI 10.1136/gut.2005.076000; Yoshihara K, 2007, EUR J IMMUNOL, V37, P2744, DOI 10.1002/eji.200737229; Zhao L, 2016, SCI REP-UK, V6, DOI 10.1038/srep25822; Zyiska-Granica B, 2017, EUR J MED CHEM, V136, P543, DOI 10.1016/j.ejmech.2017.05.034	80	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								886213	10.3389/fimmu.2022.886213	http://dx.doi.org/10.3389/fimmu.2022.886213			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I7FG	35592318	Green Published, gold			2022-12-18	WOS:000797392300001
J	Mise, J; Jukic, IL; Marinovic, B				Mise, Josko; Jukic, Ines Lakos; Marinovic, Branka			Rituximab-Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study	FRONTIERS IN IMMUNOLOGY			English	Article						pemphigus; rituximab; remission; relapse; efficacy; desmoglein	OUTCOMES; THERAPY; RELAPSE	Pemphigus is a rare autoimmune disease characterized by the production of pathogenic autoantibodies against desmosomal adhesion proteins, desmoglein 1 and 3. The pathophysiological process leads to the development of blisters and erosions on mucosal and/or skin surfaces as the main clinical manifestation of the disease. Rituximab emerged as the first-line therapeutic option for pemphigus due to its ability to induce remission by depleting peripheral B lymphocytes. Our aim was to assess the efficacy of rituximab in the treatment of patients in Croatia. A single-center, retrospective study was conducted on 19 patients treated with rituximab following a rheumatoid arthritis dosing protocol between October 2015 and March 2021, with a mean follow-up of 24.1 months. After the first rituximab cycle, two patients achieved complete remission off therapy (10.5%), and six patients achieved complete remission on minimal therapy (31.6%). Partial remission was observed among ten patients (52.6%). Eight patients (44.4%) relapsed after the first rituximab cycle. The mean relapse time was 21 months. Seven patients received two rituximab cycles, and three patients received three cycles. Overall, 13 out of 19 patients experienced complete remission at some point during the study, while there were no non-responders after the rituximab treatment. No statistically significant associations were observed between age, sex, type of disease involvement and clinical remission, either on or off therapy. A steady decrease in anti-desmoglein 1 and anti-desmoglein 3 levels was measured among all patients following rituximab treatment. One patient experienced a treatment-related adverse event of infectious etiology (cellulitis). One patient died following the first rituximab cycle, with the cause of death likely not to be associated with the treatment. Rituximab is an effective disease-modifying agent in the treatment of pemphigus with the main benefit of reducing corticosteroid exposure and steroid-related side effects among pemphigus patients. However, a feature of rituximab therapy is high relapse rates and the need for repeated treatment cycles to achieve complete remission. Developing an optimal protocol for rituximab treatment and finding suitable markers for predicting relapse will improve the management of pemphigus patients.	[Mise, Josko; Jukic, Ines Lakos; Marinovic, Branka] Univ Hosp Ctr Zagreb, European Reference Network, Skin Reference Ctr, Dept Dermatol & Venereol, Zagreb, Croatia; [Jukic, Ines Lakos; Marinovic, Branka] Univ Zagreb, Sch Med, Zagreb, Croatia	University of Zagreb; University of Zagreb	Marinovic, B (corresponding author), Univ Hosp Ctr Zagreb, European Reference Network, Skin Reference Ctr, Dept Dermatol & Venereol, Zagreb, Croatia.; Marinovic, B (corresponding author), Univ Zagreb, Sch Med, Zagreb, Croatia.	branka.marinovic@kbc-zagreb.hr						Abasq C, 2009, ARCH DERMATOL, V145, P529, DOI 10.1001/archdermatol.2009.9; Albers LN, 2017, J AM ACAD DERMATOL, V77, P1074, DOI 10.1016/j.jaad.2017.07.012; Amber KT, 2015, J EUR ACAD DERMATOL, V29, P777, DOI 10.1111/jdv.12678; Amber KT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01190; Balighi K, 2018, DERMATOL THER, V31, DOI 10.1111/dth.12671; Baum S, 2020, ACTA DERM-VENEREOL, V100, DOI 10.2340/00015555-3649; Colliou N, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005166; Currimbhoy S, 2016, J EUR ACAD DERMATOL, V30, P1050, DOI 10.1111/jdv.13103; De D, 2020, INDIAN J DERMATOL VE, V86, P39, DOI 10.4103/ijdvl.IJDVL_848_17; Di Lernia V, 2020, DERMATOL PRACT CONCE, V10, DOI 10.5826/dpc.1003a50; Didona D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01418; Joly P, 2020, J EUR ACAD DERMATOL, V34, P1900, DOI 10.1111/jdv.16752; Joly P, 2017, LANCET, V389, P2031, DOI 10.1016/S0140-6736(17)30070-3; Kim TH, 2017, J DERMATOL, V44, P615, DOI 10.1111/1346-8138.13757; Kushner CJ, 2019, JAMA DERMATOL, V155, P1404, DOI 10.1001/jamadermatol.2019.3236; Leandro MJ, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar3908; Lee DSW, 2021, NAT REV DRUG DISCOV, V20, P179, DOI 10.1038/s41573-020-00092-2; Loi C, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12763; Lunardon L, 2012, ARCH DERMATOL, V148, P1031, DOI 10.1001/archdermatol.2012.1522; Marinovic B, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111555; Marinovic B, 2011, DERMATOL CLIN, V29, P677, DOI 10.1016/j.det.2011.07.003; Murrell DE, 2008, J AM ACAD DERMATOL, V58, P1043, DOI 10.1016/j.jaad.2008.01.012; Murrell DF, 2020, J AM ACAD DERMATOL, V82, P575, DOI 10.1016/j.jaad.2018.02.021; Salopek TG, 2002, J AM ACAD DERMATOL, V47, P785, DOI 10.1067/mjd.2002.126273; Schmidt E, 2019, LANCET, V394, P882, DOI 10.1016/S0140-6736(19)31778-7; Sharma VK, 2020, INT J DERMATOL, V59, P76, DOI 10.1111/ijd.14546; Shimanovich I, 2020, J EUR ACAD DERMATOL, V34, P2884, DOI 10.1111/jdv.16561; Sinha AA, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00218; Toosi R, 2021, J DERMATOL TREAT, V32, P33, DOI 10.1080/09546634.2019.1617831; Vinay K, 2018, J AM ACAD DERMATOL, V78, P806, DOI 10.1016/j.jaad.2017.11.024; Wang HH, 2015, ACTA DERM-VENEREOL, V95, P928, DOI 10.2340/00015555-2116; Zhou SR, 2020, J INVEST DERMATOL, V140, P309, DOI 10.1016/j.jid.2019.07.717	32	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								884931	10.3389/fimmu.2022.884931	http://dx.doi.org/10.3389/fimmu.2022.884931			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I6WC	35592312	gold, Green Published			2022-12-18	WOS:000797368200001
J	Nguyen, KG; Mantooth, SM; Vrabel, MR; Zaharoff, DA				Nguyen, Khue G.; Mantooth, Siena M.; Vrabel, Maura R.; Zaharoff, David A.			Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2	FRONTIERS IN IMMUNOLOGY			English	Article						Intranasal vaccination; COVID-19; mucosal immunity; SARS-CoV-2; Receptor binding domain (RBD); chitosan; CpG	INFLAMMASOME ACTIVATION; CHITOSAN; INTERLEUKIN-12; IMMUNITY; MARKERS; BOOST; KEY; DNA	Despite the remarkable efficacy of currently approved COVID-19 vaccines, there are several opportunities for continued vaccine development against SARS-CoV-2 and future lethal respiratory viruses. In particular, restricted vaccine access and hesitancy have limited immunization rates. In addition, current vaccines are unable to prevent breakthrough infections, leading to prolonged virus circulation. To improve access, a subunit vaccine with enhanced thermostability was designed to eliminate the need for an ultra-cold chain. The exclusion of infectious and genetic materials from this vaccine may also help reduce vaccine hesitancy. In an effort to prevent breakthrough infections, intranasal immunization to induce mucosal immunity was explored. A prototype vaccine comprised of receptor-binding domain (RBD) polypeptides formulated with additional immunoadjuvants in a chitosan (CS) solution induced high levels of RBD-specific antibodies in laboratory mice after 1 or 2 immunizations. Antibody responses were durable with high titers persisting for at least five months following subcutaneous vaccination. Serum anti-RBD antibodies contained both IgG1 and IgG2a isotypes suggesting that the vaccine induced a mixed Th1/Th2 response. RBD vaccination without CS formulation resulted in minimal anti-RBD responses. The addition of CpG oligonucleotides to the CS plus RBD vaccine formulation increased antibody titers more effectively than interleukin-12 (IL-12). Importantly, generated antibodies were cross-reactive against RBD mutants associated with SARS-CoV-2 variants of concern, including alpha, beta and delta variants, and inhibited binding of RBD to its cognate receptor angiotensin converting enzyme 2 (ACE2). With respect to stability, vaccines did not lose activity when stored at either room temperature (21-22 degrees C) or 4 degrees C for at least one month. When delivered intranasally, vaccines induced RBD-specific mucosal IgA antibodies, which may protect against breakthrough infections in the upper respiratory tract. Altogether, data indicate that the designed vaccine platform is versatile, adaptable and capable of overcoming key constraints of current COVID-19 vaccines.	[Nguyen, Khue G.; Mantooth, Siena M.; Vrabel, Maura R.; Zaharoff, David A.] Univ N Carolina, Joint Dept Biomed Engn, Raleigh, NC 27599 USA; [Nguyen, Khue G.; Mantooth, Siena M.; Vrabel, Maura R.; Zaharoff, David A.] North Carolina State Univ, Raleigh, NC 27695 USA; [Mantooth, Siena M.; Vrabel, Maura R.; Zaharoff, David A.] North Carolina State Univ, Comparat Med Inst, Raleigh, NC 27695 USA	University of North Carolina; University of North Carolina; North Carolina State University; University of North Carolina; North Carolina State University	Zaharoff, DA (corresponding author), Univ N Carolina, Joint Dept Biomed Engn, Raleigh, NC 27599 USA.; Zaharoff, DA (corresponding author), North Carolina State Univ, Raleigh, NC 27695 USA.; Zaharoff, DA (corresponding author), North Carolina State Univ, Comparat Med Inst, Raleigh, NC 27695 USA.	dazaharo@ncsu.edu		Mantooth, Siena/0000-0002-6747-2075				Aguilar-Mahecha A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038290; An XY, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103037; [Anonymous], STUDY CANDIDATE COVI; [Anonymous], 2022, COVID DATA TRACKER W; [Anonymous], STUDY LIVE RNDV BASE; [Anonymous], STUDY INTRANASAL CHA; Aziz N, 2016, CYTOKINE, V84, P17, DOI 10.1016/j.cyto.2016.05.010; Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/erv.10.174, 10.1586/ERV.10.174]; Bueter CL, 2014, J IMMUNOL, V192, P5943, DOI 10.4049/jimmunol.1301695; Bueter CL, 2011, J BIOL CHEM, V286, P35447, DOI 10.1074/jbc.M111.274936; Carroll EC, 2016, IMMUNITY, V44, P597, DOI 10.1016/j.immuni.2016.02.004; Choi A, 2021, NAT MED, V27, P2025, DOI 10.1038/s41591-021-01527-y; Cosgrove CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152038; Du YY, 2021, VACCINE, V39, P2287, DOI 10.1016/j.vaccine.2021.03.006; Fialova L, 2017, J CLIN LAB ANAL, V31, DOI 10.1002/jcla.22121; Gil-Etayo FJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.624483; Gupta S, 2021, HEALTH AFFAIR, V40, P1465, DOI 10.1377/hlthaff.2021.00619; Hamza T, 2010, INT J MOL SCI, V11, P789, DOI 10.3390/ijms11030789; Hassan AO, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109452; Hassan AO, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100230; Heffernan MJ, 2011, BIOMATERIALS, V32, P926, DOI 10.1016/j.biomaterials.2010.09.058; Jangra S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.729189; Jayanthi S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05382-1; Jayanthi S, 2014, PROTEIN EXPRES PURIF, V102, P76, DOI 10.1016/j.pep.2014.07.002; Jearanaiwitayakul T, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9070768; Jeyanathan M, 2020, NAT REV IMMUNOL, V20, P615, DOI 10.1038/s41577-020-00434-6; Kayraklioglu N, 2021, METHODS MOL BIOL, V2197, P51, DOI 10.1007/978-1-0716-0872-2_4; King RG, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9080881; Krieg AM, 2012, NUCLEIC ACID THER, V22, P77, DOI 10.1089/nat.2012.0340; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; Lin HT, 2021, INT J BIOL MACROMOL, V193, P1885, DOI 10.1016/j.ijbiomac.2021.11.020; Liu XQ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2109744118; Lu S, 2009, CURR OPIN IMMUNOL, V21, P346, DOI 10.1016/j.coi.2009.05.016; Marien J, 2021, J VIROL METHODS, V297, DOI 10.1016/j.jviromet.2021.114228; Matuchansky C, 2021, CLIN MICROBIOL INFEC, V27, P1724, DOI 10.1016/j.cmi.2021.08.008; Moore JP, 2021, JAMA-J AM MED ASSOC, V325, P821, DOI 10.1001/jama.2021.1114; Moyle PM, 2013, CHEMMEDCHEM, V8, P360, DOI 10.1002/cmdc.201200487; Munro APS, 2021, LANCET, V398, P2258, DOI 10.1016/S0140-6736(21)02717-3; National Center for Immunization and Respiratory Diseases (NCIRD), 2021, SARS COV 2 VAR CLASS; National Center for Immunization and Respiratory Diseases (NCIRD) DoVD, 2021, POSS COVID 19 VACC B; National Center for Immunization and Respiratory Diseases (NCIRD) DoVD, 2021, COVID 19 VACC US; Nguyen KG., 2018, 13419349 U N CAROLIN, P177; Nguyen KG, 2021, BLADDER CANCER, V7, P427, DOI 10.3233/BLC-211542; Nguyen KG, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575597; Nguyen KG, 2019, J BIOL CHEM, V294, P4412, DOI 10.1074/jbc.RA118.006193; O'Shea J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9040320; Oh HLJ, 2012, EMERG MICROBES INFEC, V1, DOI 10.1038/emi.2012.26; Panamerican Health Organization, 2022, PAHO COVID 19 RESP; Park JH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050524; Pilicheva B, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13101612; Pratesi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060672; Russell MW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.611337; Schneider EC, 2021, COMMONWEALTH FUND, DOI [10.26099/3542-5n54, DOI 10.26099/3542-5N54]; Scobie HM, 2021, MMWR-MORBID MORTAL W, V70, P1284, DOI 10.15585/mmwr.mm7037e1; Shaw RH, 2021, LANCET, V397, P2043, DOI [10.1016/S0140-6736(21)01158-2, 10.1016/S0140-6736(21)01115-6]; Shroff RT, 2021, NAT MED, V27, P2002, DOI 10.1038/s41591-021-01542-z; Simpson S, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154829; Skogstrand K, 2008, J IMMUNOL METHODS, V336, P78, DOI 10.1016/j.jim.2008.04.006; Tan CW, 2020, NAT BIOTECHNOL, V38, P1073, DOI 10.1038/s41587-020-0631-z; Tiboni M, 2021, INT J PHARMACEUT, V603, DOI 10.1016/j.ijpharm.2021.120686; van der Ley PA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.781280; Vasiliev YM, 2015, EXPERT REV VACCINES, V14, P37, DOI 10.1586/14760584.2015.956729; Vijayakurup V, 2019, CANCER PREV RES, V12, P225, DOI 10.1158/1940-6207.CAPR-18-0437; Vollmer J, 2009, ADV DRUG DELIVER REV, V61, P195, DOI 10.1016/j.addr.2008.12.008; Walensky DR., 2021, AP INTERVIEW CDC CHI; Wang M, 2016, BIOENGINEERED, V7, P155, DOI 10.1080/21655979.2016.1191707; Zaharoff DA, 2007, VACCINE, V25, P8673, DOI 10.1016/j.vaccine.2007.10.037; Zaharoff DA, 2007, VACCINE, V25, P2085, DOI 10.1016/j.vaccine.2006.11.034; Zhao J, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.602256; Zhou RH, 2022, EBIOMEDICINE, V75, DOI 10.1016/j.ebiom.2021.103762	71	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								858904	10.3389/fimmu.2022.858904	http://dx.doi.org/10.3389/fimmu.2022.858904			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1FM	35592324	gold, Green Published			2022-12-18	WOS:000796982000001
J	Stewart, A; Sinclair, E; Ng, JCF; O'Hare, JS; Page, A; Serangeli, I; Margreitter, C; Orsenigo, F; Longman, K; Frampas, C; Costa, C; Lewis, HM; Kasar, N; Wu, BY; Kipling, D; Openshaw, PJ; Chiu, C; Baillie, JK; Scott, JT; Semple, MG; Bailey, MJ; Fraternali, F; Dunn-Walters, DK				Stewart, Alexander; Sinclair, Emma; Ng, Joseph Chi-Fung; O'Hare, Joselli Silva; Page, Audrey; Serangeli, Ilaria; Margreitter, Christian; Orsenigo, Federica; Longman, Katherine; Frampas, Cecile; Costa, Catia; Lewis, Holly-May; Kasar, Nora; Wu, Bryan; Kipling, David; Openshaw, Peter J. M.; Chiu, Christopher; Baillie, J. Kenneth; Scott, Janet T.; Semple, Malcolm G.; Bailey, Melanie J.; Fraternali, Franca; Dunn-Walters, Deborah K.			Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus	FRONTIERS IN IMMUNOLOGY			English	Article						B cell; COVID-19; ebola; RSV (respiratory syncytial virus); immunity; repertoire; class-switch recombination (CSR)	CLASS SWITCH RECOMBINATION; CYTIDINE DEAMINASE AID; ANTIBODY-RESPONSES; MEMORY; HYPERMUTATION; MECHANISM; INFECTION; IGM	Immunoglobulin gene heterogeneity reflects the diversity and focus of the humoral immune response towards different infections, enabling inference of B cell development processes. Detailed compositional and lineage analysis of long read IGH repertoire sequencing, combining examples of pandemic, epidemic and endemic viral infections with control and vaccination samples, demonstrates general responses including increased use of IGHV4-39 in both Zaire Ebolavirus (EBOV) and COVID-19 patient cohorts. We also show unique characteristics absent in Respiratory Syncytial Virus or yellow fever vaccine samples: EBOV survivors show unprecedented high levels of class switching events while COVID-19 repertoires from acute disease appear underdeveloped. Despite the high levels of clonal expansion in COVID-19 IgG1 repertoires there is a striking lack of evidence of germinal centre mutation and selection. Given the differences in COVID-19 morbidity and mortality with age, it is also pertinent that we find significant differences in repertoire characteristics between young and old patients. Our data supports the hypothesis that a primary viral challenge can result in a strong but immature humoral response where failures in selection of the repertoire risk off-target effects.	[Stewart, Alexander; Sinclair, Emma; O'Hare, Joselli Silva; Orsenigo, Federica; Kasar, Nora; Kipling, David; Dunn-Walters, Deborah K.] Univ Surrey, Sch Biosci & Med, Guildford, England; [Ng, Joseph Chi-Fung; Fraternali, Franca] Kings Coll London, Randall Ctr Cell & Mol Biophys, London, England; [O'Hare, Joselli Silva; Page, Audrey; Wu, Bryan] Kings Coll London, Fac Life Sci & Med, London, England; [Serangeli, Ilaria] Sapienza Univ Roma, Dipartimento Biol & Biotecnol Charles Darwin, Rome, Italy; [Margreitter, Christian; Longman, Katherine; Frampas, Cecile; Costa, Catia; Lewis, Holly-May; Bailey, Melanie J.] Univ Surrey, Dept Chem, Guildford, England; [Orsenigo, Federica] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy; [Openshaw, Peter J. M.; Chiu, Christopher] Imperial Coll London, Fac Med, London, England; [Baillie, J. Kenneth] Univ Edinburgh, Roslin Inst, Edinburgh, Scotland; [Scott, Janet T.] Univ Glasgow, MRC Univ Glasgow Ctr Virus Res, Glasgow, Scotland; [Semple, Malcolm G.] Univ Liverpool, Fac Hlth & Life Sci, Liverpool, England	University of Surrey; University of London; King's College London; University of London; King's College London; Sapienza University Rome; University of Surrey; University of Milano-Bicocca; Imperial College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; University of Glasgow; University of Liverpool	Stewart, A; Dunn-Walters, DK (corresponding author), Univ Surrey, Sch Biosci & Med, Guildford, England.	Alexander.stewart@surrey.ac.uk; d.dunn-walters@surrey.ac.uk	Baillie, John Kenneth/F-3124-2011; Baillie, Kenneth/AEK-6650-2022; Sinclair, Emma/GWM-4590-2022; Fraternali, Franca/C-8912-2009; Semple, Malcolm Gracie/A-8790-2008	Baillie, John Kenneth/0000-0001-5258-793X; Baillie, Kenneth/0000-0001-5258-793X; Margreitter, Christian/0000-0002-5473-6318; Fraternali, Franca/0000-0002-3143-6574; Semple, Malcolm Gracie/0000-0001-9700-0418				Adaken C, 2021, NATURE, V590, P468, DOI 10.1038/s41586-020-03146-y; Ademokun A, 2011, AGING CELL, V10, P922, DOI 10.1111/j.1474-9726.2011.00732.x; Allman D, 2019, IMMUNOL REV, V288, P128, DOI 10.1111/imr.12754; Avnir Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep20842; Bashford-Rogers RJM, 2019, NATURE, V574, P122, DOI 10.1038/s41586-019-1595-3; Bashford-Rogers RJM, 2013, GENOME RES, V23, P1874, DOI 10.1101/gr.154815.113; Bastard P, 2020, SCIENCE, V370, P423, DOI 10.1126/science.abd4585; Bordi L, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.8.2000170; Brouwer PJM, 2020, SCIENCE, V369, P643, DOI 10.1126/science.abc5902; Chi XY, 2020, IMMUNOLOGY, V160, P233, DOI 10.1111/imm.13176; Colonna-Romano G, 2009, MECH AGEING DEV, V130, P681, DOI 10.1016/j.mad.2009.08.003; Cortjens B, 2017, J VIROL, V91, DOI 10.1128/JVI.02357-16; Davis CW, 2019, CELL, V177, P1566, DOI 10.1016/j.cell.2019.04.036; Dugan HL, 2021, IMMUNITY, V54, P1290, DOI 10.1016/j.immuni.2021.05.001; Dunbar J, 2014, NUCLEIC ACIDS RES, V42, pD1140, DOI 10.1093/nar/gkt1043; Dunn-Walters DK, 2016, CLIN EXP IMMUNOL, V183, P50, DOI 10.1111/cei.12700; Dunn-Walters D, 2018, IMMUNOL REV, V284, P132, DOI 10.1111/imr.12659; Dunn-Walters DK, 2020, INTERD T GERONT GERI, V43, P56, DOI 10.1159/000504479; Feldman J, 2021, SCI IMMUNOL, V6, DOI [10.1126/sciimmunol.abl5842, 10.1101/2021.02.02.429458]; Felsenstein J., 2005, CLADISTICS; FERRANTE A, 1990, PEDIATR INFECT DIS J, V9, pS16; Flower B, 2020, THORAX, V75, P1082, DOI 10.1136/thoraxjnl-2020-215732; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Gilman MSA, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaj1879; Goodwin E, 2018, IMMUNITY, V48, P339, DOI 10.1016/j.immuni.2018.01.005; Gudbjartsson DF, 2020, NEW ENGL J MED, V383, P1724, DOI 10.1056/NEJMoa2026116; Habibi MS, 2015, AM J RESP CRIT CARE, V191, P1040, DOI 10.1164/rccm.201412-2256OC; Higgins RL, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247797; Jaaskelainen AJ, 2020, J CLIN VIROL, V129, DOI 10.1016/j.jcv.2020.104512; Kennedy JR, 2020, MED HYPOTHESES, V135, DOI 10.1016/j.mehy.2019.109462; King HW, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abe6291; Knight SR, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3339; Kreer C, 2020, CELL, V182, P843, DOI 10.1016/j.cell.2020.06.044; Laffy JMJ, 2017, PROG BIOPHYS MOL BIO, V128, P47, DOI 10.1016/j.pbiomolbio.2016.09.002; Lord JM, 2013, HUM VACC IMMUNOTHER, V9, P1364, DOI 10.4161/hv.24696; Margreitter C, 2018, NUCLEIC ACIDS RES, V46, pW264, DOI 10.1093/nar/gky276; Martin V, 2015, ANN NY ACAD SCI, V1362, P153, DOI 10.1111/nyas.12823; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nielsen SCA, 2020, CELL HOST MICROBE, V28, P516, DOI 10.1016/j.chom.2020.09.002; Osorio D, 2015, R J, V7, P4; Pape KA, 2003, J EXP MED, V197, P1677, DOI 10.1084/jem.20012065; Perchiacca JM, 2012, PROTEIN ENG DES SEL, V25, P591, DOI 10.1093/protein/gzs042; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Pone EJ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1769; Richter AG, 2021, CLIN EXP IMMUNOL, V205, P99, DOI 10.1111/cei.13623; Robbiani DF, 2020, NATURE, V584, P437, DOI 10.1038/s41586-020-2456-9; Roco JA, 2019, IMMUNITY, V51, P337, DOI 10.1016/j.immuni.2019.07.001; Rossi D, 2013, BLOOD, V121, P4902, DOI 10.1182/blood-2013-02-486209; Scheepers C, 2015, J IMMUNOL, V194, P4371, DOI 10.4049/jimmunol.1500118; Seow J, 2020, NAT MICROBIOL, V5, P1598, DOI [10.1038/s41564-020-00813-8, DOI 10.1038/S41564-020-00813-8, 10.1101/2020.07.09.20148429]; Siggins MK, 2021, TRENDS MICROBIOL, V29, P648, DOI 10.1016/j.tim.2021.03.016; Smith SA, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03163; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Stephenson E, 2021, NAT MED, V27, P904, DOI 10.1038/s41591-021-01329-2; Stern JNH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008879; Taylor JJ, 2012, J EXP MED, V209, P597, DOI 10.1084/jem.20111696; Tedder RS, 2018, TRANSFUSION, V58, P1289, DOI 10.1111/trf.14580; Toellner KM, 1996, J EXP MED, V183, P2303, DOI 10.1084/jem.183.5.2303; Townsend CL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00388; Unterman A, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-021-27716-4; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Whitman JD, 2020, NAT BIOTECHNOL, V38, P1174, DOI [10.1038/s41587-020-0659-0, 10.1101/2020.04.25.20074856]; Woodruff MC, 2020, NAT IMMUNOL, V21, P1506, DOI 10.1038/s41590-020-00814-z; Wu JL, 2020, J INFECTION, V81, P435, DOI 10.1016/j.jinf.2020.06.023; Wu YC, 2010, BLOOD, V116, P1070, DOI 10.1182/blood-2010-03-275859; Wu YCB, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00193; Xu ZM, 2012, NAT REV IMMUNOL, V12, P517, DOI 10.1038/nri3216; Yamayoshi S, 2018, J CLIN VIROL, V108, P105, DOI 10.1016/j.jcv.2018.09.016; Yeung YA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13376; Zampieri CA, 2007, NAT IMMUNOL, V8, P1159, DOI 10.1038/ni1519; Zhang Y, 2004, PROTEINS, V57, P702, DOI 10.1002/prot.20264; Zost SJ, 2020, NAT MED, V26, DOI [10.1038/s41591-020-0998-x, 10.1101/2020.05.12.091462]	73	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								807104	10.3389/fimmu.2022.807104	http://dx.doi.org/10.3389/fimmu.2022.807104			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1HB	35592326	Green Published, Green Submitted, Green Accepted, gold			2022-12-18	WOS:000796986100001
J	Tu, ZW; Peng, J; Long, XY; Li, JY; Wu, L; Huang, K; Zhu, XE				Tu, Zewei; Peng, Jie; Long, Xiaoyan; Li, Jingying; Wu, Lei; Huang, Kai; Zhu, Xingen			Sperm Autoantigenic Protein 17 Predicts the Prognosis and the Immunotherapy Response of Cancers: A Pan-Cancer Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						sperm autoantigenic protein 17 (SPA17); pan-cancer; prognostic biomarker; immunotherapy response; CMap	SP17; EXPRESSION; ANTIGEN; INHIBITORS; ANTI-PD-1; PD-1	BackgroundSperm autoantigen protein 17 (SPA17) is a highly conserved mammalian protein that participates in the acrosome reaction during fertilization and is a recently reported member of the cancer-testicular antigen (CTA) family. It has been reported that the SPA17 expression is limited in adult somatic tissues and re-expressed in tumor tissues. Recently, studies have found that SPA17 regulates the progression of various cancers, but its role in cancer immunotherapy is not clear. MethodsThe pan-cancer and normal tissue transcriptional data were acquired from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) datasets. We explored the SPA17 pan-cancer genomic alteration analysis in the cBioPortal webtool. The Human Protein Atlas (HPA) and ComPPI websites were used to mine the SPA17 protein information. We performed a western blotting assay to validate the upregulated SPA17 expression in clinical glioblastoma (GBM) samples. The univariate Cox regression and Kaplan-Meier method were used to assess the prognostic role of SPA17 in pan-cancer. Gene Set Enrichment Analysis (GSEA) was used to search the associated cancer hallmarks with SPA17 expression in each cancer type. TIMER2.0 was the main platform to investigate the immune cell infiltrations related to SPA17 in pan-cancer. The associations between SPA17 and immunotherapy biomarkers were performed by Spearman correlation analysis. The drug sensitivity information from the Connectivity Map (CMap) dataset was downloaded to perform SAP17-specific inhibitor sensitivity analysis. FindingsSPA17 was aberrantly expressed in most cancer types and exhibited prognosis predictive ability in various cancers. In addition, our results also show that SPA17 was significantly correlated with immune-activated hallmarks (including pathways and biological processes), immune cell infiltrations, and immunoregulator expressions. The most exciting finding was that SPA17 could significantly predict anti-PDL1 and anti-PD1 therapy responses in cancer patients. Finally, specific inhibitors, like irinotecan and puromycin, which correlate with SPA17 expression in different cancer types, were also screened using Connectivity Map (CMap). ConclusionsOur results reveal that SPA17 was abnormally expressed in cancer tissues, and this expression pattern could be associated with immune cell infiltrations in tumor microenvironments. Clinically, SPA17 not only acted as a potent prognostic factor to predict the clinical outcomes of cancer patients but was also a promising immunotherapy predictive biomarker for cancer patients treated with immune-checkpoint inhibitors (ICIs).	[Tu, Zewei; Wu, Lei; Huang, Kai; Zhu, Xingen] Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang, Peoples R China; [Tu, Zewei; Wu, Lei; Huang, Kai; Zhu, Xingen] Jiangxi Key Lab Neurol Tumors & Cerebrovascular D, Nanchang, Peoples R China; [Tu, Zewei; Wu, Lei; Huang, Kai; Zhu, Xingen] Nanchang Univ, Inst Neurosci, Nanchang, Peoples R China; [Tu, Zewei; Wu, Lei; Huang, Kai; Zhu, Xingen] Jiangxi Hlth Commiss JXHC Key Lab Neurol Med, Nanchang, Peoples R China; [Peng, Jie] Nanchang Univ, Clin Med Coll 2, Nanchang, Peoples R China; [Long, Xiaoyan] East China Inst Digital Med Engn, Shangrao, Peoples R China; [Li, Jingying] Nanchang Univ, Dept Comprehens Intens Care Unit, Affiliated Hosp 2, Nanchang, Peoples R China	Nanchang University; Nanchang University; Nanchang University; Nanchang University	Wu, L; Huang, K; Zhu, XE (corresponding author), Nanchang Univ, Dept Neurosurg, Affiliated Hosp 2, Nanchang, Peoples R China.; Wu, L; Huang, K; Zhu, XE (corresponding author), Jiangxi Key Lab Neurol Tumors & Cerebrovascular D, Nanchang, Peoples R China.; Wu, L; Huang, K; Zhu, XE (corresponding author), Nanchang Univ, Inst Neurosci, Nanchang, Peoples R China.; Wu, L; Huang, K; Zhu, XE (corresponding author), Jiangxi Hlth Commiss JXHC Key Lab Neurol Med, Nanchang, Peoples R China.	doctorleiming@163.com; kaihuang@ncu.edu.cn; ndefy89006@ncu.edu.cn		Peng, Jie/0000-0003-4040-0327	National Natural Science Foundation [81860448, 82002660, 82172989]; Natural Science Foundation of Jiangxi Province [20192BAB205077, 20202ACB216004]; Jiangxi Key research and development projects Key Project [20212BBG71012]; Jiangxi Provincial Science and Technology Innovation Base Plan Provincial Key Laboratory [20212BCD42008]; Construction of Science and Technology Innovation Base-Clinical Medicine Research Center [2021ZDG02001]; Jiangxi Key research and development projects [20212BBG73021]; Province Youth Talent Project [20212BCJ23023]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangxi Province(Natural Science Foundation of Jiangxi Province); Jiangxi Key research and development projects Key Project; Jiangxi Provincial Science and Technology Innovation Base Plan Provincial Key Laboratory; Construction of Science and Technology Innovation Base-Clinical Medicine Research Center; Jiangxi Key research and development projects; Province Youth Talent Project	The research project is supported by the National Natural Science Foundation (grant nos. 81860448, 82002660 and 82172989), the Natural Science Foundation of Jiangxi Province (grant no.20192BAB205077 and 20202ACB216004), the Jiangxi Key research and development projects Key Project (20212BBG71012), Jiangxi Provincial Science and Technology Innovation Base Plan Provincial Key Laboratory (20212BCD42008), Construction of Science and Technology Innovation Base-Clinical Medicine Research Center (2021ZDG02001), Jiangxi Key research and development projects (20212BBG73021), Province Youth Talent Project (20212BCJ23023).	Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741; Bailly C, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104398; Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Cheng Q, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.686909; Chiriva-Internati M, 2002, CANCER-AM CANCER SOC, V94, P2447, DOI 10.1002/cncr.10506; Chiriva-Internati M, 2002, BLOOD, V100, P961, DOI 10.1182/blood-2002-02-0408; Chiriva-Internati M, 2007, J IMMUNOL METHODS, V321, P86, DOI 10.1016/j.jim.2007.01.010; Chiriva-Internati M, 2011, INT REV IMMUNOL, V30, P138, DOI 10.3109/08830185.2011.569903; Chiriva-Internati Maurizio, 2008, Cancer Immun, V8, P8; Chiriva-Internati M, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-61; Cordell GA, 2001, PHYTOTHER RES, V15, P183, DOI 10.1002/ptr.890; Corgnac S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01904; Dadabayev AR, 2005, AM J HEMATOL, V80, P6, DOI 10.1002/ajh.20415; Dahlin HR, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.100927; Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3; Enam SU, 2020, ELIFE, V9, DOI 10.7554/eLife.60303; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Giles AJ, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0371-5; Gjerstorff MF, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-466; Goldman MJ, 2020, NAT BIOTECHNOL, V38, P675, DOI 10.1038/s41587-020-0546-8; Gordeeva O, 2018, SEMIN CANCER BIOL, V53, P75, DOI 10.1016/j.semcancer.2018.08.006; Gotwals P, 2017, NAT REV CANCER, V17, P286, DOI 10.1038/nrc.2017.17; Grizzi F, 2015, INT REV IMMUNOL, V34, P143, DOI 10.3109/08830185.2015.1018418; Grizzi F, 2004, J HISTOCHEM CYTOCHEM, V52, P549, DOI 10.1177/002215540405200414; Gupta G, 2007, INT J CANCER, V120, P1739, DOI 10.1002/ijc.22463; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Haeussler M, 2019, NUCLEIC ACIDS RES, V47, pD853, DOI 10.1093/nar/gky1095; Knutson KL, 2005, CANCER IMMUNOL IMMUN, V54, P721, DOI 10.1007/s00262-004-0653-2; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Lea Isabel A, 2004, Reprod Biol Endocrinol, V2, P57, DOI 10.1186/1477-7827-2-57; Lee J, 2020, EUR J CANCER, V132, P150, DOI 10.1016/j.ejca.2020.03.029; Li CW, 2021, NUCLEIC ACIDS RES, V49, pW242, DOI 10.1093/nar/gkab418; Li FQ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-429; Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407; Li ZF, 2007, INT J CANCER, V121, P1507, DOI 10.1002/ijc.22842; Lin Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19949-6; Mahoney KM, 2015, CLIN THER, V37, P764, DOI 10.1016/j.clinthera.2015.02.018; Malta TM, 2018, CELL, V173, P338, DOI 10.1016/j.cell.2018.03.034; Mao Y, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0793-7; Mayes PA, 2018, NAT REV DRUG DISCOV, V17, P509, DOI 10.1038/nrd.2018.75; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Okazaki T, 2013, NAT IMMUNOL, V14, P1212, DOI 10.1038/ni.2762; Principe N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584423; Qin S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1091-2; Ramos-Casals M, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-0160-6; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rotte A, 2018, ANN ONCOL, V29, P71, DOI 10.1093/annonc/mdx686; Salmaninejad A, 2016, IMMUNOL INVEST, V45, P619, DOI 10.1080/08820139.2016.1197241; Samanta L, 2018, J UROLOGY, V200, P414, DOI 10.1016/j.juro.2018.03.009; Shuvalov O, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00482-4; Song YX, 2021, ANDROLOGIA, V53, DOI 10.1111/and.13986; Straughn JM, 2004, INT J CANCER, V108, P805, DOI 10.1002/ijc.11617; Tu ZW, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.588368; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Veres DV, 2015, NUCLEIC ACIDS RES, V43, pD485, DOI 10.1093/nar/gku1007; Wang YY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00939-6; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; Wen Y, 2001, BIOCHEM J, V357, P25, DOI 10.1042/0264-6021:3570025; Xu AX, 2015, ONCOL LETT, V10, P1402, DOI 10.3892/ol.2015.3472; Yang P, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188558; Yang YH, 2016, J CELL PHYSIOL, V231, P2570, DOI 10.1002/jcp.25349; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zhao PF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0738-1; Zhou YT, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00710	66	0	0	6	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								844736	10.3389/fimmu.2022.844736	http://dx.doi.org/10.3389/fimmu.2022.844736			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N0SU	35592314	Green Published, gold			2022-12-18	WOS:000800374700001
J	Zhang, XZ; Wu, ZX; Hao, YY; Yu, T; Li, X; Liang, Y; Li, JF; Huang, LS; Xu, Y; Li, XZ; Xu, XH; Wang, WQ; Xu, GB; Zhang, XH; Lv, QH; Fang, YM; Xu, RZ; Qian, WB				Zhang, Xuzhao; Wu, Zhaoxing; Hao, Yuanyuan; Yu, Teng; Li, Xian; Liang, Yun; Li, Jinfan; Huang, Liansheng; Xu, Yang; Li, Xiuzhen; Xu, Xiaohua; Wang, Weiqin; Xu, Genbo; Zhang, Xiaohong; Lv, Qinghua; Fang, Yongming; Xu, Rongzhen; Qian, Wenbin			Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma	FRONTIERS IN IMMUNOLOGY			English	Article						TP53 mutation; APOBEC3B; DLBCL; refractory; relapse	CYTIDINE DEAMINASES; P53 MUTATIONS; TP53 GENE; DNA; VIRUS; EXPRESSION; CHEMOTHERAPY; MUTAGENESIS; SURVIVAL; RISK	Tumor protein 53 (TP53) mutation predicts an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL), but the molecular basis for this association remains unclear. In several malignancies, the cytidine deaminase apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) has been reported to be associated with the TP53 G/C-to-A/T mutation. Here, we show that the frequency of this mutation was significantly higher in relapsed/refractory (R/R) than in non-R/R DLBCL, which was positively associated with the APOBEC3B expression level. APOBEC3B overexpression induced the TP53 G/C-to-A/T mutation in vitro, resulting in a phenotype similar to that of DLBCL specimens. Additionally, APOBEC3B-induced p53 mutants promoted the growth of DLBCL cells and enhanced drug resistance. These results suggest that APOBEC3B is a critical factor in mutant p53-driven R/R DLBCL and is therefore a potential therapeutic target.	[Zhang, Xuzhao; Wu, Zhaoxing; Hao, Yuanyuan; Yu, Teng; Li, Xian; Liang, Yun; Huang, Liansheng; Xu, Yang; Xu, Xiaohua; Wang, Weiqin; Xu, Genbo; Zhang, Xiaohong; Xu, Rongzhen; Qian, Wenbin] Zhejiang Univ, Dept Hematol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China; [Zhang, Xuzhao; Lv, Qinghua; Fang, Yongming; Xu, Rongzhen] Zhejiang Univ, Canc Inst, Key Lab Canc Prevent & Intervent, China Natl Minist Educ,Affiliated Hosp 2,Sch Med, Hangzhou, Peoples R China; [Zhang, Xuzhao] Zhejiang Univ, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou, Peoples R China; [Li, Jinfan; Li, Xiuzhen] Zhejiang Univ, Sch Med, Dept Pathol, Affiliated Hosp 2, Hangzhou, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University; Zhejiang University	Zhang, XZ; Qian, WB (corresponding author), Zhejiang Univ, Dept Hematol, Affiliated Hosp 2, Sch Med, Hangzhou, Peoples R China.; Zhang, XZ (corresponding author), Zhejiang Univ, Canc Inst, Key Lab Canc Prevent & Intervent, China Natl Minist Educ,Affiliated Hosp 2,Sch Med, Hangzhou, Peoples R China.; Zhang, XZ (corresponding author), Zhejiang Univ, Zhejiang Prov Key Lab Canc Mol Cell Biol, Hangzhou, Peoples R China.	zxzzju@zju.edu.cn; qianwb@zju.edu.cn			National Natural Science Foundation of China [81000895]; Zhejiang Provincial Natural Science Foundation of China [LQ22H080007]; Leukemia Research Innovative Team of Zhejiang Province [2011R50015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Zhejiang Provincial Natural Science Foundation of China(Natural Science Foundation of Zhejiang Province); Leukemia Research Innovative Team of Zhejiang Province	Funding This work was supported by a grant from the National Natural Science Foundation of China (81000895 to XZZ), a grant from the Zhejiang Provincial Natural Science Foundation of China (LY14H160032 to XZZ), and a grant from the Leukemia Research Innovative Team of Zhejiang Province (2011R50015 to XZZ). This work was also partly supported by a grant from the Zhejiang Provincial Natural Science Foundation of China (LQ22H080007 to ZW).	Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Barrans SL, 2002, BLOOD, V99, P1136, DOI 10.1182/blood.V99.4.1136; Barzak FM, 2019, ORG BIOMOL CHEM, V17, P9435, DOI 10.1039/c9ob01781j; Baugh EH, 2018, CELL DEATH DIFFER, V25, P154, DOI 10.1038/cdd.2017.180; Boettcher S, 2019, SCIENCE, V365, P599, DOI 10.1126/science.aax3649; Bonvin M, 2006, HEPATOLOGY, V43, P1364, DOI 10.1002/hep.21187; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Chen T, 2013, LEUKEMIA, V27, P1469, DOI 10.1038/leu.2013.8; Cheson BD, 2007, J CLIN ONCOL, V25, P579, DOI 10.1200/JCO.2006.09.2403; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Flynt E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020287; FREBOURG T, 1992, P NATL ACAD SCI USA, V89, P6413, DOI 10.1073/pnas.89.14.6413; Giglia-Mari G, 2003, HUM MUTAT, V21, P217, DOI 10.1002/humu.10179; Gu Y, 2012, BLOOD, V120, P4829, DOI 10.1182/blood-2012-06-434894; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kvach MV, 2020, CHEMBIOCHEM, V21, P1028, DOI 10.1002/cbic.201900505; Kvach MV, 2019, BIOCHEMISTRY-US, V58, P391, DOI 10.1021/acs.biochem.8b00858; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; Li J, 2014, HUM MUTAT, V35, P575, DOI 10.1002/humu.22528; Mahieux R, 2005, J GEN VIROL, V86, P2489, DOI 10.1099/vir.0.80973-0; Mareschal S, 2016, GENE CHROMOSOME CANC, V55, P251, DOI 10.1002/gcc.22328; Morin RD, 2016, CLIN CANCER RES, V22, P2290, DOI 10.1158/1078-0432.CCR-15-2123; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Osada M, 1999, ANTI-CANCER DRUG DES, V14, P107; Peng G, 2006, J EXP MED, V203, P41, DOI 10.1084/jem.20051512; Periyasamy M, 2017, NUCLEIC ACIDS RES, V45, P11056, DOI 10.1093/nar/gkx721; Quesnel S, 1999, ONCOGENE, V18, P3970, DOI 10.1038/sj.onc.1202783; Reles A, 2001, CLIN CANCER RES, V7, P2984; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; Roschewski M, 2014, NAT REV CLIN ONCOL, V11, P12, DOI 10.1038/nrclinonc.2013.197; Serebrenik AA, 2019, P NATL ACAD SCI USA, V116, P22158, DOI 10.1073/pnas.1904024116; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Suspene R, 2005, P NATL ACAD SCI USA, V102, P8321, DOI 10.1073/pnas.0408223102; Suspene R, 2005, J GEN VIROL, V86, P125, DOI 10.1099/vir.0.80426-0; Tessoulin B, 2017, BLOOD REV, V31, P251, DOI 10.1016/j.blre.2017.03.001; Xu RZ, 2007, HEPATOLOGY, V46, P1810, DOI 10.1002/hep.21893; Xu-Monette ZY, 2012, BLOOD, V120, P3986, DOI 10.1182/blood-2012-05-433334; Yamazaki H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43575-y; Young KH, 2008, BLOOD, V112, P3088, DOI 10.1182/blood-2008-01-129783; Zenz T, 2017, INT J CANCER, V141, P1381, DOI 10.1002/ijc.30838; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	46	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 3	2022	13								888250	10.3389/fimmu.2022.888250	http://dx.doi.org/10.3389/fimmu.2022.888250			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I1QA	35592333	Green Published, gold			2022-12-18	WOS:000797009400001
J	Costa-Madeira, JC; Trindade, GB; Almeida, PHP; Silva, JS; Carregaro, V				Costa-Madeira, Juliana C.; Trindade, Gabrielly B.; Almeida, Paulo H. P.; Silva, Joao S.; Carregaro, Vanessa			T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis	FRONTIERS IN IMMUNOLOGY			English	Review						visceral leishmanaisis; T cell exhaustion; Th subsets; inflammation; inhibitory receptor	TGF-BETA; CUTANEOUS LEISHMANIASIS; IMMUNE-RESPONSE; CELL EXHAUSTION; INDOLEAMINE 2,3-DIOXYGENASE; INTERFERON-GAMMA; IFN-GAMMA; IN-VITRO; MEDIATES SUSCEPTIBILITY; DONOVANI INFECTION	A key point of immunity against protozoan Leishmania parasites is the development of an optimal T cell response, which includes a low apoptotic rate, high proliferative activity and polyfunctionality. During acute infection, antigen-specific T cells recognize the pathogen resulting in pathogen control but not elimination, promoting the development and the maintenance of a population of circulating effector cells that mount rapid response quickly after re-exposure to the parasite. However, in the case of visceral disease, the functionality of specific T cells is lost during chronic infection, resulting in inferior effector functions, poor response to specific restimulation, and suboptimal homeostatic proliferation, a term referred to as T cell exhaustion. Multiple factors, including parasite load, infection duration and host immunity, affect T lymphocyte exhaustion. These factors contribute to antigen persistence by promoting inhibitory receptor expression and sustained production of soluble mediators, influencing suppressive cell function and the release of endogenous molecules into chronically inflamed tissue. Together, these signals encourage several changes, reprogramming cells into a quiescent state, which reflects disease progression to more severe forms, and development of acquired resistance to conventional drugs to treat the disease. These points are discussed in this review.	[Costa-Madeira, Juliana C.; Trindade, Gabrielly B.; Almeida, Paulo H. P.; Silva, Joao S.; Carregaro, Vanessa] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Ribeirao Preto, Brazil; [Silva, Joao S.] Fiocruz Biinst Translat Med Project, Ribeirao Preto, Brazil	Universidade de Sao Paulo	Carregaro, V (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, Ribeirao Preto, Brazil.	vcarregaro@usp.br	Silva, Joao/A-4484-2008; Carregaro, Vanessa/D-2913-2012	Silva, Joao/0000-0002-3410-3927; Carregaro, Vanessa/0000-0002-8435-0766				Abdoli A, 2019, LANCET, V393, P872, DOI 10.1016/S0140-6736(18)33044-7; Abidin BM, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006422; Adem E, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004468; Alexander J, 2005, IMMUNOL LETT, V99, P17, DOI 10.1016/j.imlet.2005.01.009; Ali N, 2013, IMMUNOTHERAPY-UK, V5, P1025, DOI 10.2217/imt.13.104; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Andrews LP, 2019, NAT IMMUNOL, V20, P1425, DOI 10.1038/s41590-019-0512-0; Ansari NA, 2011, J IMMUNOL, V186, P3977, DOI 10.4049/jimmunol.1003588; Asad M, 2021, FASEB J, V35, DOI 10.1096/fj.202002356RR; Asad M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00616; Attanasio J, 2016, IMMUNITY, V44, P1052, DOI 10.1016/j.immuni.2016.04.022; Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519; Banerjee H, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109699; Banerjee R, 2011, IMMUNOL CELL BIOL, V89, P466, DOI 10.1038/icb.2010.108; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; Benevides L, 2019, J ALLERGY CLIN IMMUN, V143, P1119, DOI 10.1016/j.jaci.2018.06.046; Bhattacharjee S, 2009, INDIAN J EXP BIOL, V47, P489; Bhattacharya P, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004422; Bhattacharya SK, 2016, LANCET INFECT DIS, V16, P142, DOI 10.1016/S1473-3099(15)00528-9; Boer MC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00217; BOGDAN C, 1990, EUR J IMMUNOL, V20, P1131, DOI 10.1002/eji.1830200528; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Boivin N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124802; Bunn PT, 2018, J IMMUNOL, V201, P3362, DOI 10.4049/jimmunol.1701582; Burza S, 2018, LANCET, V392, P951, DOI 10.1016/S0140-6736(18)31204-2; Cai JJ, 2019, ONCOTARGETS THER, V12, P8437, DOI 10.2147/OTT.S221340; Carregaro V, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003600; Champiat S, 2019, ANN ONCOL, V30, P1028, DOI 10.1093/annonc/mdz184; Champiat S, 2018, NAT REV CLIN ONCOL, V15, P748, DOI 10.1038/s41571-018-0111-2; Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741; Chappuis F, 2007, NAT REV MICROBIOL, V5, P873, DOI 10.1038/nrmicro1748; Charpentier T, 2016, CELL IMMUNOL, V309, P42, DOI 10.1016/j.cellimm.2016.06.002; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; Chevolet I, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.982382; Chihara N, 2018, NATURE, V558, P454, DOI 10.1038/s41586-018-0206-z; Chocarro L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105282; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Clarencio J, 2009, INT IMMUNOL, V21, P137, DOI 10.1093/intimm/dxn131; Collison LW, 2007, NATURE, V450, P566, DOI 10.1038/nature06306; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; Corthay A, 2009, SCAND J IMMUNOL, V70, P326, DOI 10.1111/j.1365-3083.2009.02308.x; Costa DL, 2013, PATHOG GLOB HEALTH, V107, P78, DOI 10.1179/2047773213Y.0000000078; Croft AM, 2006, LANCET, V367, P112, DOI 10.1016/S0140-6736(06)67960-9; Dayakar A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00670; de Carvalho RVH, 2020, TRENDS PARASITOL, V36, P459, DOI 10.1016/j.pt.2020.02.006; de Moura RG, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.632667; de Oca MM, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005398; de Souza MC, 2010, ACTA TROP, V115, P262, DOI 10.1016/j.actatropica.2010.04.007; DeLong Jonathan H, 2019, Immunohorizons, V3, P13, DOI 10.4049/immunohorizons.1800083; Dorlo TPC, 2016, LANCET INFECT DIS, V16, P777, DOI 10.1016/S1473-3099(16)30091-3; Marques LHD, 2017, PARASITOLOGY, V144, P546, DOI 10.1017/S0031182016002134; dos Santos PL, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004375; Edner NM, 2020, NAT REV DRUG DISCOV, V19, P860, DOI 10.1038/s41573-020-0081-9; Engwerda CR, 2004, TRENDS PARASITOL, V20, P524, DOI 10.1016/j.pt.2004.08.009; Esch KJ, 2013, J IMMUNOL, V191, P5542, DOI 10.4049/jimmunol.1301810; de Figueiredo WME, 2019, EXP PARASITOL, V207, DOI 10.1016/j.exppara.2019.107789; Faleiro RJ, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002914; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gangneux JP, 2013, INNATE IMMUN-LONDON, V19, P564, DOI 10.1177/1753425912473170; Gantt KR, 2003, J IMMUNOL, V170, P2613, DOI 10.4049/jimmunol.170.5.2613; Gautam S, 2014, J INFECT DIS, V209, P290, DOI 10.1093/infdis/jit401; Gautam S, 2011, J INFECT DIS, V204, P1134, DOI 10.1093/infdis/jir461; GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570; Ghosh S, 2021, CYTOKINE, V147, DOI 10.1016/j.cyto.2020.155266; Gidwani K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001296; Gidwani K, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001042; Gigley JP, 2012, TRENDS PARASITOL, V28, P377, DOI 10.1016/j.pt.2012.07.001; Giunchetti RC, 2019, VET PARASITOL, V271, P87, DOI 10.1016/j.vetpar.2019.05.006; Gocher AM, 2022, NAT REV IMMUNOL, V22, P158, DOI 10.1038/s41577-021-00566-3; Gomes NA, 1998, J INFECT DIS, V178, P1847, DOI 10.1086/314520; Gomes NA, 2000, J IMMUNOL, V164, P2001, DOI 10.4049/jimmunol.164.4.2001; Gomes RS, 2015, MICROBES INFECT, V17, P295, DOI 10.1016/j.micinf.2014.12.009; Gonzalez-Tafoya E, 2020, CELL IMMUNOL, V358, DOI 10.1016/j.cellimm.2020.104196; GREEN SJ, 1990, J IMMUNOL, V145, P4290; Gunton JE, 2020, J CLIN INVEST, V130, P5063, DOI 10.1172/JCI137556; Gupta G, 2011, MED MICROBIOL IMMUN, V200, P241, DOI 10.1007/s00430-011-0197-y; Gurung P, 2015, CELL MICROBIOL, V17, P1286, DOI 10.1111/cmi.12484; Habib S, 2018, INFECT IMMUN, V86, DOI [10.1128/IAI.00019-18, 10.1128/iai.00019-18]; Hajilooi M, 2014, JUNDISHAPUR J MICROB, V7, DOI 10.5812/jjm.12143; Hammami A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21891-z; Hammami A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006616; Hammami A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004938; Han YY, 2020, AM J CANCER RES, V10, P727; Hernandez-Ruiz J, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000871; Hirahara K, 2012, IMMUNITY, V36, P1017, DOI 10.1016/j.immuni.2012.03.024; Hirsch CS, 1997, P NATL ACAD SCI USA, V94, P3926, DOI 10.1073/pnas.94.8.3926; Hsu TS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18731-y; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Iniesta V, 2001, J EXP MED, V193, P777, DOI 10.1084/jem.193.6.777; Jafarzadeh A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01573; Jones GW, 2018, CLIN EXP IMMUNOL, V193, P37, DOI 10.1111/cei.13116; Joshi T, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000431; Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116; KARP CL, 1993, J CLIN INVEST, V91, P1644, DOI 10.1172/JCI116372; Kumar P, 2018, CLIN EXP IMMUNOL, V191, P318, DOI 10.1111/cei.13074; Kumar R, 2020, CELL REP, V30, P2512, DOI 10.1016/j.celrep.2020.01.099; Kumar R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01492; Kumar R, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003198; Kumar V, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00385; Lima MHF, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00815; Nascimento MSL, 2015, J INFECT DIS, V211, P1015, DOI 10.1093/infdis/jiu531; Lin MH, 2014, CLIN IMMUNOL, V151, P101, DOI 10.1016/j.clim.2014.02.006; Makala LHC, 2011, J INFECT DIS, V203, P715, DOI 10.1093/infdis/jiq095; Matte C, 2021, INFECT IMMUN, V89, DOI 10.1128/IAI.00009-21; Mauricio IL, 2000, PARASITOL TODAY, V16, P188, DOI 10.1016/S0169-4758(00)01637-9; MCELRATH MJ, 1988, J EXP MED, V167, P1927, DOI 10.1084/jem.167.6.1927; Medina-Colorado AA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169496; Mesquita I, 2020, CELL REP, V30, P4052, DOI 10.1016/j.celrep.2020.02.098; Morrow KN, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102093; Moulik S, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12783; Mukhopadhyay D, 2011, J INFECT DIS, V204, P1427, DOI 10.1093/infdis/jir551; Murphy ML, 1998, J IMMUNOL, V161, P4153; Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10&lt;2848::AID-IMMU2848&gt;3.0.CO;2-T; Murray HW, 2003, INFECT IMMUN, V71, P6453, DOI 10.1128/IAI.71.11.6453-6462.2003; Murray HW, 2003, J INFECT DIS, V188, P458, DOI 10.1086/376510; Murray HW, 2002, INFECT IMMUN, V70, P6284, DOI 10.1128/IAI.70.11.6284-6293.2002; Nascimento MSL, 2016, J INFECT DIS, V214, P1647, DOI 10.1093/infdis/jiw446; Nigg AP, 2007, J IMMUNOL, V178, P7251, DOI 10.4049/jimmunol.178.11.7251; Nutt SL, 2008, J CLIN IMMUNOL, V28, P97, DOI 10.1007/s10875-007-9151-6; Nutt SL, 2007, NAT REV IMMUNOL, V7, P923, DOI 10.1038/nri2204; Nylen S, 2007, TRENDS IMMUNOL, V28, P378, DOI 10.1016/j.it.2007.07.004; Nylen S, 2007, J EXP MED, V204, P805, DOI 10.1084/jem.20061141; Omer FM, 2000, PARASITOL TODAY, V16, P18, DOI 10.1016/S0169-4758(99)01562-8; Papatriantafyllou M, 2013, NAT REV IMMUNOL, V13, DOI 10.1038/nri3506; Patsoukis N, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abd2712; Peres-Sampaio CE, 2001, Z NATURFORSCH C, V56, P820; Peters NC, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004538; Prendergast GC, 2018, INT REV CEL MOL BIO, V336, P175, DOI 10.1016/bs.ircmb.2017.07.004; Prendergast GC, 2017, CANCER RES, V77, P6795, DOI 10.1158/0008-5472.CAN-17-2285; Quirino GFS, 2016, INFECT IMMUN, V84, P2289, DOI 10.1128/IAI.00283-16; Rai AK, 2011, PARASITE IMMUNOL, V33, P632, DOI 10.1111/j.1365-3024.2011.01315.x; Ravi R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02696-6; Reynoso ED, 2009, J IMMUNOL, V182, P2102, DOI 10.4049/jimmunol.0802769; Robert C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17670-y; Rodrigues OR, 2009, IMMUNOBIOLOGY, V214, P101, DOI 10.1016/j.imbio.2008.07.001; Rodrigues V, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002567; Rosas LE, 2006, AM J PATHOL, V168, P158, DOI 10.2353/ajpath.2006.050013; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; SACKS DL, 1987, J IMMUNOL, V138, P908; Sacramento LA, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00262; Sacramento LA, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008435; Sacramento LA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/264270; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Salehi S, 2012, J IMMUNOL, V189, P5682, DOI 10.4049/jimmunol.1201966; Sauer KA, 2008, J IMMUNOL, V181, P6148, DOI 10.4049/jimmunol.181.9.6148; Sawant DV, 2019, NAT IMMUNOL, V20, P724, DOI 10.1038/s41590-019-0346-9; Schaut RG, 2016, VACCINE, V34, P5225, DOI 10.1016/j.vaccine.2016.09.016; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; Scott P, 2016, NAT REV IMMUNOL, V16, P581, DOI 10.1038/nri.2016.72; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shen P, 2014, NATURE, V507, P366, DOI 10.1038/nature12979; Shevchenko I, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1744946; Silva RDE, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.620144; Singh AK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038489; Singh B, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12669; Singh OP, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00296; Singh OP, 2012, CLIN VACCINE IMMUNOL, V19, P961, DOI 10.1128/CVI.00143-12; Stumhofer JS, 2008, IMMUNOL LETT, V117, P123, DOI 10.1016/j.imlet.2008.01.011; Sullivan RJ, 2022, NAT REV DRUG DISCOV, V21, P495, DOI 10.1038/s41573-021-00259-5; Takenaka MC, 2016, TRENDS IMMUNOL, V37, P427, DOI 10.1016/j.it.2016.04.009; Teles LD, 2021, PARASITE IMMUNOL, V43, DOI 10.1111/pim.12880; Terrazas C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14935-3; Thakur CP, 2003, T ROY SOC TROP MED H, V97, P409, DOI 10.1016/S0035-9203(03)90071-X; Tiwananthagorn S, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001798; TOKUDA Y, 1993, ANTIMICROB AGENTS CH, V37, P2228, DOI 10.1128/AAC.37.10.2228; Tripathi P, 2007, FEMS IMMUNOL MED MIC, V51, P229, DOI 10.1111/j.1574-695X.2007.00311.x; Tumis ME, 2016, IMMUNITY, V44, P316, DOI 10.1016/j.immuni.2016.01.013; van Griensven J, 2010, LANCET INFECT DIS, V10, P184, DOI 10.1016/S1473-3099(10)70011-6; Viana AG, 2019, PARASITE IMMUNOL, V41, DOI 10.1111/pim.12659; Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366; Vijayamahantesh, 2016, CYTOKINE, V79, P38, DOI 10.1016/j.cyto.2015.12.016; Wadhone P, 2009, J IMMUNOL, V182, P7146, DOI 10.4049/jimmunol.0803859; Wilson ME, 2005, MICROB PATHOGENESIS, V38, P147, DOI 10.1016/j.micpath.2004.11.002; Wilson ME, 2002, EUR J IMMUNOL, V32, P3556, DOI 10.1002/1521-4141(200212)32:12&lt;3556::AID-IMMU3556&gt;3.0.CO;2-Q; Wykes MN, 2018, NAT REV IMMUNOL, V18, P91, DOI 10.1038/nri.2017.112; Yoshida H, 2008, INT J BIOCHEM CELL B, V40, P2379, DOI 10.1016/j.biocel.2008.05.020; Zaph C, 2004, NAT MED, V10, P1104, DOI 10.1038/nm1108; Zubairi S, 2004, EUR J IMMUNOL, V34, P1433, DOI 10.1002/eji.200324021; Zundler S, 2019, NAT IMMUNOL, V20, P288, DOI 10.1038/s41590-018-0298-5	181	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								835711	10.3389/fimmu.2022.835711	http://dx.doi.org/10.3389/fimmu.2022.835711			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H2XX	35585983	gold, Green Published			2022-12-18	WOS:000796410600001
J	Desel, C; Murray, PJ; Lehmann, CHK; Heger, L; Christensen, D; Andersen, P; Mack, M; Dudziak, D; Lang, RL				Desel, Christiane; Murray, Peter J.; Lehmann, Christian H. K.; Heger, Lukas; Christensen, Dennis; Andersen, Peter; Mack, Matthias; Dudziak, Diana; Lang, Roland			Monocytes Elicit a Neutrophil-Independent Th1/Th17 Response Upon Immunization With a Mincle-Dependent Glycolipid Adjuvant	FRONTIERS IN IMMUNOLOGY			English	Article						adjuvant; vaccination; TDB; Th17; monocytes; neutrophils	T-CELL RESPONSES; C-TYPE LECTIN; MYCOBACTERIUM-TUBERCULOSIS; DENDRITIC CELLS; CORD FACTOR; VACCINE; INFECTION; CCR2; ACTIVATION; CYTOKINES	Successful subunit vaccination with recombinant proteins requires adjuvants. The glycolipid trehalose-dibehenate (TDB), a synthetic analog of the mycobacterial cord factor, potently induces Th1 and Th17 immune responses and is a candidate adjuvant for human immunization. TDB binds to the C-type lectin receptor Mincle and triggers Syk-Card9-dependent APC activation. In addition, interleukin (IL)-1 receptor/MyD88-dependent signaling is required for TDB adjuvanticity. The role of different innate immune cell types in adjuvant-stimulated Th1/Th17 responses is not well characterized. We investigated cell recruitment to the site of injection (SOI) and to the draining lymph nodes (dLNs) after immunization with the TDB containing adjuvant CAF01 in a protein-based vaccine. Recruitment of monocytes and neutrophils to the SOI and the dramatic increase in lymph node cellularity was partially dependent on both Mincle and MyD88. Despite their large numbers at the SOI, neutrophils were dispensable for the induction of Th1/Th17 responses. In contrast, CCR2-dependent monocyte recruitment was essential for the induction of Th1/Th17 cells. Transport of adjuvant to the dLN did not require Mincle, MyD88, or CCR2. Together, adjuvanticity conferred by monocytes can be separated at the cellular level from potential tissue damage by neutrophils.	[Desel, Christiane; Lang, Roland] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Clin Microbiol Immunol & Hyg, Erlangen, Germany; [Murray, Peter J.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN USA; [Murray, Peter J.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN USA; [Lehmann, Christian H. K.; Heger, Lukas; Dudziak, Diana] Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Dept Dermatol, Lab Dendrit Cell Biol, Erlangen, Germany; [Christensen, Dennis; Andersen, Peter] Statens Serum Inst, Dept Infect Dis Immunol, Copenhagen, Denmark; [Mack, Matthias] Univ Hosp Regensburg, Dept Nephrol, Regensburg, Germany; [Desel, Christiane] Univ klinikum Magdeburg A o R, Otto von Guericke Univ Magdeburg, Dept Neurol, Magdeburg, Germany	University of Erlangen Nuremberg; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Erlangen Nuremberg; Statens Serum Institut; University of Regensburg; Otto von Guericke University	Desel, C; Lang, RL (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Univ Hosp Erlangen, Inst Clin Microbiol Immunol & Hyg, Erlangen, Germany.	christiane.desel@med.ovgu.de; roland.lang@uk-erlangen.de	Murray, Peter J/K-4725-2018	Murray, Peter J/0000-0001-6329-9802	Deutsche Forschungsgemeinschaft [SFB796, LA1262/8-1, RTG2599, 421758891]; European Union; Bavarian Research Network: New Strategies Against MultiResistant Pathogens by Means of Digital Networkingbayresq.net; University Hospital Erlangen [ELAN-Fonds]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); European Union(European Commission); Bavarian Research Network: New Strategies Against MultiResistant Pathogens by Means of Digital Networkingbayresq.net; University Hospital Erlangen [ELAN-Fonds]	The technical assistance of Katrin Jozefowski and Simone Dorfler is greatly appreciated. We thank Manfred Kirsch and Lisa Hornung for excellent animal care. This work was supported by grants from the Deutsche Forschungsgemeinschaft [SFB796 and LA1262/8-1 to RL, RTG2599 (421758891), P1 to DD], the European Union (FP7 NEWTBVAC to DC and RL), the Bavarian Research Network: New Strategies Against MultiResistant Pathogens by Means of Digital Networkingbayresq.net (to DD), and the University Hospital Erlangen [ELAN-Fonds to CD, IZKF to DD (A80), and CL (A87)].	Abadie V, 2005, BLOOD, V106, P1843, DOI 10.1182/blood-2005-03-1281; Abraham S, 2019, LANCET INFECT DIS, V19, P1091, DOI 10.1016/S1473-3099(19)30279-8; Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Bird JH, 2018, J ORG CHEM, V83, P7593, DOI 10.1021/acs.joc.7b03269; Biswas A, 2015, J IMMUNOL, V194, P3223, DOI 10.4049/jimmunol.1402037; Bonneau M, 2006, J LEUKOCYTE BIOL, V79, P268, DOI 10.1189/jlb.0605288; Bosteels C, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.606805; Bosteels C, 2020, IMMUNITY, V52, P1039, DOI 10.1016/j.immuni.2020.04.005; Bruhl H, 2007, ARTHRITIS RHEUM, V56, P2975, DOI 10.1002/art.22854; Caproni E, 2012, J IMMUNOL, V188, P3088, DOI 10.4049/jimmunol.1101764; Carr KD, 2011, EUR J IMMUNOL, V41, P2666, DOI 10.1002/eji.201041363; Cruz A, 2010, J EXP MED, V207, P1609, DOI 10.1084/jem.20100265; Daley JM, 2008, J LEUKOCYTE BIOL, V83, P64, DOI 10.1189/jlb.0407247; Dangerfield EM, 2022, CARBOHYD RES, V511, DOI 10.1016/j.carres.2021.108461; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; Decout A, 2017, P NATL ACAD SCI USA, V114, P2675, DOI 10.1073/pnas.1612421114; Delany I, 2014, EMBO MOL MED, V6, P708, DOI 10.1002/emmm.201403876; Desel C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053531; Dunlap MD, 2018, MUCOSAL IMMUNOL, V11, P1727, DOI 10.1038/s41385-018-0071-y; Ersland K, 2010, CELL HOST MICROBE, V7, P474, DOI 10.1016/j.chom.2010.05.010; Hohl TM, 2009, CELL HOST MICROBE, V6, P470, DOI 10.1016/j.chom.2009.10.007; Huber A, 2016, INNATE IMMUN-LONDON, V22, P405, DOI 10.1177/1753425916651132; Hupfer T, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00423; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Kamath AT, 2008, EUR J IMMUNOL, V38, P1247, DOI 10.1002/eji.200737889; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Knudsen NPH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19570; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Lindenstrom T, 2014, EUR J IMMUNOL, V44, P1699, DOI 10.1002/eji.201344358; Lindenstrom T, 2012, INFECT IMMUN, V80, P3533, DOI 10.1128/IAI.00550-12; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Mack M, 2001, J IMMUNOL, V166, P4697, DOI 10.4049/jimmunol.166.7.4697; Mosca F, 2008, P NATL ACAD SCI USA, V105, P10501, DOI 10.1073/pnas.0804699105; Olafsdottir TA, 2016, SCI REP-UK, V6, DOI 10.1038/srep39097; Ostrop J, 2015, J IMMUNOL, V195, P2417, DOI 10.4049/jimmunol.1500102; Pedersen GK, 2018, SEMIN IMMUNOL, V39, P4, DOI 10.1016/j.smim.2018.10.003; Petermann M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.670219; Peters W, 2001, P NATL ACAD SCI USA, V98, P7958, DOI 10.1073/pnas.131207398; Rasheed OK, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115564; Ryter KT, 2020, J MED CHEM, V63, P309, DOI 10.1021/acs.jmedchem.9b01598; Samstein M, 2013, ELIFE, V2, DOI 10.7554/eLife.01086; Sato N, 2000, J EXP MED, V192, P205, DOI 10.1084/jem.192.2.205; Schauer C, 2014, NAT MED, V20, P511, DOI 10.1038/nm.3547; Schick J, 2020, J IMMUNOL, V205, P323, DOI 10.4049/jimmunol.2000420; Schoenen H, 2010, J IMMUNOL, V184, P2756, DOI 10.4049/jimmunol.0904013; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Shenderov K, 2013, J IMMUNOL, V190, P5722, DOI 10.4049/jimmunol.1203343; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Steimer DA, 2009, BLOOD, V113, P2805, DOI 10.1182/blood-2008-05-159145; Tima HG, 2017, J INNATE IMMUN, V9, P162, DOI 10.1159/000450955; Traynor TR, 2000, J IMMUNOL, V164, P2021, DOI 10.4049/jimmunol.164.4.2021; van Dissel JT, 2014, VACCINE, V32, P7098, DOI 10.1016/j.vaccine.2014.10.036; Wee JLK, 2011, VET IMMUNOL IMMUNOP, V144, P95, DOI 10.1016/j.vetimm.2011.07.007; Wells CA, 2008, J IMMUNOL, V180, P7404, DOI 10.4049/jimmunol.180.11.7404; Werninghaus K, 2009, J EXP MED, V206, P89, DOI 10.1084/jem.20081445; Windon RG, 2001, VACCINE, V20, P490, DOI 10.1016/S0264-410X(01)00332-2; Zhang X, 2009, IMMUNITY, V31, P761, DOI 10.1016/j.immuni.2009.09.016	59	0	0	4	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								880474	10.3389/fimmu.2022.880474	http://dx.doi.org/10.3389/fimmu.2022.880474			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I0RW	35585969	gold, Green Published			2022-12-18	WOS:000796946100001
J	Guo, ZY; Du, XL; Zhou, Y; Xu, DD; Xu, XY; Lu, S; Ran, F				Guo, Zhiye; Du, Xiaolong; Zhou, Yu; Xu, Dandan; Xu, Xingyu; Lu, Shan; Ran, Feng			Melatonin Alleviates Venous Dysfunction in a Mouse Model of Iliac Vein Occlusion	FRONTIERS IN IMMUNOLOGY			English	Article						iliac vein occlusion; melatonin; venous permeability; venous inflammatory response; venous dysfunction	LEPTIN	The iliac vein can be severely stenosed and occluded due to thrombosis, tumor compression, or an anatomical abnormality. Such occlusion could result in limb swelling, venous claudication, and persistent leg ulcers. Its devastating sequelae heavily impact patients lifestyles and the social economy. Due to a lack of a stable and easy-to-operate iliac vein occlusion (IVO) model, its underlying molecular mechanism and pathophysiological process has not been completely understood. Melatonin (MLT) plays a critical role in anti-inflammation, but the potential protective effect of melatonin on venous dysfunction induced by IVO has not been revealed. In this study, a mouse model of IVO was established to study the effects of MLT on injured veins. The results of laser speckle images and Evans blue showed that MLT inhibited venous permeability in an IVO mouse model. Furthermore, MLT suppressed inflammation of surrounding tissues close to the affected vein by inhibiting the mRNA levels of TNF-alpha, IL-1 alpha, and MCP-1. In addition, endothelial injury was inhibited by MLT using zonula occludens protein-1 (ZO-1) staining. Taken together, we elucidated the therapeutic effect of MLT on vascular dysfunction induced by IVO, mainly by inhibiting the TNF-alpha, IL-1 alpha, and MCP-1 mRNA levels, improving endothelial function, and inhibiting vascular leakage.	[Guo, Zhiye; Zhou, Yu; Xu, Dandan; Xu, Xingyu; Lu, Shan] Nanjing Med Univ, Collaborat Innovat Ctr Cardiovasc Dis Translat Med, Key Lab Cardiovasc & Cerebrovasc Med, Nanjing, Peoples R China; [Du, Xiaolong; Ran, Feng] Nanjing Univ, Nanjing Drum Tower Hosp, Dept Vasc Surg, Affiliated Hosp,Med Sch, Nanjing, Peoples R China	Nanjing Medical University; Nanjing University	Lu, S (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Cardiovasc Dis Translat Med, Key Lab Cardiovasc & Cerebrovasc Med, Nanjing, Peoples R China.; Ran, F (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, Dept Vasc Surg, Affiliated Hosp,Med Sch, Nanjing, Peoples R China.	shnlu@njmu.edu.cn; doctor_ran@163.com						Andreozzi GM, 2012, AM J CARDIOVASC DRUG, V12, P73, DOI 10.2165/11599360-000000000-00000; Chelazzi C, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0741-z; Chen LY, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.754235; Cipolla-Neto J, 2018, ENDOCR REV, V39, P990, DOI 10.1210/er.2018-00084; DALE WA, 1968, ANN SURG, V168, P319, DOI 10.1097/00000658-196809000-00002; de Souza MDC, 2018, EUR J VASC ENDOVASC, V55, P694, DOI 10.1016/j.ejvs.2018.02.009; Fazel R, 2007, NEW ENGL J MED, V357, P53, DOI 10.1056/NEJMcps061337; Goldim Mariana Pereira de Souza, 2019, Curr Protoc Immunol, V126, pe83, DOI 10.1002/cpim.83; Hu ZP, 2020, VASC PHARMACOL, V127, DOI 10.1016/j.vph.2020.106659; Hu ZP, 2013, J PINEAL RES, V55, P388, DOI 10.1111/jpi.12085; Prado NJ, 2018, CURR HYPERTENS REP, V20, DOI 10.1007/s11906-018-0842-6; Ley EJ, 2004, ANN VASC SURG, V18, P228, DOI 10.1007/s10016-003-0096-9; Limbourg A, 2009, NAT PROTOC, V4, P1737, DOI 10.1038/nprot.2009.185; Mahnken AH, 2014, CARDIOVASC INTER RAD, V37, P889, DOI 10.1007/s00270-014-0875-4; Dana PM, 2020, IUBMB LIFE, V72, P2355, DOI 10.1002/iub.2384; Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465; Meng S, 2018, CIRCULATION, V138, P913, DOI [10.1161/CIRCULATIONAHA.118.033939, 10.1161/CIRCULATIONAHA.118.036328]; Narayan A, 2012, RADIOLOGY, V265, P949, DOI 10.1148/radiol.12111580; Radu M, 2013, JOVE-J VIS EXP, DOI 10.3791/50062; Raju S, 2006, J VASC SURG, V44, P136, DOI 10.1016/j.jvs.2006.02.065; Reiter RJ, 2017, CELL MOL LIFE SCI, V74, P3863, DOI 10.1007/s00018-017-2609-7; Shi WY, 2015, THROMB RES, V135, P1172, DOI 10.1016/j.thromres.2015.03.006; Song YM, 2009, ACTA BIOL HUNG, V60, P399, DOI 10.1556/ABiol.60.2009.4.6; Szewczyk-Golec K, 2015, J PINEAL RES, V59, P277, DOI 10.1111/jpi.12257; Takase S, 2004, J VASC SURG, V39, P1329, DOI 10.1016/j.jvs.2004.02.044; Ulloa JH, 2019, ADV THER, V36, P20, DOI 10.1007/s12325-019-0884-4; Witt-Enderby PA, 2012, J PINEAL RES, V53, P374, DOI 10.1111/j.1600-079X.2012.01007.x; Zhang JY, 2020, CARDIOVASC RES, V116, P2156, DOI 10.1093/cvr/cvz312; Zhou H, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12438	29	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								870981	10.3389/fimmu.2022.870981	http://dx.doi.org/10.3389/fimmu.2022.870981			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H5GA	35585973	Green Published, gold			2022-12-18	WOS:000796571200001
J	Kwiecien, I; Rutkowska, E; Sokolowski, R; Bednarek, J; Raniszewska, A; Jahnz-Rozyk, K; Rzepecki, P; Domagala-Kulawik, J				Kwiecien, Iwona; Rutkowska, Elzbieta; Sokolowski, Rafal; Bednarek, Joanna; Raniszewska, Agata; Jahnz-Rozyk, Karina; Rzepecki, Piotr; Domagala-Kulawik, Joanna			Effector Memory T Cells and CD45RO+Regulatory T Cells in Metastatic vs. Non-Metastatic Lymph Nodes in Lung Cancer Patients	FRONTIERS IN IMMUNOLOGY			English	Article						lymph nodes; CD4+cells; CD8+cells; EBUS-TBNA; regulatory T cells; recent thymic emigrants cells; effector memory T cells; Th17-related cells	TUMOR-INFILTRATING LYMPHOCYTES; IMMUNE-RESPONSE; INTERLEUKIN-17; SUBSETS; NAIVE; DIFFERENTIATION; SUBPOPULATIONS; POPULATIONS; MACROPHAGES; MODULATION	Lymphocytes play a leading role in regulation of the immune system in lung cancer patients. The recognition of T cells profile may help in prediction of effectiveness of anticancer immunotherapy. The aim of the study was to determine the dominant subpopulation of CD4+ and CD8+ lymphocytes in metastatic and non-metastatic lymph nodes (LNs) of lung cancer patients. LNs aspirates were obtained during EBUS/TBNA procedure and cells were analyzed by flow cytometry. We showed a higher percentage of CD4+ and CD8+ effector memory T cells in the metastatic than in the non-metastatic LNs (28.6 vs. 15.3% and 28.6 vs. 14.0%, p< 0.05). The proportion of CD45RO+ T regulatory cells (CD45RO+ Tregs) was higher in the metastatic LNs than in the non-metastatic ones (65.6 vs. 31%, p< 0.05). We reported the significant differences in T cell subsets depending on the lung cancer metastatic process. We observed that the effector memory T cells were predominant subpopulations in metastatic LNs. Lymphocyte profile in LNs is easy to evaluate by flow cytometry of EBUS/TBNA samples and may reflect the immune status in lung cancer.	[Kwiecien, Iwona; Rutkowska, Elzbieta; Raniszewska, Agata] Mil Inst Med, Dept Internal Med & Hematol, Lab Flow Cytometry, Warsaw, Poland; [Sokolowski, Rafal; Bednarek, Joanna; Jahnz-Rozyk, Karina] Mil Inst Med, Dept Internal Med Pulmonol Allergol & Clin Immunol, Warsaw, Poland; [Rzepecki, Piotr] Mil Inst Med, Dept Internal Med & Hematol, Warsaw, Poland; [Domagala-Kulawik, Joanna] Med Univ Warsaw, Dept Internal Med Pulm Dis & Allergy, Warsaw, Poland	Military Institute of Aviation Medicine; Military Institute of Aviation Medicine; Military Institute of Aviation Medicine; Medical University of Warsaw	Kwiecien, I (corresponding author), Mil Inst Med, Dept Internal Med & Hematol, Lab Flow Cytometry, Warsaw, Poland.	ikwiecien@wim.mil.pl		Kwiecien, Iwona/0000-0003-2266-971X; Jahnz-Rozyk, Karina/0000-0002-3505-1858	Military Institute of Medicine [559]	Military Institute of Medicine	Funding This study was funded by Military Institute of Medicine, grant number 559.	Aerts JG, 2013, CANCER RES, V73, P2381, DOI 10.1158/0008-5472.CAN-12-3932; Amarillo D, 2021, INT ASS STUDY LUNG C, V16, pS220, DOI [10.1016/j.jtho.2021.01.134, DOI 10.1016/J.JTHO.2021.01.134]; Boldt A, 2014, CYTOM PART B-CLIN CY, V86, P191, DOI 10.1002/cyto.b.21162; Booth NJ, 2010, J IMMUNOL, V184, P4317, DOI 10.4049/jimmunol.0903781; Carmi Y, 2011, J IMMUNOL, V186, P3462, DOI 10.4049/jimmunol.1002901; Chang JT, 2014, NAT IMMUNOL, V15, P1104, DOI 10.1038/ni.3031; Chang SH, 2019, ARCH PHARM RES, V42, P549, DOI 10.1007/s12272-019-01146-9; Chen C, 2014, INT IMMUNOPHARMACOL, V18, P255, DOI 10.1016/j.intimp.2013.12.004; Chen X, 2010, LUNG CANCER, V69, P348, DOI 10.1016/j.lungcan.2009.11.013; Dankers W, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02532-9; Detterbeck FC, 2017, CHEST, V151, P193, DOI 10.1016/j.chest.2016.10.010; Djenidi F, 2015, J IMMUNOL, V194, P3475, DOI 10.4049/jimmunol.1402711; Domagala-Kulawik J, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/5185034; Domagala-Kulawik J, 2014, TRANSL LUNG CANCER R, V3, P15, DOI 10.3978/j.issn.2218-6751.2013.11.03; Domagala-Kulawik Joanna, 2014, Pneumonol Alergol Pol, V82, P286, DOI 10.5603/PiAP.2014.0034; Erfani N, 2012, LUNG CANCER, V77, P306, DOI 10.1016/j.lungcan.2012.04.011; Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588; Fink PJ, 2013, ANNU REV IMMUNOL, V31, P31, DOI 10.1146/annurev-immunol-032712-100010; Franciszkiewicz K, 2009, CANCER RES, V69, P6249, DOI 10.1158/0008-5472.CAN-08-3571; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Guarize J, 2021, J BRAS PNEUMOL, V47, DOI 10.36416/1806-3756/e20200584; Hampton HR, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01168; Herth FJF, 2006, EUR RESPIR J, V28, P1264, DOI 10.1183/09031936.00013806; Hirota K, 2010, SEMIN IMMUNOPATHOL, V32, P3, DOI 10.1007/s00281-009-0187-y; Hu GM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11122-2; Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010; Jones D, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00036; Kataki A, 2002, J LAB CLIN MED, V140, P320, DOI 10.1067/mlc.2002.128317; Kilvaer TK, 2016, BRIT J CANCER, V114, P1145, DOI 10.1038/bjc.2016.92; Kotsakis A, 2016, SCI REP-UK, V6, DOI 10.1038/srep39247; Kunimasa K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020597; Kwiecien I, 2022, CANCER IMMUNOL IMMUN, V71, P2469, DOI 10.1007/s00262-022-03178-5; Kwiecien I, 2021, WORLD J CLIN ONCOL, V12, P966, DOI 10.5306/wjco.v12.i11.966; Kwiecien I, 2020, CANCERS, V12, DOI 10.3390/cancers12092513; Kwiecien I, 2019, CENT EUR J IMMUNOL, V44, P395, DOI 10.5114/ceji.2019.92795; Kwiecien I, 2019, CANCERS, V11, DOI 10.3390/cancers11040567; Kwiecien I, 2017, CANCER IMMUNOL IMMUN, V66, P161, DOI 10.1007/s00262-016-1930-6; Li QC, 2012, IMMUNOL LETT, V148, P144, DOI 10.1016/j.imlet.2012.10.011; Li XY, 2019, NAT REV CLIN ONCOL, V16, P425, DOI 10.1038/s41571-019-0203-7; Li Y., 2018, MEDIATORS INFLAMM, V2018, DOI [10.1155/2018/6587296, DOI 10.1155/2018/6587296]; Li Y, 2011, CANCER BIOL THER, V12, P610, DOI 10.4161/cbt.12.7.16302; Maggi L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00450; Manjarrez-Orduno N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01613; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Martinez-Lostao L, 2015, CLIN CANCER RES, V21, P5047, DOI 10.1158/1078-0432.CCR-15-0685; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Muroyama Y, 2021, CSH PERSPECT BIOL, V13, DOI 10.1101/cshperspect.a037929; Najafi S, 2019, IMMUNOPHARM IMMUNOT, V41, P16, DOI 10.1080/08923973.2019.1566925; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; Ogino S, 2011, NAT REV CLIN ONCOL, V8, P711, DOI 10.1038/nrclinonc.2011.122; Ohue Y, 2019, CANCER SCI, V110, P2080, DOI 10.1111/cas.14069; Okeke EB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00680; Okita R, 2005, ONCOL REP, V14, P1269; Pan B, 2015, SCI REP-UK, V5, DOI 10.1038/srep16053; Paulissen SMJ, 2015, CYTOKINE, V74, P43, DOI 10.1016/j.cyto.2015.02.002; Postmus PE, 2017, ANN ONCOL, V28, P1, DOI 10.1093/annonc/mdx222; Principe N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.584423; Raniszewska A, 2021, CANCER IMMUNOL IMMUN, V70, P453, DOI 10.1007/s00262-020-02648-y; Raniszewska A, 2021, CANCERS, V13, DOI 10.3390/cancers13122996; Raniszewska A, 2020, CANCERS, V12, DOI 10.3390/cancers12040838; Restorick SM, 2017, BRAIN BEHAV IMMUN, V64, P71, DOI 10.1016/j.bbi.2017.03.008; Romero P, 2007, J IMMUNOL, V178, P4112, DOI 10.4049/jimmunol.178.7.4112; Rutkowska E, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10123404; Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Saravia J, 2019, CELL MOL IMMUNOL, V16, P634, DOI 10.1038/s41423-019-0220-6; Shih HY, 2014, IMMUNOL REV, V261, P23, DOI 10.1111/imr.12208; Thompson ED, 2010, J EXP MED, V207, P1791, DOI 10.1084/jem.20092454; Tian Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01728-5; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Wang W, 2012, INT J CANCER, V131, pE928, DOI 10.1002/ijc.27613; Wilke CM, 2011, CARCINOGENESIS, V32, P643, DOI 10.1093/carcin/bgr019; Wu YJ, 2020, FRONT SURG, V7, DOI 10.3389/fsurg.2020.580203; Xu CH, 2014, BIOMARKERS, V19, P287, DOI 10.3109/1354750X.2014.908954; Yang B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/623759; Yu P, 2004, NAT IMMUNOL, V5, P141, DOI 10.1038/ni1029; Zambrano-Zaragoza Jose Francisco, 2014, Int J Inflam, V2014, P651503, DOI 10.1155/2014/651503	78	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								864497	10.3389/fimmu.2022.864497	http://dx.doi.org/10.3389/fimmu.2022.864497			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H3EG	35585972	Green Published, gold			2022-12-18	WOS:000796427200001
J	Liu, LQ; Tang, L; Zhang, L; Li, XF; Huang, P; Xiong, J; Xiao, YY; Liu, LJ				Liu, Liqun; Tang, Li; Zhang, Lu; Li, Xingfang; Huang, Peng; Xiong, Jie; Xiao, Yangyang; Liu, Lingjuan			The First Case Report of Preschool-Onset SS/SLE Coexisting With NMOSD of Chinese Origin	FRONTIERS IN IMMUNOLOGY			English	Article						neuromyelitis optica spectrum disorder; systemic lupus erythematosus; Sjogren's syndrome; AQP-4; child SS; SLE overlap syndrome with NMOSD	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CONNECTIVE-TISSUE DISEASE; OPTICA SPECTRUM DISORDER; NEUROMYELITIS-OPTICA; SJOGRENS-SYNDROME; DEMYELINATING SYNDROME; DEVICS-DISEASE; ASTROCYTOPATHY; ANTIBODIES; CRITERIA	Systemic lupus erythematosus (SLE) is an autoimmune connective tissue disease (CTD), the main features of which are multiple serum autoantibodies and extensive involvement of multiple systems. The onset age of patients varies from childhood to middle age, with nearly 1/5 in childhood. Sjogren's syndrome (SS) is also an autoimmune disease characterized by high-degree lymphocytic infiltration of exocrine glands, usually occurring in middle-aged and older women, and rarely in childhood. Neuromyelitis optica spectrum disorder (NMOSD) is an immune-mediated inflammatory demyelinating disease of the central nervous system (CNS) mainly involving the optic nerve and spinal cord. The coexistence of NMOSD and SLE and/or SS is well recognized by both neurologists and rheumatologists, but cases in children have been rarely reported. In this paper, we reported a case of a girl with onset at age 5 clinically featured by recurrent parotid gland enlargement, pancytopenia, hypocomplementemia, multiple positive serum antibodies, and cirrhosis. She was initially diagnosed with SS/SLE overlap syndrome at age 5. Four years later, the patient suffered a sudden vision loss and was examined to have positive AQP4 antibodies in serum and cerebrospinal fluid (CSF), and long segmental spinal swelling, in line with the diagnostic criteria for NMOSD. Up to now, the current patient is of the youngest onset age to develop SS/SLE coexisting with NMOSD, also with cirrhosis. It is important for clinicians to be aware of the possibility of CTDs coexisting with NMOSD in children, especially in those with positive anti-multiple autoantibodies, and to decrease the rate of missed diagnosis.	[Liu, Liqun; Tang, Li; Zhang, Lu; Li, Xingfang; Huang, Peng; Xiong, Jie; Xiao, Yangyang; Liu, Lingjuan] Second Xiangya Hosp Cent South Univ, Dept Pediat, Changsha, Peoples R China; [Liu, Liqun; Tang, Li; Zhang, Lu; Li, Xingfang; Huang, Peng; Xiong, Jie; Xiao, Yangyang; Liu, Lingjuan] Second Xiangya Hosp Cent South Univ, Childrens Med Ctr, Dept Pediat Neurol, Changsha, Peoples R China	Central South University; Central South University	Liu, LJ (corresponding author), Second Xiangya Hosp Cent South Univ, Dept Pediat, Changsha, Peoples R China.; Liu, LJ (corresponding author), Second Xiangya Hosp Cent South Univ, Childrens Med Ctr, Dept Pediat Neurol, Changsha, Peoples R China.	liulingjuan@csu.edu.cn			China National Natural Scientific Foundation [81873762, 81501039]; Science and Technology Department of Hunan Province Funds [2022SK2032, 2018SK2069]; Health Select Commission of Hunan Province Funds [B20180311]	China National Natural Scientific Foundation(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Hunan Province Funds; Health Select Commission of Hunan Province Funds	Funding This project was supported by China National Natural Scientific Foundation grants (Nos. 81873762 and 81501039), Science and Technology Department of Hunan Province Funds (Nos. 2022SK2032 and 2018SK2069), and Health Select Commission of Hunan Province Funds (No. B20180311).	Adawi M, 2014, CLIN MED INSIGHT-CAS, V7, P41, DOI 10.4137/CCRep.S15177; Akaishi T, 2021, J NEUROL, V268, P1938, DOI 10.1007/s00415-020-10377-6; Barilla-LaBarca ML, 2013, CLIN IMMUNOL, V148, P313, DOI 10.1016/j.clim.2013.02.014; Beh SC, 2017, J NEUROL SCI, V372, P187, DOI 10.1016/j.jns.2016.11.012; Birnbaum J, 2008, NAT CLIN PRACT RHEUM, V4, P381, DOI 10.1038/ncprheum0818; Bushra A., 2017, J RHEUM DIS TREAT, V3, P051, DOI [10.23937/2469-5726/1510051, DOI 10.23937/2469-5726/1510051]; Chessa E, 2017, REUMATISMO, V69, P175, DOI 10.4081/reumatismo.2017.1007; Cho JH, 2011, NEW ENGL J MED, V365, P1612, DOI 10.1056/NEJMra1100030; Collado P, 2018, REUMATOL CLIN, V14, P227, DOI 10.1016/j.reuma.2017.01.015; Cruz RA, 2021, CURR RHEUMATOL REP, V23, DOI 10.1007/s11926-021-01000-2; Gkaniatsou T, 2020, ACTA NEUROL BELG, V120, P223, DOI 10.1007/s13760-019-01176-6; Jarius S, 2011, MULT SCLER J, V17, P1067, DOI 10.1177/1352458511403958; Jarius S, 2010, NAT REV NEUROL, V6, P383, DOI 10.1038/nrneurol.2010.72; Javed A, 2008, MULT SCLER, V14, P809, DOI 10.1177/1352458508088941; Katsumata Y, 2012, MOD RHEUMATOL, V22, P676, DOI 10.1007/s10165-011-0572-y; Kim SM, 2009, MULT SCLER J, V15, P1062, DOI 10.1177/1352458509106636; Kolfenbach JR, 2011, ARTHRIT CARE RES, V63, P1203, DOI 10.1002/acr.20486; Kovacs KT, 2016, MULT SCLER J, V22, P1192, DOI 10.1177/1352458515613165; Lucchinetti CF, 2014, BRAIN PATHOL, V24, P83, DOI 10.1111/bpa.12099; Martin-Nares E, 2019, LUPUS, V28, P1302, DOI 10.1177/0961203319877255; Mehta LR, 2008, MULT SCLER, V14, P425, DOI 10.1177/1352458507084107; Min JH, 2010, MULT SCLER J, V16, P762, DOI 10.1177/1352458510361740; Mottaghi P, 2009, CLIN RHEUMATOL, V28, P1239, DOI 10.1007/s10067-009-1232-x; Palace J, 2019, BRAIN, V142, P1310, DOI 10.1093/brain/awz054; Paolilo RB, 2020, NEUROL-NEUROIMMUNOL, V7, DOI 10.1212/NXI.0000000000000837; Papp V, 2018, NEUROLOGY, V91, pE2265, DOI [10.1212/WNL.0000000000006645, 10.1212/wnl.0000000000006645]; Piga M, 2017, AUTOIMMUN REV, V16, P244, DOI 10.1016/j.autrev.2017.01.011; Pittock SJ, 2019, NEW ENGL J MED, V381, P614, DOI 10.1056/NEJMoa1900866; Pittock SJ, 2008, ARCH NEUROL-CHICAGO, V65, P78, DOI 10.1001/archneurol.2007.17; Pittock SJ, 2016, ANN NY ACAD SCI, V1366, P20, DOI 10.1111/nyas.12794; Qiao L, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001145; Ramos-Casals M., 2021, RHEUMATOL OXFORD, V60, P4558, DOI [10.1093/rheumatology/keab032, DOI 10.1093/RHEUMATOLOGY/KEAB032]; Richard C, 2020, BRAIN, V143, P2721, DOI 10.1093/brain/awaa227; Stefanski AL, 2017, DTSCH ARZTEBL INT, V114, P354, DOI 10.3238/arztebl.2017.0354; Griggs RC, 2016, NEUROLOGY, V86, P491, DOI 10.1212/WNL.0000000000002366; Tarvin SE, 2018, PEDIATR CLIN N AM, V65, P711, DOI 10.1016/j.pcl.2018.04.001; Tenembaum S, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00339; Tishler M, 2001, J RHEUMATOL, V28, P795; Voigt A, 2015, BIOL OPEN, V4, P1410, DOI 10.1242/bio.013771	39	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								887041	10.3389/fimmu.2022.887041	http://dx.doi.org/10.3389/fimmu.2022.887041			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H3GA	35585974	gold, Green Published			2022-12-18	WOS:000796432000001
J	Louis, TJ; Qasem, A; Naser, SA				Louis, Taylor J.; Qasem, Ahmad; Naser, Saleh A.			Attenuation of Excess TNF-alpha Release in Crohn's Disease by Silencing of iRHOMs 1/2 and the Restoration of TGF-beta Mediated Immunosuppression Through Modulation of TACE Trafficking	FRONTIERS IN IMMUNOLOGY			English	Article						TACE (TNF-a converting enzyme); rhomboid proteins; mycobacteria paratuberculosis; Crohn's disease; ectodomain shedding; iRHOM 1/2	BOWEL-DISEASE; TUBERCULOSIS; PARATUBERCULOSIS; MACROPHAGES; CELLS	TNF alpha converting enzyme (TACE) is a transmembrane metalloprotease that sheds an assortment of signaling receptors, cytokines, growth factors, and pro-inflammatory mediators. In Crohn's disease (CD), TACE activity is upregulated, resulting in a marked increase of TNF alpha secretion and inflammation. Although treatment of CD with TNF alpha monoclonal antibodies is beneficial, many patients are at risk for acquiring opportunistic infections, and the treatment efficacy of TNF alpha monoclonal antibodies typically decreases over time. This study investigated an alternative approach for mitigating TNF alpha release by knocking down TACE membrane translocation in macrophages via inhibitory rhomboid proteins 1 and 2 (iRHOMs 1/2) siRNA treatment. First we measured TGF beta RII shedding in ex vivo plasma samples collected from CD patients and healthy control subjects (N=40 per group). Then, we measured TGF beta RII shedding and the expression and production of TGF beta ligand, TNF alpha, IL-6, IL-1 beta, IL-10, and total versus membranous TACE in vitro with THP-1 derived macrophage infected with Mycobacterium avium subspecies paratuberculosis (MAP), a highly studied CD-related pathogen. We determined that TGF beta RII shedding was significantly higher in CD patients compared to healthy controls [515.52 +/- 54.23 pg/mL vs 310.81 +/- 43.16 pg/mL, respectively], and MAP-infected CD plasma samples had significantly more TGF beta RII shedding (601.83 +/- 49.56 pg/mL) than MAP-negative CD samples (430.37 +/- 45.73 pg/mL). Moreover, we also determined that TACE production; TGF beta ligand expression and production; and TGF beta RII shedding were also higher in MAP-infected THP-1 macrophages. Nevertheless, once we transfected the MAP infected macrophages with iRHOM siRNA, TACE production and membrane localization were significantly decreased, resulting in a significant decrease in TGF beta RII shedding; an increase in Smad3 phosphorylation; a decrease in the expression and production of pro-inflammatory cytokines; and a decrease in the expression and production of stricture-associated factor, plasminogen activator inhibitor-1 (PAI-1). Our data clearly demonstrates that the regression of TACE trafficking, via iRHOM 1/2 silencing, significantly reduces the release of TNF alpha and restores the immunosuppressive capabilities of TGF beta signaling, which ultimately reverses inflammatory tissue damage. Accordingly, this study may provide a framework for the creation of newer, safer therapeutic options designed to treat inflammatory autoimmune diseases such as CD and rheumatoid arthritis.	[Louis, Taylor J.; Qasem, Ahmad; Naser, Saleh A.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Div Mol Microbiol, Orlando, FL 32816 USA	State University System of Florida; University of Central Florida	Naser, SA (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Div Mol Microbiol, Orlando, FL 32816 USA.	saleh.naser@ucf.edu			Florida legislative	Florida legislative	This study was supported in part by the Florida legislative grant.	Abdelaal Ahmed M, 2021, NAR Cancer, V3, pzcab030, DOI 10.1093/narcan/zcab030; Ariel O, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02874; Blaydon DC, 2011, NEW ENGL J MED, V365, P1502, DOI 10.1056/NEJMoa1100721; Cao BL, 2018, WORLD J GASTROENTERO, V24, P2764, DOI 10.3748/wjg.v24.i25.2764; Co DO, 2004, CLIN IMMUNOL, V113, P130, DOI 10.1016/j.clim.2004.08.012; Cooper AM, 2009, ANNU REV IMMUNOL, V27, P393, DOI 10.1146/annurev.immunol.021908.132703; Cummings JRF, 2008, BMJ-BRIT MED J, V336, P1062, DOI 10.1136/bmj.39547.603218.AE; Gilbert RWD, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4020021; Gong DP, 2012, BMC IMMUNOL, V13, DOI 10.1186/1471-2172-13-31; Hammer T., 2020, DIGESTIVE MED RES, V3, P1, DOI [10.21037/dmr-20-149, DOI 10.21037/DMR-20-149]; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Ihara S, 2017, J GASTROENTEROL, V52, P777, DOI 10.1007/s00535-017-1350-1; Imai J, 2020, INTEST RES, V18, P219, DOI 10.5217/ir.2019.00037; Jairath V, 2020, LANCET GASTROENTEROL, V5, P2, DOI 10.1016/S2468-1253(19)30358-9; Jiang LL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13045; Jones CV, 2013, ORGANOGENESIS, V9, P249, DOI 10.4161/org.25676; Lee MY, 2016, BIOMOL THER, V24, P109, DOI 10.4062/biomolther.2015.149; Li JY, 2009, DEV CELL, V16, P35, DOI 10.1016/j.devcel.2008.12.002; Lin PL, 2015, SEMIN IMMUNOPATHOL, V37, P239, DOI 10.1007/s00281-015-0490-8; Malapeira J, 2011, ONCOGENE, V30, P1912, DOI 10.1038/onc.2010.565; McNees AL, 2015, EXPERT REV GASTROENT, V9, P1523, DOI 10.1586/17474124.2015.1093931; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; Naser A, 2018, CAN J PHYSIOL PHARM, V96, P662, DOI 10.1139/cjpp-2017-0700; Naser SA, 2004, LANCET, V364, P1039, DOI 10.1016/S0140-6736(04)17058-X; Poggioli Gilberto, 2007, Ther Clin Risk Manag, V3, P301, DOI 10.2147/tcrm.2007.3.2.301; Qasem A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-02050-3; Qasem A, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8110513; Qasem A, 2019, BMJ OPEN GASTROENTER, V6, DOI 10.1136/bmjgast-2018-000246; Qasem A, 2018, BMJ OPEN GASTROENTER, V5, DOI 10.1136/bmjgast-2018-000216; Qasem A, 2017, EXPERT REV ANTI-INFE, V15, P637, DOI 10.1080/14787210.2017.1328276; Qasem A, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0127-z; Qasem A, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0090-8; Rajaram MVS, 2010, J IMMUNOL, V185, P929, DOI 10.4049/jimmunol.1000866; Richmond JM, 2012, INFECT IMMUN, V80, P3858, DOI 10.1128/IAI.00060-12; Souza C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075924; Torres J, 2017, LANCET, V389, P1741, DOI 10.1016/S0140-6736(16)31711-1; Turner J, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty026; Upadhyay S, 2018, PATHOG DIS, V76, DOI 10.1093/femspd/fty037; Wynn TA, 2010, SEMIN LIVER DIS, V30, P245, DOI 10.1055/s-0030-1255354; Xu PL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002689; Zhang MM, 2021, BIOCHEM PHARMACOL, V189, DOI 10.1016/j.bcp.2021.114432; Zhang MF, 1999, PEDIATR RES, V46, P657, DOI 10.1203/00006450-199912000-00017	42	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								887830	10.3389/fimmu.2022.887830	http://dx.doi.org/10.3389/fimmu.2022.887830			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I3ZW	35585977	Green Published, gold			2022-12-18	WOS:000797171100001
J	Meyer, B; Martinez-Murillo, PA; Lemaitre, B; Blanchard-Rohner, G; Didierlaurent, AM; Fontannaz, P; Manzanas, CE; Lambert, PH; Loevy, N; Kaiser, L; Sartoretti, J; Tougne, C; Villard, J; Huttner, A; Siegrist, CA; Eberhardt, CS				Meyer, Benjamin; Martinez-Murillo, Paola Andrea; Lemaitre, Barbara; Blanchard-Rohner, Geraldine; Didierlaurent, Arnaud M.; Fontannaz, Paola; Manzanas, Chloe Eugercios; Lambert, Paul-Henri; Loevy, Natasha; Kaiser, Laurent; Sartoretti, Julie; Tougne, Chantal; Villard, Jean; Huttner, Angela; Siegrist, Claire-Anne; Eberhardt, Christiane S.			Fitness of B-Cell Responses to SARS-CoV-2 WT and Variants Up to One Year After Mild COVID-19-A Comprehensive Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; plasmablasts; memory B cells; antibody response; COVID-19; neutralization; avidity		ObjectiveTo comprehensively evaluate SARS-CoV-2 specific B-cell and antibody responses up to one year after mild COVID-19. MethodsIn 31 mildly symptomatic COVID-19 participants SARS-CoV-2-specific plasmablasts and antigen-specific memory B cells were measured by ELISpot. Binding antibodies directed against the proteins spike (S), domain S1, and nucleocapsid (N) were estimated using rIFA, ELISA, and commercially available assays, and avidity measured using thiocyanate washout. Neutralizing antibodies against variants of concern were measured using a surrogate-neutralization test. ResultsPlasmablast responses were assessed in all participants who gave sequential samples during the first two weeks after infection; they preceded the rise in antibodies and correlated with antibody titers measured at one month. S1 and N protein-specific IgG memory B-cell responses remained stable during the first year, whereas S1-specific IgA memory B-cell responses declined after 6 months. Antibody titers waned over time, whilst potent affinity maturation was observed for anti-RBD antibodies. Neutralizing antibodies against wild-type (WT) and variants decayed during the first 6 months but titers significantly increased for Alpha, Gamma and Delta between 6 months and one year. Therefore, near-similar titers were observed for WT and Alpha after one year, and only slightly lower antibody levels for the Delta variant compared to WT. Anti-RBD antibody responses correlated with the neutralizing antibody titers at all time points, however the predicted titers were 3-fold lower at one year compared to one month. ConclusionIn mild COVID-19, stable levels of SARS-CoV-2 specific memory B cells and antibodies neutralizing current variants of concern are observed up to one year post infection. Care should be taken when predicting neutralizing titers using commercial assays that measure binding antibodies.	[Meyer, Benjamin; Martinez-Murillo, Paola Andrea; Blanchard-Rohner, Geraldine; Didierlaurent, Arnaud M.; Fontannaz, Paola; Manzanas, Chloe Eugercios; Lambert, Paul-Henri; Sartoretti, Julie; Tougne, Chantal; Huttner, Angela; Siegrist, Claire-Anne; Eberhardt, Christiane S.] Univ Geneva, Dept Pathol & Immunol, Ctr Vaccinol & Neonatal Immunol, Geneva, Switzerland; [Lemaitre, Barbara] Geneva Univ Hosp, Div Lab Med, Dept Diagnost & Med Specialties, Geneva, Switzerland; [Lemaitre, Barbara] Univ Geneva, Geneva, Switzerland; [Blanchard-Rohner, Geraldine; Siegrist, Claire-Anne] Geneva Univ Hosp, Div Gen Pediat, Dept Pediat, Pediat Immunol & Vaccinol Unit, Geneva, Switzerland; [Blanchard-Rohner, Geraldine; Siegrist, Claire-Anne] Univ Geneva, Geneva, Switzerland; [Loevy, Natasha] Univ Hosp Geneva, Dept Woman Child & Adolescent Med, Pediat Platform Clin Res, Geneva, Switzerland; [Loevy, Natasha] Univ Geneva, Fac Med, Geneva, Switzerland; [Kaiser, Laurent; Huttner, Angela] Univ Hosp Geneva, Div Infect Dis, Geneva, Switzerland; [Kaiser, Laurent] Univ Hosp Geneva, Div Lab Med, Virol Lab, Geneva, Switzerland; [Kaiser, Laurent] Univ Hosp Geneva, Geneva Ctr Emerging Viral Dis, Geneva, Switzerland; [Sartoretti, Julie; Eberhardt, Christiane S.] Univ Geneva, Div Gen Pediat, Dept Woman Child & Adolescent Med, Geneva, Switzerland; [Villard, Jean] Geneva Univ Hosp & Fac, Div Nephol & Hypertens, Immunol & Transplant Unit, Geneva, Switzerland; [Huttner, Angela] Univ Hosp Geneva, Clin Res Ctr, Geneva, Switzerland; [Huttner, Angela] Univ Geneva, Fac Med, Geneva, Switzerland; [Siegrist, Claire-Anne; Eberhardt, Christiane S.] Univ Hosp Geneva, Ctr Vaccinol, Geneva, Switzerland	University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva; University of Geneva	Meyer, B; Eberhardt, CS (corresponding author), Univ Geneva, Dept Pathol & Immunol, Ctr Vaccinol & Neonatal Immunol, Geneva, Switzerland.; Eberhardt, CS (corresponding author), Univ Geneva, Div Gen Pediat, Dept Woman Child & Adolescent Med, Geneva, Switzerland.; Eberhardt, CS (corresponding author), Univ Hosp Geneva, Ctr Vaccinol, Geneva, Switzerland.	Benjamin.Meyer@unige.ch; Christiane.Eberhardt@unige.ch	Meyer, Benjamin/F-3285-2018	Meyer, Benjamin/0000-0003-0601-3550; Eberhardt, Christiane Sigrid/0000-0001-7495-258X; Kaiser, Laurent/0000-0002-0857-2252; Blanchard-Rohner, Geraldine/0000-0002-9974-2172; Didierlaurent, Arnaud/0000-0002-4736-9003; Martinez Murillo, Paola Andrea/0000-0003-0888-3867	Swiss National Science Foundation [31CA30_196732/1]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This work was supported by the Swiss National Science Foundation (grant number 31CA30_196732/1 to C-AS).	Cho A, 2021, NATURE, V600, P517, DOI 10.1038/s41586-021-04060-7; Cohen KW, 2021, CELL REP MED, V2, DOI [10.1016/j.xcrm.2021.100354, 10.1101/2021.04.19.21255739]; Collier AY, 2021, NEW ENGL J MED, V385, P2010, DOI 10.1056/NEJMc2115596; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Earle KA, 2021, VACCINE, V39, P4423, DOI 10.1016/j.vaccine.2021.05.063; Feng CQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25312-0; Gaebler C, 2021, NATURE, V591, P639, DOI [10.1038/s41586-021-03207-w, 10.1101/2020.11.03.367391]; Gallais F, 2021, EBIOMEDICINE, V71, DOI 10.1016/j.ebiom.2021.103561; Gao Y, 2022, NAT MED, V28, P472, DOI 10.1038/s41591-022-01700-x; Goel RR, 2021, SCIENCE, V374, P1214, DOI 10.1126/science.abm0829; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Haveri A, 2021, EUR J IMMUNOL, V51, P3202, DOI 10.1002/eji.202149535; Hoffmann M, 2021, CELL, V184, P2384, DOI 10.1016/j.cell.2021.03.036; Iyer AS, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe0367; Koblischke M, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.592629; Krammer F, 2021, NEW ENGL J MED, V384, P1372, DOI 10.1056/NEJMc2101667; L'Huillier AG, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.01.005; Madelon N, 2022, JAMA NEUROL, V79, P399, DOI 10.1001/jamaneurol.2022.0245; Mathieu E, 2021, NAT HUM BEHAV, V5, P947, DOI 10.1038/s41562-021-01122-8; Muecksch F, 2021, IMMUNITY, V54, P1853, DOI 10.1016/j.immuni.2021.07.008; Perez-Saez J, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.06.040; Planas D, 2021, NATURE, V596, P276, DOI 10.1038/s41586-021-03777-9; Sandberg JT, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1306; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; Turner JS, 2021, NATURE, V596, P109, DOI 10.1038/s41586-021-03738-2; Turner JS, 2021, NATURE, V595, P421, DOI 10.1038/s41586-021-03647-4; Vetter P, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.02.010; Vetter P, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00827-20; Vono M, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109773; Wec AZ, 2020, P NATL ACAD SCI USA, V117, P6675, DOI 10.1073/pnas.1921388117; Wheatley AK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21444-5; Wibmer CK, 2021, NAT MED, V27, DOI [10.1038/s41591-021-01285-x, 10.1101/2021.01.18.427166]; World Health Organization, 2021, NATURE, DOI DOI 10.1101/2020.06.17.156455; World Health Organization, 2021, GUIDANCE; Zhang J, 2021, SCIENCE, V374, P1353, DOI [10.1101/2021.08.17.456689, 10.1126/science.abl9463]	35	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								841009	10.3389/fimmu.2022.841009	http://dx.doi.org/10.3389/fimmu.2022.841009			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I0LX	35585978	gold, Green Published			2022-12-18	WOS:000796930400001
J	Towlerton, AMH; Ravishankar, S; Coffey, DG; Puronen, CE; Warren, EH				Towlerton, Andrea M. H.; Ravishankar, Shashidhar; Coffey, David G.; Puronen, Camille E.; Warren, Edus H.			Serial Analysis of the T-Cell Receptor beta-Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; T-cell repertoire analysis; Antiretroviral therapy (ART); Immune restoration; TCR sequencing	LIFE EXPECTANCY; DIVERSITY; IMMUNODEFICIENCY; DYNAMICS; ADULTS; BLOOD; DEEP	Long-term antiretroviral therapy (ART) in people living with HIV (PLHIV) is associated with sustained increases in CD4(+) T-cell count, but its effect on the peripheral blood T-cell repertoire has not been comprehensively evaluated. In this study, we performed serial profiling of the composition and diversity of the T-cell receptor beta-chain (TRB) repertoire in 30 adults with HIV infection before and after the initiation of ART to define its long-term impact on the TRB repertoire. Serially acquired blood samples from 30 adults with HIV infection collected over a mean of 6 years (range, 1-12) years, with 1-4 samples collected before and 2-8 samples collected after the initiation of ART, were available for analysis. TRB repertoires were characterized via high-throughput sequencing of the TRB variable region performed on genomic DNA extracted from unsorted peripheral blood mononuclear cells. Additional laboratory and clinical metadata including serial measurements of HIV viral load and CD4(+) T-cell count were available for all individuals in the cohort. A previously published control group of 189 TRB repertoires from peripheral blood samples of adult bone marrow transplant donors was evaluated for comparison. ART initiation in PLHIV was associated with a sustained reduction in viral load and a significant increase in TRB repertoire diversity. However, repertoire diversity in PLHIV remained significantly lower than in the control group even after long-term ART. The composition of TRB repertoires of PLHIV after ART also remained perturbed compared to the control cohort, as evidenced by large persistent private clonal expansions, reduced efficiency in the generation of TRB CDR3 amino acid sequences, and a narrower range of CDR3 lengths. Network analysis revealed an antigen-experienced structure in the TRB repertoire of PLHIV both before and after ART initiation that was quite distinct from the structure of control repertoires, with a slight shift toward a more naive structure observed after ART initiation. Though we observe significant improvement in TRB repertoire diversity with durable viral suppression in PLHIV on long-term ART, the composition and structure of these repertoires remain significantly perturbed compared to the control cohort of adult bone marrow transplant donors.	[Towlerton, Andrea M. H.; Ravishankar, Shashidhar; Coffey, David G.; Puronen, Camille E.; Warren, Edus H.] Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA; [Coffey, David G.; Puronen, Camille E.; Warren, Edus H.] Univ Washington, Div Med Oncol, Seattle, WA 98109 USA; [Coffey, David G.] Univ Miami, Div Hematol, Miami, FL USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Miami	Warren, EH (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA.; Warren, EH (corresponding author), Univ Washington, Div Med Oncol, Seattle, WA 98109 USA.	ehwarren@fredhutch.org		Warren, Edus/0000-0002-9570-2755	National Cancer Institute [U54 CA190146]; University of Washington Center for AIDS Research (CFAR); NIAID; NICHD; NIMH; NIA; NIGMS; NIDDK; Specimen Processing and Research Cell Bank of the Fred Hutch/University of Washington Cancer Consortium; Genomics and Bioinformatics Shared Resources of the Fred Hutch/University of Washington Cancer Consortium [P30 CA015704]; Scientific Computing Infrastructure at Fred Hutch - ORIP grant [S10OD028685]; NIH; NCI [P30 AI027757]; NHLBI; NIDA; FIC; OAR	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Washington Center for AIDS Research (CFAR); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Specimen Processing and Research Cell Bank of the Fred Hutch/University of Washington Cancer Consortium; Genomics and Bioinformatics Shared Resources of the Fred Hutch/University of Washington Cancer Consortium; Scientific Computing Infrastructure at Fred Hutch - ORIP grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); FIC; OAR	This research was supported by an award from the National Cancer Institute (U54 CA190146) and by the University of Washington Center for AIDS Research (CFAR), an NIH funded program (P30 AI027757) which is supported by the following NIH Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA, NIMH, NIA, NIGMS, NIDDK, FIC, and OAR. This research was also supported by the Specimen Processing and Research Cell Bank and the Genomics and Bioinformatics Shared Resources of the Fred Hutch/University of Washington Cancer Consortium (P30 CA015704). Bioinformatic analysis was supported by the Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685.	Amoriello R, 2021, EBIOMEDICINE, V68, DOI 10.1016/j.ebiom.2021.103429; Amoriello R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00559; Anderson EM, 2018, RETROVIROLOGY, V15, DOI 10.1186/s12977-018-0448-8; Attaf M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02539; Bagaev DV, 2020, NUCLEIC ACIDS RES, V48, pD1057, DOI 10.1093/nar/gkz874; Baum PD, 2012, BLOOD, V119, P3469, DOI 10.1182/blood-2011-11-395384; Borst J, 2018, NAT REV IMMUNOL, V18, P635, DOI 10.1038/s41577-018-0044-0; Britanova OV, 2016, J IMMUNOL, V196, P5005, DOI 10.4049/jimmunol.1600005; Britanova OV, 2014, J IMMUNOL, V192, P2689, DOI 10.4049/jimmunol.1302064; Brunson J., 2020, JOSS, V5, P2017, DOI [10.21105/joss.02017, DOI 10.21105/JOSS.02017]; Carter JA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01516; Chiu CG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3229-1; Clifford GM, 2005, JNCI-J NATL CANCER I, V97, P425, DOI 10.1093/jnci/dji072; Conrad JA, 2012, J VIROL, V86, P4213, DOI 10.1128/JVI.06000-11; Costa AI, 2015, J VIROL, V89, P110, DOI 10.1128/JVI.01765-14; Dean J, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0238-z; Di Tommaso P, 2017, NAT BIOTECHNOL, V35, P316, DOI 10.1038/nbt.3820; Dixon P, 2003, J VEG SCI, V14, P927, DOI 10.1111/j.1654-1103.2003.tb02228.x; Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782; Gantner P, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17898-8; Genetics S, 2019, HLA 24S V6 PROTOCOL; Heather JM, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00644; Hou XL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00299; Huang H, 2020, NAT BIOTECHNOL, V38, P1194, DOI 10.1038/s41587-020-0505-4; Jani C, 2021, TROP MED INFECT DIS, V6, DOI 10.3390/tropicalmed6040213; Kassambara Alboukadel, 2020, CRAN; Kostense S, 1998, AIDS, V12, pF235, DOI 10.1097/00002030-199818000-00001; Li CX, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865-019-0311-2; Lindau P, 2019, J IMMUNOL, V202, P476, DOI 10.4049/jimmunol.1800217; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Lurain Kathryn, 2019, Am Soc Clin Oncol Educ Book, V39, P36, DOI 10.1200/EDBK_100017; Madi A, 2017, ELIFE, V6, DOI 10.7554/eLife.22057; Malik A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189612; Marcus JL, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.7954; Miho E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09278-8; Ostrand-Rosenberg S, 2005, CANCER INVEST, V23, P413, DOI 10.1081/CNV-200067428; Pedersen, 2020, TIDYGRAPH TIDY API G; Pedersen Thomas Lin, 2019, PATCHWORK COMPOSER P; Ravishankar S., 2021, LYMPHOSEQ2 R; Robins H, 2013, CURR OPIN IMMUNOL, V25, P646, DOI 10.1016/j.coi.2013.09.017; Shugay M, 2018, NUCLEIC ACIDS RES, V46, pD419, DOI 10.1093/nar/gkx760; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Smiley CL, 2021, LANCET HIV, V8, pe266, DOI 10.1016/S2352-3018(20)30358-1; Springer I, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664514; Team R.C, 2015, R LANG ENV STAT COMP; Thrift A. P., 2018, Current Infectious Disease Reports, V20, P22, DOI 10.1007/s11908-018-0626-9; Tickotsky N, 2017, BIOINFORMATICS, V33, P2924, DOI 10.1093/bioinformatics/btx286; Trickey A, 2017, LANCET HIV, V4, pE349, DOI 10.1016/S2352-3018(17)30066-8; Turner CT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.634489; Wandeler G, 2016, CURR OPIN HIV AIDS, V11, P492, DOI 10.1097/COH.0000000000000298; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Willis A, 2015, BIOMETRICS, V71, P1042, DOI 10.1111/biom.12332; World Health Organization, 2016, CONSOLIDATED GUIDELI, P480; World Health Organization (WHO), 2018, HIVAIDS; Yang XD, 2020, J LEUKOCYTE BIOL, V107, P597, DOI 10.1002/JLB.4MR1019-189R; Yin L, 2009, CLIN VACCINE IMMUNOL, V16, P1293, DOI 10.1128/CVI.00074-09	56	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	MAY 2	2022	13								879190	10.3389/fimmu.2022.879190	http://dx.doi.org/10.3389/fimmu.2022.879190			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1N0TO	35585986	gold, Green Published			2022-12-18	WOS:000800376700001
J	Bajwa, G; Arber, C				Bajwa, Gagan; Arber, Caroline			Rapid Generation of TCR and CD8 alpha beta Transgenic Virus Specific T Cells for Immunotherapy of Leukemia	FRONTIERS IN IMMUNOLOGY			English	Article						immunotherapy; virus-specific T cells; cytokine capture; transgenic TCR; transgenic CD8; engineered T cells; interferon-gamma	VIRAL-INFECTIONS; CYTOMEGALOVIRUS; RECONSTITUTION; MALIGNANCIES; MULTICENTER; RECIPIENTS; IMMUNITY; THERAPY; CD4(+)	BackgroundVirus-specific T cells (VSTs) are an attractive cell therapy platform for the delivery of tumor-targeted transgenic receptors. However, manufacturing with conventional methods may require several weeks and intensive handling. Here we evaluated the feasibility and timelines when combining IFN-gamma cytokine capture (CC) with retroviral transduction for the generation of T cell receptor (TCR) and CD8 alpha beta (TCR8) transgenic VSTs to simultaneously target several viral and tumor antigens in a single product. MethodsHealthy donor peripheral blood mononuclear cells were stimulated with cytomegalovirus (CMV) and Epstein-Barr-Virus (EBV) peptide mixtures derived from immunogenic viral proteins, followed by CC bead selection. After 3 days in culture, cells were transduced with a retroviral vector encoding four genes (a survivin-specific alpha beta TCR and CD8 alpha beta). TCR8-transgenic or control VSTs were expanded and characterized for their phenotype, specificity and anti-viral and anti-tumor functions. ResultsCC selected cells were efficiently transduced with TCR8. Average fold expansion was 269-fold in 10 days, and cells contained a high proportion of CD8+ T central memory cells. TCR8+ VSTs simultaneously expressed native anti-viral and transgenic anti-survivin TCRs on their cell surface. Both control and TCR8+ VSTs produced cytokines to and killed viral targets, while tumor targets were only recognized and killed by TCR8+ VSTs. ConclusionsIFN-gamma cytokine capture selects and activates CMV and EBV-specific memory precursor CD8+ T cells that can be efficiently gene-modified by retroviral transduction and rapidly ex vivo expanded. Our multi-specific T cells are polyfunctional and recognize and kill viral and leukemic targets expressing the cognate antigens.	[Bajwa, Gagan; Arber, Caroline] Houston Methodist Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA; [Bajwa, Gagan; Arber, Caroline] Texas Childrens Hosp, Houston, TX 77030 USA; [Arber, Caroline] Univ Lausanne UNIL, Lausanne Univ Hosp CHUV, Dept Oncol UNIL CHUV, Lausanne, Switzerland; [Arber, Caroline] Ludwig Inst Canc Res, Lausanne Branch, Lausanne, Switzerland	Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Baylor College of Medicine; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Ludwig Institute for Cancer Research	Arber, C (corresponding author), Houston Methodist Hosp, Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.; Arber, C (corresponding author), Texas Childrens Hosp, Houston, TX 77030 USA.; Arber, C (corresponding author), Univ Lausanne UNIL, Lausanne Univ Hosp CHUV, Dept Oncol UNIL CHUV, Lausanne, Switzerland.; Arber, C (corresponding author), Ludwig Inst Canc Res, Lausanne Branch, Lausanne, Switzerland.	caroline.arber@unil.ch						Abou-el-Enein M, 2021, BLOOD CANCER DISCOV, V2, P408, DOI 10.1158/2643-3230.BCD-21-0084; Arber C, 2015, J CLIN INVEST, V125, P157, DOI 10.1172/JCI75876; Bajwa G, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001487; Bollard CM, 2016, BLOOD, V127, P3331, DOI 10.1182/blood-2016-01-628982; Campillo-Davo D, 2021, CANCERS, V13, DOI 10.3390/cancers13184519; Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9; Cruz CRY, 2013, BLOOD, V122, P2965, DOI 10.1182/blood-2013-06-506741; Feuchtinger T, 2010, BLOOD, V116, P4360, DOI 10.1182/blood-2010-01-262089; Haque T, 2007, BLOOD, V110, P1123, DOI 10.1182/blood-2006-12-063008; Irving M, 2021, HUM GENE THER, V32, P1044, DOI 10.1089/hum.2021.173; Joedicke JJ, 2022, MOL THER-METH CLIN D, V24, P181, DOI 10.1016/j.omtm.2021.12.005; Kim N, 2018, TRANSFUS MED HEMOTH, V45, P13, DOI 10.1159/000479238; Lapteva N, 2019, CLIN CANCER RES, V25, P7340, DOI 10.1158/1078-0432.CCR-18-3199; Leen AM, 2013, BLOOD, V121, P5113, DOI 10.1182/blood-2013-02-486324; Mo FY, 2021, NAT BIOTECHNOL, V39, P56, DOI 10.1038/s41587-020-0601-5; Ngo MC, 2014, J IMMUNOTHER, V37, P193, DOI 10.1097/CJI.0000000000000014; Novy P, 2007, J IMMUNOL, V179, P8243, DOI 10.4049/jimmunol.179.12.8243; O'Reilly RJ, 2019, BONE MARROW TRANSPL, V54, P759, DOI 10.1038/s41409-019-0614-1; Perez C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583716; Pourgheysari B, 2009, BONE MARROW TRANSPL, V43, P853, DOI 10.1038/bmt.2008.403; Priesner C, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00393; Prockop S, 2020, J CLIN INVEST, V130, P733, DOI 10.1172/JCI121127; Quach DH, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1988-y; Rath JA, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz7809; Rauser G, 2004, BLOOD, V103, P3565, DOI 10.1182/blood-2003-09-3056; Rossig C, 2017, LEUKEMIA, V31, P1087, DOI 10.1038/leu.2017.39; Swain SL, 2012, NAT REV IMMUNOL, V12, P136, DOI 10.1038/nri3152; Tzannou I, 2019, BLOOD ADV, V3, P2571, DOI 10.1182/bloodadvances.2019000371; van Balen P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01804; WALTER EA, 1995, NEW ENGL J MED, V333, P1038, DOI 10.1056/NEJM199510193331603; Withers B, 2018, BIOL BLOOD MARROW TR, V24, P2433, DOI 10.1016/j.bbmt.2018.08.024; Withers B, 2017, BLOOD ADV, V1, P2193, DOI 10.1182/bloodadvances.2017010223	32	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								830021	10.3389/fimmu.2022.830021	http://dx.doi.org/10.3389/fimmu.2022.830021			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G2BU	35572604	gold, Green Published			2022-12-18	WOS:000795659100001
J	Borys, SM; Bag, AK; Brossay, L; Adeegbe, DO				Borys, Samantha M.; Bag, Arup K.; Brossay, Laurent; Adeegbe, Dennis O.			The Yin and Yang of Targeting KLRG1(+) Tregs and Effector Cells	FRONTIERS IN IMMUNOLOGY			English	Review						regulatory T cells (T reg); cancer; KLRG1; immune modulation; Treg targeting	REGULATORY T-CELLS; FUNCTION-ASSOCIATED ANTIGEN; E-CADHERIN; RECEPTOR KLRG1; CUTTING EDGE; EPITHELIAL-CELLS; IL-2 RECEPTOR; EXPRESSION; NK; DIFFERENTIATION	The literature surrounding KLRG1 has primarily focused on NK and CD8(+) T cells. However, there is evidence that the most suppressive Tregs express KLRG1. Until now, the role of KLRG1 on Tregs has been mostly overlooked and remains to be elucidated. Here we review the current literature on KLRG1 with an emphasis on the KLRG1(+) Treg subset role during cancer development and autoimmunity. KLRG1 has been recently proposed as a new checkpoint inhibitor target, but these studies focused on the effects of KLRG1 blockade on effector cells. We propose that when designing anti-tumor therapies targeting KLRG1, the effects on both effector cells and Tregs will have to be considered.	[Borys, Samantha M.; Brossay, Laurent] Brown Univ Alpert Med Sch, Dept Mol Microbiol & Immunol, Div Biol & Med, Providence, RI USA; [Bag, Arup K.; Adeegbe, Dennis O.] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL USA	Brown University; H Lee Moffitt Cancer Center & Research Institute	Brossay, L (corresponding author), Brown Univ Alpert Med Sch, Dept Mol Microbiol & Immunol, Div Biol & Med, Providence, RI USA.; Adeegbe, DO (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL USA.	Laurent_Brossay@brown.edu; Dennis.Adeegbe@moffitt.org						Abramson J, 2002, MOL IMMUNOL, V38, P1307, DOI 10.1016/S0161-5890(02)00080-9; Adeegbe DO, 2018, CANCER IMMUNOL RES, V6, P1234, DOI 10.1158/2326-6066.CIR-18-0077; Agle K, 2018, BLOOD, V132, P435, DOI 10.1182/blood-2017-09-807156; Akamatsu M, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw2707; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Beyersdorf N, 2007, EUR J IMMUNOL, V37, P3445, DOI 10.1002/eji.200737126; Bin Dhuban K, 2014, IMMUNOL REV, V259, P140, DOI 10.1111/imr.12168; Blanquart E, 2022, J ALLERGY CLIN IMMUN, V149, P237, DOI 10.1016/j.jaci.2021.04.029; Blaser C, 1998, J IMMUNOL, V161, P6451; Bogenrieder T, 2003, ONCOGENE, V22, P6524, DOI 10.1038/sj.onc.1206757; Bull NC, 2019, MUCOSAL IMMUNOL, V12, P555, DOI 10.1038/s41385-018-0109-1; Burzyn D, 2013, CELL, V155, P1282, DOI 10.1016/j.cell.2013.10.054; Butcher S, 1998, EUR J IMMUNOL, V28, P3755, DOI 10.1002/(SICI)1521-4141(199811)28:11<3755::AID-IMMU3755>3.0.CO;2-3; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Cheng GY, 2012, J IMMUNOL, V189, P1780, DOI 10.4049/jimmunol.1103768; Chinen T, 2016, NAT IMMUNOL, V17, P1322, DOI 10.1038/ni.3540; Chockley PJ, 2018, J CLIN INVEST, V128, P1384, DOI 10.1172/JCI97611; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; Cyktor JC, 2013, INFECT IMMUN, V81, P1090, DOI 10.1128/IAI.01199-12; Delacher M, 2021, IMMUNITY, V54, P702, DOI 10.1016/j.immuni.2021.03.007; Delacher M, 2020, IMMUNITY, V52, P295, DOI 10.1016/j.immuni.2019.12.002; Delacher M, 2017, NAT IMMUNOL, V18, P1160, DOI 10.1038/ni.3799; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; Dias S, 2017, IMMUNITY, V46, P78, DOI 10.1016/j.immuni.2016.12.017; Feuerer M, 2010, P NATL ACAD SCI USA, V107, P5919, DOI 10.1073/pnas.1002006107; Gabriely G, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aaj1738; Greenberg Steven A, 2019, Oncotarget, V10, P1399, DOI 10.18632/oncotarget.26659; Grundemann C, 2010, EUR J IMMUNOL, V40, P1303, DOI 10.1002/eji.200939771; Grundemann C, 2006, J IMMUNOL, V176, P1311, DOI 10.4049/jimmunol.176.3.1311; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; GUTHMANN MD, 1995, INT ARCH ALLERGY IMM, V107, P82, DOI 10.1159/000236938; Ha D, 2019, P NATL ACAD SCI USA, V116, P609, DOI 10.1073/pnas.1812186116; Hale JS, 2009, IMMUNOL CELL BIOL, V87, P58, DOI 10.1038/icb.2008.87; Han XJ, 2019, P NATL ACAD SCI USA, V116, P4471, DOI 10.1073/pnas.1800494116; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanke T, 1998, EUR J IMMUNOL, V28, P4409, DOI 10.1002/(SICI)1521-4141(199812)28:12<4409::AID-IMMU4409>3.0.CO;2-3; Henao-Tamayo M, 2011, TUBERCULOSIS, V91, P308, DOI 10.1016/j.tube.2011.04.001; Henson SM, 2009, AGE, V31, P285, DOI 10.1007/s11357-009-9100-9; Henson SM, 2009, BLOOD, V113, P6619, DOI 10.1182/blood-2009-01-199588; Herndler-Brandstetter D, 2018, IMMUNITY, V48, P716, DOI 10.1016/j.immuni.2018.03.015; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Holderried TAW, 2013, P NATL ACAD SCI USA, V110, P21089, DOI 10.1073/pnas.1320999110; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hu ZD, 2018, J INFECT DIS, V217, P1491, DOI 10.1093/infdis/jiy046; Huang YF, 2015, NAT IMMUNOL, V16, P161, DOI 10.1038/ni.3078; Huntington ND, 2007, J IMMUNOL, V178, P4764, DOI 10.4049/jimmunol.178.8.4764; Ito M, 2006, J EXP MED, V203, P289, DOI 10.1084/jem.20051986; Joshi NS, 2015, IMMUNITY, V43, P579, DOI 10.1016/j.immuni.2015.08.006; Kabata H, 2018, IMMUNOL REV, V286, P37, DOI 10.1111/imr.12706; KARECLA PI, 1995, EUR J IMMUNOL, V25, P852, DOI 10.1002/eji.1830250333; Kim HJ, 2015, SCIENCE, V350, P334, DOI 10.1126/science.aad0616; Kim HJ, 2011, P NATL ACAD SCI USA, V108, P2010, DOI 10.1073/pnas.1018974108; Kim HJ, 2010, NATURE, V467, P328, DOI 10.1038/nature09370; Kornete M, 2017, AUTOIMMUNITY, V50, P354, DOI 10.1080/08916934.2017.1364368; Kunisada Y, 2017, EBIOMEDICINE, V25, P154, DOI 10.1016/j.ebiom.2017.10.009; Li A, 2019, CELL REP, V29, P2998, DOI 10.1016/j.celrep.2019.10.120; Li G, 2001, CANCER RES, V61, P3819; Li L, 2016, ONCOTARGET, V7, P61670, DOI 10.18632/oncotarget.11430; Li YL, 2009, IMMUNITY, V31, P35, DOI 10.1016/j.immuni.2009.04.019; Lindenstrom T, 2013, J IMMUNOL, V190, P6311, DOI 10.4049/jimmunol.1300248; Liu B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08300-3; Marcolino I, 2004, EUR J IMMUNOL, V34, P2672, DOI 10.1002/eji.200425282; Marques A N, 1968, Hospital (Rio J), V74, P549; Matta BM, 2014, J IMMUNOL, V193, P4010, DOI 10.4049/jimmunol.1400481; McMahon CW, 2002, J IMMUNOL, V169, P1444, DOI 10.4049/jimmunol.169.3.1444; Meinicke H, 2017, IMMUNOLOGY, V152, P65, DOI 10.1111/imm.12749; Meinicke H, 2017, IMMUNOLOGY, V152, P74, DOI 10.1111/imm.12750; Mijnheer G, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22975-7; Mishra S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.708874; Mishra S, 2021, J EXP MED, V218, DOI 10.1084/jem.20200030; Moguche AO, 2017, CELL HOST MICROBE, V21, P695, DOI 10.1016/j.chom.2017.05.012; Mousavi SF, 2008, J IMMUNOL, V181, P5990, DOI 10.4049/jimmunol.181.9.5990; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Rauch KS, 2017, ONCOTARGET, V8, P102835, DOI 10.18632/oncotarget.22159; Reiley WW, 2010, P NATL ACAD SCI USA, V107, P19408, DOI 10.1073/pnas.1006298107; Rifa'i M, 2004, J EXP MED, V200, P1123, DOI 10.1084/jem.20040395; Robbins SH, 2003, J IMMUNOL, V170, P5876, DOI 10.4049/jimmunol.170.12.5876; Robbins SH, 2002, J IMMUNOL, V168, P2585, DOI 10.4049/jimmunol.168.6.2585; Rosshart S, 2008, EUR J IMMUNOL, V38, P3354, DOI 10.1002/eji.200838690; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Schiering C, 2014, NATURE, V513, P564, DOI 10.1038/nature13577; Schwartzkopff S, 2007, J IMMUNOL, V179, P1022, DOI 10.4049/jimmunol.179.2.1022; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shi L, 2014, J IMMUNOL, V192, P649, DOI 10.4049/jimmunol.1302069; Shields BD, 2019, CANCER RES, V79, P1113, DOI 10.1158/0008-5472.CAN-18-1722; Sidwell T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14112-2; Siede J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161507; Stephens GL, 2007, J IMMUNOL, V178, P6901, DOI 10.4049/jimmunol.178.11.6901; Tata A, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1933808; Tauro S, 2013, EUR J IMMUNOL, V43, P1195, DOI 10.1002/eji.201242881; Tessmer MS, 2007, INT IMMUNOL, V19, P391, DOI 10.1093/intimm/dxm004; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thimme R, 2005, J VIROL, V79, P12112, DOI 10.1128/JVI.79.18.12112-12116.2005; Vicente R, 2016, J IMMUNOL, V196, P298, DOI 10.4049/jimmunol.1501069; Voehringer D, 2001, J IMMUNOL, V167, P4838, DOI 10.4049/jimmunol.167.9.4838; Voehringer D, 2002, BLOOD, V100, P3698, DOI 10.1182/blood-2002-02-0657; Wang JM, 2013, J VIROL, V87, P11626, DOI 10.1128/JVI.01515-13; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Woodworth JS, 2014, J IMMUNOL, V192, P3247, DOI 10.4049/jimmunol.1300283; Worthington JJ, 2015, IMMUNITY, V42, P903, DOI 10.1016/j.immuni.2015.04.012; Xu R, 2001, J IMMUNOL, V167, P6394, DOI 10.4049/jimmunol.167.11.6394; Yang JF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.122014; Yates K, 2018, P NATL ACAD SCI USA, V115, P2162, DOI 10.1073/pnas.1720447115; Yuan XM, 2014, IMMUNOL REV, V259, P103, DOI 10.1111/imr.12163; Zhou Chenhao, 2021, Immunohorizons, V5, P102, DOI 10.4049/immunohorizons.2100006	108	0	0	7	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								894508	10.3389/fimmu.2022.894508	http://dx.doi.org/10.3389/fimmu.2022.894508			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F3YD	35572605	gold, Green Published			2022-12-18	WOS:000795105500001
J	Chen, MC; Lai, KSL; Chien, KL; Teng, ST; Lin, YR; Chao, W; Lee, MJ; Wei, PL; Huang, YH; Kuo, HP; Weng, CM; Chou, CL				Chen, Mei-Chuan; Lai, Kevin Shu-Leung; Chien, Ko-Ling; Teng, Sing Teck; Lin, Yuh-Rong; Chao, Wei; Lee, Meng-Jung; Wei, Po-Li; Huang, Yen-Hua; Kuo, Han-Pin; Weng, Chih-Ming; Chou, Chun-Liang			pcMSC Modulates Immune Dysregulation in Patients With COVID-19-Induced Refractory Acute Lung Injury	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; mesenchymal stem cell; severe lung injury; immune response; Treg cells	MESENCHYMAL STEM-CELLS; REGULATORY T-CELLS; INDOLEAMINE 2,3-DIOXYGENASE; PROGNOSTIC VALUE; CYTOKINE STORM; THERAPY; LYMPHOPENIA; ARDS	Background and ObjectivesThe novel coronavirus disease 2019 (COVID-19) has been a pandemic health issue in 30 January 2020. The mortality rate is as high as 50% in critically ill patients. Stem cell therapy is effective for those who are refractory to standard treatments. However, the immune responses that underlie stem cell therapy have not been well reported, particularly, in patients associated with moderate to severe acute respiratory distress syndrome (ARDS). MethodsOn Days 0 and 4, an intravenous infusion of 2 x 10(7) placenta-derived mesenchymal stem cells (pcMSCs) (MatriPlax) were administered to five severe COVID-19 patients refractory to current standard therapies. Peripheral blood inflammatory markers and immune profiles were determined by multi-parameter flow cytometry and studied at Days 0, 4, and 8. Clinical outcomes were also observed. ResultsNone of the pc-MSC treated patients experienced 28-day mortality compared with the control group and showed a significant improvement in the PaO2/FiO(2) ratio, Murray's lung injury scores, reduction in serum ferritin, lactate dehydrogenase (LDH), and C-reactive protein (CRP) levels. The cytokine profiles also showed a reduction in IL-1 beta, IFN-gamma, IL-2, and IL-6, and an increase in IL-13 and IL-5 type 2 cytokines within 7 days of therapy. Lymphopenia was also significantly improved after 7 days of treatment. Immune cell profiles showed an increase in the proportions of CD4(+) T cells (namely, CD4(+) naive T cells and CD4(+) memory T cell subtypes), Treg cells, CD19(+) B cells (namely, CD19(+) naive B cells, CD27(+) switched B cell subtypes) and dendritic cells, and a significant decrease in the proportion of CD14(+) monocytes (namely, CD16(-) classical and CD16(+) non-classical subtypes), and plasma/plasmablast cells. No adverse effects were seen at the serial follow-up visits for 2 months after initial therapy. Conclusionpc-MSCs therapy suppressed hyper-inflammatory states of the innate immune response to COVID-19 infection by increasing Treg cells, decreasing monocytes and plasma/plasmablast cells, and promoting CD4(+) T cells and CD19(+) B cells toward adaptive immune responses in severely critically ill COVID-19 patients with moderate to severe ARDS, especially those who were refractory to current standard care and immunosuppressive therapies.	[Chen, Mei-Chuan; Lai, Kevin Shu-Leung; Chien, Ko-Ling; Kuo, Han-Pin; Chou, Chun-Liang] Taipei Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taipei, Taiwan; [Chen, Mei-Chuan; Lai, Kevin Shu-Leung; Chien, Ko-Ling; Lin, Yuh-Rong; Chao, Wei; Lee, Meng-Jung; Kuo, Han-Pin; Weng, Chih-Ming; Chou, Chun-Liang] Taipei Med Univ, Pulm Med Res Ctr, Taipei, Taiwan; [Lai, Kevin Shu-Leung; Teng, Sing Teck] Taipei Med Univ Hosp, Dept Crit Care Med, Taipei, Taiwan; [Wei, Po-Li] Taipei Med Univ Hosp, Dept Surg, Div Colorectal Surg, Taipei, Taiwan; [Wei, Po-Li] Taipei Med Univ, Coll Med, Dept Surg, Taipei, Taiwan; [Wei, Po-Li] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan; [Huang, Yen-Hua] Taipei Med Univ, Coll Med, Sch Med, Dept Biochem & Mol Cell Biol, Taipei, Taiwan; [Weng, Chih-Ming] Taipei Med Univ, Coll Med, Sch Resp therapy, Taipei, Taiwan	Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University Hospital; Taipei Medical University; Taipei Medical University; Taipei Medical University; Taipei Medical University	Chou, CL (corresponding author), Taipei Med Univ Hosp, Dept Internal Med, Div Pulm Med, Taipei, Taiwan.; Weng, CM; Chou, CL (corresponding author), Taipei Med Univ, Pulm Med Res Ctr, Taipei, Taiwan.; Weng, CM (corresponding author), Taipei Med Univ, Coll Med, Sch Resp therapy, Taipei, Taiwan.	m109090013@tmu.edu.tw; drchou1024@gmail.com						Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Arabpour E, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.737590; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; de Witte SFH, 2018, STEM CELLS, V36, P602, DOI 10.1002/stem.2779; Deng ZF, 2020, INT J INFECT DIS, V98, P353, DOI 10.1016/j.ijid.2020.07.003; Engela AU, 2013, CLIN EXP IMMUNOL, V173, P343, DOI 10.1111/cei.12120; Ge W, 2010, TRANSPLANTATION, V90, P1312, DOI 10.1097/TP.0b013e3181fed001; Guo YR, 2020, MILITARY MED RES, V7, DOI 10.1186/s40779-020-00240-0; Harrell CR, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/4236973; Henry BM, 2020, AM J EMERG MED, V38, P1722, DOI 10.1016/j.ajem.2020.05.073; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Horby PW, 2021, LANCET, V397, P1637, DOI 10.1016/S0140-6736(21)00676-0; Hu B, 2021, NAT REV MICROBIOL, V19, P141, DOI 10.1038/s41579-020-00459-7; Huang G, 2020, EMERG INFECT DIS, V26, P1839, DOI 10.3201/eid2608.201160; Jagadeesh A, 2020, DYNAMICS OF IMMUNE ACTIVATION IN VIRAL DISEASES, P139, DOI 10.1007/978-981-15-1045-8_9; Kalil AC, 2021, NEW ENGL J MED, V384, P795, DOI 10.1056/NEJMoa2031994; Khosravi M, 2017, GENE, V627, P327, DOI 10.1016/j.gene.2017.06.012; Leng ZK, 2020, AGING DIS, V11, P216, DOI 10.14336/AD.2020.0228; Li YY, 2017, MOL MED REP, V16, P8137, DOI 10.3892/mmr.2017.7605; Li YY, 2018, MOL MED REP, V17, P5336, DOI 10.3892/mmr.2018.8462; Lu CY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00517-3; Luz-Crawford P, 2016, STEM CELLS, V34, P483, DOI 10.1002/stem.2254; Mahendiratta S, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111300; Mahmoudi S, 2020, J CLIN IMMUNOL, V40, P974, DOI 10.1007/s10875-020-00824-4; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; McKechnie JL, 2020, CELL HOST MICROBE, V27, P863, DOI 10.1016/j.chom.2020.05.009; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Rodda LB, 2021, CELL, V184, P169, DOI [10.1016/j.cell.2020.11.029, 10.21203/rs.3.rs-57112/v1, 10.1101/2020.08.11.20171843]; Ruddell RG, 2009, HEPATOLOGY, V49, P887, DOI 10.1002/hep.22716; Singh S, 2020, BASIC RES CARDIOL, V115, DOI 10.1007/s00395-020-0795-1; Spaggiari GM, 2008, BLOOD, V111, P1327, DOI 10.1182/blood-2007-02-074997; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Thompson M, 2020, ECLINICALMEDICINE, V19, DOI 10.1016/j.eclinm.2019.100249; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wang F, 2020, J INFECT DIS, V221, P1762, DOI 10.1093/infdis/jiaa150; Wu YK, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/4960831; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00679-0; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zanirati G, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536-021-00181-9; Zhao QW, 2020, INT J INFECT DIS, V96, P131, DOI 10.1016/j.ijid.2020.04.086; Zhou YG, 2020, NATL SCI REV, V7, P998, DOI 10.1093/nsr/nwaa041; Zhuang WZ, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-021-00725-7	50	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								871828	10.3389/fimmu.2022.871828	http://dx.doi.org/10.3389/fimmu.2022.871828			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H9EC	35585988	gold, Green Published			2022-12-18	WOS:000796841200001
J	Chen, N; Peng, C; Li, D				Chen, Nian; Peng, Cheng; Li, Dan			Epigenetic Underpinnings of Inflammation: A Key to Unlock the Tumor Microenvironment in Glioblastoma	FRONTIERS IN IMMUNOLOGY			English	Review						glioblastoma; inflammation; microenvironment; epigenetic regulation; GBM tumor cells; glioma-associated microglia; macrophages	EPITHELIAL-MESENCHYMAL TRANSITION; NONCODING RNAS; MACROPHAGE POLARIZATION; EMERGING ROLES; EXPRESSION; CELLS; MECHANISMS; AXIS; ACTIVATION; MICROGLIA	Glioblastoma (GBM) is the most common malignant brain tumor in adults, and immunotherapies and genetic therapies for GBM have evolved dramatically over the past decade, but GBM therapy is still facing a dilemma due to the high recurrence rate. The inflammatory microenvironment is a general signature of tumors that accelerates epigenetic changes in GBM and helps tumors avoid immunological surveillance. GBM tumor cells and glioma-associated microglia/macrophages are the primary contributors to the inflammatory condition, meanwhile the modification of epigenetic events including DNA methylation, non-coding RNAs, and histone methylation and deacetylases involved in this pathological process of GBM, finally result in exacerbating the proliferation, invasion, and migration of GBM. On the other hand, histone deacetylase inhibitors, DNA methyltransferases inhibitors, and RNA interference could reverse the inflammatory landscapes and inhibit GBM growth and invasion. Here, we systematically review the inflammatory-associated epigenetic changes and regulations in the microenvironment of GBM, aiming to provide a comprehensive epigenetic profile underlying the recognition of inflammation in GBM.	[Chen, Nian; Peng, Cheng; Li, Dan] Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Southwestern Characterist Chinese Me, Chengdu, Peoples R China	Chengdu University of Traditional Chinese Medicine	Peng, C; Li, D (corresponding author), Chengdu Univ Tradit Chinese Med, Sch Pharm, State Key Lab Southwestern Characterist Chinese Me, Chengdu, Peoples R China.	pengcheng_cd@126.com; lidan@cdutcm.edu.cn			National Natural Science Foundation of China [82104477, U19A2010]; multidisciplinary interdisciplinary innovation team for multidimensional evaluation of southwestern characteristic Chinese medicine resources [ZYYCXTD-D-202209]; China Postdoctoral Science Foundation [2019M663456, 2019TQ0044]; Xinglin Scholar Research Promotion Project of Chengdu University of TCM [BSH2019008]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); multidisciplinary interdisciplinary innovation team for multidimensional evaluation of southwestern characteristic Chinese medicine resources; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Xinglin Scholar Research Promotion Project of Chengdu University of TCM	Funding Financial support by the National Natural Science Foundation of China (82104477 and U19A2010) and multidisciplinary interdisciplinary innovation team for multidimensional evaluation of southwestern characteristic Chinese medicine resources (NO. ZYYCXTD-D-202209), and special support from the China Postdoctoral Science Foundation (2019M663456 and 2019TQ0044), Xinglin Scholar Research Promotion Project of Chengdu University of TCM (BSH2019008) are gratefully acknowledged.	Abels ER, 2019, CELL REP, V28, P3105, DOI 10.1016/j.celrep.2019.08.036; Akcora-Yildiz D, 2022, MED ONCOL, V39, DOI 10.1007/s12032-021-01590-y; Aldape K, 2015, ACTA NEUROPATHOL, V129, P829, DOI 10.1007/s00401-015-1432-1; Angel I, 2020, ONCOGENE, V39, P6990, DOI 10.1038/s41388-020-01506-6; Arvanitis CD, 2020, NAT REV CANCER, V20, P26, DOI 10.1038/s41568-019-0205-x; Baker KJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01197; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bayarsaihan D, 2011, J DENT RES, V90, P9, DOI 10.1177/0022034510378683; Bennett RL, 2018, ANNU REV PHARMACOL, V58, P187, DOI 10.1146/annurev-pharmtox-010716-105106; Bowman RL, 2016, CELL REP, V17, P2445, DOI 10.1016/j.celrep.2016.10.052; Broekman ML, 2018, NAT REV NEUROL, V14, P482, DOI 10.1038/s41582-018-0025-8; Burgess R, 2008, CANCER BIOL THER, V7, P1326, DOI 10.4161/cbt.7.9.6992; Butler M, 2020, TRENDS CANCER, V6, P380, DOI 10.1016/j.trecan.2020.02.010; Cenciarini M, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00065; Chen ZH, 2017, CANCER RES, V77, P2266, DOI 10.1158/0008-5472.CAN-16-2310; Chen Z, 2020, J CONTROL RELEASE, V320, P469, DOI 10.1016/j.jconrel.2020.01.044; Chicoine MR, 2007, NEUROSURGERY, V60, P372, DOI 10.1227/01.NEU.0000249280.61761.2E; Chiou GY, 2013, MOL CELL, V52, P693, DOI 10.1016/j.molcel.2013.11.009; Chuang HY, 2019, J CLIN MED, V8, DOI 10.3390/jcm8070959; Cohen AL, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-35; Couto M, 2019, J CELL PHYSIOL, V234, P19750, DOI 10.1002/jcp.28575; Cui B, 2014, BLOOD, V124, P546, DOI 10.1182/blood-2014-03-559690; Cui X, 2018, BIOMATERIALS, V161, P164, DOI 10.1016/j.biomaterials.2018.01.053; Czimmerer Z, 2018, IMMUNITY, V48, P75, DOI 10.1016/j.immuni.2017.12.010; Darmanis S, 2017, CELL REP, V21, P1399, DOI 10.1016/j.celrep.2017.10.030; Dasgupta Y, 2018, LEUKEMIA LYMPHOMA, V59, P1746, DOI 10.1080/10428194.2017.1397662; Daskalaki MG, 2018, J CELL PHYSIOL, V233, P6495, DOI 10.1002/jcp.26497; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; De Boeck A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18569-4; DeCordova S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01402; Deng JY, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.759691; DeOcesano-Pereira C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072611; Desland FA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197358; Ding QP, 2018, PATHOL RES PRACT, V214, P1330, DOI 10.1016/j.prp.2018.05.012; Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741; Dong F, 2021, CANCER RES, V81, P5876, DOI 10.1158/0008-5472.CAN-21-1456; Dong Z, 2019, SEMIN CANCER BIOL, V57, P45, DOI 10.1016/j.semcancer.2018.09.002; Dou ZX, 2017, NATURE, V550, P402, DOI 10.1038/nature24050; Dumas AA, 2020, EMBO J, V39, DOI 10.15252/embj.2019103790; Duque MB, 2019, J MOL NEUROSCI, V68, P49, DOI 10.1007/s12031-019-01280-5; Erin N, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100715; Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074; Fang KM, 2014, NEURO-ONCOLOGY, V16, P552, DOI 10.1093/neuonc/not234; Foray C, 2021, THERANOSTICS, V11, P2020, DOI 10.7150/thno.47269; Gangoso E, 2021, CELL, V184, P2454, DOI 10.1016/j.cell.2021.03.023; Ghiboub M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.550769; Gramatzki D, 2016, ONCOL LETT, V12, P445, DOI 10.3892/ol.2016.4626; Gromeier M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20469-6; Gupta P, 2013, CELL SIGNAL, V25, P682, DOI 10.1016/j.cellsig.2012.12.001; Gurgis FMS, 2015, ONCOGENE, V34, P2934, DOI 10.1038/onc.2014.225; Ham SW, 2019, CELL DEATH DIFFER, V26, P409, DOI 10.1038/s41418-018-0126-3; Hasan T, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1387-6; He LZ, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109955; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457; Hong S, 2021, THERANOSTICS, V11, P9687, DOI 10.7150/thno.60851; Huang YH, 2011, CELL MOL LIFE SCI, V68, P407, DOI 10.1007/s00018-010-0582-5; Hubner M., 2020, NEUROONCOL ADV, V2, DOI [10.1093/noajnl/vdaa047, DOI 10.1093/NOAJNL/VDAA047]; Hubner M, 2020, CANCERS, V12, DOI 10.3390/cancers12020433; Hurmath KF, 2014, CELL BIOL INT, V38, P1415, DOI 10.1002/cbin.10353; Ivashkiv LB, 2020, NAT REV IMMUNOL, V20, P85, DOI 10.1038/s41577-019-0259-8; Jiang Y, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0210-1; Johnson KC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13177; Kaminska B, 2016, BBA-MOL BASIS DIS, V1862, P339, DOI 10.1016/j.bbadis.2015.10.026; Katrib A, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00488; Kes MMG, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188427; Kesarwani P, 2017, NEURO-ONCOLOGY, V19, P1308, DOI 10.1093/neuonc/nox079; Lamano JB, 2019, CLIN CANCER RES, V25, P3643, DOI 10.1158/1078-0432.CCR-18-2402; Larionova I, 2020, CANCERS, V12, DOI 10.3390/cancers12061411; Lawrence M, 2016, TRENDS GENET, V32, P42, DOI 10.1016/j.tig.2015.10.007; Le Rhun E, 2019, CANCER TREAT REV, V80, DOI 10.1016/j.ctrv.2019.101896; Lee SY, 2017, MOL CELLS, V40, P515, DOI 10.14348/molcells.2017.0089; Li ZZ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1371-0; Litak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215347; Liu ZQ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.772211; Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1; Lu J, 2020, CANCER SCI, V111, P1979, DOI 10.1111/cas.14408; Maleszewska M, 2021, GLIA, V69, P109, DOI 10.1002/glia.23887; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Matias D, 2019, MOL NEUROBIOL, V56, P1517, DOI 10.1007/s12035-018-1150-5; Matsui M, 2017, NAT REV DRUG DISCOV, V16, P167, DOI 10.1038/nrd.2016.117; Morisse MC, 2018, EXPERT REV NEUROTHER, V18, P729, DOI 10.1080/14737175.2018.1510321; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Najafi M, 2019, J CELL PHYSIOL, V234, P5700, DOI 10.1002/jcp.27425; Piperi C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111398; Piperi C, 2010, MOL MED, V16, P1, DOI 10.2119/molmed.2009.00140; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian JW, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1330-2; Rao R, 2022, NEURO-ONCOLOGY, V24, P584, DOI 10.1093/neuonc/noab228; Sampson JH, 2020, NAT REV CANCER, V20, P12, DOI 10.1038/s41568-019-0224-7; Sena IFG, 2018, CANCER MED-US, V7, P1232, DOI 10.1002/cam4.1375; Sharma V, 2011, J MOL MED, V89, P123, DOI 10.1007/s00109-010-0683-5; Sheikh T, 2021, CYTOKINE, V140, DOI 10.1016/j.cyto.2020.155418; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Stazi G, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0763-5; Swartz MA, 2012, CANCER RES, V72, P2473, DOI 10.1158/0008-5472.CAN-12-0122; Tan AC, 2020, CA-CANCER J CLIN, V70, P299, DOI 10.3322/caac.21613; Tarassishin L, 2013, J NEURO-ONCOL, V113, P185, DOI 10.1007/s11060-013-1109-3; Tezcan G, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.607881; Tomaszewski W, 2019, CLIN CANCER RES, V25, P4202, DOI 10.1158/1078-0432.CCR-18-1627; Tong LQ, 2020, THERANOSTICS, V10, P5943, DOI 10.7150/thno.41498; Touat M, 2017, ANN ONCOL, V28, P1457, DOI 10.1093/annonc/mdx106; Nguyen TTT, 2020, J CLIN INVEST, V130, P3699, DOI 10.1172/JCI129049; van der Vos KE, 2016, NEURO-ONCOLOGY, V18, P58, DOI 10.1093/neuonc/nov244; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Venza I, 2012, EPIGENETICS-US, V7, P1315, DOI 10.4161/epi.22446; Vigneswaran K, 2021, CLIN CANCER RES, V27, P1553, DOI 10.1158/1078-0432.CCR-20-0018; Wang J, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2107507118; Wang L, 2019, J CELL PHYSIOL, V234, P5319, DOI 10.1002/jcp.27340; Wang QW, 2020, ONCOTARGETS THER, V13, P95, DOI 10.2147/OTT.S238332; Wang QH, 2017, CANCER CELL, V32, P42, DOI 10.1016/j.ccell.2017.06.003; Waters MR, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0146-y; Wenger A, 2019, NEURO-ONCOLOGY, V21, P616, DOI 10.1093/neuonc/noz011; Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023; Wu N, 2013, BRIT J CANCER, V109, P2853, DOI 10.1038/bjc.2013.672; Wu WN, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1132-0; Wu XC, 2017, NEURO-ONCOLOGY, V19, P1195, DOI 10.1093/neuonc/nox017; Xie Q, 2018, CELL, V175, P1228, DOI 10.1016/j.cell.2018.10.006; Xue H, 2016, AUTOPHAGY, V12, P1129, DOI 10.1080/15548627.2016.1178446; Yang L, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0430-2; Yang R, 2020, BRIT J CANCER, V123, P1445, DOI 10.1038/s41416-020-01032-y; Yang WB, 2020, NEURO-ONCOLOGY, V22, P1439, DOI 10.1093/neuonc/noaa103; Yao MJ, 2020, CELL, V180, P502, DOI 10.1016/j.cell.2019.12.024; Yelton Caleb J, 2018, Neuroimmunol Neuroinflamm, V5, DOI 10.20517/2347-8659.2018.58; Yeung YT, 2013, BRIT J PHARMACOL, V168, P591, DOI 10.1111/bph.12008; Yeung YT, 2012, J NEURO-ONCOL, V109, P35, DOI 10.1007/s11060-012-0875-7; Yin YT, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0993-4; Zanotto-Filho A, 2017, CANCER LETT, V390, P176, DOI 10.1016/j.canlet.2016.12.015; Zhail K, 2021, NAT CANCER, V2, P1136, DOI 10.1038/s43018-021-00267-9; Zhang HK, 2021, J CANCER, V12, P2756, DOI 10.7150/jca.48419; Zhang JF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56696-1; Zhang PF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09482-6; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhou D, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1420-6; Zhu CB, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0405-5; Zhu LN, 2015, INT REV IMMUNOL, V34, P82, DOI 10.3109/08830185.2014.969421	136	0	0	7	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								869307	10.3389/fimmu.2022.869307	http://dx.doi.org/10.3389/fimmu.2022.869307			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G1JH	35572545	Green Published, gold			2022-12-18	WOS:000795610700001
J	Chen, Y; Sun, ZP; Wan, L; Chen, HZ; Xi, TJ; Jiang, YM				Chen, Yan; Sun, Zepang; Wan, Li; Chen, Hongzhuan; Xi, Tieju; Jiang, Yuming			Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response	FRONTIERS IN IMMUNOLOGY			English	Article						tumor microenvironment; gastric cancer; recurrence; prognosis; chemotherapy; immunotherapy; classifier (classification tool)	MICROSATELLITE INSTABILITY; IMMUNE; THERAPY; PEMBROLIZUMAB; SUBTYPES; SURGERY; CELLS	BackgroundThe tumor microenvironment (TME) is crucial for tumor recurrence, prognosis, and therapeutic responses. We comprehensively investigated the TME characterization associated with relapse and survival outcomes of gastric cancer (GC) to predict chemotherapy and immunotherapy response. MethodsA total of 2,456 GC patients with complete gene-expression data and clinical annotations from twelve cohorts were included. The TME characteristics were evaluated using three proposed computational algorithms. We then developed a TME-classifier, a TME-cluster, and a TME-based risk score for the assessment of tumor recurrence and prognosis in patients with GC to predict chemotherapy and immunotherapy response. ResultsPatients with tumor recurrence presented with inactive immunogenicity, namely, high infiltration of tumor-associated stromal cells, low infiltration of tumor-associated immunoactivated lymphocytes, high stromal score, and low immune score. The TME-classifier of 4 subtypes with distinct clinicopathology, genomic, and molecular characteristics was significantly associated with tumor recurrence (P = 0.002), disease-free survival (DFS, P <0.001), and overall survival (OS, P <0.001) adjusted by confounding variables in 1,193 stage I-III GC patients who underwent potential radical surgery. The TME cluster and TME-based risk score can also predict DFS (P <0.001) and OS (P <0.001). More importantly, we found that patients in the TMEclassifier-A, TMEclassifier-C, and TMEclassifier-D groups benefited from adjuvant chemotherapy, and patients in the TMEclassifier-B group without chemotherapy benefit responded best to pembrolizumab treatment (PD-1 inhibitor), followed by patients in the TMEclassifier-A, while patients in the C and D groups of the TMEclassifier responded poorly to immunotherapy. ConclusionWe determined that TME characterization is significantly associated with tumor recurrence and prognosis. The TME-classifier we proposed can guide individualized chemotherapy and immunotherapy decision-making.	[Chen, Yan; Wan, Li; Chen, Hongzhuan; Xi, Tieju] Guangzhou Med Univ, Shenzhen Hosp Integrated Tradit Chinese & Western, Peoples Hosp Baoan Shenzhen 2, Shenzhen Baoan Shajing Peoples Hosp,Shatou Communi, Shenzhen, Peoples R China; [Sun, Zepang; Jiang, Yuming] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China; [Jiang, Yuming] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA USA	Guangzhou Medical University; Southern Medical University - China; Stanford University	Chen, Y (corresponding author), Guangzhou Med Univ, Shenzhen Hosp Integrated Tradit Chinese & Western, Peoples Hosp Baoan Shenzhen 2, Shenzhen Baoan Shajing Peoples Hosp,Shatou Communi, Shenzhen, Peoples R China.; Jiang, YM (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China.; Jiang, YM (corresponding author), Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA USA.	494357044@qq.com; jiangymbest@163.com						Ajani JA, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.36; Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388; Badgwell B, 2016, J NATL COMPR CANC NE, V14, P1321, DOI 10.6004/jnccn.2016.0139; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chao J, 2020, J CLIN ONCOL, V38; Chen LJ, 2013, CANCER IMMUNOL IMMUN, V62, P553, DOI 10.1007/s00262-012-1358-6; Chen Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685992; Chen YY, 2020, CANCERS, V12, DOI 10.3390/cancers12082236; Choi YY, 2019, ANN SURG, V270, P309, DOI 10.1097/SLA.0000000000002803; Cristescu R, 2015, NAT MED, V21, P449, DOI 10.1038/nm.3850; Cunningham D, 2006, NEW ENGL J MED, V355, P11, DOI 10.1056/NEJMoa055531; D'Angelica M, 2004, ANN SURG, V240, P808, DOI 10.1097/01.sla.0000143245.28656.15; Frederick LGMD, 2002, AJCC CANC STAGING MA; Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101; Grunberg N, 2021, CANCER RES, V81, P1639, DOI 10.1158/0008-5472.CAN-20-2756; Hasbahceci M, 2018, J CANCER RES THER, V14, P1225, DOI 10.4103/0973-1482.184518; Isobe Y, 2011, GASTRIC CANCER, V14, P301, DOI 10.1007/s10120-011-0085-6; Janjigian YY, 2018, CANCER DISCOV, V8, P49, DOI 10.1158/2159-8290.CD-17-0787; Jiang YM, 2019, CANCER IMMUNOL RES, V7, P2065, DOI 10.1158/2326-6066.CIR-19-0311; Jiang YM, 2018, CLIN CANCER RES, V24, P5574, DOI 10.1158/1078-0432.CCR-18-0848; Jiang YM, 2018, ANN SURG, V267, P504, DOI 10.1097/SLA.0000000000002116; Joshi Smita S, 2021, CA Cancer J Clin, V71, P264, DOI 10.3322/caac.21657; Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5; Kikuchi H, 2014, ANN SURG ONCOL, V21, P3954, DOI 10.1245/s10434-014-3781-8; Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z; Li BL, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136570; Lin YL, 2021, NPJ GENOM MED, V6, DOI 10.1038/s41525-021-00249-x; Maron SB, 2019, CLIN CANCER RES, V25, P7098, DOI 10.1158/1078-0432.CCR-19-1704; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5; Oh SC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04179-8; Pietrantonio F, 2019, J CLIN ONCOL, V37, P3392, DOI 10.1200/JCO.19.01124; Qian ZL, 2014, GENE CHROMOSOME CANC, V53, P883, DOI 10.1002/gcc.22196; Sakamoto S, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1671760; Sasako M, 2011, J CLIN ONCOL, V29, P4387, DOI 10.1200/JCO.2011.36.5908; Shitara K, 2020, J CLIN ONCOL, V38; Shitara K, 2018, LANCET, V392, P123, DOI 10.1016/S0140-6736(18)31257-1; Smyth EC, 2017, JAMA ONCOL, V3, P1197, DOI 10.1001/jamaoncol.2016.6762; Sun ZP, 2021, RADIOTHER ONCOL, V165, P179, DOI 10.1016/j.radonc.2021.11.003; Thompson ED, 2017, GUT, V66, P794, DOI 10.1136/gutjnl-2015-310839; Wang GS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063826; Wang Z, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-19; Washington K, 2010, ANN SURG ONCOL, V17, P3077, DOI 10.1245/s10434-010-1362-z; Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170; Yoo CH, 2000, BRIT J SURG, V87, P236, DOI 10.1046/j.1365-2168.2000.01360.x; Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zeng DQ, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002467; Zeng DQ, 2019, CANCER IMMUNOL RES, V7, P737, DOI 10.1158/2326-6066.CIR-18-0436	51	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								890922	10.3389/fimmu.2022.890922	http://dx.doi.org/10.3389/fimmu.2022.890922			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G2FB	35572498	Green Published, gold			2022-12-18	WOS:000795667600001
J	Ciruela, F; Jacobson, KA				Ciruela, Francisco; Jacobson, Kenneth A.			Optical Control of Adenosine A(3) Receptor Signaling: Towards a Multimodal Phototherapy in Psoriasis?	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						psoriasis; phototherapy; adenosine; anti-inflammatory; adenosine A(3) receptor; photopharmacology			[Ciruela, Francisco] Univ Barcelona, Inst Neurosci, Fac Med & Hlth Sci, Pharmacol Unit,Dept Pathol & Expt Therapeut, Barcelona, Spain; [Ciruela, Francisco] Inst Invest Biomed Bellvitge, IDIBELL, Neurosci Program, Neuropharmacol & Pain Grp, Barcelona, Spain; [Jacobson, Kenneth A.] NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Ciruela, F (corresponding author), Univ Barcelona, Inst Neurosci, Fac Med & Hlth Sci, Pharmacol Unit,Dept Pathol & Expt Therapeut, Barcelona, Spain.; Ciruela, F (corresponding author), Inst Invest Biomed Bellvitge, IDIBELL, Neurosci Program, Neuropharmacol & Pain Grp, Barcelona, Spain.	fciruela@ub.edu						Antonioli L, 2019, PHARMACOL REV, V71, P345, DOI 10.1124/pr.117.014878; Armstrong AW, 2020, JAMA-J AM MED ASSOC, V323, P1945, DOI 10.1001/jama.2020.4006; Borea PA, 2016, TRENDS PHARMACOL SCI, V37, P419, DOI 10.1016/j.tips.2016.02.006; Greb JE, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.82; Heath MS, 2019, EXPERT OPIN PHARMACO, V20, P443, DOI 10.1080/14656566.2018.1559819; Hull K, 2018, CHEM REV, V118, P10710, DOI 10.1021/acs.chemrev.8b00037; Jacobson KA, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00124; Jacobson KA, 2018, MED RES REV, V38, P1031, DOI 10.1002/med.21456; Lopez-Cano M, 2021, PHARMACOL RES, V170, DOI 10.1016/j.phrs.2021.105731; Morstein J, 2019, CURR OPIN CHEM BIOL, V50, P145, DOI 10.1016/j.cbpa.2019.03.013; Tosh DK, 2015, PURINERG SIGNAL, V11, P371, DOI 10.1007/s11302-015-9459-2; Yiu ZZN, 2016, AM J CLIN DERMATOL, V17, P191, DOI 10.1007/s40257-016-0179-3	12	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								904762	10.3389/fimmu.2022.904762	http://dx.doi.org/10.3389/fimmu.2022.904762			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H3MF	35572558	gold, Green Published			2022-12-18	WOS:000796448500001
J	Ding, L; Wu, HR; Wang, Y; Li, Y; Liang, ZP; Xia, XH; Zheng, JLC				Ding, Lu; Wu, Huiran; Wang, Yi; Li, Yun; Liang, Zhanping; Xia, Xiaohuan; Zheng, Jialin C.			m6A Reader Igf2bp1 Regulates the Inflammatory Responses of Microglia by Stabilizing Gbp11 and Cp mRNAs	FRONTIERS IN IMMUNOLOGY			English	Article						Igf2bp1; Gbp11; Cp; m6A reader; microglial activation; neuroinflammation	EXPRESSION; CELLS; ACTIVATION	Microglia are brain resident cells that function as brain phagocytic macrophages. The inflammatory responses of microglia induced by pathologic insults are key regulators in the progression of various neurological disorders. Currently, little is known about how these responses are regulated intrinsically. Here, it is observed that LPS-activated microglia exhibit distinct N6-methyladenosine (m6A) methylation patterns that are positively correlated with the expression patterns of corresponding mRNAs. High-throughput analyses and molecular studies both identified Igf2bp1 as the most significantly regulated m6A modifiers in activated microglia. Perturbation of function approaches further indicated Igf2bp1 as a key mediator for LPS-induced m6A modification and microglial activation presumably via enhancing the m6A methylation and stability of Gbp11 and Cp mRNAs. Thus, our study provides a possible mechanism for the m6A methylation-mediated microglia regulation and identifies Igf2bp1 as a potential target for modulating the inflammatory responses of microglia.	[Ding, Lu; Wu, Huiran; Li, Yun; Liang, Zhanping; Xia, Xiaohuan] Tongji Univ, Ctr Translat Neurodegenerat & Regenerat Therapy, Sch Med, Tongji Hosp, Shanghai, Peoples R China; [Wang, Yi] Tongji Univ, Translat Res Ctr, Sch Med, Shanghai Yangzhi Rehabil Hosp, Shanghai, Peoples R China; [Xia, Xiaohuan; Zheng, Jialin C.] Tongji Univ, Translat Res Inst Brain & Brain Intelligence, Sch Med, Shanghai Peoples Hosp 4, Shanghai, Peoples R China; [Xia, Xiaohuan; Zheng, Jialin C.] Tongji Univ, Shanghai Frontiers Sci Ctr Nanocatalyt Med, Shanghai, Peoples R China; [Zheng, Jialin C.] Tongji Univ, Collaborat Innovat Ctr Brain Sci, Shanghai, Peoples R China	Tongji University; Tongji University; Tongji University; Tongji University; Tongji University	Xia, XH (corresponding author), Tongji Univ, Ctr Translat Neurodegenerat & Regenerat Therapy, Sch Med, Tongji Hosp, Shanghai, Peoples R China.; Xia, XH; Zheng, JLC (corresponding author), Tongji Univ, Translat Res Inst Brain & Brain Intelligence, Sch Med, Shanghai Peoples Hosp 4, Shanghai, Peoples R China.; Xia, XH; Zheng, JLC (corresponding author), Tongji Univ, Shanghai Frontiers Sci Ctr Nanocatalyt Med, Shanghai, Peoples R China.; Zheng, JLC (corresponding author), Tongji Univ, Collaborat Innovat Ctr Brain Sci, Shanghai, Peoples R China.	xiaohuan_xia@163.com; JialinZheng@tongil.edu.cn						Al-Quraishy S, 2018, PARASITOL RES, V117, P1115, DOI 10.1007/s00436-018-5789-7; Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Colonna M, 2017, ANNU REV IMMUNOL, V35, P441, DOI 10.1146/annurev-immunol-051116-052358; Conway AE, 2016, CELL REP, V15, P666, DOI 10.1016/j.celrep.2016.03.052; Deng YY, 2021, AGING-US, V13, P24086, DOI 10.18632/aging.203652; Dong G, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.731810; Gao G, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00264; Hammer NA, 2005, REPRODUCTION, V130, P203, DOI 10.1530/rep.1.00664; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Lee KH, 2007, BRAIN RES, V1171, P1, DOI 10.1016/j.brainres.2007.07.053; Li Q, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02205-z; Mao KM, 2020, AGING-US, V12, P18716, DOI 10.18632/aging.104042; Mazumder B, 2005, MOL CELLS, V20, P167; Mu QC, 2015, CANCER BIOL THER, V16, P623, DOI 10.1080/15384047.2015.1019185; Nishino J, 2013, ELIFE, V2, DOI 10.7554/eLife.00924; Prinz M, 2019, CELL, V179, P292, DOI 10.1016/j.cell.2019.08.053; Qin YH, 2020, INT J MOL MED, V46, P1958, DOI 10.3892/ijmm.2020.4746; Wang CX, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2004880; Wang X, 2021, ADV SCI, V8, DOI 10.1002/advs.202100209; Wen LB, 2022, NEUROREPORT, V33, P243, DOI 10.1097/WNR.0000000000001550; Widagdo J, 2018, J NEUROCHEM, V147, P137, DOI 10.1111/jnc.14481; Wolf SA, 2017, ANNU REV PHYSIOL, V79, P619, DOI 10.1146/annurev-physiol-022516-034406; Wright-Jin EC, 2019, TRENDS MOL MED, V25, P967, DOI 10.1016/j.molmed.2019.08.013; Wu Y, 2018, J NEUROSCI RES, V96, P1265, DOI 10.1002/jnr.24221; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhou Hongxiu, 2021, Front Cell Neurosci, V15, P774305, DOI 10.3389/fncel.2021.774305; Zhu S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15403-9	28	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								872252	10.3389/fimmu.2022.872252	http://dx.doi.org/10.3389/fimmu.2022.872252			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G2GP	35572575	gold, Green Published			2022-12-18	WOS:000795671600001
J	Du, HB; Jiang, SB; Zhao, ZA; Zhang, H; Zhang, LM; Wang, Z; Guo, YX; Zhai, JY; Wang, P; Zhao, ZG; Niu, CY; Jiang, LN				Du, Hui-Bo; Jiang, Sun-Ban; Zhao, Zhen-Ao; Zhang, Hong; Zhang, Li-Min; Wang, Zhao; Guo, Ya-Xiong; Zhai, Jia-Yi; Wang, Peng; Zhao, Zi-Gang; Niu, Chun-Yu; Jiang, Li-Na			TLR2/TLR4-Enhanced TIPE2 Expression Is Involved in Post-Hemorrhagic Shock Mesenteric Lymph-Induced Activation of CD4+T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						hemorrhagic shock; mesenteric lymph; immune dysfunction; CD4+T lymphocyte; tumor necrosis factor alpha induced protein 8 like-2	REGULATORY T-CELLS; HEMORRHAGIC-SHOCK; CARDIAC DYSFUNCTION; LUNG INJURY; MECHANISMS; TRAUMA; APOPTOSIS; RESPONSES; INNATE; MODELS	Purpose: Post hemorrhagic shock mesenteric lymph (PHSML) return contributes to CD4(+) T cell dysfunction, which leads to immune dysfunction and uncontrolled inflammatory response. Tumor necrosis factor alpha induced protein 8 like-2 (TIPE2) is one of the essential proteins to maintain the immune homeostasis. This study investigated the role of TIPE2 in regulation of CD4(+) T lymphocyte function in interaction of PHSML and TLR2/TLR4. Methods: The splenic CD4(+) T cells were isolated from various mice (WT, TLR2(-/-), TLR4(-/-)) by immunomagnetic beads, and stimulated with PHSML, normal lymphatic fluid (NML), respectively. Application of TIPE2-carrying interfering fragments of lentivirus were transfected to WT, TLR4(-/-), and TLR2(-/-) CD4(+) T cells, respectively. After interference of TIPE2, they were stimulated with PHSML and NML for the examinations of TIPE2, TLR2, and TLR4 mRNA expressions, proliferation, activation molecules on surface, and cytokine secretion function. Results: PHSML stimulation significantly upregulated TIPE2, TLR2, and TLR4 mRNA expressions, decreased proliferation, CD25 expression, and IFN-gamma secretion, and increased the secretion ability of IL-4 in WT CD4(+) T cells. TIPE2 silencing enhanced proliferative capacity, upregulated CD25 expression, and increased IFN gamma secretion in CD4(+) T cells. PHSML stimulated TLR2(-/-)CD4(+) T or TLR4(-/-)CD4(+) T cells of which TIPE2 were silenced. TLR2 or TLR4 knockout attenuated PHSML-induced CD4(+) T cells dysfunction; PHSML stimulation of silent TIPE2-expressing TLR2(-/-)CD4(+) T or TLR4(-/-)CD4(+) T revealed that the coexistence of low TIPE2 expression with lack of TLR2 or TLR4 eliminated this beneficial effect. Conclusion: TIPE2 improves the PHSML-mediated CD4(+)T cells dysfunction by regulating TLR2/TLR4 pathway, providing a new intervention target following hemorrhagic shock-induced immune dysfunction.	[Du, Hui-Bo; Jiang, Sun-Ban; Zhao, Zhen-Ao; Zhang, Hong; Zhang, Li-Min; Wang, Zhao; Guo, Ya-Xiong; Zhai, Jia-Yi; Wang, Peng; Zhao, Zi-Gang; Jiang, Li-Na] Hebei North Univ, Inst Microcirculat, Zhangjiakou, Peoples R China; [Du, Hui-Bo; Zhao, Zhen-Ao; Zhang, Hong; Zhang, Li-Min; Guo, Ya-Xiong; Zhao, Zi-Gang; Niu, Chun-Yu; Jiang, Li-Na] Hebei Key Lab Crit Dis Mech & Intervent, Shijiazhuang, Peoples R China; [Du, Hui-Bo; Zhao, Zhen-Ao; Zhang, Hong; Zhang, Li-Min; Guo, Ya-Xiong; Zhao, Zi-Gang; Niu, Chun-Yu; Jiang, Li-Na] Key Lab Microcirculat & Shock Zhangjiakou City, Zhangjiakou, Peoples R China; [Niu, Chun-Yu] Hebei Med Univ, Coll Basic Med, Shijiazhuang, Peoples R China	Hebei North University; Hebei Medical University	Zhao, ZG; Jiang, LN (corresponding author), Hebei North Univ, Inst Microcirculat, Zhangjiakou, Peoples R China.; Zhao, ZG; Niu, CY; Jiang, LN (corresponding author), Hebei Key Lab Crit Dis Mech & Intervent, Shijiazhuang, Peoples R China.; Zhao, ZG; Niu, CY; Jiang, LN (corresponding author), Key Lab Microcirculat & Shock Zhangjiakou City, Zhangjiakou, Peoples R China.; Niu, CY (corresponding author), Hebei Med Univ, Coll Basic Med, Shijiazhuang, Peoples R China.	zzghyl@126.com; ncylxf@126.com; jln1020@1653.com			National Natural Science Foundation of China [81701963]; Natural Science Foundation of Hebei Province [H2020405023]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hebei Province(Natural Science Foundation of Hebei Province)	Funding This work was supported by grants from the National Natural Science Foundation of China (No. 81701963), the Natural Science Foundation of Hebei Province (H2020405023).	Akhade AS, 2015, EUR J IMMUNOL, V45, P2628, DOI 10.1002/eji.201545553; Albeituni S, 2019, BLOOD, V134, P147, DOI 10.1182/blood.2019000761; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Caldwell NW, 2020, AM J NURS, V120, P36, DOI 10.1097/01.NAJ.0000697640.04470.21; Cohen JT, 2021, STEM CELL REP, V16, P324, DOI 10.1016/j.stemcr.2020.12.014; Cong L, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107477; Dominguez-Andres J, 2019, CELL METAB, V29, P211, DOI 10.1016/j.cmet.2018.09.003; Du HB, 2015, ACTA CIR BRAS, V30, P439, DOI 10.1590/S0102-865020150060000010; Eppensteiner J, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127925; Fei Xiang, 2019, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V31, P772, DOI 10.3760/cma.j.issn.2095-4352.2019.06.022; Filho IT, 2018, COMPR PHYSIOL, V8, P61, DOI 10.1002/cphy.c170006; Fitzgerald JC, 2017, CRIT CARE MED, V45, pE124, DOI 10.1097/CCM.0000000000002053; Gupta DL, 2016, CYTOKINE, V88, P214, DOI 10.1016/j.cyto.2016.09.010; Hu Y, 2016, J GASTROEN HEPATOL, V31, P676, DOI 10.1111/jgh.13183; Huang H, 2019, MED SCI MONITOR, V25, P7547, DOI 10.12659/MSM.917229; Isayama K, 2012, J SURG RES, V172, P137, DOI 10.1016/j.jss.2010.07.042; Jiang LN, 2020, J SURG RES, V256, P220, DOI 10.1016/j.jss.2020.06.044; Kawabe T, 2016, EUR J IMMUNOL, V46, P1119, DOI 10.1002/eji.201545907; Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017; Koch U, 2011, ANNU REV CELL DEV BI, V27, P539, DOI 10.1146/annurev-cellbio-092910-154008; Kong L, 2013, HEPATOL INT, V7, P844, DOI 10.1007/s12072-013-9435-2; Kong Q, 2020, MICROVASC RES, V130, DOI 10.1016/j.mvr.2020.104009; Lelubre C, 2018, NAT REV NEPHROL, V14, P417, DOI 10.1038/s41581-018-0005-7; Liu MW, 2015, INT J MOL MED, V36, P386, DOI 10.3892/ijmm.2015.2241; Liu MW, 2015, MOL MED REP, V11, P1675, DOI 10.3892/mmr.2014.2965; Liu YP, 2021, HEPATOLOGY, V74, P1300, DOI 10.1002/hep.31832; Lou YW, 2020, J IMMUNOL, V204, P2122, DOI 10.4049/jimmunol.1901142; Luan YY, 2011, MOL IMMUNOL, V49, P219, DOI 10.1016/j.molimm.2011.08.016; Maslanka T, 2014, VET IMMUNOL IMMUNOP, V160, P192, DOI 10.1016/j.vetimm.2014.05.003; Munoz K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105244; Niu CY, 2010, RENAL FAILURE, V32, P584, DOI 10.3109/08860221003778031; Obert DP, 2019, SHOCK, V52, pE76, DOI 10.1097/SHK.0000000000001298; Ono S, 2013, SURGERY, V153, P262, DOI 10.1016/j.surg.2012.06.023; Ono-Ohmachi A, 2021, MUCOSAL IMMUNOL, V14, P1335, DOI 10.1038/s41385-021-00434-2; Peng YP, 2016, ONCOL REP, V35, P2480, DOI 10.3892/or.2016.4562; Pol JG, 2020, J EXP MED, V217, DOI 10.1084/jem.20191247; Shi BQ, 2020, AM J PHYSIOL-LUNG C, V319, pL163, DOI 10.1152/ajplung.00069.2020; Shi CY, 2017, MOL MED REP, V16, P6346, DOI 10.3892/mmr.2017.7311; Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026; Wang HY, 2021, RESP RES, V22, DOI 10.1186/s12931-021-01826-5; Wang Q, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01717; Wang WY, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107936; Wang XR, 2021, J SURG RES, V266, P245, DOI 10.1016/j.jss.2021.04.008; Washburn ML, 2019, J IMMUNOL, V203, P1897, DOI 10.4049/jimmunol.1900560; Wesch D, 2011, CELL MOL LIFE SCI, V68, P2357, DOI 10.1007/s00018-011-0699-1; Whiteside TL, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv276; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Williams EC, 2019, J TRAUMA ACUTE CARE, V86, P52, DOI 10.1097/TA.0000000000002093; Wilson NM, 2017, SHOCK, V48, P401, DOI 10.1097/SHK.0000000000000882; Xu ZH, 2020, INT IMMUNOPHARMACOL, V87, DOI 10.1016/j.intimp.2020.106792; Yi J, 2015, SHOCK, V44, P336, DOI 10.1097/SHK.0000000000000431; Zhang H, 2019, ACTA CIR BRAS, V34, DOI 10.1590/s0102-865020190090000003; Zhang K, 2020, THORAX, V75, P209, DOI 10.1136/thoraxjnl-2019-213613; Zhang Y, 2015, J NEUROIMMUNE PHARM, V10, P635, DOI 10.1007/s11481-015-9638-5; Zhang Y, 2014, SHOCK, V42, P218, DOI 10.1097/SHK.0000000000000211	55	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								838618	10.3389/fimmu.2022.838618	http://dx.doi.org/10.3389/fimmu.2022.838618			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G2XM	35572554	gold, Green Published			2022-12-18	WOS:000795716000001
J	Gao, LX; Yang, J; Feng, JT; Liu, ZY; Dong, Y; Luo, JY; Yu, LZT; Wang, JM; Fan, HY; Ma, WF; Liu, TC				Gao, Lixia; Yang, Jie; Feng, Jutao; Liu, Ziying; Dong, Ying; Luo, Jiangyan; Yu, Liangzhentian; Wang, Jiamei; Fan, Hongying; Ma, Weifeng; Liu, Tiancai			PreS/2-21-Guided siRNA Nanoparticles Target to Inhibit Hepatitis B Virus Infection and Replication	FRONTIERS IN IMMUNOLOGY			English	Article						HBV; siRNA; peptide; liposomal nanoparticles; targeting	HBV; GENE; THERAPY; NTCP; DELIVERY; INNATE	A viable therapy is needed to overcome the deadlock of the incurable chronic hepatitis B (CHB). The prolonged existence of covalently closed circular DNA (cccDNA) and integrated HBV DNA in the nucleus of hepatocytes is the root cause of CHB. As a result, it is critical to successfully suppress HBV DNA replication and eliminate cccDNA. RNA interference has been proven in recent research to silence the expression of target genes and thereby decrease HBV replication. However, siRNA is susceptible to be degraded by RNA enzymes in vivo, making it difficult to deliver successfully and lacking of tissue targeting. To exploit the advantages of siRNA technology while also overcoming its limitations, we designed a new strategy and prepared biomimetic nanoparticles that were directed by PreS/2-21 peptides and precisely loaded HBV siRNA. Experiments on these nanoparticles in vitro and in vivo revealed that they are tiny, stable, safe and highly targetable, with high inhibitory effects on HBV DNA, pgRNA, cccDNA, HBeAg and HBsAg. PreS/2-21-directed nanoparticles loaded with HBV gene therapy drugs are expected to be promising for the treatment of CHB.	[Gao, Lixia; Yang, Jie; Luo, Jiangyan; Yu, Liangzhentian; Wang, Jiamei; Fan, Hongying; Ma, Weifeng] Southern Med Univ, Sch Publ Hlth, Dept Microbiol, Guangzhou, Peoples R China; [Feng, Jutao] Guangzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Guangzhou, Peoples R China; [Liu, Ziying] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, State Key Lab Organ Failure Res,Guangdong Prov Key, Guangzhou, Peoples R China; [Dong, Ying; Liu, Tiancai] Southern Med Univ, Inst Antibody Engn, Sch Lab Med & Biotechnol, Guangzhou, Peoples R China	Southern Medical University - China; Guangzhou Medical University; Southern Medical University - China; Southern Medical University - China	Ma, WF (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Microbiol, Guangzhou, Peoples R China.; Liu, TC (corresponding author), Southern Med Univ, Inst Antibody Engn, Sch Lab Med & Biotechnol, Guangzhou, Peoples R China.	maweifeng919@163.com; liutc@smu.edu.cn	Fan, Hongying/CAG-7568-2022; Fan, Hongying/GLN-4000-2022	Fan, Hongying/0000-0002-0725-1596; 	Natural Science Foundation of Guangdong Province [2021A1515011828, 2022A1515010985]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	Funding This work was supported by the Natural Science Foundation of Guangdong Province (grant no. 2021A1515011828 and no. 2022A1515010985).	Al Shaer D, 2019, PHARMACEUTICALS-BASE, V12, DOI 10.3390/ph12020052; [Anonymous], 2018, LANCET GASTROENTEROL, DOI [DOI 10.1016/S2468-1253(18)30056-6, 10.1016/S2468-1253(18)30056-6]; Bhat P, 2011, J VIROL, V85, P12474, DOI 10.1128/JVI.05344-11; Bian Zhong-qi, 2012, Zhonghua Yi Xue Za Zhi, V92, P768; Blanco MJ, 2020, ACS MED CHEM LETT, V11, P228, DOI 10.1021/acsmedchemlett.9b00582; Fu LL, 2014, CELL PROLIFERAT, V47, P326, DOI 10.1111/cpr.12117; Gane EJ, 2017, LIVER INT, V37, P40, DOI 10.1111/liv.13304; Gish RG, 2015, ANTIVIR RES, V121, P47, DOI 10.1016/j.antiviral.2015.06.008; Hamada-Tsutsumi S, 2019, ALIMENT PHARM THER, V49, P1060, DOI 10.1111/apt.15197; [韩超 Han Chao], 2014, [免疫学杂志, Immunological Journal], V30, P240; Han QJ, 2019, ANTIVIR RES, V161, P36, DOI 10.1016/j.antiviral.2018.11.006; Han QJ, 2011, HEPATOLOGY, V54, P1179, DOI 10.1002/hep.24505; Huang WJ, 2014, HEPATOL RES, V44, P897, DOI 10.1111/hepr.12189; Ichihara H, 2003, YAKUGAKU ZASSHI, V123, P25, DOI 10.1248/yakushi.123.25; Jiang C, 2017, CELL RES, V27, P440, DOI 10.1038/cr.2017.16; Klein C, 2003, GASTROENTEROLOGY, V125, P9, DOI 10.1016/S0016-5085(03)00720-0; Kornyeyev D, 2019, J VIROL, V93, DOI 10.1128/JVI.00248-19; Lan TY, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01509-z; Li JS, 2015, CLIN MOL HEPATOL, V21, P193, DOI 10.3350/cmh.2015.21.3.193; Manzoor S, 2015, WORLD J GASTROENTERO, V21, P12558, DOI 10.3748/wjg.v21.i44.12558; Megahed FAK, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12030285; Meng ZJ, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03127; Nanna AR, 2020, NUCLEIC ACIDS RES, V48, P5281, DOI 10.1093/nar/gkaa286; Peng B., 2020, LAB MED CLIN, V17, P3106, DOI [10.3969/j.issn.1672-9455.2020.21.009, DOI 10.3969/J.ISSN.1672-9455.2020.21.009]; Qureshi A, 2018, REV MED VIROL, V28, DOI 10.1002/rmv.1976; Revill PA, 2019, LANCET GASTROENTEROL, V4, P545, DOI 10.1016/S2468-1253(19)30119-0; Richner JM, 2017, CELL, V168, P1114, DOI 10.1016/j.cell.2017.02.017; Rybicka M, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8091416; Sardh E, 2019, NEW ENGL J MED, V380, P549, DOI 10.1056/NEJMoa1807838; Saw PE, 2020, SCI CHINA LIFE SCI, V63, P485, DOI 10.1007/s11427-018-9438-y; Schulze A, 2010, J VIROL, V84, P1989, DOI 10.1128/JVI.01902-09; Shin D, 2006, VIRUS RES, V119, P146, DOI 10.1016/j.virusres.2005.12.012; Slagle BL, 2018, CURR OPIN VIROL, V30, P32, DOI 10.1016/j.coviro.2018.01.007; Soriano V, 2017, EXPERT OPIN INV DRUG, V26, P843, DOI 10.1080/13543784.2017.1333105; Spyrou E, 2020, GASTROENTEROL CLIN N, V49, P215, DOI 10.1016/j.gtc.2020.01.003; Wang JW, 2019, HEPATOLOGY, V69, P974, DOI 10.1002/hep.30248; Wang YZ, 2020, ACS APPL MATER INTER, V12, P4308, DOI 10.1021/acsami.9b21214; Watashi K, 2014, INT J MOL SCI, V15, P2892, DOI 10.3390/ijms15022892; Wen WH, 2007, HEPATOLOGY, V46, P84, DOI 10.1002/hep.21663; Yan H, 2013, J VIROL, V87, P7977, DOI 10.1128/JVI.03540-12; Yan H, 2012, ELIFE, V1, DOI 10.7554/eLife.00049; Yao JJ, 2008, J HUAZHONG U SCI-MED, V28, P266, DOI 10.1007/s11596-008-0308-1	42	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								856463	10.3389/fimmu.2022.856463	http://dx.doi.org/10.3389/fimmu.2022.856463			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F8GV	35572586	gold, Green Published			2022-12-18	WOS:000795401400001
J	Gross, G; Carmi, Y; Abken, H				Gross, Gideon; Carmi, Yaron; Abken, Hinrich			Editorial: Implementing Logic Gates in Adoptive Cell Therapy	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Boolean logic gates; cancer immunotherapy; tumor-associated antigens; tumor microenvironment; precision targeting	EXPRESS		[Gross, Gideon] MIGALGalilee Res Inst, Lab Immunol, Kiryat Shmona, Israel; [Gross, Gideon] Tel Hai Coll, Dept Biotechnol, Upper Galilee, Israel; [Carmi, Yaron] Tel Aviv Univ, Sackler Fac Med, Dept Pathol, Tel Aviv, Israel; [Abken, Hinrich] Univ Hosp Regensburg, Regensburg Ctr Intervent Immunol, Dept Genet Immunotherapy, Regensburg, Germany	Tel Hai Academy College; Tel Aviv University; Sackler Faculty of Medicine; University of Regensburg	Gross, G (corresponding author), MIGALGalilee Res Inst, Lab Immunol, Kiryat Shmona, Israel.; Gross, G (corresponding author), Tel Hai Coll, Dept Biotechnol, Upper Galilee, Israel.							Ankri C, 2013, J IMMUNOL, V191, P4121, DOI 10.4049/jimmunol.1203085; Chmielewski M, 2015, EXPERT OPIN BIOL TH, V15, P1145, DOI 10.1517/14712598.2015.1046430; Guo JT, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002628; Hamburger AE, 2020, MOL IMMUNOL, V128, P298, DOI 10.1016/j.molimm.2020.09.012; Hwang MS, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2022410118; Prosser ME, 2012, MOL IMMUNOL, V51, P263, DOI 10.1016/j.molimm.2012.03.023; Sandberg ML, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abm0306; Tay JCK, 2017, IMMUNOTHERAPY-UK, V9, P1339, DOI 10.2217/imt-2017-0103; Tokatlian T, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003826; Zimmermann K, 2020, CANCERS, V12, DOI 10.3390/cancers12020375	10	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								902594	10.3389/fimmu.2022.902594	http://dx.doi.org/10.3389/fimmu.2022.902594			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H3JZ	35572501	gold, Green Published			2022-12-18	WOS:000796442600001
J	Kaaijk, P; Pimentel, VO; Emmelot, ME; Poelen, MCM; Cevirgel, A; Schepp, RM; den Hartog, G; Reukers, DFM; Beckers, L; van Beek, J; van Els, CACM; Meijer, A; Rots, NY; de Wit, J				Kaaijk, Patricia; Pimentel, Veronica Olivo; Emmelot, Maarten E.; Poelen, Martien C. M.; Cevirgel, Alper; Schepp, Rutger M.; den Hartog, Gerco; Reukers, Daphne F. M.; Beckers, Lisa; van Beek, Josine; van Els, Cecile A. C. M.; Meijer, Adam; Rots, Nynke Y.; de Wit, Jelle			Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response Up to 10 Months (vol 13, 3389, 2022)	FRONTIERS IN IMMUNOLOGY			English	Correction						SARS-CoV-2; COVID-19; mild symptoms; children; T cell immunity; adaptive immunity; antibody response; cytokines			[Kaaijk, Patricia; Pimentel, Veronica Olivo; Emmelot, Maarten E.; Poelen, Martien C. M.; Cevirgel, Alper; Schepp, Rutger M.; den Hartog, Gerco; Reukers, Daphne F. M.; Beckers, Lisa; van Beek, Josine; van Els, Cecile A. C. M.; Meijer, Adam; Rots, Nynke Y.; de Wit, Jelle] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands; [van Els, Cecile A. C. M.] Univ Utrecht, Fac Vet Med, Utrecht, Netherlands	Netherlands National Institute for Public Health & the Environment; Utrecht University	Kaaijk, P (corresponding author), Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, Bilthoven, Netherlands.	patricia.kaaijk@rivm.nl		Emmelot, Maarten/0000-0002-4930-6268				Kaaijk P, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.817876	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								893720	10.3389/fimmu.2022.893720	http://dx.doi.org/10.3389/fimmu.2022.893720			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I4QU	35572580	Green Published, gold			2022-12-18	WOS:000797215400001
J	Kozlowski, PA; Mantis, NJ; Frey, A				Kozlowski, Pamela A.; Mantis, Nicholas J.; Frey, Andreas			Editorial: Mucosal Vaccination: Strategies to Induce and Evaluate Mucosal Immunity	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						adjuvant; formulation; IgA; mucosal vaccine; protection; targeted delivery			[Kozlowski, Pamela A.] Louisiana State Univ, Dept Microbiol Immunol & Parasitol, Hlth Sci Ctr, New Orleans, LA USA; [Mantis, Nicholas J.] Wadsworth Ctr, Div Infect Dis, Albany, NY USA; [Mantis, Nicholas J.; Frey, Andreas] Leibniz Lung Ctr, Program Area Chron Lung Dis, Div Mucosal Immunol & Diagnost, Res Ctr Borstel, Borstel, Germany; New York State Dept Hlth, Albany, NY USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Wadsworth Center; Forschungszentrum Borstel; State University of New York (SUNY) System	Frey, A (corresponding author), Leibniz Lung Ctr, Program Area Chron Lung Dis, Div Mucosal Immunol & Diagnost, Res Ctr Borstel, Borstel, Germany.	afrey@fz-borstel.de						Aylward RB, 2006, ANN TROP MED PARASIT, V100, P401, DOI 10.1179/136485906X97354; Folorunso OS, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030341	2	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								905150	10.3389/fimmu.2022.905150	http://dx.doi.org/10.3389/fimmu.2022.905150			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H3MO	35572599	gold, Green Published			2022-12-18	WOS:000796449500001
J	Pelletier, A; Stockmann, C				Pelletier, Abigaelle; Stockmann, Christian			The Metabolic Basis of ILC Plasticity	FRONTIERS IN IMMUNOLOGY			English	Review						Innate Lymphoid Cells (ILCs); metabolism; plasticity; OxPhos; glycolysis; cytokines	INNATE LYMPHOID-CELLS; NATURAL-KILLER-CELLS; NK CELLS; T-CELLS; TGF-BETA; HYPOXIA; ACTIVATION; EXPRESSION; TRANSCRIPTION; GROWTH	Innate Lymphoid Cells (ILCs) are the innate counterpart of adaptive lymphoid T cells. They are key players in the regulation of tissues homeostasis and early inflammatory host responses. ILCs are divided into three groups, and further subdivided into five subsets, that are characterised by distinct transcription factors, surface markers and their cytokine expression profiles. Group 1 ILCs, including natural killer (NK) cells and non-NK cell ILC1s, express T-bet and produce IFN-gamma. Group 2 ILCs depend on GATA3 and produce IL-4, IL-5 and IL-13. Group 3 ILCs, composed of ILC3s and Lymphoid Tissue Inducer (LTi) cells, express ROR gamma t and produce IL-17 and IL-22. Even though, the phenotype of each subset is well defined, environmental signals can trigger the interconversion of phenotypes and the plasticity of ILCs, in both mice and humans. Several extrinsic and intrinsic drivers of ILC plasticity have been described. However, the changes in cellular metabolism that underlie ILC plasticity remain largely unexplored. Given that metabolic changes critically affect fate and effector function of several immune cell types, we, here, review recent findings on ILC metabolism and discuss the implications for ILC plasticity.	[Pelletier, Abigaelle; Stockmann, Christian] Univ Zurich, Inst Anat, Fac Med, Zurich, Switzerland	University of Geneva; University of Zurich	Pelletier, A (corresponding author), Univ Zurich, Inst Anat, Fac Med, Zurich, Switzerland.	abigaelle.pelletier@anatomy.uzh.ch						Assmann N, 2017, NAT IMMUNOL, V18, P1197, DOI 10.1038/ni.3838; Bal SM, 2020, NAT REV IMMUNOL, V20, P552, DOI 10.1038/s41577-020-0282-9; Bal SM, 2016, NAT IMMUNOL, V17, P636, DOI 10.1038/ni.3444; Bernink JH, 2019, NAT IMMUNOL, V20, P992, DOI 10.1038/s41590-019-0423-0; Bernink JH, 2015, IMMUNITY, V43, P146, DOI 10.1016/j.immuni.2015.06.019; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Cai T, 2019, J ALLERGY CLIN IMMUN, V143, P229, DOI 10.1016/j.jaci.2018.03.007; Campbell EL, 2014, IMMUNITY, V40, P66, DOI 10.1016/j.immuni.2013.11.020; Cella M, 2019, NAT IMMUNOL, V20, P980, DOI 10.1038/s41590-019-0425-y; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Corral D, 2021, bioRxiv, DOI 10.1101/2021.01.19.427257; Cortez VS, 2017, NAT IMMUNOL, V18, P995, DOI 10.1038/ni.3809; Cuff AO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02180; Cupedo T, 2009, NAT IMMUNOL, V10, P66, DOI 10.1038/ni.1668; de la Cruz Lopez KG., 2019, Front Oncol, V9, DOI 10.3389/FONC.2019.01373/BIBTEX; Di Luccia B, 2019, J EXP MED, V216, P2231, DOI 10.1084/jem.20180549; Donnelly RP, 2014, J IMMUNOL, V193, P4477, DOI 10.4049/jimmunol.1401558; DuPage M, 2016, NAT REV IMMUNOL, V16, P149, DOI 10.1038/nri.2015.18; Eisenring M, 2010, NAT IMMUNOL, V11, P1030, DOI 10.1038/ni.1947; Fachi JL, 2021, MUCOSAL IMMUNOL, V14, P828, DOI 10.1038/s41385-020-00371-6; Fagundes RR, 2017, J APPL PHYSIOL, V123, P1328, DOI 10.1152/japplphysiol.00203.2017; Galle-Treger L, 2020, J ALLERGY CLIN IMMUN, V145, P502, DOI 10.1016/j.jaci.2019.10.035; Gao YL, 2017, NAT IMMUNOL, V18, P1004, DOI 10.1038/ni.3800; Gardiner CM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00367; Genestier L, 1999, J EXP MED, V189, P231, DOI 10.1084/jem.189.2.231; Golebski K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09883-7; Goverse G, 2016, J IMMUNOL, V196, P5148, DOI 10.4049/jimmunol.1501106; Gronke K, 2016, IMMUNOL LETT, V179, P9, DOI 10.1016/j.imlet.2016.07.004; Gury-BenAri M, 2016, CELL, V166, P1231, DOI 10.1016/j.cell.2016.07.043; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Keating SE, 2016, J IMMUNOL, V196, P2552, DOI 10.4049/jimmunol.1501783; Keppel MP, 2015, J IMMUNOL, V194, P1954, DOI 10.4049/jimmunol.1402099; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Klose CSN, 2013, NATURE, V494, P261, DOI 10.1038/nature11813; Krzywinska E, 2022, J EXP MED, V219, DOI 10.1084/jem.20210909; Krzywinska E, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01599-w; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Li Q, 2018, IMMUNITY, V48, P258, DOI 10.1016/j.immuni.2017.12.013; Lim AI, 2016, J EXP MED, V213, P569, DOI 10.1084/jem.20151750; Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442; Loftus RM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04719-2; Mah AY, 2016, CRIT REV IMMUNOL, V36, P131, DOI 10.1615/CritRevImmunol.2016017387; Mao YM, 2016, BLOOD, V128, P1475, DOI 10.1182/blood-2016-02-698027; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Mazzurana L, 2019, EUR J IMMUNOL, V49, P1344, DOI 10.1002/eji.201848075; Meininger I, 2020, TRENDS IMMUNOL, V41, P902, DOI 10.1016/j.it.2020.08.009; Mielke LA, 2013, J EXP MED, V210, P1117, DOI 10.1084/jem.20121588; Mikami Y, 2018, EUR J IMMUNOL, V48, P1174, DOI 10.1002/eji.201847480; Monticelli LA, 2016, NAT IMMUNOL, V17, P656, DOI 10.1038/ni.3421; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ni J, 2020, IMMUNITY, V52, P1075, DOI 10.1016/j.immuni.2020.05.001; Oestreich KJ, 2014, NAT IMMUNOL, V15, P957, DOI 10.1038/ni.2985; Park E, 2019, ELIFE, V8, DOI 10.7554/eLife.47605; Parker ME, 2020, J EXP MED, V217, DOI 10.1084/jem.20191030; Pellicoro A, 2014, NAT REV IMMUNOL, V14, P181, DOI 10.1038/nri3623; Pokrovskii M, 2019, IMMUNITY, V51, P185, DOI 10.1016/j.immuni.2019.06.001; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rankin LC, 2013, NAT IMMUNOL, V14, P389, DOI 10.1038/ni.2545; Raykova A, 2017, BLOOD ADV, V1, P2679, DOI 10.1182/bloodadvances.2017008839; Saravia J, 2019, CELL MOL IMMUNOL, V16, P634, DOI 10.1038/s41423-019-0220-6; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Silver JS, 2016, NAT IMMUNOL, V17, P626, DOI 10.1038/ni.3443; Slattery K, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002044; Slattery K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02915; Spencer SP, 2014, SCIENCE, V343, P432, DOI 10.1126/science.1247606; Spits H, 2016, NAT IMMUNOL, V17, P758, DOI 10.1038/ni.3482; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Surace L, 2021, NAT IMMUNOL, V22, P1367, DOI 10.1038/s41590-021-01043-8; Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200; van de Pavert SA, 2016, INT IMMUNOL, V28, P35, DOI 10.1093/intimm/dxv052; van de Pavert SA, 2014, NATURE, V508, P123, DOI 10.1038/nature13158; Velasquez SY, 2016, J BIOL CHEM, V291, P12960, DOI 10.1074/jbc.M116.721753; Viel S, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad1884; Villegas-Mendez Ana, 2020, J Immunol, V205, P1608, DOI 10.4049/jimmunol.2000450; Vivier E, 2018, CELL, V174, P1054, DOI 10.1016/j.cell.2018.07.017; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Vonarbourg C, 2010, IMMUNITY, V33, P736, DOI 10.1016/j.immuni.2010.10.017; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilhelm C, 2016, J EXP MED, V213, P1409, DOI 10.1084/jem.20151448; Xu X, 2018, BONE RES, V6, DOI 10.1038/s41413-017-0005-4; Zaiatz-Bittencourt V, 2018, J IMMUNOL, V200, P3934, DOI 10.4049/jimmunol.1701461	85	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								858051	10.3389/fimmu.2022.858051	http://dx.doi.org/10.3389/fimmu.2022.858051			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G9WV	35572512	Green Published, gold			2022-12-18	WOS:000796198600001
J	Schopf, S; Gotzmann, G; Dietze, M; Gerschke, S; Kenner, L; Koenig, U				Schopf, Simone; Gotzmann, Gaby; Dietze, Marleen; Gerschke, Stephanie; Kenner, Lysann; Koenig, Ulla			Investigations Into the Suitability of Bacterial Suspensions as Biological Indicators for Low-Energy Electron Irradiation	FRONTIERS IN IMMUNOLOGY			English	Article						bacteria; dosimetry; liquid; inactivation; impedance spectroscopy	GAMMA-IRRADIATION; BEAM IRRADIATION; E. COLI; INACTIVATION; POPULATIONS	Low-energy electron irradiation is an emerging alternative technology for attenuated or complete pathogen inactivation with respect to medical, biotechnological, and pharmaceutical applications. Pathogen inactivation by ionizing radiation depends mainly on the absorbed electron dose. In low-energy electron irradiation processes, determination of the absorbed electron dose is challenging due to the limited, material-dependent penetration depth of the accelerated electrons into the matter. In general, there are established dosimetry systems to evaluate the absorbed dose under dry irradiation conditions. However, there is no system for precise dose monitoring of low-energy irradiation processes in liquids or suspensions so far. Therefore, in this study three different bacterial species were investigated as biological dose indicators, especially in the range of low doses (< 6.5 kGy) in aqueous solutions or suspensions. Escherichia coli, Bacillus subtilis, and Staphylococcus warneri were comparatively evaluated for their suitability as biological dose indicators. Thin homogeneous films of the respective bacterial suspensions were irradiated with increasing doses of low-energy accelerated electrons. The average absorbed dose was determined using a colorimetric dosimeter based on a tetrazolium salt solution. The maximum and minimum absorbed doses were measured with a referenced film dosimeter. Subsequently, the inactivation kinetics was determined in terms of inactivation curves and D-10 values. Thus, the minimum inactivation dose of bacterial growth was assessed for E. coli and S. warneri. The effect of irradiation with low-energy accelerated electrons on the growth behavior and activity of the bacteria was studied in more detail using impedance spectroscopy. With increasing irradiation doses growth was delayed.	[Schopf, Simone] Fraunhofer Inst Organ Elect, Div Med & Biotechnol Applicat, Electron Beam & Plasma Technol, Dresden, Germany	Fraunhofer Gesellschaft	Schopf, S (corresponding author), Fraunhofer Inst Organ Elect, Div Med & Biotechnol Applicat, Electron Beam & Plasma Technol, Dresden, Germany.	simone.schopf@fep.fraunhofer.de						AbdelFattah AA, 1996, RADIAT PHYS CHEM, V47, P611, DOI 10.1016/0969-806X(95)00037-X; Bayer L, 2018, VACCINE, V36, P1561, DOI 10.1016/j.vaccine.2018.02.014; Bhatia SS, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00694; Deutsches Institut fr Normung/ International Organization for Standardization, 2020, 111371202004 DINISO; Fan XT, 2017, RADIAT PHYS CHEM, V130, P306, DOI 10.1016/j.radphyschem.2016.09.015; Fertey J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69347-7; Fertey J, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010113; Fertey J, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8110319; Gotzmann G, 2018, RADIAT PHYS CHEM, V150, P9, DOI 10.1016/j.radphyschem.2018.04.008; Gotzmann G, 2017, SURF COAT TECH, V311, P248, DOI 10.1016/j.surfcoat.2016.12.080; Hammad AA., 2008, TRENDS RAD STERILIZA; Helt-Hansen J, 2010, RADIAT PHYS CHEM, V79, P66, DOI 10.1016/j.radphyschem.2009.09.002; Hertwig C, 2018, TRENDS FOOD SCI TECH, V77, P131, DOI 10.1016/j.tifs.2018.05.011; Hieke ASC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02138; International Organization for Standardization/ASTM, 2013, 51607201306 ISO ASTM; Koschnitzki D, 2021, ARCH MICROBIOL, V203, P1299, DOI 10.1007/s00203-020-02125-1; Lamb JL, 2002, J FOOD PROTECT, V65, P1800, DOI 10.4315/0362-028X-65.11.1800; Lara J. de, 2002, Innovative Food Science and Emerging Technologies, V3, P379, DOI 10.1016/S1466-8564(02)00053-X; Mayer-Miebach E, 2005, FOOD CONTROL, V16, P701, DOI 10.1016/j.foodcont.2004.06.007; MILLER A, 1988, RADIAT PHYS CHEM, V31, P491; Mintier AM, 2006, J FOOD PROTECT, V69, P570, DOI 10.4315/0362-028X-69.3.570; MONK JD, 1995, J FOOD PROTECT, V58, P197, DOI 10.4315/0362-028X-58.2.197; Pillai SD., 2017, APPL RAD CHEM FIELDS, P249, DOI DOI 10.1007/978-3-319-54145-7_9; Praveen C, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243417; Pribil W, 2007, WATER ENVIRON RES, V79, P720, DOI 10.2175/106143007X175889; PRINCE HN, 1976, APPL ENVIRON MICROB, V31, P999, DOI 10.1128/AEM.31.6.999-1000.1976; RILEY PA, 1994, INT J RADIAT BIOL, V65, P27, DOI 10.1080/09553009414550041; Rogner FH., 2009, 52 ANN TECHNICAL C P; Sharpe P., 2009, NPL REP CIRM, V29, P1; Tallentire A, 2010, RADIAT PHYS CHEM, V79, P701, DOI 10.1016/j.radphyschem.2010.01.010; Thabet A, 2019, VET PARASITOL, V266, P18, DOI 10.1016/j.vetpar.2019.01.001; Ha TMH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177571; Urgiles E, 2007, AEROSP CONF PROC, P239; Zhang YF, 2020, FOOD MICROBIOL, V87, DOI 10.1016/j.fm.2019.103353; Zhang YF, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02720	35	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								814767	10.3389/fimmu.2022.814767	http://dx.doi.org/10.3389/fimmu.2022.814767			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F8CH	35572499	Green Published, gold			2022-12-18	WOS:000795389600001
J	Tong, HP; Sun, JJ; Fang, JQ; Zhang, M; Liu, H; Xia, RX; Zhou, WC; Liu, KJ; Chen, X				Tong, Haipeng; Sun, Jinju; Fang, Jingqin; Zhang, Mi; Liu, Huan; Xia, Renxiang; Zhou, Weicheng; Liu, Kaijun; Chen, Xiao			A Machine Learning Model Based on PET/CT Radiomics and Clinical Characteristics Predicts Tumor Immune Profiles in Non-Small Cell Lung Cancer: A Retrospective Multicohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						positron emission tomography; computed tomography; radiomics; tumor immune microenvironment; lung cancer; machine learning	FDG-PET; MICROENVIRONMENT; EXPRESSION; PEMBROLIZUMAB; HETEROGENEITY; CHEMOTHERAPY; METASTASES; PD-L1; NSCLC	BackgroundThe tumor immune microenvironment (TIME) phenotypes have been reported to mainly impact the efficacy of immunotherapy. Given the increasing use of immunotherapy in cancers, knowing an individual's TIME phenotypes could be helpful in screening patients who are more likely to respond to immunotherapy. Our study intended to establish, validate, and apply a machine learning model to predict TIME profiles in non-small cell lung cancer (NSCLC) by using F-18-FDG PET/CT radiomics and clinical characteristics. MethodsThe RNA-seq data of 1145 NSCLC patients from The Cancer Genome Atlas (TCGA) cohort were analyzed. Then, 221 NSCLC patients from Daping Hospital (DPH) cohort received(18)F-FDG PET/CT scans before treatment and CD8 expression of the tumor samples were tested. The Artificial Intelligence Kit software was used to extract radiomic features of PET/CT images and develop a radiomics signature. The models were established by radiomics, clinical features, and radiomics-clinical combination, respectively, the performance of which was calculated by receiver operating curves (ROCs) and compared by DeLong test. Moreover, based on radiomics score (Rad-score) and clinical features, a nomogram was established. Finally, we applied the combined model to evaluate TIME phenotypes of NSCLC patients in The Cancer Imaging Archive (TCIA) cohort (n = 39). ResultsTCGA data showed CD8 expression could represent the TIME profiles in NSCLC. In DPH cohort, PET/CT radiomics model outperformed CT model (AUC: 0.907 vs. 0.861, P = 0.0314) to predict CD8 expression. Further, PET/CT radiomics-clinical combined model (AUC = 0.932) outperformed PET/CT radiomics model (AUC = 0.907, P = 0.0326) or clinical model (AUC = 0.868, P = 0.0036) to predict CD8 expression. In the TCIA cohort, the predicted CD8-high group had significantly higher immune scores and more activated immune pathways than the predicted CD8-low group (P = 0.0421). ConclusionOur study indicates that F-18-FDG PET/CT radiomics-clinical combined model could be a clinically practical method to non-invasively detect the tumor immune status in NSCLCs.	[Tong, Haipeng; Sun, Jinju; Zhang, Mi; Xia, Renxiang; Zhou, Weicheng; Chen, Xiao] Army Med Univ, Daping Hosp, Dept Nucl Med, Chongqing, Peoples R China; [Tong, Haipeng; Fang, Jingqin] Army Med Univ, Daping Hosp, Dept Radiol, Chongqing, Peoples R China; [Fang, Jingqin; Chen, Xiao] Chongqing Clin Res Ctr Imaging & Nucl Med, Chongqing, Peoples R China; [Liu, Huan] GE Healthcare, Adv Applicat Team, Shanghai, Peoples R China; [Liu, Kaijun] Army Med Univ, Daping Hosp, Dept Gastroenterol, Chongqing, Peoples R China	Army Medical University; Army Medical University; General Electric; Army Medical University	Chen, X (corresponding author), Army Med Univ, Daping Hosp, Dept Nucl Med, Chongqing, Peoples R China.; Chen, X (corresponding author), Chongqing Clin Res Ctr Imaging & Nucl Med, Chongqing, Peoples R China.; Liu, KJ (corresponding author), Army Med Univ, Daping Hosp, Dept Gastroenterol, Chongqing, Peoples R China.	kliu_tmmu@126.com; xiaochen229@foxmail.com			Science and Technology Innovation Ability Enhancement Project of Army Medical University [2019XLC3054]; Natural Science Foundation of Chongqing [cstc2019jcyj-msxmX0123]; Talent Innovation Ability Training Program of Daping Hospital [2019CXLCC010]; National Natural Science Foundation of China [81801672]; Chongqing Clinical Research Centre of Imaging and Nuclear Medicine [CSTC2015YFPT-gcjsyjzx0175]	Science and Technology Innovation Ability Enhancement Project of Army Medical University; Natural Science Foundation of Chongqing(Natural Science Foundation of Chongqing); Talent Innovation Ability Training Program of Daping Hospital; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chongqing Clinical Research Centre of Imaging and Nuclear Medicine	This work was supported by grants from Science and Technology Innovation Ability Enhancement Project of Army Medical University (2019XLC3054), the Natural Science Foundation of Chongqing (cstc2019jcyj-msxmX0123), Talent Innovation Ability Training Program of Daping Hospital (2019CXLCC010), the National Natural Science Foundation of China (81801672), and Chongqing Clinical Research Centre of Imaging and Nuclear Medicine (CSTC2015YFPT-gcjsyjzx0175).	Aerts HJWL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5006; Aghighi M, 2018, CLIN CANCER RES, V24, P4110, DOI 10.1158/1078-0432.CCR-18-0673; Ansell SM, 2016, AM J HEMATOL, V91, P109, DOI 10.1002/ajh.24226; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Gajewski TF, 2017, ADV EXP MED BIOL, V1036, P19, DOI 10.1007/978-3-319-67577-0_2; Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y; Han Y, 2021, EUR J NUCL MED MOL I, V48, P350, DOI 10.1007/s00259-020-04771-5; Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Iravani A, 2020, J NUCL MED, V61, P943, DOI 10.2967/jnumed.119.234278; Jimenez-Sanchez A, 2017, CELL, V170, P927, DOI 10.1016/j.cell.2017.07.025; Kather JN, 2018, ELIFE, V7, DOI 10.7554/eLife.36967; Kim HY, 2018, ACS NANO, V12, P12015, DOI 10.1021/acsnano.8b04338; Kirienko M, 2021, EUR J NUCL MED MOL I, V48, P3643, DOI 10.1007/s00259-021-05371-7; Kuriyama K, 2020, CANCER SCI, V111, P1969, DOI 10.1111/cas.14421; Lambin P, 2017, NAT REV CLIN ONCOL, V14, P749, DOI 10.1038/nrclinonc.2017.141; Limkin EJ, 2017, ANN ONCOL, V28, P1191, DOI 10.1093/annonc/mdx034; Lin YC, 2020, EUR RADIOL, V30, P1297, DOI 10.1007/s00330-019-06467-3; Lin ZY, 2019, J CANCER, V10, P211, DOI 10.7150/jca.26444; Lindau D, 2012, IMMUNOLOGY, V137, P589, DOI 10.1111/imm.12036; Lopci E, 2016, EUR J NUCL MED MOL I, V43, P1954, DOI 10.1007/s00259-016-3425-2; Luker GD, 2021, RADIOLOGY, V298, P133, DOI 10.1148/radiol.2020203799; Mansfield AS, 2016, ANN ONCOL, V27, P1953, DOI 10.1093/annonc/mdw289; Martinez-Lostao L, 2015, CLIN CANCER RES, V21, P5047, DOI 10.1158/1078-0432.CCR-15-0685; Mazzaschi G, 2020, LUNG CANCER, V144, P30, DOI 10.1016/j.lungcan.2020.04.006; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McLaughlin J, 2016, JAMA ONCOL, V2, P46, DOI 10.1001/jamaoncol.2015.3638; Mezquita L, 2018, JAMA ONCOL, V4, P351, DOI 10.1001/jamaoncol.2017.4771; Munari E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.680973; Munari E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105123; Na KJ, 2018, J NUCL MED, V59, P31, DOI 10.2967/jnumed.117.194217; Newman JH, 2020, P NATL ACAD SCI USA, V117, P1119, DOI 10.1073/pnas.1904022116; Ng TSC, 2021, RADIOLOGY, V298, P123, DOI 10.1148/radiol.2020201791; Ock CY, 2016, CLIN CANCER RES, V22, P2261, DOI 10.1158/1078-0432.CCR-15-2834; Park C, 2020, THERANOSTICS, V10, P10838, DOI 10.7150/thno.50283; Pepe F, 2021, CANCER CYTOPATHOL, V129, P460, DOI 10.1002/cncy.22400; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Reinfeld BI, 2021, NATURE, V593, P282, DOI 10.1038/s41586-021-03442-1; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Sun R, 2018, LANCET ONCOL, V19, P1180, DOI 10.1016/S1470-2045(18)30413-3; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Wang Y, 2020, EUR J NUCL MED MOL I, V47, P1127, DOI 10.1007/s00259-019-04500-7; Wu CX, 2021, EUR J NUCL MED MOL I, V48, P4054, DOI 10.1007/s00259-021-05399-9; Zhu J, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.618374	48	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								859323	10.3389/fimmu.2022.859323	http://dx.doi.org/10.3389/fimmu.2022.859323			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0AX	35572597	gold, Green Published			2022-12-18	WOS:000796209300001
J	Toyoda, K; Matsuoka, M				Toyoda, Kosuke; Matsuoka, Masao			Functional and Pathogenic Roles of Retroviral Antisense Transcripts	FRONTIERS IN IMMUNOLOGY			English	Review						human T-cell leukemia virus type 1 (HTLV-1); HTLV-1 bZIP factor (HBZ); human immunodeficiency virus type 1 (HIV-1); bovine leukemia virus (BLV); long non-coding RNA (lncRNA)	T-CELL LEUKEMIA; HTLV-1 BZIP FACTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; LEUCINE-ZIPPER-FACTOR; FACTOR HBZ; SUPPORTS PROLIFERATION; PROTEINS HBZ; RNA; GENE; EXPRESSION	Exogenous retroviruses such as human immunodeficiency virus type 1 (HIV-1), human T-cell leukemia virus type 1 (HTLV-1) and bovine leukemia virus (BLV) can cause various diseases including immunodeficiency, inflammatory diseases and hematologic malignancies. These retroviruses persistently infect their hosts. Therefore, they need to evade host immune surveillance. One way in which these viruses might avoid immune detection is to utilize functional RNAs, rather than proteins, for certain activities, because RNAs are not recognized by the host immune system. HTLV-1 encodes the HTLV-1 bZIP factor (HBZ) gene in the antisense strand of the provirus. The HBZ protein is constantly expressed in HTLV-1 carriers and patients with adult T-cell leukemia-lymphoma, and it plays critical roles in pathogenesis. However, HBZ not only encodes this protein, but also functions as mRNA. Thus, HBZ gene mRNA is bifunctional. HIV-1 and BLV also encode long non-coding RNAs as antisense transcripts. In this review, we reshape our current understanding of how these antisense transcripts function and how they influence disease pathogenesis.	[Toyoda, Kosuke; Matsuoka, Masao] Kumamoto Univ, Fac Life Sci, Dept Hematol, Rheumatol & Infect Dis, Kumamoto, Japan	Kumamoto University	Matsuoka, M (corresponding author), Kumamoto Univ, Fac Life Sci, Dept Hematol, Rheumatol & Infect Dis, Kumamoto, Japan.	mamatsu@kumamoto-u.ac.jp						Arpin-Andre C, 2014, PLASMID, V74, P45, DOI 10.1016/j.plasmid.2014.06.001; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; Bet A, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0135-y; BUKRINSKY MI, 1990, AIDS RES HUM RETROV, V6, P425, DOI 10.1089/aid.1990.6.425; Caetano BFR, 2021, CANCER LETT, V499, P14, DOI 10.1016/j.canlet.2020.11.019; Campbell M, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00637-y; Cassan E, 2016, P NATL ACAD SCI USA, V113, P11537, DOI 10.1073/pnas.1605739113; Cavrois M, 1998, ONCOGENE, V17, P77, DOI 10.1038/sj.onc.1201906; Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008; Chen CYA, 2011, WIRES RNA, V2, P167, DOI 10.1002/wrna.40; Clerc I, 2008, J BIOL CHEM, V283, P23903, DOI 10.1074/jbc.M803116200; Cook LB, 2021, BLOOD, V137, P459, DOI 10.1182/blood.2019004045; Durkin K, 2016, RETROVIROLOGY, V13, DOI 10.1186/s12977-016-0267-8; Etoh K, 1997, CANCER RES, V57, P4862; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Gazon H, 2020, BLOOD ADV, V4, P5574, DOI 10.1182/bloodadvances.2020001675; Gazon H, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02686; Ge ZH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.699895; Gillet N, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-18; Gillet NA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005588; Grey F, 2007, PLOS PATHOG, V3, P1593, DOI 10.1371/journal.ppat.0030163; Hagiya K, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-19; Haller C, 2014, J VIROL, V88, P14241, DOI 10.1128/JVI.02333-14; Higuchi Y, 2020, P NATL ACAD SCI USA, V117, P13740, DOI 10.1073/pnas.1922884117; Hivin P, 2005, J CELL SCI, V118, P1355, DOI 10.1242/jcs.01727; Hivin P, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-14; Igakura T, 2003, SCIENCE, V299, P1713, DOI 10.1126/science.1080115; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200/JCO.2011.37.3472; Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018; Joller N, 2014, IMMUNITY, V40, P569, DOI 10.1016/j.immuni.2014.02.012; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; Khorkova O, 2014, HUM MOL GENET, V23, pR54, DOI 10.1093/hmg/ddu207; Kincaid RP, 2012, P NATL ACAD SCI USA, V109, P3077, DOI 10.1073/pnas.1116107109; Kinosada H, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006120; Kobayashi-Ishihara M, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-38; Kogure Y, 2022, BLOOD, V139, P967, DOI 10.1182/blood.2021013568; LAROCCA D, 1989, BIOCHEM BIOPH RES CO, V163, P1006, DOI 10.1016/0006-291X(89)92322-X; Laverdure S, 2012, J VIROL, V86, P13785, DOI 10.1128/JVI.01723-12; Lemasson I, 2007, J VIROL, V81, P1543, DOI 10.1128/JVI.00480-06; Ma GY, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2014783118; Malim MH, 2008, CELL HOST MICROBE, V3, P388, DOI 10.1016/j.chom.2008.04.008; Matsuoka M, 2020, RETROVIROLOGY, V17, DOI 10.1186/s12977-020-0511-0; Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-71; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; McCarthy N, 2004, NAT REV CANCER, V4, P837, DOI 10.1038/nrc1486; Mesnard JM, 2006, BLOOD, V108, P3979, DOI 10.1182/blood-2006-03-007732; MICHAEL NL, 1994, J VIROL, V68, P979, DOI 10.1128/JVI.68.2.979-987.1994; MILLER RH, 1988, SCIENCE, V239, P1420, DOI 10.1126/science.3347840; Mitobe Y, 2015, CANCER RES, V75, P4143, DOI 10.1158/0008-5472.CAN-15-0942; Munz C, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.657387; Munz C, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.605258; Murakami H, 2017, VIRUS RES, V238, P213, DOI 10.1016/j.virusres.2017.07.005; Murphy J, 2016, VIROLOGY, V494, P129, DOI 10.1016/j.virol.2016.04.012; Nakagawa M, 2014, J EXP MED, V211, P2497, DOI 10.1084/jem.20140987; Nakamura N, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.013243; Ohnuki N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83909-3; Ohshima T, 2010, J CELL BIOCHEM, V111, P187, DOI 10.1002/jcb.22687; Overbaugh J, 2001, SCIENCE, V292, P1106, DOI 10.1126/science.1059128; Pais-Correia AM, 2010, NAT MED, V16, P83, DOI 10.1038/nm.2065; Pengelly AR, 2013, SCIENCE, V339, P698, DOI 10.1126/science.1231382; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; Reinke AW, 2010, BIOCHEMISTRY-US, V49, P1985, DOI 10.1021/bi902065k; Rende F, 2011, BLOOD, V117, P4855, DOI 10.1182/blood-2010-11-316463; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; Rosewick N, 2013, P NATL ACAD SCI USA, V110, P2306, DOI 10.1073/pnas.1213842110; Saayman S, 2014, MOL THER, V22, P1164, DOI 10.1038/mt.2014.29; Safari R, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008502; Sato T, 2018, NEW ENGL J MED, V378, P529, DOI 10.1056/NEJMoa1704827; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Schurich A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00468; SCHWARTZ I, 1994, VET RES, V25, P521; Stanietsky N, 2009, P NATL ACAD SCI USA, V106, P17858, DOI 10.1073/pnas.0903474106; Stern-Ginossar N, 2007, SCIENCE, V317, P376, DOI 10.1126/science.1140956; Stewart M, 2019, J BIOL CHEM, V294, P2977, DOI 10.1074/jbc.REV118.005594; Sugata K, 2016, CANCER RES, V76, P5068, DOI 10.1158/0008-5472.CAN-16-0361; Sugata K, 2015, BLOOD, V126, P1095, DOI 10.1182/blood-2015-04-641118; Sun LY, 2021, MOL CELL, V81, P4493, DOI 10.1016/j.molcel.2021.08.033; Sun QY, 2018, TRENDS GENET, V34, P142, DOI 10.1016/j.tig.2017.11.005; Tagaya Yutaka, 2019, F1000Res, V8, DOI 10.12688/f1000research.17479.1; Tanaka A, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00461; VANHEEBROSSOLLET C, 1995, VIROLOGY, V206, P196, DOI 10.1016/S0042-6822(95)80034-4; Virgin HW, 2009, CELL, V138, P30, DOI 10.1016/j.cell.2009.06.036; Yamamoto-Taguchi N, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003630; Yasuma K, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005372; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Yoshie O, 2002, BLOOD, V99, P1505, DOI 10.1182/blood.V99.5.1505; Yoshie O, 2015, INT IMMUNOL, V27, P11, DOI 10.1093/intimm/dxu079; Zapata JC, 2017, VIROLOGY, V506, P34, DOI 10.1016/j.virol.2017.03.002; Zhao TJ, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-159; Zhao TJ, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00247; Zhao TJ, 2011, BLOOD, V118, P1865, DOI 10.1182/blood-2010-12-326199; Ziegelbauer JM, 2009, NAT GENET, V41, P130, DOI 10.1038/ng.266	95	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								875211	10.3389/fimmu.2022.875211	http://dx.doi.org/10.3389/fimmu.2022.875211			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G1MV	35572593	gold, Green Published			2022-12-18	WOS:000795620100001
J	van de Ven, R; Bifulco, CB; Luke, JJ; Church, SE				Van De Ven, Rieneke; Bifulco, Carlo B.; Luke, Jason J.; Church, Sarah E.			Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						tumor micreoenvironment (TME); lymphocyte exclusion; anti-tumor immune response; immune cell infiltration; immune suppression			[Van De Ven, Rieneke] Vrije Univ Amsterdam, Dept Otolaryngol Head & Neck Surg, Amsterdam UMC, Amsterdam, Netherlands; [Van De Ven, Rieneke] Canc Ctr Amsterdam, Amsterdam, Netherlands; [Van De Ven, Rieneke] Amsterdam Inst Infect & Immun, Amsterdam, Netherlands; [Bifulco, Carlo B.] Providence Genom & Earle A Chiles Res Inst, Portland, OR USA; [Bifulco, Carlo B.] Providence Canc Inst, Portland, OR USA; [Bifulco, Carlo B.] Providence Hlth & Serv Oregon, Dept Pathol, Portland, OR USA; [Luke, Jason J.] Univ Pittsburgh Med Ctr UPMC, Div Hematol Oncol, Hillman Canc Ctr, Pittsburgh, PA USA; [Luke, Jason J.] Univ Pittsburgh Med Ctr, Canc Immunotherapeut Ctr, Pittsburgh, PA USA; [Church, Sarah E.] NanoString Technol Inc, Seatlle, WA USA	University of Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Vrije Universiteit Amsterdam; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	van de Ven, R (corresponding author), Vrije Univ Amsterdam, Dept Otolaryngol Head & Neck Surg, Amsterdam UMC, Amsterdam, Netherlands.; van de Ven, R (corresponding author), Canc Ctr Amsterdam, Amsterdam, Netherlands.; van de Ven, R (corresponding author), Amsterdam Inst Infect & Immun, Amsterdam, Netherlands.; Church, SE (corresponding author), NanoString Technol Inc, Seatlle, WA USA.	R.vandeven@amsterdamumc.nl; church.immunology@gmail.com							0	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								908612	10.3389/fimmu.2022.908612	http://dx.doi.org/10.3389/fimmu.2022.908612			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H1BP	35572530	Green Published, gold			2022-12-18	WOS:000796281100001
J	York, J; Gowrishankar, K; Micklethwaite, K; Palmer, S; Cunningham, AL; Nasr, N				York, Jarrod; Gowrishankar, Kavitha; Micklethwaite, Kenneth; Palmer, Sarah; Cunningham, Anthony L.; Nasr, Najla			Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir via CAR T Cell Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						HIV-1; CD4; CD8; chimeric antigen receptor; latency; reactivation	ACTIVE ANTIRETROVIRAL THERAPY; ANTITUMOR-ACTIVITY; CLONAL EXPANSION; LATENT RESERVOIR; KILL STRATEGIES; PLASMA VIREMIA; I INTERFERONS; GENE-THERAPY; INFECTION; RECEPTOR	Although the advent of ART has significantly reduced the morbidity and mortality associated with HIV infection, the stable pool of HIV in latently infected cells requires lifelong treatment adherence, with the cessation of ART resulting in rapid reactivation of the virus and productive HIV infection. Therefore, these few cells containing replication-competent HIV, known as the latent HIV reservoir, act as the main barrier to immune clearance and HIV cure. While several strategies involving HIV silencing or its reactivation in latently infected cells for elimination by immune responses have been explored, exciting cell based immune therapies involving genetically engineered T cells expressing synthetic chimeric receptors (CAR T cells) are highly appealing and promising. CAR T cells, in contrast to endogenous cytotoxic T cells, can function independently of MHC to target HIV-infected cells, are efficacious and have demonstrated acceptable safety profiles and long-term persistence in peripheral blood. In this review, we present a comprehensive picture of the current efforts to target the HIV latent reservoir, with a focus on CAR T cell therapies. We highlight the current challenges and advances in this field, while discussing the importance of novel CAR designs in the efforts to find a HIV cure.	[York, Jarrod; Palmer, Sarah; Cunningham, Anthony L.; Nasr, Najla] Westmead Inst Med Res, Ctr Virus Res, Westmead, NSW, Australia; [York, Jarrod; Gowrishankar, Kavitha; Micklethwaite, Kenneth] Westmead Inst Med Res, Ctr Canc Res, Westmead, NSW, Australia; [Gowrishankar, Kavitha] Childrens Hosp Westmead, Sydney Childrens Hosp Network, Childrens Canc Res Unit, Kids Res, Westmead, NSW, Australia; [Gowrishankar, Kavitha; Micklethwaite, Kenneth; Palmer, Sarah; Cunningham, Anthony L.; Nasr, Najla] Univ Sydney, Sydney Inst Infect Dis, Fac Med & Hlth, Sch Med Sci, Sydney, NSW, Australia; [Micklethwaite, Kenneth] Westmead Hosp, Dept Haematol, Blood Transplant & Cell Therapies Program, Sydney, NSW, Australia; [Micklethwaite, Kenneth] Inst Clin Pathol & Med Res ICPMR Westmead, NSW Hlth Pathol Blood Transplant & Cell Therapies, Sydney, NSW, Australia	University of Sydney; Westmead Institute for Medical Research; University of Sydney; Westmead Institute for Medical Research; University of Sydney; University of Sydney; University of Sydney	Cunningham, AL; Nasr, N (corresponding author), Westmead Inst Med Res, Ctr Virus Res, Westmead, NSW, Australia.; Cunningham, AL; Nasr, N (corresponding author), Univ Sydney, Sydney Inst Infect Dis, Fac Med & Hlth, Sch Med Sci, Sydney, NSW, Australia.	tony.cunningham@sydney.edu.au; najla.nasr@sydney.edu.au		nasr, najla/0000-0001-6249-9204	Australian Centre for HIV and Hepatitis Virology Research (ACH2); Delaney AIDS Research Enterprise (DARE) - US National Institutes of Health [1UM1AI164560-01]; Australian National Health and Medical Research Council [APP1149990]	Australian Centre for HIV and Hepatitis Virology Research (ACH2); Delaney AIDS Research Enterprise (DARE) - US National Institutes of Health; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	The Westmead Institute for Medical Research paid for open access publication. JY was supported by a grant from the Australian Centre for HIV and Hepatitis Virology Research (ACH2) granted to AC, KM, NN and KG. SP was supported by the Delaney AIDS Research Enterprise (DARE) to Find a Cure funded by the US National Institutes of Health (1UM1AI164560-01) and the Australian National Health and Medical Research Council (APP1149990).	Ahlenstiel CL, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00474; Anthony-Gonda K, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav5685; Arts EJ, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007161; Ayala VI, 2017, J VIROL, V91, DOI 10.1128/JVI.02507-16; Bar KJ, 2016, NEW ENGL J MED, V375, P2037, DOI 10.1056/NEJMoa1608243; Barber-Axthelm IM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.141502; Barouch DH, 2013, NATURE, V503, P224, DOI 10.1038/nature12744; Barre-Sinoussi F, 2013, NAT REV MICROBIOL, V11, P877, DOI 10.1038/nrmicro3132; Beatty GL, 2018, GASTROENTEROLOGY, V155, P29, DOI 10.1053/j.gastro.2018.03.029; Bertram KM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10697-w; Bishop DC, 2018, MOL THER, V26, P1883, DOI 10.1016/j.ymthe.2018.05.007; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Boukli Nawal M, 2012, Clin Proteomics, V9, P11, DOI 10.1186/1559-0275-9-11; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Cartwright EK, 2016, IMMUNITY, V45, P656, DOI 10.1016/j.immuni.2016.08.018; Caruana I, 2015, NAT MED, V21, P524, DOI 10.1038/nm.3833; Caskey M, 2020, CURR OPIN HIV AIDS, V15, P49, DOI 10.1097/COH.0000000000000600; Chandrasekar AP, 2020, CLIN MICROBIOL REV, V33, DOI 10.1128/CMR.00107-19; Cherkassky L, 2016, J CLIN INVEST, V126, P3130, DOI 10.1172/JCI83092; Deeken JF, 2012, CLIN INFECT DIS, V55, P1228, DOI 10.1093/cid/cis613; Deeks SG, 2002, MOL THER, V5, P788, DOI 10.1006/mthe.2002.0611; Deeks SG, 2021, NAT MED, V27, P2085, DOI 10.1038/s41591-021-01590-5; Dirk BS, 2016, SCI REP-UK, V6, DOI 10.1038/srep37021; Doehle BP, 2012, J VIROL, V86, P8367, DOI 10.1128/JVI.00423-12; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Douek DC, 2002, NATURE, V417, P95, DOI 10.1038/417095a; Duette G, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI154422; Ferrari G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001273; Fry TJ, 2018, NAT MED, V24, P20, DOI 10.1038/nm.4441; Garrido C, 2018, J VIROL, V92, DOI 10.1128/JVI.00235-18; Gaudinski MR, 2019, LANCET HIV, V6, pE667, DOI 10.1016/S2352-3018(19)30181-X; Ghanem MH, 2018, CYTOTHERAPY, V20, P407, DOI 10.1016/j.jcyt.2017.11.001; Guedan S, 2019, MOL THER-METH CLIN D, V12, P145, DOI 10.1016/j.omtm.2018.12.009; Habib R, 2020, ADV EXP MED BIOL, V1263, P117, DOI 10.1007/978-3-030-44518-8_8; Hajduczki A, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00242; Hale M, 2017, MOL THER, V25, P570, DOI 10.1016/j.ymthe.2016.12.023; Halper-Stromberg A, 2016, J CLIN INVEST, V126, P415, DOI 10.1172/JCI80561; Hamilton JR, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109207; Haran KP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00492; Harman AN, 2015, J VIROL, V89, P6575, DOI 10.1128/JVI.00889-15; Helleberg M, 2015, J INFECT DIS, V211, P1726, DOI 10.1093/infdis/jiu669; Herzig E, 2019, CELL, V179, P880, DOI 10.1016/j.cell.2019.10.002; Huang SH, 2018, J CLIN INVEST, V128, P876, DOI [10.1172/jci97555, 10.1172/JCI97555]; Iwamoto N, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248973; JACOBSON JM, 1993, J INFECT DIS, V168, P298, DOI 10.1093/infdis/168.2.298; Jiang ZT, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.684016; Jin C, 2016, EMBO MOL MED, V8, P702, DOI 10.15252/emmm.201505869; Jin X, 1999, J EXP MED, V189, P991, DOI 10.1084/jem.189.6.991; Jones RB, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005545; Kaartinen T, 2017, CYTOTHERAPY, V19, P689, DOI 10.1016/j.jcyt.2017.03.067; Kessing CF, 2017, CELL REP, V21, P600, DOI 10.1016/j.celrep.2017.09.080; Kim Y, 2018, CELL HOST MICROBE, V23, P14, DOI 10.1016/j.chom.2017.12.004; Kloss CC, 2013, NAT BIOTECHNOL, V31, P71, DOI 10.1038/nbt.2459; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Lajoie MJ, 2020, SCIENCE, V369, P1637, DOI 10.1126/science.aba6527; Lal KG, 2017, J IMMUNOL, V198; Lanitis E, 2013, CANCER IMMUNOL RES, V1, P43, DOI 10.1158/2326-6066.CIR-13-0008; Lavender KJ, 2016, J VIROL, V90, P6001, DOI 10.1128/JVI.00451-16; Leibman RS, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006613; Leong YA, 2016, NAT IMMUNOL, V17, P1187, DOI 10.1038/ni.3543; Leslie AJ, 2004, NAT MED, V10, P282, DOI 10.1038/nm992; Li QS, 2009, NATURE, V458, P1034, DOI 10.1038/nature07831; Liu BF, 2016, J VIROL, V90, P9712, DOI 10.1128/JVI.00852-16; Liu HZ, 2009, J IMMUNOL, V183, P1022, DOI 10.4049/jimmunol.0900408; Liu L, 2015, J VIROL, V89, P6685, DOI 10.1128/JVI.00474-15; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Maldini CR, 2020, NAT MED, V26, P1776, DOI 10.1038/s41591-020-1039-5; Maldini CR, 2020, MOL THER, V28, P1585, DOI 10.1016/j.ymthe.2020.05.012; Marsden MD, 2018, VIROLOGY, V520, P83, DOI 10.1016/j.virol.2018.05.006; Massanella M, 2016, J CLIN INVEST, V126, P464, DOI 10.1172/JCI80567; Matusali G, 2013, FASEB J, V27, P2440, DOI 10.1096/fj.12-223057; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; McNab F, 2015, NAT REV IMMUNOL, V15, P87, DOI 10.1038/nri3787; Melenhorst JJ, 2022, NATURE, V602, P503, DOI 10.1038/s41586-021-04390-6; Mendoza P, 2018, NATURE, V561, P479, DOI 10.1038/s41586-018-0531-2; Mikulak J, 2017, AIDS, V31, P2317, DOI 10.1097/QAD.0000000000001645; Mitsuyasu RT, 2000, BLOOD, V96, P785, DOI 10.1182/blood.V96.3.785.015k10_785_793; MOORE JP, 1990, SCIENCE, V250, P1139, DOI 10.1126/science.2251501; Moriggl R, 1999, IMMUNITY, V11, P225, DOI 10.1016/S1074-7613(00)80097-7; Murray AJ, 2016, J IMMUNOL, V197, P407, DOI 10.4049/jimmunol.1600343; Nasr N, 2012, BLOOD, V120, P778, DOI 10.1182/blood-2012-01-407395; Neelapu SS, 2019, HEMATOL ONCOL, V37, P48, DOI 10.1002/hon.2595; O'Neil TR, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13030359; Oxenius A, 2000, P NATL ACAD SCI USA, V97, P3382, DOI 10.1073/pnas.97.7.3382; Pache L, 2015, CELL HOST MICROBE, V18, P345, DOI 10.1016/j.chom.2015.08.009; Palella FJ, 2006, JAIDS-J ACQ IMM DEF, V43, P27, DOI 10.1097/01.qai.0000233310.90484.16; Pampusch Mary S, 2022, Methods Mol Biol, V2421, P171, DOI 10.1007/978-1-0716-1944-5_12; Paszkiewicz PJ, 2016, J CLIN INVEST, V126, P4262, DOI 10.1172/JCI84813; Perdomo-Celis F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01896; Pestka S, 2004, IMMUNOL REV, V202, P8, DOI 10.1111/j.0105-2896.2004.00204.x; Petravic J, 2017, J VIROL, V91, DOI 10.1128/JVI.02092-16; Petrovas C, 2006, J EXP MED, V203, P2281, DOI 10.1084/jem.20061496; Rafiq S, 2020, NAT REV CLIN ONCOL, V17, P147, DOI 10.1038/s41571-019-0297-y; Rasmussen TA, 2016, TRENDS MICROBIOL, V24, P90, DOI 10.1016/j.tim.2015.11.003; Ren YQ, 2020, J CLIN INVEST, V130, P2542, DOI 10.1172/JCI132374; Rice AP, 2017, CURR PHARM DESIGN, V23, P4098, DOI 10.2174/1381612823666170704130635; Ringpis GEE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053492; Roberts ER, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006135; ROBERTS MR, 1994, BLOOD, V84, P2878; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; Roth TL, 2018, NATURE, V559, P405, DOI 10.1038/s41586-018-0326-5; Roybal KT, 2016, CELL, V167, P419, DOI 10.1016/j.cell.2016.09.011; Ruella M, 2016, J CLIN INVEST, V126, P3814, DOI 10.1172/JCI87366; Rupp LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00462-8; Sadowski I, 2019, CELL MOL LIFE SCI, V76, P3583, DOI 10.1007/s00018-019-03156-8; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Saez-Cirion A, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003211; Samri A, 2016, AIDS, V30, P2299, DOI 10.1097/QAD.0000000000001195; Sandler NG, 2014, NATURE, V511, P601, DOI 10.1038/nature13554; Schroder ARW, 2002, CELL, V110, P521, DOI 10.1016/S0092-8674(02)00864-4; Schweneker M, 2008, J IMMUNOL, V180, P6490, DOI 10.4049/jimmunol.180.10.6490; Seif M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02711; Shimabukuro-Vornhagen A, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0343-9; Sockolosky JT, 2018, SCIENCE, V359, P1037, DOI 10.1126/science.aar3246; Sonti S, 2021, VIRUS RES, V303, DOI 10.1016/j.virusres.2021.198523; Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504; Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08; Sun JC, 2004, NAT IMMUNOL, V5, P927, DOI 10.1038/ni1105; Takata H, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag1809; Thorlund K, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2683-3; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Tong O, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009522; Tsai A, 2017, J VIROL, V91, DOI [10.1128/JVI.02166-16, 10.1128/jvi.02166-16]; Turnbull EL, 2009, J IMMUNOL, V182, P7131, DOI 10.4049/jimmunol.0803658; Van der Sluis RM, 2020, J IMMUNOL, V204, P1242, DOI 10.4049/jimmunol.1901191; Vansant G, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010084; Vozzolo L, 2010, J BIOL CHEM, V285, P39314, DOI 10.1074/jbc.M110.155275; Walker RE, 2000, BLOOD, V96, P467; Walker-Sperling VE, 2016, EBIOMEDICINE, V8, P217, DOI 10.1016/j.ebiom.2016.04.019; Ward J, 2007, BLOOD, V110, P1207, DOI 10.1182/blood-2006-06-028175; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Witte K, 2010, CYTOKINE GROWTH F R, V21, P237, DOI 10.1016/j.cytogfr.2010.04.002; Xiao QQ, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00069; Yang OO, 1997, P NATL ACAD SCI USA, V94, P11478, DOI 10.1073/pnas.94.21.11478; Yoon DH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020340; Zhang P, 2019, CLIN CANCER RES, V25, P1749, DOI 10.1158/1078-0432.CCR-18-3069; Zhen Anjie, 2017, PLoS Pathog, V13, pe1006753, DOI 10.1371/journal.ppat.1006753	138	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 29	2022	13								873701	10.3389/fimmu.2022.873701	http://dx.doi.org/10.3389/fimmu.2022.873701			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G7VG	35572509	Green Published, gold			2022-12-18	WOS:000796057900001
J	Ghione, S; Racoeur, C; Mabrouk, N; Shan, JX; Groetz, E; Ballot, E; Truntzer, C; Chouchane, L; Vegran, F; Paul, C; Plenchette, S; Bettaieb, A				Ghione, Silvia; Racoeur, Cindy; Mabrouk, Nesrine; Shan, Jingxuan; Groetz, Emma; Ballot, Elise; Truntzer, Caroline; Chouchane, Lotfi; Vegran, Frederique; Paul, Catherine; Plenchette, Stephanie; Bettaieb, Ali			Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						H89; kinase inhibitor; colorectal cancer; immunotherapy; immunoprophylaxis	ESMO CONSENSUS GUIDELINES; GLYCERYL TRINITRATE; ANTITUMOR; CELLS; SUPPRESSION; MANAGEMENT; PROGNOSIS; PREDICT; MODELS	Immunotherapy has allowed major advances in oncology in the past years, in particular with the development of immune checkpoint inhibitors, but the clinical benefits are still limited, particularly in colorectal cancer (CRC). Our scientific approach is based on the search for innovative immunotherapy with a final goal that aims to induce an effective antitumor immune response in CRC. Here, we focused on a multikinase inhibitor, H89. We carried out in vivo experiments based on syngeneic mouse models of colon cancer in BALB/c mice and chemically colon tumorigenesis. Flow cytometry, RNAseq, RT-qPCR, antibody-specific immune cell depletion, and Western blot were used to identify the immune cell type involved in the preventive and antitumor activity of H89. We demonstrated that H89 delays colon oncogenesis and prevents tumor growth. This latter effect seems to involve NK cells. H89 also inhibits colon tumor growth in a T-cell-dependent manner. Analysis of the immune landscape in the tumor microenvironment showed an increase of CD4(+) Th1 cells and CD8(+) cytotoxic T cells but a decrease of CD4(+) T-reg cell infiltration. Mechanistically, we showed that H89 could promote naive CD4(+) T-cell differentiation into Th1, a decrease in T-reg differentiation, and an increase in CD8(+) T-cell activation and cytotoxicity ex vivo. Furthermore, H89 induced overexpression of genes involved in antitumor immune response, such as IL-15RA, which depletion counteracts the antitumor effect of H89. We also found that H89 regulated Akt/PP2A pathway axis, involved in TCR and IL-15 signaling transduction. Our findings identify the H89 as a potential strategy for immune system activation leading to the prevention and treatment of CRC.	[Ghione, Silvia; Racoeur, Cindy; Mabrouk, Nesrine; Groetz, Emma; Paul, Catherine; Plenchette, Stephanie; Bettaieb, Ali] Univ Bourgogne Franche Comte, Lab Immunol & Immunotherapie Canc LIIC, EA7269, Dijon, France; [Ghione, Silvia; Racoeur, Cindy; Mabrouk, Nesrine; Groetz, Emma; Paul, Catherine; Plenchette, Stephanie; Bettaieb, Ali] Paris Sci & Lettres PSL Res Univ, Ecole Prat Hautes Etud EPHE, LIIC, Paris, France; [Shan, Jingxuan; Chouchane, Lotfi] Qatar Fdn, Genet Intelligence Lab, Weill Cornell Med Qatar, Doha, Qatar; [Ballot, Elise; Truntzer, Caroline; Vegran, Frederique] Ctr Georges Francois Leclerc, Plateforme Transfert Biol Cancerol, Dijon, France; [Ballot, Elise; Truntzer, Caroline; Vegran, Frederique] Inst Natl Sante & Rech Medicale INSERM, Team CAdIR, U1231, Lipids Nutrit & Canc, Dijon, France; [Vegran, Frederique] Univ Burgundy & Franche Comte, Dijon, France	Universite de Bourgogne; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Qatar Foundation (QF); Weill Cornell Medical College Qatar; UNICANCER; Centre Georges-Francois Leclerc; Institut Agro; AgroSup Dijon; Universite de Bourgogne	Plenchette, S; Bettaieb, A (corresponding author), Paris Sci & Lettres PSL Res Univ, Ecole Prat Hautes Etud EPHE, LIIC, Paris, France.	stephanie.plenchette-colas@ephe.psl.eu; ali.bettaieb@ephe.psl.eu	Paul, Catherine/F-8376-2019	Paul, Catherine/0000-0002-7657-5535; /0000-0001-6187-2142	La Ligue Contre le CancerConference de Coordination InterRegionale Est (CCIR Est) [2021-0093]; Department of Genetic Medicine, Weill Cornell Medicine-Qatar (Qatar Foundation, Doha, Qatar) [NRP9-459-3-090]; University of Burgundy; EPHE	La Ligue Contre le CancerConference de Coordination InterRegionale Est (CCIR Est); Department of Genetic Medicine, Weill Cornell Medicine-Qatar (Qatar Foundation, Doha, Qatar)(Qatar Foundation (QF)); University of Burgundy; EPHE	This work was supported by the "La Ligue Contre le CancerConference de Coordination InterRegionale Est (CCIR Est) under grant No. 2021-0093; the Department of Genetic Medicine, Weill Cornell Medicine-Qatar (Qatar Foundation, Doha, Qatar) under grant No. NRP9-459-3-090; and the University of Burgundy and EPHE.	Abou-Elkacem L, 2013, MOL CANCER THER, V12, P1322, DOI 10.1158/1535-7163.MCT-12-1162; Ali-Boina R., 2013, J CARCINOG MUTAGEN, VS8, P004, DOI [10.4172/2157-2518.S8-004, DOI 10.4172/2157-2518.S8-004]; Bender U, 2019, CURR ONCOL, V26, pS43, DOI 10.3747/co.26.5605; Bernard A, 2021, CANCER IMMUNOL RES, V9, P324, DOI 10.1158/2326-6066.CIR-19-0679; Bouaouiche S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168449; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Buque A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17644-0; Castle JC, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-190; Cheeseman SL, 2002, BRIT J CANCER, V87, P393, DOI 10.1038/sj.bjc.6600467; Cortier M, 2015, ONCOTARGET, V6, P6877, DOI 10.18632/oncotarget.3124; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Desbois M, 2016, J IMMUNOL, V197, P168, DOI 10.4049/jimmunol.1600019; Dumortier C, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8122039; E JF, 2018, HUM IMMUNOL, V79, P446, DOI 10.1016/j.humimm.2018.03.003; Eil R, 2016, NATURE, V537, P539, DOI 10.1038/nature19364; Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Guan Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00586; Guo Y, 2017, CYTOKINE GROWTH F R, V38, P10, DOI 10.1016/j.cytogfr.2017.08.002; Harnik Y, 2021, NAT METAB, V3, P1680, DOI 10.1038/s42255-021-00504-6; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; Karin N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00976; Li L, 2017, INT J CLIN EXP PATHO, V10, P11603; Marais A, 2014, NAT IMMUNOL, V15, P749, DOI 10.1038/ni.2936; Marisa L, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx136; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899; Ocansey DKW, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-02922-2; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Rosenberg DW, 2009, CARCINOGENESIS, V30, P183, DOI 10.1093/carcin/bgn267; Schmieder R, 2014, INT J CANCER, V135, P1487, DOI 10.1002/ijc.28669; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shresta S, 1998, CURR OPIN IMMUNOL, V10, P581, DOI 10.1016/S0952-7915(98)80227-6; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; SWAIN SL, 1995, J LEUKOCYTE BIOL, V57, P795, DOI 10.1002/jlb.57.5.795; Tay RE, 2021, CANCER GENE THER, V28, P5, DOI 10.1038/s41417-020-0183-x; Tirapu I, 2006, CANCER RES, V66, P2442, DOI 10.1158/0008-5472.CAN-05-1681; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260; Vanpouille-Box C, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1373237; Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690; Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z; Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738; Zhang JL, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1177690; Zhang JF, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190884	47	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								875764	10.3389/fimmu.2022.875764	http://dx.doi.org/10.3389/fimmu.2022.875764			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G5LP	35572581	Green Published, gold			2022-12-18	WOS:000795889600001
J	Guo, HD; Wang, M; Wang, BX; Guo, LP; Cheng, YF; Wang, ZD; Sun, YQ; Wang, Y; Chang, YJ; Huang, XJ				Guo, Huidong; Wang, Ming; Wang, Bixia; Guo, Liping; Cheng, Yifei; Wang, Zhidong; Sun, Yu-Qian; Wang, Yu; Chang, Ying-Jun; Huang, Xiao-Jun			PRDM1 Drives Human Primary T Cell Hyporesponsiveness by Altering the T Cell Transcriptome and Epigenome	FRONTIERS IN IMMUNOLOGY			English	Article						PRDM1; multiomics; T cell hyporesponsiveness; HSCT; GvHD	FACTOR BATF CONTROLS; REPRESSOR BLIMP-1; B-CELLS; DIFFERENTIATION; EXPRESSION; FOXP3; HOMEOSTASIS; REGULATORS; RECEPTORS; INSIGHTS	T cell hyporesponsiveness is crucial for the functional immune system and prevents the damage induced by alloreactive T cells in autoimmune pathology and transplantation. Here, we found low expression of PRDM1 in T cells from donor and recipients both related to the occurrence of acute graft-versus-host disease (aGVHD). Our systematic multiomics analysis found that the transcription factor PRDM1 acts as a master regulator during inducing human primary T cell hyporesponsiveness. PRDM1-overexpression in primary T cells expanded Treg cell subset and increased the expression level of FOXP3, while decreased expression had the opposite effects. Moreover, the binding motifs of key T cell function regulators, such as FOS, JUN and AP-1, were enriched in PRDM1 binding sites and that PRDM1 altered the chromatin accessibility of these regions. Multiomics analysis showed that PRDM1 directly upregulated T cell inhibitory genes such as KLF2 and KLRD1 and downregulated the T cell activation gene IL2, indicating that PRDM1 could promote a tolerant transcriptional profile. Further analysis showed that PRDM1 upregulated FOXP3 expression level directly by binding to FOXP3 upstream enhancer region and indirectly by upregulating KLF2. These results indicated that PRDM1 is sufficient for inducing human primary T cell hyporesponsiveness by transcriptomic and epigenetic manners.	[Guo, Huidong; Guo, Liping; Cheng, Yifei; Wang, Zhidong; Sun, Yu-Qian; Wang, Yu; Chang, Ying-Jun; Huang, Xiao-Jun] Peking Univ, Peoples Hosp, Beijing, Peoples R China; [Guo, Huidong; Guo, Liping; Cheng, Yifei; Wang, Zhidong; Sun, Yu-Qian; Wang, Yu; Chang, Ying-Jun; Huang, Xiao-Jun] Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China; [Wang, Ming; Wang, Bixia; Huang, Xiao-Jun] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China; [Huang, Xiao-Jun] Peking Univ, Sch Life Sci, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China; [Huang, Xiao-Jun] Chinese Acad Med Sci, Res Unit Key Tech Diag & Treatments Hematol Malig, Beijing, Peoples R China	Peking University; Peking University; Southern Medical University - China; Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College	Huang, XJ (corresponding author), Peking Univ, Peoples Hosp, Beijing, Peoples R China.; Huang, XJ (corresponding author), Peking Univ, Inst Hematol, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China.; Huang, XJ (corresponding author), Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China.; Huang, XJ (corresponding author), Peking Univ, Sch Life Sci, Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China.; Huang, XJ (corresponding author), Chinese Acad Med Sci, Res Unit Key Tech Diag & Treatments Hematol Malig, Beijing, Peoples R China.	xjhrm@medmail.com.cn						Andre P, 2018, CELL, V175, P1731, DOI 10.1016/j.cell.2018.10.014; Bailey-Bucktrout SL, 2013, IMMUNITY, V39, P949, DOI 10.1016/j.immuni.2013.10.016; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Bikoff EK, 2009, CURR OPIN GENET DEV, V19, P379, DOI 10.1016/j.gde.2009.05.005; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Chen ZY, 2021, CELL, V184, P1262, DOI 10.1016/j.cell.2021.02.019; Cimmino L, 2008, J IMMUNOL, V181, P2338, DOI 10.4049/jimmunol.181.4.2338; Cretney E, 2011, NAT IMMUNOL, V12, P304, DOI 10.1038/ni.2006; Desmots F, 2019, CLIN CANCER RES, V25, P735, DOI 10.1158/1078-0432.CCR-18-1153; Dixon ML, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01450-3; Filipovich AH, 2005, BIOL BLOOD MARROW TR, V11, P945, DOI 10.1016/j.bbmt.2005.09.004; Fu SH, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0354-8; Furlong EEM, 2018, SCIENCE, V361, P1341, DOI 10.1126/science.aau0320; Garg G, 2019, CELL REP, V26, P1854, DOI 10.1016/j.celrep.2019.01.070; Gong DP, 2007, J IMMUNOL, V178, P242, DOI 10.4049/jimmunol.178.1.242; Gustafson CE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00692; Ise W, 2011, NAT IMMUNOL, V12, P536, DOI 10.1038/ni.2037; Johnston RJ, 2009, SCIENCE, V325, P1006, DOI 10.1126/science.1175870; Kallies A, 2006, NAT IMMUNOL, V7, P466, DOI 10.1038/ni1321; Kamiya T, 2019, J CLIN INVEST, V129, P2094, DOI 10.1172/JCI123955; Kawakami R, 2021, IMMUNITY, V54, P947, DOI 10.1016/j.immuni.2021.04.005; Kaya-Okur HS, 2020, NAT PROTOC, V15, P3264, DOI 10.1038/s41596-020-0373-x; Kaya-Okur HS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09982-5; Kim S, 2019, MOL CELL, V76, P306, DOI 10.1016/j.molcel.2019.08.010; Lebbink RJ, 2007, MOL IMMUNOL, V44, P2153, DOI 10.1016/j.molimm.2006.11.014; Li R., 2020, BIORXIV, DOI [10.1101/2020.03.11.988253, DOI 10.1101/2020.03.11.988253]; Ma J, 2016, LEUKEMIA, V30, P594, DOI 10.1038/leu.2015.285; Marrone G, 2015, GUT, V64, P1434, DOI 10.1136/gutjnl-2014-308338; Martins GA, 2006, NAT IMMUNOL, V7, P457, DOI 10.1038/ni1320; Martins GA, 2008, J EXP MED, V205, P1959, DOI 10.1084/jem.20080526; Nutt SL, 2007, NAT REV IMMUNOL, V7, P923, DOI 10.1038/nri2204; Ogawa C, 2018, CELL REP, V25, P19, DOI 10.1016/j.celrep.2018.09.016; Ohkura N, 2011, NAT IMMUNOL, V12, P283, DOI 10.1038/ni0411-283; Pabbisetty SK, 2016, P NATL ACAD SCI USA, V113, pE4662, DOI 10.1073/pnas.1605849113; Pabbisetty SK, 2014, P NATL ACAD SCI USA, V111, P9579, DOI 10.1073/pnas.1323493111; Patterson SJ, 2016, J CLIN INVEST, V126, P1039, DOI 10.1172/JCI83987; Pertea M, 2016, NAT PROTOC, V11, P1650, DOI 10.1038/nprot.2016.095; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Wang AYL, 2018, MOL IMMUNOL, V99, P53, DOI 10.1016/j.molimm.2018.04.004; Xin A, 2016, NAT IMMUNOL, V17, P422, DOI 10.1038/ni.3410; Yoshikawa T, 2022, BLOOD, V139, P2156, DOI 10.1182/blood.2021012714; Zhang P, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aah7152	47	0	0	10	16	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								879501	10.3389/fimmu.2022.879501	http://dx.doi.org/10.3389/fimmu.2022.879501			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F0EF	35572579	gold, Green Published			2022-12-18	WOS:000794849200001
J	Jamerson, TA; Li, QMG; Sreeskandarajan, S; Budunova, IV; He, Z; Kang, J; Gudjonsson, JE; Patrick, MT; Tsoi, LC				Jamerson, Taylor A.; Li, Qinmengge; Sreeskandarajan, Sutharzan; Budunova, Irina V.; He, Zhi; Kang, Jian; Gudjonsson, Johann E.; Patrick, Matthew T.; Tsoi, Lam C.			Roles Played by Stress-Induced Pathways in Driving Ethnic Heterogeneity for Inflammatory Skin Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						African America; psoriasis; atopic dermatitis; stress; minority	ATOPIC-DERMATITIS; AFRICAN-AMERICANS; HEALTH-CARE; PSORIASIS; INTERLEUKIN-18; DISCRIMINATION; ASSOCIATION; PREVALENCE; EXPRESSION; IL-18	Immune-mediated skin conditions (IMSCs) are a diverse group of autoimmune diseases associated with significant disease burden. Atopic dermatitis and psoriasis are among the most common IMSCs in the United States and have disproportionate impact on racial and ethnic minorities. African American patients are more likely to develop atopic dermatitis compared to their European American counterparts; and despite lower prevalence of psoriasis among this group, African American patients can suffer from more extensive disease involvement, significant post-inflammatory changes, and a decreased quality of life. While recent studies have been focused on understanding the heterogeneity underlying disease mechanisms and genetic factors at play, little emphasis has been put on the effect of psychosocial or psychological stress on immune pathways, and how these factors contribute to differences in clinical severity, prevalence, and treatment response across ethnic groups. In this review, we explore the heterogeneity of atopic dermatitis and psoriasis between African American and European American patients by summarizing epidemiological studies, addressing potential molecular and environmental factors, with a focus on the intersection between stress and inflammatory pathways.							National Psoriasis Foundation; National Institutes of Health [K01AR072129, 1P30AR075043]; Dermatology Foundation	National Psoriasis Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dermatology Foundation	Funding This work was supported by the National Psoriasis Foundation (LT, MP, and JG), and awards from the National Institutes of Health (K01AR072129 to LT; 1P30AR075043 to LT, MP, and JG). MP, LT, TJ were also supported by the Dermatology Foundation.	AAD, 2016, BURD SKIN DIS; Abuabara K, 2020, J ALLERGY CLIN IMMUN, V145, P192, DOI 10.1016/j.jaci.2019.06.044; Alexis Andrew F, 2014, J Clin Aesthet Dermatol, V7, P16; Alexopoulos A, 2016, REV ENDOCR METAB DIS, V17, P295, DOI 10.1007/s11154-016-9367-y; Almoguera B, 2019, J ALLERGY CLIN IMMUN, V143, P1229, DOI 10.1016/j.jaci.2018.10.038; Bath KG, 2013, NEUROSCIENCE, V239, P149, DOI 10.1016/j.neuroscience.2013.01.074; Baurecht H, 2015, AM J HUM GENET, V96, P104, DOI 10.1016/j.ajhg.2014.12.004; Bejaoui Y, 2019, EXP DERMATOL, V28, P623, DOI 10.1111/exd.13926; Brondolo E, 2005, J APPL SOC PSYCHOL, V35, P335, DOI 10.1111/j.1559-1816.2005.tb02124.x; Brunner PM, 2019, ANN ALLERG ASTHMA IM, V122, P449, DOI 10.1016/j.anai.2018.11.015; Brunoni AR, 2015, BRAZ J MED BIOL RES, V48, P711, DOI 10.1590/1414-431X20154574; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; CDC, 2017, HEALTH-LONDON; de Brouwer SJM, 2014, BRIT J DERMATOL, V170, P824, DOI 10.1111/bjd.12697; Fan X, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000038; Furue M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155382; Gao PS, 2012, J INVEST DERMATOL, V132, P650, DOI 10.1038/jid.2011.374; Gelfand JM, 2005, J AM ACAD DERMATOL, V52, P23, DOI 10.1016/j.jaad.2004.07.045; Gutowska-Owsiak D, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0407-2; Hanifin IM, 2007, DERMATITIS, V18, P82, DOI 10.2310/6620.2007.06034; Iskandar IYK, 2021, BRIT J DERMATOL, V184, P243, DOI 10.1111/bjd.19169; Kantor R, 2017, EXPERT REV CLIN IMMU, V13, P15, DOI 10.1080/1744666X.2016.1212660; Kaufman BP, 2018, AM J CLIN DERMATOL, V19, P405, DOI 10.1007/s40257-017-0332-7; Kaufman BP, 2018, EXP DERMATOL, V27, P340, DOI 10.1111/exd.13514; Kerr GS, 2015, CLIN RHEUMATOL, V34, P1753, DOI 10.1007/s10067-014-2763-3; Klopot A, 2022, J INVEST DERMATOL, V142, P1360, DOI 10.1016/j.jid.2021.09.031; Knight J, 2012, HUM MOL GENET, V21, P5185, DOI 10.1093/hmg/dds344; Lebre MC, 2003, J INVEST DERMATOL, V120, P990, DOI 10.1046/j.1523-1747.2003.12245.x; Lee C, 2009, ETHNIC DIS, V19, P330; Li BS, 2014, J INVEST DERMATOL, V134, P1828, DOI 10.1038/jid.2014.28; Lili LN, 2019, J INVEST DERMATOL, V139, P2281, DOI 10.1016/j.jid.2019.04.021; Lin TK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102131; Liu PZ, 2018, CURR GENOMICS, V19, P653, DOI 10.2174/1389202919666171228164350; Margolis DJ, 2014, J ALLERGY CLIN IMMUN, V133, P784, DOI 10.1016/j.jaci.2013.09.015; Margolis DJ, 2012, J ALLERGY CLIN IMMUN, V130, P912, DOI 10.1016/j.jaci.2012.07.008; McMichael AJ, 2012, J DRUGS DERMATOL, V11, P478; Mizawa M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/138027; Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Nevid JS., 2007, PSYCHOL CHALLENGES L, V10th; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ogawa K, 2020, J DERMATOL SCI, V99, P2, DOI 10.1016/j.jdermsci.2020.05.008; Parisi R, 2013, J INVEST DERMATOL, V133, P377, DOI 10.1038/jid.2012.339; Park HJ, 2005, J INVEST DERMATOL, V124, P751, DOI 10.1111/j.0022-202X.2005.23656.x; Patrick MT, 2021, J INVEST DERMATOL, V141, P1493, DOI 10.1016/j.jid.2020.11.025; Patrick MT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06672-6; Peek ME, 2011, MED CARE, V49, P618, DOI 10.1097/MLR.0b013e318215d925; Prescott SL, 2017, WORLD ALLERGY ORGAN, V10, DOI 10.1186/s40413-017-0160-5; Rachakonda TD, 2014, J AM ACAD DERMATOL, V70, P512, DOI 10.1016/j.jaad.2013.11.013; Roth W, 2012, J CELL SCI, V125, P5269, DOI 10.1242/jcs.116574; Sarkar MK, 2017, J INVEST DERMATOL, V137, P1474, DOI 10.1016/j.jid.2017.02.972; Schmeer KK, 2018, J HEALTH SOC BEHAV, V59, P411, DOI 10.1177/0022146518784592; Silverberg JI, 2017, DERMATOL CLIN, V35, P283, DOI 10.1016/j.det.2017.02.002; Sollberger G, 2018, SCI IMMUNOL, V3, DOI 10.1126/sciimmunol.aar6689; Suarez AL, 2012, ACTA DERM-VENEREOL, V92, P7, DOI 10.2340/00015555-1188; Tackett KJ, 2020, PEDIATR DERMATOL, V37, P142, DOI 10.1111/pde.14058; Truzzi F, 2011, CELL DEATH DIFFER, V18, P948, DOI 10.1038/cdd.2010.162; Tsoi LC, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139558; Tsoi LC, 2020, J ALLERGY CLIN IMMUN, V145, P1406, DOI 10.1016/j.jaci.2019.11.047; Tsoi LC, 2019, J INVEST DERMATOL, V139, P1480, DOI 10.1016/j.jid.2018.12.018; Tsoi LC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15382; Tsoi LC, 2012, NAT GENET, V44, P1341, DOI 10.1038/ng.2467; Uppala R, 2021, CELL MOL IMMUNOL, V18, P307, DOI 10.1038/s41423-020-0519-3; Vachiramon V, 2012, PEDIATR DERMATOL, V29, P395, DOI 10.1111/j.1525-1470.2012.01740.x; Vasiadi M, 2012, J ALLERGY CLIN IMMUN, V129, P1410, DOI 10.1016/j.jaci.2012.01.041; Vojdani A, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/437231; Wang D, 2008, ARTHRITIS RHEUM, V58, P3205, DOI 10.1002/art.23868; Wittmann M, 2009, AUTOIMMUN REV, V9, P45, DOI 10.1016/j.autrev.2009.03.003; Wongvibulsin S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90105-w; Yin XY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7916; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; Zbytek B, 2003, J INVEST DERMATOL, V121, P1496, DOI 10.1111/j.1523-1747.2003.12612.x; Zedan K, 2015, J CLIN DIAGN RES, V9, pWC1, DOI 10.7860/JCDR/2015/12261.5742; Zhu YQ, 2021, J INVEST DERMATOL, V141, P1855, DOI 10.1016/j.jid.2020.12.022	75	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								845655	10.3389/fimmu.2022.845655	http://dx.doi.org/10.3389/fimmu.2022.845655			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C2VB	35572606	gold, Green Published			2022-12-18	WOS:000881877600001
J	Kim, JS; Kim, HK; Cho, E; Mun, SJ; Jang, S; Jang, J; Yang, CS				Kim, Jae-Sung; Kim, Hyo Keun; Cho, Euni; Mun, Seok-Jun; Jang, Sein; Jang, Jichan; Yang, Chul-Su			PE_PGRS38 Interaction With HAUSP Downregulates Antimycobacterial Host Defense via TRAF6	FRONTIERS IN IMMUNOLOGY			English	Article						Mycobacterium tuberculosis PE_PGRS38; Mycobacterium smegmatis; HAUSP; TRAF6; Macrophages; Ubiquitination	UBIQUITIN-SPECIFIC PROTEASE; PE-PGRS PROTEINS; MYCOBACTERIUM-TUBERCULOSIS; INTRACELLULAR SURVIVAL; INNATE IMMUNITY; SMEGMATIS; MACROPHAGE; GENE; DEUBIQUITINASE; INHIBITION	Mycobacterium tuberculosis (Mtb) is the causative pathogen of tuberculosis (TB), which manipulates the host immunity to ensure survival and colonization in the host. Mtb possess a unique family of proteins, named PE_PGRS, associated with Mtb pathogenesis. Thus, elucidation of the functions of PE_PGRS proteins is necessary to understand TB pathogenesis. Here, we investigated the role of PE_PGRS38 binding to herpesvirus-associated ubiquitin-specific protease (HAUSP, USP7) in regulating the activity of various substrate proteins by modulating their state of ubiquitination. We constructed the recombinant PE_PGRS38 expressed in M. smegmatis (Ms_PE_PGRS38) to investigate the role of PE_PGRS38. We found that Ms_PE_PGRS38 regulated the cytokine levels in murine bone marrow-derived macrophages by inhibiting the deubiquitination of tumor necrosis factor receptor-associated factor (TRAF) 6 by HAUSP. Furthermore, the PE domain in PE_PGRS38 was identified as essential for mediating TRAF6 deubiquitination. Ms_PE_PGRS38 increased the intracellular burden of bacteria by manipulating cytokine levels in vitro and in vivo. Overall, we revealed that the interplay between HAUSP and PE_PGRS38 regulated the inflammatory response to increase the survival of mycobacteria.	[Kim, Jae-Sung; Cho, Euni; Mun, Seok-Jun] Hanyang Univ, Dept Bionano Technol, Seoul, South Korea; [Kim, Jae-Sung] Hanyang Univ, Inst Nat Sci & Technol, Ansan, South Korea; [Kim, Hyo Keun; Jang, Sein; Yang, Chul-Su] Hanyang Univ, Dept Mol & Life Sci, Ansan, South Korea; [Kim, Hyo Keun; Cho, Euni; Mun, Seok-Jun; Jang, Sein; Yang, Chul-Su] Hanyang Univ, Ctr Bionano Intelligence Educ & Res, Ansan, South Korea; [Jang, Jichan] Gyeongsang Natl Univ, Res Inst Life Sci, Dept Bio & Med Big Data, Brain Korea Four Program 21, Jinju, South Korea	Hanyang University; Hanyang University; Hanyang University; Hanyang University; Gyeongsang National University	Yang, CS (corresponding author), Hanyang Univ, Dept Mol & Life Sci, Ansan, South Korea.; Yang, CS (corresponding author), Hanyang Univ, Ctr Bionano Intelligence Educ & Res, Ansan, South Korea.; Jang, J (corresponding author), Gyeongsang Natl Univ, Res Inst Life Sci, Dept Bio & Med Big Data, Brain Korea Four Program 21, Jinju, South Korea.	jichanjang@gnu.ac.kr; chulsuyang@hanyang.ac.kr						Abramovitch RB, 2011, MOL MICROBIOL, V80, P678, DOI 10.1111/j.1365-2958.2011.07601.x; Bansal K, 2010, J IMMUNOL, V184, P3495, DOI 10.4049/jimmunol.0903299; Banu S, 2002, MOL MICROBIOL, V44, P9, DOI 10.1046/j.1365-2958.2002.02813.x; Bhattacharya S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0012-y; Buchweitz JP, 2007, J PHARMACOL EXP THER, V323, P675, DOI 10.1124/jpet.107.124719; Chai QY, 2020, CELL MOL LIFE SCI, V77, P1859, DOI 10.1007/s00018-019-03353-5; Chai QY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09955-8; Chaturvedi R, 2010, J BIOL CHEM, V285, P30389, DOI 10.1074/jbc.M110.135251; Chavoshi S, 2016, J BIOL CHEM, V291, P6281, DOI 10.1074/jbc.M115.710632; Chen TA, 2010, MICROB PATHOGENESIS, V49, P311, DOI 10.1016/j.micpath.2010.07.004; Ching W, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003273; Cohen I, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00236; Coombs N, 2011, INT J MED MICROBIOL, V301, P213, DOI 10.1016/j.ijmm.2010.09.004; Cummins JM, 2004, NATURE, V428, DOI 10.1038/nature02501; De Maio F, 2020, VIRULENCE, V11, P898, DOI 10.1080/21505594.2020.1785815; Deb C, 2006, J BIOL CHEM, V281, P3866, DOI 10.1074/jbc.M505556200; Delogu G, 2004, MOL MICROBIOL, V52, P725, DOI 10.1111/j.1365-2958.2004.04007.x; Deng WY, 2017, SCI REP-UK, V7, DOI 10.1038/srep46716; Dheenadhayalan V, 2006, MICROBES INFECT, V8, P262, DOI 10.1016/j.micinf.2005.06.021; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Grover S, 2018, MBIO, V9, DOI 10.1128/mBio.01017-18; Guo Z, 2005, BIOCHEMISTRY-US, V44, P15423, DOI 10.1021/bi0518601; Hmama Z, 2015, IMMUNOL REV, V264, P220, DOI 10.1111/imr.12268; Huang Y, 2010, MOL CELL BIOCHEM, V340, P223, DOI 10.1007/s11010-010-0421-x; Iantomasi R, 2012, CELL MICROBIOL, V14, P356, DOI 10.1111/j.1462-5822.2011.01721.x; Jager W, 2012, J VIROL, V86, P6745, DOI 10.1128/JVI.06840-11; Karboul A, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-107; Kennedy RJ, 2000, BRIT J SURG, V87, P1346, DOI 10.1046/j.1365-2168.2000.01615.x; Kim SY, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012497; Koh HJ, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006126; Lee HR, 2011, NAT STRUCT MOL BIOL, V18, P1336, DOI 10.1038/nsmb.2142; Li JD, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01517-z; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Liu CH, 2017, CELL MOL IMMUNOL, V14, P963, DOI 10.1038/cmi.2017.88; Long QX, 2019, J CELL PHYSIOL, V234, P19774, DOI 10.1002/jcp.28577; Machowski EE, 2007, J BACTERIOL, V189, P2190, DOI 10.1128/JB.01647-06; Meena LS, 2015, BIOTECHNOL APPL BIOC, V62, P145, DOI 10.1002/bab.1266; Saini NK, 2016, NAT MICROBIOL, V1, DOI [10.1038/nmicrobiol.2016.133, 10.1038/NMICROBIOL.2016.133]; Salsman J, 2012, J VIROL, V86, P806, DOI 10.1128/JVI.05442-11; Sivachandran N, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000170; Talarico S, 2007, TUBERCULOSIS, V87, P338, DOI 10.1016/j.tube.2007.03.003; Walsh MC, 2015, IMMUNOL REV, V266, P72, DOI 10.1111/imr.12302; Wang L, 2020, NATURE, V577, P682, DOI 10.1038/s41586-019-1915-7; Yamamoto M, 2021, P JPN ACAD B-PHYS, V97, P145, DOI 10.2183/pjab.97.009; Yang CS, 2012, CELL HOST MICROBE, V11, P264, DOI 10.1016/j.chom.2012.01.018; Yang WM, 2017, APOPTOSIS, V22, P502, DOI 10.1007/s10495-016-1336-0; Zhao XB, 2020, AGING-US, V12, P10969, DOI 10.18632/aging.103309; Zheng F, 2011, J CELL BIOCHEM, V112, P2716, DOI 10.1002/jcb.23232; Zhou J, 2018, MED CHEM, V14, P3, DOI 10.2174/1573406413666171020115539; Zumbo A, 2013, PATHOG DIS, V69, P232, DOI 10.1111/2049-632X.12096	51	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								862628	10.3389/fimmu.2022.862628	http://dx.doi.org/10.3389/fimmu.2022.862628			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1E2QB	35572598	gold, Green Published			2022-12-18	WOS:000794338900001
J	Koers, J; Pollastro, S; Tol, S; Pico-Knijnenburg, I; Derksen, NIL; van Schouwenburg, PA; van der Burg, M; van Ham, SM; Rispens, T				Koers, Jana; Pollastro, Sabrina; Tol, Simon; Pico-Knijnenburg, Ingrid; Derksen, Ninotska I. L.; van Schouwenburg, Pauline A.; van der Burg, Mirjam; van Ham, S. Marieke; Rispens, Theo			CD45RB Glycosylation and Ig Isotype Define Maturation of Functionally Distinct B Cell Subsets in Human Peripheral Blood	FRONTIERS IN IMMUNOLOGY			English	Article						CD45RB glycosylation; CD27; B cell subset heterogeneity; naive B cells; memory B cells	MARGINAL ZONE; MEMORY; NAIVE; DIFFERENTIATION; IDENTIFICATION; HYPERMUTATION; POPULATIONS; COMPARTMENT; INFECTION; SUGGESTS	Glycosylation of CD45RB (RB+) has recently been identified to mark antigen-experienced B cells, independent of their CD27 expression. By using a novel combination of markers including CD45RB glycosylation, CD27 and IgM/IgD isotype expression we segregated human peripheral blood B cell subsets and investigated their IGHV repertoire and in vitro functionality. We observed distinct maturation stages for CD27-RB+ cells, defined by differential expression of non-switched Ig isotypes. CD27-RB+ cells, which only express IgM, were more matured in terms of Ig gene mutation levels and function as compared to CD27-RB+ cells that express both IgM and IgD or cells that were CD27-RB-. Moreover, CD27-RB+IgM+ cells already showed remarkable rigidity in IgM isotype commitment, different from CD27-RB+IgMD+ and CD27-RB- cells that still demonstrated great plasticity in B cell fate decision. Thus, glycosylation of CD45RB is indicative for antigen-primed B cells, which are, dependent on the Ig isotype, functionally distinct.	[Koers, Jana; Pollastro, Sabrina; Derksen, Ninotska I. L.; van Ham, S. Marieke; Rispens, Theo] Univ Amsterdam, Dept Immunopathol, Landsteiner Lab, Sanquin Res, Amsterdam, Netherlands; [Tol, Simon] Amsterdam Univ Med Ctr UMC, Univ Amsterdam, Dept Res Facil, Landsteiner Lab,Sanquin Res, Amsterdam, Netherlands; [Pico-Knijnenburg, Ingrid; van Schouwenburg, Pauline A.; van der Burg, Mirjam] Leiden Univ Med Ctr, Dept Pediat, Lab Pediat Immunol, Leiden, Netherlands; [van Ham, S. Marieke] Univ Amsterdam, Swammerdam Inst Life Sci, Amsterdam, Netherlands	University of Amsterdam; University of Amsterdam; Leiden University; Leiden University Medical Center (LUMC); University of Amsterdam	Koers, J (corresponding author), Univ Amsterdam, Dept Immunopathol, Landsteiner Lab, Sanquin Res, Amsterdam, Netherlands.	j.koers@sanquin.nl		Pollastro, Sabrina/0000-0002-0950-7583	Landsteiner Foundation for Blood Transfusion Research [Grant1626]	Landsteiner Foundation for Blood Transfusion Research	Funding This study was supported by Landsteiner Foundation for Blood Transfusion Research (Grant1626).	Bautista D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00736; Bemark M, 2013, CLIN IMMUNOL, V149, P421, DOI 10.1016/j.clim.2013.08.011; Berkowska MA, 2011, BLOOD, V118, P2150, DOI 10.1182/blood-2011-04-345579; Brochet X, 2008, NUCLEIC ACIDS RES, V36, pW503, DOI 10.1093/nar/gkn316; Burton BR, 2018, ELIFE, V7, DOI [10.7554/eLife.26832, 10.7554/elife.26832]; Colonna-Romano G, 2009, MECH AGEING DEV, V130, P681, DOI 10.1016/j.mad.2009.08.003; Deenick EK, 2013, J EXP MED, V210, P2739, DOI 10.1084/jem.20130323; DeKosky BJ, 2016, P NATL ACAD SCI USA, V113, pE2636, DOI 10.1073/pnas.1525510113; Dogan I, 2009, NAT IMMUNOL, V10, P1292, DOI 10.1038/ni.1814; DUNNWALTERS DK, 1995, J EXP MED, V182, P559, DOI 10.1084/jem.182.2.559; Glass DR, 2020, IMMUNITY, V53, P217, DOI 10.1016/j.immuni.2020.06.013; Gupta NT, 2015, BIOINFORMATICS, V31, P3356, DOI 10.1093/bioinformatics/btv359; Gutzeit C, 2018, EUR J IMMUNOL, V48, P1101, DOI 10.1002/eji.201646547; Jackson SM, 2009, BLOOD, V113, P3999, DOI 10.1182/blood-2008-03-145979; Jimenez-Saiz R, 2019, J ALLERGY CLIN IMMUN, V144, P336, DOI 10.1016/j.jaci.2019.04.001; Keating R, 2013, NAT IMMUNOL, V14, P1266, DOI 10.1038/ni.2741; Koethe S, 2011, J LEUKOCYTE BIOL, V90, P5, DOI 10.1189/jlb.0710404; Rojas OL, 2008, VIROLOGY, V380, P234, DOI 10.1016/j.virol.2008.08.004; Merrell KT, 2006, IMMUNITY, V25, P953, DOI 10.1016/j.immuni.2006.10.017; Moir S, 2008, J EXP MED, V205, P1797, DOI 10.1084/jem.20072683; Obukhanych TV, 2006, J EXP MED, V203, P305, DOI 10.1084/jem.20052036; Pape KA, 2011, SCIENCE, V331, P1203, DOI 10.1126/science.1201730; Quach TD, 2011, J IMMUNOL, V186, P4640, DOI 10.4049/jimmunol.1001946; Racanelli V, 2006, J VIROL, V80, P3923, DOI 10.1128/JVI.80.8.3923-3934.2006; Sanz I, 2008, SEMIN IMMUNOL, V20, P67, DOI 10.1016/j.smim.2007.12.006; Scheeren FA, 2008, J EXP MED, V205, P2033, DOI 10.1084/jem.20070447; Seifert M, 2015, P NATL ACAD SCI USA, V112, pE546, DOI 10.1073/pnas.1416276112; Sims GP, 2005, BLOOD, V105, P4390, DOI 10.1182/blood-2004-11-4284; Unger PPA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10051183; van Asten SD, 2021, J IMMUNOL, V207, P449, DOI 10.4049/jimmunol.2001390; van Gent R, 2009, CLIN IMMUNOL, V133, P95, DOI 10.1016/j.clim.2009.05.020; Vander Heiden JA, 2014, BIOINFORMATICS, V30, P1930, DOI 10.1093/bioinformatics/btu138; Wei C, 2007, J IMMUNOL, V178, P6624, DOI 10.4049/jimmunol.178.10.6624; Weill JC, 2020, CURR OPIN IMMUNOL, V63, P1, DOI 10.1016/j.coi.2019.09.003; Weller S, 2001, P NATL ACAD SCI USA, V98, P1166, DOI 10.1073/pnas.98.3.1166; Wu YC, 2010, BLOOD, V116, P1070, DOI 10.1182/blood-2010-03-275859; Wu YCB, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00081; Zhao Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06089-1; Zuccarino-Catania GV, 2014, NAT IMMUNOL, V15, P631, DOI 10.1038/ni.2914	40	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								891316	10.3389/fimmu.2022.891316	http://dx.doi.org/10.3389/fimmu.2022.891316			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1E2PD	35572548	Green Published, gold			2022-12-18	WOS:000794336500001
J	Kondo, H; Kageyama, T; Tanaka, S; Otsuka, K; Tsukumo, SI; Mashimo, Y; Onouchi, Y; Nakajima, H; Yasutomo, K				Kondo, Hiroyuki; Kageyama, Takahiro; Tanaka, Shigeru; Otsuka, Kunihiro; Tsukumo, Shin-ichi; Mashimo, Yoichi; Onouchi, Yoshihiro; Nakajima, Hiroshi; Yasutomo, Koji			Markers of Memory CD8 T Cells Depicting the Effect of the BNT162b2 mRNA COVID-19 Vaccine in Japan	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; T cell; CD8; vaccine; markers; antigen	SEX-DIFFERENCES	BNT162b2, a nucleoside-modified mRNA vaccine for SARS-CoV-2 spike glycoprotein (S), provides approximately 95% efficacy for preventing COVID-19. However, it remains unclear how effectively memory CD8+ T cells are generated and which genetic and environmental factors affect the generation and function of memory CD8+ T cells elicited by this vaccine. Here, we investigated the frequency and functions of memory CD8+ T cells 3 weeks after the second vaccination in the Japanese population. Using a peptide-MHC pentamer, we detected an increased number of memory CD8+ T cells together with increased serum anti-S protein antibody in females compared with that in males, but the frequency of pentamer-positive cells was not positively correlated with antibody titers. Memory precursor effector cells (KLRG1-CD127+) among both CD8+ cells and pentamer+ cells and effector cells (CD38-HLA-DR+) among pentamer+ cells were more abundant in females than in males. Upon S protein-mediated stimulation of T cells, the intensity of CD107a and granzyme B expression was increased in females compared with that in males, indicating stronger memory CD8+ T cell responses in females than in males. Our studies showed that the BNT162b2 vaccine elicits increased memory CD8+ T cell proliferation and secondary CTL responses in females compared with those in males in the Japanese population. These findings provide an important basis for the distinct sex difference in cellular immune responses to mRNA vaccination and suggest that memory precursor effector cells can be one of markers to evaluate and boost cellular immunity induced by BNT162b2.	[Kondo, Hiroyuki; Otsuka, Kunihiro; Tsukumo, Shin-ichi; Yasutomo, Koji] Tokushima Univ, Grad Sch Med, Dept Immunol & Parasitol, Tokushima, Japan; [Kageyama, Takahiro; Tanaka, Shigeru; Nakajima, Hiroshi] Chiba Univ, Grad Sch Med, Dept Allergy & Clin Immunol, Chiba, Japan; [Mashimo, Yoichi; Onouchi, Yoshihiro] Chiba Univ, Grad Sch Med, Dept Publ Hlth, Chiba, Japan; [Yasutomo, Koji] Tokushima Univ, Inst Postled Photon, Dept Interdisciplinary Res Med & Photon, Tokushima, Japan; [Yasutomo, Koji] Tokushima Univ, Res Cluster Program Immunol Dis, Tokushima, Japan; [Yasutomo, Koji] Tokushima Univ, Tokushima Int Sci Inst TISI, Tokushima, Japan	Tokushima University; Chiba University; Chiba University; Tokushima University; Tokushima University; Tokushima University	Yasutomo, K (corresponding author), Tokushima Univ, Grad Sch Med, Dept Immunol & Parasitol, Tokushima, Japan.; Nakajima, H (corresponding author), Chiba Univ, Grad Sch Med, Dept Allergy & Clin Immunol, Chiba, Japan.; Yasutomo, K (corresponding author), Tokushima Univ, Inst Postled Photon, Dept Interdisciplinary Res Med & Photon, Tokushima, Japan.; Yasutomo, K (corresponding author), Tokushima Univ, Res Cluster Program Immunol Dis, Tokushima, Japan.; Yasutomo, K (corresponding author), Tokushima Univ, Tokushima Int Sci Inst TISI, Tokushima, Japan.	nakajimh@faculty.chiba-u.jp; yasutomo@tokushima-u.ac.jp	Nakajima, Hiroshi/AFU-9313-2022	Nakajima, Hiroshi/0000-0001-8595-9381; Kageyama, Takahiro/0000-0002-9450-5848; Tanaka, Shigeru/0000-0002-8466-110X				Berry R, 2020, NAT REV IMMUNOL, V20, P113, DOI 10.1038/s41577-019-0225-5; Chang JT, 2014, NAT IMMUNOL, V15, P1104, DOI 10.1038/ni.3031; Chow KT, 2018, ANNU REV IMMUNOL, V36, P667, DOI 10.1146/annurev-immunol-042617-053309; Di Resta C, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050522; Furman D, 2014, P NATL ACAD SCI USA, V111, P869, DOI 10.1073/pnas.1321060111; Goel RR, 2021, SCIENCE, V374, P1214, DOI 10.1126/science.abm0829; Grifoni A, 2021, CELL HOST MICROBE, V29, P1076, DOI 10.1016/j.chom.2021.05.010; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Ikeda N, 2015, TISSUE ANTIGENS, V85, P252, DOI 10.1111/tan.12536; Kageyama T, 2021, CLIN MICROBIOL INFEC, V27, DOI 10.1016/j.cmi.2021.07.042; Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90; Krause PR, 2021, NEW ENGL J MED, V385, P179, DOI 10.1056/NEJMsr2105280; Mariano G, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.605236; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Ngono AE, 2018, ANNU REV IMMUNOL, V36, P279, DOI 10.1146/annurev-immunol-042617-053142; Oberhardt V, 2021, NATURE, V597, P268, DOI 10.1038/s41586-021-03841-4; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Rha MS, 2021, IMMUNITY, V54, P44, DOI 10.1016/j.immuni.2020.12.002; Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; Sahin U, 2021, NATURE, V595, P572, DOI 10.1038/s41586-021-03653-6; Shomuradova AS, 2020, IMMUNITY, V53, P1245, DOI 10.1016/j.immuni.2020.11.004; St John AL, 2019, NAT REV IMMUNOL, V19, P218, DOI 10.1038/s41577-019-0123-x; Tregoning JS, 2021, NAT REV IMMUNOL, V21, P626, DOI 10.1038/s41577-021-00592-1; Vassallo Amy, 2021, Front Glob Womens Health, V2, P761511, DOI 10.3389/fgwh.2021.761511; Walsh EE, 2020, NEW ENGL J MED, V383, P2439, DOI 10.1056/NEJMoa2027906; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhou RH, 2020, IMMUNITY, V53, P864, DOI 10.1016/j.immuni.2020.07.026; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	30	0	0	1	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								836923	10.3389/fimmu.2022.836923	http://dx.doi.org/10.3389/fimmu.2022.836923			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1E3HW	35572546	gold, Green Published, Green Submitted			2022-12-18	WOS:000794385200001
J	Palterer, B; Salvati, L; Capone, M; Mecheri, V; Maggi, L; Mazzoni, A; Cosmi, L; Volpi, N; Tiberi, L; Provenzano, A; Giglio, S; Parronchi, P; Maggiore, G; Gallo, O; Bartoloni, A; Annunziato, F; Zammarchi, L; Liotta, F				Palterer, Boaz; Salvati, Lorenzo; Capone, Manuela; Mecheri, Valentina; Maggi, Laura; Mazzoni, Alessio; Cosmi, Lorenzo; Volpi, Nila; Tiberi, Lucia; Provenzano, Aldesia; Giglio, Sabrina; Parronchi, Paola; Maggiore, Giandomenico; Gallo, Oreste; Bartoloni, Alessandro; Annunziato, Francesco; Zammarchi, Lorenzo; Liotta, Francesco			Variants Disrupting CD40L Transmembrane Domain and Atypical X-Linked Hyper-IgM Syndrome: A Case Report With Leishmaniasis and Review of the Literature	FRONTIERS IN IMMUNOLOGY			English	Review						CD40LG gene; CD40LG mutation; Leishmania; leishmaniasis; CPT2 deficiency; CPT2 gene; hyper-IgM immunodeficiency syndrome; WES; whole-exome sequencing	VISCERAL LEISHMANIASIS; LIGAND; DEFICIENCY; MUTATION; EXPRESSION; CELL; IMMUNODEFICIENCY; PATIENT; GENE	X-linked hyper-IgM (XHIGM) syndrome is caused by mutations of the CD40LG gene, encoding the CD40L protein. The clinical presentation is characterized by early-onset infections, with profound hypogammaglobulinemia and often elevated IgM, susceptibility to opportunistic infections, such as Pneumocystis jirovecii pneumonia, biliary tract disease due to Cryptosporidium parvum, and malignancy. We report a 41-year-old male presenting with recurrent leishmaniasis, hypogammaglobulinemia, and myopathy. Whole-exome sequencing (WES) identified a missense variant in the CD40LG gene (c.107T>A, p.M36K), involving the transmembrane domain of the protein and a missense variant in the carnitine palmitoyl-transferase II (CPT2; c.593C>G; p.S198C) gene, leading to the diagnosis of hypomorphic XHIGM and CPT2 deficiency stress-induced myopathy. A review of all the previously reported cases of XHIGM with variants in the transmembrane domain showcased that these patients could present with atypical clinical features. Variants in the transmembrane domain of CD40LG act as hypomorphic generating a protein with a lower surface expression. Unlike large deletions or extracellular domain variants, they do not abolish the interaction with CD40, therefore preserving some biological activity.	[Palterer, Boaz; Salvati, Lorenzo; Capone, Manuela; Mecheri, Valentina; Maggi, Laura; Mazzoni, Alessio; Cosmi, Lorenzo; Parronchi, Paola; Annunziato, Francesco; Zammarchi, Lorenzo; Liotta, Francesco] Univ Florence, Dept Expt & Clin Med, Florence, Italy; [Palterer, Boaz; Annunziato, Francesco] Careggi Univ Hosp, Flow Cytometr Diagnost Ctr & Immunotherapy, Florence, Italy; [Cosmi, Lorenzo; Parronchi, Paola; Liotta, Francesco] Careggi Univ Hosp, Immunol & Cell Therapies Unit, Florence, Italy; [Volpi, Nila] Univ Siena, Dept Med Surg & Neurol Sci, Unit Neurol & Neurophysiol, Siena, Italy; [Tiberi, Lucia; Provenzano, Aldesia] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Florence, Italy; [Tiberi, Lucia] Meyer Univ Hosp, Med Genet Unit, Florence, Italy; [Giglio, Sabrina] Univ Cagliari, Dept Med Sci & Publ Hlth, Med Genet Unit, Cagliari, Italy; [Maggiore, Giandomenico; Gallo, Oreste] Careggi Univ Hosp, Dept Otorhinolaryngol, Florence, Italy; [Bartoloni, Alessandro; Zammarchi, Lorenzo] Careggi Univ Hosp, Infect & Trop Dis Unit, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Siena; University of Florence; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of Cagliari; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi	Liotta, F (corresponding author), Univ Florence, Dept Expt & Clin Med, Florence, Italy.; Liotta, F (corresponding author), Careggi Univ Hosp, Immunol & Cell Therapies Unit, Florence, Italy.	Francesco.liotta@unifi.it	maggiore, giandomenico/AAA-1846-2021; Salvati, Lorenzo/GZL-7831-2022; Palterer, Boaz/K-1072-2018	maggiore, giandomenico/0000-0002-2741-4460; Salvati, Lorenzo/0000-0001-5831-0392; Palterer, Boaz/0000-0003-2499-8250				Blaeser F, 2005, CLIN IMMUNOL, V117, P231, DOI 10.1016/j.clim.2005.08.005; Cabral-Marques O, 2018, J ALLERGY CLIN IMMUN, V142, P1571, DOI 10.1016/j.jaci.2018.02.026; Coraglia A, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4951587; Danielian S, 2007, J CLIN IMMUNOL, V27, P455, DOI 10.1007/s10875-007-9089-8; de la Morena MT, 2017, J ALLERGY CLIN IMMUN, V139, P1282, DOI 10.1016/j.jaci.2016.07.039; de Saint Basile G, 1999, EUR J IMMUNOL, V29, P367, DOI 10.1002/(SICI)1521-4141(199901)29:01<367::AID-IMMU367>3.0.CO;2-4; de Vries E, 1999, BLOOD, V94, P1488, DOI 10.1182/blood.V94.4.1488; Drabe CH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.567856; Ferrua F, 2019, J ALLERGY CLIN IMMUN, V143, P2238, DOI 10.1016/j.jaci.2018.12.1010; Franca TT, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00130; Garber E, 1999, J BIOL CHEM, V274, P33545, DOI 10.1074/jbc.274.47.33545; Gunaydin NC, 2014, CLIN IMMUNOL, V153, P288, DOI 10.1016/j.clim.2014.05.001; HOLLENBAUGH D, 1994, J CLIN INVEST, V94, P616, DOI 10.1172/JCI117377; Gonzalez-Granado LI, 2016, J CLIN IMMUNOL, V36, P363, DOI 10.1007/s10875-016-0270-9; Joshi PR, 2014, J NEUROL SCI, V338, P107, DOI 10.1016/j.jns.2013.12.026; Kato T, 1996, J IMMUNOL, V156, P3932; Katz F, 1996, HUM MUTAT, V8, P223, DOI 10.1002/(SICI)1098-1004(1996)8:3<223::AID-HUMU5>3.0.CO;2-A; Kaye P, 2011, NAT REV MICROBIOL, V9, P604, DOI 10.1038/nrmicro2608; Kelsall BL, 1996, ANN NY ACAD SCI, V795, P116, DOI 10.1111/j.1749-6632.1996.tb52660.x; Khalid MB, 2022, PEDIAT ALLERG IMM-UK, V33, DOI 10.1111/pai.13653; Kiani-Alikhan S, 2012, J CLIN IMMUNOL, V32, P70, DOI 10.1007/s10875-011-9607-6; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; Kracker S, 2015, J ALLERGY CLIN IMMUN, V135, P998, DOI 10.1016/j.jaci.2014.08.030; Le Coz C, 2018, J ALLERGY CLIN IMMUN, V141, P2308, DOI 10.1016/j.jaci.2018.02.010; Leven EA, 2016, J CLIN IMMUNOL, V36, P490, DOI 10.1007/s10875-016-0291-4; Lohoff M, 1998, INT ARCH ALLERGY IMM, V115, P191, DOI 10.1159/000023900; Lougaris V, 2018, CLIN IMMUNOL, V190, P11, DOI 10.1016/j.clim.2018.02.008; Ma CS, 2015, J ALLERGY CLIN IMMUN, V136, P993, DOI 10.1016/j.jaci.2015.05.036; Martin JC, 1996, CLIN INFECT DIS, V23, P1188, DOI 10.1093/clinids/23.5.1188; Parvaneh N, 2017, PEDIATR BLOOD CANCER, V64, DOI 10.1002/pbc.26362; Rossi M, 2018, INT IMMUNOL, V30, P103, DOI 10.1093/intimm/dxx075; Seyama K, 1998, J INFECT DIS, V178, P318, DOI 10.1086/515633; Thaventhiran JED, 2020, NATURE, V583, P90, DOI 10.1038/s41586-020-2265-1; Thusberg J, 2007, PROTEIN ENG DES SEL, V20, P133, DOI 10.1093/protein/gzm004; Wada T, 2008, CURR OPIN ALLERGY CL, V8, P510, DOI 10.1097/ACI.0b013e328314b651; Yazdani R, 2019, CLIN IMMUNOL, V198, P19, DOI 10.1016/j.clim.2018.11.007; Yong PFK, 2008, J CLIN PATHOL, V61, P1220, DOI 10.1136/jcp.2008.058362; Zijlstra EE, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003258	38	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								840767	10.3389/fimmu.2022.840767	http://dx.doi.org/10.3389/fimmu.2022.840767			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1E5JX	35572607	Green Published, gold			2022-12-18	WOS:000794525700001
J	Shi, BQ; Hao, YQ; Li, W; Dong, HN; Xu, MT; Gao, P				Shi, Bingqing; Hao, Yuqiu; Li, Wei; Dong, Hongna; Xu, Mengting; Gao, Peng			TIPE2 May Target the Nrf2/HO-1 Pathway to Inhibit M1 Macrophage-Related Neutrophilic Inflammation in Asthma	FRONTIERS IN IMMUNOLOGY			English	Article						asthma; phenotype; inflammation; macrophages; TIPE2	AIRWAY INFLAMMATION; POLARIZATION; EXPRESSION; CELLS; DISRUPTION; RESISTANCE; ROLES; MOUSE	PurposeAlthough recent studies have highlighted the link of TIPE2 and asthma airway inflammation, its roles and molecular mechanisms in different asthma inflammatory phenotypes remain largely unknown. We evaluated sputum TIPE2 expression level and its correlation with different asthma phenotypes. Additionally, we explored the roles and mechanism of TIPE2 in M1 polarization of macrophages. MethodsA total of 102 asthma patients who underwent sputum induction were enrolled to evaluate the expression level of TIPE2 and its association with different asthma phenotypes. To explore the roles and mechanism of TIPE2 in M1 polarization of macrophages, THP-1 monocytes stimulated with phorbol-12-myristate-13-acetate, were used as a model of undifferentiated (M0) macrophages, and M0 macrophages were treated with lipopolysaccharide to induce M1 macrophages. ResultsThe sputum TIPE2 level was significantly lower in patients with neutrophilic asthma (NA) and higher in patients with eosinophilic asthma (EA) compared with patients with paucigranulocytic asthma. The levels of IL-1 beta, TNF-alpha and IL-6 were highest in NA compared with other groups. TIPE2 levels in sputum negatively correlated with IL-1 beta and TNF-alpha levels but positively correlated with IL-4, IL-5, IL-13, and IL-10 levels (P < 0.05). In vitro, TIPE2 enhanced Nrf2/HO-1 pathway activation in macrophages and inhibited LPS-induced M1 macrophage differentiation and related cytokine release. Further analysis showed that the Nrf2 inhibitor ML385 weakened TIPE2-induced activation of the Nrf2/HO-1 pathway, as well as TIPE2-induced suppression in M1 polarization of macrophage and inflammatory cytokines secretion. ConclusionsTIPE2 expression level was highly down-regulated in NA and was negatively correlated with inflammatory factors (IL-1 beta and TNF-alpha). Aberrant expression of TIPE2 may target the Nrf2/HO-1 pathway to inhibit M1 macrophage-related neutrophilic inflammation in asthma.	[Shi, Bingqing; Hao, Yuqiu; Li, Wei; Dong, Hongna; Xu, Mengting; Gao, Peng] Second Hosp Jilin Univ, Dept Resp Med, Changchun, Peoples R China	Jilin University	Gao, P (corresponding author), Second Hosp Jilin Univ, Dept Resp Med, Changchun, Peoples R China.	gaopeng1234@sina.com			Natural Science Foundation of Jilin Province [20210101460JC]; National Natural Science Foundation of China [82070037]; Jilin Province Natural Science Foundation [202000201384JC]; Jilin Province Development and Reform Commission Plan [2019C047-7]; Jilin Provincial Department of Finance , Provincial Talent Project [2019SCZT033]	Natural Science Foundation of Jilin Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jilin Province Natural Science Foundation; Jilin Province Development and Reform Commission Plan; Jilin Provincial Department of Finance , Provincial Talent Project	This research was funded by the Natural Science Foundation of Jilin Province (20210101460JC), National Natural Science Foundation of China (82070037), Jilin Province Natural Science Foundation (202000201384JC), Jilin Province Development and Reform Commission Plan (2019C047-7), and Jilin Provincial Department of Finance, Provincial Talent Project (2019SCZT033). The design of the study and writing of the manuscript were performed in accordance with the rules of the funding bodies.	Baines KJ, 2011, THORAX, V66, P942, DOI 10.1136/thx.2010.157719; Bruijnzeel PLB, 2015, J LEUKOCYTE BIOL, V98, P549, DOI 10.1189/jlb.3VMR1214-600RR; Choi JS, 2012, RESPIROLOGY, V17, P322, DOI 10.1111/j.1440-1843.2011.02097.x; Choy DF, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab3142; Ding JR, 2015, CELL PHYSIOL BIOCHEM, V37, P2425, DOI 10.1159/000438595; Fayngerts SA, 2017, NAT IMMUNOL, V18, P1353, DOI 10.1038/ni.3866; Gao P, 2015, RESP RES, V16, DOI 10.1186/s12931-014-0163-5; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36, DOI 10.1164/ajrccm.158.1.9705031; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Global Initiative for Asthma, 2019, GINA; Hastie AT, 2018, CLIN EXP ALLERGY, V48, P787, DOI 10.1111/cea.13129; Helou DG, 2019, J IMMUNOL, V202, P2189, DOI 10.4049/jimmunol.1801065; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Jais A, 2014, CELL, V158, P25, DOI 10.1016/j.cell.2014.04.043; Jiang JS, 2017, MOL MED REP, V16, P6313, DOI 10.3892/mmr.2017.7364; Jiang Y, 2018, MOL MED REP, V17, P952, DOI 10.3892/mmr.2017.7991; Kim KH, 2016, BIOCHEM BIOPH RES CO, V474, P534, DOI 10.1016/j.bbrc.2016.04.122; Kobayashi EH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11624; Kong Q, 2020, INFLAMMATION, V43, P833, DOI 10.1007/s10753-019-01169-w; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Lou YW, 2013, J IMMUNOL, V191, P4849, DOI 10.4049/jimmunol.1300053; Lourenco LO, 2022, CLIN REV ALLERG IMMU, V62, P240, DOI 10.1007/s12016-021-08894-x; Ma Y, 2013, SCAND J IMMUNOL, V78, P523, DOI 10.1111/sji.12110; Murdoch JR, 2010, MUTAT RES-FUND MOL M, V690, P24, DOI 10.1016/j.mrfmmm.2009.09.005; Ntontsi P, 2017, ALLERGY, V72, P1761, DOI 10.1111/all.13184; Pareek TK, 2011, SCI REP-UK, V1, DOI 10.1038/srep00201; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Reddel HK, 2015, EUR RESPIR J, V46, P622, DOI 10.1183/13993003.00853-2015; Robbe P, 2015, AM J PHYSIOL-LUNG C, V308, pL358, DOI 10.1152/ajplung.00341.2014; Saha S, 2020, MOLECULES, V25, DOI 10.3390/molecules25225474; Saradna A, 2018, TRANSL RES, V191, P1, DOI 10.1016/j.trsl.2017.09.002; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2010, RESPIRATION, V79, P147, DOI 10.1159/000245899; Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651; Sun HH, 2008, CELL, V133, P415, DOI 10.1016/j.cell.2008.03.026; Wang Q, 2019, J INFECT DIS, V220, P1008, DOI 10.1093/infdis/jiz246; Williams MA, 2008, J IMMUNOL, V181, P4545, DOI 10.4049/jimmunol.181.7.4545; Wong HH, 1997, AM J RESP CRIT CARE, V156, P299, DOI 10.1164/ajrccm.156.1.9610114; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu XJ, 2019, INFLAMM RES, V68, P981, DOI 10.1007/s00011-019-01280-6; Xi WJ, 2011, MOL IMMUNOL, V48, P1203, DOI 10.1016/j.molimm.2011.03.002; Yao Y, 2017, INT FORUM ALLERGY RH, V7, P963, DOI 10.1002/alr.21984; Ye XB, 2008, J EXP MED, V205, P1303, DOI 10.1084/jem.20071393	43	0	0	7	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								883885	10.3389/fimmu.2022.883885	http://dx.doi.org/10.3389/fimmu.2022.883885			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G5GT	35572500	Green Published, gold			2022-12-18	WOS:000795876700001
J	Valeff, NJ; Ventimiglia, MS; Dibo, M; Markert, UR; Jensen, F				Valeff, Natalin J.; Ventimiglia, Maria S.; Dibo, Marcos; Markert, Udo R.; Jensen, Federico			Splenic B1 B Cells Acquire a Proliferative and Anti-Inflamatory Profile During Pregnancy in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						B cells; B1 B cells; pregnancy; autoimmunity; tolerance	B-1 CELLS; DISTINCT; IL-10; PROGENITORS	B cells are a heterogeneous cell population with differential ontogeny, anatomical location, and functions. B1 B cells are a distinct subpopulation characterized by their unique capacity of self-renewal, the production of large quantities of IL-10, and the ability to secrete protective, anti-inflammatory natural antibodies (NAbs), presumably upon down-regulation of CD1d expression. Although natural antibodies are thought to be protective, due to their polyreactivity, their participation in certain autoimmune diseases has been suggested. In the context of pregnancy, the role of B1 B cells has been discussed controversially. While in human pregnancies B1 B cells and natural/polyreactive antibodies they produce are involved in the development of preeclampsia, in mice they promote healthy gestation and fetal protection. In this work, we aimed to functionally characterize the splenic B1 B cell population during pregnancy in mice. Functional enrichment analysis using only up-regulated transcripts from a transcriptomic profile performed on total splenic B cells from pregnant compared to non-pregnant mice showed augmented cell cycle and DNA replication pathways. Proliferation studies by flow cytometry showed augmented Ki-67 proliferation marker expression and percentages of B1 B cells. Furthermore, B1 B cells produced higher levels of IL-10 and lower levels of TNF-alpha leading to an increased IL-10/TNF-alpha ratio and showing an immunoregulatory phenotype. Finally, we observed lower expression of CD1d on B1 B cells, suggesting a higher capacity to produce NAbs in the context of pregnancy. In summary, our results showed not only an expanded and proliferative splenic B1 B cell population during pregnancy but also the acquisition of immunomodulatory capacities suggesting its critical role in the intricate process of pregnancy tolerance.	[Valeff, Natalin J.; Ventimiglia, Maria S.; Dibo, Marcos; Jensen, Federico] UBA, Lab Inmunol Reprod, CEFYBO, CONICET, Buenos Aires, Argentina; [Markert, Udo R.] Univ Hosp Jena, Dept Obstet, Placenta Lab, Jena, Germany; [Jensen, Federico] Univ Bernardo OHiggins, Ctr Integrat Biol & Quim Aplicada, Santiago, Chile	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Friedrich Schiller University of Jena; Universidad  Bernardo O'Higgins	Jensen, F (corresponding author), UBA, Lab Inmunol Reprod, CEFYBO, CONICET, Buenos Aires, Argentina.; Markert, UR (corresponding author), Univ Hosp Jena, Dept Obstet, Placenta Lab, Jena, Germany.; Jensen, F (corresponding author), Univ Bernardo OHiggins, Ctr Integrat Biol & Quim Aplicada, Santiago, Chile.	udo.markert@med.uni-jena.de; fedejensen2012@gmail.com	MARKERT, UDO Rudolf/AAP-1663-2021	MARKERT, UDO Rudolf/0000-0001-5299-595X	Agencia Nacional de Promocion Cientifica y Tecnologica PICT [2016/004]; PICT [2016-201-0151]; PICT-PRH [2016-004]	Agencia Nacional de Promocion Cientifica y Tecnologica PICT(ANPCyT); PICT(ANPCyT); PICT-PRH	This study was supported by grants from Agencia Nacional de Promocion Cientifica y Tecnologica PICT (2016/004), PICT (2016-201-0151), and PICT-PRH (2016-004) to FJ.	Abu-Raya B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.575197; Allman D, 2008, CURR OPIN IMMUNOL, V20, P149, DOI 10.1016/j.coi.2008.03.014; Arcanjo Angelica F, 2017, World J Biol Chem, V8, P151, DOI 10.4331/wjbc.v8.i2.151; Aziz M, 2017, J IMMUNOL, V199, P750, DOI 10.4049/jimmunol.1602056; Aziz M, 2015, IMMUNOL RES, V63, P153, DOI 10.1007/s12026-015-8708-3; Baumgarth N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00324; Berland R, 2002, ANNU REV IMMUNOL, V20, P253, DOI 10.1146/annurev.immunol.20.100301.064833; Biswas TK, 2020, ANTIBODIES, V9, DOI 10.3390/antib9030030; Duan B, 2006, AUTOIMMUN REV, V5, P403, DOI 10.1016/j.autrev.2005.10.007; Gary-Gouy H, 2002, BLOOD, V100, P4537, DOI 10.1182/blood-2002-05-1525; Ghosn EEB, 2011, P NATL ACAD SCI USA, V108, P2879, DOI 10.1073/pnas.1019764108; Hardy RR, 2006, J IMMUNOL, V177, P2749, DOI 10.4049/jimmunol.177.5.2749; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; Hua ZL, 2020, IMMUNOL REV, V296, P24, DOI 10.1111/imr.12859; ISHIDA H, 1992, J EXP MED, V175, P1213, DOI 10.1084/jem.175.5.1213; Jensen F, 2012, HYPERTENSION, V59, P861, DOI 10.1161/HYPERTENSIONAHA.111.188276; Jorgensen N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00911; Kaislasuo J, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13195; Gonzaga WFKM, 2015, PARASITOLOGY, V142, P1506, DOI 10.1017/S0031182015000943; KROESE FGM, 1992, ANN NY ACAD SCI, V651, P44; LaMarca B, 2011, HYPERTENSION, V57, P865, DOI 10.1161/HYPERTENSIONAHA.110.167569; LeBien TW, 2008, BLOOD, V112, P1570, DOI 10.1182/blood-2008-02-078071; Montecino-Rodriguez E, 2006, NAT IMMUNOL, V7, P293, DOI 10.1038/ni1301; Muzzio DO, 2016, REPRODUCTION, V151, P29, DOI 10.1530/REP-15-0274; Muzzio DO, 2014, BIOL REPROD, V91, DOI 10.1095/biolreprod.114.122366; Muzzio DO, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00006; OGARRA A, 1992, EUR J IMMUNOL, V22, P711, DOI 10.1002/eji.1830220314; Palma J, 2018, CENT EUR J IMMUNOL, V43, P466, DOI 10.5114/ceji.2018.81354; Ramachandra S, 1996, J CLIN INVEST, V98, P1788, DOI 10.1172/JCI118978; Rodriguez-Pinto D, 2005, CELL IMMUNOL, V238, P67, DOI 10.1016/j.cellimm.2006.02.005; Schmidt A, 2021, PLACENTA, V115, P70, DOI 10.1016/j.placenta.2021.09.011; Schumacher A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01045; Srikakulapu P, 2016, ARTERIOSCL THROM VAS, V36, P1174, DOI 10.1161/ATVBAHA.115.306983; Tachikawa S, 2008, CLIN EXP IMMUNOL, V153, P448, DOI 10.1111/j.1365-2249.2008.03709.x; Tung JW, 2006, P NATL ACAD SCI USA, V103, P6293, DOI 10.1073/pnas.0511305103; Valeff N, 2021, GENOMICS, V113, P2614, DOI 10.1016/j.ygeno.2021.06.016; Luu VP, 2014, AUTOIMMUNITY, V47, P1, DOI 10.3109/08916934.2013.856006; Xia Y, 2009, CLIN IMMUNOL, V133, P1, DOI 10.1016/j.clim.2009.05.004; Yuseff MI, 2013, NAT REV IMMUNOL, V13, P475, DOI 10.1038/nri3469; Ziegler KB, 2018, J REPROD IMMUNOL, V129, P40, DOI 10.1016/j.jri.2018.07.003	40	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								873493	10.3389/fimmu.2022.873493	http://dx.doi.org/10.3389/fimmu.2022.873493			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G2IA	35572585	Green Published, gold			2022-12-18	WOS:000795675300001
J	Wang, JQ; Zhou, JD; Wang, CX; Fukunaga, A; Li, SJ; Yodoi, J; Tian, H				Wang, Jinquan; Zhou, Jiedong; Wang, Cuixue; Fukunaga, Atsushi; Li, Shujing; Yodoi, Junji; Tian, Hai			Thioredoxin-1: A Promising Target for the Treatment of Allergic Diseases	FRONTIERS IN IMMUNOLOGY			English	Review						allergic disease; anti-inflammatory; glucocorticoid resistance; migration inhibitory factor; thioredoxin-1	MIGRATION INHIBITORY FACTOR; RECOMBINANT HUMAN THIOREDOXIN; REDOX REGULATION; CELL-DIFFERENTIATION; MOLECULAR-MECHANISMS; AIRWAY INFLAMMATION; FACTOR MIF; SUPPRESSES; EXPRESSION; KINASE	Thioredoxin-1 (Trx1) is an important regulator of cellular redox homeostasis that comprises a redox-active dithiol. Trx1 is induced in response to various stress conditions, such as oxidative damage, infection or inflammation, metabolic dysfunction, irradiation, and chemical exposure. It has shown excellent anti-inflammatory and immunomodulatory effects in the treatment of various human inflammatory disorders in animal models. This review focused on the protective roles and mechanisms of Trx1 in allergic diseases, such as allergic asthma, contact dermatitis, food allergies, allergic rhinitis, and drug allergies. Trx1 plays an important role in allergic diseases through processes, such as antioxidation, inhibiting macrophage migration inhibitory factor (MIF), regulating Th1/Th2 immune balance, modulating allergic inflammatory cells, and suppressing complement activation. The regulatory mechanism of Trx1 differs from that of glucocorticoids that regulates the inflammatory reactions associated with immune response suppression. Furthermore, Trx1 exerts a beneficial effect on glucocorticoid resistance of allergic inflammation by inhibiting the production and internalization of MIF. Our results suggest that Trx1 has the potential for future success in translational research.	[Wang, Jinquan; Zhou, Jiedong; Wang, Cuixue; Li, Shujing; Tian, Hai] Shaoxing Univ, Dept Basic Med, Coll Med, Shaoxing, Peoples R China; [Fukunaga, Atsushi] Kobe Univ, Div Dermatol, Dept Internal Related, Grad Sch Med, Kobe, Hyogo, Japan; [Yodoi, Junji] Kyoto Univ, Inst Virus Res, Dept Biol Response, Lab Infect & Prevent, Kyoto, Japan; [Tian, Hai] Jiaozhimei Biotechnol Shaoxing Co Ltd, Dept Res & Dev, Shaoxing, Peoples R China	Shaoxing University; Kobe University; Kyoto University	Tian, H (corresponding author), Shaoxing Univ, Dept Basic Med, Coll Med, Shaoxing, Peoples R China.; Tian, H (corresponding author), Jiaozhimei Biotechnol Shaoxing Co Ltd, Dept Res & Dev, Shaoxing, Peoples R China.	tianhai2820044@yahoo.co.jp						Aeberli D, 2006, RHEUMATOLOGY, V45, P937, DOI 10.1093/rheumatology/kel142; Agnello D, 2003, J CLIN IMMUNOL, V23, P147, DOI 10.1023/A:1023381027062; Angelini G, 2002, P NATL ACAD SCI USA, V99, P1491, DOI 10.1073/pnas.022630299; Arner ESJ, 2009, BBA-GEN SUBJECTS, V1790, P495, DOI 10.1016/j.bbagen.2009.01.014; Awan MUN, 2022, ANTIOXID REDOX SIGN, V36, P1023, DOI 10.1089/ars.2021.0186; Barnes PJ, 1996, BRIT J CLIN PHARMACO, V42, P3, DOI 10.1046/j.1365-2125.1996.03721.x; Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004; Boehme SA, 1999, J IMMUNOL, V163, P1611; Boonpiyathad T, 2020, ASIAN PAC J ALLERGY, V38, P139, DOI 10.12932/AP-030220-0754; Bozza MT, 2020, CLIN REV ALLERG IMMU, V58, P15, DOI 10.1007/s12016-019-08726-z; Brown RH, 2015, RESP RES, V16, DOI 10.1186/s12931-015-0253-z; Buchanan BB, 1997, P NATL ACAD SCI USA, V94, P5372, DOI 10.1073/pnas.94.10.5372; Cairns JA, 2005, PULM PHARMACOL THER, V18, P55, DOI 10.1016/j.pupt.2004.09.032; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; Chen PL, 2002, J IMMUNOL, V169, P6408, DOI 10.4049/jimmunol.169.11.6408; Chuang CY, 2009, INHAL TOXICOL, V21, P153, DOI [10.1080/08958370802368730, 10.1080/08958370802368730 ]; Cook KM, 2013, J BIOL CHEM, V288, P34920, DOI 10.1074/jbc.M113.523506; Cvetko F, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.RA120.016551; Das D, 2016, CELL SIGNAL, V28, P12, DOI 10.1016/j.cellsig.2015.10.007; Das R, 2011, J CLIN IMMUNOL, V31, P666, DOI 10.1007/s10875-011-9541-7; del Val G, 1999, J ALLERGY CLIN IMMUN, V103, P690, DOI 10.1016/S0091-6749(99)70244-7; Du YT, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.392225; Edinger AL, 2002, P NATL ACAD SCI USA, V99, P1107, DOI 10.1073/pnas.042707999; Edo Yukako, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5040124; EKLUND H, 1991, PROTEINS, V11, P13, DOI 10.1002/prot.340110103; Fan HP, 2014, ARTHRITIS RHEUMATOL, V66, P2059, DOI 10.1002/art.38689; Fukunaga A, 2009, ANTIOXID REDOX SIGN, V11, P1227, DOI [10.1089/ars.2008.2340, 10.1089/ARS.2008.2340]; Galli E, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0229-8; Hammad H, 2021, CELL, V184, P1469, DOI 10.1016/j.cell.2021.02.016; Hanschmann EM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.561724; Hanschmann EM, 2013, ANTIOXID REDOX SIGN, V19, P1539, DOI 10.1089/ars.2012.4599; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; Hirai K, 2019, BIOL PHARM BULL, V42, P1746, DOI 10.1248/bpb.b19-00476; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; Hosoki K, 2016, CURR OPIN ALLERGY CL, V16, P45, DOI 10.1097/ACI.0000000000000231; Ichiki H, 2005, BIOCHEM BIOPH RES CO, V334, P1141, DOI 10.1016/j.bbrc.2005.07.007; Imaoka H, 2007, BIOCHEM BIOPH RES CO, V360, P525, DOI 10.1016/j.bbrc.2007.06.019; Imaoka Haruki, 2009, Allergology International, V58, P403, DOI 10.2332/allergolint.09-OA-0086; Ingram JL, 2012, J ALLERGY CLIN IMMUN, V130, P829, DOI 10.1016/j.jaci.2012.06.034; Inomata Y, 2008, INVEST OPHTH VIS SCI, V49, P5118, DOI 10.1167/iovs.07-1659; Ito W, 2011, INT ARCH ALLERGY IMM, V155, P142, DOI 10.1159/000327501; Jaganjac M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111151; Jia JJ, 2013, CELL SIGNAL, V25, P1194, DOI 10.1016/j.cellsig.2013.02.007; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kang MW, 2008, CELL PHYSIOL BIOCHEM, V21, P215, DOI 10.1159/000113763; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Kim SH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-64; King BC, 2012, J IMMUNOL, V188, P4103, DOI 10.4049/jimmunol.1101295; Kleemann R, 1998, J MOL BIOL, V280, P85, DOI 10.1006/jmbi.1998.1864; Kobayashi N, 2009, ALLERGY, V64, P1130, DOI 10.1111/j.1398-9995.2009.01969.x; Kondo N, 2004, IMMUNOL LETT, V92, P143, DOI 10.1016/j.imlet.2003.11.030; Kondo N, 2006, ANTIOXID REDOX SIGN, V8, P1881, DOI 10.1089/ars.2006.8.1881; Kramer MF, 2006, AM J OTOLARYNG, V27, P190, DOI 10.1016/j.amjoto.2005.09.013; Kulka M, 2009, CURR TOP MED CHEM, V9, P1611, DOI 10.2174/156802609789941898; Lang TL, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00577; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lee S, 2013, ANTIOXID REDOX SIGN, V18, P1165, DOI 10.1089/ars.2011.4322; Leonard A, 2019, CLIN REV ALLERG IMMU, V56, P1, DOI 10.1007/s12016-018-8685-0; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lim JO, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189924; Lin H, 2021, AM J RHINOL ALLERGY, V35, P607, DOI 10.1177/1945892420982411; Lu J, 2014, ANTIOXID REDOX SIGN, V21, P457, DOI 10.1089/ars.2014.5849; Lu J, 2012, ANTIOXID REDOX SIGN, V17, P1738, DOI 10.1089/ars.2012.4650; Makino Y, 1996, J CLIN INVEST, V98, P2469, DOI 10.1172/JCI119065; Matsumoto T, 2007, ANN ALLERG ASTHMA IM, V98, P599, DOI 10.1016/S1081-1206(10)60746-6; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; Mitsui A, 2002, ANTIOXID REDOX SIGN, V4, P693, DOI 10.1089/15230860260220201; MIYACHI Y, 1985, ARCH DERMATOL RES, V277, P288, DOI 10.1007/BF00509082; Mokra D, 2013, ADV EXP MED BIOL, V756, P341, DOI 10.1007/978-94-007-4549-0_41; Mougiakakos D, 2011, BLOOD, V117, P857, DOI 10.1182/blood-2010-09-307041; Nakamura H, 2001, P NATL ACAD SCI USA, V98, P15143, DOI 10.1073/pnas.191498798; Nakamura H, 2006, SEMIN CANCER BIOL, V16, P444, DOI 10.1016/j.semcancer.2006.09.001; Nakamura H, 2009, ADV DRUG DELIVER REV, V61, P303, DOI 10.1016/j.addr.2009.01.003; Nembrini C, 2006, J IMMUNOL, V176, P7180, DOI 10.4049/jimmunol.176.12.7180; Ono R, 2012, J DERMATOL, V39, P843, DOI 10.1111/j.1346-8138.2012.01566.x; Papi A, 2018, LANCET, V391, P783, DOI 10.1016/S0140-6736(17)33311-1; Pichler WJ, 2018, J ALLERGY CLIN IMMUN, V141, P89, DOI 10.1016/j.jaci.2017.11.002; Plugis NM, 2018, P NATL ACAD SCI USA, V115, P8781, DOI 10.1073/pnas.1805288115; Qian Y, 2022, PHARM BIOL, V60, P347, DOI 10.1080/13880209.2022.2032205; Rhee SG, 2005, FREE RADICAL BIO MED, V38, P1543, DOI 10.1016/j.freeradbiomed.2005.02.026; Richards A, 2007, ADV IMMUNOL, V96, P141, DOI 10.1016/S0065-2776(07)96004-6; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Roesner LM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47769-2; Roger T, 2005, EUR J IMMUNOL, V35, P3405, DOI 10.1002/eji.200535413; Sampson HA, 2013, J ALLER CL IMM-PRACT, V1, P15, DOI 10.1016/j.jaip.2012.10.009; Sato A, 2006, ANTIOXID REDOX SIGN, V8, P1891, DOI 10.1089/ars.2006.8.1891; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Schwertassek U, 2007, EMBO J, V26, P3086, DOI 10.1038/sj.emboj.7601746; Shahriari-Farfani T, 2019, APPL BIOCHEM BIOTECH, V187, P649, DOI 10.1007/s12010-018-2793-4; Shi QP, 2018, ONCOL LETT, V16, P3193, DOI 10.3892/ol.2018.8984; Son A, 2006, CELL RES, V16, P230, DOI 10.1038/sj.cr.7310031; Son A, 2009, ANTIOXID REDOX SIGN, V11, P2595, DOI [10.1089/ars.2009.2522, 10.1089/ARS.2009.2522]; Suzuki Y, 2003, J IMMUNOL, V171, P6119, DOI 10.4049/jimmunol.171.11.6119; Suzuki Y, 2005, CHEM IMMUNOL ALLERGY, V87, P32, DOI 10.1159/000087569; Taketani Y, 2011, BIOSCI BIOTECH BIOCH, V75, P1872, DOI 10.1271/bbb.100734; Tamaki H, 2006, GASTROENTEROLOGY, V131, P1110, DOI 10.1053/j.gastro.2006.08.023; Tan SX, 2010, J BIOL CHEM, V285, P6118, DOI 10.1074/jbc.M109.062844; Thau L., 2021, PHYSL OPSONIZATION; Thiele M, 2005, ANTIOXID REDOX SIGN, V7, P1234, DOI 10.1089/ars.2005.7.1234; Tian H, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00269; Tinkov AA, 2018, CELL MOL LIFE SCI, V75, P1567, DOI 10.1007/s00018-018-2745-8; Torii M, 2010, EUR J IMMUNOL, V40, P787, DOI 10.1002/eji.200939724; Ueda S, 2006, LIFE SCI, V79, P1170, DOI 10.1016/j.lfs.2006.03.026; Vickery BP, 2014, J ALLERGY CLIN IMMUN, V133, P468, DOI 10.1016/j.jaci.2013.11.007; Wang FF, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3828; Wang XZ, 2020, AM J PHYSIOL-LUNG C, V318, pL888, DOI 10.1152/ajplung.00186.2019; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Weiss ST, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0501-6; Wolfreys K, 1997, EUR J IMMUNOL, V27, P297, DOI 10.1002/eji.1830270143; Yagi J, 2006, INT IMMUNOL, V18, P1681, DOI 10.1093/intimm/dxl102; Yamada Y, 2003, IMMUNOL LETT, V86, P199, DOI 10.1016/S0165-2478(03)00006-3; Yoshimaru T, 2002, CLIN EXP ALLERGY, V32, P612, DOI 10.1046/j.0954-7894.2002.01263.x; Zhou JD, 2020, ANTIOXID REDOX SIGN, V32, P785, DOI 10.1089/ars.2019.7807	114	0	0	8	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								883116	10.3389/fimmu.2022.883116	http://dx.doi.org/10.3389/fimmu.2022.883116			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C2ZS	35572600	gold, Green Published			2022-12-18	WOS:000881889700001
J	Wang, Z; Song, JR; Azami, NLB; Sun, MY				Wang, Zheng; Song, Jingru; Azami, Nisma Lena Bahaji; Sun, Mingyu			Identification of a Novel Immune Landscape Signature for Predicting Prognosis and Response of Colon Cancer to Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Article						colon cancer; immune-related gene prognostic index; weighted gene co-expression network analysis (WGCNA); prognosis; signature	CONSENSUS MOLECULAR SUBTYPES; COLORECTAL-CANCER; MUTANT P53; INFLAMMATION; MICROENVIRONMENT; INFILTRATION; MACROPHAGES; CONTEXTURE; EXPRESSION; MELANOMA	PurposeTo construct an immune-related gene prognostic index (IRGPI) for colon cancer and elucidate the molecular and immune characteristics as well as the benefit of immune checkpoint inhibitor (ICI) therapy in IRGPI-defined groups of colon cancer. Experimental DesignTranscriptional and clinical data of colon cancer samples were obtained from The Cancer Genome Atlas (TCGA) (n = 521). Immune-related genes were obtained from ImmPort and InnateDB databases. 21 immune-related hub genes were identified byweighted gene co-expression network analysis (WGCNA). the Cox regression method was used to construct IRGPI and validated with Gene Expression Omnibus (GEO) dataset (n = 584). Finally, the molecular and immune profiles in the groups defined by IRGPI and the benefit of ICI treatment were analyzed. Results8 genes were identified to construct IRGPI. IRGPI-low group had a better overall survival (OS) than IRGPI-high group. And this was well validated in the GEO cohort. Overall results showed that those with low IRGPI scores were enriched in antitumor metabolism, and collated with high infiltration of resting memory CD4 T cells and less aggressive phenotypes, benefiting more from ICI treatment. Conversely, high IRGPI scores were associated with cell adhesion molecules (CAMs) and chemokine signaling pathways, high infiltration of macrophage M1, suppressed immunity, more aggressive colon cancer phenotypes, as well as reduced therapeutic benefit from ICI treatment. ConclusionsIRGPI is a promising biomarker to differentiate the prognostic and molecular profile of colon cancer, as well as the therapeutic benefits of ICI treatment.	[Wang, Zheng; Song, Jingru; Azami, Nisma Lena Bahaji; Sun, Mingyu] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China; [Song, Jingru; Azami, Nisma Lena Bahaji; Sun, Mingyu] Shanghai Univ Tradit Chinese Med, Inst Liver Dis, Key Lab Liver & Kidney Dis, Shuguang Hosp, Shanghai, Peoples R China	Shanghai University of Traditional Chinese Medicine; Shanghai University of Traditional Chinese Medicine	Sun, MY (corresponding author), Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China.; Sun, MY (corresponding author), Shanghai Univ Tradit Chinese Med, Inst Liver Dis, Key Lab Liver & Kidney Dis, Shuguang Hosp, Shanghai, Peoples R China.	mysun248@hotmail.com			Shanghai Municipal S and T Commission [19401972300]; Shandong Province Key R&D Program (Major Science and Technology Innovation Project) [2021CXGC010509]; Shanghai Key Laboratory of Traditional Chinese Clinical Medicine; Key Disciplines of Liver and Gall Bladder Diseases; Key Laboratory of Chronic Deficiency Liver Disease of the State Administration of Traditional Chinese Medicine of the People's Republic of China [20DZ2272200]; Shanghai University of Traditional Chinese Medicine Postgraduate Innovation Training Program [Y2021087]	Shanghai Municipal S and T Commission; Shandong Province Key R&D Program (Major Science and Technology Innovation Project); Shanghai Key Laboratory of Traditional Chinese Clinical Medicine; Key Disciplines of Liver and Gall Bladder Diseases; Key Laboratory of Chronic Deficiency Liver Disease of the State Administration of Traditional Chinese Medicine of the People's Republic of China; Shanghai University of Traditional Chinese Medicine Postgraduate Innovation Training Program	This work was supported by the major project of Shanghai Municipal S and T Commission (no. 19401972300), Shandong Province Key R&D Program (Major Science and Technology Innovation Project, 2021CXGC010509), Shanghai Key Laboratory of Traditional Chinese Clinical Medicine, Key Disciplines of Liver and Gall Bladder Diseases, and Key Laboratory of Chronic Deficiency Liver Disease of the State Administration of Traditional Chinese Medicine of the People's Republic of China (20DZ2272200). Shanghai University of Traditional Chinese Medicine Postgraduate Innovation Training Program (Y2021087).	Algars A, 2012, INT J CANCER, V131, P864, DOI 10.1002/ijc.26457; Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Bao XW, 2020, MOL ONCOL, V14, P917, DOI 10.1002/1878-0261.12670; Becht E, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1070-5; Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x; Blanche P, 2013, STAT MED, V32, P5381, DOI 10.1002/sim.5958; Chaput N, 2013, BRIT J CANCER, V109, P1013, DOI 10.1038/bjc.2013.362; Chen WZ, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6290261; Cho YA, 2017, ONCOTARGET, V8, P8550, DOI 10.18632/oncotarget.14347; Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w; D'Angelo SP, 2017, J CLIN ONCOL, V35, P226, DOI 10.1200/JCO.2016.67.9258; D'Errico I, 2011, P NATL ACAD SCI USA, V108, P6603, DOI 10.1073/pnas.1016354108; Damotte D, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2100-3; Danaher P, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0367-1; Deng D, 2021, AGING-US, V13, P19696, DOI 10.18632/aging.203380; Dolan RD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16955-5; Dudgeon C, 2010, MOL CANCER THER, V9, P2893, DOI 10.1158/1535-7163.MCT-10-0635; Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045; Enciu AM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/7801202; Feng QY, 2019, CLIN CANCER RES, V25, P3896, DOI 10.1158/1078-0432.CCR-18-2076; Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Galon J, 2007, CANCER RES, V67, P1883, DOI 10.1158/0008-5472.CAN-06-4806; Galon J, 2013, IMMUNITY, V39, P11, DOI 10.1016/j.immuni.2013.07.008; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; He Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1002-1; Herrera M, 2013, CANCER SCI, V104, P437, DOI 10.1111/cas.12096; Huang TX, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0427-z; Hwang S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57218-9; Jiang P, 2018, NAT MED, V24, P1550, DOI 10.1038/s41591-018-0136-1; Kim JE, 2021, EXP MOL MED, V53, P446, DOI 10.1038/s12276-021-00583-1; Kim Y, 2018, HISTOPATHOLOGY, V73, P663, DOI 10.1111/his.13674; Koelzer VH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1106677; Labianca R, 2013, ANN ONCOL, V24, P64, DOI 10.1093/annonc/mdt354; Li DF, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.723802; Li JY, 2020, INT J COLORECTAL DIS, V35, P1203, DOI 10.1007/s00384-020-03593-z; Lichtenstern CR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030618; Liu M, 2018, ONCOL REP, V40, P1251, DOI 10.3892/or.2018.6525; Liu ML, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109250; Long MD, 2017, J STEROID BIOCHEM, V173, P130, DOI 10.1016/j.jsbmb.2016.12.013; Lopez-Janeiro A., 2020, SYST REV META ANAL M, V33, P1458, DOI [10.1038/s41379-020-0534-z, DOI 10.1038/S41379-020-0534-Z]; Lorent M, 2014, STAT MED, V33, P2379, DOI 10.1002/sim.6079; Madar S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061353; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Martinez V, 2004, PEPTIDES, V25, P1733, DOI 10.1016/j.peptides.2004.05.025; Mayakonda A, 2018, GENOME RES, V28, P1747, DOI 10.1101/gr.239244.118; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Niemira M, 2020, CANCERS, V12, DOI 10.3390/cancers12010037; Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88; Qiu XP, 2016, ONCOL REP, V36, P811, DOI 10.3892/or.2016.4871; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Soldevilla B, 2019, EUR J CANCER, V123, P118, DOI 10.1016/j.ejca.2019.09.008; Song JJ, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00148; Taube JM, 2018, MODERN PATHOL, V31, P214, DOI 10.1038/modpathol.2017.156; Thorsson V, 2018, IMMUNITY, V48, P812, DOI 10.1016/j.immuni.2018.03.023; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Trivedi M, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.52; Tuomisto AE, 2019, WORLD J GASTROENTERO, V25, P4383, DOI 10.3748/wjg.v25.i31.4383; van Neerven SM, 2021, NATURE, V594, P436, DOI 10.1038/s41586-021-03558-4; Vayrynen JP, 2021, CANCER IMMUNOL RES, V9, P8, DOI 10.1158/2326-6066.CIR-20-0527; Xiao W, 2019, MOL CANCER RES, V17, P420, DOI 10.1158/1541-7786.MCR-18-0455; Xu Y, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00053; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Zeng DQ, 2020, THERANOSTICS, V10, P7002, DOI 10.7150/thno.46176; Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128; Zhang QW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050946; Zhang TF, 2016, ONCOTARGET, V7, P73068, DOI 10.18632/oncotarget.12230; Zhou Y, 2020, CANCER CELL, V38, P818, DOI 10.1016/j.ccell.2020.09.015	70	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								802665	10.3389/fimmu.2022.802665	http://dx.doi.org/10.3389/fimmu.2022.802665			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G4TT	35572595	gold, Green Published			2022-12-18	WOS:000795842000001
J	Yang, SH; Lee, JC; Chen, BB; Kuo, SH; Hsu, C; Bai, LY				Yang, Shih-Hung; Lee, Jen-Chieh; Chen, Bang-Bin; Kuo, Sung-Hsin; Hsu, Chiun; Bai, Li-Yuan			Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma	FRONTIERS IN IMMUNOLOGY			English	Article						pancreatic ductal adenocarcinoma; maintenance therapy; chemotherapy; nivolumab; case report	NAB-PACLITAXEL; GEMCITABINE; CANCER	Maintenance therapy is rarely considered in pancreatic ductal adenocarcinoma (PDAC). We describe the case of a 57-year-old man with metastatic PDAC treated with an initially full but subsequently de-escalated dose of combination chemotherapy due to intolerance to neurotoxicity. After a complete response to combined radiofrequency ablation for the liver metastasis and radiotherapy for the pancreatic tumor was achieved, chemotherapy was terminated and maintenance therapy was applied: nivolumab plus cytokine-induced killer cell therapy initially and then a de-escalated dosing interval of nivolumab monotherapy subsequently. No adverse events occurred during nivolumab therapy for more than 2 years, and the patient remains disease-free. To date, this is the first report of maintenance nivolumab after successful multimodality therapy in metastatic PDAC.	[Yang, Shih-Hung; Kuo, Sung-Hsin; Hsu, Chiun] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan; [Yang, Shih-Hung; Kuo, Sung-Hsin; Hsu, Chiun] Natl Taiwan Univ, Grad Inst Oncol, Coll Med, Taipei, Taiwan; [Lee, Jen-Chieh] Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; [Chen, Bang-Bin] Natl Taiwan Univ Hosp, Dept Med Imaging & Radiol, Taipei, Taiwan; [Hsu, Chiun] Natl Taiwan Univ, Coll Med, Canc Ctr, Taipei, Taiwan; [Bai, Li-Yuan] China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; China Medical University Taiwan; China Medical University Hospital - Taiwan	Bai, LY (corresponding author), China Med Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Taichung, Taiwan.	lybai6@gmail.com		CHEN, BANG-BIN/0000-0001-7058-1427; Hsu, Chiun/0000-0002-1122-0055	Ono Pharmaceutical Co., Ltd	Ono Pharmaceutical Co., Ltd(Ono Pharmaceutical Co Ltd)	Ono Pharmaceutical Co., Ltd. supported nivolumab for an ongoing investigator-initiated clinical trial in pancreatic cancer at National Taiwan University Hospital (principal investigator: S-HY).	Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Dahan L, 2021, J CLIN ONCOL, V39, P3242, DOI 10.1200/JCO.20.03329; Fei QL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02787-1; Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387; Gout J, 2021, GUT, V70, P743, DOI 10.1136/gutjnl-2019-319970; Han Y, 2021, THORAC CANCER, V12, P145, DOI 10.1111/1759-7714.13731; O'Reilly EM, 2019, JAMA ONCOL, V5, P1431, DOI 10.1001/jamaoncol.2019.1588; Reni M, 2013, EUR J CANCER, V49, P3609, DOI 10.1016/j.ejca.2013.06.041; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Wainberg ZA, 2020, CLIN CANCER RES, V26, P4814, DOI 10.1158/1078-0432.CCR-20-0099; Weiss GJ, 2018, INVEST NEW DRUG, V36, P96, DOI 10.1007/s10637-017-0525-1; Wu AA, 2020, CLIN CANCER RES, V26, P5129, DOI 10.1158/1078-0432.CCR-20-1025	12	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								870406	10.3389/fimmu.2022.870406	http://dx.doi.org/10.3389/fimmu.2022.870406			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G5LK	35572526	gold, Green Published			2022-12-18	WOS:000795889100001
J	Zhang, Y; Hao, SF; Xiao, N; Zhang, Y; Wang, HQ; Li, LJ; Fu, R; Shao, ZH				Zhang, Yang; Hao, Shanfeng; Xiao, Na; Zhang, Yu; Wang, Huaquan; Li, Lijuan; Fu, Rong; Shao, Zonghong			Ferritin Light Chain: A Candidate Autoantigen in Immuno-Related Pancytopenia	FRONTIERS IN IMMUNOLOGY			English	Article						pancytopenia; antigenic epitopes; FTL; phage random peptide library; ELISPOT	APLASTIC-ANEMIA; HLA-DR; EXPRESSION; AUTOANTIBODIES; CELLS; DP	The characteristic feature of immune-related pancytopenia (IRP) is autoantibody-mediated bone marrow (BM) damage and peripheral blood cytopenia. We found that the potential antigen of IRP was Ferritin light chain (FTL) by SEREX (serological analysis of recombinant cDNA expression libraries) in the previous study. In this study, we tried to explore the antigenic epitopes of FTL and verify its antigenicity in IRP. We found the possible FTL epitope: VNLYLQASYTYLSLG by phage random peptide library. Through ELISPOT, it was found that peptide VNLYLQASYTYLSLG can significantly stimulate the production of interleukin-4 and cannot stimulate the production of interferon-gamma, which suggested that the peptide can obviously activate Th2 cells. Peptide-major histocompatibility complex tetramer elicited antigen-specific T cell responses. The expression levels of FTL were significantly increased in the patients with untreated IRP (P < 0.05). In conclusion, we found that FTL is the target antigen for some patients with IRP. The peptide of VNLYLQASYTYLSLG is an epitope of the target antigen. The target antigen is abnormally overexpressed on the membrane of BM cells, especially on the surface of CD34+ BM cells of patients with IRP. In addition, it is related to the severity of disease. These results provide a possible new target for the treatment of IRP in the future.	[Zhang, Yang; Hao, Shanfeng; Xiao, Na; Zhang, Yu; Wang, Huaquan; Li, Lijuan; Fu, Rong; Shao, Zonghong] Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China	Tianjin Medical University	Shao, ZH (corresponding author), Tianjin Med Univ Gen Hosp, Dept Hematol, Tianjin, Peoples R China.	shaozonghong@sina.com						Baerlecken NT, 2012, ANN RHEUM DIS, V71, P943, DOI 10.1136/annrheumdis-2011-200413; Fan YM, 2014, BBA-MOL CELL RES, V1843, P2775, DOI 10.1016/j.bbamcr.2014.06.015; Fu Rong, 2010, Zhonghua Yi Xue Za Zhi, V90, P2989; Fu Rong, 2010, Zhonghua Xue Ye Xue Za Zhi, V31, P684; Fu Rong, 2004, Zhonghua Xue Ye Xue Za Zhi, V25, P213; Fu Rong, 2003, Zhonghua Xue Ye Xue Za Zhi, V24, P177; Gray CP, 2002, BLOOD, V99, P3326, DOI 10.1182/blood.V99.9.3326; Hao SF, 2020, MOL MED REP, V22, P2012, DOI 10.3892/mmr.2020.11280; Hao SF, 2017, INT J HEMATOL, V106, P622, DOI 10.1007/s12185-017-2287-0; He H, 2001, Zhonghua Xue Ye Xue Za Zhi, V22, P79; Hosseini S, 2019, TRANSFUS APHER SCI, V58, P669, DOI 10.1016/j.transci.2019.08.019; Karosiene E, 2013, IMMUNOGENETICS, V65, P711, DOI 10.1007/s00251-013-0720-y; Kunireddy N, 2018, INDIAN J CLIN BIOCHE, V33, P406, DOI 10.1007/s12291-017-0702-1; Mewar D, 2005, ARTHRITIS RHEUM, V52, P3868, DOI 10.1002/art.21483; Mohamed W, 2006, MOL GENET GENOMICS, V275, P344, DOI 10.1007/s00438-005-0090-8; Mohamed W, 2010, INFECT IMMUN, V78, P3306, DOI 10.1128/IAI.00210-10; Nesher G, 2014, ISR MED ASSOC J, V16, P454; Nielsen M, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000107; Paul Sinu, 2016, Curr Protoc Immunol, V114, DOI 10.1002/cpim.12; Saunthararajah Y, 2002, BLOOD, V100, P1570, DOI 10.1182/blood.V100.5.1570.h81702001570_1570_1574; Shao Q, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/6503539; Shao WS, 2000, INT J HEMATOL, V71, P350; Sottile R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00224; Sugimori C, 2007, EXP HEMATOL, V35, P13, DOI 10.1016/j.exphem.2006.09.002; Teng Guang-shuai, 2012, Zhonghua Xue Ye Xue Za Zhi, V33, P865; Valent P, 2007, LEUKEMIA RES, V31, P727, DOI 10.1016/j.leukres.2006.11.009; Wang P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-568; Wang P, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000048; Wang T, 2017, Zhonghua Yi Xue Za Zhi, V97, P1406, DOI 10.3760/cma.j.issn.0376-2491.2017.18.011; Wang YH, 2014, CLIN LAB, V60, P729, DOI 10.7754/Clin.Lab.2013.130220; Wimazal F, 2007, LEUKEMIA RES, V31, P1461, DOI 10.1016/j.leukres.2007.03.015; Xiao N, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12911; Yu H, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9777; Yu H, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/730450	34	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								851096	10.3389/fimmu.2022.851096	http://dx.doi.org/10.3389/fimmu.2022.851096			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1E3XN	35572557	Green Published, gold			2022-12-18	WOS:000794425900001
J	Zheng, LB; Cao, HM; Qiu, JY; Chi, CF				Zheng, Libing; Cao, Huimin; Qiu, Jiayin; Chi, Changfeng			Inhibitory Effect of FMRFamide on NO Production During Immune Defense in Sepiella japonica	FRONTIERS IN IMMUNOLOGY			English	Article						Sepiella japonica; FMRFamide; nitric oxide; inhibitory effect; immune response	NITRIC-OXIDE; NERVOUS-SYSTEM; NEUROPEPTIDE; GANGLIA; SNAIL; FAMILY	Neuropeptide Phe-Met-Arg-Phe-NH2 (FMRFamide), specifically existing in invertebrates, plays pivotal roles in various physiological processes. The involvement in neuroendocrine-immune regulation was explored in recent years, and it could modulate nitric oxide (NO) production under immune stress. However, detailed knowledge is still little known. In this study, we identified FMRFamide as an inhibitory factor on NO production in the immune reaction of Sepiella japonica. Firstly, Vibrio harveyi incubation caused significantly upregulated expression of FMRFamide precursor and NO synthase (NOS) in just hatched cuttlefish with quantitative Real-time PCR (qRT-PCR), which indicated that both were likely to be involved in the immune defense. The whole-mount in situ hybridization (ISH) detected FMRFamide precursor and NOS-positive signals appeared colocalization, suggesting that at histological and anatomical levels FMRFamide might interact with NOS. Next, NOS mRNA was highly significantly upregulated at 72 h when FMRFamide precursor mRNA was knocked down effectively with the RNA interference (RNAi) method; the results hinted that FMRFamide was likely to regulate NO production. Continuously, the inflammatory model was constructed in RAW 264.7 cells induced by lipopolysaccharide (LPS), FMRFamide administration resulted in a highly significant reduction of the NO level in dose- and time-response manners. Although the addition of the selected inducible NOS (iNOS) inhibitor had inhibited the NO production induced by LPS, the additional FMRFamide could still furtherly sharpen the process. Collectively, it was concluded that neuropeptide FMRFamide could indeed inhibit NO production to serve as feedback regulation at the late stage of immune response to protect hosts from excessive immune cytotoxicity. The inhibitory effect on NO production could not only be mediated by the NOS pathway but also be implemented through other pathways that needed to be furtherly explored. The results will provide data for comparing the structure and immune function of neuroendocrine-immune system (NEIS) between "advanced" cephalopods and other invertebrates and will provide new information for understanding the NEIS of cephalopods.	[Zheng, Libing; Cao, Huimin; Qiu, Jiayin; Chi, Changfeng] Zhejiang Ocean Univ, Sch Marine Sci & Technol, Natl & Prov Joint Lab Explorat & Utilizat Marine A, Zhoushan, Peoples R China	Zhejiang Ocean University	Chi, CF (corresponding author), Zhejiang Ocean Univ, Sch Marine Sci & Technol, Natl & Prov Joint Lab Explorat & Utilizat Marine A, Zhoushan, Peoples R China.	chicf@zjou.edu.cn			National Natural Science Foundation of China [31872547]; Natural Science Foundation of Zhejiang Province, China [LY20C190007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province, China(Natural Science Foundation of Zhejiang Province)	This work was supported by the National Natural Science Foundation of China (NSFC; No. 31872547) and the Natural Science Foundation of Zhejiang Province, China (LY20C190007).	Altura MA, 2011, CELL MICROBIOL, V13, P527, DOI 10.1111/j.1462-5822.2010.01552.x; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Burbach JPH, 2014, BIOL OPEN, V3, P50, DOI 10.1242/bio.20136890; Castellanos-Martinez S, 2018, AQUACULTURE, V497, P487, DOI 10.1016/j.aquaculture.2018.08.022; CHIN GJ, 1994, BIOL BULL, V187, P185, DOI 10.2307/1542241; Cummins SF, 2011, J COMP NEUROL, V519, P2043, DOI 10.1002/cne.22621; Davidson SK, 2004, CELL MICROBIOL, V6, P1139, DOI 10.1111/j.1462-5822.2004.00429.x; Di Cosmo A, 1998, J COMP NEUROL, V398, P1, DOI 10.1002/(SICI)1096-9861(19980817)398:1<1::AID-CNE1>3.0.CO;2-5; Dockray GJ, 2004, EXP PHYSIOL, V89, P229, DOI 10.1113/expphysiol.2004.027169; ELEKES K, 1994, J NEUROCYTOL, V23, P758, DOI 10.1007/BF01268088; Fang Q, 2005, PEPTIDES, V26, P791, DOI 10.1016/j.peptides.2004.12.009; FRANCHINI A, 1995, COMP BIOCHEM PHYS B, V110, P403, DOI 10.1016/0305-0491(94)00163-O; Gifondorwa DJ, 2006, BIOL BULL-US, V210, P109, DOI 10.2307/4134600; Jezzini SH, 2005, J NEUROSCI METH, V149, P15, DOI 10.1016/j.jneumeth.2005.05.007; Jiang QF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06963; Jiang QF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069158; Kent BV, 2021, J SCI STUD RELIG, V60, P198, DOI 10.1111/jssr.12695; Li MJ, 2019, FISH SHELLFISH IMMUN, V88, P480, DOI 10.1016/j.fsi.2019.03.023; Li Y, 2018, MOLECULES, V23, DOI 10.3390/molecules23040742; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu ZM, 2016, GENOM DATA, V7, P155, DOI 10.1016/j.gdata.2015.12.011; Lu ZM, 2016, J EXP ZOOL PART A, V325, P181, DOI 10.1002/jez.2011; MARTIN R, 1987, EXPERIENTIA, V43, P537, DOI 10.1007/BF02143582; McFall-Ngai M, 2010, SEMIN IMMUNOL, V22, P48, DOI 10.1016/j.smim.2009.11.003; Nyholm SV, 2004, NAT REV MICROBIOL, V2, P632, DOI 10.1038/nrmicro957; PRICE DA, 1977, PREP BIOCHEM, V7, P261, DOI 10.1080/00327487708061643; REGULSKI M, 1995, P NATL ACAD SCI USA, V92, P9072, DOI 10.1073/pnas.92.20.9072; Roszer T, 2004, CELL TISSUE RES, V316, P255, DOI 10.1007/s00441-004-0870-1; Roszer T, 2004, BRAIN BEHAV EVOLUT, V63, P23, DOI 10.1159/000073757; Roszer T, 2006, CELL TISSUE RES, V325, P567, DOI 10.1007/s00441-006-0185-5; Roszer T, 2014, CELL TISSUE RES, V358, P371, DOI 10.1007/s00441-014-1966-x; SALZET M, 1994, EUR J BIOCHEM, V221, P269, DOI 10.1111/j.1432-1033.1994.tb18738.x; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; Sharma D, 2010, MUTAT RES-GEN TOX EN, V703, P149, DOI 10.1016/j.mrgentox.2010.08.010; Shi H., ANN C CHINESE FISHER; Starunov VV, 2017, FRONT ZOOL, V14, DOI 10.1186/s12983-017-0211-3; Straub VA, 2007, J NEUROPHYSIOL, V97, P1088, DOI 10.1152/jn.01048.2006; Terahara K, 2008, CURR PHARM DESIGN, V14, P131, DOI 10.2174/138161208783378725; Thomas DD, 2008, FREE RADICAL BIO MED, V45, P18, DOI 10.1016/j.freeradbiomed.2008.03.020; Torreilles Jean, 2001, BMC Immunology, V2, P1, DOI 10.1186/1471-2172-2-1; Wang TF, 2017, PARASITE VECTOR, V10, DOI 10.1186/s13071-017-2218-1; Zatylny-Gaudin C, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00178; Zhang GF, 2012, NATURE, V490, P49, DOI 10.1038/nature11413; Zheng LB, 2020, FISH SHELLFISH IMMUN, V99, P52, DOI 10.1016/j.fsi.2020.01.017	45	0	0	5	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 28	2022	13								825634	10.3389/fimmu.2022.825634	http://dx.doi.org/10.3389/fimmu.2022.825634			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G5EW	35572529	gold, Green Published			2022-12-18	WOS:000795871500001
J	Atmar, K; Ruivenkamp, CAL; Hooimeijer, L; Nibbeling, EAR; Eckhardt, CL; Huisman, EJ; Lankester, AC; Bartels, M; Santen, GWE; Smiers, FJ; van der Burg, M; Mohseny, AB				Atmar, Khaled; Ruivenkamp, Claudia A. L.; Hooimeijer, Louise; Nibbeling, Esther A. R.; Eckhardt, Corien L.; Huisman, Elise J.; Lankester, Arjan C.; Bartels, Marije; Santen, Gijs W. E.; Smiers, Frans J.; van der Burg, Mirjam; Mohseny, Alexander B.			Diagnostic Value of a Protocolized In-Depth Evaluation of Pediatric Bone Marrow Failure: A Multi-Center Prospective Cohort Study	FRONTIERS IN IMMUNOLOGY			English	Article						bone marrow failure; BMF; aplastic anemia; AA; cytopenia; next-generation sequencing; diagnostics	SEVERE APLASTIC-ANEMIA; NATURAL-KILLER-CELLS; MYELODYSPLASTIC SYNDROMES; CLONAL HEMATOPOIESIS; MUTATIONS CAUSE; GERM-LINE; MANAGEMENT; PATHOPHYSIOLOGY; MANIFESTATIONS; DEFICIENCY	BackgroundSevere multilineage cytopenia in childhood caused by bone marrow failure (BMF) often represents a serious condition requiring specific management. Patients are at risk for invasive infections and bleeding complications. Previous studies report low rates of identifiable causes of pediatric BMF, rendering most patients with a descriptive diagnosis such as aplastic anemia (AA). MethodsWe conducted a multi-center prospective cohort study in which an extensive diagnostic approach for pediatric patients with suspected BMF was implemented. After exclusion of malignant and transient causes of BMF, patients entered thorough diagnostic evaluation including bone marrow analysis, whole exome sequencing (WES) including copy number variation (CNV) analysis and/or single nucleotide polymorphisms (SNP) array analysis. In addition, functional and immunological evaluation were performed. Here we report the outcomes of the first 50 patients (2017-2021) evaluated by this approach. ResultsIn 20 patients (40%) a causative diagnosis was made. In this group, 18 diagnoses were established by genetic analysis, including 14 mutations and 4 chromosomal deletions. The 2 remaining patients had short telomeres while no causative genetic defect was found. Of the remaining 30 patients (60%), 21 were diagnosed with severe aplastic anemia (SAA) based on peripheral multi-lineage cytopenia and hypoplastic bone marrow, and 9 were classified as unexplained cytopenia without bone marrow hypoplasia. In total 28 patients had undergone hematopoietic stem cell transplantation (HSCT) of which 22 patients with an unknown cause and 6 patients with an identified cause for BMF. ConclusionWe conclude that a standardized in-depth diagnostic protocol as presented here, can increase the frequency of identifiable causes within the heterogeneous group of pediatric BMF. We underline the importance of full genetic analysis complemented by functional tests of all patients as genetic causes are not limited to patients with typical (syndromal) clinical characteristics beyond cytopenia. In addition, it is of importance to apply genome wide genetic analysis, since defects in novel genes are frequently discovered in this group. Identification of a causal abnormality consequently has implications for the choice of treatment and in some cases prevention of invasive therapies.	[Atmar, Khaled; Lankester, Arjan C.; Smiers, Frans J.; van der Burg, Mirjam; Mohseny, Alexander B.] Willem Alexander Childrens Hosp, Leiden Univ Med Ctr, Dept Pediat Hematol & Stem Cell Transplantat, Leiden, Netherlands; [Ruivenkamp, Claudia A. L.; Nibbeling, Esther A. R.; Santen, Gijs W. E.] Leiden Univ, Dept Clin Genet, Med Ctr, Leiden, Netherlands; [Hooimeijer, Louise] Univ Med Ctr Groningen, Beatrix Childrens Hosp, Dept Pediat Hematol, Groningen, Netherlands; [Eckhardt, Corien L.] Univ Amsterdam, Dept Pediat Hematol, Med Ctr, Amsterdam, Netherlands; [Huisman, Elise J.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Pediat Hematol, Rotterdam, Netherlands; [Bartels, Marije] Univ Med Ctr Utrecht, Wilhelmina Childrens Hosp, Dept Pediat Hematol, Utrecht, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Groningen; University of Amsterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Mohseny, AB (corresponding author), Willem Alexander Childrens Hosp, Leiden Univ Med Ctr, Dept Pediat Hematol & Stem Cell Transplantat, Leiden, Netherlands.							Baumann I, 2012, HISTOPATHOLOGY, V61, P10, DOI 10.1111/j.1365-2559.2011.04156.x; Bluteau O, 2018, BLOOD, V131, P717, DOI 10.1182/blood-2017-09-806489; CAMITTA BM, 1988, LANCET, V1, P303; Carrillo N, 2018, NEUROTHERAPEUTICS, V15, P900, DOI 10.1007/s13311-018-0671-y; Chen DH, 2016, AM J HUM GENET, V98, P1146, DOI 10.1016/j.ajhg.2016.04.009; Churpek JE, 2013, LEUKEMIA LYMPHOMA, V54, P28, DOI 10.3109/10428194.2012.701738; Davidsson J, 2018, LEUKEMIA, V32, P1106, DOI 10.1038/s41375-018-0074-4; de Latour RP, 2016, BLOOD, V127, P2971, DOI 10.1182/blood-2016-01-583625; de Latour RP, 2010, BLOOD, V116, P4175, DOI 10.1182/blood-2010-01-266098; Desai SR, 2021, INDIAN J HEMATOL BLO, V37, P157, DOI 10.1007/s12288-020-01346-0; Fattizzo B, 2021, LEUKEMIA, V35, P3223, DOI 10.1038/s41375-021-01190-9; Ferreira MSV, 2020, ANN NY ACAD SCI, V1466, P93, DOI 10.1111/nyas.14248; Galaverna F, 2018, CURR OPIN ONCOL, V30, P402, DOI 10.1097/CCO.0000000000000488; Ganapathi KA, 2015, BLOOD, V125, P56, DOI 10.1182/blood-2014-06-580340; Garaycoechea JI, 2014, BLOOD, V123, P26, DOI 10.1182/blood-2013-09-427740; Ghemlas I, 2015, J MED GENET, V52, P575, DOI 10.1136/jmedgenet-2015-103270; Giudice V, 2018, HAEMATOLOGICA, V103, P759, DOI 10.3324/haematol.2017.176701; Gluckman E, 2008, BONE MARROW TRANSPL, V41, P127, DOI 10.1038/sj.bmt.1705960; Hartung HD, 2013, PEDIATR CLIN N AM, V60, P1311, DOI 10.1016/j.pcl.2013.08.011; Hasle H, 2016, HEMATOL-AM SOC HEMAT, P598, DOI 10.1182/asheducation-2016.1.598; Iwafuchi H, 2019, HISTOPATHOLOGY, V74, P239, DOI 10.1111/his.13721; Keel SB, 2016, HAEMATOLOGICA, V101, P1343, DOI 10.3324/haematol.2016.149476; Killick SB, 2016, BRIT J HAEMATOL, V172, P187, DOI 10.1111/bjh.13853; Kordasti S, 2016, BLOOD, V128, P1193, DOI 10.1182/blood-2016-03-703702; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Latham SL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06713-0; Li Zhi-shang, 2011, Zhonghua Yi Xue Za Zhi, V91, P1084; Lin FC, 2014, BLOOD, V124, P3699, DOI 10.1182/blood-2014-01-549527; Liu CY, 2014, IMMUNOL INVEST, V43, P491, DOI 10.3109/08820139.2014.888448; Liu S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162382; Malcovati L, 2017, BLOOD, V129, P3371, DOI 10.1182/blood-2017-01-763425; Michniacki TF, 2018, J CLIN IMMUNOL, V38, P166, DOI 10.1007/s10875-018-0480-4; Mohseny AB, 2021, J PEDIAT HEMATOL ONC, V43, pE1025, DOI 10.1097/MPH.0000000000001991; Muramatsu H, 2017, GENET MED, V19, P796, DOI 10.1038/gim.2016.197; Narumi S, 2016, NAT GENET, V48, P792, DOI 10.1038/ng.3569; Niemeyer CM, 2011, HEMATOL-AM SOC HEMAT, P84, DOI 10.1182/asheducation-2011.1.84; Ogawa S, 2016, BLOOD, V128, P337, DOI 10.1182/blood-2016-01-636381; Pagliuca S, 2021, BLOOD, V138, P2781, DOI 10.1182/blood.2021012900; Park M, 2015, APPL IMMUNOHISTO M M, V23, P139, DOI 10.1097/PAI.0000000000000023; Parker C, 2005, BLOOD, V106, P3699, DOI 10.1182/blood-2005-04-1717; PARSONS HG, 1995, CLIN INVEST MED, V18, P389; Reinke SO, 2012, BIOL CHEM, V393, P731, DOI 10.1515/hsz-2012-0195; Savage SA, 2017, SEMIN HEMATOL, V54, P105, DOI 10.1053/j.seminhematol.2017.04.004; Savage SA, 2010, GENET MED, V12, P753, DOI 10.1097/GIM.0b013e3181f415b5; Scheinberg P, 2010, HAEMATOL-HEMATOL J, V95, P1075, DOI 10.3324/haematol.2009.017889; Shimamura A, 2016, HEMATOL-AM SOC HEMAT, P74, DOI 10.1182/asheducation-2016.1.74; Shimamura Akiko, 2009, Hematology Am Soc Hematol Educ Program, P329, DOI 10.1182/asheducation-2009.1.329; Shimamura A, 2010, BLOOD REV, V24, P101, DOI 10.1016/j.blre.2010.03.002; Steensma DP, 2015, BLOOD, V126, P2349, DOI 10.1182/blood-2015-10-672659; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Tesi B, 2017, BLOOD, V129, P2266, DOI 10.1182/blood-2016-10-743302; Townsley DM, 2014, BLOOD, V124, P2775, DOI 10.1182/blood-2014-05-526285; Turro E, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7666; Verloes A., 1993, GENEREVIEWS; Wegman-Ostrosky T, 2017, BRIT J HAEMATOL, V177, P526, DOI 10.1111/bjh.14535; Wlodarski MW, 2016, BLOOD, V127, P1387, DOI 10.1182/blood-2015-09-669937; Young NS, 2018, NEW ENGL J MED, V379, P1643, DOI 10.1056/NEJMra1413485; Young NS, 2015, NEW ENGL J MED, V373, P1675, DOI 10.1056/NEJMc1509703; Zhang MY, 2015, HAEMATOLOGICA, V100, P42, DOI 10.3324/haematol.2014.113456; Zieger B, 2022, THROMB HAEMOSTASIS, V122, P1139, DOI 10.1055/s-0041-1742207	60	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								883826	10.3389/fimmu.2022.883826	http://dx.doi.org/10.3389/fimmu.2022.883826			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0OC	35572556	Green Published, gold			2022-12-18	WOS:000795555600001
J	Brennan, L; Brouwer-Visser, J; Nuesch, E; Karpova, M; Heller, A; Gaire, F; Schneider, M; Gomes, B; Korski, K				Brennan, Laura; Brouwer-Visser, Jurriaan; Nueesch, Eveline; Karpova, Maria; Heller, Astrid; Gaire, Fabien; Schneider, Meike; Gomes, Bruno; Korski, Konstanty			T-Cell Heterogeneity in Baseline Tumor Samples: Implications for Early Clinical Trial Design and Analysis	FRONTIERS IN IMMUNOLOGY			English	Article						IHC; immunohistochemistry; CD8 T-cells; Tregs (regulatory T cells); tumor infiltrating lymphocytes (TILs); prior treatment; cancer immunotherapy; intrapatient heterogeneity; multivariate statistics	LYMPHOCYTES; SURVIVAL; ALPHA	Background: In early stage clinical trials, changes to levels of tumor infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) are critical biomarkers of the mechanism of action of novel immunotherapies. However, baseline heterogeneity of tumor samples, both between and within patients, and the resultant impact on the validity of clinical trial data is not well defined. Here we identify and quantify the impact of baseline variables on the heterogeneity of FoxP3+ and proliferating CD8+ T-cells levels (MKi67+CD8A+) in the TME both between and within patients for the purpose of informing clinical trial design and analysis. Methods: We compared levels of FoxP3+ and MKi67+CD8+ cell densities (counts/mm(2)) from >1000 baseline tumor samples from clinical trials and commercially available sources. Using multivariate hierarchical regression techniques, we investigated whether inter-person heterogeneity of activated or regulatory T-cells could be attributed to baseline characteristics including demographics, indication, lesion type, tissue of excision, biopsy method, prior cancer treatment, and tissue type i.e., "fresh" or "archival" status. We also sought to characterize within-patient heterogeneity by lesion type and tissue type. Results: Prior cancer treatment with hormone therapy or chemotherapy that induces immunogenic cell death may alter the TME. Archival tissue is an unreliable substitute for fresh tissue for determining baseline TIL levels. Baseline and on treatment biopsies should be matched by lesion type to avoid bias.	[Brennan, Laura; Brouwer-Visser, Jurriaan] Roche Innovat Ctr New York, Early Biomarker Dev Oncol, Roche Pharma Res & Early Dev, Little Falls, NJ 10016 USA; [Nueesch, Eveline; Schneider, Meike; Gomes, Bruno] Roche Innovat Ctr Basel, Roche Pharma & Early Dev, Basel, Switzerland; [Karpova, Maria; Heller, Astrid; Gaire, Fabien; Korski, Konstanty] Roche Innovat Ctr Munich, Roche Pharma & Early Dev, Penzberg, Germany	Roche Holding	Brennan, L (corresponding author), Roche Innovat Ctr New York, Early Biomarker Dev Oncol, Roche Pharma Res & Early Dev, Little Falls, NJ 10016 USA.	ella_bea@yahoo.com			Roche's Pharma Research and Early Development Department - Roche Postdoctoral Fellowship	Roche's Pharma Research and Early Development Department - Roche Postdoctoral Fellowship	Funding was provided by Roche's Pharma Research and Early Development Department. LB's postdoc in the Early Biomarker Development Oncology group was funded by the Roche Postdoctoral Fellowship.	Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191; Bhat P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.67; Brouwer-Visser J, 2018, CANCER EPIDEM BIOMAR, V27, P103, DOI 10.1158/1055-9965.EPI-17-0461; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Cheng JH, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00968; Combs SE, 2016, LAB INVEST, V96, P264, DOI 10.1038/labinvest.2015.138; Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432; Curtsinger JM, 2012, J IMMUNOL, V189, P659, DOI 10.4049/jimmunol.1102727; Dancey JE, 2010, CLIN CANCER RES, V16, P1745, DOI 10.1158/1078-0432.CCR-09-2167; Dannenfelser R, 2017, ONCOTARGET, V8, P57121, DOI 10.18632/oncotarget.19078; de Ruiter EJ, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356148; Ferry-Galow KV, 2018, J ONCOL PRACT, V14, P690, DOI 10.1200/JOP.18.00092; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Fucikova J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03221-2; Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588; Grillo F, 2017, J CLIN PATHOL, V70, P988, DOI 10.1136/jclinpath-2017-204387; Iwamoto T, 2017, ONCOTARGET, V8, P26122, DOI 10.18632/oncotarget.15385; Kmiecik J, 2013, J NEUROIMMUNOL, V264, P71, DOI 10.1016/j.jneuroim.2013.08.013; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Lee K, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221065; Mohammad I, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aap9415; Morris SC, 2009, J IMMUNOL, V182, P1429, DOI 10.4049/jimmunol.182.3.1429; Nakano O, 2001, CANCER RES, V61, P5132; Navarro F. C., 2018, GEND GENOME, V2, P81, DOI DOI 10.1177/2470289718801379; Navarro FC., 2017, GEND GENOME, V1, P1, DOI [10.1089/gg.2017.0014, DOI 10.1089/GG.2017.0014]; Olson EM, 2011, NAT REV CLIN ONCOL, V8, P620, DOI 10.1038/nrclinonc.2011.114; Parchment RE, 2016, SEMIN ONCOL, V43, P427, DOI 10.1053/j.seminoncol.2016.07.001; Piersma SJ, 2007, CANCER RES, V67, P354, DOI 10.1158/0008-5472.CAN-06-3388; Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151; Tao H, 2012, LUNG CANCER, V75, P95, DOI 10.1016/j.lungcan.2011.06.002; van Horssen R, 2006, ONCOLOGIST, V11, P397, DOI 10.1634/theoncologist.11-4-397; Vanmeerbeek I, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1703449; Wong CH, 2019, BIOSTATISTICS, V20, P273, DOI 10.1093/biostatistics/kxx069; Zhang D, 2021, LARYNGOSCOPE, V131, pE1249, DOI 10.1002/lary.29196	34	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								760763	10.3389/fimmu.2022.760763	http://dx.doi.org/10.3389/fimmu.2022.760763			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G7HH	35558070	gold, Green Published			2022-12-18	WOS:000884922100001
J	Dhupar, R; Jones, KE; Powers, AA; Eisenberg, SH; Ding, K; Chen, FY; Nasarre, C; Cen, ZP; Gong, YN; LaRue, AC; Yeh, ELZBS.; Luketich, JD; Lee, ADV.; Oesterreich, S; Lotze, MT; Gemmill, RM; Soloff, AC				Dhupar, Rajeev; Jones, Katherine E.; Powers, Amy A.; Eisenberg, Seth H.; Ding, Kai; Chen, Fangyuan; Nasarre, Cecile; Cen, Zhanpeng; Gong, Yi-Nan; LaRue, Amanda C.; Yeh, Elizabeth S.; Luketich, James D.; Lee, Adrian V.; Oesterreich, Steffi; Lotze, Michael T.; Gemmill, Robert M.; Soloff, Adam C.			Isoforms of Neuropilin-2 Denote Unique Tumor-Associated Macrophages in Breast Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						neuropilin; tumor-associated macrophage; breast cancer; neuropilin-2; neuropilin isoforms; neuropilin-2a; neuropilin-2b	MYELOID CELLS; EXPRESSION; METASTASIS; MONOCYTES; PATHWAY; PROTEIN; GROWTH; GENES; INTERLEUKIN-10; ANGIOGENESIS	Tumor-associated macrophages (TAMs) exert profound influence over breast cancer progression, promoting immunosuppression, angiogenesis, and metastasis. Neuropilin-2 (NRP2), consisting of the NRP2a and NRP2b isoforms, is a co-receptor for heparin-binding growth factors including VEGF-C and Class 3 Semaphorins. Selective upregulation in response to environmental stimuli and independent signaling pathways endow the NRP2 isoforms with unique functionality, with NRP2b promoting increased Akt signaling via receptor tyrosine kinases including VEGFRs, MET, and PDGFR. Although NRP2 has been shown to regulate macrophage/TAM biology, the role of the individual NRP2a/NRP2b isoforms in TAMs has yet to be evaluated. Using transcriptional profiling and spectral flow cytometry, we show that NRP2 isoform expression was significantly higher in TAMs from murine mammary tumors. NRP2a/NRP2b levels in human breast cancer metastasis were dependent upon the anatomic location of the tumor and significantly correlated with TAM infiltration in both primary and metastatic breast cancers. We define distinct phenotypes of NRP2 isoform-expressing TAMs in mouse models of breast cancer and within malignant pleural effusions from breast cancer patients which were exclusive of neuropilin-1 expression. Genetic depletion of either NRP2 isoform in macrophages resulted in a dramatic reduction of LPS-induced IL-10 production, defects in phagosomal processing of apoptotic breast cancer cells, and increase in cancer cell migration following co-culture. By contrast, depletion of NRP2b, but not NRP2a, inhibited production of IL-6. These results suggest that NRP2 isoforms regulate both shared and unique functionality in macrophages and are associated with distinct TAM subsets in breast cancer.	[Dhupar, Rajeev; Jones, Katherine E.; Powers, Amy A.; Eisenberg, Seth H.; Luketich, James D.; Soloff, Adam C.] Univ Pittsburgh, Dept Cardiothorac Surg, Sch Med, Pittsburgh, PA USA; [Dhupar, Rajeev; Cen, Zhanpeng; Gong, Yi-Nan; Lotze, Michael T.; Soloff, Adam C.] Univ Pittsburgh Med Ctr UPMC, Canc Immunol & Immunotherapy Program, Hillman Canc Ctr, Pittsburgh, PA USA; [Dhupar, Rajeev] VA Pittsburgh Healthcare Syst, Surg Serv Div, Pittsburgh, PA USA; [Ding, Kai; Chen, Fangyuan; Lee, Adrian V.; Oesterreich, Steffi] Magee Womens Res Inst, Womens Canc Res Ctr, UPMC Hillman Canc Ctr, Pittsburgh, PA USA; [Nasarre, Cecile; Gemmill, Robert M.] Med Univ South Carolina, Dept Med, Div Hematol, Charleston, SC USA; [Nasarre, Cecile; Gemmill, Robert M.] Med Univ South Carolina, Dept Med, Div Oncol, Charleston, SC USA; [Nasarre, Cecile; LaRue, Amanda C.; Gemmill, Robert M.; Soloff, Adam C.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA; [Cen, Zhanpeng] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Cen, Zhanpeng; Gong, Yi-Nan; Lotze, Michael T.] Univ Pittsburgh, Dept Immunol, Sch Med, Pittsburgh, PA USA; [LaRue, Amanda C.] Med Univ South Carolina, Dept Pathol, Lab Med, Charleston, SC USA; [LaRue, Amanda C.; Soloff, Adam C.] Ralph H Johnson VA Hlth Care Syst, Res Serv, Charleston, SC USA; [Yeh, Elizabeth S.] Indiana Univ, Simon Canc Ctr, Dept Pharmacol & Toxicol, Sch Med, Indianapolis, IN USA; [Lee, Adrian V.; Oesterreich, Steffi] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Lotze, Michael T.] Univ Pittsburgh, Dept Surg, Sch Med, Pittsburgh, PA USA; [Lotze, Michael T.] Univ Pittsburgh, Dept Bioengn, Sch Med, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Tsinghua University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical University of South Carolina; Indiana University System; Indiana University-Purdue University Indianapolis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Soloff, AC (corresponding author), Univ Pittsburgh, Dept Cardiothorac Surg, Sch Med, Pittsburgh, PA USA.; Soloff, AC (corresponding author), Univ Pittsburgh Med Ctr UPMC, Canc Immunol & Immunotherapy Program, Hillman Canc Ctr, Pittsburgh, PA USA.; Soloff, AC (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC USA.; Soloff, AC (corresponding author), Ralph H Johnson VA Hlth Care Syst, Res Serv, Charleston, SC USA.	AdamSoloff@pitt.edu			Susan G. Komen Foundation [CCR15329745]; U.S. Department of Defense [W81XWH1910650]; Pennsylvania Department of Health (PA CURE); American Lung Association/Thoracic Surgery Foundation; Department of Veteran's Affairs Career Development Award [CX001771-01A2]; University of Pittsburgh's Dean Faculty Advancement Award; NCI of the NIH [R01CA181450, R01CA206012, R03 CA245774]; Department of Cardiothoracic Surgery; ITTC/UPMCE	Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); U.S. Department of Defense(United States Department of Defense); Pennsylvania Department of Health (PA CURE); American Lung Association/Thoracic Surgery Foundation; Department of Veteran's Affairs Career Development Award; University of Pittsburgh's Dean Faculty Advancement Award; NCI of the NIH; Department of Cardiothoracic Surgery; ITTC/UPMCE	This work was supported by awards from the Susan G. Komen Foundation (CCR15329745), U.S. Department of Defense (W81XWH1910650), Pennsylvania Department of Health (PA CURE), and American Lung Association/Thoracic Surgery Foundation to AS. RD was supported by funding from a Department of Veteran's Affairs Career Development Award (CX001771-01A2) and the University of Pittsburgh's Dean Faculty Advancement Award. EY was supported by the NCI of the NIH under R03 CA245774. ML was supported by the NCI of the NIH under awards R01CA181450 and R01CA206012 as well as ITTC/UPMCE. RD and AS were further supported by funding from the Department of Cardiothoracic Surgery.	Aung NY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147358; Bae D, 2008, J BIOL CHEM, V283, P28074, DOI 10.1074/jbc.M804203200; Borkowetz A, 2020, INT J CANCER, V146, P2619, DOI 10.1002/ijc.32679; Boro A, 2015, AM J TRANSL RES, V7, P640; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Cai HB, 1999, J NEUROSCI, V19, P6519; Cao Y, 2013, CANCER RES, V73, P4579, DOI 10.1158/0008-5472.CAN-13-0529; Carrell RK, 2018, VACCINE, V36, P6262, DOI 10.1016/j.vaccine.2018.09.010; Casazza A, 2013, CANCER CELL, V24, P695, DOI 10.1016/j.ccr.2013.11.007; Chen H, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005112; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Delgoffe GM, 2013, NATURE, V501, P252, DOI 10.1038/nature12428; Deng HB, 2012, EXP CELL RES, V318, P2592, DOI 10.1016/j.yexcr.2012.08.008; Dhupar R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176178; Dimou A, 2021, J THORAC CARDIOV SUR, V162, P463, DOI 10.1016/j.jtcvs.2020.03.166; Forster S, 2021, GENES-BASEL, V12, DOI 10.3390/genes12040550; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Gemmill RM, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag0528; Gunzl P, 2010, J LEUKOCYTE BIOL, V88, P1259, DOI 10.1189/jlb.0110001; Guilliams M, 2018, IMMUNITY, V49, P595, DOI 10.1016/j.immuni.2018.10.005; Hobbs S, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13914; Immormino RM, 2018, AM J PHYSIOL-LUNG C, V315, pL202, DOI 10.1152/ajplung.00067.2018; Iyer SS, 2010, J IMMUNOL, V185, P6599, DOI 10.4049/jimmunol.1002041; Ji JD, 2009, HUM IMMUNOL, V70, P211, DOI 10.1016/j.humimm.2009.01.026; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; Koch S, 2014, DEV CELL, V28, P633, DOI 10.1016/j.devcel.2014.02.010; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Lee HJ, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-8; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Mazzieri R, 2011, CANCER CELL, V19, P512, DOI 10.1016/j.ccr.2011.02.005; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nakamura F, 2002, ADV EXP MED BIOL, V515, P55; Nasarre P, 2013, CANCER RES, V73, P7111, DOI 10.1158/0008-5472.CAN-13-1755; Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]; Noori MS, 2020, EUR J PHARMACOL, V883, DOI 10.1016/j.ejphar.2020.173340; Ojalvo LS, 2009, AM J PATHOL, V174, P1048, DOI 10.2353/ajpath.2009.080676; Okenwa C, 2013, J IMMUNOL, V191, P2589, DOI 10.4049/jimmunol.1300466; Pengal RA, 2006, MOL IMMUNOL, V43, P1557, DOI 10.1016/j.molimm.2005.09.022; Powers AA, 2021, LIFE SCI, V282, DOI 10.1016/j.lfs.2021.119839; Priedigkeit N, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95703; Priedigkeit N, 2017, JAMA ONCOL, V3, P666, DOI 10.1001/jamaoncol.2016.5630; Pucci F, 2009, BLOOD, V114, P901, DOI 10.1182/blood-2009-01-200931; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Rego D, 2011, J IMMUNOL, V186, P5443, DOI 10.4049/jimmunol.1003551; Rey-Gallardo A, 2010, GLYCOBIOLOGY, V20, P1139, DOI 10.1093/glycob/cwq078; Rizzolio S, 2018, CANCER RES, V78, P1058, DOI 10.1158/0008-5472.CAN-17-2020; Rossignol M, 2000, GENOMICS, V70, P211, DOI 10.1006/geno.2000.6381; Roy S, 2018, CANCER RES, V78, P5600, DOI 10.1158/0008-5472.CAN-18-0562; Roy S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01228; Schellenburg S, 2017, MOL IMMUNOL, V90, P239, DOI 10.1016/j.molimm.2017.08.010; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Soloff AC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02027; Stamatos NM, 2014, GLYCOBIOLOGY, V24, P864, DOI 10.1093/glycob/cwu050; Werneburg S, 2016, GLIA, V64, P1314, DOI 10.1002/glia.23004; Williams CB, 2016, NPJ BREAST CANCER, V2, DOI 10.1038/npjbcancer.2015.25; Yasuoka H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-220; Zhang B, 2015, J SURG ONCOL, V111, P382, DOI 10.1002/jso.23842; Zhu L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0755-1	60	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								830169	10.3389/fimmu.2022.830169	http://dx.doi.org/10.3389/fimmu.2022.830169			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0PF	35651620	gold, Green Published			2022-12-18	WOS:000795558500001
J	Du, SY; Li, YJ; Geng, Z; Zhang, Q; Buhler, LH; Gonelle-Gispert, C; Wang, Y				Du, Suya; Li, Yanjiao; Geng, Zhen; Zhang, Qi; Buhler, Leo H.; Gonelle-Gispert, Carmen; Wang, Yi			Engineering Islets From Stem Cells: The Optimal Solution for the Treatment of Diabetes?	FRONTIERS IN IMMUNOLOGY			English	Review						stem cell; islet; diabetes; engineering; therapeutic efficacy	PANCREATIC-BETA-CELLS; BONE-MARROW; EXTRACELLULAR-MATRIX; INSULIN-SECRETION; PROGENITOR CELLS; BIOARTIFICIAL PANCREAS; REGENERATIVE MEDICINE; ENCAPSULATED ISLETS; PD-L1 EXPRESSION; CEREBRAL-PALSY	Diabetes is a metabolic disease characterized by insulin deficiency. Bioengineering of stem cells with the aim to restore insulin production and glucose regulation has the potential to cure diabetic patients. In this review, we focus on the recent developments for bioengineering of induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and pancreatic progenitor cells in view of generating insulin producing and glucose regulating cells for beta-cell replacement therapies. Recent clinical trials using islet cells derived from stem cells have been initiated for the transplantation into diabetic patients, with crucial bottlenecks of tumorigenesis, post-transplant survival, genetic instability, and immunogenicity that should be further optimized. As a new approach given high expectations, bioengineered islets from stem cells occupies considerable potential for the future clinical application and addressing the treatment dilemma of diabetes.	[Du, Suya] Univ Elect Sci & Technol China, Dept Clin Pharm, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr,Sch Med, Chengdu, Peoples R China; [Li, Yanjiao; Zhang, Qi] Univ Elect Sci & Technol China, Sch Med, Chengdu, Peoples R China; [Geng, Zhen; Buhler, Leo H.; Wang, Yi] Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Ctr Organ Transplantat, Chengdu, Peoples R China; [Geng, Zhen; Wang, Yi] Univ Elect Sci & Technol China, Inst Organ Transplantat, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China; [Geng, Zhen; Wang, Yi] Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China; [Buhler, Leo H.; Gonelle-Gispert, Carmen] Univ Fribourg, Fac Sci & Med, Fribourg, Switzerland	University of Electronic Science & Technology of China; University of Electronic Science & Technology of China; Sichuan Provincial People's Hospital; Sichuan Provincial People's Hospital; University of Electronic Science & Technology of China; Chinese Academy of Sciences; University of Fribourg	Buhler, LH; Wang, Y (corresponding author), Sichuan Acad Med Sci & Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Ctr Organ Transplantat, Chengdu, Peoples R China.; Wang, Y (corresponding author), Univ Elect Sci & Technol China, Inst Organ Transplantat, Sichuan Prov Peoples Hosp, Chengdu, Peoples R China.; Wang, Y (corresponding author), Chinese Acad Sci, Sichuan Translat Med Res Hosp, Chengdu, Peoples R China.; Buhler, LH; Gonelle-Gispert, C (corresponding author), Univ Fribourg, Fac Sci & Med, Fribourg, Switzerland.	leo.buhler@unifr.ch; carmen.gonelle@unifr.ch; w_yi2022@163.com	Wang, Yi/GSD-4852-2022; Wang, Yi/GLU-8903-2022	Wang, Yi/0000-0001-9921-0304; 	National Science Foundation of China [81802504]; Sichuan Medical Association [Q19037]; Chengdu Science and Technology Bureau [2021-YF05-00225-SN]; Insuleman foundation; Child foundation; foundation la Colombe; Sichuan Science and Technology Bureau; Health Commission of Sichuan Province; Sichuan Administration of Traditional Chinese Medicine; Beijing Xisike Clinical Oncology Research;  [2022YFT0005];  [2019YFS0439];  [[2019]30];  [2020JC0114];  [Y-QL202101-0125]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Medical Association; Chengdu Science and Technology Bureau; Insuleman foundation; Child foundation; foundation la Colombe; Sichuan Science and Technology Bureau; Health Commission of Sichuan Province; Sichuan Administration of Traditional Chinese Medicine; Beijing Xisike Clinical Oncology Research; ; ; ; ; 	This study was sponsored by the National Science Foundation of China (81802504), the grant from Sichuan Medical Association (Q19037) and the grant from Chengdu Science and Technology Bureau (2021-YF05-00225-SN) for YW. CG-G and LB are supported by the Insuleman foundation, Child foundation and the foundation la Colombe. YW and LB are supported by Sichuan Science and Technology Bureau (No. 2022YFT0005 and 2019YFS0439). This study is also supported by grants from Health Commission of Sichuan Province (No.[2019]30), from Sichuan Administration of Traditional Chinese Medicine (No. 2020JC0114) and from Beijing Xisike Clinical Oncology Research (No. Y-QL202101-0125).	Abdelalim EM, 2014, STEM CELL REV REP, V10, P327, DOI 10.1007/s12015-014-9503-6; Abdellatif H, 2018, INT J STEM CELLS, V11, P78, DOI 10.15283/ijsc17047; Acosta ND, 2016, J LAW MED ETHICS, V44, P419, DOI 10.1177/1073110516667939; Akolpoglu MB, 2021, BIOMATERIALS, V269, DOI 10.1016/j.biomaterials.2020.120627; del Barrio JLA, 2017, CORNEA, V36, P952, DOI 10.1097/ICO.0000000000001228; Appasani K, 2011, STEM CELLS BIOL REG, P3, DOI 10.1007/978-1-60761-860-7_1; Assady S, 2001, DIABETES, V50, P1691, DOI 10.2337/diabetes.50.8.1691; Augsornworawat P, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108067; Ayenehdeh JM, 2017, IMMUNOL LETT, V188, P21, DOI 10.1016/j.imlet.2017.05.006; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Bansal Himanshu, 2016, J Stem Cells, V11, P37; Barkai Uriel, 2016, World J Transplant, V6, P69, DOI 10.5500/wjt.v6.i1.69; Basta G, 2021, J DIABETES INVEST, V12, P301, DOI 10.1111/jdi.13372; Beattie GM, 1996, DIABETES, V45, P1223, DOI 10.2337/diabetes.45.9.1223; Berman DM, 2010, DIABETES, V59, P2558, DOI 10.2337/db10-0136; Bhansali A, 2014, CELL TRANSPLANT, V23, P1075, DOI 10.3727/096368913X665576; Bhasin A, 2011, CEREBROVASC DIS EXTR, V1, P93, DOI 10.1159/000333381; Bishawi M, 2021, CARDIOVASC PATHOL, V54, DOI 10.1016/j.carpath.2021.107331; Biswas A, 2007, STEM CELLS DEV, V16, P213, DOI 10.1089/scd.2006.0081; Bluestone JA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad4134; Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904; Bonner-Weir S, 2000, TRENDS ENDOCRIN MET, V11, P375, DOI 10.1016/S1043-2760(00)00305-2; Bonner-Weir S, 2005, NAT BIOTECHNOL, V23, P857, DOI 10.1038/nbt1115; Bonner-Weir S, 2008, BIOCHEM SOC T, V36, P353, DOI 10.1042/BST0360353; Bosco D, 2000, DIABETES, V49, P233, DOI 10.2337/diabetes.49.2.233; Bracamonte-Baran W, 2021, CIRC-HEART FAIL, V14, P1052, DOI 10.1161/CIRCHEARTFAILURE.120.007982; Brioli A, 2015, BONE MARROW TRANSPL, V50, P673, DOI 10.1038/bmt.2014.322; Bulotta A, 2002, J MOL ENDOCRINOL, V29, P347, DOI 10.1677/jme.0.0290347; Carlsson PO, 2015, DIABETES, V64, P587, DOI 10.2337/db14-0656; Chase LG, 2007, DIABETES, V56, P3, DOI 10.2337/db06-1165; Chen LB, 2004, WORLD J GASTROENTERO, V10, P3016; D'Amour KA, 2006, NAT BIOTECHNOL, V24, P1392, DOI 10.1038/nbt1259; Daoud J, 2010, CELL TRANSPLANT, V19, P1523, DOI 10.3727/096368910X515872; Desai T, 2017, NAT REV DRUG DISCOV, V16, DOI 10.1038/nrd.2017.67; Deuse T, 2019, NAT BIOTECHNOL, V37, P1137, DOI 10.1038/s41587-019-0227-7; Dor Y, 2004, NATURE, V429, P41, DOI 10.1038/nature02520; Dulak J, 2015, ACTA BIOCHIM POL, V62, P329, DOI 10.18388/abp.2015_1023; El-Halawani SM, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03914; Ernst AU, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900423; Federation ID ., 2019, IDF DIAB ATL 9 ED 20; Figliuzzi M, 2009, TRANSPL P, V41, P1797, DOI 10.1016/j.transproceed.2008.11.015; Figliuzzi Marina, 2014, World J Stem Cells, V6, P163, DOI 10.4252/wjsc.v6.i2.163; Giraldo Jaime A, 2010, J Diabetes Sci Technol, V4, P1238; Grimm AJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep15907; Gu GQ, 2003, MECH DEVELOP, V120, P35, DOI 10.1016/S0925-4773(02)00330-1; Gurusamy N, 2018, PROG MOL BIOL TRANSL, V160, P1, DOI 10.1016/bs.pmbts.2018.07.009; Gutierrez-Aranda I, 2010, STEM CELLS, V28, P1568, DOI 10.1002/stem.471; Hammar E, 2004, DIABETES, V53, P2034, DOI 10.2337/diabetes.53.8.2034; Han L, 2022, STEM CELLS DEV, DOI 10.1089/scd.2021.0255; Harding J, 2014, J BIOL CHEM, V289, P4585, DOI 10.1074/jbc.R113.463737; Haufroid M, 2019, ACTA CRYSTALLOGR D, V75, P592, DOI 10.1107/S2059798319006867; Heller M, 2016, INT J COMPUT DENT, V19, P301; Hirabaru M, 2015, TISSUE ENG PART C-ME, V21, P1205, DOI [10.1089/ten.tec.2015.0035, 10.1089/ten.TEC.2015.0035]; Hirshberg Boaz, 2007, Curr Diab Rep, V7, P301, DOI 10.1007/s11892-007-0048-9; Ho SS, 2016, STEM CELL TRANSL MED, V5, P773, DOI 10.5966/sctm.2015-0211; Hoffman RA, 2002, TRANSPLANTATION, V74, P836, DOI 10.1097/00007890-200209270-00018; Honmou O, 2011, BRAIN, V134, P1790, DOI 10.1093/brain/awr063; Inada A, 2008, P NATL ACAD SCI USA, V105, P19915, DOI 10.1073/pnas.0805803105; Ito T, 2010, TRANSPLANTATION, V89, P1438, DOI 10.1097/TP.0b013e3181db09c4; Javaid MS, 2017, CRIT REV EUKAR GENE, V27, P1, DOI 10.1615/CritRevEukaryotGeneExpr.2016018251; Jiang JJ, 2007, STEM CELLS, V25, P1940, DOI 10.1634/stemcells.2006-0761; Jiang YH, 2002, EXP HEMATOL, V30, P896, DOI 10.1016/S0301-472X(02)00869-X; Jin L, 2013, P NATL ACAD SCI USA, V110, P3907, DOI 10.1073/pnas.1301889110; Jo Eun Hee, 2015, Biomater Res, V19, P21, DOI 10.1186/s40824-015-0042-2; Jung EJ, 2011, CYTOTHERAPY, V13, P19, DOI 10.3109/14653249.2010.518608; Kim YJ, 2018, CORNEA, V37, P76, DOI 10.1097/ICO.0000000000001409; Kogawa R, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090299; Kolata G., 2021, CURE TYPE 1 DIABETES; Kroon E, 2008, NAT BIOTECHNOL, V26, P443, DOI 10.1038/nbt1393; Kucia M, 2007, DEV DYNAM, V236, P3309, DOI 10.1002/dvdy.21180; Kuol N, 2018, IMMUNOTHERAPY-UK, V10, P149, DOI 10.2217/imt-2017-0120; Lan KC, 2018, ARTIF CELL NANOMED B, V46, pS328, DOI 10.1080/21691401.2018.1492421; Laporte C, 2020, BIOCHEM BIOPH RES CO, V528, P650, DOI 10.1016/j.bbrc.2020.05.107; Lee JS, 2010, STEM CELLS, V28, P1099, DOI 10.1002/stem.430; Li ZY, 2016, INTEGR BIOL-UK, V8, P1022, DOI 10.1039/c6ib00162a; Nguyen LT, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0859-z; Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798; Liu XB, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1149-0; Longoni B, 2010, DIABETES TECHNOL THE, V12, P435, DOI 10.1089/dia.2009.0154; Ludwig B, 2015, LANGENBECK ARCH SURG, V400, P531, DOI 10.1007/s00423-015-1314-y; Ludwig B, 2013, P NATL ACAD SCI USA, V110, P19054, DOI 10.1073/pnas.1317561110; Lu SH, 2009, TISSUE ENG PT A, V15, P1611, DOI 10.1089/ten.tea.2008.0187; Lumelsky N, 2001, SCIENCE, V292, P1389, DOI 10.1126/science.1058866; Lysy PA, 2013, CURR DIABETES REP, V13, P695, DOI 10.1007/s11892-013-0400-1; Mancias-Guerra C, 2014, CYTOTHERAPY, V16, P810, DOI 10.1016/j.jcyt.2014.01.008; Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368; Manzoli V, 2018, AM J TRANSPLANT, V18, P590, DOI 10.1111/ajt.14547; Mardomi A, 2020, J CELL PHYSIOL, V235, P4183, DOI 10.1002/jcp.29369; Montanari E, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0646-7; Mummery CL, 2012, CIRC RES, V111, P344, DOI 10.1161/CIRCRESAHA.110.227512; Muncie JM, 2018, CURR TOP DEV BIOL, V130, P1, DOI 10.1016/bs.ctdb.2018.02.002; Nakamura K, 2019, CURR STEM CELL RES T, V14, P52, DOI 10.2174/1574888X13666180912125157; Neufeld T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070150; Niedbala W, 2006, ANN RHEUM DIS, V65, P37, DOI 10.1136/ard.2006.058446; Nishino K, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002085; Noguchi H, 2007, ENDOCR J, V54, P7, DOI 10.1507/endocrj.KR-86; Nostro MC, 2015, STEM CELL REP, V4, P591, DOI 10.1016/j.stemcr.2015.02.017; Oberg-Welsh C, 2001, PANCREAS, V22, P157; Opara EC, 2010, J INVEST MED, V58, P831, DOI 10.231/JIM.0b013e3181ed3807; Oshima Y, 2007, GASTROENTEROLOGY, V132, P720, DOI 10.1053/j.gastro.2006.11.027; Pagliuca FW, 2014, CELL, V159, P428, DOI 10.1016/j.cell.2014.09.040; Pagliuca FW, 2013, DEVELOPMENT, V140, P2472, DOI 10.1242/dev.093187; Pan G, 2019, ANN ENDOCRINOL-PARIS, V80, P47, DOI 10.1016/j.ando.2018.06.1084; Patel DM, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/496218; Pepper AR, 2015, TRANSPLANTATION, V99, P2294, DOI 10.1097/TP.0000000000000864; Peters AL., 2022, CURE TYPE 1 DIABETES; Pinkse GGM, 2006, DIABETES, V55, P312, DOI 10.2337/diabetes.55.02.06.db04-0195; Polchert D, 2008, EUR J IMMUNOL, V38, P1745, DOI 10.1002/eji.200738129; Prabhasawat P, 2016, CELL TISSUE BANK, V17, P491, DOI 10.1007/s10561-016-9575-4; Presnell SC, 2002, SEMIN CELL DEV BIOL, V13, P369, DOI 10.1016/S1084952102000939; Rachdi L, 2001, DIABETES, V50, P2021, DOI 10.2337/diabetes.50.9.2021; Raikwar SP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116582; Rezania A, 2013, STEM CELLS, V31, P2432, DOI 10.1002/stem.1489; Rezania A, 2012, DIABETES, V61, P2016, DOI 10.2337/db11-1711; Ris F, 2002, DIABETOLOGIA, V45, P841, DOI 10.1007/s00125-002-0840-7; Rong ZL, 2014, CELL STEM CELL, V14, P121, DOI 10.1016/j.stem.2013.11.014; Roy-Chowdhury N, 2017, HEPATOL INT, V11, P54, DOI 10.1007/s12072-016-9757-y; Samsonraj RM, 2017, STEM CELL TRANSL MED, V6, P2173, DOI 10.1002/sctm.17-0129; Santos E, 2014, J BIOMED MATER RES A, V102, P3965, DOI 10.1002/jbm.a.35073; Sapir T, 2005, P NATL ACAD SCI USA, V102, P7964, DOI 10.1073/pnas.0405277102; Savitz SI, 2005, CEREBROVASC DIS, V20, P101, DOI 10.1159/000086518; Scharp DW, 2014, ADV DRUG DELIVER REV, V67-68, P35, DOI 10.1016/j.addr.2013.07.018; Schulz TC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037004; SCHUPPIN GT, 1993, IN VITRO CELL DEV-AN, V29A, P339; Serr I, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10991; Shapiro A M James, 2012, Rev Diabet Stud, V9, P385, DOI 10.1900/RDS.2012.9.385; Sharma A, 2012, CELL TRANSPLANT, V21, pS79, DOI 10.3727/096368912X633798; Shi YF, 2018, NAT REV NEPHROL, V14, P493, DOI 10.1038/s41581-018-0023-5; Shimizu T, 2003, BIOMATERIALS, V24, P2309, DOI 10.1016/S0142-9612(03)00110-8; Si ZZ, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108765; Skyler JS, 2015, DIABETES CARE, V38, P1742, DOI 10.2337/dc14-2830; Slack JMW, 2007, NAT REV MOL CELL BIO, V8, P369, DOI 10.1038/nrm2146; Soetedjo AAP, 2021, TRENDS ENDOCRIN MET, V32, P609, DOI 10.1016/j.tem.2021.05.007; Song JQ, 2016, BIOFABRICATION, V8, DOI 10.1088/1758-5090/8/3/035009; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Stock AA, 2020, STEM CELL REP, V14, P91, DOI 10.1016/j.stemcr.2019.11.004; Strand BL, 2017, STEM CELL TRANSL MED, V6, P1053, DOI 10.1002/sctm.16-0116; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tao HY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1314709; Tao TT, 2019, LAB CHIP, V19, P948, DOI 10.1039/c8lc01298a; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Todorova D, 2016, STEM CELLS, V34, P510, DOI 10.1002/stem.2227; Tomei AA, 2014, P NATL ACAD SCI USA, V111, P10514, DOI 10.1073/pnas.1402216111; Trivedi HL, 2008, TRANSPL P, V40, P1135, DOI 10.1016/j.transproceed.2008.03.113; Tuch BE, 2014, FRONT BIOSCI-LANDMRK, V19, P126, DOI 10.2741/4199; Turinetto V, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091952; Vaithilingam V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10359-1; Vaithilingam Vijayaganapathy, 2017, Rev Diabet Stud, V14, P51, DOI 10.1900/RDS.2017.14.51; Vaithilingam V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059120; van der Bogt KEA, 2008, CIRCULATION, V118, pS121, DOI 10.1161/CIRCULATIONAHA.107.759480; van der Torren CR, 2017, DIABETOLOGIA, V60, P126, DOI 10.1007/s00125-016-4125-y; Vasandan AB, 2016, SCI REP-UK, V6, DOI 10.1038/srep38308; Vegas AJ, 2016, NAT MED, V22, P306, DOI 10.1038/nm.4030; Vertex, 2021, VERTEX ANNOUNCES POS; Vogel G, 2014, SCIENCE, V346, P148, DOI 10.1126/science.346.6206.148; Wang DS, 2020, CELL, V180, P1198, DOI 10.1016/j.cell.2020.02.048; Wang G, 2018, CELL DEATH DIFFER, V25, P1209, DOI 10.1038/s41418-017-0006-2; Wang RN, 1999, J ENDOCRINOL, V163, P181, DOI 10.1677/joe.0.1630181; Weber LM, 2008, TISSUE ENG PT A, V14, P1959, DOI 10.1089/ten.tea.2007.0238; Weissman IL, 2015, P NATL ACAD SCI USA, V112, P8922, DOI 10.1073/pnas.1505464112; White AM, 2020, ACS BIOMATER SCI ENG, V6, P2543, DOI 10.1021/acsbiomaterials.9b01406; Xiao B, 2016, J NEUROL NEUROSUR PS, V87, P697, DOI 10.1136/jnnp-2015-312036; Xu LC, 2019, J BIOMATER APPL, V33, P1252, DOI 10.1177/0885328219831391; Xu XB, 2008, CELL, V132, P197, DOI 10.1016/j.cell.2007.12.015; Yin QA, 2020, EUR J HISTOCHEM, V64, DOI 10.4081/ejh.2020.3152; Yoshihara E, 2020, NATURE, V586, P606, DOI 10.1038/s41586-020-2631-z; Yu CG, 2019, CURR MED CHEM, V26, P1891, DOI 10.2174/0929867324666171009115356; Yuan T, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt224; Zanoni M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163876; Zhang DH, 2009, CELL RES, V19, P429, DOI 10.1038/cr.2009.28; Zhang YM, 2012, CELL CYCLE, V11, P4536, DOI 10.4161/cc.22575; Zhang YQ, 2005, J CELL MOL MED, V9, P331, DOI 10.1111/j.1582-4934.2005.tb00359.x; Zhang YQ, 2003, DIABETES-METAB RES, V19, P363, DOI 10.1002/dmrr.406; Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021; Zhao TB, 2011, NATURE, V474, P212, DOI 10.1038/nature10135; Zimmermann WH, 2002, CIRC RES, V90, P223, DOI 10.1161/hh0202.103644	177	0	0	4	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								869514	10.3389/fimmu.2022.869514	http://dx.doi.org/10.3389/fimmu.2022.869514			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F6TO	35572568	gold, Green Published			2022-12-18	WOS:000795299200001
J	Hu, B; Jadhav, RR; Gustafson, CE; Le Saux, S; Ye, ZD; Li, XY; Tian, L; Weyand, CM; Goronzy, JJ				Hu, Bin; Jadhav, Rohit R.; Gustafson, Claire E.; Le Saux, Sabine; Ye, Zhongde; Li, Xuanying; Tian, Lu; Weyand, Cornelia M.; Goronzy, Jorg J.			Distinct Age-Related Epigenetic Signatures in CD4 and CD8 T Cells (vol 11, 585168, 2020)	FRONTIERS IN IMMUNOLOGY			English	Correction						ribosomal proteins; chromatin accessibility; epigenetics; T-cell; aging; T-cell homeostasis			[Hu, Bin; Jadhav, Rohit R.; Gustafson, Claire E.; Le Saux, Sabine; Ye, Zhongde; Li, Xuanying; Weyand, Cornelia M.; Goronzy, Jorg J.] Stanford Univ, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA; [Hu, Bin; Jadhav, Rohit R.; Gustafson, Claire E.; Le Saux, Sabine; Ye, Zhongde; Li, Xuanying; Weyand, Cornelia M.; Goronzy, Jorg J.] Palo Alto Vet Adm Healthcare Syst, Dept Med, Palo Alto, CA 94304 USA; [Tian, Lu] Stanford Univ, Departmentof Biomed Data Sci, Stanford, CA USA	Stanford University; Stanford University	Goronzy, JJ (corresponding author), Stanford Univ, Dept Med, Div Immunol & Rheumatol, Stanford, CA 94305 USA.; Goronzy, JJ (corresponding author), Palo Alto Vet Adm Healthcare Syst, Dept Med, Palo Alto, CA 94304 USA.	jgoronzy@stanford.edu		Goronzy, Jorg/0000-0001-7670-1856; tian, lu/0000-0002-5893-0169				Hu B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585168	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								911132	10.3389/fimmu.2022.911132	http://dx.doi.org/10.3389/fimmu.2022.911132			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G4GI	35572522	gold, Green Published			2022-12-18	WOS:000795806800001
J	Isaeva, OI; Ketelaars, SLC; Kvistborg, P				Isaeva, Olga I.; Ketelaars, Steven L. C.; Kvistborg, Pia			In Silico Analysis Predicts a Limited Impact of SARS-CoV-2 Variants on CD8 T Cell Recognition	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; CD8 T cell epitopes; SARS-CoV-2 variants; CD8 T cells; bioinformatics & computational biology	CROSS-REACTIVITY; ANTIGENIC DRIFT; COVID-19	Since the start of the COVID-19 pandemic, mutations have led to the emergence of new SARS-CoV-2 variants, and some of these have become prominent or dominant variants of concern. This natural course of development can have an impact on how protective the previously naturally or vaccine induced immunity is. Therefore, it is crucial to understand whether and how variant specific mutations influence host immunity. To address this, we have investigated how mutations in the recent SARS-CoV-2 variants of interest and concern influence epitope sequence similarity, predicted binding affinity to HLA, and immunogenicity of previously reported SARS-CoV-2 CD8 T cell epitopes. Our data suggests that the vast majority of SARS-CoV-2 CD8 T cell recognized epitopes are not altered by variant specific mutations. Interestingly, for the CD8 T cell epitopes that are altered due to variant specific mutations, our analyses show there is a high degree of sequence similarity between mutated and reference SARS-CoV-2 CD8 T cell epitopes. However, mutated epitopes, primarily derived from the spike protein, in SARS-CoV-2 variants Delta, AY.4.2 and Mu display reduced predicted binding affinity to their restriction element. These findings indicate that the recent SARS-CoV-2 variants of interest and concern have limited ability to escape memory CD8 T cell responses raised by vaccination or prior infection with SARS-CoV-2 early in the pandemic. The overall low impact of the mutations on CD8 T cell cross-recognition is in accordance with the notion that mutations in SARS-CoV-2 are primarily the result of receptor binding affinity and antibody selection pressures exerted on the spike protein, unrelated to T cell immunity.	[Isaeva, Olga I.; Ketelaars, Steven L. C.; Kvistborg, Pia] Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands; [Isaeva, Olga I.] Netherlands Canc Inst, Dept Tumor Biol & Immunol, Amsterdam, Netherlands; [Isaeva, Olga I.] Oncode Inst, Utrecht, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Kvistborg, P (corresponding author), Netherlands Canc Inst, Dept Mol Oncol & Immunol, Amsterdam, Netherlands.	p.kvistborg@nki.nl		Isaeva, Olga/0000-0001-7377-0944	Netherlands Cancer Institute Kvistborg group	Netherlands Cancer Institute Kvistborg group	The project was funded with the Netherlands Cancer Institute Kvistborg group start-up funding.	[Anonymous], TRACKING SARS COV 2; [Anonymous], HOME GRAPHPAD; [Anonymous], OUTBREAKINFO; Bergamaschi L, 2021, IMMUNITY, V54, P1257, DOI 10.1016/j.immuni.2021.05.010; Borges V., 2021, BIORXIV, DOI [10.1101/2021.05.19.444774, DOI 10.1101/2021.05.19.444774]; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Das SR, 2013, CELL HOST MICROBE, V13, P314, DOI 10.1016/j.chom.2013.02.008; Davis C, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1010022; Dhanda SK, 2018, IMMUNOLOGY, V155, P331, DOI 10.1111/imm.12984; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Du J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.735125; Duffy S, 2008, NAT REV GENET, V9, P267, DOI 10.1038/nrg2323; Elbe S, 2017, GLOB CHALL, V1, P33, DOI 10.1002/gch2.1018; European Centre for Disease Prevention and Control, COVID 19 SIT UPD WOR; European Centre for Disease Prevention and Control, SARS COV 2 VARIANTS; Frankild S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001831; Gangaev A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22811-y; Hadfield J, 2018, BIOINFORMATICS, V34, P4121, DOI 10.1093/bioinformatics/bty407; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Huang KYA, 2015, J CLIN INVEST, V125, P2631, DOI 10.1172/JCI81104; IEDB.org, FREE EP DAT PRED RES; Jordan SC, 2021, CELL MOL IMMUNOL, V18, P2554, DOI 10.1038/s41423-021-00767-9; Keeton R, 2022, NATURE, V603, P488, DOI 10.1038/s41586-022-04460-3; Kvistborg P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008918; Lam ME, 2021, HUM SOC SCI COMMUN, V8, DOI 10.1057/s41599-020-00679-5; Lambert H, 2020, LANCET PLANET HEALTH, V4, pE312, DOI 10.1016/S2542-5196(20)30168-6; Lee JK, 2004, J EXP MED, V200, P1455, DOI 10.1084/jem.20041251; Liu Q., 2020, MEDRXIV, DOI [10.2139/ssrn.3557995, DOI 10.2139/SSRN.3557995]; Luo M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.139024; Martin DP, 2021, CELL, V184, P5189, DOI 10.1016/j.cell.2021.09.003; Martinez-Flores D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.701501; McMahan K, 2021, NATURE, V590, DOI 10.1038/s41586-020-03041-6; Melo-Gonzalez F, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.747830; Planas D, 2022, NATURE, V602, P671, DOI 10.1038/s41586-021-04389-z; Reynisson B, 2020, NUCLEIC ACIDS RES, V48, pW449, DOI 10.1093/nar/gkaa379; Ritchie H., CORONAVIRUS COVID 19; Roberts DL, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009620; Sanjuan R, 2016, CELL MOL LIFE SCI, V73, P4433, DOI 10.1007/s00018-016-2299-6; Shu Y., 2017, NUCLEIC ACIDS RES, V22, DOI [10.2807/1560-7917.ES.2017.22.13.30494, DOI 10.2807/1560-7917.ES.2017.22.13.30494]; Sun J, 2020, CELL, V182, P734, DOI 10.1016/j.cell.2020.06.010; Tarke A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100355; Thiruvengadam R, 2022, LANCET INFECT DIS, V22, P473, DOI 10.1016/S1473-3099(21)00680-0; Vita R, 2019, NUCLEIC ACIDS RES, V47, pD339, DOI 10.1093/nar/gky1006; Worobey M, 2021, SCIENCE, V374, P1202, DOI 10.1126/science.abm4454; Yewdell JW, 2021, IMMUNITY, V54, P2681, DOI 10.1016/j.immuni.2021.11.016	45	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								891524	10.3389/fimmu.2022.891524	http://dx.doi.org/10.3389/fimmu.2022.891524			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0NV	35572563	Green Published, gold, Green Submitted			2022-12-18	WOS:000795554900001
J	Li, JA; Wang, LL; Ding, JL; Cheng, YX; Diao, LH; Li, LF; Zhang, Y; Yin, TL				Li, Jianan; Wang, Linlin; Ding, Jinli; Cheng, Yanxiang; Diao, Lianghui; Li, Longfei; Zhang, Yan; Yin, Tailang			Multiomics Studies Investigating Recurrent Pregnancy Loss: An Effective Tool for Mechanism Exploration	FRONTIERS IN IMMUNOLOGY			English	Review						omics; villus; decidua; blood; recurrent pregnancy loss	HUMAN CHORIONIC VILLI; EXPRESSION PROFILE; GENE-EXPRESSION; NONCODING RNAS; MISCARRIAGE; METHYLATION; PROTEOMICS; PROTEINS; DECIDUA; WOMEN	Patients with recurrent pregnancy loss (RPL) account for approximately 1 %-5% of women aiming to achieve childbirth. Although studies have shown that RPL is associated with failure of endometrial decidualization, placental dysfunction, and immune microenvironment disorder at the maternal-fetal interface, the exact pathogenesis remains unknown. With the development of high-throughput technology, more studies have focused on the genomics, transcriptomics, proteomics and metabolomics of RPL, and new gene mutations and new biomarkers of RPL have been discovered, providing an opportunity to explore the pathogenesis of RPL from different biological processes. Bioinformatics analyses of these differentially expressed genes, proteins and metabolites also reflect the biological pathways involved in RPL, laying a foundation for further research. In this review, we summarize the findings of omics studies investigating decidual tissue, villous tissue and blood from patients with RPL and identify some possible imitations of current studies.	[Li, Jianan; Wang, Linlin; Ding, Jinli; Cheng, Yanxiang; Yin, Tailang] Wuhan Univ, Reprod Med Ctr, Dept Obstet & Gynecol, Renmin Hosp, Wuhan, Peoples R China; [Wang, Linlin; Diao, Lianghui; Li, Longfei] Shenzhen Zhongshan Urol Hosp, Shenzhen Zhongshan Inst Reprod & Genet, Shenzhen Key Lab Reprod Immunol Peri Implantat, Shenzhen, Peoples R China; [Zhang, Yan] Wuhan Univ, Dept Clin Lab, Renmin Hosp, Wuhan, Peoples R China	Wuhan University; Wuhan University	Yin, TL (corresponding author), Wuhan Univ, Reprod Med Ctr, Dept Obstet & Gynecol, Renmin Hosp, Wuhan, Peoples R China.; Li, LF (corresponding author), Shenzhen Zhongshan Urol Hosp, Shenzhen Zhongshan Inst Reprod & Genet, Shenzhen Key Lab Reprod Immunol Peri Implantat, Shenzhen, Peoples R China.; Zhang, Y (corresponding author), Wuhan Univ, Dept Clin Lab, Renmin Hosp, Wuhan, Peoples R China.	lilongfei2005@163.com; peneyyan@maustc.edu.cn; reproductive@whu.edu.cn			National Key Research & Developmental Program of China [2018YFC1004601, 2018YFC1003900/04]; Guangdong Basic and Applied Basic Research Foundation [2019A1515011315]; Shenzhen Fundamental Research Program [JCYJ20190813161010761, JCYJ20210324123601004]; National Natural Science Foundation of China [82071655, 81801540]	National Key Research & Developmental Program of China; Guangdong Basic and Applied Basic Research Foundation; Shenzhen Fundamental Research Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	The project was funded by National Key Research & Developmental Program of China (2018YFC1004601, 2018YFC1003900/04), Guangdong Basic and Applied Basic Research Foundation (2019A1515011315), Shenzhen Fundamental Research Program (JCYJ20190813161010761, JCYJ20210324123601004), and National Natural Science Foundation of China (No. 82071655, No. 81801540).	Albrecht ED, 2020, REPROD SCI, V27, P1932, DOI 10.1007/s43032-020-00212-8; Allison JL, 2009, CURR OPIN ENDOCRINOL, V16, P446, DOI 10.1097/MED.0b013e3283327fc5; Amin I, 2021, REPROD BIOMED ONLINE, V43, P1035, DOI 10.1016/j.rbmo.2021.08.009; An HJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133319; Aslam B, 2017, J CHROMATOGR SCI, V55, P182, DOI 10.1093/chromsci/bmw167; Bai X, 2009, PLACENTA, V30, P855, DOI 10.1016/j.placenta.2009.07.006; Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015; Bell CE, 2009, HUM REPROD, V24, P1373, DOI 10.1093/humrep/dep010; Boycott KM, 2013, NAT REV GENET, V14, P681, DOI 10.1038/nrg3555; Brown LY, 2013, BIOL REPROD, V89, DOI 10.1095/biolreprod.113.113142; Calame K, 2007, GENE DEV, V21, P1145, DOI 10.1101/gad.1559007; Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310; Cha JY, 2012, NAT MED, V18, P1754, DOI 10.1038/nm.3012; Chen PF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.689019; Conesa A, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0258-4; Coppinger JA, 2004, BLOOD, V103, P2096, DOI 10.1182/blood-2003-08-2804; Cui Y, 2019, CLIN PROTEOM, V16, DOI 10.1186/s12014-019-9256-y; Dhaenens L, 2019, REPROD BIOMED ONLINE, V38, P442, DOI 10.1016/j.rbmo.2018.11.022; Dimitriadis E, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00228-z; Diniz-da-Costa M, 2021, STEM CELLS, V39, P1067, DOI 10.1002/stem.3367; Nunes MKD, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098-017-0284-3; Du GZ, 2020, J CELL MOL MED, V24, P7072, DOI 10.1111/jcmm.15335; Du LL, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.13125; Ellard S, 2015, EUR J HUM GENET, V23, P401, DOI 10.1038/ejhg.2014.120; Erkenbrack EM, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005594; Evans J, 2016, NAT REV ENDOCRINOL, V12, P654, DOI 10.1038/nrendo.2016.116; Ferretti C, 2007, HUM REPROD UPDATE, V13, P121, DOI 10.1093/humupd/dml048; Filges I, 2014, CLIN GENET, V86, P220, DOI 10.1111/cge.12301; Gellersen B, 2014, ENDOCR REV, V35, P851, DOI 10.1210/er.2014-1045; Gelmini GF, 2016, AM J REPROD IMMUNOL, V76, P439, DOI 10.1111/aji.12587; Gharesi-Fard B, 2014, J REPROD DEVELOP, V60, P261, DOI 10.1262/jrd.2013-096; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Granne I, 2022, MUCOSAL IMMUNOL, V15, P120, DOI 10.1038/s41385-021-00451-1; Guo C, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-020-00236-z; Hanna CW, 2013, AM J PATHOL, V182, P2276, DOI 10.1016/j.ajpath.2013.02.021; Harden SL, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.626619; Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1; He SY, 2017, ONCOL LETT, V14, P8156, DOI 10.3892/ol.2017.7234; Hong L, 2021, BIOL REPROD, V105, P393, DOI 10.1093/biolre/ioab101; Horn KH, 2011, ACTA HISTOCHEM, V113, P150, DOI 10.1016/j.acthis.2009.09.006; Huang ZY, 2021, MOL THER-NUCL ACIDS, V24, P104, DOI 10.1016/j.omtn.2021.02.018; Huang ZY, 2018, EBIOMEDICINE, V38, P162, DOI 10.1016/j.ebiom.2018.11.015; Huppertz B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010289; Ivanov I, 2015, GENE, V573, P1, DOI 10.1016/j.gene.2015.07.073; Jaremek A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.674162; Jeon YJ, 2013, AM J REPROD IMMUNOL, V70, P238, DOI 10.1111/aji.12110; Karahalil B, 2016, CURR MED CHEM, V23, P4221, DOI 10.2174/0929867323666160926150617; King AE, 2007, PLACENTA, V28, P1099, DOI 10.1016/j.placenta.2007.06.002; Kostakis ID, 2010, EUR J OBSTET GYN R B, V151, P3, DOI 10.1016/j.ejogrb.2010.03.006; Krieg SA, 2012, MOL HUM REPROD, V18, P442, DOI 10.1093/molehr/gas017; Kroksveen AC, 2015, PROTEOMICS, V15, P3361, DOI 10.1002/pmic.201400142; Kurdyukov Sergey, 2016, Biology-Basel, V5, DOI 10.3390/biology5010003; Kusama K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132017; Lee BK, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.673065; Lessey BA, 2002, J REPROD IMMUNOL, V55, P101, DOI 10.1016/S0165-0378(01)00139-5; Li QL, 2002, MOL HUM REPROD, V8, P934, DOI 10.1093/molehr/8.10.934; Li TC, 2002, HUM REPROD UPDATE, V8, P463, DOI 10.1093/humupd/8.5.463; Li XC, 2018, MED SCI MONITOR, V24, P4038, DOI 10.12659/MSM.907653; Li YH, 2021, REPROD SCI, V28, P2261, DOI 10.1007/s43032-021-00482-w; Long X, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.4; Lucas ES, 2016, STEM CELLS, V34, P346, DOI 10.1002/stem.2222; Lunghi L, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-6; Lv XF, 2015, INT J NEUROPSYCHOPH, V18, DOI 10.1093/ijnp/pyv030; Maddirevula S, 2020, HUM GENET, V139, P605, DOI 10.1007/s00439-020-02143-5; Manzoni C, 2018, BRIEF BIOINFORM, V19, P286, DOI 10.1093/bib/bbw114; Mishra J, 2019, GENE, V704, P68, DOI 10.1016/j.gene.2019.04.036; Murata H, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020351; Nevalainen T, 2015, AGE, V37, DOI 10.1007/s11357-015-9814-9; Ohinata Y, 2005, NATURE, V436, P207, DOI 10.1038/nature03813; Ouseph MM, 2012, DEV CELL, V22, P849, DOI 10.1016/j.devcel.2012.01.013; Pan HT, 2018, PLACENTA, V61, P1, DOI [10.1016/0.placenta.2017.11.001, 10.1016/j.placenta.2017.11.001]; Pan H, 2019, AM J PATHOL, V189, P124, DOI 10.1016/j.ajpath.2018.09.010; Paul S, 2017, PLACENTA, V60, pS61, DOI 10.1016/j.placenta.2017.05.005; Pi L, 2020, PEERJ, V8, DOI 10.7717/peerj.8196; Pringle KG, 2010, HUM REPROD UPDATE, V16, P415, DOI 10.1093/humupd/dmp046; Qi Lu, 2014, Yichuan, V36, P679, DOI 10.3724/SP.J.1005.2014.0679; Qiao Y, 2016, MOL HUM REPROD, V22, P364, DOI 10.1093/molehr/gaw008; Quintero-Ronderos P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186149; Rai R, 2006, LANCET, V368, P601, DOI 10.1016/S0140-6736(06)69204-0; Rull K, 2013, PLACENTA, V34, P141, DOI 10.1016/j.placenta.2012.11.032; Rull Kristiina, 2012, Frontiers in Genetics, V3, P34, DOI 10.3389/fgene.2012.00034; Rytkonen KT, 2019, REPROD SCI, V26, P323, DOI 10.1177/1933719118802056; Salker MS, 2018, J MOL MED, V96, P173, DOI 10.1007/s00109-017-1610-9; Salker MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052252; Sato Y, 2020, MOL CELL ENDOCRINOL, V503, DOI 10.1016/j.mce.2019.110699; Scott K, 2021, PHYSIOL GENOMICS, V53, P160, DOI 10.1152/physiolgenomics.00159.2020; Shiio Y, 2006, NAT PROTOC, V1, P139, DOI 10.1038/nprot.2006.22; Sober S, 2016, SCI REP-UK, V6, DOI 10.1038/srep38439; Stamou MI, 2015, ENDOCR REV, V36, P603, DOI [10.1210/er.2015-1045, 10.1210/er.2015-1045.2016.1]; Sun YV, 2016, ADV GENET, V93, P147, DOI 10.1016/bs.adgen.2015.11.004; Tang LS, 2016, GENE, V576, P366, DOI 10.1016/j.gene.2015.10.047; Taniguchi N, 2009, P NATL ACAD SCI USA, V106, P1181, DOI 10.1073/pnas.0806062106; Tian FJ, 2016, J PATHOL, V239, P36, DOI 10.1002/path.4694; Ticconi C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215332; Tsurusaki Y, 2014, CLIN GENET, V85, P592, DOI 10.1111/cge.12215; Tyers M, 2003, NATURE, V422, P193, DOI 10.1038/nature01510; Valeff N, 2021, GENOMICS, V113, P2614, DOI 10.1016/j.ygeno.2021.06.016; Verloes A, 2017, STEM CELL RES, V19, P118, DOI 10.1016/j.scr.2017.01.005; Wang C, 2020, P NATL ACAD SCI USA, V117, P19425, DOI 10.1073/pnas.2003913117; Wang FY, 2021, GENOM PROTEOM BIOINF, V19, P208, DOI 10.1016/j.gpb.2020.11.002; Wang FY, 2021, CELL MOL IMMUNOL, V18, P2101, DOI 10.1038/s41423-021-00739-z; Wang JM, 2016, ARCH GYNECOL OBSTET, V293, P1125, DOI 10.1007/s00404-016-4038-5; Wang LL, 2017, CLIN CHIM ACTA, V464, P17, DOI 10.1016/j.cca.2016.11.001; Wang LL, 2021, PLACENTA, V112, P45, DOI 10.1016/j.placenta.2021.07.001; Wang XH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23827-0; Worheide MA, 2021, ANAL CHIM ACTA, V1141, P144, DOI 10.1016/j.aca.2020.10.038; Wu Y, 2017, MOL MED REP, V16, P2367, DOI 10.3892/mmr.2017.6890; Xiong YM, 2021, BIOL REPROD, V105, P1246, DOI 10.1093/biolre/ioab140; Yin XJ, 2021, CLIN PROTEOM, V18, DOI 10.1186/s12014-021-09312-2; Yu MM, 2018, EBIOMEDICINE, V35, P334, DOI 10.1016/j.ebiom.2018.07.042; Zhou Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.738962	111	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								826198	10.3389/fimmu.2022.826198	http://dx.doi.org/10.3389/fimmu.2022.826198			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G7ZA		Green Published, gold			2022-12-18	WOS:000884968600001
J	Liu, YF; Huang, H; Sun, Y; Li, YW; Luo, BY; Cui, J; Zhu, MM; Bi, FK; Chen, KJ; Liu, Y				Liu, Yanfei; Huang, Hui; Sun, Yu; Li, Yiwen; Luo, Binyu; Cui, Jing; Zhu, Mengmeng; Bi, Fukun; Chen, Keji; Liu, Yue			Monosodium Glutamate-Induced Mouse Model With Unique Diabetic Retinal Neuropathy Features and Artificial Intelligence Techniques for Quantitative Evaluation	FRONTIERS IN IMMUNOLOGY			English	Article						type 2 diabetic retinopathy; artificial intelligence; quantitative evaluation; unique diabetic retinal neuropathy features; mice	FIBRILLARY ACIDIC PROTEIN	Objective: To establish an artificial intelligence-based method to quantitatively evaluate subtle pathological changes in retinal nerve cells and synapses in monosodium glutamate (MSG) mice and provide an effective animal model and technique for quantitative evaluation of retinal neurocytopathies. Methods: ICR mice were subcutaneously injected with MSG to establish a model of metabolic syndrome. We then established a mouse model of type 1 diabetes, type 2 diabetes, and KKAy mouse model as control. The HE sections of the retina were visualized using an optical microscope. AI technology was used for quantitative evaluation of the retinal lesions in each group of rats. The surface area custom parameters of the retinal nerve fiber layer (RNFL), inner plexiform layer (IPL), inner nuclear layer (INL), and outer plexiform layer (OPL) were defined as SR, SIPL, SINL, and SOPL, respectively. Their heights were defined as HR, HIPL, HINL, and HOPL, and the number of ganglion cells was defined as A. Then, the attention-augmented fully convolutional Unet network was used to segment the retinal HE images, and AI technology to identify retinal neurocytopathies quantitatively. Results: The attention-augmented fully convolutional Unet network increased PA and IOU parameters for INL, OPL, RNFL, and ganglion cells and was superior in recognizing fine structures. A quantitative AI identification of the height of each layer of the retina showed that the heights of the IPL and INL of the MSG model were significantly less than those of the control groups; the retinas of the other diabetic models did not exhibit this pathological feature. The RNFLs of type 2 diabetes were thinner, and the characteristics of retinopathy were not obvious in the other animal models. The pathological changes seen on HE images were consistent with the results of the quantitative AI evaluation. Immunohistochemistry results showed that NMDAR2A, GluR2, and NRG1 were significantly downregulated in the retina of MSG mice. Conclusions: The MSG retinopathy model is closely associated with neurotransmitter abnormalities and exhibits important characteristics of retinal neurodegeneration, making it suitable for studying retinal neurocytopathies. The AI recognition technology for retinal images established in the present study can be used for the quantitative and objective evaluation of drug efficacy.	[Liu, Yanfei; Li, Yiwen; Luo, Binyu; Cui, Jing; Zhu, Mengmeng; Chen, Keji; Liu, Yue] China Acad Chinese Med Sci, Natl Clin Res Ctr Chinese Med Cardiol, Xiyuan Hosp, Beijing, Peoples R China; [Huang, Hui] Beijing Duan Dian Pharmaceut Res & Dev Co Ltd, Beijing, Peoples R China; [Sun, Yu; Bi, Fukun] North China Univ Technol, Beijing, Peoples R China	China Academy of Chinese Medical Sciences; Xiyuan Hospital, CACMS; North China University of Technology	Liu, Y (corresponding author), China Acad Chinese Med Sci, Natl Clin Res Ctr Chinese Med Cardiol, Xiyuan Hosp, Beijing, Peoples R China.	liuyueheart@hotmail.com			Fundamental Research Funds for the Central public welfare research institutes of China Academy of Chinese Medical Sciences [ZZ15-YQ-017, ZZ13-YQ-001-A1]	Fundamental Research Funds for the Central public welfare research institutes of China Academy of Chinese Medical Sciences	This work was supported by grants from the Fundamental Research Funds for the Central public welfare research institutes of China Academy of Chinese Medical Sciences (ZZ15-YQ-017, ZZ13-YQ-001-A1).	Bahadoran Z, 2019, METHODS MOL BIOL, V1916, P49, DOI 10.1007/978-1-4939-8994-2_3; De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6; Duh EJ, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93751; Farhat F, 2021, NEUROPHARMACOLOGY, V196, DOI 10.1016/j.neuropharm.2021.108654; Jin L, 2018, NEUROSCI LETT, V682, P39, DOI 10.1016/j.neulet.2018.06.008; Kong XC, 2020, ENDOCR RES, V45, P111, DOI 10.1080/07435800.2019.1690504; Kowluru RA, 2016, METABOLISM, V65, P1570, DOI 10.1016/j.metabol.2016.07.012; Liberatore F, 2017, NEUROSCIENCE, V363, P142, DOI 10.1016/j.neuroscience.2017.09.005; Liu W, 2010, AUTON NEUROSCI-BASIC, V154, P79, DOI 10.1016/j.autneu.2009.12.003; Liu YF, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00172; Moccia S, 2018, COMPUT METH PROG BIO, V158, P71, DOI 10.1016/j.cmpb.2018.02.001; Moldovan OL, 2021, FOOD CHEM TOXICOL, V153, DOI 10.1016/j.fct.2021.112290; O'Brien J, 2018, ANNU REV VIS SCI, V4, P79, DOI 10.1146/annurev-vision-091517-034133; Prabhu S, 2011, J MED IMAG HEALTH IN, V1, P97, DOI 10.1166/jmihi.2011.1015; Praidou A, 2017, J DIABETES COMPLICAT, V31, P456, DOI 10.1016/j.jdiacomp.2016.06.027; Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971; Safi H, 2018, SURV OPHTHALMOL, V63, P601, DOI 10.1016/j.survophthal.2018.04.003; Shi R, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0769-3; Tsiknakis N, 2021, COMPUT BIOL MED, V135, DOI 10.1016/j.compbiomed.2021.104599; VERDERBER L, 1995, INVEST OPHTH VIS SCI, V36, P1137; Wang W, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061816; Xie QW, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104986; Zeng ZT, 2019, IEEE ACCESS, V7, P21420, DOI 10.1109/ACCESS.2019.2896920	23	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								862702	10.3389/fimmu.2022.862702	http://dx.doi.org/10.3389/fimmu.2022.862702			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G7XF	35572527	gold, Green Published			2022-12-18	WOS:000884963600001
J	Macatangay, BJC; Landay, AL; Garcia, F; Rinaldo, CR				Macatangay, Bernard J. C.; Landay, Alan L.; Garcia, Felipe; Rinaldo, Charles R.			Editorial: Advances in T Cell Therapeutic Vaccines for HIV	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						HIV; therapeutic vaccine; T cell; HIV remission; immunotherapy			[Macatangay, Bernard J. C.; Rinaldo, Charles R.] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA; [Landay, Alan L.] Rush Med Coll, Dept Internal Med, Chicago, IL USA; [Garcia, Felipe] Hosp Clin Barcelona, Infect Dis Dept, Barcelona, Spain	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Rush University; University of Barcelona; Hospital Clinic de Barcelona	Macatangay, BJC (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15260 USA.	macatangaybj@upmc.edu	, Felipe/F-4242-2014	, Felipe/0000-0001-7658-5832	National Institutes of Health [U01-HL146203, U01-AI131285, INT21/00033]; Spanish Ministry of Science [RTI2018-096309-B-I00, 731626]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Spanish Ministry of Science(Ministry of Science and Innovation, Spain (MICINN)Spanish Government)	This publication is supported in part by the National Institutes of Health Cooperative Agreement U01-HL146203 and U01-AI131285, and by INT21/00033, Spanish Ministry of Science RTI2018-096309-B-I00, HIVACAR H2020-SC1-2016-2017 (H2020-SC1-2016-RTD) Proposal 731626.	Allers K, 2011, BLOOD, V117, P2791, DOI 10.1182/blood-2010-09-309591; Board NL, 2022, NAT REV IMMUNOL, V22, P499, DOI 10.1038/s41577-021-00649-1; Caskey M, 2020, CURR OPIN HIV AIDS, V15, P49, DOI 10.1097/COH.0000000000000600; Garcia F, 2013, HUM VACC IMMUNOTHER, V9, P2445, DOI 10.4161/hv.25876; Garcia F, 2012, HUM VACC IMMUNOTHER, V8, P569, DOI 10.4161/hv.19555; Gay CL, 2021, JAIDS-J ACQ IMM DEF, V87, pE234, DOI 10.1097/QAI.0000000000002716; Gay CL, 2017, J INFECT DIS, V215, P1725, DOI 10.1093/infdis/jix191; Gray GE, 2016, CURR OPIN VIROL, V17, P104, DOI 10.1016/j.coviro.2016.02.010; Gupta RK, 2019, NATURE, V568, P244, DOI 10.1038/s41586-019-1027-4; Hutter G, 2009, NEW ENGL J MED, V360, P692, DOI 10.1056/NEJMoa0802905; Ko EJ, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12010024; Li JZ, 2022, CLIN INFECT DIS, V74, P865, DOI 10.1093/cid/ciab541; Naranjo-Gomez M, 2019, CURR OPIN HIV AIDS, V14, P325, DOI 10.1097/COH.0000000000000555; Niessl J, 2020, NAT MED, V26, P222, DOI 10.1038/s41591-019-0747-1; Rinaldo CR, 2009, J INTERN MED, V265, P138, DOI 10.1111/j.1365-2796.2008.02047.x; Stephenson KE, 2018, CURR OPIN HIV AIDS, V13, P408, DOI 10.1097/COH.0000000000000491	16	0	0	12	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								905836	10.3389/fimmu.2022.905836	http://dx.doi.org/10.3389/fimmu.2022.905836			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G4EM	35572584	Green Published, gold			2022-12-18	WOS:000795802000001
J	Nicola, AM; Desai, JV; Swidergall, M; Shey, M; Dambuza, IM				Nicola, Andre Moraes; Desai, Jigar V.; Swidergall, Marc; Shey, Muki; Dambuza, Ivy M.			Editorial: Immunological Memory to Fungal Infections and Vaccine Development	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						vaccine; immunological memory; fungi; aspergillosis; paracoccidioidomycosis; histoplasmosis; mycoses; candidiasis			[Nicola, Andre Moraes] Univ Brasilia, Fac Med, Brasilia, Brazil; [Desai, Jigar V.] NIAID, NIH, Fungal Pathogenesis Sect, Lab Clin Immunol & Microbiol, Bethesda, MD USA; [Swidergall, Marc] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA USA; [Shey, Muki] Univ Cape Town, Inst Infect Dis & Mol Med, Fac Hlth Sci, Dept Med, Cape Town, South Africa; [Shey, Muki; Dambuza, Ivy M.] Univ Exeter, MRC Ctr Med Mycol, Exeter, England; Univ Cape Town, Inst Infect Dis & Mol Med, Fac Hlth Sci, Wellcome Ctr Infect Dis Res Afr CIDRI Afr, Cape Town, South Africa	Universidade de Brasilia; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Cape Town; University of Exeter; University of Cape Town	Nicola, AM (corresponding author), Univ Brasilia, Fac Med, Brasilia, Brazil.; Dambuza, IM (corresponding author), Univ Exeter, MRC Ctr Med Mycol, Exeter, England.				Fundacao de Apoio a Pesquisa do Distrito Federal (FAP-DF) [0193.001048/2015, 0193.001561/2017]; Conselho Nacional de Desenvolvimento Cient'fico e Tecnologico (CNPq) grant [437484/2018-1]; Division of Intramural Research (DIR) of the National Institute of Allergy and Infectious Diseases (NIAID); NIH [R00DE026856]; American Association of Immunologists Careers in Immunology Fellowship; Wellcome Trust [211360/Z/18/Z]; National Research Foundation of South Africa (NRF) [UID127558]; Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology [097377]; TLI seed grant	Fundacao de Apoio a Pesquisa do Distrito Federal (FAP-DF)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Conselho Nacional de Desenvolvimento Cient'fico e Tecnologico (CNPq) grant(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)Fundacao de Apoio a Pesquisa do Distrito Federal (FAPDF)); Division of Intramural Research (DIR) of the National Institute of Allergy and Infectious Diseases (NIAID); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Association of Immunologists Careers in Immunology Fellowship; Wellcome Trust(Wellcome Trust); National Research Foundation of South Africa (NRF)(National Research Foundation - South Africa); Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology; TLI seed grant	AMN was funded by the Fundacao de Apoio a Pesquisa do Distrito Federal (FAP-DF) awards 0193.001048/2015 and 0193.001561/2017 and the Conselho Nacional de Desenvolvimento Cienti ' fico e Tecnolo ' gico (CNPq) grant 437484/2018-1. JVD was supported by the Division of Intramural Research (DIR) of the National Institute of Allergy and Infectious Diseases (NIAID). MaS was supported by NIH grant R00DE026856, an American Association of Immunologists Careers in Immunology Fellowship, and a TLI seed grant. MuS was supported by the Wellcome Trust (grant#: 211360/Z/18/Z) and the National Research Foundation of South Africa (NRF, grant#: UID127558). IMD was supported by the Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology (grant#097377).	Brown GD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004404; Schmidt CS, 2012, VACCINE, V30, P7594, DOI 10.1016/j.vaccine.2012.10.038; Taborda CP, 1998, INFECT IMMUN, V66, P786, DOI 10.1128/IAI.66.2.786-793.1998	3	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								880037	10.3389/fimmu.2022.880037	http://dx.doi.org/10.3389/fimmu.2022.880037			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G4HD	35572566	gold, Green Published			2022-12-18	WOS:000795809000001
J	Papathanasiou, E; Scott, AR; Trotman, CA; Beale, C; Price, LL; Huggins, GS; Zhang, Y; Georgakoudi, I; Van Dyke, TE				Papathanasiou, Evangelos; Scott, Andrew R.; Trotman, Carroll Ann; Beale, Corinna; Price, Lori Lyn; Huggins, Gordon S.; Zhang, Yang; Georgakoudi, Irene; Van Dyke, Thomas E.			Specialized Pro-Resolving Mediators Reduce Scarring After Cleft Lip Repair	FRONTIERS IN IMMUNOLOGY			English	Article						scar; inflammation; cleft lip; lipoxins; collagen; rabbit; wound healing; surgery	WOUND REPAIR; INFLAMMATION; MECHANISMS; MACROPHAGES; MANAGEMENT; INFECTION; RABBITS; INJURY	ObjectiveResidual scarring after cleft lip repair surgery remains a challenge for both surgeons and patients and novel therapeutics are critically needed. The objective of this preclinical experimental study was to evaluate the impact of the methyl-ester of pro-resolving lipid mediator lipoxin A(4) (LXA(4)-ME) on scarring in a novel rabbit model of cleft lip repair. MethodsA defect of the lip was surgically created and repaired in eight six-week old New Zealand white rabbits to simulate human cleft lip scars. Rabbits were randomly assigned to topical application of PBS (control) or 1 ug of LXA(4)-ME (treatment). 42 days post surgery all animals were euthanized. Photographs of the cleft lip area defect and histologic specimens were evaluated. Multiple scar assessment scales were used to compare scarring. ResultsAnimals treated with LXA(4)-ME exhibited lower Visual Scar Assessment scores compared to animals treated with PBS. Treatment with LXA(4)-ME resulted in a significant reduction of inflammatory cell infiltrate and density of collagen fibers. Control animals showed reduced 2D directional variance (orientation) of collagen fibers compared to animals treated with LXA(4)-ME demonstrating thicker and more parallel collagen fibers, consistent with scar tissue. ConclusionsThese data suggest that LXA(4)-ME limits scarring after cleft lip repair and improves wound healing outcomes in rabbits favoring the resolution of inflammation. Further studies are needed to explore the mechanisms that underlie the positive therapeutic impact of LXA(4)-ME on scarring to set the stage for future human clinical trials of LXA(4)-ME for scar prevention or treatment after cleft lip repair.	[Papathanasiou, Evangelos] Tufts Univ, Sch Dent Med, Dept Periodontol, Boston, MA 02111 USA; [Papathanasiou, Evangelos; Van Dyke, Thomas E.] Forsyth Inst, Ctr Clin & Translat Res, Cambridge, MA 02142 USA; [Scott, Andrew R.] Tufts Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Boston, MA 02111 USA; [Trotman, Carroll Ann] Ohio State Univ, Coll Dent, Columbus, OH 43210 USA; [Beale, Corinna] Tufts Univ, Tufts Comparat Med Serv, Boston, MA 02111 USA; [Price, Lori Lyn] Tufts Univ, Tufts Clin & Translat Sci Inst, Boston, MA 02111 USA; [Price, Lori Lyn] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA; [Huggins, Gordon S.] Tufts Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; [Huggins, Gordon S.] Tufts Med Ctr, Cardiol Div, Boston, MA 02111 USA; [Huggins, Gordon S.] Tufts Univ, Sch Med, Boston, MA 02111 USA; [Zhang, Yang; Georgakoudi, Irene] Tufts Univ, Sch Engn, Dept Biomed Engn, Medford, MA 02155 USA; [Van Dyke, Thomas E.] Harvard Univ, Fac Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA	Tufts University; Harvard University; Forsyth Institute; Tufts University; University System of Ohio; Ohio State University; Tufts University; Tufts University; Tufts Medical Center; Tufts Medical Center; Tufts Medical Center; Tufts University; Tufts University; Harvard University	Van Dyke, TE (corresponding author), Forsyth Inst, Ctr Clin & Translat Res, Cambridge, MA 02142 USA.; Van Dyke, TE (corresponding author), Harvard Univ, Fac Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.	tvandyke@forsyth.org						Abramov Y, 2007, WOUND REPAIR REGEN, V15, P80, DOI 10.1111/j.1524-475X.2006.00188.x; Ariel A, 2013, J PATHOL, V229, P250, DOI 10.1002/path.4108; Bao YW, 2020, AESTHET PLAST SURG, V44, P207, DOI 10.1007/s00266-019-01518-y; BARDACH J, 1977, CLEFT PALATE J, V14, P88; Bartkowska P, 2020, J COSMET DERMATOL-US, V19, P1866, DOI 10.1111/jocd.13511; Basil MC, 2016, NAT REV IMMUNOL, V16, P51, DOI 10.1038/nri.2015.4; Beausang E, 1998, PLAST RECONSTR SURG, V102, P1954, DOI 10.1097/00006534-199811000-00022; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bohr S, 2013, WOUND REPAIR REGEN, V21, P35, DOI 10.1111/j.1524-475X.2012.00853.x; COMINELLI F, 1989, GASTROENTEROLOGY, V97, P1400, DOI 10.1016/0016-5085(89)90382-X; Dalli J, 2015, NAT MED, V21, P1071, DOI 10.1038/nm.3911; Dixon MJ, 2011, NAT REV GENET, V12, P167, DOI 10.1038/nrg2933; Dovi JV, 2003, J LEUKOCYTE BIOL, V73, P448, DOI 10.1189/jlb.0802406; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337; Feng Y, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01101; Fredman G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12859; Gauglitz GG, 2011, MOL MED, V17, P113, DOI 10.2119/molmed.2009.00153; Giannakis N, 2019, NAT IMMUNOL, V20, P626, DOI 10.1038/s41590-019-0356-7; Gold MH, 2014, DERMATOL SURG, V40, P817, DOI 10.1111/dsu.0000000000000049; Grieb G, 2011, INT REV CEL MOL BIO, V291, P1, DOI 10.1016/B978-0-12-386035-4.00001-X; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05-4724fje; Hasturk H, 2007, J IMMUNOL, V179, P7021, DOI 10.4049/jimmunol.179.10.7021; Hasturk H, 2015, ARTERIOSCL THROM VAS, V35, P1123, DOI 10.1161/ATVBAHA.115.305324; Hellmann J, 2012, CURR OPIN ENDOCRINOL, V19, P104, DOI 10.1097/MED.0b013e3283514e00; Herrera BS, 2015, BIOCHEM BIOPH RES CO, V464, P1072, DOI 10.1016/j.bbrc.2015.07.076; Karin M, 2016, NATURE, V529, P307, DOI 10.1038/nature17039; Kasperek R, 2015, ACTA POL PHARM, V72, P527; Kenchegowda S, 2010, J LIPID RES, V51, P879, DOI 10.1194/jlr.R001347; Kida T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096481; Ko JH, 2012, PLAST RECONSTR SURG, V129, p252E, DOI 10.1097/PRS.0b013e31823aea10; Kronke G, 2012, ANN RHEUM DIS, V71, P1081, DOI 10.1136/annrheumdis-2011-200745; Li Y, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.810290; Lu SW, 2014, MOL BIOL REP, V41, P2143, DOI 10.1007/s11033-014-3063-3; Lumbroso D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00358; Mak K, 2009, J DERMATOL SCI, V56, P168, DOI 10.1016/j.jdermsci.2009.09.005; Nedelec B, 2001, SURGERY, V130, P798, DOI 10.1067/msy.2001.116453; Nguyen TA, 2015, SEMIN CUTAN MED SURG, V34, P28, DOI 10.12788/j.sder.2015.0125; Papathanasiou E, 2017, J DENT RES, V96, P1370, DOI 10.1177/0022034517717261; Papathanasiou E, 2016, J DENT RES, V95, P1018, DOI 10.1177/0022034516645332; Papathanasiou E, 2022, FACIAL PLAST SURG AE, V24, P66, DOI 10.1089/fpsam.2020.0525; Perez-Hernandez J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.768133; Pierce GF, 2001, AM J PATHOL, V159, P399, DOI 10.1016/S0002-9440(10)61709-9; Qian LW, 2016, WOUND REPAIR REGEN, V24, P26, DOI 10.1111/wrr.12381; Quinn KP, 2016, SCI REP-UK, V6, DOI 10.1038/srep35823; Quinn KP, 2015, EXP DERMATOL, V24, P78, DOI 10.1111/exd.12553; Quinn KP, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.4.046003; Ramazanzadeh B, 2015, J CRANIOFAC SURG, V26, P1539, DOI 10.1097/SCS.0000000000001837; SAHL WJ, 1994, INT J DERMATOL, V33, P681, DOI 10.1111/j.1365-4362.1994.tb01511.x; Seo BF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/423147; Serhan CN, 2020, MOL ASPECTS MED, V74, DOI 10.1016/j.mam.2020.100894; Serhan CN, 2018, J CLIN INVEST, V128, P2657, DOI 10.1172/JCI97943; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Serhan CN, 2003, J IMMUNOL, V171, P6856, DOI 10.4049/jimmunol.171.12.6856; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Sidgwick GP, 2015, ARCH DERMATOL RES, V307, P461, DOI 10.1007/s00403-015-1572-0; Smith BJ, 2014, WOUND REPAIR REGEN, V22, P228, DOI 10.1111/wrr.12141; Soltani Ali M, 2012, Clin Epidemiol, V4, P187, DOI 10.2147/CLEP.S31119; Tang YN, 2013, DIABETES, V62, P618, DOI 10.2337/db12-0684; Tiberi M, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.673549; Torricelli AAM, 2014, MOL VIS, V20, P1710; Trotman CA, 2010, J DENT RES, V89, P728, DOI 10.1177/0022034510365485; Wilson ADH, 2008, CLEFT PALATE-CRAN J, V45, P614, DOI 10.1597/07-072.1; Wu SH, 2013, BRIT J DERMATOL, V168, P172, DOI 10.1111/j.1365-2133.2012.11177.x; Wynn TA, 2012, NAT MED, V18, P1028, DOI 10.1038/nm.2807; Xue ML, 2015, ADV WOUND CARE, V4, P119, DOI 10.1089/wound.2013.0485; Yang WH, 2020, J COSMET DERMATOL-US, V19, P799, DOI 10.1111/jocd.13139	68	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								871200	10.3389/fimmu.2022.871200	http://dx.doi.org/10.3389/fimmu.2022.871200			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1D5CD	35572588	gold, Green Published			2022-12-18	WOS:000793817200001
J	Phelps, DS; Chinchilli, VM; Zhang, XS; Shearer, D; Weisz, J; Floros, J				Phelps, David S.; Chinchilli, Vernon M.; Zhang, Xuesheng; Shearer, Debra; Weisz, Judith; Floros, Joanna			Comparison of the Toponomes of Alveolar Macrophages From Wild Type and Surfactant Protein A Knockout Mice and Their Response to Infection	FRONTIERS IN IMMUNOLOGY			English	Article						phagocytosis; phenotype; SP-A; surfactant; innate immunity; immunohistochemistry; immunophenotype	KLEBSIELLA-PNEUMONIAE INFECTION; SEX-DIFFERENCES; PHAGOCYTOSIS; RECEPTOR; IMPACT; LUNG; RECOGNITION; VARIANTS; SURVIVAL; REVEALS	BackgroundSurfactant protein-A (SP-A) plays a critical role in lung innate immunity by regulating alveolar macrophages (AM), expression of inflammatory mediators, and other host defense proteins. The toponome imaging system (TIS), a serial immunostainer, was used to study the AM toponome because it characterizes the localization of multiple markers and identifies marker combinations in each pixel as combinatorial molecular phenotypes (CMPs). We used TIS to study the AM toponome from wild type (WT) and SP-A knockout (KO) mice and changes following Klebsiella pneumoniae exposure. MethodsWT or KO mice received intratracheal K. pneumoniae or vehicle and AM were obtained by bronchoalveolar lavage after one hour. AM were attached to slides and underwent TIS analysis. Images were analyzed to characterize all pixels. AM CMPs from WT vehicle (n=3) and infected (n=3) mice were compared to each other and to AM from KO (n=3 vehicle; n=3 infected). Histograms provided us with a tool to summarize the representation of each marker in a set of CMPs. ResultsUsing the histograms and other tools we identified markers of interest and observed that: 1) Both comparisons had conserved (present in all group members) CMPs, only in vehicle AM and only in infected AM, or common to both vehicle and infected AM, (i.e., unaffected by the condition). 2) the CMP number decreased with infection in WT and KO versus vehicle controls. 3) More infection-specific CMPs in WT vs KO AM. 4) When AM from WT and KO vehicle or infected were compared, there were more unique CMPs exclusive to the KO AM. 5) All comparisons showed CMPs shared by both groups. ConclusionsThe decrease of CMPs exclusive to infected AM in KO mice may underlie the observed susceptibility of KO mice to infection. However, both KO groups had more exclusive CMPs than the corresponding WT groups, perhaps indicating a vigorous effort by KO to overcome deficits in certain proteins and CMPs that are dysregulated by the absence of SP-A. Moreover, the presence of shared CMPs in the compared groups indicates that regulation of these CMPs is not dependent on either infection or the presence or absence of SP-A.	[Phelps, David S.; Zhang, Xuesheng; Floros, Joanna] Penn State Univ Coll Med, Penn State Ctr Host Def, Inflammat & Lung Dis CHILD Res & Dept Pediat, Hershey, PA USA; [Chinchilli, Vernon M.] Penn State Univ Coll Med, Publ Hlth Sci, Hershey, PA USA; [Shearer, Debra; Weisz, Judith; Floros, Joanna] Penn State Univ Coll Med, Obstet & Gynecol, Hershey, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Phelps, DS; Floros, J (corresponding author), Penn State Univ Coll Med, Penn State Ctr Host Def, Inflammat & Lung Dis CHILD Res & Dept Pediat, Hershey, PA USA.; Floros, J (corresponding author), Penn State Univ Coll Med, Obstet & Gynecol, Hershey, PA USA.	dsp4@psu.edu; jfloros@psu.edu			National Institutes of Health (NIH) [1R21AI113050-01A1]; G. Pedlow Research Fund	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); G. Pedlow Research Fund	This work was supported by a grant from the National Institutes of Health (NIH 1R21AI113050-01A1) and by the G. Pedlow Research Fund.	Al Barashdi MA, 2021, J CLIN PATHOL, V74, P548, DOI 10.1136/jclinpath-2020-206927; Ali Mehboob, 2010, Proteome Sci, V8, P34, DOI 10.1186/1477-5956-8-34; Amash A, 2016, J IMMUNOL, V196, P3331, DOI 10.4049/jimmunol.1502198; Beharka AA, 2002, J IMMUNOL, V169, P3565, DOI 10.4049/jimmunol.169.7.3565; Bhattacharya S, 2010, J PROTEOME RES, V9, P6112, DOI 10.1021/pr100157p; Bode M, 2008, PROTEOMICS, V8, P1170, DOI 10.1002/pmic.200700742; Ciesielska A, 2021, CELL MOL LIFE SCI, V78, P1233, DOI 10.1007/s00018-020-03656-y; Crocker PR, 2007, NAT REV IMMUNOL, V7, P255, DOI 10.1038/nri2056; Depicolzuane L, 2022, FRONT PEDIATR, V9, DOI 10.3389/fped.2021.799693; Fagerholm SC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00254; Fitzgerald KA, 2020, CELL, V180, P1044, DOI 10.1016/j.cell.2020.02.041; Floros J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.681639; Gordon S, 2016, IMMUNITY, V44, P463, DOI 10.1016/j.immuni.2016.02.026; Henning LN, 2008, J IMMUNOL, V180, P7847, DOI 10.4049/jimmunol.180.12.7847; Hollingsworth JW, 2007, AM J RESP CELL MOL, V37, P248, DOI 10.1165/rcmb.2006-0363OC; Jakel A, 2013, FRONT BIOSCI-LANDMRK, V18, P1129, DOI 10.2741/4168; Kazuo T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55289-2; Koptides M, 1997, AM J PHYSIOL-LUNG C, V273, pL382, DOI 10.1152/ajplung.1997.273.2.L382; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL996, DOI 10.1152/ajplung.1997.272.5.L996; Kuroki Y, 2007, CELL MICROBIOL, V9, P1871, DOI 10.1111/j.1462-5822.2007.00953.x; Lu MY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.648184; Mikerov AN, 2005, AM J PHYSIOL-LUNG C, V288, pL150, DOI 10.1152/ajplung.00135.2004; Mikerov AN, 2008, AM J PHYSIOL-LUNG C, V294, pL121, DOI 10.1152/ajplung.00288.2007; Mikerov AN, 2007, INFECT IMMUN, V75, P1403, DOI 10.1128/IAI.01341-06; Mikerov AN, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-77; Mikerov AN, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-24; Noutsios GT, 2017, BIOL SEX DIFFER, V8, DOI 10.1186/s13293-017-0158-2; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Phelps DS, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-08114-2; Phelps DS, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.141410; Phelps DS, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-019-0181-z; Phelps David S, 2013, J Proteom Genom Res, V1, P2; Phelps DS, 2014, J PROTEOMICS, V108, P427, DOI 10.1016/j.jprot.2014.06.007; Phelps DS, 2012, PROTEOME SCI, V10, DOI 10.1186/1477-5956-10-44; Phelps DS, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-67; Phelps DS, 2001, PEDIATR PATHOL MOL M, V20, P269, DOI 10.1080/152279501750412225; Rheinlander A, 2018, IMMUNOL LETT, V196, P22, DOI 10.1016/j.imlet.2018.01.009; Saunders AE, 2010, CELL SIGNAL, V22, P339, DOI 10.1016/j.cellsig.2009.10.003; Schubert W, 2006, CYTOM PART A, V69A, P109, DOI 10.1002/cyto.a.20234; Schubert W, 2006, NAT BIOTECHNOL, V24, P1270, DOI 10.1038/nbt1250; Schubert W, 2014, P NATL ACAD SCI USA, V111, pE215, DOI 10.1073/pnas.1319017111; Schubert W, 2014, J MOL RECOGNIT, V27, P3, DOI 10.1002/jmr.2326; St-Pierre J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071531; Thorenoor N, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121190; Thorenoor N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01290; Thorenoor N, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01960; Thorenoor N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02404; Tsotakos N, 2016, BIOL SEX DIFFER, V7, DOI 10.1186/s13293-016-0071-0; Wang GR, 2000, AM J PHYSIOL-LUNG C, V278, pL946, DOI 10.1152/ajplung.2000.278.5.L946; Zamze S, 2002, J BIOL CHEM, V277, P41613, DOI 10.1074/jbc.M207057200	52	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								853611	10.3389/fimmu.2022.853611	http://dx.doi.org/10.3389/fimmu.2022.853611			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0OV	35572576	Green Published, gold			2022-12-18	WOS:000795557500001
J	Porto, BN				Porto, Barbara N.			Insights Into the Role of the Lung Virome During Respiratory Viral Infections	FRONTIERS IN IMMUNOLOGY			English	Review						lung virome; microbiome; respiratory virus; virus infection; disease pathogenesis	PNEUMONIA REQUIRING HOSPITALIZATION; DNA VIRUSES; GUT VIROME; BACTERIOPHAGES	The virome constitutes the viral component of the microbiome and it consists of the genomes of all the viruses that inhabit a particular region of the human body, including those that cause acute, persistent or latent infection, and retroviral elements integrated to host chromosomes. The human virome is composed by eukaryotic viruses, bacteriophages and archaeal viruses. The understanding of the virome composition and role on human health has been delayed by the absence of specific tools and techniques to accurately characterize viruses. However, more recently, advanced methods for viral diagnostics, such as deep sequencing and metagenomics, have allowed a better understanding of the diverse viral species present in the human body. Previous studies have shown that the respiratory virome modulates the host immunity and that, since childhood, the human lung is populated by viruses for whom there is no disease association. Whether these viruses are potentially pathogenic and the reason for their persistence remain elusive. Increased respiratory viral load can cause exacerbation of chronic pulmonary diseases, including COPD, cystic fibrosis, and asthma. Moreover, the presence of resident viral populations may contribute to the pathogenesis of community-acquired respiratory virus infections. In this mini review, I will discuss the recent progress on our understanding of the human lung virome and summarize the up-to-date knowledge on the relationships among community-acquired respiratory viruses, the lung virome and the immune response to better understand disease pathophysiology and the factors that may lead to viral persistence.	[Porto, Barbara N.] Univ Manitoba, Rady Fac Hlth Sci, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada; [Porto, Barbara N.] Childrens Hosp Res Inst Manitoba, Biol Breathing Grp, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Porto, BN (corresponding author), Univ Manitoba, Rady Fac Hlth Sci, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada.; Porto, BN (corresponding author), Childrens Hosp Res Inst Manitoba, Biol Breathing Grp, Winnipeg, MB, Canada.	barbara.porto@umanitoba.ca			University of Manitoba Start-Up Funds	University of Manitoba Start-Up Funds	This study was supported by University of Manitoba Start-Up Funds to BNP.	Abbas AA, 2019, CELL HOST MICROBE, V25, P719, DOI 10.1016/j.chom.2019.04.001; Abeles SR, 2014, ISME J, V8, P1753, DOI 10.1038/ismej.2014.31; BARFOOT R, 1989, IMMUNOLOGY, V68, P233; Canchaya C, 2003, CURR OPIN MICROBIOL, V6, P417, DOI 10.1016/S1369-5274(03)00086-9; Cao JB, 2021, GUT MICROBES, V13, P1, DOI 10.1080/19490976.2021.1887722; Colvin Joshua M, 2012, Pediatrics, V130, pe1455, DOI 10.1542/peds.2012-1391; De Vlaminck I, 2013, CELL, V155, P1178, DOI 10.1016/j.cell.2013.10.034; Delwart E, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003146; Duerkop BA, 2013, NAT IMMUNOL, V14, P654, DOI 10.1038/ni.2614; Eriksson F, 2009, J IMMUNOL, V182, P3105, DOI 10.4049/jimmunol.0800224; Ferravante C, 2022, J MED VIROL, V94, P2275, DOI 10.1002/jmv.27571; Foxman EF, 2011, NAT REV MICROBIOL, V9, P254, DOI 10.1038/nrmicro2541; Gogarten JP, 2002, MOL BIOL EVOL, V19, P2226, DOI 10.1093/oxfordjournals.molbev.a004046; Gorski A, 2006, TRANSPL P, V38, P331, DOI 10.1016/j.transproceed.2005.12.073; Jain S, 2015, NEW ENGL J MED, V373, P415, DOI [10.1056/NEJMoa1500245, 10.1056/NEJMc1511751]; Jain S, 2015, NEW ENGL J MED, V372, P835, DOI 10.1056/NEJMoa1405870; Jankauskaite L, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54050072; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105924; Li YP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10294-x; Lysholm F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030875; Merenstein C, 2021, MBIO, V12, DOI [10.1128/mBio.01777-21, 10.1101/2021.04.02.21254514]; Minot S, 2011, GENOME RES, V21, P1616, DOI 10.1101/gr.122705.111; Mori K, 1996, ANTIVIR RES, V31, P79, DOI 10.1016/0166-3542(96)00951-5; Naureen Zakira, 2020, Acta Biomed, V91, pe2020024, DOI 10.23750/abm.v91i13-S.10819; Nazareth R, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-1082-5; Nguyen S, 2017, MBIO, V8, DOI 10.1128/mBio.01874-17; Nokso-Koivisto J, 2002, J MED VIROL, V66, P417, DOI 10.1002/jmv.2161; Perez-Brocal V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191867; Pride DT, 2012, ISME J, V6, P915, DOI 10.1038/ismej.2011.169; Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446; Raman R, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070993; Reyes A, 2010, NATURE, V466, P334, DOI 10.1038/nature09199; Rodrigues RAL, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01673; Roux S., 2021, ENCYCL VIROL, V1, P133, DOI [10.1016/B978-0-12-809633-8.20957-6, DOI 10.1016/B978-0-12-809633-8.20957-6, 10.1016/b978-0-12-809633-8.20957-6]; Singanayagam A, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-27; Spezia PG, 2020, J CLIN VIROL, V131, DOI 10.1016/j.jcv.2020.104586; Sweere JM, 2019, SCIENCE, V363, P1416, DOI 10.1126/science.aat9691; Virgin HW, 2014, CELL, V157, P142, DOI 10.1016/j.cell.2014.02.032; Wang Y, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2016.01.006; Willner D, 2012, AM J RESP CELL MOL, V46, P127, DOI 10.1165/rcmb.2011-0253OC; Willner D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007370; Wylie KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0027735; Yang J, 2011, J CLIN MICROBIOL, V49, P3463, DOI 10.1128/JCM.00273-11; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou P, 2020, NATURE, V588, pE6, DOI [10.1038/s41586-020-2012-7, 10.1038/s41586-020-2951-z]	45	0	0	1	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								885341	10.3389/fimmu.2022.885341	http://dx.doi.org/10.3389/fimmu.2022.885341			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G7HP	35572506	gold, Green Published			2022-12-18	WOS:000884923000001
J	Ravichandran, R; Bansal, S; Rahman, M; Sureshbabu, A; Sankpal, N; Fleming, T; Bharat, A; Mohanakumar, T				Ravichandran, Ranjithkumar; Bansal, Sandhya; Rahman, Mohammad; Sureshbabu, Angara; Sankpal, Narendra; Fleming, Timothy; Bharat, Ankit; Mohanakumar, Thalachallour			Extracellular Vesicles Mediate Immune Responses to Tissue-Associated Self-Antigens: Role in Solid Organ Transplantations	FRONTIERS IN IMMUNOLOGY			English	Review						extracellular vesicles; transplantation; immune responses; tissue-associated self-antigens; antibodies	NON-HLA ANTIBODIES; LUNG ALLOGRAFT DYSFUNCTION; DONOR-SPECIFIC ANTIBODIES; REGULATORY T-CELLS; BRONCHIOLITIS OBLITERANS SYNDROME; PRIMARY GRAFT DYSFUNCTION; II TYPE-1 RECEPTOR; CHRONIC REJECTION; HEART-TRANSPLANTATION; DENDRITIC CELLS	Transplantation is a treatment option for patients diagnosed with end-stage organ diseases; however, long-term graft survival is affected by rejection of the transplanted organ by immune and nonimmune responses. Several studies have demonstrated that both acute and chronic rejection can occur after transplantation of kidney, heart, and lungs. A strong correlation has been reported between de novo synthesis of donor-specific antibodies (HLA-DSAs) and development of both acute and chronic rejection; however, some transplant recipients with chronic rejection do not have detectable HLA-DSAs. Studies of sera from such patients demonstrate that immune responses to tissue-associated antigens (TaAgs) may also play an important role in the development of chronic rejection, either alone or in combination with HLA-DSAs. The synergistic effect between HLA-DSAs and antibodies to TaAgs is being established, but the underlying mechanism is yet to be defined. We hypothesize that HLA-DSAs damage the transplanted donor organ resulting in stress and leading to the release of extracellular vesicles, which contribute to chronic rejection. These vesicles express both donor human leukocyte antigen (HLA) and non-HLA TaAgs, which can activate antigen-presenting cells and lead to immune responses and development of antibodies to both donor HLA and non-HLA tissue-associated Ags. Extracellular vesicles (EVs) are released by cells under many circumstances due to both physiological and pathological conditions. Primarily employing clinical specimens obtained from human lung transplant recipients undergoing acute or chronic rejection, our group has demonstrated that circulating extracellular vesicles display both mismatched donor HLA molecules and lung-associated Ags (collagen-V and K-alpha 1 tubulin). This review focuses on recent studies demonstrating an important role of antibodies to tissue-associated Ags in the rejection of transplanted organs, particularly chronic rejection. We will also discuss the important role of extracellular vesicles released from transplanted organs in cross-talk between alloimmunity and autoimmunity to tissue-associated Ags after solid organ transplantation.										Admyre C, 2003, EUR RESPIR J, V22, P578, DOI 10.1183/09031936.03.00041703; Agarwal A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00555; Aiello S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08617-3; Akbarpour M, 2019, HUM IMMUNOL, V80, P595, DOI 10.1016/j.humimm.2019.04.016; Alexander M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8321; Almaghrabi RS, 2017, EXPERT REV RESP MED, V11, P377, DOI 10.1080/17476348.2017.1317596; Angaswamy N, 2014, AM J TRANSPLANT, V14, P685, DOI 10.1111/ajt.12592; Angaswamy N, 2010, HUM IMMUNOL, V71, P560, DOI 10.1016/j.humimm.2010.02.021; Anglicheau D, 2009, P NATL ACAD SCI USA, V106, P5330, DOI 10.1073/pnas.0813121106; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Azimzadeh AM, 2005, AM J TRANSPLANT, V5, P2349, DOI 10.1111/j.1600-6143.2005.01022.x; Banasik M, 2014, TRANSPL P, V46, P2618, DOI 10.1016/j.transproceed.2014.09.029; Bansal S, 2022, J HEART LUNG TRANSPL, V41, P24, DOI 10.1016/j.healun.2021.09.001; Bansal S, 2021, J IMMUNOL, V207, P2405, DOI 10.4049/jimmunol.2100637; Bansal S, 2021, TRANSPL IMMUNOL, V69, DOI 10.1016/j.trim.2021.101480; Bartel G, 2008, AM J TRANSPLANT, V8, P2652, DOI 10.1111/j.1600-6143.2008.02428.x; Bery AI, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2019.11.86; Bharat A, 2006, AM J TRANSPLANT, V6, P1799, DOI 10.1111/j.1600-6143.2006.01383.x; Bharat A, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/6312514; Bharat A, 2016, AM J RESP CELL MOL, V55, P532, DOI 10.1165/rcmb.2016-0077OC; Bharat A, 2010, ANN THORAC SURG, V90, P1637, DOI 10.1016/j.athoracsur.2010.06.048; Bharat A, 2010, ANN THORAC SURG, V90, P1094, DOI 10.1016/j.athoracsur.2010.06.009; Bracamonte-Baran W, 2017, P NATL ACAD SCI USA, V114, P1099, DOI 10.1073/pnas.1618364114; Braun RK, 2009, TRANSPLANTATION, V88, P1341, DOI 10.1097/TP.0b013e3181bcde7b; Budding K, 2015, J CYST FIBROS, V14, P42, DOI 10.1016/j.jcf.2014.07.007; Bulow RD, 2019, J HISTOCHEM CYTOCHEM, V67, P643, DOI 10.1369/0022155419849388; Burlingham WJ, 2007, J CLIN INVEST, V117, P3498, DOI 10.1172/JCI28031; Butler CL, 2020, AM J TRANSPLANT, V20, P2768, DOI 10.1111/ajt.15863; Cailhier JF, 2008, J BIOL CHEM, V283, P27220, DOI 10.1074/jbc.M801164200; Calles A, 2015, CLIN CANCER RES, V21, P2851, DOI 10.1158/1078-0432.CCR-14-3112; Cardinal H, 2013, AM J TRANSPLANT, V13, P861, DOI 10.1111/ajt.12168; Chen HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1030-2; Chen-Yoshikawa TF, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061333; Chiu S, 2016, J IMMUNOL, V197, P51, DOI 10.4049/jimmunol.1502539; Christakoudi S, 2019, EBIOMEDICINE, V41, P571, DOI 10.1016/j.ebiom.2019.01.060; Chuang HC, 2014, CURR PHARM DESIGN, V20, P2607, DOI 10.2174/13816128113199990485; Clancy JW, 2019, NAT CELL BIOL, V21, P856, DOI 10.1038/s41556-019-0345-y; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Cunniff B, 2016, MOL BIOL CELL, V27, P2662, DOI 10.1091/mbc.E16-05-0286; de Candia P, 2016, J BIOL CHEM, V291, P7221, DOI 10.1074/jbc.R115.708842; De Toro J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00203; Dieude M, 2020, AM J TRANSPLANT, V20, P726, DOI 10.1111/ajt.15707; Dieude M, 2019, HUM IMMUNOL, V80, P608, DOI 10.1016/j.humimm.2019.04.009; Dragun D, 2005, NEW ENGL J MED, V352, P558, DOI 10.1056/NEJMoa035717; Dragun D, 2016, KIDNEY INT, V90, P280, DOI 10.1016/j.kint.2016.03.019; Eskandary F, 2017, TRANSPLANTATION, V101, P631, DOI 10.1097/TP.0000000000001195; Fedoseyeva EV, 1999, J IMMUNOL, V162, P6836; Fisher CE, 2016, J HEART LUNG TRANSPL, V35, P946, DOI 10.1016/j.healun.2016.04.004; Franco-Acevedo A, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10020060; Fukami N, 2012, AM J TRANSPLANT, V12, P867, DOI 10.1111/j.1600-6143.2011.03917.x; Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032; Goers TA, 2008, J IMMUNOL, V180, P4487, DOI 10.4049/jimmunol.180.7.4487; Golebiewska JE, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10112989; Gonzalez-Nolasco B, 2018, CURR OPIN ORGAN TRAN, V23, P22, DOI 10.1097/MOT.0000000000000489; Gregson AL, 2015, AM J RESP CRIT CARE, V192, P1490, DOI 10.1164/rccm.201503-0558OC; Gunasekaran M, 2017, AM J TRANSPLANT, V17, P474, DOI 10.1111/ajt.13915; Gunasekaran M, 2020, J HEART LUNG TRANSPL, V39, P379, DOI 10.1016/j.healun.2019.12.009; Gunasekaran M, 2018, J IMMUNOL, V200, P2535, DOI 10.4049/jimmunol.1701587; Hachem RR, 2012, AM J TRANSPLANT, V12, P2164, DOI 10.1111/j.1600-6143.2012.04079.x; Hachem RR, 2018, AM J TRANSPLANT, V18, P2285, DOI 10.1111/ajt.14893; Hachem RR, 2010, J HEART LUNG TRANSPL, V29, P973, DOI 10.1016/j.healun.2010.05.006; Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95; Hesemann LE, 2015, PEDIATR TRANSPLANT, V19, P499, DOI 10.1111/petr.12531; Hiemann NE, 2012, TRANSPLANTATION, V94, P919, DOI 10.1097/TP.0b013e3182692ad2; Hirsch HH, 2013, AM J TRANSPLANT, V13, P179, DOI 10.1111/ajt.12110; Hong CS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14661-w; Hosseini Hamideh Mahmoodzadeh, 2013, Inflammation & Allergy Drug Targets, V12, P29; Huang HJ, 2008, AM J TRANSPLANT, V8, P2454, DOI 10.1111/j.1600-6143.2008.02389.x; Itabashi Yoshihiro, 2021, Transplantation, V105, P1337, DOI 10.1097/TP.0000000000003428; Itoda Y, 2019, J HEART LUNG TRANSPL, V38, pS405, DOI 10.1016/j.healun.2019.01.1031; Ius F, 2014, J HEART LUNG TRANSPL, V33, P1255, DOI 10.1016/j.healun.2014.06.015; Iwata T, 2008, J IMMUNOL, V181, P5738, DOI 10.4049/jimmunol.181.8.5738; Jaramillo A, 1999, TRANSPLANTATION, V67, P1155, DOI 10.1097/00007890-199904270-00012; Kalache S, 2011, J IMMUNOL, V187, P1023, DOI 10.4049/jimmunol.1004195; Keller MR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079601; Kroshus TJ, 1997, J THORAC CARDIOV SUR, V114, P195, DOI 10.1016/S0022-5223(97)70144-2; Kuo E, 2005, IMMUNOL RES, V32, P179, DOI 10.1385/IR:32:1-3:179; Lema DA, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12807; Levine DJ, 2016, J HEART LUNG TRANSPL, V35, P397, DOI 10.1016/j.healun.2016.01.1223; Li F, 2019, TRANSPL P, V51, P715, DOI 10.1016/j.transproceed.2019.01.051; Li X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044045; Liu Q, 2016, J CLIN INVEST, V126, P2805, DOI 10.1172/JCI84577; Loebel M, 2016, BRAIN BEHAV IMMUN, V52, P32, DOI 10.1016/j.bbi.2015.09.013; Lugini L, 2012, J IMMUNOL, V189, P2833, DOI 10.4049/jimmunol.1101988; Mahesh B, 2007, AM J PATHOL, V170, P1415, DOI 10.2353/ajpath.2007.060728; Mahesh B, 2010, TRANSPLANTATION, V90, P4, DOI 10.1097/TP.0b013e3181dfa694; Marino J, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8759; Mastoridis Sotiris, 2020, World J Transplant, V10, P330, DOI 10.5500/wjt.v10.i11.330; Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006; Menke J, 2014, CURR OPIN ORGAN TRAN, V19, P395, DOI 10.1097/MOT.0000000000000090; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Mimura T, 2015, AM J PATHOL, V185, P1564, DOI 10.1016/j.ajpath.2015.03.002; Mizobucbi T, 2003, J IMMUNOL, V171, P1140, DOI 10.4049/jimmunol.171.3.1140; Mohanakumar T, 2019, J THORAC CARDIOV SUR, V157, P2096, DOI 10.1016/j.jtcvs.2018.12.105; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Morgun A, 2004, J HEART LUNG TRANSPL, V23, P204, DOI 10.1016/S1053-2498(03)00114-1; Mori DN, 2014, IMMUNOL REV, V258, P132, DOI 10.1111/imr.12146; Nath DS, 2010, HUM IMMUNOL, V71, P1191, DOI 10.1016/j.humimm.2010.09.012; Nath DS, 2010, J HEART LUNG TRANSPL, V29, P1277, DOI 10.1016/j.healun.2010.05.025; Nayak DK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1243; Nickeleit V, 1998, KIDNEY BLOOD PRESS R, V21, P230, DOI 10.1159/000025862; Njue F, 2019, CURR TRANSPLANT REP, V6, P300, DOI 10.1007/s40472-019-00254-1; O'Riordan E, 2008, PROTEOM CLIN APPL, V2, P1025, DOI 10.1002/prca.200780137; Ochando J, 2019, CELL MOL IMMUNOL, V16, P350, DOI 10.1038/s41423-019-0216-2; ODERMATT BF, 1984, P NATL ACAD SCI-BIOL, V81, P7343, DOI 10.1073/pnas.81.23.7343; Pang XL, 2019, AGING-US, V11, P8911, DOI 10.18632/aging.102346; Philogene MC, 2019, HUM IMMUNOL, V80, P561, DOI 10.1016/j.humimm.2019.04.012; Philogene MC, 2017, TRANSPLANTATION, V101, P608, DOI 10.1097/TP.0000000000001231; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Quaglia M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00074; Rahman M, 2022, AM J TRANSPLANT, V22, P843, DOI 10.1111/ajt.16903; Ramachandran Sabarinathan, 2012, Clin Transpl, P261; Ravichandran R, 2021, J HEART LUNG TRANSPL, V40, P1517, DOI 10.1016/j.healun.2021.08.016; Ravichandran R, 2019, HUM IMMUNOL, V80, P588, DOI 10.1016/j.humimm.2019.03.012; Reinsmoen NL, 2017, TRANSPLANTATION, V101, P1215, DOI 10.1097/TP.0000000000001389; Reinsmoen NL, 2010, TRANSPLANTATION, V90, P1473, DOI 10.1097/TP.0b013e3181fd97f1; Riesco L, 2019, TRANSPL IMMUNOL, V52, P53, DOI 10.1016/j.trim.2018.11.002; Rout-Pitt N, 2018, RESP RES, V19, DOI 10.1186/s12931-018-0834-8; Roux A, 2019, AM J TRANSPLANT, V19, P21, DOI 10.1111/ajt.14990; Roux A, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00155; Saini D, 2011, J HEART LUNG TRANSPL, V30, P624, DOI 10.1016/j.healun.2011.01.708; Salvadori Maurizio, 2015, World J Transplant, V5, P52, DOI 10.5500/wjt.v5.i2.52; Sawinski D, 2015, J AM SOC NEPHROL, V26, P966, DOI 10.1681/ASN.2014010119; Saxena M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.208314; Schinstock CA, 2017, AM J TRANSPLANT, V17, P1574, DOI 10.1111/ajt.14161; Seifert ME, 2017, J AM SOC NEPHROL, V28, P1314, DOI 10.1681/ASN.2016030285; Sharma M, 2020, J HEART LUNG TRANSPL, V39, P1210, DOI 10.1016/j.healun.2020.07.001; Sharma M, 2018, AM J TRANSPLANT, V18, P1626, DOI 10.1111/ajt.14650; Shaver CM, 2017, EXPERT REV RESP MED, V11, P119, DOI 10.1080/17476348.2017.1280398; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Silva-Vilches C, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02581; Smith JD, 2011, AM J TRANSPLANT, V11, P312, DOI 10.1111/j.1600-6143.2010.03383.x; Smith MA, 1998, J THORAC CARDIOV SUR, V116, P812, DOI 10.1016/S0022-5223(98)00444-9; Smyth LA, 2013, EUR J IMMUNOL, V43, P2430, DOI 10.1002/eji.201242909; Soltaninejad E, 2015, TRANSPL IMMUNOL, V33, P1, DOI 10.1016/j.trim.2015.05.002; Song JP, 2016, SCI REP-UK, V6, DOI 10.1038/srep20077; Soulez M, 2012, CIRC RES, V110, P94, DOI 10.1161/CIRCRESAHA.111.250431; Stanbrook MB, 1999, AM J RESP CRIT CARE, V160, P2034, DOI 10.1164/ajrccm.160.6.9801037; Suarez H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11249-2; Subramanian V, 2014, AM J TRANSPLANT, V14, P2359, DOI 10.1111/ajt.12908; Sullivan JA, 2020, CELL REP, V30, P1039, DOI 10.1016/j.celrep.2019.12.081; Sun Q, 2007, KIDNEY INT, V71, P24, DOI 10.1038/sj.ki.5001870; Thakur S, 2015, AM J PATHOL, V185, P2168, DOI 10.1016/j.ajpath.2015.04.014; Thaunat O, 2012, KIDNEY INT, V81, P207, DOI 10.1038/ki.2011.317; Thaunat O, 2010, J IMMUNOL, V185, P717, DOI 10.4049/jimmunol.0903589; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Thery C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567; Tikkanen JM, 2016, AM J RESP CRIT CARE, V194, P596, DOI 10.1164/rccm.201509-1857OC; Tinel C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.738795; Tiriveedhi V, 2012, CLIN EXP IMMUNOL, V167, P158, DOI 10.1111/j.1365-2249.2011.04486.x; Tiriveedhi V, 2013, J HEART LUNG TRANSPL, V32, P807, DOI 10.1016/j.healun.2013.06.003; Tissot A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01681; Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043; Tung SL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24531-8; Utsumi K, 2001, TRANSPLANTATION, V71, P1757, DOI 10.1097/00007890-200106270-00010; Vallabhajosyula P, 2017, J CLIN INVEST, V127, P1375, DOI 10.1172/JCI87993; van den Akker EK, 2015, J TRANSPLANT, V2015, DOI 10.1155/2015/354826; van der Pol E, 2012, PHARMACOL REV, V64, P676, DOI 10.1124/pr.112.005983; Vatter FAP, 2021, J EXP MED, V218, DOI 10.1084/jem.20202579; Verleden SE, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01248-2017; Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057; Wallace WD, 2016, J HEART LUNG TRANSPL, V35, P40, DOI 10.1016/j.healun.2015.08.021; Warraich RS, 2000, TRANSPLANTATION, V69, P1609; Wilkey BJ, 2020, SEMIN CARDIOTHORAC V, V24, P54, DOI 10.1177/1089253219881980; Witt CA, 2013, J HEART LUNG TRANSPL, V32, P1034, DOI 10.1016/j.healun.2013.07.004; Xu Z, 2015, AM J TRANSPLANT, V15, P1933, DOI 10.1111/ajt.13185; Xu ZP, 2017, TRANSPLANTATION, V101, P2461, DOI 10.1097/TP.0000000000001595; Yang B, 2016, AM J TRANSPLANT, V16, P3416, DOI 10.1111/ajt.13866; Yoshida S, 2006, AM J TRANSPLANT, V6, P724, DOI 10.1111/j.1600-6143.2006.01236.x; Yu XS, 2013, CELL IMMUNOL, V285, P62, DOI 10.1016/j.cellimm.2013.06.010; Zeng FR, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb0122; Zhang QH, 2016, NAT REV NEPHROL, V12, P484, DOI 10.1038/nrneph.2016.88; Zhang RB, 2018, CLIN J AM SOC NEPHRO, V13, P182, DOI 10.2215/CJN.00700117; Zhang XH, 2020, HUM IMMUNOL, V81, P671, DOI 10.1016/j.humimm.2020.09.003; Zhang XH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00434; Zhou W, 2014, GENES DIS, V1, P64, DOI 10.1016/j.gendis.2014.06.002; Zou JL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757674; Zou YZ, 2007, NEW ENGL J MED, V357, P1293, DOI 10.1056/NEJMoa067160	178	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								861583	10.3389/fimmu.2022.861583	http://dx.doi.org/10.3389/fimmu.2022.861583			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C3IE	35572510	Green Published, gold			2022-12-18	WOS:000881911700001
J	Rosa, GD; Krieck, AMT; Padula, ET; Stievani, FD; Rossi, MC; Pfeifer, JPH; Basso, RM; Braz, AMM; Golim, MD; Alves, ALG				Rosa, Gustavo Dos Santos; Teramoto Krieck, Andre Massahiro; Padula, Enrico Topan; Stievani, Fernanda de Castro; Rossi, Mariana Correa; Hubbe Pfeifer, Joao Pedro; Basso, Roberta Martins; Marques Braz, Aline Marcia; Golim, Marjorie de Assis; Garcia Alves, Ana Liz			Production of Cytotoxic Antibodies After Intra-Articular Injection of Allogeneic Synovial Membrane Mesenchymal Stem Cells With and Without LPS Administration	FRONTIERS IN IMMUNOLOGY			English	Article						humoral immune response; mesenchymal stromal cells; MHC; intraarticular injection; microcytotoxicity; cell rejection reactions; horses	IMMUNE-RESPONSE; IN-VITRO; VACCINATION; THERAPY; SERUM	Allogeneic mesenchymal stem cells (MSC) are widely used in clinical routine due to the shorter expansion time and reliability of its quality. However, some recipients can produce alloantibodies that recognize MSCs and activate the immune system, resulting in cell death. Although antibody production was already described after MSC injection, no previous studies described the immune response after intra-articular MSC injection in acute synovitis. This study aimed to evaluate the influence of inflammation on immune response after single and repeated intra-articular injections of synovial membrane MSC (SMMSC). Horses were divided in three groups: control group (AUTO) received autologous synovial membrane MSCs; whereas group two (ALLO) received allogeneic SMMSCs and group three (ALLO LPS) was submitted to acute experimental synovitis 8 h before SMMSCs injection. The procedure was repeated for all groups for 28 days. Physical and lameness evaluations and synovial fluid analysis were performed. Sera from all animals were obtained before and every 7 days after each injection up to 4 weeks, to perform microcytotoxicity assays incubating donor SMMSCs with recipients' sera. The first injection caused a mild and transient synovitis in all groups, becoming more evident and longer in ALLO and ALLO LPS groups after the second injection. Microcytotoxicity assays revealed significant antibody production as soon as 7 days after SMMSC injection in ALLO and ALLO LPS groups, and cytotoxicity scores of both groups showed no differences at any time point, being equally different from AUTO group. Although inflammation is capable of inducing MHC expression in MSCs, which enhances immune recognition, cytotoxicity scores were equally high in ALLO and ALLO LPS groups, making it difficult to determine the potentiation effect of inflammation on antibody production. Our findings suggest that inflammation does not display a pivotal role in immune recognition on first allogeneic MSC injection. In a translational way, since specific antibodies were produced against MSCs, patients that need more than one MSC injection may benefit from a first allogeneic injection followed by subsequent autologous injections.	[Rosa, Gustavo Dos Santos; Teramoto Krieck, Andre Massahiro; Padula, Enrico Topan; Stievani, Fernanda de Castro; Rossi, Mariana Correa; Hubbe Pfeifer, Joao Pedro; Garcia Alves, Ana Liz] Sao Paulo State Univ, Sch Vet Med & Anim Sci, Dept Vet Surg & Anim Reprod, Regenerat Med Lab,UNESP, Botucatu, SP, Brazil; [Basso, Roberta Martins] Sao Paulo State Univ, Sch Vet Med & Anim Sci, Dept Vet Clin, UNESP, Botucatu, SP, Brazil; [Marques Braz, Aline Marcia; Golim, Marjorie de Assis] Botucatu Med Sch, Flow Cytometry Lab, Appl Biotechnol Lab, Clin Hosp, Botucatu, SP, Brazil; [Golim, Marjorie de Assis] Sao Paulo State Univ, Botucatu Med Sch, Grad Program Res & Dev Med Biotechnol, UNESP, Botucatu, SP, Brazil	Universidade Estadual Paulista; Universidade Estadual Paulista; Universidade Estadual Paulista	Alves, ALG (corresponding author), Sao Paulo State Univ, Sch Vet Med & Anim Sci, Dept Vet Surg & Anim Reprod, Regenerat Med Lab,UNESP, Botucatu, SP, Brazil.	ana.liz@unesp.br		Stievani, Fernanda/0000-0001-7260-1081	Sao Paulo Research Foundation [2017/14460-4, 2017/12815-0]; Coordination for the Improvement of Higher Education Personnel (CAPES) [001]; National Council for Scientific and Technological Development (CNPq) [155915/2019-3 GD]	Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordination for the Improvement of Higher Education Personnel (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); National Council for Scientific and Technological Development (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	We thank the Sao Paulo Research Foundation (FAPESP grant number 2017/14460-4 and 2017/12815-0), the Coordination for the Improvement of Higher Education Personnel (CAPES funding code 001) and the National Council for Scientific and Technological Development (CNPq grant number 155915/2019-3 GD), for funding this research project.	Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Ankrum JA, 2014, NAT BIOTECHNOL, V32, P252, DOI 10.1038/nbt.2816; Badillo AT, 2007, BIOL BLOOD MARROW TR, V13, P412, DOI 10.1016/j.bbmt.2006.12.447; Barrachina L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-020-1571-8; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Berglund AK, 2017, EQUINE VET J, V49, P539, DOI 10.1111/evj.12647; Boone L., 2013, INTRAARTICULAR ADM A; Brandao JS, 2018, RES VET SCI, V118, P423, DOI 10.1016/j.rvsc.2018.03.012; Carrade DD, 2012, CELL MED, V4, P1, DOI 10.3727/215517912X647217; Colbath AC, 2017, OPER TECHN SPORT MED, V25, P41, DOI 10.1053/j.otsm.2016.12.007; Guest DJ, 2008, STEM CELLS CLONING, V1, P1, DOI 10.2147/SCCAA.S3824; Hatsushika D, 2014, OSTEOARTHR CARTILAGE, V22, P941, DOI 10.1016/j.joca.2014.04.028; Ilic D, 2012, LANCET, V379, P877, DOI 10.1016/S0140-6736(12)60155-X; Joswig AJ, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0503-8; Kawase A, 2006, VACCINE, V24, P5535, DOI 10.1016/j.vaccine.2006.04.056; Koch TG, 2007, EXPERT OPIN BIOL TH, V7, P1621, DOI 10.1517/14712598.7.11.1621; Kondo S, 2017, J ORTHOP RES, V35, P1274, DOI 10.1002/jor.23211; Li W, 2012, CELL DEATH DIFFER, V19, P1505, DOI 10.1038/cdd.2012.26; Mackensen A, 2000, CANCER IMMUNOL IMMUN, V49, P152, DOI 10.1007/s002620050614; Maki CB, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00570; Mochizuki T, 2006, ARTHRITIS RHEUM-US, V54, P843, DOI 10.1002/art.21651; Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012; Owens SD, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5830103; Paterson YZ, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt479; Pezzanite LM, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0053-x; Pigott JH, 2013, VET IMMUNOL IMMUNOP, V156, P99, DOI 10.1016/j.vetimm.2013.09.003; Poncelet AJ, 2007, TRANSPLANTATION, V83, P783, DOI 10.1097/01.tp.0000258649.23081.a3; Ribitsch I, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00972; Rowland AL, 2021, STEM CELL TRANSL MED, V10, P694, DOI 10.1002/sctm.20-0435; Ryan SO, 2012, SEMIN IMMUNOPATHOL, V34, P425, DOI 10.1007/s00281-012-0309-9; Schnabel LV, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt402; Selvaggi TA, 1997, BLOOD, V89, P776, DOI 10.1182/blood.V89.3.776; Uchi H, 2000, J DERMATOL SCI, V24, pS29, DOI 10.1016/S0923-1811(00)00138-9; van Velthoven CTJ, 2010, J NEUROSCI, V30, P9603, DOI 10.1523/JNEUROSCI.1835-10.2010; Williams LB, 2016, EQUINE VET J, V48, P619, DOI 10.1111/evj.12477	35	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								871216	10.3389/fimmu.2022.871216	http://dx.doi.org/10.3389/fimmu.2022.871216			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G7WD	35572507	gold, Green Published			2022-12-18	WOS:000884960800001
J	Sengupta, S; Bhattacharya, G; Chatterjee, S; Datey, A; Shaw, SK; Suranjika, S; Nath, P; Barik, PK; Prasad, P; Chattopadhyay, S; Swain, RK; Parida, A; Devadas, S				Sengupta, Soumya; Bhattacharya, Gargee; Chatterjee, Sanchari; Datey, Ankita; Shaw, Shubham K.; Suranjika, Sandhya; Nath, Paritosh; Barik, Prakash K.; Prasad, Punit; Chattopadhyay, Soma; Swain, Rajeeb K.; Parida, Ajay; Devadas, Satish			Underlying Co-Morbidity Reveals Unique Immune Signatures in Type II Diabetes Patients Infected With SARS-CoV2	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV2; type II diabetes; whole blood immunophenotyping; innate immune response; adaptive immune response	DENDRITIC CELLS; ACTIVATION; MATURATION; INHIBITION; MECHANISMS; SEVERITY; COVID-19	BackgroundSARS-CoV2 infection in patients with comorbidities, particularly T2DM, has been a major challenge globally and has been shown to be associated with high morbidity and mortality. Here, we did whole blood immunophenotyping along with plasma cytokine, chemokine, antibody isotyping, and viral load from oropharyngeal swab to understand the immune pathology in the T2DM patients infected with SARS-CoV2. MethodsBlood samples from 25 Covid-19 positive patients having T2DM, 10 Covid-19 positive patients not having T2DM, and 10 Covid-19 negative, non-diabetic healthy controls were assessed for various immune cells by analyzing for their signature surface proteins in mass cytometry. Circulating cytokines, chemokines, and antibody isotypes were determined from plasma while viral copy number was determined from oropharyngeal swabs. All our representative data corroborated with laboratory findings. ResultsOur observations encompass T2DM patients having elevated levels of both type I and type II cytokines and higher levels of circulating IgA, IgM, IgG1, and IgG2 as compared to NDM and healthy volunteers. They also displayed higher percentages of granulocytes, mDCs, plasmablasts, Th2-like cells, CD4(+) EM cells, and CD8(+) TE cells as compared to healthy volunteers. T2DM patients also displayed lower percentages of pDCs, lymphocytes, CD8(+) TE cells, CD4(+), and CD8(+) EM. ConclusionOur study demonstrated that patients with T2DM displayed higher inflammatory markers and a dysregulated anti-viral and anti-inflammatory response when compared to NDM and healthy controls and the dysregulated immune response may be attributed to meta inflammation.						Kumar Shaw, Shubham/0000-0002-6345-8882; Sengupta, Soumya/0000-0002-2003-3227				Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Ansari A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636768; Bagwell CB, 2020, CYTOM PART B-CLIN CY, V98, P146, DOI 10.1002/cyto.b.21858; Berlin DA, 2020, NEW ENGL J MED, V383, P2451, DOI 10.1056/NEJMcp2009575; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Cervantes-Barragan L, 2007, BLOOD, V109, P1131, DOI 10.1182/blood-2006-05-023770; Chatterjee S, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.725035; Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681; Chi Y, 2020, J INFECT DIS, V222, P746, DOI 10.1093/infdis/jiaa363; Dodev TS, 2015, ALLERGY, V70, P720, DOI 10.1111/all.12607; Geanon D, 2021, CYTOM PART A, V99, P446, DOI 10.1002/cyto.a.24317; Gil-Etayo FJ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.624483; Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319; Han H, 2020, EMERG MICROBES INFEC, V9, P1123, DOI 10.1080/22221751.2020.1770129; Harty JT, 2000, ANNU REV IMMUNOL, V18, P275, DOI 10.1146/annurev.immunol.18.1.275; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang JP, 2012, BLOOD, V120, P3030, DOI 10.1182/blood-2012-05-427799; Iba T, 2020, J THROMB HAEMOST, V18, P2103, DOI 10.1111/jth.14975; Jogdand GM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01041; Jouan Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20200872; Kuri-Cervantes L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd7114; Li GR, 2021, INT J ENDOCRINOL, V2021, DOI 10.1155/2021/7394378; Lipsitch M, 2020, NAT REV IMMUNOL, V20, P709, DOI 10.1038/s41577-020-00460-4; Liu HY, 2018, ONCOTARGET, V9, P2887, DOI 10.18632/oncotarget.20812; Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Mazzoni A, 2020, J CLIN INVEST, V130, P4694, DOI [10.1172/JCI138554, 10.1172/JCI138554.]; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Ozsurekci Y, 2021, J MED VIROL, V93, P2828, DOI 10.1002/jmv.26683; Parrot T, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe1670; Arolas HPI, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83040-3; Prodjinotho UF, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005777; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Reiser J, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/8941260; Richter JR, 2014, SHOCK, V42, P525, DOI 10.1097/SHK.0000000000000253; Shrotri M, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0245532; Sohn Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092924; Sterlin D, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd2223; Sun YT, 2021, J PERS MED, V11, DOI 10.3390/jpm11030195; Tani-ichi S, 2013, P NATL ACAD SCI USA, V110, P612, DOI 10.1073/pnas.1219242110; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; van der Molen RG, 2004, HEPATOLOGY, V40, P738, DOI 10.1002/hep.20366; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415; Verbist KC, 2012, CYTOKINE, V59, P467, DOI 10.1016/j.cyto.2012.05.020; Vitte J, 2020, J INFECT DIS, V222, P1985, DOI 10.1093/infdis/jiaa591; Yao K, 2011, CARDIOVASC DIABETOL, V10, DOI 10.1186/1475-2840-10-50; Yaribeygi H, 2020, J DIABETES RES, V2020, DOI 10.1155/2020/5436832; Zaja-Milatovic S, 2008, HISTOL HISTOPATHOL, V23, P1399, DOI 10.14670/HH-23.1399; Zhai X, 2016, CELL PHYSIOL BIOCHEM, V38, P1257, DOI 10.1159/000443073; Zhao JJ, 2020, CLIN INFECT DIS, V71, P2027, DOI 10.1093/cid/ciaa344; Zhao RX, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/6914878; Zou LR, 2020, NEW ENGL J MED, V382, P1177, DOI 10.1056/NEJMc2001737	52	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								848335	10.3389/fimmu.2022.848335	http://dx.doi.org/10.3389/fimmu.2022.848335			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C3OO	35572555	gold, Green Submitted, Green Published			2022-12-18	WOS:000881928300001
J	Soni, S; O'Dea, KP; Abe, E; Khamdan, M; Shah, SV; Sarathchandra, P; Wilson, MR; Takata, M				Soni, Sanooj; O'Dea, Kieran P.; Abe, Eiko; Khamdan, Maryam; Shah, Sneh V.; Sarathchandra, Padmini; Wilson, Michael R.; Takata, Masao			Microvesicle-Mediated Communication Within the Alveolar Space: Mechanisms of Uptake by Epithelial Cells and Alveolar Macrophages	FRONTIERS IN IMMUNOLOGY			English	Article						extracellular vesicles; microvesicle internalization; alveolar space; intercellular communication; microvesicle processing	SCAVENGER-RECEPTOR; PLATELET MICROPARTICLES; ENDOTHELIAL-CELLS; INTERNALIZATION; NANOPARTICLES; PHAGOCYTOSIS; STIMULATION; ENDOCYTOSIS; CLEARANCE; EXOSOMES	Intra-alveolar microvesicles (MVs) are important mediators of inter-cellular communication within the alveolar space, and are key components in the pathophysiology of lung inflammation such as acute respiratory distress syndrome (ARDS). Despite the abundance of data detailing the pro-inflammatory effects of MVs, it remains unclear how MVs interact or signal with target cells in the alveolus. Using both in vivo and in vitro alveolar models, we analyzed the dynamics of MV uptake by resident alveolar cells: alveolar macrophages and epithelial cells. Under resting conditions, the overwhelming majority of MVs were taken up by alveolar macrophages. However, following lipopolysaccharide (LPS)-mediated inflammation, epithelial cells internalized significantly more MVs (p<0.01) whilst alveolar macrophage internalization was significantly reduced (p<0.01). We found that alveolar macrophages adopted a pro-inflammatory phenotype after internalizing MVs under resting conditions, but reduction of MV uptake following LPS pre-treatment was associated with loss of inflammatory phenotype. Instead, MVs induced significant epithelial cell inflammation following LPS pre-treatment, when MV internalization was most significant. Using pharmacological inhibitors, we interrogated the mechanisms of MV internalization to identify which endocytic pathways and cell surface receptors are involved. We demonstrated that epithelial cells are exclusively dependent on the clathrin and caveolin dependent endocytotic pathway, whereas alveolar macrophage uptake may involve a significant phagocytic component. Furthermore, alveolar macrophages predominantly engulf MVs via scavenger receptors whilst, epithelial cells internalize MVs via a phosphatidylserine/integrin receptor mediated pathway (specifically alpha V beta III), which can be inhibited with phosphatidylserine-binding protein (i.e. annexin V). In summary, we have undertaken a comprehensive evaluation of MV internalization within the alveolar space. Our results demonstrate that different environmental conditions can modulate MV internalization, with inflammatory stimuli strongly enhancing epithelial cell uptake of MVs and inducing epithelial cell activation. Our data reveal the unique mechanisms by which alveolar macrophages and epithelial cells internalize MVs thereby elucidating how MVs exert their pathophysiological effect during lung inflammation and injury. As MVs are potential novel therapeutic targets in conditions such as ARDS, these data provide crucial insights into the dynamics of MV-target cell interactions and highlight potential avenues for researchers to modulate and inhibit their pro-inflammatory actions within the alveolar space.	[Soni, Sanooj; O'Dea, Kieran P.; Abe, Eiko; Khamdan, Maryam; Shah, Sneh V.; Wilson, Michael R.; Takata, Masao] Chelsea & Westminster Hosp, Imperial Coll London, Fac Med, Div Anaesthet Pain Med & Intens Care, London, England; [Sarathchandra, Padmini] Harefield Hosp, Natl Heart & Lung Inst, Imperial Coll London, Heart Sci Ctr, Harefield, England	Imperial College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital	Takata, M (corresponding author), Chelsea & Westminster Hosp, Imperial Coll London, Fac Med, Div Anaesthet Pain Med & Intens Care, London, England.	m.takata@imperial.ac.uk			Medical research Council and British Journal of Anaesthesia [P54008]; Academy of Medical Sciences [P86239]; Chelsea and Westminster Health Charity	Medical research Council and British Journal of Anaesthesia; Academy of Medical Sciences(Academy of Medical Sciences (AMS)); Chelsea and Westminster Health Charity	P54008: Medical research Council and British Journal of Anaesthesia; P86239: Academy of Medical Sciences; Chelsea and Westminster Health Charity.	Al-Nedawi K, 2009, P NATL ACAD SCI USA, V106, P3794, DOI 10.1073/pnas.0804543106; Bacha NC, 2018, STEM CELL REV REP, V14, P223, DOI 10.1007/s12015-017-9778-5; BACHURSKI CJ, 1995, J BIOL CHEM, V270, P19402, DOI 10.1074/jbc.270.33.19402; Beyer C, 2010, NAT REV RHEUMATOL, V6, P21, DOI 10.1038/nrrheum.2009.229; Bourdonnay E, 2015, J EXP MED, V212, P729, DOI 10.1084/jem.20141675; Cicko Sanja, 2018, Oncotarget, V9, P30635, DOI 10.18632/oncotarget.25761; Dasgupta SK, 2012, CIRCULATION, V125, P1664, DOI 10.1161/CIRCULATIONAHA.111.068833; Dodd CE, 2016, J IMMUNOL, V197, P4727, DOI 10.4049/jimmunol.1600856; Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540; Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600-0854.2010.01041.x; Fitzner D, 2011, J CELL SCI, V124, P447, DOI 10.1242/jcs.074088; Franca A, 2011, NANOMEDICINE-UK, V6, P1175, DOI [10.2217/nnm.11.41, 10.2217/NNM.11.41]; Fritz JM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-76; Ganesan S, 2012, AM J PATHOL, V180, P61, DOI 10.1016/j.ajpath.2011.09.029; Han CZ, 2016, NATURE, V539, P570, DOI 10.1038/nature20141; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hulsmans M, 2013, CARDIOVASC RES, V100, P7, DOI 10.1093/cvr/cvt161; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Ismail N, 2013, BLOOD, V121, P984, DOI 10.1182/blood-2011-08-374793; Kanno S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78464-2; Kazeros A, 2008, AM J RESP CELL MOL, V39, P747, DOI 10.1165/rcmb.2007-0306OC; Knijff-Dutmer EAJ, 2002, ARTHRITIS RHEUM-US, V46, P1498, DOI 10.1002/art.10312; Kuhn DA, 2014, BEILSTEIN J NANOTECH, V5, P1625, DOI 10.3762/bjnano.5.174; Lee H, 2017, J IMMUNOL, V199, P1453, DOI 10.4049/jimmunol.1700165; Lee TH, 2011, SEMIN IMMUNOPATHOL, V33, P455, DOI 10.1007/s00281-011-0250-3; Macia E, 2006, DEV CELL, V10, P839, DOI 10.1016/j.devcel.2006.04.002; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; Mohning MP, 2018, AM J PHYSIOL-LUNG C, V314, pL69, DOI 10.1152/ajplung.00058.2017; Montecalvo A, 2012, BLOOD, V119, P756, DOI 10.1182/blood-2011-02-338004; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; O'Dea KP, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1706708; Odrljin TM, 2001, AM J RESP CELL MOL, V24, P12, DOI 10.1165/ajrcmb.24.1.3992; Osteikoetxea X, 2015, ORG BIOMOL CHEM, V13, P9775, DOI 10.1039/c5ob01451d; Palecanda A, 1999, J EXP MED, V189, P1497, DOI 10.1084/jem.189.9.1497; Pande P, 2006, TOXICOL APPL PHARM, V210, P70, DOI 10.1016/j.taap.2005.07.017; Parolini I, 2009, J BIOL CHEM, V284, P34211, DOI 10.1074/jbc.M109.041152; Pfeiler S, 2019, FASEB J, V33, P1860, DOI 10.1096/fj.201800985R; Pizzirani C, 2007, BLOOD, V109, P3856, DOI 10.1182/blood-2005-06-031377; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Platt N, 2001, J CLIN INVEST, V108, P649, DOI 10.1172/JCI200113903; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Raggi F, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01097; Reid VL, 2012, BRIT J ANAESTH, V109, P503, DOI 10.1093/bja/aes321; Schneider DJ, 2017, J BIOL CHEM, V292, P20897, DOI 10.1074/jbc.M117.792416; Sharma AK, 2007, AM J PHYSIOL-LUNG C, V293, pL105, DOI 10.1152/ajplung.00470.2006; Song L, 2011, J LIPID RES, V52, P1542, DOI 10.1194/jlr.M015412; Soni S, 2021, AM J PHYSIOL-LUNG C, V320, pL73, DOI 10.1152/ajplung.00099.2020; Soni S, 2019, EXPERT OPIN THER TAR, V23, P931, DOI 10.1080/14728222.2019.1692816; Soni S, 2019, FASEB J, V33, P6442, DOI 10.1096/fj.201802386R; Soni S, 2016, THORAX, V71, P1020, DOI 10.1136/thoraxjnl-2015-208032; Takahashi T, 2012, THORAX, V67, P1067, DOI 10.1136/thoraxjnl-2011-201395; Tan YY, 2017, FASEB J, V31; Thelen T, 2010, J IMMUNOL, V185, P4328, DOI 10.4049/jimmunol.1000989; Voigt J, 2014, P NATL ACAD SCI USA, V111, P2942, DOI 10.1073/pnas.1322356111; Wang JG, 2011, BLOOD, V118, P2366, DOI 10.1182/blood-2011-01-330878	56	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								853769	10.3389/fimmu.2022.853769	http://dx.doi.org/10.3389/fimmu.2022.853769			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0OI	35572508	Green Published, gold			2022-12-18	WOS:000795556200001
J	Traore, A; Guindo, MA; Konate, D; Traore, B; Diakite, SA; Kante, S; Dembele, A; Cisse, A; Incandela, NC; Kodio, M; Coulibaly, YI; Faye, O; Kajava, AV; Pratesi, F; Migliorini, P; Papini, AM; Pacini, L; Rovero, P; Errante, F; Diakite, M; Arevalo-Herrera, M; Herrera, S; Corradin, G; Balam, S				Traore, Abdouramane; Guindo, Merepen A.; Konate, Drissa; Traore, Bourama; Diakite, Seidina A.; Kante, Salimata; Dembele, Assitan; Cisse, Abdourhamane; Incandela, Nathan C.; Kodio, Mamoudou; Coulibaly, Yaya I.; Faye, Ousmane; Kajava, Andrey V.; Pratesi, Federico; Migliorini, Paola; Papini, Anna Maria; Pacini, Lorenzo; Rovero, Paolo; Errante, Fosca; Diakite, Mahamadou; Arevalo-Herrera, Myriam; Herrera, Socrates; Corradin, Giampietro; Balam, Saidou			Seroreactivity of the Severe Acute Respiratory Syndrome Coronavirus 2 Recombinant S Protein, Receptor-Binding Domain, and Its Receptor-Binding Motif in COVID-19 Patients and Their Cross-Reactivity With Pre-COVID-19 Samples From Malaria-Endemic Areas	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2 S protein; seroreactivity; COVID-19 samples; cross-reactivity; Pre-COVID-19 samples; malaria endemic-area	B-CELL ACTIVATION; NEUTRALIZING ANTIBODIES; SARS-COV-2; INFECTION; TRANSMISSION; RESPONSES; IMMUNITY; ACE2	Despite the global interest and the unprecedented number of scientific studies triggered by the COVID-19 pandemic, few data are available from developing and low-income countries. In these regions, communities live under the threat of various transmissible diseases aside from COVID-19, including malaria. This study aims to determine the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroreactivity of antibodies from COVID-19 and pre-COVID-19 samples of individuals in Mali (West Africa). Blood samples from COVID-19 patients (n = 266) at Bamako Dermatology Hospital (HDB) and pre-COVID-19 donors (n = 283) from a previous malaria survey conducted in Dangassa village were tested by ELISA to assess IgG antibodies specific to the full-length spike (S) protein, the receptor-binding domain (RBD), and the receptor-binding motif (RBM436-507). Study participants were categorized by age, gender, treatment duration for COVID-19, and comorbidities. In addition, the cross-seroreactivity of samples from pre-COVID-19, malaria-positive patients against the three antigens was assessed. Recognition of the SARS-CoV-2 proteins by sera from COVID-19 patients was 80.5% for S, 71.1% for RBD, and 31.9% for RBM (p < 0.001). While antibody responses to S and RBD tended to be age-dependent, responses to RBM were not. Responses were not gender-dependent for any of the antigens. Higher antibody levels to S, RBD, and RBM at hospital entry were associated with shorter treatment durations, particularly for RBD (p < 0.01). In contrast, higher body weights negatively influenced the anti-S antibody response, and asthma and diabetes weakened the anti-RBM antibody responses. Although lower, a significant cross-reactive antibody response to S (21.9%), RBD (6.7%), and RBM (8.8%) was detected in the pre-COVID-19 and malaria samples. Cross-reactive antibody responses to RBM were mostly associated (p < 0.01) with the absence of current Plasmodium falciparum infection, warranting further study.	[Traore, Abdouramane; Guindo, Merepen A.; Konate, Drissa; Diakite, Seidina A.; Kante, Salimata; Dembele, Assitan; Cisse, Abdourhamane; Diakite, Mahamadou; Balam, Saidou] Univ Sci Tech & Technol Bamako USTTB, Immunogenet Lab & Parasitol, Bamako, Mali; [Traore, Bourama; Kodio, Mamoudou; Coulibaly, Yaya I.; Faye, Ousmane] Hop Dermatol Bamako HDB, Dept Minist Hlth & Social Dev, Bamako, Mali; [Incandela, Nathan C.] Univ Calif Santa Barbara, Ctr Polymers & Organ Solids, Dept Chem & Biochem, Santa Barbara, CA USA; [Kajava, Andrey V.] Univ Montpellier, Montpellier Cell Biol Res Ctr CRBM, CNRS, Montpellier, France; [Pratesi, Federico; Migliorini, Paola] Univ Pisa, Dept Clin & Expt Med, Immuno Allergol Unit, Pisa, Italy; [Papini, Anna Maria; Pacini, Lorenzo] Univ Florence, Dept Chem Ugo Schiff, Interdept Res Unit Peptide & Prot Chem & Biol, Florence, Italy; [Rovero, Paolo; Errante, Fosca] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth, Interdept Res Unit Peptide & Prot Chem & Biol, Sect Pharmaceut Sci & Nutraceut, Florence, Italy; [Arevalo-Herrera, Myriam; Herrera, Socrates] Malaria Vaccine & Drug Dev Ctr, Dept Immunol, Cali, Colombia; [Arevalo-Herrera, Myriam; Herrera, Socrates] Caucaseco Sci Res Ctr, Dept Immunol, Cali, Colombia; [Corradin, Giampietro] Univ Lausanne, Biochem Dept, Lausanne, Switzerland; [Balam, Saidou] Univ Hosp Regensburg, Dept Nephrol, Regensburg, Germany	University of Science & Technology of Bamako; University of California System; University of California Santa Barbara; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; University of Pisa; University of Florence; University of Florence; University of Lausanne; University of Regensburg	Balam, S (corresponding author), Univ Sci Tech & Technol Bamako USTTB, Immunogenet Lab & Parasitol, Bamako, Mali.; Balam, S (corresponding author), Univ Hosp Regensburg, Dept Nephrol, Regensburg, Germany.	Saidou.balam@gmail.com	Errante, Fosca/HDM-7430-2022	Errante, Fosca/0000-0001-7790-9886; BALAM, Dr Saidou/0000-0002-7178-7758; Papini, Anna Maria/0000-0002-2947-7107; TRAORE, Bouarama/0000-0002-4967-5987	University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali	University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali	Funding support was received from the University of Sciences, Techniques and Technologies of Bamako (USTTB), Mali.	Alcazar-Arroyo R, 2021, CLIN KIDNEY J, V14, P1835, DOI 10.1093/ckj/sfab048; Algaissi A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73491-5; Altschul SF, 2005, FEBS J, V272, P5101, DOI 10.1111/j.1742-4658.2005.04945.x; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; ARNEBORN P, 1983, CLIN EXP IMMUNOL, V51, P165; Arshad Abdul Rehman, 2020, Discoveries (Craiova), V8, pe120, DOI 10.15190/d.2020.17; Bajaj V, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.571416; BIBERFELD G, 1983, YALE J BIOL MED, V56, P639; Byrnes JR, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00802-20; Callender LA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01991; Cassaniti I, 2020, J MED VIROL, V92, P1724, DOI 10.1002/jmv.25800; Chen YY, 2021, AGEING RES REV, V65, DOI 10.1016/j.arr.2020.101205; Chi XY, 2020, SCIENCE, V369, P650, DOI 10.1126/science.abc6952; Chiodini J, 2020, TRAVEL MED INFECT DI, V35, DOI 10.1016/j.tmaid.2020.101758; Corradin Giarnpietro, 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P259, DOI 10.2174/187153007782794371; Costagliola G, 2021, IMMUN INFLAMM DIS, V9, P331, DOI 10.1002/iid3.404; Coulibaly D, 2021, AM J TROP MED HYG, V104, P1342, DOI 10.4269/ajtmh.20-0622; Dai JH, 2006, ANAL CHEM, V78, P135, DOI 10.1021/ac0513966; DeLano W.L., 2002, PYMOL OPEN SOURCE MO; Doumbia S, 2020, HEALTH RES POLICY SY, V18, DOI 10.1186/s12961-020-00623-8; Fehr AR, 2015, METHODS MOL BIOL, V1282, P1, DOI 10.1007/978-1-4939-2438-7_1; Fountoulakis M, 2004, AMINO ACIDS, V27, P249, DOI 10.1007/s00726-004-0141-1; French MA, 2020, RESPIROLOGY, V25, P680, DOI 10.1111/resp.13852; Gaddi AV, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124446; Gadi N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02147; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Grzelak L, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abc3103; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Guo L, 2020, CLIN INFECT DIS, V71, P778, DOI 10.1093/cid/ciaa310; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang AT, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18450-4; Huang B, 2021, BMC INFECT DIS, V21, DOI 10.1186/s12879-021-06313-2; Hussein MIH, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03541-w; Iesa MAM, 2020, NEW MICROB NEW INFEC, V38, DOI 10.1016/j.nmni.2020.100817; Indari Omkar, 2021, Biosaf Health, V3, P230, DOI 10.1016/j.bsheal.2021.04.001; Indenbaum V, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0241164; Jiang SB, 2020, TRENDS IMMUNOL, V41, P355, DOI 10.1016/j.it.2020.03.007; KENNA JG, 1985, J IMMUNOL METHODS, V85, P409, DOI 10.1016/0022-1759(85)90150-4; Khatri I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570018; Klein SL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008570; Kouriba B, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12111251; Lan J, 2020, NATURE, V581, P215, DOI 10.1038/s41586-020-2180-5; Lanzavecchia A, 2007, CURR OPIN IMMUNOL, V19, P268, DOI 10.1016/j.coi.2007.04.002; Lapidus Sarah, 2021, medRxiv, DOI 10.1101/2021.05.10.21256855; Latiano A, 2021, INT J INFECT DIS, V104, P159, DOI 10.1016/j.ijid.2020.12.067; Liu L, 2020, MICROBES INFECT, V22, P206, DOI 10.1016/j.micinf.2020.05.008; Long QX, 2020, NAT MED, V26, P845, DOI 10.1038/s41591-020-0897-1; Lou B, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.00763-2020; Lv Huibin, 2020, bioRxiv, DOI 10.1101/2020.03.15.993097; Ma H, 2020, CELL MOL IMMUNOL, V17, P773, DOI 10.1038/s41423-020-0474-z; Ma ZR, 2020, LANCET MICROBE, V1, pE151; Bouassa RSM, 2021, J MED VIROL, V93, P2196, DOI 10.1002/jmv.26628; Napoli PE, 2020, J CLIN MED, V9, DOI 10.3390/jcm9041138; Ng KW, 2020, SCIENCE, V370, P1339, DOI 10.1126/science.abe1107; O'Driscoll M, 2020, NATURE, DOI 10.1038/s41586-020-2918-0; Okba NMA, 2020, EMERG INFECT DIS, V26, P1478, DOI 10.3201/eid2607.200841; Olugbile S, 2011, VACCINE, V29, P7090, DOI 10.1016/j.vaccine.2011.06.122; Onosakponome EO, 2020, J PARASITOL RES, V2020, DOI 10.1155/2020/8829848; Palaiodimos L, 2020, METABOLISM, V108, DOI 10.1016/j.metabol.2020.154262; Peiris JSM, 2004, NAT MED, V10, pS88, DOI 10.1038/nm1143; Perera RAPM, 2020, EUROSURVEILLANCE, V25, P14, DOI 10.2807/1560-7917.ES.2020.25.16.2000421; Nguyen-Contant P, 2020, MBIO, V11, DOI 10.1128/mBio.01991-20; RATCLIFFE MJH, 1982, EUR J IMMUNOL, V12, P634, DOI 10.1002/eji.1830120803; Rice GI, 2004, BIOCHEM J, V383, P45, DOI 10.1042/BJ20040634; Sagaon-Teyssier L, 2020, TROP MED HEALTH, V48, DOI 10.1186/s41182-020-00228-5; Salvatori G, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02392-y; Sardar S, 2020, IDCases, V21, DOI 10.1016/j.idcr.2020.e00879; Shereen MA, 2020, J ADV RES, V24, P91, DOI 10.1016/j.jare.2020.03.005; Singh AK, 2020, DIABETES OBES METAB, V22, P1915, DOI 10.1111/dom.14124; Sokal A, 2021, CELL, V184, P1201, DOI 10.1016/j.cell.2021.01.050; Stadlbauer D, 2020, NATURE, DOI 10.1038/s41586-020-2912-6; Steiner-Monard V, 2019, CLIN INFECT DIS, V68, P466, DOI 10.1093/cid/ciy514; Steinhardt LC, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.00514-21; Suhandynata RT, 2020, J APPL LAB MED, V5, P908, DOI 10.1093/jalm/jfaa079; Sun BQ, 2020, EMERG MICROBES INFEC, V9, P940, DOI 10.1080/22221751.2020.1762515; Sun ZY, 2021, ENGINEERING-PRC, V7, P1441, DOI 10.1016/j.eng.2020.07.014; Tadiri CP, 2020, CAN MED ASSOC J, V192, pE1041, DOI 10.1503/cmaj.200971; Tai WB, 2020, ANTIVIR RES, V179, DOI 10.1016/j.antiviral.2020.104820; Tai WB, 2020, CELL MOL IMMUNOL, V17, P613, DOI 10.1038/s41423-020-0400-4; Takahashi T, 2020, NATURE, V588, DOI 10.1038/s41586-020-2700-3; Tan TK, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20654-7; Wajnberg A, 2020, SCIENCE, V370, P1227, DOI 10.1126/science.abd7728; Walsh EE, 2013, J INFECT DIS, V208, P1634, DOI 10.1093/infdis/jit393; Waterboer T, 2006, J IMMUNOL METHODS, V309, P200, DOI 10.1016/j.jim.2005.11.008; (WHO) O.m.d.l.S , 2019, GUID PRAT APPL REGL; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu JM, 2022, CRIT REV FOOD SCI, V62, P783, DOI [10.1080/10408398.2020.1828813, 10.1038/s41591-020-0822-7]; Xiang F, 2020, CLIN INFECT DIS, V71, P1930, DOI 10.1093/cid/ciaa461; Xiong XL, 2020, NAT STRUCT MOL BIOL, V27, P934, DOI 10.1038/s41594-020-0478-5; Yadouleton A, 2021, EMERG INFECT DIS, V27, P233, DOI 10.3201/eid2701.203281; Yang Y, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00523-5; Ye Q, 2021, J MED VIROL, V93, P4242, DOI 10.1002/jmv.26937; Zaki AM, 2012, NEW ENGL J MED, V367, P1814, DOI 10.1056/NEJMoa1211721; Zeng FF, 2020, J MED VIROL, V92, P2050, DOI 10.1002/jmv.25989; Zhang HB, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1882-z; Zhou Y, 2021, DIABETES-METAB RES, V37, DOI 10.1002/dmrr.3377; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	98	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								856033	10.3389/fimmu.2022.856033	http://dx.doi.org/10.3389/fimmu.2022.856033			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I5MC	35585976	Green Published, gold			2022-12-18	WOS:000797272200001
J	Vijayan, KKV; Cross, KA; Curtis, AD; Van Rompay, KKA; Pollara, J; Fox, CB; Tomai, M; Hanke, T; Fouda, G; Hudgens, MG; Permar, SR; De Paris, K				Vijayan, K. K. Vidya; Cross, Kaitlyn A.; Curtis, Alan D.; Van Rompay, Koen K. A.; Pollara, Justin; Fox, Christopher B.; Tomai, Mark; Hanke, Tomas; Fouda, Genevieve; Hudgens, Michael G.; Permar, Sallie R.; De Paris, Kristina			Early Post-Vaccination Gene Signatures Correlate With the Magnitude and Function of Vaccine-Induced HIV Envelope-Specific Plasma Antibodies in Infant Rhesus Macaques	FRONTIERS IN IMMUNOLOGY			English	Article						systems biology; innate gene signatures; vaccine-induced antibody response; early life HIV vaccine; rhesus macaque model	CD4(+) T-CELLS; FOLLICULAR HELPER-CELLS; INNATE IMMUNE-RESPONSE; SYSTEMS BIOLOGY; B-CELLS; ACTIVATION; ADJUVANTS; IL-21; ADENOVIRUS; INDUCTION	A better understanding of the impact of early innate immune responses after vaccine priming on vaccine-elicited adaptive immune responses could inform rational design for effective HIV vaccines. The current study compared the whole blood molecular immune signatures of a 3M-052-SE adjuvanted HIV Env protein vaccine to a regimen combining the adjuvanted Env protein with simultaneous administration of a modified Vaccinia Ankara vector expressing HIV Env in infant rhesus macaques at days 0, 1, and 3 post vaccine prime. Both vaccines induced a rapid innate response, evident by elevated inflammatory plasma cytokines and altered gene expression. We identified 25 differentially-expressed genes (DEG) on day 1 compared to day 0 in the HIV protein vaccine group. In contrast, in the group that received both the Env protein and the MVA-Env vaccine only two DEG were identified, implying that the MVA-Env modified the innate response to the adjuvanted protein vaccine. By day 3, only three DEG maintained altered expression, indicative of the transient nature of the innate response. The DEG represented immune pathways associated with complement activation, type I interferon and interleukin signaling, pathogen sensing, and induction of adaptive immunity. DEG expression on day 1 was correlated to Env-specific antibody responses, in particular antibody-dependent cytotoxicity responses at week 34, and Env-specific follicular T helper cells. Results from network analysis supported the interaction of DEG and their proteins in B cell activation. These results emphasize that vaccine-induced HIV-specific antibody responses can be optimized through the modulation of the innate response to the vaccine prime.										Andersen-Nissen E, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009363; Belanger S, 2016, NAT IMMUNOL, V17, P1135, DOI 10.1038/ni.3561; Braun D, 2002, INT IMMUNOL, V14, P411, DOI 10.1093/intimm/14.4.411; Cable J, 2020, ANN NY ACAD SCI, V1462, P14, DOI 10.1111/nyas.14235; Chea LS, 2019, J VIROL, V93, DOI 10.1128/JVI.01648-18; Crotty S, 2015, NAT REV IMMUNOL, V15, P185, DOI 10.1038/nri3803; Curtis AD, 2020, MSPHERE, V5, DOI 10.1128/mSphere.00162-20; Dan JM, 2016, J IMMUNOL, V197, P983, DOI 10.4049/jimmunol.1600318; Delaloye J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000480; Dennis M, 2019, J VIROL, V93, DOI 10.1128/JVI.01783-18; Derking R, 2021, J INT AIDS SOC, V24, DOI 10.1002/jia2.25797; Di Pasquale A, 2015, VACCINES-BASEL, V3, P320, DOI 10.3390/vaccines3020320; Diehl SA, 2012, IMMUNOL CELL BIOL, V90, P802, DOI 10.1038/icb.2012.17; Dienz O, 2009, J EXP MED, V206, P69, DOI 10.1084/jem.20081571; Dowling David J, 2018, Immunohorizons, V2, P185, DOI 10.4049/immunohorizons.1700063; Ehrenberg PK, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw4236; Falivene J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032220; Fink K, 2006, EUR J IMMUNOL, V36, P2094, DOI 10.1002/eji.200635993; Francica JR, 2017, BLOOD ADV, V1, P2329, DOI 10.1182/bloodadvances.2017011411; Gaestel M, 2009, NAT REV DRUG DISCOV, V8, P480, DOI 10.1038/nrd2829; GIBSON SJ, 1995, J INTERF CYTOK RES, V15, P537, DOI 10.1089/jir.1995.15.537; Hagan T, 2015, VACCINE, V33, P5294, DOI 10.1016/j.vaccine.2015.03.072; Hartman ZC, 2007, J VIROL, V81, P1796, DOI 10.1128/JVI.01936-06; Harwood NE, 2010, ANNU REV IMMUNOL, V28, P185, DOI 10.1146/annurev-immunol-030409-101216; Havenar-Daughton C, 2016, J IMMUNOL, V197, P994, DOI 10.4049/jimmunol.1600320; Heer AK, 2007, J IMMUNOL, V178, P2182, DOI 10.4049/jimmunol.178.4.2182; Kazmin D, 2017, P NATL ACAD SCI USA, V114, P2425, DOI 10.1073/pnas.1621489114; Kwissa M, 2012, BLOOD, V119, P2044, DOI 10.1182/blood-2011-10-388579; Li S, 2014, NAT IMMUNOL, V15, P195, DOI 10.1038/ni.2789; Li SZ, 2013, SEMIN IMMUNOL, V25, P209, DOI 10.1016/j.smim.2013.05.003; Linterman Michelle A, 2016, F1000Res, V5, DOI 10.12688/f1000research.7388.1; Ma CS, 2009, IMMUNOL CELL BIOL, V87, P590, DOI 10.1038/icb.2009.64; Matthews K, 2012, J IMMUNOL, V189, P5729, DOI 10.4049/jimmunol.1200601; Mosaheb MM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00225; Moser B, 2002, TRENDS IMMUNOL, V23, P250, DOI 10.1016/S1471-4906(02)02218-4; Nakaya HI, 2012, CURR OPIN HIV AIDS, V7, P24, DOI 10.1097/COH.0b013e32834dc37b; Nakaya HI, 2011, NAT IMMUNOL, V12, P786, DOI 10.1038/ni.2067; Nociari M, 2007, J VIROL, V81, P4145, DOI 10.1128/JVI.02685-06; Obermoser G, 2013, IMMUNITY, V38, P831, DOI 10.1016/j.immuni.2012.12.008; Ondondo B, 2016, MOL THER, V24, P832, DOI 10.1038/mt.2016.3; Palgen JL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21222-2; Phillips B, 2018, J VIROL, V92, DOI 10.1128/JVI.01051-18; Pulendran B, 2021, NAT REV DRUG DISCOV, V20, P454, DOI 10.1038/s41573-021-00163-y; Pulendran B, 2014, P NATL ACAD SCI USA, V111, P12300, DOI 10.1073/pnas.1400476111; Querec TD, 2009, NAT IMMUNOL, V10, P116, DOI 10.1038/ni.1688; Raudvere U, 2019, NUCLEIC ACIDS RES, V47, pW191, DOI 10.1093/nar/gkz369; Rawlings DJ, 2012, NAT REV IMMUNOL, V12, P282, DOI 10.1038/nri3190; Ray P, 2010, ANN NY ACAD SCI, V1183, P104, DOI 10.1111/j.1749-6632.2009.05122.x; Smith AJ, 2016, VACCINE, V34, P4304, DOI 10.1016/j.vaccine.2016.06.080; Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131; TOMAI MA, 1995, ANTIVIR RES, V28, P253, DOI 10.1016/0166-3542(95)00054-P; UNIADS.org, 2021, 2021 GLOB AIDS UPD; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vasilakos JP, 2013, EXPERT REV VACCINES, V12, P809, DOI 10.1586/14760584.2013.811208; Vinuesa CG, 2005, NAT REV IMMUNOL, V5, P853, DOI 10.1038/nri1714; Volz A, 2017, ADV VIRUS RES, V97, P187, DOI 10.1016/bs.aivir.2016.07.001; Waibler Z, 2007, J VIROL, V81, P12102, DOI 10.1128/JVI.01190-07; Waibler Z, 2009, J VIROL, V83, P1563, DOI 10.1128/JVI.01617-08; Yamaguchi T, 2007, HUM GENE THER, V18, P753, DOI 10.1089/hum.2007.016; Yashima S, 2010, VACCINE, V28, P3257, DOI 10.1016/j.vaccine.2010.01.065; Zak DE, 2012, P NATL ACAD SCI USA, V109, pE3503, DOI 10.1073/pnas.1208972109; Zhu JG, 2007, J VIROL, V81, P3170, DOI 10.1128/JVI.02192-06	62	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								840976	10.3389/fimmu.2022.840976	http://dx.doi.org/10.3389/fimmu.2022.840976			22	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C3FH	35572573	gold, Green Published			2022-12-18	WOS:000881904200001
J	Wang, JC; Shen, KF; Mu, W; Li, WG; Zhang, ML; Zhang, W; Li, Z; Ge, T; Zhu, ZJ; Zhang, SK; Chen, CX; Xing, SG; Zhu, L; Chen, LT; Wang, N; Huang, L; Li, DJ; Xiao, M; Zhou, JF				Wang, Jiachen; Shen, Kefeng; Mu, Wei; Li, Weigang; Zhang, Meilan; Zhang, Wei; Li, Zhe; Ge, Tong; Zhu, Zhoujie; Zhang, Shangkun; Chen, Caixia; Xing, Shugang; Zhu, Li; Chen, Liting; Wang, Na; Huang, Liang; Li, Dengju; Xiao, Min; Zhou, Jianfeng			T Cell Defects: New Insights Into the Primary Resistance Factor to CD19/CD22 Cocktail CAR T-Cell Immunotherapy in Diffuse Large B-Cell Lymphoma	FRONTIERS IN IMMUNOLOGY			English	Article						CAR-T cell immunotherapy; immune resistance; primary immunodeficiencies; T cell dysfunction; germline alterations; LDH; lactate dehydrogenase; cytokine release syndrome (CRS); DLBCL; diffuse large B cell lymphoma	THERAPY; CLASSIFICATION; PATHOGENESIS; EXPRESSION; MANAGEMENT; KINETICS; HODGKIN; CANCER	Despite impressive progress, a significant portion of patients still experience primary or secondary resistance to chimeric antigen receptor (CAR) T-cell immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). The mechanism of primary resistance involves T-cell extrinsic and intrinsic dysfunction. In the present study, a total of 135 patients of DLBCL treated with murine CD19/CD22 cocktail CAR T-therapy were assessed retrospectively. Based on four criteria (maximal expansion of the transgene/CAR-positive T-cell levels post-infusion [C-max], initial persistence of the transgene by the CAR transgene level at +3 months [T-last], CD19+ B-cell levels [B-cell recovery], and the initial response to CAR T-cell therapy), 48 patients were included in the research and divided into two groups (a T-normal group [n=22] and a T-defect [n=26] group). According to univariate and multivariate regression analyses, higher lactate dehydrogenase (LDH) levels before leukapheresis (hazard ratio (HR) = 1.922; p = 0.045) and lower cytokine release syndrome (CRS) grade after CAR T-cell infusion (HR = 0.150; p = 0.026) were independent risk factors of T-cell dysfunction. Moreover, using whole-exon sequencing, we found that germline variants in 47 genes were significantly enriched in the T-defect group compared to the T-normal group (96% vs. 41%; p<0.0001), these genes consisted of CAR structure genes (n=3), T-cell signal 1 to signal 3 genes (n=13), T cell immune regulation- and checkpoint-related genes (n=9), cytokine- and chemokine-related genes (n=13), and T-cell metabolism-related genes (n=9). Heterozygous germline UNC13D mutations had the highest intergroup differences (26.9% vs. 0%; p=0.008). Compound heterozygous CX3CR1(I249/M280) variants, referred to as pathogenic and risk factors according to the ClinVar database, were enriched in the T-defect group (3 of 26). In summary, the clinical characteristics and T-cell immunodeficiency genetic features may help explain the underlying mechanism of treatment primary resistance and provide novel insights into CAR T-cell immunotherapy.										Abreu TR, 2020, J CONTROL RELEASE, V319, P246, DOI 10.1016/j.jconrel.2019.12.047; Allen SD, 2014, RADIOLOGY, V272, P73, DOI 10.1148/radiol.14131789; Awasthi R, 2020, BLOOD ADV, V4, P560, DOI 10.1182/bloodadvances.2019000525; Bryceson YT, 2007, BLOOD, V110, P1906, DOI 10.1182/blood-2007-02-074468; Calcinotto A, 2012, CANCER RES, V72, P2746, DOI 10.1158/0008-5472.CAN-11-1272; Cao WY, 2020, BLOOD, V136, P516, DOI 10.1182/blood.2020004907; Cao Y, 2021, TRANSPL CELL THER, V27, DOI 10.1016/j.jtct.2021.08.012; Chapuy B, 2018, NAT MED, V24, P679, DOI 10.1038/s41591-018-0016-8; Chen LT, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000364; Cheng HH, 2019, J NATL COMPR CANC NE, V17, P515, DOI 10.6004/jnccn.2019.7307; Cheson BD, 2014, J CLIN ONCOL, V32, P3059, DOI 10.1200/JCO.2013.54.8800; Chinn IK, 2018, BLOOD, V132, P89, DOI 10.1182/blood-2017-11-814244; Cichocki F, 2014, J EXP MED, V211, P1079, DOI 10.1084/jem.20131131; Finney OC, 2019, J CLIN INVEST, V129, P2123, DOI 10.1172/JCI125423; Fraietta JA, 2018, NATURE, V558, P307, DOI 10.1038/s41586-018-0178-z; Fraietta JA, 2018, NAT MED, V24, P563, DOI 10.1038/s41591-018-0010-1; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; Goodnow CC, 2007, CELL, V130, P25, DOI 10.1016/j.cell.2007.06.033; Grimbacher Bodo, 2016, J Allergy Clin Immunol, V137, P3, DOI 10.1016/j.jaci.2015.11.004; Hans CP, 2004, BLOOD, V103, P275, DOI 10.1182/blood-2003-05-1545; Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141; Hirayama AV, 2019, BLOOD, V133, P1876, DOI 10.1182/blood-2018-11-887067; Ishii K, 2020, J CLIN INVEST, V130, P5425, DOI 10.1172/JCI130059; Kloss CC, 2018, MOL THER, V26, P1855, DOI 10.1016/j.ymthe.2018.05.003; Larson RC, 2021, NAT REV CANCER, V21, P145, DOI 10.1038/s41568-020-00323-z; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Leeksma OC, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.15; Lemoine J, 2022, EUR J CANCER, V160, P235, DOI 10.1016/j.ejca.2021.10.022; Lin JK, 2019, J CLIN ONCOL, V37, P2105, DOI 10.1200/JCO.18.02079; Liu C, 2021, CLIN PHARMACOL THER, V109, P716, DOI 10.1002/cpt.2040; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Majzner RG, 2019, NAT MED, V25, P1341, DOI 10.1038/s41591-019-0564-6; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; McCusker C, 2018, ALLERGY ASTHMA CL IM, V14, DOI 10.1186/s13223-018-0290-5; Mensa-Vilaro A, 2019, J ALLERGY CLIN IMMUN, V143, P359, DOI 10.1016/j.jaci.2018.09.009; Nastoupil LJ, 2020, J CLIN ONCOL, V38, P3119, DOI 10.1200/JCO.19.02104; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Paszkiewicz PJ, 2016, J CLIN INVEST, V126, P4262, DOI 10.1172/JCI84813; Prinzing B, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abh0272; Ram R, 2022, HAEMATOLOGICA, V107, P1111, DOI 10.3324/haematol.2021.278288; Reddy A, 2017, CELL, V171, P481, DOI 10.1016/j.cell.2017.09.027; Reiss KA, 2021, J CLIN ONCOL, V39, P2497, DOI 10.1200/JCO.21.00003; Schmitz R, 2018, NEW ENGL J MED, V378, P1396, DOI 10.1056/NEJMoa1801445; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Sheih A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13880-1; Shibata H, 2018, BLOOD, V131, P2016, DOI 10.1182/blood-2017-10-812503; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; Vercellino L, 2020, BLOOD ADV, V4, P5607, DOI 10.1182/bloodadvances.2020003001; Wang JC, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2020-002029; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wang N, 2020, BLOOD, V135, P17, DOI 10.1182/blood.2019000017; Wei J, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.176; Wei J, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0790-y; Wright GW, 2020, CANCER CELL, V37, P551, DOI 10.1016/j.ccell.2020.03.015; Xu-Monette ZY, 2012, BLOOD, V119, P3668, DOI 10.1182/blood-2011-11-366062; Yamauchi T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21619-0; Yamauchi T, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133920; Yan YY, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.97828; Zhang W, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07198-1	61	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								873789	10.3389/fimmu.2022.873789	http://dx.doi.org/10.3389/fimmu.2022.873789			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6C3DS	35572515	Green Published, gold			2022-12-18	WOS:000881900100001
J	Wang, QQ; Huang, C; Ding, Y; Wen, SD; Wang, X; Guo, SW; Gao, QZ; Chen, ZH; Zhao, YY; Wang, M; Shen, B; Zhu, W				Wang, Qianqian; Huang, Chao; Ding, Ying; Wen, Shaodi; Wang, Xin; Guo, Shuwei; Gao, Qiuzhi; Chen, Zhihong; Zhao, Yuanyuan; Wang, Mei; Shen, Bo; Zhu, Wei			Inhibition of CCCTC Binding Factor-Programmed Cell Death Ligand 1 Axis Suppresses Emergence of Chemoresistance Induced by Gastric Cancer-Derived Mesenchymal Stem Cells	FRONTIERS IN IMMUNOLOGY			English	Article						mesenchymal stem cells; gastric cancer; 5-FU; paclitaxel; PD-L1; CTCF; chemotherapy resistance		Background: Gastric cancer (GC) is the third leading cause of cancer-associated deaths worldwide. Stromal cells, especially mesenchymal stem cells (MSCs), play significant roles in the development of therapy resistance depending on their paracrine function. The PD-1/PD-L1 crosstalk between cancer and immune cells has been well studied. Emerging evidence suggests that PD-L1 also contributes to tumor resistance to therapy. Methods: Cell survival and apoptosis were assessed using CCK-8, colony formation, and flow cytometry assays. Protein alterations were analyzed via Western blot. Gene knockdown and overexpression were achieved with siRNA/shRNA and lentiviral infection, respectively. Drug effects on tumors in vivo were assessed with xenografts in nude mice. In addition, GC patient samples after chemotherapy treatment were collected to observe the relationship between chemotherapy effect and CTCF or PD-L1. Results: In response to 5-fluorouracil or paclitaxel treatment, GCMSC-CM enhanced the cell viability and decreased the apoptosis rate. Furthermore, blocking PD-L1 or CTCF in GC cells prevented GCMSC-induced drug resistance accompanied by a decline in cell stemness. Consistent with these in vitro observations, mice treated with GCMSC-CM showed a lower sensitivity to 5-fluorouracil. In addition, high expression of CTCF and PD-L1 was associated with poor chemotherapy progression in the clinic. Conclusion: Study results demonstrate a mechanism where GCMSC-CM promotes GC chemoresistance by upregulating CTCF-PD-L1 and provide strong evidence in support of targeting CTCF-PD-L1 signaling as a strategy to prevent resistance in the clinic.	[Wang, Qianqian; Huang, Chao; Ding, Ying; Guo, Shuwei; Gao, Qiuzhi; Zhao, Yuanyuan; Wang, Mei; Zhu, Wei] Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China; [Wen, Shaodi; Wang, Xin; Shen, Bo] Nanjing Med Univ, Dept Oncol, Jiangsu Canc Hosp, Nanjing, Peoples R China; [Chen, Zhihong] Jiangsu Univ, Dept Gastrointestinal Surg, Affiliated Peoples Hosp, Zhenjiang, Jiangsu, Peoples R China	Jiangsu University; Nanjing Medical University; Jiangsu University	Zhu, W (corresponding author), Jiangsu Univ, Sch Med, Zhenjiang, Jiangsu, Peoples R China.; Shen, B (corresponding author), Nanjing Med Univ, Dept Oncol, Jiangsu Canc Hosp, Nanjing, Peoples R China.	shenbo987@njmu.edu.cn; zhuwei@ujs.edu.cn		wen, shaodi/0000-0001-7951-0123	National Science Foundation of China [81972822, 81972313]	National Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Science Foundation of China (Grant Nos. 81972822 and 81972313).	Assenat E, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100318; Azwar S, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10090854; Chen B, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/9501747; Cheng DF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.719855; Ciciarello M, 2021, CANCERS, V13, DOI 10.3390/cancers13215319; Folprecht G, 2022, CANCER TREAT REV, V102, DOI 10.1016/j.ctrv.2021.102301; Gao XY, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02793-9; Huang L, 2021, IMMUNOL RES, V69, P558, DOI 10.1007/s12026-021-09237-w; Jiang YH, 2022, BBA-MOL CELL RES, V1869, DOI 10.1016/j.bbamcr.2021.119144; Katai H, 2020, LANCET GASTROENTEROL, V5, P142, DOI 10.1016/S2468-1253(19)30332-2; La XQ, 2019, J AGR FOOD CHEM, V67, P2510, DOI 10.1021/acs.jafc.8b06665; Li HD, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0429-z; Liang YB, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082030; Liu CB, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.625633; Liu Y, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.841411; Majidi M, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01556-0; Matsuoka T, 2021, WORLD J GASTRO ONCOL, V13, DOI 10.4251/wjgo.v13.i5.366; McCall NS, 2018, CLIN CANCER RES, V24, P1271, DOI 10.1158/1078-0432.CCR-17-3269; Nilendu P, 2018, CELL ONCOL, V41, P353, DOI 10.1007/s13402-018-0388-2; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Shen CX, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-4544; Sun L, 2020, THERANOSTICS, V10, P11950, DOI 10.7150/thno.49717; Tian W, 2021, THORAC CANCER, V12, P2551, DOI 10.1111/1759-7714.14136; Timaner M, 2018, CANCER RES, V78, P1253, DOI 10.1158/0008-5472.CAN-17-1547; Valverde M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910548; Vogeley C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00754-0; Wu LJ, 2021, INT IMMUNOPHARMACOL, V94, DOI 10.1016/j.intimp.2021.107443; Xuan XY, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02300-4; Xue BZ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02458-8; Yamashita K, 2021, ANN GASTROENT SURG, V5, P446, DOI 10.1002/ags3.12439; Ye LX, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10113247; Yu L, 2021, DIGEST LIVER DIS, V53, P486, DOI 10.1016/j.dld.2020.12.006; Yuan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01219-0; Zhao LX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.731393	34	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								884373	10.3389/firninu.2022.884373	http://dx.doi.org/10.3389/firninu.2022.884373			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G7HL	35572560				2022-12-18	WOS:000884922600001
J	Wang, X; Zhao, LA; Wang, J; Yao, Y; Wang, JJ; Ji, SW; Hua, T; Wang, SY; Cheng, H; Shi, M; Li, ZY; Zeng, LY; Zheng, JN; Xu, KL; Cao, J				Wang, Xue; Zhao, Lina; Wang, Jing; Yao, Yue; Wang, Jiaojiao; Ji, Shengwei; Hua, Tian; Wang, Shiyuan; Cheng, Hai; Shi, Ming; Li, Zhenyu; Zeng, Lingyu; Zheng, Junnian; Xu, Kailin; Cao, Jiang			Correlation of Cytokine Release Syndrome With Prognosis After Chimeric Antigen Receptor T Cell Therapy: Analysis of 54 Patients With Relapsed or Refractory Multiple Myeloma	FRONTIERS IN IMMUNOLOGY			English	Article						multiple myeloma; cytokine release syndrome; chimeric antigen receptor T cell; CD19; B cell maturation antigen	MANAGEMENT; REMISSIONS; BIOMARKERS; DIAGNOSIS	Although chimeric antigen receptor T (CAR-T) cell therapy has proven to be effective in treating relapsed or refractory multiple myeloma (R/R MM), the severity of cytokine release syndrome (CRS) can affect patient survival and the risk factors for CRS remain an intractable issue. We enrolled 54 patients with R/R MM following combined infusion of anti-CD19 and anti-B-cell maturation antigen (BCMA) CAR-T cells. The results showed the overall response rate was 94% (51/54) after CAR-T cell infusion, with a 100% incidence of CRS, including 47 patients with grade 1-2 (mild) CRS and 7 patients with grade 3-5 (severe) CRS. In the mild CRS group, the median progression-free survival (PFS) was 18.2 months (95% CI, 6.5 to 30.1) and the median overall survival (OS) was not reached yet. In the severe CRS group, median PFS and median OS were 1.9 months (95% CI, 0.2 to 3.8). Further analysis demonstrated that severe CRS had a shorter median PFS and OS than mild CRS (p=0.029, p=0.020). Bone marrow tumor burden was found to be independently associated with CRS. The grade of CRS was positively correlated with six serum cytokines levels including G-CSF, IL-6, IL-8, IP-10, MIP-1a and RANTES. In conclusion, early detection and management of CRS are imperative for the prevention of life-threatening complications and improvement in the survival of patients of CAR-T cell therapy.	[Wang, Xue; Zhao, Lina; Wang, Jing; Wang, Jiaojiao; Ji, Shengwei; Hua, Tian; Wang, Shiyuan; Cheng, Hai; Li, Zhenyu; Xu, Kailin; Cao, Jiang] Xuzhou Med Univ, Affiliated Hosp, Dept Hematol, Xuzhou, Peoples R China; [Yao, Yue] Xuzhou Med Univ, Clin Med Coll 1, Xuzhou, Peoples R China; [Shi, Ming; Zheng, Junnian] Xuzhou Med Univ, Canc Inst, Xuzhou, Peoples R China; [Zeng, Lingyu] Jiangsu Bone Marrow Stem Cell Inst, Xuzhou, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical University	Xu, KL; Cao, J (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Dept Hematol, Xuzhou, Peoples R China.; Zheng, JN (corresponding author), Xuzhou Med Univ, Canc Inst, Xuzhou, Peoples R China.	jnzheng@xzhmu.edu.cn; lihmd@163.com; zimu05067@163.com			Natural Science Foundation of China [81930005]; Key Research & Development Plan of Jiangsu Province [BE2018634]; Xuzhou Medical Leading Talents Training Program [XWRCHT20210028]; Key Research & Development Plan of Xuzhou [KC18102]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research & Development Plan of Jiangsu Province; Xuzhou Medical Leading Talents Training Program; Key Research & Development Plan of Xuzhou	This work was supported by the grants from the Natural Science Foundation of China (81930005), Key Research & Development Plan of Jiangsu Province (BE2018634), Xuzhou Medical Leading Talents Training Program (XWRCHT20210028), and Key Research & Development Plan of Xuzhou (KC18102).	Brudno JN, 2019, BLOOD REV, V34, P45, DOI 10.1016/j.blre.2018.11.002; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Hao ZN, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164-020-00171-5; Hay KA, 2017, BLOOD, V130, P2295, DOI 10.1182/blood-2017-06-793141; Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Mailankody S, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-119717; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; National Cancer Institute, COMMON TERMINOLOGY C; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Palumbo A, 2014, J CLIN ONCOL, V32, P587, DOI 10.1200/JCO.2013.48.7934; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; van Dongen JJM, 2012, LEUKEMIA, V26, P1908, DOI 10.1038/leu.2012.120; Xu J, 2019, P NATL ACAD SCI USA, V116, P9543, DOI 10.1073/pnas.1819745116; Yan ZL, 2019, LANCET HAEMATOL, V6, pE521, DOI 10.1016/S2352-3026(19)30115-2; Zhao YF, 2018, TUBERCULOSIS, V111, P45, DOI 10.1016/j.tube.2018.05.004	22	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 27	2022	13								814548	10.3389/fimmu.2022.814548	http://dx.doi.org/10.3389/fimmu.2022.814548			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F6WK	35572513	Green Published, gold			2022-12-18	WOS:000795306600001
J	Cao, JJ; Zhou, MX; Chen, XY; Sun, ML; Wei, CM; Peng, QS; Cheng, Z; Sun, WC; Wang, HB				Cao, Jinjin; Zhou, Ming-Xue; Chen, Xinyan; Sun, Menglu; Wei, Congmin; Peng, Qisheng; Cheng, Zhou; Sun, Wanchun; Wang, Hongbing			Sec-O-Glucosylhamaudol Inhibits RANKL-Induced Osteoclastogenesis by Repressing 5-LO and AKT/GSK3 beta Signaling	FRONTIERS IN IMMUNOLOGY			English	Article						Sec-O-glucosylhamaudol; osteoclasts; NFATc1; GSK3 beta; 5-lipoxygenase; AKT	5-LIPOXYGENASE INHIBITORS; BONE LOSS; DIFFERENTIATION; IMMUNE; OSTEOPOROSIS; EXPRESSION; OSTEOBLAST	Sec-O-glucosylhamaudol (SOG), an active flavonoid compound derived from the root of Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk., exhibits analgesic, anti-inflammatory, and high 5-lipoxygenase (5-LO) inhibitory effects. However, its effect on osteoclastogenesis was unclear. We demonstrated that SOG markedly attenuated RANKL-induced osteoclast formation, F-actin ring formation, and mineral resorption by reducing the induction of key transcription factors NFATc1, c-Fos, and their target genes such as TRAP, CTSK, and DC-STAMP during osteoclastogenesis. Western blotting showed that SOG significantly inhibited the phosphorylation of AKT and GSK3 beta at the middle-late stage of osteoclastogenesis without altering calcineurin catalytic subunit protein phosphatase-2 beta-A alpha expression. Moreover, GSK3 beta inhibitor SB415286 partially reversed SOG-induced inhibition of osteoclastogenesis, suggesting that SOG inhibits RANKL-induced osteoclastogenesis by activating GSK3 beta, at least in part. 5-LO gene silencing by small interfering RNA in mouse bone marrow macrophages markedly reduced RANKL-induced osteoclastogenesis by inhibiting NFATc1. However, it did not affect the phosphorylation of AKT or GSK3 beta, indicating that SOG exerts its inhibitory effects on osteoclastogenesis by suppressing both the independent 5-LO pathway and AKT-mediated GSK3 beta inactivation. In support of this, SOG significantly improved bone destruction in a lipopolysaccharide-induced mouse model of bone loss. Taken together, these results suggest a potential therapeutic effect for SOG on osteoclast-related bone lysis disease.	[Cao, Jinjin; Chen, Xinyan; Sun, Menglu; Wei, Congmin; Cheng, Zhou; Wang, Hongbing] Tongji Univ, Putuo Peoples Hosp, Sch Life Sci & Technol, Shanghai, Peoples R China; [Zhou, Ming-Xue] Guangxi Tradit Chinese Med TCM Univ, Dept Neurol, Ruikang Hosp, Nanning, Peoples R China; [Peng, Qisheng; Sun, Wanchun] Jilin Univ, Key Lab Zoonoses Res, Inst Zoonosis, Minist Educ, Changchun, Peoples R China	Tongji University; Guangxi University of Chinese Medicine; Jilin University	Cheng, Z; Wang, HB (corresponding author), Tongji Univ, Putuo Peoples Hosp, Sch Life Sci & Technol, Shanghai, Peoples R China.; Sun, WC (corresponding author), Jilin Univ, Key Lab Zoonoses Res, Inst Zoonosis, Minist Educ, Changchun, Peoples R China.	chengzhou@tongji.edu.cn; wanchunsun@jlu.edu.cn; hbwang@tongji.edu.cn			National Natural Science Foundation [31670347, 81001369, 31170327, 31870121]; Shanghai Science and Technology Commission of Shanghai Municipality [21015800500]	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission of Shanghai Municipality(Science & Technology Commission of Shanghai Municipality (STCSM))	This research was funded by the National Natural Science Foundation (grant no. 31670347, 81001369, 31170327 and 31870121) and Shanghai Science and Technology Commission of Shanghai Municipality (No. 21015800500).	Amirhosseini M, 2018, J CELL PHYSIOL, V233, P2398, DOI 10.1002/jcp.26111; Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150; Bouchareychas L, 2017, J IMMUNOL, V198, P452, DOI 10.4049/jimmunol.1601346; Boyce BF, 2013, J DENT RES, V92, P860, DOI 10.1177/0022034513500306; Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35; Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885; Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658; Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.e04-12-1117; Cao JJ, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107137; Chen ZK, 2010, ARTIF CELL BLOOD SUB, V38, P52, DOI 10.3109/10731190903495785; Dan HC, 2016, ONCOTARGET, V7, P21064, DOI 10.18632/oncotarget.8383; Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003; Fu J, 2016, J CLIN INVEST, V126, P1759, DOI 10.1172/JCI80276; Paula-Silva FWG, 2020, ARCH ORAL BIOL, V112, DOI 10.1016/j.archoralbio.2020.104670; Golden LH, 2004, BONE, V34, P3, DOI 10.1016/j.bone.2003.09.005; Hikiji H, 2009, P NATL ACAD SCI USA, V106, P21294, DOI 10.1073/pnas.0905209106; Hu LF, 2016, TOXICOL IN VITRO, V37, P97, DOI 10.1016/j.tiv.2016.09.002; Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768; Kang JH, 2015, BIOORGAN MED CHEM, V23, P7069, DOI 10.1016/j.bmc.2015.09.025; Koh GH, 2019, KOREAN J PAIN, V32, P87, DOI 10.3344/kjp.2019.32.2.87; Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102; Lee JM, 2012, J IMMUNOL, V189, P5284, DOI 10.4049/jimmunol.1003738; Lee K, 2016, INT J BIOL SCI, V12, P235, DOI 10.7150/ijbs.13814; Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756-3282(01)00657-3; Liu GM, 2022, SPECTROCHIM ACTA A, V274, DOI 10.1016/j.saa.2022.121100; Liu GM, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20194230; Liu YCG, 2010, PERIODONTOL 2000, V52, P163, DOI 10.1111/j.1600-0757.2009.00321.x; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Matsushita T, 2009, MOL CELL BIOL, V29, P5843, DOI 10.1128/MCB.01549-08; Min SK, 2018, CELL DEATH DIFFER, V25, P268, DOI 10.1038/cdd.2017.153; Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254; Moussa FM, 2021, BONE, V145, DOI 10.1016/j.bone.2020.115470; Mukherjee K, 2016, BIOCHEM PHARMACOL, V117, P10, DOI 10.1016/j.bcp.2016.04.010; Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; Negishi-Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600-065X.2009.00821.x; Park JH, 2017, MOL CELLS, V40, P706, DOI 10.14348/molcells.2017.0225; Sahin E, 2014, J IMMUNOL, V193, P1717, DOI 10.4049/jimmunol.1302167; Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062; Tan YH, 2020, BRIT J PHARMACOL, V177, P4242, DOI 10.1111/bph.15179; Taubman MA, 2005, J PERIODONTOL, V76, P2033, DOI 10.1902/jop.2005.76.11-S.2033; Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123; Wei JY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01025; Xiao DL, 2020, J CELL BIOCHEM, V121, P4542, DOI 10.1002/jcb.29677; Xiao L, 2020, AGING-US, V12, P21706, DOI 10.18632/aging.103976; Yan DY, 2020, J CELL MOL MED, V24, P2330, DOI 10.1111/jcmm.14915; Yuan K, 2020, INT J NANOMED, V15, P6355, DOI 10.2147/IJN.S257741; Yue S, 2014, J IMMUNOL, V192, P5343, DOI 10.4049/jimmunol.1400280; Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463; Zhao AQ, 2016, J FUNCT FOODS, V24, P244, DOI 10.1016/j.jff.2016.04.011	50	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								880988	10.3389/fimmu.2022.880988	http://dx.doi.org/10.3389/fimmu.2022.880988			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8JQ	35558084	gold, Green Published			2022-12-18	WOS:000884997900001
J	de Bouille, JG; Epelboin, L; Henaff, F; Migaud, M; Abboud, P; Blanchet, D; Aznar, C; Djossou, F; Lortholary, O; Elenga, N; Puel, A; Lanternier, F; Demar, M				de Bouille, Jeanne Goupil; Epelboin, Loic; Henaff, Fanny; Migaud, Melanie; Abboud, Philippe; Blanchet, Denis; Aznar, Christine; Djossou, Felix; Lortholary, Olivier; Elenga, Narcisse; Puel, Anne; Lanternier, Fanny; Demar, Magalie			Case Report: Invasive Cryptococcosis in French Guiana: Immune and Genetic Investigation in Six Non-HIV Patients	FRONTIERS IN IMMUNOLOGY			English	Article						cryptococcosis; immunocompetent; STAT1 gene; autoantibodies against GM-CSF; antibodies against IFN-gamma; fungal infection	GATTII	Objectives: We describe the clinical, mycological, immunological, and genetic characteristics of six HIV-negative patients presenting with invasive cryptococcosis.& nbsp;Methods: Patients with cryptococcosis without any of the classical risk factors, such as HIV infection, followed at Cayenne Hospital, were prospectively included. An immunologic and genetic assessment was performed.& nbsp;Results: Five male patients and one female patient, 5 adults and one child, were investigated. All presented a neuromeningeal localization. Cryptococcus neoformans var. gattii and C. neoformans var. grubii were isolated in two and three patients, respectively, whereas one patient could not be investigated. Overall, we did not observe any global leukocyte defect. Two patients were found with high levels of circulating autoantibodies against Granulocyte macrophage-colony stimulating factor (GM-CSF), and none had detectable levels of autoantibodies against Interferon gamma (IFN-gamma) Sequencing of STAT1 exons and flanking regions performed for four patients was wild type.& nbsp;Conclusion: To better understand cryptococcosis in patients with cryptococcosis but otherwise healthy, further explorations are needed with repeated immune checkups and strain virulence studies.	[de Bouille, Jeanne Goupil] Assistance Publ Hop Paris, Avicenne Hosp, Bobigny, France; [de Bouille, Jeanne Goupil] Univ Sorbonne Paris Nord, Lab Educ & Pratique Sante, Bobigny, France; [Epelboin, Loic; Henaff, Fanny; Abboud, Philippe; Blanchet, Denis; Aznar, Christine; Djossou, Felix; Elenga, Narcisse; Demar, Magalie] Cayenne Hosp, Cayenne, French Guiana; [Epelboin, Loic; Blanchet, Denis; Aznar, Christine; Djossou, Felix; Elenga, Narcisse; Demar, Magalie] Univ French Guiana, Cayenne, French Guiana; [Migaud, Melanie; Puel, Anne; Lanternier, Fanny] Paris C Univ, Imagine Inst, Paris, France; [Lortholary, Olivier; Puel, Anne; Lanternier, Fanny] Assitance Publ Hop Paris, APHP, Inst Natl Sante & Rech Med U1163, Necker Branch,Necker Hosp,Lab Human Genet Infect D, Paris, France; [Puel, Anne] Rockefeller Univ, St Giles Lab Human Genet Infect Dis, New York, NY USA; [Lanternier, Fanny] Univ Paris, Pasteur Inst Paris, Unite Mixte Rech 2000, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Rockefeller University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	de Bouille, JG (corresponding author), Assistance Publ Hop Paris, Avicenne Hosp, Bobigny, France.; de Bouille, JG (corresponding author), Univ Sorbonne Paris Nord, Lab Educ & Pratique Sante, Bobigny, France.	jeanne.goupildebouille@aphp.fr	ELENGA, Narcisse NE/C-2272-2015; Goupil de Bouillé, Jeanne/AHC-3086-2022; Puel, Anne/H-7305-2017	ELENGA, Narcisse NE/0000-0003-0624-4180; Puel, Anne/0000-0003-2603-0323	French National Research Agency (ANR) under the "Investments for the future" program [ANR-10-IAHU-01]; National Institute of Allergy and Infectious Diseases of the NIH [R01AI127564]; ANR-FNS LTh-MSMD-CMCD [ANR-18-CE930008-01]; Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence [ANR-10-LABX-62-IBEID]	French National Research Agency (ANR) under the "Investments for the future" program(French National Research Agency (ANR)); National Institute of Allergy and Infectious Diseases of the NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ANR-FNS LTh-MSMD-CMCD(French National Research Agency (ANR)); Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence	The work was funded by the French National Research Agency (ANR) under the "Investments for the future" program (ANR-10-IAHU-01), the ANR-FNS LTh-MSMD-CMCD (ANR-18-CE930008-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), and the National Institute of Allergy and Infectious Diseases of the NIH (grant no. R01AI127564).	Blaizot R, 2019, PEDIATR INFECT DIS J, V38, pE39, DOI 10.1097/INF.0000000000002130; Browne SK, 2012, NEW ENGL J MED, V367, P725, DOI 10.1056/NEJMoa1111160; Chandesris MO, 2012, MEDICINE, V91, pE1, DOI 10.1097/MD.0b013e31825f95b9; Chen S, 2000, CLIN INFECT DIS, V31, P499, DOI 10.1086/313992; Chen SCA, 2014, CLIN MICROBIOL REV, V27, P980, DOI 10.1128/CMR.00126-13; Debourgogne A, 2011, MED MYCOL, V49, P864, DOI 10.3109/13693786.2011.584198; Desnos-Ollivier M, 2015, MBIO, V6, DOI 10.1128/mBio.00311-15; DEVROEY C, 1989, MYCOSES, V32, P675, DOI 10.1111/j.1439-0507.1989.tb02200.x; Dixit Ashwin, 2009, Interdiscip Perspect Infect Dis, V2009, P840452, DOI 10.1155/2009/840452; Donnelly JP, 2020, CLIN INFECT DIS, V71, P1367, DOI 10.1093/cid/ciz1008; Dromer F, 2007, PLOS MED, V4, P297, DOI 10.1371/journal.pmed.0040021; Eldin C, 2014, AM J TROP MED HYG, V91, P771, DOI 10.4269/ajtmh.14-0282; Epelboin L, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004598; Escandon P, 2018, J FUNGI, V4, DOI 10.3390/jof4010032; Favalessa OC, 2014, MYCOSES, V57, P639, DOI 10.1111/myc.12210; Gangneux JP., 2016, ESTIMATION BURDEN SE; Herkert PF, 2017, J FUNGI, V3, DOI 10.3390/jof3040062; Hoang LMN, 2004, J MED MICROBIOL, V53, P935, DOI 10.1099/jmm.0.05427-0; Jean SS, 2002, QJM-INT J MED, V95, P511, DOI 10.1093/qjmed/95.8.511; Jongwutiwes U, 2008, JPN J INFECT DIS, V61, P111; Lui G, 2006, QJM-INT J MED, V99, P143, DOI 10.1093/qjmed/hcl014; Marr KA, 2020, CLIN INFECT DIS, V70, P252, DOI 10.1093/cid/ciz193; Mosnier E, 2018, AM J TROP MED HYG, V98, P1727, DOI 10.4269/ajtmh.17-0609; Odio CD, 2015, J ALLERGY CLIN IMMUN, V136, P1411, DOI 10.1016/j.jaci.2015.07.003; Pappas Peter G, 2013, Trans Am Clin Climatol Assoc, V124, P61; Pappas PG, 2001, CLIN INFECT DIS, V33, P690, DOI 10.1086/322597; Perfect JR, 2010, CLIN INFECT DIS, V50, P291, DOI 10.1086/649858; Rosen LB, 2013, J IMMUNOL, V190, P3959, DOI 10.4049/jimmunol.1202526; Rujirachun P, 2020, BMC INFECT DIS, V20, DOI 10.1186/s12879-020-4949-4; Saijo T, 2014, MBIO, V5, DOI 10.1128/mBio.00912-14; Sorrell TC, 2001, MED MYCOL, V39, P155, DOI 10.1080/mmy.39.2.155.168; SPEED B, 1995, CLIN INFECT DIS, V21, P28, DOI 10.1093/clinids/21.1.28; Toubiana J, 2016, BLOOD, V127, P3154, DOI 10.1182/blood-2015-11-679902; Voelz K, 2010, EUKARYOT CELL, V9, P835, DOI 10.1128/EC.00039-10; Wager CML, 2015, INFECT IMMUN, V83, P4513, DOI 10.1128/IAI.00935-15; Winkelstein JA, 2003, MEDICINE, V82, P373, DOI 10.1097/01.md.0000100046.06009.b0; Wongkulab P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076371; Zhang WJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654406; Zhu LP, 2010, MED MYCOL, V48, P570, DOI 10.3109/13693780903437876; Zonios DI, 2007, MEDICINE, V86, P78, DOI 10.1097/md.0b013e31803b52f5	40	0	0	0	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								881352	10.3389/fimmu.2022.881352	http://dx.doi.org/10.3389/fimmu.2022.881352			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G2ND	35558066	Green Published, gold			2022-12-18	WOS:000795688600001
J	Giral, H; Franke, V; Moobed, M; Mueller, MF; Luebking, L; James, DM; Hartung, J; Kuschnerus, K; Meteva, D; Seppelt, C; Jakob, P; Klingenberg, R; Kraenkel, N; Leistner, D; Zeller, T; Blankenberg, S; Zimmermann, F; Haghikia, A; Luescher, TF; Akalin, A; Landmesser, U; Kratzer, A				Giral, Hector; Franke, Vedran; Moobed, Minoo; Mueller, Maja F.; Luebking, Laura; James, Divya Maria; Hartung, Johannes; Kuschnerus, Kira; Meteva, Denitsa; Seppelt, Claudio; Jakob, Philipp; Klingenberg, Roland; Kraenkel, Nicolle; Leistner, David; Zeller, Tanja; Blankenberg, Stefan; Zimmermann, Friederike; Haghikia, Arash; Luescher, Thomas F.; Akalin, Altuna; Landmesser, Ulf; Kratzer, Adelheid			Rapid Inflammasome Activation Is Attenuated in Post-Myocardial Infarction Monocytes	FRONTIERS IN IMMUNOLOGY			English	Article						inflammasome; interleukin 18; monocytes; acute myocardial infarction; refractory behavior; IRAKM; TNFAIP3 (A20)	ACUTE MYOCARDIAL-INFARCTION; NF-KAPPA-B; NLRP3 INFLAMMASOME; IRAK-M; INTERLEUKIN-18; A20; INHIBITOR; PROTEIN; INJURY; DEUBIQUITINATION	Inflammasomes are crucial gatekeepers of the immune response, but their maladaptive activation associates with inflammatory pathologies. Besides canonical activation, monocytes can trigger non-transcriptional or rapid inflammasome activation that has not been well defined in the context of acute myocardial infarction (AMI). Rapid transcription-independent inflammasome activation induced by simultaneous TLR priming and triggering stimulus was measured by caspase-1 (CASP1) activity and interleukin release. Both classical and intermediate monocytes from healthy donors exhibited robust CASP1 activation, but only classical monocytes produced high mature interleukin-18 (IL18) release. We also recruited a limited number of coronary artery disease (CAD, n=31) and AMI (n=29) patients to evaluate their inflammasome function and expression profiles. Surprisingly, monocyte subpopulations isolated from blood collected during percutaneous coronary intervention (PCI) from AMI patients presented diminished CASP1 activity and abrogated IL18 release despite increased NLRP3 gene expression. This unexpected attenuated rapid inflammasome activation was accompanied by a significant increase of TNFAIP3 and IRAKM expression. Moreover, TNFAIP3 protein levels of circulating monocytes showed positive correlation with high sensitive troponin T (hsTnT), implying an association between TNFAIP3 upregulation and the severity of tissue injury. We suggest this monocyte attenuation to be a protective phenotype aftermath following a very early inflammatory wave in the ischemic area. Damage-associated molecular patterns (DAMPs) or other signals trigger a transitory negative feedback loop within newly recruited circulating monocytes as a mechanism to reduce post-injury tissue damage.					Haghikia, Arash/F-1348-2016	Seppelt, Claudio/0000-0003-4892-6809; Kraenkel, Nicolle/0000-0002-9363-1770; Zeller, Tanja/0000-0003-3379-2641; Kratzer, Adelheid/0000-0002-6151-5097; Leistner, David/0000-0002-4351-420X; Hartung, Johannes Jakob/0000-0002-4747-7266	DFG-funded sorter facility at CBF [INST 335/597-1 FUGG]	DFG-funded sorter facility at CBF(German Research Foundation (DFG))	Funding This study received funding from a Novartis research grant. The funder was not involved in the study design, collection, analysis and interpretation of data, the writing of this article or the decision to submit it for publication. The work was also supported by grants from Leducq, SNF (310030_149990, 31030_166576, SPUM 33CM30-124112 and 32473B_163271) as well as the DZHK (German Centre for Cardiovascular Research) (81Z2100202) and the Berlin Institute of Health (BIH).	Anand PK, 2012, NATURE, V488, P389, DOI 10.1038/nature11250; Anderson P, 2008, NAT IMMUNOL, V9, P353, DOI 10.1038/ni1584; Arfvidsson J, 2017, INT J CARDIOL, V231, P47, DOI 10.1016/j.ijcard.2016.12.182; Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883; Barsky LW, 2016, CYTOM PART A, V89A, P1017, DOI 10.1002/cyto.a.23016; Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363; Bertheloot D, 2017, CELL MOL IMMUNOL, V14, P43, DOI 10.1038/cmi.2016.34; Blankenberg S, 2003, CIRCULATION, V108, P2453, DOI 10.1161/01.CIR.0000099509.76044.A2; Cain DW, 2017, NAT REV IMMUNOL, V17, P233, DOI 10.1038/nri.2017.1; Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010; Catrysse L, 2014, TRENDS IMMUNOL, V35, P22, DOI 10.1016/j.it.2013.10.005; Chen W, 2012, ARTERIOSCL THROM VAS, V32, P2598, DOI 10.1161/ATVBAHA.112.300310; Coll RC, 2015, NAT MED, V21, P248, DOI 10.1038/nm.3806; Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289; Duong BH, 2015, IMMUNITY, V42, P55, DOI 10.1016/j.immuni.2014.12.031; Epelman S, 2015, NAT REV IMMUNOL, V15, P117, DOI 10.1038/nri3800; Fantuzzi G, 1999, J CLIN IMMUNOL, V19, P1, DOI 10.1023/A:1020506300324; Fernandez-Ruiz I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095073; Furman D, 2017, NAT MED, V23, P174, DOI 10.1038/nm.4267; Getzin T, 2018, EMBO MOL MED, V10, P151, DOI 10.15252/emmm.201707502; Ghonime MG, 2014, J IMMUNOL, V192, P3881, DOI 10.4049/jimmunol.1301974; Gritsenko A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565924; Gu HF, 2015, TRANSPL INT, V28, P1436, DOI 10.1111/tri.12683; Hernandez-Jimenez E, 2017, J IMMUNOL, V198, P2038, DOI 10.4049/jimmunol.1601594; Ito M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8360; Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130; Kany S, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1752836; Kawashima A, 2017, J IMMUNOL, V199, P3614, DOI 10.4049/jimmunol.1700184; Kim BH, 2016, NAT IMMUNOL, V17, P481, DOI 10.1038/ni.3440; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Krishnan SM, 2019, CARDIOVASC RES, V115, P776, DOI 10.1093/cvr/cvy252; Lamkanfi M, 2011, IMMUNOL REV, V243, P163, DOI 10.1111/j.1600-065X.2011.01042.x; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Leuschner F, 2012, J EXP MED, V209, P123, DOI 10.1084/jem.20111009; Marchetti C, 2014, J CARDIOVASC PHARM, V63, P316, DOI 10.1097/FJC.0000000000000053; O'Brien LC, 2014, MOL MED, V20, P221, DOI 10.2119/molmed.2014.00034; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Paik S, 2021, CELL MOL IMMUNOL, V18, P1141, DOI 10.1038/s41423-021-00670-3; Palazon-Riquelme P, 2018, EMBO REP, V19, DOI 10.15252/embr.201744766; Pradhan K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.778830; Py BF, 2013, MOL CELL, V49, P331, DOI 10.1016/j.molcel.2012.11.009; Quintar A, 2017, CIRC RES, V120, P1789, DOI 10.1161/CIRCRESAHA.117.310739; Richter K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01604; Ridker PM, 2017, NEW ENGL J MED, V377, P1119, DOI 10.1056/NEJMoa1707914; Rogacev KS, 2012, J AM COLL CARDIOL, V60, P1512, DOI 10.1016/j.jacc.2012.07.019; Sandanger O, 2013, CARDIOVASC RES, V99, P164, DOI 10.1093/cvr/cvt091; Shenoy AR, 2012, SCIENCE, V336, P481, DOI 10.1126/science.1217141; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Siebers K, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00877; Song H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13727; Swirski FK, 2013, SCIENCE, V339, P161, DOI 10.1126/science.1230719; Toldo S, 2018, NAT REV CARDIOL, V15, P203, DOI 10.1038/nrcardio.2017.161; Toldo S, 2015, ANTIOXID REDOX SIGN, V22, P1146, DOI 10.1089/ars.2014.5989; Turer EE, 2008, J EXP MED, V205, P451, DOI 10.1084/jem.20071108; van der Laan AM, 2014, EUR HEART J, V35, P376, DOI 10.1093/eurheartj/eht331; van Hout GPJ, 2017, EUR HEART J, V38, P828, DOI 10.1093/eurheartj/ehw247; Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009; Vande Walle L, 2014, NATURE, V512, P69, DOI 10.1038/nature13322; Venkatachalam K, 2009, J BIOL CHEM, V284, P7853, DOI 10.1074/jbc.M808824200; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; Weber ANR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01454; Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022; Zeller T, 2015, CIRC-CARDIOVASC GENE, V8, P717, DOI 10.1161/CIRCGENETICS.115.001079; Ziegler-Heitbrock L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00023	64	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								857455	10.3389/fimmu.2022.857455	http://dx.doi.org/10.3389/fimmu.2022.857455			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V2WT	35558073	Green Published, Green Accepted, gold			2022-12-18	WOS:000805957100001
J	Ham, H; Medlyn, M; Billadeau, DD				Ham, Hyoungjun; Medlyn, Michael; Billadeau, Daniel D.			Locked and Loaded: Mechanisms Regulating Natural Killer Cell Lytic Granule Biogenesis and Release	FRONTIERS IN IMMUNOLOGY			English	Review						natural killer cells; lytic granule; degranulation; primary immunodeficiency; cytotoxicity	NUCLEOTIDE EXCHANGE FACTOR; PAPILLON-LEFEVRE-SYNDROME; CYTOTOXIC T-LYMPHOCYTES; SECRETORY LYSOSOMES; GRANZYME-B; FAS LIGAND; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; IMMUNOLOGICAL SYNAPSE; MYOSIN-IIA; MEDIATED APOPTOSIS	NK cell-mediated cytotoxicity is a critical element of our immune system required for protection from microbial infections and cancer. NK cells bind to and eliminate infected or cancerous cells via direct secretion of cytotoxic molecules toward the bound target cells. In this review, we summarize the current understanding of the molecular regulations of NK cell cytotoxicity, focusing on lytic granule development and degranulation processes. NK cells synthesize apoptosis-inducing proteins and package them into specialized organelles known as lytic granules (LGs). Upon activation of NK cells, LGs converge with the microtubule organizing center through dynein-dependent movement along microtubules, ultimately polarizing to the cytotoxic synapse where they subsequently fuse with the NK plasma membrane. From LGs biogenesis to degranulation, NK cells utilize several strategies to protect themselves from their own cytotoxic molecules. Additionally, molecular pathways that enable NK cells to perform serial killing are beginning to be elucidated. These advances in the understanding of the molecular pathways behind NK cell cytotoxicity will be important to not only improve current NK cell-based anti-cancer therapies but also to support the discovery of additional therapeutic opportunities.	[Ham, Hyoungjun; Billadeau, Daniel D.] Mayo Clin, Div Oncol Res, Rochester, MN 55902 USA; [Medlyn, Michael; Billadeau, Daniel D.] Mayo Clin, Dept Immunol, Coll Med, Rochester, MN 55902 USA	Mayo Clinic; Mayo Clinic	Billadeau, DD (corresponding author), Mayo Clin, Div Oncol Res, Rochester, MN 55902 USA.; Billadeau, DD (corresponding author), Mayo Clin, Dept Immunol, Coll Med, Rochester, MN 55902 USA.	billadeau.daniel@mayo.edu		Ham, Hyoungjun/0000-0002-8669-6875	NIH [AI120949]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported in part of by NIH grant AI120949 to DDB.	Ambrose AR, 2020, P NATL ACAD SCI USA, V117, P23717, DOI 10.1073/pnas.2010274117; Anderson DH, 2003, J MOL BIOL, V325, P355, DOI 10.1016/S0022-2836(02)01234-2; Andzelm MM, 2007, J EXP MED, V204, P2285, DOI 10.1084/jem.20071143; Anft M, 2020, CELL MOL IMMUNOL, V17, P347, DOI 10.1038/s41423-019-0277-2; Arneson LN, 2007, J IMMUNOL, V179, P3397, DOI 10.4049/jimmunol.179.6.3397; Asensio-Juarez G, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061458; Badolato R, 2007, J ALLERGY CLIN IMMUN, V120, P735, DOI 10.1016/j.jaci.2007.08.039; BAETZ K, 1995, J IMMUNOL, V154, P6122; Balaji KN, 2002, J EXP MED, V196, P493, DOI 10.1084/jem.20011836; Balint S, 2020, SCIENCE, V368, P897, DOI 10.1126/science.aay9207; Banerjee PP, 2007, J EXP MED, V204, P2305, DOI 10.1084/jem.20061893; Baran K, 2006, J BIOL CHEM, V281, P30485, DOI 10.1074/jbc.M602007200; Baran K, 2009, IMMUNITY, V30, P684, DOI 10.1016/j.immuni.2009.03.016; Beal AM, 2009, IMMUNITY, V31, P632, DOI 10.1016/j.immuni.2009.09.004; Beise N, 2011, J CELL SCI, V124, P4141, DOI 10.1242/jcs.087007; Ben-Shmuel A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.609532; Bhat R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000326; Bi JC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00760; Billadeau DD, 2000, J EXP MED, V192, P381, DOI 10.1084/jem.192.3.381; Billadeau DD, 1998, J EXP MED, V188, P549, DOI 10.1084/jem.188.3.549; Bin NR, 2018, J IMMUNOL, V201, P700, DOI 10.4049/jimmunol.1800426; Blott EJ, 2001, J CELL SCI, V114, P2405; Blott EJ, 2002, NAT REV MOL CELL BIO, V3, P122, DOI 10.1038/nrm732; Bodmer JL, 2002, TRENDS BIOCHEM SCI, V27, P19, DOI 10.1016/S0968-0004(01)01995-8; Boning MAL, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03144; Bossi G, 1999, NAT MED, V5, P90, DOI 10.1038/4779; Boswell KL, 2012, J CELL BIOL, V197, P301, DOI 10.1083/jcb.201109132; Brito C, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071590; Bryceson YT, 2007, BLOOD, V110, P1906, DOI 10.1182/blood-2007-02-074468; Bryceson YT, 2005, J EXP MED, V202, P1001, DOI 10.1084/jem.20051143; BURKHARDT JK, 1993, J CELL SCI, V104, P151; BURKHARDT JK, 1993, J EXP MED, V178, P1845, DOI 10.1084/jem.178.6.1845; Cantalupo G, 2001, EMBO J, V20, P683, DOI 10.1093/emboj/20.4.683; Capuano C, 2012, BLOOD, V119, P2252, DOI 10.1182/blood-2010-12-324160; Carrega P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00347; Casey TM, 2007, MOL CELL PROTEOMICS, V6, P767, DOI 10.1074/mcp.M600365-MCP200; Chen YY, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/6437057; Chiang SCC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00426; Choi PJ, 2013, P NATL ACAD SCI USA, V110, P6488, DOI 10.1073/pnas.1221312110; Chowdhury D, 2008, ANNU REV IMMUNOL, V26, P389, DOI 10.1146/annurev.immunol.26.021607.090404; Clark R, 2003, CURR OPIN IMMUNOL, V15, P516, DOI 10.1016/S0952-7915(03)00113-4; Clark RH, 2003, NAT IMMUNOL, V4, P1111, DOI 10.1038/ni1000; Cohnen A, 2013, BLOOD, V122, P1411, DOI 10.1182/blood-2012-07-441832; Combs J, 2006, P NATL ACAD SCI USA, V103, P14883, DOI 10.1073/pnas.0600914103; Cote M, 2009, J CLIN INVEST, V119, P3765, DOI 10.1172/JCI40732; D'Angelo ME, 2010, J BIOL CHEM, V285, P20514, DOI 10.1074/jbc.M109.094573; D'Orlando O, 2013, EUR J IMMUNOL, V43, P194, DOI 10.1002/eji.201142343; Davis Lianne C, 2015, Messenger (Los Angel), V4, P53; Davis LC, 2012, CURR BIOL, V22, P2331, DOI 10.1016/j.cub.2012.10.035; de la Roche M, 2016, NAT REV IMMUNOL, V16, P421, DOI 10.1038/nri.2016.54; de Saint Basile G, 2010, NAT REV IMMUNOL, V10, P568, DOI 10.1038/nri2803; Dell'Angelica EC, 2000, FASEB J, V14, P1265, DOI 10.1096/fj.14.10.1265; Dell'Angelica EC, 2009, CURR OPIN CELL BIOL, V21, P552, DOI 10.1016/j.ceb.2009.04.014; Dieckmann NMG, 2015, TRAFFIC, V16, P1330, DOI 10.1111/tra.12337; Dimitrova D, 2017, DERMATOL CLIN, V35, P11, DOI 10.1016/j.det.2016.07.002; Dressel R, 2010, J IMMUNOL, V185, P1005, DOI 10.4049/jimmunol.1000770; Elstak ED, 2011, BLOOD, V118, P1570, DOI 10.1182/blood-2011-02-339523; Enders A, 2006, BLOOD, V108, P81, DOI 10.1182/blood-2005-11-4413; Ewen CL, 2012, CELL DEATH DIFFER, V19, P28, DOI 10.1038/cdd.2011.153; Fanger NA, 1999, J EXP MED, V190, P1155, DOI 10.1084/jem.190.8.1155; Fauriat C, 2010, BLOOD, V115, P2167, DOI 10.1182/blood-2009-08-238469; Federici C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00262; Feldmann J, 2003, CELL, V115, P461, DOI 10.1016/S0092-8674(03)00855-9; Fernandez-Chacon R, 2001, NATURE, V410, P41, DOI 10.1038/35065004; Fontana S, 2006, BLOOD, V107, P4857, DOI 10.1182/blood-2005-11-4398; Fostel LV, 2006, INT IMMUNOL, V18, P1305, DOI 10.1093/intimm/dxl063; Fraser SA, 2000, J IMMUNOL, V164, P4150, DOI 10.4049/jimmunol.164.8.4150; Fujita-Yoshigaki J, 2006, BIOCHEM BIOPH RES CO, V344, P283, DOI 10.1016/j.bbrc.2006.03.130; Fukuda M, 2013, TRAFFIC, V14, P949, DOI 10.1111/tra.12083; Ghosh D, 2010, J MASS SPECTROM, V45, P1, DOI 10.1002/jms.1696; Gil-Krzewska A, 2018, J ALLERGY CLIN IMMUN, V142, P914, DOI 10.1016/j.jaci.2017.10.040; Gismondi A, 2004, BLOOD, V104, P436, DOI 10.1182/blood-2003-07-2621; Griffiths Gillian M., 2002, Current Molecular Medicine (Hilversum), V2, P479, DOI 10.2174/1566524023362258; GRIFFITHS GM, 1993, J CELL BIOL, V120, P885, DOI 10.1083/jcb.120.4.885; Guillerey C, 2016, NAT IMMUNOL, V17, P1025, DOI 10.1038/ni.3518; Gwalani LA, 2018, J IMMUNOL, V200, P3231, DOI 10.4049/jimmunol.1701500; Hackmann Y, 2013, P NATL ACAD SCI USA, V110, pE4482, DOI 10.1073/pnas.1313474110; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; Ham H, 2015, J IMMUNOL, V194, P3984, DOI 10.4049/jimmunol.1402897; Ham H, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00002; Ham H, 2013, J IMMUNOL, V190, P3661, DOI 10.4049/jimmunol.1202792; Hanson DA, 1999, MOL IMMUNOL, V36, P413, DOI 10.1016/S0161-5890(99)00063-2; Hattab FN., 2019, STOMATOLOGICAL DIS S, P1, DOI [10.20517/2573-0002.2018.22, DOI 10.20517/2573-0002.2018.22]; HERMANSKY F, 1975, THROMB DIATH HAEMOST, V34, P360; Holt O, 2008, TRAFFIC, V9, P446, DOI 10.1111/j.1600-0854.2008.00714.x; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Hooikaas PJ, 2020, ELIFE, V9, DOI 10.7554/eLife.62876; Hornak I, 2020, BIOPHYS J, V118, P1733, DOI 10.1016/j.bpj.2020.01.045; House IG, 2017, EMBO REP, V18, P1775, DOI 10.15252/embr.201744351; Huizing M, 2001, MOL BIOL CELL, V12, P2075, DOI 10.1091/mbc.12.7.2075; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Iizuka Y, 2015, J IMMUNOL, V195, P4760, DOI 10.4049/jimmunol.1500979; Imai A, 2013, ARCH BIOCHEM BIOPHYS, V536, P31, DOI 10.1016/j.abb.2013.05.002; ITO M, 1989, INT J IMMUNOPHARMACO, V11, P185, DOI 10.1016/0192-0561(89)90070-2; James AM, 2013, BLOOD, V121, P2627, DOI 10.1182/blood-2012-06-437012; Jenkins MR, 2015, J EXP MED, V212, P307, DOI 10.1084/jem.20140964; Jenkins MR, 2009, IMMUNITY, V31, P621, DOI 10.1016/j.immuni.2009.08.024; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; Jewett A, 1996, J IMMUNOL, V156, P907; JEWETT A, 1995, CELL IMMUNOL, V160, P91, DOI 10.1016/0008-8749(95)80013-9; Johansson M, 2007, J CELL BIOL, V176, P459, DOI 10.1083/jcb.200606077; Johnson JL, 2016, J BIOL CHEM, V291, P3423, DOI 10.1074/jbc.M115.705871; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; Jordens I, 2001, CURR BIOL, V11, P1680, DOI 10.1016/S0960-9822(01)00531-0; Kaplan J, 2008, CURR OPIN HEMATOL, V15, P22, DOI 10.1097/MOH.0b013e3282f2bcce; Kasai K, 2005, J CLIN INVEST, V115, P388, DOI 10.1172/JCI200522955; Kaschek L, 2021, SEMIN CELL DEV BIOL, V115, P10, DOI 10.1016/j.semcdb.2020.12.002; Kaspar AA, 2001, J IMMUNOL, V167, P350, DOI 10.4049/jimmunol.167.1.350; Kataoka T, 1997, IMMUNOLOGY, V91, P493, DOI 10.1046/j.1365-2567.1997.00257.x; Kennedy MK, 2000, J EXP MED, V191, P771, DOI 10.1084/jem.191.5.771; Kolset SO, 2008, CELL MOL LIFE SCI, V65, P1073, DOI 10.1007/s00018-007-7455-6; Konjar S, 2010, IMMUNOLOGY, V131, P257, DOI 10.1111/j.1365-2567.2010.03299.x; Kopf A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.635511; Krensky AM, 2009, TISSUE ANTIGENS, V73, P193, DOI 10.1111/j.1399-0039.2008.01218.x; Krzewski K, 2013, BLOOD, V121, P4672, DOI 10.1182/blood-2012-08-453738; Krzewski K, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00335; Krzewski K, 2011, EUR J IMMUNOL, V41, P3323, DOI 10.1002/eji.201141582; Kuhn JR, 2002, IMMUNITY, V16, P111, DOI 10.1016/S1074-7613(02)00262-5; Kumar S, 2018, IMMUNOLOGY, V154, P383, DOI 10.1111/imm.12921; KUPFER A, 1985, J MOL CELL IMMUNOL, V2, P37; Kurowska M, 2012, BLOOD, V119, P3879, DOI 10.1182/blood-2011-09-382556; Lattao R, 2021, DEV CELL, V56, P1000, DOI 10.1016/j.devcel.2021.02.019; Lee J, 2018, IMMUN INFLAMM DIS, V6, P312, DOI 10.1002/iid3.219; Lettau M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.804895; Lettau M, 2018, INT IMMUNOL, V30, P215, DOI 10.1093/intimm/dxy007; Li JZ, 2014, J IMMUNOL, V193, P519, DOI 10.4049/jimmunol.1301668; Li P, 2010, CELL MOL LIFE SCI, V67, P3197, DOI 10.1007/s00018-010-0377-8; Li Y, 2021, PLOS BIOL, V19, DOI 10.1371/journal.pbio.3001328; Liu DF, 2005, P NATL ACAD SCI USA, V102, P123, DOI 10.1073/pnas.0405737102; Liu D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012870; Liu DF, 2009, IMMUNITY, V31, P99, DOI 10.1016/j.immuni.2009.05.009; Long EO, 2013, ANNU REV IMMUNOL, V31, P227, DOI 10.1146/annurev-immunol-020711-075005; Loo LS, 2009, EUR J IMMUNOL, V39, P3520, DOI 10.1002/eji.200939378; Lopez JA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00529; Lopez JA, 2013, J IMMUNOL, V191, P2328, DOI 10.4049/jimmunol.1301205; Lopez JA, 2012, TRENDS IMMUNOL, V33, P406, DOI 10.1016/j.it.2012.04.001; Lugini L, 2012, J IMMUNOL, V189, P2833, DOI 10.4049/jimmunol.1101988; Luzio JP, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016840; Mace EM, 2014, IMMUNOL CELL BIOL, V92, P245, DOI 10.1038/icb.2013.96; Mace EM, 2012, J IMMUNOL, V189, P4870, DOI 10.4049/jimmunol.1201296; Malmberg KJ, 2017, SEMIN IMMUNOL, V31, P20, DOI 10.1016/j.smim.2017.08.002; Marcet-Palacios M, 2008, BIOCHEM BIOPH RES CO, V366, P617, DOI 10.1016/j.bbrc.2007.11.079; MASSON D, 1990, BIOCHEMISTRY-US, V29, P11229, DOI 10.1021/bi00503a011; Matti U, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2467; McKenney RJ, 2014, SCIENCE, V345, P337, DOI 10.1126/science.1254198; Meade JL, 2006, BLOOD, V107, P3665, DOI 10.1182/blood-2005-03-1140; Menager MM, 2007, NAT IMMUNOL, V8, P257, DOI 10.1038/ni1431; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Mendoza MC, 2013, SEMIN CELL DEV BIOL, V24, P272, DOI 10.1016/j.semcdb.2013.01.007; Mentlik AN, 2010, MOL BIOL CELL, V21, P2241, DOI 10.1091/mbc.E09-11-0930; Metkar SS, 2002, IMMUNITY, V16, P417, DOI 10.1016/S1074-7613(02)00286-8; Mollinedo F, 2006, J IMMUNOL, V177, P2831, DOI 10.4049/jimmunol.177.5.2831; Monleon I, 2001, J IMMUNOL, V167, P6736, DOI 10.4049/jimmunol.167.12.6736; MONTEL AH, 1995, CELL IMMUNOL, V166, P236, DOI 10.1006/cimm.1995.9974; MONTEL AH, 1995, CELL IMMUNOL, V165, P312, DOI 10.1006/cimm.1995.1219; Munafo DB, 2007, BIOCHEM J, V402, P229, DOI 10.1042/BJ20060950; Myers JA, 2021, NAT REV CLIN ONCOL, V18, P85, DOI 10.1038/s41571-020-0426-7; Netter P, 2017, J IMMUNOL, V199, P2528, DOI 10.4049/jimmunol.1700394; Nunez-Andrade N, 2016, J CELL SCI, V129, P1305, DOI 10.1242/jcs.180885; OLSEN I, 1990, EUR J IMMUNOL, V20, P2161, DOI 10.1002/eji.1830201003; Orange JS, 2008, NAT REV IMMUNOL, V8, P713, DOI 10.1038/nri2381; Orange JS, 2011, J CLIN INVEST, V121, P1535, DOI 10.1172/JCI44862; Orange JS, 2003, P NATL ACAD SCI USA, V100, P14151, DOI 10.1073/pnas.1835830100; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Pattu V, 2011, TRAFFIC, V12, P890, DOI 10.1111/j.1600-0854.2011.01193.x; Paul S, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01124; Peden AA, 2004, J CELL BIOL, V164, P1065, DOI 10.1083/jcb.200311064; Pham CTN, 2004, J IMMUNOL, V173, P7277, DOI 10.4049/jimmunol.173.12.7277; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Phatarpekar PV, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.202002145; Phatarpekar PV, 2020, J CELL SCI, V133, DOI 10.1242/jcs.240424; Prager I, 2019, J LEUKOCYTE BIOL, V105, P1319, DOI 10.1002/JLB.MR0718-269R; Puri N, 2006, TRAFFIC, V7, P1482, DOI 10.1111/j.1600-0854.2006.00490.x; Raja SM, 2002, J BIOL CHEM, V277, P49523, DOI 10.1074/jbc.M209607200; Rak GD, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001151; Reefman E, 2010, J IMMUNOL, V184, P4852, DOI 10.4049/jimmunol.0803954; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rudd-Schmidt JA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13385-x; Sakai Y, 2013, BLOOD, V122, P386, DOI 10.1182/blood-2012-12-475897; Sanborn KB, 2011, BLOOD, V118, P5862, DOI 10.1182/blood-2011-03-344846; Sanborn KB, 2009, J IMMUNOL, V182, P6969, DOI 10.4049/jimmunol.0804337; Sandusky MM, 2006, EUR J IMMUNOL, V36, P3268, DOI 10.1002/eji.200636146; Sayers TJ, 2001, J IMMUNOL, V166, P765, DOI 10.4049/jimmunol.166.2.765; Schmidt H, 2008, PROTEOMICS, V8, P2911, DOI 10.1002/pmic.200800170; Schmidt H, 2011, J PROTEOME RES, V10, P1603, DOI 10.1021/pr100967v; Schmidt H, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-41; Sedelies KA, 2004, J BIOL CHEM, V279, P26581, DOI 10.1074/jbc.M312481200; Seri M, 2003, MEDICINE, V82, P203, DOI 10.1097/00005792-200305000-00006; Shin OH, 2009, P NATL ACAD SCI USA, V106, P16469, DOI 10.1073/pnas.0908798106; Shoae-Hassani A, 2017, J IMMUNOTHER, V40, P265, DOI 10.1097/CJI.0000000000000179; Shuh M, 2011, J VIROL, V85, P4623, DOI 10.1128/JVI.00839-10; Sieni E, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00167; SMYTH MJ, 1995, J IMMUNOL, V154, P6299; Spessott WA, 2017, P NATL ACAD SCI USA, V114, pE2176, DOI 10.1073/pnas.1617981114; Spessott WA, 2015, BLOOD, V125, P1566, DOI 10.1182/blood-2014-11-610816; Srpan K, 2018, J CELL BIOL, V217, P3267, DOI 10.1083/jcb.201712085; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Stinchcombe JC, 2006, NATURE, V443, P462, DOI 10.1038/nature05071; Stinchcombe JC, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-45; Stinchcombe JC, 1999, J CELL BIOL, V147, P1, DOI 10.1083/jcb.147.1.1; Stinchcombe JC, 2001, IMMUNITY, V15, P751, DOI 10.1016/S1074-7613(01)00234-5; Stinchcombe JC, 2000, TRAFFIC, V1, P435, DOI 10.1034/j.1600-0854.2000.010508.x; SUDA T, 1995, J IMMUNOL, V154, P3806; Sugita M, 2002, IMMUNITY, V16, P697, DOI 10.1016/S1074-7613(02)00311-4; Thomas WD, 1998, J IMMUNOL, V161, P2195; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Topham NJ, 2009, IMMUNOLOGY, V128, P7, DOI 10.1111/j.1365-2567.2009.03123.x; Tuli A, 2013, MOL BIOL CELL, V24, P3721, DOI 10.1091/mbc.E13-05-0259; Uellner R, 1997, EMBO J, V16, P7287, DOI 10.1093/emboj/16.24.7287; Vanherberghen B, 2013, BLOOD, V121, P1326, DOI 10.1182/blood-2012-06-439851; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; Voskoboinik I, 2015, NAT REV IMMUNOL, V15, P388, DOI 10.1038/nri3839; Vyas YM, 2001, J IMMUNOL, V167, P4358, DOI 10.4049/jimmunol.167.8.4358; Walch M, 2014, CELL, V157, P1309, DOI 10.1016/j.cell.2014.03.062; Ward DM, 2000, TRAFFIC, V1, P816; Watzl C, 2014, ADV IMMUNOL, V124, P137, DOI 10.1016/B978-0-12-800147-9.00005-4; Wilton KM, 2018, J IMMUNOL, V201, P2899, DOI 10.4049/jimmunol.1800254; Wood SM, 2009, BLOOD, V114, P4117, DOI 10.1182/blood-2009-06-225359; Wu FF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.658698; Yi JS, 2013, J CELL BIOL, V202, P779, DOI 10.1083/jcb.201301004; Zhu YT, 2016, ONCOTARGET, V7, P47163, DOI 10.18632/oncotarget.9980; Zingoni A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00476; Zografou S, 2012, J CELL SCI, V125, P4780, DOI 10.1242/jcs.104174; Zuccato E, 2007, J CELL SCI, V120, P191, DOI 10.1242/jcs.03315; zur Stadt U, 2005, HUM MOL GENET, V14, P827, DOI 10.1093/hmg/ddi076; zur Stadt U, 2009, AM J HUM GENET, V85, P482, DOI 10.1016/j.ajhg.2009.09.005	227	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								871106	10.3389/fimmu.2022.871106	http://dx.doi.org/10.3389/fimmu.2022.871106			19	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8JJ	35558071	Green Published, gold			2022-12-18	WOS:000884997000001
J	Liu, XN; Li, LW; Gao, F; Jiang, YF; Yuan, WZ; Li, GX; Yu, LX; Zhou, YJ; Tong, GZ; Zhao, K				Liu, Xiao-Na; Li, Li-Wei; Gao, Fei; Jiang, Yi-Feng; Yuan, Wan-Zhe; Li, Guo-Xin; Yu, Ling-Xue; Zhou, Yan-Jun; Tong, Guang-Zhi; Zhao, Kuan			cGAS Restricts PRRSV Replication by Sensing the mtDNA to Increase the cGAMP Activity	FRONTIERS IN IMMUNOLOGY			English	Article						PRRSV; cGAS; mtDNA; cGAMP; replication; antiviral activity	SYNDROME VIRUS-REPLICATION; RESPIRATORY SYNDROME; PATHOGENESIS; DNA; 2ND-MESSENGER	Porcine reproductive and respiratory syndrome virus (PRRSV) is an RNA virus that causes great economic losses globally to the swine industry. Innate immune RNA receptors mainly sense it during infection. As a DNA sensor, cyclic GMP-AMP synthase (cGAS) plays an important role in sensing cytosolic DNA and activating innate immunity to induce IFN-I and establish an antiviral cellular state. In contrast, the role of innate immune DNA sensors during PRRSV infection has not been elucidated. In this study, we found that cGAS facilitates the production of IFN-beta during PRRSV infection. Western blot and virus titer assays suggested that cGAS overexpression suppressed the replication of multiple PRRSV strains, while knockout of cGAS increased viral titer and nucleocapsid protein expression. Besides, our results indicated that the mitochondria were damaged during PRRSV infection and leaked mitochondrial DNA (mtDNA) into the cytoplasm. The mtDNA in the cytoplasm co-localizes with the cGAS, and the cGAMP activity was increased when the cGAS was overexpressed during PRRSV infection. Furthermore, the cGAMP also possesses an anti-PRRSV effect. These results indicate for the first time that cGAS restricts PRRSV replication by sensing the mtDNA in the cytoplasm to increase cGAMP activity, which not only explains the molecular mechanism by which cGAS inhibits PRRSV replication but also provides research ideas for studying the role of the cGAS-STING signaling pathway in the process of RNA virus infection.					jiang, yifeng/GWM-9104-2022					Ablasser A, 2013, NATURE, V498, P380, DOI 10.1038/nature12306; Aguirre S, 2017, J VIROL, V91, DOI 10.1128/JVI.01081-16; Aguirre S, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2017.37; Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921; Bookout Angie L, 2006, Curr Protoc Mol Biol, VChapter 15, DOI 10.1002/0471142727.mb1508s73; Chan YK, 2016, NAT REV MICROBIOL, V14, P360, DOI 10.1038/nrmicro.2016.45; Chand RJ, 2012, CURR OPIN VIROL, V2, P256, DOI 10.1016/j.coviro.2012.02.002; Civril F, 2013, NATURE, V498, P332, DOI 10.1038/nature12305; Franz KM, 2018, P NATL ACAD SCI USA, V115, pE2058, DOI 10.1073/pnas.1716937115; Han J, 2017, VET MICROBIOL, V209, P30, DOI 10.1016/j.vetmic.2017.02.020; Han MY, 2014, VET MICROBIOL, V174, P279, DOI 10.1016/j.vetmic.2014.10.007; Holm CK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10680; Huang C, 2014, J VIROL, V88, P10934, DOI 10.1128/JVI.01396-14; Li LW, 2019, VET MICROBIOL, V235, P310, DOI 10.1016/j.vetmic.2019.07.024; Li SF, 2016, ONCOTARGET, V7, P56002, DOI 10.18632/oncotarget.10817; Lunney JK, 2016, ANNU REV ANIM BIOSCI, V4, P129, DOI 10.1146/annurev-animal-022114-111025; Ma F, 2015, J IMMUNOL, V194, P1545, DOI 10.4049/jimmunol.1402066; Ma Z, 2016, CELL HOST MICROBE, V19, P150, DOI 10.1016/j.chom.2016.01.010; Ni GX, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007148; REED L. J., 1938, AMER JOUR HYG, V27, P493; Schoggins JW, 2014, NATURE, V505, P691, DOI 10.1038/nature12862; Shi M, 2010, VIRUS RES, V154, P7, DOI 10.1016/j.virusres.2010.08.014; Sun B, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03932-1; Tian KG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000526; Tong GZ, 2007, EMERG INFECT DIS, V13, P1434, DOI 10.3201/eid1309.070399; Wang HY, 2016, J INTERF CYTOK RES, V36, P129, DOI 10.1089/jir.2015.0077; Webb LG, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008999; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963; Xu YL, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13091829; Yoo D, 2010, VIRUS RES, V154, P48, DOI 10.1016/j.virusres.2010.07.019; Yun SI, 2013, J MICROBIOL, V51, P711, DOI 10.1007/s12275-013-3431-z; Zhao MM, 2017, MICROB PATHOGENESIS, V111, P14, DOI 10.1016/j.micpath.2017.08.011	33	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								887054	10.3389/fimmu.2022.887054	http://dx.doi.org/10.3389/fimmu.2022.887054			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V2UN	35558078	Green Published, gold			2022-12-18	WOS:000805951200001
J	Pikalo, J; Porfiri, L; Akimkin, V; Roszyk, H; Pannhorst, K; Kangethe, RT; Wijewardana, V; Sehl-Ewert, J; Beer, M; Cattoli, G; Blome, S				Pikalo, Jutta; Porfiri, Luca; Akimkin, Valerij; Roszyk, Hanna; Pannhorst, Katrin; Kangethe, Richard Thiga; Wijewardana, Viskam; Sehl-Ewert, Julia; Beer, Martin; Cattoli, Giovanni; Blome, Sandra			Vaccination With a Gamma Irradiation-Inactivated African Swine Fever Virus Is Safe But Does Not Protect Against a Challenge	FRONTIERS IN IMMUNOLOGY			English	Article						African swine fever virus; gamma irradiation; inactivated vaccine; adjuvant; efficiency; domestic pigs	INFECTION; IMMUNOGENICITY; ADJUVANTS; ENHANCE	African swine fever (ASF) is among the most devastating viral diseases of pigs and wild boar worldwide. In recent years, the disease has spread alarmingly. Despite intensive research activities, a commercialized vaccine is still not available, and efficacious live attenuated vaccine candidates raise safety concerns. From a safety perspective, inactivated preparations would be most favourable. However, both historical and more recent trials with chemical inactivation did not show an appreciable protective effect. Under the assumption that the integrity of viral particles could enhance presentation of antigens, we used gamma irradiation for inactivation. To this means, gamma irradiated ASFV "Estonia 2014" was adjuvanted with either Polygen (TM) or Montanide (TM) ISA 201 VG, respectively. Subsequently, five weaner pigs per preparation were immunized twice with a three-week interval. Six weeks after the first immunization, all animals were challenged with the highly virulent ASFV strain "Armenia 2008". Although ASFV p72-specific IgG antibodies were detectable in all vaccinated animals prior challenge, no protection could be observed. All animals developed an acute lethal course of ASF and had to be euthanized at a moderate humane endpoint within six days. Indeed, the vaccinated pigs showed even higher clinical scores and a higher inner body temperature than the control group. However, significantly lower viral loads were detectable in spleen and liver of immunized animals at the time point of euthanasia. This phenomenon suggests an immune mediated disease enhancement that needs further investigation.	[Pikalo, Jutta; Roszyk, Hanna; Beer, Martin; Blome, Sandra] Friedrich Loeffler Inst, Inst Diagnost Virol, Greifswald, Germany; [Porfiri, Luca; Kangethe, Richard Thiga; Wijewardana, Viskam; Cattoli, Giovanni] Int Atom Energy Agcy IAEA, Anim Prod & Hlth Lab, IAEA Labs, Joint FAO IAEA Ctr Nucl Tech Food & Agr, Seibersdorf, Austria; [Akimkin, Valerij] Off Stuttgart, Chem & Vet Invest, Fellbach, Germany; [Pannhorst, Katrin] Friedrich Loeffler Inst, Inst Mol Virol & Cell Biol, Greifswald, Germany; [Sehl-Ewert, Julia] Friedrich Loeffler Inst, Dept Expt Anim Facil & Biorisk Management, Greifswald, Germany	Friedrich Loeffler Institute; International Atomic Energy Agency; Friedrich Loeffler Institute; Friedrich Loeffler Institute	Blome, S (corresponding author), Friedrich Loeffler Inst, Inst Diagnost Virol, Greifswald, Germany.	Sandra.blome@fli.de		Kangethe, Richard/0000-0002-2598-9324				Alejo A, 2018, J VIROL, V92, DOI 10.1128/JVI.01293-18; Andres G, 2020, J BIOL CHEM, V295, P1, DOI 10.1074/jbc.AC119.011196; Andrianarivo AG, 2000, INT J PARASITOL, V30, P985, DOI 10.1016/S0020-7519(00)00088-6; Andrianarivo AG, 1999, INT J PARASITOL, V29, P1613, DOI 10.1016/S0020-7519(99)00116-2; Argilaguet JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040942; Barasona JA, 2019, FRONT VET SCI, V6, DOI 10.3389/fvets.2019.00137; Beck Z, 2008, VACCINE, V26, P3078, DOI 10.1016/j.vaccine.2007.12.028; Blome S, 2020, VIRUS RES, V287, DOI 10.1016/j.virusres.2020.198099; Blome S, 2014, VACCINE, V32, P3879, DOI 10.1016/j.vaccine.2014.05.051; Boudarkov V. A., 2016, Russian Agricultural Sciences, V42, P375, DOI 10.3103/S1068367416050025; Bouguyon E, 2015, VIRAL IMMUNOL, V28, P524, DOI 10.1089/vim.2014.0149; Cadenas-Fernandez E, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9030242; Chapman NM, 2017, VIRULENCE, V8, P643, DOI 10.1080/21505594.2016.1269048; Dar P, 2013, VACCINE, V31, P3327, DOI 10.1016/j.vaccine.2013.05.078; Fischer M, 2020, TRANSBOUND EMERG DIS, V67, P2318, DOI 10.1111/tbed.13650; Galindo-Cardiel I, 2013, VIRUS RES, V173, P180, DOI 10.1016/j.virusres.2012.12.018; Gallardo C, 2018, VACCINE, V36, P2694, DOI 10.1016/j.vaccine.2018.03.040; Halstead SB, 2014, MICROBIOL SPECTR, V2, DOI 10.1128/microbiolspec.AID-0022-2014; Huisman W, 2009, VACCINE, V27, P505, DOI 10.1016/j.vaccine.2008.10.087; Jain R, 2021, INDIAN J MED RES, V153, P196, DOI 10.4103/ijmr.IJMR_2789_20; Jancovich JK, 2018, J VIROL, V92, DOI [10.1128/JVI.02219-17, 10.1128/jvi.02219-17]; Jang SI, 2010, VET PARASITOL, V172, P221, DOI 10.1016/j.vetpar.2010.04.042; King DP, 2003, J VIROL METHODS, V107, P53, DOI 10.1016/S0166-0934(02)00189-1; Lokhandwala S, 2019, VET MICROBIOL, V235, P10, DOI 10.1016/j.vetmic.2019.06.006; MCVICAR JW, 1982, AM J VET RES, V43, P318; Milian-Suazo F, 2011, RES VET SCI, V90, P419, DOI 10.1016/j.rvsc.2010.07.018; Netherton CL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01318; Nurmoja I, 2017, TRANSBOUND EMERG DIS, V64, P2034, DOI 10.1111/tbed.12614; Oura CAL, 2005, J GEN VIROL, V86, P2445, DOI 10.1099/vir.0.81038-0; Pietschmann J, 2015, ARCH VIROL, V160, P1657, DOI 10.1007/s00705-015-2430-2; Romani N, 2012, CURR TOP MICROBIOL, V351, P113, DOI 10.1007/82_2010_118; Rubbenstroth D, 2019, TRANSBOUND EMERG DIS, V66, P552, DOI 10.1111/tbed.13065; Salehi B, 2018, ACTA MICROBIOL IMM H, V65, P163, DOI 10.1556/030.65.2018.025; Sang H, 2020, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.00084; Sastre P, 2016, BMC VET RES, V12, DOI 10.1186/s12917-016-0831-4; Sehl J, 2020, PATHOGENS, V9, DOI 10.3390/pathogens9080662; Seo HS, 2015, CLIN EXP VACCINE RES, V4, P145, DOI 10.7774/cevr.2015.4.2.145; STONE SS, 1967, AM J VET RES, V28, P475; Sun EC, 2021, SCI CHINA LIFE SCI, V64, P752, DOI 10.1007/s11427-021-1904-4; Sunwoo SY, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7010012; Tobin GJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228006; Turlewicz-Podbielska H, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071212; Ulrich H, 2020, CYTOM PART A, V97, P662, DOI 10.1002/cyto.a.24047; Ward MP, 2021, TRANSBOUND EMERG DIS, V68, P2637, DOI 10.1111/tbed.14245; Wolff J, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9010004; Zani L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24740-1	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								832264	10.3389/fimmu.2022.832264	http://dx.doi.org/10.3389/fimmu.2022.832264			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8JG	35558083	gold, Green Published			2022-12-18	WOS:000884996600001
J	Qiu, QT; Xing, LG; Wang, Y; Feng, AL; Wen, Q				Qiu, Qingtao; Xing, Ligang; Wang, Yu; Feng, Alei; Wen, Qiang			Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer	FRONTIERS IN IMMUNOLOGY			English	Article						radiomics nomogram; immune checkpoint inhibitor-related pneumonitis; radiation pneumonitis; NSCLC; differential diagnosis	DEATH 1; RADIOTHERAPY; BLOCKADE; FEATURES; INJURY	BackgroundThe combination of immunotherapy and chemoradiotherapy has become the standard therapeutic strategy for patients with unresected locally advance-stage non-small cell lung cancer (NSCLC) and induced treatment-related adverse effects, particularly immune checkpoint inhibitor-related pneumonitis (CIP) and radiation pneumonitis (RP). The aim of this study is to differentiate between CIP and RP by pretreatment CT radiomics and clinical or radiological parameters. MethodsA total of 126 advance-stage NSCLC patients with pneumonitis were enrolled in this retrospective study and divided into the training dataset (n =88) and the validation dataset (n = 38). A total of 837 radiomics features were extracted from regions of interest based on the lung parenchyma window of CT images. A radiomics signature was constructed on the basis of the predictive features by the least absolute shrinkage and selection operator. A logistic regression was applied to develop a radiomics nomogram. Receiver operating characteristics curve and area under the curve (AUC) were applied to evaluate the performance of pneumonitis etiology identification. ResultsThere was no significant difference between the training and the validation datasets for any clinicopathological parameters in this study. The radiomics signature, named Rad-score, consisting of 11 selected radiomics features, has potential ability to differentiate between CIP and RP with the empirical and alpha-binormal-based AUCs of 0.891 and 0.896. These results were verified in the validation dataset with AUC = 0.901 and 0.874, respectively. The clinical and radiological parameters of bilateral changes (p < 0.001) and sharp border (p = 0.001) were associated with the identification of CIP and RP. The nomogram model showed good performance on discrimination in the training dataset (AUC = 0.953 and 0.950) and in the validation dataset (AUC = 0.947 and 0.936). ConclusionsCT-based radiomics features have potential values for differentiating between patients with CIP and patients with RP. The addition of bilateral changes and sharp border produced superior model performance on classifying, which could be a useful method to improve related clinical decision-making.	[Qiu, Qingtao] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Phys & Technol, Jinan, Peoples R China; [Xing, Ligang] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan, Peoples R China; [Wang, Yu; Feng, Alei; Wen, Qiang] Shandong First Med Univ, Shandong Prov Hosp, Dept Radiat Oncol, Jinan, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences	Wen, Q (corresponding author), Shandong First Med Univ, Shandong Prov Hosp, Dept Radiat Oncol, Jinan, Peoples R China.	wq890425@126.com			National Natural Science Foundation of China [82001902]; Shandong Provincial Natural Science Foundation [ZR2020QH198, ZR2020QH200]; Radiation Oncology Translational Medicine Foundation for Scientific Research of Bethune [flzh202123]; Special Tumor Foundation for Scientific Research of Saifu [fszl202106]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong Provincial Natural Science Foundation(Natural Science Foundation of Shandong Province); Radiation Oncology Translational Medicine Foundation for Scientific Research of Bethune; Special Tumor Foundation for Scientific Research of Saifu	Funding This study was supported by the National Natural Science Foundation of China (grant number 82001902), Shandong Provincial Natural Science Foundation (grant numbers ZR2020QH198 and ZR2020QH200), Radiation Oncology Translational Medicine Foundation for Scientific Research of Bethune (grant number flzh202123), and the Special Tumor Foundation for Scientific Research of Saifu (grant number fszl202106). The funding sources had no role in the study design, data collection, analysis of interpretation, or writing of this manuscript.	Andruska Neal, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2018-225937; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937; Arpin D, 2005, J CLIN ONCOL, V23, P8748, DOI 10.1200/JCO.2005.01.7145; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Barabino E, 2022, CANCERS, V14, DOI 10.3390/cancers14020350; Bledsoe TJ, 2017, CLIN CHEST MED, V38, P201, DOI 10.1016/j.ccm.2016.12.004; Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0; Brahmer JR, 2018, J CLIN ONCOL, V36, P1714, DOI 10.1200/JCO.2017.77.6385; Brodersen K. H., 2010, Proceedings of the 2010 20th International Conference on Pattern Recognition (ICPR 2010), P4263, DOI 10.1109/ICPR.2010.1036; Cameron BD, 2018, RADIAT RES, V190, P99, DOI 10.1667/RR15059.1; Chen X, 2020, INT J RADIAT ONCOL, V108, pS163; Chen XG, 2021, ONCOLOGIST, V26, pE1822, DOI 10.1002/onco.13900; Cheng J, 2022, MED PHYS, V49, P1547, DOI 10.1002/mp.15451; Colen RR, 2018, INVEST NEW DRUG, V36, P601, DOI 10.1007/s10637-017-0524-2; Cong P, 2021, TRANSL CANCER RES, V10, P4375, DOI 10.21037/tcr-21-702; Du F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.596013; Ettinger DS, 2021, J NATL COMPR CANC NE, V19, P254, DOI 10.6004/jnccn.2021.0013; Gillies RJ, 2016, RADIOLOGY, V278, P563, DOI 10.1148/radiol.2015151169; Johnson DB, 2019, CLIN CANCER RES, V25, P1452, DOI 10.1158/1078-0432.CCR-18-3858; Kawahara D, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95643-x; Khunger M, 2017, CHEST, V152, P271, DOI 10.1016/j.chest.2017.04.177; Ko EC, 2018, CLIN CANCER RES, V24, P5792, DOI 10.1158/1078-0432.CCR-17-3620; Kong FM, 2006, INT J RADIAT ONCOL, V65, P1075, DOI 10.1016/j.ijrobp.2006.01.051; Li MQ, 2019, BBA-REV CANCER, V1871, P323, DOI 10.1016/j.bbcan.2019.02.004; Lin XQ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.698832; Liu LJ, 2020, AGING-US, V12, P1186, DOI 10.18632/aging.102676; Liu XL, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091181; Matsukane R, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79397-6; Michot JM, 2016, EUR J CANCER, V54, P139, DOI 10.1016/j.ejca.2015.11.016; Naidoo J, 2015, ANN ONCOL, V26, P2375, DOI 10.1093/annonc/mdv383; Naidoo J, 2017, J CLIN ONCOL, V35, P709, DOI 10.1200/JCO.2016.68.2005; Nishino M, 2016, JAMA ONCOL, V2, P1607, DOI 10.1001/jamaoncol.2016.2453; Refaee T, 2020, RESPIRATION, V99, P99, DOI 10.1159/000505429; Saito A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082460; Schoenfeld JD, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0583-3; Tabatabaei Mohsen, 2021, Iran J Med Sci, V46, P420, DOI 10.30476/ijms.2021.88036.1858; Voong KR, 2019, CLIN LUNG CANCER, V20, pE470, DOI 10.1016/j.cllc.2019.02.018; Wen Q, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.620246; Yang LF, 2019, EUR RADIOL, V29, P2196, DOI 10.1007/s00330-018-5770-y; Yang N, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-97497-9; Zhang ZF, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.774807	42	0	0	7	7	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								870842	10.3389/fimmu.2022.870842	http://dx.doi.org/10.3389/fimmu.2022.870842			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F4OF	35558076	gold, Green Published			2022-12-18	WOS:000795147300001
J	Sowa, AS; Haas, E; Huebener-Schmid, J; Lorentz, A				Sowa, Anna S.; Haas, Eva; Huebener-Schmid, Jeannette; Lorentz, Axel			Ataxin-3, The Spinocerebellar Ataxia Type 3 Neurodegenerative Disorder Protein, Affects Mast Cell Functions	FRONTIERS IN IMMUNOLOGY			English	Article						ataxin-3; MJD; SCA3; mast cell; cytokine; neurodegeneration; inflammation	NF-KAPPA-B; GENE; DISEASE; CXCL1	Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph Disease, is a progressive neurodegenerative disorder characterized by loss of neuronal matter due to the expansion of the CAG repeat in the ATXN3/MJD1 gene and subsequent ataxin-3 protein. Although the underlying pathogenic protein expansion has been known for more than 20 years, the complexity of its effects is still under exploration. The ataxin-3 protein in its expanded form is known to aggregate and disrupt cellular processes in neuronal tissue but the role of the protein on populations of immune cells is unknown. Recently, mast cells have emerged as potential key players in neuroinflammation and neurodegeneration. Here, we examined the mast cell-related effects of ataxin-3 expansion in the brain tissues of 304Q ataxin-3 knock-in mice and SCA3 patients. We also established cultures of mast cells from the 304Q knock-in mice and examined the effects of 304Q ataxin-3 knock-in on the immune responses of these cells and on markers involved in mast cell growth, development and function. Specifically, our results point to a role for expanded ataxin-3 in suppression of mast cell marker CD117/c-Kit, pro-inflammatory cytokine TNF-alpha and NF-kappa B inhibitor I kappa B alpha along with an increased expression of the granulocyte-attracting chemokine CXCL1. These results are the beginning of a more holistic understanding of ataxin-3 and could point to the development of novel therapeutic targets which act on inflammation to mitigate symptoms of SCA3.										Ashraf NS, 2020, NEUROBIOL DIS, V137, DOI 10.1016/j.nbd.2019.104697; Bolitho C, 2010, ENDOCR-RELAT CANCER, V17, P929, DOI 10.1677/ERC-10-0107; Burke SJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE131, DOI 10.1152/ajpendo.00347.2013; Chang YY, 2015, J AGR FOOD CHEM, V63, P192, DOI 10.1021/jf504013n; Chikahisa S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078434; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; Evert BO, 2003, J NEUROPATH EXP NEUR, V62, P1006, DOI 10.1093/jnen/62.10.1006; Falvo JV, 2010, CURR DIR AUTOIMMUN, V11, P27, DOI 10.1159/000289196; Feuser K, 2011, MOL IMMUNOL, V48, P546, DOI 10.1016/j.molimm.2010.10.010; Gough P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.585880; Haas E, 2022, MOL NEUROBIOL, V59, P495, DOI 10.1007/s12035-021-02610-8; Hagenlocher Y, 2017, EUR J NUTR, V56, P1609, DOI 10.1007/s00394-016-1207-z; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2014, SEMIN IMMUNOL, V26, P253, DOI 10.1016/j.smim.2014.05.004; Hendrikus E, 2017, NEUROSCI BIOBEHAV R, V83, P774, DOI 10.1016/j.neubiorev.2017.10.030; Jones MK, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00171; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Krystel-Whittemore M, 2016, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00620; Liu YC, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00637-3; Lorentz A, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00143; Matos CA, 2019, J NEUROCHEM, V148, P8, DOI 10.1111/jnc.14541; Omari KM, 2009, AM J PATHOL, V174, P164, DOI 10.2353/ajpath.2009.080350; Perez-Rodriguez MJ, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01758-9; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Skaper SD, 2014, IMMUNOLOGY, V141, P314, DOI 10.1111/imm.12170; Sowa AS, 2021, MOL BRAIN, V14, DOI 10.1186/s13041-020-00723-0; Stankov K, 2014, CURR PHARM DESIGN, V20, P2849, DOI 10.2174/13816128113199990593; Stone KD, 2010, J ALLERGY CLIN IMMUN, V125, pS73, DOI 10.1016/j.jaci.2009.11.017; Takahashi T, 2010, J MOL CELL BIOL, V2, P180, DOI 10.1093/jmcb/mjq005; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; Weber JJ, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/701758; Winborn BJ, 2008, J BIOL CHEM, V283, P26436, DOI 10.1074/jbc.M803692200	32	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								870966	10.3389/fimmu.2022.870966	http://dx.doi.org/10.3389/fimmu.2022.870966			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V2TO	35558088	gold, Green Published			2022-12-18	WOS:000805948700001
J	Taramasso, L; Bozzano, F; Casabianca, A; Orlandi, C; Bovis, F; Mora, S; Giacomini, M; Moretta, L; Magnani, M; Di Biagio, A; De Maria, A				Taramasso, Lucia; Bozzano, Federica; Casabianca, Anna; Orlandi, Chiara; Bovis, Francesca; Mora, Sara; Giacomini, Mauro; Moretta, Lorenzo; Magnani, Mauro; Di Biagio, Antonio; De Maria, Andrea			Persistence of Unintegrated HIV DNA Associates With Ongoing NK Cell Activation and CD34+DNAM-1brightCXCR4+Precursor Turnover in Vertically Infected Patients Despite Successful Antiretroviral Treatment	FRONTIERS IN IMMUNOLOGY			English	Article						HIV; reservoir; natural killer; residual replication; inflammatory precursor; CD34; ART; unintegrated HIV-DNA	NATURAL-KILLER-CELL; VIRAL REPLICATION; LATENT RESERVOIR; DECAY DYNAMICS; T-CELLS; VIRUS; THERAPY; BLOOD; CHILDREN; HISTORY	The quantification of proviral DNA is raising interest in view of clinical management and functional HIV eradication. Measures of all unintegrated HIV DNA (uDNA) forms in infected reservoir cells provides information on recent replication events that is not found from other proviral DNA assays. To evaluate its actual relevance in a cohort of perinatally-infected adult HIV patients (PHIV), we studied how peripheral blood mononuclear cell uDNA levels correlated with total HIV DNA (tDNA) and with overall replication or innate immune control parameters including NK cell activation/exhaustion and lymphoid turnover. Twenty-two PHIV were included, with successfully controlled HIV (HIV RNA <50 copies/mL) on combined antiretroviral therapy for mean of 8.7 +/- 3.9 years. uDNA accounted for 16 [5.2-83.5] copies/mu g and was strongly correlated with tDNA (rho=0.700, p=0.001). Flow cytometric analysis of peripheral NK cells showed that CD69 expression was directly correlated uDNA (p=0.0412), but not with tDNA. Interestingly, CD56(-)CD16(+)NK cells which include newly described inflammatory precursors and terminally differentiated cells were directly correlated with uDNA levels (p<0.001), but not with tDNA, and an inverse association was observed between the proportion of NKG2D(+) NK cells and uDNA (rho=-0.548, p=0.015). In addition, CD34(+)DNAM-1(bright)CXCR4(+) inflammatory precursor frequency correlated directly with uDNA levels (rho=0.579, p=0.0075). The frequencies of CD56(-)CD16(+) and CD34(+)DNAM-1(bright)CXCR4(+) cells maintained association with uDNA levels in a multivariable analysis (p=0.045 and p=0.168, respectively). Thus, control of HIV-1 reservoir in aviremic patients on ART is an active process associated with continuous NK cell intervention and turnover, even after many years of treatment. Quantification of linear and circular uDNA provides relevant information on the requirement for ongoing innate immune control in addition to ART, on recent replication history and may help stratify patients for functional HIV eradication protocols with targeted options.						Magnani, Mauro/0000-0001-6456-6626				Abdel-Mohsen M, 2020, NAT MED, V26, P1339, DOI 10.1038/s41591-020-1022-1; Alter G, 2007, J EXP MED, V204, P3027, DOI 10.1084/jem.20070695; Ananworanich J, 2016, EBIOMEDICINE, V11, P68, DOI 10.1016/j.ebiom.2016.07.024; Avettand-Fenoel V, 2021, CLIN INFECT DIS, V73, pE4214, DOI 10.1093/cid/ciaa1931; Avettand-Fenoel V, 2012, J INFECT DIS, V205, P1520, DOI 10.1093/infdis/jis233; Besson GJ, 2014, CLIN INFECT DIS, V59, P1312, DOI 10.1093/cid/ciu585; Bisio F, 2013, IMMUNOL LETT, V152, P16, DOI 10.1016/j.imlet.2013.03.003; Bozzano F, 2021, J ALLERGY CLIN IMMUN, V147, P2343, DOI 10.1016/j.jaci.2020.12.648; Bozzano F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9109; Bruner KM, 2019, NATURE, V566, P120, DOI 10.1038/s41586-019-0898-8; Casabianca A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111919; Chun TW, 2001, P NATL ACAD SCI USA, V98, P253, DOI 10.1073/pnas.98.1.253; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Contreras GA, 2016, J INFECTION, V72, P353, DOI 10.1016/j.jinf.2015.12.005; Davey RT, 1999, P NATL ACAD SCI USA, V96, P15109, DOI 10.1073/pnas.96.26.15109; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Foster C, 2021, J PEDIAT INF DIS SOC, V10, P295, DOI 10.1093/jpids/piaa071; Frenkel LM, 2003, J VIROL, V77, P5721, DOI 10.1128/JVI.77.10.5721-5730.2003; Fromentin R, 2021, SEMIN IMMUNOL, V51, DOI 10.1016/j.smim.2020.101438; Gandhi RT, 2021, J INFECT DIS, V223, P225, DOI 10.1093/infdis/jiaa532; Garcia-Broncano P, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7350; Gazzarata R, 2017, J HEALTHC ENG, V2017, DOI 10.1155/2017/2190679; Hocqueloux L, 2013, J ANTIMICROB CHEMOTH, V68, P1169, DOI 10.1093/jac/dks533; Huang SH, 2018, J CLIN INVEST, V128, P876, DOI [10.1172/jci97555, 10.1172/JCI97555]; Jones RB, 2012, AIDS RES HUM RETROV, V28, P1687, DOI [10.1089/aid.2012.0115, 10.1089/AID.2012.0115]; Katusiime MG, 2020, J VIROL, V94, DOI 10.1128/JVI.01519-19; Lau CY, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13122512; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; Lichtfuss GF, 2012, J IMMUNOL, V189, P1491, DOI 10.4049/jimmunol.1200458; Lorenzo-Redondo R, 2016, NATURE, V530, P51, DOI 10.1038/nature16933; Maldarelli F, 2016, J CLIN INVEST, V126, P438, DOI 10.1172/JCI80564; Malnati MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep42470; Marras F, 2017, J VIROL, V91, DOI 10.1128/JVI.00647-17; Marras F, 2013, P NATL ACAD SCI USA, V110, P11970, DOI 10.1073/pnas.1302090110; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Miller RL, 2019, J VIROL, V93, DOI 10.1128/JVI.00755-19; Mugavero MJ, 2011, CLIN INFECT DIS, V53, P927, DOI 10.1093/cid/cir526; Newell ML, 1996, LANCET, V347, P213, DOI 10.1016/S0140-6736(96)90401-8; O. World Health, 2014, ACC ANT DRUGS LOW MI; Orlandi C, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02368-y; Palmer S, 2008, P NATL ACAD SCI USA, V105, P3879, DOI 10.1073/pnas.0800050105; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2021, GUIDELINES USE ANTIR; Papasavvas E, 2021, CLIN INFECT DIS, V72, P495, DOI 10.1093/cid/ciaa809; Payne H, 2021, AIDS RES THER, V18, DOI 10.1186/s12981-021-00389-1; PECKHAM CS, 1991, LANCET, V337, P253; Petitjean G, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-60; Pierson TC, 2002, J VIROL, V76, P8518, DOI 10.1128/JVI.76.17.8518-8513.2002; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Sadowski I, 2019, CELL MOL LIFE SCI, V76, P3583, DOI 10.1007/s00018-019-03156-8; Sarteschi G, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0240550; Sharkey M, 2005, J VIROL, V79, P5203, DOI 10.1128/JVI.79.8.5203-5210.2005; Sloan RD, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-52; Sneller MC, 2020, J INFECT DIS, V222, P1655, DOI 10.1093/infdis/jiaa270; Stevenson EM, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142640; Surdo M, 2018, ANTIVIR RES, V160, P165, DOI 10.1016/j.antiviral.2018.10.017; Tomescu C, 2012, AIDS, V26, P1869, DOI 10.1097/QAD.0b013e32835861b0; Tremeaux P, 2019, EBIOMEDICINE, V41, P455, DOI 10.1016/j.ebiom.2019.02.016; Tsiara CG, 2012, AIDS RES HUM RETROV, V28, P366, DOI 10.1089/aid.2011.0032; Ungaro R, 2019, CLIN MICROBIOL INFEC, V25, P1443, DOI 10.1016/j.cmi.2019.07.004; Uprety P, 2015, CLIN INFECT DIS, V61, P1862, DOI 10.1093/cid/civ688; Viard JP, 2004, AIDS, V18, P45, DOI 10.1097/00002030-200401020-00005; Wang RB, 2018, AIDS, V32, P2547, DOI [10.1097/QAD.0000000000001986, 10.1097/qad.0000000000001986]; Whitney JB, 2014, NATURE, V512, P74, DOI 10.1038/nature13594; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992	64	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								847816	10.3389/fimmu.2022.847816	http://dx.doi.org/10.3389/fimmu.2022.847816			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V2VV	35558085	Green Published, gold			2022-12-18	WOS:000805954600001
J	Xu, QW; Xue, L; An, FR; Xu, H; Wang, L; Geng, LQ; Zhang, XH; Song, KD; Yao, W; Wan, X; Tong, J; Liu, HL; Liu, X; Zhu, XY; Zhai, ZM; Sun, ZM; Wang, XB				Xu, Qianwen; Xue, Lei; An, Furun; Xu, Hui; Wang, Li; Geng, Liangquan; Zhang, Xuhan; Song, Kaidi; Yao, Wen; Wan, Xiang; Tong, Juan; Liu, Huilan; Liu, Xin; Zhu, Xiaoyu; Zhai, Zhimin; Sun, Zimin; Wang, Xingbing			Impact of Consolidative Unrelated Cord Blood Transplantation on Clinical Outcomes of Patients With Relapsed/Refractory Acute B Lymphoblastic Leukemia Entering Remission Following CD19 Chimeric Antigen Receptor T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						chimeric antigen receptor (CAR); unrelated cord blood transplantation; acute B lymphoblastic leukemia; CD19; prognosis	BONE-MARROW; CAR; CHILDREN; TRIALS; THERAPY; ADULTS; MUTATIONS; SAFETY	Background: While chimeric antigen receptor (CAR)-T cell therapy is becoming widely used in hematological malignancies with remarkable remission rate, their high recurrence remains an obstacle to overcome. The role of consolidative transplantation following CAR-T cell-mediated remission remains controversial. We conducted a retrospective study to explore whether bridging to unrelated cord blood transplantation (UCBT) could improve the prognosis of patients entering remission after CAR-T therapy with different characteristics through subgroup analyses. Methods: We reviewed 53 patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) successfully infused with CD19 CAR-T cells and achieved complete remission (CR). In this study, 25 patients received consolidative UCBT (UCBT group) and 28 patients did not accept any intervention until relapse (non-UCBT group). Subgroup analysis on prognosis was then performed according to gender, age, number of previous relapses, tumor burden, presence of poor prognostic markers, and structure of CAR. Results: Compared with the non-UCBT group, patients who underwent consolidative UCBT had better median event-free survival (EFS; 12.3 months vs. 6.2 months; P = 0.035) and relapse-free survival (RFS; 22.3 months vs. 7.2 months; P = 0.046), while no significant difference was found in overall survival (05; 30.8 months vs. 15.3 months; P = 0.118). Subsequent multivariate analysis revealed that bridging to UCBT was a protective factor for RFS (P = 0.048) but had no significant effect on EFS (P = 0.205) or OS (P = 0.541). In the subgroup analysis, UCBT has an added benefit in patients with specific characteristics. Patients who experienced >= 2 relapses or with sustained non-remission (NR) showed better RFS (P = 0.025) after UCBT. Better EFS was seen in patients with poor prognostic markers (P = 0.027). In the subgroup with pre-infusion minimal residual disease (MRD) >= 5% or with extramedullary disease (EMD), UCBT significantly prolonged EFS (P = 0.009), RFS (P = 0.017), and OS (P = 0.026). Patients with occurrence of acute graft-versus-host disease (aGVHD) appeared to have a longer duration of remission (P = 0.007). Conclusion: Consolidative UCBT can, to some extent, improve clinical outcomes of patients with R/R B-ALL entering remission following CD19 CAR-T therapy, especially in patients with more recurrences before treatment, patients with poor prognostic markers, and patients with a higher tumor burden. The occurrence of aGVHD after UCBT was associated with better RFS.	[Xu, Qianwen; Xue, Lei; Xu, Hui; Wang, Li; Geng, Liangquan; Zhang, Xuhan; Song, Kaidi; Yao, Wen; Wan, Xiang; Tong, Juan; Liu, Huilan; Liu, Xin; Zhu, Xiaoyu; Sun, Zimin; Wang, Xingbing] Univ Sci & Technol China, Affiliated Hosp 1, Dept Hematol, Anhui Prov Hosp,Div Life Sci & Med,Univ Sci & Tec, Hefei, Peoples R China; [An, Furun; Zhai, Zhimin] Anhui Med Univ SHAMU, Hematol Dept, Hosp 2, Hefei, Peoples R China	Chinese Academy of Sciences; University of Science & Technology of China, CAS	Wang, XB (corresponding author), Univ Sci & Technol China, Affiliated Hosp 1, Dept Hematol, Anhui Prov Hosp,Div Life Sci & Med,Univ Sci & Tec, Hefei, Peoples R China.	wangxingbing@ustc.edu.cn			National Natural Science Foundation of China [82170221]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study received funding from the National Natural Science Foundation of China #1 under Grant 82170221. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. All authors declare no other competing interests.	Brentjens RJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005930; Cao J, 2018, AM J HEMATOL, V93, P851, DOI 10.1002/ajh.25108; Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226; Eapen M, 2007, LANCET, V369, P1947, DOI 10.1016/S0140-6736(07)60915-5; Eapen M, 2010, LANCET ONCOL, V11, P653, DOI 10.1016/S1470-2045(10)70127-3; Eyquem J, 2017, NATURE, V543, P113, DOI 10.1038/nature21405; Foa R, 2003, BRIT J HAEMATOL, V120, P484, DOI 10.1046/j.1365-2141.2003.04113.x; Forero-Castro M, 2017, BRIT J CANCER, V117, P256, DOI 10.1038/bjc.2017.152; Gardner R, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113126; Gardner R, 2016, BLOOD, V127, P2406, DOI 10.1182/blood-2015-08-665547; Gardner RA, 2017, BLOOD, V129, P3322, DOI 10.1182/blood-2017-02-769208; Ghosh A, 2017, NAT MED, V23, P242, DOI 10.1038/nm.4258; Gleissner B, 2002, BLOOD, V99, P1536, DOI 10.1182/blood.V99.5.1536; Gokbuget N, 2009, SEMIN HEMATOL, V46, P64, DOI 10.1053/j.seminhematol.2008.09.003; Grupp SA, 2013, NEW ENGL J MED, V368, P1509, DOI 10.1056/NEJMoa1215134; Guedan S, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.96976; Hamieh M, 2019, NATURE, V568, P112, DOI 10.1038/s41586-019-1054-1; Hay KA, 2019, BLOOD, V133, P1652, DOI 10.1182/blood-2018-11-883710; Huang L, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113714; Huang L, 2017, BLOOD, V130; Iqbal Z, 2015, MOL DIAGN THER, V19, P277, DOI 10.1007/s40291-015-0149-0; Jacoby E, 2018, AM J HEMATOL, V93, P1485, DOI 10.1002/ajh.25274; Jacoby E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12320; Jagasia MH, 2015, BIOL BLOOD MARROW TR, V21, P389, DOI 10.1016/j.bbmt.2014.12.001; Jiang HW, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00247-8; Jiang HW, 2019, AM J HEMATOL, V94, P1113, DOI 10.1002/ajh.25582; June CH, 2018, NEW ENGL J MED, V379, P64, DOI 10.1056/NEJMra1706169; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kebriaei P, 2016, J CLIN INVEST, V126, P3363, DOI 10.1172/JCI86721; Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140-6736(14)61403-3; Lee DW, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.218.218; Li AM, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-112572; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; Maude SL, 2014, NEW ENGL J MED, V371, P1507, DOI 10.1056/NEJMoa1407222; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Pan J, 2017, LEUKEMIA, V31, P2587, DOI 10.1038/leu.2017.145; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Rocha V, 2001, BLOOD, V97, P2962, DOI 10.1182/blood.V97.10.2962; Ruggeri A, 2017, BIOL BLOOD MARROW TR, V23, P96, DOI 10.1016/j.bbmt.2016.10.014; Schlieben S, 1996, LEUKEMIA, V10, P957; Schoemans HM, 2018, BONE MARROW TRANSPL, V53, P1401, DOI 10.1038/s41409-018-0204-7; Shadman M, 2019, BLOOD ADV, V3, P3062, DOI 10.1182/bloodadvances.2019000593; Shah BD, 2021, LANCET, V398, P491, DOI 10.1016/S0140-6736(21)01222-8; Shah NN, 2021, J CLIN ONCOL, V39, P1650, DOI 10.1200/JCO.20.02262; Shalabi H, 2018, BIOL BLOOD MARROW TR, V24, pS23, DOI 10.1016/j.bbmt.2017.12.018; Singh H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064138; Sotillo E, 2015, CANCER DISCOV, V5, P1282, DOI 10.1158/2159-8290.CD-15-1020; Sun GY, 2022, TRANSPL CELL THER, V28, DOI 10.1016/j.jtct.2021.11.011; Wang MH, 2020, NEW ENGL J MED, V382, P1331, DOI 10.1056/NEJMoa1914347; Yang JF, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-114415; Zhang HR, 2012, BIOL BLOOD MARROW TR, V18, P1164, DOI 10.1016/j.bbmt.2012.01.015; Zhang TF, 2015, ONCOTARGET, V6, P33961, DOI 10.18632/oncotarget.5582; Zhao ZG, 2015, CANCER CELL, V28, P415, DOI 10.1016/j.ccell.2015.09.004; Zhu XY, 2017, BIOL BLOOD MARROW TR, V23, P2118, DOI 10.1016/j.bbmt.2017.08.011	55	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								879030	10.3389/fimmu.2022.879030	http://dx.doi.org/10.3389/fimmu.2022.879030			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	6G8JO	35558072	gold, Green Published			2022-12-18	WOS:000884997600001
J	Yang, J; Hu, Y; Zhang, BJ; Liang, X; Li, X				Yang, Jia; Hu, Yuan; Zhang, Binjing; Liang, Xiao; Li, Xin			The JMJD Family Histone Demethylases in Crosstalk Between Inflammation and Cancer	FRONTIERS IN IMMUNOLOGY			English	Review						cancer; inflammation; cancer therapeutics; JMJD family; histone demethylases	NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA CELLS; TUMOR-ASSOCIATED MACROPHAGES; HELICOBACTER-PYLORI; GASTRIC-CANCER; COLORECTAL-CANCER; BETA-CATENIN; LONG-TERM; CYCLOOXYGENASE-2 EXPRESSION	Inflammation has emerged as a key player in regulating cancer initiation, progression, and therapeutics, acting as a double edged sword either facilitating cancer progression and therapeutic resistance or inducing anti-tumor immune responses. Accumulating evidence has linked the epigenetic modifications of histones to inflammation and cancer, and histone modifications-based strategies have shown promising therapeutic potentials against cancer. The jumonji C domain-containing (JMJD) family histone demethylases have exhibited multiple regulator functions in inflammatory processes and cancer development, and a number of therapeutic strategies targeting JMJD histone demethylases to modulate inflammatory cells and their products have been successfully evaluated in clinical or preclinical tumor models. This review summarizes current understanding of the functional roles and mechanisms of JMJD histone demethylases in crosstalk between inflammation and cancer, and highlights recent clinical and preclinical progress on harnessing the JMJD histone demethylases to regulate cancer-related inflammation for future cancer therapeutics.	[Yang, Jia; Hu, Yuan; Liang, Xiao] Sichuan Univ, West China Hosp 2, Dept Gynecol & Obstet & Pediat Nephrol Nursing, Dev & Related Dis Women & Children Key Lab Sichuan, Chengdu, Peoples R China; [Zhang, Binjing; Li, Xin] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu, Peoples R China	Sichuan University; Sichuan University	Liang, X (corresponding author), Sichuan Univ, West China Hosp 2, Dept Gynecol & Obstet & Pediat Nephrol Nursing, Dev & Related Dis Women & Children Key Lab Sichuan, Chengdu, Peoples R China.; Li, X (corresponding author), Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu, Peoples R China.	xiaoliang9101@163.com; lixin0914071@126.com		liang, xiao/0000-0003-0330-7027	National Natural Science Foundation of China [81903033, 81902662, 81821002]; Sichuan Science and Technology Program [2021YJ0011]; Basic research project of Nursing Department of West China Second Hospital [HLBKJ202126]; Foundation of Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province [2022003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Sichuan Science and Technology Program; Basic research project of Nursing Department of West China Second Hospital; Foundation of Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province	This study was funded by grants from the National Natural Science Foundation of China (No. 81903033), the National Natural Science Foundation of China (No. 81902662), the National Natural Science Foundation of China (No. 81821002), Sichuan Science and Technology Program 2021YJ0011. This study was also supported by the Basic research project of Nursing Department of West China Second Hospital (HLBKJ202126) and Foundation of Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province (Grant No.2022003).	Allemani C, 2018, LANCET, V391, P1023, DOI 10.1016/S0140-6736(17)33326-3; Allis CD, 2016, NAT REV GENET, V17, P487, DOI 10.1038/nrg.2016.59; Arcipowski KM, 2016, CURR OPIN GENET DEV, V36, P59, DOI 10.1016/j.gde.2016.03.010; Atretkhany KSN, 2016, PHARMACOL THERAPEUT, V168, P98, DOI 10.1016/j.pharmthera.2016.09.011; Bahri R, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.1002721; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Baxter NN, 2005, GASTROENTEROLOGY, V128, P819, DOI 10.1053/j.gastro.2004.12.038; Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300; Bhavsar AP, 2007, NATURE, V449, P827, DOI 10.1038/nature06247; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bronte-Tinkew DM, 2009, CANCER RES, V69, P632, DOI 10.1158/0008-5472.CAN-08-1191; Butz H, 2012, TRENDS PHARMACOL SCI, V33, P382, DOI 10.1016/j.tips.2012.04.003; Cantacorps L, 2019, J PSYCHOPHARMACOL, V33, P1562, DOI 10.1177/0269881119856001; Cao Z, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03354-4; Carbia-Nagashima A, 2007, CELL, V131, P309, DOI 10.1016/j.cell.2007.07.044; Cascante A, 2014, J MOL BIOL, V426, P3467, DOI 10.1016/j.jmb.2014.04.008; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Chang YJ, 2005, J IMMUNOL, V175, P8242, DOI 10.4049/jimmunol.175.12.8242; Chen WQ, 2015, CHINESE J CANCER RES, V27, P1, DOI 10.3978/j.issn.1000-9604.2015.02.07; Cho SO, 2010, DIGEST DIS SCI, V55, P988, DOI 10.1007/s10620-009-0828-y; Chou J, 2013, CELL CYCLE, V12, P3262, DOI 10.4161/cc.26087; Chua ACG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078850; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Couture JF, 2006, CURR OPIN STRUC BIOL, V16, P753, DOI 10.1016/j.sbi.2006.10.002; Das ND, 2013, NEUROTOX RES, V23, P154, DOI 10.1007/s12640-012-9346-3; Das ND, 2012, CELL BIOCHEM FUNCT, V30, P224, DOI 10.1002/cbf.1839; Das PP, 2014, MOL CELL, V53, P32, DOI 10.1016/j.molcel.2013.11.011; De Angulo A, 2015, PROSTATE, V75, P449, DOI 10.1002/pros.22931; de la Chapelle A, 2004, NAT REV CANCER, V4, P769, DOI 10.1038/nrc1453; De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271; Melo FDE, 2016, CANCERS, V8, DOI 10.3390/cancers8070060; Del Rizzo PA, 2012, MOL CELL BIOL, V32, P4044, DOI 10.1128/MCB.00513-12; Ding SZ, 2010, FUTURE ONCOL, V6, P851, DOI [10.2217/fon.10.37, 10.2217/FON.10.37]; Ernst PB, 2006, GASTROENTEROLOGY, V130, P188, DOI 10.1053/j.gastro.2005.06.032; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Franco AT, 2005, P NATL ACAD SCI USA, V102, P10646, DOI 10.1073/pnas.0504927102; Fu LN, 2012, CARCINOGENESIS, V33, P1664, DOI 10.1093/carcin/bgs217; Fu XT, 2015, INT J ONCOL, V46, P587, DOI 10.3892/ijo.2014.2761; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Giglia MD, 2016, CLIN COLON RECT SURG, V29, P185, DOI 10.1055/s-0036-1584290; Gnad T, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-31; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Han FJ, 2016, ONCOTARGET, V7, P38626, DOI 10.18632/oncotarget.9573; Hann HW, 2014, CANCER MED-US, V3, P390, DOI 10.1002/cam4.197; Harpel K, 2016, PHYS MED BIOL, V61, pN60, DOI 10.1088/0031-9155/61/3/N60; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Henderson TO, 2012, ANN INTERN MED, V156, P757, DOI 10.7326/0003-4819-156-11-201206050-00002; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Herszenyi L, 2015, DIGEST DIS, V33, P52, DOI 10.1159/000368447; Hino S, 2016, CANCER SCI, V107, P1187, DOI 10.1111/cas.13004; Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104; Houghton J, 2005, GASTROENTEROLOGY, V128, P1567, DOI 10.1053/j.gastro.2005.03.037; Hsieh IY, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109728; Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116; Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155; Kamikawa YF, 2014, EPIGENETICS-US, V9, P834, DOI 10.4161/epi.28524; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Katoh M, 2004, INT J ONCOL, V24, P1623; Kawazu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017830; Khoury-Haddad H, 2014, P NATL ACAD SCI USA, V111, pE728, DOI 10.1073/pnas.1317585111; Kim JG, 2012, BBA-GENE REGUL MECH, V1819, P1200, DOI 10.1016/j.bbagrm.2012.10.001; Kim TD, 2014, AM J TRANSL RES, V6, P236; Kim TD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034618; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041; Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Kouwaki T, 2016, J VIROL, V90, P3530, DOI 10.1128/JVI.02776-15; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lawrence M, 2016, TRENDS GENET, V32, P42, DOI 10.1016/j.tig.2015.10.007; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Leurs U, 2012, BIOORG MED CHEM LETT, V22, P5811, DOI 10.1016/j.bmcl.2012.07.091; Lhuissier E, 2019, IUBMB LIFE, V71, P1711, DOI 10.1002/iub.2110; Li WJ, 2011, BIOCHEM BIOPH RES CO, V416, P372, DOI 10.1016/j.bbrc.2011.11.045; Li XJ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0503-4; Liang X, 2022, CANCER COMMUN, V42, P205, DOI 10.1002/cac2.12272; Lim HY, 2000, CLIN CANCER RES, V6, P519; Lin MT, 2005, CLIN CANCER RES, V11, P5809, DOI 10.1158/1078-0432.CCR-04-2639; Lippitz BE, 2013, LANCET ONCOL, V14, pE218, DOI 10.1016/S1470-2045(12)70582-X; Liu Y, 2014, CELL MOL IMMUNOL, V11, P49, DOI [10.1038/cmi.2013.40, 10.1038/cmi.2014.83]; Liu YX, 2013, GUT, V62, P571, DOI 10.1136/gutjnl-2011-301059; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Loh YH, 2007, GENE DEV, V21, P2545, DOI 10.1101/gad.1588207; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Markolovic S, 2016, CURR OPIN STRUC BIOL, V41, P62, DOI 10.1016/j.sbi.2016.05.013; Markolovic S, 2015, J BIOL CHEM, V290, P20712, DOI 10.1074/jbc.R115.662627; Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761; McNeill LA, 2002, BIOCHEM J, V367, P571, DOI 10.1042/BJ20021162; Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294; Nagy TA, 2009, J INFECT DIS, V199, P641, DOI 10.1086/596660; Naito Y, 2017, CELL MOL LIFE SCI, V74, P697, DOI 10.1007/s00018-016-2346-3; Nardone G, 2007, DIGEST DIS, V25, P225, DOI 10.1159/000103890; Naylor GM, 2006, GUT, V55, P1545, DOI 10.1136/gut.2005.080358; Neveu B, 2014, RES REP UROL, V6, P27, DOI 10.2147/RRU.S58643; Nickoloff BJ, 2005, J INVEST DERMATOL, V124, pX, DOI 10.1111/j.0022-202X.2005.23724.x; Nighot Prashant, 2021, Inflamm Bowel Dis, V27, P283, DOI 10.1093/ibd/izaa141; Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605; Ocker M, 2019, CANCERS, V11, DOI 10.3390/cancers11091343; Park MH, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020015; Peek RM, 2006, J PATHOL, V208, P233, DOI 10.1002/path.1868; Peeters PJHL, 2015, DIABETES CARE, V38, P495, DOI 10.2337/dc14-1175; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Plath K, 2003, SCIENCE, V300, P131, DOI 10.1126/science.1084274; Polakis P, 2000, GENE DEV, V14, P1837; Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238; Punturieri A, 2009, JNCI-J NATL CANCER I, V101, P554, DOI 10.1093/jnci/djp023; Radaeva S, 2004, HEPATOLOGY, V39, P1332, DOI 10.1002/hep.20184; Raghuraman S, 2016, TRENDS ENDOCRIN MET, V27, P782, DOI 10.1016/j.tem.2016.06.008; Reulen RC, 2011, JAMA-J AM MED ASSOC, V305, P2311, DOI 10.1001/jama.2011.747; Rius J, 2008, NATURE, V453, P807, DOI 10.1038/nature06905; Rodriguez C, 2008, CELL SIGNAL, V20, P1625, DOI 10.1016/j.cellsig.2008.05.008; Rose NR, 2010, J MED CHEM, V53, P1810, DOI 10.1021/jm901680b; Saccani A, 2006, CANCER RES, V66, P11432, DOI 10.1158/0008-5472.CAN-06-1867; Sansone P, 2011, CURR OPIN GENET DEV, V21, P80, DOI 10.1016/j.gde.2010.11.001; Scanlon SE, 2015, DNA REPAIR, V32, P180, DOI 10.1016/j.dnarep.2015.04.030; Sherry-Lynes MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174775; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027; Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; Srinivasan T, 2016, CANCER RES, V76, P3411, DOI 10.1158/0008-5472.CAN-15-3198; Sun LL, 2013, AM J CANCER RES, V3, P509; Sun XX, 2015, CELL CYCLE, V14, P243, DOI 10.4161/15384101.2014.977112; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Suzuki T, 2018, HEPATOL COMMUN, V2, P571, DOI 10.1002/hep4.1175; Swigut T, 2007, CELL, V131, P29, DOI 10.1016/j.cell.2007.09.026; Tabassam FH, 2009, CELL MICROBIOL, V11, P70, DOI 10.1111/j.1462-5822.2008.01237.x; Takahashi Ken, 2013, Journal of UOEH, V35, P121; Takeuch O, 2011, EUR J IMMUNOL, V41, P2490, DOI 10.1002/eji.201141792; Tan HD, 2008, MOL BIOL REP, V35, P551, DOI 10.1007/s11033-007-9121-3; Thiel A, 2011, CANCER METAST REV, V30, P387, DOI 10.1007/s10555-011-9312-1; Tokunaga R, 2016, ANN SURG ONCOL, V23, P678, DOI 10.1245/s10434-015-4879-3; Toyokawa G, 2011, CANCER PREV RES, V4, P2051, DOI 10.1158/1940-6207.CAPR-11-0290; Travis LB, 2005, JNCI-J NATL CANCER I, V97, P1354, DOI 10.1093/jnci/dji278; Trewick SC, 2005, EMBO REP, V6, P315, DOI 10.1038/sj.embor.7400379; Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008; Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433; Tu T, 2017, BIOL CHEM, V398, P817, DOI 10.1515/hsz-2017-0118; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; van Kempen LCLT, 2003, EUR J CELL BIOL, V82, P539, DOI 10.1078/0171-9335-00346; Waldner MJ, 2014, SEMIN IMMUNOL, V26, P75, DOI 10.1016/j.smim.2013.12.003; Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614; Wang DZ, 2013, ANNU REV MED, V64, P131, DOI 10.1146/annurev-med-112211-154330; Wang HP, 2013, ACTA CRYSTALLOGR D, V69, P1911, DOI 10.1107/S0907444913016600; Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035; Wang XM, 2018, CYTOKINE, V111, P230, DOI 10.1016/j.cyto.2018.08.024; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wolf AMD, 2018, CA-CANCER J CLIN, V68, P250, DOI 10.3322/caac.21457; Wu BH, 2016, ONCOTARGET, V7, P6847, DOI 10.18632/oncotarget.6867; Wu RT, 2017, NUCLEIC ACIDS RES, V45, P169, DOI 10.1093/nar/gkw848; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83; Yamac D, 2008, PATHOL RES PRACT, V204, P527, DOI 10.1016/j.prp.2008.01.002; Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174; Yan Q, 2014, CELL SIGNAL, V26, P1783, DOI 10.1016/j.cellsig.2014.03.025; Yang J, 2010, CANCER RES, V70, P6456, DOI 10.1158/0008-5472.CAN-10-0413; Yang XS, 2014, MOL ENDOCRINOL, V28, P565, DOI 10.1210/me.2013-1293; Yang ZQ, 2000, CANCER RES, V60, P4735; Yasmin R, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/201703; Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009; Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794; Yu SQ, 2017, BIOCHEM BIOPH RES CO, V485, P62, DOI 10.1016/j.bbrc.2017.02.020; Zhang JB, 2020, THERANOSTICS, V10, P10016, DOI 10.7150/thno.47081; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053; Zhao L, 2013, CLIN CANCER RES, V19, P6419, DOI 10.1158/1078-0432.CCR-13-0254; Zhuo MH, 2020, ONCOGENE, V39, P3336, DOI 10.1038/s41388-020-1219-2; Zoabi M, 2014, NUCLEIC ACIDS RES, V42, P13026, DOI 10.1093/nar/gku1021	184	0	0	9	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								881396	10.3389/fimmu.2022.881396	http://dx.doi.org/10.3389/fimmu.2022.881396			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1F3UZ	35558079	Green Published, gold			2022-12-18	WOS:000795097300001
J	Zhou, JJ; Blevins, LK; Crawford, RB; Kaminski, NE				Zhou, Jiajun; Blevins, Lance K.; Crawford, Robert B.; Kaminski, Norbert E.			Role of Programmed Cell Death Protein-1 and Lymphocyte Specific Protein Tyrosine Kinase in the Aryl Hydrocarbon Receptor- Mediated Impairment of the IgM Response in Human CD5(+) Innate-Like B Cells	FRONTIERS IN IMMUNOLOGY			English	Article						Lck; AhR (aryl hydrocarbon receptor); PD1 (programmed cell death protein 1); innate-like B cells; IFNgamma; IgM; TCDD	INTERFERON-GAMMA PRODUCTION; IFN-GAMMA; T-CELLS; PD-L1 EXPRESSION; B-1 CELLS; MOLECULAR-MECHANISMS; NEGATIVE REGULATOR; MESSENGER-RNA; BONE-MARROW; IN-VIVO	Innate-like B cells (ILBs) are a heterogeneous population B cells which participate in innate and adaptive immune responses. This diverse subset of B cells is characterized by the expression of CD5 and has been shown to secrete high levels of immunoglobulin M (IgM) in the absence of infection or vaccination. Further, CD5(+) ILBs have been shown to express high basal levels of lymphocyte specific protein tyrosine kinase (LCK) and programmed cell death protein-1 (PD-1), which are particularly sensitive to stimulation by interferon gamma (IFN gamma). Previous studies have demonstrated that activation of the aryl hydrocarbon receptor (AHR), a cytosolic ligand-activated transcription factor, results in suppressed IgM responses and is dependent on LCK. A recent study showed that CD5(+) ILBs are particularly sensitive to AHR activation as evidenced by a significant suppression of the IgM response compared to CD5(-) B cells, which were refractory. Therefore, the objective of this study was to further investigate the role of LCK and PD-1 signaling in AHR-mediated suppression of CD5(+) ILBs. In addition, studies were conducted to establish whether IFN gamma alters the levels of LCK and PD-1 in CD5(+) ILBs. We found that AHR activation led to a significant upregulation of total LCK and PD-1 proteins in CD5(+) ILBs, which correlated with suppression of IgM. Interestingly, treatment with recombinant IFN gamma reduced LCK protein levels and reversed AHR-mediated IgM suppression in CD5(+) ILBs in a similar manner as LCK inhibitors. Collectively, these results support a critical role for LCK and PD-1 in AHR-mediated suppression of the IgM response in human CD5(+) ILBs.							NIH [P42 ES004911]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding The work was supported by NIH grant P42 ES004911.	Abbott BD, 1999, TOXICOL SCI, V47, P62, DOI 10.1093/toxsci/47.1.62; ABED NS, 1994, J IMMUNOL, V153, P3369; Abiko K, 2015, BRIT J CANCER, V112, P1501, DOI 10.1038/bjc.2015.101; Arasanz H, 2017, ONCOTARGET, V8, P51936, DOI 10.18632/oncotarget.17232; Arase H, 1996, J EXP MED, V183, P2391, DOI 10.1084/jem.183.5.2391; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bao Y, 2014, CELL RES, V24, P161, DOI 10.1038/cr.2013.155; Barouki R, 2007, FEBS LETT, V581, P3608, DOI 10.1016/j.febslet.2007.03.046; Baumgarth N, 2000, J EXP MED, V192, P271, DOI 10.1084/jem.192.2.271; Baumgarth N, 2017, J IMMUNOL, V199, P3387, DOI 10.4049/jimmunol.1700943; Baumgarth N, 2013, ADV EXP MED BIOL, V785, P57, DOI 10.1007/978-1-4614-6217-0_7; Blevins LK, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.635748; Blevins LK, 2020, CELL SIGNAL, V65, DOI 10.1016/j.cellsig.2019.109447; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Cheong JE, 2018, TRENDS PHARMACOL SCI, V39, P307, DOI 10.1016/j.tips.2017.11.007; Choi YS, 2012, EUR J IMMUNOL, V42, P120, DOI 10.1002/eji.201141890; Dal Porto JM, 2004, IMMUNITY, V21, P443, DOI 10.1016/j.immuni.2004.07.018; Dong YN, 2017, ONCOTARGET, V8, P2171, DOI 10.18632/oncotarget.13895; Efremov DG, 2007, AUTOIMMUN REV, V7, P102, DOI 10.1016/j.autrev.2007.02.021; FERNANDEZSALGUERO P, 1995, SCIENCE, V268, P722, DOI 10.1126/science.7732381; Fukushima A, 2002, BRIT J OPHTHALMOL, V86, P1166, DOI 10.1136/bjo.86.10.1166; Gagro A, 2000, IMMUNOLOGY, V101, P201, DOI 10.1046/j.1365-2567.2000.00098.x; Garcia-Diaz A, 2017, CELL REP, V19, P1189, DOI 10.1016/j.celrep.2017.04.031; Ghanekar SA, 2001, CLIN DIAGN LAB IMMUN, V8, P628, DOI 10.1128/CDLI.8.3.628-631.2001; Grasseau A, 2020, CLIN REV ALLERG IMMU, V58, P92, DOI 10.1007/s12016-019-08748-7; Griffin DO, 2011, J EXP MED, V208, P67, DOI 10.1084/jem.20101499; Haas KM, 2011, J IMMUNOL, V187, P5183, DOI 10.4049/jimmunol.1101990; Halminen M, 1997, SCAND J IMMUNOL, V46, P388, DOI 10.1046/j.1365-3083.1997.d01-144.x; Haro MA, 2016, CANCER IMMUNOL RES, V4, P1027, DOI 10.1158/2326-6066.CIR-16-0184; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; Haury M, 1997, EUR J IMMUNOL, V27, P1557, DOI 10.1002/eji.1830270635; HOLSAPPLE MP, 1986, IMMUNOPHARMACOLOGY, V12, P175, DOI 10.1016/0162-3109(86)90001-9; Horvath Curt M, 2004, Sci STKE, V2004, ptr10, DOI 10.1126/stke.2602004tr10; Hui EF, 2014, NAT STRUCT MOL BIOL, V21, P133, DOI 10.1038/nsmb.2762; Kearney JF, 2015, ANNU REV IMMUNOL, V33, P475, DOI 10.1146/annurev-immunol-032713-120140; Kortylewski M, 2004, J INVEST DERMATOL, V122, P414, DOI 10.1046/j.0022-202X.2004.22237.x; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Li J, 2015, CANCER RES, V75, P508, DOI 10.1158/0008-5472.CAN-14-1215; Li JP, 2017, J IMMUNOL, V199, P3504, DOI 10.4049/jimmunol.1700289; Li JP, 2017, TOXICOLOGY, V378, P17, DOI 10.1016/j.tox.2016.12.010; Lu HT, 2011, TOXICOL APPL PHARM, V255, P251, DOI 10.1016/j.taap.2011.06.026; Majolini MB, 1998, BLOOD, V91, P3390, DOI 10.1182/blood.V91.9.3390.3390_3390_3396; McKay JT, 2017, J IMMUNOL, V199, P2020, DOI 10.4049/jimmunol.1700555; Mckay JT, 2015, J IMMUNOL, V194, P2289, DOI 10.4049/jimmunol.1401673; Mimura K, 2018, CANCER SCI, V109, P43, DOI 10.1111/cas.13424; Nguyen NT, 2013, INT IMMUNOL, V25, P335, DOI 10.1093/intimm/dxt011; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Nika K, 2010, IMMUNITY, V32, P766, DOI 10.1016/j.immuni.2010.05.011; Nishimura H, 1998, INT IMMUNOL, V10, P1563, DOI 10.1093/intimm/10.10.1563; North CM, 2010, TOXICOL SCI, V116, P99, DOI 10.1093/toxsci/kfq095; North CM, 2009, TOXICOL SCI, V107, P85, DOI 10.1093/toxsci/kfn223; NOVELLI F, 1994, J IMMUNOL, V152, P496; Panjwani PK, 2018, HUM PATHOL, V71, P91, DOI 10.1016/j.humpath.2017.10.029; Phadnis-Moghe AS, 2016, TOXICOL APPL PHARM, V310, P41, DOI 10.1016/j.taap.2016.08.014; Phadnis-Moghe AS, 2015, TOXICOL SCI, V144, P39, DOI 10.1093/toxsci/kfu257; Poeck H, 2010, NAT IMMUNOL, V11, P63, DOI 10.1038/ni.1824; Prasad DVR, 2004, J IMMUNOL, V173, P2500, DOI 10.4049/jimmunol.173.4.2500; Pritchard NR, 2003, IMMUNOLOGY, V108, P263, DOI 10.1046/j.1365-2567.2003.01592.x; Romero-Ramirez S, 2019, J LEUKOCYTE BIOL, V105, P843, DOI 10.1002/JLB.MR0618-227R; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Safe S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186654; Schmidt JV, 1996, P NATL ACAD SCI USA, V93, P6731, DOI 10.1073/pnas.93.13.6731; Seifert M, 2012, J EXP MED, V209, P2183, DOI 10.1084/jem.20120833; Sheppard KA, 2004, FEBS LETT, V574, P37, DOI 10.1016/j.febslet.2004.07.083; Shi XS, 2013, NATURE, V493, P111, DOI 10.1038/nature11699; Smith BW, 2013, BLOOD, V122, P376, DOI 10.1182/blood-2012-11-466722; Sorg O, 2014, TOXICOL LETT, V230, P225, DOI 10.1016/j.toxlet.2013.10.039; Suh WK, 2003, NAT IMMUNOL, V4, P899, DOI 10.1038/ni967; Sulentic CEW, 2011, TOXICOL SCI, V120, pS171, DOI 10.1093/toxsci/kfq324; Sun JB, 2015, CELL REP, V13, P1110, DOI 10.1016/j.celrep.2015.09.070; Talab F, 2013, MOL CANCER RES, V11, P541, DOI 10.1158/1541-7786.MCR-12-0415-T; Thurmond TS, 2000, TOXICOL APPL PHARM, V165, P227, DOI 10.1006/taap.2000.8942; Till KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17021-w; Tsay GJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01064; Villa M, 2017, EMBO J, V36, P116, DOI 10.15252/embj.201695027; Wang Gui-Zhen, 2019, Nat Commun, V10, P1125, DOI 10.1038/s41467-019-08887-7; Wlasiuk P, 2016, CLIN EXP MED, V16, P503, DOI 10.1007/s10238-015-0385-y; YANG Y, 1992, P NATL ACAD SCI USA, V89, P4928, DOI 10.1073/pnas.89.11.4928; Zhang XM, 2013, CELL MOL IMMUNOL, V10, P113, DOI 10.1038/cmi.2012.63; Zhou F, 2009, INT REV IMMUNOL, V28, P239, DOI 10.1080/08830180902978120; Zhou JJ, 2018, TOXICOL SCI, V165, P322, DOI 10.1093/toxsci/kfy133; Zhou JJ, 2018, TOXICOL SCI, V163, P319, DOI 10.1093/toxsci/kfy036	82	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 26	2022	13								884203	10.3389/fimmu.2022.884203	http://dx.doi.org/10.3389/fimmu.2022.884203			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V2UK	35558082	Green Published, gold			2022-12-18	WOS:000805950900001
J	Casasnovas, JM; Margolles, Y; Noriega, MA; Guzman, M; Arranz, R; Melero, R; Casanova, M; Corbera, JA; Jimenez-de-Oya, N; Gastaminza, P; Garaigorta, U; Saiz, JC; Martin-Acebes, MA; Fernandez, LA				Casasnovas, Jose M.; Margolles, Yago; Noriega, Maria A.; Guzman, Maria; Arranz, Rocio; Melero, Roberto; Casanova, Mercedes; Corbera, Juan Alberto; Jimenez-de-Oya, Nereida; Gastaminza, Pablo; Garaigorta, Urtzi; Saiz, Juan Carlos; Martin-Acebes, Miguel Angel; Fernandez, Luis Angel			Nanobodies Protecting From Lethal SARS-CoV-2 Infection Target Receptor Binding Epitopes Preserved in Virus Variants Other Than Omicron	FRONTIERS IN IMMUNOLOGY			English	Article						coronavirus; COVID-19; nanobodies; neutralizing antibodies; SARS-CoV-2 variants	SINGLE-DOMAIN ANTIBODIES; NEUTRALIZES SARS-COV-2; SPIKE; CORONAVIRUS; GENERATION; MUTATIONS; VERSATILE; ACE2; RBD	The emergence of SARS-CoV-2 variants that escape from immune neutralization are challenging vaccines and antibodies developed to stop the COVID-19 pandemic. Thus, it is important to establish therapeutics directed toward multiple or specific SARS-CoV-2 variants. The envelope spike (S) glycoprotein of SARS-CoV-2 is the key target of neutralizing antibodies (Abs). We selected a panel of nine nanobodies (Nbs) from dromedary camels immunized with the receptor-binding domain (RBD) of the S, and engineered Nb fusions as humanized heavy chain Abs (hcAbs). Nbs and derived hcAbs bound with subnanomolar or picomolar affinities to the S and its RBD, and S-binding cross-competition clustered them in two different groups. Most of the hcAbs hindered RBD binding to its human ACE2 (hACE2) receptor, blocked cell entry of viruses pseudotyped with the S protein and neutralized SARS-CoV-2 infection in cell cultures. Four potent neutralizing hcAbs prevented the progression to lethal SARS-CoV-2 infection in hACE2-transgenic mice, demonstrating their therapeutic potential. Cryo-electron microscopy identified Nb binding epitopes in and out the receptor binding motif (RBM), and showed different ways to prevent virus binding to its cell entry receptor. The Nb binding modes were consistent with its recognition of SARS-CoV-2 RBD variants; mono and bispecific hcAbs efficiently bound all variants of concern except omicron, which emphasized the immune escape capacity of this latest variant.	[Casasnovas, Jose M.; Margolles, Yago; Noriega, Maria A.; Guzman, Maria; Arranz, Rocio; Melero, Roberto; Casanova, Mercedes; Gastaminza, Pablo; Garaigorta, Urtzi; Fernandez, Luis Angel] CSIC, Ctr Nacl Biotecnol, Dept Macromol Struct, Microbial Biotechnol & Cellular & Mol Biol,CNB CSI, Madrid, Spain; [Corbera, Juan Alberto] Univ Palmas Gran Canaria ULPGC, Inst Univ Invest Biomed & Sanitaria IUIBS, Fac Vet, Campus Univ Arucas, Arucas, Spain; [Jimenez-de-Oya, Nereida; Saiz, Juan Carlos; Martin-Acebes, Miguel Angel] CSIC, Dept Biotechnol, Inst Nacl Invest & TecnologiaAgraria & Alimentaria, INIA,CSIC, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC)	Casasnovas, JM; Fernandez, LA (corresponding author), CSIC, Ctr Nacl Biotecnol, Dept Macromol Struct, Microbial Biotechnol & Cellular & Mol Biol,CNB CSI, Madrid, Spain.	jcasasnovas@cnb.csic.es; lafdez@cnb.csic.es	Jiménez de Oya, Nereida/K-8470-2016; Corbera, Juan Alberto/K-2289-2014; Fernández-Herrero, Luis Ángel/AAA-2583-2021; Fernández, Luis Ángel/D-2713-2009; Garaigorta, Urtzi/E-3268-2016	Jiménez de Oya, Nereida/0000-0003-3129-813X; Corbera, Juan Alberto/0000-0001-7812-2065; Fernández-Herrero, Luis Ángel/0000-0001-5920-0638; Fernández, Luis Ángel/0000-0001-5920-0638; Garaigorta, Urtzi/0000-0002-0683-5725	Ministerio de Ciencia e Innovacion (MICIN); Spanish Research Council (CSIC) [202020E079, SGL 2103051, SGL 2103053]; NextGeneration EU funds from the European Union; European Virus Archive Global (EVag) of the European Union's Horizon 2020 research and innovation programme [871029]; EU-FEDER CRIOMECORR project [ESFRI-2019-01-CSIC-16]; Instruct Image Processing Center (I2PC) [PID16168, PID14989]	Ministerio de Ciencia e Innovacion (MICIN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Spanish Research Council (CSIC); NextGeneration EU funds from the European Union; European Virus Archive Global (EVag) of the European Union's Horizon 2020 research and innovation programme; EU-FEDER CRIOMECORR project; Instruct Image Processing Center (I2PC)	This work was partially funded by Ministerio de Ciencia e Innovacio ' n (MICIN; https://www.ciencia.gob.es/) and the Spanish Research Council (CSIC; https://www.csic.es/) under grants PIE-RD-COVID 19 (No 202020E079) and PTI+ Salud Global REC_EU (No SGL 2103051, NextGenerationEU) to LF, JMC, PG, and UG, and (No SGL 2103053, NextGenerationEU) to MM-A. This study was partially conducted within the CSIC Antiviral Screening Network, an infrastructure supported by NextGeneration EU funds (https://ec.europa.eu/info/strategy/recovery-plan-europe_es) from the European Union and the European Virus Archive Global (EVag) of the European Union's Horizon 2020 (https://ec.europa.eu/programmes/horizon2020/en/home) research and innovation programme (No 871029) to PG and UG. EM facilities of CNB-CSIC were supported by Ministerio de Ciencia e Innovacion (MICIN; https://www.ciencia.gob.es/), EU-FEDER (https://ec.europa.eu/regional_ policy/es/funding/erdf/) CRIOMECORR project (ESFRI-2019-01-CSIC-16). JMC access to the European Synchrotron Radiation Facility (ESRF) CM01 line through the Iberian-BAG, and to the Instruct Image Processing Center (I2PC, http://i2pc.es/) by projects PID16168 and PID14989. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnes CO, 2020, NATURE, V588, P682, DOI 10.1038/s41586-020-2852-1; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Corti D, 2021, CELL, V184, P3086, DOI [10.1016/j.cell.2021.07.027, 10.1016/j.cell.2021.05.005]; De Genst E, 2006, P NATL ACAD SCI USA, V103, P4586, DOI 10.1073/pnas.0505379103; de la Rosa-Trevin JM, 2016, J STRUCT BIOL, V195, P93, DOI 10.1016/j.jsb.2016.04.010; De Vlieger D, 2018, ANTIBODIES, V8, DOI 10.3390/antib8010001; Dong JB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74761-y; Garcia-Arriaza J, 2021, J VIROL, V95, DOI 10.1128/JVI.02260-20; Gonzalez-Sapienza G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00977; Greaney Allison J, 2020, bioRxiv, DOI [10.1016/j.chom.2020.11.007, 10.1101/2020.09.10.292078]; Guttler T, 2021, EMBO J, V40, DOI 10.15252/embj.2021107985; Hanke Leo, 2020, Nat Commun, V11, P4420, DOI 10.1038/s41467-020-18174-5; Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0; Hastie KM, 2021, SCIENCE, V374, P472, DOI 10.1126/science.abh2315; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hsieh Ching-Lin, 2020, Science, V369, P1501, DOI [10.1101/2020.05.30.125484, 10.1126/science.abd0826]; Johnson BA, 2021, NATURE, V591, P293, DOI 10.1038/s41586-021-03237-4; Jovcevska I, 2020, BIODRUGS, V34, P11, DOI 10.1007/s40259-019-00392-z; Ke ZL, 2020, NATURE, V588, P498, DOI 10.1038/s41586-020-2665-2; Khan A, 2021, J CELL PHYSIOL, V236, P7045, DOI 10.1002/jcp.30367; Koenig PA, 2021, SCIENCE, V371, P691, DOI 10.1126/science.abe6230; Konings F, 2021, NAT MICROBIOL, V6, P821, DOI 10.1038/s41564-021-00932-w; Kumar S, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009885; Li F, 2012, J VIROL, V86, P2856, DOI 10.1128/JVI.06882-11; Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471; Lu QZ, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00768-w; Mannar D, 2022, SCIENCE, V375, P760, DOI 10.1126/science.abn7760; Martinez-Fleta P, 2020, J IMMUNOL, V205, P3130, DOI 10.4049/jimmunol.2000842; McCallum M, 2021, SCIENCE, V373, P648, DOI 10.1126/science.abi7994; Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449; Ovacik M, 2018, CTS-CLIN TRANSL SCI, V11, P540, DOI 10.1111/cts.12567; Piccoli L, 2020, CELL, V183, P1024, DOI 10.1016/j.cell.2020.09.037; Pymm P, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101918118; Rees-Spear C, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2021.108890; Reguera J, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002859; Salema V, 2017, MICROB BIOTECHNOL, V10, P1468, DOI 10.1111/1751-7915.12819; Salema V, 2016, J BIOTECHNOL, V234, P58, DOI 10.1016/j.jbiotec.2016.07.025; Salema V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075126; Schoof M, 2020, SCIENCE, V370, P1473, DOI 10.1126/science.abe3255; Shang J, 2020, NATURE, V581, P221, DOI 10.1038/s41586-020-2179-y; Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75; Starr Tyler N, 2021, Cell Rep Med, V2, P100255, DOI [10.1101/2021.02.17.431683, 10.1016/j.xcrm.2021.100255]; Steeland S, 2016, DRUG DISCOV TODAY, V21, P1076, DOI 10.1016/j.drudis.2016.04.003; Stijlemans B, 2004, J BIOL CHEM, V279, P1256, DOI 10.1074/jbc.M307341200; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Nieto GV, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82833-w; Van Heeke G, 2017, PHARMACOL THERAPEUT, V169, P47, DOI 10.1016/j.pharmthera.2016.06.012; Walls AC, 2020, CELL, V181, P281, DOI [10.1016/j.cell.2020.02.058, 10.1016/j.cell.2020.11.032]; Winkler ES, 2020, NAT IMMUNOL, V21, P1327, DOI 10.1038/s41590-020-0778-2; Wrapp D, 2020, CELL, V181, P1004, DOI 10.1016/j.cell.2020.04.031; Wrapp D, 2020, SCIENCE, V367, P1260, DOI [10.1101/2020.02.11.944462, 10.1126/science.abb2507]; Wu XL, 2021, CELL REP, V37, DOI 10.1016/j.celrep.2021.109869; Xiang YF, 2020, SCIENCE, V370, P1479, DOI 10.1126/science.abe4747; Xu JL, 2021, NATURE, V595, P278, DOI 10.1038/s41586-021-03676-z; Yamin R, 2021, NATURE, V599, P465, DOI 10.1038/s41586-021-04017-w; Zhou B, 2021, NATURE, V592, P122, DOI 10.1038/s41586-021-03361-1; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7; Zhou TQ, 2020, CELL HOST MICROBE, V28, P867, DOI 10.1016/j.chom.2020.11.004	58	0	0	2	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								863831	10.3389/fimmu.2022.863831	http://dx.doi.org/10.3389/fimmu.2022.863831			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G0SF	35547740	Green Published, gold			2022-12-18	WOS:000795566300001
J	Chentoufi, AA; Dhanushkodi, NR; Srivastava, R; Prakash, S; Coulon, PGA; Zayou, L; Vahed, H; Chentoufi, HA; Hormi-Carver, KK; BenMohamed, L				Chentoufi, Aziz A.; Dhanushkodi, Nisha R.; Srivastava, Ruchi; Prakash, Swayam; Coulon, Pierre-Gregoire A.; Zayou, Latifa; Vahed, Hawa; Chentoufi, Hiba A.; Hormi-Carver, Kathy K.; BenMohamed, Lbachir			Combinatorial Herpes Simplex Vaccine Strategies: From Bedside to Bench and Back	FRONTIERS IN IMMUNOLOGY			English	Review						herpes simplex virus; clinical trials; vaccines; asymptomatic; immune checkpoint blockade	CD8(+) T-CELLS; VIRUS TYPE-2 VACCINE; RECOMBINANT GLYCOPROTEIN VACCINE; INFECTED TRIGEMINAL GANGLIA; PROTECTIVE IMMUNE-RESPONSE; GUINEA-PIG MODEL; GENITAL HERPES; THERAPEUTIC VACCINE; SUBUNIT VACCINE; HERPES-SIMPLEX-VIRUS-2 DL5-29	The development of vaccines against herpes simplex virus type 1 and type 2 (HSV1 and HSV-2) is an important goal for global health. In this review we reexamined (i) the status of ocular herpes vaccines in clinical trials; and (ii) discusses the recent scientific advances in the understanding of differential immune response between HSV infected asymptomatic and symptomatic individuals that form the basis for the new combinatorial vaccine strategies targeting HSV; and (iii) shed light on our novel "asymptomatic" herpes approach based on protective immune mechanisms in seropositive asymptomatic individuals who are "naturally" protected from recurrent herpetic diseases. We previously reported that phenotypically and functionally distinct HSV-specific memory CD8(+) T cell subsets in asymptomatic and symptomatic HSV-infected individuals. Moreover, a better protection induced following a prime/pull vaccine approach that consists of first priming anti-viral effector memory T cells systemically and then pulling them to the sites of virus reactivation (e.g., sensory ganglia) and replication (e.g., eyes and vaginal mucosa), following mucosal administration of vectors expressing T cell-attracting chemokines. In addition, we reported that a combination of prime/pull vaccine approach with approaches to reverse T cell exhaustion led to even better protection against herpes infection and disease. Blocking PD-1, LAG-3, TIGIT and/or TIM-3 immune checkpoint pathways helped in restoring the function of antiviral HSV-specific CD8(+) T cells in latently infected ganglia and increased efficacy and longevity of the prime/pull herpes vaccine. We discussed that a prime/pull vaccine strategy that use of asymptomatic epitopes, combined with immune checkpoint blockade would prove to be a successful herpes vaccine approach.	[Chentoufi, Aziz A.; Dhanushkodi, Nisha R.; Srivastava, Ruchi; Prakash, Swayam; Coulon, Pierre-Gregoire A.; Zayou, Latifa; Hormi-Carver, Kathy K.; BenMohamed, Lbachir] Univ Calif Irvine, Sch Med, Gavin Herbert Eye Inst, Lab Cellular & Mol Immunol, Irvine, CA 92697 USA; [Vahed, Hawa] Univ Lab Partners, Dept Vaccines & Immunotherapies, Ltd Liabil Co LLC, TechImmune, Irvine, CA USA; [Chentoufi, Hiba A.; BenMohamed, Lbachir] Univ Ottawa, Biomed Sci, Ottawa, ON, Canada; [BenMohamed, Lbachir] Univ Calif Irvine, Sch Med, Inst Immunol, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of Ottawa; University of California System; University of California Irvine	BenMohamed, L (corresponding author), Univ Calif Irvine, Sch Med, Gavin Herbert Eye Inst, Lab Cellular & Mol Immunol, Irvine, CA 92697 USA.; BenMohamed, L (corresponding author), Univ Ottawa, Biomed Sci, Ottawa, ON, Canada.; BenMohamed, L (corresponding author), Univ Calif Irvine, Sch Med, Inst Immunol, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.	Lbenmoha@uci.edu						Abitorabi MA, 1996, J IMMUNOL, V156, P3111; Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765; Akhrameyeva NV, 2011, J VIROL, V85, P5036, DOI 10.1128/JVI.02548-10; Allen SJ, 2011, J VIROL, V85, P4184, DOI 10.1128/JVI.02290-10; Allen SJ, 2010, J VIROL, V84, P12315, DOI 10.1128/JVI.01600-10; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Arora S, 2015, AM J TRANSPLANT, V15, P1967, DOI 10.1111/ajt.13214; Awasthi S, 2014, CURR OPIN VIROL, V6, P6, DOI 10.1016/j.coviro.2014.02.006; Awasthi S, 2012, J VIROL, V86, P4586, DOI 10.1128/JVI.07203-11; Banerjee K, 2005, J LEUKOCYTE BIOL, V77, P24, DOI 10.1189/jlb.0904486; Belshe RB, 2012, NEW ENGL J MED, V366, P34, DOI 10.1056/NEJMoa1103151; Bernard MC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121518; Bernstein DI, 2017, J INFECT DIS, V215, P856, DOI 10.1093/infdis/jix004; Bertke AS, 2009, J VIROL, V83, P10007, DOI 10.1128/JVI.00559-09; Boenisch O, 2010, J IMMUNOL, V185, P5806, DOI 10.4049/jimmunol.0903435; Bourne N, 2003, J INFECT DIS, V187, P542, DOI 10.1086/374002; Boursnell MEG, 1997, J INFECT DIS, V175, P16, DOI 10.1093/infdis/175.1.16; Brittle EE, 2008, J VIROL, V82, P8431, DOI 10.1128/JVI.00551-08; CAPPEL R, 1976, ARCH VIROL, V52, P29, DOI 10.1007/BF01317862; Chentoufi AA, 2011, J VIROL, V85, P9127, DOI 10.1128/JVI.00587-11; Chentoufi AA, 2008, J IMMUNOL, V180, P426, DOI 10.4049/jimmunol.180.1.426; Chentoufi AA, 2012, VIRAL IMMUNOL, V25, P204, DOI 10.1089/vim.2011.0091; Chentoufi AA, 2010, FUTURE VIROL, V5, P525, DOI 10.2217/FVL.10.44; Chentoufi AA, 2008, J VIROL, V82, P11792, DOI 10.1128/JVI.00692-08; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; Cunningham AL, 2006, J INFECT DIS, V194, pS11, DOI 10.1086/505359; Da Costa XJ, 2001, VIROLOGY, V288, P256, DOI 10.1006/viro.2001.1094; DaCosta XJ, 1997, VIROLOGY, V232, P1, DOI 10.1006/viro.1997.8564; Dai SY, 2005, J IMMUNOL, V175, P2974, DOI 10.4049/jimmunol.175.5.2974; Dasgupta G, 2012, J VIROL, V86, P4358, DOI 10.1128/JVI.07107-11; Dasgupta G, 2010, FUTURE MICROBIOL, V5, P1, DOI 10.2217/FMB.09.101; Day CL, 2006, NATURE, V443, P350, DOI 10.1038/nature05115; Delagrave S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046714; Dervillez X, 2013, J IMMUNOL, V191, P5124, DOI 10.4049/jimmunol.1301415; Dervillez X, 2012, FUTURE VIROL, V7, P371, DOI 10.2217/FVL.12.22; Diaz F, 2018, VIROLOGY, V513, P129, DOI 10.1016/j.virol.2017.10.011; Divito S, 2006, IMMUNOL RES, V36, P119, DOI 10.1385/IR:36:1:119; Dudek T, 2006, VIROLOGY, V344, P230, DOI 10.1016/j.virol.2005.09.020; Dudek T, 2008, VIROLOGY, V372, P165, DOI 10.1016/j.virol.2007.10.014; Dutton JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076407; Eo SK, 2001, J IMMUNOL, V167, P3592, DOI 10.4049/jimmunol.167.7.3592; Flechtner JB, 2016, VACCINE, V34, P5314, DOI 10.1016/j.vaccine.2016.09.001; Frank GM, 2010, J IMMUNOL, V184, P277, DOI 10.4049/jimmunol.0902373; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gebhardt T, 2011, NATURE, V477, P216, DOI 10.1038/nature10339; Geltz JJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116091; Gilbert PB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176428; Halford WP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065523; Halford WP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017748; Halford WP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012251; Harari A, 2009, J VIROL, V83, P2862, DOI 10.1128/JVI.02528-08; Hashimoto M, 2018, ANNU REV MED, V69, P301, DOI 10.1146/annurev-med-012017-043208; Held K, 2012, J NEUROVIROL, V18, P62, DOI 10.1007/s13365-011-0067-9; Hoshino Y, 2008, VACCINE, V26, P4034, DOI 10.1016/j.vaccine.2008.05.022; Hoshino Y, 2009, J INFECT DIS, V200, P1088, DOI 10.1086/605645; Ishida M, 2002, IMMUNOL LETT, V84, P57, DOI 10.1016/S0165-2478(02)00142-6; Iwai Y, 2002, P NATL ACAD SCI USA, V99, P12293, DOI 10.1073/pnas.192461099; Iyer AV, 2013, VIROL J, V10, DOI 10.1186/1743-422X-10-317; Jameson SC, 2009, IMMUNITY, V31, P859, DOI 10.1016/j.immuni.2009.11.007; Jeon S, 2018, J IMMUNOL, V200, P3711, DOI 10.4049/jimmunol.1700417; Jiang XZ, 2011, J VIROL, V85, P2325, DOI 10.1128/JVI.01791-10; Johnston C, 2016, VACCINE, V34, P2948, DOI 10.1016/j.vaccine.2015.12.076; Kasagi S, 2010, J IMMUNOL, V184, P2337, DOI 10.4049/jimmunol.0901652; Kashiwagi S, 2014, HUM VACC IMMUNOTHER, V10, P1892, DOI 10.4161/hv.28840; Khan AA, 2018, J VIROL, V92, DOI 10.1128/JVI.00535-18; Khan AA, 2017, J IMMUNOL, V199, P186, DOI 10.4049/jimmunol.1700145; Khan AA, 2015, J VIROL, V89, P6619, DOI 10.1128/JVI.00788-15; Khan AA, 2015, J VIROL, V89, P3776, DOI 10.1128/JVI.03419-14; Khan AA, 2014, HUM VACC IMMUNOTHER, V10, P945, DOI 10.4161/hv.27762; Khanna KM, 2004, TRENDS IMMUNOL, V25, P230, DOI 10.1016/j.it.2004.02.010; Knickelbein JE, 2008, SCIENCE, V322, P268, DOI 10.1126/science.1164164; Knipe DM, 2014, VACCINE, V32, P1561, DOI 10.1016/j.vaccine.2014.01.052; Kuo T, 2014, VACCINE, V32, P6733, DOI 10.1016/j.vaccine.2014.10.002; Laing KJ, 2010, J CLIN IMMUNOL, V30, P703, DOI 10.1007/s10875-010-9441-2; Lal H, 2015, NEW ENGL J MED, V372, P2087, DOI 10.1056/NEJMoa1501184; LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001; Liu C, 2011, CARCINOGENESIS, V32, P129, DOI 10.1093/carcin/bgq224; Liu T, 2000, J EXP MED, V191, P1459, DOI 10.1084/jem.191.9.1459; Liu T, 2001, J VIROL, V75, P11178, DOI 10.1128/JVI.75.22.11178-11184.2001; Liu X, 2009, VACCINE, V27, P2760, DOI 10.1016/j.vaccine.2009.03.003; Looker KJ, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0114989, 10.1371/journal.pone.0140765]; Lopes PP, 2018, J VIROL, V92, DOI 10.1128/JVI.02156-17; Mackay CR, 1996, EUR J IMMUNOL, V26, P2433, DOI 10.1002/eji.1830261025; Mackay LK, 2012, P NATL ACAD SCI USA, V109, P7037, DOI 10.1073/pnas.1202288109; Mackay LK, 2012, J IMMUNOL, V188, P2173, DOI 10.4049/jimmunol.1102719; Mahoney KM, 2015, NAT REV DRUG DISCOV, V14, P561, DOI 10.1038/nrd4591; Masopust D, 2012, J IMMUNOL, V188, P5811, DOI 10.4049/jimmunol.1102695; McLean CS, 1996, VACCINE, V14, P987, DOI 10.1016/0264-410X(95)00259-4; Mebius RE, 1996, P NATL ACAD SCI USA, V93, P11019, DOI 10.1073/pnas.93.20.11019; METCALF JF, 1980, ARCH OPHTHALMOL-CHIC, V98, P893; Mohan T, 2018, IMMUNOBIOLOGY, V223, P477, DOI 10.1016/j.imbio.2017.12.001; Morrison LA, 2008, VIROLOGY, V376, P205, DOI 10.1016/j.virol.2008.03.010; Mundle ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057224; Nelson MH, 2011, J REPROD IMMUNOL, V89, P10, DOI 10.1016/j.jri.2011.01.013; Ohashi M, 2011, J VIROL, V85, P3030, DOI 10.1128/JVI.02426-10; Petro C, 2015, ELIFE, V4, DOI 10.7554/eLife.06054; Pope C, 2001, J IMMUNOL, V166, P3402, DOI 10.4049/jimmunol.166.5.3402; Prichard MN, 2005, VACCINE, V23, P5424, DOI 10.1016/j.vaccine.2005.02.028; RAJCANI J, 1980, ACTA VIROL, V24, P183; Reszka NJ, 2010, VACCINE, V28, P2754, DOI 10.1016/j.vaccine.2010.01.030; Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348; Rizvi NA, 2015, LANCET ONCOL, V16, P257, DOI 10.1016/S1470-2045(15)70054-9; Rott LS, 1996, J IMMUNOL, V156, P3727; Royer DJ, 2017, J VIROL, V91, DOI 10.1128/JVI.02342-16; Russell MW, 2002, AM J REPROD IMMUNOL, V47, P265, DOI 10.1034/j.1600-0897.2002.01099.x; Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643; Samandary S, 2014, HUM IMMUNOL, V75, P715, DOI 10.1016/j.humimm.2014.04.016; Sandgren KJ, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.44; Sato A, 2014, J VIROL, V88, P13699, DOI 10.1128/JVI.02279-14; Schiffer JT, 2013, ANTIMICROB AGENTS CH, V57, P5820, DOI 10.1128/AAC.01114-13; Schiffer JT, 2013, NAT MED, V19, P280, DOI 10.1038/nm.3103; Schiffer Joshua T, 2010, Proc Natl Acad Sci U S A, V107, P18973, DOI 10.1073/pnas.1006614107; Sehrawat S, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000882; Sehrawat S, 2009, J IMMUNOL, V182, P3191, DOI 10.4049/jimmunol.0803673; Sheridan BS, 2009, J VIROL, V83, P2237, DOI 10.1128/JVI.01699-08; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Sin JI, 2000, J VIROL, V74, P11173, DOI 10.1128/JVI.74.23.11173-11180.2000; Skoberne M, 2013, J VIROL, V87, P3930, DOI 10.1128/JVI.02745-12; Spector FC, 1998, J INFECT DIS, V177, P1143, DOI 10.1086/515278; Srivastava R, 2017, J VIROL, V91, DOI 10.1128/JVI.00278-17; Srivastava R, 2017, J VIROL, V91, DOI 10.1128/JVI.01793-16; Stanberry Lawrence R, 2004, Herpes, V11 Suppl 3, p161A; Stanfield BA, 2018, VACCINE, V36, P2842, DOI 10.1016/j.vaccine.2018.03.075; Stanfield BA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109890; Straus SE, 1997, J INFECT DIS, V176, P1129, DOI 10.1086/514103; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; Suni MA, 2001, EUR J IMMUNOL, V31, P2512, DOI 10.1002/1521-4141(200108)31:8<2512::AID-IMMU2512>3.0.CO;2-M; Tang VA, 2010, J REPROD IMMUNOL, V87, P39, DOI 10.1016/j.jri.2010.06.155; Us Durdal, 2006, Mikrobiyoloji Bulteni, V40, P413; Vagvala SP, 2009, J VIROL, V83, P953, DOI 10.1128/JVI.02022-08; van Lint A, 2004, J IMMUNOL, V172, P392, DOI 10.4049/jimmunol.172.1.392; Van Wagoner N, 2018, J INFECT DIS, V218, P1890, DOI 10.1093/infdis/jiy415; Veselenak RL, 2012, VACCINE, V30, P7046, DOI 10.1016/j.vaccine.2012.09.057; Visalli RJ, 2014, VACCINE, V32, P1398, DOI 10.1016/j.vaccine.2013.10.079; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Wald A, 2002, J INFECT DIS, V185, P45, DOI 10.1086/338231; Wang KN, 2016, J VIROL, V90, P562, DOI 10.1128/JVI.01845-15; Wang KN, 2012, J VIROL, V86, P12891, DOI 10.1128/JVI.01055-12; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Zhang PW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101373; Zhang X, 2009, MUCOSAL IMMUNOL, V2, P129, DOI 10.1038/mi.2008.81; Zhang XL, 2012, J IMMUNOL, V189, P4496, DOI 10.4049/jimmunol.1201121	142	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								849515	10.3389/fimmu.2022.849515	http://dx.doi.org/10.3389/fimmu.2022.849515			17	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1D5CT	35547736	gold, Green Published			2022-12-18	WOS:000793818800001
J	Cui, YM; Wei, JB; Peng, X				Cui, Yanming; Wei, Jianbo; Peng, Xiang			Case Report: Rabies Vaccine-Induced Thrombotic Thrombocytopenic Purpura in a Patient With Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						vaccine; thrombotic thrombocytopenic purpura; systemic lupus erythematosus; autoimmune disease; ADAMTS13		For patients with autoimmune diseases, vaccination is controversial. The use of vaccination in patients with autoimmune diseases is controversial. There are many reports of secondary thrombotic thrombocytopenic purpura cases after various vaccinations. Thrombotic thrombocytopenic purpura is a rare thrombotic microangiopathy characterized by microvascular pathological hemolytic anemia, severe thrombocytopenia, and ischemic organ damage with a very high fatality rate. We report a case of thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus after rabies vaccination. She developed gastrointestinal bleeding nearly a month after the vaccination. Laboratory tests confirmed a severe deficiency of ADAMTS13 and the presence of ADAMTS13 autoantibodies. Through early identification of thrombotic thrombocytopenic purpura, immunosuppressive therapy, and plasma exchange treatment, the patient was saved from danger. This case suggests that attenuated vaccines may also have unexpected adverse effects in patients with long-term use of immunosuppressive drugs and autoimmune diseases. To our knowledge, this is the first case report of thrombotic thrombocytopenic purpura in a patient with systemic lupus erythematosus secondary to rabies vaccination.	[Cui, Yanming; Wei, Jianbo; Peng, Xiang] Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Dept Rheumatol & Immunol, Guangzhou, Guangdong, Peoples R China	Guangzhou Medical University	Peng, X (corresponding author), Guangzhou Med Univ, Affiliated Hosp 6, Qingyuan Peoples Hosp, Dept Rheumatol & Immunol, Guangzhou, Guangdong, Peoples R China.	617258225@qq.com						Blombery P, 2014, J BLOOD MED, V5, P15, DOI 10.2147/JBM.S46458; de Bruijn S, 2021, J THROMB HAEMOST, V19, P2014, DOI 10.1111/jth.15418; Garg M, 2018, AUTOIMMUN REV, V17, P990, DOI 10.1016/j.autrev.2018.04.006; Kadikoylu G, 2014, TRANSFUSION MED, V24, P428, DOI 10.1111/tme.12160; Maayan H, 2021, J THROMB HAEMOST, V19, P2314, DOI 10.1111/jth.15420; Ruhrman-Shahar N, 2017, IMMUNOL RES, V65, P157, DOI 10.1007/s12026-016-8822-x; Schultz NH, 2021, NEW ENGL J MED, V384, P2124, DOI 10.1056/NEJMoa2104882; Scully M, 2008, BRIT J HAEMATOL, V142, P819, DOI 10.1111/j.1365-2141.2008.07276.x; Sukumar S, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030536; Wang Ling-yun, 2008, Chinese Journal of Biologicals, V21, P1115; Yavasoglu I, 2020, TURK J HEMATOL, V37, P218, DOI 10.4274/tjh.galenos.2020.2020.0060; Yocum A, 2021, AM J EMERG MED, V49, DOI 10.1016/j.ajem.2021.05.001	12	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								851316	10.3389/fimmu.2022.851316	http://dx.doi.org/10.3389/fimmu.2022.851316			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H8KU	35558074	gold, Green Published			2022-12-18	WOS:000796789600001
J	Hu, CL; Li, JL; Tan, YS; Liu, Y; Bai, C; Gao, J; Zhao, SL; Yao, MY; Lu, XX; Qiu, LX; Xing, LH				Hu, Chunling; Li, Junlu; Tan, Yingshuai; Liu, Yang; Bai, Chen; Gao, Jing; Zhao, Shilong; Yao, Mengying; Lu, Xiaoxiao; Qiu, Lingxiao; Xing, Lihua			Tanreqing Injection Attenuates Macrophage Activation and the Inflammatory Response via the lncRNA-SNHG1/HMGB1 Axis in Lipopolysaccharide-Induced Acute Lung Injury	FRONTIERS IN IMMUNOLOGY			English	Article						acute lung injury; acute respiratory distress syndrome (ALI; ARDS); macrophage polarization; tanreqing injection; NF-kappa B signaling pathway; long noncoding RNA (lncRNA); high mobility group protein 1 (HMGB1)	NF-KAPPA-B; PROMOTES; TRANSCRIPTION; POLARIZATION; LIFE	The etiology of acute lung injury (ALI) is not clear, and the treatment of ALI presents a great challenge. This study aimed to investigate the pathogenesis and potential therapeutic targets of ALI and to define the target gene of Tanreqing (TRQ), which is a traditional Chinese medicine formula composed of five medicines, scutellaria baicalensis, bear bile powder, goat horn powder, honeysuckle and forsythia. Macrophage activation plays a critical role in many pathophysiological processes, such as inflammation. Although the regulation of macrophage activation has been extensively investigated, there is little knowledge of the role of long noncoding RNAs (lncRNAs) in this process. In this study, we found that lncRNA-SNHG1 expression is distinctly regulated in differently activated macrophages in that it is upregulated in LPS. LncRNA-SNHG1 knockdown attenuates LPS-induced M1 macrophage activation. The SNHG1 promoter was bound by NF-kappa B subunit p65, indicative of SNHG1 being a direct transcriptional target of LPS-induced NF-kappa B activation. SNHG1 acts as a proinflammatory driver that leads to the production of inflammatory cytokines and the activation of macrophages and cytokine storms by physically interacting with high-mobility group box 1 (HMGB1) in ALI. TRQ inhibited NF-kappa B signaling activation and binding of NF-kappa B to the SNHG1 promoter. In conclusion, this study defined TRQ target genes, which can be further elucidated as mechanism(s) of TRQ action, and provides insight into the molecular pathogenesis of ALI. The lncRNA-SNHG1/HMGB1 axis is an ideal therapeutic for ALI treatment.	[Hu, Chunling; Li, Junlu; Tan, Yingshuai; Liu, Yang; Gao, Jing; Zhao, Shilong; Yao, Mengying; Lu, Xiaoxiao; Xing, Lihua] Zhengzhou Univ, Dept Resp Intens Care Unit, Affiliated Hosp 1, Zhengzhou, Peoples R China; [Bai, Chen] Beijing Univ Chinese Med, Sch Tradit Chinese Med, Beijing, Peoples R China; [Qiu, Lingxiao] Zhengzhou Univ, Dept Resp Med, Affiliated Hosp 1, Zhengzhou, Peoples R China	Zhengzhou University; Beijing University of Chinese Medicine; Zhengzhou University	Xing, LH (corresponding author), Zhengzhou Univ, Dept Resp Intens Care Unit, Affiliated Hosp 1, Zhengzhou, Peoples R China.	xinglihua95088@163.com			National Natural Science Foundation of China [82074212]; Science and Technology Department of Henan Province (CN) [SB201901036]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Department of Henan Province (CN)	This work was supported by the National Natural Science Foundation of China (Number 82074212) and the Science and Technology Department of Henan Province (CN) (Number SB201901036).	Altemeier WA, 2005, J IMMUNOL, V175, P3369, DOI 10.4049/jimmunol.175.5.3369; Banerjee S, 2013, J IMMUNOL, V190, P6542, DOI 10.4049/jimmunol.1202496; Cao BQ, 2018, NEUROSCIENCE, V388, P118, DOI 10.1016/j.neuroscience.2018.07.019; Chen C, 2017, CANCER LETT, V388, P21, DOI 10.1016/j.canlet.2016.11.027; Combes A, 2018, NEW ENGL J MED, V378, P1965, DOI 10.1056/NEJMoa1800385; Cui HC, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124522; Cui HC, 2018, J IMMUNOL, V200, P3218, DOI 10.4049/jimmunol.1701571; Dong SJ, 2013, J TRADIT CHIN MED, V33, P505, DOI 10.1016/S0254-6272(13)60156-9; Du M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02229-1; Eissmann M, 2012, RNA BIOL, V9, P1076, DOI 10.4161/rna.21089; Franklin TC, 2018, BRAIN BEHAV IMMUN, V72, P2, DOI 10.1016/j.bbi.2017.10.025; Gibbings SL, 2015, BLOOD, V126, P1357, DOI 10.1182/blood-2015-01-624809; Gong GW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35817-2; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Huppert LA, 2019, SEMIN RESP CRIT CARE, V40, P31, DOI 10.1055/s-0039-1683996; Jiang JY, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101638; Juan CX, 2021, J CELL MOL MED, V25, P4786, DOI 10.1111/jcmm.16449; Kang M, 2019, SEMIN RESP CRIT CARE, V40, P3, DOI 10.1055/s-0039-1683884; Landsman L, 2007, J IMMUNOL, V179, P3488, DOI 10.4049/jimmunol.179.6.3488; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Li WD, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1177-0; Li Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04006-0; Liang WJ, 2020, CELL BIOL INT, V44, P317, DOI 10.1002/cbin.11235; Liao HD, 2020, AGING-US, V12, P20198, DOI 10.18632/aging.103752; Lin SS, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.659707; Ling M, 2012, FREE RADICAL BIO MED, V52, P1508, DOI 10.1016/j.freeradbiomed.2012.02.020; Liu L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1698-7; Liu W, 2020, J ETHNOPHARMACOL, V249, DOI 10.1016/j.jep.2019.112425; Lotze MT, 2007, IMMUNOL REV, V220, P60, DOI 10.1111/j.1600-065X.2007.00579.x; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Lu F, 2021, FRONT BIOSCI-LANDMRK, V26, P572, DOI 10.52586/4968; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Murray PJ, 2011, J LEUKOCYTE BIOL, V89, P557, DOI 10.1189/jlb.0710409; Picano E, 2006, J AM SOC ECHOCARDIOG, V19, P356, DOI 10.1016/j.echo.2005.05.019; Rubin JM, 2016, ULTRASOUND MED BIOL, V42, P2525, DOI 10.1016/j.ultrasmedbio.2016.05.020; Schaper F, 2016, RHEUMATOLOGY, V55, P2260, DOI 10.1093/rheumatology/kew324; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Tang JL, 2008, LANCET, V372, P1938, DOI 10.1016/S0140-6736(08)61354-9; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Tugal D, 2013, ARTERIOSCL THROM VAS, V33, P1135, DOI 10.1161/ATVBAHA.113.301453; Wang H, 2004, NAT MED, V10, P1216, DOI 10.1038/nm1124; Xie N, 2015, AM J PHYSIOL-LUNG C, V309, pL1076, DOI 10.1152/ajplung.00286.2015; Xu JH, 2020, MOL THER-NUCL ACIDS, V21, P354, DOI 10.1016/j.omtn.2020.06.010; Xue ZY, 2019, CELL DEATH DIFFER, V26, P130, DOI 10.1038/s41418-018-0105-8; Ye CT, 2012, P NATL ACAD SCI USA, V109, P21052, DOI 10.1073/pnas.1216195109; Zhou JH, 2021, NEUROCHEM RES, V46, P945, DOI 10.1007/s11064-020-03224-7	48	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								820718	10.3389/fimmu.2022.820718	http://dx.doi.org/10.3389/fimmu.2022.820718			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G4MJ	35547731	gold, Green Published			2022-12-18	WOS:000795822700001
J	Keller, GLJ; Weiss, LI; Baker, BM				Keller, Grant L. J.; Weiss, Laura, I; Baker, Brian M.			Physicochemical Heuristics for Identifying High Fidelity, Near-Native Structural Models of Peptide/MHC Complexes	FRONTIERS IN IMMUNOLOGY			English	Article						peptide; major histocompatibility complex; neoantigen; structure; prediction; support vector machine	STRUCTURE PREDICTION; ANTIGEN RECOGNITION; PROTEIN STRUCTURES; NEURAL-NETWORKS; BOUND PEPTIDES; BINDING; NEOANTIGENS; REFINEMENT; INTERFACE; VACCINES	There is long-standing interest in accurately modeling the structural features of peptides bound and presented by class I MHC proteins. This interest has grown with the advent of rapid genome sequencing and the prospect of personalized, peptide-based cancer vaccines, as well as the development of molecular and cellular therapeutics based on T cell receptor recognition of peptide-MHC. However, while the speed and accessibility of peptide-MHC modeling has improved substantially over the years, improvements in accuracy have been modest. Accuracy is crucial in peptide-MHC modeling, as T cell receptors are highly sensitive to peptide conformation and capturing fine details is therefore necessary for useful models. Studying nonameric peptides presented by the common class I MHC protein HLA-A*02:01, here we addressed a key question common to modern modeling efforts: from a set of models (or decoys) generated through conformational sampling, which is best? We found that the common strategy of decoy selection by lowest energy can lead to substantial errors in predicted structures. We therefore adopted a data-driven approach and trained functions capable of predicting near native decoys with exceptionally high accuracy. Although our implementation is limited to nonamer/HLA-A*02:01 complexes, our results serve as an important proof of concept from which improvements can be made and, given the significance of HLA-A*02:01 and its preference for nonameric peptides, should have immediate utility in select immunotherapeutic and other efforts for which structural information would be advantageous.	[Baker, Brian M.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; Univ Notre Dame, Harper Canc Res Inst, Notre Dame, IN 46556 USA	University of Notre Dame; University of Notre Dame	Baker, BM (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	brian-baker@nd.edu		Weiss, Laura/0000-0002-6794-9187; Keller, Grant/0000-0001-7645-121X				Abella JR, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01583; Abella JR, 2019, MOLECULES, V24, DOI 10.3390/molecules24050881; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Ain QU, 2015, WIRES COMPUT MOL SCI, V5, P405, DOI 10.1002/wcms.1225; Akhter N, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100607; Alford RF, 2017, J CHEM THEORY COMPUT, V13, P3031, DOI 10.1021/acs.jctc.7b00125; Amini A, 2007, PROTEINS, V69, P823, DOI 10.1002/prot.21782; Andreatta M, 2016, BIOINFORMATICS, V32, P511, DOI 10.1093/bioinformatics/btv639; Antes I, 2006, BIOINFORMATICS, V22, pE16, DOI 10.1093/bioinformatics/btl216; Antunes DA, 2020, JCO CLIN CANCER INFO, V4, P623, DOI 10.1200/CCI.19.00123; Antunes DA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22173-4; Antunes DA, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01210; Baek M, 2021, SCIENCE, V373, P871, DOI 10.1126/science.abj8754; Baker BM, 2000, IMMUNITY, V13, P475, DOI 10.1016/S1074-7613(00)00047-9; Bianchi V, 2016, J BIOL CHEM, V291, P8951, DOI 10.1074/jbc.M115.707414; Borbulevych OY, 2007, J MOL BIOL, V372, P1123, DOI 10.1016/j.jmb.2007.07.025; Borbulevych OY, 2011, J IMMUNOL, V186, P2950, DOI 10.4049/jimmunol.1003150; Brennick CA, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI142823; Burley SK, 2021, NUCLEIC ACIDS RES, V49, pD437, DOI 10.1093/nar/gkaa1038; Cerutti DS, 2019, WIRES COMPUT MOL SCI, V9, DOI 10.1002/wcms.1402; Chaudhury S, 2010, BIOINFORMATICS, V26, P689, DOI 10.1093/bioinformatics/btq007; Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073; Das R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020044; Davis-Harrison RL, 2005, J MOL BIOL, V346, P533, DOI 10.1016/j.jmb.2004.11.063; Devlin JR, 2020, NAT CHEM BIOL, V16, P1269, DOI 10.1038/s41589-020-0610-1; Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308; Ebrahimi-Nik H, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.129152; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Fagerberg T, 2006, J MOL BIOL, V356, P521, DOI 10.1016/j.jmb.2005.11.059; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; Feng PY, 2021, BIOINFORMATICS, V37, pI254, DOI 10.1093/bioinformatics/btab312; Frenz B, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.558247; Fritsch EF, 2020, CANCER IMMUNOL RES, V8, P1465, DOI 10.1158/2326-6066.CIR-20-0526; Gfeller D, 2018, J IMMUNOL, V201, P3705, DOI 10.4049/jimmunol.1800914; Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008; Han Y, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1997-x; Hellman LM, 2019, MOL THER, V27, P300, DOI 10.1016/j.ymthe.2018.12.010; Insaidoo FK, 2011, J BIOL CHEM, V286, P40163, DOI 10.1074/jbc.M111.283564; Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586-021-03819-2; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kaufmann KW, 2010, BIOCHEMISTRY-US, V49, P2987, DOI 10.1021/bi902153g; Kyeong HH, 2018, BIOINFORMATICS, V34, P469, DOI 10.1093/bioinformatics/btx589; Liu W, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-182; Liu ZH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37214-1; Lu Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044967; Mishto M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02572; Misura KMS, 2005, PROTEINS, V59, P15, DOI 10.1002/prot.20376; Nerli Santrupti, 2020, Front Med Technol, V2, P553478, DOI 10.3389/fmedt.2020.553478; Noble WS, 2006, NAT BIOTECHNOL, V24, P1565, DOI 10.1038/nbt1206-1565; O'Meara MJ, 2015, J CHEM THEORY COMPUT, V11, P609, DOI 10.1021/ct500864r; Oneto L., 2015, IJCNN, P1, DOI DOI 10.1109/IJCNN.2015.7280413; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pang Yuan-Ping, 2018, Immunohorizons, V2, P216, DOI 10.4049/immunohorizons.1800048; Park MS, 2013, MOL IMMUNOL, V56, P81, DOI 10.1016/j.molimm.2013.04.011; Patskovska L., 2022, HUMAN LEUKOCYTE ANTI; Perez MAS., 2022, COMPUTATIONAL PEPTID, P245; Qiu J, 2008, PROTEINS, V71, P1175, DOI 10.1002/prot.21809; Rajasagi M, 2014, BLOOD, V124, P453, DOI 10.1182/blood-2014-04-567933; Raveh B, 2010, PROTEINS, V78, P2029, DOI 10.1002/prot.22716; Rigo MM, 2015, SCI REP-UK, V5, DOI 10.1038/srep18413; Riley TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02047; Riley TP, 2018, NAT CHEM BIOL, V14, P934, DOI 10.1038/s41589-018-0130-4; Rognan D, 1999, J MED CHEM, V42, P4650, DOI 10.1021/jm9910775; ROSENFELD R, 1993, J MOL BIOL, V234, P515, DOI 10.1006/jmbi.1993.1607; Rubenstein AB, 2018, J CHEM THEORY COMPUT, V14, P6015, DOI 10.1021/acs.jctc.8b00303; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Schmidt J, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100194; Schueler-Furman O, 1998, FOLD DES, V3, P549, DOI 10.1016/S1359-0278(98)00070-4; Sezerman U, 1996, PROTEIN SCI, V5, P1272, DOI 10.1002/pro.5560050706; Shinkawa T, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2020.1870062; Smith AR, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2018125118; Spear TT, 2016, J LEUKOCYTE BIOL, V100, P545, DOI 10.1189/jlb.2A1215-561R; Stein A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063090; Stronen E, 2016, SCIENCE, V352, P1337, DOI 10.1126/science.aaf2288; Szeto C, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102096; Tong JC, 2004, PROTEIN SCI, V13, P2523, DOI 10.1110/ps.04631204; Toor JS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00099; Wu DC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16755-y; Zhu YT, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.682325	80	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								887759	10.3389/fimmu.2022.887759	http://dx.doi.org/10.3389/fimmu.2022.887759			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1D4ZD	35547730	gold, Green Published			2022-12-18	WOS:000793809300001
J	Moon, Y				Moon, Yuseok			Editorial: Molecular Pathways Controlling Epithelial Inflammation in the Gut	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						mucosal immunity; gut microbiota; epithelial barrier; microbial metabolites; mucosal immunoregulation; epithelial inflammation	NF-KAPPA-B; PPAR-GAMMA; EXPRESSION; CELLS; IRF-1		[Moon, Yuseok] Pusan Natl Univ, Dept Integrat Biomed Sci & Anat, Lab Mucosal Exposome & Biomodulat, Yangsan, South Korea; [Moon, Yuseok] Pusan Natl Univ, Grad Program Genom Data Sci, Yangsan, South Korea	Pusan National University; Pusan National University	Moon, Y (corresponding author), Pusan Natl Univ, Dept Integrat Biomed Sci & Anat, Lab Mucosal Exposome & Biomodulat, Yangsan, South Korea.; Moon, Y (corresponding author), Pusan Natl Univ, Grad Program Genom Data Sci, Yangsan, South Korea.	moon@pnu.edu			Pusan National University	Pusan National University(Pusan National University)	This work was supported by a 2-Year Research Grant of Pusan National University.	Cowan MJ, 2006, J APPL PHYSIOL, V101, P1127, DOI 10.1152/japplphysiol.01287.2005; Dubuquoy L, 2003, GASTROENTEROLOGY, V124, P1265, DOI 10.1016/S0016-5085(03)00271-3; Eun CS, 2006, DIGEST DIS SCI, V51, P693, DOI 10.1007/s10620-006-3193-0; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Mansen A, 1996, BIOCHEM BIOPH RES CO, V222, P844, DOI 10.1006/bbrc.1996.0832; McCole DF, 2007, CURR OPIN GASTROEN, V23, P647, DOI 10.1097/MOG.0b013e3282f0153b; Nakagaki H, 2010, INFECT IMMUN, V78, P1185, DOI 10.1128/IAI.01224-09; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Newberry RD, 2021, J ALLERGY CLIN IMMUN, V147, P45, DOI 10.1016/j.jaci.2020.10.030; Noiri E, 1996, AM J PHYSIOL-CELL PH, V270, pC794, DOI 10.1152/ajpcell.1996.270.3.C794; Onizawa M, 2009, AM J PHYSIOL-GASTR L, V296, pG850, DOI 10.1152/ajpgi.00071.2008; Oshima S, 2004, MOL CELL BIOL, V24, P6298, DOI 10.1128/MCB.24.14.6298-6310.2004; Smith EA, 1996, J APPL BACTERIOL, V81, P288, DOI 10.1111/j.1365-2672.1996.tb04331.x; Tokunaga F, 2013, J BIOCHEM, V154, P313, DOI 10.1093/jb/mvt079; Venkatesh M, 2014, IMMUNITY, V41, P296, DOI 10.1016/j.immuni.2014.06.014; Wullaert A, 2011, CELL RES, V21, P146, DOI 10.1038/cr.2010.175	16	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								897587	10.3389/fimmu.2022.897587	http://dx.doi.org/10.3389/fimmu.2022.897587			4	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1E1HG	35547741	gold, Green Published			2022-12-18	WOS:000794246200001
J	Serrano, I; Luque, A; Mitjavila, F; Blom, AM; de Cordoba, SR; Vega, MC; Torras, J; Aran, JM				Serrano, Inmaculada; Luque, Ana; Mitjavila, Francesca; Blom, Anna M.; de Cordoba, Santiago Rodriguez; Vega, M. Cristina; Torras, Joan; Aran, Josep M.			The Hidden Side of Complement Regulator C4BP: Dissection and Evaluation of Its Immunomodulatory Activity	FRONTIERS IN IMMUNOLOGY			English	Article						PRP6-HO7; lupus nephritis; dendritic cells; inflammation; immunomodulation; C4BP(beta-)	HUMAN C4B-BINDING PROTEIN; BETA-CHAIN; STRUCTURAL REQUIREMENTS; ALPHA-CHAIN; RECEPTOR; EXPRESSION; AUTOIMMUNITY; MONOCYTES; COMPONENT; ISOFORMS	C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(beta-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the beta-chain to the C4BP alpha-chain oligomer interferes with this immunomodulatory activity of C4BP. Moreover, an oligomeric form including only the complement control protein 6 (CCP6) domain of the C4BP alpha-chain (PRP6-HO7) is sufficient to "reprogram " monocyte-derived DCs (Mo-DCs) from a pro-inflammatory and immunogenic phenotype to an anti-inflammatory and tolerogenic state. PRP6-HO7 lacks complement regulatory activity but retains full immunomodulatory activity over inflammatory Mo-DCs induced by TLRs, characterized by downregulation of relevant surface markers such as CD83, HLA-DR, co-stimulatory molecules such as CD86, CD80 and CD40, and pro-inflammatory cytokines such as IL-12 and TNF-alpha. Furthermore, PRP6-HO7-treated Mo-DCs shows increased endocytosis, significantly reduced CCR7 expression and CCL21-mediated chemotaxis, and prevents T cell alloproliferation. Finally, PRP6-HO7 shows also full immunomodulatory activity over Mo-DCs isolated from lupus nephritis patients with active disease, even without further pro-inflammatory stimulation. Therefore PRP6-HO7, retaining the immunomodulatory activity of C4BP(beta-) and lacking its complement regulatory activity, might represent a promising and novel alternative to treat autoimmune diseases.	[Serrano, Inmaculada; Luque, Ana; Aran, Josep M.] Inst Invest Biomed Bellvitge IDIBELL, Immune inflammatory Proc & Gene Therapeut Grp, Hosp Llobregat, Barcelona, Spain; [Mitjavila, Francesca] Univ Barcelona, Bellvitge Univ Hosp, Inst Invest Biomed Bellvitge IDIBELL, Internal Med Serv, Barcelona, Spain; [Blom, Anna M.] Lund Univ, Dept Translat Med, Sect Med Prot Chem, Malmo, Sweden; [de Cordoba, Santiago Rodriguez] Ctr Invest Biol Margarita Salas CSIC, Mol Pathol Genet Complement Grp, Madrid, Spain; [Vega, M. Cristina] Ciber Enfermedades Raras CIBERER, Madrid, Spain; [Vega, M. Cristina] Ctr Invest Biol Margarita Salas CSIC, Struct Biol Host Pathogen Interact Grp, Madrid, Spain; [Torras, Joan] Univ Barcelona, Bellvitge Univ Hosp, Inst Invest Biomed Bellvitge IDIBELL, Nephrol Dept, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona; Lund University; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; University of Barcelona	Aran, JM (corresponding author), Inst Invest Biomed Bellvitge IDIBELL, Immune inflammatory Proc & Gene Therapeut Grp, Hosp Llobregat, Barcelona, Spain.	jaran@idibell.cat	Blom, Anna/B-9607-2009	Blom, Anna/0000-0002-1348-1734	Ministerio de Ciencia, Innovacion y Universidades (Madrid, Spain) - FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe [FIS-ISCIII PI20/00464, PI16/00377, DTS20/00016]; Departament de Recerca i Universitats de la Generalitat de Catalunya - FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe [2019PROD00081, 2017SGR291]; Spanish "Ministerio de Ciencia, Innovacion y Universidades/FEDER" [RTI2018-102242-B-I00]; Spanish "Ministerio de Economia y Competitividad/FEDER" [SAF201566287-R]; Autonomous Region of Madrid [S2017/BMD3673]; European Commission -NextGenerationEU through CSIC's Global Health Platform ("PTI Salud Global") [SGL2103020]	Ministerio de Ciencia, Innovacion y Universidades (Madrid, Spain) - FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe; Departament de Recerca i Universitats de la Generalitat de Catalunya - FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe; Spanish "Ministerio de Ciencia, Innovacion y Universidades/FEDER"; Spanish "Ministerio de Economia y Competitividad/FEDER"(Spanish Government); Autonomous Region of Madrid; European Commission -NextGenerationEU through CSIC's Global Health Platform ("PTI Salud Global")	We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work was supported by the Ministerio de Ciencia, Innovacion y Universidades (Madrid, Spain) (grants FIS-ISCIII PI20/00464, PI16/00377 and DTS20/00016), and the "Departament de Recerca i Universitats de la Generalitat de Catalunya" (grants 2019PROD00081 and 2017SGR291), all co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe-. Dr. Vega is supported by the Spanish "Ministerio de Ciencia, Innovacion y Universidades/FEDER" [RTI2018-102242-B-I00]. Dr. Rodriguez de Cordoba is supported by the Spanish "Ministerio de Economia y Competitividad/FEDER [SAF201566287-R]. Dr. Vega and Dr. Rodriguez de Cordoba are also funded by the Autonomous Region of Madrid [S2017/BMD3673] and the European Commission -NextGenerationEU through CSIC's Global Health Platform ("PTI Salud Global") [SGL2103020]. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bandlow V, 2017, J AM CHEM SOC, V139, P16389, DOI 10.1021/jacs.7b09967; Blom AM, 2004, MOL IMMUNOL, V40, P1333, DOI 10.1016/j.molimm.2003.12.002; Blom AM, 2002, BIOCHEM SOC T, V30, P978, DOI 10.1042/bst0300978; Blom AM, 2003, J BIOL CHEM, V278, P43437, DOI 10.1074/jbc.M306620200; Blom AM, 2001, J BIOL CHEM, V276, P27136, DOI 10.1074/jbc.M102445200; Buffalo CZ, 2016, NAT MICROBIOL, V1, DOI [10.1038/NMICROBIOL.2016.155, 10.1038/nmicrobiol.2016.155]; Christiansen D, 2000, J VIROL, V74, P4672, DOI 10.1128/JVI.74.10.4672-4678.2000; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1986, J BIOL CHEM, V261, P2022; DAHLBACK B, 1983, P NATL ACAD SCI-BIOL, V80, P3461, DOI 10.1073/pnas.80.11.3461; DE FRUTOS PG, 1994, BLOOD, V84, P815; DECORDOBA SR, 1994, GENOMICS, V21, P501, DOI 10.1006/geno.1994.1308; Ermert D, 2016, IMMUNOL LETT, V169, P82, DOI 10.1016/j.imlet.2015.11.014; Ermert D, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005043; Webb Benjamin, 2016, Curr Protoc Bioinformatics, V54, DOI [10.1002/0471140864.ps0209s50, 10.1002/cpps.20, 10.1002/0471250953.bi0506s15, 10.1002/cpbi.3]; Freeley S, 2016, IMMUNOL REV, V274, P16, DOI 10.1111/imr.12472; Galimidi RP, 2015, CELL, V160, P433, DOI 10.1016/j.cell.2015.01.016; GARCIA OC, 1995, J IMMUNOL, V155, P4037; Grosche L, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00721; Hardig Y, 1996, J BIOL CHEM, V271, P20861, DOI 10.1074/jbc.271.34.20861; Hillarp A, 1997, J IMMUNOL, V158, P1315; HILLARP A, 1990, P NATL ACAD SCI USA, V87, P1183, DOI 10.1073/pnas.87.3.1183; HILLARP A, 1988, J BIOL CHEM, V263, P12759; Hofmeyer T, 2013, J MOL BIOL, V425, P1302, DOI 10.1016/j.jmb.2012.12.017; Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9; Hovingh ES, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.02004; Iberg CA, 2020, J IMMUNOL, V204, P733, DOI 10.4049/jimmunol.1901121; Kask L, 2004, J BIOL CHEM, V279, P23869, DOI 10.1074/jbc.C400159200; Kask L, 2004, PROTEIN SCI, V13, P1356, DOI 10.1110/ps.03516504; Kask L, 2002, BIOCHEMISTRY-US, V41, P9349, DOI 10.1021/bi025980+; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kazazian NH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02015; Koopman JJE, 2020, RHEUMATOLOGY, V59, P3751, DOI 10.1093/rheumatology/keaa174; KRISTENSEN T, 1987, BIOCHEMISTRY-US, V26, P4668, DOI 10.1021/bi00389a012; Lech M, 2013, J AM SOC NEPHROL, V24, P1357, DOI 10.1681/ASN.2013010026; Li Y, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3017; Li Y, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2590; Libyh MT, 1997, BLOOD, V90, P3978, DOI 10.1182/blood.V90.10.3978; Liszewski MK, 2015, J INTERN MED, V277, P294, DOI 10.1111/joim.12338; Luque A, 2020, KIDNEY INT, V97, P551, DOI 10.1016/j.kint.2019.10.016; Luque A, 2019, SEMIN CELL DEV BIOL, V85, P143, DOI 10.1016/j.semcdb.2017.11.022; Mohlin FC, 2014, METHODS MOL BIOL, V1100, P169, DOI 10.1007/978-1-62703-724-2_14; Morante-Palacios O, 2021, TRENDS IMMUNOL, V42, P59, DOI 10.1016/j.it.2020.11.001; Olivar R, 2013, J IMMUNOL, V190, P2857, DOI 10.4049/jimmunol.1200503; Passeri L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168415; SANCHEZCORRAL P, 1995, J IMMUNOL, V155, P4030; Sander J, 2017, IMMUNITY, V47, P1051, DOI 10.1016/j.immuni.2017.11.024; Santiago-Raber ML, 2010, J AUTOIMMUN, V34, P339, DOI 10.1016/j.jaut.2009.11.001; Scarlatescu E, 2016, J CRIT CARE MED, V2, P156, DOI 10.1515/jccm-2016-0024; Schreibelt G, 2010, CANCER IMMUNOL IMMUN, V59, P1573, DOI 10.1007/s00262-010-0833-1; Seguin-Devaux C, 2019, MOL ONCOL, V13, P2531, DOI 10.1002/1878-0261.12554; Shen MY, 2006, PROTEIN SCI, V15, P2507, DOI 10.1110/ps.062416606; Sterner Rosalie M, 2014, J Clin Cell Immunol, V5; Trouw LA, 2005, J EXP MED, V201, P1937, DOI 10.1084/jem.20050189; Valldorf B, 2016, ANGEW CHEM INT EDIT, V55, P5085, DOI 10.1002/anie.201511894; Villoutreix BO, 1999, IMMUNOPHARMACOLOGY, V42, P121, DOI 10.1016/S0162-3109(99)00022-3; Williams CJ, 2018, PROTEIN SCI, V27, P293, DOI 10.1002/pro.3330; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; ZICCARDI RJ, 1984, J BIOL CHEM, V259, P3674	59	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								883743	10.3389/fimmu.2022.883743	http://dx.doi.org/10.3389/fimmu.2022.883743			16	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1E2EV	35547734	gold, Green Published			2022-12-18	WOS:000794309100001
J	Shen, J; Tao, Z; Chen, W; Sun, J; Li, Y; Fu, FW				Shen, Jie; Tao, Zi; Chen, Wei; Sun, Jing; Li, Yan; Fu, Fangwang			Malignant Isolated Cortical Vein Thrombosis as the Initial Manifestation of Primary Antiphospholipid Syndrome: Lessons on Diagnosis and Management From a Case Report	FRONTIERS IN IMMUNOLOGY			English	Article						cortical vein thrombosis; antiphospholipid syndrome; anticoagulation; decompressive craniectomy; magnetic resonance; case report	CEREBRAL VENOUS THROMBOSIS; SINUS THROMBOSIS; CLINICAL MANAGEMENT; ASSOCIATION; ANTIBODIES; SPECTRUM; DISEASE; UPDATE	BackgroundAntiphospholipid syndrome (APS) with isolated cortical vein thrombosis (ICoVT) is an extremely rare but potentially malignant entity. It is particularly challenging to diagnose APS-related ICoVT because of the non-specific clinical manifestations and the frequent absence of typical neuroimaging. Moreover, there is currently limited knowledge on the clinical features and management strategies for the condition. Delays in diagnosis and treatment may lead to life-threatening consequences. Case PresentationWe present a rare case of a 74-year-old Chinese woman who presented with sudden onset of headache and right arm weakness that mimicked acute ischemic stroke. Her initial computed tomography was unremarkable, and intravenous thrombolysis was performed. Serial neuroimages confirmed ICoVT 4 days after symptom onset, and low-molecular-weight heparin (LMWH) was started at a dose of 0.4 ml twice per day, according to the 2019 Chinese guidelines. The workup for the predisposing causes of ICoVT revealed triple positivity APS. LMWH dose was adjusted according to the anti-Xa chromogenic assay. However, the patient's condition deteriorated rapidly, and there was a progressive enlargement of the venous infarction despite treatment with anticoagulants. Transtentorial herniation developed on day 12, and decompressive craniectomy was immediately performed. The patient's symptoms did not improve significantly after surgery, and she remained aphasic and hemiplegic at the 3-month follow-up, with a modified Rankin Scale score of 5. ConclusionICoVT is a rare yet potentially fatal manifestation of APS, and its diagnosis and treatment are extremely challenging. Timely diagnosis, prompt treatment, and close monitoring are essential to improve the clinical prognosis of patients with APS-related ICoVT.	[Shen, Jie; Tao, Zi; Sun, Jing; Li, Yan; Fu, Fangwang] Wenzhou Med Univ, Dept Neurol, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China; [Shen, Jie; Tao, Zi; Sun, Jing; Li, Yan; Fu, Fangwang] Wenzhou Med Univ, Dept Neurol, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China; [Chen, Wei] Wenzhou Med Univ, Dept Radiol, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China; [Chen, Wei] Wenzhou Med Univ, Dept Radiol, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Li, Y; Fu, FW (corresponding author), Wenzhou Med Univ, Dept Neurol, Affiliated Hosp 2, Wenzhou, Zhejiang, Peoples R China.; Li, Y; Fu, FW (corresponding author), Wenzhou Med Univ, Dept Neurol, Yuying Childrens Hosp, Wenzhou, Zhejiang, Peoples R China.	yanli@wzhealth.com; wangpaper@163.com			Medical Science and Technology Project of Zhejiang Province of China [2021KY797]; Natural Science Foundation of Zhejiang Province of China [LY21H090015]; Wenzhou Basic Scientific Research Project [Y20210900]	Medical Science and Technology Project of Zhejiang Province of China; Natural Science Foundation of Zhejiang Province of China(Natural Science Foundation of Zhejiang Province); Wenzhou Basic Scientific Research Project	Funding This work was supported by the Medical Science and Technology Project of Zhejiang Province of China (No. 2021KY797), the Natural Science Foundation of Zhejiang Province of China (No. LY21H090015), and the Wenzhou Basic Scientific Research Project (No. Y20210900).	Arachchillage DRJ, 2020, BRIT J HAEMATOL, V189, P216, DOI 10.1111/bjh.16431; Aveneli R, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00511; Baharvahdat H, 2019, WORLD NEUROSURG, V128, pE918, DOI 10.1016/j.wneu.2019.05.028; Brouns R, 2009, J NEUROL SCI, V285, P185, DOI 10.1016/j.jns.2009.06.032; Busch MA, 2016, EUR J NEUROL, V23, P1387, DOI 10.1111/ene.13064; Coutinho JM, 2014, STROKE, V45, P1836, DOI 10.1161/STROKEAHA.113.004414; Coutinho JM, 2014, STROKE, V45, P1338, DOI 10.1161/STROKEAHA.113.004666; de Laat B, 2008, NAT CLIN PRACT RHEUM, V4, P192, DOI 10.1038/ncprheum0740; Erkan D, 2021, ARTHRITIS RHEUMATOL, V73, P1780, DOI 10.1002/art.41891; Fan YH, 2020, STROKE VASC NEUROL, V5, P152, DOI 10.1136/svn-2020-000358; Feldmann E., 1995, ANN NEUROL, V37 Suppl 1, P114, DOI 10.1002/ana.410370712; Ferro JM, 2017, EUR STROKE J, V2, P195, DOI 10.1177/2396987317719364; Guo XB, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78570-1; Guo XB, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01185; Ilyas A, 2017, J NEUROINTERV SURG, V9, P1086, DOI 10.1136/neurintsurg-2016-012938; Jerez-Lienas A, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11121641; Kelly J, 2002, ARCH INTERN MED, V162, P747, DOI 10.1001/archinte.162.7.747; Krajickova D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78434-8; Kravvariti E, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102491; Leach JL, 2006, RADIOGRAPHICS, V26, pS19, DOI 10.1148/rg.26si055174; Mahale R, 2017, J THROMB THROMBOLYS, V43, P530, DOI 10.1007/s11239-017-1489-x; Mangla R, 2015, EMERG RADIOL, V22, P181, DOI 10.1007/s10140-014-1251-z; Meng R, 2014, INT J STROKE, V9, P166, DOI 10.1111/ijs.12034; Miranda HV, 2007, REV MED CHILE, V135, P1313, DOI /S0034-98872007001000012; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Murumkar V, 2021, J CLIN NEUROSCI, V91, P369, DOI 10.1016/j.jocn.2021.07.018; Numata K, 2017, INTERNAL MED, V56, P1235, DOI 10.2169/internalmedicine.56.7864; Palmer CF, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-230915; Polster SP, 2020, WORLD NEUROSURG, V139, P215, DOI 10.1016/j.wneu.2020.03.220; Radin M, 2020, SEMIN ARTHRITIS RHEU, V50, P553, DOI 10.1016/j.semarthrit.2020.01.007; Radin M, 2017, INT J CARDIOL, V240, P72, DOI 10.1016/j.ijcard.2017.02.155; Radin M, 2019, SEMIN ARTHRITIS RHEU, V49, P464, DOI 10.1016/j.semarthrit.2019.04.009; Saposnik G, 2011, STROKE, V42, P1158, DOI 10.1161/STR.0b013e31820a8364; Sato T, 2017, J NEUROL SCI, V381, P328, DOI 10.1016/j.jns.2017.09.008; Schmidt-Tanguy A, 2013, J THROMB HAEMOST, V11, P1927, DOI 10.1111/jth.12363; Shen HX, 2021, CLIN APPL THROMB-HEM, V27, DOI 10.1177/1076029621999104; Silvis SM, 2017, NAT REV NEUROL, V13, P555, DOI 10.1038/nrneurol.2017.104; Singh R, 2015, J NEUROSURG, V123, P427, DOI 10.3171/2014.9.JNS141813; Song SY, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.680040; Song SY, 2021, J THROMB THROMBOLYS, V51, P734, DOI 10.1007/s11239-020-02229-x; Theaudin M, 2010, STROKE, V41, P727, DOI 10.1161/STROKEAHA.109.572909; Bagan AT, 2021, FRONT NEUROL, V12, DOI 10.3389/fneur.2021.753110; Tumian NR, 2022, J CLIN MED, V11, DOI 10.3390/jcm11030735; Urban P, 2005, J NEUROL, V252, P1476, DOI 10.1007/s00415-005-0893-x	44	0	0	4	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								882032	10.3389/fimmu.2022.882032	http://dx.doi.org/10.3389/fimmu.2022.882032			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1V2DE	35547735	Green Published, gold			2022-12-18	WOS:000805906100001
J	Wang, LM; Xu, DM; Chu, YW				Wang, Luman; Xu, Damo; Chu, Yiwei			Editorial: Insights into Regulatory B Cells	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						Breg; phenotype; function; applications; organ specific			[Wang, Luman; Chu, Yiwei] Fudan Univ, Inst Biomed Sci, Sch Basic Med Sci, Dept Immunol, Shanghai, Peoples R China; [Xu, Damo] Shenzhen Univ, Sch Med, State Key Lab Resp Dis Allergy, Shenzhen, Peoples R China	Fudan University; Shenzhen University; State Key Laboratory of Respiratory Disease	Chu, YW (corresponding author), Fudan Univ, Inst Biomed Sci, Sch Basic Med Sci, Dept Immunol, Shanghai, Peoples R China.	yiweichu@fudan.edu.cn							0	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								903711	10.3389/fimmu.2022.903711	http://dx.doi.org/10.3389/fimmu.2022.903711			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G4QE	35547742	gold, Green Published			2022-12-18	WOS:000795832700001
J	Yu, BM; Wang, F; Wang, YF				Yu, Beiming; Wang, Feng; Wang, Yanfeng			Advances in the Structural and Physiological Functions of SHARPIN	FRONTIERS IN IMMUNOLOGY			English	Review						SHARPIN in LUBAC; SHARPIN alone; structure; cellular role; physiological function	NF-KAPPA-B; P53 TUMOR-SUPPRESSOR; MHC CLASS-I; CHRONIC PROLIFERATIVE DERMATITIS; TNF-R1 SIGNALING COMPLEX; LINEAR UBIQUITIN CHAINS; ESTROGEN-RECEPTOR-ALPHA; POSTSYNAPTIC DENSITY; INTEGRIN ACTIVATION; CANCER STATISTICS	SHARPIN was initially found as a SHANK-associated protein. SHARPIN can be used as an important component to form the linear ubiquitin chain assembly complex (LUBAC) with HOIL-1L, HOIP to produce a linear ubiquitin chain connected N-terminal Met1, playing a critical role in various cellular processes including NF-kappa B signaling, inflammation, embryogenesis and apoptosis. SHARPIN alone can also participate in many critical physiological activities and cause various disorders such as chronic dermatitis, tumor, and Alzheimer's disease. Mice with spontaneous autosomal recessive mutations in the SHARPIN protein mainly exhibit chronic dermatitis and immunodeficiency with elevated IgM. Additionally, SHARPIN alone also plays a key role in various cellular events, such as B cells activation and platelet aggregation. Structural studies of the SHARPIN or LUBAC have been reported continuously, advancing our understanding of it at the molecular level. However, the full-length structure of the SHARPIN or LUBAC was lagging, and the molecular mechanism underlying these physiological processes is also unclear. Herein, we summarized the currently resolved structure of SHARPIN as well as the emerging physiological role of SHARPIN alone or in LUBAC. Further structural and functional study of SHARPIN will provide insight into the role and underlying mechanism of SHARPIN in disease, as well as its potential application in therapeutic.	[Yu, Beiming; Wang, Feng; Wang, Yanfeng] Beijing Inst Technol, Sch Life Sci, Key Lab Mol Med & Biotherapy, Beijing, Peoples R China	Beijing Institute of Technology	Wang, YF (corresponding author), Beijing Inst Technol, Sch Life Sci, Key Lab Mol Med & Biotherapy, Beijing, Peoples R China.	yf@bit.edu.cn	Wang, Feng/AAC-6221-2022	Wang, Feng/0000-0002-9403-4337	National Natural Science Foundation of China [31770827, 21736002]; Youth Project of Beijing Natural Science Foundation [5214027]; Beijing Institute of Technology Research Fund Program for Young Scholars	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Project of Beijing Natural Science Foundation; Beijing Institute of Technology Research Fund Program for Young Scholars	Funding This work was supported by the National Natural Science Foundation of China Grants 32101021, the Youth Project of Beijing Natural Science Foundation 5214027, the National Natural Science Foundation of China Grants 31770827 and 21736002, the Beijing Institute of Technology Research Fund Program for Young Scholars.	Ades F, 2014, J CLIN ONCOL, V32, P2794, DOI 10.1200/JCO.2013.54.1870; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Asanomi Y, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0090-5; Asaoka T, 2016, EMBO REP, V17, P1624, DOI 10.15252/embr.201642378; Bachrati CZ, 1999, EUR J CELL BIOL, V78, P561, DOI 10.1016/S0171-9335(99)80021-1; Berry NB, 2008, MOL ENDOCRINOL, V22, P1535, DOI 10.1210/me.2007-0449; Blander JM, 2016, IMMUNOL REV, V272, P65, DOI 10.1111/imr.12428; Boeckers TM, 2002, J NEUROCHEM, V81, P903, DOI 10.1046/j.1471-4159.2002.00931.x; Boisson B, 2012, NAT IMMUNOL, V13, P1178, DOI 10.1038/ni.2457; Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756-3282(99)00105-2; Bremm A, 2011, TRENDS BIOCHEM SCI, V36, P355, DOI 10.1016/j.tibs.2011.04.004; Butterfield DA, 2013, ANTIOXID REDOX SIGN, V19, P823, DOI 10.1089/ars.2012.5027; Carvajal AR, 2021, ELIFE, V10, DOI 10.7554/eLife.60660; Chapman LM, 2012, J IMMUNOL, V189, P916, DOI 10.4049/jimmunol.1200580; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen G, 2019, BIOCHEM BIOPH RES CO, V509, P797, DOI 10.1016/j.bbrc.2019.01.001; CHEN JD, 1995, MOL MED, V1, P142, DOI 10.1007/BF03401562; Cho EC, 2012, EMBO J, V31, P1785, DOI 10.1038/emboj.2012.17; Dai YS, 2004, J AM ACAD DERMATOL, V51, P718, DOI 10.1016/j.jaad.2004.05.032; De Franceschi N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143423; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dye BT, 2007, ANNU REV BIOPH BIOM, V36, P131, DOI 10.1146/annurev.biophys.36.040306.132820; Emmerich CH, 2013, P NATL ACAD SCI USA, V110, P15247, DOI 10.1073/pnas.1314715110; Emmerich CH, 2011, ADV EXP MED BIOL, V691, P115, DOI 10.1007/978-1-4419-6612-4_12; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fiil BK, 2014, FEBS J, V281, P4337, DOI 10.1111/febs.12944; Fujita H, 2018, CELL REP, V23, P1192, DOI 10.1016/j.celrep.2018.03.112; Fujita H, 2014, MOL CELL BIOL, V34, P1322, DOI 10.1128/MCB.01538-13; Fuseya Y, 2020, NAT CELL BIOL, V22, P663, DOI 10.1038/s41556-020-0517-9; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Gatti M, 2015, CELL REP, V10, P226, DOI 10.1016/j.celrep.2014.12.021; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Geserick P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.55; Gijbels MJJ, 1996, AM J PATHOL, V148, P941; Gomez-Diaz C, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103241; Grumati P, 2018, J BIOL CHEM, V293, P5404, DOI 10.1074/jbc.TM117.000117; Gupta N, 2015, ARTERIOSCL THROM VAS, V35, P2657, DOI 10.1161/ATVBAHA.115.306054; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hadian K, 2011, J BIOL CHEM, V286, P26107, DOI 10.1074/jbc.M111.233163; Harachi M, 2020, MOL CANCER RES, V18, P1142, DOI 10.1158/1541-7786.MCR-20-0024; Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152; Hatakeyama Shigetsugu, 2012, JAKSTAT, V1, P168, DOI 10.4161/jkst.21560; He LZ, 2010, J CLIN INVEST, V120, P2094, DOI 10.1172/JCI40778; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Hochstrasser M, 2006, CELL, V124, P27, DOI 10.1016/j.cell.2005.12.025; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; HOGENESCH H, 1993, AM J PATHOL, V143, P972; Hostager BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023061; Hsieh JJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.9; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Iwai K, 2009, EMBO REP, V10, P706, DOI 10.1038/embor.2009.144; Jackson SP, 2013, MOL CELL, V49, P795, DOI 10.1016/j.molcel.2013.01.017; Jansson M, 2008, NAT CELL BIOL, V10, P1431, DOI 10.1038/ncb1802; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756-3282(98)00077-5; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; Jung J, 2010, MOL CELL BIOCHEM, V340, P161, DOI 10.1007/s11010-010-0413-x; Kaiser WJ, 2011, NATURE, V471, P368, DOI 10.1038/nature09857; Kashani-Sabet M, 2009, P NATL ACAD SCI USA, V106, P6268, DOI 10.1073/pnas.0901185106; Kasirer-Friede A, 2019, P NATL ACAD SCI USA, V116, P4983, DOI 10.1073/pnas.1819156116; Kelsall IR, 2019, P NATL ACAD SCI USA, V116, P13293, DOI 10.1073/pnas.1905873116; Khan MH, 2017, J CELL SCI, V130, P3094, DOI 10.1242/jcs.200329; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Klinkenberg M, 2001, FEBS LETT, V498, P93, DOI 10.1016/S0014-5793(01)02504-2; Krishnan D, 2020, NEUROBIOL AGING, V93, P131, DOI 10.1016/j.neurobiolaging.2020.02.001; Kumari S, 2014, ELIFE, V3, DOI 10.7554/eLife.03422; Lafont E, 2017, EMBO J, V36, P1147, DOI 10.15252/embj.201695699; Landgraf K, 2010, MOL CELL BIOL, V30, P5764, DOI 10.1128/MCB.01645-09; Larjava H, 2008, EMBO REP, V9, P1203, DOI 10.1038/embor.2008.202; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Lee JW, 2004, EXP MOL MED, V36, P1, DOI 10.1038/emm.2004.1; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lilja J, 2017, NAT CELL BIOL, V19, P292, DOI 10.1038/ncb3487; Lim S, 2001, MOL CELL NEUROSCI, V17, P385, DOI 10.1006/mcne.2000.0940; Lim S, 1999, J BIOL CHEM, V274, P29510, DOI 10.1074/jbc.274.41.29510; Liu JP, 2017, CELL REP, V21, P27, DOI 10.1016/j.celrep.2017.09.031; Liu QS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101504; MacKay C, 2014, CANCER RES, V74, P2246, DOI 10.1158/0008-5472.CAN-13-2131; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Manzanillo PS, 2013, NATURE, V501, P512, DOI 10.1038/nature12566; Miyamoto S, 2011, CELL RES, V21, P116, DOI 10.1038/cr.2010.179; Mondal C, 2021, INT REV CEL MOL BIO, V360, P65, DOI 10.1016/bs.ircmb.2020.09.004; Moser M, 2009, SCIENCE, V324, P895, DOI 10.1126/science.1163865; Nassani N, 2013, CLIN BIOCHEM, V46, P1701, DOI 10.1016/j.clinbiochem.2013.07.018; Neefjes J, 2011, NAT REV IMMUNOL, V11, P823, DOI 10.1038/nri3084; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Ohnishi Yozo, 2002, Gan To Kagaku Ryoho, V29, P2031; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Peltzer N, 2018, NATURE, V557, P112, DOI 10.1038/s41586-018-0064-8; Phillips P, 2002, J CELL BIOCHEM, V84, P100, DOI 10.1002/jcb.1269; Pouwels J, 2013, CELL REP, V5, P619, DOI 10.1016/j.celrep.2013.10.011; Prasher JM, 2001, ONCOGENE, V20, P2946, DOI 10.1038/sj.onc.1204395; Preta G, 2010, BIOCHEM BIOPH RES CO, V399, P324, DOI 10.1016/j.bbrc.2010.06.133; Rahighi S, 2009, CELL, V136, P1098, DOI 10.1016/j.cell.2009.03.007; Rantala JK, 2011, NAT CELL BIOL, V13, P1315, DOI 10.1038/ncb2340; Rickard JA, 2014, ELIFE, V3, DOI 10.7554/eLife.03464; Rittinger K, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170026; Sato Y, 2011, P NATL ACAD SCI USA, V108, P20520, DOI 10.1073/pnas.1109088108; Scoumanne A, 2009, NUCLEIC ACIDS RES, V37, P4965, DOI 10.1093/nar/gkp516; Seymour RE, 2007, GENES IMMUN, V8, P416, DOI 10.1038/sj.gene.6364403; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Sheng M, 2000, J CELL SCI, V113, P1851; Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI [10.3322/caac.21332, 10.3322/caac.21590, 10.3322/caac.21708]; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Stieglitz B, 2012, J BIOL CHEM, V287, P20823, DOI 10.1074/jbc.M112.359547; Sundberg JP, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235295; Takayama N, 2012, METHODS MOL BIOL, V788, P205, DOI 10.1007/978-1-61779-307-3_15; Taraborrelli L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06155-8; Thys A, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2020.101939; Tian ZL, 2019, BIOMED PHARMACOTHER, V119, DOI 10.1016/j.biopha.2019.109414; Tobin NP, 2015, ANN ONCOL, V26, P81, DOI 10.1093/annonc/mdu498; Tokunaga F, 2012, ENDOCR J, V59, P641, DOI 10.1507/endocrj.EJ12-0148; Tokunaga F, 2012, MICROBES INFECT, V14, P563, DOI 10.1016/j.micinf.2012.01.011; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Tokunaga F, 2009, NAT CELL BIOL, V11, P123, DOI 10.1038/ncb1821; Wang CY, 2016, INT J BIOCHEM CELL B, V80, P132, DOI 10.1016/j.biocel.2016.09.029; Wang LD, 2010, NAT GENET, V42, P759, DOI 10.1038/ng.648; Wang MN, 2021, J CANCER, V12, P6216, DOI 10.7150/jca.62402; Wu YL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000586; Xian-Peng G, 2011, OSTEOARTHR CARTILAGE, V19, P111, DOI 10.1016/j.joca.2010.10.016; Yang HJ, 2017, NEOPLASIA, V19, P84, DOI 10.1016/j.neo.2016.12.002; Yin RS, 2021, CANCER SCI, V112, P4100, DOI 10.1111/cas.15096; Yuan WC, 2014, MOL CELL, V54, P586, DOI 10.1016/j.molcel.2014.03.035; Zeng C, 2020, ONCOL LETT, V20, P2579, DOI 10.3892/ol.2020.11850; Zeng HM, 2016, THORAC CANCER, V7, P232, DOI 10.1111/1759-7714.12322; Zhang AJ, 2020, NEOPLASIA, V22, P76, DOI 10.1016/j.neo.2019.12.001; Zhou ST, 2020, J INVEST DERMATOL, V140, P395, DOI 10.1016/j.jid.2019.07.696; Zhu G, 2007, CURR BIOL, V17, P1438, DOI 10.1016/j.cub.2007.07.041; Zhu J, 2019, ONCOGENE, V38, P299, DOI 10.1038/s41388-018-0502-y; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573; Zufferey A, 2017, BLOOD ADV, V1, P1773, DOI 10.1182/bloodadvances.2017007021	135	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 25	2022	13								858505	10.3389/fimmu.2022.858505	http://dx.doi.org/10.3389/fimmu.2022.858505			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1D0VA	35547743	gold, Green Published			2022-12-18	WOS:000793526600001
J	Bauer, A; Habior, A				Bauer, Alicja; Habior, Andrzej			Concentration of Serum Matrix Metalloproteinase-3 in Patients With Primary Biliary Cholangitis	FRONTIERS IN IMMUNOLOGY			English	Article						primary biliary cholangitis; liver fibrosis; autoantibodies; metalloproteinases; MMP-3	CHRONIC HEPATITIS-C; LIVER FIBROSIS; ANTINUCLEAR ANTIBODIES; EXPRESSION; PROGRESSION; MMPS; ASSOCIATION; ENDOSTATIN; PROGNOSIS; DIAGNOSIS	Background and AimsMetalloproteinases (MMPs) are involved in many distinct processes in the liver. Matrix metalloproteinase-3 (MMP-3) plays an important role in connective tissue remodeling, degradation of collagen (types II, III, IV, IX, and X), proteoglycans, fibronectin, laminin, and elastin. In addition, MMP-3 can also activate other MMPs such as MMP-1, MMP-7, and MMP-9. Primary biliary cholangitis (PBC) is a cholestatic, autoimmune liver disease, characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis, fibrosis, cirrhosis, and liver failure. Fibrosis is the result of an imbalance between production and degradation of the extracellular matrix surrounding hepatocytes. Our aim in the present study was to determine whether the measurement of serum MMP-3 is clinically useful for assessing ongoing liver fibrosis in patients with PBC. MethodsThe MMP-3 concentration was determined in 182 PBC patients and 80 non-PBC controls using a commercially available ELISA kit. ResultsHigher concentrations of MMP-3 were found in 61% of PBC patients. PBC subjects had greater MMP-3 levels than controls: 68.9 +/- 62.6 vs 21.3 +/- 7.4 ng/mL, p < 0.001 for healthy subjects; 68.9 +/- 62.6 vs 22.7 +/- 7.6 ng/mL, p = 0.022 for autoimmune hepatitis controls; and 68.9 +/- 62.6 vs 37.2 +/- 17.4 ng/mL, p = 0.002 for primary sclerosing cholangitis controls. The serum MMP-3 concentration was significantly elevated in patients with higher bilirubin concentration (107.6 +/- 85.8 vs 61.6 +/- 46.1 ng/mL, p < 0.001) and was correlated with the level of antimitochondrial antibodies specific for PBC. The concentration of MMP-3 in sera of PBC patients was also found to correlate with the state of liver fibrosis (OR = 4.3; p < 0.01). ConclusionsOur study demonstrated significantly higher MMP-3 levels in PBC patients than in healthy and pathological controls. Increased MMP-3 concentrations were positively correlated with various clinical and immunological parameters, and advanced liver fibrosis. The level of MMP-3 was associated with hepatic dysfunction and could play a role in the pathophysiology of hepatic fibrosis in PBC.							Centre of Postgraduate Medical Education, Warsaw, Poland [501-1-025-01-21]	Centre of Postgraduate Medical Education, Warsaw, Poland	The study was supported by grant: 501-1-025-01-21 from the Centre of Postgraduate Medical Education, Warsaw, Poland.	Ando W, 2018, CLIN MOL HEPATOL, V24, P61, DOI 10.3350/cmh.2017.0030; Arthur MJP, 2000, AM J PHYSIOL-GASTR L, V279, pG245; Attallah AM, 2015, ANN HEPATOL, V14, P225, DOI 10.1016/S1665-2681(19)30785-9; Bassiouni W, 2021, FEBS J, V288, P7162, DOI 10.1111/febs.15701; Bauer A, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11040587; Bauer A, 2019, ANN LAB MED, V39, P291, DOI 10.3343/alm.2019.39.3.291; Benedetta TBP, 2019, J AUTOIMMUN, V105, DOI 10.1016/j.jaut.2019.102328; Benyon RC, 2001, SEMIN LIVER DIS, V21, P373, DOI 10.1055/s-2001-17552; Beuers U, 2009, J HEPATOL, V51, P237, DOI 10.1016/j.jhep.2009.04.009; Bhattacharyya P, 2009, LUNG INDIA, V26, P81, DOI 10.4103/0970-2113.53231; Carey EJ, 2015, LANCET, V386, P1565, DOI 10.1016/S0140-6736(15)00154-3; Chew M., 2018, LIVER RES, V2, P81, DOI [10.1016/j.livres.2018.03.004, DOI 10.1016/J.LIVRES.2018.03.004]; Chuang HM, 2019, MOLECULES, V24, DOI 10.3390/molecules24224188; Cichoz-Lach H, 2018, ARCH IMMUNOL THER EX, V66, P443, DOI 10.1007/s00005-018-0515-9; Cui N, 2017, PROG MOL BIOL TRANSL, V147, P1, DOI 10.1016/bs.pmbts.2017.02.005; Cursio R, 2001, FASEB J, V15, P93, DOI 10.1096/fj.01-0279fje; Fingleton B, 2008, SEMIN CELL DEV BIOL, V19, P61, DOI 10.1016/j.semcdb.2007.06.006; Geervliet E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051212; Giannandrea M, 2014, DIS MODEL MECH, V7, P193, DOI 10.1242/dmm.012062; Granito A, 2006, ALIMENT PHARM THER, V24, P1575, DOI 10.1111/j.1365-2036.2006.03172.x; Granito A, 2021, ALLERGY ASTHMA CL IM, V17, DOI 10.1186/s13223-021-00539-0; Granito A, 2012, EXPERT REV MOL DIAGN, V12, P65, DOI 10.1586/ERM.11.82; Granito A, 2010, AM J GASTROENTEROL, V105, P125, DOI 10.1038/ajg.2009.596; He J, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00451-x; Heljasvaara R, 2005, EXP CELL RES, V307, P292, DOI 10.1016/j.yexcr.2005.03.021; Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003; Hirschfield GM, 2021, EXPERT REV GASTROENT, V15, P929, DOI 10.1080/17474124.2021.1945919; Hirschfield GM, 2017, J HEPATOL, V67, P145, DOI 10.1016/j.jhep.2017.03.022; Honsawek S, 2011, PEDIATR SURG INT, V27, P681, DOI 10.1007/s00383-010-2816-x; Irvine KM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82315-z; Kotajima L, 1998, CLIN EXP RHEUMATOL, V16, P409; Kouroumalis E, 2018, HEPATIC MED-EVID RES, V10, P43, DOI 10.2147/HMER.S135337; Lam S, 2020, HEPATOL COMMUN, V4, P1680, DOI 10.1002/hep4.1589; Lammers WJ, 2014, GASTROENTEROLOGY, V147, P1338, DOI 10.1053/j.gastro.2014.08.029; Laronha H, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051076; Lerner A, 2018, BEST PRACT RES CL RH, V32, P550, DOI 10.1016/j.berh.2019.01.006; Lichtinghagen R, 2003, CLIN SCI, V105, P373, DOI 10.1042/CS20030098; Lichtinghagen R, 1998, VIRCHOWS ARCH, V432, P153, DOI 10.1007/s004280050149; Lindor KD, 2019, HEPATOLOGY, V69, P394, DOI 10.1002/hep.30145; Luckman SP, 2011, AUTOIMMUN DIS, V2011, DOI 10.4061/2011/151258; Mak K.M., 2014, AUSTIN BIOMARK DIAGN, V1, P9, DOI DOI 10.1007/978-94-007-7675-3_6; Martinez-Castillo M, 2021, WORLD J HEPATOL, V13, P218, DOI 10.4254/wjh.v13.i2.218; Monvoisin A, 2002, INT J CANCER, V97, P157, DOI 10.1002/ijc.1595; Perez CFM, 2020, AM J GASTROENTEROL, V115, P1066, DOI 10.14309/ajg.0000000000000557; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Naim A, 2017, J CLIN EXP HEPATOL, V7, P367, DOI 10.1016/j.jceh.2017.09.004; Okamoto K, 2005, J GASTROEN HEPATOL, V20, P1102, DOI 10.1111/j.1440-1746.2005.03860.x; Okamoto K, 2005, RES COMMUN MOL PATH, V117, P77; Okamoto K, 2010, INTERNAL MED, V49, P887, DOI 10.2169/internalmedicine.49.3268; Ozaslan E, 2016, CLIN RES HEPATOL GAS, V40, P553, DOI 10.1016/j.clinre.2016.06.001; Prystupa A, 2015, ANN AGR ENV MED, V22, P325, DOI 10.5604/12321966.1152088; Cancado ELR, 2015, FRONT IMMUNOL, V6, P1, DOI 10.3389/fimmu.2015.00309; Richter AG, 2009, THORAX, V64, P156, DOI 10.1136/thx.2008.102814; Roeb E, 2018, MATRIX BIOL, V68-69, P463, DOI 10.1016/j.matbio.2017.12.012; Sharma P, 2020, TRANSL GASTROENT HEP, V5, DOI 10.21037/tgh.2019.10.02; Si-Tayeb K, 2006, AM J PATHOL, V169, P1390, DOI 10.2353/ajpath.2006.060005; Stijn W, 2013, ANN THORAC MED, V8, P38, DOI 10.4103/1817-1737.105718; TERADA T, 1995, AM J PATHOL, V147, P1207; Tsuneyama K, 2017, J MED INVESTIG, V64, P7, DOI 10.2152/jmi.64.7; Tuncer T, 2019, ADV CLIN EXP MED, V28, P665, DOI 10.17219/acem/94065; Veidal SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024753; Wan JT, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.663978; Wang C, 2019, HEPATOLOGY, V70, P294, DOI 10.1002/hep.30604; Yamashita CM, 2011, AM J PATHOL, V179, P1733, DOI 10.1016/j.ajpath.2011.06.041; You H, 2022, HEPATOL INT, V16, P1, DOI 10.1007/s12072-021-10276-6; Zhang Q, 2019, GASTROENT RES PRACT, V2019, DOI 10.1155/2019/8959103; ZUCKER S, 1994, J RHEUMATOL, V21, P2329	67	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								885229	10.3389/fimmu.2022.885229	http://dx.doi.org/10.3389/fimmu.2022.885229			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T9OH	35529854	Green Published, gold			2022-12-18	WOS:000876185500001
J	Constant, O; Maarifi, G; Blanchet, FP; van de Perre, P; Simonin, Y; Salinas, S				Constant, Orianne; Maarifi, Ghizlane; Blanchet, Fabien P.; van de Perre, Philippe; Simonin, Yannick; Salinas, Sara			Role of Dendritic Cells in Viral Brain Infections	FRONTIERS IN IMMUNOLOGY			English	Review						viral infection; dendritic cell; blood-brain barrier; neuroinflammation; neuroinfections; blood-cerebrospinal barrier	CENTRAL-NERVOUS-SYSTEM; WEST-NILE-VIRUS; HUMAN CHOROID-PLEXUS; CEREBROSPINAL-FLUID; LANGERHANS CELLS; T-CELLS; JAPANESE ENCEPHALITIS; MOLECULAR-MECHANISMS; ANTIVIRAL RESPONSE; IMMUNE-RESPONSES	To gain access to the brain, a so-called immune-privileged organ due to its physical separation from the blood stream, pathogens and particularly viruses have been selected throughout evolution for their use of specific mechanisms. They can enter the central nervous system through direct infection of nerves or cerebral barriers or through cell-mediated transport. Indeed, peripheral lymphoid and myeloid immune cells can interact with the blood-brain and the blood-cerebrospinal fluid barriers and allow viral brain access using the "Trojan horse" mechanism. Among immune cells, at the frontier between innate and adaptive immune responses, dendritic cells (DCs) can be pathogen carriers, regulate or exacerbate antiviral responses and neuroinflammation, and therefore be involved in viral transmission and spread. In this review, we highlight an important contribution of DCs in the development and the consequences of viral brain infections.						Constant, Orianne/0000-0003-4141-5563; simonin, yannick/0000-0002-3475-1369	ANR (the French National Research Agency) under the "Investissements d'avenir" program [ANR-16-IDEX-0006]; la Region Occitanie through the PhD funding program [R19068FF]	ANR (the French National Research Agency) under the "Investissements d'avenir" program(French National Research Agency (ANR)); la Region Occitanie through the PhD funding program	This work was publicly funded through ANR (the French National Research Agency) under the "Investissements d'avenir" program with the reference ANR-16-IDEX-0006" and by la Re ' gion Occitanie through the PhD funding program with the reference R19068FF.	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Afonso PV, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000205; Alculumbre S, 2019, SEMIN CELL DEV BIOL, V86, P24, DOI 10.1016/j.semcdb.2018.02.014; Anandasabapathy N, 2011, J EXP MED, V208, P1695, DOI 10.1084/jem.20102657; Ayhan N, 2020, CLIN MICROBIOL INFEC, V26, P1017, DOI 10.1016/j.cmi.2019.12.015; Bailey SL, 2007, NAT IMMUNOL, V8, P172, DOI 10.1038/ni1430; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Basu A, 2004, J NEUROSCI RES, V78, P151, DOI 10.1002/jnr.20266; Belz GT, 2012, NAT REV IMMUNOL, V12, P101, DOI 10.1038/nri3149; Berth SH, 2009, FRONT BIOSCI-LANDMRK, V14, P5239, DOI 10.2741/3595; Bertram KM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10697-w; Bjornevik K, 2022, SCIENCE, V375, P296, DOI 10.1126/science.abj8222; Bogovic P, 2010, TRAVEL MED INFECT DI, V8, P246, DOI 10.1016/j.tmaid.2010.05.011; Brehin AC, 2008, J IMMUNOL, V180, P6760, DOI 10.4049/jimmunol.180.10.6760; Bulloch K, 2008, J COMP NEUROL, V508, P687, DOI 10.1002/cne.21668; Cacciotti G, 2015, VIROLOGY, V485, P189, DOI 10.1016/j.virol.2015.07.015; Canet G, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00307; Carbaugh DL, 2020, J VIROL, V94, DOI 10.1128/JVI.00104-20; Carson MJ, 1999, AM J PATHOL, V154, P481, DOI 10.1016/S0002-9440(10)65294-7; Cassady KA., 2004, INFECT CENTRAL NERVO, V44, P57; Chapagain ML, 2010, J INFECT DIS, V202, P184, DOI 10.1086/653823; Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039; Clarkson BD, 2012, ADV EXP MED BIOL, V946, P309, DOI 10.1007/978-1-4614-0106-3_18; Clay CC, 2007, J VIROL, V81, P12040, DOI 10.1128/JVI.00133-07; Cle M, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-020-02060-4; Cle M, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01904-3; Collin M, 2018, IMMUNOLOGY, V154, P3, DOI 10.1111/imm.12888; Colton CA, 2013, J NEUROIMMUNE PHARM, V8, P145, DOI 10.1007/s11481-012-9414-8; Couderc T, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040029; Courret N, 2006, BLOOD, V107, P309, DOI 10.1182/blood-2005-02-0666; Croese T, 2021, NAT IMMUNOL, V22, P1083, DOI 10.1038/s41590-021-00994-2; Cusi MG, 2016, J NEUROVIROL, V22, P307, DOI 10.1007/s13365-015-0395-2; D'Agostino PM, 2012, ACTA NEUROPATHOL, V124, P599, DOI 10.1007/s00401-012-1018-0; Dando SJ, 2014, CLIN MICROBIOL REV, V27, P691, DOI 10.1128/CMR.00118-13; Daniels BP, 2014, MBIO, V5, DOI 10.1128/mBio.01476-14; DANIELS TE, 1984, J INVEST DERMATOL, V82, P21, DOI 10.1111/1523-1747.ep12259038; De Laere M, 2018, J NEUROPATH EXP NEUR, V77, P178, DOI 10.1093/jnen/nlx114; Decembre E, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004434; Diamond MS, 2004, NAT MED, V10, P1294, DOI 10.1038/nm1204-1294; Dittmar S, 2008, J VIROL, V82, P11273, DOI 10.1128/JVI.00775-08; Doebel T, 2017, TRENDS IMMUNOL, V38, P817, DOI 10.1016/j.it.2017.06.008; Dohner K, 2005, TRENDS MICROBIOL, V13, P320, DOI 10.1016/j.tim.2005.05.010; Durrant DM, 2013, J EXP MED, V210, P503, DOI 10.1084/jem.20121897; Eisenbarth SC, 2019, NAT REV IMMUNOL, V19, P89, DOI 10.1038/s41577-018-0088-1; ESIRI MM, 1982, J NEUROL SCI, V54, P209, DOI 10.1016/0022-510X(82)90183-6; FALANGOLA MF, 1995, J NEUROPATH EXP NEUR, V54, P497, DOI 10.1097/00005072-199507000-00003; Felger JC, 2010, BRAIN BEHAV IMMUN, V24, P724, DOI 10.1016/j.bbi.2009.11.002; Fischer HG, 2001, J IMMUNOL, V166, P2717, DOI 10.4049/jimmunol.166.4.2717; Fischer HG, 2000, J IMMUNOL, V164, P4826, DOI 10.4049/jimmunol.164.9.4826; Fredericksen BL, 2014, J NEUROVIROL, V20, P113, DOI 10.1007/s13365-013-0180-z; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; Ginwala R, 2016, J NEUROIMMUNE PHARM, V11, P36, DOI 10.1007/s11481-015-9617-x; Gnanadurai CW, 2016, ONCOTARGET, V7, P10694, DOI 10.18632/oncotarget.7428; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; Guilliams M, 2016, IMMUNITY, V45, P669, DOI 10.1016/j.immuni.2016.08.015; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Hanly A, 1998, HUM PATHOL, V29, P88, DOI 10.1016/S0046-8177(98)90395-1; Hatterer E, 2006, BLOOD, V107, P806, DOI 10.1182/blood-2005-01-0154; Hatterer E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003321; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Hesske L, 2010, BRAIN, V133, P1637, DOI 10.1093/brain/awq081; Hussain A, 2022, MOL NEUROBIOL, V59, P603, DOI 10.1007/s12035-021-02622-4; Jain P, 2010, J IMMUNOL, V184, P7196, DOI 10.4049/jimmunol.0901404; Johnston Miles, 2004, Cerebrospinal Fluid Res, V1, P2, DOI 10.1186/1743-8454-1-2; Kanneganti TD, 2010, NAT REV IMMUNOL, V10, P688, DOI 10.1038/nri2851; Keaney J, 2015, FEBS J, V282, P4067, DOI 10.1111/febs.13412; Kim J, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008204; Kim JH, 2016, COMP IMMUNOL MICROB, V48, P22, DOI 10.1016/j.cimid.2016.07.007; Kooij G, 2014, ACTA NEUROPATHOL, V128, P267, DOI 10.1007/s00401-013-1227-1; Koyuncu OO, 2013, CELL HOST MICROBE, V13, P379, DOI 10.1016/j.chom.2013.03.010; Lambert H, 2006, CELL MICROBIOL, V8, P1611, DOI 10.1111/j.1462-5822.2006.00735.x; Lamers SL, 2016, J NEUROVIROL, V22, P275, DOI 10.1007/s13365-015-0399-y; Letscher H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84023-0; Li WZ, 2022, THERANOSTICS, V12, P1117, DOI 10.7150/thno.66026; Li XW, 2013, BRAIN RES BULL, V91, P8, DOI 10.1016/j.brainresbull.2012.11.007; Librizzi L, 2007, EPILEPSIA, V48, P743, DOI 10.1111/j.1528-1167.2007.01047.x; Liou ML, 1998, CELL TISSUE RES, V293, P389, DOI 10.1007/s004410051130; Liu K, 2010, EUR J IMMUNOL, V40, P2099, DOI 10.1002/eji.201040501; Liu YL, 2000, J NEUROVIROL, V6, pS70; Ludewig P, 2016, BBA-MOL BASIS DIS, V1862, P352, DOI 10.1016/j.bbadis.2015.11.003; Marchetti Luca, 2020, Vasc Biol, V2, pH1, DOI 10.1530/VB-19-0033; Marques F, 2017, NEUROBIOL DIS, V107, P32, DOI 10.1016/j.nbd.2016.08.011; Mass E, 2016, SCIENCE, V353, DOI 10.1126/science.aaf4238; Maximova OA, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0004980; McCandless EE, 2009, J IMMUNOL, V183, P613, DOI 10.4049/jimmunol.0802258; McGavern DB, 2011, NAT REV IMMUNOL, V11, P318, DOI 10.1038/nri2971; McMahon EJ, 2005, NAT MED, V11, P335, DOI 10.1038/nm1202; McMenamin PG, 1999, J COMP NEUROL, V405, P553, DOI 10.1002/(SICI)1096-9861(19990322)405:4<553::AID-CNE8>3.0.CO;2-6; Meeker RB, 2012, CELL ADHES MIGR, V6, P390, DOI 10.4161/cam.21054; Meeker RB, 2012, CELL TISSUE RES, V347, P443, DOI 10.1007/s00441-011-1301-8; Meinhardt J, 2021, NAT NEUROSCI, V24, P168, DOI 10.1038/s41593-020-00758-5; Michlmayr D, 2017, NAT MICROBIOL, V2, P1462, DOI 10.1038/s41564-017-0035-0; Miller F, 2012, VIRULENCE, V3, P222, DOI 10.4161/viru.19697; Miller SD, 2007, ANN NY ACAD SCI, V1103, P179, DOI 10.1196/annals.1394.023; Mnich ME, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.00309; Munz C, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00308; Mustafa YM, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00525; Nagata N, 2004, J GEN VIROL, V85, P2981, DOI 10.1099/vir.0.79883-0; Nasr N, 2014, J IMMUNOL, V193, P2554, DOI 10.4049/jimmunol.1400630; Neal JW, 2014, J INFECTION, V69, P203, DOI 10.1016/j.jinf.2014.05.010; Newman TA, 2005, J NEUROIMMUNOL, V166, P167, DOI 10.1016/j.jneuroim.2005.04.026; O'Hara BA, 2018, J VIROL, V92, DOI 10.1128/JVI.00105-18; Ohka S, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00147; Ou R, 2008, J VIROL, V82, P2952, DOI 10.1128/JVI.02191-07; Owens T, 2008, J NEUROPATH EXP NEUR, V67, P1113, DOI 10.1097/NEN.0b013e31818f9ca8; Papa MP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02557; Pashenkov M, 2002, TRENDS IMMUNOL, V23, P69, DOI 10.1016/S1471-4906(01)02114-7; Paul AM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04839-7; PELUSO R, 1985, VIROLOGY, V147, P231, DOI 10.1016/0042-6822(85)90246-6; Petito CK, 1999, J NEUROVIROL, V5, P670, DOI 10.3109/13550289909021295; Lenza MP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122691; Pollara G, 2005, INT J EXP PATHOL, V86, P187, DOI 10.1111/j.0959-9673.2005.00440.x; Potratz M, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01074-6; Press R, 2005, J NEUROIMMUNOL, V159, P165, DOI 10.1016/j.jneuroim.2004.09.020; Ransohoff RM, 2012, NAT REV IMMUNOL, V12, P623, DOI 10.1038/nri3265; Reizis B, 2019, IMMUNITY, V50, P37, DOI 10.1016/j.immuni.2018.12.027; Rhodes JW, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22375-x; Rhodes JW, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01088; Rhodes RH, 2007, EPILEPSIA, V48, P1184, DOI 10.1111/j.1528-1167.2007.01034.x; Roe K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102598; Rustenhoven J, 2021, CELL, V184, P1000, DOI 10.1016/j.cell.2020.12.040; Rustenhoven J, 2017, TRENDS PHARMACOL SCI, V38, P291, DOI 10.1016/j.tips.2016.12.001; Sabahi M, 2021, J MOL NEUROSCI, V71, P1410, DOI 10.1007/s12031-021-01818-6; Sagar D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-245; Sagar D, 2012, J NEUROIMMUNE PHARM, V7, P74, DOI 10.1007/s11481-011-9302-7; Salinas S, 2020, M S-MED SCI, V36, P775, DOI 10.1051/medsci/2020122; Salinas S, 2010, NAT REV MICROBIOL, V8, P645, DOI 10.1038/nrmicro2395; Samuel MA, 2007, P NATL ACAD SCI USA, V104, P17140, DOI 10.1073/pnas.0705837104; Samuel MA, 2006, J VIROL, V80, P9349, DOI 10.1128/JVI.01122-06; Savarin C, 2010, J VIROL, V84, P4878, DOI 10.1128/JVI.00051-10; Scheld M.W., 2014, INFECT CENTRAL NERVO, V4th; Schneider H, 2012, VIRUS RES, V170, P66, DOI 10.1016/j.virusres.2012.08.019; Schonrich G, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00417; Schwerk C, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00080; See P, 2017, SCIENCE, V356, DOI 10.1126/science.aag3009; Shives KD, 2017, J NEUROIMMUNOL, V308, P102, DOI 10.1016/j.jneuroim.2017.03.006; Silvin A, 2020, CELL, V182, P1401, DOI 10.1016/j.cell.2020.08.002; Singh G, 2008, EPILEPSIA, V49, P2, DOI 10.1111/j.1528-1167.2008.01749.x; Sodeik B, 2000, TRENDS MICROBIOL, V8, P465, DOI 10.1016/S0966-842X(00)01824-2; Solomon T, 2000, J NEUROL NEUROSUR PS, V68, P405, DOI 10.1136/jnnp.68.4.405; Song ER, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100288; Soto JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01513; Soung A, 2018, TRENDS MOL MED, V24, P950, DOI 10.1016/j.molmed.2018.09.001; Spindler KR, 2012, TRENDS MICROBIOL, V20, P282, DOI 10.1016/j.tim.2012.03.009; SPRECHER E, 1989, ARCH VIROL, V107, P191, DOI 10.1007/BF01317916; Spudich S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a007120; Stamatovic SM, 2008, CURR NEUROPHARMACOL, V6, P179, DOI 10.2174/157015908785777210; Swiecki M, 2015, NAT REV IMMUNOL, V15, P471, DOI 10.1038/nri3865; Sy M, 2011, AM J PATHOL, V178, P2811, DOI 10.1016/j.ajpath.2011.02.012; Tabor-Godwin JM, 2010, J NEUROSCI, V30, P8676, DOI 10.1523/JNEUROSCI.1860-10.2010; Takeshita Y, 2012, IMMUNOL REV, V248, P228, DOI 10.1111/j.1600-065X.2012.01127.x; Tay MZ, 2020, NAT REV IMMUNOL, V20, P363, DOI 10.1038/s41577-020-0311-8; Terry RL, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-270; Thepmankorn P, 2021, CYTOKINE, V138, DOI 10.1016/j.cyto.2020.155404; Tietz S, 2015, J CELL BIOL, V209, P493, DOI 10.1083/jcb.201412147; Tiong V, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02747; Trifilo MJ, 2004, VIROLOGY, V327, P8, DOI 10.1016/j.virol.2004.06.027; TSIANG H, 1979, J NEUROPATH EXP NEUR, V38, P286, DOI 10.1097/00005072-197905000-00008; Valverde P, 2020, CHEMBIOCHEM, V21, P2999, DOI 10.1002/cbic.202000238; Van de Beek D, 2021, LANCET, V398, P1171, DOI 10.1016/S0140-6736(21)00883-7; van den Pol AN, 2009, NEURON, V64, P17, DOI 10.1016/j.neuron.2009.09.023; van Riel D, 2015, J PATHOL, V235, P277, DOI 10.1002/path.4461; Varani S, 2015, VIRUSES-BASEL, V7, P5831, DOI 10.3390/v7112909; Verma S, 2010, VIROLOGY, V397, P130, DOI 10.1016/j.virol.2009.10.036; Veroni C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.665718; Vezzani A, 2014, EPILEPSY CURR, V14, P3, DOI 10.5698/1535-7511-14.s2.3; Villani AC, 2017, SCIENCE, V356, DOI 10.1126/science.aah4573; Walter BA, 2006, NEUROPATH APPL NEURO, V32, P388, DOI 10.1111/j.1365-2990.2006.00737.x; Wang SH, 2008, J IMMUNOL, V181, P2084, DOI 10.4049/jimmunol.181.3.2084; Wang YZ, 2015, J NEUROIMMUNOL, V283, P1, DOI 10.1016/j.jneuroim.2015.03.019; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Wu XD, 2016, J EXP MED, V213, P2553, DOI 10.1084/jem.20160600; Wuest TR, 2008, J IMMUNOL, V181, P7985, DOI 10.4049/jimmunol.181.11.7985; Young VA, 2009, CURR TOP MICROBIOL, V330, P3; Zozulya AL, 2007, J IMMUNOL, V178, P520, DOI 10.4049/jimmunol.178.1.520	176	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								862053	10.3389/fimmu.2022.862053	http://dx.doi.org/10.3389/fimmu.2022.862053			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B9BV	35529884	Green Published, gold			2022-12-18	WOS:000810476600001
J	Guihot, A; Plu, I; Soulie, C; Rousseau, A; Nakid-Cordero, C; Dorgham, K; Parizot, C; Litvinova, E; Mayaux, J; Malet, I; Quentric, P; Combadiere, B; Combadiere, C; Bonduelle, O; Adam, L; Rosenbaum, P; Beurton, A; Hemon, P; Debre, P; Vieillard, V; Autran, B; Seilhean, D; Charlotte, F; Marcelin, AG; Gorochov, G; Luyt, CE				Guihot, Amelie; Plu, Isabelle; Soulie, Cathia; Rousseau, Alice; Nakid-Cordero, Cecilia; Dorgham, Karim; Parizot, Christophe; Litvinova, Elena; Mayaux, Julien; Malet, Isabelle; Quentric, Paul; Combadiere, Behazine; Combadiere, Christophe; Bonduelle, Olivia; Adam, Lucille; Rosenbaum, Pierre; Beurton, Alexandra; Hemon, Patrice; Debre, Patrice; Vieillard, Vincent; Autran, Brigitte; Seilhean, Danielle; Charlotte, Frederic; Marcelin, Anne-Genevieve; Gorochov, Guy; Luyt, Charles-Edouard			Memory CD4+T-Cell Lymphocytic Angiopathy in Fatal Forms of COVID-19 Pulmonary Infection	FRONTIERS IN IMMUNOLOGY			English	Article						COVID<bold; >-19; T cell responses; Broncho-alveolar lavage (BAL); Autopsia; Vasculitis		The immunopathological pulmonary mechanisms leading to Coronavirus Disease (COVID-19)-related death in adults remain poorly understood. Bronchoalveolar lavage (BAL) and peripheral blood sampling were performed in 74 steroid and non-steroid-treated intensive care unit (ICU) patients (23-75 years; 44 survivors). Peripheral effector SARS-CoV-2-specific T cells were detected in 34/58 cases, mainly directed against the S1 portion of the spike protein. The BAL lymphocytosis consisted of T cells, while the mean CD4/CD8 ratio was 1.80 in non-steroid- treated patients and 1.14 in steroid-treated patients. Moreover, strong BAL SARS-CoV-2 specific T-cell responses were detected in 4/4 surviving and 3/3 non-surviving patients. Serum IFN-gamma and IL-6 levels were decreased in steroid-treated patients when compared to non-steroid treated patients. In the lung samples from 3 (1 non-ICU and 2 ICU) additional deceased cases, a lymphocytic memory CD4 T-cell angiopathy colocalizing with SARS-CoV-2 was also observed. Taken together, these data show that disease severity occurs despite strong antiviral CD4 T cell-specific responses migrating to the lung, which could suggest a pathogenic role for perivascular memory CD4 T cells upon fatal COVID-19 pneumonia.					SOULIE, CATHIA/AIF-3965-2022	Gorochov, Guy/0000-0003-2097-9677	ANR Flash COVID19 program and Sorbonne Universite; FIA Foundation	ANR Flash COVID19 program and Sorbonne Universite(French National Research Agency (ANR)); FIA Foundation	The authors thank the ANR Flash COVID19 program and Sorbonne Universite for financial support; T4/T8 department for reception of samples; ImmunoCOVID-Rea (PI:AG), Laura Wakselman, URC Pitie Salpetriere, AP-HP for administrative support; Fondation Dormeur for Elispot reader; COVITIS Biobank (Department of Neuropathology, Pitie Salpetriere Hospital, Assistance Publique-Hppitaux de Paris) for providing lung postmortem samples. The autopsy cases were part of the Coco-neurosciences cohort (study sponsored by APHP and funded by the generous support of the FIA, the FIA Foundation and donors of Paris Brain Institute - ICM). The authors acknowledge the Cytometry core facility Hyperion (Brest, France) for their technical assistance. Publication fees were afforded by Fondation SCOR pour la Science.	Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; Bacher P, 2020, IMMUNITY, V53, P1258, DOI 10.1016/j.immuni.2020.11.016; Chastre J, 2016, INTENS CARE MED, V42, P1159, DOI 10.1007/s00134-016-4239-1; Chen XH, 2020, CLIN INFECT DIS, V71, P1937, DOI 10.1093/cid/ciaa449; Chen YX, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008796; Chu H, 2020, CLIN INFECT DIS, V71, P1400, DOI 10.1093/cid/ciaa410; Monsalvo AC, 2011, NAT MED, V17, P195, DOI 10.1038/nm.2262; Dorgham K, 2021, J ALLERGY CLIN IMMUN, V147, P2098, DOI 10.1016/j.jaci.2021.03.047; Ferguson ND, 2012, INTENS CARE MED, V38, P1573, DOI 10.1007/s00134-012-2682-1; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guihot A, 2014, AM J RESP CRIT CARE, V189, P1240, DOI 10.1164/rccm.201311-2071OC; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2022926, 10.1056/NEJMoa2021436]; Kamphuis E, 2006, BLOOD, V108, P3253, DOI 10.1182/blood-2006-06-027599; Mathew D, 2020, SCIENCE, V369, P1209, DOI 10.1126/science.abc8511; Nakid-Cordero C, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224211; Papazian L, 2020, INTENS CARE MED, V46, P888, DOI 10.1007/s00134-020-05980-0; Peng YC, 2020, NAT IMMUNOL, V21, P1336, DOI [10.1038/s41590-020-0782-6, 10.1101/2020.06.05.134551]; Schmidt M, 2020, LANCET RESP MED, V8, P1121, DOI 10.1016/S2213-2600(20)30328-3; Schub D, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.142167; Sokal A, 2021, CELL, V184, P1201, DOI 10.1016/j.cell.2021.01.050; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Wang YQ, 2020, J CLIN INVEST, V130, P5235, DOI [10.1172/JCI138759, 10.1172/JCI138759.]; Wichmann D, 2020, ANN INTERN MED, V173, P268, DOI 10.7326/M20-2003; Yang Y, 2020, J ALLERGY CLIN IMMUN, V146, P119, DOI 10.1016/j.jaci.2020.04.027	25	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								844727	10.3389/fimmu.2022.844727	http://dx.doi.org/10.3389/fimmu.2022.844727			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T9ZB	35529881	gold, Green Published			2022-12-18	WOS:000876213600001
J	He, CY; Yang, JH; Ye, YB; Zhao, HL; Liu, MZ; Yang, QL; Liu, BS; He, S; Chen, ZL				He, Chuan-Yu; Yang, Jiang-Hua; Ye, Yin-Bo; Zhao, Hai-Long; Liu, Meng-Zhi; Yang, Qi-Lin; Liu, Bao-Shan; He, Sun; Chen, Ze-Liang			Proteomic and Antibody Profiles Reveal Antigenic Composition and Signatures of Bacterial Ghost Vaccine of Brucella abortus A19	FRONTIERS IN IMMUNOLOGY			English	Article						brucellosis; bacterial ghost; vaccine; comparative proteomics; antibody profile	DNA VACCINE; BOVINE BRUCELLOSIS; IMMUNE-RESPONSES; PROTECTION; PROTEIN; MICE; IMMUNIZATION; CANDIDATE; LIPOPOLYSACCHARIDE; IDENTIFICATION	Brucellosis is an important zoonotic disease that causes great economic losses. Vaccine immunisation is the main strategy for the prevention and control of brucellosis. Although live attenuated vaccines play important roles in the prevention of this disease, they also have several limitations, such as residual virulence and difficulty in the differentiation of immunisation and infection. We developed and evaluated a new bacterial ghost vaccine of Brucella abortus A19 by a new double inactivation method. The results showed that the bacterial ghost vaccine of Brucella represents a more safe and efficient vaccine for brucellosis. We further characterised the antigenic components and signatures of the vaccine candidate A19BG. Here, we utilised a mass spectrometry-based label-free relative quantitative proteomics approach to investigate the global proteomics changes in A19BGs compared to its parental A19. The proteomic analysis identified 2014 proteins, 1116 of which were differentially expressed compared with those in A19. The common immunological proteins of OMPs (Bcsp31, Omp25, Omp10, Omp19, Omp28, and Omp2a), HSPs (DnaK, GroS, and GroL), and SodC were enriched in the proteome of A19BG. By protein micro array-based antibody profiling, significant differences were observed between A19BG and A19 immune response, and a number of signature immunogenic proteins were identified. Two of these proteins, the BMEII0032 and BMEI0892 proteins were significantly different (P < 0.01) in distinguishing between A19 and A19BG immune sera and were identified as differential diagnostic antigens for the A19BG vaccine candidate. In conclusion, using comparative proteomics and antibody profiling, protein components and signature antigens were identified for the ghost vaccine candidate A19BG, which are valuable for further developing the vaccine and its monitoring assays.	[He, Chuan-Yu; Yang, Jiang-Hua; Ye, Yin-Bo; Liu, Bao-Shan; Chen, Ze-Liang] Shenyang Agr Univ, Key Lab Livestock Infect Dis, Minist Educ, Shenyang, Peoples R China; [He, Chuan-Yu; Zhao, Hai-Long; Liu, Meng-Zhi; Yang, Qi-Lin; He, Sun; Chen, Ze-Liang] Tecon Biol Co Ltd, Technol Ctr, Urumqi, Peoples R China; [Chen, Ze-Liang] Inner Mongolia Minzu Univ, Innovat Inst Zoonoses, Key Lab Zoonose Prevent & Control Univ Inner Mong, Tongliao, Peoples R China; [Chen, Ze-Liang] Sun Yat Sen Univ, Sch Publ Hlth, Natl Med Prod Adm NMPA Key Lab Qual Monitoring &, Key Lab Trop Dis Control, Guangzhou, Peoples R China	Shenyang Agricultural University; Sun Yat Sen University	Liu, BS; Chen, ZL (corresponding author), Shenyang Agr Univ, Key Lab Livestock Infect Dis, Minist Educ, Shenyang, Peoples R China.; He, S; Chen, ZL (corresponding author), Tecon Biol Co Ltd, Technol Ctr, Urumqi, Peoples R China.; Chen, ZL (corresponding author), Inner Mongolia Minzu Univ, Innovat Inst Zoonoses, Key Lab Zoonose Prevent & Control Univ Inner Mong, Tongliao, Peoples R China.; Chen, ZL (corresponding author), Sun Yat Sen Univ, Sch Publ Hlth, Natl Med Prod Adm NMPA Key Lab Qual Monitoring &, Key Lab Trop Dis Control, Guangzhou, Peoples R China.	lbslgy@syau.edu.cn; hesun@tecon-bio.com; zeliangchen@yahoo.com						Abbassi-Daloii T, 2018, APMIS, V126, P65, DOI 10.1111/apm.12778; Al Dahouk S, 2006, J IMMUNOL METHODS, V309, P34, DOI 10.1016/j.jim.2005.11.003; Arsene F, 2000, INT J FOOD MICROBIOL, V55, P3, DOI 10.1016/S0168-1605(00)00206-3; Batah AM, 2020, EXPERT REV VACCINES, V19, P549, DOI 10.1080/14760584.2020.1777862; Breijyeh Z, 2020, MOLECULES, V25, DOI 10.3390/molecules25061340; CAROFF M, 1984, INFECT IMMUN, V46, P384, DOI 10.1128/IAI.46.2.384-388.1984; CAROFF M, 1984, EUR J BIOCHEM, V139, P195, DOI 10.1111/j.1432-1033.1984.tb07994.x; Cassataro J, 2005, INFECT IMMUN, V73, P6537, DOI 10.1128/IAI.73.10.6537-6546.2005; Chen JS, 2014, VACCINE, V32, P6054, DOI 10.1016/j.vaccine.2014.09.014; Cheng ZM, 2021, VET MICROBIOL, V254, DOI 10.1016/j.vetmic.2021.109007; Connolly JP, 2006, PROTEOMICS, V6, P3767, DOI 10.1002/pmic.200500730; Crasta OR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002193; Avila-Calderon ED, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/743509; Fasaei BN, 2019, IRAN J BIOTECHNOL, V17, P63, DOI 10.29252/ijb.2159; Fu XF, 2014, STRUCTURE, V22, P1875, DOI 10.1016/j.str.2014.09.017; Galperin MY, 2015, NUCLEIC ACIDS RES, V43, pD261, DOI 10.1093/nar/gku1223; Gene Ontology Consortium, 2015, Nucleic Acids Res, V43, pD1049, DOI 10.1093/nar/gku1179; Goel D, 2013, VACCINE, V31, P1231, DOI 10.1016/j.vaccine.2012.12.043; Goel D, 2012, MOL IMMUNOL, V51, P159, DOI 10.1016/j.molimm.2012.02.126; Gonzalez-Espinoza G, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020186; Gonzalez-Smith A, 2006, IMMUNOBIOLOGY, V211, P65, DOI 10.1016/j.imbio.2005.09.004; Goodwin ZI, 2016, VET IMMUNOL IMMUNOP, V181, P54, DOI 10.1016/j.vetimm.2016.03.011; He CY, 2022, MICROB PATHOGENESIS, V162, DOI 10.1016/j.micpath.2021.105363; Hensel A, 2000, VACCINE, V18, P2945, DOI 10.1016/S0264-410X(00)00107-9; Huy TXN, 2021, FRONT VET SCI, V7, DOI 10.3389/fvets.2020.577026; Im YB, 2018, JPN J INFECT DIS, V71, P197, DOI [10.7883/yoken.jjid.2017.019, 10.7883/yoken.JJID.2017.019]; Jawale CV, 2014, AVIAN PATHOL, V43, P506, DOI 10.1080/03079457.2014.966303; Jawale CV, 2014, VACCINE, V32, P5925, DOI 10.1016/j.vaccine.2014.08.072; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Khurana SK, 2021, VET QUART, V41, P61, DOI 10.1080/01652176.2020.1868616; Kim JY, 2014, VET IMMUNOL IMMUNOP, V160, P218, DOI 10.1016/j.vetimm.2014.05.009; Ko JY, 2003, CLIN MICROBIOL REV, V16, P65, DOI 10.1128/CMR.16.1.65-78.2003; Kudela P, 2010, VACCINE, V28, P5760, DOI 10.1016/j.vaccine.2010.06.087; Langemann Timo, 2010, Bioeng Bugs, V1, P326, DOI 10.4161/bbug.1.5.12540; Liu J, 2015, VET IMMUNOL IMMUNOP, V166, P138, DOI 10.1016/j.vetimm.2015.04.008; Luo D, 2006, INFECT IMMUN, V74, P2734, DOI 10.1128/IAI.74.5.2734-2741.2006; Marchart J, 2003, VACCINE, V21, P3988, DOI 10.1016/S0264-410X(03)00383-9; MAYFIELD JE, 1988, GENE, V63, P1, DOI 10.1016/0378-1119(88)90540-9; Mayr UB, 2005, INFECT IMMUN, V73, P4810, DOI 10.1128/IAI.73.8.4810-4817.2005; Minhas P, 2021, ARCH MICROBIOL, V203, P2719, DOI 10.1007/s00203-021-02190-0; Munoz PM, 2005, CLIN DIAGN LAB IMMUN, V12, P141, DOI 10.1128/CDLI.12.1.141-151.2005; Olsen SC, 2014, VET PATHOL, V51, P1076, DOI 10.1177/0300985814540545; Pasquevich KA, 2009, INFECT IMMUN, V77, P436, DOI 10.1128/IAI.01151-08; Poetsch A, 2020, PROTEOMES, V8, DOI 10.3390/proteomes8020008; Ponsart C, 2019, VET RES, V50, DOI 10.1186/s13567-019-0717-0; SCHURIG GG, 1991, VET MICROBIOL, V28, P171, DOI 10.1016/0378-1135(91)90091-S; Walcher Petra, 2004, Expert Rev Vaccines, V3, P681, DOI 10.1586/14760584.3.6.681; Wang SL, 2020, MOL IMMUNOL, V124, P117, DOI 10.1016/j.molimm.2020.06.002; Wang SY, 2020, GENOMICS, V112, P1444, DOI 10.1016/j.ygeno.2019.08.015; WITTE A, 1992, ARCH MICROBIOL, V157, P381, DOI 10.1007/BF00248685; Yang JH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.679560; Yu DH, 2007, DNA CELL BIOL, V26, P435, DOI 10.1089/dna.2006.0552; Zhang N, 2018, PREV VET MED, V160, P105, DOI 10.1016/j.prevetmed.2018.10.002; Zhao ZP, 2011, SCI CHINA LIFE SCI, V54, P880, DOI 10.1007/s11427-011-4218-2; Zheng RJ, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5712920	55	0	0	4	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								874871	10.3389/fimmu.2022.874871	http://dx.doi.org/10.3389/fimmu.2022.874871			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T9SV	35529865	gold, Green Published			2022-12-18	WOS:000876197400001
J	Iaiza, A; Tito, C; Ganci, F; Sacconi, A; Gallo, E; Masciarelli, S; Fontemaggi, G; Fatica, A; Melis, E; Petrozza, V; Venuta, F; Marino, M; Blandino, G; Fazi, F				Iaiza, Alessia; Tito, Claudia; Ganci, Federica; Sacconi, Andrea; Gallo, Enzo; Masciarelli, Silvia; Fontemaggi, Giulia; Fatica, Alessandro; Melis, Enrico; Petrozza, Vincenzo; Venuta, Federico; Marino, Mirella; Blandino, Giovanni; Fazi, Francesco			Long Non-Coding RNAs in the Cell Fate Determination of Neoplastic Thymic Epithelial Cells	FRONTIERS IN IMMUNOLOGY			English	Review						thymoma; thymic carcinoma; thymic epithelial tumors (TETs); ncRNAs (non coding RNAs); miRNA; microRNA; lncRNA; long noncoding RNA; MALAT1; myasthenia gravis	MYASTHENIA-GRAVIS; THYMOMA; CANCER; PROMOTES; CLASSIFICATION; EXPRESSION; IDENTIFICATION; PROGRESSION; CARCINOMA; BIOMARKER	Thymic Epithelial Tumors (TETs) arise from epithelial cells of the thymus and are very rare neoplasms comprising Thymoma, Thymic carcinoma, and Thymic Neuroendocrine tumors that still require in-depth molecular characterization. Long non-coding RNAs (lncRNAs) are emerging as relevant gene expression modulators involved in the deregulation of several networks in almost all types of human cancer, including TETs. LncRNAs act at different control levels in the regulation of gene expression, from transcription to translation, and modulate several pathways relevant to cell fate determination under normal and pathological conditions. The activity of lncRNAs is strongly dependent on their expression, localization, and post-transcriptional modifications. Starting from our recently published studies, this review focuses on the involvement of lncRNAs in the acquisition of malignant traits by neoplastic thymic epithelial cells, and describes the possible use of these molecules as targets for the design of novel therapeutic approaches specific for TET. Furthermore, the involvement of lncRNAs in myasthenia gravis (MG)-related thymoma, which is still under investigation, is discussed.					Gallo, Enzo/AAB-3121-2020; sacconi, andrea/J-3669-2018; Fontemaggi, Giulia/K-9702-2016	Gallo, Enzo/0000-0002-4938-4071; sacconi, andrea/0000-0002-8276-0438; Fontemaggi, Giulia/0000-0001-8332-8842				Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99; Bellissimo T, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0655-2; Bellissimo T, 2016, CANCER BIOL THER, V17, P79, DOI 10.1080/15384047.2015.1108493; Beloor Suresh A., 2022, MYASTHENIA GRAVIS ST; Benjamin DJ, 2019, CLIN LUNG CANCER, V20, P477, DOI 10.1016/j.cllc.2019.06.005; Bhat Shakil Ahmad, 2016, Noncoding RNA Res, V1, P43, DOI 10.1016/j.ncrna.2016.11.002; Blandino G, 2014, FEBS LETT, V588, P2639, DOI 10.1016/j.febslet.2014.03.033; Bortone F, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00142; Chen KG, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026271; Chen M, 2020, DIGEST DIS SCI, V65, P2442, DOI 10.1007/s10620-019-05916-9; Conforti F, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102014; Cong ZZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1361-3; Cordiglieri C, 2014, J AUTOIMMUN, V52, P74, DOI 10.1016/j.jaut.2013.12.013; Corthay A, 2009, SCAND J IMMUNOL, V70, P326, DOI 10.1111/j.1365-3083.2009.02308.x; Cron MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01074; Enkner F, 2017, PATHOL ONCOL RES, V23, P551, DOI 10.1007/s12253-016-0144-8; Fazi F, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00116; Fujii Y, 2013, SURG TODAY, V43, P461, DOI 10.1007/s00595-012-0318-2; Ganci F, 2014, LUNG CANCER, V85, P197, DOI 10.1016/j.lungcan.2014.04.008; Gao N, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.598817; Gilhus NE, 2015, LANCET NEUROL, V14, P1023, DOI 10.1016/S1474-4422(15)00145-3; Gong J, 2018, CLIN LAB, V64, P1193, DOI 10.7754/Clin.Lab.2018.180136; Grillone K, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01622-x; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Han DM, 2018, ONCOTARGET, V9, P2395, DOI 10.18632/oncotarget.23416; Han Y, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.407; He RZ, 2019, GENES DIS, V6, P6, DOI 10.1016/j.gendis.2019.01.003; Hu B, 2020, SCAND J IMMUNOL, V92, DOI 10.1111/sji.12886; Hu LW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0123-z; Huang WZ, 2017, ONCOL REP, V38, P1402, DOI 10.3892/or.2017.5837; Iaiza A, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01159-6; Ji GL, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.929727; Jiang HY, 2020, EUR REV MED PHARMACO, V24, P2380, DOI 10.26355/eurrev_202003_20505; Kashima J, 2017, J THORAC DIS, V9, P3656, DOI 10.21037/jtd.2017.09.126; Ke J, 2022, THORAC CANCER, V13, P15, DOI 10.1111/1759-7714.14201; Koneczny I, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070671; Kong XT, 2019, J CELL BIOCHEM, V120, P5542, DOI 10.1002/jcb.27838; Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7; Lai XY, 2021, CELL BIOL INT, V45, P2287, DOI 10.1002/cbin.11676; Lazaridis K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00212; Li N, 2020, J CELL MOL MED, V24, P11318, DOI 10.1111/jcmm.15713; Li SL, 2019, AGING-US, V11, P11609, DOI 10.18632/aging.102563; Li ZX, 2018, CANCER MANAG RES, V10, P6757, DOI 10.2147/CMAR.S169406; Liu HQ, 2018, J CELL BIOCHEM, V119, P1679, DOI 10.1002/jcb.26328; Lopez-Jimenez E, 2021, NON-CODING RNA, V7, DOI 10.3390/ncrna7010017; Lu JY, 2013, NEUROSCI LETT, V555, P85, DOI 10.1016/j.neulet.2013.09.014; Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034; Luo ZH, 2015, BMC MED GENOMICS, V8, DOI 10.1186/s12920-015-0087-z; Lv J, 2021, CLIN IMMUNOL, V224, DOI 10.1016/j.clim.2021.108676; Marino M, 2021, PATHOLOGICA, V113, P360, DOI 10.32074/1591-951X-539; Marx A, 2022, J THORAC ONCOL, V17, P200, DOI 10.1016/j.jtho.2021.10.010; Marx A, 2021, SEMIN IMMUNOPATHOL, V43, P45, DOI 10.1007/s00281-021-00842-3; Niu L, 2020, CLIN EXP PHARMACOL P, V47, P989, DOI 10.1111/1440-1681.13280; Nogales-Gadea G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091927; Obata Y, 2014, NAT IMMUNOL, V15, P571, DOI 10.1038/ni.2886; Palazzo AF, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00002; Patop IL, 2018, CURR OPIN GENET DEV, V48, P121, DOI 10.1016/j.gde.2017.11.007; Petrini I, 2014, NAT GENET, V46, P844, DOI 10.1038/ng.3016; Pruszko M, 2017, EMBO REP, V18, P1331, DOI 10.15252/embr.201643370; Punga T, 2014, ANN CLIN TRANSL NEUR, V1, P49, DOI 10.1002/acn3.24; Qu SB, 2018, CANCER LETT, V414, P301, DOI 10.1016/j.canlet.2017.11.022; Radovich M, 2018, CANCER CELL, V33, P244, DOI 10.1016/j.ccell.2018.01.003; Radovich M, 2016, BRIT J CANCER, V114, P477, DOI 10.1038/bjc.2015.425; Romano G, 2017, CARCINOGENESIS, V38, P485, DOI 10.1093/carcin/bgx026; Romi F, 2017, CURR OPIN IMMUNOL, V49, P9, DOI 10.1016/j.coi.2017.07.006; Scorsetti M, 2016, CRIT REV ONCOL HEMAT, V99, P332, DOI 10.1016/j.critrevonc.2016.01.012; Shi DY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1363-0; Shi Y, 2020, CLIN TRANSL ONCOL, V22, P2162, DOI 10.1007/s12094-020-02371-1; Sohel MMH, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117473; Su YC, 2020, THORAC CANCER, V11, P1773, DOI 10.1111/1759-7714.13439; Sun TT, 2016, CANCER DISCOV, V6, P784, DOI 10.1158/2159-8290.CD-15-0921; Tan S, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12846; Thapa P, 2019, THORAC SURG CLIN, V29, P123, DOI 10.1016/j.thorsurg.2018.12.001; Tito C, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03171-9; Uzawa A, 2014, CLIN EXP IMMUNOL, V176, P232, DOI 10.1111/cei.12272; Venuta F, 2012, GEN THORAC CARDIOVAS, V60, P1, DOI 10.1007/s11748-011-0814-0; Wan JF, 2020, EUR REV MED PHARMACO, V24, P6818, DOI 10.26355/eurrev_202006_21671; Wang J, 2021, ONCOL REP, V45, DOI 10.3892/or.2021.8068; Wang JY, 2019, CLIN CHIM ACTA, V490, P17, DOI 10.1016/j.cca.2018.12.013; Wang ML, 2019, TRANSL CANCER RES, V8, P2636, DOI 10.21037/tcr.2019.10.22; Wang SH, 2018, EXPERT REV NEUROTHER, V18, P573, DOI 10.1080/14737175.2018.1491310; Wang YS, 2014, SCI REP-UK, V4, DOI 10.1038/srep07336; Wang Z, 2012, SCAND J IMMUNOL, V76, P54, DOI 10.1111/j.1365-3083.2012.02703.x; Wen SM, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01293-4; Wolfien M, 2019, METHODS MOL BIOL, V1912, P111, DOI 10.1007/978-1-4939-8982-9_5; Wu QJ, 2021, THORAC CANCER, V12, P1312, DOI 10.1111/1759-7714.13873; Wu Y, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.593431; Xiu DH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1100-8; Yang J, 2019, AGING-US, V11, P6422, DOI 10.18632/aging.102197; Ye D, 2019, CANCER MANAG RES, V11, P969, DOI 10.2147/CMAR.S191696; Yilmaz V, 2007, HUM IMMUNOL, V68, P544, DOI 10.1016/j.humimm.2007.02.003; Yu FJ, 2015, J BIOL CHEM, V290, P28286, DOI 10.1074/jbc.M115.683813; Yuan JH, 2017, NAT CELL BIOL, V19, P820, DOI 10.1038/ncb3538; Zhang H, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00880; Zhang PJ, 2019, J INTEGR BIOINFORMAT, V16, DOI 10.1515/jib-2019-0027; Zhang ZF, 2016, ONCOL LETT, V11, P4177, DOI 10.3892/ol.2016.4528; Zhao WY, 2018, CANCER MED-US, V7, P842, DOI 10.1002/cam4.1353; Zhuang JM, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.756493	98	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								867181	10.3389/fimmu.2022.867181	http://dx.doi.org/10.3389/fimmu.2022.867181			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T9DV	35529877	gold, Green Published			2022-12-18	WOS:000876158300001
J	Jones, K; Ramirez-Perez, S; Niu, S; Gangishetti, U; Drissi, H; Bhattaram, P				Jones, Kyle; Ramirez-Perez, Sergio; Niu, Sean; Gangishetti, Umesh; Drissi, Hicham; Bhattaram, Pallavi			SOX4 and RELA Function as Transcriptional Partners to Regulate the Expression of TNF- Responsive Genes in Fibroblast-Like Synoviocytes	FRONTIERS IN IMMUNOLOGY			English	Article						NF-kappaB; SOX4 transcription factor; RelA; p65; synovial fibroblasts (FLS); TNF; rheumatoid arthritis	NF-KAPPA-B; SYNOVIAL FIBROBLASTS; INFLAMMATION; ARTHRITIS	SOX4 belongs to the group C of the SOX transcription factor family. It is a critical mediator of tumor necrosis factor alpha (TNF)-induced transformation of fibroblast-like s-ynoviocytes (FLS) in arthritis. In this study we investigated the genome wide association between the DNA binding and transcriptional activities of SOX4 and the NF-kappaB signaling transcription factor RELA/p65 downstream of TNF signaling. We used ChIP-seq assays in mouse FLS to compare the global DNA binding profiles of SOX4 and RELA. RNA-seq of TNF-induced wildtype and SoxC-knockout FLS was used to identify the SOX4-dependent and independent aspects of the TNF-regulated transcriptome. We found that SOX4 and RELA physically interact with each other on the chromatin. Interestingly, ChIP-seq assays revealed that 70.4% of SOX4 peak summits were within 50bp of the RELA peak summits suggesting that both proteins bind in close-proximity on regulatory sequences, enabling them to co-operatively regulate gene expression. By integrating the ChIP-seq results with RNA-seq from SoxC-knockout FLS we identified a set of TNF-responsive genes that are targets of the RELA-SOX4 transcriptional complex. These TNF-responsive and RELA-SOX4-depenedent genes included inflammation mediators, histone remodeling enzymes and components of the AP-1 signaling pathway. We also identified an autoregulatory mode of SoxC gene expression that involves a TNF-mediated switch from RELA binding to SOX4 binding in the 3' UTR of Sox4 and Sox11 genes. In conclusion, our results show that SOX4 and RELA together orchestrate a multimodal regulation of gene expression downstream of TNF signaling. Their interdependent activities play a pivotal role in the transformation of FLS in arthritis and in the inflammatory pathology of diverse tissues where RELA and SOX4 are co-expressed.						Ramirez-Perez, Sergio/0000-0002-3130-8695; drissi, hicham/0000-0002-3322-281X	National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Disease [R01 AR070736]; Startup funds from the Department of Orthopaedics; Emory University School of Medicine	National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Disease; Startup funds from the Department of Orthopaedics; Emory University School of Medicine	We thank the support from the National Institutes of Health/National Institute of Arthritis, Musculoskeletal and Skin Disease grant (R01 AR070736) and Startup funds from the Department of Orthopaedics, Emory University School of Medicine to PB.	Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Ahmed AS, 2018, J IMMUNOL, V201, P1918, DOI 10.4049/jimmunol.1800486; Ahmed EA, 2021, J MED FOOD, V24, P282, DOI 10.1089/jmf.2020.4862; Armaka M., 2009, PROTOCOL EXCHANGE, V1038, DOI [10.1038/nprot.2009.102, DOI 10.1038/NPROT.2009.102]; Bhattaram P, 2018, ARTHRITIS RHEUMATOL, V70, P371, DOI 10.1002/art.40386; Bhattaram P, 2015, ONCOTARGET, V6, P24596, DOI 10.18632/oncotarget.5237; Bhattaram P, 2014, J CELL BIOL, V207, P657, DOI 10.1083/jcb.201405098; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Chawla M, 2021, CURR OPIN IMMUNOL, V68, P21, DOI 10.1016/j.coi.2020.08.005; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162; Gangishetti U, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77380-9; Gao Y, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2020.111814; Gu XD, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.105752; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Kawabata Tomoko, 2010, Arthritis Res Ther, V12, pR133, DOI 10.1186/ar3071; Kielbasa SM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003210; Lefebvre V, 2019, CURR TOP DEV BIOL, V133, P171, DOI 10.1016/bs.ctdb.2019.01.007; Li G, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02454-x; Lim CA, 2007, MOL CELL, V27, P622, DOI 10.1016/j.molcel.2007.06.038; Liu S, 2021, CLIN IMMUNOL, V230, DOI 10.1016/j.clim.2021.108793; Ma WX, 2014, NAT PROTOC, V9, P1428, DOI 10.1038/nprot.2014.083; Makarov SS, 2001, ARTHRITIS RES, V3, P200, DOI 10.1186/ar300; Mead TJ, 2013, NUCLEIC ACIDS RES, V41, P4459, DOI 10.1093/nar/gkt140; Mulero MC, 2019, NUCLEIC ACIDS RES, V47, P9967, DOI 10.1093/nar/gkz739; Ngondo RP, 2014, NUCLEIC ACIDS RES, V42, P2171, DOI 10.1093/nar/gkt1136; Ntougkos E, 2017, ARTHRITIS RHEUMATOL, V69, P1588, DOI 10.1002/art.40128; Nygaard G, 2020, NAT REV RHEUMATOL, V16, P316, DOI 10.1038/s41584-020-0413-5; Pap T, 2020, SEMIN CELL DEV BIOL, V101, P140, DOI 10.1016/j.semcdb.2019.12.006; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Seok J, 2021, J PERS MED, V11, DOI 10.3390/jpm11080823; Shao L, 2019, BIOCHEM BIOPH RES CO, V519, P166, DOI 10.1016/j.bbrc.2019.08.092; Simmonds RE, 2008, RHEUMATOLOGY, V47, P584, DOI 10.1093/rheumatology/kem298; Suehiro KI, 2021, CELL MOL IMMUNOL, V18, P1729, DOI 10.1038/s41423-020-0384-0; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Takahata Y, 2019, FASEB J, V33, P619, DOI 10.1096/fj.201800259R; Tanaka S, 2018, J EXP MED, V215, P2509, DOI 10.1084/jem.20172082; Vervoort SJ, 2018, NUCLEIC ACIDS RES, V46, P9578, DOI 10.1093/nar/gky755; Wang WJ, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02456-4; Xiong XY, 2021, ACS OMEGA, V6, P7638, DOI 10.1021/acsomega.0c06212; Xu JM, 2020, AM J TRANSL RES, V12, P8162; Ye XK, 2021, EXP GERONTOL, V156, DOI 10.1016/j.exger.2021.111616; Zhang F, 2019, NAT IMMUNOL, V20, P928, DOI 10.1038/s41590-019-0378-1; Zhang WF, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/9941733; Zhao W, 2011, J IMMUNOL, V186, P3173, DOI 10.4049/jimmunol.1003626	46	0	0	0	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								789349	10.3389/fimmu.2022.789349	http://dx.doi.org/10.3389/fimmu.2022.789349			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T9QG	35529852	Green Published, gold			2022-12-18	WOS:000876190600001
J	Kawasoe, J; Uchida, Y; Kawamoto, H; Miyauchi, T; Watanabe, T; Saga, K; Tanaka, K; Ueda, S; Terajima, H; Taura, K; Hatano, E				Kawasoe, Junya; Uchida, Yoichiro; Kawamoto, Hiroshi; Miyauchi, Tomoyuki; Watanabe, Takeshi; Saga, Kenichi; Tanaka, Kosuke; Ueda, Shugo; Terajima, Hiroaki; Taura, Kojiro; Hatano, Etsuro			Propionic Acid, Induced in Gut by an Inulin Diet, Suppresses Inflammation and Ameliorates Liver Ischemia and Reperfusion Injury in Mice	FRONTIERS IN IMMUNOLOGY			English	Article						liver ischemia-reperfusion injury; inulin diet; short-chain fatty acid; gut microbiota; propionic acid	CHAIN FATTY-ACIDS; HEPATIC ISCHEMIA/REPERFUSION INJURY; HISTONE DEACETYLASE; BUTYRATE; CELL; MICROBIOTA; ASSOCIATION; APOPTOSIS; BENEFITS; NECROSIS	Liver ischemia and reperfusion injury (IRI) is one of the obstacles in liver surgery such as liver resection and transplantation. In this study, we investigated the preventive effect on mouse liver IRI by feeding mice with inulin, which is a heterogeneous blend of indigestible fructose polymer. Mice were fed either a control ordinary diet (CD) or an inulin diet (ID) containing 5% inulin in the CD, for 14 days before the ischemia and reperfusion (IR) maneuver. IR induced-liver damages were significantly ameliorated in the ID group, compared with those in the CD group. Feeding mice with an ID, but not a CD, elevated levels of Bacteroidetes among gut microbiota, and especially increased Bacteroides acidifaciens in mouse feces, which resulted in significant elevation of short-chain fatty acids (SCFAs) in the portal vein of mice. Among SCFAs, propionic acid (PA) was most significantly increased. The microbial gene functions related to PA biosynthesis were much higher in the fecal microbiome of the ID group compared to the CD. However, the action of PA on liver IRI has not been yet clarified. Direct intraperitoneal administration of PA alone prior to the ischemia strongly suppressed liver cell damages as well as inflammatory responses caused by liver IR. Furthermore, PA suppressed the secretion of inflammatory cytokines from peritoneal macrophages stimulated in vitro through TLR-4 with high-mobility group box 1 protein (HMGB-1), known to be released from apoptotic liver cells during the IR insult. The present study shows that PA may play a key role in the inulin-induced amelioration of mouse liver IRI.	[Kawasoe, Junya; Uchida, Yoichiro; Kawamoto, Hiroshi; Saga, Kenichi; Tanaka, Kosuke; Terajima, Hiroaki; Taura, Kojiro; Hatano, Etsuro] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan; [Kawasoe, Junya; Uchida, Yoichiro; Kawamoto, Hiroshi; Miyauchi, Tomoyuki; Saga, Kenichi; Tanaka, Kosuke; Ueda, Shugo; Terajima, Hiroaki] Kitano Hosp Med Res Inst, Dept Gastroenterol Surg & Oncol, Osaka, Japan; [Watanabe, Takeshi] Kyoto Univ, Inst Frontier Life & Med Sci, Div Immunol, Kyoto, Japan	Kyoto University; Kitano Hospital; Kyoto University	Uchida, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan.; Uchida, Y (corresponding author), Kitano Hosp Med Res Inst, Dept Gastroenterol Surg & Oncol, Osaka, Japan.	uchiday@kuhp.kyoto-u.ac.jp		Tanaka, Kosuke/0000-0003-4958-4345	Ministry of Education, Culture, Science and Sports, Japan [18K08609, 20H03743, 19K24019]; Tazuke Kofukai Medical Research Institute, Kitano Hospital	Ministry of Education, Culture, Science and Sports, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Tazuke Kofukai Medical Research Institute, Kitano Hospital	This study was supported by a Grant-in-Aid for Scientific Research C: 18K08609, B: 20H03743 and Research Activity Start-up: 19K24019 from the Ministry of Education, Culture, Science and Sports, Japan and by the Kitano Research Grant from The Tazuke Kofukai Medical Research Institute, Kitano Hospital.	Aguilar-Nascimento José Eduardo de, 2006, Acta Cir. Bras., V21, P21, DOI 10.1590/S0102-86502006000100006; Bartolomaeus H, 2019, CIRCULATION, V139, P1407, DOI 10.1161/CIRCULATIONAHA.118.036652; Bindels LB, 2012, BRIT J CANCER, V107, P1337, DOI 10.1038/bjc.2012.409; Castillo-Lopez E, 2020, J DAIRY SCI, V103, P8020, DOI 10.3168/jds.2019-18036; Chijiiwa R, 2020, MICROBIOME, V8, DOI 10.1186/s40168-019-0779-2; Colletti LM, 1996, HEPATOLOGY, V23, P506; Dar WA, 2019, LIVER INT, V39, DOI 10.1111/liv.14091; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Hirao H, 2020, FREE RADICAL BIO MED, V157, P75, DOI 10.1016/j.freeradbiomed.2020.02.012; Igarashi M, 2020, PEERJ, V8, DOI 10.7717/peerj.8893; Kadono K, 2017, AM J TRANSPLANT, V17, P69, DOI 10.1111/ajt.13991; Kawase T, 2020, CHROMATOGRAPHY, V41, P63, DOI 10.15583/jpchrom.2019.025; Kawasoe J, 2021, AM J TRANSPLANT, V21, P540, DOI 10.1111/ajt.16269; Kohli V, 1999, TRANSPLANTATION, V67, P1099, DOI 10.1097/00007890-199904270-00003; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Le Bastard Q, 2020, EUR J CLIN MICROBIOL, V39, P403, DOI 10.1007/s10096-019-03721-w; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lentsch AB, 1998, HEPATOLOGY, V27, P507, DOI 10.1002/hep.510270226; Liu B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106184; Liu XQ, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054077, 10.1371/journal.pone.0077367, 10.1371/journal.pone.0058489]; Macfarlane S, 2003, P NUTR SOC, V62, P67, DOI 10.1079/PNS2002207; Melloul E, 2016, WORLD J SURG, V40, P2425, DOI 10.1007/s00268-016-3700-1; Miyauchi T, 2019, P NATL ACAD SCI USA, V116, P13533, DOI 10.1073/pnas.1820282116; Miyauchi T, 2019, JPEN-PARENTER ENTER, V43, P133, DOI 10.1002/jpen.1308; Nace GW, 2013, HEPATOLOGY, V58, P374, DOI 10.1002/hep.26346; Qiao YL, 2014, J SURG RES, V187, P653, DOI 10.1016/j.jss.2013.08.028; Qiao YL, 2015, J SURG RES, V197, P324, DOI 10.1016/j.jss.2015.04.031; Reeves PG., 1997, J NUTR, V127, p41s, DOI [10.1093/jn/127/5/838S, DOI 10.1093/JN/127/5/838S]; Roberfroid M, 2000, CRIT REV FOOD SCI, V40, P461, DOI 10.1080/10408690091189239; Rodriguez-Carrio J, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00023; Rudiger HA, 2002, GASTROENTEROLOGY, V122, P202, DOI 10.1053/gast.2002.30304; Salonen A, 2014, ISME J, V8, P2218, DOI 10.1038/ismej.2014.63; Shoaib M, 2016, CARBOHYD POLYM, V147, P444, DOI 10.1016/j.carbpol.2016.04.020; Silva LG, 2018, J ANIM SCI, V96, P5244, DOI 10.1093/jas/sky373; Sivaprakasam S, 2016, PHARMACOL THERAPEUT, V164, P144, DOI 10.1016/j.pharmthera.2016.04.007; Spychala MS, 2018, ANN NEUROL, V84, P23, DOI 10.1002/ana.25250; Sugatani J, 2006, DRUG METAB DISPOS, V34, P1677, DOI 10.1124/dmd.106.010645; Sun J, 2014, INT J MOL SCI, V15, P21069, DOI 10.3390/ijms151121069; Sun J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/395895; Suzuki M, 2002, JPN J PHARMACOL, V89, P36, DOI 10.1254/jjp.89.36; SUZUKI S, 1993, TRANSPLANTATION, V55, P1265; Then CK, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00836-x; Tian XL, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00159; Tirosh A, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav0120; Tsukahara T, 2014, ANIM SCI J, V85, P494, DOI 10.1111/asj.12188; Tsung A, 2005, J EXP MED, V201, P1135, DOI 10.1084/jem.20042614; Wang YR, 2019, AGING-US, V11, P5535, DOI 10.18632/aging.102136; Wang Z, 2020, INT IMMUNOPHARMACOL, V78, DOI 10.1016/j.intimp.2019.106062; Watanabe T, 2005, J SURG RES, V124, P59, DOI 10.1016/j.jss.2004.10.019; Yang RD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.573475; Yoon SH, 2017, INT J SYST EVOL MICR, V67, P1613, DOI 10.1099/ijsem.0.001755; Zhai Y, 2013, NAT REV GASTRO HEPAT, V10, P79, DOI 10.1038/nrgastro.2012.225; Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981; Zhang W, 2007, TRANSPL P, V39, P1332, DOI 10.1016/j.transproceed.2006.11.021; Zheng W, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205055; Zhou JB, 2020, LIVER TRANSPLANT, V26, P1034, DOI 10.1002/lt.25779; Zhu LL, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-019-1167-4	57	0	0	3	4	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								862503	10.3389/fimmu.2022.862503	http://dx.doi.org/10.3389/fimmu.2022.862503			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1G5WV	35572528	gold, Green Published			2022-12-18	WOS:000795919400001
J	Li, H; Lin, X; Liu, LL; Qin, L; Zheng, YH; Liu, XH; Wei, XH; Liang, S; Liu, YL; Zhang, J; Chen, XY; Cao, ZH				Li, Hong; Lin, Xiao; Liu, Lili; Qin, Ling; Zheng, Yanhong; Liu, Xiaohui; Wei, Xinhuan; Liang, Shan; Liu, Yali; Zhang, Jing; Chen, Xinyue; Cao, Zhenhuan			Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers	FRONTIERS IN IMMUNOLOGY			English	Article						inactive HBsAg carriers; HBsAg clearance; pegylated interferon; lgG; predictor	SUSTAINED RESPONSE; PEGINTERFERON; EXPRESSION	PurposeOur recent study showed a high rate of HBsAg clearance in inactive HBsAg carriers (IHCs) treated with pegylated IFN (PEG-IFN). To better understand the immune-mediated component of HBsAg clearance, this study investigated the role of serum immunoglobulin G (IgG) and its subclasses in predicting HBsAg clearance in IHCs with PEG-IFN therapy. MethodsIn this study, IHCs received PEG-IFN for 96 weeks. Subjects who achieved clearance of HBsAg were considered responders (R group), and those in whom HBsAg was not cleared were considered non-responders (NR group). The HBsAg, ALT, and serum lgG subtypes (lgG1, IgG2, IgG3, lgG4) were tested at baseline, and at 12 and 24 weeks of treatment. To evaluate the factors in predicting HBsAg clearance, univariate and multivariate logistic regression analyses were performed. The receiver operator characteristic curves and the area under the receiver operator characteristic curve (AUROC) were used to evaluate prognostic values. ResultsOur results showed that 39 cases obtained HBsAg clearance (group R), while 21 cases did not (group NR). There was no significant difference in age, ALT, and AST levels between the two groups. The serum levels of IgG1, lgG2, lgG3 and lgG4 at baseline, and at 12 and 24 weeks were significantly lower in IHC with HBsAg clearance than in the NR group. Univariate logistic regression analysis showed that serum IgG1, IgG2, IgG3, and IgG4 levels at baseline, and at 12, and 24 weeks were all strong predictors of HBsAg clearance. In all indicators, lgG2 had the highest AUROC at baseline and lgG3 the highest AUROC at week 12. A multifactor logistic analysis was performed with y=33.933-0.001*BaselinelgG1-0.002*BaselinelgG2. The area under the curve was 0.941 with 100% sensitivity and 76.19% specificity. ConclusionTogether, our findings suggest that serum IgG has a higher predictive value compared to the convention predictors of HBsAg and ALT for HBsAg clearance and thus may be a better clinical predictor of HBsAg clearance in IHCs.					chen, xinyue/HHR-9308-2022		Chinese National Natural Science Foundation [81900537]; Beijing Hospitals Authority Clinical medicine Development of special funding support [XMLX202125]; Capital Health Research and Development Projects [2020-1-2181]; Capital Characteristic Clinical Application Research [Z211100002921059]	Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Beijing Hospitals Authority Clinical medicine Development of special funding support; Capital Health Research and Development Projects; Capital Characteristic Clinical Application Research	The authors disclose receipt of the following financial support for the research, authorship and/or publication of this article: Chinese National Natural Science Foundation (81900537), Beijing Hospitals Authority Clinical medicine Development of special funding support (XMLX202125), Capital Health Research and Development Projects (2020-1-2181), The Capital Characteristic Clinical Application Research (Z211100002921059).	Arends P, 2014, J VIRAL HEPATITIS, V21, P897, DOI 10.1111/jvh.12218; Cao ZH, 2017, HEPATOLOGY, V66, P1058, DOI 10.1002/hep.29213; Chinese Society of Infectious Diseases Chinese Medical Association, 2019, Zhonghua Gan Zang Bing Za Zhi, V27, P938, DOI 10.3760/cma.j.issn.1007-3418.2019.12.007; Collins AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00235; HASSAN MS, 1992, J IMMUNOL, V148, P2555; Kawanaka M, 2021, WORLD J GASTROENTERO, V27, P7497, DOI 10.3748/wjg.v27.i43.7497; Li MH, 2019, J VIRAL HEPATITIS, V26, P32, DOI 10.1111/jvh.13151; Li MH, 2016, WORLD J HEPATOL, V8, P637, DOI 10.4254/wjh.v8.i15.637; Li ZH, 2020, MINERVA MED, V111, P491, DOI 10.23736/S0026-4806.20.06621-5; OCHS HD, 1987, ANNU REV MED, V38, P325, DOI 10.1146/annurev.me.38.020187.001545; Sonneveld MJ, 2013, HEPATOLOGY, V58, P872, DOI 10.1002/hep.26436; Sonneveld MJ, 2010, HEPATOLOGY, V52, P1251, DOI 10.1002/hep.23844; Vidarsson G, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00520; Wu FP, 2021, LIVER INT, V41, P2032, DOI 10.1111/liv.14897; Yao KF, 2021, J VIRAL HEPATITIS, V28, P1025, DOI 10.1111/jvh.13511; Yuan CJ., 2020, J N SICHUAN MED COLL, V35, P432, DOI [10.3969 /j.issn.1005-3697. 2020.03.019, DOI 10.3969/J.ISSN.1005-3697.2020.03.019]; Zhang GL, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1538439; Zhang W H, 2017, Zhonghua Gan Zang Bing Za Zhi, V25, P678, DOI 10.3760/cma.j.issn.1007-3418.2017.09.007; Zhou J., 2020, J MILITARY SURG SW C, V22, P110, DOI [10. 3969/j. issn. 1672-7193.2020.02.003, DOI 10.3969/J.ISSN.1672-7193.2020.02.003]	19	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								864354	10.3389/fimmu.2022.864354	http://dx.doi.org/10.3389/fimmu.2022.864354			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T9FB	35529845	gold, Green Published			2022-12-18	WOS:000876161500001
J	Pereira, JM; Xu, SY; Leong, JM; Sousa, S				Pereira, Joana M.; Xu, Shuying; Leong, John M.; Sousa, Sandra			The Yin and Yang of Pneumolysin During Pneumococcal Infection	FRONTIERS IN IMMUNOLOGY			English	Review						Streptococcus pneumoniae; pore-forming toxin; cholesterol-dependent cytolysin; plasma membrane; pneumonia; pro- and anti-inflammatory immune responses; pneumolysin	PORE-FORMING TOXIN; RESISTANT STREPTOCOCCUS-PNEUMONIAE; THIOL-ACTIVATED TOXIN; LUNG EPITHELIAL-CELLS; NEUTROPHIL ELASTASE; ENDOTHELIAL-CELLS; NLRP3 INFLAMMASOME; IN-VITRO; NEUROTOXIN PNEUMOLYSIN; CASPASE-1 ACTIVATION	Pneumolysin (PLY) is a pore-forming toxin produced by the human pathobiont Streptococcus pneumoniae, the major cause of pneumonia worldwide. PLY, a key pneumococcal virulence factor, can form transmembrane pores in host cells, disrupting plasma membrane integrity and deregulating cellular homeostasis. At lytic concentrations, PLY causes cell death. At sub-lytic concentrations, PLY triggers host cell survival pathways that cooperate to reseal the damaged plasma membrane and restore cell homeostasis. While PLY is generally considered a pivotal factor promoting S. pneumoniae colonization and survival, it is also a powerful trigger of the innate and adaptive host immune response against bacterial infection. The dichotomy of PLY as both a key bacterial virulence factor and a trigger for host immune modulation allows the toxin to display both "Yin" and "Yang" properties during infection, promoting disease by membrane perforation and activating inflammatory pathways, while also mitigating damage by triggering host cell repair and initiating anti-inflammatory responses. Due to its cytolytic activity and diverse immunomodulatory properties, PLY is integral to every stage of S. pneumoniae pathogenesis and may tip the balance towards either the pathogen or the host depending on the context of infection.						Pereira, Joana Maria Abreu Carvalho/0000-0001-9733-9665	FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 -Operational Programme for Competitiveness and Internationalization (POCI), Portugal 2020; Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior [POCI-01-0145-FEDER-030863 (PTDC/BIA-CEL/30863/2017)]; NIH [R21 AG071268-01]; FCT [SFRH/BD/143940/2019]	FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 -Operational Programme for Competitiveness and Internationalization (POCI), Portugal 2020; Portuguese funds through FCT-Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino Superior(Portuguese Foundation for Science and Technology); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	SS research receives funds from FEDER-Fundo Europeu de Desenvolvimento Regional funds through the COMPETE 2020 -Operational Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through FCT-Fundacao para a Cie<^>ncia e a Tecnologia/Ministe ' rio da Cie<^>ncia, Tecnologia e Ensino Superior in the framework of the project POCI-01-0145-FEDER-030863 (PTDC/BIA-CEL/30863/2017). Research in JL's laboratory is supported by NIH R21 AG071268-01. JMP is the recipient of an FCT fellowship (SFRH/BD/143940/2019). SS received support from FCT in the framework of CEEC-Institutional 2017 program.	Adams W, 2020, J IMMUNOL, V204, P101, DOI 10.4049/jimmunol.1800748; Aguilar JL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008076; ALEXANDER JE, 1994, INFECT IMMUN, V62, P5683, DOI 10.1128/IAI.62.12.5683-5688.1994; Alhamdi Y, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004836; Ali YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082583; Allegrucci M, 2006, J BACTERIOL, V188, P2325, DOI 10.1128/JB.188.7.2325-2335.2006; Anderson R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041147; Anderson R, 2017, J INFECTION, V74, P527, DOI 10.1016/j.jinf.2017.03.005; Baba H, 2001, BIOCHEM BIOPH RES CO, V281, P37, DOI 10.1006/bbrc.2001.4297; Babiychuk EB, 2015, SEMIN CELL DEV BIOL, V45, P39, DOI 10.1016/j.semcdb.2015.10.016; Badgujar DC, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009016; Balachandran P, 2001, J BACTERIOL, V183, P3108, DOI 10.1128/JB.183.10.3108-3116.2001; Bandara M, 2017, MICROBES INFECT, V19, P402, DOI 10.1016/j.micinf.2017.04.003; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Bello C, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1009152; Beno SM, 2020, J INFECT DIS, V222, P1882, DOI 10.1093/infdis/jiaa295; BENTON KA, 1995, INFECT IMMUN, V63, P448, DOI 10.1128/IAI.63.2.448-455.1995; Bermpohl D, 2005, J CLIN INVEST, V115, P1607, DOI 10.1172/JCI23223; BERRY AM, 1989, INFECT IMMUN, V57, P2324, DOI 10.1128/IAI.57.8.2324-2330.1989; Beurg M, 2005, J PHYSIOL-LONDON, V568, P211, DOI 10.1113/jphysiol.2005.092478; Bewley MA, 2014, MBIO, V5, DOI 10.1128/mBio.01710-14; Bhowmick R, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00280-17; Bhowmick R, 2013, J IMMUNOL, V191, P5115, DOI 10.4049/jimmunol.1300522; Billington SJ, 2000, FEMS MICROBIOL LETT, V182, P197, DOI 10.1016/S0378-1097(99)00536-4; Bischofberger M, 2012, CELL HOST MICROBE, V12, P266, DOI 10.1016/j.chom.2012.08.005; Bouillot S, 2018, TOXINS, V10, DOI 10.3390/toxins10100387; Boxio R, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0449-x; Braun JS, 2007, INFECT IMMUN, V75, P4245, DOI 10.1128/IAI.00031-07; Braun JS, 1999, INFECT IMMUN, V67, P3750, DOI 10.1128/IAI.67.8.3750-3756.1999; Braun JS, 2002, J CLIN INVEST, V109, P19; Brissac T, 2018, INFECT IMMUN, V86, DOI 10.1128/IAI.00569-17; Brito C, 2019, CELL MOL LIFE SCI, V76, P1319, DOI 10.1007/s00018-018-2992-8; Brooks LRK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01366; Brown AO, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004383; CANVIN JR, 1995, J INFECT DIS, V172, P119, DOI 10.1093/infdis/172.1.119; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Chen HC, 2004, J BIOMED SCI, V11, P49, DOI 10.1159/000075288; Christie Michelle P, 2018, Biophys Rev, V10, P1337, DOI 10.1007/s12551-018-0448-x; Cockeran R, 2009, EUR RESPIR J, V34, P1167, DOI 10.1183/09031936.00007109; Cockeran R, 2001, INFECT IMMUN, V69, P3494, DOI 10.1128/IAI.69.5.3494-3496.2001; Cockeran R, 2001, J INFECT DIS, V183, P604, DOI 10.1086/318536; Colino J, 2003, J IMMUNOL, V171, P2354, DOI 10.4049/jimmunol.171.5.2354; COMIS SD, 1993, ACTA OTO-LARYNGOL, V113, P152, DOI 10.3109/00016489309135784; Cremers AJH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14952; Cuypers F, 2020, J INFECT DIS, V222, P1702, DOI 10.1093/infdis/jiaa277; Czaikoski PG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148142; Dal Peraro M, 2016, NAT REV MICROBIOL, V14, P77, DOI 10.1038/nrmicro.2015.3; Das R, 2014, J IMMUNOL, V193, P764, DOI 10.4049/jimmunol.1400133; delosToyos JR, 1996, INFECT IMMUN, V64, P480, DOI 10.1128/IAI.64.2.480-484.1996; Denoel P, 2011, VACCINE, V29, P5495, DOI 10.1016/j.vaccine.2011.05.051; Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532; Domon H, 2021, MICROBIOL SPECTR, V9, DOI 10.1128/Spectrum.00318-21; Domon H, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.615959; Domon H, 2016, SCI REP-UK, V6, DOI 10.1038/srep38013; Ebrahimi F, 2018, EUR RESPIR J, V51, DOI 10.1183/13993003.01389-2017; Ercoli G, 2018, NAT MICROBIOL, V3, P600, DOI 10.1038/s41564-018-0147-1; Etxaniz A, 2018, TOXINS, V10, DOI 10.3390/toxins10060234; Fang RD, 2011, J IMMUNOL, V187, P4890, DOI 10.4049/jimmunol.1100381; Farrand AJ, 2010, P NATL ACAD SCI USA, V107, P4341, DOI 10.1073/pnas.0911581107; Fickl H, 2005, CLIN EXP IMMUNOL, V140, P274, DOI 10.1111/j.1365-2249.2005.02757.x; Fliegauf M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059925; Fortsch C, 2011, TOXINS, V3, P43, DOI 10.3390/toxins3010043; Garcia-Suarez MD, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-3; Geldhoff M, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-358; Ghanem ENB, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005126; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Gilbert RJC, 2016, EUR BIOPHYS J BIOPHY, V45, P365, DOI 10.1007/s00249-015-1106-x; Gilbert RJC, 2013, CELL MOL LIFE SCI, V70, P2083, DOI 10.1007/s00018-012-1153-8; Gilley RP, 2016, INFECT IMMUN, V84, P1457, DOI 10.1128/IAI.00007-16; Ginzberg HH, 2001, AM J PHYSIOL-GASTR L, V281, pG705, DOI 10.1152/ajpgi.2001.281.3.G705; Gonzalez-Juarbe N, 2017, CELL DEATH DIFFER, V24, P917, DOI 10.1038/cdd.2017.49; Gonzalez-Juarbe N, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005337; Greaney AJ, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00570; Green AE, 2021, MOL BIOL EVOL, V38, P2209, DOI 10.1093/molbev/msab018; Greene NG, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004996; Hagio T, 2008, PULM PHARMACOL THER, V21, P884, DOI 10.1016/j.pupt.2008.10.002; Hartog CM, 2003, AM J RESP CRIT CARE, V167, P593, DOI 10.1164/rccm.200203-258OC; Harvey RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103625; HILL J, 1994, INFECT IMMUN, V62, P757, DOI 10.1128/IAI.62.2.757-758.1994; Hirst RA, 2004, CLIN EXP IMMUNOL, V138, P195, DOI 10.1111/j.1365-2249.2004.02611.x; Hirst RA, 2003, INFECT IMMUN, V71, P6095, DOI 10.1128/IAI.71.10.6095-6100.2003; Hirst RA, 2000, PEDIATR RES, V47, P381, DOI 10.1203/00006450-200003000-00016; Hirst RA, 2000, INFECT IMMUN, V68, P1557, DOI 10.1128/IAI.68.3.1557-1562.2000; Hoegen T, 2011, J IMMUNOL, V187, P5440, DOI 10.4049/jimmunol.1100790; Hotomi M, 2016, FOLIA MICROBIOL, V61, P375, DOI 10.1007/s12223-016-0445-z; HOULDSWORTH S, 1994, INFECT IMMUN, V62, P1501, DOI 10.1128/IAI.62.4.1501-1503.1994; Hu XX, 2019, FEBS J, V286, P4754, DOI 10.1111/febs.15001; Hupp S, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1491-7; Hupp S, 2013, J MOL BIOL, V425, P636, DOI 10.1016/j.jmb.2012.11.034; Hupp S, 2012, GLIA, V60, P137, DOI 10.1002/glia.21256; Iliev AI, 2007, P NATL ACAD SCI USA, V104, P2897, DOI 10.1073/pnas.0608213104; Iliev AI, 2009, MOL MICROBIOL, V71, P461, DOI 10.1111/j.1365-2958.2008.06538.x; Inomata M, 2020, P NATL ACAD SCI USA, V117, P33561, DOI 10.1073/pnas.2015368117; Jacques LC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15751-6; Jahn K, 2020, BLOOD ADV, V4, P6315, DOI 10.1182/bloodadvances.2020002372; Jefferies JMC, 2007, J INFECT DIS, V196, P936, DOI 10.1086/520091; Jimenez AJ, 2017, CURR OPIN CELL BIOL, V47, P99, DOI 10.1016/j.ceb.2017.03.011; JOHNSON MK, 1990, CURR EYE RES, V9, P1107, DOI 10.3109/02713689008997584; JOHNSON MK, 1977, FEMS MICROBIOL LETT, V2, P243; Jones RN, 2013, DIAGN MICR INFEC DIS, V75, P107, DOI 10.1016/j.diagmicrobio.2012.08.024; Jounblat R, 2003, INFECT IMMUN, V71, P1813, DOI 10.1128/IAI.71.4.1813-1819.2003; Kadioglu A, 2002, INFECT IMMUN, V70, P2886, DOI 10.1128/IAI.70.6.2886-2890.2002; Karmakar M, 2015, J IMMUNOL, V194, P1763, DOI 10.4049/jimmunol.1401624; Keller LE, 2016, MBIO, V7, DOI 10.1128/mBio.01792-15; Keller LE, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00055; Kim JY, 2015, ONCOTARGET, V6, P44161, DOI 10.18632/oncotarget.6592; Kim J, 2017, BBA-GEN SUBJECTS, V1861, P2663, DOI 10.1016/j.bbagen.2017.07.008; Kim YJ, 2013, J MICROBIOL, V51, P194, DOI 10.1007/s12275-013-2579-x; Kirkham LAS, 2006, INFECT IMMUN, V74, P586, DOI 10.1128/IAI.74.1.586-593.2006; Kloft N, 2009, BIOCHEM BIOPH RES CO, V385, P503, DOI 10.1016/j.bbrc.2009.05.121; Koffel R, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01688; Koppe U, 2012, J IMMUNOL, V188, P811, DOI 10.4049/jimmunol.1004143; Kwon IS, 2017, TOXICON, V129, P100, DOI 10.1016/j.toxicon.2017.02.017; LaRock CN, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00518; Larpin Y, 2020, FASEB J, V34, P1665, DOI 10.1096/fj.201901737RR; Lawrence SL, 2015, SCI REP-UK, V5, DOI 10.1038/srep14352; Lemon JK, 2015, INFECT IMMUN, V83, P3204, DOI 10.1128/IAI.00224-15; Lemon JK, 2015, MBIO, V6, DOI 10.1128/mBio.02110-14; Leroux-Roels G, 2014, VACCINE, V32, P6838, DOI 10.1016/j.vaccine.2014.02.052; Letsiou E, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88897-y; Leung C, 2014, ELIFE, V3, DOI 10.7554/eLife.04247; Li HE, 2017, SCI REP-UK, V7, DOI 10.1038/srep42015; Li HE, 2015, SCI REP-UK, V5, DOI 10.1038/srep17668; Li P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122753; Littmann M, 2009, EMBO MOL MED, V1, P211, DOI 10.1002/emmm.200900025; Lv QH, 2020, MICROB PATHOGENESIS, V140, DOI 10.1016/j.micpath.2019.103934; Mann B, 2014, J INFECT DIS, V209, P1116, DOI 10.1093/infdis/jit502; Marriott HM, 2008, CURR MOL MED, V8, P497, DOI 10.2174/156652408785747924; Marriott HM, 2004, FASEB J, V18, P1126, DOI 10.1096/fj.03-1450fje; Marshall JE, 2015, SCI REP-UK, V5, DOI 10.1038/srep13293; Martner A, 2008, INFECT IMMUN, V76, P4079, DOI 10.1128/IAI.01747-07; Masomian M, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010132; Maurer J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34031-4; Maus UA, 2004, J IMMUNOL, V173, P1307, DOI 10.4049/jimmunol.173.2.1307; McNeela EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001191; Mitchell Tim J, 2014, Subcell Biochem, V80, P145, DOI 10.1007/978-94-017-8881-6_8; MITCHELL TJ, 1991, MOL MICROBIOL, V5, P1883, DOI 10.1111/j.1365-2958.1991.tb00812.x; Mohammed BJ, 1999, MICROB PATHOGENESIS, V27, P303, DOI 10.1006/mpat.1999.0306; Moraes TJ, 2006, CURR OPIN HEMATOL, V13, P21, DOI 10.1097/01.moh.0000190113.31027.d5; Moreland JG, 2006, AM J PHYSIOL-LUNG C, V290, pL833, DOI 10.1152/ajplung.00333.2005; Morgan PJ, 1997, FEBS LETT, V412, P563, DOI 10.1016/S0014-5793(97)00838-7; Mori Y, 2012, J BIOL CHEM, V287, P10472, DOI 10.1074/jbc.M111.280321; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Narasaraju T, 2011, AM J PATHOL, V179, P199, DOI 10.1016/j.ajpath.2011.03.013; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; Negash AA, 2021, INFECT DRUG RESIST, V14, P1765, DOI 10.2147/IDR.S309876; Neill DR, 2014, AM J RESP CRIT CARE, V189, P1250, DOI 10.1164/rccm.201401-0128OC; Neill DR., 2015, STREPTOCOCCUS PNEUMO, P257, DOI [10.1016/B978-0-12-410530-0.00014-4, DOI 10.1016/B978-0-12-410530-0.00014-4]; Nel JG, 2016, CLIN EXP IMMUNOL, V184, P358, DOI 10.1111/cei.12766; Nel JG, 2016, LUNG, V194, P589, DOI 10.1007/s00408-016-9900-5; Nerlich A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18468-7; Ng EWM, 1997, RETINA-J RET VIT DIS, V17, P521; Nganje CN, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211632; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Nishimoto AT, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.01543; Nollmann M, 2004, BIOPHYS J, V86, P3141, DOI 10.1016/S0006-3495(04)74362-3; Norcross Erin W, 2011, J Bacteriol Parasitol, V2, P108; Ogawa M, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0753-3; Ogawa M, 2018, CELL MICROBIOL, V20, DOI 10.1111/cmi.12846; Ogunniyi AD, 2001, INFECT IMMUN, V69, P5997, DOI 10.1128/IAI.69.10.5997-6003.2001; OWEN RHG, 1994, FEMS MICROBIOL LETT, V121, P217, DOI 10.1111/j.1574-6968.1994.tb07101.x; Pahal P., 2021, TYPICAL BACTERIAL PN; Panagiotou S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73454-w; Parker D, 2011, MBIO, V2, DOI 10.1128/mBio.00016-11; PATON JC, 1983, INFECT IMMUN, V40, P548, DOI 10.1128/IAI.40.2.548-552.1983; PATON JC, 1984, INFECT IMMUN, V43, P1085, DOI 10.1128/IAI.43.3.1085-1087.1984; Pechous RD, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00160; Porta H, 2011, PEPTIDES, V32, P601, DOI 10.1016/j.peptides.2010.06.012; Potez S, 2011, J BIOL CHEM, V286, P17982, DOI 10.1074/jbc.M110.187625; Price KE, 2012, J BACTERIOL, V194, P3651, DOI 10.1128/JB.00114-12; Price KE, 2009, J BACTERIOL, V191, P2163, DOI 10.1128/JB.01489-08; Prymula R, 2014, VACCINE, V32, P3025, DOI 10.1016/j.vaccine.2014.03.066; Rabes A, 2016, CURR TOP MICROBIOL, V397, P215, DOI 10.1007/978-3-319-41171-2_11; Rai P, 2016, SCI REP-UK, V6, DOI 10.1038/srep22972; Ratner AJ, 2006, J BIOL CHEM, V281, P12994, DOI 10.1074/jbc.M511431200; RAYNER CFJ, 1995, INFECT IMMUN, V63, P442, DOI 10.1128/IAI.63.2.442-447.1995; Recchia FM, 2005, ARCH OPHTHALMOL-CHIC, V123, P341, DOI 10.1001/archopht.123.3.341; Riegler AN, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00615; Rogers PD, 2003, INFECT IMMUN, V71, P2087, DOI 10.1128/IAI.71.4.2087-2094.2003; Rosch JW, 2010, J CLIN INVEST, V120, P627, DOI 10.1172/JCI39843; RUBINS JB, 1994, INFECT IMMUN, V62, P3829, DOI 10.1128/IAI.62.9.3829-3836.1994; Rubins JB, 1998, J LAB CLIN MED, V131, P21, DOI 10.1016/S0022-2143(98)90073-7; RUBINS JB, 1992, INFECT IMMUN, V60, P1740, DOI 10.1128/IAI.60.5.1740-1746.1992; RUBINS JB, 1993, INFECT IMMUN, V61, P1352, DOI 10.1128/IAI.61.4.1352-1358.1993; Sanders ME, 2010, J OCUL PHARMACOL TH, V26, P571, DOI 10.1089/jop.2010.0077; Schaaf Bernhard, 2008, BMC Pulm Med, V8, P12, DOI 10.1186/1471-2466-8-12; Schachern PA, 2013, JAMA OTOLARYNGOL, V139, P937, DOI 10.1001/jamaoto.2013.4104; Segal AW, 2005, ANNU REV IMMUNOL, V23, P197, DOI 10.1146/annurev.immunol.23.021704.115653; Shenoy AT, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006582; Shewell LK, 2014, P NATL ACAD SCI USA, V111, pE5312, DOI 10.1073/pnas.1412703111; Shin HS, 2010, FEMS IMMUNOL MED MIC, V60, P171, DOI 10.1111/j.1574-695X.2010.00733.x; Shoma S, 2008, INFECT IMMUN, V76, P1547, DOI 10.1128/IAI.01269-07; Skinner LJ, 2004, ACTA OTO-LARYNGOL, V124, P1000, DOI 10.1080/00016480410017125; Sonnen AFP, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140044; Spreer A, 2003, ANTIMICROB AGENTS CH, V47, P2649, DOI 10.1128/AAC.47.8.2649-2654.2003; Standish AJ, 2009, J IMMUNOL, V183, P2602, DOI 10.4049/jimmunol.0900688; Statt S, 2015, AM J RESP CELL MOL, V53, P689, DOI 10.1165/rcmb.2014-0391OC; STEINFORT C, 1989, INFECT IMMUN, V57, P2006, DOI 10.1128/IAI.57.7.2006-2013.1989; Stringaris AK, 2002, NEUROBIOL DIS, V11, P355, DOI 10.1006/nbdi.2002.0561; Subramanian K, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.202012695; Subramanian K, 2019, CELL MICROBIOL, V21, DOI 10.1111/cmi.13077; Subramanian K, 2019, NAT MICROBIOL, V4, P62, DOI 10.1038/s41564-018-0280-x; Surve MV, 2019, FUTURE MICROBIOL, V14, P647, DOI 10.2217/fmb-2019-0096; Surve MV, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007168; Suzuki T, 2009, AM J RESP CELL MOL, V41, P742, DOI 10.1165/rcmb.2008-0157OC; Tabusi M, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009432; Tagami T, 2011, RESPIROLOGY, V16, P953, DOI 10.1111/j.1440-1843.2011.01997.x; Taylor SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061300; Tettelin H., 2015, STREPTOCOCCUS PNEUMO, P81, DOI 10.1016/B978-0-12-410530-0.00005-3; Thapa R, 2020, TOXINS, V12, DOI 10.3390/toxins12090531; Tilley SJ, 2005, CELL, V121, P247, DOI 10.1016/j.cell.2005.02.033; Tong S, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3529-4; Troeger C, 2018, LANCET INFECT DIS, V18, P1191, DOI 10.1016/S1473-3099(18)30310-4; van Pee K, 2016, NANO LETT, V16, P7915, DOI 10.1021/acs.nanolett.6b04219; van Pee K, 2017, ELIFE, V6, DOI 10.7554/eLife.23644; Verhoeven D, 2014, CLIN VACCINE IMMUNOL, V21, P1037, DOI 10.1128/CVI.00052-14; Vidal JE, 2011, INFECT IMMUN, V79, P4050, DOI 10.1128/IAI.05186-11; Vogele M, 2019, P NATL ACAD SCI USA, V116, P13352, DOI 10.1073/pnas.1904304116; WATANABE H, 1990, J BIOCHEM-TOKYO, V108, P753, DOI 10.1093/oxfordjournals.jbchem.a123277; Weinberger DM, 2010, CLIN INFECT DIS, V51, P692, DOI 10.1086/655828; Weiser JN, 2018, NAT REV MICROBIOL, V16, P354, DOI 10.1038/s41579-018-0001-8; Wilkinson TS, 2012, CHEST, V142, P1425, DOI 10.1378/chest.11-3273; Winter AJ, 1997, INFECT IMMUN, V65, P4411, DOI 10.1128/IAI.65.11.4411-4418.1997; Wippel C, 2011, J INFECT DIS, V204, P930, DOI 10.1093/infdis/jir434; Witherden IR, 2004, AM J RESP CELL MOL, V30, P500, DOI 10.1165/rcmb.4890; Witzenrath M, 2011, J IMMUNOL, V187, P434, DOI 10.4049/jimmunol.1003143; Wolfmeier H, 2016, BBA-GEN SUBJECTS, V1860, P2498, DOI 10.1016/j.bbagen.2016.07.022; Wolfmeier H, 2015, BBA-MOL CELL RES, V1853, P2045, DOI 10.1016/j.bbamcr.2014.09.005; Wroe PC, 2012, J INFECT DIS, V205, P1589, DOI 10.1093/infdis/jis240; Yau B, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113555; Yoo IH, 2010, FEMS IMMUNOL MED MIC, V60, P28, DOI 10.1111/j.1574-695X.2010.00699.x; Yuste J, 2005, J IMMUNOL, V175, P1813, DOI 10.4049/jimmunol.175.3.1813; Zafar MA, 2017, CELL HOST MICROBE, V21, P73, DOI 10.1016/j.chom.2016.12.005; Zhang DM, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3326-z; Zhao XR, 2017, BIOL PHARM BULL, V40, P61, DOI 10.1248/bpb.b16-00598; Zhao XR, 2016, MOL PHARMACOL, V89, P376, DOI 10.1124/mol.115.100610; Zhou A, 2012, INT J MOL MED, V29, P1025, DOI 10.3892/ijmm.2012.946; Zukauskas A, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00303-18; Zysk G, 2001, INFECT IMMUN, V69, P845, DOI 10.1128/IAI.69.2.845-852.2001	239	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								878244	10.3389/fimmu.2022.878244	http://dx.doi.org/10.3389/fimmu.2022.878244			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5U0FG	35529870	gold, Green Published			2022-12-18	WOS:000876229700001
J	Tarancon-Diez, L; Consuegra, I; Vazquez-Alejo, E; Ramos-Ruiz, R; Ramos, JT; Navarro, ML; Munoz-Fernandez, MA				Tarancon-Diez, Laura; Consuegra, Irene; Vazquez-Alejo, Elena; Ramos-Ruiz, Ricardo; Ramos, Jose Tomas; Navarro, Maria Luisa; Munoz-Fernandez, M. angeles			miRNA Profile Based on ART Delay in Vertically Infected HIV-1 Youths Is Associated With Inflammatory Biomarkers and Activation and Maturation Immune Levels	FRONTIERS IN IMMUNOLOGY			English	Article						miRNA profile; vertically acquired-HIV-1 infection; ART; youths; inflammatory profile	EARLY ANTIRETROVIRAL THERAPY; CELL; REPLICATION; MICRORNAS	Early antiretroviral treatment (ART) in vertically acquired HIV-1-infection is associated with a rapid viral suppression, small HIV-1 reservoir, reduced morbimortality and preserved immune functions. We investigated the miRNA profile from vertically acquired HIV-1-infected young adults based on ART initiation delay and its association with the immune system activation. Using a microRNA panel and multiparametric flow cytometry, miRNome profile obtained from peripheral blood mononuclear cells and its association with adaptive and innate immune components were studied on vertically HIV-1-infected young adults who started ART early (EARLY, 0-53 weeks after birth) and later (LATE, 120-300 weeks). miR-1248 and miR-155-5p, were significantly upregulated in EARLY group compared with LATE group, while miR-501-3p, miR-548d-5p, miR-18a-3p and miR-296-5p were significantly downregulated in EARLY treated group of patients. Strong correlations were obtained between miRNAs levels and soluble biochemical biomarkers and immunological parameters including CD4 T-cell count and maturation by CD69 expression on CD4 T-cells and activation by HLA-DR on CD16(high) NK cell subsets for miR-1248 and miR-155-5p. In this preliminary study, a distinct miRNA signature discriminates early treated HIV-1-infected young adults. The role of those miRNAs target genes in the modulation of HIV-1 replication and latency may reveal new host signaling pathways that could be manipulated in antiviral strategies. Correlations between miRNAs levels and inflammatory and immunological markers highlight those miRNAs as potential biomarkers for immune inflammation and activation in HIV-1-infected young adults who initiated a late ART.					ramos-ruiz, ricardo/Q-2237-2016	ramos-ruiz, ricardo/0000-0002-6331-9786; Munoz-Fernandez/0000-0002-0813-4500				Aguilera-Alonso D, 2021, JAIDS-J ACQ IMM DEF, V86, P240, DOI 10.1097/QAI.0000000000002539; Ananworanich J, 2014, AIDS, V28, P1015, DOI 10.1097/QAD.0000000000000178; Ayala-Suarez R, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082452; Bailey WJ, 2019, TOXICOL SCI, V168, P110, DOI 10.1093/toxsci/kfy282; Barlow-Mosha L, 2017, J INT AIDS SOC, V20, DOI 10.7448/IAS.20.1.21552; Bignami F, 2012, BLOOD, V119, P6259, DOI 10.1182/blood-2011-09-379503; Cardenas-Bedoya J, 2020, GENET MOL BIOL, V43, DOI [10.1590/1678-4685-GMB-2020-0017, 10.1590/1678-4685-gmb-2020-0017]; Carrasco I, 2021, J INT AIDS SOC, V24, DOI 10.1002/jia2.25804; Chang Y, 2019, CANCER BIOL THER, V20, P31, DOI 10.1080/15384047.2018.1504721; Colpaert RMW, 2021, GENOMICS, V113, P540, DOI 10.1016/j.ygeno.2020.12.042; Dalzini A, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8041616; Deshmane SL, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-477; Dominguez-Rodriguez S, 2019, JAIDS-J ACQ IMM DEF, V82, P483, DOI 10.1097/QAI.0000000000002188; Dong HQ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00044; Duette G, 2018, MBIO, V9, DOI 10.1128/mBio.00757-18; Fadel HJ, 2014, J VIROL, V88, P9704, DOI 10.1128/JVI.01397-14; Foster C, 2021, J PEDIAT INF DIS SOC, V10, P295, DOI 10.1093/jpids/piaa071; Garcia-Merino I, 2010, AIDS RES HUM RETROV, V26, P241, DOI 10.1089/aid.2009.0122; Heinson AI, 2021, AIDS RES HUM RETROV, V37, P109, DOI [10.1089/aid.2020.0150, 10.1089/AID.2020.0150]; Houzet L, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-118; Jin C, 2017, HIV MED, V18, P354, DOI 10.1111/hiv.12470; Kared H, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00686; Kula A, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-60; Li HY, 2019, INT J BIOL SCI, V15, P2438, DOI 10.7150/ijbs.38146; Liu Y, 2019, J NEUROVIROL, V25, P508, DOI 10.1007/s13365-019-00751-0; Manganaro L, 2010, NAT MED, V16, P329, DOI 10.1038/nm.2102; Martinez-Bonet M, 2015, CLIN INFECT DIS, V61, P1169, DOI 10.1093/cid/civ456; Milush JM, 2013, RETROVIROLOGY, V10, DOI 10.1186/1742-4690-10-158; Pedretti S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218432; Price NL, 2018, CELL REP, V22, P2133, DOI 10.1016/j.celrep.2018.01.074; Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862; Reynoso R, 2014, SCI REP-UK, V4, DOI 10.1038/srep05915; Rinaldi S, 2020, J IMMUNOL, V204, P540, DOI 10.4049/jimmunol.1900856; Ryo A, 2008, P NATL ACAD SCI USA, V105, P294, DOI 10.1073/pnas.0704831105; Seddiki N, 2014, IMMUNOLOGY, V142, P32, DOI 10.1111/imm.12227; Tagarro A, 2018, JAIDS-J ACQ IMM DEF, V79, P269, DOI [10.1097/qai.0000000000001789, 10.1097/QAI.0000000000001789]; Tarancon-Diez L, 2021, J ANTIMICROB CHEMOTH, V76, P2993, DOI 10.1093/jac/dkab277; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Uhl J, 2019, J CELL COMMUN SIGNAL, V13, P209, DOI 10.1007/s12079-018-0493-z; UNAIDS, 2020, GLOB HIV AIDS STAT; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Wang LP, 2000, J IMMUNOL, V164, P5369, DOI 10.4049/jimmunol.164.10.5369; Wang PF, 2015, VIROLOGY, V486, P228, DOI 10.1016/j.virol.2015.09.016; Wang XL, 2021, GUT, V70, P784, DOI 10.1136/gutjnl-2020-322526; Wei MF, 2020, NEOPLASMA, V67, P1085, DOI 10.4149/neo_2020_191014N1034; Zawislak CL, 2013, P NATL ACAD SCI USA, V110, P6967, DOI 10.1073/pnas.1304410110; Zhang JH, 2018, MOL IMMUNOL, V103, P144, DOI 10.1016/j.molimm.2018.09.011; Zhang LM, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/1980921; Zhang SM, 2012, CELL CYCLE, V11, P1217, DOI 10.4161/cc.11.6.19664	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								878630	10.3389/fimmu.2022.878630	http://dx.doi.org/10.3389/fimmu.2022.878630			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5U0FH	35529880	Green Published, gold			2022-12-18	WOS:000876229800001
J	Tarn, J; Lendrem, D; Barnes, M; Casement, J; Ng, WF				Tarn, Jessica; Lendrem, Dennis; Barnes, Michael; Casement, John; Ng, Wan-Fai			Comorbidities in the UK Primary Sjogren's Syndrome Registry	FRONTIERS IN IMMUNOLOGY			English	Article						Sjogren's syndrome; comorbidity; crossectional analysis; polypharmacy; stratified medicine		IntroductionPrimary Sjogren's Syndrome (PSS) is a chronic disease characterised by symptoms of oral and ocular dryness, pain, fatigue, anxiety and depression. PSS patients can be subclassified by the pattern of severity of these five key symptoms using the Newcastle Sjogren's Stratification Tool (NSST). Although PSS is often associated with one or more comorbidities, the relationship between comorbidities, polypharmacy, and PSS symptom burden is unclear. Using data from the UK Primary Sjogren's Syndrome Registry (UKPSSR) we describe the landscape of polypharmacy and comorbidities in PSS. MethodsThe UKPSSR is research biobank of clinically well-defined PSS patients where clinical, demographic, comorbidities and concomitant medications data are recorded. Patients were subclassified into the four NSST subgroups: Low Symptom Burden (LSB), High Symptom Burden (HSB), Dryness Dominated Fatigue (DDF) and Pain Dominated Fatigue (PDF). Group analyses of comorbid conditions and polypharmacy scores were performed. Comorbidity and Polypharmacy Scores (CPS) were modelled as a function of age, sex, symptom duration, body mass index (BMI), current immunosuppressant and hydroxychloroquine prescriptions and NSST subgroup. ResultsThere were marked differences in the number and the nature of comorbidities associated with the NSST subgroups. LSB and DDF patients were characterized by fewer comorbidities and medications. In contrast, HSB and PDF patients were associated with more comorbidities and were more likely to be prescribed multiple medications. Group analysis shows that HSB patients are more closely associated with peripheral vascular disease and infection whereas the PDF patients were associated with cardiovascular disease and gastrointestinal comorbidities. Comorbidity and polypharmacy scores increase with age and BMI regardless of symptom subgroup and symptom duration. In addition, the longer the reported symptom duration the higher the associated comorbidities and polypharmacy scores. ConclusionComorbid conditions are more prevalent in some subgroups of the PSS cohort but increase with age and BMI across the entire cohort. It is unclear from these data whether specific comorbid conditions are a consequence of PSS or represent shared aetiology or pathogenetic susceptibility. Regardless, these findings may have implications for disease management and clinical trial design.	[Tarn, Jessica; Lendrem, Dennis; Casement, John; Ng, Wan-Fai] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Northumberland, England; [Barnes, Michael] Queen Mary Univ London QMUL, Ctr forTranslat Bioinformat, London, England; [Ng, Wan-Fai] Newcastle Tyne Hosp NHS Fdn Trust, Natl Inst Hlth & Care Res NIHR, Newcastle Biomed Res Ctr, Newcastle Clin Res Fac, Newcastle Upon Tyne, Northumberland, England	Newcastle University - UK; University of London; Queen Mary University London; Newcastle Upon Tyne Hospitals NHS Foundation Trust	Ng, WF (corresponding author), Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, Northumberland, England.; Ng, WF (corresponding author), Newcastle Tyne Hosp NHS Fdn Trust, Natl Inst Hlth & Care Res NIHR, Newcastle Biomed Res Ctr, Newcastle Clin Res Fac, Newcastle Upon Tyne, Northumberland, England.	Wan-Fai.Ng@newcastle.ac.uk		Casement, John/0000-0003-3514-7259				Albrecht Katinka, 2020, Clin Exp Rheumatol, V38 Suppl 126, P78; [Anonymous], 2021, JMP VERSION 15, P1989; Bartoloni E, 2015, J INTERN MED, V278, P185, DOI 10.1111/joim.12346; Berardicurti O, 2018, REV RECENT CLIN TRIA, V13, P164, DOI 10.2174/1574887113666180315130336; Bowman SJ, 2009, RHEUMATOLOGY, V48, P140, DOI 10.1093/rheumatology/ken426; Fox RI, 2011, SJOGREN'S SYNDROME: PRACTICAL GUIDELINES TO DIAGNOSIS AND THERAPY, P285, DOI 10.1007/978-1-60327-957-4_17; Juarez M, 2014, ARTHRIT CARE RES, V66, P757, DOI 10.1002/acr.22227; Kang JH, 2010, J RHEUMATOL, V37, P1188, DOI 10.3899/jrheum.090942; Kim-Lee C, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-1557-7; Ng WF, 2011, RHEUMATOLOGY, V50, P32, DOI 10.1093/rheumatology/keq240; Patel R, 2014, CLIN EPIDEMIOL, V6, P247, DOI 10.2147/CLEP.S47399; Pego-Reigosa JM, 2021, RHEUMATOLOGY, V60, P2075, DOI 10.1093/rheumatology/key329; R Core Team, 2018, R LANG ENV STAT COMP, P10, DOI [DOI 10.1038/SJ.HDY.6800737, 10.1108/eb003648]; Seror R, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen-2014-000022; Seror R, 2011, ANN RHEUM DIS, V70, P968, DOI 10.1136/ard.2010.143743; Tarn J, 2022, J INTERN MED, V291, P849, DOI 10.1111/joim.13451; Tarn JR, 2019, LANCET RHEUMATOL, V1, pE85, DOI 10.1016/S2665-9913(19)30042-6; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Yang DH, 2020, J CLIN MED, V9, DOI 10.3390/jcm9113469; Yokoe I, 2021, INT J RHEUM DIS, V24, P1482, DOI 10.1111/1756-185X.14227; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	21	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								864448	10.3389/fimmu.2022.864448	http://dx.doi.org/10.3389/fimmu.2022.864448			6	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1I8ZJ	35603172	gold, Green Published			2022-12-18	WOS:000797515500001
J	Ulrich-Lewis, JT; Draves, KE; Roe, K; O'Connor, MA; Clark, EA; Fuller, DH				Ulrich-Lewis, Justin Theophilus; Draves, Kevin E.; Roe, Kelsey; O'Connor, Megan A.; Clark, Edward A.; Fuller, Deborah Heydenburg			STING Is Required in Conventional Dendritic Cells for DNA Vaccine Induction of Type I T Helper Cell- Dependent Antibody Responses	FRONTIERS IN IMMUNOLOGY			English	Article						DNA vaccine; STING; dendritic cells; type I interferon; cGAS	IMMUNE-RESPONSES; INTRAMUSCULAR INJECTION; INTERFERON-GAMMA; GENE GUN; CD8; IMMUNIZATION; ACTIVATION; PROTECTION; CYTOKINES; ANTIGEN	DNA vaccines elicit antibody, T helper cell responses and CD8(+) T cell responses. Currently, little is known about the mechanism that DNA vaccines employ to induce adaptive immune responses. Prior studies have demonstrated that stimulator of interferon genes (STING) and conventional dendritic cells (cDCs) play critical roles in DNA vaccine induced antibody and T cell responses. STING activation by double stranded (dsDNA) sensing proteins initiate the production of type I interferon (IFN),but the DC-intrinsic effect of STING signaling is still unclear. Here, we investigated the role of STING within cDCs on DNA vaccine induction of antibody and T cell responses. STING knockout (STING(-/-)) and conditional knockout mice that lack STING in cDCs (cDC STING cKO), were immunized intramuscularly with a DNA vaccine that expressed influenza A nucleoprotein (pNP). Both STING(-/-) and cDC STING cKO mice had significantly lower type I T helper (Th1) type antibody (anti-NP IgG(2C)) responses and lower frequencies of Th1 associated T cells (NP-specific IFN-gamma(+)CD4(+) T cells) post-immunization than wild type (WT) and cDC STING littermate control mice. In contrast, all mice had similar Th2-type NP-specific (IgG(1)) antibody titers. STING(-/-) mice developed significantly lower polyfunctional CD8(+) T cells than WT, cDC STING cKO and cDC STING littermate control mice. These findings suggest that STING within cDCs mediates DNA vaccine induction of type I T helper responses including IFN-gamma(+)CD4(+) T cells, and Th1-type IgG(2C) antibody responses. The induction of CD8(+) effector cell responses also require STING, but not within cDCs. These findings are the first to show that STING is required within cDCs to mediate DNA vaccine induced Th1 immune responses and provide new insight into the mechanism whereby DNA vaccines induce Th1 responses.										Akbari O, 1999, J EXP MED, V189, P169, DOI 10.1084/jem.189.1.169; Au-Yeung BB, 2017, J IMMUNOL, V198, P2445, DOI 10.4049/jimmunol.1601453; Bagadia P, 2019, NAT IMMUNOL, V20, P1174, DOI 10.1038/s41590-019-0449-3; Belperron AA, 1999, INFECT IMMUN, V67, P5163, DOI 10.1128/IAI.67.10.5163-5169.1999; CANN AJ, 1984, NUCLEIC ACIDS RES, V12, P7787, DOI 10.1093/nar/12.20.7787; Casares S, 1997, J EXP MED, V186, P1481, DOI 10.1084/jem.186.9.1481; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; Collins DP, 1998, CYTOMETRY, V33, P249, DOI 10.1002/(SICI)1097-0320(19981001)33:2<249::AID-CYTO21>3.0.CO;2-T; Curtsinger JM, 2010, CURR OPIN IMMUNOL, V22, P333, DOI 10.1016/j.coi.2010.02.013; Donnelly JJ, 1996, J INFECT DIS, V173, P314, DOI 10.1093/infdis/173.2.314; Dupuis M, 2000, J IMMUNOL, V165, P2850, DOI 10.4049/jimmunol.165.5.2850; Ekkens MJ, 2007, INFECT IMMUN, V75, P2291, DOI 10.1128/IAI.01328-06; Franz KM, 2018, P NATL ACAD SCI USA, V115, pE2058, DOI 10.1073/pnas.1716937115; FULLER DH, 1994, AIDS RES HUM RETROV, V10, P1433, DOI 10.1089/aid.1994.10.1433; Gallagher KME, 2009, J IMMUNOL, V183, P2915, DOI 10.4049/jimmunol.0801607; Gracie JA, 1996, EUR J IMMUNOL, V26, P1217, DOI 10.1002/eji.1830260605; Guo Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03341-9; Hervas-Stubbs S, 2012, J IMMUNOL, V189, P3299, DOI 10.4049/jimmunol.1102495; Hobernik D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113605; Ishii KJ, 2008, NATURE, V451, P725, DOI 10.1038/nature06537; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Jeon YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139845; Kalia V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02987; Kawano Y, 1996, IMMUNOLOGY, V88, P40, DOI 10.1046/j.1365-2567.1996.d01-634.x; KAWANO Y, 1994, J IMMUNOL, V153, P4948; Koday MT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189780; Ladislau L, 2018, CELL DEATH DIS, V9, DOI [10.1038/S41419-018-0426-z, 10.1038/s41419-018-0426-z]; Larkin B, 2017, J IMMUNOL, V199, P397, DOI 10.4049/jimmunol.1601999; Larsen M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042403; Lee S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.710647; Leitner WW, 2003, J CLIN INVEST, V112, P22, DOI 10.1172/JCI200319069; Li ZH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02064; Lohard S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13689-y; Lutz MB, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22796; Mildner A, 2014, IMMUNITY, V40, P642, DOI 10.1016/j.immuni.2014.04.016; Schoggins JW, 2011, CURR OPIN VIROL, V1, P519, DOI 10.1016/j.coviro.2011.10.008; Schoggins JW, 2011, NATURE, V472, P481, DOI 10.1038/nature09907; Shirota H, 2007, J IMMUNOL, V179, P329, DOI 10.4049/jimmunol.179.1.329; Smith TRF, 2014, MOL THER-METH CLIN D, V1, DOI 10.1038/mtm.2014.54; Starbeck-Miller GR, 2014, J EXP MED, V211, P105, DOI 10.1084/jem.20130901; Sudowe S, 2003, MOL THER, V8, P567, DOI 10.1016/S1525-0016(03)00242-9; Suschak JJ, 2016, J IMMUNOL, V196, P310, DOI 10.4049/jimmunol.1501836; Tudor D, 2005, VACCINE, V23, P1258, DOI 10.1016/j.vaccine.2004.09.001; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; Vatner RE, 2019, MOL IMMUNOL, V110, P13, DOI 10.1016/j.molimm.2017.12.001; Wang SX, 2006, VIROLOGY, V350, P34, DOI 10.1016/j.virol.2006.02.032; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Yu JF, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00876-4	48	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								861710	10.3389/fimmu.2022.861710	http://dx.doi.org/10.3389/fimmu.2022.861710			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B9GZ	35529875	gold, Green Published			2022-12-18	WOS:000810490400001
J	Wang, L; Zhang, HB; Pan, CH; Yi, J; Cui, XL; Li, N; Wang, JQ; Gao, ZB; Wu, DF; Chen, J; Jiang, JZ; Chu, Q				Wang, Lei; Zhang, Hongbing; Pan, Chaohu; Yi, Jian; Cui, Xiaoli; Li, Na; Wang, Jiaqian; Gao, Zhibo; Wu, Dongfang; Chen, Jun; Jiang, Jizong; Chu, Qian			Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model	FRONTIERS IN IMMUNOLOGY			English	Article						immune checkpoint inhibitors; durable responses; multi-feature model; genetic biomarkers; non-small cell lung cancer; cancer immunity and immunotherapy	BLOCKADE; DOCETAXEL; ANTIBODY; SAFETY	Due to the complex mechanisms affecting anti-tumor immune response, a single biomarker is insufficient to identify patients who will benefit from immune checkpoint inhibitors (ICIs) treatment. Therefore, a comprehensive predictive model is urgently required to predict the response to ICIs. A total of 162 non-small-cell lung cancer (NSCLC) patients undergoing ICIs treatment from three independent cohorts were enrolled and used as training and test cohorts (training cohort = 69, test cohort1 = 72, test cohort2 = 21). Eight genomic markers were extracted or calculated for each patient. Ten machine learning classifiers, such as the gaussian process classifier, random forest, and support vector machine (SVM), were evaluated. Three genomic biomarkers, namely tumor mutation burden, intratumoral heterogeneity, and loss of heterozygosity in human leukocyte antigen were screened out, and the SVM_poly method was adopted to construct a durable clinical benefit (DCB) prediction model. Compared with a single biomarker, the DCB multi-feature model exhibits better predictive value with the area under the curve values equal to 0.77 and 0.78 for test cohort1 and cohort2, respectively. The patients predicted to have DCB showed improved median progression-free survival (mPFS) and median overall survival (mOS) than those predicted to have non-durable clinical benefit.						Yi, Jian/0000-0001-5471-8243	Natural Science Foundation of China [62131009, 82072597]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This study was supported by Natural Science Foundation of China (NO. 62131009 and 82072597).	Anagnostou V, 2020, NAT CANCER, V1, P99, DOI 10.1038/s43018-019-0008-8; [Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210; Bodor JN, 2020, CANCER-AM CANCER SOC, V126, P260, DOI 10.1002/cncr.32468; Brahmer J, 2015, NEW ENGL J MED, V373, P123, DOI 10.1056/NEJMoa1504627; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brueckl WM, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07690-8; Chen YX, 2017, GIGASCIENCE, V7, DOI 10.1093/gigascience/gix120; Chowell D, 2019, NAT MED, V25, P1715, DOI 10.1038/s41591-019-0639-4; Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572; Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695; Fang WF, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01331-9; Heinzerling L, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0152-y; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Hellmann MD, 2018, CANCER CELL, V33, P843, DOI 10.1016/j.ccell.2018.03.018; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7; Khoja L, 2017, ANN ONCOL, V28, P2377, DOI 10.1093/annonc/mdx286; Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111; Leprieur EG, 2017, EUR J CANCER, V78, P16, DOI 10.1016/j.ejca.2016.12.041; Lin ZH, 2020, CANCER COMMUN, V40, P370, DOI 10.1002/cac2.12070; Liu D, 2019, NAT MED, V25, P1916, DOI 10.1038/s41591-019-0654-5; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; McGranahan N, 2017, CELL, V171, P1259, DOI 10.1016/j.cell.2017.10.001; Montesion M, 2021, CANCER DISCOV, V11, P282, DOI 10.1158/2159-8290.CD-20-0672; Nielsen M, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0288-x; Perets R, 2021, ANN ONCOL, V32, P395, DOI 10.1016/j.annonc.2020.11.020; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Sacher AG, 2016, JAMA ONCOL, V2, P1217, DOI 10.1001/jamaoncol.2016.0639; Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8; Shi YF, 2021, CANCER MED-US, V10, P2216, DOI 10.1002/cam4.3649; Shukla SA, 2015, NAT BIOTECHNOL, V33, P1152, DOI 10.1038/nbt.3344; Szolek A, 2014, BIOINFORMATICS, V30, P3310, DOI 10.1093/bioinformatics/btu548; Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Wang ZJ, 2018, CANCER RES, V78, P6486, DOI 10.1158/0008-5472.CAN-18-1814; Weber JS, 2012, J CLIN ONCOL, V30, P2691, DOI 10.1200/JCO.2012.41.6750; Yi Jian, 2021, Brief Bioinform, V22, DOI 10.1093/bib/bbaa143	38	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								829634	10.3389/fimmu.2022.829634	http://dx.doi.org/10.3389/fimmu.2022.829634			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B9BF	35529874	Green Published, gold			2022-12-18	WOS:000810474900001
J	Xiao, WH; Chen, ZL; Zhang, YH; Wu, YL; Jiang, H; Zhang, HX; Qu, M; Lin, Q; Qin, G				Xiao, Wanghong; Chen, Zelin; Zhang, Yanhong; Wu, Yongli; Jiang, Han; Zhang, Huixian; Qu, Meng; Lin, Qiang; Qin, Geng			Hepcidin Gene Co-Option Balancing Paternal Immune Protection and Male Pregnancy	FRONTIERS IN IMMUNOLOGY			English	Article						seahorse; paternal immune care; male pregnancy; gene co-option; hepcidin	BROOD POUCH; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL PEPTIDE; HIPPOCAMPUS-ERECTUS; FETAL-DEATH; EXPRESSION; EVOLUTION; SEAHORSES; CLONING; ENDOTOXIN	Viviparity has originated independently more than 150 times in vertebrates, while the male pregnancy only emerged in Syngnathidae fishes, such as seahorses. The typical male pregnancy seahorses have closed sophisticated brood pouch that act as both uterus and placenta, representing an excellent model system for studying the evolutionary process of paternal immune protection. Phylogenetic analysis indicated that the hampII gene family has multiple tandem duplicated genes and shows independent lineage-specific expansion in seahorses, and they had the highest ratio of nonsynonymous substitutions to synonymous substitutions (dN/dS) in the seahorse phylogenetic branch. The expression levels of hampIIs in the brood pouch placenta were significantly higher during pregnancy than non-pregnancy. Both LPS stimulation test in vivo and cytotoxicity test in vitro proved the immunological protection function of hampIIs against pathogen infection in seahorse. Besides, seahorse hampII peptides exhibit weaker antibacterial function, but stronger agglutination and free endotoxin inhibition. We assumed that the modified immunological function seemed to be a trade-off between the resistance to microbial attack and offspring protection. In brief, this study suggests that the rapid co-option of hampIIs contributes to the evolutionary adaption to paternal immune care during male pregnancy.							Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou) [GML2019ZD0407, GML2019ZD0401]; National Natural Science Foundation of China [42076131, 42176120]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB42030204]; Hainan Province Science and Technology Special Fund [ZDYF2021SHFZ109]; Key Deployment Project of Centre for Ocean Mega-Research of Science, Chinese Academy of Sciences [COMS2020Q14]; Hainan Provincial Science and Technology Plan Sanya Yazhou Bay Science and Technology City Joint Project [320LH046]	Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Hainan Province Science and Technology Special Fund; Key Deployment Project of Centre for Ocean Mega-Research of Science, Chinese Academy of Sciences; Hainan Provincial Science and Technology Plan Sanya Yazhou Bay Science and Technology City Joint Project	This research was supported by the Key Special Project for Introduced Talents Team of Southern Marine Science and Engineering Guangdong Laboratory (Guangzhou) (GML2019ZD0407 and GML2019ZD0401), the National Natural Science Foundation of China (42076131, 42176120), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB42030204), the Hainan Province Science and Technology Special Fund (ZDYF2021SHFZ109), the Key Deployment Project of Centre for Ocean Mega-Research of Science, Chinese Academy of Sciences (COMS2020Q14), and the Hainan Provincial Science and Technology Plan Sanya Yazhou Bay Science and Technology City Joint Project (320LH046).	Beemelmanns A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37026-3; Bjorstad A, 2009, ANTIMICROB AGENTS CH, V53, P1027, DOI 10.1128/AAC.01310-08; Blackburn DG, 2015, J MORPHOL, V276, P961, DOI 10.1002/jmor.20272; Boumaiza M, 2019, VITAM HORM, V110, P1, DOI 10.1016/bs.vh.2019.01.001; Buckley J, 2010, J EXP BIOL, V213, P3787, DOI 10.1242/jeb.042929; Chen J, 2018, PROBIOTICS ANTIMICRO, V10, P176, DOI 10.1007/s12602-017-9352-0; Chen XY, 2020, MAR DRUGS, V18, DOI 10.3390/md18010030; Chucri TM, 2010, J REPROD IMMUNOL, V87, P14, DOI 10.1016/j.jri.2010.08.062; Conant GC, 2008, NAT REV GENET, V9, P938, DOI 10.1038/nrg2482; Dang YF, 2018, FISH SHELLFISH IMMUN, V72, P367, DOI 10.1016/j.fsi.2017.11.013; Entrican G, 2002, J COMP PATHOL, V126, P79, DOI 10.1053/jcpa.2001.0539; Fedorov S, 2010, TOXICON, V55, P811, DOI 10.1016/j.toxicon.2009.11.016; Frew L, 2011, REPRODUCTION, V141, P725, DOI 10.1530/REP-10-0537; Gillespie MJ, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-452; Go HJ, 2019, FISH SHELLFISH IMMUN, V93, P683, DOI 10.1016/j.fsi.2019.08.017; Hanson MA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02620; Huang L, 2019, FISH SHELLFISH IMMUN, V95, P679, DOI 10.1016/j.fsi.2019.10.058; HURLEY JC, 1992, CLIN INFECT DIS, V15, P840, DOI 10.1093/clind/15.5.840; Kim HS, 2002, J IMMUNOL, V168, P2356, DOI 10.4049/jimmunol.168.5.2356; Laksanawimol P, 2006, MAR FRESHWATER RES, V57, P497, DOI 10.1071/MF05112; Lee M, 2015, BIOCHEM PHARMACOL, V94, P130, DOI [10.1016/j.bcP.2015.02.003, 10.1016/j.bcp.2015.02.003]; Li CY, 2020, INNOVATION-AMSTERDAM, V1, DOI 10.1016/j.xinn.2020.100052; Li F, 2015, J WORLD AQUACULT SOC, V46, P263, DOI 10.1111/jwas.12189; Li Z, 2016, FISH SHELLFISH IMMUN, V56, P239, DOI 10.1016/j.fsi.2016.07.025; Lin Q, 2017, GIGASCIENCE, V6, DOI 10.1093/gigascience/gix030; Lin Q, 2016, NATURE, V540, P395, DOI 10.1038/nature20595; Lin TT, 2016, FISH SHELLFISH IMMUN, V50, P247, DOI 10.1016/j.fsi.2016.01.039; Martin-Antonio B, 2009, FISH SHELLFISH IMMUN, V26, P483, DOI 10.1016/j.fsi.2009.01.012; Melamed P, 2005, FEBS J, V272, P1221, DOI 10.1111/j.1742-4658.2005.04556.x; Mu YN, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0207-3; Neves JV, 2015, J IMMUNOL, V195, P2696, DOI 10.4049/jimmunol.1501153; Palsson-McDermott EM, 2004, IMMUNOLOGY, V113, P153, DOI 10.1111/j.1365-2567.2004.01976.x; Parker J, 2022, MOL ECOL, DOI 10.1111/mec.16333; Pasquier J, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-2709-z; Piktel E, 2016, ARCH IMMUNOL THER EX, V64, P33, DOI 10.1007/s00005-015-0359-5; Rajanbabu V, 2011, FISH SHELLFISH IMMUN, V30, P39, DOI 10.1016/j.fsi.2010.09.005; Roth O, 2020, P NATL ACAD SCI USA, V117, P9431, DOI 10.1073/pnas.1916251117; Sarvari S, 2015, CELL MOL BIOL, V61, P30; Scindia Y, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00615; Shan ZG, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01140; Shirdel I, 2019, FISH SHELLFISH IMMUN, V90, P288, DOI 10.1016/j.fsi.2019.05.010; SILVER RM, 1995, J CLIN INVEST, V95, P725, DOI 10.1172/JCI117719; Stolting KN, 2007, BIOESSAYS, V29, P884, DOI 10.1002/bies.zm.uzh.ch; True JR, 2002, ANNU REV CELL DEV BI, V18, P53, DOI 10.1146/annurev.cellbio.18.020402.140619; Wang KJ, 2009, PEPTIDES, V30, P638, DOI 10.1016/j.peptides.2008.12.014; Whittington CM, 2020, BIOL REV, V95, P1252, DOI 10.1111/brv.12607; Whittington CM, 2015, MOL BIOL EVOL, V32, P3114, DOI 10.1093/molbev/msv177; Wu YL, 2021, AQUACULTURE, V533, DOI 10.1016/j.aquaculture.2020.736064; Xiao Wanghong, 2022, Figshare, DOI 10.3389/fimmu.2022.884417.s002; Xu DX, 2007, TOXICOLOGY, V234, P167, DOI 10.1016/j.tox.2007.02.010; Xu QH, 2008, MOL BIOL EVOL, V25, P1099, DOI 10.1093/molbev/msn056; Yarbrough VL, 2015, HUM REPROD UPDATE, V21, P353, DOI 10.1093/humupd/dmu065; Zhang B, 2021, MAR LIFE SCI TECH, V3, P416, DOI 10.1007/s42995-021-00099-7; Zhang B, 2019, J FISH DIS, V42, P1085, DOI 10.1111/jfd.13006; Zhang TF, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010376	55	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 22	2022	13								884417	10.3389/fimmu.2022.884417	http://dx.doi.org/10.3389/fimmu.2022.884417			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5T9BG	35529860	gold, Green Published			2022-12-18	WOS:000876151600001
J	Belaid, B; Mahammed, LL; Drali, O; Oussaid, AM; Touri, NS; Melzi, S; Dehimi, A; Berkani, LM; Merah, F; Larab, Z; Allam, I; Khemici, O; Kirane, SY; Boutaba, M; Belbouab, R; Bekkakcha, H; Guedouar, A; Chelali, A; Baamara, B; Noui, D; Baaziz, H; Rezak, R; Azzouz, SM; Aichaoui, M; Moktefi, A; Benhatchi, RM; Oussalah, M; Benaissa, N; Laredj, A; Bouchetara, A; Adria, A; Habireche, B; Tounsi, N; Dahmoun, F; Touati, R; Boucenna, H; Bouferoua, F; Sekfali, L; Bouhafs, N; Aboura, R; Kherra, S; Inouri, Y; Dib, S; Medouri, N; Khelfaoui, N; Redjedal, A; Zelaci, A; Yahiaoui, S; Medjadj, S; Touhami, TK; Kadi, A; Amireche, F; Frada, I; Houasnia, S; Benarab, K; Boubidi, C; Ferhani, Y; Benalioua, H; Sokhal, S; Benamar, N; Aggoune, S; Hadji, K; Bellouti, A; Rahmoune, H; Boutrid, N; Okka, K; Ammour, A; Saadoune, H; Amroun, M; Belhadj, H; Ghanem, A; Abbaz, H; Boudrioua, S; Zebiche, B; Ayad, A; Hamadache, Z; Ouaras, N; Achour, N; Bouchair, N; Boudiaf, H; Bekkat-Berkani, D; Maouche, H; Bouzrar, Z; Aissat, L; Ibsaine, O; Bioud, B; Kedji, L; Dahlouk, D; Bensmina, M; Radoui, A; Bessahraoui, M; Bensaadi, N; Mekki, A; Zeroual, Z; Chan, KW; Leung, D; Tebaibia, A; Ayoub, S; Mekideche, D; Gharnaout, M; Casanova, JL; Puel, A; Lau, YL; Cherif, N; Ladj, S; Smati, L; Boukari, R; Benhalla, N; Djidjik, R				Belaid, Brahim; Lamara Mahammed, Lydia; Drali, Ouardia; Oussaid, Aida Mohand; Touri, Nabila Souad; Melzi, Souhila; Dehimi, Abdelhak; Berkani, Lylia Meriem; Merah, Fatma; Larab, Zineb; Allam, Ines; Khemici, Ouarda; Kirane, Sonya Yasmine; Boutaba, Mounia; Belbouab, Reda; Bekkakcha, Hadjira; Guedouar, Assia; Chelali, Abdelhakim; Baamara, Brahim; Noui, Djamila; Baaziz, Hadda; Rezak, Radia; Azzouz, Sidi Mohamed; Aichaoui, Malika; Moktefi, Assia; Benhatchi, Redha Mohamed; Oussalah, Meriem; Benaissa, Naila; Laredj, Amel; Bouchetara, Assia; Adria, Abdelkader; Habireche, Brahim; Tounsi, Noureddine; Dahmoun, Fella; Touati, Rabah; Boucenna, Hamza; Bouferoua, Fadila; Sekfali, Lynda; Bouhafs, Nadjet; Aboura, Rawda; Kherra, Sakina; Inouri, Yacine; Dib, Saadeddine; Medouri, Nawel; Khelfaoui, Noureddine; Redjedal, Aicha; Zelaci, Amara; Yahiaoui, Samah; Medjadj, Sihem; Touhami, Tahar Khelifi; Kadi, Ahmed; Amireche, Fouzia; Frada, Imane; Houasnia, Shahrazed; Benarab, Karima; Boubidi, Chahynez; Ferhani, Yacine; Benalioua, Hayet; Sokhal, Samia; Benamar, Nadia; Aggoune, Samira; Hadji, Karima; Bellouti, Asma; Rahmoune, Hakim; Boutrid, Nada; Okka, Kamelia; Ammour, Assia; Saadoune, Houssem; Amroun, Malika; Belhadj, Hayet; Ghanem, Amina; Abbaz, Hanane; Boudrioua, Sana; Zebiche, Besma; Ayad, Assia; Hamadache, Zahra; Ouaras, Nassima; Achour, Nassima; Bouchair, Nadira; Boudiaf, Houda; Bekkat-Berkani, Dahila; Maouche, Hachemi; Bouzrar, Zahir; Aissat, Lynda; Ibsaine, Ouardia; Bioud, Belkacem; Kedji, Leila; Dahlouk, Djazia; Bensmina, Manoubia; Radoui, Abdelkarim; Bessahraoui, Mimouna; Bensaadi, Nadia; Mekki, Azzeddine; Zeroual, Zoulikha; Chan, Koon-Wing; Leung, Daniel; Tebaibia, Amar; Ayoub, Soraya; Mekideche, Dalila; Gharnaout, Merzak; Casanova, Jean Laurent; Puel, Anne; Lau, Yu Lung; Cherif, Nacira; Ladj, Samir; Smati, Leila; Boukari, Rachida; Benhalla, Nafissa; Djidjik, Reda			Inborn Errors of Immunity in Algerian Children and Adults: A Single-Center Experience Over a Period of 13 Years (2008-2021)	FRONTIERS IN IMMUNOLOGY			English	Article						primary immunodeficiency; inborn errors of immunity; Algeria; epidemiology; molecular diagnosis; clinical features; diagnosis	PRIMARY IMMUNODEFICIENCY DISEASES; QUALITY-OF-LIFE; REGISTRY; COMPLICATIONS; PREVALENCE; PATIENT; RISK; CONSANGUINITY; DISORDERS; WORLDWIDE	BackgroundInborn errors of immunity (IEI) predispose patients to various infectious and non-infectious complications. Thanks to the development and expanding use of flow cytometry and increased awareness, the diagnostic rate of IEI has markedly increased in Algeria the last decade. AimThis study aimed to describe a large cohort of Algerian patients with probable IEI and to determine their clinical characteristics and outcomes. MethodsWe collected and analyzed retrospectively the demographic data, clinical manifestations, immunologic, genetic data, and outcome of Algerian IEI patients - diagnosed in the department of medical immunology of Beni Messous university hospital center, Algiers, from 2008 to 2021. ResultsEight hundred and seven patients with IEI (482 males and 325 females) were enrolled, 9.7% of whom were adults. Consanguinity was reported in 50.3% of the cases and a positive family history in 32.34%. The medium age at disease onset was 8 months and at diagnosis was 36 months. The median delay in diagnosis was 16 months. Combined immunodeficiencies were the most frequent (33.8%), followed by antibody deficiencies (24.5%) and well-defined syndromes with immunodeficiency (24%). Among 287 patients tested for genetic disorders, 129 patients carried pathogenic mutations; 102 having biallelic variants mostly in a homozygous state (autosomal recessive disorders). The highest mortality rate was observed in patients with combined immunodeficiency (70.1%), especially in patients with severe combined immunodeficiency (SCID), Omenn syndrome, or Major Histocompatibility Complex (MHC) class II deficiency. ConclusionThe spectrum of IEI in Algeria is similar to that seen in most countries of the Middle East and North Africa (MENA) region, notably regarding the frequency of autosomal recessive and/or combined immunodeficiencies.					Rahmoune, Hakim/AAF-1963-2019; Lau, Yu Lung/C-4322-2009; Puel, Anne/H-7305-2017	Djidjik, Reda/0000-0003-0820-692X; Lau, Yu Lung/0000-0002-4780-0289; Puel, Anne/0000-0003-2603-0323; GHARNAOUT, MERZAK/0000-0002-9463-6071; Rahmoune, Hakim/0000-0002-9604-3675; Leung, Daniel/0000-0002-9360-6233; BELAID, Brahim/0000-0001-7618-4051	Howard Hughes Medical Institute; Rockefeller University; St. Giles Foundation; National Institutes of Health (NIH) [P01AI06109, R01AI095983, R01AI127564, UL1TR001866]; French National Research Agency (ANR) [ANR-10-IAHU-01, ANR-10-LABX-62-IBEID, ANR-16-CE17-0005-01, ANR-18-CE93-0008-01]; French Foundation for Medical Research (FRM) [EQU201903007798]; European Unions Horizon 2020 research and innovation programme [824110]; Square Foundation; SCOR Corporate Foundation for Science, Institut National de la Sante et de la Recherche Medicale (INSERM); University Paris Cite; Grandir - Fonds de solidarite pour lenfance	Howard Hughes Medical Institute(Howard Hughes Medical Institute); Rockefeller University; St. Giles Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); French National Research Agency (ANR)(French National Research Agency (ANR)); French Foundation for Medical Research (FRM)(Fondation pour la Recherche Medicale); European Unions Horizon 2020 research and innovation programme; Square Foundation; SCOR Corporate Foundation for Science, Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University Paris Cite; Grandir - Fonds de solidarite pour lenfance	We thank the patients who participated in the study and made this research study possible. We also would like to thank Prof. Raif Geha and Dr. Janet Chou for providing genetic analyses, and prof Mohamed Ridha Barbouche for his critical reading of the manuscript. Thanks to the Laboratory of Human Genetics of Infectious Diseases which is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (P01AI06109, R01AI095983, R01AI127564, UL1TR001866), the French National Research Agency (ANR) under the Investments for the Future program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), ANR-GENMSMD (ANR-16-CE17-0005-01), ANR FNS LTh-MSMD-CMCD (ANR-18-CE93-0008-01), the French Foundation for Medical Research (FRM) (EQU201903007798), the European Unions Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-genomics), the Square Foundation, Grandir - Fonds de solidarite pour lenfance, the SCOR Corporate Foundation for Science, Institut National de la Sante et de la Recherche Medicale (INSERM), and the University Paris Cite.	Abolhassani H, 2020, EXPERT REV CLIN IMMU, V16, P717, DOI 10.1080/1744666X.2020.1801422; Abolhassani H, 2018, J CLIN IMMUNOL, V38, P816, DOI 10.1007/s10875-018-0556-1; Aghamohammadi A, 2021, J CLIN IMMUNOL, V41, P1339, DOI 10.1007/s10875-021-01053-z; Al-Hammadi Suleiman, 2017, BMC Res Notes, V10, P177, DOI 10.1186/s13104-017-2499-7; Al-Herz W, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01754; Al-Saud B, 2015, J CLIN IMMUNOL, V35, P651, DOI 10.1007/s10875-015-0197-6; Al-Tamemi S, 2016, J CLIN IMMUNOL, V36, P785, DOI 10.1007/s10875-016-0337-7; [Anonymous], BIRTH RATE COUNTRY 2; [Anonymous], ESID EUROPEAN SOC IM; Anwar WA, 2014, EUR J PUBLIC HEALTH, V24, P57, DOI 10.1093/eurpub/cku104; Barbouche MR, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00737; Barbouche MR, 2011, ANN NY ACAD SCI, V1238, P42, DOI 10.1111/j.1749-6632.2011.06260.x; Barbouche MR., 2014, STIEHMS IMMUNE DEFIC, V41, P957, DOI [10.1016/B978-0-12-405546-9.00054-6, DOI 10.1016/B978-0-12-405546-9.00054-6]; Barlogis V, 2018, J PEDIATR-US, V194, P211, DOI 10.1016/j.jpeds.2017.10.029; Barzaghi F, 2018, J ALLERGY CLIN IMMUN, V141, P1036, DOI 10.1016/j.jaci.2017.10.041; Binstadt BA, 2003, J ALLERGY CLIN IMMUN, V111, P697, DOI 10.1067/mai.2003.1380; Blazina S., 2015, Zdravniski Vestnik, V84, P797; Bonilla FA, 2018, J ALLERGY CLIN IMMUN, V141, P474, DOI 10.1016/j.jaci.2017.12.980; Bousfiha AA, 2014, J CLIN IMMUNOL, V34, P459, DOI 10.1007/s10875-014-0005-8; Bousfiha AA, 2013, J CLIN IMMUNOL, V33, P1, DOI 10.1007/s10875-012-9751-7; Bousfiha A, 2020, J CLIN IMMUNOL, V40, P66, DOI 10.1007/s10875-020-00758-x; Boyle JM, 2007, J CLIN IMMUNOL, V27, P497, DOI 10.1007/s10875-007-9103-1; Casanova JL, 2021, SCIENCE, V374, P1080, DOI 10.1126/science.abj7965; Casanova JL, 2021, ANNU REV PATHOL-MECH, V16, P23, DOI 10.1146/annurev-pathol-031920-101429; CEREDIH: The French PID study group, 2010, CLIN IMMUNOL, V135, P264, DOI [10.1016/j.clim.2010.02.021, DOI 10.1016/J.CLIM.2010.02.021]; Chi CY, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003927; Darr A, 2016, J COMMUN GENET, V7, P65, DOI 10.1007/s12687-015-0252-2; de Valles-Ibanez G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00636; Ehlayel MS, 2013, J CLIN IMMUNOL, V33, P317, DOI 10.1007/s10875-012-9812-y; El-Helou SM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01272; ESID-European Society for Immunodeficiencies, US; Galal N, 2016, J CLIN IMMUNOL, V36, P649, DOI 10.1007/s10875-016-0314-1; Gathmann B, 2009, CLIN EXP IMMUNOL, V157, P3, DOI 10.1111/j.1365-2249.2009.03954.x; Grimbacher B, 2014, CLIN EXP IMMUNOL, V178, P18, DOI 10.1111/cei.12496; Ishimura M, 2011, J CLIN IMMUNOL, V31, P968, DOI 10.1007/s10875-011-9594-7; Jonkman-Berk BM, 2015, CLIN IMMUNOL, V156, P154, DOI 10.1016/j.clim.2014.10.003; Kerner G, 2021, AM J HUM GENET, V108, P517, DOI 10.1016/j.ajhg.2021.02.009; Kilic SS, 2013, J CLIN IMMUNOL, V33, P74, DOI 10.1007/s10875-012-9763-3; Kirkpatrick P, 2007, J CLIN IMMUNOL, V27, P517, DOI 10.1007/s10875-007-9105-z; Kobrynski L, 2014, J CLIN IMMUNOL, V34, P954, DOI 10.1007/s10875-014-0102-8; Lam D. S. T., 2005, Hong Kong Medical Journal, V11, P90; Lee WI, 2005, J CLIN IMMUNOL, V25, P162, DOI 10.1007/s10875-005-2822-2; Leiva LE, 2007, J CLIN IMMUNOL, V27, P101, DOI 10.1007/s10875-006-9052-0; Leung D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01605; Lim D. L., 2003, SMJ Singapore Medical Journal, V44, P579; Lopes JP, 2020, IMMUNOL ALLERGY CLIN, V40, P385, DOI 10.1016/j.iac.2020.03.002; Lougaris V, 2020, J CLIN IMMUNOL, V40, P1026, DOI 10.1007/s10875-020-00844-0; Ludviksson BR, 2015, J CLIN IMMUNOL, V35, P75, DOI 10.1007/s10875-014-0107-3; Marciano BE, 2014, J ALLERGY CLIN IMMUN, V133, P1134, DOI 10.1016/j.jaci.2014.02.028; Marschall K, 2015, CLIN EXP IMMUNOL, V182, P45, DOI 10.1111/cei.12661; Mellouli F, 2015, J CLIN IMMUNOL, V35, P745, DOI 10.1007/s10875-015-0206-9; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Modell V, 2016, IMMUNOL RES, V64, P736, DOI 10.1007/s12026-016-8784-z; Mukhina AA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01491; Naidoo R, 2011, J CLIN IMMUNOL, V31, P99, DOI 10.1007/s10875-010-9465-7; Norouzi S, 2012, J INFECTION, V64, P543, DOI 10.1016/j.jinf.2012.03.012; Notarangelo LD, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abb1662; Notarangelo LD, 2010, J ALLERGY CLIN IMMUN, V125, pS182, DOI 10.1016/j.jaci.2009.07.053; Palareti G, 2016, INT J LAB HEMATOL, V38, P42, DOI 10.1111/ijlh.12426; Randall TD, 2014, MUCOSAL IMMUNOL, V7, P455, DOI 10.1038/mi.2014.11; Reda SM, 2009, J CLIN IMMUNOL, V29, P343, DOI 10.1007/s10875-008-9260-x; Reisi M, 2017, EUR ANN ALLERGY CLIN, V49, P122; Rhim JW, 2012, J KOREAN MED SCI, V27, P788, DOI 10.3346/jkms.2012.27.7.788; Schmidt RE, 2018, NAT REV RHEUMATOL, V14, P7, DOI 10.1038/nrrheum.2017.198; Shillitoe B, 2018, CLIN EXP IMMUNOL, V192, P284, DOI 10.1111/cei.13125; Tadmouri Ghazi O, 2009, Reprod Health, V6, P17, DOI 10.1186/1742-4755-6-17; Tangye SG, 2021, J CLIN IMMUNOL, V41, P666, DOI 10.1007/s10875-021-00980-1; Tangye SG, 2020, J CLIN IMMUNOL, V40, P24, DOI 10.1007/s10875-019-00737-x; van Zelm MC, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03148; Wang LL, 2011, J CLIN IMMUNOL, V31, P297, DOI 10.1007/s10875-010-9493-3; Wu JH, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1729-7; Yagoubi A, 2021, RES SQUARE, P1, DOI [10.21203/rs.3.rs-1287012/v1, DOI 10.21203/RS.3.RS-1287012/V1]; Yamashita M, 2021, INFLAMM REGEN, V41, DOI 10.1186/s41232-021-00159-6; Zebracki K, 2004, ANN ALLERG ASTHMA IM, V93, P557, DOI 10.1016/S1081-1206(10)61263-X; Zhang Q, 2022, NATURE, V603, P587, DOI [10.1038/s41586-022-04447-0, 10.1159/000524200]	75	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								900091	10.3389/fimmu.2022.900091	http://dx.doi.org/10.3389/fimmu.2022.900091			18	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B7YX	35529857	gold, Green Published			2022-12-18	WOS:000810400900001
J	Chen, Q; Wang, J; Xiang, MM; Wang, YL; Zhang, ZX; Liang, J; Xu, JH				Chen, Qian; Wang, Jie; Xiang, Mengmeng; Wang, Yilun; Zhang, Zhixiong; Liang, Jun; Xu, Jinhua			The Potential Role of Ferroptosis in Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Review						systemic lupus erythematosus; ferroptosis; autoimmunity; immunity; inflammation	LIPID-PEROXIDATION; OXIDATIVE STRESS; RHEUMATOID-ARTHRITIS; IRON HOMEOSTASIS; T-CELLS; ATHEROSCLEROSIS; MACROPHAGES; GLUTATHIONE; DYSFUNCTION; METABOLISM	Systemic lupus erythematosus (SLE) is an autoimmune disease that is accompanied with autoantibody production and inflammation. Other features of SLE pathogenesis include iron accumulation, oxidative stress, and lipid peroxidation, which are also major biochemical characteristics of ferroptosis, a novel non-apoptotic regulated form of cell death. To date, ferroptosis has been demonstrated to be an important driver of lupus progression, and several ferroptosis inhibitors have therapeutic effect in lupus-prone mice. Given the emerging link between ferroptosis and SLE, it can be postulated that ferroptosis is an integral component in the vicious cycle of immune dysfunction, inflammation, and tissue damage in SLE pathogenesis. In this review, we summarize the potential links between ferroptosis and SLE, with the aim of elucidating the underlying pathogenic mechanism of ferroptosis in lupus, and providing a new promising therapeutic strategy for SLE.							National Natural Science Foundation of China [81773324, 81872526]; Startup Foundation of Huashan Hospital [2020QD007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Startup Foundation of Huashan Hospital	Funding This work was supported by grants from the National Natural Science Foundation of China (grant no. 81773324, 81872526); and the Startup Foundation of Huashan Hospital (2020QD007).	Abdulahad DA, 2010, AUTOIMMUN REV, V9, P661, DOI 10.1016/j.autrev.2010.05.015; Ames PRJ, 1999, RHEUMATOLOGY, V38, P529, DOI 10.1093/rheumatology/38.6.529; Anders HJ, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0141-9; Ashrafizadeh M, 2019, J CELL PHYSIOL, V234, P19471, DOI 10.1002/jcp.28740; Bai T, 2020, FREE RADICAL BIO MED, V160, P92, DOI 10.1016/j.freeradbiomed.2020.07.026; Ben Mansour R, 2008, SCAND J RHEUMATOL, V37, P103, DOI 10.1080/03009740701772465; Bergamo P, 2007, FREE RADICAL BIO MED, V43, P71, DOI 10.1016/j.freeradbiomed.2007.03.023; BISSETT DL, 1991, PHOTOCHEM PHOTOBIOL, V54, P215, DOI 10.1111/j.1751-1097.1991.tb02009.x; Blanco LP, 2020, ARTHRITIS RHEUMATOL, V72, P454, DOI 10.1002/art.41128; Bowlus CL, 2003, AUTOIMMUN REV, V2, P73, DOI 10.1016/S1568-9972(02)00143-X; Brown A C, 2000, J Ren Nutr, V10, P170, DOI 10.1053/jren.2000.16323; Chapman EA, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00423; Conca W, 2009, CLIN EXP RHEUMATOL, V27, P834; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0; Gagliardi M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2143-7; Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042; Gheita TA, 2014, METHODS MOL BIOL, V1134, P193, DOI 10.1007/978-1-4939-0326-9_14; Gomes MF, 2021, J NEPHROL, V34, P1897, DOI 10.1007/s40620-021-01007-z; Hassan SZ, 2011, INT J RHEUM DIS, V14, P325, DOI 10.1111/j.1756-185X.2011.01630.x; Hinze CH, 2009, ARTHRITIS RHEUM-US, V60, P2772, DOI 10.1002/art.24751; Hong SOC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.578952; Hu CL, 2019, J NEUROCHEM, V148, P426, DOI 10.1111/jnc.14604; Irazabal MV, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061342; Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8; Jiang YH, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11002-5; Kapralov AA, 2020, NAT CHEM BIOL, V16, P278, DOI 10.1038/s41589-019-0462-8; Kim SY, 2020, ARTHRITIS RHEUMATOL, V72, P20, DOI 10.1002/art.41059; Kojima M, 2000, PATHOL INT, V50, P304, DOI 10.1046/j.1440-1827.2000.01052.x; Lee H, 2020, NAT CELL BIOL, V22, DOI 10.1038/s41556-020-0461-8; Lee SY, 2017, J IMMUNOL, V198, P2661, DOI 10.4049/jimmunol.1403088; Li PC, 2021, NAT IMMUNOL, V22, P1107, DOI 10.1038/s41590-021-00993-3; Liew PX, 2019, PHYSIOL REV, V99, P1223, DOI 10.1152/physrev.00012.2018; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Liu BC, 2018, KIDNEY INT, V93, P568, DOI 10.1016/j.kint.2017.09.033; Liu TY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01057; Lopez-Pedrera C, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10040600; Mahajan A, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00035; Mak TW, 2017, IMMUNITY, V46, P675, DOI 10.1016/j.immuni.2017.03.019; Marks ES, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13029-4; Martines AMF, 2013, NAT REV NEPHROL, V9, P385, DOI 10.1038/nrneph.2013.98; Matsushita M, 2015, J EXP MED, V212, P555, DOI 10.1084/jem.20140857; Morel L, 2017, NAT REV RHEUMATOL, V13, P280, DOI 10.1038/nrrheum.2017.43; Murao A, 2021, APOPTOSIS, V26, P152, DOI 10.1007/s10495-021-01663-3; Muri J, 2019, CELL REP, V29, P2731, DOI 10.1016/j.celrep.2019.10.070; Nie YX, 2022, CLIN REV ALLERG IMMU, V62, P301, DOI 10.1007/s12016-020-08820-7; Niki E, 2014, BBA-GEN SUBJECTS, V1840, P809, DOI 10.1016/j.bbagen.2013.03.020; Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001; Perl A, 2004, INT REV IMMUNOL, V23, P293, DOI 10.1080/08830180490452576; Perl A, 2013, NAT REV RHEUMATOL, V9, P674, DOI 10.1038/nrrheum.2013.147; Perricone C, 2009, AUTOIMMUN REV, V8, P697, DOI 10.1016/j.autrev.2009.02.020; Piattini F, 2021, EUR J IMMUNOL, V51, P2417, DOI 10.1002/eji.202049114; Recalcati S, 2012, AUTOIMMUN REV, V11, P883, DOI 10.1016/j.autrev.2012.03.003; Safi R, 2019, EXP DERMATOL, V28, P1348, DOI 10.1111/exd.14040; Sahebari M, 2019, CURR RHEUMATOL REV, V15, P123, DOI 10.2174/1573397114666181016112342; Schaper F, 2014, MOL MED, V20, P72, DOI 10.2119/molmed.2014.00019; Scindia Y, 2020, KIDNEY INT, V98, P100, DOI 10.1016/j.kint.2020.01.025; Shah D, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-23; Shi X, 2020, FREE RADICAL RES, V54, P765, DOI 10.1080/10715762.2020.1843651; Skaggs BJ, 2012, NAT REV RHEUMATOL, V8, P214, DOI 10.1038/nrrheum.2012.14; Su LJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/5080843; Sun YT, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110108; Swaminathan S, 2018, NEPHRON, V140, P156, DOI 10.1159/000490808; Tang DL, 2021, CELL RES, V31, P107, DOI 10.1038/s41422-020-00441-1; Telorack M, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005800; Ursini F, 2020, FREE RADICAL BIO MED, V152, P175, DOI 10.1016/j.freeradbiomed.2020.02.027; Vats K, 2021, REDOX BIOL, V47, DOI 10.1016/j.redox.2021.102143; Wang D, 2018, BIOCHEM BIOPH RES CO, V503, P1689, DOI 10.1016/j.bbrc.2018.07.100; Wang J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1097-5; Wang J, 2018, SCI CHINA LIFE SCI, V61, P523, DOI 10.1007/s11427-017-9169-6; Wang Y, 2020, EUR J PHARMACOL, V888, DOI 10.1016/j.ejphar.2020.173574; Wang ZZ, 2018, IMMUNITY, V49, P80, DOI 10.1016/j.immuni.2018.05.008; Wen QR, 2019, BIOCHEM BIOPH RES CO, V510, P278, DOI 10.1016/j.bbrc.2019.01.090; Wlazlo E, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.643686; Wu Y, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20202924; Xepapadaki E, 2020, ANGIOLOGY, V71, P112, DOI 10.1177/0003319719854609; Xu Y, 2020, AUTOPHAGY, V16, P3, DOI 10.1080/15548627.2019.1603547; Zhang HS, 2019, FREE RADICAL BIO MED, V142, P16, DOI 10.1016/j.freeradbiomed.2019.06.004; Zhao M, 2018, CLIN IMMUNOL, V187, P113, DOI 10.1016/j.clim.2017.11.002	79	0	0	7	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								855622	10.3389/fimmu.2022.855622	http://dx.doi.org/10.3389/fimmu.2022.855622			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B7PE	35529869	gold, Green Published			2022-12-18	WOS:000810375600001
J	Jiang, YZ; Lin, JX; Zheng, HY; Zhu, P				Jiang, Yanzhi; Lin, Jianxin; Zheng, Haiyun; Zhu, Ping			The Role of Purinergic Signaling in Heart Transplantation	FRONTIERS IN IMMUNOLOGY			English	Review						purinergic signaling; ATP; adenosine; ischemia reperfusion injury; heart transplantation	INTERNATIONAL SOCIETY; ADENOSINE RECEPTORS; ORGAN TRANSPLANT; P2Y(12) RECEPTOR; NELADENOSON BIALANATE; MYOCARDIAL PROTECTION; NUCLEOTIDE RECEPTOR; ACTIVATED PLATELETS; FUNCTIONAL RECOVERY; P2Y(6) RECEPTORS	Heart transplantation remains the optimal treatment option for patients with end-stage heart disease. Growing evidence demonstrates that purinergic signals mediated by purine nucleotides and nucleosides play vital roles in heart transplantation, especially in the era of ischemia-reperfusion injury (IRI) and allograft rejection. Purinergic signaling consists of extracellular nucleotides and nucleosides, ecto-enzymes, and cell surface receptors; it participates in the regulation of many physiological and pathological processes. During transplantation, excess adenosine triphosphate (ATP) levels are released from damaged cells, and driver detrimental inflammatory responses largely via purinergic P2 receptors. Ecto-nucleosidases sequentially dephosphorylate extracellular ATP to ADP, AMP, and finally adenosine. Adenosine exerts a cardioprotective effect by its anti-inflammatory, antiplatelet, and vasodilation properties. This review focused on the role of purinergic signaling in IRI and rejection after heart transplantation, as well as the clinical applications and prospects of purinergic signaling.	[Jiang, Yanzhi; Lin, Jianxin; Zheng, Haiyun; Zhu, Ping] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China	Guangdong Academy of Medical Sciences & Guangdong General Hospital	Zhu, P (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Guangdong Cardiovasc Inst, Guangzhou, Peoples R China.	zhuping_gz@163.com			National Key Research and Development Program of China [2018YFA0108700]; NSFC Projects of International Cooperation and Exchanges [81720108004]; National Natural Science Foundation of China [81974019]; Research Team Project of Natural Science Foundation of Guangdong Province of China [2017A030312007]; key program of guangzhou science research plan [201904020047]; Special Project of Dengfeng Program of Guangdong Provincial People's Hospital [DFJH201812, KJ012019119, KJ012019423]; Postdoctoral Sustentation Fund of Guangdong Provincial People's Hospital [BY012020015]	National Key Research and Development Program of China; NSFC Projects of International Cooperation and Exchanges; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research Team Project of Natural Science Foundation of Guangdong Province of China; key program of guangzhou science research plan; Special Project of Dengfeng Program of Guangdong Provincial People's Hospital; Postdoctoral Sustentation Fund of Guangdong Provincial People's Hospital	This work was supported in part by research grants from the National Key Research and Development Program of China (2018YFA0108700), NSFC Projects of International Cooperation and Exchanges (81720108004), National Natural Science Foundation of China (81974019), the Research Team Project of Natural Science Foundation of Guangdong Province of China (2017A030312007), the key program of guangzhou science research plan (201904020047), the Special Project of Dengfeng Program of Guangdong Provincial People's Hospital (DFJH201812, KJ012019119, KJ012019423), and the Postdoctoral Sustentation Fund of Guangdong Provincial People's Hospital (BY012020015).	Abraham MK, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091504; Antonioli L, 2013, TRENDS MOL MED, V19, P355, DOI 10.1016/j.molmed.2013.03.005; Aymerich I, 2005, BIOCHEM SOC T, V33, P216, DOI 10.1042/BST0330216; Bar-Yehuda S, 2005, NEOPLASIA, V7, P85, DOI 10.1593/neo.04364; Benoist L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48006-6; Berwick ZC, 2010, MICROCIRCULATION, V17, P600, DOI 10.1111/j.1549-8719.2010.00054.x; Bonner F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034730; Borea PA, 2018, PHYSIOL REV, V98, P1591, DOI 10.1152/physrev.00049.2017; Bourguignon T, 2019, J THORAC CARDIOV SUR, V158, P780, DOI 10.1016/j.jtcvs.2018.12.014; BURNSTOCK G, 1980, CIRC RES, V46, pI175; BURNSTOCK G, 1972, PHARMACOL REV, V24, P509; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; Burnstock Geoffrey, 2018, Brain Neurosci Adv, V2, p2398212818817494, DOI 10.1177/2398212818817494; Burnstock G, 2016, PURINERG SIGNAL, V12, P59, DOI 10.1007/s11302-015-9493-0; Castillo-Leon E, 2018, CURR OPIN ORGAN TRAN, V23, P34, DOI 10.1097/MOT.0000000000000484; Cekic C, 2016, NAT REV IMMUNOL, V16, P177, DOI 10.1038/nri.2016.4; Certal M, 2015, CELL CALCIUM, V58, P518, DOI 10.1016/j.ceca.2015.08.004; Chambers DC, 2017, J HEART LUNG TRANSPL, V36, P1047, DOI 10.1016/j.healun.2017.07.016; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Clouet S, 2016, J BIOL CHEM, V291, P15841, DOI 10.1074/jbc.M115.684118; Cohen R, 2011, BIOCHEM PHARMACOL, V82, P1126, DOI 10.1016/j.bcp.2011.07.094; Coukell AJ, 1997, DRUGS, V54, P745, DOI 10.2165/00003495-199754050-00006; D'Addio F, 2018, J CLIN INVEST, V128, P3490, DOI 10.1172/JCI94524; Dettori I, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.588757; Di Virgilio F, 2020, AM J PHYSIOL-CELL PH, V318, pC832, DOI 10.1152/ajpcell.00053.2020; Di Virgilio F, 2018, NAT REV CANCER, V18, P601, DOI 10.1038/s41568-018-0037-0; Dierada Z, 2017, PHARMACOL RES, V118, P5, DOI 10.1016/j.phrs.2016.08.009; DiNicolantonio JJ, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.110051; Dong SZ, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12159; dos Anjos F, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8632048; Dost T, 2020, PHARMACOL REP, V72, P672, DOI 10.1007/s43440-019-00046-5; Duran SR, 2021, PEDIATR RADIOL, V51, P1311, DOI 10.1007/s00247-021-04977-1; Dwyer KM, 2004, J CLIN INVEST, V113, P1440, DOI 10.1172/JCI200419560; Dzeja PP, 2007, J BIOL CHEM, V282, P31366, DOI 10.1074/jbc.M705268200; Eckle T, 2012, NAT MED, V18, P774, DOI 10.1038/nm.2728; Elliott MR, 2017, J IMMUNOL, V198, P1387, DOI 10.4049/jimmunol.1601520; Eltzschig HK, 2013, TRENDS MOL MED, V19, P345, DOI 10.1016/j.molmed.2013.02.005; Emaminia A, 2011, ANN THORAC SURG, V92, P1840, DOI 10.1016/j.athoracsur.2011.06.062; Ferenbach DA, 2012, KIDNEY INT, V82, P928, DOI 10.1038/ki.2012.207; Flyer JN, 2017, CIRCULATION, V135, P2485, DOI 10.1161/CIRCULATIONAHA.117.028087; Francica A, 2021, J CLIN MED, V10, DOI 10.3390/jcm10194485; Fredholm BB, 2001, PHARMACOL REV, V53, P527; Frye CC, 2021, CELL MOL LIFE SCI, V78, P581, DOI 10.1007/s00018-020-03615-7; Giuliani AL, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.619458; Giuliani AL, 2019, IMMUNOL LETT, V205, P16, DOI 10.1016/j.imlet.2018.11.006; Granja T, 2019, CRIT CARE MED, V47, pE420, DOI 10.1097/CCM.0000000000003682; Hasegawa Tomomi, 2008, Circ Res, V103, P1410, DOI 10.1161/CIRCRESAHA.108.180059; Hasko G, 2018, BIOCHEM PHARMACOL, V151, P307, DOI 10.1016/j.bcp.2018.02.002; Hesse J, 2017, FASEB J, V31, P3040, DOI 10.1096/fj.201601307R; Hjortbak MV, 2021, BASIC RES CARDIOL, V116, DOI 10.1007/s00395-021-00870-y; Hu YH, 2021, STEM CELL TRANSL MED, V10, P465, DOI 10.1002/sctm.20-0154; Idzko M, 2014, NATURE, V509, P310, DOI 10.1038/nature13085; Imai M, 2000, TRANSPLANTATION, V70, P864, DOI 10.1097/00007890-200009270-00003; Jacobson KA, 2006, NAT REV DRUG DISCOV, V5, P247, DOI 10.1038/nrd1983; Jacobson KA, 2020, BRIT J PHARMACOL, V177, P2413, DOI [10.1111/bph.15005, 10.1111/bph.1500510.1111/bph.15005]; Jain S, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114739; Joglar JA, 2021, CIRC-ARRHYTHMIA ELEC, V14, P379, DOI 10.1161/CIRCEP.120.007954; Kawaguchi M, 2011, CIRCULATION, V123, P594, DOI 10.1161/CIRCULATIONAHA.110.982777; Kaza Elisabeth A, 2017, JACC Basic Transl Sci, V2, P465, DOI 10.1016/j.jacbts.2017.04.002; Khush KK, 2021, J HEART LUNG TRANSPL, V40, P1035, DOI 10.1016/j.healun.2021.07.015; Kishore BK, 2018, PURINERG SIGNAL, V14, P109, DOI 10.1007/s11302-017-9596-x; Kohler D, 2007, CIRCULATION, V116, P1784, DOI 10.1161/CIRCULATIONAHA.107.690180; Koeppen M, 2011, ADV PHARMACOL, V61, P145, DOI 10.1016/B978-0-12-385526-8.00006-0; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; Kopp R, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00183; Korkmaz-Icoz S, 2017, EUR J CARDIO-THORAC, V51, P829, DOI 10.1093/ejcts/ezw426; Koyamada N, 1996, TRANSPLANTATION, V62, P1739, DOI 10.1097/00007890-199612270-00008; Kristiansen SB, 2018, SCAND CARDIOVASC J, V52, P340, DOI 10.1080/14017431.2018.1552793; Kudira R, 2016, HEPATOLOGY, V63, P2004, DOI 10.1002/hep.28492; Lau CL, 2020, J HEART LUNG TRANSPL, V39, P563, DOI 10.1016/j.healun.2020.02.003; Laurain A, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586831; Laxson David, 1993, American Journal of Physiology, V265, pH1471; Le Duc D, 2017, ADV IMMUNOL, V136, P85, DOI 10.1016/bs.ai.2017.05.006; Le TTT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01633; Lemaire A, 2017, STEM CELLS DEV, V26, P363, DOI 10.1089/scd.2016.0166; Lewis CJ, 2001, J VASC RES, V38, P332, DOI 10.1159/000051064; Li ZZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22143; Linden J, 2019, ANNU REV IMMUNOL, V37, P325, DOI 10.1146/annurev-immunol-051116-052406; Liverani E, 2016, ARTERIOSCL THROM VAS, V36, P961, DOI 10.1161/ATVBAHA.116.307401; Liverani E, 2014, CURR DRUG TARGETS, V15, P720, DOI 10.2174/1389450115666140519162133; Liverani E, 2014, J LEUKOCYTE BIOL, V95, P313, DOI 10.1189/jlb.1012518; Lovaszi M, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2021.114419; Lund LH, 2017, J HEART LUNG TRANSPL, V36, P1037, DOI 10.1016/j.healun.2017.07.019; Ma D, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1230-5; Madani MH, 2012, J HEART LUNG TRANSPL, V31, P1234, DOI 10.1016/j.healun.2012.06.001; Magni G, 2019, BRAIN RES BULL, V151, P132, DOI 10.1016/j.brainresbull.2019.02.011; Mahaut-Smith MP, 2011, PURINERG SIGNAL, V7, P341, DOI 10.1007/s11302-011-9224-0; Mancini D, 2017, AM J TRANSPLANT, V17, P3193, DOI 10.1111/ajt.14499; Mendez-Carmona N, 2021, J HEART LUNG TRANSPL, V40, P1396, DOI 10.1016/j.healun.2021.07.028; Mesto N, 2022, J CELL PHYSIOL, V237, P881, DOI 10.1002/jcp.30564; Minor M, 2019, AM J PHYSIOL-CELL PH, V317, pC1079, DOI 10.1152/ajpcell.00285.2019; Mulloy DP, 2013, ANN THORAC SURG, V95, P1762, DOI 10.1016/j.athoracsur.2013.01.059; Ngamjariyawat A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061828; Ni YY, 2018, J SURG RES, V232, P442, DOI 10.1016/j.jss.2018.06.042; Ohana G, 2003, BRIT J CANCER, V89, P1552, DOI 10.1038/sj.bjc.6601315; Onorati F, 2016, J AM COLL CARDIOL, V67, P1751, DOI 10.1016/j.jacc.2015.12.071; Orriss IR, 2017, J ENDOCRINOL, V233, P341, DOI 10.1530/JOE-17-0042; Perera LMB, 2019, J INVEST DERMATOL, V139, P890, DOI 10.1016/j.jid.2018.10.027; Pomerantz BJ, 2001, P NATL ACAD SCI USA, V98, P2871, DOI 10.1073/pnas.041611398; Pucar D, 2002, AM J PHYSIOL-HEART C, V283, pH776, DOI 10.1152/ajpheart.00116.2002; Quillen EE, 2006, J BIOL CHEM, V281, P20728, DOI 10.1074/jbc.M513042200; Ran H, 2015, J NEUROPATH EXP NEUR, V74, P305, DOI 10.1097/NEN.0000000000000174; Rana A, 2015, JAMA SURG, V150, P252, DOI 10.1001/jamasurg.2014.2038; Reichelt ME, 2009, ANTIOXID REDOX SIGN, V11, P2641, DOI [10.1089/ars.2009.2644, 10.1089/ARS.2009.2644]; Rivard Andrew L, 2009, J Extra Corpor Technol, V41, P140; Roberts V, 2013, PURINERG SIGNAL, V9, P135, DOI 10.1007/s11302-012-9342-3; Rork TH, 2008, AM J PHYSIOL-HEART C, V295, pH1825, DOI 10.1152/ajpheart.495.2008; Rothermel BA, 2008, CIRCULATION, V118, P1691, DOI 10.1161/CIRCULATIONAHA.108.810101; Saemann L, 2021, J HEART LUNG TRANSPL, V40, P1135, DOI 10.1016/j.healun.2021.07.009; Sandanger O, 2013, CARDIOVASC RES, V99, P164, DOI 10.1093/cvr/cvt091; Sanjani MS, 2011, AM J PHYSIOL-HEART C, V301, pH2322, DOI 10.1152/ajpheart.00052.2011; Savi P, 2001, BIOCHEM BIOPH RES CO, V283, P379, DOI 10.1006/bbrc.2001.4816; Shah SJ, 2019, JAMA-J AM MED ASSOC, V321, P2101, DOI 10.1001/jama.2019.6717; Sharma AK, 2018, AM J PHYSIOL-LUNG C, V315, pL301, DOI 10.1152/ajplung.00004.2018; Shi YY, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.680706; Shokoples BG, 2021, ARTERIOSCL THROM VAS, V41, P186, DOI 10.1161/ATVBAHA.120.315116; Shryock JC, 1998, CIRCULATION, V98, P711, DOI 10.1161/01.CIR.98.7.711; Singh TP, 2021, J HEART LUNG TRANSPL, V40, P1050, DOI 10.1016/j.healun.2021.07.022; Smith SB, 2017, LIFE SCI, V179, P54, DOI 10.1016/j.lfs.2016.10.016; Sophocleous RA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228572; Springthorpe B, 2007, BIOORG MED CHEM LETT, V17, P6013, DOI 10.1016/j.bmcl.2007.07.057; Srivastava P, 2020, EXP NEUROL, V329, DOI 10.1016/j.expneurol.2020.113308; Stehlik J, 2018, CIRCULATION, V137, P71, DOI 10.1161/CIRCULATIONAHA.117.029753; Sui YT, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.663011; Sunggip C, 2017, PHARMACOL RES, V120, P51, DOI 10.1016/j.phrs.2017.03.013; Tang LM, 2010, TRANSPL P, V42, P1915, DOI 10.1016/j.transproceed.2010.02.084; Tian DL, 2021, J DIABETES RES, V2021, DOI 10.1155/2021/5584871; Vassort G, 2001, PHYSIOL REV, V81, P767, DOI 10.1152/physrev.2001.81.2.767; Vergani A, 2013, CIRCULATION, V127, P463, DOI 10.1161/CIRCULATIONAHA.112.123653; Verma R, 2017, BRAIN BEHAV IMMUN, V66, P302, DOI 10.1016/j.bbi.2017.07.155; Vessey DA, 2011, AM J PHYSIOL-HEART C, V301, pH881, DOI 10.1152/ajpheart.00305.2011; Vessey DA, 2011, MOL CELL BIOCHEM, V351, P77, DOI 10.1007/s11010-011-0713-9; Vessey DA, 2010, J CARDIOVASC PHARM T, V15, P190, DOI 10.1177/1074248409360356; Voors AA, 2019, EUR J HEART FAIL, V21, P1426, DOI 10.1002/ejhf.1591; Voors AA, 2017, J CLIN PHARMACOL, V57, P440, DOI 10.1002/jcph.828; Wheeler DG, 2012, J MOL CELL CARDIOL, V52, P958, DOI 10.1016/j.yjmcc.2012.01.002; White CW, 2016, AM J TRANSPLANT, V16, P773, DOI 10.1111/ajt.13574; White CW, 2013, J HEART LUNG TRANSPL, V32, P734, DOI 10.1016/j.healun.2013.04.016; Wolff G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135086; Woods LT, 2021, BIOCHEM PHARMACOL, V187, DOI 10.1016/j.bcp.2021.114406; Wu C, 2016, AM J TRANSPLANT, V16, P2563, DOI 10.1111/ajt.13808; Wu YJL, 2013, CIRC-CARDIOVASC IMAG, V6, P965, DOI 10.1161/CIRCIMAGING.113.000674; Xu XM, 2020, BRAIN RES BULL, V165, P290, DOI 10.1016/j.brainresbull.2020.10.004; Yang C, 2016, EUR J CARDIO-THORAC, V49, P1354, DOI 10.1093/ejcts/ezv413; Yegutkin GG, 2014, CRIT REV BIOCHEM MOL, V49, P473, DOI 10.3109/10409238.2014.953627; Yeudall S, 2020, AM J TRANSPLANT, V20, P633, DOI 10.1111/ajt.15651; Young JD, 2016, BIOCHEM SOC T, V44, P869, DOI 10.1042/BST20160038; Zeiser R, 2016, AM J TRANSPLANT, V16, P2781, DOI 10.1111/ajt.13801; Zhang CP, 2008, BRAIN RES BULL, V75, P77, DOI 10.1016/j.brainresbull.2007.07.031; Zhang JJ, 2016, J AM SOC NEPHROL, V27, P92, DOI 10.1681/ASN.2014121248; Zhang XJ, 2021, BIOENGINEERED, V12, P3737, DOI 10.1080/21655979.2021.1953217; Zhong EH, 2021, AM J PHYSIOL-CELL PH, V320, pC15, DOI 10.1152/ajpcell.00430.2020; Zhu YJ, 2021, EUR HEART J, V42, P4934, DOI 10.1093/eurheartj/ehab416; Ziegler M, 2018, EUR HEART J, V39, P111, DOI 10.1093/eurheartj/ehx218; Zimmermann H, 2012, PURINERG SIGNAL, V8, P437, DOI 10.1007/s11302-012-9309-4; Zuo X, 2021, FOOD FUNCT, V12, P5793, DOI [10.1039/d1fo00531f, 10.1039/D1FO00531F]	156	0	0	5	5	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								826943	10.3389/fimmu.2022.826943	http://dx.doi.org/10.3389/fimmu.2022.826943			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1D0DV	35529844	gold, Green Published			2022-12-18	WOS:000793481800001
J	Li, ZH; Ludwig, N; Thomas, K; Mersmann, S; Lehmann, M; Vestweber, D; Pittet, JF; Gomez, H; Kellum, JA; Rossaint, J; Zarbock, A				Li, Zhenhan; Ludwig, Nadine; Thomas, Katharina; Mersmann, Sina; Lehmann, Martin; Vestweber, Dietmar; Pittet, Jean-Francois; Gomez, Hernando; Kellum, John A.; Rossaint, Jan; Zarbock, Alexander			The Pathogenesis of Ischemia-Reperfusion Induced Acute Kidney Injury Depends on Renal Neutrophil Recruitment Whereas Sepsis-Induced AKI Does Not	FRONTIERS IN IMMUNOLOGY			English	Article						neutrophils; kidney; ischemia-reperfusion injury; cecal ligation and puncture; sepsis; acute kidney injury	OXIDATIVE STRESS; ISCHEMIA/REPERFUSION INJURY; POLYMICROBIAL SEPSIS; FREE-RADICALS; DYSFUNCTION; PATHOPHYSIOLOGY; FAILURE; CELL; CONTRIBUTES; MECHANISMS	Acute kidney injury (AKI) may be induced by different causes, including renal ischemia-reperfusion injury and sepsis, which represent the most common reasons for AKI in hospitalized patients. AKI is defined by reduced urine production and/or increased plasma creatinine. However, this definition does not address the molecular mechanisms of different AKI entities, and uncertainties remain regarding distinct pathophysiological events causing kidney injury in the first place. In particular, sepsis-induced AKI is considered not to be associated with leukocyte infiltration into the kidney, but a direct investigation of this process is missing to this date. In this study, we used two murine AKI models induced by either renal ischemia-reperfusion injury (IRI) or cecal ligation and puncture (CLP) to investigate the contribution of neutrophils to tissue injury and kidney function. By using VEC-Y731F mice, in which neutrophil recruitment is impaired, we analyzed the specific contribution of neutrophil recruitment to the pathogenesis of IRI- and CLP-induced AKI. We observed that the degree of renal injury evaluated by plasma creatinine, urinary biomarkers and histological analyses, following IRI-induction was dependent on neutrophil migration into the kidney, whereas the pathogenesis of CLP-induced AKI was independent of neutrophil recruitment. Furthermore, plasma transfer experiments suggest that the pathogenesis of CLP-induced AKI relies on circulating inflammatory mediators. These results extend our knowledge of the AKI pathogenesis and may help in the development of prophylactic and therapeutic treatments for AKI patients.					Kellum, John A/HCH-2944-2022	Kellum, John A/0000-0003-1995-2653; Ludwig, Nadine/0000-0001-5910-1277; Lehmann, Martin/0000-0003-2179-5765	Center for Interdisciplinary Clinical Research [Ross2/010/18]; Deutsche Forschungsgemeinschaft [RO4537/4-1, ZA428/17-1, SFB1009A05, TRR332C01]	Center for Interdisciplinary Clinical Research; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Center for Interdisciplinary Clinical Research (IZKF Muenster, Ross2/010/18 to JR) and the Deutsche Forschungsgemeinschaft (RO4537/4-1 to JR and ZA428/17-1, SFB1009A05 and TRR332C01 to AZ).	Al-Harbi NO, 2019, BIOCHIMIE, V158, P102, DOI 10.1016/j.biochi.2018.12.014; Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x; Bird L, 2010, NAT REV IMMUNOL, V10, DOI 10.1038/nri2877; Block H, 2012, J EXP MED, V209, P407, DOI 10.1084/jem.20111493; Bonavia A, 2018, PEDIATR NEPHROL, V33, P1629, DOI 10.1007/s00467-017-3774-5; Bonventre JV, 2011, J CLIN INVEST, V121, P4210, DOI 10.1172/JCI45161; Brealey D, 2004, AM J PHYSIOL-REG I, V286, pR491, DOI 10.1152/ajpregu.00432.2003; Brealey David, 2003, Curr Infect Dis Rep, V5, P365, DOI 10.1007/s11908-003-0015-9; Calzavacca P, 2015, CRIT CARE MED, V43, pE431, DOI 10.1097/CCM.0000000000001198; Cao Y, 2015, FEBS J, V282, P3799, DOI 10.1111/febs.13379; Castoldi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037584; de Buhr N, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4604713; De Filippo K, 2013, BLOOD, V121, P4930, DOI 10.1182/blood-2013-02-486217; Di Giantomasso D, 2003, CHEST, V124, P1053, DOI 10.1378/chest.124.3.1053; Exline MC, 2008, FRONT BIOSCI-LANDMRK, V13, P5030; Ferenbach David A, 2016, Nephrol Ther, V12 Suppl 1, pS41, DOI 10.1016/j.nephro.2016.02.005; Francis A, 2017, DIVING HYPERB MED, V47, P110; Gao L, 2016, ELIFE, V5, DOI [10.7554/elife.18542, 10.7554/eLife.18542]; Garley M, 2018, ARCH IMMUNOL THER EX, V66, P21, DOI 10.1007/s00005-017-0476-4; Gomez H, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000052; Han SJ, 2019, KIDNEY RES CLIN PRAC, V38, P427, DOI 10.23876/j.krcp.19.062; Herter JM, 2014, J INNATE IMMUN, V6, P597, DOI 10.1159/000358238; Heyman SN, 2011, CONTRIB NEPHROL, V174, P138, DOI 10.1159/000329383; Incalza MA, 2018, VASC PHARMACOL, V100, P1, DOI 10.1016/j.vph.2017.05.005; Jang HR, 2015, NAT REV NEPHROL, V11, P88, DOI 10.1038/nrneph.2014.180; Jin LL, 2014, J IMMUNOL, V193, P3549, DOI 10.4049/jimmunol.1401138; KAKO K, 1988, AM J PHYSIOL, V254, pC330, DOI 10.1152/ajpcell.1988.254.2.C330; Kalakeche R, 2011, J AM SOC NEPHROL, V22, P1505, DOI 10.1681/ASN.2011020203; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; Kosieradzki M, 2008, TRANSPL P, V40, P3279, DOI 10.1016/j.transproceed.2008.10.004; Leliefeld PHC, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1250-4; Levey AS, 2017, ANN INTERN MED, V167, pITC65, DOI 10.7326/AITC201711070; Li L, 2010, J CLIN INVEST, V120, P331, DOI 10.1172/JCI38702; Liang H, 2018, BIOMED PHARMACOTHER, V106, P879, DOI 10.1016/j.biopha.2018.07.031; Malek M, 2015, J RENAL INJ PREV, V4, P20, DOI 10.12861/jrip.2015.06; Nadeem A, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107123; Ohms M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00532; PANG C Y, 1990, Journal of Reconstructive Microsurgery, V6, P77, DOI 10.1055/s-2007-1006807; Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105; Parikh SM, 2015, SEMIN NEPHROL, V35, P108, DOI 10.1016/j.semnephrol.2015.01.011; Pefanis A, 2019, KIDNEY INT, V96, P291, DOI 10.1016/j.kint.2019.02.009; Perico N, 2004, LANCET, V364, P1814, DOI 10.1016/S0140-6736(04)17406-0; Post EH, 2017, KIDNEY INT, V91, P45, DOI 10.1016/j.kint.2016.07.032; Rittirsch D, 2009, NAT PROTOC, V4, P31, DOI 10.1038/nprot.2008.214; Ronco C, 2019, LANCET, V394, P1949, DOI 10.1016/S0140-6736(19)32563-2; Sawant KV, 2016, SCI REP-UK, V6, DOI 10.1038/srep33123; Sharfuddin AA, 2011, NAT REV NEPHROL, V7, P189, DOI 10.1038/nrneph.2011.16; Singbartl K, 2005, J AM SOC NEPHROL, V16, P720, DOI 10.1681/ASN.2004050381; Sun J, 2019, J AM SOC NEPHROL, V30, P1151, DOI 10.1681/ASN.2018111126; Sun SJ, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01323; Wang X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02456; Wang Z, 2012, AM J PATHOL, V180, P505, DOI 10.1016/j.ajpath.2011.10.011; Wessel F, 2014, NAT IMMUNOL, V15, P223, DOI 10.1038/ni.2824; Woodfin A, 2016, BLOOD, V127, P898, DOI 10.1182/blood-2015-08-664995; Wu HL, 2008, J AM SOC NEPHROL, V19, P2331, DOI 10.1681/ASN.2008020170; Wu LP, 2007, J AM SOC NEPHROL, V18, P1807, DOI 10.1681/ASN.2006121402; Yang QH, 2009, J INFECTION, V58, P459, DOI 10.1016/j.jinf.2009.04.003; Yoo JY, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108245; Zarbock A, 2007, CRIT CARE MED, V35, P2156, DOI 10.1097/01.CCM.0000280570.82885.32; Zheng L, 2019, CURR PROTEIN PEPT SC, V20, P770, DOI 10.2174/1389203720666190507102529; Zweier JL, 2006, CARDIOVASC RES, V70, P181, DOI 10.1016/j.cardiores.2006.02.025	61	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								843782	10.3389/fimmu.2022.843782	http://dx.doi.org/10.3389/fimmu.2022.843782			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B7YB	35529856	gold, Green Published			2022-12-18	WOS:000810398700001
J	Lu, Y; Chang, N; Zhao, XH; Xue, RM; Liu, J; Yang, L; Li, LY				Lu, Yu; Chang, Na; Zhao, Xinhao; Xue, Renmin; Liu, Jing; Yang, Lin; Li, Liying			Activated Neutrophils Secrete Chitinase-Like 1 and Attenuate Liver Inflammation by Inhibiting Pro-Inflammatory Macrophage Responses	FRONTIERS IN IMMUNOLOGY			English	Article						activated neutrophil; liver inflammation; Chitinase-like 1; pro-inflammatory macrophage; Sphingosine 1-phosphate	INJURY; REGENERATION; RECRUITMENT; PHENOTYPE; FIBROSIS; YKL-40; MARKER; REPAIR; AXIS	Excessive activation and recruitment of neutrophils are generally considered to be associated with pathological aggravation of multiple diseases. However, as the role of neutrophils in tissue injury repair is receiving increasing attention, it is necessary to further explore the beneficial role of activated neutrophils in promoting the resolution of inflammation after injury. In this study, we found that activated neutrophils have a crucial function in suppressing liver inflammation. In methionine-choline-deficient and high-fat (MCDHF) diet induced liver inflammation in mice, tail vein injection of activated neutrophils (A-Neu, stimulated by sphingosine 1-phosphate) inhibited the expressions of pro-inflammatory cytokines in the liver, including C-C chemokine motif ligand 4, tumor necrosis factor and nitric oxide synthase 2, and attenuated liver injury. However, non-activated neutrophils (N-Neu) did not have these effects. In vitro, pro-inflammatory macrophages were co-cultured with N-Neu or A-Neu by transwell, respectively. A-Neu was found to suppress the pro-inflammatory phenotype of macrophages by using RT-qPCR, western blot and cytometric bead array. Microarray analysis showed that there were systematic variations in transcript expression levels between N-Neu and A-Neu. GeneVenn software was used to show the gene expression overlap between GO terms including Regulation of Cell Communication, Cytokine Secretion, Inflammatory Response and Extracellular Space clusters. We identified that Chitinase-like 1 (CHIL1) secreted by S1P activated neutrophils may be an important mediators affecting the pro-inflammatory macrophage responses. In the injured liver of mice induced by MCDHF diet, the expression of Chil1 mRNA increased and was positively correlated with the neutrophil marker Ly6g. Moreover, the secretion of CHIL1 in A-Neu increased significantly. Strikingly, the effect of A-Neu on macrophage response was reproduced by incubating pro-inflammatory macrophages with recombinant CHIL1. A-Neu conditioned medium were incubated with CHIL1 antibody-conjugated protein G beads, magnetically separated to immunodepletion CHIL1 from the A-Neu supernatant, which can partially weaken its inhibitory effect of A-Neu on the production of macrophage pro-inflammatory cytokines. Together, the conclusions indicated that A-Neu could inhibit the pro-inflammatory macrophage responses by secreting CHIL1, thereby effectively inhibiting liver inflammation.					Lu, Yu/HHC-7032-2022		National Natural and Science Foundation of China [81970532, 81670550]	National Natural and Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by grants from the National Natural and Science Foundation of China (81970532, 81670550).	Ballesteros I, 2020, CELL, V183, P1282, DOI 10.1016/j.cell.2020.10.003; Calvente CJ, 2019, J CLIN INVEST, V129, P4091, DOI 10.1172/JCI122258; Cartier A, 2019, SCIENCE, V366, P323, DOI 10.1126/science.aar5551; Che JY, 2020, ADV MATER, V32, DOI 10.1002/adma.202003598; Cho Y, 2021, HEPATOLOGY, V74, P503, DOI 10.1002/hep.31680; Cohen N, 2017, ONCOGENE, V36, P4457, DOI 10.1038/onc.2017.65; Dal-Secco D, 2015, J EXP MED, V212, P447, DOI 10.1084/jem.20141539; Daley JM, 2005, J IMMUNOL, V174, P2265, DOI 10.4049/jimmunol.174.4.2265; de Oliveira S, 2016, NAT REV IMMUNOL, V16, P378, DOI 10.1038/nri.2016.49; Dragomir ACD, 2012, J IMMUNOL, V189, P5934, DOI 10.4049/jimmunol.1201851; Eghbalzadeh K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02313; Han Z, 2012, HEPATOLOGY, V56, P350, DOI 10.1002/hep.25672; Hong CW, 2017, IMMUNE NETW, V17, P298, DOI 10.4110/in.2017.17.5.298; Horckmans M, 2017, EUR HEART J, V38, P187, DOI 10.1093/eurheartj/ehw002; Ikeda H, 2009, J LIPID RES, V50, P556, DOI 10.1194/jlr.M800496-JLR200; Im JH, 2020, EXP NEUROL, V323, DOI 10.1016/j.expneurol.2019.113082; Jaeger BN, 2012, J EXP MED, V209, P565, DOI 10.1084/jem.20111908; Kjaergaard AD, 2016, CRIT REV CL LAB SCI, V53, P396, DOI 10.1080/10408363.2016.1190683; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Koyama Y, 2017, J CLIN INVEST, V127, P55, DOI 10.1172/JCI88881; Laskin DL, 2011, ANNU REV PHARMACOL, V51, P267, DOI 10.1146/annurev.pharmtox.010909.105812; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Lee DH, 2019, METABOLISM, V95, P46, DOI 10.1016/j.metabol.2019.03.010; Li CY, 2011, J HEPATOL, V54, P1205, DOI 10.1016/j.jhep.2010.08.028; Li SY, 2021, ADV MATER, V33, DOI 10.1002/adma.202006160; Liu QL, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03524-y; Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003; Ohnstedt E, 2019, EXPERT OPIN DRUG DIS, V14, P485, DOI 10.1080/17460441.2019.1588879; Oved JH, 2021, BLOOD, V137, P392, DOI 10.1182/blood.2020005505; Robinson MW, 2016, CELL MOL IMMUNOL, V13, P267, DOI 10.1038/cmi.2016.3; Schuster S, 2018, NAT REV GASTRO HEPAT, V15, P349, DOI 10.1038/s41575-018-0009-6; Serriere-Lanneau V, 2007, FASEB J, V21, P2005, DOI 10.1096/fj.06-6889com; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Silvestre-Roig C, 2019, TRENDS IMMUNOL, V40, P565, DOI 10.1016/j.it.2019.04.012; Soehnlein O, 2010, NAT REV IMMUNOL, V10, P427, DOI 10.1038/nri2779; Sun BC, 2012, J HEPATOL, V56, P704, DOI 10.1016/j.jhep.2011.09.020; Sun YY, 2017, SCAND J IMMUNOL, V85, P166, DOI 10.1111/sji.12468; Syed MA, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/457189; Vind I, 2003, SCAND J GASTROENTERO, V38, P599, DOI 10.1080/00365520310000537; Vos K, 2000, ANN RHEUM DIS, V59, P544, DOI 10.1136/ard.59.7.544; Wang J, 2017, SCIENCE, V358, P111, DOI 10.1126/science.aam9690; Wright HL, 2010, RHEUMATOLOGY, V49, P1618, DOI 10.1093/rheumatology/keq045; Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015; Xu RN, 2014, CELL MOL IMMUNOL, V11, P224, DOI 10.1038/cmi.2014.2; Xue JW, 2017, NAT NANOTECHNOL, V12, P692, DOI [10.1038/nnano.2017.54, 10.1038/NNANO.2017.54]; Yang JJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194695; Yang L, 2020, MOL THER-NUCL ACIDS, V20, P725, DOI 10.1016/j.omtn.2020.04.010; Yang L, 2013, J HEPATOL, V59, P114, DOI 10.1016/j.jhep.2013.02.021; Yang WT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09046-8; Zhao XH, 2021, CELL IMMUNOL, V359, DOI 10.1016/j.cellimm.2020.104243; Zhao XH, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2582-1	51	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								824385	10.3389/fimmu.2022.824385	http://dx.doi.org/10.3389/fimmu.2022.824385			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B8IC	35529851	gold, Green Published			2022-12-18	WOS:000810425000001
J	Nunes-Cabaco, H; Moita, D; Rola, C; Mendes, AM; Prudencio, M				Nunes-Cabaco, Helena; Moita, Diana; Rola, Catarina; Mendes, Antonio M.; Prudencio, Miguel			Impact of Dietary Protein Restriction on the Immunogenicity and Efficacy of Whole-Sporozoite Malaria Vaccination	FRONTIERS IN IMMUNOLOGY			English	Article						malaria; vaccination; nutrition; dietary protein; immune response	ENERGY MALNUTRITION; PLASMODIUM-FALCIPARUM; T-CELLS; LIVER; INFECTION; PROTECTION; IMMUNITY; SUBSETS; DEFENSE; IMPAIRS	Malaria remains one of the world's most prevalent infectious diseases. Several vaccination strategies currently under investigation aim at hampering the development of the Plasmodium parasite during the clinically silent liver stage of its life cycle in the mammalian host, preventing the subsequent disease-associated blood stage of infection. Immunization with radiation-attenuated sporozoites (RAS), the liver-infecting parasite forms, can induce sterile protection against malaria. However, the efficacy of vaccine candidates in malaria-naive individuals in high-income countries is frequently higher than that found in populations where malaria is endemic. Malnutrition has been associated with immune dysfunction and with a delay or impairment of the immune response to some vaccines. Since vaccine efficacy depends on the generation of competent immune responses, and malaria-endemic regions are often associated with malnutrition, we hypothesized that an inadequate host nutritional status, specifically resulting from a reduction in dietary protein, could impact on the establishment of an efficient anti-malarial immune response. We developed a model of RAS immunization under low protein diet to investigate the impact of a reduced host protein intake on the immunogenicity and protective efficacy of this vaccine. Our analysis of the circulating and tissue-associated immune compartments revealed that a reduction in dietary protein intake during immunization resulted in a decrease in the frequency of circulating CD4+ T cells and of hepatic NK cells. Nevertheless, the profile of CD8+ T cells in the blood, liver and spleen was robust and minimally affected by the dietary protein content during RAS immunization, as assessed by supervised and in-depth unsupervised X-shift clustering analysis. Although mice immunized under low protein diet presented higher parasite liver load upon challenge than those immunized under adequate protein intake, the two groups displayed similar levels of protection from disease. Overall, our data indicate that dietary protein reduction may have minimal impact on the immunogenicity and efficacy of RAS-based malaria vaccination. Importantly, this experimental model can be extended to assess the impact of other nutrient imbalances and immunization strategies, towards the refinement of future translational interventions that improve vaccine efficacy in malnourished individuals.						Nunes Cabaco, Helena/0000-0001-7213-2879				Ampong I, 2020, BRIT J NUTR, V123, P601, DOI 10.1017/S0007114519003064; Ariyasinghe A, 2006, J PARASITOL, V92, P531, DOI 10.1645/GE-551R1.1; BAKKER NPM, 1992, ACTA TROP, V50, P285, DOI 10.1016/0001-706X(92)90063-4; Chatraw JH, 2008, J NUTR, V138, P806, DOI 10.1093/jn/138.4.806; Cockburn IA, 2018, NAT IMMUNOL, V19, P1199, DOI 10.1038/s41590-018-0228-6; Das D, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1177-5; Draper SJ, 2018, CELL HOST MICROBE, V24, P43, DOI 10.1016/j.chom.2018.06.008; Edirisinghe J S, 1981, Ann Trop Paediatr, V1, P87; Epstein JE, 2011, SCIENCE, V334, P475, DOI 10.1126/science.1211548; FAOSTAT, FAOSTAT; Fernandez-Ruiz D, 2016, IMMUNITY, V45, P889, DOI 10.1016/j.immuni.2016.08.011; Fevang Per, 2018, Malar Res Treat, V2018, P7153173, DOI 10.1155/2018/7153173; Geiger R, 2016, CELL, V167, P829, DOI 10.1016/j.cell.2016.09.031; Goh YS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01227; Herndler-Brandstetter D, 2018, IMMUNITY, V48, P716, DOI 10.1016/j.immuni.2018.03.015; Hoang T, 2015, INFECT IMMUN, V83, P2118, DOI 10.1128/IAI.03030-14; Ibrahim MK, 2017, CLIN MICROBIOL REV, V30, P919, DOI 10.1128/CMR.00119-16; Iyer SS, 2012, J IMMUNOL, V188, P77, DOI 10.4049/jimmunol.1004027; Jongo SA, 2018, AM J TROP MED HYG, V99, P338, DOI 10.4269/ajtmh.17-1014; King T, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005118; Kurup SP, 2019, NAT REV IMMUNOL, V19, P457, DOI 10.1038/s41577-019-0158-z; Lefebvre MN, 2020, TRENDS PARASITOL, V36, P147, DOI 10.1016/j.pt.2019.11.004; Martin MD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02692; Masuoka H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74122-9; Mendes AM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0091-3; Mendes AM, 2018, NPJ VACCINES, V3, DOI 10.1038/s41541-018-0068-2; Menezes AL, 2013, NUTR RES, V33, P494, DOI 10.1016/j.nutres.2013.04.010; MENGHERI E, 1992, J INTERFERON RES, V12, P17, DOI 10.1089/jir.1992.12.17; Mordmuller B, 2017, NATURE, V542, P445, DOI 10.1038/nature21060; Nassar M. F., 2007, Eastern Mediterranean Health Journal, V13, P1031; Nganou-Makamdop K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036508; PENACRUZ V, 1989, J VIROL, V63, P3541, DOI 10.1128/JVI.63.8.3541-3544.1989; Pied S, 2000, J IMMUNOL, V164, P1463, DOI 10.4049/jimmunol.164.3.1463; Ploemen IHJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007881; Prudencio M, 2011, TRENDS PARASITOL, V27, P565, DOI 10.1016/j.pt.2011.09.004; Rai D, 2009, J IMMUNOL, V183, P7672, DOI 10.4049/jimmunol.0902874; Reuling IJ, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay2578; Rytter MJH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105017; Samusik N, 2016, NAT METHODS, V13, P493, DOI [10.1038/NMETH.3863, 10.1038/nmeth.3863]; Sanches-Vaz M, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1008145; Sato Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02554; Savy M, 2009, J NUTR, V139, p2154S, DOI 10.3945/jn.109.105312; Schmidt NW, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000998; Seder RA, 2013, SCIENCE, V341, P1359, DOI 10.1126/science.1241800; Semba RD., 2001, NUTR HLTH DEV COUNTR, DOI [10.1385/1592592252, DOI 10.1385/1592592252]; Shankar AH, 2000, J INFECT DIS, V182, pS37, DOI 10.1086/315906; Sissoko MS, 2017, LANCET INFECT DIS, V17, P498, DOI [10.1016/S1473-3099(17)30104-4, 10.1016/s1473-3099(17)30104-4]; Taylor AK, 2013, J INFECT DIS, V207, P501, DOI 10.1093/infdis/jis527; Wada Y, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00064; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, UN DEC ACT NUTR; Wolf AS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00212; Zarling S, 2015, METHODS MOL BIOL, V1325, P39, DOI 10.1007/978-1-4939-2815-6_3	53	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								869757	10.3389/fimmu.2022.869757	http://dx.doi.org/10.3389/fimmu.2022.869757			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C8EO	35529859	Green Published, gold			2022-12-18	WOS:000811094700001
J	Seaver, K; Kourko, O; Gee, K; Greer, PA; Basta, S				Seaver, Kyle; Kourko, Olena; Gee, Katrina; Greer, Peter A.; Basta, Sameh			IL-27 Improves Prophylactic Protection Provided by a Dead Tumor Cell Vaccine in a Mouse Melanoma Model	FRONTIERS IN IMMUNOLOGY			English	Article						IL-27; adjuvant; cancer vaccine; cell death; prophylactic; melanoma	MHC CLASS-I; HEAT-SHOCK PROTEINS; DENDRITIC CELLS; T-CELLS; APOPTOTIC CELLS; CALRETICULIN EXPOSURE; MOLECULAR-PATTERNS; ANTITUMOR IMMUNITY; CROSS-PRESENTATION; CLINICAL-OUTCOMES	The protocol used to induce cell death for generating vaccines from whole tumor cells is a critical consideration that impacts vaccine efficacy. Here we compared how different protocols used to induce cell death impacted protection provided by a prophylactic whole tumor cell vaccine in a mouse melanoma model. We found that melanoma cells exposed to gamma-irradiation or lysis combined with UV-irradiation (LyUV) provided better protection against tumor challenge than lysis only or cells exposed to UV-irradiation. Furthermore, we found that the immunoregulatory cytokine, IL-27 enhanced protection against tumor growth in a dose-dependent manner when combined with either LyUV or gamma-irradiated whole tumor cell vaccine preparations. Taken together, this data supports the use of LyUV as a potential protocol for developing whole tumor cell prophylactic cancer vaccines. We also showed that IL-27 can be used at low doses as a potent adjuvant in combination with LyUV or gamma-irradiation treated cancer cells to improve the protection provided by a prophylactic cancer vaccine in a mouse melanoma model.										Ahrends T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13438-1; Alatery A, 2008, J IMMUNOL METHODS, V338, P47, DOI 10.1016/j.jim.2008.07.009; Alothaimeen T, 2020, VIRAL IMMUNOL, V33, P477, DOI 10.1089/vim.2019.0178; Basta S, 2005, J IMMUNOL, V175, P796, DOI 10.4049/jimmunol.175.2.796; Basu S, 2000, INT IMMUNOL, V12, P1539, DOI 10.1093/intimm/12.11.1539; Beizavi Z, 2021, INT REV IMMUNOL, V40, P319, DOI 10.1080/08830185.2020.1840565; Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y; Boon T, 1997, IMMUNOL TODAY, V18, P267, DOI 10.1016/S0167-5699(97)80020-5; Briukhovetska D, 2021, NAT REV CANCER, V21, P481, DOI 10.1038/s41568-021-00363-z; Brouckaert G, 2004, MOL BIOL CELL, V15, P1089, DOI 10.1091/mbc.E03-09-0668; BRUNDA MJ, 1993, J EXP MED, V178, P1223, DOI 10.1084/jem.178.4.1223; Capitini Christian M, 2009, Am J Immunol, V5, P65; Car BD, 1999, TOXICOL PATHOL, V27, P58, DOI 10.1177/019262339902700112; Chen WS, 2004, EUR J IMMUNOL, V34, P194, DOI 10.1002/eji.200324257; Chiba Y, 2018, CANCER RES, V78, P182, DOI 10.1158/0008-5472.CAN-17-0960; Chmielewski M, 2011, CANCER RES, V71, P5697, DOI 10.1158/0008-5472.CAN-11-0103; Creagh EM, 2000, LEUKEMIA, V14, P1161, DOI 10.1038/sj.leu.2401841; Crews DW, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.626463; Danilo M, 2018, CELL REP, V22, P2107, DOI 10.1016/j.celrep.2018.01.072; Deacon DH, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-360; Demaria S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00153; Dhatchinamoorthy K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636568; Dudek AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00438; Dudley ME, 2002, SCIENCE, V298, P850, DOI 10.1126/science.1076514; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fang JX, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.7; FIDLER IJ, 1975, CANCER RES, V35, P218; Finn OJ, 2018, NAT REV IMMUNOL, V18, P183, DOI 10.1038/nri.2017.140; Finn OJ, 2014, CANCER IMMUNOL RES, V2, P708, DOI 10.1158/2326-6066.CIR-14-0110; Fucikova J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03221-2; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Gao YC, 2007, SCAND J CLIN LAB INV, V67, P741, DOI 10.1080/00365510701297480; Garner H, 2020, NAT REV IMMUNOL, V20, P483, DOI 10.1038/s41577-019-0271-z; Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; Greene JAL, 1996, J BIOL CHEM, V271, P26762, DOI 10.1074/jbc.271.43.26762; Guallar-Garrido S, 2020, IMMUNOTARGETS THER, V9, P1, DOI 10.2147/ITT.S202006; Hatfield P, 2008, J IMMUNOTHER, V31, P620, DOI 10.1097/CJI.0b013e31818213df; Hernandez C, 2016, ONCOGENE, V35, P5931, DOI 10.1038/onc.2016.104; Hibbert L, 2003, J INTERF CYTOK RES, V23, P513, DOI 10.1089/10799900360708632; Hisada M, 2004, CANCER RES, V64, P1152, DOI 10.1158/0008-5472.CAN-03-2084; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hu AY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00210; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Jung JY, 2015, IMMUNOLOGY, V144, P649, DOI 10.1111/imm.12417; Karakhanova S, 2011, J LEUKOCYTE BIOL, V89, P837, DOI 10.1189/jlb.1209788; Kilgore AM, 2020, J IMMUNOL, V204, P510, DOI 10.4049/jimmunol.1901357; Kim J, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/218752; Knutson KL, 2020, CLIN CANCER RES, V26, P1045, DOI 10.1158/1078-0432.CCR-19-2123; Kotera Y, 2001, CANCER RES, V61, P8105; Kourko O, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00969; Kourko O, 2019, J INTERF CYTOK RES, V39, P483, DOI 10.1089/jir.2018.0166; Kumar P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41478-6; Lasek W, 2014, CANCER IMMUNOL IMMUN, V63, P419, DOI 10.1007/s00262-014-1523-1; Lemay CG, 2012, MOL THER, V20, P1791, DOI 10.1038/mt.2012.128; Liu ZZ, 2013, EUR J IMMUNOL, V43, P468, DOI 10.1002/eji.201242930; Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75; Mascanfroni ID, 2013, NAT IMMUNOL, V14, P1054, DOI 10.1038/ni.2695; Mosch B, 2009, INT J RADIAT BIOL, V85, P1002, DOI 10.3109/09553000903258871; Mougel A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00467; Nace G, 2012, J INNATE IMMUN, V4, P6, DOI 10.1159/000334245; Neller MA, 2008, SEMIN IMMUNOL, V20, P286, DOI 10.1016/j.smim.2008.09.006; NOHRIA A, 1994, BIOTHERAPY, V7, P261, DOI 10.1007/BF01878491; Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Park YJ, 2019, P NATL ACAD SCI USA, V116, P3106, DOI 10.1073/pnas.1810254116; Pennock ND, 2014, P NATL ACAD SCI USA, V111, P16472, DOI 10.1073/pnas.1407393111; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; QUILL H, 1987, J IMMUNOL, V138, P3704; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Rainone V, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146622; Rakhmilevich AL, 1997, HUM GENE THER, V8, P1303, DOI 10.1089/hum.1997.8.11-1303; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Restifo NP, 1996, J NATL CANCER I, V88, P100, DOI 10.1093/jnci/88.2.100; RIEBER MS, 1994, BIOCHEM BIOPH RES CO, V203, P1629, DOI 10.1006/bbrc.1994.2373; Rizza Paola, 2002, Trends in Immunology, V23, P381, DOI 10.1016/S1471-4906(02)02276-7; Rovere P, 2000, BLOOD, V96, P4300; Rovere-Querini P, 2004, EMBO REP, V5, P825, DOI 10.1038/sj.embor.7400205; Sabel Michael S, 2002, Am J Clin Dermatol, V3, P609, DOI 10.2165/00128071-200203090-00003; Salcedo R, 2004, J IMMUNOL, V173, P7170, DOI 10.4049/jimmunol.173.12.7170; Salewski I, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02570-y; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Scheffer SR, 2003, INT J CANCER, V103, P205, DOI 10.1002/ijc.10777; Seya T, 2010, CANCER SCI, V101, P313, DOI 10.1111/j.1349-7006.2009.01442.x; Sharabi AB, 2015, CANCER IMMUNOL RES, V3, P345, DOI 10.1158/2326-6066.CIR-14-0196; Shen ZH, 1997, J IMMUNOL, V158, P2723; Shimizu M, 2006, J IMMUNOL, V176, P7317, DOI 10.4049/jimmunol.176.12.7317; Siddiqui S, 2011, J VIROL, V85, P13224, DOI 10.1128/JVI.05996-11; Slingluff CL, 2004, J CLIN ONCOL, V22, P4474, DOI 10.1200/JCO.2004.10.212; Slingluff CL, 2008, J CLIN ONCOL, V26, P4973, DOI 10.1200/JCO.2008.17.3161; Slingluff CL, 2007, CLIN CANCER RES, V13, P6386, DOI 10.1158/1078-0432.CCR-07-0486; Sobol RE, 2006, CANCER GENE THER, V13, P725, DOI 10.1038/sj.cgt.7700950; Subauste CS, 1998, J IMMUNOL, V160, P1831; Suzuki H, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-97; Tagliamonte M, 2014, HUM VACC IMMUNOTHER, V10, P3332, DOI 10.4161/21645515.2014.973317; Tang S, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106700; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; Tovey MG, 2010, METHODS MOL BIOL, V626, P287, DOI 10.1007/978-1-60761-585-9_19; van Mierlo GJD, 2004, J IMMUNOL, V173, P6753, DOI 10.4049/jimmunol.173.11.6753; Vandenberk L, 2016, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00663; Vandenberk L, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1083669; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wei J, 2013, J IMMUNOL, V191, P500, DOI 10.4049/jimmunol.1300328; West MA, 2004, SCIENCE, V305, P1153, DOI 10.1126/science.1099153; Yee C, 2002, P NATL ACAD SCI USA, V99, P16168, DOI 10.1073/pnas.242600099; Zamora AE, 2018, J IMMUNOL, V200, P392, DOI 10.4049/jimmunol.1701413; ZEH HJ, 1993, J IMMUNOTHER, V14, P155, DOI 10.1097/00002371-199308000-00012; Zhao H, 2001, CANCER RES, V61, P7819; Zhou F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02562; Zhu JM, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.98745	112	0	0	1	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								884827	10.3389/fimmu.2022.884827	http://dx.doi.org/10.3389/fimmu.2022.884827			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C7YZ	35529885	Green Published, gold			2022-12-18	WOS:000811080200001
J	Wan, XT; Song, MY; Wang, AY; Zhao, Y; Wei, ZH; Lu, Y				Wan, Xueting; Song, Mengyao; Wang, Aiyun; Zhao, Yang; Wei, Zhonghong; Lu, Yin			Microbiome Crosstalk in Immunotherapy and Anti-Angiogenesis Therapy (vol 12, 747914, 2021)	FRONTIERS IN IMMUNOLOGY			English	Correction						microbiome; immunotherapy; immune checkpoint; angiogenesis; prebiotics; Chinese medicine			[Wan, Xueting; Song, Mengyao; Wang, Aiyun; Zhao, Yang; Wei, Zhonghong; Lu, Yin] Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing, Peoples R China; [Wan, Xueting; Song, Mengyao; Wang, Aiyun; Zhao, Yang; Wei, Zhonghong; Lu, Yin] Jiangsu Joint Int Res Lab Chinese Med & Regenerat, Nanjing, Peoples R China; [Lu, Yin] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Tradit Chinese Med, Nanjing, Peoples R China; [Zhao, Yang] Nanjing Univ Chinese Med, Sch Med Holist Integrat Med, Dept Biochem & Mol Biol, Nanjing, Peoples R China	Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine; Nanjing University of Chinese Medicine	Wei, ZH; Lu, Y (corresponding author), Nanjing Univ Chinese Med, Sch Pharm, Jiangsu Key Lab Pharmacol & Safety Evaluat Chines, Nanjing, Peoples R China.; Wei, ZH; Lu, Y (corresponding author), Jiangsu Joint Int Res Lab Chinese Med & Regenerat, Nanjing, Peoples R China.; Lu, Y (corresponding author), Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Tradit Chinese Med, Nanjing, Peoples R China.	wzh1225@njucm.edu.cn; luyingreen@njucm.edu.cn						Wan XT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.747914	1	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 21	2022	13								887775	10.3389/fimmu.2022.887775	http://dx.doi.org/10.3389/fimmu.2022.887775			1	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5U0UM	35529843	gold, Green Published			2022-12-18	WOS:000876269600001
J	Albrecht-Schgoer, K; Lackner, P; Schmutzhard, E; Baier, G				Albrecht-Schgoer, Karin; Lackner, Peter; Schmutzhard, Erich; Baier, Gottfried			Cerebral Malaria: Current Clinical and Immunological Aspects	FRONTIERS IN IMMUNOLOGY			English	Review						cerebral malaria (CM); CD8+; T cell sequestration; blood brain barrier (BBB); pathophysiology of CM; activation of the brain endothelium; parasite virulence factors; host virulence factors	CD8(+) T-CELLS; INTERCELLULAR-ADHESION MOLECULE-1; TUMOR-NECROSIS-FACTOR; PLASMODIUM-FALCIPARUM MALARIA; ENDOTHELIAL NITRIC-OXIDE; INFECTED ERYTHROCYTES; EPCR-BINDING; GENOME-WIDE; BRAIN; CHILDREN	This review focuses on current clinical and immunological aspects of cerebral malaria induced by Plasmodium falciparum infection. Albeit many issues concerning the inflammatory responses remain unresolved and need further investigations, current knowledge of the underlying molecular mechanisms is highlighted. Furthermore, and in the light of significant limitations in preventative diagnosis and treatment of cerebral malaria, this review mainly discusses our understanding of immune mechanisms in the light of the most recent research findings. Remarkably, the newly proposed CD8+ T cell-driven pathophysiological aspects within the central nervous system are summarized, giving first rational insights into encouraging studies with immune-modulating adjunctive therapies that protect from symptomatic cerebral participation of Plasmodium falciparum infection.	[Albrecht-Schgoer, Karin; Baier, Gottfried] Med Univ Innsbruck, Div Translat Cell Genet, Innsbruck, Austria; [Lackner, Peter] Klin Floridsdorf, Dept Neurol, Vienna, Austria; [Schmutzhard, Erich] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck	Albrecht-Schgoer, K (corresponding author), Med Univ Innsbruck, Div Translat Cell Genet, Innsbruck, Austria.	karin.albrecht@i-med.ac.at	Albrecht-Schgoer, Karin/AAG-4463-2020	Albrecht-Schgoer, Karin/0000-0001-8551-4067				Akanmori BD, 2000, EUR CYTOKINE NETW, V11, P113; Amiah MA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.561142; Ataide MA, 2020, NAT IMMUNOL, V21, P1397, DOI 10.1038/s41590-020-0786-2; Auburn S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010017; Band G, 2015, NATURE, V526, P253, DOI 10.1038/nature15390; Baptista FG, 2010, INFECT IMMUN, V78, P4033, DOI 10.1128/IAI.00079-10; Barber BE, 2018, EMERG MICROBES INFEC, V7, DOI 10.1038/s41426-018-0105-2; Barrera V, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01747; Batinovic S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16044; Belnoue E, 2002, J IMMUNOL, V169, P6369, DOI 10.4049/jimmunol.169.11.6369; BERENDT AR, 1989, NATURE, V341, P57, DOI 10.1038/341057a0; Bernabeu M, 2016, P NATL ACAD SCI USA, V113, pE3270, DOI 10.1073/pnas.1524294113; Blisnick T, 2000, MOL BIOCHEM PARASIT, V111, P107, DOI 10.1016/S0166-6851(00)00301-7; Brown H, 2001, AM J TROP MED HYG, V64, P207, DOI 10.4269/ajtmh.2001.64.207; Campanella GSV, 2008, P NATL ACAD SCI USA, V105, P4814, DOI 10.1073/pnas.0801544105; Canavese M, 2014, PATHOG GLOB HEALTH, V108, P67, DOI 10.1179/2047773214Y.0000000130; Capellino S, 2020, CELL MOL IMMUNOL, V17, P705, DOI 10.1038/s41423-020-0477-9; Chandramohan D, 2021, NEW ENGL J MED, V385, P1005, DOI 10.1056/NEJMoa2026330; Chesnokov O, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36071-2; Conroy AL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015291; D'Ombrain MC, 2008, CLIN INFECT DIS, V47, P1380, DOI 10.1086/592971; de Azevedo-Quintanilha IG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224610; de Jong GM, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1624-8; De Niz M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11659; Dietmann A, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-253; Dunst J, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00324; Engwerda C, 2005, CURR TOP MICROBIOL, V297, P103; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; Fauconnier M, 2012, J IMMUNOL, V188, P1905, DOI 10.4049/jimmunol.1101978; Fauconnier M, 2011, AM J PATHOL, V178, P212, DOI 10.1016/j.ajpath.2010.11.008; Favre N, 1999, MICROBES INFECT, V1, P961, DOI 10.1016/S1286-4579(99)80513-9; Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004; Fonager J, 2012, J EXP MED, V209, P93, DOI 10.1084/jem.20110762; Franke-Fayard B, 2005, P NATL ACAD SCI USA, V102, P11468, DOI 10.1073/pnas.0503386102; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Ghazanfari N, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02016; Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145; Gupta H, 2015, INFECT GENET EVOL, V34, P188, DOI 10.1016/j.meegid.2015.06.010; Haque A, 2011, J IMMUNOL, V186, P6148, DOI 10.4049/jimmunol.1003955; Harawa V, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2590-0; Hawkes MT, 2015, MALARIA J, V14, DOI 10.1186/s12936-015-0946-2; Hedrick PW, 2011, HEREDITY, V107, P283, DOI 10.1038/hdy.2011.16; Howland SW, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004963; Hsieh FL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12837; Hviid L, 2015, ADV PARASIT, V88, P51, DOI 10.1016/bs.apar.2015.02.004; Idro R, 2005, LANCET NEUROL, V4, P827, DOI 10.1016/S1474-4422(05)70247-7; Jain V, 2008, MALARIA J, V7, DOI 10.1186/1475-2875-7-83; Jallow M, 2009, NAT GENET, V41, P657, DOI 10.1038/ng.388; Jensen AR, 2020, IMMUNOL REV, V293, P230, DOI 10.1111/imr.12807; Joste V, 2020, MBIO, V11, DOI 10.1128/mBio.02103-20; Kariuki SM, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-365; Karnad DR, 2018, J CRIT CARE, V43, P356, DOI 10.1016/j.jcrc.2017.11.007; Kassa FA, 2016, SCI REP-UK, V6, DOI 10.1038/srep33615; Kessler A, 2017, CELL HOST MICROBE, V22, P601, DOI 10.1016/j.chom.2017.09.009; King T, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005118; Kuehlwein JM, 2020, IMMUNOLOGY, V159, P193, DOI 10.1111/imm.13137; Lau CKY, 2015, CELL HOST MICROBE, V17, P118, DOI 10.1016/j.chom.2014.11.007; Loos T, 2006, LAB INVEST, V86, P902, DOI 10.1038/labinvest.3700453; Lovegrove FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004912; Luzzatto L, 2012, MEDITERR J HEMATOL I, V4, DOI 10.4084/MJHID.2012.065; Malaria S, 2014, TROP MED INT HEALTH, V19, P7, DOI [10.1111/tmi.12313, 10.1111/tmi.12313_2]; Manning L, 2011, CLIN INFECT DIS, V52, P440, DOI 10.1093/cid/ciq105; Medana IM, 2006, INT J PARASITOL, V36, P555, DOI 10.1016/j.ijpara.2006.02.004; Miu J, 2008, J IMMUNOL, V180, P1217, DOI 10.4049/jimmunol.180.2.1217; Nitcheu J, 2003, J IMMUNOL, V170, P2221, DOI 10.4049/jimmunol.170.4.2221; Omi K, 2003, AM J HUM GENET, V72, P364, DOI 10.1086/346091; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Pais TF, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03100; Pal P, 2016, MBIO, V7, DOI 10.1128/mBio.00617-16; Palomo J, 2015, EUR J IMMUNOL, V45, P1354, DOI 10.1002/eji.201445206; Perkins DJ, 2000, J INFECT DIS, V182, P988, DOI 10.1086/315762; Piguet PF, 2002, LAB INVEST, V82, P1155, DOI 10.1097/01.LAB.0000028822.94883.8A; Ramos TN, 2013, J BIOL CHEM, V288, P10962, DOI 10.1074/jbc.C113.457028; Randall LM, 2008, J IMMUNOL, V181, P7458, DOI 10.4049/jimmunol.181.11.7458; Ravenhall M, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007172; Razakandrainibe R, 2012, TRENDS PARASITOL, V28, P151, DOI 10.1016/j.pt.2012.01.004; Reis PA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000963; Renia L, 2020, J CLIN INVEST, V130, P1109, DOI 10.1172/JCI135510; Riggle BA, 2020, J CLIN INVEST, V130, P1128, DOI 10.1172/JCI133474; Riggle BA, 2020, J IMMUNOL, V204, P327, DOI 10.4049/jimmunol.1900829; Rubach MP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035985; Sahu PK, 2015, FRONT CELL INFECT MI, V5, DOI 10.3389/fcimb.2015.00075; Schmutzhard J, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0616-4; Seydel KB, 2015, NEW ENGL J MED, V372, P1126, DOI 10.1056/NEJMoa1400116; Spycher C, 2003, J BIOL CHEM, V278, P35373, DOI 10.1074/jbc.M305851200; Steed E, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-95; Storm J, 2014, FRONT CELL INFECT MI, V4, DOI 10.3389/fcimb.2014.00100; Strangward P, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006267; Swanson PA, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1006022; Tangteerawatana P, 2007, ACTA TROP, V101, P258, DOI 10.1016/j.actatropica.2007.02.008; Tanwar GS, 2011, ANN TROP PAEDIATR, V31, P351, DOI 10.1179/1465328111Y.0000000040; Taylor SM, 2012, LANCET INFECT DIS, V12, P457, DOI 10.1016/S1473-3099(12)70055-5; Taylor TE, 2015, ANN NY ACAD SCI, V1342, P44, DOI 10.1111/nyas.12690; Timmann C, 2012, NATURE, V489, P443, DOI 10.1038/nature11334; Tinto H, 2015, LANCET, V386, P31, DOI 10.1016/S0140-6736(15)60721-8; Tripathi AK, 2006, INFECT IMMUN, V74, P3262, DOI 10.1128/IAI.01625-05; Turner L, 2013, NATURE, V498, P502, DOI 10.1038/nature12216; Uyoga S, 2015, LANCET HAEMATOL, V2, pE437, DOI 10.1016/S2352-3026(15)00152-0; vanHensbroek MB, 1996, J INFECT DIS, V174, P1091, DOI 10.1093/infdis/174.5.1091; Villegas-Mendez A, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.01035-16; Walk J, 2019, TRENDS IMMUNOL, V40, P186, DOI 10.1016/j.it.2019.01.002; Wassmer SC, 2017, INT J PARASITOL, V47, P145, DOI 10.1016/j.ijpara.2016.08.002; WHO, 2011, WORLD MALARIA REPORT 2011, P1; WHO, 2015, GUID TREATM MAL; Wilson NO, 2011, DIS MARKERS, V30, P39, DOI [10.1155/2011/828256, 10.3233/DMA-2011-0763]; Wu XZ, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100615; Wu XZ, 2021, J IMMUNOL, V206, P118, DOI 10.4049/jimmunol.2000779; Yeo TW, 2008, P NATL ACAD SCI USA, V105, P17097, DOI 10.1073/pnas.0805782105; Yeo TW, 2014, J INFECT DIS, V210, P1627, DOI 10.1093/infdis/jiu308; Zhang L, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-87	110	0	0	13	15	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								863568	10.3389/fimmu.2022.863568	http://dx.doi.org/10.3389/fimmu.2022.863568			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C3PL	35514965	gold, Green Published			2022-12-18	WOS:000810784000001
J	Berning, P; Huang, L; Razavi, AC; Boakye, E; Osuji, N; Stokes, AC; Martin, SS; Ayers, JW; Blaha, MJ; Dzaye, O				Berning, Philipp; Huang, Leu; Razavi, Alexander C.; Boakye, Ellen; Osuji, Ngozi; Stokes, Andrew C.; Martin, Seth S.; Ayers, John W.; Blaha, Michael J.; Dzaye, Omar			Association of Online Search Trends With Vaccination in the United States: June 2020 Through May 2021	FRONTIERS IN IMMUNOLOGY			English	Article						google trends; infodemiology; SARS-CoV-2 vaccination; influenza vaccination; flu vaccination	COVID-19 VACCINATION; HERD-IMMUNITY	Stagnating COVID-19 vaccination rates and vaccine hesitancy remain a threat to public health. Improved strategies for real-time tracking and estimation of population-level behavior regarding vaccinations are needed. The aim of this study was to evaluate whether online search trends for COIVD-19 and influenza mirror vaccination rates. State-level weekly fraction of online searches for top vaccination-related search terms and CDC vaccination data were obtained from June 1, 2020, to May 31, 2021. Next, trends in online search and vaccination data for COVID-19 and influenza were analyzed for visual and quantitative correlation patterns using Spearman's rank correlation analysis. Online searches in the US for COVID-19 vaccinations increased 2.71-fold (95% CI: 1.98-3.45) in the 4 weeks after the FDA emergency authorization compared to the precedent 4 weeks. In March-April 2021, US online searches reached a plateau that was followed by a decline of 83.3% (95% CI: 31.2%-135.3%) until May 31, 2021. The timing of peaks in online searches varied across US states. Online searches were strongly correlated with vaccination rates (r=0.71, 95% CI: 0.45 - 0.87), preceding actual reported vaccination rates in 44 of 51 states. Online search trends preceded vaccination trends by a median of 3.0 weeks (95% CI: 2.0-4.0 weeks) across all states. For influenza vaccination searches, seasonal peaks in September-October between 2016-2020 were noted. Influenza search trends highly correlated with the timing of actual vaccinations for the 2019-2020 (r=0.82, 95% CI: 0.64 - 0.93) and 2020-2021 season (r=0.91, 95% CI: 0.78 - 0.97). Search trends and real-world vaccination rates are highly correlated. Temporal alignment and correlation levels were higher for influenza vaccinations; however, only online searches for COVID-19 vaccination preceded vaccination trends. These findings indicate that US online search data can potentially guide public health efforts, including policy changes and identifying geographical areas to expand vaccination campaigns.							National Institutes of Health [T32 HL007227]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funding Author OD received support from National Institutes of Health grant T32 HL007227.	Aleem A, 2021, EMERGING VARIANTS SA; Alosaimi B, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01594-0; Anthes E., 2021, HITTING BIDENS TARGE, V19, P2021; Ayers JW, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.34261; Bai L, 2021, CELL RES, V31, P395, DOI 10.1038/s41422-021-00473-1; Bernal JL, 2021, NEW ENGL J MED, V385, P585, DOI 10.1056/NEJMoa2108891; Centers for Disease Control and Prevention, 2021, WHO NEEDS FLU VACCIN; Centers of Disease Control and Prevention, 2021, COVID 19 VACC US; Cihan P, 2021, APPL SOFT COMPUT, V111, DOI 10.1016/j.asoc.2021.107708; Dzaye O, 2021, INTERN MED J, V51, P1328, DOI 10.1111/imj.15399; Effenberger M, 2020, INT J INFECT DIS, V95, P192, DOI 10.1016/j.ijid.2020.04.033; El Sahly HM, 2021, NEW ENGL J MED, V385, P1774, DOI 10.1056/NEJMoa2113017; Eysenbach G, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1157; Ferdinands JM, 2021, J INFECT DIS, V224, P151, DOI 10.1093/infdis/jiaa772; Fine P, 2011, CLIN INFECT DIS, V52, P911, DOI 10.1093/cid/cir007; Fisher KA, 2020, ANN INTERN MED, V173, P964, DOI 10.7326/M20-3569; Grohskopf LA, 2020, MMWR RECOMM REP, V69, P1, DOI 10.15585/mmwr.rr6908a1; Hardt K, 2016, VACCINE, V34, P6691, DOI 10.1016/j.vaccine.2016.10.078; Kumar N, 2018, MAYO CLIN PROC, V93, P1185, DOI 10.1016/j.mayocp.2018.07.011; Li YD, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00695-2; Liu C, 2021, CELL, V184, P4220, DOI 10.1016/j.cell.2021.06.020; Lustig Y, 2021, EUROSURVEILLANCE, V26, DOI 10.2807/1560-7917.ES.2021.26.26.2100557; Machingaidze S, 2021, NAT MED, V27, P1338, DOI 10.1038/s41591-021-01459-7; Mallory ML, 2018, J ALLERGY CLIN IMMUN, V142, P64, DOI 10.1016/j.jaci.2018.05.007; Mavragani A, 2020, J MED INTERNET RES, V22, DOI 10.2196/16206; Nguyen KH, 2021, MMWR-MORBID MORTAL W, V70, P217, DOI 10.15585/mmwr.mm7006e3; Noori M, 2022, REV MED VIROL, V32, DOI 10.1002/rmv.2277; Osterholm MT, 2012, LANCET INFECT DIS, V12, P36, DOI 10.1016/S1473-3099(11)70295-X; Paltiel AD, 2021, HEALTH AFFAIR, V40, P42, DOI 10.1377/hlthaff.2020.02054; Perez-Vilar S, 2021, J INFECT DIS, V223, P416, DOI 10.1093/infdis/jiaa543; Petersen E, 2022, INT J INFECT DIS, V114, P268, DOI 10.1016/j.ijid.2021.11.040; Randolph HE, 2020, IMMUNITY, V52, P737, DOI 10.1016/j.immuni.2020.04.012; Shaw J, 2021, CLIN INFECT DIS, V73, P1776, DOI 10.1093/cid/ciab054; Thomas Stephen J, 2021, N Engl J Med, V385, P1761, DOI 10.1056/NEJMoa2110345; Treanor JJ, 2016, NEW ENGL J MED, V375, P1261, DOI 10.1056/NEJMcp1512870; Voordouw ACG, 2004, JAMA-J AM MED ASSOC, V292, P2089, DOI 10.1001/jama.292.17.2089; Weintraub RL, 2021, HEALTH AFFAIR, V40, P33, DOI 10.1377/hlthaff.2020.01523; WHO, 2020, PNEUM UNKN CAUS CHIN; Yue HH, 2020, J MED VIROL, V92, P2870, DOI 10.1002/jmv.26163; Zeraatkar K, 2018, HEALTH INFO LIBR J, V35, P91, DOI 10.1111/hir.12216	40	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								884211	10.3389/fimmu.2022.884211	http://dx.doi.org/10.3389/fimmu.2022.884211			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C3MP	35514956	Green Published, gold			2022-12-18	WOS:000810776600001
J	Han, P; Hou, C; Zheng, X; Cao, LL; Shi, XM; Zhang, XH; Ye, H; Pan, HD; Liu, L; Li, TT; Hu, FL; Li, ZG				Han, Peng; Hou, Chao; Zheng, Xi; Cao, Lulu; Shi, Xiaomeng; Zhang, Xiaohui; Ye, Hua; Pan, Hudan; Liu, Liang; Li, Tingting; Hu, Fanlei; Li, Zhanguo			Serum Antigenome Profiling Reveals Diagnostic Models for Rheumatoid Arthritis	FRONTIERS IN IMMUNOLOGY			English	Article						rheumatoid arthritis; antigenome; biomarkers; mass spectrometry; random forest	CITRULLINATED PEPTIDE; PROTEOMIC ANALYSIS; ANTIBODIES; CLASSIFICATION; MARKER; CCP	ObjectiveThe study aimed to investigate the serum antigenomic profiling in rheumatoid arthritis (RA) and determine potential diagnostic biomarkers using label-free proteomic technology implemented with machine-learning algorithm. MethodSerum antigens were captured from a cohort consisting of 60 RA patients (45 ACPA-positive RA patients and 15 ACPA-negative RA patients), together with sex- and age-matched 30 osteoarthritis (OA) patients and 30 healthy controls. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was then performed. The significantly upregulated and downregulated proteins with fold change > 1.5 (p < 0.05) were selected. Based on these differentially expressed proteins (DEPs), a machine learning model was trained and validated to classify RA, ACPA-positive RA, and ACPA-negative RA. ResultsWe identified 62, 71, and 49 DEPs in RA, ACPA-positive RA, and ACPA-negative RA, respectively, as compared to OA and healthy controls. Typical pathway enrichment and protein-protein interaction networks were shown among these DEPs. Three panels were constructed to classify RA, ACPA-positive RA, and ACPA-negative RA using random forest models algorithm based on the molecular signature of DEPs, whose area under curve (AUC) were calculated as 0.9949 (95% CI = 0.9792-1), 0.9913 (95% CI = 0.9653-1), and 1.0 (95% CI = 1-1). ConclusionThis study illustrated the serum auto-antigen profiling of RA. Among them, three panels of antigens were identified as diagnostic biomarkers to classify RA, ACPA-positive, and ACPA-negative RA patients.						HOU, CHAO/0000-0003-4806-7637	Guangdong Basic and Applied Basic Research Foundation [2020B1515130005]; National Natural Science Foundation of China [U1903210, 82171773, 81971523]; Beijing Nova Program [Z181100006218044, Z211100002121163]; Beijing Science and Technology Planning Project [Z191100006619109]; Macao Science and Technology Development Fund [0094/2018/A3]; Fundamental Research Funds for the Central Universities: Peking University Clinical Medicine Plus X-Young Scholars Project [PKU2021LCXQ014]; Peking University People's Hospital Research and Development Funds [RDX2020-01]	Guangdong Basic and Applied Basic Research Foundation; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Nova Program(Beijing Municipal Science & Technology Commission); Beijing Science and Technology Planning Project; Macao Science and Technology Development Fund; Fundamental Research Funds for the Central Universities: Peking University Clinical Medicine Plus X-Young Scholars Project; Peking University People's Hospital Research and Development Funds	This work was supported by grants from Guangdong Basic and Applied Basic Research Foundation (2020B1515130005 to LL), the National Natural Science Foundation of China (U1903210 to ZL, 82171773 and 81971523 to FH), the Beijing Nova Program (Z181100006218044 and Z211100002121163 to FH), the Beijing Science and Technology Planning Project (Z191100006619109 to HY), Macao Science and Technology Development Fund (0094/2018/A3 to ZL), as well as by the Fundamental Research Funds for the Central Universities: Peking University Clinical Medicine Plus X-Young Scholars Project (PKU2021LCXQ014 to FH) and the Peking University People's Hospital Research and Development Funds (RDX2020-01 to FH).	Aletaha D, 2018, JAMA-J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI 10.1002/art.27584; Cai AJ, 2015, CTS-CLIN TRANSL SCI, V8, P579, DOI 10.1111/cts.12265; Chandra PE, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3383; Charles-Schoeman C, 2009, ARTHRITIS RHEUM-US, V60, P2870, DOI 10.1002/art.24802; Colasanti T, 2020, J AUTOIMMUN, V113, DOI 10.1016/j.jaut.2020.102470; Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591; De Rycke L, 2004, ANN RHEUM DIS, V63, P1587, DOI 10.1136/ard.2003.017574; Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094; Kampstra ASB, 2019, ANN RHEUM DIS, V78, P908, DOI 10.1136/annrheumdis-2018-214950; Kashyap RS, 2009, CLIN CHIM ACTA, V402, P160, DOI 10.1016/j.cca.2009.01.009; Li KT, 2021, ANN RHEUM DIS, V80, P739, DOI 10.1136/annrheumdis-2020-218460; Li R, 2012, RHEUMATOLOGY, V51, P721, DOI 10.1093/rheumatology/ker370; Li XH, 2018, PATHOL ONCOL RES, V24, P663, DOI 10.1007/s12253-017-0285-4; Liao WX, 2018, MOL MED REP, V17, P2827, DOI 10.3892/mmr.2017.8250; Ligoudistianou C, 2005, BIOCHEM J, V387, P165, DOI 10.1042/BJ20041196; Mahler M, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102506; Maksymowych WP, 2014, J RHEUMATOL, V41, P2104, DOI 10.3899/jrheum.131446; Markiewicz A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115575; McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965; Mun S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184368; Nishimura K, 2007, ANN INTERN MED, V146, P797, DOI 10.7326/0003-4819-146-11-200706050-00008; Peffers MJ, 2019, EXPERT REV PROTEOMIC, V16, P287, DOI 10.1080/14789450.2019.1578214; Petersen HH, 2004, VET RES, V35, P163, DOI 10.1051/vetres:2004002; Scott DL, 2007, BEST PRACT RES CL RH, V21, P943, DOI 10.1016/j.berh.2007.05.006; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shen B, 2020, CELL, V182, P59, DOI 10.1016/j.cell.2020.05.032; Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140-6736(16)30173-8; Sun YY, 2021, CLIN CHIM ACTA, V523, P365, DOI 10.1016/j.cca.2021.10.022; Swan AL, 2013, OMICS, V17, P595, DOI 10.1089/omi.2013.0017; Tobon GJ, 2010, J AUTOIMMUN, V35, P10, DOI 10.1016/j.jaut.2009.12.009; van Venrooij WJ, 2011, NAT REV RHEUMATOL, V7, P391, DOI 10.1038/nrrheum.2011.76; Walsh DS, 2005, J DERMATOL SCI, V37, P61, DOI 10.1016/j.jdermsci.2004.10.003; Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590-020-00816-x; Xiao Q, 2021, ADV DRUG DELIVER REV, V176, DOI 10.1016/j.addr.2021.113844; Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6	37	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								884462	10.3389/fimmu.2022.884462	http://dx.doi.org/10.3389/fimmu.2022.884462			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B9VJ	35514972	Green Published, gold			2022-12-18	WOS:000810528500001
J	Han, YC; Bian, ZH; Yang, SY; Wang, CB; Li, L; Yang, YQ; Ansari, AA; Gershwin, ME; Zeng, XF; Lian, ZX; Zhao, ZB				Han, Yichen; Bian, Zhen-Hua; Yang, Si-Yu; Wang, Cheng-Bo; Li, Liang; Yang, Yan-Qing; Ansari, Aftab A.; Gershwin, M. Eric; Zeng, Xiaofeng; Lian, Zhe-Xiong; Zhao, Zhi-Bin			Single-Cell Characterization of Hepatic CD8(+) T Cells in a Murine Model of Primary Biliary Cholangitis	FRONTIERS IN IMMUNOLOGY			English	Article						primary biliary cholangitis; CD8(+) T cells; single-cell sequencing; TCR repertoire; liver	AUTOIMMUNE CHOLANGITIS; PATHOGENESIS; CIRRHOSIS; MEMORY; LYMPHOCYTES	Primary biliary cholangitis (PBC), an organ-specific autoimmune disease, is characterized by injury to small bile ducts, inflammatory cell infiltrates within the liver, progressive cholestasis, and in some cases, cirrhosis with unclear pathogenesis. We aimed to clarify the importance role of hepatic immunce cells in the pathogenesis of human and experimental PBC.The dominant-negative TGF beta receptor type II transgenic (dnTGF beta RII) mice, a well-studied and established murine model of PBC were used to identify changes of immune cells, especially the pathogenic CD8(+) T cells. The high-throughput single-cell RNA sequencing technology were applied and found functional heterogeneity among the hepatic CD8(+) T cells subsets in dnTGF beta RII mice. CD8(+) T cells were confirmed the key cells leading to the pathogenesis of PBC in dnTGF beta RII mice, and identified the terminally differentiated CD8 alpha alpha T cells and CD8 alpha beta T cell subsets in the liver of dnTGF beta RII mice. While terminally differentiated CD8 alpha alpha T cells have higher cytokine production ability and cytotoxicity, the terminally differentiated CD8 alpha beta T cells retain their proliferative profile. Our work suggests that there are developmental and differentiated trajectories of pathogenic CD8(+) T cell subsets in the pathogenesis of PBC. A further clarification of their roles would be helpful to our understanding of the pathogenesis of PBC and may potentially lead to identifying novel therapeutic modalities.										Bowlus CL, 2019, J AUTOIMMUN, V101, P26, DOI 10.1016/j.jaut.2019.04.005; Carey EJ, 2015, LANCET, V386, P1565, DOI 10.1016/S0140-6736(15)00154-3; Chuang YH, 2006, J AUTOIMMUN, V26, P232, DOI 10.1016/j.jaut.2006.04.001; Deng CW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01619; Glaser F, 2019, J HEPATOL, V71, P783, DOI 10.1016/j.jhep.2019.05.030; Gulamhusein AF, 2020, NAT REV GASTRO HEPAT, V17, P93, DOI 10.1038/s41575-019-0226-7; Harada K, 2011, LIVER INT, V31, P245, DOI 10.1111/j.1478-3231.2010.02367.x; Huang WT, 2014, J AUTOIMMUN, V50, P123, DOI 10.1016/j.jaut.2014.01.034; Jameson SC, 2009, IMMUNITY, V31, P859, DOI 10.1016/j.immuni.2009.11.007; Kita H, 2002, J CLIN INVEST, V109, P1231, DOI 10.1172/JCI200214698; Konno A, 2002, BLOOD, V100, P4090, DOI 10.1182/blood-2002-04-1136; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; Kwon B, 2021, CELL MOL IMMUNOL, V18, P1641, DOI 10.1038/s41423-021-00712-w; Lan RY, 2006, HEPATOLOGY, V43, P729, DOI 10.1002/hep.21123; Levy Cynthia, 2017, Hepatology, V65, P1405, DOI 10.1002/hep.29053; Liao W, 2013, IMMUNITY, V38, P13, DOI 10.1016/j.immuni.2013.01.004; Lindor KD, 2019, HEPATOLOGY, V69, P394, DOI 10.1002/hep.30145; Liu SP, 2020, CLIN REV ALLERG IMMU, V58, P252, DOI 10.1007/s12016-020-08778-6; Lleo A, 2020, SEMIN LIVER DIS, V40, P34, DOI 10.1055/s-0039-1697617; Ma HD, 2017, J AUTOIMMUN, V78, P19, DOI 10.1016/j.jaut.2016.12.012; MATHEW J, 1994, HISTOPATHOLOGY, V25, P65, DOI 10.1111/j.1365-2559.1994.tb00599.x; NAKANUMA Y, 1993, HEPATOLOGY, V18, P570, DOI 10.1002/hep.1840180315; Oertelt S, 2006, J IMMUNOL, V177, P1655, DOI 10.4049/jimmunol.177.3.1655; Peng AP, 2016, CLIN EXP MED, V16, P511, DOI 10.1007/s10238-015-0381-2; Purohit T, 2015, WORLD J HEPATOL, V7, P926, DOI 10.4254/wjh.v7.i7.926; Wu RH, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102645; Yang GX, 2008, HEPATOLOGY, V47, P1974, DOI 10.1002/hep.22226; Yang SY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.711980; Ye CX, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0002-5; Younossi ZM, 2019, AM J GASTROENTEROL, V114, P48, DOI 10.1038/s41395-018-0390-3; Zhao SX, 2020, J CELL MOL MED, V24, P1268, DOI 10.1111/jcmm.14752; Zhao ZB, 2020, CELL MOL IMMUNOL, V17, P178, DOI 10.1038/s41423-019-0199-z	32	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								860311	10.3389/fimmu.2022.860311	http://dx.doi.org/10.3389/fimmu.2022.860311			13	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5U0JM	35514982	Green Published, gold			2022-12-18	WOS:000876240800001
J	Li, XX; Zhang, YF; He, F; Gao, D; Che, B; Cao, XL; Huang, SY; Zheng, MH; Han, H				Li, Xinxin; Zhang, Yufei; He, Fei; Gao, Dan; Che, Bo; Cao, Xiuli; Huang, Siyong; Zheng, Minhua; Han, Hua			miR-582 Suppresses the Proliferation of B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells and Protects Them From Natural Killer Cell-Mediated Cytotoxicity	FRONTIERS IN IMMUNOLOGY			English	Article						BCP-ALL; miR-582; PPTC7; mitochondria; metabolism; NK cells; immune checkpoint; CD276	CHRONIC LYMPHOCYTIC-LEUKEMIA; MESSENGER-RNA; CANCER; PROGRESSION; EXPRESSION; APOPTOSIS; PATHWAY; STRESS; B7-H3	B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a malignancy characterized by the aberrant accumulation of immature B-cell precursors in bone marrow and other lymphoid organs. Although several intrinsic regulatory signals participating in BCP-ALL have been clarified, detailed intrinsic and extrinsic mechanisms that regulate BCP-ALL progression have not been fully understood. In the current study, we report that miR-582 is downregulated in BCP-ALL cells compared with normal B cells. Forced overexpression of miR-582 attenuated BCP-ALL cell proliferation and survival. We found that miR-582 overexpression disturbed the mitochondrial metabolism of BCP-ALL cells, leading to less ATP but more ROS production. Mechanistically, we identified PPTC7 as a direct target of miR-582. MiR-582 overexpression inhibited the activity of CoQ10, which is downstream of PPTC7 and played an important positive regulatory role in mitochondrial electron transportation. Finally, we found that overexpression of miR-582 upregulated the expression of immune checkpoint molecule CD276 and reduced NK cell-mediated cytotoxicity against BCP-ALL cells. CD276 blockade significantly increased NK cell-mediated cytotoxicity against miR-582-overexpressing BCP-ALL cells. Together, our research demonstrates that miR-582 acts as a negative regulator of BCP-ALL cells by reducing proliferation and survival, but protects BCP-ALL cells from NK cell-mediated cytotoxicity, suggesting that miR-582 may be a new therapeutic biomarker for BCP-ALL with CD276 blocker.					Zhang, yufei/HHC-7375-2022	Zheng, Min Hua/0000-0002-5279-9366	Natural Science Basic Research Program of Shaanxi [2020JQ-147]; Guangdong Basic and Applied Basic Research Foundation [2020A1515110094]; Fundamental Research Funds for the Central Universities of China [3102019YX01004]; National Natural Science Foundation [31730041, 91339115, 31671523]	Natural Science Basic Research Program of Shaanxi; Guangdong Basic and Applied Basic Research Foundation; Fundamental Research Funds for the Central Universities of China(Fundamental Research Funds for the Central Universities); National Natural Science Foundation(National Natural Science Foundation of China (NSFC))	Funding This work was supported by Natural Science Basic Research Program of Shaanxi (Program No. 2020JQ-147), Guangdong Basic and Applied Basic Research Foundation (2020A1515110094) and the Fundamental Research Funds for the Central Universities of China (3102019YX01004), and National Natural Science Foundation (31730041, 91339115, 31671523) of China.	Anselmi L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176251; Birk AV, 2014, BRIT J PHARMACOL, V171, P2017, DOI 10.1111/bph.12468; Buske C, 1997, LEUKEMIA, V11, P386, DOI 10.1038/sj.leu.2400586; Dai TY, 2021, BIOENGINEERED, V12, P10771, DOI 10.1080/21655979.2021.2003662; de Oliveira JC, 2012, PEDIATR BLOOD CANCER, V59, P599, DOI 10.1002/pbc.24167; Deng MQ, 2021, GYNECOL ONCOL, V162, P190, DOI 10.1016/j.ygyno.2021.04.013; Fei F, 2021, bioRxiv, DOI 10.1101/2021.09.22.461145; Geron I, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28218-7; Godbersen JC, 2014, CLIN CANCER RES, V20, P1576, DOI 10.1158/1078-0432.CCR-13-0987; Gollapudi S, 2016, AM J CLIN EXP IMMUNO, V5, P41; Gonzalez-Mariscal I, 2018, BBA-BIOENERGETICS, V1859, P1235, DOI 10.1016/j.bbabio.2018.09.369; Grote S., 2020, ADV CELL GENE THER, V4, DOI [10.1002/acg2.105, DOI 10.1002/ACG2.105]; Huang DD, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.13056; Huang S, 2019, MOL THER-NUCL ACIDS, V16, P91, DOI 10.1016/j.omtn.2019.01.004; Jia L, 2017, BIOCHEM BIOPH RES CO, V488, P425, DOI 10.1016/j.bbrc.2017.05.074; Kanchan RK, 2020, BRAIN PATHOL, V30, P732, DOI 10.1111/bpa.12829; Lee CC, 2021, LIFE SCI, V277, DOI 10.1016/j.lfs.2021.119438; Li HX, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0184-7; Li J, 2018, ONCOL LETT, V15, P361, DOI 10.3892/ol.2017.7287; Li XX, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04560-y; Li XX, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1431085; Ma XT, 2014, INT J MED SCI, V11, P810, DOI 10.7150/ijms.8647; Neri LM, 2014, LEUKEMIA, V28, P739, DOI 10.1038/leu.2013.226; Niemi NM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11047-6; Oh YS, 2013, J ENDOCRINOL, V216, P343, DOI 10.1530/JOE-12-0311; Pastorczak A, 2021, CANCERS, V13, DOI 10.3390/cancers13071536; Picarda E, 2016, CLIN CANCER RES, V22, P3425, DOI 10.1158/1078-0432.CCR-15-2428; Rouce RH, 2016, LEUKEMIA, V30, P800, DOI 10.1038/leu.2015.327; Sbirkov Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.632181; Shyu AB, 2008, EMBO J, V27, P471, DOI 10.1038/sj.emboj.7601977; Sonkoly E, 2010, J ALLERGY CLIN IMMUN, V126, P581, DOI 10.1016/j.jaci.2010.05.045; Stein M, 2017, CELL DEATH DIFFER, V24, P1239, DOI 10.1038/cdd.2017.52; Tian YD, 2020, CANCER MANAG RES, V12, P11933, DOI 10.2147/CMAR.S274835; Wang FM, 2022, CANCER GENE THER, V29, P292, DOI 10.1038/s41417-021-00309-5; Wang LL, 2018, EUR REV MED PHARMACO, V22, P7760, DOI 10.26355/eurrev_201811_16397; Wang WM, 2020, MOL CELLS, V43, P718, DOI 10.14348/molcells.2020.0065; Wang XM, 2020, CELL BIOL INT, V44, P2021, DOI 10.1002/cbin.11408; Wang ZS, 2021, MOL CELL TOXICOL, V17, P357, DOI 10.1007/s13273-021-00143-8; Xie MY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01208-3; Xie TQ, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01034; Yang S, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01089; Yong HM, 2020, MOL CELL PROBE, V53, DOI 10.1016/j.mcp.2020.101601; Zhang X, 2015, CANCER GENE THER, V22, P475, DOI 10.1038/cgt.2015.44; Zhang Y, 2015, TUMOR BIOL, V36, P8309, DOI 10.1007/s13277-015-3582-0; Zhao LN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1886-5; Zhu BW, 2021, CANCERS, V13, DOI 10.3390/cancers13040756	46	0	0	1	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								853094	10.3389/fimmu.2022.853094	http://dx.doi.org/10.3389/fimmu.2022.853094			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5U0KZ	35514986	Green Published, gold			2022-12-18	WOS:000876244700001
J	Masip, J; Rallon, N; Yeregui, E; Olona, M; Resino, S; Benito, JM; Vilades, C; Garcia-Pardo, G; Alcami, J; Ruiz-Mateos, E; Gomez-Bertomeu, F; Vargas, M; Navarro, M; Oteo, JA; Pineda, JA; Marti, A; Alba, V; Vidal, F; Peraire, J; Rull, A				Masip, Jenifer; Rallon, Norma; Yeregui, Elena; Olona, Montserrat; Resino, Salvador; Benito, Jose M.; Vilades, Consuelo; Garcia-Pardo, Graciano; Alcami, Jose; Ruiz-Mateos, Ezequiel; Gomez-Bertomeu, Frederic; Vargas, Montserrat; Navarro, Marta; Oteo, Jose A.; Pineda, Juan A.; Marti, Anna; Alba, Veronica; Vidal, Francesc; Peraire, Joaquin; Rull, Anna			Elevated alpha-Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control	FRONTIERS IN IMMUNOLOGY			English	Article						metabolomics; lipidomics; elite controllers (ECs); HIV infection; Kreb's cycle; long-term; viral; mass spectrometry	ELITE CONTROLLERS; NONPROGRESSORS; ACTIVATION; PROFILES; GLUCOSE; ABSENCE; CYCLE	Long-term elite controllers (LTECs) are a fascinating small subset of HIV individuals with viral and immunological HIV control in the long term that have been designated as models of an HIV functional cure. However, data on the LTEC phenotype are still scarce, and hence, the metabolomics and lipidomics signatures in the LTEC-extreme phenotype, LTECs with more than 10 years of viral and immunological HIV control, could be pivotal to finding the keys for functional HIV remission. Metabolomics and lipidomics analyses were performed using high-resolution mass spectrometry (ultra-high-performance liquid chromatography-electrospray ionization-quadrupole time of flight [UHPLC-(ESI) qTOF] in plasma samples of 13 patients defined as LTEC-extreme, a group of 20 LTECs that lost viral and/or immunological control during the follow-up study (LTEC-losing) and 9 EC patients with short-term viral and immunological control (less than 5 years; no-LTEC patients). Long-term viral and immunological HIV-1 control was found to be strongly associated with elevated tricarboxylic acid (TCA) cycle function. Interestingly, of the nine metabolites identified in the TCA cycle, alpha-ketoglutaric acid (p = 0.004), a metabolite implicated in the activation of the mTOR complex, a modulator of HIV latency and regulator of several biological processes, was found to be a key metabolite in the persistent control. On the other hand, a lipidomics panel combining 45 lipid species showed an optimal percentage of separation and an ability to differentiate LTEC-extreme from LTEC-losing, revealing that an elevated lipidomics plasma profile could be a predictive factor for the reignition of viral replication in LTEC individuals.					Alcami, Jose/T-2242-2018	Alcami, Jose/0000-0003-0023-7377; Resino, Salvador/0000-0001-8783-0450; GOMEZ, FREDERIC/0000-0002-8039-2889	Instituto de Salud Carlos III, Spanish Health Ministry [RD06/0006/0035, RD12/0017/0037, RD16/0025/0019]; Plan Nacional R + D + I; ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER) - Instituto de Salud Carlos III [RIS C03/173, RD12/0017/0018, RD16/0002/0006]; Plan Nacional R+D+I; ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER); Proteomics and Metabolomics Facilities of the Centre for Omic Sciences	Instituto de Salud Carlos III, Spanish Health Ministry(Instituto de Salud Carlos IIISpanish Government); Plan Nacional R + D + I; ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER) - Instituto de Salud Carlos III; Plan Nacional R+D+I; ISCIII-Subdireccion General de Evaluacion y el Fondo Europeo de Desarrollo Regional (FEDER); Proteomics and Metabolomics Facilities of the Centre for Omic Sciences	This work was supported by the Fondo de Investigacion Sanitaria [PI13/0796, PI16/00503, PI16/0684, PI18/1532, PI19/00004, PI19/01127, PI19/01337 PI16/001769, PI19/00973, and PI20/00326]-ISCIII-FEDER (co-funded by the European Regional Development Fund/European Social Fund; "A way to make Europe"/"Investing in your future"); Programa de Suport als Grups de Recerca AGAUR (2017SGR948); Gilead Fellowship Program GLD14/293; The SPANISH AIDS Research Network [RD16/0002/0001, RD16/0002/0002, RD16/0025/0006, RD16/0025/0013, and RD16/0025/0020]-ISCIII-FEDER (Spain); and the Centro de Investigacion Biomedica en Red de Enfermedades Infecciosas-ISCIII [CB21/13/00015, CB21/13/00020, and CB21/13/00044], Madrid, Spain. JM is supported by the Universitat Rovira I Virgili under grant agreement "2019PMF-PIPF-18," through the call "Marti Franques Research Fellowship Programme." NR is a Miguel Servet researcher from the ISCIII [CPII19/00025]. EY is supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement "FI20/0011800" through the program "Contratos Predoctorales de Formacion en Investigacion en Salud." ER-M was supported by the Spanish National Research Council (CSIC). FV is supported by grants from the Programa de Intensificacion de Investigadores (INT20/00031)-ISCIII and by "Premi a la Trajectoria Investigadora als Hospitals de l'ICS 2018." AR is supported by IISPV through the project "2019/IISPV/05" (Boosting Young Talent), by GeSIDA through the "III Premio para Jovenes Investigadores 2019," and by the Instituto de Salud Carlos III (ISCIII) under grant agreement "CP19/00146" through the Miguel Servet Program.	Autran B, 2011, CURR OPIN HIV AIDS, V6, P181, DOI 10.1097/COH.0b013e328345a328; Bowman ER, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00785; Casado C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58696-y; Chi H, 2012, NAT REV IMMUNOL, V12, P325, DOI 10.1038/nri3198; Chowdhury FZ, 2018, AIDS, V32, P2669, DOI [10.1097/QAD.0000000000002007, 10.1097/qad.0000000000002007]; Deeks SG, 2007, IMMUNITY, V27, P406, DOI 10.1016/j.immuni.2007.08.010; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; El-Far M, 2016, SCI REP-UK, V6, DOI 10.1038/srep22902; El-Sadr W, 2005, HIV MED, V6, P114, DOI 10.1111/j.1468-1293.2005.00273.x; Giron LB, 2021, MBIO, V12, DOI 10.1128/mBio.03444-20; Grabar S, 2009, AIDS, V23, P1163, DOI 10.1097/QAD.0b013e32832b44c8; Grunfeld Carl, 2010, Top HIV Med, V18, P112; Hollenbaugh JA, 2011, VIROLOGY, V415, P153, DOI 10.1016/j.virol.2011.04.007; Isnard S, 2021, CLIN INFECT DIS, V73, P144, DOI 10.1093/cid/ciaa1129; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kind T, 2009, ANAL CHEM, V81, P10038, DOI 10.1021/ac9019522; Leon A, 2016, AIDS, V30, P1209, DOI 10.1097/QAD.0000000000001050; Lopez-Galindez C, 2019, FUTURE VIROL, V14, P287, DOI 10.2217/fvl-2018-0207; Loucif H, 2022, AUTOPHAGY, V18, P1256, DOI 10.1080/15548627.2021.1972403; Loucif H, 2021, AUTOPHAGY, V17, P3408, DOI 10.1080/15548627.2021.1874134; Masip J, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.474; Mathis D, 2011, NAT REV IMMUNOL, V11, P81, DOI 10.1038/nri2922; Navarrete-Munoz MA, 2020, VIRULENCE, V11, P889, DOI 10.1080/21505594.2020.1788887; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Palmer CS, 2014, AIDS, V28, P297, DOI 10.1097/QAD.0000000000000128; Pang ZQ, 2021, NUCLEIC ACIDS RES, V49, pW388, DOI 10.1093/nar/gkab382; Pereyra F, 2008, J INFECT DIS, V197, P563, DOI 10.1086/526786; Pernas M, 2018, J VIROL, V92, DOI 10.1128/JVI.01805-17; Planas D, 2021, EBIOMEDICINE, V65, DOI 10.1016/j.ebiom.2021.103270; Planas D, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.93230; Rodriguez-Gallego E, 2019, J INFECT DIS, V219, P867, DOI 10.1093/infdis/jiy599; Ruiz-Mateos Ezequiel, 2020, Pathog Immun, V5, P121, DOI 10.20411/pai.v5i1.364; Saez-Cirion A, 2021, NAT REV IMMUNOL, V21, P5, DOI 10.1038/s41577-020-0381-7; SCHUTZE S, 1995, IMMUNOBIOLOGY, V193, P193, DOI 10.1016/S0171-2985(11)80543-7; Shoji-Kawata S, 2009, BBA-MOL CELL RES, V1793, P1478, DOI 10.1016/j.bbamcr.2009.02.008; Tall AR, 2015, NAT REV IMMUNOL, V15, P104, DOI 10.1038/nri3793; Tarancon-Diez L, 2019, EBIOMEDICINE, V42, P86, DOI 10.1016/j.ebiom.2019.03.004; Turk G, 2022, ANN INTERN MED, V175, P95, DOI 10.7326/L21-0297; Yang CD, 2014, MOL CELL, V56, P414, DOI 10.1016/j.molcel.2014.09.025	39	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								822272	10.3389/fimmu.2022.822272	http://dx.doi.org/10.3389/fimmu.2022.822272			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5U0KX	35514981	Green Published, gold			2022-12-18	WOS:000876244500001
J	Mizuno, M; Nakano, R; Nose, S; Matsumura, M; Nii, Y; Kurogochi, K; Sugiya, H; Uechi, M				Mizuno, Masashi; Nakano, Rei; Nose, Saki; Matsumura, Moeka; Nii, Yasuyuki; Kurogochi, Kentaro; Sugiya, Hiroshi; Uechi, Masami			Canonical NF-kappa B p65, but Not p105, Contributes to IL-1 beta-Induced IL-8 Expression in Cardiac Fibroblasts	FRONTIERS IN IMMUNOLOGY			English	Article						cardiac fibroblasts; inflammation; interleukin 1b; interleukin 8; NF-kB p65	NECROSIS-FACTOR-ALPHA; MYOCARDIAL-ISCHEMIA; SYNOVIAL FIBROBLASTS; INTERLEUKIN-8 IL-8; NF-KAPPA-B1 P105; GENE-EXPRESSION; REPERFUSION; PHOSPHORYLATION; CYTOKINES; PATHWAYS	Cardiac fibroblasts participate in the inflammatory process of heart diseases as sentinel cells of the cardiac tissue. In this study, we investigated the effect of the proinflammatory cytokine, interleukin 1 beta (IL-1 beta), on the expression of interleukin 8 (IL-8), which contributes to the induction of innate immunity via the activation and recruitment of innate immune cells, such as neutrophils, to the site of inflammation in canine cardiac fibroblasts. IL-1 beta mediates IL-8 mRNA expression and protein release in a dose- and time-dependent manner. The IL-beta-mediated IL-8 protein release and mRNA expression were inhibited by 2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide, an inhibitor of the transcription factor, nuclear factor (NF)-kappa B. In cells treated with IL-1 beta, NF-kappa B p65 and p105 were transiently phosphorylated, indicating the activation of NF-kappa B. However, IL-1 beta failed to induce IL-8 mRNA expression in the cells transfected with p65 small interfering RNA (siRNA), but not in those transfected with p105 siRNA. These observations suggest that IL-1 beta induces IL-8 expression via the activation of NF-kappa B p65 in canine cardiac fibroblasts.						Nakano, Rei/0000-0003-0255-6347	Ministry of Education, Science, Sports, and Culture of Japan [18K14594]	Ministry of Education, Science, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by a Grant-in-Aid for Scientific Research (grant no. 18K14594, RN) from the Ministry of Education, Science, Sports, and Culture of Japan (https://www.jsps.go.jp/j-grantsinaid/). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbate A, 2010, AM J CARDIOL, V105, P1371, DOI 10.1016/j.amjcard.2009.12.059; ABE Y, 1993, BRIT HEART J, V70, P132; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Boyle EM, 1998, J THORAC CARDIOV SUR, V116, P114, DOI 10.1016/S0022-5223(98)70249-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujak M, 2008, AM J PATHOL, V173, P57, DOI 10.2353/ajpath.2008.070974; Camelliti P, 2005, CARDIOVASC RES, V65, P40, DOI 10.1016/j.cardiores.2004.08.020; Diaz-Araya G, 2015, PHARMACOL RES, V101, P30, DOI 10.1016/j.phrs.2015.07.001; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; FUJIMOTO K, 1995, GENE, V165, P183, DOI 10.1016/0378-1119(95)00507-3; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; HAMMOND MEW, 1995, J IMMUNOL, V155, P1428; HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hu L, 2017, EXP THER MED, V14, P5509, DOI 10.3892/etm.2017.5246; Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kitanaka N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222869; Kitanaka N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220262; Kitanaka N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208955; Kitanaka T, 2017, SCI REP-UK, V7, DOI 10.1038/srep39914; Kohl P, 1996, CARDIOVASC RES, V32, P62, DOI 10.1016/0008-6363(95)00224-3; Konno T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166707; KUKIELKA GL, 1995, J CLIN INVEST, V95, P89, DOI 10.1172/JCI117680; KUNSCH C, 1993, MOL CELL BIOL, V13, P6137, DOI 10.1128/MCB.13.10.6137; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; LARSEN CG, 1989, IMMUNOLOGY, V68, P31; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369; Li Y, 2017, BIOMED REP, V7, P361, DOI 10.3892/br.2017.976; MacKenna D, 2000, CARDIOVASC RES, V46, P257, DOI 10.1016/S0008-6363(00)00030-4; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Marui N, 2005, BIOCHEM J, V390, P317, DOI 10.1042/BJ20041659; Michael Lloyd H., 1995, American Journal of Physiology, V269, pH2147; Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331; Nakano R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.579266; Nakano R, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229892; Nakano R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26473-7; Nakano R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141581; Nakano R, 2015, J VET MED SCI, V77, P27, DOI 10.1292/jvms.14-0284; Namba S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182923; Naruke A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0259489; OZ MC, 1995, CIRCULATION, V92, P428, DOI 10.1161/01.CIR.92.9.428; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484; RATHANASWAMI P, 1993, ARTHRITIS RHEUM, V36, P1295, DOI 10.1002/art.1780360914; Riesenberg K, 1997, EUR J CLIN INVEST, V27, P398, DOI 10.1046/j.1365-2362.1997.1270667.x; Rosenkilde MM, 2004, APMIS, V112, P481, DOI 10.1111/j.1600-0463.2004.apm11207-0808.x; Sager HB, 2015, CIRCULATION, V132, P1880, DOI 10.1161/CIRCULATIONAHA.115.016160; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Sodin-Semrl S, 2000, J IMMUNOL, V164, P2660, DOI 10.4049/jimmunol.164.5.2660; Souders CA, 2009, CIRC RES, V105, P1164, DOI 10.1161/CIRCRESAHA.109.209809; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; Sun Y, 2002, BASIC RES CARDIOL, V97, P343, DOI 10.1007/s00395-002-0365-8; Suwabe Y, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0243859; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; Tsuchiya H, 2015, VET IMMUNOL IMMUNOP, V168, P223, DOI 10.1016/j.vetimm.2015.10.003; Turner NA, 2013, FIBROGENESIS TISSUE, V6, DOI 10.1186/1755-1536-6-5; Wan S, 1996, J THORAC CARDIOV SUR, V111, P469, DOI 10.1016/S0022-5223(96)70458-0; Zarrouk-Mahjoub S, 2016, INT J CARDIOL, V221, P632, DOI 10.1016/j.ijcard.2016.07.073	68	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								863309	10.3389/fimmu.2022.863309	http://dx.doi.org/10.3389/fimmu.2022.863309			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C3FU	35514973	gold, Green Published			2022-12-18	WOS:000810758900001
J	Parriott, G; Kee, BL				Parriott, Geoffrey; Kee, Barbara L.			E Protein Transcription Factors as Suppressors of T Lymphocyte Acute Lymphoblastic Leukemia	FRONTIERS IN IMMUNOLOGY			English	Review						Leukemia; E protein; TAL1; LYL1; murine; T lymphocyte	LOOP-HELIX PROTEINS; GENOME-WIDE ANALYSIS; CELL DEVELOPMENT; DNA-BINDING; HEMATOPOIETIC STEM; TUMOR-SUPPRESSOR; GENE-EXPRESSION; TAL1 COMPLEX; CHROMOSOMAL TRANSLOCATION; LINEAGE SPECIFICATION	T Lymphocyte Acute Lymphoblastic Leukemia (ALL) is an aggressive disease arising from transformation of T lymphocytes during their development. The mutation spectrum of T-ALL has revealed critical regulators of the growth and differentiation of normal and leukemic T lymphocytes. Approximately, 60% of T-ALLs show aberrant expression of the hematopoietic stem cell-associated helix-loop-helix transcription factors TAL1 and LYL1. TAL1 and LYL1 function in multiprotein complexes that regulate gene expression in T-ALL but they also antagonize the function of the E protein homodimers that are critical regulators of T cell development. Mice lacking E2A, or ectopically expressing TAL1, LYL1, or other inhibitors of E protein function in T cell progenitors, also succumb to an aggressive T-ALL-like disease highlighting that E proteins promote T cell development and suppress leukemogenesis. In this review, we discuss the role of E2A in T cell development and how alterations in E protein function underlie leukemogenesis. We focus on the role of TAL1 and LYL1 and the genes that are dysregulated in E2a(-/-) T cell progenitors that contribute to human T-ALL. These studies reveal novel mechanisms of transformation and provide insights into potential therapeutic targets for intervention in this disease.										Allman D, 2001, J EXP MED, V194, P99, DOI 10.1084/jem.194.1.99; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Ashworth TD, 2010, BLOOD, V116, P5455, DOI 10.1182/blood-2010-05-286328; Aster JC, 2011, J PATHOL, V223, P262, DOI 10.1002/path.2789; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Banerjee A, 2013, IMMUNITY, V38, P930, DOI 10.1016/j.immuni.2013.01.014; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; Belver L, 2019, CANCER DISCOV, V9, P1774, DOI 10.1158/2159-8290.CD-19-0471; Belver L, 2016, NAT REV CANCER, V16, P494, DOI 10.1038/nrc.2016.63; Bergqvist I, 2000, EUR J IMMUNOL, V30, P2857, DOI 10.1002/1521-4141(200010)30:10<2857::AID-IMMU2857>3.0.CO;2-G; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Braunstein M, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/678705; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; Carr T, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.845488; Chagraoui H, 2011, BLOOD, V118, P723, DOI 10.1182/blood-2011-01-328765; Chan WYI, 2007, BLOOD, V109, P1908, DOI 10.1182/blood-2006-05-023226; Chiang MY, 2016, BLOOD, V128, P2229, DOI 10.1182/blood-2016-01-692855; Choi SH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185762; Ciciro Y, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00309-y; Coustan-Smith E, 2009, LANCET ONCOL, V10, P147, DOI 10.1016/S1470-2045(08)70314-0; Crusio KM, 2010, ONCOGENE, V29, P4865, DOI 10.1038/onc.2010.222; De Obaldia ME, 2013, NAT IMMUNOL, V14, P1277, DOI 10.1038/ni.2760; de Poote RF, 2019, J IMMUNOL, V202, P2837, DOI 10.4049/jimmunol.1801220; de Sousa AP, 2012, J IMMUNOL, V189, P3822, DOI 10.4049/jimmunol.1103723; Dias S, 2008, IMMUNITY, V29, P217, DOI 10.1016/j.immuni.2008.05.015; Doan LL, 2004, NUCLEIC ACIDS RES, V32, P2508, DOI 10.1093/nar/gkh570; Egawa T, 2007, J EXP MED, V204, P1945, DOI 10.1084/jem.20070133; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Feder K, 2020, LEUKEMIA, V34, P1027, DOI 10.1038/s41375-019-0635-1; Ferrando AA, 2003, SEMIN HEMATOL, V40, P274, DOI 10.1016/S0037-1963(03)00195-1; Ferreira Antonio, 2022, Semin Cancer Biol, V85, P95, DOI 10.1016/j.semcancer.2021.04.008; FITZGERALD TJ, 1991, BLOOD, V78, P2686; Fransecky L, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0324-8; Furness CL, 2018, LEUKEMIA, V32, P1984, DOI 10.1038/s41375-018-0046-8; Garcia-Ojeda ME, 2013, BLOOD, V121, P1749, DOI 10.1182/blood-2012-06-440065; Geimer Le Lay AS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004545; Gekas C, 2009, BLOOD, V113, P3461, DOI 10.1182/blood-2008-07-167577; Germar K, 2011, P NATL ACAD SCI USA, V108, P20060, DOI 10.1073/pnas.1110230108; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Gomez-del Arco P, 2010, IMMUNITY, V33, P685, DOI 10.1016/j.immuni.2010.11.008; Guo X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125429; Gutierrez A, 2010, BLOOD, V115, P2845, DOI 10.1182/blood-2009-07-234377; Harly C, 2019, NAT IMMUNOL, V20, P1150, DOI 10.1038/s41590-019-0445-7; Herranz D, 2014, NAT MED, V20, P1130, DOI 10.1038/nm.3665; Hoang T, 2016, CURR TOP DEV BIOL, V118, P163, DOI 10.1016/bs.ctdb.2016.01.004; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Iacobucci I, 2021, J CLIN MED, V10, DOI 10.3390/jcm10173792; Ikawa T, 2006, J EXP MED, V203, P1329, DOI 10.1084/jem.20060268; Jeannet R, 2010, BLOOD, V116, P5443, DOI 10.1182/blood-2010-05-286658; Kee BL, 2009, NAT REV IMMUNOL, V9, P175, DOI 10.1038/nri2507; Kelliher MA, 1996, EMBO J, V15, P5160, DOI 10.1002/j.1460-2075.1996.tb00900.x; Kim D, 1999, MOL CELL BIOL, V19, P8240; Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829; Krishnamoorthy V, 2015, J IMMUNOL, V194, P3191, DOI 10.4049/jimmunol.1402443; Layer JH, 2020, MOL CELL BIOL, V40, DOI 10.1128/MCB.00652-19; Layer JH, 2016, MOL CELL BIOL, V36, P488, DOI 10.1128/MCB.00901-15; Lehal R, 2020, P NATL ACAD SCI USA, V117, P16292, DOI 10.1073/pnas.1922606117; Liu XF, 2018, J CANCER, V9, P1259, DOI 10.7150/jca.23992; Lukov GL, 2011, LEUKEMIA RES, V35, P405, DOI 10.1016/j.leukres.2010.07.023; Mansour MR, 2014, SCIENCE, V346, P1373, DOI 10.1126/science.1259037; Mansour MR, 2013, J EXP MED, V210, P1545, DOI 10.1084/jem.20122516; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; McCarter AC, 2020, BLOOD CANCER DISCOV, V1, P178, DOI 10.1158/2643-3230.BCD-20-0026; McCormack MP, 2013, BLOOD, V122, P2093, DOI 10.1182/blood-2012-09-458570; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Miyamoto A, 1996, MOL CELL BIOL, V16, P2394; Miyazaki M, 2017, IMMUNITY, V46, P818, DOI 10.1016/j.immuni.2017.04.022; Moore G, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061503; Morrow MA, 1999, MOL IMMUNOL, V36, P491, DOI 10.1016/S0161-5890(99)00071-1; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; Nawijn MC, 2001, J IMMUNOL, V167, P715, DOI 10.4049/jimmunol.167.2.715; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; Nie L, 2008, MOL CELL BIOL, V28, P2078, DOI 10.1128/MCB.00844-07; Noronha EP, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00316; O'Neil J, 2006, BLOOD, V107, P781, DOI 10.1182/blood-2005-06-2553; O'Neil J, 2004, CANCER CELL, V5, P587, DOI 10.1016/j.ccr.2004.05.023; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; Ono Y, 1998, MOL CELL BIOL, V18, P6939, DOI 10.1128/MCB.18.12.6939; Petropoulos K, 2008, J EXP MED, V205, P515, DOI 10.1084/jem.20071875; Qian LY, 2019, J EXP MED, V216, P884, DOI 10.1084/jem.20182100; Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074-7613(00)80054-0; Rahman S, 2017, BLOOD, V129, P3221, DOI 10.1182/blood-2016-09-742148; Reschly EJ, 2006, BLOOD, V107, P4115, DOI 10.1182/blood-2005-09-3551; Rodriguez-Caparros A, 2019, J IMMUNOL, V202, P2460, DOI 10.4049/jimmunol.1801650; Sanda T, 2017, EXP HEMATOL, V53, P7, DOI 10.1016/j.exphem.2017.06.001; Sanda T, 2012, CANCER CELL, V22, P209, DOI 10.1016/j.ccr.2012.06.007; Santiago L, 2017, AM J CANCER RES, V7, P1389; Schlaeger TM, 2005, BLOOD, V105, P3871, DOI 10.1182/blood-2004-11-4467; Schlaeger TM, 2004, MOL CELL BIOL, V24, P7491, DOI 10.1128/MCB.24.17.7491-7502.2004; Scripture-Adams DD, 2014, J IMMUNOL, V193, P3470, DOI 10.4049/jimmunol.1301663; Sharma VM, 2007, CELL CYCLE, V6, P927, DOI 10.4161/cc.6.8.4134; Shaw TI, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84647-2; Souroullas GP, 2009, CELL STEM CELL, V4, P180, DOI 10.1016/j.stem.2009.01.001; Spaulding C, 2007, BLOOD, V110, P2650, DOI 10.1182/blood-2007-04-084202; Staal FJT, 2003, CURR OPIN IMMUNOL, V15, P204, DOI 10.1016/S0952-7915(03)00003-7; Staal FJT, 2012, IMMUNITY, V37, P761, DOI 10.1016/j.immuni.2012.10.008; Taghon T, 2007, NAT IMMUNOL, V8, P845, DOI 10.1038/ni1486; Tan SH, 2016, LEUKEMIA, V30, P959, DOI 10.1038/leu.2015.195; Tan TK, 2019, INT J HEMATOL, V109, P5, DOI 10.1007/s12185-018-2518-z; Tatarek J, 2011, BLOOD, V118, P1579, DOI 10.1182/blood-2010-08-300343; Thompson BJ, 2007, J EXP MED, V204, P1825, DOI 10.1084/jem.20070872; Tiemessen MM, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001430; Tijssen MR, 2011, DEV CELL, V20, P597, DOI 10.1016/j.devcel.2011.04.008; Van de Walle I, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11171; van Hamburg JP, 2008, MOL IMMUNOL, V45, P3085, DOI 10.1016/j.molimm.2008.03.018; Van Vlierberghe P, 2012, J CLIN INVEST, V122, P3398, DOI 10.1172/JCI61269; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Wang F, 2021, CELL MOL IMMUNOL, V18, P644, DOI 10.1038/s41423-020-00527-1; Wang HC, 2017, J IMMUNOL, V198, P3149, DOI 10.4049/jimmunol.1602009; Wang HF, 2014, P NATL ACAD SCI USA, V111, P705, DOI 10.1073/pnas.1315023111; Wang HF, 2011, P NATL ACAD SCI USA, V108, P14908, DOI 10.1073/pnas.1109023108; Weber BN, 2011, NATURE, V476, P63, DOI 10.1038/nature10279; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wikstrom I, 2008, MOL IMMUNOL, V45, P3302, DOI 10.1016/j.molimm.2008.02.012; Wilson NK, 2009, BLOOD, V113, P5456, DOI 10.1182/blood-2009-01-200048; Xu W, 2007, BLOOD, V109, P4406, DOI 10.1182/blood-2006-08-043331; Xu W, 2013, BLOOD, V121, P1534, DOI 10.1182/blood-2012-08-449447; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Yang Q, 2008, J IMMUNOL, V181, P5885, DOI 10.4049/jimmunol.181.9.5885; Yu SY, 2012, IMMUNITY, V37, P813, DOI 10.1016/j.immuni.2012.08.009; Yucel R, 2003, J EXP MED, V197, P831, DOI 10.1084/jem.20021417; Zheng RY, 2020, EXP HEMATOL ONCOL, V9, DOI 10.1186/s40164-020-00187-x; Zhong Y, 2007, ONCOGENE, V26, P6937, DOI 10.1038/sj.onc.1210494; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; Zlotoff DA, 2010, BLOOD, V115, P1897, DOI 10.1182/blood-2009-08-237784; Zohren F, 2012, NAT IMMUNOL, V13, P761, DOI 10.1038/ni.2365	133	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								885144	10.3389/fimmu.2022.885144	http://dx.doi.org/10.3389/fimmu.2022.885144			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B9OQ	35514954	gold, Green Published			2022-12-18	WOS:000810510900001
J	Reid, KM; Kitchener, EJA; Butler, CA; Cockram, TOJ; Brown, GC				Reid, Kyle M.; Kitchener, Emily J. A.; Butler, Claire A.; Cockram, Tom O. J.; Brown, Guy C.			Brain Cells Release Calreticulin That Attracts and Activates Microglia, and Inhibits Amyloid Beta Aggregation and Neurotoxicity	FRONTIERS IN IMMUNOLOGY			English	Article						microglia; calreticulin; alarmin; brain; amyloid beta; chaperone; neurotoxicity	RECEPTOR-RELATED PROTEIN; IN-VIVO; EXTRACELLULAR CHAPERONES; SURFACE CALRETICULIN; APOPTOTIC CELLS; CANCER; C1Q; FRAGMENT; ATP; CLEARANCE	Calreticulin is a chaperone, normally found in the endoplasmic reticulum, but can be released by macrophages into the extracellular medium. It is also found in cerebrospinal fluid bound to amyloid beta (A beta). We investigated whether brain cells release calreticulin, and whether extracellular calreticulin had any effects on microglia and neurons relevant to neuroinflammation and neurodegeneration. We found that microglia release nanomolar levels of calreticulin when inflammatory-activated with lipopolysaccharide, when endoplasmic reticulum stress was induced by tunicamycin, or when cell death was induced by staurosporine, and that neurons release calreticulin when crushed. Addition of nanomolar levels of extracellular calreticulin was found to chemoattract microglia, and activate microglia to release cytokines TNF-alpha, IL-6 and IL-1 beta, as well as chemokine (C-C motif) ligand 2. Calreticulin blocked A beta fibrillization and modified A beta oligomerization, as measured by thioflavin T fluorescence and transmission electron microscopy. Extracellular calreticulin also altered microglial morphology and proliferation, and prevented A beta-induced neuronal loss in primary neuron-glial cultures. Thus, calreticulin is released by microglia and neurons, and acts: as an alarmin to recruit and activate microglia, as an extracellular chaperone to prevent A beta aggregation, and as a neuroprotectant against A beta neurotoxicity.					Brown, Guy C./HHC-1102-2022	Butler, Claire/0000-0001-9320-8297				Abdullahi A, 2017, SHOCK, V47, P506, DOI 10.1097/SHK.0000000000000759; Allendorf DH, 2020, GLIA, V68, P989, DOI 10.1002/glia.23757; Alur M, 2009, AM J PATHOL, V175, P882, DOI 10.2353/ajpath.2009.080417; Amin L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23507-z; Bajor A, 2011, CLIN EXP IMMUNOL, V165, P220, DOI 10.1111/j.1365-2249.2011.04423.x; Bak SP, 2008, MOL IMMUNOL, V45, P1414, DOI 10.1016/j.molimm.2007.08.020; Bellver-Landete V, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08446-0; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Brifault C, 2017, J BIOL CHEM, V292, P18699, DOI 10.1074/jbc.M117.798413; Cardoso LS, 2007, MICROB CELL FACT, V6, DOI 10.1186/1475-2859-6-1; Carrillo-Jimenez A, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00313; Chen ZH, 2016, J NEUROCHEM, V136, P10, DOI 10.1111/jnc.13062; Cockram TOJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02647; Coppolino MG, 1998, INT J BIOCHEM CELL B, V30, P553, DOI 10.1016/S1357-2725(97)00153-2; Dabbs RA., 2010, EXTRACELLULAR CHAPER, P1, DOI [10.1007/128_2010_85, DOI 10.1007/128_2010_85]; Dello Russo C, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1288-0; Dubbelaar ML, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01753; Duus K, 2008, PROTEIN PEPTIDE LETT, V15, P103; EGGLETON P, 1994, CLIN IMMUNOL IMMUNOP, V72, P405, DOI 10.1006/clin.1994.1160; Erickson RR, 2005, BIOCHEM BIOPH RES CO, V332, P50, DOI 10.1016/j.bbrc.2005.04.090; Feng MY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05211-7; Fricker M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-196; Fuger P, 2017, NAT NEUROSCI, V20, P1371, DOI 10.1038/nn.4631; Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Gold LI, 2006, J INVEST DERM SYMP P, V11, P57, DOI 10.1038/sj.jidsymp.5650011; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Hong C, 2010, J IMMUNOL, V185, P4561, DOI 10.4049/jimmunol.1000536; Li Y, 2015, INT J CLIN EXP MED, V8, P7288; Lively S, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00215; Lu YC, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/526524; Mannini B, 2012, P NATL ACAD SCI USA, V109, P12479, DOI 10.1073/pnas.1117799109; Martins I, 2010, ANN NY ACAD SCI, V1209, P77, DOI 10.1111/j.1749-6632.2010.05740.x; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Narayan P, 2012, BIOCHEMISTRY-US, V51, P9270, DOI 10.1021/bi301277k; Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Ohsawa K, 2007, GLIA, V55, P604, DOI 10.1002/glia.20489; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; Paidassi H, 2011, J MOL BIOL, V408, P277, DOI 10.1016/j.jmb.2011.02.029; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Schcolnik-Cabrera A, 2019, APOPTOSIS, V24, P245, DOI 10.1007/s10495-019-01532-0; Shen XL, 2016, NAT IMMUNOL, V17, P1282, DOI 10.1038/ni.3545; Simenc J, 2012, RADIOL ONCOL, V46, P312, DOI 10.2478/v10019-012-0036-9; Stine WB, 2011, METHODS MOL BIOL, V670, P13, DOI 10.1007/978-1-60761-744-0_2; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; Torres-Platas SG, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-12; Town T, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742-2094-2-24; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; Wakelin SJ, 2006, IMMUNOL LETT, V106, P1, DOI 10.1016/j.imlet.2006.04.007; Weng WC, 2015, MOL NEUROBIOL, V52, P758, DOI 10.1007/s12035-014-8901-8; Williams DB, 2006, J CELL SCI, V119, P615, DOI 10.1242/jcs.02856; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; Wollmer MA, 2001, J NEUROIMMUNOL, V115, P19, DOI 10.1016/S0165-5728(01)00257-0; Wyatt AR, 2013, ANNU REV BIOCHEM, V82, P295, DOI 10.1146/annurev-biochem-072711-163904; Wyatt AR, 2012, J MOL BIOL, V421, P499, DOI 10.1016/j.jmb.2012.01.004	61	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								859686	10.3389/fimmu.2022.859686	http://dx.doi.org/10.3389/fimmu.2022.859686			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D2DV	35514983	Green Published, gold			2022-12-18	WOS:000811365200001
J	Scholz, JL; Eleftherianos, I; Kobe, B				Scholz, Jean L.; Eleftherianos, Ioannis; Kobe, Bostjan			Editorial: Evolution of Innate Immunity in Eukarya: Advances and Implications	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						innate immunity; host-pathogen interactions; comparative immunology; immune signaling; cellular immunity							Kobe, Bostjan/D-1292-2009	Kobe, Bostjan/0000-0001-9413-9166	National Science Foundation [2019869]; National Health and Medical Research Council (NHMRC) [1160570]; Australian Research Council (ARC) [DP190102526, DP220102832, FL180100109]	National Science Foundation(National Science Foundation (NSF)); National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council (ARC)(Australian Research Council)	The research in the authors' laboratories was funded by the National Science Foundation (Award Number 2019869) to IE, the National Health and Medical Research Council (NHMRC) (Project Grant 1160570) and the Australian Research Council (ARC) (Discovery Projects DP190102526, DP220102832 and Laureate Fellowship FL180100109) to BK.		0	0	0	3	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								879429	10.3389/fimmu.2022.879429	http://dx.doi.org/10.3389/fimmu.2022.879429			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2C3IK	35514967	gold, Green Published			2022-12-18	WOS:000810765700001
J	Wirsching, S; Harder, L; Heymanns, M; Groendahl, B; Hilbert, K; Kowalzik, F; Meyer, C; Gehring, S				Wirsching, Sebastian; Harder, Laura; Heymanns, Markus; Groendahl, Britta; Hilbert, Katja; Kowalzik, Frank; Meyer, Claudius; Gehring, Stephan			Long-Term, CD4(+) Memory T Cell Response to SARS-CoV-2	FRONTIERS IN IMMUNOLOGY			English	Article						SARS-CoV-2; HCoV; T cell immunity; long-term memory; cross-reactivity	CORONAVIRUS; ANTIBODIES	The first cases of coronavirus disease-19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported by Chinese authorities at the end of 2019. The disease spread quickly and was declared a global pandemic shortly thereafter. To respond effectively to infection and prevent viral spread, it is important to delineate the factors that affect protective immunity. Herein, a cohort of convalescent healthcare workers was recruited and their immune responses were studied over a period of 3 to 9 months following the onset of symptoms. A cross-reactive T cell response to SARS-CoV-2 and endemic coronaviruses, i.e., OC43 and NL63, was demonstrated in the infected, convalescent cohort, as well as a cohort composed of unexposed individuals. The convalescent cohort, however, displayed an increased number of SARS-CoV-2-specific CD4(+) T cells relative to the unexposed group. Moreover, unlike humoral immunity and quickly decreasing antibody titers, T cell immunity in convalescent individuals was maintained and stable throughout the study period. This study also suggests that, based on the higher CD4 T cell memory response against nucleocapsid antigen, future vaccine designs may include nucleocapsid as an additional antigen along with the spike protein.										Akagi K, 2022, JPN J INFECT DIS, V75, P121, DOI 10.7883/yoken.JJID.2021.250; Anderson EM, 2021, CELL, V184, P1858, DOI 10.1016/j.cell.2021.02.010; Bonifacius A, 2021, IMMUNITY, V54, P340, DOI 10.1016/j.immuni.2021.01.008; Braun J, 2020, NATURE, V587, P270, DOI 10.1038/s41586-020-2598-9; Chen J, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1319; Chen RTE, 2021, NAT MED, V27, DOI 10.1038/s41591-021-01294-w; Cohen KW, 2021, CELL REP MED, V2, DOI [10.1016/j.xcrm.2021.100354, 10.1101/2021.04.19.21255739]; Corbett Kizzmekia S, 2020, bioRxiv, DOI [10.1038/s41586-020-2622-0, 10.1101/2020.06.11.145920]; Dan JM, 2021, SCIENCE, V371, P587, DOI 10.1126/science.abf4063; Edridge AWD, 2020, NAT MED, V26, P1691, DOI 10.1038/s41591-020-1083-1; Gorse GJ, 2010, CLIN VACCINE IMMUNOL, V17, P1875, DOI 10.1128/CVI.00278-10; Grifoni A, 2020, CELL, V181, P1489, DOI 10.1016/j.cell.2020.05.015; Grobben M, 2021, ELIFE, V10, DOI [10.7554/eLife.70330, 10.7554/eLife.70330.sa0, 10.7554/eLife.70330.sa1, 10.7554/eLife.70330.sa2]; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Imai K, 2021, INT J INFECT DIS, V111, P68, DOI 10.1016/j.ijid.2021.08.026; Isho B, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abe5511; Johns Hopkins coronavirus resource center, COVID 19 MAP; Jung JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24377-1; Lau EHY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20247-4; Le Bert N, 2020, NATURE, V584, P457, DOI 10.1038/s41586-020-2550-z; Long QX, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00250-9; Loyal L, 2021, SCIENCE, V374, P171, DOI 10.1126/science.abh1823; Masia M, 2021, J AUTOIMMUN, V123, DOI 10.1016/j.jaut.2021.102703; Mateus J, 2020, SCIENCE, V370, P89, DOI 10.1126/science.abd3871; Moderbacher CR, 2020, CELL, V183, P996, DOI 10.1016/j.cell.2020.09.038; Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023; O'Grady NP, 2002, CLIN INFECT DIS, V35, P1281, DOI 10.1086/344188; Olea B, 2021, J CLIN VIROL, V142, DOI 10.1016/j.jcv.2021.104943; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Sandberg JT, 2021, CLIN TRANSL IMMUNOL, V10, DOI 10.1002/cti2.1306; Schlickeiser S, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.628971; Schwarzkopf S, 2021, EMERG INFECT DIS, V27, P122, DOI 10.3201/eid2701.203772; Sekine T, 2020, CELL, V183, P158, DOI 10.1016/j.cell.2020.08.017; Steiner S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687449; Supasa P, 2021, CELL, V184, P2201, DOI 10.1016/j.cell.2021.02.033; Thummler L, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11081439; Tillett RL, 2021, LANCET INFECT DIS, V21, P52, DOI 10.1016/S1473-3099(20)30764-7; Van Elslande J, 2021, CLIN INFECT DIS, V73, P354, DOI 10.1093/cid/ciaa1330; Vogel AB, 2021, NATURE, V592, P283, DOI 10.1038/s41586-021-03275-y; Weiskopf D, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.abd2071; Woldemeskel BA, 2020, J CLIN INVEST, V130, P6631, DOI 10.1172/JCI143120; World Health Organization, ARCHIVED WHO TIMELIN; Woudenberg T, 2021, EBIOMEDICINE, V70, DOI 10.1016/j.ebiom.2021.103495; Wu AP, 2020, CELL HOST MICROBE, V27, P325, DOI 10.1016/j.chom.2020.02.001; Xiang TD, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.708523; Yamaguchi T, 2021, INT J INFECT DIS, V109, P261, DOI 10.1016/j.ijid.2021.07.015; Zhou P, 2020, NATURE, V579, P270, DOI 10.1038/s41586-020-2012-7	49	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								800070	10.3389/fimmu.2022.800070	http://dx.doi.org/10.3389/fimmu.2022.800070			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B9VU	35514974	Green Published, gold			2022-12-18	WOS:000810529600001
J	Yu, WT; Zong, SM; Zhou, P; Wei, JH; Wang, EH; Ming, RJ; Xiao, HJ				Yu, Wenting; Zong, Shimin; Zhou, Peng; Wei, Jiahui; Wang, Enhao; Ming, Ruijie; Xiao, Hongjun			Cochlear Marginal Cell Pyroptosis Is Induced by Cisplatin via NLRP3 Inflammasome Activation	FRONTIERS IN IMMUNOLOGY			English	Article						pyroptosis; cisplatin; marginal cells; NLRP3; TXNIP	THIOREDOXIN-INTERACTING PROTEIN; GASDERMIN-D; INDUCED OTOTOXICITY; OXIDATIVE STRESS; INDUCED NEPHROTOXICITY; MOLECULAR-MECHANISMS; STRIA VASCULARIS; HAIR-CELLS; DAMAGE; APOPTOSIS	Better understanding the mechanism of cisplatin-induced ototoxicity is of great significance for clinical prevention and treatment of cisplatin-related hearing loss. However, the mechanism of cisplatin-induced inflammatory response in cochlear stria vascularis and the mechanism of marginal cell (MC) damage have not been fully clarified. In this study, a stable model of cisplatin-induced MC damage was established in vitro, and the results of PCR and Western blotting showed increased expressions of NLRP3, Caspase-1, IL-1 beta, and GSDMD in MCs. Incomplete cell membranes including many small pores appearing on the membrane were also observed under transmission electron microscopy and scanning electron microscopy. In addition, downregulation of NLRP3 by small interfering RNA can alleviate cisplatin-induced MC pyroptosis, and reducing the expression level of TXNIP possesses the inhibition effect on NLRP3 inflammasome activation and its mediated pyroptosis. Taken together, our results suggest that NLRP3 inflammasome activation may mediate cisplatin-induced MC pyroptosis in cochlear stria vascularis, and TXNIP is a possible upstream regulator, which may be a promising therapeutic target for alleviating cisplatin-induced hearing loss.	[Yu, Wenting; Zong, Shimin; Zhou, Peng; Wei, Jiahui; Wang, Enhao; Ming, Ruijie; Xiao, Hongjun] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan, Peoples R China	Huazhong University of Science & Technology	Xiao, HJ (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otorhinolaryngol, Wuhan, Peoples R China.	xhjent_whxh@hust.edu.cn			National Natural Science Foundation of China [81771002, 82071057]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	Funding This work was supported by the National Natural Science Foundation of China (Grant numbers 81771002 and 82071057).	Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113; Bahar E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22083916; Bao XG, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/6389568; Breglio AM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01837-1; Bu CA, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420-022-00879-9; Burdette BE, 2021, ACTA PHARM SIN B, V11, P2768, DOI 10.1016/j.apsb.2021.02.006; Chen CY, 2017, REDOX BIOL, V11, P263, DOI 10.1016/j.redox.2016.12.018; Chen M, 2021, PULM PHARMACOL THER, V68, DOI 10.1016/j.pupt.2021.102018; Chen MY, 2021, INFLAMMATION, V44, P1229, DOI 10.1007/s10753-021-01439-6; Cheng C, 2021, J GENET GENOMICS, V48, P324, DOI 10.1016/j.jgg.2021.03.010; Cheng C, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1437-0; Dasgupta S, 2021, J LARYNGOL OTOL, V135, P373, DOI 10.1017/S0022215121000748; Domingues A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041693; El-Naga RN, 2014, TOXICOL APPL PHARM, V274, P87, DOI 10.1016/j.taap.2013.10.031; Fu XL, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2107357119; Fu XL, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.692762; Fu XL, 2021, MOL NEUROBIOL, DOI 10.1007/s12035-021-02422-w; Gao H, 2020, TOXICOLOGY, V440, DOI 10.1016/j.tox.2020.152487; Garcia-Pastor C, 2019, BBA-MOL BASIS DIS, V1865, P2504, DOI 10.1016/j.bbadis.2019.06.008; Gentilin E, 2019, TRENDS MOL MED, V25, P1123, DOI 10.1016/j.molmed.2019.08.002; Guo LN, 2021, FRONT CELL NEUROSCI, V15, DOI 10.3389/fncel.2021.760422; Han SY, 2020, BIOSENS BIOELECTRON, V154, DOI 10.1016/j.bios.2020.112073; He WT, 2015, CELL RES, V25, P1285, DOI 10.1038/cr.2015.139; He ZH, 2021, AUTOPHAGY, V17, P4341, DOI 10.1080/15548627.2021.1916194; He ZH, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101364; He ZH, 2017, AUTOPHAGY, V13, P1884, DOI 10.1080/15548627.2017.1359449; Herr DR, 2020, NEUROMOL MED, V22, P293, DOI 10.1007/s12017-019-08586-y; Huang Y, 2021, CELL MOL IMMUNOL, V18, P2114, DOI 10.1038/s41423-021-00740-6; Jiang HY, 2018, REDOX BIOL, V14, P361, DOI 10.1016/j.redox.2017.10.002; Jiang P, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-022-04164-x; Kim YJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126327; Li A, 2018, DRUG DELIV, V25, P1033, DOI 10.1080/10717544.2018.1461277; Li CY, 2020, J CELL PHYSIOL, V235, P3721, DOI 10.1002/jcp.29266; Li H, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00139; Li LX, 2019, J ALZHEIMERS DIS, V68, P255, DOI 10.3233/JAD-180814; Li ZW, 2019, MOL THER-NUCL ACIDS, V17, P92, DOI 10.1016/j.omtn.2019.05.007; Lin L, 2021, MICROVASC RES, V138, DOI 10.1016/j.mvr.2021.104215; Liu DL, 2020, BIOCHEM PHARMACOL, V175, DOI 10.1016/j.bcp.2020.113863; Liu WW, 2021, AUTOPHAGY, V17, P4159, DOI 10.1080/15548627.2021.1905466; Liu WW, 2019, ANTIOXID REDOX SIGN, V30, P1389, DOI 10.1089/ars.2017.7288; Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629; Lu FF, 2020, J CELL PHYSIOL, V235, P3207, DOI 10.1002/jcp.29268; Lv J, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.630361; Markovic BS, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/1315378; Monteleone M, 2018, CELL REP, V24, P1425, DOI 10.1016/j.celrep.2018.07.027; Moon SK, 2019, ANN OTO RHINOL LARYN, V128, p8S, DOI 10.1177/0003489419837689; Mwangi M, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00314; Ohlemiller KK, 2009, BRAIN RES, V1277, P70, DOI 10.1016/j.brainres.2009.02.079; Paik S, 2021, CELL MOL IMMUNOL, V18, P1141, DOI 10.1038/s41423-021-00670-3; Park HJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12073-0; Prasad KN, 2020, MECH AGEING DEV, V185, DOI 10.1016/j.mad.2019.111191; Prayuenyong P, 2021, FRONT NEUROSCI-SWITZ, V15, DOI 10.3389/fnins.2021.695268; Qayyum N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052754; Qi LY, 2019, CHEM RES TOXICOL, V32, P1469, DOI 10.1021/acs.chemrestox.9b00204; Qian FP, 2020, AGING-US, V12, P18804, DOI 10.18632/aging.103840; Raudenska M, 2019, METALLOMICS, V11, P1182, DOI 10.1039/c9mt00049f; Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028; Sheth S, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00338; Shi XR, 2016, HEARING RES, V338, P52, DOI 10.1016/j.heares.2016.01.010; Sluyter S, 2003, HEARING RES, V185, P49, DOI 10.1016/S0378-5955(03)00260-0; So H, 2008, JARO-J ASSOC RES OTO, V9, P290, DOI 10.1007/s10162-008-0126-y; Steyger PS, 2021, AM J AUDIOL, V30, P887, DOI 10.1044/2021_AJA-21-00006; Tang Q, 2021, EUR J PHARM BIOPHARM, V163, P60, DOI 10.1016/j.ejpb.2021.03.008; Thomas JP, 2006, MOL PHARMACOL, V70, P23, DOI 10.1124/mol.106.022244; Volarevic V, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0518-9; Wang CL, 2022, J MOL BIOL, V434, DOI 10.1016/j.jmb.2021.167297; Wang MH, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-021-04029-9; Wang X, 2021, LAB INVEST, V101, P1118, DOI 10.1038/s41374-021-00607-4; Wu P, 2021, NEURAL PLAST, V2021, DOI 10.1155/2021/4909237; Yancey A, 2012, PEDIATR BLOOD CANCER, V59, P144, DOI 10.1002/pbc.24138; Yoshihara E, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080765; Yu DH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00999; Zeng Q, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00182; Zhang BL, 2019, AGING-US, V11, P8239, DOI 10.18632/aging.102317; Zhang DP, 2019, J NEUROSCI RES, V97, P645, DOI 10.1002/jnr.24385; Zhang N, 2020, NEURAL PLAST, V2020, DOI 10.1155/2020/8851525; Zhang SS, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.625867; Zhang Y, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.631904; Zhao XY, 2013, HEARING RES, V296, P13, DOI 10.1016/j.heares.2012.11.007; Zheng M, 2020, IMMUNOL REV, V297, P26, DOI 10.1111/imr.12909; Zhong ZH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00712; Zhou H, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03110-8; Zhou HX, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23312; Zhou JB, 2013, MITOCHONDRION, V13, P163, DOI 10.1016/j.mito.2012.06.004; Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831; Zhou YF, 2021, BIOCHEM BIOPH RES CO, V559, P106, DOI 10.1016/j.bbrc.2021.04.090	86	0	0	6	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 20	2022	13								823439	10.3389/fimmu.2022.823439	http://dx.doi.org/10.3389/fimmu.2022.823439			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1C7IX	35529876	gold, Green Published			2022-12-18	WOS:000793289300001
J	Albonici, L; Alminana, SL; Tanaka, T; Bei, R				Albonici, Loredana; Labiano Alminana, Sara; Tanaka, Toshihide; Bei, Roberto			Editorial: The Impact of Angiogenic Growth Factors and Hypoxia on the Antitumor Immune Response	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						angiogenic growth factors; hypoxia; TME (tumor microenvironment); anti-tumor innate immune cell; antitumor adaptive immune cells							Bei, Roberto/W-8023-2019						0	0	0	6	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								903105	10.3389/fimmu.2022.903105	http://dx.doi.org/10.3389/fimmu.2022.903105			2	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D0WI	35514971	Green Published, gold			2022-12-18	WOS:000811277200001
J	Blase, JR; Frame, D; Michniacki, TF; Walkovich, K				Blase, Jennifer R.; Frame, David; Michniacki, Thomas F.; Walkovich, Kelly			Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies	FRONTIERS IN IMMUNOLOGY			English	Article						serum sickness; ITP (idiopathic thrombocytopenic purpura); rituximab; obinutuzumab; case report	PURPURA; CHILD	Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients. However, neutralizing antibodies to rituximab that nullify therapeutic response and may lead to serum sickness have been rarely reported. Here, we present a case of a young adult woman with Evans syndrome treated with rituximab, complicated by the development of serum sickness, acute respiratory distress syndrome, and platelet refractoriness presumed secondary to neutralizing antibodies to rituximab. She was successfully treated with the humanized anti-CD20 monoclonal antibody, obinutuzumab, with subsequent symptom resolution. Additionally, a review of 10 previously published cases of serum-sickness associated with the use of rituximab for idiopathic thrombocytopenic purpura (ITP) is summarized. This case highlights that recognition of more subtle or rare symptoms of rituximab-induced serum sickness is important to facilitate rapid intervention.										Bayer G, 2019, EUR J INTERN MED, V67, P59, DOI 10.1016/j.ejim.2019.06.009; Bayram MT, 2020, TURKISH J PEDIATR, V62, P884, DOI 10.24953/turkjped.2020.05.025; Bennett CM, 2006, BLOOD, V107, P2639, DOI 10.1182/blood-2005-08-3518; Boyer-Suavet S, 2020, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.03069; Fouda GE, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.572863; Godeau B, 2008, BLOOD, V112, P999, DOI 10.1182/blood-2008-01-131029; Goto S, 2009, INT J HEMATOL, V89, P305, DOI 10.1007/s12185-009-0269-6; Harding FA, 2010, MABS-AUSTIN, V2, P256, DOI 10.4161/mabs.2.3.11641; Hasan A, 2009, AM J HEMATOL, V84, P661, DOI 10.1002/ajh.21512; Herishanu Y, 2002, AM J HEMATOL, V70, P329, DOI 10.1002/ajh.10127; Herishanu Y, 2021, BRIT J HAEMATOL, V192, pE1, DOI 10.1111/bjh.17105; Karmacharya P, 2015, SEMIN ARTHRITIS RHEU, V45, P334, DOI 10.1016/j.semarthrit.2015.06.014; Klein C, 2013, MABS-AUSTIN, V5, P22, DOI 10.4161/mabs.22771; Lucchini E, 2019, HAEMATOLOGICA, V104, P1124, DOI 10.3324/haematol.2019.218883; Manko A., 2014, CHEST, V146, p269A, DOI [10.1378/chest.1958613, DOI 10.1378/CHEST.1958613]; Medeot M, 2008, EUR J HAEMATOL, V81, P165, DOI 10.1111/j.1600-0609.2008.01100.x; Neunert C, 2019, BLOOD ADV, V3, P3829, DOI 10.1182/bloodadvances.2019000966; Paul F, 2019, EXPERT REV CLIN IMMU, V15, P383, DOI 10.1080/1744666X.2019.1562905; Picard M, 2017, J ALLER CL IMM-PRACT, V5, P600, DOI 10.1016/j.jaip.2016.12.001; Rixe N., 2021, SERUM SICKNESS; Wang J, 2005, J PEDIATR-US, V146, P217, DOI 10.1016/j.jpeds.2004.09.004	21	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								863177	10.3389/fimmu.2022.863177	http://dx.doi.org/10.3389/fimmu.2022.863177			5	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	5U0YZ	35514985	gold, Green Published			2022-12-18	WOS:000876281400001
J	Hu, LN; Zhao, XY; Li, P; Zeng, YY; Zhang, YM; Shen, Y; Wang, YK; Sun, XL; Lai, BB; Zhong, C				Hu, Luni; Zhao, Xingyu; Li, Peng; Zeng, Yanyu; Zhang, Yime; Shen, Yang; Wang, Yukai; Sun, Xiaolin; Lai, Binbin; Zhong, Chao			Proximal and Distal Regions of Pathogenic Th17 Related Chromatin Loci Are Sequentially Accessible During Pathogenicity of Th17	FRONTIERS IN IMMUNOLOGY			English	Article						autoimmune disease; regulatory Th17; pathogenic Th17; pro-inflammatory Th1; chromatin accessibility; transcriptional regulation	ROR-GAMMA-T; T(H)17 CELL-DIFFERENTIATION; TGF-BETA; MULTIPLE-SCLEROSIS; GM-CSF; C-MAF; TRANSCRIPTION; EXPRESSION; LYMPHOCYTES; RECRUITMENT	Pathogenic Th17, featured by their production of pro-inflammatory cytokines, are considered as a key player in most autoimmune diseases. The transcriptome of them is obviously distinct from that of conventional regulatory Th17. However, chromatin accessibility of the two Th17 groups have not been comprehensively compared yet. Here, we found that their chromatin-accessible regions(ChARs) significantly correlated with the expression of related genes, indicating that they might engage in the regulation of these genes. Indeed, pathogenic Th17 specific ChARs (patho-ChARs) exhibited a significant distribution preference in TSS-proximal region. We further filtered the patho-ChARs based on their conservation among mammalians or their concordance with the expression of their related genes. In either situation, the filtered patho-ChARs also showed a preference for TSS-proximal region. Enrichment of expression concordant patho-ChARs related genes suggested that they might involve in the pathogenicity of Th17. Thus, we also examined all ChARs of patho-ChARs related genes, and defined an opening ChAR set according to their changes in the Th17 to Th1 conversion. Interestingly, these opening ChARs displayed a sequential accessibility change from TSS-proximal region to TSS-distal region. Meanwhile, a group of patho-TFs (transcription factors) were identified based on the appearance of their binding motifs in the opening ChARs. Consistently, some of them also displayed a similar preference for binding the TSS-proximal region. Single-cell transcriptome analysis further confirmed that these patho-TFs were involved in the generation of pathogenic Th17. Therefore, our results shed light on a new regulatory mechanism underlying the generation of pathogenic Th17, which is worth to be considered for autoimmune disease therapy.										Aguilar-Flores C, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8065147; Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014; Cande J, 2009, P NATL ACAD SCI USA, V106, P14414, DOI 10.1073/pnas.0905754106; Carr TM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00380-3; Cartier A, 2019, SCIENCE, V366, P323, DOI 10.1126/science.aar5551; Chen J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17371-5; Choi JY, 2020, NAT IMMUNOL, V21, P777, DOI 10.1038/s41590-020-0706-5; Chong WP, 2020, IMMUNITY, V53, P384, DOI 10.1016/j.immuni.2020.06.022; Collins PL, 2010, J IMMUNOL, V185, P1492, DOI 10.4049/jimmunol.1000124; Cui GL, 2011, J CLIN INVEST, V121, P658, DOI 10.1172/JCI42974; Daassi D, 2016, BIOCHEM BIOPH RES CO, V473, P118, DOI 10.1016/j.bbrc.2016.03.063; Elyaman W, 2009, P NATL ACAD SCI USA, V106, P12885, DOI 10.1073/pnas.0812530106; Evans HG., 2012, J TRANS MED, V10, pP49, DOI [10.1186/1479-5876-10-S3-P49, DOI 10.1186/1479-5876-10-S3-P49]; Fitzgerald DC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-130; Gagliani N, 2015, NATURE, V523, P221, DOI 10.1038/nature14452; Gaublomme JT, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.009; Ghoreschi K, 2010, NATURE, V467, P967, DOI 10.1038/nature09447; Glal D, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02522; Gocke AR, 2007, J IMMUNOL, V178, P1341, DOI 10.4049/jimmunol.178.3.1341; Goto Y, 2014, IMMUNITY, V40, P594, DOI 10.1016/j.immuni.2014.03.005; Harbour SN, 2015, P NATL ACAD SCI USA, V112, P7061, DOI 10.1073/pnas.1415675112; Hare EE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000106; Hatton RD, 2006, IMMUNITY, V25, P717, DOI 10.1016/j.immuni.2006.09.007; Hu D, 2020, P NATL ACAD SCI USA, V117, P30639, DOI 10.1073/pnas.2007935117; Imbratta C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42486-2; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Iwakura Y, 2006, J CLIN INVEST, V116, P1218, DOI 10.1172/JCI28508; Kebir H, 2007, NAT MED, V13, P1173, DOI 10.1038/nm1651; Kebir H, 2009, ANN NEUROL, V66, P390, DOI 10.1002/ana.21748; Kellis M, 2014, P NATL ACAD SCI USA, V111, P6131, DOI 10.1073/pnas.1318948111; Kim SK., MSBOSTON 2014 C, P396; Klemm SL, 2019, NAT REV GENET, V20, P207, DOI 10.1038/s41576-018-0089-8; Koliesnik IO, 2018, IMMUNOBIOLOGY, V223, P191, DOI 10.1016/j.imbio.2017.10.026; Krummey SM, 2014, AM J TRANSPLANT, V14, P607, DOI 10.1111/ajt.12600; Lebson L, 2010, J IMMUNOL, V185, P7161, DOI 10.4049/jimmunol.1002750; Lee JY., 2020, PREPRINT, DOI [10.2139/ssrn.3758209, DOI 10.2139/SSRN.3758209]; Lee PH, 2014, J IMMUNOL, V192, P178, DOI 10.4049/jimmunol.1301372; Lee PW, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91663; Lee W, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.157; Lee Y, 2012, NAT IMMUNOL, V13, P991, DOI 10.1038/ni.2416; Li Q, 2013, ACTA BIOCH BIOPH SIN, V45, P593, DOI 10.1093/abbs/gmt049; Luu M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08711-2; McGeachy MJ, 2011, NAT IMMUNOL, V12, P521, DOI 10.1038/ni.2044; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Miura S, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075-021-02520-z; Muranski P, 2011, IMMUNITY, V35, P972, DOI 10.1016/j.immuni.2011.09.019; Nicholas E., 2016, LANCET NEUROL, V18, P88; Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109; Qian Y, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109602; Qiu R, 2020, J IMMUNOL, V204, P3160, DOI 10.4049/jimmunol.2000060; Qu XB, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1579-0; Quintana FJ, 2012, NAT IMMUNOL, V13, P770, DOI 10.1038/ni.2363; Ramesh R, 2014, J EXP MED, V211, P89, DOI 10.1084/jem.20130301; Ratajewski M, 2012, J IMMUNOL, V189, P3034, DOI 10.4049/jimmunol.1200519; Raveney BJE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056595; Restorick SM, 2017, BRAIN BEHAV IMMUN, V64, P71, DOI 10.1016/j.bbi.2017.03.008; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Shetty A, 2021, ACS OMEGA, V6, P24834, DOI 10.1021/acsomega.1c03681; Shi ZR, 2021, ARTHRITIS RHEUMATOL, V73, P2271, DOI 10.1002/art.41882; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Stockinger B, 2017, NAT REV IMMUNOL, V17, P535, DOI 10.1038/nri.2017.50; Sun H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-38189-9; Sweeney CM, 2011, BRAIN BEHAV IMMUN, V25, P1170, DOI 10.1016/j.bbi.2011.03.007; Tsompana M, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-33; Tzartos JS, 2008, AM J PATHOL, V172, P146, DOI 10.2353/ajpath.2008.070690; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Voss TC, 2014, NAT REV GENET, V15, P69, DOI 10.1038/nrg3623; Wang LM, 2018, BRAIN BEHAV IMMUN, V68, P44, DOI 10.1016/j.bbi.2017.09.015; Wei L, 2007, J BIOL CHEM, V282, P34605, DOI 10.1074/jbc.M705100200; Xu JN, 2009, J IMMUNOL, V182, P6226, DOI 10.4049/jimmunol.0900123; Yang YH, 2009, J EXP MED, V206, P1549, DOI 10.1084/jem.20082584; Yasuda K, 2019, SEMIN IMMUNOPATHOL, V41, P283, DOI 10.1007/s00281-019-00733-8; Yoshida Y, 2014, IMMUNITY, V40, P187, DOI 10.1016/j.immuni.2013.11.022; Yu XF, 2013, SCIENCE, V342, P727, DOI 10.1126/science.1243884; Zhang F, 2014, MUCOSAL IMMUNOL, V7, P521, DOI 10.1038/mi.2013.69; Zhao M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38619; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	78	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								864314	10.3389/fimmu.2022.864314	http://dx.doi.org/10.3389/fimmu.2022.864314			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A8OC	35514969	Green Published, gold			2022-12-18	WOS:000809754100001
J	Huang, XL; Luu, LDW; Jia, N; Zhu, J; Fu, J; Xiao, F; Liu, CY; Li, SN; Shu, GX; Hou, J; Kang, M; Zhang, D; Xu, YJ; Wang, Y; Cui, XD; Lai, JM; Li, JQ; Tai, J				Huang, Xiaolan; Luu, Laurence Don Wai; Jia, Nan; Zhu, Jia; Fu, Jin; Xiao, Fei; Liu, Chunyan; Li, Shengnan; Shu, Gaixiu; Hou, Jun; Kang, Min; Zhang, Dan; Xu, Yingjie; Wang, Yi; Cui, Xiaodai; Lai, Jianming; Li, Jieqiong; Tai, Jun			Multi-Platform Omics Analysis Reveals Molecular Signatures for Pathogenesis and Activity of Systemic Lupus Erythematosus	FRONTIERS IN IMMUNOLOGY			English	Article						systemic lupus erythematosus; proteomic; metabolomic; lipidomic; pathogenesis	DYSLIPIDEMIA; AUTOIMMUNITY; COMPLEMENT	Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations and the pathogenesis of SLE is still unclear. Various omics results have been reported for SLE, but the molecular hallmarks of SLE, especially in patients with different disease activity, using an integrated multi-omics approach have not been fully investigated. Here, we collected blood samples from 10 healthy controls (HCs) and 40 SLE patients with different clinical activity including inactive (IA), low activity (LA), and high activity (HA). Using an integrative analysis of proteomic, metabolomic and lipidomic profiles, we report the multi-omics landscape for SLE. The molecular changes suggest that both the complement system and the inflammatory response were activated in SLEs and were associated with disease activity. Additionally, activation of the immunoglobulin mediated immune response were observed in the LA stage of the disease, however this immune response was suppressed slightly in the HA stage. Finally, an imbalance in lipid metabolism, especially in sphingolipid metabolism, accompanied with dysregulated apolipoproteins were observed to contribute to the disease activity of SLE. The multi-omics data presented in this study and the characterization of peripheral blood from SLE patients may thus help provide important clues regarding the pathogenesis of SLE.					Li, jie/GXG-4583-2022; wang, yiting/GYU-5306-2022	Wang, Yi/0000-0002-2031-087X	Public service development and reform pilot project of Beijing Medical Research Institute [BMR2019-11]; National natural science foundation of China [81970900]; Beijing Social Science Foundation Project [19GLB033]	Public service development and reform pilot project of Beijing Medical Research Institute; National natural science foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Social Science Foundation Project	This work was supported by grants from Public service development and reform pilot project of Beijing Medical Research Institute (BMR2019-11), National natural science foundation of China (81970900) and Beijing Social Science Foundation Project (19GLB033).	Angel A.Q., 2021, STATPEARLS, P2021; Bashant KR, 2021, ANN RHEUM DIS, V80, P209, DOI 10.1136/annrheumdis-2020-218338; Basta F, 2020, RHEUMATOL THER, V7, P433, DOI 10.1007/s40744-020-00212-9; Chen C, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.04.58; Chen JQ, 2016, CLIN REV ALLERG IMMU, V50, P1, DOI 10.1007/s12016-015-8473-z; Collins CE, 2020, RHEUMATOL THER, V7, P949, DOI 10.1007/s40744-020-00243-2; Dong Z, 2011, MOL MED, V17, P1357, DOI 10.2119/molmed.2011.00186; Durante Alessandro, 2015, J Clin Med Res, V7, P379, DOI 10.14740/jocmr2122w; Fava A, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138345; Gladman DD, 2002, J RHEUMATOL, V29, P288; Hammad SM, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.694318; Harden OC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.586737; Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1; Kanter JE, 2019, J CLIN INVEST, V129, P4165, DOI 10.1172/JCI127308; Kwankaew J, 2015, INT J RHEUM DIS, V18, P447, DOI 10.1111/1756-185X.12384; Lintner KE, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00036; Lou HT, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02928-6; Lu L, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8040105; Macedo ACL, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00055; Margery-Muir AA, 2017, AUTOIMMUN REV, V16, P258, DOI 10.1016/j.autrev.2017.01.007; Martin M, 2016, IMMUNOL REV, V274, P218, DOI 10.1111/imr.12462; Nagafuchi Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020140; Pan L, 2020, WORLD J PEDIATR, V16, P19, DOI 10.1007/s12519-019-00229-3; Ruchakorn N, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-2029-1; Ryu H, 2019, MOL CELLS, V42, P747, DOI 10.14348/molcells.2019.0196; Song LJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-175; Szabo MZ, 2017, IMMUNOL RES, V65, P543, DOI 10.1007/s12026-016-8892-9; Taylor PR, 2000, J EXP MED, V192, P359, DOI 10.1084/jem.192.3.359; Teruel M, 2017, RHEUMATOLOGY, V56, P78, DOI 10.1093/rheumatology/kew339; Trouw LA, 2017, NAT REV RHEUMATOL, V13, DOI 10.1038/nrrheum.2017.125; Volz R, 2021, BMC BIOTECHNOL, V21, DOI 10.1186/s12896-020-00661-8; Wang YD, 2020, DISCOV MED, V30, P49; Xiao ZX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0139-5; Yap DYH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246231; Zhong LJ, 2017, INT J CLIN EXP PATHO, V10, P10681	35	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								833699	10.3389/fimmu.2022.833699	http://dx.doi.org/10.3389/fimmu.2022.833699			15	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A9CL	35514958	Green Published, gold			2022-12-18	WOS:000809791800001
J	Kuttke, M; Hromadova, D; Yildirim, C; Brunner, JS; Vogel, A; Paar, H; Peters, S; Weber, M; Hofmann, M; Kerndl, M; Kieler, M; Datler, H; Musiejovsky, L; Salzmann, M; Lang, MCL; Soukup, K; Halfmann, A; Sharif, O; Schabbauer, G				Kuttke, Mario; Hromadova, Dominika; Yildirim, Ceren; Brunner, Julia S.; Vogel, Andrea; Paar, Hannah; Peters, Sophie; Weber, Maria; Hofmann, Melanie; Kerndl, Martina; Kieler, Markus; Datler, Hannes; Musiejovsky, Laszlo; Salzmann, Manuel; Lang, Michaela; Soukup, Klara; Halfmann, Angela; Sharif, Omar; Schabbauer, Gernot			PI3K Signaling in Dendritic Cells Aggravates DSS-Induced Colitis	FRONTIERS IN IMMUNOLOGY			English	Article						PI3K; PTEN; dendritic cells; DSS-induced colitis; Interleukin-6; Th1-response	SPONTANEOUS PROLIFERATION; GERM-FREE; INFLAMMATION; INNATE; MICE; IL-6; PATHWAY; DISEASE; INDUCTION; LIGAND	Aberrant innate immune responses to the gut microbiota are causally involved in the pathogenesis of inflammatory bowel diseases (IBD). The exact triggers and main signaling pathways activating innate immune cells and how they modulate adaptive immunity in IBD is still not completely understood. Here, we report that the PI3K/PTEN signaling pathway in dendritic cells enhances IL-6 production in a model of DSS-induced colitis. This results in exacerbated Th1 cell responses and increased mortality in DC-specific PTEN knockout (PTEN Delta DC) animals. Depletion of the gut microbiota using antibiotics as well as blocking IL-6R signaling rescued mortality in PTEN Delta DC mice, whereas adoptive transfer of Flt3L-derived PTEN-/- DCs into WT recipients exacerbated DSS-induced colitis and increased mortality. Taken together, we show that the PI3K signaling pathway in dendritic cells contributes to disease pathology by promoting IL-6 mediated Th1 responses.						Hromadova, Dominika/0000-0002-7888-0090; Lang, Michaela/0000-0002-8444-3719; Halfmann, Angela/0000-0002-1068-3322; Vogel, Andrea/0000-0002-2613-140X	Austrian Science Fund (FWF) [P24802, P30026, P31106]	Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	Funding The present study was funded by the Austrian Science Fund (FWF) projects P24802, P30026 to GS and P31106 to MKu.	Abe K, 2007, P NATL ACAD SCI USA, V104, P17022, DOI 10.1073/pnas.0708469104; Anderson P, 2013, GUT, V62, P1131, DOI 10.1136/gutjnl-2012-302152; Berndt BE, 2007, J IMMUNOL, V179, P6255, DOI 10.4049/jimmunol.179.9.6255; Czarnewski P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10769-x; Feng T, 2010, J EXP MED, V207, P1321, DOI 10.1084/jem.20092253; Golinski ML, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00032; Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025; Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001; Guo YX, 2021, INT J BIOL SCI, V17, P204, DOI 10.7150/ijbs.51362; Gupta J., 2014, BIOPROTOC, V4, pe1289, DOI [10.21769/BioProtoc.1289, DOI 10.21769/BIOPROTOC.1289]; Hakansson A, 2015, CLIN EXP MED, V15, P107, DOI 10.1007/s10238-013-0270-5; Hernandez-Chirlaque C, 2016, J CROHNS COLITIS, V10, P1324, DOI 10.1093/ecco-jcc/jjw096; Ito R, 2006, CLIN EXP IMMUNOL, V146, P330, DOI 10.1111/j.1365-2249.2006.03214.x; Kang SJ, 2019, IMMUNITY, V50, P1007, DOI 10.1016/j.immuni.2019.03.026; Kitajima S, 2001, EXP ANIM TOKYO, V50, P387, DOI 10.1538/expanim.50.387; Knop L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00140; Kral JB, 2016, SCI REP-UK, V6, DOI 10.1038/srep23034; Kuhn KA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114195; Kuttke M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1164918; Li BF, 2018, J IMMUNOL, V201, P2934, DOI 10.4049/jimmunol.1800016; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Luyendyk JP, 2008, J IMMUNOL, V180, P4218, DOI 10.4049/jimmunol.180.6.4218; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Nish SA, 2014, ELIFE, V3, DOI 10.7554/eLife.01949; Noguchi D, 2007, INT IMMUNOL, V19, P1431, DOI 10.1093/intimm/dxm114; Pastorelli Luca, 2011, Therap Adv Gastroenterol, V4, P311, DOI 10.1177/1756283X11410770; Pastorelli L, 2010, P NATL ACAD SCI USA, V107, P8017, DOI 10.1073/pnas.0912678107; Powell N, 2015, GASTROENTEROLOGY, V149, P456, DOI 10.1053/j.gastro.2015.04.017; Qualls JE, 2009, INFLAMM BOWEL DIS, V15, P236, DOI 10.1002/ibd.20733; Roy U, 2017, CELL REP, V21, P994, DOI 10.1016/j.celrep.2017.09.097; Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045; Sahin E, 2014, J IMMUNOL, V193, P5350, DOI 10.4049/jimmunol.1490039; Sahin E, 2015, J IMMUNOL, V195, P2560, DOI 10.4049/jimmunol.1402511; Sathaliyawala T, 2010, IMMUNITY, V33, P597, DOI 10.1016/j.immuni.2010.09.012; Schabbauer G, 2010, J IMMUNOL, V185, P468, DOI 10.4049/jimmunol.0902221; Shea-Donohue T, 2008, INNATE IMMUN-LONDON, V14, P117, DOI 10.1177/1753425908088724; Stagg AJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02883; Tajima M, 2008, J EXP MED, V205, P1019, DOI 10.1084/jem.20071133; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Waldner MJ, 2014, SEMIN IMMUNOL, V26, P75, DOI 10.1016/j.smim.2013.12.003; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Yamamoto M, 2000, J IMMUNOL, V164, P4878, DOI 10.4049/jimmunol.164.9.4878	42	0	0	5	6	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								695576	10.3389/fimmu.2022.695576	http://dx.doi.org/10.3389/fimmu.2022.695576			11	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B1BP	35514976	Green Published, gold			2022-12-18	WOS:000809929400001
J	Li, S; Zou, DW; Chen, WH; Cheng, YT; Britz, GW; Weng, YL; Liu, ZQ				Li, Shuang; Zou, Dawei; Chen, Wenhao; Cheng, Yating; Britz, Gavin W.; Weng, Yi-Lan; Liu, Zhaoqian			Ablation of BATF Alleviates Transplant Rejection via Abrogating the Effector Differentiation and Memory Responses of CD8(+) T Cells	FRONTIERS IN IMMUNOLOGY			English	Article						BATF; CD8(+) T cells; effector differentiation; allograft rejection; transplantation; memory	TRANSCRIPTION FACTOR IRF4; REGULATORY FACTOR 4; TERMINAL DIFFERENTIATION; PERIPHERAL-BLOOD; BET; CHECKPOINT; EXPRESSION; COOPERATE; EXPANSION; ZEB2	Allogeneic CD8(+) T cells are prominently involved in allograft rejection, but how their effector differentiation and function are regulated at a transcriptional level is not fully understood. Herein, we identified the basic leucine zipper ATF-like transcription factor (BATF) as a key transcription factor that drives the effector program of allogeneic CD8(+) T cells. We found that BATF is highly expressed in graft-infiltrating CD8(+) T cells, and its ablation in CD8(+) T cells significantly prolonged skin allograft survival in a fully MHC-mismatched transplantation model. To investigate how BATF dictates allogeneic CD8(+) T cell response, BATF(-/-) and wild-type (WT) CD8(+) T cells were mixed in a 1:1 ratio and adoptively transferred into B6.Rag1(-/-) mice 1 day prior to skin transplantation. Compared with WT CD8(+) T cells at the peak of rejection response, BATF(-/-) CD8(+) T cells displayed a dysfunctional phenotype, evident by their failure to differentiate into CD127(-)KLRG1(+) terminal effectors, impaired proliferative capacity and production of pro-inflammatory cytokines/cytotoxic molecules, and diminished capacity to infiltrate allografts. In association with the failure of effector differentiation, BATF(-/-) CD8(+) T cells largely retained TCF1 expression and expressed significantly low levels of T-bet, TOX, and Ki67. At the memory phase, BATF-deficient CD8(+) T cells displayed impaired effector differentiation upon allogeneic antigen re-stimulation. Therefore, BATF is a critical transcriptional determinant that governs the terminal differentiation and memory responses of allogeneic CD8(+) T cells in the transplantation setting. Targeting BATF in CD8(+) T cells may be an attractive therapeutic approach to promote transplant acceptance.						Zou, Dawei/0000-0003-4130-0280				Bao K, 2016, J IMMUNOL, V197, P4371, DOI 10.4049/jimmunol.1601371; Barnitz RA, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.3946.3946; Berrien-Elliott MM, 2015, CANCER IMMUNOL RES, V3, P116, DOI 10.1158/2326-6066.CIR-14-0159; Chen Y, 2021, NAT IMMUNOL, V22, P996, DOI 10.1038/s41590-021-00965-7; Chen ZY, 2019, IMMUNITY, V51, P840, DOI 10.1016/j.immuni.2019.09.013; Choy JC, 2010, CELL DEATH DIFFER, V17, P567, DOI 10.1038/cdd.2009.161; Combadiere B, 2000, EUR J IMMUNOL, V30, P3598, DOI 10.1002/1521-4141(200012)30:12<3598::AID-IMMU3598>3.0.CO;2-E; Danilo M, 2018, CELL REP, V22, P2107, DOI 10.1016/j.celrep.2018.01.072; Delacher M, 2020, IMMUNITY, V52, P295, DOI 10.1016/j.immuni.2019.12.002; Diamond AS, 2000, J IMMUNOL, V165, P247, DOI 10.4049/jimmunol.165.1.247; Dominguez CX, 2015, J EXP MED, V212, P2041, DOI 10.1084/jem.20150186; Gerlach C, 2016, IMMUNITY, V45, P1270, DOI 10.1016/j.immuni.2016.10.018; Grusdat M, 2014, CELL DEATH DIFFER, V21, P1050, DOI 10.1038/cdd.2014.19; Harper SJF, 2015, P NATL ACAD SCI USA, V112, P12788, DOI 10.1073/pnas.1513533112; Ise W, 2011, NAT IMMUNOL, V12, P536, DOI 10.1038/ni.2037; Ishizaki K, 2007, J IMMUNOL, V178, P605, DOI 10.4049/jimmunol.178.1.605; Iwata A, 2017, NAT IMMUNOL, V18, P563, DOI 10.1038/ni.3714; Jabeen R, 2013, J CLIN INVEST, V123, P4641, DOI 10.1172/JCI69489; Jacquemont L, 2020, J AM SOC NEPHROL, V31, P876, DOI 10.1681/ASN.2019080847; Ji Y, 2011, NAT IMMUNOL, V12, P1230, DOI 10.1038/ni.2153; Kamphorst AO, 2017, P NATL ACAD SCI USA, V114, P4993, DOI 10.1073/pnas.1705327114; Kanhere A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2260; Khattar M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0225624; Kurachi M, 2014, NAT IMMUNOL, V15, P373, DOI 10.1038/ni.2834; Kuroda S, 2011, P NATL ACAD SCI USA, V108, P14885, DOI 10.1073/pnas.1105133108; Li P, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02738; Li P, 2012, NATURE, V490, P543, DOI 10.1038/nature11530; Man K, 2013, NAT IMMUNOL, V14, P1155, DOI 10.1038/ni.2710; Omilusik KD, 2018, J EXP MED, V215, P773, DOI 10.1084/jem.20171584; Omilusik KD, 2015, J EXP MED, V212, P2027, DOI 10.1084/jem.20150194; Raczkowski F, 2013, P NATL ACAD SCI USA, V110, P15019, DOI 10.1073/pnas.1309378110; Rocha PN, 2003, IMMUNOL REV, V196, P51, DOI 10.1046/j.1600-065X.2003.00090.x; Safinia N, 2010, KIDNEY INT, V78, pS2, DOI 10.1038/ki.2010.416; Schowengerdt KO, 2000, TRANSPLANTATION, V69, P2102, DOI 10.1097/00007890-200005270-00023; Schraml BU, 2009, NATURE, V460, P405, DOI 10.1038/nature08114; Sekine T, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aba7918; Seo H, 2021, NAT IMMUNOL, V22, P983, DOI 10.1038/s41590-021-00964-8; Soares A, 2010, J IMMUNOL METHODS, V362, P43, DOI 10.1016/j.jim.2010.08.007; Sopel N, 2016, CYTOKINE GROWTH F R, V30, P39, DOI 10.1016/j.cytogfr.2016.03.004; Sullivan BM, 2003, P NATL ACAD SCI USA, V100, P15818, DOI 10.1073/pnas.2636938100; Tiemessen MM, 2014, J IMMUNOL, V193, P5480, DOI 10.4049/jimmunol.1303417; Topchyan P, 2021, CANCERS, V13, DOI 10.3390/cancers13061263; Tsukumo S, 2013, P NATL ACAD SCI USA, V110, P10735, DOI 10.1073/pnas.1306691110; Wang CW, 2013, J EXP MED, V210, P475, DOI 10.1084/jem.20121088; Wang YX, 2022, AM J TRANSPLANT, V22, P414, DOI 10.1111/ajt.16861; Williams KL, 2001, EUR J IMMUNOL, V31, P1620, DOI 10.1002/1521-4141(200105)31:5<1620::AID-IMMU1620>3.0.CO;2-3; Wong YC, 2016, CLIN TRANSL IMMUNOL, V5, DOI 10.1038/cti.2016.53; Wu J, 2017, IMMUNITY, V47, P1114, DOI 10.1016/j.immuni.2017.11.003; Yang CY, 2011, NAT IMMUNOL, V12, P1221, DOI 10.1038/ni.2158; Yao SY, 2013, IMMUNITY, V39, P833, DOI 10.1016/j.immuni.2013.10.007; Yap M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00547; Youssef AR, 2004, TRANSPL IMMUNOL, V13, P297, DOI 10.1016/j.trim.2004.10.005; Zhu YB, 2010, J IMMUNOL, V185, P3174, DOI 10.4049/jimmunol.1000749; Zou DW, 2020, IMMUNOLOGY, V161, P364, DOI 10.1111/imm.13258; Zou DW, 2020, AM J TRANSPLANT, V20, P2540, DOI 10.1111/ajt.15870	55	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								882721	10.3389/fimmu.2022.882721	http://dx.doi.org/10.3389/fimmu.2022.882721			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A8BE	35514970	gold, Green Published			2022-12-18	WOS:000809720100001
J	Mocci, S; Littera, R; Tranquilli, S; Provenzano, A; Mascia, A; Cannas, F; Lai, SR; Giuressi, E; Chessa, L; Angioni, G; Campagna, M; Firinu, D; Del Zompo, M; La Nasa, G; Perra, A; Giglio, S				Mocci, Stefano; Littera, Roberto; Tranquilli, Stefania; Provenzano, Aldesia; Mascia, Alessia; Cannas, Federica; Lai, Sara; Giuressi, Erika; Chessa, Luchino; Angioni, Goffredo; Campagna, Marcello; Firinu, Davide; Del Zompo, Maria; La Nasa, Giorgio; Perra, Andrea; Giglio, Sabrina			A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population	FRONTIERS IN IMMUNOLOGY			English	Article						COVID-19; SARS-CoV-2; Neanderthal Covid-19 risk haplotype; rs35044562 variant; HLA-A*02; 01; B*18; DRB*03 extended haplotype	CELL; INFECTION; DIVERSITY; HISTORY; GENOME; GENES	Sardinia has one of the lowest incidences of hospitalization and related mortality in Europe and yet a very high frequency of the Neanderthal risk locus variant on chromosome 3 (rs35044562), considered to be a major risk factor for a severe SARS-CoV-2 disease course. We evaluated 358 SARS-CoV-2 patients and 314 healthy Sardinian controls. One hundred and twenty patients were asymptomatic, 90 were pauci-symptomatic, 108 presented a moderate disease course and 40 were severely ill. All patients were analyzed for the Neanderthal-derived genetic variants reported as being protective (rs1156361) or causative (rs35044562) for severe illness. The beta degrees 39 C>T Thalassemia variant (rs11549407), HLA haplotypes, KIR genes, KIRs and their HLA class I ligand combinations were also investigated. Our findings revealed an increased risk for severe disease in Sardinian patients carrying the rs35044562 high risk variant [OR 5.32 (95% CI 2.53 - 12.01), p = 0.000]. Conversely, the protective effect of the HLA-A*02:01, B*18:01, DRB*03:01 three-loci extended haplotype in the Sardinian population was shown to efficiently contrast the high risk of a severe and devastating outcome of the infection predicted for carriers of the Neanderthal locus [OR 15.47 (95% CI 5.8 - 41.0), p < 0.0001]. This result suggests that the balance between risk and protective immunogenetic factors plays an important role in the evolution of COVID-19. A better understanding of these mechanisms may well turn out to be the biggest advantage in the race for the development of more efficient drugs and vaccines.					LAI, SARA/GXV-2963-2022; Cannas, Federica/AHB-0677-2022; Chessa, Luchino/H-7561-2012	Cannas, Federica/0000-0001-9827-2730; PROVENZANO, ALDESIA/0000-0002-4249-8412; Chessa, Luchino/0000-0002-9474-0995				Ahmadi K, 2020, J FAM MED PRIM CARE, V9, P4473, DOI 10.4103/jfmpc.jfmpc_733_20; Aneli S, 2021, HUM GENET, V140, P1417, DOI 10.1007/s00439-021-02328-6; [Anonymous], DISP RISK OUTC COVID; [Anonymous], 2021, MINISTERO SALUTE; Asgari S, 2021, NATURE, V600, P390, DOI 10.1038/d41586-021-01773-7; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Bertuzzo E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18050-2; Calo CM, 2021, ANN HUM BIOL, V48, P203, DOI 10.1080/03014460.2021.1944312; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Cerwenka A, 2001, IMMUNOL REV, V181, P158, DOI 10.1034/j.1600-065X.2001.1810113.x; Chakraborty C, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724936; Chiang CWK, 2018, NAT GENET, V50, P1426, DOI 10.1038/s41588-018-0215-8; Cisneros E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00440; Correale P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155205; Deb P, 2022, HLA, V99, P281, DOI 10.1111/tan.14560; Di Gaetano C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091237; Douillard V, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.774922; Ellinghaus D, 2020, NEW ENGL J MED, V383, P1522, DOI 10.1056/NEJMoa2020283; Eurostat, 2021, EUROPEAN COMMISSION; Fiorito G, 2016, EUR J HUM GENET, V24, P1056, DOI 10.1038/ejhg.2015.233; Galanello R, 2010, ORPHANET J RARE DIS, V5, DOI 10.1186/1750-1172-5-11; Gomez-Lozano N, 2002, TISSUE ANTIGENS, V59, P184, DOI 10.1034/j.1399-0039.2002.590302.x; Guilger-Casagrande M, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.598875; GUMPERZ JE, 1995, J EXP MED, V181, P1133, DOI 10.1084/jem.181.3.1133; Hajeer A, 2022, CLIN IMMUNOL, V234, DOI 10.1016/j.clim.2021.108911; Huffman JE, 2022, NAT GENET, V54, P125, DOI 10.1038/s41588-021-00996-8; ISTAT, US; Jiang W, 2012, GENOME RES, V22, P1845, DOI 10.1101/gr.137976.112; Komarova NL, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2020.0518; Kristiansen H, 2010, J VIROL, V84, P11898, DOI 10.1128/JVI.01003-10; Kumar R, 2021, CURR GENOMICS, V22, P339, DOI 10.2174/1389202922666210921101728; Langton DJ, 2021, HLA, V98, P14, DOI 10.1111/tan.14284; Littera R, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0255608; Littera R, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.605688; Marcus JH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14523-6; Maruthamuthu S, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.845474; Melis M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226615; Migliorini F, 2021, EUR J MED RES, V26, DOI 10.1186/s40001-021-00563-1; Niemi MEK, 2021, NATURE, V600, P472, DOI 10.1038/s41586-021-03767-x; Novelli A, 2020, HLA, V96, P610, DOI 10.1111/tan.14047; Olivieri A, 2017, MOL BIOL EVOL, V34, P1230, DOI 10.1093/molbev/msx082; Pisanti S, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02515-5; Prufer K, 2017, SCIENCE, V358, P655, DOI 10.1126/science.aao1887; Roy Sourav, 2020, SN Compr Clin Med, V2, P1077, DOI 10.1007/s42399-020-00376-z; Secolin R, 2021, HUM GENOME VAR, V8, DOI 10.1038/s41439-021-00146-w; SeyedAlinaghi S, 2021, EUR J MED RES, V26, DOI 10.1186/s40001-021-00516-8; Sikora M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004353; Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596; Vernot B, 2014, SCIENCE, V343, P1017, DOI 10.1126/science.1245938; Vilches C, 2007, TISSUE ANTIGENS, V70, P415, DOI 10.1111/j.1399-0039.2007.00923.x; Villalobos C, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00489; Wang YB, 2020, CYTOKINE, V126, DOI 10.1016/j.cyto.2019.154867; Zeberg H, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026309118; Zeberg H, 2020, NATURE, V587, P610, DOI 10.1038/s41586-020-2818-3; Zhang Q, 2022, NATURE, V603, P587, DOI [10.1038/s41586-022-04447-0, 10.1159/000524200]; Zoledziewska M, 2015, NAT GENET, V47, P1352, DOI 10.1038/ng.3403	56	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								891147	10.3389/fimmu.2022.891147	http://dx.doi.org/10.3389/fimmu.2022.891147			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B0UK	35514995	Green Published, gold			2022-12-18	WOS:000809910100001
J	Motsoeneng, BM; Dhar, N; Nunes, MC; Krammer, F; Madhi, SA; Moore, PL; Richardson, SI				Motsoeneng, Boitumelo M.; Dhar, Nisha; Nunes, Marta C.; Krammer, Florian; Madhi, Shabir A.; Moore, Penny L.; Richardson, Simone I.			Influenza Vaccination Results in Differential Hemagglutinin Stalk-Specific Fc-Mediated Functions in Individuals Living With or Without HIV	FRONTIERS IN IMMUNOLOGY			English	Article						influenza vaccination; Fc effector functions; HIV co-infection; hemagglutinin stalk antibodies; antibody-dependent cellular phagocytosis (ADCP); antibody-dependent complement deposition (ADCD); antibody- dependent cellular cytotoxicity (ADCC)	DEPENDENT CELLULAR CYTOTOXICITY; 2009 H1N1 INFLUENZA; ANTIBODY-RESPONSES; SOUTH-AFRICA; DOUBLE-BLIND; PROTECTION; VACCINES; ADULTS; IMMUNOGENICITY; GLYCOSYLATION	Influenza virus hemagglutinin (HA) stalk-specific antibodies have been shown to potently induce Fc-mediated effector functions which are important in protection from disease. In placebo-controlled maternal influenza (MatFlu) vaccination trials of pregnant women living with or without HIV, reduced risk of influenza illness was associated with high HA stalk antibody titers following trivalent inactivated vaccination (TIV). However, the mechanisms of immunity conferred by the HA stalk antibodies were not well understood. Here, we investigated HA stalk-specific Fc effector functions including antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent complement deposition (ADCD), and Fc gamma RIIa and Fc gamma RIIIa binding in response to seasonal influenza vaccination. These were measured pre- and 1-month post-vaccination in 141 HIV-uninfected women (67 TIV and 74 placebo recipients) and 119 women living with HIV (WLWH; 66 TIV and 53 placebo recipients). In contrast to HIV-uninfected women, where HA stalk-specific ADCP and Fc gamma RIIa binding were significantly boosted, WLWH showed no increase in response to vaccination. HA stalk-specific ADCC potential and Fc gamma RIIIa binding were not boosted regardless of HIV status but were higher in WLWH compared with HIV-uninfected women prior to vaccination. HA stalk-specific ADCD was significantly increased by vaccination in all women, but was significantly lower in the WLWH both pre- and post- vaccination. Co-ordination between HA stalk-specific ADCP and ADCD in WLWH was improved by vaccination. Fc polyfunctionality was enhanced by vaccination in HIV-uninfected women and driven by the HA stalk antibody titers. However, in the WLWH, higher pre-vaccination Fc polyfunctionality was maintained post-vaccination but was decoupled from titer. Overall, we showed differential regulation of Fc effector HA stalk responses, suggesting that HIV infection results in unique humoral immunity in response to influenza vaccination, with relevance for future strategies that aim to target the HA stalk in this population.					Krammer, Florian/H-3237-2019	Krammer, Florian/0000-0003-4121-776X				Ackerman ME, 2013, J CLIN INVEST, V123, P2183, DOI 10.1172/JCI65708; Ackerman ME, 2011, J IMMUNOL METHODS, V366, P8, DOI 10.1016/j.jim.2010.12.016; Alter G, 2018, SEMIN IMMUNOL, V39, P102, DOI 10.1016/j.smim.2018.05.003; Ana-Sosa-Batiz F, 2017, VACCINE, V35, P6451, DOI 10.1016/j.vaccine.2017.09.062; Ana-Sosa-Batiz F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154461; Andrews SF, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aan2676; Arunkumar GA, 2019, J VIROL, V93, DOI 10.1128/JVI.01696-18; Boudreau CM, 2020, J CLIN INVEST, V130, P662, DOI 10.1172/JCI129520; Boudreau CM, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00440; Butler SE, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.618685; Cheng HD, 2021, RETROVIROLOGY, V18, DOI 10.1186/s12977-021-00579-9; Chromikova V, 2020, VACCINE, V38, P1953, DOI 10.1016/j.vaccine.2020.01.008; Chung AW, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007736; Cohen C, 2012, CLIN INFECT DIS, V55, P996, DOI 10.1093/cid/cis549; Cooper C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017758; Dhar N, 2020, CLIN INFECT DIS, V71, P1072, DOI 10.1093/cid/ciz927; DiLillo DJ, 2014, NAT MED, V20, P143, DOI 10.1038/nm.3443; Estrada LD, 2019, J IMMUNOL, V202, P392, DOI 10.4049/jimmunol.1801054; Fischinger S, 2019, J IMMUNOL METHODS, V473, DOI 10.1016/j.jim.2019.07.002; Florek KR, 2014, J VIROL, V88, P13418, DOI 10.1128/JVI.01219-14; HASHIMOTO G, 1983, J INFECT DIS, V148, P785, DOI 10.1093/infdis/148.5.785; Jegaskanda S, 2016, J INFECT DIS, V214, P945, DOI 10.1093/infdis/jiw262; Jegaskanda S, 2013, J INFECT DIS, V208, P1051, DOI 10.1093/infdis/jit294; Kirkpatrick E, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28706-1; Kristensen AB, 2016, J VIROL, V90, P5724, DOI 10.1128/JVI.00285-16; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; Lau YF, 2017, HUM VACC IMMUNOTHER, V13, P551, DOI 10.1080/21645515.2016.1246636; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Madhi SA, 2014, NEW ENGL J MED, V371, P918, DOI 10.1056/NEJMoa1401480; Madhi SA, 2011, CLIN INFECT DIS, V52, P128, DOI 10.1093/cid/ciq004; Malaspina A, 2005, J INFECT DIS, V191, P1442, DOI 10.1086/429298; McMorrow ML, 2019, VACCINE, V37, P25, DOI 10.1016/j.vaccine.2018.11.048; Miller MS, 2013, J INFECT DIS, V207, P98, DOI 10.1093/infdis/jis652; Mullarkey CE, 2016, MBIO, V7, DOI 10.1128/mBio.01624-16; Natarajan H, 2021, MBIO, V12, DOI 10.1128/mBio.00765-21; Nunes MC, 2020, LANCET HIV, V7, pE91, DOI 10.1016/S2352-3018(19)30322-4; Ohmit SE, 2011, J INFECT DIS, V204, P1879, DOI 10.1093/infdis/jir661; Pallikkuth S, 2018, AIDS, V32, P1085, DOI 10.1097/QAD.0000000000001774; Rattan A, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006248; Richardson SI, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006987; Tan GS, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005578; Tasker SA, 1999, ANN INTERN MED, V131, P430, DOI 10.7326/0003-4819-131-6-199909210-00006; Tebas P, 2010, AIDS, V24, P2187, DOI 10.1097/QAD.0b013e32833c6d5c; Tempia S, 2019, CLIN INFECT DIS, V69, P1036, DOI 10.1093/cid/ciy1017; Tempia S, 2015, EMERG INFECT DIS, V21, P600, DOI 10.3201/eid2104.141033; Terajima M, 2012, J VIROL, V86, P1901, DOI 10.1128/JVI.06884-11; Vanderven HA, 2020, VACCINE, V38, P2368, DOI 10.1016/j.vaccine.2020.01.066; Vanderven HA, 2018, J INFECT DIS, V217, P12, DOI 10.1093/infdis/jix554; Vanderven HA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92750; Vanderven HA, 2017, CURR OPIN VIROL, V22, P89, DOI 10.1016/j.coviro.2016.12.002; Weinberg A, 2010, JAIDS-J ACQ IMM DEF, V55, P189, DOI 10.1097/QAI.0b013e3181e46308; Wines BD, 2016, J IMMUNOL, V197, P1507, DOI 10.4049/jimmunol.1502551	56	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								873191	10.3389/fimmu.2022.873191	http://dx.doi.org/10.3389/fimmu.2022.873191			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1DY	35514992	Green Published, gold			2022-12-18	WOS:000811297500001
J	Niznik, S; Rapoport, MJ; Avnery, O; Lubetsky, A; Yahia, SH; Ellis, MH; Agmon-Levin, N				Niznik, Stanley; Rapoport, Micha J.; Avnery, Orly; Lubetsky, Aharon; Haj Yahia, Soad; Ellis, Martin H.; Agmon-Levin, Nancy			Patterns of Recurrent Thrombosis in Primary Antiphospholipid Syndrome-Multicenter, Real-Life Long-Term Follow-Up	FRONTIERS IN IMMUNOLOGY			English	Article						antiphospholipid syndrome; thrombosis; immunology; recurrence; cardiovascular disease; AGAPSS; therapy	RISK-FACTORS; ANTICARDIOLIPIN ANTIBODIES; CLASSIFICATION CRITERIA; LUPUS ANTICOAGULANTS; CLINICAL-COURSE; TASK-FORCE; APS; MANAGEMENT; MORBIDITY; MORTALITY	BackgroundAntiphospholipid syndrome (APS) is an acquired hypercoagulable condition associated with antiphospholipid antibody (aPL) presence. Data on re-thrombosis following APS-diagnosis are limited. MethodsThis is a retrospective analysis of new thrombotic events among primary APS (pAPS) patients followed for up to 15 years in three medical centers in Israel. ResultsAmong 312 primary-APS patients, 143 (46%) had new thrombotic event classified to three patterns: (1) Arterial-associated with heart valve disease (OR 7.24, 95% C.I. 2.26-24.6), hypertension (OR 3, 95% C.I. 1.44-6.25), elevated anti-B2-GPI IgM (OR 1.04, 95% C.I. 0.996-1.08), arterial thrombosis at presentation (OR 1.74 95% C.I. 0.992-3.26), and older age (41 vs. 34 years, p < 0.001). (2) Venous-linked with venous thrombosis at presentation (OR 12.9, 95% C.I. 5.27-31.6, p < 0.001), heart valve disease (OR 9.81 95% C.I. 1.82-52.9, p = 0.018), aGAPSS (OR 1.15 95% C.I. 1.02-1.29), and younger age (31 vs. 36.5 years, p = 0.001); and (3) Combined pattern-associated with heart valve disease (OR 40.5 95% C.I. 7.7-212) and pulmonary embolism (OR 7.47 95% C.I. 1.96-28.5). A 4th variant "the Breakthrough pattern" defined by re-thrombosis despite prophylactic therapy was observed in 100/143 (70%) patients and linked with heart valve disease (OR 8. 95% C.I. 2.43-26.3), venous thrombosis at presentation (OR 2.61 95% C.I. 1.47-4.66), leg ulcers (OR 12.2, 95% C.I. 1.4-107), hypertension (OR 1.99, 95% C.I. 0.92-4.34), and higher aGAPSS (OR 1.08, 95% C.I. 0.99-1.18). ConclusionIn this real-life observation, re-thrombosis was common among pAPS patients including in those recommended to receive prophylactic therapy. Different patterns of recurrence were identified and linked with presenting symptoms, specific serological markers, APS manifestations, and comorbidities. Studies that will address interventions to prevent recurrences of APS-related events are needed.						Haj Yahia, Soad/0000-0002-9249-6052	Bayern Scholarship for research in field of thrombosis and coagulation disorders; Israeli Association of Internal Medicine	Bayern Scholarship for research in field of thrombosis and coagulation disorders; Israeli Association of Internal Medicine	Publication fees were funded by the grant from the Bayern Scholarship for research in the field of thrombosis and coagulation disorders granted to SN by Israeli Association of Internal Medicine.	Agmon-Levin N, 2021, CLIN EXP RHEUMATOL, V39, P1049, DOI 10.55563/clinexprheumatol/cc5taf; Al Jameil N, 2015, INT J CLIN EXP PATHO, V8, P3204; Alessandri C, 2017, IMMUNOL RES, V65, P524, DOI 10.1007/s12026-017-8899-x; Bazzan M, 2016, LUPUS, V25, P479, DOI 10.1177/0961203315617538; Bazzan M, 2013, AUTOIMMUN REV, V12, P826, DOI 10.1016/j.autrev.2012.11.007; Brandt JT, 1995, THROMB HAEMOSTASIS, V74, P1597; Cervera R, 2015, ANN RHEUM DIS, V74, P1011, DOI 10.1136/annrheumdis-2013-204838; Cervera R, 2011, LUPUS, V20, P165, DOI 10.1177/0961203310395051; Chighizola CB, 2018, J AUTOIMMUN, V90, P1, DOI 10.1016/j.jaut.2018.02.003; de Jesus GR, 2019, BJOG-INT J OBSTET GY, V126, P656, DOI 10.1111/1471-0528.15469; Dufrost V, 2018, AUTOIMMUN REV, V17, P1011, DOI 10.1016/j.autrev.2018.04.009; Erkan D, 2000, J RHEUMATOL, V27, P2817; Mosteirin NF, 2017, LUPUS, V26, P1328, DOI 10.1177/0961203317703493; Finazzi G, 1996, AM J MED, V100, P530, DOI 10.1016/S0002-9343(96)00060-5; Galli M, 2003, BLOOD, V101, P1827, DOI 10.1182/blood-2002-02-0441; Grika EP, 2012, J RHEUMATOL, V39, P516, DOI 10.3899/jrheum.110800; Jackson WG, 2017, BLOOD ADV, V1, P2320, DOI 10.1182/bloodadvances.2017008185; KHAMASHTA MA, 1995, NEW ENGL J MED, V332, P993, DOI 10.1056/NEJM199504133321504; Khan F, 2021, ANN INTERN MED, V174, P1420, DOI 10.7326/M21-1094; Kravvariti E, 2020, AUTOIMMUN REV, V19, DOI 10.1016/j.autrev.2020.102491; Les I, 2012, SEMIN THROMB HEMOST, V38, P339, DOI 10.1055/s-0032-1304720; Miyakis S, 2006, J THROMB HAEMOST, V4, P295, DOI 10.1111/j.1538-7836.2006.01753.x; Pengo V, 2010, J THROMB HAEMOST, V8, P237, DOI 10.1111/j.1538-7836.2009.03674.x; Petri M, 2012, ARTHRITIS RHEUM-US, V64, P2677, DOI 10.1002/art.34473; Radin M, 2017, INT J CARDIOL, V240, P72, DOI 10.1016/j.ijcard.2017.02.155; Radin M, 2019, SEMIN ARTHRITIS RHEU, V49, P464, DOI 10.1016/j.semarthrit.2019.04.009; Rodriguez-Pinto I, 2016, AUTOIMMUN REV, V15, P1120, DOI 10.1016/j.autrev.2016.09.010; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; Ruiz-Irastorza G, 2011, LUPUS, V20, P206, DOI 10.1177/0961203310395803; Sayar Z, 2021, THROMB RES, V198, P213, DOI 10.1016/j.thromres.2020.10.010; Sciascia S, 2013, RHEUMATOLOGY, V52, P1397, DOI 10.1093/rheumatology/kes388; Taraborelli M, 2017, J RHEUMATOL, V44, P1165, DOI 10.3899/jrheum.161364; Tektonidou MG, 2019, ANN RHEUM DIS, V78, P1296, DOI 10.1136/annrheumdis-2019-215213; Turiel M, 2005, STROKE, V36, P1490, DOI 10.1161/01.STR.0000170645.40562.09; Urbanski G, 2018, STROKE, V49, P2770, DOI 10.1161/STROKEAHA.118.023021; Vinatier D, 2001, EUR J OBSTET GYN R B, V96, P37, DOI 10.1016/S0301-2115(00)00404-8; Volkov I, 2020, AUTOIMMUN HIGHLIGHTS, V11, DOI 10.1186/s13317-020-00131-3	37	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								843718	10.3389/fimmu.2022.843718	http://dx.doi.org/10.3389/fimmu.2022.843718			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2B1JH	35514968	gold, Green Published			2022-12-18	WOS:000809949900001
J	Sekiya, T				Sekiya, Takashi			Comparison Between Nr4a Transcription Factor Regulation and Function in Lymphoid and Tumor Treg Cells	FRONTIERS IN IMMUNOLOGY			English	Review						Treg; antitumor immunity; autoimmunity; Nr4a; PGE2	STEROID-RECEPTOR NUR77; T-CELLS; NUCLEAR RECEPTORS; CLONAL DELETION; APOPTOSIS; BCL-2; REG; DIFFERENTIATION; PROTECTOR; SELECTION	Although the "lymphoid" function of regulatory T (Treg) cells is crucial for organismal homeostasis, these cells are also known to suppress the antitumor immune response in the tumor microenvironments. Thus, a detailed understanding of Treg cell maintenance and function in both lymphoid organs and tumor environments may help to establish novel methods for the reactivating antitumor immunity, while retaining necessary immune tolerance towards self and non-hazardous antigens. Previous studies have hypothesized that Treg cells behave similarly in lymphoid organs and in tumor environments; however, few studies have been conducted specifically researching Treg cell activity in tumor environments. In addition, several recent studies identified a novel mechanism regulating Treg cell function in tumor environments. Our group has previously described the critical roles of the Nr4a family of nuclear orphan receptors, comprising Nr4a1, Nr4a2, and Nr4a3, in the differentiation and maintenance of Treg cells in lymphoid organs. Subsequently, it was found that Nr4a factors help to maintain Treg cell function in tumor environments, thereby playing a suppressive role against T cell antitumor immunity. Importantly, there were some differences between the activities of these Nr4a factors under these conditions, including the specific function of the COX/PGE2 axis in tumor environments. This review was designed to investigate the role of Nr4a factors in the regulation of Treg cell activities both in the lymphoid organs and tumor environments, highlighting the commonalities and differences in their behaviors between Treg cells in these two different environments.							JSPS KAKENHI [21H02756, 19H04822, 20H04958, 21K19393]; Takeda Science Foundation; Grant for National Center for Global Health and Medicine [20A1005]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Grant for National Center for Global Health and Medicine	This work was supported by JSPS KAKENHI Grant-in-Aid for Scientific Research (B) 21H02756, for Scientific Research on Innovative Areas 19H04822 and 20H04958, for Challenging Exploratory Research 21K19393, the Takeda Science Foundation, and Grant for National Center for Global Health and Medicine (20A1005).	Ashouri JF, 2017, J IMMUNOL, V198, P657, DOI 10.4049/jimmunol.1601301; Baldwin TA, 2007, J IMMUNOL, V179, P837, DOI 10.4049/jimmunol.179.2.837; CALNAN BJ, 1995, IMMUNITY, V3, P273; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Cheng ZK, 2011, EUR HEART J, V32, P2179, DOI 10.1093/eurheartj/ehq496; Cho SD, 2007, CANCER RES, V67, P674, DOI 10.1158/0008-5472.CAN-06-2907; Cipolletta D, 2012, NATURE, V486, P549, DOI 10.1038/nature11132; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687; Fassett MS, 2012, P NATL ACAD SCI USA, V109, P3891, DOI 10.1073/pnas.1200090109; Finetti F, 2020, BIOLOGY-BASEL, V9, DOI 10.3390/biology9120434; Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181; Hibino S, 2018, CANCER RES, V78, P3027, DOI 10.1158/0008-5472.CAN-17-3102; Hill JA, 2007, IMMUNITY, V27, P786, DOI 10.1016/j.immuni.2007.09.010; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Kamada T, 2019, P NATL ACAD SCI USA, V116, P9999, DOI 10.1073/pnas.1822001116; Kim CH, 2015, P NATL ACAD SCI USA, V112, P8756, DOI 10.1073/pnas.1509742112; Kolluri SK, 2008, CANCER CELL, V14, P285, DOI 10.1016/j.ccr.2008.09.002; Kurakula K, 2014, BBA-MOL CELL RES, V1843, P2543, DOI 10.1016/j.bbamcr.2014.06.010; Labani-Motlagh A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00940; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin W, 2007, NAT IMMUNOL, V8, P359, DOI 10.1038/ni1445; Liu XD, 2019, NATURE, V567, P525, DOI 10.1038/s41586-019-0979-8; Maira M, 2003, MOL CELL BIOL, V23, P763, DOI 10.1128/MCB.23.3.763-776.2003; Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308; Panduro M, 2016, ANNU REV IMMUNOL, V34, P609, DOI 10.1146/annurev-immunol-032712-095948; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Rodriguez PC, 2005, J EXP MED, V202, P931, DOI 10.1084/jem.20050715; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sekiya T, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102166; Sekiya T, 2018, CELL REP, V24, P1627, DOI 10.1016/j.celrep.2018.07.008; Sekiya T, 2016, MICROBES INFECT, V18, P378, DOI 10.1016/j.micinf.2016.02.004; Sekiya T, 2015, J EXP MED, V212, P1623, DOI 10.1084/jem.20142088; Sekiya T, 2013, NAT IMMUNOL, V14, P230, DOI 10.1038/ni.2520; Sekiya T, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1272; Shibutani S, 2005, TRANSPLANTATION, V79, P904, DOI 10.1097/01.TP.0000158023.21233.DE; Stritesky GL, 2012, ANNU REV IMMUNOL, V30, P95, DOI 10.1146/annurev-immunol-020711-075035; Thompson J, 2008, J EXP MED, V205, P1029, DOI 10.1084/jem.20080101; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Zagani R, 2009, GASTROENTEROLOGY, V137, P1358, DOI 10.1053/j.gastro.2009.06.039; Zhan YP, 2008, NAT CHEM BIOL, V4, P548, DOI 10.1038/nchembio.106; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	46	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								866339	10.3389/fimmu.2022.866339	http://dx.doi.org/10.3389/fimmu.2022.866339			7	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D4ZQ	35514961	Green Published, gold			2022-12-18	WOS:000811557600001
J	Sun, ZS; Xu, C; Chen, YX; Liu, DJ; Wu, P; Gao, Q				Sun, Zhaosheng; Xu, Chong; Chen, Yuxi; Liu, Danjie; Wu, Ping; Gao, Qian			Characterization of Pannexin1, Connexin32, and Connexin43 in Spotted Sea Bass (Lateolabrax maculatus): They Are Important Neuro-Related Immune Response Genes Involved in Inflammation-Induced ATP Release	FRONTIERS IN IMMUNOLOGY			English	Article						pannexin1; connexin32; connexin43; innate immunity; ATP release; Lateolabrax maculatus	GAP-JUNCTION PROTEIN; EXTRACELLULAR ATP; 1 CHANNELS; IDENTIFICATION; HEMICHANNELS; EXPRESSION; FAMILY; ROLES	Many immunological diseases can be treated by regulating neurobehavior, in which extracellular ATP is a vital member of endogenous danger-associated molecular pattern signaling molecule that plays a crucial part in innate neuro-related immunity. It is actively released through pannexin (Panx) and connexin (Cx) hemichannels from activated or stressed cells during inflammation, injury, or apoptosis. In addition to participating in ATP release, Panxs and Cxs also have crucial immune functions. In this study, pannexin1, three connexin32 isoforms and connexin43 were identified and characterized in spotted sea bass (Lateolabrax maculatus), which were named LmPanx1, LmCx32.2, LmCx32.3, LmCx32.7, and LmCx43. Their similar topological structures were discovered by sequence analysis: a relatively unconserved C-terminal region and four highly conserved transmembrane (TM) domains, and so on. Each extracellular (ECL) region of Panx1 has two conserved cysteine residues. Unlike Panx1, each ECL region of Cx32 and Cx43 contains three conserved cysteine residues, forming two conserved motifs: CX6CX3C motif in ECL1 and CX4CX5C motif in ECL2. Furthermore, Panx1 and Cx43 share similar genomic organization and synteny with their counterparts in selected vertebrates. Cx32 and CX43 were located in the same locus in fish, but diverged into two loci from amphibian. Moreover, despite varying expression levels, the identified genes were constitutively expressed in all examined tissues. All genes were upregulated by PAMP [lipopolysaccharide and poly(I:C)] stimulation or bacterial infection in vivo and in vitro, but they were downregulated in the brain at 6 or 12 h after stimulation. Especially, the three LmCx32 isoforms and LmCx43 were upregulated by ATP stimulation in primary head kidney leukocytes; however, downregulation of LmCx32.3 and LmCx43 expression were noted at 12 h. Conversely, ATP treatment inhibited the expression of LmPanx1. Importantly, we showed that the spotted sea bass Panx1, Cx43, and Cx32 were localized on the cellular membrane and involved in inflammation-induced ATP release. Taken together, our results demonstrated that Panx1, Cx32, and Cx43 are important neuro-related immune response genes involved in inflammation-induced ATP release.						Wu, Ping/0000-0002-0551-6300				Adamson SE, 2014, FEBS LETT, V588, P1416, DOI 10.1016/j.febslet.2014.03.009; Angosto D, 2012, INNATE IMMUN-LONDON, V18, P815, DOI 10.1177/1753425912441956; Bai DL, 2014, BIOCHEM J, V458, P1, DOI 10.1042/BJ20131162; Bond SR, 2012, J MEMBRANE BIOL, V245, P483, DOI 10.1007/s00232-012-9497-4; Cai X, 2022, GENE, V809, DOI 10.1016/j.gene.2021.146032; Ceelen L, 2011, CELL MOL LIFE SCI, V68, P3047, DOI 10.1007/s00018-011-0737-z; Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413; Chen H, 2020, FISH SHELLFISH IMMUN, V103, P169, DOI 10.1016/j.fsi.2020.04.063; Chen KY, 2021, GENE, V780, DOI 10.1016/j.gene.2021.145487; Chen P, 2021, NANO ENERGY, V89, DOI 10.1016/j.nanoen.2021.106327; Chen P, 2021, NANO ENERGY, V86, DOI 10.1016/j.nanoen.2021.106123; DAHL G, 1991, EUR J BIOCHEM, V197, P141, DOI 10.1111/j.1432-1033.1991.tb15892.x; Faas MM, 2017, MOL ASPECTS MED, V55, P9, DOI 10.1016/j.mam.2017.01.002; Glass AM, 2015, CELL MOL LIFE SCI, V72, P2899, DOI 10.1007/s00018-015-1966-3; Iacobas DA, 2007, GENOMICS, V89, P113, DOI 10.1016/j.ygeno.2006.09.007; Jiang XY, 2019, FISH SHELLFISH IMMUN, V87, P254, DOI 10.1016/j.fsi.2019.01.009; Kang J, 2008, J NEUROSCI, V28, P4702, DOI 10.1523/JNEUROSCI.5048-07.2008; Lazarowski ER, 2012, PURINERG SIGNAL, V8, P359, DOI 10.1007/s11302-012-9304-9; Li S, 2021, AQUACULTURE, V537, DOI 10.1016/j.aquaculture.2021.736511; Li S, 2020, FISH SHELLFISH IMMUN, V106, P181, DOI 10.1016/j.fsi.2020.07.066; Li S, 2020, INNATE IMMUN-LONDON, V26, P413, DOI 10.1177/1753425918804635; Li S, 2019, BMC VET RES, V15, DOI 10.1186/s12917-018-1763-y; Li S, 2018, FISH SHELLFISH IMMUN, V81, P470, DOI 10.1016/j.fsi.2018.07.050; Li S, 2017, FISH SHELLFISH IMMUN, V67, P536, DOI 10.1016/j.fsi.2017.06.043; Li S, 2016, FISH SHELLFISH IMMUN, V55, P348, DOI 10.1016/j.fsi.2016.06.014; Li S, 2016, FISH SHELLFISH IMMUN, V50, P79, DOI 10.1016/j.fsi.2016.01.029; Li S, 2014, FISH SHELLFISH IMMUN, V40, P164, DOI 10.1016/j.fsi.2014.06.034; Li X, 2020, FISH SHELLFISH IMMUN, V106, P1014, DOI 10.1016/j.fsi.2020.08.041; Lohman AW, 2014, FEBS LETT, V588, P1379, DOI 10.1016/j.febslet.2014.02.004; Maes M, 2015, CELL MOL LIFE SCI, V72, P2809, DOI 10.1007/s00018-015-1961-8; Okamoto T, 2011, EXP CELL RES, V317, P348, DOI 10.1016/j.yexcr.2010.10.018; Panchin Y, 2000, CURR BIOL, V10, pR473, DOI 10.1016/S0960-9822(00)00576-5; Qiu F, 2009, AM J PHYSIOL-CELL PH, V296, pC250, DOI 10.1152/ajpcell.00433.2008; SAEZ JC, 1990, EUR J BIOCHEM, V192, P263, DOI 10.1111/j.1432-1033.1990.tb19223.x; Silverman WR, 2009, J BIOL CHEM, V284, P18143, DOI 10.1074/jbc.M109.004804; Sun ZS, 2021, DEV COMP IMMUNOL, V116, DOI 10.1016/j.dci.2020.103905; Svobodova I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00192; Vinken M, 2010, CELL MOL LIFE SCI, V67, P907, DOI 10.1007/s00018-009-0220-2; Willebrords J, 2016, CRIT REV BIOCHEM MOL, V51, P413, DOI 10.1080/10409238.2016.1204980; Woehrle T, 2010, BLOOD, V116, P3475, DOI 10.1182/blood-2010-04-277707; Wood JN, 2022, AUTON NEUROSCI-BASIC, V237, DOI 10.1016/j.autneu.2021.102902; Wu P, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00709; Xie JS, 2018, DEV COMP IMMUNOL, V79, P1, DOI 10.1016/j.dci.2017.09.021; Yi L, 2017, INFECT IMMUN, V85, DOI [10.1128/IAI.00322-17, 10.1128/iai.00322-17]; Zhang XY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173238; Zhang X, 2020, FISH SHELLFISH IMMUN, V97, P58, DOI 10.1016/j.fsi.2019.12.023	46	0	0	11	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								870679	10.3389/fimmu.2022.870679	http://dx.doi.org/10.3389/fimmu.2022.870679			14	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A8AP	35514966	Green Published, gold			2022-12-18	WOS:000809718600001
J	Tian, XX; Zhang, YF; He, ZYF; Li, SS; Yan, DM; Zhu, ZQ; Wan, YM; Wang, WH				Tian, Xiangxiang; Zhang, Yifan; He, Zhangyufan; Li, Shaoshuai; Yan, Dongmei; Zhu, Zhaoqin; Wan, Yanmin; Wang, Wanhai			Successive Site Translocating Inoculation Improved T Cell Responses Elicited by a DNA Vaccine Encoding SARS-CoV-2 S Protein	FRONTIERS IN IMMUNOLOGY			English	Article						successive site translocating inoculation; DNA vaccine; protein vaccine; T cell response; antibody response	IMMUNOGENICITY; DELIVERY	A variety of methods have been explored to increase delivery efficiencies for DNA vaccine. However, the immunogenicity of DNA vaccines has not been satisfactorily improved. Unlike most of the previous attempts, we provided evidence suggesting that changing the injection site successively (successively site-translocated inoculation, SSTI) could significantly enhance the immunogenicity of DNA vaccines in a previous study. To simplify the strategy and to evaluate its impact on candidate SARS-CoV-2 vaccines, we immunized mice with either a SARS-CoV-2 spike-based DNA vaccine or a spike protein subunit vaccine via three different inoculation strategies. Our data demonstrated that S protein specific antibody responses elicited by the DNA vaccine or the protein subunit vaccine showed no significant difference among different inoculation strategies. Of interest, compared with the conventional site fixed inoculation (SFI), both successive site-translocating inoculation (SSTI) and the simplified translocating inoculation (STI) strategy improved specific T cell responses elicited by the DNA vaccine. More specifically, the SSTI strategy significantly improved both the monofunctional (IFN-gamma+IL-2(-)TNF-alpha(-)CD8(+)) and the multifunctional (IFN-gamma+IL-2(-)TNF-alpha(+)CD8(+), IFN-gamma+IL-2(-)TNF-alpha(+)CD4(+), IFN-gamma+IL-2(+)TNF-alpha(+)CD4(+)) T cell responses, while the simplified translocating inoculation (STI) strategy significantly improved the multifunctional CD8(+) (IFN-gamma+IL-2(-)TNF-alpha(+)CD8(+), IFN-gamma+IL-2(+)TNF-alpha(+)CD8(+)) and CD4(+) (IFN-gamma+IL-2(-)TNF-alpha(+)CD4(+), IFN-gamma+IL-2(+)TNF-alpha(+)CD4(+)) T cell responses. The current study confirmed that changing the site of intra muscular injection can significantly improve the immunogenicity of DNA vaccines.										Amanna IJ, 2011, VIROLOGY, V411, P206, DOI 10.1016/j.virol.2010.12.016; Baden LR, 2021, NEW ENGL J MED, V384, P403, DOI 10.1056/NEJMoa2035389; Bergmann-Leitner ES, 2015, METHODS MOL BIOL, V1325, P289, DOI 10.1007/978-1-4939-2815-6_22; Bernstein DI, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0129-1; Broni FK, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.770821; Eusebio D, 2021, DRUG DISCOV TODAY, V26, P2575, DOI 10.1016/j.drudis.2021.06.008; Fan WJ, 2020, CYTOKINE, V125, DOI 10.1016/j.cyto.2019.154814; Gopinath S, 2020, J IMMUNOL, V204, P1703, DOI 10.4049/jimmunol.1900462; Khan Kishwar Hayat, 2013, Germs, V3, P26, DOI 10.11599/germs.2013.1034; Kundu Rhia, 2022, Nat Commun, V13, P80, DOI 10.1038/s41467-021-27674-x; Kyriakidis NC, 2021, NPJ VACCINES, V6, DOI 10.1038/s41541-021-00292-w; L. Jia, 2021, medRxiv, DOI 10.1101/2021.07.13.21260404; Lang-Meli J., 2022, US, DOI [10.21203/rs.3.rs-1269004/v1, DOI 10.21203/RS.3.RS-1269004/V1]; Leifert JA., 2013, MADAME CURIE BIOSCIE, P2000; Liu MA, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7020037; Mohanan D, 2010, J CONTROL RELEASE, V147, P342, DOI 10.1016/j.jconrel.2010.08.012; Mukhopadhyay L, 2021, INDIAN J MED RES, V153, P93, DOI 10.4103/ijmr.IJMR_4431_20; Nagy A, 2021, COMPUT STRUCT BIOTEC, V19, P2508, DOI 10.1016/j.csbj.2021.04.061; Ndwandwe D, 2021, CURR OPIN IMMUNOL, V71, P111, DOI 10.1016/j.coi.2021.07.003; Park JH, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050524; Polack FP, 2020, NEW ENGL J MED, V383, P2603, DOI 10.1056/NEJMoa2034577; Pratesi F, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9060672; Qin FR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.633776; Ren YQ, 2015, SCI REP-UK, V5, DOI 10.1038/srep18099; Roces CB, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8010010; Sadarangani M, 2021, NAT REV IMMUNOL, V21, P475, DOI 10.1038/s41577-021-00578-z; Sardesai NY, 2011, CURR OPIN IMMUNOL, V23, P421, DOI 10.1016/j.coi.2011.03.008; Sauer K, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.581807; Sheridan C, 2021, NAT BIOTECHNOL, V39, P1479, DOI [10.1038/d41587-021-00023-5, 10.1038/s41587-021-01166-1]; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Shooshtari P, 2010, CYTOM PART A, V77A, P873, DOI 10.1002/cyto.a.20943; Silveira MM, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118919; Tarke A, 2022, CELL, V185, P847, DOI 10.1016/j.cell.2022.01.015; van Riel D, 2020, NAT MATER, V19, P810, DOI 10.1038/s41563-020-0746-0; Versteeg L, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040122; Wan YM, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/478052; World Health Organization, 2013, CORR VACC IND IND PR; Zhang L, 2015, EXPERT REV VACCINES, V14, P1509, DOI 10.1586/14760584.2015.1081067	38	0	0	2	2	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								875236	10.3389/fimmu.2022.875236	http://dx.doi.org/10.3389/fimmu.2022.875236			9	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D1DG	35514964	Green Published, gold			2022-12-18	WOS:000811295700001
J	Toppi, E; Sireno, L; Lembo, M; Banaj, N; Messina, B; Golesorkhtafti, S; Spalletta, G; Bossu, P				Toppi, Elisa; Sireno, Laura; Lembo, Micaela; Banaj, Nerisa; Messina, Beatrice; Golesorkhtafti, Sedigheh; Spalletta, Gianfranco; Bossu, Paola			IL-33 and IL-10 Serum Levels Increase in MCI Patients Following Homotaurine Treatment	FRONTIERS IN IMMUNOLOGY			English	Article						tramiprosate; inflammation; mild cognitive impairment; anti-inflammatory cytokines; interleukin-33; interleukin-10	MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; EPISODIC MEMORY; NEUROINFLAMMATION; TRAMIPROSATE; INFLAMMATION	Homotaurine is a potential therapeutic compound for treatment of Alzheimer's disease (AD), but its efficacy is still under investigation. Emerging data have shown that other than neuroprotective, homotaurine is endowed with anti-inflammatory activities, though with still unclear underlying mechanisms. Inflammation plays a critical role in the pathogenesis of AD and we previously suggested that homotaurine supplementation in patients with amnestic mild cognitive impairment (MCI) plays beneficial effects associated to a decrease in the circulating levels of the pro-inflammatory cytokine IL-18. Here we report that MCI patients supplemented with homotaurine for 12 months show elevated serum levels of IL-10 and IL-33, as compared to baseline, in addition to the described IL-18 decrease. Furthermore, we observed a significant positive correlation between IL-10 and IL-33 levels after treatment but not at the baseline, underlining the effectiveness of the compound in modulating both cytokines in an inter-related fashion and in regulating the pro/anti-inflammation balance. Furthermore, the elevation of both IL-10 and IL-33 is significantly associated with an improvement of episodic memory of treated patients, as measured by the Delayed Verbal Ray Test. In conclusion, our results confirm that homotaurine treatment exerts an overall anti-inflammatory action in MCI patients, based not only on the down-regulation of pro-inflammatory IL-18, but also on up-regulation of the anti-inflammatory IL-33 and IL-10 cytokines, which in turn are associated with an amelioration of patient's cognitive functions. Future studies should be addressed to investigate the molecular mechanisms of homotaurine anti-inflammatory activity and its therapeutic exploitation in early AD.					Banaj, Nerisa/AAC-3880-2022	Banaj, Nerisa/0000-0002-6317-8549; Messina, Beatrice/0000-0001-7733-8593; Lembo, Micaela/0000-0002-0693-5451	Italian Ministry of Health(RC 2018-2021)	Italian Ministry of Health(RC 2018-2021)	Funding This project was supported by the Italian Ministry of Health (RC 2018-2021; ADIMB project, CoEN 2019-Pathfinder IV).	Abushakra S, 2017, JPAD-J PREV ALZHEIM, V4, P149, DOI 10.14283/jpad.2017.26; Aisen PS, 2011, ARCH MED SCI, V7, P102, DOI 10.5114/aoms.2011.20612; Bossu P, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00285; Bossu P, 2010, CURR PHARM DESIGN, V16, P4213, DOI 10.2174/138161210794519147; Calsolaro V, 2016, ALZHEIMERS DEMENT, V12, P719, DOI 10.1016/j.jalz.2016.02.010; Caltagirone C, 2012, AGING CLIN EXP RES, V24, P580, DOI 10.3275/8585; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; Chakrabarty P, 2015, NEURON, V85, P519, DOI 10.1016/j.neuron.2014.11.020; Cuello AC, 2017, TRENDS PHARMACOL SCI, V38, P956, DOI 10.1016/j.tips.2017.07.005; Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621; Estevez-Gonzalez A, 2003, INT J GERIATR PSYCH, V18, P1021, DOI 10.1002/gps.1010; Fu AKY, 2016, P NATL ACAD SCI USA, V113, pE2705, DOI 10.1073/pnas.1604032113; Gervais F, 2007, NEUROBIOL AGING, V28, P537, DOI 10.1016/j.neurobiolaging.2006.02.015; Guillot-Sestier MV, 2015, NEURON, V85, P534, DOI 10.1016/j.neuron.2014.12.068; Hampel H, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00456; Hey JA, 2018, CNS DRUGS, V32, P849, DOI 10.1007/s40263-018-0554-0; Kinney Jefferson W, 2018, Alzheimers Dement (N Y), V4, P575, DOI 10.1016/j.trci.2018.06.014; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; Lee M, 2011, GLIA, V59, P152, DOI 10.1002/glia.21087; Liang CS, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00652-z; Lobo-Silva D, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0763-8; Manzano S, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00614; Martorana A, 2018, J GERONTOL GERIATR, V66, P15; Martorana A, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00254; Migliorini P, 2010, EUR CYTOKINE NETW, V21, P264, DOI 10.1684/ecn.2010.0210; MURDOCK BB, 1962, J EXP PSYCHOL, V64, P482, DOI 10.1037/h0045106; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Saresella M, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-01806-4; Shen XN, 2019, J NEUROL NEUROSUR PS, V90, P590, DOI 10.1136/jnnp-2018-319148; Spalletta G, 2016, J ALZHEIMERS DIS, V50, P807, DOI 10.3233/JAD-150484; Sutinen EM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-199; Tian J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84751-3; Tian Jide, 2019, Immunohorizons, V3, P498, DOI 10.4049/immunohorizons.1900019; Tian JD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32733-3; Tolar M, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00663-w; Wolk DA, 2011, NEUROIMAGE, V54, P1530, DOI 10.1016/j.neuroimage.2010.09.005; Zhang HF, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.183	37	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								813951	10.3389/fimmu.2022.813951	http://dx.doi.org/10.3389/fimmu.2022.813951			8	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2D4XM	35515001	gold, Green Published			2022-12-18	WOS:000811552000001
J	Zheng, SY; Dong, JZ				Zheng, Shi-Yue; Dong, Jian-Zeng			Role of Toll-Like Receptors and Th Responses in Viral Myocarditis	FRONTIERS IN IMMUNOLOGY			English	Review						viral myocarditis; TLRs; Th cells; regulatory T cell; immune response	EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; TH1/TH2 CYTOKINE BALANCE; CELL-ACTIVATION; CLINICAL-COURSE; CVB3 INFECTION; CARDIAC MYOSIN; RECOGNITION; DIAGNOSIS; INNATE; DIFFERENTIATION	Myocarditis is the common cause of sudden cardiac death, dilated cardiomyopathy (DCM) and heart failure (HF) in young adults. The most common type of myocarditis is viral myocarditis (VMC). Toll-like receptors (TLRs) are vital to identify pathogens in vivo. TLRs promote the differentiation of naive CD4(+)T cells to T helper (Th) cells, activate the immune response, and participate in the pathogenesis of autoimmune and allergic diseases. Although the pathogenesis of VMC is unclear, autoimmune responses have been confirmed to play a significant role; hence, it could be inferred that VMC is closely related to TLRs and Th responses. Some drugs have been found to improve the prognosis of VMC by regulating the immune response through activated TLRs. In this review, we discuss the role of TLRs and Th responses in VMC.										Abston ED, 2013, AM J PHYSIOL-REG I, V304, pR267, DOI 10.1152/ajpregu.00516.2011; Ammirati E, 2022, CURR CARDIOL REP, V24, P597, DOI 10.1007/s11886-022-01680-x; Ammirati E, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.120.007405; Annunziato F, 2015, J ALLERGY CLIN IMMUN, V135, P626, DOI 10.1016/j.jaci.2014.11.001; Basso C, 2013, HEART FAIL REV, V18, P673, DOI 10.1007/s10741-012-9355-6; Bekeredjian-Ding I, 2006, J IMMUNOL, V176, P7438, DOI 10.4049/jimmunol.176.12.7438; Caforio ALP, 2013, EUR HEART J, V34, P2636, DOI 10.1093/eurheartj/eht210; Cervantes JL, 2012, CELL MOL IMMUNOL, V9, P434, DOI 10.1038/cmi.2012.38; Chen JQ, 2016, CLIN REV ALLERG IMMU, V50, P1, DOI 10.1007/s12016-015-8473-z; Cheng HL, 2016, CENT EUR J IMMUNOL, V41, P64, DOI 10.5114/ceji.2016.58817; Chodisetti SB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01632; Ciesielska A, 2021, CELL MOL LIFE SCI, V78, P1233, DOI 10.1007/s00018-020-03656-y; Cunningham MW, 2001, AM J PATHOL, V159, P5, DOI 10.1016/S0002-9440(10)61665-3; de Marcken M, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw1347; Deng YT, 2019, MOL IMMUNOL, V112, P266, DOI 10.1016/j.molimm.2019.06.006; Desnues B, 2014, P NATL ACAD SCI USA, V111, P1497, DOI 10.1073/pnas.1314121111; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Eng HL, 2018, BIOCHEM BIOPH RES CO, V497, P319, DOI 10.1016/j.bbrc.2018.02.079; Fairweather D, 2012, CURR OPIN RHEUMATOL, V24, P401, DOI 10.1097/BOR.0b013e328353372d; Flores-Langarica A, 2015, EUR J IMMUNOL, V45, P2299, DOI 10.1002/eji.201545564; Friedrich MG, 2009, J AM COLL CARDIOL, V53, P1475, DOI 10.1016/j.jacc.2009.02.007; Fujinami RS, 2006, CLIN MICROBIOL REV, V19, P80, DOI 10.1128/CMR.19.1.80-94.2006; Fung G, 2016, CIRC RES, V118, P496, DOI 10.1161/CIRCRESAHA.115.306573; Fuse K, 2003, CLIN EXP IMMUNOL, V134, P403, DOI 10.1111/j.1365-2249.2003.02312.x; Fuse K, 2001, JPN CIRC J, V65, P1082, DOI 10.1253/jcj.65.1082; Gagliani N, 2017, METHODS MOL BIOL, V1514, P19, DOI 10.1007/978-1-4939-6548-9_2; Gorbea C, 2010, J BIOL CHEM, V285, P23206, DOI 10.1074/jbc.M109.047464; Guo GZ, 2019, PHARMACOLOGY, V103, P136, DOI 10.1159/000495755; Hare JM, 2001, EUR HEART J, V22, P269, DOI 10.1053/euhj.2000.2272; Heidecker B, 2011, CIRCULATION, V123, P1174, DOI 10.1161/CIRCULATIONAHA.110.002857; Hess NJ, 2017, J LEUKOCYTE BIOL, V101, P1245, DOI 10.1189/jlb.3A1116-492R; Huber SA, 2016, CURR PHARM DESIGN, V22, P408, DOI 10.2174/1381612822666151222160500; Imanaka-Yoshida K, 2020, PATHOL INT, V70, P1, DOI 10.1111/pin.12868; Javmen A, 2020, J LEUKOCYTE BIOL, V108, P1697, DOI 10.1002/JLB.2HI0819-180R; Jin B, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/836485; Jin HB, 2016, VIROL J, V13, DOI 10.1186/s12985-016-0626-z; Kamdar K, 2013, VIRULENCE, V4, P207, DOI 10.4161/viru.23354; Kim J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070868; Kociol RD, 2020, CIRCULATION, V141, pE69, DOI 10.1161/CIR.0000000000000745; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kumagai Y, 2008, ADV DRUG DELIVER REV, V60, P795, DOI 10.1016/j.addr.2007.12.004; Kumar Vijay, 2022, Handb Exp Pharmacol, V276, P95, DOI 10.1007/164_2021_543; Kuzmich NN, 2017, VACCINES-BASEL, V5, DOI 10.3390/vaccines5040034; Lai CY, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/7807313; Lasrado N, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2131; Lee AJ, 2017, J IMMUNOL, V199, P409, DOI 10.4049/jimmunol.1602062; Lee GR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030730; Li ZP, 2013, CARDIOVASC PATHOL, V22, P373, DOI 10.1016/j.carpath.2013.02.004; Lim KH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011247; Liu H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22040; Liu TL, 2019, INT J BIOL MACROMOL, V126, P179, DOI 10.1016/j.ijbiomac.2018.12.207; Liu W, 2005, J AUTOIMMUN, V25, P258, DOI 10.1016/j.jaut.2005.06.005; Liu YF, 2012, INT IMMUNOL, V24, P605, DOI 10.1093/intimm/dxs056; Long Q, 2016, FRONT CELL INFECT MI, V6, DOI 10.3389/fcimb.2016.00171; Luetkens JA, 2016, EUR HEART J-CARD IMG, V17, P154, DOI 10.1093/ehjci/jev246; Marchant D, 2008, CURR TOP MICROBIOL, V323, P177; Marinho FAV, 2013, EUR J IMMUNOL, V43, P2373, DOI 10.1002/eji.201243208; Matsumoto M, 2008, ADV DRUG DELIVER REV, V60, P805, DOI 10.1016/j.addr.2007.11.005; McGettrick AF, 2010, CURR OPIN IMMUNOL, V22, P20, DOI 10.1016/j.coi.2009.12.002; Mills KHG, 2011, NAT REV IMMUNOL, V11, P807, DOI 10.1038/nri3095; Mueller Thomas, 2008, V183, P51; Mukherjee S, 2019, SCAND J IMMUNOL, V90, DOI 10.1111/sji.12771; Muzio M, 2000, BIOCHEM SOC T, V28, P563, DOI 10.1042/bst0280563; Myers JM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85851; Narovlyanskaya O, 2020, DIMENS CRIT CARE NUR, V39, P75, DOI 10.1097/DCC.0000000000000402; Negishi H, 2008, P NATL ACAD SCI USA, V105, P20446, DOI 10.1073/pnas.0810372105; Noreen M, 2015, IMMUNOL RES, V62, P234, DOI 10.1007/s12026-015-8640-6; Nyirenda MH, 2011, J IMMUNOL, V187, P2278, DOI 10.4049/jimmunol.1003715; Olejniczak M, 2020, J CARDIOTHOR VASC AN, V34, P1591, DOI 10.1053/j.jvca.2019.12.052; Plociennikowska A, 2015, CELL MOL LIFE SCI, V72, P557, DOI 10.1007/s00018-014-1762-5; Pollack A, 2015, NAT REV CARDIOL, V12, P670, DOI 10.1038/nrcardio.2015.108; Riad A, 2010, AM J PHYSIOL-HEART C, V298, pH2024, DOI 10.1152/ajpheart.01188.2009; Rifkin IR, 2005, IMMUNOL REV, V204, P27, DOI 10.1111/j.0105-2896.2005.00239.x; Rivadeneyra L, 2018, J MOL CELL CARDIOL, V125, P149, DOI 10.1016/j.yjmcc.2018.08.029; Roberts BJ, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-25; Roberts BJ, 2013, EXP MOL PATHOL, V94, P58, DOI 10.1016/j.yexmp.2012.06.005; Sacramento LA, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008435; Saruta M, 2009, EUR J IMMUNOL, V39, P2195, DOI 10.1002/eji.200939216; Seferovic PM, 2021, EUR J HEART FAIL, V23, P854, DOI 10.1002/ejhf.2190; Sharma RK, 2019, IMMUNOL INVEST, V48, P79, DOI 10.1080/08820139.2018.1515223; Su R, 2020, MBIO, V11, DOI 10.1128/mBio.02540-20; Suzuki JI, 2006, J MOL CELL CARDIOL, V40, P688, DOI 10.1016/j.yjmcc.2006.01.006; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tamassia N, 2019, J LEUKOCYTE BIOL, V105, P1155, DOI 10.1002/JLB.MA0818-308R; Vaure C, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00316; Vdovenko D, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/4396351; Vidya MK, 2018, INT REV IMMUNOL, V37, P20, DOI 10.1080/08830185.2017.1380200; Vijay K, 2018, INT IMMUNOPHARMACOL, V59, P391, DOI 10.1016/j.intimp.2018.03.002; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; Wagner H, 2006, ADV IMMUNOL, V91, P159, DOI 10.1016/S0065-2776(06)91004-9; Wang JY, 2006, J BIOL CHEM, V281, P37427, DOI 10.1074/jbc.M605311200; Xu QQ, 2015, CELL BIOL INT, V39, P1120, DOI 10.1002/cbin.10485; Yan LH, 2016, J MOL MED, V94, P1063, DOI 10.1007/s00109-016-1414-3; Yoon SI, 2012, SCIENCE, V335, P859, DOI 10.1126/science.1215584; Yu L, 2010, J CELL MOL MED, V14, P2592, DOI 10.1111/j.1582-4934.2010.01127.x; Yu YM, 2003, AM J PHYSIOL-GASTR L, V285, pG282, DOI 10.1152/ajpgi.00503.2002; Yuan J, 2010, J CLIN IMMUNOL, V30, P226, DOI 10.1007/s10875-009-9355-z; Zhang P, 2009, J IMMUNOL, V183, P27, DOI 10.4049/jimmunol.0800861; Zhang SX, 2016, INFLAMMATION, V39, P678, DOI 10.1007/s10753-015-0294-y; Zhao Z, 2015, BIOCHEMISTRY-MOSCOW+, V80, P455, DOI 10.1134/S0006297915040094; Zhou R, 2021, J MED VIROL, V93, P6116, DOI 10.1002/jmv.27265; Zhu JF, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a030338; Zhu XL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218011	103	0	0	1	1	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 19	2022	13								843891	10.3389/fimmu.2022.843891	http://dx.doi.org/10.3389/fimmu.2022.843891			10	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	2A7NT	35514979	gold, Green Published			2022-12-18	WOS:000809684800001
J	Bagri, P; Anipindi, VC; Kaushic, C				Bagri, Puja; Anipindi, Varun C.; Kaushic, Charu			The Role of IL-17 During Infections in the Female Reproductive Tract	FRONTIERS IN IMMUNOLOGY			English	Review						IL-17; FRT; infection; fungal; bacterial; HIV; HSV; mucosal	CD4(+) T-CELLS; CHLAMYDIA-TRACHOMATIS INFECTION; VULVO-VAGINAL CANDIDIASIS; TH17 CELLS; NEISSERIA-GONORRHOEAE; IMMUNE-RESPONSES; IMMUNODEFICIENCY-VIRUS; SEX-HORMONES; HOST-DEFENSE; ANTIBODY-RESPONSES	Interleukin-17 (IL-17A) is a cytokine involved in a complex array of both protective and detrimental processes. Although early biological studies focused on the pro-inflammatory function of IL-17 in the context of autoimmune and inflammatory disorders, it has become increasingly evident that the roles of IL-17 are far more nuanced. Recent work has demonstrated that the functions of IL-17 are highly context- and tissue-dependent, and there is a fine balance between the pathogenic and protective functions of IL-17. This is especially evident in mucosal tissues such as the female reproductive tract, where IL-17 has been shown to play an important role in the immune response generated during fungal, bacterial and viral infections associated with protection, but also with inflammation. In this review, we discuss the evolving landscape of IL-17 biology within the context of the vaginal mucosa, focusing on key findings that highlight the importance of this cytokine in genital mucosal immunity.	[Bagri, Puja; Anipindi, Varun C.; Kaushic, Charu] McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON, Canada; [Bagri, Puja; Anipindi, Varun C.; Kaushic, Charu] McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University; McMaster University	Kaushic, C (corresponding author), McMaster Univ, McMaster Immunol Res Ctr, Hamilton, ON, Canada.; Kaushic, C (corresponding author), McMaster Univ, Dept Med, Hamilton, ON, Canada.	kaushic@mcmaster.ca			Canadian Institutes of Health Research (CIHR) [93615]; Ontario HIV Treatment Network (OHTN) [779]	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ontario HIV Treatment Network (OHTN)	This research was funded by operating grants from the Canadian Institutes of Health Research (CIHR) to CK (FRN #93615) and an Applied HIV Research Chair Award to CK from the Ontario HIV Treatment Network (OHTN) (AHRC #779).	Amatya N, 2017, TRENDS IMMUNOL, V38, P310, DOI 10.1016/j.it.2017.01.006; Andrew DW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076664; Anipindi Varun C, 2019, Immunohorizons, V3, P317, DOI 10.4049/immunohorizons.1900040; Anipindi VC, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005589; Bagri P, 2021, J VIROL, V95, DOI 10.1128/JVI.01206-20; Bagri P, 2017, J VIROL, V91, DOI 10.1128/JVI.01234-17; Bai H, 2017, CELL MOL IMMUNOL, V14, P850, DOI 10.1038/cmi.2016.53; Beagley KW, 2000, J REPROD IMMUNOL, V48, P47, DOI 10.1016/S0165-0378(00)00069-3; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Boily-Larouche G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11706-y; Brotman RM, 2014, VACCINE, V32, P1543, DOI 10.1016/j.vaccine.2013.10.010; Burgener A, 2015, CURR OPIN IMMUNOL, V36, P22, DOI 10.1016/j.coi.2015.06.004; Cecchinato V, 2010, CURR OPIN HIV AIDS, V5, P141, DOI 10.1097/COH.0b013e32833653ec; Chege D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043670; Cicala C, 2009, P NATL ACAD SCI USA, V106, P20877, DOI 10.1073/pnas.0911796106; Conti HR, 2015, J IMMUNOL, V195, P780, DOI 10.4049/jimmunol.1500909; Conti HR, 2009, J EXP MED, V206, P299, DOI 10.1084/jem.20081463; Cua DJ, 2010, NAT REV IMMUNOL, V10, P479, DOI 10.1038/nri2800; Cunningham AL, 2006, J INFECT DIS, V194, pS11, DOI 10.1086/505359; Dandekar S, 2010, CURR OPIN HIV AIDS, V5, P173, DOI 10.1097/COH.0b013e328335eda3; Darville T, 2003, J IMMUNOL, V171, P6187, DOI 10.4049/jimmunol.171.11.6187; Darville T, 1997, INFECT IMMUN, V65, P3065, DOI 10.1128/IAI.65.8.3065-3073.1997; Do JS, 2011, J IMMUNOL, V186, P4546, DOI 10.4049/jimmunol.1004021; Do JS, 2012, IMMUNOL CELL BIOL, V90, P396, DOI 10.1038/icb.2011.50; Dobbs ME, 2005, J VIROL, V79, P14546, DOI 10.1128/JVI.79.23.14546-14554.2005; Dockterman J, 2021, PATHOG DIS, V79, DOI 10.1093/femspd/ftab012; Dongari-Bagtzoglou A, 2005, MED MYCOL, V43, P545, DOI 10.1080/13693780500064557; El Hed A, 2010, J INFECT DIS, V201, P843, DOI 10.1086/651021; Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052; Eyerich K, 2008, J INVEST DERMATOL, V128, P2640, DOI 10.1038/jid.2008.139; Farris CM, 2011, INFECT IMMUN, V79, P986, DOI 10.1128/IAI.00881-10; Feinen B, 2010, MUCOSAL IMMUNOL, V3, P312, DOI 10.1038/mi.2009.139; Feinen B, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00011; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Fidel PL, 2007, AM J REPROD IMMUNOL, V57, P2, DOI 10.1111/j.1600-0897.2006.00450.x; Fidel PL, 1996, CLIN MICROBIOL REV, V9, P335, DOI 10.1128/CMR.9.3.335; Frazer LC, 2013, AM J REPROD IMMUNOL, V70, P472, DOI 10.1111/aji.12171; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Gaffen SL, 2014, NAT REV IMMUNOL, V14, P585, DOI 10.1038/nri3707; Gagliardi MC, 2011, FEMS IMMUNOL MED MIC, V61, P129, DOI 10.1111/j.1574-695X.2010.00759.x; Gosselin A, 2010, J IMMUNOL, V184, P1604, DOI 10.4049/jimmunol.0903058; Haase AT, 2011, ANNU REV MED, V62, P127, DOI 10.1146/annurev-med-080709-124959; Hafner L, 2008, MUCOSAL IMMUNOL, V1, P116, DOI 10.1038/mi.2007.19; Harandi AM, 2001, J GEN VIROL, V82, P845, DOI 10.1099/0022-1317-82-4-845; Hedges SR, 1999, INFECT IMMUN, V67, P3937, DOI 10.1128/IAI.67.8.3937-3946.1999; Hedges SR, 1998, J INFECT DIS, V178, P742, DOI 10.1086/515372; Herring A, 2006, NAT REV MICROBIOL, pS41, DOI 10.1038/nrmicro1562; Hladik F, 2008, NAT REV IMMUNOL, V8, P447, DOI 10.1038/nri2302; Huang WT, 2004, J INFECT DIS, V190, P624, DOI 10.1086/422329; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jerse AE, 1999, INFECT IMMUN, V67, P5699, DOI 10.1128/IAI.67.11.5699-5708.1999; Jha R, 2011, MICROBES INFECT, V13, P167, DOI 10.1016/j.micinf.2010.10.012; Kim CJ, 2012, MUCOSAL IMMUNOL, V5, P670, DOI 10.1038/mi.2012.72; Kim JO, 2012, IMMUNOL LETT, V147, P34, DOI 10.1016/j.imlet.2012.05.006; Kimberlin DW, 2004, NEW ENGL J MED, V350, P1970, DOI 10.1056/NEJMcp023065; Kinnunen A, 2000, HUM REPROD, V15, P1484, DOI 10.1093/humrep/15.7.1484; Klatt NR, 2012, MUCOSAL IMMUNOL, V5, P646, DOI 10.1038/mi.2012.38; Korn T, 2007, SEMIN IMMUNOL, V19, P362, DOI 10.1016/j.smim.2007.10.007; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Lampe MF, 1998, INFECT IMMUN, V66, P5457, DOI 10.1128/IAI.66.11.5457-5461.1998; Lewis DA, 2007, SEX TRANSM INFECT, V83, P508, DOI 10.1136/sti.2007.028142; Li LX, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003707; Liang SC, 2006, J EXP MED, V203, P2271, DOI 10.1084/jem.20061308; Liu Y, 2017, MUCOSAL IMMUNOL, V10, P1594, DOI 10.1038/mi.2017.11; Liu Y, 2012, MUCOSAL IMMUNOL, V5, P320, DOI 10.1038/mi.2012.12; Liu YR, 2011, MBIO, V2, DOI 10.1128/mBio.00095-11; Looker KJ, 2008, B WORLD HEALTH ORGAN, V86, P805, DOI 10.2471/BLT.07.046128; Looker KJ, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0114989, 10.1371/journal.pone.0140765]; Magliani W, 2002, TRENDS MOL MED, V8, P121, DOI 10.1016/S1471-4914(01)02268-7; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Masson L, 2015, IMMUNOLOGY, V146, P557, DOI 10.1111/imm.12527; Mayor MT, 2012, AM FAM PHYSICIAN, V86, P931; McKinnon LR, 2012, CURR OPIN HIV AIDS, V7, P195, DOI 10.1097/COH.0b013e3283504941; McKinnon LR, 2011, J IMMUNOL, V187, P6032, DOI 10.4049/jimmunol.1101836; Mengesha BG, 2017, J FUNGI, V3, DOI 10.3390/jof3040052; Monin L, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028522; Morrison RP, 2002, INFECT IMMUN, V70, P2741, DOI 10.1128/IAI.70.6.2741-2751.2002; Morrison SG, 2005, J IMMUNOL, V175, P7536, DOI 10.4049/jimmunol.175.11.7536; Naglik JR, 2008, FEMS MICROBIOL LETT, V283, P129, DOI 10.1111/j.1574-6968.2008.01160.x; Nazli A, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000852; O'Meara CP, 2014, CURR MOL MED, V14, P396, DOI 10.2174/15665240113136660078; Onishi RM, 2010, IMMUNOLOGY, V129, P311, DOI 10.1111/j.1365-2567.2009.03240.x; Packiam M, 2010, INFECT IMMUN, V78, P433, DOI 10.1128/IAI.00711-09; Papotto PH, 2017, NAT IMMUNOL, V18, P604, DOI 10.1038/ni.3726; Pappu R, 2012, TRENDS IMMUNOL, V33, P343, DOI 10.1016/j.it.2012.02.008; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Parr MB, 2003, INT REV IMMUNOL, V22, P43, DOI 10.1080/08830180305228; Parsonage G, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2406; Peters BM, 2020, J INFECT DIS, V221, P1554, DOI 10.1093/infdis/jiz649; Pietrella D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022770; Pirofski LA, 2009, J EXP MED, V206, P269, DOI 10.1084/jem.20090093; Ramsey KH, 2005, INFECT IMMUN, V73, P6962, DOI 10.1128/IAI.73.10.6962-6973.2005; RAMSEY KH, 1988, INFECT IMMUN, V56, P1320, DOI 10.1128/IAI.56.5.1320-1325.1988; Rodriguez-Garcia M, 2014, MUCOSAL IMMUNOL, V7, P1375, DOI 10.1038/mi.2014.26; Rosentul Diana C, 2014, Front Microbiol, V5, P483, DOI 10.3389/fmicb.2014.00483; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Rowley J, 2019, B WORLD HEALTH ORGAN, V97, P548, DOI 10.2471/BLT.18.228486; Sandquist Ivy, 2018, F1000Res, V7, P205, DOI 10.12688/f1000research.13020.1; Scurlock AM, 2011, INFECT IMMUN, V79, P1349, DOI 10.1128/IAI.00984-10; Shah AA, 2005, SEX TRANSM DIS, V32, P49, DOI 10.1097/01.olq.0000148299.14513.11; Sinkora M, 2005, IMMUNOLOGY, V115, P544, DOI 10.1111/j.1365-2567.2005.02194.x; Sobel JD, 1998, AM J OBSTET GYNECOL, V178, P203, DOI 10.1016/S0002-9378(98)80001-X; Song WX, 2008, VACCINE, V26, P5741, DOI 10.1016/j.vaccine.2008.08.020; Stamm WE, 1999, J INFECT DIS, V179, pS380, DOI 10.1086/513844; Stevens JS, 2018, CURR OPIN HEMATOL, V25, P13, DOI 10.1097/MOH.0000000000000394; Stieh DJ, 2016, CELL HOST MICROBE, V19, P529, DOI 10.1016/j.chom.2016.03.005; Su H, 1997, INFECT IMMUN, V65, P1993, DOI 10.1128/IAI.65.6.1993-1999.1997; Sutton CE, 2009, IMMUNITY, V31, P331, DOI 10.1016/j.immuni.2009.08.001; Toy D, 2006, J IMMUNOL, V177, P36, DOI 10.4049/jimmunol.177.1.36; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; Veldhoen M, 2017, NAT IMMUNOL, V18, P612, DOI 10.1038/ni.3742; Villanova F, 2014, J INVEST DERMATOL, V134, P984, DOI 10.1038/jid.2013.477; Wessels JM, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035147; Wi T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002344; Wiesenfeld HC, 2002, J INFECT DIS, V186, P792, DOI 10.1086/342417; Wira CR, 2015, NAT REV IMMUNOL, V15, P217, DOI 10.1038/nri3819; Wira CR, 2014, AM J REPROD IMMUNOL, V72, P236, DOI 10.1111/aji.12252; World Health Organization, HIV DAT STAT 2020; Yano J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046311; Zhang XY, 2009, J IMMUNOL, V183, P1291, DOI 10.4049/jimmunol.0803075; Zhang ZQ, 1999, SCIENCE, V286, P1353, DOI 10.1126/science.286.5443.1353; Zhang ZQ, 2004, P NATL ACAD SCI USA, V101, P5640, DOI 10.1073/pnas.0308425101; Zhou LA, 2007, NAT IMMUNOL, V8, P967, DOI 10.1038/ni1488	125	0	0	0	0	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								861444	10.3389/fimmu.2022.861444	http://dx.doi.org/10.3389/fimmu.2022.861444			12	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H0IU	35493460	Green Published, gold			2022-12-18	WOS:000796230200001
J	Chen, X; Jin, CC; Facciabene, A; Guo, XH; Zhang, YB				Chen, Xin; Jin, Chengcheng; Facciabene, Andrea; Guo, Xiaohuan; Zhang, Yanbo			Editorial: Deciphering the Microbiome-Immunity-Cancer Axis	FRONTIERS IN IMMUNOLOGY			English	Editorial Material						microbiome; immunity; cancer; CRC; lung cancer; pancreatic cancer; metabolites			[Chen, Xin; Facciabene, Andrea] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Jin, Chengcheng] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Jin, Chengcheng] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA; [Facciabene, Andrea] Univ Penn, Perelman Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA; [Guo, Xiaohuan] Tsinghua Univ, Inst Immunol, Beijing, Peoples R China; [Zhang, Yanbo] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA; [Zhang, Yanbo] Harvard Med Sch, Evergrande Ctr Immunol Dis, Boston, MA 02115 USA; [Zhang, Yanbo] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA	Tsinghua University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Tsinghua University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Chen, X; Facciabene, A (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.; Jin, CC (corresponding author), Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA.; Jin, CC (corresponding author), Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA.; Facciabene, A (corresponding author), Univ Penn, Perelman Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA.; Guo, XH (corresponding author), Tsinghua Univ, Inst Immunol, Beijing, Peoples R China.	cx10@tsinghua.org.cn; Chengcheng.Jin@pennmedicine.upenn.edu; facciabe@mail.med.upenn.edu; guoxiaohuan@tsinghua.edu.cn	Chen, Xin/GNH-1799-2022; Guo, Xiaohuan/I-3710-2017	Chen, Xin/0000-0001-6212-2335; Guo, Xiaohuan/0000-0001-5152-3010				Gaiser RA, 2019, GUT, V68, P2186, DOI 10.1136/gutjnl-2018-317458; Mitsuhashi K, 2015, ONCOTARGET, V6, P7209, DOI 10.18632/oncotarget.3109; Riquelme E, 2019, CELL, V178, P795, DOI 10.1016/j.cell.2019.07.008; Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943	4	0	0	2	3	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								897811	10.3389/fimmu.2022.897811	http://dx.doi.org/10.3389/fimmu.2022.897811			3	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H7FJ	35493451	Green Published, gold			2022-12-18	WOS:000796704700001
J	Dai, WJ; Zhang, JG; Li, SQ; He, FJ; Liu, Q; Gong, J; Yang, ZT; Gong, Y; Tang, F; Wang, ZH; Xie, CH				Dai, Weijing; Zhang, Jianguo; Li, Siqi; He, Fajian; Liu, Qiao; Gong, Jun; Yang, Zetian; Gong, Yan; Tang, Fang; Wang, Zhihao; Xie, Conghua			Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy	FRONTIERS IN IMMUNOLOGY			English	Review						protein arginine methyltransferases (PRMTs); cancer immunity; cancer immunotherapy; post translational; modification; molecular mechanism	TERTIARY LYMPHOID STRUCTURES; MHC CLASS-I; TUMOR-INFILTRATING LYMPHOCYTES; REGULATORY T-CELLS; METHYLTRANSFERASE 5; IFN-GAMMA; ANTITUMOR IMMUNITY; GENE-EXPRESSION; C-MYC; ALTERNATIVE ACTIVATION	In recent years, protein arginine methyltransferases (PRMTs) have emerged as new members of a gene expression regulator family in eukaryotes, and are associated with cancer pathogenesis and progression. Cancer immunotherapy has significantly improved cancer treatment in terms of overall survival and quality of life. Protein arginine methylation is an epigenetic modification function not only in transcription, RNA processing, and signal transduction cascades, but also in many cancer-immunity cycle processes. Arginine methylation is involved in the activation of anti-cancer immunity and the regulation of immunotherapy efficacy. In this review, we summarize the most up-to-date information on regulatory molecular mechanisms and different underlying arginine methylation signaling pathways in innate and adaptive immune responses during cancer. We also outline the potential of PRMT-inhibitors as effective combinatorial treatments with immunotherapy.	[Dai, Weijing; Zhang, Jianguo; Li, Siqi; He, Fajian; Liu, Qiao; Gong, Jun; Tang, Fang; Wang, Zhihao; Xie, Conghua] Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, Wuhan, Peoples R China; [Dai, Weijing; Zhang, Jianguo; Li, Siqi; He, Fajian; Liu, Qiao; Gong, Jun; Tang, Fang; Wang, Zhihao; Xie, Conghua] Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Zhongnan Hosp, Wuhan, Peoples R China; [Gong, Jun; Tang, Fang; Wang, Zhihao; Xie, Conghua] Wuhan Univ, Hubei Canc Clin Study Ctr, Zhongnan Hosp, Wuhan, Peoples R China; [Yang, Zetian] Wuhan Univ, Dept Thorac Surg, Zhongnan Hosp, Wuhan, Peoples R China; [Gong, Yan] Wuhan Univ, Dept Biol Repositories, Zhongnan Hosp, Wuhan, Peoples R China; [Gong, Yan] Wuhan Univ, Hubei Engn Res Ctr, Tumor Precis Diag & Treatment Technol & Translat M, Zhongnan Hosp, Wuhan, Peoples R China	Wuhan University; Wuhan University; Wuhan University; Wuhan University; Wuhan University; Wuhan University	Tang, F; Wang, ZH; Xie, CH (corresponding author), Wuhan Univ, Dept Radiat & Med Oncol, Zhongnan Hosp, Wuhan, Peoples R China.; Tang, F; Wang, ZH; Xie, CH (corresponding author), Wuhan Univ, Hubei Key Lab Tumor Biol Behav, Zhongnan Hosp, Wuhan, Peoples R China.; Tang, F; Wang, ZH; Xie, CH (corresponding author), Wuhan Univ, Hubei Canc Clin Study Ctr, Zhongnan Hosp, Wuhan, Peoples R China.	tangfanghappy@whu.edu.cn; chxie_65@whu.edu.cn; wzhwuhanu@outlook.com			National Natural Science Foundation of China [81773236, 81800429, 81972852]; Key Research & Development Project of Hubei Province [2020BCA069]; Nature Science Foundation of Hubei Province [2020CFB612]; Health Commission of Hubei Province Medical Leading Talent Project, Young and Middle-Aged Medical Backbone Talents of Wuhan [WHQG201902]; Application Foundation Frontier Project of Wuhan [2020020601012221]; Zhongnan Hospital of Wuhan University Talented Doctor Program [ZNYB2021008]; Zhongnan Hospital of Wuhan University Medical Science and Technology Innovation Platform Program [PTXM2022025]; Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund [znpy2019001, znpy2019048]; Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University [ZNJC201922, ZNJC202007]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research & Development Project of Hubei Province; Nature Science Foundation of Hubei Province(Natural Science Foundation of Hubei Province); Health Commission of Hubei Province Medical Leading Talent Project, Young and Middle-Aged Medical Backbone Talents of Wuhan; Application Foundation Frontier Project of Wuhan; Zhongnan Hospital of Wuhan University Talented Doctor Program; Zhongnan Hospital of Wuhan University Medical Science and Technology Innovation Platform Program; Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund; Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University	This study was supported by the National Natural Science Foundation of China (grant nos. 81773236, 81800429 and 81972852), the Key Research & Development Project of Hubei Province (grant no. 2020BCA069), the Nature Science Foundation of Hubei Province (grant no. 2020CFB612), the Health Commission of Hubei Province Medical Leading Talent Project, Young and Middle-Aged Medical Backbone Talents of Wuhan (grant no. WHQG201902), the Application Foundation Frontier Project of Wuhan (grant no. 2020020601012221), the Zhongnan Hospital of Wuhan University Talented Doctor Program (grant nos. ZNYB2021008), the Zhongnan Hospital of Wuhan University Medical Science and Technology Innovation Platform Program (grant nos. PTXM2022025), the Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund (grant nos. znpy2019001 and znpy2019048) and the Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University (grant nos. ZNJC201922 and ZNJC202007).	Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; Acuto O, 2003, NAT REV IMMUNOL, V3, P939, DOI 10.1038/nri1248; Andreu-Perez P, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001936; Ascierto PA, 2019, NAT MED, V25, P941, DOI 10.1038/s41591-019-0448-9; Avasarala S, 2020, MOL CANCER RES, V18, P166, DOI 10.1158/1541-7786.MCR-19-0204; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Banasavadi-Siddegowda YK, 2017, ONCOGENE, V36, P263, DOI 10.1038/onc.2016.199; Bauer CA, 2014, J CLIN INVEST, V124, P2425, DOI 10.1172/JCI66375; Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013; Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808; Bengsch B, 2016, IMMUNITY, V45, P358, DOI 10.1016/j.immuni.2016.07.008; Blanc RS, 2017, MOL CELL, V65, P8, DOI 10.1016/j.molcel.2016.11.003; Blanchet F, 2005, J EXP MED, V202, P371, DOI 10.1084/jem.20050176; Boisvert FM, 2005, CELL CYCLE, V4, P1834, DOI 10.4161/cc.4.12.2250; Bonham K, 2010, FEBS J, V277, P2096, DOI 10.1111/j.1742-4658.2010.07623.x; Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Cabrita R, 2020, NATURE, V577, P561, DOI 10.1038/s41586-019-1914-8; Cha B, 2011, ONCOGENE, V30, P2379, DOI 10.1038/onc.2010.610; Chan LH, 2018, CELL REP, V25, P690, DOI 10.1016/j.celrep.2018.09.053; Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349; Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012; Chen H, 2017, ONCOGENE, V36, P373, DOI 10.1038/onc.2016.205; Chen Q, 2016, NAT IMMUNOL, V17, P1142, DOI 10.1038/ni.3558; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019; Cheng DH, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800117; Chheda ZS, 2016, J IMMUNOL, V197, P2016, DOI 10.4049/jimmunol.1502376; Chung J, 2019, J BIOL CHEM, V294, P7692, DOI 10.1074/jbc.RA119.007640; Cornel AM, 2020, CANCERS, V12, DOI 10.3390/cancers12071760; Cote J, 2005, J BIOL CHEM, V280, P28476, DOI 10.1074/jbc.M414328200; Cote-Sierra J, 2004, P NATL ACAD SCI USA, V101, P3880, DOI 10.1073/pnas.0400339101; Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500; Croasdell A, 2015, PPAR RES, V2015, DOI 10.1155/2015/549691; Cui SF, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108490; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; David R, 2009, BLOOD, V113, P3696, DOI 10.1182/blood-2008-09-176511; Demaria O, 2019, NATURE, V574, P45, DOI 10.1038/s41586-019-1593-5; Dhar S, 2013, SCI REP-UK, V3, DOI 10.1038/srep01311; Dieu-Nosjean MC, 2016, IMMUNOL REV, V271, P260, DOI 10.1111/imr.12405; Dolezal E, 2017, NAT IMMUNOL, V18, P911, DOI 10.1038/ni.3774; Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360; Fan ZW, 2017, SCI REP-UK, V7, DOI 10.1038/srep40531; Fan ZW, 2016, BBA-GENE REGUL MECH, V1859, P687, DOI 10.1016/j.bbagrm.2016.03.004; Fedoriw A, 2019, CANCER CELL, V36, P100, DOI 10.1016/j.ccell.2019.05.014; Feng JW, 2019, P NATL ACAD SCI USA, V116, P6868, DOI 10.1073/pnas.1811028116; Fong JY, 2019, CANCER CELL, V36, P194, DOI 10.1016/j.ccell.2019.07.003; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Forero A, 2016, CANCER IMMUNOL RES, V4, P390, DOI 10.1158/2326-6066.CIR-15-0243; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Fuhrmann J, 2015, CHEM REV, V115, P5413, DOI 10.1021/acs.chemrev.5b00003; Fulton MD, 2018, CHEM REC, V18, P1792, DOI 10.1002/tcr.201800082; Ganesh S, 2018, MOL THER, V26, P2567, DOI 10.1016/j.ymthe.2018.09.005; Gao GZ, 2019, NUCLEIC ACIDS RES, V47, P5038, DOI 10.1093/nar/gkz200; Gao GZ, 2017, NUCLEIC ACIDS RES, V45, P4359, DOI 10.1093/nar/gkw1367; Gautam S, 2019, NAT IMMUNOL, V20, P337, DOI 10.1038/s41590-018-0311-z; Guccione E, 2019, NAT REV MOL CELL BIO, V20, P642, DOI 10.1038/s41580-019-0155-x; Gupta P, 2016, EXP CELL RES, V347, P293, DOI 10.1016/j.yexcr.2016.08.008; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Harris DP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148905; Harris DP, 2014, J BIOL CHEM, V289, P15328, DOI 10.1074/jbc.M114.547349; Hata K, 2016, FEBS LETT, V590, P1200, DOI 10.1002/1873-3468.12161; Helmink BA, 2020, NATURE, V577, P549, DOI 10.1038/s41586-019-1922-8; Henning AN, 2018, NAT REV IMMUNOL, V18, P340, DOI 10.1038/nri.2017.146; Henrich FC, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1184802; Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962; Hodge MR, 1996, SCIENCE, V274, P1903, DOI 10.1126/science.274.5294.1903; Hofmeyer KA, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/451694; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hou FJ, 2011, CELL, V146, P448, DOI 10.1016/j.cell.2011.06.041; Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158; Hu YB, 2021, GENE, V791, DOI 10.1016/j.gene.2021.145718; Infantino S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01009-1; Infantino S, 2010, J EXP MED, V207, P711, DOI 10.1084/jem.20091303; Inoue M, 2018, NAT IMMUNOL, V19, P1265, DOI 10.1038/s41590-018-0222-z; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Jarnicki AG, 2006, J IMMUNOL, V177, P896, DOI 10.4049/jimmunol.177.2.896; Jarrold J, 2019, TRENDS MOL MED, V25, P993, DOI 10.1016/j.molmed.2019.05.007; Jiang H, 2018, CANCER MED-US, V7, P869, DOI 10.1002/cam4.1360; Jiang YS, 2021, THERANOSTICS, V11, P9162, DOI 10.7150/thno.59605; Jin YL, 2016, J CLIN INVEST, V126, P3961, DOI 10.1172/JCI85239; Jing PY, 2018, CANCER LETT, V427, P38, DOI 10.1016/j.canlet.2018.04.019; Johnson DB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10582; Jongsma MLM, 2019, MOL IMMUNOL, V113, P16, DOI 10.1016/j.molimm.2017.12.005; Jurado M, 2021, COMPUT BIOL MED, V133, DOI 10.1016/j.compbiomed.2021.104339; Kagoya Y, 2019, J AUTOIMMUN, V97, P10, DOI 10.1016/j.jaut.2018.09.011; Kalbasi Anusha, 2020, Nat Rev Immunol, V20, P25, DOI 10.1038/s41577-019-0218-4; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kim H, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz5683; Kinoshita T, 2016, ANN ONCOL, V27, P2117, DOI 10.1093/annonc/mdw319; Kobayashi KS, 2012, NAT REV IMMUNOL, V12, P813, DOI 10.1038/nri3339; Kumar S, 2021, CANCER DISCOV, V11, P2050, DOI 10.1158/2159-8290.CD-20-1144; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Lawson BR, 2007, J IMMUNOL, V178, P5366, DOI 10.4049/jimmunol.178.8.5366; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Leonard WJ, 2019, IMMUNITY, V50, P832, DOI 10.1016/j.immuni.2019.03.028; Litzler LC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07884-6; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Liu L, 2016, CANCER RES, V76, P1260, DOI 10.1158/0008-5472.CAN-15-1766; Liu M, 2020, THERANOSTICS, V10, P4437, DOI 10.7150/thno.42047; Lorenzi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046928; Lu SX, 2021, CELL, V184, P4032, DOI 10.1016/j.cell.2021.05.038; Lu XQ, 2018, BLOOD, V132, P2026, DOI 10.1182/blood-2018-02-831438; Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942; Luo YH, 2021, HEPATOLOGY, V74, P1932, DOI 10.1002/hep.31864; Ma DP, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abc1834; Man K, 2017, IMMUNITY, V47, P1129, DOI 10.1016/j.immuni.2017.11.021; Marjon K, 2016, CELL REP, V15, P574, DOI 10.1016/j.celrep.2016.03.043; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Meissner TB, 2010, P NATL ACAD SCI USA, V107, P13794, DOI 10.1073/pnas.1008684107; Melero I, 2021, NAT REV CLIN ONCOL, V18, P558, DOI 10.1038/s41571-021-00507-y; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Metz PJ, 2020, CELL REP, V30, P1935, DOI 10.1016/j.celrep.2020.01.054; Moon JW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18132-0; Mowen KA, 2004, MOL CELL, V15, P559, DOI 10.1016/j.molcel.2004.06.042; Nagai Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00174; O'Connor MJ, 2015, MOL CELL, V60, P547, DOI 10.1016/j.molcel.2015.10.040; O'Donnell JS, 2018, SEMIN CANCER BIOL, V48, P91, DOI 10.1016/j.semcancer.2017.04.015; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Ono M, 2007, NATURE, V446, P685, DOI 10.1038/nature05673; Ou CY, 2011, MOL CANCER RES, V9, P660, DOI 10.1158/1541-7786.MCR-10-0223; Ouyang WM, 2012, NATURE, V491, P554, DOI 10.1038/nature11581; Papewalis C, 2008, J IMMUNOL, V180, P1462, DOI 10.4049/jimmunol.180.3.1462; Pawlak MR, 2000, MOL CELL BIOL, V20, P4859, DOI 10.1128/MCB.20.13.4859-4869.2000; Pello OM, 2012, BLOOD, V119, P411, DOI 10.1182/blood-2011-02-339911; Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520; Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283; Petitprez F, 2020, NATURE, V577, P556, DOI 10.1038/s41586-019-1906-8; Pitt JM, 2016, ANN ONCOL, V27, P1482, DOI 10.1093/annonc/mdw168; Polo SE, 2012, MOL CELL, V45, P505, DOI 10.1016/j.molcel.2011.12.035; Reintjes A, 2016, P NATL ACAD SCI USA, V113, P4326, DOI 10.1073/pnas.1522372113; Ribas A, 2019, NAT MED, V25, P936, DOI 10.1038/s41591-019-0476-5; Richard S, 2005, BIOCHEM J, V388, P379, DOI 10.1042/BJ20040373; Rochman Y, 2009, NAT REV IMMUNOL, V9, P480, DOI 10.1038/nri2580; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Sautes-Fridman C, 2019, NAT REV CANCER, V19, P307, DOI 10.1038/s41568-019-0144-6; Schachter J, 2017, LANCET, V390, P1853, DOI 10.1016/S0140-6736(17)31601-X; Schonfeld M, 2020, J BIOL CHEM, V295, P7126, DOI 10.1074/jbc.RA120.013401; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Sen S, 2018, J IMMUNOL, V201, P440, DOI 10.4049/jimmunol.1701654; Shen YY, 2018, ONCOL REP, V39, P2604, DOI 10.3892/or.2018.6350; Shimano H, 2017, NAT REV ENDOCRINOL, V13, P710, DOI 10.1038/nrendo.2017.91; Shin SH, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06606-2; Simpson JAD, 2010, GUT, V59, P926, DOI 10.1136/gut.2009.194472; Siu LL, 2019, ANN ONCOL, V30, P159; Snyder KJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131099; Song C, 2020, CELL ONCOL, V43, P51, DOI 10.1007/s13402-019-00435-1; Spranger S, 2018, NAT REV CANCER, V18, P139, DOI 10.1038/nrc.2017.117; Srour N, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110582; Strobl CD, 2020, MOL CANCER THER, V19, P409, DOI 10.1158/1535-7163.MCT-19-0189; Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591-019-0474-7; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tan L, 2020, AGING-US, V12, P8728, DOI 10.18632/aging.103198; Tanaka Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00621; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Thompson MR, 2014, J BIOL CHEM, V289, P23568, DOI 10.1074/jbc.M114.554147; Tikhanovich I, 2017, J BIOL CHEM, V292, P13333, DOI 10.1074/jbc.M117.797928; Tikhanovich I, 2017, J BIOL CHEM, V292, P6882, DOI 10.1074/jbc.M117.778761; Tikhanovich I, 2015, J BIOL CHEM, V290, P22236, DOI 10.1074/jbc.M115.653543; Tokunaga R, 2018, CANCER TREAT REV, V63, P40, DOI 10.1016/j.ctrv.2017.11.007; Ushmorov A, 2018, SEMIN CANCER BIOL, V50, P132, DOI 10.1016/j.semcancer.2017.07.008; Wang N, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03064-x; Wang QQ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00173; Webb LM, 2020, J CLIN INVEST, V130, P1683, DOI [10.1172/JCI131254, 10.1172/JCl131254]; Webb LM, 2017, J IMMUNOL, V198, P1439, DOI 10.4049/jimmunol.1601702; Wei H, 2013, P NATL ACAD SCI USA, V110, P13516, DOI 10.1073/pnas.1311784110; Wei TYW, 2012, CANCER SCI, V103, P1640, DOI 10.1111/j.1349-7006.2012.02367.x; Wei TYW, 2014, CELL SIGNAL, V26, P2940, DOI 10.1016/j.cellsig.2014.09.014; Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004; Williams MA, 2006, NATURE, V441, P890, DOI 10.1038/nature04790; Wolchok J, 2018, CELL, V175, P1452, DOI 10.1016/j.cell.2018.11.006; Wu Q, 2021, NAT REV DRUG DISCOV, V20, P509, DOI 10.1038/s41573-021-00159-8; Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043; Xia YQ, 2020, ADV MATER, V32, DOI 10.1002/adma.202002054; Yaddanapudi K, 2013, J IMMUNOL, V190, P2984, DOI 10.4049/jimmunol.1201650; Yamagata K, 2008, MOL CELL, V32, P221, DOI 10.1016/j.molcel.2008.09.013; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Yan ZZ, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109731; Yang L, 2021, THERANOSTICS, V11, P3742, DOI 10.7150/thno.53023; Yang ML, 2013, AUTOIMMUNITY, V46, P21, DOI 10.3109/08916934.2012.732133; Yang YZ, 2014, MOL CELL, V53, P484, DOI 10.1016/j.molcel.2014.01.011; Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409; Yin SS, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23833-2; Ying ZZ, 2015, J IMMUNOL, V195, P1538, DOI 10.4049/jimmunol.1500224; Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113; Zhang BL, 2015, ONCOTARGET, V6, P22799, DOI 10.18632/oncotarget.4332; Zhang H, 2019, CELL MOL IMMUNOL, V16, P800, DOI 10.1038/s41423-018-0057-4; Zhang SK, 2019, J CELL MOL MED, V23, P1333, DOI 10.1111/jcmm.14036; Zhang XH, 2017, INT J CLIN ONCOL, V22, P1026, DOI 10.1007/s10147-017-1161-7; Zhao Jie, 2019, Gene Expression, V19, P137, DOI 10.3727/105221618X15372014086197; Zhao X, 2008, GENE DEV, V22, P640, DOI 10.1101/gad.1632608; Zhao Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1595-0; Zheng NN, 2020, WORLD J GASTROENTERO, V26, DOI 10.3748/wjg.v26.i26.3737; Zheng YX, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00596; Zhu F, 2019, LEUKEMIA, V33, P2898, DOI 10.1038/s41375-019-0489-6; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154; Zhu JJ, 2021, J IMMUNOL, V207, P2570, DOI 10.4049/jimmunol.2100627; Zhu JJ, 2021, MOL CELL, V81, P3171, DOI 10.1016/j.molcel.2021.06.004; Zhu JJ, 2020, FASEB J, V34, P10212, DOI 10.1096/fj.201902569R; Zhu JJ, 2020, FASEB J, V34, P988, DOI 10.1096/fj.201902219R; Zhu YY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1087-y; Zika E, 2005, P NATL ACAD SCI USA, V102, P16321, DOI 10.1073/pnas.0505045102; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845	205	0	0	7	13	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-3224			FRONT IMMUNOL	Front. Immunol.	APR 14	2022	13								865964	10.3389/fimmu.2022.865964	http://dx.doi.org/10.3389/fimmu.2022.865964			21	Immunology	Science Citation Index Expanded (SCI-EXPANDED)	Immunology	1H2BX	35493527	Green Published, gold			2022-12-18	WOS:000796351400001
